<SEC-DOCUMENT>0001745114-23-000003.txt : 20230309
<SEC-HEADER>0001745114-23-000003.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309160134
ACCESSION NUMBER:		0001745114-23-000003
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		145
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLECULAR PARTNERS AG
		CENTRAL INDEX KEY:			0001745114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40488
		FILM NUMBER:		23719645

	BUSINESS ADDRESS:	
		STREET 1:		WAGISTRASSE 14
		CITY:			Z?RICH-SCHLIEREN
		STATE:			V8
		ZIP:			8952
		BUSINESS PHONE:		41 44 755 77 00

	MAIL ADDRESS:	
		STREET 1:		WAGISTRASSE 14
		CITY:			Z?RICH-SCHLIEREN
		STATE:			V8
		ZIP:			8952
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>moln-20221231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:d5bc598d-29c0-45ac-9809-ee4bc6e3f0aa,g:d67c3c2e-5cb8-4330-bb94-e6e901fa056b,d:60bed4b3015345c8b90a9ba4194a5e91--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:moln="http://www.molecularpartners.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>moln-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl8xLTEtMS0xLTEwOTYxOA_38da190d-2a08-42d8-938c-2c5ef5f9e1d9">false</ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl8yLTEtMS0xLTEwOTYxOA_2582f81f-7c78-40e3-840d-8e31fff4e5d3">2022</ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl8zLTEtMS0xLTEwOTYxOA_92bdac7b-5410-479c-b156-dee15392ee19">FY</ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl80LTEtMS0xLTEwOTYxOA_cd066924-9294-4c0b-b85d-5574e400b09a">0001745114</ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:NoTradingSymbolFlag" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl81LTEtMS0xLTEwOTYxOA_124437ce-630f-4851-b79c-6c2d1b1d0c4f">true</ix:nonNumeric><ix:nonNumeric contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIwNw_9040953b-cb8b-40fb-a37f-f83b25c57861">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxMQ_05ecdaa7-ecd6-4736-951d-8a9dde75aba2">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ieffd03daf5f049beadb8aa9b7a149884_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyMg_8b946c45-4517-4e69-84b4-4b2d7403ff98">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i0c649c507ba24f33a40832e35ce5a3e0_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyNg_6be1f36f-6243-4b7f-bbee-a9ede8c3610e">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="moln-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">moln:AmericanDepositorySharesTheNasdaqStockMarketLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0d265762d384de3bc912a8791ed2b7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="chfPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia354966cf31e42aaaa6b703a60e1341a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af2f1be9ad44d51b81ad6f3e39f3917_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec7c73caeed425b977de2350cb9e35d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66ad877b195477caaa63da51066504e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc9a065301142489cf73ad6591f13da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc7f91b995e4a8e8339b8aec0df0032_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id00f48490e1649a289d5d3945dc00e92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i535054e5b34d4a6aaeb7b886535df3dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fba67aaaf88433581c2a71e67a97f3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15e5ef472f264809b3c22976835aa54a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae7e5cc7cd4c4a6ab9342ae37f83b666_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb7fef9acf84e13bae5ef3655a07afa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35d2bc98f85c42efaf80ceebcbf879d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c02508d8664ebaad3f69a80bf22ab3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a62605a2a64c89a0a34d7bbc035e7d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c118ee100384a299e971a96bc0a67db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida1ef664b85047599beb657c0edeb373_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c9db8103d514df6aea83be7bdf65bb2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4566f4cc772449408ec24a9a58cbf560_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ec354c9f8f4c9a9d165067d15652b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>moln:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2e80d6a46f79433a9f1419880a584236_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f89c5d3edd409a893e4a981cc24bd0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib359265a93b948b2b6a8eefcd3139fe8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e1e929b08e148649e795b949412ce45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134827d19330412b856f8be3015f6a0b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">moln:VSAOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">moln:VoluntaryComplementaryPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>moln:employee</xbrli:measure></xbrli:unit><xbrli:context id="ia75b3bef6aac446986fe84984a05f946_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">moln:VoluntaryComplementaryPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56649e20c0b0463da822d9678ae13d6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7afdf7fbdcd3403f9eab53aecc3a73dd_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86479feb060c435da9376e68efd6bae0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09ac87f9d574f82a6928c8d06b64069_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36fa71d491c847329fa6c34d14edfb51_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74229b204f0a4e65a5b4572fda04aa7d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cfad794c98341a992833dca18dfb48a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">moln:CommercialSupplyOfProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6153f573e54a3eac1c9d6b41928f25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81750a7eb8914110a2c5e64c43bc2de0_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0215c4c9fa24e1aa58a4a62c6f6dcac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9358dea0732b40a194894bcf6ddddaec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c7f8788e1743f68a27f638c26a39bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fa8e94c14b481ca8ccfc64c63add77_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6f6a0e23734f59bbbb2a62cce89125_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbcbcc25f484b88a862620fa45229ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3059de8c6f0f4f34a718c2a08e7fe684_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c93a9c3be2d4ab1aca8bcaec0a3ece3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2f00f6e1d34d28bc572c7a3716463d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithNovartisAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b9c15b3a534e53bbe14f8fb49c9c04_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithNovartisAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69206f52bb344692804141964f0b8919_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithNovartisAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d96b78adfc4421949448ba38c3278e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithFOPHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43e19cfc5e6468284394d74ddd1c6b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithFOPHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6429be12154d0ba42dc47086ea5532_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithFOPHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9455742d8ced4b6aa55b012e2998f544_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7779c743611545a1a5466aeccce603f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039f8aa8b8604b2e883f7b3401f7a929_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7552852e9d984715b1fdd598bf43ceef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd82706cc4f64d05a8031db8ac29d402_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6bbe794bea748fba48087bb12f33b68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e0b443e7594af9817dff19575a130a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id866ae6d346e441aa470d04134f56aea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4189b498f848ccbfe85984bfc5754f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fdd67cc72964dfbacdf60557d1afe8a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i929b7236fc1c4b00a1fbffece5751b1f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bfb7ab39c194903bc349d24d15bdff3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449ea807ec98486b91b11b3611579b53_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i721fcb345fbe4680839954bebb736c75_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae809b4cb3c34e5e883367b1b36f9a41_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700c3d4d5945423fb23d62d557025628_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442e98a6f284460eb60903633206fee4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied5bd6f58f8f48858390908d4e2a3e7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a4b7bf00f14853a994219c229c2c99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67bd3877ed504b9aa0d90579b46a85dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8209c15b7f84b6c9ad36754465a7bb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c56aac02e0548818298a1b40775502a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0b882b89ca4bc19848d14f02c8a322_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87deb100db7642138360f124b7b83f30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07001daad34a409cb04dc3e2f9fddf5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6db54fee24e4009b68217ec1b72ecdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75365a982a614edc804e839f45c5b05d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078bf95a5a1b404484fa9d710b87ffcc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice16a04c397c47bca71d3d2d60a51120_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1102832e1f4e1fafce024fd7eb6448_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e85bbf49b974c1ea7e5b7900e92843f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c79a462ea7412a93e68016da430184_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7021179595f4067925348f27617f344_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b61e3a808b46ecb5fd9e84efd88fb1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd725be5cb634d3ab32c12364784d95e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623979330c12419785c4e5ddc7af24af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8693395446c5444f8dea66e3b926bfc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42028a51dd041c8adf064ec5e6ff3ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb97834871d4133bebda22f171f379c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4515285a8328425c8e01df63e4618b0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad950054a9b34e23b44f9eadcd5ac579_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0b75f40939487cb5f179a9d998733b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf076ebc35b49ddbe4032b44413da3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54edf24cb9164d1dbfea8b8935a712b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea606ad4acc0477bbea8cec093c5f28a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca2744f82cc4290b5c5196c97ed6050_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26412b3157954911862c5a447f325fd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bc5a3445ce443b98c1b2827a0abbf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacafa94802ef4385b1333762542ab2f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610b20f353ba4dea967f7adf9a040527_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96855ceb0f64121a493479e560bef93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9417e12bdb64e3bafac232b9b8e7099_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2dba62e38a349b5bd2d7fb9c9475d34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9d4dcab9014ff6a5667ed415cacf65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e266b3fb54b46679c03b9f807b42f18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic872fe1c5a64452688768d06a4b4096c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400d3c0abd194c8e869aa1b7e6a16268_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f28cfe913d4066ba37fda6c47ac60d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i337a906d7c4e48bc876b5ed46aa717c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1742ca85635d45afaa2bb5e7b5c34750_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ce32bfd0d64572b4c65f93443e740f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icab5d29cfc93414ea6aba3b898a8cf72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica8eaf81db894ce0b611d7d987fef5f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f9aad96b06470c9ded02ebad46915c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97000304b6a7470ba15cf385bc4113c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1b6d0b84ef47739e20d7569c9e7102_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c236926219843fc950064245dabb01c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da99d7da3114dd5a669a798631979bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d43267d2666482cbd65715b80893cc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab1da6a1258a4f2f824c654908d097f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcab65890a354c7eb8e9eaaa6083e002_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1330a3506b934eb6a59f96f40d105eca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ae0c8e6c1242e094cae93b6edbc064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i322fcb8657fc434286b60a943aabbd22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a000e55273047dba1042898c89c120b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f2da050b044a43bb1f4bbaaedd6819_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e65b8ceef04aa9a9e140cd7cd7c323_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137ae661167d42648f19a81509b45e09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61e00b45a7c4b488678787526592c08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a2cc30e5c64038a201d238fbf11978_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c8f0e30de34329b9dd662589d2625a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6e38e9a01048c6a7e34827d9d57b9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib278e099451c4b7e9229b48c30d76025_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bbbdd9cb75406c8df9b0ed579152dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef84e56318a489a8550043d9384b54b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac28997728a9430bb0713563ae32e639_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a6529b985e46fea5bb9ea34f1efa71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f2c57f37114335bb14a01f1e265d33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5978b0e87e0e41418a1eb6893998c62a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bef516c67454da38f24cc8f5ef7b00f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd992de4c1764c598225f05b506bb29b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829b948cf2c94f18aebf743811865ac2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32257a4e4494aacb101dba09b0114a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6313d1eb0624defb28c64aa01dea0b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9789cf293a2a4a9b8bb9f043c05612a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b9f00779e44405b197ec74e74a0439_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:TradePayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27040b2af4143aab5074a6b04e2ced4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:AccruedProjectCostsAndRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i587a7a797df14da6b6b0b353a5dbac42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28fffe2b94ca408ca522a3764d0a9a7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:OtherNonEmployeeRelatedAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideda6d7323e8434683a468cdbdbfaad9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304edf7fc9dc4af086181703ec172bbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:TradePayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786fc55946ab49a5b3e6894295ca6683_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:AccruedProjectCostsAndRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff33ff9bbe6c47fdacddc7317235393c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f4ee1fc220b4633b70d08183faf0864_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:OtherNonEmployeeRelatedAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bddec936def48f8835419a973c2564e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if10f3857f8be428ea614cef6b5f0cfdc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b566efcfd8e4616a1184a3238a19919_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3dd2f40888e4d59961b586143204f41_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18995551c1f4e4f88287c5b9130f130_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1e5f5e6ec145b3bceebef0cf07f8db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee446437d91845ccb79f71155459c929_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150e9865322b40bf976dd456472c9667_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>moln:position</xbrli:measure></xbrli:unit><xbrli:unit id="bank"><xbrli:measure>moln:bank</xbrli:measure></xbrli:unit><xbrli:context id="ie1e6b625e94e4ef8b99a049db65e38b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i297e474b905f4802b3fc5c84517b4244_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62d6f3c76c74566abf3f5f15fb7e4a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4cf686055c46f0990c5475b479feab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a813a501bc4b9b8b3d48933008d151_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf5c6ab807f470abff7a20928b54739_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>moln:vote</xbrli:measure></xbrli:unit><xbrli:context id="i95512f09473b4296a07c0bf49732b9f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36e31ef12d534128ba81206be595d4b6_D20220413-20220413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffee4313ed1e4200a7baafdb5092cc29_I20220412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226a1800b6a24a9ab618c75812acf641_I20220413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0473678da046f9afdd55eced60e2d5_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a78a9b245d4218947bfd4a0acbd239_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">moln:ConditionalShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a375d0b11f458fbd6bc7e1aaf8675f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">moln:ConditionalShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ddb4cbe7d484358b5bf5ba0089d4386_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">moln:ConditionalShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b22ff48cfa44ceaa5de97b4809b8b54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ShareOptionsPSUsAndRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a22766f4574cdab095ce240d4ab462_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ShareOptionsPSUsAndRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie47af3905cff436a87efc3199975fdcc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ShareOptionsPSUsAndRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46461ef8c2bf4ad194fcc5da61eb4790_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859523f38bfc4cef886b0469de3d3c27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i918edbfe84d34f33a0b487a26eeba31e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4738c29a9abd4ebdb07a22bac9da094f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b7ff2364ee43b4a7559bda1f8cfdc7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:LaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6592e0e0184441c58126d7e24b37d82e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56ff0ffb76b4ef7bdd5f9a0f0de46ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if631f991ae9c444c817903110fa5596a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a9cc51038a4f4d95c67fe474148918_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a4c1ad6eff4eaa80acba6bc1f1a654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:LaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c25c613d894005a9d3a3b959ee5252_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40be771ab47427dab17aa01b8815550_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e790e4d70ba47b7811ed9628565b55a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f724f166614126b409c627fece74f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11110b5c186941989d4682d8c5456ae1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id871d1f18f9746c1968f95282a63c920_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092e160ceafe420685da4b0eed564d63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">moln:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">moln:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc53d874499145cdad911dfc92439430_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">moln:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief90048dd4494347a75a5ce67581ab00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if164200b3a3a403cb3987f2f289dfaab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66792e0d15a34af9b27cee6aec9fbcae_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfUtrechtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3f5143278948b68b6427ace3f8dade_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfUtrechtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ac96852f4042b3a422b02e00b4ff71_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfUtrechtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477f396e4168445ea6fbd216e6f8a944_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2698db5ae60649b096fe74b1692909bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b64a6fd6d004538825e688a02e1881a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26558c7e2e90408aaf310a75bba70d80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3319cb244b7e4172804e14694e32ba95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e07ae88ae04fad8ed31f5f90d82653_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d575c9c1d347f3ade30668167c5c96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff310e7d99a4295bb708e767bfd827a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e9a73043d041f097d4b73f09999ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie370090677a545b69199494d00542b66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a252953f884104bde7e1a0d7c46591_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf864ef90754f278e13ffa37235877e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">moln:ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8202c8045424e74acc574ebe5b785fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">moln:ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8670303e14b477492db59a0f50b6eec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345d907a04bf4819bb7da74c7aa2c045_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d91352ae9f40a98d596b751938d675_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfLifeExpectancyAfterRetirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdef4a2f3f49473fa1da77464227f8d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfLifeExpectancyAfterRetirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e47e2a1d2f42d6b887d22d3f1fda3a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:ActiveMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c53ee898715434fac2e14c485a6b3ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:ActiveMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied315fa7934d4ceca93243eef84aeb2b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:PensionersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i718f06d2648742acbc789cc2611558ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:PensionersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ESOP2009AndESOP2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a79e3fe3be49e5918a663e53a05813_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ESOP2009AndESOP2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16708e73e7aa4355b85eac7ce415b78b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ESOP2009AndESOP2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>moln:plan</xbrli:measure></xbrli:unit><xbrli:context id="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5fa38f116e34565a5e36d42a37700a5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>moln:tranche</xbrli:measure></xbrli:unit><xbrli:context id="ieffd03daf5f049beadb8aa9b7a149884_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c649c507ba24f33a40832e35ce5a3e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c7b494d350479797a5d1c4c82ccba2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a4f932a6df488d9cc6ed653efcf1f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied19b6e08547434f9cdba0fd054a6b2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a85516e9d14b69b127030c7418be86_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91457d4200b443229b7716268dcc0131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c84992c462c4044bf0e6a6000d7fa91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b1e70d913e41eb90a4644426c8401b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48dcfaff35049b2936b8df362cf345b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4215e729f94983af2861f952675797_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ac6f2ae72f4533ab1243a7f02391ee_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie860cc1afbd34f37b81b8c5b43ca86a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d5712930e540a9b8c8240c3972c7ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45b9f3adc9745569f9195e24eefccdd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf36213d4e434ddab3aee4d16f583fc3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ed7f76d9f64feb954d4407df356caa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab6a4e5dc284abeadf7a60e68289a52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7c058068224203b33c7fcd1f1b017f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f487997ebf84760b436351b9cd07415_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18556d3232ec4e46aaa9d8f104201d8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2287ef5f8e94d59ac113037e7dd05ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f51f1fee3243008271209344707ab6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4eea0ffff4540458374ebbc176fc17e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f264b7c466b43e2be89711f4ad6b777_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">moln:MolecularPartnersIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601f0ea0b2a5490cade7bed682109126_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">moln:MolecularPartnersIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ced05873ca5491bbfebf6675070c334_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">moln:MolecularPartnersIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07c5697db104aff83e8133bcbfd34e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b15b456e71466f914f4fb77e4fbfc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e4c0c2414646e3920288a6e3d93b50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a33d4e0e53241cb86e82f186e53b0d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448b10a8ed3a4b459f511c18fe6a4023_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i309bd18113fa4d088977cb2d88cd4092_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64fa509207d47efa0e81300d9d73cd3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9273a8f19ab4459a81e57dbd2f441d17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875b50cd70744049a9efbc6796621651_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2651abe27944dcdaf65a2279954b10f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf748a46ec9a4ba8b9feba532a6b4da2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfae2f7fb65743218e1d395982995a0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc42f5752df44c938ff23151446565fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11f395ed16342c5ba81005541468e8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4de6e75b42b401296433bd018ede76d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac4cc8da2f54efab0f4f0d53dcfdf39_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5811d9f19074f96a9cbb5482d36febc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LeaseFacilitiesSchlierenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87b69197a5e41b68d889d5a9f94133c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e09613a3fb4d9ca1c6817d2d362664_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe3972176af4d07b4e1942adcf6c075_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6b2661b6384f1fa68e0f05fada4e22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4735c93b327e4729bb263ba18457993f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc9f9f10e83045df9c56d3e82d087d4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075b63d9ec7248cfaea163eaee0d8389_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fcf3db326314fe697ed5cd42ecbbada_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfcf107f070c4e4881afc0cfb8a17695_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i535d9072a4a54202a9a35ca03151f8e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6257911404da432da8c7b7b86e6e80fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2714f74d10b649b4b454a1f1bde37423_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5431eb0aa5e34ad0b9389372b7ea9eb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001bd3a832b04bf5bbcaa90c5bc76c16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f458970fd1a437482bffbf1e51aa71e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctMTAtMS0xLTEwOTYxOA_81e9a3f8-57df-4400-8006-52fd92ab8808 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtMTAtMS0xLTEwOTYxOA_0ac734fe-7da4-46b8-a08a-45fa65d58b36 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtNy0xLTEtMTA5NjE4_b7151253-29da-4569-86f9-977d9f4426c9 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTctMS0xLTEwOTYxOA_118e40e9-7c10-4528-8c2e-3f7aad743281 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTQtMS0xLTEwOTYxOA_527836ae-cfb1-442d-8184-b9f6a8fd7dc6 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTctMS0xLTEwOTYxOA_3a27d870-a318-403c-ba95-cbcbfffae1a7 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTEwLTEtMS0xMDk2MTg_a87347bb-4fa7-441d-9b78-40752564d044 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTEwLTEtMS0xMDk2MTg_6c785a61-4fb9-4251-8527-22403d85ed74 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTQtMS0xLTEwOTYxOA_2287db37-eedb-4c7e-a09c-1ecd05f3c8d0 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctNC0xLTEtMTA5NjE4_a97d247c-d856-4e0f-892e-d1533f366f60 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTEwLTEtMS0xMDk2MTg_7ed81ab2-ad36-4a94-9833-448ac1b7a03b id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTEwLTEtMS0xMDk2MTg_2f807717-1707-4db6-ac76-98e239d570f0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTEyNjA3_af072b3f-1e50-41b8-b6b8-cbf670de7fcf id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTAtMS0xLTEwOTYxOA_4c6651d5-7f01-43c4-9e46-404640a69305 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEwLTEtMS0xMDk2MTg_e49fe919-6ca9-47de-ba92-30a2f9e66e7b id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEwLTEtMS0xMDk2MTg_0d64f99b-c9bf-487e-8e5a-831571c9a9d2 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEzLTEtMS0xMTI2NjI_8da5f5ce-3d30-4198-b089-9046a41774a7 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTA5NjE4_b6b1c5dd-2641-4163-8598-f315946fdfca id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEwLTEtMS0xMDk2MTg_8aa88b7e-551f-482d-9c98-dbd1fded96aa id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEtMS0xLTEwOTYxOA_38d8992f-68f1-42ef-a115-51091c077c82 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTMtMS0xLTExMjYxOQ_e38e3c45-1c18-46c4-be93-cd9e2b526228 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTQtMS0xLTEwOTYxOA_57613203-4c3d-4e30-a631-9b9fe3296547 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEtMS0xLTEwOTYxOA_670a7f4f-b6e2-42bd-a261-d268e6320676 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEwLTEtMS0xMDk2MTg_f95e8681-0fd4-427b-9667-19e15823a877 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEtMS0xLTEwOTYxOA_cec4ceeb-2c61-4b37-adb3-ebdce63e799e id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTQtMS0xLTEwOTYxOA_202d8e85-7a71-4acd-82de-993522c1a6db id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTExMjY2Ng_b52e114c-bb80-4f50-87bc-744a4b0672fd id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTEyNjEz_ed0190b7-f838-444c-ad0f-70993d1b3c88 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEtMS0xLTEwOTYxOA_427e864e-e104-4b8b-968a-31771e944e2d id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTA5NjE4_7379f947-28f2-4610-af08-490f855bfdf0 id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTQtMS0xLTEwOTYxOA_3538464b-a523-4092-951d-4e0aed8bea48" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAz_b44e5f8f-7771-49d3-ae3b-176a5913026c">20-F</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Mark One) </span></div><div style="margin-bottom:6pt;padding-left:0.12pt;padding-right:0.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:21.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:443.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YzQ4MThlMGViYjE2NDk4YmIwNzA3NWVlNjE1MzJlNDYvdGFibGVyYW5nZTpjNDgxOGUwZWJiMTY0OThiYjA3MDc1ZWU2MTUzMmU0Nl8wLTAtMS0xLTEwOTYxOA_3f391e6a-1dfd-45d9-829c-09827bd262e4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-bottom:6pt;padding-left:0.12pt;padding-right:0.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:21.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:443.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YWJhODI0NjA2OThlNDA4Nzg5YWI1ZWNkODUzOGFjMjgvdGFibGVyYW5nZTphYmE4MjQ2MDY5OGU0MDg3ODlhYjVlY2Q4NTM4YWMyOF8wLTAtMS0xLTEwOTYxOA_7354047c-823f-4458-99f2-4a72d7b28144">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV8xMzc_22c4bfc5-e9b6-40c9-84ff-9d6e9e7109ae"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV8xMzc_d19a5df1-5a22-4002-85e0-70289fefbd3d">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-bottom:6pt;padding-left:0.12pt;padding-right:0.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:21.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:443.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6MTgyOTE4NmNlYjg3NGQ3OWFkNzUyNTdjNzZmNDE2ZjEvdGFibGVyYW5nZToxODI5MTg2Y2ViODc0ZDc5YWQ3NTI1N2M3NmY0MTZmMV8wLTAtMS0xLTEwOTYxOA_9e26e913-4ba1-423a-b53d-3da8e5109b13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the transition period from to </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-bottom:6pt;padding-left:0.12pt;padding-right:0.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:21.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:443.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6Zjg4YTFhNjk5OWQ3NGVlZDg2YjViN2IwYjZjNjA1OWUvdGFibGVyYW5nZTpmODhhMWE2OTk5ZDc0ZWVkODZiNWI3YjBiNmM2MDU5ZV8wLTAtMS0xLTEwOTYxOA_8f1aec91-e18b-4a7b-baa4-52b00485c277">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of event requiring this shell company report </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTE3_aab14802-a6a3-4c00-bcda-7468d20958f4">001-40488</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTE4_625e0649-9766-4403-b68f-da825a879df5">MOLECULAR PARTNERS AG</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter and translation of registrant&#8217;s name into English) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA4_9c491deb-02a6-466f-8808-ed5a8ccb34dc">Switzerland</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Jurisdiction of incorporation or organization) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTEz_d7636496-c7ae-48ac-bbca-05b9813d0446">Wagistrasse 14</ix:nonNumeric><br/><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80Nzk_fa937c97-9bc7-4d32-8017-2581efc520e3">8952</ix:nonNumeric> <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA0_a221be1a-3574-4d1e-9ec5-511642e5d82c">Zurich-Schlieren</ix:nonNumeric><br/><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA5_7a80fd54-9e0a-4856-9dac-850ec666ff4d">Switzerland</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Address of principal executive offices) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:ContactPersonnelName" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk1_05d33968-df11-4ae0-b0f8-e29c8b91da9f">Patrick Amstutz</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chief Executive Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Molecular Partners AG </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA1_7b3ce974-1b35-4458-82b9-30393ee2a343">Wagistrasse 14</ix:nonNumeric><br/><ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV82MzM_7dbbc48e-845c-4842-8ace-fd8de2eda1e8">8952</ix:nonNumeric> <ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk5_4e9554f5-8231-47fc-bd50-a9a5f9386153">Zurich-Schlieren</ix:nonNumeric><br/><ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAw_304bc077-633f-4b5c-bb42-35bbc802e593">Switzerland</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tel: +<ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV82NzI_7e8a2f50-16d3-43e5-b7b6-fbfde3b4a3af">41</ix:nonNumeric> <ix:nonNumeric contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTE2_d87b90f7-8bd4-4883-a78a-7359cff4daf7">44 755 77 00</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section 12(b) of the Act. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:29.52pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.820%"><tr><td style="width:1.0%"></td><td style="width:37.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:21.5pt;padding-right:21.5pt;text-align:center;text-indent:-43pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><ix:nonNumeric contextRef="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8xLTAtMS0xLTEwOTYxOA_a13d0220-17b4-4ab7-8dfd-e7256367ee74"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">American depositary shares (each representing</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">one common share, CHF 0.10 nominal value per share)</span></div></ix:nonNumeric></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"><div style="padding-left:21.5pt;padding-right:21.5pt;text-align:center;text-indent:-43pt"><span><br/></span></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8xLTItMS0xLTEwOTYxOA_8a2ca305-ade2-44a0-8de7-676cdbef081b">MOLN</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8xLTQtMS0xLTEwOTYxOA_e118bef4-a651-4a73-ad96-982a424078a7">The Nasdaq Stock Market LLC</ix:nonNumeric> </span></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8yLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjc4NzljYzRjYTI5MDQwYTBiNzFjOTY5Njc2ZmNlYzQ4XzU_91428dae-2df9-415b-98cf-803eb1e5f334">Common shares, CHF 0.10 nominal value per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"><div style="padding-left:21.5pt;padding-right:21.5pt;text-align:center;text-indent:-43pt"><span><br/></span></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8yLTQtMS0xLTEwOTYxOA_89f01ce0-d581-4fb4-af2c-edc1d4cb4625">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* Not for trading, but only in connection with the listing on the Nasdaq Global Select Market of the American depositary shares.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section 12(g) of the Act. None </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report. </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ordinary shares, CHF 0.10 nominal value per share: <ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV81NDk3NTU4MTk2NzI_5cd5e58f-9b82-4901-9e0a-6fea6b90b158">36,044,706</ix:nonFraction> ordinary shares outstanding as of December 31, 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAx_42d9474f-d10d-4b11-bb83-b732e7a1c7f1">No</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAy_685ef6fe-4386-4e6b-a367-bfc2721b741a">No</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA2_5c72a816-d43c-464e-af27-d68a79461597">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk2_6fe98727-cc78-4c37-b4d0-c51d2fdbd481">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YjNkZGQ3NDIyNWRjNGI0OGFlYTY2YjFmYjBjZDIzODIvdGFibGVyYW5nZTpiM2RkZDc0MjI1ZGM0YjQ4YWVhNjZiMWZiMGNkMjM4Ml8xLTAtMS0xLTEwOTYxOA_8960f2f3-4900-4c0f-8fd5-f8a69164df5b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YjNkZGQ3NDIyNWRjNGI0OGFlYTY2YjFmYjBjZDIzODIvdGFibGVyYW5nZTpiM2RkZDc0MjI1ZGM0YjQ4YWVhNjZiMWZiMGNkMjM4Ml8xLTYtMS0xLTEwOTYxOA_ea9d5f14-bc62-4ad3-a2ea-90c9764811f7">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk3_888a3555-9797-434a-b39e-f6d778713944">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA3_6b6343a7-79f9-4615-a01f-501900484608">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant in the filing reflect the correction of an error to previously filed financial statements. &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by checkmark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. GAAP </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:DocumentAccountingStandard" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NGRjNjc4NWZjM2RhNDk1NWEwNzRlOWQ1ZWMyMGFmOTMvdGFibGVyYW5nZTo0ZGM2Nzg1ZmMzZGE0OTU1YTA3NGU5ZDVlYzIwYWY5M18wLTItMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjNlZjNiZmVkM2Y5MTQxYmE4Mjg1MjE1YzBiZDRhNmY2XzU_d0d48105-39de-496e-9e80-abfce5ec7025">International Financial Reporting Standards</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as issued</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by the International Accounting Standards Board </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Item 17 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Item 18 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTEx_a1d241b5-7543-4682-a4ba-b4d101f07018">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PAGE</span></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_7">INTRODUCTION</a></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_16">PART I</a></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_19">Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_19">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Offer Statistics and Expected Timetable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_22">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_25">Key Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_25">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_28">A. [Reserved]</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_31">B. Capitalization and Indebtedness</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_34">C. Reasons for the Offer and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_37">D. Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_37">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_40">Information on the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_40">88</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_43">A. History and Development of the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_43">88</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_46">B. Business Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_46">88</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_49">C. Organizational Structure</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_49">123</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_52">D. Property, Plants and Equipment</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_52">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4A.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_55">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_55">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_58">Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_58">123</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_64">A. Operating Results</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_64">130</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_67">B. Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_67">131</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_70">C. Research and Development, Patents and Licenses</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_70">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_73">D. Trend Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_73">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_76">E. Critical Accounting Esti</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_76">134</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_79">Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_79">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_82">A. Directors and Senior Management</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_82">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_85">B. Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_85">139</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_88">C. Board Practices</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_88">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_91">D. Employees</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_91">149</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_94">E. Share Ownership</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_94">149</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 7.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_97">Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_97">149</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_100">A. Major Shareholders</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_100">149</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_103">B. Related Party Transactions</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_103">153</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_106">C. Interests of Experts and Counsel</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_106">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 8.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_109">Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_109">155</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_112">A. Consolidated Statements and Other Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_112">155</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_115">B. Significant Changes</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_115">157</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 9.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_118">The Offer and Listing</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_118">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_121">A. Offer and Listing Details</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_121">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_124">B. Plan of Distribution</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_124">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_127">C. Markets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_127">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_130">D. Selling Shareholders</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_130">157</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_133">E. Dilution</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_133">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_136">F. Expenses of the Issue</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_136">157</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 10.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_139">Additional Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_139">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_142">A. Share Capital</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_142">157</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_145">B. Memorandum and Articles of Association</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_145">158</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_148">C. Material Contracts</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_148">163</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_151">D. Exchange Controls</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_151">163</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_154">E. Taxation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_154">164</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_157">F. Dividends and Paying Agents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_157">172</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_160">G. Statement by Experts</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_160">172</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_163">H. Documents on Display</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_163">172</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_166">I. Subsidiary Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_166">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_1462">J. Annual Report to Security Holders</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_1462">173</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 11.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_169">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_169">173</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 12.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_172">Description of Securities Other than Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_172">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_175">A. Debt Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_175">174</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_178">B. Warrants and Rights</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_178">174</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_181">C. Other Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_181">174</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_184">D. American Depositary Shares</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_184">175</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_187">PART II</a></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 13.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_190">Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_190">177</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 14.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_193">Material Modifications to the Rights of Security Holders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_193">177</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 15.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_196">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_196">178</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16A.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_202">Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_202">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16B.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_205">Code of Ethics</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_205">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16C.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_208">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_208">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16D.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_211">Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_211">180</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16E.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_214">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_214">180</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16F.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_217">Change in Registrant&#8217;s Certifying Accountant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_217">180</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16G.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_220">Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_220">180</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16H.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_223">Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_223">181</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16I.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_1448">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_1448">181</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_226">PART III</a></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 17.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_229">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_229">182</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 18.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_232">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_232">182</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 19.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_235">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_235">183</a></span></div></td></tr></table></div><div style="margin-top:18pt"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_7"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INTRODUCTION </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this Annual Report on Form 20-F to the &#8220;Company,&#8221; &#8220;Molecular Partners,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Molecular Partners AG and its wholly-owned subsidiary. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We own trademark registrations for &#8220;Molecular Partners</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;DARPin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in Switzerland, the European Union, the United States and Japan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All other trade names, trademarks and service marks of other companies appearing in this Annual Report on Form 20-F are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report on Form 20-F may be referred to without the&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;and&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8482;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We present our consolidated financial statements in CHF and in accordance with International Financial Reporting Standards, or IFRS. None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The terms &#8220;dollar,&#8221; &#8220;USD&#8221; or &#8220;$&#8221; refer to U.S. dollars and the terms &#8220;Swiss Francs&#8221; or &#8220;CHF&#8221; refer to the legal currency of Switzerland. Unless otherwise indicated, all references to currency amounts in this Annual Report on Form 20-F are in U.S. dollars. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have made rounding adjustments to some of the figures included in this Annual Report on Form 20-F. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_10"></div><div style="margin-bottom:8pt;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Annual Report on Form 20-F contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than present and historical facts and conditions contained in this Annual Report on Form 20-F, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this Annual Report on Form 20-F, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;designed,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;should,&#8221; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our clinical trials and preclinical studies, and our research and development programs;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance product candidates into, and successfully complete, clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of regulatory filings and the likelihood of favorable regulatory outcomes and approvals;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory treatment of our product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the European Union, United States and other countries;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of our product candidates, if and once approved;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our product candidates, if and once approved;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract on commercially reasonable terms with third-party suppliers and manufacturers;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model and strategy and the development of our product candidates and technology platforms;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish, obtain and maintain for intellectual property rights covering our product candidates and technology and our ability to protect and enforce such rights;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing on, misappropriating or otherwise violating the intellectual property rights of others;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of third parties with whom we contract to successfully conduct, supervise and monitor clinical trials for our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our expenses, future revenues, earnings, capital requirements and our needs for additional financing;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">he timing and amount of milestone and royalty payments that we may receive under our strategic collaboration agreements;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain additional funding for our operations;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of our strategic collaboration agreements and our ability to enter into future strategic arrangements;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and establish collaborations or obtain additional funding;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of, and pricing for, our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of macro-economic factors, including the COVID-19 pandemic, rising inflation, the U.S Federal reserve raising interest rates and the Russia-Ukraine war, on our business, operations and prospects and on our clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific and management personnel;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry, including competing therapies;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future trading price of the ADSs and impact of securities analysts reports on these prices; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You should refer to the section of this Annual Report on Form 20-F titled &#8220;Item 3.D-Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 20-F will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 20-F and the documents that we reference in this Annual Report on Form 20-F and have filed as exhibits to this Annual Report on Form 20-F completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 20-F, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Annual Report on Form 20-F contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this Annual Report on Form 20-F is generally reliable, such information is inherently imprecise. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_13"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our business faces significant risks. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors set forth under the caption &#8220;Risk Factors&#8221; in Item 3.D. in Part I of this Annual Report on Form 20-F. An investment in our ADSs involves a high degree of risk. Any of the factors set forth under &#8220;Risk Factors&#8221; may limit our ability to successfully execute our business strategy. You should carefully consider all of the information set forth in this Annual Report on Form 20-F and, in particular, should evaluate the specific factors set forth under &#8220;Risk Factors&#8221; in deciding whether to invest in our securities. Among these risks are the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have incurred significant losses since our inception, we expect to incur losses in future periods and may not maintain profitability in the upcoming years. We may need substantial additional funding in order to complete the development and commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development or research operations.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We may need substantial additional funding in order to complete the development and commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development or research operations.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">The effects of health epidemics, including the ongoing COVID-19 coronavirus pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business, including our preclinical studies and clinical trials, as well as the business or operations of third parties with whom we conduct business</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">We are heavily dependent on the success of our DARPin platform to identify and develop product candidates. If we or our collaborators are unable to successfully develop and commercialize product candidates based on our platform or experience significant delays in doing so, our business may be harmed. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our product candidates are in preclinical or various stages of clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates, particularly product candidates that we have licensed to our partners are prolonged or delayed, we or our collaborators may be unable to obtain required regulatory approvals, and therefore will be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical drug development is uncertain. Some or all of our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or price reimbursement or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Positive results from early preclinical studies of our product candidates would not necessarily be predictive of the results of later preclinical studies and any future clinical trials of our product candidates. If we were to achieve positive results from preclinical studies, but were unable to then replicate those positive results in our later preclinical studies and ongoing or future clinical trials, we might be unable to successfully develop, obtain regulatory or marketing approval or price reimbursement for, and commercialize our product candidates.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any of our product candidates has negative side effects, public perception of our DARPin platform and commercial opportunities for all of our current and future product candidates could be adversely affected. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our financial prospects are dependent upon the research, manufacture, development and marketing efforts of our licensees. Our licensees may act in their best interest rather than in our best interest, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on patents and other intellectual property rights to protect our product candidates and the DARPin technology, the prosecution, grant, enforcement, defense and maintenance of which may be challenging and costly. Failure to obtain, maintain, enforce or protect these rights adequately could harm our ability to compete and impair our business.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">The base patents relating to the DARPin base technology we use to generate our DARPin product candidates, which we had exclusively licensed from the University of Zurich, have expired in September 2021 (except for one patent in the United States), and, therefore we have terminated the exclusive license agreement effective October 2021. After base patent expiry, our competitors may use the technology claimed in such patents, which may materially adversely affect our business and competitive position. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities and negative outcomes could result in adverse effects on our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_16"></div><div style="margin-bottom:8pt;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART I </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_19"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1. Identity of Directors, Senior Management and Advisers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_22"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Offer Statistics and Expected Timetable. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_25"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Key Information. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_28"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. [Reserved] </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_31"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Capitalization and Indebtedness </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_34"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Reasons for the Offer and Use of Proceeds </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_37"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Risk Factors </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investing in the ADSs involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information in this Annual Report on Form 20-F before making an investment decision. Our business, financial condition or results of operations could be adversely affected if any of these risks occurs, and as a result, the market price of the ADSs could decline and you could lose all or part of your investment. This report also contains forward-looking statements that involve risks and uncertainties. See "Special Note Regarding Forward-Looking Statements." Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception, we expect to incur losses in future periods and may not maintain profitability in the upcoming years. We may need substantial additional funding in order to complete the development and commercialization of our product candidates. Failure to obtain </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">this necessary capital when needed may force us to delay, limit or terminate certain of our product development or research operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses, including negative net results, attributable to shareholders. For the year ended December&#160;31, 2022 we recorded a positive net result, attributable to shareholders of CHF&#160;117.9&#160;million and for the year ended December&#160;31, 2021, we incurred a negative net result, attributable to shareholders of CHF&#160;63.8&#160;million. As of December&#160;31, 2022, we had cumulative losses of CHF&#160;127.8&#160;million. The positive result in 2022 was largely driven by the January 2022 payment of CHF 150 million by Novartis following exercise of its option under a collaboration agreement with us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our historical losses resulted principally from costs incurred in research and development, preclinical testing, clinical development of our product candidates as well as costs incurred for research programs and from selling, general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials and regulatory compliance activities that, together with anticipated selling, general and administrative expenses, may result in incurring losses in future periods. Our losses, among other things, will continue to cause our working capital and shareholders' equity to decrease. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">complete the Phase 1 clinical trial of MP0317, one of our product candidates in our oncology program;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue to prepare for and complete the Phase 1 clinical trial of MP0533, our CD3 T-cell engaging candidate against acute myeloid leukemia or AML;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue our research activities for developing suitable candidates that could neutralize viruses such as the Respiratory Syncytial Virus or the BK Polyomavirus;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue the research and development of our other clinical- and preclinical-stage product candidates and discovery stage programs including within the radioligand therapeutic space; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue the research and development of our other product candidates; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek to enhance our DARPin technology and build on our proprietary product pipeline; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek regulatory approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates for which we may obtain regulatory approval; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand, protect and enforce our intellectual property and other proprietary rights and obtain licenses to third-party intellectual property;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">add clinical, regulatory, scientific, operational, financial, legal, intellectual property, compliance and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">experience any delays or encounter any issues relating to any of the above, including failed studies, ambiguous trial results, safety issues, other regulatory challenges or third party supply or manufacturing issues. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception in 2004, we have invested most of our resources in developing our product candidates, building our intellectual property portfolio, developing our supply chain, conducting business </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">planning, raising capital and providing general and administrative support for these operations. We do not currently have any approved products and have never generated any revenue from product sales. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us or our licensees to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to sustain or increase profitability on a quarterly or annual basis. Our failure to remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other comparable foreign authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase and revenue could be further delayed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if we do generate product royalties or product sales, we may never sustain profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of the ADSs and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of the ADSs also could cause you to lose all or a part of your investment. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may need substantial additional funding in order to complete the development and commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development or research operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To date, we have funded our operations through public and private placements of equity securities, upfront, milestone, option exercise, reservation fee, expense reimbursement, sponsored research payments received from our collaborators, recharging of third party costs and interest income from the investment of our cash, cash equivalents and financial assets. We expect to require additional funding in the future to sufficiently finance our operations and advance development of our product candidates. On July 1, 2022, we entered into a sales agreement with SVB Securities LLC, or the Sales Agreement, to sell ordinary shares from time to time at our discretion under an &#8220;at the market&#8221; program, with aggregate gross sales proceeds of up to $100.0 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We expect that our existing cash, cash equivalents, together with anticipated funding through collaborations, will enable us to fund our operating expenses and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements for MP0317 and MP0533 or our preclinical programs will depend on many factors, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and completion of preclinical testing and clinical trials for our current or any future product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of potential new product candidates we identify and decide to develop; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or any future product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing patent applications, maintaining and enforcing patents or defending against infringement, misappropriation or other claims raised by third parties; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of our existing license and collaboration agreements and the entry into new license and collaboration agreements; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our current or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenues, if any, we may derive either directly or in the form of milestone and royalty payments from future sales of our product candidates, if approved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. Further, as a Swiss corporation, we have less flexibility to raise capital than U.S. companies, particularly in a quick and efficient manner. As a result, we may not be able to access the capital markets as frequently as comparable U.S. companies. See the Risk Factor entitled &#8220;Our status as a Swiss corporation means that our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs&#8221; for additional information related to our ability to timely raise capital. If adequate funds are not available on commercially acceptable terms or at all when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or product candidates or we may be unable to take advantage of future business opportunities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The effects of health epidemics, including the ongoing COVID-19 pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business, including our preclinical studies and clinical trials, as well as the business or operations of third parties with whom we conduct business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third party manufacturers and contract research organizations, or CROs, upon whom we rely. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As the result of the pandemic, we may experience disruptions that could impact our business, preclinical studies and clinical trials, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">delay of submissions to, and approvals of, regulatory authorities;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of regulatory authorities, which may impact review and approval timelines, including delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidates or target material from our contract manufacturing organizations, or CMOs and other suppliers due to staffing shortages, shortages in supply of production materials, production slowdowns or stoppages and disruptions in delivery systems; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions in preclinical studies due to restricted or limited operations at our facilities; limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays to our sourced discovery and clinical activities.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which the COVID-19 outbreak or any future outbreaks of contagious disease ultimately impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the emergence of variants, the transition to endemic status, travel restrictions and social distancing in Switzerland, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in countries around the world to contain and treat the disease.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to holders of our ordinary shares or ADSs, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our operations with our existing cash, cash equivalents and current financial assets, proceeds from debt or equity offerings, revenue from our collaborations and interest income from the investment of our cash, cash equivalents and financial assets. In order to further advance the development of our product candidates, discover additional product candidates and pursue our other business objectives, however, we will need to seek additional funds. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We cannot guarantee that future financing will be available in sufficient amounts or on commercially reasonable terms, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our ordinary shares or ADSs and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs and our ordinary shares to decline. The sale of additional equity or convertible securities would dilute all of our existing shareholders and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any of our product candidates, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to the Development and Clinical Testing of Our Product Candidates </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our DARPin platform to identify and develop product candidates. If we or our collaborators are unable to successfully develop and commercialize product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">candidates based on our platforms or experience significant delays in doing so, our business may be harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are heavily dependent on the success of our DARPin platform technology and the product candidates currently in our core programs. Our commercial prospects will be heavily dependent on product candidates identified and developed using our DARPin platform. To date, we have invested substantially all of our efforts and financial resources to identify, acquire intellectual property for, and develop our DARPin platform technology and our programs, including conducting preclinical studies and early-stage clinical trials, and providing general and administrative support for these operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We may not be successful in our efforts to further develop our DARPin platform technology and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, European Commission (granted on the basis of a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, or EMA and commonly referred to as EMA approval) or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">All of our product candidates are in preclinical or various stages of clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates, particularly MP0317, MP0533, abicipar and product candidates that we have licensed to our partners, including ensovibep, are prolonged, delayed or not commercially viable, we or our collaborators may be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we or our collaborators for such candidates must demonstrate through extensive preclinical studies and clinical trials that our products are safe, pure and potent or effective in humans. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Prior to obtaining approval to commercialize a product candidate in the United States or in other countries, we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Additionally, clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to obtain regulatory approval to commence a trial; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to obtain institutional review board, or IRB, or ethics committee approval at each site; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or failure to recruit suitable patients to participate in a trial; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding new clinical trial sites; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities of product candidate for use in clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party actions claiming infringement by our product candidates in clinical trials and obtaining injunctions interfering with our progress; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or tolerability concerns could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower than anticipated retention rates of patients and volunteers in clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in establishing the appropriate dosage levels in clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality or stability of the product candidate falling below acceptable standards.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted or ethics committees, by the Data Review Committee, or DRC, or Data Safety Monitoring Board, or DSMB, for such trial or by the EMA, the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the EMA, the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class to which our product candidates belong, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, we have faced and may face in the future bioburden during drug substance production campaigns or particles in drug product preparations at our CMOs which led or may lead to regulatory actions, including from the FDA. While we and our partners endeavor to maintain appropriate backup supply with respect to our product candidates, and not all such bioburden or particles result in regulatory action or delays, we cannot assure that any such issues would not result in delays in our clinical trials or product development or other adverse impacts on our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates being stopped early. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials must be conducted in accordance with the FDA, the EMA and other applicable regulatory authorities' legal requirements and regulations, and are subject to oversight by these governmental agencies, IRBs at the medical institutions where the clinical trials are conducted or ethics committees. In addition, clinical trials must be conducted with supplies of our product candidates produced under cGMP requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with GCP requirements. To the extent our collaborators or the CROs or investigators fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, conducting clinical trials in multiple countries presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with adhering to GCP, regulations and other foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, future clinical trials that could be conducted in countries outside Switzerland, the European Union and the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-European Union and non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our platform to build a pipeline of product candidates with commercial value.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our platform to build a pipeline of product candidates and progress these product candidates through clinical development. So far none of the product candidates originating from our platform has received marketing approval from the FDA or other regulatory authorities. The scientific discoveries that form the basis for our efforts to discover and develop targeted oncology therapeutic candidates for cancer patients are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. There can be no assurance that any development problems we may experience in the future related to our platform will not cause significant delays or unanticipated costs or that such development problems can be solved. Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Preclinical drug development is uncertain. Some or all of our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to obtain FDA or EMA approval to market a new pharmaceutical or biological product we must demonstrate proof of safety, purity and potency or efficacy in humans. To meet these requirements we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned Investigational New Drug application, or IND, in the United States, or a Clinical Trial Authorization Application, or CTA, in Europe. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or EMA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of these product candidates. Thus, we cannot be sure that we will be able to submit INDs or CTAs for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or CTAs will result in the FDA or EMA allowing clinical trials to begin. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per product candidate. Delays associated with product candidates for which we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. We may encounter similar or different safety issues in this trial or our other clinical trials in the future. Moreover, we may continue to be affected by delays associated with the preclinical testing and studies of certain product candidates conducted by our potential partners over which we have no control. The commencement and rate of completion of preclinical studies and studies for a product candidate may be delayed by many factors, including, for example:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching a consensus with regulatory agencies on study design; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or EMA not allowing us to rely on previous findings of safety and efficacy for other similar but approved products and published scientific literature.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, even if clinical trials do begin for our preclinical programs, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate sufficient safety, purity and potency or efficacy to obtain the requisite regulatory approvals for any of our product candidates or product candidates employing our technology. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Positive results from early preclinical studies of our product candidates would not necessarily be predictive of the results of later preclinical studies and any ongoing or future clinical trials of our product candidates. If we were to achieve positive results from preclinical studies, but were unable to then replicate those positive results in our later preclinical studies and ongoing future clinical trials, we might be unable to successfully develop, obtain regulatory or marketing approval for and commercialize our product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any positive results from our preclinical studies of our product candidates may not necessarily be predictive of the results from required later preclinical studies and clinical trials, and there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. For example, while we have observed positive biological activity in patient samples following administration of initial doses in the MP0317 Phase 1 clinical trial, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">there can be no assurance that such biological activity will be similarly observed and maintained following administration of additional doses or any drop in biological activity could be overcome with additional development regarding more frequent dosing regimens. Similarly, even if we are able to complete our planned preclinical studies or any future clinical trials of our product candidates according to our current development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. In addition, positive results in later stage clinical trials of one of our product candidates in an indication may not be predictive of the safety or efficacy of our other product candidates in other indications, even if they employ a similar mechanism of action. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. For example, our therapeutics in oncology, ophthalmology and virology has in the past and may in the future result in the creation of anti-drug antibodies that can neutralize the effects of the therapeutic, require that higher doses be used to obtain a therapeutic effect or cause adverse events. Whether anti-drug antibodies will be created and how they react can often not be predicted from nonclinical or even clinical studies, and their detection or appearance can be delayed. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Some of our product candidates utilize a novel mechanism of action which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some of our product candidates, such as MP0317 and MP0533, the lead product candidates from our oncology program, utilize novel mechanisms of action which may result in greater research and development expenses, regulatory and development or CMC issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#8217; lack of experience with the novel mechanisms of action. The novelty of our mechanism of action may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanisms of action also means that fewer people are trained in or experienced with product candidates of such type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. Any such events could adversely impact our business prospects, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could harm our product development strategy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As one of the key elements of our clinical development strategy, we seek to identify patient subsets within a disease category who may derive selective and meaningful benefit from the product candidates we are developing. In collaboration with partners, we may develop companion diagnostics to help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. The FDA generally expects contemporaneous regulatory approvals of the companion diagnostic and the therapeutic product. We do not develop companion diagnostics internally and thus we are dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining regulatory approval for these companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, our collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our products. In addition, the diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical trials may change as more patient data become available. Preliminary or interim data from our clinical trials are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary and interim data should be viewed with caution until the final data are available. Adverse changes in the final data compared to the interim data could significantly harm our business prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the preliminary and interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Because the number of patients in certain of our clinical trials is small, the results from such trials may be less reliable than results achieved in larger clinical trials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A study design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, thus making the study results less reliable than studies with a larger number of subjects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If side effects are identified during the development of our product candidates or following approval, if any, we may need to abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or other comparable foreign authorities. While our preclinical and clinical studies for our product candidates to date have generally been well tolerated from a risk-benefit perspective, the results from ongoing and future trials may not support this conclusion. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The results of future clinical studies may show that our product candidates cause undesirable or unacceptable side effects or even death. In such an event, our trials could be suspended or terminated and the FDA, the EMA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our prospects significantly. Further, because all of our product candidates and preclinical programs are based on our DARPin technology, any adverse safety or efficacy findings related to any product candidate or preclinical program may adversely impact the viability of our other product candidates or preclinical programs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, if any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products and require us to take our approved product off the market; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">regulatory authorities may require additional clinical trials;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If any of our product candidates has negative side effects, public perception of our DARPin platform and commercial opportunities for all of our current and future product candidates could be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverse side effects that may be caused by any of our product candidates could negatively impact the public perception of and commercial opportunities for all of our product candidates. The clinical and commercial success of our product candidates will depend in part on the absence of negative side effects caused by our product candidates. Even if an adverse side effect that results from one of our product candidates is unlikely to occur in our other product candidates, all of our product candidates could be adversely affected because the negative side effect may be perceived to be a likely side effect of all of our product candidates. In the clinical trials performed by AbbVie for abicipar in wet AMD, for example, ocular inflammation has been reported as an undesirable side effect. In June 2020, the FDA sent a CRL to AbbVie stating that ocular inflammation results in an unfavorable benefit-risk ratio in the treatment of nAMD. However unlikely it is that ocular inflammation will be a side effect of our other product candidates in indications outside of ophthalmology, the public may perceive our DARPin technology or our product candidates to pose a heightened risk of inflammation, thus negatively affecting the commercial opportunities of our current and future product candidates. These adverse events may negatively affect the perception of the DARPin technology platform, the commercial opportunity for our product candidates or cause us to suspend clinical trials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The market for pharmaceutical products is highly competitive. Our competitors include many established pharmaceutical companies, biotechnology companies, universities and other research or commercial institutions, many of which have substantially greater financial, research and development resources than us. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. Smaller and early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, the development of our products. The fields in which we operate are characterized by rapid technological change and innovation. There can be no assurance that our competitors are not currently developing, or will not in the future develop, technologies and products that are equally or more effective or are more economically attractive as any of our current or future technology or product. Competing products or technology platforms may gain faster or greater market acceptance than our products or technology platform and medical advances or rapid technological development by competitors may result in our product candidates or technology platforms becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. Additionally, certain of our product candidates may be administered in combination with approved pharmaceutical products. Our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ability to develop and ultimately commercialize our product candidates used in combination with other therapies will depend on our ability to access these drugs on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a sufficient supply of these drugs on commercially reasonable terms or at all. If we, our product candidates or our technology platforms do not compete effectively, it may have an adverse effect on our business and results of operation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We depend on enrollment of patients in our clinical trials for our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business could be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors, including the size and nature of the patient population, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating, and clinicians' and patients' perceptions as to the potential advantages of the drug being studied in relation to other available therapies. Since some of our product candidates could be focused on addressing sub-groups of cancer patients, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Furthermore, if the actual number of patients with these pathologies is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our drug candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of one of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, our ability to successfully initiate, enroll and complete clinical trials in foreign countries is subject to numerous risks unique to conducting business in foreign countries, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards for the conduct of clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in identifying and partnering with qualified local consultants, physicians and partners; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology research and products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">candidates by us and our corporate collaborators in clinical trials, and the potential sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies, our corporate collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could adversely affect the market for our product candidates or any prospects for commercialization of our product candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products due to negative public perception and injury to our reputation; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend or settle the related litigation; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management's time and our resources; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues from product sales; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to commercialize any of our product candidates, if approved. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although we maintain adequate clinical trial insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. Should any of the events described above occur, this could have an adverse effect on our business and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We conduct clinical trials for our product candidates outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We also conduct clinical trials outside the United States, including in Europe and are likely to continue to do so in these or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and medical practice; (ii) the trials were performed by clinical investigators of recognized competence and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable but typically takes many years, if obtained at all, following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate or product candidates licensed to our partners and it is possible that none of such existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including the size of our clinical trials or the doses tested; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that a product candidate is safe, pure and potent or effective for its proposed indication; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials or may require us to test additional dose regimens of our product candidates; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License Application, or BLA, to the FDA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business. The FDA, the EMA and other comparable foreign authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We or our partners may seek fast-track designation for some or all of our product candidates, but we may not receive such designation, and even if we do, it may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that such product candidates will receive marketing approval. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We or our partners may seek fast-track designation and review for some or all of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition or disease, and nonclinical or clinical data demonstrate the potential to address an unmet medical need, the product may qualify for FDA fast track designation, for which sponsors must apply. The FDA has broad discretion whether or not to grant this designation. Thus, even if we or our collaborators believe a particular product candidate is eligible for this designation, such as we received for ensovibep in June 2021, the FDA may decide not to grant it. Moreover, even if we do receive fast track designation, we or our collaborators may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from the clinical development program.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the FDA, the EMA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, recordkeeping, exporting and importing for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA, the EMA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">negative impact to our reputation; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label based on the physician&#8217;s independent medical judgement. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our product candidates are classified as biologics in the United States and, therefore, can only be sold if we obtain a BLA from the FDA. The holder of a BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of a BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Failure to comply with a BLA or any other ongoing regulatory obligation may result in suspension of approval to manufacture or distribute the relevant product, as well as fines or imprisonment for violations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we or one of our distributors, licensees or co-marketers are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or in other countries. For example, the policies and executive actions of the Biden administration may impact our business and industry. It is difficult to predict how these policies and executive actions will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these policies or executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular compounds, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for our lead product candidates, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, the European Union and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Among the provisions of the ACA of importance to our potential product candidates are the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage plans; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding the types of entities eligible for the 340B drug discount program; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing the Medicare Part D coverage gap discount program, which requires manufacturers to now provide 70% point-of-sale-discount off the negotiated price of applicable products to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient products to be covered under Medicare Part D; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare and Medicaid Innovation within Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription product spending.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011, among other things, includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect until 2031 unless additional U.S. Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. Further, the Biden administration released an additional executed order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. No legislation or administrative actions have been finalized to implement these principles. It is unclear whether these or similar policy initiatives will be implemented in the future. In addition, Congress is considering additional health reform measures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to healthcare laws, regulation and enforcement. Our failure to comply with these laws could harm our results of operations and financial conditions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, our current and future operations may be directly, or indirectly through our relationships with healthcare providers, healthcare institutions, patients, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws impact, among other things, our proposed sales, marketing and education programs and constrain our business and financial arrangements and relationships with third-party payors, healthcare professionals and healthcare institutions who participate in our clinical research programs, healthcare professionals and others who recommend, purchase, or provide our approved products, and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including, without limitation, the civil False Claims Act (which can be enforced through "qui tam," or whistleblower actions, by private citizens on behalf of the federal government), which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent or for knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, and as amended again by the Final HIPAA Omnibus Rule, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by certain health plans, healthcare clearinghouses and healthcare providers, known as covered entities, as well as their business associates that perform certain services involving the use, disclosure or transmission of individually identifiable health information for or on behalf of a covered entity, and their covered subcontractors; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">the U.S. federal physician payment transparency legislation, commonly referred to as Physician Payments Sunshine Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children's Health Insurance Program to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities, state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">European and other foreign law equivalents of each of the above laws, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid or comparable foreign programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The risk of us being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. For example, the definition of the &#8220;remuneration&#8221; under the U.S. federal Anti-Kickback Statute has been interpreted to include anything of value. Further, courts have found that if &#8220;one purpose&#8221; of remuneration is to induce referrals, the U.S. federal Anti-Kickback Statute is violated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, recent healthcare reform legislation has strengthened federal and state healthcare fraud and abuse laws. For example, the ACA amends the intent requirement of the U.S. federal Anti-Kickback Statute and criminal healthcare fraud statutes to clarify that liability under these statutes does not require a person or entity to have actual knowledge of the statutes or a specific intent to violate them in order to have committed a violation. Moreover, the ACA provides that the government may assert that a claim that includes items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Because of the breadth of these laws </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The availability of coverage and adequate reimbursement by third-party payors, including governmental healthcare programs such as Medicare and Medicaid, private health insurers and managed care organizations, is essential for most patients to be able to afford products such as our product candidates, assuming approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by third-party payors will have an effect on our ability to successfully commercialize, and attract additional collaboration partners to invest in the development of our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidate and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidate, pricing of existing drugs may limit the amount we will be able to charge for our product candidate. Third-party payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If coverage and reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on products that we may develop. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is significant uncertainty related to the third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the European Union, the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The future commercial success of our product candidates will depend on the degree of market acceptance of our potential products among physicians, patients, healthcare payors and the medical community. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our product candidates are at varying stages of development and we may never have a product that is commercially successful. To date, we have no product authorized for marketing. Our lead product candidates are in the relatively early stages of clinical development. Our lead product candidates will require further clinical investigation, regulatory review, significant marketing efforts and substantial investment before they can provide us with any revenues. Furthermore, if and when available on the market, our products may not achieve an adequate level of acceptance by physicians, patients and the medical community, and we may not become profitable. If our products are not accepted, we may need to increase our efforts to educate the medical community and third-party payors on the benefits of our products, which may require significant resources and may never be successful. Market acceptance of our future products by physicians, patients and healthcare payors will depend on a number of factors, many of which are beyond our control, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the wording of the product label; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care as well as recommendations from relevant national and/or international associations for the targeted indications for any product candidate; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales, marketing and distribution support; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, patients and healthcare payors of each product as safe and effective; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience, ease of use, ease of administration and other perceived advantages over alternative products;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of coverage and adequate reimbursement from third-party payors and the willingness of patients to pay out-of-pocket in the absence of adequate reimbursement; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of adverse events or publicity; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment with our products in relation to alternative treatments; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which products are approved for inclusion and reimbursed on formularies of hospitals and managed care organizations; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our products are designated in the label, under physician treatment guidelines or under reimbursement guidelines as a first-line, second-line, third-line or last-line therapy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If our product candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched. Furthermore, even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues. In addition, we are entitled to royalties on future commercial sales of ensovibep made by or on behalf of Novartis in certain territories but have agreed to forgo royalties in other territories, including lower income countries; if our product candidates are commercialized more largely </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in territories for which we have agreed to forgo royalties, this could have a material adverse impact on our revenues and financial results. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our products on our own or together with suitable collaboration partners. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of pharmaceutical products. To achieve commercial success for any approved product, we must develop or acquire a sales and marketing organization, outsource these functions to third parties or enter into collaboration or license arrangements with third parties. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the extent possible, we may establish our own sales and marketing capabilities and promote our product candidates if and when regulatory approval has been obtained in the major European Union countries and the United States for certain of our product candidates. There are risks involved should we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. Even if we establish sales and marketing capabilities, we may fail to launch or market our products effectively since we have no experience in the sales and marketing of pharmaceutical products. In addition, recruiting and training a sales force is expensive and time consuming and could delay any product launch. In the event that any such launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of marketing and promotion above those anticipated by us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues or profitability could be lower than if we were to market and sell any products that we develop ourselves. Such collaborative arrangements may place the commercialization of our products outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator's willingness or ability to complete its obligations, and our obligations under our arrangements, may be adversely affected by business combinations or significant changes in our collaborator's business strategy. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention to sell and market our products effectively. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our products, which in turn would have a material adverse effect on our business, prospects, financial condition and results of operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to U.S. Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The European Union provides opportunities for data and market exclusivity related to marketing authorizations. Upon receiving a marketing authorization, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until 10 years have elapsed from the initial marketing authorization of the reference product in the European Union. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We also believe that our product candidates in the EEA should benefit from this data and market exclusivity. As with the U.S., however, if competitors obtain marketing authorization for their biosimilar products, our products may become subject to competition from these biosimilars, with the attendant competitive pressure and consequences.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates or any future product candidates may be delayed, and our business will be harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For planning purposes, we estimate the timing of achieving various scientific, clinical, regulatory, and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of clinical trials, receipt of regulatory approval, or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, which may cause the timing of achieving the milestones to vary considerably from our estimates, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our available capital resources or capital constraints we experience;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress, costs, and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of approvals by the FDA, EMA and comparable foreign regulatory authorities, and the timing thereof;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">other actions, decisions, or rules issued by regulators;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to access sufficient, reliable, and affordable supplies of materials used in the manufacture of our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts of our collaborators with respect to the commercialization of our approved products, if any; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the securing of, costs related to, and timing issues associated with, commercial product manufacturing, as well as sales and marketing activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of our current or any future product candidates may be delayed, and our business, results of operations, financial condition, and prospects may be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Nearly all aspects of our activities are subject to substantial regulation. No assurance can be given that any of our product candidates will fulfill regulatory compliance. Failure to comply with such regulations could result in delays, suspension, refusals and withdrawal of approvals, as well as fines. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The international biopharmaceutical and medical technology industry is highly regulated by the FDA, the EMA and other comparable foreign authorities and by other national or supra-national regulatory authorities that impose substantial requirements covering nearly all aspects of our activities notably on research and development, manufacturing, preclinical tests, clinical trials, labeling, marketing, sales, storage, record keeping, promotion and pricing of our product candidates. Such regulation is further subject to regular review by the FDA, the EMA and other comparable foreign authorities which may result in changes in applicable regulation. If we do not comply with one or more of these requirements in a timely manner, or at all, our product development could experience significant delays as a result of the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FDA, the EMA or other comparable regulatory authorities recommending non-approval or restrictions on approval of a product candidate, leading to an inability to successfully commercialize any of our product candidates, which would materially harm our business. Any failure of any of our product candidates in clinical studies or to receive regulatory approval could have a material adverse effect on our business, results of operations and financial condition. If any of our product candidates fails to obtain approval on the basis of any applicable condensed regulatory approval process, this will prevent such product candidate from obtaining approval in a shortened time frame, or at all, resulting in increased expenses which would materially harm our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance with requirements laid down by local regulatory authorities is necessary in each country where we, or any of our partners or licensees, conduct said activities in whole or in part. Local regulatory authorities notably include the EMA and the FDA. In order to market our future products in regions such as the European Economic Area, United States of America, Asia Pacific and many other foreign jurisdictions, we must obtain separate regulatory approvals. The approval procedures vary among countries and can require additional clinical testing, and the time required to obtain approval may differ from that required to obtain for example FDA or EMA approval. Moreover, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EMA does not ensure approval by the comparable foreign authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA or EMA. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There can be no assurance that our product candidates will fulfil the criteria required to obtain necessary regulatory approval to access the market. Also, at this time, we cannot guarantee or know the exact nature, precise timing and detailed costs of the efforts that will be necessary to complete the remainder of the development of our research programs and products candidates. Each of the FDA, the EMA and other comparable foreign authorities may impose its own requirements, may discontinue an approval or revoke a license, may refuse to grant approval, or may require additional data before granting approval, notwithstanding that approval may have been granted by the FDA, the EMA or one or more other comparable foreign authority. The FDA, the EMA or other comparable foreign authorities may also approve a product candidate for fewer or more limited indications or patient sub-segments than requested or may grant approval subject to the performance of post-marketing studies. The EMA's, the FDA's or other regulatory authority's approval may be delayed, limited or denied for a number of reasons, most of which are beyond our control. Such reasons could include, among others, the production process or site not meeting the applicable requirements for the manufacture of regulated products, or the products not meeting applicable requirements for safety, purity or potency, or efficacy, during the clinical development stage or after marketing. No assurance can be given that clinical trials will be approved the FDA, the EMA or other comparable foreign authorities or that products will be approved for marketing by such regulatory authorities in any pre-determined indication or intended use. Any of the FDA, the EMA and other comparable foreign authorities may disagree with our interpretation of data submitted for their review. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We and our collaborative partners are, or may become subject to, numerous ongoing other regulatory obligations, such as data protection, environmental, health and safety laws and restrictions on the experimental use of animals. The costs of compliance with such applicable regulations, requirements or guidelines could be substantial, and failure to comply could result in sanctions, including fines, injunctions, civil penalties, denial of applications for marketing authorization of our products, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly increase our or our collaborative partners' costs or delay the development and commercialization of our product candidates. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new or existing product candidates from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our professional liability insurance and our accident insurance, which cover for costs and expenses we may incur due to environmental liability that may be asserted against us or due to injuries to our employees resulting from the use of hazardous materials, may not provide adequate coverage against potential liabilities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our product candidates or products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products, if approved. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and negligent conduct or unauthorized activities that violate: the regulations of the FDA, the EMA and other comparable foreign authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our high dependency on public perception of our products may negatively influence the success of these products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of the safety and quality of our products. We could be adversely affected if we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were subject to negative publicity or if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perception, any adverse publicity associated with illness or other adverse effects resulting from patients' use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our business and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future adverse events in research into the oncology and virology fields that we focus our research efforts on, or the biopharmaceutical industry more generally, could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for our product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully identify, develop and commercialize additional products or product candidates could impair our ability to grow. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our product candidates in our current pipeline, a key element of our long-term growth strategy is to develop and market additional product candidates. Because we have limited managerial resources, research programs to identify product candidates will require substantial additional technical, financial and human resources, whether or not any product candidates are ultimately identified. The success of this strategy depends partly upon our ability to identify, select and develop promising product candidates and products. Our technology platforms may fail to discover and to generate additional product candidates that are suitable for further development. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics that indicate that it is unlikely to be a product that will receive approval by the FDA, the EMA and other comparable foreign regulatory authorities and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our DARPin technology approach, we may not be able to obtain product or collaboration revenues in future periods, which would adversely affect our business and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular DARPin product candidate or indication and fail to capitalize on DARPin product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and DARPin product candidates for specific indications, mode of actions or targets. As a result, we may forego or delay pursuit of opportunities with other DARPin product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and DARPin product candidates for specific indications may not yield any commercially viable products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we do not accurately evaluate the commercial potential or target market for a particular DARPin product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Service or supply failures, or other failures, business interruptions or other disasters affecting the manufacturing facilities of any party participating in the supply chain would adversely affect our ability to supply our products, if approved. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our product candidates are biologics and require processing steps that are more difficult than those required for most chemical pharmaceuticals. Accordingly, multiple steps are needed to control the manufacturing processes. Problems with these manufacturing processes, even minor deviations from the normal process or from the materials used in the manufacturing process, which may not be detectable by us in a timely manner, could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims and insufficient inventory. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Also, certain raw materials or other products necessary for the manufacture and formulation of our product candidates, some of which are difficult to source, are provided by single-source unaffiliated third-party suppliers. The COVID-19 pandemic has caused delays and difficulties in the timely shipping and delivery of supplies, samples and products required for our clinical trials. In addition, we rely on certain third parties to perform filling, finishing, distribution, laboratory testing and other services related to the manufacture of our product candidates, and to supply various raw materials and other products. We would be unable to obtain these raw materials, other products, or services for an indeterminate period of time if any of these third parties were to cease or interrupt production or otherwise fail to supply these materials, products, or services to us for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contamination, business interruptions, or labor shortages or disputes. In any such circumstances, we may not be able to engage a backup or alternative supplier or service provider in a timely manner or at all. This, in turn, could materially and adversely affect our ability to supply product candidates, which could materially and adversely affect our business and future prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may develop our DARPin platform and other current or future product candidates, in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may develop our DARPin platform and other current or future product candidates in combination with one or more currently approved therapies. Even if any product candidates we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our DARPin platform or any other current or future product candidates or that safety, efficacy, manufacturing, or supply issues could arise with these existing therapies. This could result in our own product candidates being removed from the market or being less successful commercially.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may also evaluate our DARPin platform or any other current or future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell our DARPin product candidates or any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. These unapproved therapies may face the same risks described with respect to our product candidates, including the emergence of adverse events and delays in their clinical trials. If the FDA or comparable foreign regulatory authorities do not approve these other therapies or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the therapies we choose to evaluate in combination with our DARPin product candidates or any other product candidate we develop, we may be unable to obtain approval of or market our DARPin product candidates or any other product candidate we develop.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (commonly known as processing) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf. In the United States, numerous federal and state laws, rules and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws that govern the collection, processing of personal information, including health-related personal information, could apply to our operations or the operations of our collaborators. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we may be subject to civil, criminal, and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Additionally, the California Consumer Privacy Act, or CCPA, imposes obligations on covered businesses. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation) and includes a private right of action for certain data breaches. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition the California Privacy Rights Act of 2020, or CPRA, effective January 1, 2023, expands the CCPA, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states have enacted data privacy laws as well. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which become effective in 2023. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. Data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s GDPR, or UK GDPR, impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, companies may face private litigation related to processing of personal data brought not only by individuals but also by classes of data subjects or consumer protection organizations authorized at law to represent their interests. Additionally, EU member states are also able to legislate separately on health and genetic data, and we must comply with these local laws where we operate. The Swiss Federal Act on Data Protection, or DPA, also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland. The DPA has been revised, and the revised version and its revised ordinances will enter into force September 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal data transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. The European Commission released a set of &#8220;Standard Contractual Clauses,&#8221; or SCCs, that are designed to be a valid mechanism to facilitate personal data transfers out of the EEA to these jurisdictions. Currently, these SCCs are a valid mechanism to transfer personal data outside of the EEA, but this mechanism is subject to legal challenge. Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. In addition, Switzerland and the UK similarly restrict personal data transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties that are subject to such cross-border data transfer or localization laws; or requiring us to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expense.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">require our customers to impose specific contractual restrictions on their service providers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We publish privacy policies, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity, additional reporting requirements and/or oversight, bans on processing personal data, orders to destroy or not use personal data, imprisonment of company officials. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may limit our ability to collect, use and disclose the information. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to interruptions or stoppages in our business operations (including, as relevant, clinical trials), inability to process personal data or to operate in certain jurisdictions, limited ability to develop or commercialize our products, expenditure of time and resources to defend any claim or inquiry, adverse publicity, or revision or restructuring of our operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We are subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the trade control laws. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">There is no assurance that we will be effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Swiss anti-corruption laws </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">or other legal requirements, including trade control laws. If we are not in compliance with the FCPA, the Swiss anti-corruption laws and other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, the Swiss anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In addition, changes in our products and product candidates or changes in applicable export or import laws and regulations may create delays in the introduction or provision of our products and product candidates in other jurisdictions, prevent others from using our products and product candidates or, in some cases, prevent the export or import of our products and product candidates to certain countries, governments or persons altogether. Any limitation on our ability to export or provide our products and product candidates could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Moreover, a growing number of investors, regulators, self-regulatory organizations and other stakeholders have expressed an interest in setting Environmental, Social and Corporate Governance, or ESG, goals and requiring the provision of new and more robust disclosure of steps taken to implement such goals. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">related legislative landscape in the EU has been evolving accordingly. For example, in December 2022, Directive No 2464/2022 on Corporate Sustainability Reporting, or CSRD, was adopted and entered into force on 5 January 2023. This new Directive strengthens the rules governing the social and environmental information that companies are required to report. The new rules expand the number of companies that are required to report ESG information and broaden the amount of ESG information that companies must report. The CSRD also requires a "double materiality" analysis. This means that companies will have to report on how sustainability issues might create financial risks for the company and on the company's own impacts on people and the environment. The CSRD will apply to; large EU companies, EU parents of a "large group", and to listed EU small or medium-sized companies. It will also apply to non-EU companies that have a certain threshold of EU-generated turnover and an EU branch or subsidiary. The specific information that will be subject to reporting will be detailed in the European Sustainability Reporting Standards, or ESRS to be adopted by the European Commission. The first set ESRS are expected be adopted by June 30, 2023. Companies subject to the CSRD will be required to fulfil their reporting obligations in accordance with a staggered timeline depending on the category of company. The first reports are expected in 2025 for the 2024 financial year. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In response to new ESG initiatives and regulations we may voluntarily elect, or be required, to adopt strategies, policies, or procedures related to ESG matters. Reporting on ESG goals and objectives may cause us to expend significant capital and human resources, and could divert management&#8217;s attention from central operational matters. Reports could also lead to the disclosure of information that which may have a negative impact on our operations and reputation which may lead to additional exposure. Failure to accurately comply with any ESG reporting obligations may result in enforcement actions, sanctions, reputational harm or private litigation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs mandated by us or by our partners, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the EMA and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we, our investigators or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We also face the risk of potential infringement, unauthorized disclosure, misappropriation or other violation of our intellectual property by our third party contractors or CROs, which may reduce our trade secret protection and allow our potential competitors or other third parties to access and exploit our proprietary technology. Our third party contractors or CROs also may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property-related proceedings that could jeopardize or invalidate our proprietary information and intellectual property. For more information regarding our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs or investigators or to do so on commercially reasonable terms. Switching or adding additional CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We rely and will continue to rely on collaborative partners regarding the development of our research programs and product candidates. If we are not able to maintain our current relationships or enter into new strategic relationships our business, financial condition, commercialization prospects and results of operations may be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are, and expect to continue to be, dependent on partnerships with partners relating to the development and commercialization of our existing and future research programs and product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We currently have collaborative research relationships with the University of Bern for MP0533 and with Novartis Pharma AG, or Novartis, primarily for radioligand therapies. We have had and will continue to have discussions on potential partnering opportunities with various pharmaceutical companies. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our products could change and our costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual property rights and other proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these intellectual property and other proprietary rights.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our dependence on collaborative partners subjects us to a number of risks, including, but not limited to, the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that the collaboration partner devotes to our research programs and product candidates; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">for collaboration agreements where we are solely or partially responsible for funding development expenses through a defined milestone event, the payments we receive from the collaboration partner may not be sufficient to cover the expenses we have or would need to incur in order to achieve that milestone event;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to relinquish significant rights, including intellectual property or other proprietary rights, marketing and distribution rights; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated payments under any partnership agreement (e.g., royalty payments for licensed products) may not materialize; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we rely on the information and data received from third parties regarding their research programs and product candidates and will not have control of the process conducted by the third party in gathering and composing such data and information. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">if rights to develop and commercialize our product candidates subject to collaborations revert to us for any reason (for example MP0310 and abicipar), we may not have sufficient financial resources to develop such product candidates, which may result in us failing to recognize any value from our investments in developing such product candidates and/or requiring us to divert our resources elsewhere;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborative partner may decide not to pursue, or discontinue the collaborative development of, our product candidates; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborative partner may develop a competing product either by itself or in collaboration with others, including one or more of our competitors; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborative partners' willingness or ability to complete their obligations under our partnership arrangements may be adversely affected by business combinations or significant changes in a collaborative partner's business strategy; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in, or increases in the costs of, the development of our research programs and product candidates due to the termination or expiration of collaborative research and development arrangements; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have disagreements with collaborative partners, including disagreements over proprietary rights, contract interpretation or the preferred course of development, that might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborative partners may not properly maintain, enforce or defend our intellectual property rights or other proprietary information or may such use proprietary information in such a way as to invite litigation or other intellectual property-related proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; or </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborative partners may infringe, misappropriate or otherwise violate the intellectual property or other proprietary rights of third parties, which may expose us to litigation and potential liability, and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">collaborators may also allege that we are liable for potential infringement, misappropriation or other violations of third-party intellectual property or proprietary rights during the research and development work for the collaboration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a partnership will depend, among other things, upon an assessment of the collaborator's resources and expertise, the terms and conditions of the proposed partnership and the proposed collaborator's evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of regulatory approval, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership regardless of the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a partnership could be more attractive than the one with us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third parties to manufacture our preclinical and clinical drug supplies and we intend to rely on third parties to provide us with required target material for developing and selecting product candidates as well as to produce commercial supplies of any approved product candidate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or capability internally to manufacture our product candidates for use in the conduct of our clinical studies or for commercial supply, if our products are approved. Instead, we rely on, and expect to continue to rely on CMOs. We currently rely mainly on a few CMOs for the manufacturing of our product candidate materials. Any replacement of our CMOs could require significant effort and expertise because there may be a limited number of qualified CMOs. Reliance on third-party providers may expose us to more risk than if we were to manufacture our product candidates ourselves. We are dependent on our CMOs for the production of our product candidates in accordance with relevant regulations (such as cGMP), which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Moreover, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting product development activities that could harm our competitive position.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we were to experience an unexpected delay in receiving required target material or loss of supply of or if any supplier were unable to meet our demand for any of our product candidates, we could experience delays in our research or planned clinical studies or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. Moreover, our suppliers are subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, would significantly delay our clinical studies and the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">commercialization of our products, if approved, which would adversely affect our business and results of operation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In complying with the manufacturing regulations of the FDA, the EMA and other comparable foreign authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against our CMOs and subsequently against us, including the seizure of products and shutting down of production. We and any of these third-party suppliers may also be subject to audits by the FDA, the EMA or other comparable foreign authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the products could suffer significant interruptions. For example, we have faced and may face in the future bioburden during drug substance production campaigns or particles in drug product preparations at our CMOs which led or may lead to regulatory actions, including from the FDA. While we and our partners endeavor to maintain appropriate backup supply with respect to our product candidates, and not all such bioburden or particles result in regulatory action or delays, we cannot assure that any such issues would not result in delays in our clinical trials or product development or other adverse impacts on our business. We face risks inherent in relying on our CMOs, as any disruption, such as a fire, natural hazards or vandalism at any such CMO could significantly interrupt our manufacturing capability. Our CMOs currently do not have alternative production plans in place or disaster-recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as the CMO builds or locates replacement facilities and seeks and obtains necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if at all. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The manufacturing of all of our product candidates requires using cells which are stored in a cell bank. We have one master cell bank for each product manufactured in accordance with cGMP. Working cell banks have not yet been manufactured. Half of each master cell bank is stored at a separate site so that in case of a catastrophic event at one site we believe sufficient vials of the master cell banks are left at the alternative storage site to continue manufacturing. We believe sufficient working cell banks could be produced from the vials of the master cell bank stored at a given site to assure product supply for the future. However, it is possible that we could lose multiple cell banks and have our manufacturing significantly impacted by the need to replace these cell banks, which could materially adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the product candidates we license to our collaboration partners. Consequently, our ability to inform our shareholders about the status of such product candidates, and to make informed operational and investment decisions about the product candidates to which we have retained development and commercialization rights, may be limited.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding the product candidates being developed and potentially commercialized by Novartis, including potentially material information about clinical trial design and execution, safety reports from clinical trials, spontaneous safety reports if the product is later approved and marketed, regulatory affairs, process development, manufacturing, marketing and other areas known by Novartis. In addition, we have confidentiality obligations under our agreement with Novartis. Thus, our ability to keep our shareholders informed about the status of product candidates under our collaboration will be limited by the degree to which Novartis keeps us informed and allows us to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disclose such information to the public. If Novartis fails to keep us informed about the clinical development and regulatory approval of our collaboration and product candidates licensed to it, we may make operational and investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our financial prospects are dependent upon the manufacture, development and marketing efforts of our licensees. Our licensees may act in their best interest rather than in our best interest, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We rely on our licensees to manufacture, fund and conduct the clinical development and commercialization of product candidates, and our licensees have complete control over such activities. Our ability to generate revenue in the near term will depend primarily on the successful development, regulatory approval, marketing and commercialization of product candidates by our licensees. Such success is subject to significant uncertainty, and we have limited control over the manufacturing processes of such product candidates as well as the resources, time and effort that licensees may devote to such product candidates. Any of several events or factors could have a material adverse effect on our ability to generate revenue from our licensee&#8217;s potential commercialization of product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, our licensees have the right to make decisions regarding the development and commercialization of product candidates under the collaborations without consulting us and may make decisions with which we do not agree. For example, in April 2022, Amgen, our collaboration partner for MP0310 (AMG 506), informed us of its decision to return global rights of MP0310 to us following a strategic pipeline review. Conflicts between our licensees and us may arise if there is a dispute about the progress of the clinical development of a product candidate, the achievement and payment of a milestone amount or the ownership of intellectual property developed during the course of our collaboration agreements. If any of our licenses terminate with our licensees, it may be necessary for us to assume responsibility at our own expense for the development of the applicable product candidates. In that event, we would likely be required to limit the size and scope of one or more of our programs or increase our expenditures and seek additional funding, which may not be available on acceptable terms or at all, which would materially adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and other intellectual property rights to protect our product candidates and the DARPin technology, the prosecution, grant, enforcement, defense and maintenance of which may be challenging and costly. Failure to obtain, maintain, enforce or protect these rights adequately could harm our ability to compete and impair our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for our product candidates, methods used to manufacture those products and methods for treating patients using those products, or on licensing in such rights. Failure to obtain, maintain, enforce, protect or extend adequate patent and other intellectual property rights could adversely affect our ability to develop and market our products and product candidates or pursue collaborations with partners for our product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We cannot be certain that patents will be issued or granted with respect to applications that are currently pending, or that issued or granted patents will not later be found to be invalid or unenforceable. The patent position of biopharmaceutical companies is generally uncertain because it involves complex legal and factual considerations, and has been the subject of much litigation in recent years. The standards applied by the United States Patent and Trademark Office, or USPTO, the European Patent Office, or EPO, and other foreign patent offices in granting patents are not always identical or applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">scope of claims allowable in biopharmaceutical patents. Consequently, patents may not issue from our pending patent applications or, if issued, patents may vary in scope depending on the jurisdiction. As such, we do not know the degree of future protection that we will have on our proprietary products and technology in the various jurisdictions. The scope of patent protection that the USPTO, the EPO and other foreign patent offices will grant with respect to the DARPin product candidates in our product pipeline is uncertain. It is possible that the USPTO, the EPO and other foreign patent offices will not allow broad claims that cover DARPin product candidates closely related to our product candidates or to the specific protein building blocks. As a result, upon receipt of EMA or FDA approval, competitors may be free to market other products almost identical to ours, thereby decreasing our market share. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, time-consuming and complex, and we and our current or future licensors, licensees or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaboration partners will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection for them. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees' or collaboration partners&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Moreover, in some circumstances, we may not have the right to control the preparation, filing, prosecution and maintenance of the licensed patent applications or other intellectual property, or to maintain the patents, or may not have the first right to enforce the intellectual property. We may need to enter into new license or royalty agreements, covering technology that we license from or license to third parties or have developed in collaboration with our collaboration partners and are reliant on patent procurement activities of our licensors, licensees or collaboration partners. Therefore, we may not be able to adequately influence the patent prosecution or enforcement of these patents and patent applications, or prevent inadvertent lapses of coverage due to failure to pay maintenance fees and we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business and that does not compromise the patent rights. If our current or future licensors, licensees or collaboration partners fail to obtain, maintain, protect or enforce such patents and other intellectual property rights, such rights may be reduced or lost. If our licensors, licensees or collaboration partners are not fully cooperative or disagree with us as to the preparation, filing, prosecution, maintenance, defense or enforcement of any licensed patent rights, such patent rights could be compromised. The patent examination process may require us or our licensors, licensees or collaboration partners to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it may invalidate patents in whole or in part or prevent patents from issuing from pending patent applications. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate an opposition, interference, re-examination, post-grant review, inter partes review, nullification, revocation, derivation, or other actions in court or before patent offices challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed, invalidated, or held unenforceable. Such proceedings have a higher impact in the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">biopharmaceutical industry than in other industries, given that biopharmaceutical products are often protected by only one or few patents. Our and our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the practiced technology. An adverse determination in any such proceeding could reduce the scope of, invalidate, or render unenforceable our patent rights, and allow third parties to commercialize our technology or products and compete directly with us, without payment to us. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Even if our patent applications or those of our licensors, licensees or collaboration partners issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether any of our DARPin platform advances or product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications are confidential for a period of time after filing, and some remain so until issued. Therefore, we cannot be certain that we or our licensors, licensees or collaborators were the first to make the inventions claimed in any patent application, or were the first to file any patent application related to a product candidate. Furthermore, as to the United States, if third parties have filed such patent applications on or before March 15, 2013, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date, or if the other party is able to obtain a compulsory license. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, including generic versions of such products. Moreover, it is possible that some future patents and patent applications owned or in-licensed by us may be co-owned with third parties, including our collaboration partners and other third parties with whom we conduct research and development. If we are unable to obtain an exclusive license to any such third party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, it is possible that some future patents and patent applications owned or in-licensed by us may be subject to a reservation of rights by one or more third parties. For example, this may happen if the research resulting in certain of our owned or in-licensed patent rights and technology was funded in part </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may fail in enforcing our intellectual property rights and issued patents covering one or more of our product candidates or DARPin technology or our intellectual property rights and issued patents could be found invalid or unenforceable if challenged in court. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To protect our competitive position, we or our licensors or collaboration partners may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of our or our licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors' or collaboration partners&#8217; efforts, we or our licensors or collaboration partners may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the European Union and the United States. We may fail in enforcing our rights, in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or unenforceable. Such an adverse court ruling could allow third parties to commercialize our products or use our DARPin technology, and then compete directly with us, without payment to us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we or one of our licensors or collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, including our DARPin technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Third parties could also raise challenges to the validity of patent claims before administrative bodies in the United States, Europe or other foreign jurisdictions, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patent claims in such a way that they no longer cover our technology or DARPin platform, or any product candidates that we may develop. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. A claim for unenforceability could involve an allegation that someone connected with prosecution of the patent withheld relevant information from or made a misleading statement to the USPTO, the EPO or other patent offices during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our issued patents, for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">example, we cannot be certain that there is no invalidating prior art, of which we, our licensors or collaboration partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose part or all of the patent protection afforded by the affected patent. Such a loss of patent protection could have a material adverse impact on our business. Further, litigation could result in substantial costs and diversion of management resources, and reputational harm, regardless of the outcome, which could harm our business and financial results. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities and negative outcomes could result in adverse effects on our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to operate without infringing the patents and other proprietary intellectual property rights of third parties. This is generally referred to as having the &#8220;freedom to operate.&#8221; The biotechnology and pharmaceutical industries in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, companies producing therapeutics in the oncology and virology fields have employed intellectual property litigation as a means to gain an advantage over their competitors. As a result, we may be required to defend against claims of intellectual property infringement, misappropriation or other violation that may be asserted by third parties against us and, if the outcome of any such litigation is adverse to us, it may affect our ability to compete effectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products or elements thereof, our manufacture or uses relevant to our products or development plans, the targets of our product candidates, or other attributes of our product candidates or our technology. In such cases, we may not be in a position to develop or commercialize the applicable products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms, or at all. In the event that a relevant patent has not expired at the time of approval of such product candidate and the patent owner were to bring an infringement action against us, we may have to argue that our product, its manufacture, importation or use does not infringe, misappropriate or otherwise violate a valid claim of the patent in question. Alternatively, if we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would need to present clear and convincing evidence as to the invalidity of the patent's claims. There is no assurance that a court would find in our favor on questions of infringement or validity. In the event that a patent is successfully asserted against us such that the patent is found to be valid and enforceable and infringed by our product, unless we obtain a license to such a patent, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize our product. Similarly, the targets for certain of our product candidates have also been the subject of research by other companies, which have filed patent applications or own issued patents on aspects related to the targets or their uses. There can be no assurance that any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, if at all, and any such litigation would be costly and time-consuming. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is also possible that we failed to identify relevant patents or applications. For example, certain U.S. applications filed after November 29, 2000 that will not be filed outside the United States may remain </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">confidential until patents issue. In general, patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing from which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform technology could have been filed by others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to gain broad coverage in the areas in which we are active. Additionally, claims in pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third-party intellectual property right holders, including our competitors, may actively bring infringement, misappropriation or other claims against us. We may not be able to successfully settle or otherwise resolve such claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we fail in any such dispute, in addition to being forced to pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing, misappropriating or violating any third-party intellectual property rights. We might also be forced to redesign product candidates so that we no longer infringe, misappropriate or otherwise violate third-party intellectual property rights, which may result in significant cost or delay to us or be technically infeasible, or to seek a license to any such third-party intellectual property rights that we are found to infringe, misappropriate or otherwise violate, which license may not be available on commercially reasonable terms, or at all. Even if we or our licensors or collaboration partners obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaboration partners, and it could require us or our licensors or collaboration partners to make substantial royalty and other payments. In addition, we could be found liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a patent. Any of these events, even if we were to ultimately prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our involvement in litigation, and in any interference, derivation, reexamination, inter partes review, post grant review, opposition or other post-grant proceedings or other intellectual property proceedings inside and outside of the European Union or the United States, even if resolved in our favor, may cause us to incur significant expenses, distract our technical and management personnel from their normal responsibilities and cause substantial delays in marketing our products. In addition, there could be public announcements of the results of hearings, motions, other interim proceedings or developments, or of final verdicts and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on our share price. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaboration partners&#8217; patents and patent applications is challenged or threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, and we may not be successful in obtaining or maintaining additional necessary rights related to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We rely upon licenses to certain patent rights and other intellectual property from third parties that are important or necessary to the development of our product candidates. We may also need to obtain additional licenses to advance the development and commercialization of any product candidates we may develop. Additionally, we have in the past collaborated and may in the future collaborate with U.S. and/or European academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In some instances, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our applicable product candidate or program. Our current license and collaborations agreements also impose, and we expect that future agreements will likely impose various reporting, prosecution, diligence, fee payment, royalty and other obligations on us. If there is any conflict, dispute, disagreement or issue of non-performance between us and our licensing or collaboration partners regarding our rights or obligations under the agreements, including any such conflict, dispute or disagreement arising from our alleged failure to satisfy payment obligations under any such agreement, we may owe damages, the counterparty may have a right to terminate the affected agreement, and our and our licensees' ability to utilize the affected intellectual property in drug discovery and development efforts, and our ability to enter into collaboration or marketing agreements for an affected product candidate, may be adversely affected. Our business could also suffer if a licensor or collaborator fails to abide by the terms of the agreement, if any licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms or at all. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. For more information regarding our license and collaboration agreements, see &#8220;Item 4.B &#8212; Business&#8212;License and Collaboration Agreements.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our current or future licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our current or future licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. We may be unable to acquire or in-license, on reasonable terms or at all, any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If in the future we do undertake any acquisitions, the process of integrating an acquired business, technology, service, products or product candidates into our business may result in unforeseen operating difficulties and expenditures, including diversions of resources and management&#8217;s attention from our core business, or any acquired intellectual property may be subject to claims of invalidity or unenforceability or held to be invalid. In addition, we may fail to retain key executives and employees of the companies we acquire, which may reduce the value of the acquisition or give rise to additional integration costs. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing shareholders. Future acquisitions could also result in the incurrence of debt, actual or contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect our operating results. In addition, we may fail to realize the anticipated benefits of any acquisition. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks or names. We may not be able to protect or enforce our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have rights senior to ours, it could interfere with our use of our current trademarks throughout the world. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Act Amendments and similar non-U.S. legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest effective U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive medications, including biosimilar medications or generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, at least not long enough to recoup the costs incurred in developing our products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act and similar legislation in the European Union and several other relevant countries around the world. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product will be shortened and our competitors may be able to enter the market with competing products sooner than we expect, and our business, financial condition, results of operations, and prospects could be materially harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The base patents relating to the DARPin base technology we use to generate our DARPin product candidates expired in September 2021 (except for one patent in the United States), after which our competitors may use the technology claimed in such patents, which may materially adversely affect our business and competitive position.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The base patents that we had licensed from the University of Zurich in 2004 expired in September 2021 (except for one patent in the United States) and we terminated the license agreement effective October 2021. Our competitors may be able to utilize the technology claimed in such patents to develop product candidates that compete with ours. In addition, we have been exploring entering into a non-exclusive license with the University of Zurich for the remaining U.S. patent that will expire in August 2023 but there can be no assurance that we will enter into such license. If we do not enter into such non-exclusive license, a third party may obtain an exclusive license to the patent that will expire in August 2023. Any of these events could harm our reputation as being the leader in the DARPin technology, and could have an adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We enjoy only limited geographical protection with respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of our intellectual property rights. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States and the European Union. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States and the European Union, or from selling or importing products made using our inventions in and into all countries outside the United States and the European Union.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We often file our first patent application, or our priority filing, at the EPO or the USPTO. International applications under the Patent Cooperation Treaty, or PCT, are usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our product candidates may be marketed. We have so far not </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competitors may use our or our licensors&#8217; or collaboration partners&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors or collaboration partners have patent protection, but enforcement is not as strong as that in the United States and the European Union. These products may compete with our product candidates, and our and our licensors' or collaboration partners' patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and the European Union, and companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proceedings to defend or enforce our and our licensors' or collaboration partners' patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors' or collaboration partners' efforts and attention from other aspects of our business, could put our and our licensors' or collaboration partners' patents at risk of being invalidated or interpreted narrowly, could put our and our licensors' or collaboration partners' patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaboration partners. We or our licensors or collaboration partners may not prevail in any lawsuits that we or our licensors or collaboration partners initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. If we or our licensors or collaborators encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system and a new European patent court will likely become effective and start operations before the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the new Unified Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">changes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, a decree was adopted by the Russian government in March 2022 as a response to economic sanctions imposed by various other governments, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have a primary place of business or profit-making activities in the U.S. and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions protected by Russian patents in Russia or from manufacturing, selling, using or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property that are important to our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a party to agreements under which we are granted rights to intellectual property that are important to our business and we expect that we may need to enter into additional license agreements in the future. Under certain license agreements, we may not control the preparation, filing, prosecution or maintenance of the licensed intellectual property, or may not have the first right to enforce or defend the intellectual property. In those cases, we may not be able to adequately influence patent prosecution, enforcement or defense, or prevent inadvertent lapses of coverage due to failure to pay maintenance fees and we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business and that does not compromise the patent rights. Existing license agreements impose, and we expect that future license agreements will impose, various development obligations as well as other obligations, such as payment of royalties. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. The termination of any license agreements or failure to adequately protect such license agreements could prevent us from commercializing product candidates covered by the licensed intellectual property. For more information regarding our license and collaboration agreements, see &#8220;Business&#8212;License and Collaboration Agreements.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any current or future collaboration relationships; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is possible that we may be unable to obtain any necessary additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, including our DARPin product candidates, manufacturing methods or future methods or products resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds that are similar or substantially equivalent to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of third parties, including patents related to repeat protein technology, may have an adverse effect on our business. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our current or future licensors or strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have licensed. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our current or future licensors or strategic partners might not have been the first to file patent applications covering certain of our or their inventions. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our current or future patent applications will not lead to issued patents.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or license may not provide us with any competitive advantage, or may be held invalid or unenforceable, including as a result of legal challenges by our competitors. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of third parties without obtaining a proper license, rendering us susceptible to claims of infringement, misappropriation or other violation of such third parties&#8217; intellectual property rights; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional technologies that are patentable; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business; in particular, our product candidates may in the future be tested for new indications, and if one proves to be effective against a specific new indication, we may be confronted with existing patents covering such indication.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our success is heavily dependent on the extent of our intellectual property rights, particularly patents. Obtaining, defending and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the European Union, United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The Leahy-Smith America Invents Act, or the AIA, was enacted in the United States in September 2011, resulting in significant changes to the U.S. patent system. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For example, assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. As of March 16, 2013, under the AIA, the United States transitioned to a "first-to-file" system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. Therefore, a third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention even if we had made the invention before it was made by the third party. This will require us to be cognizant of the time from invention to filing of a patent application, and circumstances could prevent or dissuade us from promptly filing patent applications on our inventions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The AIA also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include changes that limit where a patentee may file a patent infringement suit and that allow third party submissions of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, and other applicable bodies in the European Union and other foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to defend and enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We consider proprietary trade secrets, confidential know-how and unpatented know-how to be important to our business and competitive position. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to protect. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors, CROs and advisors to enter into confidentiality agreements with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and, despite these efforts, any of these parties may unintentionally or willfully breach the agreements and use or disclose our confidential information to competitors, and such agreements may not provide an adequate remedy in the event of unauthorized disclosure or use of confidential information. Enforcing a claim that a third party illegally disclosed or misappropriated trade secrets or confidential know-how is expensive, time-consuming and unpredictable. In addition, the enforceability of confidentiality agreements and trade secrets may vary from jurisdiction to jurisdiction. Furthermore, if a third party lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such third party from using that technology or information to compete with us or from disclosing it to others, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to effectively maintain and protect trade secrets or confidential know-how could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors may be able to limit our use of our trade secrets or confidential know-how. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that we or our employees have infringed, misappropriated or otherwise violated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many of our consultants and employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these consultants and employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our consultants and employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these consultants and employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information, of any such consultant's or employee's current or former employer, or have breached their non-competition agreement. Litigation may be necessary to defend against such claims. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, we or our licensors may be subject to claims that former employees, consultants, collaborators or other third parties have an interest in our owned or in-licensed patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our consultants and employees who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any of our owned or licensed patents and patent applications are due to be paid to the USPTO, the EPO and other foreign patent agencies in several stages over the lifetime of the patents and patent applications. The USPTO, the EPO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market earlier with similar products or technology, which would have an adverse effect on our business. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Organization and Operations </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our success depends upon the continued contributions of our key management, scientific and technical personnel, many of whom have been instrumental for us and have substantial experience with our therapies and related technologies. These key management individuals include the members of our board of directors and executive management, including Dr. Patrick Amstutz, our Chief Executive Officer, Dr. Alexander Z&#252;rcher, our Chief Operating Officer, Dr. Michael Tobias Stumpp, our EVP Projects, Dr. Nicolas Leupin, our Chief Medical Officer and Renate Gloggner, our EVP People and Culture.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The loss of key managers and senior scientists could delay our research and development activities. In addition, our ability to compete in the highly competitive biotechnology and pharmaceutical industries, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and particularly, in the oncology field, depends upon our ability to attract and retain highly qualified management, scientific and medical personnel. Many other biotechnology and pharmaceutical companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Therefore, we might not be able to attract or retain these key persons on conditions that are economically acceptable. Furthermore, we will need to recruit new managers and qualified scientific personnel to develop our business if we expand into fields that will require additional skills. Additionally, there is a larger pool of qualified scientific and medical personnel in the United States than in Switzerland, and we may need to increase our presence in the United States in order to attract and retain the necessary human resources. Our inability to attract and retain these key persons could prevent us from achieving our objectives and implementing our business strategy, which could have an adverse effect on our business and prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development, regulatory and sales and marketing capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, sales and marketing and support functions such as finance, human resources, legal, intellectual property, information technology and administration. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to integrate efficiently or achieve the expected benefits of any acquisitions of complementary businesses, product candidates or technologies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception in 2004, we have grown organically without any acquisitions. Should we in the future contemplate to acquire any complementary business, product candidates or technologies, our ability to integrate and manage acquired businesses, product candidates or technologies effectively will depend upon a number of factors including the size of the acquired business, the complexity of any product candidate or technology and the resulting difficulty of integrating the acquired business's operations, if any. Our relationship with current employees or employees of any acquired business may become impaired. We may also be subject to unexpected claims and liabilities arising from such acquisitions. These claims and liabilities could be costly to defend, could be material to our financial position and might exceed either the limitations of any applicable indemnification provisions or the financial resources of the indemnifying parties. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to economic, political, regulatory and other risks associated with international operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, increase of interest rates, or political instability in particular economies and markets; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements for drug approvals; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially reduced ability to obtain, maintain, protect and enforce intellectual property rights and other proprietary rights;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations and customs, tariffs and trade barriers; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in currency exchange rates of the euro, U.S. dollar and Swiss franc and currency controls; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in a specific country's or region's political or economic environment; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain international markets; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative consequences from changes in tax laws; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment in different jurisdictions of stock options granted under our employee stock plan; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation or administrative actions resulting from claims against us by current or former employees or consultants individually or as part of class actions, including claims of wrongful terminations, discrimination, misclassification or other violations of labor law or other alleged conduct; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation resulting from claims against us by third parties, including claims of breach of noncompete and confidentiality provisions of our employees' former employment agreements with such third parties; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">business interruptions resulting from cyber-attacks, geo-political actions, including war (such as the Russia-Ukraine war) and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Additionally, in connection with the ongoing war between Russia and Ukraine, the U.S. government and other governments have imposed enhanced export controls on certain products and sanctions on certain industry sectors and parties in Russia, and have indicated they will consider imposing additional sanctions and other similar measures in the near future. Although we do not have any operations in Russia or Ukraine, further escalation of geopolitical tensions could have a broader impact that expands into other markets where we do business, which could adversely affect our business, our supply chain or our collaborators. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Exchange rate fluctuations or abandonment of the euro currency may materially affect our results of operations and financial condition. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Due to the international scope of our operations, our assets, earnings and cash flows are influenced by movements in exchange rates of several currencies, particularly regarding U.S. dollars, euros, British pounds and Swiss francs. Our functional currency is the Swiss franc and the majority of our operating expenses are paid in Swiss francs, but we also may receive payments from our business partners, including Novartis in U.S. dollars or euros and we regularly acquire services, consumables and materials in U.S. dollars, euros and Swiss francs. Further, potential future revenue may be derived from abroad, particularly from the United States and the European Union. As a result, our business and share price may be affected by fluctuations in foreign exchange rates between the Swiss franc, the euro, the U.S. dollar and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period. Besides our natural hedging, currently, we do not have any exchange rate hedging arrangements in place. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the possible abandonment of the euro by one or more members of the European Union could materially affect our business in the future. Despite measures taken by the European Union to provide funding to certain European Union member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more European Union member states, or in more extreme circumstances, the abandonment of the euro or the dissolution of the European Union. The effects on our business of a potential dissolution of the European Union, the exit of one or more European Union member states from the European Union or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions, including as a result of the ongoing military action by Russia in Ukraine, could have a negative impact on our operations, which could materially and adversely affect our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 24, 2022, Russian forces launched significant military action against Ukraine, and sustained conflict and disruption in the region is possible. The impact to Ukraine as well as actions taken by other countries, including new and stricter sanctions imposed by Canada, the United Kingdom, the European Union, the United States. and other countries and companies and organizations against officials, individuals, regions, and industries in Russia and Ukraine, and actions taken by Russia in response to such sanctions, and responses of countries and political bodies to such sanctions, tensions, and military actions and the potential for more widespread conflict, have resulted in supply chain disruptions, and resulting increases in inflation, financial market volatility and capital markets disruption, potentially increasing in magnitude, and such effects on the global economy and financial markets could affect our business, operations, operating results and financial condition as well as the price of our common stock and our ability to raise additional capital when needed on acceptable terms. In addition, any or all of these effects could disrupt our and our collaborators&#8217; supply chains and adversely affect our and our collaborators&#8217; ability to conduct ongoing and future clinical trials of our product candidates. The extent and duration of the military action, sanctions and resulting economic, market and other disruptions are impossible to predict, but could be substantial. Any such disruptions may magnify the impact of the other risks described in this report.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Recent developments relating to the United Kingdom's referendum vote in favor of withdrawal from the European Union could adversely affect our ability to develop, manufacture and commercialize our product candidates in the United Kingdom. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom was subject to a transition period until December 31, 2020, or the Transition Period, during which European Union rules continued to apply. The Trade and Cooperation Agreement, or the Trade and Cooperation Agreement, which outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> and formally entered into force on May 1, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from European Union directives and regulations, Brexit has had, and will continue to have, a material impact on the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom. For example, Great Britain is no longer covered by the centralized procedures for obtaining European Union-wide marketing authorizations from the EMA, and a separate marketing authorization will be required to market our product candidates in Great Britain. It is currently unclear whether the Medicines &amp; Healthcare products Regulatory Agency in the United Kingdom is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would delay or prevent us from commercializing our product candidates in the United Kingdom and limit our ability to generate revenue and achieve and sustain profitability. We could face significant additional expenses to obtain regulatory approval for our products in the United Kingdom.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">We are exposed to unanticipated changes in tax laws and regulations, adjustments to our tax provisions, exposure to additional tax liabilities, or forfeiture of our tax assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The determination of our provision for income taxes and other tax liabilities requires significant judgment, including the adoption of certain accounting policies and our determination of whether we will be able to obtain a future tax benefit from our deferred tax assets. We cannot guarantee that our interpretations will not be challenged by the relevant tax authorities, or that the relevant tax laws and regulations, or the interpretation thereof, including through tax rulings, by the relevant tax authorities, will not be subject to change. Any adverse outcome of such a challenge may lead to adjustments in the amounts recorded in our financial statements, and could have a material adverse effect on our operating results and financial condition. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are subject to laws and regulations on tax levies and other charges or contributions in different countries, including transfer pricing and tax regulations applicable to the compensation of personnel and third parties. Transactions between current group companies, as well as additional companies that may form part of our group in the future, are subject to transfer pricing regulations, which may be subject to change or our existing transfer pricing system could be challenged by the relevant tax authority, and any such changes or challenges could adversely affect us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our effective tax rate could be adversely affected by changes in tax laws, treaties and regulations, both internationally and domestically, or the interpretation thereof by the relevant tax authorities, including changes to the U.K. research and development tax credit regime or the "patent box" regime, possible changes to the corporate income tax base, changes to the additional deduction for expenditure on research and development personnel in Switzerland and other tax incentives. An increase in our effective tax rate could have an adverse effect on our business, financial position, results of operations and cash flows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, we may not be able to use, or changes in tax regulations may affect the use of, certain tax loss carryforwards that we have generated in prior years. For instance, as of December 31, 2022, we had substantial tax loss carry forwards. In general, some of these tax loss carry forwards may be forfeited in whole, or in part, as a result of various transactions, or their utilization may be restricted by statutory law in the relevant jurisdiction. Any corporate reorganization by us or any transaction relating to our shareholding structure may result in partial or complete forfeiture of tax loss carry forwards. If not used, tax loss carryforwards for Swiss corporate income tax purposes expire seven years after the tax year in which they were incurred. Due to our limited future / expected income, there is a high risk that our tax loss carryforwards will expire in part or in their entirety and therefore will not be able to be used to offset future taxable income for Swiss corporate income tax purposes. Furthermore, any tax loss carry forwards that we report on our Swiss tax returns are subject to review and confirmation by the competent Swiss tax authorities in their tax assessment of the tax year for which the tax loss carryforwards are used to offset taxable income. Consequently, we are exposed to the risk that the competent Swiss tax authorities may not accept the reported tax loss carryforwards in part or in their entirety.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Changes in our effective tax rate or tax liability may have an adverse effect on our results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our effective tax rate could increase due to several factors, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the relative amounts of income before taxes in the jurisdictions in which we operate that have differing statutory tax rates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax laws, tax treaties, and regulations or the interpretation of them;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to our assessment about our ability to realize any deferred tax assets that are based on estimates of our future results, the prudence and feasibility of possible tax planning strategies, and the economic and political environments in which we do business;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any current or future tax audits, examinations, or administrative appeals; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">any limitations or adverse findings regarding our ability to do business in some jurisdictions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any of these developments could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">As a result of changes in, or in the interpretation of, tax laws, treaties, rulings, regulations or agreements of Switzerland or any other country in which we currently operate or may in the future operate, the loss of a major tax dispute or a challenge to our operating structure, intercompany pricing policies or the taxable presence of our existing or any future subsidiaries in certain countries, or other factors, our effective income tax rates may increase in the future, which could adversely affect our net income and cash flows. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We operate in multiple jurisdictions and our profits are taxed pursuant to the tax laws of these jurisdictions. The tax laws applicable to our business activities, however, are subject to changes in interpretation. Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in jurisdictions in which we currently do or may in the future elect to do business. Our effective income tax rate may be affected by changes in or interpretations of tax laws, treaties, rulings, regulations or agreements in any such jurisdiction, the resolution of issues arising from any future tax audits with various tax authorities, utilization of net operating loss and tax credit carryforwards, changes in geographical allocation of income and expense, and changes in management&#8217;s assessment of matters such as the realizability of deferred tax assets. In the past, we have experienced fluctuations in our effective </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">income tax rate. Our actual tax rate may vary from our expectation and that variance may be material. Our effective income tax rate in a given fiscal year reflects a variety of factors that may not be present in the succeeding fiscal year or years. There is no assurance that our effective income tax rate will not change in future periods.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Due to the Swiss corporate tax law reform that took effect on January 1, 2020, all Swiss cantons, including the Canton of Zurich, have abolished previously existing cantonal tax privileges. Therefore, since January 1, 2020, we are subject to standard cantonal taxation. The standard effective corporate tax rate in Schlieren, Canton of Zurich, can change from time to time. The standard combined (federal, cantonal, municipal) effective corporate income tax rate, except for dividend income for which we could claim a participation exemption, for 2022 in Schlieren, Canton of Zurich, is approximately 19.4%. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We urge our shareholders to consult with their legal and tax advisors with respect to the potential tax consequences of investing in or holding our ADSs and ordinary shares.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The price of our ADSs may be volatile and may fluctuate due to factors beyond our control. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The market price of our ADSs and our ordinary shares may fluctuate significantly due to a variety of factors, many of which are beyond our control, including: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive or negative results of testing and clinical trials reported or conducted by us, strategic partners or competitors; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in entering into strategic relationships with respect to development or commercialization of our product candidates or entering into strategic relationships on terms that are not deemed to be favorable to us; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations or commercial product introductions by us or competitors; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in government regulations; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning proprietary rights, including patents and litigation matters; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern relating to the commercial value or safety of any of our product candidates; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">financing or other corporate transactions; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">impact of macroeconomic factors, including the COVID-19 pandemic, rising inflation, the U.S. Federal Reserve raising interest rates and the Russia-Ukraine war, on the global economy or financial markets; or</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">price and volume fluctuations attributable to inconsistent trading volume levels of our ADSs and/or ordinary shares.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These and other market and industry factors may cause the market price and demand for our ADSs and ordinary shares to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs or ordinary shares and may otherwise negatively affect the liquidity of our ADSs and ordinary shares. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have and will continue to incur increased costs as a result of operating as a U.S.-listed public company, and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a public company in the United States, and particularly after we no longer qualify as an emerging growth company, we have and will continue to incur significant legal, accounting and other expenses that we did not incur as a public company listed only on the SIX Swiss Exchange. We are a corporation (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesellschaft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), organized under the laws of Switzerland in accordance with articles 620 et seqq. CO and subject to the listing rules and the applicable regulations for companies listed on the SIX Swiss Exchange, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Stock Market, or Nasdaq, and other applicable securities rules and regulations that impose various requirements on non-U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and certain additional corporate governance practices. Our board of directors and other personnel are required to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report on our internal control over financial reporting beginning with our current Form 20-F. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are documenting and evaluating our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources, continue to engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Certain significant shareholders will continue to own a substantial number of our securities and as a result, may be able to exercise significant influence over the outcome of shareholder votes. These shareholders may have different interests from us or your interests. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have a number of significant shareholders. For an overview of our current significant shareholders, please see "Principal Shareholders." </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Currently, we are not aware that any of our existing shareholders have entered or will enter into a shareholders' agreement with respect to the exercise of their voting rights. Nevertheless, depending on the level of attendance at our general meetings of shareholders, or the General Meeting, these significant shareholders could have the ability to significantly influence the outcome of decisions taken at any such General Meeting. Any such voting by these shareholders may not be in accordance with our interests or those of our other shareholders. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our ADSs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Future sales, or the possibility of future sales, of a substantial number of our securities could adversely affect the price of the shares and dilute shareholders. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If our existing shareholders sell, or indicate an intent to sell, substantial amounts of our securities in the public market, the trading price of our ADSs and our ordinary shares could decline significantly. As of December&#160;31, 2022, we had 36,044,706 ordinary shares outstanding including 3,500,000 treasury shares held through our wholly-owned subsidiary Molecular Partners Inc and 3,000,000 ADS representing our ordinary shares issued and outstanding. In addition, ordinary shares subject to outstanding options under our equity incentive plans and the ordinary shares reserved for future issuance under our equity incentive plan will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We intend to register all ordinary shares that we may issue under our equity compensation plans. Once we register these ordinary shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and any applicable lock-up agreements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our articles of association or Swiss corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then board of directors. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provisions of our articles of association may make it more difficult for a third party to acquire control of us. For example, our board of directors is authorized to deny the preemptive rights of shareholders and allocate them to third parties as a defense of an actual, threatened or potential takeover bid, in relation to which our board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, several provisions of Swiss corporate law and certain other provisions of Swiss law, such as obligations to disclose significant shareholdings and merger control regulations, that apply to us may make an unsolicited tender offer, merger, change in management or other change in control of our company more difficult. These provisions could discourage potential takeover attempts that other shareholders may consider to be in their best interest and could adversely affect the market price of our securities. These provisions may also have the effect of depriving ADS holders of the opportunity to sell their ADSs at a premium. In addition, the board of directors of Swiss companies may in certain instances, and subject to prior authorization by the shareholders, deter or frustrate public takeover bids through dilutive issuances of equity securities (pursuant to the authorized capital) or through share buy-backs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fluctuations in exchange rates may increase the risk of holding ADSs and ordinary shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Due to the international scope of our operations, our assets, earnings and cash flows are influenced by movements in exchange rates of several currencies, particularly the euro, U.S. dollar and Swiss franc. Our functional currency is the Swiss franc, and the majority of our operating expenses are paid in Swiss franc, but we also receive or may receive payments from business partners in U.S. dollars, and we regularly acquire services, consumables and materials in U.S. dollars and euros. Further, potential future revenue may be derived from abroad, particularly from the United States or the European Union. As a result, our business and the price of our ADSs and ordinary shares may be affected by fluctuations in foreign exchange rates between the Swiss franc and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period. Besides natural hedging, currently, we do not have any exchange rate hedging arrangements in place. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, because our ordinary shares currently trade on the SIX Swiss Exchange in Swiss francs, and our ADSs trade on the Nasdaq Global Select Market in U.S. dollars, fluctuations in the exchange rate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">between the U.S. dollar and the Swiss franc may result in temporary differences between the value of our ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit such differences. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our ordinary shares and ADSs are traded on more than one market and this may result in price variations and adversely affect the liquidity and value of the ADSs; in addition, investors may not be able to easily move ordinary shares for trading between such markets. Furthermore, because of this dual listing, securities and stock exchange laws, regulations and rules apply to us that may be irreconcilable or otherwise difficult to comply with contemporaneously. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our ordinary shares have traded on the SIX Swiss Exchange since 2014 and our ADSs have traded on the Nasdaq Global Select Market since June 2021. Trading in our ADSs or ordinary shares on these markets takes place in different currencies (U.S. dollars on the Nasdaq Global Select Market and Swiss Francs on the SIX Swiss Exchange), at different times (resulting from different time zones, different trading days and different public holidays in the United States and Switzerland) and among a different investor base. The trading prices of our ordinary shares and our ADSs on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on the SIX Swiss Exchange could cause a decrease in the trading price of our ADSs on the Nasdaq Global Select Market. Investors could seek to sell or buy our ordinary shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could create unexpected volatility in both our share prices on one exchange and the ordinary shares available for trading on the other exchange. In addition, holders of ADSs cannot immediately surrender their ADSs and withdraw the underlying ordinary shares for trading on the other market without effecting necessary procedures with the depositary. This could result in time delays and additional cost for holders of ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because different types of our equity securities are admitted to trading and listed on two different stock exchanges in two different jurisdictions, two sets of securities laws and regulations and stock exchange rules apply to us contemporaneously. It cannot be excluded that the laws, regulations and/or rules of one jurisdiction or trading venue may require us to effect disclosures or filings or grant shareholders and/or holders of our ADSs certain rights that would be unlawful under the laws, regulations and/or rules of the respective other jurisdiction or trading venue. For this or other reasons, it may prove difficult or impossible for us to at all times comply with the laws, regulations and/or rules of both jurisdictions and trading venues at the same time. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs are not treated as holders of our ordinary shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holders of our ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying our ADSs. Holders of our ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders' meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior consent of the ADS holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary. Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship with the depositary. In the event that the terms of an amendment are materially disadvantageous to ADS holders, ADS holders will only receive 30 days&#8217; advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement. Furthermore, we may decide to direct the depositary to terminate the ADS facility at any time for any reason. For example, terminations may occur if we become the subject of a takeover or a going-private transaction. If the ADS facility will terminate, ADS holders will receive at least 30 days&#8217; prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shares, but will have no right to any compensation whatsoever.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The deposit agreement governing the ADSs representing our ordinary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to the ADSs or the deposit agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, as the jury trial waiver relates to claims arising out of or relating to the ADSs or the deposit agreement, we believe that, as a matter of construction of the clause, the waiver would likely to continue to apply to ADS holders who withdraw the ordinary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shares from the ADS facility with respect to claims arising before the cancellation of the ADSs and the withdrawal of the ordinary shares, and the waiver would most likely not apply to ADS holders who subsequently withdraw the ordinary shares represented by ADSs from the ADS facility with respect to claims arising after the withdrawal. However, to our knowledge, there has been no case law on the applicability of the jury trial waiver to ADS holders who withdraw the ordinary shares represented by the ADSs from the ADS facility.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">You will not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise your right to vote. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as described in this Annual Report on Form 20-F and the deposit agreement, holders of the ADSs are not able to exercise voting rights attached to the ordinary shares represented by the ADSs. Under the terms of the deposit agreement, holders of the ADSs may instruct the depositary to vote the ordinary shares underlying their ADSs. Otherwise, holders of ADSs are not able to exercise their right to vote unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations to vote them in person or by proxy in accordance with applicable Swiss laws and regulations and our articles of association. Even so, ADS holders may not know about a meeting far enough in advance to withdraw those ordinary shares. If we ask for the instructions of holders of the ADSs, the depositary, upon timely notice from us, will notify ADS holders of the upcoming vote and arrange to deliver our voting materials to them. Upon our request, the depositary will mail to holders a shareholder meeting notice that contains, among other things, a statement as to the manner in which voting instructions may be given. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs. In addition, regardless of whether timely voting instructions are provided to the depositary, at our request, the depositary will represent all ordinary shares underlying the ADSs for the purpose of establishing a quorum at a meeting of our shareholders. A shareholder is only entitled to participate in, and vote at, the meeting of shareholders, provided that its shares are recorded in its name at midnight (Central European Time) at the end of the 28th day preceding the date of the meeting of shareholders. In addition, the depositary's liability to ADS holders for failing to execute voting instructions or for the manner of executing voting instructions is limited by the deposit agreement. As a result, holders of ADSs may not be able to exercise their right to give voting instructions or to vote in person or by proxy and they may not have any recourse against the depositary or us if their ordinary shares are not voted as they have requested or if their shares cannot be voted. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">A beneficial owner of our ordinary shares that is not registered in our shareholders register may not be able to exercise certain rights attached to the ordinary shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The financial rights attached to our ordinary shares transfer to a holder of those shares upon purchasing such shares in a stock market transaction. Any voting rights or rights related to voting rights only transfer once the acquirer has been registered in the shareholders' register as shareholder of such ordinary shares. A beneficial owner that is not directly registered in the shareholders' register can enjoy the financial rights, voting rights and rights related to voting rights only through the entity that acts as nominee or depositary for those ordinary shares and is recorded in the shareholders' register as the shareholder of record of those shares. This is also the case if you hold ADSs. It is possible that a nominee or a depositary will be unwilling to exercise certain rights attached to the ordinary shares, such as rights that require litigation. Therefore, failing to register in the shareholders' register may result in your inability to exercise certain rights as a shareholder. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay dividends in the foreseeable future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have not paid any dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing dividends. In addition, payment of any future dividends to shareholders would be subject to shareholder approval at our General Meeting, upon proposal of the board of directors, which proposal would be subject to the approval of the majority of the non-executive directors after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, certain limitations apply to the payment of future dividends pursuant to Swiss law and our articles of association. In addition, payment of future cash dividends may be made only if our shareholders' equity exceeds the sum of our paid-in and called-up share capital plus the reserves required to be maintained by Swiss law or by our articles of association. Accordingly, investors cannot rely on cash dividend income from ADSs and any returns on an investment in the ADSs will likely depend entirely upon any future appreciation in the price of the ADSs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">You may not receive distributions on our ordinary shares represented by our ADS or any value for them if it is illegal or impractical to make them available to holders of ADSs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The depositary for our ADSs will pay to you or distribute the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution of our ADSs, ordinary shares, rights or anything else to holders of our ADSs. This means that you may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impracticable to make them available to you. These restrictions may have a material adverse effect on the value of your ADSs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Holders of our ordinary shares outside Switzerland and ADS holders may not be able to exercise pre-emptive rights.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under Swiss law, shareholders may receive certain pre-emptive rights to subscribe on a pro rata basis for issuance of equity or other securities that are convertible into equity. Due to laws and regulations in their respective jurisdictions, however, non-Swiss shareholders may not be able to exercise such rights unless we take action to register or otherwise qualify the rights offering under the laws of that jurisdiction. There can be no assurance that we would take any such action and we reserve the right to determine whether we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">should take such action in any jurisdiction. If shareholders in such jurisdictions were unable to exercise their subscription rights, their ownership interest in the Company would be diluted. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADS holders have no pre-emptive rights to subscribe to newly issued shares unless we grant such rights to the foreign depositary. The right to exercise such pre-emptive rights is set out in the agreement between the ADS holder and the depositary.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are a Swiss corporation. The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a Swiss corporation. Our corporate affairs are governed by our articles of association and organizational rules and by the laws governing companies, including listed companies, incorporated in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board of directors is required by Swiss law to consider the interests of our company, and may also have regard to the interests of our shareholders, our employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a holder of ADSs. Swiss corporate law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of directors but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of our board of directors for breach of fiduciary duty would have to be brought to the competent courts in Schlieren, Canton of Zurich, Switzerland, or where the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders against us must be brought exclusively to the competent courts in Schlieren, Canton of Zurich, Switzerland. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On January 1, 2023, legislation that modernized certain aspects of Swiss corporate law (the Swiss corporate law reform (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Aktienrechtsrevision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">)) entered into force. The new legislation altered the rights of shareholders under Swiss law, and as a consequence the rights of holders of our ADSs. The Swiss corporate law reform is subject to certain transitional periods as provided for therein. In particular, Swiss stock corporations registered with the Commercial Register on January 1, 2023, are required to amend their articles of incorporation and organizational regulations in line with the new legislation within a transitional period of two years (i.e., until January 1, 2025).Accordingly, we intend to propose certain amendments to our articles of incorporation at the next annual general meeting of shareholders. Until such amendments have been adopted and approved by the general meeting of shareholders, our current articles of association remain in full force and effect. See "Item 10. - Memorandum and Articles of Association - Swiss Corporate Law Reform." There can be no assurance that Swiss law will not once again change in the future, which could adversely affect the rights of our shareholders or holders of our ADSs. Furthermore, there can be no guarantee that Swiss law does or will protect our shareholders or the holders of our ADSs in a similar fashion as the laws of U.S. jurisdictions would, in particular as regards corporate law principles, if we were a U.S.-incorporated company.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our ordinary shares are issued under the laws of Switzerland, which may not provide investors with the same protections provided by incorporation in Delaware.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are organized under the laws of Switzerland. A further summary of applicable Swiss law is contained in this Annual Report on Form 20-F. There can be no assurance that Swiss law will not change in the future or that it will provide investors with the same protections afforded to investors of a Delaware corporation, which could adversely affect the rights of investors. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Claims of U.S. civil liabilities may not be enforceable against us. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are incorporated under the laws of Switzerland and our registered office and domicile is located in Schlieren, Switzerland. Substantially all of our assets are located outside the United States. A number of our directors and executive officers are not residents of the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained against them or us in U.S. courts, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on Private International Law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The United States currently does not have a treaty with Switzerland providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in Switzerland. In order to obtain a judgment which is enforceable in Switzerland, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in Switzerland. Such party may submit to the Swiss court the final judgment rendered by the U.S. court. If and to the extent that the Swiss court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the court of Switzerland will, in principle, give binding effect to the judgment of the U.S. court, unless such judgment contravenes principles of public policy of Switzerland. Also, mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply. Swiss courts may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Swiss court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of U.S. courts in Switzerland are solely governed by the provisions of the Swiss Federal Private International Law Act. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment of such non-Swiss court has become final and non-appealable;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment does not contravene Swiss public policy;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against us or members of our board of directors or certain experts named herein who are residents of Switzerland or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our status as a Swiss corporation means that our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Swiss law reserves for approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also requires that our shareholders themselves resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize share capital that can be issued by our board of directors without additional shareholder approval, Swiss law limits this authorization to 50% of the share capital registered in the commercial register at the time of the authorization. The authorization, furthermore, has a limited duration of up to five years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital. For an overview of the changes in Swiss corporate law due to the Swiss corporate law reform that came into effect on January 1, 2023, see "Item 10. - Memorandum and Articles of Association - Swiss Corporate Law Reform." Additionally, subject to specified exceptions, including exceptions explicitly described in our articles of association, Swiss law grants preemptive rights to existing shareholders to subscribe for new issuances of shares, which may be limited or withdrawn only under certain limited conditions. Swiss law also does not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the laws of some other jurisdictions. These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided benefits to our shareholders. For changes to Swiss corporate law potentially affecting the rights of the holders of our ADSs, see also "Item 10. - Memorandum and Articles of Association - Swiss Corporate Law Reform" </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are a foreign private issuer and, as a result, we are not subject to U.S. proxy rules and are subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer and as permitted by the listing requirements of Nasdaq, we rely on certain home country governance practices rather than the corporate governance requirements of Nasdaq. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a foreign private issuer. As a result, in accordance with Nasdaq Listing Rule 5615(a)(3), we comply with home country governance requirements and certain exemptions thereunder rather than complying with certain of the corporate governance requirements of Nasdaq.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Swiss law does not require that a majority of our board of directors consist of independent directors. Our board of directors therefore may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we are not subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors regularly have scheduled meetings at which only independent directors are present.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although Swiss law also requires that we adopt a compensation committee, we follow home country requirements with respect to such committee. As a result, our practice varies from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees. We have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the independent director oversight of director nominations requirements of Nasdaq Listing Rule 5605(e).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, in accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. Our practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. To this extent, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may lose our foreign private issuer status which would then require us to comply with the Exchange Act's domestic reporting regime and cause us to incur significant legal, accounting and other expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may no longer be a foreign private issuer as of June 30 for a given fiscal year (the end of our second fiscal quarter for a given fiscal year), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of January 1 of such year. In order to maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50% of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United States. If we lost foreign private issuer status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We would be required to change our accounting from reporting under IFRS to reporting under U.S. generally accepted accounting principles. We would also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are an "emerging growth company," and a "smaller reporting company" and we cannot be certain if the reduced reporting requirements applicable to "emerging growth companies" will make our ADSs less attractive to investors. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are an "emerging growth company," as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an "emerging growth company," we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies," including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We may take advantage of these exemptions until we are no longer an "emerging growth company." We could be an "emerging growth company" for up to the last day of the fiscal year ending after the fifth anniversary of our initial U.S. public offering (June 2021), although circumstances could cause us to lose that status earlier, including if the aggregate market value of our ordinary shares held by non-affiliates exceeds $700 million as of any June 30 (the end of our second fiscal quarter) before that time, in which case we would no longer be an "emerging growth company" as of the following December 31 (our fiscal year-end). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, because the market value of our ordinary shares held by non-affiliates was less than $560 million as of June 30, 2022 and our revenue for the year ended December 31, 2021 were less than $100 million, we qualify as a &#8220;smaller reporting company&#8221; under the Exchange Act as of June 30, 2022. We may continue to be a smaller reporting company if either (i) the market value of our ordinary shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100.0 million during the most recently completed fiscal year and the market value of our ordinary shares held by non-affiliates is less than $700.0 million. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We cannot predict if investors will find our ordinary shares less attractive because we may rely on the exemptions and reduced disclosure obligations applicable to emerging growth companies and smaller reporting companies. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our shares or ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of ADSs representing our shares or our shares.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Management is required to assess the effectiveness of our internal controls annually beginning with this annual report on Form 20-F to be filed with the SEC. However, for as long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements requiring us to incur the expense of remediation and could also result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we are classified as a passive foreign investment company, U.S. Holders of ADSs may be subject to adverse U.S. federal income tax consequences.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For U.S. federal income tax purposes, we generally will be classified as a passive foreign investment company, or PFIC, for any taxable year, in which, after the application of certain look-through rules with respect to our subsidiaries, at least 75% of our gross income is passive income, or at least 50% of the average value (determined on the basis of a weighted quarterly average) of our assets for the taxable year is attributable to assets that produce passive income or are held for the production of passive income, including cash. For purposes of these tests, passive income includes, among other things, dividends, interest, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares or ADSs) and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Generally, in determining whether a non-U.S. corporation is a PFIC, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based upon our analysis of the value of our assets and the nature and composition of our income and assets, we believe that we were a PFIC for the taxable year ended December 31, 2022. However, the determination of whether or not we are a PFIC for any taxable year is a factual determination made annually after the end of each taxable year, and because the applicable law is subject to varying interpretations, we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year. If we are characterized as a PFIC for any taxable year during which U.S. Holders (as defined in &#8220;Item 10. E Taxation &#8211; Material U.S. Federal Income Tax Consequences for U.S. Holders&#8221; below) hold our ADSs, U.S. Holders of our ADSs may suffer adverse tax consequences regardless of whether we continue to qualify as a PFIC, including having gains realized on the sale of our ADSs treated as ordinary income rather than capital gain, the loss of the preferential rate applicable to dividends received on ADSs by individuals who are U.S. Holders, and having interest charges apply to certain distributions by us and gains from the sales of our ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The tax consequences that would apply if we are classified as a PFIC would be different from those described above if a U.S. Holder of ADSs were able to make a valid qualified electing fund, or QEF, election, or, in some circumstances, a &#8220;mark-to-market&#8221; election. We currently expect to provide U.S. holders of ADSs with the information necessary for a U.S. shareholder to make a QEF election if we were treated as a PFIC for any taxable year, although there is no assurance that we will do so.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S. shareholders, see &#8220;Item 10. E Taxation &#8211; Material U.S. Federal Income Tax Consequences for U.S. Holders.&#8221; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">If we are a controlled foreign corporation, there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our ordinary shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">If a United States person is treated as owning (directly, indirectly, or constructively) at least 10% of the value or voting power of our shares (including through ADSs), such person may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group. Because our group includes one or more U.S. subsidiaries, we expect that certain of our future non-U.S. subsidiaries will be treated as controlled foreign corporations (regardless of whether or not we are treated as a controlled foreign corporation). A United States shareholder of a controlled foreign corporation may be required to report annually and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income,&#8221; and investments in U.S. property by controlled foreign corporations, regardless of whether the controlled foreign corporations make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations from starting with respect to such shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether any of our non-U.S. subsidiaries is treated as a controlled foreign corporation or whether any investor is treated as a United States shareholder with respect to any such controlled foreign corporation, or that we will furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations. A United States investor should consult its advisors regarding the potential application of these rules to an investment in our ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">General Risks</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any failure of these systems could harm our business. Security incidents, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we may process large amounts of confidential and sensitive data, including personal data (such as health-related data), intellectual property, and proprietary business information (collectively, sensitive information). We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to sensitive information. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive information with or from third parties.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and have generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We and the third parties upon which we rely may also be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us and our business operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the prevalent use of mobile devices that access confidential information increases the risk of lost or stolen devices and security incidents, which could lead to the loss of sensitive information. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to conduct our business. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We experience such security incidents of varying degrees from time to time, and we incur costs in protecting against or remediating such security incidents. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We take steps to detect and remediate vulnerabilities, but we may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. These vulnerabilities pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include governmental enforcement actions (for example, investigations, fines, penalties, audits, and inspections), additional reporting requirements and/or oversight, restrictions on processing sensitive information (including personal data), litigation (including class claims), indemnification obligations, negative publicity, reputational harm, monetary fund diversions, interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts cease coverage of us, or publish inaccurate or unfavorable research about our business, the price of the ADSs and our trading volume could decline. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The trading market for the ADSs and our ordinary shares depends in part on the research and reports that securities or industry analysts publish about us or our business. If no or too few securities or industry analysts cover us, the trading price for the ADSs and our ordinary shares would likely be negatively affected. If one or more of the analysts who cover us downgrade the ADSs or our ordinary shares or publish inaccurate or unfavorable research about our business, the price of the ADSs and our ordinary shares would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for the ADSs and our ordinary shares could decrease, which might cause the price of the ADSs and our ordinary shares and trading volume to decline. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. For example, in July 2022, a securities class action complaint was filed in the U.S. District Court for the Southern District of New York against us, our directors and certain of our current and former executive officers. The case is still in the early stages. However, regardless of outcome, this or any future securities litigation could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities. See Part I, Item 8.A &#8220;Consolidated Statements and Other Financial Information &#8211; Legal Proceedings&#8221; for more information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_40"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Information on the Company. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_43"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. History and Development of the Company </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our corporate name is Molecular Partners AG. We were incorporated in Switzerland as an&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesellschaft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or AG, on November 22, 2004 and are subject to article 620 et seq. of the Swiss Code of Obligations. Our principal executive offices are located at Wagistrasse 14, 8952 Schlieren, Switzerland. We are registered with the commercial register of the Canton of Zurich under number CHE-112.115.136. In November 2014, we completed the initial public offering of our ordinary shares on the SIX Swiss Exchange. In June 2021, we completed the initial public offering of our ADSs on the Nasdaq Global Select Market. Our telephone number at our principal executive offices in Switzerland is +41 44 755 77 00. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Molecular Partners AG is the sole shareholder of Molecular Partners Inc., a Delaware corporation, with a registered office at 245 Main Street, Cambridge, Massachusetts 02142, with a secondary address at 33, Bradford Street, Concord, Massachusetts 01742. Molecular Partners Inc. is our agent for service of process in the United States. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our website address is www.molecularpartners.com. The reference to our website is an inactive textual reference only and information contained in, or that can be accessed through, our website or any other website cited in this registration statement is not part of this Annual Report on Form 20-F. The SEC maintains a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_46"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Business Overview </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company pioneering DARPin candidates to treat serious diseases, with a current focus on oncology and virology. Our DARPin platform, which is built using designed ankyrin repeat proteins, or DARPins, allows us to generate candidates with multiple mechanisms of action, or MOAs, to address complex biological problems. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DARPins are a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics. Our DARPin candidates have been extensively tested in preclinical studies and clinical trials, including in approximately 2,500 patients, and have been observed to be highly active and generally well-tolerated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Leveraging our DARPin platform, we have designed product candidates with multiple MOAs that we believe have the potential to offer patients therapeutic options with higher efficacy and fewer adverse events as compared to the current standard of care. Among these multiple MOAs, DARPin product candidates have been designed to block growth factors, localize activity, conditionally activate, neutralize viruses, adjust half-life as needed, and initiate cell death. We apply these features across our portfolio to elicit a specific therapeutic response.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We believe that our DARPin platform has the potential to yield novel product candidates with broad therapeutic application given their ability to overcome many of the limitations of antibody and other conventional protein-based therapeutics. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Our Pipeline</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Molecular Partners&#8217; pipeline includes two key areas: oncology (blue) and virology (green). In addition we are reviewing opportunities in ophthalmology (gray). </span></div><div><img src="moln-20221231_g1.jpg" alt="moln-20221231_g1.jpg" style="height:340px;margin-bottom:5pt;vertical-align:text-bottom;width:604px"/></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">While our DARPin candidates have distinct therapeutic features and particular targets, each DARPin therapeutic modality can be utilized across multiple programs. Our pipeline programs benefit from the learnings of earlier discoveries, such as: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The use of fibroblast activation protein, or FAP as a localized activator for both MP0317, and previously MP0310;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Multi-specificity and avidity-driven selectivity to boost tumor specificity for our Acute Myeloid Leukemia, or AML, candidate MP0533; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Cooperative binding for increased antiviral neutralization by ensovibep for COVID-19;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have research collaboration agreements with Novartis as well as other third party collaborators. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Team</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We were founded in 2004 by the inventors of our DARPin platform. Our senior management, which includes two of our company&#8217;s co-founders, have significant prior experience in oncology, research, drug development and finance. Members of our team have served as senior executives at other well-established companies including argenx, Bavarian Nordic, Celgene, Roche, Novartis and Tesaro. Additionally, our board of directors includes current and former senior executives of AbbVie (Allergan), Biogen, Novartis AG, Novo Holdings Advisory Group, Roche and Takeda (Millennium Pharmaceuticals, Shire). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As our name indicates, partnership and collaboration are at the core of our company, our research activities and our therapeutic designs. Molecular Partners embodies an international working environment comprised of 170+ individuals from numerous disciplines who contribute to our shared values of scientific excellence, respectful teamwork and personal aspiration. Whether it stems from our long-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">standing goal of improving the lives of patients with cancer, or to our more recent efforts to deploy our technology against COVID-19, we are a group dedicated to moving the needle of medicine. We foster true innovation and creative thinking to advance our therapeutic product candidates, and we continue to be inspired by the difference we can make for our patients. Our team members possess a curiosity and a passion to advance our shared goal of providing better treatment options for patients with serious diseases. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are committed to leveraging our proprietary DARPin platform to unlock and expand the inherent advantages of DARPin molecules to potentially deliver innovative therapies to patients suffering from severe disease with significant unmet medical needs. Key aspects of our strategy include the following: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">Rapidly advance our tri-specific T-cell engaging DARPin, MP0533, for patients with AML and high-risk MDS. Presently in a Phase 1 clinical trial, we plan to establish the safety and tolerability profile of the program, and will aim to identify a therapeutic dose level for additional clinical evaluation. Initial preliminary clinical data is anticipated to be reported by the end of 2023. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Unlock novel biological solutions and expand therapeutic applications of clinically validated DARPin approaches. As the inventors of the DARPin class of drugs, we believe we are the world leaders in DARPin engineering and research. With this expertise, we have developed a strategy of unlocking various technical hurdles which may limit other discovery platforms, and then expanding our clinical product candidates based upon each technological solution. Examples of this include the conditional activation of our oncology programs MP0317 and MP0310, the avidity driven mechanism of MP0533, and multi-specificity of our COVID-19 antiviral ensovibep.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Maintain a robust discovery program leveraging our proprietary DARPin libraries and novel DARPin-based biological solutions. DARPins are designed to be added to new product candidates in a modular fashion to address novel disease biology. This process enables us to construct and screen multi-specific DARPin molecules for new disease areas and to quickly identify and progress differentiated candidates for our oncology and virology programs. In pursuit of a sustainable and diversified portfolio, we plan to develop potentially innovative and transformational constructs directed against the most promising targets in our areas of focus. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Continue a strategic approach to in-house versus partnered development. To unlock and expand the full potential of our DARPin platform, we intend to independently develop and commercialize product candidates in our core focus areas, where we believe we have an established clinical and regulatory approval pathway and the resources to commercialize successfully. To complement this approach, we also plan to collaborate with biopharmaceutical companies on product candidates that have promising utility in target areas or patient populations requiring greater global development capabilities or those outside of our strategic focus. </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">This strategy has allowed us to pursue major therapeutic innovations for the DARPin platform, often in parallel, across our oncology and virology focus areas. To this end, we continue to support our partners across our portfolio as we advance our Radio DARPin-Therapy Platform, both independently and in collaboration with Novartis; and our research collaboration with the University of Bern for MP0533. </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-26.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">We will also seek to collaborate with companies developing complementary technology to our platform when we see the strategic rationale to combine our industry-leading DARPin capabilities with other modalities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our DARPin Platform</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our DARPin platform was invented over twenty years ago by the co-founders of our company, who were then researchers at the University of Zurich. DARPin molecules were discovered as a result of our co-founders&#8217; quest to find a versatile protein-based therapeutic class that was highly differentiated from antibodies. The ability to design multi-specific molecules, along with the ease of use and manufacturing, made DARPin technology an ideal platform for us from which to pursue treatments beyond traditional protein therapeutics. The foundational technology we use in our DARPin platform to generate our product candidates was initially licensed to us by the University of Zurich. Leveraging our DARPin platform, we have designed product candidates with MOAs that we believe have the potential to offer patients therapeutic options with higher efficacy and fewer adverse events compared to the current standard of care. Among these multiple MOAs, DARPin product candidates have been designed to block growth factors, localize activity, conditionally activate, neutralize viruses, adjust half-life as needed and initiate cell death. We apply these features across our portfolio to elicit a specific therapeutic response.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that our DARPin platform has the potential to yield novel product candidates with broad therapeutic application given their ability to overcome many of the limitations of antibody and other conventional protein-based therapeutics. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Benefits and Advantages of our DARPin Platform over Traditional Approaches </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe the benefits of our DARPin platform include: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Ability of DARPin product candidates to target multiple escape pathways in parallel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"><br/>When cancer cells or a virus are targeted by conventional therapies, they often develop resistance by loss of target, mutational escape or activating multiple escape pathways at once. To create effective products, we believe that we must understand the dynamics of these escape pathways and then target their key components in parallel. We believe our DARPin product candidates are ideally suited for this approach because of their ability to bind to multiple targets and inhibit multiple escape pathways at once. Our approach allows us to efficiently test product candidates to determine the affinity and target binding of our DARPin proteins in the relevant setting. The most effective combination of DARPin proteins is assembled into one DARPin product candidate for further product development. These DARPin product candidates can demonstrate cooperative binding, leading to high potency and preventing escape as demonstrated by our antiviral product candidates. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Capacity to find and address new biology on known targets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br/>Using our DARPin approach, we are able to select DARPin proteins that bind to known targets in novel ways, thereby unlocking additional therapeutic solutions. For example, we can achieve conditional activation where the molecule will activate only in the presence of a particular tumor-associated antigen, or TAA. One of our product candidates, MP0533 utilizes the power of multi-specific targeting to potentially enhance efficacy and minimize tumor resistance through simultaneously targeting three known antigens associated with AML, which, to our knowledge, had not previously been addressed in one molecule. In addition, positive topline data from the global EMPATHY Phase 2 clinical trial of ensovibep was a clinical validation of our platform&#8217;s ability to deliver multi-specific candidates that enact simultaneous binding for unique clinical effect. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Flexible architecture to engage and locally activate immune cells</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br/>Immune-mediated therapies rely on the activation of a patient&#8217;s immune response to fight tumors. In some cases, blocking negative checkpoint signals can produce a deep and durable effect in stopping the growth of, and regressing, tumors. We believe that our DARPin platform is well </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">suited for the combined approaches of blocking negative checkpoint signals and engaging and activating immune cells. We have unlocked approaches that utilize DARPins to direct tumor-localized activation of immune cells, resulting in the selective activation of immune system cells within a tumor, which may potentially avoid systemic adverse events. We have designed two of our DARPin product candidates, MP0310 and MP0317, to cluster, thereby locally activating immune cells more effectively. MP0310 is a tumor-restricted 4-1BB immune-cell activator for the potential treatment of FAP-positive cancers, and MP0317 activates CD40, also in an FAP-dependent manner. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Tailored pharmacokinetic profile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> <br/>All or our DARPin product candidates are constructed to benefit from high-yield microbial manufacturing. Unlike manufacturing using traditional mammalian cell lines, productions of DARPin molecules via microbial manufacturing allow for several key competitive advantages, including the ability to manufacture clinical batches every seven to ten days, versus a thirty-day mammalian campaign. This advantage is critical to allow drug supply on a global scale. Additional benefits include high production yield of raw drug substance, 12-15g/L for example, as well as high thermal stability, with certain programs demonstrating shelf stability at 4 degrees centigrade for several years. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Background of Our DARPin Platform: A Source of Virtually Unlimited Binding Proteins</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fundamental building block for all of our DARPin product candidates is the single DARPin protein. A DARPin protein consists of an engineered protein base structure, which we refer to as the scaffold. The DARPin scaffold is formed from consecutive copies of ankyrin repeat proteins, which are chains of 33 amino acids stacked together. The scaffold can be generated to provide a binding site to specifically recognize, or permit binding to, a desired target protein or other molecule, similar to how monoclonal antibodies can be generated to recognize a single target antigen. We have developed and upgraded our libraries to include over one trillion DARPin proteins, each of which can potentially bind to a specific target structure. From this library we can screen and select DARPins within weeks that are highly specific and have high affinity for any given target structure. We use these selected DARPins to build our product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DARPins are small, with a molecular weight of approximately 14&#8211;18 kilodaltons, or approximately the tenth of the size of a monoclonal antibody. We believe this smaller size potentially enables increased tissue penetration and a higher potency at lower doses. The natural biophysical properties of DARPins, including high affinity due to the rigidity of the scaffold and high solubility of the base structure, enable more distinct specificity for a particular target, or a specific site on a particular target, such as an epitope. These benefits have the potential to increase activity and efficacy of our product candidates for their targets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">How We Use DARPins </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We can select DARPins to bind to a given target and form the basis of a product candidate, or we can genetically assemble DARPins into DARPin product candidates using different linkers. This allows us to screen our libraries that contain over one trillion DARPins to select those with the optimal properties. We believe this process is more difficult with multi-specific antibodies or other complex proteins. Further, we can add additional elements either to increase the half-life of our product candidates to match the therapeutic need or to add functionality. While antibodies generally have a long systemic half-life, most repeat proteins have a short half-life. The half-life of a single DARPin is usually a few hours when injected into the blood stream. To increase the half-life of DARPin product candidates, we have created proprietary, patent protected, specific DARPins that bind to human serum albumin, or HSA. HSA is the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">most abundant protein in human blood and has a half-life of approximately three weeks. When administered intravenously, the HSA-DARPin binds to its target to extend its half-life to the same period as HSA. This approach allows us to tailor the half-life of our individual product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our accumulated preclinical and clinical experience of developing and testing DARPin candidates has allowed us to establish an intellectual property portfolio that, as of December 31, 2022, included over 180 granted patents and over 190 additional pending U.S. and foreign patent applications across more than 30 patent families, covering both core and derivative aspects of our DARPin platform. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Our Oncology Programs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cancer Background and Treatment </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The rapid development of immune-mediated therapies for multiple types of cancer has transformed the oncology treatment landscape and improved the long-term outlook for many cancer patients. Rather than targeting treatments directly at the tumor, these therapies generally engage the immune system to promote its recognition and eradication of tumor cells. Key features of immune-mediated therapy include specificity, breadth of response, and memory. These features can contribute to complete tumor regressions, often providing more durable clinical outcomes and improved quality of life relative to other therapies. However, despite the early success observed with immune mediated therapies, it has become clear that these treatments can currently help only a minority of patients and are more effective in some tumor types than others. This limit arises from various factors, including differential target expression patterns by cancer cells, variable immune responses to the treatment, and cancer immune-escape via mutagenesis and proliferation of non-targeted cellular populations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that, through years of building our DARPin expertise, we have developed DARPin candidates that can unlock and expand these immune-mediated capabilities through several mechanisms, which include targeting immuno-stimulatory proteins through multi-specific DARPin candidates and using delayed and/or conditional activation of our immune engagers. These attributes allow us to optimize the potency, localization and/or exposure of our product candidates and reduce the risk of off-target toxicity in order to improve their therapeutic index and overall profile. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Localized Immune Agonists: MP0317 and MP0533 Product Candidates </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In our oncology program we are currently developing and assessing two product candidates with localized immune agonists: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">MP0317, which allows for tumor-restricted immune-cell CD40 activation for the treatment of FAP positive cancers; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">MP0533, which targets CD3, CD70, CD123 and CD 33 for the treatment of AML.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Development of our MP0317 and MP0533 product candidates has leveraged the learnings from our two first-generation product candidates in our oncology program, MP0250, MP0274 and MP0310. Those candidates have shown efficacy and tolerability in preclinical and clinical studies in patient populations who were resistant and /or refractory to previous standard of care treatments. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">However, MP0317 and MP0533 both utilize novel mechanisms of action, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or the discovery of unknown or unanticipated adverse effects. See &#8220;Risk Factors&#8212;Risks Related to the Development and Clinical Testing of Our Product Candidates&#8212;Some of our product candidates utilize a novel mechanism of action which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.&#8221; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MP0317: DARPin Product Candidate Targeting FAP x CD40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Designed to activate CD40 only in FAP-high tumor tissue.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Localized activation by FAP targeting underpins the therapeutic benefits while expanding the range of immune cell activation. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Designed to reinforce the effect of other immune stimulating therapies. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Shown </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to repolarize M2 macrophages and revert T-cell suppression. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Positive interim Phase 1 clinical trial data presented at SITC in the fourth quarter of 2022. </span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g2.jpg" alt="moln-20221231_g2.jpg" style="height:146px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"/></div><div style="margin-bottom:8pt"><img src="moln-20221231_g3.jpg" alt="moln-20221231_g3.jpg" style="height:232px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The tumor-localized immune agonist MP0317 is one of our product candidates currently being developed in our oncology pipeline. MP0317 comprises a localizer to FAP and immune stimulator binding to CD40. FAP is found in the tumor stroma in high density and its binding is intended to create a cluster of CD40 on immune cells enabling immune activation. MP0317 is designed to simultaneously engage FAP and CD40 to create tightly bound clusters around tumors, which are necessary to induce CD40-mediated local immune activation. CD40 plays a critical role in antigen presentation and the monocyte maturation process, and therefore, indirectly, T-cell activation. One of the main functions of CD40 signaling is to enhance antigen-presentation to T-cells by activating dendritic cells, or DCs. CD40 engagement on the surface of DCs promotes cytokine and chemokine production, induces expression of costimulatory molecules, and facilitates the cross-presentation of antigens. This step increases the interaction of DCs with T-cells by upregulating surface proteins such as CD54 and CD86, thereby activating the surface proteins. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agonist anti-CD40 antibody treatments have been associated with mild to moderate toxicity in the clinic, which we believe is related to on-target but off tumor effects causing CRS and liver toxicity. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Aiming to avoid CD40-related toxicity, we developed MP0317 to work as a locally activated CD40 engager, designed to only activate the immune system when both FAP and CD40 are simultaneously engaged. We expect this localizing mechanism to reduce the likelihood of extra-tumoral systemic side effects and allow an increase of the therapeutic index. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April 2021, we presented new data at the 2021 AACR virtual annual meeting, showing further supportive evidence of MP0317&#8217;s unique therapeutic potential in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> model system. The results demonstrated an MP0317-dependent repolarization of macrophage phenotypes and reveal a release of T-cells from macrophage-mediated suppression. The preclinical study has additionally demonstrated FAP-dependent activation of CD40-expressing B-cell and myeloid cell populations in dissociated human tumors. </span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g4.jpg" alt="moln-20221231_g4.jpg" style="height:268px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In November 2021, we announced the first patient had been dosed in our Phase 1 clinical trial evaluating the safety and tolerability of MP0317. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The open-label dose escalation study is designed to assess the safety and tolerability as well as pharmacokinetics and pharmacodynamics of MP0317 as a monotherapy in patients with solid tumors known to express fibroblast activation protein (FAP) and CD40. A total of up to 30 patients are expected to be enrolled across six dosing cohorts and up to 15 patients will be enrolled in a dose expansion cohort. In addition to evaluating monotherapy dynamics, the study will gather a wide variety of biomarker data to support the establishment of combination therapies with MP0317 in specific indications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our team presented positive interim results from the ongoing Phase 1 trial of for the treatment of solid tumors at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2022. These data demonstrated the first clinical observation of tumor localized CD40 activation provided by MP0317, which was also observed to be safe and well-tolerated. There was no dose-limiting CD40-related systemic toxicities observed to-date as well as no signs of inflammatory cytokine release. We are continuing this ongoing dose escalation Phase 1 clinical trial, with patient recruitment in the dose escalation portion of the trial expected to be completed in the first half of 2023. Our team expects the final data set to inform the therapeutic dose for evaluation in a potential Phase 1b/2 trial in combination with relevant cancer treatment. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MP0533: DARPin Product Candidate Targeting CD3, CD70, CD123 and CD33 for the Treatment of AML</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g5.jpg" alt="moln-20221231_g5.jpg" style="height:107px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">MP0533 is another DARPin product candidate designed to engage CD3 on T-cells and target AML cells by the tumor-associated antigens, or TAAs, CD70, CD123 and CD33. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The unmet medical need in AML remains high. Despite the achievement of remission for a majority of patients, up to 70% of adults and 30% of children will not survive beyond five years after initial clinical response due to relapsing disease. Further, the treatment of relapsed/refractory AML, or r/r AML, is therapeutically challenging due to high relapse rates with current standard of care treatments and the aggressive nature of the disease. Currently, a variety of highly potent mono-targeting TCE and CAR-T therapies have entered clinical development, but those therapies are often accompanied by dose limiting toxicities, such as cytokine release syndrome, or CRS, and myelotoxicities, preventing dose escalation to induce robust anti-tumor efficacy. More selective therapies addressing the growing number of subclasses and rationally designed target combinations are needed to allow for extended dose escalation with a more acceptable safety profile and to achieve more durable responses.</span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g6.jpg" alt="moln-20221231_g6.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In AML, leukemic stem cells, or LSCs, produce all the leukemic cells in the patient and therefore a lasting cure for this disease is dependent on eradication of these cells. However, LSCs are relatively resistant to standard therapies. For example, these cells are less sensitive to killing by daunorubicin and cytarabine, two commonly used chemotherapeutic agents. This is partially due to increased expression by LSCs of multidrug resistance genes, and also to their quiescent state, which reduces the effects of cytotoxic agents that target rapidly replicating cells. It is therefore essential to primarily target LSCs to achieve durable disease control. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some cancer antigens are also present on many healthy cells, but at a lower concentration, and as such it is difficult to select any single target to sufficiently differentiate between cancer cells and healthy tissue. To overcome this limitation and increase specificity, we leveraged our unique DARPin platform to generate a multi-specific T-cell engager (TCE) DARPin molecule, targeting CD33, CD70 and CD123, by a fine-tuned and tailored avidity-driven affinity to these TAAs, in conjunction with our CD3-binding DARPin molecule. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In avidity-driven selectivity, the presence of two or more binding targets on the cell, and the molecular interaction with these targets increases the effective concentration of the binder and the resulting binding strength. This dependency of binding strength on the presence of more than one cancer antigen conveys a far superior selectivity to these multi-specific binders. This approach is a concept that is well known in the scientific community but has so far been limited by the availability of an optimal therapeutic platform to address the associated technical challenges. In order to find the right target combination, the optimal affinity to increase tumor specificity via avidity, as well as the best molecular architecture, we took advantage of our unique modular DARPin platform and screened thousands of combinations of multi-specific DARPin molecules, binding simultaneously to the three different TAAs &#8212; CD33, CD70 and CD123. Furthermore, we combined our three DARPin binders with our CD3-binding TCE DARPin into our candidate, MP0533. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our approach allows for the design of multi-specific TCEs which are designed to simultaneously target CD33, CD70 and CD123, three well-known AML antigens that are co-expressed on approximately 50% of AML cells and of which at least two are expressed on approximately 70% of AML cells. To further optimize our molecules, we have devised a concentration dependent MOA utilizing moderate affinity binders rather than high affinity ones. When such a DARPin encounters a cell expressing only one antigen, we believe there should only be a transient interaction and the DARPin should quickly disengage the target with limited cytotoxic effect. However, when there are two or three targets, the mechanism of aviditydriven selectivity is activated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In preclinical tests against AML cells, we observed MP0533 delivered highly potent and specific activity and the potential for a reduced effect on healthy normal cells. As well as its increased selectivity,  MP0533's ability to target three TAAs simultaneously gives it additional potential to counteract target escape mechanisms expected due to tumor heterogeneity. In addition, this mechanism is designed to capture a larger population of AML patients due to its ability to engage with any two of these targets simultaneously, while maintaining specificity. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In preclinical studies, MP0533's targeting of three different AML antigens with potentially optimized affinity and geometry demonstrated substantial avidity gain and an increased selectivity window. The avidity gain resulted in strongly enhanced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> potency as shown by activation of both CD8+ and CD4+ T-cells and subsequent killing of AML tumor cells. Bioactivity was in the range of established TCE benchmark formats such as BiTE and DART and compared to reference constructs where TAA-specific DARPin binders were replaced by non-binding-DARPin modules. We generated selectivity data by comparing our multi-specific DARPin constructs on MOLM-13 AML cell lines where the respective TAAs have been knocked out individually or in combination. The tumor specificity, and resulting potential for a better safety profile, of our DARPin construct has been confirmed in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> blood assay testing potential CRS liabilities. In this assay, our multi-specific DARPin construct induced profoundly less cytokine release as compared to benchmark molecules indicating an improved therapeutic window. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2021, we announced a research collaboration with the University of Bern, to advance the development of MP0533, into the clinic. The collaboration aims to leverage our DARPin technology and the University of Bern group&#8217;s expertise in AML, and specifically in LSCs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting in December 2022, we presented preclinical results showing MP0533, can induce preferential killing of cells expressing two or three tumor-associated antigens, or TAAs compared to cells expressing a single TAA. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0533 was demonstrated to activate T cells and destroy AML cells in samples from newly diagnosed and previously treated AML patients with different TAA expressions. Humanized mouse models showed MP0533&#8217;s ability to activate intra-tumoral T-cells and control tumor growth. The research also showed that MP0533 was able to directly target and kill LSCs, while sparing a variety of healthy cells including hematopoietic stem cells. This targeted feature of MP0533 was further supported by several other parameters including a lower level of cytokine release relative to benchmark mono-targeted T-cell engagers, both i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">n vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in a whole blood assay and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the humanized mouse AML models. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2023, the first patient was dosed in our Phase 1 clinical trial of MP0533. Interim preliminary clinical results from this trial are expected to be reported by the fourth quarter of 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">MP0310: DARPin Molecule Targeting 4-1BB x FAP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0310 is a dual-targeted compound, targeting both FAP and 4-1BB, that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April 2022, Amgen, our collaboration partner for MP0310 (AMG 506), informed us of its decision to return global rights of MP0310 to us following a strategic pipeline review. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Radio DARPin Therapy Platform</span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g7.jpg" alt="moln-20221231_g7.jpg" style="height:223px;margin-bottom:5pt;vertical-align:text-bottom;width:446px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We are developing DARPin-based radiotherapeutic candidates, both proprietary as well as in  collaboration with Novartis. In 2022, we progressed our Radio DARPin Therapy (RDT) Platform, selecting tumor-associated protein Delta-like ligand 3, or DLL3, as the first target of our in-house RDT program. Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting through the high-affinity and specificity offered by DARPins.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In December 2021, we announced a new collaboration with Novartis in the form of a license and collaboration agreement to develop, manufacture and commercialize DARPin-based radiotherapeutics. By harnessing the power of radioactive atoms, or radionuclides, and applying it to cancers through targeted radioligand therapy, DARPin-based radiotherapeutics have the potential to selectively deliver molecularly targeted radiation to tumor cells anywhere in the body, while sparing healthy tissue. DARPins have significant potential to enable robust, tumor-specific delivery of radionuclides owing to their small size in combination with high specificity and affinity. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The collaboration will combine our industry-leading ability to rapidly generate high-affinity DARPins and the radioligand therapies, or RLT, capabilities and expertise of Novartis. Under the terms of the agreement, we will collaborate with Novartis to discover DARPin-based radiotherapeutic candidates that target specific tumor associated antigens. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novartis will be responsible for all clinical development and commercialization activities. Under the terms of the agreement, we received a $20 million upfront payment from Novartis in January 2022, and are entitled to total potential development, regulatory and commercialization milestone payments of up to $560 million based on future achievements, and up to low double-digit percent of royalties to the extent that sales occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe DARPins' attributes along with their small size and platform optimizations to minimize kidney accumulatio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">make DARPins ideal delivery vectors for therapeutic radionuclides to efficiently target cancer cells with minimal systemic side effects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We plan to present our research of Radio DARPin Therapy candidates and their potential differentiation as tumor targeting moieties in scientific conferences in 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Virology Program</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2020 we launched the first product candidate from our virology program, ensovibep (MP0420), which targets the SARS-CoV-2 virus. Our rapid candidate design and assessment process allowed us to quickly </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">substantiate the potential of an antiviral DARPin approach and its differentiation compared to other therapeutic modalities. Based on the potential of DARPin therapeutics as antivirals, we are actively assessing other global viral threats with high unmet need as potential targets for new product candidates in our virology program. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COVID-19 Product Candidate: Ensovibep (MP0420) </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ensovibep is a first-in-class, multi-specific DARPin therapeutic candidate, designed to bind three different epitopes on the receptor-binding domain, or RBD, of the SARS-CoV-2 spike protein simultaneously. </span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g8.jpg" alt="moln-20221231_g8.jpg" style="height:125px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2022, Novartis exercised its option to in-license ensovibep and is now solely responsible for further development, manufacturing, and commercialization activities. Upon exercise of the option, Molecular Partners received a payment of CHF 150 million, which was in addition to the upfront cash payment of CHF 20 million and CHF 40 million worth of ordinary shares that Novartis acquired in 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary analysis from Phase 2 of the EMPATHY clinical trial was presented at the 2022 <br/>European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in April 2022. Key preclinical data documenting the unique design and mechanism of action of ensovibep were published in Nature Biotechnology in July 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ensovibep was submitted in February 2022 for Emergency Use Authorization or EUA following the successful global EMPATHY clinical study. Later, the U.S. Food and Drug Administration, or FDA asked that Phase 3 data be provided for their review. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The clinical development of ensovibep was halted in 2022 due to a lack of neutralization activity against omicron subvariants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Programs </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Abicipar</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Abicipar is a DARPin therapeutic candidate designed to inhibit vascular endothelial growth factor (VEGF). It is at the registrational stage as an investigational candidate for the treatment of neovascular (wet) age-related macular degeneration (nAMD). Abicipar is also an investigational candidate for diabetic macular edema, or DME. Abicipar is designed to remain in the eye longer than current treatments and consequently offers the potential for less frequent dosing. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Molecular Partners regained global development and commercial rights to abicipar for the treatment of neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME). The Company has reported two positive Phase 3 clinical trials of abicipar, CEDAR and SEQUOIA, which supported the non-inferior efficacy of its quarterly dosing regimen with 50 % fewer injections than ranibizumab.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are currently evaluating potential business development opportunities for abicipar.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain, maintain, enforce and defend patents and other intellectual property and proprietary protection for our product candidates and technology</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to preserve the confidentiality of our trade secrets,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to operate without infringing, misappropriating or otherwise violating patents and other proprietary rights of others, and to prevent others from infringing, misappropriating or otherwise violating our patent and other proprietary rights. We seek to protect our proprietary position by, among other methods, filing patent applications covering our proprietary technology, improvements thereof, product candidates, and other inventions in Europe, the United States, and Japan, as well as in other relevant jurisdictions that are important to the development of our business, including Australia, Canada, South Korea and China. To protect </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, we rely on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">trade secrets, know-how, confidential information and continuing technological innovation. We also rely on in-licensing opportunities to develop and maintain our proprietary position. We may further rely on statutory market exclusivity and patent term extensions that may be available for our product candidates once they achieve regulatory approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We maintain three categories of patent protection for, respectively, our DARPin technology platform, key single-binding domain DARPin proteins binding to specific targets and our DARPin product candidates. The first category of protection covers our DARPin technology platform:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In an effort to stay a leader in the field of repeat protein technology, we have continued to work on improving the basic ankyrin repeat protein technology and have filed patent applications covering these improvements. Furthermore, we have enhanced our efforts to innovate in the ankyrin repeat protein field, including by developing new molecular designs, by generating ankyrin repeat proteins with novel modes of action, and by applying the ankyrin repeat protein technology to new disease areas and new target classes. We have translated this enhanced innovation into the generation of new intellectual property and have expanded our patent portfolio in the last couple of years. Taken together, we have made progress in protecting improvements of the DARPin base technology and innovative new aspects and applications of the DARPin technology in newly filed patent applications. However, we can provide no assurances that any such patent applications will be issued as patents.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">One example of a patent family that we own in this category is based on international patent application WO 2012/069655, relating to DARPin binding proteins comprising certain improved N-terminal capping modules. As of December 31, 2022, we owned three issued U.S. patents, nine issued foreign patents (i.e. patents granted in jurisdictions other than the U.S.) and one pending foreign patent application in this family. Any issued patents in this family are expected to expire in 2031. The disclosed improvement of the DARPin platform is included in our DARPin product candidates MP0250, MP0274, MP0310, MP0317, MP0420 (ensovibep), MP0423 and MP0533.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Other patent applications falling in this category have been filed and are currently being prosecuted.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A second category of protection covers our key single-binding domain DARPin proteins binding to specific targets. These single domain DARPin binding proteins can be used in multiple DARPin product candidates. Our patent applications and corresponding patents directed to key single domain DARPin binding proteins currently include: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">One example of a patent family that we own in this category is based on international patent application WO 2010/060748, relating to single domain DARPin binding proteins with specificity for vascular endothelial growth factor A, or VEGF-A. As of December 31, 2022, we owned one issued U.S. patent and 31 issued foreign patents in this family. Any issued patents in this family are expected to expire in 2029, with the exception of one U.S. patent that received patent term adjustment and is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expected to expire in 2031. VEGF-specific DARPin binding proteins are used in our DARPin product candidates abicipar and MP0250.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2014/191574, relating to single domain DARPin binding proteins with specificity for hepatocyte growth factor, or HGF. As of December 31, 2022, we owned one issued U.S. patent and seven issued foreign patents in this family. Any issued patents in this patent family are expected to expire in 2034. An HGF-specific DARPin binding protein is used in our DARPin product candidate MP0250.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2012/069654, relating to single domain DARPin binding proteins with specificity for human serum albumin, or HSA. As of December 31, 2022, we owned two issued U.S. patents, 21 issued foreign patents and seven pending foreign patent applications in this family. Any issued patents in this family are expected to expire in 2031. HSA-specific DARPin binding proteins are used in our DARPin product candidates MP0250, MP0274, MP0310, MP0317, MP0420 (ensovibep), MP0423 and MP0533.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2014/083208, relating to DARPin product candidates comprising two different DARPin binding proteins that bind to specific, but distinct, sites on HER2. As of December 31, 2022, we owned one issued U.S. patent, 13 issued foreign patents and three pending foreign patent applications in this family. Any issued patents in this patent family are expected to expire in 2033. Such a DARPin molecule comprising two different HER2-specific DARPin binding proteins is used in our product candidate MP0274.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2020/245173, relating to single domain DARPin binding proteins with specificity for fibroblast activation protein, or FAP. As of December 31, 2022, we owned one pending U.S. patent application and 12 pending foreign patent applications in this family. Any issued patents in this family are expected to expire in 2040. FAP-specific DARPin binding proteins are used in our DARPin product candidates MP0310 and MP0317.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2020/245175, relating to single domain DARPin binding proteins with specificity for 4-1BB. As of December 31, 2022, we owned one pending U.S. patent application and six pending foreign patent applications in this family. Any issued patents in this family are expected to expire in 2040. 4-1BB-specific DARPin binding proteins are used in our DARPin product candidate MP0310.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2020/245171, relating to improved single domain DARPin binding proteins with specificity for HSA. As of December 31, 2022, we owned one pending U.S. patent application and 13 pending foreign patent applications in this family. Any issued patents in this family are expected to expire in 2040. Disclosed HSA-specific DARPin binding proteins are used in our DARPin product candidates MP0310, MP0317 and MP0533.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Other patent applications falling in this category have been filed and are currently being prosecuted.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A third category of protection covers the composition of matter of certain of our DARPin product candidates (e.g., the specific combination and structure of DARPin binding proteins and additional elements that constitute the DARPin product candidate) as well as other product-specific inventions (e.g. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">formulation, manufacturing process or dosing schedule). Our patent applications and corresponding patents directed to our DARPin product candidates currently include:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">One example of a patent family that we own in this category is based on international patent application WO 2011/135067, relating to abicipar. As of December 31, 2022, we owned four issued U.S. patents, one pending U.S. patent application, 63 issued foreign patents and five pending foreign patent applications in this family. Any issued patents in this family are expected to expire in 2031, not considering any patent term extensions that may be available in various jurisdictions if abicipar obtains regulatory approval there.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of patent family in this category is based on international patent application WO 2016/156596, relating to MP0250. As of December 31, 2022, we owned three issued U.S. patents, 11 issued foreign patents and 17 pending foreign patent applications in this family. Any patent that has been or may be granted in this patent family is expected to expire in 2036, not considering any patent term extensions that may be available in various jurisdictions if MP0250 obtains regulatory approval there.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2018/054971, relating to MP0274. As of December 31, 2022, we owned one issued U.S. patent, 11 issued foreign patents and 12 pending foreign patent applications in this family. Any patent that has been or may be granted in this patent family is expected to expire in 2037, not considering any patent term extensions that may be available in various jurisdictions if MP0274 obtains regulatory approval there.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Another example of a patent family in this category is based on international patent application WO 2020/245746, relating to MP0310. As of December 31, 2022, we owned one pending U.S. patent application and 22 pending foreign patent applications in this family. Any patents that may be granted in this patent family are expected to expire in 2040, not considering any patent term extensions that may be available in various jurisdictions if MP0310 obtains regulatory approval there.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Other patent applications falling in this category have been filed, including patent applications relating to abicipar, MP0317, ensovibep, MP0423 and MP0533. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The actual protection afforded by a patent may vary on a product-by-product basis and from country to country and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term of an individual patent depends upon the legal term for patents in the countries in which they are granted. In most jurisdictions, including the United States and countries that are members of the European Patent Convention, the patent term is generally 20 years from the earliest effective filing date of a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over a co-owned patent or patent application having an earlier expiration date or over a non-commonly owned patent or patent application having an earlier expiration date that was filed as a result of activities undertaken within the scope of a joint research agreement. In addition, patent term provisions are available in the United States, the member states of the European Union and certain other jurisdictions to extend the term of a patent that covers an approved drug to recapture a portion of the term effectively lost as a result of the regulatory review period. However, in the United States, the restoration period cannot be longer than five years, the total patent term including the restoration period must not exceed 14 years following FDA approval, only one patent applicable to each regulatory review period may be extended </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and only those claims covering the approved drug, a method for using it or a method of manufacturing it may be extended. In the future, if and when our product candidates, including abicipar, MP0250, MP0274, MP0310, MP0317, ensovibep, MP0423 and MP0533, receive approval by the FDA, EMA or any other relevant jurisdiction&#8217;s regulatory authorities, we expect, where possible, to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each product candidate and other factors. The expiration dates referred to above are without regard to potential patent term extensions that may be available to us and without regard to potential patent term adjustments or terminal disclaimers that may become applicable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding our efforts, we cannot be sure that patents will be granted with respect to any patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or that have been granted to us, or any patents that may be licensed or granted to us in the future, will not be challenged, invalidated, rendered unenforceable or circumvented or that such patents will be commercially useful in protecting our technologies or product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may rely, in some circumstances, on trade secrets and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">know-how</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to protect our technology. However, trade secrets and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">know-how</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> can be difficult to protect. We seek to protect our proprietary technology and processes, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We own registrations for certain trademarks, including &#8220;Molecular Partners&#8221;, in Switzerland, the European Union, the United States and Japan. Further, we intend to build up a trademark portfolio for our technologies and product candidates as potential branding and commercialization approaches.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">License and Collaboration Agreement with Novartis in the Area of DARPIN Conjugated Radioligand Therapies </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December&#160;14, 2021, we entered into a license and collaboration agreement with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology, or the Novartis Radioligand Agreement. Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. We are primarily responsible for the generation of DARPins for tumor-specific delivery of radioligands. We are able to invoice Novartis for our employee-related expenses associated with the research activities. Novartis is responsible for all clinical development and commercialization activities. In January 2022, Novartis paid us an upfront fee of $20 million (CHF 18.6 million). Additionally , we are eligible to receive milestone payments of up to $560&#160;million, relating to development, regulatory and commercialization activities. We are also entitled to receive tiered royalties based on commercial sale levels from mid-single digit to low double-digit percentages of royalties on net sales of licensed products for a specified period beginning with the first commercial sale of a licensed product in a given country of sale and expiring on the latest of (a) the expiration of the last valid claim covering such product, (b) ten years after such sale and (c) expiration of the regulatory exclusivity.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option and Equity Rights Agreement with Novartis for Ensovibep</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2020, we entered into an agreement with Novartis, granting Novartis the exclusive option to in-license global rights in relation to MP0420 (ensovibep), or the Option and Equity Rights Agreement. Under the terms of the agreement, we in 2020 received an upfront, non-refundable fee of CHF&#160;20&#160;million </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the technology transfer and manufacturing of MP0420. We are eligible to utilize up to the maximum amount of this upfront fee for the manufacturing of the commercial supply for MP0420, which is required to be manufactured by Sandoz, a division of the Novartis Group. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As of December&#160;31, 2021, the entire CHF&#160;20&#160;million had been utilized for the manufacturing of commercial supply for MP0420. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ensovibep License Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2022, following positive Phase 2 clinical trial results, Novartis exercised its option for ensovibep, triggering a milestone payment of CHF&#160;150&#160;million due to us, which was received in 2022. Relatedly, we were eligible to invoice Novartis CHF&#160;13.1&#160;million for other items related to ensovibep.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following the exercise of such option, we entered into a license agreement, or the Ensovibep License Agreement, with Novartis under which we granted Novartis a sublicensable worldwide license to research, develop, manufacture, commercialize and otherwise use ensovibep and products comprising the compound in all indications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are eligible to receive a 22% royalty on future commercial sales. We agreed to forgo royalties in lower income countries, and are aligned with Novartis&#8217; plans to ensure affordability based on countries&#8217; needs and capabilities. Novartis is responsible for all further development and commercialization activities of ensovibep.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In January 2023 Novartis informed us that it has submitted a request to withdraw the Emergency Use Authorization (EUA) application from the FDA for ensovibep. Ensovibep is not presently in clinical development.The EUA application for ensovibep was withdrawn effective January 25, 2023</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reservation agreement with the Swiss Federal Office of Public Health / Bundesamt f&#252;r Gesundheit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August&#160;11, 2020, we announced the reservation by the Federal Office of Public Health, or FOPH, of a defined number of initial doses of our anti-COVID-19 candidate, MP0420. Under the terms of the agreement, we received a reservation fee of CHF&#160;7.0&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2021, we and the FOPH entered into an amendment to extend the term of the reservation agreement by six months. The amendment also allowed the agreement to be assigned to Novartis upon its exercise of the option under the Option and Equity Rights Agreement. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License and Collaboration Agreement with Amgen</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2018, we entered into a license and collaboration agreement with Amgen for the clinical development and commercialization of MP0310 / AMG 506, or the Amgen Collaboration Agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the agreement we received a non-refundable upfront payment of $50&#160;million and we granted to Amgen an exclusive worldwide, royalty-bearing, sublicensable license under our patents and know-how relating to MP0310 / AMG206 to develop and commercialize MP0310 / AMG506. We were primarily responsible for performing certain clinical development, manufacturing and regulatory activities in the first clinical phase.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April&#160;26, 2022 we announced that Amgen had informed us of its decision to return the global rights of MP0310 following a strategic pipeline review.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Government authorities in the United States (at the federal, state and local level) and in other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">U.S. Product Development Process</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, the FDA regulates pharmaceutical and biological products under the Federal Food, Drug and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">submission to the FDA of a Biologics Licensing Application, or BLA, for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FDA review and approval or licensure of the BLA.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">U.S. Review and Approval Processes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any product for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication or indications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physician deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. Violations, including actual or alleged promotion of products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or comparable foreign bodies. Any actual or alleged failure to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective information to healthcare practitioners, injunctions, or civil or criminal penalties.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. Other potential consequences include, among other things:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">restrictions on the marketing or manufacturing of the product;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">fines, warning letters, untitled letters, or clinical holds;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">adverse publicity, FDA mandated corrective advertising or communications with doctors;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">U.S. Marketing Exclusivity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act, or BPCIA, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from approving biosimilar applications referencing that biologic for 12 years after an innovator biological product receives initial marketing approval. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Laws</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A biopharmaceutical company&#8217;s operations may be directly, or indirectly through relationships with healthcare providers, healthcare institutions, patients, customers and third-party payors, subject to various federal and state healthcare laws and regulations. These laws impact, among other things, sales, marketing and education programs and may constrain business and financial arrangements and relationships with third-party payors, healthcare professionals and healthcare institutions who participate in a biopharmaceutical company&#8217;s clinical research programs, healthcare professionals and others who recommend, purchase, or provide a biopharmaceutical company&#8217;s approved drug products, and other parties through which it markets, sells and distributes its approved drug products. In addition, a biopharmaceutical company may be subject to patient data privacy and security regulation by both the federal government and the states in which it conducts its business. The laws that may affect a biopharmaceutical company&#8217;s ability to operate include:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the federal civil and criminal false claims laws, including, without limitation, the civil False Claims Act (which can be enforced through "qui tam," or whistleblower actions, by private citizens on behalf of the federal government), and the federal civil monetary penalties law, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or for knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, and as amended again by the Final HIPAA Omnibus Rule, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization on certain health plans, healthcare clearinghouses and healthcare providers, known as covered entities, as well as their business associates that perform certain services involving the use, disclosure or transmission of individually identifiable health information for or on behalf of a covered entity, and their covered subcontractors; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the Federal Food, Drug, and Cosmetic Act which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">the federal physician payment transparency legislation commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies (with certain exceptions) that are reimbursable under Medicare, Medicaid, or the Children's Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid, or CMS, information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is possible that governmental authorities will conclude that a biopharmaceutical company&#8217;s business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If a biopharmaceutical company&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, it may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The risk of being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. For example, the definition of "remuneration" under the federal Anti-Kickback Statute has been interpreted to include anything of value. Further, courts have found that if "one purpose" of remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, recent healthcare reform legislation has strengthened federal and state healthcare fraud and abuse laws. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes to clarify that liability under these statutes does not require a person or entity to have actual knowledge of the statutes or a specific intent to violate them in order to have committed a violation. Moreover, the ACA provides that the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a biopharmaceutical company&#8217;s business activities could be subject to challenge under one or more of such laws. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, there have been a number of legislative and regulatory changes at the federal and state levels which seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Among the provisions of the ACA of importance to biopharmaceutical companies are the following:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expansion of manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid drug rebates on outpatient </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage plans; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expanding the types of entities eligible for the 340B drug discount program; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing the Medicare Part D coverage gap discount program, which requires manufacturers to now provide a 70% point-of-sale-discount off the negotiated price of applicable products to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient products to be covered under Medicare Part D; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a licensure framework for follow-on biologic products;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishment of the Center for Medicare and Medicaid Innovation within CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription product spending.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, included a provision, which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argue the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011, among other things, includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2031 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning on January 1, 2024.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Further, there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Specifically, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials in the European Union</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the international council for harmonization, or ICH, guidelines on GCP. Additional GCP guidelines from the EC, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. The sponsor must take out a clinical trial insurance policy, and in most European Union countries, the sponsor is liable to provide &#8220;no fault&#8221; compensation to any study subject injured in the clinical trial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Previously, in the European Union, pursuant to the EU Clinical Trials Directive 2001/20/EC, a CTA had to be submitted to each country&#8217;s national regulatory authority in which the clinical trial was to take place, together with an independent ethics committee, much like the FDA and IRB, respectively. Although the Directive had sought to harmonize the EU clinical trials regulatory framework, EU Member States transposed and applied the provisions of the Directive differently, leading to significant variation in the regulatory regimes of the member states. In 2014, a new Clinical Trials Regulation 536/2014, replacing the current Directive, was adopted. The new Regulation is directly applicable in all EU Member States (without national implementation) and entered into application on 31 January 2022. The new Regulation seeks to simplify and streamline the approval of clinical trials in the European Union. Pursuant to the Regulation, the sponsor shall submit a single CTA via the EMA's Clinical Trials Information System, or CTIS, which will cover all regulatory and ethics assessments from the member states concerned.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any submissions made from January 31, 2023 onwards must be made through CTIS and all trials authorized pursuant to the Directive that are still ongoing on January 31, 2025 must be made through CTIS. Once the CTA is approved in accordance with a member state's requirements, clinical trial development may proceed. Approval and monitoring of clinical trials in the European Union is, as it was under the Directive, the responsibility of individual member states, but compared to the position prior to the applicability of the Clinical Trials Regulation there is likely to be more collaboration, information-sharing, and decision-making between member states. The new Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements, such as mandatory submission of a summary of the clinical trial results to a new E.U. Database. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials must be manufactured in accordance with cGMP. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the development of a medicinal product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the EMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and national medicines regulators within the European Union provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Marketing Authorizations in the European Union</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to market a new medicinal product in the European Union, a company must submit a marketing authorization application, or MAA, to either the EMA using the centralized procedure, or competent authorities in European Union Member States using the other procedures </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(decentralized procedure, national procedure, or mutual recognition procedure). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A marketing authorization, or MA may only be granted to an applicant established in the European Union, or Norway, Iceland, and Liechtenstein, who are members of the European Economic Area, or European Economic Area. Medicinal products can only be commercialized after obtaining an MA pursuant to one of the three processes outlined below:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the Centralized MA, which is issued by the European Commission through the Centralized Procedure, based on the scientific opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the European Union/European Economic Area. The Centralized Procedure is mandatory for certain types of products, such as (i) biotechnology medicinal products such as genetic engineering, (ii) orphan medicinal products, (iii) medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases and (iv) advanced-therapy medicines, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the European Union/European Economic Area, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Decentralized Procedure MAs are available for products not falling within the mandatory scope of the Centralized Procedure. An identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS, to lead the evaluation of the regulatory submission. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or SmPC, and a draft of the labeling and package leaflet as distilled from the preliminary evaluation, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">which are sent to the other Member States (referred to as the Concerned Member States) for their approval. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging proposed by the RMS, the RMS records the agreement, closes the procedure and informs the applicant accordingly. Each Member State concerned by the procedure is required to adopt a national decision to grant a national MA in conformity with the approved assessment report, SmPC and the labeling and package leaflet as approved. Where a product has already been authorized for marketing in a Member State of the European Economic Area, the granted national MA can be used for mutual recognition in other Member States through the Mutual Recognition Procedure, or MRP, resulting in progressive national approval of the product in the European Union/European Economic Area. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">National MAs, which are issued by a single competent authority of the Member States of the European Economic Area and only covers their respective territory, are also available for products not falling within the mandatory scope of the Centralized Procedure. Once a product has been authorized for marketing in a Member State of the European Economic Area through the National Procedure, this National MA can also be recognized in other Member States through the Mutual Recognition Procedure. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the procedures described above, before granting the MA, the EMA or the competent authority(ies) of the member state(s) of the European Economic Area prepare an assessment of the risk-benefit balance of the product against the scientific criteria concerning its quality, safety and efficacy. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Data Exclusivity in the European Union</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under Regulation (EC) No 726/2004/EC and Directive 2001/83/EC (each as amended), the European Union has adopted a harmonized approach to data and market protection or exclusivity (known as the 8 + 2 + 1 formula). The data exclusivity period begins to run on the date when the first MA is granted in the European Union. It confers on the MA holder of the reference medicinal product eight years of data exclusivity and ten years of market exclusivity. A reference medicinal product is defined to mean a medicinal product authorized based on a full dossier consisting of pharmaceutical and preclinical testing results and clinical trial data, such as a medicinal product containing a new active substance. The ten-year market protection can be extended cumulatively to a maximum period of eleven years if during the first eight years of those ten years of protection period, the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The exclusivity period means that an applicant for a generic medicinal product is not permitted to rely on preclinical pharmacological, toxicological, and clinical data contained in the file of the reference medicinal product of the originator until the first eight years of data exclusivity have expired. Thereafter, a generic product application may be submitted and generic companies may rely on the preclinical and clinical data relating to the reference medicinal product to support approval of the generic product. However, a generic product cannot market until ten years have elapsed from the initial authorization of the reference medicinal product or eleven years if the protection period is extended, based on the formula of 8+2+1.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the above, where an application is made for a new indication for a well-established substance, a non-cumulative period of one year of data exclusivity may be granted, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Finally, where a change of classification of a medicinal product has been authorized on the basis of significant preclinical tests or clinical trials, the competent authority shall not refer to the results of those tests or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">trials when examining an application by another applicant for or holder of marketing authorization for a change of classification of the same substance for one year after the initial change was authorized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 8 + 2 + 1 exclusivity scheme applies to products that have been authorized in the European Union by the European Commission through the Centralized Procedure or the competent authorities of the Member States of the European Economic Area nationally, including through the Decentralized and Mutual Recognition procedures. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For a medicinal product which has received orphan designation under Regulation 141/2000, it will, benefit from a period of ten years of orphan market exclusivity which essentially constitutes a period of market monopoly. During this period of orphan market exclusivity, no European Union regulatory authority is permitted to accept or approve an application for marketing authorization for a similar medicinal product or an extension application for the same therapeutic indication. This period can be extended cumulatively to a total of twelve years if the marketing authorization holder or applicant complies with the requirements for an agreed pediatric investigation plan pursuant to Regulation 1901/2006. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Post Authorization Obligations in the European Union</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The holder of a Centralized MA or National MA is subject to various obligations under the applicable European Union laws, such as pharmacovigilance obligations, requiring it to, among other things, report and maintain detailed records of adverse reactions, and to submit periodic safety update reports, or PSURs, to the competent authorities. All new marketing authorization applications must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. The holder must also ensure that the manufacturing and batch release of its product is in compliance with the applicable requirements. The MA holder is further obligated to ensure that the advertising and promotion of its products complies with applicable European Union laws and industry code of practice as implemented in the domestic laws of the Member States of the European Union/European Economic Area. The advertising and promotional rules are enforced nationally by the European Union/European Economic Area Member States.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Development in the European Union</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or PIP, with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The marketing authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Pricing and Reimbursement in the European Union </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Governments influence the price of medicinal products in the European Union through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other European Union Member States allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Brexit and the Regulatory Framework in the United Kingdom </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following the result of a referendum in 2016, the United Kingdom officially withdrew from the European Union on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom was subject to a transition period until December 31, 2020, during which European Union rules continued to apply. A trade and cooperation agreement, or the Trade and Cooperation Agreement, which outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020 and formally entered into force on May 1, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Great Britain is no longer covered by the European Union&#8217;s procedures for the grant of marketing authorizations (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). Various national procedures are now available to place a drug on the market in the United Kingdom, Great Britain, or Northern Ireland, with the main national procedure having a maximum timeframe of 150 days (excluding time taken to provide any further information or data required). The data exclusivity periods in the United Kingdom are currently in line with those in the European Union, but the Trade and Cooperation Agreement provides that the periods for both data and market exclusivity are to be determined by domestic law, and so there could be divergence in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Orphan designation in Great Britain following Brexit is, unlike in the European Union, not available pre-marketing authorization. Applications for orphan designation are made at the same time as an application for a marketing authorization. The criteria to be granted an orphan drug designation are essentially identical to those in the European Union, but based on the prevalence of the condition in Great Britain. It is therefore possible that conditions that were or would have been designated as orphan conditions in Great Britain prior to the end of the Transition Period are or would no longer be and that conditions that were not or would not have been designated as orphan conditions in the European Union will be designated as such in Great Britain. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The European Union&#8217;s regulatory environment for clinical trials has been harmonized as part of the Clinical Trials Regulation, which entered into application on January 31, 2022. The MHRA has opened a consultation on proposed revisions to United Kingdom clinical trials legislation, but it is currently unclear as to what extent the United Kingdom will seek to align its regulations with the European Union. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The availability of coverage and adequate reimbursement by third-party payors, including governmental healthcare programs such as Medicare and Medicaid, private health insurers and managed care organizations, is essential for most patients to be able to afford drug products. Achieving acceptable levels of coverage and reimbursement for drug products by third-party payors affects a biopharmaceutical company&#8217;s ability to successfully commercialize, and attract collaboration partners to invest in, the development its drug products. Even if coverage is obtained from a third-party payor for a given drug product, the resulting reimbursement rates may not be adequate or may require co-payments that patients find unacceptably high. There is no guarantee that coverage and reimbursement will be provided for a given drug product, and any reimbursement that may become available can be decreased or eliminated in the future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging prices charged for drug products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drug products when an equivalent generic drug product or a less expensive therapy is available. It is possible that a third-party payor may consider a drug product and other therapies as substitutable and only offer to reimburse patients for the less expensive drug product or therapy. Even if a drug product shows improved efficacy or improved convenience of administration, pricing of existing drug products may limit the amount that can be charged for a new drug product. Third-party payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed drug products at levels that are too low to enable a biopharmaceutical company to realize an appropriate return on its investment in drug product development. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drug products. In the United States, third-party payors play an important role in determining the extent to which new drugs products will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drug products. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug products before they will reimburse health care providers who use such therapies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that requires the provision of scientific and clinical support for the use of a drug product to each payor separately. Furthermore, rules and regulations regarding reimbursement change frequently and, in some cases, upon short notice. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations. Increasing emphasis on cost-containment initiatives in Europe, Canada and other countries puts pressure on the pricing and usage of drug products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">systems. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of drug products, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of drug products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of drug products by relevant health service providers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Increasing efforts by governmental and third-party payors in the European Union, the United States and abroad to cap or reduce healthcare costs can cause such organizations to limit coverage and reimbursement for drug products. Additionally, a trend toward managed healthcare, and the influence of health maintenance organizations, have increased pricing pressure on the sale of drug products. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We compete in a highly innovative industry characterized by a rapidly growing understanding of disease biology, evolving technologies and strong intellectual property barriers to entry. While we believe that our DARPin platform and product candidates, strategic collaborations and scientific expertise may provide us with competitive advantages, our business may be impacted competitively from many different sources. We compete with a wide range of pharmaceutical companies, biotechnology companies, academic institutions and other research organizations for novel therapeutic antibody targets, new technologies for optimizing antibodies, talent, financial resources, intellectual property rights and collaboration opportunities. Many of our competitors and potential competitors have substantially greater scientific, research and product development capabilities, and greater financial, manufacturing, marketing and sales and human resources than we do. In addition, there is intense competition for establishing clinical trial sites and recruiting and registering patients for clinical trials. Many specialized biotechnology companies have formed collaborations with large, established companies to support the research, development and commercialization of products that may be competitive with ours. Accordingly, our competitors may be more successful than we may be in developing, commercializing and achieving widespread market acceptance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regarding ensovibep and MP0423, our COVID-19 antiviral product candidates, there are a number of preventative vaccines in development for COVID-19, with three receiving an Emergency Use Authorization to date. However, as, in our view, vaccine coverage and efficacy will be less than 100%, we believe there will remain a need for therapeutic intervention for COVID-19 patients. There are hundreds of clinical trials examining various methods of treating COVID-19. To date, only a small number of these trials have resulted in data positive enough for regulators to approve therapeutics on either an emergency use or permanent basis. Therapeutics receiving Emergency Use Authorization for the treatment of COVID-19 patients include Paxlovid from Pfizer, Inc., baricitinib (in combination with remdesivir), and bamlanivimab from Eli Lilly, and remdesivir from Gilead Sciences, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competition in the oncology space is intense, with several common methods of treatment for patients with cancer, including surgery, radiation and drug therapy, and approved drugs that are well established therapies widely accepted by physicians, patients and third party payers. In addition, companies focused on immunotherapies, such as checkpoint inhibitors, seek to differentiate their oncology products either by identifying novel immune checkpoint targets or by combining established immune checkpoint inhibitors. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If approved, MP0317 would compete with agents that are currently in development including monoclonal antibodies, or mAbs, and other small molecule approaches. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We face competition from segments of the pharmaceutical, biotechnology and other related markets with respect to our CD3 and peptide-MHC, or pMHC, programs. Any product candidates that we successfully develop and commercialize from these platforms may compete with existing products and new products that may become available in the future. There is intense competition in the field from multiple different treatment modalities and new approaches are continually emerging from different competitors, including Adaptimmune Therapeutics plc, TCR&#178; Therapeutics, Immatics N.V., Immunocore Holdings plc and Harpoon Therapeutics Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competition in the ophthalmology space is intense, with currently approved anti-vascular endothelial growth factors, or VEGFs, such as Lucentis, Beovu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Eylea, as well as Avastin, which is widely prescribed off-label, are well established therapies and are widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of nAMD. There are several other companies with marketed products or products in development for the treatment of nAMD, including Novartis, Roche, Bayer, Kodiak Sciences, REGENXBIO and Adverum Biotechnologies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If approved for the treatment of nAMD, abicipar is expected to compete with both approved anti-VEGF monotherapies, anti-platelet-derived growth factor, or PDGF therapies that are currently in development for combination therapy and multispecific drugs targeting both VEGF and PDGF. In addition, we may face competition from a number of product candidates currently in development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If approved for treatment of DME, abicipar is expected to compete with currently approved therapies including steroids, laser therapy and anti-VEGF agents. Anti-VEGF drugs currently approved for DME include Lucentis, Eylea, Macugen,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as well as Avastin, which is used off-label. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors&#8217; products prove to be safer and more tolerable, more effective, more convenient to dose, less expensive, faster to approve, or more effectively marketed and reimbursed than any of our product candidates that may gain regulatory approval. In addition, the level of generic competition and the availability of reimbursement from government and other third-party payors will impact the commercial viability of our programs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our DARPin product candidates. We utilize third-party contract manufacturers for the manufacture of drug substances and products for human use. Since we rely on third-party contract manufacturers to produce our proprietary product candidates, we have recruited personnel with experience to manage the third-party contract manufacturers that will produce our proprietary product candidates in clinical or commercial quantities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We design and develop the manufacturing process for the mono-DARPin proteins and multi-DARPin product candidates that are included in our DARPin product candidates, whether or not they are partnered. For purposes of our and our partner&#8217;s DARPin preclinical studies, we supply high quality gram scale DARPin material that we produce in our own facilities. We currently operate both a five- and ten-liter fermenter, which provides us with sufficient capacity to produce the quantities needed for DARPin preclinical studies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 175 full-time equivalent employees (December&#160;31, 2021: 163 full-time equivalents). None of our employees are represented by collective bargaining agreements. We believe </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that we maintain good relations with our employees. At each date shown, we had the following number of full-time equivalent employees, broken out by department. The majority of our employees are based in Zurich, Switzerland. Two of our employees are based in the United States of America.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Full-time equivalent employees</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">At December 31,</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">At December 31,</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Function</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">142.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">134.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">175.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">163.2</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_49"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Organizational Structure. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following diagram illustrates our corporate structure: </span></div><div style="margin-bottom:8pt"><img src="moln-20221231_g9.jpg" alt="moln-20221231_g9.jpg" style="height:190px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_52"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Property, Plants and Equipment. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We lease our principal executive office and laboratory space, animal facility and other facilities, consisting of an aggregate of 3,200 square meters, in Zurich-Schlieren, Switzerland. The leases for our principal executive office and laboratory space expire on December 31, 2026. We also have an office in Massachusetts for our U.S. subsidiary, Molecular Partners Inc. consisting of 19 square meters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe our current facilities are sufficient to meet our short-term needs. If we need to add new facilities or expand existing facilities as we add employees, we believe that suitable additional space will be available to accommodate any such expansion of our operations.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_55"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4A. Unresolved Staff Comments. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_58"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5. Operating and Financial Review and Prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company pioneering designed ankyrin repeat proteins or DARPin candidates to treat serious diseases, with a current focus on oncology and virology. Our DARPin </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">platform, which is built using designed DARPins, allows us to generate candidates with multiple mechanisms of action to address complex biological problems. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DARPins are a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics. Our DARPin candidates have been extensively tested in preclinical studies and clinical trials, including in approximately 2,500 patients since our founding, and have been observed to be highly active and generally well-tolerated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We were founded in 2004 by the inventors of our DARPin platform. Our senior management, which includes two of our company&#8217;s co-founders, have significant prior experience in oncology, research, drug development and finance. Members of our team have served as senior executives at other well-established companies including argenx, Bavarian Nordic, Celgene, Roche, Novartis and Tesaro. Additionally, our board of directors includes current and former senior executives of AbbVie (Allergan), Biogen, Novartis, Novo Holdings Advisory Group, Roche and Takeda (Millennium Pharmaceuticals, Shire). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have research collaboration agreements with Novartis as well as other third party collaborators. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our operations to date have focused upon organizing and staffing our company, business planning, raising capital, developing our DARPin platform and conducting research and preclinical studies and clinical trials. We do not have any products approved for sale. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we incurred a positive net result, attributable to shareholders of CHF 117.9 million whereas for the years ended December 31, 2021 and 2020, we incurred negative net results, attributable to shareholders of CHF 63.8 million and CHF 62.8 million, respectively. As of December&#160;31, 2022, we had cumulative losses of CHF 127.8 million. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is no assurance that such positive net results similar to the year ended December 31, 2022 will be achieved or maintained in future periods, as the Company plans to continue to invest into research and development activities as they are fundamental to executing its strategic objectives. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, we have received a total of CHF 446.2 million in funding from our major partnership agreements. From inception through December&#160;31, 2022, we have obtained a total of CHF 322.5 million in eight equity financing rounds, net of cost of capital increases. Since November 2014, we have been listed on the SIX Swiss Exchange, or SIX, under the symbol &#8220;MOLN.&#8221; Since June 16, 2021, we have also been listed on the Nasdaq Global Select Market, under the symbol &#8220;MOLN.&#8221; As of December&#160;31, 2022, we had cash and cash equivalents plus short-term time deposits of CHF 249.1 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Macroeconomic Considerations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unfavorable conditions in the economy both in the United States and abroad may negatively affect the growth of our business and our results of operations. For example, macroeconomic events, including the COVID-19 pandemic, rising inflation, the U.S. Federal Reserve and other foreign financial regulatory agencies raising interest rates and the Russia-Ukraine war, have led to economic uncertainty globally. The effect of macroeconomic conditions may not be fully reflected in our results of operations until future periods. If, however, economic uncertainty increases or the global economy worsens, our business, financial condition and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events on our business, financial condition, and operating results, see the section titled &#8220;Risk Factors.&#8221;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensing and Collaboration Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">License and Collaboration Agreement with Novartis in the Area of DARPIN-Conjugated Radioligand Therapies ("Novartis Radioligand Agreement") </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December&#160;14, 2021, we entered into the Novartis Radioligand Agreement with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2022, we received a non-refundable upfront payment of $20&#160;million (CHF 18.6 million) from Novartis. In addition, we are eligible to receive milestone payments of up to $560 million relating to  development, regulatory and commercialization activities. We are also entitled to receive tiered royalties based on commercial sale levels from mid-single digit to low double-digit percentages of net sales of licensed products for a specified period beginning with the first commercial sale of a licensed product in a given country of sale and expiring on the latest of (a) the expiration of the last valid claim covering such product, (b) ten years after such sale, and (c) expiration of regulatory exclusivity. See &#8220;Item 4.B-Business Overview of License and Collaboration Agreements.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option and Equity Rights Agreement with Novartis for Ensovibep (the "Option and Equity Rights Agreement")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2020, we entered into an agreement with Novartis, granting Novartis the exclusive option to in-license global rights in relation to MP0420 (ensovibep). Under the terms of the Option and Equity Rights Agreement, in 2020 we received an upfront, non-refundable fee of CHF&#160;20&#160;million for the technology transfer and manufacturing of MP0420. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are eligible to utilize up to the maximum amount of this upfront fee for the manufacturing of the commercial supply for MP0420, which is required to be manufactured by Sandoz, a division of the Novartis Group. All such amounts paid for manufacturing performed by the Novartis Group is considered to be a consideration payable to a customer. See &#8220;Item 4.B-Business Overview of License and Collaboration Agreements.&#8221;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ensovibep License Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2022, following positive Phase 2 clinical trial results, Novartis exercised its option for ensovibep, triggering a milestone payment of CHF&#160;150&#160;million due to us, which was received in 2022. Relatedly, we were eligible to invoice Novartis CHF&#160;13.1&#160;million for other items related to ensovibep.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following the exercise of such option, we entered into the Ensovibep License Agreement, with Novartis under which we granted Novartis a sublicensable worldwide license to research, develop, manufacture, commercialize and otherwise use ensovibep and products comprising the compound in all indications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are eligible to receive a 22% royalty on future commercial sales. We agreed to forgo royalties in lower income countries, and are aligned with Novartis&#8217; plans to ensure affordability based on countries&#8217; needs and capabilities. Novartis is responsible for all further development and commercialization activities of ensovibep. See &#8220;Item 4.B-Business Overview of License and Collaboration Agreements.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reservation Agreement with the Swiss Federal Office of Public Health / Bundesamt f&#252;r Gesundheit ("FOPH")</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August&#160;11, 2020, we announced the reservation by the FOPH of a defined number of initial doses of our anti-COVID-19 candidate, MP0420. Under the terms of the agreement, we received a reservation fee of CHF&#160;7.0&#160;million. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2021, we and the FOPH entered into an amendment to extend the term of the reservation by six months. The amendment also allowed the agreement to be assigned to Novartis upon its exercise of the option under the Option and Equity Rights Agreement. Following the exercise of the option by Novartis in January 2022 and the subsequent assignment of the agreement to Novartis, we recognized the CHF&#160;7.0&#160;million contract liability as revenue in 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License and Collaboration Agreement with Amgen (the "Amgen Collaboration Agreement")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2018, we entered into the Amgen Collaboration Agreement for the clinical development and commercialization of MP0310 / AMG 506. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Under the agreement, we granted to Amgen an exclusive worldwide, royalty-bearing, sublicensable license under our patents and know-how relating to MP0310 / AMG 506 to develop and commercialize MP0310 / AMG 506. In April 2022, Amgen informed us of its decision to return the global rights of MP0310 to us following a strategic pipeline review.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Royalties and License Fees</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until October 2021, we held an exclusive perpetual license from the University of Zurich on patent applications and patents relating to the DARPin base technology. We terminated the applicable license agreement with effect as of October 2021 as the main patents under this agreement expired in September 2021. For the years ended December 31, 2021 and 2020 the minimum amounts of CHF 50,000 were payable by us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We currently now only hold a non-exclusive perpetual license from the University of Zurich on patent applications and patents relating to Phage Display technology. The amount we are required to pay is CHF 10,000 per annum. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In May 2020, we entered into a research collaboration agreement with the University of Utrecht regarding the development of our COVID-19 program. Under this agreement, we paid a fee of CHF 250,000 to the University of Utrecht in December 2020. An additional fee of CHF 250,000 was accrued as per December&#160;31, 2021 and payable under this agreement. With Novartis exercising its option under the Option and Equity Rights Agreement, the University of Utrecht was owed a further CHF&#160;1.0&#160;million that was expensed and paid during 2022.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_61"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As described above, we have entered into partnerships pursuant to which we generally have been and will be entitled to upfront fees and milestone payments upon the achievement of pre-determined development, regulatory and sales events. Our revenue to date has primarily consisted of amounts received under our collaboration agreements, including upfront fees, option exercise fees, milestone payments and sponsored research payments. In addition, under the collaboration agreements, we will generally be entitled to royalty payments on the net sales of products ultimately developed and commercialized under our partnerships. For any of our proprietary product candidates that we have not yet licensed, we may decide to retain all or a portion of the commercialization rights. To date, we have not generated any revenue from commercial product sales.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our revenue may vary substantially from quarter to quarter and year to year, depending on the structure and timing of milestone events, as well as the development and marketing strategies of commercialization partners from whom we will be entitled to receive royalty and other payments. We believe that period-to-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">period comparisons of our results of operations are therefore not meaningful and should not be relied on or to be indicative of our future performance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our operating expenses consist primarily of costs associated with research, preclinical studies and clinical testing, personnel-related costs and, to a lesser extent, royalty and license fees, facility expenses, professional fees for legal, tax, audit and strategic purposes, administrative expenses and depreciation of property, plant and equipment. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our operating expenses to increase as compared to prior periods in connection with our ongoing activities, particularly as we continue the development of our proprietary product candidates, expand our proprietary product pipeline and invest in our DARPin platform. Our operating expenses may vary substantially from period to period mainly driven by the timing of enrollment of patients in clinical trials and other research and development activities. Following our listing on the Nasdaq Global Select Market in June 2021, we have and expect to continue to incur additional costs associated with operating as a public company in the United States. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of compensation and other expenses related to:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development personnel; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical studies and clinical trials of our product candidates, including the costs of manufacturing the product candidates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and services under our partnership agreements; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Attributable facility expenses, including depreciation and amortization of equipment and any intangible research and development assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, we cumulatively have spent a cash amount of approximately CHF&#160;431&#160;million on research and development activities which we classify as research and development expense for financial reporting purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing product candidates, including the uncertainty of: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that we may develop; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates that we pursue; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing, and outcomes of regulatory approvals; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing and distribution capabilities; and </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone and royalty payments thereunder. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our current or future product candidates could mean a significant change in the costs and timing associated with the development of such product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At this time, due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of many of our programs and/or product candidates, we generally do not track our internal research and development expenses on a program-by-program basis as they primarily relate to personnel, research and consumable costs, which are deployed across multiple projects under development. A portion of our research and development costs are external costs, which we do track on a program-by-program basis following the program's nomination to the development candidate stage. Included in table below are our external research and development expenses as well as external clinical and regulatory costs, presented by our most significant programs:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:55.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the year ended</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the year ended</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the year ended</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">External research and development expense</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0250</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0274</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0310</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0317</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0533</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MP0420 / MP0423</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other research and development expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18,540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">26,701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">27,260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We charge all research and development expenses, including internal patent filing and patent maintenance costs, to research and development expenses when incurred, as the criteria for capitalization are currently not met.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our selling, general and administrative costs principally consist of salaries and related benefits, including share-based compensation, for personnel in our executive, finance and other administrative functions. Other selling, general and administrative costs include facility-related costs and professional services fees for auditing, tax and general legal services, as well as expenses associated with the requirements of being a listed public company listed both in Switzerland on the SIX and in the United States on Nasdaq. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Financial income and financial expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial income consists primarily of interest earned on our cash and cash equivalents and short-term time deposits as well as realized and unrealized gains of foreign exchange. The financial expenses are driven by realized and unrealized foreign exchange losses and negative interest on certain cash balances. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Income taxes and taxation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have operating entities in two jurisdictions. In Switzerland, due to losses incurred to-date, we have not paid any income taxes since inception. For our U.S. based activities, we have paid the required tax amounts of both federal and state taxes, which are not material to our financial results.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Deferred taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are entitled under Swiss laws to carry forward any losses incurred for a period of seven years and can offset our losses carried forward against future taxes. As of December&#160;31, 2022, in Switzerland, we had tax loss carry-forwards totaling CHF&#160;88.2&#160;million. No deferred tax assets have been recognized for these tax loss carry-forwards because as of December&#160;31, 2022 it was not probable that such loss carry-forwards can be utilized in the foreseeable future. In addition, no deferred tax assets were recognized on other deductible temporary differences (e.g. pension liabilities) due to the significant tax losses carried forward. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based upon the 2022 received payments from Novartis, we are reporting an operating profit as well as positive cash flows from operations for the year ended December&#160;31, 2022. There is no assurance that such positive metrics will be achieved or maintained in future periods, as we plan to continue to invest into research and development activities as they are fundamental to executing Molecular Partners&#8217; strategic objectives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Operating Results </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Analysis of Results of Operations </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Operations for the Years Ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table sets forth summaries of our statements of income for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands CHF):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:60.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the year ended </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the year ended </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the year ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenues and other income</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenues from research and development collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">189,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">189,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(50,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(55,718)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(56,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(17,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(11,595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(72,987)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(73,172)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(67,670)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating result</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">116,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(63,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(58,326)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,859&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Result before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">117,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(63,783)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(62,775)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net result, attributable to shareholders</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">117,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(63,785)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(62,764)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Revenues and other income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the year ended December&#160;31, 2022, we recognized total revenues and other income of CHF&#160;189.6&#160;million, an increase of CHF&#160;179.8&#160;million compared to the previous year. Revenues in 2022 were primarily driven by the funds received from Novartis following its exercise of the option under the Ensovibep License Agreement. In addition, we recorded revenue derived from the Novartis Radioligand Agreement. The revenue in 2021 and 2020 related largely to the Amgen Collaboration Agreement. In 2022 and 2021 we also recorded other income related to agency fees that were invoiced to Novartis. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses (including depreciation and amortization)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2022 total operating expenses remained largely similar, decreasing by CHF&#160;0.2&#160;million to CHF&#160;73.0&#160;million (2021: CHF&#160;73.2&#160;million, 2020: CHF&#160;67.7&#160;million). These costs included CHF&#160;6.2&#160;million in non-cash effective share-based compensation and pension costs as well as CHF&#160;2.4&#160;million in depreciation. The two major expense categories were consistently personnel expenses of CHF&#160;39.9&#160;million (55% of total operating expenses) and research consumables and project costs totaling CHF&#160;17.2&#160;million (24% of total operating expenses). </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total research and development expenses in 2022 were CHF&#160;50.7&#160;million (2021: CHF&#160;55.7&#160;million, 2020: CHF&#160;56.1&#160;million). We charge all research and development expenses, including internal patent filing and patent maintenance costs, to the income statement when incurred. While the research and development expenses for the years ended December 31, 2021 and 2020 increased due to the development of MP0420, these expenses were reduced in the year ended December 31, 2022, following the exercise of the option under the Ensovibep License Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total SG&amp;A expenses in 2022 increased by CHF&#160;4.8&#160;million (+28%) to CHF&#160;22.3&#160;million (2021: CHF&#160;17.5&#160;million, 2020: CHF&#160;11.6&#160;million), mainly reflecting the first full 12 month period of D&amp;O insurance cost and professional services costs associated with our June 2021 listing on the NASDAQ as well as growth in personnel costs for the administrative functions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Financial income / financial expense</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2022, we recorded a net financial gain of CHF&#160;1.2&#160;million, mainly driven by interest income and exchange gains on the cash positions held in foreign currencies, whereas in 2021 there was a net financial loss of CHF&#160;0.4&#160;million mainly driven by interest expense (2020: net financial loss of CHF&#160;4.4&#160;million)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial income / expense in all three years are primarily driven by foreign exchange results on the cash positions held in foreign currencies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Swiss legal entity of the Company did not have to pay nor accrue any income taxes in the reporting period as the 2022 taxable income in the period was fully offset by the utilization of accumulated tax losses. Including the net operating profit of 2022, the remaining tax losses of CHF&#160;88.2&#160;million may be used as tax loss carryforwards to offset future taxable income over a period of seven years. No deferred tax assets have been recognized for these tax loss carryforwards, because at December&#160;31, 2022, it was unlikely that such loss carryforwards could be utilized in the foreseeable future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future taxable income in Switzerland will be subject to federal, cantonal and communal income taxes. The applicable income tax rate in Switzerland for the year ended December&#160;31, 2022 was 19.4%.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_67"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, we have raised an aggregate of CHF&#160;322.5&#160;million of net proceeds from the sale of our ordinary shares to founders and investors and collected cash under our partnership agreements in an aggregate of CHF&#160;446.2&#160;million. Our primary uses of cash is to fund our ongoing research and development activities and other operating expenses. We currently have no ongoing material financing commitments, such as lines of credit or guarantees.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had CHF&#160;249.1&#160;million in cash and cash equivalents and short-term time deposits. In June 2021, we completed our initial public offering in the U.S. raising approximately $55.9 million in net proceeds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2022, we received from Novartis CHF 150 million related to its exercise of its option as well as the $20 million (CHF 18.6 million) from the license and collaboration agreement with Novartis signed in December 2021. We are investing our cash in risk-free money market instruments in line with our treasury guidelines to accommodate our financial needs over time.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to program sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of current or future collaborators. Furthermore, following our June 2021 listing on the Nasdaq Global Select Market, we have and will continue to incur additional costs associated with operating as a public company in the United States. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comparison of cash and cash equivalents and short-term time deposits as of December&#160;31, 2022, 2021 and 2020 and cash flows for the years ended December&#160;31, 2022, 2021 and 2020. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:53.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of and for the year ended</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of and for the year ended</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of and for the year ended</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">87,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">71,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">161,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">249,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">132,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">173,721</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash from (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">118,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(90,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(28,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(101,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(21,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash (used in) from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exchange gain (loss) on cash positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(61,907)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">58,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The short-term time deposits denominated in CHF at December&#160;31, 2022 contained six positions with three Swiss banks, the short-term time deposits denominated in USD contained three positions with three Swiss banks and the short-term time deposits denominated in EUR contained one position with one Swiss bank. The short-term time deposits in CHF at December&#160;31, 2021 contained one position with one Swiss bank and the short-term time deposits denominated in USD contained three positions with two Swiss banks. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Net cash from (used in) operating activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, operating activities generated CHF&#160;118.6&#160;million of cash, primarily as a result of the positive net result attributable to shareholders of CHF&#160;117.8&#160;million driven by the option exercise by Novartis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, operating activities used CHF&#160;91.0&#160;million of cash, primarily as a result of the negative net result attributable to shareholders of CHF&#160;63.8&#160;million together with a reduction in contract liability and an increase in trade and other receivables following the Novartis license and collaboration agreement signed in December 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, operating activities used CHF&#160;29.0&#160;million of cash, primarily as a result of the negative net result attributable to shareholders of CHF&#160;62.8&#160;million partially offset by an </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increase in contract liability of CHF&#160;17.6&#160;million, non-cash share based compensation costs of CHF&#160;2.9&#160;million, and CHF&#160;4.8&#160;million of financial expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, cash used in investing activities primarily related to movements in investments in short-term time deposits of CHF&#160;100.2&#160;million, CHF&#160;21.0&#160;million and CHF&#160;20.6&#160;million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recorded a cash outflow for the acquisition of property, plant and equipment and intangible assets of CHF&#160;1.4&#160;million, CHF&#160;1.3&#160;million and CHF&#160;1.7&#160;million, respectively. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Net cash from (used in) financing activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash used in financing activities was CHF&#160;1.6&#160;million, driven primarily by payments of our lease liabilities and the investment related to the creation of treasury shares.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash from financing activities was CHF&#160;50.6&#160;million, primarily related to the proceeds from issuance of new shares, net of transaction costs, following our initial public offering of ADSs in the U.S. in June 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, net cash from financing activities was CHF&#160;113.2&#160;million, primarily related to the proceeds from issuance of new shares, net of transaction costs, that were issued following a financing round completed in July 2020, and as a result of the Option and Equity Rights agreement concluded with Novartis in October 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Funding requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents and short-term time deposits as of December&#160;31, 2022, will be sufficient to fund our operating expenses and capital expenditure requirements into 2026. However, our present and future funding requirements may change and will depend on many factors, including, among other things:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">timelines for preclinical and clinical development programs;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">change in product development plans needed to address any set-backs in our research and development activities;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">scope, prioritization and number of clinical trials and research and development activities;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">rate of progress and cost of the clinical trials, and other research and development activities;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">terms and timing of any collaborative, licensing and other arrangements that may be established;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and timing of preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need or decision to acquire or license complementary compounds, technologies or complementary businesses or companies;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory approval, manufacturing or commercialization of our product candidates for which we receive marketing approval through partners;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and timing of future commercialization activities, including drug manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory policies or laws that affect our operations; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing medical treatment and market developments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our operating expenses to increase over the next several years as we expand our research and development activities. Until such time as we can generate significant revenue from product sales or royalties, if ever, we expect to finance our operations through a combination of public or private equity and debt financings or other sources, including payments upon achievement of certain development, regulatory and sales milestone events and royalty payments under our existing partnership agreements, and future collaborations with other third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders' ownership interest may be diluted, and the terms of any additional securities may include liquidation or other preferences that adversely affect the rights of our shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_70"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Research and Development </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For a discussion of our research and development activities, see &#8220;Item 4.B-Business Overview&#8221; and &#8220;Item 5.A-Operating Results.&#8221; </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_73"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Trend Information </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For a discussion of trends, see &#8220;Item 5.A-Operating Results&#8221; and &#8220;Item 5.B-Liquidity and Capital Resources.&#8221; </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_76"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E. Critical Accounting Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_79"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 6. Directors, Senior Management and Employees.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_82"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Directors and Senior Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table sets forth information regarding our executive officers, also referred to as members of the Management Board, and directors as of December 31, 2022. Unless otherwise stated, the business address for our directors and executive officers is c/o Molecular Partners AG, Wagistrasse 14, 8952 Schlieren, Switzerland. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Age</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Patrick Amstutz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Andreas Emmenegger</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Renate Gloggner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EVP People and Community</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Nicolas Leupin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Medical Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Michael Tobias Stumpp</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EVP Projects</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alexander Z&#252;rcher</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Operating Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">William M. Burns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chairman of the Board</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Agnete Fredriksen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Dominik H&#246;chli</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Steven H. Holtzman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sandip Kapadia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Vito Palombella</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Michael Vasconcelles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. Patrick Amstutz, Ph.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">., one of our founders, has served as our Chief Executive Officer since November 2016, as an executive director since 2017 and as a member of the Company&#8217;s management team since its inception in 2004. Previously, he served as our Chief Operating Officer from 2014 to 2016 and as our Chief Business Officer from 2006 to 2014. Since 2017, Dr. Amstutz has served as Vice-President of the Board of the Swiss Biotech Association. Dr. Amstutz holds a Master of Science from the ETH Zurich and a Ph.D. in molecular biology from the University of Zurich. Our board of directors believes that Dr. Amstutz's leadership of our company since its inception as well as his scientific background provide him with the qualifications and skills to serve as a director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Andreas Emmenegger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> served as our Chief Financial Officer since February 2007 until December 31, 2022. Prior to joining Molecular Partners, he was the Chief Financial Officer of Glycart Biotechnology AG where he had a leading role in the CHF 235 million trade sale to F. Hoffmann-La Roche AG in 2005. Mr. Emmenegger was Head of Strategic Alliance Finance (Genentech) for Roche Headquarters, Basel, Switzerland. He has more than 20 years of experience as a chief financial officer of several public and private multinational companies, 15 years of which have been in the biotechnology industry. He led our SIX Swiss Exchange initial public offering in 2014 and our Nasdaq initial public offering in 2021. In addition, Mr. Emmenegger has more than 10 years of international industry experience in banking, capital markets, mergers and acquisitions and human resources. Since 2016, he has been a member of the board of directors of the Luzerner Kantonalbank, Switzerland, a publicly listed bank. Mr. Emmenegger holds a degree in finance, economics and business administration as well as an Executive MBA degree from IESE Business School, Barcelona.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Renate Gloggner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> has served as EVP People and Community and a Member of the Management Board of Molecular Partners since July 2022. She joined the Company in October 2021. Prior to joining Molecular Partners, Renate held European and International Human Resource leadership positions at two US companies, Global Blood Therapeutics and Tesaro Bio. In both companies, she built strong teams with an engaging culture in the European headquarter as well as in several European countries, allowing these teams to successfully gain market access and launch products. Renate began her career in biotech at </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Biogen and Amgen working in a variety of HR roles in the international headquarter as well as in country roles. She holds an MBA from the University of Bern, Switzerland and an executive coaching degree from the University of the West of England, Bristol.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. Nicolas Leupin, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, has served as our Chief Medical Officer since September 2019 Dr. Leupin is a medical oncologist with a successful track record in drug development, most recently as Chief Medical Officer of argenx from 2016 to 2019, a clinical-stage biotechnology company developing antibody-based therapies for treatment of severe autoimmune diseases and cancer. In that role he led the company&#8217;s global clinical strategy and execution, successfully supporting the company&#8217;s transformation into a late-stage clinical company, and was responsible for translating preclinical hypotheses into innovative proof-of concept clinical trials. Prior to argenx, Dr. Leupin held roles of increasing responsibility at Celgene, where he supported the clinical development of several drug candidates in lymphoma and multiple myeloma, resulting in regulatory filings in Europe and the United States.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. Michael Tobias Stumpp, Ph.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">., one of our founders, has served as EVP Projects and a Member of the Management Board of Molecular Partners. Michael is a co-founder of Molecular Partners and was part of the team that invented the DARPin technology. Michael previously served as Chief Scientific Officer of Molecular Partners, in which capacity he oversaw development of the DARPin pipeline. He started his scientific career at the ETH Zurich and then progressed to the Imperial College London and the Tokyo Institute of Technology. Michael has published his research in many international, peer-reviewed scientific journals and presented his findings at numerous congresses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Alexander Z&#252;rcher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> has served as Chief Operating Officer and a Member of the Management Board of Molecular Partners. Prior to this role, he served as SVP of Development, where he oversaw project and portfolio management, manufacturing, pharmacology, and quality assurance activities. Alexander has also previously been VP Operations and Director of CMC. He has more than 17 years of industry experience, with prior work in drug development as Director of Drug Product Development at Cytos Biotechnology and Head of R&amp;D Operations at Spirig Pharma. Alexander holds a M.Sc. degree in biology from the University of Basel, as well as certificates in business and project management from the University of Zurich.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Directors </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">William M. Burns </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">has served as Chairman of our board of directors since April 2018 and a director since October 2017. His professional career has been spent in the Life Sciences sector. His career in Roche took him to CEO of the Pharma Division and to the Boards of Genentech and Chugai. From 2010 to 2014 he also served as a Non-Executive Director of F Hoffmann La Roche. He is currently chair of Vestergaard sarl, vice chair of Mesoblast in Australia and is a Trustee of the Institute of Cancer Research in London. He also serves on a Cancer Advisory board to the Universities of Aachen/Bonn/Cologne and Dusseldorf. Mr. Burns holds an honors degree in economics from the University of Strathclyde, Glasgow, Scotland. Our board of directors believes that Mr. Burns' experience with the healthcare and pharmaceutical industries and his broad management experience provide him with the qualifications and skills to serve as a director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. Agnete Fredriksen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> has served as a director since April 2021. Dr. Fredriksen has served as a co-founder and chief scientific officer of Nykode Therapeutics AS (formerly Vaccibody AS) from 2007 to 2017, as president and chief scientific officer from 2017 to June 2021, and as chief innovation and strategy officer since June 1, 2021. Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for cancer and infectious diseases. Prior to founding Vaccibody Dr. Fredriksen previously held researcher roles at Affitech AS, a private technology transfer company, and Medinnova AS, a technology transfer company. Dr. Fredriksen is the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. She holds an MSc and a Ph.D. from the Institute of Immunology, Oslo University Hospital, Rikshospitalet in Oslo, Norway. Our board of directors believes that Dr. Fredriksen&#8217;s experience in immunotherapy and vaccine development, as well as her medical and scientific background, provide her with the qualifications and skills to serve as a director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. Dominik H&#246;chli</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> has served as a director since April 2021. He has more than 20 years of experience as a marketing and medical affairs executive. Since spring 2021 he is the CEO of Catapult Therapeutics, a clinical stage biotech company in the Netherlands. Previously he worked at AbbVie as Vice President, Head of Global Medical Affairs and member of the R&amp;D and the Commercial leadership team. He led global product launches for major blockbuster products, including HUMIRA, Maviret, Venetoclax and Skyrizi, and his leadership experience ranges from smaller country organizations to large global functions. He began his corporate career at McKinsey &amp; Co. Dr. H&#246;chli is a Swiss national and obtained his medical degree (M.D.) from the University of Bern in Switzerland. Our board of directors believes that Dr. H&#246;chli&#8217;s over 20 years of experience as a marketing and medical affairs executive, as well as his broad business experience provide him with the qualifications and skills to serve as a director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Steven H. Holtzman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">has served as a director since May 2014. He has served as chair of the board of directors of, and strategic business advisor to, CAMP4 Therapeutics Corporation, a private biopharmaceutical company, since October 2019, executive chair of the board of directors of, and a strategic business advisor to, Qihan Biotech, a private biopharmaceutical company, since April 2019, and as a founder, a strategic business advisor, and a member and the lead independent director of the board of directors of Shoreline Bio, a private biopharmaceutical company, since June 2020. From July 2016 to January 2020, Mr. Holtzman was the first President and Chief Executive Officer and a member of the board of directors of Decibel Therapeutics, Inc., a public biopharmaceutical company. From January 2011 to March 2016, he served as the Executive Vice President of Corporate Development at Biogen, Inc., a public biopharmaceutical company. From 2001 to 2010, he served as a founder, chair of the board of directors, and Chief Executive Officer of Infinity Pharmaceuticals, Inc., a public biopharmaceutical company. Additionally, Mr. Holtzman was Chief Business Officer of Millennium Pharmaceuticals, Inc., a public biopharmaceutical company, from May 1994 to June 2001, and a founder, member of the board of directors, and Executive Vice President of DNX Corporation, a public biopharmaceutical company, from August 1986 to March 1994. He is a trustee of The Berklee College of Music and a Senior Fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School. He received his B.A. in Philosophy from Michigan State University and his B.Phil. in Philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar. Our board of directors believes that Mr. Holtzman's experience in the biotechnology industry and his broad management experience provide him with the qualifications and skills to serve as a director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sandip Kapadia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> has served as a director since April 2020. Mr. Kapadia brings over 25 years of science industry experience and has served as the Chief Financial Officer (CFO) for Harmony Biosciences since March 2021. Previously Mr. Kapadia was CFO for Intercept Pharmaceuticals. Before Intercept, Mr. Kapadia served in various leadership capacities within finance for more than 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the US. Mr. Kapadia received a B.S. in Accounting from Montclair State University and an M.B.A. from Rutgers University, and is also a US Certified Public Accountant. Mr. Kapadia currently serves on the boards of directors of VectivBio Holding AG and Passage Bio. We believe that Mr. Kapadia is qualified to serve on our board of directors due to his leadership experience in the biopharmaceutical industry and finance expertise. Our board of directors believes that Mr. Kapadia&#8217;s over 25 years of experience in the life science industry and his broad finance and management experience provide him with the qualifications and skills to serve as a director.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. Vito J. Palombella, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, has served as a director since April 2020. Vito J. Palombella, Ph.D., has over 25 years of scientific leadership and experience advancing first-in-class therapeutic programs, as well as a successful track record of building drug discovery and development organizations. Currently, Dr. Palombella is the chief scientific officer of Surface Oncology, where he has led the company&#8217;s drug discovery and translational research efforts since 2016. Prior to joining Surface Oncology, Dr. Palombella was executive vice president and chief scientific officer from 2010 to 2016, and vice president, biology/research, from 2004 to 2010, at Infinity Pharmaceuticals, Inc., where he was responsible for drug discovery and preclinical development. Prior to that, he was director of molecular biology and protein chemistry at Syntonix Pharmaceuticals, and senior director of cell and molecular biology at Millennium Pharmaceuticals and held a number of positions at LeukoSite and ProScript.. Dr. Palombella was involved in the discovery and development of bortezomib (Velcade&#174;), a proteasome inhibitor, and duvelisib (Copiktra&#174;), a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PI3K-d/g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> inhibitor, both for cancer therapy. Dr. Palombella earned his bachelor&#8217;s degree in microbiology from Rutgers University and a master&#8217;s degree and doctorate degree in viral oncology and immunology from the New York University Medical Center and completed his post-doctoral training at Harvard University. Our board of directors believes that Dr. Palombella&#8217;s over 25 years of scientific leadership and experience, as well as his medical and scientific background, provide him with the qualifications and skills to serve as a director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Dr. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Michael Vasconcelles, M.D., is currently Executive Vice President, Research, Development, and Medical Affairs at Immunogen. He was most recently the chief medical officer and Head of the Medical and Scientific Organization at Flatiron Health, a healthcare technology and services company focused on creating digital solutions to accelerate cancer research and improving patient care. Prior to joining Flatiron Health in 2019, Dr. Vasconcelles served as the Chief Medical Officer of Unum Therapeutics Inc. (Unum) from 2015-2019. A Cambridge, MA-based cell and gene therapy company, Prior to Unum, Dr. Vasconcelles spent several years at Takeda/Millennium, where he was Senior Vice President, Head of the Oncology Therapy Area Unit and member of the R&amp;D Executive Team, accountable for strategic and operational oversight of the oncology research and development portfolio globally. Prior to Takeda/Millennium, Dr. Vasconcelles was Group Vice President and the Global Therapeutic Area Head, Transplant and Oncology, at Genzyme Corporation, where he was responsible for clinical development of the transplant and oncology portfolio and a member of the Transplant and Oncology Business Unit Management Team. Following Sanofi&#8217;s acquisition of Genzyme, Dr. Vasconcelles joined Sanofi Oncology as Head, Personalized Medicine and Companion Diagnostics. From 1996 -2021, Dr. Vasconcelles was a faculty member of the Harvard Medical School and an associate physician at Brigham and Women&#8217;s Hospital and Dana-Farber Cancer Institute. He received both his B.A. and M.D. from Northwestern University. Our board of directors believes that Dr.Vasconcelles&#8217; extensive experience in the life sciences industry and clinical development programs, as well as his medical and scientific background, provide him with the qualifications and skills to serve as a director.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The table below provides certain highlights of the composition of our board members and nominees. Each of the categories listed in the below table has the meaning as it is used in Nasdaq Rule 5605(f). </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Board Diversity Matrix</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Country of Principal Executive Offices:</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Switzerland</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Foreign Private Issuer</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Yes</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Disclosure Prohibited under Home Country Law</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">No</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Total Number of Directors</span></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Female</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Male</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non- Binary</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Part I: Gender Identity</span></td><td colspan="12" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Directors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Part II: Demographic Background</span></td><td colspan="12" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LGBTQ+</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Family Relationships </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no family relationships among any of our executive officers or directors. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_85"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Compensation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Compensation of Executive Officers and Directors </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The aggregate compensation paid by us to our executive officers and directors, including share-based compensation, for the year ended December 31, 2022, was CHF 5,814,000. Out of this amount a total of CHF 296,000 related to pension benefits.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As required by the "Say on Pay" rules, our articles of association set out the principles for the elements of the compensation of the members of our board of directors. The compensation of the members of our board of directors may consist of fixed and variable compensation. The total compensation takes into account the position and level of responsibility of the respective member of the board of directors, including board and committee chairmanship and membership and a travel fee. Members of our board of directors are paid for their service over one year starting with their election at the ordinary shareholders&#8217; meeting and ending with the subsequent ordinary shareholders&#8217; meeting. Our shareholders at the 2021 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">annual general meeting held on April 21, 2021, set the maximum aggregate amount of compensation for the board of directors for their term of office until the 2022 general meeting at CHF 1,091,400. Our shareholders at the 2022 annual general meeting held on April 13, 2022, set the maximum aggregate amount of compensation for the board of directors for their term of office until the 2022 general meeting at CHF 1,091,400.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the compensation of the members of our board of directors consisted of fixed compensation only. Compensation of the members of our board of directors for the year ended December 31, 2022 consisted of a fixed cash fee and restricted share units, or RSUs. The following table sets out information regarding the compensation earned by our directors for service on our board of directors during the year ended December 31, 2022. Dr. Amstutz, our Chief Executive Officer and a member of our board of directors, does not receive any additional compensation for his service as a director. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fees Earned</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:0.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">William M. Burns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">170</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">295</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Steven H. Holtzman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sandip Kapadia&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vito J. Palombella&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Michael Vasconcelles&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Agnete Fredriksen&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Dominik H&#246;chli&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Patrick Amstutz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">The total compensation awarded to the members of the board of directors shown in this table does not include the payments of TCHF 14 we made in 2022 to cover the mandatory employer social security contribution on the base fees. In addition, upon vesting of the RSUs 2022 in 2025, we will be obliged to make employer contributions to social security pursuant to applicable mandatory law. As an estimate based on currently applicable contribution rates, the employer contributions on the RSUs 2022 expected to vest in 2025 will amount to TCHF 26.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">For our Chief Executive Officer&#8217;s compensation other than in connection with his service on our board of directors, please refer to &#8220;&#8212; Executive Compensation.&#8221; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2022, all members of our board of directors were non-executives, except for Dr. Amstutz. None of the members of our board of directors has any significant business connections with the Company or was a member of the Management Board of the Company, except for Dr. Amstutz, who has been a member of the Management Board since the Company's inception in 2004.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as described in the section of this Annual Report on Form 20-F entitled &#8220;Related Party Transactions&#8212;Agreements with Our Directors and Executive Officers&#8221;, there are no arrangements or understandings between us and any of our directors providing for benefits upon termination of their service as our directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The compensation of the Management Board, also referred to herein as our executive officers, may consist of fixed and variable compensation. Fixed compensation comprises the base salary and the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">corresponding pension contributions. Variable compensation comprises short-term and long-term variable compensation elements:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the short-term variable compensation, paid as a cash bonus, is determined exclusively by the achievement of pre-defined annual corporate goals; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">the long-term variable compensation, granted as Performance Share Units, or PSUs, is determined based on (i) the achievement of annual corporate goals, (ii) the achievement of long-term value-driving milestones outside of such corporate goals and (iii) the development of the share price of the Company.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table sets out information regarding compensation earned by members of the Management Board during the year ended December 31, 2022. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name and principal position</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Salary</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:0.65pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bonus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:0.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Awards</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Equity</span></div><div style="padding-left:0.02pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Plan</span></div><div style="padding-left:0.02pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:0.65pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">All Other Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:0.65pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Patrick Amstutz</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">383</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">179</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">385</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,005</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer, Director and Co-Founder</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Management Board</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,982</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">787</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,679</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">296</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,744</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Represents amounts earned in 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Represents pension contributions.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">All other compensation awarded to the members of the Management Board shown in this table does not include the payments of TCHF 173 we made in 2022 to cover the mandatory employer social security contribution on the base salary and on the bonus. In addition, upon vesting of the PSUs 2022 in 2025, we will be obliged to make employer contributions to social security pursuant to applicable mandatory law. As an estimate based on currently applicable contribution rates, the employer contributions on the PSUs 2022 expected to vest in 2025 will amount to approximately TCHF 97 (assuming 100% target achievement and full vesting of the PSUs).</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">The total compensation awarded to members of the Management Board shown in this table does not include the items mentioned in the foregoing note (3).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation Arrangements </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For a discussion of our employment arrangements with our executive officers, see the section of this Annual Report on Form 20-F entitled &#8220;Related Party Transactions&#8212;Agreements with Our Directors and Executive Officers&#8212;Employment Arrangements.&#8221; Except for the arrangements described in the section of this Annual Report on Form 20-F entitled &#8220;Related Party Transactions&#8212;Agreements with Our Directors and Executive Officers&#8212;Employment Arrangements,&#8221; there are no arrangements or understanding between us and any of our other executive officers providing for benefits upon termination of their employment, other than as required by applicable law.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Liability and Indemnification Matters</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under Swiss corporate law, an indemnification of a director or member of the executive management in relation to potential personal liability is not effective to the extent the director or member of the executive management intentionally or negligently violated his or her corporate duties towards the company (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification). Most violations of corporate law are regarded as violations of duties towards the company rather than towards the shareholders. In addition, indemnification of controlling persons is not permitted under Swiss corporate law, including shareholders of the company.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nevertheless, the articles of association of a Swiss corporation may set forth that the company shall indemnify and hold harmless to the extent permitted by the law, the directors and executive managers out of assets of the company against threatened, pending or completed actions. However, our articles of association do not provide for such an indemnification provision.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Within the same limitations, articles of association of a Swiss corporation may also provide that the directors shall be entitled to the reimbursement of all expenses incurred in the interests of the corporation. Our articles of association contain such a provision.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, a corporation may enter into and pay for directors' and officers' liability insurance which typically covers negligent acts as well.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We extended liability insurance for our directors and officers, including insurance coverage for liability under the Securities Act. We believe that this insurance is necessary to attract qualified directors and executive officers.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Incentives</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that our ability to grant incentive awards is a valuable and necessary compensation tool that allows us to attract and retain the best available personnel for positions of substantial responsibility, provides additional incentives to directors, executive officers, and employees and promotes the success of our business. Historically, we have granted several different equity incentive instruments to our directors, employees and other service providers, including: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted Share Units, or RSUs, granted to our directors;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance Share Units, or PSUs, granted to our executive officers and employees; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">share options granted to employees, directors and selected advisors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our articles of association authorize the board of directors to issue one or more participation plans and/or policies. An amendment or renewal of the relevant provision in our articles of association must be approved by an absolute majority of the votes represented at the general meeting of shareholders. Once our board of directors' authority is approved by our shareholders, the maximum aggregate amounts of the variable compensation elements actually granted to the directors and executive officers must be approved by an absolute majority of the votes represented at the general meeting of shareholders and shall continue for the duration of the current financial year. Compensation may be paid out prior to approval by the general meeting of shareholders subject to subsequent approval. If the general meeting of shareholders does not approve a proposal of the board of directors, the board of directors must newly determine the maximum aggregate amount or maximum partial amounts taking into account all relevant factors and submit such amounts for approval to the same general meeting of shareholders, to an extraordinary general meeting of shareholders or to the next ordinary general meeting of shareholders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Share Options </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to our initial public offering on SIX Swiss Exchange on November 5, 2014, which we refer to as our Swiss IPO, our board of directors established three share option plans: (i) the Employee Share Option Plan 2007, or ESOP 2007, (ii) the Employee Share Option Plan 2009, or ESOP 2009, and (iii) the Employee Share Option Plan 2014, or ESOP 2014, with similar features as the ESOP 2009, but no longer providing for accelerated vesting of options in the event of our Swiss IPO. Each option entitles its holder to purchase one of our shares at the pre-defined exercise price. The number of options granted to each participant was determined by the board of directors based on a participant&#8217;s position and level of responsibility. As a rule, the options vested quarterly over a four-year period. At the end of the option term, the unexercised options expire without value. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, no options were outstanding under the ESOP 2007, and an aggregate of 282,105 options were outstanding under the ESOP 2009 and ESOP 2014, together. As of December&#160;31, 2022, all of the outstanding options were fully vested.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following our Swiss IPO, no further grants were made under any of the ESOP 2007, ESOP 2009 or ESOP 2014, and we do not intend to make any further grants under any of these plans in the future. For additional information, see Note 18 to our consolidated financial statements as of and for the year ended December&#160;31, 2022 included elsewhere in this Annual Report on Form 20-F.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Units (RSUs)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the LTI Plans, described in &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Incentive Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; below, members of our board of directors are eligible to be granted RSUs. RSUs are contingent rights to receive a certain number of our shares at the end of a three-year blocking period. RSUs vest over a one-year period from their date of grant, following the lapse of which they are no longer subject to forfeiture if a member of our board resigns. The number of shares to be received is not variable, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the number of shares does not depend on the achievement of certain pre-defined performance metrics. In certain circumstances, including a change of control, a full or partial early vesting of the RSUs may occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 96,001 RSUs were outstanding.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Units (PSUs)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the LTI Plans, described in &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Incentive Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; below, executive officers and employees are eligible to be granted PSUs. PSUs are contingent rights to receive a variable number of our shares either in aggregate at the end of a three-year cliff-vesting period or in annual installments over a three-year vesting period. The number of PSUs granted to a plan participant is calculated by dividing the CHF amount approved for the respective individual by the fair value of each PSU at the grant date based on the average share price in the two months preceding the grant date. While the PSUs are designed to allow the beneficiaries to participate in the long-term share price development, the number of shares to be earned in relation to a PSU depends on (i) the achievement of annual corporate goals for the respective year, (ii) the achievement of long-term value-driving milestones outside of such corporate goals during such year and (iii) the development of the share price of the Company. In accordance with these parameters, the number of shares to be issued based on the PSUs can be between zero and 120% of the number of PSUs granted. Even after the determination of goal achievement, participants may lose their entitlements in full or in part depending on certain conditions relating to their employment. In certain circumstances, including a change of control, a full or partial accelerated vesting of the PSUs may occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 604,800 PSUs were outstanding.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plans</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our long-term incentive plans established in March of 2015, March of 2016, March of 2017, March of 2018, March of 2019, March of 2020, March of 2021 and March of 2022, respectively, which we collectively refer to as the LTI Plans, are rolled out annually. This allows our board of directors to review and adjust the terms and targets of the LTI Plans on an annual basis. Employees generally receive the grants on April 1 of each calendar year. With respect to members of the Management Board, the annual grants are usually made on April 1 subject to approval of the ordinary shareholders&#8217; meeting at which the necessary amounts for variable compensation are approved by the shareholders. With respect to members of our board of directors, the annual grants are made following the ordinary shareholders&#8217; meeting, at which the necessary amounts for variable compensation are approved by the shareholders.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_88"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Board Practices. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We currently have eight directors, four&#160;of whom are citizens or residents of the United States. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our articles of association provide that our board of directors shall consist of a minimum of three members and maximum of eleven members. All directors (including the chairperson of the board of directors) are appointed to and removed from the board of directors exclusively by shareholders&#8217; resolution for a maximum term of office of one year, extending until completion of the next annual shareholders' meeting. Directors may be re-elected at any time. In the event the office of the chairperson is vacant, the board of directors shall appoint a new chairperson from its members for the remaining term of office. The board of directors may elect a vice-chairperson from its members each year immediately following the annual shareholders' meeting for a term ending at the closing of the following annual shareholders' meeting. The board of directors shall further appoint the secretary, who need not be a member of the board of directors. The secretary shall be entitled to participate in the deliberations and discussions of the board of directors, but shall not vote, unless he or she is a member of the board of directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table sets forth the names of our directors, the year of their initial appointment as directors and the expiration dates of their current term:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Current Position</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year of Initial Appointment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:0.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Term Expiration Year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">William M. Burns</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chairman of the Board</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Patrick Amstutz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Executive Officer, Director and Co-Founder</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Steven H. Holtzman</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sandip Kapadia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Vito Palombella</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Michael Vasconcelles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Agnete Fredriksen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Dominik H&#246;chli</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">At the end of the general meeting of shareholders during the year in which their term office expires, in each case as indicated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Director Independence </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a foreign private issuer, under Nasdaq rule 560(a)(2), we are not required to have independent directors on our board of directors, except to the extent that our audit committee is required to consist of independent directors, subject to certain phase-in schedules. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nevertheless, our board of directors has undertaken a review of the independence of the directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from, and provided by, each director concerning such director&#8217;s background, employment and affiliations, including family relationships, our board of directors determined that William M. Burns, Agnete Fredriksen, Dominik H&#246;chli, Steven H. Holtzman, Sandip Kapadia, Vito J. Palombella and Michael Vasconcelles are &#8220;independent directors&#8221; as defined under applicable Nasdaq rules and the independence requirements contemplated by Rule 10A-3 under the Securities Exchange Act of 1933, as amended, or the Exchange Act. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining the director&#8217;s independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities (if any). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Role of the Board in Risk Oversight </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our board of directors is primarily responsible for the oversight of our risk management activities and has delegated to the Audit and Finance Committee the responsibility to assist our board of directors in this task. The Audit and Finance Committee also monitors the issues relating to the preparation and supervision of accounting and financial information. The Audit and Finance Committee, among other things, monitors the effectiveness of the internal control and risk management systems with regard to the procedures relating to the preparation and processing of accounting and financial information, without undermining the independence of the board of directors. While our board of directors oversees our risk management, our management is responsible for day-to-day risk management processes. Our board of directors expects our management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Governance Practices </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act of 2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including our company, to comply with various corporate governance practices. In addition, Nasdaq rules provide that foreign private issuers may follow home country practice in lieu of the Nasdaq corporate governance standards, subject to certain exceptions and except to the extent that such exemptions would be contrary to U.S. federal securities laws. However, if the laws of a foreign private issuer&#8217;s home country require that any such matter be approved by the board of directors or the shareholders, the audit committee&#8217;s responsibilities or powers with respect to such matter may instead be advisory. Under Swiss law, the audit committee may only have an advisory role and appointment of our statutory auditors, in particular, must be decided by the shareholders at our annual meeting.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because we are a foreign private issuer, our members of our board of directors, executive board members and senior management are not subject to short-swing profit and insider trading reporting obligations under Section 16 of the Exchange Act. They are, however, subject to the obligations to report changes in share ownership under Section 13 of the Exchange Act and related SEC rules.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board Committees </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On January 1, 2023, Swiss ordinance against excessive compensation in listed stock corporations, known as the &#8220;Say on Pay&#8221; rule, was incorporated in the Swiss Code of Obligations. Pursuant to Swiss corporate law, companies listed on the SIX Swiss Exchange are required to establish a compensation committee. Our board of directors has established an Audit and Finance Committee, a Nomination and Compensation Committee and a Research and Development Committee, which operate pursuant to our articles of association, the charter of the Audit and Finance Committee, the charter of the Nomination and Compensation Committee and the charter of the Research and Development Committee. The composition and functioning of all of our committees is designed to comply with all applicable requirements of Swiss law, the Exchange Act, Nasdaq and SEC rules and regulations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Audit and Finance Committee </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our Audit and Finance Committee assists our board of directors in its oversight of our corporate accounting and financial reporting by making an independent assessment of the quality of the external auditors, our financial statements and our internal controls. Sandip Kapadia, Dr. Dominik H&#246;chli and Steven Holtzman currently serve on our Audit and Finance Committee. Mr. Kapadia is chairperson of our Audit and Finance Committee. Our board of directors has determined that each of Mr. Kapadia, Dr. H&#246;chli and Mr. Holtzman&#160;is independent within the meaning of the applicable Nasdaq listing rules and the independence requirements contemplated by Rule 10A-3 under the Exchange Act. Our board of directors has further determined that Mr. Kapadia is an &#8220;audit committee financial expert&#8221; as defined by SEC rules and regulations and that each of the members of the Audit and Finance Committee qualifies as financially sophisticated under the applicable exchange listing rules. The principal duties and responsibilities of our Audit and Finance Committee include (1) analyzing economic and financial information and (2) ensuring the accuracy and honesty of our company&#8217;s financial statements, as well as the quality of the information provided. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our board of directors has specifically assigned the following duties to the Audit and Finance Committee:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">assessing the quality and effectiveness of the external audit;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">assessing the quality of the internal control system, including risk management and the efficiency and state of compliance and monitoring with applicable norms within the Company;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing the stand-alone Swiss statutory and consolidated financial statements as well as all reporting prepared by the external auditor;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">deciding whether the year-end stand-alone Swiss statutory and consolidated financial statements be recommended to the board of directors for presentation to the general shareholders&#8217; meeting;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">assessing the performance and the fees charged by the external auditors and ascertain their independence;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">annually review written disclosures from the external auditors delineating all relationships between the external auditors and the Company and take appropriate action to oversee the independence of the external auditors;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing the scope of the prospective external audit, the estimated fees thereof and any other matters pertaining to such audit;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">approve the annual engagement letter of external auditor, including the scope of the audit and the fees and terms for the planned audit works </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">pre-approve all audit review or attest services and permitted non-audit services by the external auditors</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">taking notice of all comments from the external auditors on accounting procedures and systems of control;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with the external auditors and/or the CFO/CEO any questions, comments or suggestions they may have regarding the internal control, risk management, accounting practices and procedures of the Company and its subsidiaries;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">discussing with the management any legal matters that may have a material impact on the Company's financial statements and any material reports or inquiries from regulatory or governmental agencies which could materially impact the Company's contingent liabilities and risks;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">reviewing with management and the external auditors, as appropriate, the Company&#8217;s MD&amp;A disclosures;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">annually reviewing and discussing with management the management&#8217;s report in relation to internal controls over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">reviewing and approving in advance any transaction that could be within the scope of a related party transaction;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">supporting the board of directors with regard to the financial planning as well as the principles of accounting and financial control; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating management&#8217;s principles and proposals for, and formulate recommendations to the board of directors in regard to financial planning (capital structure, management of resources, inter-company financing), dividend policy and capital market relations;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing proposed concepts of financial objectives such as costs of capital, enhancement of shareholders&#8217; value, Company and divisional objectives, project objectives (capital expenditures and M&amp;A); and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing finance policy and operations in treasury, controlling, insurance, taxes and investment and acquisitions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Nomination and Compensation Committee</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our Nomination and Compensation Committee assists our board of directors in establishing and reviewing the compensation strategy and guidelines as well as in preparing the compensation plans and proposals to the general meeting of shareholders regarding the compensation of the board of directors and executive officers. William M. Burns, Steven H. Holtzman and Dr. Michael Vasconcelles currently serve on the Nomination and Compensation Committee. Mr. Burns is the chairperson of our Nomination and Compensation Committee. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are subject to the Swiss ordinance against excessive compensation in listed stock corporations, known as the &#8220;Say on Pay&#8221; rule. As a result of the Say on Pay rule, the members of the Nomination and Compensation Committee must be elected by our shareholders and the aggregate compensation of our board of directors and executive officers must also be approved by our shareholders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal duties and responsibilities of our Nomination and Compensation Committee include: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations regarding the compensation strategy and guidelines of the Company;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations regarding the compensation of the members of the board of directors and the executive management;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations regarding compensation plans (cash and/or equity-based plans), and where appropriate or required, make recommendations to adopt, amend and terminate such plans;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">administering the compensation plans;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations regarding any employment agreements (including any benefits) for members of the executive management;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations regarding the proposals of the board of directors for the aggregate amount of the compensation of the board of directors and of the executive management to be submitted to the annual general shareholders' meeting for approval; </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring that any reporting obligation with respect to compensation matters, specifically any necessary disclosures in the annual report and/or compensation report, are met;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing considerations relating to the composition of the board of directors, including the size and the criteria for membership on the board of directors;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating candidates to the board of directors and making recommendations to the board of directors in this respect; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating candidates to the Management Board and making recommendations to the board of directors in this respect.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Committee</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Research and Development Committee (i) provides strategic advice and brings recommendations to the Management Board and the board of directors regarding current and planned research and development programs, (ii) provides strategic advice to the board of directors regarding emerging science and technology issues and trends, and (iii) conducts a review of the effectiveness and competitiveness of our research and development function. Dr. Michael Vasconcelles, Dr. Agnete Fredriksen and Dr. Vito Palombella currently serve on the Research and Development Committee. Dr. Vasconcelles is the chairperson of the Research and Development Committee. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have adopted a Code of Conduct which is applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">www.molecularpartners.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Audit and Finance Committee of our board of directors is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct will be disclosed on our website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Employees. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 175 full-time equivalent employees (December&#160;31, 2021: 163 full-time equivalents). None of our employees are represented by collective bargaining agreements. We believe that we maintain good relations with our employees. At each date shown, we had the following number of full time employees, broken out by department. The majority of our employees are based in Zurich, Switzerland. Two of our employees are based in the United States of America.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Full-time equivalent employees</span></td><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">At December 31,</span></td><td colspan="9" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">At December 31,</span></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Function</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">142.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">134.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">175.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">163.2</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_94"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E. Share Ownership. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the number of ordinary shares, options, RSUs and PSUs held by the individual members of the board of directors and the Management Board, as of December&#160;31, 2022.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">William M. Burns</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Steven H. Holtzman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sandip Kapadia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vito J. Palombella</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Michael Vasconcelles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Agnete Fredriksen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Dominik H&#246;chli</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Patrick Amstutz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">695,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">70,080&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Michael Tobias Stumpp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">757,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Andreas Emmenegger</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">238,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Nicolas Leupin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Renate Gloggner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alexander Z&#252;rcher</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_97"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 7. Major Shareholders and Related Party Transactions </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_100"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Major shareholders. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table and accompanying footnotes set forth, as of December&#160;31, 2022, information regarding beneficial ownership of our ordinary shares by: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person, or group of affiliated persons, known by us to beneficially own more than 3% of our ordinary shares;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our executive officers;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our executive officers and directors as a group.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting power or investment power with respect to that security, including ordinary shares that vest within 60 days of December&#160;31, 2022 and options and warrants that are currently exercisable or exercisable within 60 days of December&#160;31, 2022. Shares issuable under PSUs or RSUs that vest within 60 days of December&#160;31, 2022 and shares subject to options currently exercisable or exercisable within 60 days of December&#160;31, 2022 are deemed to be outstanding for computing the percentage ownership of the person holding these free shares, options and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as indicated in the footnotes below, we believe, based on the information furnished or otherwise known to us, that the persons named in the table below have sole voting and investment power with respect to all shares shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act or applicable Swiss law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our calculation of the percentage of beneficial ownership is based on 35,792,648 of our ordinary shares registered with the commercial register of the canton of Zurich as of December&#160;31, 2022 and includes 3,500,000 treasury shares indirectly held through our wholly-owned subsidiary Molecular Partners Inc. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise indicated in the following table, addresses of the directors, executive officers and named beneficial owners are in care of Molecular Partners AG, Wagistrasse 14, 8952 Schlieren, Switzerland.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:51.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shares Beneficially Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Name of Beneficial Owner</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Percentage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principal Shareholders</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Entities affiliated with Biotechnology Value Fund, L.P.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,510,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oleg Nodelman (EcoR1 Capital Funds) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1) (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,049,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hansjorg Wyss Revocable Trust</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,041,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Entities affiliated with Suvretta Capital Management, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(2)(6</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novartis Pharma AG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,739,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">UBS Fund Management (Switzerland) AG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(2)(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">995,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Directors and Executive Officers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Patrick Amstutz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">766,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Andreas Emmenegger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">274,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.02pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Renate Gloggner </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Nicolas Leupin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Michael Tobias Stumpp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">793,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">William M. Burns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Agnete Fredriksen</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Dominik H&#246;chli</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Steven H. Holtzman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">31,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sandip Kapadia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Vito Palombella</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Michael Vasconcelles</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.02pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alexander Z&#252;rcher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All current directors and executive officers as a group (13 individuals)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(17)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,935,934&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Number of voting rights carried by shares as reported by our shareholders in notifications filed with SIX Swiss Exchange.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">The information reported is in part derived from reports filed with the SEC pursuant to the Exchange Act. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.27pt">Based on a Schedule 13G/A filed with the SEC on February 14, 2023, the shares provided in the table above consist of 443,221 ADSs and 4,066,851 ordinary shares of the Company held by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS, L.P. ("Trading Fund OS") and a managed account for BVF Partners L.P. (the "Partners Managed Account," and collectively, the "BVF Funds"). BVF GP LLC is the general partner of BVF and may be deemed to beneficially own the shares beneficially owned by BVF. BVF II GP LLC is the general partner of BVF2 and may be deemed to beneficially own the shares beneficially owned by BVF2. BVF Partners OS Ltd. is the general partner of Trading Fund OS and may be deemed to beneficially own the shares beneficially owned by Trading Fund OS. BVF GP </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Holdings LLC, as the sole member of BVF GP LLC and BVF II GP LLC, may be deemed to beneficially own the shares beneficially owned by BVF and BVF2. BVF Partners L.P. ("Partners"), as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of BVF Partners OS Ltd, may be deemed to beneficially own the shares held by BVF, BVF2, Trading Fund OS and the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by Partners. Mark Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. Each of Partners, BVF Inc. and Mark Lampert disclaims beneficial ownership of the shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account. The address for the BVF Funds is 44 Montgomery St., 40th Floor, San Francisco, California 94104. According to a Schedule 13G/A filed with the SEC on February 14, 2023, Mark N. Lampert (Biotechnology Value Funds) held 4,510,072 shares (corresponding to 12.60% of voting rights), consisting of 443,221 ADSs and 4,066,851 ordinary shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Shares of the Company are held by EcoR1 Capital Fund Qualified, L.P. (5.393689%) and EcoR1 Capital Fund, L.P. (0.331476%). Oleg Nodelmann is the beneficial owner and may exercise voting power over the shares. The address of EcoR1 Capital Fund Qualified, L.P. is 357 Tehama Street #3, San Francisco, CA 94103, USA and the address of EcoR1 Capital Fund, L.P. is 357 Tehama Street #3, San Francisco, CA 94103, USA.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Shares of the Company are held by Hansjoerg Wyss Revocable Trust dated December 16, 1994. Hansjoerg Wyss is the beneficial owner, who may exercise voting power over the shares.As of January 10, 2023 Hansjoerg Wyss Revocable Trust sold its shareholdings in the Company.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Includes 400,000 ADSs purchased in the Company's initial public offering of ADSs in the U.S. Shares of the Company are held by Suvretta Master Fund, Ltd., Averill Master Fund, Ltd., Vitruvius US Equity and Suvretta Long Master Fund, Ltd. Suvretta Capital Management, LLC is the beneficial owner and may exercise voting power over the shares. Aaron Cowen may also be deemed to have shared dispositive power and voting power with respect to the shares by virtue of his role at Suvretta Capital Management, LLC. The address for Suvretta Capital Management, LLC is 540 Madison Avenue, 7th Floor, New York, New York 10022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Shares of the Company are held by Novartis Pharma AG. Novartis Pharma AG is a direct wholly-owned subsidiary of Novartis AG, which is the beneficial owner and may exercise voting power over the shares. The address of Novartis AG is Lichtstrasse 35, 4056 Basel, Switzerland.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Shares of the Company are held by UBS Fund Management (Switzerland) AG. UBS Fund Management (Switzerland) AG is a direct wholly-owned subsidiary of UBS Group AG, which is the beneficial owner and may exercise voting power over the shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.27pt">Consists of 695,920 ordinary shares and 70,080 ordinary shares issuable upon exercise of options that are exercisable within 60 days of December 31, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 757,044 ordinary shares and 36,070 ordinary shares issuable upon exercise of options that are exercisable within 60 days of December 31, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 238,485 ordinary shares and 36,070 ordinary shares issuable upon exercise of options that are exercisable within 60 days of December 31, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 18,222 ordinary shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 11,212 ordinary shares and 20,000 ordinary shares issuable upon exercise of options that are exercisable within 60 days of December 31, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 3,912 ordinary shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 16,800 ordinary shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 19,079 ordinary shares and 13,040 ordinary shares issuable upon exercise of options that are exercisable within 60 days of December 31, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.52pt">Consists of 1,760,674 ordinary shares and 175,260 ordinary shares issuable upon exercise of options that are exercisable within 60 days of December 31, 2022.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In June 2021, we completed our initial public offering in the U.S. and listed our ADSs on the Nasdaq Global Select Market. In the initial public offering, we issued and sold 3,000,000 ADSs representing 3,000,000 ordinary shares. Upon the completion of our initial public offering, 32,157,793 ordinary shares were outstanding (including shares in the form of ADSs). While none of our existing shareholders sold ordinary shares in the offering, the percentage ownership held by certain shareholders decreased as a result of the issuance of the ADSs sold by us in the offering.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To our knowledge, other than as provided in the table above, our other filings with the SEC and this Annual Report on Form 20-F, the significant changes in the percentage ownership held by our principal shareholders since January 1, 2019 are as a result of the transactions described in the final prospectus related to our initial public offering dated June 15, 2021, filed with the SEC on June 16, 2021 pursuant to Rule 424(b), under the heading &#8220;Related Party Transactions-Agreements with Shareholders&#8221; and the dilution resulting from our initial public offering of ADSs in the U.S.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2022, our issued share capital as recorded in the commercial register of the Canton of Zurich was CHF3,579,264.80, consisting of 35,792,648 ordinary shares with a nominal value of CHF 0.10 each. All shares rank </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with each other and no preferred shares exist.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As of December 31, 2022, to the best of our knowledge and assuming that all of our ordinary shares represented by ADSs are held by residents of the United States, we estimate that 27% of our issued ordinary shares (including ordinary shares underlying ADSs) as identified in publicly available filings were held in the United States by approximately 20 holders of record. The actual number of holders is potentially greater than these numbers of record holders, and includes beneficial owners whose ordinary shares or ADSs are held in street name by brokers and other nominees. This number of holders of record also does not include holders whose shares may be held in trust by other entities.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_103"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Related Party Transactions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since January 1, 2022, we have engaged in the following transactions with our directors, executive officers and holders of more than 3% of our outstanding voting securities and their affiliates, which we refer to as our related parties. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreements with Our Directors and Executive Officers </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employment Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have entered into customary employment agreements with all of our executive officers. These agreements provide for a base salary and annual incentive bonus opportunity, as well as participation in our equity incentive plans. These agreements generally require advance notice of termination of six months.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have entered into indemnification agreements with each of our directors and executive officers. See the section of this Annual Report on Form 20-F entitled &#8220;Item 6.B - Compensation&#8212;Compensation of Executive Officers&#8212;Limitations on Liability and Indemnification Matters.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreements with Shareholders</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See &#8220;Item 4.B - Business Overview&#8212;License and Collaboration Agreements" for information regarding the Novartis Option Agreement, the Ensovibep License Agreement and the Novartis Radioligand Agreement with Novartis. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Related Party Transactions Policy</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000 or which is unusual in its nature or conditions. Transactions involving compensation for services provided to us as an employee, consultant or director are not covered by this policy. A related person is any enterprise that controls, is controlled by or is under common control with the Company, or in which the Company has significant influence or which has significant influence over the Company; an individual owning, directly or indirectly, an interest in the voting power of the Company that gives them significant influence over the Company, and close members of any such individual&#8217;s family; key management personnel, including directors and senior management and close members of such individuals' families; and any enterprise in which a substantial interest in the voting power of the Company is owned, directly or indirectly, by any person described in the foregoing list or over which such a person is able to exercise significant influence, including enterprises owned by directors or major shareholders of the Company and enterprises that have a member of key management in common with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the policy, any proposed transaction that has been identified as a related person transaction may be consummated or materially amended only following approved by our Audit and Finance Committee, or, if Audit and Finance Committee approval would be inappropriate, another independent body of our board of directors. Any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation shall be submitted for review and ratification by our Audit and Finance Committee, The presentation of such related party transactions shall include a description of, among other things, the parties thereto, the interests, direct and indirect, of the related persons, the purpose and material facts of the transaction,, the benefits to the Company of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third- party or to or from employees generally, and management's recommendation with respect to the transaction. The Audit and Finance Committee shall approve only those related person transactions that, in light of known circumstances, are in, or are not inconsistent with, the best interests of the Company and its shareholders, as the Audit and Finance Committee determines in the good faith. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, while related party transaction policies are generally not required by statutory Swiss law, our articles of association provide for the following rules in connection with transactions with members of the board of directors and the executive management:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may enter into mandate or other agreements with the members of our board of directors regarding their compensation as directors for a fixed term or for an indefinite term. The duration and termination are subject to term of office and the law. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may enter into employment agreements with the members of the executive management for a fixed term or for an indefinite term. The duration of fixed term agreements may not exceed one year. A renewal of a fixed term agreement is permissible. Agreements for an indefinite term may have a termination notice period of a maximum of one year. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may enter into non-competition agreements with members of the executive management for the period after the termination of the employment agreement. The duration of any such non-competition undertaking by a member of the executive management shall not exceed two years, and the consideration paid for a non-competition undertaking shall not exceed the sum of the total annual compensation of the respective member of the executive management last paid.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loans to members of the board of directors and the executive management may be granted, provided they are at standard market rates and the aggregate amount of the loan extended to the member of the board of directors or executive management does not exceed 200% of the total annual compensation of the respective member of the executive management last paid or payable for the first time.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subject to the approval by the meeting of shareholders, we may grant to members of our board of directors or the executive management post-retirement benefits beyond the occupational benefit scheme, if such post-retirement benefits do not exceed 100% of the total annual compensation of the respective member last paid. In case of capital settlements, the value is determined by recognized actuarial methods.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_106"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Interests of Experts and Counsel. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_109"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 8. Financial Information </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_112"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Consolidated Statements and Other Financial Information. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Financial Statements </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our consolidated financial statements are appended at the end of this Annual Report, starting at page F-1, and incorporated herein by reference. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Distribution Policy </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our ordinary shares and we do not anticipate paying dividends on our equity securities in the foreseeable future. Instead, we intend to retain any earnings for use in the operation and expansion of our business, including for continued advancement of our proprietary DARPin product candidates, investment in research and development, building up our late-stage clinical development and, eventually, commercialization abilities. As a result, investors in our ordinary shares or ADSs will benefit in the foreseeable future only if the ordinary shares or ADSs appreciate in value.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order for us to declare and pay dividends, the distribution must be approved by shareholders holding an absolute majority of the ordinary shares represented at the general meeting of shareholders. Our board of directors may propose distributions in the form of a common dividend or in the form of a distribution of cash or property that is based upon a reduction of our share capital recorded in the commercial register.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common dividends may be paid only if we have sufficient distributable profits from previous years (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Gewinnvortrag</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or freely distributable reserves to allow the distribution of a dividend, in each case, as presented on our annual statutory standalone balance sheet prepared in accordance with Swiss company law after deduction of allocated statutory reserves and reserves required by our articles of association (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Statuten</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">). Our auditor must confirm that a proposal made by the board of directors to shareholders regarding the appropriation of our available earnings conforms to the requirements of the Swiss Code of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Obligations of March 30, 1911, as amended, the CO, and our articles of association. In order for us to pay dividends to our shareholders out of reserves from capital contributions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), a shareholders&#8217; meeting must approve by the absolute majority of votes represented the reclassification of such reserves from capital contributions to freely distributable reserves (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">frei verf&#252;gbare Reserven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) (to the extent permissible by the CO). Furthermore, dividends can be paid out of reserves from capital reserves only if the same amount is paid out of the annual profit or ordinary reserves. Dividends and distributions against reserves from capital contributions are usually due and payable after the shareholders&#8217; resolution relating to the allocation of profit and distribution against reserves from capital contributions (if applicable) has been passed at the shareholders&#8217; meeting or at a later date as determined by the shareholders&#8217; dividend resolution. Under Swiss law, the statute of limitations with respect to dividend payments is five years. Dividends not collected within five years after their due date accrue to us and will be allocated to our general reserves. Dividends paid on ordinary shares are subject to Swiss federal withholding tax, except if paid out of reserves from capital contributions. See &#8220;Swiss Tax Implications for U.S. Holders&#8212;Swiss Tax Considerations&#8212;Swiss Federal Withholding Tax&#8221; for a summary of certain Swiss tax consequences regarding dividends and other distributions distributed to holders of our ordinary shares. As of December&#160;31, 2022, we had reserves from capital contributions in an aggregate amount of CHF 327,226,982, of which CHF 179,226,982 were legal capital reserves and CHF 148,000,000 were free reserves.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A distribution of cash or property that is based on a reduction of our share capital requires a special audit report confirming that the claims of our creditors remain fully covered by our assets despite the reduction in the share capital recorded in the commercial register. Upon approval by the general meeting of the shareholders of the capital reduction, our board of directors must give public notice of the capital reduction in the Swiss Official Gazette of Commerce three times and notify our creditors that they may request, within two months of the third publication, satisfaction of or security for their claims. Distributions of cash or property that are based upon a capital reduction are not subject to Swiss federal withholding tax. See &#8220;Swiss Tax Implications for U.S. Holders&#8212;Swiss Tax Considerations&#8212;Swiss Federal Withholding Tax&#8221; for a summary of certain Swiss tax consequences regarding distributions paid on the ordinary shares that are based upon a capital reduction. For a description of share capital reductions under the revised Swiss corporate law that entered into force in 2023, see "Item 10.B. Memorandum and Articles of Association Swiss Corporate Law Reform."</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividend distributions, if any in the future, will be declared and paid in Swiss francs and converted into U.S. dollars with respect to our ADSs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our board of directors determines the date on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends in quarterly or other installments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 12, 2022, a putative class action complaint was filed in the U.S. District Court for the Southern District of New York against the Company, its directors, and certain of its executive officers. The complaint alleges that the defendants violated federal securities laws by, among other things, making misrepresentations and omissions regarding its product candidates ensovibep and MP0310. The complaint seeks unspecified compensatory damages, as well as an award of reasonable attorneys&#8217; fees and other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">costs, on behalf of persons and/or entities which purchased (a) the Company&#8217;s American Depositary Shares (ADSs) pursuant to certain offering documents issued in connection with the Company's initial public offering of ADSs; and/or (b) our securities between June 16, 2021 and April 26, 2022 inclusive. A motion to appoint a lead plaintiff and counsel was filed on September 12, 2022 and is still pending. The matter remains in its early stages. The Company disputes these claims and intends to defend itself accordingly. The Company expresses no assurances as to the ultimate outcome of this matter.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_115"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Significant Changes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A discussion of significant changes in our business can be found under "Item 4. Information on the Company - 4.B. Business Overview."</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_118"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 9. The Offer and Listing. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_121"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Offer and Listing Details. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our ADSs have been listed on the Nasdaq Global Select Market under the symbol &#8220;MOLN&#8221; since June 16, 2021. Prior to June 16, 2021, there was no public trading market for ADSs. Our ordinary shares have been listed on the SIX Swiss Exchange, or SIX, under the symbol &#8220;MOLN&#8221; since November 5, 2014. Prior to November 5, 2014, there was no public trading market for ordinary shares. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_124"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Plan of Distribution. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_127"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Markets. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our ADSs have been listed on the Nasdaq Global Select Market under the symbol &#8220;MOLN&#8221; since June 16, 2021, and our ordinary shares have been listed on SIX under the symbol &#8220;MOLN&#8221; since November 5, 2014.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_130"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Selling Shareholders. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_133"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E. Dilution. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_136"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">F. Expenses of the Issue. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_139"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 10. Additional Information. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_142"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Share Capital. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Memorandum and Articles of Association. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the specifications mentioned below, the information set forth in our Registration Statement on Form F-1 (File No. 333-255447) as filed with the SEC on June 14, 2021 and declared effective by the SEC on June 15, 2021, under the headings &#8220;Description of Share Capital and Articles of Association &#8211; The Company,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; General Meeting of Shareholders,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Voting Rights,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Dividends and Other Distributions,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Transfer of Shares,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Inspection of Books and Records,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Compulsory Acquisitions; Appraisal Rights,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Board of Directors,&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Conflict of Interest, Management Transactions&#8221; &#8220;Description of Share Capital and Articles of Association &#8211; Principles of the Compensation of the Board of Directors and the Executive Management,&#8221; &#8220;Comparison of Swiss Law and Delaware Law&#8221; and &#8220;Enforcement of Judgments&#8221; is incorporated herein by reference.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Swiss Corporate Law Reform</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On January 1, 2023, legislation that modernized certain aspects of Swiss corporate law (the Swiss corporate law reform (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Aktienrechtsrevision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">)) entered into force. Most relevantly, the legislative reform addressed, among other topics, (i) the modernization and increased flexibility for a stock corporation's capital base, (ii) the strengthening of shareholder rights and the protection of minorities, (iii) certain changes to financial distress/restructuring measures, (iv) corporate governance and executive compensation matters (amongst others, the incorporation of the ordinance against excessive compensation in listed stock corporations (OaEC) into the Swiss Code of Obligations (CO), and (v) certain socio-political topics (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, gender representation and disclosure requirements for companies active in the raw materials sector, which, subject to transitional periods, entered into force on January 1, 2021). The Swiss corporate law reform is subject to certain transitional periods as provided for therein. In particular, Swiss stock corporations registered with the Commercial Register on January 1, 2023, are required to amend their articles of association and organizational regulations in line with the new legislation within a transitional period of two years (i.e., until January 1, 2025). Accordingly, we intend to propose certain amendments to our articles of association at the next annual general meeting of shareholders. Until such amendments have been adopted and approved by the general meeting of shareholders, our current articles of association remain in full force and effect. In light of these reforms, certain information (x) set out below and (y) incorporated by reference herein in the above-referenced sections of our Registration Statement on Form F-1 (File No. 333-255447) as filed with the SEC on June 14, 2021 and declared effective by the SEC on June 15, 2021, will be subject to the changes and modifications pursuant to this new legislation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Share Capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of each of December 31, 2022, our issued share capital as recorded in the commercial register of the Canton of Zurich was CHF 3,579,264.80, consisting of 35,792,648 ordinary shares with a nominal value of CHF 0.10 each. As of March 1, 2023, our issued share capital as recorded in the commercial register of the Canton of Zurich was CHF 3,604,470.60 , consisting of 36,044,706 ordinary shares with a nominal value of CHF 0.10 each.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under our articles of association, in their current version dated January 19, 2023, our board of directors is authorized to increase the share capital at any time on or before April 13, 2024, by a maximum aggregate amount of CHF 457,316.20 through the issuance of not more than 4,573,162 shares, which would have to be fully paid-in, with a nominal value of CHF 0.10 each.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Increases in partial amounts are permitted. The board of directors has the power to determine the type of contributions, the issue price and the date on which the dividend entitlement starts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The board of directors is also authorized to withdraw or limit pre-emptive rights as described above. This authorization is exclusively linked to the particular available authorized share capital set out in the respective article. If the period to increase the share capital lapses without having been used by the board of directors, the authorization to withdraw or to limit the pre-emptive rights lapses simultaneously with such capital. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">From January 1, 2019 through December 31, 2022, the number of our issued ordinary shares as recorded in the commercial register of the Canton of Zurich underwent the following changes:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2019</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on January 1, 2019</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,044,062</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reflecting in commercial register on January 22, 2019 of prior issuance of new shares with a nominal value of CHF 0.10 each issued (but not reflected) in the one-year period ended December 31, 2018 out of conditional share capital</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">184,531</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on December 31, 2019</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,228,593</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on January 1, 2020</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,228,593</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reflecting in commercial register on January 20, 2020 of prior issuance of new shares with a nominal value of CHF 0.10 each issued (but not reflected) in the one-year period ended December 31, 2019 out of conditional share capital</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">372,599</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issuance in an accelerated bookbuilding transaction of new shares with a nominal value of CHF 0.10 each on July 8, 2020 out of authorized share capital immediately reflected in the commercial register on July 8, 2020</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,528,089</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issuance of new shares with a nominal value of CHF 0.10 each to Novartis Pharma AG on October 28, 2020 out of conditional share capital, immediately reflected in commercial register on October 28, 2020</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,739,130</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on December 31, 2020</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,868,411</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2021</span></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on January 1, 2021</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,868,411</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reflecting in commercial register on January 20, 2021 of prior issuance of new shares with a nominal value of CHF 0.10 each issued (but not reflected) in the one-year period ended December 31, 2020 out of conditional share capital</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">278,581</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on April 30, 2021</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,146,992&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issuance for our US IPO of new shares with a nominal value of CHF 0.10 each on June 16, 2021 out of authorized share capital immediately reflected in the commercial register on June 16, 2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on December 31, 2021</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,146,992</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on January 1, 2022</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,146,992</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reflecting in commercial register on January 20, 2022 of prior issuance of new shares with a nominal value of CHF 0.10 each issued (but not reflected) in the one-year period ended December 31, 2021 out of conditional share capital</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;145,656</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on March 1, 2022</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,292,648</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issuance of new shares for treasury shares fully owned by Molecular Partners, Inc. with a nominal value of CHF 0.10 each on August 24, 2022 out of authorized share capital immediately reflected in the commercial register on August 24, 2022</span></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on August 24, 2022</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,792,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on December 31, 2022</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,792,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on January 1, 2023</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,792,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reflecting in commercial register on January 19, 2023 of prior issuance of new shares with a nominal value of CHF 0.10 each issued (but not reflected) in the one-year period ended December 31, 2022 out of conditional share capital</span></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">252,058&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issued shares recorded on March 1, 2023</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,044,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">History of Securities Issuances</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From January 1, 2019 through December 31, 2022, the events set out above and further described below have changed our issued share capital and, in parallel, the number of our issued ordinary shares, in each case as recorded in the commercial register of the Canton of Zurich.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 22, 2019, our share capital was increased by CHF 18,453.10 through the issuance of 184,531 new shares with a nominal value of CHF 0.10 each. These shares had been issued out of conditional share capital (but were not recorded in the commercial register until January 22, 2019) in the one-year period ended December 31, 2018, based on the resolution of the general meeting of shareholders held on October 6, 2014 regarding a conditional capital increase of up to CHF 400,000 through the issuance of up to 4,000,000 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 20, 2020, our share capital was increased by CHF 37,259.90 through the issuance of 372,599 new shares with a nominal value of CHF 0.10 each. These shares had been issued out of conditional share capital (but were not recorded in the commercial register until January 20, 2020) in the one-year period ended December 31, 2019, based on the resolution of the general meeting of shareholders held on October 6, 2014 regarding a conditional capital increase of up to CHF 400,000 through the issuance of up to 4,000,000 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">On July 8, 2020, our share capital was increased by CHF 552,808.90 through the issuance of 5,528,089 new shares with a nominal value of CHF 0.10 each. These shares were issued out of authorized share capital based on the resolution of the general meeting of shareholders held on April 29, 2020 regarding an authorized share capital increase of up to CHF 565,986 through the issuance of up to 5,659,860 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each on or before April 29, 2022. The new shares were placed with institutional investors in an accelerated bookbuilding transaction, under withdrawal of statutory pre-emptive rights of existing shareholders. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">On October 28, 2020, our share capital was increased by CHF 173,913.00 through the issuance of 1,739,130 new shares with a nominal value of CHF 0.10 each. These shares were issued out of conditional share capital based on the resolution of the general meeting of shareholders held on October 6, 2014 regarding a conditional capital increase of up to CHF 400,000 through the issuance of up to 4,000,000 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each. The new shares were issued to Novartis Pharma AG in connection with an option and equity rights agreement providing for a collaboration to develop, manufacture and commercialize certain product candidates and/or therapies. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 20, 2021, our share capital was increased by CHF 27,858.10 through the issuance of 278,581 new shares with a nominal value of CHF 0.10 each. These shares had been issued out of conditional share capital (but were not recorded in the commercial register until January 20, 2021) in the one-year period ended December 31, 2020, based on the resolution of the general meeting of shareholders held on October 6, 2014 regarding a conditional capital increase of up to CHF 400,000 through the issuance of up to 4,000,000 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">On June 16, 2021, our share capital was increased by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CHF 28,641.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through the issuance of 3,000,000 new shares with a nominal value of CHF 0.10 each. These shares were issued out of authorized share capital based on the resolution of the general meeting of shareholders held on April 21, 2021 regarding an authorized share capital increase of up to CHF 728,675 through the issuance of up to 7,286,750 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each on or before April 21, 2023. These 3,000,000 new shares issued under withdrawal of statutory preemptive rights of existing shareholders, are underlying the 3,000,000 American Depositary Shares created within the framework of the IPO of the Company on the Nasdaq Global Selected Market that were placed with institutional investors. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:15.73pt">On January 20, 2022, our share capital was increased by CHF 14,565.60 through the issuance of 145,656 new shares with a nominal value of CHF 0.10 each. These shares had been issued out of conditional share capital (but were not recorded in the commercial register until January 20, 2022) in the one-year period ended December 31, 2021, based on the resolution of the general meeting of shareholders held on October 6, 2014 regarding a conditional capital increase of up to CHF 400,000 through the issuance of up to 4,000,000 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we issued 3,500,000 common shares at par value CHF 0.1 per share. The shares were fully subscribed for by Molecular Partners Inc., a fully owned subsidiary of the Company. As of December 31, 2022, all 3,500,000 common shares were held as treasury shares of the Company. The purpose of the share issuance was to replenish our pool of treasury shares that we can use in the future to raise funds, including in connection with our at-the-market sales program for American Depositary Shares established in July 2022.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:15.73pt">On January 19, 2023, our share capital was increased by CHF 25,205.80 through the issuance of 252,058 new shares with a nominal value of CHF 0.10 each. These shares had been issued out of conditional share capital (but were not recorded in the commercial register until January 19, 2023) in the one-year period ended December 31, 2022, based on the resolution of the general meeting of shareholders held on October 6, 2014 regarding a conditional capital increase of up to CHF 400,000 through the issuance of up to 4,000,000 registered shares with a nominal value of CHF 0.10 (to be fully paid in) each. Our articles of incorporation were amended accordingly to reflect the new share capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Articles of Association</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under our current articles of association, our board of directors is authorized to increase the share capital at any time on or before April 13, 2024, by a maximum aggregate amount of CHF 457,316 through the issuance of not more than 4,573,162 shares, which would have to be fully paid-in, with a nominal value of CHF 0.10 each.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Increases in partial amounts are permitted. The board of directors has the power to determine the type of contributions, the issue price and the date on which the dividend entitlement starts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The board of directors is also authorized to withdraw or limit pre-emptive rights as described above. This authorization is exclusively linked to the particular available authorized share capital set out in the respective article. If the period to increase the share capital lapses without having been used by the board of directors, the authorization to withdraw or to limit the pre-emptive rights lapses simultaneously with such capital. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our share capital may as of December 31, 2022 be increased by a (following the transactions set out in "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">History of Securities Issuances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">", residual) maximum aggregate amount of CHF 136,296.30 through the issuance of not more than 1,362,963 ordinary shares, which would need to be fully paid-in, with a nominal value of CHF 0.10 each, through the direct or indirect issuance of shares, options or pre-emptive rights thereof granted to employees and members of our board of directors as well as to members of any advisory boards. Shares, options or pre-emptive rights thereof shall be issued in accordance with one or more participation plans and/or policies to be issued by our board of directors and in accordance with our articles of association.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, our share capital may be increased by a (following the transactions set out in "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">History of Securities Issuances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">", residual) maximum aggregate amount of CHF 226,087 through the issuance of up to 2,260,870 fully paid up shares with a nominal value of CHF 0.10 each through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights for the subscription of shares granted to shareholders or third parties alone or in connection with bonds, notes, options, warrants or other securities or contractual obligations by us or any of our group companies.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_148"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Material Contracts. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In addition to the contracts described elsewhere in this Annual Report, the following are summaries of each material contract to which we are a party for the two years preceding the date of this Annual Report.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Underwriting Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In June 2021, we entered into an underwriting agreement with J.P. Morgan Securities LLC, SVB Leerink LLC and Cowen and Company, LLC, as representatives of the underwriters, with respect to the ADSs sold in our initial public offering. We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect of such liabilities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sales Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 1, 2022, we entered into the Sales Agreement with SVB Securities LLC to sell ordinary shares from time to time at our discretion under an &#8220;at the market&#8221;, or ATM, program, with aggregate gross sales proceeds of up to $100.0 million. The Sales Agreement provides that the commission payable to SVB Securities LLC, as sales agent, for sales of ordinary shares under the ATM program shall be up to 3.0% of the aggregate gross proceeds of any ordinary shares sold under the Sales Agreement. The Sales Agreement contains customary representations and warranties of the parties and indemnification and contribution provisions, including our agreement to indemnify SVB Securities LLC against certain liabilities, including liabilities under the Securities Act. We and SVB Securities LLC have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement.<br/>As of March 8, 2023, we have not made any sales under the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For additional information on our material contracts, please see &#8220;Item 4. - Information on the Company,&#8221; &#8220;Item 6. - Directors, Senior Management and Employees,&#8221; and &#8220;Item 7.B. - Related Party Transactions&#8221; of this Annual Report.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_151"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Exchange Controls.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no Swiss governmental laws, decrees or regulations that restrict, in a manner material to us, the export or import of capital, including any foreign exchange controls, or that generally affect the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">remittance of dividends or other payments to non-residents or non-citizens of Switzerland who hold our ordinary shares. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_154"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E. Taxation. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Swiss Federal, Cantonal and Communal Individual Income Tax and Corporate Income Tax</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Non-Resident Shareholders</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holders of ADSs representing our shares who are not resident in Switzerland for tax purposes, and who, during the relevant taxation year, have not engaged in a trade or business carried on through a permanent establishment or fixed place of business situated in Switzerland for tax purposes (all such shareholders are hereinafter referred to as the Non-Resident Shareholders), will not be subject to any Swiss federal, cantonal and communal income tax on dividends and similar cash or in-kind distributions on ADSs representing our shares (including dividends on liquidation proceeds and stock dividends) (hereinafter referred to as the Dividends), distributions based upon a capital reduction (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nennwertr&#252;ckzahlungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or paid out of reserves from capital contributions (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) on shares underlying the ADSs, or capital gains realized on the sale or other disposition of ADSs (see, however, "</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Swiss Federal Withholding Tax</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">" for a summary of Swiss federal withholding tax on Dividends). </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Resident Private Shareholders</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Swiss resident individuals who hold their ADSs as private assets (all such shareholders are hereinafter referred to as the Resident Private Shareholders) are required to include Dividends, but not distributions based upon a capital reduction (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nennwertr&#252;ckzahlungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or paid out of reserves from capital contributions (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of the shares underlying the ADSs, in their personal income tax return and are subject to Swiss federal, cantonal and communal income tax on any net taxable income for the relevant taxation period, including the Dividends, but not the distributions based upon a capital reduction (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nennwertr&#252;ckzahlungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or paid out of reserves from capital contributions (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">). Capital gains resulting from the sale or other dispositions of ADSs are not subject to Swiss federal, cantonal and communal income tax, and conversely, capital losses are not tax-deductible for Resident Private Shareholders. See "</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Domestic Commercial Shareholders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">" for a summary of the taxation treatment applicable to Swiss resident individuals, who, for income tax purposes, are classified as "professional securities dealers." </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Domestic Commercial Shareholders</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate and individual shareholders who are resident in Switzerland for tax purposes and corporate and individual shareholder who are not resident in Switzerland, and who, in each case, hold their ADSs as part of a trade or business carried on in Switzerland, in the case of corporate and individual shareholders not resident in Switzerland, through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are required to recognize Dividends, distributions based upon a capital reduction (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nennwertr&#252;ckzahlungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or paid out of reserves from capital contributions (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) received on shares underlying the ADSs and capital gains or losses realized on the sale or other disposition of ADSs in their income statement for the relevant taxation period and are subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings for such taxation period. The same taxation treatment also applies to Swiss-resident private individuals who, for income tax purposes, are classified as "professional securities dealers" for reasons of, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter alia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, frequent dealing, or leveraged investments in ADSs and other securities (the shareholders referred to in this section, the Domestic Commercial Shareholders). Domestic Commercial Shareholders who are corporate taxpayers may be eligible for dividend relief (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Beteiligungsabzug</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">respect of Dividends and distributions based upon a capital reduction (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nennwertr&#252;ckzahlungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or paid out of reserves from capital contributions (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) if the shares underlying the ADSs held by them as part of a Swiss business have an aggregate market value of at least CHF 1 million. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Swiss Cantonal and Communal Private Wealth Tax and Capital Tax</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Non-Resident Shareholders</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Resident Shareholders are not subject to Swiss cantonal and communal private wealth tax or capital tax. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Resident Private Shareholders and Domestic Commercial Shareholders</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Resident Private Shareholders and Domestic Commercial Shareholders who are individuals are required to report their ADSs as part of private wealth or their Swiss business assets, as the case may be, and will be subject to Swiss cantonal and communal private wealth tax on any net taxable wealth (including the ADSs), in the case of Domestic Commercial Shareholders to the extent the aggregate taxable wealth is allocated in Switzerland. Domestic Commercial Shareholders who are corporate taxpayers are subject to Swiss cantonal and communal capital tax on taxable capital to the extent the aggregate taxable capital is allocated to Switzerland. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Swiss Federal Withholding Tax</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividends that the Company pays on the shares underlying the ADSs are subject to Swiss Federal withholding tax (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Verrechnungssteuer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) at a rate of 35% on the gross amount of the Dividend. The Company is required to withhold the Swiss federal withholding tax from the Dividend and remit it to the Swiss Federal Tax Administration. Distributions based upon a capital reduction (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nennwertr&#252;ckzahlungen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or paid out of reserves from capital contributions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reserven aus Kapitaleinlagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) are not subject to Swiss federal withholding tax. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Swiss federal withholding tax on a Dividend will be refundable in full to a Resident Private Shareholder and to a Domestic Commercial Shareholder, who, in each case, inter alia, as a condition to refund, duly reports the Dividend in his or her individual income tax return as income or recognizes the Dividends in its income statement as earnings, as applicable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A Non-Resident Shareholder may be entitled to a partial refund of the Swiss federal withholding tax on Dividend if the country of his or her residence for tax purposes has entered into a bilateral treaty for the avoidance of double taxation with Switzerland and the conditions of such treaty are met. Such shareholders should be aware that the procedures for claiming tax treaty benefits (and the time required for obtaining a refund) might be different from country to country. For example, a shareholder who is resident of the U.S. for the purposes of the bilateral treaty between the U.S. and Switzerland is eligible for a refund of the amount of the withholding tax in excess of the 15% treaty rate, provided such shareholder: (i) qualifies for benefits under this treaty and qualifies as beneficial owner of the Dividends; (ii) hold, directly or indirectly, less than 10% of the voting stock of the Company; (iii) does not qualify as a pension scheme or retirement arrangement for the purpose of the bilateral treaty; and (iv) does not conduct business through a permanent establishment or fixed base in Switzerland to which the ADSs are attributable. Such an eligible U.S. shareholder may apply for a refund of the amount of the withholding tax in excess of the 15% treaty rate. The applicable refund request form may be filed with the Swiss Federal Tax Administration following receipt of the dividend and the relevant deduction certificate, however no later than December 31 of the third year following the calendar year in which the dividend was payable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Swiss Federal Stamp Taxes</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any dealings in the ADSs, where a bank or another securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act, acts as intermediary or is a party to the transaction, are, subject to certain exemptions provided for in the Swiss Federal Stamp Tax Act, subject to Swiss securities turnover tax at an aggregate tax rate of up to 0.15% of the consideration paid for such ADSs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">International Automatic Exchange of Information in Tax Matters</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 19, 2014, Switzerland signed the Multilateral Competent Authority Agreement, which is based on article 6 of the OECD/Council of Europe administrative assistance convention and is intended to ensure the uniform implementation of automatic exchange of information, or the AEOI. The Federal Act on the International Automatic Exchange of Information in Tax Matters, or the AEOI Act, entered into force on January 1, 2017. The AEOI Act is the legal basis for the implementation of the AEOI standard in Switzerland.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The AEOI is being introduced in Switzerland through bilateral agreements or multilateral agreements. The agreements have, and will be, concluded on the basis of guaranteed reciprocity, compliance with the principle of specialty (i.e., the information exchanged may only be used to assess and levy taxes (and for criminal tax proceedings) and adequate data protection.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on such multilateral agreements and bilateral agreements and the implementing laws of Switzerland, Switzerland exchanges data in respect of financial assets, including the Shares, held in, and income derived thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals resident in an EU member state or in a treaty state.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Swiss Facilitation of the Implementation of the U.S. Foreign Account Tax Compliance Act</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Switzerland has concluded an intergovernmental agreement with the U.S. to facilitate the implementation of FATCA. The agreement ensures that the accounts held by U.S. persons with Swiss financial institutions are disclosed to the U.S. tax authorities either with the consent of the account holder or by means of group requests within the scope of administrative assistance. Information will not be transferred automatically in the absence of consent, and instead will be exchanged only within the scope of administrative assistance on the basis of the double taxation agreement between the U.S. and Switzerland. On October 8, 2014, the Swiss Federal Council approved a mandate for negotiations with the U.S. on changing the current direct-notification-based regime to a regime where the relevant information is sent to the Swiss Federal Tax Administration, which in turn provides the information to the U.S. tax authorities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Material U.S. Federal Income Tax Consequences for U.S. Holders</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs by U.S. Holders (as defined below). This discussion applies to U.S. Holders that hold ADSs as capital assets (generally, property held for investment) within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based on the Code, U.S. Treasury Regulations promulgated thereunder, the income tax treaty between the United States and Switzerland, or the Treaty, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies, broker&#8209;dealers and traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes, tax&#8209;exempt entities, retirement plans, regulated investment </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">companies, real estate investment trusts, certain former citizens or residents of the United States, persons who hold ADSs as part of a &#8220;straddle,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or integrated investment, persons who received their ADSs as compensatory payments, persons that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons that own directly, indirectly or through attribution 10% or more of the voting power or value of our ADSs, corporations that accumulate earnings to avoid U.S. federal income tax, S-corporations, partnerships (including entities or arrangements treated as partnerships for U.S. federal income tax purposes) and other pass&#8209;through entities, and investors in such pass&#8209;through entities, or persons who hold our ADSs in connection with a trade or business, permanent establishment or fixed place of business outside the United States, including a permanent establishment in Switzerland). This discussion relates only to U.S. federal income taxes and does not address any other taxes, including but not limited to, U.S. state or local or non&#8209;U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences, or the special tax accounting rules under Section 451(b) of the Code.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of ADSs that is, for U.S. federal income tax purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds ADSs, the U.S. federal income tax consequences relating to an investment in the ADSs will depend in part upon the status and activities of such entity or arrangement and the particular partner. Any such entity or arrangement should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. A U.S. Holder of ADSs will generally be treated for U.S. federal income tax purposes as holding the ordinary shares represented by the ADSs, and, accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Passive Foreign Investment Company Consequences</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In general, a corporation organized outside the United States will be treated as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year in which, after the application of certain look-through rules with respect to income and assets of its subsidiaries, either (1) at least 75% of its gross income is &#8220;passive income,&#8221; or (2) on average at least 50% of its assets, determined on a quarterly basis, for the taxable year are assets that produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non&#8209;U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which, may be determined in large part by reference to the market price of the ADSs, which is likely to continue to fluctuate) in each year, and because the determination of whether or not we are a PFIC for any taxable year is a factual determination made annually after the end of each taxable year and because the applicable law is subject to varying interpretations, we cannot provide any assurance regarding our PFIC status. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based upon our analysis of the value of our assets and the nature and composition of our income and assets, we believe that we were a PFIC for the taxable year ended December 31, 2022. However, the determination of whether or not we are a PFIC is a fact-intensive determination made annually after the end of the taxable year and because the applicable law is subject to varying interpretations, we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year. Furthermore, there can be no assurance that the IRS will agree with our conclusion or that the IRS will not successfully challenge our position. Accordingly, we cannot provide any assurances regarding our PFIC status for the current or future taxable years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are a PFIC in any taxable year during which a U.S. Holder owns ADSs, the U.S. Holder could be liable for additional taxes and interest charges under the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution made during a taxable year that is greater than 125% of the average annual distributions made in the three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s holding period for the ADSs, and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of the ADSs, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for ADSs. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, for ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are a PFIC for any year during which a U.S. Holder holds ADSs, we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. Holder holds the ADSs, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#8220;deemed sale&#8221; election with respect to the ADSs. If this election is made, the U.S. Holder will be deemed to sell the ADSs it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC. Any gain recognized from such deemed sale will be taxed under the PFIC excess distribution regime, and any loss will not be recognized. The U.S. Holder&#8217;s tax basis in its ADSs will be increased by the amount of gain recognized, and the U.S. Holder&#8217;s holding period for its ADSs will start on the day after the last day of the last taxable year in which we qualified as a PFIC. After the deemed sale election, the U.S. Holder&#8217;s ADSs will not be treated as shares of a PFIC unless we subsequently become a PFIC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are a PFIC for any taxable year during which a U.S. Holder holds ADSs and at any time have a non&#8209;U.S. corporate subsidiary that is also a PFIC (i.e., a lower&#8209;tier PFIC), such U.S. Holder generally will be treated as owning a proportionate amount (by value) of the shares of the lower&#8209;tier PFIC and will be taxed under the PFIC excess distribution regime on distributions by the lower&#8209;tier PFIC and on gain from the disposition of shares of the lower&#8209;tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our non&#8209;U.S. subsidiaries.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on ADSs if such U.S. Holder makes a valid &#8220;mark&#8209;to&#8209;market&#8221; election </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for our ADSs. A mark&#8209;to&#8209;market election is available to a U.S. Holder only for &#8220;marketable stock.&#8221; Our ADSs will be marketable stock as long as they remain listed on the Nasdaq Global Select Market and are regularly traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. If a mark&#8209;to&#8209;market election is in effect, a U.S. Holder generally will take into account, as ordinary income for each taxable year of the U.S. Holder, any excess of the fair market value of ADSs held at the end of such taxable year over the U.S. Holder's adjusted tax basis in such ADSs. The U.S. Holder will also take into account, as an ordinary loss for each taxable year, any excess of its adjusted tax basis in such ADSs over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark&#8209;to&#8209;market election. The U.S. Holder&#8217;s tax basis in ADSs will be adjusted to reflect any income or loss recognized as a result of the mark&#8209;to&#8209;market election. Any gain from a sale, exchange or other disposition of ADSs in any taxable year in which we are a PFIC will be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark&#8209;to&#8209;market gains previously included in income) and thereafter as capital loss.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A mark&#8209;to&#8209;market election will not apply to ADSs for any taxable year during which we are not a PFIC but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any non&#8209;U.S. subsidiaries that we may organize or acquire in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower&#8209;tier PFICs that we may organize or acquire in the future notwithstanding the U.S. Holder&#8217;s mark&#8209;to&#8209;market election for the ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid qualified electing fund, or QEF, election for taxable years during which the U.S. Holder holds our ADSs and in which we are a PFIC. Instead, a U.S. Holder that makes a QEF election is required for each taxable year to include in income (i) the U.S. Holder&#8217;s pro rata share of the PFIC&#8217;s ordinary earnings as ordinary income or (ii) the U.S. Holder&#8217;s pro rata share of the EF net capital gains as capital gain, regardless of whether such earnings or gain have in fact been distributed, for each taxable year that the entity is classified as a PFIC. If a U.S. Holder makes a QEF election with respect to us, any distributions paid by us out of our earnings and profits that were previously included in the U.S. Holder&#8217;s income under the QEF election would not be taxable to the U.S. Holder. A U.S. Holder will increase its tax basis in its ADSs by an amount equal to any income included under the QEF election and will decrease its tax basis by any amount distributed on the ADSs that is not included in the U.S. Holder&#8217;s income. If a U.S. Holder has made a QEF election with respect to its ADSs, any gain or loss recognized by the U.S. Holder on a sale or other disposition of such ADSs will constitute capital gain or loss. In addition, if a U.S. Holder makes a timely QEF election, our ADSs will not be considered shares in a PFIC in years in which we are not a PFIC, even if the U.S. Holder had held ADSs in prior years in which we were a PFIC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Holders should consult their tax advisors regarding making QEF elections in their particular circumstances. If a U.S. Holder does not make and maintain a QEF election for the U.S. Holder&#8217;s entire holding period for our ADSs by making the election for the first year in which the U.S. Holder owns our ADSs, the U.S. Holder will be subject to the adverse PFIC rules discussed above unless the U.S. Holder can properly make a &#8220;purging election&#8221; with respect to our ADSs in connection with the U.S. Holder&#8217;s QEF election. A purging election may require the U.S. Holder to recognize taxable gain on the U.S. Holder&#8217;s ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to comply with the requirements of a QEF election, a U.S. Holder must receive certain information from us. The QEF election is made on a shareholder-by-shareholder basis and can be revoked only with the consent of the IRS. A shareholder makes a QEF election by attaching a completed IRS </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form 8621, including the information provided in the PFIC annual information statement, to a timely filed U.S. federal income tax return and by filing a copy of the form with the IRS. We may / expect to provide the information necessary for a U.S. Holder to make a QEF election if we were treated as a PFIC for any taxable year, although, there is no assurance that we will do so. There is no assurance that we have not been previously classified as a PFIC during a U.S. Holder&#8217;s holding period for ADSs. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Holders should consult their tax advisors to determine whether any of these above elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Each U.S. person (as defined in the Code) that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">The U.S. federal income tax rules relating to PFICs are very complex. U.S. Holders are strongly urged to consult their own tax advisors with respect to the impact of PFIC status on the ownership and disposition of ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect to the ownership and disposition of ADSs of a PFIC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Distributions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not anticipate declaring or paying dividends to holders of our ADSs in the foreseeable future. However, if we make a distribution contrary to this expectation, subject to the discussion above under &#8220;- Passive Foreign Investment Company Consequences,&#8221; a U.S. Holder that receives a distribution with respect to ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&#8217;s pro rata share of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and accumulated earnings and profits, it will be treated first as a taxfree return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s ADSs. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#8217;s ADSs, the excess will be taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to them to be treated as dividends. The amount of any dividend income paid in a currency other than the U.S. dollar will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Distributions on ADSs that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Subject to certain complex conditions and limitations and subject to the discussion above regarding concerns expressed by the U.S. Treasury, Swiss taxes withheld on any distributions on ADSs at a rate not exceeding the rate provided by the Treaty may be eligible for credit against a U.S. Holder&#8217;s federal income tax liability. The rules relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders should consult their tax advisors regarding the availability of a foreign tax credit in their particular circumstances and the possibility of claiming a deduction (in lieu of the foreign tax credit) for any foreign taxes paid or withheld.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividends paid by a &#8220;qualified foreign corporation&#8221; are eligible for taxation to noncorporate U.S. Holders at a reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met, including holding period and the absence of certain risk reduction transaction requirements. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Prospective investors should be aware, however, that dividends paid by a company that is a PFIC in the taxable year in which the distribution is paid or in the preceding taxable year are not eligible to be taxed at such reduced rate. Distributions on ADSs that are treated as dividends generally will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A non U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ADSs that are readily tradable on an established securities market in the United States. We believe that we qualify as a resident of Switzerland for purposes of, and are eligible for the benefits of the Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange of information provision. Our ADSs will generally be considered to be readily tradable on an established securities marked in the United States if they are listed on Nasdaq Global Select Market, as we intend our ADSs to be. U.S. Holders should consult their own tax advisors regarding the availability of the lower rate for dividends paid with respect to our ADSs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale, Exchange or Other Disposition of ADSs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the discussion above under &#8220;- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Passive Foreign Investment Company Consequences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of ADSs in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the ADSs. Such capital gain or loss generally will be longterm capital gain taxable at a reduced rate for noncorporate U.S. Holders or longterm capital loss if, on the date of sale, exchange or other disposition, the ADSs were held by the U.S. Holder for more than one year. Any capital gain of a noncorporate U.S. Holder that is not longterm capital gain will be taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of ADSs will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Medicare Tax</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ADSs. If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income and gains in respect of your investment in ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Information Reporting and Backup Withholding</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to their investment in ADSs, including, among others, IRS Form 8938 (Statement of Specified Foreign </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Assets). As described above under &#8220;Passive Foreign Investment Company Consequences&#8221;, each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividends on and proceeds from the sale or other disposition of ADSs may be subject to U.S. backup withholding unless the U.S. Holder establishes a basis for exemption. Backup withholding generally would apply if the holder (1) fails to provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption (usually on IRS Form W-9), or (2) establishes an exemption from information reporting and backup withholding. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Holders paying more than US$100,000 for our ADSs may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Holders should consult their own tax advisors regarding the backup withholding and information reporting rules.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_157"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">F. Dividends and Paying Agents. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_160"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G. Statement by Experts. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_163"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">H. Documents on Display. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements will file reports with the SEC. Those reports may be inspected without charge at the locations described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. Nevertheless, we will file with the SEC an Annual Report on Form 20-F containing financial statements that have been examined and reported on, with and opinion expressed by an independent registered public accounting firm. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We maintain a corporate website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">www.molecularpartners.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. We intend to post our Annual Report on Form 20-F on our website promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Securities and Exchange Commission maintains a website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) that contains reports, proxy and information statements and other information regarding registrants, such as Molecular Partners, that file electronically with the SEC. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to references made in this Annual Report on Form 20-F to any contract or other document of our company, such references are not necessarily complete and you should refer to the exhibits attached or incorporated by reference to this Annual Report on Form 20-F for copies of the actual contract or document.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_166"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I. Subsidiary Information. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not required. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_1462"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">J. Annual Report to Security Holders</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company intends to submit any annual report provided to security holders in electronic format as an exhibit to a current report on Form 6-K.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_169"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 11. Quantitative and Qualitative Disclosures About Market Risk. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We operate primarily in Switzerland, Europe and in the United States and are therefore exposed to market risk, which represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and cash equivalents plus short-term time deposits of CHF&#160;249.1&#160;million. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We operate primarily in Switzerland, Europe and in the United States and our functional currency is the Swiss franc, and as a result, we are exposed to (1) transactional foreign exchange risk when we enter into a transaction in a currency other than our functional currency and (2) translational foreign exchange risk when we translate our financial statements from USD into our functional currency. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to reduce our foreign exchange exposure, we may enter into currency contracts with selected high-quality financial institutions to hedge against foreign currency exchange rate risks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Group&#8217;s primary exposure to financial risk is due to fluctuation of exchange rates between CHF, USD and EUR. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our hedging policy is (1) to maximize natural hedging by matching expected future cash flows in the different currencies and (2), if market conditions allow and as the need arises, to consider hedging some of the remaining expected net currency exposure. However, due to market volatilities and uncertainties in the cash flows, a 100% hedging of the currency exposure is impossible.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The maximum credit risk on financial instruments corresponds to the carrying amounts of our cash and cash equivalents, short-term time deposits and receivables. We have not entered into any guarantees or similar obligations that would increase the risk over and above the carrying amounts. As of December 31, 2022, substantially all of our cash and cash equivalents, and short-term time deposits were held at major financial institutions located in Switzerland. We believe that these financial institutions are of high credit quality and continually monitor the credit worthiness of these financial institutions. We enter into partnerships with partners that have the appropriate credit history and a commitment to ethical business practices. Other receivables with credit risk mainly include interest receivables.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_172"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 12. Description of Securities Other than Equity Securities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Debt Securities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_178"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Warrants and Rights. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_181"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Other Securities. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. American Depositary Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fees and Charges </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holders of our ADSs are required to pay the following service fees to the depositary under the terms of our deposit agreement: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Service</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Fees</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the ADS(s)-to- common share(s) ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares)</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS issued</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to- common share(s) ratio, or for any other reason)</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS canceled</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS held</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Distribution of ADSs pursuant to stock dividends, other free stock distributions or exercise of rights to purchase additional ADSs.</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS held</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS held</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;ADS Services</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS held on the applicable record date(s) established by the depositary</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Registration of ADS Transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason).</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS transferred</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferable ADSs, and vice versa).</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Up to U.S. $0.05 per ADS converted</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holders of ADSs are also responsible to pay certain fees, expenses, taxes and governmental charges such as: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;taxes (including applicable interest and penalties) and other governmental charges;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;such registration fees as may from time to time be in effect for the registration of ordinary shares or other deposited securities on the share register and applicable to transfers of ordinary shares or other deposited securities to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the deposit agreement to be at the expense of the person depositing ordinary shares or withdrawing deposited property or of the holders and beneficial owners of ADSs;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;in connection with the conversion of foreign currency, the fees, expenses, spreads, taxes and other charges of the depositary and/or conversion service providers (which may be a division, branch or affiliate of the depositary). Such fees, expenses, spreads, taxes, and other charges shall be deducted from the foreign currency;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;any reasonable and customary out-of-pocket expenses incurred in such conversion and/or on behalf of the holders and beneficial owners in complying with currency exchange control or other governmental requirements; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;the fees, charges, costs and expenses incurred by the depositary, the custodian, or any nominee in connection with the ADR program.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADS fees and charges for (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of refusal to pay the depositary fees or other charges, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees or other charges from any distribution to be made to the ADS holder. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fees and charges holders of ADSs may be required to pay may vary over time and may be changed by us and by the depositary. Holders of ADSs will receive prior notice of such changes. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the depositary fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary may agree from time to time.</span></div><div><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_187"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_190"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 13. Defaults, Dividend Arrearages and Delinquencies. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_193"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds. </span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A. Not applicable.</span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Not applicable.</span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Not applicable.</span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Not applicable.</span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E. Use of Proceeds.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In June 2021, we completed an offering of an aggregate of 3,000,000 ADSs representing 3,000,000 ordinary shares, The offering was in the form of ADSs, each representing one ordinary share, at an offering price of $21.25 per ADS for aggregate gross proceeds of approximately $63.8 million. The net offering proceeds to us, after deducting underwriting discounts and commissions of $4.5 million and additional offering expenses of $3.4 million, were approximately $55.9 million. The offering commenced on June 15, 2021 and did not terminate before all of the securities registered in the registration statement were sold. The effective date of the Registration Statement on Form F-1 (File No. 333-255447) for our offering was June 15, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">J.P. Morgan Securities LLC, SVB Leerink LLC and Cowen and Company, LLC acted as joint book-running mangers for the offering.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The net proceeds from our offering have been used, and are expected to continue to be used, as described in the final prospectus for the offering filed with the U.S. Securities and Exchange Commission on June 16, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None of the net proceeds of our offering were paid directly or indirectly to any director, officer, general partner of ours or to their associates, persons owning ten percent or more of any class of our equity securities, or to any of our affiliates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_196"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 15. Controls and Procedures. </span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">A. Disclosure Controls and Procedures </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and VP Finance, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and VP Finance, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2022. Based on such evaluation, our Chief Executive Officer and VP Finance have concluded that, as of December 31, 2022, our disclosure controls and procedures were effective. </span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B. Management&#8217;s Annual Report on Internal Control over Financial Reporting </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) and for the assessment of the effectiveness of our internal control over financial reporting. Under the supervision and with the participation of our Chief Executive Officer (principal executive officer) and VP Finance (principal financial officer), management assessed our internal control over financial reporting based upon the framework in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, our management has concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2022.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements, and can only provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C. Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm regarding the effectiveness of our internal control over financial reporting due to an exemption provided by the JOBS Act for emerging growth companies. </span></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D. Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the period covered by this Annual Report that has materially affected, or is reasonably likely to materially affect, internal control over financial reporting.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_199"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16. Reserved. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_202"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16A. Audit Committees Financial Expert. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our board of directors has further determined that Sandip Kapadia is an &#8220;audit committee financial expert&#8221; as defined by SEC rules and regulations and that each of the members of the Audit and Finance Committee qualifies as financially sophisticated under the applicable exchange listing rules. Mr. Kapadia is independent as such term is defined in Rule 10A-3 under the Exchange Act and under the listing standards of Nasdaq.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_205"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16B. Code of Business Conduct and Ethics. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have adopted a Code of Conduct which is applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">www.molecularpartners.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Audit and Finance Committee of our board of directors is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct will be disclosed on our website.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_208"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16C. Principal Accountant Fees and Services.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The aggregate fees for services rendered by KPMG AG, Zurich, Switzerland (PCAOB ID 3240), for professional services were as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.794%"><tr><td style="width:1.0%"></td><td style="width:62.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Audit fees</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">643&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Audit related fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tax fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">643</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">917</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Audit Fees </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Audit fees include the standard audit work performed each fiscal year necessary to allow the auditor to issue an opinion on our Consolidated Financial Statements and to issue an opinion on the local statutory financial statements of the Company and its subsidiaries. Audit fees also include services that can be provided only by the auditor such as reviews of quarterly financial results, review of the registration statement filed with the SEC and comfort letters delivered to underwriters in connection with equity offerings.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Audit related fees</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These services consisting primarily of agreed-upon procedure reports, accounting consultations and other attest services related to financial reporting that are not required by statute or regulation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax fees</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fees for tax services represent income tax and indirect tax compliance services as well as tax advisory services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">All other fees</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fees for other services not included in the above three categories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pre-Approval Procedures and Policies</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with the requirements of the U.S. Sarbanes-Oxley Act of 2002 and rules issued by the SEC, we utilize a procedure for the review and pre-approval of any services performed by KPMG. The procedure requires that all proposed engagements of KPMG for audit and permitted non-audit services are submitted to the Audit and Finance Committee for approval prior to the beginning of any such services. In accordance with this policy, all services performed by and fees paid to KPMG in 2022 and 2021 were approved by the Audit and Finance Committee.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_211"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16D. Exemptions from the Listing Standards for Audit Committees. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_214"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_217"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16F. Change in Registrant&#8217;s Certifying Accountant. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_220"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16G. Corporate Governance. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Corporate Governance Differences From Nasdaq Listing Standards </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a "foreign private issuer" as defined by the SEC. As a result, in accordance with Nasdaq Listing Rule 5615(a)(3), we comply with home country governance requirements and certain exemptions thereunder rather than complying with certain of the corporate governance requirements of Nasdaq.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Swiss law does not require that a majority of our board of directors consist of independent directors. Our board of directors therefore may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we are not subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors regularly have scheduled meetings at which only independent directors are present.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although Swiss law also requires that we adopt a compensation committee, we follow home country requirements with respect to such committee. As a result, our practice varies from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees. To this extent, our practice varies from the independent director oversight of director nominations requirements of Nasdaq Listing Rule 5605(e).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. Our practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_223"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16H. Mine Safety Disclosure. </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_1448"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_226"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART III </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_229"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 17. Financial Statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See pages F-1 through page F-</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8a24760184ad47a3b117e57502390cc6_5030">41</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  of this Annual Report on Form 20-F </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_232"></div><div style="margin-bottom:8pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 18. Financial Statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_235"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 19. Exhibits. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:11.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Incorporated by Reference</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule/</span></div><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Form</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">File</span></div><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">File</span></div><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a112022_aoaxmpasofjanuary1.htm">Articles of Association, as currently in effect.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a12organizationalrulesofth.htm">Organizational Rules of the registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a21-depositagreement1.htm">Deposit Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a21-depositagreement1.htm#if7724931561a4e79bc4853d8d987da59_10">Form of American Depositary Receipt (included in Exhibit 2.1).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a23-descriptionofsecuritie.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit101-fx1.htm">Form of indemnification agreement between the registrant and each of its executive officers and directors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit103-fx1.htm">Collaboration and License Agreement, dated as of December 18, 2018, by and between Molecular Partners AG and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit106-fx1.htm">Option and Equity Rights Agreement, dated as of October 27, 2020, by and between Molecular Partners AG and Novartis Pharma AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a44licenseagreementdatedas.htm">License Agreement, dated as of January 17, 2022, by and between Molecular Partners AG and Novartis Pharma AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a45molecularpartners-novar.htm">License and Collaboration Agreement, dated as of December 13, 2021, by and between Molecular Partners AG and Novartis Pharma AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit108-fx1.htm">Performance Share Plan 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhbit109-fx1.htm">Performance Share Plan 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.8#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit1010-fx1.htm">Performance Share Plan 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.9#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit1011-fx1.htm">Performance Share Plan 2021 - Employees</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.10*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a410psuplan2021formanageme.htm">Performance Share Plan 2021 - Management</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.11*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a411psuplan2022foremployee.htm">Performance Share Plans 2022 - Employees</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.12*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a412psuplan2022_formanagem.htm">Performance Share Plans 2022 - Management</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.13*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a413psuplan2023_foremploye.htm">Performance Share Plans 2023 - Employees</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.14*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a414psuplan2023_formanagem.htm">Performance Share Plans 2023 - Management</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit1014-fx1.htm">Restricted Share Plan 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:11.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.16#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit1015-fx1.htm">Restricted Share Plan 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit1016-fx1.htm">Restricted Share Plan 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit1017-fx1.htm">Restricted Share Plan 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.19*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a419restrictedshareplan2022.htm">Restricted Share Plan 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.20*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a420restrictedshareplan2023.htm">Restricted Share Plan 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1745114/000162828021007388/exhibit211-fx1.htm">List of subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-255447</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/22/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a121section302certification.htm">Certification of Chief Executive Officer Pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a122section302certification.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a122section302certification.htm">VP Finance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a122section302certification.htm"> Pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a131section906certification.htm">Certification of Chief Executive Officer and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a131section906certification.htm">VP Finance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a131section906certification.htm"> Pursuant to Rule 13(a)-14(b) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a151auditorconsent.htm">Consent of KPMG AG, independent registered public accounting firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">** Furnished herewith.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8224; Certain portions of this exhibit (indicated by asterisks) have been redacted because they are both not material and are the type that the Registrant treats as private or confidential.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:280.79pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.346%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Molecular Partners AG</span></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ Patrick Amstutz</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patrick Amstutz</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date: March 9, 2023</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_241"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.365%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements as of and for the years ended December 31, 2022 and December 31, 2021 and December 31, 2020</span></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_244">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNDEvZnJhZzo3ODc2OWJkZDJlY2M0OWNhOGM0ZDA2MTBlZWFlYzA1NS90YWJsZTpmNDk3NzkwZGVkZGE0NWY4YTMzMzQ0M2UwNWNlODA5OS90YWJsZXJhbmdlOmY0OTc3OTBkZWRkYTQ1ZjhhMzMzNDQzZTA1Y2U4MDk5XzMtMC0xLTEtMTA5NjE4L3RleHRyZWdpb246OTNhZGNlMGIwMjc2NDQ4NDhmM2JmZWMxNzc2MTkyZGNfNjI_2198439d-ed9d-4b08-b8b7-8184eb413442">3240</ix:nonNumeric>)</span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_244">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_244">2</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_250">Consolidated Statement of Financial Position for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_250">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_250">3</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_253">Consolidated Statement of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_253">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_253">4</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_256">Consolidated Statement of Cash Flows for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_256">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_256">5</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_259">Consolidated Statement of Changes in Equity for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_259">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_259">6</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_262">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_262">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60bed4b3015345c8b90a9ba4194a5e91_262">7</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_244"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of financial position of Molecular Partners AG and subsidiary (the Group) as of December 31, 2022 and 2021, the related consolidated statements of comprehensive income, cash flows, and changes in equity for each of the years in the three-year period ended December 31, 2022, and the related notes to the consolidated financial statements (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Group as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three&#8209;year period ended December 31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Group&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Group is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Group&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNDQvZnJhZzplNmYwMjQwOTlkZWY0NzYwOTRjMmM4N2EwMTI2OTI2NC90ZXh0cmVnaW9uOmU2ZjAyNDA5OWRlZjQ3NjA5NGMyYzg3YTAxMjY5MjY0XzUzMTE_f0ebfbea-85be-481f-b60e-55ee2c522ef0">KPMG AG</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Group&#8217;s auditor since 2009.</span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNDQvZnJhZzplNmYwMjQwOTlkZWY0NzYwOTRjMmM4N2EwMTI2OTI2NC90ZXh0cmVnaW9uOmU2ZjAyNDA5OWRlZjQ3NjA5NGMyYzg3YTAxMjY5MjY0XzUzMTM_9b9942c2-dcc3-4270-b03e-09d6a1b5b301">Zurich, Switzerland</ix:nonNumeric> </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 8, 2023</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_250"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">Consolidated Statement of Financial Position</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">as of December 31,</span></td><td colspan="6" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMtNC0xLTEtMTA5NjE4_80821b77-b0f9-4330-b5da-e1cc4fec2436">7,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMtNy0xLTEtMTA5NjE4_cdbffc23-4a7e-4bc6-af91-560d66671ca0">8,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzQtNC0xLTEtMTA5NjE4_bcb9aa44-a4a2-41a6-9577-d5b449b8ee0e">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzQtNy0xLTEtMTA5NjE4_0f076513-58aa-428a-ad33-e2cb4f01b645">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total non-current assets</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzUtNC0xLTEtMTA5NjE4_dc9015d5-1690-4477-8721-2d3c69ec6e80">7,506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzUtNy0xLTEtMTA5NjE4_0cf17505-402d-49c7-809e-eaee6585a17e">8,477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzctNC0xLTEtMTA5NjE4_1f5494c4-fafa-4367-9175-d8a0a8b174cf">161,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzctNy0xLTEtMTA5NjE4_4cacc76d-f1e6-4187-bcb2-1cb84c0dab56">61,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzgtNC0xLTEtMTA5NjE4_ae13e406-f8f2-4027-8c7e-455c3488ef70">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzgtNy0xLTEtMTA5NjE4_a6a777fc-bb05-4772-a08b-eb60cdab91e8">5,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzktNC0xLTEtMTA5NjE4_ac584565-1f2d-47f0-a848-2dd5b3988acf">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzktNy0xLTEtMTA5NjE4_70b1f396-8452-42ad-ad00-9b41cb764abd">25,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEwLTQtMS0xLTEwOTYxOA_639d63de-cd06-47e9-a3b9-441b54ce9bc6">87,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEwLTctMS0xLTEwOTYxOA_4134f6bd-fff8-434b-a9c4-276bc8873978">71,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzExLTQtMS0xLTEwOTYxOA_e8d95164-9684-4d5b-bd13-c48168c7b515">254,752</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzExLTctMS0xLTEwOTYxOA_e02b3723-4ebe-4582-9c35-cec481625fa3">164,191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEzLTQtMS0xLTEwOTYxOA_996f710b-d494-4c6c-950f-5957131bef10">262,258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEzLTctMS0xLTEwOTYxOA_4a20bdf0-4085-4422-9171-7ebaaf54751a">172,668</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders' equity and liabilities</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE2LTQtMS0xLTEwOTYxOA_0f05f07f-c676-4da5-bda7-5f827dde2bfb">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE2LTctMS0xLTEwOTYxOA_f27bb330-15b4-4f1d-9da1-6b254d0a665a">3,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE3LTQtMS0xLTEwOTYxOA_c9c90f6c-e7fe-4c17-a0c5-9915b9bedc0e">360,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE3LTctMS0xLTEwOTYxOA_87ae71b7-cc7e-4a8f-992d-0dc98831a2b8">355,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury share reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTQtMS0xLTExMjQ5Ng_15c8f3fb-8ddb-44f0-9423-2b90799e0e01">981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TreasuryShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTctMS0xLTExMjQ5OQ_864b9785-7266-4783-82c6-dd68f6f9ec30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative losses</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTQtMS0xLTEwOTYxOA_d6f52072-f95a-47aa-85c4-6933e4d4c418">127,780</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTctMS0xLTEwOTYxOA_b9d7b17f-632e-4a16-a5d5-6c6fe260e14e">250,950</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE5LTQtMS0xLTEwOTYxOA_6b588273-6090-4f0c-877d-472392c08805">235,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE5LTctMS0xLTEwOTYxOA_df8d5891-6860-438a-bcf1-09e8675469d1">107,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIxLTQtMS0xLTEwOTYxOA_40a3d5d9-38bb-4e8b-9897-2e3a19dc1f30">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIxLTctMS0xLTEwOTYxOA_bbbb5c48-9958-4ae0-b425-e51b33a75037">6,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIyLTQtMS0xLTEwOTYxOA_86449c35-c370-477c-9def-537172ec2418">3,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIyLTctMS0xLTEwOTYxOA_a771a6c8-07f6-43d2-9251-0d1bd35bc1a6">4,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIzLTQtMS0xLTEwOTYxOA_09465c86-3d6e-4736-9715-0a8a24822dd7">2,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIzLTctMS0xLTEwOTYxOA_a85571b8-ad2e-4b68-acca-3b78d9140068">6,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total non-current liabilities</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI0LTQtMS0xLTEwOTYxOA_2962e55a-2fbb-4842-b299-6db16136b274">9,841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI0LTctMS0xLTEwOTYxOA_595f6eb4-2afe-451e-8c93-b002360c4077">18,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI2LTQtMS0xLTEwOTYxOA_d60e9c21-8a58-45d8-9b5e-a5dcb51b2e3d">2,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI2LTctMS0xLTEwOTYxOA_1f731b2d-e95b-4e3a-8aa1-13c44b1bbfb9">7,389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI3LTQtMS0xLTEwOTYxOA_f2874694-979e-481b-b120-2baeab0177c7">7,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI3LTctMS0xLTEwOTYxOA_dec0e40a-3cf9-4c5c-aa0c-49a20bc63b5e">9,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI4LTQtMS0xLTEwOTYxOA_e12f3f24-11cb-4f83-9de3-c51ab8ca280d">6,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI4LTctMS0xLTEwOTYxOA_7a321736-5c29-4c4e-b21e-8d1b3e7bfac7">28,312</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI5LTQtMS0xLTEwOTYxOA_e5e0759e-108e-4ce9-b595-25412bb754ac">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI5LTctMS0xLTEwOTYxOA_151e54f6-b62d-4163-9715-402b12e7a6bb">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMwLTQtMS0xLTEwOTYxOA_a56d3a9b-b479-4b90-92eb-73157d721fff">17,251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMwLTctMS0xLTEwOTYxOA_510b5b6f-3214-4024-abe7-2afa3314b556">46,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMxLTQtMS0xLTEwOTYxOA_4cfbce7b-64c2-4e3d-b00b-e8f2b2f025d7">27,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMxLTctMS0xLTEwOTYxOA_b3f71b34-ebba-4fb6-9b02-0ce767c3b90c">65,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total shareholders' equity and liabilities</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMzLTQtMS0xLTEwOTYxOA_2afbfb54-0d0e-4ddd-9fbd-82e2bc498973">262,258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMzLTctMS0xLTEwOTYxOA_91020095-323b-474f-8390-cd3d090db543">172,668</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes, which form an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_253"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">Consolidated Statement of Comprehensive Income</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:52.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">for the year ended December 31,</span></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues and other income</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from research and development collaborations</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzQtNC0xLTEtMTA5NjE4_e3baf974-0ec2-4a8a-a7e3-f4e1fce7f5a9">189,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzQtNy0xLTEtMTA5NjE4_7a1edd25-c974-4cf7-8b3e-f8e472612ef0">9,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzQtMTAtMS0xLTEwOTYxOA_37438ba3-95c8-4ce8-af59-4cfb5899cd10">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzUtNC0xLTEtMTA5NjE4_006dc753-b00b-4134-8326-d7426d11a401">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzUtNy0xLTEtMTA5NjE4_155eef06-cb43-4077-a984-fb71dab10cbc">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzUtMTAtMS0xLTEwOTYxOA_0f7db0a0-e3db-47ab-b691-628949e354cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzYtNC0xLTEtMTA5NjE4_7234358f-1dab-43dd-a4de-1a6eac544c46">189,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzYtNy0xLTEtMTA5NjE4_12e07976-f641-44cb-99ba-3515abbe7a02">9,754</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzYtMTAtMS0xLTEwOTYxOA_8b1a861d-a89d-4aa5-8f90-0a2dc5bd6892">9,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzktNC0xLTEtMTA5NjE4_a05f88f0-0f0b-48fa-b25a-8bf1b6def125">50,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzktNy0xLTEtMTA5NjE4_940305fc-640d-43a4-84dc-d49c39a41fa2">55,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzktMTAtMS0xLTEwOTYxOA_920f372d-d3c4-4984-8d29-16e58cf18b2d">56,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEwLTQtMS0xLTEwOTYxOA_4bad8fb3-3a4c-4eb2-9f9b-5fbcd829d028">22,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEwLTctMS0xLTEwOTYxOA_74b040e1-d5e9-4e78-a522-e8a0202557de">17,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEwLTEwLTEtMS0xMDk2MTg_59898afa-1eab-4db3-a832-532069b77fb1">11,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzExLTQtMS0xLTEwOTYxOA_8e7231ae-b412-4866-98e7-0d9403c7d10e">72,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzExLTctMS0xLTEwOTYxOA_6b09888b-8979-411a-9c0a-bcddb95500a3">73,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzExLTEwLTEtMS0xMDk2MTg_0ff4a6f1-7d82-4285-8f8a-a905a49dde3f">67,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating result</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEzLTQtMS0xLTEwOTYxOA_eb3f4cfb-f74f-41ae-b46e-8675c3cf2444">116,613</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEzLTctMS0xLTEwOTYxOA_4d24e67f-c048-460d-bad2-66768d2614c0">63,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEzLTEwLTEtMS0xMDk2MTg_e9a2187e-c8f3-4a2e-abf2-a87252140857">58,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE1LTQtMS0xLTEwOTYxOA_2a18b2ca-3ffb-4e19-97d4-47af686c2b83">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE1LTctMS0xLTEwOTYxOA_bc49e657-ed9f-490e-8df5-438d127fbbb3">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE1LTEwLTEtMS0xMDk2MTg_3e3615fc-0164-4eb9-a36a-673b626eadb8">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE2LTQtMS0xLTEwOTYxOA_e0a91baf-1528-4091-8671-7a19fb08f2c9">619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE2LTctMS0xLTEwOTYxOA_dc9ffb33-ff01-4be2-83a0-3a3d9015a0e7">556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE2LTEwLTEtMS0xMDk2MTg_477a320c-5838-4ac3-ba30-0d685f3e8416">4,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net finance result</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE3LTQtMS0xLTEwOTYxOA_3c7f77b8-36d2-446e-a75e-3260b04a272d">1,240</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE3LTctMS0xLTEwOTYxOA_0e239acf-dbda-40f4-b912-50cf371fa107">365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE3LTEwLTEtMS0xMDk2MTg_96114c03-c75e-4310-95d9-d41c58fee5d4">4,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Result before income taxes</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE5LTQtMS0xLTEwOTYxOA_a99be057-50ad-41ca-982d-0af3b6b474e3">117,853</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE5LTctMS0xLTEwOTYxOA_8ab0f1c6-7377-453b-bd05-cc8bb3a90b99">63,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE5LTEwLTEtMS0xMDk2MTg_d9ff90ee-49b3-43be-8cef-3ab4b48feb41">62,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIxLTQtMS0xLTEwOTYxOA_617e3e00-bd85-4f8c-accc-81c39a8f593d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIxLTctMS0xLTEwOTYxOA_52005751-4bdb-4a71-b6a1-2e35a3f88156">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIxLTEwLTEtMS0xMDk2MTg_1dc0a622-2571-4f8b-a2d3-6fd8239d0c2e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net result, attributable to shareholders</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIyLTQtMS0xLTEwOTYxOA_e8d94d38-c465-42eb-8305-440dbca3c061">117,853</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIyLTctMS0xLTEwOTYxOA_15d320bc-5c4f-45e7-ba68-5443949e3f03">63,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIyLTEwLTEtMS0xMDk2MTg_5f474f53-da44-44c2-bad7-91523c9866b0">62,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other comprehensive result</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items that will not be reclassified to profit or loss</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzI3LTQtMS0xLTEwOTYxOA_54638c24-280c-485a-864f-c4f5247cac07">5,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzI3LTctMS0xLTEwOTYxOA_bec696fd-2663-4f14-8352-77eb78309156">8,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzI3LTEwLTEtMS0xMDk2MTg_52dfd530-d33b-4a39-a785-bdaba2352f38">1,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items that are or may be reclassified subsequently to profit or loss</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences on translating foreign operations</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMwLTQtMS0xLTEwOTYxOA_4b35fec1-d700-45bd-8eca-70939eb9d373">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMwLTctMS0xLTEwOTYxOA_08dea2dc-2ac6-402c-8358-c76b6954a372">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMwLTEwLTEtMS0xMDk2MTg_451b0a8b-c309-4f97-b527-c445a3bed032">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other comprehensive result, net of tax</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMyLTQtMS0xLTEwOTYxOA_37e8bd2c-14bd-4768-966d-815dbe034e24">5,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMyLTctMS0xLTEwOTYxOA_e485f48d-8892-4b3c-9aa7-7c1658483765">8,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMyLTEwLTEtMS0xMDk2MTg_e1876538-e017-433e-8cc9-53e32993a968">1,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total comprehensive result, attributable to shareholders</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM0LTQtMS0xLTEwOTYxOA_13eb5fa5-00f8-4552-8949-22127888f38a">123,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM0LTctMS0xLTEwOTYxOA_c3c0caf6-c6d3-49e2-8c52-cd2ea4e31a02">55,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM0LTEwLTEtMS0xMDk2MTg_f178e19d-0d2d-4f9b-b50e-a77eeebe91e8">64,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net result per share (in CHF)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM2LTQtMS0xLTEwOTYxOA_bdb586b1-c688-46bc-b471-e9af7f8d5fbc">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM2LTctMS0xLTEwOTYxOA_56ab0a8c-ebbf-493e-b40b-4a21ab64ec00">2.06</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chfPerShare" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM2LTEwLTEtMS0xMDk2MTg_d066d430-e9f3-49e8-822d-1debf7cbf253">2.51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net result per share (in CHF)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM3LTQtMS0xLTExMjUwOQ_421fae4b-d41a-44aa-b7cb-b8e934b238d1">3.54</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM3LTctMS0xLTExMjUxMg_0e6564db-4cf3-4e92-bce9-a7368b239eed">2.06</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chfPerShare" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM3LTEwLTEtMS0xMTI1MTU_70e58c45-4793-43da-a2e6-86407031f348">2.51</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes, which form an integral part of these consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_256"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">Consolidated Statement of Cash Flows</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">for the year ended December 31,</span></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net result attributable to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMtNC0xLTEtMTA5NjE4_4305ccae-2789-4868-8d9b-2de8ca44bea9">117,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMtNy0xLTEtMTA5NjE4_de58d8eb-94f3-4469-815c-273a5c9340d0">63,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMtMTAtMS0xLTEwOTYxOA_403685cd-414f-4032-a59e-7082462844c7">62,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzUtNC0xLTEtMTA5NjE4_603103db-84ff-46a5-932a-b52ff613d364">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzUtNy0xLTEtMTA5NjE4_2cc454b7-9175-451c-9413-e9e213d35a67">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzUtMTAtMS0xLTEwOTYxOA_5eecc022-d6ec-45a1-82da-bf37260adcdf">2,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzYtNC0xLTEtMTA5NjE4_d551a3fe-4b77-416f-952e-1c9e6ee2e870">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzYtNy0xLTEtMTA5NjE4_64c8abc0-0f6f-4044-ae8b-14727775a866">4,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzYtMTAtMS0xLTEwOTYxOA_221fdf25-14a8-48c5-8a62-88d9ae93e23a">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzctNC0xLTEtMTA5NjE4_a0571fb8-25d2-40fa-9c1c-b46140171f19">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzctNy0xLTEtMTA5NjE4_2d723ee9-a101-438c-b4f5-c81ba0f82edd">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzctMTAtMS0xLTEwOTYxOA_dfe37a4e-fd45-46d3-9380-ec76c44ac5c6">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzgtNC0xLTEtMTA5NjE4_096b202a-af88-4705-8bf8-56970c08bc4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzgtNy0xLTEtMTA5NjE4_f5fcf05a-6c1c-400f-b07b-35085b49da4d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncomeTaxExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzgtMTAtMS0xLTEwOTYxOA_fad74f4c-7142-4e82-bc43-7f4d2d261dab">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzktNC0xLTEtMTA5NjE4_58376ee6-0e2a-4ab8-a334-f410718ece9e">1,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzktNy0xLTEtMTA5NjE4_7e71f6dc-0c02-4f11-a371-891e9b88d345">191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzktMTAtMS0xLTEwOTYxOA_0cb327d2-d0b9-4430-8bca-73a119cd990b">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEwLTQtMS0xLTEwOTYxOA_d6de0e83-2dac-4ea4-afb4-2b042d7b8b8a">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEwLTctMS0xLTEwOTYxOA_4016e562-09a5-4f08-8bcc-116aa8ad3c84">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEwLTEwLTEtMS0xMDk2MTg_9a3372c2-ef2a-49da-89b5-d1519f6c512f">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEyLTQtMS0xLTEwOTYxOA_90c233dc-7c41-43fa-ab54-0e5913504423">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEyLTctMS0xLTEwOTYxOA_43056218-71cd-4e87-9ee0-39fca48cdc01">4,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEyLTEwLTEtMS0xMDk2MTg_d1110e58-0dfe-4e86-a7da-31b187507bc1">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in trade and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEzLTQtMS0xLTEwOTYxOA_02218164-3607-4826-b9d1-cb856ec5927f">25,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEzLTctMS0xLTEwOTYxOA_99b9e14d-cf7f-4faf-94ba-a0f63104a58e">23,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEzLTEwLTEtMS0xMDk2MTg_61be0e1c-5755-42e7-bd5b-0a2eb11769a4">552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE0LTQtMS0xLTEwOTYxOA_b2545eda-7e5f-46d5-903f-d066c01a07f9">5,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE0LTctMS0xLTEwOTYxOA_87021b82-207e-466d-94ef-2e4605b3b301">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE0LTEwLTEtMS0xMDk2MTg_8201d7c6-50c4-4730-9172-f4d8919b4560">3,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in contract liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE1LTQtMS0xLTEwOTYxOA_e27a0ec4-d5ab-4d5c-98e2-b9dad1225a52">25,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE1LTctMS0xLTEwOTYxOA_6dd9e4ba-5ca6-4c28-aa70-027777f75296">10,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE1LTEwLTEtMS0xMDk2MTg_a4492a1b-19ed-4f6c-ab69-519591a15081">17,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE2LTQtMS0xLTEwOTYxOA_2733d90d-c012-4f62-97ac-2ea2f30c98bd">2,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE2LTctMS0xLTEwOTYxOA_1ebeb90d-36c6-4963-8c22-af1a58f61f75">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE2LTEwLTEtMS0xMDk2MTg_47575849-984c-4da7-9e3a-bc4e22250ae3">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange (loss) gain on working capital positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE3LTQtMS0xLTEwOTYxOA_eb5f9d85-2fbf-4790-b872-561ae784225a">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE3LTctMS0xLTEwOTYxOA_f3389e2b-a2c4-49e3-9912-b83c3e1d34f6">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE3LTEwLTEtMS0xMDk2MTg_d93c2be7-8c2a-49f3-8dc8-333bf505e6ee">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE4LTQtMS0xLTEwOTYxOA_6ece472e-e343-4454-bf39-b032bfa9a840">646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE4LTctMS0xLTEwOTYxOA_3e2fd3d1-9199-4720-82d4-3b45ebe64512">583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE4LTEwLTEtMS0xMDk2MTg_f14f7a37-02e8-401e-b68a-ce8f5793ed1f">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE5LTQtMS0xLTEwOTYxOA_f1cca18b-b988-46bc-be2d-64506ccebc10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE5LTctMS0xLTEwOTYxOA_31434e16-27d8-40e8-8560-e47c37e28d9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE5LTEwLTEtMS0xMDk2MTg_9133ec17-370a-4d4f-84f5-bfa6815cb382">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIwLTQtMS0xLTEwOTYxOA_8e3fb290-f608-4d50-ae92-e9e569247467">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIwLTctMS0xLTEwOTYxOA_d42dbfe4-7bb8-4957-ac8b-65433982ed55">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIwLTEwLTEtMS0xMDk2MTg_f8e629eb-eefd-4352-aa8a-1779114230d8">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash from (used in) operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIxLTQtMS0xLTEwOTYxOA_066c0623-66a3-46ac-88ca-3ac83dc55c3c">118,566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIxLTctMS0xLTEwOTYxOA_b6995ee5-2a22-4f11-8187-b5b750f1d51c">90,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIxLTEwLTEtMS0xMDk2MTg_fe78dc5a-449c-4220-83c4-513be85f8bbe">28,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from investments in short-term time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIzLTQtMS0xLTEwOTYxOA_7ee61164-50b0-4cec-8928-1c12ae0d8e81">199,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIzLTctMS0xLTEwOTYxOA_a117daaf-6a93-4bb7-9227-b68320c7812b">67,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIzLTEwLTEtMS0xMDk2MTg_d5b575ed-4d75-4ff1-8eb0-e9c5cb38efc9">52,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in short-term time deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI0LTQtMS0xLTEwOTYxOA_40517ae5-0137-430d-958d-973b51bac31e">299,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI0LTctMS0xLTEwOTYxOA_ead651ae-0290-48cf-a19c-232f2cd3ebf6">88,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI0LTEwLTEtMS0xMDk2MTg_0b4a0353-27d6-4bfa-b5d0-05709e981ac7">73,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI1LTQtMS0xLTEwOTYxOA_2ea5cf33-fa45-44d5-a09e-7e673555719b">1,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI1LTctMS0xLTEwOTYxOA_c5bf64cf-4a92-41f5-b749-ca9bb001d58e">933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI1LTEwLTEtMS0xMDk2MTg_c14a7d3e-ffa3-42f1-b07c-53a2fb4a2a3e">1,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI2LTQtMS0xLTEwOTYxOA_2fa3574f-a46a-4059-82df-76dbecdc1a86">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI2LTctMS0xLTEwOTYxOA_28d5d7ed-65cb-432f-b58b-0370e6f8cd6e">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI2LTEwLTEtMS0xMDk2MTg_3daacfb7-8b50-40e5-bd27-ffb27a762cda">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI3LTQtMS0xLTEwOTYxOA_186bc2a7-5c7f-47e7-b12a-19dd434fc641">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI3LTctMS0xLTEwOTYxOA_be049d3a-0021-4b7e-903e-1df8e99d11b1">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI3LTEwLTEtMS0xMDk2MTg_1c1f33e6-8773-459a-ac1d-d15954cc7f87">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI4LTQtMS0xLTEwOTYxOA_b33b117e-4bfa-4654-bf5f-8a29c978b6a1">101,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI4LTctMS0xLTEwOTYxOA_d1fc9f2a-54b2-4e39-92e2-ec69e4386766">22,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI4LTEwLTEtMS0xMDk2MTg_0ccf2923-2dee-4d5c-8540-c7e516fb1a17">21,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of new shares, net of transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMwLTQtMS0xLTEwOTYxOA_9b9ce15b-7805-417d-b6ea-803674e8f7e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMwLTctMS0xLTEwOTYxOA_b6ed4673-bd4b-429b-af6e-8f8d78221c89">51,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMwLTEwLTEtMS0xMDk2MTg_00a3ddbf-56c0-440d-83b5-62bf7478bc1e">113,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTQtMS0xLTExMjUyNQ_37c3bcff-e576-4a37-9aec-9c5473e4d0c3">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTctMS0xLTExMjUyOA_1f76d408-cc32-4d59-a793-0f9e68f17726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTEwLTEtMS0xMTI1MzE_7f5d73bc-e472-4ca0-a16e-d044238bf4d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from exercise of stock options, net of transaction costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTQtMS0xLTEwOTYxOA_e09cdf70-30b7-48ed-891d-4f26824cac2f">250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTctMS0xLTEwOTYxOA_3b9f859f-c18e-45da-9cb3-905f51295ce7">267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTEwLTEtMS0xMDk2MTg_e20c6f94-41b8-4831-bd54-3c31cf0eb7d6">840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMyLTQtMS0xLTEwOTYxOA_9070e256-b243-43bb-9969-f4db4532ca32">1,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMyLTctMS0xLTEwOTYxOA_eb89a0d8-17ad-4c4c-9a80-9962cadc631d">1,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMyLTEwLTEtMS0xMDk2MTg_1ddf5a28-f17e-49af-9a35-39a791730374">1,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash (used in) from financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMzLTQtMS0xLTEwOTYxOA_fc976e86-5d75-451d-b283-9975dbf01ee4">1,570</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMzLTctMS0xLTEwOTYxOA_b792012e-ed44-425d-a26b-21512ca34759">50,581</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMzLTEwLTEtMS0xMDk2MTg_4ebd997b-66af-487a-8c68-cc86af5212f5">113,202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange gain (loss) on cash positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM1LTQtMS0xLTEwOTYxOA_333fcb5f-b4cc-4825-b237-4cbf8b9b7786">258</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM1LTctMS0xLTEwOTYxOA_780a09c2-7b78-4440-8d52-44e95e85b4e2">701</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM1LTEwLTEtMS0xMDk2MTg_d6bb726d-aaa1-41e2-b630-8b4f820a6383">4,464</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM2LTQtMS0xLTEwOTYxOA_536f47ae-ed3c-4085-95e2-7e21a9eabb52">16,133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM2LTctMS0xLTEwOTYxOA_e4e8d8db-faca-4c89-94c0-edacb28c3091">61,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM2LTEwLTEtMS0xMDk2MTg_2f27d838-ebb7-49a1-8497-a23bf47446c6">58,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM4LTQtMS0xLTEwOTYxOA_d0793833-f878-4f05-9326-c3d562bfc63f">71,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM4LTctMS0xLTEwOTYxOA_87981db1-9f27-430f-9fd5-53bc3e255c8d">133,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM4LTEwLTEtMS0xMDk2MTg_c91ed266-311c-4c17-b6b6-ce2b1b10c569">75,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents at December 31</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzQwLTQtMS0xLTEwOTYxOA_8c7108d9-bf3b-45a1-bd84-330e405f9896">87,946</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzQwLTctMS0xLTEwOTYxOA_9a3f4d00-1994-4827-8473-aa26aa2ba404">71,813</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzQwLTEwLTEtMS0xMDk2MTg_8d5a33d9-ef06-484c-8a4a-63eaac8fe867">133,721</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes, which form an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_259"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">Consolidated Statement of Changes in Equity</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share capital</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Treasury share reserve</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative losses</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia354966cf31e42aaaa6b703a60e1341a_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItMS0xLTEtMTA5NjE4_409bb373-26a2-485f-94f5-e597300da200">2,160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8af2f1be9ad44d51b81ad6f3e39f3917_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItNC0xLTEtMTA5NjE4_77e511b1-66d4-4ca5-b81c-eaf723ee266d">182,849</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0ec7c73caeed425b977de2350cb9e35d_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItNy0xLTEtMTA5NjE4_b4668b67-be56-4a86-9325-60265428d99c">130,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItMTAtMS0xLTEwOTYxOA_0591dc2c-ab31-4bc6-a58c-e4225a5a86d0">54,139</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net result</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzMtNy0xLTEtMTA5NjE4_59eedfff-e627-44a1-90ad-19ea66989635">62,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzMtMTAtMS0xLTEwOTYxOA_fe07bb36-1430-48a1-9dfe-96b968cf9748">62,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtNy0xLTEtMTA5NjE4_b7151253-29da-4569-86f9-977d9f4426c9">1,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtMTAtMS0xLTEwOTYxOA_0ac734fe-7da4-46b8-a08a-45fa65d58b36">1,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences on translating foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzUtNy0xLTEtMTA5NjE4_d305efb4-6853-4429-a6b7-94d14890cbb4">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzUtMTAtMS0xLTEwOTYxOA_091b54d8-66fb-4164-9f8c-1c5bfdaa5be7">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzYtNy0xLTEtMTA5NjE4_999902db-a300-409c-b0b7-a6043e815001">64,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzYtMTAtMS0xLTEwOTYxOA_9b1a2388-c99f-41fc-8c6c-c8815987b533">64,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id66ad877b195477caaa63da51066504e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctNC0xLTEtMTA5NjE4_a97d247c-d856-4e0f-892e-d1533f366f60">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctMTAtMS0xLTEwOTYxOA_81e9a3f8-57df-4400-8006-52fd92ab8808">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of new shares, net of transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6dc9a065301142489cf73ad6591f13da_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTEyNjA3_af072b3f-1e50-41b8-b6b8-cbf670de7fcf">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id66ad877b195477caaa63da51066504e_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTEyNjEz_ed0190b7-f838-444c-ad0f-70993d1b3c88">112,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTMtMS0xLTExMjYxOQ_e38e3c45-1c18-46c4-be93-cd9e2b526228">113,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of stock options, net of transaction costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6dc9a065301142489cf73ad6591f13da_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTA5NjE4_b6b1c5dd-2641-4163-8598-f315946fdfca">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id66ad877b195477caaa63da51066504e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTA5NjE4_7379f947-28f2-4610-af08-490f855bfdf0">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTAtMS0xLTEwOTYxOA_4c6651d5-7f01-43c4-9e46-404640a69305">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5cc7f91b995e4a8e8339b8aec0df0032_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktMS0xLTEtMTA5NjE4_df743f3d-951e-4c25-9052-d9d0987de894">2,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id00f48490e1649a289d5d3945dc00e92_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktNC0xLTEtMTA5NjE4_7f5670b7-80ef-4b5c-a8fd-e42b244392a5">299,479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i535054e5b34d4a6aaeb7b886535df3dd_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktNy0xLTEtMTA5NjE4_3e54ff40-358c-4ead-bde1-529ac8765dd3">195,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktMTAtMS0xLTEwOTYxOA_a58dc30c-f86f-4e8b-b84c-1132730d4438">107,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net result</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEyLTctMS0xLTEwOTYxOA_c05f3ff2-ebaf-489d-b1ff-e95871ed6660">63,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEyLTEwLTEtMS0xMDk2MTg_1844d52c-1365-4895-869d-80edcd534abe">63,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTctMS0xLTEwOTYxOA_3a27d870-a318-403c-ba95-cbcbfffae1a7">8,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTEwLTEtMS0xMDk2MTg_7ed81ab2-ad36-4a94-9833-448ac1b7a03b">8,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences on translating foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE0LTctMS0xLTEwOTYxOA_09cfad7c-367d-4713-9b21-de40abf4413f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE0LTEwLTEtMS0xMDk2MTg_bcaadd9b-2409-4b6e-af96-0cbfa6e8750f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE1LTctMS0xLTEwOTYxOA_c09f1c2e-ac3f-4e25-b55a-1274e50da75e">55,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE1LTEwLTEtMS0xMDk2MTg_5635ab28-5ee7-4ee3-8bf9-baa5cb7949c3">55,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTQtMS0xLTEwOTYxOA_527836ae-cfb1-442d-8184-b9f6a8fd7dc6">4,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTEwLTEtMS0xMDk2MTg_2f807717-1707-4db6-ac76-98e239d570f0">4,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of new shares, net of transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9fba67aaaf88433581c2a71e67a97f3b_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEtMS0xLTEwOTYxOA_38d8992f-68f1-42ef-a115-51091c077c82">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTQtMS0xLTEwOTYxOA_202d8e85-7a71-4acd-82de-993522c1a6db">51,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEwLTEtMS0xMDk2MTg_8aa88b7e-551f-482d-9c98-dbd1fded96aa">51,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of stock options, net of transaction costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9fba67aaaf88433581c2a71e67a97f3b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEtMS0xLTEwOTYxOA_cec4ceeb-2c61-4b37-adb3-ebdce63e799e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTQtMS0xLTEwOTYxOA_57613203-4c3d-4e30-a631-9b9fe3296547">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEwLTEtMS0xMDk2MTg_e49fe919-6ca9-47de-ba92-30a2f9e66e7b">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i15e5ef472f264809b3c22976835aa54a_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTEtMS0xLTEwOTYxOA_74a4480b-6df6-4ba4-9e04-616a6acbf170">3,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iae7e5cc7cd4c4a6ab9342ae37f83b666_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTQtMS0xLTEwOTYxOA_7f7bf8d0-2ee5-4547-8cf6-13366eaa1e7d">355,010</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ieeb7fef9acf84e13bae5ef3655a07afa_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIwLTctMS0xLTExMjYyNw_c1390445-8f4b-4166-a811-a35b1be90639">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i35d2bc98f85c42efaf80ceebcbf879d3_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTctMS0xLTEwOTYxOA_cc89f0f5-a272-45a5-a90c-268ab7ebdbaf">250,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTEwLTEtMS0xMDk2MTg_49b56ac0-2665-4464-8e13-7ffc2d8e3339">107,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net result</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIyLTctMS0xLTEwOTYxOA_2dbb8a92-9e0c-47a9-98a7-8a4df4b493d3">117,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIyLTEwLTEtMS0xMDk2MTg_6081a502-af3e-48c1-bd4f-11700fdffdc0">117,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTctMS0xLTEwOTYxOA_118e40e9-7c10-4528-8c2e-3f7aad743281">5,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTEwLTEtMS0xMDk2MTg_a87347bb-4fa7-441d-9b78-40752564d044">5,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference on translation foreign costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI0LTctMS0xLTEwOTYxOA_deaedea4-e831-4279-94c8-23dc70860b85">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI0LTEwLTEtMS0xMDk2MTg_802c9ec2-a534-4bce-bc9f-d074e82be74c">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total comprehensive income</span><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI1LTctMS0xLTEwOTYxOA_2610354a-5464-48ee-94a0-03b095e5858d">123,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI1LTEwLTEtMS0xMDk2MTg_cbfa059f-f16d-47ee-a976-fe620005f674">123,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i97c02508d8664ebaad3f69a80bf22ab3_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTQtMS0xLTEwOTYxOA_2287db37-eedb-4c7e-a09c-1ecd05f3c8d0">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTEwLTEtMS0xMDk2MTg_6c785a61-4fb9-4251-8527-22403d85ed74">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of new shares, net of transaction costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i79a62605a2a64c89a0a34d7bbc035e7d_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEtMS0xLTEwOTYxOA_670a7f4f-b6e2-42bd-a261-d268e6320676">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEwLTEtMS0xMDk2MTg_0d64f99b-c9bf-487e-8e5a-831571c9a9d2">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of treasury shares incl. transaction costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7c118ee100384a299e971a96bc0a67db_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTExMjY2Ng_b52e114c-bb80-4f50-87bc-744a4b0672fd">981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEzLTEtMS0xMTI2NjI_8da5f5ce-3d30-4198-b089-9046a41774a7">981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of stock options, net of transaction costs </span><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i79a62605a2a64c89a0a34d7bbc035e7d_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEtMS0xLTEwOTYxOA_427e864e-e104-4b8b-968a-31771e944e2d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i97c02508d8664ebaad3f69a80bf22ab3_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTQtMS0xLTEwOTYxOA_3538464b-a523-4092-951d-4e0aed8bea48">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEwLTEtMS0xMDk2MTg_f95e8681-0fd4-427b-9667-19e15823a877">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ida1ef664b85047599beb657c0edeb373_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEtMS0xLTEwOTYxOA_0bde11ac-1c1d-4d94-b7a9-933e92f0a740">3,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i4c9db8103d514df6aea83be7bdf65bb2_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTQtMS0xLTEwOTYxOA_9fb73987-902b-4660-add0-a5dae928a80e">360,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i4566f4cc772449408ec24a9a58cbf560_I20221231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzMwLTctMS0xLTExMjYzMg_e58af3a2-225c-44f1-b11f-bc66dc3658e6">981</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i42ec354c9f8f4c9a9d165067d15652b6_I20221231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTEwOTYxOA_4e879f11-0e55-4067-b2f6-4a53f1980a85">127,780</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEwLTEtMS0xMDk2MTg_c6dc082b-5ebb-4f30-b768-b3ad71a4febe">235,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08" footnoteRole="http://www.xbrl.org/2003/role/footnote">See note 18</ix:footnote></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e" footnoteRole="http://www.xbrl.org/2003/role/footnote">See note 12</ix:footnote></span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">See accompanying notes, which form an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_262"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Notes to the IFRS Consolidated Financial Statements</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_265"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjUvZnJhZzo4MWI4MjBiMGRkMTM0MjhjYWFlMTY3ZjBiZmJjMzQ0Yy90ZXh0cmVnaW9uOjgxYjgyMGIwZGQxMzQyOGNhYWUxNjdmMGJmYmMzNDRjXzY0_bb335957-e042-4040-8b4f-d9894283c9e2" continuedAt="ie543dec74f874f0b9831abab7cd0704d" escape="true">General information</ix:nonNumeric></span></div><ix:continuation id="ie543dec74f874f0b9831abab7cd0704d"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG ("Company") and its subsidiary (collectively "Molecular Partners" or, "Group") is a clinical-stage biopharmaceutical company pioneering designed ankyrin proteins ("DARPin") candidates to treat serious diseases, with a current focus on oncology and virology. DARPins are a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics. The Company was founded on November 22, 2004, and is domiciled at Wagistrasse 14, 8952 Schlieren, Canton of Zurich, Switzerland. It is subject to the provisions of the articles of association and to article 620 et seq. of the Swiss Code of Obligations, which describe the legal requirements for limited companies (&#8220;Aktiengesellschaften&#8221;).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc. is a wholly owned subsidiary of Molecular Partners AG. Molecular Partners Inc. was incorporated in the United States in the State of Delaware on October 8, 2018. Molecular Partners Inc. is based in Cambridge, Massachusetts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These audited consolidated financial statements as of and for the year ended December&#160;31, 2022 comprise Molecular Partners AG and Molecular Partners Inc. </span></div><div style="margin-bottom:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s shares are listed on the SIX Swiss Exchange (Ticker: MOLN) since November&#160;5, 2014 and on the Nasdaq Global Select Market (Ticker: MOLN) since June&#160;16, 2021.</span></div></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_268"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2MQ_d8598488-84be-4c3d-bab7-d21343d2436c" continuedAt="ib9bdf849c1df47dc9b83a638b219bbd9" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="ib9bdf849c1df47dc9b83a638b219bbd9" continuedAt="ifaa807dc768f412ebd2016bf49a14058"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:StatementOfIFRSCompliance" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0Ng_c0beeee7-b16a-44ed-a0fa-2a22455bf772" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of preparation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the IASB. The accounting policies set forth below have been consistently applied to all years presented. Unless stated otherwise, all financial statements are presented in thousands of Swiss Francs (&#8220;TCHF&#8221;).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4 &#8220;Critical accounting estimates and judgments&#8221;.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Group's cash position at December&#160;31, 2022, the Group deemed there to be no material uncertainties that would cast doubt on the Group's ability to operate on a going concern basis. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements as of and for the year ended December&#160;31, 2022 were approved for issuance by the Company's Board of Directors on March&#160;8, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to rounding, the numbers presented in the financial statements might not precisely equal those included in the accompanying notes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Nw_043232e8-bb45-47f6-8b3d-2933f9d5d7b3" continuedAt="i33645c0f3e3849dd9a9b7b9d41afd05f" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Subsidiaries</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifaa807dc768f412ebd2016bf49a14058" continuedAt="ic5f325bf80b64f2f95dac0131306e102"><ix:continuation id="i33645c0f3e3849dd9a9b7b9d41afd05f"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Transactions eliminated on consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.</span></div></ix:continuation><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Mw_40ea66a2-3ebd-4ce4-b10b-a81aaeb8f939" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New or revised IFRS standards and interpretations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new or revised standards that became effective during 2022 did not have a material effect on these consolidated financial statements:</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Onerous Contracts - Costs of fulfilling a contract - amendments to IAS 37</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Annual Improvements to IFRS standards 2018-2020</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Property, Plant and Equipment: Proceeds before intended use - amendments to IAS 16</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several new or revised standards have been published that are not yet effective and that have not been early adopted. No significant impacts on the Group's consolidated financial statements are expected.</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0Nw_79f1b29b-7153-4cd0-a9e0-2ea96bb86532" continuedAt="ic1853f373aa2419fb8dd42e6984e765a" escape="true">Segment reporting</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1853f373aa2419fb8dd42e6984e765a">The Group operates in <ix:nonFraction unitRef="segment" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzcx_d0fd6cf1-0da1-468a-b5af-3f223460ffd5">one</ix:nonFraction> segment, focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The executive management, acting together as the chief operating decision makers, assess the financial performance and allocate resources on an aggregated level, and monitor the Group's operating expenses. Accounting policies applied are the same for both internal and external reporting purposes. The Group derives its research and collaboration revenues from research and development collaborations with third parties.</ix:continuation> </span></div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2Mg_d4eac75e-5924-4ea5-b309-f0a417872f28" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation / transactions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are presented in thousands of CHF. The presentation currency of the Group is the functional currency of the Company. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assets and liabilities are translated at the closing rate at the date of the respective balance sheet;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">income and expenses for each consolidated statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates at the dates of the transactions); and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all resulting exchange differences are recognized in other comprehensive result.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2Mw_71ee2e09-d5ef-4066-a362-51c4833c2022" continuedAt="id052ab8c0e614ab387e2d3a4628804ab" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment, Office equipment, IT hardware and Leasehold improvements are stated at historical cost less accumulated depreciation and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2NA_cba1c10e-b34d-4e38-b7ab-ba4547a77c42" continuedAt="ib0e916db366442db9df1e3387530fa04" escape="true">The applicable estimated useful lives are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><ix:continuation id="ib0e916db366442db9df1e3387530fa04" continuedAt="ibafb5a863d294050b675d122f669e93b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2e80d6a46f79433a9f1419880a584236_D20220101-20221231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90YWJsZTo2MmFlYTRhZjAwNGI0MTdmYjY3ZWU0NmNkYTY4MDA3Yy90YWJsZXJhbmdlOjYyYWVhNGFmMDA0YjQxN2ZiNjdlZTQ2Y2RhNjgwMDdjXzAtMS0xLTEtMTA5NjE4_b8d0a3de-bdb1-46ee-b1a1-4af287e143d4">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i58f89c5d3edd409a893e4a981cc24bd0_D20220101-20221231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90YWJsZTo2MmFlYTRhZjAwNGI0MTdmYjY3ZWU0NmNkYTY4MDA3Yy90YWJsZXJhbmdlOjYyYWVhNGFmMDA0YjQxN2ZiNjdlZTQ2Y2RhNjgwMDdjXzEtMS0xLTEtMTA5NjE4_0a68fab3-4e83-4880-8c92-ce85ae43fc04">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT hardware:</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib359265a93b948b2b6a8eefcd3139fe8_D20220101-20221231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90YWJsZTo2MmFlYTRhZjAwNGI0MTdmYjY3ZWU0NmNkYTY4MDA3Yy90YWJsZXJhbmdlOjYyYWVhNGFmMDA0YjQxN2ZiNjdlZTQ2Y2RhNjgwMDdjXzItMS0xLTEtMTA5NjE4_329209fa-1b51-494b-b07f-a78e86eccff9">2</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic5f325bf80b64f2f95dac0131306e102" continuedAt="ib18e6b76503f4e649d97eb07b97784d0"><ix:continuation id="id052ab8c0e614ab387e2d3a4628804ab"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements and right-of-use assets are depreciated using the straight line method over the shorter of their estimated useful life and the lease term. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent costs are included in each asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. An asset&#8217;s carrying amount is written down to its recoverable amount, if the asset's carrying amount exceeds its estimated recoverable amount.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost and accumulated depreciation related to assets retired or otherwise disposed are derecognized at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of retirement or disposal.</span></div></ix:continuation><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1OA_f164076f-ca28-4d0d-8217-0753157d7b24" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are solely comprised of software. They are stated at historical cost less accumulated amortization and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Amortization is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful life of intangible assets is determined to be <ix:nonNumeric contextRef="i7e1e929b08e148649e795b949412ce45_D20220101-20221231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzExNw_1e7ebf23-4f7f-4a15-b05c-66fce7ad9387">two years</ix:nonNumeric>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0OA_278e26ab-f84f-4e44-8106-9f1df317cdce" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, the Group assesses whether a contract is, or contains a lease. This is the case if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets (threshold of CHF 5,000) and short-term leases. Short-term leases are leases with a lease term of twelve months or less that do not contain a purchase option. For all other leases the Group recognizes a right-of-use asset and a lease liability at the lease commencement date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. Subsequently the right-of-use asset is depreciated using the straight-line method over the shorter of the asset's useful life and the lease term.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments required over the lease term that are not paid at the commencement date, discounted using the Group's incremental borrowing rate, as the interest rate implicit in the lease generally cannot be readily determined. Lease payments that are included in the measurement of the lease liability include fixed payments or in-substance fixed payments and variable payments that depend on an index. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequently, the lease liability is measured at amortized cost using the effective interest method. The Group remeasures the lease liability when there is a change in future lease payments arising from a change in index, or if the Group changes its assessment of whether it will exercise an extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the lease liability for each period. The Group does not provide residual value guarantees and does not have any leases not yet commenced to which it is committed. The Group is presenting right-of-use assets in Property, Plant and Equipment, whereas lease liabilities are presented separately within current and non-current liabilities in the consolidated statement of financial position.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib18e6b76503f4e649d97eb07b97784d0" continuedAt="i5ee2473646884dae885ba688fa7ea3bd"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0OQ_5ceee685-cddd-481d-a934-b89c6a39d1ce" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Impairment of non-financial assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount exceeds their recoverable amount. An impairment loss is recognized for this difference. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1NA_f1fb0e2b-b7a8-48f0-936d-414e0ae53d7d" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial assets at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents / short-term deposits / trade and other receivables (except for VAT and withholding taxes) (and when applicable accrued interest income) are all considered held-to-collect items and are labeled under financial assets measured at amortized costs, with the following definition / accounting policy:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at amortized cost are assets that meet both of the following conditions: (1) the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They arise when the Group provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities longer than 12 months after the balance sheet date which are classified as non-current assets. Interest income on the short-term deposit is accounted for on the statement of comprehensive income as financial income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, financial assets, except for trade receivables, are measured at their fair value plus, in the case of financial assets not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset; for the Group these are considered to be immaterial. Trade receivables are initially measured at their transaction price. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent measurement for the financial assets mentioned above which are classified as measured at amortized cost, is based on the effective interest method, reduced by any impairment loss. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets measured at amortized cost, a loss allowance for expected credit losses on the financial assets is recognized. Measurement of any impairment loss is based on the &#8216;expected credit loss&#8217; (ECL) model, which is based on a predictive model. The loss allowance for a financial asset is measured at an amount equal to the lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Group measures the loss allowance / impairment loss for that financial asset at an amount equal to 12-month expected credit losses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trade receivables, the Group applies a simplified approach which requires expected credit losses to be recognized from initial recognition (measuring the loss allowance at an amount equal to lifetime expected credit losses). This takes into consideration past history, combined with predictive information which accounts for the specific circumstances of the customer (e.g. credit rating etc.), and other relevant factors such as the economic environment. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other financial assets at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables generally arise from transactions outside the usual operating activities of the Group.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1OQ_6d8c3ae6-66cc-45de-98df-2eb847868efc" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial liabilities at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables and non-employee related accrued expense are measured at amortized costs and classified as financial liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5ee2473646884dae885ba688fa7ea3bd" continuedAt="if1363885f4e14529a987048e5b53d1e2"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1NQ_c5b5dcd1-bc70-404f-bf80-a8856353f837" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash includes cash at banks. The Group considers all short-term, highly liquid investments convertible into known amounts of cash with maturities of three months or less from the date of acquisition to be cash equivalents, provided that they are subject to an insignificant risk of changes in value. The cash flow statement is based on cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1MA_43931c05-2957-4b82-91d4-93043b00dcb7" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share capital / Additional paid-in capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds. The Group has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzIxOTkwMjMyNzEyNzQ_595c3ca0-9c24-48bd-abe8-71f5d5e5205f" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Treasury shares</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the consideration paid for the acquisition of treasury shares, which includes directly attributable costs, is recognized as a deduction from equity. When treasury shares are sold subsequently, the amount received is recognized as an increase in equity, and the resulting surplus or deficit on the transaction is presented in additional paid-in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1MQ_b1d8561d-d3b9-4c90-bf81-97cd0374aa80" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include current and deferred taxes. Current income taxes are recognized on taxable profits at applicable tax rates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are calculated using the balance sheet liability method. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled based on tax rates enacted or substantially enacted at the balance sheet date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized if it is probable that sufficient taxable profits will be available against which the deferred tax assets can be utilized. At each balance sheet date, the Group reassesses unrecognized deferred tax assets and the carrying amount of recognized deferred tax assets. The Group recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. The Group conversely reduces the carrying amount of a deferred tax asset to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or the entire deferred tax asset to be utilized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of deferred tax liabilities and deferred tax assets reflects the tax consequences on the balance sheet date of the Group's expectation of recovery or settlement of the carrying amounts of its assets and liabilities. Deferred tax assets and liabilities are not discounted and are classified as non-current assets and liabilities in the statement of financial position. They are offset against each other if they relate to the same taxable entity and tax authority.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have to pay income taxes in Switzerland in the presented reporting periods for 2022, 2021 and 2020. The Company&#8217;s accumulated taxable losses may be used as tax loss carry forwards to offset future taxable income over a period of seven years in Switzerland. No deferred tax assets have been established for these losses, because the Company does not have a history of sustainable taxable profits, increasing research costs are expected to be incurred in the foreseeable future and future revenues are highly volatile and uncertain. No deferred tax assets were recognized on deductible temporary differences on pension liabilities for the same reasons. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc, the Group's US subsidiary, is subject to US federal and Massachusetts and New York state minimal tax.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if1363885f4e14529a987048e5b53d1e2" continuedAt="ie03d9e2db32f496b86a4b0bbd4131d73"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2MA_4e57a332-1b34-4824-a9e5-15c0a495fc4f" continuedAt="id42308e074ff46a8a0a9a4029687fddd" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee benefits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Postretirement benefits (pension plans)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides retirement, death and disability benefits to its Swiss employees in line with local customs and requirements through two separate plans, which are both accounted for as defined benefit plans. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first plan is the compulsory defined benefit plan which is funded through employer (<ix:nonFraction unitRef="number" contextRef="i134827d19330412b856f8be3015f6a0b_D20220101-20221231" decimals="INF" name="moln:DefinedBenefitPlanEmployerContribution" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzIyMg_6335e948-488a-4532-a621-9929078afa60">60</ix:nonFraction>%) and employee (<ix:nonFraction unitRef="number" contextRef="i134827d19330412b856f8be3015f6a0b_D20220101-20221231" decimals="INF" name="moln:DefinedBenefitPlanEmployeeContribution" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzIyNg_7a657408-3e6f-40b9-a435-d0b6662ab8a7">40</ix:nonFraction>%) contributions to VSAO, a Switzerland based plan. This Company-wide plan has been in place since inception of the Company and all employees of the Company are eligible to its benefits. On retirement, the plan participant will receive his or her accumulated savings, which consist of all contributions paid in by the employer and the employee (net of any withdrawals) and the interest granted on those savings at the discretion of the pension foundation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At that time, the plan participant has the right to choose between a lump-sum payment and an annuity, or a combination thereof. The annuity is calculated using a fixed conversion rate determined by the pension foundation. The VSAO&#8217;s plan assets are pooled and the Company&#8217;s share is calculated based on its share of retirement savings. Additional funding requirements may be determined by the pension foundation in case of a severe underfunding. Should the Company withdraw from the plan, the withdrawal may qualify as a partial liquidation under Swiss law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second plan is a voluntary complementary defined management benefit scheme established as of January&#160;1, 2014, in which only employees with a certain management level and / or above a certain salary level are eligible to participate. <ix:nonFraction unitRef="employee" contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231" decimals="INF" name="moln:DefinedBenefitPlanNumberOfEmployeesThatParticipated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI0OQ_da5b8ac5-5a74-48c1-8a6b-5d330a5fb313">33</ix:nonFraction> of the <ix:nonFraction unitRef="employee" contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231" decimals="INF" name="moln:DefinedBenefitPlanNumberOfEligibleEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI1Mw_8f335008-c287-43e4-84ef-fc74c2037f1f">33</ix:nonFraction> eligible employees participated in this plan as of December&#160;31, 2022 (2021: <ix:nonFraction unitRef="employee" contextRef="ia75b3bef6aac446986fe84984a05f946_D20210101-20211231" decimals="INF" name="moln:DefinedBenefitPlanNumberOfEmployeesThatParticipated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI2NQ_d63dbb44-e4a5-4e83-9897-93e407ce496e">32</ix:nonFraction> out of <ix:nonFraction unitRef="employee" contextRef="ia75b3bef6aac446986fe84984a05f946_D20210101-20211231" decimals="INF" name="moln:DefinedBenefitPlanNumberOfEligibleEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI2OQ_2527a6c7-bc48-4bde-bc78-63130cc1910a">32</ix:nonFraction>). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This plan is set up as a collective foundation with Swiss Life, a Switzerland-based insurance company, for which contributions are <ix:nonFraction unitRef="number" contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231" decimals="INF" name="moln:DefinedBenefitPlanEmployeeContribution" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI4MA_84d2f8fd-c536-4626-8805-7cfb9ec493ec">30</ix:nonFraction>% funded by the employee and <ix:nonFraction unitRef="number" contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231" decimals="INF" name="moln:DefinedBenefitPlanEmployerContribution" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI4NA_bbd87785-9251-4ac4-b3f1-830f589c8484">70</ix:nonFraction>% funded by the Company. The purpose of this voluntary plan is to allow higher savings opportunity in a tax effective manner and risk benefits for senior management. In addition, plan participants are entitled to a lump sum payment of five times their annual base salary in case of death. This is a fully insured Swiss pension plan that covers all investment and actuarial risks, including invalidity and death.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VSAO pension plan accounts for over <ix:nonFraction unitRef="number" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI5MQ_a655a61c-6290-4eda-a9ce-85c98b1f26b7">90</ix:nonFraction>% of both the Company&#8217;s defined benefit obligation and plan assets. The liability recognized in the statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligations at the balance sheet date less the fair value of plan assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows. Pension liabilities are determined on an actuarial basis using a number of assumptions, such as the discount rate and expected salary increases applied to determine the defined benefit obligation and an estimate of the fair value of plan assets attributable to the Company. In determining the appropriate discount rate, for example, the Company considers the interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. In determining the fair value of plan assets, the Company adds to the participants&#8217; savings a share of the pension plan&#8217;s technical and fluctuation reserves. Additional information is disclosed in note 18.1.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and past service costs as well as the net interest on the defined benefit obligation are recognized in profit or loss in the period in which they are incurred, and are presented as part of personnel expenses. Remeasurements of the defined benefit pension plans are recognized in other comprehensive result.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has set up a 401k plan for its US based employees. Under the plan the US entity matches the employee's contribution and provides a true-up in matched contributions at year end. The 401k plan qualifies as a defined contribution plan and the associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has set up a defined contribution plan for its UK based employees. Under the plan the Company and the employee both contribute into the plan. The associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie03d9e2db32f496b86a4b0bbd4131d73" continuedAt="ie4dd4416719345a09dc59bd2bc630233"><ix:continuation id="id42308e074ff46a8a0a9a4029687fddd"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group operates share-based compensation plans that qualify as equity-settled plans. The fair value of the employee services received in exchange for the grant of equity instruments is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the equity instruments granted, which is determined at grant date. The fair values are determined by management with the assistance of an independent valuation expert. At each reporting date, estimates of the number of equity instruments that are expected to vest are revised. The impact of the revision of the previous estimates, if any, is recognized as part of share-based compensation (non-cash effective) with a corresponding adjustment to equity. When the vested equity instruments are exercised, any proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bonus plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group recognizes an accrual where contractually obliged or where there is a past practice that has created a constructive obligation. Bonuses are based on a formula that takes into consideration the achievement of the Group&#8217;s goals.</span></div></ix:continuation><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Ng_3b75df64-94c9-4f65-9544-5a6816442c12" continuedAt="iaa85df95104d4c03ae2d6c8d3e926135" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a guiding principle of IFRS 15, revenues from research and development collaboration agreements are recognized when earned based upon the performance requirements of the respective agreements. For revenue arrangements with separately identifiable components (separate performance obligations), the revenue recognition criteria are applied to each component. The transaction price is determined as the consideration expected to be received from the arrangement and is allocated amongst the separate components based on their relative stand-alone selling prices. The corresponding amount of transaction price allocated to each component is recognized as revenue when (or as) the Group satisfies the performance obligation by transferring the good or service to the customer, which generally is over time for upfront payments or at a point in time for milestone payments and development option payments. Payments received in excess of revenue recognized are recorded as contract liabilities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include fees such as upfront payments received in connection with out-licensing of products and/or access the knowledge without transfer of a license as well as in connection with discovery alliances, as well as fees for maintenance of patents, R&amp;D support and services, participation in Joint Steering Committees and other involvement in collaboration agreements. In exchange for these non-refundable upfront fees, the Group does not immediately transfer a good or a service to the customer, rather the upfront fee consists of an advance payment for future services and the right to access the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input-based method to measure its progress towards complete satisfaction of the performance obligation. Accordingly, revenue is recognized over time based on the percentage of actual costs incurred to date relative to the Group's estimate of total costs expected to satisfy the performance obligation. Estimated costs are reviewed and updated routinely for contracts in progress to reflect any changes of which the Group becomes aware. The cumulative effect of any change in estimate is recorded in the period when the change in estimate is determined.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues could include fees such as milestone and development option payments received in connection with out-licensing of products and in connection with discovery alliances. Upon meeting the set milestone or upon a development option being exercised, the Group obtains a right to a non-refundable payment and the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations for the Group. Consequently, the related revenues are typically recognized at a point in time, either when the milestone is met or the option is exercised by the customer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue could also include reservation fees that will be recognized into revenue in case of successful development of a final drug and exercise or lapse of the related reservation right or, alternatively, in case the results from the research will not justify further development of the drug. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie4dd4416719345a09dc59bd2bc630233" continuedAt="id2e44d90dbfd4264a642e7c07b8c4117"><ix:continuation id="iaa85df95104d4c03ae2d6c8d3e926135"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable to a customer is recorded as a reduction of the arrangement's transaction price, if it relates to the same arrangement, thereby reducing the amount of revenue recognized, unless the payment is for a distinct good or service received from the customer consistent with IFRS 15.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of the accounting policy, based on the type of payments received, are set out below. Under IFRS 15, revenue is recognized as or when a customer obtains control of the services. Determining the timing of the transfer of control - at a point in time or over time - requires judgment. </span></div><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2NQ_a69b7ec4-80e0-4109-83cf-5dd688b95da4" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Type of payments received</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Timing of revenue recognition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of upfront payments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of milestone payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of payments received for development options exercises</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition for reservation fees</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr></table></ix:nonNumeric></div></ix:continuation><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Mg_961595b7-1bcc-4af2-b499-5d1884afab1b" continuedAt="ic9793b88e344482ab3fef3d7048f5878" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses as disclosed in note 16 consist primarily of compensation and other expenses related to:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development personnel;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical studies and clinical trials of the Group's product candidates, including the costs of manufacturing the product candidates;</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id2e44d90dbfd4264a642e7c07b8c4117"><ix:continuation id="ic9793b88e344482ab3fef3d7048f5878"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and services performed under collaboration agreements;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development services outsourced to research institutions; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">attributable facility expenses, including depreciation of equipment and amortization. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed that will generate probable future economic benefits, and when the cost of such an asset can be measured reliably. The Group does not currently have any such internal development costs that qualify for capitalization as intangible assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its internal research and development activities, the Group is also party to in-licensing and similar arrangements with its collaboration partners. The Group may also acquire in-process research and development assets, either through business combinations or through purchases of specific assets. Intangible assets are initially recorded at cost. Intangible assets are amortized over their useful lives on a straight-line basis beginning from the point when they are available for use. The estimated useful life of intangible assets is regularly reviewed. The Group does not currently have any such externally acquired in-process research and development assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group charges all research and development expenses, including internal patent filing and patent maintenance costs, to profit or loss when incurred, as the criteria for recognition as an asset are not currently met.</span></div></ix:continuation></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_271"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzEvZnJhZzo1ZWYzNGJhZTI3YmI0NzI2YjU5OWVhMGNiNzJhNmY5NS90ZXh0cmVnaW9uOjVlZjM0YmFlMjdiYjQ3MjZiNTk5ZWEwY2I3MmE2Zjk1XzM1_6975d309-63a9-4e48-856f-2d40d5a1f923" continuedAt="i6a54787b519145b3a21ecc87b9209f21" escape="true">Financial risk management</ix:nonNumeric></span></div><ix:continuation id="i6a54787b519145b3a21ecc87b9209f21" continuedAt="ie79765bfd8a34c87bf2bd5e06d63a3ac"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial risk factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, uncertainties regarding the effectiveness and safety of new drugs, new and unproven technologies, development process and outcome of clinical trials, rigorous governmental regulation and uncertainty regarding regulatory approvals, long product development cycles, continuing capital requirements to fund research and development, history of operating losses and uncertainty of future profitability, uncertainty regarding commercial success and acceptance, third party reimbursements, uncertainties regarding patents and legally protected products or technologies, uncertainty regarding third party intellectual property rights, dependence on third parties, dependence on publicly available scientific findings and research data, lack of experience with production facilities, dependence on third party manufacturers and service providers, competition, concentration of operations, product liability, dependence on important employees, environment, health, data protection and safety, lack of experience in marketing and sales, litigation, currency fluctuation risks and other financial risks, volatility of market value, as well as limited liquidity and shares eligible for future sale.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is developing several products currently not generating constant revenue streams which results in volatile cash flow from operating activities. Currently, the Group&#8217;s revenues stem mainly from irregular and difficult to predict income from product out-licensing, milestone payments and fees from R&amp;D collaboration agreements. This will likely remain the same at least until the first product reaches the market on the Group&#8217;s own or through a partner. This results in a lack of regular positive operating cash flow, which may expose the Group to financing risks in the medium-term. Furthermore, management has taken actions to manage financial risks, such as foreign exchange risk and liquidity risk.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners conducts research and development activities primarily in Switzerland, the European Union and the United States. As a result, the Group is exposed to a variety of financial risks, such as foreign exchange rate risk, credit risk, liquidity risk, cash-flow and interest rate risk. The Group&#8217;s overall financial risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Further details are disclosed under note 25.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital management</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is not regulated and not subject to specific capital requirements. The amount of equity depends on the Group&#8217;s funding needs and statutory capital requirements. The Group monitors capital periodically on an interim and annual basis. From time to time, the Group may take appropriate measures or propose capital increases to its </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie79765bfd8a34c87bf2bd5e06d63a3ac" continuedAt="ic1ed7667b427408aa17ff53fbc317570">shareholders to ensure the necessary capital remains intact. The Group did not have any short-term or long-term debt outstanding as of December&#160;31, 2022 and 2021.</ix:continuation></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_274"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzQvZnJhZzpiMmRmMjI2OWY5ZjQ0NGRmODljOTQxM2E0M2RlNWMwNC90ZXh0cmVnaW9uOmIyZGYyMjY5ZjlmNDQ0ZGY4OWM5NDEzYTQzZGU1YzA0XzIx_7b9a07b2-ead2-4d0f-b820-c9ba27bdb8ba" continuedAt="ia1c250a36d6b4d968ba0a7b2a38bee3e" escape="true">Critical accounting estimates and judgments</ix:nonNumeric></span></div><ix:continuation id="ia1c250a36d6b4d968ba0a7b2a38bee3e"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s accounts are prepared on a going concern basis. The preparation of the consolidated financial statements in conformity with IFRS requires that management and the Board of Directors make estimates and assumptions which affect the amounts of the assets and liabilities, contingent liabilities, as well as the income and expenses reported in the consolidated financial statements. These estimates take into consideration historic experience as well as developments in the economic circumstances and are further based on management&#8217;s best knowledge of current events and actions that the Group may undertake in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates are subject to risks and uncertainties. The actual results can deviate from these estimates. The estimates and assumptions identified by the Group, which have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in a future period or have a significant effect on reported results, are discussed below:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuation in revenues is common to biopharmaceutical companies focused on research and development as the revenues are often linked to up-front fees, reservation fees, milestones or license payments as well as income for delivery of drug substance, which occur sporadically. Depending on the complexity of the relevant agreements, judgment (for instance in regard to the performance obligations recognized using the cost-based method, where revenue is recognized based on costs incurred in relation to the Group&#8217;s estimate of total estimated costs to complete satisfaction of the underlying performance obligations) is required to reflect the substance of the arrangement in the recognition of revenues. Under the cost-based method, the Group&#8217;s estimate of total costs to be incurred under certain agreements is for example, based on actual project-related contracts and history of similar contracts of other collaborations as well as industry experience. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is required to evaluate whether any changes in operational and/or technical collaboration and project requirements could lead to a change in the timing and/or amount of estimated project costs, and how such changes, if any, impact the recognition of revenue. Other revenue related judgments with regard to the determination of performance obligations under reservation agreements relate to assumptions on future production costs and market prices. More information on revenue recognition is provided in the respective accounting policy. Additional information related to the Group&#8217;s significant revenue agreements is disclosed in note 5.</span></div></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_277"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfRevenueExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzM2Ng_bb0b0d50-084a-4a83-94c8-341fa9d09ec3" continuedAt="ic962ce83ce6c4e70952652f1c86106f6" escape="true">Revenue, other income and entity-wide disclosures</ix:nonNumeric></span></div><ix:continuation id="ic962ce83ce6c4e70952652f1c86106f6" continuedAt="ief88efad65924c45817bead3cc2beb46"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group assesses and estimates the progress of its projects with alliance partners at each reporting date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">License and Collaboration Agreement with Novartis in the Area of DARPIN-Conjugated Radioligand Therapies ("Novartis Radioligand Agreement") </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;14, 2021, the Group entered into a License and Collaboration Agreement with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology. Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. The Group will be primarily responsible for the generation of DARPins for tumor-specific delivery of radioligands. The Group is eligible to invoice Novartis for its employee-related expenses associated with the research activities. Novartis is responsible for all clinical development and commercialization activities. As of December&#160;31, 2021 the Group recognized a receivable for the upfront fee of USD <ix:nonFraction unitRef="usd" contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTEwNA_db90b115-89ee-4f3b-a104-a34b79ad5490">20</ix:nonFraction> million (CHF <ix:nonFraction unitRef="chf" contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTExMA_1256b448-f0bd-4e9b-b98f-b0adc3e9d684">18.6</ix:nonFraction> million) payable from Novartis in trade and other receivables and a corresponding contract liability in the consolidated statement of financial position. In January 2022, Novartis paid Molecular Partners the upfront fee. The Group will be eligible to receive milestone payments of up to USD&#160;<ix:nonFraction unitRef="usd" contextRef="i7afdf7fbdcd3403f9eab53aecc3a73dd_D20211214-20211214" decimals="-6" name="moln:PotentialFutureMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE0Ng_3fbad312-a081-4b5b-b8dc-cc8c34164481">560</ix:nonFraction>&#160;million, relating to development, regulatory and commercialization activities, plus tiered royalties based on commercial sale levels from mid-single digit to low double-digit percentages of royalties on net sales of products commercialized by Novartis.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ief88efad65924c45817bead3cc2beb46" continuedAt="i94093564f44f44528318029180483a1a"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group identified one combined performance obligation consisting of the license and the research activities to be provided. Revenue related to the upfront payment of USD <ix:nonFraction unitRef="usd" contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE2Mg_db90b115-89ee-4f3b-a104-a34b79ad5490">20</ix:nonFraction> million (CHF <ix:nonFraction unitRef="chf" contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE2OA_1256b448-f0bd-4e9b-b98f-b0adc3e9d684">18.6</ix:nonFraction> million) is being recognized over time in line with the progress made over the duration of the contractually agreed three-year research plan. Progress towards completion of the research plan is based on the cost-based method and is measured by employee costs on the related research activities as specified in the agreement relative to the total employee costs estimated to be incurred. During 2022, the Group recognized total revenue of CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i86479feb060c435da9376e68efd6bae0_D20220101-20221231" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE4OQ_226b0abd-ca89-47bf-9ef0-ddd2dc438d7b">9.8</ix:nonFraction>&#160;million of which CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231" decimals="-5" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTQwMg_764904cc-b3ea-40cb-bdc8-83cb937facc1">8.5</ix:nonFraction>&#160;million related to the recognition of the upfront fee and CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i86479feb060c435da9376e68efd6bae0_D20220101-20221231" decimals="-5" name="moln:RevenueFromRechargeOfEmployeeRelatedExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTIwMQ_e2686274-a039-4188-91ec-a4ab1ec8a3dd">1.3</ix:nonFraction>&#160;million related to the recharge of employee related expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future milestone payments and royalties under the agreement will be recognized as revenue at a point in time, when a milestone is achieved or any subsequent sales by Novartis occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option and Equity Rights Agreement with Novartis for Ensovibep (the "Option and Equity Rights Agreement")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Group entered into the Option and Equity Rights Agreement with Novartis, granting Novartis the exclusive option to in-license global rights in relation to MP0420 (ensovibep). Under the terms of the agreement, in 2020, the Group in 2020  received an upfront, non-refundable fee of CHF <ix:nonFraction unitRef="chf" contextRef="ie09ac87f9d574f82a6928c8d06b64069_D20200101-20201231" decimals="-6" name="moln:UpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzQx_d220b7c9-2177-4d78-bc92-550c359ac041">20</ix:nonFraction> million for the technology transfer and manufacturing of MP0420. The Group committed to utilize up to the maximum amount of this upfront fee for the manufacturing of the commercial supply for MP0420, which is required to be manufactured by Sandoz, a division of the Novartis Group. All such amounts paid for manufacturing performed by the Novartis Group is considered to be a consideration payable to a customer. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant inter-dependencies between the upfront fee and the manufacturing activities, the manufacturing costs paid to the Novartis Group are offset against the upfront non-refundable fee from the contract (see below, as well as note 15). As of December&#160;31, 2021, the entire CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i36fa71d491c847329fa6c34d14edfb51_D20211231-20211231" decimals="-6" name="moln:UpfrontPaymentAmountUtilizedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzQ5_cbcb3524-41a6-4e13-bc62-94998cd5656e">20</ix:nonFraction>&#160;million has been utilized for the manufacturing of commercial supply for MP0420. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensovibep License Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, following positive Phase 2 clinical trial results, Novartis exercised its option for ensovibep, triggering a milestone payment of CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i74229b204f0a4e65a5b4572fda04aa7d_D20220101-20221231" decimals="-6" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk3ODg_ba3181e5-1352-4261-b98b-2e9a8e5cea63">150</ix:nonFraction>&#160;million to the Group, which was received in 2022. Relatedly, the Group was eligible to invoice Novartis CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i4cfad794c98341a992833dca18dfb48a_D20220101-20221231" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk4MTI_96b5ddf0-45bc-4338-b41d-c9cd908f2047">13.1</ix:nonFraction>&#160;million for other items related to ensovibep..</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the exercise of such option, the Group entered into a license agreement, the Ensovibep License Agreement, with Novartis under which the Group granted Novartis a sublicensable worldwide license to research, develop, manufacture, commercialize and otherwise use ensovibep and products comprising the compound in all indications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is eligible to receive a <ix:nonFraction unitRef="number" contextRef="i74229b204f0a4e65a5b4572fda04aa7d_D20220101-20221231" decimals="INF" name="moln:RoyaltyIncomePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk4NTA_43aac4f6-3078-4013-b72e-422f1e7ba0fe">22</ix:nonFraction>% royalty on future commercial sales. Molecular Partners has agreed to forgo royalties in lower income countries, and is aligned with Novartis&#8217; plans to ensure affordability based on countries&#8217; needs and capabilities. Novartis is responsible for all further development and commercialization activities of ensovibep.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In early  January 2023 Novartis informed the Group that it has submitted a request to withdraw, with an effective date of January 25, 2023 the Emergency Use Authorization (EUA) application from the U.S. Food and Drug Administration (FDA) for ensovibep. Ensovibep is not presently in clinical development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reservation Agreement with the Swiss Federal Office of Public Health / Bundesamt f&#252;r Gesundheit ("FOPH")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2020, the Group announced the reservation by the FOPH of a defined number of initial doses of the Group's anti-COVID-19 candidate, MP0420. Under the terms of the agreement, the Group received a reservation fee of CHF&#160;<ix:nonFraction unitRef="chf" contextRef="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5ODM_788278c5-2553-4b35-948f-a709ed82895a"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5ODM_85f40d64-3c0e-499b-b630-2869ff85f6c5">7.0</ix:nonFraction></ix:nonFraction>&#160;million which resulted in a current contract liability of CHF&#160;<ix:nonFraction unitRef="chf" contextRef="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5OTI_788278c5-2553-4b35-948f-a709ed82895a"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5OTI_85f40d64-3c0e-499b-b630-2869ff85f6c5">7.0</ix:nonFraction></ix:nonFraction>&#160;million, as presented in the consolidated statement of financial position for the years 2020 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Group met the contractually agreed milestone specified in the agreement, resulting in the reservation fee received from the FOPH becoming no longer refundable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Group and the FOPH entered into an amendment to extend the term of the reservation agreement by <ix:nonNumeric contextRef="i81750a7eb8914110a2c5e64c43bc2de0_D20211201-20211231" name="moln:ExtendedPeriodOfReservationAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDAwMzQ_a92e34b1-1a06-44e9-b526-91556db4ed5e">six months</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment also allowed the agreement to be assigned to Novartis upon its exercise </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i94093564f44f44528318029180483a1a" continuedAt="i5ad45e07ffe44be8a5b986957918780f"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the option under the Option and Equity Rights Agreement. With the exercise of the option by Novartis in January 2022 and the subsequent assignment of the agreement to Novartis, the Group recognized the CHF&#160;<ix:nonFraction unitRef="chf" contextRef="ib0215c4c9fa24e1aa58a4a62c6f6dcac_D20220101-20221231" decimals="-5" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTQxNA_007e88b0-5188-460d-9f91-653e0323ec9f">7.0</ix:nonFraction>&#160;million contract liability as revenue in 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreement with Amgen (the "Amgen Collaboration Agreement")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Group entered into a license and collaboration agreement with Amgen for the clinical development and commercialization of MP0310 / AMG 506. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement the Group received a non-refundable upfront payment of USD&#160;<ix:nonFraction unitRef="usd" contextRef="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231" decimals="-6" name="moln:UpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI2NDQ_e3629a1c-2a8b-408d-b456-56155c6feec0">50</ix:nonFraction>&#160;million. The Group was primarily responsible for performing certain clinical development, manufacturing and regulatory activities in the first clinical phase and the Group assigned the full USD&#160;<ix:nonFraction unitRef="usd" contextRef="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231" decimals="-6" name="moln:UpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI2NjI_e3629a1c-2a8b-408d-b456-56155c6feec0">50</ix:nonFraction>&#160;million (TCHF <ix:nonFraction unitRef="chf" contextRef="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231" decimals="-3" name="moln:UpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI2Njg_53a31a15-8042-45ea-85b0-2c819c4fb8f1">49,625</ix:nonFraction>) upfront payment as the transaction price to this performance obligation, based on the Group's development plan and the Amgen Collaboration Agreement. The Group recognized the related revenue using the cost-based method to measure it progress by reference to actual costs incurred in relation to the Group's best estimate of total expected costs to satisfy the performance obligation. This cost-based method is subject to the assessment of the management of the Group.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;26, 2022 the Group announced that Amgen, had informed the Group of its decision to return the global rights of MP0310 following a strategic pipeline review. With no remaining performance obligations under the Amgen Collaboration Agreement, the Group recognized the remaining balance of the Amgen contract liability as revenue for a total amount reported in 2022 of TCHF <ix:nonFraction unitRef="chf" contextRef="i9358dea0732b40a194894bcf6ddddaec_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI3MzU_e9f5978e-e9fb-4fed-a1d6-66cd709aee32">9,653</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzM2Nw_30250abe-fcca-4166-bd51-07aeed53d6c9" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the years ended December&#160;31, 2022, 2021 and 2020, the Group recognized revenues as disclosed in the table below. Revenues in the table below are attributable to individual countries and are based on the location of the Group's alliance partner. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues by country</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands, for the years ended December 31</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i11c7f8788e1743f68a27f638c26a39bc_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItMS0xLTEtMTEyNjgx_b885c4e6-3030-465c-8854-e2844bf8b645">179,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i28fa8e94c14b481ca8ccfc64c63add77_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNC0xLTEtMTEyNjg0_67339144-e2dd-4aec-94c0-2b66621926ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibb6f6a0e23734f59bbbb2a62cce89125_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNy0xLTEtMTEyNjg3_bdd09910-4b63-4d70-8751-fb441ec18b81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues USA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iccbcbcc25f484b88a862620fa45229ea_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItMS0xLTEtMTA5NjE4_0c319448-d5dd-4cbc-9517-b6ce4ce2119b">9,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3059de8c6f0f4f34a718c2a08e7fe684_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNC0xLTEtMTA5NjE4_d8840ff8-3e9a-4f83-8b3c-17aac6572fd7">9,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1c93a9c3be2d4ab1aca8bcaec0a3ece3_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNy0xLTEtMTA5NjE4_da898e12-33e8-460d-8f78-0f8112196681">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzMtMS0xLTEtMTA5NjE4_87d6c20c-892a-40f5-ba12-019c3e1b32ac">189,556</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzMtNC0xLTEtMTA5NjE4_d8212d48-66f6-447d-b348-55611606c697">9,330</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzMtNy0xLTEtMTA5NjE4_833c0194-fd82-40bb-9961-645a110a7366">9,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Analysis of revenue by major alliance partner</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands, for the years ended December 31</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis AG, Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9f2f00f6e1d34d28bc572c7a3716463d_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItMS0xLTEtMTEyNzAx_d3eaad92-c437-479f-8a00-58cdd7fc0770">172,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i98b9c15b3a534e53bbe14f8fb49c9c04_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNC0xLTEtMTEyNzA0_79f5238e-0a4f-4db2-920e-078b2860ef83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i69206f52bb344692804141964f0b8919_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNy0xLTEtMTEyNzA3_3e8a3e02-8372-4e5d-832c-9bcfd0b30b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH, Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i03d96b78adfc4421949448ba38c3278e_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtMS0xLTEtMTEyNzAx_0f852cc9-b560-4da9-9af4-f16bff4ce899">7,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie43e19cfc5e6468284394d74ddd1c6b6_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNC0xLTEtMTEyNzA0_efada4b7-9fa8-4f63-ab2d-f6d7e6a7dbb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9d6429be12154d0ba42dc47086ea5532_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNy0xLTEtMTEyNzA3_e29d8ee5-e15c-4051-bb08-7e9f266730c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc., USA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9358dea0732b40a194894bcf6ddddaec_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItMS0xLTEtMTA5NjE4_e9f5978e-e9fb-4fed-a1d6-66cd709aee32">9,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9455742d8ced4b6aa55b012e2998f544_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNC0xLTEtMTA5NjE4_34b7f875-de2d-4891-a433-29ff07f0e30e">9,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7779c743611545a1a5466aeccce603f7_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNy0xLTEtMTA5NjE4_ea9e499d-7dc2-4dde-af52-9d6451670120">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtMS0xLTEtMTA5NjE4_55acdbb7-051d-4a44-9a25-46d3fb2c6127">189,556</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNC0xLTEtMTA5NjE4_7b5af922-2dde-459e-a519-a6e782794e17">9,330</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNy0xLTEtMTA5NjE4_50953119-1827-48a1-aa97-aa69c43fac7d">9,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income </span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ad45e07ffe44be8a5b986957918780f">In the first quarter of 2021 the Group entered into an agreement with Novartis to facilitate manufacturing of MP0420 drug supply at a third party supplier. The related agency services earned during 2022 amounted to TCHF <ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI5NTI_006dc753-b00b-4134-8326-d7426d11a401">44</ix:nonFraction> (2021: TCHF <ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI5NjQ_155eef06-cb43-4077-a984-fb71dab10cbc">424</ix:nonFraction>) and are presented as Other income in the consolidated statement of comprehensive income.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_280"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90ZXh0cmVnaW9uOjAwOGQzNmY0NGQxNjRhYzM5NzkxYzhmMTQ5ZTgxNzY3XzQw_f7769d13-3bd0-4002-a24f-769cfbe0179c" continuedAt="id6c129fa944b4aa1b3aca35763bddf6b" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="id6c129fa944b4aa1b3aca35763bddf6b"><div style="margin-bottom:8pt"><ix:continuation id="ibafb5a863d294050b675d122f669e93b" continuedAt="i3f3e3659fcde4446a93e923efbe14890"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i039f8aa8b8604b2e883f7b3401f7a929_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMS0xLTEtMTA5NjE4_d4cdde50-93f6-48ff-b178-bb3e306daff0">8,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7552852e9d984715b1fdd598bf43ceef_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtNC0xLTEtMTA5NjE4_257f8977-92dc-4c6b-8e32-5d31ae4c9b20">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibd82706cc4f64d05a8031db8ac29d402_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtNy0xLTEtMTA5NjE4_ba4610b0-08f8-4362-866b-c86d6009cab2">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia6bbe794bea748fba48087bb12f33b68_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMTAtMS0xLTEwOTYxOA_3781782d-e236-4be1-abc2-05dd0fa3cf14">9,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i88e0b443e7594af9817dff19575a130a_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMTMtMS0xLTEwOTYxOA_43402806-0185-4d6f-8848-6d4991240e7b">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id866ae6d346e441aa470d04134f56aea_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMTYtMS0xLTEwOTYxOA_6b94c9bd-4aa3-45d1-a1a2-1d67ad6050e5">20,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8f4189b498f848ccbfe85984bfc5754f_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMS0xLTEtMTA5NjE4_193a6126-1931-472c-ad65-2a55f867fc26">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3fdd67cc72964dfbacdf60557d1afe8a_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtNC0xLTEtMTA5NjE4_f0c2fe71-c15c-4709-ac8e-3145b5c78cf3">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i929b7236fc1c4b00a1fbffece5751b1f_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtNy0xLTEtMTA5NjE4_7ef5b083-e714-4d4c-a1be-9eb6d261ff8f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i0bfb7ab39c194903bc349d24d15bdff3_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMTAtMS0xLTEwOTYxOA_99268bff-b2b4-457f-9911-c51370302718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i449ea807ec98486b91b11b3611579b53_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMTMtMS0xLTEwOTYxOA_e0e92447-ba77-477e-a4ba-000733a35d21">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i721fcb345fbe4680839954bebb736c75_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMTYtMS0xLTEwOTYxOA_9500c96d-068c-4e2d-bed3-60f7b1762e70">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8f4189b498f848ccbfe85984bfc5754f_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMS0xLTEtMTA5NjE4_1f960984-4783-4983-80b0-22c8943d3439">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3fdd67cc72964dfbacdf60557d1afe8a_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtNC0xLTEtMTA5NjE4_05b0a16d-1993-4b3c-ae8e-3801c755b1d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i929b7236fc1c4b00a1fbffece5751b1f_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtNy0xLTEtMTA5NjE4_b7efb31b-532b-42b4-be6d-0bf08054c4e6">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i0bfb7ab39c194903bc349d24d15bdff3_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMTAtMS0xLTEwOTYxOA_689dd451-b46d-4851-8200-c468d3baff8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i449ea807ec98486b91b11b3611579b53_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMTMtMS0xLTEwOTYxOA_86b23f1e-9ce4-4df9-8ebc-124b5a79c08f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i721fcb345fbe4680839954bebb736c75_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMTYtMS0xLTEwOTYxOA_cf86fd32-b5d7-47ba-adda-778ea2138413">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iae809b4cb3c34e5e883367b1b36f9a41_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMS0xLTEtMTA5NjE4_7c420aaa-b909-4d61-bdb4-24f6cf61e040">9,646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i700c3d4d5945423fb23d62d557025628_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtNC0xLTEtMTA5NjE4_a86442f1-7a19-4417-97ba-4861bfb0c49e">731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i442e98a6f284460eb60903633206fee4_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtNy0xLTEtMTA5NjE4_719ee655-21c7-4348-bc62-e6b1de1392f8">1,315</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ied5bd6f58f8f48858390908d4e2a3e7e_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMTAtMS0xLTEwOTYxOA_3b82cffc-5226-4409-9e7f-cef181985f22">9,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i62a4b7bf00f14853a994219c229c2c99_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMTMtMS0xLTEwOTYxOA_dd409026-8d4e-4b7a-b4d3-af1cc0ffb10b">624</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i67bd3877ed504b9aa0d90579b46a85dc_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMTYtMS0xLTEwOTYxOA_91fd2ff9-5408-4709-b8f7-4ee0760a864f">21,932</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ia8209c15b7f84b6c9ad36754465a7bb6_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMS0xLTEtMTA5NjE4_e2db9bd2-6804-473d-a77f-f452dc1322cf">7,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8c56aac02e0548818298a1b40775502a_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtNC0xLTEtMTA5NjE4_72db48ae-4cb9-4df1-b605-b939559c8fc2">653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="iad0b882b89ca4bc19848d14f02c8a322_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtNy0xLTEtMTA5NjE4_7b4b9400-04b0-4af7-b1af-5fbbf4e9a561">1,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87deb100db7642138360f124b7b83f30_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMTAtMS0xLTEwOTYxOA_f5544574-9497-4793-bc65-f0d07e7b8705">3,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i07001daad34a409cb04dc3e2f9fddf5d_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMTMtMS0xLTEwOTYxOA_5ef5249f-911f-4c22-b74b-19225f66cf7c">298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib6db54fee24e4009b68217ec1b72ecdb_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMTYtMS0xLTEwOTYxOA_1094b690-0e59-421a-a8db-e4788892acbf">12,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i75365a982a614edc804e839f45c5b05d_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMS0xLTEtMTA5NjE4_c841c39b-a52b-4b9d-a7e4-aad69303e54a">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i078bf95a5a1b404484fa9d710b87ffcc_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktNC0xLTEtMTA5NjE4_02a71cb0-658f-4f2b-8948-a02108e761e3">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ice16a04c397c47bca71d3d2d60a51120_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktNy0xLTEtMTA5NjE4_d83bde6d-521d-4bae-a719-33e72352e85d">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i3b1102832e1f4e1fafce024fd7eb6448_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMTAtMS0xLTEwOTYxOA_e59de82b-56b0-48df-a50f-d3c1d6a3d27f">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i6e85bbf49b974c1ea7e5b7900e92843f_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMTMtMS0xLTEwOTYxOA_e46b0fa8-9754-4519-8e9c-679b48d7760c">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i70c79a462ea7412a93e68016da430184_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMTYtMS0xLTEwOTYxOA_4f5f362a-7102-4f31-be30-5cdac2abf42d">2,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i75365a982a614edc804e839f45c5b05d_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTEtMS0xLTEwOTYxOA_197dc206-d62f-4118-a034-7754d02380a2">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i078bf95a5a1b404484fa9d710b87ffcc_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTQtMS0xLTEwOTYxOA_8c7254eb-b190-4da3-b234-9465f6a5281e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ice16a04c397c47bca71d3d2d60a51120_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTctMS0xLTEwOTYxOA_c3fb4200-1ad3-4300-a04e-72fd528297a4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3b1102832e1f4e1fafce024fd7eb6448_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTEwLTEtMS0xMDk2MTg_4c546899-ee7a-4ac4-8556-921e4ae77514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6e85bbf49b974c1ea7e5b7900e92843f_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTEzLTEtMS0xMDk2MTg_c8651b3d-4c04-4017-bdd4-68354ce70870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i70c79a462ea7412a93e68016da430184_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTE2LTEtMS0xMDk2MTg_cf657a00-d7da-4fd8-8b7c-339652cd3533">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="id7021179595f4067925348f27617f344_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTEtMS0xLTEwOTYxOA_653796db-e514-436c-bfd8-415b312b24d9">7,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i56b61e3a808b46ecb5fd9e84efd88fb1_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTQtMS0xLTEwOTYxOA_acfd0d3a-471d-43e2-a4eb-d916becbd3fb">687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icd725be5cb634d3ab32c12364784d95e_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTctMS0xLTEwOTYxOA_1eecd969-58b6-40c0-a740-211310a2ac07">1,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i623979330c12419785c4e5ddc7af24af_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTEwLTEtMS0xMDk2MTg_953c7631-3be6-497b-9067-61f433ce1dfe">4,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8693395446c5444f8dea66e3b926bfc8_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTEzLTEtMS0xMDk2MTg_606a8a53-c78b-41cb-b959-e11d0cd4eaaa">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="id42028a51dd041c8adf064ec5e6ff3ce_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTE2LTEtMS0xMDk2MTg_9ef3b8ae-13cb-4dd8-af3a-f88a01bf73ff">14,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3eb97834871d4133bebda22f171f379c_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTEtMS0xLTEwOTYxOA_caaef95e-76c2-4cea-94f0-65f34c604285">1,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i4515285a8328425c8e01df63e4618b0e_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTQtMS0xLTEwOTYxOA_69ca4d95-7a9f-42cf-8e2d-0539a9033766">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iad950054a9b34e23b44f9eadcd5ac579_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTctMS0xLTEwOTYxOA_67da88ee-3205-4f4b-a95d-80070c0889b8">143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="icc0b75f40939487cb5f179a9d998733b_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTEwLTEtMS0xMDk2MTg_b91b2a03-eb0d-4416-8232-6d11ff0befe7">4,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="icbf076ebc35b49ddbe4032b44413da3d_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTEzLTEtMS0xMDk2MTg_449af92e-96b5-4e29-a1d1-60f61f43ed77">260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTE2LTEtMS0xMDk2MTg_d44f78a4-da6a-45b5-ae7b-451000047916">7,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use assets relate to the facilities the Group is leasing in Schlieren, Switzerland.</span></div><div style="margin-bottom:8pt"><ix:continuation id="i3f3e3659fcde4446a93e923efbe14890"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i54edf24cb9164d1dbfea8b8935a712b1_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMS0xLTEtMTA5NjE4_9cf82d8d-2298-4477-a2c8-f4f2c100422c">8,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iea606ad4acc0477bbea8cec093c5f28a_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtNC0xLTEtMTA5NjE4_4de6a7e7-5a09-43e5-8f35-af5874e1e6ee">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6ca2744f82cc4290b5c5196c97ed6050_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtNy0xLTEtMTA5NjE4_3dee1d69-48a6-4b36-a992-799c1e824eab">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i26412b3157954911862c5a447f325fd2_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMTAtMS0xLTEwOTYxOA_a6f4953d-16b7-4c29-8171-073d006de18f">9,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i18bc5a3445ce443b98c1b2827a0abbf8_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMTMtMS0xLTEwOTYxOA_a5c7a144-dc28-4ac2-9a2f-ad3d86775c00">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iacafa94802ef4385b1333762542ab2f3_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMTYtMS0xLTEwOTYxOA_8638bb47-bc9d-4f59-99e6-39e779a56b67">20,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i610b20f353ba4dea967f7adf9a040527_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMS0xLTEtMTA5NjE4_5d5fd567-8a20-4b62-b453-984c07ff613a">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib96855ceb0f64121a493479e560bef93_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtNC0xLTEtMTA5NjE4_a1712fda-16d8-47df-9f83-0f9ac1b1ff0a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia9417e12bdb64e3bafac232b9b8e7099_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtNy0xLTEtMTA5NjE4_ab4563f6-0e1a-42d4-bd82-3dd79a4440c9">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id2dba62e38a349b5bd2d7fb9c9475d34_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMTAtMS0xLTEwOTYxOA_fe1f402f-1538-40e1-bf4a-53baed49a4ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iaa9d4dcab9014ff6a5667ed415cacf65_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMTMtMS0xLTEwOTYxOA_40423e82-4ff0-4e49-8409-cf0135dd817c">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9e266b3fb54b46679c03b9f807b42f18_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMTYtMS0xLTEwOTYxOA_3d5ea0e5-ee2b-43d2-8f9b-ca9a68e557ca">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i610b20f353ba4dea967f7adf9a040527_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMS0xLTEtMTA5NjE4_b5bc35c5-a4fa-4599-b063-b19a1334e73e">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib96855ceb0f64121a493479e560bef93_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtNC0xLTEtMTA5NjE4_535bad18-ef66-4200-b582-50b1d89736b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ia9417e12bdb64e3bafac232b9b8e7099_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtNy0xLTEtMTA5NjE4_4f3ee8f6-ae7d-48e0-86fe-6753c19cc6f2">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic872fe1c5a64452688768d06a4b4096c_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMTAtMS0xLTEwOTYxOA_8407dac0-925f-4794-88ec-77151dd191b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iaa9d4dcab9014ff6a5667ed415cacf65_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMTMtMS0xLTEwOTYxOA_93aa4a0d-4601-45a3-af5b-a11548393582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i9e266b3fb54b46679c03b9f807b42f18_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMTYtMS0xLTEwOTYxOA_298772e8-f45f-47bf-8745-046bb36745c6">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i039f8aa8b8604b2e883f7b3401f7a929_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMS0xLTEtMTA5NjE4_163d88a2-f9f1-4cd3-82c3-23c0847ee860">8,754</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7552852e9d984715b1fdd598bf43ceef_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtNC0xLTEtMTA5NjE4_639d02eb-bc52-4727-bba0-c4c9394f98da">711</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibd82706cc4f64d05a8031db8ac29d402_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtNy0xLTEtMTA5NjE4_39f2da1d-79d3-4875-a9f4-93635315c49b">1,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia6bbe794bea748fba48087bb12f33b68_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMTAtMS0xLTEwOTYxOA_e22a94f2-47c9-45f9-b1de-2c1d0d04a554">9,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i88e0b443e7594af9817dff19575a130a_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMTMtMS0xLTEwOTYxOA_2b0f9300-e527-4714-bb36-f0fe07469aa3">607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id866ae6d346e441aa470d04134f56aea_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMTYtMS0xLTEwOTYxOA_4d5c6459-3431-494a-9bb3-e56e7acf9eb0">20,887</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i400d3c0abd194c8e869aa1b7e6a16268_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMS0xLTEtMTA5NjE4_0bf92e63-ecc9-4680-82bc-8ffded7963c7">6,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i74f28cfe913d4066ba37fda6c47ac60d_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtNC0xLTEtMTA5NjE4_d4aba85f-5d9e-4e95-87b3-726c42797839">617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i337a906d7c4e48bc876b5ed46aa717c3_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtNy0xLTEtMTA5NjE4_1d8b53fa-0e4a-4d44-90d2-fac74034728e">757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i1742ca85635d45afaa2bb5e7b5c34750_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMTAtMS0xLTEwOTYxOA_158f137e-e6f9-4608-b76e-1bce4cefcd88">2,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib8ce32bfd0d64572b4c65f93443e740f_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMTMtMS0xLTEwOTYxOA_ec7acac9-6a43-4d1d-8a4d-3c03efb39dde">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icab5d29cfc93414ea6aba3b898a8cf72_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMTYtMS0xLTEwOTYxOA_0a5b54c1-8fbf-4584-b42d-7772f06cc8e7">10,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ica8eaf81db894ce0b611d7d987fef5f4_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMS0xLTEtMTA5NjE4_c8caa493-4aac-46ab-bc59-3b2c4a17daa1">583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i15f9aad96b06470c9ded02ebad46915c_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktNC0xLTEtMTA5NjE4_03d5367b-1034-450b-ad24-c298ed2cc35d">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i97000304b6a7470ba15cf385bc4113c1_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktNy0xLTEtMTA5NjE4_aa0c8ad3-5928-4123-9978-768ed9ee60e8">329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idd1b6d0b84ef47739e20d7569c9e7102_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMTAtMS0xLTEwOTYxOA_25c16f61-3b0f-4438-9aeb-43941ca4b809">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0c236926219843fc950064245dabb01c_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMTMtMS0xLTEwOTYxOA_85348138-e641-49af-9477-d7b25a66d384">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7da99d7da3114dd5a669a798631979bb_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMTYtMS0xLTEwOTYxOA_199893f5-d15e-462c-a08b-5e41dace3786">2,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ica8eaf81db894ce0b611d7d987fef5f4_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTEtMS0xLTEwOTYxOA_3c35320c-657b-4457-ae3c-d6ed86d38960">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i15f9aad96b06470c9ded02ebad46915c_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTQtMS0xLTEwOTYxOA_4a58f099-5961-4857-91ac-cb0c84ff0856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i97000304b6a7470ba15cf385bc4113c1_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTctMS0xLTEwOTYxOA_0f2dc528-65d7-4e73-9f20-729b7bf71ad7">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idd1b6d0b84ef47739e20d7569c9e7102_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTEwLTEtMS0xMDk2MTg_b148ee08-3861-489a-a731-1bba0c1a454b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i0c236926219843fc950064245dabb01c_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTEzLTEtMS0xMDk2MTg_d329b6a0-1847-45e0-87f2-ecee12cc5d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7da99d7da3114dd5a669a798631979bb_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTE2LTEtMS0xMDk2MTg_c597192e-8191-435c-a064-93fcab7c2a68">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ia8209c15b7f84b6c9ad36754465a7bb6_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTEtMS0xLTEwOTYxOA_01e861d6-d2ac-417b-b007-dcd5281c1c71">7,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8c56aac02e0548818298a1b40775502a_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTQtMS0xLTEwOTYxOA_c828882a-1272-4eeb-91f1-b5df89c7ce1f">653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="iad0b882b89ca4bc19848d14f02c8a322_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTctMS0xLTEwOTYxOA_a545588d-cf59-4a38-8d3e-446205a2b3bb">1,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87deb100db7642138360f124b7b83f30_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTEwLTEtMS0xMDk2MTg_49da6d7a-5193-4f5e-9aab-3d3585427d60">3,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i07001daad34a409cb04dc3e2f9fddf5d_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTEzLTEtMS0xMDk2MTg_c4df6b47-2fc7-44a1-8fe9-0aa4cdce8948">298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib6db54fee24e4009b68217ec1b72ecdb_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTE2LTEtMS0xMDk2MTg_124b4d73-523f-4c03-a18f-da07275d3374">12,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1d43267d2666482cbd65715b80893cc7_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTEtMS0xLTEwOTYxOA_48882fb3-0560-40ed-89d8-27db713f9f9b">1,590</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iab1da6a1258a4f2f824c654908d097f9_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTQtMS0xLTEwOTYxOA_8b39c143-7403-4922-a755-63c28232e5d5">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibcab65890a354c7eb8e9eaaa6083e002_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTctMS0xLTEwOTYxOA_6211cd89-1a98-4780-9453-c53a77b7150e">186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1330a3506b934eb6a59f96f40d105eca_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTEwLTEtMS0xMDk2MTg_0fd7f143-5c70-473d-b3c7-47d350edba7d">6,001</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i60ae0c8e6c1242e094cae93b6edbc064_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTEzLTEtMS0xMDk2MTg_4ec01da6-e139-43c2-8e9c-8f4cb3603023">309</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTE2LTEtMS0xMDk2MTg_18d24150-75a3-4372-a29b-3e3c1a3135da">8,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_283"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90ZXh0cmVnaW9uOmNmODhkMTE2MzJlZjRiOWZiM2JmNjQyMTg2ZWNlMDMwXzEz_05a7c547-489b-45df-87b1-5ad9e3470cd6" continuedAt="i44988bd083df4f458442065a092c7b11" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="i44988bd083df4f458442065a092c7b11"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90ZXh0cmVnaW9uOmNmODhkMTE2MzJlZjRiOWZiM2JmNjQyMTg2ZWNlMDMwXzE0_d46444e7-51e8-4e29-923b-4587f6ce99ed" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Software</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i322fcb8657fc434286b60a943aabbd22_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzMtMS0xLTEtMTA5NjE4_db2f0b06-1bbc-4d92-81a4-9387de0798e3">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2a000e55273047dba1042898c89c120b_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzQtMS0xLTEtMTA5NjE4_7a0e52c7-dfb1-4824-8d5c-f3d7d8440868">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i2a000e55273047dba1042898c89c120b_D20220101-20221231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzUtMS0xLTEtMTA5NjE4_509812ac-a182-4f45-9840-af9406ecb099">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i40f2da050b044a43bb1f4bbaaedd6819_I20221231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzYtMS0xLTEtMTA5NjE4_e0ce944d-a746-4510-8923-389752d43387">2,122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i14e65b8ceef04aa9a9e140cd7cd7c323_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzgtMS0xLTEtMTA5NjE4_ab599e5c-1034-4a8d-b1e6-196d16ce1354">1,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i137ae661167d42648f19a81509b45e09_D20220101-20221231" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzktMS0xLTEtMTA5NjE4_5432010a-48dc-4d11-9598-d0517fc876aa">299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i137ae661167d42648f19a81509b45e09_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzEwLTEtMS0xLTEwOTYxOA_8e561c45-13dd-4450-8cae-655030ff6db9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib61e00b45a7c4b488678787526592c08_I20221231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzExLTEtMS0xLTEwOTYxOA_8238ed11-19aa-4b92-9cc9-fcde8d71b1a4">1,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib0a2cc30e5c64038a201d238fbf11978_I20221231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzEyLTEtMS0xLTEwOTYxOA_3ebd2231-3e9c-4e59-911e-b7d4c15f8ad0">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Software</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if9c8f0e30de34329b9dd662589d2625a_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzMtMS0xLTEtMTA5NjE4_10f43fc5-4fd8-4639-91fa-6fbad95a911a">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iaf6e38e9a01048c6a7e34827d9d57b9c_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzQtMS0xLTEtMTA5NjE4_a8e27e30-a623-485f-bb34-c35bd7c006aa">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iaf6e38e9a01048c6a7e34827d9d57b9c_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzUtMS0xLTEtMTA5NjE4_39c08f3d-0b46-459c-a186-0805201afb4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i322fcb8657fc434286b60a943aabbd22_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzYtMS0xLTEtMTA5NjE4_9fe68a58-f2f3-46a6-8cb8-10b731592f43">1,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib278e099451c4b7e9229b48c30d76025_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzgtMS0xLTEtMTA5NjE4_5b04a528-7dbc-4b13-a4ef-ecc04c7f7458">1,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ia8bbbdd9cb75406c8df9b0ed579152dd_D20210101-20211231" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzktMS0xLTEtMTA5NjE4_1f5342a8-764f-4a83-a3a4-0a3ff48fcb88">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia8bbbdd9cb75406c8df9b0ed579152dd_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzEwLTEtMS0xLTEwOTYxOA_2a3d2449-d1bc-4f1d-8bc7-b2f5afbd8daf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i14e65b8ceef04aa9a9e140cd7cd7c323_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzExLTEtMS0xLTEwOTYxOA_21290e9c-273f-49de-8d8b-6a4741b89f3a">1,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i0ef84e56318a489a8550043d9384b54b_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzEyLTEtMS0xLTEwOTYxOA_c976360d-6d59-4848-abcb-482071c0f229">331</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_286"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90ZXh0cmVnaW9uOmE5NjU4MDcxNzk0YzRhMTRiOTJiNmExNjIzNjQyNmUwXzIz_7f81f168-28a0-4ded-ab9f-000d94432c7b" continuedAt="id756359018a0440da6e9a45666596131" escape="true">Financial instruments</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><ix:continuation id="id756359018a0440da6e9a45666596131" continuedAt="i396070f7dda4452e8c9cd89bd5a824b2"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90ZXh0cmVnaW9uOmE5NjU4MDcxNzk0YzRhMTRiOTJiNmExNjIzNjQyNmUwXzI0_f1f1b94c-ed6b-40ed-8b24-ffa4b8ed8167" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets at amortized costs</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iac28997728a9430bb0713563ae32e639_I20221231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzItMS0xLTEtMTA5NjE4_0cb13c15-28a3-4e9c-b170-13a28ba3702e">87,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id7a6529b985e46fea5bb9ea34f1efa71_I20221231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzMtMS0xLTEtMTA5NjE4_25e4c455-bc41-4c85-9683-646798f764f7">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i08f2c57f37114335bb14a01f1e265d33_I20221231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzQtMS0xLTEtMTA5NjE4_e54c82a3-e12a-46af-a158-4dc648d2dff8">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5978b0e87e0e41418a1eb6893998c62a_I20221231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzUtMS0xLTEtMTA5NjE4_831f1cb4-f130-444c-b087-1120b23c450f">161,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9bef516c67454da38f24cc8f5ef7b00f_I20221231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzYtMS0xLTEtMTA5NjE4_b614a088-d64d-4d47-8a92-29ddf3919073">250,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifd992de4c1764c598225f05b506bb29b_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzgtMS0xLTEtMTA5NjE4_a87adb07-7fbd-42ef-8052-0cf19f9d1966">71,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i829b948cf2c94f18aebf743811865ac2_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzktMS0xLTEtMTA5NjE4_1bc21463-1ea0-4a4c-b357-5d8d53213400">23,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id32257a4e4494aacb101dba09b0114a2_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzEwLTEtMS0xLTEwOTYxOA_e0393618-61ab-4bc0-b1fa-a3969dca54b3">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic6313d1eb0624defb28c64aa01dea0b9_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzExLTEtMS0xLTEwOTYxOA_839b31e9-3fbb-41be-bded-68bb9a99bd0d">61,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9789cf293a2a4a9b8bb9f043c05612a7_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzEyLTEtMS0xLTEwOTYxOA_1e623582-0ee3-4919-ad17-9d37359f2160">156,599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i396070f7dda4452e8c9cd89bd5a824b2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above mentioned amounts were neither past due nor impaired at the end of the respective reporting period and were of highly rated quality. Please also see note 25.</span></div><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90ZXh0cmVnaW9uOmE5NjU4MDcxNzk0YzRhMTRiOTJiNmExNjIzNjQyNmUwXzI1_30d2ae15-b76b-4a64-8c87-6cf0abf78654" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities at amortized cost</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i61b9f00779e44405b197ec74e74a0439_I20221231" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzItMS0xLTEtMTA5NjE4_59a1b763-02cb-4114-9ad0-7a1cbdfef64e">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie27040b2af4143aab5074a6b04e2ced4_I20221231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzMtMS0xLTEtMTA5NjE4_b5bc85b7-67d0-42db-b1a6-e83d195ef382">2,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i587a7a797df14da6b6b0b353a5dbac42_I20221231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzQtMS0xLTEtMTA5NjE4_340d6fd6-7002-46e3-8fa6-e91778270fba">4,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-employee related accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i28fffe2b94ca408ca522a3764d0a9a7d_I20221231" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzUtMS0xLTEtMTA5NjE4_fddbb4b1-42b2-45c3-a3f0-f8585434e58f">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ideda6d7323e8434683a468cdbdbfaad9_I20221231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzYtMS0xLTEtMTA5NjE4_10ece931-0e18-47ab-9574-b9d245989adb">8,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i304edf7fc9dc4af086181703ec172bbf_I20211231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzgtMS0xLTEtMTA5NjE4_bab1c094-a602-4e2a-a9ad-14313ad64af3">4,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i786fc55946ab49a5b3e6894295ca6683_I20211231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzktMS0xLTEtMTA5NjE4_73435e0c-a2f3-4ce3-993a-2f3d7d2d1eae">3,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iff33ff9bbe6c47fdacddc7317235393c_I20211231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzEwLTEtMS0xLTEwOTYxOA_839474a6-76ba-443b-a543-5a9983c1779a">6,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-employee related accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5f4ee1fc220b4633b70d08183faf0864_I20211231" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzExLTEtMS0xLTEwOTYxOA_fea76590-4a00-4a96-aa3b-bd8a25d6e843">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i4bddec936def48f8835419a973c2564e_I20211231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzEyLTEtMS0xLTEwOTYxOA_77c07ee8-95fb-4dc8-962d-33d7e06e2059">14,848</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of financial assets and financial liabilities not measured at fair value (except for lease liabilities) is a reasonable approximation of fair value.</span></div></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_289"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90ZXh0cmVnaW9uOmZjMjliZTUyNWFlOTRmNzU4MDdmODQ3YTEwNmM2MTc3XzE5_aaea3d8d-bd61-4f34-ab75-7075529dbe5c" continuedAt="iee230caeee4b4196bab4d7abd920ae2d" escape="true">Other current assets</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><ix:continuation id="iee230caeee4b4196bab4d7abd920ae2d"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90ZXh0cmVnaW9uOmZjMjliZTUyNWFlOTRmNzU4MDdmODQ3YTEwNmM2MTc3XzIw_26b32305-37c9-43a6-b61d-b14b50e4c492" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzEtMS0xLTEtMTA5NjE4_9bf5224a-bcb1-46f9-8030-52633f7b6fba">3,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzEtNC0xLTEtMTA5NjE4_413cfe8a-5717-49a9-af7e-0d4ac09ec97d">5,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentAccruedIncomeOtherThanCurrentContractAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzItMS0xLTEtMTA5NjE4_5daacd73-2bd0-4a71-a14d-c5693ec894d2">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentAccruedIncomeOtherThanCurrentContractAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzItNC0xLTEtMTA5NjE4_a06ebd44-9ec1-4cf8-9986-070ef611133c">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzMtMS0xLTEtMTA5NjE4_634c7335-2118-483b-8d14-04748083f60c">4,589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzMtNC0xLTEtMTA5NjE4_25b5d011-a48e-42e4-a94e-bb9be9ea801a">5,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_292"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90ZXh0cmVnaW9uOjAwZTNiYTczYjgyMzQ3ZTVhNGI0MjU5OTQyZTEwMzBjXzQ0_3e360874-eea2-46e0-95c2-c22afdf64ed2" continuedAt="i97ca2e1acdfd45839cb2878c052b2d6a" escape="true">Trade and other receivables</ix:nonNumeric></span></div><ix:continuation id="i97ca2e1acdfd45839cb2878c052b2d6a"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90ZXh0cmVnaW9uOjAwZTNiYTczYjgyMzQ3ZTVhNGI0MjU5OTQyZTEwMzBjXzQ1_3da8b6b2-71be-4fb8-b32a-7d7de5f012d4" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzEtMS0xLTEtMTA5NjE4_09cc10d2-58d7-4364-91fe-152fdffb6d34">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzEtNC0xLTEtMTA5NjE4_30ce7643-fc88-4f9e-8249-74910e007c7b">23,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value added tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzItMS0xLTEtMTA5NjE4_813634dd-76a7-4944-86b2-da529956c367">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzItNC0xLTEtMTA5NjE4_08b91915-1adc-47d9-8ff8-6c3817ca6df9">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Withholding tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzMtMS0xLTEtMTA5NjE4_b01c0a93-b460-47d6-b92f-a7d7aa6bc434">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzMtNC0xLTEtMTA5NjE4_2d04b67d-ed21-487e-a3a3-fa090b9c122e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzQtMS0xLTEtMTA5NjE4_0b74f371-92a9-4d20-b706-baafe9d840e1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzQtNC0xLTEtMTA5NjE4_d8f014a9-98aa-4280-ba11-984eb974969b">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzUtMS0xLTEtMTA5NjE4_f04bcdb6-0066-4ebe-9557-0dd4a6d0f114">1,019</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzUtNC0xLTEtMTA5NjE4_3931eea3-3229-43c8-a288-2748fe89c43f">25,650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables are denominated in the following currencies:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzEtMS0xLTEtMTA5NjE4_980d801e-11e1-4037-9962-b792e73c5997">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzEtNC0xLTEtMTA5NjE4_f6f1ef66-2741-4d41-8204-3de36963488e">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzItMS0xLTEtMTA5NjE4_2c8e216a-24ba-4633-9469-0e2b7a0c9d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzItNC0xLTEtMTA5NjE4_fcb07f3d-e206-4fbf-94bc-fa3665c202bf">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzMtMS0xLTEtMTA5NjE4_9bc7619d-7903-4827-b4ef-2956d5d68905">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzMtNC0xLTEtMTA5NjE4_20245feb-70ac-4a57-9cfe-f6a914dd5423">19,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzQtMS0xLTEtMTA5NjE4_d1104317-ae6e-43c0-8869-9fdfc972b093">521</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzQtNC0xLTEtMTA5NjE4_391b79b7-d3cb-4dae-a904-5d654cf427b6">23,710</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in trade receivables for 2022 mainly related to the License and Collaboration Agreement with Novartis entered into in December 2021. The amount invoiced to Novartis in December 2021 was received in cash in January 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_295"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0_7c86ee19-7297-4d19-93a2-4ab90a8488a0" continuedAt="iedf3ff5a8c1c4f38a11201ce9613027e" escape="true">Cash, cash equivalents and short-term time deposits</ix:nonNumeric></span></div><ix:continuation id="iedf3ff5a8c1c4f38a11201ce9613027e"><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU1_14a644af-2eef-45a3-8b19-2895e588618e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzEtMS0xLTEtMTA5NjE4_3147ae58-67f4-4534-9ee4-11eec58f461f">67,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzEtNC0xLTEtMTA5NjE4_77e20fdf-b95c-42f7-a309-c6d997560c6e">44,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzItMS0xLTEtMTA5NjE4_101eb846-5d02-4f43-9e8a-7925878a4eda">7,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzItNC0xLTEtMTA5NjE4_69229f1d-09c3-472e-af4b-7bb1fcb4c602">20,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzMtMS0xLTEtMTA5NjE4_58b124c8-3d96-4733-9ee8-8d8b297b2bda">12,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzMtNC0xLTEtMTA5NjE4_55adb384-df3a-43d5-b7b2-47307a7265ba">5,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifd1e5f5e6ec145b3bceebef0cf07f8db_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzQtMS0xLTEtMTA5NjE4_d279fa45-6e72-40d8-ab86-8def7f26f01a">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iee446437d91845ccb79f71155459c929_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzQtNC0xLTEtMTA5NjE4_989d3b54-958d-47e0-a309-d5434c85c35c">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total cash at bank at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzUtMS0xLTEtMTA5NjE4_319740a7-3ec2-4b81-8cf5-6e8b6044e1fd">87,946</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzUtNC0xLTEtMTA5NjE4_13057b77-f90e-489d-b786-05b735281cad">71,813</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzctMS0xLTEtMTA5NjE4_2220eac0-b7e2-4be9-882d-4732b410e76d">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzctNC0xLTEtMTA5NjE4_41a28201-cd5d-4bc7-abb6-4d94e93ccb4d">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtMS0xLTEtMTEyNzMw_6b445bbf-4d1c-4e0a-902d-0efe35950c9b">4,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtNC0xLTEtMTEyNzMz_f232b5fd-1b0d-414e-a416-e7a6f8425d61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in USD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtMS0xLTEtMTA5NjE4_c431faef-8719-481a-96eb-922e024fae91">46,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtNC0xLTEtMTA5NjE4_d5d0d166-ff01-41f3-96d7-0c8a2eca8f18">41,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total short-term deposits at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzktMS0xLTEtMTA5NjE4_f851f675-053a-4050-ac6a-34e780984d4d">161,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzktNC0xLTEtMTA5NjE4_07537003-90b5-46b0-ba2d-de5166a54e7f">61,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The short-term time deposits denominated in CHF at December&#160;31, 2022 contained <ix:nonFraction unitRef="position" contextRef="i150e9865322b40bf976dd456472c9667_D20220101-20221231" decimals="INF" name="moln:NumberOfShortTermTimeDepositPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk1Nw_496e8fe0-f11b-459d-b2be-aa5f2301d05b">six</ix:nonFraction> positions with <ix:nonFraction unitRef="bank" contextRef="i150e9865322b40bf976dd456472c9667_D20220101-20221231" decimals="INF" name="moln:NumberOfBanksWhereDepositsAreHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk2Mw_ded9d2e7-a6fb-4f26-922d-08fc9ce51cd4">three</ix:nonFraction> Swiss banks, the short-term time deposits denominated in USD contained <ix:nonFraction unitRef="position" contextRef="ie1e6b625e94e4ef8b99a049db65e38b2_D20220101-20221231" decimals="INF" name="moln:NumberOfShortTermTimeDepositPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk2OQ_d48b83f3-f430-43b6-8fb8-162e615af340">three</ix:nonFraction> positions with <ix:nonFraction unitRef="bank" contextRef="ie1e6b625e94e4ef8b99a049db65e38b2_D20220101-20221231" decimals="INF" name="moln:NumberOfBanksWhereDepositsAreHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk3NQ_39e198fd-edd0-434b-9347-961152bf1408">three</ix:nonFraction> Swiss banks and the short-term time deposits denominated in EUR contained <ix:nonFraction unitRef="position" contextRef="i297e474b905f4802b3fc5c84517b4244_D20220101-20221231" decimals="INF" name="moln:NumberOfShortTermTimeDepositPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk4MQ_c6ed3146-6107-40b5-b698-c59eda184b68">one</ix:nonFraction> position with <ix:nonFraction unitRef="bank" contextRef="i297e474b905f4802b3fc5c84517b4244_D20220101-20221231" decimals="INF" name="moln:NumberOfBanksWhereDepositsAreHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzEwOTk1MTE2Mjg3MjI_371ec1cd-45ca-4356-a478-afa7a584ae5f">one</ix:nonFraction> Swiss bank. The short-term time deposits in CHF at December&#160;31, 2021 contained <ix:nonFraction unitRef="position" contextRef="if62d6f3c76c74566abf3f5f15fb7e4a0_D20210101-20211231" decimals="INF" name="moln:NumberOfShortTermTimeDepositPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk5OQ_0f39775a-986b-4201-93dc-1235de1a881e">one</ix:nonFraction> position with <ix:nonFraction unitRef="bank" contextRef="if62d6f3c76c74566abf3f5f15fb7e4a0_D20210101-20211231" decimals="INF" name="moln:NumberOfBanksWhereDepositsAreHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxNDAwNQ_84a04cb8-728e-46c4-b3bb-ea3740cb5182">one</ix:nonFraction> Swiss bank and the short-term time deposits denominated in USD contained <ix:nonFraction unitRef="position" contextRef="i7b4cf686055c46f0990c5475b479feab_D20210101-20211231" decimals="INF" name="moln:NumberOfShortTermTimeDepositPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxNDAxMQ_6e43514a-8baa-4f25-a860-9b30d040286c">three</ix:nonFraction> positions with <ix:nonFraction unitRef="bank" contextRef="i7b4cf686055c46f0990c5475b479feab_D20210101-20211231" decimals="INF" name="moln:NumberOfBanksWhereDepositsAreHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxNDAxNw_d7b6affa-3cc4-4f26-89a9-ef38e6fbad36">two</ix:nonFraction> Swiss banks. Please also refer to note 25.</span></div></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_298"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Shareholders&#8217; equity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i92a813a501bc4b9b8b3d48933008d151_I20220831" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI1OA_ff7df3f8-69f4-44e7-a1ed-8cfa815f67db">3,500,000</ix:nonFraction> common shares at par value CHF <ix:nonFraction unitRef="chfPerShare" contextRef="i92a813a501bc4b9b8b3d48933008d151_I20220831" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI2NA_d967de99-e585-4b40-bfea-5f1a25803be2">0.10</ix:nonFraction> per share. The shares were fully subscribed for by Molecular Partners Inc., a fully owned subsidiary of the Company. As of December&#160;31, 2022, all <ix:nonFraction unitRef="shares" contextRef="i92a813a501bc4b9b8b3d48933008d151_I20220831" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI3Ng_ff7df3f8-69f4-44e7-a1ed-8cfa815f67db">3,500,000</ix:nonFraction> common shares were held as treasury shares of the Company. The purpose of the share issuance was to replenish the Company&#8217;s pool of treasury shares that the Company can use in the future to raise funds, including in connection with the Company&#8217;s at-the-market sales program for American Depositary Shares established in July 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount presented as Treasury shares reserve in the consolidated statement of financial position, is comprised of CHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:TreasurySharesNominalValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI5OA_44a40820-c2cf-4509-89b7-360ec8a22b23">350,000</ix:nonFraction> of the nominal value of the treasury shares and CHF <ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="0" name="moln:IssuanceCostsOfTreasuryShareTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDMwNA_6107347a-01bd-4e41-a1c2-e708fac7fa4b">631,336</ix:nonFraction> of transaction costs incurred directly related to the issuance. The amount of CHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:TreasurySharesNominalValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDMxMw_44a40820-c2cf-4509-89b7-360ec8a22b23">350,000</ix:nonFraction> is a non-cash transaction for the Group. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Classes of share capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ordinary share capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, the Company&#8217;s issued share capital amounted to CHF <ix:nonFraction unitRef="chf" contextRef="ida1ef664b85047599beb657c0edeb373_I20221231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU3_c5e85fcb-7b0e-4cc2-9950-5d14b675e777">3,604,471</ix:nonFraction> divided into <ix:nonFraction unitRef="shares" contextRef="ida1ef664b85047599beb657c0edeb373_I20221231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzYx_fdf6a476-6edb-4982-9b75-18524d1367fa">36,044,706</ix:nonFraction> fully paid registered shares with a par value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzY1_4bb43c96-8366-4918-875f-1250f34073d3">0.10</ix:nonFraction> each. Ordinary shares are entitled to <ix:nonFraction unitRef="vote" contextRef="ibdf5c6ab807f470abff7a20928b54739_D20220101-20221231" decimals="INF" name="moln:NumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2Xzkz_163dac0f-9770-4ae4-9c5e-ae7950e5a1e6">one</ix:nonFraction> vote per share and rank equally with regard to the Company's residual assets and dividends (if any should be declared in the future).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzIxOTkwMjMyNjQ1MTI_5c357942-054a-46b5-99ef-c71f9dcb6797" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:74.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt 0 1.02pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ordinary shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzEtMS0xLTEtMTM0MTk0_ca733041-fa0e-43b5-bc7e-5ec8d82784af">21,601,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to capital raise in July 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="INF" name="moln:NumberOfSharesIssuedInRelationToCapitalRaiseEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzItMS0xLTEtMTM0MTk0_0e744fa7-1e19-4fc3-9b87-3ca9649c074d">5,528,089</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to Novartis agreement in October 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="INF" name="moln:NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzMtMS0xLTEtMTM0MTk0_e702815d-4250-447a-a5b2-ea1b3e697243">1,739,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to vesting of PSU, RSU and options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="INF" name="moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzQtMS0xLTEtMTM0MTk0_ceabd18a-6007-429f-b2ef-cd14512b88ed">278,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzItMS0xLTEtMTMxNjA0_a8fcbcc8-9458-4bcc-935c-b4135b56b828">29,146,992</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to June 2021 IPO</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzMtMS0xLTEtMTMxNjA0_9db348d7-611e-41ee-8394-f32969d9c02b">3,000,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to vesting of PSU, RSU and options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzQtMS0xLTEtMTMxNjA0_1632d346-5480-4c79-a919-3d9bc0e19b71">145,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzUtMS0xLTEtMTMxNjA0_790f416e-0672-4d8a-a386-301adce93c2b">32,292,648</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to creation of treasury shares in August 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfSharesIssuedTreasurySharesEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzYtMS0xLTEtMTMxNjA0_c3517173-22d5-4483-8904-67f2c6f84a9b">3,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to vesting of PSU, RSU and options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzctMS0xLTEtMTMxNjA0_8e7ca176-97c3-4444-b1bd-03a5cb9e67ef">252,058</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzgtMS0xLTEtMTMxNjA0_4637e177-b193-458c-9528-78db7c1e6c66">36,044,706</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share capital registered with the Swiss Commercial Register on December&#160;31, 2022 amounted to CHF <ix:nonFraction unitRef="chf" contextRef="i95512f09473b4296a07c0bf49732b9f3_I20221231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwMQ_fe18e0cd-6b91-4916-9a32-599a64924b2f">3,579,265</ix:nonFraction> divided into <ix:nonFraction unitRef="shares" contextRef="i95512f09473b4296a07c0bf49732b9f3_I20221231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwNQ_e35ef410-d149-4ff2-b7c3-b47396376f6e">35,792,648</ix:nonFraction> fully paid up registered shares with a par value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOQ_3d75aa8f-fb1c-4327-8a65-c8648321d60a">0.10</ix:nonFraction> per share. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corresponding capital increases in 2022 were registered with the commercial register in two steps on August&#160;25, 2022 for the treasury shares and on February&#160;3, 2023 for the option exercises and the vesting of Performance Share Units ("PSU") and Restricted Share Units ("RSU"), from the RSU Plan 2019 and the PSU Plans 2021, 2019 and 2018.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corresponding capital increases in 2021 were registered with the commercial register in two steps on June&#160;18, 2021 for the transaction in June and on February&#160;16, 2022 for the option exercises and the vesting of the RSU plan 2018 and the PSU plans 2018 and 2017.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, the Company had an authorized share capital in the amount of up to CHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="0" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMDY_56bb8dee-f8c9-46ee-838b-0969383952e9">457,316</ix:nonFraction> through the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMTI_6754a41e-52f3-4f53-bd65-2cd36b3dc1b2">4,573,162</ix:nonFraction> fully paid up registered shares with a par value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMTg_b859f619-8fe6-48a2-b24c-53ad031a3597">0.10</ix:nonFraction> per share, which is valid until April&#160;13, 2024. This authorized capital of up to CHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="0" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMzA_56bb8dee-f8c9-46ee-838b-0969383952e9">457,316</ix:nonFraction> equates to approximately <ix:nonFraction unitRef="number" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMzY_48e43d46-ae6d-4c6e-98cb-9fa8bb5cdcf6">13</ix:nonFraction>% of the existing share capital. As approved by the annual general meeting on April&#160;13, 2022, the authorized share capital was increased by CHF <ix:nonFraction unitRef="chf" contextRef="i36e31ef12d534128ba81206be595d4b6_D20220413-20220413" decimals="0" name="moln:IncreaseDecreaseInAuthorizedShareCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNDg_5e82de81-cde3-4a37-9cc0-7a984dadbacd">378,641</ix:nonFraction> from CHF <ix:nonFraction unitRef="chf" contextRef="iffee4313ed1e4200a7baafdb5092cc29_I20220412" decimals="0" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNTQ_956fae05-548d-4f46-87bd-dc59e6f3ff84">428,675</ix:nonFraction> to CHF <ix:nonFraction unitRef="chf" contextRef="i226a1800b6a24a9ab618c75812acf641_I20220413" decimals="0" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNjA_9eb1bca8-6771-4335-8e7b-102976eb30f5">807,316</ix:nonFraction>. In August 2022, the authorized share capital was subsequently reduced by CHF <ix:nonFraction unitRef="chf" contextRef="iaf0473678da046f9afdd55eced60e2d5_D20220801-20220831" decimals="INF" sign="-" name="moln:IncreaseDecreaseInAuthorizedShareCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNjY_3aa8c6be-7bde-4533-980c-b4a83f248b0f">350,000</ix:nonFraction> from CHF <ix:nonFraction unitRef="chf" contextRef="i226a1800b6a24a9ab618c75812acf641_I20220413" decimals="0" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNzI_9eb1bca8-6771-4335-8e7b-102976eb30f5">807,316</ix:nonFraction> to CHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="0" name="moln:MaximumAmountOfShareCapitalIncreaseAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNzg_56bb8dee-f8c9-46ee-838b-0969383952e9">457,316</ix:nonFraction> due to the creation of treasury shares.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is authorized to determine the issue price, type of payment, time of the issuance, conditions for the exercise of the preemptive rights and the date from which the shares carry the right to dividends. The Board of Directors can issue new shares by means of an underwriting arrangement by a bank or another third party with a subsequent offer of these shares to the existing shareholders or third parties (if the preemptive rights of the existing shareholders have been denied or not been duly exercised). The Board of Directors is authorized to permit, to restrict or to deny the trade of preemptive rights. The Board of Directors may permit preemptive rights that have been granted but not exercised to expire or it may place these rights respectively the shares as to which preemptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interest of the Group.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is further authorized to restrict or deny the preemptive rights of shareholders and to allocate them to third parties: (a) for the acquisition of companies, parts of companies or participations, for the acquisition of products, intellectual property or licenses, for investment projects or for the financing or refinancing of such transactions through a placement of shares, (b) for the purpose of broadening the shareholder constituency or in connection with a listing of shares on domestic or foreign stock exchanges, (c) if the issue price of the new shares is determined by reference to the market price, (d) for purposes of granting an over-allotment option (greenshoe) of up to <ix:nonFraction unitRef="number" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI1NQ_51cd63d8-9db0-4951-bbd1-64ba3e77e964">20</ix:nonFraction>% of the total number of shares in a placement or sale of shares to the respective initial purchasers or underwriters, (e) following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of <ix:nonFraction unitRef="number" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI1OQ_f24299ce-bdf1-4b9f-b714-8278f1fbf4dc">15</ix:nonFraction>% of the share capital registered with the commercial register of the Canton of Zurich, without having submitted to the other shareholders a take-over offer recommended by the Board of Directors, or (f) </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the defense of an actual, threatened or potential takeover bid, in relation to which the Board of Directors has not recommended to the shareholders acceptance on the basis that the Board of Directors has not found the takeover bid to be financially fair to the shareholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conditional share capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 the Company&#8217;s share capital was allowed to be increased by an amount not to exceed CHF <ix:nonFraction unitRef="chf" contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231" decimals="0" name="moln:AuthorizedShareCapitalEmployeeParticipation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI3Mw_d083bd9d-5812-4055-ba76-f1caf5f2dd7a">136,296</ix:nonFraction> through the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231" decimals="INF" name="moln:NumberOfSharesAuthorizedEmployeeParticipation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI3Nw_80a819c1-7c60-45b9-8b88-a75d6f5b3623">1,362,963</ix:nonFraction> fully paid up shares with a par value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI4MQ_9aa6eec6-8bc8-49fc-ac8c-b3a5e3461153">0.10</ix:nonFraction> per share through the direct or indirect issuance of shares, options or preemptive rights granted to employees, members of the Board of Directors or members of any advisory boards. During 2022, the share capital was increased out of this conditional capital for employee participation (Article 3b of the Articles of Association). As a result, the available conditional capital for employee participation was reduced by CHF <ix:nonFraction unitRef="chf" contextRef="i13a375d0b11f458fbd6bc7e1aaf8675f_D20220101-20221231" decimals="0" sign="-" name="moln:IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI4OQ_222c9aa7-e944-4108-8b86-28a4f4caef15">25,206</ix:nonFraction> from CHF <ix:nonFraction unitRef="chf" contextRef="i9ddb4cbe7d484358b5bf5ba0089d4386_I20211231" decimals="0" name="moln:AuthorizedShareCapitalEmployeeParticipation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI5Mw_bffe0ad4-358d-4ee0-898f-933ba618a934">161,502</ix:nonFraction> to CHF <ix:nonFraction unitRef="chf" contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231" decimals="0" name="moln:AuthorizedShareCapitalEmployeeParticipation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI5Nw_d083bd9d-5812-4055-ba76-f1caf5f2dd7a">136,296</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the share capital may be increased by an amount not to exceed CHF <ix:nonFraction unitRef="chf" contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231" decimals="INF" name="moln:AuthorizedShareCapitalFinancingTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMwMQ_41029f86-515f-4269-85f7-b3bdac49417f">226,087</ix:nonFraction> through the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231" decimals="INF" name="moln:NumberOfSharesAuthorizedFinancingTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMwNQ_70b0a1e3-a835-4c75-bcf2-8293e4e23cba">2,260,870</ix:nonFraction> fully paid up shares with a par value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMwOQ_7353ea4e-695b-44a0-9898-e1cca5c92635">0.10</ix:nonFraction> per share through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights for the subscription of shares granted to shareholders or third parties alone or in connection with bonds, notes, options, warrants or other securities or contractual obligations by or of the Company. During 2022, this conditional capital for financing transactions and other purposes (Article 3c of the Articles of Association) remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the cash proceeds from the exercise of share options and the vesting of Performance Share Units (&#8220;PSU&#8221;) and Restricted Share Units ("RSU"), amounted to CHF <ix:nonFraction unitRef="chf" contextRef="i5b22ff48cfa44ceaa5de97b4809b8b54_D20220101-20221231" decimals="0" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMyMQ_471f11b6-90f1-43d7-a0a4-ea021d874e34">251,957</ix:nonFraction> and all was completed from the issuance of new shares (conditional share capital). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the cash proceeds from the exercise of share options and the vesting of Performance Share Units (&#8220;PSU&#8221;) and Restricted Share Units ("RSU"), amounted to CHF <ix:nonFraction unitRef="chf" contextRef="i23a22766f4574cdab095ce240d4ab462_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMyOQ_338fa3e4-0023-4315-a75d-6284c73f6135">269,552</ix:nonFraction> and all was completed from the issuance of new shares (conditional share capital). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the cash proceeds from the exercise of share options and the vesting of Performance Share Units (&#8220;PSU&#8221;) and Restricted Share Units ("RSU"), amounted to CHF <ix:nonFraction unitRef="chf" contextRef="ie47af3905cff436a87efc3199975fdcc_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzM0MA_b2901e70-914c-45f7-9355-4718037f4341">848,340</ix:nonFraction> and all was completed from the issuance of new shares (conditional share capital). </span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_301"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90ZXh0cmVnaW9uOjU2MWZkNDYyNGQ2ZjRmYzQ5NTYwNDcyMDE3ZDk2Y2EzXzE3_cb251fad-a3d0-4714-9bb5-358625f025dc" continuedAt="i9d67f59c5d0040f3b9a760d33728a387" escape="true">Trade and other payables</ix:nonNumeric></span></div><ix:continuation id="i9d67f59c5d0040f3b9a760d33728a387"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90ZXh0cmVnaW9uOjU2MWZkNDYyNGQ2ZjRmYzQ5NTYwNDcyMDE3ZDk2Y2EzXzE4_e8877a62-c44a-4d44-82d6-949f391beafe" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzEtMS0xLTEtMTA5NjE4_a469c290-ea4c-4c9b-be23-f93f2d06dfaf">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzEtNC0xLTEtMTA5NjE4_5efb7a8b-76bc-466c-9c16-fa8454ac1c81">4,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social security</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzItMS0xLTEtMTA5NjE4_9bf27f57-c715-4871-b6a3-ff1f99cb9fda">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzItNC0xLTEtMTA5NjE4_fc17a486-6386-4ae1-820e-fd3babfdf771">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value added tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentValueAddedTaxPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzMtMS0xLTEtMTA5NjE4_cc86718a-b631-4499-b762-c2b57997107c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentValueAddedTaxPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzMtNC0xLTEtMTA5NjE4_47350678-37f2-4f9a-9ffa-a66e21f56abb">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzQtMS0xLTEtMTA5NjE4_a073e553-05aa-4e57-bc0c-411ee0379af5">2,143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzQtNC0xLTEtMTA5NjE4_9ff78de3-aeb4-491a-8e19-e1ce1295b9b0">7,389</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables are denominated in the following currencies:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzEtMS0xLTEtMTA5NjE4_8bfb5f89-6e39-4f2c-be41-ac0345995713">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzEtNC0xLTEtMTA5NjE4_6713ce10-cef4-485f-9d82-c557214aad58">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzItMS0xLTEtMTA5NjE4_76c01a50-6125-4d43-af2a-16974f00ad94">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzItNC0xLTEtMTA5NjE4_8039146d-bcc3-4ac7-8a81-5a64dd2bf938">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzMtMS0xLTEtMTA5NjE4_927e884c-4355-44e2-bc40-58cf3735aa1e">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzMtNC0xLTEtMTA5NjE4_8af994ec-b525-46df-94c1-538bad4cbadd">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifd1e5f5e6ec145b3bceebef0cf07f8db_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzQtMS0xLTEtMTA5NjE4_24062f5f-bdef-4731-b5e1-e71fe9290755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iee446437d91845ccb79f71155459c929_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzQtNC0xLTEtMTA5NjE4_1b10e5c0-e81c-49c2-882e-31c396405d85">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzUtMS0xLTEtMTA5NjE4_cb167ca6-1f80-44c4-b694-9124443179fa">997</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzUtNC0xLTEtMTA5NjE4_eff9b995-e76f-465a-b787-4a648f805aa5">4,862</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_304"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90ZXh0cmVnaW9uOjViNzBjZGRiMDkyZTQ3M2U4YWQyM2E2N2VlNDY0MTU1XzEy_78df942e-36c6-48bf-a5f6-1b1dea15df90" continuedAt="i1544243c05d244a88be523a3c48e421e" escape="true">Accrued expenses</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><ix:continuation id="i1544243c05d244a88be523a3c48e421e"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90ZXh0cmVnaW9uOjViNzBjZGRiMDkyZTQ3M2U4YWQyM2E2N2VlNDY0MTU1XzEz_2df09340-b7e8-4cb3-8193-a66d55bb9ad8" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:CurrentAccruedProjectCostsAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzEtMS0xLTEtMTA5NjE4_5294e1c8-965e-487f-a9c7-abd664895d18">2,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="moln:CurrentAccruedProjectCostsAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzEtNC0xLTEtMTA5NjE4_c3b22def-f873-48e8-99ea-5bd0b605c150">3,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued payroll and bonuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzItMS0xLTEtMTA5NjE4_a59faf88-7b8e-4e81-8764-5a65703eb14b">4,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzItNC0xLTEtMTA5NjE4_4aade9ed-35a0-4db6-9d0c-4b49c94ef3d2">6,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzMtMS0xLTEtMTA5NjE4_732db787-2def-4222-bfec-7b34fc490195">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzMtNC0xLTEtMTA5NjE4_ef3c92b5-745c-425b-90a1-9923b022e71f">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzQtMS0xLTEtMTA5NjE4_25700f49-6732-495c-a163-facb1172ce20">7,501</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzQtNC0xLTEtMTA5NjE4_1c627d64-6464-4016-9671-1a472ede597e">9,975</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_307"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzc5_6277c3ee-66b0-44f5-b090-aba5501613a5" continuedAt="ie6da42d9b8ad4554a8b6488bfa31103e" escape="true">Contract liability</ix:nonNumeric></span></div><ix:continuation id="ie6da42d9b8ad4554a8b6488bfa31103e" continuedAt="ibdca822e23024e58b8b6ca8a2b9b94be"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzgw_2b23c3dc-d0c6-40bd-8fdb-1e0354a053c1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group expects the contract liability to be recognized as revenue or, in case of consideration payable to a customer, reduction of costs, as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year one after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i46461ef8c2bf4ad194fcc5da61eb4790_I20221231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzEtMS0xLTEtMTA5NjE4_74e09c35-0ff9-4b5f-8a02-632be26ad020">6,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year two after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i859523f38bfc4cef886b0469de3d3c27_I20221231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzItMS0xLTEtMTA5NjE4_c5b6d1a5-98ae-4218-97ad-15a1d4231698">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year three after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i918edbfe84d34f33a0b487a26eeba31e_I20221231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzMtMS0xLTEtMTA5NjE4_fbf462d7-9dea-4a87-be4d-168e27e8f45d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year four after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i4738c29a9abd4ebdb07a22bac9da094f_I20221231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzQtMS0xLTEtMTA5NjE4_4594fe0e-9784-4a92-b5db-1b5ef3f92660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year five and later after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i44b7ff2364ee43b4a7559bda1f8cfdc7_I20221231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzUtMS0xLTEtMTA5NjE4_b150cb82-a283-45cd-926a-d5de475c8979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzYtMS0xLTEtMTA5NjE4_50583090-ab47-48f1-bec4-eb199c165794">10,046</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year one after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6592e0e0184441c58126d7e24b37d82e_I20211231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzEtMS0xLTEtMTA5NjE4_f501ce41-336a-459a-8597-f8b1c97d33a4">28,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year two after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if56ff0ffb76b4ef7bdd5f9a0f0de46ec_I20211231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzItMS0xLTEtMTA5NjE4_a7486895-1b5a-4644-a6bb-962852412beb">5,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year three after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if631f991ae9c444c817903110fa5596a_I20211231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzMtMS0xLTEtMTA5NjE4_0a8e689c-ae9e-44e1-a832-04d649af5984">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year four after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i16a9cc51038a4f4d95c67fe474148918_I20211231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzQtMS0xLTEtMTA5NjE4_bd63276c-cd3d-47d1-a1d2-39899a3ba77e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year five and later after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic9a4c1ad6eff4eaa80acba6bc1f1a654_I20211231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzUtMS0xLTEtMTA5NjE4_0fbaa059-0b49-4728-8991-9c0beadf2948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzYtMS0xLTEtMTA5NjE4_8e35d122-a010-4d14-9e30-87a066c93455">35,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzgx_9abcb5a4-6eeb-4681-97ab-b42ba78146a4" continuedAt="id36b727f4d614422998a727c4592655c" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the movement on the contract liability:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at January 1,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recognized as revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Offset of costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItMS0xLTEtMTA5NjE4_6a61f981-ab6d-465d-9ab2-ad47642999dc">9,653</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie40be771ab47427dab17aa01b8815550_D20220101-20221231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItNC0xLTEtMTA5NjE4_3512db37-57bf-4116-998b-258e140f7633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ie40be771ab47427dab17aa01b8815550_D20220101-20221231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItNy0xLTEtMTA5NjE4_513696ac-0696-448e-ae32-b20a19b31ac1">9,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie40be771ab47427dab17aa01b8815550_D20220101-20221231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItMTAtMS0xLTEwOTYxOA_8263f15e-ebc9-4496-bd60-4a57ba405b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5e790e4d70ba47b7811ed9628565b55a_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItMTMtMS0xLTEwOTYxOA_86b59d17-3a55-4d2a-b93e-a399fc0d5b1a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i25f724f166614126b409c627fece74f2_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtMS0xLTEtMTA5NjE4_a03cc1a4-26ea-4d9b-8e17-fce92bdc2c86">18,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtNC0xLTEtMTA5NjE4_dc146720-2f72-4d7e-bab4-3497b11d6218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtNy0xLTEtMTA5NjE4_eb7a78b2-9f69-499d-b43c-5a870623d6fb">8,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtMTAtMS0xLTEwOTYxOA_51a283e9-504f-450a-80c2-f8f57e0f758b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtMTMtMS0xLTEwOTYxOA_fd135142-a596-497f-a586-abcaa3a1d581">10,046</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtMS0xLTEtMTA5NjE4_3a10ff36-1264-4294-9dda-9e383eb3ae15">7,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtNC0xLTEtMTA5NjE4_28141207-1118-4218-9a13-59cc82071aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtNy0xLTEtMTA5NjE4_54e10340-c0ca-4062-a373-05caf0019ed8">7,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtMTAtMS0xLTEwOTYxOA_f020218a-ae37-4333-90fd-91c92750fe56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i11110b5c186941989d4682d8c5456ae1_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtMTMtMS0xLTEwOTYxOA_0e17ecec-0826-4257-af2e-df6fb2478e9a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtMS0xLTEtMTA5NjE4_5e04415d-0934-48be-84be-7ae8b75d0a4f">35,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtNC0xLTEtMTA5NjE4_129a0b4b-4889-44f9-a091-7538808a2f1f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtNy0xLTEtMTA5NjE4_261e374d-99c8-4bea-9283-b837928b6ead">25,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtMTAtMS0xLTEwOTYxOA_2c1e0b47-d042-465d-8ae3-dd2ac5126cc0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtMTMtMS0xLTEwOTYxOA_0640ee6d-43a3-41cb-be24-a506bb9b7693">10,046</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibdca822e23024e58b8b6ca8a2b9b94be"><div style="margin-bottom:8pt"><ix:continuation id="id36b727f4d614422998a727c4592655c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at January 1,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recognized as revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Offset of costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="id871d1f18f9746c1968f95282a63c920_I20201231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItMS0xLTEtMTA5NjE4_dbf64ce7-d71e-4b96-9b2f-81aac29df67d">18,983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItNC0xLTEtMTA5NjE4_4d99face-2cee-471f-a4ec-8c7ea4cc71ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItNy0xLTEtMTA5NjE4_b71e982d-b1bb-4f56-9274-c34f1babd988">9,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItMTAtMS0xLTEwOTYxOA_61ce8981-707e-4f2b-a9f9-28c6410eff9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItMTMtMS0xLTEwOTYxOA_81b8c2f1-9941-453c-b507-76a4c6f5cba3">9,653</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i092e160ceafe420685da4b0eed564d63_I20201231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtMS0xLTEtMTA5NjE4_a4f3121d-701e-4f69-a2e1-681c5d09de42">19,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtNC0xLTEtMTA5NjE4_53da3e56-30d2-4782-9e82-91871fc3e32c">18,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtNy0xLTEtMTA5NjE4_ea2d5d25-2f77-4073-b00b-7756e171284d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtMTAtMS0xLTEwOTYxOA_411b0f06-8bed-4467-8f2a-3b48cc4a1ac5">19,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i25f724f166614126b409c627fece74f2_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtMTMtMS0xLTEwOTYxOA_11798456-1627-406b-b1ba-36bc95d9cd9d">18,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtMS0xLTEtMTA5NjE4_4217694d-14df-40ff-8635-cce6224c8d9b">7,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtNC0xLTEtMTA5NjE4_fdfd0e11-2ade-4c26-8c3b-4c2fd7a47651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtNy0xLTEtMTA5NjE4_fbdd8992-0955-46b6-b0a9-dbb1853c3e7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtMTAtMS0xLTEwOTYxOA_9793f80c-5263-4123-9bd4-210f356a0dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtMTMtMS0xLTEwOTYxOA_33107334-bbd4-4221-92ab-a68eb47f09a4">7,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtMS0xLTEtMTA5NjE4_b9664695-fe74-46fc-bf28-d6a244deeb1c">45,887</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:IncreaseThroughAdditionsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtNC0xLTEtMTA5NjE4_ac04206a-d7f5-48bd-ba88-f85ce0b801c2">18,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtNy0xLTEtMTA5NjE4_ee93a9ad-f3fd-42d9-ab00-0c38142ba6df">9,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtMTAtMS0xLTEwOTYxOA_f3c9d6c3-fce6-4c8e-97ca-606a555bfbdf">19,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtMTMtMS0xLTEwOTYxOA_6bd9c00d-8ad9-48d4-a517-1ad0e09ed9f2">35,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License and Collaboration Agreement with Novartis entered into in December 2021 resulted in a contract liability of TCHF <ix:nonFraction unitRef="chf" contextRef="i25f724f166614126b409c627fece74f2_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4XzU5_7c823c5b-9b80-4d69-8e8f-f7b4e5cc3648">18,584</ix:nonFraction> (TUSD <ix:nonFraction unitRef="usd" contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4XzYz_fe3777c6-8696-4f4a-87fc-f74da631a3f7">20,000</ix:nonFraction>). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, an amount of TCHF <ix:nonFraction unitRef="chf" contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231" decimals="-3" name="moln:DecreaseThroughOffsetOfCostsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4XzU0OTc1NTgxNTE0OQ_f7978675-29a8-465d-ab4e-ff1b0964ecec">19,904</ix:nonFraction> has been released to offset a corresponding amount of costs paid to the Novartis Group for the manufacturing of the drug product to establish the commercial supply of MP0420 under the Option and Equity Rights Agreement entered into in October 2020 (see note 5).</span></div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzc4_fca51629-d698-4805-870a-265976533cc9" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzItMS0xLTEtMTA5NjE4_47adf00c-8d74-4f53-b368-8f55eb5d2798">6,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzItNC0xLTEtMTA5NjE4_e2e633b2-fd26-4558-bb19-a28cbc058ea0">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzItNy0xLTEtMTA5NjE4_f50c5494-c912-44db-8271-0be61c0c0a13">10,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzQtMS0xLTEtMTA5NjE4_89388ec2-b0f8-4c52-badd-dbde94653313">6,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzQtNC0xLTEtMTA5NjE4_4f88b97a-553e-4eec-87ef-eb7652bdb7a0">3,637</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzQtNy0xLTEtMTA5NjE4_f693ceaa-2894-4b11-9ebc-2f4e30d2948b">10,046</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzEtMS0xLTEtMTA5NjE4_c5deabe4-af66-4c0c-b097-39fb8be6d5d3">9,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzEtNC0xLTEtMTA5NjE4_47030331-e936-4825-8eb7-cf00ee2c769e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzEtNy0xLTEtMTA5NjE4_b4a394fc-0d13-4fdd-9ca3-191e7eff5c6d">9,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i25f724f166614126b409c627fece74f2_I20211231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzItMS0xLTEtMTA5NjE4_0bf5a028-7d3c-4443-95a1-284dec7e8371">11,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i25f724f166614126b409c627fece74f2_I20211231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzItNC0xLTEtMTA5NjE4_55fba5df-bb1f-4ff7-9d26-6c04556bd7bc">6,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i25f724f166614126b409c627fece74f2_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzItNy0xLTEtMTA5NjE4_36f66bb0-b10f-4863-8b6f-033002d8fd45">18,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzMtMS0xLTEtMTA5NjE4_0c93af43-5c68-4715-8c77-a1cffd347b88">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzMtNC0xLTEtMTA5NjE4_907f34ec-0346-47f5-9ac0-62ebbbc109dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzMtNy0xLTEtMTA5NjE4_88c4ff90-b1c1-4b07-9de7-525b93ace2b3">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzQtMS0xLTEtMTA5NjE4_d55d18aa-63a0-4693-af66-385f914f20a0">28,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzQtNC0xLTEtMTA5NjE4_ce502e71-bcbf-4d6e-ba5c-99c8a273fed5">6,925</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzQtNy0xLTEtMTA5NjE4_c82f6421-c910-4e8a-915c-b79462746a0b">35,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_310"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzYz_49e3629a-7153-43b6-a3be-154eb859e9ae" continuedAt="i4577b1bf0b3e458eb486c32c0d766ebd" escape="true">Additional information on the nature of expenses</ix:nonNumeric></span></div><ix:continuation id="i4577b1bf0b3e458eb486c32c0d766ebd"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzY0_7a511043-05d1-4470-b97a-8df4eca298b5" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and development expenses</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research consumables and external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzItMS0xLTEtMTA5NjE4_e44bd2b4-e155-4711-9bfa-7f29284f9e1b">17,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzItNC0xLTEtMTA5NjE4_2c7af06c-7377-4eee-81d1-763e788323a7">26,342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzItNy0xLTEtMTA5NjE4_49f44d85-8bb1-4e70-99c5-8d19dc7d368a">26,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see also note 18</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzMtMS0xLTEtMTA5NjE4_9695218f-17b4-4edd-a289-d400359f27fd">28,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzMtNC0xLTEtMTA5NjE4_1c583fd7-ba53-45eb-9bb7-e91199446a2b">25,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzMtNy0xLTEtMTA5NjE4_dff0fd1a-aac8-4395-901e-c8e9ae41363c">25,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzQtMS0xLTEtMTA5NjE4_429a317a-4ea0-497c-9abc-5984a2dbc019">1,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzQtNC0xLTEtMTA5NjE4_ad25f186-788d-4a87-b463-6d655b44566c">2,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzQtNy0xLTEtMTA5NjE4_436b3d41-75b0-4027-83dd-fc36a6d2bedf">2,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="moln:IntellectualPropertyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzUtMS0xLTEtMTA5NjE4_c8f11bd5-b5ac-43f7-a5fd-4196378ee485">957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="moln:IntellectualPropertyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzUtNC0xLTEtMTA5NjE4_942df570-fd41-434d-9cee-77dda60fa7e5">636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="moln:IntellectualPropertyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzUtNy0xLTEtMTA5NjE4_9624d49d-8cc6-4230-af37-967a2760ff46">492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="ifrs-full:OccupancyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzYtMS0xLTEtMTA5NjE4_5140d9a2-75a6-477b-9d20-4843597a7b75">854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="ifrs-full:OccupancyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzYtNC0xLTEtMTA5NjE4_8c34b307-03ad-4517-bf00-b588eac199de">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="ifrs-full:OccupancyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzYtNy0xLTEtMTA5NjE4_c272c09a-5ee3-4c3a-a6ef-73e109d5c1f7">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="moln:OtherResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzctMS0xLTEtMTA5NjE4_a7747c98-92d8-4ed4-9f2c-e72cab42bba7">703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="moln:OtherResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzctNC0xLTEtMTA5NjE4_f07a9d62-af7a-4a8b-9407-8bf2e122f683">259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="moln:OtherResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzctNy0xLTEtMTA5NjE4_aaed2ec5-a545-434f-a391-35291f829bdb">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and license fees, see also note 17</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="moln:RoyaltiesAndLicenseFeesExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzgtMS0xLTEtMTA5NjE4_5b4b3807-e36e-46b7-8df8-da71ec9a70cc">1,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="moln:RoyaltiesAndLicenseFeesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzgtNC0xLTEtMTA5NjE4_aab03222-061b-4125-9074-a471689a7211">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="moln:RoyaltiesAndLicenseFeesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzgtNy0xLTEtMTA5NjE4_be2b2c5b-f948-4454-ad5a-76605a1a3e0c">562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzktMS0xLTEtMTA5NjE4_65e59a40-366a-4f77-b1f7-120a6ab30a9f">50,749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzktNC0xLTEtMTA5NjE4_af35379d-d82c-4187-b0e5-805172674ae9">55,718</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzktNy0xLTEtMTA5NjE4_d5a8087f-5cbf-4525-9057-5c41f3804813">56,075</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see also note 18</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzEzLTEtMS0xLTEwOTYxOA_651db15b-a380-4f98-bd38-b29ce00106fc">11,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzEzLTQtMS0xLTEwOTYxOA_6b847969-4d3f-4d7f-9567-885e61a6abeb">10,604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzEzLTctMS0xLTEwOTYxOA_ccc195a2-a8a7-4c11-85ad-cd15c2ca31ac">8,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="ifrs-full:AdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE0LTEtMS0xLTEwOTYxOA_c8d1fa2a-d189-431e-b1fb-8e3019da2f0c">9,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="ifrs-full:AdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE0LTQtMS0xLTEwOTYxOA_41e9b3af-fac9-485e-9611-3fe5081f54cb">6,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="ifrs-full:AdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE0LTctMS0xLTEwOTYxOA_00e7bb61-e209-4a51-8a4d-cced24db33cd">2,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE1LTEtMS0xLTEwOTYxOA_96e5e696-4f95-4cbb-ba79-b24e6d1b1be9">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE1LTQtMS0xLTEwOTYxOA_c13a7919-93e4-4218-afad-6c51586e27e0">549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE1LTctMS0xLTEwOTYxOA_6a9aa1f1-ec05-40c3-abd0-6d2f96e79b55">568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="ifrs-full:OccupancyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE2LTEtMS0xLTEwOTYxOA_51d3c25f-0630-4fba-82e7-ed0c603ee700">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="ifrs-full:OccupancyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE2LTQtMS0xLTEwOTYxOA_a3ed564e-5753-40cc-a268-301de76d3fa9">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="ifrs-full:OccupancyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE2LTctMS0xLTEwOTYxOA_1ad96ce9-fa05-438b-baa7-69afa05e8b34">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE3LTEtMS0xLTEwOTYxOA_ff5addd1-20c5-40cf-abd9-53a29778df00">22,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE3LTQtMS0xLTEwOTYxOA_0d329f04-7a19-41bc-af32-89f15d941d4a">17,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE3LTctMS0xLTEwOTYxOA_7801354b-9cfb-4a8c-a23b-6ad1935be30c">11,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE5LTEtMS0xLTEwOTYxOA_4d547dd3-c895-40bd-92f1-05a666fc389e">72,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE5LTQtMS0xLTEwOTYxOA_4d0a58c6-b775-42a5-9dff-6fbea4c29316">73,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE5LTctMS0xLTEwOTYxOA_c5abf255-4206-4e71-a7b8-6df3e037a1b8">67,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development non-cash effective pension and share-based compensation costs were TCHF <ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzE2_85e82184-76d3-4b6c-9cb6-e7ae217c94db">3,856</ix:nonFraction> in 2022, TCHF <ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzI0_95633b23-e42f-43f2-b9d8-b4dd6acb4042">3,045</ix:nonFraction> in 2021 and TCHF <ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzMy_7d8d8b08-3639-41cd-a95a-628ddecb59e9">2,612</ix:nonFraction> in 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative non-cash effective pension and share based compensation costs were TCHF <ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzQw_6591a417-69f1-4945-b84c-d008c608311d">2,329</ix:nonFraction> in 2022, TCHF <ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzQ4_da33a6a8-950f-4c27-ad49-565fa8237551">2,113</ix:nonFraction> in 2021 and TCHF <ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzU2_8f0b6689-589f-461e-9530-c30b27d3231b">1,573</ix:nonFraction> in 2020.</span></div></ix:nonNumeric></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_313"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzgz_0201971b-fec6-4f14-81b8-c8faa76745b4" continuedAt="i3a52014634fc4293ba93052af04afa64" escape="true">Royalties and license fees</ix:nonNumeric></span></div><ix:continuation id="i3a52014634fc4293ba93052af04afa64"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until October 2021, the Group held an exclusive perpetual license from the University of Zurich on patent applications and patents relating to the DARPin base technology. The Group terminated the applicable license agreement with effect as of October 2021 as the main patents under this agreement expired in September 2021. For the years ended December 31, 2021 and 2020 the minimum amounts of CHF <ix:nonFraction unitRef="chf" contextRef="i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231" decimals="-3" name="ifrs-full:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxMzk4OQ_41d06b78-5c0f-4a69-be9d-43e2661e7c84"><ix:nonFraction unitRef="chf" contextRef="ief90048dd4494347a75a5ce67581ab00_D20200101-20201231" decimals="-3" name="ifrs-full:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxMzk4OQ_b4cdc3e3-8998-46c5-aacd-6be7a17af3a1"><ix:nonFraction unitRef="chf" contextRef="if164200b3a3a403cb3987f2f289dfaab_D20210101-20211231" decimals="-3" name="ifrs-full:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxMzk4OQ_dc99d2f4-0192-4c54-bce3-a41c65cb5533">50,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> were payable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group currently now only holds a non-exclusive perpetual license from the University of Zurich on patent applications and patents relating to Phage Display technology. The amount payable by us is CHF <ix:nonFraction unitRef="chf" contextRef="i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231" decimals="-3" name="moln:RoyaltiesMinimumAnnualAmountTotal" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxNDAzMg_079eb0c3-43a8-404d-af43-d7ea60f8ab77">10,000</ix:nonFraction> per annum. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Group entered into a research collaboration agreement with the University of Utrecht regarding the development of the Group's COVID-19 program. Under this agreement, the Group paid a fee of CHF <ix:nonFraction unitRef="chf" contextRef="i66792e0d15a34af9b27cee6aec9fbcae_D20201201-20201231" decimals="0" name="moln:LicenseFeesExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzYw_fca579eb-ffc7-4361-b9a8-72178db03eda">250,000</ix:nonFraction> to the University of Utrecht in December 2020. An additional fee of CHF <ix:nonFraction unitRef="chf" contextRef="i5e3f5143278948b68b6427ace3f8dade_I20211231" decimals="0" name="moln:CurrentAccruedProjectCostsAndRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzY4_21eee2e7-d3c6-408b-b7b8-ad7d96bb9094">250,000</ix:nonFraction> was accrued as per December 2021 and payable under this agreement. With Novartis exercising its option under the Option and Equity Rights Agreement, the University of Utrecht was owed a further CHF&#160;<ix:nonFraction unitRef="chf" contextRef="i46ac96852f4042b3a422b02e00b4ff71_D20220101-20221231" decimals="-5" name="moln:RoyaltyPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzc2_02420dca-596f-4fe8-a055-2084908e1381">1.0</ix:nonFraction>&#160;million that was expensed and paid during 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_316"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1MA_62cdf938-6ef9-4ba9-a72e-de9ad7c7c0c1" continuedAt="i9ba4859448a84e0ba123b5c6d572f3ea" escape="true">Personnel expenses</ix:nonNumeric></span></div><ix:continuation id="i9ba4859448a84e0ba123b5c6d572f3ea" continuedAt="i6d5a9413177045ccb967820f4ab8bf16"><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1NA_2b053c93-b572-4e70-8537-cdca803dea98" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEtMS0xLTEtMTA5NjE4_4141df67-be65-476c-a8e1-67fbfe2afce4">27,737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEtNC0xLTEtMTA5NjE4_0781f697-b564-4760-8743-1451a447a01c">25,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEtNy0xLTEtMTA5NjE4_356efa23-c78d-4646-bea5-1fe8f457e713">23,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation (non-cash effective)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzItMS0xLTEtMTA5NjE4_f0241507-9427-4245-9908-bcb5e1d5b825">5,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzItNC0xLTEtMTA5NjE4_e109cd55-05d9-482b-a88d-ae87e5e8349d">4,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzItNy0xLTEtMTA5NjE4_5ec3cd35-8279-4aa5-9317-5c1f8c5f42dd">2,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzMtMS0xLTEtMTA5NjE4_f46f46a4-cff6-4d39-9886-cb1c849ad97f">3,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzMtNC0xLTEtMTA5NjE4_652c01d8-200b-4bd8-8ffb-bfd2208f19c9">3,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzMtNy0xLTEtMTA5NjE4_10980168-1d30-4c9f-b281-3c52eafbf97f">3,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social security costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzQtMS0xLTEtMTA5NjE4_fcbda96a-7db7-4e44-99cf-d700b89b886e">2,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzQtNC0xLTEtMTA5NjE4_5e57c4fb-af43-45e9-8235-2aed5a99f571">2,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzQtNy0xLTEtMTA5NjE4_f52b1b4a-ede1-4993-900f-f9d8923af7d5">2,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other personnel expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzUtMS0xLTEtMTA5NjE4_dda0d4a6-e7cd-4430-835a-46b28c30995c">1,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherEmployeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzUtNC0xLTEtMTA5NjE4_73cc9c9b-1f91-4dc2-b01e-a2598ea3fd4c">663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzUtNy0xLTEtMTA5NjE4_f06eba62-8531-404f-a32c-b48d5691c343">1,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzYtMS0xLTEtMTA5NjE4_1bbfc146-5f63-4f3e-8c7a-0395ff401da9">39,889</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzYtNC0xLTEtMTA5NjE4_c40494f0-1e58-42a7-82a7-529b5ea73e5f">36,251</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzYtNy0xLTEtMTA5NjE4_dc8d7f83-ae1f-4b85-93dd-31e8765c3a7f">33,634</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Full-time equivalents and head count</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average number of full-time equivalents</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="1" name="moln:AverageNumberOfFullTimeEquivalentEmployees" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzktMS0xLTEtMTA5NjE4_a051e47b-84c4-4126-94fb-6e8424aa78cb">167.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="1" name="moln:AverageNumberOfFullTimeEquivalentEmployees" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzktNC0xLTEtMTA5NjE4_40161d90-c6fa-4b94-9c1b-10ddf423da6a">158.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="1" name="moln:AverageNumberOfFullTimeEquivalentEmployees" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzktNy0xLTEtMTA5NjE4_0341f3ab-0b98-47b9-8134-5b8f7817515c">142.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full-time equivalents at year end</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="1" name="moln:NumberOfFullTimeEquivalentEmployees" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEwLTEtMS0xLTEwOTYxOA_2b5f2406-2fe7-4805-bb1a-e52ed550f76c">175.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="1" name="moln:NumberOfFullTimeEquivalentEmployees" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEwLTQtMS0xLTEwOTYxOA_d9f26100-045d-4087-94cb-75d395d7a8c6">163.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="1" name="moln:NumberOfFullTimeEquivalentEmployees" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEwLTctMS0xLTEwOTYxOA_b5cc9769-29d2-4448-803f-af8fffd2dccc">145.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headcount at year end</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:NumberOfEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzExLTEtMS0xLTEwOTYxOA_b1a4c71d-895e-453c-841e-209bc08bcf43">191</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:NumberOfEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzExLTQtMS0xLTEwOTYxOA_9a4ce4a4-9181-4321-8edc-726361f1db9a">177</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="INF" name="ifrs-full:NumberOfEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzExLTctMS0xLTEwOTYxOA_2ea22f84-712c-489d-bc11-cd907acea328">159</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.1&#160;&#160;&#160;&#160;Pension costs and liabilities</span></div><div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1NQ_772a7064-bcc6-4cb6-8692-e101360a1dd9" continuedAt="i1a4948150aa2495aa09761eccfeec39b" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit pension plans</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial assumptions</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate at January 1</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMtMS0xLTEtMTA5NjE4_0373a5d0-0a45-455c-a48f-576e9285bc20">0.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMtNC0xLTEtMTA5NjE4_7ec13401-7924-441e-a97f-39a9b7b21842">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQtMS0xLTItMTA5NjE4_dcadca12-b6a0-4cba-9a28-c973f3d3f054">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQtNC0xLTItMTA5NjE4_47b083d6-69be-404a-a843-a9a85f62278d">0.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future salary increases at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUtMS0xLTItMTA5NjE4_60da7700-d7f0-44b6-ae49-41cb6a18fd78">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUtNC0xLTItMTA5NjE4_b21cb5d6-db55-439e-b91a-6c93dbfe3b15">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortality tables</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVG2020 GT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVG2020 GT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of last actuarial valuation</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.12.2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.12.2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of the amount recognized in the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzktMS0xLTEtMTA5NjE4_52f9a14e-806f-4926-b103-12d6facf8dcd">52,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzktNC0xLTEtMTA5NjE4_67ff5aeb-56b3-4e8c-a91a-313dd31133f6">54,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of plan assets at December 31</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEwLTEtMS0xLTEwOTYxOA_7e94570d-4743-4b4a-8474-d59477643cc6">50,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEwLTQtMS0xLTEwOTYxOA_5e5127a5-f2a5-4a4e-b85a-ddf3ecc3c916">47,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net defined benefit liability at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzExLTEtMS0xLTEwOTYxOA_a161e82c-ba49-4d66-8082-60a4890e4a14">2,245</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzExLTQtMS0xLTEwOTYxOA_9ef51b2b-2f1c-455e-82ef-37e16626beda">6,483</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of defined benefit cost in profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEzLTEtMS0xLTEwOTYxOA_a037f677-cbd2-4672-a9e3-a14cdf3977f6">3,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEzLTQtMS0xLTEwOTYxOA_d087b850-3a06-464d-b93c-ff02a6bcc54d">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PastServiceCostDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE0LTEtMS0xLTEwOTYxOA_066a7544-b20b-4295-a299-09ec47ebb1e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:PastServiceCostDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE0LTQtMS0xLTEwOTYxOA_0f8a6dce-46e7-43e4-a5c8-feeef5fb84bb">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE1LTEtMS0xLTEwOTYxOA_10b023cd-62be-40e2-82d8-a2b509f686b5">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE1LTQtMS0xLTEwOTYxOA_8a54d606-687c-4d3c-aa29-9ccc77dd902d">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE2LTEtMS0xLTEwOTYxOA_a207d6b7-58dd-4ee8-b0fd-d889bec158dc">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE2LTQtMS0xLTEwOTYxOA_8b4033d6-6bbb-4cfd-9a7c-b3f17d5a91fd">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost excl. cost for managing plan assets</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE3LTEtMS0xLTEwOTYxOA_fa86a5a1-541f-4b79-a206-97a1dab16744">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE3LTQtMS0xLTEwOTYxOA_ff4b582a-982b-45d5-b5e5-cd10cd38b25d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit cost recognized in profit or loss</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE4LTEtMS0xLTEwOTYxOA_a01d23b9-5b24-4fa2-8b24-fa65ddf4745c">3,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE4LTQtMS0xLTEwOTYxOA_c57249ee-1934-4c76-825f-ea9b97333b1d">3,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof service cost and administrative cost</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE5LTEtMS0xLTEwOTYxOA_bacbe7fe-7c47-4bce-9de1-39444d83f520">3,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE5LTQtMS0xLTEwOTYxOA_c7c48849-e4e1-440e-910b-96a34d44c9ef">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof net interest expense on the net defined benefit liability</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIwLTEtMS0xLTEwOTYxOA_bbd11a7a-b8b1-413b-9bae-3ced9b3ef0b1">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIwLTQtMS0xLTEwOTYxOA_27792bf7-11e6-498b-aea6-3b6af34f3a6f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of net defined benefit liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net defined benefit liability at January 1</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIyLTEtMS0xLTEwOTYxOA_e9f287c7-2d82-413d-9c54-175ca773b27f">6,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIyLTQtMS0xLTEwOTYxOA_9e64fc68-a17a-4758-adce-e987e5084c23">13,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit cost recognized in profit or loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIzLTEtMS0xLTEwOTYxOA_f1e95922-3810-47ce-95e1-99ddc059324b">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIzLTQtMS0xLTEwOTYxOA_53eac376-79f3-4ff3-a07c-8e4a0662b238">3,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI0LTEtMS0xLTEwOTYxOA_845e2274-3834-493e-bf20-f97fd800ec76">5,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI0LTQtMS0xLTEwOTYxOA_f2b18a98-bb20-435a-83a3-cf7f057fbd29">8,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions by the employer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI1LTEtMS0xLTEwOTYxOA_cc323f3b-ae38-4abe-8b20-81c72d6b58e1">2,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI1LTQtMS0xLTEwOTYxOA_d72a25cb-f2c5-418f-bd90-08e33f58d041">1,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net defined benefit liability at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI2LTEtMS0xLTEwOTYxOA_9bcc46fb-ec98-4555-ac56-2402befe88aa">2,245</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI2LTQtMS0xLTEwOTYxOA_f9e2702e-1894-4af6-9c0f-b8a20b56f370">6,483</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i6d5a9413177045ccb967820f4ab8bf16" continuedAt="i586bc5022f0a40d5a331d3e01a724ba6"><ix:continuation id="i1a4948150aa2495aa09761eccfeec39b" continuedAt="iea29a48f35ee4281a239220d53f693be"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of defined benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at January 1</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i477f396e4168445ea6fbd216e6f8a944_I20211231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI4LTEtMS0xLTEwOTYxOA_5ed83b69-3a98-4d24-9bc0-8f001e0747d0">54,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2698db5ae60649b096fe74b1692909bc_I20201231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI4LTQtMS0xLTEwOTYxOA_89f7d991-8e55-4b97-9874-5140f79d4c83">54,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expenses on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI5LTEtMS0xLTEwOTYxOA_5d9bc0ea-b827-4a7b-98dc-2238ebed3f28">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI5LTQtMS0xLTEwOTYxOA_45db47de-29eb-4ae4-b15d-3405efe55abe">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMwLTEtMS0xLTEwOTYxOA_d567ad92-5a05-4f05-8a2f-ae5811cc5e67">3,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMwLTQtMS0xLTEwOTYxOA_0ebbe5a7-d0ae-4d73-b04e-2683a2ae6253">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by plan participants</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMxLTEtMS0xLTEwOTYxOA_d9a09e4c-813d-4a2d-ab7c-76bd54f4ab5d">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMxLTQtMS0xLTEwOTYxOA_d807296f-dc34-484a-9987-4308fb518686">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits (paid)/deposited</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMyLTEtMS0xLTEwOTYxOA_09feff73-3144-4633-a703-b66d169e42b3">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMyLTQtMS0xLTEwOTYxOA_77109b1b-55b0-4c99-9aeb-a1dbb77a356e">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMzLTEtMS0xLTEwOTYxOA_1e257495-adf9-4ab9-b86f-fb07cd1492ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMzLTQtMS0xLTEwOTYxOA_b28708c1-5c50-43fd-b6b8-b352bf25d76a">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost (excl. cost for managing plan assets)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM0LTEtMS0xLTEwOTYxOA_2cec4de1-389b-408d-8758-9613ce9d5536">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM0LTQtMS0xLTEwOTYxOA_d05bb6b8-d9a5-4b6c-8c31-cab1878b0935">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM1LTEtMS0xLTEwOTYxOA_697b877e-1cff-4774-b967-e17735765c26">8,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM1LTQtMS0xLTEwOTYxOA_fcc3de30-e0ea-4561-9465-b427fefc1a84">5,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit obligation at December 31</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3b64a6fd6d004538825e688a02e1881a_I20221231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM2LTEtMS0xLTEwOTYxOA_9887f539-211e-47db-85f2-ec4b82d7f1c9">52,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i477f396e4168445ea6fbd216e6f8a944_I20211231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM2LTQtMS0xLTEwOTYxOA_e37becb2-0830-4fa7-ba7e-19914d03eca7">54,461</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of amount recognized in OCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in financial assumptions</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM4LTEtMS0xLTEwOTYxOA_f964a3a2-42bd-4d29-882b-67e32fe096cc">12,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM4LTQtMS0xLTEwOTYxOA_9aedd531-7331-4e35-bd0d-f6afab139464">2,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in demographic assumptions</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM5LTEtMS0xLTEwOTYxOA_fcaba9a2-8ef1-402d-954a-800322966395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM5LTQtMS0xLTEwOTYxOA_3e5177f3-41e4-4310-838f-a45c2a738040">2,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss arising from experience adjustments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQwLTEtMS0xLTEwOTYxOA_cce17613-7b73-45f7-9050-dea5d4371e32">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQwLTQtMS0xLTEwOTYxOA_4295f8f3-50ad-4d15-9937-0db1ad91b159">773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQxLTEtMS0xLTEwOTYxOA_e8ed03e6-e2de-46b9-a88f-f3f13088e392">8,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQxLTQtMS0xLTEwOTYxOA_6f39fd2e-5c9a-4415-a7cc-c7107006a2c5">5,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excluding interest income</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQyLTEtMS0xLTEwOTYxOA_6586dc3d-2aff-4aa0-9bf0-1449e8dcbfa6">3,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQyLTQtMS0xLTEwOTYxOA_1ca6fe24-7062-4da8-90e4-0bad9307ec4a">2,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQzLTEtMS0xLTEwOTYxOA_2041f829-7c08-4d31-abcc-c3195aa8df1b">5,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQzLTQtMS0xLTEwOTYxOA_0ebbeba0-ed33-47b0-bb48-2609d5686afd">8,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of plan assets at January 1</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i26558c7e2e90408aaf310a75bba70d80_I20211231" decimals="-3" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ1LTEtMS0xLTEwOTYxOA_440ffff6-330a-44db-9218-bdafb409f538">47,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i3319cb244b7e4172804e14694e32ba95_I20201231" decimals="-3" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ1LTQtMS0xLTEwOTYxOA_20c195d7-6c7d-48a9-afae-a43829c508bd">41,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ2LTEtMS0xLTEwOTYxOA_f61aed05-5360-4283-870b-b4453c30aef8">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ2LTQtMS0xLTEwOTYxOA_829d28b1-4306-4987-be25-d4a21ac2417b">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by the employer</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231" decimals="-3" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ3LTEtMS0xLTEwOTYxOA_0ee47338-9930-42e3-b54a-7748c9056419">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231" decimals="-3" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ3LTQtMS0xLTEwOTYxOA_13efbaa4-aadb-405c-9401-7ddf315b417a">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by plan participants</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231" decimals="-3" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ4LTEtMS0xLTEwOTYxOA_60129b86-70c8-4d22-b7d6-504e9fa02f81">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231" decimals="-3" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ4LTQtMS0xLTEwOTYxOA_f8d0f06a-124f-486a-b813-d9c8d1aa656a">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits (paid)/deposited</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231" decimals="-3" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ5LTEtMS0xLTEwOTYxOA_360af30e-7282-4a2e-8a49-6bb17813b8e5">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231" decimals="-3" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ5LTQtMS0xLTEwOTYxOA_0d096052-b302-4380-8744-985cb305b750">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excl. interest income</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUwLTEtMS0xLTEwOTYxOA_73501053-7ae4-4b54-a9cc-5f5d9cbef887">3,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231" decimals="-3" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUwLTQtMS0xLTEwOTYxOA_ec0f092d-c911-460a-b24e-ac765cf5d006">2,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of plan assets at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib9e07ae88ae04fad8ed31f5f90d82653_I20221231" decimals="-3" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUxLTEtMS0xLTEwOTYxOA_e546cb9d-72a6-491a-bdc5-5a731866e9d2">50,284</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i26558c7e2e90408aaf310a75bba70d80_I20211231" decimals="-3" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUxLTQtMS0xLTEwOTYxOA_9acb23e1-ce99-49dc-8110-4ecf0ad61bd6">47,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Best estimate of contributions of next year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by the employer</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUzLTEtMS0xLTEwOTYxOA_e22b4b95-b7ab-4d50-8b57-c5c6d1f1572f">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUzLTQtMS0xLTEwOTYxOA_098a1dbb-38ad-4f13-8e58-704caaf30ae5">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan asset classes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU1LTEtMS0xLTEwOTYxOA_9067f954-917d-4740-a38c-20e940f0ce22">7,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU1LTQtMS0xLTEwOTYxOA_20284400-22f1-463d-868a-b1e156f1cfbd">9,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231" decimals="-3" name="ifrs-full:EquityInstrumentsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU2LTEtMS0xLTEwOTYxOA_2044d38c-3176-4750-ba51-bda4d9c69bad">20,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231" decimals="-3" name="ifrs-full:EquityInstrumentsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU2LTQtMS0xLTEwOTYxOA_5a77e96b-b34f-45ae-8a5f-edac6616a687">20,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt instruments (e.g. bonds)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231" decimals="-3" name="ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU3LTEtMS0xLTEwOTYxOA_f3069cd5-166a-4ce3-a9e5-fd66f00a5e48">8,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231" decimals="-3" name="ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU3LTQtMS0xLTEwOTYxOA_852b9a23-5605-49ff-acda-9dac31e86164">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate funds</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231" decimals="-3" name="ifrs-full:PropertyAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU4LTEtMS0xLTEwOTYxOA_02ec1b0a-64bc-4097-83f8-37ab53306f36">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231" decimals="-3" name="ifrs-full:PropertyAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU4LTQtMS0xLTEwOTYxOA_9a8e99ce-f343-426c-b741-ea56109407ba">1,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231" decimals="-3" name="ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU5LTEtMS0xLTEwOTYxOA_7de4cbac-ff5a-4600-955b-75170e72a474">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231" decimals="-3" name="ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU5LTQtMS0xLTEwOTYxOA_1cfda344-575c-4216-a416-44e1ff080fd8">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value (quoted market price)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYwLTEtMS0xLTEwOTYxOA_cc6edd7d-24e8-48e1-86b9-532921b268da">40,391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYwLTQtMS0xLTEwOTYxOA_1eef52a6-8ff3-4b80-a020-a7e86282a5f8">39,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifff310e7d99a4295bb708e767bfd827a_I20221231" decimals="-3" name="ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYxLTEtMS0xLTEwOTYxOA_4a88c765-111c-4e06-8db9-0ce8461f806f">9,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i59e9a73043d041f097d4b73f09999ed1_I20211231" decimals="-3" name="ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYxLTQtMS0xLTEwOTYxOA_4b13e50c-36b8-4aa5-8104-d6735eae07f4">8,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value (non-quoted market price)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifff310e7d99a4295bb708e767bfd827a_I20221231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYyLTEtMS0xLTEwOTYxOA_aad5deab-3d82-4239-be2c-50cf87605fb4">9,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i59e9a73043d041f097d4b73f09999ed1_I20211231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYyLTQtMS0xLTEwOTYxOA_4aef8557-7ff7-4280-9614-00e033664d27">8,862</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYzLTEtMS0xLTEwOTYxOA_e89d7aa5-23c7-4be0-a266-2a6c59e13f60">50,284</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYzLTQtMS0xLTEwOTYxOA_3de6e4ea-e29e-41b4-9eb7-9bd79990279b">47,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof entity's own transferable financial instruments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY0LTEtMS0xLTEwOTYxOA_ce8bab57-4ecf-4a25-9c28-c4b0ca01cf88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY0LTQtMS0xLTEwOTYxOA_6430777a-933a-4d6b-af6f-5a05a6c53f62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof property occupied or other assets used by the entity</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY1LTEtMS0xLTEwOTYxOA_c35dd4d3-e756-4ea4-ba8f-9839acd7085f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="moln:PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY1LTQtMS0xLTEwOTYxOA_bf25344a-c0cf-420f-a0c2-f787d6dc3494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sensitivity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with discount rate -<ix:nonFraction unitRef="number" contextRef="ie370090677a545b69199494d00542b66_I20221231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmY0OTdlMGIxMzk0ZDRjMTJiYjJjODE4YzgyNGE0YTYxXzY1_2c10a6c9-4925-4c94-b43b-2fcf154dfaed"><ix:nonFraction unitRef="number" contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmY0OTdlMGIxMzk0ZDRjMTJiYjJjODE4YzgyNGE0YTYxXzY1_49f15a45-8a60-45ff-9efc-90ed7bca151a">0.25</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie370090677a545b69199494d00542b66_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTEtMS0xLTEwOTYxOA_3ce4a0bf-93fa-4f52-91fb-076a83aaecd9">54,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTQtMS0xLTEwOTYxOA_bb92d81d-1f4c-4d77-9ccd-6595e43f69ba">57,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with discount rate +<ix:nonFraction unitRef="number" contextRef="ie370090677a545b69199494d00542b66_I20221231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmE2NTgzNzFjYjU4YTQxNzQ5YmYwZTM5M2RmZDFhMmMwXzY1_29daf00f-7441-4fbe-9929-d59f49914c44"><ix:nonFraction unitRef="number" contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmE2NTgzNzFjYjU4YTQxNzQ5YmYwZTM5M2RmZDFhMmMwXzY1_ae2e93ef-3913-4c19-81e0-44a914167835">0.25</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie370090677a545b69199494d00542b66_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTEtMS0xLTEwOTYxOA_cb43dff5-9237-426f-a16c-bf790758f07f">50,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTQtMS0xLTEwOTYxOA_7665d5f2-a975-4c0f-8e10-37693776b840">52,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with interest rate on retirement savings capital -<ix:nonFraction unitRef="number" contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMzZjlmZTUzNjVmMzRjMjE5NjlmNDY0MDVkYzAzMjFhXzk1_5b718a93-5362-422c-94ff-623870b367d8"><ix:nonFraction unitRef="number" contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMzZjlmZTUzNjVmMzRjMjE5NjlmNDY0MDVkYzAzMjFhXzk1_d508d1fc-1994-41d4-a476-d8934a030902">0.25</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTEtMS0xLTEwOTYxOA_716a1d9c-bb74-41d7-9696-a2d656a0be78">51,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTQtMS0xLTEwOTYxOA_c81d057a-ecbc-42b3-b236-1cf31f0b5617">53,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i586bc5022f0a40d5a331d3e01a724ba6" continuedAt="i12e9b24d8bc94b72a33d85ac88682bda"><ix:continuation id="iea29a48f35ee4281a239220d53f693be"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with interest rate on retirement savings capital +<ix:nonFraction unitRef="number" contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM5MjgzN2U0ZWZhYTRiZjI5NjYwYTRjZWIzNzQxNDY4Xzk1_67eaebde-08d2-4970-9953-35b32253be58"><ix:nonFraction unitRef="number" contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM5MjgzN2U0ZWZhYTRiZjI5NjYwYTRjZWIzNzQxNDY4Xzk1_b0793946-7b78-4bc7-b396-01b6f7ca9999">0.25</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTEtMS0xLTEwOTYxOA_0494c1a8-8ac4-42c1-bf06-327f0e9a1cc2">53,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTQtMS0xLTEwOTYxOA_517b0709-de8f-46bc-a3ca-acd025146a79">55,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with salary increases -<ix:nonFraction unitRef="number" contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM0NzQ0M2E0OTFjZDQyY2Y4Mzk3ZWNkZTFhYjE4N2VhXzY4_2c5b278b-cdbb-4713-99be-16df5ce0187f"><ix:nonFraction unitRef="number" contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM0NzQ0M2E0OTFjZDQyY2Y4Mzk3ZWNkZTFhYjE4N2VhXzY4_c6462219-925e-4f8d-b9cd-13d8e06641cf">0.25</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTEtMS0xLTEwOTYxOA_507bc1a4-0b40-4e53-8161-34fcd5bafdf6">52,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTQtMS0xLTEwOTYxOA_d0df930b-ff53-4c12-a429-8be1f4c03758">53,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with salary increases +<ix:nonFraction unitRef="number" contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjEyZTg2MDViMWFhYjQ0MDdhNzJiZWJlMzk1MmNiOTJmXzY4_479bf9bd-cb45-4109-9e3b-0a86cd56fd0b"><ix:nonFraction unitRef="number" contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjEyZTg2MDViMWFhYjQ0MDdhNzJiZWJlMzk1MmNiOTJmXzY4_fc007c9d-1b12-4283-a96f-ae2abf77c961">0.25</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTEtMS0xLTEwOTYxOA_36ff9586-83e8-4702-90f8-fee8d11dd3ee">52,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTQtMS0xLTEwOTYxOA_927182c4-ce00-4c50-9934-64c646a1d768">54,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with life expectancy +<ix:nonNumeric contextRef="i90d91352ae9f40a98d596b751938d675_I20211231" name="moln:ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjNmOTIxNWUxNDAwODRmODE4NjJhZTUxNDkzNWVhNmU1XzY4_84517c98-675c-487a-9a44-89b0814a7d4c"><ix:nonNumeric contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231" name="moln:ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjNmOTIxNWUxNDAwODRmODE4NjJhZTUxNDkzNWVhNmU1XzY4_90086918-5022-4d8e-a8e8-a06d84e10c01">1</ix:nonNumeric></ix:nonNumeric> year</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTEtMS0xLTEwOTYxOA_bf2162de-0bc9-4bbd-a06c-0073ab26698b">53,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i90d91352ae9f40a98d596b751938d675_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTQtMS0xLTEwOTYxOA_fc62beed-2b3c-4c30-9ed4-ff6ca62bc78a">55,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with life expectancy -<ix:nonNumeric contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231" name="moln:ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjMwMWQ5ZTIwYWFlNjQ2ZGI4OWZjMTJmZTY5NjQxMzJjXzY4_b27abe48-85eb-4dcd-8b21-5aa1c3de5e1b"><ix:nonNumeric contextRef="i90d91352ae9f40a98d596b751938d675_I20211231" name="moln:ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjMwMWQ5ZTIwYWFlNjQ2ZGI4OWZjMTJmZTY5NjQxMzJjXzY4_c9b261c1-fa39-4cb6-ac56-bfa537d68ba6">1</ix:nonNumeric></ix:nonNumeric> year</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTEtMS0xLTEwOTYxOA_370fa8bb-3845-4441-a12f-bfa82817ad07">51,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i90d91352ae9f40a98d596b751938d675_I20211231" decimals="-3" name="moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTQtMS0xLTEwOTYxOA_1554b47d-18e1-4724-8f2b-4109a309a49b">53,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity profile of defined benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc2LTEtMS0xLTEwOTYxOA_676db116-0225-42cb-ace0-c9bb1f70876d">15.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc2LTQtMS0xLTEwOTYxOA_cb092f01-38fc-4443-8614-5af7f61e4dd3">18.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31 for active members</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i87e47e2a1d2f42d6b887d22d3f1fda3a_D20220101-20221231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc3LTEtMS0xLTEwOTYxOA_8ae3b577-c98c-408b-99fb-318d8630e73b">14.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5c53ee898715434fac2e14c485a6b3ee_D20210101-20211231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc3LTQtMS0xLTEwOTYxOA_02b8f6ea-796e-4668-ad12-64e349564c7f">18.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31 for pensioners</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ied315fa7934d4ceca93243eef84aeb2b_D20220101-20221231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc4LTEtMS0xLTEwOTYxOA_b2088d77-dbd2-48b8-8664-95efffa1612d">16.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i718f06d2648742acbc789cc2611558ee_D20210101-20211231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc4LTQtMS0xLTEwOTYxOA_1dd79c97-1152-43c2-8d2d-6088b917695e">19.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discount rates are based on industry benchmarks related to benefits with a <ix:nonNumeric contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" name="moln:IndustryBenchmarkDiscountRatesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI2_f4a202f1-b044-417b-bf05-c99d49968343">20</ix:nonNumeric> year duration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In liabilities for employee benefits, as presented in the consolidated statement of financial position included are also TCHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:AccruedSabbaticalCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzMw_5ba9013c-2274-4fc4-ab46-04afde555a72">307</ix:nonFraction> (2021: TCHF <ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="moln:AccruedSabbaticalCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM4_5daa3cba-7861-45fe-8008-c3e4283cc60c">257</ix:nonFraction>; 2020: TCHF <ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="moln:AccruedSabbaticalCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzQ2_eaf482b0-086d-43fc-b079-96d4a90a1bfb">255</ix:nonFraction>) for accrued sabbatical cost.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The sum of these two positions represent the non-cash effective pension costs recognized in the profit and loss section of the consolidated statement of comprehensive income of which TCHF <ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzUw_e8292bfa-7d04-43e7-9403-41109b25d858">846</ix:nonFraction> are research and development costs (2021: TCHF <ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzU4_68f0217e-9dfb-49c0-9fb0-f801540a85db">837</ix:nonFraction>; 2020: TCHF <ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzY2_8f1655ec-652a-4018-90bd-827a55504e84">1,039</ix:nonFraction>) and TCHF <ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzcw_73270677-9acf-48b6-b1df-18dbbf78d6d2">250</ix:nonFraction> are selling, general and administrative costs (2021: TCHF <ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzc4_cb735f31-9fe5-4fa3-bb49-e74655d6eaf8">235</ix:nonFraction>; 2020: TCHF <ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzg2_fca7fc69-684a-473c-83f9-70dc4de96642">214</ix:nonFraction>).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the most important parameters which influence the pension obligation of the Company a sensitivity analysis was performed. The discount rate and the assumption for salary increases were modified by a certain percentage value. Sensitivity on mortality was calculated by changing the mortality with a constant factor for all age groups. With this procedure the Company could change the longevity for most of the age categories by <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzkz_68781a81-9380-4639-b1a7-4d99c0d6c3e4">one year</ix:nonNumeric> longer or shorter than the baseline value.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i12e9b24d8bc94b72a33d85ac88682bda" continuedAt="i257d3ed4ff8d4284b274c5172886cc84"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1MQ_1ef444d5-65ef-4232-ad92-82ebbc1f256f" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the amounts that are reflected in the statement of comprehensive income for the periods indicated:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of defined benefit cost in profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzMtMS0xLTEtMTA5NjE4_a037f677-cbd2-4672-a9e3-a14cdf3977f6">3,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzMtNC0xLTEtMTA5NjE4_d087b850-3a06-464d-b93c-ff02a6bcc54d">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzMtNy0xLTEtMTA5NjE4_8998ca09-02f9-4062-bd89-1b1819842ea5">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PastServiceCostDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzQtMS0xLTEtMTA5NjE4_066a7544-b20b-4295-a299-09ec47ebb1e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:PastServiceCostDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzQtNC0xLTEtMTA5NjE4_0f8a6dce-46e7-43e4-a5c8-feeef5fb84bb">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PastServiceCostDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzQtNy0xLTEtMTA5NjE4_b5a6c0bb-9288-4c91-82b6-a8fadab4ef4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on defined benefit obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzUtMS0xLTEtMTA5NjE4_10b023cd-62be-40e2-82d8-a2b509f686b5">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzUtNC0xLTEtMTA5NjE4_8a54d606-687c-4d3c-aa29-9ccc77dd902d">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzUtNy0xLTEtMTA5NjE4_676efcae-cd09-4961-9083-56b4ef8a9c4c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzYtMS0xLTEtMTA5NjE4_a207d6b7-58dd-4ee8-b0fd-d889bec158dc">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzYtNC0xLTEtMTA5NjE4_8b4033d6-6bbb-4cfd-9a7c-b3f17d5a91fd">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzYtNy0xLTEtMTA5NjE4_76dfc071-d894-4019-9f94-2b2e7a373305">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost excl. cost for managing plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzctMS0xLTEtMTA5NjE4_fa86a5a1-541f-4b79-a206-97a1dab16744">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzctNC0xLTEtMTA5NjE4_ff4b582a-982b-45d5-b5e5-cd10cd38b25d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzctNy0xLTEtMTA5NjE4_e7532241-e619-4e91-9a45-d44f497babc1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit cost recognized in profit or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzgtMS0xLTEtMTA5NjE4_a01d23b9-5b24-4fa2-8b24-fa65ddf4745c">3,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzgtNC0xLTEtMTA5NjE4_c57249ee-1934-4c76-825f-ea9b97333b1d">3,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzgtNy0xLTEtMTA5NjE4_32649527-2cdf-4ee8-a7d4-ee1642b0b285">3,080</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof service cost and administrative cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzktMS0xLTEtMTA5NjE4_bacbe7fe-7c47-4bce-9de1-39444d83f520">3,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzktNC0xLTEtMTA5NjE4_c7c48849-e4e1-440e-910b-96a34d44c9ef">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzktNy0xLTEtMTA5NjE4_9123af97-07e6-4cc0-a5f4-b560d98303cb">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof net interest expense on the net defined benefit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEwLTEtMS0xLTEwOTYxOA_bbd11a7a-b8b1-413b-9bae-3ced9b3ef0b1">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEwLTQtMS0xLTEwOTYxOA_27792bf7-11e6-498b-aea6-3b6af34f3a6f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseIncomeDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEwLTctMS0xLTEwOTYxOA_7a13a011-4b07-41cd-b52c-8ff3feb1bb5c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of amount recognized in OCI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in financial assumptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEzLTEtMS0xLTEwOTYxOA_f964a3a2-42bd-4d29-882b-67e32fe096cc">12,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEzLTQtMS0xLTEwOTYxOA_9aedd531-7331-4e35-bd0d-f6afab139464">2,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEzLTctMS0xLTEwOTYxOA_844f34f9-3cc0-44a6-a427-b775af11c43f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in demographic assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE0LTEtMS0xLTEwOTYxOA_fcaba9a2-8ef1-402d-954a-800322966395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE0LTQtMS0xLTEwOTYxOA_3e5177f3-41e4-4310-838f-a45c2a738040">2,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE0LTctMS0xLTEwOTYxOA_05ebdab0-155c-4acb-bd69-bbf282d3b93e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss arising from experience adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE1LTEtMS0xLTEwOTYxOA_cce17613-7b73-45f7-9050-dea5d4371e32">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE1LTQtMS0xLTEwOTYxOA_4295f8f3-50ad-4d15-9937-0db1ad91b159">773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE1LTctMS0xLTEwOTYxOA_1e55999c-503f-480c-b97b-5f9656f67ea4">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE2LTEtMS0xLTEwOTYxOA_e8ed03e6-e2de-46b9-a88f-f3f13088e392">8,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE2LTQtMS0xLTEwOTYxOA_6f39fd2e-5c9a-4415-a7cc-c7107006a2c5">5,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE2LTctMS0xLTEwOTYxOA_4b6ed920-4b26-4d0b-9c87-14e16dbc7883">335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excluding interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE3LTEtMS0xLTEwOTYxOA_6586dc3d-2aff-4aa0-9bf0-1449e8dcbfa6">3,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE3LTQtMS0xLTEwOTYxOA_1ca6fe24-7062-4da8-90e4-0bad9307ec4a">2,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE3LTctMS0xLTEwOTYxOA_64e26fa0-6386-40fc-8b7c-ca07271175e4">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE4LTEtMS0xLTEwOTYxOA_2041f829-7c08-4d31-abcc-c3195aa8df1b">5,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE4LTQtMS0xLTEwOTYxOA_0ebbeba0-ed33-47b0-bb48-2609d5686afd">8,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE4LTctMS0xLTEwOTYxOA_a836888e-d8a9-469a-afbc-57fe3aba8689">1,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2&#160;&#160;&#160;&#160;Share-based compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2.1&#160;&#160;&#160;&#160;Employee Share Option Plans (&#8220;ESOP&#8221;)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;ESOP 2009 established in December 2009</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;ESOP 2014 established in July 2014 </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ESOP is an incentive tool that fosters the entrepreneurial spirit and performance by way of financial participation in the Group's long term success. It gives employees, members of the Board of Directors and selected advisors a beneficial opportunity to purchase shares of the Company. Each option entitles its holder to purchase one share of the Company at a pre-defined exercise price. The number of options granted to each participant was determined by the Board of Directors based on a participant&#8217;s position and level of responsibility. The options generally vested quarterly over <ix:nonNumeric contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE0Mg_8791729a-c4a1-468c-a8ea-85243519ab1c">four years</ix:nonNumeric>, with vesting of <ix:nonFraction unitRef="number" contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231" decimals="INF" name="moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE0Ng_9c49746d-e2c4-4262-b248-71eeddfbf251">25</ix:nonFraction>% after <ix:nonNumeric contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE1MA_0b600d4f-20a6-49a1-a27f-26ccb8b32bd9">one year</ix:nonNumeric>. At the end of the 10 year option term, unexercised options expire without value. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i76a79e3fe3be49e5918a663e53a05813_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE2MQ_f2309263-f0f8-4ab0-ad9e-0efd2f581ad7">282,105</ix:nonFraction> options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i16708e73e7aa4355b85eac7ce415b78b_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE3Mg_0b685d2c-21f6-47e2-9b3a-eed912b29d5f">318,902</ix:nonFraction> options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the initial public offering of the Company on the SIX Swiss Exchange on November&#160;5, 2014, no further option grants have been made under any of these <ix:nonFraction unitRef="plan" contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231" decimals="INF" name="moln:NumberOfShareOptionPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE4NA_d824e7cc-ede2-4337-a00e-f6bca8546634">two</ix:nonFraction> share option plans. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i257d3ed4ff8d4284b274c5172886cc84" continuedAt="i9bafd0bc7c90469e8f559696d0de7f7b"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2.2&#160;&#160;&#160;&#160;Long Term Incentive (&#8220;LTI&#8221;) Plans: Restricted Share Units ("RSU'') and Performance Share Units ("PSU")</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2018 established in March 2018</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2019 established in March 2019</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2020 established in March 2020</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2021 established in March 2021</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2022 established in March 2022</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LTI plans, members of the Board of Directors are eligible to be granted RSUs, whereas members of the Management Board and other employees are eligible to be granted PSUs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are contingent rights to receive a certain number of shares of the Company at the end of a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIwNw_9040953b-cb8b-40fb-a37f-f83b25c57861">three</span>-year blocking period. The number of RSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each RSU as at the grant date. In certain circumstances, including a change of control, a full or partial accelerated vesting of the RSUs may occur. RSUs vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxMQ_05ecdaa7-ecd6-4736-951d-8a9dde75aba2">one</span>-year period from date of grant. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSUs are contingent rights to receive a variable number of shares of the Company. Since 2021, PSUs granted to employees (except for members of the Management Board) will vest in <ix:nonFraction unitRef="tranche" contextRef="ib5fa38f116e34565a5e36d42a37700a5_D20220101-20221231" decimals="INF" name="moln:VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxOA_bacca4cd-76b4-4482-ab31-31358dbe27eb">three</ix:nonFraction> tranches of one third each. The first tranche of the PSUs shall vest on the first anniversary of the grant date, the second tranche on the second anniversary of the grant date and the third tranche on the third anniversary of the grant date. For the members of the Management Board, the vesting schedule remains unchanged and PSU's will vest at the end of a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyMg_8b946c45-4517-4e69-84b4-4b2d7403ff98">three</span> year cliff-vesting period. PSUs granted to all employees under PSU plans prior to 2021 will continue to vest at the end of a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyNg_6be1f36f-6243-4b7f-bbee-a9ede8c3610e">three</span>-year cliff-vesting period. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of PSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each PSU as of the grant date. While the PSUs are designed to let the beneficiaries participate in the long-term share price development, the number of shares to be earned in relation to a PSU also depends on the achievement of pre-defined corporate goals for the respective year. Accordingly, the number of shares to be issued based on the PSUs can be between <ix:nonFraction unitRef="number" contextRef="ie1c7b494d350479797a5d1c4c82ccba2_D20220101-20221231" decimals="INF" name="moln:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIzMw_ead708e1-2a06-49cd-85dd-90b76cff8ebf">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i97a4f932a6df488d9cc6ed653efcf1f7_D20220101-20221231" decimals="INF" name="moln:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIzNw_ed254c71-e137-46e3-b104-2dd1b0651cda">150</ix:nonFraction>% of the number of PSUs granted. Even after the determination of goal achievement, participants may lose their entitlements in full or in part depending on certain conditions relating to their employment. In certain circumstances, including a change of control, a full or partial accelerated vesting of the PSUs may occur. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LTI plans are issued annually, which allows the Board of Directors to review the terms and determine the targets on an annual basis. Employees generally receive the grants on April 1 of each calendar year, or for new employees on the first day of the calendar quarter after the start of their employment. Members of the Management Board and the Board of Directors receive the annual grants after the approval of the ordinary shareholders&#8217; meeting. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="ied19b6e08547434f9cdba0fd054a6b2f_I20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI1NQ_f3477044-bbac-4593-b7b5-ba741171002d">604,800</ix:nonFraction> PSUs and <ix:nonFraction unitRef="shares" contextRef="i72a85516e9d14b69b127030c7418be86_I20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI1OQ_35921681-1e2e-4fff-a2f0-990922576d2f">96,001</ix:nonFraction> RSUs were outstanding. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i91457d4200b443229b7716268dcc0131_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI2Nw_50834197-9e17-43f4-97b0-ef2ee08d305b">547,485</ix:nonFraction> PSUs and <ix:nonFraction unitRef="shares" contextRef="i4c84992c462c4044bf0e6a6000d7fa91_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI3MQ_674a812d-bb49-412c-aa82-aa5617413cdd">95,635</ix:nonFraction> RSUs were outstanding.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9bafd0bc7c90469e8f559696d0de7f7b" continuedAt="i2e738703a8304acc9219761ed74aa2fa"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2.3&#160;&#160;&#160;&#160;Conditions attached to and measurement of fair values of equity-settled share-based payment arrangements</span></div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM0Nw_9df37919-79b2-42db-ae2f-5da40399aad8" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the conditions as well as the inputs used in the measurement of the values at grant dates:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:67.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU/PSU, conditions and assumptions</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nature of arrangement</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant of PSU/RSU</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant of PSU/RSU</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant date RSU</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 13, 2022</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 21, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant dates PSU</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan&#160;1 - Oct&#160;1</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan&#160;1 - Oct&#160;1</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of RSU granted</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzQtMS0xLTEtMTA5NjE4_032e56e6-b576-471a-8df2-80b27d595320">33,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i73b1e70d913e41eb90a4644426c8401b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzQtMy0xLTEtMTA5NjE4_306f069a-a3c3-4ba4-a67d-4827c2df24d6">29,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of PSU granted</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0c649c507ba24f33a40832e35ce5a3e0_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzUtMS0xLTEtMTA5NjE4_af35ac15-f799-42a4-ad8c-8269e47ba2e7">307,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia48dcfaff35049b2936b8df362cf345b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzUtMy0xLTEtMTA5NjE4_a985c538-4da6-4447-8bf0-7c4e67a9c358">230,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzYtMS0xLTEtMTA5NjE4_a6c47541-e261-4643-9661-2e8a0fb290d9">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzYtMy0xLTEtMTA5NjE4_5f3cf399-0e09-4a45-a16e-716ba0f0de62">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price (CHF)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="2" name="moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMS0xLTEtMTA5NjE4L3RleHRyZWdpb246NDEyNDFiYzZjZjk1NDUyYjlhYzZmZjNhNTUzOTcwYjRfNA_966fc4f5-948e-45e0-82aa-214015367345">6.55</ix:nonFraction> - <ix:nonFraction unitRef="chfPerShare" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="2" name="moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMS0xLTEtMTA5NjE4L3RleHRyZWdpb246NDEyNDFiYzZjZjk1NDUyYjlhYzZmZjNhNTUzOTcwYjRfOQ_f00b0e25-8b20-4b19-a051-a264a9cf6791">18.88</ix:nonFraction></span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="2" name="moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMy0xLTEtMTA5NjE4L3RleHRyZWdpb246N2RiMzVmYzA1YWQ1NDUxNDhlN2U5YWY3ZmQ3MGQyNTFfNA_e9eb5e2e-f2d6-47de-a406-b5c1bea23f2c">17.90</ix:nonFraction> - <ix:nonFraction unitRef="chfPerShare" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="2" name="moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMy0xLTEtMTA5NjE4L3RleHRyZWdpb246N2RiMzVmYzA1YWQ1NDUxNDhlN2U5YWY3ZmQ3MGQyNTFfOQ_5f7a218e-58c5-429d-ab2d-0001113eca8e">23.25</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for RSU (years)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzgtMS0xLTEtMTA5NjE4_0d49c45e-4f7b-416c-837e-b263f3f8e16e">1.00</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i73b1e70d913e41eb90a4644426c8401b_D20210101-20211231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzgtMy0xLTEtMTA5NjE4_2f55b4ed-a843-48d7-b3a6-48c3e7a88f7b">1.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full contractual life for RSU (years)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i58ac6f2ae72f4533ab1243a7f02391ee_D20220101-20221231" name="moln:FullContractualLifeOtherEquityInstruments" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzktMS0xLTEtMTA5NjE4L3RleHRyZWdpb246YmY1ZmFlN2NhNWJmNDljNWJhMzdlZWNjMzUyNDNjODZfNA_897b4eec-7e93-4fe3-9a12-2e8c87ba3674">3.00</ix:nonNumeric></span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie860cc1afbd34f37b81b8c5b43ca86a4_D20210101-20211231" name="moln:FullContractualLifeOtherEquityInstruments" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzktMy0xLTEtMTA5NjE4L3RleHRyZWdpb246ODE3NDQ0NmE2ZWE5NGRjMmE2MGU5NjU0YmFkNDM2YTRfNA_3b5ace30-bb75-478d-baab-2a54a9ebd660">3.00</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for PSU (years), Management Board</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieffd03daf5f049beadb8aa9b7a149884_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEwLTEtMS0xLTEwOTYxOA_4e7cd230-596a-4250-a6e1-230a9bd44074">3.00</ix:nonNumeric></span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id4d5712930e540a9b8c8240c3972c7ea_D20210101-20211231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEwLTMtMS0xLTEwOTYxOA_a84c537d-1476-4095-bc0a-5c03f76aeb48">3.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for PSU (years), employees excluding Management Board</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzExLTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmI2MWUzNzhmZjE4ZDQxOWVhNjhiZjI2MGQ5Zjg1MDMzXzEwOTk1MTE2Mjc4MTU_93461b59-e9f9-4278-a8d3-42a9be4f7d95">3.00</ix:nonNumeric> (pro-rata annual vesting)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzExLTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMxODQ3NTVmNjgwNTQ5ZjU4OWRjOGI5NTRmNDBjYWUzXzEwOTk1MTE2Mjc4MTU_df6592f7-ac6e-4649-ac5d-e7bc085dd4d0">3.00</ix:nonNumeric> (pro-rata annual vesting)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full contractual life for PSU (years)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1c7b494d350479797a5d1c4c82ccba2_D20220101-20221231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEyLTEtMS0xLTEwOTYxOA_364407b9-97ef-4e2b-a406-ddfd380cd35d">3.00</ix:nonNumeric></span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231" name="moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEyLTMtMS0xLTEwOTYxOA_1d8f6b5c-70a6-4c39-ba46-7c1e3d3f1381">3.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Shares</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on Common shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="4" name="moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMxZmYwY2E5YjZhOTQ3ZmQ5MzI0OGI1Y2ZhNDExNjM4XzQ_937384cd-bfe6-4a2e-b79e-92d6b37f55b9">64.69</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="4" name="moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMxZmYwY2E5YjZhOTQ3ZmQ5MzI0OGI1Y2ZhNDExNjM4Xzk_8a685cc8-fc8d-4c3d-97b2-0d136358f0d6">76.84</ix:nonFraction></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="4" name="moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmIxNmMwMTNlZWQ0NzRhZGE4NTQ2MTcyMWEyZTA0ZGIzXzQ_3596c371-0192-4aba-9e04-17931a93a5cb">58.57</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="4" name="moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmIxNmMwMTNlZWQ0NzRhZGE4NTQ2MTcyMWEyZTA0ZGIzXzk_97a89ffb-7753-463e-b7b2-6596e2a065a6">61.69</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / CHF LIBOR / Common shares</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="4" sign="-" name="moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjlmNThjODM5ZTdkYjQ3MmE4YTY2YzkxMTk4ZDcwODgwXzQ_e26332e0-5856-4f3b-b3d7-48f350dd35a2">0.54</ix:nonFraction>) - (<ix:nonFraction unitRef="number" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="4" sign="-" name="moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjlmNThjODM5ZTdkYjQ3MmE4YTY2YzkxMTk4ZDcwODgwXzk_db4d750a-10d1-4d91-833c-7a1d53ec9100">0.71</ix:nonFraction>)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="4" sign="-" name="moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmNkNmY0YzYzNDA3OTQzYWRiYWEwYWU4OWExYmQyMmY4XzQ_83e45b1d-569b-4eb9-b446-579f37d1d79d">0.58</ix:nonFraction>) - (<ix:nonFraction unitRef="number" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="4" sign="-" name="moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmNkNmY0YzYzNDA3OTQzYWRiYWEwYWU4OWExYmQyMmY4Xzk_1d8bf81f-3c90-4eb6-a96f-c3c1801b4e2b">0.61</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on NBI</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="4" name="moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmZhMTQ2Mzc0ODhjODRmOWZiY2IxMmQzZTFkNjU1MTAxXzQ_64c5a00a-81af-4c82-9f98-45ccb31b399d">25.89</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="4" name="moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmZhMTQ2Mzc0ODhjODRmOWZiY2IxMmQzZTFkNjU1MTAxXzk_b633b632-2265-4a94-b40b-1acdbc311dce">28.16</ix:nonFraction></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="4" name="moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRmY2JkOTVhMDE4OTRhNzE4NTkxYmMxZjM3ZjE1ZWFmXzQ_8f8e5fd0-42a9-45e1-9100-4585b60fba32">26.21</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="4" name="moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRmY2JkOTVhMDE4OTRhNzE4NTkxYmMxZjM3ZjE1ZWFmXzk_0d7bccd4-e7b7-496e-a867-841d4a625167">27.01</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / USD LIBOR / NBI</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="4" name="moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjhmMTA1NzQ1N2ZiMjRjMTc4YTIxODI2NmVhNTYzMWI0XzQ_fe792cda-f891-40ed-a7a5-5fbda27136f4">0.58</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="4" name="moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjhmMTA1NzQ1N2ZiMjRjMTc4YTIxODI2NmVhNTYzMWI0Xzk_ae07f8d7-ee2e-4f5d-87b9-066169fa0556">4.78</ix:nonFraction></span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="4" name="moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRjYTI4YTY4YTQ5MTRiYzVhMmYwNDFhNWNlYjUzNWJhXzQ_538f342b-0f49-4a38-bc89-c16c0b6bf1db">0.24</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="4" name="moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRjYTI4YTY4YTQ5MTRiYzVhMmYwNDFhNWNlYjUzNWJhXzk_472025a1-bc00-4db9-827e-0c2e1bffb2df">0.34</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on SPI</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="4" name="moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmFkNTE2OTg3MjNiYTRmZjJhNmFjODNiNjllZThiMDg3XzQ_0d26ec49-e9fe-4d34-ba9b-7ad06af470fc">15.57</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="4" name="moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmFkNTE2OTg3MjNiYTRmZjJhNmFjODNiNjllZThiMDg3Xzk_1aa660de-9e8b-49fa-8073-9570061b565b">17.02</ix:nonFraction></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="4" name="moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjc5MDAzNTQ0MDA3NDQ4OWJiYjUwNmQ1NzNjYjVmMTJmXzQ_1d5fa597-e110-4f34-8fad-06fa8ce10488">15.96</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="4" name="moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjc5MDAzNTQ0MDA3NDQ4OWJiYjUwNmQ1NzNjYjVmMTJmXzk_75174eb4-59c6-4e9c-9b19-82b1532d4f72">16.15</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / CHF LIBOR / SPI</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231" decimals="4" sign="-" name="moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjA1YWE2NzdjZmFmYjQ2YzI5YzhlM2UwY2E2MDMyYjRhXzQ_3ed27653-60cf-4b82-af95-2b4cdecce694">0.54</ix:nonFraction>) - (<ix:nonFraction unitRef="number" contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231" decimals="4" sign="-" name="moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjA1YWE2NzdjZmFmYjQ2YzI5YzhlM2UwY2E2MDMyYjRhXzk_57a1684c-5902-4fba-9fab-e6e24e17415c">0.71</ix:nonFraction>)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231" decimals="4" sign="-" name="moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmU3NWFlMDE4OTRiYTQ4Y2FiMjcwMTRjYzczNWNjMjE0XzQ_cb279c0d-2ee1-4635-a54e-e751aa52b7d2">0.58</ix:nonFraction>) - (<ix:nonFraction unitRef="number" contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231" decimals="4" sign="-" name="moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmU3NWFlMDE4OTRiYTQ4Y2FiMjcwMTRjYzczNWNjMjE0Xzk_bded6ed9-5b95-4f66-9e0d-a7faaba52c9b">0.61</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend (CHF)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:ExpectedDividendOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIxLTEtMS0xLTEwOTYxOA_1554a52b-bdba-4600-8fa7-1e580f0b0932">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:ExpectedDividendOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIxLTMtMS0xLTEwOTYxOA_c5693bdc-535a-4cd2-ae70-122d49b753ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of rights granted (CHF)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIyLTEtMS0xLTEwOTYxOA_363112df-c978-457d-a56a-1c03087bc5e1">17.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIyLTMtMS0xLTEwOTYxOA_2a919820-092b-4c6c-bb1f-13ab7395f007">24.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Latest expiry date</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sep 30, 2025</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sep 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation model</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monte Carlo</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monte Carlo</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional comments:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility: Historical share prices of the Company have been used.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The indices, Nasdaq Biotechnology Index ('NBI") and Swiss performance Index ("SPI") are used as inputs in determining the fair values for the 2021 and 2022 PSU Plans.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2e738703a8304acc9219761ed74aa2fa" continuedAt="i9079c5d39a15416ca730afa2318ffea2"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM0OA_5cdbda59-85ce-4a24-8b61-727bfb294183" escape="true"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1Mg_273617d4-fbf2-43e9-b189-2ac8781105b9" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movements in the number of all issued RSUs, PSUs and share options are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share option / PSU / RSU movements</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU/RSU (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="INF" name="moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMS0xLTEtMTA5NjE4_6b943928-1a58-49ec-bea1-f94ae6451f07">915,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtNC0xLTEtMTA5NjE4_b2d0cf73-8e1a-463e-86c4-bd0ce04e2371">2.74</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtNy0xLTEtMTA5NjE4_d140c382-f1cf-4ef0-8fd1-94a501008e71">382,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMTAtMS0xLTEwOTYxOA_61227059-b430-4b06-b4b4-11299a94a45d">6.42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMTMtMS0xLTEwOTYxOA_8a8c5393-8b22-449d-b43f-f56140f82f3c">533,104</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMTYtMS0xLTEwOTYxOA_940d50e4-f66d-4a9e-b678-4682ddc2bf39">0.10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMS0xLTEtMTA5NjE4_3e37c165-aebd-49d7-98dc-4fb11b881e1c">260,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItNC0xLTEtMTA5NjE4_0bac546d-5506-4072-bf3b-977a567282e1">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItNy0xLTEtMTA5NjE4_af9f991f-6dc7-455e-a7ab-9bfad10c9898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMTAtMS0xLTEwOTYxOA_212f3028-1af0-421c-b977-47af4a1cb476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMTMtMS0xLTEwOTYxOA_1af26d5d-6deb-4737-9bec-05405f7c541d">260,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMTYtMS0xLTEwOTYxOA_6a0e81c8-745b-4149-ad79-4d1309cdf264">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMS0xLTEtMTA5NjE4_8a727a20-6ef0-4650-8fb3-8f2f12f9de05">1,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtNC0xLTEtMTA5NjE4_0a74c39e-231f-4cc1-a166-f28b7de2920b">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtNy0xLTEtMTA5NjE4_0b38481a-7d4e-4afe-af7f-60f55dd70792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMTAtMS0xLTEwOTYxOA_d8b46cc7-6244-49ae-96ab-9e5f695f951b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMTMtMS0xLTEwOTYxOA_7b6883ea-a183-41a6-9937-fe8d7906fb32">1,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMTYtMS0xLTEwOTYxOA_3be3408b-40be-4b59-8b65-cfd6de3041e3">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMS0xLTEtMTA5NjE4_37e135b3-dd5d-406d-9db4-ae8653463f05">66,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtNC0xLTEtMTA5NjE4_b1d4651c-e59c-4129-8a09-21daaa368165">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtNy0xLTEtMTA5NjE4_3479d6a7-ea45-430a-91aa-4e14945fb33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMTAtMS0xLTEwOTYxOA_54255fc2-2833-410a-aeec-bc2e4e206ff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMTMtMS0xLTEwOTYxOA_e9895286-2b97-456f-a246-8d20807340ee">66,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMTYtMS0xLTEwOTYxOA_c7b96cbc-f9da-4528-8d70-b1f9c42ddf44">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMS0xLTEtMTA5NjE4_22741e7b-e62d-4a95-8275-8926c2ef4e7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtNC0xLTEtMTA5NjE4_c34d2300-bb74-480a-9d58-72529d03c711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtNy0xLTEtMTA5NjE4_10cfb562-f413-447a-8580-9bad651c1bd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMTAtMS0xLTEwOTYxOA_17cff91e-ceba-4099-9109-8fa47cfb6f62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMTMtMS0xLTEwOTYxOA_24b7fd69-817e-453a-bf38-3e954a1b38e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMTYtMS0xLTEwOTYxOA_0abff26e-5a40-41a4-abfc-5fceba7c15ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="moln:NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMS0xLTEtMTA5NjE4_7c60a109-a8b4-438c-80fe-d029bcfa6105">145,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtNC0xLTEtMTA5NjE4_3f064121-9bed-4de7-b1c4-2371ce9505c2">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtNy0xLTEtMTA5NjE4_099bc862-b990-4e2e-9470-789381c7b52b">63,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMTAtMS0xLTEwOTYxOA_05c1f865-6dd6-4a2e-8405-8e6d4bea2348">4.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMTMtMS0xLTEwOTYxOA_8e9a2a6f-7f89-4080-a779-89aa4d38ef44">82,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMTYtMS0xLTEwOTYxOA_0c6dd91d-7d41-4007-9fc3-9ae109a8be32">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMS0xLTEtMTA5NjE4_ea22c0b6-f916-454e-9ae0-7bc5b3a8aded">962,022</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctNC0xLTEtMTA5NjE4_6cc9e77e-6fab-4b47-b018-c200c9a1c7e2">2.35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctNy0xLTEtMTA5NjE4_c6df9de5-4ac6-4ea4-b3fc-e778b64e82fc">318,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMTAtMS0xLTEwOTYxOA_d097e238-c6a6-45e9-a301-4397b1a36a55">6.87</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMTMtMS0xLTEwOTYxOA_e96499fc-01de-4149-a343-809b7a366822">643,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMTYtMS0xLTEwOTYxOA_b76ac5ae-7529-4338-92c6-d8060ac0c1f8">0.10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMS0xLTEtMTA5NjE4_af51e9f5-0000-4f19-9d72-a62ba1f3fc0a">340,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtNC0xLTEtMTA5NjE4_b958a69f-1829-4cdb-a707-43cc5874961d">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtNy0xLTEtMTA5NjE4_6cab9c61-1931-4857-87ff-6aadad3e5011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMTAtMS0xLTEwOTYxOA_9e5f87a0-edd8-475b-81e0-d6755696771b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMTMtMS0xLTEwOTYxOA_5dce6ac1-cad2-4e19-8214-71b185d81229">340,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMTYtMS0xLTEwOTYxOA_58a29192-c5e2-4249-86f1-28c501876f40">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMS0xLTEtMTA5NjE4_ca8b9f49-d33e-4c50-bd02-e166a652b5e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktNC0xLTEtMTA5NjE4_b50b3f26-2bab-4e07-8e2d-bf7d72665114">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktNy0xLTEtMTA5NjE4_308b92bc-b4d4-4825-81e6-06d22fee314d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMTAtMS0xLTEwOTYxOA_9720a92f-cd89-435c-bc31-dcb541b23fbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMTMtMS0xLTEwOTYxOA_848bb28a-e481-4904-8557-87a44c73ee67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMTYtMS0xLTEwOTYxOA_98cb9858-4ca4-438c-8b9c-b751e2e5c7af">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTEtMS0xLTEwOTYxOA_10dac0e0-4417-47cf-b4a5-18a75ae10fb2">63,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTQtMS0xLTEwOTYxOA_86360a92-a51f-4e6c-b2cb-32a2843a45de">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTctMS0xLTEwOTYxOA_ce68ac92-b309-4192-8d21-ffb7ce663512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTEwLTEtMS0xMDk2MTg_41cf2a39-72ce-4ada-8814-3ab1553abcd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTEzLTEtMS0xMDk2MTg_4a7feb68-c724-45b6-a563-859e29ff9a5c">63,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTE2LTEtMS0xMDk2MTg_1ef1b03e-9e95-43a3-9e0a-c7b7e20831fa">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTEtMS0xLTEwOTYxOA_4e58b13f-4528-4239-b368-a0040e853d6f">3,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTQtMS0xLTEwOTYxOA_aebb7251-1f4c-49c0-b4d2-0d84b94c2192">5.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTctMS0xLTEwOTYxOA_456dc3f8-ed67-427e-99bf-422b053f1b32">3,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTEwLTEtMS0xMDk2MTg_0162a0eb-a29e-477c-8034-a63843b6f81e">5.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTEzLTEtMS0xMDk2MTg_f6d9b821-7315-4d26-a28c-a2c4db787ac4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTE2LTEtMS0xMDk2MTg_173c4ac4-a339-4dc4-b88f-d3495851a6a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTEtMS0xLTEwOTYxOA_fd68a07f-aef5-4d2f-a942-1892201098bf">252,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTQtMS0xLTEwOTYxOA_5998fcc7-6989-4716-958b-abca1693df96">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTctMS0xLTEwOTYxOA_5bc4b277-71be-43ba-b570-85a097e5b4b3">33,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTEwLTEtMS0xMDk2MTg_a7218890-2607-42f8-b9f3-7e57342aa3e6">6.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTEzLTEtMS0xMDk2MTg_949f9848-6ee4-4f47-803b-dc9710769f60">218,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTE2LTEtMS0xMDk2MTg_5a1d24e7-1b0d-41c8-9c5f-e589c8ad8f5c">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTEtMS0xLTEwOTYxOA_9c345de5-c7cb-41b9-acbf-5408efb01492">982,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTQtMS0xLTEwOTYxOA_54e83d93-c5a2-4d21-9780-7c5425de453e">2.05</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTctMS0xLTEwOTYxOA_9996dc0d-fbeb-4806-a800-2ecef71039b7">282,105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTEwLTEtMS0xMDk2MTg_fab73de5-75d1-4af5-9ca3-a14c27cb74b4">6.89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTEzLTEtMS0xMDk2MTg_b5d7f32e-fcd8-4f12-b38a-681a185e4707">700,801</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTE2LTEtMS0xMDk2MTg_a680db0b-e943-4bae-b071-3df6d1adb319">0.10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance adjustments indicate forfeitures due to non-market performance conditions not achieved</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forfeited due to service conditions not fulfilled</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF <ix:nonFraction unitRef="chfPerShare" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="2" name="moln:WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzMxNg_10cbe746-a4b6-4b80-86df-803b449ca86a">22.35</ix:nonFraction></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     (2021: CHF <ix:nonFraction unitRef="chfPerShare" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="2" name="moln:WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzMyNA_ba3524eb-fae0-4fcc-b921-e9463cbd5927">19.87</ix:nonFraction>)</span></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1Mw_e4a0bf06-746d-4488-8f57-e2b5d2d4eee8" continuedAt="ia60ec2c20f434c9fbe1466ce47f94198" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2022:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise price<br/>CHF</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options / <br/>PSU/RSU<br/>(number)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remaining life<br/>(years)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thereof exercisable options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="id45b9f3adc9745569f9195e24eefccdd_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtMC0xLTEtMTA5NjE4_0934500b-5141-4069-bf32-554a525c3b66">6.06</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id45b9f3adc9745569f9195e24eefccdd_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtMS0xLTEtMTA5NjE4_69203454-692d-405b-b101-f3128933ae92">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icf36213d4e434ddab3aee4d16f583fc3_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtNC0xLTEtMTA5NjE4_602a2ed2-7d77-4de3-95d5-d4acfb6e3273">1.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id45b9f3adc9745569f9195e24eefccdd_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtNi0xLTEtMTA5NjE4_46524f29-dd41-49fb-8e9d-c890291e0095">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i69ed7f76d9f64feb954d4407df356caa_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtMC0xLTEtMTA5NjE4_12af9d38-37e4-43e7-b596-8b14f2a9e604">6.94</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i69ed7f76d9f64feb954d4407df356caa_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtMS0xLTEtMTA5NjE4_e0ced487-950e-4d37-a407-9e46b4d88627">266,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ab6a4e5dc284abeadf7a60e68289a52_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtNC0xLTEtMTA5NjE4_f7f3e522-0c73-4d69-b8ba-44930168cc39">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i69ed7f76d9f64feb954d4407df356caa_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtNi0xLTEtMTA5NjE4_12e5696e-5a40-449c-a511-de7baba76230">266,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU/RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i0f7c058068224203b33c7fcd1f1b017f_I20221231" decimals="2" name="moln:ExercicePriceOfOutstandingOtherEquityInstruments" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctMC0xLTEtMTA5NjE4_e2b5b0eb-8322-4b99-8ce8-dd06ae1ecfc7">0.10</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctMS0xLTEtMTA5NjE4_bf4da345-4252-4a61-b427-e4abd83e5f8b">700,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctNC0xLTEtMTA5NjE4_ec3485ee-f4ec-4768-b370-0d18c17cdc63">1.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" xsi:nil="true" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctNi0xLTEtMTA5NjE4_4bfb14d2-8541-4bf2-aec8-060e9d3e1f7e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzgtMS0xLTEtMTA5NjE4_e34d0316-55ce-4156-ab95-664dd4a2ea14">982,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="INF" name="moln:NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzgtNi0xLTEtMTA5NjE4_380acdf3-1717-4ebc-9e6f-13c1d92ea117">282,105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9079c5d39a15416ca730afa2318ffea2"><ix:continuation id="ia60ec2c20f434c9fbe1466ce47f94198"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2021:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise price<br/>CHF</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options / <br/>PSU/RSU<br/>(number)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remaining life<br/>(years)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thereof exercisable options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i3f487997ebf84760b436351b9cd07415_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItMC0xLTEtMTA5NjE4_bf62dfb6-d186-4f09-927a-1040dd1da0f8">2.31</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3f487997ebf84760b436351b9cd07415_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItMS0xLTEtMTA5NjE4_a85dde1e-1612-42c0-8cac-ca2d8ddc0b6c">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i18556d3232ec4e46aaa9d8f104201d8c_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItNC0xLTEtMTA5NjE4_e9465b65-85b9-430d-8ead-83141dc72905">0.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3f487997ebf84760b436351b9cd07415_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItNy0xLTEtMTA5NjE4_6a9816cf-75e1-47f9-aa34-aa980cf1f166">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtMC0xLTEtMTA5NjE4_4cd09695-c21a-45a3-95f5-e5a7f98a5cec">6.05</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtMS0xLTEtMTA5NjE4_c8bac9e6-11ec-4fa3-95f5-e6b613376a85">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie2287ef5f8e94d59ac113037e7dd05ac_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtNC0xLTEtMTA5NjE4_1c037e3c-a4c1-4786-be05-637e9d584971">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtNy0xLTEtMTA5NjE4_7d19dcba-86d5-4b78-9121-4876cd5f7f97">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtMC0xLTEtMTA5NjE4_cc5448e7-7919-4c74-988e-cfe4a46c1cf8">6.06</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtMS0xLTEtMTA5NjE4_8b903621-4257-41dc-9cb2-32b98a347740">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i09f51f1fee3243008271209344707ab6_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtNC0xLTEtMTA5NjE4_f66ce897-004f-49ad-a9eb-67feefbf1639">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtNy0xLTEtMTA5NjE4_dfa308a5-1e65-499d-85ea-130fdf2f19ad">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="ia4eea0ffff4540458374ebbc176fc17e_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtMC0xLTEtMTA5NjE4_3b573dfd-4779-4243-b8f9-612953ddd6e3">6.94</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia4eea0ffff4540458374ebbc176fc17e_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtMS0xLTEtMTA5NjE4_46ab86d6-27e7-41e2-8040-9976ccb2bbfd">299,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2f264b7c466b43e2be89711f4ad6b777_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtNC0xLTEtMTA5NjE4_3dccfb15-51a2-45b2-983e-9ad50e726285">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia4eea0ffff4540458374ebbc176fc17e_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtNy0xLTEtMTA5NjE4_dcf68790-e052-44ee-bf47-2c13eddc96d9">299,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU/RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chfPerShare" contextRef="i3f487997ebf84760b436351b9cd07415_I20211231" decimals="2" name="moln:ExercicePriceOfOutstandingOtherEquityInstruments" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctMC0xLTEtMTA5NjE4_8ff2148b-6fa8-449c-b667-3ed73f0f4713">0.10</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctMS0xLTEtMTA5NjE4_2b31238a-bfe2-405b-9493-95a74283e78a">643,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" name="moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctNC0xLTEtMTA5NjE4_05bae8fa-2187-4645-8ebf-6a64219f81bd">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" xsi:nil="true" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctNy0xLTEtMTA5NjE4_ef129133-9efa-4fb0-93d1-55c10de10883"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzgtMS0xLTEtMTA5NjE4_df1cfe2e-8e69-4c33-95e4-19a9535bbf3b">962,022</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="INF" name="moln:NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzgtNy0xLTEtMTA5NjE4_bdb3e215-b2b2-4130-a835-8a64042acf6a">318,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM0OQ_47f92baa-234d-421f-a602-40a5863f8897" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash costs for share-based payments recognized in the statement of comprehensive income can be attributed to the Group&#8217;s two functions as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzEtMS0xLTEtMTA5NjE4_6c836c16-9a91-4cca-88c3-828bae112ce3">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzEtNC0xLTEtMTA5NjE4_4696666c-b094-4684-8460-b60d23a338c6">2,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzEtNy0xLTEtMTA5NjE4_2fd6111d-6e8a-4629-bfd0-8dba427454ce">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzItMS0xLTEtMTA5NjE4_25bdb6f6-455a-40a5-9ef5-c16c8997226b">2,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzItNC0xLTEtMTA5NjE4_a7377ad7-28cb-41fe-b8dd-52d0ba799dab">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzItNy0xLTEtMTA5NjE4_3f00bbe4-6260-4d74-9ac1-0f6e80f02283">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzMtMS0xLTEtMTA5NjE4_863597aa-b849-4874-9c72-3ea4c8e7b9e7">5,088</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzMtNC0xLTEtMTA5NjE4_f2ed8813-fd77-4a83-9f06-1a53912ed863">4,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzMtNy0xLTEtMTA5NjE4_6088fa1c-da79-47fc-9cdf-2950f1ef1d87">2,932</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_319"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90ZXh0cmVnaW9uOjViY2JmMGE1YTUzODQwYjc5ODBlMDQ4ZmNkMTFkNzc1XzIw_5e05796c-0a63-4a6f-b0d7-ffe0adbf44ea" continuedAt="iab0797deafd34e869b9d52cfef615526" escape="true">Financial income and financial expense</ix:nonNumeric></span></div><ix:continuation id="iab0797deafd34e869b9d52cfef615526"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90ZXh0cmVnaW9uOjViY2JmMGE1YTUzODQwYjc5ODBlMDQ4ZmNkMTFkNzc1XzIx_ac370d5d-9a97-45c0-a279-ac2afd79c010" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:58.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on financial assets held at amortized costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzEtMS0xLTEtMTA5NjE4_7150d3ca-8165-43dd-8d92-1af4ae5ab3db">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzEtNC0xLTEtMTA5NjE4_af8521f5-28fa-426e-95e2-5ac5b9ce2d7f">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzEtNy0xLTEtMTA5NjE4_a74edc72-95bc-415d-a49f-c32c52d409e2">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net foreign exchange gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:NetForeignExchangeGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzItMS0xLTEtMTA5NjE4_91f5980a-c8e1-45f8-882b-27b52b19f349">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:NetForeignExchangeGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzItNC0xLTEtMTA5NjE4_2d942ed6-85d4-4161-9922-5b538f29d797">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:NetForeignExchangeGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzItNy0xLTEtMTA5NjE4_5b08ec60-6dcc-47a4-8559-0d89da15386d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzMtMS0xLTEtMTA5NjE4_413f637b-b5a8-44b2-988d-aed4240d4241">1,859</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzMtNC0xLTEtMTA5NjE4_8e14015a-f947-47f1-9236-f89f43cb0de4">191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzMtNy0xLTEtMTA5NjE4_6775caeb-61d3-46b9-8374-fab830e4c9ec">367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90ZXh0cmVnaW9uOjViY2JmMGE1YTUzODQwYjc5ODBlMDQ4ZmNkMTFkNzc1XzIy_d73ac9f8-6f01-4039-bdf2-75dbfea7be2b" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial expense</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:58.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzEtMS0xLTEtMTA5NjE4_2d8794bf-c1d5-4026-9fcd-6ef95ea9d17a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzEtNC0xLTEtMTA5NjE4_503eadb4-4a7c-4bb8-be42-299b1958df48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzEtNy0xLTEtMTA5NjE4_606f6c90-f5d4-4964-a559-441218e158e1">4,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative interest on financial assets held at amortized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzItMS0xLTEtMTA5NjE4_44cb8b81-9b65-4712-9c52-1e3b701db1aa">562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzItNC0xLTEtMTA5NjE4_af671ced-8f77-4a5d-ac68-3256c359f944">495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzItNy0xLTEtMTA5NjE4_e3c1969e-9971-4bc1-9054-19792fad5426">271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzMtMS0xLTEtMTA5NjE4_96a1060a-e697-417d-ace0-c051c6ac5320">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzMtNC0xLTEtMTA5NjE4_29f9b2d8-2b2a-4533-bbe8-3bb3c8ddbc90">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzMtNy0xLTEtMTA5NjE4_048e8f01-ae1a-47af-96a5-6ac294acc4b8">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:OtherFinanceCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzQtMS0xLTEtMTA5NjE4_aa19e989-e839-4784-b421-1e785b0a78b7">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherFinanceCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzQtNC0xLTEtMTA5NjE4_d32f9d10-d43e-4b71-a417-017f53fa9899">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:OtherFinanceCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzQtNy0xLTEtMTA5NjE4_53fdafc7-1613-4c4f-8da4-5aca3b1db9b4">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzUtMS0xLTEtMTA5NjE4_44e8882e-8ff5-44ae-8392-07a10ccebf11">619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzUtNC0xLTEtMTA5NjE4_a4fc90af-3da2-4418-8ef1-0cb44d9dbb2f">556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzUtNy0xLTEtMTA5NjE4_c718809f-44cf-4edf-8b82-d905aed4acb3">4,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_322"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE3OA_ec42e320-e297-40d6-b97c-1d706c18502e" continuedAt="ifcf228b6c5f744cca2bd46a002d0094e" escape="true">Taxes</ix:nonNumeric></span></div><ix:continuation id="ifcf228b6c5f744cca2bd46a002d0094e" continuedAt="i95e7af9f38d84580a1441759baf5ccbf"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 the Company generated a taxable profit whereas in 2021 and 2020 the Company generated a taxable loss in Switzerland, all of which are reflected in the Company&#8217;s cumulative tax loss carry forward. The Company did not have to pay or accrue any income taxes in the reporting periods as the 2022 taxable income in the period is fully offset by the utilization of accumulated tax losses. Any future taxable income will be subject to Swiss federal, cantonal and communal income taxes. The Company&#8217;s applicable income tax rate for the year 2022 is 19.4% (2021: 19.4%; 2020: 20.8%).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i95e7af9f38d84580a1441759baf5ccbf"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc., which is incorporated in the United States in the State of Delaware, is subject to statutory U.S. federal corporate income taxes and minimal state taxes for Massachusetts and New York. </span></div><div style="margin-bottom:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, current income tax expense of TCHF <ix:nonFraction unitRef="chf" contextRef="i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231" decimals="-2" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzYx_f2331bd2-d43f-47c5-9911-57da8047c74c">0.3</ix:nonFraction> (TUSD <ix:nonFraction unitRef="usd" contextRef="i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231" decimals="-2" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzY1_c3739f58-a7a6-48c8-9423-843866bfb063">0.3</ix:nonFraction>) was recognized by the Group's U.S. based subsidiary for estimated U.S. tax obligations of the subsidiary based on intra-Group activity (for the year ended December&#160;31, 2021: tax credit of TCHF <ix:nonFraction unitRef="chf" contextRef="i601f0ea0b2a5490cade7bed682109126_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzc1_9f391459-55ee-4219-9413-32e0c4df89bf">2</ix:nonFraction> (TUSD <ix:nonFraction unitRef="usd" contextRef="i601f0ea0b2a5490cade7bed682109126_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzc5_10e1f131-a9d6-44ca-a22b-c99a4f97ce48">2</ix:nonFraction>) and for the year ended December 31, 2020: tax expense of TCHF <ix:nonFraction unitRef="chf" contextRef="i3ced05873ca5491bbfebf6675070c334_D20200101-20201231" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzg3_491b53f8-a5d2-4dc6-b4e8-de7343c52455">11</ix:nonFraction> (TUSD <ix:nonFraction unitRef="usd" contextRef="i3ced05873ca5491bbfebf6675070c334_D20200101-20201231" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzkx_d04c8d99-9657-479f-8d8c-a60774635f19">13</ix:nonFraction>)). The tax expense amount comprises of the sum of the minimal taxes payable for federal taxes and for the various states in which Molecular Partners Inc. is liable for taxes. The applicable income tax rates are 21% federal tax plus 8.00% state tax (Massachusetts) and 6.50% (New York). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net operating profit for tax purposes amounted to TCHF <ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:NetOperatingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzExNw_9f057846-b552-484e-8021-4e3738dbd604">124,020</ix:nonFraction> in 2022 whereas prior years generated net operating losses of TCHF <ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:NetOperatingLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNTQ2MQ_e91fc7dd-eb32-4645-a157-1f888f9e92eb">58,632</ix:nonFraction> in 2021 and TCHF <ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:NetOperatingLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNTQ5OA_fe929ea7-60c8-4bdd-adb8-345e62c17542">58,631</ix:nonFraction> in 2020.The remaining tax losses as of December 31, 2022 of TCHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE0MQ_be806e52-b064-4404-a283-427f423a5a7e">88,198</ix:nonFraction> may be used as tax loss carry forwards to offset future taxable income over a period of <ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:TaxLossCarryforwardsExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE0NQ_63364d82-d49c-4f63-81b6-3a5845024872">seven years</ix:nonNumeric>, with the amount of TCHF <ix:nonFraction unitRef="chf" contextRef="ia07c5697db104aff83e8133bcbfd34e9_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE0OQ_ef132c27-c92e-4796-b6b0-fd1cb8efc634">29,566</ix:nonFraction> to expire in 2027 and TCHF <ix:nonFraction unitRef="chf" contextRef="ia0b15b456e71466f914f4fb77e4fbfc2_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNTYwMg_29056bec-7d61-4569-95e0-77f55d6f4b8c">58,632</ix:nonFraction> to expire in 2028. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred tax assets have been recognized for these tax loss carry forwards, because as of December&#160;31, 2022, it was not considered probable that such loss carry forwards can be utilized in the foreseeable future. In addition, no deferred tax positions were recognized on other deductible temporary differences (e.g. pension liabilities under IAS 19 for a total of TCHF <ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE2NQ_a161e82c-ba49-4d66-8082-60a4890e4a14">2,245</ix:nonFraction>, see also note 18.1) due to the tax losses carried forwards. Income tax expense has been calculated for the year ending December&#160;31, 2022, based on the effective income tax rate expected for the full financial year, being <ix:nonFraction unitRef="number" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNzA5MQ_9ba8b94b-4b32-4398-b3f3-eec02ed812ed">0</ix:nonFraction>% on December&#160;31, 2022, given that the 2022 taxable income in the period is fully offset by the utilization of accumulated tax losses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the facts above, as well as the fact that the Company incurred no significant tax expense in the reporting periods presented, a numerical reconciliation of the effective tax rate is not provided. The primary reconciling item is the effect of unrecognized deferred tax assets for tax losses and deductible temporary differences.</span></div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE3OQ_0b1f8c24-6a21-42a9-8707-2ecfaa62be12" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the expiry of tax loss carry forwards for the Company, for which no deferred tax asset was recognized:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie9e4c0c2414646e3920288a6e3d93b50_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzMtMS0xLTEtMTA5NjE4_f99e675d-9cce-4c16-b8aa-a6c525b23757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i5a33d4e0e53241cb86e82f186e53b0d5_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzMtNC0xLTEtMTA5NjE4_f03977a8-90e6-4ff0-92b4-a47d9e6781bc">15,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i448b10a8ed3a4b459f511c18fe6a4023_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzQtMS0xLTEtMTA5NjE4_1fdb8dd1-6994-42c1-b43f-5dbd839cfa0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i309bd18113fa4d088977cb2d88cd4092_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzQtNC0xLTEtMTA5NjE4_244198c7-8e0d-4dae-9f3e-0e2dc32729aa">21,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia64fa509207d47efa0e81300d9d73cd3_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzUtMS0xLTEtMTA5NjE4_a55f3283-3ee8-40ac-ab5b-9c440c8e6dd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i9273a8f19ab4459a81e57dbd2f441d17_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzUtNC0xLTEtMTA5NjE4_87e1d8b4-aff3-4c97-b409-5e0af05659b6">23,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i875b50cd70744049a9efbc6796621651_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzYtMS0xLTEtMTA5NjE4_7ea1b8d7-78a4-4a81-8d37-f6f26f862f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic2651abe27944dcdaf65a2279954b10f_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzYtNC0xLTEtMTA5NjE4_417d3cd7-fc1b-4327-87f4-2062071aaf22">33,446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ia07c5697db104aff83e8133bcbfd34e9_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzctMS0xLTEtMTA5NjE4_ebb9af83-d09f-40f2-9b99-011a6d6b5dc1">29,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ibf748a46ec9a4ba8b9feba532a6b4da2_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzctNC0xLTEtMTA5NjE4_fd6ec585-261c-4e17-8ddf-3ddc20a3ec84">58,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ia0b15b456e71466f914f4fb77e4fbfc2_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzgtMS0xLTEtMTA5NjE4_f78d4427-9449-44ba-9f60-6b7f740b715b">58,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="icfae2f7fb65743218e1d395982995a0e_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzgtNC0xLTEtMTA5NjE4_b980491a-bea1-4efa-8ed3-dd30e86d9c36">58,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifc42f5752df44c938ff23151446565fc_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzktMS0xLTEtMTA5NjE4_5f2e7218-cfcd-4a36-b213-5c5a17ed6c0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ia11f395ed16342c5ba81005541468e8a_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzktNC0xLTEtMTA5NjE4_a41a0b4f-67c6-47f6-9041-d136499d76b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total tax loss carry forwards as at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzEwLTEtMS0xLTEwOTYxOA_c9ce1dc7-d22c-43c0-a222-57b3ee30c4a4">88,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="moln:TaxLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzEwLTQtMS0xLTEwOTYxOA_71ec72f0-92a1-4798-b3bb-bb7f46840c58">212,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_325"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzU4_e1738639-85c4-4740-8708-fa9b992c4915" continuedAt="i681d9521e2c64d8b970f2cb73931c0dc" escape="true">Earnings per share</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i681d9521e2c64d8b970f2cb73931c0dc" continuedAt="idc4378b26f924cc9973d83a64c803945">Basic earnings per share is calculated by dividing the net result attributable to the shareholders of the Company by the weighted average number of shares issued and outstanding during the reporting period, excluding any shares held as treasury shares. Diluted earnings per share additionally takes into account the potential conversion of all dilutive potential ordinary shares. </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idc4378b26f924cc9973d83a64c803945"><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:EarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzU2_636720b0-cb64-4af6-97d4-1750396b8993" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares used in computing basic earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzEtMS0xLTEtMTA5NjE4_e3197fb3-7497-4e65-9b54-1f15dcb7ffef">32,469,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzEtNC0xLTEtMTA5NjE4_5d4bac1b-bd9c-447a-9dce-2fb03521b367">31,005,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzEtNy0xLTEtMTA5NjE4_51fd6cf0-6ca4-4377-8232-44fa7cf80dd6">25,000,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares used in computing diluted earnings per share</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzItMS0xLTEtMTI5NzI0_66886844-0b37-4ed5-8297-3eb2d0e948bd">33,265,567</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzItNC0xLTEtMTI5NzI3_f177326f-71a9-4c15-a2c5-59fa204f7dc9">31,005,171</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzItNy0xLTEtMTI5NzMw_873ed1e5-8bbf-470a-aeb5-e47f673e83db">25,000,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the number of shares that are dilutive, is <ix:nonFraction unitRef="shares" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="0" name="moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzM1_fc856eeb-5dd6-4d91-a5ad-1de4ba298014">795,610</ix:nonFraction>. For all comparative prior periods presented all potential ordinary shares were anti-dilutive. The number of shares that potentially could be dilutive in the future were <ix:nonFraction unitRef="shares" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="0" name="moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzQz_b883cf75-3665-400c-952a-3abb5a800f3b">835,422</ix:nonFraction> as at December&#160;31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="0" name="moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzUx_24764bba-9460-4ee1-9d7a-6f5a92233752">794,377</ix:nonFraction> as at December&#160;31, 2020.</span></div></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_328"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExNw_1562a2fc-f576-4dfe-b830-788ed8ebb122" continuedAt="i16f75bd53e4b49f5b9c03a4232fcfc60" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i16f75bd53e4b49f5b9c03a4232fcfc60" continuedAt="i2f4642ea7ed3426fbb3e1cfd11b0ef61"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group leases office and laboratory facilities in Schlieren, Switzerland. These leases generally have terms between <ix:nonNumeric contextRef="if4de6e75b42b401296433bd018ede76d_D20220101-20221231" name="moln:LeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzE0_fd752879-2c21-490c-8ce0-172205078332">2</ix:nonNumeric> and <ix:nonNumeric contextRef="iaac4cc8da2f54efab0f4f0d53dcfdf39_D20220101-20221231" name="moln:LeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzE4_f3243d89-fcbe-4a0b-946c-f3a875f969de">10</ix:nonNumeric> years and contain extension or terminations options exercisable by the Group up to <ix:nonNumeric contextRef="iaac4cc8da2f54efab0f4f0d53dcfdf39_D20220101-20221231" name="moln:LeaseExtensionOrTerminationOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzIy_30c3baf2-39cd-401d-bc21-419cfa96a637">one year</ix:nonNumeric> before the end of the non&#8209;cancellable contract period. These terms are used to maximize operational flexibility in terms of managing contracts. The options to extend are held by the Company and the termination options are held both by the Company and the lessor. As of December&#160;31, 2020, the Group exercised the option to extend the lease on its facilities in Schlieren by <ix:nonNumeric contextRef="ie5811d9f19074f96a9cbb5482d36febc_D20200101-20201231" name="moln:LeaseExtensionTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzMw_811f8afd-0649-4d1a-93fe-aeeeccd832db">five years</ix:nonNumeric> with a new lease term ending on December&#160;31, 2026. The earliest contractual termination date for both the lessor and the Group on the major real estate lease is December&#160;31, 2025. For information about the right-of-use assets please also see note 6.</span></div><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExOA_de62a082-04e1-425f-8f8a-5e01f113b6e8" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below are the carrying amounts of the lease liabilities and the movements during the period:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as at January 1,</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEtMS0xLTEtMTA5NjE4_72d4db79-9ec1-4897-b6fd-506c7d110ba8">6,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEtNC0xLTEtMTA5NjE4_7fb0208e-d879-4369-8e49-31f7f14fb3a6">7,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions / new leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:IncreaseThroughNewLeasesOperatingLeases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzItMS0xLTEtMTA5NjE4_652cf571-9fca-48b4-9249-0588e3832526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:IncreaseThroughNewLeasesOperatingLeases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzItNC0xLTEtMTA5NjE4_9662e4d9-f1b9-4ded-baac-81ffba9edb7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzMtMS0xLTEtMTA5NjE4_27f5225c-57a4-4b71-81d6-e254117489c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzMtNC0xLTEtMTA5NjE4_7c4b1858-21fb-4f16-b61a-44d18c5191ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzQtMS0xLTEtMTA5NjE4_ecdca11e-0e3b-4b3c-8306-b0bce71839d9">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzQtNC0xLTEtMTA5NjE4_48a56737-4154-4c9e-9bf5-3bb2948b5c2e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzUtMS0xLTEtMTA5NjE4_eed6d847-899a-4742-bbef-65f291515a54">1,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzUtNC0xLTEtMTA5NjE4_4e9e5956-e34e-453d-ba4a-e98449770f6d">1,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as at December 31,</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzYtMS0xLTEtMTA5NjE4_4cde766e-22a8-43a4-986f-a45f6bce430b">4,850</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzYtNC0xLTEtMTA5NjE4_3aa26eab-d537-437d-acab-d01ed36b4ef2">6,039</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzgtMS0xLTEtMTA5NjE4_18c49f60-386a-4ea8-a9d4-ea31acd26bba">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzgtNC0xLTEtMTA5NjE4_5f4b3884-9163-4921-aa62-95d0641860fb">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzktMS0xLTEtMTA5NjE4_afc0c0d4-4ab5-4f30-9f4b-51a8dc8561d0">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzktNC0xLTEtMTA5NjE4_c6a2d81e-ad31-4c75-9c06-d7e180e49db7">4,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as at December 31,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEwLTEtMS0xLTEwOTYxOA_f40bb559-7c0e-492f-ac07-d5560758c39d">4,850</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEwLTQtMS0xLTEwOTYxOA_7bd882f1-b8f4-46a7-94f5-9312d78274a0">6,039</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="15" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExNQ_5789e782-192d-451b-be37-174023d03ba2" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the expense amounts recognized in the consolidated statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:58.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation on right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzEtMS0xLTEtMTA5NjE4_fc9a5c0b-69de-4540-9c55-2e3243243f16">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzEtNC0xLTEtMTA5NjE4_d527c733-fbce-4226-ba71-cf8a92eb5c50">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzEtNy0xLTEtMTA5NjE4_3c5484da-f1a5-4250-bf4c-1c062fcea901">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzItMS0xLTEtMTA5NjE4_4b3cf030-f5e5-4572-b800-7466d85972d3">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzItNC0xLTEtMTA5NjE4_088c8c29-0a6f-45cc-bd5e-f6dcaf3b2956">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzItNy0xLTEtMTA5NjE4_90cbd60c-d79c-4257-882d-7c58b33ea25b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzMtMS0xLTEtMTA5NjE4_87185449-c61e-487b-a349-1abf15a26c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzMtNC0xLTEtMTA5NjE4_277f71a8-0df0-40f8-b3d6-63523d214c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzMtNy0xLTEtMTA5NjE4_990a0971-028f-4f48-bc21-cc98dd9089be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total amount recognized in profit or loss</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:LeaseCostRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzQtMS0xLTEtMTA5NjE4_95f11ae7-b03e-4eec-b901-a4d94c58a4ef">1,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="moln:LeaseCostRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzQtNC0xLTEtMTA5NjE4_99f93a2d-bcd8-4208-b4a2-0b6cefe680ab">1,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="moln:LeaseCostRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzQtNy0xLTEtMTA5NjE4_761f0a26-af68-469b-8d95-2ddac524d96b">1,280</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cash outflow for leases for the year ended December&#160;31, 2022 amounted to TCHF <ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2Xzg0_184925db-b5ce-4119-a00c-d10a86ff435d">1,232</ix:nonFraction> (year ended December&#160;31, 2021 TCHF <ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2Xzk2_b858f4ab-85a9-4112-97d0-facc35902999">1,232</ix:nonFraction>; year ended December&#160;31, 2020 TCHF <ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzEwOA_859fb679-1e2b-46c7-ac87-5840c9755952">1,275</ix:nonFraction>).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2f4642ea7ed3426fbb3e1cfd11b0ef61"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExNg_af4c47be-af64-4535-b0d4-cf894aecd995" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual maturities of financial liabilities at December 31, 2022</span></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1 year</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and 2 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 2 and 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total contractual cashflows</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying Amount lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i46461ef8c2bf4ad194fcc5da61eb4790_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtMS0xLTEtMTA5NjE4_4ec7e113-d755-436e-82c0-fe12b6530612">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i859523f38bfc4cef886b0469de3d3c27_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtMy0xLTEtMTA5NjE4_6f37c091-736b-4063-ac61-e244c3656de9">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ie87b69197a5e41b68d889d5a9f94133c_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtNS0xLTEtMTA5NjE4_7a9cf37c-3d14-40b4-bd17-cc99fcd9ee55">2,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i20e09613a3fb4d9ca1c6817d2d362664_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtNy0xLTEtMTA5NjE4_c7eb243d-ac43-4590-a34a-c73e58112862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtOS0xLTEtMTA5NjE4_73f41b0d-1a0b-485e-a360-d3d15f9b0b72">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtMTEtMS0xLTEwOTYxOA_c12379e5-627c-425a-8e9e-160fe3f29116">4,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual maturities of financial liabilities at December 31, 2021</span></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1 year</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and 2 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 2 and 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total contractual cashflows</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying Amount lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6592e0e0184441c58126d7e24b37d82e_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtMS0xLTEtMTA5NjE4_13dceecf-7dcf-479f-9faa-4aa7bcb46f17">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="if56ff0ffb76b4ef7bdd5f9a0f0de46ec_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtMy0xLTEtMTA5NjE4_3ea80005-ef49-4f71-935b-888533b687ea">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6fe3972176af4d07b4e1942adcf6c075_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtNS0xLTEtMTA5NjE4_081e9641-659b-47c3-aed2-2e1d5fa2f829">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6f6b2661b6384f1fa68e0f05fada4e22_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtNy0xLTEtMTA5NjE4_092d90b6-a418-4ed6-9f0a-1dcdf9e178ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtOS0xLTEtMTA5NjE4_4249e343-900b-4936-bde8-4430af5235d0">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtMTEtMS0xLTEwOTYxOA_5f99987a-d3bc-4ca4-97db-44d0a46e99ea">6,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_331"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzQy_12169646-ff94-494b-9a84-626980ce99c5" continuedAt="if5b7f8ce30934959899c1d6b30b3e68f" escape="true">Related party disclosures</ix:nonNumeric></span></div><ix:continuation id="if5b7f8ce30934959899c1d6b30b3e68f"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzQz_39683149-0c0d-4b63-b539-750f492a8f65" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs of key management, which includes executive management and the Board of Directors, are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term employee benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzEtMS0xLTEtMTA5NjE4_9e912bfd-2de4-4969-be9c-06a0d4f9df81">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzEtNC0xLTEtMTA5NjE4_f5d703fc-46b2-4d60-b009-1301b190a4a9">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzEtNy0xLTEtMTA5NjE4_f1a4677f-5987-4db7-bbbb-d0f8fa8b65ba">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-employment benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzItMS0xLTEtMTA5NjE4_b0329695-ab60-47c3-8e06-9abbae38d668">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzItNC0xLTEtMTA5NjE4_607ee237-4adf-43d2-bc89-f50be755bfd6">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzItNy0xLTEtMTA5NjE4_90553a76-f4b5-4c93-b851-4b77a12cb831">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzMtMS0xLTEtMTA5NjE4_7baae529-8366-4590-9f13-d9012c883cd8">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzMtNC0xLTEtMTA5NjE4_68d6358d-9a42-4c2a-93f5-fb8f41c76b84">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzMtNy0xLTEtMTA5NjE4_6c1942ae-bf24-4c49-a411-8fe664da994c">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzQtMS0xLTEtMTA5NjE4_1c0f34f6-3e17-48b2-b557-75e2d84ab3a4">5,567</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzQtNC0xLTEtMTA5NjE4_b00c76c1-10a1-404a-a06f-3ab73cb50d09">4,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzQtNy0xLTEtMTA5NjE4_39be0dab-2b8c-4934-a9e6-0c71d8c15336">4,214</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pamela Trail departed from her role as Chief Scientific Officer in July 2019. She has continued to support the Group as a consultant after this date. For the year ended December&#160;31, 2022, Pamela Trail's consulting fees amounted to TCHF <ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzEwOTk1MTE2Mjg1ODk_cbb10263-5241-4491-b4e8-5922c7c24d09">nil</ix:nonFraction> (2021: TCHF <ix:nonFraction unitRef="chf" contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzU0OTc1NTgxNDY0MQ_c4ac91a6-44e6-4744-af7c-8093f92b618e">13</ix:nonFraction>, 2020: TCHF <ix:nonFraction unitRef="chf" contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzEwOTk1MTE2Mjg1OTI_b44e0e7a-417e-4c10-93ce-5d97bce0f9f7">45</ix:nonFraction>). In 2022, there was a further payment of TCHF <ix:nonFraction unitRef="chf" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="-3" name="moln:PaymentForTermOfEmploymentRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzU0OTc1NTgxNDY2NQ_67751612-1f6e-4aa3-b285-1f2d1aae4564">21</ix:nonFraction> made to Pamela Trail settling an outstanding amount relating to her term of employment.</span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_334"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzQvZnJhZzpkOTYxY2U0ZTY5MTk0ZmE0OTQ0OWVhNzIwOTdhN2E1Mi90ZXh0cmVnaW9uOmQ5NjFjZTRlNjkxOTRmYTQ5NDQ5ZWE3MjA5N2E3YTUyXzIx_1a4fa5ff-c336-46c9-ab06-06ec866f021b" continuedAt="id85ef5adeae74a35a438875a78487827" escape="true">Capital commitments</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id85ef5adeae74a35a438875a78487827">As of December&#160;31, 2022 and December&#160;31, 2021, the Group did not have any capital commitments.</ix:continuation></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_337"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.&#160;&#160;&#160;&#160;<ix:continuation id="ic1ed7667b427408aa17ff53fbc317570" continuedAt="ifea587a60141489db69db29d66f51b0b">Financial risk management</ix:continuation></span></div><ix:continuation id="ifea587a60141489db69db29d66f51b0b" continuedAt="ia917168d803f47a99789da28b9b8cc87"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to reduce its foreign exchange exposure, Molecular Partners may enter into currency contracts with selected high-quality financial institutions to hedge against foreign currency exchange rate risks. The Group&#8217;s primary exposure to financial risk is due to fluctuation of exchange rates between CHF, USD and EUR.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s hedging policy is (1) to maximize natural hedging by matching expected future cash flows in the different currencies and (2) if market conditions allow to consider hedging certain of the remaining expected net currency exposure as the need arises. However, due to market volatilities, the impact of negative interest rates during most of 2022 in Switzerland and uncertainties in the cash flows, a 100% hedging of the currency exposure is impossible or not appropriate. Molecular Partners does not engage in speculative transactions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Group did not enter into any forward currency transactions. No forward currency transactions were outstanding as of December 31, 2022 and 2021.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia917168d803f47a99789da28b9b8cc87" continuedAt="i82fad1bb96754025abf39a01428a2c20"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90ZXh0cmVnaW9uOjE2ZmUyOWJlM2Y1NDQzYThiODU5M2QxNWI3NjIwMzczXzc3_b5b3ae65-af10-4e63-88c9-baeb528c2252" continuedAt="i93ec2715d58b4de38927dc46651ddf6e" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table demonstrates the sensitivity to a reasonably possible change in exchange rates for the Group's main foreign currencies, USD and EUR, with all other variables held constant, of the Group&#8217;s result before taxes. There is no direct impact on the Group&#8217;s equity.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. exchange rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231" decimals="2" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzItMS0xLTEtMTA5NjE4_3bd29b07-bdf6-408d-a3af-386b3d400713">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzItNC0xLTEtMTA5NjE4_85441b83-1fc2-4ee6-8c97-d25575f75115">5,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzMtMS0xLTEtMTA5NjE4_c5bdebb3-f84c-47b1-8a67-11307be7a82e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzMtNC0xLTEtMTA5NjE4_77bdb23e-73a4-47f6-9a4d-51df9bdd8a9e">5,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231" decimals="2" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzQtMS0xLTEtMTA5NjE4_f22bea8b-c8a0-4711-81a4-6bf7c6ac3a7d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzQtNC0xLTEtMTA5NjE4_98fc1607-d52f-4cef-b787-2f5ff2e83ef3">6,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzUtMS0xLTEtMTA5NjE4_9bb51d1f-d825-40bf-8c0a-da00fdda0b6a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzUtNC0xLTEtMTA5NjE4_c65ddb2e-5938-40f6-9a84-758408a3162a">6,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231" decimals="2" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzYtMS0xLTEtMTA5NjE4_e14dbe9d-4434-46e5-ae22-aec18ada3b46">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzYtNC0xLTEtMTA5NjE4_0612c886-666f-484e-b1e1-86594f08647b">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzctMS0xLTEtMTA5NjE4_4e859b3f-b865-4f3e-b819-1e7964d56a89">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzctNC0xLTEtMTA5NjE4_bc6e6084-ddc7-47e9-8412-aab8451a8978">2,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231" decimals="2" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzktMS0xLTEtMTA5NjE4_639017af-655a-4155-b9b2-e8baac24cd92">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzktNC0xLTEtMTA5NjE4_32845329-9a88-4c94-884a-4e5b998a68de">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEwLTEtMS0xLTEwOTYxOA_c81398bd-266f-4214-966c-3dd1d0f5fae1">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEwLTQtMS0xLTEwOTYxOA_32b13255-2647-4abe-bc6f-ec19eb498579">1,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231" decimals="2" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzExLTEtMS0xLTEwOTYxOA_b9267f07-adac-4168-be4c-ae112acdfa55">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzExLTQtMS0xLTEwOTYxOA_aaddcd22-0d78-4eb3-b6fe-a2cf6dfebdba">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEyLTEtMS0xLTEwOTYxOA_e1ccc80b-c56f-46f1-a223-d1ce40b64fcb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEyLTQtMS0xLTEwOTYxOA_57a43284-1172-4c2c-bcce-28018a9c0e39">2,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231" decimals="2" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEzLTEtMS0xLTEwOTYxOA_a9a5b28e-4f3f-4d5f-8302-349e42680b3c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEzLTQtMS0xLTEwOTYxOA_1dffc1d2-847a-442f-9465-ce2b1a59b5c5">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzE0LTEtMS0xLTEwOTYxOA_d175abd3-eb9a-46b9-9783-f314a684569c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzE0LTQtMS0xLTEwOTYxOA_e05b632d-e7c4-4cc2-8ecc-06b611669836">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners earns or pays interest on cash and cash equivalents, and its profit and loss may be influenced by changes in market interest rates. The Group does invest its cash balances into a variety of current and deposit accounts in <ix:nonFraction unitRef="bank" contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" decimals="INF" name="moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90ZXh0cmVnaW9uOjE2ZmUyOWJlM2Y1NDQzYThiODU5M2QxNWI3NjIwMzczXzUx_22cab5fc-44b0-4ad6-a35e-6a8d9eaddb87">four</ix:nonFraction> different Swiss banks to optimize interest. In addition, the Group does invest a portion of its cash into risk free money market investments in line with its treasury guidelines.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group strives to optimize the net balance of interest paid and interest received by monitoring the interest rates applicable over the major currencies the Group holds as well as the offered holding periods. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i93ec2715d58b4de38927dc46651ddf6e" continuedAt="ib7df9ff4ba4e4d84a490a5382ad7d792">The following table demonstrates the sensitivity of the main currencies used in the Group, to reasonably possible changes in interest rates, with all other variables held constant, of the Group&#8217;s results before tax. There is no direct impact on the Group&#8217;s equity.</ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i82fad1bb96754025abf39a01428a2c20" continuedAt="i2278aa244dc8401fb29db0901038175e"><div style="margin-bottom:8pt"><ix:continuation id="ib7df9ff4ba4e4d84a490a5382ad7d792"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. interest rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHF Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzItMS0xLTEtMTA5NjE4_3b7bf98a-39a2-405b-a8c3-2c82cbda8fea">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzItNC0xLTEtMTA5NjE4_77618f8e-37ef-4b57-8797-c3576ffacc6e">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzMtMS0xLTEtMTA5NjE4_7258ab1a-365c-4616-a80f-9fd75c85e5aa">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzMtNC0xLTEtMTA5NjE4_4ba873f9-42a3-4fe8-be00-19bc05758a7d">888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzQtMS0xLTEtMTA5NjE4_477922ac-6237-443d-a90d-260c45ba567b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzQtNC0xLTEtMTA5NjE4_e23aecdc-890f-4bcb-bd2d-c9d02b29f2c5">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzUtMS0xLTEtMTA5NjE4_547de7d8-c9d7-4273-bea6-50e20757d176">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzUtNC0xLTEtMTA5NjE4_52437581-6063-413e-90b2-323863009922">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzYtMS0xLTEtMTA5NjE4_061af2f6-8d85-4296-9941-b87ccd2481ed">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzYtNC0xLTEtMTA5NjE4_8df49456-52db-4813-a265-a2beba4bd5fd">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzctMS0xLTEtMTA5NjE4_bc212912-b225-4724-a64f-459cfdb2442f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzctNC0xLTEtMTA5NjE4_303a22ba-4171-4395-b5c2-bb29dea202a5">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzktMS0xLTEtMTA5NjE4_c5989fda-7695-43aa-8282-aaffa578ce12">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzktNC0xLTEtMTA5NjE4_d2d92c4e-8cbf-4162-931a-acb61037eeb2">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEwLTEtMS0xLTEwOTYxOA_5b4b1a08-f0ec-4a29-9015-1799d86585e6">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEwLTQtMS0xLTEwOTYxOA_db853c1e-7077-4107-8f0d-6164d0bc7e9e">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzExLTEtMS0xLTEwOTYxOA_6f0ad1d5-5206-4a66-bec5-b49a53329280">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzExLTQtMS0xLTEwOTYxOA_c443c952-a4ca-46e3-a8b6-2e377a5de130">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEyLTEtMS0xLTEwOTYxOA_2ce36ff1-07c4-4c95-b020-7dc07b5c945a">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEyLTQtMS0xLTEwOTYxOA_4036476e-fd72-41de-85ed-d1a49c7d6783">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEzLTEtMS0xLTEwOTYxOA_f5004416-1ac3-4691-8527-f161b4189d04">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEzLTQtMS0xLTEwOTYxOA_67ac8355-ce59-4c40-a436-8f94e09fb769">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE0LTEtMS0xLTEwOTYxOA_5e735c18-8441-4922-ae60-b8021d0af13c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE0LTQtMS0xLTEwOTYxOA_ccb14483-8fdb-403a-aba6-a52c626cb806">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE2LTEtMS0xLTEwOTYxOA_f285ac56-1d82-4cae-a8c8-e1c5fb11d0d8">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE2LTQtMS0xLTEwOTYxOA_1cc33b9a-3ff9-4938-930a-027403fc446a">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE3LTEtMS0xLTEwOTYxOA_03ca2ec6-7d1b-42cf-a817-06b909a68e13">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE3LTQtMS0xLTEwOTYxOA_179878ed-a310-482c-b3a3-7bd24f166a6a">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE4LTEtMS0xLTEwOTYxOA_7941fee4-d1ca-439c-93c0-f324281de7cd">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE4LTQtMS0xLTEwOTYxOA_87d98923-d819-4463-92a4-52a6aeb586b5">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE5LTEtMS0xLTEwOTYxOA_caa70c42-dd68-4b79-8ae5-8c3a618b00e4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE5LTQtMS0xLTEwOTYxOA_89d19629-39d2-42f2-8d5d-b204d67a53df">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+<ix:nonFraction unitRef="number" contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231" decimals="3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIwLTEtMS0xLTEwOTYxOA_6035c6b4-8f06-461f-a4bf-6b5d381dd2d3">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIwLTQtMS0xLTEwOTYxOA_6c1ac547-8dc0-4a24-9d7f-9107bc648d82">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-<ix:nonFraction unitRef="number" contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231" decimals="INF" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIxLTEtMS0xLTEwOTYxOA_bccb924b-a9d4-4b73-a60c-4b5e0f6180f4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="chf" contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231" decimals="-3" name="moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIxLTQtMS0xLTEwOTYxOA_d5dfeec5-da0a-44f6-b038-39b939373e53">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk on financial assets corresponds to the carrying amounts of the Group&#8217;s cash and cash equivalents, short-term time deposits and receivables. The Group has not entered into any guarantees or similar obligations that would increase the risk over and above the carrying amounts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and cash equivalents and short-term deposits are considered low risk and were held at Swiss banks with Standard &amp; Poor long-term credit ratings as of December 31, 2022 of AAA (Z&#252;rcher Kantonalbank), AA (Luzerner Kantonalbank), A+ (UBS) and A- (Credit Suisse) and therefore any impact resulting from the expected credit loss model is considered immaterial. Analysis performed included assessing the cumulative default rates by credit rating category and applying these rates to the cash and short-term deposit balances at reporting dates. The calculated loss allowance based on the ECL is considered immaterial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group enters into agreements with partners that have appropriate credit history and a commitment to ethical business practices. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2278aa244dc8401fb29db0901038175e"><ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfCreditRiskExposureExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90ZXh0cmVnaW9uOjE2ZmUyOWJlM2Y1NDQzYThiODU5M2QxNWI3NjIwMzczXzc5_79f60f4b-8639-47bc-9da0-1813e98e81a6" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk as of the balance sheet date was as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Credit risk</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="ifc9f9f10e83045df9c56d3e82d087d4b_I20221231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzItMS0xLTEtMTA5NjE4_46d7fb33-52e6-44d5-a0ba-fe49f00b3f48">87,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i075b63d9ec7248cfaea163eaee0d8389_I20211231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzItNC0xLTEtMTA5NjE4_59a25227-ae5a-4239-a6e4-57625e0399fe">71,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i7fcf3db326314fe697ed5cd42ecbbada_I20221231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzMtMS0xLTEtMTA5NjE4_b5e90694-c197-4049-94d3-c4a17ec85289">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="icfcf107f070c4e4881afc0cfb8a17695_I20211231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzMtNC0xLTEtMTA5NjE4_0a5dbb36-97d5-4702-a2bc-cca79afb8a43">23,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i535d9072a4a54202a9a35ca03151f8e8_I20221231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzQtMS0xLTEtMTA5NjE4_453de71f-2376-4df2-ab20-f2606ca168e1">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i6257911404da432da8c7b7b86e6e80fb_I20211231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzQtNC0xLTEtMTA5NjE4_25620a12-0da9-4d5c-a00f-ac1e5e2c1740">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i2714f74d10b649b4b454a1f1bde37423_I20221231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzUtMS0xLTEtMTA5NjE4_e818c332-fdd6-4ddd-a4d3-199f0ff8bfeb">161,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i5431eb0aa5e34ad0b9389372b7ea9eb3_I20211231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzUtNC0xLTEtMTA5NjE4_c602bd06-35f8-43c3-9a24-331e96ecfa65">61,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total credit risk as at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i001bd3a832b04bf5bbcaa90c5bc76c16_I20221231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzYtMS0xLTEtMTA5NjE4_30f70880-9073-404b-acaa-22c9a99b54f0">250,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="chf" contextRef="i4f458970fd1a437482bffbf1e51aa71e_I20211231" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzYtNC0xLTEtMTA5NjE4_1b1a8bbf-6cdd-419e-8228-d021e98e7d43">156,599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group&#8217;s liquidity risk is considered low by management due to the financial assets at the reporting date, giving the Group a secure source of funding for its research and development activities.</span></div></ix:continuation><div id="i60bed4b3015345c8b90a9ba4194a5e91_1408"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfContingentLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xNDA4L2ZyYWc6MTRhYjE0OGRkYzRkNDE4ZjhkN2U3YmVjZTdiODlmYmIvdGV4dHJlZ2lvbjoxNGFiMTQ4ZGRjNGQ0MThmOGQ3ZTdiZWNlN2I4OWZiYl8yMTk5MDIzMjU1NjEx_164395de-1982-4b9e-9b76-5d32d80a9de1" continuedAt="id07fc263101b43d5b339a9af2d953a04" escape="true">Putative Class Action</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id07fc263101b43d5b339a9af2d953a04">On July&#160;12, 2022, a putative class action complaint was filed in the U.S. District Court for the Southern District of New York against the Company, its directors, and certain of its executive officers. The complaint alleges that the defendants violated federal securities laws by, among other things, making misrepresentations and omissions regarding its product candidates ensovibep and MP0310. The complaint seeks unspecified compensatory damages, as well as an award of reasonable attorneys&#8217; fees and other costs, on behalf of persons and/or entities which purchased (a) the Company's American Depositary Shares (ADSs ) pursuant to certain offering documents issued in connection with the Company's initial public offering of ADSs; and/or (b) the Company's securities between June&#160;16, 2021 and April&#160;26, 2022 inclusive. A motion to appoint a lead plaintiff and counsel was filed on September 12, 2022 and is still pending. The matter remains in its early stages. The Company disputes these claims and intends to defend itself accordingly. The Company expresses no assurances as to the ultimate outcome of this matter.</ix:continuation></span></div><div id="i60bed4b3015345c8b90a9ba4194a5e91_340"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zNDAvZnJhZzo4YTI0NzYwMTg0YWQ0N2EzYjExN2U1NzUwMjM5MGNjNi90ZXh0cmVnaW9uOjhhMjQ3NjAxODRhZDQ3YTNiMTE3ZTU3NTAyMzkwY2M2XzEyOA_f97c1b41-cd95-454c-abe1-578bcdcba771" continuedAt="ie43b96d1aa474c5580f5c4593b7b6b22" escape="true">Events after the balance sheet date</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><span id="i8a24760184ad47a3b117e57502390cc6_5030"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie43b96d1aa474c5580f5c4593b7b6b22">No events occurred between the balance sheet date and the date on which these consolidated financial statements were approved by the Board of Directors that would require adjustment to the consolidated financial statements or disclosure under this heading.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>a112022_aoaxmpasofjanuary1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i394a28c07c214af9a8ad4cc21c0085dc_1"></div><div style="min-height:77.76pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Exhibit 1.1</font></div></div><div style="margin-bottom:18pt"><font><br></font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:127%">Statuten</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:127%">von Molecular Partners AG</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">vom 19. Januar 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:127%">Articles of Incorporation of</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:127%">Molecular Partners Ltd</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">as of</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">January 19, 2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">This is a translation of the original German version. In case of any discrepancy, the German version shall prevail.</font></div></td></tr></table></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 2 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 1&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> <br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Firma, Sitz, Zweck und Dauer der Gesellschaft</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 1&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Name, Place of Incorporation, Purpose and Duration of the Company</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Firma, Sitz</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Unter der Firma</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Molecular Partners AG (Molecular Partners SA) (Molecular Partners Ltd) (die </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Gesellschaft</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">besteht eine Aktiengesellschaft, die den vorliegenden Statuten und den Vorschriften des 26. Titels des Schweizerischen Obligationenrechts (das </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">) untersteht.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name, Place of Incorporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under the name </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Molecular Partners AG (Molecular Partners SA) (Molecular Partners Ltd) (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">there exists a corporation as defined in title 26 of the Swiss Code of Obligations (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">) and in these Articles of Incorporation.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Sitz der Gesellschaft ist in Schlieren, Kanton Z&#252;rich. Die Dauer der Gesellschaft ist unbeschr&#228;nkt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The registered office of the Company is in Schlieren, Canton of Zurich. The duration of the Company is unlimited.</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zweck</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 2</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purpose</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 2</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zweck der Gesellschaft ist die Forschung, Entwicklung, Herstellung und der Verkauf von Produkten in den Gebieten der Biotechnologie, der Pharmazie, Medizintechnologie, Diagnose und Therapie sowie der Kauf, Verkauf und die Verwendung von Patenten und Lizenzen auf diesem Gebiet. Die Gesellschaft kann alle Gesch&#228;fte t&#228;tigen, die geeignet erscheinen, den Zweck der Gesellschaft zu f&#246;rdern, oder die mit diesem zusammenh&#228;ngen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company's purpose is to research, develop, produce and sell products in the fields of biotechnology, pharamceutica, medical technology, diagnosis and therapy as well as to purchase, sell and use patents and licences in this field. The Company may engage in all types of transactions that appear appropriate to promote the purpose of the Company or that are related thereto.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft kann Grundst&#252;cke im In- und Ausland erwerben, verwalten, belasten, verwerten und verkaufen sowie andere Gesellschaften finanzieren.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may acquire, administer, encumber, exploit or sell real estate in Switzerland and aborad and may also finance other companies.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 3 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft kann Zweigniederlassungen und Tochtergesellschaften im In- und Ausland errichten und sich an anderen Unternehmen beteiligen oder mit diesen fusionieren.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may establish branches and subsidiaries within Switzerland or abroad and may acquire participations in other companies.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 2&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Aktienkapital</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 2&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Share Capital</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aktienkapital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Das Aktienkapital der Gesellschaft betr&#228;gt CHF&#160;3&#8216;604&#8216;470.60 und ist eingeteilt in 36&#8216;044&#8216;706 Namenaktien mit einem Nennwert von je CHF 0.10.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share Capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The share capital of the Company is CHF&#160;3,604,470.60 and is divided into 36,044,706 registered shares. Each registered share has a par value of CHF 0.10.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Aktien sind voll liberiert.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shares are fully paid up.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durch Statuten&#228;nderung kann die Generalversammlung jederzeit Namenaktien in Inhaberaktien und Inhaberaktien in Namenaktien umwandeln.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon resolution of the general meeting of shareholders, registered shares may be converted into bearer shares and bearer shares may be converted into registered shares.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 3a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 3a</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genehmigtes Aktienkapital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Der Verwaltungsrat ist erm&#228;chtigt, jederzeit bis zum 13.&#160;April 2024 das Aktienkapital im Maximalbetrag von CHF&#160;457'316.20 durch Ausgabe von h&#246;chstens 4'573'162 vollst&#228;ndig zu liberierenden Namenaktien mit einem Nennwert von je CHF&#160;0.10 zu erh&#246;hen. Erh&#246;hungen in Teilbetr&#228;gen sind gestattet.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized Share Capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The board of directors is authorized to increase the share capital, at any time until April 13, 2024, by a maximum amount of CHF&#160;457,316.20 by issuing a maximum of 4,573,162 fully paid up registered shares with a par value of CHF&#160;0.10 each. An increase of the share capital in partial amounts shall be permissible.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zeichnung und Erwerb der neuen Aktien sowie jede nachfolgende &#220;bertragung der Aktien unterliegen den Beschr&#228;nkungen von Artikel&#160;5 dieser Statuten.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The acquisition of shares and each subsequent transfer of the shares shall be subject to the restrictions of Article&#160;5 of these Articles of Incorporation.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 4 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat legt den Ausgabebetrag, die Art der Einlagen, den Zeitpunkt der Ausgabe, die Bedingungen der Bezugsrechtsaus&#252;bung und den Beginn der Dividendenberechtigung fest. Dabei kann der Verwaltungsrat neue Aktien mittels Fest&#252;bernahme durch eine Bank oder einen anderen Dritten und anschliessendem Angebot an die bisherigen Aktion&#228;re oder an Dritte (sofern die Bezugsrechte der bisherigen Aktion&#228;re aufgehoben sind oder nicht g&#252;ltig ausge&#252;bt werden) ausgeben. Der Verwaltungsrat ist erm&#228;chtigt, den Handel mit Bezugsrechten zu erm&#246;glichen, zu beschr&#228;nken oder auszuschliessen. Nicht ausge&#252;bte Bezugsrechte kann der Verwaltungsrat verfallen lassen, oder er kann diese bzw. Aktien, f&#252;r welche Bezugsrechte einger&#228;umt, aber nicht ausge&#252;bt werden, zu Marktkonditionen platzieren oder anderweitig im Interesse der Gesellschaft verwenden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors shall determine the issue price, the type of payment, the time of the issuance, the conditions for the exercise of the preemptive rights and the date from which the shares carry the right to dividends. The board of directors can issue new shares by means of an underwriting by a bank or another third party with a subsequent offer of these shares to the existing shareholders or third parties (if the preemptive rights of the existing shareholders have been denied or not been duly exercised). The board of directors is authorized to permit, to restrict or to deny the trade of preemptive rights. The board of directors may permit preemptive rights that have been granted but not exercised to expire or it may place these rights respectively the shares as to which preemptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interest of the Company.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 5 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Der Verwaltungsrat ist ferner erm&#228;chtigt, das Bezugsrecht der Aktion&#228;re zu beschr&#228;nken oder aufzuheben und Dritten zuzuweisen&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">f&#252;r die &#220;bernahme von Unternehmen, Unternehmensteilen oder Beteiligungen, den Erwerb von Produkten, Immaterialg&#252;tern oder Lizenzen oder f&#252;r Investitionsvorhaben oder f&#252;r die Finanzierung oder Refinanzierung solcher Transaktionen durch eine Aktienplatzierung&#59; oder</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">zum Zwecke der Erweiterung des Aktion&#228;rskreises oder im Zusammenhang mit der Kotierung der Aktien an inl&#228;ndischen oder an ausl&#228;ndischen B&#246;rsen&#59; oder</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">wenn der Ausgabebetrag der neuen Aktien unter Ber&#252;cksichtigung des Marktpreises festgesetzt wird&#59; oder</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">f&#252;r die Einr&#228;umung einer Mehrzuteilungsoption (Greenshoe) von bis zu 20% der zu platzierenden oder zu verkaufenden Aktien an die betreffenden Erstk&#228;ufer oder Fest&#252;bernehmer im Rahmen einer Aktienplatzierung oder eines Aktienverkaufs&#59; oder</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">wenn ein Aktion&#228;r oder eine Gruppe von in gemeinsamer Absprache handelnden Aktion&#228;ren mehr als 15% des im Handelsregister eingetragenen Aktienkapitals der Gesellschaft auf sich vereinigt hat, ohne den &#252;brigen Aktion&#228;ren ein vom Verwaltungsrat empfohlenes &#220;bernahmeangebot zu unterbreiten&#59; oder </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.37pt">zur Abwehr eines unterbreiteten, angedrohten oder potentiellen &#220;bernahmeangebotes, welches der Verwaltungsrat, nach Konsultation mit einem von ihm beigezogenen unabh&#228;ngigen Finanzberater, den Aktion&#228;ren nicht zur Annahme empfohlen hat, weil der Verwaltungsrat das &#220;bernahmeangebot in finanzieller Hinsicht gegen&#252;ber den Aktion&#228;ren nicht als fair beurteilt hat.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The board of directors is further authorized to restrict or deny the preemptive rights of shareholders and to allocate them to third parties&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.55pt;padding-right:0.9pt;text-align:justify;text-indent:-24.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.43pt">for the acquisition of companies, parts of companies or participations, for the acquisition of products, intellectual property or licenses, or for investment projects or for the financing or refinancing of such transactions through a placement of shares&#59; or<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">for the purpose of broadening the shareholder constituency or in connection with a listing of shares on domestic or foreign stock exchanges&#59; or</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">if the issue price of the new Shares is determined by reference to the market price&#59; or</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">for purposes of granting an over-allotment option (Greenshoe) of up to 20% of the total number of Shares in a placement or sale of Shares to the respective initial purchasers or underwriters&#59; or</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to the other shareholders a takeover offer recommended by the board of directors&#59; or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%"> </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.55pt;padding-right:0.9pt;text-align:justify;text-indent:-24.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.22pt">for the defense of an actual, threatened or potential takeover bid, in relation to which the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders.</font></div></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 6 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 3b</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 3b</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bedingtes Aktienkapital f&#252;r Mitarbeiterbeteiligung</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Das Aktienkapital kann sich durch Ausgabe von h&#246;chstens 1'362&#8217;963 voll zu liberierenden Namenaktien im Nennwert von je CHF&#160;0.10 um h&#246;chstens CHF&#160;136'296.30 erh&#246;hen durch direkte oder indirekte Ausgabe von Aktien, Optionen oder diesbez&#252;glichen Bezugsrechten an Mitarbeiter und Mitglieder des Verwaltungsrats der Gesellschaft und ihrer Konzerngesellschaften sowie an Mitglieder von Beir&#228;ten. </font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conditional Share Capital for Employee Participation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The share capital may be increased in an amount not to exceed CHF&#160;136,296.30 through the issuance of up to 1,362,963 fully paid up registered shares with a par value of CHF&#160;0.10 per share through the direct or indirect issuance of shares, options or preemptive rights thereof granted to employees and members of the board of directors of the Company or its subsidiaries as well as to members of any advisory boards. </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:174%">2</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bei der Ausgabe von Aktien, Optionen oder diesbez&#252;glichen Bezugsrechten sind das Bezugsrecht wie auch das Vorwegzeichnungsrecht der Aktion&#228;re der Gesellschaft ausgeschlossen. Die Ausgabe von Aktien, Optionen oder diesbez&#252;glichen Bezugsrechten erfolgt gem&#228;ss einem oder mehreren vom Verwaltungsrat zu erlassenden Beteiligungspl&#228;nen und&#47;oder Reglementen und unter Beachtung von Abschnitt 4 dieser Statuten.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The preemptive rights and advance subscription rights of the shareholders of the Company shall be excluded in connection with the issuance of any shares, options or preemptive rights thereof. Shares, options or preemptive rights thereof shall be issued in accordance with one or more participation plans and&#47;or policies to be issued by the board of directors and in accordance with Section 4 of these Articles of Incorporation.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:174%">3</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die neuen Aktien, welche durch Mitarbeiter, Mitglieder des Verwaltungsrats der Gesellschaft und ihrer Konzerngesellschaften oder Mitglieder von Beir&#228;ten im Rahmen eines Mitarbeiterbeteiligungsprogramms direkt oder indirekt erworben werden, sowie jede nachfolgende &#220;bertragung der Aktien unterliegen den Beschr&#228;nkungen von Artikel&#160;5 dieser Statuten.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The new shares directly or indirectly acquired by employees, members of the board of directors of the Company or its subsidiaries or members of any advisory boards in connection with an employee participation program and any subsequent transfer of such shares shall be restricted by Article&#160;5 of these Articles of Incorporation.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 3c</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 3c</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 7 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bedingtes Aktienkapital f&#252;r Finanzierungen, Akquisitionen und andere Zwecke</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Das Aktienkapital kann sich durch Ausgabe von h&#246;chstens 2'260'870 voll zu liberierenden Namenaktien im Nennwert von je CHF 0.10 um h&#246;chstens CHF&#160;226'087 erh&#246;hen durch die Aus&#252;bung oder Zwangsaus&#252;bung von Wandel-, Tausch-, Options-, Bezugs- oder &#228;hnlichen Rechten auf den Bezug von Aktien, welche Aktion&#228;ren oder Dritten allein oder in Verbindung mit Anleihensobligationen, Darlehen, Optionen, Warrants oder anderen Finanzmarktinstrumenten oder vertraglichen Verpflichtungen der Gesellschaft oder einer ihrer Gruppengesellschaften einger&#228;umt werden (nachfolgend zusammen die </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Finanzinstrumente</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">).</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conditional Share Capital for Financing, Acquisitions and other Purposes</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The share capital may be increased in an amount not to exceed CHF 226,087 through the issuance of up to 2,260,870  fully paid up registered shares with a par value of CHF 0.10 per share through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights for the subscription of shares granted to shareholders or third parties alone or in connection with bonds, notes, options, warrants or other securities or contractual obligations by or of the Company or any of its group companies (hereinafter collectively, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Financial Instruments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">).</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bei der Ausgabe von Aktien bei Aus&#252;bung der Finanzinstrumente ist das Bezugsrecht der Aktion&#228;re ausgeschlossen. Zum Bezug der neuen Aktien, die bei Aus&#252;bung von Finanzinstrumenten ausgegeben werden, sind die jeweiligen Inhaber der Finanzinstrumente berechtigt. Die Bedingungen der Finanzinstrumente sind durch den Verwaltungsrat festzulegen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The preemptive rights of the shareholders shall be excluded in connection with the issuance of shares upon the exercise of any Financial Instruments. The then-current owners of such Financial Instruments shall be entitled to acquire the new shares issued upon conversion, exchange or exercise of any Financial Instruments. The conditions of the Financial Instruments shall be determined by the board of directors.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 8 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Der Verwaltungsrat ist erm&#228;chtigt, die Vorwegzeichnungsrechte der Aktion&#228;re im Zusammenhang mit der Ausgabe von Finanzinstrumenten durch die Gesellschaft oder eine ihrer Gruppengesellschaften zu beschr&#228;nken oder aufzuheben, falls (1) die Ausgabe zum Zwecke der Finanzierung oder Refinanzierung der &#220;bernahme von Unternehmen, Unternehmensteilen, Beteiligungen oder Investitionen, oder (2) die Ausgabe auf nationalen oder internationalen Finanzm&#228;rkten oder im Rahmen einer Privatplatzierung erfolgt.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Wird das Vorwegzeichnungsrecht weder direkt noch indirekt durch den Verwaltungsrat gew&#228;hrt, gilt Folgendes&#58; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">Die Finanzinstrumente sind zu markt&#252;blichen Bedingungen auszugeben oder einzugehen&#59; und </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">der Umwandlungs-, Tausch- oder sonstige Aus&#252;bungspreis der Finanzinstrumente ist unter Ber&#252;cksichtigung des Marktpreises im Zeitpunkt der Ausgabe der Finanzinstrumente festzusetzen&#59; und</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">die Finanzinstrumente sind h&#246;chstens w&#228;hrend 10 Jahren ab dem jeweiligen Zeitpunkt der betreffenden Ausgabe oder des betreffenden Abschlusses wandel-, tausch- oder aus&#252;bbar.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The board of directors shall be authorized to withdraw or limit the advance subscription rights of the shareholders in connection with the issuance by the Company or one of its group companies of Financial Instruments if (1) the issuance is for purposes of financing or refinancing the acquisition of an enterprise, parts of an enterprise, participations or investments or (2) the issuance occurs in national or international capital markets or through a private placement.  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If the advance subscription rights are neither granted directly nor indirectly by the board of directors, the following shall apply&#58; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the Financial Instruments shall be issued or entered into at market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.55pt;padding-right:0.9pt;text-align:justify;text-indent:-24.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.43pt">the conversion, exchange or exercise price of the Financial Instruments shall be set with reference to the market conditions prevailing at the date on which the Financial Instruments are issued&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">the Financial Instruments may be converted, exchanged or exercised during a maximum period of 10 years from the date of the relevant issuance or entry.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die neuen Aktien, welche &#252;ber die Aus&#252;bung von Finanzinstrumenten direkt oder indirekt erworben werden, sowie jede nachfolgende &#220;bertragung der Aktien unterliegen den Beschr&#228;nkungen von Artikel&#160;5 dieser Statuten.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The new shares directly or indirectly acquired through the exercise of Financial Instruments and any subsequent transfer of such shares shall be restricted by Article&#160;5 of these Articles of Incorporation.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 4</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 9 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aktienzertifikate und Bucheffekten</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft gibt ihre Namenaktien in Form von Einzelurkunden, Globalurkunden oder Wertrechten aus. Der Gesellschaft steht es im Rahmen der gesetzlichen Vorgaben frei, ihre in einer dieser Formen ausgegebenen Namenaktien jederzeit und ohne Zustimmung der Aktion&#228;re in eine andere Form umzuwandeln.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share Certificates and Intermediated Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may issue its registered shares in the form of single certificates, global certificates and uncertificated securities. Under the conditions set forth by statutory law, the Company may convert its registered shares from one form into another form at any time and without the approval of the shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Aktion&#228;r hat keinen Anspruch auf Umwandlung von in bestimmter Form ausgegebenen Namenaktien in eine andere Form. Jeder Aktion&#228;r kann jedoch von der Gesellschaft jederzeit die Ausstellung einer Bescheinigung &#252;ber die von ihm gem&#228;ss Aktienbuch gehaltenen Namenaktien verlangen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shareholder has no right to demand a conversion of the form of the registered shares. Each shareholder may, however, at any time request a written confirmation from the Company of the registered shares held by such shareholder, as reflected in the share register.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bucheffekten, denen Namenaktien der Gesellschaft zugrunde liegen, k&#246;nnen nicht durch Zession &#252;bertragen werden. An diesen Bucheffekten k&#246;nnen auch keine Sicherheiten durch Zession bestellt werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intermediated securities based on registered shares of the Company cannot be transferred by way of assignment. Further, a security interest in any such intermediated securities cannot be granted by way of assignment.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aktienbuch, &#220;bertragungsbeschr&#228;nkungen, Nominees</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft f&#252;hrt f&#252;r die Namenaktien ein Aktienbuch, in welches die Eigent&#252;mer und Nutzniesser mit Namen und Vornamen (bei juristischen Personen die Firma), Adresse und Staatsangeh&#246;rigkeit (bei juristischen Personen der Sitz) eingetragen werden. Wechselt eine im Aktienbuch eingetragene Person ihre Adresse, so hat sie dies der Gesellschaft mitzuteilen. Solange dies nicht geschehen ist, erfolgen alle brieflichen Mitteilungen rechtsg&#252;ltig an die bisher im Aktienbuch eingetragene Adresse.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share Register, Transfer Restrictions, Nominees</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company shall maintain a share register that lists the surname, first name, address and citizenship (in the case of legal entities, the company name and company seat) of the holders and usufructuaries of the registered shares. A person recorded in the share register shall notify the Company of any change in address. Until such notification shall have occurred, all written communication from the Company to persons of record shall be deemed to have validly been made if sent to the address recorded in the share register.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erwerber von Namenaktien werden auf Gesuch als Aktion&#228;re mit Stimmrecht im Aktienbuch eingetragen, falls sie ausdr&#252;cklich erkl&#228;ren, diese Namenaktien im eigenen Namen und f&#252;r eigene Rechnung erworben zu haben.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An acquirer of registered shares shall be recorded upon request in the share register as a shareholder with voting rights, if such acquirer expressly declares to have acquired the registered shares in his own name and for his own account.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 10 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Der Verwaltungsrat tr&#228;gt einzelne Personen, die im Eintragungsgesuch nicht ausdr&#252;cklich erkl&#228;ren, die Namenaktien auf eigene Rechnung zu halten (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Nominees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">), mit Stimmrecht im Aktienbuch ein, wenn der Nominee mit dem Verwaltungsrat eine Vereinbarung &#252;ber seine Stellung abgeschlossen hat und einer anerkannten Bank- oder Finanzaufsicht untersteht.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The board of directors records persons who do not declare to hold the registered shares for their own account (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Nominees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">) as shareholders with voting rights in the share register, if such Nominee has entered into an agreement regarding its position with the board of directors and is subject to a recognized banking or finance supervision.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat kann nach Anh&#246;rung des eingetragenen Aktion&#228;rs oder Nominees Eintragungen im Aktienbuch mit R&#252;ckwirkung auf das Datum der Eintragung streichen, wenn diese durch falsche Angaben zustande gekommen sind. Der Betroffene muss &#252;ber die Streichung informiert werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After hearing the registered shareholder concerned, the board of directors may cancel the registration of such shareholder as a shareholder with voting rights in the share register with retroactive effect as of the date of registration, if such registration was made based on false or misleading information. The relevant shareholder shall be informed of the cancellation.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat regelt die Einzelheiten und trifft die zur Einhaltung der vorstehenden Bestimmungen notwendigen Anordnungen. Er kann in besonderen F&#228;llen Ausnahmen von der Nomineeregelung bewilligen. Er kann seine Aufgaben delegieren.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors shall regulate the details and issue the instructions necessary for compliance with the preceding provisions. In special cases, it may grant exemptions from the rule concerning Nominees. The board of directors may delegate its duties.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:180%">Article 6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rechtsaus&#252;bung</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft anerkennt nur einen Vertreter pro Aktie.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">The Company shall only accept one representative per share.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Das Stimmrecht und die damit zusammenh&#228;ngenden Rechte aus einer Namenaktie k&#246;nnen der Gesellschaft gegen&#252;ber nur von einem Aktion&#228;r, Nutzniesser oder Nominee, der mit Stimmrecht im Aktienbuch eingetragen ist, ausge&#252;bt werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Voting rights and appurtenant rights associated therewith may be exercised in relation to the Company by a shareholder, usufructuary of shares or nominee only to the extent that such person is recorded in the share register as a shareholder with voting rights.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 11 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 3&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Organe</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 3&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Corporate Bodies</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Die Organe der Gesellschaft sind&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;die Generalversammlung&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;der Verwaltungsrat&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;die Revisionsstelle.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bodies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company's bodies are&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;the general meeting of shareholders&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;the board of directors&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;the auditors.</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">A. Generalversammlung</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">A. General Meeting of Shareholders</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 8</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 12 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Befugnisse</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Oberstes Organ der Gesellschaft ist die Generalversammlung der Aktion&#228;re. Ihr stehen folgende un&#252;bertragbare Befugnisse zu&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Festsetzung und &#196;nderung der Statuten&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Wahl der Mitglieder des Verwaltungsrats, des Pr&#228;sidenten des Verwaltungsrats, der Mitglieder des Verg&#252;tungsausschusses, des unabh&#228;ngigen Stimmrechtsvertreters und der Revisionsstelle&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">die Genehmigung des Lageberichts und der Konzernrechnung&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Genehmigung der Jahresrechnung sowie die Beschlussfassung &#252;ber die Verwendung des Bilanzgewinnes, insbesondere die Festsetzung der Dividende&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Genehmigung der Verg&#252;tung des Verwaltungsrats und der Gesch&#228;ftsleitung gem&#228;ss Art. 28 dieser Statuten&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.37pt">die Entlastung der Mitglieder des Verwaltungsrats und der mit der Gesch&#228;ftsleitung betrauten Personen&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Beschlussfassung &#252;ber die Gegenst&#228;nde, die der Generalversammlung durch das Gesetz oder die Statuten vorbehalten sind.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Powers</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The general meeting of shareholders is the supreme corporate body of the Company. It has the following non-delegable powers&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">adoption and amendment of the Articles of Incorporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.55pt;padding-right:0.9pt;text-align:justify;text-indent:-24.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.43pt">election of the members of the board of directors, the chairman of the board of directors, the members of the compensation committee, the independent voting rights representative and the auditors&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">approval of the annual management report and the consolidated financial statements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">approval of the annual financial statements and decision on the allocation of profits shown on the balance sheet, in particular with regard to dividends&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">approval of the compensation of the board of directors and of the executive management pursuant to Article 28 of these Articles of Incorporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.37pt">granting discharge to the members of the board of directors and the persons entrusted with the executive management&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">passing of resolutions as to all matters reserved by law or under these Articles of Incorporation to the authority of the general meeting of shareholders.</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 9</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 13 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr style="height:42pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ordentliche und ausserordentliche Generalversammlungen</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die ordentliche Generalversammlung findet allj&#228;hrlich innerhalb von sechs Monaten nach Schluss des Gesch&#228;ftsjahres statt.</font></td><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ordinary and Extraordinary General Meeting of Shareholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The ordinary general meeting of shareholders shall be held each year within six months after the close of the fiscal year of the Company.</font></td></tr><tr style="height:104pt"><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ausserordentliche Generalversammlungen finden statt, wenn der Verwaltungsrat oder die Revisionsstelle es f&#252;r angezeigt erachten oder wenn es eine Generalversammlung beschliesst. Dar&#252;ber hinaus k&#246;nnen Aktion&#228;re, die zusammen mindestens 10 Prozent des Aktienkapitals vertreten, gemeinsam schriftlich unter Angabe des Verhandlungsgegenstandes und des Antrages, bei Wahlen der Namen der vorgeschlagenen Kandidaten, die Einberufung einer ausserordentlichen Generalversammlung verlangen.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extraordinary general meetings of shareholders shall be held when deemed necessary by the board of directors or the auditors. Furthermore, extraordinary general meetings of shareholders shall be convened upon resolution of a general meeting of shareholders or if this is requested by one or more shareholders who represent an aggregate of at least one-tenth of the share capital and who submit a written request specifying the agenda items and the proposals, in case of elections the name of the proposed candidates.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Einberufung</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Generalversammlung wird durch den Verwaltungsrat, n&#246;tigenfalls die Revisionsstelle, sp&#228;testens 20 Tage vor der Versammlung einberufen. Das Einberufungsrecht steht auch den Liquidatoren zu.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notice</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notice of a general meeting of shareholders shall be given by the board of directors or, if necessary, by the auditors, no later than twenty calendar days prior to the date of the general meeting of shareholders. The liquidators may also call the general meeting of shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Einberufung erfolgt durch einmalige Bekanntmachung im Publikationsorgan der Gesellschaft. Namenaktion&#228;re k&#246;nnen &#252;berdies schriftlich orientiert werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notice of the general meeting of shareholders shall be given by way of a one-time announcement in the official means of publication of the Company. In addtion, shareholders of record may be informed by ordinary mail.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sp&#228;testens 20 Tage vor der ordentlichen Generalversammlung sind der Gesch&#228;ftsbericht, der Verg&#252;tungsbericht und die Revisionsberichte am Sitz der Gesellschaft zur Einsicht der Aktion&#228;re aufzulegen. Die Aktion&#228;re sind dar&#252;ber in der Einberufung zu orientieren.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The annual report, the compensation report and the auditors' reports shall be made available for inspection by the shareholders at the registered office of the Company no later than twenty calendar days prior to the annual general meeting of shareholders. The notice of the general meeting of shareholders shall inform the shareholders about the availability of the annual report, the compensation report and the auditors's reports.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 14 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Einberufung muss die Verhandlungsgegenst&#228;nde sowie die Antr&#228;ge des Verwaltungsrats und der Aktion&#228;re, welche die Durchf&#252;hrung einer Generalversammlung oder die Traktandierung eines Verhandlungsgegenstandes verlangt haben, und bei Wahlgesch&#228;ften die Namen der vorgeschlagenen Kandidaten enthalten.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notice of a general meeting of shareholders shall specify the items on the agenda and the proposals of the board of directors and the shareholders who requested that a general meeting of shareholders be held or an item be included on the agenda, and, in the event of elections, the names of the candidates that has or have been put on the ballot for election.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 11</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Traktandierung</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aktion&#228;re, die alleine oder zusammen entweder Aktien im Nennwert von mindestens CHF 1'000'000 oder mindestens 10 Prozent des Aktienkapitals vertreten, k&#246;nnen die Traktandierung eines Verhandlungsgegenstandes verlangen. Die Traktandierung muss mindestens 45&#160;Tage vor der Versammlung schriftlich unter Angabe des Verhandlungsgegenstandes und der Antr&#228;ge des Aktion&#228;re anbegehrt werden.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Agenda</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One or more shareholders whose combined shareholdings represent an aggregate par value of at least CHF&#160;1'000'000 or at least 10 percent of the share capital may request that an item be included on the agenda of a general meeting of shareholders. Such inclusion of an item on the agenda must be requested in writing at least 45 calendar days prior to the meeting and shall specify the agenda items and proposals of such shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#220;ber Antr&#228;ge zu nicht geh&#246;rig angek&#252;ndigten Verhandlungsgegenst&#228;nden kann die Generalversammlung keine Beschl&#252;sse fassen&#59; ausgenommen sind Antr&#228;ge auf Einberufung einer ausserordentlichen Generalversammlung und auf Durchf&#252;hrung einer Sonderpr&#252;fung.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No resolutions may be passed at a general meeting of shareholders concerning agenda items for which proper notice was not given. This provision shall not apply, however, to proposals made during a general meeting of shareholders to convene an extraordinary general meeting of shareholders or to initiate a special audit.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zur Stellung von Antr&#228;gen im Rahmen der Verhandlungsgegenst&#228;nde und zu Verhandlungen ohne Beschlussfassung bedarf es keiner vorg&#228;ngigen Ank&#252;ndigung.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No previous notification shall be required for proposals concerning items included on the agenda and for debates as to which no vote is taken.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 12</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 12</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 15 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vorsitz der Generalversammlung, Stimmenz&#228;hler, Protokoll</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Pr&#228;sident des Verwaltungsrats f&#252;hrt den Vorsitz in der Generalversammlung. Bei seiner Abwesenheit f&#252;hrt der Vizepr&#228;sident des Verwaltungsrats den Vorsitz. Ist auch dieser abwesend, so wird der Vorsitzende durch den Verwaltungsrat gew&#228;hlt.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acting Chair, Vote Counters, Minutes</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At the general meeting of shareholders, the Chairman of the board of directors or, in his absence, the Vice-Chairman or, in his absence, any other person designated by the board of directors shall take the chair.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Vorsitzende bezeichnet einen Protokollf&#252;hrer und die Stimmenz&#228;hler, die nicht Aktion&#228;re sein m&#252;ssen. Das Protokoll ist vom Vorsitzenden und vom Protokollf&#252;hrer zu unterzeichnen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The acting chair of the general meeting of shareholders shall appoint the secretary and the vote counters, none of whom need be shareholders. The minutes of the general meeting of shareholders shall be signed by the acting chair and the secretary.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stimmrecht, Vertretung</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jede mit Stimmrecht im Aktienbuch eingetragene Aktie berechtigt zu einer Stimme.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Voting Rights, Representation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each share registered in the share register grants one vote.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat erl&#228;sst die Verfahrensvorschriften &#252;ber die Teilnahme und Vertretung an der Generalversammlung. Ein Aktion&#228;r kann sich an der Generalversammlung nur durch den unabh&#228;ngigen Stimmrechtsvertreter (mittels schriftlicher oder elektronischer Vollmacht), seinen gesetzlichen Vertreter oder (mittels schriftlicher Vollmacht) einen anderen stimmberechtigten Aktion&#228;r vertreten lassen. Alle von einem Aktion&#228;r gehaltenen Aktien k&#246;nnen nur von einer Person vertreten werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The board of directors shall issue procedural rules regarding participation in and representation at the general meeting of shareholders. A shareholder may be represented only by the independent voting rights representative (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">unabh&#228;ngiger Stimmrechtsvertreter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">) (by way of a written or electronic proxy), his legal representative or, by means of a written proxy, another shareholder with the right to vote. All shares held by one shareholder must be represented by only one representative.</font></div></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 16 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Generalversammlung w&#228;hlt den unabh&#228;ngigen Stimmrechtsvertreter f&#252;r eine Amtsdauer bis zum Abschluss der n&#228;chsten ordentlichen Generalversammlung. Wiederwahl ist m&#246;glich. Hat die Gesellschaft aus irgendwelchen Gr&#252;nden keinen unabh&#228;ngigen Stimmrechtsvertreter, bezeichnet der Verwaltungsrat f&#252;r die n&#228;chste stattfindende Generalversammlung einen unabh&#228;ngigen Stimmrechtsvertreter.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The general meeting of shareholders shall elect the independent voting rights representative at a general meeting of shareholders for a term of office extending until completion of the next ordinary general meeting of shareholders. Re-election is possible. If the company does not have an independent voting rights representative for whatever reason, the board of directors shall appoint the independent voting rights representative for the next meeting of shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat regelt die Anforderungen an die Vollmachten und Weisungen an den unabh&#228;ngigen Stimmrechtsvertreter.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors shall issue the particulars for the proxy of and for providing instructions to the independent voting rights representative.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beschl&#252;sse, Wahlen</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Generalversammlung beschliesst und w&#228;hlt, soweit das Gesetz und die Statuten es nicht anders bestimmen, mit der absoluten Mehrheit der vertretenen Aktienstimmen.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Resolutions and Elections</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise required by law or these Articles of Incorporation, the general meeting of shareholders shall take resolutions and decide elections upon an absolute majority of the votes represented at the general meeting of shareholders.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 17 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Ein Beschluss der Generalversammlung, der mindestens zwei Drittel der vertretenen Stimmen und die absolute Mehrheit der vertretenen Aktiennennwerte auf sich vereinigt, ist erforderlich f&#252;r&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die &#196;nderung des Gesellschaftszweckes&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Einf&#252;hrung von Stimmrechtsaktien&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">die Beschr&#228;nkung der &#220;bertragbarkeit von Namenaktien und die Aufhebung einer solchen Beschr&#228;nkung&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">eine genehmigte oder eine bedingte Kapitalerh&#246;hung&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Kapitalerh&#246;hung aus Eigenkapital, gegen Sacheinlage oder zwecks Sach&#252;bernahme und die Gew&#228;hrung von besonderen Vorteilen&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.37pt">die Einschr&#228;nkung oder Aufhebung des Bezugsrechtes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Verlegung des Sitzes der Gesellschaft&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Aufl&#246;sung der Gesellschaft.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The approval of at least two-thirds of the votes and the absolute majority of the par value of shares, each as represented at a general meeting of shareholders, shall be required for resolutions with respect to&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">The amendment or modification of the purpose of the Company&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the creation of shares with privileged voting rights&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">the restriction on the transferability of registered shares and the cancelation of such restriction&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">an authorized or conditional increase of the share capital&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">an increase of the share capital through the conversion of capital surplus, through contribution in kind or for purposes of an acquisition of assets, or the granting of special privileges&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.37pt">the limitation or withdrawal of preemptive rights&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the relocation of the registered office of the Company&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the dissolution of the Company.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Abstimmungen und Wahlen erfolgen offen, es sei denn, dass die Generalversammlung schriftliche Abstimmung respektive Wahl (einschliesslich elektronische Abstimmungsverfahren) beschliesst oder der Vorsitzende dies anordnet.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resolutions and elections shall be decided by a show of hands, unless a written ballot (including electronic voting systems) is resolved by the general meeting of shareholders or is ordered by the acting chair of the general meeting of shareholders.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">B. Verwaltungsrat</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">B. Board of Directors</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 15</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 18 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anzahl der Verwaltungsr&#228;te</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat besteht aus mindestens 3 und h&#246;chstens 11 Mitgliedern.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors shall consist of no less than 3 and no more than 11 members.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 16</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wahl, Amtsdauer</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Mitglieder des Verwaltungsrats und der Pr&#228;sident des Verwaltungsrats werden von der Generalversammlung einzeln f&#252;r eine Amtsdauer bis zum Abschluss der n&#228;chsten ordentlichen Generalversammlung gew&#228;hlt.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Election, Term of Office</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify;text-indent:-1.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The shareholders shall elect the members of the board of directors and the chair of the board of directors individually at a general meeting of shareholders for a term of office extending until completion of the next ordinary general meeting of shareholders.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Mitglieder des Verwaltungsrats sind jederzeit wieder w&#228;hlbar.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members of the board of directors may be re-elected at any time.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ist das Pr&#228;sidium vakant, bezeichnet der Verwaltungsrat aus seiner Mitte einen neuen Pr&#228;sidenten f&#252;r eine Amtsdauer bis zum Abschluss der n&#228;chsten ordentlichen Generalsversammlung.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the office of the chair of the board of directors is vacant, the board of directors shall appoint the chair from among its members for a term of office extending until completion of the next ordinary general meeting of shareholders.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 17</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organisation des Verwaltungsrats, Ersatz der Auslagen</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vorbeh&#228;ltlich der Wahl des Pr&#228;sidenten des Verwaltungsrats und der Mitglieder des Verg&#252;tungsausschusses durch die Generalversammlung konstituiert sich der Verwaltungsrat selbst. Er kann aus seiner Mitte einen oder mehrere Vize-Pr&#228;sidenten w&#228;hlen. Er bestellt einen Sekret&#228;r, der nicht Mitglied des Verwaltungsrats zu sein braucht.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organization of the Board of Directors, Reimbursement of Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except for the election of the chairman of the board of directors and the members of the compensation committee by the general meeting of shareholders, the board of directors shall constitute itself. It may elect from among its members one or several vice-chairmen. It shall appoint a secretary who need not be a member of the board of directors.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat ordnet im &#220;brigen im Rahmen von Gesetz und Statuten seine Organisation und Beschlussfassung durch ein Organisationsreglement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to applicable law and these Articles of Incorporation, the board of directors shall establish the particulars of its organization in organizational regulations.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 19 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Mitglieder des Verwaltungsrats haben Anspruch auf Ersatz ihrer im Interesse der Gesellschaft aufgewendeten Auslagen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The members of the board of directors shall be entitled to the reimbursement of all expenses incurred in the interests of the Company.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 18</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Einberufung, Beschlussfassung, Protokoll</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitzungen des Verwaltungsrats werden vom Pr&#228;sidenten oder im Falle seiner Verhinderung vom Vize-Pr&#228;sidenten oder einem andern Mitglied des Verwaltungsrats einberufen, so oft dies als notwendig erscheint oder wenn ein Mitglied es schriftlich unter Angabe der Gr&#252;nde verlangt. Sitzungen k&#246;nnen auch per Telefon- oder Videokonferenz durchgef&#252;hrt werden.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Invitation, Resolutions, Minutes</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The chairman or, should he be unable to do so, the vice-chairman or any other member of the board of directors shall convene meetings of the board of directors if and when the need arises or whenever a member indicating the reasons so requests in writing. Meetings may also be held by telephone or video conference.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat fasst seine Beschl&#252;sse mit der Mehrheit der abgegebenen Stimmen. Der Vorsitzende hat den Stichentscheid.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resolutions of the board of directors shall be adopted upon a majority of the votes cast. In the event of a tie, the chairman shall have the casting vote.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zur Beschlussf&#228;higkeit des Verwaltungsrats ist die Anwesenheit der Mehrheit seiner Mitglieder erforderlich. Kein Pr&#228;senzquorum ist erforderlich f&#252;r die Anpassungs- und Feststellungsbeschl&#252;sse des Verwaltungsrats im Zusammenhang mit Kapitalerh&#246;hungen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to pass resolutions, at least a majority of the members of the board of directors must be present. No attendance quorum shall be required for confirmation or amendment resolutions of the board of directors in connection with capital increases.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beschl&#252;sse k&#246;nnen auch auf schriftlichem Weg gefasst werden, sofern nicht ein Mitglied m&#252;ndliche Beratung verlangt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resolutions may be passed by way of circulation (in writing), provided that no member requests oral deliberation.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Beschl&#252;sse sind in einem Protokoll festzuhalten, das vom Sitzungspr&#228;sidenten und dem Sekret&#228;r zu unterzeichnen ist.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The resolutions shall be confirmed in the minutes, which are to be signed by the acting chair and the secretary.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 19</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 19</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 20 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Befugnisse des Verwaltungsrates</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat kann in allen Angelegenheiten Beschluss fassen, die nicht nach Gesetz, Statuten oder Reglement einem anderen Organ der Gesellschaft &#252;bertragen sind.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Powers of the Board of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may pass resolutions with respect to all matters that are not reserved to the general meeting of shareholders or any other corporate body by law or under these Articles of Incorporation.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 21 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Er hat folgende un&#252;bertragbare und unentziehbare Aufgaben&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Oberleitung der Gesellschaft und die Erteilung der n&#246;tigen Weisungen&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Festlegung der Organisation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">die Ausgestaltung des Rechnungswesens, der Finanzkontrolle sowie der Finanzplanung&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Ernennung und Abberufung der mit der Gesch&#228;ftsf&#252;hrung und der Vertretung betrauten Personen und die Regelung von deren Zeichnungsberechtigung&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Oberaufsicht &#252;ber die mit der Gesch&#228;ftsf&#252;hrung betrauten Personen, namentlich im Hinblick auf die Befolgung der Gesetze, Statuten, Reglemente und Weisungen&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.37pt">die Erstellung des Gesch&#228;ftsberichts und des Verg&#252;tungsberichts sowie die Vorbereitung der Generalversammlung und die Ausf&#252;hrung ihrer Beschl&#252;sse&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Beschlussfassung &#252;ber nachtr&#228;gliche Leistung von Einlagen auf nicht vollst&#228;ndig liberierten Aktien und daraus folgende Statuten&#228;nderungen&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">die Beschlussfassung &#252;ber die Erh&#246;hung des Aktienkapitals, soweit dies in der Kompetenz des Verwaltungsrats liegt (Art. 651 Abs. 4 OR), die Feststellung von Kapitalerh&#246;hungen, die Erstellung des Kapitalerh&#246;hungsberichts und die Vornahme der entsprechenden Statuten&#228;nderungen&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.92pt">die gem&#228;ss Fusionsgesetz un&#252;bertragbaren und unentziehbaren Aufgaben und Befugnisse des Verwaltungsrats&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.92pt">die Benachrichtigung des Richters im Falle der &#220;berschuldung&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">andere durch Gesetz oder Statuten dem Verwaltungsrat vorbehaltene Aufgaben und Befugnisse.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The board of directors has the following non-delegable and inalienable duties&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the ultimate direction of the business of the Company and the issuance of the necessary instructions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the determination of the organization of the Company&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">the administration of accounting, financial control and financial planning&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the appointment and removal of the persons entrusted with executive management and their representation of the Company&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the ultimate supervision of the persons entrusted with management of the Company, specifically in view of their compliance with the law, these Articles of Incorporation, the regulations and directives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.55pt;padding-right:0.9pt;text-align:justify;text-indent:-24.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.22pt">the preparation of the business report, the compensation report and the general meetings of shareholders as well as the implementation of the resolutions adopted by the general meetings of shareholders&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the adoption of resolutions regarding the subsequent payment of capital with respect to non-fully paid up shares and the amendments to the articles of association related thereto&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the adoption of resolutions concerning an increase of the share capital to the extent that such power is vested in the board of directors (art. 651 para. 4 CO) and of resolutions concerning the confirmation of capital increases and corresponding amendments to the Articles of Incorporation, as well as the preparation of the required report on the capital increase&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.92pt">the non-delegable and inalienable duties and powers of the board of directors pursuant to the Merger Act&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.92pt">the notification of the court if liabilities exceed assets&#59;<br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">any other matter reserved to the board of directors by the law or the Articles of Incorporation.</font></div></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 22 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 1.92pt"><font style="font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Im &#220;brigen kann der Verwaltungsrat die Gesch&#228;ftsf&#252;hrung sowie die Vertretung der Gesellschaft im Rahmen der gesetzlichen Bestimmungen durch Erlass eines Organisationsreglements ganz oder teilweise an einzelne oder mehrere seiner Mitglieder oder an andere nat&#252;rliche Personen &#252;bertragen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may delegate the executive management of the Company in whole or in part to one or several individual directors or to individuals other than directors pursuant to organizational regulations.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 20</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anzahl der Mitglieder des Verg&#252;tungsausschusses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verg&#252;tungsausschuss besteht aus mindestens zwei Mitgliedern.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Members of the Compensation Committee</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The compensation committee shall consist of no less than two members.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 21</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 21</font></td></tr><tr style="height:78pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wahl und  Amtsdauer der Mitglieder des Verg&#252;tungsausschusses</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Mitglieder des Verg&#252;tungsausschusses werden von der Generalversammlung einzeln f&#252;r eine Amtsdauer bis zum Abschluss der n&#228;chsten ordentlichen Generalversammlung gew&#228;hlt. W&#228;hlbar sind nur Mitglieder des Verwaltungsrates.</font></td><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Election and Term of Office of Members of the Compensation Committee</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The general meeting of shareholders shall elect the members of the compensation committee individually for a term of office extending until completion of the next ordinary general meeting of shareholders. Only members of the board of directors may be elected.</font></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Mitglieder des Verg&#252;tungsausschusses sind jederzeit wieder w&#228;hlbar.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members of the compensation committee may be re-elected at any time.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bei Vakanzen im Verg&#252;tungsausschuss kann der Verwaltungsrat aus seiner Mitte Ersatzmitglieder f&#252;r eine Amtsdauer bis zum Abschluss der n&#228;chsten ordentlichen Generalversammlung bezeichnen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If there are vacancies on the compensation committee, the board of directors shall appoint from among its members substitutes for a term of office extending until completion of the next ordinary general meeting of shareholders.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 22</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 22</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 23 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organisation des Verg&#252;tungsausschusses</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verg&#252;tungsausschuss konstituiert sich unter Vorbehalt der Kompetenzen der Generalversammlung und des Verwaltungsrats selbst. Der Verwaltungsrat bezeichnet den Vorsitzenden des Verg&#252;tungsausschusses.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organization of the Compensation Committee</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The compensation committee constitutes itself subject to the powers of the general meeting of shareholders and the board of directors. The board of directors shall elect the chair of the compensation committee.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Im &#220;brigen erl&#228;sst der Verwaltungsrat ein Reglement &#252;ber die Organisation und Beschlussfassung des Verg&#252;tungsausschusses.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors shall establish the particulars of the organization and adoption of resolutions of the compensation committee in regulations.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Befugnisse des Verg&#252;tungsausschusses</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verg&#252;tungsausschuss unterst&#252;tzt den Verwaltungsrat bei der Festsetzung und &#220;berpr&#252;fung der Verg&#252;tungsstrategie und -richtlinien sowie bei der Vorbereitung der Antr&#228;ge zuhanden der Generalversammlung betreffend die Verg&#252;tung des Verwaltungsrats und der Gesch&#228;ftsleitung und kann dem Verwaltungsrat Antr&#228;ge zu weiteren Verg&#252;tungsfragen unterbreiten.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Powers of the Compensation Committee</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The compensation committee shall support the board of directors in establishing and reviewing the compensation strategy and guidelines as well as in preparing the proposals to the general meeting of shareholders regarding the compensation of the board of directors and of the executive management, and may submit proposals to the board of directors in other compensation-related issues.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat legt in einem Reglement fest, f&#252;r welche Funktionen des Verwaltungsrats und der Gesch&#228;ftsleitung der Verg&#252;tungsausschuss dem Verwaltungsrat Vorschl&#228;ge f&#252;r die Leistungswerte, Zielwerte und die Verg&#252;tung unterbreitet und f&#252;r welche Funktionen er selbst im Rahmen der Statuten und der vom Verwaltungsrat erlassenen Verg&#252;tungsrichtlinien die Leistungswerte, Zielwerte und die Verg&#252;tung festsetzt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors shall determine in regulations for which positions of the board of directors and of the executive management, the compensation committee shall submit proposals for the performance metrics, target values and the compensation to the board of directors, and for which positions it shall itself determine, in accordance with the Articles of Incorporation and the compensation guidelines established by the board of directors, the performance metrics, target values and the compensation.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat kann dem Verg&#252;tungsausschuss weitere Aufgaben zuweisen, die in einem Reglement festgehalten werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may determine in regulations to delegate further authorities and duties to the compensation committee.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 24 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">C. Die Revisionsstelle</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">C. Auditors</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 24</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wahl, Amtsdauer</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Generalversammlung w&#228;hlt die Revisionsstelle.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Election, Term of Office</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The auditors shall be elected by the general meeting of shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Revisionsstelle wird von der Generalversammlung f&#252;r eine Amtsdauer bis zum Abschluss der n&#228;chsten ordentlichen Generalversammlung gew&#228;hlt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shareholders shall elect the auditors at a general meeting of shareholders for a term of office extending until completion of the next ordinary general meeting of shareholders.</font></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 25</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pr&#252;fungs-, Berichterstattungspflicht</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Revisionsstelle nimmt ihre Pr&#252;fungs- und Berichterstattungspflichten in &#220;bereinstimmung mit dem Gesetz wahr.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duty of Auditing and Reporting</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The auditors shall perform their duties to audit and report in accordance with the law.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 26</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Besondere Abkl&#228;rungen, Zwischenrevisionen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat kann die Revisionsstelle jederzeit beauftragen, besondere Abkl&#228;rungen, insbesondere Zwischenrevisionen, durchzuf&#252;hren und dar&#252;ber Bericht zu erstatten.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Special Audits, Interim Audits</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may at any time request the auditors to conduct special audits, including interim audits, and to submit a respective report.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 4&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Verg&#252;tung der Mitglieder des Verwaltungsrates und der Gesch&#228;ftsleitung</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 4&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Compensation of the Board of Directors and the Executive Management</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 27</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 27</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 25 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grunds&#228;tze der Verg&#252;tungen</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Verg&#252;tung der Mitglieder des Verwaltungsrats kann fixe und variable Verg&#252;tungselemente umfassen. Die Gesamtverg&#252;tung ber&#252;cksichtigt Funktion und Verantwortungsstufe des Empf&#228;ngers.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General Compensation Principles</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Compensation of the members of the board of directors may consist of fixed and variable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">compensation. Total compensation shall take into account the position and level of responsibility of the recipient.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Verg&#252;tung der Mitglieder der Gesch&#228;ftsleitung besteht aus fixen und variablen Verg&#252;tungselementen. Die fixe Verg&#252;tung umfasst das Basissal&#228;r und weitere nicht-variable Verg&#252;tungselemente. Die variable Verg&#252;tung kann kurzfristige und langfristige variable Verg&#252;tungselemente umfassen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation of the members of the executive management consists of fixed and variable compensation elements. Fixed compensation comprises the base salary and other non-variable compensation elements. Variable compensation may comprise short-term and long-term variable compensation elements.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die kurzfristigen variablen Verg&#252;tungselemente orientieren sich an Leistungswerten, die das Erreichen von operativen, strategischen, finanziellen oder anderen Zielen, das Ergebnis der Gesellschaft, des Konzerns oder Teilen davon und&#47;oder individuelle Ziele ber&#252;cksichtigen, und deren Erreichung sich in der Regel w&#228;hrend eines einj&#228;hrigen Zeitraums bemisst. Je nach erreichter Leistung kann sich die Verg&#252;tung auf einen vordefinierten Multiplikator des Zielwerts belaufen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term variable compensation elements shall be governed by performance metrics that take into account the achievement of operational, strategic, financial or other objectives, the results of the Company, the group or parts thereof and&#47;or individual targets, and achievement of which is generally measured during a one-year period. Depending on achieved performance, the compensation may amount to a multiplier of target level.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 26 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die langfristigen variablen Verg&#252;tungselemente orientieren sich an Leistungswerten, welche die Entwicklung des Aktienkurses oder Aktienergebnisses absolut oder im Verh&#228;ltnis zu Vergleichsgruppen oder Indices und&#47;oder das Ergebnis der Gesellschaft, des Konzerns oder Teilen davon und&#47;oder das Erreichen von operativen, strategischen, finanziellen oder anderen Zielen absolut oder im Vergleich zum Markt, anderen Unternehmen oder vergleichbaren Richtgr&#246;ssen und&#47;oder Elemente zwecks Mitarbeiterbindung ber&#252;cksichtigen. Die Zielerreichung bemisst sich in der Regel w&#228;hrend eines mehrj&#228;hrigen Zeitraums, sowie an Elementen zwecks Mitarbeiterbindung. Je nach erreichter Leistung kann sich die Verg&#252;tung auf einen vordefinierten Multiplikator des Zielwerts belaufen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Long-term variable compensation elements shall be governed by performance metrics that take into account the development of the share price or share performance in absolute terms or in relation to peer groups or indices and&#47;or the results of the Company, the group or parts thereof and&#47;or the achievement of operational, strategic, financial or other objectives in absolute terms or in relation to the market, other companies or comparable benchmarks and&#47;or retention elements. An achievement of the objectives is generally measured over a period of several years. Depending on achieved performance, the compensation may amount to a multiplier of target level.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat oder, soweit an ihn delegiert, der Verg&#252;tungsausschuss legen Leistungs- und Zielwerte sowie deren Gewichtung und Erreichung fest.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors or, to the extent delegated to it, the compensation committee shall determine the performance metrics and target levels of the short- and long-term variable compensation elements, as well as their achievement.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 27 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">Die Verg&#252;tung kann in der Form von Geld, Aktien oder Sach- oder Dienstleistungen ausgerichtet werden</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:147%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:147%">werden&#59; Verg&#252;tung der Mitglieder der Gesch&#228;ftsleitung kann zus&#228;tzlich in der Form von aktienbasierten Instrumenten oder Einheiten ausgerichtet werden. Der Verwaltungsrat oder, soweit an ihn delegiert, der Verg&#252;tungsausschuss legen Zuteilungs-, Vesting-, Aus&#252;bungs- und Verfallsbedingungen fest. Sie k&#246;nnen insbesondere vorsehen, dass aufgrund des Eintritts im Voraus bestimmter Ereignisse, wie eines Kontrollwechsels oder der Beendigung des Arbeits- oder Mandatsverh&#228;ltnisses, Vesting-, Aus&#252;bungs- und Verfallsbedingungen weitergelten, verk&#252;rzt oder aufgehoben werden, Verg&#252;tungen unter der Annahme der Erreichung von Zielwerten ausgerichtet werden oder Verg&#252;tungen verfallen. Die Gesellschaft kann die erforderlichen Aktien auf dem Markt erwerben, aus Best&#228;nden eigener Aktien entnehmen oder unter Verwendung von bedingtem oder genehmigtem Kapital bereitstellen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:129%">Compensation may be paid in the form of cash, shares, or in the form of other types of benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:129%">benefits&#59; for the executive management, compensation may in addition be paid in the form of share-based instruments or units. The board of directors or, to the extent delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions. In particular, they may provide for continuation, acceleration or removal of vesting, exercise and forfeiture conditions, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of pre-determined events such as a change-of-control or termination of an employment or mandate agreement. The Company may procure the required shares through purchases in the market, from treasury shares or by using contingent or authorized share capital.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Verg&#252;tung kann durch die Gesellschaft oder durch von ihr kontrollierte Unternehmen ausgerichtet werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation may be paid by the Company or companies controlled by it.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 28</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 28</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 28 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genehmigung der Verg&#252;tungen</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Die Generalversammlung genehmigt die Antr&#228;ge des Verwaltungsrats in Bezug auf die maximalen Gesamtbetr&#228;ge der </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">Verg&#252;tung des Verwaltungsrats f&#252;r die kommende Amtsdauer&#59; und</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">der fixen Verg&#252;tung der Gesch&#228;ftsleitung f&#252;r die Periode vom 1. Juli des laufenden bis zum 30. Juni des folgenden Jahres&#59; und</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">der variablen Verg&#252;tungselemente der Gesch&#228;ftsleitung f&#252;r das laufende Gesch&#228;ftsjahr.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approval of Compensation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The general meeting of shareholders shall approve the proposals of the board of directors in relation to the maximum aggregate amounts of&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">the compensation of the board of directors for the next term of office&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">of the fixed compensation of the executive management for the period of July 1 of the current year until June 30 of the following year&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.14pt">of the variable compensation elements of the executive management for the current financial year.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Verwaltungsrat kann der Generalversammlung abweichende, zus&#228;tzliche oder bedingte Antr&#228;ge in Bezug auf die maximalen Gesamtbetr&#228;ge, mehrere maximale Teilbetr&#228;ge f&#252;r die gleichen oder andere Zeitperioden und&#47;oder einzelne Verg&#252;tungselemente und&#47;oder in Bezug auf Zusatzbetr&#228;ge f&#252;r besondere Verg&#252;tungselemente zur Genehmigung vorlegen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may submit for approval by the general meeting of shareholders deviating, additional or conditional proposals relating to the maximum aggregate amount or maximum partial amounts for the same or different periods and&#47;or specific compensation components and&#47;or in relation to additional amounts for specific compensation components.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Verg&#252;tung kann vor der Genehmigung durch die Generalversammlung unter Vorbehalt der nachtr&#228;glichen Genehmigung ausgerichtet werden.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation may be paid out prior to approval by the general meeting of shareholders subject to subsequent approval.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genehmigt die Generalversammlung einen Antrag des Verwaltungsrats nicht, setzt der Verwaltungsrat den entsprechenden (maximalen) Gesamtbetrag oder (maximale) Teilbetr&#228;ge unter Ber&#252;cksichtigung aller relevanten Faktoren neu fest und unterbreitet den oder die so festgesetzten Betr&#228;ge der gleichen Generalversammlung, einer ausserordentlichen Generalversammlung oder der n&#228;chsten ordentlichen Generalversammlung zur Genehmigung.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the general meeting of shareholders does not approve a proposal of the board of directors, the board of directors newly determines the maximum aggregate amount or maximum partial amounts taking into account all relevant factors and submits such amounts for approval to the same general meeting of shareholders, to an extraordinary general meeting of shareholders or to the next ordinary general meeting of shareholders.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 29 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 29</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zusatzbetrag</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft oder von ihr kontrollierte Gesellschaften sind erm&#228;chtigt, Mitgliedern der Gesch&#228;ftsleitung, die w&#228;hrend einer Periode, f&#252;r welche die Verg&#252;tung der Gesch&#228;ftsleitung bereits genehmigt ist, in die Gesch&#228;ftsleitung eintreten oder bef&#246;rdert werden, einen Zusatzbetrag auszurichten, sofern der f&#252;r die betreffende Periode bereits genehmigte Gesamtbetrag f&#252;r deren Verg&#252;tung nicht ausreicht.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplementary Amount</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company or companies under its control shall be authorized to pay a supplementary amount of compensation ratified by the shareholders at a general meeting of shareholders to members of the executive management who joined or were promoted during a compensation period for which the maximum aggregate amount of compensation has already been approved, but is insufficient to cover compensation of such members of the executive management.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Der Zusatzbetrag darf je Verg&#252;tungsperiode je Mitglied 50% des letzten genehmigten maximalen Gesamtbetrags der Verg&#252;tung der Gesch&#228;ftsleitung nicht &#252;bersteigen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The supplementary amount per compensation period per member shall not exceed 50% of the maximum aggregate amount of compensation of the executive management last approved.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 5&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Vertr&#228;ge mit Mitgliedern des Verwaltungsrats und der Gesch&#228;ftsleitung</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 5&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Agreements regarding Compensation with Members of the Board of Directors and the Executive Management</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 30</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vertr&#228;ge mit Mitgliedern des Verwaltungsrats und der Gesch&#228;ftsleitung</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft oder von ihr kontrollierte Gesellschaften k&#246;nnen mit Mitgliedern des Verwaltungsrats befristete oder unbefristete Vertr&#228;ge &#252;ber deren Mandat und Verg&#252;tung abschliessen. Dauer und Beendigung richten sich nach Amtsdauer und Gesetz.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Agreements with Members of the Board of Directors and the Executive Management</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company or companies under its control may enter into mandate or other agreements with the members of the board of directors regarding their compensation as directors for a fixed term or for an indefinite term. The duration and termination are subject to term of office and the law.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 30 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft oder von ihr kontrollierte Gesellschaften k&#246;nnen mit Mitgliedern der Gesch&#228;ftsleitung befristete oder unbefristete Arbeitsvertr&#228;ge abschliessen. Befristete Arbeitsvertr&#228;ge haben eine H&#246;chstdauer von einem Jahr. Eine Erneuerung ist zul&#228;ssig. Unbefristete Vertr&#228;ge haben eine K&#252;ndigungsfrist von maximal einem Jahr.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company or companies under its control may enter into employment agreements with the members of the executive management for a fixed term or for an indefinite term. The duration of fixed term agreements may not exceed one year. A renewal of a fixed term agreement is permissible. Agreements for an indefinite term may have a termination notice period of a maximum of one year.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Gesellschaft oder von ihr kontrollierte Gesellschaften k&#246;nnen mit Mitgliedern der Gesch&#228;ftsleitung Konkurrenzverbote f&#252;r die Zeit nach Beendigung des Arbeitsverh&#228;ltnisses vereinbaren. Deren Dauer soll zwei Jahre nicht &#252;bersteigen. Zur Abgeltung eines solchen Konkurrenzverbots darf eine Entsch&#228;digung ausgerichtet werden, deren H&#246;he die letzte Gesamtjahresverg&#252;tung des betreffenden Mitglieds der Gesch&#228;ftsleitung nicht &#252;bersteigt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company or companies under its control may enter into non-competition agreements with members of the executive management for the period after the termination of the employment agreement. The duration of any such non-competition undertaking by a member of the executive management shall not exceed two years, and the consideration paid for a non-competition undertaking shall not exceed the sum of the total annual compensation of the respective member of the executive management last paid.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 6&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Darlehen, Kredite und Vorsorgeleistungen an die Mitglieder des Verwaltungsrats und der Gesch&#228;ftsleitung</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 6&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Loans, Credits, Post-Retirement Benefits to members of the Board of Directors and the Executive Management</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 31</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Darlehen und Kredite</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kredite an Mitglieder des Verwaltungsrats und der Gesch&#228;ftsleitung d&#252;rfen von der Gesellschaft oder von ihr kontrollierten Gesellschaften nur zu Marktbedingungen und nur solange ausgerichtet werden, als die Gesamtsumme der insgesamt ausstehenden Kredite an dieses Mitglied des Verwaltungsrats oder der Gesch&#228;ftsleitung einschliesslich der zu gew&#228;hrenden Kredite das Zweifache der letztmalig an dieses Mitglied bezahlten oder erstmaligen Jahresverg&#252;tung nicht &#252;bersteigt.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans and Credits</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits to members of the board of directors and the executive management can solely be granted at standard market rates and the aggregate amount of credit to the member of the board of directors or executive management may not exceed double the total annual compensation of the respective member of the executive management last paid or payable for the first time.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 31 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 32</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 32</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vorsorgeleistungen ausserhalb der beruflichen Vorsorge</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vorbeh&#228;ltlich der Genehmigung durch die Generalversammlung gem&#228;ss Artikel&#160;28 dieser Statuten k&#246;nnen die Gesellschaft oder von ihr kontrollierte Gesellschaften an Mitglieder des Verwaltungsrates und der Gesch&#228;ftsleitung Vorsorgeleistungen ausserhalb der beruflichen Vorsorge ausrichten, soweit solche Vorsorgeleistungen 100% der letztmalig an dieses Mitglied bezahlten Jahresverg&#252;tung nicht &#252;bersteigen. Im Fall von Kapitalabfindungen wird der Wert aufgrund anerkannter versicherungsmathematischer Methoden ermittelt.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Post-Retirement Benefits beyond Occupational Benefit Scheme</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the approval by the meeting of shareholders pursuant to Article&#160;28 of these Articles of Incorporation, the Company or companies under its control may grant to members of the board of directors or the executive management post-retirement benefits beyond the occupational benefit scheme, if such post-retirement benefits do not exceed 100% of the total annual compensation of the respective member last paid. In case of capital settlements, the value is determined by recognized actuary methods.</font></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 7&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Mandate ausserhalb des Konzerns</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 7&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Mandates Outside the Group</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 33</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 33</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mandate ausserhalb des Konzerns</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Die Anzahl der Mandate in den obersten Leitungs- und Verwaltungsorganen von Rechtseinheiten ausserhalb des Konzerns, die in das schweizerische Handelsregister oder ein vergleichbares ausl&#228;ndisches Register einzutragen sind, ist beschr&#228;nkt&#58; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">f&#252;r Mitglieder des Verwaltungsrats auf nicht mehr als f&#252;nfzehn zus&#228;tzliche Mandate&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">f&#252;r Mitglieder der Gesch&#228;ftsleitung auf nicht mehr als f&#252;nf zus&#228;tzliche Mandate. </font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mandates Outside the Group</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The number of mandates in the board of directors and the executive management of legal entities which are to register in the Swiss Commercial Register or a similar foreign register outside the group is limited to&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">for members of the board of directors to fifteen mandates&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:25.7pt;padding-right:0.9pt;text-align:justify;text-indent:-24.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12.58pt">for members of the executive management to five mandates.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Werden Mandate in verschiedenen Rechtseinheiten desselben Konzerns oder im Auftrag dieses Konzerns respektive einer Rechtseinheit ausge&#252;bt, werden diese jeweils als ein Mandat gez&#228;hlt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mandates in different legal entities being part of the same group or for the same group are deemed to be one mandate.</font></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 32 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicht unter diese Beschr&#228;nkung fallen Mandate in Vereinen, gemeinn&#252;tzigen Stiftungen, Familienstiftungen und Einrichtungen der beruflichen Vorsorge. Die Anzahl dieser Mandate darf insgesamt zehn nicht &#252;bersteigen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mandates in associations, charitable organizations, family trusts and foundations relating to post-retirement benefits are not subject to the above limitations. No member of the board of directors or the executive management shall hold more than ten such mandates.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 8&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Gesch&#228;ftsjahr, Gewinnverteilung</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 8&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Fiscal Year, Profit Allocation</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 34</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 34</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gesch&#228;ftsjahr</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Das Gesch&#228;ftsjahr der Gesellschaft wird vom Verwaltungsrat festgesetzt.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Year</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors determines the fiscal year.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 35</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 35</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Verteilung des Bilanzgewinnes, Reserven</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#220;ber den Bilanzgewinn verf&#252;gt die Generalversammlung im Rahmen der gesetzlichen Vorschriften. Der Verwaltungsrat unterbreitet ihr seine Antr&#228;ge.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of Profits,<br>Reserves</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The profit shown on the annual statutory balance sheet shall be allocated by the general meeting of shareholders in accordance with applicable law. The board of directors shall submit its proposals to the general meeting of shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neben der gesetzlichen Reserve kann die Generalversammlung weitere Reserven schaffen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further reserves may be taken in addition to the reserves required by law by the general meeting of shareholders.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividenden, die w&#228;hrend f&#252;nf Jahren von ihrem Verfalltag an nicht bezogen worden sind, fallen der Gesellschaft zu und werden der allgemeinen Reserve zugeteilt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends that have not been collected within five years after their payment date shall enure to the Company and be allocated to the general statutory reserves.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 9&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Aufl&#246;sung, Liquidation </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 9&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Winding-Up and Liquidation </font></div></td></tr></table></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- 33 -</font></div></div><div style="margin-bottom:0.18pt;padding-left:3.55pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.791%"><tr><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.480%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 36</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 36</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aufl&#246;sung, Liquidation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Generalversammlung kann jederzeit die Aufl&#246;sung und Liquidation der Gesellschaft nach Massgabe der gesetzlichen und statutarischen Vorschriften beschliessen.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Winding-Up, Liquidation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The general meeting of shareholders may at any time resolve on the winding-up and liquidation of the Company pursuant to applicable law and the provisions set forth in these Articles of Incorporation.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Liquidation wird durch den Verwaltungsrat durchgef&#252;hrt, sofern sie nicht durch die Generalversammlung anderen Personen &#252;bertragen wird.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The liquidation shall be effected by the board of directors, unless the general meeting of shareholders shall appoint other persons as liquidators.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Die Liquidation der Gesellschaft erfolgt nach Massgabe der Art. 742 ff. OR. Die Liquidatoren sind erm&#228;chtigt, Aktiven (Grundst&#252;cke eingeschlossen) auch freih&#228;ndig zu verkaufen.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The liquidation of the Company shall be effectuated pursuant to art. 742 et seq. CO. The liquidators are authorized to sell assets (including real estate) in the open market.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nach erfolgter Tilgung der Schulden wird das Verm&#246;gen unter den Aktion&#228;ren nach Massgabe der einbezahlten Betr&#228;ge verteilt.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon discharge of all liabilities, the assets of the Company shall be distributed to the shareholders pursuant to the amounts paid in.</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Abschnitt 10&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Mitteilungen, Bekanntmachungen </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:0.9pt;padding-right:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Section 10&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Communications, Announcements </font></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Artikel 37</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 37</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.92pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mitteilungen, Publikationsorgan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publikationsorgan der Gesellschaft ist das Schweizerische Handelsamtsblatt. Der Verwaltungsrat kann weitere Publikationsorgane bezeichnen.</font></td><td colspan="3" style="padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Communications, Official Means of Publication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The official means of publication of the Company shall be the Swiss Official Gazette of Commerce. The board of directors may designate additional means of publication.</font></td></tr></table></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>a12organizationalrulesofth.htm
<DESCRIPTION>EX-1.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if435862b82554e77b6a4d86943154a7c_1"></div><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400">Exhibit 1.2</font></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:174%">ORGANIZATIONAL RULES</font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:174%">OF</font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:174%">MOLECULAR PARTNERS AG</font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:174%">Approved by the Board of Directors </font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:174%">October 6, 2014</font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:174%">(as amended as of May 12, 2017, September 20, 2017, <br>February 5, 2019, April 29, 2020 and March 14, 2022)</font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">TABLE OF CONTENTS</font></div><div style="padding-left:14.17pt;padding-right:14.17pt;text-align:center;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">I.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">GENERAL PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">1.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">BASIS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">2.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">SCOPE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">II.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">BOARD OF DIRECTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">3.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">ORGANIZATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">4.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">FUNCTION AND POWERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">5.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">DUTIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">6.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">DELEGATION AND SIGNING AUTHORITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">7.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">MEETINGS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">8.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">AGENDA</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">9.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">PRESENCE AND QUORUM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">10.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">RESOLUTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">11.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">INFORMATION AND REPORTING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">III.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"> </a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">CHAIRPERSON, VICE-CHAIRPERSON AND SECRETARY OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">12.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">CHAIRPERSON AND VICE-CHAIRPERSON</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">13.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">SECRETARY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">14.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">BOARD COMMITTEES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">IV.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"> </a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">MANAGEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">15.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">CHIEF EXECUTIVE OFFICER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">16.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">CHIEF FINANCIAL OFFICER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">17.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">MANAGEMENT BOARD</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">V.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">18.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">CONFLICTS OF INTERESTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12</a></font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">19.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">CONFIDENTIALITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">20.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">SIGNATORY POWER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">21.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">FINANCIAL YEAR AND ACCOUNTING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">22.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">INSURANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">23.</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:155%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:155%;text-decoration:underline">FINAL PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#if435862b82554e77b6a4d86943154a7c_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13</a></font></div></td></tr></table></div><div style="margin-bottom:8pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%;padding-left:10.78pt">GENERAL PROVISIONS</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">BASIS</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.03pt">These organizational rules (the &#34;Rules&#34;) are adopted by the board of directors (the &#34;Board of Directors&#34;) of Molecular Partners AG (the &#34;Company&#34;) pursuant to article 716b of the Swiss Code of Obligations (&#34;CO&#34;) and article 17 of its articles of association (the &#34;Articles of Association&#34;).</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.03pt">These Rules govern the internal organisation as well as functions, powers and duties of the following corporate bodies and persons&#58; </font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.59pt">the Board of Directors and the members of the Board of Directors (the &#34;Directors&#34;)&#59; </font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:16.15pt">the chairperson (the &#34;Chairperson&#34;), the vice-chairperson (the &#34;Vice-Chairperson&#34;) and the secretary of the Board of Directors (the &#34;Secretary&#34;)&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.71pt">the board committees (the &#34;Board Committees&#34;) established from time to time pursuant to the Articles of Association and these Rules&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">the chief executive officer (the &#34;Chief Executive Officer&#34;)&#59; </font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.53pt">the chief financial officer (the &#34;Chief Financial Officer&#34;)&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">the management board of the Company (the &#34;Management Board&#34;).</font></div><div style="padding-left:56.7pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">SCOPE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">These Rules shall ensure that the Company's business is guided, directed and managed according to clear and uniform principles.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%;padding-left:7.17pt">BOARD OF DIRECTORS</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">ORGANIZATION</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Board of Directors shall consist of not less than 3 and not more than 11 members (including the Chairperson). The shareholders' meeting of the Company (the &#34;Shareholders' Meeting&#34;) shall elect the members of the Board of Directors and the Chairperson of the Board of Directors individually for a term of office extending until completion of the next annual Shareholders' Meeting. Members of the Board of Directors may be re-elected at any time. If the office of the Chairperson is vacant, the Board of Directors shall appoint a new Chairperson from its members for the remaining term of office. </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Board of Directors may elect a Vice-Chairperson from its members each year immediately following the annual Shareholders' Meeting for a term ending at the closing of the following annual Shareholders' Meeting. The Board of Directors shall further appoint the Secretary, who need not be a member of the Board of Directors. The Secretary shall be entitled to participate in the deliberations and discussions of the Board of Directors, but shall not vote, unless he or she is a member of the Board of Directors. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">FUNCTION AND POWERS</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Subject to the legal and statutory powers and duties of the Shareholders' Meeting and the statutory auditors, the Board of Directors shall be the ultimate executive body of the Company.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Board of Directors shall have the authority to pass resolutions in all matters of the Company that are not reserved to the Shareholders' Meeting or to another corporate body by law, the Articles of Association or these Rules.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Subject to the limitations set out in this section&#160;4, the Board of Directors shall have the authority to perform all acts that the business objectives of the Company may entail.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">DUTIES</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Board of Directors shall have, in particular, the following non-delegable and inalienable powers and duties (articles 716a and 716b CO and article 19 of the Articles of Association)&#58;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.59pt">the ultimate direction of the business of the Company and the issuance of the necessary instructions&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:16.15pt">the determination of the organisation of the Company, including the adoption and revision of these Rules&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.71pt">the organization of accounting, financial control and financial planning of the Company&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">the appointment and removal of the persons entrusted with the executive management and their representation of the Company&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.53pt">the ultimate supervision of the persons entrusted with the management of the Company, specifically in view of their compliance with the law, the Articles of Association, these Rules and the directives of the Board of Directors&#59;</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">the preparation of the business report, the compensation report and the Shareholders' Meetings as well as the implementation of the resolutions adopted by the Shareholders' Meeting&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.65pt">the adoption of resolutions regarding the subsequent payment of capital with respect to non-fully paid up shares and the amendments to the Articles of Association related thereto&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:8.21pt">the adoption of resolutions concerning an increase of the share capital to the extent that such power is vested in the Board of Directors (article 651 paragraph 4 CO) and of resolutions concerning the confirmation of capital increases and corresponding amendments to the Articles of Association, as well as the preparation of the required report on the capital increase&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">the non-delegable and inalienable duties and powers of the Board of Directors pursuant to the Swiss Merger Act and any other law&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(x)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.53pt">the notification of the court if liabilities exceed assets&#59; and</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(xi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">any other matter reserved to the Board of Directors by the law or the Articles of Association.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">In addition, the Board of Directors shall have the following powers and duties&#58; </font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.59pt">approve or make any material change to the business plan, the operational plan or the annual budget&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:16.15pt">approve individual expenditure (including capital expenditure) in excess of CHF&#160;1,000,000 if such expenditure is not included in the approved annual budget&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.71pt">agree to credit lines, other financial indebtedness or leases exceeding CHF 1,000,000&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">create any liens or encumbrances of assets outside the normal and ordinary course of business&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.53pt">establish the Company's dividend policy&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">establish a directive and procedure on public disclosure, reporting and securities trading&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.65pt">review and approve the recommendations of the Board Committees&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:8.21pt">adopt or amend any equity incentive plan, such as a stock option plan and the related documentation, as well as grant or delegate the grant of shares, stock options or other rights under any equity incentive plan&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">create or close a subsidiary or any joint venture partnership or similar business association of the Company&#59;</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(x)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.53pt">transfer or license any material intellectual property right, other than by entering into material transfer agreements or similar agreements under the strategy agreed by the Board of Directors&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(xi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">enter into any transaction between the Company and any member of the Board of Directors (a &#34;Director&#34;) or member of the Management Board, except for ordinary course compensation and expense&#59; and</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(xii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:10.65pt">enter into any transaction which would result in a direct or indirect acquisition of, or entering into any legally binding agreement or commitment to acquire, the assets of, or effective voting or contractual control over (whether resulting from a purchase of shares, by merger, by consolidation, or otherwise), any other entity.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">DELEGATION AND SIGNING AUTHORITY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Subject to the terms of these Rules, the Board of Directors hereby delegates all other duties as well as the day-to-day and operational management of the Company's business to.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">the Chairperson and Vice-Chairperson (article&#160;12)</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">the Secretary (article&#160;13)&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">the Board Committees (article&#160;14)&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">the Chief Executive Officer (article&#160;15),</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">the Chief Financial Officer (article&#160;16)&#59; and</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">the Management Board (article&#160;17).</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">MEETINGS</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chairperson or, should he or she be unable to do so, the Vice-Chairperson or any other Director shall convene meetings of the Board of Directors if and when the need arises or whenever a Director indicating the reasons so requests in writing. Meetings may also be held by telephone or video conference.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Notice of meetings shall be given at least 10 days prior to the meeting and the notice shall set forth the agenda. In urgent cases, a meeting may be held on appropriate shorter notice. Any Director who is unable to attend a meeting in person shall have the right to attend the meeting by means of telephone or video conference so that all persons participating and attending such meeting can hear and be heard by all others participating and attending the meeting. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">If a Director requests that a meeting be called, he or she shall submit the respective demand to the Chairperson and indicate the grounds for such a request and the </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">agenda of the meeting. In such an event, the Chairperson shall convene the meeting within 10 days after receipt of the respective demand.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">In the event that the Board of Directors is to resolve on an increase of the share capital (article 651 paragraph 4 CO) and on resolutions concerning the confirmation of capital increases and corresponding amendments to the Articles of Association as well as the preparation of the required report on the capital increase, no invitations to the Directors shall have to be sent out.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Any meeting of the Board of Directors shall be held in English and all written communications and minutes shall be in English, other than as required by applicable law.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">AGENDA</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The items on the agenda of the meetings of the Board of Directors shall be determined by the Chairperson.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Each Director may request an item to be put on the agenda. Such a request shall, if reasonably possible, be sent to the Chairperson in writing at least 5 days prior to the meeting. In such event, the Chairperson shall immediately communicate the additional items on the agenda to the other Directors before the beginning of the meeting.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">No resolution shall be taken on items that were not on the agenda of the meeting unless all Directors are attending the meeting and agree that such resolution be taken or in case of urgency.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:19.19pt">PRESENCE AND QUORUM</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">In order to pass resolutions, at least a majority of the Directors must be present. No attendance quorum shall be required for confirmation or amendment resolutions of the Board of Directors in connection with capital increases. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chairperson, or in his absence another Director specifically designated by the majority of the other Directors present at the meeting, shall determine the non-members who may attend the meetings as guests.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">RESOLUTIONS</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The adoption of resolutions of the Board of Directors requires a simple majority of the votes cast. Each Director shall have one vote. In the event of a tie, the Chairperson shall have the casting vote.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Resolutions may be passed by way of circulation (in writing, including by PDF sent by e-mail, or through electronic board tool), provided that no Director requests oral deliberation.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The resolutions shall be confirmed in the minutes, which are to be signed by the acting chairperson and the Secretary.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">INFORMATION AND REPORTING</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Each Director shall be entitled to request information concerning all affairs of the Company. In the meetings of the Board of Directors, all Directors and all persons entrusted with the management of the Company's business shall furnish the requested information.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Outside the meetings of the Board of Directors, each Director may request information from the persons entrusted with the management of the Company's business concerning the course of business and, upon authorization by the Chairperson, concerning particular aspects thereof.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">To the extent necessary to fulfil his or her duties, each Director may request that the Chairperson authorizes the inspection of the books and records of the Company. If the Chairperson rejects a request for information, hearing or inspection, the Board of Directors shall decide whether to grant such request.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Notwithstanding the foregoing, individual resolutions of the Board of Directors may confer upon the Directors' additional rights to request information, hearing or inspection.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%;padding-left:3.56pt">CHAIRPERSON, VICE-CHAIRPERSON AND SECRETARY OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">CHAIRPERSON AND VICE-CHAIRPERSON</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chairperson shall chair the meetings of the Board of Directors and the Shareholders' Meeting.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Should the Chairperson be temporarily unable or unavailable to exercise his or her functions, his or her functions shall be assumed by the Vice-Chairperson, or if the latter should also be temporarily unable or unavailable, another Director appointed by the Chairperson, the Vice-Chairperson or the Board of Directors.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">SECRETARY</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Secretary shall keep the minutes of the meetings of the Board of Directors. </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Secretary shall also be responsible for the correct management of the share register.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">BOARD COMMITTEES</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Subject to the powers of the Shareholders' Meeting, the Board of Directors may appoint from among its members Board Committees for specific areas. Together with the appointment of a Board Committee, the Board of Directors shall establish the appropriate rules with respect to the mission, the authority and the reporting of the Board Committee. Notwithstanding the generality of the above, the following Board Committees shall be appointed&#58;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.59pt">a nomination and compensation committee (the &#34;Nomination and Compensation Committee&#34;)&#59; </font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:16.15pt">an audit and finance committee (the &#34;Audit and Finance Committee&#34;)&#59; and</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.71pt">a research and development committee (the &#8220;Research and Development Committee&#8221;).</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Shareholder's Meeting shall elect the members of the Nomination and Compensation Committee individually for a term of office extending until completion of the next annual Shareholders' Meeting. The members of the Audit and Finance Committee and of the Research and Development Committee shall be appointed by the Board of Directors for a term of office extending until completion of the next annual Shareholders' Meeting.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Members of the Board Committees may be re-elected at any time. If there are vacancies on the Board Committees, the Board of Directors shall appoint from its members suitable substitutes for a term of office extending until completion of the next annual Shareholders' Meeting. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Further to the principle powers of the Compensation Committee set forth in Article 23 of the Articles of Association, the duties and responsibilities of the Nomination and Compensation Committee, the Audit and Finance Committee and the Research and Development Committee are attached to these Rules (Annexes 1, 2 and 3) and shall be incorporated herein by reference.</font></div><div style="padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%;padding-left:2.11pt">MANAGEMENT</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">CHIEF EXECUTIVE OFFICER</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chief Executive Officer shall be appointed by the Board of Directors for an indeterminate term of office. </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Subject to these Rules and the mandatory provisions of Swiss law, the Board of Directors hereby delegates the executive management of the Company to the Chief Executive Officer. Accordingly, the Chief Executive Officer shall be responsible for the executive management of the Company and its supporting functions. In particular, the Chief Executive Officer shall have the following powers and duties&#58;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:18.59pt">implementing the strategy of the Company and the decisions taken by the Board of Directors and the Board Committees&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:16.15pt">monitoring and assessing progress against the Company's target and budget&#59;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.71pt">preparing and submitting to the Board of Directors for approval the following matters&#58;</font></div><div style="padding-left:85.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:24.5pt">the Company's strategy&#59;</font></div><div style="padding-left:85.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:24.5pt">subject to the powers and duties of the Board Committees, proposals to the Shareholders' Meeting&#59; and</font></div><div style="padding-left:85.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:24.5pt">amendments to the Articles of Association, these Rules and signatory authorities of the Company.</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.09pt">managing, supervising and coordinating the ongoing business operations of the Company&#59; and</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:15.53pt">determining the communication policy of the Company and representing the overall interest of the Company towards its shareholders and third parties and the promotion of investor relations.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chief Executive Officer shall involve the Management Board in all relevant matters and resolutions pertaining to his powers and duties. He or she shall be entitled to delegate some of his or her duties to other members of the Management Board or to third parties. The tasks according to article&#160;16 shall be delegated to the Chief Financial Officer.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chief Executive Officer shall regularly inform the Board of Directors at the meeting of the Board of Directors on the current course of business and all major business matters of the Company including anticipated opportunities and risks. Extraordinary matters including significant unanticipated developments shall immediately be reported to the Chairperson.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Subject to the Rules and the mandatory provisions of Swiss law, the Chief Financial Officer shall be responsible for financial matters of the Company and shall report directly to the Chief </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Executive Officer. In particular, the Chief Financial Officer shall have the following powers and duties&#58;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">preparing and submitting to the Board of Directors and the Chief Executive Officer for approval the annual budgets, including statements of income, cash-flow statements and balance sheets, and the annual financial statements and statutory accounts for the Company, including statements of income, cash-flow statements, and balance sheets&#59; </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">organizing and managing the accounting system as well as the financial control, financial planning and financial reporting of the Company&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">operating and continuously improving the internal control system&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">regular, at least on a quarterly basis, information and reporting of the financial situation of the Company  to the Board of Directors&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">immediate reporting of extraordinary business developments and matters of urgent nature to the chairperson of the Audit and Finance Committee and to the Chief Executive Officer&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">organizing, supervising and coordinating pension, insurance and risk management matters of the Company&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">monitoring the optimal financing of the Company&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">ensuring compliance with all applicable tax laws and optimizing the Company's effective tax rate&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">maintaining investor relations, in consultation with the Chief Executive Officer and the SVP Investor Relations&#59;</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:6.97pt">supervising compliance with the formal requirements of the capital markets, in particular ongoing reporting obligations with respect to the listing, disclosure and notification obligation according to the Swiss Stock Exchange Act and the Company's policies, in particular the Public Disclosure, Reporting and Securities Trading Policy&#59; and</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:6.97pt">participate in the decisions with respect to disclosure of price sensitive facts (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">ad hoc</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> publicity) and prohibition of trading in any securities relating to the Company in accordance with the laws and the Company's policies, in particular the Public Disclosure, Reporting and Securities Trading Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">MANAGEMENT BOARD</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Management Board shall include as a minimum the Chief Executive Officer, the Chief Financial Officer, the Chief Operating Officer and the Chief Medical Officer. Other members may be appointed by the Board of Directors from time to time. Except in the case of the Chief Executive Officer and the Chief Financial Officer, a member of the </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Management Board may assume more than one of the mentioned offices. The Management Board shall be chaired by the Chief Executive Officer.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">All members of the Management Board shall be proposed by the Chief Executive Officer and the Board of Directors shall approve their appointments. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Management Board shall be responsible for the management of the Company. It shall implement the strategy of the Company decided by the Board of Directors and shall ensure the execution of the decisions of the Board of Directors in accordance with the law, the Articles of Association, these Rules and the resolutions by the Shareholders' Meeting.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Meetings of the Management Board shall generally take place at least every four weeks and shall be called by the Chief Executive Officer or his or her delegate or by another member of the Management Board. Every member shall be entitled to ask the Chief Executive Officer to call a meeting by indicating the items to be discussed.  Meetings of the Management Board may take place as part of meetings with other members of the leadership team. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Notice of meetings shall be given within a reasonable time period in advance in writing or by another suitable means indicating the agenda. Every member of the Management Board may request an item to be put on the agenda and other employees of the Company to participate in the meeting.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">In order to pass resolutions, at least a majority of the members of the Management Board, and amongst them the Chief Executive Officer or, in his or her absence, his or her delegate, must be present. Resolutions shall be taken with the absolute majority of the votes represented. In the event of a tie, the Chief Executive Officer shall have the casting vote.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chief Executive Officer shall appoint the secretary of the Management Board who shall keep the minutes.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Every member of the Management Board may request from the Chief Executive Officer and the other members of the Management Board, at any time in and outside of the meetings of the Management Board, to receive information about the Company's affairs and to inspect business documents.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Management Board shall take note, generally on a monthly basis, of the reports of the Chief Financial Officer regarding the financial situation of the Company as well as of the other members' reports in the meetings of the Management Board.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:125%;padding-left:5.72pt">MISCELLANEOUS</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">DUTY OF CARE AND LOYALTY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Each Director and each member of the Management Board shall be under a duty to carry out his or her responsibilities with due care and to safeguard and further the best interests of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">CONFLICTS OF INTERESTS</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Directors and the members of the Management Board shall arrange their personal and business affairs so as to avoid, as much as possible, a conflict of interest.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Each Director and each member of the Management Board shall disclose to the Chairman and the Chief Executive Officer, respectively, any conflict of interest generally arising or relating to any matter to be discussed at a meeting, as soon as the Director and member of the Management Board becomes aware of its potential existence.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Chairman and the Chief Executive Officer, respectively, shall decide upon appropriate measures to avoid any interference of such conflict of interests with the forming of will and decisions of the Company. In the event of doubt, the Chairman and the Chief Executive Officer, respectively, shall request the respective corporate body to determine whether a conflict of interest exists and to decide upon appropriate measures.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">As a rule, subject to exceptional circumstances in which the best interests of the Company dictate otherwise, the Director or member of the Management Board shall not participate in discussions and decision-making involving the matter at stake. The person with a conflict shall have the right to, or may be required by the Chairman and the Chief Executive Officer, respectively, to provide a statement of his or her view of the matter before leaving the discussion.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">While, in minor cases, the information flow may not be affected by the conflict of interest, the Chairman and the Chief Executive Officer, respectively, may decide to limit the information flow to the relevant Director or member of the Management Board or to keep the matter entirely secret with respect to the relevant Director or member of the Management Board. The Chairman and the Chief Executive Officer, respectively, shall advise the respective corporate body of the conflict of interest.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">CONFIDENTIALITY</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The members of the Board of Directors and the Management Board shall keep confidential and shall not disclose to any third party information and documents obtained or inspected in connection with the exercise of their function or with the performance of their duties on behalf of the Company. They shall be bound by the obligation of confidentiality even after the termination of their mandate.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">Upon termination of their function, the members of the Board of Directors and the Management Board shall return all documents and data storage media related to the Company.</font></div><div style="padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">SIGNATORY POWER</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Each Director shall be entitled to sign jointly together with another Director. All other persons entrusted by the Board of Directors with the representation of the Company shall also be entitled to sign jointly together with another person.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">FINANCIAL YEAR AND ACCOUNTING</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Company's financial year shall correspond to the calendar year.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Company's accounting policies shall be determined by the Chief Financial Officer in consultation with the Audit and Finance Committee.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Company shall establish its annual financial statements as at December&#160;31.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Company shall establish semi-annual financial statements to be published to investors.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Company shall establish monthly interim financial statements for internal use only.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">INSURANCE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The Company may procure directors' and officers' liability insurance for the members of the Board of Directors and the Management Board in line with best practice for Swiss and US listed companies. </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:148%;padding-left:13.08pt">FINAL PROVISIONS</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">These Rules shall enter into force as of the first day of trading of the shares of the Company on the SIX Swiss Exchange Ltd.</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">The Board of Directors shall be entitled to issue executive regulations to these Rules.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.08pt">These Rules may be amended by the Board of Directors at any time.</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Schlieren, March 14, 2022</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">For the Board of Directors</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">William M. Burns, Chairman</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:174%">Annexes</font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:174%">Annex 1&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%"> Charter of the Nomination and Compensation Committee </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:174%">Annex 2&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%"> Charter of the Audit and Finance Committee </font></div><div style="padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:174%">Annex 3&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%"> Charter of the Research and Development Committee</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>4
<FILENAME>a21-depositagreement1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if7724931561a4e79bc4853d8d987da59_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 2.1</font></div><div><font><br></font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:97.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:36pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT AGREEMENT</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:97.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:30pt;margin-top:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and among</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CITIBANK, N.A.,</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Depositary,</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE HOLDERS AND BENEFICIAL OWNERS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMERICAN DEPOSITARY SHARES </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISSUED HEREUNDER</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:97.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of June 18, 2021</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE I DEFINITIONS</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;ADS Record Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Agent&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;American Depositary Receipt(s)&#8221;, &#8220;ADR(s)&#8221; and &#8220;Receipt(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;American Depositary Share(s)&#8221; and &#8220;ADS(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Articles of Incorporation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Beneficial Owner&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Certificated ADS(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Citibank&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Commission&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Custodian&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deliver&#8221; and &#8220;Delivery&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deposit Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.15</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Depositary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.16</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deposited Property&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.17</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deposited Securities&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.18</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Dollars&#8221; and &#8220;$&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.19</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;DTC&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.20</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;DTC Participant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.21</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Exchange Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.22</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Foreign Currency&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.23</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Full Entitlement ADR(s)&#8221;, &#8220;Full Entitlement ADS(s)&#8221; and &#8220;Full Entitlement Share(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.24</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Holder(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.25</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Partial Entitlement ADR(s)&#8221;, &#8220;Partial Entitlement ADS(s)&#8221; and &#8220;Partial Entitlement Share(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.26</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Principal Office&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.27</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Registrar&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.28</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Restricted ADR(s)&#8221;, &#8220;Restricted ADS(s)&#8221; and &#8220;Restricted Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.29</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Restricted Securities&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.30</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Securities Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.31</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Share Registrar&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.32</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.33</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Swiss Franc&#8221; and &#8220;CHF&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.34</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Uncertificated ADS(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.35</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;United States&#8221; and &#8220;U.S.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II APPOINTMENT OF DEPOSITARY&#59; FORM OF RECEIPTS&#59; DEPOSIT OF SHARES&#59; EXECUTION AND DELIVERY, TRANSFER AND SURRENDER OF RECEIPTS</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appointment of Depositary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form and Transferability of ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Deposit of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></td></tr></table></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Registration and Safekeeping of Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transfer, Combination and Split-up of ADRs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Surrender of ADSs and Withdrawal of Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Limitations on Execution and Delivery, Transfer, etc. of ADSs&#59; Suspension of Delivery, Transfer, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lost ADRs, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cancellation and Destruction of Surrendered ADRs&#59; Maintenance of Records.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Escheatment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partial Entitlement ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Certificated&#47;Uncertificated ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III CERTAIN OBLIGATIONS OF HOLDERS AND BENEFICIAL OWNERS OF ADSs</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proofs, Certificates and Other Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Liability for Taxes and Other Charges.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Representations and Warranties on Deposit of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Information Requests.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ownership Restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reporting Obligations and Regulatory Approvals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV THE DEPOSITED SECURITIES</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cash Distributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distribution in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Elective Distributions in Cash or Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distribution of Rights to Purchase Additional ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distributions Other Than Cash, Shares or Rights to Purchase Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distributions with Respect to Deposited Securities in Bearer Form.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Redemption.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conversion of Foreign Currency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fixing of ADS Record Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Voting of Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Changes Affecting Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Available Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.15</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Taxation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V THE DEPOSITARY, THE CUSTODIAN AND THE COMPANY</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Maintenance of Office and Transfer Books by the Registrar.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exoneration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard of Care.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Resignation and Removal of the Depositary&#59; Appointment of Successor Depositary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Custodian.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notices and Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of Additional Shares, ADSs etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADS Fees and Charges.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Securities Owners.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VI AMENDMENT AND TERMINATION</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment&#47;Supplement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VII MISCELLANEOUS</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Third-Party Beneficiaries&#47;Acknowledgments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Holders and Beneficial Owners as Parties&#59; Binding Effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governing Law and Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Assignment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with, and No Disclaimer under, U.S. Securities Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Switzerland Law References.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Titles and References.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBITS</font></div><div style="padding-left:1.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Form of ADR.</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-1</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fee Schedule.</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B-1</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv</font></div></div></div><div id="if7724931561a4e79bc4853d8d987da59_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT AGREEMENT</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, dated as of June 18, 2021, by and among (i) MOLECULAR PARTNERS AG, a corporation incorporated under the laws of Switzerland, and its successors (the &#8220;Company&#8221;), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the &#8220;Depositary&#8221;), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">W I T N E S S E T H T H A T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company desires to establish with the Depositary an ADR facility to provide for the deposit of the Shares (as hereinafter defined) and the creation of American Depositary Shares representing the Shares so deposited and for the execution and Delivery (as hereinafter defined) of American Depositary Receipts (as hereinafter defined) evidencing such American Depositary Shares&#59; and</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Depositary is willing to act as the Depositary for such ADR facility upon the terms set forth in the Deposit Agreement (as hereinafter defined)&#59; and</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any American Depositary Receipts issued pursuant to the terms of the Deposit Agreement are to be substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto, with appropriate insertions, modifications and omissions, as hereinafter provided in the Deposit Agreement&#59; and</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEFINITIONS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms used, but not otherwise defined, herein shall have the meanings set forth below, unless otherwise clearly indicated&#58;</font></div><div style="margin-bottom:0.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the meaning given to such term in Section 4.9.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.2 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the meaning assigned to such term by the Commission (as hereinafter defined) under Regulation C promulgated under the Securities Act (as hereinafter defined), or under any successor regulation thereto.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given to such term in Section 7.6.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">American Depositary Receipt(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Receipt(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the certificate(s) issued by the Depositary to evidence the American Depositary Shares issued under the terms of the Deposit Agreement in the form of Certificated ADS(s) (as hereinafter defined), as such ADRs may be amended from time to time in accordance with the provisions of the Deposit Agreement. An ADR may evidence any number of ADSs and may, in the case of ADSs held through a central depository such as DTC, be in the form of a &#8220;Balance Certificate.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">American Depositary Share(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the rights and interests in the Deposited Property (as hereinafter defined) granted to the Holders and Beneficial Owners pursuant to the terms and conditions of the Deposit Agreement and, if issued as Certificated ADS(s) (as hereinafter defined),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the ADR(s) issued to evidence such ADSs. ADS(s) may be issued under the terms of the Deposit Agreement in the form of (a) Certificated ADS(s) (as hereinafter defined), in which case the ADS(s) are evidenced by ADR(s), or (b) Uncertificated ADS(s) (as hereinafter defined), in which case the ADS(s) are not evidenced by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADR(s) but are reflected on the direct registration system maintained by the Depositary for such purposes under the terms of Section 2.13. Unless otherwise specified in the Deposit Agreement or in any ADR, or unless the context otherwise requires, any reference to ADS(s) shall include Certificated ADS(s) and Uncertificated ADS(s), individually or collectively, as the context may require.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each ADS shall represent the right to receive, and to exercise the beneficial ownership interests in, the number of Shares specified in the form of ADR attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (as amended from time to time)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that are on deposit with the Depositary and&#47;or the Custodian, subject, in each case, to the terms and conditions of the Deposit Agreement and the applicable ADR (if issued as a Certificated ADS), until there shall occur a distribution upon Deposited Securities referred to in Section 4.2 or a change in Deposited Securities referred to in Section 4.11 with respect to which additional ADSs are not issued, and thereafter each ADS shall represent the right to receive, and to exercise the beneficial ownership interests in, the applicable Deposited Property on deposit with the Depositary and the Custodian determined in accordance with the terms of such Sections, subject, in each case, to the terms and conditions of the Deposit Agreement and the applicable ADR (if issued as a Certificated ADS). In addition, the ADS(s)-to-Share(s) ratio is subject to amendment as provided in Articles IV and VI of the Deposit Agreement (which may give rise to Depositary fees).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.6 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Articles of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean the Articles of Incorporation of the Company, as amended and restated from time to time.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, as to any ADS, any person or entity having a beneficial interest deriving from the ownership of such ADS. Notwithstanding anything else contained in the Deposit Agreement, any ADR(s) or any other instruments or agreements relating to the ADSs and the corresponding Deposited Property, the Depositary, the Custodian and their respective nominees are intended to be, and shall at all times during the term of the Deposit Agreement be, the record holders only of the Deposited Property represented by the ADSs for the benefit of the Holders and Beneficial Owners of the corresponding ADSs. The Depositary, on its own behalf and on behalf of the Custodian and their respective nominees, disclaims any beneficial ownership interest in the Deposited Property held on behalf of the Holders and Beneficial Owners of ADSs. The beneficial ownership interests in the Deposited </font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property are intended to be, and shall at all times during the term of the Deposit Agreement continue to be, vested in the Beneficial Owners of the ADSs representing the Deposited Property. The beneficial ownership interests in the Deposited Property shall, unless otherwise agreed by the Depositary, be exercisable by the Beneficial Owners of the ADSs only through the Holders of such ADSs, by the Holders of the ADSs (on behalf of the applicable Beneficial Owners) only through the Depositary, and by the Depositary (on behalf of the Holders and Beneficial Owners of the corresponding ADSs) directly, or indirectly through the Custodian or their respective nominees, in each case upon the terms of the Deposit Agreement and, if applicable, the terms of the ADR(s) evidencing the ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Beneficial Owner of ADSs may or may not be the Holder of such ADSs. A Beneficial Owner shall be able to exercise any right or receive any benefit hereunder solely through the person who is the Holder of the ADSs owned by such Beneficial Owner. Unless otherwise identified to the Depositary, a Holder shall be deemed to be the Beneficial Owner of all the ADSs registered in his&#47;her&#47;its name.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The manner in which a Beneficial Owner holds ADSs (e.g., in a brokerage account vs. as registered holder) may affect the rights and obligations of, the manner in which, and the extent to which, services are made available to, Beneficial Owners pursuant to the terms of the Deposit Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Certificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.13.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.9 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean Citibank, N.A., a national banking association organized under the laws of the United States of America, and its successors. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Securities and Exchange Commission of the United States or any successor governmental agency thereto in the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Molecular Partners AG, a company incorporated and existing under the laws of Switzerland, and its successors.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Custodian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (i) as of the date hereof, Citibank N.A. London Branch, having its principal office at Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB, United Kingdom, as the custodian of Deposited Property for the purposes of the Deposit Agreement, (ii) Citibank, N.A., acting as custodian of Deposited Property pursuant to the Deposit Agreement, and (iii) any other entity that may be appointed by the Depositary pursuant to the terms of Section 5.5 as successor, substitute or additional custodian hereunder. The term &#8220;Custodian&#8221; shall mean any Custodian individually or all Custodians collectively, as the context requires.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deliver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (x) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">when used in respect of Shares and other Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any of (i) the physical delivery of the certificate(s) representing such securities, or (ii) the book-entry transfer and recordation of such securities on the books of the Share Registrar (as hereinafter defined) or in the applicable book-entry settlement system, and (y) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">when used in respect of ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any of (i) the physical delivery of ADR(s) evidencing the ADSs, or (ii) the book-entry transfer and recordation of ADSs on the books of the Depositary or any book-entry settlement system in which the ADSs are settlement-eligible.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean this Deposit Agreement and all exhibits hereto, as the same may from time to time be amended and supplemented from time to time in accordance with the terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Citibank, N.A., a national banking association organized under the laws of the United States, in its capacity as depositary under the terms of the Deposit Agreement, and any successor depositary hereunder.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.16 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposited Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean the Deposited Securities and any cash and other property held on deposit by the Depositary and the Custodian in respect of the ADSs under the terms of the Deposit Agreement, subject, in the case of cash, to the provisions of Section 4.8. All Deposited Property shall be held by the Custodian, the Depositary and their respective nominees for the benefit of the Holders and Beneficial Owners of the ADSs representing the Deposited Property. The Deposited Property is not intended to, and shall not, constitute proprietary assets of the Depositary, the Custodian or their nominees. Beneficial ownership in the Deposited Property is intended to be, and shall at all times during the term of the Deposit Agreement continue to be, vested in the Beneficial Owners of the ADSs representing the Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.17 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean the Shares and any other securities held on deposit by the Custodian from time to time in respect of the ADSs under the Deposit Agreement and constituting Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.18 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall refer to the lawful currency of the United States.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.19 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean The Depository Trust Company, a national clearinghouse and the central book-entry settlement system for securities traded in the United States and, as such, the custodian for the securities of DTC Participants (as hereinafter defined) maintained in DTC, and any successor thereto. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.20 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DTC Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any financial institution (or any nominee of such institution) having one or more participant accounts with DTC for receiving, holding and delivering the securities and cash held in DTC. A DTC Participant may or may not be a Beneficial Owner. If a DTC Participant is not the Beneficial Owner of the ADSs credited to its account at DTC, or of the ADSs in respect of which the DTC Participant is otherwise acting, such DTC Participant shall be deemed, for all purposes hereunder, to have all requisite authority </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to act on behalf of the Beneficial Owner(s) of the ADSs credited to its account at DTC or in respect of which the DTC Participant is so acting. A DTC Participant, upon acceptance in any one of its DTC accounts of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the Deposit Agreement, shall (notwithstanding any explicit or implicit disclosure that it may be acting on behalf of another party) be deemed for all purposes to be a party to, and bound by, the terms of the Deposit Agreement and the applicable ADR(s) to the same extent as, and as if the DTC Participant were, the Holder of such ADSs. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.21 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.22 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any currency other than Dollars.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.23 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Full Entitlement ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Full Entitlement ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Full Entitlement Share(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the respective meanings set forth in Section 2.12.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.24 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Holder(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the person(s) in whose name the ADSs are registered on the books of the Depositary (or the Registrar, if any) maintained for such purpose. A Holder may or may not be a Beneficial Owner. If a Holder is not the Beneficial Owner of the ADS(s) registered in its name, such person shall be deemed, for all purposes hereunder, to have all requisite authority to act on behalf of the Beneficial Owners of the ADSs registered in its name. The manner in which a Holder holds ADSs (e.g., in certificated vs. uncertificated form) may affect the rights and obligations of, and the manner in which, and the extent to which, the services are made available to, Holders pursuant to the terms of the Deposit Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement Share(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the respective meanings set forth in Section 2.12.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.26 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Principal Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, when used with respect to the Depositary, the principal office of the Depositary at which at any particular time its depositary receipts business shall be administered, which, at the date of the Deposit Agreement, is located at 388 Greenwich Street, New York, New York 10013, U.S.A.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.27 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Depositary or any bank or trust company having an office in the Borough of Manhattan, The City of New York, which shall be appointed by the Depositary to register issuances, transfers and cancellations of ADSs as herein provided, and shall include any co-registrar appointed by the Depositary for such purposes. Registrars (other than the Depositary) may be removed and substitutes appointed by the Depositary. Each Registrar (other than the Depositary) appointed pursuant to the Deposit Agreement shall be required to give notice in writing to the Depositary accepting such appointment and agreeing to be bound by the applicable terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.28 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the respective meanings set forth in Section 2.14.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.29 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Shares, Deposited Securities or ADSs which (i) have been acquired directly or indirectly from the Company or any of its Affiliates in a transaction or chain of transactions not involving any public offering and are subject to resale limitations under the Securities Act or the rules issued thereunder, or (ii) are held by an executive officer or director (or persons performing similar functions) or other Affiliate of the Company, or (iii) are subject to other restrictions on sale or deposit under the laws of the United States, Switzerland, or under a shareholder agreement or the Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation of the Company or under the regulations of an applicable securities exchange unless, in each case, such Shares, Deposited Securities or ADSs are being transferred or sold to persons other than an Affiliate of the Company in a transaction (a) covered by an effective resale registration statement, or (b) exempt from the registration requirements of the Securities Act (as hereinafter defined), and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shares, Deposited Securities or ADSs are not, when held by such person(s), Restricted Securities. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.30 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States Securities Act of 1933, as amended from time to time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.31 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Share Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean areg.ch ag, Fabrikstrasse 10, 4614 H&#228;gendorf, a company incorporated under the laws of Switzerland, or any other institution organized under the laws of Switzerland appointed by the Company (including for the avoidance of doubt, if applicable, the Company) from time to time to carry out the duties of registrar for the Shares, and any successor thereto.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.32 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s common shares, with a nominal value of CHF 0.10 each, validly issued and outstanding and fully paid and may, if the Depositary so agrees after consultation with the Company, include evidence of the right to receive Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in no event shall Shares include evidence of the right to receive Shares with respect to which the full purchase price has not been paid or Shares as to which preemptive rights have theretofore not been validly waived or exercised&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if there shall occur any change in nominal or par value, split-up, consolidation, reclassification, exchange, conversion or any other event described in Section 4.11 in respect of the Shares of the Company, the term &#8220;Shares&#8221; shall thereafter, to the maximum extent permitted by law, represent the successor securities resulting from such event.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.33 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Swiss Franc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall refer to the lawful currency of Switzerland.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.34 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Uncertificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.13.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.35 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning assigned to it in Regulation S as promulgated by the Commission under the Securities Act.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">APPOINTMENT OF DEPOSITARY&#59; FORM OF RECEIPTS&#59;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT OF SHARES&#59; EXECUTION AND</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DELIVERY, TRANSFER AND SURRENDER OF RECEIPTS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Appointment of Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company hereby appoints the Depositary as depositary for the Deposited Property and hereby authorizes and directs the Depositary to act in accordance with the terms and conditions set forth in the Deposit Agreement and the applicable ADRs. Each Holder and each Beneficial Owner, upon acceptance of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the Deposit Agreement shall be deemed for all purposes to (a) be a party to and bound by the terms of the Deposit Agreement and the applicable ADR(s), and (b) appoint the Depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the Deposit Agreement and the applicable ADR(s), to adopt any and all procedures necessary to comply with applicable law and to take such action as the Depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the Deposit Agreement and the applicable ADR(s), the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Form and Transferability of ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certificated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADSs shall be evidenced by definitive ADRs which shall be engraved, printed, lithographed or produced in such other manner as may be agreed upon by the Company and the Depositary. ADRs may be issued under the Deposit Agreement in denominations of any whole number of ADSs. The ADRs shall be substantially in the form set </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Deposit Agreement, with any appropriate insertions, modifications and omissions, in each case as otherwise contemplated in the Deposit Agreement or required by law. ADRs shall be (i) dated, (ii) signed by the manual or facsimile signature of a duly authorized signatory of the Depositary, (iii) countersigned by the manual or facsimile signature of a duly authorized signatory of the Registrar, and (iv) registered in the books maintained by the Registrar for the registration of issuances and transfers of ADSs. No ADR and no Certificated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS evidenced thereby shall be entitled to any benefits under the Deposit Agreement or be valid or enforceable for any purpose against the Depositary or the Company, unless such ADR shall have been so dated, signed, countersigned and registered.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADRs bearing the facsimile signature of a duly-authorized signatory of the Depositary or the Registrar, who at the time of signature was a duly-authorized signatory of the Depositary or the Registrar, as the case may be, shall bind the Depositary, notwithstanding the fact that such signatory has ceased to be so authorized prior to the Delivery of such ADR by the Depositary. The ADRs shall bear a CUSIP number that is different from any CUSIP number that was, is or may be assigned to any depositary receipts previously or subsequently issued pursuant to any other arrangement between the Depositary (or any other depositary) and the Company and which are not ADRs outstanding hereunder.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The ADRs may be endorsed with, or have incorporated in the text thereof, such legends or recitals not inconsistent with the provisions of the Deposit Agreement as may be (i) necessary to enable the Depositary and the Company to perform their respective obligations hereunder, (ii) required to comply with any applicable laws or regulations, or with the rules and regulations of any securities exchange or market upon which ADSs may be traded, listed or quoted, or to conform with any usage with respect thereto, (iii) necessary to indicate any special limitations or restrictions to which any particular ADRs or ADSs are subject by reason of the date of issuance of the Deposited Securities or otherwise, or (iv) required by any book-entry system in which the ADSs are held. Holders and Beneficial Owners shall be deemed, for all purposes, to have notice of, and to be bound by, the terms and conditions of the legends set forth, in the case of Holders, on the ADR registered in the name of the applicable Holders or, in the case of Beneficial Owners, on the ADR representing the ADSs owned by such Beneficial Owners.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the limitations contained herein and in the ADR, title to an ADR (and to each Certificated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS evidenced thereby) shall be transferable upon the same terms as a certificated security under the laws of the State of New York, provided that, in the case of Certificated ADSs, such ADR has been properly endorsed or is accompanied by proper instruments of transfer. Notwithstanding any notice to the contrary, the Depositary and the Company may deem and treat the Holder of an ADS (that is, the person in whose name an ADS is registered on the books of the Depositary) as the absolute owner thereof for all purposes. Neither the Depositary nor the Company shall have any obligation nor be subject to any liability under the Deposit Agreement or any ADR to any holder or any Beneficial Owner unless, in the case of a holder of ADSs, such holder is the Holder registered on the books of the Depositary or, in the case of a Beneficial Owner, such Beneficial Owner, or the Beneficial Owner&#8217;s representative, is the Holder registered on the books of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Book-Entry Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall make arrangements for the acceptance of the ADSs into DTC. All ADSs held through DTC will be registered in the name of the nominee for DTC (currently &#8220;Cede &#38; Co.&#8221;). As such, the nominee for DTC will be the only &#8220;Holder&#8221; of all ADSs held through DTC. Unless issued by the Depositary as Uncertificated ADSs, the ADSs registered in the name of Cede &#38; Co. will be evidenced by one or more ADR(s) in the form of a &#8220;Balance Certificate,&#8221; which will provide that it represents the aggregate number of ADSs from time to time indicated in the records of the Depositary as being issued hereunder and that the aggregate number of ADSs represented thereby may from time to time be increased or decreased by making adjustments on such records of the Depositary and of DTC or its nominee as hereinafter provided. Citibank, N.A. (or such other entity as is appointed by DTC or its nominee) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may hold the &#8220;Balance Certificate&#8221; as custodian for DTC. Each Beneficial Owner of ADSs held through DTC must rely upon the procedures of DTC and the DTC Participants to exercise or be entitled to any rights attributable to such ADSs. The DTC Participants shall for all purposes be deemed to have all requisite power and authority to act on behalf of the Beneficial Owners of the ADSs held in the DTC Participants&#8217; respective accounts in DTC and the Depositary shall for all purposes be authorized to rely upon any instructions and information given to it by DTC Participants. So long as ADSs are held through DTC or unless otherwise required by law, ownership of beneficial interests in the ADSs registered in the name of the nominee for DTC will be shown on, and transfers of such ownership will be effected only through, records maintained by (i) DTC or its nominee (with respect to the interests of DTC Participants), or (ii) DTC Participants or their nominees (with respect to the interests of clients of DTC Participants). Any distributions made, and any notices given, by the Depositary to DTC under the terms of the Deposit Agreement shall (unless otherwise specified by the Depositary) satisfy the Depositary&#8217;s obligations under the Deposit Agreement to make such distributions, and give such notices, in respect of the ADSs held in DTC (including, for avoidance of doubt, to the DTC Participants holding the ADSs in their DTC accounts and to the Beneficial Owners of such ADSs). </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of the Deposit Agreement and applicable law, Shares or evidence of rights to receive Shares (other than Restricted Securities) may be deposited by any person (including the Depositary in its individual capacity but subject, however, in the case of the Company or any Affiliate of the Company, to Section 5.7) at any time, whether or not the transfer books of the Company or the Share Registrar, if any, are closed, by Delivery of the Shares to the Custodian. Every deposit of Shares shall be accompanied by the following&#58; (A) (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of Shares represented by certificates issued in registered form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, appropriate instruments of transfer or endorsement, in a form satisfactory to the Custodian, (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of Shares represented by certificates in bearer form,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the requisite coupons and talons pertaining thereto, and (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of Shares delivered by book-entry transfer and recordation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, confirmation of such book-entry transfer and recordation in the books of the Share Registrar or of the applicable book-entry settlement entity, as applicable, to the Custodian or that irrevocable instructions have been given to cause such Shares to be so transferred and recorded, (B) such certifications and payments (including, without limitation, the Depositary&#8217;s fees and related charges) and evidence of such payments (including, without </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limitation, stamping or otherwise marking such Shares by way of receipt) as may be required by the Depositary or the Custodian in accordance with the provisions of the Deposit Agreement and applicable law, (C) if the Depositary so requires, a written order directing the Depositary to issue and deliver to, or upon the written order of, the person(s) stated in such order the number of ADSs representing the Shares so deposited, (D) evidence reasonably satisfactory to the Depositary (which may be an opinion of counsel) that all necessary approvals have been granted by, or there has been compliance with the rules and regulations of, any applicable governmental agency in Switzerland, and (E) if the Depositary so requires, (i) an agreement, assignment or instrument satisfactory to the Depositary or the Custodian which provides for the prompt transfer by any person in whose name the Shares are or have been recorded to the Custodian of any distribution, or right to subscribe for additional Shares or to receive other property in respect of any such deposited Shares or, in lieu thereof, such indemnity or other agreement as shall be satisfactory to the Depositary or the Custodian and (ii) if the Shares are registered in the name of the person on whose behalf they are presented for deposit, a proxy or proxies entitling the Custodian to exercise voting rights in respect of the Shares for any and all purposes until the Shares so deposited are registered in the name of the Depositary, the Custodian or any nominee.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting any other provision of the Deposit Agreement, the Depositary shall instruct the Custodian not to, and the Depositary shall not knowingly, accept for deposit (a) any Restricted Securities (except as contemplated by Section 2.14) nor (b) any fractional Shares or fractional Deposited Securities nor (c) a number of Shares or Deposited Securities which upon application of the ADS to Shares ratio would give rise to fractional ADSs. No Shares shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accepted for deposit unless accompanied by evidence, if any is required by the Depositary, that is reasonably satisfactory to the Depositary or the Custodian that all conditions to such deposit have been satisfied by the person depositing such Shares under the laws and regulations of Switzerland and any necessary approval has been granted by any applicable governmental body in Switzerland, if any. The Depositary may issue ADSs against evidence of rights to receive Shares from the Company, any agent of the Company or any custodian, registrar, transfer agent, clearing agency or other entity involved in ownership or transaction records in respect of the Shares. Such evidence of rights shall consist of written blanket or specific guarantees of ownership of Shares furnished by the Company or any such custodian, registrar, transfer agent, clearing agency or other entity involved in ownership or transaction records in respect of the Shares.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation of the foregoing, the Depositary shall not knowingly accept for deposit under the Deposit Agreement (A) any Shares or other securities required to be registered under the provisions of the Securities Act, unless (i) a registration statement is in effect as to such Shares or other securities or (ii) the deposit is made upon terms contemplated in Section 2.14, or (B) any Shares or other securities the deposit of which would violate any provisions of the Articles of Incorporation of the Company or the laws and regulations of Switzerland. For purposes of the foregoing sentence, the Depositary shall be entitled to rely upon representations and warranties made or deemed made pursuant to the Deposit Agreement and shall not be required to make any further investigation. The Depositary will comply with written instructions of the Company (received by the Depositary reasonably in advance) not to accept for deposit hereunder any Shares identified in such instructions at such times and under such circumstances as may reasonably be specified in such instructions in order to facilitate the Company's compliance with the securities laws of the United States. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Registration and Safekeeping of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall instruct the Custodian upon each Delivery of registered Shares being deposited hereunder with the Custodian (or other Deposited Securities pursuant to Article IV hereof), together with the other documents above specified, to present such Shares, together with the appropriate instrument(s) of transfer or endorsement, duly stamped, to the Share Registrar for transfer and registration of the Shares (as soon as transfer and registration can be accomplished and at the expense of the person for whom the deposit is made) in the name of the Depositary, the Custodian or a nominee of either. Deposited Securities shall be held by the Depositary, or by a Custodian for the account and to the order of the Depositary or a nominee of the Depositary, in each case, on behalf of the Holders and Beneficial Owners, at such place(s) as the Depositary or the Custodian shall determine. Notwithstanding anything else contained in the Deposit Agreement, any ADR(s), or any other instruments or agreements relating to the ADSs and the corresponding Deposited Property, the registration of the Deposited Securities in the name of the Depositary, the Custodian or any of their respective nominees, shall, to the maximum extent permitted by applicable law, vest in the Depositary, the Custodian or the applicable nominee the record ownership in the applicable Deposited Securities with the beneficial ownership rights and interests in such Deposited Securities being at all times vested with the Beneficial Owners of the ADSs representing the Deposited Securities. Notwithstanding the foregoing, the Depositary, the Custodian and the applicable nominee shall at all times be entitled to exercise the beneficial ownership rights in all Deposited Property, in each case only on behalf of the Holders and Beneficial Owners of the ADSs representing the Deposited Property, upon the terms set forth in the Deposit Agreement and, if applicable, the ADR(s) representing the ADSs. The Depositary, the Custodian and their respective nominees shall for all purposes be deemed to have all requisite power and authority to act in respect of Deposited Property on behalf of the Holders and Beneficial Owners of ADSs representing the Deposited Property, and upon making payments to, or acting upon instructions from, or information provided by, the Depositary, the Custodian or their respective nominees all persons shall be authorized to rely upon such power and authority. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Issuance of ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary has made arrangements with the Custodian for the Custodian to confirm to the Depositary upon receipt of a deposit of Shares (i) that a deposit of Shares has been made pursuant to Section 2.3, (ii) that such Deposited Securities have been recorded in the name of the Depositary, the Custodian or a nominee of either on the shareholders&#8217; register maintained by or on behalf of the Company by the Share Registrar or on the books of the applicable book-entry settlement entity, (iii) that all required documents have been received, and (iv) the person(s) to whom or upon whose order ADSs are deliverable in respect thereof and the number of ADSs to be so delivered. Such notification may be made by letter, cable, telex, SWIFT message or, at the risk and expense of the person making the deposit, by facsimile or other means of electronic transmission. Upon receiving such notice from the Custodian, the Depositary, subject to the terms and conditions of the Deposit Agreement and applicable law, shall issue the ADSs representing the Shares so deposited to or upon the order of the person(s) named in the notice delivered to the Depositary and, if applicable,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall execute and deliver at its Principal Office Receipt(s) registered in the name(s) requested by such person(s) and evidencing the aggregate number of ADSs to which such person(s) is&#47;are entitled, but, in each case, only upon payment to the Depositary of the charges of the Depositary for accepting a deposit of Shares and issuing ADSs (as set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto) and all taxes and governmental charges and fees payable in connection with such deposit and the transfer of the Shares and the issuance of the ADS(s). The Depositary shall only issue ADSs in whole numbers and deliver, if applicable, ADR(s) evidencing whole numbers of ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer, Combination and Split-up of ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall register the transfer of ADRs (and of the ADSs represented thereby) on the books maintained for such purpose and the Depositary shall (x) cancel such ADRs and execute new ADRs evidencing the same aggregate number of ADSs as those evidenced by the ADRs canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs and (z) Deliver such new ADRs to or upon the order of the person entitled thereto, if each of the following conditions has been satisfied&#58; (i) the ADRs have been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a transfer thereof, (ii) the surrendered ADRs have been properly endorsed or are accompanied by proper instruments of transfer (including signature guarantees in accordance with standard securities industry practice), (iii) the surrendered ADRs have been duly stamped (if required by the laws of the State of New York or of the United States), and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the terms and conditions of the applicable ADRs, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Combination &#38; Split-Up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall register the split-up or combination of ADRs (and of the ADSs represented thereby) on the books maintained for such purpose and the Depositary shall (x) cancel such ADRs and execute new ADRs for the number of ADSs requested, but in the aggregate not exceeding the number of ADSs evidenced by the ADRs canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs and (z) Deliver such new ADRs to or upon the order of the Holder thereof, if each of the following conditions has been satisfied&#58; (i) the ADRs have been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a split-up or combination thereof, and (ii) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of the applicable ADRs, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Surrender of ADSs and Withdrawal of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Holder of ADSs shall be entitled to Delivery (at the Custodian&#8217;s designated office) of the Deposited Securities at the time represented by the ADSs upon satisfaction of each of the following conditions&#58; (i) the Holder (or a duly-authorized attorney of the Holder) has duly Delivered ADSs to the Depositary at its Principal Office (and if applicable, the ADRs evidencing such ADSs) for the purpose of withdrawal of the Deposited Securities represented thereby, (ii) if applicable and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so required by the Depositary, the ADRs Delivered to the Depositary for such purpose have been properly endorsed in blank or are accompanied by proper instruments of transfer in blank (including signature guarantees in accordance with standard securities industry practice), (iii) if so required by the Depositary, the Holder of the ADSs has executed and delivered to the Depositary a written order directing the Depositary to cause the Deposited Securities being withdrawn to be Delivered to or upon the written order of the person(s) designated in such order, and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) have been paid,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of the ADRs evidencing the surrendered ADSs, of the Deposit Agreement, of the Company&#8217;s Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation and of any applicable laws and the rules of the applicable book-entry settlement entity, and to any provisions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon satisfaction of each of the conditions specified above, the Depositary (i) shall cancel the ADSs Delivered to it (and, if applicable, the ADR(s) evidencing the ADSs so Delivered), (ii) shall direct the Registrar to record the cancellation of the ADSs so Delivered on the books maintained for such purpose, and (iii) shall direct the Custodian to Deliver, or cause the Delivery of, in each case, without unreasonable delay, the Deposited Securities represented by the ADSs so canceled together with any certificate or other document of title for the Deposited Securities, or evidence of the electronic transfer thereof (if available), as the case may be, to or upon the written order of the person(s) designated in the order delivered to the Depositary for such purpose, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject however, in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the terms and conditions of the Deposit Agreement, of the ADRs evidencing the ADSs so canceled, of the Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation of the Company, of any applicable laws and of the rules of the applicable book-entry settlement entity, and to the terms and conditions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not accept for surrender ADSs representing less than one (1) Share. In the case of Delivery to it of ADSs representing a number other than a whole number of Shares, the Depositary shall cause ownership of the appropriate whole number of Shares to be Delivered in accordance with the terms hereof, and shall, at the discretion of the Depositary, either (i) return to the person surrendering such ADSs the number of ADSs representing any remaining fractional Share, or (ii) sell or cause to be sold the fractional Share represented by the ADSs so surrendered and remit the proceeds of such sale (net of (a) applicable fees and charges of, and expenses incurred by, the Depositary and (b) taxes withheld) to the person surrendering the ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in any ADR or the Deposit Agreement, the Depositary may make delivery at the Principal Office of the Depositary of Deposited Property consisting of (i) any cash dividends or cash distributions, or (ii) any proceeds from the sale of any non-cash distributions, which are at the time held by the Depositary in respect of the Deposited Securities represented by the ADSs surrendered for cancellation and withdrawal. At the request, risk and expense of any Holder so surrendering ADSs, and for the account of such Holder, the Depositary shall direct the Custodian to forward (to the extent permitted by law) any Deposited Property (other than Deposited Securities) held by the Custodian in respect of such ADSs to the Depositary for delivery at the Principal Office of the Depositary. Such direction </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be given by letter or, at the request, risk and expense of such Holder, by cable, telex or facsimile transmission.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Limitations on Execution and Delivery, Transfer, etc. of ADSs&#59; Suspension of Delivery, Transfer, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As a condition precedent to the execution and Delivery, the registration of issuance, transfer, split-up, combination or surrender, of any ADS, the delivery of any distribution thereon, or the withdrawal of any Deposited Property, the Depositary or the Custodian may require (i) payment from the depositor of Shares or presenter of ADSs or of an ADR of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees and charges of the Depositary as provided in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (ii) the production of proof satisfactory to it as to the identity and genuineness of any signature or any other matter contemplated by Section 3.1, and (iii) compliance with (A) any laws or governmental regulations relating to the execution and Delivery of ADRs or ADSs or to the withdrawal of Deposited Securities and (B) such reasonable regulations as the Depositary and the Company may establish consistent with the provisions of the representative ADR, if applicable, the Deposit Agreement and applicable law.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The issuance of ADSs against deposits of Shares generally or against deposits of particular Shares may be suspended, or the deposit of particular Shares may be refused, or the registration of transfer of ADSs in particular instances may be refused, or the registration of transfers of ADSs generally may be suspended, during any period when the transfer books of the Company, the Depositary, a Registrar or the Share Registrar are closed or if any such action is deemed necessary or advisable by the Depositary or the Company, in good faith, at any time or from time to time because of any requirement of law or regulation, any government or governmental body or commission or any securities exchange on which the ADSs or Shares are listed, or under any provision of the Deposit Agreement or the representative ADR(s), if applicable, or under any provision of, or governing, the Deposited Securities, or because of a meeting of shareholders of the Company or for any other reason, subject, in all cases, to Section 7.8(a).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Regulatory Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of the Deposit Agreement or any ADR(s) to the contrary, Holders are entitled to surrender outstanding ADSs to withdraw the Deposited Securities associated herewith at any time subject only to (i) temporary delays caused by closing the transfer books of the Depositary or the Company or the deposit of Shares in connection with voting at a shareholders&#8217; meeting or the payment of dividends, (ii) the payment of fees, taxes and similar charges, (iii) compliance with any U.S. or foreign laws or governmental regulations relating to the ADSs or to the withdrawal of the Deposited Securities, and (iv) other circumstances specifically contemplated by Instruction I.A.(l) of the General Instructions to Form F-6 (as such General Instructions may be amended from time to time).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Lost ADRs, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In case any ADR shall be mutilated, destroyed, lost, or stolen, the Depositary shall execute and deliver a new ADR of like tenor at the expense of the Holder (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of a mutilated ADR, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in exchange of and substitution for such mutilated ADR upon cancellation thereof, or (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of a destroyed, lost or stolen ADR,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in lieu of and in substitution for such destroyed, lost, or stolen ADR, after the Holder thereof (i) has submitted to the Depositary a written request for such exchange and substitution before the Depositary has notice that the ADR has been acquired by a bona fide purchaser, (ii) has provided such security or indemnity (including an indemnity bond) as may be required by the Depositary to save it and any of its agents harmless, and (iii) has satisfied any other reasonable requirements imposed by the Depositary, including, without limitation, evidence satisfactory to the Depositary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such destruction, loss or theft of such ADR, the authenticity thereof and the Holder&#8217;s ownership thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cancellation and Destruction of Surrendered ADRs&#59; Maintenance of Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> All ADRs surrendered to the Depositary shall be canceled by the Depositary. Canceled ADRs shall not be entitled to any benefits under the Deposit Agreement or be valid or enforceable against the Depositary for any purpose. The Depositary is authorized to destroy ADRs so canceled, provided the Depositary maintains a record of all destroyed ADRs. Any ADSs held in book-entry form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, through accounts at DTC) shall be deemed canceled when the Depositary causes the number of ADSs evidenced by the Balance Certificate to be reduced by the number of ADSs surrendered (without the need to physically destroy the Balance Certificate).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Escheatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event any unclaimed property relating to the ADSs, for any reason, is in the possession of Depositary and has not been claimed by the Holder thereof or cannot be delivered to the Holder thereof through usual channels, the Depositary shall, upon expiration of any applicable statutory period relating to abandoned property laws, escheat such unclaimed property to the relevant authorities in accordance with the laws of each of the relevant States of the United States. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event any Shares are deposited which (i) entitle the holders thereof to receive a per-share distribution or other entitlement in an amount different from the Shares then on deposit or (ii) are not fully fungible (including, without limitation, as to settlement or trading) with the Shares then on deposit (the Shares then on deposit collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Full Entitlement Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the Shares with different entitlement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partial Entitlement Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Depositary shall (i) cause the Custodian to hold Partial Entitlement Shares separate and distinct from Full Entitlement Shares, and (ii) subject to the terms of the Deposit Agreement, issue ADSs representing Partial Entitlement Shares which are separate and distinct from the ADSs representing Full Entitlement Shares, by means of separate CUSIP numbering and legending (if necessary) and, if applicable, by issuing ADRs evidencing such ADSs with applicable notations thereon (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partial Entitlement ADSs&#47;ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Full Entitlement ADSs&#47;ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, respectively). If and when Partial Entitlement Shares become Full Entitlement Shares, the Depositary shall (a) give notice thereof to Holders of Partial Entitlement ADSs and give Holders of Partial Entitlement ADRs the opportunity to exchange such Partial Entitlement ADRs for Full Entitlement ADRs, (b) cause the Custodian to transfer the Partial Entitlement Shares into the account of the Full Entitlement Shares, and (c) take such actions as are necessary to remove the distinctions between (i) the Partial Entitlement ADRs and ADSs, on the one hand, and (ii) the Full Entitlement ADRs and ADSs on the other. Holders and Beneficial Owners of Partial Entitlement ADSs shall only be entitled to the entitlements of Partial Entitlement Shares. Holders and Beneficial Owners of Full Entitlement ADSs shall be entitled only to the entitlements of Full Entitlement Shares. All provisions and conditions of the Deposit Agreement shall apply to Partial Entitlement ADRs and ADSs to the same extent as Full Entitlement ADRs and ADSs, except as contemplated by this Section 2.12. The Depositary is authorized to take any and all other actions as may be necessary (including, without limitation, making the necessary notations on ADRs) to give effect to the terms of this Section 2.12. The Company agrees to give timely written notice to the Depositary if any Shares issued or to be issued are Partial Entitlement Shares and shall assist the Depositary with the establishment of procedures enabling the identification of Partial Entitlement Shares upon Delivery to the Custodian. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Certificated&#47;Uncertificated ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provision of the Deposit Agreement, the Depositary may, at any time and from time to time, issue ADSs that are not evidenced by ADRs (such ADSs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Uncertificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the ADS(s) evidenced by ADR(s), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). When issuing and maintaining Uncertificated ADS(s) under the Deposit Agreement, the Depositary shall at all times be subject to (i) the standards </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable to registrars and transfer agents maintaining direct registration systems for equity securities in New York and issuing uncertificated securities under New York law, and (ii) the terms of New York law applicable to uncertificated equity securities. Uncertificated ADSs shall not be represented by any instruments but shall be evidenced by registration in the books of the Depositary maintained for such purpose. Holders of Uncertificated ADSs, that are not subject to any registered pledges, liens, restrictions or adverse claims of which the Depositary has notice at such time, shall at all times have the right to exchange the Uncertificated ADS(s) for Certificated ADS(s) of the same type and class, subject in each case to (x) applicable laws and any rules and regulations the Depositary may have established in respect of the Uncertificated ADSs, and (y) the continued availability of Certificated ADSs in the U.S. Holders of Certificated ADSs shall, if the Depositary maintains a direct registration system for the ADSs, have the right to exchange the Certificated ADSs for Uncertificated ADSs upon (i) the due surrender of the Certificated ADS(s) to the Depositary for such purpose and (ii) the presentation of a written request to that effect to the Depositary, subject in each case to (a) all liens and restrictions noted on the ADR evidencing the Certificated ADS(s) and all adverse claims of which the Depositary then has notice, (b) the terms of the Deposit Agreement and the rules and regulations that the Depositary may establish for such purposes hereunder, (c) applicable law, and (d) payment of the Depositary fees and expenses applicable to such exchange of Certificated ADS(s) for Uncertificated ADS(s). Uncertificated ADSs shall in all material respects be identical to Certificated ADS(s) of the same type and class, except that (i) no ADR(s) shall be, or shall need to be, issued to evidence Uncertificated ADS(s), (ii) Uncertificated ADS(s) shall, subject to the terms of the Deposit Agreement, be transferableupon the same terms and conditions as uncertificated securities under New York law, (iii) the ownership of Uncertificated ADS(s) shall be recorded on the books of the Depositary maintained for such purpose and evidence of such ownership shall be reflected in periodic statements provided by the Depositary to the Holder(s) in accordance with applicable New York law, (iv) the Depositary may from time to time, upon notice to the Holders of Uncertificated ADSs affected thereby, establish rules and regulations, and amend or supplement existing rules and regulations, as may be deemed reasonably necessary to maintain Uncertificated ADS(s) on behalf of Holders, provided that (a) such rules and regulations do not conflict with the terms of the Deposit Agreement and applicable law, and (b) the terms of such rules and regulations are readily available to Holders upon request, (v) the Uncertificated ADS(s) shall not be entitled to any benefits under the Deposit Agreement or be valid or enforceable for any purpose against the Depositary or the Company unless such Uncertificated ADS(s) is&#47;are registered on the books of the Depositary maintained for such purpose, (vi) the Depositary may, in connection with any deposit of Shares resulting in the issuance of Uncertificated ADSs and with any transfer, pledge, release and cancellation of Uncertificated ADSs, require the prior receipt of such documentation as the Depositary may deem reasonably appropriate, and (vii) upon termination of the Deposit Agreement, the Depositary shall not require Holders of Uncertificated ADSs to affirmatively instruct the Depositary before remitting proceeds from the sale of the Deposited Property represented by such Holders' Uncertificated ADSs under the terms of Section 6.2. When issuing ADSs under the terms of the Deposit Agreement, including, without limitation, issuances pursuant to Sections 2.5, 4.2, 4.3, 4.4, 4.5 and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.11, the Depositary may in its discretion determine to issue Uncertificated ADSs rather than Certificated ADSs, unless otherwise specifically instructed by the applicable Holder to issue Certificated ADSs. All provisions and conditions of the Deposit Agreement shall apply to Uncertificated ADSs to the same extent as to Certificated ADSs, except as contemplated by this Section 2.13. The Depositary is authorized and directed to take any and all actions and establish any and all procedures deemed reasonably necessary to give effect to the terms of this Section 2.13. Any references in the Deposit Agreement or any ADR(s) to the terms &#8220;American Depositary Share(s)&#8221; or &#8220;ADS(s)&#8221; shall, unless the context otherwise requires, include Certificated ADS(s) and Uncertificated ADS(s). Except as set forth in this Section 2.13 and except as required by applicable law, the Uncertificated ADSs shall be treated as ADSs issued and outstanding under the terms of the Deposit Agreement. In the event that, in determining the rights and obligations of parties hereto with respect to any Uncertificated ADSs, any conflict arises between (a) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms of the Deposit Agreement (other than this Section 2.13) and (b) the terms of this Section 2.13, the terms and conditions set forth in this Section 2.13 shall be controlling and shall govern the rights and obligations of the parties to the Deposit Agreement pertaining to the Uncertificated ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall, at the request and expense of the Company, establish procedures enabling the deposit hereunder of Shares that are Restricted Securities in order to enable the holder of such Shares to hold its ownership interests in such Restricted Securities in the form of ADSs issued under the terms hereof (such Shares, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Upon receipt of a written request from the Company to accept Restricted Shares for deposit hereunder, the Depositary agrees to establish procedures permitting the deposit of such Restricted Shares and the issuance of ADSs representing the right to receive, subject to the terms of the Deposit Agreement and the applicable ADR (if issued as a Certificated ADS), such deposited Restricted Shares (such ADSs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and the ADRs evidencing such Restricted ADSs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything contained in this Section 2.14, the Depositary and the Company may, to the extent not prohibited by law, agree to issue the Restricted ADSs in uncertificated form (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Uncertificated Restricted ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon such terms and conditions as the Company and the Depositary may deem necessary and appropriate. The Company shall assist the Depositary in the establishment of such procedures and agrees that it shall take all steps necessary and satisfactory to the Depositary to ensure that the establishment of such procedures does not violate the provisions of the Securities Act or any other applicable laws. The depositors of such Restricted Shares and the Holders of the Restricted ADSs may be required prior to the deposit of such Restricted Shares, the transfer of the Restricted ADRs and Restricted ADSs or the withdrawal of the Restricted Shares represented by Restricted ADSs to provide such written certifications or agreements as the Depositary or the Company may require. The Company shall provide to the Depositary in writing the legend(s) to be affixed to the Restricted ADRs (if the Restricted ADSs are to be issued as Certificated ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or to be included in the statements issued from time to time to Holders of Uncertificated ADSs (if issued as Uncertificated Restricted ADSs), which legends shall (i) be in a form reasonably satisfactory to the Depositary and (ii) contain the specific circumstances under which the Restricted ADSs, and, if applicable, the Restricted ADRs evidencing the Restricted ADSs, may be transferred or the Restricted Shares withdrawn. The Restricted ADSs issued upon the deposit of Restricted Shares shall be separately identified on the books of the Depositary and the Restricted Shares so deposited shall, to the extent required by law, be held separate and distinct from the other Deposited Securities held hereunder. The Restricted ADSs shall not be eligible for inclusion in any book-entry settlement system, including, without limitation, DTC (unless (x) otherwise agreed by the Company and the Depositary, (y) the inclusion of Restricted ADSs is acceptable to the applicable clearing system, and (z) the terms of such inclusion are generally accepted by the Commission for Restricted Securities of that type), and shall not in any way be fungible with the ADSs issued under the terms hereof that are not Restricted ADSs. The Restricted ADSs, and, if applicable, the Restricted ADRs evidencing the Restricted ADSs, shall be transferable only by the Holder thereof upon delivery to the Depositary of (i) all documentation otherwise contemplated by the Deposit Agreement and (ii) an opinion of counsel reasonably satisfactory to the Depositary setting forth, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the conditions upon which the Restricted ADSs presented, and, if applicable, the Restricted ADRs evidencing the Restricted ADSs, are transferable by the Holder thereof under applicable securities laws and the transfer restrictions contained in the legend applicable to the Restricted ADSs presented for transfer. Except as set forth in this Section 2.14 and except as required by applicable law, the Restricted ADSs and the Restricted ADRs evidencing Restricted ADSs shall be treated as ADSs and ADRs issued and outstanding under the terms of the Deposit Agreement. In the event that, in determining the rights and obligations of parties hereto with respect to any Restricted ADSs, any conflict arises between (a) the terms of the Deposit Agreement (other than this Section 2.14) and (b) the terms of (i) this Section 2.14 or (ii) the applicable Restricted ADR, the terms and conditions set forth in this Section 2.14 and of the Restricted ADR shall be controlling and shall govern the rights and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations of the parties to the Deposit Agreement pertaining to the deposited Restricted Shares, the Restricted ADSs and Restricted ADRs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Restricted ADRs, the Restricted ADSs and the Restricted Shares cease to be Restricted Securities, the Depositary, upon receipt of (x) an opinion of counsel reasonably satisfactory to the Depositary setting forth, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Restricted ADRs, the Restricted ADSs and the Restricted Shares are not as of such time Restricted Securities, and (y) instructions from the Company to remove the restrictions applicable to the Restricted ADRs, the Restricted ADSs and the Restricted Shares, shall (i) eliminate the distinctions and separations that may have been established between the applicable Restricted Shares held on deposit under this Section 2.14 and the other Shares held on deposit under the terms of the Deposit Agreement that are not Restricted Shares, (ii) treat the newly unrestricted ADRs and ADSs on the same terms as, and fully fungible with, the other ADRs and ADSs issued and outstanding under the terms of the Deposit Agreement that are not Restricted ADRs or Restricted ADSs, and (iii) take all actions necessary to remove any distinctions, limitations and restrictions previously existing under this Section 2.14 between the applicable Restricted ADRs and Restricted ADSs, respectively, on the one hand, and the other ADRs and ADSs that are not Restricted ADRs or Restricted ADSs, respectively, on the other hand, including, without limitation, by making the newly-unrestricted ADSs eligible for inclusion in the applicable book-entry settlement systems. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN OBLIGATIONS OF HOLDERS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND BENEFICIAL OWNERS OF ADSs</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Proofs, Certificates and Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any person presenting Shares for deposit, any Holder and any Beneficial Owner may be required, and every Holder and Beneficial Owner agrees, from time to time to provide to the Depositary and the Custodian such proof of citizenship or residence, taxpayer status, payment of all applicable taxes or other governmental charges, exchange control approval, legal or beneficial ownership of ADSs and Deposited Property, compliance with applicable laws, the terms of the Deposit Agreement or the ADR(s) evidencing the ADSs and the provisions of, or governing, the Deposited Property, to execute such certifications and to make such representations and warranties, and to provide such other information and documentation (or, in the case of Shares in registered form presented for deposit, such information relating to the registration on the books of the Company or of the Share Registrar) as the Depositary or the Custodian may deem necessary or proper or as the Company may reasonably require by written request to the Depositary consistent with its obligations under the Deposit Agreement and the applicable ADR(s). The Depositary and the Registrar, as applicable, may withhold the execution or delivery or registration of transfer of any ADR or ADS or the distribution or sale of any dividend or distribution of rights or of the proceeds thereof or, to the extent not limited by the terms of Section 7.8(a), the delivery of any Deposited Property until such proof or other information is filed or such certifications are executed, or such representations and warranties are made, or such other documentation or information provided, in each case to the Depositary&#8217;s, the Registrar&#8217;s and the Company&#8217;s satisfaction. The Depositary shall provide the Company, in a timely manner, with copies or originals if necessary and appropriate of (i) any such proofs of citizenship or residence, taxpayer status, or exchange control approval or copies of written representations and warranties which it receives from Holders and Beneficial Owners, and (ii) any other information or documents which the Company may reasonably request and which the Depositary shall request and receive from any Holder or Beneficial Owner or any person presenting Shares for deposit or ADSs for cancellation, transfer or withdrawal. Nothing herein shall obligate the Depositary to (i) obtain any information for the Company if not provided by the Holders or Beneficial Owners, or (ii) verify or vouch for the accuracy of the information so provided by the Holders or Beneficial Owners.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Liability for Taxes and Other Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any tax or other governmental charge payable by the Custodian or by the Depositary with respect to any Deposited Property, ADSs or ADRs shall be payable by the Holders and Beneficial Owners to the Depositary. The Company, the Custodian and&#47;or the Depositary may withhold or deduct from any distributions made in respect of Deposited Property held on behalf of such Holder and&#47;or Beneficial Owner, and may sell for the account of a Holder and&#47;or Beneficial Owner any or all of such Deposited Property and apply such distributions and sale proceeds in payment of, any taxes (including applicable interest and penalties) or charges that are or may be payable by Holders or Beneficial Owners in respect of the ADSs, Deposited Property and ADRs, the Holder and the Beneficial Owner remaining liable for any deficiency. The Custodian may refuse the deposit of Shares and the Depositary may refuse to issue ADSs, to deliver ADRs, register the transfer of ADSs, register the split-up or combination of ADRs and (subject to Section 7.8(a)) the withdrawal of Deposited Property until payment in full of such tax, charge, penalty or interest is received. Every Holder and Beneficial Owner agrees to indemnify the Depositary, the Company, the Custodian, and any of their agents, officers, employees and Affiliates for, and to hold each of them harmless from, any claims with respect to taxes (including applicable interest and penalties thereon) arising from (i) any ADSs held by such Holder and&#47;or owned by such Beneficial Owner, (ii) the Deposited Property represented by the ADSs, and (iii) any transaction entered into by such Holder and&#47;or Beneficial Owner in respect of the ADSs and&#47;or the Deposited Property represented thereby . Notwithstanding anything to the contrary contained in the Deposit Agreement or any ADR, the obligations of Holders and Beneficial Owners under this Section 3.2 shall survive any transfer of ADSs, any cancellation of ADSs and withdrawal of Deposited Securities, and the termination of the Deposit Agreement. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Representations and Warranties on Deposit of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each person depositing Shares under the Deposit Agreement shall be deemed thereby to represent and warrant that (i) such Shares and the certificates therefor are duly authorized, validly issued, fully paid, non-assessable and legally obtained by such person, (ii) all preemptive (and similar) rights, if any, with respect to such Shares have been validly waived or exercised, (iii) the person making such deposit is duly authorized so to do, (iv) the Shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, (v) the Shares presented for deposit are not, and the ADSs issuable upon such deposit will not be, Restricted Securities (except as contemplated in Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (vi) the Shares presented for deposit have not been stripped of any rights or entitlements, and (vii) the deposit of the Shares does not violate any applicable provisions of the laws of Switzerland. Such representations and warranties shall survive the deposit and withdrawal of Shares, the issuance and cancellation of ADSs in respect thereof and the transfer of such ADSs. If any such representations or warranties are false in any way, the Company and the Depositary shall be authorized, at the cost and expense of the person depositing Shares, to take any and all actions necessary to correct the consequences thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Information Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision included or incorporated by reference in the Deposit Agreement or any ADR(s) to any other effect, each Holder and Beneficial Owner agrees to comply with requests from the Company pursuant to applicable law, the rules and requirements of any stock exchange on which the Shares or ADSs are, or will be, registered, traded or listed or the Articles of Incorporation of the Company, which are made to provide information, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as to the capacity in which such Holder or Beneficial Owner owns ADSs (and Shares as the case may be) and regarding the identity of any other person(s) interested in such ADSs and the nature of such interest and various other matters, whether or not they are Holders and&#47;or Beneficial Owners at the time of such request. The Depositary agrees to use its reasonable efforts to forward, upon the request of the Company and at the Company&#8217;s expense, any such request from the Company to the Holders and to forward to the Company any such responses to such requests received by the Depositary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision included or incorporated by reference in the Deposit Agreement or any ADR(s) to any other effect, the Company may restrict transfers of the Shares where such transfer might result in ownership of Shares exceeding limits imposed by applicable law or the Articles of Incorporation of the Company. The Company may also restrict, in such manner as it deems appropriate, transfers of the ADSs where such transfer may result in the total number of Shares represented by the ADSs owned by a single Holder or Beneficial Owner to exceed any such limits. The Company may, in its sole discretion but subject to applicable law, instruct the Depositary to take action with respect to the ownership interest of any Holder or Beneficial Owner in excess of the limits set forth in the preceding sentence, including, but not limited to, the imposition of restrictions on the transfer of ADSs, the removal or limitation of voting rights or mandatory sale or disposition on behalf of a Holder or Beneficial Owner of the Shares represented by the ADSs held by such Holder or Beneficial Owner in excess of such limitations, if and to the extent such disposition is permitted by applicable law and the Articles of Incorporation of the Company. Nothing herein shall be interpreted as obligating the Depositary or the Company to ensure compliance with the ownership restrictions described in this Section 3.5.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reporting Obligations and Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Applicable laws and regulations may require holders and beneficial owners of Shares, including the Holders and Beneficial Owners of ADSs, to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. Holders and Beneficial Owners of ADSs are solely responsible for determining and complying with such reporting requirements and obtaining such approvals. Each Holder and each Beneficial Owner hereby agrees to make such determination, file such reports, and obtain such approvals to the extent and in the form required by applicable laws and regulations as in effect from time to time. Neither the Depositary, the Custodian, the Company or any of their respective agents or affiliates shall be required to take any actions whatsoever on behalf of Holders or Beneficial Owners to determine or satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IV</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE DEPOSITED SECURITIES</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Company intends to make a distribution of a cash dividend or other cash distribution in respect of any Deposited Securities, the Company shall give notice thereof to the Depositary at least twenty (20) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable for determining the holders of Deposited Securities entitled to receive such distribution. Upon the timely receipt of such notice, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9. Upon confirmation of the receipt of (x) any cash dividend or other cash distribution in respect of any Deposited Property (whether from the Company or otherwise), or (y) proceeds from the sale of any Deposited Property held in respect of the ADSs under the terms hereof, the Depositary will (i) if any amounts are received in a Foreign Currency, promptly convert or cause to be converted such cash dividend, distribution or proceeds into Dollars (subject to the terms and conditions of Section 4.8), (ii) if applicable and unless previously established, establish the ADS Record Date upon the terms described in Section 4.9, and (iii) distribute promptly the amount thus received (net of (a) the applicable fees and charges set forth in the Fee Schedule attached hereto as Exhibit B, and (b) applicable taxes withheld) to the Holders entitled thereto as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date. The Depositary shall distribute only such amount, however, as can be distributed without attributing to any Holder a fraction of one cent, and any balance not so distributed shall be held by the Depositary (without liability for interest thereon) and shall be added to and become part of the next sum received by the Depositary for distribution to Holders of ADSs outstanding at the time of the next distribution. If the Company, the Custodian or the Depositary is required to withhold </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and does withhold from any cash dividend or other cash distribution in respect of any Deposited Securities, or from any cash proceeds from the sales of Deposited Property, an amount on account of taxes, duties or other governmental charges, the amount distributed to Holders on the ADSs shall be reduced accordingly. Such withheld amounts shall be forwarded by the Company, the Custodian or the Depositary to the relevant governmental authority. Evidence of payment thereof by the Company shall be forwarded by the Company to the Depositary upon request. The Depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable Holders and Beneficial Owners of ADSs until the distribution can be effected or the funds that the Depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in this Section 4.1, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.1, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.1 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distribution in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Company intends to make a distribution that consists of a dividend in, or free distribution of, Shares, the Company shall give notice thereof to the Depositary at least twenty (20) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution, specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable to holders of Deposited Securities entitled to receive such distribution. Upon the timely receipt of such notice from the Company, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9. Upon receipt of confirmation from the Custodian of the receipt of the Shares so distributed by the Company, the Depositary shall either (i) subject to Section 5.9, distribute to the Holders as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date, additional ADSs, which represent in the aggregate the number of Shares received as such dividend, or free distribution, subject to the other terms of the Deposit Agreement (including, without limitation, (a) the applicable fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes), or (ii) if additional ADSs are not so distributed, take all actions necessary so that each ADS issued and outstanding after the ADS Record Date shall, to the extent permissible by law, thenceforth also represent rights and interests in the additional integral number of Shares distributed upon the Deposited Securities represented thereby (net of (a) the applicable fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes). In lieu of delivering fractional ADSs, the Depositary shall sell the number of Shares or ADSs, as the case may be, represented by the aggregate of such fractions and distribute the net proceeds upon the terms described in Section 4.1. In the event that the Depositary determines that any distribution in property (including Shares) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, or, if the Company in the fulfillment of its obligation under Section 5.7, has furnished an opinion of U.S. counsel determining that Shares must be registered under the Securities Act or other laws in order to be distributed to Holders (and no such registration statement has been declared effective), the Depositary may dispose of all or a portion of such property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable, and the Depositary shall distribute the net proceeds of any such sale (after deduction of (a) applicable taxes and (b) fees and charges of, and expenses incurred by, the Depositary) to Holders entitled thereto upon the terms described in Section 4.1. The Depositary shall hold and&#47;or distribute any unsold balance of such property in accordance with the provisions of the Deposit Agreement. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in this Section 4.2, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.2, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.2 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Elective Distributions in Cash or Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Company intends to make a distribution payable at the election of the holders of Deposited Securities in cash or in additional Shares, the Company shall give notice thereof to the Depositary at least sixty (60) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable to holders of Deposited Securities entitled to receive such elective distribution and whether or not it wishes such elective distribution to be made available to Holders of ADSs. Upon the timely receipt of a notice indicating that the Company wishes such elective distribution to be made available to Holders of ADSs, the Depositary shall consult with the Company to determine, and the Company shall assist the Depositary in its determination, whether it is lawful and reasonably practicable to make such elective distribution available to the Holders of ADSs. The Depositary shall make such elective distribution available to Holders only if (i) the Company shall have timely requested that the elective distribution be made available to Holders, (ii) the Depositary shall have determined that such distribution is reasonably practicable and (iii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7. If the above conditions are not satisfied or if the Company requests such elective distribution not to be made available to Holders of ADSs, the Depositary shall establish the ADS Record Date on the terms described in Section 4.9 and, to the extent permitted by law, distribute to the Holders, on the basis of the same determination as is made in Switzerland in respect of the Shares for which no election is made, either (X) cash upon the terms described in Section 4.1 or (Y) additional ADSs representing such additional Shares upon the terms described in Section 4.2. If the above conditions are satisfied, the Depositary shall establish an ADS Record Date on the terms described in Section 4.9 and establish procedures to enable Holders to elect the receipt of the proposed distribution in cash or in additional ADSs. The Company shall assist the Depositary in establishing such procedures to the extent necessary. If a Holder elects to receive the proposed distribution (X) in cash, the distribution shall be made upon the terms described in Section 4.1, or (Y) in ADSs, the distribution shall be made upon the terms described in Section 4.2. Nothing herein shall obligate the Depositary to make available to Holders a method to receive the elective distribution in Shares (rather than ADSs). There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of Shares. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in this Section 4.3, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.3, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.3 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distribution of Rights to Purchase Additional ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distribution to ADS Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whenever the Company intends to distribute to the holders of the Deposited Securities rights to subscribe for additional Shares, the Company shall give notice thereof to the Depositary at least sixty (60) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable to holders of Deposited Securities entitled to receive such distribution and whether or not it wishes such rights to be made available to Holders of ADSs. Upon the timely receipt of a notice indicating that the Company wishes such rights to be made available to Holders of ADSs, the Depositary shall consult with the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to determine, and the Company shall assist the Depositary in its determination, whether it is lawful and reasonably practicable to make such rights available to the Holders. The Depositary shall make such rights available to Holders only if (i) the Company shall have timely requested that such rights be made available to Holders, (ii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7, and (iii) the Depositary shall have determined that such distribution of rights is reasonably practicable. In the event any of the conditions set forth above are not satisfied or if the Company requests that the rights not be made available to Holders of ADSs, the Depositary shall proceed with the sale of the rights as contemplated in Section 4.4(b) below. In the event all conditions set forth above are satisfied, the Depositary shall establish the ADS Record Date (upon the terms described in Section 4.9) and establish procedures to (x) distribute rights to purchase additional ADSs (by means of warrants or otherwise), (y) enable the Holders to exercise such rights (upon payment of the subscription price and of the applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes), and (z) deliver ADSs upon the valid exercise of such rights. The Company shall assist the Depositary to the extent necessary in establishing such procedures. Nothing herein shall obligate the Depositary to make available to the Holders a method to exercise rights to subscribe for Shares (rather than ADSs).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sale of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (i) the Company does not timely request the Depositary to make the rights available to Holders or requests that the rights not be made available to Holders, (ii) the Depositary fails to receive satisfactory documentation within the terms of Section 5.7, or determines it is not reasonably practicable to make the rights available to Holders, or (iii) any rights made available are not exercised and appear to be about to lapse, the Depositary shall determine whether it is lawful and reasonably practicable to sell such rights, in a riskless principal capacity, at such place and upon such terms (including public or private sale) as it may deem practicable. The Company shall assist the Depositary to the extent necessary to determine such legality and practicability. The Depositary shall, upon such sale, convert and distribute proceeds of such sale (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) upon the terms set forth in Section 4.1.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Lapse of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Depositary is unable to make any rights available to Holders upon the terms described in Section 4.4(a) or to arrange for the sale of the rights upon the terms described in Section 4.4(b), the Depositary shall allow such rights to lapse.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for (i) any failure to accurately determine whether it may be lawful or practicable to make such rights available to Holders in general or any Holders in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale, or exercise, or (iii) the content of any materials forwarded to the Holders on behalf of the Company in connection with the rights distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Section 4.4, if registration (under the Securities Act or any other applicable law) of the rights or the securities to which any rights relate may be required in order for the Company to offer such rights or such securities to Holders and to sell the securities represented by such rights, the Depositary will not distribute such rights to the Holders (i) unless and until a registration statement under the Securities Act (or other applicable law) covering such offering is in effect or (ii) unless the Company furnishes the Depositary opinion(s) of counsel for the Company in the United States and counsel to the Company in any other applicable country in which rights would be distributed, in each case reasonably satisfactory to the Depositary, to the effect that the offering and sale of such securities to Holders and Beneficial Owners are exempt from, or do not require registration under, the provisions of the Securities Act or any other applicable laws. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Company, the Depositary or the Custodian shall be required to withhold and does withhold from any distribution of Deposited Property (including rights) an amount on account of taxes or other governmental charges, the amount distributed to the Holders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of ADSs shall be reduced accordingly. In the event that the Depositary determines that any distribution of Deposited Property (including Shares and rights to subscribe therefor) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, the Depositary may dispose of all or a portion of such Deposited Property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable to pay any such taxes or charges.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive or exercise rights on the same terms and conditions as the holders of Shares or be able to exercise such rights. Nothing herein shall obligate the Company to file any registration statement in respect of any rights or Shares or other securities to be acquired upon the exercise of such rights.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distributions Other Than Cash, Shares or Rights to Purchase Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whenever the Company intends to distribute to the holders of Deposited Securities property other than cash, Shares or rights to purchase additional Shares, the Company shall give timely notice thereof to the Depositary and shall indicate whether or not it wishes such distribution to be made to Holders of ADSs. Upon receipt of a notice indicating that the Company wishes such distribution to be made to Holders of ADSs, the Depositary shall consult with the Company, and the Company shall assist the Depositary, to determine whether such distribution to Holders is lawful and reasonably practicable. The Depositary shall not make such distribution unless (i) the Company shall have requested the Depositary to make such distribution to Holders, (ii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7, and (iii) the Depositary shall have determined that such distribution is reasonably practicable.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon receipt of satisfactory documentation and the request of the Company to distribute property to Holders of ADSs and after making the requisite determinations set forth in (a) above, the Depositary shall distribute the property so received to the Holders of record, as of the ADS Record Date, in proportion to the number of ADSs held by them respectively and in such manner as the Depositary may deem practicable for accomplishing such distribution (i) upon receipt of payment or net of the applicable fees and charges of, and expenses incurred by, the Depositary, and (ii) net of any applicable taxes withheld. The Depositary may dispose of all or a portion of the property so distributed and deposited, in such amounts and in such manner (including public or private sale) as the Depositary may deem practicable or necessary to satisfy any taxes (including applicable interest and penalties) or other governmental charges applicable to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (i) the Company does not request the Depositary to make such distribution to Holders or requests the Depositary not to make such distribution to Holders, (ii) the Depositary does not receive satisfactory documentation within the terms of Section 5.7, or (iii) the Depositary determines that all or a portion of such distribution is not reasonably practicable, the Depositary shall sell or cause such property to be sold in a public or private sale, at such place or places and upon such terms as it may deem practicable and shall (i) cause the proceeds of such sale, if any, to be converted into Dollars and (ii) distribute the proceeds of such conversion received by the Depositary (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) to the Holders as of the ADS Record Date upon the terms of Section 4.1. If the Depositary is unable to sell such property, the Depositary may dispose of such property for the account of the Holders in any way it deems reasonably practicable under the circumstances.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Depositary nor the Company shall be liable for (i) any failure to accurately determine whether it is lawful or practicable to make the property described in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.5 available to Holders in general or any Holders in particular, nor (ii) any loss incurred in connection with the sale or disposal of such property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distributions with Respect to Deposited Securities in Bearer Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms of this Article IV, distributions in respect of Deposited Securities that are held by the Depositary or the Custodian in bearer form shall be made to the Depositary for the account of the respective Holders of ADS(s) with respect to which any such distribution is made upon due presentation by the Depositary or the Custodian to the Company of any relevant coupons, talons, or certificates. The Company shall promptly notify the Depositary of such distributions. The Depositary or the Custodian shall promptly present such coupons, talons or certificates, as the case may be, in connection with any such distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If the Company intends to exercise any right of redemption in respect of any of the Deposited Securities, the Company shall give notice thereof to the Depositary at least sixty (60) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the intended date of redemption which notice shall set forth the particulars of the proposed redemption. Upon timely receipt of (i) such notice and (ii) satisfactory documentation given by the Company to the Depositary within the terms of Section 5.7, and only if the Depositary shall have determined that such proposed redemption is practicable, the Depositary shall provide to each Holder a notice setting forth the intended exercise by the Company of the redemption rights and any other particulars set forth in the Company&#8217;s notice to the Depositary. The Depositary shall instruct the Custodian to present to the Company the Deposited Securities in respect of which redemption rights are being exercised against payment of the applicable redemption price. Upon receipt of confirmation from the Custodian that the redemption has taken place and that funds representing the redemption price have been received, the Depositary shall convert, transfer, and distribute the proceeds (net of applicable (a) fees and charges of, and the expenses incurred by, the Depositary, and (b) taxes), retire ADSs and cancel ADRs, if applicable, upon delivery of such ADSs by Holders thereof and the terms set forth in Sections 4.1 and 6.2. If less than all outstanding Deposited Securities are redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as may be determined by the Depositary. The redemption price per ADS shall be the dollar equivalent of the per share amount received by the Depositary (adjusted to reflect the ADS(s)-to-Share(s) ratio) upon the redemption of the Deposited Securities represented by ADSs (subject to the terms of Section 4.8 and the applicable fees and charges of, and expenses incurred by, the Depositary, and applicable taxes) multiplied by the number of Deposited Securities represented by each ADS redeemed.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed redemption provided for in this Section 4.7, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.7, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.7 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conversion of Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Depositary or the Custodian shall receive Foreign Currency, by way of dividends or other distributions or the net proceeds from the sale of Deposited Property, which in the judgment of the Depositary can at such time be converted on a practicable basis, by sale or in any other manner that it may determine in accordance with applicable law, into Dollars transferable to the United States and distributable to the Holders entitled thereto, the Depositary shall convert or cause to be converted, by sale or in any other manner that it may reasonably determine, such Foreign Currency into Dollars, and shall distribute such Dollars (net of the fees and charges set forth in the Fee Schedule attached hereto as Exhibit B, and applicable taxes withheld) in accordance with the terms of the applicable sections of the Deposit Agreement. The Depositary and&#47;or its agent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(which may be a division, branch or Affiliate of the Depositary) may act as principal for any conversion of Foreign Currency. If the Depositary shall have distributed warrants or other instruments that entitle the holders thereof to such Dollars, the Depositary shall distribute such Dollars to the holders of such warrants and&#47;or instruments upon surrender thereof for cancellation, in either case without liability for interest thereon. Such distribution may be made upon an averaged or other practicable basis without regard to any distinctions among Holders on account of any application of exchange restrictions or otherwise.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If such conversion or distribution generally or with regard to a particular Holder can be effected only with the approval or license of any government or agency thereof, the Depositary shall have authority to file such application for approval or license, if any, as it may deem desirable. In no event, however, shall the Depositary be obligated to make such a filing.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If at any time the Depositary shall determine that in its judgment the conversion of any Foreign Currency and the transfer and distribution of proceeds of such conversion received by the Depositary is not practicable or lawful, or if any approval or license of any governmental authority or agency thereof that is required for such conversion, transfer and distribution is denied or, in the opinion of the Depositary, not obtainable at a reasonable cost or within a reasonable period, the Depositary may, in its discretion, (i) make such conversion and distribution in Dollars to the Holders for whom such conversion, transfer and distribution is lawful and practicable, (ii) distribute the Foreign Currency (or an appropriate document evidencing the right to receive such Foreign Currency) to Holders for whom this is lawful and practicable, or (iii) hold (or cause the Custodian to hold) such Foreign Currency (without liability for interest thereon) for the respective accounts of the Holders entitled to receive the same.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fixing of ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever (a) the Depositary shall receive notice of the fixing of a record date by the Company for the determination of holders of Deposited Securities entitled to receive any distribution (whether in cash, Shares, rights, or other distribution), (b) for any reason the Depositary causes a change in the number of Shares that are represented by each ADS, (c) the Depositary shall receive notice of any meeting of, or solicitation of consents or proxies of, holders of Shares or other Deposited Securities, or (d) theDepositary shall find it necessary or convenient in connection with the giving of any notice, solicitation of any consent or any other matter, the Depositary shall fix the record date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the determination of the Holders of ADS(s) who shall be entitled to receive such distribution, to give instructions for the exercise of voting rights at any such meeting, to give or withhold such consent, to receive such notice or solicitation or to otherwise take action, or to exercise the rights of Holders with respect to such changed number of Shares represented by each ADS. The Depositary shall make reasonable efforts to establish the ADS Record Date as closely as practicable to the applicable record date for the Deposited Securities (if any) set by the Company in Switzerland and shall not announce the establishment of any ADS Record Date prior to the relevant corporate action having been made public by the Company (if such corporate action affects the Deposited Securities). Subject to applicable law and the provisions of Section 4.1 through 4.8 and to the other terms and conditions of the Deposit Agreement, only the Holders of ADSs at the close of business in New York on such ADS Record Date shall be entitled to receive such distribution, to give such voting instructions, to receive such notice or solicitation, or otherwise take action.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Voting of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As soon as practicable after receipt of notice of any meeting at which the holders of Deposited Securities are entitled to vote, or of solicitation of consents or proxies from holders of Deposited Securities, the Depositary shall fix the ADS Record Date in respect of such meeting or solicitation of consent or proxy in accordance with Section 4.9. The Depositary shall, if requested by the Company in writing in a timely manner (the Depositary having no obligation to take any further action if the request shall not have been received by the Depositary at least thirty (30) days prior to the date of such meeting or consent or proxy solicitation), at the Company&#8217;s expense and provided no U.S. legal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prohibitions exist, distribute to Holders as of the ADS Record Date&#58; (a) such notice of meeting or solicitation of consent or proxy, (b) a statement that the Holders at the close of business on the ADS Record Date will be entitled, subject to any applicable law, the provisions of the Deposit Agreement, the Articles of Incorporation of the Company and the provisions of or governing the Deposited Securities (which provisions, if any, shall be summarized in pertinent part by the Company), to instruct the Depositary as to the exercise of the voting rights, if any, pertaining to the Deposited Securities represented by such Holder&#8217;s ADSs, and (c) a brief statement as to the manner in which such voting instructions may be given. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement or any ADR, the Depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the Depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of Deposited Securities, distribute to the Holders a notice that provides Holders with, or otherwise publicizes to Holders, instructions on how to retrieve such materials or receive such materials upon request (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Voting instructions may be given only in respect of a number of ADSs representing an integral number of Deposited Securities. Upon the timely receipt from a Holder of ADSs as of the ADS Record Date of voting instructions in the manner specified by the Depositary, the Depositary shall endeavor, insofar as practicable and permitted under applicable law, the provisions of the Deposit Agreement, Articles of Incorporation of the Company and the provisions of the Deposited Securities, to vote, or cause the Custodian to vote, the Deposited Securities (in person or by proxy) represented by such Holder&#8217;s ADSs in accordance with such voting instructions. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposited Securities represented by ADSs for which no timely voting instructions are received by the Depositary from the Holder shall not be voted. Neither the Depositary nor the Custodian shall under any circumstances exercise any discretion as to voting and neither the Depositary nor the Custodian shall vote, attempt to exercise the right to vote, or in any way make use of, the Deposited Securities represented by ADSs, except pursuant to and in accordance with the voting instructions timely received from Holders or as otherwise contemplated herein. If the Depositary timely receives voting instructions from a Holder which fail to specify the manner in which the Depositary is to vote the Deposited Securities represented by such Holder&#8217;s ADSs, the Depositary will deem such Holder (unless otherwise specified in the notice distributed to Holders) to have instructed the Depositary to take all steps necessary to enable the independent proxy holder, as elected by the shareholders of the Company, to vote in accordance with the written proposals or recommendations of the Company&#8217;s Board of Directors. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained herein, the Depositary shall, if so requested in writing by the Company, represent all Deposited Securities (whether or not voting instructions have been received in respect of such Deposited Securities from Holders as of the ADS Record Date) for the sole purpose of establishing quorum at a meeting of shareholders.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in the Deposit Agreement or any ADR, the Depositary shall not have any obligation to take any action with respect to any meeting, or solicitation of consents or proxies, of holders of Deposited Securities if the taking of such action would violate U.S. laws. The Company agrees to take any and all actions reasonably necessary and as permitted by the law of Switzerland to enable Holders and Beneficial Owners to exercise the voting rights accruing to the Deposited Securities and to deliver to the Depositary an opinion of U.S. counsel addressing any actions reasonably requested to be taken if so requested by the Depositary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally or any Holder in particular will receive the notice described above with sufficient time to enable the Holder to return voting instructions to the Depositary, or otherwise take action, in a timely manner.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Changes Affecting Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon any change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of Deposited Securities, or upon any recapitalization, reorganization, merger, consolidation or sale of assets affecting the Company or to which it is a party, any property which shall be received by the Depositary or the Custodian in exchange for, or in conversion of, or replacement of, or otherwise in respect of, such Deposited Securities shall, to the extent permitted by law, be treated as new Deposited Property under the Deposit Agreement, and the ADSs shall, subject to the provisions of the Deposit Agreement, any ADR(s) evidencing such ADSs and applicable law, represent the right to receive such additional or replacement Deposited Property. In giving effect to such change, split-up, cancellation, consolidation or other reclassification of Deposited Securities,</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recapitalization, reorganization, merger, consolidation or sale of assets, the Depositary may, with the Company&#8217;s approval, and shall, if the Company shall so request, subject to the terms of the Deposit Agreement (including, without limitation, (a) the applicable fees and charges of, and expenses incurred by, the Depositary, and (b) applicable taxes) and receipt of an opinion of counsel to the Company reasonably satisfactory to the Depositary that such actions are not in violation of any applicable laws or regulations, (i) issue and deliver additional ADSs as in the case of a stock dividend on the Shares, (ii) amend the Deposit Agreement and the applicable ADRs, (iii) amend the applicable Registration Statement(s) on Form F-6 as filed with the Commission in respect of the ADSs, (iv) call for the surrender of outstanding ADRs to be exchanged for new ADRs, and (v) take such other actions as are appropriate to reflect the transaction with respect to the ADSs. The Company agrees to, jointly with the Depositary, amend the Registration Statement on Form F-6 as filed with the Commission to permit the issuance of such new form of ADRs. Notwithstanding the foregoing, in the event that any Deposited Property so received may not be lawfully distributed to some or all Holders, the Depositary may, with the Company&#8217;s approval, and shall, if the Company requests, subject to receipt of an opinion of Company&#8217;s counsel reasonably satisfactory to the Depositary that such action is not in violation of any applicable laws or regulations, sell such Deposited Property at public or private sale, at such place or places and upon such terms as it may deem proper and may allocate the net proceeds of such sales (net of (a) fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes) for the account of the Holders otherwise entitled to such Deposited Property upon an averaged or other practicable basis without regard to any distinctions among such Holders and distribute the net proceeds so allocated to the extent practicable as in the case of a distribution received in cash pursuant to Section 4.1. The Depositary shall not be responsible for (i) any failure to determine that it may be lawful or practicable to make such Deposited Property available to Holders in general or to any Holder in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale, or (iii) any liability to the purchaser of such Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Available Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company is subject to the periodic reporting requirements of the Exchange Act and, accordingly, is required to file or furnish certain reports with the Commission. These reports can be retrieved from the Commission's website (www.sec.gov) and can be inspected and copied at the public reference facilities maintained by the Commission located (as of the date of the Deposit Agreement) at 100 F Street, N.E., Washington D.C. 20549.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall make available for inspection by Holders at its Principal Office any reports and communications, including any proxy soliciting materials, received from the Company which are both (a) received by the Depositary, the Custodian, or the nominee of either of them as the holder of the Deposited Property and (b) made generally available to the holders of such Deposited Property by the Company. The Depositary shall also </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide or make available to Holders copies of such reports when furnished by the Company pursuant to Section 5.6.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">List of Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Promptly upon written request by the Company, the Depositary shall furnish to it a list, as of a recent date, of the names, addresses and holdings of ADSs of all Holders.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Depositary will, and will instruct the Custodian to, forward to the Company or its agents such information from its records as the Company may reasonably request to enable the Company or its agents to file the necessary tax reports with governmental authorities or agencies. The Depositary, the Custodian or the Company and its agents may file such reports as are necessary to reduce or eliminate applicable taxes on dividends and on other distributions in respect of Deposited Property under applicable tax treaties or laws for the Holders and Beneficial Owners. In accordance with instructions from the Company and to the extent practicable, the Depositary or the Custodian will take reasonable administrative actions to obtain tax refunds, reduced withholding of tax at source on dividends and other benefits under applicable tax treaties or laws with respect to dividends and other distributions on the Deposited Property. As a condition to receiving such benefits, Holders and Beneficial Owners of ADSs may be required from time to time, and in a timely manner, to file such proof of taxpayer status, residence and beneficial ownership (as applicable), to execute such certificates and to make such representations and warranties, or to provide any other information or documents, as the Depositary or the Custodian may deem necessary or proper to fulfill the Depositary&#8217;s or the Custodian&#8217;s obligations under applicable law. The Depositary and the Company shall have no obligation or liability to any person if any Holder or Beneficial Owner fails to provide such information or if such information does not reach the relevant tax authorities in time for any Holder or Beneficial Owner to obtain the benefits of any tax treatment. The Holders and Beneficial Owners shall indemnify the Depositary, the Company, the Custodian and any of their respective directors, employees, agents and Affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or other tax benefit obtained.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company (or any of its agents) withholds from any distribution any amount on account of taxes or governmental charges, or pays any other tax in respect of such distribution (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, stamp duty tax, capital gains or other similar tax), the Company shall (or shall cause such agent to) remit promptly to the Depositary information about such taxes or governmental charges withheld or paid, and, if so requested, the tax receipt (or other proof of payment to the applicable governmental authority) therefor, in each case, in a form reasonably satisfactory to the Depositary. The Depositary shall, to the extent required by U.S. law, report to Holders any taxes withheld by it or the Custodian, and, if such information is provided to it by the Company, any taxes withheld by the Company. The Depositary and the Custodian shall not be required to provide the Holders with any evidence of the remittance by the Company (or its agents) of any taxes withheld, or of the payment of taxes by the Company, except to the extent the evidence is provided by the Company to the Depositary or the Custodian, as applicable. Neither the Depositary nor the Custodian shall be liable for the failure by any Holder or Beneficial Owner to obtain the benefits of credits on the basis of non-U.S. tax paid against such Holder&#8217;s or Beneficial Owner&#8217;s income tax liability.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary is under no obligation to provide the Holders and Beneficial Owners with any information about the tax status of the Company. The Depositary shall not incur any liability for any tax consequences that may be incurred by Holders and Beneficial Owners on account of their ownership of the ADSs, including without limitation, tax consequences resulting from the Company (or any of its subsidiaries) being treated as a &#8220;Passive Foreign Investment Company&#8221; (in each case as defined in the U.S. Internal Revenue Code and the regulations issued thereunder) or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE DEPOSITARY, THE CUSTODIAN AND THE COMPANY</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Maintenance of Office and Transfer Books by the Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Until termination of the Deposit Agreement in accordance with its terms, the Registrar shall maintain in the Borough of Manhattan, the City of New York, an office and facilities for the issuance and delivery of ADSs, the acceptance for surrender of ADS(s) for the purpose of withdrawal of Deposited Securities, the registration of issuances, cancellations, transfers, combinations and split-ups of ADS(s) and, if applicable, to countersign ADRs evidencing the ADSs so issued, transferred, combined or split-up, in each case in accordance with the provisions of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall keep books for the registration of ADSs which at all reasonable times shall be open for inspection by the Company and by the Holders of such ADSs, provided that such inspection shall not be, to the Registrar&#8217;s knowledge, for the purpose of communicating with Holders of such ADSs in the interest of a business or object other than the business of the Company or other than a matter related to the Deposit Agreement or the ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar may close the transfer books with respect to the ADSs, at any time or from time to time, when deemed necessary or advisable by it in good faith in connection with the performance of its duties hereunder, or at the reasonable written request of the Company subject, in all cases, to Section 7.8(a).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any ADSs are listed on one or more stock exchanges or automated quotation systems in the United States, the Depositary shall act as Registrar or appoint a Registrar or one or more co-registrars for registration of issuances, cancellations, transfers, combinations and split-ups of ADSs and, if applicable, to countersign ADRs evidencing the ADSs so issued, transferred, combined or split-up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in accordance with any requirements of such exchanges or systems. Such Registrar or co-registrars may be removed and a substitute or substitutes appointed by the Depositary. As promptly as practicable, the Depositary shall notify the Company of any such removal or appointment.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exoneration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement or any ADR, neither the Depositary nor the Company shall be obligated to do or perform any act or thing which is inconsistent with the provisions of the Deposit Agreement or incur any liability (to the extent not limited by Section 7.8(b)) (i) if the Depositary, the Custodian, the Company or their respective agents shall be prevented or forbidden from, hindered or delayed in, doing or performing any act or thing required or contemplated by the terms of the Deposit Agreement, by reason of any provision of any present or future law or regulation of the United States, Switzerland or any other country, or of any other governmental authority or regulatory authority or stock exchange, or on account of potential criminal or civil penalties or restraint, or by reason of any provision, present or future, of the Articles of Incorporation of the Company or any provision of or governing any Deposited Securities, or by reason of any act of God or other event or circumstance beyond its control (including, without limitation, fire, flood, earthquake, tornado, hurricane, tsunami, explosion, or other natural disaster, nationalization, expropriation, currency restriction, work stoppage, strikes, civil unrest, act of war (whether declared or not) or terrorism, revolution, rebellion, embargo, computer failure, failure of public infrastructure (including communication or utility failure), failure of common carriers, nuclear, cyber or biochemical incident, any pandemic, epidemic or other prevalent disease or illness with an actual or probable threat to human life, any quarantine order or travel restriction imposed by a governmental authority or other competent public health authority, or the failure or unavailability of the United States Federal Reserve Bank (or other central banking system) or DTC (or other clearing system)), (ii) by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement or in the Articles of Incorporation of the Company or provisions of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or governing Deposited Securities, (iii) for any action or inaction in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Holder, any Beneficial Owner or authorized representative thereof, or any other person believed by it in good faith to be competent to give such advice or information, (iv) for the inability by a Holder or Beneficial Owner to benefit from any distribution, offering, right or other benefit which is made available to holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Holders of ADSs, (v) for any action or inaction of any clearing or settlement system (and any participant thereof) for the Deposited Property or the ADSs, or (vi) for any consequential or punitive damages (including lost profits) for any breach of the terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary, its controlling persons, its agents, any Custodian and the Company, its controlling persons and its agents may rely and shall be protected in acting upon any written notice, request or other document believed by it to be genuine and to have been signed or presented by the proper party or parties.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Standard of Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company and the Depositary assume no obligation and shall not be subject to any liability under the Deposit Agreement or any ADRs to any Holder(s) or Beneficial Owner(s), except that the Company and the Depositary agree to perform their respective obligations specifically set forth in the Deposit Agreement or the applicable ADRs without negligence or bad faith.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation of the foregoing, neither the Depositary, nor the Company, nor any of their respective controlling persons, or agents, shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Property or in respect of the ADSs, which in its opinion may involve it in expense or liability, unless indemnity satisfactory to it against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be required (and no Custodian shall be under any obligation whatsoever with respect to such proceedings, the responsibility of the Custodian being solely to the Depositary).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary and its agents shall not be liable for any failure to carry out any instructions to vote any of the Deposited Securities, or for the manner in which any vote is cast or the effect of any vote, provided that any such action or omission is in good faith and without negligence and in accordance with the terms of the Deposit Agreement. The Depositary shall not incur any liability for any failure to accurately determine that any distribution or action may be lawful or reasonably practicable, for the content of any information submitted to it by the Company for distribution to the Holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the Deposited Property, for the validity or worth of the Deposited Property, for the value of any Deposited Property or any distribution thereon, for any interest on Deposited Property, for any tax consequences that may result from the ownership of ADSs, Shares or other Deposited Property, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the Deposit Agreement, for the failure or timeliness of any notice from the Company, or for any action of or failure to act by, or any information provided or not provided by, DTC or any DTC Participant.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a predecessor depositary whether in connection with an act or omission of the Depositary or in connection with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any matter arising wholly prior to the appointment of the Depositary or after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Resignation and Removal of the Depositary&#59; Appointment of Successor Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may at any time resign as Depositary hereunder by written notice of resignation delivered to the Company, such resignation to be effective on the earlier of (i) the 90th day after delivery thereof to the Company (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2), or (ii) the appointment by the Company of a successor depositary and its acceptance of such appointment as hereinafter provided.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may at any time be removed by the Company by written notice of such removal, which removal shall be effective on the later of (i) the 90th day after delivery thereof to the Depositary (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2), or (ii) upon the appointment by the Company of a successor depositary and its acceptance of such appointment as hereinafter provided.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In case at any time the Depositary acting hereunder shall resign or be removed, the Company shall use its commercially reasonable efforts to appoint a successor depositary, which shall be a bank or trust company having an office in the Borough of Manhattan, the City of New York. Every successor depositary shall be required by the Company to execute and deliver to its predecessor and to the Company an instrument in writing accepting its appointment hereunder, and thereupon such successor depositary, without any further act or deed (except as required by applicable law), shall become fully vested with all the rights, powers, duties and obligations of its predecessor (other than as contemplated in Sections 5.8 and 5.9). The predecessor depositary, upon payment of all sums due it and on the written request of the Company, shall, (i) execute and deliver an instrument transferring to such successor all rights and powers of such predecessor hereunder (other than as contemplated in Sections 5.8 and 5.9), (ii) duly assign, transfer and deliver all of the Depositary&#8217;s right, title and interest to the Deposited Property to such successor, and (iii) deliver to such successor a list of the Holders of all outstanding ADSs and such other information relating to ADSs and Holders thereof as the successor may reasonably request. Any such successor depositary shall promptly provide notice of its appointment to such Holders.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any entity into or with which the Depositary may be merged or consolidated shall be the successor of the Depositary without the execution or filing of any document or any further act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">The Custodian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary has initially appointed Citibank N.A. London Branch as Custodian for the purpose of the Deposit Agreement. The Custodian or its successors in acting hereunder shall be authorized to act as custodian in Switzerland and shall be subject at all times and in all respects to the direction of the Depositary for the Deposited Property for which the Custodian acts as custodian and shall be responsible solely to it. If any Custodian resigns or is discharged from its duties hereunder with respect to any Deposited Property and no other Custodian has previously been appointed hereunder, the Depositary shall promptly appoint a substitute custodian. The Depositary shall require such resigning or discharged Custodian to Deliver, or cause the Delivery of, the Deposited Property held by it, together with all such records maintained by it as Custodian with respect to such Deposited Property as the Depositary may request, to the Custodian designated by the Depositary. Whenever the Depositary determines, in its discretion, that it is appropriate to do so, it may appoint an additional custodian with respect to any Deposited Property, or discharge the Custodian with respect to any Deposited Property and appoint a substitute custodian, which shall thereafter be Custodian hereunder with respect to the Deposited Property. Immediately upon any such change, the Depositary shall give notice thereof in writing to all Holders of ADSs, each other Custodian and the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Citibank may at any time act as Custodian of the Deposited Property pursuant to the Deposit Agreement, in which case any reference to Custodian shall mean Citibank solely in its capacity as Custodian pursuant to the Deposit Agreement. Notwithstanding anything contained in the Deposit Agreement or any ADR to the contrary, the Depositary shall not be obligated to give notice to the Company, any Holders of ADSs or any other Custodian of its acting as Custodian pursuant to the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the appointment of any successor depositary, any Custodian then acting hereunder shall, unless otherwise instructed by the Depositary, continue to be the Custodian of the Deposited Property without any further act or writing, and shall be subject to the direction of the successor depositary. The successor depositary so appointed shall, nevertheless, on the written request of any Custodian, execute and deliver to such Custodian all such instruments as may be proper to give to such Custodian full and complete power and authority to act on the direction of such successor depositary.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices and Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> On or before the first date on which the Company gives notice, by publication or otherwise, of any meeting of holders of Shares or other Deposited Securities, or of any adjourned meeting of such holders, or of the taking of any action by such holders other than at a meeting, or of the taking of any action in respect of any cash or other distributions or the offering of any rights in respect of Deposited Securities, the Company shall transmit to the Depositary and the Custodian a copy of the notice thereof in the English language but otherwise in the form given or to be given to holders of Shares or other Deposited Securities. The Company shall also furnish to the Custodian and the Depositary a summary, in English, of any applicable provisions or proposed provisions of the Articles of Incorporation of the Company that may be relevant or pertain to such notice of meeting or be the subject of a vote thereat.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will also transmit to the Depositary (a) an English language version of the other notices, reports and communications which are made generally available by the Company to holders of its Shares or other Deposited Securities and (b) the English-language versions of the Company&#8217;s annual and semi-annual reports prepared in accordance with the applicable requirements of the Commission to the extent such notices, reports and communications are not available on the Company&#8217;s website or are not otherwise publicly available. The Depositary shall arrange, at the request of the Company and at the Company&#8217;s expense, to provide copies thereof to all Holders or make such notices, reports and other communications available to all Holders on a basis similar to that for holders of Shares or other Deposited Securities or on such other basis as the Company may advise the Depositary or as may be required by any applicable law, regulation or stock exchange requirement. The Company has made available to the Depositary and the Custodian a copy of the Company&#8217;s Articles of Incorporation along with the provisions of or governing the Shares and any other Deposited Securities issued by the Company in connection with such Shares, and promptly upon any amendment thereto or change therein, the Company shall deliver to the Depositary and the Custodian a copy of such amendment thereto or change therein. The Depositary may rely upon such copy for all purposes of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary will, at the expense of the Company, make available a copy of any such notices, reports or communications issued by the Company and delivered to the Depositary for inspection by the Holders of the ADSs at the Depositary&#8217;s Principal Office, at the office of the Custodian and at any other designated transfer office.</font></div><div style="margin-bottom:0.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Issuance of Additional Shares, ADSs etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company agrees that in the event it or any of its Affiliates proposes (i) an issuance, sale or distribution of additional Shares, (ii) an offering of rights to subscribe for Shares or other Deposited Securities, (iii) an issuance or assumption of securities convertible into or exchangeable for Shares, (iv) an issuance of rights to subscribe for securities convertible into or exchangeable for Shares, (v) an elective dividend of cash or Shares, (vi) a redemption of Deposited Securities, (vii) a meeting of holders of Deposited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Securities, or solicitation of consents or proxies, relating to any reclassification of securities, merger or consolidation or transfer of assets, (viii) any assumption, reclassification, recapitalization, reorganization, merger, consolidation or sale of assets which affects the Deposited Securities, or (ix) a distribution of securities other than Shares, it will obtain U.S. legal advice and take all steps necessary to ensure that the application of the proposed transaction to</font></div><div style="margin-bottom:0.1pt;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holders and Beneficial Owners does not violate the registration provisions of the Securities Act, or any other applicable laws (including, without limitation, the Investment Company Act of 1940, as amended, the Exchange Act and the securities laws of the states of the U.S.). In support of the foregoing, the Company will furnish to the Depositary (a) a written opinion of U.S. counsel (reasonably satisfactory to the Depositary) stating whether such transaction (1) requires a registration statement under the Securities Act to be in effect or (2) is exempt from the registration requirements of the Securities Act and (b) an opinion of Swiss counsel stating that (1) making the transaction available to Holders and Beneficial Owners does not violate the laws or regulations of Switzerland and (2) all requisite regulatory consents and approvals have been obtained in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Switzerland. If the filing of a registration statement is required, the Depositary shall not have any obligation to proceed with the transaction unless it shall have received evidence reasonably satisfactory to it that such registration statement has been declared effective. If, being advised by counsel, the Company determines that a transaction is required to be registered under the Securities Act, the Company will either (i) register such transaction to the extent necessary, (ii) alter the terms of the transaction to avoid the registration requirements of the Securities Act or (iii) direct the Depositary to take specific measures, in each case as contemplated in the Deposit Agreement, to prevent such transaction from violating the registration requirements of the Securities Act. The Company agrees with the Depositary that neither the Company nor any of its Affiliates will at any time (i) deposit any Shares or other Deposited Securities, either upon original issuance or upon a sale of Shares or other Deposited Securities previously issued and reacquired by the Company or by any such Affiliate, or (ii) issue additional Shares, rights to subscribe for such Shares, securities convertible into or exchangeable for Shares or rights to subscribe for such securities or distribute securities other than Shares, unless such transaction and the securities issuable in such transaction do not violate the registration provisions of the Securities Act, or any other applicable laws (including, without limitation, the Investment Company Act of 1940, as amended, the Exchange Act and the securities laws of the states of the U.S.).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in the Deposit Agreement, nothing in the Deposit Agreement shall be deemed to obligate the Company to file any registration statement in respect of any proposed transaction.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary agrees to indemnify the Company and its directors, officers, employees, agents and Affiliates against, and hold each of them harmless from, any direct loss, liability, tax, charge or expense of any kind whatsoever (including, but not limited to, the documented reasonable fees and expenses of counsel) which may arise out of acts performed or omitted by the Depositary under the terms hereof due to the negligence or bad faith of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company agrees to indemnify the Depositary, the Custodian and any of their respective directors, officers, employees, agents and Affiliates against, and hold each of them harmless from, any direct loss, liability, tax, charge or expense of any kind whatsoever (including, but not limited to, the documented reasonable fees and expenses of counsel) that may arise (a) out of, or in connection with, any offer, issuance, sale, resale, transfer, deposit or withdrawal of ADRs, ADSs, the Shares, or other Deposited Securities, as the case may be, (b) out of, or as a result of, any offering documents in respect thereof or (c) out of acts performed or </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">omitted, including, but not limited to, any delivery by the Depositary on behalf of the Company of information regarding the Company, in connection with the Deposit Agreement, any ancillary or supplemental agreement entered into between the Company and the Depositary, the ADRs, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADSs, the Shares, or any Deposited Property, in any such case (i) by the Depositary, the Custodian or any of their respective directors, officers, employees, agents and Affiliates, except to the extent such loss, liability, tax, charge or expense is due to the negligence or bad faith of any of them, or (ii) by the Company or any of its directors, officers, employees, agents and Affiliates. The Company shall not indemnify the Depositary or the Custodian (for so long as the Custodian is a branch of Citibank) against (x) any liability or expense arising out of information relating to the Depositary or such Custodian, as the case may be, furnished in a signed writing to the Company, executed by the Depositary expressly for use in any registration statement, prospectus or preliminary prospectus relating to any Deposited Securities represented by the ADSs, or (y) any fees, charges or expenses payable by Holders or Beneficial Owners other than the Company under this Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations set forth in this Section shall survive the termination of the Deposit Agreement and the succession or substitution of any party hereto.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any person seeking indemnification hereunder (an &#8220;indemnified person&#8221;) shall notify the person from whom it is seeking indemnification (the &#8220;indemnifying person&#8221;) of the commencement of any indemnifiable action or claim promptly after such indemnified person becomes aware of such commencement (provided that the failure to make such notification shall not affect such indemnified person&#8217;s rights to seek indemnification except to the extent the indemnifying person is materially prejudiced by such failure) and shall consult in good faith with the indemnifying person as to the conduct of the defense of such action or claim that may give rise to an indemnity hereunder, which defense shall be reasonable in the circumstances. No indemnified person shall compromise or settle any action or claim that may give rise to an indemnity hereunder without the consent of the indemnifying person, which consent shall not be unreasonably withheld. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Fees and Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company, the Holders, the Beneficial Owners, persons depositing Shares or withdrawing Deposited Securities in connection with the issuance and cancellation of ADSs, and persons receiving ADSs upon issuance or whose ADSs are being cancelled shall be required to pay the Depositary&#8217;s fees and related charges identified as payable by them respectively in the Fee Schedule attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All ADS fees and charges so payable may be deducted from distributions or must be remitted to the Depositary, or its designee, and may, at any time and from time to time, be changed by agreement between the Depositary and the Company, but, in the case of ADS fees and charges payable by Holders and Beneficial Owners, only in the manner contemplated in Section 6.1. The Depositary shall provide, without charge, a copy of its latest ADS fee schedule to anyone upon request. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS fees and charges for (i) the issuance of ADSs and (ii) the cancellation of ADSs will be payable by the person for whom the ADSs are so issued by the Depositary (in the case of ADS issuances) and by the person for whom ADSs are being cancelled (in the case of ADS cancellations). In the case of ADSs issued by the Depositary into DTC or presented to the Depositary via DTC, the ADS issuance and cancellation fees and charges will be payable by the DTC Participant(s) receiving the ADSs from the Depositary or the DTC Participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the Beneficial Owner(s) and will be charged by the DTC Participant(s) to the account(s) of the applicable Beneficial Owner(s) in accordance with the procedures and practices of the DTC Participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are payable by Holders as of the applicable ADS Record Date established by the Depositary. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, the applicable Holders as of the ADS Record Date established by the Depositary will be invoiced for the amount of the ADS fees and charges and such ADS fees may be deducted from distributions made to Holders. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be charged to the DTC Participants in accordance with the procedures and practices prescribed by DTC from time to time and the DTC Participants in turn charge the amount of such ADS fees and charges to the Beneficial Owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may reimburse the Company for certain expenses incurred by the Company in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Company and the Depositary agree from time to time. The Company shall pay to the Depositary such fees and charges, and reimburse the Depositary for such out-of-pocket expenses, as the Depositary and the Company may agree from time to time. Responsibility for payment of such fees, charges and reimbursements may from time to time be changed by agreement between the Company and the Depositary. Unless otherwise agreed, the Depositary shall present its statement for such fees, charges and reimbursements to the Company once every three months. The charges and expenses of the Custodian are for the sole account of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of Holders and Beneficial Owners to pay ADS fees and charges shall survive the termination of the Deposit Agreement. As to any Depositary, upon the resignation or removal of such Depositary as described in Section 5.4, the right to collect ADS fees and charges shall extend for those ADS fees and charges incurred prior to the effectiveness of such resignation or removal.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Securities Owners</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company agrees to advise in writing each of the persons or entities who, to the knowledge of the Company, holds Restricted Securities that such Restricted Securities are ineligible for deposit hereunder (except under the circumstances contemplated in Section 2.14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and, to the extent practicable, shall require each of such persons to represent in writing that such person will not deposit Restricted Securities hereunder (except under the circumstances contemplated in Section 2.14).</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VI</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT AND TERMINATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment&#47;Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of this Section 6.1 and applicable law, the ADRs outstanding at any time, the provisions of the Deposit Agreement and the form of ADR attached hereto and to be issued under the terms hereof may at any time and from time to time be amended or supplemented by written agreement between the Company and the Depositary in any respect which they may deem necessary or desirable without the prior written consent of the Holders or Beneficial Owners. Any amendment or supplement which shall impose or increase any fees or charges (other than charges in connection with foreign exchange control regulations, and taxes and other governmental charges, delivery and other such expenses), or which shall otherwise materially prejudice any substantial existing right of Holders or Beneficial Owners, shall not, however, become effective as to outstanding ADSs until the expiration of thirty (30) days after notice of such amendment or supplement shall have been given to the Holders of outstanding ADSs. Notice of any amendment to the Deposit Agreement or any ADR shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific amendments in any such notice shall not render such notice invalid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in each such case, the notice given to the Holders identifies a means for Holders and Beneficial Owners to retrieve or receive the text of such amendment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon retrieval from the Commission&#8217;s, the Depositary&#8217;s or the Company&#8217;s website or upon request from the Depositary). The parties hereto agree that any amendments or supplements which (i) are reasonably necessary (as agreed by the Company and the Depositary) in order for (a) the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs to be settled solely in electronic book-entry form and (ii) do not in either such case impose or increase any fees or charges to be borne by Holders, shall be deemed not to materially prejudice any substantial existing rights of Holders or Beneficial Owners. Every Holder and Beneficial Owner at the time any amendment or supplement so becomes effective shall be deemed, by continuing to hold such ADSs, to consent and agree to such amendment or supplement and to be bound by the Deposit Agreement and the ADR, if applicable, as amended or supplemented thereby. In no event shall any amendment or supplement impair the right of the Holder to surrender such ADS and receive therefor the Deposited Securities represented thereby, except in order to comply with mandatory provisions of applicable law. Notwithstanding the foregoing, if any governmental body should adopt new laws, rules or regulations which would require an amendment of, or supplement to, the Deposit Agreement to ensure compliance therewith, the Company and the Depositary may amend or supplement the Deposit Agreement and any ADRs at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the Deposit Agreement and any ADRs in such circumstances may become effective before a notice of such amendment or supplement is given to Holders or within any other period of time as required for compliance with such laws, rules or regulations.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall, at any time at the written direction of the Company, terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. If (i) ninety (90) days shall have expired after the Depositary shall have delivered to the Company a written notice of its election to resign, or (ii) ninety (90) days shall have expired after the Company shall have delivered to the Depositary a written notice of the removal of the Depositary, and, in either case, a successor depositary shall not have been appointed and accepted its appointment as provided in Section 5.4 of the Deposit Agreement, the Depositary may terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. The date so fixed for termination of the Deposit Agreement in any termination notice so distributed by the Depositary to the Holders of ADSs is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. Until the Termination Date, the Depositary shall continue to perform all of its obligations under the Deposit Agreement, and the Holders and Beneficial Owners will be entitled to all of their rights under the Deposit Agreement. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any ADSs shall remain outstanding after the Termination Date, the Registrar and the Depositary shall not, after the Termination Date, have any obligation to perform any further acts under the Deposit Agreement, except that the Depositary shall, subject, in each case, to the terms and conditions of the Deposit Agreement, continue to (i) collect dividends and other distributions pertaining to Deposited Securities, (ii) sell Deposited Property received in respect of Deposited Securities, (iii) deliver Deposited Securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any other Deposited Property, in exchange for ADSs surrendered to the Depositary (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (iv) take such actions as may be required under applicable law in connection with its role as Depositary under the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time after the Termination Date, the Depositary may sell the Deposited Property then held under the Deposit Agreement and shall after such sale hold un-invested the net proceeds of such sale, together with any other cash then held by it under the Deposit Agreement, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in an un-segregated account and without liability for interest, for the pro rata benefit of the Holders whose ADSs have not theretofore been surrendered. After making such sale, the Depositary shall be discharged from all obligations under the Deposit Agreement except (i) to account for such net proceeds and other cash (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (ii) as may be required at law in connection with the termination of the Deposit Agreement. After the Termination Date, the Company shall be discharged from all obligations under the Deposit Agreement, except for its obligations to the Depositary under Sections 5.8, 5.9 and 7.6 of the Deposit Agreement. The obligations under the terms of the Deposit Agreement of Holders and Beneficial Owners of ADSs outstanding as of the Termination Date shall survive the Termination Date and shall be discharged only when the applicable ADSs are presented by their Holders to the Depositary for cancellation under the terms of the Deposit Agreement (except as specifically provided in the Deposit Agreement).</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of such counterparts together shall constitute one and the same agreement. Copies of the Deposit Agreement shall be maintained with the Depositary and shall be open to inspection by any Holder during business hours.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Third-Party Beneficiaries&#47;Acknowledgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement is for the exclusive benefit of the parties hereto (and their successors) and shall not be deemed to give any legal or equitable right, remedy or claim whatsoever to any other person, except to the extent specifically set forth in the Deposit Agreement. Nothing in the Deposit Agreement shall be deemed to give rise to a partnership or joint venture among the parties nor establish a fiduciary or similar relationship among the parties. The parties hereto acknowledge and agree that (i) Citibank and its Affiliates may at any time have multiple banking relationships with the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (ii) Citibank and its Affiliates may own and deal in any class of securities of the Company and its Affiliates and in ADSs, and may be engaged at any time in transactions in which parties adverse to the Company, the Holders, the Beneficial Owners or their respective Affiliates may have interests, (iii) the Depositary and its Affiliates may from time to time have in their possession non-public information about the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (iv) nothing contained in the Deposit Agreement shall (a) preclude Citibank or any of its Affiliates from engaging in such transactions or establishing or maintaining such relationships, or (b) obligate Citibank or any of its Affiliates to disclose such information, transactions or relationships, or to account for any profit made or payment received in such transactions or relationships, (v) the Depositary shall not be deemed to have knowledge of any information any other division of Citibank or any of its Affiliates may have about the Company, the Holders, the Beneficial Owners, or any of their respective Affiliates, and (vi) the Company, the Depositary, the Custodian and their respective agents and controlling persons may be subject to the laws and regulations of jurisdictions other than the U.S. and Switzerland, and the authority of courts and regulatory authorities of such other jurisdictions, and, consequently, the requirements and the limitations of such other laws and regulations, and the decisions and orders of such other courts and regulatory authorities, may affect the rights and obligations of the parties to the Deposit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may execute transactions contemplated herein (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, foreign currency conversions, and sales of Deposited Property) through one or more divisions of Citibank or through one or more Citibank Affiliates, and any such entity may act as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and may earn and retain revenue from such transactions, including, without, without limitation, transaction spreads, commissions, etc. The Depositary does not guarantee or represent that the price or rate obtained in any such transaction, or the method for obtaining such price or rate, will be the most favorable that could be obtained at that time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In case any one or more of the provisions contained in the Deposit Agreement or in the ADRs should be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein or therein shall in no way be affected, prejudiced or disturbed thereby.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Holders and Beneficial Owners as Parties&#59; Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Holders and Beneficial Owners from time to time of ADSs issued hereunder shall be parties to the Deposit Agreement and shall be bound by all of the terms and conditions hereof and of any ADR evidencing their ADSs by acceptance thereof or any beneficial interest therein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any and all notices to be given to the Company shall be deemed to have been duly given if personally delivered or sent by mail, air courier or cable, telex or facsimile transmission, confirmed by letter personally delivered or sent by mail or air courier, addressed to Molecular Partners AG, Wagistrasse 14, 8952 Schlieren, Switzerland, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Company Secretary, or to any other address which the Company may specify in writing to the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any and all notices to be given to the Depositary shall be deemed to have been duly given if personally delivered or sent by mail, air courier or cable, telex or facsimile transmission, confirmed by letter personally delivered or sent by mail or air courier, addressed to Citibank, N.A., 388 Greenwich Street, New York, New York 10013, U.S.A., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Depositary Receipts Department, or to any other address which the Depositary may specify in writing to the Company.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any and all notices to be given to any Holder shall be deemed to have been duly given (a) if personally delivered or sent by mail or cable, telex or facsimile transmission, confirmed by letter, addressed to such Holder at the address of such Holder as it appears on the books of the Depositary or, if such Holder shall have filed with the Depositary a request that notices intended for such Holder be mailed to some other address, at the address specified in such request, or (b) if a Holder shall have designated such means of notification as an acceptable means of notification under the terms of the Deposit Agreement, by means of electronic messaging addressed for delivery to the e-mail address designated by the Holder for such purpose. Notice to Holders shall be deemed to be notice to Beneficial Owners for all purposes of the Deposit Agreement. Failure to notify a Holder or any defect in the notification to a Holder shall not affect the sufficiency of notification to other Holders or to the Beneficial Owners of ADSs held by such other Holders. Any notices given to DTC under the terms of the Deposit Agreement shall (unless otherwise specified by the Depositary) constitute notice to the DTC Participants who hold the ADSs in their DTC accounts and to the Beneficial Owners of such ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delivery of a notice sent by mail, air courier or cable, telex or facsimile transmission shall be deemed to be effective at the time when a duly addressed letter containing the same (or a confirmation thereof in the case of a cable, telex or facsimile transmission) is deposited, postage prepaid, in a post-office letter box or delivered to an air courier service, without regard for the actual receipt or time of actual receipt thereof by a Holder. The Depositary or the Company may, however, act upon any cable, telex or facsimile transmission received by it from any Holder, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Custodian, the Depositary, or the Company, notwithstanding that such cable, telex or facsimile transmission shall not be subsequently confirmed by letter.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delivery of a notice by means of electronic messaging shall be deemed to be effective at the time of the initiation of the transmission by the sender (as shown on the sender&#8217;s records), notwithstanding that the intended recipient retrieves the message at a later date, fails to retrieve such message, or fails to receive such notice on account of its failure to maintain the designated e-mail address, its failure to designate a substitute e-mail address or for any other reason.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law and Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement, the ADRs and the ADSs shall be interpreted in accordance with, and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by, the laws of the State of New York applicable to contracts made and to be wholly performed in that State. Notwithstanding anything contained in the Deposit Agreement to the contrary, any ADR or any present or future provisions of the laws of the State of New York, the rights of holders of Shares and of any other Deposited Securities and the obligations and duties of the Company in respect of the holders of Shares and other Deposited Securities, as such, shall be governed by the laws of Switzerland (or, if applicable, such other laws as may govern the Deposited Securities).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as set forth in the following paragraph of this Section 7.6, the Company and the Depositary agree that the federal or state courts in the City of New York shall have jurisdiction to hear and determine any suit, action or proceeding and to settle any dispute between them that may arise out of or in connection with the Deposit Agreement and, for such purposes, each irrevocably submits to the non-exclusive jurisdiction of such courts. The Company hereby irrevocably designates, appoints and empowers Molecular Partners Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) now at 245 Main Street, Cambridge, Massachusetts 02142, United States of America as its authorized agent to receive and accept for and on its behalf, and on behalf of its properties, assets and revenues, service by mail of any and all legal process, summons, notices and documents that may be served in any suit, action or proceeding brought against the Company in any federal or state court as described in the preceding sentence or in the next paragraph of this Section 7.6. If for any reason the Agent shall cease to be available to act as such, the Company agrees to designate a new agent in New York on the terms and for the purposes of this Section 7.6 reasonably satisfactory to the Depositary. The Company further hereby irrevocably consents and agrees to the service of any and all legal process, summons, notices and documents in any suit, action or proceeding against the Company, by service by mail of a copy thereof upon the Agent (whether or not the appointment of such Agent shall for any reason prove to be ineffective or such Agent shall fail to accept or acknowledge such service), with a copy mailed to the Company by registered or certified air mail, postage prepaid, to its address provided in Section 7.5. The Company agrees that the failure of the Agent to give any notice of such service to it shall not impair or affect in any way the validity of such service or any judgment rendered in any action or proceeding based thereon.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Depositary and the Company unconditionally agree that in the event that any Holder or Beneficial Owner, or any third-party, brings a suit, action or proceeding against (a) the Company, (b) the Depositary in its capacity as Depositary under the Deposit Agreement or (c) against both the Company and the Depositary, in any such case, in any state or federal court of the United States, and the Depositary or the Company have any claim, for indemnification or otherwise, against each other arising out of the subject matter of such suit, action or proceeding, then the Company and the Depositary may pursue such claim against each other in the state or federal court in the United States in which such suit, action, or proceeding is pending and, for such purposes, the Company and the Depositary irrevocably submit to the non-exclusive jurisdiction of such courts. The Company agrees that service of process upon the Agent in the manner set forth in the preceding paragraph shall be effective service upon it for any suit, action or proceeding brought against it as described in this paragraph.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of venue of any actions, suits or proceedings brought in any court as provided in this Section 7.6, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, and agrees not to plead or claim, any right of immunity from legal action, suit or proceeding, from setoff or counterclaim, from the jurisdiction of any court, from service of process, from attachment upon or prior to judgment, from attachment in aid of execution or judgment, from execution of judgment, or from any other legal process or proceeding for the giving of any relief or for the enforcement of any judgment, and consents to such relief and enforcement against it, its assets and its revenues in any jurisdiction, in each case with respect to any matter arising out of, or in connection with, the Deposit Agreement, any ADR or the Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EACH OF THE PARTIES TO THE DEPOSIT AGREEMENT (INCLUDING, WITHOUT LIMITATION, EACH HOLDER AND BENEFICIAL OWNER) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING AGAINST THE COMPANY AND&#47;OR THE DEPOSITARY ARISING OUT OF, OR RELATING TO, THE DEPOSIT AGREEMENT, ANY ADR AND ANY TRANSACTIONS CONTEMPLATED THEREIN (WHETHER BASED ON CONTRACT, TORT, COMMON LAW OR OTHERWISE). </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of this Section 7.6 shall survive any termination of the Deposit Agreement, in whole or in part.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the provisions of Section 5.4, the Deposit Agreement may not be assigned by either the Company or the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with, and No Disclaimer under, U.S. Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything in the Deposit Agreement to the contrary, the withdrawal or delivery of Deposited Securities will not be suspended by the Company or the Depositary except as would be permitted by Instruction I.A.(1) of the General Instructions to Form F-6 Registration Statement, as amended from time to time, under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each of the parties to the Deposit Agreement (including, without limitation, each Holder and Beneficial Owner), acknowledges and agrees that no provision of the Deposit Agreement or any ADR shall, or shall be deemed to, disclaim any liability under the Securities Act or the Exchange Act, in each case to the extent established under applicable U.S. laws.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Switzerland Law References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any summary of the laws and regulations of Switzerland and of the terms of the Company&#8217;s Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation set forth in the Deposit Agreement have been provided by the Company solely for the convenience of Holders, Beneficial Owners and the Depositary. While such summaries are believed by the Company to be accurate as of the date of the Deposit Agreement, (i) they are summaries and as such may not include all aspects of the materials summarized applicable to a Holder or Beneficial Owner, and (ii) these laws and regulations and the Company&#8217;s Articles of Incorporation may change after the date of the Deposit Agreement. Neither the Depositary nor the Company has any obligation under the terms of the Deposit Agreement to update any such summaries.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Titles and References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> All references in the Deposit Agreement to exhibits, articles, sections, subsections, and other subdivisions refer to the exhibits, articles, sections, subsections and other subdivisions of the Deposit Agreement unless expressly provided otherwise. The words &#8220;the Deposit Agreement&#8221;, &#8220;herein&#8221;, &#8220;hereof&#8221;, &#8220;hereby&#8221;, &#8220;hereunder&#8221;, and words of similar import refer to the Deposit Agreement as a whole as in effect at the relevant time between the Company, the Depositary and the Holders and Beneficial Owners of ADSs and not to any particular subdivision unless expressly so limited. Pronouns in masculine, feminine and neuter gender shall be construed to include any other gender, and words in the singular form shall be construed to include the plural and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless the context otherwise requires. Titles to sections of the Deposit Agreement are included for convenience only and shall be disregarded in construing the language contained in the Deposit Agreement. References to &#8220;applicable laws and regulations&#8221; shall refer to laws and regulations applicable to ADRs, ADSs or Deposited Property as in effect at the relevant time of determination, unless otherwise required by law or regulation.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> All references in any ADR(s) to paragraphs, exhibits, articles, sections, subsections, and other subdivisions refer to the paragraphs, exhibits, articles, sections, subsections and other subdivisions of the ADR(s) in question unless expressly provided otherwise. The words &#8220;the Receipt&#8221;, &#8220;the ADR&#8221;, &#8220;herein&#8221;, &#8220;hereof&#8221;, &#8220;hereby&#8221;, &#8220;hereunder&#8221;, and words of similar import used in any ADR refer to the ADR as a whole and as in effect at the relevant time, and not to any particular subdivision unless expressly so limited. Pronouns in masculine, feminine and neuter gender in any ADR shall be construed to include any other gender, and words in the singular form shall be construed to include the plural and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless the context otherwise requires. Titles to paragraphs of any ADR are included for convenience only and shall be disregarded in construing the language contained in the ADR. References to &#8220;applicable laws and regulations&#8221; shall refer to laws and regulations applicable to </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, the Depositary, the Custodian, their agents and controlling persons, the ADRs, the ADSs and the Deposited Property as in effect at the relevant time of determination, unless otherwise required by law or regulation.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, MOLECULAR PARTNERS AG and CITIBANK, N.A. have duly executed the Deposit Agreement as of the day and year first above set forth and all Holders and Beneficial Owners shall become parties hereto upon acceptance by them of ADSs issued in accordance with the terms hereof, or upon acquisition of any beneficial interest therein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MOLECULAR PARTNERS AG</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A.</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;DEPOSIT AGREEMENT&#93;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><div id="if7724931561a4e79bc4853d8d987da59_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;FORM OF ADR&#93;</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUSIP NUMBER&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">American Depositary Shares (each American Depositary Share representing the right to receive one (1) fully paid common share)</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMERICAN DEPOSITARY RECEIPT</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMERICAN DEPOSITARY SHARES</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">representing</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEPOSITED COMMON SHARES</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Incorporated under the laws of Switzerland)</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A., a national banking association organized and existing under the laws of the United States of America, as depositary (the &#8220;Depositary&#8221;), hereby certifies that _____________is the owner of ______________ American Depositary Shares (hereinafter &#8220;ADS&#8221;) representing deposited common shares, including evidence of rights to receive such common shares (the &#8220;Shares&#8221;), of Molecular Partners AG, a corporation incorporated under the laws of Switzerland (the &#8220;Company&#8221;). As of the date of issuance of this ADR, each ADS represents the right to receive one Share deposited under the Deposit Agreement (as hereinafter defined) with the Custodian, which at the date of issuance of this ADR is Citibank N.A. London Branch (the &#8220;Custodian&#8221;). The ADS(s)-to-Share(s) ratio is subject to amendment as provided in Articles IV and VI of the Deposit Agreement. The Depositary&#8217;s Principal Office is located at 388 Greenwich Street, New York, New York 10013, U.S.A.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">The Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This American Depositary Receipt is one of an issue of American Depositary Receipts (&#8220;ADRs&#8221;), all issued and to be issued upon the terms and conditions set forth in the Deposit Agreement, dated as of ____________, 2021 (as amended and supplemented from time to time, the &#8220;Deposit Agreement&#8221;), by and among the Company, the Depositary, and all Holders and Beneficial Owners from time to time of ADSs issued thereunder. The Deposit Agreement sets forth the rights and obligations of Holders and Beneficial Owners of ADSs and the rights and duties of the Depositary in respect of the Shares deposited thereunder and any and all other Deposited Property (as defined in the Deposit Agreement) from time to time received and held on deposit in respect of the ADSs. Copies of the Deposit Agreement are on file at the Principal Office of the Depositary and with the Custodian. Each Holder and each Beneficial Owner, upon acceptance of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the Deposit Agreement, shall be deemed for all purposes to (a) be a party to and bound by the terms of the Deposit Agreement and the applicable ADR(s), and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) appoint the Depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the Deposit Agreement and the applicable ADR(s), to adopt any and all procedures necessary to comply with applicable law and to take such action as the Depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the Deposit Agreement and the applicable ADR(s), the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof. The manner in which a Beneficial Owner holds ADSs (e.g., in a brokerage account vs. as registered holder) may affect the rights and obligations of, the manner in which, and the extent to which, services are made available to, Beneficial Owners pursuant to the terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The statements made on the face and reverse of this ADR are summaries of certain provisions of the Deposit Agreement and the Articles of Incorporation (as in effect on the date of the signing of the Deposit Agreement) and are qualified by and subject to the detailed provisions of the Deposit Agreement and the Articles of Incorporation, to which reference is hereby made. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms not defined herein shall have the meanings ascribed thereto in the Deposit Agreement. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary makes no representation or warranty as to the validity or worth of the Deposited Property. The Depositary has made arrangements for the acceptance of the ADSs into DTC. Each Beneficial Owner of ADSs held through DTC must rely on the procedures of DTC and the DTC Participants to exercise and be entitled to any rights attributable to such ADSs. The Depositary may issue Uncertificated ADSs subject, however, to the terms and conditions of Section 2.13 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Surrender of ADSs and Withdrawal of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Holder of this ADR (and of the ADSs evidenced hereby) shall be entitled to Delivery (at the Custodian&#8217;s designated office) of the Deposited Securities at the time represented by the ADSs evidenced hereby upon satisfaction of each of the following conditions&#58; (i) the Holder (or a duly-authorized attorney of the Holder) has duly Delivered ADSs to the Depositary at its Principal Office the ADSs evidenced hereby (and, if applicable, this ADR evidencing such ADSs) for the purpose of withdrawal of the Deposited Securities represented thereby, (ii) if applicable and so required by the Depositary, this ADR Delivered to the Depositary for such purpose has been properly endorsed in blank or is accompanied by proper instruments of transfer in blank (including signature guarantees in accordance with standard securities industry practice), (iii) if so required by the Depositary, the Holder of the ADSs has executed and delivered to the Depositary a written order directing the Depositary to cause the Deposited Securities being withdrawn to be Delivered to or upon the written order of the person(s) designated in such order, and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement) have been paid,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of this ADR evidencing the surrendered ADSs, of the Deposit Agreement, of the Company&#8217;s Articles of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and of any applicable laws and the rules of the applicable book-entry settlement entity, and to any provisions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon satisfaction of each of the conditions specified above, the Depositary (i) shall cancel the ADSs Delivered to it (and, if applicable, this ADR(s) evidencing the ADSs so Delivered), (ii) shall direct the Registrar to record the cancellation of the ADSs so Delivered on the books maintained for such purpose, and (iii) shall direct the Custodian to Deliver, or cause the Delivery of, in each case, without unreasonable delay, the Deposited Securities represented by the ADSs so canceled together with any certificate or other document of title for the Deposited Securities, or evidence of the electronic transfer thereof (if available), as the case may be, to or upon the written order of the person(s) designated in the order delivered to the Depositary for such purpose, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit Agreement, of this ADR evidencing the ADS so canceled, of the Articles of Incorporation of the Company, of any applicable laws and of the rules of the applicable book-entry settlement entity, and to the terms and conditions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not accept for surrender ADSs representing less than one (1) Share. In the case of Delivery to it of ADSs representing a number other than a whole number of Shares, the Depositary shall cause ownership of the appropriate whole number of Shares to be Delivered in accordance with the terms hereof, and shall, at the discretion of the Depositary, either (i) return to the person surrendering such ADSs the number of ADSs representing any remaining fractional Share, or (ii) sell or cause to be sold the fractional Share represented by the ADSs so surrendered and remit the proceeds of such sale (net of (a) applicable fees and charges of, and expenses incurred by, the Depositary and (b) taxes withheld) to the person surrendering the ADSs. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in this ADR or the Deposit Agreement, the Depositary may make delivery at the Principal Office of the Depositary of Deposited Property consisting of (i) any cash dividends or cash distributions, or (ii) any proceeds from the sale of any non-cash distributions, which are at the time held by the Depositary in respect of the Deposited Securities represented by the ADSs surrendered for cancellation and withdrawal. At the request, risk and expense of any Holder so surrendering ADSs represented by this ADR, and for the account of such Holder, the Depositary shall direct the Custodian to forward (to the extent permitted by law) any Deposited Property (other than Deposited Securities) held by the Custodian in respect of such ADSs to the Depositary for delivery at the Principal Office of the Depositary. Such direction shall be given by letter or, at the request, risk and expense of such Holder, by cable, telex or facsimile transmission.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer, Combination and Split-up of ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Registrar shall register the transfer of this ADR (and of the ADSs represented hereby) on the books maintained for such purpose and the Depositary shall (x) cancel this ADR and execute new ADRs evidencing the same aggregate number of ADSs as those evidenced by this ADR canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs, and (z) Deliver such new ADRs to or upon the order of the person entitled thereto, if each of the following conditions has been satisfied&#58; (i) this ADR has been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a transfer thereof, (ii) this surrendered ADR has been properly endorsed or is accompanied by proper instruments of transfer (including signature guarantees in accordance with standard securities industry practice), (iii) this surrendered ADR has been duly stamped (if required by the laws of the State of New York or of the United States), and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the terms and conditions of this ADR, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall register the split-up or combination of this ADR (and of the ADSs represented hereby) on the books maintained for such purpose and the Depositary shall (x) cancel this ADR and execute new ADRs for the number of ADSs requested, but in the aggregate not exceeding the number of ADSs evidenced by this ADR canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs, and (z) Deliver such new ADRs to or upon the order of the Holder thereof, if each of the following conditions has been satisfied&#58; (i) this ADR has been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a split-up or combination hereof, and (ii) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions of this ADR, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Pre-Conditions to Registration, Transfer, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As a condition precedent to the execution and Delivery, the registration of issuance, transfer, split-up, combination or surrender, of any ADS, the delivery of any distribution thereon, or the withdrawal of any Deposited Property, the Depositary or the Custodian may require (i) payment from the depositor of Shares or presenter of ADSs or of this ADR of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees and charges of the Depositary as provided in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement and in this ADR, (ii) the production of proof satisfactory to it as to the identity and genuineness of any signature or any other matter contemplated by Section 3.1 of the Deposit Agreement, and (iii) compliance with (A) any laws or governmental regulations relating to the execution and Delivery of this ADR or ADSs or to the withdrawal of Deposited Securities and (B) such reasonable regulations as the Depositary and the Company may establish consistent with the provisions of this ADR, if applicable, the Deposit Agreement and applicable law.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The issuance of ADSs against deposits of Shares generally or against deposits of particular Shares may be suspended, or the deposit of particular Shares may be refused, or the registration of transfer of ADSs in particular instances may be refused, or the registration of transfer of ADSs generally may be suspended, during any period when the transfer books of the Company, the Depositary, a Registrar or the Share Registrar are closed or if any such action is deemed necessary or advisable by the Depositary or the Company, in good faith, at any time or from time to time because of any requirement of law or regulation, any government or governmental body or commission or any securities exchange on which the ADSs or Shares are listed, or under any provision of the Deposit Agreement or this ADR, if applicable, or under any provision of, or governing, the Deposited Securities, or because of a meeting of shareholders of the Company or for any other reason, subject, in all cases to Section 7.8(a) of the Deposit Agreement and paragraph (25) of this ADR. Notwithstanding any provision of the Deposit Agreement or this ADR to the contrary, Holders are entitled to surrender outstanding ADSs to withdraw the Deposited Securities associated therewith at any time subject only to (i) temporary delays caused by closing the transfer books of the Depositary or the Company or the deposit of Shares in connection with voting at a shareholders&#8217; meeting or the payment of dividends, (ii) the payment of fees, taxes and similar charges, (iii) compliance with any U.S. or foreign laws or governmental regulations relating to the ADSs or to the withdrawal of the Deposited Securities, and (iv) other circumstances specifically contemplated by Instruction I.A.(1) of the General Instructions to Form F-6 (as such General Instructions may be amended from time to time).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Information Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provision included or incorporated by reference in the Deposit Agreement or this ADR to any other effect, each Holder and Beneficial Owner of the ADSs represented hereby agrees to comply with requests from the Company pursuant to applicable law, the rules and requirements of any stock exchange on which the Shares or ADSs are, or will be, registered, traded or listed, or the Articles of Incorporation of the Company, which are made to provide information, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as to the capacity in which such Holder or Beneficial Owner owns ADSs (and the Shares represented by such ADSs, as the case may be) and regarding the identity of any other person(s) interested in such ADSs (and the Shares represented by such ADSs, as the case may be) and the nature of such interest and various other matters, whether or not they are Holders and&#47;or Beneficial Owners at the time of such request. The Depositary agrees to use its reasonable efforts to forward, upon the request of the Company and at the Company&#8217;s expense, any such request from the Company to the Holders and to forward to the Company any such responses to such requests received by the Depositary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(6) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision included or incorporated by reference in this ADR or of the Deposit Agreement to any other effect, the Company may restrict transfers of the Shares where such transfer might result in ownership of Shares exceeding limits imposed by applicable law or the Articles of Incorporation of the Company. The Company may also restrict, in such manner as it deems appropriate, transfers of the ADSs where such transfer may result in the total number of Shares represented by the ADSs owned by a single Holder or Beneficial Owner to exceed any such limits. The Company may, in its sole discretion but subject to applicable law, instruct the Depositary to take action with respect to the ownership interest of any Holder or Beneficial Owner in excess of the limits set forth in the preceding sentence, including but not limited to, the imposition of restrictions on the transfer of ADSs, the removal or limitation of voting rights or mandatory sale or disposition on behalf of a Holder or Beneficial Owner of the Shares represented by the ADSs held by such Holder or Beneficial Owner in excess of such limitations, if and to the extent such disposition is permitted by applicable law and the Articles of Incorporation of the Company. Nothing herein or in the Deposit Agreement shall be interpreted as obligating the Depositary or the Company to ensure compliance with the ownership restrictions described herein or in Section 3.5 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(7) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reporting Obligations and Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Applicable laws and regulations may require holders and beneficial owners of Shares, including the Holders and Beneficial Owners of ADSs, to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. Holders and Beneficial Owners of ADSs are solely responsible for determining and complying with such reporting requirements and obtaining such approvals. Each Holder and each Beneficial Owner hereby agrees to make such determination, file such reports, and obtain such approvals to the extent and in the form required by applicable laws and regulations as in effect from time to time. Neither the Depositary, the Custodian, the Company or any of their respective agents or affiliates shall be required to take any actions whatsoever on behalf of Holders or Beneficial Owners to determine or satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(8) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Liability for Taxes and Other Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any tax or other governmental charge payable by the Custodian or by the Depositary with respect to any Deposited Property, ADSs or this ADR shall be payable by the Holders and Beneficial Owners to the Depositary. The Company, the Custodian and&#47;or the Depositary may withhold or deduct from any distributions made in respect of Deposited Property held on behalf of such Holder and&#47;or Beneficial Owner, and may sell for the account of a Holder and&#47;or Beneficial Owner any or all of such Deposited Property and apply such distributions and sale proceeds in payment of, any taxes (including applicable interest and penalties) or charges that are or may be payable by Holders or Beneficial Owners in respect of the ADSs, Deposited Property and this ADR, the Holder and the Beneficial Owner hereof remaining liable for any deficiency. The Custodian may refuse the deposit of Shares and the Depositary may refuse to issue ADSs, to deliver ADRs, register the transfer of ADSs, register the split-up or combination of ADRs and (subject to paragraph (25) of this ADR and Section 7.8(a) of the Deposit Agreement) the withdrawal of Deposited Property until payment in full of such tax, charge, penalty or interest is received. Every Holder and Beneficial Owner agrees to indemnify the Depositary, the Company, the Custodian, and any of their agents, officers, employees and Affiliates for, and to hold each of them harmless from, any claims with respect to taxes (including applicable interest and penalties thereon) arising from (i) any ADSs held by such Holder and&#47;or owned by such Beneficial Owner, (ii) the Deposited Property represented by the ADSs, and (iii) any transaction entered into by such Holder and&#47;or Beneficial Owner in respect of the ADSs and&#47;or the Deposited Property represented thereby. Notwithstanding anything to the contrary contained in the Deposit Agreement or any ADR, the obligations of Holders and Beneficial Owners under Section 3.2 of the Deposit Agreement shall survive any transfer of ADSs, any cancellation of ADSs and withdrawal of Deposited Securities, and the termination of the Deposit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(9) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Representations and Warranties on Deposit of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each person depositing Shares under the Deposit Agreement shall be deemed thereby to represent and warrant that (i) such Shares and the certificates therefor are duly authorized, validly issued, fully paid, non-assessable and legally obtained by such person, (ii) all preemptive (and similar) rights, if any, with respect to such Shares have been validly waived or exercised, (iii) the person making such deposit is duly authorized so to do, (iv) the Shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, (v) the Shares presented for deposit are not, and the ADSs issuable upon such deposit will not be, Restricted Securities (except as contemplated in Section 2.14 of the Deposit Agreement), (vi) the Shares presented for deposit have not been stripped of any rights or entitlements, and (vii) the deposit of the Shares does not violate any applicable provisions of the laws of Switzerland. Such representations and warranties shall survive the deposit and withdrawal of Shares, the issuance and cancellation of ADSs in respect thereof and the transfer of such ADSs. If any such representations or warranties are false in any way, the Company and the Depositary shall be authorized, at the cost and expense of the person depositing Shares, to take any and all actions necessary to correct the consequences thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(10) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Proofs, Certificates and Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any person presenting Shares for deposit, any Holder and any Beneficial Owner may be required, and every Holder and Beneficial Owner agrees, from time to time to provide to the Depositary and the Custodian such proof of citizenship or residence, taxpayer status, payment of all applicable taxes or other governmental charges, exchange control approval, legal or beneficial ownership of ADSs and Deposited Property, compliance with applicable laws, the terms of the Deposit Agreement or this ADR evidencing the ADSs and the provisions of, or governing, the Deposited Property, to execute such certifications and to make such representations and warranties, and to provide such other information and documentation (or, in the case of Shares in registered form presented for deposit, such information relating to the registration on the books of the Company or of the Share Registrar) as the Depositary or the Custodian may deem necessary or proper or as the Company may reasonably require by written request to the Depositary consistent with its obligations under the Deposit Agreement and this ADR. The Depositary and the Registrar, as applicable, may withhold the execution or delivery or registration of transfer of any ADR or ADS or the distribution or sale of any dividend or distribution of rights or of the proceeds thereof or, to the extent not limited by paragraph (25) and Section 7.8(a) of the Deposit Agreement, the delivery of any Deposited Property until such proof or other information is filed or such certifications are executed, or such representations and warranties are made or such other documentation or information provided, in each case to the Depositary&#8217;s, the Registrar&#8217;s and the Company&#8217;s satisfaction. The Depositary shall provide the Company, in a timely manner, with copies or originals if necessary and appropriate of (i) any such proofs of citizenship or residence, taxpayer status, or exchange control approval or copies of written representations and warranties which it receives from Holders and Beneficial Owners, and (ii) any other information or documents which the Company may reasonably request and which the Depositary shall request and receive from any Holder or Beneficial Owner or any person presenting Shares for deposit or ADSs for cancellation, transfer or withdrawal. Nothing herein shall obligate the Depositary to (i) obtain any information for the Company if not provided by the Holders or Beneficial Owners, or (ii) verify or vouch for the accuracy of the information so provided by the Holders or Beneficial Owners.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(11) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Fees and Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following ADS fees are payable under the terms of the Deposit Agreement&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Issuance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any person for whom ADSs are issued (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an issuance upon a deposit of Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (iv) below, a fee not in excess of U.S. $5.00 per </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100 ADSs (or fraction thereof) issued under the terms of the Deposit Agreement&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Cancellation Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any person for whom ADSs are being cancelled (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a cancellation of ADSs for Delivery of deposited Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Distribution Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADSs, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held for the distribution of cash dividends or other cash distributions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon a sale of rights and other entitlements)&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Distribution &#47;Rights Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held for the distribution of ADSs pursuant to (a) stock dividends or other free stock distributions, or (b) an exercise of rights to purchase additional ADSs&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Distribution Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held for the distribution of </font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">securities other than ADSs or rights to purchase additional ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, spin-off shares)&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Services Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the Depositary&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Registration of ADS Transfer Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s) being transferred or by any person to whom ADSs are transferred, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) transferred (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or for any other reason)&#59; and </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Conversion Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s) being converted or by any person to whom the converted ADSs are delivered, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) converted from one ADS series to another ADS series (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferrable ADSs, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, Holders, Beneficial Owners, persons depositing Shares or withdrawing Deposited Securities in connection with ADS issuances and cancellations, and persons for whom ADSs are issued or cancelled shall be responsible for the following ADS charges under the terms of the Deposit Agreement&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) such registration fees as may from time to time be in effect for the registration of Shares or other Deposited Securities on the share register and applicable to transfers of Shares or other Deposited Securities to or from the name of the Custodian, the Depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the Deposit Agreement to be at the expense of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">person depositing Shares or withdrawing Deposited Property or of the Holders and Beneficial Owners of ADSs&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) in connection with the conversion of Foreign Currency, the fees, expenses, spreads, taxes and other charges of the Depositary and&#47;or conversion service providers (which may be a division, branch or Affiliate of the Depositary). Such fees, expenses, spreads, taxes and other charges shall be deducted from the Foreign Currency&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) any reasonable and customary out-of-pocket expenses incurred in such conversion and&#47;or on behalf of the Holders and Beneficial Owners in complying with currency exchange control or other governmental requirements&#59; and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) the fees, charges, costs and expenses incurred by the Depositary, the Custodian, or any nominee in connection with the ADR program.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All ADS fees and charges so payable maybe deducted from distributions or must be remitted to the Depositary, or its designee, and may, at any time and from time to time, be changed by agreement between the Depositary and Company but, in the case of ADS fees and charges payable by Holders and Beneficial Owners, only in the manner contemplated by paragraph (23) of this ADR and as contemplated in Section 6.1 of the Deposit Agreement. The Depositary shall provide, without charge, a copy of its latest ADS fee schedule to anyone upon request. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS fees and charges for (i) the issuance of ADSs and (ii) the cancellation of ADSs will be payable by the person for whom the ADSs are so issued by the Depositary (in the case of ADS issuances) and by the person for whom ADSs are being cancelled (in the case of ADS cancellations). In the case of ADSs issued by the Depositary into DTC or presented to the Depositary via DTC, the ADS issuance and cancellation fees and charges will be payable by the DTC Participant(s) receiving the ADSs from the Depositary or the DTC Participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the Beneficial Owner(s) and will be charged by the DTC Participant(s) to the account(s) of the applicable Beneficial Owner(s) in accordance with the procedures and practices of the DTC Participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are payable by Holders as of the applicable ADS Record Date established by the Depositary. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, the applicable Holders as of the ADS Record Date established by the Depositary will be invoiced for the amount of the ADS fees and charges and such ADS fees may be deducted from distributions made to Holders. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC Participants in accordance with the procedures and practices prescribed by DTC from time to time and the DTC Participants in turn charge the amount of such ADS fees and charges to the Beneficial Owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may reimburse the Company for certain expenses incurred by the Company in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Company and the Depositary agree from time to time. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company shall pay to the Depositary such fees and charges, and reimburse the Depositary for such out-of-pocket expenses, as the Depositary and the Company may agree from time to time. Responsibility for payment of such fees, charges and reimbursements may from time to time be changed by agreement between the Company and the Depositary. Unless otherwise agreed, the Depositary shall present its statement for such fees, charges and reimbursements to the Company once every three months. The charges and expenses of the Custodian are for the sole account of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of Holders and Beneficial Owners to pay ADS fees and charges shall survive the termination of the Deposit Agreement. As to any Depositary, upon the resignation or removal of such Depositary as described in Section 5.4 of the Deposit Agreement, the right to collect ADS fees and charges shall extend for those ADS fees and charges incurred prior to the effectiveness of such resignation or removal.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(12) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Title to ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the limitations contained in the Deposit Agreement and in this ADR, it is a condition of this ADR, and every successive Holder of this ADR by accepting or holding the same consents and agrees, that title to this ADR (and to each Certificated ADS evidenced hereby) shall be transferable upon the same terms as a certificated security under the laws of the State of New York, provided that, in the case of Certificated ADSs, this ADR has been properly endorsed or is accompanied by proper instruments of transfer. Notwithstanding any notice to the contrary, the Depositary and the Company may deem and treat the Holder of this ADR (that is, the person in whose name this ADR is registered on the books of the Depositary) as the absolute owner thereof for all purposes. Neither the Depositary nor the Company shall have any obligation nor be subject to any liability under the Deposit Agreement or this ADR to any holder of this ADR or any Beneficial Owner unless, in the case of a holder of ADSs, such holder is the Holder of this ADR registered on the books of the Depositary or, in the case of a Beneficial Owner, such Beneficial Owner, or the Beneficial Owner&#8217;s representative, is the Holder registered on the books of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(13) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Validity of ADR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Holder(s) of this ADR (and the ADSs represented hereby) shall not be entitled to any benefits under the Deposit Agreement or be valid or enforceable for any purpose against the Depositary or the Company unless this ADR has been (i) dated, (ii) signed by the manual or facsimile signature of a duly-authorized signatory of the Depositary, (iii) countersigned by the manual or facsimile signature of a duly-authorized signatory of the Registrar, and (iv) registered in the books maintained by the Registrar for the registration of issuances and transfers of ADRs. An ADR bearing the facsimile signature of a duly-authorized signatory of the Depositary or the Registrar, who at the time of signature was a duly authorized signatory of the Depositary or the Registrar, as the case may be, shall bind the Depositary, notwithstanding the fact that such signatory has ceased to be so authorized prior to the delivery of such ADR by the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(14) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Available Information&#59; Reports&#59; Inspection of Transfer Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company is subject to the periodic reporting requirements of the Exchange Act and, accordingly, is required to file or furnish certain reports with the Commission. These reports can be retrieved from the Commission's website (</font><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and can be inspected and copied at the public reference facilities maintained by the Commission located (as of the date of the Deposit Agreement) at 100 F Street, N.E., Washington D.C. 20549. The Depositary shall make available for inspection by Holders at its Principal Office any reports and communications, including any proxy soliciting materials, received from the Company which are both (a) received by the Depositary, the Custodian, or the nominee of either of them as the holder of the Deposited Property and (b) made generally available to the holders of such Deposited Property by the Company. The Depositary shall also provide or make available to the Holders copies of such reports when furnished by the Company pursuant to Section 5.6 of the Deposit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall keep books for the registration of ADSs which at all reasonable times shall be open for inspection by the Company and by the Holders of such ADSs, provided that such inspection shall not be, to the Registrar&#8217;s knowledge, for the purpose of communicating with Holders of such ADSs in the interest of a business or object other than the business of the Company or other than a matter related to the Deposit Agreement or the ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar may close the transfer books with respect to the ADSs, at any time or from time to time, when deemed necessary or advisable by it in good faith in connection with the performance of its duties hereunder, or at the reasonable written request of the Company subject, in all cases, to paragraph (25) and Section 7.8(a) of the Deposit Agreement.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A.<br>Transfer Agent and Registrar</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A.<br>as Depositary</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized Signatory</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized Signatory</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The address of the Principal Office of the Depositary is 388 Greenwich Street, New</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">York, New York 10013, U.S.A.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;FORM OF REVERSE OF ADR&#93;</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SUMMARY OF CERTAIN ADDITIONAL PROVISIONS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OF THE DEPOSIT AGREEMENT</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(15) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dividends and Distributions in Cash, Shares, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cash Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt by the Depositary of a notice from the Company that it intends to make a distribution of a cash dividend or other cash distribution, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9 of the Deposit Agreement. Upon confirmation of the receipt of (x) any cash dividend or other cash distribution in respect of any Deposited Property (whether from the Company or otherwise), or (y) proceeds from the sale of any Deposited Property held in respect of the ADSs under the terms of the Deposit Agreement, the Depositary will (i) if any amounts are received in a Foreign Currency, promptly convert or cause to be converted such cash dividend, distribution or proceeds into Dollars (subject to the terms and conditions of Section 4.8 of the Deposit Agreement), (ii) if applicable and unless previously established, establish the ADS Record Date upon the terms described in Section 4.9 of the Deposit Agreement, and (iii) distribute promptly the amount thus received (net of (a) the applicable fees and charges set forth in the Fee Schedule attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Deposit Agreement and (b) applicable taxes withheld) to the Holders entitled thereto as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date. The Depositary shall distribute only such amount, however, as can be distributed without attributing to any Holder a fraction of one cent, and any balance not so distributed shall be held by the Depositary (without liability for interest thereon) and shall be added to and become part of the next sum received by the Depositary for distribution to Holders of ADSs outstanding at the time of the next distribution. If the Company, the Custodian or the Depositary is required to withhold and does withhold from any cash dividend or other cash distribution in respect of any Deposited Securities, or from any cash proceeds from the sales of Deposited Property, an amount on account of taxes, duties or other governmental charges, the amount distributed to Holders on the ADSs shall be reduced accordingly. Such withheld amounts shall be forwarded by the Company, the Custodian or the Depositary to the relevant governmental authority. Evidence of payment thereof by the Company shall be forwarded by the Company to the Depositary upon request. The Depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable Holders and Beneficial Owners of ADSs until the distribution can be effected or the funds that the Depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in Section 4.1 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.1 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.1 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Share Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt by the Depositary of a notice from the Company that it intends to make a distribution that consists of a dividend in, or free distribution of Shares, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9 of the Deposit Agreement. Upon receipt of confirmation from the Custodian of the receipt of the Shares so distributed by the Company, the Depositary shall either (i) subject to Section 5.9 of the Deposit Agreement, distribute to the Holders as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date, additional ADSs, which represent in the aggregate the number of Shares received as such dividend, or free distribution, subject to the other terms of the Deposit Agreement (including, without limitation, (a) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes), or (ii) if additional ADSs are not so distributed, take all actions necessary so that each ADS issued and outstanding after the ADS Record Date shall, to the extent permissible by law, thenceforth also represent rights and interests in the additional integral number of Shares distributed upon the Deposited Securities represented thereby (net of (a) the applicable fees and charges of, and expenses incurred by, the Depositary, and (b) applicable taxes). In lieu of delivering fractional ADSs, the Depositary shall sell the number of Shares or ADSs, as the case may be, represented by the aggregate of such fractions and distribute the net proceeds upon the terms described in Section 4.1 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Depositary determines that any distribution in property (including Shares) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, or, if the Company in the fulfillment of its obligations under Section 5.7 of the Deposit Agreement, has furnished an opinion of U.S. counsel determining that Shares must be registered under the Securities Act or other laws in order to be distributed to Holders (and no such registration statement has been declared effective), the Depositary may dispose of all or a portion of such property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable, and the Depositary shall distribute the net proceeds of any such sale (after deduction of (a) applicable taxes and (b) fees and charges of, and the expenses incurred by, the Depositary) to Holders entitled thereto upon the terms of Section 4.1 of the Deposit Agreement. The Depositary shall hold and&#47;or distribute any unsold balance of such property in accordance with the provisions of the Deposit Agreement. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in Section 4.2 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.2 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.2 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Elective Distributions in Cash or Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt of a notice indicating that the Company wishes an elective distribution to be made available to Holders of ADSs, the Depositary shall consult with the Company to determine, and the Company shall assist the Depositary in its determination, whether it is lawful and reasonably practicable to make such elective distribution available to Holders of ADSs. The Depositary shall make such elective distribution available to Holders only if (i) the Company shall have timely requested that the elective distribution be made available to Holders, (ii) the Depositary shall have determined that such distribution is reasonably practicable and (iii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7 of the Deposit Agreement. If the above conditions are satisfied, the Depositary shall, subject to the terms and conditions of the Deposit Agreement, establish the ADS Record Date on the terms described in paragraph (17) and Section 4.9 of the Deposit Agreement and establish procedures to enable the Holder hereof to elect to the receipt of the proposed distribution in cash or in additional ADSs. The Company shall assist the Depositary in establishing such procedures to the extent necessary. If a Holder elects to receive the distribution in cash, the distribution shall be made as in the case of a distribution in cash. If the Holder hereof elects to receive the distribution in additional ADSs, the distribution shall be made as in the case of a distribution in Shares upon the terms described in the Deposit Agreement. If such elective distribution is not reasonably practicable or if the Depositary did not receive satisfactory documentation set forth in the Deposit Agreement, the Depositary shall establish an ADS Record Date upon the terms of Section 4.9 of the Deposit Agreement and, to the extent permitted by law, distribute to Holders, on the basis of the same determination as is made in Switzerland in respect of the Shares for which no election is made, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either (x) in cash, upon the terms described in Section 4.1 of the Deposit Agreement or (y) additional ADSs representing such additional Shares, in each case, upon the terms described in Section 4.2 of the Deposit Agreement. Nothing herein or in the Deposit Agreement shall obligate the Depositary to make available to the Holder hereof a method to receive the elective distribution in Shares (rather than ADSs). There can be no assurance that the Holder hereof, or any Holders generally, will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of Shares. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in Section 4.3 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.3 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.3 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Distribution of Rights to Purchase Additional ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt by the Depositary of a notice indicating that the Company wishes rights to subscribe for additional Shares to be made available to Holders of ADSs, the Depositary upon consultation with the Company, shall determine, whether it is lawful and reasonably practicable to make such rights available to the Holders. The Depositary shall make such rights available to any Holders only if (i) the Company shall have timely requested that such rights be made available to Holders, (ii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7 of the Deposit Agreement, and (iii) the Depositary shall have determined that such distribution of rights is reasonably practicable. If such conditions are not satisfied or if the Company requests that the rights not be made available to Holders of ADSs, the Depositary shall proceed with the sale of rights as described in Section 4.4(b) of the Deposit Agreement. In the event all conditions set forth above are satisfied, the Depositary shall establish the ADS Record Date (upon the terms described in Section 4.9 of the Deposit Agreement) and establish procedures to (x) distribute rights to purchase additional ADSs (by means of warrants or otherwise), (y) enable the Holders to exercise such rights (upon payment of the subscription price and of the applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes), and (z) deliver ADSs upon the valid exercise of such rights. The Company shall assist the Depositary to the extent necessary in establishing such procedures. Nothing herein or in the Deposit Agreement shall obligate the Depositary to make available to the Holders a method to exercise rights to subscribe for Shares (rather than ADSs). If (i) the Company does not timely request the Depositary to make the rights available to Holders or requests that the rights not be made available to Holders, (ii) the Depositary fails to receive satisfactory documentation within the terms of Section 5.7 of the Deposit Agreement or determines it is not reasonably practicable to make the rights available to Holders, or (iii) any rights made available are not exercised and appear to be about to lapse, the Depositary shall determine whether it is lawful and reasonably practicable to sell such rights, in a riskless principal capacity, at such place and upon such terms (including public and private sale) as it may deem practicable. The Depositary shall, upon such sale, convert and distribute proceeds of such sale (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) upon the terms hereof and of Section 4.1 of the Deposit Agreement. If the Depositary is unable to make any rights available to Holders upon the terms described in Section 4.4(a) of the Deposit Agreement or to arrange for the sale of the rights upon the terms described in Section 4.4(b) of the Deposit Agreement, the Depositary shall allow such rights to lapse. The Depositary shall not be liable for (i) any failure to accurately determine whether it may be lawful or practicable to make such rights available to Holders in general or any Holders in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale, or exercise, or (iii) the content of any materials forwarded to the Holders on behalf of the Company in connection with the rights distribution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein or in Section 4.4 of the Deposit Agreement to the contrary, if registration (under the Securities Act or any other applicable law) of the rights or the securities to which any rights relate may be required in order for the Company to offer such rights or such securities to Holders and to sell the securities represented by such rights, the Depositary will not distribute such rights to the Holders (i) unless and until a registration statement under the Securities Act (or other applicable law) covering such offering is in effect or (ii) unless the Company furnishes the Depositary opinion(s) of counsel for the Company in the United States and counsel to the Company in any other applicable country in which rights would be distributed, in each case reasonably satisfactory to the Depositary, to the effect that the offering and sale of such securities to Holders and Beneficial Owners are exempt from, or do not require registration under, the provisions of the Securities Act or any other applicable laws. In the event that the Company, the Depositary or the Custodian shall be required to withhold and does withhold from any distribution of Deposited Property (including rights) an amount on account of taxes or other governmental charges, the amount distributed to the Holders of ADSs shall be reduced accordingly. In the event that the Depositary determines that any distribution of Deposited Property (including Shares and rights to subscribe therefor) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, the Depositary may dispose of all or a portion of such Deposited Property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable to pay any such taxes or charges.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive or exercise rights on the same terms and conditions as the holders of Shares or be able to exercise such rights. Nothing herein or in the Deposit Agreement shall obligate the Company to file any registration statement in respect of any rights or Shares or other securities to be acquired upon the exercise of such rights.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Distributions other than Cash, Shares or Rights to Purchase Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon receipt of a notice indicating that the Company wishes property other than cash, Shares or rights to purchase additional Shares to be made to Holders of ADSs, the Depositary shall determine whether such distribution to Holders is lawful and reasonably practicable. The Depositary shall not make such distribution unless (i) the Company shall have requested the Depositary to make such distribution to Holders, (ii) the Depositary shall have received satisfactory documentation contemplated in Section 5.7 of the Deposit Agreement, and (iii) the Depositary shall have determined that such distribution is reasonably practicable. Upon satisfaction of such conditions, the Depositary shall distribute the property so received to the Holders of record, as of the ADS Record Date, in proportion to the number of ADSs held by them respectively and in such manner as the Depositary may deem practicable for accomplishing such distribution (i) upon receipt of payment or net of the applicable fees and charges of, and expenses incurred by, the Depositary, and (ii) net of any applicable taxes withheld. The Depositary may dispose of all or a portion of the property so distributed and deposited, in such amounts and in such manner (including public or private sale) as the Depositary may deem practicable or necessary to satisfy any taxes (including applicable interest and penalties) or other governmental charges applicable to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the conditions above are not satisfied, the Depositary shall sell or cause such property to be sold in a public or private sale, at such place or places and upon such terms as it may deem practicable and shall (i) cause the proceeds of such sale, if any, to be converted into Dollars and (ii) distribute the proceeds of such conversion received by the Depositary (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) to the Holders as of the ADS Record Date upon the terms hereof and of Section 4.1 of the Deposit Agreement. If the Depositary is unable to sell such property, the Depositary may dispose of such property for the account of the Holders in any way it deems reasonably practicable under the circumstances.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Depositary nor the Company shall be responsible for (i) any failure to determine whether it is lawful or practicable to make the property described in Section 4.5 of the Deposit Agreement available to Holders in general or any Holders in particular, nor (ii) any loss incurred in connection with the sale or disposal of such property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(16) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon timely receipt of notice from the Company that it intends to exercise its right of redemption in respect of any of the Deposited Securities, and satisfactory documentation, and only if the Depositary shall have determined that such proposed redemption is practicable, the Depositary shall provide to each Holder a notice setting forth the Company&#8217;s intention to exercise the redemption rights and any other particulars set forth in the Company&#8217;s notice to the Depositary. The Depositary shall instruct the Custodian to present to the Company the Deposited Securities in respect of which redemption rights are being exercised against payment of the applicable redemption price. Upon receipt of confirmation from the Custodian that the redemption has taken place and that funds representing the redemption price have been received, the Depositary shall convert, transfer, and distribute the proceeds (net of applicable (a) fees and charges of, and the expenses incurred by, the Depositary, and (b) taxes), retire ADSs and cancel ADRs, if applicable, upon delivery of such ADSs by Holders thereof and the terms set forth in Sections 4.1 and 6.2 of the Deposit Agreement. If less than all outstanding Deposited Securities are redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as may be determined by the Depositary. The redemption price per ADS shall be the dollar equivalent of the per share amount received by the Depositary (adjusted to reflect the ADS(s)-to-Share(s) ratio) upon the redemption of the Deposited Securities represented by ADSs (subject to the terms of Section 4.8 of the Deposit Agreement and the applicable fees and charges of, and expenses incurred by, the Depositary, and applicable taxes) multiplied by the number of Deposited Securities represented by each ADS redeemed. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed redemption provided for in Section 4.7 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.7 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.7 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(17) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fixing of ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever (a) the Depositary shall receive notice of the fixing of a record date by the Company for the determination of holders of Deposited Securities entitled to receive any distribution (whether in cash, Shares, rights or other distribution), (b) for any reason the Depositary causes a change in the number of Shares that are represented by each ADS, (c) the Depositary shall receive notice of any meeting of, or solicitation of consents or proxies of, holders of Shares or other Deposited Securities, or (d) the Depositary shall find it necessary or convenient in connection with the giving of any notice, solicitation of any consent or any other matter, the Depositary shall fix the record date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the determination of the Holders of ADS(s) who shall be entitled to receive such distribution, to give instructions for the exercise of voting rights at any such meeting, to give or withhold such consent, to receive such notice or solicitation or to otherwise take action, or to exercise the rights of Holders with respect to such changed number of Shares represented by each ADS. The Depositary shall make reasonable efforts to establish the ADS Record Date as closely as practicable to the applicable record date for the Deposited Securities (if any) set by the Company in Switzerland and shall not announce the establishment of any ADS Record Date prior to the relevant corporate action having been made public by the Company (if such corporate action affects the Deposited Securities).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to applicable law, the terms and conditions of this ADR and Sections 4.1 through 4.8 of the Deposit Agreement, only the Holders of ADSs at the close of business in New York on such ADS Record Date shall be entitled to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receive such distribution, to give such voting instructions, to receive such notice or solicitation, or otherwise take action.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(18) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Voting of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As soon as practicable after receipt of notice of any meeting at which the holders of Deposited Securities are entitled to vote, or of solicitation of consents or proxies from holders of Deposited Securities, the Depositary shall fix the ADS Record Date in respect of such meeting or solicitation of consent or proxy in accordance with Section 4.9 of the Deposit Agreement. The Depositary shall, if requested by the Company in writing in a timely manner (the Depositary having no obligation to take any further action if the request shall not have been received by the Depositary at least thirty (30) days prior to the date of such meeting or consent or proxy solicitation), at the Company&#8217;s expense and provided no U.S. legal prohibitions exist, distribute to Holders as of the ADS Record Date&#58; (a) such notice of meeting or solicitation of consent or proxy, (b) a statement that the Holders at the close of business on the ADS Record Date will be entitled, subject to any applicable law, the provisions of the Deposit Agreement, the Articles of Incorporation of the Company and the provisions of or governing the Deposited Securities (which provisions, if any, shall be summarized in pertinent part by the Company), to instruct the Depositary as to the exercise of the voting rights, if any, pertaining to the Deposited Securities represented by such Holder&#8217;s ADSs, and (c) a brief statement as to the manner in which such voting instructions may be given.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement or this ADR, the Depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the Depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of Deposited Securities, distribute to the Holders a notice that provides Holders with, or otherwise publicizes to Holders, instructions on how to retrieve such materials or receive such materials upon request (e.g., by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Voting instructions may be given only in respect of a number of ADSs representing an integral number of Deposited Securities. Upon the timely receipt from a Holder of ADSs as of the ADS Record Date of voting instructions in the manner specified by the Depositary, the Depositary shall endeavor, insofar as practicable and permitted under applicable law, the provisions of the Deposit Agreement, the Articles of Incorporation of the Company and the provisions of the Deposited Securities, to vote, or cause the Custodian to vote, the Deposited Securities (in person or by proxy) represented by such Holder&#8217;s ADSs in accordance with such voting instructions.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposited Securities represented by ADSs for which no timely voting instructions are received by the Depositary from the Holder shall not be voted. Neither the Depositary nor the Custodian shall under any circumstances exercise any discretion as to voting and neither the Depositary nor the Custodian shall vote, attempt to exercise the right to vote, or in any way make use of, the Deposited Securities represented by ADSs, except pursuant to and in accordance with the voting instructions timely received from Holders or as otherwise contemplated in the Deposit Agreement or herein. If the Depositary timely receives voting instructions from a Holder which fail to specify the manner in which the Depositary is to vote the Deposited Securities represented by such Holder&#8217;s ADSs, the Depositary will deem such Holder (unless otherwise specified in the notice distributed to Holders) to have instructed the Depositary to take all steps necessary to enable the independent proxy holder, as elected by the shareholders of the Company, to vote in accordance with the written proposals or recommendations of the Company's Board of Directors. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained herein, the Depositary shall, if so requested in writing by the Company, represent all Deposited Securities (whether or not voting instructions have been received in respect of such Deposited Securities from Holders as of the ADS Record Date) for the sole purpose of establishing quorum at a meeting of shareholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in the Deposit Agreement or this ADR, the Depositary shall not have any obligation to take any action with respect to any meeting, or solicitation of consents or proxies, of holders of Deposited Securities if the taking of such action would violate U.S. laws. The Company agrees to take any and all actions reasonably necessary and as permitted by the law of Switzerland to enable Holders and Beneficial Owners to exercise the voting rights accruing to the Deposited Securities and to deliver to the Depositary an opinion of U.S. counsel addressing any actions reasonably requested to be taken if so requested by the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally or any Holder in particular will receive the notice described above with sufficient time to enable the Holder to return voting instructions to the Depositary, or otherwise take action, in a timely manner.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(19) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Changes Affecting Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon any change in nominal or par value, split up, cancellation, consolidation or any other reclassification of Deposited Securities, or upon any recapitalization, reorganization, merger, consolidation or sale of assets affecting the Company or to which it is a party, any property which shall be received by the Depositary or the Custodian in exchange for, or in conversion of, or replacement of, or otherwise in respect of, such Deposited Securities shall, to the extent permitted by law, be treated as new Deposited Property under the Deposit Agreement, and this ADR shall, subject to the provisions of the Deposit Agreement, this ADR evidencing such ADSs and applicable law, represent the right to receive such additional or replacement Deposited Property. In giving effect to such change, split-up, cancellation, consolidation or other reclassification of Deposited Securities, recapitalization, reorganization, merger, consolidation or sale of assets, the Depositary may, with the Company&#8217;s approval, and shall, if the Company shall so request, subject to the terms of the Deposit Agreement (including, without limitation, (a) the applicable fees and charges of, and expenses incurred by, the Depositary, and (b) applicable taxes) and receipt of an opinion of counsel to the Company reasonably satisfactory to the Depositary that such actions are not in violation of any applicable laws or regulations, (i) issue and deliver additional ADSs as in the case of a stock dividend on the Shares, (ii) amend the Deposit Agreement and the applicable ADRs, (iii) amend the applicable Registration Statement(s) on Form F-6 as filed with the Commission in respect of the ADSs, (iv) call for the surrender of outstanding ADRs to be exchanged for new ADRs, and (v) take such other actions as are appropriate to reflect the transaction with respect to the ADSs. The Company agrees to, jointly with the Depositary, amend the Registration Statement on Form F-6 as filed with the Commission to permit the issuance of such new form of ADSs. Notwithstanding the foregoing, in the event that any Deposited Property so received may not be lawfully distributed to some or all Holders, the Depositary may, with the Company&#8217;s approval, and shall, if the Company requests, subject to receipt of an opinion of Company&#8217;s counsel reasonably satisfactory to the Depositary that such action is not in violation of any applicable laws or regulations, sell such Deposited Property at public or private sale, at such place or places and upon such terms as it may deem proper and may allocate the net proceeds of such sales (net of (a) fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes) for the account of the Holders otherwise entitled to such Deposited Property upon an averaged or other practicable basis without regard to any distinctions among such Holders and distribute the net proceeds so allocated to the extent practicable as in the case of a distribution received in cash pursuant to Section 4.1 of the Deposit Agreement. The Depositary shall not be responsible for (i) any failure to determine that it may be lawful or practicable to make such Deposited Property available to Holders in general or to any Holder in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale or (iii) any liability to the purchaser of such Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(20) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exoneration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything contained in the Deposit Agreement or this ADR, neither the Depositary nor the Company shall be obligated to do or perform any act which is inconsistent with the provisions of the Deposit Agreement or incur any liability (to the extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not limited by paragraph (25) hereof and Section 7.8(b) of the Deposit Agreement) (i) if the Depositary, the Custodian, the Company or their respective agents shall be prevented or forbidden from, hindered or delayed in, doing or performing any act or thing required or contemplated by the terms of the Deposit Agreement and this ADR, by reason of any provision of any present or future law or regulation of the United States, Switzerland or any other country, or of any other governmental authority or regulatory authority or stock exchange, or on account of potential criminal or civil penalties or restraint, or by reason of any provision, present or future, of the Articles of Incorporation of the Company or any provision of or governing any Deposited Securities, or by reason of any act of God or other event or circumstances beyond its control (including, without limitation, fire, flood, earthquake, tornado, hurricane, tsunami, explosion, or other natural disaster, nationalization, expropriation, currency restrictions, work stoppage, strikes, civil unrest, act of war (whether declared or not) or terrorism, revolutions, rebellion, embargo, computer failure, failure of public infrastructure (including communication or utility failure), failure of common carriers, nuclear, cyber or biochemical incident, any pandemic, epidemic or other prevalent disease or illness with an actual or probable threat to human life, any quarantine order or travel restriction imposed by a governmental authority or other competent public health authority, or the failure or unavailability of the United States Federal Reserve Bank (or other central banking system) or DTC (or other clearing system), (ii) by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement or in the Articles of Incorporation of the Company or provisions of or governing Deposited Securities, (iii) for any action or inaction in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Holder, any Beneficial Owner or authorized representative thereof, or any other person believed by it in good faith to be competent to give such advice or information, (iv) for the inability by a Holder or Beneficial Owner to benefit from any distribution, offering, right or other benefit which is made available to holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Holders of ADSs, (v) for any action or inaction of any clearing or settlement system (and any participant thereof) for the Deposited Property or the ADSs, or (vi) for any consequential or punitive damages (including lost profits) for any breach of the terms of the Deposit Agreement. The Depositary, its controlling persons, its agents, any Custodian and the Company, its controlling persons and its agents may rely and shall be protected in acting upon any written notice, request or other document believed by it to be genuine and to have been signed or presented by the proper party or parties. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(21) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Standard of Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company and the Depositary assume no obligation and shall not be subject to any liability under the Deposit Agreement or this ADR to any Holder(s) or Beneficial Owner(s), except that the Company and the Depositary agree to perform their respective obligations specifically set forth in the Deposit Agreement or this ADR without negligence or bad faith. Without limitation of the foregoing, neither the Depositary, nor the Company, nor any of their respective controlling persons, or agents, shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Property or in respect of the ADSs, which in its opinion may involve it in expense or liability, unless indemnity satisfactory to it against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be required (and no Custodian shall be under any obligation whatsoever with respect to such proceedings, the responsibility of the Custodian being solely to the Depositary). </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary and its agents shall not be liable for any failure to carry out any instructions to vote any of the Deposited Securities, or for the manner in which any vote is cast or the effect of any vote, provided that any such action or omission is in good faith and without negligence and in accordance with the terms of the Deposit Agreement. The Depositary shall not incur any liability for any failure to accurately determine that any distribution or action may be lawful or reasonably practicable, for the content of any information submitted to it by the Company for distribution to the Holders or for any inaccuracy of any translation thereof, for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">investment risk associated with acquiring an interest in the Deposited Property, for the validity or worth of the Deposited Property, for the value of any Deposited Property or any distribution thereon, for any interest on Deposited Property, for any tax consequences that may result from the ownership of ADSs, Shares or other Deposited Property, for the credit worthiness of any third party, for allowing any rights to lapse upon the terms of the Deposit Agreement, for the failure or timeliness of any notice from the Company, or for any action of or failure to act by, or any information provided or not provided by, DTC or any DTC Participant.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a predecessor depositary whether in connection with an act or omission of the Depositary or in connection with any matter arising wholly prior to the appointment of the Depositary or after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(22) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Resignation and Removal of the Depositary&#59; Appointment of Successor Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary may at any time resign as Depositary under the Deposit Agreement by written notice of resignation delivered to the Company, such resignation to be effective on the earlier of (i) the 90th day after delivery thereof to the Company (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2 of the Deposit Agreement), or (ii) the appointment by the Company of a successor depositary and its acceptance of such appointment as provided in the Deposit Agreement. The Depositary may at any time be removed by the Company by written notice of such removal, which removal shall be effective on the later of (i) the 90th day after delivery thereof to the Depositary (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2 of the Deposit Agreement), or (ii) upon the appointment by the Company of a successor depositary and its acceptance of such appointment as provided in the Deposit Agreement. In case at any time the Depositary acting hereunder shall resign or be removed, the Company shall use its commercially reasonable efforts to appoint a successor depositary, which shall be a bank or trust company having an office in the Borough of Manhattan, the City of New York. Every successor depositary shall be required by the Company to execute and deliver to its predecessor and to the Company an instrument in writing accepting its appointment hereunder, and thereupon such successor depositary, without any further act or deed (except as required by applicable law), shall become fully vested with all the rights, powers, duties and obligations of its predecessor (other than as contemplated in Sections 5.8 and 5.9 of the Deposit Agreement). The predecessor depositary, upon payment of all sums due it and on the written request of the Company shall (i) execute and deliver an instrument transferring to such successor all rights and powers of such predecessor hereunder (other than as contemplated in Sections 5.8 and 5.9 of the Deposit Agreement), (ii) duly assign, transfer and deliver all of the Depositary&#8217;s right, title and interest to the Deposited Property to such successor, and (iii) deliver to such successor a list of the Holders of all outstanding ADSs and such other information relating to ADSs and Holders thereof as the successor may reasonably request. Any such successor depositary shall promptly provide notice of its appointment to such Holders. Any entity into or with which the Depositary may be merged or consolidated shall be the successor of the Depositary without the execution or filing of any document or any further act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(23) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment&#47;Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of this paragraph 23, and Section 6.1 of the Deposit Agreement and applicable law, this ADR and any provisions of the Deposit Agreement may at any time and from time to time be amended or supplemented by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written agreement between the Company and the Depositary in any respect which they may deem necessary or desirable without the prior written consent of the Holders or Beneficial Owners. Any amendment or supplement which shall impose or increase any fees or charges (other than charges in connection with foreign exchange control regulations, and taxes and other governmental charges, delivery and other such expenses), or which shall otherwise materially prejudice any substantial existing right of Holders or Beneficial Owners, shall not, however, become effective as to outstanding ADSs until the expiration of thirty (30) days after notice of such amendment or supplement shall have been given to the Holders of outstanding ADSs. Notice of any amendment to the Deposit Agreement or any ADR shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific amendments in any such notice shall not render such notice invalid, provided, however, that, in each such case, the notice given to the Holders identifies a means for Holders and Beneficial Owners to retrieve or receive the text of such amendment (e.g., upon retrieval from the Commission&#8217;s, the Depositary&#8217;s or the Company&#8217;s website or upon request from the Depositary). The parties hereto agree that any amendments or supplements which (i) are reasonably necessary (as agreed by the Company and the Depositary) in order for (a) the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs to be settled solely in electronic book-entry form and (ii) do not in either such case impose or increase any fees or charges to be borne by Holders, shall be deemed not to materially prejudice any substantial existing rights of Holders or Beneficial Owners. Every Holder and Beneficial Owner at the time any amendment or supplement so becomes effective shall be deemed, by continuing to hold such ADSs, to consent and agree to such amendment or supplement and to be bound by the Deposit Agreement and this ADR, if applicable, as amended or supplemented thereby. In no event shall any amendment or supplement impair the right of the Holder to surrender such ADS and receive therefor the Deposited Securities represented thereby, except in order to comply with mandatory provisions of applicable law. Notwithstanding the foregoing, if any governmental body should adopt new laws, rules or regulations which would require an amendment of, or supplement to, the Deposit Agreement to ensure compliance therewith, the Company and the Depositary may amend or supplement the Deposit Agreement and this ADR at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the Deposit Agreement and this ADR in such circumstances may become effective before a notice of such amendment or supplement is given to Holders or within any other period of time as required for compliance with such laws, rules or regulations.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(24) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall, at any time at the written direction of the Company, terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. If (i) ninety (90) days shall have expired after the Depositary shall have delivered to the Company a written notice of its election to resign, or (ii) ninety (90) days shall have expired after the Company shall have delivered to the Depositary a written notice of the removal of the Depositary, and, in either case, a successor depositary shall not have been appointed and accepted its appointment as provided in Section 5.4 of the Deposit Agreement, the Depositary may terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. The date so fixed for termination of the Deposit Agreement in any termination notice so distributed by the Depositary to the Holders of ADSs is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. Until the Termination Date, the Depositary shall continue to perform all of its obligations under the Deposit Agreement, and the Holders and Beneficial Owners will be entitled to all of their rights under the Deposit Agreement. If any ADSs shall remain outstanding after the Termination Date, the Registrar and the Depositary shall not, after the Termination Date, have any obligation to perform any further acts under the Deposit Agreement, except that the Depositary shall, subject, in each case, to the terms and conditions of the Deposit Agreement, continue to (i) collect dividends and other distributions pertaining to Deposited Securities, (ii) sell Deposited Property received in respect of Deposited Securities, (iii) deliver Deposited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any other Deposited Property, in exchange for ADSs surrendered to the Depositary (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (iv) take such actions as may be required under applicable law in connection with its role as Depositary under the Deposit Agreement. At any time after the Termination Date, the Depositary may sell the Deposited Property then held under the Deposit Agreement and shall after such sale hold un-invested the net proceeds of such sale, together with any other cash then held by it under the Deposit Agreement, in an un-segregated account and without liability for interest, for the pro rata benefit of the Holders whose ADSs have not theretofore been surrendered. After making such sale, the Depositary shall be discharged from all obligations under the Deposit Agreement except (i) to account for such net proceeds and other cash (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (ii) as may be required at law in connection with the termination of the Deposit Agreement. After the Termination Date, the Company shall be discharged from all obligations under the Deposit Agreement, except for its obligations to the Depositary under Sections 5.8, 5.9 and 7.6 of the Deposit Agreement. The obligations under the terms of the Deposit Agreement of Holders and Beneficial Owners of ADSs outstanding as of the Termination Date shall survive the Termination Date and shall be discharged only when the applicable ADSs are presented by their Holders to the Depositary for cancellation under the terms of the Deposit Agreement (except as specifically provided in the Deposit Agreement).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(25) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with, and No Disclaimer under, U.S. Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) Notwithstanding any provisions in this ADR or the Deposit Agreement to the contrary, the withdrawal or delivery of Deposited Securities will not be suspended by the Company or the Depositary except as would be permitted by Instruction I.A.(1) of the General Instructions to the Form F-6 Registration Statement, as amended from time to time, under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) Each of the parties to the Deposit Agreement (including, without limitation, each Holder and Beneficial Owner) acknowledges and agrees that no provision of the Deposit Agreement or any ADR shall, or shall be deemed to, disclaim any liability under the Securities Act or the Exchange Act, in each case to the extent established under applicable U.S. laws.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(26) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Third Party Beneficiaries&#47;Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement is for the exclusive benefit of the parties hereto (and their successors) and shall not be deemed to give any legal or equitable right, remedy or claim whatsoever to any other person, except to the extent specifically set forth in the Deposit Agreement. Nothing in the Deposit Agreement shall be deemed to give rise to a partnership or joint venture among the parties nor establish a fiduciary or similar relationship among the parties. The parties hereto acknowledge and agree that (i) Citibank and its Affiliates may at any time have multiple banking relationships with the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (ii) Citibank and its Affiliates may own and deal in any class of securities of the Company and its Affiliates and in ADSs, and may be engaged at any time in transactions in which parties adverse to the Company, the Holders, the Beneficial Owners or their respective Affiliates may have interests, (iii) the Depositary and its Affiliates may from time to time have in their possession non-public information about the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (iv) nothing contained in the Deposit Agreement shall (a) preclude Citibank or any of its Affiliates from engaging in such transactions or establishing or maintaining such relationships, or (b) obligate Citibank or any of its Affiliates to disclose such information, transactions or relationships, or to account for any profit made or payment received in such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transactions or relationships, (v) the Depositary shall not be deemed to have knowledge of any information any other division of Citibank or any of its Affiliates may have about the Company, the Holders, the Beneficial Owners, or any of their respective Affiliates, and (vi) the Company, the Depositary, the Custodian and their respective agents and controlling persons may be subject to the laws and regulations of jurisdictions other than the U.S. and Switzerland, and the authority of courts and regulatory authorities of such other jurisdictions, and, consequently, the requirements and the limitations of such other laws and regulations, and the decisions and orders of such other courts and regulatory authorities, may affect the rights and obligations of the parties to the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may execute transactions contemplated herein (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, foreign currency conversions, and sales of Deposited Property) through one or more divisions of Citibank or through one or more Citibank Affiliates, and any such entity may act as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and may earn and retain revenue from such transactions, including, without, without limitation, transaction spreads, commissions, etc. The Depositary does not guarantee or represent that the price or rate obtained in any such transaction, or the method for obtaining such price or rate, will be the most favorable that could be obtained at that time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(27) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law &#47; Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement, the ADRs and the ADSs shall be interpreted in accordance with, and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by, the laws of the State of New York applicable to contracts made and to be wholly performed in that State. Notwithstanding anything contained in the Deposit Agreement to the contrary, any ADR or any present or future provisions of the laws of the State of New York, the rights of holders of Shares and of any other Deposited Securities and the obligations and duties of the Company in respect of the holders of Shares and other Deposited Securities, as such, shall be governed by the laws of Switzerland (or, if applicable, such other laws as may govern the Deposited Securities). </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EACH OF THE PARTIES TO THE DEPOSIT AGREEMENT (INCLUDING, WITHOUT LIMITATION, EACH HOLDER AND BENEFICIAL OWNER) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING AGAINST THE COMPANY AND&#47;OR THE DEPOSITARY ARISING OUT OF, OR RELATING TO, THE DEPOSIT AGREEMENT, ANY ADR AND ANY TRANSACTIONS CONTEMPLATED THEREIN (WHETHER BASED ON CONTRACT, TORT, COMMON LAW OR OTHERWISE).</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ASSIGNMENT AND TRANSFER SIGNATURE LINES)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FOR VALUE RECEIVED, the undersigned Holder hereby sell(s), assign(s) and transfer(s) unto ______________________________ whose taxpayer identification number is _______________________ and whose address including postal zip code is ________________, the within ADR and all rights thereunder, hereby irrevocably constituting and appointing ________________________ attorney-in-fact to transfer said ADR on the books of the Depositary with full power of substitution in the premises.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICE&#58; The signature of the Holder to this assignment must correspond with the name as written upon the face of the within instrument in every particular, without alteration or enlargement or any change whatsoever.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the endorsement be executed by an attorney, executor, administrator, trustee or guardian, the person executing the endorsement must give his&#47;her full title in such capacity and proper evidence of authority to act in such capacity, if not on file with the Depositary, must be forwarded with this ADR.</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURE GUARANTEED</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All endorsements or assignments of ADRs must be guaranteed by a member of a Medallion Signature Program approved by the Securities Transfer Association, Inc.</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Legends</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;The ADRs issued in respect of Partial Entitlement American Depositary Shares shall bear the following legend on the face of the ADR&#58; &#8220;This ADR evidences ADSs representing 'partial entitlement' Shares of Molecular Partners AG and as such do not entitle the holders thereof to the same per-share entitlement as other Shares (which are 'full entitlement' Shares) issued and outstanding at such time. The ADSs represented by this ADR shall entitle holders to distributions and entitlements identical to other ADSs when the Shares represented by such ADSs become 'full entitlement' Shares.&#8221;&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FEE SCHEDULE</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADS FEES AND RELATED CHARGES</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms used but not otherwise defined herein shall have the meaning given to such terms in the Deposit Agreement. Except as otherwise specified herein, any reference to ADSs herein includes Partial Entitlement ADSs, Full Entitlement ADSs, Certificated ADSs, Uncertificated ADSs, and Restricted ADSs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Fees</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following ADS fees are payable under the terms of the Deposit Agreement&#58;</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Service</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rate</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By Whom Paid</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) Issuance of ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an issuance upon a deposit of Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (4) below.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom ADSs are issued.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) Cancellation of ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a cancellation of ADSs for Delivery of deposited Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom ADSs are being cancelled.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3) Distribution of cash dividends or other cash distributions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon a sale of rights and other entitlements).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person to whom the distribution is made.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4) Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) an exercise of rights to purchase additional ADSs.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person to whom the distribution is made.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5) Distribution of securities other than ADSs or rights to purchase additional ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, spin-off shares).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person to whom the distribution is made.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6) ADS Services.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the Depositary.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person holding ADSs on the applicable record date(s) established by the Depositary.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7) Registration of ADS Transfers (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or for any other reason).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) transferred.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom or to whom ADSs are transferred.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8) Conversion of ADSs of one series for ADSs of another series (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferable ADSs, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) converted.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom ADSs are converted or to whom the converted ADSs are delivered.</font></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Charges</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, Holders, Beneficial Owners, persons depositing Shares or withdrawing Deposited Securities in connection with ADS issuances and cancellations, and persons for whom ADSs are issued or cancelled shall be responsible for the following ADS charges under the terms of the Deposit Agreement&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) such registration fees as may from time to time be in effect for the registration of Shares or other Deposited Securities on the share register and applicable to transfers of Shares or other Deposited Securities to or from the name of the Custodian, the Depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the Deposit Agreement to be at the expense of the person depositing Shares or withdrawing Deposited Property or of the Holders and Beneficial Owners of ADSs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) in connection with the conversion of Foreign Currency, the fees, expenses, spreads, taxes and other charges of the Depositary and&#47;or conversion service providers (which may be a division, branch or Affiliate of the Depositary). Such fees, expenses, spreads, taxes, and other charges shall be deducted from the Foreign Currency&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) any reasonable and customary out-of-pocket expenses incurred in such conversion and&#47;or on behalf of the Holders and Beneficial Owners in complying with currency exchange control or other governmental requirements&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi) the fees, charges, costs and expenses incurred by the Depositary, the Custodian, or any nominee in connection with the ADR program.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above fees and charges may at any time and from time to time be changed by agreement between the Company and the Depositary.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Execution Version</font></div><div><font><br></font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:97.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:36pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT AGREEMENT</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:97.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:30pt;margin-top:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and among</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CITIBANK, N.A.,</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Depositary,</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE HOLDERS AND BENEFICIAL OWNERS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMERICAN DEPOSITARY SHARES </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISSUED HEREUNDER</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:97.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of &#91;&#93;, 2021</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE I DEFINITIONS</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;ADS Record Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Agent&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;American Depositary Receipt(s)&#8221;, &#8220;ADR(s)&#8221; and &#8220;Receipt(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;American Depositary Share(s)&#8221; and &#8220;ADS(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Articles of Incorporation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Beneficial Owner&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Certificated ADS(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Citibank&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Commission&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Custodian&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deliver&#8221; and &#8220;Delivery&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deposit Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.15</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Depositary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.16</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deposited Property&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.17</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Deposited Securities&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.18</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Dollars&#8221; and &#8220;$&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.19</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;DTC&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.20</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;DTC Participant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.21</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Exchange Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.22</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Foreign Currency&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.23</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Full Entitlement ADR(s)&#8221;, &#8220;Full Entitlement ADS(s)&#8221; and &#8220;Full Entitlement Share(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.24</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Holder(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.25</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Partial Entitlement ADR(s)&#8221;, &#8220;Partial Entitlement ADS(s)&#8221; and &#8220;Partial Entitlement Share(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.26</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Principal Office&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.27</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Registrar&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.28</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Restricted ADR(s)&#8221;, &#8220;Restricted ADS(s)&#8221; and &#8220;Restricted Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.29</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Restricted Securities&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.30</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Securities Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.31</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Share Registrar&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.32</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.33</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Swiss Franc&#8221; and &#8220;CHF&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.34</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Uncertificated ADS(s)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.35</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;United States&#8221; and &#8220;U.S.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II APPOINTMENT OF DEPOSITARY&#59; FORM OF RECEIPTS&#59; DEPOSIT OF SHARES&#59; EXECUTION AND DELIVERY, TRANSFER AND SURRENDER OF RECEIPTS</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appointment of Depositary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form and Transferability of ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Deposit of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></td></tr></table></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Registration and Safekeeping of Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transfer, Combination and Split-up of ADRs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Surrender of ADSs and Withdrawal of Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Limitations on Execution and Delivery, Transfer, etc. of ADSs&#59; Suspension of Delivery, Transfer, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lost ADRs, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cancellation and Destruction of Surrendered ADRs&#59; Maintenance of Records.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Escheatment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partial Entitlement ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Certificated&#47;Uncertificated ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III CERTAIN OBLIGATIONS OF HOLDERS AND BENEFICIAL OWNERS OF ADSs</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proofs, Certificates and Other Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Liability for Taxes and Other Charges.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Representations and Warranties on Deposit of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Information Requests.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ownership Restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reporting Obligations and Regulatory Approvals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV THE DEPOSITED SECURITIES</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cash Distributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distribution in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Elective Distributions in Cash or Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distribution of Rights to Purchase Additional ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distributions Other Than Cash, Shares or Rights to Purchase Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distributions with Respect to Deposited Securities in Bearer Form.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Redemption.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conversion of Foreign Currency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fixing of ADS Record Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Voting of Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Changes Affecting Deposited Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Available Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.15</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Taxation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V THE DEPOSITARY, THE CUSTODIAN AND THE COMPANY</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Maintenance of Office and Transfer Books by the Registrar.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exoneration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard of Care.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Resignation and Removal of the Depositary&#59; Appointment of Successor Depositary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Custodian.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notices and Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of Additional Shares, ADSs etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADS Fees and Charges.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Securities Owners.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VI AMENDMENT AND TERMINATION</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment&#47;Supplement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VII MISCELLANEOUS</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.1</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Third-Party Beneficiaries&#47;Acknowledgments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.3</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.4</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Holders and Beneficial Owners as Parties&#59; Binding Effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.5</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.6</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governing Law and Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.7</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Assignment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.8</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with, and No Disclaimer under, U.S. Securities Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.9</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Switzerland Law References.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Titles and References.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBITS</font></div><div style="padding-left:1.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Form of ADR.</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-1</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"><div style="text-indent:-0.75pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fee Schedule.</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:-0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B-1</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT AGREEMENT</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, dated as of ___________, 2021, by and among (i) MOLECULAR PARTNERS AG, a corporation incorporated under the laws of Switzerland, and its successors (the &#8220;Company&#8221;), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the &#8220;Depositary&#8221;), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">W I T N E S S E T H T H A T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company desires to establish with the Depositary an ADR facility to provide for the deposit of the Shares (as hereinafter defined) and the creation of American Depositary Shares representing the Shares so deposited and for the execution and Delivery (as hereinafter defined) of American Depositary Receipts (as hereinafter defined) evidencing such American Depositary Shares&#59; and</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Depositary is willing to act as the Depositary for such ADR facility upon the terms set forth in the Deposit Agreement (as hereinafter defined)&#59; and</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any American Depositary Receipts issued pursuant to the terms of the Deposit Agreement are to be substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto, with appropriate insertions, modifications and omissions, as hereinafter provided in the Deposit Agreement&#59; and</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEFINITIONS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms used, but not otherwise defined, herein shall have the meanings set forth below, unless otherwise clearly indicated&#58;</font></div><div style="margin-bottom:0.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the meaning given to such term in Section 4.9.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.2 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the meaning assigned to such term by the Commission (as hereinafter defined) under Regulation C promulgated under the Securities Act (as hereinafter defined), or under any successor regulation thereto.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given to such term in Section 7.6.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">American Depositary Receipt(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Receipt(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the certificate(s) issued by the Depositary to evidence the American Depositary Shares issued under the terms of the Deposit Agreement in the form of Certificated ADS(s) (as hereinafter defined), as such ADRs may be amended from time to time in accordance with the provisions of the Deposit Agreement. An ADR may evidence any number of ADSs and may, in the case of ADSs held through a central depository such as DTC, be in the form of a &#8220;Balance Certificate.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">American Depositary Share(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the rights and interests in the Deposited Property (as hereinafter defined) granted to the Holders and Beneficial Owners pursuant to the terms and conditions of the Deposit Agreement and, if issued as Certificated ADS(s) (as hereinafter defined),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the ADR(s) issued to evidence such ADSs. ADS(s) may be issued under the terms of the Deposit Agreement in the form of (a) Certificated ADS(s) (as hereinafter defined), in which case the ADS(s) are evidenced by ADR(s), or (b) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Uncertificated ADS(s) (as hereinafter defined), in which case the ADS(s) are not evidenced by ADR(s) but are reflected on the direct registration system maintained by the Depositary for such purposes under the terms of Section 2.13. Unless otherwise specified in the Deposit Agreement or in any ADR, or unless the context otherwise requires, any reference to ADS(s) shall include Certificated ADS(s) and Uncertificated ADS(s), individually or collectively, as the context may require.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each ADS shall represent the right to receive, and to exercise the beneficial ownership interests in, the number of Shares specified in the form of ADR attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (as amended from time to time)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that are on deposit with the Depositary and&#47;or the Custodian, subject, in each case, to the terms and conditions of the Deposit Agreement and the applicable ADR (if issued as a Certificated ADS), until there shall occur a distribution upon Deposited Securities referred to in Section 4.2 or a change in Deposited Securities referred to in Section 4.11 with respect to which additional ADSs are not issued, and thereafter each ADS shall represent the right to receive, and to exercise the beneficial ownership interests in, the applicable Deposited Property on deposit with the Depositary and the Custodian determined in accordance with the terms of such Sections, subject, in each case, to the terms and conditions of the Deposit Agreement and the applicable ADR (if issued as a Certificated ADS). In addition, the ADS(s)-to-Share(s) ratio is subject to amendment as provided in Articles IV and VI of the Deposit Agreement (which may give rise to Depositary fees).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.6 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Articles of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean the Articles of Incorporation of the Company, as amended and restated from time to time.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, as to any ADS, any person or entity having a beneficial interest deriving from the ownership of such ADS. Notwithstanding anything else contained in the Deposit Agreement, any ADR(s) or any other instruments or agreements relating to the ADSs and the corresponding Deposited Property, the Depositary, the Custodian and their respective nominees are intended to be, and shall at all times during the term of the Deposit Agreement be, the record holders only of the Deposited Property represented by the ADSs for the benefit of the Holders and Beneficial Owners of the corresponding ADSs. The Depositary, on its own behalf and on behalf of the Custodian and their respective nominees, disclaims any beneficial ownership interest in the Deposited Property held on behalf of the Holders and Beneficial Owners of ADSs. The beneficial ownership interests in the Deposited </font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property are intended to be, and shall at all times during the term of the Deposit Agreement continue to be, vested in the Beneficial Owners of the ADSs representing the Deposited </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property. The beneficial ownership interests in the Deposited Property shall, unless otherwise agreed by the Depositary, be exercisable by the Beneficial Owners of the ADSs only through the Holders of such ADSs, by the Holders of the ADSs (on behalf of the applicable Beneficial Owners) only through the Depositary, and by the Depositary (on behalf of the Holders and Beneficial Owners of the corresponding ADSs) directly, or indirectly through the Custodian or their respective nominees, in each case upon the terms of the Deposit Agreement and, if applicable, the terms of the ADR(s) evidencing the ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Beneficial Owner of ADSs may or may not be the Holder of such ADSs. A Beneficial Owner shall be able to exercise any right or receive any benefit hereunder solely through the person who is the Holder of the ADSs owned by such Beneficial Owner. Unless otherwise identified to the Depositary, a Holder shall be deemed to be the Beneficial Owner of all the ADSs registered in his&#47;her&#47;its name.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The manner in which a Beneficial Owner holds ADSs (e.g., in a brokerage account vs. as registered holder) may affect the rights and obligations of, the manner in which, and the extent to which, services are made available to, Beneficial Owners pursuant to the terms of the Deposit Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Certificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.13.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.9 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean Citibank, N.A., a national banking association organized under the laws of the United States of America, and its successors. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Securities and Exchange Commission of the United States or any successor governmental agency thereto in the United States.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Molecular Partners AG, a company incorporated and existing under the laws of Switzerland, and its successors.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Custodian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (i) as of the date hereof, Citibank N.A. London Branch, having its principal office at Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB, United Kingdom, as the custodian of Deposited Property for the purposes of the Deposit Agreement, (ii) Citibank, N.A., acting as custodian of Deposited Property pursuant to the Deposit Agreement, and (iii) any other entity that may be appointed by the Depositary pursuant to the terms of Section 5.5 as successor, substitute or additional custodian hereunder. The term &#8220;Custodian&#8221; shall mean any Custodian individually or all Custodians collectively, as the context requires.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deliver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (x) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">when used in respect of Shares and other Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any of (i) the physical delivery of the certificate(s) representing such securities, or (ii) the book-entry transfer and recordation of such securities on the books of the Share Registrar (as hereinafter defined) or in the applicable book-entry settlement system, and (y) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">when used in respect of ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any of (i) the physical delivery of ADR(s) evidencing the ADSs, or (ii) the book-entry transfer and recordation of ADSs on the books of the Depositary or any book-entry settlement system in which the ADSs are settlement-eligible.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean this Deposit Agreement and all exhibits hereto, as the same may from time to time be amended and supplemented from time to time in accordance with the terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Citibank, N.A., a national banking association organized under the laws of the United States, in its capacity as depositary under the terms of the Deposit Agreement, and any successor depositary hereunder.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.16 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposited Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean the Deposited Securities and any cash and other property held on deposit by the Depositary and the Custodian in respect of the ADSs under the terms of the Deposit Agreement, subject, in the case of cash, to the provisions of Section 4.8. All Deposited Property shall be held by the Custodian, the Depositary and their respective nominees for the benefit of the Holders and Beneficial Owners of the ADSs representing the Deposited Property. The Deposited Property is not intended to, and shall not, constitute proprietary assets of the Depositary, the Custodian or their nominees. Beneficial ownership in the Deposited Property is intended to be, and shall at all times during the term of the Deposit Agreement continue to be, vested in the Beneficial Owners of the ADSs representing the Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.17 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean the Shares and any other securities held on deposit by the Custodian from time to time in respect of the ADSs under the Deposit Agreement and constituting Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.18 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall refer to the lawful currency of the United States.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.19 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean The Depository Trust Company, a national clearinghouse and the central book-entry settlement system for securities traded in the United States and, as such, the custodian for the securities of DTC Participants (as hereinafter defined) maintained in DTC, and any successor thereto. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.20 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DTC Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any financial institution (or any nominee of such institution) having one or more participant accounts with DTC for receiving, holding and delivering the securities and cash held in DTC. A DTC Participant may or may not be a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Beneficial Owner. If a DTC Participant is not the Beneficial Owner of the ADSs credited to its account at DTC, or of the ADSs in respect of which the DTC Participant is otherwise acting, such DTC Participant shall be deemed, for all purposes hereunder, to have all requisite authority to act on behalf of the Beneficial Owner(s) of the ADSs credited to its account at DTC or in respect of which the DTC Participant is so acting. A DTC Participant, upon acceptance in any one of its DTC accounts of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the Deposit Agreement, shall (notwithstanding any explicit or implicit disclosure that it may be acting on behalf of another party) be deemed for all purposes to be a party to, and bound by, the terms of the Deposit Agreement and the applicable ADR(s) to the same extent as, and as if the DTC Participant were, the Holder of such ADSs. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.21 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.22 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any currency other than Dollars.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.23 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Full Entitlement ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Full Entitlement ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Full Entitlement Share(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the respective meanings set forth in Section 2.12.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.24 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Holder(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the person(s) in whose name the ADSs are registered on the books of the Depositary (or the Registrar, if any) maintained for such purpose. A Holder may or may not be a Beneficial Owner. If a Holder is not the Beneficial Owner of the ADS(s) registered in its name, such person shall be deemed, for all purposes hereunder, to have all requisite authority to act on behalf of the Beneficial Owners of the ADSs registered in its name. The manner in which a Holder holds ADSs (e.g., in certificated vs. uncertificated form) may affect the rights and obligations of, and the manner in which, and the extent to which, the services are made available to, Holders pursuant to the terms of the Deposit Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement Share(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall have the respective meanings set forth in Section 2.12.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.26 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Principal Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, when used with respect to the Depositary, the principal office of the Depositary at which at any particular time its depositary receipts business shall be administered, which, at the date of the Deposit Agreement, is located at 388 Greenwich Street, New York, New York 10013, U.S.A.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.27 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Depositary or any bank or trust company having an office in the Borough of Manhattan, The City of New York, which shall be appointed by the Depositary to register issuances, transfers and cancellations of ADSs as herein provided, and shall include any co-registrar appointed by the Depositary for such purposes. Registrars (other than the Depositary) may be removed and substitutes appointed by the Depositary. Each Registrar (other than the Depositary) appointed pursuant to the Deposit Agreement shall be required to give notice in writing to the Depositary accepting such appointment and agreeing to be bound by the applicable terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.28 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted ADR(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the respective meanings set forth in Section 2.14.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.29 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Shares, Deposited Securities or ADSs which (i) have been acquired directly or indirectly from the Company or any of its Affiliates in a transaction or chain of transactions not involving any public offering and are subject to resale limitations under the Securities Act or the rules issued thereunder, or (ii) are held by an executive officer or director (or persons performing similar functions) or other Affiliate of the Company, or (iii) are subject to other restrictions on sale or deposit under the laws of the United States, Switzerland, or under a shareholder agreement or the Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation of the Company or under the regulations of an applicable securities exchange unless, in each case, such Shares, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposited Securities or ADSs are being transferred or sold to persons other than an Affiliate of the Company in a transaction (a) covered by an effective resale registration statement, or (b) exempt from the registration requirements of the Securities Act (as hereinafter defined), and the Shares, Deposited Securities or ADSs are not, when held by such person(s), Restricted Securities. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.30 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States Securities Act of 1933, as amended from time to time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.31 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Share Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean areg.ch ag, Fabrikstrasse 10, 4614 H&#228;gendorf, a company incorporated under the laws of Switzerland, or any other institution organized under the laws of Switzerland appointed by the Company (including for the avoidance of doubt, if applicable, the Company) from time to time to carry out the duties of registrar for the Shares, and any successor thereto.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.32 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s common shares, with a nominal value of CHF 0.10 each, validly issued and outstanding and fully paid and may, if the Depositary so agrees after consultation with the Company, include evidence of the right to receive Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in no event shall Shares include evidence of the right to receive Shares with respect to which the full purchase price has not been paid or Shares as to which preemptive rights have theretofore not been validly waived or exercised&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if there shall occur any change in nominal or par value, split-up, consolidation, reclassification, exchange, conversion or any other event described in Section 4.11 in respect of the Shares of the Company, the term &#8220;Shares&#8221; shall thereafter, to the maximum extent permitted by law, represent the successor securities resulting from such event.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.33 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Swiss Franc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall refer to the lawful currency of Switzerland.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.34 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Uncertificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.13.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.35 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning assigned to it in Regulation S as promulgated by the Commission under the Securities Act.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">APPOINTMENT OF DEPOSITARY&#59; FORM OF RECEIPTS&#59;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEPOSIT OF SHARES&#59; EXECUTION AND</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DELIVERY, TRANSFER AND SURRENDER OF RECEIPTS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Appointment of Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company hereby appoints the Depositary as depositary for the Deposited Property and hereby authorizes and directs the Depositary to act in accordance with the terms and conditions set forth in the Deposit Agreement and the applicable ADRs. Each Holder and each Beneficial Owner, upon acceptance of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the Deposit Agreement shall be deemed for all purposes to (a) be a party to and bound by the terms of the Deposit Agreement and the applicable ADR(s), and (b) appoint the Depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the Deposit Agreement and the applicable ADR(s), to adopt any and all procedures necessary to comply with applicable law and to take such action as the Depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the Deposit Agreement and the applicable ADR(s), the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Form and Transferability of ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certificated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADSs shall be evidenced by definitive ADRs which shall be engraved, printed, lithographed or produced in such other manner as may be agreed upon by the Company and the Depositary. ADRs may be issued under the Deposit Agreement in denominations of any whole number of ADSs. The ADRs shall be substantially in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Deposit Agreement, with any appropriate insertions, modifications and omissions, in each case as otherwise contemplated in the Deposit Agreement or required by law. ADRs shall be (i) dated, (ii) signed by the manual or facsimile signature of a duly authorized signatory of the Depositary, (iii) countersigned by the manual or facsimile signature of a duly authorized signatory of the Registrar, and (iv) registered in the books maintained by the Registrar for the registration of issuances and transfers of ADSs. No ADR and no Certificated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS evidenced thereby shall be entitled to any benefits under the Deposit Agreement or be valid or enforceable for any purpose against the Depositary or the Company, unless such ADR shall have been so dated, signed, countersigned and registered.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADRs bearing the facsimile signature of a duly-authorized signatory of the Depositary or the Registrar, who at the time of signature was a duly-authorized signatory of the Depositary or the Registrar, as the case may be, shall bind the Depositary, notwithstanding the fact that such signatory has ceased to be so authorized prior to the Delivery of such ADR by the Depositary. The ADRs shall bear a CUSIP number that is different from any CUSIP number that was, is or may be assigned to any depositary receipts previously or subsequently issued pursuant to any other arrangement between the Depositary (or any other depositary) and the Company and which are not ADRs outstanding hereunder.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The ADRs may be endorsed with, or have incorporated in the text thereof, such legends or recitals not inconsistent with the provisions of the Deposit Agreement as may be (i) necessary to enable the Depositary and the Company to perform their respective obligations hereunder, (ii) required to comply with any applicable laws or regulations, or with the rules and regulations of any securities exchange or market upon which ADSs may be traded, listed or quoted, or to conform with any usage with respect thereto, (iii) necessary to indicate any special limitations or restrictions to which any particular ADRs or ADSs are subject by reason of the date of issuance of the Deposited Securities or otherwise, or (iv) required by any book-entry system in which the ADSs are held. Holders and Beneficial Owners shall be deemed, for all purposes, to have notice of, and to be bound by, the terms and conditions of the legends set forth, in the case of Holders, on the ADR registered in the name of the applicable Holders or, in the case of Beneficial Owners, on the ADR representing the ADSs owned by such Beneficial Owners.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the limitations contained herein and in the ADR, title to an ADR (and to each Certificated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS evidenced thereby) shall be transferable upon the same terms as a certificated security under the laws of the State of New York, provided that, in the case of Certificated ADSs, such ADR has been properly endorsed or is accompanied by proper instruments of transfer. Notwithstanding any notice to the contrary, the Depositary and the Company may deem and treat the Holder of an ADS (that is, the person in whose name an ADS is registered on the books of the Depositary) as the absolute owner thereof for all purposes. Neither the Depositary nor the Company shall have any obligation nor be subject to any liability under the Deposit Agreement or any ADR to any holder or any Beneficial Owner unless, in the case of a holder of ADSs, such holder is the Holder registered on the books of the Depositary or, in the case of a Beneficial Owner, such Beneficial Owner, or the Beneficial Owner&#8217;s representative, is the Holder registered on the books of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Book-Entry Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall make arrangements for the acceptance of the ADSs into DTC. All ADSs held through DTC will be registered in the name of the nominee for DTC (currently &#8220;Cede &#38; Co.&#8221;). As such, the nominee for DTC will be the only &#8220;Holder&#8221; of all ADSs held through DTC. Unless issued by the Depositary as Uncertificated ADSs, the ADSs registered in the name of Cede &#38; Co. will be evidenced by one or more ADR(s) in the form of a &#8220;Balance Certificate,&#8221; which will provide that it represents the aggregate number of ADSs from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to time indicated in the records of the Depositary as being issued hereunder and that the aggregate number of ADSs represented thereby may from time to time be increased or decreased by making adjustments on such records of the Depositary and of DTC or its nominee as hereinafter provided. Citibank, N.A. (or such other entity as is appointed by DTC or its nominee) may hold the &#8220;Balance Certificate&#8221; as custodian for DTC. Each Beneficial Owner of ADSs held through DTC must rely upon the procedures of DTC and the DTC Participants to exercise or be entitled to any rights attributable to such ADSs. The DTC Participants shall for all purposes be deemed to have all requisite power and authority to act on behalf of the Beneficial Owners of the ADSs held in the DTC Participants&#8217; respective accounts in DTC and the Depositary shall for all purposes be authorized to rely upon any instructions and information given to it by DTC Participants. So long as ADSs are held through DTC or unless otherwise required by law, ownership of beneficial interests in the ADSs registered in the name of the nominee for DTC will be shown on, and transfers of such ownership will be effected only through, records maintained by (i) DTC or its nominee (with respect to the interests of DTC Participants), or (ii) DTC Participants or their nominees (with respect to the interests of clients of DTC Participants). Any distributions made, and any notices given, by the Depositary to DTC under the terms of the Deposit Agreement shall (unless otherwise specified by the Depositary) satisfy the Depositary&#8217;s obligations under the Deposit Agreement to make such distributions, and give such notices, in respect of the ADSs held in DTC (including, for avoidance of doubt, to the DTC Participants holding the ADSs in their DTC accounts and to the Beneficial Owners of such ADSs). </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of the Deposit Agreement and applicable law, Shares or evidence of rights to receive Shares (other than Restricted Securities) may be deposited by any person (including the Depositary in its individual capacity but subject, however, in the case of the Company or any Affiliate of the Company, to Section 5.7) at any time, whether or not the transfer books of the Company or the Share Registrar, if any, are closed, by Delivery of the Shares to the Custodian. Every deposit of Shares shall be accompanied by the following&#58; (A) (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of Shares represented by certificates issued in registered form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, appropriate instruments of transfer or endorsement, in a form satisfactory to the Custodian, (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of Shares represented by certificates in bearer form,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the requisite coupons and talons pertaining thereto, and (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of Shares delivered by book-entry transfer and recordation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, confirmation of such book-entry transfer and recordation in the books of the Share Registrar or of the applicable book-entry settlement entity, as applicable, to the Custodian or that irrevocable instructions have been given to cause such Shares to be so transferred and recorded, (B) such certifications and payments (including, without limitation, the Depositary&#8217;s fees and related charges) and evidence of such payments (including, without </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limitation, stamping or otherwise marking such Shares by way of receipt) as may be required by the Depositary or the Custodian in accordance with the provisions of the Deposit Agreement and applicable law, (C) if the Depositary so requires, a written order directing the Depositary to issue and deliver to, or upon the written order of, the person(s) stated in such order the number of ADSs representing the Shares so deposited, (D) evidence reasonably satisfactory to the Depositary (which may be an opinion of counsel) that all necessary approvals have been granted by, or there has been compliance with the rules and regulations of, any applicable governmental agency in Switzerland, and (E) if the Depositary so requires, (i) an agreement, assignment or instrument satisfactory to the Depositary or the Custodian which provides for the prompt transfer by any person in whose name the Shares are or have been recorded to the Custodian of any distribution, or right to subscribe for additional Shares or to receive other property in respect of any such deposited Shares or, in lieu thereof, such indemnity or other agreement as shall be satisfactory to the Depositary or the Custodian and (ii) if the Shares are registered in the name of the person on whose behalf they are presented for deposit, a proxy or proxies entitling the Custodian to exercise voting rights in respect of the Shares for any and all purposes until the Shares so deposited are registered in the name of the Depositary, the Custodian or any nominee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting any other provision of the Deposit Agreement, the Depositary shall instruct the Custodian not to, and the Depositary shall not knowingly, accept for deposit (a) any Restricted Securities (except as contemplated by Section 2.14) nor (b) any fractional Shares or fractional Deposited Securities nor (c) a number of Shares or Deposited Securities which upon application of the ADS to Shares ratio would give rise to fractional ADSs. No Shares shall be accepted for deposit unless accompanied by evidence, if any is required by the Depositary, that is reasonably satisfactory to the Depositary or the Custodian that all conditions to such deposit have been satisfied by the person depositing such Shares under the laws and regulations of Switzerland and any necessary approval has been granted by any applicable governmental body in Switzerland, if any. The Depositary may issue ADSs against evidence of rights to receive Shares from the Company, any agent of the Company or any custodian, registrar, transfer agent, clearing agency or other entity involved in ownership or transaction records in respect of the Shares. Such evidence of rights shall consist of written blanket or specific guarantees of ownership of Shares furnished by the Company or any such custodian, registrar, transfer agent, clearing agency or other entity involved in ownership or transaction records in respect of the Shares.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation of the foregoing, the Depositary shall not knowingly accept for deposit under the Deposit Agreement (A) any Shares or other securities required to be registered under the provisions of the Securities Act, unless (i) a registration statement is in effect as to such Shares or other securities or (ii) the deposit is made upon terms contemplated in Section 2.14, or (B) any Shares or other securities the deposit of which would violate any provisions of the Articles of Incorporation of the Company or the laws and regulations of Switzerland. For purposes of the foregoing sentence, the Depositary shall be entitled to rely upon representations and warranties made or deemed made pursuant to the Deposit Agreement and shall not be required to make any further investigation. The Depositary will comply with written instructions of the Company (received by the Depositary reasonably in advance) not to accept for deposit hereunder any Shares identified in such instructions at such times and under such circumstances as may reasonably be specified in such instructions in order to facilitate the Company's compliance with the securities laws of the United States. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Registration and Safekeeping of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall instruct the Custodian upon each Delivery of registered Shares being deposited hereunder with the Custodian (or other Deposited Securities pursuant to Article IV hereof), together with the other documents above specified, to present such Shares, together with the appropriate instrument(s) of transfer or endorsement, duly stamped, to the Share Registrar for transfer and registration of the Shares (as soon as transfer and registration can be accomplished and at the expense of the person for whom the deposit is made) in the name of the Depositary, the Custodian or a nominee of either. Deposited Securities shall be held by the Depositary, or by a Custodian for the account and to the order of the Depositary or a nominee of the Depositary, in each case, on behalf of the Holders and Beneficial Owners, at such place(s) as the Depositary or the Custodian shall determine. Notwithstanding anything else contained in the Deposit Agreement, any ADR(s), or any other instruments or agreements relating to the ADSs and the corresponding Deposited Property, the registration of the Deposited Securities in the name of the Depositary, the Custodian or any of their respective nominees, shall, to the maximum extent permitted by applicable law, vest in the Depositary, the Custodian or the applicable nominee the record ownership in the applicable Deposited Securities with the beneficial ownership rights and interests in such Deposited Securities being at all times vested with the Beneficial Owners of the ADSs representing the Deposited Securities. Notwithstanding the foregoing, the Depositary, the Custodian and the applicable nominee shall at all times be entitled to exercise the beneficial ownership rights in all Deposited Property, in each case only on behalf of the Holders and Beneficial Owners of the ADSs representing the Deposited Property, upon the terms set forth in the Deposit Agreement and, if applicable, the ADR(s) representing the ADSs. The Depositary, the Custodian and their respective nominees shall for all purposes be deemed to have all requisite </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">power and authority to act in respect of Deposited Property on behalf of the Holders and Beneficial Owners of ADSs representing the Deposited Property, and upon making payments to, or acting upon instructions from, or information provided by, the Depositary, the Custodian or their respective nominees all persons shall be authorized to rely upon such power and authority. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Issuance of ADSs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary has made arrangements with the Custodian for the Custodian to confirm to the Depositary upon receipt of a deposit of Shares (i) that a deposit of Shares has been made pursuant to Section 2.3, (ii) that such Deposited Securities have been recorded in the name of the Depositary, the Custodian or a nominee of either on the shareholders&#8217; register maintained by or on behalf of the Company by the Share Registrar or on the books of the applicable book-entry settlement entity, (iii) that all required documents have been received, and (iv) the person(s) to whom or upon whose order ADSs are deliverable in respect thereof and the number of ADSs to be so delivered. Such notification may be made by letter, cable, telex, SWIFT message or, at the risk and expense of the person making the deposit, by facsimile or other means of electronic transmission. Upon receiving such notice from the Custodian, the Depositary, subject to the terms and conditions of the Deposit Agreement and applicable law, shall issue the ADSs representing the Shares so deposited to or upon the order of the person(s) named in the notice delivered to the Depositary and, if applicable,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall execute and deliver at its Principal Office Receipt(s) registered in the name(s) requested by such person(s) and evidencing the aggregate number of ADSs to which such person(s) is&#47;are entitled, but, in each case, only upon payment to the Depositary of the charges of the Depositary for accepting a deposit of Shares and issuing ADSs (as set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto) and all taxes and governmental charges and fees payable in connection with such deposit and the transfer of the Shares and the issuance of the ADS(s). The Depositary shall only issue ADSs in whole numbers and deliver, if applicable, ADR(s) evidencing whole numbers of ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer, Combination and Split-up of ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall register the transfer of ADRs (and of the ADSs represented thereby) on the books maintained for such purpose and the Depositary shall (x) cancel such ADRs and execute new ADRs evidencing the same aggregate number of ADSs as those evidenced by the ADRs canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs and (z) Deliver such new ADRs to or upon the order of the person entitled thereto, if each of the following conditions has been satisfied&#58; (i) the ADRs have been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a transfer thereof, (ii) the surrendered ADRs have been properly endorsed or are accompanied by proper instruments of transfer (including signature guarantees in accordance with standard securities industry practice), (iii) the surrendered ADRs have been duly stamped (if required by the laws of the State of New York or of the United States), and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the terms and conditions of the applicable ADRs, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Combination &#38; Split-Up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall register the split-up or combination of ADRs (and of the ADSs represented thereby) on the books maintained for such purpose and the Depositary shall (x) cancel such ADRs and execute new ADRs for the number of ADSs requested, but in the aggregate not exceeding the number of ADSs evidenced by the ADRs canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs and (z) Deliver such new ADRs to or upon the order of the Holder thereof, if each of the following conditions has been satisfied&#58; (i) the ADRs have been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a split-up or combination thereof, and (ii) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of the applicable ADRs, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Surrender of ADSs and Withdrawal of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Holder of ADSs shall be entitled to Delivery (at the Custodian&#8217;s designated office) of the Deposited Securities at the time represented by the ADSs upon satisfaction of each of the following conditions&#58; (i) the Holder (or a duly-authorized attorney of the Holder) has duly Delivered ADSs to the Depositary at its Principal Office (and if applicable, the ADRs evidencing such ADSs) for the purpose of withdrawal of the Deposited Securities represented thereby, (ii) if applicable and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so required by the Depositary, the ADRs Delivered to the Depositary for such purpose have been properly endorsed in blank or are accompanied by proper instruments of transfer in blank (including signature guarantees in accordance with standard securities industry practice), (iii) if so required by the Depositary, the Holder of the ADSs has executed and delivered to the Depositary a written order directing the Depositary to cause the Deposited Securities being withdrawn to be Delivered to or upon the written order of the person(s) designated in such order, and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) have been paid,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of the ADRs evidencing the surrendered ADSs, of the Deposit Agreement, of the Company&#8217;s Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation and of any applicable laws and the rules of the applicable book-entry settlement entity, and to any provisions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon satisfaction of each of the conditions specified above, the Depositary (i) shall cancel the ADSs Delivered to it (and, if applicable, the ADR(s) evidencing the ADSs so Delivered), (ii) shall direct the Registrar to record the cancellation of the ADSs so Delivered on the books maintained for such purpose, and (iii) shall direct the Custodian to Deliver, or cause the Delivery of, in each case, without unreasonable delay, the Deposited Securities represented by the ADSs so canceled together with any certificate or other document of title for the Deposited Securities, or evidence of the electronic transfer thereof (if available), as the case may be, to or upon the written order of the person(s) designated in the order delivered to the Depositary for such purpose, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject however, in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the terms and conditions of the Deposit Agreement, of the ADRs evidencing the ADSs so canceled, of the Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation of the Company, of any applicable laws and of the rules of the applicable book-entry settlement entity, and to the terms and conditions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not accept for surrender ADSs representing less than one (1) Share. In the case of Delivery to it of ADSs representing a number other than a whole number of Shares, the Depositary shall cause ownership of the appropriate whole number of Shares to be Delivered in accordance with the terms hereof, and shall, at the discretion of the Depositary, either (i) return to the person surrendering such ADSs the number of ADSs representing any remaining fractional Share, or (ii) sell or cause to be sold the fractional Share represented by the ADSs so surrendered and remit the proceeds of such sale (net of (a) applicable fees and charges of, and expenses incurred by, the Depositary and (b) taxes withheld) to the person surrendering the ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in any ADR or the Deposit Agreement, the Depositary may make delivery at the Principal Office of the Depositary of Deposited Property consisting of (i) any cash dividends or cash distributions, or (ii) any proceeds from the sale of any non-cash distributions, which are at the time held by the Depositary in respect of the Deposited Securities represented by the ADSs surrendered for cancellation and withdrawal. At the request, risk and expense of any Holder so surrendering ADSs, and for the account of such Holder, the Depositary shall direct the Custodian to forward (to the extent permitted by law) any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposited Property (other than Deposited Securities) held by the Custodian in respect of such ADSs to the Depositary for delivery at the Principal Office of the Depositary. Such direction shall be given by letter or, at the request, risk and expense of such Holder, by cable, telex or facsimile transmission.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Limitations on Execution and Delivery, Transfer, etc. of ADSs&#59; Suspension of Delivery, Transfer, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As a condition precedent to the execution and Delivery, the registration of issuance, transfer, split-up, combination or surrender, of any ADS, the delivery of any distribution thereon, or the withdrawal of any Deposited Property, the Depositary or the Custodian may require (i) payment from the depositor of Shares or presenter of ADSs or of an ADR of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees and charges of the Depositary as provided in Section 5.9 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (ii) the production of proof satisfactory to it as to the identity and genuineness of any signature or any other matter contemplated by Section 3.1, and (iii) compliance with (A) any laws or governmental regulations relating to the execution and Delivery of ADRs or ADSs or to the withdrawal of Deposited Securities and (B) such reasonable regulations as the Depositary and the Company may establish consistent with the provisions of the representative ADR, if applicable, the Deposit Agreement and applicable law.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The issuance of ADSs against deposits of Shares generally or against deposits of particular Shares may be suspended, or the deposit of particular Shares may be refused, or the registration of transfer of ADSs in particular instances may be refused, or the registration of transfers of ADSs generally may be suspended, during any period when the transfer books of the Company, the Depositary, a Registrar or the Share Registrar are closed or if any such action is deemed necessary or advisable by the Depositary or the Company, in good faith, at any time or from time to time because of any requirement of law or regulation, any government or governmental body or commission or any securities exchange on which the ADSs or Shares are listed, or under any provision of the Deposit Agreement or the representative ADR(s), if applicable, or under any provision of, or governing, the Deposited Securities, or because of a meeting of shareholders of the Company or for any other reason, subject, in all cases, to Section 7.8(a).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Regulatory Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of the Deposit Agreement or any ADR(s) to the contrary, Holders are entitled to surrender outstanding ADSs to withdraw the Deposited Securities associated herewith at any time subject only to (i) temporary delays caused by closing the transfer books of the Depositary or the Company or the deposit of Shares in connection with voting at a shareholders&#8217; meeting or the payment of dividends, (ii) the payment of fees, taxes and similar charges, (iii) compliance with any U.S. or foreign laws or governmental regulations relating to the ADSs or to the withdrawal of the Deposited Securities, and (iv) other circumstances specifically contemplated by Instruction I.A.(l) of the General Instructions to Form F-6 (as such General Instructions may be amended from time to time).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Lost ADRs, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In case any ADR shall be mutilated, destroyed, lost, or stolen, the Depositary shall execute and deliver a new ADR of like tenor at the expense of the Holder (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of a mutilated ADR, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in exchange of and substitution for such mutilated ADR upon cancellation thereof, or (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in the case of a destroyed, lost or stolen ADR,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in lieu of and in substitution for such destroyed, lost, or stolen ADR, after the Holder thereof (i) has submitted to the Depositary a written request for such exchange and substitution before the Depositary has notice that the ADR has been acquired by a bona fide purchaser, (ii) has provided such security or indemnity (including an indemnity bond) as may be required by the Depositary to save it and any of its agents harmless, and (iii) has satisfied any other reasonable requirements </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">imposed by the Depositary, including, without limitation, evidence satisfactory to the Depositary of such destruction, loss or theft of such ADR, the authenticity thereof and the Holder&#8217;s ownership thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cancellation and Destruction of Surrendered ADRs&#59; Maintenance of Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> All ADRs surrendered to the Depositary shall be canceled by the Depositary. Canceled ADRs shall not be entitled to any benefits under the Deposit Agreement or be valid or enforceable against the Depositary for any purpose. The Depositary is authorized to destroy ADRs so canceled, provided the Depositary maintains a record of all destroyed ADRs. Any ADSs held in book-entry form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, through accounts at DTC) shall be deemed canceled when the Depositary causes the number of ADSs evidenced by the Balance Certificate to be reduced by the number of ADSs surrendered (without the need to physically destroy the Balance Certificate).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Escheatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event any unclaimed property relating to the ADSs, for any reason, is in the possession of Depositary and has not been claimed by the Holder thereof or cannot be delivered to the Holder thereof through usual channels, the Depositary shall, upon expiration of any applicable statutory period relating to abandoned property laws, escheat such unclaimed property to the relevant authorities in accordance with the laws of each of the relevant States of the United States. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partial Entitlement ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event any Shares are deposited which (i) entitle the holders thereof to receive a per-share distribution or other entitlement in an amount different from the Shares then on deposit or (ii) are not fully fungible (including, without limitation, as to settlement or trading) with the Shares then on deposit (the Shares then on deposit collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Full Entitlement Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the Shares with different entitlement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partial Entitlement Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Depositary shall (i) cause the Custodian to hold Partial Entitlement Shares separate and distinct from Full Entitlement Shares, and (ii) subject to the terms of the Deposit Agreement, issue ADSs representing Partial Entitlement Shares which are separate and distinct from the ADSs representing Full Entitlement Shares, by means of separate CUSIP numbering and legending (if necessary) and, if applicable, by issuing ADRs evidencing such ADSs with applicable notations thereon (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partial Entitlement ADSs&#47;ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Full Entitlement ADSs&#47;ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, respectively). If and when Partial Entitlement Shares become Full Entitlement Shares, the Depositary shall (a) give notice thereof to Holders of Partial Entitlement ADSs and give Holders of Partial Entitlement ADRs the opportunity to exchange such Partial Entitlement ADRs for Full Entitlement ADRs, (b) cause the Custodian to transfer the Partial Entitlement Shares into the account of the Full Entitlement Shares, and (c) take such actions as are necessary to remove the distinctions between (i) the Partial Entitlement ADRs and ADSs, on the one hand, and (ii) the Full Entitlement ADRs and ADSs on the other. Holders and Beneficial Owners of Partial Entitlement ADSs shall only be entitled to the entitlements of Partial Entitlement Shares. Holders and Beneficial Owners of Full Entitlement ADSs shall be entitled only to the entitlements of Full Entitlement Shares. All provisions and conditions of the Deposit Agreement shall apply to Partial Entitlement ADRs and ADSs to the same extent as Full Entitlement ADRs and ADSs, except as contemplated by this Section 2.12. The Depositary is authorized to take any and all other actions as may be necessary (including, without limitation, making the necessary notations on ADRs) to give effect to the terms of this Section 2.12. The Company agrees to give timely written notice to the Depositary if any Shares issued or to be issued are Partial Entitlement Shares and shall assist the Depositary with the establishment of procedures enabling the identification of Partial Entitlement Shares upon Delivery to the Custodian. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Certificated&#47;Uncertificated ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provision of the Deposit Agreement, the Depositary may, at any time and from time to time, issue ADSs that are not evidenced by ADRs (such ADSs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Uncertificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the ADS(s) evidenced by ADR(s), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certificated ADS(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). When issuing and maintaining Uncertificated ADS(s) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the Deposit Agreement, the Depositary shall at all times be subject to (i) the standards applicable to registrars and transfer agents maintaining direct registration systems for equity securities in New York and issuing uncertificated securities under New York law, and (ii) the terms of New York law applicable to uncertificated equity securities. Uncertificated ADSs shall not be represented by any instruments but shall be evidenced by registration in the books of the Depositary maintained for such purpose. Holders of Uncertificated ADSs, that are not subject to any registered pledges, liens, restrictions or adverse claims of which the Depositary has notice at such time, shall at all times have the right to exchange the Uncertificated ADS(s) for Certificated ADS(s) of the same type and class, subject in each case to (x) applicable laws and any rules and regulations the Depositary may have established in respect of the Uncertificated ADSs, and (y) the continued availability of Certificated ADSs in the U.S. Holders of Certificated ADSs shall, if the Depositary maintains a direct registration system for the ADSs, have the right to exchange the Certificated ADSs for Uncertificated ADSs upon (i) the due surrender of the Certificated ADS(s) to the Depositary for such purpose and (ii) the presentation of a written request to that effect to the Depositary, subject in each case to (a) all liens and restrictions noted on the ADR evidencing the Certificated ADS(s) and all adverse claims of which the Depositary then has notice, (b) the terms of the Deposit Agreement and the rules and regulations that the Depositary may establish for such purposes hereunder, (c) applicable law, and (d) payment of the Depositary fees and expenses applicable to such exchange of Certificated ADS(s) for Uncertificated ADS(s). Uncertificated ADSs shall in all material respects be identical to Certificated ADS(s) of the same type and class, except that (i) no ADR(s) shall be, or shall need to be, issued to evidence Uncertificated ADS(s), (ii) Uncertificated ADS(s) shall, subject to the terms of the Deposit Agreement, be transferable upon the same terms and conditions as uncertificated securities under New York law, (iii) the ownership of Uncertificated ADS(s) shall be recorded on the books of the Depositary maintained for such purpose and evidence of such ownership shall be reflected in periodic statements provided by the Depositary to the Holder(s) in accordance with applicable New York law, (iv) the Depositary may from time to time, upon notice to the Holders of Uncertificated ADSs affected thereby, establish rules and regulations, and amend or supplement existing rules and regulations, as may be deemed reasonably necessary to maintain Uncertificated ADS(s) on behalf of Holders, provided that (a) such rules and regulations do not conflict with the terms of the Deposit Agreement and applicable law, and (b) the terms of such rules and regulations are readily available to Holders upon request, (v) the Uncertificated ADS(s) shall not be entitled to any benefits under the Deposit Agreement or be valid or enforceable for any purpose against the Depositary or the Company unless such Uncertificated ADS(s) is&#47;are registered on the books of the Depositary maintained for such purpose, (vi) the Depositary may, in connection with any deposit of Shares resulting in the issuance of Uncertificated ADSs and with any transfer, pledge, release and cancellation of Uncertificated ADSs, require the prior receipt of such documentation as the Depositary may deem reasonably appropriate, and (vii) upon termination of the Deposit Agreement, the Depositary shall not require Holders of Uncertificated ADSs to affirmatively instruct the Depositary before remitting proceeds from the sale of the Deposited Property represented by such Holders' Uncertificated ADSs under the terms of Section 6.2. When issuing ADSs under the terms of the Deposit Agreement, including, without limitation, issuances pursuant to Sections 2.5, 4.2, 4.3, 4.4, 4.5 and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.11, the Depositary may in its discretion determine to issue Uncertificated ADSs rather than Certificated ADSs, unless otherwise specifically instructed by the applicable Holder to issue Certificated ADSs. All provisions and conditions of the Deposit Agreement shall apply to Uncertificated ADSs to the same extent as to Certificated ADSs, except as contemplated by this Section 2.13. The Depositary is authorized and directed to take any and all actions and establish any and all procedures deemed reasonably necessary to give effect to the terms of this Section 2.13. Any references in the Deposit Agreement or any ADR(s) to the terms &#8220;American Depositary Share(s)&#8221; or &#8220;ADS(s)&#8221; shall, unless the context otherwise requires, include Certificated ADS(s) and Uncertificated ADS(s). Except as set forth in this Section 2.13 and except as required by applicable law, the Uncertificated ADSs shall be treated as ADSs issued and outstanding under the terms of the Deposit Agreement. In the event that, in determining the rights and obligations </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of parties hereto with respect to any Uncertificated ADSs, any conflict arises between (a) the terms of the Deposit Agreement (other than this Section 2.13) and (b) the terms of this Section 2.13, the terms and conditions set forth in this Section 2.13 shall be controlling and shall govern the rights and obligations of the parties to the Deposit Agreement pertaining to the Uncertificated ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall, at the request and expense of the Company, establish procedures enabling the deposit hereunder of Shares that are Restricted Securities in order to enable the holder of such Shares to hold its ownership interests in such Restricted Securities in the form of ADSs issued under the terms hereof (such Shares, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Upon receipt of a written request from the Company to accept Restricted Shares for deposit hereunder, the Depositary agrees to establish procedures permitting the deposit of such Restricted Shares and the issuance of ADSs representing the right to receive, subject to the terms of the Deposit Agreement and the applicable ADR (if issued as a Certificated ADS), such deposited Restricted Shares (such ADSs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and the ADRs evidencing such Restricted ADSs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything contained in this Section 2.14, the Depositary and the Company may, to the extent not prohibited by law, agree to issue the Restricted ADSs in uncertificated form (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Uncertificated Restricted ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon such terms and conditions as the Company and the Depositary may deem necessary and appropriate. The Company shall assist the Depositary in the establishment of such procedures and agrees that it shall take all steps necessary and satisfactory to the Depositary to ensure that the establishment of such procedures does not violate the provisions of the Securities Act or any other applicable laws. The depositors of such Restricted Shares and the Holders of the Restricted ADSs may be required prior to the deposit of such Restricted Shares, the transfer of the Restricted ADRs and Restricted ADSs or the withdrawal of the Restricted Shares represented by Restricted ADSs to provide such written certifications or agreements as the Depositary or the Company may require. The Company shall provide to the Depositary in writing the legend(s) to be affixed to the Restricted ADRs (if the Restricted ADSs are to be issued as Certificated ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or to be included in the statements issued from time to time to Holders of Uncertificated ADSs (if issued as Uncertificated Restricted ADSs), which legends shall (i) be in a form reasonably satisfactory to the Depositary and (ii) contain the specific circumstances under which the Restricted ADSs, and, if applicable, the Restricted ADRs evidencing the Restricted ADSs, may be transferred or the Restricted Shares withdrawn. The Restricted ADSs issued upon the deposit of Restricted Shares shall be separately identified on the books of the Depositary and the Restricted Shares so deposited shall, to the extent required by law, be held separate and distinct from the other Deposited Securities held hereunder. The Restricted ADSs shall not be eligible for inclusion in any book-entry settlement system, including, without limitation, DTC (unless (x) otherwise agreed by the Company and the Depositary, (y) the inclusion of Restricted ADSs is acceptable to the applicable clearing system, and (z) the terms of such inclusion are generally accepted by the Commission for Restricted Securities of that type), and shall not in any way be fungible with the ADSs issued under the terms hereof that are not Restricted ADSs. The Restricted ADSs, and, if applicable, the Restricted ADRs evidencing the Restricted ADSs, shall be transferable only by the Holder thereof upon delivery to the Depositary of (i) all documentation otherwise contemplated by the Deposit Agreement and (ii) an opinion of counsel reasonably satisfactory to the Depositary setting forth, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the conditions upon which the Restricted ADSs presented, and, if applicable, the Restricted ADRs evidencing the Restricted ADSs, are transferable by the Holder thereof under applicable securities laws and the transfer restrictions contained in the legend applicable to the Restricted ADSs presented for transfer. Except as set forth in this Section 2.14 and except as required by applicable law, the Restricted ADSs and the Restricted ADRs evidencing Restricted ADSs shall be treated as ADSs and ADRs issued and outstanding under the terms of the Deposit Agreement. In the event that, in determining the rights and obligations of parties hereto with respect to any Restricted ADSs, any conflict arises between (a) the terms of the Deposit Agreement (other than this Section 2.14) and (b) the terms of (i) this Section 2.14 or (ii) the applicable Restricted ADR, the terms and conditions set forth in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.14 and of the Restricted ADR shall be controlling and shall govern the rights and obligations of the parties to the Deposit Agreement pertaining to the deposited Restricted Shares, the Restricted ADSs and Restricted ADRs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Restricted ADRs, the Restricted ADSs and the Restricted Shares cease to be Restricted Securities, the Depositary, upon receipt of (x) an opinion of counsel reasonably satisfactory to the Depositary setting forth, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Restricted ADRs, the Restricted ADSs and the Restricted Shares are not as of such time Restricted Securities, and (y) instructions from the Company to remove the restrictions applicable to the Restricted ADRs, the Restricted ADSs and the Restricted Shares, shall (i) eliminate the distinctions and separations that may have been established between the applicable Restricted Shares held on deposit under this Section 2.14 and the other Shares held on deposit under the terms of the Deposit Agreement that are not Restricted Shares, (ii) treat the newly unrestricted ADRs and ADSs on the same terms as, and fully fungible with, the other ADRs and ADSs issued and outstanding under the terms of the Deposit Agreement that are not Restricted ADRs or Restricted ADSs, and (iii) take all actions necessary to remove any distinctions, limitations and restrictions previously existing under this Section 2.14 between the applicable Restricted ADRs and Restricted ADSs, respectively, on the one hand, and the other ADRs and ADSs that are not Restricted ADRs or Restricted ADSs, respectively, on the other hand, including, without limitation, by making the newly-unrestricted ADSs eligible for inclusion in the applicable book-entry settlement systems. </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN OBLIGATIONS OF HOLDERS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND BENEFICIAL OWNERS OF ADSs</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Proofs, Certificates and Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any person presenting Shares for deposit, any Holder and any Beneficial Owner may be required, and every Holder and Beneficial Owner agrees, from time to time to provide to the Depositary and the Custodian such proof of citizenship or residence, taxpayer status, payment of all applicable taxes or other governmental charges, exchange control approval, legal or beneficial ownership of ADSs and Deposited Property, compliance with applicable laws, the terms of the Deposit Agreement or the ADR(s) evidencing the ADSs and the provisions of, or governing, the Deposited Property, to execute such certifications and to make such representations and warranties, and to provide such other information and documentation (or, in the case of Shares in registered form presented for deposit, such information relating to the registration on the books of the Company or of the Share Registrar) as the Depositary or the Custodian may deem necessary or proper or as the Company may reasonably require by written request to the Depositary consistent with its obligations under the Deposit Agreement and the applicable ADR(s). The Depositary and the Registrar, as applicable, may withhold the execution or delivery or registration of transfer of any ADR or ADS or the distribution or sale of any dividend or distribution of rights or of the proceeds thereof or, to the extent not limited by the terms of Section 7.8(a), the delivery of any Deposited Property until such proof or other information is filed or such certifications are executed, or such representations and warranties are made, or such other documentation or information provided, in each case to the Depositary&#8217;s, the Registrar&#8217;s and the Company&#8217;s satisfaction. The Depositary shall provide the Company, in a timely manner, with copies or originals if necessary and appropriate of (i) any such proofs of citizenship or residence, taxpayer status, or exchange control approval or copies of written representations and warranties which it receives from Holders and Beneficial Owners, and (ii) any other information or documents which the Company may reasonably request and which the Depositary shall request and receive from any Holder or Beneficial Owner or any person presenting Shares for deposit or ADSs for cancellation, transfer or withdrawal. Nothing herein shall obligate the Depositary to (i) obtain any information for the Company if not provided by the Holders or Beneficial Owners, or (ii) verify or vouch for the accuracy of the information so provided by the Holders or Beneficial Owners.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Liability for Taxes and Other Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any tax or other governmental charge payable by the Custodian or by the Depositary with respect to any Deposited Property, ADSs or ADRs shall be payable by the Holders and Beneficial Owners to the Depositary. The Company, the Custodian and&#47;or the Depositary may withhold or deduct from any distributions made in respect of Deposited Property held on behalf of such Holder and&#47;or Beneficial Owner, and may sell for the account of a Holder and&#47;or Beneficial Owner any or all of such Deposited Property and apply such distributions and sale proceeds in payment of, any taxes (including applicable interest and penalties) or charges that are or may be payable by Holders or Beneficial Owners in respect of the ADSs, Deposited Property and ADRs, the Holder and the Beneficial Owner remaining liable for any deficiency. The Custodian may refuse the deposit of Shares and the Depositary may refuse to issue ADSs, to deliver ADRs, register the transfer of ADSs, register the split-up or combination of ADRs and (subject to Section 7.8(a)) the withdrawal of Deposited Property until payment in full of such tax, charge, penalty or interest is received. Every Holder and Beneficial Owner agrees to indemnify the Depositary, the Company, the Custodian, and any of their agents, officers, employees and Affiliates for, and to hold each of them harmless from, any claims with respect to taxes (including applicable interest and penalties thereon) arising from (i) any ADSs held by such Holder and&#47;or owned by such Beneficial Owner, (ii) the Deposited Property represented by the ADSs, and (iii) any transaction entered into by such Holder and&#47;or Beneficial Owner in respect of the ADSs and&#47;or the Deposited Property represented thereby . Notwithstanding anything to the contrary contained in the Deposit Agreement or any ADR, the obligations of Holders and Beneficial Owners under this Section 3.2 shall survive any transfer of ADSs, any cancellation of ADSs and withdrawal of Deposited Securities, and the termination of the Deposit Agreement. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Representations and Warranties on Deposit of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each person depositing Shares under the Deposit Agreement shall be deemed thereby to represent and warrant that (i) such Shares and the certificates therefor are duly authorized, validly issued, fully paid, non-assessable and legally obtained by such person, (ii) all preemptive (and similar) rights, if any, with respect to such Shares have been validly waived or exercised, (iii) the person making such deposit is duly authorized so to do, (iv) the Shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, (v) the Shares presented for deposit are not, and the ADSs issuable upon such deposit will not be, Restricted Securities (except as contemplated in Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (vi) the Shares presented for deposit have not been stripped of any rights or entitlements, and (vii) the deposit of the Shares does not violate any applicable provisions of the laws of Switzerland. Such representations and warranties shall survive the deposit and withdrawal of Shares, the issuance and cancellation of ADSs in respect thereof and the transfer of such ADSs. If any such representations or warranties are false in any way, the Company and the Depositary shall be authorized, at the cost and expense of the person depositing Shares, to take any and all actions necessary to correct the consequences thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Information Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision included or incorporated by reference in the Deposit Agreement or any ADR(s) to any other effect, each Holder and Beneficial Owner agrees to comply with requests from the Company pursuant to applicable law, the rules and requirements of any stock exchange on which the Shares or ADSs are, or will be, registered, traded or listed or the Articles of Incorporation of the Company, which are made to provide information, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as to the capacity in which such Holder or Beneficial Owner owns ADSs (and Shares as the case may be) and regarding the identity of any other person(s) interested in such ADSs and the nature of such interest and various other matters, whether or not they are Holders and&#47;or Beneficial Owners at the time of such request. The Depositary agrees to use its reasonable efforts to forward, upon the request of the Company and at the Company&#8217;s expense, any such request from the Company to the Holders and to forward to the Company any such responses to such requests received by the Depositary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision included or incorporated by reference in the Deposit Agreement or any ADR(s) to any other effect, the Company may restrict transfers of the Shares where such transfer might result in ownership of Shares exceeding limits imposed by applicable law or the Articles of Incorporation of the Company. The Company may also restrict, in such manner as it deems appropriate, transfers of the ADSs where such transfer may result in the total number of Shares represented by the ADSs owned by a single Holder or Beneficial Owner to exceed any such limits. The Company may, in its sole discretion but subject to applicable law, instruct the Depositary to take action with respect to the ownership interest of any Holder or Beneficial Owner in excess of the limits set forth in the preceding sentence, including, but not limited to, the imposition of restrictions on the transfer of ADSs, the removal or limitation of voting rights or mandatory sale or disposition on behalf of a Holder or Beneficial Owner of the Shares represented by the ADSs held by such Holder or Beneficial Owner in excess of such limitations, if and to the extent such disposition is permitted by applicable law and the Articles of Incorporation of the Company. Nothing herein shall be interpreted as obligating the Depositary or the Company to ensure compliance with the ownership restrictions described in this Section 3.5.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reporting Obligations and Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Applicable laws and regulations may require holders and beneficial owners of Shares, including the Holders and Beneficial Owners of ADSs, to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. Holders and Beneficial Owners of ADSs are solely responsible for determining and complying with such reporting requirements and obtaining such approvals. Each Holder and each Beneficial Owner hereby agrees to make such determination, file such reports, and obtain such approvals to the extent and in the form required by applicable laws and regulations as in effect from time to time. Neither the Depositary, the Custodian, the Company or any of their respective agents or affiliates shall be required to take any actions whatsoever on behalf of Holders or Beneficial Owners to determine or satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IV</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE DEPOSITED SECURITIES</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Company intends to make a distribution of a cash dividend or other cash distribution in respect of any Deposited Securities, the Company shall give notice thereof to the Depositary at least twenty (20) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable for determining the holders of Deposited Securities entitled to receive such distribution. Upon the timely receipt of such notice, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9. Upon confirmation of the receipt of (x) any cash dividend or other cash distribution in respect of any Deposited Property (whether from the Company or otherwise), or (y) proceeds from the sale of any Deposited Property held in respect of the ADSs under the terms hereof, the Depositary will (i) if any amounts are received in a Foreign Currency, promptly convert or cause to be converted such cash dividend, distribution or proceeds into Dollars (subject to the terms and conditions of Section 4.8), (ii) if applicable and unless previously established, establish the ADS Record Date upon the terms described in Section 4.9, and (iii) distribute promptly the amount thus received (net of (a) the applicable fees and charges set forth in the Fee Schedule attached hereto as Exhibit B, and (b) applicable taxes withheld) to the Holders entitled thereto as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date. The Depositary shall distribute only such amount, however, as can be distributed without attributing to any Holder a fraction of one cent, and any balance not so distributed shall be held by the Depositary (without liability for interest thereon) and shall be added to and become part of the next sum received by the Depositary for distribution to Holders of ADSs outstanding at the time of the next distribution. If the Company, the Custodian or the Depositary is required to withhold </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and does withhold from any cash dividend or other cash distribution in respect of any Deposited Securities, or from any cash proceeds from the sales of Deposited Property, an amount on account of taxes, duties or other governmental charges, the amount distributed to Holders on the ADSs shall be reduced accordingly. Such withheld amounts shall be forwarded by the Company, the Custodian or the Depositary to the relevant governmental authority. Evidence of payment thereof by the Company shall be forwarded by the Company to the Depositary upon request. The Depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable Holders and Beneficial Owners of ADSs until the distribution can be effected or the funds that the Depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in this Section 4.1, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.1, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.1 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distribution in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Company intends to make a distribution that consists of a dividend in, or free distribution of, Shares, the Company shall give notice thereof to the Depositary at least twenty (20) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution, specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable to holders of Deposited Securities entitled to receive such distribution. Upon the timely receipt of such notice from the Company, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9. Upon receipt of confirmation from the Custodian of the receipt of the Shares so distributed by the Company, the Depositary shall either (i) subject to Section 5.9, distribute to the Holders as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date, additional ADSs, which represent in the aggregate the number of Shares received as such dividend, or free distribution, subject to the other terms of the Deposit Agreement (including, without limitation, (a) the applicable fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes), or (ii) if additional ADSs are not so distributed, take all actions necessary so that each ADS issued and outstanding after the ADS Record Date shall, to the extent permissible by law, thenceforth also represent rights and interests in the additional integral number of Shares distributed upon the Deposited Securities represented thereby (net of (a) the applicable fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes). In lieu of delivering fractional ADSs, the Depositary shall sell the number of Shares or ADSs, as the case may be, represented by the aggregate of such fractions and distribute the net proceeds upon the terms described in Section 4.1. In the event that the Depositary determines that any distribution in property (including Shares) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, or, if the Company in the fulfillment of its obligation under Section 5.7, has furnished an opinion of U.S. counsel determining that Shares must be registered under the Securities Act or other laws in order to be distributed to Holders (and no such registration statement has been declared effective), the Depositary may dispose of all or a portion of such property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable, and the Depositary shall distribute the net proceeds of any such sale (after deduction of (a) applicable taxes and (b) fees and charges of, and expenses incurred by, the Depositary) to Holders entitled thereto upon the terms described in Section 4.1. The Depositary shall hold and&#47;or distribute any unsold balance of such property in accordance with the provisions of the Deposit Agreement. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in this Section 4.2, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.2, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.2 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Elective Distributions in Cash or Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Company intends to make a distribution payable at the election of the holders of Deposited Securities in cash or in additional Shares, the Company shall give notice thereof to the Depositary at least sixty (60) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable to holders of Deposited Securities entitled to receive such elective distribution and whether or not it wishes such elective distribution to be made available to Holders of ADSs. Upon the timely receipt of a notice indicating that the Company wishes such elective distribution to be made available to Holders of ADSs, the Depositary shall consult with the Company to determine, and the Company shall assist the Depositary in its determination, whether it is lawful and reasonably practicable to make such elective distribution available to the Holders of ADSs. The Depositary shall make such elective distribution available to Holders only if (i) the Company shall have timely requested that the elective distribution be made available to Holders, (ii) the Depositary shall have determined that such distribution is reasonably practicable and (iii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7. If the above conditions are not satisfied or if the Company requests such elective distribution not to be made available to Holders of ADSs, the Depositary shall establish the ADS Record Date on the terms described in Section 4.9 and, to the extent permitted by law, distribute to the Holders, on the basis of the same determination as is made in Switzerland in respect of the Shares for which no election is made, either (X) cash upon the terms described in Section 4.1 or (Y) additional ADSs representing such additional Shares upon the terms described in Section 4.2. If the above conditions are satisfied, the Depositary shall establish an ADS Record Date on the terms described in Section 4.9 and establish procedures to enable Holders to elect the receipt of the proposed distribution in cash or in additional ADSs. The Company shall assist the Depositary in establishing such procedures to the extent necessary. If a Holder elects to receive the proposed distribution (X) in cash, the distribution shall be made upon the terms described in Section 4.1, or (Y) in ADSs, the distribution shall be made upon the terms described in Section 4.2. Nothing herein shall obligate the Depositary to make available to Holders a method to receive the elective distribution in Shares (rather than ADSs). There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of Shares. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in this Section 4.3, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.3, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.3 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distribution of Rights to Purchase Additional ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distribution to ADS Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whenever the Company intends to distribute to the holders of the Deposited Securities rights to subscribe for additional Shares, the Company shall give notice thereof to the Depositary at least sixty (60) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the proposed distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifying, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the record date applicable to holders of Deposited Securities entitled to receive such distribution and whether or not it wishes such rights to be made available to Holders of ADSs. Upon the timely receipt of a notice indicating that the Company wishes such rights to be made available to Holders of ADSs, the Depositary shall consult with the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to determine, and the Company shall assist the Depositary in its determination, whether it is lawful and reasonably practicable to make such rights available to the Holders. The Depositary shall make such rights available to Holders only if (i) the Company shall have timely requested that such rights be made available to Holders, (ii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7, and (iii) the Depositary shall have determined that such distribution of rights is reasonably practicable. In the event any of the conditions set forth above are not satisfied or if the Company requests that the rights not be made available to Holders of ADSs, the Depositary shall proceed with the sale of the rights as contemplated in Section 4.4(b) below. In the event all conditions set forth above are satisfied, the Depositary shall establish the ADS Record Date (upon the terms described in Section 4.9) and establish procedures to (x) distribute rights to purchase additional ADSs (by means of warrants or otherwise), (y) enable the Holders to exercise such rights (upon payment of the subscription price and of the applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes), and (z) deliver ADSs upon the valid exercise of such rights. The Company shall assist the Depositary to the extent necessary in establishing such procedures. Nothing herein shall obligate the Depositary to make available to the Holders a method to exercise rights to subscribe for Shares (rather than ADSs).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sale of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (i) the Company does not timely request the Depositary to make the rights available to Holders or requests that the rights not be made available to Holders, (ii) the Depositary fails to receive satisfactory documentation within the terms of Section 5.7, or determines it is not reasonably practicable to make the rights available to Holders, or (iii) any rights made available are not exercised and appear to be about to lapse, the Depositary shall determine whether it is lawful and reasonably practicable to sell such rights, in a riskless principal capacity, at such place and upon such terms (including public or private sale) as it may deem practicable. The Company shall assist the Depositary to the extent necessary to determine such legality and practicability. The Depositary shall, upon such sale, convert and distribute proceeds of such sale (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) upon the terms set forth in Section 4.1.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Lapse of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Depositary is unable to make any rights available to Holders upon the terms described in Section 4.4(a) or to arrange for the sale of the rights upon the terms described in Section 4.4(b), the Depositary shall allow such rights to lapse.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for (i) any failure to accurately determine whether it may be lawful or practicable to make such rights available to Holders in general or any Holders in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale, or exercise, or (iii) the content of any materials forwarded to the Holders on behalf of the Company in connection with the rights distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Section 4.4, if registration (under the Securities Act or any other applicable law) of the rights or the securities to which any rights relate may be required in order for the Company to offer such rights or such securities to Holders and to sell the securities represented by such rights, the Depositary will not distribute such rights to the Holders (i) unless and until a registration statement under the Securities Act (or other applicable law) covering such offering is in effect or (ii) unless the Company furnishes the Depositary opinion(s) of counsel for the Company in the United States and counsel to the Company in any other applicable country in which rights would be distributed, in each case reasonably satisfactory to the Depositary, to the effect that the offering and sale of such securities to Holders and Beneficial Owners are exempt from, or do not require registration under, the provisions of the Securities Act or any other applicable laws. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Company, the Depositary or the Custodian shall be required to withhold and does withhold from any distribution of Deposited Property (including rights) an amount on account of taxes or other governmental charges, the amount distributed to the Holders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of ADSs shall be reduced accordingly. In the event that the Depositary determines that any distribution of Deposited Property (including Shares and rights to subscribe therefor) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, the Depositary may dispose of all or a portion of such Deposited Property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable to pay any such taxes or charges.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive or exercise rights on the same terms and conditions as the holders of Shares or be able to exercise such rights. Nothing herein shall obligate the Company to file any registration statement in respect of any rights or Shares or other securities to be acquired upon the exercise of such rights.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distributions Other Than Cash, Shares or Rights to Purchase Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whenever the Company intends to distribute to the holders of Deposited Securities property other than cash, Shares or rights to purchase additional Shares, the Company shall give timely notice thereof to the Depositary and shall indicate whether or not it wishes such distribution to be made to Holders of ADSs. Upon receipt of a notice indicating that the Company wishes such distribution to be made to Holders of ADSs, the Depositary shall consult with the Company, and the Company shall assist the Depositary, to determine whether such distribution to Holders is lawful and reasonably practicable. The Depositary shall not make such distribution unless (i) the Company shall have requested the Depositary to make such distribution to Holders, (ii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7, and (iii) the Depositary shall have determined that such distribution is reasonably practicable.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon receipt of satisfactory documentation and the request of the Company to distribute property to Holders of ADSs and after making the requisite determinations set forth in (a) above, the Depositary shall distribute the property so received to the Holders of record, as of the ADS Record Date, in proportion to the number of ADSs held by them respectively and in such manner as the Depositary may deem practicable for accomplishing such distribution (i) upon receipt of payment or net of the applicable fees and charges of, and expenses incurred by, the Depositary, and (ii) net of any applicable taxes withheld. The Depositary may dispose of all or a portion of the property so distributed and deposited, in such amounts and in such manner (including public or private sale) as the Depositary may deem practicable or necessary to satisfy any taxes (including applicable interest and penalties) or other governmental charges applicable to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (i) the Company does not request the Depositary to make such distribution to Holders or requests the Depositary not to make such distribution to Holders, (ii) the Depositary does not receive satisfactory documentation within the terms of Section 5.7, or (iii) the Depositary determines that all or a portion of such distribution is not reasonably practicable, the Depositary shall sell or cause such property to be sold in a public or private sale, at such place or places and upon such terms as it may deem practicable and shall (i) cause the proceeds of such sale, if any, to be converted into Dollars and (ii) distribute the proceeds of such conversion received by the Depositary (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) to the Holders as of the ADS Record Date upon the terms of Section 4.1. If the Depositary is unable to sell such property, the Depositary may dispose of such property for the account of the Holders in any way it deems reasonably practicable under the circumstances.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Depositary nor the Company shall be liable for (i) any failure to accurately determine whether it is lawful or practicable to make the property described in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.5 available to Holders in general or any Holders in particular, nor (ii) any loss incurred in connection with the sale or disposal of such property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Distributions with Respect to Deposited Securities in Bearer Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms of this Article IV, distributions in respect of Deposited Securities that are held by the Depositary or the Custodian in bearer form shall be made to the Depositary for the account of the respective Holders of ADS(s) with respect to which any such distribution is made upon due presentation by the Depositary or the Custodian to the Company of any relevant coupons, talons, or certificates. The Company shall promptly notify the Depositary of such distributions. The Depositary or the Custodian shall promptly present such coupons, talons or certificates, as the case may be, in connection with any such distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If the Company intends to exercise any right of redemption in respect of any of the Deposited Securities, the Company shall give notice thereof to the Depositary at least sixty (60) days (or such other number of days as mutually agreed to in writing by the Depositary and the Company) prior to the intended date of redemption which notice shall set forth the particulars of the proposed redemption. Upon timely receipt of (i) such notice and (ii) satisfactory documentation given by the Company to the Depositary within the terms of Section 5.7, and only if the Depositary shall have determined that such proposed redemption is practicable, the Depositary shall provide to each Holder a notice setting forth the intended exercise by the Company of the redemption rights and any other particulars set forth in the Company&#8217;s notice to the Depositary. The Depositary shall instruct the Custodian to present to the Company the Deposited Securities in respect of which redemption rights are being exercised against payment of the applicable redemption price. Upon receipt of confirmation from the Custodian that the redemption has taken place and that funds representing the redemption price have been received, the Depositary shall convert, transfer, and distribute the proceeds (net of applicable (a) fees and charges of, and the expenses incurred by, the Depositary, and (b) taxes), retire ADSs and cancel ADRs, if applicable, upon delivery of such ADSs by Holders thereof and the terms set forth in Sections 4.1 and 6.2. If less than all outstanding Deposited Securities are redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as may be determined by the Depositary. The redemption price per ADS shall be the dollar equivalent of the per share amount received by the Depositary (adjusted to reflect the ADS(s)-to-Share(s) ratio) upon the redemption of the Deposited Securities represented by ADSs (subject to the terms of Section 4.8 and the applicable fees and charges of, and expenses incurred by, the Depositary, and applicable taxes) multiplied by the number of Deposited Securities represented by each ADS redeemed.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed redemption provided for in this Section 4.7, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in this Section 4.7, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in this Section 4.7 where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conversion of Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever the Depositary or the Custodian shall receive Foreign Currency, by way of dividends or other distributions or the net proceeds from the sale of Deposited Property, which in the judgment of the Depositary can at such time be converted on a practicable basis, by sale or in any other manner that it may determine in accordance with applicable law, into Dollars transferable to the United States and distributable to the Holders entitled thereto, the Depositary shall convert or cause to be converted, by sale or in any other manner that it may reasonably determine, such Foreign Currency into Dollars, and shall distribute such Dollars (net of the fees and charges set forth in the Fee Schedule attached hereto as Exhibit B, and applicable taxes withheld) in accordance with the terms of the applicable sections of the Deposit Agreement. The Depositary and&#47;or its agent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(which may be a division, branch or Affiliate of the Depositary) may act as principal for any conversion of Foreign Currency. If the Depositary shall have distributed warrants or other instruments that entitle the holders thereof to such Dollars, the Depositary shall distribute such Dollars to the holders of such warrants and&#47;or instruments upon surrender thereof for cancellation, in either case without liability for interest thereon. Such distribution may be made upon an averaged or other practicable basis without regard to any distinctions among Holders on account of any application of exchange restrictions or otherwise.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If such conversion or distribution generally or with regard to a particular Holder can be effected only with the approval or license of any government or agency thereof, the Depositary shall have authority to file such application for approval or license, if any, as it may deem desirable. In no event, however, shall the Depositary be obligated to make such a filing.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If at any time the Depositary shall determine that in its judgment the conversion of any Foreign Currency and the transfer and distribution of proceeds of such conversion received by the Depositary is not practicable or lawful, or if any approval or license of any governmental authority or agency thereof that is required for such conversion, transfer and distribution is denied or, in the opinion of the Depositary, not obtainable at a reasonable cost or within a reasonable period, the Depositary may, in its discretion, (i) make such conversion and distribution in Dollars to the Holders for whom such conversion, transfer and distribution is lawful and practicable, (ii) distribute the Foreign Currency (or an appropriate document evidencing the right to receive such Foreign Currency) to Holders for whom this is lawful and practicable, or (iii) hold (or cause the Custodian to hold) such Foreign Currency (without liability for interest thereon) for the respective accounts of the Holders entitled to receive the same.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fixing of ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever (a) the Depositary shall receive notice of the fixing of a record date by the Company for the determination of holders of Deposited Securities entitled to receive any distribution (whether in cash, Shares, rights, or other distribution), (b) for any reason the Depositary causes a change in the number of Shares that are represented by each ADS, (c) the Depositary shall receive notice of any meeting of, or solicitation of consents or proxies of, holders of Shares or other Deposited Securities, or (d) the Depositary shall find it necessary or convenient in connection with the giving of any notice, solicitation of any consent or any other matter, the Depositary shall fix the record date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the determination of the Holders of ADS(s) who shall be entitled to receive such distribution, to give instructions for the exercise of voting rights at any such meeting, to give or withhold such consent, to receive such notice or solicitation or to otherwise take action, or to exercise the rights of Holders with respect to such changed number of Shares represented by each ADS. The Depositary shall make reasonable efforts to establish the ADS Record Date as closely as practicable to the applicable record date for the Deposited Securities (if any) set by the Company in Switzerland and shall not announce the establishment of any ADS Record Date prior to the relevant corporate action having been made public by the Company (if such corporate action affects the Deposited Securities). Subject to applicable law and the provisions of Section 4.1 through 4.8 and to the other terms and conditions of the Deposit Agreement, only the Holders of ADSs at the close of business in New York on such ADS Record Date shall be entitled to receive such distribution, to give such voting instructions, to receive such notice or solicitation, or otherwise take action.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Voting of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As soon as practicable after receipt of notice of any meeting at which the holders of Deposited Securities are entitled to vote, or of solicitation of consents or proxies from holders of Deposited Securities, the Depositary shall fix the ADS Record Date in respect of such meeting or solicitation of consent or proxy in accordance with Section 4.9. The Depositary shall, if requested by the Company in writing in a timely manner (the Depositary having no obligation to take any further action if the request shall not have been received by the Depositary at least thirty (30) days prior to the date of such meeting or consent or proxy solicitation), at the Company&#8217;s expense and provided no U.S. legal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prohibitions exist, distribute to Holders as of the ADS Record Date&#58; (a) such notice of meeting or solicitation of consent or proxy, (b) a statement that the Holders at the close of business on the ADS Record Date will be entitled, subject to any applicable law, the provisions of the Deposit Agreement, the Articles of Incorporation of the Company and the provisions of or governing the Deposited Securities (which provisions, if any, shall be summarized in pertinent part by the Company), to instruct the Depositary as to the exercise of the voting rights, if any, pertaining to the Deposited Securities represented by such Holder&#8217;s ADSs, and (c) a brief statement as to the manner in which such voting instructions may be given. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement or any ADR, the Depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the Depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of Deposited Securities, distribute to the Holders a notice that provides Holders with, or otherwise publicizes to Holders, instructions on how to retrieve such materials or receive such materials upon request (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Voting instructions may be given only in respect of a number of ADSs representing an integral number of Deposited Securities. Upon the timely receipt from a Holder of ADSs as of the ADS Record Date of voting instructions in the manner specified by the Depositary, the Depositary shall endeavor, insofar as practicable and permitted under applicable law, the provisions of the Deposit Agreement, Articles of Incorporation of the Company and the provisions of the Deposited Securities, to vote, or cause the Custodian to vote, the Deposited Securities (in person or by proxy) represented by such Holder&#8217;s ADSs in accordance with such voting instructions. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposited Securities represented by ADSs for which no timely voting instructions are received by the Depositary from the Holder shall not be voted. Neither the Depositary nor the Custodian shall under any circumstances exercise any discretion as to voting and neither the Depositary nor the Custodian shall vote, attempt to exercise the right to vote, or in any way make use of, the Deposited Securities represented by ADSs, except pursuant to and in accordance with the voting instructions timely received from Holders or as otherwise contemplated herein. If the Depositary timely receives voting instructions from a Holder which fail to specify the manner in which the Depositary is to vote the Deposited Securities represented by such Holder&#8217;s ADSs, the Depositary will deem such Holder (unless otherwise specified in the notice distributed to Holders) to have instructed the Depositary to take all steps necessary to enable the independent proxy holder, as elected by the shareholders of the Company, to vote in accordance with the written proposals or recommendations of the Company&#8217;s Board of Directors. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained herein, the Depositary shall, if so requested in writing by the Company, represent all Deposited Securities (whether or not voting instructions have been received in respect of such Deposited Securities from Holders as of the ADS Record Date) for the sole purpose of establishing quorum at a meeting of shareholders.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in the Deposit Agreement or any ADR, the Depositary shall not have any obligation to take any action with respect to any meeting, or solicitation of consents or proxies, of holders of Deposited Securities if the taking of such action would violate U.S. laws. The Company agrees to take any and all actions reasonably necessary and as permitted by the law of Switzerland to enable Holders and Beneficial Owners to exercise the voting rights accruing to the Deposited Securities and to deliver to the Depositary an opinion of U.S. counsel addressing any actions reasonably requested to be taken if so requested by the Depositary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally or any Holder in particular will receive the notice described above with sufficient time to enable the Holder to return voting instructions to the Depositary, or otherwise take action, in a timely manner.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Changes Affecting Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon any change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of Deposited Securities, or upon any recapitalization, reorganization, merger, consolidation or sale of assets affecting the Company or to which it is a party, any property which shall be received by the Depositary or the Custodian in exchange for, or in conversion of, or replacement of, or otherwise in respect of, such Deposited Securities shall, to the extent permitted by law, be treated as new Deposited Property under the Deposit Agreement, and the ADSs shall, subject to the provisions of the Deposit Agreement, any ADR(s) evidencing such ADSs and applicable law, represent the right to receive such additional or replacement Deposited Property. In giving effect to such change, split-up, cancellation, consolidation or other reclassification of Deposited Securities, recapitalization, reorganization, merger, consolidation or sale of assets, the Depositary may, with the Company&#8217;s approval, and shall, if the Company shall so request, subject to the terms of the Deposit Agreement (including, without limitation, (a) the applicable fees and charges of, and expenses incurred by, the Depositary, and (b) applicable taxes) and receipt of an opinion of counsel to the Company reasonably satisfactory to the Depositary that such actions are not in violation of any applicable laws or regulations, (i) issue and deliver additional ADSs as in the case of a stock dividend on the Shares, (ii) amend the Deposit Agreement and the applicable ADRs, (iii) amend the applicable Registration Statement(s) on Form F-6 as filed with the Commission in respect of the ADSs, (iv) call for the surrender of outstanding ADRs to be exchanged for new ADRs, and (v) take such other actions as are appropriate to reflect the transaction with respect to the ADSs. The Company agrees to, jointly with the Depositary, amend the Registration Statement on Form F-6 as filed with the Commission to permit the issuance of such new form of ADRs. Notwithstanding the foregoing, in the event that any Deposited Property so received may not be lawfully distributed to some or all Holders, the Depositary may, with the Company&#8217;s approval, and shall, if the Company requests, subject to receipt of an opinion of Company&#8217;s counsel reasonably satisfactory to the Depositary that such action is not in violation of any applicable laws or regulations, sell such Deposited Property at public or private sale, at such place or places and upon such terms as it may deem proper and may allocate the net proceeds of such sales (net of (a) fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes) for the account of the Holders otherwise entitled to such Deposited Property upon an averaged or other practicable basis without regard to any distinctions among such Holders and distribute the net proceeds so allocated to the extent practicable as in the case of a distribution received in cash pursuant to Section 4.1. The Depositary shall not be responsible for (i) any failure to determine that it may be lawful or practicable to make such Deposited Property available to Holders in general or to any Holder in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale, or (iii) any liability to the purchaser of such Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Available Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company is subject to the periodic reporting requirements of the Exchange Act and, accordingly, is required to file or furnish certain reports with the Commission. These reports can be retrieved from the Commission's website (www.sec.gov) and can be inspected and copied at the public reference facilities maintained by the Commission located (as of the date of the Deposit Agreement) at 100 F Street, N.E., Washington D.C. 20549.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall make available for inspection by Holders at its Principal Office any reports and communications, including any proxy soliciting materials, received from the Company which are both (a) received by the Depositary, the Custodian, or the nominee of either of them as the holder of the Deposited Property and (b) made generally available to the holders of such Deposited Property by the Company. The Depositary shall also </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide or make available to Holders copies of such reports when furnished by the Company pursuant to Section 5.6.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">List of Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Promptly upon written request by the Company, the Depositary shall furnish to it a list, as of a recent date, of the names, addresses and holdings of ADSs of all Holders.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Depositary will, and will instruct the Custodian to, forward to the Company or its agents such information from its records as the Company may reasonably request to enable the Company or its agents to file the necessary tax reports with governmental authorities or agencies. The Depositary, the Custodian or the Company and its agents may file such reports as are necessary to reduce or eliminate applicable taxes on dividends and on other distributions in respect of Deposited Property under applicable tax treaties or laws for the Holders and Beneficial Owners. In accordance with instructions from the Company and to the extent practicable, the Depositary or the Custodian will take reasonable administrative actions to obtain tax refunds, reduced withholding of tax at source on dividends and other benefits under applicable tax treaties or laws with respect to dividends and other distributions on the Deposited Property. As a condition to receiving such benefits, Holders and Beneficial Owners of ADSs may be required from time to time, and in a timely manner, to file such proof of taxpayer status, residence and beneficial ownership (as applicable), to execute such certificates and to make such representations and warranties, or to provide any other information or documents, as the Depositary or the Custodian may deem necessary or proper to fulfill the Depositary&#8217;s or the Custodian&#8217;s obligations under applicable law. The Depositary and the Company shall have no obligation or liability to any person if any Holder or Beneficial Owner fails to provide such information or if such information does not reach the relevant tax authorities in time for any Holder or Beneficial Owner to obtain the benefits of any tax treatment. The Holders and Beneficial Owners shall indemnify the Depositary, the Company, the Custodian and any of their respective directors, employees, agents and Affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or other tax benefit obtained.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company (or any of its agents) withholds from any distribution any amount on account of taxes or governmental charges, or pays any other tax in respect of such distribution (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, stamp duty tax, capital gains or other similar tax), the Company shall (or shall cause such agent to) remit promptly to the Depositary information about such taxes or governmental charges withheld or paid, and, if so requested, the tax receipt (or other proof of payment to the applicable governmental authority) therefor, in each case, in a form reasonably satisfactory to the Depositary. The Depositary shall, to the extent required by U.S. law, report to Holders any taxes withheld by it or the Custodian, and, if such information is provided to it by the Company, any taxes withheld by the Company. The Depositary and the Custodian shall not be required to provide the Holders with any evidence of the remittance by the Company (or its agents) of any taxes withheld, or of the payment of taxes by the Company, except to the extent the evidence is provided by the Company to the Depositary or the Custodian, as applicable. Neither the Depositary nor the Custodian shall be liable for the failure by any Holder or Beneficial Owner to obtain the benefits of credits on the basis of non-U.S. tax paid against such Holder&#8217;s or Beneficial Owner&#8217;s income tax liability.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary is under no obligation to provide the Holders and Beneficial Owners with any information about the tax status of the Company. The Depositary shall not incur any liability for any tax consequences that may be incurred by Holders and Beneficial Owners on account of their ownership of the ADSs, including without limitation, tax consequences resulting from the Company (or any of its subsidiaries) being treated as a &#8220;Passive Foreign Investment Company&#8221; (in each case as defined in the U.S. Internal Revenue Code and the regulations issued thereunder) or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE DEPOSITARY, THE CUSTODIAN AND THE COMPANY</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Maintenance of Office and Transfer Books by the Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Until termination of the Deposit Agreement in accordance with its terms, the Registrar shall maintain in the Borough of Manhattan, the City of New York, an office and facilities for the issuance and delivery of ADSs, the acceptance for surrender of ADS(s) for the purpose of withdrawal of Deposited Securities, the registration of issuances, cancellations, transfers, combinations and split-ups of ADS(s) and, if applicable, to countersign ADRs evidencing the ADSs so issued, transferred, combined or split-up, in each case in accordance with the provisions of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall keep books for the registration of ADSs which at all reasonable times shall be open for inspection by the Company and by the Holders of such ADSs, provided that such inspection shall not be, to the Registrar&#8217;s knowledge, for the purpose of communicating with Holders of such ADSs in the interest of a business or object other than the business of the Company or other than a matter related to the Deposit Agreement or the ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar may close the transfer books with respect to the ADSs, at any time or from time to time, when deemed necessary or advisable by it in good faith in connection with the performance of its duties hereunder, or at the reasonable written request of the Company subject, in all cases, to Section 7.8(a).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any ADSs are listed on one or more stock exchanges or automated quotation systems in the United States, the Depositary shall act as Registrar or appoint a Registrar or one or more co-registrars for registration of issuances, cancellations, transfers, combinations and split-ups of ADSs and, if applicable, to countersign ADRs evidencing the ADSs so issued, transferred, combined or split-up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in accordance with any requirements of such exchanges or systems. Such Registrar or co-registrars may be removed and a substitute or substitutes appointed by the Depositary. As promptly as practicable, the Depositary shall notify the Company of any such removal or appointment.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exoneration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement or any ADR, neither the Depositary nor the Company shall be obligated to do or perform any act or thing which is inconsistent with the provisions of the Deposit Agreement or incur any liability (to the extent not limited by Section 7.8(b)) (i) if the Depositary, the Custodian, the Company or their respective agents shall be prevented or forbidden from, hindered or delayed in, doing or performing any act or thing required or contemplated by the terms of the Deposit Agreement, by reason of any provision of any present or future law or regulation of the United States, Switzerland or any other country, or of any other governmental authority or regulatory authority or stock exchange, or on account of potential criminal or civil penalties or restraint, or by reason of any provision, present or future, of the Articles of Incorporation of the Company or any provision of or governing any Deposited Securities, or by reason of any act of God or other event or circumstance beyond its control (including, without limitation, fire, flood, earthquake, tornado, hurricane, tsunami, explosion, or other natural disaster, nationalization, expropriation, currency restriction, work stoppage, strikes, civil unrest, act of war (whether declared or not) or terrorism, revolution, rebellion, embargo, computer failure, failure of public infrastructure (including communication or utility failure), failure of common carriers, nuclear, cyber or biochemical incident, any pandemic, epidemic or other prevalent disease or illness with an actual or probable threat to human life, any quarantine order or travel restriction imposed by a governmental authority or other competent public health authority, or the failure or unavailability of the United States Federal Reserve Bank (or other central banking system) or DTC (or other clearing system)), (ii) by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement or in the Articles of Incorporation of the Company or provisions of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or governing Deposited Securities, (iii) for any action or inaction in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Holder, any Beneficial Owner or authorized representative thereof, or any other person believed by it in good faith to be competent to give such advice or information, (iv) for the inability by a Holder or Beneficial Owner to benefit from any distribution, offering, right or other benefit which is made available to holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Holders of ADSs, (v) for any action or inaction of any clearing or settlement system (and any participant thereof) for the Deposited Property or the ADSs, or (vi) for any consequential or punitive damages (including lost profits) for any breach of the terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary, its controlling persons, its agents, any Custodian and the Company, its controlling persons and its agents may rely and shall be protected in acting upon any written notice, request or other document believed by it to be genuine and to have been signed or presented by the proper party or parties.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Standard of Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company and the Depositary assume no obligation and shall not be subject to any liability under the Deposit Agreement or any ADRs to any Holder(s) or Beneficial Owner(s), except that the Company and the Depositary agree to perform their respective obligations specifically set forth in the Deposit Agreement or the applicable ADRs without negligence or bad faith.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation of the foregoing, neither the Depositary, nor the Company, nor any of their respective controlling persons, or agents, shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Property or in respect of the ADSs, which in its opinion may involve it in expense or liability, unless indemnity satisfactory to it against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be required (and no Custodian shall be under any obligation whatsoever with respect to such proceedings, the responsibility of the Custodian being solely to the Depositary).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary and its agents shall not be liable for any failure to carry out any instructions to vote any of the Deposited Securities, or for the manner in which any vote is cast or the effect of any vote, provided that any such action or omission is in good faith and without negligence and in accordance with the terms of the Deposit Agreement. The Depositary shall not incur any liability for any failure to accurately determine that any distribution or action may be lawful or reasonably practicable, for the content of any information submitted to it by the Company for distribution to the Holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the Deposited Property, for the validity or worth of the Deposited Property, for the value of any Deposited Property or any distribution thereon, for any interest on Deposited Property, for any tax consequences that may result from the ownership of ADSs, Shares or other Deposited Property, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the Deposit Agreement, for the failure or timeliness of any notice from the Company, or for any action of or failure to act by, or any information provided or not provided by, DTC or any DTC Participant.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a predecessor depositary whether in connection with an act or omission of the Depositary or in connection with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any matter arising wholly prior to the appointment of the Depositary or after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Resignation and Removal of the Depositary&#59; Appointment of Successor Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may at any time resign as Depositary hereunder by written notice of resignation delivered to the Company, such resignation to be effective on the earlier of (i) the 90th day after delivery thereof to the Company (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2), or (ii) the appointment by the Company of a successor depositary and its acceptance of such appointment as hereinafter provided.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may at any time be removed by the Company by written notice of such removal, which removal shall be effective on the later of (i) the 90th day after delivery thereof to the Depositary (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2), or (ii) upon the appointment by the Company of a successor depositary and its acceptance of such appointment as hereinafter provided.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In case at any time the Depositary acting hereunder shall resign or be removed, the Company shall use its commercially reasonable efforts to appoint a successor depositary, which shall be a bank or trust company having an office in the Borough of Manhattan, the City of New York. Every successor depositary shall be required by the Company to execute and deliver to its predecessor and to the Company an instrument in writing accepting its appointment hereunder, and thereupon such successor depositary, without any further act or deed (except as required by applicable law), shall become fully vested with all the rights, powers, duties and obligations of its predecessor (other than as contemplated in Sections 5.8 and 5.9). The predecessor depositary, upon payment of all sums due it and on the written request of the Company, shall, (i) execute and deliver an instrument transferring to such successor all rights and powers of such predecessor hereunder (other than as contemplated in Sections 5.8 and 5.9), (ii) duly assign, transfer and deliver all of the Depositary&#8217;s right, title and interest to the Deposited Property to such successor, and (iii) deliver to such successor a list of the Holders of all outstanding ADSs and such other information relating to ADSs and Holders thereof as the successor may reasonably request. Any such successor depositary shall promptly provide notice of its appointment to such Holders.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any entity into or with which the Depositary may be merged or consolidated shall be the successor of the Depositary without the execution or filing of any document or any further act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">The Custodian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary has initially appointed Citibank N.A. London Branch as Custodian for the purpose of the Deposit Agreement. The Custodian or its successors in acting hereunder shall be authorized to act as custodian in Switzerland and shall be subject at all times and in all respects to the direction of the Depositary for the Deposited Property for which the Custodian acts as custodian and shall be responsible solely to it. If any Custodian resigns or is discharged from its duties hereunder with respect to any Deposited Property and no other Custodian has previously been appointed hereunder, the Depositary shall promptly appoint a substitute custodian. The Depositary shall require such resigning or discharged Custodian to Deliver, or cause the Delivery of, the Deposited Property held by it, together with all such records maintained by it as Custodian with respect to such Deposited Property as the Depositary may request, to the Custodian designated by the Depositary. Whenever the Depositary determines, in its discretion, that it is appropriate to do so, it may appoint an additional custodian with respect to any Deposited Property, or discharge the Custodian with respect to any Deposited Property and appoint a substitute custodian, which shall thereafter be Custodian hereunder with respect to the Deposited Property. Immediately upon any such change, the Depositary shall give notice thereof in writing to all Holders of ADSs, each other Custodian and the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Citibank may at any time act as Custodian of the Deposited Property pursuant to the Deposit Agreement, in which case any reference to Custodian shall mean Citibank solely in its capacity as Custodian pursuant to the Deposit Agreement. Notwithstanding anything contained in the Deposit Agreement or any ADR to the contrary, the Depositary shall not be obligated to give notice to the Company, any Holders of ADSs or any other Custodian of its acting as Custodian pursuant to the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the appointment of any successor depositary, any Custodian then acting hereunder shall, unless otherwise instructed by the Depositary, continue to be the Custodian of the Deposited Property without any further act or writing, and shall be subject to the direction of the successor depositary. The successor depositary so appointed shall, nevertheless, on the written request of any Custodian, execute and deliver to such Custodian all such instruments as may be proper to give to such Custodian full and complete power and authority to act on the direction of such successor depositary.</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices and Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> On or before the first date on which the Company gives notice, by publication or otherwise, of any meeting of holders of Shares or other Deposited Securities, or of any adjourned meeting of such holders, or of the taking of any action by such holders other than at a meeting, or of the taking of any action in respect of any cash or other distributions or the offering of any rights in respect of Deposited Securities, the Company shall transmit to the Depositary and the Custodian a copy of the notice thereof in the English language but otherwise in the form given or to be given to holders of Shares or other Deposited Securities. The Company shall also furnish to the Custodian and the Depositary a summary, in English, of any applicable provisions or proposed provisions of the Articles of Incorporation of the Company that may be relevant or pertain to such notice of meeting or be the subject of a vote thereat.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will also transmit to the Depositary (a) an English language version of the other notices, reports and communications which are made generally available by the Company to holders of its Shares or other Deposited Securities and (b) the English-language versions of the Company&#8217;s annual and semi-annual reports prepared in accordance with the applicable requirements of the Commission to the extent such notices, reports and communications are not available on the Company&#8217;s website or are not otherwise publicly available. The Depositary shall arrange, at the request of the Company and at the Company&#8217;s expense, to provide copies thereof to all Holders or make such notices, reports and other communications available to all Holders on a basis similar to that for holders of Shares or other Deposited Securities or on such other basis as the Company may advise the Depositary or as may be required by any applicable law, regulation or stock exchange requirement. The Company has made available to the Depositary and the Custodian a copy of the Company&#8217;s Articles of Incorporation along with the provisions of or governing the Shares and any other Deposited Securities issued by the Company in connection with such Shares, and promptly upon any amendment thereto or change therein, the Company shall deliver to the Depositary and the Custodian a copy of such amendment thereto or change therein. The Depositary may rely upon such copy for all purposes of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary will, at the expense of the Company, make available a copy of any such notices, reports or communications issued by the Company and delivered to the Depositary for inspection by the Holders of the ADSs at the Depositary&#8217;s Principal Office, at the office of the Custodian and at any other designated transfer office.</font></div><div style="margin-bottom:0.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Issuance of Additional Shares, ADSs etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company agrees that in the event it or any of its Affiliates proposes (i) an issuance, sale or distribution of additional Shares, (ii) an offering of rights to subscribe for Shares or other Deposited Securities, (iii) an issuance or assumption of securities convertible into or exchangeable for Shares, (iv) an issuance of rights to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subscribe for securities convertible into or exchangeable for Shares, (v) an elective dividend of cash or Shares, (vi) a redemption of Deposited Securities, (vii) a meeting of holders of Deposited Securities, or solicitation of consents or proxies, relating to any reclassification of securities, merger or consolidation or transfer of assets, (viii) any assumption, reclassification, recapitalization, reorganization, merger, consolidation or sale of assets which affects the Deposited Securities, or (ix) a distribution of securities other than Shares, it will obtain U.S. legal advice and take all steps necessary to ensure that the application of the proposed transaction to Holders and Beneficial Owners does not violate the registration provisions of the Securities Act, or any other applicable laws (including, without limitation, the Investment Company Act of 1940, as amended, the Exchange Act and the securities laws of the states of the U.S.). In support of the foregoing, the Company will furnish to the Depositary (a) a written opinion of U.S. counsel (reasonably satisfactory to the Depositary) stating whether such transaction (1) requires a registration statement under the Securities Act to be in effect or (2) is exempt from the registration requirements of the Securities Act and (b) an opinion of Swiss counsel stating that (1) making the transaction available to Holders and Beneficial Owners does not violate the laws or regulations of Switzerland and (2) all requisite regulatory consents and approvals have been obtained in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Switzerland. If the filing of a registration statement is required, the Depositary shall not have any obligation to proceed with the transaction unless it shall have received evidence reasonably satisfactory to it that such registration statement has been declared effective. If, being advised by counsel, the Company determines that a transaction is required to be registered under the Securities Act, the Company will either (i) register such transaction to the extent necessary, (ii) alter the terms of the transaction to avoid the registration requirements of the Securities Act or (iii) direct the Depositary to take specific measures, in each case as contemplated in the Deposit Agreement, to prevent such transaction from violating the registration requirements of the Securities Act. The Company agrees with the Depositary that neither the Company nor any of its Affiliates will at any time (i) deposit any Shares or other Deposited Securities, either upon original issuance or upon a sale of Shares or other Deposited Securities previously issued and reacquired by the Company or by any such Affiliate, or (ii) issue additional Shares, rights to subscribe for such Shares, securities convertible into or exchangeable for Shares or rights to subscribe for such securities or distribute securities other than Shares, unless such transaction and the securities issuable in such transaction do not violate the registration provisions of the Securities Act, or any other applicable laws (including, without limitation, the Investment Company Act of 1940, as amended, the Exchange Act and the securities laws of the states of the U.S.).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in the Deposit Agreement, nothing in the Deposit Agreement shall be deemed to obligate the Company to file any registration statement in respect of any proposed transaction.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary agrees to indemnify the Company and its directors, officers, employees, agents and Affiliates against, and hold each of them harmless from, any direct loss, liability, tax, charge or expense of any kind whatsoever (including, but not limited to, the documented reasonable fees and expenses of counsel) which may arise out of acts performed or omitted by the Depositary under the terms hereof due to the negligence or bad faith of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company agrees to indemnify the Depositary, the Custodian and any of their respective directors, officers, employees, agents and Affiliates against, and hold each of them harmless from, any direct loss, liability, tax, charge or expense of any kind whatsoever (including, but not limited to, the documented reasonable fees and expenses of counsel) that may arise (a) out of, or in connection with, any offer, issuance, sale, resale, transfer, deposit or withdrawal of ADRs, ADSs, the Shares, or other Deposited Securities, as the case may be, (b) out of, or as a result of, any offering documents in respect thereof or (c) out of acts performed or omitted, including, but not limited to, any delivery by the Depositary on behalf of the Company of information regarding the Company, in connection with the Deposit Agreement, any ancillary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or supplemental agreement entered into between the Company and the Depositary, the ADRs, the ADSs, the Shares, or any Deposited Property, in any such case (i) by the Depositary, the Custodian or any of their respective directors, officers, employees, agents and Affiliates, except to the extent such loss, liability, tax, charge or expense is due to the negligence or bad faith of any of them, or (ii) by the Company or any of its directors, officers, employees, agents and Affiliates. The Company shall not indemnify the Depositary or the Custodian (for so long as the Custodian is a branch of Citibank) against (x) any liability or expense arising out of information relating to the Depositary or such Custodian, as the case may be, furnished in a signed writing to the Company, executed by the Depositary expressly for use in any registration statement, prospectus or preliminary prospectus relating to any Deposited Securities represented by the ADSs, or (y) any fees, charges or expenses payable by Holders or Beneficial Owners other than the Company under this Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations set forth in this Section shall survive the termination of the Deposit Agreement and the succession or substitution of any party hereto.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any person seeking indemnification hereunder (an &#8220;indemnified person&#8221;) shall notify the person from whom it is seeking indemnification (the &#8220;indemnifying person&#8221;) of the commencement of any indemnifiable action or claim promptly after such indemnified person becomes aware of such commencement (provided that the failure to make such notification shall not affect such indemnified person&#8217;s rights to seek indemnification except to the extent the indemnifying person is materially prejudiced by such failure) and shall consult in good faith with the indemnifying person as to the conduct of the defense of such action or claim that may give rise to an indemnity hereunder, which defense shall be reasonable in the circumstances. No indemnified person shall compromise or settle any action or claim that may give rise to an indemnity hereunder without the consent of the indemnifying person, which consent shall not be unreasonably withheld. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Fees and Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company, the Holders, the Beneficial Owners, persons depositing Shares or withdrawing Deposited Securities in connection with the issuance and cancellation of ADSs, and persons receiving ADSs upon issuance or whose ADSs are being cancelled shall be required to pay the Depositary&#8217;s fees and related charges identified as payable by them respectively in the Fee Schedule attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All ADS fees and charges so payable may be deducted from distributions or must be remitted to the Depositary, or its designee, and may, at any time and from time to time, be changed by agreement between the Depositary and the Company, but, in the case of ADS fees and charges payable by Holders and Beneficial Owners, only in the manner contemplated in Section 6.1. The Depositary shall provide, without charge, a copy of its latest ADS fee schedule to anyone upon request. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS fees and charges for (i) the issuance of ADSs and (ii) the cancellation of ADSs will be payable by the person for whom the ADSs are so issued by the Depositary (in the case of ADS issuances) and by the person for whom ADSs are being cancelled (in the case of ADS cancellations). In the case of ADSs issued by the Depositary into DTC or presented to the Depositary via DTC, the ADS issuance and cancellation fees and charges will be payable by the DTC Participant(s) receiving the ADSs from the Depositary or the DTC Participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the Beneficial Owner(s) and will be charged by the DTC Participant(s) to the account(s) of the applicable Beneficial Owner(s) in accordance with the procedures and practices of the DTC Participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are payable by Holders as of the applicable ADS Record Date established by the Depositary. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, the applicable Holders as of the ADS Record Date established by the Depositary will be invoiced for the amount of the ADS fees and charges and such ADS fees may be deducted from distributions made to Holders. For ADSs held through DTC, the ADS fees and charges for distributions other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC Participants in accordance with the procedures and practices prescribed by DTC from time to time and the DTC Participants in turn charge the amount of such ADS fees and charges to the Beneficial Owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may reimburse the Company for certain expenses incurred by the Company in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Company and the Depositary agree from time to time. The Company shall pay to the Depositary such fees and charges, and reimburse the Depositary for such out-of-pocket expenses, as the Depositary and the Company may agree from time to time. Responsibility for payment of such fees, charges and reimbursements may from time to time be changed by agreement between the Company and the Depositary. Unless otherwise agreed, the Depositary shall present its statement for such fees, charges and reimbursements to the Company once every three months. The charges and expenses of the Custodian are for the sole account of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of Holders and Beneficial Owners to pay ADS fees and charges shall survive the termination of the Deposit Agreement. As to any Depositary, upon the resignation or removal of such Depositary as described in Section 5.4, the right to collect ADS fees and charges shall extend for those ADS fees and charges incurred prior to the effectiveness of such resignation or removal.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Securities Owners</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company agrees to advise in writing each of the persons or entities who, to the knowledge of the Company, holds Restricted Securities that such Restricted Securities are ineligible for deposit hereunder (except under the circumstances contemplated in Section 2.14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and, to the extent practicable, shall require each of such persons to represent in writing that such person will not deposit Restricted Securities hereunder (except under the circumstances contemplated in Section 2.14).</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VI</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT AND TERMINATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment&#47;Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of this Section 6.1 and applicable law, the ADRs outstanding at any time, the provisions of the Deposit Agreement and the form of ADR attached hereto and to be issued under the terms hereof may at any time and from time to time be amended or supplemented by written agreement between the Company and the Depositary in any respect which they may deem necessary or desirable without the prior written consent of the Holders or Beneficial Owners. Any amendment or supplement which shall impose or increase any fees or charges (other than charges in connection with foreign exchange control regulations, and taxes and other governmental charges, delivery and other such expenses), or which shall otherwise materially prejudice any substantial existing right of Holders or Beneficial Owners, shall not, however, become effective as to outstanding ADSs until the expiration of thirty (30) days after notice of such amendment or supplement shall have been given to the Holders of outstanding ADSs. Notice of any amendment to the Deposit Agreement or any ADR shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific amendments in any such notice shall not render such notice </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">invalid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in each such case, the notice given to the Holders identifies a means for Holders and Beneficial Owners to retrieve or receive the text of such amendment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon retrieval from the Commission&#8217;s, the Depositary&#8217;s or the Company&#8217;s website or upon request from the Depositary). The parties hereto agree that any amendments or supplements which (i) are reasonably necessary (as agreed by the Company and the Depositary) in order for (a) the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs to be settled solely in electronic book-entry form and (ii) do not in either such case impose or increase any fees or charges to be borne by Holders, shall be deemed not to materially prejudice any substantial existing rights of Holders or Beneficial Owners. Every Holder and Beneficial Owner at the time any amendment or supplement so becomes effective shall be deemed, by continuing to hold such ADSs, to consent and agree to such amendment or supplement and to be bound by the Deposit Agreement and the ADR, if applicable, as amended or supplemented thereby. In no event shall any amendment or supplement impair the right of the Holder to surrender such ADS and receive therefor the Deposited Securities represented thereby, except in order to comply with mandatory provisions of applicable law. Notwithstanding the foregoing, if any governmental body should adopt new laws, rules or regulations which would require an amendment of, or supplement to, the Deposit Agreement to ensure compliance therewith, the Company and the Depositary may amend or supplement the Deposit Agreement and any ADRs at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the Deposit Agreement and any ADRs in such circumstances may become effective before a notice of such amendment or supplement is given to Holders or within any other period of time as required for compliance with such laws, rules or regulations.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall, at any time at the written direction of the Company, terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. If (i) ninety (90) days shall have expired after the Depositary shall have delivered to the Company a written notice of its election to resign, or (ii) ninety (90) days shall have expired after the Company shall have delivered to the Depositary a written notice of the removal of the Depositary, and, in either case, a successor depositary shall not have been appointed and accepted its appointment as provided in Section 5.4 of the Deposit Agreement, the Depositary may terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. The date so fixed for termination of the Deposit Agreement in any termination notice so distributed by the Depositary to the Holders of ADSs is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. Until the Termination Date, the Depositary shall continue to perform all of its obligations under the Deposit Agreement, and the Holders and Beneficial Owners will be entitled to all of their rights under the Deposit Agreement. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any ADSs shall remain outstanding after the Termination Date, the Registrar and the Depositary shall not, after the Termination Date, have any obligation to perform any further acts under the Deposit Agreement, except that the Depositary shall, subject, in each case, to the terms and conditions of the Deposit Agreement, continue to (i) collect dividends and other distributions pertaining to Deposited Securities, (ii) sell Deposited Property received in respect of Deposited Securities, (iii) deliver Deposited Securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any other Deposited Property, in exchange for ADSs surrendered to the Depositary (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (iv) take such actions as may be required under applicable law in connection with its role as Depositary under the Deposit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time after the Termination Date, the Depositary may sell the Deposited Property then held under the Deposit Agreement and shall after such sale hold un-invested the net proceeds of such sale, together with any other cash then held by it under the Deposit Agreement, in an un-segregated account and without liability for interest, for the pro rata benefit of the Holders whose ADSs have not theretofore been surrendered. After making such sale, the Depositary shall be discharged from all obligations under the Deposit Agreement except (i) to account for such net proceeds and other cash (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (ii) as may be required at law in connection with the termination of the Deposit Agreement. After the Termination Date, the Company shall be discharged from all obligations under the Deposit Agreement, except for its obligations to the Depositary under Sections 5.8, 5.9 and 7.6 of the Deposit Agreement. The obligations under the terms of the Deposit Agreement of Holders and Beneficial Owners of ADSs outstanding as of the Termination Date shall survive the Termination Date and shall be discharged only when the applicable ADSs are presented by their Holders to the Depositary for cancellation under the terms of the Deposit Agreement (except as specifically provided in the Deposit Agreement).</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of such counterparts together shall constitute one and the same agreement. Copies of the Deposit Agreement shall be maintained with the Depositary and shall be open to inspection by any Holder during business hours.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Third-Party Beneficiaries&#47;Acknowledgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement is for the exclusive benefit of the parties hereto (and their successors) and shall not be deemed to give any legal or equitable right, remedy or claim whatsoever to any other person, except to the extent specifically set forth in the Deposit Agreement. Nothing in the Deposit Agreement shall be deemed to give rise to a partnership or joint venture among the parties nor establish a fiduciary or similar relationship among the parties. The parties hereto acknowledge and agree that (i) Citibank and its Affiliates may at any time have multiple banking relationships with the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (ii) Citibank and its Affiliates may own and deal in any class of securities of the Company and its Affiliates and in ADSs, and may be engaged at any time in transactions in which parties adverse to the Company, the Holders, the Beneficial Owners or their respective Affiliates may have interests, (iii) the Depositary and its Affiliates may from time to time have in their possession non-public information about the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (iv) nothing contained in the Deposit Agreement shall (a) preclude Citibank or any of its Affiliates from engaging in such transactions or establishing or maintaining such relationships, or (b) obligate Citibank or any of its Affiliates to disclose such information, transactions or relationships, or to account for any profit made or payment received in such transactions or relationships, (v) the Depositary shall not be deemed to have knowledge of any information any other division of Citibank or any of its Affiliates may have about the Company, the Holders, the Beneficial Owners, or any of their respective Affiliates, and (vi) the Company, the Depositary, the Custodian and their respective agents and controlling persons may be subject to the laws and regulations of jurisdictions other than the U.S. and Switzerland, and the authority of courts and regulatory authorities of such other jurisdictions, and, consequently, the requirements and the limitations of such other laws and regulations, and the decisions and orders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such other courts and regulatory authorities, may affect the rights and obligations of the parties to the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may execute transactions contemplated herein (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, foreign currency conversions, and sales of Deposited Property) through one or more divisions of Citibank or through one or more Citibank Affiliates, and any such entity may act as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and may earn and retain revenue from such transactions, including, without, without limitation, transaction spreads, commissions, etc. The Depositary does not guarantee or represent that the price or rate obtained in any such transaction, or the method for obtaining such price or rate, will be the most favorable that could be obtained at that time.</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In case any one or more of the provisions contained in the Deposit Agreement or in the ADRs should be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein or therein shall in no way be affected, prejudiced or disturbed thereby.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Holders and Beneficial Owners as Parties&#59; Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Holders and Beneficial Owners from time to time of ADSs issued hereunder shall be parties to the Deposit Agreement and shall be bound by all of the terms and conditions hereof and of any ADR evidencing their ADSs by acceptance thereof or any beneficial interest therein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any and all notices to be given to the Company shall be deemed to have been duly given if personally delivered or sent by mail, air courier or cable, telex or facsimile transmission, confirmed by letter personally delivered or sent by mail or air courier, addressed to Molecular Partners AG, Wagistrasse 14, 8952 Schlieren, Switzerland, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Company Secretary, or to any other address which the Company may specify in writing to the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any and all notices to be given to the Depositary shall be deemed to have been duly given if personally delivered or sent by mail, air courier or cable, telex or facsimile transmission, confirmed by letter personally delivered or sent by mail or air courier, addressed to Citibank, N.A., 388 Greenwich Street, New York, New York 10013, U.S.A., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Depositary Receipts Department, or to any other address which the Depositary may specify in writing to the Company.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any and all notices to be given to any Holder shall be deemed to have been duly given (a) if personally delivered or sent by mail or cable, telex or facsimile transmission, confirmed by letter, addressed to such Holder at the address of such Holder as it appears on the books of the Depositary or, if such Holder shall have filed with the Depositary a request that notices intended for such Holder be mailed to some other address, at the address specified in such request, or (b) if a Holder shall have designated such means of notification as an acceptable means of notification under the terms of the Deposit Agreement, by means of electronic messaging addressed for delivery to the e-mail address designated by the Holder for such purpose. Notice to Holders shall be deemed to be notice to Beneficial Owners for all purposes of the Deposit Agreement. Failure to notify a Holder or any defect in the notification to a Holder shall not affect the sufficiency of notification to other Holders or to the Beneficial Owners of ADSs held by such other Holders. Any notices given to DTC under the terms of the Deposit Agreement shall (unless otherwise specified by the Depositary) constitute notice to the DTC Participants who hold the ADSs in their DTC accounts and to the Beneficial Owners of such ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delivery of a notice sent by mail, air courier or cable, telex or facsimile transmission shall be deemed to be effective at the time when a duly addressed letter containing the same (or a confirmation thereof in the case of a cable, telex or facsimile transmission) is deposited, postage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prepaid, in a post-office letter box or delivered to an air courier service, without regard for the actual receipt or time of actual receipt thereof by a Holder. The Depositary or the Company may, however, act upon any cable, telex or facsimile transmission received by it from any Holder, the Custodian, the Depositary, or the Company, notwithstanding that such cable, telex or facsimile transmission shall not be subsequently confirmed by letter.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delivery of a notice by means of electronic messaging shall be deemed to be effective at the time of the initiation of the transmission by the sender (as shown on the sender&#8217;s records), notwithstanding that the intended recipient retrieves the message at a later date, fails to retrieve such message, or fails to receive such notice on account of its failure to maintain the designated e-mail address, its failure to designate a substitute e-mail address or for any other reason.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law and Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement, the ADRs and the ADSs shall be interpreted in accordance with, and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by, the laws of the State of New York applicable to contracts made and to be wholly performed in that State. Notwithstanding anything contained in the Deposit Agreement to the contrary, any ADR or any present or future provisions of the laws of the State of New York, the rights of holders of Shares and of any other Deposited Securities and the obligations and duties of the Company in respect of the holders of Shares and other Deposited Securities, as such, shall be governed by the laws of Switzerland (or, if applicable, such other laws as may govern the Deposited Securities).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as set forth in the following paragraph of this Section 7.6, the Company and the Depositary agree that the federal or state courts in the City of New York shall have jurisdiction to hear and determine any suit, action or proceeding and to settle any dispute between them that may arise out of or in connection with the Deposit Agreement and, for such purposes, each irrevocably submits to the non-exclusive jurisdiction of such courts. The Company hereby irrevocably designates, appoints and empowers Molecular Partners Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) now at 245 Main Street, Cambridge, Massachusetts 02142, United States of America as its authorized agent to receive and accept for and on its behalf, and on behalf of its properties, assets and revenues, service by mail of any and all legal process, summons, notices and documents that may be served in any suit, action or proceeding brought against the Company in any federal or state court as described in the preceding sentence or in the next paragraph of this Section 7.6. If for any reason the Agent shall cease to be available to act as such, the Company agrees to designate a new agent in New York on the terms and for the purposes of this Section 7.6 reasonably satisfactory to the Depositary. The Company further hereby irrevocably consents and agrees to the service of any and all legal process, summons, notices and documents in any suit, action or proceeding against the Company, by service by mail of a copy thereof upon the Agent (whether or not the appointment of such Agent shall for any reason prove to be ineffective or such Agent shall fail to accept or acknowledge such service), with a copy mailed to the Company by registered or certified air mail, postage prepaid, to its address provided in Section 7.5. The Company agrees that the failure of the Agent to give any notice of such service to it shall not impair or affect in any way the validity of such service or any judgment rendered in any action or proceeding based thereon.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Depositary and the Company unconditionally agree that in the event that any Holder or Beneficial Owner, or any third-party, brings a suit, action or proceeding against (a) the Company, (b) the Depositary in its capacity as Depositary under the Deposit Agreement or (c) against both the Company and the Depositary, in any such case, in any state or federal court of the United States, and the Depositary or the Company have any claim, for indemnification or otherwise, against each other arising out of the subject matter of such suit, action or proceeding, then the Company and the Depositary may pursue such claim against each other in the state or federal court in the United States in which such suit, action, or proceeding is pending and, for such purposes, the Company and the Depositary irrevocably submit to the non-exclusive jurisdiction of such courts. The Company agrees that service of process upon the Agent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the manner set forth in the preceding paragraph shall be effective service upon it for any suit, action or proceeding brought against it as described in this paragraph.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of venue of any actions, suits or proceedings brought in any court as provided in this Section 7.6, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, and agrees not to plead or claim, any right of immunity from legal action, suit or proceeding, from setoff or counterclaim, from the jurisdiction of any court, from service of process, from attachment upon or prior to judgment, from attachment in aid of execution or judgment, from execution of judgment, or from any other legal process or proceeding for the giving of any relief or for the enforcement of any judgment, and consents to such relief and enforcement against it, its assets and its revenues in any jurisdiction, in each case with respect to any matter arising out of, or in connection with, the Deposit Agreement, any ADR or the Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EACH OF THE PARTIES TO THE DEPOSIT AGREEMENT (INCLUDING, WITHOUT LIMITATION, EACH HOLDER AND BENEFICIAL OWNER) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING AGAINST THE COMPANY AND&#47;OR THE DEPOSITARY ARISING OUT OF, OR RELATING TO, THE DEPOSIT AGREEMENT, ANY ADR AND ANY TRANSACTIONS CONTEMPLATED THEREIN (WHETHER BASED ON CONTRACT, TORT, COMMON LAW OR OTHERWISE). </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of this Section 7.6 shall survive any termination of the Deposit Agreement, in whole or in part.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the provisions of Section 5.4, the Deposit Agreement may not be assigned by either the Company or the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with, and No Disclaimer under, U.S. Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything in the Deposit Agreement to the contrary, the withdrawal or delivery of Deposited Securities will not be suspended by the Company or the Depositary except as would be permitted by Instruction I.A.(1) of the General Instructions to Form F-6 Registration Statement, as amended from time to time, under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each of the parties to the Deposit Agreement (including, without limitation, each Holder and Beneficial Owner), acknowledges and agrees that no provision of the Deposit Agreement or any ADR shall, or shall be deemed to, disclaim any liability under the Securities Act or the Exchange Act, in each case to the extent established under applicable U.S. laws.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Switzerland Law References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any summary of the laws and regulations of Switzerland and of the terms of the Company&#8217;s Articles of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation set forth in the Deposit Agreement have been provided by the Company solely for the convenience of Holders, Beneficial Owners and the Depositary. While such summaries are believed by the Company to be accurate as of the date of the Deposit Agreement, (i) they are summaries and as such may not include all aspects of the materials summarized applicable to a Holder or Beneficial Owner, and (ii) these laws and regulations and the Company&#8217;s Articles of Incorporation may change after the date of the Deposit Agreement. Neither the Depositary nor the Company has any obligation under the terms of the Deposit Agreement to update any such summaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Titles and References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> All references in the Deposit Agreement to exhibits, articles, sections, subsections, and other subdivisions refer to the exhibits, articles, sections, subsections and other subdivisions of the Deposit Agreement unless expressly provided otherwise. The words &#8220;the Deposit Agreement&#8221;, &#8220;herein&#8221;, &#8220;hereof&#8221;, &#8220;hereby&#8221;, &#8220;hereunder&#8221;, and words of similar import refer to the Deposit Agreement as a whole as in effect at the relevant time between the Company, the Depositary and the Holders and Beneficial Owners of ADSs and not to any particular subdivision unless expressly so limited. Pronouns in masculine, feminine and neuter gender shall be construed to include any other gender, and words in the singular form shall be construed to include the plural and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless the context otherwise requires. Titles to sections of the Deposit Agreement are included for convenience only and shall be disregarded in construing the language contained in the Deposit Agreement. References to &#8220;applicable laws and regulations&#8221; shall refer to laws and regulations applicable to ADRs, ADSs or Deposited Property as in effect at the relevant time of determination, unless otherwise required by law or regulation.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> All references in any ADR(s) to paragraphs, exhibits, articles, sections, subsections, and other subdivisions refer to the paragraphs, exhibits, articles, sections, subsections and other subdivisions of the ADR(s) in question unless expressly provided otherwise. The words &#8220;the Receipt&#8221;, &#8220;the ADR&#8221;, &#8220;herein&#8221;, &#8220;hereof&#8221;, &#8220;hereby&#8221;, &#8220;hereunder&#8221;, and words of similar import used in any ADR refer to the ADR as a whole and as in effect at the relevant time, and not to any particular subdivision unless expressly so limited. Pronouns in masculine, feminine and neuter gender in any ADR shall be construed to include any other gender, and words in the singular form shall be construed to include the plural and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless the context otherwise requires. Titles to paragraphs of any ADR are included for convenience only and shall be disregarded in construing the language contained in the ADR. References to &#8220;applicable laws and regulations&#8221; shall refer to laws and regulations applicable to the Company, the Depositary, the Custodian, their agents and controlling persons, the ADRs, the ADSs and the Deposited Property as in effect at the relevant time of determination, unless otherwise required by law or regulation.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, MOLECULAR PARTNERS AG and CITIBANK, N.A. have duly executed the Deposit Agreement as of the day and year first above set forth and all Holders and Beneficial Owners shall become parties hereto upon acceptance by them of ADSs issued in accordance with the terms hereof, or upon acquisition of any beneficial interest therein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MOLECULAR PARTNERS AG</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andreas Emmenegger</font></div></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Andreas Emmenegger</font></div></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer</font></div></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A.</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Keith Galfo</font></div></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Keith Galfo</font></div></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  Vice President</font></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;DEPOSIT AGREEMENT&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-69</font></div></div></div><div id="if7724931561a4e79bc4853d8d987da59_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;FORM OF ADR&#93;</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUSIP NUMBER&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">American Depositary Shares (each American Depositary Share representing the right to receive one (1) fully paid common share)</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMERICAN DEPOSITARY RECEIPT</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMERICAN DEPOSITARY SHARES</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">representing</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEPOSITED COMMON SHARES</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Incorporated under the laws of Switzerland)</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A., a national banking association organized and existing under the laws of the United States of America, as depositary (the &#8220;Depositary&#8221;), hereby certifies that _____________is the owner of ______________ American Depositary Shares (hereinafter &#8220;ADS&#8221;) representing deposited common shares, including evidence of rights to receive such common shares (the &#8220;Shares&#8221;), of Molecular Partners AG, a corporation incorporated under the laws of Switzerland (the &#8220;Company&#8221;). As of the date of issuance of this ADR, each ADS represents the right to receive one Share deposited under the Deposit Agreement (as hereinafter defined) with the Custodian, which at the date of issuance of this ADR is Citibank N.A. London Branch (the &#8220;Custodian&#8221;). The ADS(s)-to-Share(s) ratio is subject to amendment as provided in Articles IV and VI of the Deposit Agreement. The Depositary&#8217;s Principal Office is located at 388 Greenwich Street, New York, New York 10013, U.S.A.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">The Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This American Depositary Receipt is one of an issue of American Depositary Receipts (&#8220;ADRs&#8221;), all issued and to be issued upon the terms and conditions set forth in the Deposit Agreement, dated as of ____________, 2021 (as amended and supplemented from time to time, the &#8220;Deposit Agreement&#8221;), by and among the Company, the Depositary, and all Holders and Beneficial Owners from time to time of ADSs issued thereunder. The Deposit Agreement sets forth the rights and obligations of Holders and Beneficial Owners of ADSs and the rights and duties of the Depositary in respect of the Shares deposited thereunder and any and all other Deposited Property (as defined in the Deposit Agreement) from time to time received and held on deposit in respect of the ADSs. Copies of the Deposit Agreement are on file at the Principal Office of the Depositary and with the Custodian. Each Holder and each Beneficial Owner, upon acceptance of any ADSs (or any interest therein) issued in accordance with the terms and conditions of the Deposit Agreement, shall be deemed for all purposes to (a) be a party to and bound by the terms of the Deposit Agreement and the applicable ADR(s), and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) appoint the Depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the Deposit Agreement and the applicable ADR(s), to adopt any and all procedures necessary to comply with applicable law and to take such action as the Depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the Deposit Agreement and the applicable ADR(s), the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof. The manner in which a Beneficial Owner holds ADSs (e.g., in a brokerage account vs. as registered holder) may affect the rights and obligations of, the manner in which, and the extent to which, services are made available to, Beneficial Owners pursuant to the terms of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The statements made on the face and reverse of this ADR are summaries of certain provisions of the Deposit Agreement and the Articles of Incorporation (as in effect on the date of the signing of the Deposit Agreement) and are qualified by and subject to the detailed provisions of the Deposit Agreement and the Articles of Incorporation, to which reference is hereby made. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms not defined herein shall have the meanings ascribed thereto in the Deposit Agreement. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary makes no representation or warranty as to the validity or worth of the Deposited Property. The Depositary has made arrangements for the acceptance of the ADSs into DTC. Each Beneficial Owner of ADSs held through DTC must rely on the procedures of DTC and the DTC Participants to exercise and be entitled to any rights attributable to such ADSs. The Depositary may issue Uncertificated ADSs subject, however, to the terms and conditions of Section 2.13 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Surrender of ADSs and Withdrawal of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Holder of this ADR (and of the ADSs evidenced hereby) shall be entitled to Delivery (at the Custodian&#8217;s designated office) of the Deposited Securities at the time represented by the ADSs evidenced hereby upon satisfaction of each of the following conditions&#58; (i) the Holder (or a duly-authorized attorney of the Holder) has duly Delivered ADSs to the Depositary at its Principal Office the ADSs evidenced hereby (and, if applicable, this ADR evidencing such ADSs) for the purpose of withdrawal of the Deposited Securities represented thereby, (ii) if applicable and so required by the Depositary, this ADR Delivered to the Depositary for such purpose has been properly endorsed in blank or is accompanied by proper instruments of transfer in blank (including signature guarantees in accordance with standard securities industry practice), (iii) if so required by the Depositary, the Holder of the ADSs has executed and delivered to the Depositary a written order directing the Depositary to cause the Deposited Securities being withdrawn to be Delivered to or upon the written order of the person(s) designated in such order, and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement) have been paid,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of this ADR evidencing the surrendered ADSs, of the Deposit Agreement, of the Company&#8217;s Articles of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and of any applicable laws and the rules of the applicable book-entry settlement entity, and to any provisions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon satisfaction of each of the conditions specified above, the Depositary (i) shall cancel the ADSs Delivered to it (and, if applicable, this ADR(s) evidencing the ADSs so Delivered), (ii) shall direct the Registrar to record the cancellation of the ADSs so Delivered on the books maintained for such purpose, and (iii) shall direct the Custodian to Deliver, or cause the Delivery of, in each case, without unreasonable delay, the Deposited Securities represented by the ADSs so canceled together with any certificate or other document of title for the Deposited Securities, or evidence of the electronic transfer thereof (if available), as the case may be, to or upon the written order of the person(s) designated in the order delivered to the Depositary for such purpose, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit Agreement, of this ADR evidencing the ADS so canceled, of the Articles of Incorporation of the Company, of any applicable laws and of the rules of the applicable book-entry settlement entity, and to the terms and conditions of or governing the Deposited Securities, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not accept for surrender ADSs representing less than one (1) Share. In the case of Delivery to it of ADSs representing a number other than a whole number of Shares, the Depositary shall cause ownership of the appropriate whole number of Shares to be Delivered in accordance with the terms hereof, and shall, at the discretion of the Depositary, either (i) return to the person surrendering such ADSs the number of ADSs representing any remaining fractional Share, or (ii) sell or cause to be sold the fractional Share represented by the ADSs so surrendered and remit the proceeds of such sale (net of (a) applicable fees and charges of, and expenses incurred by, the Depositary and (b) taxes withheld) to the person surrendering the ADSs. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in this ADR or the Deposit Agreement, the Depositary may make delivery at the Principal Office of the Depositary of Deposited Property consisting of (i) any cash dividends or cash distributions, or (ii) any proceeds from the sale of any non-cash distributions, which are at the time held by the Depositary in respect of the Deposited Securities represented by the ADSs surrendered for cancellation and withdrawal. At the request, risk and expense of any Holder so surrendering ADSs represented by this ADR, and for the account of such Holder, the Depositary shall direct the Custodian to forward (to the extent permitted by law) any Deposited Property (other than Deposited Securities) held by the Custodian in respect of such ADSs to the Depositary for delivery at the Principal Office of the Depositary. Such direction shall be given by letter or, at the request, risk and expense of such Holder, by cable, telex or facsimile transmission.</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer, Combination and Split-up of ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Registrar shall register the transfer of this ADR (and of the ADSs represented hereby) on the books maintained for such purpose and the Depositary shall (x) cancel this ADR and execute new ADRs evidencing the same aggregate number of ADSs as those evidenced by this ADR canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs, and (z) Deliver such new ADRs to or upon the order of the person entitled thereto, if each of the following conditions has been satisfied&#58; (i) this ADR has been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a transfer thereof, (ii) this surrendered ADR has been properly endorsed or is accompanied by proper instruments of transfer (including signature guarantees in accordance with standard securities industry practice), (iii) this surrendered ADR has been duly stamped (if required by the laws of the State of New York or of the United States), and (iv) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the terms and conditions of this ADR, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall register the split-up or combination of this ADR (and of the ADSs represented hereby) on the books maintained for such purpose and the Depositary shall (x) cancel this ADR and execute new ADRs for the number of ADSs requested, but in the aggregate not exceeding the number of ADSs evidenced by this ADR canceled by the Depositary, (y) cause the Registrar to countersign such new ADRs, and (z) Deliver such new ADRs to or upon the order of the Holder thereof, if each of the following conditions has been satisfied&#58; (i) this ADR has been duly Delivered by the Holder (or by a duly authorized attorney of the Holder) to the Depositary at its Principal Office for the purpose of effecting a split-up or combination hereof, and (ii) all applicable fees and charges of, and expenses incurred by, the Depositary and all applicable taxes and governmental charges (as are set forth in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Deposit Agreement) have been paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">subject, however, in each case</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the terms and conditions of this ADR, of the Deposit Agreement and of applicable law, in each case as in effect at the time thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Pre-Conditions to Registration, Transfer, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As a condition precedent to the execution and Delivery, the registration of issuance, transfer, split-up, combination or surrender, of any ADS, the delivery of any distribution thereon, or the withdrawal of any Deposited Property, the Depositary or the Custodian may require (i) payment from the depositor of Shares or presenter of ADSs or of this ADR of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees and charges of the Depositary as provided in Section 5.9 of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to, the Deposit Agreement and in this ADR, (ii) the production of proof satisfactory to it as to the identity and genuineness of any signature or any other matter contemplated by Section 3.1 of the Deposit Agreement, and (iii) compliance with (A) any laws or governmental regulations relating to the execution and Delivery of this ADR or ADSs or to the withdrawal of Deposited Securities and (B) such reasonable regulations as the Depositary and the Company may establish consistent with the provisions of this ADR, if applicable, the Deposit Agreement and applicable law.</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The issuance of ADSs against deposits of Shares generally or against deposits of particular Shares may be suspended, or the deposit of particular Shares may be refused, or the registration of transfer of ADSs in particular instances may be refused, or the registration of transfer of ADSs generally may be suspended, during any period when the transfer books of the Company, the Depositary, a Registrar or the Share Registrar are closed or if any such action is deemed necessary or advisable by the Depositary or the Company, in good faith, at any time or from time to time because of any requirement of law or regulation, any government or governmental body or commission or any securities exchange on which the ADSs or Shares are listed, or under any provision of the Deposit Agreement or this ADR, if applicable, or under any provision of, or governing, the Deposited Securities, or because of a meeting of shareholders of the Company or for any other reason, subject, in all cases to Section 7.8(a) of the Deposit Agreement and paragraph (25) of this ADR. Notwithstanding any provision of the Deposit Agreement or this ADR to the contrary, Holders are entitled to surrender outstanding ADSs to withdraw the Deposited Securities associated therewith at any time subject only to (i) temporary delays caused by closing the transfer books of the Depositary or the Company or the deposit of Shares in connection with voting at a shareholders&#8217; meeting or the payment of dividends, (ii) the payment of fees, taxes and similar charges, (iii) compliance with any U.S. or foreign laws or governmental regulations relating to the ADSs or to the withdrawal of the Deposited Securities, and (iv) other circumstances specifically contemplated by Instruction I.A.(1) of the General Instructions to Form F-6 (as such General Instructions may be amended from time to time).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Information Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provision included or incorporated by reference in the Deposit Agreement or this ADR to any other effect, each Holder and Beneficial Owner of the ADSs represented hereby agrees to comply with requests from the Company pursuant to applicable law, the rules and requirements of any stock exchange on which the Shares or ADSs are, or will be, registered, traded or listed, or the Articles of Incorporation of the Company, which are made to provide information, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as to the capacity in which such Holder or Beneficial Owner owns ADSs (and the Shares represented by such ADSs, as the case may be) and regarding the identity of any other person(s) interested in such ADSs (and the Shares represented by such ADSs, as the case may be) and the nature of such interest and various other matters, whether or not they are Holders and&#47;or Beneficial Owners at the time of such request. The Depositary agrees to use its reasonable efforts to forward, upon the request of the Company and at the Company&#8217;s expense, any such request from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company to the Holders and to forward to the Company any such responses to such requests received by the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(6) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision included or incorporated by reference in this ADR or of the Deposit Agreement to any other effect, the Company may restrict transfers of the Shares where such transfer might result in ownership of Shares exceeding limits imposed by applicable law or the Articles of Incorporation of the Company. The Company may also restrict, in such manner as it deems appropriate, transfers of the ADSs where such transfer may result in the total number of Shares represented by the ADSs owned by a single Holder or Beneficial Owner to exceed any such limits. The Company may, in its sole discretion but subject to applicable law, instruct the Depositary to take action with respect to the ownership interest of any Holder or Beneficial Owner in excess of the limits set forth in the preceding sentence, including but not limited to, the imposition of restrictions on the transfer of ADSs, the removal or limitation of voting rights or mandatory sale or disposition on behalf of a Holder or Beneficial Owner of the Shares represented by the ADSs held by such Holder or Beneficial Owner in excess of such limitations, if and to the extent such disposition is permitted by applicable law and the Articles of Incorporation of the Company. Nothing herein or in the Deposit Agreement shall be interpreted as obligating the Depositary or the Company to ensure compliance with the ownership restrictions described herein or in Section 3.5 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(7) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reporting Obligations and Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Applicable laws and regulations may require holders and beneficial owners of Shares, including the Holders and Beneficial Owners of ADSs, to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. Holders and Beneficial Owners of ADSs are solely responsible for determining and complying with such reporting requirements and obtaining such approvals. Each Holder and each Beneficial Owner hereby agrees to make such determination, file such reports, and obtain such approvals to the extent and in the form required by applicable laws and regulations as in effect from time to time. Neither the Depositary, the Custodian, the Company or any of their respective agents or affiliates shall be required to take any actions whatsoever on behalf of Holders or Beneficial Owners to determine or satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(8) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Liability for Taxes and Other Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any tax or other governmental charge payable by the Custodian or by the Depositary with respect to any Deposited Property, ADSs or this ADR shall be payable by the Holders and Beneficial Owners to the Depositary. The Company, the Custodian and&#47;or the Depositary may withhold or deduct from any distributions made in respect of Deposited Property held on behalf of such Holder and&#47;or Beneficial Owner, and may sell for the account of a Holder and&#47;or Beneficial Owner any or all of such Deposited Property and apply such distributions and sale proceeds in payment of, any taxes (including applicable interest and penalties) or charges that are or may be payable by Holders or Beneficial Owners in respect of the ADSs, Deposited Property and this ADR, the Holder and the Beneficial Owner hereof remaining liable for any deficiency. The Custodian may refuse the deposit of Shares and the Depositary may refuse to issue ADSs, to deliver ADRs, register the transfer of ADSs, register the split-up or combination of ADRs and (subject to paragraph (25) of this ADR and Section 7.8(a) of the Deposit Agreement) the withdrawal of Deposited Property until payment in full of such tax, charge, penalty or interest is received. Every Holder and Beneficial Owner agrees to indemnify the Depositary, the Company, the Custodian, and any of their agents, officers, employees and Affiliates for, and to hold each of them harmless from, any claims with respect to taxes (including applicable interest and penalties thereon) arising from (i) any ADSs held by such Holder and&#47;or owned by such Beneficial Owner, (ii) the Deposited Property represented by the ADSs, and (iii) any transaction entered into by such Holder and&#47;or Beneficial Owner in respect of the ADSs and&#47;or the Deposited Property represented thereby. Notwithstanding anything to the contrary contained in the Deposit Agreement or any ADR, the obligations of Holders and Beneficial Owners under Section 3.2 of the Deposit Agreement shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">survive any transfer of ADSs, any cancellation of ADSs and withdrawal of Deposited Securities, and the termination of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(9) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Representations and Warranties on Deposit of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each person depositing Shares under the Deposit Agreement shall be deemed thereby to represent and warrant that (i) such Shares and the certificates therefor are duly authorized, validly issued, fully paid, non-assessable and legally obtained by such person, (ii) all preemptive (and similar) rights, if any, with respect to such Shares have been validly waived or exercised, (iii) the person making such deposit is duly authorized so to do, (iv) the Shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, (v) the Shares presented for deposit are not, and the ADSs issuable upon such deposit will not be, Restricted Securities (except as contemplated in Section 2.14 of the Deposit Agreement), (vi) the Shares presented for deposit have not been stripped of any rights or entitlements, and (vii) the deposit of the Shares does not violate any applicable provisions of the laws of Switzerland. Such representations and warranties shall survive the deposit and withdrawal of Shares, the issuance and cancellation of ADSs in respect thereof and the transfer of such ADSs. If any such representations or warranties are false in any way, the Company and the Depositary shall be authorized, at the cost and expense of the person depositing Shares, to take any and all actions necessary to correct the consequences thereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(10) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Proofs, Certificates and Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any person presenting Shares for deposit, any Holder and any Beneficial Owner may be required, and every Holder and Beneficial Owner agrees, from time to time to provide to the Depositary and the Custodian such proof of citizenship or residence, taxpayer status, payment of all applicable taxes or other governmental charges, exchange control approval, legal or beneficial ownership of ADSs and Deposited Property, compliance with applicable laws, the terms of the Deposit Agreement or this ADR evidencing the ADSs and the provisions of, or governing, the Deposited Property, to execute such certifications and to make such representations and warranties, and to provide such other information and documentation (or, in the case of Shares in registered form presented for deposit, such information relating to the registration on the books of the Company or of the Share Registrar) as the Depositary or the Custodian may deem necessary or proper or as the Company may reasonably require by written request to the Depositary consistent with its obligations under the Deposit Agreement and this ADR. The Depositary and the Registrar, as applicable, may withhold the execution or delivery or registration of transfer of any ADR or ADS or the distribution or sale of any dividend or distribution of rights or of the proceeds thereof or, to the extent not limited by paragraph (25) and Section 7.8(a) of the Deposit Agreement, the delivery of any Deposited Property until such proof or other information is filed or such certifications are executed, or such representations and warranties are made or such other documentation or information provided, in each case to the Depositary&#8217;s, the Registrar&#8217;s and the Company&#8217;s satisfaction. The Depositary shall provide the Company, in a timely manner, with copies or originals if necessary and appropriate of (i) any such proofs of citizenship or residence, taxpayer status, or exchange control approval or copies of written representations and warranties which it receives from Holders and Beneficial Owners, and (ii) any other information or documents which the Company may reasonably request and which the Depositary shall request and receive from any Holder or Beneficial Owner or any person presenting Shares for deposit or ADSs for cancellation, transfer or withdrawal. Nothing herein shall obligate the Depositary to (i) obtain any information for the Company if not provided by the Holders or Beneficial Owners, or (ii) verify or vouch for the accuracy of the information so provided by the Holders or Beneficial Owners.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(11) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Fees and Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following ADS fees are payable under the terms of the Deposit Agreement&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Issuance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any person for whom ADSs are issued (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an issuance upon a deposit of Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (iv) below, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) issued under the terms of the Deposit Agreement&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Cancellation Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any person for whom ADSs are being cancelled (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a cancellation of ADSs for Delivery of deposited Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Distribution Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADSs, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held for the distribution of cash dividends or other cash distributions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon a sale of rights and other entitlements)&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Distribution &#47;Rights Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held for the distribution of ADSs pursuant to (a) stock dividends or other free stock distributions, or (b) an exercise of rights to purchase additional ADSs&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Distribution Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held for the distribution of </font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">securities other than ADSs or rights to purchase additional ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, spin-off shares)&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Services Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s), a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the Depositary&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Registration of ADS Transfer Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s) being transferred or by any person to whom ADSs are transferred, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) transferred (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or for any other reason)&#59; and </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Conversion Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; by any Holder of ADS(s) being converted or by any person to whom the converted ADSs are delivered, a fee not in excess of U.S. $5.00 per 100 ADSs (or fraction thereof) converted from one ADS series to another ADS series (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferrable ADSs, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, Holders, Beneficial Owners, persons depositing Shares or withdrawing Deposited Securities in connection with ADS issuances and cancellations, and persons for whom ADSs are issued or cancelled shall be responsible for the following ADS charges under the terms of the Deposit Agreement&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) such registration fees as may from time to time be in effect for the registration of Shares or other Deposited Securities on the share register and applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to transfers of Shares or other Deposited Securities to or from the name of the Custodian, the Depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the Deposit Agreement to be at the expense of the person depositing Shares or withdrawing Deposited Property or of the Holders and Beneficial Owners of ADSs&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) in connection with the conversion of Foreign Currency, the fees, expenses, spreads, taxes and other charges of the Depositary and&#47;or conversion service providers (which may be a division, branch or Affiliate of the Depositary). Such fees, expenses, spreads, taxes and other charges shall be deducted from the Foreign Currency&#59; </font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) any reasonable and customary out-of-pocket expenses incurred in such conversion and&#47;or on behalf of the Holders and Beneficial Owners in complying with currency exchange control or other governmental requirements&#59; and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) the fees, charges, costs and expenses incurred by the Depositary, the Custodian, or any nominee in connection with the ADR program.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All ADS fees and charges so payable maybe deducted from distributions or must be remitted to the Depositary, or its designee, and may, at any time and from time to time, be changed by agreement between the Depositary and Company but, in the case of ADS fees and charges payable by Holders and Beneficial Owners, only in the manner contemplated by paragraph (23) of this ADR and as contemplated in Section 6.1 of the Deposit Agreement. The Depositary shall provide, without charge, a copy of its latest ADS fee schedule to anyone upon request. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADS fees and charges for (i) the issuance of ADSs and (ii) the cancellation of ADSs will be payable by the person for whom the ADSs are so issued by the Depositary (in the case of ADS issuances) and by the person for whom ADSs are being cancelled (in the case of ADS cancellations). In the case of ADSs issued by the Depositary into DTC or presented to the Depositary via DTC, the ADS issuance and cancellation fees and charges will be payable by the DTC Participant(s) receiving the ADSs from the Depositary or the DTC Participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the Beneficial Owner(s) and will be charged by the DTC Participant(s) to the account(s) of the applicable Beneficial Owner(s) in accordance with the procedures and practices of the DTC Participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are payable by Holders as of the applicable ADS Record Date established by the Depositary. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, the applicable Holders as of the ADS Record Date established by the Depositary will be invoiced for the amount of the ADS fees and charges and such ADS fees may be deducted from distributions made to Holders. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC Participants in accordance with the procedures and practices prescribed by DTC from time to time and the DTC Participants in turn charge the amount of such ADS fees and charges to the Beneficial Owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may reimburse the Company for certain expenses incurred by the Company in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Company and the Depositary agree from time to time. The Company shall pay to the Depositary such fees and charges, and reimburse the Depositary for such out-of-pocket expenses, as the Depositary and the Company may agree from time to time. Responsibility for payment of such fees, charges and reimbursements may from time to time be changed by agreement between the Company and the Depositary. Unless otherwise agreed, the Depositary shall present its statement for such fees, charges and reimbursements to the Company once every three months. The charges and expenses of the Custodian are for the sole account of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of Holders and Beneficial Owners to pay ADS fees and charges shall survive the termination of the Deposit Agreement. As to any Depositary, upon the resignation or removal of such Depositary as described in Section 5.4 of the Deposit Agreement, the right to collect ADS fees and charges shall extend for those ADS fees and charges incurred prior to the effectiveness of such resignation or removal.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(12) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Title to ADRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the limitations contained in the Deposit Agreement and in this ADR, it is a condition of this ADR, and every successive Holder of this ADR by accepting or holding the same consents and agrees, that title to this ADR (and to each Certificated ADS evidenced hereby) shall be transferable upon the same terms as a certificated security under the laws of the State of New York, provided that, in the case of Certificated ADSs, this ADR has been properly endorsed or is accompanied by proper instruments of transfer. Notwithstanding any notice to the contrary, the Depositary and the Company may deem and treat the Holder of this ADR (that is, the person in whose name this ADR is registered on the books of the Depositary) as the absolute owner thereof for all purposes. Neither the Depositary nor the Company shall have any obligation nor be subject to any liability under the Deposit Agreement or this ADR to any holder of this ADR or any Beneficial Owner unless, in the case of a holder of ADSs, such holder is the Holder of this ADR registered on the books of the Depositary or, in the case of a Beneficial Owner, such Beneficial Owner, or the Beneficial Owner&#8217;s representative, is the Holder registered on the books of the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(13) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Validity of ADR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Holder(s) of this ADR (and the ADSs represented hereby) shall not be entitled to any benefits under the Deposit Agreement or be valid or enforceable for any purpose against the Depositary or the Company unless this ADR has been (i) dated, (ii) signed by the manual or facsimile signature of a duly-authorized signatory of the Depositary, (iii) countersigned by the manual or facsimile signature of a duly-authorized signatory of the Registrar, and (iv) registered in the books maintained by the Registrar for the registration of issuances and transfers of ADRs. An ADR bearing the facsimile signature of a duly-authorized signatory of the Depositary or the Registrar, who at the time of signature was a duly authorized signatory of the Depositary or the Registrar, as the case may be, shall bind the Depositary, notwithstanding the fact that such signatory has ceased to be so authorized prior to the delivery of such ADR by the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(14) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Available Information&#59; Reports&#59; Inspection of Transfer Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company is subject to the periodic reporting requirements of the Exchange Act and, accordingly, is required to file or furnish certain reports with the Commission. These reports can be retrieved from the Commission's website (</font><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and can be inspected and copied at the public reference facilities maintained by the Commission located (as of the date of the Deposit Agreement) at 100 F Street, N.E., Washington D.C. 20549. The Depositary shall make </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available for inspection by Holders at its Principal Office any reports and communications, including any proxy soliciting materials, received from the Company which are both (a) received by the Depositary, the Custodian, or the nominee of either of them as the holder of the Deposited Property and (b) made generally available to the holders of such Deposited Property by the Company. The Depositary shall also provide or make available to the Holders copies of such reports when furnished by the Company pursuant to Section 5.6 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar shall keep books for the registration of ADSs which at all reasonable times shall be open for inspection by the Company and by the Holders of such ADSs, provided that such inspection shall not be, to the Registrar&#8217;s knowledge, for the purpose of communicating with Holders of such ADSs in the interest of a business or object other than the business of the Company or other than a matter related to the Deposit Agreement or the ADSs.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Registrar may close the transfer books with respect to the ADSs, at any time or from time to time, when deemed necessary or advisable by it in good faith in connection with the performance of its duties hereunder, or at the reasonable written request of the Company subject, in all cases, to paragraph (25) and Section 7.8(a) of the Deposit Agreement.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A.<br>Transfer Agent and Registrar</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A.<br>as Depositary</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized Signatory</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized Signatory</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The address of the Principal Office of the Depositary is 388 Greenwich Street, New</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">York, New York 10013, U.S.A.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;FORM OF REVERSE OF ADR&#93;</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SUMMARY OF CERTAIN ADDITIONAL PROVISIONS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OF THE DEPOSIT AGREEMENT</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(15) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dividends and Distributions in Cash, Shares, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cash Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt by the Depositary of a notice from the Company that it intends to make a distribution of a cash dividend or other cash distribution, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9 of the Deposit Agreement. Upon confirmation of the receipt of (x) any cash dividend or other cash distribution in respect of any Deposited Property (whether from the Company or otherwise), or (y) proceeds from the sale of any Deposited Property held in respect of the ADSs under the terms of the Deposit Agreement, the Depositary will (i) if any amounts are received in a Foreign Currency, promptly convert or cause to be converted such cash dividend, distribution or proceeds into Dollars (subject to the terms and conditions of Section 4.8 of the Deposit Agreement), (ii) if applicable and unless previously established, establish the ADS Record Date upon the terms described in Section 4.9 of the Deposit Agreement, and (iii) distribute promptly the amount thus received (net of (a) the applicable fees and charges set forth in the Fee Schedule attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Deposit Agreement and (b) applicable taxes withheld) to the Holders entitled thereto as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date. The Depositary shall distribute only such amount, however, as can be distributed without attributing to any Holder a fraction of one cent, and any balance not so distributed shall be held by the Depositary (without liability for interest thereon) and shall be added to and become part of the next sum received by the Depositary for distribution to Holders of ADSs outstanding at the time of the next distribution. If the Company, the Custodian or the Depositary is required to withhold and does withhold from any cash dividend or other cash distribution in respect of any Deposited Securities, or from any cash proceeds from the sales of Deposited Property, an amount on account of taxes, duties or other governmental charges, the amount distributed to Holders on the ADSs shall be reduced accordingly. Such withheld amounts shall be forwarded by the Company, the Custodian or the Depositary to the relevant governmental authority. Evidence of payment thereof by the Company shall be forwarded by the Company to the Depositary upon request. The Depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable Holders and Beneficial Owners of ADSs until the distribution can be effected or the funds that the Depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in Section 4.1 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.1 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.1 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Share Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt by the Depositary of a notice from the Company that it intends to make a distribution that consists of a dividend in, or free distribution of Shares, the Depositary shall establish the ADS Record Date upon the terms described in Section 4.9 of the Deposit Agreement. Upon receipt of confirmation from the Custodian of the receipt of the Shares so distributed by the Company, the Depositary shall either (i) subject to Section 5.9 of the Deposit Agreement, distribute to the Holders as of the ADS Record Date in proportion to the number of ADSs held as of the ADS Record Date, additional ADSs, which represent in the aggregate the number of Shares received as such dividend, or free distribution, subject to the other terms of the Deposit Agreement (including, without limitation, (a) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes), or (ii) if additional ADSs are not so distributed, take all actions necessary so that each ADS issued and outstanding after the ADS Record Date shall, to the extent permissible by law, thenceforth also represent rights and interests in the additional integral number of Shares distributed upon the Deposited Securities represented thereby (net of (a) the applicable fees and charges of, and expenses incurred by, the Depositary, and (b) applicable taxes). In lieu of delivering fractional ADSs, the Depositary shall sell the number of Shares or ADSs, as the case may be, represented by the aggregate of such fractions and distribute the net proceeds upon the terms described in Section 4.1 of the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Depositary determines that any distribution in property (including Shares) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, or, if the Company in the fulfillment of its obligations under Section 5.7 of the Deposit Agreement, has furnished an opinion of U.S. counsel determining that Shares must be registered under the Securities Act or other laws in order to be distributed to Holders (and no such registration statement has been declared effective), the Depositary may dispose of all or a portion of such property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable, and the Depositary shall distribute the net proceeds of any such sale (after deduction of (a) applicable taxes and (b) fees and charges of, and the expenses incurred by, the Depositary) to Holders entitled thereto upon the terms of Section 4.1 of the Deposit Agreement. The Depositary shall hold and&#47;or distribute any unsold balance of such property in accordance with the provisions of the Deposit Agreement. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in Section 4.2 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.2 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.2 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Elective Distributions in Cash or Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt of a notice indicating that the Company wishes an elective distribution to be made available to Holders of ADSs, the Depositary shall consult with the Company to determine, and the Company shall assist the Depositary in its determination, whether it is lawful and reasonably practicable to make such elective distribution available to Holders of ADSs. The Depositary shall make such elective distribution available to Holders only if (i) the Company shall have timely requested that the elective distribution be made available to Holders, (ii) the Depositary shall have determined that such distribution is reasonably practicable and (iii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7 of the Deposit Agreement. If the above conditions are satisfied, the Depositary shall, subject to the terms and conditions of the Deposit Agreement, establish the ADS Record Date on the terms described in paragraph (17) and Section 4.9 of the Deposit Agreement and establish procedures to enable the Holder hereof to elect to the receipt of the proposed distribution in cash or in additional ADSs. The Company shall assist the Depositary in establishing such procedures to the extent necessary. If a Holder elects to receive the distribution in cash, the distribution shall be made as in the case of a distribution in cash. If the Holder hereof elects to receive the distribution in additional ADSs, the distribution shall be made as in the case of a distribution in Shares upon the terms described in the Deposit Agreement. If such elective distribution is not reasonably practicable or if the Depositary did not receive satisfactory documentation set forth in the Deposit Agreement, the Depositary shall establish an ADS Record Date upon the terms of Section 4.9 of the Deposit Agreement and, to the extent permitted by law, distribute to Holders, on the basis of the same determination as is made in Switzerland in respect of the Shares for which no election is made, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either (x) in cash, upon the terms described in Section 4.1 of the Deposit Agreement or (y) additional ADSs representing such additional Shares, in each case, upon the terms described in Section 4.2 of the Deposit Agreement. Nothing herein or in the Deposit Agreement shall obligate the Depositary to make available to the Holder hereof a method to receive the elective distribution in Shares (rather than ADSs). There can be no assurance that the Holder hereof, or any Holders generally, will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of Shares. Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed distribution provided for in Section 4.3 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.3 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.3 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Distribution of Rights to Purchase Additional ADSs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon the timely receipt by the Depositary of a notice indicating that the Company wishes rights to subscribe for additional Shares to be made available to Holders of ADSs, the Depositary upon consultation with the Company, shall determine, whether it is lawful and reasonably practicable to make such rights available to the Holders. The Depositary shall make such rights available to any Holders only if (i) the Company shall have timely requested that such rights be made available to Holders, (ii) the Depositary shall have received satisfactory documentation within the terms of Section 5.7 of the Deposit Agreement, and (iii) the Depositary shall have determined that such distribution of rights is reasonably practicable. If such conditions are not satisfied or if the Company requests that the rights not be made available to Holders of ADSs, the Depositary shall proceed with the sale of rights as described in Section 4.4(b) of the Deposit Agreement. In the event all conditions set forth above are satisfied, the Depositary shall establish the ADS Record Date (upon the terms described in Section 4.9 of the Deposit Agreement) and establish procedures to (x) distribute rights to purchase additional ADSs (by means of warrants or otherwise), (y) enable the Holders to exercise such rights (upon payment of the subscription price and of the applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes), and (z) deliver ADSs upon the valid exercise of such rights. The Company shall assist the Depositary to the extent necessary in establishing such procedures. Nothing herein or in the Deposit Agreement shall obligate the Depositary to make available to the Holders a method to exercise rights to subscribe for Shares (rather than ADSs). If (i) the Company does not timely request the Depositary to make the rights available to Holders or requests that the rights not be made available to Holders, (ii) the Depositary fails to receive satisfactory documentation within the terms of Section 5.7 of the Deposit Agreement or determines it is not reasonably practicable to make the rights available to Holders, or (iii) any rights made available are not exercised and appear to be about to lapse, the Depositary shall determine whether it is lawful and reasonably practicable to sell such rights, in a riskless principal capacity, at such place and upon such terms (including public and private sale) as it may deem practicable. The Depositary shall, upon such sale, convert and distribute proceeds of such sale (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) upon the terms hereof and of Section 4.1 of the Deposit Agreement. If the Depositary is unable to make any rights available to Holders upon the terms described in Section 4.4(a) of the Deposit Agreement or to arrange for the sale of the rights upon the terms described in Section 4.4(b) of the Deposit Agreement, the Depositary shall allow such rights to lapse. The Depositary shall not be liable for (i) any failure to accurately determine whether it may be lawful or practicable to make such rights available to Holders in general or any Holders in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale, or exercise, or (iii) the content of any materials forwarded to the Holders on behalf of the Company in connection with the rights distribution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein or in Section 4.4 of the Deposit Agreement to the contrary, if registration (under the Securities Act or any other applicable law) of the rights or the securities to which any rights relate may be required in order for the Company to offer such rights or such securities to Holders and to sell the securities represented by such rights, the Depositary will not distribute such rights to the Holders (i) unless and until a registration statement under the Securities Act (or other applicable law) covering such offering is in effect or (ii) unless the Company furnishes the Depositary opinion(s) of counsel for the Company in the United States and counsel to the Company in any other applicable country in which rights would be distributed, in each case reasonably satisfactory to the Depositary, to the effect that the offering and sale of such securities to Holders and Beneficial Owners are exempt from, or do not require registration under, the provisions of the Securities Act or any other applicable laws. In the event that the Company, the Depositary or the Custodian shall be required to withhold and does withhold from any distribution of Deposited Property (including rights) an amount on account of taxes or other governmental charges, the amount distributed to the Holders of ADSs shall be reduced accordingly. In the event that the Depositary determines that any distribution of Deposited Property (including Shares and rights to subscribe therefor) is subject to any tax or other governmental charges which the Depositary is obligated to withhold, the Depositary may dispose of all or a portion of such Deposited Property (including Shares and rights to subscribe therefor) in such amounts and in such manner, including by public or private sale, as the Depositary deems necessary and practicable to pay any such taxes or charges.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive or exercise rights on the same terms and conditions as the holders of Shares or be able to exercise such rights. Nothing herein or in the Deposit Agreement shall obligate the Company to file any registration statement in respect of any rights or Shares or other securities to be acquired upon the exercise of such rights.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Distributions other than Cash, Shares or Rights to Purchase Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Upon receipt of a notice indicating that the Company wishes property other than cash, Shares or rights to purchase additional Shares to be made to Holders of ADSs, the Depositary shall determine whether such distribution to Holders is lawful and reasonably practicable. The Depositary shall not make such distribution unless (i) the Company shall have requested the Depositary to make such distribution to Holders, (ii) the Depositary shall have received satisfactory documentation contemplated in Section 5.7 of the Deposit Agreement, and (iii) the Depositary shall have determined that such distribution is reasonably practicable. Upon satisfaction of such conditions, the Depositary shall distribute the property so received to the Holders of record, as of the ADS Record Date, in proportion to the number of ADSs held by them respectively and in such manner as the Depositary may deem practicable for accomplishing such distribution (i) upon receipt of payment or net of the applicable fees and charges of, and expenses incurred by, the Depositary, and (ii) net of any applicable taxes withheld. The Depositary may dispose of all or a portion of the property so distributed and deposited, in such amounts and in such manner (including public or private sale) as the Depositary may deem practicable or necessary to satisfy any taxes (including applicable interest and penalties) or other governmental charges applicable to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the conditions above are not satisfied, the Depositary shall sell or cause such property to be sold in a public or private sale, at such place or places and upon such terms as it may deem practicable and shall (i) cause the proceeds of such sale, if any, to be converted into Dollars and (ii) distribute the proceeds of such conversion received by the Depositary (net of applicable (a) fees and charges of, and expenses incurred by, the Depositary and (b) taxes) to the Holders as of the ADS Record Date upon the terms hereof and of Section 4.1 of the Deposit Agreement. If the Depositary is unable to sell such property, the Depositary may dispose of such property for the account of the Holders in any way it deems reasonably practicable under the circumstances.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Depositary nor the Company shall be responsible for (i) any failure to determine whether it is lawful or practicable to make the property described in Section 4.5 of the Deposit Agreement available to Holders in general or any Holders in particular, nor (ii) any loss incurred in connection with the sale or disposal of such property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(16) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon timely receipt of notice from the Company that it intends to exercise its right of redemption in respect of any of the Deposited Securities, and satisfactory documentation, and only if the Depositary shall have determined that such proposed redemption is practicable, the Depositary shall provide to each Holder a notice setting forth the Company&#8217;s intention to exercise the redemption rights and any other particulars set forth in the Company&#8217;s notice to the Depositary. The Depositary shall instruct the Custodian to present to the Company the Deposited Securities in respect of which redemption rights are being exercised against payment of the applicable redemption price. Upon receipt of confirmation from the Custodian that the redemption has taken place and that funds representing the redemption price have been received, the Depositary shall convert, transfer, and distribute the proceeds (net of applicable (a) fees and charges of, and the expenses incurred by, the Depositary, and (b) taxes), retire ADSs and cancel ADRs, if applicable, upon delivery of such ADSs by Holders thereof and the terms set forth in Sections 4.1 and 6.2 of the Deposit Agreement. If less than all outstanding Deposited Securities are redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as may be determined by the Depositary. The redemption price per ADS shall be the dollar equivalent of the per share amount received by the Depositary (adjusted to reflect the ADS(s)-to-Share(s) ratio) upon the redemption of the Deposited Securities represented by ADSs (subject to the terms of Section 4.8 of the Deposit Agreement and the applicable fees and charges of, and expenses incurred by, the Depositary, and applicable taxes) multiplied by the number of Deposited Securities represented by each ADS redeemed. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement to the contrary, in the event the Company fails to give the Depositary timely notice of the proposed redemption provided for in Section 4.7 of the Deposit Agreement, the Depositary agrees to use commercially reasonable efforts to perform the actions contemplated in Section 4.7 of the Deposit Agreement, and the Company, the Holders and the Beneficial Owners acknowledge that the Depositary shall have no liability for the Depositary&#8217;s failure to perform the actions contemplated in Section 4.7 of the Deposit Agreement where such notice has not been so timely given, other than its failure to use commercially reasonable efforts, as provided herein.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(17) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fixing of ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Whenever (a) the Depositary shall receive notice of the fixing of a record date by the Company for the determination of holders of Deposited Securities entitled to receive any distribution (whether in cash, Shares, rights or other distribution), (b) for any reason the Depositary causes a change in the number of Shares that are represented by each ADS, (c) the Depositary shall receive notice of any meeting of, or solicitation of consents or proxies of, holders of Shares or other Deposited Securities, or (d) the Depositary shall find it necessary or convenient in connection with the giving of any notice, solicitation of any consent or any other matter, the Depositary shall fix the record date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADS Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the determination of the Holders of ADS(s) who shall be entitled to receive such distribution, to give instructions for the exercise of voting rights at any such meeting, to give or withhold such consent, to receive such notice or solicitation or to otherwise take action, or to exercise the rights of Holders with respect to such changed number of Shares represented by each ADS. The Depositary shall make reasonable efforts to establish the ADS Record Date as closely as practicable to the applicable record date for the Deposited Securities (if any) set by the Company in Switzerland and shall not announce the establishment of any ADS Record Date prior to the relevant corporate action having been made public by the Company (if such corporate action affects the Deposited Securities).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to applicable law, the terms and conditions of this ADR and Sections 4.1 through 4.8 of the Deposit Agreement, only the Holders of ADSs at the close of business in New York on such ADS Record Date shall be entitled to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receive such distribution, to give such voting instructions, to receive such notice or solicitation, or otherwise take action.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(18) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Voting of Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As soon as practicable after receipt of notice of any meeting at which the holders of Deposited Securities are entitled to vote, or of solicitation of consents or proxies from holders of Deposited Securities, the Depositary shall fix the ADS Record Date in respect of such meeting or solicitation of consent or proxy in accordance with Section 4.9 of the Deposit Agreement. The Depositary shall, if requested by the Company in writing in a timely manner (the Depositary having no obligation to take any further action if the request shall not have been received by the Depositary at least thirty (30) days prior to the date of such meeting or consent or proxy solicitation), at the Company&#8217;s expense and provided no U.S. legal prohibitions exist, distribute to Holders as of the ADS Record Date&#58; (a) such notice of meeting or solicitation of consent or proxy, (b) a statement that the Holders at the close of business on the ADS Record Date will be entitled, subject to any applicable law, the provisions of the Deposit Agreement, the Articles of Incorporation of the Company and the provisions of or governing the Deposited Securities (which provisions, if any, shall be summarized in pertinent part by the Company), to instruct the Depositary as to the exercise of the voting rights, if any, pertaining to the Deposited Securities represented by such Holder&#8217;s ADSs, and (c) a brief statement as to the manner in which such voting instructions may be given.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Deposit Agreement or this ADR, the Depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the Depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of Deposited Securities, distribute to the Holders a notice that provides Holders with, or otherwise publicizes to Holders, instructions on how to retrieve such materials or receive such materials upon request (e.g., by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Voting instructions may be given only in respect of a number of ADSs representing an integral number of Deposited Securities. Upon the timely receipt from a Holder of ADSs as of the ADS Record Date of voting instructions in the manner specified by the Depositary, the Depositary shall endeavor, insofar as practicable and permitted under applicable law, the provisions of the Deposit Agreement, the Articles of Incorporation of the Company and the provisions of the Deposited Securities, to vote, or cause the Custodian to vote, the Deposited Securities (in person or by proxy) represented by such Holder&#8217;s ADSs in accordance with such voting instructions.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposited Securities represented by ADSs for which no timely voting instructions are received by the Depositary from the Holder shall not be voted. Neither the Depositary nor the Custodian shall under any circumstances exercise any discretion as to voting and neither the Depositary nor the Custodian shall vote, attempt to exercise the right to vote, or in any way make use of, the Deposited Securities represented by ADSs, except pursuant to and in accordance with the voting instructions timely received from Holders or as otherwise contemplated in the Deposit Agreement or herein. If the Depositary timely receives voting instructions from a Holder which fail to specify the manner in which the Depositary is to vote the Deposited Securities represented by such Holder&#8217;s ADSs, the Depositary will deem such Holder (unless otherwise specified in the notice distributed to Holders) to have instructed the Depositary to take all steps necessary to enable the independent proxy holder, as elected by the shareholders of the Company, to vote in accordance with the written proposals or recommendations of the Company's Board of Directors. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained herein, the Depositary shall, if so requested in writing by the Company, represent all Deposited Securities (whether or not voting instructions have been received in respect of such Deposited Securities from Holders as of the ADS Record Date) for the sole purpose of establishing quorum at a meeting of shareholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything else contained in the Deposit Agreement or this ADR, the Depositary shall not have any obligation to take any action with respect to any meeting, or solicitation of consents or proxies, of holders of Deposited Securities if the taking of such action would violate U.S. laws. The Company agrees to take any and all actions reasonably necessary and as permitted by the law of Switzerland to enable Holders and Beneficial Owners to exercise the voting rights accruing to the Deposited Securities and to deliver to the Depositary an opinion of U.S. counsel addressing any actions reasonably requested to be taken if so requested by the Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There can be no assurance that Holders generally or any Holder in particular will receive the notice described above with sufficient time to enable the Holder to return voting instructions to the Depositary, or otherwise take action, in a timely manner.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(19) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Changes Affecting Deposited Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon any change in nominal or par value, split up, cancellation, consolidation or any other reclassification of Deposited Securities, or upon any recapitalization, reorganization, merger, consolidation or sale of assets affecting the Company or to which it is a party, any property which shall be received by the Depositary or the Custodian in exchange for, or in conversion of, or replacement of, or otherwise in respect of, such Deposited Securities shall, to the extent permitted by law, be treated as new Deposited Property under the Deposit Agreement, and this ADR shall, subject to the provisions of the Deposit Agreement, this ADR evidencing such ADSs and applicable law, represent the right to receive such additional or replacement Deposited Property. In giving effect to such change, split-up, cancellation, consolidation or other reclassification of Deposited Securities, recapitalization, reorganization, merger, consolidation or sale of assets, the Depositary may, with the Company&#8217;s approval, and shall, if the Company shall so request, subject to the terms of the Deposit Agreement (including, without limitation, (a) the applicable fees and charges of, and expenses incurred by, the Depositary, and (b) applicable taxes) and receipt of an opinion of counsel to the Company reasonably satisfactory to the Depositary that such actions are not in violation of any applicable laws or regulations, (i) issue and deliver additional ADSs as in the case of a stock dividend on the Shares, (ii) amend the Deposit Agreement and the applicable ADRs, (iii) amend the applicable Registration Statement(s) on Form F-6 as filed with the Commission in respect of the ADSs, (iv) call for the surrender of outstanding ADRs to be exchanged for new ADRs, and (v) take such other actions as are appropriate to reflect the transaction with respect to the ADSs. The Company agrees to, jointly with the Depositary, amend the Registration Statement on Form F-6 as filed with the Commission to permit the issuance of such new form of ADSs. Notwithstanding the foregoing, in the event that any Deposited Property so received may not be lawfully distributed to some or all Holders, the Depositary may, with the Company&#8217;s approval, and shall, if the Company requests, subject to receipt of an opinion of Company&#8217;s counsel reasonably satisfactory to the Depositary that such action is not in violation of any applicable laws or regulations, sell such Deposited Property at public or private sale, at such place or places and upon such terms as it may deem proper and may allocate the net proceeds of such sales (net of (a) fees and charges of, and expenses incurred by, the Depositary and (b) applicable taxes) for the account of the Holders otherwise entitled to such Deposited Property upon an averaged or other practicable basis without regard to any distinctions among such Holders and distribute the net proceeds so allocated to the extent practicable as in the case of a distribution received in cash pursuant to Section 4.1 of the Deposit Agreement. The Depositary shall not be responsible for (i) any failure to determine that it may be lawful or practicable to make such Deposited Property available to Holders in general or to any Holder in particular, (ii) any foreign exchange exposure or loss incurred in connection with such sale or (iii) any liability to the purchaser of such Deposited Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(20) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exoneration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything contained in the Deposit Agreement or this ADR, neither the Depositary nor the Company shall be obligated to do or perform any act which is inconsistent with the provisions of the Deposit Agreement or incur any liability (to the extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not limited by paragraph (25) hereof and Section 7.8(b) of the Deposit Agreement) (i) if the Depositary, the Custodian, the Company or their respective agents shall be prevented or forbidden from, hindered or delayed in, doing or performing any act or thing required or contemplated by the terms of the Deposit Agreement and this ADR, by reason of any provision of any present or future law or regulation of the United States, Switzerland or any other country, or of any other governmental authority or regulatory authority or stock exchange, or on account of potential criminal or civil penalties or restraint, or by reason of any provision, present or future, of the Articles of Incorporation of the Company or any provision of or governing any Deposited Securities, or by reason of any act of God or other event or circumstances beyond its control (including, without limitation, fire, flood, earthquake, tornado, hurricane, tsunami, explosion, or other natural disaster, nationalization, expropriation, currency restrictions, work stoppage, strikes, civil unrest, act of war (whether declared or not) or terrorism, revolutions, rebellion, embargo, computer failure, failure of public infrastructure (including communication or utility failure), failure of common carriers, nuclear, cyber or biochemical incident, any pandemic, epidemic or other prevalent disease or illness with an actual or probable threat to human life, any quarantine order or travel restriction imposed by a governmental authority or other competent public health authority, or the failure or unavailability of the United States Federal Reserve Bank (or other central banking system) or DTC (or other clearing system), (ii) by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement or in the Articles of Incorporation of the Company or provisions of or governing Deposited Securities, (iii) for any action or inaction in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Holder, any Beneficial Owner or authorized representative thereof, or any other person believed by it in good faith to be competent to give such advice or information, (iv) for the inability by a Holder or Beneficial Owner to benefit from any distribution, offering, right or other benefit which is made available to holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Holders of ADSs, (v) for any action or inaction of any clearing or settlement system (and any participant thereof) for the Deposited Property or the ADSs, or (vi) for any consequential or punitive damages (including lost profits) for any breach of the terms of the Deposit Agreement. The Depositary, its controlling persons, its agents, any Custodian and the Company, its controlling persons and its agents may rely and shall be protected in acting upon any written notice, request or other document believed by it to be genuine and to have been signed or presented by the proper party or parties. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(21) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Standard of Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company and the Depositary assume no obligation and shall not be subject to any liability under the Deposit Agreement or this ADR to any Holder(s) or Beneficial Owner(s), except that the Company and the Depositary agree to perform their respective obligations specifically set forth in the Deposit Agreement or this ADR without negligence or bad faith. Without limitation of the foregoing, neither the Depositary, nor the Company, nor any of their respective controlling persons, or agents, shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Property or in respect of the ADSs, which in its opinion may involve it in expense or liability, unless indemnity satisfactory to it against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be required (and no Custodian shall be under any obligation whatsoever with respect to such proceedings, the responsibility of the Custodian being solely to the Depositary). </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary and its agents shall not be liable for any failure to carry out any instructions to vote any of the Deposited Securities, or for the manner in which any vote is cast or the effect of any vote, provided that any such action or omission is in good faith and without negligence and in accordance with the terms of the Deposit Agreement. The Depositary shall not incur any liability for any failure to accurately determine that any distribution or action may be lawful or reasonably practicable, for the content of any information submitted to it by the Company for distribution to the Holders or for any inaccuracy of any translation thereof, for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">investment risk associated with acquiring an interest in the Deposited Property, for the validity or worth of the Deposited Property, for the value of any Deposited Property or any distribution thereon, for any interest on Deposited Property, for any tax consequences that may result from the ownership of ADSs, Shares or other Deposited Property, for the credit worthiness of any third party, for allowing any rights to lapse upon the terms of the Deposit Agreement, for the failure or timeliness of any notice from the Company, or for any action of or failure to act by, or any information provided or not provided by, DTC or any DTC Participant.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary shall not be liable for any acts or omissions made by a predecessor depositary whether in connection with an act or omission of the Depositary or in connection with any matter arising wholly prior to the appointment of the Depositary or after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(22) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Resignation and Removal of the Depositary&#59; Appointment of Successor Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary may at any time resign as Depositary under the Deposit Agreement by written notice of resignation delivered to the Company, such resignation to be effective on the earlier of (i) the 90th day after delivery thereof to the Company (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2 of the Deposit Agreement), or (ii) the appointment by the Company of a successor depositary and its acceptance of such appointment as provided in the Deposit Agreement. The Depositary may at any time be removed by the Company by written notice of such removal, which removal shall be effective on the later of (i) the 90th day after delivery thereof to the Depositary (whereupon the Depositary shall be entitled to take the actions contemplated in Section 6.2 of the Deposit Agreement), or (ii) upon the appointment by the Company of a successor depositary and its acceptance of such appointment as provided in the Deposit Agreement. In case at any time the Depositary acting hereunder shall resign or be removed, the Company shall use its commercially reasonable efforts to appoint a successor depositary, which shall be a bank or trust company having an office in the Borough of Manhattan, the City of New York. Every successor depositary shall be required by the Company to execute and deliver to its predecessor and to the Company an instrument in writing accepting its appointment hereunder, and thereupon such successor depositary, without any further act or deed (except as required by applicable law), shall become fully vested with all the rights, powers, duties and obligations of its predecessor (other than as contemplated in Sections 5.8 and 5.9 of the Deposit Agreement). The predecessor depositary, upon payment of all sums due it and on the written request of the Company shall (i) execute and deliver an instrument transferring to such successor all rights and powers of such predecessor hereunder (other than as contemplated in Sections 5.8 and 5.9 of the Deposit Agreement), (ii) duly assign, transfer and deliver all of the Depositary&#8217;s right, title and interest to the Deposited Property to such successor, and (iii) deliver to such successor a list of the Holders of all outstanding ADSs and such other information relating to ADSs and Holders thereof as the successor may reasonably request. Any such successor depositary shall promptly provide notice of its appointment to such Holders. Any entity into or with which the Depositary may be merged or consolidated shall be the successor of the Depositary without the execution or filing of any document or any further act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(23) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment&#47;Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of this paragraph 23, and Section 6.1 of the Deposit Agreement and applicable law, this ADR and any provisions of the Deposit Agreement may at any time and from time to time be amended or supplemented by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written agreement between the Company and the Depositary in any respect which they may deem necessary or desirable without the prior written consent of the Holders or Beneficial Owners. Any amendment or supplement which shall impose or increase any fees or charges (other than charges in connection with foreign exchange control regulations, and taxes and other governmental charges, delivery and other such expenses), or which shall otherwise materially prejudice any substantial existing right of Holders or Beneficial Owners, shall not, however, become effective as to outstanding ADSs until the expiration of thirty (30) days after notice of such amendment or supplement shall have been given to the Holders of outstanding ADSs. Notice of any amendment to the Deposit Agreement or any ADR shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific amendments in any such notice shall not render such notice invalid, provided, however, that, in each such case, the notice given to the Holders identifies a means for Holders and Beneficial Owners to retrieve or receive the text of such amendment (e.g., upon retrieval from the Commission&#8217;s, the Depositary&#8217;s or the Company&#8217;s website or upon request from the Depositary). The parties hereto agree that any amendments or supplements which (i) are reasonably necessary (as agreed by the Company and the Depositary) in order for (a) the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs to be settled solely in electronic book-entry form and (ii) do not in either such case impose or increase any fees or charges to be borne by Holders, shall be deemed not to materially prejudice any substantial existing rights of Holders or Beneficial Owners. Every Holder and Beneficial Owner at the time any amendment or supplement so becomes effective shall be deemed, by continuing to hold such ADSs, to consent and agree to such amendment or supplement and to be bound by the Deposit Agreement and this ADR, if applicable, as amended or supplemented thereby. In no event shall any amendment or supplement impair the right of the Holder to surrender such ADS and receive therefor the Deposited Securities represented thereby, except in order to comply with mandatory provisions of applicable law. Notwithstanding the foregoing, if any governmental body should adopt new laws, rules or regulations which would require an amendment of, or supplement to, the Deposit Agreement to ensure compliance therewith, the Company and the Depositary may amend or supplement the Deposit Agreement and this ADR at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the Deposit Agreement and this ADR in such circumstances may become effective before a notice of such amendment or supplement is given to Holders or within any other period of time as required for compliance with such laws, rules or regulations.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(24) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Depositary shall, at any time at the written direction of the Company, terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. If (i) ninety (90) days shall have expired after the Depositary shall have delivered to the Company a written notice of its election to resign, or (ii) ninety (90) days shall have expired after the Company shall have delivered to the Depositary a written notice of the removal of the Depositary, and, in either case, a successor depositary shall not have been appointed and accepted its appointment as provided in Section 5.4 of the Deposit Agreement, the Depositary may terminate the Deposit Agreement by distributing notice of such termination to the Holders of all ADSs then outstanding at least thirty (30) days prior to the date fixed in such notice for such termination. The date so fixed for termination of the Deposit Agreement in any termination notice so distributed by the Depositary to the Holders of ADSs is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. Until the Termination Date, the Depositary shall continue to perform all of its obligations under the Deposit Agreement, and the Holders and Beneficial Owners will be entitled to all of their rights under the Deposit Agreement. If any ADSs shall remain outstanding after the Termination Date, the Registrar and the Depositary shall not, after the Termination Date, have any obligation to perform any further acts under the Deposit Agreement, except that the Depositary shall, subject, in each case, to the terms and conditions of the Deposit Agreement, continue to (i) collect dividends and other distributions pertaining to Deposited Securities, (ii) sell Deposited Property received in respect of Deposited Securities, (iii) deliver Deposited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any other Deposited Property, in exchange for ADSs surrendered to the Depositary (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (iv) take such actions as may be required under applicable law in connection with its role as Depositary under the Deposit Agreement. At any time after the Termination Date, the Depositary may sell the Deposited Property then held under the Deposit Agreement and shall after such sale hold un-invested the net proceeds of such sale, together with any other cash then held by it under the Deposit Agreement, in an un-segregated account and without liability for interest, for the pro rata benefit of the Holders whose ADSs have not theretofore been surrendered. After making such sale, the Depositary shall be discharged from all obligations under the Deposit Agreement except (i) to account for such net proceeds and other cash (after deducting, or charging, as the case may be, in each case, the fees and charges of, and expenses incurred by, the Depositary, and all applicable taxes or governmental charges for the account of the Holders and Beneficial Owners, in each case upon the terms set forth in Section 5.9 of the Deposit Agreement), and (ii) as may be required at law in connection with the termination of the Deposit Agreement. After the Termination Date, the Company shall be discharged from all obligations under the Deposit Agreement, except for its obligations to the Depositary under Sections 5.8, 5.9 and 7.6 of the Deposit Agreement. The obligations under the terms of the Deposit Agreement of Holders and Beneficial Owners of ADSs outstanding as of the Termination Date shall survive the Termination Date and shall be discharged only when the applicable ADSs are presented by their Holders to the Depositary for cancellation under the terms of the Deposit Agreement (except as specifically provided in the Deposit Agreement).</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(25) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with, and No Disclaimer under, U.S. Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) Notwithstanding any provisions in this ADR or the Deposit Agreement to the contrary, the withdrawal or delivery of Deposited Securities will not be suspended by the Company or the Depositary except as would be permitted by Instruction I.A.(1) of the General Instructions to the Form F-6 Registration Statement, as amended from time to time, under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) Each of the parties to the Deposit Agreement (including, without limitation, each Holder and Beneficial Owner) acknowledges and agrees that no provision of the Deposit Agreement or any ADR shall, or shall be deemed to, disclaim any liability under the Securities Act or the Exchange Act, in each case to the extent established under applicable U.S. laws.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(26) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Third Party Beneficiaries&#47;Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement is for the exclusive benefit of the parties hereto (and their successors) and shall not be deemed to give any legal or equitable right, remedy or claim whatsoever to any other person, except to the extent specifically set forth in the Deposit Agreement. Nothing in the Deposit Agreement shall be deemed to give rise to a partnership or joint venture among the parties nor establish a fiduciary or similar relationship among the parties. The parties hereto acknowledge and agree that (i) Citibank and its Affiliates may at any time have multiple banking relationships with the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (ii) Citibank and its Affiliates may own and deal in any class of securities of the Company and its Affiliates and in ADSs, and may be engaged at any time in transactions in which parties adverse to the Company, the Holders, the Beneficial Owners or their respective Affiliates may have interests, (iii) the Depositary and its Affiliates may from time to time have in their possession non-public information about the Company, the Holders, the Beneficial Owners, and their respective Affiliates, (iv) nothing contained in the Deposit Agreement shall (a) preclude Citibank or any of its Affiliates from engaging in such transactions or establishing or maintaining such relationships, or (b) obligate Citibank or any of its Affiliates to disclose such information, transactions or relationships, or to account for any profit made or payment received in such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transactions or relationships, (v) the Depositary shall not be deemed to have knowledge of any information any other division of Citibank or any of its Affiliates may have about the Company, the Holders, the Beneficial Owners, or any of their respective Affiliates, and (vi) the Company, the Depositary, the Custodian and their respective agents and controlling persons may be subject to the laws and regulations of jurisdictions other than the U.S. and Switzerland, and the authority of courts and regulatory authorities of such other jurisdictions, and, consequently, the requirements and the limitations of such other laws and regulations, and the decisions and orders of such other courts and regulatory authorities, may affect the rights and obligations of the parties to the Deposit Agreement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Depositary may execute transactions contemplated herein (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, foreign currency conversions, and sales of Deposited Property) through one or more divisions of Citibank or through one or more Citibank Affiliates, and any such entity may act as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and may earn and retain revenue from such transactions, including, without, without limitation, transaction spreads, commissions, etc. The Depositary does not guarantee or represent that the price or rate obtained in any such transaction, or the method for obtaining such price or rate, will be the most favorable that could be obtained at that time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(27) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law &#47; Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Deposit Agreement, the ADRs and the ADSs shall be interpreted in accordance with, and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by, the laws of the State of New York applicable to contracts made and to be wholly performed in that State. Notwithstanding anything contained in the Deposit Agreement to the contrary, any ADR or any present or future provisions of the laws of the State of New York, the rights of holders of Shares and of any other Deposited Securities and the obligations and duties of the Company in respect of the holders of Shares and other Deposited Securities, as such, shall be governed by the laws of Switzerland (or, if applicable, such other laws as may govern the Deposited Securities). </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EACH OF THE PARTIES TO THE DEPOSIT AGREEMENT (INCLUDING, WITHOUT LIMITATION, EACH HOLDER AND BENEFICIAL OWNER) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING AGAINST THE COMPANY AND&#47;OR THE DEPOSITARY ARISING OUT OF, OR RELATING TO, THE DEPOSIT AGREEMENT, ANY ADR AND ANY TRANSACTIONS CONTEMPLATED THEREIN (WHETHER BASED ON CONTRACT, TORT, COMMON LAW OR OTHERWISE).</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ASSIGNMENT AND TRANSFER SIGNATURE LINES)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FOR VALUE RECEIVED, the undersigned Holder hereby sell(s), assign(s) and transfer(s) unto ______________________________ whose taxpayer identification number is _______________________ and whose address including postal zip code is ________________, the within ADR and all rights thereunder, hereby irrevocably constituting and appointing ________________________ attorney-in-fact to transfer said ADR on the books of the Depositary with full power of substitution in the premises.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICE&#58; The signature of the Holder to this assignment must correspond with the name as written upon the face of the within instrument in every particular, without alteration or enlargement or any change whatsoever.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the endorsement be executed by an attorney, executor, administrator, trustee or guardian, the person executing the endorsement must give his&#47;her full title in such capacity and proper evidence of authority to act in such capacity, if not on file with the Depositary, must be forwarded with this ADR.</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURE GUARANTEED</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All endorsements or assignments of ADRs must be guaranteed by a member of a Medallion Signature Program approved by the Securities Transfer Association, Inc.</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Legends</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;The ADRs issued in respect of Partial Entitlement American Depositary Shares shall bear the following legend on the face of the ADR&#58; &#8220;This ADR evidences ADSs representing 'partial entitlement' Shares of Molecular Partners AG and as such do not entitle the holders thereof to the same per-share entitlement as other Shares (which are 'full entitlement' Shares) issued and outstanding at such time. The ADSs represented by this ADR shall entitle holders to distributions and entitlements identical to other ADSs when the Shares represented by such ADSs become 'full entitlement' Shares.&#8221;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-23</font></div></div></div><div id="if7724931561a4e79bc4853d8d987da59_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FEE SCHEDULE</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADS FEES AND RELATED CHARGES</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms used but not otherwise defined herein shall have the meaning given to such terms in the Deposit Agreement. Except as otherwise specified herein, any reference to ADSs herein includes Partial Entitlement ADSs, Full Entitlement ADSs, Certificated ADSs, Uncertificated ADSs, and Restricted ADSs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADS Fees</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following ADS fees are payable under the terms of the Deposit Agreement&#58;</font></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Service</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rate</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By Whom Paid</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) Issuance of ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an issuance upon a deposit of Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (4) below.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom ADSs are issued.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) Cancellation of ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a cancellation of ADSs for Delivery of deposited Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom ADSs are being cancelled.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3) Distribution of cash dividends or other cash distributions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon a sale of rights and other entitlements).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person to whom the distribution is made.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4) Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) an exercise of rights to purchase additional ADSs.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person to whom the distribution is made.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5) Distribution of securities other than ADSs or rights to purchase additional ADSs (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, spin-off shares).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person to whom the distribution is made.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6) ADS Services.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the Depositary.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person holding ADSs on the applicable record date(s) established by the Depositary.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7) Registration of ADS Transfers (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or for any other reason).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) transferred.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom or to whom ADSs are transferred.</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8) Conversion of ADSs of one series for ADSs of another series (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferable ADSs, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) converted.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person for whom ADSs are converted or to whom the converted ADSs are delivered.</font></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Charges</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, Holders, Beneficial Owners, persons depositing Shares or withdrawing Deposited Securities in connection with ADS issuances and cancellations, and persons for whom ADSs are issued or cancelled shall be responsible for the following ADS charges under the terms of the Deposit Agreement&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) such registration fees as may from time to time be in effect for the registration of Shares or other Deposited Securities on the share register and applicable to transfers of Shares or other Deposited Securities to or from the name of the Custodian, the Depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the Deposit Agreement to be at the expense of the person depositing Shares or withdrawing Deposited Property or of the Holders and Beneficial Owners of ADSs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) in connection with the conversion of Foreign Currency, the fees, expenses, spreads, taxes and other charges of the Depositary and&#47;or conversion service providers (which may be a division, branch or Affiliate of the Depositary). Such fees, expenses, spreads, taxes, and other charges shall be deducted from the Foreign Currency&#59;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) any reasonable and customary out-of-pocket expenses incurred in such conversion and&#47;or on behalf of the Holders and Beneficial Owners in complying with currency exchange control or other governmental requirements&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi) the fees, charges, costs and expenses incurred by the Depositary, the Custodian, or any nominee in connection with the ADR program.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The above fees and charges may at any time and from time to time be changed by agreement between the Company and the Depositary.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B-2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>5
<FILENAME>a23-descriptionofsecuritie.htm
<DESCRIPTION>EX-2.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i999c86ffb42f495898d86dd25f1e9562_1"></div><div style="min-height:66.96pt;width:100%"><div style="margin-bottom:8pt;padding-right:-22.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 2.3</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br>DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following description sets forth certain material terms and provisions of the securities of Molecular Partners AG (&#8220;Molecular Partners,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). This description also summarizes relevant provisions of the laws of Switzerland. The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the applicable provisions of the laws of Switzerland and our articles of association, a copy of which is filed as an exhibit to the Annual Report on 20-F of which this Exhibit is a part. We encourage you to read our articles of association and the applicable provisions of the laws of Switzerland for additional information.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our securities include (a) our ordinary shares, CHF 0.10 nominal value per share, and (b) our American Depositary Shares (the &#8220;ADSs&#8221;), each representing one ordinary share, CHF 0.10 nominal value per share. Our ordinary shares are registered under the Exchange Act not for trading, but only in connection with the listing of the ADSs on The Nasdaq Global Select Market.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our ADSs are listed on The Nasdaq Global Select Market under the trading symbol &#8220;MOLN.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a description of the rights of (i) the holders of ordinary shares and (ii) ADS holders. Ordinary shares underlying the outstanding ADSs are held by Citibank N.A., as depositary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Swiss Corporate Law Reform</font></div><div style="text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 1, 2023 legislation that modernized certain aspects of Swiss corporate law (the Swiss corporate law reform (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Aktienrechtsrevision</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">)) entered into force. Most relevantly, the legislative reform addressed, among other topics, (i) the modernization and increased flexibility for a stock corporation's capital base, (ii) the strengthening of shareholder rights and the protection of minorities, (iii) certain changes to financial distress&#47;restructuring measures, (iv) corporate governance and executive compensation matters (amongst others, the incorporation of the ordinance against excessive compensation in listed stock corporations (the &#8220;OaEC&#8221;) into the Swiss Code of Obligations (the &#8220;CO&#8221;), and (v) certain socio-political topics (e.g., gender representation and disclosure requirements for companies active in the raw materials sector, which, subject to transitional periods, entered into force on January 1, 2021). The Swiss corporate law reform is subject to certain transitional periods as provided for therein. In particular, Swiss stock corporations registered with the Commercial Register on January 1, 2023, are required to amend their articles of association and organizational regulations in line with the new legislation within a transitional period of two years, i.e., until January 1, 2025. For that purpose, we intend to propose to our shareholders the approval of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">certain amendments to our articles of association at the next annual general meeting of shareholders. Until such amendments have been adopted and approved by the general meeting of shareholders, our current articles of association remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ordinary Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a summary of the rights of our holders of our ordinary shares as specified in our articles of association.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Type and Class of Securities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each ordinary share has a nominal value of CHF 0.10 per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Ordinary Capital Increase, Authorized and Conditional Share Capital</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Swiss corporate law, we may increase our share capital (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Aktienkapital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) with a resolution of the general meeting of shareholders (ordinary capital increase) that must be carried out by the board of directors within six months in order to become effective. Under Swiss corporate law, in case of a subscription and increase against contributions in cash, a resolution passed by an absolute majority of the votes represented at the general meeting of shareholders is required. In the case of a subscription and increase through the conversion of equity surplus, against </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributions in kind, by set-off against a claim, the granting of special benefits, or when shareholders&#8217; statutory pre-emptive rights are limited or withdrawn,  a resolution passed by two-thirds of the votes represented at a general meeting of shareholders and the majority of the nominal value of the shares represented is required.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furthermore, under the CO, our shareholders, by a resolution passed by two-thirds of the votes represented at a general meeting of shareholders and the majority of the nominal value of the shares represented, at such meeting may empower the board of directors to issue shares of a specific aggregate nominal amount up to a maximum of 50% of the existing issued share capital as Registered in the Commercial Register, in the form of&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">conditional capital&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(bedingtes Kapital)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;for the purpose of issuing (i) through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights for the subscription of shares granted to shareholders or third parties in connection with bonds, notes, options warrants or other securities or contractual obligations of the Company or one of our subsidiaries or (ii) through the issuance of rights to subscribe for new shares to employees, members of the board of directors, members of the executive committee, contractors or consultants of the Company or one of our subsidiaries or other persons providing services to the Company or one of our subsidiaries (conversion or option rights)&#59; and&#47;or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a capital range (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Kapitalband</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) to be utilized by the board of directors, for capital increases and&#47;or capital reductions, as applicable, subject to the articles of association, within a period determined by the shareholders but not exceeding five years from the date of the shareholder approval. If and when adopted and approved by the general meeting of shareholders, the capital range will replace the authorized capital (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">genehmigtes Kapital</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) as currently provided for in our articles of association which expires on April 13, 2024.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Preemptive Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, any share issue, whether for cash or non-cash consideration, is subject to the prior approval of the shareholders at a general meeting of shareholders. Shareholders have certain pre-emptive rights (Bezugsrechte) to subscribe for new issues of shares and advance subscription rights (Vorwegzeichnungsrechte) to subscribe convertible or warrant-bearing bonds or other financial market instruments in proportion to the nominal amount of shares held. A resolution adopted at a general meeting of shareholders by a majority of at least two-thirds of the votes and the majority of the nominal share capital each as represented at such a meeting, may limit or withdraw pre-emptive rights or advance subscription rights in certain circumstances. Under our articles of association, the board of directors is authorized to limit or withdraw pre-emptive rights and advance subscription rights based on the authorized share capital and the conditional share capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If pre-emptive rights are granted, but not exercised, the board of directors may allocate the pre-emptive rights as it elects. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With respect to our authorized share capital, which, following the entry into force of the Swiss corporate law reform, remains in full force and effect until the earlier of (i) the introduction of a capital range by the general meeting of shareholders, or (ii) the expiry of the authorized share capital on April 13, 2024, the board of directors is authorized by our articles of association to withdraw or limit the pre-emptive rights of shareholders, and to allocate them to certain shareholders and third parties if the shares are to be used&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">for the acquisition of companies, part of companies or participations, for the acquisition of products, intellectual property or licenses or for investment projects or for the financing or refinancing of such transactions through a placement of shares&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">for the purpose of broadening the shareholder constituency or in connection with a listing of shares on domestic or foreign stock exchanges&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">if the issue price of the new shares is determined by reference to the market price&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">for purposes of granting an over-allotment option (greenshoe) of up to 20% of the total number of shares in a placement or sale of shares to the respective initial purchaser or underwriters&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to the other shareholders a takeover offer recommended by the board of directors&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">for the defense of an actual, threatened or potential takeover bid, in relation to which the board of directors, upon consultation with an independent financial advisor retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may permit pre-emptive rights that have been granted but not exercised to expire or it may place these rights respectively the shares as to which pre-emptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interest of the Company. Any shares for which the granted preferential subscription rights have not been exercised will be at the disposal of the board of directors, who may sell them at market conditions or use them for other purposes in the interest of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limits of Qualifications</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Registration Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Articles of Association</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our ordinary shares have the rights and restrictions described in &#8220;Key Provisions of Our Articles of Association&#8221; below. The following summarizes the rights of holders of our ordinary shares&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">each holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">holders of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Key Provisions of Our Articles of Association, Organizational Rules and Swiss Law</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following is a summary of certain important provisions of our articles of association, organizational rules and certain related provisions of Swiss law. Please note that this is only a summary and as such is not, is not  intended to be and does not purport to be exhaustive. For a more complete discussion, please refer to our articles of association and organizational rules.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The articles of association contain, among other things, provisions to the following effect&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Voting Rights </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each of our shares entitles a holder to one vote. The shares are not divisible. The right to vote and the other rights of share ownership may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third person with written authorization to act as proxy or the shareholder&#8217;s legal representative.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Dividends and Other Distributions </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our board of directors may propose to shareholders that a dividend or other distribution be paid but cannot itself authorize the distribution. Under our articles of association, dividend payments require a resolution passed by an absolute majority of the votes represented at a general meeting of shareholders. In addition, our auditors must confirm that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Swiss corporate law, we may pay dividends only if we have sufficient distributable profits brought forward from the previous business years, or if we have distributable reserves, each as evidenced by our audited stand-alone statutory balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the articles of association have been deducted. As of January 1, 2023, our shareholders may also resolve to pay interim dividends out of profit of the current business year on the basis of interim accounts.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Distributable reserves are booked either as voluntary &#8220;retained earnings&#8221; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">freiwillige Gewinnreserven</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), as statutory &#34;retained earnings&#34; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">gesetzliche Gewinnreserve</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), as statutory capital reserves (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">gesetzliche Kapitalreserve</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) or as reserves from capital contributions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Kapitaleinlagereserven</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). Under the CO, if our statutory retained earnings and our statutory capital reserves amount to less than 20% of our paid-in nominal share capital recorded in the commercial register (i.e., 20% of the aggregate nominal value of our issued capital), then at least 5% of our annual profit must be retained as statutory &#34;retained earnings&#34;. In addition, if our general reserves amount to less than 50% of our share capital, 10% of the amounts distributed beyond payment of a dividend of 5% must be retained as general reserves. The CO permits us to accrue additional voluntary reserves. Further, we are required to present the amount of the purchase price of own shares repurchased (whether by us or a subsidiary) as a negative item in equity, or as reserves for own shares, respectively, in our annual stand-alone statutory balance sheet, and such amount may not be used for dividends or subsequent repurchases. A purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which are not distributable.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Distributions out of issued share capital (i.e., the aggregate nominal value of our issued shares) are not allowed and may be made only by way of a share capital reduction. Such a capital reduction requires a resolution passed by an majority of the votes represented at a general meeting of shareholders. The resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that claims of our creditors remain fully covered despite the reduction in the share capital recorded in the commercial register. Upon approval by the general meeting of shareholders of the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official Gazette of Commerce and notify creditors that they may request security by registering their claims. In this case we must secure the creditors&#8217; claims to the extent that the previous cover has been reduced by the capital reduction, provided the creditors request us to do so within 30 days of publication in the Swiss Official Gazette of Commerce. The reduction of the share capital may be implemented only if all the requirements for reducing the share capital are met.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Uncertificated Securities</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our shares are uncertificated securities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Wertrechte</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, within the meaning of article 973c of the CO) and, when administered by a custodian (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verwahrungsstelle</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, within the meaning of the Federal Act on Intermediated Securities, or FISA), and credited to one or more securities deposit account (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effektenkonto</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), qualify as intermediated securities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bucheffekten</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, within the meaning of the FISA). In accordance with article 973c of the CO, we maintain a non-public register of uncertificated securities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Wertrechtebuch</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). We may at any time without the approval of our shareholders and at our cost convert shares issued as uncertificated securities into another form (including global certificates) or convert shares issued in one form into another form. Following the entry in the share register, a shareholder may at any time request from us a written confirmation in respect of the shares held by such shareholder. Shareholders are not entitled, however, to request the printing and delivery of certificates or the conversion of the shares in one form into another form. We may print and deliver certificates for shares at any time.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Transfer of Shares and Transfer Restrictions</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">So long as shares are intermediated securities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bucheffekten</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> within the meaning of the Swiss Federal Act on Intermediated Securities, or FISA) based on uncertificated securities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Wertrechte</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) entered into the main register of a custodian and credited to one or more securities deposit account (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effektenkonto</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), (i) any transfer of shares is effected by a corresponding entry in the securities deposit account of a bank or a depository institution, (ii) no shares can be transferred by way of assignment, and (iii) a security interest in any shares cannot be granted by way of assignment. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company maintains its share register through areg.ch ag, an external service provider, and enters the full name, address and nationality (in the case of legal entities, the company name and registered office) of the shareholders (including nominees) and usufructuaries therein. A person entered into the share register must notify the share registrar of any change in address. Until such notification occurs, all written communication from the Company to persons entered in the share register is deemed to have been validly made if sent to the relevant address recorded in the share register. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any person who acquires shares may submit an application to the Company requesting it to enter such person into the share register as a shareholder with voting rights, provided such person expressly declares to the Company that it has acquired and holds such shares in its own name and for its own account. Any such person that does not expressly state in his or her application to the Company that the relevant shares were acquired for his or her own account (any such person, a nominee) may be entered in the share register as a shareholder with voting rights for the relevant shares, provided that nominee has entered into an agreement with the Company regarding its position and is subject to a recognized banking or finance supervision. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may, after having heard the concerned shareholder of record or nominee, cancel entries in the share register that were based on inaccurate or misleading information, or if such information becomes inaccurate or misleading, with retroactive effect to the date of the entry. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any acquirer of shares who is not registered in the share register as a shareholder with voting rights may not vote at or participate in any general meetings of shareholders of the Company, but will still be entitled to dividends and other rights with financial value with respect to such shares. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Ownership of ADSs or Shares by Non-Swiss Residents </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except for the limitations on voting rights described above applicable to shareholders generally and the sanctions referred to below, there is no limitation under Swiss corporate law or our articles of association on the right of non-Swiss residents or nationals to own ADSs or common shares or to exercise voting rights attached to the common shares underlying the ADSs.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Foreign Investment and Exchange Control Regulations in Switzerland</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other than in connection with government sanctions imposed on certain persons from, in or related to the Republic of Iraq, Iran, Central African Republic, Yemen, Lebanon, Libya, Sudan, the Republic of South Sudan, the Republic of Mali, Burundi, the Democratic Republic of Congo, Myanmar (Burma), Somalia, Syria, Guinea, Guinea-Bissau, Zimbabwe, Belarus, the Democratic People's Republic of Korea (North Korea), Venezuela, Nicaragua, persons and organizations with a connection to Osama bin Laden, the &#34;Al-Qaeda&#34; group or the Taliban and certain persons in connection with the assassination of Rafik Hariri as well as measures to prevent the circumvention of international sanctions in connection with the situation in Ukraine, there are currently no governmental laws, decrees or regulations in Switzerland that restrict the export or import of capital, including, but not limited to, Swiss foreign exchange controls on the payment of dividends, interest or liquidation proceeds, if any, to non-resident holders of shares.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Annual General Meetings</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Ordinary and Extraordinary General Meetings of Shareholders</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The general meeting of shareholders is our supreme corporate body. Under Swiss corporate law, ordinary and extraordinary general meetings of shareholders may be held. An ordinary general meeting of shareholders must be held annually within six months after the end of a corporation&#8217;s financial year. In our case, this means on or before June&#160;30 of any calendar year.The annual general meeting of shareholders is convened by our board of directors or, if necessary, our auditors.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An extraordinary general meeting of shareholders may be called by a resolution of the board of directors or, under certain circumstances, by our auditor, liquidator or the representatives of bondholders, if any. In addition, the board of directors is required to convene an extraordinary general meeting of shareholders if shareholders representing at least 10% of the share capital request such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. In accordance with the Swiss corporate law reform, we intend proposing to our shareholders an amendment to our articles of association allowing shareholders who hold, alone or together, ordinary shares representing at least 5% of the share capital or the votes to request the calling of an extraordinary general meeting of shareholders.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, our board of directors may convene an extraordinary general meeting of shareholders and propose financial restructuring measures falling within the powers of the general meeting of shareholders if (i) we are threatened to become illiquid or (ii) based on our annual stand-alone statutory balance sheet, our assets less the liabilities no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">longer cover half of the sum of the share capital, the statutory capital reserve not to be repaid to the shareholders and the statutory retained earnings.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Powers</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Swiss corporate law, the following powers are vested exclusively in the general meeting of shareholders&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">adoption and amendment of our articles of association&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">election of the members of the board of directors, the chairperson of the board of directors, the members of the nomination and compensation committee, the independent voting rights representative and the auditors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">approval of the annual management report and the consolidated financial statements&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">approval of the annual financial statements and decision on the allocation of profits shown on the balance sheet, in particular with regard to dividends&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the determination of interim dividends and the approval of the interim financial statements required for this purpose&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the resolution on the repayment of the statutory capital reserve&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">approval of the compensation of the board of directors and of the executive management pursuant to article 28 of our articles of association&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">granting discharge to the members of the board of directors and the persons entrusted with the executive management&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the delisting of the Company's equity securities&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">passing of resolutions as to all matters reserved by law or under our articles of association to the authority of the general meeting of shareholders.</font></div><div><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Voting and Quorum Requirements</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder resolutions and elections (including elections of members of the board of directors) require the affirmative vote of the majority of the votes represented at the general meeting of shareholders, unless otherwise stipulated by law or our articles of association.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law and our articles of association, a resolution of the general meeting of the shareholders passed by two-thirds of the votes represented at the meeting, and the majority of the nominal value of the shares represented is required for&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the amendment or modification of the purpose of the company&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the combination of shares (reverse share split)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the creation of shares with privileged voting rights&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the restriction on the transferability of shares and the cancellation of such restriction&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the introduction of conditional share capital or the introduction of a capital range&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">an increase of the share capital through the conversion of capital surplus, through contribution in kind, by set-off against a claim or the granting of special privileges&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the limitation or withdrawal of pre-emptive rights&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the introduction of the casting vote of the acting chair in the general meeting of shareholders &#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the delisting of the Company's equity securities&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the relocation of the registered office of the company&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the relocation of the place of incorporation of the company&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the introduction of an arbitration clause in the articles of association&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the dissolution of the company.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a rule, the same voting requirements apply to resolutions regarding transactions among corporations based on Switzerland&#8217;s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets of 2003, as amended, or the Swiss Merger Act (including a merger, demerger or conversion of a corporation). See &#8220;&#8212;Compulsory Acquisitions&#59; Appraisal Rights.&#8221;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Swiss corporate law and generally accepted business practices, our articles of association do not provide for quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Swiss corporate law and our articles of  association, general meetings of shareholders must be convened by the board of directors at least twenty days before the date of the meeting. The general meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed by mail. The notice of a general meeting of shareholders must state the date, the starting time, the form and the location of the general meeting, the items on the agenda, the proposals to be acted upon and short explanations for these proposals, in case of elections, the names of the nominated candidates and if applicable, the shareholders' motions with a short explanation and&#47;or the name and address of the independent voting representative. Except in the limited circumstances listed below, a resolution may not be passed at a general meeting without proper notice. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Swiss corporate law, our annual report, the compensation report and the auditors' reports must be made available electronically to the shareholders at least 20 days prior to the annual general meeting of shareholders.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The owners or representatives of all of our shares may, if no objection is raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders (a universal meeting). This universal meeting of shareholders may discuss and pass binding resolutions on all matters within the purview of the ordinary general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of shareholders, specifying the agenda item and the proposal or proposals.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agenda Requests</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to our articles of association, one or more shareholders whose combined shareholdings represent the lower of (1) one tenth of the share capital or (2) an aggregate nominal value of at least CHF 1,000,000, may request that an item be included on the agenda for a general meeting of shareholders. To be timely, the shareholder&#8217;s request must be received by us at least 45 calendar days in advance of the meeting.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with the Swiss corporate law reform, we intend proposing to our shareholders an amendment to our articles of association allowing shareholders who hold alone or together ordinary shares representing at least 0.5% of the share capital or the votes to request that an item be included on the agenda or a proposal relating to an agenda item be included in the notice convening a general meeting of shareholders.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shareholder Proposals</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, at any general meeting of shareholders any shareholder may put proposals to the meeting if the proposal is part of an agenda item. In addition, even if the proposal is not part of any agenda item, any shareholder may propose to the meeting to convene an extraordinary general meeting of shareholders or to have a specific matter investigated by means of a special investigation where this is necessary for the proper exercise of shareholders&#8217; rights.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Number of Directors</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our articles of association provide that our board of directors shall consist of a minimum of three members and a maximum of eleven members.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The members of our board of directors and the chairperson are elected annually by the general meeting of shareholders for a term of office until completion of the next annual general meeting of shareholders and are eligible for re-election. Each member of our board of directors must be elected individually.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Powers</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">According to Swiss corporate law, the board of directors has the following non-delegable and inalienable powers and duties&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the ultimate direction of the business of the company and the issuance of the necessary instructions&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the determination of the organization of the company&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the administration of accounting, financial control and financial planning&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the appointment and removal of the persons entrusted with executive management and their representation of the company&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the ultimate supervision of the persons entrusted with management of the company, specifically in view of their compliance with the law, these articles of association, the regulations and directives&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the preparation of the business report and the compensation report and&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">thre preparation of the general meetings of shareholders as well as the implementation of the resolutions adopted by the general meetings of shareholders&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the adoption of resolutions regarding the subsequent payment of capital with respect to non-fully paid up shares and the amendments to the articles of association related thereto&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the adoption of resolutions on the change of the share capital to the extent that such power is vested in the board of directors, the ascertainment of capital changes the preparation of the report on the capital increase, and the respective amendments of the articles of association (including deletions)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the non-delegable and inalienable duties and powers of the board of directors pursuant to the Merger Act&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the submission of a petition for debt restructuring moratorium and the notification of the court if liabilities exceed assets&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any other matter reserved to the board of directors by the law or the articles of association.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may, while retaining such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, managing directors, committees or to third parties who need be neither members of the board of directors nor shareholders. Pursuant to Swiss corporate law, details of the delegation must be set in the organizational rules issued by the board of directors. The organizational rules may also contain other procedural rules such as quorum requirements.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Indemnification of Executive Management and Directors</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties under the employment agreement with the employer. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We intend to enter into indemnification agreements with each of the members of our board of directors and executive management. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Conflict of Interest, Management Transactions</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Swiss corporate law </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provides that all members of the board of directors and of the executive committee must inform the board of directors without delay of any conflicts of interest. In such an event, the board of directors has to take such measures as are necessary to safeguard the company's interests. Further, the CO contains a provision that requires our directors and executive management to safeguard the company&#8217;s interests and imposes a duty of loyalty and duty of care on our directors and executive management. This rule is generally understood to disqualify directors and executive management from participation in decisions that directly affect them. Our directors and executive officers are personally liable to us for breach of these provisions. In addition, Swiss law contains provisions under which directors and all persons engaged in the company&#8217;s management are liable to the company, each shareholder and the company&#8217;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss corporate law contains a provision under which payments made to any of the company&#8217;s shareholders or directors, executive officers or members of the advisory board (if any)  or any person associated with any such person, other than payments made at arm&#8217;s length, must be repaid to the company if such person,  or associated person acted in bad faith.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Code of Conduct and organizational rules also cover a broad range of matters, including the handling of conflicts of interest.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Principles of the Compensation of the Board of Directors and the Executive Management</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Swiss corporate law, the company is subject to certain rules related to the compensation of the members of the board of directors and of the executive committee applicable to listed companies. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to Swiss corporate law, our shareholders must annually approve the compensation of the board of directors and the persons whom the board of directors has, fully or partially, entrusted with our management, which we refer to as our &#8220;executive management&#8221;. The board of directors is responsible for the annual preparation of a written compensation report in accordance with Swiss corporate law. Our statutory auditor conducts an audit of the compensation report as required by Swiss law and Swiss auditing standards. The compensation report must disclose all compensation, loans and other forms of indebtedness granted by us, directly or indirectly, to current or former members of the board of directors and executive management to the extent related to their former role or not on customary market terms.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The disclosure concerning compensation, loans and other forms of indebtedness must include&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the aggregate amount for the board of directors as well as the particular amount for each member of the board of directors, specifying the name and function of each respective person&#59; and</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the aggregate amount for the executive management as well as the particular amount for the member of the executive management with the highest compensation, specifying the name and function of such member.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain forms of compensation are prohibited for members of our board of directors and executive management, such as&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">severance payments provided for either contractually or in the articles of association (compensation due during the notice period before termination of a contractual relationship does not qualify as severance payment)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">compensation related to a non-competition undertaking that exceeds the average remuneration for the last three financial years, or compensation related to a non-competition undertaking that is not justified on business grounds&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">advance compensation&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">incentive fees for the acquisition or transfer of corporations or parts thereof by us or by companies being, directly or indirectly, controlled by the us&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association&#59; and</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">equity securities and conversion and option rights awards not provided for in the articles of association.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation to members of the board of directors and executive management for activities in entities that are, directly or indirectly, controlled by us is prohibited if the compensation (1) would have been prohibited if it was paid directly by us, (2) is not provided for in our articles of association and (3) has not been approved by the general meeting of shareholders.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our shareholders annually vote on the proposals of the board of directors with respect to&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the maximum aggregate amount of compensation of the board of directors until the next annual general meeting&#59; and</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the maximum aggregate amount of (1) fixed compensation of the executive management for the period from July 1 of a given year to June 30 of the following year and (2) variable compensation of the executive management for the current financial year.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The board of directors may submit for approval at the general meeting of shareholders deviating or additional proposals relating to the same or different periods.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the general meeting of shareholders does not approve a compensation proposal made by the board of directors, the board of directors must convene an extraordinary general meeting and submit a new compensation proposal to such meeting.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to fixed compensation, members of the executive management and, under certain circumstances, the board of directors may be paid variable compensation, depending on the achievement of certain performance criteria or for retention purposes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The performance criteria may include corporate targets and targets in relation to the market, other companies or comparable benchmarks and individual targets, taking into account the position and level of responsibility of the recipient of the variable compensation. The board of directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria and the respective target values.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation may be paid or granted in the form of cash, shares, financial instruments, or in the form of other types of benefits. The board of directors or, where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Borrowing Powers</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neither Swiss law nor our articles of association restrict in any way our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our board of directors, and no approval by the shareholders is required in relation to any such borrowing.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Repurchases of Shares and Purchases of Own Shares</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The CO limits our right to purchase and hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that (1) we have freely distributable reserves in the amount of the purchase price&#59; and (2) the aggregate nominal value of all shares held by us does not exceed 10% of our share capital. Pursuant to Swiss corporate law, where shares are acquired in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20%. We currently do not have any transfer restriction in our articles of association. If we own shares that exceed the threshold of 10% of our share capital, the excess must be sold or cancelled by means of a capital reduction within two years.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares held by us or our subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and pre-emptive rights in the case of share capital increases.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, selective share repurchases are only permitted under certain circumstances. Within these limitations, as is customary for Swiss corporations, we may purchase and sell our own shares from time to time in order to meet our obligations under our equity plans, to meet imbalances of supply and demand, to provide liquidity and to even out variances in the market price of shares.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notification and Disclosure of Substantial Share Interests</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The disclosure obligations generally applicable to shareholders of Swiss corporations under the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading of 2015, or the Financial Market Infrastructure Act, are applicable to us. Under the Financial Market Infrastructure Act, persons who directly, indirectly or in concert with other parties acquire or dispose of common shares or are granted the power to exercise voting rights attached to common shares at their own discretion, or delegated voting rights, or acquire or dispose of purchase or sale rights relating to common shares, and thereby reach, exceed or fall below a threshold of 3, 5, 10, 15, 20, 25, 33 1&#8260;3, 50 or 66 2&#8260;3 percent of our voting rights (whether exercisable or not) must report such acquisition or disposal to us and the SIX Swiss Exchange in writing within four trading days. Within two trading days of the receipt of such notification, we must publish such information through SIX Swiss Exchange's electronic reporting and publishing platform. For purposes of calculating whether a threshold has been reached or crossed, shares, delegated voting rights and acquisition rights or obligations, or Acquisition Positions, on the one hand and sale rights or obligations, or Disposal Positions, on the other hand may not be netted. Rather the Acquisition Positions and the Disposal Positions need to be accounted for separately and may each trigger disclosure obligations if the respective positions reach one of the thresholds. In addition, actual share ownership and delegated voting rights must be reported separately from other Purchase Positions if they reach one of the thresholds.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Mandatory Bid Rules</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the applicable provisions of the Financial Market Infrastructure Act, any person that acquires shares of a listed Swiss company, whether directly or indirectly or acting in concert with third parties, which shares, when taken </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">together with any other shares of such company held by such person, exceed the threshold of 33 1&#47;3% of the voting rights (whether exercisable or not) of such company, must make a takeover bid to acquire all the other listed shares of such company. A company&#8217;s articles of association may either eliminate this provision of the Financial Market Infrastructure Act or may raise the relevant threshold to 49%, opting-out or opting-up, respectively. Our articles of association do not contain any opting-out or opting-up provision. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A waiver of the mandatory rules may be granted by the Swiss Takeover Board or FINMA under certain circumstances. If no waiver is granted, the mandatory takeover bid must be made pursuant to the procedural rules set forth in the Financial Market Infrastructure Act and the implementing ordinances thereunder. </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There is no obligation to make a takeover bid under the Financial Market Infrastructure Act if the voting rights in question are acquired as a result of a gift, succession or partition of an estate, a transfer based upon matrimonial property law or execution proceedings.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limitation of Liability and Indemnification </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Differences in Corporate Law</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:20pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">We are a corporation (Aktiengesellschaft), organized under the laws of Switzerland in accordance with articles 620 et seqq. CO. The laws applicable to a Swiss Aktiengesellschaft differ from laws applicable to U.S. corporations and their shareholders. The following discussion summarizes material differences between the rights of holders of our common shares and the rights of holders of the common shares of a typical corporation incorporated under the laws of the state of Delaware, which result from differences in governing documents and the laws of Switzerland and Delaware. For a more complete discussion, please refer to the Delaware General Corporation Law, or the DGCL, Swiss law, and our governing corporate statutes.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delaware</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Directors</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, the board of directors must consist of at least one member, unless the articles of association set out a specific number of directors. Our articles of association provide that our board of directors shall consist of a minimum of three members and a maximum of eleven members.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws, unless the certificate of incorporation fixes the number of directors, in which case a change in the number of directors shall be made only by amendment of the certificate of incorporation.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director Qualifications</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any natural person can be elected as a member of the board of directors even without being a shareholder of the corporation. As a minimum standard a director has to be in the position to fulfill his or her fiduciary duties, the duty of care and the duty of loyalty. It lies within the competence of the board of directors to determine a set of qualifications when proposing potential candidates to the general meeting of shareholders for election, or the articles of association may set out guidelines. While our articles of association generally do not set out such guidelines, our organizational regulations and committee charters stipulate certain requirements as to independence and, with respect to the audit and finance committee, financial literacy.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Further, the corporation must be able to be represented by one person who is resident in Switzerland with sole signature authority or two persons who are resident in Switzerland with joint signature authority by two. This person or these persons may be either a member of the board of directors or an executive officer. They must have access to the share register and the register of beneficial owners notified to the company.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a corporation may prescribe qualifications for directors under its certificate of incorporation or bylaws.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard of Conduct for Directors</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A director of a Swiss corporation has a fiduciary duty to the corporation only. This duty has two components&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the duty of care&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the duty of loyalty.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The duty of care requires that a director acts in good faith, with the care that an ordinary prudent director would exercise under similar circumstances.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The duty of loyalty requires that a director acts in a manner he or she reasonably believes to be in the best interest of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits in principle self-dealing by a director and mandates that the best interest of the corporation take precedence over a director&#8217;s interest.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors must afford the shareholders equal treatment in equal circumstances.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The burden of proof for a violation of these duties is with the corporation or with the shareholder (or creditor) bringing a suit against the director.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Swiss Federal Supreme Court established the doctrine to restrict its review of a business decision if the decision has been taken upon proper preparation, on an informed basis and without conflicts of interest.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The DGCL does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnification of Directors and Executive Committee and Limitation of Liability</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, a corporation cannot limit the personal liability of a director or another person entrusted with its management. However, the general meeting of shareholders may grant discharge to the directors and the persons entrusted with its management from liability arising from actions taken during the past financial year. Such discharge is effective only, however, for disclosed facts and only against the corporation and those shareholders who approved the discharge or who have since acquired shares in full knowledge of the discharge.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, subject to certain limitations, a corporation may indemnify and hold harmless directors and other persons entrusted with its management out of the assets of the corporation from and against actions, costs, charges, losses, damages and expenses which they or any of them may incur or sustain by or by reason of any act done, concurred in or omitted, in connection with the execution of their statutory duties, provided that such indemnity (if any) shall not extend to any matter in which any of said persons is found to have committed an intentional or grossly negligent breach of his or her duties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the limitations described above, the articles of association of a Swiss corporation may therefore provide that the corporation shall indemnify and hold harmless to the extent permitted by law the directors and members of the executive committee out of assets of the corporation against threatened, pending or completed actions. Within the same limitations, articles of association of a Swiss corporation may also provide that the directors shall be entitled to the reimbursement of all expenses incurred in the interests of the corporation. Our articles of association contain such a provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, a corporation may enter into and pay for directors&#8217; and officers&#8217; liability insurance which may cover negligent acts as well.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages arising from a breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director for&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any breach of the director&#8217;s duty of loyalty to the corporation or its shareholders&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">intentional or negligent payment of unlawful dividends or unlawful share purchases or redemptions&#59; or</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transaction from which the director derives an improper personal benefit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding, other than an action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation&#59; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless ordered by a court, any foregoing indemnification is subject to a determination that the director or officer has met the applicable standard of conduct&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">by a majority vote of the directors who are not parties to the proceeding, even though less than a quorum&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">by a committee of directors designated by a majority vote of the eligible directors, even though less than a quorum&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">by independent legal counsel in a written opinion if there are no eligible directors, or if the eligible directors so direct&#59; or</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">by the shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Moreover, a Delaware corporation may not indemnify a director or officer in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Vote on Board Renewal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The general meeting of shareholders elects annually and individually the members of the board of directors, the chairperson of the board of directors and the members of the compensation committee for a term of office until completion of the next annual general meeting of shareholders. Re-election is possible.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">One-year terms are mandatory under Swiss corporate law for listed companies. Classified boards are therefore not permitted.</font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Cumulative voting is not permitted under Swiss corporate law. Our directors, the chairperson of the board of directors and the members of the compensation committee are elected by the affirmative vote of the absolute majority of the votes represented at the general meeting of shareholders.</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Unless directors are elected by written consent in lieu of an annual meeting, directors are elected in an annual meeting of shareholders on a date and at a time designated by or in the manner provided in the bylaws. Re-election is possible.</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Classified boards are permitted.</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cumulative voting for elections of directors is not permitted unless the corporation&#8217;s certificate of incorporation provides for it.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Removal of Directors</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The general meeting of shareholders may remove, with or without cause, any director at any time with a resolution passed by an absolute majority of the votes represented at a general meeting of shareholders where a proposal for such removal was properly set on the agenda. The articles of association may require the approval by a qualified majority of the shares represented at a meeting for the removal of a director.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, unless otherwise provided in the certificate of incorporation, stockholders may effect such removal only for cause.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vacancies on the Board of Directors</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to fill a vacancy on the board of directors, a new member of the board of directors must be elected by a general meeting of shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In the event the office of the chairperson of the board of directors is vacant, the board of directors shall appoint a new chairperson from among its members for the remaining term of office. If there are vacancies on the compensation committee, the board of directors may appoint substitute members from among its members for the remaining term of office. The articles of association may set forth other rules to fill vacancies on the compensation committee. Our articles of association do not stipulate such other rules.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, unless otherwise provided in the certificate of incorporation or bylaws, a vacancy or a newly created directorship may be filled by a majority of the directors then in office, although less than a quorum, or by the sole remaining director. Any newly elected director usually holds office for the remainder of the full term expiring at the annual meeting of shareholders at which the term of the class of directors to which the newly elected director has been elected expires.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual General Meeting or Special Meetings</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The annual general meeting of shareholders must take place annually within six months after the close of the financial year. Amongst other competences, the general meeting of shareholders individually elects the members of the board of directors, the chairperson of the board of directors and the members of the compensation committee. The notice of convening the meeting must include the place and date of the general meeting, the agenda items, the proposals by the board of directors and shareholders (if any), and necessary directions and instructions by the board of the directors.</font></div><div><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extraordinary general meetings of shareholders shall be called as often as necessary by the board of directors or, if necessary, by the statutory auditors as well as in all other cases required by law. One or more shareholders holding, alone or together, ordinary shares representing at least 5% of the share capital or of the votes may request in writing that the board of directors call an extraordinary general meeting of shareholders. The request must contain an agenda and the suggested proposals.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be provided by the certificate of incorporation or by the bylaws, or by the board of directors if neither the certificate of incorporation or bylaws so provide.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, unless directors are elected by written consent in lieu of an annual meeting as permitted by the DGCL, the annual meeting of stockholders shall be held for the election of directors on a date and at a time as designated by or in the manner provided in the bylaws.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></div></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Proposals</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At any general meeting of shareholders any shareholder may put proposals to the meeting if the proposal is part of an agenda item. Generally, no resolution may be passed on proposals relating to agenda items that were not duly notified. Pursuant to our articles of association, one or more shareholders whose combined shareholdings represent the lower of (1) one tenth of the share capital or (2) an aggregate nominal value of at least CHF 1,000,000, may request that an item be included on the agenda for a scheduled general meeting of shareholders provided such request is made with appropriate notice. Our articles of association provide that such request must be made at least 45 calendar days prior to a general meeting of shareholders specifying the agenda item and the proposal or proposals. In  accordance with the Swiss corporate law reform, we intend proposing to our shareholders an amendment to our articles of association allowing shareholders who hold, alone or together, ordinary shares representing at least 0,5 % of the share capital or the votes to request that an item be included on the agenda or a proposal relating to an agenda item be included in the notice convening a general meeting of shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, any shareholder is entitled, at a general meeting of shareholders and without advance notice, to (i) request information from the board of directors on the affairs of the company (note, however, that the right to obtain such information is limited), (ii) request information from the statutory auditors on the methods and results of their audit, (iii) propose that an extraordinary general meeting of shareholders be called or (iv) propose that a special investigation be carried out.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under the DGCL, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">A stockholder of a Delaware corporation has the right to put any proposal before the annual meeting of stockholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but stockholders may be precluded from calling special meetings.</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of General Meetings</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law and our articles of association, notice of the general meeting of shareholders has to be given at least 20 calendar days before the date for which the meeting is scheduled in the form prescribed by the articles of association. The agenda must specify the place, date, hour, agenda items, and the proposals of the board of directors and short explanations for these proposals, if applicable, the proposals of the shareholders who have requested that a general meeting be called or an item be placed on the agenda (if any) with a short explanation and if applicable, the address of the independent voting representative. Our annual report, the compensation report and the auditors' reports must be made available electronically to the shareholders at least 20 days prior to the annual general meeting of shareholders.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour and purpose or purposes of the meeting.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proxy</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss law requires that the independent proxy must be present at a general meeting of shareholders. Registered shareholders may give proxy and voting instructions to the independent proxy in writing or electronically. Pursuant to our articles of association, registered shareholders may also give proxy to a representative of their choice.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, each shareholder entitled to vote at a meeting of shareholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such shareholders by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Action by Written Consent</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of January 1, 2023, shareholders of a Swiss corporation may also act by written consents if no shareholder or representative of a shareholder requests an oral debate.</font></div><div><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shareholders of record may vote at the general meeting of shareholders through proxy and related instructions (&#8220;&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;).</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL a corporation&#8217;s certificate of incorporation (1) may permit shareholders to act by written consent if such action is signed by all shareholders, (2) may permit shareholders to act by written consent signed by shareholders having the minimum number of votes that would be necessary to take such action at a meeting or (3) may prohibit actions by written consent. Unless otherwise provided in the certificate of incorporation, any action that is required by the DGCL to be, or that can be, taken at an annual or special meeting of the shareholders may be taken without a meeting, without prior notice and without a vote, if written consent to the action is signed by the holders of outstanding shares having not less than the minimum number of votes necessary to authorize or take the action at a meeting at which all shares entitled to vote thereon were present and voted.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-emptive Rights</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Under Swiss corporate law, shareholders have pre-emptive rights to subscribe for newly issued shares and advance subscription rights to subscribe for warrants, convertible bonds or similar debt&#47;finance instruments with option or conversion rights. Under certain circumstances, shareholders may limit or withdraw, or authorize the board of directors to limit or withdraw, pre-emptive rights or advance subscription rights. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">However, the shareholders&#8217; pre-emptive rights or advance subscription rights can only be limited or withdrawn for valid reasons. Preventing a particular shareholder to exercise influence over the company is generally believed not to be a valid reason to limit or withdraw shareholders&#8217; pre-emptive rights.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, no shareholder shall have any pre-emptive right to subscribe to an additional issue of shares or to any security convertible into such shares unless, and except to the extent that, such right is expressly granted to such shareholder in the corporation&#8217;s certificate of incorporation.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sources of Dividends</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dividend payments are subject to the approval of the general meeting of shareholders. The board of directors may propose to shareholders that a dividend be paid but cannot itself authorize the distribution.</font></div><div><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Payments out of share capital of a Swiss corporation (in other words, the aggregate nominal value of the corporation&#8217;s registered share capital) in the form of dividends are not allowed&#59; however, payments out of share capital may be made by way of a capital reduction. Dividends may be paid only from the profits brought forward from the previous financial years or if the corporation has distributable reserves, each as will be presented on the corporation&#8217;s audited stand-alone statutory balance sheet. The dividend may be determined only after the allocations to reserves required by Swiss law or the articles of association have been deducted and the corporation&#8217;s statutory auditors have confirmed that the dividend proposal complies with Swiss law and the corporation&#8217;s articles of association. As of January 1, 2023, our shareholders may also resolve to pay interim dividends out of profit of the current business year on the basis of interim accounts.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, subject to any restrictions contained in the certificate of incorporation, the directors of a corporation may declare and pay dividends upon the shares of its capital stock either (1) out of its surplus or (2) if there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and&#47;or the preceding fiscal year, except when the capital of the corporation is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by the issued and outstanding shares of all classes having a preference on the distribution of assets. &#8220;Surplus&#8221; is defined in the DGCL as the excess of the net assets of the corporation over capital, as such capital may be adjusted by the board of directors.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Repurchase of Shares</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A Swiss corporation (or its subsidiaries) may repurchase its own shares under the following conditions&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">it can only repurchase its own shares out of freely disposable equity capital in the required amount&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the combined value of all such shares cannot exceed 10% of the share capital. Where shares are acquired in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20%&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the voting rights on the corporation&#8217;s own shares are suspended&#59; and</font></div><div style="margin-bottom:1.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the amount of the purchase price for the shares repurchased is presented on its stand-alone statutory balance sheet as a negative item in its equity.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a corporation may generally purchase or redeem shares of its stock&#59; provided, however, that no corporation shall purchase or redeem its own shares of capital stock if the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the corporation, except that a corporation may purchase or redeem out of capital any of its own shares which are entitled upon any distribution of its assets to a preference over another class or series of its shares, or, if no shares entitled to such a preference are outstanding, any of its own shares, if such shares will be retired upon their acquisition and the capital of the corporation reduced in accordance with the DGCL.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Voting Rights and Transfer Restrictions</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each common share carries one vote at any general meeting of shareholders. A shareholder must be registered in the corporation&#8217;s share register as a shareholder with voting rights in order to exercise his, her or its voting rights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The articles of association may restrict the registration of a shareholder in the corporation&#8217;s share register in order to ensure that no person or entity is registered as a shareholder with voting rights for more than a certain percentage, and that no person or entity directly or indirectly, formally, constructively or beneficially owns, or otherwise controls or directs voting rights (whether exercisable or not) with respect to a certain percentage of the share capital registered in the Commercial Register. Furthermore, a corporation may under certain circumstances refuse to enter an acquirer of shares in the share register as a shareholder with voting rights if such acquirer fails to declare to the corporation that the relevant shares were acquired for his, her or its own account. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Limitations Affecting Shareholders of a Swiss Company&#8212;Transfer of Shares and Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, the articles of association may provide that no shareholder may exercise, directly or indirectly, voting rights with respect to own or represented shares in excess of a certain percentage of the share capital registered in the Commercial Register.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The articles of association of a Swiss corporation may, subject to certain limitations, provide for shares with preferred voting rights. Our current articles of association do not contain such a provision.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, unless otherwise provided in the certificate of incorporation, each shareholder is entitled to one vote for each share of capital stock held by such shareholder.</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Vote on Certain Transactions</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under Swiss corporate law, with certain exceptions, a merger or a demerger of the corporation pursuant to the Swiss Merger Act or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the votes represented at the respective general meeting of shareholders as well as the absolute majority of the nominal value of shares represented at such meeting. The articles of association may increase the voting threshold (which is not the case under our articles of association). Swiss law also requires that if the merger agreement provides only for a compensation payment, at least 90% of all members in the transferring legal entity who are entitled to vote shall approve the merger agreement. However, there has been some uncertainty and dispute as to whether the 90% approval requirement relates to the total number of votes represented by all shares of the target company outstanding, or the total number of shareholders of the target company entitled to vote.</font></div><div><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Swiss law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary of which it owns at least 90% of the shares without a shareholder vote by shareholders of such subsidiary if the shareholders of the subsidiary are offered the payment of the fair value in cash as an alternative to shares of the parent.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, certain fundamental changes such as amendments to the certificate of incorporation, a merger, consolidation, sale, lease, exchange or other disposition of all or substantially all of the property of a corporation not in the usual and regular course of the corporation&#8217;s business, or a dissolution of the corporation, are generally required to be approved by the holders of a majority of the outstanding shares entitled to vote on the matter, unless the certificate of incorporation requires a higher percentage.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">However, under the DGCL, mergers in which less than 20% of a corporation&#8217;s shares outstanding immediately prior to the effective date of the merger is issued generally do not require shareholder approval. In addition, mergers in which one corporation owns 90% or more of each class of shares of a second corporation may be completed without the vote of the second corporation&#8217;s board of directors or shareholders. In certain situations, the approval of a business combination may require approval by a certain number of the holders of a class or series of shares. In addition, Section 251(h) of the DGCL provides that shareholders of a constituent corporation need not vote to approve a merger if&#58; (i) the merger agreement permits or requires the merger to be effected under Section 251(h) and provides that the merger shall be effected as soon as practicable following the tender offer or exchange offer, (ii) a corporation consummates a tender or exchange offer for any and all of the outstanding shares of such constituent corporation that would otherwise be entitled to vote to approve the merger, (iii) following the consummation of the offer, the stock accepted for purchase or exchanges plus the stock owned by the consummating corporation equals at least the percentage of stock that would be required to adopt the agreement of merger under the DGCL, (iv) the corporation consummating the offer merges with or into such constituent corporation, and (v) each outstanding share of each class or series of stock of the constituent corporation that was the subject of and not irrevocably accepted for purchase or exchange in the offer is to be converted in the merger into, or the right to receive, the same consideration to be paid for the shares of such class or series of stock of the constituent corporation irrevocably purchased or exchanged in such offer.</font></div></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Vote on Board and Management Compensation</font></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the Compensation Ordinance, the aggregate amount of compensation for the members of the board of directors and the executive committee must be approved by the general meeting of shareholders.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dissenters&#8217; Appraisal Rights</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For business combinations effected in the form of a statutory merger or demerger, the Swiss Merger Act provides that if the equity rights have not been adequately preserved or compensation payments in the transaction are not adequate, a shareholder may request the competent court to determine an adequate amount of compensation.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Shareholders who consider their equity rights not to have been adequately preserved or the compensation received to be inadequate are entitled to exercise appraisal rights in accordance with the Swiss Merger Act by filing a suit against the surviving corporation with the competent Swiss civil court at the registered office of the surviving corporation or of the transferring corporation. The suit must be filed within two months after the merger or demerger resolution has been published in the Swiss Official Gazette of Commerce. If such a suit is filed, the court must assess whether the equity rights have been adequately preserved or the compensation paid or to be paid to the shareholders of the transferring corporation is adequate and, should the court consider it to be inadequate, determine any additional adequate compensation. A decision issued by a competent court in this respect can be acted upon by any person who has the same legal status as the claimant. The filing of an appraisal suit will not prevent completion of the merger or demerger.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, any shareholder of a corporation who holds share of stock on the date of making a demand for appraisal of such shareholder&#8217;s shares under the DGCL, who continuously holds such shares through the effective date of a merger or consolidation, who has neither voted in favor of the merger or consolidation nor consented thereto shall be entitled to an appraisal by the Delaware Court of Chancery of the fair value of the shareholder&#8217;s shares of stock&#59; provided, however, that no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 shareholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">shares of stock of the surviving corporation&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">shares of stock of another corporation that are either listed on a national securities exchange or held of record by more than 2,000 shareholders&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">cash in lieu of fractional shares of the stock described in the two preceding bullet points&#59; or</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#160;any combination of the above.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, appraisal rights shall be available for the shares of any class or series of stock of a constituent corporation if the holders of such corporation are required by the agreement of merger or consolidation to accept for such stock anything but&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">shares of stock of the surviving corporation or depository receipts in respect thereof&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">shares of stock of another corporation, or depository receipts in respect thereof, that are either listed on a national securities exchange or held of record by more than 2,000 shareholders&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">cash in lieu of fractional shares or fractional depository receipts described in the two preceding bullet points&#59; or</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any combination of the above.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the shareholders of the surviving corporation.</font></div></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Lawsuits</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under Swiss corporate law, an individual shareholder may bring an action in the shareholder&#8217;s own name, for the benefit of the corporation, against the corporation&#8217;s directors, officers or liquidators to recover any damages the corporation has incurred as a result of an intentional or negligent breach of duties by such directors, officers or liquidators. Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may, to a limited extent, have a similar effect.</font></div><div><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, the winning party is generally entitled to recover or partially recover attorney's fees incurred in connection with such action, provided, however, that the court has discretion to permit the shareholder whose claim has been dismissed to recover attorney's fees incurred to the extent he or she acted in good faith.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a shareholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must state that the plaintiff was a shareholder at the time of the transaction of which the plaintiff complains or that the plaintiff&#8217;s shares thereafter devolved on the plaintiff by operation of law&#59; provided, however, that under Delaware case law, the plaintiff generally must be a shareholder not only at the time of the transaction which is the subject of the suit, but through the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff, unless such demand would be futile. An individual also may commence a class action suit on behalf of himself or herself and other similarly situated shareholders where the requirements for maintaining a class action have been met.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment of Governing Documents</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The articles of association of a Swiss corporation may generally be amended by the general meeting of shareholders with a resolution passed by an absolute majority of the votes represented at such meeting, unless otherwise provided in the articles of association or required by law. There are a number of resolutions, such as an amendment of the stated purpose of the corporation and the introduction of authorized and conditional capital, that pursuant to Swiss law require the approval by two-thirds of the votes and an absolute majority of the nominal value of the shares represented at the general meeting of shareholders. The articles of association may increase the voting thresholds.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Subject to certain requirements, shareholders may submit a proposal to be voted on at a general meeting of shareholders to amend the articles of association</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a corporation may amend its certificate of incorporation if&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">its board of directors has adopted a resolution setting forth the amendment proposed and declaring its advisability&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">if a majority of the outstanding stock entitled to vote on the amendment, and a majority of the outstanding stock of each class entitled to vote on the amendment as a class, has been voted in favor of the amendment.</font></div><div style="margin-bottom:1pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, the shareholders entitled to vote have the power to adopt, amend or repeal bylaws. A corporation may also confer, in its certificate of incorporation, such power upon the directors. The fact that such power has been so conferred upon the directors shall not divest the shareholders of the power nor limit their power to adopt, amend or repeal bylaws.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Creation and Issuance of New Shares</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The creation of new shares requires a resolution of the general meeting of shareholders. Under the CO, our shareholders, by a resolution passed by two-thirds of the votes represented at a general meeting of shareholders and the majority of the nominal value of the shares represented at such meeting, may empower the board of directors to issue shares of a specific aggregate nominal amount, in each case up to a maximum of 50% of the existing issued share capital as registered in the Commercial Register, in the form of&#58;<br>&#8226;&#160;&#160;&#160;&#160;conditional capital (bedingtes Kapital) for the purpose of issuing shares (i) through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights for the subscription of shares granted to shareholders or third parties in connection with bonds, notes, options warrants or other securities or contractual obligations of the Company or one of our subsidiaries or (ii) through the issuance of rights to subscribe for new shares to employees, members of the board of directors, members of the executive committee, contractors or consultants of the Company or one of our subsidiaries or other persons providing services to the Company or one of our subsidiaries (conversion or option rights)&#59; and&#47;or<br>&#8226;&#160;&#160;&#160;&#160;a capital range (Kapitalband) to be utilized by the board of directors, for capital increases and&#47;or capital reductions, as applicable, subject to the articles of incorporation, within a period determined by the shareholders but not exceeding five years from the date of the shareholder approval. If and when adopted and approved by the general meeting of shareholders, the capital range will replace the authorized capital (genehmigtes Kapital) as currently provided for in our articles of association which expires on April 13, 2024. <br></font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&#8217;s certificate of incorporation.</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inspection of Books and Records</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Swiss corporate law, a shareholder may request to inspect a corporation&#8217;s minutes of general meetings of shareholders. A corporation&#8217;s annual report, compensation report and the auditors&#8217; reports must be made available electronically to shareholders at least 20 calendar days prior to each annual general meeting of shareholders. If the documents are not electronically accessible, any shareholder may for one year following the general meeting request that they be sent the annual report in the form approved by the general meeting together with the audit reports.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders who hold, alone or together, ordinary shares representing at least 0,5% of the share capital or the votes may request to inspect our books and records. Subject to the safeguarding of a corporation&#8217;s business secrets and other legitimate interests, our board of directors may authorize such inspection to the extent necessary to exercise shareholder rights within four months following receipt of such requests. At a general meeting of shareholders, any shareholder may request information from the board of directors concerning the corporation&#8217;s affairs. Shareholders may also ask the corporation&#8217;s statutory auditors questions regarding their audit of the corporation. The board of directors and the statutory auditors must answer shareholders&#8217; questions to the extent necessary for the exercise of shareholders&#8217; rights and subject to prevailing business secrets or other material interests of the corporation.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of stockholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Lawsuits</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under Swiss corporate law, an individual shareholder may bring an action in the shareholder&#8217;s own name, for the benefit of the corporation, against the corporation&#8217;s directors, officers or liquidators to recover any damages the corporation has incurred as a result of an intentional or negligent breach of duties by such directors, officers or liquidators. Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may, to a limited extent, have a similar effect.</font></div><div><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Under Swiss law, the winning party is generally entitled to recover a limited amount of attorneys&#8217; fees incurred in connection with such action. The court has discretion to permit the shareholder who lost the lawsuit to recover attorneys&#8217; fees incurred to the extent that he, she or it acted in good faith.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the DGCL, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff&#8217;s shares thereafter devolved on the plaintiff by operation of law&#59; provided, however, that under Delaware case law, the plaintiff generally must be a stockholder not only at the time of the transaction which is the subject of the suit, but through the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff, unless such demand would be futile. An individual also may commence a class action suit on behalf of himself or herself and other similarly situated stockholders where the requirements for maintaining a class action have been met.</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dissolution&#59; Winding-up</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under Swiss corporate law, a corporation may be dissolved at any time by way of liquidation, based on a shareholders&#8217; resolution. Such resolution requires the approval by two-thirds of the votes represented as well as the absolute majority of the nominal value of the shares represented at the general meeting of shareholders passing a resolution on such dissolution and winding up. The articles of association may increase the voting thresholds required for such a resolution (which is not the case under our articles of association).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dissolution by law or court order is possible if, for example, a corporation becomes bankrupt.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Under Swiss corporate law, any surplus arising out of a liquidation (after the settlement of all claims of all creditors) is distributed to shareholders in proportion to the paid up nominal value of shares held. The articles of association may provide for another distribution (which is not the case under our articles of association).</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">American Depositary Shares </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Depositary</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have appointed Citibank, N.A., or Citibank, as the depositary for the ADSs pursuant to a deposit agreement. Citibank&#8217;s depositary offices are located at 388 Greenwich Street, New York, New York 10013.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A copy of the deposit agreement is filed as an exhibit to the annual report on Form 20-F of which this exhibit forms a part. You may obtain a copy of the deposit agreement from the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and from the SEC&#8217;s website (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">). Please refer to Registration Number 333-255447 when retrieving such copy.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each ADS represents the right to receive and to exercise the beneficial ownership interests in&#160;one common share that is on deposit with the depositary and&#47;or the custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the ADS-to-common share ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs.  Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, by the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and by the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. Swiss law, which may be different from the laws in the United States, governs shareholder rights and our obligations to the holders of common shares. However, as an ADS holder, you will not be treated as one of our shareholders and you will not have shareholder rights. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary, nor the custodian, nor us nor any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">obtain such regulatory approvals under applicable laws and regulations. For the requirement to disclose major shareholdings with SIX Swiss Exchange see &#34;--Notification and Disclosure of Substantial Share Interests.&#34;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The manner in which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations under the deposit agreement, and the manner in which, and extent to which, the depositary&#8217;s services are made available to you.  As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the shareholder rights attached to the common shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the common shares represented by your ADSs through the depositary only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary, commonly referred to as the direct registration system, or DRS. The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary to the holders of the ADSs. The direct registration system includes automated transfers between the depositary and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#8220;holder.&#8221; When we refer to &#8220;you,&#8221; we assume the reader owns ADSs and will own ADSs at the relevant time. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The registration of the common shares in the name of the depositary or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary or the custodian the record ownership in the applicable common shares, with the beneficial ownership rights and interests in such common shares being at all times vested with the beneficial owners of the ADSs representing the common shares.  The depositary or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Dividends and Distributions </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of a specified record date, after deduction the applicable fees, taxes and expenses. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Distributions of Cash </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">the U.S. dollars to the holders, subject to Swiss laws and regulations. The depositary or a division, branch or affiliate of the depositary may act as a principal for any such conversion.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States and distributable to the ADS holders entitled thereto. If it is unlawful or impracticable to convert such foreign currency and distribute U.S. dollars to the holders, the depositary may, in its discretion, convert such foreign currency and make such distribution to such holders as may be lawful and practicable, distribute foreign currency to holders as may be lawful and practicable or hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Distributions of Shares </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever we make a free distribution of common shares for the securities on deposit with the custodian, we will deposit the applicable number of common shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to holders new ADSs representing the common shares deposited or modify the ADS-to- common share ratio, in which case each ADS you hold will represent rights and interests in the additional common shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The distribution of new ADSs or the modification of the ADS-to- common share ratio upon a distribution of common shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new common shares so distributed. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">No such distribution of new ADSs will be made if it would violate any law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">, the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the common shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Distributions of Rights </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever we intend to distribute rights to subscribe for additional common shares, we will give prior notice to the depositary and will indicate whether we wish the rights distribution to be made available to you. In such case, we will assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new common shares other than in the form of ADSs. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> distribute the rights to you if&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we do not timely request that the rights be distributed to you or we request that the rights not be distributed to you&#59; or</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we fail to deliver satisfactory documents to the depositary&#59; or</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">it is not reasonably practicable to distribute the rights.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Elective Distributions </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in Switzerland would receive upon failing to make an election, as more fully described in the deposit agreement. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Other Distributions </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever we intend to distribute property other than cash, common shares or rights to subscribe for additional common shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If it is reasonably practicable to distribute such property to you and if we provide to the depositary all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> distribute the property to you and will sell the property if&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we do not request that the property be distributed to you or if we ask that the property not be distributed to you&#59; or</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we do not deliver satisfactory documents to the depositary&#59; or</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the depositary determines that all or a portion of the distribution to you is not reasonably practicable.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Redemption </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the holders. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will convert the redemption funds received in a currency other than U.S. dollars into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary may determine. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Changes Affecting Common Shares </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The common shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, a split-up, cancellation, consolidation or reclassification of such common shares or a recapitalization, reorganization, merger, consolidation or sale of assets. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the common shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form F-6, call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the common shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Issuance of ADSs upon Deposit of Common Shares </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary may create ADSs on your behalf if you or your broker deposits common shares with the custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the common shares to the custodian. Your ability to deposit common shares and receive ADSs may be limited by U.S. and Swiss legal considerations applicable at the time of deposit. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The issuance of ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been given and that the common shares have been duly transferred to the custodian. The depositary will only issue ADSs in whole numbers. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">When you make a deposit of common shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to represent and warrant that&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The common shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">All pre-emptive (and similar) rights, if any, with respect to such common shares have been validly waived or exercised.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">You are duly authorized to deposit the common shares.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The common shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#8220;restricted securities&#8221; (as defined in the deposit agreement).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The common shares presented for deposit have not been stripped of any rights or entitlements.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The deposit of the common shares does not violate any applicable provisions of the laws of Switzerland.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If any of the representations or warranties are incorrect in any way, we and the depositary may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Transfer, Combination and Split Up of ADRs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary and also must&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">provide such proof of identity and genuineness of signatures as the depositary deems appropriate&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">provide any transfer stamps required by the State of New York or the United States&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the transfer of ADRs.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may restrict transfers of ADSs where such transfer may result in the total number of shares represented by the ADSs owned by a single holder or beneficial owner to exceed limits imposed by applicable law or the Articles. We may instruct the depositary to take actions with respect to the ownership interests of any holder or beneficial owner in excess of such limits including the imposing of restrictions on transfers of ADSs, the removal or limitation of voting rights, or mandatory sale or disposition of ADSs held by such holder of beneficial owner in excess of such limitations.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Withdrawal of Common Shares Upon Cancellation of ADSs </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of underlying common shares at the custodian&#8217;s offices. Your ability to withdraw the common shares held in respect of the ADSs may be limited by U.S. and Swiss legal considerations applicable at the time of withdrawal. In order to withdraw the common shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the common shares being withdrawn. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If you hold ADSs registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the common shares represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">You will have the right to withdraw the securities represented by your ADSs at any time subject to&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">temporary delays that may arise because (i)&#160;the transfer books for the ADSs or common shares are closed, or (ii)&#160;common shares are immobilized on account of a shareholders&#8217; meeting or a payment of dividends&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">obligations to pay fees, taxes and similar charges&#59; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit&#59; or</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">other circumstances specifically contemplated by Instruction I.A.(l) of the General Instructions to Form F-6 Registration Statement, as amended from time to time, under the Securities Act.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Voting Rights </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the common shares represented by your ADSs. The voting rights of holders of common shares are described in the sections titled &#8220;Description of Share Capital and Articles of Association&#8221; and &#8220;Limitations Affecting Shareholders of a Swiss Company.&#8221; </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">At our timely request, the depositary will distribute to you any notice of general meetings of shareholders or other solicitations of consents received from us and arrange to deliver our voting materials to you, or provide notice with instructions on how to retrieve such materials. Those materials will describe the matters to be voted on and explain how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. For instructions to be valid, they must reach the depositary by a date set by the depositary.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will try, as far as practical, and subject to the laws of Switzerland and to the Articles, to vote or cause to be voted the common shares underlying the ADSs in accordance with instructions timely received from ADS holders. If the depositary does not timely receive voting instructions with respect to certain ADSs, it will not vote the common shares represented by such ADSs, except as otherwise contemplated in the deposit agreement. If the depositary timely receives voting instructions from a holder that fail to specify the manner in which the common shares are to be voted, the depositary will deem such holder (unless otherwise specified in the notice distributed to holders) to have instructed the depositary to take all steps necessary to enable the independent proxy holder, as elected by the shareholders of the Company, to vote the common shares underlying such ADS holder's ADSs in accordance with the written proposals or recommendations of the Company's board of directors. At our request, the depositary will represent all common shares underlying the ADSs for the purpose of establishing a quorum at a meeting of our shareholders.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. Common shares for which no voting instructions have been timely received will not be voted except as provided above with respect to representing common shares to establish a quorum, and as otherwise contemplated in the deposit agreement. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions, for the manner in which any vote is cast or for the effect of any vote, provided that the depositary acted in good faith, without negligence and in accordance with the deposit agreement. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your common shares are not voted as you requested. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited shares, if we request the depositary to act, we will give the depositary notice of the applicable meeting or vote and details concerning the matters to be voted upon in a timely manner in advance of the meeting or vote, the depositary having no obligation to take any action with respect to any vote or meeting if it receives such request later than 30 days before the vote or meeting. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Fees and Charges </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As an ADS holder, you will be required to pay the following service fees to the depositary under the terms of the deposit agreement&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Service</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Fees</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of common shares, upon a change in the ADS(s)-to- common share(s) ratio, or for any other reason), excluding ADS issuances as a result of distributions of common shares)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05&#160;per ADS issued</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to- common share(s) ratio, or for any other reason)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05 per ADS canceled</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05 per ADS held</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Distribution of ADSs pursuant to stock dividends, other free stock distributions or exercise of rights to purchase additional ADSs.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05&#160;per ADS held</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05&#160;per ADS held</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ADS Services</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05&#160;per ADS held on the applicable record date(s) established by the depositary</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Registration of ADS Transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason).</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05 per ADS transferred</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferable ADSs, and vice versa).</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to U.S. $0.05 per ADS converted</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As an ADS holder you will also be responsible to pay certain fees, expenses, taxes and governmental charges such as&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">such registration fees as may from time to time be in effect for the registration of common shares or other deposited securities on the share register and applicable to transfers of common shares or other deposited securities to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the deposit agreement to be at the expense of the person depositing common shares or withdrawing deposited property or of the holders and beneficial owners of ADSs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">in connection with the conversion of foreign currency, the fees, expenses, spreads, taxes and other charges of the depositary and&#47;or conversion service providers (which may be a division, branch or affiliate of the depositary).  Such fees, expenses, spreads, taxes, and other charges shall be deducted from the foreign currency&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any reasonable and customary out-of-pocket expenses incurred in such conversion and&#47;or on behalf of the holders and beneficial owners in complying with currency exchange control or other governmental requirements&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the fees, charges, costs and expenses incurred by the depositary, the custodian, or any nominee in connection with the ADR program.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">ADS fees and charges for (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations).  In the case of ADSs issued by the depositary into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time.  </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date.  In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed.  In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs.  For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the event of refusal to pay the depositary fees or other charges, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees or other charges from any distribution to be made to the ADS holder. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of such changes. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the depositary fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary may agree from time to time.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Amendments and Termination </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#8217; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the common shares represented by your ADSs (except as permitted by law). </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with any termination of the deposit agreement, the depositary may make available to owners of ADSs a means to withdraw the common shares represented by ADSs and to direct the deposit of such common shares into an unsponsored ADS program established by the depositary.  The ability to receive unsponsored ADSs upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored ADSs and the payment of applicable depositary fees.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Books of Depositary </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Limitations on Obligations and Liabilities </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The deposit agreement limits our obligations and the depositary&#8217;s obligations to you. Please note the following&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in common shares, for the validity or worth of the common shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our Articles, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our Articles or in any provisions of or governing the securities on deposit.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting common shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of common shares but is not, under the terms of the deposit agreement, made available to you.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary and you as ADS holder.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Nothing in the deposit agreement precludes Citibank, N.A. (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank, N.A. to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those transactions.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Taxes </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Foreign Currency Conversion </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary may take the following actions in its discretion&#58; </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">distribute the foreign currency to holders for whom the distribution is lawful and practical&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">hold the foreign currency (without liability for interest) for the applicable holders.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Governing Law&#47;Waiver of Jury Trial</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The deposit agreement and the ADRs will be interpreted in accordance with the laws of the State of New York.  The rights of holders of common shares (including common shares represented by ADSs) are governed by the laws of Switzerland. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Except as otherwise provided in the deposit agreement, we and the depositary have agreed that any legal action arising out of the deposit agreement between us and the depositary may be instituted in a state or federal court in the City of New York, and we and the depositary have irrevocably submitted to the non-exclusive jurisdiction of such courts for such purpose.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING AGAINST US AND&#47;OR THE DEPOSITARY. ARISING OUT OF OR RELATING TO THE DEPOSIT AGREEMENT, THE ADRs OR THE TRANSACTIONS CONTEMPLATED THEREIN.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Such waiver of your right to trial by jury may apply to any claim under U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-22.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">38</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>6
<FILENAME>a44licenseagreementdatedas.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2e72dd0eb7b6468fa17739133421dc6e_1"></div><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.4</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#00ff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;  &#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________________________________________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BY AND BETWEEN</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">NOVARTIS PHARMA AG</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AND</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________________________________________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Table of Contents</font></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DEFINITIONS AND INTERPRETATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">LICENSE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">GOVERNANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">TRANFER OF MPAG KNOW-HOW and regulatory materials.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DEVELOPMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">24</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">6.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MANUFACTURING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">7.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">COMMERCIALIZATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">8.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">FINANCIAL PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">9.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">REPORTS AND PAYMENT TERMS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">INTELLECTUAL PROPERTY RIGHTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CONFIDENTIALITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">12.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">TERM AND TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">13.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EFFECT OF TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">14.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS, WARRANTIES AND COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">15.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">INDEMNIFICATION&#59; LIABILITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">16.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PUBLICATIONS AND PUBLICITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">17.</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i2e72dd0eb7b6468fa17739133421dc6e_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT A &#8211; COMPOUNDS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT B &#8211; &#91;PURPOSEFULLY BLANK&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT C &#8211; PURCHASED INVENTORY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT D &#8211; DEVELOPMENT PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT E &#8211; SAMPLE INVOICE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT F &#8211; MPAG PATENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT G &#8211; PRESS RELEASE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHEDULE 13.2(C)&#8211; RESOLUTION OF TRANSITION PLAN AGREEMENTS</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHEDULE 14.2&#8211; DISCLOSURES</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This LICENSE AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made as of this 17th day of January, 2022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and between (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Pharma AG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Swiss corporation with offices at Lichtstrasse 35, CH-4056 Basel, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and (b)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Molecular Partners AG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Swiss corporation, with offices at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Novartis and MPAG are each referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, MPAG owns or otherwise Controls the MPAG Patents and MPAG Know-How (each as defined below) relating to the MPAG Compounds and Products (as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, pursuant to that certain Option and Equity Rights Agreement between the Parties, dated as of October 27, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Novartis has exercised its exclusive option to obtain the License (as defined below) with respect to the MPAG Patents and MPAG Know-How relating to the MPAG Compounds and Products&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, pursuant to the terms and conditions of this License Agreement, MPAG desires to grant, and Novartis desires to accept, a right and license to develop, manufacture and commercialize the Products on a worldwide basis in the Field, subject to paying MPAG certain payments set out herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties agree as follows.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">DEFINITIONS AND INTERPRETATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The terms in this License Agreement with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, IFRS (International Financial Reporting Standards), as generally and consistently applied by Novartis and its Affiliates. Novartis shall promptly notify MPAG in the event that it changes the Accounting Standards pursuant to which its records are maintained, it being understood that Novartis may only use internationally recognized accounting principles (e.g., IFRS, US GAAP).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, any person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, &#8220;control&#8221; shall mean, direct or indirect, ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest, in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%) and, in such case, such lower percentage shall be substituted in the preceding sentence&#59; provided, that such foreign investor has the power to direct the management and policies of such entity.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all applicable laws, statutes, rules, regulations and other pronouncements having the effect of law of any federal, national, multinational, state, cantonal, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including any applicable rules, regulations, guidelines, or other requirements of the Regulatory Authorities that may be in effect from time to time.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audited Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in a particular country with respect to a particular Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reference Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), any biopharmaceutical product that&#58; (a) has received all necessary approvals by the applicable Regulatory Authorities in such country to market and sell such product as a biopharmaceutical product through reference to the MAA and Regulatory Approval of the Reference Product pursuant to an expedited regulatory approval process governing approval of generic biologics based on the then-current standards for regulatory approval in such country (e.g., the Biologics Price Competition and Innovation Act of 2009 or an equivalent under foreign law)&#59; (b) is marketed or sold in such country by a Third Party that (i) has not obtained the rights to market or sell such product as a sublicensee or distributor of Novartis or any of its Affiliates or sublicensees, including pursuant to a license or settlement in connection with litigation with Novartis, its Affiliate or a sublicensee under the Biologics Price Competition and Innovation Act of 2009 or an equivalent under foreign law and (ii) did not purchase such product in a chain of distribution that included Novartis or any of its Affiliates or sublicensees&#59; and (c) is approved as (i) a &#8220;biosimilar&#8221; (as defined in the United States under 42 U.S.C. &#167; 262(i)(2)) of the Reference Product, (ii) a &#8220;similar biological medicinal product&#8221; (in the EU in accordance with Directive 2001&#47;83&#47;EC) with respect to which the Reference Product is the &#8220;reference medicinal product,&#8221; or (iii) if not in the US or EU, the foreign equivalent of a &#8220;biosimilar&#8221; or &#8220;similar biological medicinal product&#8221; of such Reference Product. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Biologics License Application as defined in the Act and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a day other than a Saturday, Sunday, or a bank or other public holiday in Basel, Switzerland.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31&#59; provided, that&#58; (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first such three (3)-month period thereafter&#59; and (b) the final Calendar Quarter of the Term shall extend from the first day of such three (3)-month period until the last day of the Term.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a period of twelve (12) consecutive calendar months ending on December&#160;31&#59; provided, that&#58; (a) the first Calendar Year of the Term shall extend from the Effective Date to December 31&#59; and (b) the final Calendar Year of the Term shall extend from January 1 until the last day of the Term.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to MPAG&#58; (a) a merger, reorganization, combination or consolidation of MPAG with a Third Party that results in the holders of beneficial ownership of the voting securities or other voting interests of MPAG (or, if applicable, the ultimate parent of MPAG) </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">immediately prior to such merger, reorganization, combination or consolidation ceasing to hold beneficial ownership of at least fifty percent (50%) of the combined voting power of the surviving entity or the ultimate parent of the surviving entity immediately after such merger, reorganization, combination or consolidation&#59; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities or other voting interest of MPAG&#59; or (c) the sale or other transfer (in one (1) transaction or a series of related transactions) to a Third Party of all or substantially all of MPAG&#8217;s assets. Notwithstanding the foregoing, a Change of Control excludes any change in domicile and any transaction involving the public issuance of securities of MPAG purely for financing purposes.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CHF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the lawful currency of Switzerland.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Third Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Clinical Collaboration Agreement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the clinical collaboration agreement between &#91;***&#93;, as amended by the parties from time to time, including as amended on or about the Execution Date.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.2(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combination Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the definition of Net Sales.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the treatment or prevention of SARS-CoV-2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Territories</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;&#59; provided, that the specific countries and jurisdictions in the Commercial Territory may be modified during the Term as agreed by the Parties in the Governance Committee.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to market, promote, distribute, import, export, offer to sell and&#47;or sell a product and&#47;or conduct other commercialization activities, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means commercialization activities relating to a product, including activities relating to marketing, promoting, distributing, importing, exporting, offering for sale and&#47;or selling a product. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has a correlative meaning.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means such reasonable, diligent, and good-faith efforts to undertake an activity as Novartis would normally use to accomplish a similar objective under similar circumstances exercising reasonable business judgment, it being understood and agreed that such efforts shall be substantially similar to those efforts and resources commonly used by Novartis for a product owned by it or to which it has rights, which product is of similar market and economic potential as the Product, and at a similar stage in its development or product life as the Product, taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of Regulatory Approval given the regulatory structure involved, the profitability, and other relevant factors commonly considered in similar circumstances (including access and coverage factors). It is anticipated that the level of effort may change over time, reflecting changes in the status of a Product.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How and other proprietary information and data of a financial, scientific, commercial or technical nature which the Disclosing Party has supplied or otherwise made available to the Recipient Party, whether made available orally, in writing or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Know-How, Patent Rights or Trademarks, that a Party owns or has a license to such Know-How, Patent Rights or Trademarks and, in each case, has the power to grant to the other Party access, a license, a sublicense or other rights (as applicable) to the same on the terms and conditions set forth in this License Agreement without violating any obligations of the granting Party to a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means drug research and development activities, including test method development and stability testing, assay development and audit development, toxicology, formulation, quality assurance&#47;quality control development, technical development, process development, statistical analysis, pre-clinical and clinical studies, packaging development, regulatory affairs, and the preparation, filing and prosecution of BLAs and MAAs. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has a correlative meaning.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Execution Date.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency or any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enabling IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MPAG Enabling Know-How and the MPAG Enabling Patents.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Encumbrance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, option, license, assignment, power of sale, retention of title, right of pre-emption, right of first refusal or security interest of any kind.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EUA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means, with respect to a Product, approval by the FDA under &#167;564 of the FD&#38;C Act to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological and nuclear threat agents when there are no adequate, approved, and available alternatives.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">European Union</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the European Union member states as then constituted. As of the Execution Date, the European Union member states are Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U. S. Federal Food, Drug, and Cosmetic Act, as amended. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U. S. Food and Drug Administration or any successor entity. </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all uses of the Products in all (existing and future) indications in humans and animals. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product in a country in the Territory, the first arm&#8217;s length sale for monetary value of such Product by Novartis, its Affiliate, or their sublicensee to a Third Party or Governmental Authority for end use or consumption of such Product in such country following Regulatory Approval for sale of such Product in such country. Sales or transfers of reasonable quantities of a Product for Development, including proof of concept studies or other clinical trial purposes, or for compassionate or similar use, shall not be considered a First Commercial Sale.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a full-time equivalent person year (consisting of a total of &#91;***&#93;) of activities undertaken by MPAG.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the rate per FTE of &#91;***&#93; with respect to activities conducted pursuant to this License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Funding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable then-current ethical and scientific quality standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including in the United States, Good Clinical Practices established through FDA guidances, and, outside the United States, Guidelines for Good Clinical Practice &#8211; ICH Harmonized Tripartite Guideline (ICH E6).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable then-current good laboratory practice standards as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including in the United States, those promulgated or endorsed by the FDA in U.S. 21 C.F.R. Part 58, or the equivalent thereof as promulgated or endorsed by the applicable Regulatory Authorities outside of the United States.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all applicable standards relating to manufacturing practices for fine chemicals, intermediates, bulk products or finished pharmaceutical products, as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, as applicable, (a)&#160;all applicable requirements detailed in the FDA&#8217;s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211, (b) all applicable requirements detailed in the EMA&#8217;s &#8220;The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products&#8221;, and (c) all equivalent Applicable Laws promulgated by any Governmental Authority having jurisdiction over the manufacture of the applicable compound or pharmaceutical product, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any court, administrative body, local authority or other governmental or quasi-governmental entity with competent jurisdiction, any supra-national, national, federal, state, municipal, provincial or local governmental, regulatory or administrative authority, agency, commission, court tribunal, arbitral body, self-regulated entity, private body exercising any regulatory, taxing, importing or other governmental or quasi-governmental authority or other governmental entity, including any relevant Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Investigational New Drug application in the U.S. filed with the FDA or the corresponding application for the investigation of pharmaceutical products in any other country or group </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of countries, as defined in the applicable laws and regulations and filed with the Regulatory Authority of a given country or group of countries.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in relation to either Party, any of the following&#58; (a) that a Party admits in writing to that the other Party that is has or will cease to function as a going concern by suspending or discontinuing its business&#59; (b) that Party shall commence any case, proceeding or other action (i) under any existing or future law of any jurisdiction relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (ii) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or any such Party shall make a general assignment for the benefit of its creditors&#59; (c) there shall be commenced against such Party any case, proceeding or other action of a nature referred to in clause (b) above that (I) results in the entry of an order for relief or any such adjudication or appointment or (II) remains undismissed, undischarged or unbonded for a period of &#91;***&#93;&#59; (d) any case, proceeding or other action has been commenced against such Party seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of its assets that results in the entry of an order for any such relief that shall not have been vacated, discharged, or stayed or bonded pending appeal within &#91;***&#93; from the entry thereof&#59; or (e) such Party shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clauses (b), (c) or (d) above.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to compounds, formulations, compositions, products or to their Manufacture, Development, registration, use or Commercialization or methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof, relevant to the Development, Manufacture, use or Commercialization of or which may be useful in studying, testing, Development, production or formulation of products, or intermediates for the synthesis thereof.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in the first paragraph of this License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How, Patent Rights, and any other intellectual property rights licensed to Novartis under the License or pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product on a country-by-country basis, the Net Sales of such Product in that country in the most recent Calendar Quarter are less than &#91;***&#93; as compared with the Net Sales of such Product in that country in the Calendar Quarter preceding the marketing or sale of the first Biosimilar Product of such Product. </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an application for the authorization to market the product in any country or group of countries outside the United States, as defined in the applicable laws and regulations and filed with the Regulatory Authority of a given country or group of countries. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a compound or product, activities directed to the sourcing and purchasing of materials, producing, manufacturing, processing, compounding, filling, finishing, packing, packaging, labeling, leafleting, quality assurance, quality control testing and release, shipping, storage, and sample retention of such compound or product. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; have correlative meanings.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Minimum Shelf Life</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MP0420</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the multi-specific designed ankyrin repeat protein with the amino acid sequence set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, including certain sequence variants thereof, and any other chemically modified versions of such proteins, and any fused or conjugated versions of any of the foregoing, &#91;***&#93; set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MP0423</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the multi-specific designed ankyrin repeat protein with the amino acid sequence set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, including certain sequence variants thereof, and any other chemically modified versions of such proteins, and any fused or conjugated versions of any of the foregoing, &#91;***&#93; set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in the first paragraph of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Background Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any intellectual property (including Patent Rights and Know-How) related to &#91;***&#93; which was Controlled by MPAG or its Affiliates prior to the Execution Date or is thereafter acquired or created by MPAG independently of and not in connection with this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Compounds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means MP0420 and MP0423, collectively, and the correlative, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means either of MP0420 or MP0423, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Controlled Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Enabling Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How (other than MPAG Products Know-How) Controlled by MPAG or any of its Affiliates as of the Execution Date or thereafter during the Term that relates to the Platform.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Enabling Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patent Rights (other than MPAG Products Patents) Controlled by MPAG or any of its Affiliates as of the Execution Date or thereafter during the Term having claims that are necessary or reasonably useful for the research, Development, Manufacture, preparation, use or Commercialization of the MPAG Compounds or any Product in the Field in the Territory. The MPAG Enabling Patents existing as of the Execution Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;F-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the MPAG Enabling Know-How and MPAG Products Know-How.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Managed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;MPAG Ongoing Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Ongoing Clinical Trial Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all documented external costs on a pass-through basis and internal expenses at the FTE Rate, in each case, that are reasonably incurred by MPAG in the conduct of an MPAG Ongoing Clinical Trial that are incurred in performance of such activities in accordance with the Development Plan (as defined in the Option Agreement) or the Development under this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Option Period Products Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MPAG Know-How existing as of &#91;***&#93; that is necessary or reasonably useful to Manufacture the MPAG Compounds and the Products.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MPAG Enabling Patents and MPAG Products Patents. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Produced Purchased Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Purchased Inventory that was Manufactured at a Manufacturing Facility (as identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto) that is not owned or controlled by Novartis or its Affiliates. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Products Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means all Know-How Controlled by MPAG or any of its Affiliates as of the Execution Date or thereafter during the Term that is necessary for and relates solely and specifically to the research, Development, Manufacture, preparation, use, or Commercialization of the MPAG Compounds or any Product. For the avoidance of doubt, MPAG Products Know-How includes Option Period Data and Option Period Inventions, but excluding the Option Period Manufacturing IP and the New Manufacturing IP. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Products Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MPAG Know-How as of Execution Date necessary or reasonably useful to Manufacture the MPAG Compounds or any Product. For the avoidance of doubt, MPAG Products Manufacturing Process includes MPAG Option Period Products Manufacturing Process. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Products Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patent Rights Controlled by MPAG or any of its Affiliates as of the Execution Date or thereafter during the Term having claims solely and specifically covering a MPAG Compound or a Product, its use, composition, formulation, preparation or Manufacture. The MPAG Products Patents existing as of the Execution Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the net sales recorded by Novartis or any of its Affiliates or sublicensees (excluding distributors and wholesalers) for any Product sold to Third Parties other than sublicensees as determined in accordance with Novartis&#8217; Accounting Standards as consistently applied, less a deduction of &#91;***&#93; for direct expenses related to the sales of the Product, distribution and warehousing expenses and uncollectible amounts on previously sold products. The deductions booked on an accrual basis by Novartis and its Affiliates under its Accounting Standards to calculate the recorded net sales from gross sales include the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;normal trade and cash discounts&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;amounts repaid or credited by reasons of defects, rejections, recalls or returns&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;rebates and chargebacks to customers and Third Parties (including Medicare, Medicaid, Managed Healthcare and similar types of rebates)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;amounts provided or credited to customers through coupons and other discount programs&#59; </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates or retroactive price reductions&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;fee for service payments to customers for any non-separable services (including compensation for maintaining agreed inventory levels and providing information)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;other reductions or specifically identifiable amounts deducted for reasons similar to those listed above in accordance with Novartis&#8217; Accounting Standards. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to the calculation of Net Sales&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Net Sales only include the value charged or invoiced on the first arm&#8217;s length sale to a Third Party and sales between or among Novartis and its Affiliates and sublicensees shall be disregarded for purposes of calculating Net Sales&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If a Product is delivered to the Third Party before being invoiced (or is not invoiced), Net Sales will be calculated at the time all the revenue recognition criteria under the Accounting Standards are met&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;In the event that a Product is sold in a finished dosage form containing a MPAG Compound or a Product in combination with one or more other active ingredients (a &#8220;Combination Product&#8221;), the Net Sales will be calculated by multiplying the Net Sales of the Combination Product by the fraction, A&#47;(A+B) where A is the weighted (by sales volume) average sale price in the relevant country of the Product containing the MPAG Compound as the sole active ingredient in finished form, and B is the weighted average sale price (by sales volume) in that country of the product(s) containing the other component(s) as the sole active ingredient(s) in finished form. Regarding prices comprised in the weighted average price when sold separately referred to above, if these are available for different dosages from the dosages of MPAG Compound and other active ingredient components that are included in the Combination Product, then &#91;***&#93;. If the weighted average sale price cannot be determined for the Product or other product(s) containing the single MPAG Compound or component(s), the calculation of Net Sales for Combination Products will be &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Net Sales shall not include &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New Manufacturing IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How or Patent Rights generated by or on behalf of either Party or its Affiliates that are improvements of the MPAG Products Manufacturing Process or are otherwise necessary for the Manufacture of the MPAG Compounds or the Products. Notwithstanding the foregoing, New Manufacturing IP excludes Novartis Background Technology and MPAG Background Technology.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NIAID Clinical Trial Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the clinical trial agreement dated &#91;***&#93; between the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in the first paragraph of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Background Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any intellectual property (including Patent Rights and Know-How) related to the formulation and Manufacturing of pharmaceutical products which was Controlled by Novartis or its Affiliates prior to the Execution Date or is acquired or created by Novartis independently of and not in connection with this License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Controlled Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Managed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the recitals of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Period Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all data (including raw data) and results generated by or on behalf either Party in the performance of the Parties&#8217; respective Development activities conducted under the Option Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Period Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all inventions, whether or not patentable, including any Know-How, that are discovered, conceived, reduced to practice or otherwise made by or on behalf of either Party in the performance of the Parties&#8217; respective Development activities conducted under the Option Agreement. Notwithstanding the foregoing, Option Period Inventions exclude Option Period Data and Option Period Manufacturing IP.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Option Period Manufacturing IP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any Know-How or Patent Rights generated by or on behalf of either Party or its Affiliates prior to the Effective Date that are improvements of the MPAG Option Period Products Manufacturing Process or are otherwise necessary for the Manufacture of MPAG Compounds or the Products. Notwithstanding the foregoing, Option Period Manufacturing IP excludes Novartis Background Technology and MPAG Background Technology.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pan-COVID Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any product (other than the Products), the rights to which are owned or controlled by MPAG, which is indicated for infections and&#47;or diseases caused by at least two coronaviruses, including in all cases SARS-CoV-2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) patents, patent applications and similar government-issued rights protecting inventions in any country or jurisdiction however denominated, (b) all priority applications, divisionals, continuations, substitutions, continuations-in-part of and similar applications claiming priority to any of the foregoing, and (c) all patents and similar government-issued rights protecting inventions issuing on any of the foregoing applications, together with all registrations, reissues, renewals, re-examinations, confirmations, supplementary protection certificates, and extensions of any of (a), (b) or (c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means MPAG&#8217;s proprietary DARPin&#174; platform technology, pursuant to which MPAG produces pharmaceutical product candidates, including the Products, utilizing DARPin&#174; libraries and protein modules and domains.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">POC Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Pan-COVID Product, the first clinical trial for which the results suggest that it is, in the reasonable opinion of &#91;***&#93;, reasonably likely that the key attributes of success for such Pan-COVID Product are present and the key causes of failure of such Pan-COVID Product are absent, taking into account all relevant factors, including safety, efficacy, pharmaceutics, and commercial and regulatory issues.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product containing either or both of MP0420 or MP0423, in any mode of administration, alone or in combination with any other active agent, including any new dosage strengths, presentations, formulations, methods of administration and line extensions Developed by or on behalf of Novartis under and pursuant to this License Agreement. </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Products IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MPAG Products Know-How and the MPAG Products Patents.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchased Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Quality Agreement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.8(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product in any country or other jurisdiction, any approval (including, where required, pricing and reimbursement approvals), registration, license or authorization from a Regulatory Authority in such country or other jurisdiction that is necessary to market and sell such Product in such country or jurisdiction, including in the US, an EUA.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any governmental agency or authority responsible for granting Regulatory Approvals for biopharmaceutical products, including the FDA, EMA, European Commission and any corresponding national or regional regulatory authorities.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any country or multi-country jurisdiction, an additional market protection, other than patent protection, granted by a Regulatory Authority in such country which confers on Novartis, its Affiliates or sublicensees the exclusive right, either through data exclusivity or market exclusivity, to market and sell a Product in such country or multi-country jurisdiction and which prevents the Regulatory Approval of any Third Party pharmaceutical or biologic product containing either or both of the MPAG Compounds as contained in such Product (e.g., new biologic entity exclusivity, new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, new patient population exclusivity, pediatric exclusivity, or any applicable data or marketing exclusivity).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product, any submission to a Regulatory Authority of any appropriate regulatory application with respect to such product, including any submission to a regulatory advisory board, marketing authorization application, EUA application, and any supplement or amendment thereto, including any IND, BLA, MAA, or the corresponding application in any other country or group of countries with respect to such product.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, all regulatory applications, submissions, notifications, communications, correspondences, registrations, approvals, and other filings submitted to, received from or otherwise conducted with a Regulatory Authority in order to exploit a MPAG Compound or Product in the Field in a particular country or jurisdiction in the Territory, including Regulatory Filings, Regulatory Approvals, and EUAs.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Election Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales &#38; Royalty Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a written report or reports showing each of&#58; (a) the date of a First Commercial Sale for each Product in each country in each Commercial Territory, (b) the amount of Net Sales in local currency and in USD, of each Product in the Commercial Territories on a country-by-country basis, during the applicable reporting period by Novartis and its Affiliates and their respective sublicensees&#59; (c)&#160;the royalties payable, in CHF, which shall have accrued hereunder with respect to such Net Sales&#59; and (d) any amounts received by Novartis, its Affiliates, or their sublicensees &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Swiss Confederation Early Research Investment and Reservation Agreement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means that certain preclinical-stage agreement (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Reservationsvertrag</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) between the Swiss Confederation and MPAG dated as of &#91;***&#93;, as amended between the parties to the agreement prior to the Execution Date.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Terminated Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means&#58; (a) in the case of termination of this License Agreement with respect to a Product pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Product subject to such termination and the applicable MPAG Compound therein&#59; and (b) in the case of termination of this License Agreement in its entirety, all Products in all countries in the Territory. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Sheet ROFN Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means worldwide.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any person other than a Party or an Affiliate of a Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration, program name, product name, delivery form name, certification mark, collective mark, domain name, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and common law rights therein and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Plan Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States of America, its territories and possessions.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">USD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the lawful currency of the United States.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an issued or pending claim in any of the patents (including pending patent applications) that are licensed to Novartis (MPAG Products Patents and MPAG Enabling Patents) or that are Joint IP&#91;***&#93; which has not expired or lapsed or been revoked, abandoned or held invalid or unenforceable by a final unappealable or unappealed decision by an applicable court or agency, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that a pending claim that has been pending for more than &#91;***&#93; shall no longer be considered a Valid Claim.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In this License Agreement, unless otherwise specified&#58;</font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#8220;includes&#8221; and &#8220;including&#8221; shall mean respectively includes and including without limitation&#59;</font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#8220;or&#8221; is used in the inclusive sense (&#8220;and&#47;or&#8221;) unless the context otherwise requires&#59; </font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#8220;hereof,&#8221; &#8220;herein,&#8221; and &#8220;herewith,&#8221; and words of similar import, shall, unless otherwise stated, be construed to refer to this License Agreement as a whole and not to any particular provision of this License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">a Party includes its permitted assignees or the respective successors in title to substantially the whole of its undertaking&#59;</font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted in accordance with any requirements with respect to such amendment or re-enactment&#59; </font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders&#59; </font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the Exhibits, Schedules and other attachments form part of the operative provision of this License Agreement and references to this License Agreement shall, unless the context otherwise requires, include references to the Exhibits, Schedules and attachments&#59; </font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">the headings in this License Agreement are for information only and shall not be considered in the interpretation of this License Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or things&#59; and </font></div><div style="margin-bottom:12pt;padding-left:93.95pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the Parties agree that the terms and conditions of this License Agreement are the result of negotiations between the Parties and that this License Agreement shall not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this License Agreement.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">LICENSE</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this License Agreement, MPAG hereby grants to Novartis (a) an exclusive (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, including as to MPAG and its Affiliates), perpetual (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), sub-licensable and worldwide license to (i) all MPAG Products Patents and MPAG Products Know-How, and (ii) MPAG&#8217;s interest in all Joint IP to the extent exclusively related to the MPAG Compounds or Products and (b) a non-exclusive, perpetual (subject to subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (other than with respect to subsection (ii))), sub-licensable license, under (i) the MPAG Enabling Patents and MPAG Enabling Know-How and (ii) MPAG&#8217;s interest in the New Manufacturing IP, in each case of the foregoing subsections (a) and (b), to research, Develop, Manufacture, Commercialize or otherwise </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">exploit the MPAG Compounds and Products in the Field in the Territory (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The License shall bear royalties in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Sublicense Rights&#59; Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to the terms and conditions of this License Agreement, Novartis may sublicense the rights granted to it by MPAG under this License Agreement through multiple tiers and without reference to MPAG, including subcontracting to Third Parties the performance of tasks and obligations with respect to the Development, Manufacture and Commercialization of the Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that (i)&#160;any such sublicenses shall be in writing, be consistent with the terms and conditions of this License Agreement, and require the applicable sublicensee to comply with all applicable terms of this License Agreement, (ii) Novartis shall remain responsible for the performance of all of its sublicensees to the same extent as if such activities were conducted by Novartis, and shall remain responsible for any payments due to MPAG under this License Agreement with respect to activities of any sublicensees, and (iii) within &#91;***&#93; after the execution of any sublicense agreement with a Third Party, Novartis shall provide MPAG with a copy of such sublicense agreement, provided, that Novartis may redact any terms of such sublicense agreement (x) to the extent not pertinent to either Party&#8217;s rights or obligations under this License Agreement or verification of compliance with the requirements of this License Agreement or (y) that are financial in nature or are otherwise competitively sensitive&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the foregoing subsection (iii) shall not apply to agreements with subcontractors.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Novartis may exercise its rights and perform its rights and obligations under this License Agreement itself or through any of its Affiliates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Novartis shall remain responsible for the performance of all of its Affiliates to the same extent as if such activities were conducted by Novartis, and shall remain responsible for any payments due to MPAG under this License Agreement with respect to activities of any Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Right of First Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Pan-COVID Product-by-Pan-COVID Product basis, upon the earlier of (i) completion of a POC Trial for such Pan-COVID Product or (ii) MPAG&#8217;s decision to commence any negotiations with any Third Party (including discussions commenced in response to an unsolicited offer received from such Third Party) regarding a transaction to license, sell, transfer, divest or otherwise encumber or dispose (other than through a Change of Control) its interest in any such Pan-COVID Product (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), MPAG shall first promptly notify Novartis in writing of the occurrence of such event (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which notice shall include (if applicable) &#91;***&#93;, and the following provision shall then apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Novartis shall have &#91;***&#93; after receipt of a ROFN Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Election Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to elect to enter into exclusive negotiations with MPAG for a ROFN Transaction with respect to the applicable Pan-COVID Product. During a ROFN Election Period, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Novartis notifies MPAG in writing during a ROFN Election Period that Novartis elects to enter into negotiations for a ROFN Transaction, MPAG shall &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Sheet ROFN Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (ii) if the Parties &#91;***&#93; (together with the Term Sheet ROFN Negotiation Period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">With respect to any Pan-COVID Product, if (i) Novartis does not elect to enter into &#91;***&#93; negotiations for a ROFN Transaction with respect to such Pan-COVID Product in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (ii) &#91;***&#93; prior to the expiration of the Term Sheet ROFN Negotiation Period in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, or (iii) &#91;***&#93; prior to the expiration of the applicable ROFN Negotiation Period in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then (in the case of any of (i),(ii), </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or (iii)) Novartis shall no longer have any rights with respect to such Pan-COVID Product (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Until the &#91;***&#93; of the Effective Date, MPAG shall not, shall ensure and herewith warrants that none of its Affiliates shall, anywhere in the Territory, directly or indirectly, &#91;***&#93; nor shall MPAG or any of its Affiliates enter into any license, agreement or other arrangement with a Third Party to do any of the foregoing (any of the foregoing prohibited activities a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (a) nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will apply to or otherwise limit a Change of Control of MPAG and (b) if after the Effective Date, any Acquirer in connection with a Change of Control of MPAG is engaged in a Competing Program as of the closing date of such transaction, the Acquirer and its Affiliates existing prior to such Change of Control may continue to Develop, Manufacture, Commercialize, and otherwise exploit such Competing Program&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, (i) none of Novartis&#8217; Confidential Information is used in connection with such Competing Program, (ii) none of the Licensed IP, or MPAG&#8217;s Confidential Information are used in connection with such Competing Program, and (iii) MPAG establishes separate working teams to work on the Competing Program and the Products hereunder and implements reasonable measures that are designed to prevent transfer to, access, or use of any Confidential Information of Novartis by the teams working on such Competing Program.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Option Period Manufacturing IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">MPAG hereby grants Novartis, a worldwide, perpetual, royalty-free, non-exclusive license under its interest in the Option Period Manufacturing IP for any application of the Option Period Manufacturing IP, including a right to sublicense to Third Parties to make and have made products&#59; provided, for clarity, if Novartis desires to obtain a license to any MPAG Background Technology that does not primarily relate to the Platform or designed ankyrin repeat protein products to practice the Option Period Manufacturing IP, then such right shall be subject to a good faith obligation of MPAG to negotiate with Novartis commercial terms on which MPAG would grant a non-exclusive license to MPAG Background Technology for such purpose.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Novartis hereby grants MPAG, a worldwide, perpetual, royalty-free, non-exclusive license under its interest in the Option Period Manufacturing IP for any application of the Option Period Manufacturing IP, including a right to sublicense to Third Parties to make and have made products&#59; provided, for clarity, if MPAG desires to obtain a license to any Novartis Background Technology to practice the Option Period Manufacturing IP to make or have made the MPAG Compounds or Products, then such right shall be subject to a good faith obligation of Novartis to negotiate with MPAG commercial terms on which Novartis would grant a non-exclusive license to Novartis Background Technology for such purpose. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the exclusive license granted by MPAG to Novartis under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, MPAG retains the rights under the Licensed IP (a) to perform its obligations and to exercise its rights under this License Agreement, whether directly or through one or more Affiliates or, upon the prior written consent of Novartis (such consent not to be unreasonably withheld or delayed), subcontractors and (b) to conduct internal pre-clinical and non-clinical research of the MPAG Compounds or Products solely to the extent such research relates to improvement of the Platform.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">No Implied Licenses&#59; Negative Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly set forth herein, neither Party shall acquire any license, right, or other intellectual property interest, including any right to file, prosecute, maintain, enforce or defend, whether by implication or otherwise, under or to any Patent Rights, Know-How, or other intellectual property owned or otherwise controlled by the other Party. For clarity, the License excludes any compounds or products that are Controlled by MPAG other than MP0420 and MP0423. Neither Party shall, nor shall permit any of its Affiliates or sublicensees to, practice any Patent Rights or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this License Agreement.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">GOVERNANCE</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Governance Committee established under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Option Agreement shall continue under this License Agreement, subject to the modified role and decision-making authority set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, to provide oversight for the collaboration between the Parties with respect to the Development, Manufacturing, and Commercialization of the MPAG Compounds and Products undertaken pursuant to the terms of this License Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Initially the membership of the Governance Committee will be comprised of each of the Parties&#8217; respective representatives serving on the Governance Committee (as defined in the Option Agreement) established under the Option Agreement as of the Effective Date and, except as otherwise set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, will be governed by the same operating procedures (including the policies for replacing Governance Committee members, policies for participation by additional representatives or consultants invited to attend Governance Committee meetings including employees of each Party or their respective Affiliates and&#47;or consultants selected by each Party and representing various development functions (e.g., clinical, medical, regulatory, technical operations, statistics, manufacturing, intellectual property) and other functions, on an ad hoc basis, and as required from time to time, and the location of meetings) established for the Governance Committee (as defined in the Option Agreement) under the Option Agreement as of the Effective Date. For the avoidance of doubt, notwithstanding anything in the foregoing to the contrary, the role and decision making authority of the Governance Committee under this License Agreement shall be as set forth in, respectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Role of Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting any of the foregoing, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Governance Committee will perform the following functions, some or all of which may be addressed directly at any given Governance Committee meeting&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">oversee the transfer and&#47;or disclosure of Know-How by MPAG in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">discuss and determine the manner in which the MPAG Ongoing Clinical Trials will be completed or transferred and the responsibilities of the Parties with respect thereto in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">discuss and approve any MPAG Compound or Product Development activities to be conducted by MPAG whether independently or in collaboration with Novartis (other than those activities conducted by MPAG pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">review and discuss (i) the Development Plan and any amendments thereto, (ii) Novartis&#8217; Development activities in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;5.4,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (iii) material interactions and material submissions to Regulatory Authorities, (iv) the Manufacture of the MPAG Compounds and Products in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and (v)&#160;Novartis&#8217; Commercialization activities in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">review and discuss proposals by Novartis or MPAG for the addition or removal of any country or territory from the list of &#8220;Commercial Territories&#8221;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">establish subcommittees pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> as it deems necessary or advisable to further the purpose of this License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">discuss and attempt to resolve any disputes between any subcommittees that may arise during the Term&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">perform such other review and advisory responsibilities as appropriate to further the purposes of this License Agreement as may be assigned to the Governance Committee by written agreement of the Parties or as is expressly set forth in this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Meeting Logistics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Governance Committee shall meet no less frequently than quarterly and at such other times as the Governance Committee or the Parties may reasonably agree. The first meeting of the Governance Committee shall be held as soon as reasonably practicable, but in no event later than &#91;***&#93; following the Effective Date. Meetings may be held in person, telephonically or by means of videoconference. &#91;***&#93; shall appoint one (1) of its representatives on the Governance Committee to act as chairperson of the Governance Committee. The chairperson shall appoint one (1) person (who need not be a member of the Governance Committee) to set agendas and manage logistical aspects for meetings and attend the meeting to record the minutes of the meeting in writing. Such minutes shall be circulated to the Parties promptly following the meeting for review, comment and approval. If no comments are received within &#91;***&#93; of the minutes&#8217; receipt by a Party, unless otherwise agreed, they shall be deemed to be approved by such Party. All participants at a Governance Committee meeting shall bound by appropriate confidentiality obligations.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Decision Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will give due consideration to, and consider in good faith, the recommendations and advice of the other Party&#8217;s members of the Governance Committee regarding matters properly before the Governance Committee. The Governance Committee will endeavor to reach consensus on all decisions to be made by the Governance Committee, however, if the Governance Committee cannot unanimously agree on a matter to be decided by the Governance Committee then &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that notwithstanding the foregoing&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#91;***&#93; shall not exercise its final decision-making authority in a manner that would require &#91;***&#93; to undertake any activity that &#91;***&#93; reasonably believes in good faith would (w)&#160;violate any Applicable Law, the requirements of any Regulatory Authority, ethical principles, principles of scientific integrity, or any agreement with any Third Party entered into by &#91;***&#93;, (x) pose an unacceptable risk or threat of harm in humans, (y)&#160;require &#91;***&#93; to infringe or misappropriate any intellectual property rights of any Third Party, in each case without &#91;***&#93; written consent, or (z) require &#91;***&#93; to perform any activities under the Development Plan or incur any material external costs or material internal expenses without &#91;***&#93; written consent&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the addition or removal of any country or territory from the list of &#8220;Commercial Territories&#8221; must be considered in good faith by both Parties, taking into consideration to the political and economic circumstances of such country or territory and its healthcare system, but any such addition or removal shall become effective only upon agreement in writing of both Parties.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Alliance Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; following the Effective Date, each Party will appoint (and notify the other Party in writing of the identity of) a senior representative having a general understanding of development and manufacturing issues to act as its alliance manager under this License Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), provided however that if no notice is given pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by a Party, such Party&#8217;s Alliance Director shall remain the Alliance Director appointed by the Party </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">pursuant to the Option Agreement. The Alliance Directors will serve as the contact point between the Parties for the purpose of having oversight and progressing and facilitating coordination of any collaborative activities to be undertaken by the Parties under this License Agreement and will be primarily responsible for&#58; (a) facilitating the flow of information and otherwise promoting communication, coordination, and collaboration between the Parties&#59; (b) raising cross-Party or cross-functional issues and disputes to their management in a timely manner and (c) resolving disputes in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party may replace its Alliance Director on written notice to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Governance Committee may, from time to time, establish one or more subcommittees to (i) resolve particular matters appropriately within the authority of the Governance Committee and delegated by the Governance Committee to such subcommittee, and (ii) inform and support decisions of the Governance Committee. Each subcommittee will meet on a quarterly basis (and at such other times as the Governance Committee or the Parties may agree) and be composed of at least &#91;***&#93; project lead from each party and other representatives of each party to be agreed at the time of formation of such subcommittee.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Costs of Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that the costs and expenses incurred by each Party in connection with its participation at any meetings under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be borne solely by such Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Limitations of Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Governance Committee and each subcommittee has only the powers expressly assigned to it in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and does not have the authority to&#58; (a)&#160;modify or amend the terms and conditions of this License Agreement&#59; (b)&#160;waive or determine either Party&#8217;s compliance with the terms and conditions of under this License Agreement&#59; or (c)&#160;decide any issue in a manner that would conflict with the express terms and conditions of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of a Change of Control of MPAG, Novartis may, upon &#91;***&#93; prior written notice to MPAG (or its successor entity) provided that such written notice is received by MPAG within &#91;***&#93; of Novartis first becoming aware of such Change of Control, disband the Governance Committee and any subcommittees, and, thereafter the exchange of information under this License Agreement shall be made through the Alliance Directors. </font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">TRANSFER OF MPAG PRODUCTS KNOW-HOW AND REGULATORY MATERIALS.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Transfer of MPAG Products Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Promptly after the Effective Date, MPAG, without additional consideration, shall transfer (and in the event of trade secrets, disclose) to Novartis or its designated Affiliate all MPAG Products Know-How and Regulatory Materials, including raw and source data as appropriate, in existence as of the Effective Date and not already transferred or disclosed to Novartis or its designee under the Option Agreement. Without limiting the foregoing, MPAG will deliver to Novartis (or its designee) all manufacturing batch records, Development reports, analytical results, filings and correspondence with any Regulatory Authority (including notes or minutes of any meetings with any Regulatory Authority), raw material and excipient sourcing information, quality audit findings and any other relevant technical information relating to the MPAG Compounds and the Products. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The transfer and disclosure of MPAG Products Know-How and Regulatory Materials undertaken pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, shall take place in an orderly fashion and in electronic format as mutually agreed by the Parties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, if any such documentation is not available in electronic format, MPAG shall provide a hard copy of such documentation. </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If Novartis or MPAG identifies other MPAG Products Know-How in MPAG&#8217;s or its Affiliates&#8217; Control as of Effective Date that is necessary for the Development and Commercialization of the MPAG Compounds and the Products, MPAG will use commercially reasonable efforts to provide such MPAG Products Know-How to the extent it remains within MPAG&#8217;s or its Affiliates&#8217; Control at the time of such identification. MPAG&#8217;s obligations under this section shall only apply to MPAG Products Know-How Controlled by MPAG and identified within &#91;***&#93; following the Effective Date or requested by a Regulatory Authority. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG shall (and shall cause its Affiliates to) transfer and assign to Novartis (or its designee), and MPAG (on behalf of itself and its Affiliates) hereby does transfer and assign to Novartis, the Regulatory Materials (including INDs) Controlled by MPAG or any of its Affiliates as of the Effective Date that solely and specifically relate to the MPAG Compounds or Products&#59; provided that any Regulatory Materials necessary to complete MPAG Ongoing Clinical Trials shall be transferred to Novartis (or its designee) upon completion thereof.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG will provide reasonable assistance to Novartis or its designated Affiliate in connection with understanding and using the MPAG Products Know-How and Regulatory Materials for purposes consistent with the License and the other rights granted to Novartis hereunder, including by providing information to assist Novartis or its designated Affiliate in developing formulations of the Products and its related activities and executing and delivering to Novartis such endorsements, assignments, and other documents as may be reasonably necessary to assign, convey, transfer, and deliver to Novartis all of MPAG&#8217;s rights, title, and interests in and to any Regulatory Materials and Regulatory Filings.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">DEVELOPMENT</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and except for any Development activities undertaken by MPAG that are approved by the Governance Committee or are expressly permitted hereunder (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), Novartis will be responsible for conducting, at its sole expense, such research and preclinical, clinical and other Development of the MPAG Compounds or Products. Novartis shall conduct the Development of the MPAG Compounds and Products pursuant to a written development plan that sets forth (a) the objectives and activities of the Development for the MPAG Compounds and Products that are consistent with the Development Plan under the Option Agreement and (b)&#160;timelines for conduct of clinical trials, key Regulatory Authority meetings, filing of applications for Regulatory Approval, and the receipt of Regulatory Approvals (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The initial Development Plan is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall update the Development Plan at least once per Calendar Quarter until the First Commercial Sale of a Product in a Commercial Territory and the Governance Committee shall review the amendments to the development Plan and the progress of activities being conducted under the Development Plan.  For the avoidance of doubt, (i) Novartis shall have no obligations with respect to the frequency of updates to the Development Plan after the First Commercial Sale of any Product in any country in the Commercial Territories and (ii) during the Term and except as expressly permitted hereunder (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), MPAG shall not conduct any research or preclinical, clinical and other Development of the MPAG Compounds or Products without Novartis&#8217; prior written consent or as agreed at the Governance Committee. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall itself, or through its Affiliates, sublicensees, or other Third Parties, use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for the Products in the Commercial Indication in the &#91;***&#93; provided however, that &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Ongoing Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As soon as practicable after the Effective Date, the Parties shall meet and discuss at the Governance Committee, the status, as of the Effective Date, of any ongoing clinical trials with respect to the Products being sponsored and&#47;or conducted pursuant to the terms of the Option </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement in order to determine the manner in which such clinical trials will be completed, the responsibilities of the Parties with respect thereto (taking into account MPAG&#8217;s reasonably available personnel resources and capabilities), and the estimated MPAG Ongoing Clinical Trial Costs that would be incurred by MPAG in the event that MPAG continued to sponsor and conduct such ongoing clinical trials after the Effective Date. To the extent the Governance Committee reasonably determines that MPAG will continue after the Effective Date to sponsor any ongoing clinical trial being sponsored and&#47;or conducted by MPAG as of the Effective Date (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Ongoing Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Novartis (i) shall be responsible for and shall reimburse MPAG after issuance of an invoice therefor, for the MPAG Ongoing Clinical Trial Costs actually incurred, (ii) shall cooperate with MPAG to transfer the sponsorship and conduct of such MPAG Ongoing Clinical Trial to Novartis or its designee as soon as reasonably practicable as determined by the Governance Committee, and (iii) shall indemnify the MPAG Indemnitees with respect to each MPAG Ongoing Clinical Trials as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall keep MPAG reasonably informed of Novartis&#8217;, its Affiliates&#8217; and their respective sublicensees&#8217; Development activities with respect to the MPAG Compounds and Products by providing updates through the Governance Committee at least once per Calendar Quarter. </font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Novartis will be responsible for all regulatory matters with respect to the MPAG Compounds or Products as it determines appropriate in its sole discretion, including the development and implementation of the strategy for, and all communications and interactions with, Regulatory Authorities with respect to the MPAG Compounds or Products and obtaining and maintaining Regulatory Approvals in the Territory in the name of Novartis or its Affiliates or sublicensees. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">MPAG shall fully cooperate with and provide reasonable assistance to Novartis in connection with any interactions with or filings made to Regulatory Authorities relating to the MPAG Compounds or Product(s) (including, to the extent applicable, filings related to the quantitative and qualitative composition of Products), including by executing any required documents, providing access to personnel and providing Novartis with copies of all reasonably required documentation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis shall notify MPAG of all Regulatory Materials that it submits for the MPAG Compounds and Products in the &#91;***&#93; and shall provide MPAG with a copy (which may be wholly or partly in electronic form) of such Regulatory Materials, in each case, as soon as reasonably practicable after such submission. Novartis shall, as soon as reasonably practicable after receipt, provide MPAG with copies of material correspondence received from the FDA or other Regulatory Authorities in the &#91;***&#93; with respect to the MPAG Compounds or Products. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Novartis shall have the right to disclose the existence of, and the results from, any clinical trials conducted under this License Agreement in accordance with its standard policies. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party agrees that, in performing its obligations under this License Agreement&#58; (a) it shall comply with all applicable current international regulatory standards, including GMP, GLP, GCP and other rules, regulations and requirements&#59; and (b) it will not employ or use any person that has been debarred under Section 306(a) or 306(b) of the US Federal Food, Drug and Cosmetic Act (21 U.S.C. 335a) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Following the Effective Date, the Parties shall agree upon and implement a procedure for the mutual exchange of adverse event reports and safety information associated with the Products. Details of the operating procedure respecting such adverse event reports and safety </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">information exchange shall be the subject of one or more mutually-agreed written pharmacovigilance agreement between the Parties which shall be entered into at a point in time that would be reasonably appropriate to ensure that that Parties&#8217; Development activities undertaken pursuant to this License Agreement are done in compliance with all Applicable Law and other requirements of any applicable Regulatory Authorities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Parties hereby acknowledge and agree that until the Pharmacovigilance Agreement is executed, the terms of the Clinical Collaboration Agreement relating to the exchange of adverse event reports and safety information associated with the Products shall apply.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Quality.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Following the Effective Date, the Parties shall negotiate in good faith one or more definitive agreements with regard to quality matters relating to clinical (GCP), non-clinical (GLP), and Manufacturing (GMP) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) which shall be entered into at a point in time that would be reasonably appropriate to ensure that that Parties&#8217; Development and Manufacturing activities undertaken pursuant to this License Agreement are done in compliance with all Applicable Law and other requirements of any applicable Regulatory Authorities. In the event of a discrepancy between this License Agreement and the Quality Agreement, the Quality Agreement governs with respect to quality matters and this License Agreement governs with respect to all other matters.  The Parties hereby acknowledge and agree that until the Quality Agreement is executed, the terms of the Clinical Collaboration Agreement relating to quality matters in connection with the Products shall apply between the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Pre-Qualification Audits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> MPAG will allow, and will use reasonable efforts to procure that its contractors and subcontractors will allow, Novartis, its Affiliate or designated Third Party to perform audits, site visits or similar inspections of any site or facility where GxP relevant Development or manufacturing activities for any of the MPAG Compounds or the Products (including drug substance, drug product or any component of the Products) were performed (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pre-Qualification Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as reasonably required by Novartis. Following a Pre-Qualification Audit, MPAG will use its reasonable efforts, and will use reasonable efforts to procure that its contractors and subcontractors will use reasonable efforts, to mutually agree any corrective and preventative remediation actions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CAPAs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) identified by the Pre-Qualification Audit within &#91;***&#93; of issue of the audit report and thereafter carry out such CAPAs within the relevant timelines agreed between the Parties. In addition, if recommended by a Pre-Qualification Audit, Novartis will be entitled (subject to reasonable approval by the applicable contractors or subcontractors) to maintain persons in plant (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PIPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or local Third Party consultants (at Novartis&#8217;s option) to continue to observe and monitor quality matters, whether in relation to Development or manufacturing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Changes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any changes or variations to the MPAG Compounds or to the Products (including the drug substance, drug product, packaging, labelling or any component(s)), the manufacturing or any facilities involved in the Development or manufacturing of the Products (including the drug substance and components) may only be made in accordance with the Quality Agreement(s).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Audits, Inspections and Patient Safety.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-37.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.73pt">Following the Effective Date, MPAG will allow, and will use reasonable efforts to procure that its contractors and subcontractors will allow, Novartis, its Affiliate or designated Third Party to perform GxP Audits of any facility where Development (including research, non-clinical and clinical) or manufacturing activities for any of the MPAG Compounds or the Products were performed on reasonable prior notice in preparation for an inspection by a Regulatory Authority or investigation of a compliance </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">issue with a Regulatory Authority. MPAG acknowledges that, in the case of suspected &#8220;critical findings&#8221;, &#91;***&#93; prior notice by MPAG shall constitute reasonable prior notice. MPAG will provide Novartis with a letter of authorization signed by the sponsor of any clinical study for the Products enabling such an audit within &#91;***&#93; of the Effective Date. MPAG will, and will use reasonable efforts to procure that its contractors and subcontractors will, use commercially reasonable efforts to mutually agree any CAPAs within &#91;***&#93; of issue of a GxP Audit report and thereafter carry out such CAPAs or required CAPAs within the relevant timelines&#59; and</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.93pt">MPAG will promptly (and in any event within &#91;***&#93; of receipt of the relevant notice by MPAG, if and to the extend MPAG is informed of such inspection) inform Novartis of any intended or planned inspection by a Regulatory Authority of any facility where Development (including research, non-clinical and clinical) or manufacturing activities for any of the MPAG Compounds or the Products were performed. If available to MPAG, MPAG will promptly provide (or use reasonable efforts to cause its subcontractors to provide) Novartis an executive summary of the results of the inspection, including explanations of any issues raised by the Regulatory Authorities which could reasonably be expected to impact the MPAG Compounds or the Products and any proposed CAPAs. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-37.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.63pt">To the extent that MPAG receives a copy of the information set out in (a) and (b) below, MPAG will procure that prompt disclosure is made to Novartis of&#58; </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">all Regulatory Authority inspection observations relating to or regarding the MPAG Compounds&#59; </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">all material correspondence or notices received from Regulatory Authorities relating to any facility where Development (including research, non-clinical and clinical) or manufacturing activities for any of the MPAG Compounds or the Products were performed to the extent such correspondences or notices are reasonably likely to adversely impact the MPAG Compounds, including&#58; EIR, 483s, warning letters, EMA or European inspection reports, serious breaches, safety urgency measures, issues on PSURs, DSURs etc. and corresponding proposed responses. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-37.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.23pt">MPAG shall notify Novartis promptly of any event relating to the MPAG Compounds or the Products that may reasonably be expected to have any adverse impact on patient safety, the efficacy or conduct of clinical trials and&#47;or the integrity of any data relating to the MPAG Compounds or the Products and&#47;or facilities where they were Developed or manufactured, and in any event such disclosure shall be made not later than &#91;***&#93; of the occurrence of such event, except in the case of warning letters which must be notified to Novartis no later than &#91;***&#93; of the receipt by MPAG of the relevant inspection report or correspondence. Following notification of such an event, MPAG will cooperate with Novartis in the preparation of any response or other communication to any Regulatory Authority, which could affect data integrity, a registration procedure or the Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Costs and Expenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis shall reimburse all documented external costs on a pass-through basis and internal expenses at the FTE Rate, in each case, that are reasonably incurred by MPAG pursuant to this Section 5.8.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.3pt">MANUFACTURING</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis or its designated sublicensee(s) and subcontractor(s) will be solely responsible, as it determines appropriate in its sole discretion, for the Manufacture and supply of the MPAG Compounds or Products being Developed or Commercialized under this License Agreement. From time to time (but in no event more than twice during any Calendar Year) upon MPAG&#8217;s reasonable request, the Parties shall meet and discuss through the Governance Committee any material updates to the Manufacturing process for the MPAG Compounds or Products.  In advance of any such updates, upon MPAG&#8217;s prior written request, Novartis shall disclose to MPAG the amount of (and any material observations or issues regarding the characteristics of) Product Manufactured by Novartis, its Affiliates or its designated sublicensees(s) or subcontractor(s) during the period of time noted in MPAG&#8217;s request. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Manufacturing Know-How and Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG shall fully cooperate with and provide assistance to Novartis or its designee in order to ensure the transfer to Novartis the technical and Manufacturing information that is required for Novartis to Manufacture the MP0420 drug substance and MP0420 drug product.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Purchase of Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly after issuance of an invoice therefor (which shall be issued by MPAG no earlier than the Effective Date), Novartis shall purchase, and MPAG shall supply, all quantities of usable inventory of the Products and raw material (including resins) used for the Products, in each case, that are under MPAG&#8217;s control as of the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchased Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at a price equal to &#91;***&#93; of MPAG&#8217;s reasonable and documented costs &#91;***&#93;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for Manufacturing such inventory &#91;***&#93;.   An itemized list of all Purchased Inventory is set forth hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Purchased Inventory shall be delivered to Novartis at the address specified by Novartis in writing in advance. For the avoidance of doubt, Novartis shall not be obligated to purchase any Products pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with a remaining shelf-life of less than &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Minimum Shelf Life</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Novartis will be solely responsible for conducting, at its sole expense, all aspects of Commercialization of the Products in the Territory, including planning and implementation, distribution, booking of sales, pricing and reimbursement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">On a country-by-country and Product-by-Product basis, Novartis shall itself, or through its Affiliates, sublicensees, or other Third Parties, upon (and subject to) receipt of Regulatory Approval for sale of a Product in any country in the Commercial Territories, use Commercially Reasonable Efforts to Commercialize the applicable Product in such country. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">For the avoidance of doubt, notwithstanding anything to the contrary set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (i) Novartis shall have sole discretion (without reference to MPAG) to set or vary the price of the Products in the Field in the Territory and (ii) Novartis shall not have any diligence obligations with respect to its efforts to Commercialize the Products in any country in the Territory outside of the Commercial Territories.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Commercialization Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall keep MPAG reasonably informed of Novartis&#8217;, its Affiliates&#8217; and their respective sublicensees&#8217; Commercialization activities with respect to the Products by providing updates through the Governance Committee at least &#91;***&#93; per Calendar Year.  Upon MPAG&#8217;s request (which may be made no more than &#91;***&#93; per Calendar Year) such updates shall include the amount of Net Sales of Products in each country in the Territory other than the Commercial Territories.  </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">No Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis hereby covenants and agrees that it shall not, and shall ensure that its Affiliates and sublicensees shall not, promote, market, distribute, import, sell, or have sold any Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like outside the Commercial Territories for the purpose of distributing such Products in the Commercial Territories. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Swiss Confederation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Novartis hereby acknowledges that the government of the Swiss Confederation committed early-, preclinical-stage funding to MPAG, and such funding enabled clinical studies and an initial production run of Product containing MP0420.  Novartis further acknowledges that, in consideration for the government of the Swiss Confederation&#8217;s commitment of such early-, preclinical-stage funding to MPAG, that government obtained from MPAG a reservation right to certain doses of Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reserved Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Novartis hereby agrees to assume MPAG's rights and obligations set out in that agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Swiss Confederation Early Research Investment and Reservation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in the manner set forth in the relevant agreed form assignment and assumption agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Swiss Confederation Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Swiss Confederation Assignment Agreement shall be executed by each of Novartis and MPAG on the Execution Date and MPAG shall give notice to the government of the Swiss Confederation that such assignment has taken place as soon as practicable following the Execution Date.  For the avoidance of doubt, if the government of the Swiss Confederation wishes to obtain Products other than the Reserved Doses for which there is the aforementioned reservation right, it must seek to procure such Products through separate commercial negotiation and agreement with Novartis.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">NIAID Clinical Trial Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Novartis hereby acknowledges and agrees to assume MPAG's rights and obligations set out in the NIAID Clinical Trial Agreement in the manner set forth in the relevant agreed form assignment and assumption agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NIAID CTA Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The NIAID CTA Assignment Agreement shall be executed by each of Novartis and MPAG on the Execution Date.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">FINANCIAL PROVISIONS</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Option Exercise Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In partial consideration of the licenses and rights granted to Novartis hereunder, Novartis shall pay to MPAG a one-time, non-refundable, non-creditable option exercise payment of one hundred fifty million Swiss francs (CHF 150,000,000) within &#91;***&#93; after receipt by Novartis of an invoice in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> from MPAG, which invoice shall be issued by MPAG no earlier than the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In partial consideration of the licenses and rights granted to Novartis hereunder, during the applicable Royalty Term and subject to the remainder of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Novartis will make royalty payments to MPAG on a &#91;***&#93; basis equal to twenty-two percent (22%) (as may be reduced pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.3,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.4,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Net Sales of Products sold by Novartis, its Affiliates, or sublicensees in the Field in the Commercial Territories.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Royalties are payable on a Product-by-Product and country-by-country basis from First Commercial Sale of such Product in such country in the Commercial Territories until the latest of (i) the expiration of the last Valid Claim covering such Product in such country, (ii) ten (10) years from the First Commercial Sale of such Product in such country, and (iii)&#160;the expiration of Regulatory Exclusivity in such country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For the avoidance of doubt, royalties shall be payable only once with respect to the same unit of Product.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Following the expiration of the Royalty Term on a Product-by-Product and country-by-country basis, the License with respect to such Product shall continue in effect, but become fully paid-up, royalty-free, transferable, perpetual and irrevocable.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Know-How Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For any period during the Royalty Term in which (i) the sale of a Product in any country is not covered by a Valid Claim covering such Product or (ii) the sale of a Product in any country is covered only by a Valid Claim in Joint IP, the Royalty Rate with respect to Net Sales of such Product in such country for the remainder of the applicable Royalty Term shall be &#91;***&#93;. The Parties acknowledge that continued payment of royalties during remaining period of the Royalty Term at such reduced rate shall be consideration for the Know-How included in the License.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Product-by-Product and country-by-country basis, if Loss of Market Exclusivity occurs with respect to a Product in a country, then the then-applicable Royalty Rate shall be reduced by &#91;***&#93;, commencing with the first Calendar Quarter after the Loss of Market Exclusivity occurs and continuing for the remainder of the Royalty Term for the applicable Product in the applicable country.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Third Party Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">MPAG shall remain responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties under any Products IP or Enabling IP that have been licensed to MPAG and that are sublicensed to Novartis under this License Agreement. All such payments shall be made promptly by MPAG in accordance with the terms of the applicable license agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">From time to time MPAG may notify Novartis in the event MPAG identifies a potential need to acquire a license to Patent Rights or Know-How owned or otherwise controlled by a Third Party that (i) would be necessary or reasonably useful for Novartis to research, Develop, Manufacture, Commercialize or otherwise exploit the MPAG Compounds and Products in the Field in the Territory and (ii) solely and specifically relates to the MPAG Compounds (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;***&#93; shall have the sole right to determine whether to acquire any such license in accordance with, and subject to, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In the event that &#91;***&#93; obtains rights to Third Party IP (in accordance with the preceding sentence or otherwise at its reasonable discretion), &#91;***&#93; to the applicable Third Party as an offset to the royalties payable for the applicable Product with respect to all Commercial Territories in which such rights are obtained. &#91;***&#93; agrees to fully cooperate with &#91;***&#93; to acquire such rights.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Notwithstanding anything to the contrary, in no event shall this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (i) apply to the applicable country if the reductions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> apply to the Royalty Rate in such country for the applicable Calendar Quarter (i.e., the Royalty Rate is already &#91;***&#93;) or (ii)&#160;reduce the then applicable Royalty Rate for any Product in any country in any Calendar Quarter by more than &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any amount that Novartis is entitled to deduct under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that is reduced by the limitation on the deduction in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be carried forward and Novartis may deduct such amount from subsequent amounts due to MPAG until the full amount that Novartis was entitled to deduct is deducted. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Sales Outside the Commercial Territories</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG and Novartis acknowledge and agree that, for the avoidance of doubt, Novartis may freely exploit the Products outside the Commercial Territories and any </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">sales in such other countries shall not be included in the Net Sales calculation for purposes of determining royalties payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">No Projections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG and Novartis acknowledge and agree that nothing in this License Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product. NEITHER MPAG NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">REPORTS AND PAYMENT TERMS</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Royalty Payments and Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall pay MPAG all royalty amounts due pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> within &#91;***&#93; after the end of each Calendar Quarter during the Term following the First Commercial Sale of a Product. Novartis will provide concurrently with each payment of royalties due to MPAG a Sales &#38; Royalty Report. </font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Payment Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Except with respect to royalty amounts due pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each Party shall provide to the other Party an invoice for all amounts due to it under this License Agreement. Unless otherwise noted, payments on such invoices shall be made within &#91;***&#93; of the other Party&#8217;s receipt of the applicable invoice. Invoices to Novartis shall be in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">All payments from Novartis to MPAG shall be made by wire transfer in CHF to the credit of such bank account as may be designated by MPAG in this License Agreement or in writing to Novartis. Any payment which falls due on a date which is not a Business Day in the location from which the payment will be made may be made on the next succeeding Business Day in such location. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All royalties under this License Agreement shall be calculated in USD and will be payable in CHF. For purposes of calculating royalties payable hereunder, (i) when conversion of payments from any foreign currency is required to be undertaken by Novartis, the USD equivalent shall be calculated using Novartis&#8217; then-current standard exchange rate methodology as consistently applied in its external reporting and (ii) when converting royalty amounts from USD to CHF for the purposes of payment to MPAG, the CHF amount shall be calculated using the average of the monthly exchange rate for such quarter using Novartis&#8217; then-current standard exchange rate methodology as consistently applied in its external reporting.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Novartis fails to pay any undisputed payment under this License Agreement by the date when such payment is due, then, without limiting any other right or remedy of MPAG, such late payment shall be paid together with interest thereon at an annual rate (but with interest accruing on a daily basis) of &#91;***&#93; as quoted on Bloomberg (or if Bloomberg no longer exists, a similarly authoritative source), from the date on which such payment was originally due until the date of payment (provided, that, such rate shall not exceed the rate permissible under Applicable Law).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">MPAG will pay any and all taxes levied on account of any payments made to it under this License Agreement. If any taxes are required to be withheld by Novartis, Novartis will&#58; (a) deduct such taxes from the payment made to MPAG&#59; (b) timely pay the taxes to the proper taxing authority&#59; (c) send proof of payment to MPAG&#59; and (d) reasonably assist MPAG in its </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">efforts to obtain a credit for such tax payment. Each Party agrees to reasonably assist the other Party in lawfully claiming exemptions from or minimizing such deductions or withholdings under double taxation laws or similar circumstances.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Each amount stated as payable under or pursuant to this License Agreement is exclusive of value added tax (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (if any). If any VAT is payable or chargeable on or in respect of any amounts payable under this License Agreement, the paying Party shall pay the amount of such VAT in addition to the relevant consideration and the receiving Party shall provide the paying Party prior to the payment with a valid VAT invoice in the appropriate form and based on local indirect tax law.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Records and Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Each Party shall keep complete, true and accurate books and records in relation to this License Agreement, including, (i) with respect to Novartis, in relation to Net Sales and royalties and (ii) with respect to MPAG, in relation to MPAG Ongoing Clinical Trial Costs.  Each Party will keep such books and records for at least &#91;***&#93; following the Calendar Year to which they pertain.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Either Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may, upon written request to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audited Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), cause an internationally-recognized independent accounting firm (which is reasonably acceptable to the Audited Party) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to inspect the relevant records of the Audited Party or its Affiliates to verify (i) with respect to Novartis, the royalties payable by Novartis and (ii) with respect to MPAG, the MPAG Ongoing Clinical Trial Costs, and, in each case the related reports, statements and books of accounts, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, the Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall only be entitled to inspect the relevant books and records of Novartis to verify royalties payable by Novartis with respect to the &#91;***&#93; prior to the Calendar Year in which such inspection request is made. Before beginning its audit, the Auditor shall execute an undertaking acceptable to the Audited Party by which the Auditor shall agree to keep confidential all Confidential Information reviewed during such audit. The Auditor shall have the right to disclose to the Auditing Party only its conclusions regarding any payments owed under this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">The Audited Party shall make their relevant records available for inspection by such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from the Auditing Party. The records shall be reviewed solely to verify the accuracy of Novartis&#8217; royalties or MPAG Ongoing Clinical Trial Costs, as applicable, and in each case, compliance with this License Agreement. Such inspection right shall not be exercised more than once in any Calendar Year and not more frequently than once with respect to records covering any specific period of time or MPAG Ongoing Clinical Trial. The Auditing Party agrees to hold in strict confidence all Confidential Information received and all Confidential Information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this License Agreement or to the extent required to comply with any law, regulation or judicial order.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">The Auditor shall provide its audit report and basis for any determination to the Audited Party at the time such report is provided to the Auditing Party, before it is considered final. The Audited Party shall have the right to request a further determination by such Auditor as to matters which the Audited Party disputes within &#91;***&#93; following receipt of such report. The Audited Party will provide the Auditing Party and the Auditor with a reasonably detailed statement of the grounds upon which it disputes any findings in the audit report and the Auditor shall undertake to complete such further determination within &#91;***&#93; after the dispute notice is provided, which </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">determination shall be limited to the disputed matters. Any matter that remains unresolved shall be resolved in accordance with the dispute resolution procedures contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by Novartis, the underpaid or overpaid amount shall be settled promptly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">The Auditing Party will pay for the fees and expenses of the Auditor, except that (i) Novartis will pay for such fees with respect to audits initiated by MPAG if Novartis is found to have underpaid MPAG by more than &#91;***&#93; of the amount that should have been paid for the audited period and (ii) MPAG will pay for such fees with respect to audits initiated by Novartis if Novartis is found to have overpaid MPAG by more than &#91;***&#93; of the amount that should have been paid for the applicable MPAG Ongoing Clinical Trial. </font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">INTELLECTUAL PROPERTY RIGHTS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Background Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly set forth herein, as between the Parties, each Party is and shall remain the owner of all intellectual property and Confidential Information that it owned as of the Effective Date or that it develops or acquires thereafter pursuant to activities independent of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All intellectual property (including Know-How, Patent Rights, and any other intellectual property rights) relating to the MPAG Compounds or Products developed by or on behalf of either Party or their respective affiliates after the Effective Date and arising from the Parties&#8217; activities under this License Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be jointly owned by the Parties, independent of inventorship&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that New Manufacturing IP shall not be considered Joint IP for the purposes of this License Agreement. Each Party hereby assigns, and agrees to assign, into the joint names of both Parties, an equal and undivided interest in and to all Joint IP. At least once per Calendar Quarter, each Party shall disclose to the other Party the development, making, conception, or reduction to practice of any Joint IP. Subject to the exclusive licenses granted by MPAG to Novartis to Joint IP under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each Party shall have the right to fully exploit (including by way of granting licenses, assignments, mortgages or otherwise, in each case, solely over its share of the Joint IP) the Joint IP without a duty of seeking consent or accounting to the other Party, including for the researching, Developing, Manufacturing, or Commercializing of products.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">New Manufacturing IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">New Manufacturing IP shall be jointly owned by the Parties, independent of inventorship and each Party hereby assigns, and agrees to assign, into the joint names of both Parties, an equal and undivided interest in and to all such New Manufacturing IP. At least &#91;***&#93; per Calendar Quarter, each Party shall disclose to the other Party the development, making, conception, or reduction to practice of any New Manufacturing IP. Novartis hereby grants MPAG, a worldwide, perpetual, royalty-free, non-exclusive license under its interest in the New Manufacturing IP for any application of the New Manufacturing IP, including a right to sublicense to Third Parties to make and have made products&#59; provided, for clarity, if MPAG desires to obtain a license to any Novartis Background Technology to practice the New Manufacturing IP to make or have made the MPAG Compounds or Products, then such right shall be subject to a good faith obligation of Novartis to negotiate with MPAG commercial terms on which Novartis would grant a non-exclusive license to Novartis Background Technology for such purpose. MPAG hereby grants Novartis, a worldwide, perpetual, royalty-free, non-exclusive license under its interest in the New Manufacturing IP for any application of the New Manufacturing IP, including a right to sublicense to Third Parties to make and have made products&#59; provided, for clarity, if Novartis desires to obtain a license to any MPAG </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Background Technology that does not primarily relate to the Platform or designed ankyrin repeat protein products to practice the New Manufacturing IP, then such right shall be subject to a good faith obligation of MPAG to negotiate with Novartis commercial terms on which MPAG would grant a non-exclusive license to MPAG Background Technology for such purpose. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">The reciprocal licenses to New Manufacturing IP described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are intended to be perpetual and shall survive the expiration or termination of the License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.55pt">Ownership of Results and Data. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All data and results arising from the Parties&#8217; activities under the License Agreement, including clinical and regulatory data and information generated for regulatory purposes relating to the MPAG Compounds or Products shall be jointly owned by the Parties. At least once per Calendar Quarter, each Party shall disclose to the other Party all such data and results arising from the Parties&#8217; activities under the License Agreement which have not previously been disclosed to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Patent Filing, Prosecution, Maintenance, Management &#38; Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#91;***&#93; for filing, prosecuting, maintaining and managing (including related strategies) (1) &#91;***&#93; and (2) any Patent Rights in the &#91;***&#93;, in each case of (1) and (2), that (i)&#160;relate exclusively to the &#91;***&#93; or (ii) do not primarily relate to the &#91;***&#93;) or &#91;***&#93; (collectively, the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), at its own cost and expense. &#91;***&#93; will fully cooperate with &#91;***&#93; in connection with the filing, prosecution, maintenance and management of the &#91;***&#93; Patents, including by providing access to relevant persons and executing all documentation reasonably requested by &#91;***&#93;. &#91;***&#93; will keep &#91;***&#93; reasonably informed of all steps with regard to the preparation, prosecution, and maintenance of the &#91;***&#93; Patents including any decision as to whether to &#8216;opt-in&#8217; or &#8216;opt-out&#8217; of the EU Unitary Patent System pursuant to Regulation (EU) No 1257&#47;2012 of December 17, 2012 as well as the Agreement on a Unified Patent Court as of February 19, 2013. &#91;***&#93; shall provide &#91;***&#93; with a copy of all communications to and from all patent authorities regarding the &#91;***&#93; Patents, including drafts of any filings or responses to be made to such patent authorities, sufficiently in advance of submitting such filings or responses so as to allow &#91;***&#93; a reasonable opportunity to review and comment thereon. &#91;***&#93; shall consider, in good faith, all reasonable requests and suggestions with respect to such drafts and any other comments or responses provided by &#91;***&#93;, it being understood and agreed that &#91;***&#93; shall make all decisions relating thereto including, for the avoidance of doubt, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#91;***&#93; will notify &#91;***&#93; of any decision not to file applications for, or to cease prosecution or maintenance of, or not to continue to pay the expenses of prosecution or maintenance of, any &#91;***&#93; Patents in the Territories. &#91;***&#93; will provide such notice at least &#91;***&#93; prior to any filing or payment due date, or any other due date that requires action, in connection with such Patent Right. In such event, &#91;***&#93; shall have the right, at its sole discretion and expense, to file or to continue prosecution or maintenance of such &#91;***&#93; Patent. If &#91;***&#93; does assume the prosecution and&#47;or maintenance of such &#91;***&#93; Patent, then, at &#91;***&#93; cost and expense, (i) &#91;***&#93; shall cooperate with &#91;***&#93; to transfer the prosecution and maintenance of the &#91;***&#93; Patent, together with all relevant documentation and the file wrapper, to &#91;***&#93; and (ii) at &#91;***&#93; sole discretion, such Patent Right shall no longer be licensed to &#91;***&#93; and shall no longer form part of the &#91;***&#93;, as the case may be. For the avoidance of doubt, such Patent Right shall not be deemed a &#91;***&#93; Patent. In the event that &#91;***&#93; assumes the prosecution and&#47;or maintenance of a &#91;***&#93; Patent which is part of the &#91;***&#93; and &#91;***&#93; decides that such Patent Right shall no longer form part of the &#91;***&#93;, then at &#91;***&#93; request and at &#91;***&#93; cost and expense, &#91;***&#93; shall execute such documents and perform such acts as may be reasonably necessary in a timely manner to effect an assignment of &#91;***&#93; interest in such Patent Right to &#91;***&#93;.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#91;***&#93; for filing, prosecuting, maintaining and managing (including related strategies) the &#91;***&#93; Patents and any Patent Rights in the &#91;***&#93; that are not &#91;***&#93; Patents </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), at its own cost and expense. &#91;***&#93; will fully cooperate with &#91;***&#93; in connection with the filing, prosecution, maintenance and management of the &#91;***&#93; Patents, including by providing access to relevant persons and executing all documentation reasonably requested by &#91;***&#93;. &#91;***&#93; will keep &#91;***&#93; reasonably informed of the status of the &#91;***&#93; Patents (including by providing &#91;***&#93; copies of all filings made with Governmental Authorities with respect thereto, any office actions or office action responses or other correspondence that &#91;***&#93;, its Affiliates or sublicensees provide to or receives from any patent office), it being understood and agreed that &#91;***&#93; shall make all decisions relating thereto including, for the avoidance of doubt, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#91;***&#93; will notify &#91;***&#93; of any decision not to file applications for, or to cease prosecution or maintenance of, or not to continue to pay the expenses of prosecution or maintenance of, any &#91;***&#93; Patents in the Territory. &#91;***&#93; will provide such notice at least &#91;***&#93; prior to any filing or payment due date, or any other due date that requires action, in connection with such Patent Right. In such event, &#91;***&#93; shall have the right, at its sole discretion and expense, to file or to continue prosecution or maintenance of such &#91;***&#93; Patent.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Patent Enforcement and Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Each Party will promptly notify the other Party of any infringement, misappropriation, or other violation by a Third Party of any of the MPAG Products Patents, the MPAG Products Know-How, or any Joint IP, New Manufacturing IP or Option Period Manufacturing IP in the Field in the Territory of which it becomes aware, including any &#8220;patent certification&#8221; filed in the United States under 42 U.S.C. &#167;262(i)(2) or &#167;262(k) or similar provisions in other jurisdictions and of any request for declaratory judgment, opposition, nullity action, interference, inter-partes reexamination, inter-partes review, post-grant review, derivation proceeding, or similar action alleging the invalidity, unenforceability or non-infringement of any of the MPAG Products Patents or Patent Rights included in the Joint IP, New Manufacturing IP or Option Period Manufacturing IP (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#91;***&#93; will have the first right to bring and control any legal action in connection with any Third Party Infringement to the extent the applicable MPAG Products Patents, MPAG Products Know-How, Joint IP, New Manufacturing IP or Option Period Manufacturing IP (i) relate exclusively to the MPAG Compounds or Products or (ii) do not primarily relate to the &#91;***&#93; or a designed ankyrin repeat protein product other than a Product (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). &#91;***&#93; right to control such legal action shall be at its own expense as it reasonably determines appropriate (including deciding on any litigation strategy), and &#91;***&#93; shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If &#91;***&#93; fails to bring an action or proceeding with respect to, or to terminate, infringement of any &#91;***&#93; Third Party Infringement (1) within &#91;***&#93; following the notice of alleged infringement or (2) prior to &#91;***&#93; before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, &#91;***&#93; shall have the right, to bring and control any such action at its own expense and by counsel of its own choice, and &#91;***&#93; shall have the right, at its own expense, to be represented in any such action by counsel of its own choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if &#91;***&#93; notifies &#91;***&#93; in writing prior to &#91;***&#93; before such time limit for the filing of any such action that &#91;***&#93; intends to file such action before the time limit, then &#91;***&#93; shall be obligated to file such action before the time limit.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#91;***&#93; will have the first right to bring and control any legal action in connection with any Third Party Infringement that is not &#91;***&#93; Third Party Infringement (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). &#91;***&#93; right to control such legal action shall be at its own expense as it </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reasonably determines appropriate (including deciding on any litigation strategy), and &#91;***&#93; shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If &#91;***&#93; fails to bring an action or proceeding with respect to, or to terminate, infringement of any &#91;***&#93; Third Party Infringement (i) within &#91;***&#93; following the notice of alleged infringement or (ii) prior to &#91;***&#93; before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, &#91;***&#93; shall have the right, to bring and control any such action at its own expense and by counsel of its own choice, and &#91;***&#93; shall have the right, at its own expense, to be represented in any such action by counsel of its own choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if &#91;***&#93; notifies &#91;***&#93; in writing prior to &#91;***&#93; before such time limit for the filing of any such action that &#91;***&#93; intends to file such action before the time limit, then &#91;***&#93; shall be obligated to file such action before the time limit.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">If a Party initiates proceedings in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the other Party agrees to be joined as a party plaintiff where necessary and to give the first Party reasonable assistance and authority to file and prosecute the proceedings. The costs and expenses of each Party incurred pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be borne by the Party initiating such proceedings. If one Party initiates proceedings in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the other Party may join such proceedings as a party plaintiff where necessary for such other Party to seek lost profits or other appropriate damages or compensation with respect to such infringement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Any damages or other monetary awards recovered with respect to a Third Party Infringement brought pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be shared as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.98pt">the amount of such recovery will first be applied to the Parties&#8217; reasonable out-of-pocket expenses incurred in connection with such Third Party Infringement legal action (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses)&#59; then</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.93pt">any remaining proceeds constituting direct or actual damages for acts of infringement will be paid to, or retained by, MPAG in respect of any Third Party Infringement brought and controlled by MPAG, and Novartis in respect of any Third Party Infringement brought and controlled by Novartis&#59; provided that any amounts received by Novartis will be included in Net Sales for the Calendar Quarter in which such amounts are received by Novartis&#59; and</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.88pt">any remaining proceeds constituting punitive or treble damages will be allocated between the Parties as follows&#58; the Party that brought and controlled the Third Party Infringement action will retain &#91;***&#93; of such proceeds and the other Party will receive &#91;***&#93; of such proceeds. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">Notwithstanding anything to the contrary under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, neither Party may enter a settlement, consent judgment or other voluntary final disposition of a suit under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue or similar immunity under any Patent Rights Controlled by the other Party or its Affiliates without first obtaining the written consent of the Party that Controls the relevant Patent Rights&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that either Party shall be entitled, without the consent of the other Party, to enter into a settlement, consent judgment or other voluntary final disposition of a suit that primarily relates to the establishment of a date by which the a generic or biosimilar product will be permitted to be Commercialized.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis shall be solely responsible for selecting, registering and maintaining the Trademarks used for the Commercialization of the Products as it determines appropriate in its sole discretion, which may vary by country or within a country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Novartis shall Control all rights in the Product Marks and register and maintain the Product Marks in the countries and regions it determines reasonably necessary and pay all relevant costs thereto. Novartis shall have the sole right to initiate, at its own discretion, legal proceedings against any infringement or threatened infringement of the Product Marks. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">MPAG hereby grants Novartis a non-exclusive, royalty-free, sublicensable (through multiple-tiers) license to use the DARPin&#174; Trademark and any other registered or unregistered Trademark, word, logo, tagline or slogan Controlled by MPAG which relates to the Products, solely in connection with the Manufacture, use, importation, sale or other Commercialization or exploitation of the Products in the Field in the Territory. Any use of any Trademark by Novartis pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall appropriately acknowledge MPAG&#8217;s ownership and, subject to Applicable Law, Novartis shall include, depending on the status of the DARPin&#174; Trademark in a country within the Territory, either of the following notifications displayed prominently on all documents, labels, packs, advertisements and other materials that utilize the DARPin&#174; Trademark&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8220;DARPin&#174; is a registered trademark owned by Molecular Partners AG, and is used under license.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8220;DARPin&#8482; is a trademark owned by Molecular Partners AG, and is used under license.&#8221; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis will be solely responsible for registering, hosting, maintaining and defending all Product Marks that are internet domain names (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under all generic Top Level Domains (gTLDs) and under all relevant country code Top Level Domains (ccTLD). For the avoidance of doubt, Novartis may register such Product Domain Names in its own name, to host on its own servers, maintain and defend the Product Domain Names and use them for websites.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Patent Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">If requested by &#91;***&#93; shall cooperate in obtaining patent term restoration (including under the Drug Price Competition and Patent Term Restoration Act), supplemental protection certificates or their equivalents, and patent term extensions with respect to the &#91;***&#93; Patents in any country or region where applicable. &#91;***&#93; shall provide all reasonable assistance requested by &#91;***&#93;, including permitting &#91;***&#93; to proceed with applications for such in the name of &#91;***&#93;, if deemed appropriate by &#91;***&#93;, and executing documents and providing any relevant information to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#91;***&#93; shall have the first right, but not the obligation, to determine in good faith what extensions or supplementary protection certificates, with respect to the &#91;***&#93; Patents, should be applied for. &#91;***&#93; shall inform &#91;***&#93; of its determination whether or not to file, in good time and shall provide a copy of all documents and other information that &#91;***&#93; may need to allow &#91;***&#93; to file such extension or supplementary protection certificate requests, whether on its own behalf or on &#91;***&#93; behalf. Each Party shall provide prompt and reasonable assistance, as requested by the other, including by taking such action as is required under any Applicable Law to obtain such patent extension or supplementary protection certificate.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">CONFIDENTIALITY </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Duty of Confidence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the other provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, all Confidential Information disclosed by a Party or any of its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under this License Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party or any of its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding the foregoing, all New Manufacturing IP is the Confidential Information of both Parties and the terms of this License Agreement are the Confidential Information of both Parties. The Recipient Party may only use the Confidential Information of the Disclosing Party for the purposes of this License Agreement. Subject to the other provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each Party shall hold as confidential such Confidential Information of the other Party or its Affiliates in the same manner and with the same protection as such Recipient Party maintains its own confidential information. Subject to the other provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Recipient Party may only disclose Confidential Information of the other Party to employees, agents, contractors, consultants and advisers of such Party and its Affiliates and sublicensees and to Third Parties, in each case, to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this License Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that such persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not apply to any information to the extent that the Recipient Party can demonstrate by competent evidence that such information&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this License Agreement by the Recipient Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">was known to, or was otherwise in the possession of, the Recipient Party prior to the time of disclosure by the Disclosing Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is disclosed to the Recipient Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">is independently developed by or on behalf of the Recipient Party, as evidenced by its written records, without reference to the Confidential Information disclosed by the Disclosing Party under this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Recipient Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Recipient Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the possession of the Recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Recipient Party unless the combination and its principles are in the public domain or in the possession of the Recipient Party.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Authorized Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Recipient Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this License Agreement, or if and to the extent such disclosure is necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">filing or prosecuting Know-How or Patent Rights as permitted by this License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">complying with applicable court orders or Applicable Laws, a bona fide legal process, the listing rules of any exchange on which such Party&#8217;s securities are traded&#59;</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">in Regulatory Filings or Regulatory Materials that the Recipient Party has the right to file, or holds, as expressly set forth in this License Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">disclosure to the Recipient Party&#8217;s Affiliates, licensees and sublicensees, potential licensees and sublicensees, who, in each case, need to know such information in order for the Recipient Party to exercise its rights or fulfill its obligations under this License Agreement, provided, that such persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this License Agreement&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">disclosure to Third Parties in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality and non-use. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event the Recipient Party is required to disclose Confidential Information of the Disclosing Party in connection with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;11.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Recipient Party shall (a)&#160;inform the Disclosing Party as soon as reasonably practicable of the required disclosure&#59; (b)&#160;limit the disclosure to the required purpose&#59; and (c)&#160;at the Disclosing Party&#8217;s request and expense, assist in an attempt to object to or limit the required disclosure.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Ongoing Obligation for Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon early termination of this License Agreement for any reason, each Party and its Affiliates shall immediately return to the other Party or destroy any Confidential Information disclosed by the other Party or any of its Affiliates, except for one copy which may be retained in its confidential files for archive or compliance purposes.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The term of this License Agreement will commence upon the Effective Date and continue, on a Product-by-Product and country-by-country basis until the expiration of the Royalty Term for such Product in such country, unless earlier terminated as permitted by this License Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding the foregoing, on a Product-by-Product and country-by-country basis, upon expiration of the Term for such Product in such country, the following provisions of this License Agreement shall survive with respect to such Product in such country&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">8.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">8.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Termination for Cause&#59; Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If either Novartis or MPAG is in material breach of any material obligation hereunder, the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and in the event such material breach is not cured within &#91;***&#93; (or &#91;***&#93; with respect to undisputed payments due under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) after the breaching Party&#8217;s receipt of such notice, the non-breaching Party shall have the right thereafter to terminate this License Agreement immediately by giving written notice to the breaching Party to such effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if such non-payment related breach is capable of being cured but cannot be cured within such &#91;***&#93; period and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have an additional &#91;***&#93; period to cure such breach. In the event that arbitration is commenced in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with respect to any alleged breach hereunder, no purported termination of this License Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall take effect until it is finally determined pursuant to such arbitration that such material breach occurred. Any termination by any Party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the effects of termination provided </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Either MPAG or Novartis may terminate this License Agreement without notice if an Insolvency Event occurs in relation to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Termination by Novartis Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis may terminate this License Agreement without cause in its entirety or on a Product-by-Product basis&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">upon &#91;***&#93; prior written notice (i) at any time prior to the date that any Product has received Regulatory Approval for the sale of such Product in any country in the Commercial Territories or (ii) at any time within &#91;***&#93; after the closing of a Change of Control of MPAG&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">upon &#91;***&#93; prior written notice at any time on or after the date that any Product has received Regulatory Approval for the sale of such Product in any country in the Commercial Territories&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">upon &#91;***&#93; prior written notice if Novartis reasonably determines in good faith that a safety issue exists that would be reasonably expected to materially and adversely affect the Development, Manufacture, or Commercialization of any MPAG Compounds or Products. </font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that this License Agreement constitutes an executory contract under Section 365 of the Code for the license of &#8220;intellectual property&#8221; as defined under Section 101 of the Code and constitutes a license of &#8220;intellectual property&#8221; for purposes of any similar laws in any other country in the Territory. The Parties further agree that Novartis, as licensee of such rights under this License Agreement, will retain and may fully exercise all of its protections, rights and elections under Section 365 of the United States Bankruptcy Code, 11 U.S.C. &#167;&#167; 101 et seq. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including Section&#160;365(n) of the Code, and any similar laws in any other country in the Territory. The Parties further agree that, in the event of an Insolvency Event by or against MPAG under the Code and any similar laws in any other country in the Territory, Novartis will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless MPAG elects to continue to perform all of its obligations under this License Agreement, or (ii) if not delivered under (i) above, following the rejection of this License Agreement by or on behalf of MPAG upon written request therefor by Novartis. All rights, powers and remedies of Novartis provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including under the Code and any similar laws in any other country in the Territory).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that &#91;***&#93; then &#91;***&#93;, by written notice to &#91;***&#93;, either &#91;***&#93; until such time as &#91;***&#93;. In the event that &#91;***&#93;, and provided that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">EFFECT OF TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Termination by Novartis for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon termination of this License Agreement by Novartis with respect to a Terminated Product pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; (i) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, any licenses and other rights granted by either Party to the other Party with respect to the Terminated Product will terminate and revert to the granting Party, and (ii) except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the rights and obligations of the Parties hereunder shall terminate as of the date of such termination with respect to the Terminated Product.</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Termination by Novartis without Cause or by MPAG for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon termination of this License Agreement by Novartis pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or by MPAG pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any licenses granted by MPAG to Novartis with respect to the Terminated Products will terminate and revert to MPAG. Any licenses granted by Novartis to MPAG with respect to the Terminated Products will continue in full force and effect. Any sublicense granted by Novartis pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">will automatically terminate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt;text-decoration:underline">Grant-Back Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the effective date of termination, Novartis shall and hereby does grant to MPAG a worldwide, exclusive, royalty-bearing license (on terms to be agreed under the Transition Plan), with the right to sublicense, under the Know-How and Patent Rights that are Controlled by Novartis that are necessary or reasonably useful to Develop, Manufacture, or Commercialize the Terminated Product, to Develop, Manufacture, use, sell, have sold, offer for sale and import the Terminated Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt;text-decoration:underline">Transition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties shall meet to discuss and agree in good faith upon the terms of a transition plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to which Novartis will facilitate an orderly and prompt transition of the Development, Manufacture, and Commercialization of the Terminated Product to MPAG and its designees, which shall include&#58; (i) the terms for the license granted to MPAG under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;13.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (ii) the transfer by Novartis to MPAG or its designee the Know-How licensed to MPAG under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;13.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the obligation for Novartis to provide reasonable assistance in connection with understanding and using the same&#59; (iii) the transfer and assignment to MPAG all Regulatory Materials and clinical trial data to the extent solely related to the Terminated Product and necessary or reasonably useful for Developing, Manufacturing or Commercializing the Terminated Product&#59; (iv) an assignment of Novartis&#8217; rights, title, and interests in and to Product Marks (but, for clarity, not any Novartis corporate or house marks) owned by Novartis and used solely in connection with the Commercialization of the Terminated Product&#59; (v) the reasonable advancement by Novartis to a reasonable conclusion or transition point before transferring any ongoing clinical trials to MPAG related solely to the Terminated Products (including the assignment of any Third Party clinical trial agreements) with the objective of minimizing disruption to the Development and Commercialization of the MPAG Compounds and Products&#59; (vi) appropriate provisions for the transfer to MPAG of the right prosecute, maintain, and enforce the rights with respect to any Patent Rights in the Joint IP&#59; and (vii) the transfer to MPAG of the safety database for the Terminated Product. MPAG will reimburse Novartis for all documented internal costs and external expenses incurred in connection with the activities conducted under the Transition Plan and in addition to such reimbursement. In consideration for the Know-How and Patent Rights generated by Novartis with respect to the Terminated Product prior to such termination and licensed to MPAG in accordance with the Transition Plan, MPAG will agree to pay Novartis reasonable compensation (whether through a royalty on Net Sales of the Terminated Product or a percentage of the amounts received from any Third Party under a license of the Terminated Product) as may be agreed by the Parties in good faith, taking into consideration the scope of the Know-How and Patent Rights licensed, the development stage pf the Terminated Products, and all other relevant factors. In the event that the Parties fail to agree on the final terms of and enter into the definitive agreements implementing the Transition Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Plan Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; following the applicable termination, then the Parties shall submit such matter for resolution in accordance with the procedure set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 13.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt;text-decoration:underline">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG shall have the option, exercisable within &#91;***&#93; following the effective date of such termination, to purchase Novartis&#8217; inventory of such Terminated Product at a price equal to &#91;***&#93; of Novartis&#8217; costs for such inventory of the Terminated Product. In the event MPAG exercises such right to purchase such inventory, Novartis shall grant, and hereby does grant, a royalty-free license to any trademarks, names, and logos of Novartis contained therein for a </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">period of &#91;***&#93; from the date of MPAG&#8217;s exercise solely to permit the orderly sale of such inventory. If such inventory is insufficient to cover MPAG&#8217;s needs, Novartis shall, and shall cause its Affiliates to, use reasonable efforts to enter into one or more customary manufacture and supply agreements with MPAG for the manufacture and supply, for up to &#91;***&#93; following termination of this License Agreement, of the Terminated Products&#59; provided, further, that during such period, MPAG shall use commercially reasonable efforts to undertake such transition and to address continuation of supply itself or through a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt;text-decoration:underline">Termination of other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the rights and obligations of the Parties hereunder (including the obligations of MPAG under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) shall terminate as of the date of such termination.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Expiration or termination of this License Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (to the extent the definitions are used in other surviving provisions), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.3, 9.6, 14.5, 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (as applicable) shall survive expiration or termination of this License Agreement. The provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11 (Confidentiality)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination or expiration of this License Agreement for a period of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Termination Not Sole Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Termination is not the sole remedy under this License Agreement and, whether or not termination is effected and notwithstanding anything contained in this License Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Representations and Warranties by Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party represents and warrants to the other Party, as of the Effective Date that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">it has full corporate power and authority to execute, deliver, and perform this License Agreement, and has taken all corporate action required by law and its organizational documents to authorize the execution and delivery of this License Agreement and the consummation of the transactions contemplated by this License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">this License Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">other than compliance with the HSR Act or as may be required to conduct clinical trials or to seek or obtain Regulatory Approvals or applicable regulatory material, all consents, approvals and authorizations from all Governmental Authorities or other Third Parties required to be obtained by such Party in connection with this License Agreement have been obtained&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">the execution and delivery of this License Agreement and the consummation of the transactions contemplated hereby do not&#58; (i)&#160;conflict with or result in a breach of any provision of its organizational documents&#59; (ii)&#160;result in a breach of any other agreement to which it is a party&#59; or (iii) violate any law&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">(i) neither such Party nor, to the actual knowledge of such Party, any employee, agent or subcontractor of such Party involved or to be involved in the Development of the MPAG Compounds or Products has been debarred under Subsection (a) or (b) of Section 306 of the Act </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) no Debarred Person who is known by such Party to have been debarred under Subsection (a) or (b) of Section 306 of the Act will be employed by such Party in the performance of any activities hereunder&#59; and (iii) to the actual knowledge of such Party, no Debarred Person on any of the FDA clinical investigator enforcement lists (including the (1) Disqualified&#47;Totally Restricted List, (2) Restricted List and (3) Adequate Assurances List) will participate in the performance of any activities hereunder. </font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Representations and Warranties by MPAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, MPAG represents and warrants to Novartis, as of the Effective Date that&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> sets forth a complete and accurate list of all MPAG Patents in existence of the Execution Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">MPAG is the sole and exclusive owner of all of the MPAG Patents and the MPAG Products Patents are free from Encumbrances&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Where MPAG Product Patents are listed in the records of any Governmental Authority, MPAG is listed as the sole and exclusive owner of record or exclusive licensee for each registration, grant and application included in such MPAG Product Patents&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">MPAG has the right to grant to Novartis the rights that MPAG purports to grant Novartis hereunder, including the right to grant (i) exclusive licenses to the MPAG Compounds and Products under the MPAG Products Patents and MPAG Products Know-How and (ii) non-exclusive licenses to the MPAG Compounds and Products under the MPAG Enabling Patents and MPAG Enabling Know-How&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">MPAG has not granted any Third Party rights that would interfere or be inconsistent with Novartis&#8217; rights hereunder, and there are no agreements or other arrangements to which MPAG or any of its Affiliates is a party relating to the Platform, MPAG Compounds, the Products, MPAG Patents, or MPAG Know-How that would limit the rights granted to Novartis under this License Agreement or that materially restrict or will result in a restriction on Novartis&#8217; ability to research, Develop, Manufacture, use, import, offer for sale, sell, have sold and otherwise Commercialize the MPAG Compounds or Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">no claims, challenges, oppositions, nullity actions, interferences, inter-partes reexaminations, inter-partes reviews, post-grant reviews, derivation proceedings or other proceedings are pending or, to MPAG&#8217;s knowledge, have been threatened as to the issued patents in the MPAG Patents, and, to MPAG&#8217;s knowledge, the issued patents in the MPAG Patents are valid and enforceable&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">neither MPAG nor any of its Affiliates has received any written Claim alleging that any of the Products IP or Enabling IP is invalid or unenforceable&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">MPAG has obtained from all individuals who have been identified as inventors of any MPAG Products Patents and MPAG Enabling Patents effective assignments of all ownership rights of such individuals in such MPAG Products Patents or MPAG Enabling Patents, either pursuant to written agreement or by operation of law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">all required application, registration, maintenance, other related fees and renewal fees in respect of the MPAG Patents have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of obtaining or maintaining the MPAG Patents&#59;</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">to MPAG&#8217;s knowledge, the Development, Manufacture, having Manufactured, use, importation, offering for sale, sale, having sold or other Commercialization of the MPAG Compounds and Products does not infringe the Patent Rights or misappropriate the Know-How of any Third Party and MPAG has not received any written notice alleging any such infringement or misappropriation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">MPAG has not initiated or been involved in any Claims in which it alleges that any Third Party is or was infringing or misappropriating any Products IP or Enabling IP, nor have any such Claims been threatened by MPAG, nor does MPAG know of any valid basis for any such Claims&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">the Products IP and Enabling IP comprises all of the intellectual property rights used by MPAG and its Affiliates in the Development of the MPAG Compounds or Products prior to the Execution Date or the Effective Date, as applicable&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">MPAG has not entered into a government funding relationship that would result in rights to any MPAG Compounds or Products residing in the US Government, National Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the US Government as set forth in Public Law 96 517 (35 U.S.C. 200 204) or any similar obligations under the laws of any other country&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">to MPAG&#8217;s knowledge, all preclinical and clinical studies or tests with respect to the MPAG Compounds or Products (other than those performed by Novartis under the Option Agreement)&#58; (i) conducted or sponsored by MPAG or any research, development, collaboration or similar partner of MPAG while acting in such capacity (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, but for clarity excluding Novartis, its Affiliates, sublicensees and subcontractors)&#59; or (ii) used to support any filing or application with a Regulatory Authority have, in each case ((i) and (ii)), have been conducted in material compliance with applicable laws and applicable rules, regulations and guidances (including the standards for good clinical practices relating to clinical trials for pharmaceuticals under applicable laws) and federal and state laws, rules, regulations and guidances restricting the use and disclosure of individually identifiable health information&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">MPAG has disclosed to Novartis all facts known to MPAG or any of its Affiliates that (i)&#160;relate to the Products&#59; and (ii) would be reasonably likely to materially affect Novartis in connection with this License Agreement or the transactions contemplated hereby, and in all cases, such facts do not contain any materially untrue statement and do not omit any facts that, in light of the circumstances, would make such facts misleading&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">neither MPAG nor, to MPAG&#8217;s knowledge, any Collaboration Partner has received any written notice or other correspondence from the FDA, EMA or any other Regulatory Authority or institutional review board or ethics committee with respect to any ongoing clinical or pre-clinical studies or tests with respect to any MPAG Compounds or Product&#58; (i) threatening the initiation of any action to place a clinical hold order on any such studies or tests&#59; or (ii) otherwise requiring the termination, suspension or material modification of any such studies or tests&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">to MPAG&#8217;s knowledge, all clinical trials and studies conducted by or on behalf of MPAG (other than by Novartis under the Option Agreement) have been conducted, all data has been generated and stored, and Manufacturing and distribution has been conducted, in each case, with respect to the MPAG Compounds and Products, in compliance with Applicable Laws in all material respects&#59; </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">MPAG has not, and to MPAG&#8217;s knowledge, no Collaboration Partner has, altered, falsified, or otherwise manipulated any data generated or used in any clinical trials or other studies related to the development, use, handling, safety, efficacy, reliability or Manufacturing of the MPAG Compounds or Products&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.4pt">the Purchased Inventory (i) has been Manufactured in compliance with all Applicable Laws, including cGMP, (ii) is free of any Encumbrances, (iii) has not been not be adulterated, mislabeled or misbranded by MPAG within the meaning of the FDCA, (iv) has been stored in accordance with the specifications, and (v), unless otherwise agreed in Exhibit C, meets the Minimum Shelf Life&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">the MPAG Produced Purchased Inventory complies with the applicable final specifications at the time of delivery to Novartis. </font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Covenants of MPAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG covenants and agrees that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">during the Term, MPAG will not (i) grant any interest in the MPAG Patents or MPAG Know-How which is inconsistent with the terms and conditions of this License Agreement, or (ii) other than in connection with a Change of Control, assign its right, title or interest in or to the MPAG Enabling Patents, MPAG Enabling Know-How, MPAG Products Patents, MPAG Products Know-How, Joint IP, New Manufacturing IP or Option Period Manufacturing IP to any Third Party in a manner which is inconsistent with the terms and conditions of this License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">if, at any time during the Term it becomes aware that it, any of its Affiliates, or any employee, agent or subcontractor of MPAG who participated, or is participating, in the performance of any activities hereunder or who is otherwise engaged in any activities in connection with the MPAG Compounds or Products is on, or is being added to the FDA Debarment List or any of the three (3) FDA Clinical Investigator Restriction Lists referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, it will provide written notice of this to Novartis within &#91;***&#93; of its becoming aware of this fact&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it shall maintain insurance with respect to its activities and obligations under this License Agreement in such amounts as are commercially reasonable in the industry for companies conducting similar business and shall require any of its Affiliates undertaking activities under this License Agreement to do the same&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">during the Term, MPAG shall not, without the prior written consent of Novartis, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Covenants of Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis covenants and agrees that&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">during the Term, Novartis will not assign its right, title or interest in or to the Joint IP, New Manufacturing IP or Option Period Manufacturing IP to any Third Party in a manner which is inconsistent with the terms and conditions of this License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">if, at any time during the Term it becomes aware that it or any employee, agent or subcontractor of Novartis who participated, or is participating, in the performance of any activities hereunder or who is otherwise engaged in any activities in connection with a MPAG Compound or Product is on, or is being added to the FDA Debarment List or any of the three (3) FDA Clinical Investigator Restriction Lists referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, it will provide written notice of this to MPAG within &#91;***&#93; of its becoming aware of this fact&#59; and</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it shall maintain insurance with respect to its activities and obligations under this License Agreement in such amounts as are commercially reasonable in the industry for companies conducting similar business and shall require any of its Affiliates undertaking activities under this License Agreement to do the same.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">No Other Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. EXCEPT AS EXPRESSLY STATED IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION&#160;14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; (A)&#160;NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF NOVARTIS OR MPAG&#59; (B)&#160;ALL OTHER CONDITIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT&#59; AND (C) NOVARTIS EXPRESSLY DISCLAIMS ANY REPRESENATION AND MAKES NO WARRANTY THAT ANY OF THE NOVARTIS&#8217; DEVELOPMENT ACTIVITIES CONDUCTED UNDER THIS LICENSE AGREEMENT WILL RESULT IN, OR CONTRIBUTE TO, THE SUCCESSFUL COMPLETION OF A CLINICAL TRAL OR REGULATORY APPROVAL OF A MPAG COMPOUND OR PRODUCT.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">INDEMNIFICATION&#59; LIABILITY</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification by MPAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MPAG shall indemnify and hold Novartis, its Affiliates, and their respective officers, directors, and employees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from any and all liabilities, damages, losses, costs, or expenses of any nature (including reasonable attorneys&#8217; fees and litigation expenses) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) incurred by or imposed upon the Novartis Indemnitees or any of them in connection with any Claim to the extent arising or resulting from&#58; (a) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, MPAG&#8217;s, or any of its Affiliates&#8217;, sublicensees&#8217; or contractors&#8217; actions in connection with the Development of the MPAG Compounds or Products prior to the Effective Date&#59; (b)(i) the MPAG Produced Purchased Inventory that fails to conform to the representations and warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or (ii) MPAG&#8217;s, or any of its Affiliates&#8217;, sublicensees&#8217; or contractors&#8217; actions or omissions in connection with the supply of the MPAG Produced Purchased Inventory&#59; (c)&#160;the gross negligence or willful misconduct of MPAG or any MPAG Indemnitee&#59; or (d) the material breach of any provision of this License Agreement or a Pharmacovigilance Agreement or Quality Agreement by MPAG&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that MPAG shall not be obliged to so indemnify and hold harmless the Novartis Indemnitees for any Claims to the extent that such Claims arise from the breach, negligence, or willful misconduct of Novartis or any Novartis Indemnitee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification by Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall indemnify and hold MPAG, its Affiliates, their respective officers, directors, and employees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPAG Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from any and all Losses incurred by or imposed upon the MPAG Indemnitees or any of them in connection with any Claim, in each case, to the extent arising or resulting from&#58; (a) Novartis&#8217;, or any of its Affiliates&#8217;, sublicensees&#8217; or contractors&#8217; actions in connection with the Development, Manufacture or Commercialization of the MPAG Compounds or Products&#59; (b) the gross negligence or willful misconduct of Novartis or any Novartis Indemnitee&#59; (c) an MPAG Ongoing Clinical Trial&#59; or (d) the material breach of any provision of this License Agreement or a Pharmacovigilance Agreement or Quality Agreement by Novartis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Novartis shall not be obliged to so indemnify and hold harmless the MPAG Indemnitees for any Claims to the extent that such Claims arise from the breach, negligence, or willful misconduct of MPAG or any MPAG Indemnitee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If any of the Novartis Indemnitees or MPAG Indemnitees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) receives written notice of the commencement of any Claim, and such Indemnified Party intends to seek indemnification pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Indemnified Party shall promptly provide </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis (if such Indemnified Party is a Novartis Indemnitee) or MPAG (if such Indemnified Party is a MPAG Indemnitee) written notice of such Claim, and such Party shall provide the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with written notice of such Claim within &#91;***&#93; of its receipt of notice from the Indemnified Party, stating the nature, basis and the amount thereof, to the extent known, along with copies of the relevant documents evidencing such Claim and the basis for indemnification sought. Failure of the Indemnified Party to give such notice within the time frame specified will not relieve the Indemnifying Party from its indemnification obligations hereunder, except to the extent that the Indemnifying Party is actually prejudiced thereby.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Indemnifying Party will have &#91;***&#93; from receipt of any such notice of a Claim to give notice to assume the defense, appeal or settlement proceedings thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the Indemnifying Party shall only be permitted to assume the defense of a Claim if it admits that it is liable to indemnify the Indemnified Party in respect of the Claim. If notice to the effect set forth in the immediately preceding sentence is given by the Indemnifying Party, the Indemnifying Party will have the right to assume the defense, appeal or settlement proceedings of the Indemnified Party against the Claim with counsel of its choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Indemnifying Party may not assume the defense, appeal or settlement of a Claim&#58; (i) involving any criminal proceeding, action, indictment, allegation or investigation&#59; (ii) in which relief other than monetary damages is sought&#59; or (iii) if the Claim relates to taxes. In addition, the Indemnifying Party may not maintain the defense of a Claim if it has failed to defend such Claim in good faith. So long as the Indemnifying Party has assumed the defense, appeal or settlement proceedings of the Claim in accordance herewith, (x)&#160;the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense, appeal or settlement proceedings of the Claim, and (y) the Indemnifying Party shall not admit to any wrongdoing by the Indemnified Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Indemnifying Party shall have the right to settle any Claim for which&#58; (i) the Indemnifying Party is responsible for &#91;***&#93; of the applicable Losses under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; and (ii) the Indemnifying Party obtains a full release of the Indemnified Party with respect to such Claim or to which settlement the Indemnified Party consents in writing (such consent not to be unreasonably withheld, conditioned or delayed). As to any Claim with respect to which the Indemnifying Party does not assume control of the defense, the Indemnified Party will afford the Indemnifying Party an opportunity to participate in such defense, at its cost and expense, and will consult with the Indemnifying Party prior to settling or otherwise disposing of any of the same. The Indemnified Party and the Indemnifying Party will act in good faith in responding to, defending against, settling or otherwise dealing with Claims. The Indemnified Party and the Indemnifying Party will also cooperate in any such defense, appeal or settlement proceedings, and give each other reasonable access to all information relevant thereto. Whether or not the Indemnifying Party has assumed the defense, appeal or settlement proceedings with respect to a Claim, such Indemnifying Party will not be obligated to indemnify the Indemnified Party for (1)&#160;any settlement entered into or any judgment that was consented to without the Indemnifying Party&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) or (2) any Losses not indemnifiable pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Survival of Option Agreement Indemnification Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary herein or in the Option Agreement, Article 11 of the Option Agreement survives expiration or termination of the Option Agreement and applies to Claims (as defined under the Option Agreement) arising under the Option Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Mitigation of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing in this </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Special, Indirect and Other Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">No Exclusion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party excludes any liability for death or personal injury caused by its negligence or that of its employees, agents or sub-contractors.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">PUBLICATIONS AND PUBLICITY</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In the event that Novartis proposes to make any scientific or other publication or presentation regarding a MPAG Compound or Product, Novartis shall provide MPAG with an advance copy of each proposed publication or presentation at least &#91;***&#93; prior to its proposed date of publication or presentation. MPAG shall have &#91;***&#93; to review and provide any comments on the proposed publication or presentation and Novartis shall consider such comments in good faith. In any event, Novartis shall comply with any request to delete reference to MPAG&#8217;s Confidential Information from such publication or presentation and will withhold publication or presentation for an additional &#91;***&#93; if so requested by MPAG, in order to permit MPAG to obtain Patent Right protection in accordance with the terms of this License Agreement. Novartis shall reasonably acknowledge MPAG&#8217;s contribution and authorship according to customary standards. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">MPAG shall not be permitted to make any scientific or other publication or presentation regarding a MPAG Compound or Product without Novartis&#8217; prior written consent&#59; provided that, the foregoing restriction shall not apply MPAG&#8217;s to ability to make any publications or presentations&#58; (i) which relate to &#91;***&#93;, or (ii) where the initial draft of such publication was first submitted for review by Novartis prior to the Effective Date. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, neither Party shall use the name, symbol, trademark, trade name or logo of the other Party or any of its Affiliates in any press release, publication or other form of public disclosure without the prior written consent of the other Party (such consent not to be unreasonably withheld or delayed), except for those disclosures for which consent has already been obtained.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;16.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each Party agrees not to issue any press release or other public statement, whether oral or written, disclosing the existence of this License Agreement, the terms hereof or any information relating to this License Agreement without the prior written consent of the other Party&#59; provided that following execution of this License Agreement MPAG shall be permitted to issue a press release in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this License Agreement that has already been publicly disclosed by such Party or by the other Party in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable and commercially justifiable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;16,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Novartis may issue press releases and other public statements as it deems appropriate in connection with the Development and Commercialization of MPAG Compounds or Products under this License Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Novartis shall first provide MPAG with an advance copy of each proposed press release or public statement at least &#91;***&#93; prior to its proposed date of publication or presentation, it being understood that such provision by Novartis shall be for informational purposes only&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Novartis shall reasonably consider any comments that MPAG may have on such press release or public statement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding the foregoing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each Party may make any disclosures required of it to comply with any duty of disclosure it may have pursuant to Applicable Law or governmental regulation or pursuant to the rules of any recognized stock exchange. In the event of a disclosure required by Applicable Law, governmental regulation or the rules of any recognized stock exchange, the Parties shall coordinate with each other with respect to the timing, form, and content of such required disclosure. If so requested by the other Party, the Party subject to such obligation shall use commercially reasonable efforts to obtain an order protecting to the maximum extent possible the confidentiality of such provisions of this License Agreement as reasonably requested by the other Party. If the Parties are unable to agree on the form or content of any required disclosure, such disclosure shall be limited to the minimum required as determined by the disclosing Party in consultation with its legal counsel. Without limiting the foregoing, each Party shall consult with the other Party and reasonably cooperate with the other Party on the provisions of this License Agreement, together with Exhibits, Schedules or other attachments attached hereto, to be redacted in any filings made by MPAG or Novartis with the Securities and Exchange Commission (or other regulatory body) or as otherwise required by law.</font></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party may assign or transfer this License Agreement or its rights and obligations under this License Agreement without the other Party&#8217;s prior written consent, except that&#58; (a)&#160;either Party may assign or transfer this License Agreement or its rights and obligations under this License Agreement or any part hereof to one (1) or more of its Affiliates without the consent of the other Party&#59; and (b)&#160;either Party may assign or transfer this License Agreement in its entirety to a successor to all or substantially all of its business or assets to which this License Agreement relates, whether by merger, sale of stock, sale of assets, or otherwise without the consent of the other Party. The assigning Party shall provide the other Party with prompt written notice of any such assignment. Any permitted assignee shall assume all obligations of its assignor under this License Agreement (or related to the assigned portion in case of a partial assignment to an Affiliate), and no permitted assignment shall relieve the assignor of liability hereunder. Any attempted assignment in contravention of the foregoing shall be void. Subject to the terms of this License Agreement, this License Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Change of Control Event Involving MPAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event MPAG is subject to a Change of Control, it will provide written notice to Novartis within &#91;***&#93; following the closing of such Change of Control, and such notice will identify the Third Party acquiring company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the contact information of the person at the Acquirer with whom Novartis will work to schedule meetings between the Acquirer and Novartis. Promptly following the closing of such Change of Control, MPAG or the Acquirer will meet or hold a teleconference with Novartis at a mutually agreed date, time and place to discuss any possible impacts of the Change of Control for this License Agreement and, if Novartis has </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">elected to terminate this License Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;12.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the orderly transition of all Development, Manufacture, and Commercialization activities of the Terminated Products to MPAG, the Acquirer or an Affiliate or designee. Notwithstanding anything to the contrary herein, in the event of a Change of Control of MPAG, the intellectual property rights of the Acquirer (and its Affiliates existing prior to the Change of Control or thereafter other than MPAG), whether controlled prior to the Change of Control or developed independently of this License Agreement, will not be included in the Products IP, the Enabling IP, or the Trademarks licensed by MPAG to Novartis hereunder.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Extension to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall have the right to extend the rights, licenses, immunities, and obligations granted in this License Agreement to one or more of its Affiliates. All applicable terms and provisions of this License Agreement shall apply to any such Affiliate to which this License Agreement has been extended to the same extent as such terms and provisions apply to such Party, and such Party shall remain fully liable for any acts or omissions of such Affiliates in breach thereof.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Should one (1) or more of the provisions of this License Agreement become invalid or unenforceable as a matter of law, then this License Agreement shall be construed as if such provision were not contained herein and the remainder of this License Agreement shall be in full force and effect, and the Parties will use their commercially reasonable efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except with respect to the Transition Plan which shall be governed by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in the event of any disputes, controversies or differences between the Parties, arising out of, in relation to, or in connection with this License Agreement, including any alleged failure to perform, or breach, of this License Agreement, or any issue relating to the validity, construction, interpretation, enforceability, breach, performance, application, or termination of this License Agreement a (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then upon the written request of either Party, the Parties agree to a meeting of the appropriate subject matter expert at each Party, as determined by each Party&#8217;s Alliance Director, and discuss in good faith an amicable resolution thereof. If the Dispute is not resolved within &#91;***&#93; following the written request for amicable resolution, then either Party may then escalate the matter to the Chief Executive Officer of each of Novartis and MPAG. If the Chief Executive Officers of the Parties cannot resolve the Dispute within &#91;***&#93; following escalation thereto for amicable resolution, then either Party may initiate arbitration under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any disputes concerning the propriety of initiating arbitration or the scope or applicability of the agreement to arbitrate shall be determined by arbitration.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.05pt">Governing Law and Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This License Agreement shall be governed by, and interpreted in accordance with, the substantive laws of Switzerland (excluding its rules on conflict of laws and excluding the UN Convention on Contracts for the International Sale of Goods). Any Dispute, shall be resolved by arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers&#8217; Arbitration Institution in force on the date on which the Notice of Arbitration is submitted in accordance with these Rules. The number of arbitrators shall be three&#59; the seat of the arbitration shall be Zurich, Switzerland&#59; the arbitral proceedings shall be conducted in English. Notwithstanding the foregoing, inventorship of any invention conceived or reduced to practice by either Party or jointly by the Parties pursuant to the License Agreement, shall follow the rules of the Laws of the U.S. (without reference to any conflict of law principles). The arbitration award shall be final and binding on the Parties and the Parties undertake to carry out any award without delay. Judgment upon the award may be entered in any court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that irreparable damage would occur if any provision of this License Agreement were not performed in accordance with the terms hereof and that each Party shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which it is entitled at law or in equity. It is therefore agreed that each Party shall be entitled to seek a temporary, </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">preliminary and&#47;or permanent injunction or injunctions to prevent breaches of this License Agreement and to enforce specifically the performance of the terms of this License Agreement, without posting any bond or other undertaking, in addition to any other remedy to which they are entitled at law or in equity, and if any action should be brought in equity to enforce any of the provisions of this License Agreement, the other Party shall not raise the defense that there is an adequate remedy at law.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party shall be responsible to the other Party for any failure or delay in performing any of its obligations under this License Agreement or for other nonperformance hereunder if such delay or nonperformance is caused by strike, stoppage of labor, lockout or other labor trouble, fire, flood, epidemic, pandemic, accident, war, act of terrorism, act of God or of the government of any country or of any local government, or by any other cause unavoidable or beyond the control of any Party hereto. In such event, the Party affected will use commercially reasonable efforts to resume performance of its obligations.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this License Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this License Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing contained in this License Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between MPAG and Novartis, or to constitute one as the agent of the other. Each Party shall act solely as an independent contractor, and nothing in this License Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All notices, consents, waivers, and other communications under this License Agreement must be in writing and will be deemed to have been duly given when&#58; (a)&#160;delivered by hand (with written confirmation of receipt)&#59; or (b)&#160;when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), in each case, to the appropriate addresses set forth below (or to such other addresses as a Party may designate by notice)&#58;</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:7.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to MPAG&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Novartis&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis and MPAG each hereby covenant and agree, without the necessity of any further consideration, to execute, acknowledge and deliver any and all such other documents and take </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any such other action as may be reasonably necessary to carry out the intent and purposes of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall perform its obligations under this License Agreement in accordance with all Applicable Laws. No Party shall, or shall be required to, undertake any activity under or in connection with this License Agreement which violates, or which it believes, in good faith, may violate, any Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of this License Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights to any Third Party (including any Third Party beneficiary rights).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This License Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of this License Agreement and, in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise expressly provided in this License Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This License Agreement, together with its Schedules and Exhibits and the Pharmacovigilance Agreement(s) and Quality Agreement(s), sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. The Parties agree that the Option Agreement is hereby expired (in accordance with Section&#160;9.1(a) thereof) as of the Effective Date, but (a) each Party&#8217;s information that was the subject of confidentiality obligations under the Option Agreement shall been deemed to be Confidential Information of such Party under this License Agreement and (b)&#160;indemnification obligations under Article 11 of the Option Agreement survive and apply to Claims (as defined under the Option Agreement) arising under the Option Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This License Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This License Agreement may be executed by facsimile or electronically transmitted signatures (including .pdf) and such signatures shall be deemed to bind each Party hereto as if they were original signatures.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No remedy referred to in this License Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this License Agreement or otherwise available under law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264813180 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i2e72dd0eb7b6468fa17739133421dc6e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to be executed by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:21.6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.336%"><tr><td style="width:1.0%"></td><td style="width:48.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOVARTIS PHARMA AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:123.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to be executed by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:21.6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.336%"><tr><td style="width:1.0%"></td><td style="width:48.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOVARTIS PHARMA AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:123.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to be executed by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:21.6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.336%"><tr><td style="width:1.0%"></td><td style="width:48.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOVARTIS PHARMA AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="height:123.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="i2e72dd0eb7b6468fa17739133421dc6e_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MPAG COMPOUNDS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#91;PURPOSEFULLY BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PURCHASED INVENTORY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">DEVELOPMENT PLAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT E</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SAMPLE INVOICE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="i2e72dd0eb7b6468fa17739133421dc6e_10"></div><hr style="page-break-after:always"><div style="min-height:88.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT F</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MPAG PATENTS</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:148%;text-decoration:underline">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="i2e72dd0eb7b6468fa17739133421dc6e_13"></div><hr style="page-break-after:always"><div style="min-height:88.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT G</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PRESS RELEASE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="i2e72dd0eb7b6468fa17739133421dc6e_16"></div><hr style="page-break-after:always"><div style="min-height:88.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE 13.2(C) </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESOLUTION OF TRANSIITION PLAN AGREEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:100.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:88.56pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE 14.2 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MPAG DISCLOSURES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:100.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>7
<FILENAME>a45molecularpartners-novar.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i98c33ecaa77f446ea2740a77c0c1ae25_1"></div><div style="min-height:131.04pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.5</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#00ff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;  &#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________________________________________________________</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BY AND BETWEEN</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">NOVARTIS PHARMA AG</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AND</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________________________________________________________</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This LICENSE AND COLLABORATION AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made as of this 13th day of December 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and between Novartis Pharma AG, located at Lichtstrasse 35, CH-4056 Basel, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Molecular Partners AG, located at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Novartis and Licensor are each referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Novartis and Licensor desire to enter into a Collaboration (as defined below) under which Licensor will generate Research Compounds (defined below) specific for particular molecular targets for further development and commercialization by Novartis&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Licensor owns or otherwise Controls the Licensor Technology (as defined below) relating to the Licensed Compounds (as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Novartis wishes to obtain, and Licensor wishes to grant, rights to Licensed Compounds and Products (as defined below) in the Field (as defined below)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Novartis will have the right to develop and commercialize Products on a worldwide basis in the Field (defined below), subject to paying Licensor the royalty and milestone payments set out or otherwise agreed herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:56.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">DEFINITIONS AND INTERPRETATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the IFRS (International Financial Reporting Standards) as generally and consistently applied throughout each Party&#8217;s organization. Each Party shall promptly notify the other Party in the event that it changes the Accounting Standards pursuant to which its records are maintained, it being understood that each Party may only use internationally recognized accounting principles (e.g., IFRS, US GAAP, etc).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means 21 C.F.R. &#167;&#167;600-680.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to a Licensed Compound a binding affinity to the applicable Target of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, any entity or person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, &#8220;control&#8221; or &#8220;controlled&#8221; means, direct or indirect, ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors in the case of a corporation or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity&#59; status as a general partner in any partnership&#59; or any other arrangement whereby the entity or person controls or has the right to control the board of directors or </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 2</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">equivalent governing body of a corporation or other entity or the ability to cause the direction of the management or policies of a corporation or other entity. The Parties acknowledge that in the case of entities organized under the laws of certain countries where the maximum percentage ownership permitted by law for a foreign investor is less than fifty percent (50%), such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement Patent Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.4(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 4.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean Net Sales of Product(s) in a Calendar Year.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7.4(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorized Biosimilar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Biosimilar Product marketed or sold by one or more Third Party(ies) who have not (a) obtained a license or sublicense from Novartis, any of its Affiliates or any of their sublicensees for the marketing or sale of such Biosimilar Product or (b) procured such Biosimilar Product through a chain of distribution that includes Novartis, any of its Affiliates or any of their sublicensees, except, in each case ((a) and (b)), to the extent that such license, sublicense, or chain of distribution was obtained or procured, as applicable, as a result of settlement of a patent dispute.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in a particular country with respect to a particular Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reference Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), any biopharmaceutical product that&#58; (a) has received all necessary approvals by the applicable Regulatory Authorities in such country to market and sell such product as a biopharmaceutical product through reference to the MAA and Regulatory Approval of the Reference Product&#59; (b) is marketed or sold in such country by a Third Party that (i) has not obtained the rights to market or sell such product as a sublicensee or distributor of Novartis or any of its Affiliates or sublicensees, including pursuant to a license or settlement in connection with litigation with Novartis, its Affiliate or a sublicensee under the Biologics Price Competition and Innovation Act of 2009 or an equivalent under foreign law and (ii) did not purchase such product in a chain of distribution that included Novartis or any of its Affiliates or sublicensees&#59; and (c) is approved as (i) a &#8220;biosimilar&#8221; (as defined in the United States under 42 U.S.C. &#167; 262(i)(2)) of the Reference Product, (ii) a &#8220;similar biological medicinal product&#8221; (in the EU in accordance with Directive 2001&#47;83&#47;EC) with respect to which the Reference Product is the &#8220;reference medicinal product,&#8221; or (iii) if not in the US or EU, the foreign equivalent of a &#8220;biosimilar&#8221; or &#8220;similar biological medicinal product&#8221; of such Reference Product&#59; in each case, for use in such country pursuant to an expedited regulatory approval process governing approval of generic biologics based on the then-current standards for regulatory approval in such country (e.g., the Biologics Price Competition and Innovation Act of 2009 or an equivalent under foreign law).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Biologics License Application as defined in the Act and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Budget Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.8(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any day that is not a Saturday, Sunday or other day on which commercial banks are authorized or required to be closed, as the case may be, in Basel, Switzerland or Cambridge, Massachusetts.</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 3</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31&#59; provided, that&#58; (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first such three (3)-month period thereafter&#59; and (b) the final Calendar Quarter of the Term shall extend from the first day of such three (3)-month period until the last day of the Term.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.3.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a period of twelve (12) consecutive calendar months ending on December 31&#59; provided, that&#58; (a) the first Calendar Year of the Term shall extend from the Effective Date to December 31&#59; and (b) the final Calendar Year of the Term shall extend from January 1 until the last day of the Term.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Candidate DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Research Compounds selected by Novartis pursuant to Section&#160;2.4 that are not identified as a Development Candidate.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following events&#58; (a) any Third Party (or group of Third Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of Licensor normally entitled to vote in elections of directors&#59; (b) Licensor consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into Licensor, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of the outstanding shares of Licensor preceding such consolidation or merger&#59; or (c) Licensor conveys, transfers or leases all or substantially all of its assets to any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Third Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any clinical trial in humans, including any Phase I Clinical Trial, Phase II Clinical Trial,  phase IIa clinical trial, phase IIb clinical trial, phase III clinical trial, Pivotal Trial, or any post-approval clinical trial in humans.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section&#160;10.2(c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combination Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the definition of Net Sales.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6.3.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6.3.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to market, promote, distribute, import, export, offer to sell and&#47;or sell a product and&#47;or conduct other commercialization, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means commercialization activities relating to a product, including activities relating to marketing, promoting, distributing, importing, exporting, offering for sale and&#47;or selling a product.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, diligent, good-faith efforts to accomplish such objective &#91;***&#93;, it being understood and agreed that, with respect to the manufacture, Development, </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 4</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">processing and Commercialization of a Product, such efforts shall be substantially equivalent to those efforts and resources commonly used &#91;***&#93;, taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of Regulatory Approval given the regulatory structure involved, the profitability, and other relevant factors commonly considered in similar circumstances. It is anticipated that the level of effort may change over time, reflecting changes in the status of a Product.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the JSC, the JRDC, or any other subcommittee formed by the JSC pursuant to Section&#160;4.2(b)(v).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How and other proprietary information and data of a financial, commercial or technical nature which the disclosing Party or any of its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has supplied or otherwise made available to the other Party or any of its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), whether made available orally, in writing or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement. Notwithstanding the foregoing the existence of, and the terms and conditions of, this Agreement shall be considered Confidential Information of each of Licensor and Novartis.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Know-How, Patent Rights, other intellectual property rights, or any proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise) of a Party to grant a license or a sublicense of or under such Know-How, Patent Rights, or intellectual property rights to another Person, or to otherwise disclose such proprietary or trade secret information to another Person, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.4(c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to given product (or component thereof) and Patent Right, that a Valid Claim of such Patent Right would, absent a license thereunder or ownership thereof, be infringed by the making, having made, use, sale, offer for sale or importation of such product or component, and for purposes of determining such infringement, considering claims of pending patent applications as Valid Claims (to the extent such claims would otherwise constitute Valid Claims) as if they have already been issued.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DARPin Binding Domain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an ankyrin repeat domain &#91;***&#93; that &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DC Selection Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.4.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 12.1(g).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means drug research and development activities, including test method development and stability testing, assay development and audit development, toxicology, formulation, quality assurance&#47;quality control development, technical development, process development, statistical analysis, pre-clinical and clinical studies, packaging development, regulatory affairs, and the preparation, filing and prosecution of BLAs and MAAs. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Candidate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Research Compound that is&#58; (i) selected for further Research and Development based on the achievement of the following, as reasonably determined by &#91;***&#93; and (ii) identified in a written notice to Licensor by Novartis pursuant to Section&#160;2.4. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Candidate Selection Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.3.</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 5</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the milestones relating to the Product as set forth in Section 6.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the payments to be made by Novartis to Licensor upon the achievement of the corresponding Development Milestone Events as set forth in Section 6.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diagnostic Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the diagnosis &#91;***&#93; of any human disease or disorder.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the definition of Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency or any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Encumbrance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, option, license, assignment, power of sale, retention of title, right of pre-emption, right of first refusal or security interest of any kind.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for Novartis, the &#91;***&#93;, and for Licensor, its &#91;***&#93;, in each case, or designees with similar authority thereto. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 4.6(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expedited Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 15.6.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration or any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Therapeutic Field and Diagnostic Field. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product, the first sale of such Product by Novartis, its Affiliate, or their sublicensee to a Third Party or governmental authority in a country following Regulatory Approval for sale of such Product in such country. Sales or transfers of reasonable quantities of a Product for Development, including proof of concept studies or other clinical trial purposes, or for compassionate or similar use, shall not be considered a First Commercial Sale.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Interpretable Results&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means, with respect to a Clinical Trial, the set of clinical and non-clinical data (if applicable) from such Clinical Trial that are set forth as constituting the first interpretable results in the applicable Clinical Trial protocol.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Patient First Dose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FPFD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date of the administration of the first dose of a Licensed Compound or Product to the first patient (or healthy subject, as relevant) while such healthy subject or volunteer is participating in a Clinical Trial.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 15.7.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a full-time employee or, in the case of less than a full-time employee, a full-time equivalent employee year, carried out by an appropriately qualified employee of a Party or any of its Affiliates directly engaged in the activities under the Research Plan, based on &#91;***&#93;. For clarity, indirect personnel (including support functions such as managerial, financial, legal or business development) shall not constitute FTEs.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any period, the FTE Rate multiplied by the number of FTEs in such period. </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 6</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the rate of &#91;***&#93; per FTE per year. For the avoidance of doubt, the FTE Rate shall be the fully-burdened rate and includes the &#91;***&#93;. Notwithstanding the foregoing, for any Calendar Year during the Term that is less than a full year, the above referenced rate will be proportionately reduced to reflect such portion of such full Calendar Year.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Human Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.12.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 15.5(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Investigational New Drug application in the US filed with the FDA or the corresponding application for the investigation of pharmaceutical products in any other country or group of countries, as defined in the applicable Laws and filed with the Regulatory Authority of a given country or group of countries.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 13.3(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 13.3(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 13.3(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in relation to either Party, any of the following&#58; (a) that Party becomes Insolvent&#59; (b) that Party shall commence any case, proceeding or other action (i) under any existing or future law of any jurisdiction relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it a bankrupt or Insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (ii) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or any such Party shall make a general assignment for the benefit of its creditors&#59; (c) there shall be commenced against such Party any case, proceeding or other action of a nature referred to in clause (b) above that (I) results in the entry of an order for relief or any such adjudication or appointment or (II)&#160;remains undismissed, undischarged or unbonded for a period of &#91;***&#93;&#59; (d) there shall be commenced against such Party any case, proceeding or other action seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of its assets that results in the entry of an order for any such relief that shall not have been vacated, discharged, or stayed or bonded pending appeal within &#91;***&#93; from the entry thereof&#59; or (e) such Party shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clauses (b), (c) or (d) above.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insolvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in relation to either Party, that&#58; (a) the sum of such Party&#8217;s debts is greater than all of such Party&#8217;s property, at a fair valuation&#59; (b) such Party shall generally not, or shall be unable to, or shall admit in writing its inability to, pay its debts as they become due&#59; or (c) the Party&#8217;s external auditor includes in their opinion of the financial statements a going concern qualification.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How, Patent Rights, trademarks, copyrights, trade secrets, and any other intellectual property rights however denominated throughout the world.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any invention, discovery or other Know-How that is discovered, generated, conceived or reduced to practice by or on behalf of a Party or its Affiliate or sublicensee through activities conducted under this Agreement (which, for clarity, includes any Development, manufacture or Commercialization of a Research Compound, Licensed Compound or Product and all activities under </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 7</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Research Plan), including all right, title and interest in and to the intellectual property rights therein and thereto.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.8(c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.1(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.1(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.1(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Product Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Joint Patent Right that specifically claims a Licensed Compound or Product or any use or method of manufacture thereof.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Research and Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the committee established as set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the committee established as set forth in Section&#160;4.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials (including cell lines and other biological materials), expertise and other technology applicable to compounds, formulations, compositions, products or to their manufacture, development, registration, use or commercialization or methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof, relevant to the development, manufacture, use or commercialization of or which may be useful in studying, testing, development, production or formulation of products, or intermediates for the synthesis thereof. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order by any governmental authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law, including GCP, GMP, and GLP, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means a compound generated in the course of the Collaboration that (a)&#160;comprises one or more DARPin Binding Domains directed to a Target that have been selected as a DC or a Candidate DC pursuant to Section 2.4, as well as &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">all such DARPin Binding Domains meet the Activity Threshold&#59; and (b) does not include any &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 13.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How owned or otherwise Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term relating to the Licensed Compounds or a Product that is necessary or reasonably useful for the Research, Development, manufacture, preparation, use or Commercialization of the Licensed Compounds or Products in the Field. Notwithstanding the foregoing, (a) Licensor Know-How will, subject to Section 6.6(b), include Know-How within Third Party IP and (b) if any Third Party becomes an Affiliate of Licensor after the Effective Date, Licensor </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 8</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know-How will exclude any Know-How that was Controlled by such Third Party (or its Affiliates in existence prior to such transaction) before such Third Party became Licensor&#8217;s Affiliate or that is acquired by such Third Party (or its Affiliates in existence prior to such transaction) independently of this Agreement and without use, practice or reference to Novartis&#8217;s Confidential Information&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the foregoing clause (b) will not apply where such Know-How Controlled by such Third Party is incorporated by Licensor into the collaboration, or otherwise utilized or relied on by Licensor in its performance of the Collaboration.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Patent Rights identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and, any other Patent Rights owned or otherwise Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term that are necessary or reasonably useful for the Research, Development, manufacture, preparation, use or Commercialization of the Licensed Compounds or Products in the Field. Licensor shall update </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> as necessary from time to time to reflect the then-current Licensor Patent Rights. For the avoidance of doubt, any Joint Patent Rights shall not be deemed Licensor Patent Rights for purposes of this Agreement. Notwithstanding the foregoing, (a) Licensor Patent Rights will, subject to Section 6.6(b) include Patent Rights within Third Party IP and (b) if any Third Party becomes an Affiliate of Licensor after the Effective Date, Licensor Patent Rights will exclude any Patent Rights that are Controlled by such Third Party (or its Affiliates in existence prior to such transaction) before such Third Party became Licensor&#8217;s Affiliate or that are filed or acquired by such Third Party (or its Affiliates in existence prior to such transaction) independently of this Agreement and without use, practice or reference to Novartis&#8217;s Confidential Information&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the foregoing clause (b) will not apply where the Invention Covered by such Patent Rights Controlled by such Third Party is incorporated by Licensor into the collaboration, or otherwise utilized or relied on by Licensor in its performance of the Collaboration.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Licensor Know-How and the Licensor Patent Rights. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product on a country-by-country basis, the Net Sales of such Product in that country in any Calendar Year are less than &#91;***&#93; as compared with the Net Sales of such Product in that country in the Calendar Year preceding the marketing or sale of the first Biosimilar Product of such Product.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all liability, damage, loss, cost or expense of any nature (including reasonable attorney&#8217;s fees and litigation expenses).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an application for the authorization to market the product in any country or group of countries outside the United States, as defined in the applicable Laws and filed with the Regulatory Authority of a given country or group of countries. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Major Markets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.10.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Development Milestone Event or a Commercial Milestone Event.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Development Milestone Payment or a Commercial Milestone Payment. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the net sales recorded by Novartis or any of its Affiliates or their sublicensees (excluding, for clarity, any distributors or wholesalers) for any Product sold to Third Parties other than sublicensees as determined in accordance with Novartis&#8217; Accounting Standards as consistently applied, </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 9</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">less a deduction of &#91;***&#93; for direct expenses related to the sales of the Product, distribution and warehousing expenses and uncollectible amounts on previously sold products. The deductions booked on an accrual basis by Novartis and its Affiliates under its Accounting Standards to calculate the recorded net sales from gross sales include the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;normal trade and cash discounts&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;amounts repaid or credited by reasons of defects, rejections, recalls or returns&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;rebates and chargebacks to customers and other Third Parties (including Medicare, Medicaid, Managed Healthcare and similar types of rebates)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;amounts provided or credited to customers through coupons and other discount programs&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates or retroactive price reductions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;fee for service payments to customers for any non-separable services (including compensation for maintaining agreed inventory levels and providing information)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;other reductions or specifically identifiable amounts deducted for reasons similar to those listed above in accordance with Novartis&#8217; Accounting Standards.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to the calculation of Net Sales&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Net Sales only include the value charged or invoiced on the first arm&#8217;s length sale to a Third Party. Sales between or among Novartis and its Affiliates and sublicensees shall be disregarded for purposes of calculating Net Sales&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If a Product is delivered to the Third Party before being invoiced (or is not invoiced), Net Sales will be calculated at the time all the revenue recognition criteria under Novartis&#8217; Accounting Standards are met&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;In the event that the Product is sold in a finished dosage form containing the Licensed Compound in combination with one (1) or more other active ingredients (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Net Sales will be calculated by multiplying the Net Sales of the Combination Product by the fraction, A&#47;(A+B) where A is the weighted (by sales volume) average sale price in the relevant country of the Product containing the Licensed Compound as the sole active ingredient in finished form, and B is the weighted average sale price (by sales volume) in that country of the product(s) containing the other component(s) as the sole active ingredient(s) in finished form. Regarding prices comprised in the weighted average price when sold separately referred to above, if these are available for different dosages from the dosages of Licensed Compound and other active ingredient components that are included in the Combination Product, then &#91;***&#93;. If the weighted average sale price cannot be determined for the Product or other product(s) containing the single Licensed Compound or component(s), the calculation of Net Sales for Combination Products will be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Background Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How and Patent Rights that are owned or otherwise controlled by Novartis or any of its Affiliates, which Know-How and Patent Rights&#58; (a) are in </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 10</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">existence as of the Effective Date&#59; or (b) arise outside of activities under this Agreement after the Effective Date and without use, practice or reference to the Licensor Technology or Licensor&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 13.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;&#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93; Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.3(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Manufacturing Product Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all (a) manufacturing batch records, SOPs for any specific process, analytical methods and records, bills of materials, cell banks, plasmids, supply of reference standards and regulatory history, in each case, generated by or on behalf of Novartis, its Affiliates or sublicensees in the manufacture of any Reversion Product and (b) any other Know-How that is used by or on behalf of Novartis, its Affiliates or sublicensees in the manufacture of any Reversion Product, including all tangible biological materials, vectors, cell banks, cells (including any derivatives or progeny thereof), cell culture processes and purification processes, reference standards, and cell culture media.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Product Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all Patent Rights that are Controlled by Novartis or its Affiliates that Cover, or are used (as of the effective date of termination) by or on behalf of Novartis, its Affiliates or sublicensees in, the Development or Commercialization of any Reversion Product, (b) all (i) material pre-clinical data and results and (ii) clinical data and results, in each case of (i) and (ii), generated by or on behalf of Novartis, its Affiliates or sublicensees (including their contractors) in the Development of any Reversion Product, and (c) all other Know-How that is Controlled by Novartis or its Affiliates that is necessary for or is being used (as of the effective date of termination) by or on behalf of Novartis, its Affiliates or sublicensees (including their contractors) in, the Development or Commercialization of any Reversion Product&#59; provided, that if any Reversion Product is not being actively Developed or Commercialized by Novartis, its Affiliate or sublicensee as of the effective date of termination, then references in this definition to &#8220;as of the effective date of termination&#8221; shall be deemed to be references to the time that such Reversion Product stopped being actively Developed or Commercialized&#59; provided, further, that Novartis Product Technology shall exclude all Novartis Manufacturing Product Technology.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Out-of-Pocket Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to certain activities performed pursuant to this Agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Licensed Compound or Product in the Territory, including payments to contract personnel (including contractors, consultants and subcontractors), in each case, pursuant to the applicable Research Plan, and provided that such expenses are been recorded as income statement items in accordance with such Party&#8217;s Accounting Standards, and will not include &#91;***&#93;, or items intended to be covered by the FTE Rate.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the first paragraph of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7.1(c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7.1(c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all patents and patent applications, including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals, extensions, registrations, supplemental protection certificates, utility models, design patents and the like of any of the foregoing. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Categories</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 9.3(c).</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 11</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase I Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product, a clinical study of such product in patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies, as described in 21 C.F.R. &#167; 312.21(a) or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a clinical trial of an investigational product in patients with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, pharmacokinetics, and dosing information as described in 21 C.F.R. 312.21(b), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pharma Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a company that is, on its own behalf, engaged in the Research, Development or Commercialization of human medicinal products that are regulated as such and Pharma Investor shall exclude any entity that is involved in the application of venture capital or private equity funding whether or not it is an Affiliate of a Pharma Investor provided that such venture capital or private equity entity is operated independently of the Pharma Investor&#8217;s human medicinal products business. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pivotal Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a biopharmaceutical product that is designed to ascertain efficacy and safety of such product in support of the preparation and submission of an MAA for such product to a competent Regulatory Authority without the need for additional future Clinical Trials, regardless of whether such trial is referred to as a phase IIa, phase IIb, or phase III clinical trial.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Licensor&#8217;s proprietary DARPin Binding Domain platform technology, pursuant to which Licensor produces pharmaceutical product candidates, including the Research Compounds, utilizing DARPin Binding Domain libraries, protein modules, and domains.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Platform Patent Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will mean any Licensor Patent Right other than the Product Patent Rights, and including the Patent Rights scheduled in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(as may be updated from time to time), that Cover the Platform.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Privacy and Data Security Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Laws, including government-issued rules, guidelines, directives, and requirements, currently in effect and as they become effective, applicable to data protection and the processing of personal data or other sensitive information (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sensitive Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) under the Agreement that may exist in any relevant jurisdiction, including security breach notification laws, laws imposing minimum security requirements and laws requiring the secure disposal of recordings containing Sensitive Information. For the avoidance of doubt, Privacy and Data Security Laws include, to the extent applicable, and the European Data Protection Laws and the Health Insurance Portability and Accountability Act of 1996, as amended.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a product incorporating or comprising one or more Licensed Compounds in finished dosage pharmaceutical form, including, in each case, all formulations and modes of administration thereof.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.5.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Development Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 5.10(b).</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 12</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Patent Right conceived or reduced to practice by or on behalf of a Party or its Affiliates, or jointly by the Parties or their Affiliates during the term of the Agreement that specifically claims a Licensed Compound or Product or any use or method of manufacture thereof in the Therapeutic Field or in the Diagnostic Field. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.5.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prosecuting and Maintaining Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.3(c).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.12.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Qualifying Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Terminated Target, any Terminated Product that binds to such Terminated Target and for which Novartis, its Affiliate or sublicensee has achieved FPFD in a Phase I Clinical Trial prior to the applicable notice of termination.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Radioligand Therapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RLT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the use of radioligands in the Therapeutic Field and Diagnostic Field, in either or both of their labeled&#47;radioactive or unlabeled&#47;non-radioactive states.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the definition of Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reference Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the definition of Biosimilar Product. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product in any country or jurisdiction, any approval (including where required, pricing and reimbursement approvals), registration, license or authorization from a Regulatory Authority in a country or other jurisdiction that is necessary to market and sell such product in such country or jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval in Europe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Regulatory Approval in at least three (3) of the following countries&#58; France, Germany, Italy, Spain, and the United Kingdom.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any governmental agency or authority responsible for granting Regulatory Approvals for biopharmaceutical products or approvals for conducting clinical trials or manufacturing products, including the FDA, EMA, European Commission, and any corresponding national or regional regulatory authorities.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any rights or protections which are recognized, afforded or granted by the FDA or any other Regulatory Authority in any country or region of the Territory pursuant to applicable Laws of such country or region, in association with the marketing authorization of the Product, providing the Product&#58; (a) a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission, submitted by a Third Party seeking to market a Biosimilar Product of such Product, or (b) a period of data exclusivity, during which a Third Party seeking to market a Biosimilar Product of such Product is precluded from either referencing or relying upon, without an express right of reference from the dossier holder, the Product&#8217;s clinical dossier or relying on previous Regulatory Authority findings of safety or effectiveness with respect to such Product to support the submission, review or approval of a marketing authorization application or similar regulatory submission before the applicable Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a compound or a product, any submission to a Regulatory Authority of any appropriate regulatory application with respect to such compound or product, including any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings shall include any IND, BLA, </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 13</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MAA or the corresponding application in any other country or group of countries with respect to such products.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Replacement Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section&#160;2.5.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Researching</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means activities, other than Development, related to target validation, the design, discovery, generation, identification, profiling, characterization, production, process development, cell line development, pre-clinical development or non-clinical or pre-clinical studies of drug candidates and products, including such non-clinical studies and other material Development activities to be undertaken to generate data sufficient to enable the filing of an IND.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a compound generated in the course of the Collaboration pursuant to the Research Plan that comprises one or more DARPin Binding Domains with respect to the applicable Target. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Research Program, FTE Costs plus Out-of-Pocket Costs. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean all tangible material, and all material data, results, and research records relating to a Target, or compounds that are directed to such Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">generated in connection with a Research Program.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.3.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.5.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reversion Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Qualifying Terminated Product that is being actively Developed or Commercialized by Novartis, its Affiliate or sublicensee as of the applicable notice of termination or, if no such Qualifying Terminated Product is being actively Developed or Commercialized by Novartis, its Affiliate or sublicensee as of such time, the most recent Qualifying Terminated Product to have been under Development or Commercialization by Novartis, its Affiliate or sublicensee.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the authority of a Party as defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Law recognized outside of the United States), to rely upon, and otherwise use, all information and data included in or used in support of any drug master file maintained by or on behalf of the other Party for the purpose of obtaining approval of a BLA, including the ability to make available the underlying raw data from the investigation for FDA audit, if necessary.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Platform Patent Right, Licensor Product Patent Right, or Joint Product Patent Right.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6.4(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales &#38; Royalty Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a written report or reports showing each of&#58; (a) the Net Sales of each Product in the Territory, on a country-by-country basis, during the reporting period by Novartis and its </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 14</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Affiliates and their respective sublicensees&#59; and (b) the royalties payable, in USD, which shall have accrued hereunder with respect to such Net Sales. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sole Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.1(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) &#91;***&#93; is replaced pursuant to Section&#160;2.5, such Replacement Target and (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Terminated Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any Target with respect to which this Agreement is terminated pursuant to Section 10.2 or Section 10.3, and (b) in the event of termination of this Agreement in its entirety, all Targets.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 11.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means worldwide.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Therapeutic Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the treatment or prevention of any human disease or disorder.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person other than a Party or an Affiliate of a Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 12.5.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8.4(a).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section&#160;3.4.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">US</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States of America, its territories and possessions. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">USD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">US$&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the lawful currency of the United States.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means either (a) a claim of an issued and unexpired Patent Right that (i) has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental authority of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and (ii) has not been canceled, withdrawn, abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a claim of a Patent Right that is a pending patent application that (i) has not been cancelled, withdrawn, abandoned or finally rejected by an administrative agency action from which no appeal can be taken, and (ii) has been pending for less than &#91;***&#93; from the earliest date on which such patent application claims priority.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In this Agreement, unless otherwise specified&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#8220;includes&#8221; and &#8220;including&#8221; shall mean respectively includes and including without limitation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#8220;or&#8221; is used in the inclusive sense (&#8220;and&#47;or&#8221;) unless the context otherwise requires&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#8220;hereof,&#8221; &#8220;herein,&#8221; and &#8220;herewith,&#8221; and words of similar import, shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement&#59;</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 15</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">&#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">a Party includes its permitted assignees or the respective successors in title to substantially the whole of its undertaking&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted in accordance with any requirements with respect to such amendment or re-enactment&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the Exhibits, Schedules and other attachments form part of the operative provision of this Agreement and references to this Agreement shall, unless the context otherwise requires, include references to the Exhibits, Schedules and attachments&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">the headings in this Agreement are for information only and shall not be considered in the interpretation of this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or things&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement shall not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">RESEARCH COLLABORATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Overview of Research Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Research Term, and in accordance with the terms and conditions of this Agreement, the Parties will collaborate on &#91;***&#93; separate Research programs (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), under which the Parties will generate Research Compounds with respect to each Target in accordance with the Research Plan (defined below), with the aim of achieving selection of &#91;***&#93; Development Candidate for each Target. Each Target and Research Compound will be Researched according to a separate Research Program, and Novartis, subject to Section 3.1(b) and Section&#160;3.5, will have the sole right to Research, Develop, and Commercialize Licensed Compounds and any corresponding Product following the Development Candidate Selection Date. Novartis may, in its sole discretion, and at its cost and expense, elect to take forward, subject to Section 5.2 and Section 5.6, any and all Licensed Compounds and Products into Development and for Commercialization.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Research Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The initial research plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the Initial Targets is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any Research Plan under this Agreement will include (i) the activities to be performed by each Party to identify Research Compounds for a given Target until the Development Candidate Selection Date for a compound directed to such Target (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) the anticipated number of FTEs to be dedicated by Licensor and its Affiliates to perform the Research Plan Activities for the corresponding Target&#59; and (iii)&#160;a budget setting out by Calendar Year the estimated FTE Costs and Out-of-Pocket Costs to be incurred by Licensor and its Affiliates in the conduct of the Research Plan Activities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). From time to time during the Research Term, but prior to the Development Candidate Selection Date for a Research Compound selected for such Target, and at least on an annual basis, which shall occur no later than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">August 15 of </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 16</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">each Calendar Year, the Parties through the JRDC will jointly develop and submit, or either Party through the JRDC may propose for submission, updates or amendments to the Research Plan and Research Budget for the JSC&#8217;s review and approval. Each Research Plan shall be consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Conduct of Research Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Research Term and subject to the JSC&#8217;s and JRDC&#8217;s review and, as applicable, approval of each Research Plan, the Parties will use Commercially Reasonable Efforts to perform (themselves or through their Affiliates or subject to Section 3.3(b) permitted subcontractors) the Research Plan Activities in accordance with the applicable Research Plan and the timelines set forth therein to achieve selection of a Research Compound with respect to a Target as a Development Candidate. On a Target-by-Target basis, the Research Program will begin on &#91;***&#93;, and end upon the earlier of (i) the date of selection by Novartis of a DC with respect to such Target pursuant to Section 2.4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Candidate Selection Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) &#91;***&#93; after the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which period may be extended by mutual written agreement of the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In performing its respective Research Plan Activities, each Party&#58; (a)&#160;will conduct such activities in a good scientific manner, in compliance with all applicable Law in all material respects, including, where applicable, cGMP, cGLP, cGCP, and current international regulatory standards&#59; and (b)&#160;will not employ or use any Debarred Person. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development Candidate Selection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Target-by-Target basis (i) at any time during the Research Term, or (ii) within &#91;***&#93; following the end of the Calendar Term, whichever is later (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DC Selection Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Novartis will have the right, but not the obligation to select, by written notice to Licensor, up to &#91;***&#93; Research Compounds to take forward into further development&#59; provided that (a) at least &#91;***&#93; such Research Compound will be identified by Novartis in such notice as a DC at or prior to the DC Selection Deadline and (b) any of the other such Research Compounds identified by Novartis in such notice but not selected as a DC will be each deemed a Candidate DC. If Novartis does not select any DC for such Target by the DC Selection Deadline, the Agreement will expire for such Target, unless the Parties agree to extend the Agreement for such Target. Upon selection of at least &#91;***&#93; DC by Novartis pursuant to this Section 2.4, the exclusive license pursuant to Section&#160;3.1(a) will become effective, and each DC and any applicable Candidate DCs, will be each deemed a Licensed Compound. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Technical Failure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> With respect to the Initial Target &#91;***&#93;, at any time during the period beginning on the Effective Date and ending &#91;***&#93; thereafter, Licensor may request that the JSC make a determination of whether there has been a technical failure in the generation of Research Compounds. In the event the JSC determines that there has been a technical failure with respect to the Research under the corresponding Research Plan of Research Compounds, the JSC shall discuss and recommend a replacement Target for &#91;***&#93; (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided that, subject to the remainder of this Section&#160;2.5 but notwithstanding anything in Section&#160;4.5 or Section 4.6, &#91;***&#93; will have the final decision, after &#91;***&#93; with respect to the selection of a Proposed Target to replace &#91;***&#93;. Notwithstanding &#91;***&#93; final decision making authority with respect to the selection of a Proposed Target to replace &#91;***&#93;, if a Proposed Target is (i) subject to exclusive rights granted by Licensor to a Third Party&#59; (ii) subject to a bona fide term sheet negotiations between Licensor and one or more Third Parties&#59; or (iii) subject to a bona fide active Licensor internal research effort (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) such Proposed Target will not be available to Novartis for selection as a Target. If such Proposed Target is a Restricted Target, then Novartis may select another Proposed Target (and another if such other Proposed Target is a Restricted Target, and so on) until such time that Novartis selects a target that is not a Restricted Target, at which point such Proposed Target will be added as a Target under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Replacement Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and &#91;***&#93; shall immediately cease to be a Target. Upon determination of the Replacement Target, the Parties shall revise the applicable Research Plan accordingly and shall agree in good faith on a revised Budget Cap. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Research Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will maintain, and cause its Affiliates and their respective employees and subcontractors to maintain, records and laboratory notebooks of its Research Plan Activities in sufficient </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 17</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">detail and in a good scientific manner appropriate for scientific, regulatory and intellectual property protection purposes, which records and laboratory notebooks shall&#58; (a)&#160;be segregated from other Research activities not performed under this Agreement&#59; (b)&#160;be complete and accurate in all material respects&#59; and (c)&#160;fully and properly reflect all work done, data and developments made, and results achieved. Novartis will have the right to audit and request a copy of such records of Licensor and its Affiliates and their respective employees and subcontractors from time to time during the Term. In the event that Novartis conducts such audit using a Third Party, Novartis shall cause such Third Party to be bound by obligations of confidentiality with respect to such records no less stringent than those set forth in Sections 9.1, 9.2, or 9.3. For the avoidance of doubt, Novartis will have the final decision with respect to whether to conduct such audit under this Section 2.6 itself or using a Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Research Reports and Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will keep the other Party reasonably informed regarding the status, progress, and results of its Research Plan Activities for each Research Program, including a review of results and progress against timelines in such Research Plan through regularly scheduled JRDC meetings. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Interim Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a &#91;***&#93; basis the Parties will jointly create and submit to the JRDC for its review and discussion, a written update, in a form agreed to by the JRDC for such updates, that includes&#58; (i)&#160;a summary of the Research Plan Activities completed during the most recently completed &#91;***&#93;&#59; (ii)&#160;prior to the Development Candidate Selection Date, a summary of all results and data generated during such period related to each Target&#59; and (iii)&#160;both Parties&#8217; progress against the timeline and Research Budget set forth in each Research Plan, with appropriate documentation to substantiate all such activities and results.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Final Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall provide the other Party with a final written report within &#91;***&#93; after the completion or earlier termination of each Research Program, which report will summarize the activities undertaken and all accomplishments and deliverables achieved as specified under such Research Program and contain a copy of all Research Results generated by or on behalf of such Party in the performance of such Research Plan. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Research Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From time to time during the Term, upon Novartis&#8217; request, and in all events within &#91;***&#93; following the earlier of the termination or completion of each Research Program for a given Target, Licensor shall transfer to Novartis all Research Results generated by or on behalf of Licensor that have not yet been provided to Novartis. Novartis will have the right to use all Research Results for all purposes, and Licensor will have the right to use all Research Results generated by Licensor or on its behalf (i) for all purposes outside the scope of the licenses granted to Novartis, subject to Section&#160;3.5, and subject to the non-compete provisions with respect to Licensor pursuant to Section 3.7 and (ii) to file, prosecute, maintain, and enforce Patent Rights as permitted in Article 8.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Research Support and Payment</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Novartis shall be responsible for &#91;***&#93; of its own costs and expenses incurred in performing the activities assigned to it under the applicable Research Plan and, subject to this Section 2.8, &#91;***&#93; of the FTE Costs and Out-of-Pocket Costs actually incurred by Licensor in performing the activities assigned to it under the applicable Research Plan. Subject to a potential replacement Target for &#91;***&#93; pursuant to Section 2.5, the sum of FTE Costs and Out-of-Pocket Costs that Novartis will be obligated to reimburse under this Agreement shall not exceed &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Budget Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), unless agreed otherwise by the Parties in writing. For clarity and </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 18</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notwithstanding anything to the contrary herein, Licensor has no obligation to incur FTE Costs or Out-of-Pocket Costs in excess of the Budget Cap unless and until the Parties agree upon revised Research Costs (including a revised number of FTEs over a revised period of time for FTE Costs) with respect to Licensor&#8217;s performance of the activities assigned to it under the Research Plan and the Budget Cap is similarly agreed in writing. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">No later than &#91;***&#93; following the beginning of each Calendar Quarter, Licensor shall provide to Novartis a good faith, non-binding estimate (in a form to be agreed by the Parties promptly following the Effective Date) of the Research Costs it anticipates incurring during such Calendar Quarter under each Research Plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Within &#91;***&#93; after the end of each Calendar Quarter during the performance of the Collaboration, Licensor shall submit to Novartis an invoice substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (accompanied by reasonable supporting documents) setting forth the Research Costs actually incurred by Licensor in such Calendar Quarter to perform activities assigned to it under a Research Plan in accordance with the Research Budget set forth therein. Such accompanying documentation will include (i) the specific budgeted item set forth in the Research Plan (e.g., FTEs conducting Collaboration activities), (ii) the applicable Collaboration activities that were conducted&#59; and (iii) if applicable, documentation supporting any Out-of-Pocket Costs. Novartis shall pay the undisputed amount of all such Invoices within &#91;***&#93; after the date of its receipt of such Invoice.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Novartis disputes in good faith any portion of an Invoice for Research Costs provided by Licensor pursuant to Section 2.8(c), Novartis shall promptly notify Licensor and the Parties shall use good faith efforts to resolve such dispute expediently. Upon resolution of such dispute, if applicable, any Research Costs subject to such dispute shall be paid by Novartis at the next Calendar Quarter Invoice submission by Licensor.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Research Costs to be reimbursed to Licensor by Novartis must be incurred in accordance with the Research Plan and shall not exceed the Research Budget set forth therein (i) for the Collaboration Term or (ii) by more than &#91;***&#93; in a given Calendar Quarter as compared to the estimate provided pursuant to Section 2.8(b) for such Calendar Quarter. Out-of-Pocket Costs incurred by Licensor will be reimbursed by Novartis as a pass-through of the direct costs charged to Licensor by the applicable subcontractor without any mark-up. Novartis will have no obligation to reimburse Licensor for any overhead charged by such subcontractor.  Licensor shall promptly notify Novartis in the event that it anticipates incurring Research Costs which would exceed the foregoing thresholds.&#160; Any amount exceeding the aforementioned &#91;***&#93; variance threshold in a Calendar Quarter will automatically roll over to the following Calendar Quarter and will be included in the next quarterly estimate for Research Costs provided pursuant to Section 2.8(b). At the end of the Research Term, any such Research Costs incurred by Licensor in excess of the Research Budget shall be borne by Licensor unless the Research Budget is increased by an amendment of the Research Plan approved by the JSC in accordance with Section 4.2(b).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Know-How Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Licensor Know-How Transfer for Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; after the Effective Date, Licensor will, for no additional compensation, provide to Novartis, in a commercially reasonable format, a copy of all Licensor Know-How necessary or reasonably useful for Novartis to conduct its activities for a Research Program pursuant to the Research Plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Licensor Know-How Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; after the date on which Novartis notifies Licensor of its selection of a Development Candidate (and any Candidate DCs, as applicable) pursuant to </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 19</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section&#160;2.4, Licensor will, for no additional compensation, provide to Novartis, in a commercially reasonable format, a copy of all Licensor Know-How necessary or reasonably useful for the Development, manufacture, or Commercialization of, including with respect to obtaining or maintaining Regulatory Approval for, Licensed Compounds or Products, in accordance with this Agreement. Thereafter, on a continuing basis during the Term as may be requested by Novartis no more than &#91;***&#93; per Calendar Quarter, Licensor shall promptly, and for no additional compensation, disclose to Novartis through the JSC or JRDC, as applicable, all additional Licensor Know-How that comes into existence since the prior disclosure, and will provide reasonable assistance to Novartis in connection with understanding and using all such Know-How for purposes consistent with the licenses and rights granted to Novartis hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Licensor will provide reasonable assistance to Novartis or its designated Affiliate in connection with understanding and using the Licensor Know-How for purposes consistent with licenses and rights granted to Novartis hereunder, including by providing information to assist Novartis or its designated Affiliate in developing formulations of the Licensed Compounds or Products and its related activities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Material Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In connection with a Research Program, each Party may transfer certain materials to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The receiving Party may use the Materials only for the purpose of performing such Research Program and shall acquire no rights therein. The Materials (a) will be used solely for performance of the Research Program at the receiving Party&#8217;s facilities, under suitable containment conditions in accordance with all applicable Laws and regulations, as well as with all guidelines for use of the Materials and for research conducted with animals&#59; (b) will under no circumstances be administered to humans&#59; (c) will not be analyzed, reverse engineered or modified other as expressly provided in the applicable Research Plan&#59; (d) will not be transferred or made available to any individual other than the relevant FTEs for the applicable Research Program without the prior written consent of the providing Party&#59; (e) are being supplied to the receiving Party with no warranties, express or implied, of merchantability or fitness for a particular purpose or otherwise, and in particular, the providing Party does not represent or warrant that the use of the Materials will not infringe or violate any patent or proprietary rights of third parties&#59; and (f) are to be used with caution and prudence in any experimental work, since not all of the characteristics of such Materials are necessarily known. The receiving Party shall bear all risk to it and&#47;or any others resulting, directly or indirectly, from use, application, storage or disposal or destruction of the Materials. At any time, the providing Party may require the receiving Party to return or destroy any unused Materials in accordance with all applicable Laws and the providing Party&#8217;s instructions (if any), and the receiving Party will return or destroy (as applicable) such Material within ten days of the providing Party&#8217;s request.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Animal Research Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. To the extent a Research Program involves the use of animals, the provisions of this Section 2.11 will apply. All such animals will be cared for, used, and disposed of in conformity with the highest legal and ethical standards of animal testing as defined by the U.S. Animal Welfare Act (P.L. 89-544, as amended) and the guidelines prescribed in DHHS Publication No. 72-23 (NIH), &#8220;Guide for the Care and Use of Laboratory Animals&#8221; (1996 edition or succeeding revised editions). The relevant environment, housing, management, veterinary care, and physical plant used in connection with such animals in a Research Program will be appropriate for type(s) of animal(s) and the nature of the Research Program. An institutional animal care and use committee, as that term is contemplated by the U.S. Animal Welfare Act (or its equivalent worldwide) must approve the activities described in a Research Plan prior to commencement of the relevant Research Program and will provide oversight of animal care, use, housing, management and disposal for the duration of the Research Program. In no circumstances will any such animals be used as food for humans or animals. If specific instructions for animal use, care, handling, or disposal are provided by Novartis, Licensor shall use good faith efforts to comply with such instructions in connection with the relevant Research Program. Each Party will have the right to review and audit the relevant facilities of the other Party and related records </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 20</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to confirm compliance with this Section&#160;2.11 not more than &#91;***&#93; per Calendar Year during the audited Party&#8217;s normal business hours to ensure conformity with the provisions of this Section 2.11.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Human Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party represents and warrants (a) that it has complied, or shall comply, with all applicable Laws relating to the collection and&#47;or use of human primary cell lines, human tissue, human clinical isolates or similar human-derived materials that have been or are to be collected in and&#47;or used in a Research Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Human Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (b) that it has obtained, or shall obtain, all necessary approvals, consents, and&#47;or authorization required by law for the collection, use and&#47;or transfer of such Human Material as contemplated by this Agreement. Each Party shall provide documentation of such approvals, consents, and authorizations upon the other Party&#8217;s request. Each Party further represents and warrants that such Human Material may be used as contemplated in this Agreement without any obligations to the individuals or entities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) other than required by applicable Law who contributed the Human Material, including any obligations of compensation to such Providers for any purposes, including any obligations of compensation to such Providers or any other Third Party for the intellectual property associated with the Human Material or the commercial use thereof for any purposes.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">LICENSE</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">License Grant to Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Licensor hereby grants an exclusive (subject to Section 3.5, even as to Licensor and its Affiliates), sub-licensable (pursuant to Section 3.3), royalty-bearing license, under the Licensor Technology to Novartis to Research, Develop, manufacture, have manufactured, use, import, offer for sale, sell, have sold and otherwise Commercialize the Licensed Compounds and Products in the Therapeutic Field in the Territory. For the avoidance of doubt and subject to Section 3.5, the foregoing license is exclusive to Novartis and Licensor has no retained rights (and will not attempt to license any rights, directly or indirectly, to any Third Party) with respect to the Licensed Compounds and Products in the Therapeutic Field in the Territory&#59; except for activities undertaken pursuant to the terms of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor hereby grants a worldwide, sublicensable, non-exclusive license under the Licensor Technology to Novartis (i) effective as of the Effective Date, to Research, Develop, manufacture, have manufactured, use, and import Licensed Compounds and Products in the Diagnostic Field, and (ii) effective as of the date on which the Parties agree in writing on terms and conditions under Section&#160;6.8, to offer for sale, sell, have sold and otherwise Commercialize Licensed Compounds and Products in the Diagnostic Field. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Licensor hereby grants a non-exclusive, worldwide, fully paid-up sublicensable license under the Licensor Technology to Novartis solely to perform Novartis&#8217; activities under the Research Plan during the Research Term. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">License Grant to Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Novartis hereby grants to Licensor a non-exclusive, worldwide, fully paid-up sublicensable license under the Novartis Background Technology solely for the purpose of performing Licensor&#8217;s activities under the Research Plan during the applicable Research Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Sublicense Rights&#59; Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to the terms and conditions of this License Agreement, Novartis may sublicense the rights granted to it by Licensor under this Agreement at any time at its sole discretion through multiple tiers and without reference to the Licensor. Novartis will ensure that all permitted sublicenses granted under this Section&#160;3.3(a) are consistent with the terms of this Agreement. </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 21</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis will remain responsible for any action or failure to act by its sublicensees to whom Novartis&#8217; obligations under this Agreement have been sublicensed, and which action or failure to act would constitute a breach of this Agreement if such action or failure to act were committed by Novartis. Within &#91;***&#93; after the execution of any sublicense agreement with a Third Party (other than subcontractors) under which Novartis grants rights to such Third Party to Develop or Commercialize Licensed Compounds or Products, Novartis shall provide Licensor with a copy of such sublicense agreement, provided, that Novartis may redact any terms of such sublicense agreement (i) to the extent not pertinent to either Party&#8217;s rights or obligations under this Agreement or verification of compliance with the requirements of this Agreement or (ii) that are financial in nature or are otherwise competitively sensitive. For clarity, distributors and wholesalers shall not be considered sublicensees. Novartis may exercise its rights and perform its rights and obligations under this Agreement itself or through any of its Affiliates, provided that Novartis remains responsible for the performance of such Affiliates as if such activities of such Affiliates were activities of Novartis under this Agreement and Novartis remains responsible for any payments due to Licensor under this Agreement with respect to activities of such Affiliates. Licensor may not sublicense the rights granted to it by Novartis under this Agreement without first obtaining, in each case, Novartis&#8217; prior written consent and complying with the terms of any such consent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Each Party may engage subcontractors to perform any obligations assigned to it under this Agreement&#59; provided that&#58; (a) Licensor shall obtain Novartis&#8217; prior written consent before subcontracting any such obligations to any subcontractor that is not either engaged by Licensor as of the Effective Date or included in an approved Research Plan&#59; (b)&#160;the subcontracting Party remains fully responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself&#59; (c)&#160;each contract between a Party and a subcontractor is consistent with the provisions of this Agreement, but only as it pertains to the obligations being performed by such subcontractor pursuant to this Agreement, including (i)&#160;obligations of confidentiality and non-use applicable to Confidential Information that are at least as stringent as those set forth in Sections 9.1, 9.2, and 9.3, and (ii)&#160;obligations of assignment of all Inventions and other Intellectual Property Rights developed in the course of performing any such work under this Agreement to the subcontracting Party and obligations of cooperation to execute any documents to confirm or perfect such assignment&#59; and (d)&#160;the subcontracting Party remains at all times fully liable for all acts or omissions of such subcontractor.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Third Party Licenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> All Intellectual Property Rights licensed to a Party from a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and sublicensed to the other Party under this Agreement will be subject to and subordinate to the terms of the applicable Third Party License to the extent such terms applies to a sublicensee of such Third Party Intellectual Property Rights. Each Party will comply with the terms of any such Third Party License&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Party shall not be obligated to comply with any such Third Party License until the relevant terms of any such Third Party License that apply to a Party&#8217;s exercise of such rights have been fully and accurately disclosed to such Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">No Implied Rights&#59; Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party nor its Affiliates grants any right or license to the other Party under Know-How, Patent Rights or other Intellectual Property Rights Controlled by such Party or its Affiliates, except as expressly granted in this Agreement. All rights not expressly granted by a Party under this Agreement are reserved to and retained by such Party. Notwithstanding the exclusive license granted by Licensor to Novartis under Section 3.1, Licensor retains the rights under the Licensor Technology (a) to perform its obligations and to exercise its rights under this License Agreement, whether directly or through one or more Affiliates or, subject to Section 3.3(b), subcontractors and (b) to conduct internal pre-clinical and non-clinical research of the Licensed Compound solely to the extent such research relates to improvement of the Platform.</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 22</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Section 365(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All rights and licenses granted under or pursuant to Section 3.1 are and shall otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code, and any similar laws in any other country, licenses of rights of &#8220;intellectual property&#8221; as defined in Section 101(35A) of the United States Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the United States Bankruptcy Code and any similar laws in any other country or jurisdiction throughout the world. Upon the Insolvency Event of a Party, the other Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">During the Term, Licensor will not, by itself or in collaboration with any Third Party, Research, Develop, manufacture or Commercialize in the Therapeutic Field a Product, Licensed Compound, or any product that includes a Licensed Compound, except as otherwise provided in Section 3.5.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">During the period beginning on the Effective Date and ending&#91;***&#93; upon receipt &#91;***&#93; of the &#91;***&#93; from the &#91;***&#93; of the &#91;***&#93;, Licensor will not, by itself or in collaboration with any Third Party, &#91;***&#93; (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Notwithstanding anything to the contrary in this Section 3.7, (a) nothing in this Section&#160;3.7 will apply to or otherwise limit a Change of Control of Licensor and (b) if after the Effective Date, any acquirer in connection with a Change of Control of Licensor is engaged in a Competing Program as of the closing date of such transaction, the acquirer and its Affiliates existing prior to such Change of Control may continue to Research, Develop, manufacture and Commercialize such Competing Program&#59; provided, that, (i) none of Novartis&#8217; Confidential Information (including any jointly owned Confidential Information) is used in connection with such Competing Program, (ii) none of the Licensor Technology, or Licensor&#8217;s Confidential Information (including jointly owned Confidential Information) or personnel of Licensor or its Affiliates are used in connection with such Competing Program, provided, that the foregoing shall not apply to any senior management of the acquiror or Licensor (or their Affiliates) who merely have knowledge of the relationship with Novartis or who are receiving general information regarding the progress of the Research, Development, or Commercialization activities but do not direct or are not otherwise directly involved in the Research, Development, or Commercialization of any Licensed Compound or Product) and (iii) Licensor immediately establishes reasonable firewall safeguards for use of or access to information to ensure that such use or access does not occur (which include appropriate administrative, physical, and technical safeguards, including underlying operating system and network security controls and other firewalls). </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">GOVERNANCE</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; following the Effective Date, each Party will appoint (and notify the other Party in writing of the identity of) a senior representative having a general understanding of pharmaceutical development and commercialization issues to act as its alliance manager under this Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Alliance Managers will serve as the contact point between the Parties for the purpose of providing the Parties with information on the progress of Novartis&#8217; Development and Commercialization of the Products and will be primarily responsible for&#58; (a) facilitating the flow of information and otherwise promoting communication, coordination and </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 23</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">collaboration between the Parties&#59; (b) providing single point communication for seeking consensus both internally within the respective Party&#8217;s organization and together regarding key global strategy and planning issues, as appropriate&#59; and (c) raising cross-Party or cross-functional disputes in a timely manner. Each Party may replace its Alliance Manager on written notice to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">The Parties will establish a Joint Steering Committee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), composed of &#91;***&#93; senior personnel of Licensor and &#91;***&#93; senior personnel of Novartis (&#91;***&#93; of which will be the Party&#8217;s Alliance Manager and which personnel for each Party, collectively, shall have a general understanding of drug manufacturing, Development and Commercialization issues).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">In addition to providing general oversight with respect to the Parties&#8217; activities under this Agreement, the JSC shall in particular have the following responsibilities&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.98pt">review, discuss, and determine whether to approve any Research Plan (including the Research Budget set forth therein) for any Replacement Target named to the Collaboration after the Effective Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.93pt">on a Target-by-Target basis, review, discuss, and determine whether to approve any amendments to each Research Plan (including the Research Budget set forth therein and amending the FTEs provided for under any such Research Plan)&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.88pt">receive and discuss reports from the other Committees&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.48pt">provide guidance to the other Committees on all significant strategic issues that fall within the scope of such Committees&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.53pt">establish such additional joint subcommittees as it deems necessary to achieve the objectives and intent of this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.48pt">resolve disputes for which the JSC is responsible as expressly provided in this Agreement&#59; and </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.43pt">perform such other functions as expressly provided in this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Joint Research and Development Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Parties hereby establish a joint research committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as a joint subcommittee under the JSC, composed of &#91;***&#93; (or a larger number agreed by the Parties) representatives of each Party, each of whom will have the appropriate experience and expertise to perform its responsibilities on the JRDC. The JRDC shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">coordinate the Collaboration and facilitate communications between the Parties with respect to the Collaboration&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">prepare a Research Plan (including the Research Budget set forth therein) for any Replacement Target named to the Collaboration after the Effective Date and submit such Research Plan to the JSC to review, discuss and determine whether to approve&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">on at least &#91;***&#93; basis during the Research Term in accordance with Section&#160;2.2, prepare amendments to each Research Plan (including the Research Budget set forth therein) and submit the Research Plan to the JSC to review, discuss and determine whether to approve such amendment&#59;</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 24</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">discuss the data and results of performance of the Research Plans and the anticipated timeline for initiating and completing the activities set forth therein&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Research of the Products, as directed by the JSC.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Meetings of the JSC and JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Within &#91;***&#93; after the Effective Date, each Party shall appoint its representatives on the JSC and the JRDC by providing written notification to the other Party. Each Party may replace its representatives on any Committee on written notice to the other Party, but each Party shall strive to maintain continuity in the representation of its Committee members. Each Party shall appoint &#91;***&#93; of its representatives on each Committee to act as a co-chairperson of such Committee. The co-chairpersons shall jointly prepare and circulate agendas to the applicable Committee&#8217;s members at least &#91;***&#93; before each Committee meeting and shall direct the preparation of reasonably detailed minutes for each Committee meeting, which shall be approved by the co-chairpersons and circulated to Committee members within &#91;***&#93; after such meeting. Each Party shall be solely responsible for the costs incurred by its representatives in attending any Committee meeting.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less frequently than (i) for the JSC, once per Calendar Quarter&#59; (ii) for the JRDC, once every month (unless otherwise agreed by the JRDC) until completion of the Collaboration on a Target-by-Target basis. Committee meetings may be held in person or by audio or video teleconference. No action taken at any Committee meeting shall be effective unless at least &#91;***&#93; representative of each Party is participating.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend JSC meetings in a non-voting capacity, with the consent of the other Party (which shall not be unreasonably withheld)&#59; provided, that such participants will be, before attending such meetings, bound by written confidentiality obligations consistent with Article 9. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">On &#91;***&#93; prior written notice, either Party may request an ad-hoc meeting of a Committee to discuss issues that urgently need to be addressed prior to the next scheduled Committee meeting and such Party will provide the relevant Committee materials reasonably adequate to enable an informed discussion by its members reasonably in advance of such meeting. Ad-hoc meetings may occur via audio or video teleconference or in-person as the Parties may agree.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All decisions within the authority of each Committee shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote. If a Committee is unable to reach agreement as to a particular matter within such Committee&#8217;s jurisdiction, within &#91;***&#93; (or a later date mutually agreed to by the Parties) after such matter has been brought to such Committee for resolution, then such disagreement shall (i) in case of disagreement of the JRDC or other joint subcommittee, be referred to the JSC for resolution, and (ii) in the case of disagreement of the JSC, except as expressly provided in Section 4.6, be referred to the Executive Officers of the Parties for resolution.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">JSC Final Decision Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If the Executive Officers do not fully resolve any matter within the JSC&#8217;s authority or referred to them under Section 4.5 within &#91;***&#93; (or a later date mutually agreed to by the Parties) of the matter being referred to them, then the resolution or course of action shall be determined by &#91;***&#93;, in its sole discretion&#59; provided, that notwithstanding the foregoing, Excluded Matters shall &#91;***&#93; (in each case acting reasonably and in good faith)&#58;</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 25</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.98pt">The approval of any new Research Plan pursuant to Section 4.2(b)(i)&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.93pt">Any amendments, changes or additions to the procedural rules or standing rules of the JSC or the JRDC&#59; or</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.88pt">Any amendments, changes or additions to a Research Plan, including any decision that (1) would expand the scope of the work to be carried out under the Research Plan that results in an increase in the Research Costs borne by Licensor (including FTE costs), or (2) would require Licensor to assume additional obligations under the Research Plan.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Costs of Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that the costs incurred by each Party in connection with its participation at any meetings under this Article 4 shall be borne solely by such Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Limitations of Committee Authority&#59; Discontinuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The activities to be performed by each Committee shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. Each Committee shall only have the powers expressly assigned to it in this Article 4 and elsewhere in this Agreement and shall not have the authority to&#58; (a)&#160;modify or amend the terms and conditions of this Agreement&#59; (b)&#160;waive or determine either Party&#8217;s compliance with the terms and conditions of under this Agreement&#59; or (c)&#160;decide any issue in a manner that would conflict with the express terms and conditions of this Agreement. Each Committee shall continue to exist until the first to occur of&#58; (A) the Parties mutually agreeing to disband the Committee&#59; (B) Licensor providing written notice to Novartis of its intention to disband and no longer participate in such Committee&#59; or (C) the expiration of the last-to-expire Research Term. Once a Committee ceases to exist as provided in the previous sentence, such Committee shall have no further obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of a Change of Control of Licensor, Novartis may, upon &#91;***&#93; prior written notice to Licensor (or its successor entity), in addition to its rights under this Agreement, terminate the provisions of this Sections 4.2&#8211;4.8. Upon such notice, (i) neither Party will have any further obligations under Sections 4.2&#8211;4.8 for the remaining Term and (ii) &#91;***&#93;. For clarity, the Alliance Managers will remain a point of information exchange as set forth in Section&#160;4.1.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">DEVELOPMENT, REGULATORY, MANUFACTURING, AND COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 5.2, Novartis will be responsible for conducting, at its sole expense, such research and preclinical, clinical and other Development of the Licensed Compounds or Products as it determines appropriate in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall itself, or through its Affiliates, sublicensees, or other Third Parties, use Commercially Reasonable Efforts to Develop at least &#91;***&#93; for each Target in the Therapeutic Field. Subject to compliance with the foregoing, the Development of the Product shall be in Novartis&#8217; sole discretion. </font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to the second sentence of Section 5.6, Novartis will be responsible for all regulatory matters with respect to the Licensed Compounds or Products as it determines appropriate in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Novartis will (i) determine the regulatory plans and strategies for the Licensed Compounds or Products, (ii) (either itself or through its Affiliates or sublicensees) make all Regulatory Filings </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 26</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with respect to the Product and (iii) be responsible for obtaining and maintaining Regulatory Approvals in the Territory in the name of Novartis or its Affiliates or sublicensees.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section&#160;5.9(c), Licensor shall fully cooperate with and provide assistance to Novartis in connection with filings to any Regulatory Authority relating to the Licensed Compounds or Product(s) (including, to the extent applicable, filings related to the quantitative and qualitative composition of Licensed Compounds or Products), including by executing any required documents, providing access to personnel and providing Novartis with copies of all reasonably required documentation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">To the extent required, Licensor shall grant or cause to be granted to Novartis and its Affiliates or sublicensees a Right of Reference to any relevant drug master files and other filings (including, to the extent applicable, filings related to the quantitative and qualitative composition of Licensed Compounds or Products) submitted by Licensor or its Affiliates with any Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis shall have the right to disclose the existence of, and the results from, any clinical trials conducted under this Agreement in accordance with Section 5.1 and its standard policies. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party agrees that, in performing its obligations under this Agreement&#58; (a) it shall comply with all applicable current international regulatory standards, including cGMP, cGLP, cGCP and other rules, regulations and requirements&#59; and (b) it will not employ or use any person that has been debarred under Section 306(a) or 306(b) of the US Federal Food, Drug and Cosmetic Act (21 U.S.C. 335a). </font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis, its Affiliates or its designated sublicensee(s) and subcontractor(s) will be solely responsible for the manufacture and supply of the Licensed Compounds and Products being Developed or Commercialized under this Agreement as it determines appropriate in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section&#160;5.9(c), during the period from the Effective Date until the First Commercial Sale of a Product under this Agreement, Licensor shall, at its expense, fully cooperate with and provide assistance to Novartis or its designee, through documentation, consultation, training and face-to-face meetings, to enable Novartis or its designee in an efficient and timely manner to proceed with Development and manufacturing of the Licensed Compounds or Products and to obtain all appropriate Regulatory Approvals for manufacturing (including qualification by the applicable Regulatory Authority of manufacturing sites).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Subject to Section&#160;5.9(c), during such period, Licensor shall make appropriate personnel available to assist Novartis or its designee at any time and from time to time as reasonably requested by Novartis, and shall provide the appropriate personnel of Novartis or its designee with access to the personnel and manufacturing and other operations of Licensor for such periods of time and in such manner as is reasonable in order to familiarize the personnel of Novartis or its designee with Licensor Know-How relating to the Development and manufacture of the Licensed Compounds or Products and the application of the same. At Novartis&#8217; request, such assistance shall also be furnished at the manufacturing facilities of Novartis or its designee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section&#160;5.9(c), Licensor shall fully cooperate with Novartis in complying with requirements of 35 U.S.C. &#167;200 through 212, including requesting waivers were appropriate. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis will be solely responsible for all aspects of Commercialization of the Products in the Territory, including planning and implementation, distribution, booking of sales, pricing and reimbursement. Novartis shall itself, or through its Affiliates, sublicensees, or other Third Parties, use Commercially Reasonable Efforts  to Commercialize in the Therapeutic Field at least &#91;***&#93; for </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 27</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">which Regulatory Approval has been obtained in each of the Major Markets. Notwithstanding the foregoing, Novartis&#8217; application of Commercially Reasonable Efforts shall not require Novartis to Commercialize a Product in any country or territory in which Novartis determines it is not commercially reasonable to do so for such Product. Subject to compliance with the foregoing, the Commercialization of the Products shall be in Novartis&#8217; sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; following the Effective Date, the Parties shall agree upon and implement a procedure for the mutual exchange of adverse event reports and safety information associated with the Products. Details of the operating procedure respecting such adverse event reports and safety information exchange shall be the subject of a mutually-agreed written pharmacovigilance agreement between the Parties which shall be entered into within such &#91;***&#93; period.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Technology and Material Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  After expiration of the Research Term with respect to a Target, Licensor shall promptly (but in no event later than &#91;***&#93; thereafter) transfer to Novartis (or, if instructed by Novartis with respect to Materials, to a Third Party working on behalf of Novartis) copies of all relevant Licensor Know-How and Materials for the applicable Target then existing and not previously provided to Novartis, including any manufacturing Licensor Know-How relating to such Licensed Compound or Product with respect to such Target. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Assistance and Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties understand and agree that, from time to time, Novartis may reasonably request assistance and cooperation from Licensor in connection with&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">following expiration of the Research Term with respect to a Target, the technology transfer contemplated by Section 5.8, including reasonable technical assistance in the practice of the Licensor Know-How in the Development and manufacture of the Licensed Compounds and Products directed to such Target, including reasonable access to Licensor&#8217;s technical personnel involved in the Research of the applicable Licensed Compounds and Products&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the preparation and submission of any Regulatory Filings to obtain, support or maintain Regulatory Approvals.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Licensor shall provide up to an aggregate of &#91;***&#93; of work relating to any assistance and cooperation contemplated by Section 5.9(a) for all Targets combined, without additional compensation or reimbursement. Licensor may invoice Novartis for the FTE Costs that relate to any such work in excess of such &#91;***&#93; and the reasonable documented Out-of-Pocket Costs, in each case, requested by Novartis and incurred by Licensor to provide such requested assistance or cooperation and Novartis shall pay all such undisputed Invoices within &#91;***&#93; of the date of receipt by Novartis of such Invoice&#59; provided, that the scope of Licensor&#8217;s assistance and cooperation and the related costs are discussed and agreed by the Parties prior to Licensor&#8217;s provision thereof. Novartis&#8217; right to request such support shall expire on a Target-by-Target basis on the &#91;***&#93; of the expiration of the Research Term for a Target.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Novartis Reporting. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section 5.10(b), on a Target-by-Target basis, Novartis will provide Licensor (or its successor entity) with &#91;***&#93; written report summarizing Development activities that Novartis and its Affiliates and their respective agents, licensees and sublicensees have conducted during the prior Calendar Year with respect to each Target and the corresponding Licensed Compounds and Products (as applicable) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Development Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in sufficient detail to permit Licensor to evaluate whether Novartis has complied with its diligence obligations pursuant to Sections 5.2 and 5.6. The first &#91;***&#93; Product Development Report shall be provided by Novartis to Licensor on the first &#91;***&#93; after the end of the Research Term for a Target, and annually on &#91;***&#93; thereafter until the First Commercial Sale of the first Product with respect to </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 28</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">each Target. Each &#91;***&#93; Product Development Report will include&#58; (a) a summary of accomplishments during the prior Calendar Year, and projects then being conducted and planned to be conducted during the current Calendar Year (including clinical trials), in each case relating to the Development and Commercialization of the relevant Target and related Licensed Compound and Products&#59; (b) Regulatory Approvals achieved during the prior Calendar Year and Regulatory Filings planned for submission during the current Calendar Year with respect to the relevant Target and related Licensed Compounds and Products For clarity, Development activities, Regulatory Filings and submissions planned for the then-current Calendar Year are intended to describe anticipated activities, and the Parties acknowledge that the actual Development of Products may change during the Calendar Year due to unforeseen or unknown developments or information.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Novartis&#8217; financial reporting obligations under Article 7 will survive a Change of Control of Licensor&#59; provided that in the event of a Change of Control of Licensor, Novartis may, in addition to its rights under Section 5.10(a), redact any competitively sensitive information from any Product Development Reports provided to Licensor (or its successor) pursuant to Section 5.10(a). </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">FINANCIAL PROVISIONS</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In consideration of the licenses and rights granted to Novartis hereunder, Novartis shall pay to Licensor a one-time, non-refundable, non-creditable upfront payment of twenty million dollars ($20,000,000) within &#91;***&#93; after receipt by Novartis of an Invoice from Licensor, which invoice shall be issued by Licensor no earlier than the Effective Date. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In consideration of the licenses and rights granted to Novartis hereunder, Novartis will make the following development and regulatory milestone payments (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on a Target-by-Target basis upon the first achievement by a Product with respect to a Target of the corresponding milestone (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by Novartis, its Affiliates, or their sublicensees. Each Development Milestone Payment will be paid once per Target, regardless if more than one Product with respect to such Target achieves the relevant milestone.</font></div><div style="padding-left:39.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.425%"><tr><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Event</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Payment (USD)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total Amount per Target if all Development Milestones Events are Achieved </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 29</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Development Milestone Payment shall be deemed earned as of the first achievement of the corresponding Development Milestone Event, as determined by Novartis. Novartis shall provide Licensor with written notice of the achievement of each Development Milestone Event within &#91;***&#93; after such Development Milestone Event is achieved. Each Development Milestone Payment set forth above shall be due and payable only once for each Target, regardless of how many times the corresponding Development Milestone Event is achieved or the number of Products that achieve such Development Milestone Event. The total amount of Development Milestone Payments for Products associated with a particular Target shall not exceed &#91;***&#93;, and the aggregate Development Milestone Payments under this Agreement with respect to all Targets and Products under this Agreement, shall not exceed &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In consideration of the licenses and rights granted to Novartis hereunder, Novartis shall make the following payments to Licensor (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) after the first achievement of the applicable commercial milestone event set forth below with respect the Annual Net Sales of a Product directed to such Target (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:40.79pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:1.0%"></td><td style="width:70.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Event</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payment (Dollars)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total Amount per Target</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:14.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Commercial Milestone Payment is payable only once with respect to the first Product specific for each Target to achieve such Commercial Milestone Event (and, for clarity, shall be deemed earned as of the first achievement of such corresponding Commercial Milestone Event by a Product specific for such Target). Novartis will notify Licensor in writing of the achievement of each Commercial Milestone Event via the applicable Sales &#38; Royalty Report, and Novartis shall pay to Licensor the corresponding Commercial Milestone Payment together with the royalty payment in the manner set forth in Section 7.1. The total amount of Commercial Milestone Payments with respect to each Target shall not exceed &#91;***&#93;, and the aggregate Commercial Milestone Payments under this Agreement with respect to all Targets and Products under this Agreement, shall not exceed &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In consideration of the licenses and rights granted to Novartis hereunder, during the applicable Royalty Term, Novartis will pay Licensor a royalty on aggregate worldwide Annual Net Sales in the Therapeutic Field of Products directed to a given Target sold by Novartis, its Affiliates, or sublicensees as set forth in the table below&#58; </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 30</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="padding-left:73.84pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.500%"><tr><td style="width:1.0%"></td><td style="width:70.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual Net Sales of Products directed to a given Target in the Therapeutic Field in the Territory during the Royalty Term</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Rate for Products</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.75pt;padding-right:3.05pt;text-indent:1.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.75pt;padding-right:3.05pt;text-indent:1.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.75pt;padding-right:3.05pt;text-indent:1.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.43pt">Royalties will be payable on a Product-by-Product and country-by-country basis from First Commercial Sale of such Product in such country until the latest of (i) the expiration of the last to expire Valid Claim of the Royalty Patents which Covers the composition of matter, manufacture, import, sale or use of such Product in such country, (ii) the expiration of Regulatory Exclusivity covering such Product in such country, and (iii) ten (10) years from the First Commercial Sale of such Product in such country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Following the expiration of the Royalty Term on a Product-by-Product and country-by-country basis, Novartis&#8217; licenses under Section 3.1 with respect to such Product shall continue in effect, but become fully paid-up, royalty-free, transferable, perpetual and irrevocable. For the avoidance of doubt, royalties shall be payable only once with respect to the same unit of Product.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Know-How Royalty&#59; Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">If, on a country-by-country basis during the Royalty Term, the relevant Product is not covered by a Valid Claim of a Royalty Patent in the applicable country, the Net Sales for such country to be included in worldwide Annual Net Sales for the purposes of the calculation of royalties due to Licensor pursuant to Section 6.4 will thereafter be reduced by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If, during the Royalty Term, there is a Loss of Market Exclusivity in a country, then, the Net Sales for such country to be included in worldwide Annual Net Sales for the purposes of the calculation of royalties due to Licensor pursuant to Section 6.4 will thereafter be reduced by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Third Party Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section 6.6(b) and Section 6.6(c), Licensor shall remain responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties under any Licensor Patent Rights or Licensor Know-How which have been licensed to Licensor as of the Effective Date, or are licensed to Licensor during the Term, and are sublicensed to Novartis under this Agreement. All such payments shall be made promptly by Licensor in accordance with the terms of the applicable license agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">If Licensor Controls any Patent Right or Know-How through a right or license from a Third Party obtained after the Effective Date, but excluding any such Patent Right or Know-How that relates solely to the Platform (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that would be included in the definition of Licensor Technology, then Licensor shall promptly disclose the terms and conditions of such license and such Third Party IP to Novartis. Following the disclosure of such license terms and conditions, such Third Party IP shall be deemed part of the Licensor Technology only if Novartis provides Licensor with written notice that (i) Novartis consents to adding such Patent Rights and Know-How to the definition of Licensor Technology, as applicable, (ii)&#160;Novartis </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 31</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">agrees to be responsible for the payment obligations set forth in this Section 6.6(b) with respect to such Third Party IP agreement, and (iii) Novartis acknowledges that its sublicense under such Third Party IP agreement is subject to the terms and conditions of such agreement. With respect to any Third Party IP for which Novartis has elected to take a sublicense in accordance with the foregoing (i)&#8211;(iii), Novartis shall reimburse Licensor for &#91;***&#93; of all payments payable by Licensor to such Third Party to the extent that such payments directly result from the Research, Development, manufacture, use, import, sale, or other Commercialization the Licensed Compounds and Products by or on behalf Novartis, its Affiliates or sublicensees in the Field in the Territory. For any payment that is owed to such Third Party that is partially due to the Research, Development, manufacture, use, import, sale, or other Commercialization the Licensed Compounds and Products by or on behalf Novartis, its Affiliates or sublicensees in the Field in the Territory (e.g., license maintenance fees where the Third Party IP is also applicable to products other than Products), &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In the event that, after the Effective Date, Novartis obtains rights to any Patent Right or Know-How owned or otherwise controlled by a Third Party that relates solely to Platform and that are necessary for the Development, manufacture, or Commercialization of a Licensed Compound, Novartis shall have the right to deduct from the royalty payments due to Licensor under Section 6.4 &#91;***&#93; of the amounts paid &#91;***&#93; by Novartis to such Third Party. Licensor agrees to fully cooperate with Novartis to acquire such rights.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">In the event that, after the Effective Date, Novartis obtains rights to any Patent Right or Know-How owned or otherwise controlled by a Third Party that does not fall under Section 6.6(c) that are necessary for the Development, manufacture, or Commercialization of a Licensed Compound, Novartis shall have the right to deduct from the royalty payments due to Licensor under Section 6.4 &#91;***&#93; of the amounts paid &#91;***&#93; by Novartis to such Third Party. Licensor agrees to fully cooperate with Novartis to acquire such rights.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Royalty Floor. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary herein, in no event shall the Calendar Quarter royalty payment on Net Sales payable to Licensor under this Agreement pursuant to Section 6.4 be reduced pursuant to Sections 6.5 and 6.6 to less than &#91;***&#93; of the amounts that would have been paid had no deductions been made pursuant to Sections 6.5 or 6.6&#59; provided, however, that if Novartis is precluded from applying the full amount it would otherwise be entitled to apply in reducing its royalty payment in any Calendar Quarter by virtue of this Section 6.7, then it shall be permitted to apply such unapplied portion to reduce its royalty obligations in subsequent Calendar Quarters until the full amount of such reductions has been applied.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Products in the Diagnostic Field.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> In the event that either Party intends to Commercialize a Product in the Diagnostic Field, then no later than the date of &#91;***&#93; for a Product in the Therapeutic Field, the Parties will initiate good faith negotiations with respect to the terms of such Commercialization, which terms may include the &#91;***&#93;. If the Parties are unable to reach agreement after &#91;***&#93; of the initiation of such negotiations, then such matter will be referred to the Executive Officers of each Party for resolution. If the Executive Officers do not fully resolve such matter within &#91;***&#93; (or a later date agreed to by each of the Parties) of the matter being referred to them, then to the extent that the matter relates to financial terms, it will be resolved by Expedited Arbitration and to the extent that the matter relates to non-financial terms, it will be resolved pursuant to Section 15.5(b). Notwithstanding the foregoing, Novartis will have no payment obligation under Section&#160;6.2 for Novartis&#8217; Development of a Product in the Diagnostic Field or use of such Product in the Diagnostic Field in the conduct of Clinical Trials of a Product in the Therapeutic Field.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">No Projections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Licensor and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 32</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">REPORTS AND PAYMENT TERMS</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Payment Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">After receipt of a notice of the achievement of a Milestone, Licensor shall submit an Invoice to Novartis with respect to the corresponding Milestone Payment, provided that no such Invoice shall be submitted prior to the Effective Date. Novartis shall make the Milestone Payment within &#91;***&#93; after receipt of such invoice. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Within &#91;***&#93; after each Calendar Quarter during the Term following the First Commercial Sale of a Product, Novartis will provide to Licensor a Sales &#38; Royalty Report. Licensor shall submit an Invoice to Novartis with respect to the royalty amount owed for such Calendar Quarter. Novartis shall pay such royalty amount within &#91;***&#93; after receipt of the Invoice.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Each Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall provide to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) an Invoice for all amounts due to it under this Agreement. Unless otherwise noted, payments on such Invoices shall be made to the Payee within &#91;***&#93; of the Payor&#8217;s receipt of the applicable Invoice. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">All payments from Novartis to Licensor shall be made by wire transfer in USD to the credit of such bank account as may be designated by Licensor in this Agreement or in writing to Novartis. Any payment which falls due on a date which is not a Business Day in the location from which the payment will be made may be made on the next succeeding Business Day in such location.&#160;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">If Payor fails to pay any payment under this Agreement by the date when such payment is due, then, without limiting any other right or remedy of Payee, such late payment shall be paid together with interest thereon at an annual rate (but with interest accruing on a daily basis) of &#91;***&#93; above the &#91;***&#93; of &#91;***&#93; rate from the date on which such payment was originally due until the date of payment (provided, that, such rate shall not exceed the rate permissible under applicable Law).. Interest shall not accrue on undisputed amounts that were paid after the due date solely as a result of mistaken Licensor actions (e.g., if a payment is late as a result of Licensor or any if its Affiliates providing an incorrect account for receipt of payment).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All payments under this Agreement shall be payable in USD. When conversion of payments from any foreign currency is required to be undertaken by Novartis, the USD equivalent shall be calculated using Novartis&#8217; then-current standard exchange rate methodology as applied in its external reporting.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In the event any payments to be made to Licensor or its Affiliates under this Agreement are subject to withholding tax under applicable Laws, including extra-territorial taxation, or if it is unclear whether the requirements of applicable Laws, including extra-territorial taxation, are met, Novartis or its Affiliates shall be authorized to deduct the withholding tax from the payments, and shall pay all such withholding tax to the relevant tax authority, so that only the </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 33</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">correspondingly reduced amount of payments (i.e. the full amount payable less withholding tax) is paid out to Licensor. Novartis shall provide Licensor with proof of the withholding tax payment. Licensor and Novartis shall make all reasonable efforts to obtain relief or reduction of withholding tax under the applicable tax treaties, including the submission or issuance of requisite forms and information. If a special procedure is required for treaty relief by Law, a treaty relief based on a tax treaty will only be taken into account if Licensor submits any exemption certificate requested by Novartis to Novartis in accordance with legal requirements on or prior to the time of the payment to Licensor.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">If no withholding tax deduction has been made on the payments to Licensor or its Affiliates under this Agreement, but tax authorities subsequently take the position that a withholding tax deduction should have been made, including extra-territorial taxation, Licensor shall provide, at its own expense, all reasonable support to Novartis to obtain relief or reduction of withholding under the applicable Laws, including tax treaties, including the submission or issuance of requisite forms and information, and the Parties will bear such liability (reimburse one another as necessary) in a manner consistent with that which would have resulted had the tax been originally withheld. Any refunds of withholding taxes that are granted to Licensor by the competent tax authority and which would cause Licensor to receive payments in excess of that which Novartis would owe under this Agreement, including related interest, shall be paid to Novartis by Licensor.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">All amounts mentioned in this Agreement are exclusive of any VAT. Licensor and Novartis shall issue all Invoices including claim of expenses etc. in full compliance with the VAT laws and regulations applicable at Licensor&#8217;s and Novartis&#8217; place of business. If any VAT is due based on local law, Licensor and Novartis will be allowed to add the amount of VAT to the amounts mentioned in this Agreement and invoice the other party the net amount plus applicable VAT.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Records and Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Each Party shall keep complete, true and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including, with respect to Novartis, in relation to Net Sales and royalties. Each Party will keep such books and records for at least &#91;***&#93; following the Calendar Year to which they pertain.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor may, upon written request to Novartis, cause an internationally-recognized independent accounting firm (which is reasonably acceptable to Novartis) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to inspect the relevant records of Novartis or its Affiliates to verify the royalties payable by Novartis and the related reports, statements and books of accounts, as applicable. Before beginning its audit, the Auditor shall execute an undertaking acceptable to Novartis by which the Auditor shall agree to keep confidential all Confidential Information reviewed during such audit. The Auditor shall have the right to disclose to Licensor only its conclusions regarding any payments owed under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis and its Affiliates shall make their records relating to each Sales &#38; Royalty Report available for inspection by such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from Licensor. The records shall be reviewed solely to verify the accuracy of Novartis&#8217; royalties and compliance with this Agreement. Such inspection right shall not be exercised more than once in any Calendar Year and not more frequently than once with respect to records covering any specific period of time. In addition, Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall only be entitled to audit the relevant books and records of Novartis from the &#91;***&#93; prior to the Calendar Year in which the audit request is made. Licensor agrees to hold in strict confidence all Confidential Information received and all </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 34</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidential Information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any law, regulation or judicial order.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">The Auditor shall provide its audit report and basis for any determination to Novartis at the time such report is provided to Licensor, before it is considered final. Novartis shall have the right to request a further determination by such Auditor as to matters which Novartis disputes within &#91;***&#93; following receipt of such report. Novartis will provide Licensor and the Auditor with a reasonably detailed statement of the grounds upon which it disputes any findings in the audit report and the Auditor shall undertake to complete such further determination within &#91;***&#93; after the dispute notice is provided, which determination shall be limited to the disputed matters. Any matter that remains unresolved shall be resolved in accordance with the dispute resolution procedures contained in Section 15.5.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by Novartis, the underpaid or overpaid amount shall be settled promptly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">Licensor shall pay for such audits, as well as its own expenses associated with enforcing its rights with respect to any payments hereunder. In addition, if an underpayment of more than &#91;***&#93; of the total payments due for the applicable audit period is discovered, the fees and expenses charged by the Auditor shall be paid by Novartis. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">INTELLECTUAL PROPERTY RIGHTS</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Ownership of Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">By Inventorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as set forth in Section 8.1(b), and Section 8.1(c) below, ownership of all Inventions shall be based on inventorship, as determined in accordance with the rules of inventorship under United States patent laws. Each Party shall solely own any Inventions made solely by its and its Affiliates&#8217; and sublicensees&#8217; employees, agents, or independent contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sole Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Parties shall jointly own any Inventions that are made jointly by employees, agents, or independent contractors of one Party and its Affiliates and sublicensees together with employees, agents, or independent contractors of the other Party and its Affiliates and sublicensees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). All (i) Know-How developed jointly by employees, agents, or independent contractors of one Party and its Affiliates and sublicensees together with employees, agents, or independent contractors of the other Party and its Affiliates and sublicensees and (ii)&#160;Patent Rights claiming patentable Joint Inventions shall be referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, respectively. Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, or pursuant to Section 3.6, each Party shall be entitled to practice, license (through multiple tiers), assign and otherwise exploit the Joint Inventions and Joint Patent Rights in all countries and jurisdictions without the duty of accounting or seeking consent from the other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Improvements to Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Section 8.1(a) and subject to Section 8.1(d), Licensor shall solely own all Inventions that are improvements to the Platform. To the extent any such Invention that belongs to Licensor under this Section 8.1(b) is made by Novartis, its Affiliates or sublicensees or its or their employees, agents, or independent contractors, whether solely or jointly, Novartis shall and hereby does assign and transfer to Licensor, without additional consideration, all right, title and interest in and to such Invention (including all rights of action and claims for damages and benefits arising due to past and present infringement of such Invention), and such Invention shall be deemed Licensor&#8217;s Sole Invention and Licensor&#8217;s Confidential Information (and not the Confidential Information of Novartis). Subject to the terms and conditions of this Agreement, Licensor hereby grants to Novartis a perpetual, </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 35</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">irrevocable, non-exclusive, fully-paid, royalty-free, worldwide, freely sublicensable license, to use the Inventions assigned to Licensor pursuant to this Section 8.1(b), for any and all purposes.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Improvements to Novartis Background Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Section 8.1(a) and subject to Section 8.1(d), Novartis shall solely own all Inventions that are improvements to the Novartis Background Technology. To the extent any such Invention that belongs to Novartis under this Section 8.1(c) is made by Licensor, its Affiliates or sublicensees or its or their employees, agents, or independent contractors, whether solely or jointly, Licensor shall and hereby does assign and transfer to Novartis, without additional consideration, all right, title and interest in and to such Invention (including all rights of action and claims for damages and benefits arising due to past and present infringement of such Invention), and such Invention shall be deemed Novartis&#8217; Sole Invention and Novartis&#8217; Confidential Information (and not the Confidential Information of Licensor). Subject to the terms and conditions of this Agreement, Novartis hereby grants to Licensor a perpetual, irrevocable, non-exclusive, fully-paid, royalty-free, worldwide, freely sublicensable license, to use the Inventions assigned to Novartis pursuant to this Section 8.1(c), for any and all purposes.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Research Term, each Party shall promptly disclose to the other Party all Inventions, including all invention disclosures or other similar documents submitted to such Party by its, or its Affiliates&#8217; or sublicensees&#8217;, employees, agents or independent contractors relating to such Inventions, and shall also respond promptly to reasonable requests from such other Party for additional information relating to such Inventions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Personnel Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each employee, agent or independent contractor of a Party or its respective Affiliates or sublicensees performing work under this Agreement shall, prior to commencing such work, be bound by invention assignment obligations, including&#58; (i)&#160;promptly reporting any invention, discovery, process or other intellectual property right to the applicable Party, its Affiliate or sublicensee&#59; (ii)&#160;presently assigning to the applicable Party, its Affiliate or sublicensee all of his or her right, title and interest in and to any invention, discovery, process or other intellectual property&#59; (iii)&#160;cooperating in the preparation, filing, prosecution, maintenance and enforcement of any patent and patent application with respect to such invention, discovery, process or other intellectual property&#59; and (iv)&#160;performing all acts and signing, executing, acknowledging and delivering any and all documents required for effecting the obligations and purposes of this Agreement. It is understood and agreed that any such invention assignment agreement need not reference or be specific to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Ownership of Results and Data. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All data and results arising from the Parties&#8217; activities under this Agreement, including clinical and regulatory data and Information generated for regulatory purposes relating to the Product shall be owned by Novartis.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Patent Filing, Prosecution, Maintenance, Management &#38; Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Responsibility for Prosecuting and Maintaining Platform Patent Rights and Certain Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms of this Section 8.3, (i) &#91;***&#93; to file, prosecute and maintain the Platform Patent Rights and (ii) &#91;***&#93; to file, prosecute and maintain the Joint Patent Rights that are &#91;***&#93;, using counsel of its own choice (including outside counsel or internal counsel) to whom &#91;***&#93; has no reasonable objection&#59; provided that, &#91;***&#93; will be deemed to have no objection to &#91;***&#93; counsel. &#91;***&#93; will keep &#91;***&#93; reasonably informed of the status of such Platform Patent Rights and will provide a copy of material substantive communications from any governmental authority concerning such Platform Patent Rights, upon &#91;***&#93; request. If &#91;***&#93; decides not to prosecute or maintain any such Joint Patent Right, &#91;***&#93; shall notify &#91;***&#93; in writing at least &#91;***&#93; prior to any relevant deadline or filing or response date, and &#91;***&#93; shall </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 36</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">thereupon have the &#91;***&#93; to assume the prosecution and maintenance of such Joint Patent Right, as applicable, subject to the terms of this Section 8.3.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Responsibility for Prosecuting and Maintaining &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93; Patents and Product Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms of this Section 8.3, &#91;***&#93; to prosecute and maintain Patent Rights claiming Inventions &#91;***&#93; (&#8220;&#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93; Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the &#91;***&#93; to file, prosecute and maintain Product Patent Rights using counsel of its own choice (including outside counsel or internal counsel) to whom &#91;***&#93; has no reasonable objection&#59; provided that, &#91;***&#93; will be deemed to have no objection to &#91;***&#93; counsel. If &#91;***&#93; decides not to prosecute or maintain any Product Patent Right, &#91;***&#93; shall notify &#91;***&#93; in writing at least &#91;***&#93; prior to any relevant deadline or filing or response date, and &#91;***&#93; shall thereupon have the &#91;***&#93; to assume the prosecution and maintenance of such Product Patent Right, as applicable, subject to the terms of this Section 8.3. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Costs&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All costs and expenses incurred by the Party which prosecutes and maintains any Platform Patent Right, Joint Patent Right, &#91;***&#93; Patent, or Product Patent Right shall be borne by such Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prosecuting and Maintaining Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Prosecuting and Maintaining Party of a Product Patent Right or Joint Patent Right will&#58; (i)&#160;keep the other Party reasonably informed of the status of such Patent Rights and provide a copy of material substantive communications from any governmental authority concerning such Patent Rights&#59; (ii)&#160;reasonably in advance of making any filings or submissions to any governmental authority with respect to such Patent Rights, such that the other Party may have a reasonable opportunity to review and comment thereon, provide a copy thereof to the other Party for its review and comment&#59; and (iii)&#160;consider in good faith all comments timely provided to the Prosecuting and Maintaining Party by the other Party on such filings and communications. Upon the Prosecuting and Maintaining Party&#8217;s request and at its expense, the other Party shall provide the Prosecuting and Maintaining Party with all reasonable assistance and cooperation in connection with its prosecution and maintenance of the applicable Patent Rights, including by providing access to relevant persons and executing all documentation reasonably requested by the Prosecuting and Maintaining Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Patent Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; will have the right to elect and file for patent term restorations or extensions, supplemental protection certificates, or any of their equivalents with respect to patent term restoration, supplemental protection certificates or their equivalents, and patent term extensions with respect to the Product Patent Rights and Joint Patent Rights in any country and&#47;or region where applicable. &#91;***&#93; shall keep &#91;***&#93; reasonably informed of its efforts to obtain such restoration or extension, supplemental protection certificate or their equivalents and shall in good faith consider &#91;***&#93; comments thereto. Licensor shall, and shall cause its Affiliates to, cooperate with and provide all reasonable assistance requested by &#91;***&#93;, including permitting &#91;***&#93;, and executing documents and providing any relevant information to &#91;***&#93;. &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Patent Enforcement and Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will promptly notify the other Party of any&#58; (i) infringement, misappropriation, or other violation by a Third Party of any of the Licensor Patent Rights, Joint Patent Rights or Product Patent Rights, of which it becomes aware arising out of the exploitation of Licensed Compounds or Products (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; or (ii) request for declaratory judgment, opposition, nullity action, interference, inter-partes reexamination, inter-partes review, post-grant review, derivation proceeding, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Licensor Patent Rights, Joint Patent Rights, Product Patent Rights or &#91;***&#93; Patents (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement Patent Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Control</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 37</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.98pt">&#91;***&#93; will have the sole right, but not the obligation, to bring and control any action in connection with a Third Party Infringement of a Platform Patent Right at its own expense as it reasonably determines appropriate. During any such action, &#91;***&#93; shall (I)&#160;provide &#91;***&#93; with drafts of all official papers and statements prior to their submission in such action, in sufficient time to allow &#91;***&#93; to review, consider and substantively comment thereon&#59; and (II) reasonably consider incorporating any such &#91;***&#93; comments.</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.98pt">&#91;***&#93; will have the first right, but not the obligation, to bring and control any action in connection with any Third Party Infringement of Joint Patent Rights, Product Patent Rights, or Licensor Patent Rights that do not constitute Platform Patent Rights at its own expense as it reasonably determines appropriate. &#91;***&#93; will have the right to join as a party to any such action and participate with its own counsel at its own expense, provided that &#91;***&#93;. During any such action, &#91;***&#93; shall (I) provide &#91;***&#93; with drafts of all official papers and statements prior to their submission in such action, in sufficient time to allow &#91;***&#93; to review, consider and substantively comment thereon&#59; and (II) reasonably consider incorporating any such &#91;***&#93; comments. Solely with respect to the Joint Patent Rights and Licensor Patent Rights , if &#91;***&#93; does not take commercially reasonable steps to prosecute any Third Party Infringement within &#91;***&#93; following the first notice provided in Section 8.4(a) above or &#91;***&#93; before the time limit, if any, for filing of such actions in accordance with applicable Law, whichever comes first, then &#91;***&#93; may prosecute such Third Party Infringement at its own expense.</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.93pt">&#91;***&#93; will have the sole right, but not the obligation to defend against any Agreement Patent Action for any Platform Patent Right at its own expense as it reasonably determines appropriate.</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.88pt">Subject to Section 8.4(b)(iv), &#91;***&#93; will have the first right, but not the obligation, to defend against any Agreement Patent Action for any Licensor  Patent Right at its own expense as it reasonably determines appropriate. &#91;***&#93; may participate in any such Agreement Patent Action for a Licensor  Patent Right with counsel of its choice at its own expense, provided that &#91;***&#93; shall control the defense in such Agreement Patent Action. If &#91;***&#93; informs &#91;***&#93; that it does not intend to defend against such an Agreement Patent Action, or if &#91;***&#93; determines to cease defending against any such Agreement Patent Action, and, in each case, such Agreement Patent Action is not brought as a defense against a Third Party Infringement, then &#91;***&#93; will have the right, but not the obligation, upon written notice to &#91;***&#93;, to defend against such Agreement Patent Action for a Licensor  Patent Right, or take over the defense of any Agreement Patent Action initiated by &#91;***&#93;, as applicable, in each case, solely as it relates to Licensor Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.48pt">&#91;***&#93; will have the first right, but not the obligation, to defend against any Agreement Patent Action for any &#91;***&#93; Patent, Product Patent Right or Joint Patent Right at its own expense as it reasonably determines appropriate. &#91;***&#93; may participate in any such Agreement Patent Action for a Product Patent Right or Joint Patent Right with counsel of its choice at its own expense, provided that &#91;***&#93; shall control the defense in such Agreement Patent Action. If &#91;***&#93; informs &#91;***&#93; that it does not intend to defend against an Agreement Patent Action with respect to a Product Patent Right or Joint Patent Right, or if &#91;***&#93; determines to cease defending against any such Agreement Patent Action with respect to a Product Patent Right or Joint Patent Right, and, in each case, such Agreement Patent Action is not brought as a defense against a Third Party Infringement, then &#91;***&#93; will have the right, but not the obligation, upon written notice to &#91;***&#93;, to defend against such Agreement Patent Action for a Product Patent Right or Joint Patent Right, or take over the defense of any Agreement Patent Action initiated by &#91;***&#93;, as applicable, in each case, solely as it relates to a Product Patent Right or Joint Patent Right.</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 38</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Cooperation and Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the request of the Party bringing and controlling any Third Party Infringement or defending any Agreement Patent Action, as applicable (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the other Party shall provide assistance in connection with such action, including by executing reasonably appropriate documents,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">providing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">access to such Party&#8217;s premises and employees, cooperating reasonably in discovery, and joining as a party to the action if requested by the Controlling Party. The Controlling Party will keep the other Party reasonably informed of all material developments in connection with any such suit, provide copies of all documents filed, and consider in good faith any comments from the other Party, and the other Party shall have the right to consult with the Controlling Party and to participate in and, if appropriate, be represented by independent but mutually agreed upon counsel in such litigation at such other Party&#8217;s own cost and expense. Neither Party shall, without the other Party&#8217;s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to the other Party or admits the invalidity or unenforceability of or adversely affects the scope of any Platform Patent Right, Product Patent Right, or Joint Patent Right, which consent shall not be unreasonably withheld, delayed, or conditioned. Any recoveries resulting from a Claim of Third Party Infringement (whether by way of settlement or otherwise) shall be first applied against payment of each Party&#8217;s costs and expenses in connection therewith (which amounts will be allocated pro rata if insufficient to cover the totality of such costs and expenses). Any remainder after such reimbursement to the extent relating to (i) Third Party Infringement &#91;***&#93;&#59; and (ii) Third Party Infringement &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall have the right to brand the Products using Novartis-related trademarks and any other trademarks and trade names it determines appropriate for the Products, which may vary by country or within a country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Novartis shall own all rights in the Product Marks and register and maintain the Product Marks in the countries and regions it determines reasonably necessary.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.45pt">CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Duty of Confidence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to the other provisions of this Article 9, all Confidential Information of a Disclosing Party under this Agreement will be maintained in confidence and otherwise safeguarded by the Recipient Party. The Recipient Party may only use the Confidential Information for the purposes of this Agreement and pursuant to the rights granted to the Recipient Party under this Agreement. Subject to the other provisions of this Article 9, each Party and its Affiliates shall hold as confidential such Confidential Information of the other Party or its Affiliates in the same manner and with the same protection as such Recipient Party maintains its own confidential information but in no event with less than a reasonable degree of care. Subject to the other provisions of this Article 9, a Recipient Party may only disclose Confidential Information of the Disclosing Party to employees, agents, contractors, consultants and advisers of the Recipient Party and its Affiliates and sublicensees and to Third Parties in each case to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement&#59; provided that such Persons are bound to maintain the confidentiality of the Confidential Information of Disclosing Party in a manner consistent with the confidentiality provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">With respect to Licensor&#8217;s obligations under this Article 9 with respect to Licensor Know-How that is solely and specifically related to a Licensed Compound or Product, Licensor shall maintain in confidence and otherwise safeguard such Licensor Know-How as such in accordance with this Article 9.</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 39</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The obligations under this Article 9 shall not apply to any information to the extent that such information&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement by the Recipient Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">was known to, or was otherwise in the possession of, the Recipient Party prior to the time of disclosure by the Disclosing Party, as demonstrated by competent evidence&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">is disclosed to the Recipient Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party&#59; or </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">is independently developed by or on behalf of the Recipient Party, as evidenced by its written records, without reference to the Confidential Information disclosed by or on behalf of the Disclosing Party under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Recipient Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Recipient Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the possession of the Recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Recipient Party unless the combination and its principles are in the public domain or in the possession of the Recipient Party.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.5pt">Authorized Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In addition to disclosures allowed under Section 9.1 and 9.2, Novartis may disclose Confidential Information belonging to Licensor or its Affiliates to the extent such disclosure is necessary in the following instances&#58; (i) filing or prosecuting and maintaining Patent Rights as permitted by this Agreement&#59; (ii) in connection with Regulatory Filings for Products&#59; (iii) prosecuting or defending litigation as permitted by this Agreement&#59; (iv) complying with applicable court orders or governmental regulations&#59; or (v) to the extent otherwise necessary in connection with exercising the license and other rights granted to it hereunder. In addition to disclosures allowed under Section 9.1 and 9.2, Licensor may disclose Confidential Information to the extent such disclosure is necessary in the following instances&#58; (i) filing or prosecuting and maintaining Patent Rights as permitted by this Agreement&#59; or (ii) prosecuting or defending litigation as permitted by this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In addition, Novartis and its Affiliates and their respective sublicensees may disclose Confidential Information of Licensor or its Affiliates to Third Parties as may be necessary or reasonably useful in connection with the Development, manufacture, preparation, use or Commercialization of the Licensed Compounds or Product(s) as contemplated by this Agreement, including in connection with subcontracting transactions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In addition, each party may disclose Confidential Information of the other Party to  actual or bona fide prospective investors, lenders, advisors, and acquirors, provided, that in each such case (x) such recipients are bound by confidentiality and non-use obligations at least as restrictive as those contained in the Agreement and (y) the term of confidentiality for recipients may be shorter than the period set forth in this Agreement as long as it is no less than &#91;***&#93;&#59; provided, further, that, solely in the case of any disclosure by a Party pursuant to this Section 9.3(c) to an actual or potential Pharma Investor, (1) except for the Permitted Categories of Information, all such disclosures of Confidential Information of the other Party will be provided to advisors of such Pharma Investor (e.g., outside legal counsel or scientific advisors) bound by </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 40</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">confidentiality and non-use obligations in accordance with the previous proviso and not directly to employees of such Pharma Investor, (2) to the extent any advisor of such Pharma Investor receives Confidential Information of Novartis or any of its Affiliates that is not also disclosed directly to such Pharma Investor in accordance with the terms of this Agreement, such advisor will be entitled to provide the Pharma Investor only a qualitative assessment of such Confidential Information reviewed, which may include (i) a recommendation as to whether to participate as an investor or lender or (ii) statements confirming that the applicable Confidential Information of Novartis or its Affiliates reviewed by such advisor provides a reasonable basis for Licensor&#8217;s prior public disclosures made in accordance with this Agreement, but in no event shall such advisor be authorized to disclose to the Pharma Investor any Confidential Information of Novartis or its Affiliates that is not otherwise provided directly to the Pharma Investor in accordance with the terms of this Agreement, and (3) Licensor will use Commercially Reasonable Efforts to provide Novartis, prior to or contemporaneously with such disclosure, written notice that a disclosure will be or is being made in accordance with this Section 9.3(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> such notice will not be required to identify the Pharma Investor.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Categories</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of Information shall comprise&#58; (A) the terms of this Agreement, (B) the status of Development of Products, including the initiation and completion of each Clinical Trial of a Product, (C) anticipated timing for achievement of any Milestone Event and (D) summary financial information.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event the Recipient Party is required to disclose Confidential Information of the Disclosing Party by Law or in connection with bona fide legal process, such disclosure shall not be a breach of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Recipient Party&#58; (i) informs the Disclosing Party as soon as reasonably practicable of the required disclosure&#59; (ii) limits the disclosure to the required purpose&#59; and (iii) at the Disclosing Party&#8217;s request and expense, assists in an attempt to object to or limit the required disclosure.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Ongoing Obligation for Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon early termination of this Agreement for any reason, each Party and its Affiliates shall immediately return to the other Party or destroy any Confidential Information disclosed by the other Party or any of its Affiliates, except for one copy which may be retained in its confidential files for archive or compliance purposes. Nothing in this Section 9.4 will require the alteration, modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business&#59; provided that the Recipient Party and its Affiliates will continue to be bound by its obligations of confidentiality and other obligations under this Article 9 with respect to any of the Disclosing Party&#8217;s Confidential Information contained in such archival tapes or other electronic back-up media. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Data Privacy and Security.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Compliance with Privacy and Data Security Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of the Parties agrees to comply with applicable Privacy and Data Security Laws in connection with the performance of its obligations or exercise of its rights hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Protections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary herein, the Parties acknowledge that in performing their obligations hereunder, each Party may obtain or have access to, or otherwise store, process or transmit, certain Sensitive Information. Without limiting a Party&#8217;s other obligations under this Agreement, each Party shall implement and maintain reasonable security procedures and practices appropriate to the nature of Sensitive Information that it obtains, accesses, stores, processes or transmits and take such other actions as are necessary to protect the security and confidentiality of such Sensitive Information against any anticipated or actual threats or hazards to the security or integrity of such Sensitive Information in accordance with Privacy and Data Security Laws.</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 41</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Breaches</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that a Party or its Affiliates or sublicensee learns of (or has reason to believe that there has been) unauthorized access to or use of, or any security breach relating to or affecting, Sensitive Information of the other Party collected, prepared or developed in connection with this Agreement, or that any person who has had access to Sensitive Information has violated or intends to violate the terms of this Section 9.5, such Party shall immediately (within &#91;***&#93;) notify the other Party of the same, and shall, at its expense, fully cooperate with the owning Party in (i) investigating and responding to the foregoing&#59; (ii) notifying affected individuals as required by Privacy and Data Security Laws or as otherwise directed by the other Party&#59; and (iii) seeking injunctive or other equitable relief against any such person or persons who have violated or attempted to violate the security of Sensitive Information. The Party whose Sensitive Information has been subject to a security breach (or alleged security breach) shall have the sole right to determine the content, timing and other details of any notices under subsection (ii). The Party who, themselves, or through their Affiliates or sublicensees has conducted or permitted to be conducted such security breach shall be responsible for reimbursing the Party owning such Sensitive Information for the costs of such notifications and fielding feedback and questions from those notified, and any other associated costs that such Party may incur in connection with responding to or managing a breach of the security of Sensitive Information (i.e., costs of credit monitoring services, call center services and forensics services, fines imposed by any government authority, fraud liability, compromise fees and other remediation costs).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.63pt">Changes to the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If during the Term a Party believes that amendments to this Agreement are required to ensure the compliance of each Party with the requirements of applicable Privacy and Data Security Laws, such Party shall notify the other Party and the Parties will promptly discuss and agree in good faith on appropriate amendments to this Agreement. Notwithstanding anything to the contrary, no Party shall be required to transfer to or process on behalf of the other Party any personal data until such amendments have been executed if such Party reasonably believes such transfer or processing would put such Party in breach of applicable Privacy and Data Security Laws.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The term of this Agreement shall commence upon the Effective Date and, unless terminated pursuant to Section 10.2 or 10.3, shall continue in full force and effect, on a Product-by-Product and country-by-country basis, until such time as the Royalty Term with respect to such Product expires in such country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). On a Product-by-Product and country-by-country basis, effective upon the expiration of the Royalty Term for such Product in such country, the licenses granted to Novartis with respect to such Product will each become non-exclusive, fully paid-up, royalty-free, irrevocable, and perpetual in such country with respect to such Product.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Termination for Cause&#59; Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">If either Novartis or Licensor is in material breach of any material obligation hereunder, the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and in the event such material breach is not cured within &#91;***&#93; (or &#91;***&#93; with respect to undisputed payments due under Section 7.1 after the breaching Party&#8217;s receipt of such notice, the non-breaching Party shall have the right thereafter to terminate this Agreement immediately on a Target-by-Target basis or in its entirety by giving written notice to the breaching Party to such effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if such breach (other than a breach with respect to undisputed payments) is capable of being cured but cannot be cured within such &#91;***&#93; period and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have an additional &#91;***&#93; period to cure such breach. In the event that arbitration is commenced in accordance with </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 42</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.5 with respect to any alleged breach hereunder, no purported termination of this Agreement pursuant to this Section 10.2(a) shall take effect until it is finally determined pursuant to such arbitration that such material breach occurred. Any termination by any Party under this Section 10.2(a) and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Either Licensor or Novartis may terminate this Agreement without notice if an Insolvency Event occurs in relation to the other Party. In any event when a Party first becomes aware of the likely occurrence of any Insolvency Event in regard to that Party, it shall promptly so notify the other Party in sufficient time to give the other Party sufficient notice to protect its interests under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis may terminate this Agreement upon written notice to Licensor in the event Licensor rejects this Agreement under Section 365 of the United States Bankruptcy Code, 11 U.S.C. &#167;&#167; 101 et seq. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or under any similar laws in any other country in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Novartis may terminate this Agreement upon &#91;***&#93; written notice to Licensor where Novartis determines that a safety or regulatory issue exists which would be reasonably expected to adversely affect the Development, Manufacture, or Commercialization of any Licensed Compound or Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis may terminate this Agreement upon written notice to Licensor in the event of a Change of Control of Licensor. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Termination by Novartis Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis may terminate this Agreement without cause at any time in its entirety or on a Target-by-Target basis (i) on &#91;***&#93; prior written notice at any time prior to the date that a Product has received Regulatory Approval or (i) on &#91;***&#93; prior written notice at any time on or after the date that a Product has received Regulatory Approval.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">The Parties agree that this Agreement constitutes an executory contract under Section 365 of the Code for the license of &#8220;intellectual property&#8221; as defined under Section 101 of the Code and constitutes a license of &#8220;intellectual property&#8221; for purposes of any similar laws in any other country in the Territory. The Parties further agree that Novartis, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Code, including Section&#160;365(n) of the Code, and any similar laws in any other country in the Territory. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Licensor under the Code and any similar laws in any other country in the Territory, Novartis will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless Licensor elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of Licensor upon written request therefor by Novartis.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">All rights, powers and remedies of Novartis provided for in this Section 10.4 are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including under the Code and any similar laws in any other country in the Territory). In the event of an Insolvency Event in relation to Licensor, Novartis, in </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 43</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity (including under the Code). The Parties agree that they intend the following Novartis rights to extend to the maximum extent permitted by law, including for purposes of the Code&#58; (i) the right of access to any intellectual property (including all embodiments thereof) of Licensor, or any Third Party with whom Licensor contracts to perform an obligation of Licensor under this Agreement which is necessary or reasonably useful for the Development, manufacture, preparation, use or Commercialization of Licensed Compounds or Products in the Territory&#59; (ii)&#160;the right to contract directly with any Third Party described in (i) to complete the contracted work, and (iii) the right to cure any breach of or default under any such agreement with a Third Party and set off the costs thereof against amounts payable to Licensor under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that &#91;***&#93; then &#91;***&#93; by written notice to &#91;***&#93; either &#91;***&#93; provided that&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.25pt">EFFECT OF TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon termination of this Agreement, (i) all licenses and other rights granted by Licensor to Novartis under this Agreement shall terminate, all sublicenses granted by Novartis shall terminate, all Products with respect to which this Agreement is terminated shall each become a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; (ii) all licenses and other rights granted by Novartis to Licensor under Section 3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and all sublicenses thereunder granted by Licensor) shall terminate with respect to Terminated Targets and Terminated Products&#59; and (iii) Licensor&#8217;s obligations under Section&#160;3.7 will terminate&#59; provided, for clarity, that if this Agreement is terminated on a Target-by-Target basis, then this Section 11.1 shall only apply to the Terminated Target and only Products directed to such Terminated Target shall be Terminated Products. </font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">License to Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective upon termination of this Agreement by Licensor pursuant to Section 10.2 or by Novartis pursuant to Section 10.3, Novartis will grant Licensor an exclusive worldwide, fee-bearing (subject to Section 11.3) license, with the right to grant sublicenses &#91;***&#93; under its interest in the Product Marks to Develop, manufacture, and Commercialize Reversion Products in the Field that are being Commercialized as of the effective date of termination.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Negotiation of Financial Terms for Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties shall negotiate in good faith reasonable financial compensation payable by Licensor to Novartis with respect to the exercise of the license granted to Licensor pursuant to Section 11.2. If the Parties cannot agree on such financial terms within a period of &#91;***&#93; of the effective date of such termination, then such dispute shall be referred to the Executive Officers of the Parties for resolution. If the Executive Officers do not fully resolve such matter within &#91;***&#93; (or a later date agreed to by each of the Parties) of the matter being referred to them, then such financial terms shall be decided by Expedited Arbitration.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Transition to Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within a reasonable period of time following the receipt of notice of termination given under this Agreement by Licensor pursuant to Section 10.2 or by Novartis pursuant to Section 10.3, the Parties shall meet to mutually agree upon a transition plan to effect an orderly and timely transition to Licensor of applicable Development, manufacture and Commercialization activities and responsibilities with respect to the Reversion Products, which shall be subject to Novartis&#8217;s sell off right in Section 11.5, if applicable, and which shall incorporate the following elements (which elements do not require mutual agreement after notice of termination) and other provisions as mutually agreed upon by the Parties&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Upon Licensor&#8217;s written request, (A) assignment and transfer to Licensor (or its designee) of all Regulatory Filings solely related to the Reversion Products and (B) to the extent not already assigned or transferred pursuant to (A) above, grant a Right of Reference or use with respect to </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 44</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any DMF that relates to any Reversion Product to the extent necessary for preparing and submitting Regulatory Filings for such Reversion Product to a competent Regulatory Authority or to the extent used or referenced by Novartis, its Affiliates or sublicensees in its Regulatory Filings for such Reversion Product, and Novartis shall take other actions reasonably requested by Licensor to provide Licensor or its designee access to and the benefit of such DMF, including the data contained or referenced therein. If Novartis is prohibited by applicable Law from assigning or transferring ownership of any of the foregoing items to Licensor, Novartis shall grant Licensor (or its designee) a Right of Reference or use to such item as provided above and shall take other actions reasonably requested by Licensor to provide Licensor or its designee access to and such benefit of such Regulatory Filings, including the data contained or referenced therein. Each Party shall take actions reasonably necessary to effect such assignment and transfer or grant of Right of Reference or use to Licensor (or its designee), including by making such filings with Regulatory Authorities in the Territory that may be necessary to record such assignment or effect such transfer and, at Licensor&#8217;s written request, to complete any pending regulatory filings with respect to the Reversion Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Upon Licensor&#8217;s written request, transfer to Licensor (or its designee) a copy of all Know-How within the Novartis Product Technology with respect to the applicable Reversion Product. For clarity, such Know-How that is solely and specifically related to any Reversion Product shall be deemed to constitute the Confidential Information of both Parties after such transfer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Upon Licensor&#8217;s written request, provide to Licensor a final Product Development Report which describes the specified Development activities performed since the last report with respect to each Terminated Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Novartis shall promptly provide Licensor with a copy of each agreement between Novartis (or its Affiliates) and a Third Party directly relating to any Reversion Product or the Development, manufacture and Commercialization of any Reversion Product, and upon Licensor&#8217;s request, Novartis shall assign or sublicense, and shall ensure that its Affiliates assign or sublicense, to Licensor (A) any such agreement that solely relates to Reversion Products, to the extent permitted under the terms thereof, and (B) for any such agreement that does not solely relate to Reversion Products and to the extent permitted under the terms of such agreement, the portion of such agreement (e.g., a work order or statement of work) that relates solely to Reversion Products. Upon Licensor&#8217;s request, Novartis shall provide reasonable assistance to Licensor in connection with Licensor obtaining rights under any such agreement that is not assignable to Licensor (or equivalent rights), such as (x) subject to appropriate indemnification and to the extent permitted by the applicable agreement, working to effect a practical assignment of the rights and obligations under such agreement to Licensor solely with respect to such Reversion Product as if Licensor was a party to such agreement for a reasonable period of time or (y) introducing Licensor to such Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis shall promptly deliver to Licensor a list of the inventory then in its (or its Affiliates&#8217;) possession or control for each Reversion Product (including its inventory of the corresponding Licensed Compound). At Licensor&#8217;s request, Novartis shall deliver to Licensor all or part of such inventory, and Licensor shall reimburse Novartis for its standard costs, calculated in accordance with Novartis&#8217; Accounting Standards, for such delivered inventory of Reversion Product and Licensed Compound, provided that such inventory complies with specifications and has been manufactured in compliance with all applicable Law, including cGMP.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">If Novartis is, itself or through its Affiliate, manufacturing any Reversion Product at the time of the notice of termination, Novartis shall, upon Licensor&#8217;s request, supply such Reversion Product to Licensor at its standard costs, calculated in accordance with Novartis&#8217; Accounting Standards, plus &#91;***&#93; for both clinical and commercial supply for a reasonable period of time </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 45</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">until Licensor establishes an alternative supplier (not to exceed &#91;***&#93;), and reasonably assist Licensor in establishing an alternative supplier for such Reversion Product. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">If any Novartis Manufacturing Product Technology is (A) necessary or reasonably useful in order to manufacture a Reversion Product and (B) generating an alternative to such Novartis Manufacturing Product Technology to manufacture a Reversion Product would result in a material delay in or material increase in the cost of the Development or Commercialization of such Reversion Product, in each case, such that further Development or Commercialization of such Reversion Product would not be commercially reasonable, then, upon the written request of Licensor, the Parties shall negotiate in good faith for up to &#91;***&#93; a reasonable mechanism for Licensor to manufacture or obtain supply of such Reversion Product, which mechanism may include (w) Novartis continuing to manufacture such Reversion Product beyond the &#91;***&#93; time period set forth in Section 11.4(f), (x) to the extent not unreasonably jeopardizing the proprietary nature of the Novartis Manufacturing Product Technology, Novartis providing access to such Novartis Manufacturing Product Technology to &#91;***&#93; or more mutually agreed upon Third Party contract manufacturers and Novartis authorizing such Third Party(ies) to manufacture such Reversion Product for Licensor, subject to reasonable terms and conditions in order to protect the proprietary nature thereof, or (y) Novartis non-exclusively licensing such Novartis Manufacturing Product Technology to Licensor on terms and conditions agreed upon by the Parties, including reasonable compensation and other reasonable terms and conditions in order to protect the proprietary nature of such Novartis Manufacturing Product Technology.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Upon the reasonable request of Licensor, Novartis will provide reasonable consulting assistance and cooperation in connection with the transition of the Development, manufacture and Commercialization of any Reversion Products to the extent contemplated by this Section 11.4. Novartis will provide up to an aggregate of &#91;***&#93; of work relating to any assistance and cooperation contemplated by this Section 11.4(h) for all Reversion Products combined without additional compensation or reimbursement, above which Novartis shall be entitled to be reimbursed, as follows&#58; Novartis may invoice Licensor at the rate of &#91;***&#93; for Novartis&#8217; internal costs which relate to any such work that exceeds such &#91;***&#93; cap, and the reasonable documented Out-of-Pocket Costs, in each case, incurred by Novartis to provide such requested assistance or cooperation and Licensor shall pay all such undisputed invoices within &#91;***&#93; of the date of its receipt of such invoice&#59; provided, that the scope of Novartis&#8217; assistance and cooperation and the related costs are discussed and agreed by the Parties prior to Novartis&#8217; provision thereof. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">If, at the time of such termination, Novartis (or its Affiliates or sublicensees) is conducting any Clinical Trials for any Reversion Product, then, at Novartis&#8217; election on a trial-by-trial and site-by-site basis&#58; (1)&#160;to the extent agreed by Licensor, Novartis shall transfer the conduct of all such Clinical Trials at such sites to Licensor and, in each such case, Licensor shall assume any and all liability for such Clinical Trials at such sites after the effective date of such termination&#59; or (2)&#160;with respect to any Clinical Trials which are not assumed by Licensor under clause (1), Novartis (or its Affiliates or sublicensees) shall, at their expense, continue to conduct, or wind down, such Clinical Trials, as determined by Novartis in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Sell-Off Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective upon any termination other than a termination by Novartis pursuant to Section&#160;10.3 and subject to the payment of all amounts required under Section 6.3 and Section 6.4, Novartis will have the right to sell or otherwise dispose of any inventory of any Terminated Product on hand at the time of such termination or in the process of manufacturing for a period of &#91;***&#93; following the effective date of termination&#59; provided, however, that any revenue obtained from such disposal will be treated as Net Sales.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise provided herein and subject to Section&#160;9.4, within &#91;***&#93; after any termination of this Agreement, each Party shall destroy or return to the other Party </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 46</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(at the other Party&#8217;s discretion) all tangible items bearing, containing, or contained in, any of the Confidential Information of the other Party. If the material is destroyed, it shall provide the other Party written certification of such destruction. For clarity, Licensor shall not be required to destroy or return to Novartis pursuant to this Section 11.6 any Confidential Information of Novartis to which Licensor has licenses or other rights pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of Articles 1, 7, 9, 11, 13 and 15 as well as Sections 2.10, 2.12, 3.5, 6.2 (solely with respect to a Development Milestone Event reached before such expiration or termination), 6.3 (solely with respect to sales of the Product made before such expiration of termination), 6.4 (solely with respect to sales of the Product made before such expiration of termination), 6.9, 8.1, 10.1, 12.1, 12.1, 12.6 and 14.2(a) shall survive expiration or termination of this Agreement. The provisions of Article 9 shall survive the termination or expiration of this Agreement for a period of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Termination Not Sole Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Representations and Warranties by Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party represents and warrants to the other Party, as of the Effective Date, that&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">such Party is an entity duly organized, validly existing and in good standing under the Laws of the state or country (as applicable) of its organization, is qualified to do business and is in good standing as a foreign entity in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such qualification would prevent it from performing its obligations under this Agreement, and has full power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">such Party is duly authorized by all requisite action to execute and deliver this Agreement, and the execution, delivery and performance of this Agreement by such Party does not require any shareholder action or approval, and the Person executing this Agreement on behalf of such Party is duly authorized to do so by all requisite action&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as may be required to conduct clinical trials or to seek or obtain Regulatory Approvals or applicable regulatory materials, all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this Agreement have been obtained&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">it shall maintain either Third Party insurance policies or a program of self-insurance with respect to its activities and obligations under this Agreement. Third Party insurance policies are to be in such amounts as are commercially reasonable in the industry for companies conducting similar business and shall require any of its Affiliates undertaking activities under this Agreement to do the same&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement, and the consummation of the transactions </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 47</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">contemplated hereby do not and shall not (i) conflict with or result in a breach of any provision of its organizational documents, (ii) result in a breach of any agreement to which it is a party&#59; or (iii) violate any applicable Law&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">(i) neither such Party nor, to the knowledge of such Party, any employee, agent or subcontractor of such Party involved or to be involved in the Development of the Licensed Compounds or the Products has been debarred under Subsection (a) or (b) of Section 306 of the Act (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) no Debarred Person who is known by such Party to have been debarred under Subsection (a) or (b) of Section 306 of the Act will be employed by such Party in the performance of any activities hereunder&#59; and (iii) to the knowledge of such Party, no Debarred Person on any of the FDA clinical investigator enforcement lists (including the (1) Disqualified&#47;Totally Restricted List, (2) Restricted List and (3) Adequate Assurances List) will participate in the performance of any activities hereunder. </font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Representations and Warranties by Licensor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Licensor represents and warrants to Novartis, as of the Effective Date, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt;text-decoration:underline">Exhibit B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">sets forth a complete and accurate list of&#58; (i) all Licensor Patent Rights in existence, indicating the owner, licensor or co-owner(s) thereof if such Licensor Patent Rights are not solely owned by Licensor&#59; and (ii) all license, assignment, distribution or other agreements relating to the Licensor Patent Rights and Licensor Know-How&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor is the sole and exclusive owner, or exclusive licensee, of all of the Licensor Patent Rights free from Encumbrances and is listed in the records of the applicable governmental agencies as the exclusive licensee or sole and exclusive owner of record for each registration, grant and application included in the Licensor Patent Rights&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Licensor has obtained from all individuals who have been identified as inventors of any Licensor Patent Rights effective assignments of all ownership rights of such individuals in such Licensor Patent Rights, either pursuant to written agreement or by operation of law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">All of its employees, officers, and consultants have executed agreements or have existing obligations under applicable laws requiring assignment to Licensor of all inventions made during the course of and as the result of their association with Licensor and obligating all such individuals to maintain as confidential Licensor&#8217;s Confidential Information as well as confidential information of other parties (including Novartis and its Affiliates) which such individual may receive, to the extent required to support Licensor&#8217;s obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Licensor has the right to grant to Novartis the licenses under the Licensor Patent Rights and Licensor Know-How that it purports to grant hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">Licensor has the right to use and disclose and to enable Novartis to use and disclose (in each case, under appropriate conditions of confidentiality) the Licensor Know-How free from Encumbrances&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">to the knowledge of Licensor, the issued patents in the Licensor Patent Rights are valid and enforceable without any Claims, challenges, oppositions, nullity actions, interferences, inter-partes reexaminations, inter-partes reviews, post-grant reviews, derivation proceedings, or other proceedings pending or threatened, and Licensor has filed and prosecuted patent applications within the Licensor Patent Rights in good faith and complied with all duties of disclosure with respect thereto&#59;</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 48</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">to Licensor&#8217;s knowledge, Licensor has not committed any act, or omitted to commit any act, that may cause the Licensor Patent Rights to expire prematurely or be declared invalid or unenforceable&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">all application, registration, maintenance, other related fees and renewal fees in respect of the Licensor Patent Rights have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of obtaining or maintaining the Licensor Patent Rights&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">Licensor has not granted to any Third Party, including any academic organization or agency, any rights to the Licensed Compounds or any Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the Licensor Technology comprises all of the intellectual property rights used by Licensor, its Affiliates, and their respective consultants and contractors (if applicable) in the Development of the Licensed Compounds subject to the limitations in the definition of Licensor Know-How&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">to Licensor&#8217;s knowledge, the Development, use, importation, offering for sale, sale, having sold or other Commercialization of the Licensed Compounds or Products do not infringe the Patent Rights or misappropriate the Know-How of any Third Party, nor has Licensor received any written notice alleging such infringement or misappropriation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.58pt">Licensor has not initiated or been involved in any Claims in which it alleges that any Third Party is or was infringing or misappropriating any Licensor Technology, nor have any such Claims been threatened by Licensor, nor does Licensor know of any valid basis for any such Claims&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">no officer or employee of Licensor is subject to any agreement with any other Third Party which requires such officer or employee to assign any interest in any Licensor Technology relating to the Licensed Compounds or Products to any Third Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor has taken all reasonable precautions to preserve the confidentiality of the Licensor Know-How related to the composition of matter of the Licensed Compounds or resulting from the Research Program&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor has not entered into a government funding relationship that would result in rights to any Licensed Compounds or Products residing in the US Government, National Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the US Government as set forth in Public Law 96 517 (35 U.S.C. 200 204) or any similar obligations under the laws of any other country&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor has not granted any Third Party rights that would otherwise interfere or be inconsistent with Novartis&#8217; rights hereunder, and there are no agreements or arrangements to which Licensor or any of its Affiliates is a party relating to the Products, Licensed Compounds, Licensor Patent Rights, or Licensor Know-How that would limit the rights granted to Novartis under this Agreement or that restrict or will result in a restriction on Novartis&#8217; ability to Develop, manufacture, import, offer for sale, sell, have sold, or otherwise Commercialize the Licensed Compounds or the Products in the Territory&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.47pt">neither Licensor nor any Person acting on its behalf has&#58; (i) made an untrue statement of a material fact or fraudulent statement to the FDA, EMA or any other Regulatory Authority or with respect to any Regulatory Filing&#59; or (ii) failed to disclose a material fact required to be disclosed to the FDA, EMA or any other Regulatory Authority, or committed any act, made a statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA, EMA or any other Regulatory Authority </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 49</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to invoke its policy regarding &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221;, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.85pt">neither Licensor nor, to Licensor&#8217;s knowledge, any Person acting on its behalf is the subject of any pending or, to Licensor&#8217;s knowledge, threatened investigation by the FDA, EMA or any other Regulatory Authority&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.08pt">Licensor has not, and to Licensor&#8217;s knowledge, no Third Parties have, altered, falsified, or otherwise manipulated any data generated or used in any clinical trials or other studies related to the development, use, handling, safety, efficacy, reliability or manufacturing of the Licensed Compounds or Products&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">notwithstanding anything to the contrary contained in this Agreement, Licensor has not failed to disclose to Novartis any fact or circumstance known to Licensor or any of its Affiliates and relating to any of the Licensed Compounds or the Products that would be reasonably material to Novartis in connection with this Agreement or the transactions contemplated herein.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Covenants of Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Licensor covenants and agrees that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">it will not grant any interest in the Licensor Patent Rights or Licensor Know-How which is inconsistent with the terms and conditions of this Agreement, nor shall Licensor assign its right, title or interest in or to any of the Licensor Patent Rights or Licensor Know-How to any Third Party and will use all reasonable precautions to preserve the confidentiality of the Licensor Know-How&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">it will not grant to any Third Party, including any academic organization or agency, any rights to the Licensed Compounds or any Product that would conflict with the rights granted to Novartis hereunder&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">if it becomes aware that it or any employee, agent or subcontractor of Licensor who participated, or is participating, in the performance of any activities hereunder is on, or is being added to the FDA Debarment List or any of the three (3) FDA Clinical Investigator Restriction Lists referenced in Section 12.1(g), it will provide written notice of this to Novartis within &#91;***&#93; of it becoming aware of this fact.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Compliance and Third Party Risk Management.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Compliance with Law. In exercising its rights and performing its obligations under this Agreement, each Party will&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.98pt">not promise, offer, pay, cause to pay, accept payment or induce payment or take any action that could be considered a bribe&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.93pt">comply with all applicable Laws, including those related to bribery and corruption (such as, but not limited to, the US Foreign Corrupt Practices Act, UK Bribery Act)&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.88pt">comply with industry standards&#59; and</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.48pt">perform its obligations under this Agreement with high ethical and moral business and personal integrity standards. </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 50</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Third Party Risk Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis has put in place a Third Party risk management framework which is aimed at promoting the societal and environmental values of the United Nations Global Compact with specific third parties that Novartis deals with (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In connection with the above, Licensor shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">comply with the Third Party Code as set out at novartis.com&#47;sites&#47;novartis_com&#47;files&#47;novartis-third-party-code-v-2.pdf&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">having regard to Section 12.6 of the Third Party Code, provide information&#47;documentation on reasonable request to Novartis (or any Third Party auditor reasonably acceptable to Licensor) to allow Novartis to verify Licensor&#8217;s compliance with the Third Party Code in the form requested&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">use its Commercially Reasonable Efforts to rectify identified non-compliances with the Third Party Code (where capable of remedy) and report remediation progress to Novartis on request&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor shall adopt standards that cover the same principles and content included in the Third Party Code when appointing its own suppliers or contractors who are engaged (and to the extent they are engaged) specifically for the purpose of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">No Other Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF NOVARTIS OR LICENSOR&#59; AND (B) ALL OTHER CONDITIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">INDEMNIFICATION&#59; LIABILITY</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Indemnification by Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Licensor shall indemnify, defend and hold Novartis, its Affiliates, and their respective officers, directors and employees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any Claims against them to the extent arising or resulting from&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Licensor&#8217;s, or any of its Affiliates&#8217;, sublicensees&#8217; or contractors&#8217; actions in connection with the Research or Development of the Licensed Compounds or Products&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the negligence or willful misconduct of Licensor or any of its Affiliates&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">the breach of any of the covenants, warranties or representations made by Licensor to Novartis under this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that Licensor shall not be obliged to so indemnify, defend and hold harmless the Novartis Indemnitees for any Claims to the extent Novartis has an obligation to indemnify Licensor Indemnitees pursuant to Section 13.2 or to the extent that such Claims arise from the breach, negligence or willful misconduct of Novartis or the Novartis Indemnitee.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Indemnification by Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall indemnify, defend and hold Licensor, its Affiliates, and their respective officers, directors and employees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensor Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any Claims against them to the extent arising or resulting from&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Novartis&#8217;, or any of its Affiliates&#8217;, sublicensees&#8217; or contractors&#8217; actions in connection with the Development or Commercialization of the Licensed Compounds or Products&#59;</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 51</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">the negligence or willful misconduct of Novartis or any of its Affiliates&#59; or </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">the breach of any of the warranties or representations made by Novartis to Licensor under this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that Novartis shall not be obliged to so indemnify, defend and hold harmless the Licensor Indemnitees for any Claims to the extent Licensor has an obligation to indemnify Novartis Indemnitees pursuant to Section 13.1 or to the extent that such Claims arise from the breach, negligence or willful misconduct of Licensor or the Licensor Indemnitee.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">All indemnification claims in respect of a Novartis Indemnitee or Licensor Indemnitee shall be made solely by Novartis or Licensor, respectively.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">A Party seeking indemnification hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall notify the other Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in writing reasonably promptly after the assertion against the Indemnified Party of any Claim or fact in respect of which the Indemnified Party intends to base a claim for indemnification hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), but the failure or delay to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent that the Indemnifying Party demonstrates that its ability to defend or resolve such Claim is adversely affected thereby. The Indemnification Claim Notice shall contain a description of the Claim and the nature and amount of the Claim (to the extent that the nature and amount of such Claim is known at such time). Upon the request of the Indemnifying Party, the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all correspondence, communications and official documents (including court documents) received or sent in respect of such Claim. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to the provisions of Sections 13.3(d) and 13.3(e), the Indemnifying Party shall have the right, upon written notice given to the Indemnified Party within &#91;***&#93; after receipt of the Indemnification Claim Notice to assume the defense and handling of such Claim, at the Indemnifying Party&#8217;s sole expense, in which case the provisions of Section 13.3(d) below shall govern. The assumption of the defense of a Claim by the Indemnifying Party shall not be construed as acknowledgement that the Indemnifying Party is liable to indemnify any indemnitee in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party&#8217;s claim for indemnification. In the event that it is ultimately decided that the Indemnifying Party is not obligated to indemnify or hold an indemnitee harmless from and against the Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including attorneys&#8217; fees and costs of suit) and any losses incurred by the Indemnifying Party in its defense of the Claim. If the Indemnifying Party does not give written notice to the Indemnified Party, within &#91;***&#93; after receipt of the Indemnification Claim Notice, of the Indemnifying Party&#8217;s election to assume the defense and handling of such Claim, the provisions of Section 13.3(e) shall govern.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Upon assumption of the defense of a Claim by the Indemnifying Party&#58; (i) the Indemnifying Party shall have the right to and shall assume sole control and responsibility for dealing with the Claim&#59; (ii) the Indemnifying Party may, at its own cost, appoint as counsel in connection with conducting the defense and handling of such Claim any law firm or counsel reasonably selected by the Indemnifying Party&#59; (iii) the Indemnifying Party shall keep the Indemnified Party informed of the status of such Claim&#59; and (iv) the Indemnifying Party shall have the right to settle the Claim on any terms the Indemnifying Party chooses&#59; provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that it shall not, without the prior written consent of the Indemnified Party, agree to a settlement of any Claim which could lead to liability or create any financial or other obligation on the part of the </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 52</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder or which admits any wrongdoing or responsibility for the claim on behalf of the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and shall be entitled to participate in, but not control, the defense of such Claim with its own counsel and at its own expense. In particular, the Indemnified Party shall furnish such records, information and testimony, provide witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making the Indemnified Party, the Novartis Indemnitees or the Licensor Indemnitees, as applicable, and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">If the Indemnifying Party does not give written notice to the Indemnified Party as set forth in Section 13.3(c) or fails to conduct the defense and handling of any Claim in good faith after having assumed such, the Indemnified Party may, at the Indemnifying Party&#8217;s expense, select counsel reasonably acceptable to the Indemnifying Party in connection with conducting the defense and handling of such Claim and defend or handle such Claim in such manner as it may deem appropriate. In such event, the Indemnified Party shall keep the Indemnifying Party timely apprised of the status of such Claim and shall not settle such Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld. If the Indemnified Party defends or handles such Claim, the Indemnifying Party shall cooperate with the Indemnified Party, at the Indemnified Party&#8217;s request but at no expense to the Indemnified Party, and shall be entitled to participate in the defense and handling of such Claim with its own counsel and at its own expense.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Mitigation of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 13. Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Special, Indirect and Other Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 13 OR AS A BREACH OF CONFIDENTIALITY UNDER ARTICLE 9 OR A BREACH OF THE PROVISIONS OF ARTICLE 8..</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">No Exclusion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party excludes any liability for death or personal injury caused by its negligence or that of its employees, agents or sub-contractors.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">PUBLICATIONS AND PUBLICITY</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Any proposed public disclosure (whether written, electronic, oral or otherwise) by Licensor relating to the Licensed Compounds or Products shall require the prior written consent of Novartis&#59; provided that the foregoing shall not apply (i) to information which is in the public domain or any public disclosure required by law or governmental regulation or by the rules of </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 53</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any recognized stock exchange, (ii) to Licensor&#8217;s ability to make any publication or presentation related to the Platform, or (iii) to any publication or presentation submitted by Licensor prior to the Effective Date. In the event that Licensor wishes to make a disclosure pursuant to this Section 14.1(a), Licensor shall provide Novartis with a complete copy of the intended disclosure at least thirty (30) days prior to submission of such disclosure for publication or prior to oral disclosure (or other form of presentation) and shall, except with respect to Section 14.1(a)(iii), remove any Novartis Confidential Information from such proposed disclosure upon the request of Novartis.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">For the avoidance of doubt, Novartis or any of its Affiliates may, without any required consents from Licensor and subject to Section 14.2 and Article 9, (i) issue press releases and other public statements as it deems appropriate in connection with the Development, manufacture, or Commercialization of the Licensed Compounds or Products under this Agreement&#59; and (ii) publish or have published information about clinical trials related to the Products, including the results of such clinical trials, provided that neither Novartis nor any of its Affiliates may publish any data or information related to the Platform without Licensor&#8217;s prior written consent, which may be granted at Licensor&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section 14.2(c), neither Party shall use the name, symbol, trademark, trade name or logo of the other Party or any of its Affiliates in any press release, publication or other form of public disclosure without the prior written consent of the other Party (such consent not to be unreasonably withheld or delayed), except for those disclosures for which consent has already been obtained. Notwithstanding the foregoing, Novartis shall be entitled to use the name of Licensor to the extent necessary or reasonably useful in connection with the Development, manufacture or Commercialization of the Licensed Compounds or Products, including in connection with sublicensing and subcontracting transactions. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Licensor may issue a press release announcing this Agreement, in a form agreed to in writing by Novartis, on or promptly following the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">Subject to Section 14.2(b), each Party agrees not to issue any press release or other public statement, whether oral or written, disclosing the existence of this Agreement, the terms hereof or any information relating to this Agreement without the prior written consent of the other Party&#59; provided that Novartis may issue press releases and other public statements as it deems appropriate in connection with the Development and Commercialization of Products under this Agreement after giving Licensor reasonable advance notice of such press release or public statement, which notice will include a summary of the substantive content of such press release or public statement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Notwithstanding the foregoing in this Section 14.2, each Party may make any disclosures required of it to comply with any duty of disclosure it may have pursuant to applicable Law, including pursuant to the rules of any recognized stock exchange. In the event of a disclosure required by applicable Law, including the rules of any recognized stock exchange, the Parties shall coordinate with each other with respect to the timing, form and content of such required disclosure. If so requested by the other Party, the Party subject to such obligation shall use commercially reasonable efforts to obtain an order protecting to the maximum extent possible the confidentiality of such provisions of this Agreement as reasonably requested by the other Party. If the Parties are unable to agree on the form or content of any required disclosure, such disclosure shall be limited to the minimum required as determined by the disclosing Party in consultation with its legal counsel. Without limiting the foregoing, each Party shall consult with the other Party on the provisions of this Agreement, together with the Exhibits, Schedules or </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 54</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">other attachments attached hereto, to be redacted in any filings made by Licensor or Novartis with the Securities and Exchange Commission (or other regulatory body) or as otherwise required by Law.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.45pt">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party may assign this Agreement or any of its rights or obligations hereunder without the other Party&#8217;s prior written consent, except that Novartis may&#58; (a) assign its rights or obligations under this Agreement or any part hereof to one or more of its Affiliates&#59; or (b) assign this Agreement to a successor to all or substantially all of its business or assets to which this Agreement relates. Any permitted assignee will assume all obligations of its assignor under this Agreement (or related to the assigned portion in case of a partial assignment). Any attempted assignment in contravention of the foregoing will be null and void. Subject to the terms of this Agreement, this Agreement will be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Extension to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis shall have the right to extend the rights, immunities and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to Novartis. Novartis shall remain primarily liable for any acts or omissions of its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Should one or more of the provisions of this Agreement become invalid, void or unenforceable as a matter of law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use commercially reasonable efforts to substitute for the invalid, void or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Governing Law and Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed under the laws of New York, without giving effect to the conflicts of laws provision thereof. The United Nations Convention on Contracts for the International Sale of Goods (1980) shall not apply to the interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.25pt">In the event of a dispute between the Parties relating to, arising out of, or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, the Parties will refer the dispute to the Alliance Managers for discussion and resolution. If the Alliance Managers are unable to resolve such a dispute within &#91;***&#93; of the dispute being referred to them, either Party may require that the Parties forward the matter to the Executive Officers, who shall attempt in good faith to resolve such dispute. If the Executive Officers cannot resolve such dispute within &#91;***&#93; of the matter being referred to them, either Party shall be free to initiate the arbitration proceedings outlined in Section 15.5(b) or 15.6, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.63pt">Subject to Section 15.6, either Party may refer any unresolved disputes between the Parties relating to, arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, for resolution by final and binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice to that effect to the other Party. The seat, or legal place, of the arbitration shall be New York, New York. Arbitration shall be held in New York, New York, according to the then-current commercial </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 55</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">rules of the International Chamber of Commerce (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The arbitration will be conducted by a panel of three arbitrators appointed in accordance with ICC rules&#59; provided, that each Party shall, within &#91;***&#93; after the institution of the arbitration proceedings, appoint an arbitrator, and such arbitrators shall together, within &#91;***&#93;, select a third arbitrator as the chairman of the arbitration panel. Each arbitrator shall have significant experience in the pharmaceutical business. If the two initial arbitrators are unable to select a third arbitrator within such &#91;***&#93; period, the third arbitrator shall be appointed in accordance with ICC rules. The arbitrators shall render their opinion within &#91;***&#93; of the final arbitration hearing. No arbitrator (nor the panel of arbitrators) shall have the power to award punitive damages under this Agreement and such award is expressly prohibited. Decisions of the panel of arbitrators shall be final and binding on the Parties. Judgment on the award so rendered may be entered in any court of competent jurisdiction. The losing Party to the arbitration (if any) as determined by the arbitrators shall pay the costs of the arbitration. The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (i)&#160;to the extent that disclosure may be required of a Party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) where such information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Expedited Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If a Party exercises its rights under this Agreement to refer a dispute to Expedited Arbitration pursuant to Section 6.8, 10.5, or 11.3, then the Parties will follow the expedited dispute resolution process in this Section 15.6 (and not the dispute resolution process in Section 15.5(b) of this Agreement) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expedited Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Parties agree and acknowledge that any good faith dispute under Expedited Arbitration will not be deemed to be a material breach of this Agreement. The Expedited Arbitration will be fast-track, binding arbitration carried out in accordance with the following (a) the Parties will refer the matter to arbitration before a mutually acceptable independent arbitrator, who shall be experienced in the pharmaceutical business&#59; (b) each Party will submit its final proposed terms to the other Party at least &#91;***&#93; prior to submission to the independent arbitrator, which final proposed terms shall be submitted to the independent arbitrator within &#91;***&#93; after such dispute is referred to Expedited Arbitration&#59; (c) the independent arbitrator will select between the two sets of terms (i.e., the independent arbitrator will select the more reasonable set of terms submitted by the Parties, and will not propose a third set of terms), and shall render his or her opinion within &#91;***&#93; after the final arbitration hearing&#59; (d) the independent arbitrator shall not have the authority to render any substantive decision other than to select the proposal submitted by either Novartis or Licensor and the independent arbitrator will have no discretion or authority with respect to modifying the positions of the Parties&#59; and (d) the decision of the arbitrator shall be final and binding on the Parties, and shall not be subject to the dispute resolution provisions set forth in Section 15.5. The Parties shall equally share the costs and expenses in connection with such Expedited Arbitration proceeding. Except in a proceeding to enforce the results of the arbitration or as otherwise required by applicable Law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.7pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that either Party is prevented from performing its obligations under this Agreement as a result of any contingency beyond its reasonable control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including any actions of governmental authorities or agencies, war, hostilities between nations, civil commotions, riots, national industry strikes, lockouts, sabotage, shortages in supplies, energy shortages, pandemics, fire, floods and acts of nature such as typhoons, hurricanes, earthquakes, or tsunamis, the Party so affected shall not be responsible to the other Party for any delay or failure of performance of its obligations hereunder, for so long as Force Majeure prevents such performance. In the event of Force Majeure, the Party immediately affected thereby shall give prompt written notice to the other Party specifying the Force Majeure event complained of, and shall use commercially reasonable efforts to </font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 56</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">resume performance of its obligations. Notwithstanding the foregoing, if such a Force Majeure induced delay or failure of performance continues for a period of more than &#91;***&#93; and such delay or failure frustrates or materially and adversely impacts achievement of the fundamental objectives of the Agreement, the Party not affected by the Force Majeure event may terminate this Agreement upon written notice to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The failure or delay of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.2pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between Licensor and Novartis, or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been duly given when&#58; (a) delivered by hand (with written confirmation of receipt)&#59; (b) sent by fax (with written confirmation of receipt)&#59; provided that a copy is immediately sent by an internationally recognized overnight delivery service (receipt requested)&#59; or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), in each case, to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as a Party may designate by notice)&#58;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Licensor&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Novartis&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novartis and Licensor hereby covenant and agree, without the necessity of any further consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall perform its obligations under this Agreement in accordance with all applicable Laws. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights to any Third Party (including any third party beneficiary rights).</font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 57</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:131.04pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL INFORMATION</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement and, in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement, together with its Exhibits and Schedules, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit or Schedule hereto, the substantive provisions of this Agreement shall prevail.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures (including .pdf) and such signatures shall be deemed to bind each Party hereto as if they were original signatures.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.7pt">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#93;</font></div><div><font><br></font></div><div style="height:68.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 58</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.342%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i98c33ecaa77f446ea2740a77c0c1ae25_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.336%"><tr><td style="width:1.0%"></td><td style="width:48.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOVARTIS PHARMA AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 59 of #NUM_PAGES#</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.604%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="padding-left:21.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.336%"><tr><td style="width:1.0%"></td><td style="width:48.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOVARTIS PHARMA AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MOLECULAR PARTNERS AG</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 60 of #NUM_PAGES#</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.604%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RESEARCH PLAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 61 of #NUM_PAGES#</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.604%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i98c33ecaa77f446ea2740a77c0c1ae25_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LICENSOR PATENT RIGHTS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.15pt;text-decoration:underline">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.5pt;padding-right:5.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 62 of #NUM_PAGES#</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.604%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SAMPLE INVOICE TO NOVARTIS PHARMA AG</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 63 of #NUM_PAGES#</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.604%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i98c33ecaa77f446ea2740a77c0c1ae25_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PLATFORM PATENT RIGHTS</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.15pt;text-decoration:underline">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 64 of #NUM_PAGES#</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.604%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264814036 v4</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>8
<FILENAME>a410psuplan2021formanageme.htm
<DESCRIPTION>EX-4.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i986df77191ed42beb290cfa79dde71f2_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.10</font></div></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Share Plan 2021</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Management Board</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Performance Share Plan 2021</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of PSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting Multiple</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Employment and Forfeiture</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">22.</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i986df77191ed42beb290cfa79dde71f2_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of PSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Performance Share Plan 2021</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this performance share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Performance Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Capitalized terms used in this Plan shall have the meaning set forth in Annex 1.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Where this Plan refers to employer, employee or employment, such terms shall apply by analogy if the relevant eligible person or Participant is not engaged as an employee, but under a different type of contract or in a different capacity, e.g. as a consultant under a mandate agreement or as a member of a corporate body (e.g. member of a board of directors or advisory board).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of PSUs that may be granted under this Plan and of shares to be allocated from the Company's conditional capital or otherwise in connection with such PSUs. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend or renew or terminate the Plan or to replace it with new editions or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any grants of PSUs to members of the Management Board shall be approved by the Board of Directors based on individual recommendations of the Nomination and Compensation Committee and will, as long as shareholder approval of variable compensation is outstanding, be conditional upon such shareholder approval. In case that the amount approved by the shareholders does not cover the full amount of contemplated aggregate variable compensation for the year of grant, the entitlements to short term and long-term variable compensation may be reduced by the Nomination and Compensation Committee in its sole discretion.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee to a third party service provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, only members of the Management Board may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant PSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed PSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the employer Group Company) and the eligible person, substantially in the form attached hereto as Annex 2. The right to receive PSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered, and have signed and returned, their individual PSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of PSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future performance share plans, regardless of the length of time a person has previously been allocated PSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of PSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to continue to be employed by any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of PSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of PSUs shall be exclusively made by way of PSU Award Agreements. The PSU Award Agreement shall set forth the number of PSUs and certain other terms and conditions of such grant. Except as otherwise determined in a PSU Award Agreement, PSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One PSU represents a conditional entitlement to purchase a number of Shares at the nominal value of a Share. The number of Shares which shall be allocated to a Participant upon vesting shall be determined pursuant to a vesting multiple as described in Section 10 hereof (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), subject to, and in accordance with, the terms and conditions of this Plan and the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grants shall be determined by the Nomination and Compensation Committee and set out in the PSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">A change of the regular working quota (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Arbeitspensum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) during the Vesting Period shall not lead to an adjustment of PSUs already granted. New Participants admitted to the Plan after the Grant Date may, if any, be granted a pro rata number of PSUs for that year, i.e. for the period between </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">the beginning of their employment and the next regular Grant Date, as an interim grant or as additional PSUs on the next regular Grant Date.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the PSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, the restrictions and procedures set out in article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs granted under this Plan and the PSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the PSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 14 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 14) or in the PSU Award Agreement, PSUs shall vest on the third anniversary of the Grant Date (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The period between the Grant Date and the Vesting Date shall be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Subject to Section 14(b) and (c) below, no PSU shall vest if, during the Vesting Period, the relevant Participant's employment is terminated (i.e. notice of termination is given (even if the notice period is still running) or another reason for termination occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), set by a Group Company. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Shares shall be delivered by or on behalf of the Company to the Participant upon and subject to signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Alternatively, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. Delivery of Shares or other consideration shall, subject to the further conditions of delivery being met, occur no later than three months following the Vesting Date of the relevant PSUs.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 16, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Company, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Company's conditional share capital and a respective maximum number of Shares out of conditional capital shall be deemed reserved, accordingly. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Vesting Multiple</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall not be lower than 0 nor higher than 1.2 (one point two). Within such range, the Vesting Multiple shall be determined by the Board of Directors upon proposal by the Nomination and Compensation Committee based on its assessment of the achievement of the goals set out in the score card (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) attached to the PSU Award Agreement or otherwise communicated by the Company to the Participant in connection with the grant (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The Goals may include any corporate goals, i.e. strategic, operating or financial goals of the Company or the Group, any personal goals and performance of the relevant Participant and&#47;or any goals relating to the total shareholder return or share price development. The LTI Score Card may attach a percentage weighting to each Goal for purposes of deriving the Vesting Multiple or require a global assessment of the achievement of goals.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall, unless the nature of the Goals demands otherwise, be determined in the year following the year of grant. Notwithstanding such determination, Vesting shall occur only at the time and subject to the conditions otherwise set out in this Plan or in the PSU Award Agreement.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Depending on the corporate goals set out in the LTI Score Card, the Vesting Multiple may be fixed (if all elements of Goal achievement are known at the time of determination) or variable (e.g. depending on further stock price development throughout the remainder of the Vesting Period).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of PSUs, on the allocation of Shares and the subsequent sale of Shares or on a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the PSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the employer Group Company. The Company and the relevant employer Group Company, shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for PSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the employer Group Company before settlement of the PSU awards. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of PSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of PSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's employment) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Employment and Forfeiture</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If (i) a Participant's employment is terminated (i.e. notice of termination is given even if the notice period is still running) or (ii) another reason for termination occurs during the Vesting period, other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO and except as set out in Section 14(b) and (c) below, all PSUs shall immediately cease and be forfeited.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant&#8217;s employment agreement is terminated by the Company or a Group Company for reasons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> pertaining to the Participant, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> number of PSUs granted to the Participant shall vest at the end of the Vesting Period with the remaining PSUs lapsing without further effect. For clarity, the pro rata calculation under this Section 14 shall be determined on a monthly basis (36&#47;36), based on the complete months of employment worked during the Vesting Period.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If the employment agreement terminates by reason of (i) death, permanent illness or disability of the Participant or (ii) retirement, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> number of PSUs granted to the Participant shall vest immediately with the remaining PSUs lapsing without further effect. In the case of (i) here before, the pro rata calculation will be made assuming that employment lasted one year longer (but in any case not longer than the end of the regular three-year Vesting Period). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Board of Directors, based on a recommendation by the Nomination and Compensation Committee, may, taking into consideration the objectives of the Plan, at its sole discretion and with final and binding effect grant further exceptions from the forfeiture clause as per Section 14 </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a) above and assess whether a Participant&#8217;s employment agreement was terminated for reasons not pertaining to the Participant pursuant to Section 14(b) above.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover regulations&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all PSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all PSUs will vest immediately&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the Vesting Multiple with respect to each PSU allocation will be determined by the Nomination and Compensation Committee at the time of the Change of Control unless the Vesting Multiple has already been determined prior to the Change of Control&#59; and</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">the PSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange PSUs or decides upon another solution to provide the Participants with the vesting value of the PSUs.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control, but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the PSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the PSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding PSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of PSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the PSU Award Agreement by the Company, the Board of Directors and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used for the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the PSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the employer Group Company.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the PSU have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of PSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the PSUs and any shares granted thereunder.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any grant of PSUs to members of the Management Board that qualifies as prohibited payment under the Compensation Ordinance or otherwise, shall be null and void.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If and to the extent that any term of this Plan, such as terms providing for early vesting in case of termination of employment or Change of Control should, at the time of the relevant event, qualify as providing additional value to a member of the Management Board in a manner that would violate the Compensation Ordinance or other legal provisions, such additional value shall be otherwise compensated, e.g. by a relevant deduction from cash compensation or other proceeds. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past PSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a PSU Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any PSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the PSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per approval of the Board of Directors, this Plan shall enter into force as of March 24, 2021.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 15 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 3 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean all Group Companies.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Management Board </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the members of the top level executive management, i.e. those managers whose compensation is subject to the Compensation Ordinance. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted PSUs through a PSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall be the multiple determined in accordance with Section 10 above. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Management Board PSU Award Agreement 2021 </font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Performance Share Plan 2021 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">PSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the PSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the PSU Plan, the Company hereby grants to you the following PSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.59pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.767%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of PSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Year of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. The number of Shares that may be allocated according to the PSU Plan shall be determined by the Nomination and Compensation Committee in accordance with the PSU Plan and the LTI Score Card setting out the corporate goals relevant for this award (&#91;communicated to you separately&#93; &#124; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">attached hereto&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">). Please note that the PSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. Any grants made to you the Participant as a member of the Management Board shall be subject to the approval of relevant compensation amounts for the Management Board by the shareholders' meeting for the year 2021. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the PSUs in accordance with this Agreement and the PSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of PSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The PSU Plan, your eligibility thereunder, the grant of PSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the PSU Plan or to receive grants of PSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2021 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date, Signature)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> ____________________<br>                                                                       <br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;Annex to the PSU Award Agreement 2021&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management Board PSU Plan 2021 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTI Score Card &#91;for &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;&#8230;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>9
<FILENAME>a411psuplan2022foremployee.htm
<DESCRIPTION>EX-4.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i82aedbff7af84ce1b8eb39eafa38d41e_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.11</font></div></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Share Plan 2022</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Employees</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Performance Share Plan 2021</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of PSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting Multiple</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Employment and Forfeiture</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">22.</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i82aedbff7af84ce1b8eb39eafa38d41e_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of PSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Performance Share Plan 2022</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this performance share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Performance Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Capitalized terms used in this Plan shall have the meaning set forth in Annex 1.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Where this Plan refers to employer, employee or employment, such terms shall apply by analogy if the relevant eligible person or Participant is not engaged as an employee, but under a different type of contract or in a different capacity, e.g. as a consultant under a mandate agreement or as a member of a corporate body (e.g. member of a board of directors or advisory board).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of PSUs that may be granted under this Plan and of shares to be allocated from the Company's conditional capital or otherwise in connection with such PSUs. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend or renew or terminate the Plan or to replace it with new editions or other plans. It may delegate, under its supervision, the implementation and administration, as well as grants of PSUs to one or several administrators (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee or, upon delegation by the Nomination and Compensation Committee, an Administrator pursuant to this Plan, including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee or the relevant Administrator to a third party service </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, employees (other than members of the Management Board) as well as selected consultants may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee or the relevant Administrator. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant PSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed PSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the employer Group Company) and the eligible person, substantially in the form attached hereto as Annex 2. The right to receive PSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered, and have signed and returned, their individual PSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of PSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future performance share plans, regardless of the length of time a person has previously been allocated PSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of PSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to continue to be employed by any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of PSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of PSUs shall be exclusively made by way of PSU Award Agreements. The PSU Award Agreement shall set forth the number of PSUs and certain other terms and conditions of such grant. Except as otherwise determined in a PSU Award Agreement, PSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One PSU represents a conditional entitlement to purchase a number of Shares at the nominal value of a Share. The number of Shares which shall be allocated to a Participant upon vesting shall be determined pursuant to a vesting multiple as described in Section 10 hereof (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), subject to, and in accordance with, the terms and conditions of this Plan and the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grants shall be determined by the Nomination and Compensation Committee or the relevant Administrator and set out in the PSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">A change of the regular working quota (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Arbeitspensum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) during the Vesting Period shall not lead to an adjustment of PSUs already granted. New Participants admitted to the Plan after the Grant Date may, if any, be granted a pro rata number of PSUs for that year, i.e. for the period between </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">the beginning of their employment and the next regular Grant Date, as an interim grant or as additional PSUs on the next regular Grant Date.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the PSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, the restrictions and procedures set out in article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs granted under this Plan and the PSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the PSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 14 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 14) or in the PSU Award Agreement, the PSUs granted by a PSU Award Agreement shall vest in three tranches of one third each. If the number of PSUs granted by a PSU Award Agreement cannot be divided by three, the two tranches vesting first shall be rounded up to the next integer and the tranche vesting last shall be rounded down and, if necessary, reduced in order to get to integers that add up to the total number of PSUs granted by the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The first tranche of the PSUs shall vest on the first anniversary of the Grant Date, the second tranche on the second anniversary of the Grant Date and the third tranche on the third anniversary of the Grant Date (each, with respect to the relevant tranche, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) The period between the Grant Date and the Vesting Date shall, with respect to the relevant tranche, be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Subject to Section 14(b) and (c) below, no PSU shall vest if, during the relevant Vesting Period, the relevant Participant's employment is terminated (i.e. effective date of termination) or another reason for termination occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The relevant number of Shares shall be delivered by or on behalf of the Company to the Participant upon and subject to signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Alternatively, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. Delivery of Shares or other consideration shall, subject to the further conditions of delivery being met, occur no later than three months following the Vesting Date of the relevant PSUs.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 16, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Company, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the Company's conditional share capital and a respective maximum number of Shares out of conditional capital shall be deemed reserved, accordingly. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Vesting Multiple</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall not be lower than 0 nor higher than 1.5 (one point five). Within such range, the Vesting Multiple shall be determined by the Board of Directors upon proposal by the Nomination and Compensation Committee based on its assessment of the achievement of the goals set out in the score card (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) attached to the PSU Award Agreement or otherwise communicated by the Company to the Participant in connection with the grant (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The Goals may include any corporate goals, i.e. strategic, operating or financial goals of the Company or the Group, any personal goals and performance of the relevant Participant and&#47;or any goals relating to the total shareholder return or share price development. The LTI Score Card may allocate a percentage weighting to each Goal for purposes of deriving the Vesting Multiple or require a global assessment of the achievement of goals.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall, unless the nature of the Goals demands otherwise, be determined for all tranches of the PSUs granted by a PSU Award Agreement in the year following the year of grant. Notwithstanding such determination, Vesting shall occur only at the time and subject to the conditions otherwise set out in this Plan or in the PSU Award Agreement.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Depending on the corporate goals set out in the LTI Score Card, the Vesting Multiple may be fixed (if all elements of Goal achievement are known at the time of determination) or variable (e.g. depending on further stock price development throughout the remainder of the Vesting Period).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of PSUs, on the allocation of Shares and the subsequent sale of Shares or on a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the PSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the employer Group Company. The Company and the relevant employer Group Company shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for PSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the employer Group Company before settlement of the PSU awards. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of PSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of PSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's employment) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Employment and Forfeiture</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If (i) a Participant's employment is terminated (i.e. effective date of termination) or (ii) another reason for termination occurs during the Vesting Period, other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO and except as set out in Section 14(b) and (c) below, all remaining unvested PSUs shall immediately cease and be forfeited.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant&#8217;s employment agreement is terminated by the Company or a Group Company for reasons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> pertaining to the Participant, under each unvested tranche of PSUs granted, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> (based on the effective date of termination) number of PSUs granted to the Participant shall vest at the end of the relevant Vesting Period with the remaining PSUs lapsing without further effect. For clarity, the pro rata calculation under this Section 14 shall be determined on a monthly basis (12&#47;12, 24&#47;24 and 36&#47;36, respectively), based on the complete months of employment worked during the relevant Vesting Period.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If the employment agreement terminates by reason of (i) death, permanent illness or disability of the Participant or (ii) retirement, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> number of PSUs granted to the Participant shall vest </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">immediately with the remaining PSUs lapsing without further effect. In the case of (i) here before, the pro rata calculation will be made assuming that employment lasted one year longer (but in any case not longer than the end of the regular three-year Vesting Period). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Management Board may, taking into consideration the objectives of the Plan, at its sole discretion and with final and binding effect grant further exceptions from the forfeiture as per Section 14 (a) above and assess whether a Participant&#8217;s employment agreement was terminated for reasons not pertaining to the Participant pursuant to Section 14(b) above.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover regulations&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all PSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all PSUs will vest immediately&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the Vesting Multiple with respect to each PSU allocation will be determined by the Nomination and Compensation Committee at the time of the Change of Control unless the Vesting Multiple has already been determined prior to the Change of Control&#59; and</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">the PSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange PSUs or decides upon another solution to provide the Participants with the vesting value of the PSUs.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control, but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the PSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the PSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding PSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of PSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the PSU Award Agreement by the Company, the Board of Directors, the Administrator and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used by the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the PSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors, any Administrator or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the employer Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the PSUs have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of PSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the PSUs and any shares granted thereunder.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past PSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a PSU Award Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any PSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the PSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per approval of the Board of Directors, this Plan shall enter into force as of March 14, 2022.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 15 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 3 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean all Group Companies.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Management Board </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the members of the top level executive management, i.e. those managers whose compensation is subject to the Compensation Ordinance. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted PSUs through a PSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall be the multiple determined in accordance with Section 10 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Employee PSU Award Agreement 2022</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Performance Share Plan 2022 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">PSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the PSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the PSU Plan, the Company hereby grants to you the following PSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.59pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.591%"><tr><td style="width:1.0%"></td><td style="width:38.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of PSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Schedule of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93; PSUs on &#91;&#9632;&#93;, &#91;&#9632;&#93; PSUs on &#91;&#9632;&#93; and &#91;&#9632;&#93; PSUs on &#91;&#9632;&#93;.</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. The number of Shares that may be allocated according to the PSU Plan shall be determined by the Nomination and Compensation Committee in accordance with the PSU Plan and the LTI Score Card setting out the Goals relevant for this award (&#91;communicated to you separately&#93; &#124; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">attached hereto&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">). Please note that the PSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">NB&#58; PSU Awards Agreements with employees of Group companies may differ from this template</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the PSUs in accordance with this Agreement and the PSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of PSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The PSU Plan, your eligibility thereunder, the grant of PSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the PSU Plan or to receive grants of PSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 - Employees</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date, Signature)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> ____________________<br>                                                                       <br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;Annex to the PSU Award Agreement 2022&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee PSU Plan 2022 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTI Score Card &#91;for &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;&#8230;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>10
<FILENAME>a412psuplan2022_formanagem.htm
<DESCRIPTION>EX-4.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id74a45dbe1804859a8ea6af1adc95a8a_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.12</font></div></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Share Plan 2022</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Management Board</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Performance Share Plan 2022</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of PSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting Multiple</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Employment and Forfeiture</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">22.</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#id74a45dbe1804859a8ea6af1adc95a8a_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of PSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Performance Share Plan 2022</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this performance share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Performance Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Capitalized terms used in this Plan shall have the meaning set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Where this Plan refers to employer, employee or employment, such terms shall apply by analogy if the relevant eligible person or Participant is not engaged as an employee, but under a different type of contract or in a different capacity, e.g. as a consultant under a mandate agreement or as a member of a corporate body (e.g. member of a board of directors or advisory board).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of PSUs that may be granted under this Plan and of shares to be allocated from the Company's conditional capital or otherwise in connection with such PSUs. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend or renew or terminate the Plan or to replace it with new editions or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any grants of PSUs to members of the Management Board shall be approved by the Board of Directors based on individual recommendations of the Nomination and Compensation Committee and will, as long as shareholder approval of variable compensation is outstanding, be conditional upon such shareholder approval. In case that the amount approved by the shareholders does not cover the full amount of contemplated aggregate variable compensation for the year of grant, the entitlements to short term and long-term variable compensation may be reduced by the Nomination and Compensation Committee in its sole discretion.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee to a third- party service provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, only members of the Management Board may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant PSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed PSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the employer Group Company) and the eligible person, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">. The right to receive PSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered, and have signed and returned, their individual PSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of PSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future performance share plans, regardless of the length of time a person has previously been allocated PSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of PSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to continue to be employed by any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of PSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of PSUs shall be exclusively made by way of PSU Award Agreements. The PSU Award Agreement shall set forth the number of PSUs and certain other terms and conditions of such grant. Except as otherwise determined in a PSU Award Agreement, PSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One PSU represents a conditional entitlement to purchase a number of Shares at the nominal value of a Share. The number of Shares which shall be allocated to a Participant upon vesting shall be determined pursuant to a vesting multiple as described in Section 10 hereof (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), subject to, and in accordance with, the terms and conditions of this Plan and the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grants shall be determined by the Nomination and Compensation Committee and set out in the PSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">A change of the regular working quota (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Arbeitspensum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) during the Vesting Period shall not lead to an adjustment of PSUs already granted. New Participants admitted to the Plan after the Grant Date may, if any, be granted a pro rata number of PSUs for that year, i.e. for the period between </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">the beginning of their employment and the next regular Grant Date, as an interim grant or as additional PSUs on the next regular Grant Date.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the PSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, the restrictions and procedures set out in article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs granted under this Plan and the PSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the PSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 14 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 14) or in the PSU Award Agreement, PSUs shall vest on the third anniversary of the Grant Date (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The period between the Grant Date and the Vesting Date shall be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Subject to Section 14(b) and (c) below, no PSU shall vest if, during the Vesting Period, the relevant Participant's employment is terminated (i.e. effective date of termination) or another reason for termination occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Shares shall be delivered by or on behalf of the Company to the Participant upon and subject to signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Alternatively, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. Delivery of Shares or other consideration shall, subject to the further conditions of delivery being met, occur no later than three months following the Vesting Date of the relevant PSUs.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 16, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Company, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Company's conditional share capital and a respective maximum number of Shares out of conditional capital shall be deemed reserved, accordingly. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Vesting Multiple</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall not be lower than 0 nor higher than 1.5 (one point five). Within such range, the Vesting Multiple shall be determined by the Board of Directors upon proposal by the Nomination and Compensation Committee based on its assessment of the achievement of the goals set out in the score card (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) attached to the PSU Award Agreement or otherwise communicated by the Company to the Participant in connection with the grant (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The Goals may include any corporate goals, i.e. strategic, operating or financial goals of the Company or the Group, any personal goals and performance of the relevant Participant and&#47;or any goals relating to the total shareholder return or share price development. The LTI Score Card may allocate a percentage weighting to each Goal for purposes of deriving the Vesting Multiple or require a global assessment of the achievement of Goals.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall, unless the nature of the Goals demands otherwise, be determined in the year following the year of grant. Notwithstanding such determination, Vesting shall occur only at the time and subject to the conditions otherwise set out in this Plan or in the PSU Award Agreement.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Depending on the corporate goals set out in the LTI Score Card, the Vesting Multiple may be fixed (if all elements of Goal achievement are known at the time of determination) or variable (e.g. depending on further stock price development throughout the remainder of the Vesting Period).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of PSUs, on the allocation of Shares and the subsequent sale of Shares or on a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the PSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the employer Group Company. The Company and the relevant employer Group Company shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for PSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the employer Group Company before settlement of the PSU awards. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of PSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of PSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's employment) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Employment and Forfeiture</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If (i) a Participant's employment is terminated (i.e. effective date of termination) or (ii) another reason for termination occurs, during the Vesting Period, other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO and except as set out in Section 14(b) and (c) below, all PSUs shall immediately cease and be forfeited.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant&#8217;s employment agreement is terminated by the Company or a Group Company for reasons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> pertaining to the Participant, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> (based on the effective date of termination) number of PSUs granted to the Participant shall vest at the end of the Vesting Period with the remaining PSUs lapsing without further effect. For clarity, the pro rata calculation under this Section 14 shall be determined on a monthly basis (36&#47;36), based on the complete months of employment worked during the Vesting Period.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If the employment agreement terminates by reason of (i) death, permanent illness or disability of the Participant or (ii) retirement, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> number of PSUs granted to the Participant shall vest immediately with the remaining PSUs lapsing without further effect. In the case of (i) here before, the pro rata calculation will be made assuming that employment lasted one year longer (but in any case not longer than the end of the regular three-year Vesting Period). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Board of Directors, based on a recommendation by the Nomination and Compensation Committee, may, taking into consideration the objectives of the Plan, at its sole discretion and with final and binding effect grant further exceptions from the forfeiture as per Section 14 (a) above and assess whether a Participant&#8217;s employment agreement was terminated for reasons not pertaining to the Participant pursuant to Section 14(b) above.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover- regulations&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all PSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all PSUs will vest immediately&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the Vesting Multiple with respect to each PSU allocation will be determined by the Nomination and Compensation Committee at the time of the Change of Control unless the Vesting Multiple has already been determined prior to the Change of Control&#59; and</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">the PSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange PSUs or decides upon another solution to provide the Participants with the vesting value of the PSUs.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the PSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the PSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding PSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of PSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the PSU Award Agreement by the Company, the Board of Directors and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used by the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the PSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the employer Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the PSUs have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of PSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the PSUs and any shares granted thereunder.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any grant of PSUs to members of the Management Board that qualifies as prohibited payment under the Compensation Ordinance or otherwise, shall be null and void.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If and to the extent that any term of this Plan, such as terms providing for early vesting in case of termination of employment or Change of Control should, at the time of the relevant event, qualify as providing additional value to a member of the Management Board in a manner that would violate the Compensation Ordinance or other legal provisions, such additional value shall be otherwise compensated, e.g. by a relevant deduction from cash compensation or other proceeds. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past PSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a PSU Award Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any PSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the PSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per approval of the Board of Directors, this Plan shall enter into force as of March 14, 2022.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 15 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean all Group Companies.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Management Board </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the members of the top level executive management, i.e. those managers whose compensation is subject to the Compensation Ordinance. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted PSUs through a PSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall be the multiple determined in accordance with Section 10 above. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Management Board PSU Award Agreement 2022 </font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Performance Share Plan 2022 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">PSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the PSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the PSU Plan, the Company hereby grants to you the following PSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.59pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.767%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of PSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Year of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. The number of Shares that may be allocated according to the PSU Plan shall be determined by the Nomination and Compensation Committee in accordance with the PSU Plan and the LTI Score Card setting out the corporate goals relevant for this award (&#91;communicated to you separately&#93; &#124; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">attached hereto&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">). Please note that the PSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. Any grants made to you as a member of the Management Board shall be subject to the approval of relevant compensation amounts for the Management Board by the shareholders' meeting for the year 2022. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the PSUs in accordance with this Agreement and the PSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of PSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The PSU Plan, your eligibility thereunder, the grant of PSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the PSU Plan or to receive grants of PSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Performance Share Plan 2022 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date, Signature)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> ____________________<br>                                                                       <br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;Annex to the PSU Award Agreement 2022&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management Board PSU Plan 2022 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTI Score Card &#91;for &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;&#8230;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>11
<FILENAME>a413psuplan2023_foremploye.htm
<DESCRIPTION>EX-4.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9dab352854f74da3a82d303ba9ce8f92_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.13</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.717%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td></tr></table></div><div style="margin-bottom:14pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Share Plan 2023</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Employees</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Performance Share Plan 2023</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of PSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting Multiple</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Employment and Forfeiture</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">22.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i9dab352854f74da3a82d303ba9ce8f92_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">10</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of PSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Performance Share Plan 2023</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this performance share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Performance Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Capitalized terms used in this Plan shall have the meaning set forth in Annex 1.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Where this Plan refers to employer, employee or employment, such terms shall apply by analogy if the relevant eligible person or Participant is not engaged as an employee, but under a different type of contract or in a different capacity, e.g. as a consultant under a mandate agreement or as a member of a corporate body (e.g. member of a board of directors or advisory board).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of PSUs that may be granted under this Plan and of shares to be allocated from the Company's conditional capital or otherwise in connection with such PSUs. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend or renew or terminate the Plan or to replace it with new editions or other plans. It may delegate, under its supervision, the implementation and administration, as well as grants of PSUs to one or several administrators (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee or, upon delegation by the Nomination and Compensation Committee, an Administrator pursuant to this Plan, including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee or the relevant Administrator to a third party service </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, employees (other than members of the Management Board) as well as selected consultants may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee or the relevant Administrator. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant PSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed PSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the employer Group Company) and the eligible person, substantially in the form attached hereto as Annex 2. The right to receive PSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered, and have signed and returned, their individual PSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of PSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future performance share plans, regardless of the length of time a person has previously been allocated PSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of PSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to continue to be employed by any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of PSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of PSUs shall be exclusively made by way of PSU Award Agreements. The PSU Award Agreement shall set forth the number of PSUs and certain other terms and conditions of such grant. Except as otherwise determined in a PSU Award Agreement, PSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One PSU represents a conditional entitlement to purchase a number of Shares at the nominal value of a Share. The number of Shares which shall be allocated to a Participant upon vesting shall be determined pursuant to a vesting multiple as described in Section 10 hereof (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), subject to, and in accordance with, the terms and conditions of this Plan and the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grants shall be determined by the Nomination and Compensation Committee or the relevant Administrator and set out in the PSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">A change of the regular working quota (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Arbeitspensum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) during the Vesting Period shall not lead to an adjustment of PSUs already granted. New Participants admitted to the Plan after the Grant Date may, if any, be granted a pro rata number of PSUs for that year, i.e. for the period between </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">the beginning of their employment and the next regular Grant Date, as an interim grant or as additional PSUs on the next regular Grant Date.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the PSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, the restrictions and procedures set out in article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs granted under this Plan and the PSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the PSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 14 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 14) or in the PSU Award Agreement, the PSUs granted by a PSU Award Agreement shall vest in three tranches of one third each. If the number of PSUs granted by a PSU Award Agreement cannot be divided by three, the two tranches vesting first shall be rounded up to the next integer and the tranche vesting last shall be rounded down and, if necessary, reduced in order to get to integers that add up to the total number of PSUs granted by the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The first tranche of the PSUs shall vest on the first anniversary of the Grant Date, the second tranche on the second anniversary of the Grant Date and the third tranche on the third anniversary of the Grant Date (each, with respect to the relevant tranche, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) The period between the Grant Date and the Vesting Date shall, with respect to the relevant tranche, be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Subject to Section 14(b) and (c) below, no PSU shall vest if, during the relevant Vesting Period, the relevant Participant's employment is terminated (i.e. effective date of termination) or another reason for termination occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The relevant number of Shares shall be delivered by or on behalf of the Company to the Participant upon and subject to signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Alternatively, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. Delivery of Shares or other consideration shall, subject to the further conditions of delivery being met, occur no later than three months following the Vesting Date of the relevant PSUs.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 16, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Company, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the Company's conditional share capital and a respective maximum number of Shares out of conditional capital shall be deemed reserved, accordingly. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Vesting Multiple</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall not be lower than 0 nor higher than 1.5 (one point five). Within such range, the Vesting Multiple shall be determined by the Board of Directors upon proposal by the Nomination and Compensation Committee based on its assessment of the achievement of the goals set out in the score card (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) attached to the PSU Award Agreement or otherwise communicated by the Company to the Participant in connection with the grant (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The Goals may include any corporate goals, i.e. strategic, operating or financial goals of the Company or the Group, any personal goals and performance of the relevant Participant and&#47;or any goals relating to the total shareholder return or share price development. The LTI Score Card may allocate a percentage weighting to each Goal for purposes of deriving the Vesting Multiple or require a global assessment of the achievement of goals.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall, unless the nature of the Goals demands otherwise, be determined for all tranches of the PSUs granted by a PSU Award Agreement in the year following the year of grant. Notwithstanding such determination, Vesting shall occur only at the time and subject to the conditions otherwise set out in this Plan or in the PSU Award Agreement.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Depending on the corporate goals set out in the LTI Score Card, the Vesting Multiple may be fixed (if all elements of Goal achievement are known at the time of determination) or variable (e.g. depending on further stock price development throughout the remainder of the Vesting Period).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of PSUs, on the allocation of Shares and the subsequent sale of Shares or on a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the PSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the employer Group Company. The Company and the relevant employer Group Company shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for PSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the employer Group Company before settlement of the PSU awards. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of PSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of PSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's employment) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Employment and Forfeiture</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If (i) a Participant's employment is terminated or (ii) another reason for termination occurs during the Vesting Period, other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO and except as set out in Section 14(b) and (c) below, all remaining unvested PSUs shall cease and be forfeited on the effective date of termination</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant&#8217;s employment agreement is terminated by the Company or a Group Company for reasons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> pertaining to the Participant, the next unvested tranche of PSUs granted would vest </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> (based on the effective date of termination) at the end of the relevant Vesting Period with the remaining PSUs lapsing without further effect. For clarity, the pro rata calculation under this Section 14 shall be determined on a monthly basis (Tranche 1, month 1 to 12, Tranche 2, month 13 to 24, Tranche 3, month 25 to 36, respectively, respectively), based on the complete months of employment worked during the relevant Vesting Period.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If the employment agreement terminates by reason of (i) death, permanent illness or disability of the Participant or (ii) retirement, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> number of PSUs granted to the Participant shall vest </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">immediately with the remaining PSUs lapsing without further effect. In the case of (i) here before, the pro rata calculation will be made assuming that employment lasted one year longer (but in any case not longer than the end of the regular three-year Vesting Period). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Management Board may, taking into consideration the objectives of the Plan, at its sole discretion and with final and binding effect grant further exceptions from the forfeiture as per Section 14 (a) above and assess whether a Participant&#8217;s employment agreement was terminated for reasons not pertaining to the Participant pursuant to Section 14(b) above. Two Management Board members needs to approve and sign such agreement.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover regulations&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all PSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all PSUs will vest immediately&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the Vesting Multiple with respect to each PSU allocation will be determined by the Nomination and Compensation Committee at the time of the Change of Control unless the Vesting Multiple has already been determined prior to the Change of Control&#59; and</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">the PSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange PSUs or decides upon another solution to provide the Participants with the vesting value of the PSUs.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control, but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the PSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the PSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding PSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of PSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the PSU Award Agreement by the Company, the Board of Directors, the Administrator and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used by the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the PSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors, any Administrator or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the employer Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the PSUs have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of PSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the PSUs and any shares granted thereunder.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past PSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a PSU Award Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any PSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the PSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per approval of the Board of Directors, this Plan shall enter into force as of March 8, 2023.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 15 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 3 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean all Group Companies.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Management Board </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the members of the top level executive management, i.e. those managers whose compensation is subject to the Compensation Ordinance. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted PSUs through a PSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall be the multiple determined in accordance with Section 10 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Employee PSU Award Agreement 2023</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Performance Share Plan 2023 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">PSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the PSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the PSU Plan, the Company hereby grants to you the following PSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.58pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.591%"><tr><td style="width:1.0%"></td><td style="width:38.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of PSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93; PSUs on &#91;&#9632;&#93;, &#91;&#9632;&#93; PSUs on &#91;&#9632;&#93; and &#91;&#9632;&#93; PSUs on &#91;&#9632;&#93;.</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. The number of Shares that may be allocated according to the PSU Plan shall be determined by the Nomination and Compensation Committee in accordance with the PSU Plan and the LTI Score Card setting out the Goals relevant for this award (&#91;communicated to you separately&#93; &#124; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">attached hereto&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">). Please note that the PSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">NB&#58; PSU Awards Agreements with employees of Group companies may differ from this template</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the PSUs in accordance with this Agreement and the PSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of PSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The PSU Plan, your eligibility thereunder, the grant of PSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the PSU Plan or to receive grants of PSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 - Employees</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date, Signature)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> ____________________<br>                                                                       <br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;Annex to the PSU Award Agreement 2023&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee PSU Plan 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTI Score Card &#91;for &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;&#8230;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>12
<FILENAME>a414psuplan2023_formanagem.htm
<DESCRIPTION>EX-4.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i686b48a9c1e4446bb951e2b0748c0817_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.14</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Share Plan 2023</font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Management Board</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Performance Share Plan 2023</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of PSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting Multiple</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Employment and Forfeiture</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">22.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i686b48a9c1e4446bb951e2b0748c0817_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">10</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of PSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Performance Share Plan 2023</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this performance share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Performance Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Capitalized terms used in this Plan shall have the meaning set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Where this Plan refers to employer, employee or employment, such terms shall apply by analogy if the relevant eligible person or Participant is not engaged as an employee, but under a different type of contract or in a different capacity, e.g. as a consultant under a mandate agreement or as a member of a corporate body (e.g. member of a board of directors or advisory board).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of PSUs that may be granted under this Plan and of shares to be allocated from the Company's conditional capital or otherwise in connection with such PSUs. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend or renew or terminate the Plan or to replace it with new editions or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any grants of PSUs to members of the Management Board shall be approved by the Board of Directors based on individual recommendations of the Nomination and Compensation Committee and will, as long as shareholder approval of variable compensation is outstanding, be conditional upon such shareholder approval. In case that the amount approved by the shareholders does not cover the full amount of contemplated aggregate variable compensation for the year of grant, the entitlements to short term and long-term variable compensation may be reduced by the Nomination and Compensation Committee in its sole discretion.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee to a third- party service provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, only members of the Management Board may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant PSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed PSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the employer Group Company) and the eligible person, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">. The right to receive PSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered, and have signed and returned, their individual PSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of PSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future performance share plans, regardless of the length of time a person has previously been allocated PSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of PSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to continue to be employed by any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of PSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of PSUs shall be exclusively made by way of PSU Award Agreements. The PSU Award Agreement shall set forth the number of PSUs and certain other terms and conditions of such grant. Except as otherwise determined in a PSU Award Agreement, PSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One PSU represents a conditional entitlement to purchase a number of Shares at the nominal value of a Share. The number of Shares which shall be allocated to a Participant upon vesting shall be determined pursuant to a vesting multiple as described in Section 10 hereof (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), subject to, and in accordance with, the terms and conditions of this Plan and the PSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grants shall be determined by the Nomination and Compensation Committee and set out in the PSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">A change of the regular working quota (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Arbeitspensum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) during the Vesting Period shall not lead to an adjustment of PSUs already granted. New Participants admitted to the Plan after the Grant Date may, if any, be granted a pro rata number of PSUs for that year, i.e. for the period between </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">the beginning of their employment and the next regular Grant Date, as an interim grant or as additional PSUs on the next regular Grant Date.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the PSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, the restrictions and procedures set out in article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">PSUs granted under this Plan and the PSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the PSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 14 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 14) or in the PSU Award Agreement, PSUs shall vest on the third anniversary of the Grant Date (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The period between the Grant Date and the Vesting Date shall be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Subject to Section 14(b) and (c) below, no PSU shall vest if, during the Vesting Period, the relevant Participant's employment is terminated (i.e. effective date of termination) or another reason for termination occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Shares shall be delivered by or on behalf of the Company to the Participant upon and subject to signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Alternatively, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. Delivery of Shares or other consideration shall, subject to the further conditions of delivery being met, occur no later than three months following the Vesting Date of the relevant PSUs.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 16, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Company, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Company's conditional share capital and a respective maximum number of Shares out of conditional capital shall be deemed reserved, accordingly. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Vesting Multiple</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall not be lower than 0 nor higher than 1.5 (one point five). Within such range, the Vesting Multiple shall be determined by the Board of Directors upon proposal by the Nomination and Compensation Committee based on its assessment of the achievement of the goals set out in the score card (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) attached to the PSU Award Agreement or otherwise communicated by the Company to the Participant in connection with the grant (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The Goals may include any corporate goals, i.e. strategic, operating or financial goals of the Company or the Group, any personal goals and performance of the relevant Participant and&#47;or any goals relating to the total shareholder return or share price development. The LTI Score Card may allocate a percentage weighting to each Goal for purposes of deriving the Vesting Multiple or require a global assessment of the achievement of Goals.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Vesting Multiple shall, unless the nature of the Goals demands otherwise, be determined in the year following the year of grant. Notwithstanding such determination, Vesting shall occur only at the time and subject to the conditions otherwise set out in this Plan or in the PSU Award Agreement.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Depending on the corporate goals set out in the LTI Score Card, the Vesting Multiple may be fixed (if all elements of Goal achievement are known at the time of determination) or variable (e.g. depending on further stock price development throughout the remainder of the Vesting Period).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of PSUs, on the allocation of Shares and the subsequent sale of Shares or on a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the PSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the employer Group Company. The Company and the relevant employer Group Company shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for PSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the employer Group Company before settlement of the PSU awards. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of PSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of PSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's employment) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Employment and Forfeiture</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If (i) a Participant's employment is terminated or (ii) another reason for termination occurs, during the Vesting Period, other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) within the meaning of Article 337 CO and except as set out in Section 14(b) and (c) below, all PSUs shall cease and be forfeited on the effective date of termination.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant&#8217;s employment agreement is terminated by the Company or a Group Company for reasons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> pertaining to the Participant, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> (based on the effective date of termination) number of PSUs granted to the Participant shall vest at the end of the Vesting Period with the remaining PSUs lapsing without further effect. For clarity, the pro rata calculation under this Section 14 shall be determined on a monthly basis (36&#47;36), based on the complete months of employment worked during the Vesting Period.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If the employment agreement terminates by reason of (i) death, permanent illness or disability of the Participant or (ii) retirement, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">pro rata</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> number of PSUs granted to the Participant shall vest immediately with the remaining PSUs lapsing without further effect. In the case of (i) here before, the pro rata calculation will be made assuming that employment lasted one year longer (but in any case not longer than the end of the regular three-year Vesting Period). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Board of Directors, based on a recommendation by the Nomination and Compensation Committee, may, taking into consideration the objectives of the Plan, at its sole discretion and with final and binding effect grant further exceptions from the forfeiture as per Section 14 (a) above and assess whether a Participant&#8217;s employment agreement was terminated for reasons </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">not pertaining to the Participant pursuant to Section 14(b) above. Two Management Board members need to approve and sign such agreement.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover- regulations&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all PSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all PSUs will vest immediately&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the Vesting Multiple with respect to each PSU allocation will be determined by the Nomination and Compensation Committee at the time of the Change of Control unless the Vesting Multiple has already been determined prior to the Change of Control&#59; and</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">the PSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange PSUs or decides upon another solution to provide the Participants with the vesting value of the PSUs.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the PSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the PSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding PSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of PSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the PSU Award Agreement by the Company, the Board of Directors and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used by the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the PSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the employer Group Company.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the PSUs have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of PSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the PSUs and any shares granted thereunder.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any grant of PSUs to members of the Management Board that qualifies as prohibited payment under the Compensation Ordinance or otherwise, shall be null and void.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If and to the extent that any term of this Plan, such as terms providing for early vesting in case of termination of employment or Change of Control should, at the time of the relevant event, qualify as providing additional value to a member of the Management Board in a manner that would violate the Compensation Ordinance or other legal provisions, such additional value shall be otherwise compensated, e.g. by a relevant deduction from cash compensation or other proceeds. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past PSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a PSU Award Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any PSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the PSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per approval of the Board of Directors, this Plan shall enter into force as of March 8, 2023.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 15 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Goal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean all Group Companies.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">LTI Score Card</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 10 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Management Board </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the members of the top level executive management, i.e. those managers whose compensation is subject to the Compensation Ordinance. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted PSUs through a PSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">PSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Multiple </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall be the multiple determined in accordance with Section 10 above. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Management Board PSU Award Agreement 2023 </font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Performance Share Plan 2023 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">PSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the PSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the PSU Plan, the Company hereby grants to you the following PSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.58pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.767%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of PSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. The number of Shares that may be allocated according to the PSU Plan shall be determined by the Nomination and Compensation Committee in accordance with the PSU Plan and the LTI Score Card setting out the corporate goals relevant for this award (&#91;communicated to you separately&#93; &#124; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">attached hereto&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">). Please note that the PSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. Any grants made to you as a member of the Management Board shall be subject to the approval of relevant compensation amounts for the Management Board by the shareholders' meeting for the year 2023. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the PSUs in accordance with this Agreement and the PSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of PSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The PSU Plan, your eligibility thereunder, the grant of PSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the PSU Plan or to receive grants of PSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Performance Share Plan 2023 &#8211; Management Board</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date, Signature)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> ____________________<br>                                                                       <br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;Annex to the PSU Award Agreement 2023&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management Board PSU Plan 2023 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTI Score Card &#91;for &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;&#8230;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;padding-left:28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>13
<FILENAME>a419restrictedshareplan2022.htm
<DESCRIPTION>EX-4.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ide833f96806042678752166dfe8e6657_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.19</font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:155%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Restricted Share Plan 2022 </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Restricted Share Plan 2021</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of RSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Relationship</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#ide833f96806042678752166dfe8e6657_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of RSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Restricted Share Plan 2022</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this restricted share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Restricted Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Capitalized terms used in this Plan shall have the meaning set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Annex 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of RSUs that may be granted under this Plan. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend, renew or terminate the Plan or to replace it with new editions or other plans. It may delegate, under its supervision, the implementation and administration, as well as grants of RSUs other than to members of the Board of Directors to one or several administrators (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any grants of RSUs to members of the Board of Directors shall be approved by the Board of Directors based on individual recommendations of the Nomination and Compensation Committee and will, as long as shareholder approval for the aggregate amount of compensation is outstanding, be conditional upon such shareholder approval. In case that the amount approved by the shareholders does not cover the full amount of contemplated aggregate compensation for the year of grant, the entitlements to long-term compensation may be reduced by the Nomination and Compensation Committee in its sole discretion.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee or, upon delegation by the Nomination and Compensation Committee, an Administrator pursuant to this Plan, including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee or the relevant Administrator to a third party service </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, members of the Board of Directors and selected consultants may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee or, other than to members of the Board of Directors, the relevant Administrator.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant RSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed RSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the relevant Group Company) and the eligible person, substantially in the form attached hereto as Annex 2. The right to receive RSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered and have signed and returned their individual RSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of RSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future restricted share plans, regardless of the length of time a person has previously been allocated RSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of RSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to a continued Relationship with any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of RSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of RSUs shall be exclusively made by way of RSU Award Agreements. The RSU Award Agreement shall set forth the number of RSUs and certain other terms and conditions of such grant. Except as otherwise determined in a RSU Award Agreement, RSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One RSU represents a conditional entitlement to purchase one Share at the nominal value of the Share. The number of Shares corresponding to the number vested RSUs shall be allocated to a Participant upon vesting, subject to, and in accordance with, the terms and conditions of this Plan and the RSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grant shall be determined by the Nomination and Compensation Committee or the relevant Administrator and set out in the RSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">RSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the RSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">RSUs granted under this Plan and the RSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the RSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 13 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 13) or in the RSU Award Agreement, RSUs shall vest in the third calendar year following the year of grant. In such case, vesting shall occur on the third anniversary of the Grant Date (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The period between the Grant Date and the Vesting Date shall be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Subject to section 13(b) below, no RSU shall vest if, during the first year of the Vesting Period (or, in case of a member of the Board of Directors, prior to the end of a full term of office), the relevant Participant's Relationship is terminated or another reason for termination of such Relationship occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), set by a Group Company.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Shares shall be delivered by or on behalf of the Company to the Participant upon signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Instead, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 15, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Nomination and Compensation Committee and the Board of Directors, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the Company's conditional share capital and a respective number of Shares out of conditional capital shall be deemed reserved, accordingly.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of RSUs, on the allocation of Shares and the subsequent sale of Shares or a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the RSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the relevant Group Company. The Company and the relevant Group Company, shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for RSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the relevant Group Company before settlement of the RSU awards. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of RSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of RSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's Relationship with the Company) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Relationship</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant's Relationship is terminated or another reason for termination occurs during the first year of the Vesting Period (or, in case of a member of the Board of Directors, prior to the end of a full term of office), other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) and except as set out in subsection 13 (b) below, all RSUs shall immediately cease and be forfeited. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If the Relationship terminates during the first year of the Vesting Period (or, in case of a member of the Board of Directors, prior to the end of a full term of office) by reason of death, permanent illness or disability of the Participant, a pro rata number of RSUs granted to the Participant shall vest immediately with the remaining RSUs lapsing without further effect. The Board of Directors may, at its sole discretion and with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the objectives of the Plan, grant further exceptions from the forfeiture clause as per section 13 (a) above. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover regulations&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all RSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all RSUs will vest immediately&#59; and</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the RSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange RSUs or decides upon another solution to provide the Participants with the vesting value of the RSUs.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control, but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the RSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the RSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding RSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of RSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the RSU Award Agreement by the Company, the Board of Directors, the Administrator and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used for the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the RSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors, any Administrator or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the relevant Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the RSU have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of RSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the RSUs and any shares granted thereunder.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any grant of RSUs to members of the Board of Directors that qualifies as prohibited payment under the Compensation Ordinance or otherwise, shall be null and void.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If and to the extent that any term of this Plan, such as terms providing for early vesting, in particular in case of termination of Relationship or Change of Control, should, at the time of the relevant event, qualify as providing additional value to a member of the Board of Directors in a manner that would violate the Compensation Ordinance or other legal provisions, such additional value shall be otherwise compensated, e.g. by a relevant deduction from cash compensation or other proceeds. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past RSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a RSU Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any RSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the RSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per the approval of the Board of Directors, this Plan shall enter into force as of March 24, 2022.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 14 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 3 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted RSUs through a RSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Relationship </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the board relationship and any relating contractual relationship of a member of the Board of Directors and the consultancy or other legal or contractual relationship of any other Participant.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">RSU Award Agreement 2022</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), a Swiss corporation, with its domicile in Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Restricted Share Plan 2022 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">RSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the RSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the RSU Plan, the Company hereby grants to you the following RSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.59pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.767%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700">Year of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. Please note that the RSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. &#91;Any grants made to members of the Board of Directors shall be subject to the approval of relevant compensation amounts for the Board of Directors by the shareholders' meeting for the year 2022.&#93;</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the RSUs in accordance with this Agreement and the RSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of RSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The RSU Plan, your eligibility thereunder, the grant of RSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the RSU Plan or to receive grants of RSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on  ____________________<br>                                                                       </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400">Molecular Partners AG&#58; Restricted Share Plan 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">(Signature)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.09pt"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.20
<SEQUENCE>14
<FILENAME>a420restrictedshareplan2023.htm
<DESCRIPTION>EX-4.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6a6e83ec295240fc99f18b511c831d07_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Exhibit 4.20</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:155%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Molecular Partners AG</font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Restricted Share Plan 2023 </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Table of Contents</font></div><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Restricted Share Plan 2023</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">1.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">2.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">3.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Responsibilities and Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">4.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Eligibility and Participation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">5.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Grant of RSUs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">6.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">7.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">No Transfer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">8.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Vesting and Delivery of Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">9.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Underlying Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">10.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Taxes and Social Security Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">11.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Disclosure Requirements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">12.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Other Obligations of the Participant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">13.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Termination of Relationship</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">14.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">15.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Corporate Events</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">16.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Data Protection</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">17.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Legal and regulatory restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">18.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">19.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">20.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Governing Law and Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">21.</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#7eacd4;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Entry into Force</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:14pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"><a href="#i6a6e83ec295240fc99f18b511c831d07_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:none">9</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Annexes</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 1&#58; Definitions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Annex 2&#58; Form of RSU Award Agreement </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:124%">Restricted Share Plan 20232023</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Purpose </font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The purpose of this restricted share plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) is to establish a framework that enables the Company to provide certain eligible persons with a variable long-term incentive to contribute to the future success and prosperity of the Company and to better align their interests with those of the Company and its shareholders by granting Restricted Share Units (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) to them. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:18.35pt">Definitions and Interpretation</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Capitalized terms used in this Plan shall have the meaning set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;text-decoration:underline">Annex 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Responsibilities and Administration</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan has been approved and issued by the Board of Directors and any amendments or new editions of this Plan or new or other plans shall require the approval by the Board of Directors. The Board of Directors shall be in charge of approving, upon recommendation of the nomination and compensation committee of the Board of Directors (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), the maximum number of RSUs that may be granted under this Plan. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The Nomination and Compensation Committee shall be responsible for the implementation and administration of the Plan and shall make recommendations to amend, renew or terminate the Plan or to replace it with new editions or other plans. It may delegate, under its supervision, the implementation and administration, as well as grants of RSUs other than to members of the Board of Directors to one or several administrators (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any grants of RSUs to members of the Board of Directors shall be approved by the Board of Directors based on individual recommendations of the Nomination and Compensation Committee and will, as long as shareholder approval for the aggregate amount of compensation is outstanding, be conditional upon such shareholder approval. In case that the amount approved by the shareholders does not cover the full amount of contemplated aggregate compensation for the year of grant, the entitlements to long-term compensation may be reduced by the Nomination and Compensation Committee in its sole discretion.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">All resolutions, decisions, determinations and interpretations made by the Nomination and Compensation Committee or, upon delegation by the Nomination and Compensation Committee, an Administrator pursuant to this Plan, including any amendments or withdrawals of grants, are final and binding, unless approval by the Board of Directors or the shareholders' meeting is required.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any technical or administrative task in connection with the Plan may be outsourced by the Nomination and Compensation Committee or the relevant Administrator to a third party service </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">provider, e.g. the bank in charge with the creation of the Shares (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Eligibility and Participation</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">As a rule, members of the Board of Directors and selected consultants may become eligible to participate in this Plan. The decision on eligibility is reserved to the Nomination and Compensation Committee or, other than to members of the Board of Directors, the relevant Administrator.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan shall provide any rights to eligible persons or any other person nor create any obligation of the Company to grant RSUs based on this Plan or otherwise. This Plan is only applicable in connection with a mutually signed RSU award agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) among the Company (or the relevant Group Company) and the eligible person, substantially in the form attached hereto as Annex 2. The right to receive RSUs shall accrue exclusively to those eligible persons who have, in accordance with this Plan, been duly and validly offered and have signed and returned their individual RSU Award Agreement by the relevant due date (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">).</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Grants of RSUs based on this Plan are discretionary and shall not create any entitlement to participate in future grants or in future participation, incentive or benefit plans, including future restricted share plans, regardless of the length of time a person has previously been allocated RSUs or other entitlements under this Plan or other plans.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the grant of RSUs, nor the transfer of Shares in connection with this Plan shall confer upon any Participant any right to a continued Relationship with any Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Grant of RSUs </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Grants of RSUs shall be exclusively made by way of RSU Award Agreements. The RSU Award Agreement shall set forth the number of RSUs and certain other terms and conditions of such grant. Except as otherwise determined in a RSU Award Agreement, RSUs shall be granted to the Participants free of charge. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">One RSU represents a conditional entitlement to purchase one Share at the nominal value of the Share. The number of Shares corresponding to the number vested RSUs shall be allocated to a Participant upon vesting, subject to, and in accordance with, the terms and conditions of this Plan and the RSU Award Agreement. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The date of grant shall be determined by the Nomination and Compensation Committee or the relevant Administrator and set out in the RSU Award Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Securities</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">RSUs are neither Shares nor securities of any kind and no shareholder rights or similar rights are attached to the RSUs. The Participants will only obtain shareholder rights (including voting and dividend rights) upon actual transfer of Shares, if any, according to the terms and conditions of the Plan and upon entry into the share register, subject to, and in accordance with, article 5 of the Company's articles of incorporation.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">No Transfer</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">RSUs granted under this Plan and the RSU Award Agreement are personal and non-transferable. Participants shall not be permitted to sell, donate, pledge, assign or otherwise dispose of the RSUs to third parties other than as provided for in the Plan. In case of death of a Participant, Section 13 hereof shall apply.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:18.35pt">Vesting and Delivery of Shares </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Unless otherwise set out in this Plan (in particular in Section 13) or in the RSU Award Agreement, RSUs shall vest in the third calendar year following the year of grant. In such case, vesting shall occur on the third anniversary of the Grant Date (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). The period between the Grant Date and the Vesting Date shall be deemed the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Subject to section 13(b) below, no RSU shall vest if, during the first year of the Vesting Period (or, in case of a member of the Board of Directors, prior to the end of a full term of office), the relevant Participant's Relationship is terminated or another reason for termination of such Relationship occurs other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">), set by a Group Company.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Shares shall be delivered by or on behalf of the Company to the Participant upon signing an acquisition declaration and payment of the nominal value of the Shares by the Participant. Instead, the Company may provide for cash-less acquisition or vesting-sale arrangements through a Plan Service Provider or otherwise. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:11.25pt">Underlying Shares</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Shares to be delivered to Participants shall, subject to adjustment, if any, pursuant to Section 15, be registered shares of the Company with a nominal value of CHF 0.10 each (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">). Such Shares shall, at the discretion of the Nomination and Compensation Committee and the Board of Directors, be sourced from conditional share capital, from treasury shares or from other sources. Unless otherwise determined by the Board of Directors or the Nomination and Compensation Committee, Shares shall be sourced from the Company's conditional share capital and a respective number of Shares out of conditional capital shall be deemed reserved, accordingly.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Taxes and Social Security Contributions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any Participant shall be responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax and social security authorities. Income, capital gain or other taxes due on the granting of RSUs, on the allocation of Shares and the subsequent sale of Shares or a respective cash equivalent are in the sole responsibility of the Participant.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">The grant, vesting, delivery or sale of Shares or other relevant event in connection with the RSUs may be subject to the withholding of tax and social security contributions by the Company or, if different, the relevant Group Company. The Company and the relevant Group Company, shall be entitled to deduct or withhold a sufficient portion of the value otherwise due to be released under this Plan or of any other payment to the relevant Participant to satisfy any withholding requirement in connection therewith. Without limitation, withholding arrangements may include the sale of Shares to be delivered for RSU awards on behalf of a Participant and withholding of proceeds or deductions from salary or bonus payments, or require a payment from the Participant to the Company or the relevant Group Company before settlement of the RSU awards. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">The Company shall have the right (but no obligation, unless required by applicable law) to notify the tax and social security authorities of the grant of RSU awards, Shares or related events.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Disclosure Requirements</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Any Participant shall be responsible to promptly comply with any applicable disclosure requirements under securities law and stock exchange regulations in connection with the receipt of grants of RSUs or Shares or upon the sale of Shares, including any disclosure requirements triggered by the thresholds for the ownership of shares and&#124;or rights to obtain shares under Article 120 Financial Market Infrastructure Act and any management transaction notifications under Article 56 of the SIX Swiss Exchange listing rules. See also the Company's public disclosure, reporting and securities trading policy.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Other Obligations of the Participant</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company is entitled to block or prohibit the issuance or release of Shares otherwise due to be issued or released if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in connection with the Participant's Relationship with the Company) to any Group Company, until the Participant has satisfied such outstanding obligations.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Termination of Relationship</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If a Participant's Relationship is terminated or another reason for termination occurs during the first year of the Vesting Period (or, in case of a member of the Board of Directors, prior to the end of a full term of office), other than through termination by the Participant for cause (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">wichtige </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Gr&#252;nde</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">) and except as set out in subsection 13 (b) below, all RSUs shall immediately cease and be forfeited. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If the Relationship terminates during the first year of the Vesting Period (or, in case of a member of the Board of Directors, prior to the end of a full term of office) by reason of death, permanent illness or disability of the Participant, a pro rata number of RSUs granted to the Participant shall vest immediately with the remaining RSUs lapsing without further effect. The Board of Directors may, at its sole discretion and with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the objectives of the Plan, grant further exceptions from the forfeiture clause as per section 13 (a) above. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Change of Control</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">For purposes of this Plan, a change of control shall mean the occurrence of any of the following events (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">the acquisition in one or more transaction by any person or group of persons acting in concert, directly or indirectly, of the beneficial ownership of Shares and &#124; or rights to acquire Shares representing 50% or more of the voting rights pertaining to the total number of Shares issued and registered in the commercial register&#59; </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">any facts or circumstances that require any person or group of persons acting in concert to launch a mandatory offer within the meaning of applicable takeover regulations&#59;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:15.03pt">a public offer for Shares by any person or persons (other than in order to implement a new parent company held by the same owners of Shares), for such number of Shares that, by itself or together with Shares already held, triggers the duty to extend the offer to all Shares outstanding, if and when such offer becomes unconditional (subject only to conditions, if any, that survive following the regular offer period)&#59;  </font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:14.47pt">the reorganization, merger, scheme of arrangement, consolidation, liquidation or similar transaction of the Company otherwise than through a transaction by which the persons who beneficially held Shares representing 100% of the voting rights pertaining to the total number of Shares issued and registered in the commercial register prior to such transaction  receive or continue to hold shares representing more than 50% of the voting rights pertaining to the total number of outstanding shares of the new or continuing entity.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">In the event of a Change of Control of the Company, the following shall apply for all RSUs in respect of which the Vesting Date has not occurred by the date of the Change of Control&#58;</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:19.47pt">all RSUs will vest immediately&#59; and</font></div><div style="margin-bottom:14pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:17.25pt">the RSUs will be paid out in Shares, unless the Nomination and Compensation Committee resolves to repurchase or exchange RSUs or decides upon another solution to provide the Participants with the vesting value of the RSUs.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">If based on a good faith assessment of the particular circumstances and effects of a Change of Control event, such event does not fall into the category and nature of cases, circumstances and consequences addressed by the definition of Change of Control, which are deemed to justify an early vesting, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to replace the consequences set forth above, by other terms that more appropriately and fairly address the situation.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If an event does not fall under the definition of Change of Control, but has substantially comparable effects as a Change of Control event, the Board of Directors may, based on a recommendation by the Nomination and Compensation Committee, decide to treat such event like a Change of Control event, providing, however, such adjustments to the consequences set forth above, that adequately and fairly address the differences to an actual Change of Control.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Corporate Events</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In the event of a stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares, issuance of options or other rights to purchase Shares at a price substantially below fair market value, or other extraordinary corporate events, which significantly dilute the value of the Shares underlying the RSUs such that an adjustment is required in order to preserve the benefits intended to be made available under this Plan, then the RSUs and related terms shall be adjusted and&#47;or, if deemed appropriate, a cash payment to Participants or persons having outstanding RSUs shall be made to compensate such dilution. Such adjustment shall be resolved by the Board of Directors at its sole discretion with final and binding effect, based on a recommendation by the Nomination and Compensation Committee and taking into consideration the acquired rights of the Participants and the objectives of the Plan.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:11.68pt">Data Protection</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">By accepting a grant of RSUs, each Participant consents to the collection and processing of personal data relating to the Participant in connection with such grant and the performance of this Plan and the RSU Award Agreement by the Company, the Board of Directors, the Administrator and any other person or entity the Company may find appropriate for the administration of the Plan. The data may be used for the aforementioned parties to perform their rights and obligations in connection with this Plan, issue certificates (if any), issue statements, disclosure and communications relating to the Plan and the RSUs, to provide for cash-less grants or sale mechanics and to generally administer and manage the Plan or keep records of participation levels.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Each Participant consents to the disclosure of such personal data by any Group Company to the Board of Directors, any Administrator or any Plan Service Provider and any other person or entity (including, without limitation, to third parties for due diligence purposes, or to tax authorities) as the Company may find appropriate. Such disclosure may include the transfer or </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">processing of such personal data in jurisdictions other than Switzerland or the jurisdiction of the relevant Group Company.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Legal and regulatory restrictions</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Neither the Shares nor the RSU have been or will be registered or listed in any jurisdiction other than, if and to the extent required, Switzerland. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Nothing in this Plan is intended to be deemed a public offering of, or solicitation of investments in, securities of the Company nor a private offering of securities into any jurisdiction or to any person in circumstances that would require compliance with licensing, filing, prospectus, registration or similar requirements in connection therewith. If and to the extent that the grant of RSUs or the delivery of Shares pursuant to this Plan or the extension of eligibility under this Plan into any jurisdiction or to any person conflicts with any securities, stock exchange or other laws and regulations or would trigger any licensing, filing, prospectus, registration or similar requirement (other than the regular listing of the Shares at SIX Swiss Exchange and their registration in the commercial register and in the book entry system to create intermediated securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:162%">Bucheffekten</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">)), such grant, delivery or extension shall be deemed null and void. In such case, the Company may (without obligation) decide in its own discretion whether and how to compensate the relevant persons in lieu of such grant, delivery or extension. </font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.69pt">Any Participant shall be required to observe trading or other bans as well as the prohibitions of insider trading and market manipulation in connection with the RSUs and any shares granted thereunder.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any grant of RSUs to members of the Board of Directors that qualifies as prohibited payment under the Compensation Ordinance or otherwise, shall be null and void.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">If and to the extent that any term of this Plan, such as terms providing for early vesting, in particular in case of termination of Relationship or Change of Control, should, at the time of the relevant event, qualify as providing additional value to a member of the Board of Directors in a manner that would violate the Compensation Ordinance or other legal provisions, such additional value shall be otherwise compensated, e.g. by a relevant deduction from cash compensation or other proceeds. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Amendment and Termination</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">In exceptional cases, the Board of Directors may terminate, suspend or amend this Plan at its sole discretion with regard to all or some future or past RSU grants. Any adverse economic effects of such termination, suspension or amendment on grants already made pursuant to a RSU Agreement shall be fairly compensated in cash, by adjustment of other terms of the grant, by replacement by other grants or benefits, or otherwise. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Severability</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The invalidity or non-enforceability of any one or more provisions of this Plan shall not affect the validity or enforceability of any other provisions of this Plan, which shall remain in full force and effect. The invalid provisions shall be replaced by valid provisions that economically come as close as possible to the original (invalid) provisions.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Governing Law and Jurisdiction</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">This Plan and any RSU Award Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland.</font></div><div style="margin-bottom:14pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%;padding-left:16.13pt">Any disputes arising under or in connection with this Plan, including any disputes under or in connection with the RSU Award Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:145%;padding-left:4.58pt">Entry into Force</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As per the approval of the Board of Directors, this Plan shall enter into force as of March 8, 2023.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 1</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:155%">Definitions</font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this Plan in capitalized form, the following terms shall have the following meaning&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Administrator </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Board of Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 14 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">CO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Swiss Code of Obligations as amended.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean Molecular Partners AG or any successor or replacement company or a new parent company, all as may be designated by the Board of Directors in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Nomination and Compensation Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 3 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Compensation Ordinance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the Federal Ordinance against Excessive Compensation in Listed Companies of November 20, 2013, as may be amended or replaced</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Grant Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 5 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean the Company and any company or entity of which at least 50% of the ownership or voting rights are directly or indirectly owned or otherwise controlled by the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall mean any eligible person to whom the Company has granted RSUs through a RSU Award Agreement based on this Plan.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 1 above.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Plan Service Provider </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 3 (e) above.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Relationship </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall mean the board relationship and any relating contractual relationship of a member of the Board of Directors and the consultancy or other legal or contractual relationship of any other Participant.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 1 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">RSU Award Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 4 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 9 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Date </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%">shall have the meaning set forth in Section 8 above. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> shall have the meaning set forth in Section 8 above.</font></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div><div style="margin-bottom:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">Annex 2</font></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:135%">RSU Award Agreement 2023</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) is made as of the Grant Date set forth below by and between Molecular Partners AG (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), a Swiss corporation, with its domicile in Schlieren, Canton of Zurich, Switzerland and &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name, Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">) in connection with the Restricted Share Plan 2023 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">RSU Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">), issued by the Company.</font></div><div style="margin-top:6pt;padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Capitalized terms used, but not defined herein, shall have the meaning assigned to them in the RSU Plan.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Subject to the terms and conditions of the RSU Plan, the Company hereby grants to you the following RSUs&#58;</font></div><div style="padding-right:-28.35pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.14pt;padding-left:13.58pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.767%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.3pt;padding-right:-27.5pt;text-align:justify;text-indent:-11.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</font></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of regular Vesting</font></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.2pt;padding-right:-27.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#9632;&#93;</font></div></td></tr></table></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The grants and any rights associated therewith are personal and not transferable. Please note that the RSU Plan includes a number of restrictions and conditions, which may lead to a complete loss of any entitlements hereunder. &#91;Any grants made to members of the Board of Directors shall be subject to the approval of relevant compensation amounts for the Board of Directors by the shareholders' meeting for the year 2023.&#93;</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By entering this Agreement, you accept the grant of the RSUs in accordance with this Agreement and the RSU Plan. In order to do so, please sign and return this Agreement no later than by &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#93; and keep a copy for your files</font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This grant of RSUs is being made, without obligation, at the sole and unrestricted discretion of the Company. The RSU Plan, your eligibility thereunder, the grant of RSUs or the allocation of Shares in connection therewith shall not confer upon you any right to participate in the RSU Plan or to receive grants of RSUs or Shares in the future. </font></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This Agreement shall be governed by, and construed in accordance with, the substantive laws of Switzerland. Any disputes arising under or in connection with this Agreement shall be submitted to the exclusive jurisdiction of the courts at the domicile of the Company (currently Schlieren, Canton of Zurich, Switzerland).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Accepted and agreed by the Participant on  ____________________<br>                                                                       </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(Date)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><br> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:160%">Molecular Partners AG&#58; Restricted Share Plan 2023</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">(Signature)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.14pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>15
<FILENAME>a121section302certification.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic7a4fb95b61f448080619bd4bd2049d6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 12.1</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CERTIFICATION*</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Patrick Amstutz, certify that&#58;</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Molecular Partners AG (the &#34;company&#34;)&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the company and have&#58;</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-34.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:1.4pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 9, 2023</font></div><div style="margin-top:3pt;padding-left:315pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.871%"><tr><td style="width:1.0%"></td><td style="width:12.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Patrick Amstutz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>16
<FILENAME>a122section302certification.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i97d5388a87464019abbb668ad966ad05_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 12.2</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CERTIFICATION*</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I,  Robert Hendriks, certify that&#58;</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Molecular Partners AG (the &#34;company&#34;)&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the company and have&#58;</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-34.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:1.4pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 9, 2023</font></div><div style="margin-top:3pt;padding-left:315pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.852%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Robert Hendriks</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VP Finance</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>17
<FILENAME>a131section906certification.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i44cbcacb26284271b503cd53760e1d74_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 13.1</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Patrick Amstutz</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Chief Executive Officer of Molecular Partners AG (the &#8220;Company&#8221;), and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert Hendriks</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, VP Finance of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.27pt">The Company&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, to which this Certification is attached as Exhibit 13.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.27pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; March 9, 2023</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the undersigned have set their hands hereto as of the 9th day of March, 2023</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Patrick Amstutz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert Hendriks</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Amstutz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Hendriks</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VP Finance</font></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;This certification accompanies the Form 20-F to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Molecular Partners AG, under the Securities Act of 1933, as amended, or the Exchange Act, as amended (whether made before or after the date of the Form 20-F), irrespective of any general incorporation language contained in such filing.&#8221;</font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>18
<FILENAME>a151auditorconsent.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6b0b89a5cbe94f02a2cf985b13eff0c4_1"></div><div style="min-height:156.24pt;width:100%"><div style="margin-top:63pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consent to the incorporation by reference in the registration statement (No. 333-265960) on Form F-3 of Molecular Partners AG of our report dated March 8, 2023, with respect to the consolidated financial statements of Molecular Partners AG.</font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; KPMG</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zurich, Switzerland</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>moln-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5bc598d-29c0-45ac-9809-ee4bc6e3f0aa,g:d67c3c2e-5cb8-4330-bb94-e6e901fa056b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:moln="http://www.molecularpartners.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.molecularpartners.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moln-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moln-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moln-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moln-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.molecularpartners.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.molecularpartners.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofFinancialPosition" roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition">
        <link:definition>0000003 - Statement - Consolidated Statement of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofComprehensiveIncome" roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statement of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>0000005 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofChangesinEquity" roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity">
        <link:definition>0000006 - Statement - Consolidated Statement of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Generalinformation" roleURI="http://www.molecularpartners.com/role/Generalinformation">
        <link:definition>0000007 - Disclosure - General information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>0000008 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialriskmanagement" roleURI="http://www.molecularpartners.com/role/Financialriskmanagement">
        <link:definition>0000009 - Disclosure - Financial risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Criticalaccountingestimatesandjudgments" roleURI="http://www.molecularpartners.com/role/Criticalaccountingestimatesandjudgments">
        <link:definition>0000010 - Disclosure - Critical accounting estimates and judgments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuesotherincomeandandentitywidedisclosures" roleURI="http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures">
        <link:definition>0000011 - Disclosure - Revenues, other income and and entity-wide disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.molecularpartners.com/role/Propertyplantandequipment">
        <link:definition>0000012 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://www.molecularpartners.com/role/Intangibleassets">
        <link:definition>0000013 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialinstruments" roleURI="http://www.molecularpartners.com/role/Financialinstruments">
        <link:definition>0000014 - Disclosure - Financial instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othercurrentassets" roleURI="http://www.molecularpartners.com/role/Othercurrentassets">
        <link:definition>0000015 - Disclosure - Other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradeandotherreceivables" roleURI="http://www.molecularpartners.com/role/Tradeandotherreceivables">
        <link:definition>0000016 - Disclosure - Trade and other receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashcashequivalentsandshorttermtimedeposits" roleURI="http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits">
        <link:definition>0000017 - Disclosure - Cash, cash equivalents and short-term time deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareholdersequity" roleURI="http://www.molecularpartners.com/role/Shareholdersequity">
        <link:definition>0000018 - Disclosure - Shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradeandotherpayables" roleURI="http://www.molecularpartners.com/role/Tradeandotherpayables">
        <link:definition>0000019 - Disclosure - Trade and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedexpenses" roleURI="http://www.molecularpartners.com/role/Accruedexpenses">
        <link:definition>0000020 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contractliability" roleURI="http://www.molecularpartners.com/role/Contractliability">
        <link:definition>0000021 - Disclosure - Contract liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Additionalinformationonthenatureofexpenses" roleURI="http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses">
        <link:definition>0000022 - Disclosure - Additional information on the nature of expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Royaltiesandlicensefees" roleURI="http://www.molecularpartners.com/role/Royaltiesandlicensefees">
        <link:definition>0000023 - Disclosure - Royalties and license fees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Personnelexpenses" roleURI="http://www.molecularpartners.com/role/Personnelexpenses">
        <link:definition>0000024 - Disclosure - Personnel expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialincomeandfinancialexpense" roleURI="http://www.molecularpartners.com/role/Financialincomeandfinancialexpense">
        <link:definition>0000025 - Disclosure - Financial income and financial expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Taxes" roleURI="http://www.molecularpartners.com/role/Taxes">
        <link:definition>0000026 - Disclosure - Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.molecularpartners.com/role/Earningspershare">
        <link:definition>0000027 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.molecularpartners.com/role/Leases">
        <link:definition>0000028 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartydisclosures" roleURI="http://www.molecularpartners.com/role/Relatedpartydisclosures">
        <link:definition>0000029 - Disclosure - Related party disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalcommitments" roleURI="http://www.molecularpartners.com/role/Capitalcommitments">
        <link:definition>0000030 - Disclosure - Capital commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialriskmanagement_1" roleURI="http://www.molecularpartners.com/role/Financialriskmanagement_1">
        <link:definition>0000031 - Disclosure - Financial risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PutativeClassAction" roleURI="http://www.molecularpartners.com/role/PutativeClassAction">
        <link:definition>0000032 - Disclosure - Putative Class Action</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Eventsafterthebalancesheetdate" roleURI="http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate">
        <link:definition>0000033 - Disclosure - Events after the balance sheet date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>0000034 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesTables" roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables">
        <link:definition>0000035 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesotherincomeandandentitywidedisclosuresTables" roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables">
        <link:definition>0000036 - Disclosure - Revenues, other income and and entity-wide disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.molecularpartners.com/role/PropertyplantandequipmentTables">
        <link:definition>0000037 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://www.molecularpartners.com/role/IntangibleassetsTables">
        <link:definition>0000038 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsTables" roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsTables">
        <link:definition>0000039 - Disclosure - Financial instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsTables" roleURI="http://www.molecularpartners.com/role/OthercurrentassetsTables">
        <link:definition>0000040 - Disclosure - Other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandotherreceivablesTables" roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesTables">
        <link:definition>0000041 - Disclosure - Trade and other receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandshorttermtimedepositsTables" roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables">
        <link:definition>0000042 - Disclosure - Cash, cash equivalents and short-term time deposits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityTables" roleURI="http://www.molecularpartners.com/role/ShareholdersequityTables">
        <link:definition>0000043 - Disclosure - Shareholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandotherpayablesTables" roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesTables">
        <link:definition>0000044 - Disclosure - Trade and other payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://www.molecularpartners.com/role/AccruedexpensesTables">
        <link:definition>0000045 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractliabilityTables" roleURI="http://www.molecularpartners.com/role/ContractliabilityTables">
        <link:definition>0000046 - Disclosure - Contract liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalinformationonthenatureofexpensesTables" roleURI="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables">
        <link:definition>0000047 - Disclosure - Additional information on the nature of expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesTables" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesTables">
        <link:definition>0000048 - Disclosure - Personnel expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialincomeandfinancialexpenseTables" roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables">
        <link:definition>0000049 - Disclosure - Financial income and financial expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesTables" roleURI="http://www.molecularpartners.com/role/TaxesTables">
        <link:definition>0000050 - Disclosure - Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.molecularpartners.com/role/EarningspershareTables">
        <link:definition>0000051 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.molecularpartners.com/role/LeasesTables">
        <link:definition>0000052 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartydisclosuresTables" roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresTables">
        <link:definition>0000053 - Disclosure - Related party disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementTables" roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementTables">
        <link:definition>0000054 - Disclosure - Financial risk management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesSegmentReportingDetails" roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesSegmentReportingDetails">
        <link:definition>0000055 - Disclosure - Summary of significant accounting policies - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails">
        <link:definition>0000056 - Disclosure - Summary of significant accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails" roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails">
        <link:definition>0000057 - Disclosure - Summary of significant accounting policies - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails" roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails">
        <link:definition>0000058 - Disclosure - Summary of significant accounting policies - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails" roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails">
        <link:definition>0000059 - Disclosure - Revenues, other income and and entity-wide disclosures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails">
        <link:definition>0000060 - Disclosure - Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Country (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails" roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails">
        <link:definition>0000061 - Disclosure - Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails" roleURI="http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails">
        <link:definition>0000062 - Disclosure - Property, plant and equipment - Disclosure of Reconciliation of Changes in Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsDetails" roleURI="http://www.molecularpartners.com/role/IntangibleassetsDetails">
        <link:definition>0000063 - Disclosure - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails">
        <link:definition>0000064 - Disclosure - Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails">
        <link:definition>0000065 - Disclosure - Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsDetails" roleURI="http://www.molecularpartners.com/role/OthercurrentassetsDetails">
        <link:definition>0000066 - Disclosure - Other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails">
        <link:definition>0000067 - Disclosure - Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails">
        <link:definition>0000068 - Disclosure - Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails">
        <link:definition>0000069 - Disclosure - Cash, cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandshorttermtimedepositsNarrativeDetails" roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails">
        <link:definition>0000070 - Disclosure - Cash, cash equivalents and short-term time deposits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityNarrativeDetails" roleURI="http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails">
        <link:definition>0000071 - Disclosure - Shareholders&#8217; equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityClassesofShareCapitalDetails" roleURI="http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails">
        <link:definition>0000072 - Disclosure - Shareholders&#8217; equity - Classes of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequitySharesIssuedDetails" roleURI="http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails">
        <link:definition>0000073 - Disclosure - Shareholders' equity - Shares Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails">
        <link:definition>0000074 - Disclosure - Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails">
        <link:definition>0000075 - Disclosure - Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesDetails" roleURI="http://www.molecularpartners.com/role/AccruedexpensesDetails">
        <link:definition>0000076 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails" roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails">
        <link:definition>0000077 - Disclosure - Contract liability - Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractliabilityExplanationofChangesinContractLiabilitiesDetails" roleURI="http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails">
        <link:definition>0000078 - Disclosure - Contract liability - Explanation of Changes in Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractliabilityAdditionalInformationDetails" roleURI="http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails">
        <link:definition>0000079 - Disclosure - Contract liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails">
        <link:definition>0000080 - Disclosure - Contract liability - Disclosure of Current and Non-Current Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalinformationonthenatureofexpensesDetails" roleURI="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails">
        <link:definition>0000081 - Disclosure - Additional information on the nature of expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltiesandlicensefeesDetails" roleURI="http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails">
        <link:definition>0000082 - Disclosure - Royalties and license fees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails">
        <link:definition>0000083 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails">
        <link:definition>0000084 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails">
        <link:definition>0000085 - Disclosure - Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1">
        <link:definition>0000085 - Disclosure - Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails">
        <link:definition>0000086 - Disclosure - Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesAdditionalInformationDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails">
        <link:definition>0000087 - Disclosure - Personnel expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails">
        <link:definition>0000088 - Disclosure - Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails">
        <link:definition>0000089 - Disclosure - Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails">
        <link:definition>0000090 - Disclosure - Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails" roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails">
        <link:definition>0000091 - Disclosure - Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails">
        <link:definition>0000092 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails">
        <link:definition>0000093 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesIncomeTaxesDetails" roleURI="http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails">
        <link:definition>0000094 - Disclosure - Taxes - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesDeferredTaxesDetails" roleURI="http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails">
        <link:definition>0000095 - Disclosure - Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" roleURI="http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails">
        <link:definition>0000096 - Disclosure - Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareDetails" roleURI="http://www.molecularpartners.com/role/EarningspershareDetails">
        <link:definition>0000097 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.molecularpartners.com/role/LeasesNarrativeDetails">
        <link:definition>0000098 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDisclosureofMovementofLeaseLiabilitiesDetails" roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails">
        <link:definition>0000099 - Disclosure - Leases - Disclosure of Movement of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails">
        <link:definition>0000100 - Disclosure - Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails">
        <link:definition>0000101 - Disclosure - Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails" roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails">
        <link:definition>0000102 - Disclosure - Related party disclosures - Disclosure of Compensation Costs of Key Management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartydisclosuresNarrativeDetails" roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails">
        <link:definition>0000103 - Disclosure - Related party disclosures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails" roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails">
        <link:definition>0000104 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementAdditionalInformationDetails" roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails">
        <link:definition>0000105 - Disclosure - Financial risk management - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails">
        <link:definition>0000106 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails">
        <link:definition>0000107 - Disclosure - Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" abstract="true" name="DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_LeaseExtensionOrTerminationOptionPeriod" abstract="false" name="LeaseExtensionOrTerminationOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" abstract="true" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_NumberOfOperatingSegments" abstract="false" name="NumberOfOperatingSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_RoyaltiesMinimumAnnualAmountTotal" abstract="false" name="RoyaltiesMinimumAnnualAmountTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" abstract="false" name="ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_DisclosureOfTradeAndOtherPayablesLineItems" abstract="true" name="DisclosureOfTradeAndOtherPayablesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_MolecularPartnersIncMember" abstract="true" name="MolecularPartnersIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_AuthorizedShareCapitalFinancingTransactions" abstract="false" name="AuthorizedShareCapitalFinancingTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" abstract="false" name="AdjustmentsForIncreaseDecreaseInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" abstract="false" name="ResearchConsumablesAndExternalResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_AccruedSabbaticalCost" abstract="false" name="AccruedSabbaticalCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_TreasurySharesNominalValue" abstract="false" name="TreasurySharesNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" abstract="false" name="NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_TaxLossCarryforwards" abstract="false" name="TaxLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" abstract="true" name="A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" abstract="false" name="NumberOfSharesIssuedInRelationToCapitalRaiseEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutLeasesTable" abstract="true" name="DisclosureOfDetailedInformationAboutLeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_TradePayablesMember" abstract="true" name="TradePayablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_IntellectualPropertyExpense" abstract="false" name="IntellectualPropertyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" abstract="false" name="DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_RevenueFromRechargeOfEmployeeRelatedExpenses" abstract="false" name="RevenueFromRechargeOfEmployeeRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_ExpiringIn2024Member" abstract="true" name="ExpiringIn2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" abstract="false" name="NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_LicenseAndCollaborationAgreementWithAmgenIncMember" abstract="true" name="LicenseAndCollaborationAgreementWithAmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_AuthorizedShareCapitalEmployeeParticipation" abstract="false" name="AuthorizedShareCapitalEmployeeParticipation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_NumberOfSharesAuthorizedEmployeeParticipation" abstract="false" name="NumberOfSharesAuthorizedEmployeeParticipation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_LaterThanFourYearsMember" abstract="true" name="LaterThanFourYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" abstract="false" name="PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_RoyaltyPayable" abstract="false" name="RoyaltyPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" abstract="false" name="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" abstract="false" name="SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_ActiveMembersMember" abstract="true" name="ActiveMembersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_LicenseFeesExpense" abstract="false" name="LicenseFeesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_OtherResearchAndDevelopmentExpense" abstract="false" name="OtherResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_ExpiringIn2028Member" abstract="true" name="ExpiringIn2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ReconciliationOfFairValueOfPlanAssetsAbstract" abstract="true" name="ReconciliationOfFairValueOfPlanAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_ActuarialAssumptionsAbstract" abstract="true" name="ActuarialAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_RoyaltyIncomePercentage" abstract="false" name="RoyaltyIncomePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" abstract="false" name="WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" abstract="true" name="PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" abstract="false" name="DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_PensionersMember" abstract="true" name="PensionersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_MaximumAmountOfShareCapitalIncreaseAuthorized" abstract="false" name="MaximumAmountOfShareCapitalIncreaseAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfTradeAndOtherPayablesTable" abstract="true" name="DisclosureOfTradeAndOtherPayablesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" abstract="false" name="DefinedBenefitPlanNumberOfEmployeesThatParticipated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" abstract="false" name="NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" abstract="true" name="ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" abstract="false" name="MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" abstract="false" name="IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" abstract="true" name="ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_OperatingExpensesAbstract" abstract="true" name="OperatingExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" abstract="false" name="PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" abstract="true" name="DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_ShareOptionsPSUsAndRSUsMember" abstract="true" name="ShareOptionsPSUsAndRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ExpiringIn2026Member" abstract="true" name="ExpiringIn2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" abstract="false" name="NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_ExpiringIn2027Member" abstract="true" name="ExpiringIn2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" abstract="true" name="DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" abstract="true" name="DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_VestingRequirementsForShareBasedPaymentArrangementPercent" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_LeaseTermOfContract" abstract="false" name="LeaseTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" abstract="false" name="NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_ESOP2009AndESOP2014Member" abstract="true" name="ESOP2009AndESOP2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_VSAOMember" abstract="true" name="VSAOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_IncreaseThroughAdditionsContractLiabilities" abstract="false" name="IncreaseThroughAdditionsContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DefinedBenefitPlanNumberOfEligibleEmployees" abstract="false" name="DefinedBenefitPlanNumberOfEligibleEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" abstract="false" name="ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_FullContractualLifeOtherEquityInstruments" abstract="false" name="FullContractualLifeOtherEquityInstruments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" abstract="true" name="AmericanDepositorySharesTheNasdaqStockMarketLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ExpiringIn2023Member" abstract="true" name="ExpiringIn2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" abstract="true" name="ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_CommercialSupplyOfProductsMember" abstract="true" name="CommercialSupplyOfProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_NumberOfSharesAuthorizedFinancingTransactions" abstract="false" name="NumberOfSharesAuthorizedFinancingTransactions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_ExpectedDividendOtherEquityInstrumentsGranted" abstract="false" name="ExpectedDividendOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_NumberOfSharesIssuedTreasurySharesEquity" abstract="false" name="NumberOfSharesIssuedTreasurySharesEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" abstract="false" name="NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" abstract="false" name="NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_DisclosureOfTradeAndOtherReceivablesTable" abstract="true" name="DisclosureOfTradeAndOtherReceivablesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" abstract="false" name="PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_FederalOfficeOfPublicHealthMember" abstract="true" name="FederalOfficeOfPublicHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_UpfrontPaymentReceived" abstract="false" name="UpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_PotentialFutureMilestonePayments" abstract="false" name="PotentialFutureMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" abstract="false" name="IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_AccruedProjectCostsAndRoyaltiesMember" abstract="true" name="AccruedProjectCostsAndRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" abstract="false" name="ServiceCostAndAdministrativeCostDefinedBenefitPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_PerformanceShareUnitsPSUManagementBoardMember" abstract="true" name="PerformanceShareUnitsPSUManagementBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_DefinedBenefitPlanEmployeeContribution" abstract="false" name="DefinedBenefitPlanEmployeeContribution" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_FinancialRiskManagementAbstract" abstract="true" name="FinancialRiskManagementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_ExercicePriceOfOutstandingOtherEquityInstruments" abstract="false" name="ExercicePriceOfOutstandingOtherEquityInstruments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_CashAndCashEquivalentsMember" abstract="true" name="CashAndCashEquivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" abstract="false" name="DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" abstract="false" name="AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" abstract="false" name="CashBalancesInvestmentsNumberOfDifferentSwissBanks" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" abstract="false" name="PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_AverageNumberOfFullTimeEquivalentEmployees" abstract="false" name="AverageNumberOfFullTimeEquivalentEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_RestrictedShareUnitsRSUMember" abstract="true" name="RestrictedShareUnitsRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_CriticalAccountingEstimatesAndJudgmentsAbstract" abstract="true" name="CriticalAccountingEstimatesAndJudgmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_UpfrontPaymentAmountUtilizedDuringPeriod" abstract="false" name="UpfrontPaymentAmountUtilizedDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_CurrentAccruedProjectCostsAndRoyalties" abstract="false" name="CurrentAccruedProjectCostsAndRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_AmgenIncMember" abstract="true" name="AmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ExpiringIn2025Member" abstract="true" name="ExpiringIn2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfShortTermTimeDepositPositions" abstract="false" name="NumberOfShortTermTimeDepositPositions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_NetOperatingProfit" abstract="false" name="NetOperatingProfit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" abstract="true" name="DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_IndustryBenchmarkDiscountRatesPeriod" abstract="false" name="IndustryBenchmarkDiscountRatesPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_IncreaseThroughNewLeasesOperatingLeases" abstract="false" name="IncreaseThroughNewLeasesOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_AccruedIncomeMember" abstract="true" name="AccruedIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ThereafterMember" abstract="true" name="ThereafterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_DisclosureOfSignificantAccountingPoliciesAbstract" abstract="true" name="DisclosureOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" abstract="false" name="NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" abstract="false" name="ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_ExtendedPeriodOfReservationAgreement" abstract="false" name="ExtendedPeriodOfReservationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_LicenseAndCollaborationAgreementWithNovartisAGMember" abstract="true" name="LicenseAndCollaborationAgreementWithNovartisAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ResearchAndDevelopmentExpenseMember" abstract="true" name="ResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" abstract="false" name="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" abstract="true" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" abstract="false" name="DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_IssuanceCostsOfTreasuryShareTransactions" abstract="false" name="IssuanceCostsOfTreasuryShareTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfTradeAndOtherReceivablesLineItems" abstract="true" name="DisclosureOfTradeAndOtherReceivablesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" abstract="false" name="WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_ReconciliationOfDefinedBenefitObligationAbstract" abstract="true" name="ReconciliationOfDefinedBenefitObligationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_IndividualsAxis" abstract="true" name="IndividualsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" abstract="true" name="OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_LeaseExtensionTermOfContract" abstract="false" name="LeaseExtensionTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_TaxLossCarryforwardsExpirationPeriod" abstract="false" name="TaxLossCarryforwardsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_DisclosureOfGeneralInformationAbstract" abstract="true" name="DisclosureOfGeneralInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_UniversityOfUtrechtMember" abstract="true" name="UniversityOfUtrechtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfFullTimeEquivalentEmployees" abstract="false" name="NumberOfFullTimeEquivalentEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_PerformanceShareUnitsPSUMember" abstract="true" name="PerformanceShareUnitsPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfVotesPerShare" abstract="false" name="NumberOfVotesPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_LicenseAndCollaborationAgreementWithFOPHMember" abstract="true" name="LicenseAndCollaborationAgreementWithFOPHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_PersonnelExpensesAbstract" abstract="true" name="PersonnelExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_IndividualsDomain" abstract="true" name="IndividualsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" abstract="false" name="NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" abstract="false" name="DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_NumberOfShareOptionPlans" abstract="false" name="NumberOfShareOptionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" abstract="true" name="DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" abstract="false" name="NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutLeasesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutLeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_ConditionalShareCapitalMember" abstract="true" name="ConditionalShareCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_OtherNonEmployeeRelatedAccruedExpensesMember" abstract="true" name="OtherNonEmployeeRelatedAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ShortTermTimeDepositsMember" abstract="true" name="ShortTermTimeDepositsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_NumberOfBanksWhereDepositsAreHeld" abstract="false" name="NumberOfBanksWhereDepositsAreHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moln_DefinedBenefitPlanEmployerContribution" abstract="false" name="DefinedBenefitPlanEmployerContribution" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" abstract="true" name="DisclosureOfDetailedInformationAboutContractLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_SignificantTransactionsMember" abstract="true" name="SignificantTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_LeaseFacilitiesSchlierenMember" abstract="true" name="LeaseFacilitiesSchlierenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_LeaseCostRecognisedInProfitOrLoss" abstract="false" name="LeaseCostRecognisedInProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_PaymentForTermOfEmploymentRelatedPartyTransactions" abstract="false" name="PaymentForTermOfEmploymentRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" abstract="false" name="NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" abstract="false" name="DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" abstract="false" name="ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" abstract="true" name="DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" abstract="false" name="DisclosureOfRoyaltiesAndLicenseFeesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" abstract="true" name="DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" abstract="false" name="DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" abstract="false" name="MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" abstract="false" name="InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" abstract="false" name="NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="moln_DecreaseThroughOffsetOfCostsContractLiabilities" abstract="false" name="DecreaseThroughOffsetOfCostsContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" abstract="false" name="DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutContractLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_ChangesInWorkingCapitalAbstract" abstract="true" name="ChangesInWorkingCapitalAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_IncomeTaxesAndDeferredTaxesAbstract" abstract="true" name="IncomeTaxesAndDeferredTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" abstract="false" name="PostEmploymentBenefitExpenseNonCashEffectivePensionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" abstract="false" name="NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" abstract="true" name="RightOfUseAssetsPropertyPlantAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_VoluntaryComplementaryPlanMember" abstract="true" name="VoluntaryComplementaryPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" abstract="false" name="ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" abstract="false" name="PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moln_NetOperatingLosses" abstract="false" name="NetOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" abstract="false" name="PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" abstract="false" name="WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moln_IncreaseDecreaseInAuthorizedShareCapital" abstract="false" name="IncreaseDecreaseInAuthorizedShareCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moln_RoyaltiesAndLicenseFeesExpense" abstract="false" name="RoyaltiesAndLicenseFeesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>moln-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5bc598d-29c0-45ac-9809-ee4bc6e3f0aa,g:d67c3c2e-5cb8-4330-bb94-e6e901fa056b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofFinancialPosition"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ff5948e8-91a5-4fd7-860a-8c6cbbe38eb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_f2a8ddf8-02cb-492d-ba95-593cddb9f080" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ff5948e8-91a5-4fd7-860a-8c6cbbe38eb1" xlink:to="loc_ifrs-full_TreasuryShares_f2a8ddf8-02cb-492d-ba95-593cddb9f080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_ec008f98-401b-4fbc-bb79-379adcb4e354" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ff5948e8-91a5-4fd7-860a-8c6cbbe38eb1" xlink:to="loc_ifrs-full_IssuedCapital_ec008f98-401b-4fbc-bb79-379adcb4e354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_90f14f05-7a1c-482c-8e2b-aa37ddabc0cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ff5948e8-91a5-4fd7-860a-8c6cbbe38eb1" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_90f14f05-7a1c-482c-8e2b-aa37ddabc0cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_08ff8277-f929-49ec-bb99-f17c2eade5cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ff5948e8-91a5-4fd7-860a-8c6cbbe38eb1" xlink:to="loc_ifrs-full_RetainedEarnings_08ff8277-f929-49ec-bb99-f17c2eade5cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_8a7a73d2-c354-4690-b4b6-6dec43f5e40d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_7ae77570-50fb-416c-ade3-ea1d91b041d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_8a7a73d2-c354-4690-b4b6-6dec43f5e40d" xlink:to="loc_ifrs-full_CurrentContractLiabilities_7ae77570-50fb-416c-ade3-ea1d91b041d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_f719dd5a-f453-4835-8313-c86d8cebeb8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_8a7a73d2-c354-4690-b4b6-6dec43f5e40d" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_f719dd5a-f453-4835-8313-c86d8cebeb8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_0a62a139-b948-434a-99c0-4e15233e8568" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_8a7a73d2-c354-4690-b4b6-6dec43f5e40d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_0a62a139-b948-434a-99c0-4e15233e8568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_8c6dbb42-68a1-425d-8aae-5147ebaf94ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_8a7a73d2-c354-4690-b4b6-6dec43f5e40d" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_8c6dbb42-68a1-425d-8aae-5147ebaf94ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_b13dbf5b-bde3-499f-b5c8-c1d8ee12a968" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_6d250bcf-f0d2-4be3-a812-080d50b90885" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b13dbf5b-bde3-499f-b5c8-c1d8ee12a968" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_6d250bcf-f0d2-4be3-a812-080d50b90885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_c98a7459-1232-489b-adc8-9f52055aba41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b13dbf5b-bde3-499f-b5c8-c1d8ee12a968" xlink:to="loc_ifrs-full_OtherCurrentAssets_c98a7459-1232-489b-adc8-9f52055aba41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_0e227d42-9ea3-4758-95fb-77faaf369960" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b13dbf5b-bde3-499f-b5c8-c1d8ee12a968" xlink:to="loc_ifrs-full_CashAndCashEquivalents_0e227d42-9ea3-4758-95fb-77faaf369960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_5ae6df88-f68f-4316-b7aa-1fbc24bba1c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b13dbf5b-bde3-499f-b5c8-c1d8ee12a968" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_5ae6df88-f68f-4316-b7aa-1fbc24bba1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_1f9ba75e-8d05-46b8-a266-87df93b829a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_df947f4b-1409-4444-8c1f-f1c3ae33ff58" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_1f9ba75e-8d05-46b8-a266-87df93b829a9" xlink:to="loc_ifrs-full_CurrentAssets_df947f4b-1409-4444-8c1f-f1c3ae33ff58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_8da0d21d-86c8-4a8e-ba67-b87793e7aad5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_1f9ba75e-8d05-46b8-a266-87df93b829a9" xlink:to="loc_ifrs-full_NoncurrentAssets_8da0d21d-86c8-4a8e-ba67-b87793e7aad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_784a79a2-788e-452f-a12a-d76b37254ae3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_d7141aae-dcab-4759-8090-2f34a18d0fd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_784a79a2-788e-452f-a12a-d76b37254ae3" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_d7141aae-dcab-4759-8090-2f34a18d0fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_320e3da3-ce7f-432f-8633-102d017009bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_784a79a2-788e-452f-a12a-d76b37254ae3" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_320e3da3-ce7f-432f-8633-102d017009bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_273b654b-073d-4a98-b55a-a4610913ecb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_784a79a2-788e-452f-a12a-d76b37254ae3" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_273b654b-073d-4a98-b55a-a4610913ecb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_176af597-8d28-4dd6-88dc-e42e1f026bac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7f048261-8fea-400f-9767-b09ce0d594bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_176af597-8d28-4dd6-88dc-e42e1f026bac" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7f048261-8fea-400f-9767-b09ce0d594bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_79ab5b4f-1471-445a-a38e-e776d699263a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_176af597-8d28-4dd6-88dc-e42e1f026bac" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_79ab5b4f-1471-445a-a38e-e776d699263a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_40531c97-f4a0-4bca-adca-88ec90db8553" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_a6cf86b7-1a07-4287-9ab2-d5789a2ff4c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_40531c97-f4a0-4bca-adca-88ec90db8553" xlink:to="loc_ifrs-full_Liabilities_a6cf86b7-1a07-4287-9ab2-d5789a2ff4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d8b51a09-433c-4200-8105-6f3b6b5f5d0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_40531c97-f4a0-4bca-adca-88ec90db8553" xlink:to="loc_ifrs-full_Equity_d8b51a09-433c-4200-8105-6f3b6b5f5d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_5da19023-f6c3-4dfb-81ab-83e51e1f1bbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_76eeef36-101a-4a31-8381-dc3da958fb84" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_5da19023-f6c3-4dfb-81ab-83e51e1f1bbc" xlink:to="loc_ifrs-full_NoncurrentLiabilities_76eeef36-101a-4a31-8381-dc3da958fb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_6386e1c6-478f-431c-9d57-96ab096d328f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_5da19023-f6c3-4dfb-81ab-83e51e1f1bbc" xlink:to="loc_ifrs-full_CurrentLiabilities_6386e1c6-478f-431c-9d57-96ab096d328f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_38a8dfeb-1fd0-47d6-ad52-9df4a24940ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_13292337-6148-43d1-ba02-13917128a1a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_38a8dfeb-1fd0-47d6-ad52-9df4a24940ec" xlink:to="loc_ifrs-full_FinanceIncomeCost_13292337-6148-43d1-ba02-13917128a1a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_c83aa6ec-ffab-44a1-baa0-418f8a838d57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_38a8dfeb-1fd0-47d6-ad52-9df4a24940ec" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_c83aa6ec-ffab-44a1-baa0-418f8a838d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_3d1421b3-3a2e-4db8-a2fb-5565dc15e147" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_c35dfd74-4334-4892-ab6c-b4bf110581bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_3d1421b3-3a2e-4db8-a2fb-5565dc15e147" xlink:to="loc_ifrs-full_OperatingExpense_c35dfd74-4334-4892-ab6c-b4bf110581bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_97bb4ebc-1186-40be-b40c-811cc4f3b28f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_3d1421b3-3a2e-4db8-a2fb-5565dc15e147" xlink:to="loc_ifrs-full_Revenue_97bb4ebc-1186-40be-b40c-811cc4f3b28f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3eeafcb8-8dec-49fd-a10f-9f5ec621ae3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_0e441d8d-24a3-4cae-b5a8-3db1fbea035e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_3eeafcb8-8dec-49fd-a10f-9f5ec621ae3a" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_0e441d8d-24a3-4cae-b5a8-3db1fbea035e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3fbabebe-02b2-4487-8fbb-5dc752424a42" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_3eeafcb8-8dec-49fd-a10f-9f5ec621ae3a" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3fbabebe-02b2-4487-8fbb-5dc752424a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_9bbb7d2e-8d98-4d26-9e65-b55ee2bd1d8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_79efa995-1a91-4334-ba16-5e3946405933" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_9bbb7d2e-8d98-4d26-9e65-b55ee2bd1d8b" xlink:to="loc_ifrs-full_FinanceIncome_79efa995-1a91-4334-ba16-5e3946405933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_14814a89-2c81-45e5-b1f5-64a5a5a9b5ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_9bbb7d2e-8d98-4d26-9e65-b55ee2bd1d8b" xlink:to="loc_ifrs-full_FinanceCosts_14814a89-2c81-45e5-b1f5-64a5a5a9b5ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_b064d928-4ae4-4d70-a30d-3d0605a87f7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_342442a4-19fe-40b0-bda1-3a3e91798815" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_b064d928-4ae4-4d70-a30d-3d0605a87f7a" xlink:to="loc_ifrs-full_OtherIncome_342442a4-19fe-40b0-bda1-3a3e91798815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_aa212a37-e9c4-43e8-b1d0-2fc449a701a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_b064d928-4ae4-4d70-a30d-3d0605a87f7a" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_aa212a37-e9c4-43e8-b1d0-2fc449a701a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_92632ec4-2e85-40f7-b120-2d4363da4bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_1460c42c-4504-40a8-9ebe-21c8e1823163" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_92632ec4-2e85-40f7-b120-2d4363da4bdd" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_1460c42c-4504-40a8-9ebe-21c8e1823163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_f86e8b0a-c9f0-478e-9f3c-5260c78f214d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_92632ec4-2e85-40f7-b120-2d4363da4bdd" xlink:to="loc_ifrs-full_ProfitLoss_f86e8b0a-c9f0-478e-9f3c-5260c78f214d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_265eef54-5fcd-49b9-95ce-1aa4a718ed5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_ba5980c6-bbde-42e0-b7dc-cc2cd5fbb5f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_265eef54-5fcd-49b9-95ce-1aa4a718ed5b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_ba5980c6-bbde-42e0-b7dc-cc2cd5fbb5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_831b0dec-ca45-4768-9a49-e28f1a56ff6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_265eef54-5fcd-49b9-95ce-1aa4a718ed5b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_831b0dec-ca45-4768-9a49-e28f1a56ff6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_c73cc821-93b6-4b8d-9ff5-67e545a991b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_a812aa86-aeef-4b5d-a3ab-dcfcce70ef93" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_c73cc821-93b6-4b8d-9ff5-67e545a991b6" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_a812aa86-aeef-4b5d-a3ab-dcfcce70ef93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_e50ff055-3726-44a6-a5f8-ad48e4b753f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_c73cc821-93b6-4b8d-9ff5-67e545a991b6" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_e50ff055-3726-44a6-a5f8-ad48e4b753f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_5b6fa23a-3001-43e0-ae55-3ce2aa4f9b56" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5094ec08-a684-45c4-875d-60584a389833" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_5b6fa23a-3001-43e0-ae55-3ce2aa4f9b56" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5094ec08-a684-45c4-875d-60584a389833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_09830bf9-339a-4474-9291-bce7189b7195" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_5b6fa23a-3001-43e0-ae55-3ce2aa4f9b56" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_09830bf9-339a-4474-9291-bce7189b7195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_5e5bbc99-b35f-4a01-a29c-4e69ba16f446" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_5b6fa23a-3001-43e0-ae55-3ce2aa4f9b56" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_5e5bbc99-b35f-4a01-a29c-4e69ba16f446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_6c25aea5-d7be-4758-a1a9-e09938bc95d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_5b6fa23a-3001-43e0-ae55-3ce2aa4f9b56" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_6c25aea5-d7be-4758-a1a9-e09938bc95d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_173a2910-02f2-4a27-88be-8dbb66875c2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_173a2910-02f2-4a27-88be-8dbb66875c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_d38c5266-f382-4d87-9fa6-1194c2ed1eed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_d38c5266-f382-4d87-9fa6-1194c2ed1eed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0e6cf893-b022-4b1a-ab76-c7dcd25a69bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0e6cf893-b022-4b1a-ab76-c7dcd25a69bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_52e7f895-39a9-4c40-b3af-172474b9ef6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_52e7f895-39a9-4c40-b3af-172474b9ef6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_2d856a84-2323-469b-a811-2c5e50e76f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_2d856a84-2323-469b-a811-2c5e50e76f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_395eb68a-ac2c-4b82-88ac-bec270a9c777" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_395eb68a-ac2c-4b82-88ac-bec270a9c777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_13ad0786-61bc-4bbe-beeb-cdb036d53dd6" xlink:href="moln-20221231.xsd#moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_13ad0786-61bc-4bbe-beeb-cdb036d53dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_8a426236-4c3b-44d0-9c25-14eaa45e3621" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_8a426236-4c3b-44d0-9c25-14eaa45e3621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_1c33f52d-8f55-49a2-a52f-5930d7ff261d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_1c33f52d-8f55-49a2-a52f-5930d7ff261d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_53646173-d499-48e1-967a-b991bc03cc22" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_53646173-d499-48e1-967a-b991bc03cc22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_1bd53af3-ba02-4d84-bc31-06f76ba321d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_1bd53af3-ba02-4d84-bc31-06f76ba321d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_a93c9851-c5c8-4229-91fc-e313baa9a5fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_a93c9851-c5c8-4229-91fc-e313baa9a5fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_a4afa112-0c24-496a-9197-f15f79adb079" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_ProfitLoss_a4afa112-0c24-496a-9197-f15f79adb079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_3d86f562-2049-4802-8688-bfcddea809d7" xlink:href="moln-20221231.xsd#moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_3d86f562-2049-4802-8688-bfcddea809d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_1175c914-daa9-4397-82e1-ff162e522c2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_1175c914-daa9-4397-82e1-ff162e522c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_3328bfe2-cbb6-4cd4-9b0b-ddbebba62adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_ce5609b1-dcfb-46d1-b32e-91efe383f01e" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_3328bfe2-cbb6-4cd4-9b0b-ddbebba62adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ee42c7ea-a330-4447-81c1-5960c21e1f94" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_90338e98-cf5a-4d44-8c6b-91c581ec5a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ee42c7ea-a330-4447-81c1-5960c21e1f94" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_90338e98-cf5a-4d44-8c6b-91c581ec5a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_a19d7fc7-d3a8-40a3-96c0-75819e3b316e" xlink:href="moln-20221231.xsd#moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ee42c7ea-a330-4447-81c1-5960c21e1f94" xlink:to="loc_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_a19d7fc7-d3a8-40a3-96c0-75819e3b316e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_3d39d306-d87d-4002-8c32-da4e9e3d9d92" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ee42c7ea-a330-4447-81c1-5960c21e1f94" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_3d39d306-d87d-4002-8c32-da4e9e3d9d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_b644f631-4a1d-41d7-9481-fa3bdad5477a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ee42c7ea-a330-4447-81c1-5960c21e1f94" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_b644f631-4a1d-41d7-9481-fa3bdad5477a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_4c567324-8983-4fef-aadf-a5de192a65b4" xlink:href="moln-20221231.xsd#moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ee42c7ea-a330-4447-81c1-5960c21e1f94" xlink:to="loc_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_4c567324-8983-4fef-aadf-a5de192a65b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2358ecf6-2bc1-4648-9295-ace0a8355bc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_d84ab839-6239-41f4-863f-408e10d7eb21" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2358ecf6-2bc1-4648-9295-ace0a8355bc3" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_d84ab839-6239-41f4-863f-408e10d7eb21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_2f94b91b-07db-4ff8-a879-a60bbbf97ae9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2358ecf6-2bc1-4648-9295-ace0a8355bc3" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_2f94b91b-07db-4ff8-a879-a60bbbf97ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_e2b1c8b8-e695-444f-9ec3-13ae43defe64" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2358ecf6-2bc1-4648-9295-ace0a8355bc3" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_e2b1c8b8-e695-444f-9ec3-13ae43defe64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_2dee6a4a-cdf9-4f7c-8d2f-14a3fe698936" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2358ecf6-2bc1-4648-9295-ace0a8355bc3" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_2dee6a4a-cdf9-4f7c-8d2f-14a3fe698936" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/OthercurrentassetsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#OthercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/OthercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_1544a4cb-086a-43c7-94b3-b9c2ed81566c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_b0a2801c-0e74-4328-81aa-aff95357620a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_1544a4cb-086a-43c7-94b3-b9c2ed81566c" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_b0a2801c-0e74-4328-81aa-aff95357620a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets_0aea0447-16ea-41ed-b02f-82d687e52d46" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_1544a4cb-086a-43c7-94b3-b9c2ed81566c" xlink:to="loc_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets_0aea0447-16ea-41ed-b02f-82d687e52d46" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_935f9cdf-ac1c-4bdc-b5d3-194d6cb61ac8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_ab8360de-6a03-440a-bef8-7115a7f3bd7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_935f9cdf-ac1c-4bdc-b5d3-194d6cb61ac8" xlink:to="loc_ifrs-full_CurrentTradeReceivables_ab8360de-6a03-440a-bef8-7115a7f3bd7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_74e7269a-63d4-42ef-a0f1-ca2ccb2b623a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_935f9cdf-ac1c-4bdc-b5d3-194d6cb61ac8" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_74e7269a-63d4-42ef-a0f1-ca2ccb2b623a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_8e706fa0-3df5-45c8-8b1b-3777f970b81f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_935f9cdf-ac1c-4bdc-b5d3-194d6cb61ac8" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_8e706fa0-3df5-45c8-8b1b-3777f970b81f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_25b6f9a3-c102-430b-a1c7-40e620dcf831" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_935f9cdf-ac1c-4bdc-b5d3-194d6cb61ac8" xlink:to="loc_ifrs-full_OtherCurrentReceivables_25b6f9a3-c102-430b-a1c7-40e620dcf831" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_beb7cad0-2711-413c-af3e-a272d294862b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_b19b46f2-a8a5-4f6c-9cbf-7aa45222eb7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_beb7cad0-2711-413c-af3e-a272d294862b" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_b19b46f2-a8a5-4f6c-9cbf-7aa45222eb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxPayables_fd45fa4c-f769-4b19-81e0-9f14f8080bd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxPayables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_beb7cad0-2711-413c-af3e-a272d294862b" xlink:to="loc_ifrs-full_CurrentValueAddedTaxPayables_fd45fa4c-f769-4b19-81e0-9f14f8080bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0c56d3c2-f850-4941-a44e-da85f3b7cb63" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_beb7cad0-2711-413c-af3e-a272d294862b" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0c56d3c2-f850-4941-a44e-da85f3b7cb63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#AccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_3ef3b792-2c96-4f29-93e4-61d1963d15fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CurrentAccruedProjectCostsAndRoyalties_f462b6bd-9622-4c73-a382-6e249437e563" xlink:href="moln-20221231.xsd#moln_CurrentAccruedProjectCostsAndRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_3ef3b792-2c96-4f29-93e4-61d1963d15fe" xlink:to="loc_moln_CurrentAccruedProjectCostsAndRoyalties_f462b6bd-9622-4c73-a382-6e249437e563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_beb0189d-1726-45a8-b690-993ce38ea30c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_3ef3b792-2c96-4f29-93e4-61d1963d15fe" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_beb0189d-1726-45a8-b690-993ce38ea30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_c53ab2fc-59b8-4cc7-ae25-707e11d5b496" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_3ef3b792-2c96-4f29-93e4-61d1963d15fe" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_c53ab2fc-59b8-4cc7-ae25-707e11d5b496" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_c4660f9e-9365-44e3-9928-0c0a47e93a08" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_75cbac39-bd13-4493-bb07-e42cdd6371a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_c4660f9e-9365-44e3-9928-0c0a47e93a08" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_75cbac39-bd13-4493-bb07-e42cdd6371a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_132ad6f4-cc8e-42f7-ab1d-bcc51ce7fe92" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_c4660f9e-9365-44e3-9928-0c0a47e93a08" xlink:to="loc_ifrs-full_CurrentContractLiabilities_132ad6f4-cc8e-42f7-ab1d-bcc51ce7fe92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#AdditionalinformationonthenatureofexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0a041e9f-f7b4-458f-950a-33ed6c01ef12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense_721cb7c2-b086-4906-a113-1b10318d8f39" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OccupancyExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0a041e9f-f7b4-458f-950a-33ed6c01ef12" xlink:to="loc_ifrs-full_OccupancyExpense_721cb7c2-b086-4906-a113-1b10318d8f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_bb376445-33b9-4f69-8d11-6ee43bc0198e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0a041e9f-f7b4-458f-950a-33ed6c01ef12" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_bb376445-33b9-4f69-8d11-6ee43bc0198e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_02ccaa07-7220-4767-bc3e-831367d6c08e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0a041e9f-f7b4-458f-950a-33ed6c01ef12" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_02ccaa07-7220-4767-bc3e-831367d6c08e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_75cca022-0732-4f27-ba55-5f3d474bf63d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0a041e9f-f7b4-458f-950a-33ed6c01ef12" xlink:to="loc_ifrs-full_AdministrativeExpense_75cca022-0732-4f27-ba55-5f3d474bf63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesAndLicenseFeesExpense_65d5d7a8-64f1-4335-9299-ed80303c1497" xlink:href="moln-20221231.xsd#moln_RoyaltiesAndLicenseFeesExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_moln_RoyaltiesAndLicenseFeesExpense_65d5d7a8-64f1-4335-9299-ed80303c1497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherResearchAndDevelopmentExpense_5d56b614-7faf-47d1-aadc-251720d9c9ad" xlink:href="moln-20221231.xsd#moln_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_moln_OtherResearchAndDevelopmentExpense_5d56b614-7faf-47d1-aadc-251720d9c9ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_5acade3c-ca72-4076-aa6b-2e70f5984792" xlink:href="moln-20221231.xsd#moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_5acade3c-ca72-4076-aa6b-2e70f5984792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense_a38ef622-d356-484a-a2db-b7f9d78288ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OccupancyExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_ifrs-full_OccupancyExpense_a38ef622-d356-484a-a2db-b7f9d78288ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_45692ae3-215e-4739-821a-7df85d6108ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_45692ae3-215e-4739-821a-7df85d6108ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IntellectualPropertyExpense_6d793992-b285-4384-bc68-7a33154bd3c0" xlink:href="moln-20221231.xsd#moln_IntellectualPropertyExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_moln_IntellectualPropertyExpense_6d793992-b285-4384-bc68-7a33154bd3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_a156b749-6884-4621-84ea-32161b7af5f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_b103d02f-1066-45c8-bff7-782263af1075" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_a156b749-6884-4621-84ea-32161b7af5f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_39b49e84-ef47-4e89-b9f5-cd583a483224" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_fc3a2641-7ed4-4b74-a112-180221f03772" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_39b49e84-ef47-4e89-b9f5-cd583a483224" xlink:to="loc_ifrs-full_WagesAndSalaries_fc3a2641-7ed4-4b74-a112-180221f03772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_b8b2e2a6-4614-4108-9634-8e39b31b72d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_39b49e84-ef47-4e89-b9f5-cd583a483224" xlink:to="loc_ifrs-full_SocialSecurityContributions_b8b2e2a6-4614-4108-9634-8e39b31b72d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_285f9b12-2cf0-4159-b607-6c8b9b75443f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_39b49e84-ef47-4e89-b9f5-cd583a483224" xlink:to="loc_ifrs-full_OtherEmployeeExpense_285f9b12-2cf0-4159-b607-6c8b9b75443f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_84e21f36-2316-4ff8-919b-6396e7170d57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_39b49e84-ef47-4e89-b9f5-cd583a483224" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_84e21f36-2316-4ff8-919b-6396e7170d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_92bfb93d-c949-4b63-bc2f-39436d6e2c18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_39b49e84-ef47-4e89-b9f5-cd583a483224" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_92bfb93d-c949-4b63-bc2f-39436d6e2c18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7ac4251c-ac48-4bcd-916d-da75d3e49552" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_2eb7546a-774d-4105-9ef7-a275df9535d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7ac4251c-ac48-4bcd-916d-da75d3e49552" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_2eb7546a-774d-4105-9ef7-a275df9535d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_b7a59b86-ae5d-40f0-aab4-db9eea8e17b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7ac4251c-ac48-4bcd-916d-da75d3e49552" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_b7a59b86-ae5d-40f0-aab4-db9eea8e17b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_a4a2e4fa-12b8-4cd6-86f4-981fa702581f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_c50047c0-600a-474a-8ddb-1a72bad6ec97" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue_a4a2e4fa-12b8-4cd6-86f4-981fa702581f" xlink:to="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_c50047c0-600a-474a-8ddb-1a72bad6ec97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_7a97b37c-ea74-4a29-9a57-7b5aa3ac7822" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue_a4a2e4fa-12b8-4cd6-86f4-981fa702581f" xlink:to="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_7a97b37c-ea74-4a29-9a57-7b5aa3ac7822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_a3971197-0681-427c-8957-f74a3a45a287" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue_a4a2e4fa-12b8-4cd6-86f4-981fa702581f" xlink:to="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_a3971197-0681-427c-8957-f74a3a45a287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_4009c9b0-1dd5-4f76-a1d2-c1a0717407a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue_a4a2e4fa-12b8-4cd6-86f4-981fa702581f" xlink:to="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_4009c9b0-1dd5-4f76-a1d2-c1a0717407a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_424d2991-2647-42b0-bec9-ff5e55557fc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue_a4a2e4fa-12b8-4cd6-86f4-981fa702581f" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_424d2991-2647-42b0-bec9-ff5e55557fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_2419c848-13c1-4500-acba-0b747efd415a" xlink:href="moln-20221231.xsd#moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_10a2eff4-5aa6-448c-9771-1162df337b12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_2419c848-13c1-4500-acba-0b747efd415a" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_10a2eff4-5aa6-448c-9771-1162df337b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_099e02d7-f40d-4b37-906a-04972908bf77" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_2419c848-13c1-4500-acba-0b747efd415a" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_099e02d7-f40d-4b37-906a-04972908bf77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_664ab225-c7fe-4a6c-bec6-87033813580c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_2419c848-13c1-4500-acba-0b747efd415a" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_664ab225-c7fe-4a6c-bec6-87033813580c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_928a181f-dc74-4ae1-92cc-42018ef4b31d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_96971090-ce6c-4a78-b8e2-b72c094a08f6" xlink:href="moln-20221231.xsd#moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_928a181f-dc74-4ae1-92cc-42018ef4b31d" xlink:to="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_96971090-ce6c-4a78-b8e2-b72c094a08f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_ce8f1ec3-44d4-4d1b-802c-3690a6d8e395" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_928a181f-dc74-4ae1-92cc-42018ef4b31d" xlink:to="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_ce8f1ec3-44d4-4d1b-802c-3690a6d8e395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_832b296b-2878-4115-99a9-268b2fd77f5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_3629f007-8991-4489-9969-9773aac417ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_832b296b-2878-4115-99a9-268b2fd77f5e" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_3629f007-8991-4489-9969-9773aac417ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_a45a124d-a88c-4dff-ba00-ef9b6f4fed0b" xlink:href="moln-20221231.xsd#moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_832b296b-2878-4115-99a9-268b2fd77f5e" xlink:to="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_a45a124d-a88c-4dff-ba00-ef9b6f4fed0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_d7c31887-d39d-4ef4-99b9-ade2c076ae5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_3bc55d3b-3277-4fa8-95ab-b5a21a67b689" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_d7c31887-d39d-4ef4-99b9-ade2c076ae5e" xlink:to="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_3bc55d3b-3277-4fa8-95ab-b5a21a67b689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_adf0f779-d091-4c8b-988c-6ec614b63bba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_d7c31887-d39d-4ef4-99b9-ade2c076ae5e" xlink:to="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_adf0f779-d091-4c8b-988c-6ec614b63bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_f6eb9650-0aef-420a-9871-9256376dc1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeDefinedBenefitPlans"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_d7c31887-d39d-4ef4-99b9-ade2c076ae5e" xlink:to="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_f6eb9650-0aef-420a-9871-9256376dc1f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_5db78605-3c92-4a79-b457-0def02a9d903" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostDefinedBenefitPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_d7c31887-d39d-4ef4-99b9-ade2c076ae5e" xlink:to="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_5db78605-3c92-4a79-b457-0def02a9d903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_7299979d-c073-4696-a464-83aa60acd8ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_d7c31887-d39d-4ef4-99b9-ade2c076ae5e" xlink:to="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_7299979d-c073-4696-a464-83aa60acd8ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_9baae5c5-358f-4417-841f-8d694130bd01" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_366036c1-d9e4-4387-ab35-1d20011ad2f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_9baae5c5-358f-4417-841f-8d694130bd01" xlink:to="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_366036c1-d9e4-4387-ab35-1d20011ad2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_058a32ae-57d6-45cc-a661-6c11136f1d88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_9baae5c5-358f-4417-841f-8d694130bd01" xlink:to="loc_ifrs-full_NetForeignExchangeGain_058a32ae-57d6-45cc-a661-6c11136f1d88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_89f67f8c-b84b-4377-9986-b918fafa1299" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_d731a250-ebe3-4655-b19a-412d99cdc543" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_89f67f8c-b84b-4377-9986-b918fafa1299" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_d731a250-ebe3-4655-b19a-412d99cdc543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_a1e558c0-c082-4228-9277-7d536b4a7f3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_89f67f8c-b84b-4377-9986-b918fafa1299" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_a1e558c0-c082-4228-9277-7d536b4a7f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceCost_67d658d8-20fd-4629-b0d3-9e3cbb09f1f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_89f67f8c-b84b-4377-9986-b918fafa1299" xlink:to="loc_ifrs-full_OtherFinanceCost_67d658d8-20fd-4629-b0d3-9e3cbb09f1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_a588db83-aca8-4ac7-83c1-030bea87f664" xlink:href="moln-20221231.xsd#moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_89f67f8c-b84b-4377-9986-b918fafa1299" xlink:to="loc_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_a588db83-aca8-4ac7-83c1-030bea87f664" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofMovementofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_f237536c-89ae-487a-a054-5885acb0d407" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_b5035332-2c35-43d0-befe-a9957de3f58f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_f237536c-89ae-487a-a054-5885acb0d407" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_b5035332-2c35-43d0-befe-a9957de3f58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_ea8f1084-531f-4e5e-9564-ae212bcc33ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_f237536c-89ae-487a-a054-5885acb0d407" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_ea8f1084-531f-4e5e-9564-ae212bcc33ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofExpensesRecognisedinProfitorLossDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseCostRecognisedInProfitOrLoss_f7d2a8c6-b4a7-449c-9b91-92f7ad633dfa" xlink:href="moln-20221231.xsd#moln_LeaseCostRecognisedInProfitOrLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_c34c0416-b06a-4bc5-9e79-dcd01a135716" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moln_LeaseCostRecognisedInProfitOrLoss_f7d2a8c6-b4a7-449c-9b91-92f7ad633dfa" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_c34c0416-b06a-4bc5-9e79-dcd01a135716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_642a09d3-85ac-4a92-9985-6e2a776d7edf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moln_LeaseCostRecognisedInProfitOrLoss_f7d2a8c6-b4a7-449c-9b91-92f7ad633dfa" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_642a09d3-85ac-4a92-9985-6e2a776d7edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_69ef450b-a5da-470e-b847-19fe88968a42" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moln_LeaseCostRecognisedInProfitOrLoss_f7d2a8c6-b4a7-449c-9b91-92f7ad633dfa" xlink:to="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_69ef450b-a5da-470e-b847-19fe88968a42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails"/>
  <link:calculationLink xlink:role="http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_fc9a13a5-5ee2-4557-8bcf-8ebf04000f9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_5f095eba-5a4c-4722-ae33-e63d21048ff5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fc9a13a5-5ee2-4557-8bcf-8ebf04000f9a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_5f095eba-5a4c-4722-ae33-e63d21048ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_612e5092-d6cc-4db3-9d10-c7abc21ad39d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fc9a13a5-5ee2-4557-8bcf-8ebf04000f9a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_612e5092-d6cc-4db3-9d10-c7abc21ad39d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_734f0d6c-64be-44a7-922e-4b3bae39975a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fc9a13a5-5ee2-4557-8bcf-8ebf04000f9a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_734f0d6c-64be-44a7-922e-4b3bae39975a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>moln-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5bc598d-29c0-45ac-9809-ee4bc6e3f0aa,g:d67c3c2e-5cb8-4330-bb94-e6e901fa056b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Cover" xlink:type="simple" xlink:href="moln-20221231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/Cover" xlink:type="extended" id="i16354a079ef44216a667347247698be2_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_09ecc5f5-376f-4f7d-bd5a-f55021276f74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentType_09ecc5f5-376f-4f7d-bd5a-f55021276f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_5ab80edf-fbf0-4cd5-8d05-f76d89c0e5ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentRegistrationStatement_5ab80edf-fbf0-4cd5-8d05-f76d89c0e5ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c86ab01f-aa32-4c4b-8112-9d740799986d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentAnnualReport_c86ab01f-aa32-4c4b-8112-9d740799986d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_574be2aa-4aab-4577-99ef-fb1f82e168d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentPeriodEndDate_574be2aa-4aab-4577-99ef-fb1f82e168d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2475790-3e6c-408d-aa2a-d71f3012d9e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2475790-3e6c-408d-aa2a-d71f3012d9e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_57dc8258-3849-436f-968d-85b9c29769fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentTransitionReport_57dc8258-3849-436f-968d-85b9c29769fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_6f8842aa-d6eb-466f-9c27-fcd327e71e87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentShellCompanyReport_6f8842aa-d6eb-466f-9c27-fcd327e71e87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3e4065ac-24be-4447-8560-e1e96a6468c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityFileNumber_3e4065ac-24be-4447-8560-e1e96a6468c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c831ea4c-6db8-406e-b1cf-af5aa74e5822" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityRegistrantName_c831ea4c-6db8-406e-b1cf-af5aa74e5822" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f55b52c7-a649-4f39-ae9f-a9acc954a5d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f55b52c7-a649-4f39-ae9f-a9acc954a5d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ea9910e3-9d47-4551-8717-01c4b3cfad20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressAddressLine1_ea9910e3-9d47-4551-8717-01c4b3cfad20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5c5ac0e1-9988-4334-bba0-cbec1cd8c252" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressPostalZipCode_5c5ac0e1-9988-4334-bba0-cbec1cd8c252" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f9319bab-b515-4584-9038-d193fa6e542c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressCityOrTown_f9319bab-b515-4584-9038-d193fa6e542c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_03d840a4-b12d-4686-b338-43fd8d59e106" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressCountry_03d840a4-b12d-4686-b338-43fd8d59e106" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_cf82c594-afd4-4413-ae25-801d9fe7e57c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_ContactPersonnelName_cf82c594-afd4-4413-ae25-801d9fe7e57c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ebb25822-d7cb-4d06-8f7b-0a5bf67116a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_CityAreaCode_ebb25822-d7cb-4d06-8f7b-0a5bf67116a5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_de75a4cd-813d-43ce-9944-3fb5cfd2e167" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_LocalPhoneNumber_de75a4cd-813d-43ce-9944-3fb5cfd2e167" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d0397f85-a9a2-4a50-ba15-df0272be2e47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_Security12bTitle_d0397f85-a9a2-4a50-ba15-df0272be2e47" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f21f697f-db93-4cdd-ae2e-a58f2960afae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_TradingSymbol_f21f697f-db93-4cdd-ae2e-a58f2960afae" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_52ccbcc8-b73b-41a7-ae89-c4d85d78cba3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_SecurityExchangeName_52ccbcc8-b73b-41a7-ae89-c4d85d78cba3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_27fffa9d-69bb-464d-9d98-6416f66cdd52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_27fffa9d-69bb-464d-9d98-6416f66cdd52" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a5bcd387-bb8a-4acc-9fb0-30c694a9188a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a5bcd387-bb8a-4acc-9fb0-30c694a9188a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_34734aa6-5ec1-4fd7-aedf-ece3613e08a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityVoluntaryFilers_34734aa6-5ec1-4fd7-aedf-ece3613e08a9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1dfe275b-63fd-44b4-bf20-40491a5a27b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityCurrentReportingStatus_1dfe275b-63fd-44b4-bf20-40491a5a27b9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1919609a-4d9d-4f7b-ac65-a39a56f651db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityInteractiveDataCurrent_1919609a-4d9d-4f7b-ac65-a39a56f651db" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1d1c736f-9b6a-4e21-8130-14f7a36381f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityFilerCategory_1d1c736f-9b6a-4e21-8130-14f7a36381f0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_71081381-6f6e-48ef-804c-c9a440250c5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityEmergingGrowthCompany_71081381-6f6e-48ef-804c-c9a440250c5f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_3eac859e-4f1c-4bd2-ad0a-fd52fde932a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityExTransitionPeriod_3eac859e-4f1c-4bd2-ad0a-fd52fde932a5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bcb8e291-29f9-4f44-94aa-c61ec8ce99cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bcb8e291-29f9-4f44-94aa-c61ec8ce99cc" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_ca471b09-edb1-4f0b-8ee5-232da4043f0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentAccountingStandard_ca471b09-edb1-4f0b-8ee5-232da4043f0e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f9ba116f-3474-4de0-8dd7-ed304a901f95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityShellCompany_f9ba116f-3474-4de0-8dd7-ed304a901f95" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_616c4549-8d15-48b0-ba62-f318144c763e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_AmendmentFlag_616c4549-8d15-48b0-ba62-f318144c763e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cb8a327e-23da-4993-9aed-7a4599980739" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentFiscalYearFocus_cb8a327e-23da-4993-9aed-7a4599980739" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e427dd92-db45-4f0c-be4a-32cd3b86cbd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e427dd92-db45-4f0c-be4a-32cd3b86cbd8" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6001ad45-61a7-4f48-bfa0-a93a8d4f1f42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityCentralIndexKey_6001ad45-61a7-4f48-bfa0-a93a8d4f1f42" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_9b9ab311-3dd6-4c70-b9d7-21a562cdacf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_NoTradingSymbolFlag_9b9ab311-3dd6-4c70-b9d7-21a562cdacf0" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_21e838ad-9772-4f16-9e8f-e82b3887a672_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:to="loc_dei_AddressTypeDomain_21e838ad-9772-4f16-9e8f-e82b3887a672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_9dbe74be-3a55-4fff-a216-b227738ed189" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:to="loc_dei_AddressTypeDomain_9dbe74be-3a55-4fff-a216-b227738ed189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_a93013f3-a0bb-413f-b50b-b50f23e1d75f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_9dbe74be-3a55-4fff-a216-b227738ed189" xlink:to="loc_dei_BusinessContactMember_a93013f3-a0bb-413f-b50b-b50f23e1d75f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:to="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_be0dd4c3-6532-4d4a-834a-82678c8abdbd_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:to="loc_dei_ExchangeDomain_be0dd4c3-6532-4d4a-834a-82678c8abdbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_50ef5458-2b4d-4700-89c3-6e5237750d20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:to="loc_dei_ExchangeDomain_50ef5458-2b4d-4700-89c3-6e5237750d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_fbbcb00a-14b0-4131-8843-6f24056b7e2b" xlink:href="moln-20221231.xsd#moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_50ef5458-2b4d-4700-89c3-6e5237750d20" xlink:to="loc_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_fbbcb00a-14b0-4131-8843-6f24056b7e2b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofChangesinEquity"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="extended" id="i91433bc402b84c288d072de7755e4545_ConsolidatedStatementofChangesinEquity">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4835162f-96ab-476d-ac06-69215699ea4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_Equity_4835162f-96ab-476d-ac06-69215699ea4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_b1b42eac-8aaa-474f-a823-d104638797ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_ProfitLoss_b1b42eac-8aaa-474f-a823-d104638797ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9bb8b4bc-6ed5-4dce-beb8-dccc624511ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9bb8b4bc-6ed5-4dce-beb8-dccc624511ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_359f454e-e948-4c33-b990-e1cb400b4134" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_359f454e-e948-4c33-b990-e1cb400b4134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_6dcd8082-9a44-4633-ac4b-2756839aa7a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_ComprehensiveIncome_6dcd8082-9a44-4633-ac4b-2756839aa7a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_71c30e6f-9e1b-4579-8833-d0060abb9168" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_71c30e6f-9e1b-4579-8833-d0060abb9168" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_144b4180-fa48-436b-b712-528b5c90072f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IssueOfEquity_144b4180-fa48-436b-b712-528b5c90072f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_88bef6df-eca5-4d40-8690-e422cabbf59d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_88bef6df-eca5-4d40-8690-e422cabbf59d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_fc7dbeaa-5ceb-40ac-904c-c4eff9de7bd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_fc7dbeaa-5ceb-40ac-904c-c4eff9de7bd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_cb3dc69e-7d9c-40d8-8cc0-e61a90150ac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_bfcab725-18bf-4567-a87a-5a073b241de1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:to="loc_ifrs-full_EquityMember_bfcab725-18bf-4567-a87a-5a073b241de1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:to="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_ef8c1a35-0479-4de4-8a0f-df72eda38005" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_IssuedCapitalMember_ef8c1a35-0479-4de4-8a0f-df72eda38005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_8d72d85c-b4a0-431e-a3ec-3e47e4c09d00" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_8d72d85c-b4a0-431e-a3ec-3e47e4c09d00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_1f8ade9d-742e-42cc-a280-506e0e128e41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_TreasurySharesMember_1f8ade9d-742e-42cc-a280-506e0e128e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_0edc231a-4dba-4d42-baf6-b93d2eec39ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_RetainedEarningsMember_0edc231a-4dba-4d42-baf6-b93d2eec39ff" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i0c00b9aabe5e46b1852f2e4cdf2c2538_SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_39e98ab7-dfc1-4071-8877-d0127b3d3a41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_1eb1d118-0627-4c9f-a4e4-ab9ec6a5876a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_39e98ab7-dfc1-4071-8877-d0127b3d3a41" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_1eb1d118-0627-4c9f-a4e4-ab9ec6a5876a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_39e98ab7-dfc1-4071-8877-d0127b3d3a41" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_733f92f7-4000-4f07-8b26-eec88426a4e0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_733f92f7-4000-4f07-8b26-eec88426a4e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LaboratoryEquipmentMember_8213cbbf-204c-450b-9163-8cc45d9c6735" xlink:href="moln-20221231.xsd#moln_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:to="loc_moln_LaboratoryEquipmentMember_8213cbbf-204c-450b-9163-8cc45d9c6735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_e3409ae9-c2aa-46cb-9ee2-73b6ef9ef455" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:to="loc_ifrs-full_OfficeEquipmentMember_e3409ae9-c2aa-46cb-9ee2-73b6ef9ef455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_062b3433-a78c-4575-a6e4-5485a376e696" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:to="loc_ifrs-full_ComputerEquipmentMember_062b3433-a78c-4575-a6e4-5485a376e696" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails" xlink:type="extended" id="i97e4155bd967458781cabb9c2eaa28c4_SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_180368f0-078f-4ae9-8bce-c04d217a414e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6204496-adfc-473d-bac6-df1bd787d30a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_180368f0-078f-4ae9-8bce-c04d217a414e" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6204496-adfc-473d-bac6-df1bd787d30a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_180368f0-078f-4ae9-8bce-c04d217a414e" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_86ecfbb7-86f0-4b88-ad0f-293414f97ba0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_86ecfbb7-86f0-4b88-ad0f-293414f97ba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c65ac4f1-2ece-454e-8e6c-37823bd1b0e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c65ac4f1-2ece-454e-8e6c-37823bd1b0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_4e2afe69-f748-4c7e-b434-f489553d29e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c65ac4f1-2ece-454e-8e6c-37823bd1b0e0" xlink:to="loc_ifrs-full_ComputerSoftwareMember_4e2afe69-f748-4c7e-b434-f489553d29e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails" xlink:type="extended" id="i724590ab4dcd4314908513bbac2b115a_SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanEmployerContribution_25f0711e-6ba8-45eb-98c8-bee2fc281d8f" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanEmployerContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanEmployerContribution_25f0711e-6ba8-45eb-98c8-bee2fc281d8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanEmployeeContribution_20d864d8-478a-4c74-a2ad-290e6a046025" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanEmployeeContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanEmployeeContribution_20d864d8-478a-4c74-a2ad-290e6a046025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_b8e00543-c26b-4c0d-bd62-372ff9d490d5" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_b8e00543-c26b-4c0d-bd62-372ff9d490d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanNumberOfEligibleEmployees_ee2f2b7c-77e9-498a-a68a-98c67779c9f6" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanNumberOfEligibleEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanNumberOfEligibleEmployees_ee2f2b7c-77e9-498a-a68a-98c67779c9f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_ac76772d-9f2e-4178-aaba-58852d52bd09" xlink:href="moln-20221231.xsd#moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_ac76772d-9f2e-4178-aaba-58852d52bd09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_ceb242d3-ee6c-4336-8f76-cca4006008a5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_ceb242d3-ee6c-4336-8f76-cca4006008a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VSAOMember_06c9cb66-d558-47f6-9a8b-8a4ca0d25bf6" xlink:href="moln-20221231.xsd#moln_VSAOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:to="loc_moln_VSAOMember_06c9cb66-d558-47f6-9a8b-8a4ca0d25bf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VoluntaryComplementaryPlanMember_d44a9f10-5fc7-4340-9012-8d29eac9064c" xlink:href="moln-20221231.xsd#moln_VoluntaryComplementaryPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:to="loc_moln_VoluntaryComplementaryPlanMember_d44a9f10-5fc7-4340-9012-8d29eac9064c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails" xlink:type="extended" id="i07e1ffc937f444de9bde459d8d460f37_RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_e787c458-5601-45eb-b356-6b51d35e41f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_CurrentTradeReceivables_e787c458-5601-45eb-b356-6b51d35e41f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PotentialFutureMilestonePayments_7b24b3bf-8288-4f39-a5fb-e3baf25bd4be" xlink:href="moln-20221231.xsd#moln_PotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_PotentialFutureMilestonePayments_7b24b3bf-8288-4f39-a5fb-e3baf25bd4be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_06987c70-9716-4767-91ec-8664179f9b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_06987c70-9716-4767-91ec-8664179f9b2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_a0705189-9914-4787-b160-c0933fb7763b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_a0705189-9914-4787-b160-c0933fb7763b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_df8b12b5-b153-448d-8722-08d6428e0ac7" xlink:href="moln-20221231.xsd#moln_RevenueFromRechargeOfEmployeeRelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_df8b12b5-b153-448d-8722-08d6428e0ac7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UpfrontPaymentReceived_3b94b824-45ca-4c66-985d-6959c2ca6582" xlink:href="moln-20221231.xsd#moln_UpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_UpfrontPaymentReceived_3b94b824-45ca-4c66-985d-6959c2ca6582" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UpfrontPaymentAmountUtilizedDuringPeriod_9311f937-3d79-4e8f-b61d-fdc9cedf43cb" xlink:href="moln-20221231.xsd#moln_UpfrontPaymentAmountUtilizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_UpfrontPaymentAmountUtilizedDuringPeriod_9311f937-3d79-4e8f-b61d-fdc9cedf43cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltyIncomePercentage_8afc5c02-dd6f-44e9-97b1-635ba87396ca" xlink:href="moln-20221231.xsd#moln_RoyaltyIncomePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_RoyaltyIncomePercentage_8afc5c02-dd6f-44e9-97b1-635ba87396ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_c1357857-118c-4785-87ff-991e20f05f56" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_CurrentContractLiabilities_c1357857-118c-4785-87ff-991e20f05f56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExtendedPeriodOfReservationAgreement_0b529d97-aa17-4751-9171-64a9e5d874fa" xlink:href="moln-20221231.xsd#moln_ExtendedPeriodOfReservationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_ExtendedPeriodOfReservationAgreement_0b529d97-aa17-4751-9171-64a9e5d874fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_ba5347db-719c-44d5-878b-71f438efc951" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_ba5347db-719c-44d5-878b-71f438efc951" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_80e0395f-d9ba-4484-a915-3b93b84e14f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_OtherIncome_80e0395f-d9ba-4484-a915-3b93b84e14f4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_489d06d2-5c20-4215-985d-f8ec298832f5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:to="loc_ifrs-full_TypesOfContractsMember_489d06d2-5c20-4215-985d-f8ec298832f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:to="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_1f1e8a42-9254-4a23-a95b-0fb7eac0861c" xlink:href="moln-20221231.xsd#moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_1f1e8a42-9254-4a23-a95b-0fb7eac0861c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_febfe27f-b867-497f-9556-c0c151549006" xlink:href="moln-20221231.xsd#moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_febfe27f-b867-497f-9556-c0c151549006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_f9268221-75ae-4f82-bbff-be8885d3a68a" xlink:href="moln-20221231.xsd#moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_f9268221-75ae-4f82-bbff-be8885d3a68a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_ead6de20-d284-4995-8037-132b5e1ab05c" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithAmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_ead6de20-d284-4995-8037-132b5e1ab05c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4005d9e1-74e8-494d-b2ef-46a27e45dd89_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:to="loc_srt_ProductsAndServicesDomain_4005d9e1-74e8-494d-b2ef-46a27e45dd89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4677a18-85d0-4123-896b-5decc9e1fb01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:to="loc_srt_ProductsAndServicesDomain_e4677a18-85d0-4123-896b-5decc9e1fb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CommercialSupplyOfProductsMember_b0aa8c5b-de38-47aa-a2fb-c539a87c2013" xlink:href="moln-20221231.xsd#moln_CommercialSupplyOfProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e4677a18-85d0-4123-896b-5decc9e1fb01" xlink:to="loc_moln_CommercialSupplyOfProductsMember_b0aa8c5b-de38-47aa-a2fb-c539a87c2013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bb177798-4d0e-432b-8533-65957b16979e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:to="loc_ifrs-full_RangesMember_bb177798-4d0e-432b-8533-65957b16979e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fa26c2fc-a04e-4781-a502-6566005134f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:to="loc_ifrs-full_RangesMember_fa26c2fc-a04e-4781-a502-6566005134f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fe329aea-5a85-4ab2-bacf-73d831fbde35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_fa26c2fc-a04e-4781-a502-6566005134f6" xlink:to="loc_srt_MaximumMember_fe329aea-5a85-4ab2-bacf-73d831fbde35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0784fbe4-6834-45f9-af2e-684deef678cd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:to="loc_ifrs-full_CounterpartiesMember_0784fbe4-6834-45f9-af2e-684deef678cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:to="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_a0bf0bd6-388e-4d43-9ec9-28fb36e4d201" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:to="loc_moln_NovartisMember_a0bf0bd6-388e-4d43-9ec9-28fb36e4d201" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember_aebe13d9-8b4b-4772-8fa6-994cc49b3ecd" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:to="loc_moln_FederalOfficeOfPublicHealthMember_aebe13d9-8b4b-4772-8fa6-994cc49b3ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_152420ce-9ec9-40d2-9a4a-145cb5648803_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:to="loc_ifrs-full_NonadjustingEventsMember_152420ce-9ec9-40d2-9a4a-145cb5648803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_6da399c0-1e63-48eb-a3c2-cb6f97356333" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:to="loc_ifrs-full_NonadjustingEventsMember_6da399c0-1e63-48eb-a3c2-cb6f97356333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SignificantTransactionsMember_8491ed4c-1b3e-4cfd-abc8-eacc4696f947" xlink:href="moln-20221231.xsd#moln_SignificantTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_6da399c0-1e63-48eb-a3c2-cb6f97356333" xlink:to="loc_moln_SignificantTransactionsMember_8491ed4c-1b3e-4cfd-abc8-eacc4696f947" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" xlink:type="extended" id="i3dd0f71a80664af2a9677414368dcaba_RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e48b3505-9a42-4910-9414-c55a9fc34509" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_82784790-3786-48fb-95d6-73c24a81d883" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e48b3505-9a42-4910-9414-c55a9fc34509" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_82784790-3786-48fb-95d6-73c24a81d883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e48b3505-9a42-4910-9414-c55a9fc34509" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:to="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_d76faf94-6ec4-4bd3-9e3e-e7022b48030a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:to="loc_ifrs-full_GeographicalAreasMember_d76faf94-6ec4-4bd3-9e3e-e7022b48030a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:to="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_0e227f6b-934e-485c-b500-ae240b09550f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:to="loc_country_CH_0e227f6b-934e-485c-b500-ae240b09550f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ba139b52-7421-48de-afbb-9c30a2601510" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:to="loc_country_US_ba139b52-7421-48de-afbb-9c30a2601510" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails" xlink:type="extended" id="i039b091ff70c4b279a97c5e382797a97_RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02323cf2-f8eb-47c3-8204-58204d2847de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_6015f1b6-71cb-49bd-9df1-522eb9a6d7b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02323cf2-f8eb-47c3-8204-58204d2847de" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_6015f1b6-71cb-49bd-9df1-522eb9a6d7b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02323cf2-f8eb-47c3-8204-58204d2847de" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:to="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_f0969833-6366-448b-b577-4592e33c8340_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:to="loc_ifrs-full_TypesOfContractsMember_f0969833-6366-448b-b577-4592e33c8340_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:to="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_4d759a2c-44cc-42e8-b064-4dc5876ab4f1" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithNovartisAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_4d759a2c-44cc-42e8-b064-4dc5876ab4f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithFOPHMember_3eca88c8-5242-4720-bbad-8e32799b5d93" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithFOPHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithFOPHMember_3eca88c8-5242-4720-bbad-8e32799b5d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_0b145ac8-1148-4c66-8f0c-e2163e296d8f" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithAmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_0b145ac8-1148-4c66-8f0c-e2163e296d8f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails" xlink:type="extended" id="iff8f919f28414b7cbb302dd52167bb87_PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_65905ddc-4c53-49b3-9186-46a9cd63db7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_65905ddc-4c53-49b3-9186-46a9cd63db7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f4efcee6-0a11-4ffd-8372-c403c4ef181e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f4efcee6-0a11-4ffd-8372-c403c4ef181e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e18524f0-93a8-4263-959d-285edeff5566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e18524f0-93a8-4263-959d-285edeff5566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7e09c9b0-ea49-47e7-b187-0fb7b8a21c24" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7e09c9b0-ea49-47e7-b187-0fb7b8a21c24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6b12d39a-409d-4b1a-90a7-e1812b883c55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_2de06df0-5298-483f-8502-be6f202a36fb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:to="loc_ifrs-full_CarryingAmountMember_2de06df0-5298-483f-8502-be6f202a36fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:to="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_24681c1b-f8ad-4101-9f1b-0b01320962fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_24681c1b-f8ad-4101-9f1b-0b01320962fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8cbd6b4b-a9fe-424a-b939-8c28d67f515d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8cbd6b4b-a9fe-424a-b939-8c28d67f515d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_e3594396-aee3-4e57-b0cd-1d512dad87c3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_e3594396-aee3-4e57-b0cd-1d512dad87c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LabEquipmentMember_0973db8d-8947-4590-a56a-272ab38e08c7" xlink:href="moln-20221231.xsd#moln_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_moln_LabEquipmentMember_0973db8d-8947-4590-a56a-272ab38e08c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_358925e9-e716-4f96-ad69-5833a71881ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_ifrs-full_OfficeEquipmentMember_358925e9-e716-4f96-ad69-5833a71881ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_357828ef-bb0b-4e18-881d-dffe3dfc11f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_ifrs-full_ComputerEquipmentMember_357828ef-bb0b-4e18-881d-dffe3dfc11f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_3803a32f-743a-4ed6-a065-f948b6ac3fbe" xlink:href="moln-20221231.xsd#moln_RightOfUseAssetsPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_3803a32f-743a-4ed6-a065-f948b6ac3fbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_e984fd05-430a-4406-a779-94b4789154b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_e984fd05-430a-4406-a779-94b4789154b2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/IntangibleassetsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#IntangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/IntangibleassetsDetails" xlink:type="extended" id="iaa310e3251ce46b08a0cbd9463132417_IntangibleassetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7e361a50-8f7f-4519-a1cc-2f5708707101" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7e361a50-8f7f-4519-a1cc-2f5708707101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ea813236-410b-409a-a37a-4def20a1a834" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ea813236-410b-409a-a37a-4def20a1a834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b3b82993-c26f-4780-9444-2552403b2798" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b3b82993-c26f-4780-9444-2552403b2798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_d0bd578a-e8fd-44de-a705-95f0af4cd875" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_d0bd578a-e8fd-44de-a705-95f0af4cd875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_717c711d-4d7e-4f95-ae0d-5a598ce0821f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_dafbe0bf-c73d-432d-be5e-3eb3dc03d364_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:to="loc_ifrs-full_CarryingAmountMember_dafbe0bf-c73d-432d-be5e-3eb3dc03d364_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:to="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_8fcd2ef5-6eff-4bfb-bc27-5d0dfa4c363d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_8fcd2ef5-6eff-4bfb-bc27-5d0dfa4c363d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_9f72aee7-560d-4620-a928-fd33336b20d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_9f72aee7-560d-4620-a928-fd33336b20d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cfffecc-153e-4674-a49f-b7ce709b0d67_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cfffecc-153e-4674-a49f-b7ce709b0d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1a1bb5a0-db18-48a5-9258-2ab889dc8028" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1a1bb5a0-db18-48a5-9258-2ab889dc8028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_c697902c-1d76-4a39-8d2e-85ca8d1e060b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1a1bb5a0-db18-48a5-9258-2ab889dc8028" xlink:to="loc_ifrs-full_ComputerSoftwareMember_c697902c-1d76-4a39-8d2e-85ca8d1e060b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" xlink:type="extended" id="if07896e5a32d4bcf8deadcf9ad7a595c_FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1d9841e9-a507-4d13-893e-1438310aaa0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_4816ac42-659c-4821-87f0-5aed5d5b5976" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1d9841e9-a507-4d13-893e-1438310aaa0b" xlink:to="loc_ifrs-full_FinancialAssets_4816ac42-659c-4821-87f0-5aed5d5b5976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1d9841e9-a507-4d13-893e-1438310aaa0b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_d7679661-2684-4282-8429-ea805d1d4266_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:to="loc_ifrs-full_FinancialAssetsMember_d7679661-2684-4282-8429-ea805d1d4266_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:to="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashAndCashEquivalentsMember_a2025fc2-55c8-42b3-8159-96c3ccfc4839" xlink:href="moln-20221231.xsd#moln_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_moln_CashAndCashEquivalentsMember_a2025fc2-55c8-42b3-8159-96c3ccfc4839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_2c77f6c1-cfe3-4942-b155-6659ff7266dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_ifrs-full_TradeReceivablesMember_2c77f6c1-cfe3-4942-b155-6659ff7266dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedIncomeMember_d368b582-d511-4b48-b6e9-5b4e7ef6d2c8" xlink:href="moln-20221231.xsd#moln_AccruedIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_moln_AccruedIncomeMember_d368b582-d511-4b48-b6e9-5b4e7ef6d2c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShortTermTimeDepositsMember_a506708b-6489-4ac7-8bd8-61d868ff9bce" xlink:href="moln-20221231.xsd#moln_ShortTermTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_moln_ShortTermTimeDepositsMember_a506708b-6489-4ac7-8bd8-61d868ff9bce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_ab4246ff-2870-4d39-ba40-a6546906d573_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_ab4246ff-2870-4d39-ba40-a6546906d573_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_4fcc7d54-7634-49a3-89b1-be8a84da9978" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_4fcc7d54-7634-49a3-89b1-be8a84da9978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e11c09e2-e805-41bd-8b6b-30d57c7cca40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_4fcc7d54-7634-49a3-89b1-be8a84da9978" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e11c09e2-e805-41bd-8b6b-30d57c7cca40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" xlink:type="extended" id="i48e988f2f33e493fb4d1581583173973_FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4c6433a5-765a-4a60-91dc-f249f61eca24" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_6a87a087-7aad-4365-8969-eefa94a465df" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4c6433a5-765a-4a60-91dc-f249f61eca24" xlink:to="loc_ifrs-full_FinancialLiabilities_6a87a087-7aad-4365-8969-eefa94a465df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4c6433a5-765a-4a60-91dc-f249f61eca24" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_903580da-0a62-4fa7-b91f-2aeda81bec1c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_903580da-0a62-4fa7-b91f-2aeda81bec1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TradePayablesMember_8f635300-3838-4e8c-a70d-b9828bff7933" xlink:href="moln-20221231.xsd#moln_TradePayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_moln_TradePayablesMember_8f635300-3838-4e8c-a70d-b9828bff7933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedProjectCostsAndRoyaltiesMember_7d57ecb9-4dcd-4e13-aa99-25fffac25c37" xlink:href="moln-20221231.xsd#moln_AccruedProjectCostsAndRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_moln_AccruedProjectCostsAndRoyaltiesMember_7d57ecb9-4dcd-4e13-aa99-25fffac25c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_4c595b2f-a058-4b19-9d17-5105ae611ec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_4c595b2f-a058-4b19-9d17-5105ae611ec2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherNonEmployeeRelatedAccruedExpensesMember_a5696efe-ebd9-4793-96e4-9c6008334581" xlink:href="moln-20221231.xsd#moln_OtherNonEmployeeRelatedAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_moln_OtherNonEmployeeRelatedAccruedExpensesMember_a5696efe-ebd9-4793-96e4-9c6008334581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_98b64db6-8498-45a7-8afc-dd637177f365_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_98b64db6-8498-45a7-8afc-dd637177f365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_4f3c0130-6f3c-4c98-b759-afeb835be27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_4f3c0130-6f3c-4c98-b759-afeb835be27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_3b28c389-86a9-4eb7-be43-bd6a32c3531f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_4f3c0130-6f3c-4c98-b759-afeb835be27e" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_3b28c389-86a9-4eb7-be43-bd6a32c3531f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="extended" id="id213abf06e034d079eb9a68485279c48_TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems_2d11d664-617c-447f-ac9e-6f8b94892b87" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherReceivablesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_30c39784-cac9-4461-8157-b3b7b731a250" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems_2d11d664-617c-447f-ac9e-6f8b94892b87" xlink:to="loc_ifrs-full_CurrentTradeReceivables_30c39784-cac9-4461-8157-b3b7b731a250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherReceivablesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems_2d11d664-617c-447f-ac9e-6f8b94892b87" xlink:to="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:to="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_d3e03128-9f50-44fe-aab1-52f1a398e418_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:to="loc_currency_AllCurrenciesDomain_d3e03128-9f50-44fe-aab1-52f1a398e418_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:to="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_fd3818cb-313a-4ffd-a975-05d9414bcd67" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:to="loc_currency_CHF_fd3818cb-313a-4ffd-a975-05d9414bcd67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_e74d7c2f-fdbc-44de-92b9-0401052e7571" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:to="loc_currency_EUR_e74d7c2f-fdbc-44de-92b9-0401052e7571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_85ced78e-b251-41b2-afd7-f05e7d7c0224" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:to="loc_currency_USD_85ced78e-b251-41b2-afd7-f05e7d7c0224" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" xlink:type="extended" id="i16a33999bbdc46459bdb9fa35bac9319_CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2ab6edae-1d5b-4242-a8d3-f088814ab502" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2ab6edae-1d5b-4242-a8d3-f088814ab502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_c09526cc-02eb-4143-b697-77e08521ae19" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_c09526cc-02eb-4143-b697-77e08521ae19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:to="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:to="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:to="loc_currency_AllCurrenciesDomain_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:to="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_7c3777ea-7dbe-4e73-94fd-febca821155d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_CHF_7c3777ea-7dbe-4e73-94fd-febca821155d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_2671299b-411f-4245-8907-c3438b446d32" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_EUR_2671299b-411f-4245-8907-c3438b446d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_553f2477-bd29-48a0-9cba-160fec12701b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_USD_553f2477-bd29-48a0-9cba-160fec12701b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_f5f270e7-4fb3-4577-9d82-2d7d05d65e90" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_GBP_f5f270e7-4fb3-4577-9d82-2d7d05d65e90" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#CashcashequivalentsandshorttermtimedepositsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails" xlink:type="extended" id="i77850a8400cd4d8e97bca095cc929836_CashcashequivalentsandshorttermtimedepositsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShortTermTimeDepositPositions_88c6b55e-399d-431e-8014-958dacd15431" xlink:href="moln-20221231.xsd#moln_NumberOfShortTermTimeDepositPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:to="loc_moln_NumberOfShortTermTimeDepositPositions_88c6b55e-399d-431e-8014-958dacd15431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfBanksWhereDepositsAreHeld_5560e57f-972a-4b4a-9a28-a47907c93732" xlink:href="moln-20221231.xsd#moln_NumberOfBanksWhereDepositsAreHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:to="loc_moln_NumberOfBanksWhereDepositsAreHeld_5560e57f-972a-4b4a-9a28-a47907c93732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:to="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_5d5138cc-d7c6-493e-9c47-3acada016252_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:to="loc_currency_AllCurrenciesDomain_5d5138cc-d7c6-493e-9c47-3acada016252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:to="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_c6b1ad0b-5662-4c33-8dea-a8bdfdb06167" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:to="loc_currency_CHF_c6b1ad0b-5662-4c33-8dea-a8bdfdb06167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_8ac49733-9f61-4664-a62c-a7aaecde4230" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:to="loc_currency_USD_8ac49733-9f61-4664-a62c-a7aaecde4230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_80e07203-2cc1-4fab-a9ad-d68b56256cea" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:to="loc_currency_EUR_80e07203-2cc1-4fab-a9ad-d68b56256cea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ShareholdersequityClassesofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails" xlink:type="extended" id="i38ee596375604653b91d005a2295815a_ShareholdersequityClassesofShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_38dc4629-96ef-4f16-9a96-24ccb68dd938" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_Equity_38dc4629-96ef-4f16-9a96-24ccb68dd938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_a5ec1761-6f3e-4803-8396-c5fa6688fc47" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_a5ec1761-6f3e-4803-8396-c5fa6688fc47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_185f3a60-8bcb-417b-8c1e-305a2e1ea4ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_ParValuePerShare_185f3a60-8bcb-417b-8c1e-305a2e1ea4ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfVotesPerShare_2f504d92-a4b7-4d87-ba71-c4c36a736c40" xlink:href="moln-20221231.xsd#moln_NumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_NumberOfVotesPerShare_2f504d92-a4b7-4d87-ba71-c4c36a736c40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_9e5ee66e-12a5-4aa1-9858-51e6567e0251" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_9e5ee66e-12a5-4aa1-9858-51e6567e0251" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_7bff6995-7005-4a08-9003-97a4db71cbed" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_7bff6995-7005-4a08-9003-97a4db71cbed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_4266fe06-f3ee-4a42-918d-84d1c8a58402" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_4266fe06-f3ee-4a42-918d-84d1c8a58402" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseInAuthorizedShareCapital_63d12c4a-7a7c-473f-a285-3c97f4a5afea" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseInAuthorizedShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_IncreaseDecreaseInAuthorizedShareCapital_63d12c4a-7a7c-473f-a285-3c97f4a5afea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_11e3e004-a969-4b37-a616-8dffa24b3205" xlink:href="moln-20221231.xsd#moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_11e3e004-a969-4b37-a616-8dffa24b3205" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_89362076-316d-4e2f-9a85-d97a0c2cb095" xlink:href="moln-20221231.xsd#moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_89362076-316d-4e2f-9a85-d97a0c2cb095" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuthorizedShareCapitalEmployeeParticipation_152fb5f9-61eb-4103-a5ca-8b7cd7c01708" xlink:href="moln-20221231.xsd#moln_AuthorizedShareCapitalEmployeeParticipation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_AuthorizedShareCapitalEmployeeParticipation_152fb5f9-61eb-4103-a5ca-8b7cd7c01708" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesAuthorizedEmployeeParticipation_7200820c-2351-4190-a2c7-a026a87b857a" xlink:href="moln-20221231.xsd#moln_NumberOfSharesAuthorizedEmployeeParticipation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_NumberOfSharesAuthorizedEmployeeParticipation_7200820c-2351-4190-a2c7-a026a87b857a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_7ca44c24-80c6-45b1-8300-d3115b5acd49" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_7ca44c24-80c6-45b1-8300-d3115b5acd49" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuthorizedShareCapitalFinancingTransactions_9c9ddb9d-c53a-4f05-8af6-a74a098bd2c2" xlink:href="moln-20221231.xsd#moln_AuthorizedShareCapitalFinancingTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_AuthorizedShareCapitalFinancingTransactions_9c9ddb9d-c53a-4f05-8af6-a74a098bd2c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesAuthorizedFinancingTransactions_827c936e-9263-4f58-8bcc-0f0ba7ed18f6" xlink:href="moln-20221231.xsd#moln_NumberOfSharesAuthorizedFinancingTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_NumberOfSharesAuthorizedFinancingTransactions_827c936e-9263-4f58-8bcc-0f0ba7ed18f6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_f79f2539-1b16-43de-a5d3-c8fda103c341" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_f79f2539-1b16-43de-a5d3-c8fda103c341" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_afff1978-12cc-4112-8d93-60f2647eeed4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:to="loc_ifrs-full_EquityMember_afff1978-12cc-4112-8d93-60f2647eeed4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a6e60324-aed8-410a-92ab-35e608f1bda4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:to="loc_ifrs-full_EquityMember_a6e60324-aed8-410a-92ab-35e608f1bda4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_31515e5a-e049-4fda-ae36-ccd0f401878d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a6e60324-aed8-410a-92ab-35e608f1bda4" xlink:to="loc_ifrs-full_IssuedCapitalMember_31515e5a-e049-4fda-ae36-ccd0f401878d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_e58439c2-59d4-4b78-ab94-9037df2981f9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_e58439c2-59d4-4b78-ab94-9037df2981f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_4ed2c082-c641-4362-acb8-4c27ffa407d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:to="loc_ifrs-full_OrdinarySharesMember_4ed2c082-c641-4362-acb8-4c27ffa407d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ConditionalShareCapitalMember_47157e78-2dd1-44af-8aef-60ebf3d2ed2e" xlink:href="moln-20221231.xsd#moln_ConditionalShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:to="loc_moln_ConditionalShareCapitalMember_47157e78-2dd1-44af-8aef-60ebf3d2ed2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7fd3f48-cc33-468f-9113-2e3b9e649479_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7fd3f48-cc33-468f-9113-2e3b9e649479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68316b6d-a27b-4208-a1fb-3d9cc0809887" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68316b6d-a27b-4208-a1fb-3d9cc0809887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_9f9af3b7-4bca-42a1-b5ab-935e274182a8" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68316b6d-a27b-4208-a1fb-3d9cc0809887" xlink:to="loc_moln_NovartisMember_9f9af3b7-4bca-42a1-b5ab-935e274182a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_159c6c1a-5c8a-4119-87ba-e34e63ffc99c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_159c6c1a-5c8a-4119-87ba-e34e63ffc99c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea78fa53-4c54-49d7-b323-bf9e141d69b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea78fa53-4c54-49d7-b323-bf9e141d69b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShareOptionsPSUsAndRSUsMember_0685b4e3-d0f5-4e43-91d8-dcaa58fe8ab3" xlink:href="moln-20221231.xsd#moln_ShareOptionsPSUsAndRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea78fa53-4c54-49d7-b323-bf9e141d69b8" xlink:to="loc_moln_ShareOptionsPSUsAndRSUsMember_0685b4e3-d0f5-4e43-91d8-dcaa58fe8ab3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="extended" id="i99f29cbc7e2a4809a5a8cb5aa71cb5c0_TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems_854173c9-40b1-4354-9ad1-85dbacd0c9a5" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherPayablesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2fb60277-166b-4d69-ad5a-bd043b9a0d78" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems_854173c9-40b1-4354-9ad1-85dbacd0c9a5" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2fb60277-166b-4d69-ad5a-bd043b9a0d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherPayablesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems_854173c9-40b1-4354-9ad1-85dbacd0c9a5" xlink:to="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:to="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b82f8eab-d289-49b7-ac0e-79ae6edb5c43_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:to="loc_currency_AllCurrenciesDomain_b82f8eab-d289-49b7-ac0e-79ae6edb5c43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:to="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_5e78238a-5345-45ba-8c46-95c291035842" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_CHF_5e78238a-5345-45ba-8c46-95c291035842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_12bb5c5c-6e1c-4369-ba5d-0316dd3729e8" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_EUR_12bb5c5c-6e1c-4369-ba5d-0316dd3729e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_ba13555e-c935-4166-9a8a-caee8b291dd1" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_USD_ba13555e-c935-4166-9a8a-caee8b291dd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_1c83f693-7bf8-4541-acda-36fcf0add095" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_GBP_1c83f693-7bf8-4541-acda-36fcf0add095" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails" xlink:type="extended" id="ic63a3d2579704c97bd16666938540908_ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_8db25394-c744-4dca-8ebf-302fe654c125" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_7a923168-8ab8-4ce0-9649-7ce073e8d85d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_8db25394-c744-4dca-8ebf-302fe654c125" xlink:to="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_7a923168-8ab8-4ce0-9649-7ce073e8d85d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_8db25394-c744-4dca-8ebf-302fe654c125" xlink:to="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:to="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ac124813-9037-42a0-8d59-b304539a23dc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ac124813-9037-42a0-8d59-b304539a23dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_497cd6ea-02e5-479e-a362-540b9ece5d08" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_497cd6ea-02e5-479e-a362-540b9ece5d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_3818d747-8eb9-447f-b026-4bc893c1aef1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_3818d747-8eb9-447f-b026-4bc893c1aef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3b1d0191-d565-48da-b8c2-2a68f2a84cb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3b1d0191-d565-48da-b8c2-2a68f2a84cb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0d1ca0dc-5995-4ca6-a311-7a8bfd05492a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0d1ca0dc-5995-4ca6-a311-7a8bfd05492a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LaterThanFourYearsMember_04ab5090-0955-4306-b1f4-385d085806cc" xlink:href="moln-20221231.xsd#moln_LaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_moln_LaterThanFourYearsMember_04ab5090-0955-4306-b1f4-385d085806cc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityExplanationofChangesinContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails" xlink:type="extended" id="ia3b795df14344541b0271876ad656354_ContractliabilityExplanationofChangesinContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_2544c7fa-9e1f-4505-9a2a-1f97b7371523" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_ifrs-full_ContractLiabilities_2544c7fa-9e1f-4505-9a2a-1f97b7371523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseThroughAdditionsContractLiabilities_80010dd0-0821-4e90-bbbe-446db8abecb9" xlink:href="moln-20221231.xsd#moln_IncreaseThroughAdditionsContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_moln_IncreaseThroughAdditionsContractLiabilities_80010dd0-0821-4e90-bbbe-446db8abecb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_123e6617-5b33-411e-a460-1a44f4b034a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_123e6617-5b33-411e-a460-1a44f4b034a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_c38869aa-8c4c-454d-8857-385c7e889de1" xlink:href="moln-20221231.xsd#moln_DecreaseThroughOffsetOfCostsContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_c38869aa-8c4c-454d-8857-385c7e889de1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_146280db-caa9-4438-ad81-ddcebf25d3e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:to="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_203ec8b1-316a-46de-8381-29d744d465db_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:to="loc_ifrs-full_CounterpartiesMember_203ec8b1-316a-46de-8381-29d744d465db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:to="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmgenIncMember_57fb8c92-1125-4b21-a3eb-8198c92838b1" xlink:href="moln-20221231.xsd#moln_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:to="loc_moln_AmgenIncMember_57fb8c92-1125-4b21-a3eb-8198c92838b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_c3b06e2d-497c-4405-a7b0-96134020f925" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:to="loc_moln_NovartisMember_c3b06e2d-497c-4405-a7b0-96134020f925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember_550991a8-0af5-4e2b-a544-9c554a2eca2e" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:to="loc_moln_FederalOfficeOfPublicHealthMember_550991a8-0af5-4e2b-a544-9c554a2eca2e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails" xlink:type="extended" id="i8eeac97fbd3344629c64ed218a64b576_ContractliabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_eab02d74-29ee-4c69-9ac0-eb65aa883ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:to="loc_ifrs-full_ContractLiabilities_eab02d74-29ee-4c69-9ac0-eb65aa883ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_0d350289-793a-47d8-8a1f-3032e81078dd" xlink:href="moln-20221231.xsd#moln_DecreaseThroughOffsetOfCostsContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:to="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_0d350289-793a-47d8-8a1f-3032e81078dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:to="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:to="loc_ifrs-full_CounterpartiesMember_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_7377a844-4cb0-4b58-a9a2-0c431aac8692" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:to="loc_ifrs-full_CounterpartiesMember_7377a844-4cb0-4b58-a9a2-0c431aac8692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_8279d546-8f40-4769-baaa-5d0c05ceefeb" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_7377a844-4cb0-4b58-a9a2-0c431aac8692" xlink:to="loc_moln_NovartisMember_8279d546-8f40-4769-baaa-5d0c05ceefeb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" xlink:type="extended" id="iac02c653b1d9477da82bc787f3424ec9_ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_8e16d160-6e3a-444a-90a8-518b4e155e9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_ifrs-full_CurrentContractLiabilities_8e16d160-6e3a-444a-90a8-518b4e155e9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_122e1467-89b2-4d85-953b-3c0ace5117fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_122e1467-89b2-4d85-953b-3c0ace5117fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6edae91e-4d95-41d0-8580-32732b75a982" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_ifrs-full_ContractLiabilities_6edae91e-4d95-41d0-8580-32732b75a982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:to="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_997039d1-1831-4a54-9d1f-04275200d1d3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:to="loc_ifrs-full_CounterpartiesMember_997039d1-1831-4a54-9d1f-04275200d1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:to="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmgenIncMember_d1b27b23-251a-4f35-b4be-45818808fb81" xlink:href="moln-20221231.xsd#moln_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:to="loc_moln_AmgenIncMember_d1b27b23-251a-4f35-b4be-45818808fb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_9bfc0267-d00b-4777-81e5-3cec8c93d287" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:to="loc_moln_NovartisMember_9bfc0267-d00b-4777-81e5-3cec8c93d287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember_140d05b6-47a2-49d7-8d53-db47c10e50e3" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:to="loc_moln_FederalOfficeOfPublicHealthMember_140d05b6-47a2-49d7-8d53-db47c10e50e3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#AdditionalinformationonthenatureofexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" xlink:type="extended" id="i740bf43a6930425e824d7da9f241811c_AdditionalinformationonthenatureofexpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_801dbb12-d522-433f-b482-1a4784cf3db5" xlink:href="moln-20221231.xsd#moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_801dbb12-d522-433f-b482-1a4784cf3db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_434c3725-dcec-410d-8c8e-1fd6343ccb02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_434c3725-dcec-410d-8c8e-1fd6343ccb02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_eed8d82d-8bcd-4416-9ded-74fdb80c1bd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_AdministrativeExpense_eed8d82d-8bcd-4416-9ded-74fdb80c1bd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_002cb2aa-fdf5-4d64-8b08-1ecc7df37cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_002cb2aa-fdf5-4d64-8b08-1ecc7df37cfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IntellectualPropertyExpense_004b2a5d-e6e0-48b7-a53f-daae7b1991f3" xlink:href="moln-20221231.xsd#moln_IntellectualPropertyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_IntellectualPropertyExpense_004b2a5d-e6e0-48b7-a53f-daae7b1991f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense_fe58f866-2998-4d42-b35c-b92bf81760a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OccupancyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_OccupancyExpense_fe58f866-2998-4d42-b35c-b92bf81760a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherResearchAndDevelopmentExpense_d6c564f1-05b9-470f-887d-4a35001c202e" xlink:href="moln-20221231.xsd#moln_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_OtherResearchAndDevelopmentExpense_d6c564f1-05b9-470f-887d-4a35001c202e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesAndLicenseFeesExpense_2df969f2-2564-4cbe-ba25-a22a91457814" xlink:href="moln-20221231.xsd#moln_RoyaltiesAndLicenseFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_RoyaltiesAndLicenseFeesExpense_2df969f2-2564-4cbe-ba25-a22a91457814" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_626da479-6d6d-4cb9-913a-0c8b4e0315d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_626da479-6d6d-4cb9-913a-0c8b4e0315d6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0c53f6a5-4721-480d-9a1d-ed4f3b6f16fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0c53f6a5-4721-480d-9a1d-ed4f3b6f16fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_178aa94a-e91f-4632-9b5b-ea0f9a5a0916" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_OperatingExpense_178aa94a-e91f-4632-9b5b-ea0f9a5a0916" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_5a204ff1-9352-4abe-9635-47bfb1aa2bd1" xlink:href="moln-20221231.xsd#moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_5a204ff1-9352-4abe-9635-47bfb1aa2bd1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_47d959f5-1572-4c77-a3fd-cd349cb39b70_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_47d959f5-1572-4c77-a3fd-cd349cb39b70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember_d37e3fe5-673f-418e-bc16-85df4722cb84" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:to="loc_moln_ResearchAndDevelopmentExpenseMember_d37e3fe5-673f-418e-bc16-85df4722cb84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_62f1218e-22c5-4faa-8230-47de45d06287" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_62f1218e-22c5-4faa-8230-47de45d06287" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RoyaltiesandlicensefeesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" xlink:type="extended" id="i8fd172ad4fb04e5ba52481697baeb9ee_RoyaltiesandlicensefeesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RoyaltyExpense_6b909ac8-c3a4-49c6-a6c1-02a3b95ecb8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_ifrs-full_RoyaltyExpense_6b909ac8-c3a4-49c6-a6c1-02a3b95ecb8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesMinimumAnnualAmountTotal_7e6d50a3-4f6f-4438-a2d9-c080c1a8e8f2" xlink:href="moln-20221231.xsd#moln_RoyaltiesMinimumAnnualAmountTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_RoyaltiesMinimumAnnualAmountTotal_7e6d50a3-4f6f-4438-a2d9-c080c1a8e8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseFeesExpense_b7080bc9-e867-4bd3-9a87-44676c6cec58" xlink:href="moln-20221231.xsd#moln_LicenseFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_LicenseFeesExpense_b7080bc9-e867-4bd3-9a87-44676c6cec58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CurrentAccruedProjectCostsAndRoyalties_6a1ca814-862e-4580-80a9-c17ead20d39d" xlink:href="moln-20221231.xsd#moln_CurrentAccruedProjectCostsAndRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_CurrentAccruedProjectCostsAndRoyalties_6a1ca814-862e-4580-80a9-c17ead20d39d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltyPayable_31ec7f2d-6586-4cd6-935a-57865adb57eb" xlink:href="moln-20221231.xsd#moln_RoyaltyPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_RoyaltyPayable_31ec7f2d-6586-4cd6-935a-57865adb57eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:to="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_c786c0b2-eaad-4025-9e72-1043fdca49ac_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:to="loc_ifrs-full_CounterpartiesMember_c786c0b2-eaad-4025-9e72-1043fdca49ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:to="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UniversityOfZurichMember_769d1657-d0df-47ea-9500-c2b04bb8fdd6" xlink:href="moln-20221231.xsd#moln_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:to="loc_moln_UniversityOfZurichMember_769d1657-d0df-47ea-9500-c2b04bb8fdd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UniversityOfUtrechtMember_a714b0b0-f024-4414-b996-fc805936d5ac" xlink:href="moln-20221231.xsd#moln_UniversityOfUtrechtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:to="loc_moln_UniversityOfUtrechtMember_a714b0b0-f024-4414-b996-fc805936d5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:to="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_93ea94be-1dcc-451b-b2b2-477121605b82_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:to="loc_ifrs-full_TypesOfContractsMember_93ea94be-1dcc-451b-b2b2-477121605b82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_7960fd09-c727-4fca-a2c0-f5e8adda886c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:to="loc_ifrs-full_TypesOfContractsMember_7960fd09-c727-4fca-a2c0-f5e8adda886c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_225de5da-001f-4365-970a-9a8cebca2ec4" xlink:href="moln-20221231.xsd#moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_7960fd09-c727-4fca-a2c0-f5e8adda886c" xlink:to="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_225de5da-001f-4365-970a-9a8cebca2ec4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended" id="i6dd44b072b7d401fb2145e00c0cf6c8e_PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1518a741-a343-4b49-9099-659a6e4e36d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1518a741-a343-4b49-9099-659a6e4e36d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_225042bd-f3d9-4557-a1d3-72c485886469" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_225042bd-f3d9-4557-a1d3-72c485886469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:href="moln-20221231.xsd#moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_b614be2f-d9d8-4599-a191-de7401992d37" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_b614be2f-d9d8-4599-a191-de7401992d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_91d2a374-b5db-4e41-8f42-f38bc86cb5d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_91d2a374-b5db-4e41-8f42-f38bc86cb5d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a246cae4-81f6-4c94-81de-9e428cebadb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a246cae4-81f6-4c94-81de-9e428cebadb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_b2fbd8d1-f1bf-448d-b387-0e5d6a3bbc18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_b2fbd8d1-f1bf-448d-b387-0e5d6a3bbc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_597e0d5d-00fa-4e65-80b0-2c660a328126" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_597e0d5d-00fa-4e65-80b0-2c660a328126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_d055e578-b7d1-4cc1-bc82-c27bd88b0adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_d055e578-b7d1-4cc1-bc82-c27bd88b0adb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_d5aef57b-0196-453c-a545-5537e7bc16d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_d5aef57b-0196-453c-a545-5537e7bc16d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_7796da14-d0b0-49c3-8b79-59389c3cbe52" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_7796da14-d0b0-49c3-8b79-59389c3cbe52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_355e525e-45f2-408a-8469-c1fa30840f7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_355e525e-45f2-408a-8469-c1fa30840f7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_43f94011-6698-4a10-ab3a-418af72c635a" xlink:href="moln-20221231.xsd#moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_43f94011-6698-4a10-ab3a-418af72c635a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_08c66c16-659e-4670-aed0-004e4c877da7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_08c66c16-659e-4670-aed0-004e4c877da7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_52ba4341-73ec-484c-a4b0-313d2e31ceaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_e226aaf2-5dc2-4bdd-8b18-acd04ea06ab0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_e226aaf2-5dc2-4bdd-8b18-acd04ea06ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6ed2fdb2-a9b4-4fb9-9abc-52ac3f2859a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6ed2fdb2-a9b4-4fb9-9abc-52ac3f2859a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_fb966abe-68f6-47bd-adb2-c0ae8cc08398" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_fb966abe-68f6-47bd-adb2-c0ae8cc08398" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_274fe58e-2595-40dd-a427-64a1c16e9349" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:href="moln-20221231.xsd#moln_ReconciliationOfDefinedBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_8c9fd689-7101-493b-9c27-d1ddea7ab7a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_13f45f62-0f03-4d73-90bd-aba3ff7bf406" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_13f45f62-0f03-4d73-90bd-aba3ff7bf406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_655b51c4-1b66-4607-bfdf-71aa6fd5a57f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_655b51c4-1b66-4607-bfdf-71aa6fd5a57f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_60241cb2-1b73-45e6-8c21-d7b8279022b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_60241cb2-1b73-45e6-8c21-d7b8279022b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_f24dfdd2-e114-4725-959d-0f67e4528a18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_f24dfdd2-e114-4725-959d-0f67e4528a18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_d86d9db8-44fe-413a-b79d-8dd0bed912dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_d86d9db8-44fe-413a-b79d-8dd0bed912dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_4b00273d-7a35-444b-86b0-f34b5a19a464" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_4b00273d-7a35-444b-86b0-f34b5a19a464" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a02cb6a1-e212-4601-8df0-2cf48b5186ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_82a41a53-d24a-4bb2-8521-0fac31d886b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_ec8e5930-c823-49eb-a906-86a7d5b66c60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_ec8e5930-c823-49eb-a906-86a7d5b66c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_656227ac-b972-45e7-b109-eb30edcf29e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_656227ac-b972-45e7-b109-eb30edcf29e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_eebf6c02-ab92-4753-95f2-4e8195c9daa8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_eebf6c02-ab92-4753-95f2-4e8195c9daa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_dff7ac74-1a16-489c-8150-509a41c8b9b9" xlink:href="moln-20221231.xsd#moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_dff7ac74-1a16-489c-8150-509a41c8b9b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_005f9c06-b45c-4ef2-824f-f742985d1733" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_005f9c06-b45c-4ef2-824f-f742985d1733" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_bf22d185-6c2d-4edb-a41f-5507054a426b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_bf22d185-6c2d-4edb-a41f-5507054a426b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:href="moln-20221231.xsd#moln_ReconciliationOfFairValueOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_97760c9f-b88e-476e-8d23-5a85e3e7e816" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_359707b6-ddca-4270-b7c1-881b7053504b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_467985bf-0d3a-4408-8860-997a2f0f14c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1bd5bdd6-567f-49fc-b083-b36e4f805a88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_5ae98df4-621c-4416-95ce-f5386ecbea43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_aaba73a7-4bae-4e9c-ab47-4129b2ec6fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_aaba73a7-4bae-4e9c-ab47-4129b2ec6fa2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b7a9f1d3-6fdf-48bf-a575-491f997d84cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_2ec3b8ad-5d85-4b4e-925c-27eda6e75edd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_2ec3b8ad-5d85-4b4e-925c-27eda6e75edd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_b5151753-aaac-490d-af7f-ab36d499db27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_b5151753-aaac-490d-af7f-ab36d499db27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_382c10e0-21ea-4d3c-a071-58c573680c41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_382c10e0-21ea-4d3c-a071-58c573680c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_58852303-18f3-4479-a0e0-981b78c88d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_58852303-18f3-4479-a0e0-981b78c88d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_94e03f43-6acd-4720-9939-59efb6309752" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_94e03f43-6acd-4720-9939-59efb6309752" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_94e4206a-3ec9-4724-88cb-cff18a41a5e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_94e4206a-3ec9-4724-88cb-cff18a41a5e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_e0d95317-d8bb-410a-bad9-063f2c57e7ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets_07d2fc03-6d65-456a-9a62-85a3f83c09d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets_07d2fc03-6d65-456a-9a62-85a3f83c09d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_31fc725c-478e-4f5d-8c38-d4befba3a3bd" xlink:href="moln-20221231.xsd#moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_31fc725c-478e-4f5d-8c38-d4befba3a3bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_3d60faba-e5dd-42af-b1d6-639c3bec2bee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_3d60faba-e5dd-42af-b1d6-639c3bec2bee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cfa7320b-9a2f-4205-8fb6-2eb856918a54" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cfa7320b-9a2f-4205-8fb6-2eb856918a54" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_c416f504-4f4f-449d-a1a5-67d2a3260ebb" xlink:href="moln-20221231.xsd#moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_c416f504-4f4f-449d-a1a5-67d2a3260ebb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_e85d76f2-aa7c-4cdf-84b6-f2cb28aec829" xlink:href="moln-20221231.xsd#moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_e85d76f2-aa7c-4cdf-84b6-f2cb28aec829" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_19bad546-70b8-4364-937c-3b6820c6b189" xlink:href="moln-20221231.xsd#moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_19bad546-70b8-4364-937c-3b6820c6b189" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9bdaa6f4-aee6-4514-8eee-d6df9a4f4d54" xlink:href="moln-20221231.xsd#moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9bdaa6f4-aee6-4514-8eee-d6df9a4f4d54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_de151693-2ca4-451f-b0f7-fb794d5e43e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_de151693-2ca4-451f-b0f7-fb794d5e43e9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndustryBenchmarkDiscountRatesPeriod_26811128-774e-422c-81e0-c044cdc6d336" xlink:href="moln-20221231.xsd#moln_IndustryBenchmarkDiscountRatesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_IndustryBenchmarkDiscountRatesPeriod_26811128-774e-422c-81e0-c044cdc6d336" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedSabbaticalCost_3c05a752-4286-45e5-bc8a-54d17aed5634" xlink:href="moln-20221231.xsd#moln_AccruedSabbaticalCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_AccruedSabbaticalCost_3c05a752-4286-45e5-bc8a-54d17aed5634" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_06ce3574-3cd0-4fd6-996a-0537b60986f7" xlink:href="moln-20221231.xsd#moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_06ce3574-3cd0-4fd6-996a-0537b60986f7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_ce48eb4d-1574-40ad-aeda-72f9d05458b2" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_ce48eb4d-1574-40ad-aeda-72f9d05458b2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_9934cf04-4e2b-47da-94f4-36b2a25e9ea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_9934cf04-4e2b-47da-94f4-36b2a25e9ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_c60e4cf6-5748-468e-b691-a159a05cdd05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:to="loc_ifrs-full_PlanAssetsMember_c60e4cf6-5748-468e-b691-a159a05cdd05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_588480e3-52b3-4bfe-9907-42ee96b3d935_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_588480e3-52b3-4bfe-9907-42ee96b3d935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_bbc7154c-9fe3-45cd-aec1-ca24c9436b7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_bbc7154c-9fe3-45cd-aec1-ca24c9436b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_267d5be2-6dd4-4c69-ad8c-9f7d2108c904" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_267d5be2-6dd4-4c69-ad8c-9f7d2108c904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_6c200866-54e5-40de-86ac-b958614ae337_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_6c200866-54e5-40de-86ac-b958614ae337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_4879467f-31f5-4bd4-93c9-a1ed97471a13" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_4879467f-31f5-4bd4-93c9-a1ed97471a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_f41dbb6b-4892-4abc-bb0b-2e065dcb2af3" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_f41dbb6b-4892-4abc-bb0b-2e065dcb2af3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_b120ef04-e860-4fd2-a266-347482bd2871" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_b120ef04-e860-4fd2-a266-347482bd2871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember_77d91676-bfe7-47b7-bdff-4317e4a55869" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember_77d91676-bfe7-47b7-bdff-4317e4a55869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:href="moln-20221231.xsd#moln_IndividualsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsDomain_98df5004-13aa-4beb-9c27-c732fb24bbdd_default" xlink:href="moln-20221231.xsd#moln_IndividualsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:to="loc_moln_IndividualsDomain_98df5004-13aa-4beb-9c27-c732fb24bbdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:href="moln-20221231.xsd#moln_IndividualsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:to="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActiveMembersMember_dd65783d-754f-4ca6-9f56-7edb375c8ea1" xlink:href="moln-20221231.xsd#moln_ActiveMembersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:to="loc_moln_ActiveMembersMember_dd65783d-754f-4ca6-9f56-7edb375c8ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PensionersMember_97f69d82-ba19-4974-8ce0-5f13e4f72864" xlink:href="moln-20221231.xsd#moln_PensionersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:to="loc_moln_PensionersMember_97f69d82-ba19-4974-8ce0-5f13e4f72864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_7a8dfceb-66e6-4e53-8247-5f592c898740_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_7a8dfceb-66e6-4e53-8247-5f592c898740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember_e24e0246-c99f-4348-9fba-8f39ff6134b9" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:to="loc_moln_ResearchAndDevelopmentExpenseMember_e24e0246-c99f-4348-9fba-8f39ff6134b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_afc8c827-87e1-4a0a-8266-4e8f6e5ea791" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_afc8c827-87e1-4a0a-8266-4e8f6e5ea791" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" xlink:type="extended" id="i1b70012d94ee496e86081c13c2031693_PersonnelexpensesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_0d26835b-a1b6-4217-992e-636e94ec18a9" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_0d26835b-a1b6-4217-992e-636e94ec18a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_cec4cce0-e167-42f8-bad9-542ecb1ec051" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_cec4cce0-e167-42f8-bad9-542ecb1ec051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_03ec74ae-e4f6-4265-8245-c86c3006dc3c" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_03ec74ae-e4f6-4265-8245-c86c3006dc3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_267efab3-1a22-4a7a-ae93-5fe6641470fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_267efab3-1a22-4a7a-ae93-5fe6641470fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShareOptionPlans_ca3f322c-a2d2-4aa4-9a9e-950aa0d97648" xlink:href="moln-20221231.xsd#moln_NumberOfShareOptionPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_NumberOfShareOptionPlans_ca3f322c-a2d2-4aa4-9a9e-950aa0d97648" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_367bc153-e0a9-4609-9dea-f6f608f02de2" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_367bc153-e0a9-4609-9dea-f6f608f02de2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_19610f34-2dbb-4568-b907-e34c024384ba" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_19610f34-2dbb-4568-b907-e34c024384ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_f0c34207-6e43-40bc-9f7f-20dbb56501d4" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_f0c34207-6e43-40bc-9f7f-20dbb56501d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_91a03165-ef02-471a-993f-3a728f30e7ea" xlink:href="moln-20221231.xsd#moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_91a03165-ef02-471a-993f-3a728f30e7ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7aca39e1-23e9-4e2e-95a3-3b932ddbb8ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7aca39e1-23e9-4e2e-95a3-3b932ddbb8ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_70610d53-7587-4231-9df2-05c17f7b8fcc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_70610d53-7587-4231-9df2-05c17f7b8fcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ESOP2009AndESOP2014Member_a94b76b9-b439-4b52-81a9-65af7a577c7f" xlink:href="moln-20221231.xsd#moln_ESOP2009AndESOP2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_ESOP2009AndESOP2014Member_a94b76b9-b439-4b52-81a9-65af7a577c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RestrictedShareUnitsRSUMember_39912bf9-7fce-4e63-bb48-2d387ffc24c5" xlink:href="moln-20221231.xsd#moln_RestrictedShareUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_RestrictedShareUnitsRSUMember_39912bf9-7fce-4e63-bb48-2d387ffc24c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_54169bbc-300f-4326-a30b-8ccc4fb93662" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_54169bbc-300f-4326-a30b-8ccc4fb93662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_752a020f-965a-4b9a-b2b1-14fba486d557" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUManagementBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_752a020f-965a-4b9a-b2b1-14fba486d557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUMember_e174904f-a3b1-48b7-9bef-db6f0773ede2" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_PerformanceShareUnitsPSUMember_e174904f-a3b1-48b7-9bef-db6f0773ede2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:to="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:to="loc_ifrs-full_RangesMember_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:to="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f2bb956-1201-4bde-a7b0-d34b97c447ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:to="loc_srt_MinimumMember_4f2bb956-1201-4bde-a7b0-d34b97c447ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06782d1c-5276-45f0-af1d-bc8ef1cce8a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:to="loc_srt_MaximumMember_06782d1c-5276-45f0-af1d-bc8ef1cce8a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" xlink:type="extended" id="i6bdb046f5e294939ac89ce6d6e685927_PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:href="moln-20221231.xsd#moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_5ce3e174-db40-411a-bfa8-1bfed60a493f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_5ce3e174-db40-411a-bfa8-1bfed60a493f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_50155be6-a691-407a-9b6a-f885251b0e48" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_50155be6-a691-407a-9b6a-f885251b0e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_722e6e66-2e67-46ad-989f-fa8fb90020a3" xlink:href="moln-20221231.xsd#moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_722e6e66-2e67-46ad-989f-fa8fb90020a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_1d23c2de-e43f-456c-bf8f-8bec12d75f50" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_1d23c2de-e43f-456c-bf8f-8bec12d75f50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FullContractualLifeOtherEquityInstruments_38268d12-faeb-4df4-9a18-74c7497b142e" xlink:href="moln-20221231.xsd#moln_FullContractualLifeOtherEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_FullContractualLifeOtherEquityInstruments_38268d12-faeb-4df4-9a18-74c7497b142e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_49557859-627a-45fd-8a39-fe26cb7a75db" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_49557859-627a-45fd-8a39-fe26cb7a75db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_2746b0b1-494d-4d64-8c5a-300d07c03b5b" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_2746b0b1-494d-4d64-8c5a-300d07c03b5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_3a5177c9-9f22-4ae7-8d83-ea301aa86057" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_3a5177c9-9f22-4ae7-8d83-ea301aa86057" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_451ff6aa-0654-4984-91a3-4e1791719926" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_451ff6aa-0654-4984-91a3-4e1791719926" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_58ba98a0-28d6-49e4-9c09-752c7c191b41" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_58ba98a0-28d6-49e4-9c09-752c7c191b41" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_d3a22d12-e3f1-47d2-9aa4-a2f55c5275bf" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_d3a22d12-e3f1-47d2-9aa4-a2f55c5275bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedDividendOtherEquityInstrumentsGranted_e38adf13-b59a-4adc-b538-677e798bd06a" xlink:href="moln-20221231.xsd#moln_ExpectedDividendOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedDividendOtherEquityInstrumentsGranted_e38adf13-b59a-4adc-b538-677e798bd06a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f3321ef5-6033-4a2a-a608-85822ed4051f" xlink:href="moln-20221231.xsd#moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f3321ef5-6033-4a2a-a608-85822ed4051f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:href="moln-20221231.xsd#moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:to="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_469c36a0-39b6-492c-9968-11bd38b1530f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:to="loc_ifrs-full_RangesMember_469c36a0-39b6-492c-9968-11bd38b1530f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:to="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bebbae48-a8b9-4be6-9788-3e3518b45c6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:to="loc_srt_MinimumMember_bebbae48-a8b9-4be6-9788-3e3518b45c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_455f8312-6a39-4993-b03b-0e8a3ebbf3aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:to="loc_srt_MaximumMember_455f8312-6a39-4993-b03b-0e8a3ebbf3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_c9931c8d-9a9b-431d-a4d1-ff61d5af2374_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_c9931c8d-9a9b-431d-a4d1-ff61d5af2374_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RestrictedShareUnitsRSUMember_1f034028-25db-4b7b-ab61-9ba26145f897" xlink:href="moln-20221231.xsd#moln_RestrictedShareUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_RestrictedShareUnitsRSUMember_1f034028-25db-4b7b-ab61-9ba26145f897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUMember_7468599f-44cd-40e7-be1f-a23cfcb4e0d5" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_PerformanceShareUnitsPSUMember_7468599f-44cd-40e7-be1f-a23cfcb4e0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_d0aeaadb-db15-4c52-bdba-77eba23cc6cf" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUManagementBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_d0aeaadb-db15-4c52-bdba-77eba23cc6cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_4c9136df-75cf-456b-a034-caa4abb7897f" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_4c9136df-75cf-456b-a034-caa4abb7897f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" xlink:type="extended" id="id1fb52aa66f641c3af231bb9bcda7e61_PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_b46b31ff-ab2f-4b19-8ff7-411481ee7f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_b46b31ff-ab2f-4b19-8ff7-411481ee7f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_9f0fbdd2-4fbf-48a8-b5a2-8fdf9e962fe7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_9f0fbdd2-4fbf-48a8-b5a2-8fdf9e962fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e1912918-a0ff-4fc6-ac7c-50a874a37d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e1912918-a0ff-4fc6-ac7c-50a874a37d55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_71808af5-9293-4034-831e-1cff76db07c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_71808af5-9293-4034-831e-1cff76db07c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercicePriceOfOutstandingOtherEquityInstruments_3d7dabb0-0a93-477d-807f-c9d44adbee50" xlink:href="moln-20221231.xsd#moln_ExercicePriceOfOutstandingOtherEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_ExercicePriceOfOutstandingOtherEquityInstruments_3d7dabb0-0a93-477d-807f-c9d44adbee50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0015f892-3029-402f-9d83-28dff2702aab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0015f892-3029-402f-9d83-28dff2702aab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_97111912-7dad-40b7-a101-4eeff4e38e5c" xlink:href="moln-20221231.xsd#moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_97111912-7dad-40b7-a101-4eeff4e38e5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_1e36102b-96f1-48aa-8cd8-10fa6cce9aca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_1e36102b-96f1-48aa-8cd8-10fa6cce9aca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_b30bd833-d4a4-40b0-a3e7-7049ccff2614" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_b30bd833-d4a4-40b0-a3e7-7049ccff2614" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_50d6c14b-661e-40d3-8742-61ef2c4ecdac" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_50d6c14b-661e-40d3-8742-61ef2c4ecdac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e72e18ee-21f9-45d7-8586-00b69ac03b18_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e72e18ee-21f9-45d7-8586-00b69ac03b18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeOneMember_b0514e43-3a5a-4296-8bf3-ce257414387a" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeOneMember_b0514e43-3a5a-4296-8bf3-ce257414387a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeTwoMember_50cc2f90-cbf1-4ff5-baa5-41250bf03ca1" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeTwoMember_50cc2f90-cbf1-4ff5-baa5-41250bf03ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeThreeMember_47b44819-47dc-41ae-aa36-c8af67b3ad6a" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeThreeMember_47b44819-47dc-41ae-aa36-c8af67b3ad6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeFourMember_47fd3ab6-89c7-4e0f-8d33-75e68b5a2ba3" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeFourMember_47fd3ab6-89c7-4e0f-8d33-75e68b5a2ba3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails" xlink:type="extended" id="if38f78f72ba84dcbb16afdbaa307b3a8_PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b249e735-d31d-44b8-9a54-5763e2b7653e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_da2c41e4-b6f4-452a-bc40-e9696c6f54db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b249e735-d31d-44b8-9a54-5763e2b7653e" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_da2c41e4-b6f4-452a-bc40-e9696c6f54db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b249e735-d31d-44b8-9a54-5763e2b7653e" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_93978154-cc96-42b4-9758-04db1d81af48_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_93978154-cc96-42b4-9758-04db1d81af48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember_0d374e35-35d2-43f7-9abc-e2477f7b9a49" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:to="loc_moln_ResearchAndDevelopmentExpenseMember_0d374e35-35d2-43f7-9abc-e2477f7b9a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_735dd699-2e94-421f-bcf0-7b7bc666907a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_735dd699-2e94-421f-bcf0-7b7bc666907a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails" xlink:type="extended" id="i595a8fdef52b4e7dba7accbf183e613a_TaxesIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_4f69935f-e51a-4c1f-ac15-a6f5391dc45b" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_fa7a4d98-5cb1-45b2-8770-837c2b6606fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_4f69935f-e51a-4c1f-ac15-a6f5391dc45b" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_fa7a4d98-5cb1-45b2-8770-837c2b6606fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_4f69935f-e51a-4c1f-ac15-a6f5391dc45b" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:to="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f3f56eba-e36e-4dfc-b323-38276db2ef96_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:to="loc_dei_EntityDomain_f3f56eba-e36e-4dfc-b323-38276db2ef96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_453b1f52-15ab-4721-ab0f-2d9f38abba70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:to="loc_dei_EntityDomain_453b1f52-15ab-4721-ab0f-2d9f38abba70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MolecularPartnersIncMember_db80a623-f8eb-453c-a096-945c0e858edb" xlink:href="moln-20221231.xsd#moln_MolecularPartnersIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_453b1f52-15ab-4721-ab0f-2d9f38abba70" xlink:to="loc_moln_MolecularPartnersIncMember_db80a623-f8eb-453c-a096-945c0e858edb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesDeferredTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails" xlink:type="extended" id="iaf80b325e94840cc93f4a0f0948b6e4b_TaxesDeferredTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NetOperatingProfit_841e2d21-9c54-462b-8d24-d9dce8b79871" xlink:href="moln-20221231.xsd#moln_NetOperatingProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_NetOperatingProfit_841e2d21-9c54-462b-8d24-d9dce8b79871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NetOperatingLosses_577afe42-c069-447a-ae38-f2ddc76fc790" xlink:href="moln-20221231.xsd#moln_NetOperatingLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_NetOperatingLosses_577afe42-c069-447a-ae38-f2ddc76fc790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwards_28339a6d-9476-4fae-a844-945189400d20" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_TaxLossCarryforwards_28339a6d-9476-4fae-a844-945189400d20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwardsExpirationPeriod_89eb60cd-0d74-48a0-8445-b7c930175974" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwardsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_TaxLossCarryforwardsExpirationPeriod_89eb60cd-0d74-48a0-8445-b7c930175974" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_315799fa-c1f6-4d24-add8-d59237214314" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_315799fa-c1f6-4d24-add8-d59237214314" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_44c1fdd4-abd3-4ee8-a914-eb409216f174" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_ifrs-full_ApplicableTaxRate_44c1fdd4-abd3-4ee8-a914-eb409216f174" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:to="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1cd6bb5f-4562-4573-82d3-34d26c01720c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1cd6bb5f-4562-4573-82d3-34d26c01720c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2027Member_c8e57c7c-eb39-48da-b1fa-0a18eba2c0e2" xlink:href="moln-20221231.xsd#moln_ExpiringIn2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:to="loc_moln_ExpiringIn2027Member_c8e57c7c-eb39-48da-b1fa-0a18eba2c0e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2028Member_182c5e72-e397-420b-99f7-25ba91454d97" xlink:href="moln-20221231.xsd#moln_ExpiringIn2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:to="loc_moln_ExpiringIn2028Member_182c5e72-e397-420b-99f7-25ba91454d97" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" xlink:type="extended" id="ib9f09bfb2c1146cca93bfbb2e87a05e5_TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_daa16522-6c34-4a00-9f4c-a066bb0e047e" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwards_ec3682ef-8d28-41d1-a414-a41d05c29a59" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_daa16522-6c34-4a00-9f4c-a066bb0e047e" xlink:to="loc_moln_TaxLossCarryforwards_ec3682ef-8d28-41d1-a414-a41d05c29a59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_daa16522-6c34-4a00-9f4c-a066bb0e047e" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:to="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_3f72279e-ed3c-44c0-8440-e13782c5b595_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_3f72279e-ed3c-44c0-8440-e13782c5b595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2023Member_7f46cca3-c214-427b-a7f0-53c59d2497b5" xlink:href="moln-20221231.xsd#moln_ExpiringIn2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2023Member_7f46cca3-c214-427b-a7f0-53c59d2497b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2024Member_01e6836f-910c-44db-8a4c-16fc80e840cb" xlink:href="moln-20221231.xsd#moln_ExpiringIn2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2024Member_01e6836f-910c-44db-8a4c-16fc80e840cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2025Member_bde912d2-4237-4925-ae97-02d7c731517e" xlink:href="moln-20221231.xsd#moln_ExpiringIn2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2025Member_bde912d2-4237-4925-ae97-02d7c731517e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2026Member_2a2fe2b8-65a7-452e-8480-a7d2c45308c9" xlink:href="moln-20221231.xsd#moln_ExpiringIn2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2026Member_2a2fe2b8-65a7-452e-8480-a7d2c45308c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2027Member_4cacbf3f-437a-4c35-9f1a-00063704ea02" xlink:href="moln-20221231.xsd#moln_ExpiringIn2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2027Member_4cacbf3f-437a-4c35-9f1a-00063704ea02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2028Member_cd57f51c-f2cf-4c2a-be8c-ed933fc339c9" xlink:href="moln-20221231.xsd#moln_ExpiringIn2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2028Member_cd57f51c-f2cf-4c2a-be8c-ed933fc339c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ThereafterMember_fdac85eb-e936-43c7-a56d-5e80b205ebfb" xlink:href="moln-20221231.xsd#moln_ThereafterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ThereafterMember_fdac85eb-e936-43c7-a56d-5e80b205ebfb" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i0fa28883b05848cc80866fb1864e6b25_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseTermOfContract_c3b13125-0b12-4f3b-b1de-bd87aed9c13d" xlink:href="moln-20221231.xsd#moln_LeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_LeaseTermOfContract_c3b13125-0b12-4f3b-b1de-bd87aed9c13d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseExtensionOrTerminationOptionPeriod_2a84dc27-d002-46d6-b5da-14fcab5022e6" xlink:href="moln-20221231.xsd#moln_LeaseExtensionOrTerminationOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_LeaseExtensionOrTerminationOptionPeriod_2a84dc27-d002-46d6-b5da-14fcab5022e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseExtensionTermOfContract_3ab1e2fc-9fd3-482a-902d-7d3725865c85" xlink:href="moln-20221231.xsd#moln_LeaseExtensionTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_LeaseExtensionTermOfContract_3ab1e2fc-9fd3-482a-902d-7d3725865c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_18071dc7-901a-4907-a98c-55318d6dd788" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_ifrs-full_CashOutflowForLeases_18071dc7-901a-4907-a98c-55318d6dd788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:to="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9753334c-56b8-4416-ba03-a8e6983db981_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:to="loc_srt_RangeMember_9753334c-56b8-4416-ba03-a8e6983db981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:to="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04d6e191-9aaa-4781-84f4-924a186d4ad0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:to="loc_srt_MinimumMember_04d6e191-9aaa-4781-84f4-924a186d4ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_48773804-7027-4865-a270-e4d8d2b679d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:to="loc_srt_MaximumMember_48773804-7027-4865-a270-e4d8d2b679d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:to="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_a2df429d-1cb0-4ffd-9080-7481997967e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:to="loc_ifrs-full_TypesOfContractsMember_a2df429d-1cb0-4ffd-9080-7481997967e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_4126be79-9799-4853-aefd-840b38bd31b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:to="loc_ifrs-full_TypesOfContractsMember_4126be79-9799-4853-aefd-840b38bd31b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseFacilitiesSchlierenMember_af9dba38-0894-4aee-bf1e-fdd21e765f9e" xlink:href="moln-20221231.xsd#moln_LeaseFacilitiesSchlierenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_4126be79-9799-4853-aefd-840b38bd31b1" xlink:to="loc_moln_LeaseFacilitiesSchlierenMember_af9dba38-0894-4aee-bf1e-fdd21e765f9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofMovementofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" xlink:type="extended" id="i155a9431f37e4edf9690007769d9e06d_LeasesDisclosureofMovementofLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_c34873f4-a728-49a0-8854-78d3f295e004" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_LeaseLiabilities_c34873f4-a728-49a0-8854-78d3f295e004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseThroughNewLeasesOperatingLeases_09600449-0933-4d8b-8ef3-45286059a93d" xlink:href="moln-20221231.xsd#moln_IncreaseThroughNewLeasesOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_moln_IncreaseThroughNewLeasesOperatingLeases_09600449-0933-4d8b-8ef3-45286059a93d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_a5710da6-8d9e-4a95-9b14-d27db69f5b4d" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_a5710da6-8d9e-4a95-9b14-d27db69f5b4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_ca80e238-88e6-40b2-87b4-13b6c59e9efb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_ca80e238-88e6-40b2-87b4-13b6c59e9efb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_fa659451-2d31-4f4d-a309-e0dc1c17531a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_CashOutflowForLeases_fa659451-2d31-4f4d-a309-e0dc1c17531a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_582cd4a1-407d-41c7-9621-447ecdd1b8c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6dd9ea4b-6e28-4977-bd6d-35d02ea91f76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_6dd9ea4b-6e28-4977-bd6d-35d02ea91f76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_ccafdbb9-6efb-4a37-8aca-75c80dea23f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_ccafdbb9-6efb-4a37-8aca-75c80dea23f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_07745a70-703d-4561-823b-bc2528b8cacb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_e9650bc6-39b4-43a0-9da4-e68a8eba5482" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_e9650bc6-39b4-43a0-9da4-e68a8eba5482" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_e9650bc6-39b4-43a0-9da4-e68a8eba5482" xlink:to="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:to="loc_ifrs-full_TypesOfContractsMember_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_df1f559d-cc3a-4e63-8304-ff7c7d151941" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:to="loc_ifrs-full_TypesOfContractsMember_df1f559d-cc3a-4e63-8304-ff7c7d151941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseFacilitiesSchlierenMember_2c56018f-6e0b-48e5-99e5-5c7deb5e50d7" xlink:href="moln-20221231.xsd#moln_LeaseFacilitiesSchlierenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_df1f559d-cc3a-4e63-8304-ff7c7d151941" xlink:to="loc_moln_LeaseFacilitiesSchlierenMember_2c56018f-6e0b-48e5-99e5-5c7deb5e50d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" xlink:type="extended" id="icadfa94616564da987303aa057206ec4_LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_3bdafda0-ade9-4822-b838-e07749900e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_3bdafda0-ade9-4822-b838-e07749900e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_6497de85-7aeb-4a19-bfb8-585b0ab05901" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:to="loc_ifrs-full_LeaseLiabilities_6497de85-7aeb-4a19-bfb8-585b0ab05901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_f6b5f9d3-abbe-494d-8b2e-64488418979d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_f6b5f9d3-abbe-494d-8b2e-64488418979d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_f6b5f9d3-abbe-494d-8b2e-64488418979d" xlink:to="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_fdfc734b-8ec3-471c-ac22-69c24de1213c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_fdfc734b-8ec3-471c-ac22-69c24de1213c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_4ad93165-821c-4a96-bc89-16c08c4b2be2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_4ad93165-821c-4a96-bc89-16c08c4b2be2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d608e628-edde-4cae-8c52-e2ee9ce3156b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d608e628-edde-4cae-8c52-e2ee9ce3156b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_9132604f-f40c-4a3e-9de1-a184770e4b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_9132604f-f40c-4a3e-9de1-a184770e4b26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_9688f05e-5738-43b3-a708-25d01011bde8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_9688f05e-5738-43b3-a708-25d01011bde8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails" xlink:type="extended" id="i09ab3fa1645c4659b92a003b9a0b60a1_FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_eb9c328c-9365-480c-8861-f317dfc9a3ad" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_eb9c328c-9365-480c-8861-f317dfc9a3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_cf04efd2-ae01-48a9-a7be-ad84cb37be13" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_cf04efd2-ae01-48a9-a7be-ad84cb37be13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_ee5727ea-e7e4-468e-927e-7fde544e2a9f" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_ee5727ea-e7e4-468e-927e-7fde544e2a9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_f9173e21-48f5-43b3-9a0d-f9d56b511bfd" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_f9173e21-48f5-43b3-9a0d-f9d56b511bfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:to="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b5346d11-7f6d-44f0-a014-8133aba7f9f3_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:to="loc_currency_AllCurrenciesDomain_b5346d11-7f6d-44f0-a014-8133aba7f9f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:to="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_37da1068-ab95-4359-9956-b1a788e29840" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:to="loc_currency_USD_37da1068-ab95-4359-9956-b1a788e29840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_8cd7a2eb-1558-4cc8-9347-76032f56d4ff" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:to="loc_currency_EUR_8cd7a2eb-1558-4cc8-9347-76032f56d4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:to="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_13e8d84b-743a-4d16-8edb-9f6a905b612f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:to="loc_ifrs-full_TypesOfRisksMember_13e8d84b-743a-4d16-8edb-9f6a905b612f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_04172908-e13c-46f8-a768-c2999ed2401f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:to="loc_ifrs-full_TypesOfRisksMember_04172908-e13c-46f8-a768-c2999ed2401f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_80558b2c-cf95-460a-ae47-d33cf1d24bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_04172908-e13c-46f8-a768-c2999ed2401f" xlink:to="loc_ifrs-full_CurrencyRiskMember_80558b2c-cf95-460a-ae47-d33cf1d24bfc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" xlink:type="extended" id="i14a379190dd14987aeac3f9c62f113d9_FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_0be3de7b-7112-4661-aebf-e112789b165f" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_0be3de7b-7112-4661-aebf-e112789b165f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_a790a935-5e90-4a71-b6c7-b325478b7bfd" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_a790a935-5e90-4a71-b6c7-b325478b7bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_6c1bd48a-b763-4cbf-b922-836ec5a51c55" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_6c1bd48a-b763-4cbf-b922-836ec5a51c55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_cf1ac171-7704-408b-ab9f-cc469ed6bae2" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_cf1ac171-7704-408b-ab9f-cc469ed6bae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:to="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:to="loc_currency_AllCurrenciesDomain_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:to="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_9624de93-de29-4f4b-a2e5-912191ff2e38" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:to="loc_currency_CHF_9624de93-de29-4f4b-a2e5-912191ff2e38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_698ff030-1bf7-46ab-a796-7389cef33638" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:to="loc_currency_USD_698ff030-1bf7-46ab-a796-7389cef33638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_2c116330-c019-4f19-9087-0132f8e5b09a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:to="loc_currency_EUR_2c116330-c019-4f19-9087-0132f8e5b09a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:to="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_28c33e67-b36d-46c2-8f33-8cf198379d3e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:to="loc_ifrs-full_TypesOfRisksMember_28c33e67-b36d-46c2-8f33-8cf198379d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_3fc65e95-5f06-48e3-b6b1-b85ca90a83b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:to="loc_ifrs-full_TypesOfRisksMember_3fc65e95-5f06-48e3-b6b1-b85ca90a83b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_54140367-61a7-4501-a4db-863f9ab134e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_3fc65e95-5f06-48e3-b6b1-b85ca90a83b9" xlink:to="loc_ifrs-full_InterestRateRiskMember_54140367-61a7-4501-a4db-863f9ab134e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"/>
  <link:definitionLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" xlink:type="extended" id="i4724b699f5f54a05b991e769ffd19c40_FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_2da2c099-3101-466a-867a-a42e4d5711ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_354a4d53-fa8d-40eb-96c3-c895a1ae5c1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_2da2c099-3101-466a-867a-a42e4d5711ce" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_354a4d53-fa8d-40eb-96c3-c895a1ae5c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_2da2c099-3101-466a-867a-a42e4d5711ce" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_6c34c223-5d65-4039-af40-74b7af03bd84_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_6c34c223-5d65-4039-af40-74b7af03bd84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashAndCashEquivalentsMember_d7a287b7-3e75-42bd-b79f-e64a625d7dc1" xlink:href="moln-20221231.xsd#moln_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_moln_CashAndCashEquivalentsMember_d7a287b7-3e75-42bd-b79f-e64a625d7dc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_f72f2dd5-3d06-41fc-83ca-2c8969aa4ea8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_ifrs-full_TradeReceivablesMember_f72f2dd5-3d06-41fc-83ca-2c8969aa4ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedIncomeMember_ddf11d19-7d96-4e93-91a1-d83486789c36" xlink:href="moln-20221231.xsd#moln_AccruedIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_moln_AccruedIncomeMember_ddf11d19-7d96-4e93-91a1-d83486789c36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShortTermTimeDepositsMember_f7f3cc93-6e8f-42ad-a7a1-215be9bdd961" xlink:href="moln-20221231.xsd#moln_ShortTermTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_moln_ShortTermTimeDepositsMember_f7f3cc93-6e8f-42ad-a7a1-215be9bdd961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_184033b2-30eb-4c22-aa4e-434ca0695ab8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:to="loc_ifrs-full_TypesOfRisksMember_184033b2-30eb-4c22-aa4e-434ca0695ab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_97d00aac-f045-4ec9-8db9-50aa81dbc3f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:to="loc_ifrs-full_TypesOfRisksMember_97d00aac-f045-4ec9-8db9-50aa81dbc3f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditRiskMember_bbb334a2-1f91-449e-a0ea-7faacfed4ab0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_97d00aac-f045-4ec9-8db9-50aa81dbc3f2" xlink:to="loc_ifrs-full_CreditRiskMember_bbb334a2-1f91-449e-a0ea-7faacfed4ab0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>moln-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5bc598d-29c0-45ac-9809-ee4bc6e3f0aa,g:d67c3c2e-5cb8-4330-bb94-e6e901fa056b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_moln_IndustryBenchmarkDiscountRatesPeriod_cfaaf6d2-87ba-4e0d-936f-d2167dd8e3a9_terseLabel_en-US" xlink:label="lab_moln_IndustryBenchmarkDiscountRatesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rates based on industry benchmark, period</link:label>
    <link:label id="lab_moln_IndustryBenchmarkDiscountRatesPeriod_label_en-US" xlink:label="lab_moln_IndustryBenchmarkDiscountRatesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Benchmark, Discount Rates, Period</link:label>
    <link:label id="lab_moln_IndustryBenchmarkDiscountRatesPeriod_documentation_en-US" xlink:label="lab_moln_IndustryBenchmarkDiscountRatesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Benchmark, Discount Rates, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndustryBenchmarkDiscountRatesPeriod" xlink:href="moln-20221231.xsd#moln_IndustryBenchmarkDiscountRatesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IndustryBenchmarkDiscountRatesPeriod" xlink:to="lab_moln_IndustryBenchmarkDiscountRatesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_1bb20c8d-8103-4383-aad2-0e195aeb7e36_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f7364186-4f33-4711-b624-756799372b53_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems_8551ccf4-7f8b-4b84-86c6-ae7b4b7c1381_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherReceivablesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:to="lab_moln_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity_9b4572f6-2956-4aac-993f-8aab6a468f3f_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in relation to June 2021 IPO</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity_label_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Relation To Initial Public Offering, Equity</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity_documentation_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Relation To Initial Public Offering, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" xlink:to="lab_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_47a6e73b-7ad8-4ab6-a438-827c90ac923a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsAtFairValue_9263e40f-7708-43e5-8617-e694aaac65de_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at December 31</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsAtFairValue_1e586d5f-9a15-449f-9fa4-57f6f9ecd918_totalLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total plan assets at fair value at December 31</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue" xlink:to="lab_ifrs-full_PlanAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_53592257-57f6-42e0-b699-a24801a55370_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GBP</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c06f7934-9600-4b36-94dd-f152fe2cbced_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fb77e42d-c391-45aa-907c-2d7d31168e1c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_aa4ded0f-07c3-4361-a664-3b69ec364267_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NovartisMember_acd25f25-7d3e-439f-81d4-28bf2e030909_terseLabel_en-US" xlink:label="lab_moln_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_moln_NovartisMember_label_en-US" xlink:label="lab_moln_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_moln_NovartisMember_documentation_en-US" xlink:label="lab_moln_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NovartisMember" xlink:to="lab_moln_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RoyaltyPayable_d811b1fd-ba1b-41e0-897b-f27c3977da3c_terseLabel_en-US" xlink:label="lab_moln_RoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, payable</link:label>
    <link:label id="lab_moln_RoyaltyPayable_label_en-US" xlink:label="lab_moln_RoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Payable</link:label>
    <link:label id="lab_moln_RoyaltyPayable_documentation_en-US" xlink:label="lab_moln_RoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltyPayable" xlink:href="moln-20221231.xsd#moln_RoyaltyPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RoyaltyPayable" xlink:to="lab_moln_RoyaltyPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasuryShares_7cc20943-e825-4e4c-83e8-5fca5ef5b9d2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury share reserve</link:label>
    <link:label id="lab_ifrs-full_TreasuryShares_label_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasuryShares" xlink:to="lab_ifrs-full_TreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpiringIn2028Member_5a3e88d8-5622-46cb-9b40-ce8db038847f_terseLabel_en-US" xlink:label="lab_moln_ExpiringIn2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_moln_ExpiringIn2028Member_label_en-US" xlink:label="lab_moln_ExpiringIn2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2028 [Member]</link:label>
    <link:label id="lab_moln_ExpiringIn2028Member_documentation_en-US" xlink:label="lab_moln_ExpiringIn2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2028Member" xlink:href="moln-20221231.xsd#moln_ExpiringIn2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpiringIn2028Member" xlink:to="lab_moln_ExpiringIn2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_d5b8578e-1b58-4b3f-a151-99f672505e92_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_15337b6f-2529-4ce2-9976-17a2eede1ebf_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_a02eb2d4-6110-4add-9ec2-584b644c7369_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" xlink:to="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_d37e5816-1fdb-4eb3-8883-2152aa704c4c_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Contract Liability [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Contract Liability [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Contract Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_d9cb3a9f-42c3-472f-9c99-a99782e51b92_terseLabel_en-US" xlink:label="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash effective pension costs</link:label>
    <link:label id="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_label_en-US" xlink:label="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefit Expense, Non-Cash Effective Pension Cost</link:label>
    <link:label id="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_documentation_en-US" xlink:label="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefit Expense, Non-Cash Effective Pension Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" xlink:href="moln-20221231.xsd#moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" xlink:to="lab_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_3fd8d363-c137-4713-a9c8-9e059669af30_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments forfeited, performance adjustment (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:to="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_70af00d6-f63d-4047-b966-3e19beb2ff34_terseLabel_en-US" xlink:label="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in CHF per share)</link:label>
    <link:label id="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="lab_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_25af62a3-8149-46df-98e5-20a12d1c5111_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_ca02a879-7d0c-49b3-a36a-3f4f7ebe43a2_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_7f65a897-3271-48d6-a38d-667ea5f1a5e0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_56cc22a3-47ba-4428-aa56-37d3d0c48ec1_terseLabel_en-US" xlink:label="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees that participated</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_label_en-US" xlink:label="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number Of Employees That Participated</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_documentation_en-US" xlink:label="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number Of Employees That Participated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" xlink:to="lab_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_987f5554-a281-4610-b256-641b557309a2_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative losses</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_73bedf77-7a67-4ffe-b04f-0fb136b91b08_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited, performance adjustment (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:to="lab_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems_2f928d6a-0e02-4dde-b40c-5fe8a4337a66_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Payables [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Payables [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherPayablesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems" xlink:to="lab_moln_DisclosureOfTradeAndOtherPayablesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_556e0c20-1c08-4dfc-b2bc-627e99ce5a88_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSU and RSU forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock_9c05c5d9-c852-4a1b-be3f-1c6f8705c421_terseLabel_en-US" xlink:label="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation Policy [Policy Text Block]</link:label>
    <link:label id="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" xlink:href="moln-20221231.xsd#moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" xlink:to="lab_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4ad091b4-23f2-461a-bb2a-3f89f9bdce8a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_f9dc3a22-ce4d-4167-a4f5-a240bb7e5557_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Financial Assets at Amortized Cost</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_3c75c6f2-acdc-40e0-9485-ae6219ccce5a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative cost (excl. cost for managing plan assets)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_68efb277-a4ac-4310-88b0-171a7a66e01f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_ca568797-762d-4707-8b26-a489bcb32f3a_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_FinancialRiskManagementAbstract_9577863f-d522-402f-8b1f-09faf29c1c74_terseLabel_en-US" xlink:label="lab_moln_FinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Risk Management [Abstract]</link:label>
    <link:label id="lab_moln_FinancialRiskManagementAbstract_label_en-US" xlink:label="lab_moln_FinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Risk Management [Abstract]</link:label>
    <link:label id="lab_moln_FinancialRiskManagementAbstract_documentation_en-US" xlink:label="lab_moln_FinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Risk Management [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_FinancialRiskManagementAbstract" xlink:to="lab_moln_FinancialRiskManagementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_TaxLossCarryforwardsExpirationPeriod_b3ccb57e-9f58-43d7-855d-f37e12ea0a82_terseLabel_en-US" xlink:label="lab_moln_TaxLossCarryforwardsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards, expiration period</link:label>
    <link:label id="lab_moln_TaxLossCarryforwardsExpirationPeriod_label_en-US" xlink:label="lab_moln_TaxLossCarryforwardsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Loss Carryforwards, Expiration Period</link:label>
    <link:label id="lab_moln_TaxLossCarryforwardsExpirationPeriod_documentation_en-US" xlink:label="lab_moln_TaxLossCarryforwardsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Loss Carryforwards, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwardsExpirationPeriod" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwardsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_TaxLossCarryforwardsExpirationPeriod" xlink:to="lab_moln_TaxLossCarryforwardsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_fd99469d-912e-4d8c-a4bf-7c66862046c8_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in other current assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_3ff099ca-4b16-4d7c-bacc-407564a38f6a_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation on right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_442fba5a-3dfa-4a8d-aa7a-dc3ce7060195_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_1ff3b027-7ccc-4df0-95f3-0ed2fe62e4bf_terseLabel_en-US" xlink:label="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions, possible increase (decrease) in longevity for most of the age categories</link:label>
    <link:label id="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_label_en-US" xlink:label="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories</link:label>
    <link:label id="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_documentation_en-US" xlink:label="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" xlink:to="lab_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_f41b2011-8cdd-49d6-b77a-556afebb6838_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net finance result</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExercisePriceRangeThreeMember_26561d90-0f7e-4c6e-b26d-cb69cd0a1c5c_terseLabel_en-US" xlink:label="lab_moln_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, range three</link:label>
    <link:label id="lab_moln_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_moln_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_moln_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_moln_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeThreeMember" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExercisePriceRangeThreeMember" xlink:to="lab_moln_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfOperatingSegments_f25969c4-7714-4769-a294-c49bafa50846_terseLabel_en-US" xlink:label="lab_moln_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_moln_NumberOfOperatingSegments_label_en-US" xlink:label="lab_moln_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Segments</link:label>
    <link:label id="lab_moln_NumberOfOperatingSegments_documentation_en-US" xlink:label="lab_moln_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOperatingSegments" xlink:href="moln-20221231.xsd#moln_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfOperatingSegments" xlink:to="lab_moln_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_8ae5be84-3a9e-4f97-920c-405b9eafef7c_negatedTerseLabel_en-US" xlink:label="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative interest on financial assets held at amortized costs</link:label>
    <link:label id="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_label_en-US" xlink:label="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative Interest Revenue For Financial Assets Measured At Amortised Cost</link:label>
    <link:label id="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_documentation_en-US" xlink:label="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative Interest Revenue For Financial Assets Measured At Amortised Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" xlink:href="moln-20221231.xsd#moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" xlink:to="lab_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_a8750391-8bba-4c15-b857-f068cdbf0314_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_e3e19fd3-435f-47ac-9f76-6ccf3a5aa253_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_58811bd9-7189-4878-bf21-278234a9202b_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock_a03bd030-8a1a-4880-87c8-1c853c7c5569_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and license fees</link:label>
    <link:label id="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Royalties And License Fees [Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Royalties And License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" xlink:to="lab_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems_dc8ce665-2b8d-4b5b-9dd7-2b64b3787a6e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_c2cd9ad9-fe84-4b58-9109-634fea4f0053_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AmgenIncMember_c7bf0d9e-5ec3-498f-abfe-0b5d905d30fc_terseLabel_en-US" xlink:label="lab_moln_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_moln_AmgenIncMember_label_en-US" xlink:label="lab_moln_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc [Member]</link:label>
    <link:label id="lab_moln_AmgenIncMember_documentation_en-US" xlink:label="lab_moln_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmgenIncMember" xlink:href="moln-20221231.xsd#moln_AmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AmgenIncMember" xlink:to="lab_moln_AmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_ef695a63-bbbb-4fd4-99b7-e2d318574b3f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_c8054742-3579-4d63-8d77-c55d33a4e2da_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_8c661f84-1b03-4d8a-9b2c-cec324ee7080_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Financial Liabilities at Amortized Cost</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ef332e8d-c41f-4960-824d-b203d26272e4_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_2139d7c3-0c9c-4f41-9617-0dd204e1f456_terseLabel_en-US" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past service cost</link:label>
    <link:label id="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from past service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_a737ee20-4e02-44c0-b834-bde0df5197ac_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_50eb0d8a-351b-4298-82ed-3735ce6e7a9a_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_e4dd3fe1-466f-4128-b7c5-0083c74ba89a_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_FinancialInstrumentsAbstract_880e3a47-b02a-49af-ba64-806386d39e60_terseLabel_en-US" xlink:label="lab_moln_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_moln_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_moln_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_moln_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_moln_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialInstrumentsAbstract" xlink:href="moln-20221231.xsd#moln_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_FinancialInstrumentsAbstract" xlink:to="lab_moln_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_b49f310a-4d4a-4496-acfc-55f173ee08c2_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ResearchAndDevelopmentExpenseMember_a6c8a729-8e5f-4147-86cc-f7b4c4fc05ea_terseLabel_en-US" xlink:label="lab_moln_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_moln_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_moln_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense [Member]</link:label>
    <link:label id="lab_moln_ResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_moln_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ResearchAndDevelopmentExpenseMember" xlink:to="lab_moln_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_64a0ecf7-c195-48a5-899d-6fd4fba7d868_terseLabel_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_e679947d-c14c-4459-bd99-573354c5d677_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of new shares, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_8f9181a8-7a00-4fa6-95b0-424362b5be52_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSU and RSU exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_e3d016d3-8b19-4ae7-b6a7-254790c0b41e_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_UniversityOfZurichMember_ef683885-dc5d-4aee-9f5e-3e8068952ccb_terseLabel_en-US" xlink:label="lab_moln_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_moln_UniversityOfZurichMember_label_en-US" xlink:label="lab_moln_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Zurich [Member]</link:label>
    <link:label id="lab_moln_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_moln_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UniversityOfZurichMember" xlink:href="moln-20221231.xsd#moln_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_UniversityOfZurichMember" xlink:to="lab_moln_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5fe4ca6a-8e64-4bb2-9cd2-a4342fcdde79_totalLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability at December 31</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7bc08e0b-ce11-44a5-86eb-1bed3195d4a5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability at January 1</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_9f954c26-54df-47cc-a357-4dcac7056d11_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability at December 31</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5a75dac3-9a5f-4388-93b7-df66022c6e17_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at January 1</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c99aa0c0-1f30-41f6-a31b-7f9476976d89_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at December 31</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5d3fffdd-ad1a-4b98-ab71-2169ac62e1fa_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_2b0bda62-ee21-4050-8731-d1261092d0e3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_b65ba8a8-72b1-48f2-af1a-fa673c3f3434_negatedLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by plan participants</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_d946246e-9756-44d9-a601-dcd36dd2aad5_terseLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by plan participants</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesIssuedTreasurySharesEquity_876d6325-3fcd-4fe5-b379-d2faee803641_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesIssuedTreasurySharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in relation to creation of treasury shares in August 2022</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedTreasurySharesEquity_label_en-US" xlink:label="lab_moln_NumberOfSharesIssuedTreasurySharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued, Treasury Shares, Equity</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedTreasurySharesEquity_documentation_en-US" xlink:label="lab_moln_NumberOfSharesIssuedTreasurySharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued, Treasury Shares, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedTreasurySharesEquity" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedTreasurySharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesIssuedTreasurySharesEquity" xlink:to="lab_moln_NumberOfSharesIssuedTreasurySharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_63b5fd94-c23c-417a-8887-a3054e014fe0_terseLabel_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_label_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_documentation_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:to="lab_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_47757e62-5a57-4203-bd3c-8f9c10bbe746_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of rights granted (in CHF per shares)</link:label>
    <link:label id="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_b18002ca-0358-4a79-b4ef-7d21c6518c1c_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_ed08a7b3-ae86-4ee4-bb2b-d3c1b730a8f8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security costs</link:label>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_label_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LaterThanFourYearsMember_216bf53d-d556-4cf5-a923-822c34c449e1_terseLabel_en-US" xlink:label="lab_moln_LaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected revenue recognition in year five and later after balance sheet date</link:label>
    <link:label id="lab_moln_LaterThanFourYearsMember_label_en-US" xlink:label="lab_moln_LaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later Than Four Years [Member]</link:label>
    <link:label id="lab_moln_LaterThanFourYearsMember_documentation_en-US" xlink:label="lab_moln_LaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later Than Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LaterThanFourYearsMember" xlink:href="moln-20221231.xsd#moln_LaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LaterThanFourYearsMember" xlink:to="lab_moln_LaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_8543e235-3323-4e9a-84b6-9b8f8750b165_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LaboratoryEquipmentMember_416d5182-8a7b-47f8-90b0-bbe3b921a283_terseLabel_en-US" xlink:label="lab_moln_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_moln_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_moln_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_moln_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_moln_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LaboratoryEquipmentMember" xlink:href="moln-20221231.xsd#moln_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LaboratoryEquipmentMember" xlink:to="lab_moln_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_6e6f1aff-3f0a-4ef3-acb7-408cb793aa76_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_15cb97da-8f54-4afb-8c08-dbe555cbc689_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of notes and other explanatory information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_fb5514ba-5a8d-4e6c-a91c-e5fb63481947_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options expired (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_169f35de-9aa2-4ee7-b97b-ae6bf30fbbc4_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsMember_a8419128-bd60-4c29-bb96-f858d6f73bca_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsMember" xlink:to="lab_ifrs-full_TypesOfContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_2cf7642b-8c0f-4742-9de3-e7141d6ea37c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in contract liability</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_35e75d59-43eb-4f33-80b7-d1793a72f847_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in employee benefits</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_dc09263f-a2df-4930-8013-bdad8c10d4f3_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Useful Lives of Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_be4fa58a-92f9-4c4f-b075-03c4ca100bcd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Reconciliation of Changes in Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_1147bc88-74b0-4f2a-9e1a-7d8efc339833_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_label_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_f99fc482-78c6-4975-9f29-060bf99afe5d_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">thereof net interest expense on the net defined benefit liability</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense (income), defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:to="lab_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_d6def118-f576-4d6e-8b3d-45c4859504bf_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_78597472-0355-474a-a74f-bd42a26830db_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation / transactions</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_48fe7ef4-a6f6-4949-a7a3-ea6f9edf6325_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_37e3207d-40c6-4a00-a946-5ce838d84c64_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_39f3562a-a325-413d-b0f3-d7375070b942_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_e90fbd44-6dc7-473f-832e-7f3eb66064d9_terseLabel_en-US" xlink:label="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, NBI</link:label>
    <link:label id="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, NBI, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, NBI, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" xlink:to="lab_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_103ac95e-d28e-400b-bf4a-5a676e1a371b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IncreaseDecreaseInAuthorizedShareCapital_a02b93d1-e74e-4730-8150-536d78259c34_terseLabel_en-US" xlink:label="lab_moln_IncreaseDecreaseInAuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in authorized share capital</link:label>
    <link:label id="lab_moln_IncreaseDecreaseInAuthorizedShareCapital_label_en-US" xlink:label="lab_moln_IncreaseDecreaseInAuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Authorized Share Capital</link:label>
    <link:label id="lab_moln_IncreaseDecreaseInAuthorizedShareCapital_documentation_en-US" xlink:label="lab_moln_IncreaseDecreaseInAuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Authorized Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseInAuthorizedShareCapital" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseInAuthorizedShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IncreaseDecreaseInAuthorizedShareCapital" xlink:to="lab_moln_IncreaseDecreaseInAuthorizedShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f72d3bdb-4cf4-407a-a6c6-c4825ff50fa1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a4cd3ffc-46cb-4c32-96e9-01a29f612905_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_f5c215e2-be7c-44a1-815a-546c43f7caa8_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_407abfe0-f067-440e-a409-36154616a0ca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_880e47d9-d041-4b4c-a8ed-584657f12072_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term time deposits</link:label>
    <link:label id="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7d91c379-28ba-4b5a-81fd-fdf4c4507142_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_CurrentAccruedProjectCostsAndRoyalties_5f5660df-6e9c-418e-a931-bb0e19198b26_terseLabel_en-US" xlink:label="lab_moln_CurrentAccruedProjectCostsAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued project costs and royalties</link:label>
    <link:label id="lab_moln_CurrentAccruedProjectCostsAndRoyalties_label_en-US" xlink:label="lab_moln_CurrentAccruedProjectCostsAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued Project Costs And Royalties</link:label>
    <link:label id="lab_moln_CurrentAccruedProjectCostsAndRoyalties_documentation_en-US" xlink:label="lab_moln_CurrentAccruedProjectCostsAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued Project Costs And Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CurrentAccruedProjectCostsAndRoyalties" xlink:href="moln-20221231.xsd#moln_CurrentAccruedProjectCostsAndRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_CurrentAccruedProjectCostsAndRoyalties" xlink:to="lab_moln_CurrentAccruedProjectCostsAndRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_aa3ce50f-ea08-48ef-a88e-ef0ccf683604_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Contract Liability [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Contract Liability [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Contract Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VSAOMember_d8bf1577-5898-4e5a-937b-534b2a894ed8_terseLabel_en-US" xlink:label="lab_moln_VSAOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSAO</link:label>
    <link:label id="lab_moln_VSAOMember_label_en-US" xlink:label="lab_moln_VSAOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSAO [Member]</link:label>
    <link:label id="lab_moln_VSAOMember_documentation_en-US" xlink:label="lab_moln_VSAOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSAO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VSAOMember" xlink:href="moln-20221231.xsd#moln_VSAOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VSAOMember" xlink:to="lab_moln_VSAOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_c6304406-afe9-43c1-a1e2-7d47742d9628_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue that was included in contract liability balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_label_en-US" xlink:label="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue that was included in contract liability balance at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_dc59c7b1-0630-406b-aa83-e2b7bd87f500_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f6d65b52-0f6b-4580-b1b1-f765cb02b007_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_32c3eee9-d59d-4c82-8151-9d26d6632f3b_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security</link:label>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AverageNumberOfFullTimeEquivalentEmployees_18beeba5-3eb6-4349-a0f6-c6efb0fb5bd9_terseLabel_en-US" xlink:label="lab_moln_AverageNumberOfFullTimeEquivalentEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of full-time equivalents</link:label>
    <link:label id="lab_moln_AverageNumberOfFullTimeEquivalentEmployees_label_en-US" xlink:label="lab_moln_AverageNumberOfFullTimeEquivalentEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Number Of Full-Time Equivalent Employees</link:label>
    <link:label id="lab_moln_AverageNumberOfFullTimeEquivalentEmployees_documentation_en-US" xlink:label="lab_moln_AverageNumberOfFullTimeEquivalentEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Number Of Full-Time Equivalent Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AverageNumberOfFullTimeEquivalentEmployees" xlink:href="moln-20221231.xsd#moln_AverageNumberOfFullTimeEquivalentEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AverageNumberOfFullTimeEquivalentEmployees" xlink:to="lab_moln_AverageNumberOfFullTimeEquivalentEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_99c0c2be-4248-42ee-b089-0175360b918a_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expenses on defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_52756a7a-203f-411e-9926-d7af1f838b3c_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on plan assets</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_b612b92a-545a-4b93-97b8-93ee3679d3e6_terseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e237e3ef-823c-4114-bfc4-285733c3ac44_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_bf2585e6-d67b-4459-b5a1-52dc58f257bb_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contractual cashflows</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_MolecularPartnersIncMember_d1f8c7ce-6811-4f1d-adaf-998f0b48a595_terseLabel_en-US" xlink:label="lab_moln_MolecularPartnersIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Partners Inc.</link:label>
    <link:label id="lab_moln_MolecularPartnersIncMember_label_en-US" xlink:label="lab_moln_MolecularPartnersIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Partners Inc. [Member]</link:label>
    <link:label id="lab_moln_MolecularPartnersIncMember_documentation_en-US" xlink:label="lab_moln_MolecularPartnersIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Partners Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MolecularPartnersIncMember" xlink:href="moln-20221231.xsd#moln_MolecularPartnersIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_MolecularPartnersIncMember" xlink:to="lab_moln_MolecularPartnersIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_a77f1d07-90cc-4fb7-b797-bfecf175f76d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accrued expenses and other liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_cc17d92c-abc5-43c5-8427-8e026b480c0a_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and other income</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks_38c85144-a85c-48ea-b20f-a719b22b6b47_terseLabel_en-US" xlink:label="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of different Swiss banks</link:label>
    <link:label id="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks_label_en-US" xlink:label="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balances Investments, Number Of Different Swiss Banks</link:label>
    <link:label id="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks_documentation_en-US" xlink:label="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balances Investments, Number Of Different Swiss Banks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" xlink:href="moln-20221231.xsd#moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" xlink:to="lab_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_4ff83568-cd5e-4e17-8479-5be3ecb445ff_terseLabel_en-US" xlink:label="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
    <link:label id="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</link:label>
    <link:label id="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_documentation_en-US" xlink:label="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="moln-20221231.xsd#moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_f437dfe8-f3b9-4a56-9e40-604f66a0cbc6_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_301d8387-b97c-4b35-836e-d889515aa750_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and accrued income</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepayments and current accrued income other than current contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:to="lab_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_fd02bb8a-cd24-4c16-bdf4-2b548c1f46db_negatedTerseLabel_en-US" xlink:label="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange (loss) gain on working capital positions</link:label>
    <link:label id="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_label_en-US" xlink:label="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment For Exchange Gains (Losses) On Working Capital Positions</link:label>
    <link:label id="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_documentation_en-US" xlink:label="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment For Exchange Gains (Losses) On Working Capital Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" xlink:href="moln-20221231.xsd#moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" xlink:to="lab_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_8d108ead-04d7-4e02-9660-4d2c73c58640_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected revenue recognition in year two after balance sheet date</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_886f8dac-a6be-463d-b046-4aa4fb9119e1_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 1 and 2 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation_a25fc6d3-7b30-472e-9735-349d57b21f77_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized, employee participation (in shares)</link:label>
    <link:label id="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation_label_en-US" xlink:label="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Authorized, Employee Participation</link:label>
    <link:label id="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation_documentation_en-US" xlink:label="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Authorized, Employee Participation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesAuthorizedEmployeeParticipation" xlink:href="moln-20221231.xsd#moln_NumberOfSharesAuthorizedEmployeeParticipation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesAuthorizedEmployeeParticipation" xlink:to="lab_moln_NumberOfSharesAuthorizedEmployeeParticipation" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ESOP2009AndESOP2014Member_b47aa935-e758-47fe-93a2-dc5e1f8b3f19_terseLabel_en-US" xlink:label="lab_moln_ESOP2009AndESOP2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESOP 2009 and ESOP 2014</link:label>
    <link:label id="lab_moln_ESOP2009AndESOP2014Member_label_en-US" xlink:label="lab_moln_ESOP2009AndESOP2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESOP 2009 And ESOP 2014 [Member]</link:label>
    <link:label id="lab_moln_ESOP2009AndESOP2014Member_documentation_en-US" xlink:label="lab_moln_ESOP2009AndESOP2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESOP 2009 And ESOP 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ESOP2009AndESOP2014Member" xlink:href="moln-20221231.xsd#moln_ESOP2009AndESOP2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ESOP2009AndESOP2014Member" xlink:to="lab_moln_ESOP2009AndESOP2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_f1d5457d-5663-4d88-bf92-421124021a39_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation charge for the year</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5298dc24-0dcf-4475-b8cd-d342a4f39f68_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_b4c728bb-622b-4230-8b1f-444765be47e5_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital / Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_b92fd969-6a76-4d14-b06d-d4554321c9d1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4ba0e33a-7657-459f-9522-d4bed1cb45bc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_5af938d8-4723-4bb4-aa27-d8cadf39faa5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_85283bf3-ccd0-4728-a6e6-d2b312029bf1_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes And Deferred Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_0e6a70dc-599e-4d6e-950f-cff0519244b5_negatedLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by the employer</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1e766aab-f3ed-43e7-8af9-bd33a031dd5c_terseLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by the employer</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock_64407312-f46f-4b23-98f1-40a6fd31735f_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel expenses</link:label>
    <link:label id="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Employee Benefits And Share-Based Payments Arrangements [Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Employee Benefits And Share-Based Payments Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" xlink:to="lab_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_c6a90cd8-770f-43ea-9ad7-a52d17e03d30_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from (used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember_6b461018-14af-4e91-9bd2-1fe815e6f896_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of life expectancy</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of life expectancy after retirement [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LeaseCostRecognisedInProfitOrLoss_d1d23a93-4bd5-4335-9b8a-4b3fe0ae26f8_totalLabel_en-US" xlink:label="lab_moln_LeaseCostRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount recognized in profit or loss</link:label>
    <link:label id="lab_moln_LeaseCostRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_moln_LeaseCostRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost Recognised In Profit Or Loss</link:label>
    <link:label id="lab_moln_LeaseCostRecognisedInProfitOrLoss_documentation_en-US" xlink:label="lab_moln_LeaseCostRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost Recognised In Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseCostRecognisedInProfitOrLoss" xlink:href="moln-20221231.xsd#moln_LeaseCostRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LeaseCostRecognisedInProfitOrLoss" xlink:to="lab_moln_LeaseCostRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_ce301062-3280-4755-9c65-9702c2d759b1_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_SignificantTransactionsMember_2cbfc726-163a-4e02-9ef1-536f1f7d0f1c_terseLabel_en-US" xlink:label="lab_moln_SignificantTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant transactions</link:label>
    <link:label id="lab_moln_SignificantTransactionsMember_label_en-US" xlink:label="lab_moln_SignificantTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Transactions [Member]</link:label>
    <link:label id="lab_moln_SignificantTransactionsMember_documentation_en-US" xlink:label="lab_moln_SignificantTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SignificantTransactionsMember" xlink:href="moln-20221231.xsd#moln_SignificantTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_SignificantTransactionsMember" xlink:to="lab_moln_SignificantTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_4e31ccbd-f965-4485-91d9-b6681bfd4730_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_9ebad7cf-55a4-4b94-bfde-80f75e00f8ee_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transaction price allocated to remaining performance obligations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transaction price allocated to remaining performance obligations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_25f839a7-15c2-48f4-b44a-6dffe0111df4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_659fb0dd-a4d9-40fc-9049-264256153e4d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical accounting estimates and judgments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_f5928afa-88b0-4e40-8fbf-576dff61271d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_d56bb167-24c6-4061-995b-de771d7abf69_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement_5b42336f-19f3-492e-9ede-d0c0643da128_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments exercised (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:to="lab_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember_f6254aa1-2a94-415d-8922-3c1228178c7a_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [member]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IncreaseThroughNewLeasesOperatingLeases_546424b8-daf0-4740-bcbf-679b62d5371c_terseLabel_en-US" xlink:label="lab_moln_IncreaseThroughNewLeasesOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions / new leases</link:label>
    <link:label id="lab_moln_IncreaseThroughNewLeasesOperatingLeases_label_en-US" xlink:label="lab_moln_IncreaseThroughNewLeasesOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through New Leases, Operating Leases</link:label>
    <link:label id="lab_moln_IncreaseThroughNewLeasesOperatingLeases_documentation_en-US" xlink:label="lab_moln_IncreaseThroughNewLeasesOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through New Leases, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseThroughNewLeasesOperatingLeases" xlink:href="moln-20221231.xsd#moln_IncreaseThroughNewLeasesOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IncreaseThroughNewLeasesOperatingLeases" xlink:to="lab_moln_IncreaseThroughNewLeasesOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_151c0aff-0c2c-490c-a254-4d7b78963c6f_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate funds</link:label>
    <link:label id="lab_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_label_en-US" xlink:label="lab_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate, amount contributed to fair value of plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets" xlink:to="lab_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PensionersMember_22df11de-b39e-4222-a93a-99e5a1c98884_terseLabel_en-US" xlink:label="lab_moln_PensionersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensioners</link:label>
    <link:label id="lab_moln_PensionersMember_label_en-US" xlink:label="lab_moln_PensionersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensioners [Member]</link:label>
    <link:label id="lab_moln_PensionersMember_documentation_en-US" xlink:label="lab_moln_PensionersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensioners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PensionersMember" xlink:href="moln-20221231.xsd#moln_PensionersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PensionersMember" xlink:to="lab_moln_PensionersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_c23be540-37a4-4a21-a045-fa6120ffa79b_terseLabel_en-US" xlink:label="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and share-based compensation costs, non-cash portion</link:label>
    <link:label id="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_label_en-US" xlink:label="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost</link:label>
    <link:label id="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_documentation_en-US" xlink:label="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" xlink:href="moln-20221231.xsd#moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" xlink:to="lab_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RoyaltyIncomePercentage_2c7c2495-cf01-433e-9910-6ebac14cd5b6_terseLabel_en-US" xlink:label="lab_moln_RoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty income, percentage</link:label>
    <link:label id="lab_moln_RoyaltyIncomePercentage_label_en-US" xlink:label="lab_moln_RoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Percentage</link:label>
    <link:label id="lab_moln_RoyaltyIncomePercentage_documentation_en-US" xlink:label="lab_moln_RoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltyIncomePercentage" xlink:href="moln-20221231.xsd#moln_RoyaltyIncomePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RoyaltyIncomePercentage" xlink:to="lab_moln_RoyaltyIncomePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities_fcdba6a5-5ba6-4e68-aab9-87eada8ccebf_negatedTerseLabel_en-US" xlink:label="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset of costs</link:label>
    <link:label id="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities_0ad7e406-6221-4524-b120-a89aa4f3178d_terseLabel_en-US" xlink:label="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset of costs</link:label>
    <link:label id="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities_label_en-US" xlink:label="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Offset Of Costs, Contract Liabilities</link:label>
    <link:label id="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities_documentation_en-US" xlink:label="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Offset Of Costs, Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:href="moln-20221231.xsd#moln_DecreaseThroughOffsetOfCostsContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:to="lab_moln_DecreaseThroughOffsetOfCostsContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_9ef86167-3b09-493c-9579-1a584c2f9558_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_43648dc7-1918-4f6a-8c25-1ed4e36429a0_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury share reserve</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_ab75853c-b973-43d8-a3d9-e255fac4f56b_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_e1b461cc-c8f6-4a2e-9635-84aae4fe665a_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable estimated useful lives, intangible assets</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_af9263b4-8d8e-4119-9075-53c532aa5c87_terseLabel_en-US" xlink:label="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">thereof property occupied or other assets used by the entity</link:label>
    <link:label id="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_label_en-US" xlink:label="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets</link:label>
    <link:label id="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_documentation_en-US" xlink:label="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" xlink:href="moln-20221231.xsd#moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" xlink:to="lab_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_461b5244-9446-49c6-91b2-864566f0119e_terseLabel_en-US" xlink:label="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Agreement with Swiss Federal Office of Public Health</link:label>
    <link:label id="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_label_en-US" xlink:label="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Agreement With Swiss Federal Office Of Public Health [Member]</link:label>
    <link:label id="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_documentation_en-US" xlink:label="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Agreement With Swiss Federal Office Of Public Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" xlink:href="moln-20221231.xsd#moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" xlink:to="lab_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CreditRiskMember_f1b8d896-257d-47c5-af18-b850794e090d_terseLabel_en-US" xlink:label="lab_ifrs-full_CreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit risk</link:label>
    <link:label id="lab_ifrs-full_CreditRiskMember_label_en-US" xlink:label="lab_ifrs-full_CreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember" xlink:to="lab_ifrs-full_CreditRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0c6e19e5-ad6a-48ee-9660-5f85c680a292_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSUs and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8b44ec74-d487-4241-be5a-7ff69f0756c5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSU and RSU outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_156027dd-8bde-4999-8ba4-79c2aa9d62a3_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSU and RSU outstanding at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExtendedPeriodOfReservationAgreement_9fa2759a-83d4-43a2-8c94-1d7506eb63eb_terseLabel_en-US" xlink:label="lab_moln_ExtendedPeriodOfReservationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended period of reservation agreement</link:label>
    <link:label id="lab_moln_ExtendedPeriodOfReservationAgreement_label_en-US" xlink:label="lab_moln_ExtendedPeriodOfReservationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Period Of Reservation Agreement</link:label>
    <link:label id="lab_moln_ExtendedPeriodOfReservationAgreement_documentation_en-US" xlink:label="lab_moln_ExtendedPeriodOfReservationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Period Of Reservation Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExtendedPeriodOfReservationAgreement" xlink:href="moln-20221231.xsd#moln_ExtendedPeriodOfReservationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExtendedPeriodOfReservationAgreement" xlink:to="lab_moln_ExtendedPeriodOfReservationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_b233be2f-4515-40f8-bfc3-a47dd2333c33_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_c20b3da2-2a8b-4108-9352-d9e3a331672f_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) from financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_9f362a5d-0cd1-43e2-bd06-599d82995568_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on leases</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_c4c4d696-e95d-4b62-b751-99dfa82f680c_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of interest on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_8c9442e3-be40-4a67-8d2a-050a99101274_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_e09a59c0-f5e7-422a-92f9-8d9b8e555333_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange gain</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_128710c7-5fa8-44c1-91b9-6845cb2c13f5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other personnel expenses</link:label>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other employee expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_5112b9ee-ea53-4d79-9fb2-003d7156e909_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding PSUs and RSUs</link:label>
    <link:label id="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_label_en-US" xlink:label="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</link:label>
    <link:label id="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_documentation_en-US" xlink:label="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:href="moln-20221231.xsd#moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:to="lab_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_bbc022a7-a49a-44b4-acca-ef3ae78b0ab7_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_6f8a29b1-256c-43c8-8b64-28c4d3665324_terseLabel_en-US" xlink:label="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share capital registered accumulated</link:label>
    <link:label id="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_label_en-US" xlink:label="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preemptive Rights, Shareholders, Percentage Of Share Capital Registered Accumulated</link:label>
    <link:label id="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_documentation_en-US" xlink:label="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preemptive Rights, Shareholders, Percentage Of Share Capital Registered Accumulated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" xlink:href="moln-20221231.xsd#moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" xlink:to="lab_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_df1ef414-7454-4631-adef-da31c07e4b7e_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_dce19e99-5cfc-45e6-9dc5-8fb924ec6d00_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_449b0815-4824-489c-8068-ef72c557c242_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_e421a1cd-b35c-493f-a62f-9b1f2b44619e_terseLabel_en-US" xlink:label="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility on Common shares</link:label>
    <link:label id="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility On Common Shares, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility On Common Shares, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" xlink:to="lab_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_782b972e-3916-4b54-9c09-f9f443da43d1_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in CHF per shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_7bb74ead-8f81-4db2-8034-f277e46c43a4_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU granted (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ActuarialAssumptionsAbstract_c3593ec2-56da-4f96-aa73-306fb368b0e8_terseLabel_en-US" xlink:label="lab_moln_ActuarialAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions</link:label>
    <link:label id="lab_moln_ActuarialAssumptionsAbstract_label_en-US" xlink:label="lab_moln_ActuarialAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumptions [Abstract]</link:label>
    <link:label id="lab_moln_ActuarialAssumptionsAbstract_documentation_en-US" xlink:label="lab_moln_ActuarialAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionsAbstract" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ActuarialAssumptionsAbstract" xlink:to="lab_moln_ActuarialAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_5f37a180-4c08-49fc-9df5-1545e732d0c0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_a34949a3-8075-4d08-8241-e5e3f0550b62_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable estimated useful lives, property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_c4bc265d-f7d3-421d-b352-93ea2af0f6e2_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_8f1874d9-3f49-4556-bff6-72604324e94e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU exercised (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_891ae0c0-0f7c-48ed-bcf3-65fcdd95f88c_terseLabel_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on plan assets excl. interest income</link:label>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_793cdf27-e6f1-4d73-99b6-ebd6b355de53_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_c1e4d450-b6b7-421c-9a10-1c5d84c6d092_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsAxis" xlink:to="lab_ifrs-full_TypesOfContractsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0b94f3af-dbe7-4d59-9c1e-a2ef5da8060f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_44709f0f-ba48-4502-ae78-84074af4df8a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_4cf869fb-2793-4224-8b58-ebe1192f9ec0_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in number of shares outstanding [abstract]</link:label>
    <link:label id="lab_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in number of shares outstanding [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract" xlink:to="lab_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_86ee0bdf-825c-42fc-87e6-81a0f97d0003_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate risk</link:label>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateRiskMember" xlink:to="lab_ifrs-full_InterestRateRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock_da1e31ac-3299-41eb-bf21-82eccabd1c06_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Timing of Revenue Recognition by Type of Payments Received</link:label>
    <link:label id="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" xlink:to="lab_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_170beb97-aa0b-4291-9d05-bf73122effb1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_be35ff64-3215-4eb7-a981-440f21c1a6c4_terseLabel_en-US" xlink:label="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets, Property Plant And Equipment [Member]</link:label>
    <link:label id="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_documentation_en-US" xlink:label="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets, Property Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" xlink:href="moln-20221231.xsd#moln_RightOfUseAssetsPropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" xlink:to="lab_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_63afd499-1545-4025-babf-b439b3c6d4f9_terseLabel_en-US" xlink:label="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by the employer</link:label>
    <link:label id="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_label_en-US" xlink:label="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of contributions expected to be paid to plan for next annual reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:to="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IndividualsAxis_e49af348-ad13-4da2-a4ea-ed3c638840e4_terseLabel_en-US" xlink:label="lab_moln_IndividualsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individuals [Axis]</link:label>
    <link:label id="lab_moln_IndividualsAxis_label_en-US" xlink:label="lab_moln_IndividualsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individuals [Axis]</link:label>
    <link:label id="lab_moln_IndividualsAxis_documentation_en-US" xlink:label="lab_moln_IndividualsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individuals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsAxis" xlink:href="moln-20221231.xsd#moln_IndividualsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IndividualsAxis" xlink:to="lab_moln_IndividualsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_93f253d3-c3a7-47d6-b5f6-15be46084fdc_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_fb50683d-6a8f-4a15-8556-5b3631bc756e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange differences on translating foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ef8e751a-7332-470e-b358-4e474ea4ba54_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange differences on translating foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_a5c5cf39-3ddf-45d0-b57c-64a0192d0f83_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension costs</link:label>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_164281a2-e0b8-47f0-addf-a10fd578b980_totalLabel_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit cost recognized in profit or loss</link:label>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment benefit expense in profit or loss, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_df6e2f0e-5be7-4b4d-86a4-df0387dc881a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dab63eba-769d-4de4-b7dd-6bd724591a43_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_f975d605-8b8a-4820-819f-46975d479e94_terseLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in exchange rates</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_22bd1945-f66c-4d1a-961e-35260a7e635f_verboseLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in interest rates</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_label_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_documentation_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:to="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_UniversityOfUtrechtMember_df4f1b09-321a-4756-a4fc-ff80f66e59e1_terseLabel_en-US" xlink:label="lab_moln_UniversityOfUtrechtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utrecht</link:label>
    <link:label id="lab_moln_UniversityOfUtrechtMember_label_en-US" xlink:label="lab_moln_UniversityOfUtrechtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Utrecht [Member]</link:label>
    <link:label id="lab_moln_UniversityOfUtrechtMember_documentation_en-US" xlink:label="lab_moln_UniversityOfUtrechtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Utrecht</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UniversityOfUtrechtMember" xlink:href="moln-20221231.xsd#moln_UniversityOfUtrechtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_UniversityOfUtrechtMember" xlink:to="lab_moln_UniversityOfUtrechtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_719884b2-ec95-4426-87b3-1a34935d6dfa_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fea42ce4-4fc3-4846-a2aa-f2c505c7f264_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7280b353-edf9-4b38-98be-ff9efe35dd25_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PerformanceShareUnitsPSUMember_0bc34635-887a-4929-9fd9-17b58d8ae609_terseLabel_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU)</link:label>
    <link:label id="lab_moln_PerformanceShareUnitsPSUMember_label_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU) [Member]</link:label>
    <link:label id="lab_moln_PerformanceShareUnitsPSUMember_documentation_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUMember" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PerformanceShareUnitsPSUMember" xlink:to="lab_moln_PerformanceShareUnitsPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_1ac4adff-a845-46a6-9614-f934d06d6785_terseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_6bb1f338-1d06-498f-98fe-64d5d419baf6_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_4179c20d-b702-4a3a-8f55-aa2ccb11930c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_2750bc89-9b7e-4a47-999f-9db3f3513b98_terseLabel_en-US" xlink:label="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in accrued expenses</link:label>
    <link:label id="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_label_en-US" xlink:label="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Increase (Decrease) In Accrued Expenses</link:label>
    <link:label id="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_documentation_en-US" xlink:label="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Increase (Decrease) In Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:href="moln-20221231.xsd#moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:to="lab_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LicenseFeesExpense_2060b443-da3f-4dad-a86f-8868ef2255f6_terseLabel_en-US" xlink:label="lab_moln_LicenseFeesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_moln_LicenseFeesExpense_label_en-US" xlink:label="lab_moln_LicenseFeesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees Expense</link:label>
    <link:label id="lab_moln_LicenseFeesExpense_documentation_en-US" xlink:label="lab_moln_LicenseFeesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseFeesExpense" xlink:href="moln-20221231.xsd#moln_LicenseFeesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LicenseFeesExpense" xlink:to="lab_moln_LicenseFeesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f6b09502-7a1b-4faf-bd29-eca1e3a31b2e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement_375d4993-5ab8-4421-96bd-cc35e4920611_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments forfeited (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:to="lab_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesMember_012f670a-24cb-4ec4-81eb-7dfdfa340718_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_99db0c73-b9d6-4d2f-a0fb-b137d9de289e_terseLabel_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff vesting percentage</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_label_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Percentage</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_documentation_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" xlink:to="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_92d026d3-1c1d-4fe1-a30d-09724859e6ed_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_label_en-US" xlink:label="lab_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, amount contributed to fair value of plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_37ca7398-ffa0-405b-9a01-f3a289dd7a70_terseLabel_en-US" xlink:label="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American depositary shares (each representing one common share, CHF 0.10 nominal value per share)</link:label>
    <link:label id="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_label_en-US" xlink:label="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares, The Nasdaq Stock Market LLC [Member]</link:label>
    <link:label id="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_documentation_en-US" xlink:label="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares, The Nasdaq Stock Market LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" xlink:href="moln-20221231.xsd#moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" xlink:to="lab_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_8277ef92-b6b4-4136-9c97-6167d04e0f28_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Contractual Maturities of Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_3008a263-bd3b-472c-b5ac-5b0ffde921e1_terseLabel_en-US" xlink:label="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably possible increase in actuarial assumptions, period</link:label>
    <link:label id="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_label_en-US" xlink:label="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably Possible Increase In Actuarial Assumptions, Period</link:label>
    <link:label id="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_documentation_en-US" xlink:label="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably Possible Increase In Actuarial Assumptions, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" xlink:href="moln-20221231.xsd#moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" xlink:to="lab_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_bf159614-66aa-49c6-9d01-b7e509de04fb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_90ce67ab-19a9-49cc-8620-8cf139363dcd_terseLabel_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis AG, Switzerland</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_label_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement With Novartis AG [Member]</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_documentation_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement With Novartis AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithNovartisAGMember" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithNovartisAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LicenseAndCollaborationAgreementWithNovartisAGMember" xlink:to="lab_moln_LicenseAndCollaborationAgreementWithNovartisAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseDefinedBenefitPlans_536c0c31-108c-4b11-ab55-753040f1ca30_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:to="lab_ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_e46a7168-b4d2-42ed-919b-b42f3cb7f45e_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_b132420e-b027-4f69-ae16-102e48146756_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_17877622-113f-4665-a12b-2b46d3f385dd_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Switzerland</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfVotesPerShare_fceeea70-2fa6-4da2-93b2-2273b5d72028_terseLabel_en-US" xlink:label="lab_moln_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_moln_NumberOfVotesPerShare_label_en-US" xlink:label="lab_moln_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:label id="lab_moln_NumberOfVotesPerShare_documentation_en-US" xlink:label="lab_moln_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfVotesPerShare" xlink:href="moln-20221231.xsd#moln_NumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfVotesPerShare" xlink:to="lab_moln_NumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_f35b9296-abf4-4977-87a5-2113cf97ad64_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term leases</link:label>
    <link:label id="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_label_en-US" xlink:label="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_0383a815-d041-42c1-9b3f-d87a332c842c_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_326fd5ef-3fa0-4558-9f86-4a5a5eb93b72_negatedLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on result before tax if interest rates decrease</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_label_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_documentation_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" xlink:to="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ConditionalShareCapitalMember_9e9fa4cb-332d-4269-b51f-892aac7714ba_terseLabel_en-US" xlink:label="lab_moln_ConditionalShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional share capital</link:label>
    <link:label id="lab_moln_ConditionalShareCapitalMember_label_en-US" xlink:label="lab_moln_ConditionalShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Share Capital [Member]</link:label>
    <link:label id="lab_moln_ConditionalShareCapitalMember_documentation_en-US" xlink:label="lab_moln_ConditionalShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ConditionalShareCapitalMember" xlink:href="moln-20221231.xsd#moln_ConditionalShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ConditionalShareCapitalMember" xlink:to="lab_moln_ConditionalShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock_86429c18-f406-49cd-9a39-fe2547d964c2_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information about Trade and Other Payables</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_37cbca73-efd8-4998-96af-3766746fc539_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_f9e8fe56-73f2-4eb7-badb-754ed57092cd_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_b3396d85-8d12-4c7a-9ab0-f08f108f7354_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IT hardware</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_972e7409-32c8-4527-b612-bb5d22db95c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Movements in the Number of PSUs and RSUs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_8209e46a-c35c-4761-b261-a6b38ad6f55e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive result</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock_031a570e-838e-43b8-bd2d-aee129c69bbf_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Expiry of Tax Loss Carryforwards</link:label>
    <link:label id="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Expiry Of Tax Loss Carryforwards [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Expiry Of Tax Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" xlink:to="lab_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_f3962aa2-3468-451d-bd46-bf7c55840586_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_FullContractualLifeOtherEquityInstruments_f7abc926-7cb4-4863-80a6-129597033848_terseLabel_en-US" xlink:label="lab_moln_FullContractualLifeOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full contractual life for RSU and PSU</link:label>
    <link:label id="lab_moln_FullContractualLifeOtherEquityInstruments_label_en-US" xlink:label="lab_moln_FullContractualLifeOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full Contractual Life, Other Equity Instruments</link:label>
    <link:label id="lab_moln_FullContractualLifeOtherEquityInstruments_documentation_en-US" xlink:label="lab_moln_FullContractualLifeOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full Contractual Life, Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FullContractualLifeOtherEquityInstruments" xlink:href="moln-20221231.xsd#moln_FullContractualLifeOtherEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_FullContractualLifeOtherEquityInstruments" xlink:to="lab_moln_FullContractualLifeOtherEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfFullTimeEquivalentEmployees_9f99f589-3fa7-4a52-9e11-c1025bb133ed_terseLabel_en-US" xlink:label="lab_moln_NumberOfFullTimeEquivalentEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full-time equivalents at year end</link:label>
    <link:label id="lab_moln_NumberOfFullTimeEquivalentEmployees_label_en-US" xlink:label="lab_moln_NumberOfFullTimeEquivalentEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Full-Time Equivalent Employees</link:label>
    <link:label id="lab_moln_NumberOfFullTimeEquivalentEmployees_documentation_en-US" xlink:label="lab_moln_NumberOfFullTimeEquivalentEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Full-Time Equivalent Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfFullTimeEquivalentEmployees" xlink:href="moln-20221231.xsd#moln_NumberOfFullTimeEquivalentEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfFullTimeEquivalentEmployees" xlink:to="lab_moln_NumberOfFullTimeEquivalentEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxPayables_d609881d-1d39-4bf1-ae19-e924cf111520_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value added tax</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxPayables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current value added tax payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxPayables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement_fc0875d9-41d1-4d3a-aa4c-d726e9db0597_negatedTerseLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments expired (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Expired In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Expired In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:to="lab_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LeaseTermOfContract_3cbdeba9-5cae-46ca-a4eb-a6152cbe5c2e_terseLabel_en-US" xlink:label="lab_moln_LeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, term</link:label>
    <link:label id="lab_moln_LeaseTermOfContract_label_en-US" xlink:label="lab_moln_LeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Term Of Contract</link:label>
    <link:label id="lab_moln_LeaseTermOfContract_documentation_en-US" xlink:label="lab_moln_LeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Term Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseTermOfContract" xlink:href="moln-20221231.xsd#moln_LeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LeaseTermOfContract" xlink:to="lab_moln_LeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_baad421d-cb4e-4c47-8e64-6c1e166733f0_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_ee28925c-a5e4-4307-a367-aace28ddbab4_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AuthorizedShareCapitalEmployeeParticipation_f246ff4b-cfac-4a33-a2fc-543579c032fe_terseLabel_en-US" xlink:label="lab_moln_AuthorizedShareCapitalEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized share capital, employee participation</link:label>
    <link:label id="lab_moln_AuthorizedShareCapitalEmployeeParticipation_label_en-US" xlink:label="lab_moln_AuthorizedShareCapitalEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Share Capital, Employee Participation</link:label>
    <link:label id="lab_moln_AuthorizedShareCapitalEmployeeParticipation_documentation_en-US" xlink:label="lab_moln_AuthorizedShareCapitalEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Share Capital, Employee Participation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuthorizedShareCapitalEmployeeParticipation" xlink:href="moln-20221231.xsd#moln_AuthorizedShareCapitalEmployeeParticipation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AuthorizedShareCapitalEmployeeParticipation" xlink:to="lab_moln_AuthorizedShareCapitalEmployeeParticipation" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock_afded96b-0ad0-4e71-ab4b-f03bab1edd58_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Accrued Expenses Explanatory</link:label>
    <link:label id="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_a78624a3-eb87-4cc6-81f4-522f787f999e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, other income and and entity-wide disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_400da602-0bb1-4a95-8fa9-aa8ce0e1c5f1_negatedTerseLabel_en-US" xlink:label="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in short-term time deposits</link:label>
    <link:label id="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities</link:label>
    <link:label id="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:href="moln-20221231.xsd#moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:to="lab_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_cda85457-adad-40cd-8a77-72d8f6abe27b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_55e7501f-9555-4231-af19-cab21e694c47_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation at December 31</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:to="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OccupancyExpense_1bdcacc7-b3cf-416f-893b-848d48a15a2a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OccupancyExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility expenses</link:label>
    <link:label id="lab_ifrs-full_OccupancyExpense_label_en-US" xlink:label="lab_ifrs-full_OccupancyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OccupancyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OccupancyExpense" xlink:to="lab_ifrs-full_OccupancyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_b1a59cca-0bba-44d2-839b-0d1990cd9907_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_23bc7977-8d7c-4466-8ed7-f697e426345f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_c630c7cc-c70e-46bb-b336-0216755bdefa_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSU and PSU granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_48c4008d-a671-4c02-ab99-dddea3095dd6_verboseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from research and development collaborations</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_626128b2-687d-44be-8761-2a2f2b853db6_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_843dd3b2-8972-432c-ba7b-b3bd131e9a20_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_a99fb76a-758d-4d26-80a6-4be063ea3619_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_3a89d3ba-66f9-4e83-ae18-00a8e2314db8_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_61001a2a-4859-4305-a8eb-e3249d5327ec_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:to="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2d722a45-0929-4690-a61b-2a4bde6ef644_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_603d33aa-d7a4-4d10-bdc0-c4bc498cc6ce_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of amount recognized in OCI</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsMember_faab0d8c-fc7f-4b48-9ca1-874105fc4c2a_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsMember_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsMember" xlink:to="lab_ifrs-full_PlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_a75be482-5e23-45cd-9d59-f76c069122c5_terseLabel_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted market price</link:label>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d3fdca2f-82a9-4f29-a38c-7423d6d9d7a3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_813093b1-df99-488d-9577-3d42ee2b2358_terseLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments exercisable (in shares</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Exercisable In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Exercisable In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" xlink:to="lab_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement_7d1dd97f-0989-4c6d-afbf-72d039f596a0_negatedTerseLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments forfeited (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Forfeited In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Forfeited In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:to="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_98d2fcf1-6b76-4c4a-b572-1b8e0122adf5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Costs of Key Management</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_feb7b7f8-b33f-4e1a-ba85-6e1e69f1454b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_2dba2350-73e2-493a-93c4-aa6a1a8bcc2b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel expenses</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_0d6204e3-24c6-422e-a9b2-ab0f13bc8c57_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel expenses</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_b6e4c83b-f4af-43b3-80af-ae9c4820ce4a_terseLabel_en-US" xlink:label="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility on SPI</link:label>
    <link:label id="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility On SPI, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility On SPI, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" xlink:to="lab_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_UpfrontPaymentReceived_86c44ad5-8153-47d9-80e0-81d90e529237_terseLabel_en-US" xlink:label="lab_moln_UpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_moln_UpfrontPaymentReceived_label_en-US" xlink:label="lab_moln_UpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Received</link:label>
    <link:label id="lab_moln_UpfrontPaymentReceived_documentation_en-US" xlink:label="lab_moln_UpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UpfrontPaymentReceived" xlink:href="moln-20221231.xsd#moln_UpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_UpfrontPaymentReceived" xlink:to="lab_moln_UpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_a1d347e0-c526-4359-b6e5-cf15585aa22a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_f29b945c-d63b-4996-b68b-0e890de21d16_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RestrictedShareUnitsRSUMember_b5c981e0-a329-4888-841f-eb4c059925f3_terseLabel_en-US" xlink:label="lab_moln_RestrictedShareUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSU)</link:label>
    <link:label id="lab_moln_RestrictedShareUnitsRSUMember_label_en-US" xlink:label="lab_moln_RestrictedShareUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSU) [Member]</link:label>
    <link:label id="lab_moln_RestrictedShareUnitsRSUMember_documentation_en-US" xlink:label="lab_moln_RestrictedShareUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RestrictedShareUnitsRSUMember" xlink:href="moln-20221231.xsd#moln_RestrictedShareUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RestrictedShareUnitsRSUMember" xlink:to="lab_moln_RestrictedShareUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_24cea129-05be-4113-b608-8166ea29a399_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_b0068729-804c-402a-96a3-526fada6cdf4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeDefinedBenefitPlans_3f2a220f-ec8d-4deb-a4f5-2c641154685c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on plan assets</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeDefinedBenefitPlans" xlink:to="lab_ifrs-full_InterestIncomeDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_428272ad-60a5-4089-9143-480fea94ab4d_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_0a469d0e-c983-42c4-80d6-e3e2683d0866_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits (paid)/deposited</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_bf06111b-790d-4624-a5b9-da9acb87c862_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits (paid)/deposited</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_cfad715d-076f-41c8-a1a2-5844dd54981c_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureTable_361a636b-d752-4cc2-8e71-e3f63ae57764_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationAndAmortisationExpense_b1041a65-e1ae-4104-aee0-4f61f589e438_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_DepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IncreaseThroughAdditionsContractLiabilities_b1d93376-07c6-4eb5-aaf1-83ad8ea536d1_terseLabel_en-US" xlink:label="lab_moln_IncreaseThroughAdditionsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_moln_IncreaseThroughAdditionsContractLiabilities_label_en-US" xlink:label="lab_moln_IncreaseThroughAdditionsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through Additions, Contract Liabilities</link:label>
    <link:label id="lab_moln_IncreaseThroughAdditionsContractLiabilities_documentation_en-US" xlink:label="lab_moln_IncreaseThroughAdditionsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through Additions, Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseThroughAdditionsContractLiabilities" xlink:href="moln-20221231.xsd#moln_IncreaseThroughAdditionsContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IncreaseThroughAdditionsContractLiabilities" xlink:to="lab_moln_IncreaseThroughAdditionsContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdministrativeExpense_d1ebd135-abd4-4beb-8ba1-627d5ba4ede7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other administrative expenses</link:label>
    <link:label id="lab_ifrs-full_AdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_AdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdministrativeExpense" xlink:to="lab_ifrs-full_AdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_f20dcb1a-43b0-4d41-b94f-7826ed1e23a0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (non-cash effective)</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_eeefc0f0-a0f1-4002-8730-e382ceb44612_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (non-cash effective)</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_869298e5-cee8-4bed-bc94-e28a10a71723_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_747a8d5a-5df4-44f7-8cd5-28997fa6783e_terseLabel_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licence and Collaboration Agreement with Amgen, Inc</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_125885f8-1f91-4f81-bfa8-83d9a4b7eaea_verboseLabel_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc., USA</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_label_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement With Amgen, Inc [Member]</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_documentation_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement With Amgen, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithAmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:to="lab_moln_LicenseAndCollaborationAgreementWithAmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock_e902d8ef-0680-4151-bdbb-cbf267c1550f_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments</link:label>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercis Price, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" xlink:to="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_2e72377e-9542-4f5d-9d74-2f7972554b2e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU expired (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of other equity instruments expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_ffe64be4-c746-4013-b03c-794c282ee833_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSU and RSU expired (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_TradePayablesMember_e84c472d-cfa0-46bd-b88a-e21d1b3a3afa_terseLabel_en-US" xlink:label="lab_moln_TradePayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_moln_TradePayablesMember_label_en-US" xlink:label="lab_moln_TradePayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Payables [Member]</link:label>
    <link:label id="lab_moln_TradePayablesMember_documentation_en-US" xlink:label="lab_moln_TradePayablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TradePayablesMember" xlink:href="moln-20221231.xsd#moln_TradePayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_TradePayablesMember" xlink:to="lab_moln_TradePayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_bc5e9307-d867-4ca5-87d3-896765959b97_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_39316bb3-da41-4116-bee5-3baeb08d8e42_negatedTerseLabel_en-US" xlink:label="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited, performance adjustment (in shares)</link:label>
    <link:label id="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_label_en-US" xlink:label="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:label id="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_documentation_en-US" xlink:label="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:href="moln-20221231.xsd#moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:to="lab_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_a87b93d5-cd45-4e86-8932-008058db040c_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bb34d698-111a-45ad-8828-d21e91eaca16_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_7f5a2165-1d84-42e6-aec8-e240a096202e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesAuthorizedFinancingTransactions_eab7fd2c-0e4c-472f-be9b-6e2cd490a8fe_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesAuthorizedFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized, financing transactions (in shares)</link:label>
    <link:label id="lab_moln_NumberOfSharesAuthorizedFinancingTransactions_label_en-US" xlink:label="lab_moln_NumberOfSharesAuthorizedFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Authorized, Financing Transactions</link:label>
    <link:label id="lab_moln_NumberOfSharesAuthorizedFinancingTransactions_documentation_en-US" xlink:label="lab_moln_NumberOfSharesAuthorizedFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Authorized, Financing Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesAuthorizedFinancingTransactions" xlink:href="moln-20221231.xsd#moln_NumberOfSharesAuthorizedFinancingTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesAuthorizedFinancingTransactions" xlink:to="lab_moln_NumberOfSharesAuthorizedFinancingTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_470c9c82-3fa5-4e16-ae63-12b161e2aa05_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net defined benefit liability</link:label>
    <link:label id="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in net defined benefit liability (asset) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock_bad39596-0d64-4d13-9818-8d45cb8bb348_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits</link:label>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" xlink:to="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LeaseFacilitiesSchlierenMember_97587ab6-8ff2-4ab6-9fc3-dbed125af9e8_terseLabel_en-US" xlink:label="lab_moln_LeaseFacilitiesSchlierenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease facilities, Schlieren</link:label>
    <link:label id="lab_moln_LeaseFacilitiesSchlierenMember_label_en-US" xlink:label="lab_moln_LeaseFacilitiesSchlierenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facilities, Schlieren [Member]</link:label>
    <link:label id="lab_moln_LeaseFacilitiesSchlierenMember_documentation_en-US" xlink:label="lab_moln_LeaseFacilitiesSchlierenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facilities, Schlieren</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseFacilitiesSchlierenMember" xlink:href="moln-20221231.xsd#moln_LeaseFacilitiesSchlierenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LeaseFacilitiesSchlierenMember" xlink:to="lab_moln_LeaseFacilitiesSchlierenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_971c503e-e813-416a-978a-6132c1dcfa0e_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSUs and RSUs exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_11425364-83e1-4b0a-81c2-c6f6babb36b9_terseLabel_en-US" xlink:label="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</link:label>
    <link:label id="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</link:label>
    <link:label id="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_documentation_en-US" xlink:label="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="moln-20221231.xsd#moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_e693a96c-699e-45a5-9295-d467a1ae0717_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_8b1bbd1e-5581-4c51-8afe-3ffc328cd1a1_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_8afb7878-e925-4f96-9f29-f5e4ef4a0648_negatedTotalLabel_en-US" xlink:label="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain)/loss on defined benefit obligation</link:label>
    <link:label id="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_label_en-US" xlink:label="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans</link:label>
    <link:label id="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_documentation_en-US" xlink:label="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" xlink:href="moln-20221231.xsd#moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" xlink:to="lab_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_029a8fe5-f310-484b-8ec1-1525a7ab128c_terseLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on result before tax if exchange rates increase</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_92e58658-7224-401b-bdf5-5e53f7f59476_verboseLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on result before tax if interest rates increase</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_label_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_documentation_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:to="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_1f416545-b3c7-4eb3-8e2d-114c527de455_terseLabel_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of share capital increase authorized, percent</link:label>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_label_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Share Capital Increase Authorized, Percent</link:label>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_documentation_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Share Capital Increase Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" xlink:to="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_b1b81083-31ac-4e0d-a869-d00aacb91f9e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Revenue by Country and by Major Alliance Partner</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIncome_10acae38-a8f7-4130-b128-f24b9130bad0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_label_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_ff1eaea0-17d8-4c5a-8a2c-b8bc039ce73b_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Prepaid Expenses And Accrued Income [Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Prepaid Expenses And Accrued Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:to="lab_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted_d3ea8d07-6bdb-4849-ac44-18e9e2228139_terseLabel_en-US" xlink:label="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedDividendOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_ExpectedDividendOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpectedDividendOtherEquityInstrumentsGranted" xlink:to="lab_moln_ExpectedDividendOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_41b551fd-3aa5-4e65-9934-fd13c6b6d32e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfGeneralInformationAbstract_label_en-US" xlink:label="lab_moln_DisclosureOfGeneralInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of General Information [Abstract]</link:label>
    <link:label id="lab_moln_DisclosureOfGeneralInformationAbstract_documentation_en-US" xlink:label="lab_moln_DisclosureOfGeneralInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of General Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfGeneralInformationAbstract" xlink:href="moln-20221231.xsd#moln_DisclosureOfGeneralInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfGeneralInformationAbstract" xlink:to="lab_moln_DisclosureOfGeneralInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_55fd4edf-b27a-49db-8600-17ed133a5e5a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_670e7d2d-1a47-48c0-ae38-caa24f46477f_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Royalties And License Fees [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Royalties And License Fees [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Royalties And License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_4cb7716b-3e8e-4dce-949d-fb1e9fef31aa_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_453f34f5-a20c-4aba-9a45-a7ffa4839c16_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected revenue recognition in year four after balance sheet date</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_10d92ac9-ac4a-4042-9e61-32e980265863_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_e3cd10e7-9b63-4d14-bf52-6c00eb09cdb1_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Result before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_079a14fd-b677-4ee0-8933-d6c9898c7843_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement_8e7f23eb-be47-4e95-961e-e48e7a4e96f8_negatedTerseLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments exercised (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Exercised In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Exercised In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:to="lab_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_c4615ead-e938-4a36-833f-cee217003fef_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Reconciliation of Changes in Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RoyaltiesMinimumAnnualAmountTotal_1410901f-90c0-4a75-a663-b8beb3803b08_terseLabel_en-US" xlink:label="lab_moln_RoyaltiesMinimumAnnualAmountTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, minimum amount required to pay in total</link:label>
    <link:label id="lab_moln_RoyaltiesMinimumAnnualAmountTotal_label_en-US" xlink:label="lab_moln_RoyaltiesMinimumAnnualAmountTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Minimum Annual Amount, Total</link:label>
    <link:label id="lab_moln_RoyaltiesMinimumAnnualAmountTotal_documentation_en-US" xlink:label="lab_moln_RoyaltiesMinimumAnnualAmountTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Minimum Annual Amount, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesMinimumAnnualAmountTotal" xlink:href="moln-20221231.xsd#moln_RoyaltiesMinimumAnnualAmountTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RoyaltiesMinimumAnnualAmountTotal" xlink:to="lab_moln_RoyaltiesMinimumAnnualAmountTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_c3f760ba-81f7-4c40-b4c7-7351581ba61a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e59dcf31-4148-4a23-a208-681f549af070_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_52112a88-05fe-4585-a520-40c5b3d4b7f9_terseLabel_en-US" xlink:label="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of fair value of plan assets</link:label>
    <link:label id="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_label_en-US" xlink:label="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Fair Value Of Plan Assets [Abstract]</link:label>
    <link:label id="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_documentation_en-US" xlink:label="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Fair Value Of Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract" xlink:href="moln-20221231.xsd#moln_ReconciliationOfFairValueOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract" xlink:to="lab_moln_ReconciliationOfFairValueOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock_8cc7e454-17ed-4654-a48b-f6eeecdd6573_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Movement of Lease Liabilities</link:label>
    <link:label id="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movement Of Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" xlink:to="lab_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_98550865-33ac-41f5-9891-4fc96aff11b6_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of new shares, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c4ff09c9-ad87-4c32-a8ce-33f1aad23328_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_552ca69b-f778-470d-b006-8ba114d92e26_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets_8f2745e1-02fb-45f4-bdc1-bc6bd62cd83d_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued income other than current contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:to="lab_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_1f21bacf-839b-4f77-b2dd-e92c6be8504d_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_e492ba7a-86ca-49f9-835c-dab77b34e53f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_88be45b5-eb21-44e2-964e-744e24c26037_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6abda363-6307-45b5-96e0-876fcb9ee1c9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_c2790d51-1893-40a9-a0e9-0b3b84b90315_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_3ebc4870-f8b8-463d-ae5f-0e853d5a1e1f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities at end of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_4988de98-51c5-46db-947c-5375a1eda442_totalLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_f7473ced-65d5-4d41-b887-f5a717cb9491_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_FederalOfficeOfPublicHealthMember_a8d7c82c-d40d-4eee-966f-256631aba0b0_terseLabel_en-US" xlink:label="lab_moln_FederalOfficeOfPublicHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FOPH</link:label>
    <link:label id="lab_moln_FederalOfficeOfPublicHealthMember_label_en-US" xlink:label="lab_moln_FederalOfficeOfPublicHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Office Of Public Health [Member]</link:label>
    <link:label id="lab_moln_FederalOfficeOfPublicHealthMember_documentation_en-US" xlink:label="lab_moln_FederalOfficeOfPublicHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Office Of Public Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_FederalOfficeOfPublicHealthMember" xlink:to="lab_moln_FederalOfficeOfPublicHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AccruedSabbaticalCost_5fc91495-1825-4b0b-afb1-a5bb21eda7b6_terseLabel_en-US" xlink:label="lab_moln_AccruedSabbaticalCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sabbatical cost</link:label>
    <link:label id="lab_moln_AccruedSabbaticalCost_label_en-US" xlink:label="lab_moln_AccruedSabbaticalCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sabbatical Cost</link:label>
    <link:label id="lab_moln_AccruedSabbaticalCost_documentation_en-US" xlink:label="lab_moln_AccruedSabbaticalCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sabbatical Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedSabbaticalCost" xlink:href="moln-20221231.xsd#moln_AccruedSabbaticalCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AccruedSabbaticalCost" xlink:to="lab_moln_AccruedSabbaticalCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_cd472135-af06-4b33-91b2-b66125368820_terseLabel_en-US" xlink:label="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSUs issued, in percentage of number of PSUs granted</link:label>
    <link:label id="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_label_en-US" xlink:label="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Equity Instruments Issued In Share-Based Payment Arrangement, In Percentage Of Number Granted</link:label>
    <link:label id="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_documentation_en-US" xlink:label="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Equity Instruments Issued In Percentage Of Number Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" xlink:href="moln-20221231.xsd#moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" xlink:to="lab_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7f6165e-99fc-4394-92f9-3180e2dabf12_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_c80fa888-1d33-445e-9d1e-a68a9919e6cd_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_148b207a-50f6-407a-80e7-cad7799a40d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_9e8ccd66-3bc7-4e6a-ade8-aa02b55aa11a_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_0d2babd9-b7f0-4b37-912f-d374f5eb5e2f_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_Equity_9a6ee990-1134-4a47-bdee-55e8b2e5570f_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_cc0da33b-a991-4dc8-86fb-3a3d5f25b41c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_2ee37fb6-5e7b-47b7-a328-6bc6f0697531_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_b699fca8-8f9f-43ed-8447-0a715f288301_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_88680957-c72d-4ce0-8868-072b96f0d465_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_6c9763cd-f92d-444e-917b-13deec2f7592_terseLabel_en-US" xlink:label="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of interest rate on retirement savings capital</link:label>
    <link:label id="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_label_en-US" xlink:label="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Interest Rate On Retirement Savings Capital [Member]</link:label>
    <link:label id="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_documentation_en-US" xlink:label="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Interest Rate On Retirement Savings Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" xlink:to="lab_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_0cabafb4-258a-427d-b4e5-045f2bd325d5_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_label_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" xlink:to="lab_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_caf092e6-a224-4b46-9306-f6633c4b408a_terseLabel_en-US" xlink:label="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably possible decrease in actuarial assumptions, period</link:label>
    <link:label id="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_label_en-US" xlink:label="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably Possible Decrease In Actuarial Assumptions, Period</link:label>
    <link:label id="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_documentation_en-US" xlink:label="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably Possible Decrease In Actuarial Assumptions, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" xlink:href="moln-20221231.xsd#moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" xlink:to="lab_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_e90fe965-37f7-43f9-974c-b2e8f8557a74_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_205102e2-d6d6-434f-90f0-4543ead36b9a_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_3870efe4-4389-4e19-bab4-817b9c634d9c_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable_3b9cdf49-77c3-4fa3-ab62-1a5d71de52ea_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Leases [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Leases [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Leases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutLeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaximumExposureToCreditRisk_5a37a6d6-d6a0-4ae3-8bfa-3e24c8761fa3_terseLabel_en-US" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum exposure to credit risk</link:label>
    <link:label id="lab_ifrs-full_MaximumExposureToCreditRisk_label_en-US" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum exposure to credit risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaximumExposureToCreditRisk" xlink:to="lab_ifrs-full_MaximumExposureToCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_4b57a322-8d98-423d-9b1a-e9cec967dd1f_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_TreasurySharesNominalValue_de6ef4d4-04d0-43c0-a679-583d9189c09b_terseLabel_en-US" xlink:label="lab_moln_TreasurySharesNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nominal value of treasury shares</link:label>
    <link:label id="lab_moln_TreasurySharesNominalValue_label_en-US" xlink:label="lab_moln_TreasurySharesNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares, Nominal Value</link:label>
    <link:label id="lab_moln_TreasurySharesNominalValue_documentation_en-US" xlink:label="lab_moln_TreasurySharesNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares, Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TreasurySharesNominalValue" xlink:href="moln-20221231.xsd#moln_TreasurySharesNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_TreasurySharesNominalValue" xlink:to="lab_moln_TreasurySharesNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7751a12d-7d24-454a-9502-83e48043ca73_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_5857fb41-01f6-4716-a8f3-2b0a61e75cd5_negatedTerseLabel_en-US" xlink:label="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research consumables and external research and development expenses</link:label>
    <link:label id="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Consumables And External Research And Development Expense</link:label>
    <link:label id="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Consumables And External Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" xlink:href="moln-20221231.xsd#moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" xlink:to="lab_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3baaa9c2-e5c1-48c6-9799-85a2d5b57360_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_cd9fa6fa-e698-4aa3-847f-ea9936ae813d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan asset classes</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of plan assets, fair value monetary amounts [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract" xlink:to="lab_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_12270d3e-4869-4bba-bf25-c9bc01a01e73_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Maximum Credit Risk Exposure</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_e1d7ae50-0a5e-4a77-ab9a-b2fd060bd63f_terseLabel_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of share capital increase authorized, number of shares (in shares)</link:label>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_label_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Share Capital Increase Authorized, Number Of Shares</link:label>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_documentation_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Share Capital Increase Authorized, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" xlink:to="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_e928f40a-9163-4a1c-8c42-628ce1fcfcd4_terseLabel_en-US" xlink:label="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and Equity Rights Agreement with Novartis</link:label>
    <link:label id="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_label_en-US" xlink:label="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option And Equity Rights Agreement With Novartis, Ensovibep [Member]</link:label>
    <link:label id="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_documentation_en-US" xlink:label="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option And Equity Rights Agreement With Novartis, Ensovibep</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" xlink:href="moln-20221231.xsd#moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" xlink:to="lab_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_35db8f82-334c-4bf9-b415-5d78b2e42e4a_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive result, attributable to shareholders</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_11776394-e01c-43bd-9ce5-a110bef2f441_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_08b522b2-9a15-45ca-ab3c-25e90c8eb32a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VoluntaryComplementaryPlanMember_0e6063bb-2db3-404f-9bb5-7831ccc0811e_terseLabel_en-US" xlink:label="lab_moln_VoluntaryComplementaryPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary complementary plan</link:label>
    <link:label id="lab_moln_VoluntaryComplementaryPlanMember_label_en-US" xlink:label="lab_moln_VoluntaryComplementaryPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Complementary Plan [Member]</link:label>
    <link:label id="lab_moln_VoluntaryComplementaryPlanMember_documentation_en-US" xlink:label="lab_moln_VoluntaryComplementaryPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Complementary Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VoluntaryComplementaryPlanMember" xlink:href="moln-20221231.xsd#moln_VoluntaryComplementaryPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VoluntaryComplementaryPlanMember" xlink:to="lab_moln_VoluntaryComplementaryPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_87d85019-2cba-4a7c-b6ff-570b0d5d62dd_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement_c366aa82-1b1d-4ce9-bbfa-514d432fac07_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments expired (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:to="lab_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0d45ed4d-dfde-495f-8893-7c2220e8a233_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock_9d2e7cab-48e4-4ff9-ae08-4b3def572751_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Non-Cash Costs for Share-Based Payments by Functions</link:label>
    <link:label id="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-Cash Costs For Share-Based Payments By Functions [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-Cash Costs For Share-Based Payments By Functions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" xlink:to="lab_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_22fa6305-57ee-48e0-8c6a-0f3a64de1bed_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of salary increases [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_TaxLossCarryforwards_018cd11f-e2ce-4c36-851d-0a0fbb9bc70b_terseLabel_en-US" xlink:label="lab_moln_TaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_moln_TaxLossCarryforwards_bf748601-05da-413c-9654-041ea6ac3665_negatedTerseLabel_en-US" xlink:label="lab_moln_TaxLossCarryforwards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_moln_TaxLossCarryforwards_label_en-US" xlink:label="lab_moln_TaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Loss Carryforwards</link:label>
    <link:label id="lab_moln_TaxLossCarryforwards_documentation_en-US" xlink:label="lab_moln_TaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwards" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_TaxLossCarryforwards" xlink:to="lab_moln_TaxLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_80e22541-26eb-40d0-be13-966aca6ba2a8_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_ac1b8ab6-580a-41b8-8db0-c1a8a6db399c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NetOperatingLosses_bb1c17d0-f8b0-4e15-9d53-d44ff5517e5a_terseLabel_en-US" xlink:label="lab_moln_NetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_moln_NetOperatingLosses_label_en-US" xlink:label="lab_moln_NetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Losses</link:label>
    <link:label id="lab_moln_NetOperatingLosses_documentation_en-US" xlink:label="lab_moln_NetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NetOperatingLosses" xlink:href="moln-20221231.xsd#moln_NetOperatingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NetOperatingLosses" xlink:to="lab_moln_NetOperatingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_cdbbeab8-6d74-471a-95aa-111e0c3a5992_terseLabel_en-US" xlink:label="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_label_en-US" xlink:label="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated to remaining performance obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_73debd54-ac4a-456c-8e15-1abc3d4e3e54_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected revenue recognition in year three after balance sheet date</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_a8f7f089-115a-45ed-9eda-f31e214476e6_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:to="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_1e9a63cd-3ffe-4080-a5ed-2fe419769c1b_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, amount contributed to fair value of plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock_9e62069f-fbf5-4caf-b157-afd610190372_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information about Trade and Other Receivables</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Receivables [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_39d79c9a-268f-47c6-b1c2-dda5296c2bc3_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding share options (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_a41928f2-60b2-4098-8a30-e350da70e562_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) / loss on changes in financial assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions, net of tax, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_bf49bf45-aa09-40ff-ace4-1061daaedaab_terseLabel_en-US" xlink:label="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential future dilutive shares (in shares)</link:label>
    <link:label id="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_label_en-US" xlink:label="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</link:label>
    <link:label id="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_documentation_en-US" xlink:label="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:href="moln-20221231.xsd#moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:to="lab_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_5fe6fb39-bff2-4354-9acf-cf9bbacc2ac8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_e9b49377-02dc-4065-b996-494235b0b70b_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued expenses and other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_6585c445-a469-4c8a-bae9-8a22422aff09_terseLabel_en-US" xlink:label="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, SPI</link:label>
    <link:label id="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, SPI, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, SPI, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" xlink:to="lab_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AuditorInformationAbstract_label_en-US" xlink:label="lab_moln_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_moln_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_moln_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuditorInformationAbstract" xlink:href="moln-20221231.xsd#moln_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AuditorInformationAbstract" xlink:to="lab_moln_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_4591ec33-98ed-4db1-8cfd-0446aeed3c51_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_675d0f65-413a-4172-8ccc-51ed42025c18_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortized costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_e4872124-c18a-4ba4-85bc-b5ffbedfc817_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_1ea101ab-3d29-4879-b3f5-bd12ae77d460_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_375fb80d-464a-4e74-bfd2-f26ba3a7b0fa_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding at beginning of period (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0b036373-1aca-4448-9eba-1424c4436f54_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding at end of period (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_2de45cc5-562c-4af1-a453-8f43a600a523_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares used in computing basic loss per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_d63868ab-4900-4fde-912f-3614db4884a6_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" xlink:to="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PerformanceShareUnitsPSUManagementBoardMember_f8f553de-4527-41ae-afb7-60ac4aa90b2a_terseLabel_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU), Management Board</link:label>
    <link:label id="lab_moln_PerformanceShareUnitsPSUManagementBoardMember_label_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU), Management Board [Member]</link:label>
    <link:label id="lab_moln_PerformanceShareUnitsPSUManagementBoardMember_documentation_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU), Management Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUManagementBoardMember" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUManagementBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PerformanceShareUnitsPSUManagementBoardMember" xlink:to="lab_moln_PerformanceShareUnitsPSUManagementBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_7c2fcec1-64bd-4350-a986-c4ef226be249_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transaction price allocated to remaining performance obligations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transaction price allocated to remaining performance obligations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfShortTermTimeDepositPositions_e9662eb6-2da8-4ba6-b507-c91c435c319e_terseLabel_en-US" xlink:label="lab_moln_NumberOfShortTermTimeDepositPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of short-term time deposit positions</link:label>
    <link:label id="lab_moln_NumberOfShortTermTimeDepositPositions_label_en-US" xlink:label="lab_moln_NumberOfShortTermTimeDepositPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Short-Term Time Deposit Positions</link:label>
    <link:label id="lab_moln_NumberOfShortTermTimeDepositPositions_documentation_en-US" xlink:label="lab_moln_NumberOfShortTermTimeDepositPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Short-Term Time Deposit Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShortTermTimeDepositPositions" xlink:href="moln-20221231.xsd#moln_NumberOfShortTermTimeDepositPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfShortTermTimeDepositPositions" xlink:to="lab_moln_NumberOfShortTermTimeDepositPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments_5e252722-5555-4e4b-8adb-03a5e73bc4ac_terseLabel_en-US" xlink:label="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding PSUs and RSUs (in CHF per share)</link:label>
    <link:label id="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments_label_en-US" xlink:label="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercice Price Of Outstanding Other Equity Instruments</link:label>
    <link:label id="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments_documentation_en-US" xlink:label="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercice Price Of Outstanding Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercicePriceOfOutstandingOtherEquityInstruments" xlink:href="moln-20221231.xsd#moln_ExercicePriceOfOutstandingOtherEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExercicePriceOfOutstandingOtherEquityInstruments" xlink:to="lab_moln_ExercicePriceOfOutstandingOtherEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e5403eed-65f1-4b35-99f8-9611f1811b18_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_fbb2d52f-28c8-4b5a-982d-f9762b37a4c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfEmployees_ab417884-e27d-4437-8653-b31e02a46f6f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headcount at year end</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees" xlink:to="lab_ifrs-full_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_ec63600a-c686-41e2-8b11-d755873c9269_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_af793531-3c01-4fae-b37e-3903d48e8255_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments</link:label>
    <link:label id="lab_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_label_en-US" xlink:label="lab_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments, amount contributed to fair value of plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_5a2977b5-eefb-45e6-85f4-2c1825699dcd_terseLabel_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of defined benefit cost in profit or loss</link:label>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_label_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment benefit expense in profit or loss, defined benefit plans [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_9d224195-05c4-460c-8a3d-f014b3ecb2dd_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_dc139124-c54e-45b0-8c7f-2a01a6fb4a9c_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at January 1</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_3c6f7262-67c0-42d0-a9d4-0ef7ac32dc1d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at December 31</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise_1838ef06-ebaa-437e-a45d-d4d29e84358e_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price, at date of exercise (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise_label_en-US" xlink:label="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise</link:label>
    <link:label id="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise_documentation_en-US" xlink:label="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" xlink:href="moln-20221231.xsd#moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" xlink:to="lab_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_1afa2797-f3ab-46e3-9816-cce2598cc477_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net result per share (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_118b2bd2-0c53-4e68-83a9-8d261a00a5df_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on financial assets held at amortized costs</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest revenue for financial assets measured at amortised cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:to="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IssuanceCostsOfTreasuryShareTransactions_877fb457-8746-40ae-8d65-279398eeead0_terseLabel_en-US" xlink:label="lab_moln_IssuanceCostsOfTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to issuance of treasury shares</link:label>
    <link:label id="lab_moln_IssuanceCostsOfTreasuryShareTransactions_label_en-US" xlink:label="lab_moln_IssuanceCostsOfTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Costs of Treasury Share Transactions</link:label>
    <link:label id="lab_moln_IssuanceCostsOfTreasuryShareTransactions_documentation_en-US" xlink:label="lab_moln_IssuanceCostsOfTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Costs of Treasury Share Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IssuanceCostsOfTreasuryShareTransactions" xlink:href="moln-20221231.xsd#moln_IssuanceCostsOfTreasuryShareTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IssuanceCostsOfTreasuryShareTransactions" xlink:to="lab_moln_IssuanceCostsOfTreasuryShareTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_c6f47ae5-8105-45fd-9a0e-035f4e4d50be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial risk management</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial risk management [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_835b2022-4d10-4464-8e39-c9c9d6af7f6c_terseLabel_en-US" xlink:label="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the amount recognized in the statement of financial position</link:label>
    <link:label id="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Amount Recognized In The Statement Of Financial Position [Abstract]</link:label>
    <link:label id="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_documentation_en-US" xlink:label="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of The Amount Recognized In The Statement Of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" xlink:href="moln-20221231.xsd#moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" xlink:to="lab_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c7759617-e891-41d7-a09c-e42475d1a151_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ShortTermTimeDepositsMember_60c83f97-f5ee-4203-a98d-3b748cb9b334_terseLabel_en-US" xlink:label="lab_moln_ShortTermTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term time deposits</link:label>
    <link:label id="lab_moln_ShortTermTimeDepositsMember_label_en-US" xlink:label="lab_moln_ShortTermTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Time Deposits [Member]</link:label>
    <link:label id="lab_moln_ShortTermTimeDepositsMember_documentation_en-US" xlink:label="lab_moln_ShortTermTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShortTermTimeDepositsMember" xlink:href="moln-20221231.xsd#moln_ShortTermTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ShortTermTimeDepositsMember" xlink:to="lab_moln_ShortTermTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees_4d695b2c-2f50-491b-924c-e37245eaa48c_terseLabel_en-US" xlink:label="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of eligible employees</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees_label_en-US" xlink:label="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number Of Eligible Employees</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees_documentation_en-US" xlink:label="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number Of Eligible Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanNumberOfEligibleEmployees" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanNumberOfEligibleEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DefinedBenefitPlanNumberOfEligibleEmployees" xlink:to="lab_moln_DefinedBenefitPlanNumberOfEligibleEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock_ea94684d-2762-430f-bf50-c54cd8ddd509_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information about Employee Expenses and Head Count</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Expenses And Head Count [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Expenses And Head Count</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_57fe751e-1b7d-40b1-99ad-a7fc46e15423_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events after the balance sheet date</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_a6882fa9-da24-4da0-bd27-58f3b7f32c54_negatedTerseLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in exchange rates</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_d5719599-0720-4843-ae27-68f90b9f3952_negatedLabel_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in interest rates</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_label_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent</link:label>
    <link:label id="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_documentation_en-US" xlink:label="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:to="lab_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_25dbf5cd-ef07-46ad-8814-a2126a4b14c4_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfShareOptionPlans_77cf93c8-75a6-4932-8d8f-ae539fed5785_terseLabel_en-US" xlink:label="lab_moln_NumberOfShareOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share option plans</link:label>
    <link:label id="lab_moln_NumberOfShareOptionPlans_label_en-US" xlink:label="lab_moln_NumberOfShareOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Option Plans</link:label>
    <link:label id="lab_moln_NumberOfShareOptionPlans_documentation_en-US" xlink:label="lab_moln_NumberOfShareOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShareOptionPlans" xlink:href="moln-20221231.xsd#moln_NumberOfShareOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfShareOptionPlans" xlink:to="lab_moln_NumberOfShareOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract_b26ada05-5851-4c5c-b9c5-30859233e05a_terseLabel_en-US" xlink:label="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of defined benefit obligation</link:label>
    <link:label id="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract_label_en-US" xlink:label="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Defined Benefit Obligation [Abstract]</link:label>
    <link:label id="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract_documentation_en-US" xlink:label="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Defined Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract" xlink:href="moln-20221231.xsd#moln_ReconciliationOfDefinedBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract" xlink:to="lab_moln_ReconciliationOfDefinedBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceCost_be92f22c-88ea-4ff1-8d71-3943390a0923_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financial expenses</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceCost_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other finance cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceCost" xlink:to="lab_ifrs-full_OtherFinanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract" xlink:to="lab_ifrs-full_ContractLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_3532974b-69c0-40cf-9e08-74b5fa048a12_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange gain (loss) on cash positions</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2650c952-0559-49b6-9762-e0daad98db95_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod_6748cde8-0d30-4fe6-abec-5acb2c065a56_terseLabel_en-US" xlink:label="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount utilized during period</link:label>
    <link:label id="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod_label_en-US" xlink:label="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment, Amount Utilized During Period</link:label>
    <link:label id="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod_documentation_en-US" xlink:label="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment, Amount Utilized During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UpfrontPaymentAmountUtilizedDuringPeriod" xlink:href="moln-20221231.xsd#moln_UpfrontPaymentAmountUtilizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_UpfrontPaymentAmountUtilizedDuringPeriod" xlink:to="lab_moln_UpfrontPaymentAmountUtilizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_12f780d0-800e-4cae-a19f-a8ecfe533188_terseLabel_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU), Employees excluding Management Board</link:label>
    <link:label id="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_label_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU), Employees Excluding Management Board [Member]</link:label>
    <link:label id="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_documentation_en-US" xlink:label="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSU), Employees Excluding Management Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" xlink:to="lab_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_0f031d82-12c9-4558-8b41-00083f9684a0_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_98e9d6a6-0134-46c0-be41-5ad201107372_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_59bc5489-930b-4fc3-bf02-9e48b209ac96_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_523714f2-bef9-41f3-ae91-6b2cbef2fa02_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares in issue at start of period</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_6da09113-b574-4a80-bede-069a19e9d35c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares in issue at end of period</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_884d73db-f680-48c8-ab22-a6b4c80aee88_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating result</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_efcf9b47-4fb3-4f00-adce-47360c5a2ef7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_d008ee07-3edf-4ee5-8e77-71e4f4b5b0fb_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_aa38dedb-f07d-4787-9635-662a2c8f2686_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_8df7a12a-ec54-46ef-a0e3-555e8e501031_terseLabel_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of share capital increase authorized</link:label>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_label_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Share Capital Increase Authorized</link:label>
    <link:label id="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_documentation_en-US" xlink:label="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Share Capital Increase Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorized" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorized" xlink:to="lab_moln_MaximumAmountOfShareCapitalIncreaseAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_b632768e-db7b-4235-89e4-6a805979535c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Withholding tax</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current receivables from taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LeaseExtensionOrTerminationOptionPeriod_de1a8259-b19c-407b-992f-16fa8a44ebca_terseLabel_en-US" xlink:label="lab_moln_LeaseExtensionOrTerminationOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, extension or termination option, period</link:label>
    <link:label id="lab_moln_LeaseExtensionOrTerminationOptionPeriod_label_en-US" xlink:label="lab_moln_LeaseExtensionOrTerminationOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Or Termination Option, Period</link:label>
    <link:label id="lab_moln_LeaseExtensionOrTerminationOptionPeriod_documentation_en-US" xlink:label="lab_moln_LeaseExtensionOrTerminationOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Or Termination Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseExtensionOrTerminationOptionPeriod" xlink:href="moln-20221231.xsd#moln_LeaseExtensionOrTerminationOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LeaseExtensionOrTerminationOptionPeriod" xlink:to="lab_moln_LeaseExtensionOrTerminationOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_1b59fc22-fe58-4b85-9da4-8ca12b82d789_terseLabel_en-US" xlink:label="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through recharge of employee related expenses</link:label>
    <link:label id="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_label_en-US" xlink:label="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Recharge Of Employee Related Expenses</link:label>
    <link:label id="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_documentation_en-US" xlink:label="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Recharge Of Employee Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RevenueFromRechargeOfEmployeeRelatedExpenses" xlink:href="moln-20221231.xsd#moln_RevenueFromRechargeOfEmployeeRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RevenueFromRechargeOfEmployeeRelatedExpenses" xlink:to="lab_moln_RevenueFromRechargeOfEmployeeRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_f1c290d4-f249-4ed3-9495-ab91e5eddc79_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ChangesInWorkingCapitalAbstract_ab6dc98d-a0e1-4a72-b2d3-7f43836a01cd_terseLabel_en-US" xlink:label="lab_moln_ChangesInWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital:</link:label>
    <link:label id="lab_moln_ChangesInWorkingCapitalAbstract_label_en-US" xlink:label="lab_moln_ChangesInWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Working Capital [Abstract]</link:label>
    <link:label id="lab_moln_ChangesInWorkingCapitalAbstract_documentation_en-US" xlink:label="lab_moln_ChangesInWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ChangesInWorkingCapitalAbstract" xlink:href="moln-20221231.xsd#moln_ChangesInWorkingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract" xlink:to="lab_moln_ChangesInWorkingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ThereafterMember_8f4458d1-430c-4c83-b89e-20dcf81e25ef_terseLabel_en-US" xlink:label="lab_moln_ThereafterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_moln_ThereafterMember_label_en-US" xlink:label="lab_moln_ThereafterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter [Member]</link:label>
    <link:label id="lab_moln_ThereafterMember_documentation_en-US" xlink:label="lab_moln_ThereafterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ThereafterMember" xlink:href="moln-20221231.xsd#moln_ThereafterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ThereafterMember" xlink:to="lab_moln_ThereafterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_35a3cb6a-ca80-4322-9c05-84ae6b7a7b17_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHF</link:label>
    <link:label id="lab_currency_CHF_cc278ae3-16a2-46b1-bc6a-a15761ccb631_verboseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHF Positions</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_38cc022b-63d8-447e-ac0c-dcec9b807e6f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions_6fa18ca7-c572-4044-9577-2d1f239ea51a_terseLabel_en-US" xlink:label="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party fees</link:label>
    <link:label id="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services received, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:to="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalCommitmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CapitalCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital commitments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalCommitmentsAbstract" xlink:to="lab_ifrs-full_CapitalCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AuthorizedShareCapitalFinancingTransactions_6b9b9f80-59be-41cd-8fb0-d8835b661f0f_terseLabel_en-US" xlink:label="lab_moln_AuthorizedShareCapitalFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized share capital, financing transactions</link:label>
    <link:label id="lab_moln_AuthorizedShareCapitalFinancingTransactions_label_en-US" xlink:label="lab_moln_AuthorizedShareCapitalFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Share Capital, Financing Transactions</link:label>
    <link:label id="lab_moln_AuthorizedShareCapitalFinancingTransactions_documentation_en-US" xlink:label="lab_moln_AuthorizedShareCapitalFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Share Capital, Financing Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuthorizedShareCapitalFinancingTransactions" xlink:href="moln-20221231.xsd#moln_AuthorizedShareCapitalFinancingTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AuthorizedShareCapitalFinancingTransactions" xlink:to="lab_moln_AuthorizedShareCapitalFinancingTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7b1db6bd-eff6-426b-b4a1-17f0b90abe3e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_4b07ba29-d88b-4004-a435-6ad5a1e9f1dc_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation costs</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_c954fc71-52a1-4da1-a96e-c3084761bc5b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_8ec4ce6b-085b-407f-a553-5129c68efc2e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in trade and other payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_d0b5cd90-764d-4f4d-8639-a35dea055240_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes And Deferred Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_0958c2df-8c4b-444a-bb3b-5935bfb4b20c_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as revenue</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_91a1ff19-e425-4d30-a6f4-bf4a24fb3517_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as revenue</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_3470c60f-4f60-4dd4-a3c2-36dc05895042_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected revenue recognition in year one after balance sheet date</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_cd0f916f-5435-4a3f-951c-44c952d85ec2_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_fc9aeb29-8b5b-4786-a6ae-f2cbc58a9a8e_terseLabel_en-US" xlink:label="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility on NBI</link:label>
    <link:label id="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility On NBI, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility On NBI, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" xlink:to="lab_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d52d00a6-a90e-42cd-87dd-ca67a06a3395_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_ceecab56-db80-406f-888a-1f36886b2af3_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpiringIn2027Member_8bcd1f63-8665-499c-84e9-c60d1df587ce_terseLabel_en-US" xlink:label="lab_moln_ExpiringIn2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_moln_ExpiringIn2027Member_label_en-US" xlink:label="lab_moln_ExpiringIn2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2027 [Member]</link:label>
    <link:label id="lab_moln_ExpiringIn2027Member_documentation_en-US" xlink:label="lab_moln_ExpiringIn2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2027Member" xlink:href="moln-20221231.xsd#moln_ExpiringIn2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpiringIn2027Member" xlink:to="lab_moln_ExpiringIn2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_80146e06-6d61-4a76-b52d-10f82b0773e4_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_7c721e1a-9a99-4494-b428-84bdf3f81f11_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income and financial expense</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_1896be83-b151-4c3b-b0ef-d72a835ffb76_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future salary increases at December 31</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ShareOptionsPSUsAndRSUsMember_a91ea979-5f97-4b7b-a6a6-e52de666f370_terseLabel_en-US" xlink:label="lab_moln_ShareOptionsPSUsAndRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSU, RSU and options</link:label>
    <link:label id="lab_moln_ShareOptionsPSUsAndRSUsMember_label_en-US" xlink:label="lab_moln_ShareOptionsPSUsAndRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options, PSUs And RSUs [Member]</link:label>
    <link:label id="lab_moln_ShareOptionsPSUsAndRSUsMember_documentation_en-US" xlink:label="lab_moln_ShareOptionsPSUsAndRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options, PSUs And RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShareOptionsPSUsAndRSUsMember" xlink:href="moln-20221231.xsd#moln_ShareOptionsPSUsAndRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ShareOptionsPSUsAndRSUsMember" xlink:to="lab_moln_ShareOptionsPSUsAndRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_d64a1056-0b56-42bb-806d-dac03e0ef29f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_2273d403-687f-4675-8646-3e8aede0fafc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_1d555d66-fc46-4e92-9d59-4c77581ee0b9_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_c34e400a-5012-4185-91f8-98b8e33e12ae_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_5d08a059-9df7-46e5-a0cf-6021ddf0d001_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AccruedProjectCostsAndRoyaltiesMember_79447194-009c-44d6-ad2b-ee06760d34a9_terseLabel_en-US" xlink:label="lab_moln_AccruedProjectCostsAndRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued project costs and royalties</link:label>
    <link:label id="lab_moln_AccruedProjectCostsAndRoyaltiesMember_label_en-US" xlink:label="lab_moln_AccruedProjectCostsAndRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Project Costs And Royalties [Member]</link:label>
    <link:label id="lab_moln_AccruedProjectCostsAndRoyaltiesMember_documentation_en-US" xlink:label="lab_moln_AccruedProjectCostsAndRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Project Costs And Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedProjectCostsAndRoyaltiesMember" xlink:href="moln-20221231.xsd#moln_AccruedProjectCostsAndRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AccruedProjectCostsAndRoyaltiesMember" xlink:to="lab_moln_AccruedProjectCostsAndRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8105f6a8-eb3f-4d48-8c08-eb6dcd317651_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_c77c0713-a6f8-4611-8f78-d44654cb399d_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_30abd04d-6bfb-4688-8d47-d121f53e0bc3_terseLabel_en-US" xlink:label="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in authorized share capital, employee participation</link:label>
    <link:label id="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_label_en-US" xlink:label="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Authorized Share Capital, Employee Participation</link:label>
    <link:label id="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_documentation_en-US" xlink:label="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Authorized Share Capital, Employee Participation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" xlink:to="lab_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_7ef30277-a73b-410b-b272-06d3bd37d87a_periodStartLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_eab5488f-6fec-41ee-91bd-7839213ca19a_periodEndLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments outstanding, end of period (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_0c0d2445-8546-4974-afe4-d6c2ee28d556_terseLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments outstanding (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Outstanding In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Outstanding In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:to="lab_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2d01b755-2ce1-4172-ac1c-b2234b576b76_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of issuance of shares</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_f500a288-e403-4097-a80e-ba7338721c26_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financial expense</link:label>
    <link:label id="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other inflows (outflows) of cash, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_OperatingExpensesAbstract_b46b80be-f87c-47aa-bb9f-dfe1ae4f8066_terseLabel_en-US" xlink:label="lab_moln_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_moln_OperatingExpensesAbstract_label_en-US" xlink:label="lab_moln_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label id="lab_moln_OperatingExpensesAbstract_documentation_en-US" xlink:label="lab_moln_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OperatingExpensesAbstract" xlink:href="moln-20221231.xsd#moln_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_OperatingExpensesAbstract" xlink:to="lab_moln_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals_7baf8ed2-e494-443a-9268-698481ed9958_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and bonuses</link:label>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals_label_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee benefits accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_fa464fbe-fd0e-4813-8412-03d7b8c7a673_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DefinedBenefitPlanEmployeeContribution_2a2d06f6-1c21-41de-be66-4f9474fb9762_terseLabel_en-US" xlink:label="lab_moln_DefinedBenefitPlanEmployeeContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, employee contribution</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanEmployeeContribution_label_en-US" xlink:label="lab_moln_DefinedBenefitPlanEmployeeContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employee Contribution</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanEmployeeContribution_documentation_en-US" xlink:label="lab_moln_DefinedBenefitPlanEmployeeContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employee Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanEmployeeContribution" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanEmployeeContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DefinedBenefitPlanEmployeeContribution" xlink:to="lab_moln_DefinedBenefitPlanEmployeeContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_43c3d26e-690f-4c4f-a4cb-049404cda8e8_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_ecbc7b20-5031-4fa0-83dc-7a96e254a97b_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_c5fccba8-bcc9-45b4-a2b2-c91f5c5187c4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IntellectualPropertyExpense_2ffbaac5-bad0-4f2d-9825-8c34a029b8b1_negatedTerseLabel_en-US" xlink:label="lab_moln_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property</link:label>
    <link:label id="lab_moln_IntellectualPropertyExpense_label_en-US" xlink:label="lab_moln_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:label id="lab_moln_IntellectualPropertyExpense_documentation_en-US" xlink:label="lab_moln_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IntellectualPropertyExpense" xlink:href="moln-20221231.xsd#moln_IntellectualPropertyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IntellectualPropertyExpense" xlink:to="lab_moln_IntellectualPropertyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_cec69f0e-ae18-49fc-b9ac-69d9ab75dad1_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_1bd8df63-f546-4ff5-b672-219f8e81ccbb_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1f1892-9e7c-403d-a4f3-7fe68053ef0c_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Royalties And License Fees [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Royalties And License Fees [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Royalties And License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_f21867a8-8e55-44bc-b64b-8e04a5b46ba9_terseLabel_en-US" xlink:label="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licence and Collaboration Agreement with Novartis</link:label>
    <link:label id="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_label_en-US" xlink:label="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 License And Collaboration Agreement With Novartis, DARPIN Conjugated Radioligand Therapies [Member]</link:label>
    <link:label id="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_documentation_en-US" xlink:label="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 License And Collaboration Agreement With Novartis, DARPIN Conjugated Radioligand Therapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" xlink:href="moln-20221231.xsd#moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" xlink:to="lab_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExercisePriceRangeFourMember_2026d55a-0a2a-4788-bb2c-1175a576f924_terseLabel_en-US" xlink:label="lab_moln_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, range four</link:label>
    <link:label id="lab_moln_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_moln_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_moln_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_moln_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeFourMember" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExercisePriceRangeFourMember" xlink:to="lab_moln_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity_795ed0a5-7fa2-4865-989a-b8507568d391_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in relation to vesting of PSU, RSU and options</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity_label_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Share Based Payment Arrangements, Equity</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity_documentation_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Share Based Payment Arrangements, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" xlink:to="lab_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_3d80e60f-0821-42dc-80b2-a43780bbecdc_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_848813b6-3512-450f-b7d6-bc2dfab632a3_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_c3f3b7e4-22b2-4186-be5f-6b0ae1f2d073_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_eb672a76-f401-43e8-84fc-bc9731cb05e0_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current service cost (employer)</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net defined benefit liability (asset) resulting from current service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PotentialFutureMilestonePayments_60a395e8-ef81-4c82-b74e-6a24a7eafca3_terseLabel_en-US" xlink:label="lab_moln_PotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_moln_PotentialFutureMilestonePayments_label_en-US" xlink:label="lab_moln_PotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments</link:label>
    <link:label id="lab_moln_PotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_moln_PotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PotentialFutureMilestonePayments" xlink:href="moln-20221231.xsd#moln_PotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PotentialFutureMilestonePayments" xlink:to="lab_moln_PotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_cd566a19-5bcc-4358-a96f-27dcab08d844_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Expenses Recognised in Profit or Loss</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of additional information about leasing activities for lessee [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_41de192b-e82e-4033-b362-a3279aa3f1cb_terseLabel_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blocking period</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_label_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Blocking Period</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_documentation_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Blocking Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" xlink:to="lab_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_CommercialSupplyOfProductsMember_c082ccf1-9727-4f3f-b5b8-5ae787de9b79_terseLabel_en-US" xlink:label="lab_moln_CommercialSupplyOfProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial supply of products</link:label>
    <link:label id="lab_moln_CommercialSupplyOfProductsMember_label_en-US" xlink:label="lab_moln_CommercialSupplyOfProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Supply Of Products [Member]</link:label>
    <link:label id="lab_moln_CommercialSupplyOfProductsMember_documentation_en-US" xlink:label="lab_moln_CommercialSupplyOfProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Supply Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CommercialSupplyOfProductsMember" xlink:href="moln-20221231.xsd#moln_CommercialSupplyOfProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_CommercialSupplyOfProductsMember" xlink:to="lab_moln_CommercialSupplyOfProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_31671521-daa1-4034-ae5b-e5ea3fe108b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_be85539f-3208-4dff-ac10-7720ba587a32_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_c81394b9-7ff4-4faf-b6fa-43094053eaed_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ActiveMembersMember_1ae164e2-95c1-4402-b702-d01035c7e3c7_terseLabel_en-US" xlink:label="lab_moln_ActiveMembersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Active members</link:label>
    <link:label id="lab_moln_ActiveMembersMember_label_en-US" xlink:label="lab_moln_ActiveMembersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Active Members [Member]</link:label>
    <link:label id="lab_moln_ActiveMembersMember_documentation_en-US" xlink:label="lab_moln_ActiveMembersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Active Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActiveMembersMember" xlink:href="moln-20221231.xsd#moln_ActiveMembersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ActiveMembersMember" xlink:to="lab_moln_ActiveMembersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_dd5addd3-6b78-4e62-8920-81868f7b3d6c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at amortized costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_76445bc6-9a4d-4cf3-9882-6ef77bd50338_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in treasury shares</link:label>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_label_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpiringIn2025Member_d47ecb10-1879-4543-a3ec-ac886d76fa7b_terseLabel_en-US" xlink:label="lab_moln_ExpiringIn2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_moln_ExpiringIn2025Member_label_en-US" xlink:label="lab_moln_ExpiringIn2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2025 [Member]</link:label>
    <link:label id="lab_moln_ExpiringIn2025Member_documentation_en-US" xlink:label="lab_moln_ExpiringIn2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2025Member" xlink:href="moln-20221231.xsd#moln_ExpiringIn2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpiringIn2025Member" xlink:to="lab_moln_ExpiringIn2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LabEquipmentMember_84db050a-7fbc-4a31-b161-9d2e88fcd5ac_terseLabel_en-US" xlink:label="lab_moln_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_moln_LabEquipmentMember_label_en-US" xlink:label="lab_moln_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_moln_LabEquipmentMember_documentation_en-US" xlink:label="lab_moln_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LabEquipmentMember" xlink:href="moln-20221231.xsd#moln_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LabEquipmentMember" xlink:to="lab_moln_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_e507cea8-b6c3-4cc4-a2b2-ae0da1413529_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_01590212-b56b-460f-82f1-7cac463961ab_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_c1c13cf9-e467-4f6f-b31e-c0a14a6ec4b9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_69c5b85a-91e0-4488-b07c-d1577111ebf6_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_OtherResearchAndDevelopmentExpense_78a7def1-ae68-477d-9740-97ee663a022c_negatedTerseLabel_en-US" xlink:label="lab_moln_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and development expenses</link:label>
    <link:label id="lab_moln_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_moln_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Research And Development Expense</link:label>
    <link:label id="lab_moln_OtherResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_moln_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherResearchAndDevelopmentExpense" xlink:href="moln-20221231.xsd#moln_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_OtherResearchAndDevelopmentExpense" xlink:to="lab_moln_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_d65eda35-cb4a-4c04-a9d7-b7f58c40270f_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-quoted market price</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2f1363a4-beed-4f82-8c24-c10082532def_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_b587fa62-7875-4f82-80af-46bd2f5d15c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transaction price allocated to remaining performance obligations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity_148c533c-ce3f-4228-8cd7-bc917848ad47_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in relation to capital raise in July 2020</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity_label_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Relation To Capital Raise, Equity</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity_documentation_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Relation To Capital Raise, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" xlink:to="lab_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4d49fac4-980d-4c80-a2b2-d755b22e3c59_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues USA</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_c749d17a-a1b8-4836-a697-8f7b9cce0257_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation costs</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_f7f49a41-3e95-4652-8bbd-f85f99decc17_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value added tax</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions_d949c9cf-08e5-4678-8cf1-51fe6b44cf0c_terseLabel_en-US" xlink:label="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments made by entity, related party transactions</link:label>
    <link:label id="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions_label_en-US" xlink:label="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Term Of Employment, Related Party Transactions</link:label>
    <link:label id="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions_documentation_en-US" xlink:label="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Term Of Employment, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PaymentForTermOfEmploymentRelatedPartyTransactions" xlink:href="moln-20221231.xsd#moln_PaymentForTermOfEmploymentRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PaymentForTermOfEmploymentRelatedPartyTransactions" xlink:to="lab_moln_PaymentForTermOfEmploymentRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_4f21a101-924a-424b-b508-75679352fef9_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_7b824d04-c96f-4ff2-a93f-9ecef7437a35_negatedTerseLabel_en-US" xlink:label="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PSU and RSU forfeited, performance adjustment (in shares)</link:label>
    <link:label id="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_label_en-US" xlink:label="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:label id="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_documentation_en-US" xlink:label="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:href="moln-20221231.xsd#moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:to="lab_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0730017c-be3a-43e4-96f3-22bd04a4f987_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_aa8af6af-9028-4c6f-8a6f-b53cd4eae318_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_3fcf78aa-7d16-487f-9104-0c792d7afa70_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU forfeited (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_d6976720-79ad-49c2-a534-26361df1a1f0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_b748e456-36bd-4d0b-b6a4-285293933461_totalLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues and other income</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_aed1f78d-6adf-4308-abcf-04d8b95b54d9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_fa7ce547-0941-4a46-82b2-c08e3335699d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_297a552f-3bbb-4a1d-932d-9c440c958b17_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IndividualsDomain_99ddf48d-6fa4-4889-926f-daf44997ef39_terseLabel_en-US" xlink:label="lab_moln_IndividualsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individuals [Domain]</link:label>
    <link:label id="lab_moln_IndividualsDomain_label_en-US" xlink:label="lab_moln_IndividualsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individuals [Domain]</link:label>
    <link:label id="lab_moln_IndividualsDomain_documentation_en-US" xlink:label="lab_moln_IndividualsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individuals [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsDomain" xlink:href="moln-20221231.xsd#moln_IndividualsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IndividualsDomain" xlink:to="lab_moln_IndividualsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_97ce20c8-b4ea-40dd-a4ba-d2216bb6a888_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_4eaa131c-fac2-4fc7-bf0e-084dce1e733d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Attribution of Expenses by Nature</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_a46058ef-107a-4434-9b1b-c085212dee78_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New or revised IFRS standards and interpretations</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_fd37247c-639e-40af-b8e0-94fdb474d484_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d108f0eb-fcc0-43da-b8f1-542dac47d8c4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock_5765bcde-70af-4918-a133-71aca0f80dd2_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Current and Non-Current Contract Liabilities</link:label>
    <link:label id="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Current And Non-Current Contract Liabilities [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Current And Non-Current Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" xlink:to="lab_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_46eb8af4-500e-4145-938b-fdbe96073557_terseLabel_en-US" xlink:label="lab_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative cost excl. cost for managing plan assets</link:label>
    <link:label id="lab_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administration costs not reflected in return on plan assets, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" xlink:to="lab_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_c5931157-5306-4d10-8666-664807b6fe4e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Net Defined Benefit Liability (Asset)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_998ac9cf-8b6c-485b-99bd-1699276870a6_periodStartLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments outstanding at beginning of period (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_dd073170-c859-420c-853f-d87559bed98d_periodEndLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments outstanding at end of period (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:to="lab_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3e0129f6-6741-45fc-9b00-6f60d3215307_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_CashAndCashEquivalentsMember_9cca1cc8-fe56-49c8-930e-1ac2fdcb58a9_terseLabel_en-US" xlink:label="lab_moln_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_moln_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_moln_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents [Member]</link:label>
    <link:label id="lab_moln_CashAndCashEquivalentsMember_documentation_en-US" xlink:label="lab_moln_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashAndCashEquivalentsMember" xlink:href="moln-20221231.xsd#moln_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_CashAndCashEquivalentsMember" xlink:to="lab_moln_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1cd4db18-58cd-409f-8f65-c75ad54020b1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of net pension liabilities, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_5e772050-358c-4e47-8ad6-aeb35105b6cf_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of net pension liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_b2d555a1-b788-495e-a4b1-560d10f94785_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of net pension liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_e371afb6-9f6f-4564-91af-f7dcaa0d5fd1_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_fd0439d2-fe77-49e1-8508-b2fe2b3edf7a_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions for employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_a24fcb42-0d4c-4d50-a4ef-65ebb7c46db6_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit cost recognized in profit or loss</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:to="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_b75352bd-0d34-42c2-a79a-3dd912e037a5_negatedTerseLabel_en-US" xlink:label="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments forfeited, performance adjustment (in shares)</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_label_en-US" xlink:label="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:label id="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_documentation_en-US" xlink:label="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:to="lab_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f8abd20-073e-4af3-a28b-a673d05b803b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_8c538511-d8ac-490d-9bd3-fa9f76b38d6c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_ffde49f5-ee97-48e0-a02d-6af03881f05f_terseLabel_en-US" xlink:label="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments in short-term time deposits</link:label>
    <link:label id="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities</link:label>
    <link:label id="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:href="moln-20221231.xsd#moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:to="lab_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c3432de1-c381-402a-a28e-dac96967e9f3_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_3c91dccb-e0f8-4cbd-8925-7f1ba3a7989e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of non-financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_eae2d1ae-1c36-4355-a10a-651bee928f66_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_853adfef-2f60-47bc-911b-4bf58ef69c4b_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Leases [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Leases [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Leases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutLeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherPayablesTable_e46b68c6-6a61-48f7-a351-70f518fa44f6_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherPayablesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Payables [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherPayablesTable_label_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherPayablesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Payables [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherPayablesTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherPayablesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherPayablesTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherPayablesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesTable" xlink:to="lab_moln_DisclosureOfTradeAndOtherPayablesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExercisePriceRangeTwoMember_6ce919b2-e3f6-4b95-a16a-6dbedea42eb1_terseLabel_en-US" xlink:label="lab_moln_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, range two</link:label>
    <link:label id="lab_moln_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_moln_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_moln_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_moln_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeTwoMember" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExercisePriceRangeTwoMember" xlink:to="lab_moln_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_ed7a3f69-b24f-4106-a517-66684989c826_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_d68f6dce-2d7f-49d2-9ad9-2efbe4c98fb6_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_label_en-US" xlink:label="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" xlink:to="lab_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_f73273b4-0551-4ff5-b4f0-cfe45ccc4f47_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_0c21825f-bc82-4236-9c40-670f2a540149_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_13a4c1e9-5071-4d42-b329-d32bd28392b9_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_fcdfbf35-f28d-4387-8d19-bab94123f6c7_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_1de64227-51b0-43a4-b019-81ebc6e0d77f_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2d4fffeb-8b53-4fe1-b729-e494ba7fe346_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_4df96407-6c25-4a28-9b50-b96666f6d3dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_1696810e-9c9f-4e41-8410-162f816afcfb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) / loss arising from experience adjustments</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains (losses) arising from experience adjustments, net of tax, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_58e6b2fe-3863-450e-8626-72f558ed9d49_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization charge for the year</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_6b026f4d-e0f6-4f0b-94ba-eef7c000c4ae_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_b6147ad6-26cb-40c0-8a87-388cd70151f9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on plan assets excluding interest income</link:label>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on plan assets excluding interest income or expense, net of tax, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RoyaltiesAndLicenseFeesExpense_448d739c-e373-4a43-b39e-cdc72194d513_negatedTerseLabel_en-US" xlink:label="lab_moln_RoyaltiesAndLicenseFeesExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and license fees</link:label>
    <link:label id="lab_moln_RoyaltiesAndLicenseFeesExpense_label_en-US" xlink:label="lab_moln_RoyaltiesAndLicenseFeesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties And License Fees Expense</link:label>
    <link:label id="lab_moln_RoyaltiesAndLicenseFeesExpense_documentation_en-US" xlink:label="lab_moln_RoyaltiesAndLicenseFeesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties And License Fees Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesAndLicenseFeesExpense" xlink:href="moln-20221231.xsd#moln_RoyaltiesAndLicenseFeesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RoyaltiesAndLicenseFeesExpense" xlink:to="lab_moln_RoyaltiesAndLicenseFeesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpiringIn2026Member_024b2c1e-0bd8-4bee-8de6-429aff628896_terseLabel_en-US" xlink:label="lab_moln_ExpiringIn2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_moln_ExpiringIn2026Member_label_en-US" xlink:label="lab_moln_ExpiringIn2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2026 [Member]</link:label>
    <link:label id="lab_moln_ExpiringIn2026Member_documentation_en-US" xlink:label="lab_moln_ExpiringIn2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2026Member" xlink:href="moln-20221231.xsd#moln_ExpiringIn2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpiringIn2026Member" xlink:to="lab_moln_ExpiringIn2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_66069370-482f-4874-ba0f-68d70a3d5acd_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_7b832fde-6e54-4b12-b605-a71e4b453b70_terseLabel_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_label_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_documentation_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" xlink:to="lab_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_c79e1187-f190-485a-8dfd-313a44a1ba12_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative losses</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_b794e03f-5876-434d-a384-788551b52342_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_4100040d-e4e3-44b9-aa01-01ce140d507d_terseLabel_en-US" xlink:label="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurements</link:label>
    <link:label id="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_label_en-US" xlink:label="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Remeasurements Of Leases, Operating Leases</link:label>
    <link:label id="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_documentation_en-US" xlink:label="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Remeasurements Of Leases, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" xlink:to="lab_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_dc4fe439-a193-4abe-9c5b-68d09e65696d_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember" xlink:to="lab_ifrs-full_ActuarialAssumptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_6df68e4b-9310-4df5-a29c-f62a31d90e86_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_8cbc92ed-2910-4af5-a3eb-18bad2ed32d6_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_ca7a1553-8fee-45ba-81b3-13327a43a39e_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits [Line Items]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_1045c5ce-084f-46c5-9787-b78d98340883_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_07572324-91e7-45ab-816b-5550221a8d57_terseLabel_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items by function [member]</link:label>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_label_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items by function [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LineItemsByFunctionMember" xlink:to="lab_ifrs-full_LineItemsByFunctionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_1e842380-fcac-476a-9683-285b101305fd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Putative Class Action</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_15c3f8a4-1a2c-475a-801c-3d6ac93de62a_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_2a591361-e2c3-4063-afb1-38cd039cf2ae_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ef74284a-0d55-4033-ae2e-4d77d2c75546_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_12670f03-0eb1-433a-8f8c-4a2ecf21807d_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_bd97a1e2-de34-4fec-b32b-4041469259ee_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_7bf5fc0b-c2da-4c1e-ac7c-ee86faf78212_terseLabel_en-US" xlink:label="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">thereof service cost and administrative cost</link:label>
    <link:label id="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_label_en-US" xlink:label="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Cost And Administrative Cost, Defined Benefit Plans</link:label>
    <link:label id="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_documentation_en-US" xlink:label="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Cost And Administrative Cost, Defined Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" xlink:href="moln-20221231.xsd#moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" xlink:to="lab_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock_0b31b4bc-743c-49fb-b735-0c74e65d07d1_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income</link:label>
    <link:label id="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:to="lab_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_4cda7206-75a3-41b4-b221-93c3f1861c1a_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Other Current Assets</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_b8b0e5f9-3730-4010-a7c6-00ae8afd1b10_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Explanation of Changes in Contract Liabilities</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_31b2d1e4-a5c8-4a53-969a-39534b568762_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PastServiceCostDefinedBenefitPlans_f72895ea-6b93-40e2-80f4-56070aa5db52_terseLabel_en-US" xlink:label="lab_ifrs-full_PastServiceCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past service cost</link:label>
    <link:label id="lab_ifrs-full_PastServiceCostDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_PastServiceCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past service cost, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PastServiceCostDefinedBenefitPlans" xlink:to="lab_ifrs-full_PastServiceCostDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RoyaltyExpense_06f6c0d4-0adc-4e12-9c75-2a3ca28e6636_terseLabel_en-US" xlink:label="lab_ifrs-full_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_ifrs-full_RoyaltyExpense_label_en-US" xlink:label="lab_ifrs-full_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RoyaltyExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RoyaltyExpense" xlink:to="lab_ifrs-full_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfBanksWhereDepositsAreHeld_70cf5bb6-c36b-4968-987d-2e259f11fb6e_terseLabel_en-US" xlink:label="lab_moln_NumberOfBanksWhereDepositsAreHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of banks where deposits are held</link:label>
    <link:label id="lab_moln_NumberOfBanksWhereDepositsAreHeld_label_en-US" xlink:label="lab_moln_NumberOfBanksWhereDepositsAreHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Banks Where Deposits Are Held</link:label>
    <link:label id="lab_moln_NumberOfBanksWhereDepositsAreHeld_documentation_en-US" xlink:label="lab_moln_NumberOfBanksWhereDepositsAreHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Banks Where Deposits Are Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfBanksWhereDepositsAreHeld" xlink:href="moln-20221231.xsd#moln_NumberOfBanksWhereDepositsAreHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfBanksWhereDepositsAreHeld" xlink:to="lab_moln_NumberOfBanksWhereDepositsAreHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_963b8958-b745-4a0d-a1c7-f103bc665727_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_5d9984a5-7b4a-475a-a82b-2e7a70b560f0_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_2513a8c4-5cd7-4e90-9b31-e771b3c5caa8_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive result, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_56156f14-59c6-4b82-8afe-8cd7ab021dff_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_ef2eeb78-6d4a-4cd1-946f-e1be30a94e0e_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_80a77c54-0461-47cc-8d24-4b3e3cde4013_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_IncomeTaxesAndDeferredTaxesAbstract_8e3e28c3-39d9-467c-b938-2d6ec7d72c1c_terseLabel_en-US" xlink:label="lab_moln_IncomeTaxesAndDeferredTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes And Deferred Taxes [Abstract]</link:label>
    <link:label id="lab_moln_IncomeTaxesAndDeferredTaxesAbstract_label_en-US" xlink:label="lab_moln_IncomeTaxesAndDeferredTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes And Deferred Taxes [Abstract]</link:label>
    <link:label id="lab_moln_IncomeTaxesAndDeferredTaxesAbstract_documentation_en-US" xlink:label="lab_moln_IncomeTaxesAndDeferredTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncomeTaxesAndDeferredTaxesAbstract" xlink:href="moln-20221231.xsd#moln_IncomeTaxesAndDeferredTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_IncomeTaxesAndDeferredTaxesAbstract" xlink:to="lab_moln_IncomeTaxesAndDeferredTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_8104c2a4-3be6-4ad7-beb1-70b1c9901cac_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_label_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:to="lab_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_5e9b0fc8-68e0-4165-890a-619a59e89f42_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets_3193f0f4-316f-406d-bf5b-51f994511274_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">thereof entity's own transferable financial instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's own financial instruments included in fair value of plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" xlink:to="lab_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_a21fdf3e-9897-4831-bbc3-626b6f04f0be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NetOperatingProfit_cf7d0cad-6bb3-4d01-b12a-fc982c4d31c3_terseLabel_en-US" xlink:label="lab_moln_NetOperatingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating profit</link:label>
    <link:label id="lab_moln_NetOperatingProfit_label_en-US" xlink:label="lab_moln_NetOperatingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Profit</link:label>
    <link:label id="lab_moln_NetOperatingProfit_documentation_en-US" xlink:label="lab_moln_NetOperatingProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NetOperatingProfit" xlink:href="moln-20221231.xsd#moln_NetOperatingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NetOperatingProfit" xlink:to="lab_moln_NetOperatingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_1be1fb49-85cb-4588-b884-f3b829741b19_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_a49c44a8-3f21-471d-a5fe-6f41af5b3754_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_97b69cfa-ec32-452b-a44a-f103a1ff8fd1_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_3f861e64-5baa-48b2-ad31-6b76204a9495_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets at end of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_50fc4fa3-2e66-4fac-a154-570aed4360c8_negatedLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of net pension liabilities</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_c5c93771-232d-450d-bea4-0f57b2be0c79_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain)/loss on defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LeaseExtensionTermOfContract_dd52f1a6-0a87-4b23-8715-71c137664b96_terseLabel_en-US" xlink:label="lab_moln_LeaseExtensionTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, extension term</link:label>
    <link:label id="lab_moln_LeaseExtensionTermOfContract_label_en-US" xlink:label="lab_moln_LeaseExtensionTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Term Of Contract</link:label>
    <link:label id="lab_moln_LeaseExtensionTermOfContract_documentation_en-US" xlink:label="lab_moln_LeaseExtensionTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Term Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseExtensionTermOfContract" xlink:href="moln-20221231.xsd#moln_LeaseExtensionTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LeaseExtensionTermOfContract" xlink:to="lab_moln_LeaseExtensionTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_eaea807f-44f3-467a-bb29-fd05db4045f5_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD</link:label>
    <link:label id="lab_currency_USD_5b46a866-3c64-447a-8fd2-fcd8dedea522_verboseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD Positions</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_55839c9d-8d95-48e9-b90a-47ebac6a068d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items that are or may be reclassified subsequently to profit or loss</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_1d534a78-f202-478b-825e-6257917a0a1b_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net result, attributable to shareholders</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_d286a4a5-7248-4e0b-bee0-97d08c57c4ef_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net result attributable to shareholders</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_7c088f10-72ee-4a67-841d-24d83d7c22a7_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net result</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_fefb0a46-a700-425d-b9ac-47b6ba29e048_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortized costs</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_69a45084-08f3-466a-b181-f6c53114a221_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_3f012863-dd1c-46b4-97cd-d6e90313c183_terseLabel_en-US" xlink:label="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of VSAO contributions in total company's defined benefit plans</link:label>
    <link:label id="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_label_en-US" xlink:label="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of VSAO Contributions In Total Company's Defined Benefit Plans</link:label>
    <link:label id="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_documentation_en-US" xlink:label="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of VSAO Contributions In Company's Total Defined Benefit Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" xlink:href="moln-20221231.xsd#moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" xlink:to="lab_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_CriticalAccountingEstimatesAndJudgmentsAbstract_label_en-US" xlink:label="lab_moln_CriticalAccountingEstimatesAndJudgmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Estimates and Judgments [Abstract]</link:label>
    <link:label id="lab_moln_CriticalAccountingEstimatesAndJudgmentsAbstract_documentation_en-US" xlink:label="lab_moln_CriticalAccountingEstimatesAndJudgmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Estimates and Judgments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CriticalAccountingEstimatesAndJudgmentsAbstract" xlink:href="moln-20221231.xsd#moln_CriticalAccountingEstimatesAndJudgmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_CriticalAccountingEstimatesAndJudgmentsAbstract" xlink:to="lab_moln_CriticalAccountingEstimatesAndJudgmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_406b1e66-b97a-4a67-aba7-8a26d7764b8b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_5e725d3a-e7db-41a2-ac86-035204f40bdf_terseLabel_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting, percent</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_label_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Percent</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_documentation_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementPercent" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VestingRequirementsForShareBasedPaymentArrangementPercent" xlink:to="lab_moln_VestingRequirementsForShareBasedPaymentArrangementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpiringIn2024Member_be162ad2-e11a-4558-a9ce-43c3d8aad880_terseLabel_en-US" xlink:label="lab_moln_ExpiringIn2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_moln_ExpiringIn2024Member_label_en-US" xlink:label="lab_moln_ExpiringIn2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2024 [Member]</link:label>
    <link:label id="lab_moln_ExpiringIn2024Member_documentation_en-US" xlink:label="lab_moln_ExpiringIn2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2024Member" xlink:href="moln-20221231.xsd#moln_ExpiringIn2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpiringIn2024Member" xlink:to="lab_moln_ExpiringIn2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_1af488a8-33a0-45ff-bf6e-831bab37398e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability at beginning of period</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_1f403174-5219-462b-a95b-323fbc9795c8_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability at end of period</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_1a4764a9-67c6-48a6-9dc6-09a9421fb36c_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_eccfd041-b73c-4b20-9584-7d5b146788fd_totalLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_96f85aba-d62f-4cbc-8006-154344fa2859_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net result per share (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock_14e40de7-c67e-45e4-8f3e-accb26ca4a89_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information about Financial Expense</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Expense [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_e2198d74-67c7-4a68-8433-fe82c02cf1a1_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 2 and 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than two years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_c0ba63db-e31e-4298-a737-062478cf3b1d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_d3f18284-5d11-4b0c-bbc4-fba79a53c56b_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Number of Shares Used in Computation</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_7667898a-f864-47cc-9159-3f3bd9613676_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_718341f8-0271-4bd5-8c25-35c76a21c0df_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of treasury shares incl. transaction costs</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through treasury share transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_e53e8ebf-7b26-4fc1-ac7b-13c65fa2f8af_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_8cd730e0-3e60-4a1c-9c5e-ede11706ec10_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_852aaf67-a127-4cb7-a521-96aa666dc64e_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentServiceCostDefinedBenefitPlans_6f85dc2d-d328-4390-92ed-c3c17e33dd9f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current service cost (employer)</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current service cost, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:to="lab_ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_904f7f96-21da-44e4-b757-bf90b502e549_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_ce15ca12-2276-4e5c-84df-a29d800fa465_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation costs</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_53149b62-9420-464f-bb52-b79722b8938d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_14a6b883-f274-4994-a55a-9e9c0838178c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_a7975fd4-3814-4fef-b147-25d4d7699c1e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of trade and other receivables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_b6559021-b6a9-4a43-b469-17ea19246c9b_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2e0f0b3b-669b-4a59-bc27-4e8bb9613bb8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement_38f7caea-3b11-4098-9080-5785167e8c70_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of instruments granted (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="lab_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DefinedBenefitPlanEmployerContribution_7e8e3526-80a5-479e-be71-3a08523f549f_terseLabel_en-US" xlink:label="lab_moln_DefinedBenefitPlanEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, employer contribution</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanEmployerContribution_label_en-US" xlink:label="lab_moln_DefinedBenefitPlanEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution</link:label>
    <link:label id="lab_moln_DefinedBenefitPlanEmployerContribution_documentation_en-US" xlink:label="lab_moln_DefinedBenefitPlanEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanEmployerContribution" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanEmployerContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DefinedBenefitPlanEmployerContribution" xlink:to="lab_moln_DefinedBenefitPlanEmployerContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_154440dc-2719-4f63-a496-0e26a8122b50_terseLabel_en-US" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis to Reasonable Possible Change in Exchange Rates and Interest Rates</link:label>
    <link:label id="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_label_en-US" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of market risk [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:to="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_932f3be6-c442-4cae-829b-28226aca2b78_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_9bb1064b-ceb2-405c-98d5-d9fca0d63e0c_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration of defined obligation in years at December 31</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration of defined benefit obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:to="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember_3d07b3a9-27c3-4511-80d7-18b17e9e5afe_terseLabel_en-US" xlink:label="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-employee related accrued expenses</link:label>
    <link:label id="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember_label_en-US" xlink:label="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Employee Related Accrued Expenses [Member]</link:label>
    <link:label id="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember_documentation_en-US" xlink:label="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Employee Related Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherNonEmployeeRelatedAccruedExpensesMember" xlink:href="moln-20221231.xsd#moln_OtherNonEmployeeRelatedAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_OtherNonEmployeeRelatedAccruedExpensesMember" xlink:to="lab_moln_OtherNonEmployeeRelatedAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_f36181c9-ecc2-4fdb-85f2-403e5e72fab7_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_99914c5e-b0cb-47d3-9051-0398ab1855fb_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_85c2d66c-a588-4fbb-9e0a-86c3d505830f_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b8d55cfb-c838-4bd2-948a-50a52e585ebc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_4a6c106a-63de-45cd-b6f8-7b183a0881f2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares used in computing diluted loss per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_c8f4d6bc-5743-4295-9585-96c4bf06a786_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at amortized cost</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_07c83bf9-7e69-4680-9a85-7b69db57136f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options expired (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember_4ab1aff6-ae5b-4b9a-9b67-d16c20bf4222_terseLabel_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FOPH, Switzerland</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember_label_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement With FOPH [Member]</link:label>
    <link:label id="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember_documentation_en-US" xlink:label="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement With FOPH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithFOPHMember" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithFOPHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_LicenseAndCollaborationAgreementWithFOPHMember" xlink:to="lab_moln_LicenseAndCollaborationAgreementWithFOPHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_9b1ffc90-bd4e-453e-817e-5bfaaf58eb7d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items that will not be reclassified to profit or loss</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_8c19970e-87db-4ba7-a151-64c4dd4dcefe_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR</link:label>
    <link:label id="lab_currency_EUR_3e9a3b5a-8979-49ee-af84-9976c91a69af_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR Positions</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_6212b99a-0b8b-431c-8966-fa3c8a71932a_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherReceivablesTable_1fae4d05-0aa9-4d07-a317-4ab778b6a83c_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherReceivablesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherReceivablesTable_label_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherReceivablesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables [Table]</link:label>
    <link:label id="lab_moln_DisclosureOfTradeAndOtherReceivablesTable_documentation_en-US" xlink:label="lab_moln_DisclosureOfTradeAndOtherReceivablesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherReceivablesTable" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherReceivablesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesTable" xlink:to="lab_moln_DisclosureOfTradeAndOtherReceivablesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExpiringIn2023Member_22e36869-d1bf-4ce5-a540-f8d511282d24_terseLabel_en-US" xlink:label="lab_moln_ExpiringIn2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_moln_ExpiringIn2023Member_label_en-US" xlink:label="lab_moln_ExpiringIn2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2023 [Member]</link:label>
    <link:label id="lab_moln_ExpiringIn2023Member_documentation_en-US" xlink:label="lab_moln_ExpiringIn2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring In 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2023Member" xlink:href="moln-20221231.xsd#moln_ExpiringIn2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExpiringIn2023Member" xlink:to="lab_moln_ExpiringIn2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_9c1be9b1-033d-4e8e-878f-9b9ef713610d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract_c6c6bcd3-efa4-44e2-8f57-fd0871a5118c_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="lab_moln_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_6e13932d-6778-4304-9587-a2c512946675_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_620c8d46-ff81-4265-bac1-f11f2722b04a_terseLabel_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff vesting period</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_label_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period</link:label>
    <link:label id="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_documentation_en-US" xlink:label="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" xlink:to="lab_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock_67879fe4-1be4-4d62-bed2-4cd71d9d034d_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information about Financial Income</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Income [Table Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" xlink:to="lab_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_ExercisePriceRangeOneMember_61ea66ce-6432-46f6-a6cf-800936d00f24_terseLabel_en-US" xlink:label="lab_moln_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, range one</link:label>
    <link:label id="lab_moln_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_moln_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_moln_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_moln_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeOneMember" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_ExercisePriceRangeOneMember" xlink:to="lab_moln_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_d3da4018-dcbe-402b-b453-3de541742148_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock_6b6af636-56a7-482d-821c-edb2c7cbb476_terseLabel_en-US" xlink:label="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term time deposits</link:label>
    <link:label id="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock_label_en-US" xlink:label="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits [Text Block]</link:label>
    <link:label id="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock_documentation_en-US" xlink:label="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" xlink:href="moln-20221231.xsd#moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" xlink:to="lab_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansMember_a4980e56-a71f-4f4d-bbb8-cc0028a3ba6a_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [member]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember" xlink:to="lab_ifrs-full_DefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_13251764-bc79-47a5-8019-3cd65ef2eb5a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU outstanding at beginning of period (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_1b69593e-1883-4364-803f-4346d7b8266f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU outstanding at end of period (in CHF per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_AccruedIncomeMember_b560af81-70a8-4798-97bd-b49608a91748_terseLabel_en-US" xlink:label="lab_moln_AccruedIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income</link:label>
    <link:label id="lab_moln_AccruedIncomeMember_label_en-US" xlink:label="lab_moln_AccruedIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income [Member]</link:label>
    <link:label id="lab_moln_AccruedIncomeMember_documentation_en-US" xlink:label="lab_moln_AccruedIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedIncomeMember" xlink:href="moln-20221231.xsd#moln_AccruedIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_AccruedIncomeMember" xlink:to="lab_moln_AccruedIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_c8775fd8-55eb-466d-8931-56389499ec25_terseLabel_en-US" xlink:label="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of total number of shares in a placement</link:label>
    <link:label id="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_label_en-US" xlink:label="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preemptive Rights, Over-Allotment Option, Maximum Percentage Of Total Number Of Shares In A Placement</link:label>
    <link:label id="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_documentation_en-US" xlink:label="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preemptive Rights, Over-Allotment Option, Maximum Percentage Of Total Number Of Shares In A Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" xlink:href="moln-20221231.xsd#moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" xlink:to="lab_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_0a6f8b92-3cb2-4acb-9f54-411bd9df89a4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) / loss on changes in demographic assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains (losses) arising from changes in demographic assumptions, net of tax, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_21fa2abe-e1e7-4d0b-9df3-740fc6885ac1_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_label_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of defined benefit obligation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:to="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_b4a6eeb2-08c7-4878-bec5-4ac0cf5d50e1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional information on the nature of expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of expenses by nature [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_b1fc6c0f-897e-4069-ad54-3965d5424a71_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_21735b2d-cf4e-44ad-87e8-9f44f60e2871_terseLabel_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of PSU and RSU forfeited, performance adjustment (in CHF per share)</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_label_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:label id="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_documentation_en-US" xlink:label="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:to="lab_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity_c4c72126-065f-48fc-9d44-8d3a61ce9bc6_terseLabel_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in relation to Novartis agreement in October 2020</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity_label_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Relation To License And Collaboration Agreement, Equity</link:label>
    <link:label id="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity_documentation_en-US" xlink:label="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Relation To License And Collaboration Agreement, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" xlink:to="lab_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_cef8d200-a811-4364-a3a3-f5a094f35b9d_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments (e.g. bonds)</link:label>
    <link:label id="lab_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_label_en-US" xlink:label="lab_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, amount contributed to fair value of plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_1d672d61-c0c0-467e-acde-2fbfb3711903_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_PersonnelExpensesAbstract_8b89807f-8c3e-4be1-b0c7-597b7566b676_terseLabel_en-US" xlink:label="lab_moln_PersonnelExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel Expenses [Abstract]</link:label>
    <link:label id="lab_moln_PersonnelExpensesAbstract_label_en-US" xlink:label="lab_moln_PersonnelExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel Expenses [Abstract]</link:label>
    <link:label id="lab_moln_PersonnelExpensesAbstract_documentation_en-US" xlink:label="lab_moln_PersonnelExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_PersonnelExpensesAbstract" xlink:to="lab_moln_PersonnelExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_136b2534-86b0-474c-ad71-aa939edaa4ac_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Movements in the Number of Share Options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_96af2019-7cb3-4225-b10a-0b58e2292965_terseLabel_en-US" xlink:label="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, common shares</link:label>
    <link:label id="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, Common Share, Other Equity Instruments Granted</link:label>
    <link:label id="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, Common Share, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" xlink:to="lab_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_4862159c-b9e9-4787-89e1-37f0ab6b3853_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>moln-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5bc598d-29c0-45ac-9809-ee4bc6e3f0aa,g:d67c3c2e-5cb8-4330-bb94-e6e901fa056b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Cover" xlink:type="simple" xlink:href="moln-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_86dcdd65-38f0-4396-992d-7ad63dc701c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86dcdd65-38f0-4396-992d-7ad63dc701c1" xlink:to="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_9dbe74be-3a55-4fff-a216-b227738ed189" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_21e838ad-9772-4f16-9e8f-e82b3887a672" xlink:to="loc_dei_AddressTypeDomain_9dbe74be-3a55-4fff-a216-b227738ed189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_a93013f3-a0bb-413f-b50b-b50f23e1d75f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_9dbe74be-3a55-4fff-a216-b227738ed189" xlink:to="loc_dei_BusinessContactMember_a93013f3-a0bb-413f-b50b-b50f23e1d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:to="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_50ef5458-2b4d-4700-89c3-6e5237750d20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_be0dd4c3-6532-4d4a-834a-82678c8abdbd" xlink:to="loc_dei_ExchangeDomain_50ef5458-2b4d-4700-89c3-6e5237750d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_fbbcb00a-14b0-4131-8843-6f24056b7e2b" xlink:href="moln-20221231.xsd#moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_50ef5458-2b4d-4700-89c3-6e5237750d20" xlink:to="loc_moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember_fbbcb00a-14b0-4131-8843-6f24056b7e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ce4661db-0291-4c57-9732-79ef989588fe" xlink:to="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_09ecc5f5-376f-4f7d-bd5a-f55021276f74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentType_09ecc5f5-376f-4f7d-bd5a-f55021276f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_5ab80edf-fbf0-4cd5-8d05-f76d89c0e5ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentRegistrationStatement_5ab80edf-fbf0-4cd5-8d05-f76d89c0e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c86ab01f-aa32-4c4b-8112-9d740799986d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentAnnualReport_c86ab01f-aa32-4c4b-8112-9d740799986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_574be2aa-4aab-4577-99ef-fb1f82e168d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentPeriodEndDate_574be2aa-4aab-4577-99ef-fb1f82e168d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2475790-3e6c-408d-aa2a-d71f3012d9e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2475790-3e6c-408d-aa2a-d71f3012d9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_57dc8258-3849-436f-968d-85b9c29769fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentTransitionReport_57dc8258-3849-436f-968d-85b9c29769fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_6f8842aa-d6eb-466f-9c27-fcd327e71e87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentShellCompanyReport_6f8842aa-d6eb-466f-9c27-fcd327e71e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3e4065ac-24be-4447-8560-e1e96a6468c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityFileNumber_3e4065ac-24be-4447-8560-e1e96a6468c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c831ea4c-6db8-406e-b1cf-af5aa74e5822" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityRegistrantName_c831ea4c-6db8-406e-b1cf-af5aa74e5822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f55b52c7-a649-4f39-ae9f-a9acc954a5d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f55b52c7-a649-4f39-ae9f-a9acc954a5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ea9910e3-9d47-4551-8717-01c4b3cfad20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressAddressLine1_ea9910e3-9d47-4551-8717-01c4b3cfad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5c5ac0e1-9988-4334-bba0-cbec1cd8c252" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressPostalZipCode_5c5ac0e1-9988-4334-bba0-cbec1cd8c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f9319bab-b515-4584-9038-d193fa6e542c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressCityOrTown_f9319bab-b515-4584-9038-d193fa6e542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_03d840a4-b12d-4686-b338-43fd8d59e106" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityAddressCountry_03d840a4-b12d-4686-b338-43fd8d59e106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_cf82c594-afd4-4413-ae25-801d9fe7e57c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_ContactPersonnelName_cf82c594-afd4-4413-ae25-801d9fe7e57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ebb25822-d7cb-4d06-8f7b-0a5bf67116a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_CityAreaCode_ebb25822-d7cb-4d06-8f7b-0a5bf67116a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_de75a4cd-813d-43ce-9944-3fb5cfd2e167" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_LocalPhoneNumber_de75a4cd-813d-43ce-9944-3fb5cfd2e167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d0397f85-a9a2-4a50-ba15-df0272be2e47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_Security12bTitle_d0397f85-a9a2-4a50-ba15-df0272be2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f21f697f-db93-4cdd-ae2e-a58f2960afae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_TradingSymbol_f21f697f-db93-4cdd-ae2e-a58f2960afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_52ccbcc8-b73b-41a7-ae89-c4d85d78cba3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_SecurityExchangeName_52ccbcc8-b73b-41a7-ae89-c4d85d78cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_27fffa9d-69bb-464d-9d98-6416f66cdd52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_27fffa9d-69bb-464d-9d98-6416f66cdd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a5bcd387-bb8a-4acc-9fb0-30c694a9188a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a5bcd387-bb8a-4acc-9fb0-30c694a9188a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_34734aa6-5ec1-4fd7-aedf-ece3613e08a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityVoluntaryFilers_34734aa6-5ec1-4fd7-aedf-ece3613e08a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1dfe275b-63fd-44b4-bf20-40491a5a27b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityCurrentReportingStatus_1dfe275b-63fd-44b4-bf20-40491a5a27b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1919609a-4d9d-4f7b-ac65-a39a56f651db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityInteractiveDataCurrent_1919609a-4d9d-4f7b-ac65-a39a56f651db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1d1c736f-9b6a-4e21-8130-14f7a36381f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityFilerCategory_1d1c736f-9b6a-4e21-8130-14f7a36381f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_71081381-6f6e-48ef-804c-c9a440250c5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityEmergingGrowthCompany_71081381-6f6e-48ef-804c-c9a440250c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_3eac859e-4f1c-4bd2-ad0a-fd52fde932a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityExTransitionPeriod_3eac859e-4f1c-4bd2-ad0a-fd52fde932a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bcb8e291-29f9-4f44-94aa-c61ec8ce99cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bcb8e291-29f9-4f44-94aa-c61ec8ce99cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_ca471b09-edb1-4f0b-8ee5-232da4043f0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentAccountingStandard_ca471b09-edb1-4f0b-8ee5-232da4043f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f9ba116f-3474-4de0-8dd7-ed304a901f95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityShellCompany_f9ba116f-3474-4de0-8dd7-ed304a901f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_616c4549-8d15-48b0-ba62-f318144c763e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_AmendmentFlag_616c4549-8d15-48b0-ba62-f318144c763e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cb8a327e-23da-4993-9aed-7a4599980739" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentFiscalYearFocus_cb8a327e-23da-4993-9aed-7a4599980739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e427dd92-db45-4f0c-be4a-32cd3b86cbd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e427dd92-db45-4f0c-be4a-32cd3b86cbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6001ad45-61a7-4f48-bfa0-a93a8d4f1f42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_EntityCentralIndexKey_6001ad45-61a7-4f48-bfa0-a93a8d4f1f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_9b9ab311-3dd6-4c70-b9d7-21a562cdacf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f4ae03d8-025a-4324-a38c-8aac5c7a1b72" xlink:to="loc_dei_NoTradingSymbolFlag_9b9ab311-3dd6-4c70-b9d7-21a562cdacf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AuditInformation" xlink:type="simple" xlink:href="moln-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuditorInformationAbstract_e5e8f90e-cdba-471f-8eec-29af5e155e37" xlink:href="moln-20221231.xsd#moln_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ef0f3633-e9cf-429e-a4a1-215a72b37a0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_AuditorInformationAbstract_e5e8f90e-cdba-471f-8eec-29af5e155e37" xlink:to="loc_dei_AuditorFirmId_ef0f3633-e9cf-429e-a4a1-215a72b37a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_e567ea82-7bd5-47f2-a679-d5c726f90009" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_AuditorInformationAbstract_e5e8f90e-cdba-471f-8eec-29af5e155e37" xlink:to="loc_dei_AuditorName_e567ea82-7bd5-47f2-a679-d5c726f90009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_471b68da-629d-4b6c-ba37-5a13478d61b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_AuditorInformationAbstract_e5e8f90e-cdba-471f-8eec-29af5e155e37" xlink:to="loc_dei_AuditorLocation_471b68da-629d-4b6c-ba37-5a13478d61b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofFinancialPosition"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_0031e5fb-6dd8-485e-aee0-7ca84e852d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0031e5fb-6dd8-485e-aee0-7ca84e852d99" xlink:to="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_94085502-4584-4fb4-bb33-2c915331817c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_94085502-4584-4fb4-bb33-2c915331817c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_c36b9cd5-6473-4131-9f7e-1ba88d6f3fd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_c36b9cd5-6473-4131-9f7e-1ba88d6f3fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_f4e7a70d-b0b0-467f-8913-ae6bc34322a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_NoncurrentAssets_f4e7a70d-b0b0-467f-8913-ae6bc34322a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_f6daa454-26e8-4fc9-b04d-20b2131011d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_f6daa454-26e8-4fc9-b04d-20b2131011d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_5aa92666-4621-459a-a454-0422df1edfc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_OtherCurrentAssets_5aa92666-4621-459a-a454-0422df1edfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_1090d142-5fc5-42c1-b656-3823c3111347" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_1090d142-5fc5-42c1-b656-3823c3111347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8acf3e62-3659-4c91-8769-40755def3999" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8acf3e62-3659-4c91-8769-40755def3999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_1856d36f-c309-4cbe-b5e9-6cd0e7e4ad79" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_CurrentAssets_1856d36f-c309-4cbe-b5e9-6cd0e7e4ad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_2d7919b6-1329-4167-ab2a-c1d3179cfe50" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6ea43ecc-04f4-44d5-87e4-5e19fa7a9f99" xlink:to="loc_ifrs-full_Assets_2d7919b6-1329-4167-ab2a-c1d3179cfe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0031e5fb-6dd8-485e-aee0-7ca84e852d99" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_2920eb93-f9d8-490d-9cd9-df4ce5190712" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_IssuedCapital_2920eb93-f9d8-490d-9cd9-df4ce5190712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_c21772ab-d3d6-45bc-8f01-a89d3bde6b01" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_c21772ab-d3d6-45bc-8f01-a89d3bde6b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_5645d07a-d41e-46a9-a4c8-f9801b488e66" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_TreasuryShares_5645d07a-d41e-46a9-a4c8-f9801b488e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_032d8934-d130-4476-a696-75e29eb005e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_RetainedEarnings_032d8934-d130-4476-a696-75e29eb005e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3e775f02-5e4b-49ab-a814-360f0187e117" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_Equity_3e775f02-5e4b-49ab-a814-360f0187e117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_1cfad209-6feb-4e5d-b229-69b9cadfcc02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_1cfad209-6feb-4e5d-b229-69b9cadfcc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_21874a6d-27dd-4e59-ae86-b87e6e3c5793" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_21874a6d-27dd-4e59-ae86-b87e6e3c5793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_cdd2d300-cbd0-40d9-8106-8167f0d5720f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_cdd2d300-cbd0-40d9-8106-8167f0d5720f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_445dd187-02a8-45d8-95d7-6628dc2932b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_NoncurrentLiabilities_445dd187-02a8-45d8-95d7-6628dc2932b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_690a80fe-d0ca-40dd-acb7-feee3b9bd91f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_690a80fe-d0ca-40dd-acb7-feee3b9bd91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_c3b4a321-d058-40f9-896a-646a0c7fb563" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_c3b4a321-d058-40f9-896a-646a0c7fb563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_d4e0eaa8-a81c-483f-802f-690490a8cecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_CurrentContractLiabilities_d4e0eaa8-a81c-483f-802f-690490a8cecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_4e2f9bce-aa29-46c2-8baf-0abc03b410f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_4e2f9bce-aa29-46c2-8baf-0abc03b410f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_33d4b22c-1164-4cfe-9c58-7908049b6adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_CurrentLiabilities_33d4b22c-1164-4cfe-9c58-7908049b6adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_acad380b-19a6-4525-8912-fff212f99706" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_Liabilities_acad380b-19a6-4525-8912-fff212f99706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_7a3044be-28de-4003-9f51-639335cad29d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_a3807973-67c1-4297-a0fc-18225284b3ae" xlink:to="loc_ifrs-full_EquityAndLiabilities_7a3044be-28de-4003-9f51-639335cad29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_f42037ed-1544-4aed-8873-f7af241ebc80" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_RevenueAbstract_f42037ed-1544-4aed-8873-f7af241ebc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_53184bb1-695e-4013-b0da-abb306a02ee8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_f42037ed-1544-4aed-8873-f7af241ebc80" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_53184bb1-695e-4013-b0da-abb306a02ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_14c13bb4-481a-4a57-8d00-687c6a12786d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_f42037ed-1544-4aed-8873-f7af241ebc80" xlink:to="loc_ifrs-full_OtherIncome_14c13bb4-481a-4a57-8d00-687c6a12786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_9b86f481-9f24-4c43-b12f-42245ccee2f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_f42037ed-1544-4aed-8873-f7af241ebc80" xlink:to="loc_ifrs-full_Revenue_9b86f481-9f24-4c43-b12f-42245ccee2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OperatingExpensesAbstract_5e205c22-5b4d-40ce-8469-ca31ed94dd67" xlink:href="moln-20221231.xsd#moln_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_moln_OperatingExpensesAbstract_5e205c22-5b4d-40ce-8469-ca31ed94dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_832b6373-a856-4b6b-b144-7fc7d81024ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_OperatingExpensesAbstract_5e205c22-5b4d-40ce-8469-ca31ed94dd67" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_832b6373-a856-4b6b-b144-7fc7d81024ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6b6fb226-492d-4d9b-b9f0-c0ab0ee5ef9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_OperatingExpensesAbstract_5e205c22-5b4d-40ce-8469-ca31ed94dd67" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6b6fb226-492d-4d9b-b9f0-c0ab0ee5ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_c91cf296-cc00-405b-8bf9-e872d6f80e14" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_OperatingExpensesAbstract_5e205c22-5b4d-40ce-8469-ca31ed94dd67" xlink:to="loc_ifrs-full_OperatingExpense_c91cf296-cc00-405b-8bf9-e872d6f80e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_a47ff220-3f9e-47cf-bc7f-a4d74fdbc8a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_a47ff220-3f9e-47cf-bc7f-a4d74fdbc8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_1d5024a5-9ee9-4500-acfd-560a38e2cf3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_FinanceIncome_1d5024a5-9ee9-4500-acfd-560a38e2cf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_50a21902-bae6-496e-9c5c-8f207def1757" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_FinanceCosts_50a21902-bae6-496e-9c5c-8f207def1757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_59fe3238-4c28-4f90-bdd8-992cf339e702" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_FinanceIncomeCost_59fe3238-4c28-4f90-bdd8-992cf339e702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_fcfbd70f-9712-490c-92c6-2977abacffc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_fcfbd70f-9712-490c-92c6-2977abacffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_7622938a-ae66-4aec-a99d-4616cf193f14" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_7622938a-ae66-4aec-a99d-4616cf193f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_177d87a8-1196-4236-a3da-0d68bd626ff7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_ProfitLoss_177d87a8-1196-4236-a3da-0d68bd626ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_159efbd4-862b-452d-bca3-554508272c82" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_159efbd4-862b-452d-bca3-554508272c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_9e669420-3146-4782-b79c-826e63fbf9b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_159efbd4-862b-452d-bca3-554508272c82" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_9e669420-3146-4782-b79c-826e63fbf9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9ae1361e-b24e-4bb1-90dc-32e0c4e35d15" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_9e669420-3146-4782-b79c-826e63fbf9b6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9ae1361e-b24e-4bb1-90dc-32e0c4e35d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1333c178-24e0-45b4-b1a3-77f622d9550f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_159efbd4-862b-452d-bca3-554508272c82" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1333c178-24e0-45b4-b1a3-77f622d9550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_15e3c295-eb68-4fef-ae28-c1734604653c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1333c178-24e0-45b4-b1a3-77f622d9550f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_15e3c295-eb68-4fef-ae28-c1734604653c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_998d6b9c-86d8-455e-a1a8-badfedfd7cd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_159efbd4-862b-452d-bca3-554508272c82" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_998d6b9c-86d8-455e-a1a8-badfedfd7cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_0488c99f-aee9-4a8c-bf78-9f773d15923a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_ComprehensiveIncome_0488c99f-aee9-4a8c-bf78-9f773d15923a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_4cd243c8-34e6-4791-8579-dc96f8de31b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_4cd243c8-34e6-4791-8579-dc96f8de31b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_bf82ca8e-a18b-4d8d-acb0-2d2ea8b58a6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_a9d4a9df-7e90-4add-8259-9da135e1c495" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_bf82ca8e-a18b-4d8d-acb0-2d2ea8b58a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_65049b0d-88b4-4f39-b4f5-3e4aed054115" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_ProfitLoss_65049b0d-88b4-4f39-b4f5-3e4aed054115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_de592d72-3492-46db-9dc5-5d57a5d9b04e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_de592d72-3492-46db-9dc5-5d57a5d9b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_fbcf0152-a0de-48bd-8980-49febd7220d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_fbcf0152-a0de-48bd-8980-49febd7220d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_00ac62c9-0831-46b2-8473-332b0acfdb0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_00ac62c9-0831-46b2-8473-332b0acfdb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_f7eb20d6-571a-4c59-a6fc-f47a5b302911" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_f7eb20d6-571a-4c59-a6fc-f47a5b302911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_f1c1e0df-2a69-43bb-b711-9f1b072ae5fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_f1c1e0df-2a69-43bb-b711-9f1b072ae5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_5427a40e-1115-441c-be1b-48370d293c61" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_5427a40e-1115-441c-be1b-48370d293c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:href="moln-20221231.xsd#moln_ChangesInWorkingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_94b5afcb-729e-46e6-b2c7-d2d5f1689cbc" xlink:to="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_0fcf3898-ba86-483b-acff-f9dda4b45d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_0fcf3898-ba86-483b-acff-f9dda4b45d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_70438d7d-af5e-4af3-9437-c7875a2cdd0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_70438d7d-af5e-4af3-9437-c7875a2cdd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_96768b05-ecdc-479a-88be-8070755ead4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_96768b05-ecdc-479a-88be-8070755ead4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e2c23613-6973-4a43-a946-8655f8fbf6b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e2c23613-6973-4a43-a946-8655f8fbf6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_f62a9dbc-dcf3-45fe-b805-f8fa5d172cd3" xlink:href="moln-20221231.xsd#moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:to="loc_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses_f62a9dbc-dcf3-45fe-b805-f8fa5d172cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_abe4cc3b-6bc2-4260-9b46-9caf21be4592" xlink:href="moln-20221231.xsd#moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ChangesInWorkingCapitalAbstract_5d066439-1bd3-4e26-a5f5-e104e074d86d" xlink:to="loc_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions_abe4cc3b-6bc2-4260-9b46-9caf21be4592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_d8a52c58-469c-43ac-aa52-d2d5f2da9ec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_d8a52c58-469c-43ac-aa52-d2d5f2da9ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_f2636de6-2dbd-4d7c-aefc-6e23275aef3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_f2636de6-2dbd-4d7c-aefc-6e23275aef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_9734a3d9-f919-43a3-8aa0-1409c230302e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_9734a3d9-f919-43a3-8aa0-1409c230302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_31d7ddf5-7f84-431c-bd45-04c8ceb19a32" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_31d7ddf5-7f84-431c-bd45-04c8ceb19a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_59109d9e-aeee-4e11-b5a6-de79ec8472cc" xlink:href="moln-20221231.xsd#moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_59109d9e-aeee-4e11-b5a6-de79ec8472cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_4fc9001d-c281-4cf4-9e41-517cc7e02946" xlink:href="moln-20221231.xsd#moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities_4fc9001d-c281-4cf4-9e41-517cc7e02946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_98983dd6-526e-4729-a530-a8419bdf67db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_98983dd6-526e-4729-a530-a8419bdf67db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_dfc7d159-9e75-4ec2-989c-7d79e079af8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_dfc7d159-9e75-4ec2-989c-7d79e079af8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_06387741-14b5-4550-b8e9-2091f2484b32" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_06387741-14b5-4550-b8e9-2091f2484b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ab422c-91e5-4098-a48a-9e7a7e25b6a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ab422c-91e5-4098-a48a-9e7a7e25b6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_a4abb406-c383-4c37-9ec8-23152d5309f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_a4abb406-c383-4c37-9ec8-23152d5309f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_49685829-426d-4306-9721-b31701a44bb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_49685829-426d-4306-9721-b31701a44bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_bf255b0e-db18-4115-814c-4f492c52433e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_bf255b0e-db18-4115-814c-4f492c52433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_e0351544-ff01-4c19-9917-c59932857453" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_e0351544-ff01-4c19-9917-c59932857453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a08b0fe4-b620-4e41-a8a7-7b0b8f5a1160" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a08b0fe4-b620-4e41-a8a7-7b0b8f5a1160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_e7c8f428-8b53-4a50-acd0-5924f655adba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_e7c8f428-8b53-4a50-acd0-5924f655adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_95f891a7-573b-4208-a795-1a68850c06a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_95f891a7-573b-4208-a795-1a68850c06a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_17152690-0ab3-45f7-9fd9-1eb0d8909483" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_CashAndCashEquivalents_17152690-0ab3-45f7-9fd9-1eb0d8909483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_664184d9-8cd6-4535-b022-93071f91987b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c9b2e626-182a-4e5e-9606-26e9216e7ff3" xlink:to="loc_ifrs-full_CashAndCashEquivalents_664184d9-8cd6-4535-b022-93071f91987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="simple" xlink:href="moln-20221231.xsd#ConsolidatedStatementofChangesinEquity"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_26f63b02-a128-40cf-b58f-8c6b08f32f63" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_26f63b02-a128-40cf-b58f-8c6b08f32f63" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bfcab725-18bf-4567-a87a-5a073b241de1" xlink:to="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_ef8c1a35-0479-4de4-8a0f-df72eda38005" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_IssuedCapitalMember_ef8c1a35-0479-4de4-8a0f-df72eda38005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_8d72d85c-b4a0-431e-a3ec-3e47e4c09d00" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_8d72d85c-b4a0-431e-a3ec-3e47e4c09d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_1f8ade9d-742e-42cc-a280-506e0e128e41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_TreasurySharesMember_1f8ade9d-742e-42cc-a280-506e0e128e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_0edc231a-4dba-4d42-baf6-b93d2eec39ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_eee2ec92-9168-4148-bd9f-4f3c75aed2c4" xlink:to="loc_ifrs-full_RetainedEarningsMember_0edc231a-4dba-4d42-baf6-b93d2eec39ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_836a6e9c-2506-40d7-b050-1dc67f1ab853" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4835162f-96ab-476d-ac06-69215699ea4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_Equity_4835162f-96ab-476d-ac06-69215699ea4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_b1b42eac-8aaa-474f-a823-d104638797ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_ProfitLoss_b1b42eac-8aaa-474f-a823-d104638797ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9bb8b4bc-6ed5-4dce-beb8-dccc624511ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9bb8b4bc-6ed5-4dce-beb8-dccc624511ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_359f454e-e948-4c33-b990-e1cb400b4134" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_359f454e-e948-4c33-b990-e1cb400b4134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_6dcd8082-9a44-4633-ac4b-2756839aa7a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_ComprehensiveIncome_6dcd8082-9a44-4633-ac4b-2756839aa7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_71c30e6f-9e1b-4579-8833-d0060abb9168" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_71c30e6f-9e1b-4579-8833-d0060abb9168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_144b4180-fa48-436b-b712-528b5c90072f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IssueOfEquity_144b4180-fa48-436b-b712-528b5c90072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_88bef6df-eca5-4d40-8690-e422cabbf59d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_88bef6df-eca5-4d40-8690-e422cabbf59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_fc7dbeaa-5ceb-40ac-904c-c4eff9de7bd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_fc7dbeaa-5ceb-40ac-904c-c4eff9de7bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_cb3dc69e-7d9c-40d8-8cc0-e61a90150ac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79765469-b18a-4cb7-aeb2-470b8f60f934" xlink:to="loc_ifrs-full_Equity_cb3dc69e-7d9c-40d8-8cc0-e61a90150ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Generalinformation" xlink:type="simple" xlink:href="moln-20221231.xsd#Generalinformation"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Generalinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfGeneralInformationAbstract_11df6a37-25dd-4819-bd13-a9e657dc5c9f" xlink:href="moln-20221231.xsd#moln_DisclosureOfGeneralInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_6673812c-8d7b-48a7-aada-7a957d35010d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfGeneralInformationAbstract_11df6a37-25dd-4819-bd13-a9e657dc5c9f" xlink:to="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_6673812c-8d7b-48a7-aada-7a957d35010d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="moln-20221231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_86da9fcb-64fe-4f3b-b3f5-2dd1a364e712" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_422815f8-07b3-451e-9574-0e055c5f0816" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_86da9fcb-64fe-4f3b-b3f5-2dd1a364e712" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_422815f8-07b3-451e-9574-0e055c5f0816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Financialriskmanagement" xlink:type="simple" xlink:href="moln-20221231.xsd#Financialriskmanagement"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Financialriskmanagement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_9f5491ef-f51b-4b4f-9ce2-471143ccbc63" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_58f84842-209a-4df6-9ed2-0a33e0fb58e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_9f5491ef-f51b-4b4f-9ce2-471143ccbc63" xlink:to="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_58f84842-209a-4df6-9ed2-0a33e0fb58e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Criticalaccountingestimatesandjudgments" xlink:type="simple" xlink:href="moln-20221231.xsd#Criticalaccountingestimatesandjudgments"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Criticalaccountingestimatesandjudgments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_CriticalAccountingEstimatesAndJudgmentsAbstract_a216dc84-0386-48cb-8a0e-a03f97629267" xlink:href="moln-20221231.xsd#moln_CriticalAccountingEstimatesAndJudgmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_ad50ab36-68a3-423b-9218-c12ff018f499" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_CriticalAccountingEstimatesAndJudgmentsAbstract_a216dc84-0386-48cb-8a0e-a03f97629267" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_ad50ab36-68a3-423b-9218-c12ff018f499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures" xlink:type="simple" xlink:href="moln-20221231.xsd#Revenuesotherincomeandandentitywidedisclosures"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_f1cbe60a-19b6-448d-91fa-4751bb535a0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_86e0c2b7-6da6-498a-8e17-f9a3b3a1c600" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_f1cbe60a-19b6-448d-91fa-4751bb535a0f" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_86e0c2b7-6da6-498a-8e17-f9a3b3a1c600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="moln-20221231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_16c72bd8-00e4-41fe-9795-3e4957677af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_9b7e96b2-d5a3-42f7-9bbf-1c9335dace83" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_16c72bd8-00e4-41fe-9795-3e4957677af4" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_9b7e96b2-d5a3-42f7-9bbf-1c9335dace83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Intangibleassets" xlink:type="simple" xlink:href="moln-20221231.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_b108d242-2759-4322-b0be-f45693da2253" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_e6f2adac-f4fe-4486-952e-5ee0b76273f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_b108d242-2759-4322-b0be-f45693da2253" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_e6f2adac-f4fe-4486-952e-5ee0b76273f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Financialinstruments" xlink:type="simple" xlink:href="moln-20221231.xsd#Financialinstruments"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Financialinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialInstrumentsAbstract_60c22663-5b3a-4d68-88a1-c8c7c4d9d639" xlink:href="moln-20221231.xsd#moln_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_cd8c542d-15db-4ad7-bc69-77cee4ff4b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialInstrumentsAbstract_60c22663-5b3a-4d68-88a1-c8c7c4d9d639" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_cd8c542d-15db-4ad7-bc69-77cee4ff4b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Othercurrentassets" xlink:type="simple" xlink:href="moln-20221231.xsd#Othercurrentassets"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Othercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b885c786-ee98-443b-8a57-64fcdf355f13" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_7e4d7f40-bf27-4add-b3d9-5c319430cbbd" xlink:href="moln-20221231.xsd#moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b885c786-ee98-443b-8a57-64fcdf355f13" xlink:to="loc_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_7e4d7f40-bf27-4add-b3d9-5c319430cbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Tradeandotherreceivables" xlink:type="simple" xlink:href="moln-20221231.xsd#Tradeandotherreceivables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Tradeandotherreceivables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_242e5a6d-f49a-4b9f-ac5f-8c42f122bb37" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_ca7b4b1a-0162-48e4-99da-82a57e09645b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_242e5a6d-f49a-4b9f-ac5f-8c42f122bb37" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_ca7b4b1a-0162-48e4-99da-82a57e09645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits" xlink:type="simple" xlink:href="moln-20221231.xsd#Cashcashequivalentsandshorttermtimedeposits"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f3eae86c-eb7d-4ebe-b111-f42cf68b6673" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock_2447e65f-7c82-4710-99e3-0f2bdef0a966" xlink:href="moln-20221231.xsd#moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f3eae86c-eb7d-4ebe-b111-f42cf68b6673" xlink:to="loc_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock_2447e65f-7c82-4710-99e3-0f2bdef0a966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Shareholdersequity" xlink:type="simple" xlink:href="moln-20221231.xsd#Shareholdersequity"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Shareholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_618a5c04-33e3-4977-841f-e83539da0d80" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_a1e324ec-05fa-409e-9cf9-737d1a2d5d8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_618a5c04-33e3-4977-841f-e83539da0d80" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_a1e324ec-05fa-409e-9cf9-737d1a2d5d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Tradeandotherpayables" xlink:type="simple" xlink:href="moln-20221231.xsd#Tradeandotherpayables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Tradeandotherpayables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_799c8755-1311-46d4-a95c-e348e221214a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_06dfb252-f98c-474f-b54d-a8b2a446f4c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_799c8755-1311-46d4-a95c-e348e221214a" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_06dfb252-f98c-474f-b54d-a8b2a446f4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Accruedexpenses" xlink:type="simple" xlink:href="moln-20221231.xsd#Accruedexpenses"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Accruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_50382f96-f1c5-47a6-a1d7-f77a14b66d05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_72d1d741-73fe-4bd2-882c-9e28a77e67da" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_50382f96-f1c5-47a6-a1d7-f77a14b66d05" xlink:to="loc_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_72d1d741-73fe-4bd2-882c-9e28a77e67da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Contractliability" xlink:type="simple" xlink:href="moln-20221231.xsd#Contractliability"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Contractliability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract_b067002f-c627-4cff-b3d3-b47af1fcdc40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_9950bb83-3d63-4f78-b231-1d2333e0501b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_b067002f-c627-4cff-b3d3-b47af1fcdc40" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_9950bb83-3d63-4f78-b231-1d2333e0501b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses" xlink:type="simple" xlink:href="moln-20221231.xsd#Additionalinformationonthenatureofexpenses"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b2b90986-1767-4928-8eec-0e0772183722" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_f2bb63e1-444b-4024-a9a0-cd63956d8889" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b2b90986-1767-4928-8eec-0e0772183722" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_f2bb63e1-444b-4024-a9a0-cd63956d8889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Royaltiesandlicensefees" xlink:type="simple" xlink:href="moln-20221231.xsd#Royaltiesandlicensefees"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Royaltiesandlicensefees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_bc3c5b75-e8c5-4c4a-aea5-76547dbd14d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock_0cfbf5ef-a96a-4a6d-80d6-e60b6402a5bc" xlink:href="moln-20221231.xsd#moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_bc3c5b75-e8c5-4c4a-aea5-76547dbd14d6" xlink:to="loc_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock_0cfbf5ef-a96a-4a6d-80d6-e60b6402a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Personnelexpenses" xlink:type="simple" xlink:href="moln-20221231.xsd#Personnelexpenses"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Personnelexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_5078f037-1257-46c3-80c8-bb2a1a195c86" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock_da4aeff9-3f85-44a4-8bf3-a093259d3f3d" xlink:href="moln-20221231.xsd#moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_5078f037-1257-46c3-80c8-bb2a1a195c86" xlink:to="loc_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock_da4aeff9-3f85-44a4-8bf3-a093259d3f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Financialincomeandfinancialexpense" xlink:type="simple" xlink:href="moln-20221231.xsd#Financialincomeandfinancialexpense"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Financialincomeandfinancialexpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9dab33e1-d4fb-41aa-a07e-ef578cb9f72d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_f887f924-956c-44ab-ac05-22a66c97429b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9dab33e1-d4fb-41aa-a07e-ef578cb9f72d" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_f887f924-956c-44ab-ac05-22a66c97429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Taxes" xlink:type="simple" xlink:href="moln-20221231.xsd#Taxes"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Taxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_cdd304c4-7f96-469e-9141-9486c7f2f188" xlink:href="moln-20221231.xsd#moln_IncomeTaxesAndDeferredTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_6a2a0d7d-0ea5-4ee8-93b0-1a14761aced5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_cdd304c4-7f96-469e-9141-9486c7f2f188" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_6a2a0d7d-0ea5-4ee8-93b0-1a14761aced5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Earningspershare" xlink:type="simple" xlink:href="moln-20221231.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_e1ef766b-0a89-49b3-a70f-b5e4d9a40541" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_04bc01f2-ce79-4436-9dfd-a558c2ef7f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_e1ef766b-0a89-49b3-a70f-b5e4d9a40541" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_04bc01f2-ce79-4436-9dfd-a558c2ef7f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Leases" xlink:type="simple" xlink:href="moln-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_c3cdfbe2-abe1-4c20-9ffd-fda09f19d2f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_2cfc98cb-68e1-4119-b2fe-4d2cbe3c907b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_c3cdfbe2-abe1-4c20-9ffd-fda09f19d2f1" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_2cfc98cb-68e1-4119-b2fe-4d2cbe3c907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Relatedpartydisclosures" xlink:type="simple" xlink:href="moln-20221231.xsd#Relatedpartydisclosures"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Relatedpartydisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_472cd088-8511-49b9-bbb2-6d3d51e36342" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_0d0617ef-1b34-45b8-a464-5c53e9c20d81" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_472cd088-8511-49b9-bbb2-6d3d51e36342" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_0d0617ef-1b34-45b8-a464-5c53e9c20d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Capitalcommitments" xlink:type="simple" xlink:href="moln-20221231.xsd#Capitalcommitments"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Capitalcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitmentsAbstract_bf31f4f7-0018-4855-8cbf-af512665b941" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_fa0750df-541b-401a-82df-7ce8720661f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CapitalCommitmentsAbstract_bf31f4f7-0018-4855-8cbf-af512665b941" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_fa0750df-541b-401a-82df-7ce8720661f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Financialriskmanagement_1" xlink:type="simple" xlink:href="moln-20221231.xsd#Financialriskmanagement_1"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Financialriskmanagement_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_6fef2c96-ef10-48d1-a96f-f559485b42a7" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_56c3707f-5431-4f3e-ade6-3487c1018b90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_6fef2c96-ef10-48d1-a96f-f559485b42a7" xlink:to="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_56c3707f-5431-4f3e-ade6-3487c1018b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PutativeClassAction" xlink:type="simple" xlink:href="moln-20221231.xsd#PutativeClassAction"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PutativeClassAction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_e896e33a-a478-42a3-8f2d-9d2619124bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_79ac6450-0295-4b9c-8925-deb37ba97ece" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_e896e33a-a478-42a3-8f2d-9d2619124bca" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_79ac6450-0295-4b9c-8925-deb37ba97ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate" xlink:type="simple" xlink:href="moln-20221231.xsd#Eventsafterthebalancesheetdate"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_fe64fc51-105d-4b08-b672-d222da3a28c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_9a5564fb-b579-4e99-87a2-2bf2a5b3e49b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_fe64fc51-105d-4b08-b672-d222da3a28c3" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_9a5564fb-b579-4e99-87a2-2bf2a5b3e49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_11303d6e-faf0-426c-b3e6-ae61d4a12f09" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_11303d6e-faf0-426c-b3e6-ae61d4a12f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock_6f7222e2-b23d-4c32-8a33-06385db8bee0" xlink:href="moln-20221231.xsd#moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock_6f7222e2-b23d-4c32-8a33-06385db8bee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_ed7022ac-61e7-48b7-ae13-e682103005c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_ed7022ac-61e7-48b7-ae13-e682103005c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_922a42c6-8735-4ad3-a690-43d188491f43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_922a42c6-8735-4ad3-a690-43d188491f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_5966ad74-03e8-4fe3-896d-f5fdc24d1bed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_5966ad74-03e8-4fe3-896d-f5fdc24d1bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_4afb40e1-5001-46e6-aabd-9079f73e4b75" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_4afb40e1-5001-46e6-aabd-9079f73e4b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_be5b6a45-d721-4c53-8224-2c072cd51449" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_be5b6a45-d721-4c53-8224-2c072cd51449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_e5ad80fa-cdde-4f6e-8b0d-f3d13da056af" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_e5ad80fa-cdde-4f6e-8b0d-f3d13da056af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1fdd08c2-9735-49c2-9bab-c484fcfd3271" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1fdd08c2-9735-49c2-9bab-c484fcfd3271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_169e8fd0-043d-40e4-9946-d463a1ae69c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_169e8fd0-043d-40e4-9946-d463a1ae69c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_0aa9fb57-9898-4863-b8f5-be68c41779e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_0aa9fb57-9898-4863-b8f5-be68c41779e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_2096aa98-66be-4da8-a54b-ecfc4cc1bf9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_2096aa98-66be-4da8-a54b-ecfc4cc1bf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_4bd9bfd3-53b0-48b1-b26a-0371df5a6c4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_4bd9bfd3-53b0-48b1-b26a-0371df5a6c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_9c940b30-9f86-47bd-ad21-2f31c42f3d97" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_9c940b30-9f86-47bd-ad21-2f31c42f3d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_6999ff55-d6e7-4677-add5-87915819c0ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_6999ff55-d6e7-4677-add5-87915819c0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_adf81fd2-d24f-4015-86c5-0aa730618978" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_adf81fd2-d24f-4015-86c5-0aa730618978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_7d9aa101-db37-4217-88e9-16c314fe24ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_7d9aa101-db37-4217-88e9-16c314fe24ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_27d4ce4d-b0c0-4906-b0d2-4cc5613d42e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_247fd97a-998a-4334-8a02-6d9ac69a0dd5" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_27d4ce4d-b0c0-4906-b0d2-4cc5613d42e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_176280ec-7591-4cfd-91ed-5bff2ba55308" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_46bceaea-9d8c-40cd-8a07-5ef348bef080" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_176280ec-7591-4cfd-91ed-5bff2ba55308" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_46bceaea-9d8c-40cd-8a07-5ef348bef080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock_b6583ae6-8c7d-402a-b062-2cb2829a2237" xlink:href="moln-20221231.xsd#moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_176280ec-7591-4cfd-91ed-5bff2ba55308" xlink:to="loc_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock_b6583ae6-8c7d-402a-b062-2cb2829a2237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_878d65c3-c2b2-4428-a43a-2f24785aeba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_c0831ffd-38d7-4acb-9c57-1e353c4f0100" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_878d65c3-c2b2-4428-a43a-2f24785aeba2" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_c0831ffd-38d7-4acb-9c57-1e353c4f0100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="moln-20221231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_94ff9102-51e9-40cb-ab42-98aa84efc3b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_ed03a00c-b3c7-4546-86ed-4eec7caa5905" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_94ff9102-51e9-40cb-ab42-98aa84efc3b7" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_ed03a00c-b3c7-4546-86ed-4eec7caa5905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="moln-20221231.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_f26698b0-af07-473d-9945-16f192c3e5b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_8ca68881-36e2-42b9-a4e3-025fefcb8f42" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_f26698b0-af07-473d-9945-16f192c3e5b9" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_8ca68881-36e2-42b9-a4e3-025fefcb8f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsTables" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialInstrumentsAbstract_f5ff7563-7d96-4ad8-a5bc-0a1d22e00a8f" xlink:href="moln-20221231.xsd#moln_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_10e53e5c-05d2-4c25-a241-741790849dce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialInstrumentsAbstract_f5ff7563-7d96-4ad8-a5bc-0a1d22e00a8f" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_10e53e5c-05d2-4c25-a241-741790849dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2923380e-a3e6-4c68-b769-3ef8c5ec57b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialInstrumentsAbstract_f5ff7563-7d96-4ad8-a5bc-0a1d22e00a8f" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2923380e-a3e6-4c68-b769-3ef8c5ec57b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/OthercurrentassetsTables" xlink:type="simple" xlink:href="moln-20221231.xsd#OthercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/OthercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_e5dfe45c-856b-41ea-81b0-6f829780dbcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_0f4ec174-17e0-4f35-8136-466d995a6809" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_e5dfe45c-856b-41ea-81b0-6f829780dbcb" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_0f4ec174-17e0-4f35-8136-466d995a6809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherreceivablesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherreceivablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ec3fe8c9-7a6c-4ea3-a435-6385560d9201" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock_a3c7d4f9-6b0a-48cd-ad6e-2abe1f3cc6c1" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ec3fe8c9-7a6c-4ea3-a435-6385560d9201" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock_a3c7d4f9-6b0a-48cd-ad6e-2abe1f3cc6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables" xlink:type="simple" xlink:href="moln-20221231.xsd#CashcashequivalentsandshorttermtimedepositsTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b502428c-75ed-4427-8deb-a0bf15e979f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock_5e63d71b-c1b2-4f46-b04d-666423cd456d" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b502428c-75ed-4427-8deb-a0bf15e979f5" xlink:to="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock_5e63d71b-c1b2-4f46-b04d-666423cd456d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ShareholdersequityTables" xlink:type="simple" xlink:href="moln-20221231.xsd#ShareholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ShareholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_6209e461-1884-4886-a5ec-e56b93da3f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_b9d8bb7d-ce07-44f5-9999-566fa9da9d5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6209e461-1884-4886-a5ec-e56b93da3f15" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_b9d8bb7d-ce07-44f5-9999-566fa9da9d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherpayablesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherpayablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3710239d-2094-40c1-89a2-f4f61c4281d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock_f8ace5df-a940-4472-8434-c23c07984b50" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3710239d-2094-40c1-89a2-f4f61c4281d1" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock_f8ace5df-a940-4472-8434-c23c07984b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_e12d481f-77fb-44d9-8217-6c35c2d7777f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock_20c5ef6b-179b-440c-8758-ef396b083117" xlink:href="moln-20221231.xsd#moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_e12d481f-77fb-44d9-8217-6c35c2d7777f" xlink:to="loc_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock_20c5ef6b-179b-440c-8758-ef396b083117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityTables" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract_60ee32cf-35d7-443b-84a0-4c50ace7b303" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_02bb26de-1261-4fe9-9953-523ba6758177" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_60ee32cf-35d7-443b-84a0-4c50ace7b303" xlink:to="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_02bb26de-1261-4fe9-9953-523ba6758177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_c7f41e92-764c-4c8b-ab5d-86f0eecbca0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_60ee32cf-35d7-443b-84a0-4c50ace7b303" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_c7f41e92-764c-4c8b-ab5d-86f0eecbca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock_53ea18fc-eec2-40bd-892e-1ff5b973b88e" xlink:href="moln-20221231.xsd#moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_60ee32cf-35d7-443b-84a0-4c50ace7b303" xlink:to="loc_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock_53ea18fc-eec2-40bd-892e-1ff5b973b88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#AdditionalinformationonthenatureofexpensesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1fd2576d-3fe4-41f6-88ca-472610083712" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_adfa0de9-d397-46d1-9a55-d4155365b836" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1fd2576d-3fe4-41f6-88ca-472610083712" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_adfa0de9-d397-46d1-9a55-d4155365b836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock_a031b85f-409e-42b1-9f52-838371c27788" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock_a031b85f-409e-42b1-9f52-838371c27788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_d4752b00-b67c-46e4-b0c4-905d16a62545" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_d4752b00-b67c-46e4-b0c4-905d16a62545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock_01871328-a291-4259-bdc1-d95849f146c0" xlink:href="moln-20221231.xsd#moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock_01871328-a291-4259-bdc1-d95849f146c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_cbde70a5-a98e-405e-b9af-f9a2b99e790f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_cbde70a5-a98e-405e-b9af-f9a2b99e790f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_4171705e-f8e5-4417-b58f-1cce9f61d6f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_4171705e-f8e5-4417-b58f-1cce9f61d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_9bcbe9b3-4f0a-4930-8e1d-b425c4b769f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_9bcbe9b3-4f0a-4930-8e1d-b425c4b769f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock_2ea0a34e-0857-4916-bfc9-a9f46e7cead6" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock_2ea0a34e-0857-4916-bfc9-a9f46e7cead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock_6e9e8dac-ca32-4153-b234-a703a3588365" xlink:href="moln-20221231.xsd#moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_f6249d33-79e1-46f9-963f-e7612aa1dc48" xlink:to="loc_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock_6e9e8dac-ca32-4153-b234-a703a3588365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialincomeandfinancialexpenseTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cd20d3ae-9c00-4cb0-a71d-ff0e0d32128f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock_8a82379d-7407-4a62-8e9c-a67ad27202c9" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cd20d3ae-9c00-4cb0-a71d-ff0e0d32128f" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock_8a82379d-7407-4a62-8e9c-a67ad27202c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock_53d7f3d3-6054-45e5-b22b-65497b68a81c" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cd20d3ae-9c00-4cb0-a71d-ff0e0d32128f" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock_53d7f3d3-6054-45e5-b22b-65497b68a81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_a11bff1a-8e9a-44d6-9594-dcc2e0edb33c" xlink:href="moln-20221231.xsd#moln_IncomeTaxesAndDeferredTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock_83cb4916-c11e-457b-9e2e-3ea574451e6c" xlink:href="moln-20221231.xsd#moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_a11bff1a-8e9a-44d6-9594-dcc2e0edb33c" xlink:to="loc_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock_83cb4916-c11e-457b-9e2e-3ea574451e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/EarningspershareTables" xlink:type="simple" xlink:href="moln-20221231.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_15e37530-5d80-4634-967e-37c5d846afcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_b26d6195-8290-4dee-b042-d29ba8434e47" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_15e37530-5d80-4634-967e-37c5d846afcc" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_b26d6195-8290-4dee-b042-d29ba8434e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesTables" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_9b01a799-ee0f-4f93-8e81-0369bdeb5e2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock_b1329937-5b0a-44ff-9095-b5fc5f70353c" xlink:href="moln-20221231.xsd#moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_9b01a799-ee0f-4f93-8e81-0369bdeb5e2b" xlink:to="loc_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock_b1329937-5b0a-44ff-9095-b5fc5f70353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_edc6709e-fabf-405a-b895-e692d8220401" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_9b01a799-ee0f-4f93-8e81-0369bdeb5e2b" xlink:to="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_edc6709e-fabf-405a-b895-e692d8220401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_8dd505d4-6c6c-4a6d-8f2a-ee16ea03deb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_9b01a799-ee0f-4f93-8e81-0369bdeb5e2b" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_8dd505d4-6c6c-4a6d-8f2a-ee16ea03deb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresTables" xlink:type="simple" xlink:href="moln-20221231.xsd#RelatedpartydisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RelatedpartydisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_b36b9e10-fd27-4e29-a458-0e63402f4fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_d365112f-f622-40a2-bb16-14a0e39eae8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_b36b9e10-fd27-4e29-a458-0e63402f4fd9" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_d365112f-f622-40a2-bb16-14a0e39eae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementTables" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementTables"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_3753ba2d-f6bc-4687-864e-a8341dcbf7cf" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_c9cf4758-8934-4839-ba6d-31eb09cf3d6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_3753ba2d-f6bc-4687-864e-a8341dcbf7cf" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_c9cf4758-8934-4839-ba6d-31eb09cf3d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_c1063fc5-acbf-4b33-a5d7-68e397ee183f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_3753ba2d-f6bc-4687-864e-a8341dcbf7cf" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_c1063fc5-acbf-4b33-a5d7-68e397ee183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesSegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_70a3cdaf-9039-41f3-b580-e450a10fe235" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOperatingSegments_7d5dcf64-91f3-4f39-91c6-c16ddcb206a8" xlink:href="moln-20221231.xsd#moln_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_70a3cdaf-9039-41f3-b580-e450a10fe235" xlink:to="loc_moln_NumberOfOperatingSegments_7d5dcf64-91f3-4f39-91c6-c16ddcb206a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_1c185376-8351-4051-ab21-a37f26191797" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_1c185376-8351-4051-ab21-a37f26191797" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_733f92f7-4000-4f07-8b26-eec88426a4e0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LaboratoryEquipmentMember_8213cbbf-204c-450b-9163-8cc45d9c6735" xlink:href="moln-20221231.xsd#moln_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:to="loc_moln_LaboratoryEquipmentMember_8213cbbf-204c-450b-9163-8cc45d9c6735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_e3409ae9-c2aa-46cb-9ee2-73b6ef9ef455" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:to="loc_ifrs-full_OfficeEquipmentMember_e3409ae9-c2aa-46cb-9ee2-73b6ef9ef455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_062b3433-a78c-4575-a6e4-5485a376e696" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c8897fab-b02a-4459-8b8a-d035fa420d88" xlink:to="loc_ifrs-full_ComputerEquipmentMember_062b3433-a78c-4575-a6e4-5485a376e696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_39e98ab7-dfc1-4071-8877-d0127b3d3a41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9aaf72d9-39cc-4694-b73d-c918cae3a9c1" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_39e98ab7-dfc1-4071-8877-d0127b3d3a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_1eb1d118-0627-4c9f-a4e4-ab9ec6a5876a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_39e98ab7-dfc1-4071-8877-d0127b3d3a41" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_1eb1d118-0627-4c9f-a4e4-ab9ec6a5876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_1c947371-7854-4791-a577-dc38625159b5" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_1c947371-7854-4791-a577-dc38625159b5" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c65ac4f1-2ece-454e-8e6c-37823bd1b0e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_86ecfbb7-86f0-4b88-ad0f-293414f97ba0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c65ac4f1-2ece-454e-8e6c-37823bd1b0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_4e2afe69-f748-4c7e-b434-f489553d29e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c65ac4f1-2ece-454e-8e6c-37823bd1b0e0" xlink:to="loc_ifrs-full_ComputerSoftwareMember_4e2afe69-f748-4c7e-b434-f489553d29e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_180368f0-078f-4ae9-8bce-c04d217a414e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_661db0b8-a7d3-4b3b-8d13-113e534d28be" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_180368f0-078f-4ae9-8bce-c04d217a414e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6204496-adfc-473d-bac6-df1bd787d30a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_180368f0-078f-4ae9-8bce-c04d217a414e" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6204496-adfc-473d-bac6-df1bd787d30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_1430a535-130b-4c51-b7e8-de9260f12a32" xlink:href="moln-20221231.xsd#moln_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfSignificantAccountingPoliciesAbstract_1430a535-130b-4c51-b7e8-de9260f12a32" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_ceb242d3-ee6c-4336-8f76-cca4006008a5" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VSAOMember_06c9cb66-d558-47f6-9a8b-8a4ca0d25bf6" xlink:href="moln-20221231.xsd#moln_VSAOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:to="loc_moln_VSAOMember_06c9cb66-d558-47f6-9a8b-8a4ca0d25bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VoluntaryComplementaryPlanMember_d44a9f10-5fc7-4340-9012-8d29eac9064c" xlink:href="moln-20221231.xsd#moln_VoluntaryComplementaryPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_5e815d09-fb0e-4cd9-895c-3037039ee6e8" xlink:to="loc_moln_VoluntaryComplementaryPlanMember_d44a9f10-5fc7-4340-9012-8d29eac9064c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable_baf8a6bd-f497-42ee-b975-678efc2d6ed7" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanEmployerContribution_25f0711e-6ba8-45eb-98c8-bee2fc281d8f" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanEmployerContribution"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanEmployerContribution_25f0711e-6ba8-45eb-98c8-bee2fc281d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanEmployeeContribution_20d864d8-478a-4c74-a2ad-290e6a046025" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanEmployeeContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanEmployeeContribution_20d864d8-478a-4c74-a2ad-290e6a046025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_b8e00543-c26b-4c0d-bd62-372ff9d490d5" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated_b8e00543-c26b-4c0d-bd62-372ff9d490d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitPlanNumberOfEligibleEmployees_ee2f2b7c-77e9-498a-a68a-98c67779c9f6" xlink:href="moln-20221231.xsd#moln_DefinedBenefitPlanNumberOfEligibleEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_DefinedBenefitPlanNumberOfEligibleEmployees_ee2f2b7c-77e9-498a-a68a-98c67779c9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_ac76772d-9f2e-4178-aaba-58852d52bd09" xlink:href="moln-20221231.xsd#moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems_e0e79bc3-1a1f-4adc-8728-222906108269" xlink:to="loc_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans_ac76772d-9f2e-4178-aaba-58852d52bd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_60fcee1c-8f80-4e92-a469-0beb5e29b506" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_60fcee1c-8f80-4e92-a469-0beb5e29b506" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_489d06d2-5c20-4215-985d-f8ec298832f5" xlink:to="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_1f1e8a42-9254-4a23-a95b-0fb7eac0861c" xlink:href="moln-20221231.xsd#moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember_1f1e8a42-9254-4a23-a95b-0fb7eac0861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_febfe27f-b867-497f-9556-c0c151549006" xlink:href="moln-20221231.xsd#moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember_febfe27f-b867-497f-9556-c0c151549006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_f9268221-75ae-4f82-bbff-be8885d3a68a" xlink:href="moln-20221231.xsd#moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_f9268221-75ae-4f82-bbff-be8885d3a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_ead6de20-d284-4995-8037-132b5e1ab05c" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithAmgenIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_98e52a1b-b264-48e8-a4b5-b57e5e59a194" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_ead6de20-d284-4995-8037-132b5e1ab05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4677a18-85d0-4123-896b-5decc9e1fb01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4005d9e1-74e8-494d-b2ef-46a27e45dd89" xlink:to="loc_srt_ProductsAndServicesDomain_e4677a18-85d0-4123-896b-5decc9e1fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CommercialSupplyOfProductsMember_b0aa8c5b-de38-47aa-a2fb-c539a87c2013" xlink:href="moln-20221231.xsd#moln_CommercialSupplyOfProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e4677a18-85d0-4123-896b-5decc9e1fb01" xlink:to="loc_moln_CommercialSupplyOfProductsMember_b0aa8c5b-de38-47aa-a2fb-c539a87c2013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fa26c2fc-a04e-4781-a502-6566005134f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_bb177798-4d0e-432b-8533-65957b16979e" xlink:to="loc_ifrs-full_RangesMember_fa26c2fc-a04e-4781-a502-6566005134f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fe329aea-5a85-4ab2-bacf-73d831fbde35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_fa26c2fc-a04e-4781-a502-6566005134f6" xlink:to="loc_srt_MaximumMember_fe329aea-5a85-4ab2-bacf-73d831fbde35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_0784fbe4-6834-45f9-af2e-684deef678cd" xlink:to="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_a0bf0bd6-388e-4d43-9ec9-28fb36e4d201" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:to="loc_moln_NovartisMember_a0bf0bd6-388e-4d43-9ec9-28fb36e4d201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember_aebe13d9-8b4b-4772-8fa6-994cc49b3ecd" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_0212627c-e7bf-45a9-8618-e2da57de379f" xlink:to="loc_moln_FederalOfficeOfPublicHealthMember_aebe13d9-8b4b-4772-8fa6-994cc49b3ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_6da399c0-1e63-48eb-a3c2-cb6f97356333" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_152420ce-9ec9-40d2-9a4a-145cb5648803" xlink:to="loc_ifrs-full_NonadjustingEventsMember_6da399c0-1e63-48eb-a3c2-cb6f97356333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SignificantTransactionsMember_8491ed4c-1b3e-4cfd-abc8-eacc4696f947" xlink:href="moln-20221231.xsd#moln_SignificantTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_6da399c0-1e63-48eb-a3c2-cb6f97356333" xlink:to="loc_moln_SignificantTransactionsMember_8491ed4c-1b3e-4cfd-abc8-eacc4696f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8573009c-2b07-481a-878c-6922b209ad12" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_e787c458-5601-45eb-b356-6b51d35e41f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_CurrentTradeReceivables_e787c458-5601-45eb-b356-6b51d35e41f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PotentialFutureMilestonePayments_7b24b3bf-8288-4f39-a5fb-e3baf25bd4be" xlink:href="moln-20221231.xsd#moln_PotentialFutureMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_PotentialFutureMilestonePayments_7b24b3bf-8288-4f39-a5fb-e3baf25bd4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_06987c70-9716-4767-91ec-8664179f9b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_06987c70-9716-4767-91ec-8664179f9b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_a0705189-9914-4787-b160-c0933fb7763b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_a0705189-9914-4787-b160-c0933fb7763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_df8b12b5-b153-448d-8722-08d6428e0ac7" xlink:href="moln-20221231.xsd#moln_RevenueFromRechargeOfEmployeeRelatedExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_RevenueFromRechargeOfEmployeeRelatedExpenses_df8b12b5-b153-448d-8722-08d6428e0ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UpfrontPaymentReceived_3b94b824-45ca-4c66-985d-6959c2ca6582" xlink:href="moln-20221231.xsd#moln_UpfrontPaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_UpfrontPaymentReceived_3b94b824-45ca-4c66-985d-6959c2ca6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UpfrontPaymentAmountUtilizedDuringPeriod_9311f937-3d79-4e8f-b61d-fdc9cedf43cb" xlink:href="moln-20221231.xsd#moln_UpfrontPaymentAmountUtilizedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_UpfrontPaymentAmountUtilizedDuringPeriod_9311f937-3d79-4e8f-b61d-fdc9cedf43cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltyIncomePercentage_8afc5c02-dd6f-44e9-97b1-635ba87396ca" xlink:href="moln-20221231.xsd#moln_RoyaltyIncomePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_RoyaltyIncomePercentage_8afc5c02-dd6f-44e9-97b1-635ba87396ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_c1357857-118c-4785-87ff-991e20f05f56" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_CurrentContractLiabilities_c1357857-118c-4785-87ff-991e20f05f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExtendedPeriodOfReservationAgreement_0b529d97-aa17-4751-9171-64a9e5d874fa" xlink:href="moln-20221231.xsd#moln_ExtendedPeriodOfReservationAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_moln_ExtendedPeriodOfReservationAgreement_0b529d97-aa17-4751-9171-64a9e5d874fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_ba5347db-719c-44d5-878b-71f438efc951" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_ba5347db-719c-44d5-878b-71f438efc951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_80e0395f-d9ba-4484-a915-3b93b84e14f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_a37a57b8-d0d7-4022-9921-57c52dd56eac" xlink:to="loc_ifrs-full_OtherIncome_80e0395f-d9ba-4484-a915-3b93b84e14f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_bd9a50bb-bc92-4e58-9116-f356ccd5785a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_bd9a50bb-bc92-4e58-9116-f356ccd5785a" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:to="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d76faf94-6ec4-4bd3-9e3e-e7022b48030a" xlink:to="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_0e227f6b-934e-485c-b500-ae240b09550f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:to="loc_country_CH_0e227f6b-934e-485c-b500-ae240b09550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ba139b52-7421-48de-afbb-9c30a2601510" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_29fc1c8a-e653-4175-a480-6b94828eaa90" xlink:to="loc_country_US_ba139b52-7421-48de-afbb-9c30a2601510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e48b3505-9a42-4910-9414-c55a9fc34509" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_ffe82a27-8086-4903-9769-85ddf911b1ea" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e48b3505-9a42-4910-9414-c55a9fc34509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_82784790-3786-48fb-95d6-73c24a81d883" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e48b3505-9a42-4910-9414-c55a9fc34509" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_82784790-3786-48fb-95d6-73c24a81d883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_c81e57b6-23eb-48d8-a827-7e4e47cc0cb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_c81e57b6-23eb-48d8-a827-7e4e47cc0cb0" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:to="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_f0969833-6366-448b-b577-4592e33c8340" xlink:to="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_4d759a2c-44cc-42e8-b064-4dc5876ab4f1" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithNovartisAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithNovartisAGMember_4d759a2c-44cc-42e8-b064-4dc5876ab4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithFOPHMember_3eca88c8-5242-4720-bbad-8e32799b5d93" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithFOPHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithFOPHMember_3eca88c8-5242-4720-bbad-8e32799b5d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_0b145ac8-1148-4c66-8f0c-e2163e296d8f" xlink:href="moln-20221231.xsd#moln_LicenseAndCollaborationAgreementWithAmgenIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_810ffaea-98ec-4518-b395-4af6c65ab371" xlink:to="loc_moln_LicenseAndCollaborationAgreementWithAmgenIncMember_0b145ac8-1148-4c66-8f0c-e2163e296d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02323cf2-f8eb-47c3-8204-58204d2847de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_0c6b078a-7253-4d5c-aab2-520b6c0f2155" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02323cf2-f8eb-47c3-8204-58204d2847de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_6015f1b6-71cb-49bd-9df1-522eb9a6d7b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02323cf2-f8eb-47c3-8204-58204d2847de" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_6015f1b6-71cb-49bd-9df1-522eb9a6d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_19b8d703-a001-4391-a2b1-5b45b8b8da20" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_19b8d703-a001-4391-a2b1-5b45b8b8da20" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2de06df0-5298-483f-8502-be6f202a36fb" xlink:to="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_24681c1b-f8ad-4101-9f1b-0b01320962fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_24681c1b-f8ad-4101-9f1b-0b01320962fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8cbd6b4b-a9fe-424a-b939-8c28d67f515d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_3731855d-b352-452a-b38e-6c064b573651" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8cbd6b4b-a9fe-424a-b939-8c28d67f515d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_e3594396-aee3-4e57-b0cd-1d512dad87c3" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LabEquipmentMember_0973db8d-8947-4590-a56a-272ab38e08c7" xlink:href="moln-20221231.xsd#moln_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_moln_LabEquipmentMember_0973db8d-8947-4590-a56a-272ab38e08c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_358925e9-e716-4f96-ad69-5833a71881ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_ifrs-full_OfficeEquipmentMember_358925e9-e716-4f96-ad69-5833a71881ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_357828ef-bb0b-4e18-881d-dffe3dfc11f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_ifrs-full_ComputerEquipmentMember_357828ef-bb0b-4e18-881d-dffe3dfc11f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_3803a32f-743a-4ed6-a065-f948b6ac3fbe" xlink:href="moln-20221231.xsd#moln_RightOfUseAssetsPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_moln_RightOfUseAssetsPropertyPlantAndEquipmentMember_3803a32f-743a-4ed6-a065-f948b6ac3fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_e984fd05-430a-4406-a779-94b4789154b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_c1c93335-6603-44cb-9a3e-e7ef64e859c3" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_e984fd05-430a-4406-a779-94b4789154b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a42570b8-fd2e-4bf0-a6e7-c01c810ed557" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_65905ddc-4c53-49b3-9186-46a9cd63db7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_65905ddc-4c53-49b3-9186-46a9cd63db7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f4efcee6-0a11-4ffd-8372-c403c4ef181e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f4efcee6-0a11-4ffd-8372-c403c4ef181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e18524f0-93a8-4263-959d-285edeff5566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e18524f0-93a8-4263-959d-285edeff5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7e09c9b0-ea49-47e7-b187-0fb7b8a21c24" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7e09c9b0-ea49-47e7-b187-0fb7b8a21c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6b12d39a-409d-4b1a-90a7-e1812b883c55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08c9a629-22b5-4802-ab55-c0b4cdb547b2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_6b12d39a-409d-4b1a-90a7-e1812b883c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/IntangibleassetsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#IntangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/IntangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_136bb6ac-cb75-4d87-bf69-dc60789f354c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_136bb6ac-cb75-4d87-bf69-dc60789f354c" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_dafbe0bf-c73d-432d-be5e-3eb3dc03d364" xlink:to="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_8fcd2ef5-6eff-4bfb-bc27-5d0dfa4c363d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_8fcd2ef5-6eff-4bfb-bc27-5d0dfa4c363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_9f72aee7-560d-4620-a928-fd33336b20d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_52d99b22-2cba-455c-8810-836b2b4aa384" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_9f72aee7-560d-4620-a928-fd33336b20d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1a1bb5a0-db18-48a5-9258-2ab889dc8028" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0cfffecc-153e-4674-a49f-b7ce709b0d67" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1a1bb5a0-db18-48a5-9258-2ab889dc8028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_c697902c-1d76-4a39-8d2e-85ca8d1e060b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1a1bb5a0-db18-48a5-9258-2ab889dc8028" xlink:to="loc_ifrs-full_ComputerSoftwareMember_c697902c-1d76-4a39-8d2e-85ca8d1e060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_cf3db5d2-4899-4613-8735-719078094294" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7e361a50-8f7f-4519-a1cc-2f5708707101" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7e361a50-8f7f-4519-a1cc-2f5708707101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ea813236-410b-409a-a37a-4def20a1a834" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ea813236-410b-409a-a37a-4def20a1a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b3b82993-c26f-4780-9444-2552403b2798" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b3b82993-c26f-4780-9444-2552403b2798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_d0bd578a-e8fd-44de-a705-95f0af4cd875" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_d0bd578a-e8fd-44de-a705-95f0af4cd875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_717c711d-4d7e-4f95-ae0d-5a598ce0821f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c7271a17-054d-4979-a383-09db7497c27e" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_717c711d-4d7e-4f95-ae0d-5a598ce0821f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialInstrumentsAbstract_97e55645-a448-46e9-aa93-317a4dc51996" xlink:href="moln-20221231.xsd#moln_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialInstrumentsAbstract_97e55645-a448-46e9-aa93-317a4dc51996" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d7679661-2684-4282-8429-ea805d1d4266" xlink:to="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashAndCashEquivalentsMember_a2025fc2-55c8-42b3-8159-96c3ccfc4839" xlink:href="moln-20221231.xsd#moln_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_moln_CashAndCashEquivalentsMember_a2025fc2-55c8-42b3-8159-96c3ccfc4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_2c77f6c1-cfe3-4942-b155-6659ff7266dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_ifrs-full_TradeReceivablesMember_2c77f6c1-cfe3-4942-b155-6659ff7266dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedIncomeMember_d368b582-d511-4b48-b6e9-5b4e7ef6d2c8" xlink:href="moln-20221231.xsd#moln_AccruedIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_moln_AccruedIncomeMember_d368b582-d511-4b48-b6e9-5b4e7ef6d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShortTermTimeDepositsMember_a506708b-6489-4ac7-8bd8-61d868ff9bce" xlink:href="moln-20221231.xsd#moln_ShortTermTimeDepositsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_66de7784-b507-4064-b09c-637878700e90" xlink:to="loc_moln_ShortTermTimeDepositsMember_a506708b-6489-4ac7-8bd8-61d868ff9bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_4fcc7d54-7634-49a3-89b1-be8a84da9978" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_ab4246ff-2870-4d39-ba40-a6546906d573" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_4fcc7d54-7634-49a3-89b1-be8a84da9978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e11c09e2-e805-41bd-8b6b-30d57c7cca40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_4fcc7d54-7634-49a3-89b1-be8a84da9978" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e11c09e2-e805-41bd-8b6b-30d57c7cca40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1d9841e9-a507-4d13-893e-1438310aaa0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_5bbea949-9d0a-4c07-bc23-956ee9057d5f" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1d9841e9-a507-4d13-893e-1438310aaa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_4816ac42-659c-4821-87f0-5aed5d5b5976" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1d9841e9-a507-4d13-893e-1438310aaa0b" xlink:to="loc_ifrs-full_FinancialAssets_4816ac42-659c-4821-87f0-5aed5d5b5976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialInstrumentsAbstract_cd4ad850-0762-4f90-af0c-1bcc0c7b8447" xlink:href="moln-20221231.xsd#moln_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialInstrumentsAbstract_cd4ad850-0762-4f90-af0c-1bcc0c7b8447" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_903580da-0a62-4fa7-b91f-2aeda81bec1c" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TradePayablesMember_8f635300-3838-4e8c-a70d-b9828bff7933" xlink:href="moln-20221231.xsd#moln_TradePayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_moln_TradePayablesMember_8f635300-3838-4e8c-a70d-b9828bff7933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedProjectCostsAndRoyaltiesMember_7d57ecb9-4dcd-4e13-aa99-25fffac25c37" xlink:href="moln-20221231.xsd#moln_AccruedProjectCostsAndRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_moln_AccruedProjectCostsAndRoyaltiesMember_7d57ecb9-4dcd-4e13-aa99-25fffac25c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_4c595b2f-a058-4b19-9d17-5105ae611ec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_4c595b2f-a058-4b19-9d17-5105ae611ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherNonEmployeeRelatedAccruedExpensesMember_a5696efe-ebd9-4793-96e4-9c6008334581" xlink:href="moln-20221231.xsd#moln_OtherNonEmployeeRelatedAccruedExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78bfa212-4337-4217-8d43-9d49e2dd0521" xlink:to="loc_moln_OtherNonEmployeeRelatedAccruedExpensesMember_a5696efe-ebd9-4793-96e4-9c6008334581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_4f3c0130-6f3c-4c98-b759-afeb835be27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_98b64db6-8498-45a7-8afc-dd637177f365" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_4f3c0130-6f3c-4c98-b759-afeb835be27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_3b28c389-86a9-4eb7-be43-bd6a32c3531f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_4f3c0130-6f3c-4c98-b759-afeb835be27e" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_3b28c389-86a9-4eb7-be43-bd6a32c3531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4c6433a5-765a-4a60-91dc-f249f61eca24" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_e4a6c2ba-2b6f-467e-933a-699012e353b5" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4c6433a5-765a-4a60-91dc-f249f61eca24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_6a87a087-7aad-4365-8969-eefa94a465df" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4c6433a5-765a-4a60-91dc-f249f61eca24" xlink:to="loc_ifrs-full_FinancialLiabilities_6a87a087-7aad-4365-8969-eefa94a465df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/OthercurrentassetsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#OthercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/OthercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d06ea181-d23a-4a88-b9d7-f15dd7e22fd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_8d945438-dc07-493c-84a4-5fa7255bcdd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d06ea181-d23a-4a88-b9d7-f15dd7e22fd0" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_8d945438-dc07-493c-84a4-5fa7255bcdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets_9259d3fb-1f6b-4b39-a396-6f8d4d09e100" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d06ea181-d23a-4a88-b9d7-f15dd7e22fd0" xlink:to="loc_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets_9259d3fb-1f6b-4b39-a396-6f8d4d09e100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_a8a6fec1-821f-4cdf-bf0b-109d07bdf09d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d06ea181-d23a-4a88-b9d7-f15dd7e22fd0" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets_a8a6fec1-821f-4cdf-bf0b-109d07bdf09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_53be93ae-e0b1-4d77-a669-3be0fdf6fcfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_37af74cb-9924-4e98-acdf-e92ec60d27f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_53be93ae-e0b1-4d77-a669-3be0fdf6fcfc" xlink:to="loc_ifrs-full_CurrentTradeReceivables_37af74cb-9924-4e98-acdf-e92ec60d27f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_3c8a2d45-5c78-4287-895f-89b511b71fbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_53be93ae-e0b1-4d77-a669-3be0fdf6fcfc" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_3c8a2d45-5c78-4287-895f-89b511b71fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_4ba0e864-967a-4342-981c-1adfb41a71fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_53be93ae-e0b1-4d77-a669-3be0fdf6fcfc" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_4ba0e864-967a-4342-981c-1adfb41a71fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_271e3332-2473-4cbb-8798-36730cac6506" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_53be93ae-e0b1-4d77-a669-3be0fdf6fcfc" xlink:to="loc_ifrs-full_OtherCurrentReceivables_271e3332-2473-4cbb-8798-36730cac6506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_8d85852c-1985-4c04-bb3e-499571095c6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_53be93ae-e0b1-4d77-a669-3be0fdf6fcfc" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_8d85852c-1985-4c04-bb3e-499571095c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_e76260e9-ab7f-4643-b862-c0fc6ffdcc59" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherReceivablesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_e76260e9-ab7f-4643-b862-c0fc6ffdcc59" xlink:to="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:to="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_d3e03128-9f50-44fe-aab1-52f1a398e418" xlink:to="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_fd3818cb-313a-4ffd-a975-05d9414bcd67" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:to="loc_currency_CHF_fd3818cb-313a-4ffd-a975-05d9414bcd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_e74d7c2f-fdbc-44de-92b9-0401052e7571" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:to="loc_currency_EUR_e74d7c2f-fdbc-44de-92b9-0401052e7571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_85ced78e-b251-41b2-afd7-f05e7d7c0224" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ddebbe2e-179c-47f9-bd91-dd7d837fac7c" xlink:to="loc_currency_USD_85ced78e-b251-41b2-afd7-f05e7d7c0224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems_2d11d664-617c-447f-ac9e-6f8b94892b87" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherReceivablesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesTable_b96a51a6-e14d-4165-ab0b-89d34f42e269" xlink:to="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems_2d11d664-617c-447f-ac9e-6f8b94892b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_30c39784-cac9-4461-8157-b3b7b731a250" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfTradeAndOtherReceivablesLineItems_2d11d664-617c-447f-ac9e-6f8b94892b87" xlink:to="loc_ifrs-full_CurrentTradeReceivables_30c39784-cac9-4461-8157-b3b7b731a250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_902ecb3d-6a88-433d-9a98-1c24e49ad49e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_902ecb3d-6a88-433d-9a98-1c24e49ad49e" xlink:to="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:to="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_f32eb2e8-7255-4e6e-9b2b-b58c33ce25ed" xlink:to="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_7c3777ea-7dbe-4e73-94fd-febca821155d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_CHF_7c3777ea-7dbe-4e73-94fd-febca821155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_2671299b-411f-4245-8907-c3438b446d32" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_EUR_2671299b-411f-4245-8907-c3438b446d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_553f2477-bd29-48a0-9cba-160fec12701b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_USD_553f2477-bd29-48a0-9cba-160fec12701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_f5f270e7-4fb3-4577-9d82-2d7d05d65e90" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_171eca32-3273-46d9-8a2d-c371d97900da" xlink:to="loc_currency_GBP_f5f270e7-4fb3-4577-9d82-2d7d05d65e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:href="moln-20221231.xsd#moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable_c56c4143-5dd5-4a9b-870b-8e61869a7183" xlink:to="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2ab6edae-1d5b-4242-a8d3-f088814ab502" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2ab6edae-1d5b-4242-a8d3-f088814ab502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_c09526cc-02eb-4143-b697-77e08521ae19" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems_4e30e2da-9fe9-44c6-8218-bd54963889f8" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_c09526cc-02eb-4143-b697-77e08521ae19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#CashcashequivalentsandshorttermtimedepositsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_be79e35e-de89-452e-afdf-540ab505d7f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_be79e35e-de89-452e-afdf-540ab505d7f2" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:to="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_5d5138cc-d7c6-493e-9c47-3acada016252" xlink:to="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_c6b1ad0b-5662-4c33-8dea-a8bdfdb06167" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:to="loc_currency_CHF_c6b1ad0b-5662-4c33-8dea-a8bdfdb06167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_8ac49733-9f61-4664-a62c-a7aaecde4230" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:to="loc_currency_USD_8ac49733-9f61-4664-a62c-a7aaecde4230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_80e07203-2cc1-4fab-a9ad-d68b56256cea" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_d131794c-a60e-4829-9904-1653310a2120" xlink:to="loc_currency_EUR_80e07203-2cc1-4fab-a9ad-d68b56256cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable_5400bc03-176c-4e90-965c-72f52620373b" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShortTermTimeDepositPositions_88c6b55e-399d-431e-8014-958dacd15431" xlink:href="moln-20221231.xsd#moln_NumberOfShortTermTimeDepositPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:to="loc_moln_NumberOfShortTermTimeDepositPositions_88c6b55e-399d-431e-8014-958dacd15431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfBanksWhereDepositsAreHeld_5560e57f-972a-4b4a-9a28-a47907c93732" xlink:href="moln-20221231.xsd#moln_NumberOfBanksWhereDepositsAreHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems_f47feadf-1928-4e82-ad94-9364f4fda03b" xlink:to="loc_moln_NumberOfBanksWhereDepositsAreHeld_5560e57f-972a-4b4a-9a28-a47907c93732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ShareholdersequityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_1ea989da-6c61-463a-9cc1-34b979e4abae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_cfac4997-437b-45a2-b35f-d5922ac2e079" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_1ea989da-6c61-463a-9cc1-34b979e4abae" xlink:to="loc_ifrs-full_NumberOfSharesIssued_cfac4997-437b-45a2-b35f-d5922ac2e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_82f9f353-6311-4b33-838c-d96a2157c5dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_1ea989da-6c61-463a-9cc1-34b979e4abae" xlink:to="loc_ifrs-full_ParValuePerShare_82f9f353-6311-4b33-838c-d96a2157c5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TreasurySharesNominalValue_4b947a06-e5a8-4645-a9fa-9f21377412f0" xlink:href="moln-20221231.xsd#moln_TreasurySharesNominalValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_1ea989da-6c61-463a-9cc1-34b979e4abae" xlink:to="loc_moln_TreasurySharesNominalValue_4b947a06-e5a8-4645-a9fa-9f21377412f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IssuanceCostsOfTreasuryShareTransactions_229d9137-f060-46be-9bb9-b9b689cf237f" xlink:href="moln-20221231.xsd#moln_IssuanceCostsOfTreasuryShareTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_1ea989da-6c61-463a-9cc1-34b979e4abae" xlink:to="loc_moln_IssuanceCostsOfTreasuryShareTransactions_229d9137-f060-46be-9bb9-b9b689cf237f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ShareholdersequityClassesofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_87f73531-e318-48d9-ad97-8c92a598aa34" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_87f73531-e318-48d9-ad97-8c92a598aa34" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a6e60324-aed8-410a-92ab-35e608f1bda4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_afff1978-12cc-4112-8d93-60f2647eeed4" xlink:to="loc_ifrs-full_EquityMember_a6e60324-aed8-410a-92ab-35e608f1bda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_31515e5a-e049-4fda-ae36-ccd0f401878d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a6e60324-aed8-410a-92ab-35e608f1bda4" xlink:to="loc_ifrs-full_IssuedCapitalMember_31515e5a-e049-4fda-ae36-ccd0f401878d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e58439c2-59d4-4b78-ab94-9037df2981f9" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_4ed2c082-c641-4362-acb8-4c27ffa407d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:to="loc_ifrs-full_OrdinarySharesMember_4ed2c082-c641-4362-acb8-4c27ffa407d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ConditionalShareCapitalMember_47157e78-2dd1-44af-8aef-60ebf3d2ed2e" xlink:href="moln-20221231.xsd#moln_ConditionalShareCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_55aa0e40-0fd6-4daf-9345-d1c5d6968c02" xlink:to="loc_moln_ConditionalShareCapitalMember_47157e78-2dd1-44af-8aef-60ebf3d2ed2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68316b6d-a27b-4208-a1fb-3d9cc0809887" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c7fd3f48-cc33-468f-9113-2e3b9e649479" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68316b6d-a27b-4208-a1fb-3d9cc0809887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_9f9af3b7-4bca-42a1-b5ab-935e274182a8" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68316b6d-a27b-4208-a1fb-3d9cc0809887" xlink:to="loc_moln_NovartisMember_9f9af3b7-4bca-42a1-b5ab-935e274182a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea78fa53-4c54-49d7-b323-bf9e141d69b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_159c6c1a-5c8a-4119-87ba-e34e63ffc99c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea78fa53-4c54-49d7-b323-bf9e141d69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShareOptionsPSUsAndRSUsMember_0685b4e3-d0f5-4e43-91d8-dcaa58fe8ab3" xlink:href="moln-20221231.xsd#moln_ShareOptionsPSUsAndRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea78fa53-4c54-49d7-b323-bf9e141d69b8" xlink:to="loc_moln_ShareOptionsPSUsAndRSUsMember_0685b4e3-d0f5-4e43-91d8-dcaa58fe8ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_be17f736-a923-49ae-b637-b26c96695de3" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_38dc4629-96ef-4f16-9a96-24ccb68dd938" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_Equity_38dc4629-96ef-4f16-9a96-24ccb68dd938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_a5ec1761-6f3e-4803-8396-c5fa6688fc47" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_a5ec1761-6f3e-4803-8396-c5fa6688fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_185f3a60-8bcb-417b-8c1e-305a2e1ea4ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_ParValuePerShare_185f3a60-8bcb-417b-8c1e-305a2e1ea4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfVotesPerShare_2f504d92-a4b7-4d87-ba71-c4c36a736c40" xlink:href="moln-20221231.xsd#moln_NumberOfVotesPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_NumberOfVotesPerShare_2f504d92-a4b7-4d87-ba71-c4c36a736c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_9e5ee66e-12a5-4aa1-9858-51e6567e0251" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorized_9e5ee66e-12a5-4aa1-9858-51e6567e0251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_7bff6995-7005-4a08-9003-97a4db71cbed" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares_7bff6995-7005-4a08-9003-97a4db71cbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_4266fe06-f3ee-4a42-918d-84d1c8a58402" xlink:href="moln-20221231.xsd#moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent_4266fe06-f3ee-4a42-918d-84d1c8a58402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseInAuthorizedShareCapital_63d12c4a-7a7c-473f-a285-3c97f4a5afea" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseInAuthorizedShareCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_IncreaseDecreaseInAuthorizedShareCapital_63d12c4a-7a7c-473f-a285-3c97f4a5afea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_11e3e004-a969-4b37-a616-8dffa24b3205" xlink:href="moln-20221231.xsd#moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement_11e3e004-a969-4b37-a616-8dffa24b3205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_89362076-316d-4e2f-9a85-d97a0c2cb095" xlink:href="moln-20221231.xsd#moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated_89362076-316d-4e2f-9a85-d97a0c2cb095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuthorizedShareCapitalEmployeeParticipation_152fb5f9-61eb-4103-a5ca-8b7cd7c01708" xlink:href="moln-20221231.xsd#moln_AuthorizedShareCapitalEmployeeParticipation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_AuthorizedShareCapitalEmployeeParticipation_152fb5f9-61eb-4103-a5ca-8b7cd7c01708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesAuthorizedEmployeeParticipation_7200820c-2351-4190-a2c7-a026a87b857a" xlink:href="moln-20221231.xsd#moln_NumberOfSharesAuthorizedEmployeeParticipation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_NumberOfSharesAuthorizedEmployeeParticipation_7200820c-2351-4190-a2c7-a026a87b857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_7ca44c24-80c6-45b1-8300-d3115b5acd49" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation_7ca44c24-80c6-45b1-8300-d3115b5acd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AuthorizedShareCapitalFinancingTransactions_9c9ddb9d-c53a-4f05-8af6-a74a098bd2c2" xlink:href="moln-20221231.xsd#moln_AuthorizedShareCapitalFinancingTransactions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_AuthorizedShareCapitalFinancingTransactions_9c9ddb9d-c53a-4f05-8af6-a74a098bd2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesAuthorizedFinancingTransactions_827c936e-9263-4f58-8bcc-0f0ba7ed18f6" xlink:href="moln-20221231.xsd#moln_NumberOfSharesAuthorizedFinancingTransactions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_moln_NumberOfSharesAuthorizedFinancingTransactions_827c936e-9263-4f58-8bcc-0f0ba7ed18f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_f79f2539-1b16-43de-a5d3-c8fda103c341" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_14051057-063b-49c2-9d8d-624686deccf2" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_f79f2539-1b16-43de-a5d3-c8fda103c341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ShareholdersequitySharesIssuedDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_31ad170a-f384-49d3-8089-fe2cb7e0641c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31ad170a-f384-49d3-8089-fe2cb7e0641c" xlink:to="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_276b9288-2ced-4169-a769-024b79226a35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_276b9288-2ced-4169-a769-024b79226a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity_28a16968-918a-44b5-abf8-fe0f91c18593" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity_28a16968-918a-44b5-abf8-fe0f91c18593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity_8586100d-e8f3-4747-856f-6ffa68e52047" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity_8586100d-e8f3-4747-856f-6ffa68e52047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity_178fc124-7e1f-4525-bbb9-fe6ec8e561a5" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity_178fc124-7e1f-4525-bbb9-fe6ec8e561a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity_aca848ac-37d4-42ae-9a23-52d6ae6a26d1" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity_aca848ac-37d4-42ae-9a23-52d6ae6a26d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfSharesIssuedTreasurySharesEquity_0f2c7521-dd17-4fe9-861d-3684f1096b54" xlink:href="moln-20221231.xsd#moln_NumberOfSharesIssuedTreasurySharesEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_moln_NumberOfSharesIssuedTreasurySharesEquity_0f2c7521-dd17-4fe9-861d-3684f1096b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_94e37ab0-4d63-4c22-b7c3-57d3c0f1efe4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract_541c62bd-9f6c-48f7-b566-e4492e14c884" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_94e37ab0-4d63-4c22-b7c3-57d3c0f1efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_95ba7c37-1690-40ab-be06-fca31d939d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_8b80de2e-28a7-4832-b95b-d0b5e98bb55f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_95ba7c37-1690-40ab-be06-fca31d939d0c" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_8b80de2e-28a7-4832-b95b-d0b5e98bb55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1e27f8f2-33a6-4fba-b9d1-4a2a077d350b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_95ba7c37-1690-40ab-be06-fca31d939d0c" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1e27f8f2-33a6-4fba-b9d1-4a2a077d350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxPayables_10da2c75-5cd6-48ba-be0d-d26bb7f6ecd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_95ba7c37-1690-40ab-be06-fca31d939d0c" xlink:to="loc_ifrs-full_CurrentValueAddedTaxPayables_10da2c75-5cd6-48ba-be0d-d26bb7f6ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_c55fc297-7c81-4282-b9a4-8e5e81464eaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_95ba7c37-1690-40ab-be06-fca31d939d0c" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_c55fc297-7c81-4282-b9a4-8e5e81464eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_33c8be06-a0d5-40bf-9f25-6b81f2b9308c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherPayablesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_33c8be06-a0d5-40bf-9f25-6b81f2b9308c" xlink:to="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:to="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_b82f8eab-d289-49b7-ac0e-79ae6edb5c43" xlink:to="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_5e78238a-5345-45ba-8c46-95c291035842" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_CHF_5e78238a-5345-45ba-8c46-95c291035842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_12bb5c5c-6e1c-4369-ba5d-0316dd3729e8" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_EUR_12bb5c5c-6e1c-4369-ba5d-0316dd3729e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_ba13555e-c935-4166-9a8a-caee8b291dd1" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_USD_ba13555e-c935-4166-9a8a-caee8b291dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_1c83f693-7bf8-4541-acda-36fcf0add095" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_adb81bda-a889-467b-be2a-e55c9f931fd5" xlink:to="loc_currency_GBP_1c83f693-7bf8-4541-acda-36fcf0add095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems_854173c9-40b1-4354-9ad1-85dbacd0c9a5" xlink:href="moln-20221231.xsd#moln_DisclosureOfTradeAndOtherPayablesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesTable_04008a1d-e877-49d1-9b41-dcff17372a17" xlink:to="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems_854173c9-40b1-4354-9ad1-85dbacd0c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2fb60277-166b-4d69-ad5a-bd043b9a0d78" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfTradeAndOtherPayablesLineItems_854173c9-40b1-4354-9ad1-85dbacd0c9a5" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2fb60277-166b-4d69-ad5a-bd043b9a0d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#AccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9aeef15-0fbc-4d7c-942d-e7e6fa25d495" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CurrentAccruedProjectCostsAndRoyalties_9d857d71-477f-4bb2-b909-38552ecb44b9" xlink:href="moln-20221231.xsd#moln_CurrentAccruedProjectCostsAndRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9aeef15-0fbc-4d7c-942d-e7e6fa25d495" xlink:to="loc_moln_CurrentAccruedProjectCostsAndRoyalties_9d857d71-477f-4bb2-b909-38552ecb44b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_c20ad62c-06b3-46bc-98a9-8c02b0782723" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9aeef15-0fbc-4d7c-942d-e7e6fa25d495" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_c20ad62c-06b3-46bc-98a9-8c02b0782723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_471bf5f9-0fbb-4803-a584-e5de53f5ef3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9aeef15-0fbc-4d7c-942d-e7e6fa25d495" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_471bf5f9-0fbb-4803-a584-e5de53f5ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_a35f40ed-685a-4e4b-84c5-e9dfee5d9f0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9aeef15-0fbc-4d7c-942d-e7e6fa25d495" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_a35f40ed-685a-4e4b-84c5-e9dfee5d9f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract_20c6cb99-32d7-4429-8c68-d2917b0fac4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_20c6cb99-32d7-4429-8c68-d2917b0fac4c" xlink:to="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:to="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_ac124813-9037-42a0-8d59-b304539a23dc" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_497cd6ea-02e5-479e-a362-540b9ece5d08" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_497cd6ea-02e5-479e-a362-540b9ece5d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_3818d747-8eb9-447f-b026-4bc893c1aef1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_3818d747-8eb9-447f-b026-4bc893c1aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3b1d0191-d565-48da-b8c2-2a68f2a84cb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3b1d0191-d565-48da-b8c2-2a68f2a84cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0d1ca0dc-5995-4ca6-a311-7a8bfd05492a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0d1ca0dc-5995-4ca6-a311-7a8bfd05492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LaterThanFourYearsMember_04ab5090-0955-4306-b1f4-385d085806cc" xlink:href="moln-20221231.xsd#moln_LaterThanFourYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5c899812-c7de-4b10-bd83-cc997c5a3826" xlink:to="loc_moln_LaterThanFourYearsMember_04ab5090-0955-4306-b1f4-385d085806cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_8db25394-c744-4dca-8ebf-302fe654c125" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable_bab3313a-b1fb-416a-a0a8-448334d35400" xlink:to="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_8db25394-c744-4dca-8ebf-302fe654c125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_7a923168-8ab8-4ce0-9649-7ce073e8d85d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems_8db25394-c744-4dca-8ebf-302fe654c125" xlink:to="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_7a923168-8ab8-4ce0-9649-7ce073e8d85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityExplanationofChangesinContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract_bfbe7252-10a1-45c3-a82a-2cd6456584ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_bfbe7252-10a1-45c3-a82a-2cd6456584ca" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:to="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_203ec8b1-316a-46de-8381-29d744d465db" xlink:to="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmgenIncMember_57fb8c92-1125-4b21-a3eb-8198c92838b1" xlink:href="moln-20221231.xsd#moln_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:to="loc_moln_AmgenIncMember_57fb8c92-1125-4b21-a3eb-8198c92838b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_c3b06e2d-497c-4405-a7b0-96134020f925" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:to="loc_moln_NovartisMember_c3b06e2d-497c-4405-a7b0-96134020f925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember_550991a8-0af5-4e2b-a544-9c554a2eca2e" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_67ee6976-71f7-49d5-bb32-f1c0925a6467" xlink:to="loc_moln_FederalOfficeOfPublicHealthMember_550991a8-0af5-4e2b-a544-9c554a2eca2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_d943728a-3fab-45e6-adae-b588b384e250" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_2544c7fa-9e1f-4505-9a2a-1f97b7371523" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_ifrs-full_ContractLiabilities_2544c7fa-9e1f-4505-9a2a-1f97b7371523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseThroughAdditionsContractLiabilities_80010dd0-0821-4e90-bbbe-446db8abecb9" xlink:href="moln-20221231.xsd#moln_IncreaseThroughAdditionsContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_moln_IncreaseThroughAdditionsContractLiabilities_80010dd0-0821-4e90-bbbe-446db8abecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_123e6617-5b33-411e-a460-1a44f4b034a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_123e6617-5b33-411e-a460-1a44f4b034a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_c38869aa-8c4c-454d-8857-385c7e889de1" xlink:href="moln-20221231.xsd#moln_DecreaseThroughOffsetOfCostsContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_c38869aa-8c4c-454d-8857-385c7e889de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_146280db-caa9-4438-ad81-ddcebf25d3e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a598ea6a-3502-455b-b9f7-f1d6f743af35" xlink:to="loc_ifrs-full_ContractLiabilities_146280db-caa9-4438-ad81-ddcebf25d3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract_44eff32d-1479-4702-908d-c90295265381" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_44eff32d-1479-4702-908d-c90295265381" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:to="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_7377a844-4cb0-4b58-a9a2-0c431aac8692" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_d8b81e0b-c4e5-4e0f-86c5-3aae8af9875b" xlink:to="loc_ifrs-full_CounterpartiesMember_7377a844-4cb0-4b58-a9a2-0c431aac8692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_8279d546-8f40-4769-baaa-5d0c05ceefeb" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_7377a844-4cb0-4b58-a9a2-0c431aac8692" xlink:to="loc_moln_NovartisMember_8279d546-8f40-4769-baaa-5d0c05ceefeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_05961cce-780e-4ecd-9dd9-02cf30eaf697" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_eab02d74-29ee-4c69-9ac0-eb65aa883ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:to="loc_ifrs-full_ContractLiabilities_eab02d74-29ee-4c69-9ac0-eb65aa883ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_0d350289-793a-47d8-8a1f-3032e81078dd" xlink:href="moln-20221231.xsd#moln_DecreaseThroughOffsetOfCostsContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_a155ff16-8f6a-4bc3-b477-b6cb1b53ec04" xlink:to="loc_moln_DecreaseThroughOffsetOfCostsContractLiabilities_0d350289-793a-47d8-8a1f-3032e81078dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilitiesAbstract_8ee569f5-546f-401e-b39c-f473ad2d4a72" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractLiabilitiesAbstract_8ee569f5-546f-401e-b39c-f473ad2d4a72" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:to="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_997039d1-1831-4a54-9d1f-04275200d1d3" xlink:to="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AmgenIncMember_d1b27b23-251a-4f35-b4be-45818808fb81" xlink:href="moln-20221231.xsd#moln_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:to="loc_moln_AmgenIncMember_d1b27b23-251a-4f35-b4be-45818808fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NovartisMember_9bfc0267-d00b-4777-81e5-3cec8c93d287" xlink:href="moln-20221231.xsd#moln_NovartisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:to="loc_moln_NovartisMember_9bfc0267-d00b-4777-81e5-3cec8c93d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FederalOfficeOfPublicHealthMember_140d05b6-47a2-49d7-8d53-db47c10e50e3" xlink:href="moln-20221231.xsd#moln_FederalOfficeOfPublicHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_188fdd1d-d7a4-4924-8b6c-7bd10a345377" xlink:to="loc_moln_FederalOfficeOfPublicHealthMember_140d05b6-47a2-49d7-8d53-db47c10e50e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityTable_3f99f776-c95c-408c-89c6-6449623ece34" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_8e16d160-6e3a-444a-90a8-518b4e155e9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_ifrs-full_CurrentContractLiabilities_8e16d160-6e3a-444a-90a8-518b4e155e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_122e1467-89b2-4d85-953b-3c0ace5117fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_122e1467-89b2-4d85-953b-3c0ace5117fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6edae91e-4d95-41d0-8580-32732b75a982" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems_5bb7e35b-2219-4927-a27e-5365e6c27299" xlink:to="loc_ifrs-full_ContractLiabilities_6edae91e-4d95-41d0-8580-32732b75a982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#AdditionalinformationonthenatureofexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_92f09e84-d743-49cc-bc05-78d8198006cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_92f09e84-d743-49cc-bc05-78d8198006cb" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_47d959f5-1572-4c77-a3fd-cd349cb39b70" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember_d37e3fe5-673f-418e-bc16-85df4722cb84" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:to="loc_moln_ResearchAndDevelopmentExpenseMember_d37e3fe5-673f-418e-bc16-85df4722cb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_62f1218e-22c5-4faa-8230-47de45d06287" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_abd5962e-3920-4422-8f24-47d6cc43fcac" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_62f1218e-22c5-4faa-8230-47de45d06287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_140eefb7-98e2-475e-af02-c472d35d7f77" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_801dbb12-d522-433f-b482-1a4784cf3db5" xlink:href="moln-20221231.xsd#moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense_801dbb12-d522-433f-b482-1a4784cf3db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_434c3725-dcec-410d-8c8e-1fd6343ccb02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_434c3725-dcec-410d-8c8e-1fd6343ccb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_eed8d82d-8bcd-4416-9ded-74fdb80c1bd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_AdministrativeExpense_eed8d82d-8bcd-4416-9ded-74fdb80c1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_002cb2aa-fdf5-4d64-8b08-1ecc7df37cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_002cb2aa-fdf5-4d64-8b08-1ecc7df37cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IntellectualPropertyExpense_004b2a5d-e6e0-48b7-a53f-daae7b1991f3" xlink:href="moln-20221231.xsd#moln_IntellectualPropertyExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_IntellectualPropertyExpense_004b2a5d-e6e0-48b7-a53f-daae7b1991f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense_fe58f866-2998-4d42-b35c-b92bf81760a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OccupancyExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_OccupancyExpense_fe58f866-2998-4d42-b35c-b92bf81760a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_OtherResearchAndDevelopmentExpense_d6c564f1-05b9-470f-887d-4a35001c202e" xlink:href="moln-20221231.xsd#moln_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_OtherResearchAndDevelopmentExpense_d6c564f1-05b9-470f-887d-4a35001c202e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesAndLicenseFeesExpense_2df969f2-2564-4cbe-ba25-a22a91457814" xlink:href="moln-20221231.xsd#moln_RoyaltiesAndLicenseFeesExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_RoyaltiesAndLicenseFeesExpense_2df969f2-2564-4cbe-ba25-a22a91457814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_626da479-6d6d-4cb9-913a-0c8b4e0315d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_626da479-6d6d-4cb9-913a-0c8b4e0315d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0c53f6a5-4721-480d-9a1d-ed4f3b6f16fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0c53f6a5-4721-480d-9a1d-ed4f3b6f16fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_178aa94a-e91f-4632-9b5b-ea0f9a5a0916" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_ifrs-full_OperatingExpense_178aa94a-e91f-4632-9b5b-ea0f9a5a0916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_5a204ff1-9352-4abe-9635-47bfb1aa2bd1" xlink:href="moln-20221231.xsd#moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b6a1c568-885a-4246-82d1-388ce580aa35" xlink:to="loc_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost_5a204ff1-9352-4abe-9635-47bfb1aa2bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RoyaltiesandlicensefeesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_025827ad-18b4-4fc6-9931-cbbca0c0e800" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_025827ad-18b4-4fc6-9931-cbbca0c0e800" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:to="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_c786c0b2-eaad-4025-9e72-1043fdca49ac" xlink:to="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UniversityOfZurichMember_769d1657-d0df-47ea-9500-c2b04bb8fdd6" xlink:href="moln-20221231.xsd#moln_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:to="loc_moln_UniversityOfZurichMember_769d1657-d0df-47ea-9500-c2b04bb8fdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_UniversityOfUtrechtMember_a714b0b0-f024-4414-b996-fc805936d5ac" xlink:href="moln-20221231.xsd#moln_UniversityOfUtrechtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_05f83ee3-251a-4115-9738-520afd9a5639" xlink:to="loc_moln_UniversityOfUtrechtMember_a714b0b0-f024-4414-b996-fc805936d5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:to="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_7960fd09-c727-4fca-a2c0-f5e8adda886c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_93ea94be-1dcc-451b-b2b2-477121605b82" xlink:to="loc_ifrs-full_TypesOfContractsMember_7960fd09-c727-4fca-a2c0-f5e8adda886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_225de5da-001f-4365-970a-9a8cebca2ec4" xlink:href="moln-20221231.xsd#moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_7960fd09-c727-4fca-a2c0-f5e8adda886c" xlink:to="loc_moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember_225de5da-001f-4365-970a-9a8cebca2ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable_9c1566d2-8df8-43f6-9a85-f9a2b5d011ac" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RoyaltyExpense_6b909ac8-c3a4-49c6-a6c1-02a3b95ecb8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RoyaltyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_ifrs-full_RoyaltyExpense_6b909ac8-c3a4-49c6-a6c1-02a3b95ecb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltiesMinimumAnnualAmountTotal_7e6d50a3-4f6f-4438-a2d9-c080c1a8e8f2" xlink:href="moln-20221231.xsd#moln_RoyaltiesMinimumAnnualAmountTotal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_RoyaltiesMinimumAnnualAmountTotal_7e6d50a3-4f6f-4438-a2d9-c080c1a8e8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LicenseFeesExpense_b7080bc9-e867-4bd3-9a87-44676c6cec58" xlink:href="moln-20221231.xsd#moln_LicenseFeesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_LicenseFeesExpense_b7080bc9-e867-4bd3-9a87-44676c6cec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CurrentAccruedProjectCostsAndRoyalties_6a1ca814-862e-4580-80a9-c17ead20d39d" xlink:href="moln-20221231.xsd#moln_CurrentAccruedProjectCostsAndRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_CurrentAccruedProjectCostsAndRoyalties_6a1ca814-862e-4580-80a9-c17ead20d39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RoyaltyPayable_31ec7f2d-6586-4cd6-935a-57865adb57eb" xlink:href="moln-20221231.xsd#moln_RoyaltyPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems_3fda9eec-682e-4721-af70-c7bef2e8faa2" xlink:to="loc_moln_RoyaltyPayable_31ec7f2d-6586-4cd6-935a-57865adb57eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_cdc138dd-3f74-4a2c-97ed-ed01d41b75dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:to="loc_ifrs-full_WagesAndSalaries_cdc138dd-3f74-4a2c-97ed-ed01d41b75dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_9c77217e-535b-44ed-b928-c7cb01f10071" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_9c77217e-535b-44ed-b928-c7cb01f10071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_c289ac36-6fa4-48a2-8191-daa0f99617f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_c289ac36-6fa4-48a2-8191-daa0f99617f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_697622ee-88c1-4030-b3ba-909d6c713d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:to="loc_ifrs-full_SocialSecurityContributions_697622ee-88c1-4030-b3ba-909d6c713d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_9431c286-a1ba-4d17-94c3-76d5c9e29cf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:to="loc_ifrs-full_OtherEmployeeExpense_9431c286-a1ba-4d17-94c3-76d5c9e29cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_4a853a5a-70ea-481e-8043-fa4462fbd51c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a725b273-c58e-4ff5-8948-8014b5b1fb27" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_4a853a5a-70ea-481e-8043-fa4462fbd51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_97b2770a-3368-457e-9473-0d0ee251436f" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AverageNumberOfFullTimeEquivalentEmployees_eb361798-bf44-4536-9137-99d511a879f4" xlink:href="moln-20221231.xsd#moln_AverageNumberOfFullTimeEquivalentEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_97b2770a-3368-457e-9473-0d0ee251436f" xlink:to="loc_moln_AverageNumberOfFullTimeEquivalentEmployees_eb361798-bf44-4536-9137-99d511a879f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfFullTimeEquivalentEmployees_582c0fc0-8a8c-4a7f-aafa-26f75a3d61a2" xlink:href="moln-20221231.xsd#moln_NumberOfFullTimeEquivalentEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_97b2770a-3368-457e-9473-0d0ee251436f" xlink:to="loc_moln_NumberOfFullTimeEquivalentEmployees_582c0fc0-8a8c-4a7f-aafa-26f75a3d61a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_005853dc-36b1-47e0-926b-1b73cbd3130e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_97b2770a-3368-457e-9473-0d0ee251436f" xlink:to="loc_ifrs-full_NumberOfEmployees_005853dc-36b1-47e0-926b-1b73cbd3130e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_a2d9f84f-f91f-41d0-bf2d-01ef8d68f66c" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_a2d9f84f-f91f-41d0-bf2d-01ef8d68f66c" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e7e6ba65-ece3-4389-89b0-3f5afe91a2ea" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_9934cf04-4e2b-47da-94f4-36b2a25e9ea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_9934cf04-4e2b-47da-94f4-36b2a25e9ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_c60e4cf6-5748-468e-b691-a159a05cdd05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_98d01183-a0dd-4c16-8fc4-2514c0b3eb32" xlink:to="loc_ifrs-full_PlanAssetsMember_c60e4cf6-5748-468e-b691-a159a05cdd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_588480e3-52b3-4bfe-9907-42ee96b3d935" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_bbc7154c-9fe3-45cd-aec1-ca24c9436b7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_bbc7154c-9fe3-45cd-aec1-ca24c9436b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_267d5be2-6dd4-4c69-ad8c-9f7d2108c904" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4ad11f68-56e4-47fb-8fb8-dbb4b3789e60" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_267d5be2-6dd4-4c69-ad8c-9f7d2108c904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_6c200866-54e5-40de-86ac-b958614ae337" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_4879467f-31f5-4bd4-93c9-a1ed97471a13" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_4879467f-31f5-4bd4-93c9-a1ed97471a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_f41dbb6b-4892-4abc-bb0b-2e065dcb2af3" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember_f41dbb6b-4892-4abc-bb0b-2e065dcb2af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_b120ef04-e860-4fd2-a266-347482bd2871" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_b120ef04-e860-4fd2-a266-347482bd2871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember_77d91676-bfe7-47b7-bdff-4317e4a55869" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_b6eb8eaa-e585-43ec-9559-38d19526c8f5" xlink:to="loc_ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember_77d91676-bfe7-47b7-bdff-4317e4a55869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:href="moln-20221231.xsd#moln_IndividualsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:href="moln-20221231.xsd#moln_IndividualsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IndividualsAxis_98df5004-13aa-4beb-9c27-c732fb24bbdd" xlink:to="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActiveMembersMember_dd65783d-754f-4ca6-9f56-7edb375c8ea1" xlink:href="moln-20221231.xsd#moln_ActiveMembersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:to="loc_moln_ActiveMembersMember_dd65783d-754f-4ca6-9f56-7edb375c8ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PensionersMember_97f69d82-ba19-4974-8ce0-5f13e4f72864" xlink:href="moln-20221231.xsd#moln_PensionersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IndividualsDomain_12ad998a-35fa-467a-836f-eab53033f010" xlink:to="loc_moln_PensionersMember_97f69d82-ba19-4974-8ce0-5f13e4f72864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_7a8dfceb-66e6-4e53-8247-5f592c898740" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember_e24e0246-c99f-4348-9fba-8f39ff6134b9" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:to="loc_moln_ResearchAndDevelopmentExpenseMember_e24e0246-c99f-4348-9fba-8f39ff6134b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_afc8c827-87e1-4a0a-8266-4e8f6e5ea791" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_fc3867e2-23d8-40bb-a762-bdfa799c11fe" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_afc8c827-87e1-4a0a-8266-4e8f6e5ea791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_e665a7f8-5e7a-44e5-8a77-0c395883f4d1" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1518a741-a343-4b49-9099-659a6e4e36d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1518a741-a343-4b49-9099-659a6e4e36d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_225042bd-f3d9-4557-a1d3-72c485886469" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ActuarialAssumptionsAbstract_c139040f-ab94-4638-b4ea-7438fb4b2fbc" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_225042bd-f3d9-4557-a1d3-72c485886469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:href="moln-20221231.xsd#moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_b614be2f-d9d8-4599-a191-de7401992d37" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_b614be2f-d9d8-4599-a191-de7401992d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_91d2a374-b5db-4e41-8f42-f38bc86cb5d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_91d2a374-b5db-4e41-8f42-f38bc86cb5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a246cae4-81f6-4c94-81de-9e428cebadb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract_b4ed436f-99d1-44cd-a63e-f95bba8edd1d" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a246cae4-81f6-4c94-81de-9e428cebadb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_b2fbd8d1-f1bf-448d-b387-0e5d6a3bbc18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_b2fbd8d1-f1bf-448d-b387-0e5d6a3bbc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_597e0d5d-00fa-4e65-80b0-2c660a328126" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_597e0d5d-00fa-4e65-80b0-2c660a328126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_d055e578-b7d1-4cc1-bc82-c27bd88b0adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_d055e578-b7d1-4cc1-bc82-c27bd88b0adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_d5aef57b-0196-453c-a545-5537e7bc16d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_d5aef57b-0196-453c-a545-5537e7bc16d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_7796da14-d0b0-49c3-8b79-59389c3cbe52" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_7796da14-d0b0-49c3-8b79-59389c3cbe52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_355e525e-45f2-408a-8469-c1fa30840f7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_355e525e-45f2-408a-8469-c1fa30840f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_43f94011-6698-4a10-ab3a-418af72c635a" xlink:href="moln-20221231.xsd#moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_43f94011-6698-4a10-ab3a-418af72c635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_08c66c16-659e-4670-aed0-004e4c877da7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_9f99b4de-d927-456c-b3b5-227f3fd12616" xlink:to="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_08c66c16-659e-4670-aed0-004e4c877da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_52ba4341-73ec-484c-a4b0-313d2e31ceaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_52ba4341-73ec-484c-a4b0-313d2e31ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_e226aaf2-5dc2-4bdd-8b18-acd04ea06ab0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_e226aaf2-5dc2-4bdd-8b18-acd04ea06ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6ed2fdb2-a9b4-4fb9-9abc-52ac3f2859a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6ed2fdb2-a9b4-4fb9-9abc-52ac3f2859a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_fb966abe-68f6-47bd-adb2-c0ae8cc08398" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_fb966abe-68f6-47bd-adb2-c0ae8cc08398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_274fe58e-2595-40dd-a427-64a1c16e9349" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_141d697b-5361-4ed8-8f5f-93f31d340df9" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_274fe58e-2595-40dd-a427-64a1c16e9349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:href="moln-20221231.xsd#moln_ReconciliationOfDefinedBenefitObligationAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_8c9fd689-7101-493b-9c27-d1ddea7ab7a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_8c9fd689-7101-493b-9c27-d1ddea7ab7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_13f45f62-0f03-4d73-90bd-aba3ff7bf406" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_13f45f62-0f03-4d73-90bd-aba3ff7bf406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_655b51c4-1b66-4607-bfdf-71aa6fd5a57f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_655b51c4-1b66-4607-bfdf-71aa6fd5a57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_60241cb2-1b73-45e6-8c21-d7b8279022b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_60241cb2-1b73-45e6-8c21-d7b8279022b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_f24dfdd2-e114-4725-959d-0f67e4528a18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_f24dfdd2-e114-4725-959d-0f67e4528a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_d86d9db8-44fe-413a-b79d-8dd0bed912dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_d86d9db8-44fe-413a-b79d-8dd0bed912dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_4b00273d-7a35-444b-86b0-f34b5a19a464" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_4b00273d-7a35-444b-86b0-f34b5a19a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a02cb6a1-e212-4601-8df0-2cf48b5186ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a02cb6a1-e212-4601-8df0-2cf48b5186ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_82a41a53-d24a-4bb2-8521-0fac31d886b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfDefinedBenefitObligationAbstract_ac48ca1d-1e52-4517-94ef-ada16c8f501b" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_82a41a53-d24a-4bb2-8521-0fac31d886b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_ec8e5930-c823-49eb-a906-86a7d5b66c60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_ec8e5930-c823-49eb-a906-86a7d5b66c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_656227ac-b972-45e7-b109-eb30edcf29e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_656227ac-b972-45e7-b109-eb30edcf29e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_eebf6c02-ab92-4753-95f2-4e8195c9daa8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_eebf6c02-ab92-4753-95f2-4e8195c9daa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_dff7ac74-1a16-489c-8150-509a41c8b9b9" xlink:href="moln-20221231.xsd#moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_dff7ac74-1a16-489c-8150-509a41c8b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_005f9c06-b45c-4ef2-824f-f742985d1733" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_005f9c06-b45c-4ef2-824f-f742985d1733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_bf22d185-6c2d-4edb-a41f-5507054a426b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_ede463d9-859f-4b8d-9a73-21170e60fec2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_bf22d185-6c2d-4edb-a41f-5507054a426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:href="moln-20221231.xsd#moln_ReconciliationOfFairValueOfPlanAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_97760c9f-b88e-476e-8d23-5a85e3e7e816" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_97760c9f-b88e-476e-8d23-5a85e3e7e816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_359707b6-ddca-4270-b7c1-881b7053504b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_359707b6-ddca-4270-b7c1-881b7053504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_467985bf-0d3a-4408-8860-997a2f0f14c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_467985bf-0d3a-4408-8860-997a2f0f14c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1bd5bdd6-567f-49fc-b083-b36e4f805a88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1bd5bdd6-567f-49fc-b083-b36e4f805a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_5ae98df4-621c-4416-95ce-f5386ecbea43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_5ae98df4-621c-4416-95ce-f5386ecbea43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_aaba73a7-4bae-4e9c-ab47-4129b2ec6fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_aaba73a7-4bae-4e9c-ab47-4129b2ec6fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b7a9f1d3-6fdf-48bf-a575-491f997d84cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_ReconciliationOfFairValueOfPlanAssetsAbstract_75693a03-7edb-4191-9749-e8cf6daec436" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b7a9f1d3-6fdf-48bf-a575-491f997d84cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_2ec3b8ad-5d85-4b4e-925c-27eda6e75edd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_2ec3b8ad-5d85-4b4e-925c-27eda6e75edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_b5151753-aaac-490d-af7f-ab36d499db27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_b5151753-aaac-490d-af7f-ab36d499db27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_382c10e0-21ea-4d3c-a071-58c573680c41" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets_382c10e0-21ea-4d3c-a071-58c573680c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_58852303-18f3-4479-a0e0-981b78c88d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets_58852303-18f3-4479-a0e0-981b78c88d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_94e03f43-6acd-4720-9939-59efb6309752" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets_94e03f43-6acd-4720-9939-59efb6309752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_94e4206a-3ec9-4724-88cb-cff18a41a5e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets_94e4206a-3ec9-4724-88cb-cff18a41a5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_e0d95317-d8bb-410a-bad9-063f2c57e7ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_e0d95317-d8bb-410a-bad9-063f2c57e7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets_07d2fc03-6d65-456a-9a62-85a3f83c09d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets_07d2fc03-6d65-456a-9a62-85a3f83c09d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_31fc725c-478e-4f5d-8c38-d4befba3a3bd" xlink:href="moln-20221231.xsd#moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract_56d95799-6391-42fd-ae80-80817b5b49d2" xlink:to="loc_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets_31fc725c-478e-4f5d-8c38-d4befba3a3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_3d60faba-e5dd-42af-b1d6-639c3bec2bee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_3d60faba-e5dd-42af-b1d6-639c3bec2bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cfa7320b-9a2f-4205-8fb6-2eb856918a54" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cfa7320b-9a2f-4205-8fb6-2eb856918a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_c416f504-4f4f-449d-a1a5-67d2a3260ebb" xlink:href="moln-20221231.xsd#moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod_c416f504-4f4f-449d-a1a5-67d2a3260ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_e85d76f2-aa7c-4cdf-84b6-f2cb28aec829" xlink:href="moln-20221231.xsd#moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod_e85d76f2-aa7c-4cdf-84b6-f2cb28aec829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_19bad546-70b8-4364-937c-3b6820c6b189" xlink:href="moln-20221231.xsd#moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_19bad546-70b8-4364-937c-3b6820c6b189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9bdaa6f4-aee6-4514-8eee-d6df9a4f4d54" xlink:href="moln-20221231.xsd#moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9bdaa6f4-aee6-4514-8eee-d6df9a4f4d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_de151693-2ca4-451f-b0f7-fb794d5e43e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_de151693-2ca4-451f-b0f7-fb794d5e43e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IndustryBenchmarkDiscountRatesPeriod_26811128-774e-422c-81e0-c044cdc6d336" xlink:href="moln-20221231.xsd#moln_IndustryBenchmarkDiscountRatesPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_IndustryBenchmarkDiscountRatesPeriod_26811128-774e-422c-81e0-c044cdc6d336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedSabbaticalCost_3c05a752-4286-45e5-bc8a-54d17aed5634" xlink:href="moln-20221231.xsd#moln_AccruedSabbaticalCost"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_AccruedSabbaticalCost_3c05a752-4286-45e5-bc8a-54d17aed5634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_06ce3574-3cd0-4fd6-996a-0537b60986f7" xlink:href="moln-20221231.xsd#moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost_06ce3574-3cd0-4fd6-996a-0537b60986f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_ce48eb4d-1574-40ad-aeda-72f9d05458b2" xlink:href="moln-20221231.xsd#moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_abe82ecf-b1ca-4c61-9c2e-39467ac8c0ee" xlink:to="loc_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories_ce48eb4d-1574-40ad-aeda-72f9d05458b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_e6ac4242-6832-4ede-bb75-0c621c982799" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_e6ac4242-6832-4ede-bb75-0c621c982799" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_00b4d60a-595c-420c-baf6-c71c205e56c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_CurrentServiceCostDefinedBenefitPlans_00b4d60a-595c-420c-baf6-c71c205e56c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_5905158c-e47d-4c08-8d52-63fd42b2b8ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_PastServiceCostDefinedBenefitPlans_5905158c-e47d-4c08-8d52-63fd42b2b8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_c8fa8da1-e8fc-4bc0-ad98-217a6536d8fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_InterestExpenseDefinedBenefitPlans_c8fa8da1-e8fc-4bc0-ad98-217a6536d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_f74d727c-1101-433d-929e-f7174c2f7888" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_InterestIncomeDefinedBenefitPlans_f74d727c-1101-433d-929e-f7174c2f7888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_90be9ec5-3a02-4852-a873-59f9c34ef7da" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans_90be9ec5-3a02-4852-a873-59f9c34ef7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_a04338fe-4cca-4f3a-a7e8-d1e865cdecf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_a04338fe-4cca-4f3a-a7e8-d1e865cdecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_2ce570ca-f71b-40cf-89fe-5f6ebc61a9d8" xlink:href="moln-20221231.xsd#moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans_2ce570ca-f71b-40cf-89fe-5f6ebc61a9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_aa41b345-f926-4fa8-9bc8-44df1eb94eb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeDefinedBenefitPlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract_c02f15ed-5d8d-4b89-bdf8-39c2f0982ae1" xlink:to="loc_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans_aa41b345-f926-4fa8-9bc8-44df1eb94eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_e6ac4242-6832-4ede-bb75-0c621c982799" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_73532ccb-2cdb-47b9-aea6-7691024d1aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans_73532ccb-2cdb-47b9-aea6-7691024d1aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_a46fd4cf-5e7a-4f00-bbaf-244ae406d795" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans_a46fd4cf-5e7a-4f00-bbaf-244ae406d795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_468c9461-685a-471f-b467-85b515efb9f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans_468c9461-685a-471f-b467-85b515efb9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_92793aa8-4d0c-4597-b95a-5e4d3aac5b53" xlink:href="moln-20221231.xsd#moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:to="loc_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans_92793aa8-4d0c-4597-b95a-5e4d3aac5b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_08b7894b-933b-4a50-a883-c7beb21453f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans_08b7894b-933b-4a50-a883-c7beb21453f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_157234f3-cc81-40ca-98d0-aa8e1789cb95" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract_1a940d46-2d23-4295-baa5-3b6c731a593d" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_157234f3-cc81-40ca-98d0-aa8e1789cb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_b44a4323-6f3c-4744-8034-e2106479c247" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_b44a4323-6f3c-4744-8034-e2106479c247" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_70610d53-7587-4231-9df2-05c17f7b8fcc" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ESOP2009AndESOP2014Member_a94b76b9-b439-4b52-81a9-65af7a577c7f" xlink:href="moln-20221231.xsd#moln_ESOP2009AndESOP2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_ESOP2009AndESOP2014Member_a94b76b9-b439-4b52-81a9-65af7a577c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RestrictedShareUnitsRSUMember_39912bf9-7fce-4e63-bb48-2d387ffc24c5" xlink:href="moln-20221231.xsd#moln_RestrictedShareUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_RestrictedShareUnitsRSUMember_39912bf9-7fce-4e63-bb48-2d387ffc24c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_54169bbc-300f-4326-a30b-8ccc4fb93662" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_54169bbc-300f-4326-a30b-8ccc4fb93662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_752a020f-965a-4b9a-b2b1-14fba486d557" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUManagementBoardMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_752a020f-965a-4b9a-b2b1-14fba486d557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUMember_e174904f-a3b1-48b7-9bef-db6f0773ede2" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0fdca027-8aed-4e54-ba2d-7ce2dd1b2c31" xlink:to="loc_moln_PerformanceShareUnitsPSUMember_e174904f-a3b1-48b7-9bef-db6f0773ede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:to="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f4f0bb6f-6fe3-4214-a7b2-c9a98ef89b38" xlink:to="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f2bb956-1201-4bde-a7b0-d34b97c447ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:to="loc_srt_MinimumMember_4f2bb956-1201-4bde-a7b0-d34b97c447ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06782d1c-5276-45f0-af1d-bc8ef1cce8a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_65875ad5-a980-48c3-8248-a15f59dfd03f" xlink:to="loc_srt_MaximumMember_06782d1c-5276-45f0-af1d-bc8ef1cce8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_39798074-50d2-40a8-b1f6-604ea109a47c" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_0d26835b-a1b6-4217-992e-636e94ec18a9" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_0d26835b-a1b6-4217-992e-636e94ec18a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_cec4cce0-e167-42f8-bad9-542ecb1ec051" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage_cec4cce0-e167-42f8-bad9-542ecb1ec051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_03ec74ae-e4f6-4265-8245-c86c3006dc3c" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod_03ec74ae-e4f6-4265-8245-c86c3006dc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_267efab3-1a22-4a7a-ae93-5fe6641470fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_267efab3-1a22-4a7a-ae93-5fe6641470fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShareOptionPlans_ca3f322c-a2d2-4aa4-9a9e-950aa0d97648" xlink:href="moln-20221231.xsd#moln_NumberOfShareOptionPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_NumberOfShareOptionPlans_ca3f322c-a2d2-4aa4-9a9e-950aa0d97648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_367bc153-e0a9-4609-9dea-f6f608f02de2" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod_367bc153-e0a9-4609-9dea-f6f608f02de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_19610f34-2dbb-4568-b907-e34c024384ba" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches_19610f34-2dbb-4568-b907-e34c024384ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_f0c34207-6e43-40bc-9f7f-20dbb56501d4" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementPercent_f0c34207-6e43-40bc-9f7f-20dbb56501d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_91a03165-ef02-471a-993f-3a728f30e7ea" xlink:href="moln-20221231.xsd#moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted_91a03165-ef02-471a-993f-3a728f30e7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7aca39e1-23e9-4e2e-95a3-3b932ddbb8ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_7ecbf7f1-6ab7-4559-ad10-e8509628036a" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7aca39e1-23e9-4e2e-95a3-3b932ddbb8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_0255e7d8-e3dd-49a0-9b03-1743cf26517d" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:href="moln-20221231.xsd#moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_0255e7d8-e3dd-49a0-9b03-1743cf26517d" xlink:to="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:to="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_469c36a0-39b6-492c-9968-11bd38b1530f" xlink:to="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bebbae48-a8b9-4be6-9788-3e3518b45c6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:to="loc_srt_MinimumMember_bebbae48-a8b9-4be6-9788-3e3518b45c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_455f8312-6a39-4993-b03b-0e8a3ebbf3aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_09dae0dc-20eb-4595-ba5e-07d21b023022" xlink:to="loc_srt_MaximumMember_455f8312-6a39-4993-b03b-0e8a3ebbf3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c9931c8d-9a9b-431d-a4d1-ff61d5af2374" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RestrictedShareUnitsRSUMember_1f034028-25db-4b7b-ab61-9ba26145f897" xlink:href="moln-20221231.xsd#moln_RestrictedShareUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_RestrictedShareUnitsRSUMember_1f034028-25db-4b7b-ab61-9ba26145f897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUMember_7468599f-44cd-40e7-be1f-a23cfcb4e0d5" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_PerformanceShareUnitsPSUMember_7468599f-44cd-40e7-be1f-a23cfcb4e0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_d0aeaadb-db15-4c52-bdba-77eba23cc6cf" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUManagementBoardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_PerformanceShareUnitsPSUManagementBoardMember_d0aeaadb-db15-4c52-bdba-77eba23cc6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_4c9136df-75cf-456b-a034-caa4abb7897f" xlink:href="moln-20221231.xsd#moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e1901d94-b0e6-4d80-9224-a42d913b5383" xlink:to="loc_moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember_4c9136df-75cf-456b-a034-caa4abb7897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:href="moln-20221231.xsd#moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable_cec02ba0-3c27-4a9a-a552-0ffa580cce9e" xlink:to="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_5ce3e174-db40-411a-bfa8-1bfed60a493f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_5ce3e174-db40-411a-bfa8-1bfed60a493f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_50155be6-a691-407a-9b6a-f885251b0e48" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_50155be6-a691-407a-9b6a-f885251b0e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_722e6e66-2e67-46ad-989f-fa8fb90020a3" xlink:href="moln-20221231.xsd#moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_722e6e66-2e67-46ad-989f-fa8fb90020a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_1d23c2de-e43f-456c-bf8f-8bec12d75f50" xlink:href="moln-20221231.xsd#moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_1d23c2de-e43f-456c-bf8f-8bec12d75f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_FullContractualLifeOtherEquityInstruments_38268d12-faeb-4df4-9a18-74c7497b142e" xlink:href="moln-20221231.xsd#moln_FullContractualLifeOtherEquityInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_FullContractualLifeOtherEquityInstruments_38268d12-faeb-4df4-9a18-74c7497b142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_49557859-627a-45fd-8a39-fe26cb7a75db" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted_49557859-627a-45fd-8a39-fe26cb7a75db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_2746b0b1-494d-4d64-8c5a-300d07c03b5b" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted_2746b0b1-494d-4d64-8c5a-300d07c03b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_3a5177c9-9f22-4ae7-8d83-ea301aa86057" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted_3a5177c9-9f22-4ae7-8d83-ea301aa86057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_451ff6aa-0654-4984-91a3-4e1791719926" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted_451ff6aa-0654-4984-91a3-4e1791719926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_58ba98a0-28d6-49e4-9c09-752c7c191b41" xlink:href="moln-20221231.xsd#moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted_58ba98a0-28d6-49e4-9c09-752c7c191b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_d3a22d12-e3f1-47d2-9aa4-a2f55c5275bf" xlink:href="moln-20221231.xsd#moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted_d3a22d12-e3f1-47d2-9aa4-a2f55c5275bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpectedDividendOtherEquityInstrumentsGranted_e38adf13-b59a-4adc-b538-677e798bd06a" xlink:href="moln-20221231.xsd#moln_ExpectedDividendOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_ExpectedDividendOtherEquityInstrumentsGranted_e38adf13-b59a-4adc-b538-677e798bd06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f3321ef5-6033-4a2a-a608-85822ed4051f" xlink:href="moln-20221231.xsd#moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems_ad6a86ec-d65c-4678-96fe-da67eb568834" xlink:to="loc_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f3321ef5-6033-4a2a-a608-85822ed4051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_ad095070-4e5c-4d11-9ada-7231ca1d1317" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_ad095070-4e5c-4d11-9ada-7231ca1d1317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_4757d126-3981-455f-88e8-5e3b24834644" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_4757d126-3981-455f-88e8-5e3b24834644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_95281f44-f9e7-4cf5-827c-8cc64c82f1ba" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_95281f44-f9e7-4cf5-827c-8cc64c82f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement_c0ae6db3-8275-4758-91c0-bd419910cdab" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement_c0ae6db3-8275-4758-91c0-bd419910cdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement_3de928af-81a8-4e45-8cd5-7c6b37500317" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement_3de928af-81a8-4e45-8cd5-7c6b37500317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement_e59bfa74-021d-4d8a-985d-a519fa36258f" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement_e59bfa74-021d-4d8a-985d-a519fa36258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_5c5c2d6c-8dec-4f0d-8c2e-bdb5e84a879e" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_5c5c2d6c-8dec-4f0d-8c2e-bdb5e84a879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_e2e3dd72-19bb-4b5d-b60e-92990c018714" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_e2e3dd72-19bb-4b5d-b60e-92990c018714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement_b3f00d45-1df1-4a1a-8774-698b150535c8" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement_b3f00d45-1df1-4a1a-8774-698b150535c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_1f0acb23-c40d-4339-bb48-f661b8ab9cb4" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_1f0acb23-c40d-4339-bb48-f661b8ab9cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement_dc4b607c-9f7c-4f32-bb8d-cdd8d2b92488" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement_dc4b607c-9f7c-4f32-bb8d-cdd8d2b92488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement_23952f28-f790-483d-bc52-b210a144d1b1" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement_23952f28-f790-483d-bc52-b210a144d1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement_28b74fa9-498a-4a96-b58f-5c3c27cc5a0a" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement_28b74fa9-498a-4a96-b58f-5c3c27cc5a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_05cceaf8-6ac7-4f59-a5f5-3c2da5b17dd4" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement_05cceaf8-6ac7-4f59-a5f5-3c2da5b17dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_fd9579b0-8420-47ff-bca8-aed9b4701766" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_fd9579b0-8420-47ff-bca8-aed9b4701766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_c58e1e3a-5239-4f22-ace3-52c127a7b932" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_c58e1e3a-5239-4f22-ace3-52c127a7b932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_c9eabd9f-4988-47d1-847e-37825720eb38" xlink:href="moln-20221231.xsd#moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_c9eabd9f-4988-47d1-847e-37825720eb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_ea9b7f59-fb46-4bd3-927c-5dda364668ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_ea9b7f59-fb46-4bd3-927c-5dda364668ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_b47982b2-bf43-40f0-a85b-7f84debfeb04" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_b47982b2-bf43-40f0-a85b-7f84debfeb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2b1a607e-2bdf-47bc-890b-b19d3e6a85e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2b1a607e-2bdf-47bc-890b-b19d3e6a85e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_2327947e-011e-4626-ab27-d7a5a28389b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_2327947e-011e-4626-ab27-d7a5a28389b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_fc2ae6f2-634a-4a88-bde5-93b440373f30" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_fc2ae6f2-634a-4a88-bde5-93b440373f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_ff6fcdfe-00a0-4b47-84a9-d23a0e4845e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_ff6fcdfe-00a0-4b47-84a9-d23a0e4845e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_0ebfa13f-79e5-41da-95db-d545254884f6" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_0ebfa13f-79e5-41da-95db-d545254884f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_bd88cee1-13a8-4200-a965-4ba1f8f8c71f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_bd88cee1-13a8-4200-a965-4ba1f8f8c71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_6fcc58e4-c40e-4f37-8a1c-50dd92c461e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_6fcc58e4-c40e-4f37-8a1c-50dd92c461e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_351800a3-ba32-4c27-8e4a-63b35f5dea03" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_351800a3-ba32-4c27-8e4a-63b35f5dea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_9a5662be-41b5-462b-bd96-2964e380c12f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_9a5662be-41b5-462b-bd96-2964e380c12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3a88aa0d-67b5-4572-af2c-22b2656eab32" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3a88aa0d-67b5-4572-af2c-22b2656eab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_52b2fb52-4ee2-41f5-b268-ea9299470ad0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_52b2fb52-4ee2-41f5-b268-ea9299470ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_5f5c80dc-22bc-4f05-95ad-4d7683de79bd" xlink:href="moln-20221231.xsd#moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_5f5c80dc-22bc-4f05-95ad-4d7683de79bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_11dad2fb-02a6-4969-a7cd-bc95d2df9565" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_11dad2fb-02a6-4969-a7cd-bc95d2df9565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_afae92de-98b3-40c2-ac9f-1fc08999fee0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_afae92de-98b3-40c2-ac9f-1fc08999fee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_b6db6a0f-b948-4b3e-8741-cba4a8737475" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_b6db6a0f-b948-4b3e-8741-cba4a8737475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7a86babe-92e4-48ca-846f-91608e325f05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7a86babe-92e4-48ca-846f-91608e325f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_e0bbb103-bb65-476d-8e52-64f61ed81e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_e0bbb103-bb65-476d-8e52-64f61ed81e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_6ef99443-5e0c-41b7-9ea2-ade07282de5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_6ef99443-5e0c-41b7-9ea2-ade07282de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_44d26aab-689a-44b7-acf2-923b4e9b0019" xlink:href="moln-20221231.xsd#moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved_44d26aab-689a-44b7-acf2-923b4e9b0019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_923d1b8d-6b8a-480d-976a-2ffb3a973e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_923d1b8d-6b8a-480d-976a-2ffb3a973e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_e4a10f3c-9c0f-4182-b8a1-11f4f2db275f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_e4a10f3c-9c0f-4182-b8a1-11f4f2db275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_83676f8f-5370-420c-8b39-851b78169ee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_83676f8f-5370-420c-8b39-851b78169ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_7b8d73f6-f21d-4223-bfa8-1f7b03188f50" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_7b8d73f6-f21d-4223-bfa8-1f7b03188f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise_85e98470-c800-448f-8635-daa8b2641206" xlink:href="moln-20221231.xsd#moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a279a61-e22c-4f74-bb98-76f8c7867406" xlink:to="loc_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise_85e98470-c800-448f-8635-daa8b2641206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_ec9edd4a-ff25-4712-86c0-90c4ea79dd49" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_ec9edd4a-ff25-4712-86c0-90c4ea79dd49" xlink:to="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e72e18ee-21f9-45d7-8586-00b69ac03b18" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeOneMember_b0514e43-3a5a-4296-8bf3-ce257414387a" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeOneMember_b0514e43-3a5a-4296-8bf3-ce257414387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeTwoMember_50cc2f90-cbf1-4ff5-baa5-41250bf03ca1" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeTwoMember_50cc2f90-cbf1-4ff5-baa5-41250bf03ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeThreeMember_47b44819-47dc-41ae-aa36-c8af67b3ad6a" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeThreeMember_47b44819-47dc-41ae-aa36-c8af67b3ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercisePriceRangeFourMember_47fd3ab6-89c7-4e0f-8d33-75e68b5a2ba3" xlink:href="moln-20221231.xsd#moln_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_62f3fab7-b52f-484d-8669-ff4cebe69b1d" xlink:to="loc_moln_ExercisePriceRangeFourMember_47fd3ab6-89c7-4e0f-8d33-75e68b5a2ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:href="moln-20221231.xsd#moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable_42e62495-a754-4f47-a903-50aa4a8cab8e" xlink:to="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_b46b31ff-ab2f-4b19-8ff7-411481ee7f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_b46b31ff-ab2f-4b19-8ff7-411481ee7f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_9f0fbdd2-4fbf-48a8-b5a2-8fdf9e962fe7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_9f0fbdd2-4fbf-48a8-b5a2-8fdf9e962fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e1912918-a0ff-4fc6-ac7c-50a874a37d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e1912918-a0ff-4fc6-ac7c-50a874a37d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_71808af5-9293-4034-831e-1cff76db07c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_71808af5-9293-4034-831e-1cff76db07c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExercicePriceOfOutstandingOtherEquityInstruments_3d7dabb0-0a93-477d-807f-c9d44adbee50" xlink:href="moln-20221231.xsd#moln_ExercicePriceOfOutstandingOtherEquityInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_ExercicePriceOfOutstandingOtherEquityInstruments_3d7dabb0-0a93-477d-807f-c9d44adbee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0015f892-3029-402f-9d83-28dff2702aab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0015f892-3029-402f-9d83-28dff2702aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_97111912-7dad-40b7-a101-4eeff4e38e5c" xlink:href="moln-20221231.xsd#moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments_97111912-7dad-40b7-a101-4eeff4e38e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_1e36102b-96f1-48aa-8cd8-10fa6cce9aca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_1e36102b-96f1-48aa-8cd8-10fa6cce9aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_b30bd833-d4a4-40b0-a3e7-7049ccff2614" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement_b30bd833-d4a4-40b0-a3e7-7049ccff2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_50d6c14b-661e-40d3-8742-61ef2c4ecdac" xlink:href="moln-20221231.xsd#moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems_ea329c10-db75-4275-a061-1fe56daadcd1" xlink:to="loc_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement_50d6c14b-661e-40d3-8742-61ef2c4ecdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_PersonnelExpensesAbstract_8a6023e2-8e85-491a-839e-88fbc4e81f65" xlink:href="moln-20221231.xsd#moln_PersonnelExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_PersonnelExpensesAbstract_8a6023e2-8e85-491a-839e-88fbc4e81f65" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_93978154-cc96-42b4-9758-04db1d81af48" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ResearchAndDevelopmentExpenseMember_0d374e35-35d2-43f7-9abc-e2477f7b9a49" xlink:href="moln-20221231.xsd#moln_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:to="loc_moln_ResearchAndDevelopmentExpenseMember_0d374e35-35d2-43f7-9abc-e2477f7b9a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_735dd699-2e94-421f-bcf0-7b7bc666907a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_be985ecd-f95e-453c-a002-27f3264b98bf" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_735dd699-2e94-421f-bcf0-7b7bc666907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b249e735-d31d-44b8-9a54-5763e2b7653e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_f550c40f-b757-468b-aa0d-7399d16ab6ce" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b249e735-d31d-44b8-9a54-5763e2b7653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_da2c41e4-b6f4-452a-bc40-e9696c6f54db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_b249e735-d31d-44b8-9a54-5763e2b7653e" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_da2c41e4-b6f4-452a-bc40-e9696c6f54db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2ee7b080-4055-4ea2-b8d3-0e9a504576ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_d5af3876-a982-4aaa-a03c-715fd826df9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2ee7b080-4055-4ea2-b8d3-0e9a504576ce" xlink:to="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_d5af3876-a982-4aaa-a03c-715fd826df9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_27967317-5b3b-44f1-937b-2e574e248d42" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2ee7b080-4055-4ea2-b8d3-0e9a504576ce" xlink:to="loc_ifrs-full_NetForeignExchangeGain_27967317-5b3b-44f1-937b-2e574e248d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_ee88685c-1cc2-45c3-93d2-c1737ef4f511" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2ee7b080-4055-4ea2-b8d3-0e9a504576ce" xlink:to="loc_ifrs-full_FinanceIncome_ee88685c-1cc2-45c3-93d2-c1737ef4f511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2035dfed-8c8f-450d-b03c-c18961acb21a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_ba78fbf5-c94e-4757-ad19-087fe19ebd27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2035dfed-8c8f-450d-b03c-c18961acb21a" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_ba78fbf5-c94e-4757-ad19-087fe19ebd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_cf44b7c0-1926-4203-8f3f-86c5fd2c5519" xlink:href="moln-20221231.xsd#moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2035dfed-8c8f-450d-b03c-c18961acb21a" xlink:to="loc_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost_cf44b7c0-1926-4203-8f3f-86c5fd2c5519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_50490175-9871-4cf6-b78b-0c34fdb3699e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2035dfed-8c8f-450d-b03c-c18961acb21a" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_50490175-9871-4cf6-b78b-0c34fdb3699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceCost_7a2edc61-0caa-4c04-bceb-f733f3c8b68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2035dfed-8c8f-450d-b03c-c18961acb21a" xlink:to="loc_ifrs-full_OtherFinanceCost_7a2edc61-0caa-4c04-bceb-f733f3c8b68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_be41fa30-660a-4558-9ff1-509748a77a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2035dfed-8c8f-450d-b03c-c18961acb21a" xlink:to="loc_ifrs-full_FinanceCosts_be41fa30-660a-4558-9ff1-509748a77a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_4d97f396-427e-4912-a246-80a38a9e9014" xlink:href="moln-20221231.xsd#moln_IncomeTaxesAndDeferredTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_4d97f396-427e-4912-a246-80a38a9e9014" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:to="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_453b1f52-15ab-4721-ab0f-2d9f38abba70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f3f56eba-e36e-4dfc-b323-38276db2ef96" xlink:to="loc_dei_EntityDomain_453b1f52-15ab-4721-ab0f-2d9f38abba70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_MolecularPartnersIncMember_db80a623-f8eb-453c-a096-945c0e858edb" xlink:href="moln-20221231.xsd#moln_MolecularPartnersIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_453b1f52-15ab-4721-ab0f-2d9f38abba70" xlink:to="loc_moln_MolecularPartnersIncMember_db80a623-f8eb-453c-a096-945c0e858edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_4f69935f-e51a-4c1f-ac15-a6f5391dc45b" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_91aa3ad6-fa07-4d6c-812e-ef6180b555d8" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_4f69935f-e51a-4c1f-ac15-a6f5391dc45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_fa7a4d98-5cb1-45b2-8770-837c2b6606fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_4f69935f-e51a-4c1f-ac15-a6f5391dc45b" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_fa7a4d98-5cb1-45b2-8770-837c2b6606fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_8d8615a6-6f4c-4246-8aef-f46c87951514" xlink:href="moln-20221231.xsd#moln_IncomeTaxesAndDeferredTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_8d8615a6-6f4c-4246-8aef-f46c87951514" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:to="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1cd6bb5f-4562-4573-82d3-34d26c01720c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2027Member_c8e57c7c-eb39-48da-b1fa-0a18eba2c0e2" xlink:href="moln-20221231.xsd#moln_ExpiringIn2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:to="loc_moln_ExpiringIn2027Member_c8e57c7c-eb39-48da-b1fa-0a18eba2c0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2028Member_182c5e72-e397-420b-99f7-25ba91454d97" xlink:href="moln-20221231.xsd#moln_ExpiringIn2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bd8a90e6-e79c-44a7-ad15-ccb55762b459" xlink:to="loc_moln_ExpiringIn2028Member_182c5e72-e397-420b-99f7-25ba91454d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_183262b0-6637-47e2-88f6-c8d055c7b014" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NetOperatingProfit_841e2d21-9c54-462b-8d24-d9dce8b79871" xlink:href="moln-20221231.xsd#moln_NetOperatingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_NetOperatingProfit_841e2d21-9c54-462b-8d24-d9dce8b79871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_NetOperatingLosses_577afe42-c069-447a-ae38-f2ddc76fc790" xlink:href="moln-20221231.xsd#moln_NetOperatingLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_NetOperatingLosses_577afe42-c069-447a-ae38-f2ddc76fc790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwards_28339a6d-9476-4fae-a844-945189400d20" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_TaxLossCarryforwards_28339a6d-9476-4fae-a844-945189400d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwardsExpirationPeriod_89eb60cd-0d74-48a0-8445-b7c930175974" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwardsExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_moln_TaxLossCarryforwardsExpirationPeriod_89eb60cd-0d74-48a0-8445-b7c930175974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_315799fa-c1f6-4d24-add8-d59237214314" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_315799fa-c1f6-4d24-add8-d59237214314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_44c1fdd4-abd3-4ee8-a914-eb409216f174" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_3b64e7d5-bc4e-4485-b96b-c606225d8e05" xlink:to="loc_ifrs-full_ApplicableTaxRate_44c1fdd4-abd3-4ee8-a914-eb409216f174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_9eaaf27b-c4ca-439c-93ce-1ba0555eb899" xlink:href="moln-20221231.xsd#moln_IncomeTaxesAndDeferredTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_IncomeTaxesAndDeferredTaxesAbstract_9eaaf27b-c4ca-439c-93ce-1ba0555eb899" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:to="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_3f72279e-ed3c-44c0-8440-e13782c5b595" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2023Member_7f46cca3-c214-427b-a7f0-53c59d2497b5" xlink:href="moln-20221231.xsd#moln_ExpiringIn2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2023Member_7f46cca3-c214-427b-a7f0-53c59d2497b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2024Member_01e6836f-910c-44db-8a4c-16fc80e840cb" xlink:href="moln-20221231.xsd#moln_ExpiringIn2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2024Member_01e6836f-910c-44db-8a4c-16fc80e840cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2025Member_bde912d2-4237-4925-ae97-02d7c731517e" xlink:href="moln-20221231.xsd#moln_ExpiringIn2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2025Member_bde912d2-4237-4925-ae97-02d7c731517e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2026Member_2a2fe2b8-65a7-452e-8480-a7d2c45308c9" xlink:href="moln-20221231.xsd#moln_ExpiringIn2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2026Member_2a2fe2b8-65a7-452e-8480-a7d2c45308c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2027Member_4cacbf3f-437a-4c35-9f1a-00063704ea02" xlink:href="moln-20221231.xsd#moln_ExpiringIn2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2027Member_4cacbf3f-437a-4c35-9f1a-00063704ea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ExpiringIn2028Member_cd57f51c-f2cf-4c2a-be8c-ed933fc339c9" xlink:href="moln-20221231.xsd#moln_ExpiringIn2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ExpiringIn2028Member_cd57f51c-f2cf-4c2a-be8c-ed933fc339c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ThereafterMember_fdac85eb-e936-43c7-a56d-5e80b205ebfb" xlink:href="moln-20221231.xsd#moln_ThereafterMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a7149d52-0f7b-4e75-ad95-0ecbe7d37842" xlink:to="loc_moln_ThereafterMember_fdac85eb-e936-43c7-a56d-5e80b205ebfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_daa16522-6c34-4a00-9f4c-a066bb0e047e" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable_e0b09d59-8bfd-4ac9-941e-799e42cbbfb6" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_daa16522-6c34-4a00-9f4c-a066bb0e047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_TaxLossCarryforwards_ec3682ef-8d28-41d1-a414-a41d05c29a59" xlink:href="moln-20221231.xsd#moln_TaxLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems_daa16522-6c34-4a00-9f4c-a066bb0e047e" xlink:to="loc_moln_TaxLossCarryforwards_ec3682ef-8d28-41d1-a414-a41d05c29a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#EarningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_378b9975-8827-4d7c-9e87-e6c467e68a19" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_2008d6ce-bac6-4cf7-b778-aaededf747e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_378b9975-8827-4d7c-9e87-e6c467e68a19" xlink:to="loc_ifrs-full_WeightedAverageShares_2008d6ce-bac6-4cf7-b778-aaededf747e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_9c47e001-3b34-4ad9-8230-a7801a836b8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_378b9975-8827-4d7c-9e87-e6c467e68a19" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_9c47e001-3b34-4ad9-8230-a7801a836b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_a82dffbb-a74c-4275-a478-39b40dfc07a5" xlink:href="moln-20221231.xsd#moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_378b9975-8827-4d7c-9e87-e6c467e68a19" xlink:to="loc_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_a82dffbb-a74c-4275-a478-39b40dfc07a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_aaad4c8c-0b25-472a-b2d1-a61f8009a485" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_aaad4c8c-0b25-472a-b2d1-a61f8009a485" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:to="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9753334c-56b8-4416-ba03-a8e6983db981" xlink:to="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04d6e191-9aaa-4781-84f4-924a186d4ad0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:to="loc_srt_MinimumMember_04d6e191-9aaa-4781-84f4-924a186d4ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_48773804-7027-4865-a270-e4d8d2b679d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fafe323b-dbfe-49d3-968f-71f2cbbba0ec" xlink:to="loc_srt_MaximumMember_48773804-7027-4865-a270-e4d8d2b679d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:to="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_4126be79-9799-4853-aefd-840b38bd31b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_a2df429d-1cb0-4ffd-9080-7481997967e9" xlink:to="loc_ifrs-full_TypesOfContractsMember_4126be79-9799-4853-aefd-840b38bd31b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseFacilitiesSchlierenMember_af9dba38-0894-4aee-bf1e-fdd21e765f9e" xlink:href="moln-20221231.xsd#moln_LeaseFacilitiesSchlierenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_4126be79-9799-4853-aefd-840b38bd31b1" xlink:to="loc_moln_LeaseFacilitiesSchlierenMember_af9dba38-0894-4aee-bf1e-fdd21e765f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_81ae7153-5f89-4338-b2fd-dffad6e07f15" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseTermOfContract_c3b13125-0b12-4f3b-b1de-bd87aed9c13d" xlink:href="moln-20221231.xsd#moln_LeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_LeaseTermOfContract_c3b13125-0b12-4f3b-b1de-bd87aed9c13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseExtensionOrTerminationOptionPeriod_2a84dc27-d002-46d6-b5da-14fcab5022e6" xlink:href="moln-20221231.xsd#moln_LeaseExtensionOrTerminationOptionPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_LeaseExtensionOrTerminationOptionPeriod_2a84dc27-d002-46d6-b5da-14fcab5022e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseExtensionTermOfContract_3ab1e2fc-9fd3-482a-902d-7d3725865c85" xlink:href="moln-20221231.xsd#moln_LeaseExtensionTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_moln_LeaseExtensionTermOfContract_3ab1e2fc-9fd3-482a-902d-7d3725865c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_18071dc7-901a-4907-a98c-55318d6dd788" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_28373959-9267-4c72-8161-979185257b90" xlink:to="loc_ifrs-full_CashOutflowForLeases_18071dc7-901a-4907-a98c-55318d6dd788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofMovementofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_e9650bc6-39b4-43a0-9da4-e68a8eba5482" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_e9650bc6-39b4-43a0-9da4-e68a8eba5482" xlink:to="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_df1f559d-cc3a-4e63-8304-ff7c7d151941" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_9989e234-9fcc-4a6a-a2fc-4c4bd2c1313a" xlink:to="loc_ifrs-full_TypesOfContractsMember_df1f559d-cc3a-4e63-8304-ff7c7d151941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseFacilitiesSchlierenMember_2c56018f-6e0b-48e5-99e5-5c7deb5e50d7" xlink:href="moln-20221231.xsd#moln_LeaseFacilitiesSchlierenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_df1f559d-cc3a-4e63-8304-ff7c7d151941" xlink:to="loc_moln_LeaseFacilitiesSchlierenMember_2c56018f-6e0b-48e5-99e5-5c7deb5e50d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:href="moln-20221231.xsd#moln_DisclosureOfDetailedInformationAboutLeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesTable_e9650bc6-39b4-43a0-9da4-e68a8eba5482" xlink:to="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_c34873f4-a728-49a0-8854-78d3f295e004" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_LeaseLiabilities_c34873f4-a728-49a0-8854-78d3f295e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseThroughNewLeasesOperatingLeases_09600449-0933-4d8b-8ef3-45286059a93d" xlink:href="moln-20221231.xsd#moln_IncreaseThroughNewLeasesOperatingLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_moln_IncreaseThroughNewLeasesOperatingLeases_09600449-0933-4d8b-8ef3-45286059a93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_a5710da6-8d9e-4a95-9b14-d27db69f5b4d" xlink:href="moln-20221231.xsd#moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases_a5710da6-8d9e-4a95-9b14-d27db69f5b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_ca80e238-88e6-40b2-87b4-13b6c59e9efb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_ca80e238-88e6-40b2-87b4-13b6c59e9efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_fa659451-2d31-4f4d-a309-e0dc1c17531a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_CashOutflowForLeases_fa659451-2d31-4f4d-a309-e0dc1c17531a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_582cd4a1-407d-41c7-9621-447ecdd1b8c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_LeaseLiabilities_582cd4a1-407d-41c7-9621-447ecdd1b8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6dd9ea4b-6e28-4977-bd6d-35d02ea91f76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_6dd9ea4b-6e28-4977-bd6d-35d02ea91f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_ccafdbb9-6efb-4a37-8aca-75c80dea23f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_ccafdbb9-6efb-4a37-8aca-75c80dea23f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_07745a70-703d-4561-823b-bc2528b8cacb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_DisclosureOfDetailedInformationAboutLeasesLineItems_4b967f4f-dbc8-445b-83d7-8486bf7319e8" xlink:to="loc_ifrs-full_LeaseLiabilities_07745a70-703d-4561-823b-bc2528b8cacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofExpensesRecognisedinProfitorLossDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_668c668c-78f9-44af-83d0-ec6cb69bc714" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_f974c12b-37fb-4d4e-a6e7-b27a263cb818" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_668c668c-78f9-44af-83d0-ec6cb69bc714" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_f974c12b-37fb-4d4e-a6e7-b27a263cb818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_b2f6e3c3-2c1d-4b01-b06e-be42a7a28957" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_668c668c-78f9-44af-83d0-ec6cb69bc714" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_b2f6e3c3-2c1d-4b01-b06e-be42a7a28957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_7d4d4424-3b0a-4385-9bf1-909aca39216f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_668c668c-78f9-44af-83d0-ec6cb69bc714" xlink:to="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_7d4d4424-3b0a-4385-9bf1-909aca39216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_LeaseCostRecognisedInProfitOrLoss_506edbb9-d9ad-494e-813e-56fe0dd5c6a7" xlink:href="moln-20221231.xsd#moln_LeaseCostRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_668c668c-78f9-44af-83d0-ec6cb69bc714" xlink:to="loc_moln_LeaseCostRecognisedInProfitOrLoss_506edbb9-d9ad-494e-813e-56fe0dd5c6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_f6b5f9d3-abbe-494d-8b2e-64488418979d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_f6b5f9d3-abbe-494d-8b2e-64488418979d" xlink:to="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_fdfc734b-8ec3-471c-ac22-69c24de1213c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_4ad93165-821c-4a96-bc89-16c08c4b2be2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_4ad93165-821c-4a96-bc89-16c08c4b2be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d608e628-edde-4cae-8c52-e2ee9ce3156b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d608e628-edde-4cae-8c52-e2ee9ce3156b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_9132604f-f40c-4a3e-9de1-a184770e4b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_9132604f-f40c-4a3e-9de1-a184770e4b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_9688f05e-5738-43b3-a708-25d01011bde8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a2075d0f-866e-4373-b9ad-b495bcf869d4" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_9688f05e-5738-43b3-a708-25d01011bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_f6b5f9d3-abbe-494d-8b2e-64488418979d" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_3bdafda0-ade9-4822-b838-e07749900e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_3bdafda0-ade9-4822-b838-e07749900e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_6497de85-7aeb-4a19-bfb8-585b0ab05901" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_4092c32e-e01f-4787-a356-c4cf3eeb9278" xlink:to="loc_ifrs-full_LeaseLiabilities_6497de85-7aeb-4a19-bfb8-585b0ab05901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_57cb58eb-e2a0-4969-bda7-0ec9dbd62eb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_259a2422-b7ad-47e9-ab17-766239cd83c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_57cb58eb-e2a0-4969-bda7-0ec9dbd62eb0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_259a2422-b7ad-47e9-ab17-766239cd83c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_814f06cb-1056-40be-b528-0fc62d228dce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_57cb58eb-e2a0-4969-bda7-0ec9dbd62eb0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_814f06cb-1056-40be-b528-0fc62d228dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_99554ab4-0cb9-4537-ad67-0abbaca59d4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_57cb58eb-e2a0-4969-bda7-0ec9dbd62eb0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_99554ab4-0cb9-4537-ad67-0abbaca59d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_eee36229-12dc-41b6-a8b8-aa090a2cc205" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_57cb58eb-e2a0-4969-bda7-0ec9dbd62eb0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_eee36229-12dc-41b6-a8b8-aa090a2cc205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#RelatedpartydisclosuresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_73e783e8-bf71-4015-95f7-15f489cdb0b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_53e4f9f7-06e0-4c91-aebb-f6c3dada768b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_73e783e8-bf71-4015-95f7-15f489cdb0b9" xlink:to="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_53e4f9f7-06e0-4c91-aebb-f6c3dada768b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_PaymentForTermOfEmploymentRelatedPartyTransactions_b1ac9300-9ab2-4339-9baf-40643494e900" xlink:href="moln-20221231.xsd#moln_PaymentForTermOfEmploymentRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_73e783e8-bf71-4015-95f7-15f489cdb0b9" xlink:to="loc_moln_PaymentForTermOfEmploymentRelatedPartyTransactions_b1ac9300-9ab2-4339-9baf-40643494e900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_a73a86e5-775f-4e1d-8f9d-4c532c747740" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_a73a86e5-775f-4e1d-8f9d-4c532c747740" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:to="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_b5346d11-7f6d-44f0-a014-8133aba7f9f3" xlink:to="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_37da1068-ab95-4359-9956-b1a788e29840" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:to="loc_currency_USD_37da1068-ab95-4359-9956-b1a788e29840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_8cd7a2eb-1558-4cc8-9347-76032f56d4ff" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3bcdf3da-e39a-4b3d-9428-7400676c7227" xlink:to="loc_currency_EUR_8cd7a2eb-1558-4cc8-9347-76032f56d4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:to="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_04172908-e13c-46f8-a768-c2999ed2401f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_13e8d84b-743a-4d16-8edb-9f6a905b612f" xlink:to="loc_ifrs-full_TypesOfRisksMember_04172908-e13c-46f8-a768-c2999ed2401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_80558b2c-cf95-460a-ae47-d33cf1d24bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_04172908-e13c-46f8-a768-c2999ed2401f" xlink:to="loc_ifrs-full_CurrencyRiskMember_80558b2c-cf95-460a-ae47-d33cf1d24bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_e814fa9c-2c11-48bd-a7b0-58a67ed971b2" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_eb9c328c-9365-480c-8861-f317dfc9a3ad" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_eb9c328c-9365-480c-8861-f317dfc9a3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_cf04efd2-ae01-48a9-a7be-ad84cb37be13" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_cf04efd2-ae01-48a9-a7be-ad84cb37be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_ee5727ea-e7e4-468e-927e-7fde544e2a9f" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_ee5727ea-e7e4-468e-927e-7fde544e2a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_f9173e21-48f5-43b3-9a0d-f9d56b511bfd" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5febcba2-038f-4bee-84b2-9f9515979e88" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_f9173e21-48f5-43b3-9a0d-f9d56b511bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_a5fc6056-832e-4ee4-a564-4f9fb33852ed" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks_1f62c01f-b005-421f-9fb7-b1755f4f5f30" xlink:href="moln-20221231.xsd#moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_a5fc6056-832e-4ee4-a564-4f9fb33852ed" xlink:to="loc_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks_1f62c01f-b005-421f-9fb7-b1755f4f5f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_af08512a-5bc8-4ee0-b9a5-e62b5f45f273" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_af08512a-5bc8-4ee0-b9a5-e62b5f45f273" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:to="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_c2b7b351-e92c-4c7d-8ea0-72e5987f7e9d" xlink:to="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_9624de93-de29-4f4b-a2e5-912191ff2e38" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:to="loc_currency_CHF_9624de93-de29-4f4b-a2e5-912191ff2e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_698ff030-1bf7-46ab-a796-7389cef33638" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:to="loc_currency_USD_698ff030-1bf7-46ab-a796-7389cef33638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_2c116330-c019-4f19-9087-0132f8e5b09a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f99c73fe-df78-43d5-b394-16cb3ece0c89" xlink:to="loc_currency_EUR_2c116330-c019-4f19-9087-0132f8e5b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:to="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_3fc65e95-5f06-48e3-b6b1-b85ca90a83b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_28c33e67-b36d-46c2-8f33-8cf198379d3e" xlink:to="loc_ifrs-full_TypesOfRisksMember_3fc65e95-5f06-48e3-b6b1-b85ca90a83b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_54140367-61a7-4501-a4db-863f9ab134e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_3fc65e95-5f06-48e3-b6b1-b85ca90a83b9" xlink:to="loc_ifrs-full_InterestRateRiskMember_54140367-61a7-4501-a4db-863f9ab134e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_f36965c3-38ba-4309-a59d-e9024ca783b5" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_0be3de7b-7112-4661-aebf-e112789b165f" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent_0be3de7b-7112-4661-aebf-e112789b165f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_a790a935-5e90-4a71-b6c7-b325478b7bfd" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent_a790a935-5e90-4a71-b6c7-b325478b7bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_6c1bd48a-b763-4cbf-b922-836ec5a51c55" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax_6c1bd48a-b763-4cbf-b922-836ec5a51c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_cf1ac171-7704-408b-ab9f-cc469ed6bae2" xlink:href="moln-20221231.xsd#moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_eee1f706-4b4d-4c63-b206-890aaaa9f759" xlink:to="loc_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax_cf1ac171-7704-408b-ab9f-cc469ed6bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" xlink:type="simple" xlink:href="moln-20221231.xsd#FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"/>
  <link:presentationLink xlink:role="http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moln_FinancialRiskManagementAbstract_f447686c-75c5-4def-b8dc-aec9f7783b70" xlink:href="moln-20221231.xsd#moln_FinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moln_FinancialRiskManagementAbstract_f447686c-75c5-4def-b8dc-aec9f7783b70" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_6c34c223-5d65-4039-af40-74b7af03bd84" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_CashAndCashEquivalentsMember_d7a287b7-3e75-42bd-b79f-e64a625d7dc1" xlink:href="moln-20221231.xsd#moln_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_moln_CashAndCashEquivalentsMember_d7a287b7-3e75-42bd-b79f-e64a625d7dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_f72f2dd5-3d06-41fc-83ca-2c8969aa4ea8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_ifrs-full_TradeReceivablesMember_f72f2dd5-3d06-41fc-83ca-2c8969aa4ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_AccruedIncomeMember_ddf11d19-7d96-4e93-91a1-d83486789c36" xlink:href="moln-20221231.xsd#moln_AccruedIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_moln_AccruedIncomeMember_ddf11d19-7d96-4e93-91a1-d83486789c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moln_ShortTermTimeDepositsMember_f7f3cc93-6e8f-42ad-a7a1-215be9bdd961" xlink:href="moln-20221231.xsd#moln_ShortTermTimeDepositsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_ea0c186c-6d2a-4012-b477-8357d922ebf5" xlink:to="loc_moln_ShortTermTimeDepositsMember_f7f3cc93-6e8f-42ad-a7a1-215be9bdd961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_97d00aac-f045-4ec9-8db9-50aa81dbc3f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_184033b2-30eb-4c22-aa4e-434ca0695ab8" xlink:to="loc_ifrs-full_TypesOfRisksMember_97d00aac-f045-4ec9-8db9-50aa81dbc3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditRiskMember_bbb334a2-1f91-449e-a0ea-7faacfed4ab0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_97d00aac-f045-4ec9-8db9-50aa81dbc3f2" xlink:to="loc_ifrs-full_CreditRiskMember_bbb334a2-1f91-449e-a0ea-7faacfed4ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_2da2c099-3101-466a-867a-a42e4d5711ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_6440d8a3-549b-4256-81ec-be4be166456b" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_2da2c099-3101-466a-867a-a42e4d5711ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_354a4d53-fa8d-40eb-96c3-c895a1ae5c1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_2da2c099-3101-466a-867a-a42e4d5711ce" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_354a4d53-fa8d-40eb-96c3-c895a1ae5c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>moln-20221231_g1.jpg
<TEXT>
begin 644 moln-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0  6@!:  #_X0",17AI9@  34T *@    @ !0$2  ,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_T/[^****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _]'^_BBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /_2_OXHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#_T_[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMBMX:_;[\.>)=8TAD\(ZO:>'_%%W+IV@ZS<>6EO?7B,42/;G=&)'&U6;//4
M!L;N@_MT^ /$6B^#+^QTRZ6\\6WE];36;LHETZ/3<FZEGZ\1H-^ ,E3ZUR/@
MG]@[4O#>L^&-'\0>.KK6/!7@K4FU;1=$DLXXGBN-[2)YMRK%I51F)P4&<D?*
M.*[SP-^Q/X&\&_'GQ;\9Y+PWMMXGAN(XM+:';':-?;?M3J^\[C*5/1%VJQ7F
MBNLD7-R7=DVK<VNZ2=[:V<92^S[K2>H47G+Y>>VK2=^739MJU]+IQCUU3:T.
M-^'_ /P4,\ ^.M>ATR30+_3;35;6_NM&NII(6%ZNG*SR*R([-"Q525#C!]>1
M3? _[?-IXLC\-:_JW@?5=%\.>*M2@TJRU:ZDC\EKB<NHX'.T/&RD^G-8GPM_
MX)ZVOPWU(>9XDM;W3[*UOK;3T&BVL-VIO590]Q=#,LQC#G;@H>V0ORUE_M _
M!K4OAO\ L3Z9^SGX=TK5_&>K1>7#IUYI-IM,%U%-YR3R@.QA3DKNRW<9&<UO
M*CDM2LJ.'5^9I7O)63YKRUMJERW3TWMY8JKF\*+JXAVY4W:T7=^[:.E]'[UK
M:[7UW^QO@U\<=)^-$?B74=#L9K;3?#^K7&DI=R,"EV]KCS)(P.=G(P3U_"OS
M]\&^+/VLOCS\'M=_:I\,>/E\.V]L]]<:1H,=E#+;&VL2WR3R.-Q9]A&3G!Y&
M <#] ?V:_A,OP1^!_AWX;R ?:[&U#7C YWW<Q,DQSW'F,P!] *^5[K]A7QOH
MVG:U\._A=\2[SP[X"\03RRW6B"QBN)(TG_UL4-RSJ\:./EP!P.N[)SR8.O@:
M5:M&+C%<T>5RCSIQ3?-I:5G+1[=U='5BZ.-J4J,I*3?++F49<C4G;EUO'2.J
MW[.S,_PW_P %!;O5]#T*UT[P3?Z[K>H^&!XAN(]/DC2&-(I)(9\F5@556B8K
M]XG*J,DYKN;G]N_PYJMEX:C^&?A35O%&J^(=(?7&L+7RTDM;*)VB=G+-AFWH
MRJJYW$=LKGKO#G[('AWP9\0E\6^%-3-MIT'@P^#X+%H-[(IE\W[0TN\;F/.Y
M=@R23N'2O)-+_8+\3>"K'PO?_"SX@3:#X@T'1YM!NM133TE6[LYIGFXB:7]T
MZ-(<,'8Y"],5LY9).3:5NU^>VJEI*U]$^7X>_5;8I9S&*3=^]N2^CCK&]M6N
M;XNW1[^@^,?VUK#1[[3?#O@WP7KNO:Y=:.-=O-,$(M;C3[/.#YXEP1(#D!%!
MSQ@X9<^<W?[7EAXA^+OP\\:^'-7FM/ >L>'-9U;4()8UW Z>K[MX 9MT3(P(
M1L$CC((KK?$G[&7C%-9T_P 9_#'XC:CHOB)=$&@ZIJ-[;KJ4FH0;MQD;S74I
M+NY#!C@!0, '*Z9^P/X%TI?"NC0:K,VB^'="U31)[9X@9;L:L'\Z7S=P$;!I
M&8#8V. #Q2IRR:$+WU:DMI-ZQEW5KWY>1KS<K,<XYO.;36B<7O%+24>SOMS<
MR?ERB^"_V]O"&N:SID/C?PSJWA72O$-G=7^C:E?A&AO(+1#)(<1DE#L&Y1SG
M(Y^89R_"?[>\7BO7/"^E+X"UBRM_&TMPNAW=S)"L5TD .6X8E"3@;3D8(.2*
MH^&_V%=8LKK1Q\3?&,_C/1O!^GW=CH&D/:1V2QI<Q>41+,K.9,)A5)7C /3*
MGY"^ WPC^.5U\7_AII>K:=XJ71? =S?2^5K6GPVEK86[*2L<-PC$W;R, -V%
M & HVY([(8+)ZL:LZ33Y4WO)+:;7+>S;TAS7TO=1Z')/&9M3E3A43]YI;1;W
M@G>UU;65K:VLWU/O_P &_MK^#_'5KX"CT#1[M]2\<ZA>6(L6=1+8_8#_ *0\
MWLBX; Y(-?:E?EK^R#\$M1O?VE?'7[1>I>'-4\-:-=32C1-/UF+R)UFO=KW<
MPAR=F63"D<%7QD[:_4JOG\ZH8:C75/#;6N];V;UY>OPIJ+\TSW<GK8FK1=3$
M[WLM+:+2_P#V\TVO)H****\<]8_*_P#X*8_M(?&?]GW_ (0K_A4.L_V1_:_]
MI?:_]'@N/,^S_9O+_P!=')MV^8WW<9SSG K\K_\ AX_^V?\ ]#G_ .4ZQ_\
MD>OT8_X*Q_#'XD_$;_A ?^%>^'M3U[['_:OVC^SK26Z\KS/LNS?Y2MMW;6QG
M&<''2OQW_P"&9/VDO^B>^)?_  4W7_QJOQOBO%9I#-*T<-4J*'NV47*WPQO:
MVF_XGQ.;UL7'%S5*4E'39NVR['N'_#Q_]L__ *'/_P IUC_\CT?\/'_VS_\
MH<__ "G6/_R/7A__  S)^TE_T3WQ+_X*;K_XU1_PS)^TE_T3WQ+_ ."FZ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
MU?[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _];^_BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"DGB?X:^ ?#WPGL-#T?P9I/V2P^(A>UTN!7E=C]C6'&)2S$L.FTDU_23I_P
M^ ^D^'=(\(:5X)T"VTGP_J":OI=E%IMNEM8ZA&S,MU;QB,)%.K,Q$J ."Q.<
MDUB_$#]EO]F7XM>(F\7_ !4^'7ACQ-JS1K$U[JND6E[<&-/NJ9)HG?:N>!G
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M]CA=?^H_K%?2-?-WQR_Y*=\&O^QPNO\ U']8KMP'\1_X9_\ I$C#$_ O6/\
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MW+_P-?\ R <M?^9?^ O_ .2/F[_ALG]D'_HJO@__ ,'ME_\ 'J/^&R?V0?\
MHJO@_P#\'ME_\>KZ1HH]IA/^?<O_  -?_(!RU_YE_P" O_Y(^;O^&R?V0?\
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M_'J^D:*/:83_ )]R_P# U_\ (!RU_P"9?^ O_P"2/F[_ (;)_9!_Z*KX/_\
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M\@'+7_F7_@+_ /DCYN_X;)_9!_Z*KX/_ /![9?\ QZC_ (;)_9!_Z*KX/_\
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M?V0?^BJ^#_\ P>V7_P >H_X;)_9!_P"BJ^#_ /P>V7_QZOI&BCVF$_Y]R_\
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M!_Z*KX/_ /![9?\ QZC_ (;)_9!_Z*KX/_\ ![9?_'J^D:*/:83_ )]R_P#
MU_\ (!RU_P"9?^ O_P"2/F[_ (;)_9!_Z*KX/_\ ![9?_'J/^&R?V0?^BJ^#
M_P#P>V7_ ,>KZ1HH]IA/^?<O_ U_\@'+7_F7_@+_ /DCYN_X;)_9!_Z*KX/_
M /![9?\ QZC_ (;)_9!_Z*KX/_\ ![9?_'J^D:*/:83_ )]R_P# U_\ (!RU
M_P"9?^ O_P"2/F[_ (;)_9!_Z*KX/_\ ![9?_'J/^&R?V0?^BJ^#_P#P>V7_
M ,>KZ1HH]IA/^?<O_ U_\@'+7_F7_@+_ /DCYN_X;)_9!_Z*KX/_ /![9?\
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MKX/_ /![9?\ QZC_ (;)_9!_Z*KX/_\ ![9?_'J^D:*/:83_ )]R_P# U_\
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MR<(I.#@,03CBN:^)?PX^)OP;\2'PA\5M#OO#VIA!*+>_A:%VC;(#KN W*2"
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M%V2W@&Z20@?PJ.2:Z'X4_"'XN_'+5[G0/A!X?OO$5[9P_:)X;&,RM'%N"[F
MZ#) _&E4X'X7@I.=!)+>]2:M?:_OZ!'B'.)64:C=]O=CK_Y*?TA?\1&,7_1'
M_P#RX/\ [WT?\1&,7_1'_P#RX/\ [WU^$>K_ +#7[9N@Z3=:[K/PWUZVL[*)
MYYY7MF"QQQ@LS$^@ )-?(W]H-_>_6IP_!7"M=-T*,96WM4F_RF55S_.:=E4J
M->L8K_VT_J5_XB,8O^B/_P#EP?\ WOH_XB,8O^B/_P#EP?\ WOK^6K^T&_O?
MK1_:#?WOUKH_U X<_P"@7_R>I_\ )F7^LN:_\_O_ "6/^1_4K_Q$8Q?]$?\
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M]^M1_J!PY_T"_P#D]3_Y,K_67-?^?W_DL?\ (_J5_P"(C&+_ *(__P"7!_\
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M5_XB,8O^B/\ _EP?_>^C_B(QB_Z(_P#^7!_][Z_EJ_M!O[WZT?V@W][]:/\
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MI6E6\4_A[QKX?UW^WK2_4$;VO[=Y ;:,CJ\:LJDY#8&&_GO^W#^]7Z0>,O\
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M&+S&C)3>6"D@ G[?HHK*3N[FB5E8****0PHHHH **** "BBB@ HHHH ****
M/D'_ (*$2>5^P/\ '"7^[X \2G\M.GK_ "R_[='K7^M3\9;K[!\(/%=]YOD^
M3H]\_F>?]FV;8'.[SO*G\O'7?Y4FWKL;&T^DU];D'$DLKH22I<W,^]MDO)]S
MQ,SRI8RHGSVLNU]_FC_(-_MT>M']NCUK_7RHKW?^(B2_Z!__ "?_ .T/._U7
M7_/W_P E_P""?Y!O]NCUH_MT>M?Z^5%'_$1)?] __D__ -H'^JZ_Y^_^2_\
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M?Z^5%'_$1)?] _\ Y/\ _:!_JNO^?O\ Y+_P3_(-_MT>M']NCUK_ %\J*/\
MB(DO^@?_ ,G_ /M _P!5U_S]_P#)?^"?Y!O]NCUH_MT>M?Z^5%'_ !$27_0/
M_P"3_P#V@?ZKK_G[_P"2_P#!/\@W^W1ZT?VZ/6O]6'PO_P G>^.?^Q/\*?\
MI;KM?2-;5^/Y4Y*/U>^D7\7=)_R^9G3X:4U?VG5K;LVNY_D&_P!NCUH_MT>M
M?Z^5%8_\1$E_T#_^3_\ VAI_JNO^?O\ Y+_P3_(-_MT>M']NCUK_ %\J*/\
MB(DO^@?_ ,G_ /M _P!5U_S]_P#)?^"?Y!O]NCUH_MT>M?Z^5%'_ !$27_0/
M_P"3_P#V@?ZKK_G[_P"2_P#!/\@W^W1ZT?VZ/6O]?*BC_B(DO^@?_P G_P#M
M _U77_/W_P E_P""?Y!O]NCUH_MT>M?Z^5%'_$1)?] __D__ -H'^JZ_Y^_^
M2_\ !/\ (-_MT>M>U_LY?!KXD?M5?&_PY^S[\([=;KQ!XGNOLULLC;(T5%:2
M660]1'%$CR.0"=JG )XK_6'HJ9^(=1Q:A0L^CYKZ^G*K_>BH\+Q33E4T]/\
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MHHHK(U"BBB@ HHHH **** "BBB@ HHHH **** /_U?[^**** "BBB@ HHHH
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M*SXR_P#!]??_ !ZL_P#8B_9F3]K3XNW/@S7-7/A[P_H^F76KZOJI0,MK;6X
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M?\-Q_MB?]%9\9?\ @^OO_CU?%7]HM_G_ /71_:+?Y_\ UT?5<'_SYA_X"O\
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M **** "OF[XY?\E.^#7_ &.%U_ZC^L5](U\W?'+_ )*=\&O^QPNO_4?UBNW
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M-1;:"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH __];^_BBBB@ HHHH
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M@EXU\7_$[XDWW[._QYU?X<_#_P",EZ;_ ,7^%DTX7L=Q)([22B*8W$6Q'9V
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M\VY[FLLQQU3&25N9Z+R6B^=MS]8R[!K"X>%!.]OSZA1117DG:%%%% !1110
M4444 %%%% !1110!\W?LJ?\ ),=4_P"QP\9?^I!J%?2-?-W[*G_),=4_['#Q
ME_ZD&H5](UVYC_O=;_%+\V887^!3]%^04445Q&X4444 %%%% !1110 4444
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M_P _O_)8_P#R)C_8>"_Y]_B_\S^/K_B%&N/^B_?^6K_]]*/^(4:X_P"B_?\
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M-<?]%^_\M7_[Z5_8+11_K=FW_/[_ ,EC_P#(A_8>"_Y]_B_\S^/K_B%&N/\
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MO%]+)?DD=F'RO"T)^TI0L_5O\V%%%%>,=X4444 %%%% !1110 4444 %%%%
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M),>!RISGHN&.%8$QQ^*--EC218KL!PI&;.<'YU9QD&/(X4YSC#84X8@'HJ*
M.=;Q1IJHSF*[PJECBSG)P(Q)P/+R3M.,#DO\GWP5ITOB;3H=V^*[.W?G;:3M
M]S;G&(SG[PQC[W.,[6QT%% 'S%^S9?0Z)\/=3L+Q9'<^+/%LN;>-[A-LVOWV
MT;X@Z[AO&]<[DPV\+M;'O\?B33Y9$C6.Z!<J!FUG ^=F09)CP.5.<]%PQPK
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MXC\B>)=S)(QPJ'&<;B-Q! R016C:_M5?L[WGP_E^*5MXML&T&&].FM=;B/\
M3 -WD!" YE*G<$"EBO(&.: LSZ!HKE?!/CCP?\2/"]IXU\!:E;ZOI-\&:"ZM
M7$D3[6*M@CNK JPZ@@@X(KJJ!'S=X7_Y.]\<_P#8G^%/_2W7:^D:^;O"_P#R
M=[XY_P"Q/\*?^ENNU](UVX_^(O\ ##_TB)AAO@?K+_TIA1117$;A1110 444
M4 %%%% !1110 4444 %%%% !1110!\W?LJ?\DQU3_L</&7_J0:A7TC7S=^RI
M_P DQU3_ +'#QE_ZD&H5](UVYC_O=;_%+\V887^!3]%^04445Q&X4444 %%%
M% !1110 4444 %%%% !1110 5\W?MD_\FA?%7_L3]<_](IJ^D:^;OVR?^30O
MBK_V)^N?^D4U=N7?[W1_Q1_-&&*_@5/1_D?2-%%%<1N%%%% !1110 4444 %
M%%% !1110 4444 %%%% !7S=\<O^2G?!K_L<+K_U']8KZ1KYN^.7_)3O@U_V
M.%U_ZC^L5VX#^(_\,_\ TB1AB?@7K'_TI'TC117@?[4OQ[\/_LN_LZ^,OV@_
M$Z>=:>$M*N-0,.<&:2-<11 ]C)(50>[5QI7=D;-I*[/3_&?C_P "?#G1W\0_
M$+6[#0=/C^_<ZC<QVL*_5Y651^=8_P /?B_\)?BYI[:M\*/%&D>)[1>LVDWL
M-[&/JT+N/UK^#&?X=W?_  4N_8Y^(?\ P4;_ &LO%WB.Y\4Z)XTTW0M(TNVO
M(4TI[?4+FTC:UMK=[=VADCCN"5=68<!G1L-GN_C-^PM\)O\ @GE^T3\5[S]G
M_P")WBWP[K'PQ\+Z=K^C7BSP-*=0N8I)6L[SRX8EE1MD;#"J-LH!5L9/=3P7
M.^12][7IV//GCG%<[C[OKW_X8_O8HK\]/^"77[;$7[?7[''AWX\7\$=IKJM+
MI>N6\7^KCU&TP)"GHLJ,DRKSM$@7)(S7X\^&?^"CW_!374/A/?>!X]#6_P#&
MOC>[U*_\*:^-*"6>D:/HEW>Q:B+R+ 1Y8X[)# &"F4W28W%=IYE1DVUV.IXB
M*2?<_J1HK^7WQ9_P4 _:\NK?Q5J?B/XNV7PVU'PUX3\,ZEHNA3>%TO9/$-[J
M&AVNH71#NI?)O)7@V0@!,!<;@2?LSX4_\%&?&[ZI\5/!?QWO8_#_ (MMM+T.
MY\*:0VGRJPN[_P /VM[/$#Y9\S9?RNF)&R,;3TH="25Q+$P;M_7]:'[;45_*
M1\(O^"C/_!0_4_V?_%?Q.\2>([34M8MO"NFW\%H-.L9WT^>^U+3;:YN7M+/_
M $H_8[>YGD,<J@ K\XR,5]+W7[<?QP\!>!_$^N>$_C7:?%V#1;KPS<75[:^$
MWLAIMC>ZG';7N^6)#;2 P.3M&9H\%SA:;P\EU$L5%ZV_(_H@HK^??XM_\%/_
M ![:?M-66I?"S7XKOX,Q>+/"ND7NJQZ8\L M[VSU.;4E$QB+G8T-MEESY><9
M&XBNO_;7_P""C?QKOM=\-:%_P3TMKKQ+;VEA<^(];U&UT*[U2&XA@9X;?30(
MX6:![J5)"TS*HC6,$'G!7L)72*^L0LWV/W9HK^9+]HS_ (*,?MM^*?&FO^-O
MV5X?%"^#;3P9H_B&RATWPM9:FD%U>Q3O/%J$EW<031>6\6QUA69E*O\ +D#/
M]%'P?\2ZSXT^$OA;QCXB:!]0U;2+&\NFM4DC@,T\*.YC64"14W$[0X# 8# '
M-3.DXI-E0JJ;:1Z+11169J%%%% !1110 4444 %%%% !1110 4444 ?_TO[^
M**** "BBB@ HHHH **** ,K7M4&AZ'>ZTR>8+."2<H#C=Y:EL9YQG%?S._"7
M_@X0_:$^.?P_N?BU\(_V0_%WB;PO8RS0W.I:3J1O(HW@4/(OR6'+(K D#G!K
M^DKQ]_R(FM?]>%S_ .BVK_/;_8KT[_@J]\-_^"2WBS]I+]BOXF_V9X#T/7=1
M&M>&;/3[9M1CC6&#[3?0W,D$DN$1D+JDB&-$9UY!KKPU.,HMR[K>_P"AS5ZD
MHM*/GL?VY?L ?MY_"3_@H=^SG;_M$?"N"YTRV2ZFT[4;"^V^=97MNJ/)&S*2
MK+LD1U<8RC D*<J/LO2=<T77H&NM#O(+V)6*%X)%D4,.H)4D9]J_BIN=8_X)
MT?"#_@@MX3\'_#W5O&VOZ1\3O%D::EIVD7MGIFIZAXB6-?M%G?RRPW$5O:1K
M#%A45F91"V6#LU>:?L4Z9\4/V+_^"H_Q)\!?"WP3;_"F]/PJUG5!X)TWQ _B
M6&*^M;3[1:+<7#LXDN/,57VG(0/\N%<BJ>%3YFG;>WR)6(:Y4_(_KT_;F_:[
MT3]BK]E_QG^TA<Z6/$LG@VWM;B72(KI;:65;NYBMURY238,R;@2ASMQ[UXK\
M-_V]?B5\3_B#\#-$\-_"#6)O"?QB\'VGBN]\413F6PT![RSDNTM)R+?;(^52
M,-OCR9%.WL?XM7_9L_9.\5?\$1O%'[>_C?QA=W_QYUSQ"]M<3R:M(]Q<2R:C
M'&]G/;M)B7S+7-XS,I?.UMVT8/ZC_#>>^M?^"CW_  3GN=,A%S<Q_ >R:&$M
ML$D@T._*KN[9.!GM5?5HJ+ZM7_!$JO)M=M/Q9_9#/J6G6UW#I]S<1QSW&[RH
MV<!WV]=H/)QWQTJ[7^>A\'/@Y^SA^V+_ ,$_/C]_P4*_;#^(MX?V@M!U34+C
M3I9M4^RSV=S:P136,$5J6!*W$[-#'M7:@4)&%,;5_83_ ,$@/BS\6_CE_P $
MV/A-\3_CE//=^)M1TJ5+BZNB3/<Q6US-!;SR,>6>:WCCD9SRY;<22<UA6H<B
MO?K8VI5N=VMYGP%XV_X+G_&*+]I;XE_LX_ G]F;Q)\3)OAAJLVFZE>:)J)E;
M;'(\:2F%+*1D\PQMM7<QX(S7Z#?\$ZO^"F'P;_X*+>$-=NO!>F:AX6\5^$+E
M;/Q#X;U=0MY83.6"GC&^,LCKDJK!D9613C/X]_\ !+#XF?#?X:_\%8_VW[SX
MC>(--T"&X\1P^4^I7<5JK[+N]+;3*R@[<C..F:\/_8__ &F/A]\/_P#@I#^W
M+_P4)\"SQ:E\+/"^@NWVRU.;/4=45X?)2&8?(YN9H)@C*2&\P,#A@3M.C%II
M1U26OK8RC5E=-O=O]3]1/''_  71^"/@?_@IQ9_\$Y;SP[++'-J5KHEQXI%\
MHMX=3NX@T<'V?RB6Q,\=N[>:-KEN/EY]T_X*??\ !3B;_@G)'\/+73/A[=?$
M/4OB+J5QI=E96=\+.43P^2$5<P3^8TK3!54 <^N:_AVD\-_'_P"(?[#OBWXF
MZQ\"_'FI>./$_C'_ (64?B=:Z=<#38[2WCD:3]ZL)_<@RW$YE$FT-M/1,U^N
MW_!3S]I;6_V\OV=/V$_CC\.=6BT;Q5XH\2O:O>")94T_7H9;*WF<Q,"&6*Z4
MR*C##)MXP:T>%@IQ5M-G]Q"Q$G&7?=?>?JYX6_X+M>)?"?QK\&?"3]L[]GGQ
M=\&+3QU?IINFZQJDOGVIN)&5%W;K>W^0,Z^84+% P8KBM'XY_P#!;/XJ^ ?V
MR_'G[&OP-_9UU[XIZMX"$$MW<:+J/SM!-%#)YI@6SE**&F5/OG)^N*_'3XA^
M#OVB'_X*Q_"S]F'_ (+:_$W4/%'A:SO(M5\$ZCIMI:V&CZE?R2)Y*7'E0PF-
M7EC$$PVM(K%0&6-_-KT>#P;^W=XU_P""]W[2VG?L"^+O#W@_Q''I=B^HW7B*
M W$$EEY&GC9&HM[C$GF%#DJ!@'GM2]C3O>RVON[;_>'M9[7ZVZ7V/V2_9Y_X
M+,:7^T]^S7\3OB=\*OA1XBN/B3\*)K>VU?X?2G;J+S7,YA58G6)G.W9+Y@:!
M71HV5E PQ_6#X,_$'6/B;\)/"OQ"\6Z'/X4U;Q#I-GJ-UHEZV;G3YKF)9)+>
M3*H2\+$HQV+R#P.E?RL_M"?\$S/B%^Q#_P $N/VK?CG^T/XTA\=_%#XK+IUY
MK5]:0^3:1"/4HY"L650LTDDS,YV1J $544*2WRYK'P(\)?M.?MD?\$_/@-\0
M)[V'P_XC^!^EPZFEA<R6DMQ:0Z?>SR6YEB*N(YUC\J4*03&S $9S4.A3E=Q>
MFOX*YHJLXV4EK_P;']QUAJ.GZK;+>Z7/'<PMD"2)@ZD@X.""1P:N5_+O_P $
M6OAYHG[,O_!3C]K+]DGX42W5IX!\/SZ==:;I<UQ)<1VSL6QM,C,Q(23878EV
M5%WLQ4&OZB*Y:L.25DSHISYE=H****S+"BBB@ HHHH _-W_@KI<BS_X)Y_$&
MX)QM_LG]=2M!7\3*>(E=PF\#)QDG K^T3_@M!<_8_P#@FI\2;G.-O]C_ *ZK
M9BOX.[+Q)8M>1+J,KK;EU\UHP&<)GYBH) )QT!(&>]?O_A5C/9915C_T]E_Z
M1 _DOQXRWZQQ!0G;_ES%?^5*A^S>D_LJ_";XG:!J@^!_C6YU*]\.:CI&F7^H
MWUHL.D74FKRB$-:2([S8A<Y97CW,@+ #I7":'^S!8MI=WXIUSQ/;S:7+HNIZ
MEI)M(IA+>RV.E2:CM(>(B)4P@??@N-P0YY')_M'?M;?LM>)OAGI7@O\ 9DU+
MQGX4M_"I@GT726LK.UM7O@RB:]N[J&]DGDN63>4DV?+PBA5+$_ NF_M!?%;1
M=&N_#NC^*M6M-/O[86=S;0WLR0S6ZHT8B=%<*T81V4*05VL1C!-?1X'&YG5I
M2DZSC=Z*27,E9;M1M?KHK*[BME)?'9GE>24*\(K#1E97;IRDX-W>B3DVDE[N
MKN[*;6K@_N/X9? ;Q'\4?@3XF^,WA^\@>70=3L-,@T[SH5GN9+S?G:K2+)N&
M$$:!"92S!,F-@.T/[#G[53ZUIWARPT&UO;[4KV;3$BM=3L9S#?0027+V\Y2<
MK#*(HI&VR%?ND=>*^=_V:?VEO@O\//AKXG\ _&*QU+4(M2UG0-:M8K!(VCN/
M['DG,MM.SRQM&DR3;1(@9EZXZ5^B#?\ !4K]F/1].FTW0[?7Y(O[6O=3M(H-
M$TO2X+2*[TR_LDMU6UN TAC>Z1FGD9F<!L 8 ;+,,_SFC6J1PL%*-WRWB]N6
M-K-27VKWO:_1]M\HX1X<Q&&H3QM5PE9<UIJ]_:3YFU*+M>'+:U[:-I[OYYT+
M]AK]JGQ/J,FEZ#HEE<R_:6M+<C5K )=RHBR2?9F:X G$:N"YC+!#E3AE8#D=
M(_92_:+UOP0GQ L]$B2PDMWO42:^M8;EK.)BCW(@DE67[.A!W2[=@4%L[037
MV?\ L":S\-?%WP^^$7Q'^*5S-9V_PIU'676^LM1L8K.UMYI#<DZE'/+%<1D.
MQ,?D)+YR$*<'@>-W'_!4/X=7/PLTR")M:L?$>B^%9/"\5A;:=I;V5QM22&&X
M:_F1[V-3&V98$7#-]UAEB>9\59Q*O.A1A"7*TF^62ZS723W48O\ NWL[[G:N
M ^'88:EB<34J0YXMI<T6W[M-]81^%RE&VKGRW5M4>!?M#?!#Q!\#?CN_P*L+
MI-=O9/LBVC6K1R23R72J%3RXI)/+<R$J(V.XC:V,,">VD_8D_:L&K6.B6OAR
M*ZGU![F%#;ZA9S1QSVD9FF@ED2<I%,D:EO+D96.#@'!QY1\1?VROANW[:WA_
M]K'X;6E_=6]K<:7J5_IVII% RW5HJ1S10O')*&C*Q@I(P5MS'*< GWO1OV[_
M -E7X4>$_$/@?X3VWBJ_MO%5SK6J7-SJD=M'+;75]IEU8VT$:1W#AT5[HM-,
M65\*,(W2NVKGV;PP]%4X*4^1<UXO65M;VDN6V_7FO96/-H\)\/U<7B76J.-)
M5'RJ,UI"ZY;7A)RYE==.2UY7.#?]D7]HY?%D?A%=(MG:73CJXOEU&T;319+)
MY33&\$WV<*)/D(,F[=QCI5S_ (8T_:>C\77W@J^T*WM+O38+2XN9+C4;.*UC
M6_W?9A]H:80EYMI"('+''3%>H?LL_&[P-\=O@/!^R+>6U](EMX6NK;4Q:SV=
MM?37 UO[?;MI_P!JFCBGV+(!-%(\3$;BF[;SWG[67[2O[)[7-U^R?\1+C7/^
M$?T:U\-7-MJ&@/::C=Q7NF6#6TMI<LTR02$))M,D<C!9@>",URRXJS58AX;E
MC=7VBV^5-)3MS]4W[OE>[V.Z' 612P<<9SS46HVO.*7.XR;IW]G]EI7GMJUR
MKXCPEOV0_C5J,6B>%]"\.W\?BFY.LM?VU_/9VUNB:1)$DAB=YP0$\P%S)M!R
M#'N7)K&C_8Y_:6E\2S^&ET>U'V>RMM1:];4K-=/:VO'>.W=;MIA WG2(Z(JN
M6+*>.#CTCXO?\%0?A;\59M2U+^Q]5L+B\\/^+=%BC BD53K26T-D6D\U68+'
M;YN#MR&/RA^375? /XF?#?\ :J_9UC_9SU&UU26+P_HVC0W:6%U86NHO>6=[
MJ4P>W2\FCBGM?*NPLK-(KPL PC9<FE_K+G-&@JU>$8J^MTWRWD];\Z325DEI
M?OT'_J5P[B,4\/A:DYNUXVDES.,(VC;V;:<I7;>MK6MU/A'XI^$?&_P6\>:A
M\,OB5:#3=;TLQBZMO,CE\LRQK*HWQLR'*.IX8XSCK7G_ /PDB_WA7J7_  49
M^)G@_P 7?MH^.=9\":A'J&E">UMH;B*43(YM;6&!\2 D/AT8;@2&QD$CFOB;
M_A)E_OU]5EV<5*V%HUJNDY1BVMK-I-JVO4^#S?ANEA\?B,/AVW3A.48O1WBI
M-)W5D[KJDD?0'_"1@S8W5^JO_!+7]CSQ7^U9\8H/'-^UQIW@_P (W4-S>7\+
M-%)+<QD21V\$BD$.2 SLIS&G.0S)G\TOV-/V;?B3^VC\==-^#?PY4QK+^_U&
M_92T-A9(0))GZ9QD*BY&]R%R,YK_ $"O@-\#?A[^SA\*=(^#OPPM/LFDZ/"(
MU)P99I#R\TK #=)(V68^IP   !\7QUQP\!AGA,++]]-;_P L7U]7T^_HK_I7
MA=X7K-<9',,='_9J36G\\EJH^BWE]W5M<;\<O^2G?!K_ +'"Z_\ 4?UBOHR>
M22*!Y8D,K*I(12 6([ D@<^YQ7SG\<O^2G?!K_L<+K_U']8KZ1K\ Q7\.A_A
M?_I<S^OZ/QU/7_VV)^4G[,_[,/Q;\*^,O ?B[XNZ AE\+Z#KVKS?Z1;RG_A)
M?$-_YLJ#;(V6CMEV"3[GS##Y!KK?A;^R[\9_!?[/>A:M_P )-XBTCQEI.G7>
MHS^&],O+)-/O-6N)Y[YHIV>*3=YDLWDNRW"IL PRXW5^EU%<1T\S/R3O/V,_
MBA!\+/A=\'_!MK'I2^%?!^OF\U S1A$\2:I8"TC8A&,C'S+BXD,BJP&!\V<9
MS-:^!'[1/Q1\ ^'-"TOP1'X#E^''@W6=+TV.>\MI6O=6U'3S8(L!MY)%CMU!
M:3S)BK,Y3*#:6K]?Z* YF?D1!\(OVE/%5[IU]_PKBVT[1_!7P]E\.Z%H^LZA
M XO+N\:WANDE-I*WE!K2 I&0V/F!9@2RKY9JW[)'[0WBKX9>(/#EOX?U*/0[
M"]T :-IFMWVGS>()-,L)VFO+"._B:5!;*WEO:I<2L R<@ \_N512L',?#_[(
MWPC\>>%-?\7_ !:^)=OJFGW_ (D:TM8+;6=0AU"]%E8*_EO</;@0"1FEDPJ%
MMJ8!8GI\.?!SP;\8_P!HCX8WNE:;X1^P:'\2/'C>,;OQ4]U;[/[*MKY9X8TB
M#_:?M&+=(HQLV!#OW\D5^X$D<<L;12J&5@001D$'L:H:/HVD>'M+M]#T"TAL
M;*T0106]O&L44:+T5$4!5 [ #%,.8_*]?V9?BSI/P#\.:^_A>/4?%C?$!_'7
MBC1!<6ZRWXDN+EUA$I?R'>!9('17D"$Q8SG KS?XK^$_'.A?%ZP_:2^(FD6-
MAJ>O^*]/U"T\&7FHVL$UQ9:#I]S DKW3O]D^UQO<?:!'YNT*BKO+*,?M57*^
M+_ O@CX@Z6-$\>Z-8ZY9*XD%OJ%O'<Q!QT;9(K+D9.#C- *1^.?[._PM\8?M
M+^.K#X]^)?#MK'X<USXA:IXDOA%-#-;B/0[/^S], .1Y^ZX,TGF1J48J6XW*
M3)XE_9Q_:G\=>.8='\2Z'J@LKWX@6^L:[<6U_IMIH=QI,%X)(GBM(2ES-+Y4
M</F-<9D#+D;S@#]IM.T[3]'L(=*TF".UM;9%CBAA4)'&BC 557   X ' JY0
M'.?E+X*_95^)&H>&_AUI?CSP]%#-J/CW4_'7C0M-!)Y<X-U+91OM=A,"[P+B
M/>%V9.!7.>*?V>OCA=:'?ZGKGA"^O9-<\;ZWXG>30M4M[/7]*F&VUTN>UEDG
M2U=3:H1-&[' <97(('Z^T4!S,^?OV6_"?Q \&? O0](^+-K96OBEUEN-5%C%
M#$DES-*[F1Q JQ-,ZD&9T&UI-Q!(.:^@:**"3YN\+_\ )WOCG_L3_"G_ *6Z
M[7TC7S=X7_Y.]\<_]B?X4_\ 2W7:^D:[<?\ Q%_AA_Z1$PPWP/UE_P"E,***
M*XC<**** "BBB@ HHHH **** "BBB@ HHHH **** /F[]E3_ ))CJG_8X>,O
M_4@U"OI&OF[]E3_DF.J?]CAXR_\ 4@U"OI&NW,?][K?XI?FS#"_P*?HOR"BB
MBN(W"BBB@ HHHH **** "BBB@ HHHH **** "OF[]LG_ )-"^*O_ &)^N?\
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M-1:.._MED6.>VWW3?97"2NA,'EAT(1@5 4=C^S[_ ,$EO^"??[+/Q+T+XQ_
M;X?)X?\ %'ARTN+*TU"+4;]W:*Z$BR^>DERT=PS"5ANF1V4;0I 1-OPY<?\
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MKEF)+$_&_P *O^"AOQ ^)'_!6[QE^P1#INDOX*T'P3;^*+'585E^WSRW L&
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MB'_H;O'?_@=I_P#\KJ\G_P"'SO[2W_0"\,?^ UU_\ET?\/G?VEO^@%X8_P#
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MR7+*P=?,4PD, XW '@-SUYK:GBHQLVNWX&53#RE?7O\ B?S9>,_A=^Q39_\
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MPNO_ %']8KZ1KYN^.7_)3O@U_P!CA=?^H_K%=N _B/\ PS_](D88GX%ZQ_\
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M 4444 %%%% '_]7^_BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT?VAO!?Q7OOCAH'BN[7Q/J89+R\EVS_:(VQE)(Y%:-D&!M0KM7 V@8&/+O\
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M_9P@\O&W;CC'ICTJEJ^FQZQI-UI$LDD*W4+PF2([9$#J5RI(.&&<@X/-:-%
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M* "OF[]LG_DT+XJ_]B?KG_I%-7TC7S=^V3_R:%\5?^Q/US_TBFKMR[_>Z/\
MBC^:,,5_ J>C_(^D:***XC<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M+R2.?O.[,Q[FNMHI3KU9IJ4V[ZZM[A"A3@TXQ2MIHEL%%%%9&H4444 %%%%
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MG'&4V@<'# GD$* #>HKG8[;Q8(T$M[:,P"[B+5P"0K!L#SSC+[2.3A01R2&
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MTJ2&V@$$-D$=F7?[U1_Q1_-&&*_@S]'^1]545SK6WBPHP6]M VT@$VKD!O+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\P^-NIP:+\&/%VL75T;&*TT6_F>Y$EQ"85C@=BX>T!N$V@9W0 RC&4!;%<K_
M ,-4?LP_]%'\+_\ @XM/_CM0_M8/Y?[+/Q+D_N^%=9/Y6DM?Q$?VNO\ ?KYG
MB'B*KE\J=*G34KW>K]%^A\/Q5Q16RFO3A2IJ7,KZWZ/R/[??^&J/V8?^BC^%
M_P#P<6G_ ,=H_P"&J/V8?^BC^%__  <6G_QVOX@O[77^_1_:Z_WZ^<_UWQ'_
M #Y7WL^6_P"(E8K_ *!X_>S^WW_AJC]F'_HH_A?_ ,'%I_\ ':/^&J/V8?\
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MWNC_ (H_FC#%?P*GH_R/I&BBBN(W"BBB@ HHHH **** "BBB@ HHHH ****
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MJP."#D5JU4L+"RTJQATO3(4M[:VC6***,!41$&%50.  !@ =!5NN$[ HHHH
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ME,****XC<**** "BBB@ HHHH **** "BBB@ HHHH **** /F[]E3_DF.J?\
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MWQB\1^#]836="^-%CX;\0>&-3MCYT5U;6T-M!+:DIGRY87@DB9&PRM&58 D
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MOVSOCGXD\#6WCR+P?<>&/!VB^$-/DM/#NEO("8I'C,,+>6LF2T:QDMYCG=D
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MDQX'*G.>BX8X5@3O44 <['XHTV6-)%BNP'"D9LYP?G5G&08\CA3G.,-A3AB
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M8'.[SO*G\O'7?Y4FWKL;&T_PP_VRO][]:_1N!^!EQ'2K7Q'LO9-?8YK\R?\
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M 'G?Q>DGB^$WBB6VDDAD72+TH\+7*2*PA?!1K,-=!@>0;=3,#_JP7Q7\ O\
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M1\3M4^'&O:]KFA7CP:5X;UNSTJY\2VNE7L=A9P65LEXT$OV614M5BBDDW!
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MF_M*?\$9_@]:_LXZ-<>+?#.F^/=:U#Q7X1@U0:-)KVG":)43[0SQ QJ8IXV
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M:?MT?]$9\>?^$[J'_P 8K_2;HKZ#_B)V,_Y\Q^]GQW_$$LN_Z"9?=$_S9/\
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M^&-/VZ/^B,^//_"=U#_XQ1_PQI^W1_T1GQY_X3NH?_&*_P!)NBC_ (B=C/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_9!_P"B5>#_ /P167_QFC_AC;]D'_HE7@__ ,$5E_\ &:/9X3_GY+_P!?\
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M8V_9!_Z)5X/_ /!%9?\ QFC_ (8V_9!_Z)5X/_\ !%9?_&:/9X3_ )^2_P#
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M ,G>^.?^Q/\ "G_I;KM?2-?-W_#&W[(/_1*O!_\ X(K+_P",T?\ #&W[(/\
MT2KP?_X(K+_XS6U>6$J24N>2TBO@71)?S];&=-5X*W*MV]WU;?\ *?2-%?-W
M_#&W[(/_ $2KP?\ ^"*R_P#C-'_#&W[(/_1*O!__ ((K+_XS6/L\)_S\E_X
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M_*O_  )__(A^RI_R3'5/^QP\9?\ J0:A7TC7S=_PQM^R#_T2KP?_ ."*R_\
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M\,;?L@_]$J\'_P#@BLO_ (S1_P ,;?L@_P#1*O!__@BLO_C-'L\)_P _)?\
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M<U?^5?\ @3_^1/I&BOF[_AC;]D'_ *)5X/\ _!%9?_&:/^&-OV0?^B5>#_\
MP167_P 9H]GA/^?DO_ %_P#)AS5_Y5_X$_\ Y$^D:*^;O^&-OV0?^B5>#_\
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M!_\ X(K+_P",T?\ #&W[(/\ T2KP?_X(K+_XS1[/"?\ /R7_ ( O_DPYJ_\
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M_DV@#^K>BOY2/^'ZO[5W_0O>$?\ P$O/_DVC_A^K^U=_T+WA'_P$O/\ Y-H
M_JWHK^4C_A^K^U=_T+WA'_P$O/\ Y-H_X?J_M7?]"]X1_P# 2\_^3: /ZMZ*
M_E(_X?J_M7?]"]X1_P# 2\_^3:/^'ZO[5W_0O>$?_ 2\_P#DV@#^K>BOY2/^
M'ZO[5W_0O>$?_ 2\_P#DVC_A^K^U=_T+WA'_ ,!+S_Y-H _JWHK^4C_A^K^U
M=_T+WA'_ ,!+S_Y-H_X?J_M7?]"]X1_\!+S_ .3: /ZMZ*_E(_X?J_M7?]"]
MX1_\!+S_ .3:/^'ZO[5W_0O>$?\ P$O/_DV@#^K>BOY2/^'ZO[5W_0O>$?\
MP$O/_DVC_A^K^U=_T+WA'_P$O/\ Y-H _JWHK^4C_A^K^U=_T+WA'_P$O/\
MY-H_X?J_M7?]"]X1_P# 2\_^3: /ZMZ*_E(_X?J_M7?]"]X1_P# 2\_^3:/^
M'ZO[5W_0O>$?_ 2\_P#DV@#^K>BOY2/^'ZO[5W_0O>$?_ 2\_P#DVC_A^K^U
M=_T+WA'_ ,!+S_Y-H _JWHK^4C_A^K^U=_T+WA'_ ,!+S_Y-H_X?J_M7?]"]
MX1_\!+S_ .3: /ZMZ*_E(_X?J_M7?]"]X1_\!+S_ .3:/^'ZO[5W_0O>$?\
MP$O/_DV@#^K>BOY2/^'ZO[5W_0O>$?\ P$O/_DVC_A^K^U=_T+WA'_P$O/\
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MVU^(WA@K;:C!MM]6T[=E[.[ R5]3&_WHW_B7T8,!]8T %%%% !1110 4444
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MR_X?_:FUB:WDTG7FA)LTW?:;:&YW^1-)D;=DH0;2"?OJ/7'@7PAT3QI^V/\
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M&1_VG#*<S01R,/(BD&<ADVNN#Z4 ?GM_:S4?VLU>;?VS%_>_S^=']LQ?WO\
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M%M-\37^F:1H"6TECJ%JES+ %N[B%Y(W@DQ+&L>&QM((VY;A2OHU^(*55;W_
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M&.F?$#P=?-8ZQH]W%>V=RN&:.>%@Z-A@5;# $A@0>A!%?;?_  XY_P""L/\
MT2H_^#S1_P#Y.H_X<<_\%8?^B5'_ ,'FC_\ R=0!Y%X__;V_:;^)^L>'=?\
M&OBC[3>>%-4FUK2I(K.UMC;W]Q*L\DP$,*!BTB!R'#+GMR<Y>I?MN_M%:QXR
M\9_$#4_$K3:Q\0=-?2-?N&MK?_2[*1$0Q;?*VQ#:BJ#$$8 <$5[C_P ..?\
M@K#_ -$J/_@\T?\ ^3J/^''/_!6'_HE1_P#!YH__ ,G4 6=#_P""O/[?7AOP
MS9>#]#^(!M]/TZVBM+>-=,T_<D,*A$7>;8N<* ,EB3W.:^)/'_QC\<_%3Q=>
M>//B-JUQK.L:@X>XN[J0R2.0 !R>@  "@8     %?:7_  XY_P""L/\ T2H_
M^#S1_P#Y.H_X<<_\%8?^B5'_ ,'FC_\ R=0!^?G_  D+?WJ/^$A;^]7Z!_\
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MC_A(6_O5^@?_  XY_P""L/\ T2H_^#S1_P#Y.H_X<<_\%8?^B5'_ ,'FC_\
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M /DZC_AQS_P5A_Z)4?\ P>:/_P#)U 'Y^?\ "0M_>H_X2%O[U?H'_P ..?\
M@K#_ -$J/_@\T?\ ^3J/^''/_!6'_HE1_P#!YH__ ,G4 ?GY_P )"W]ZC_A(
M6_O5^@?_  XY_P""L/\ T2H_^#S1_P#Y.H_X<<_\%8?^B5'_ ,'FC_\ R=0!
M^?G_  D+?WJ/^$A;^]7Z!_\ #CG_ (*P_P#1*C_X/-'_ /DZC_AQS_P5A_Z)
M4?\ P>:/_P#)U 'Y^?\ "0M_>H_X2%O[U?H'_P ..?\ @K#_ -$J/_@\T?\
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M  D+?WJ/^$A;^]7Z!_\ #CG_ (*P_P#1*C_X/-'_ /DZC_AQS_P5A_Z)4?\
MP>:/_P#)U 'Y^?\ "0M_>H_X2%O[U?H'_P ..?\ @K#_ -$J/_@\T?\ ^3J/
M^''/_!6'_HE1_P#!YH__ ,G4 ?GY_P )"W]ZC_A(6_O5^@?_  XY_P""L/\
MT2H_^#S1_P#Y.H_X<<_\%8?^B5'_ ,'FC_\ R=0!^?G_  D+?WJ/^$A;^]7Z
M!_\ #CG_ (*P_P#1*C_X/-'_ /DZC_AQS_P5A_Z)4?\ P>:/_P#)U 'Y^?\
M"0M_>H_X2%O[U?H'_P ..?\ @K#_ -$J/_@\T?\ ^3J/^''/_!6'_HE1_P#!
MYH__ ,G4 ?GY_P )"W]ZC_A(6_O5^@?_  XY_P""L/\ T2H_^#S1_P#Y.H_X
M<<_\%8?^B5'_ ,'FC_\ R=0!^?G_  D+?WJ/^$A;^]7Z!_\ #CG_ (*P_P#1
M*C_X/-'_ /DZC_AQS_P5A_Z)4?\ P>:/_P#)U 'Y^?\ "0M_>H_X2%O[U?H'
M_P ..?\ @K#_ -$J/_@\T?\ ^3J/^''/_!6'_HE1_P#!YH__ ,G4 >#?LF_
M+XH?M?\ QMTGX'?"F#S;_4GWSW#@F&RM4(\VXF(Z)&#]68A5RS '_1 _9>_9
MJ^&_[)?P7TGX*?#"#99:<FZ>Y<#SKRZ<#S;B4CJ[D?15 4850!\=_P#!*O\
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MWO\ /YT?VR?[W^?SH_UWQ'_/F/WL/^(E8O\ Z!X_>S^X'_AJC]F'_HH_A?\
M\'%I_P#':/\ AJC]F'_HH_A?_P '%I_\=K^'[^V3_>_S^=']LG^]_G\Z/]=\
M1_SYC][#_B)6+_Z!X_>S^X'_ (:H_9A_Z*/X7_\ !Q:?_':/^&J/V8?^BC^%
M_P#P<6G_ ,=K^'[^V3_>_P _G1_;)_O?Y_.C_7?$?\^8_>P_XB5B_P#H'C][
M/[@?^&J/V8?^BC^%_P#P<6G_ ,=H_P"&J/V8?^BC^%__  <6G_QVOX?O[9/]
M[_/YT?VR?[W^?SH_UWQ'_/F/WL/^(E8O_H'C][/[@?\ AJC]F'_HH_A?_P '
M%I_\=H_X:H_9A_Z*/X7_ /!Q:?\ QVOX?O[9/][_ #^=']LG^]_G\Z/]=\1_
MSYC][#_B)6+_ .@>/WL_N!_X:H_9A_Z*/X7_ /!Q:?\ QVC_ (:H_9A_Z*/X
M7_\ !Q:?_':_A^_MD_WO\_G1_;)_O?Y_.C_7?$?\^8_>P_XB5B_^@>/WL_N!
M_P"&J/V8?^BC^%__  <6G_QVC_AJC]F'_HH_A?\ \'%I_P#':_A^_MD_WO\
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M[#_B)6+_ .@>/WL_N!_X:H_9A_Z*/X7_ /!Q:?\ QVC_ (:H_9A_Z*/X7_\
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MW^?SH_UWQ'_/F/WL/^(E8O\ Z!X_>S^X'_AJC]F'_HH_A?\ \'%I_P#':/\
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M[_"XFGB*4:U)WBS]5P6-I8NA'$4'>,E=?UW74****Z#J"BBB@ HHHH ****
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M36\3QV_V1=7-I$;];?G]T+C;YH3D_+NQSTH6*E=N78'AXVM'N?E%_P $L_\
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M@P^JL]S_ +9]Z/[9]Z\,_P"$F;^_1_PDS?WZ/8,/JK/<_P"V?>C^V?>O#/\
MA)F_OT?\),W]^CV##ZJSW/\ MGWH_MGWKPS_ (29O[]'_"3-_?H]@P^JL]S_
M +9]Z:VL?+UKP[_A)F_OT?\ "3-_?H]@P^JL^R_@1^T-X\_9W^*&F?%?X=W!
MAU#39,M&W^JN(6XDAE QN1QP1U'!&& (_MX_9F_:)\"?M2_!_3/B_P" '(M[
MT&.YMG.9+2ZC \R%_=21@]&4AAP17\-O[&7[-GQ$_;.^-EC\)_ ^Z"U&+C5=
M1*EHK&S4@/(W3+'.V-,_,Y X&2/[P?@Y\(? GP'^&ND_"CX;68LM(T>$0PIU
M=SU:21N-TCL2SMW8FON>$*6)BIM_POU\OU^1^E\ T,7!5&W^Y?1_S>7RW^1Z
M;1117VY^DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RO
M^V#^T!=?LU_">V^(FFQ1WE[)K&G6$%@X):]^U3*DD49!!$@A\R1#S\R#((R*
M\ _9)/Q-@_;5_:7LO&OB'5-4T.TU?P]#HEE?7DL]K9+/I_VJ9;6*1BD09IUW
M",#.T9Z5I_MO>!M;U/XK?!CXK:A9W&H^#O!?B":[UR&VC:=H&E1!:W;1H"QC
MMY5)=@#L5LXQFO0O&-[\'(_"GQ!UKP]J%IXCU#QR5FAM--D6ZN)IXK.&U@"+
M$6;*M$'#CA,YR,9KS(9Y]369.O;EY(J">EVG&;DG9OWO@T3^%Z7/?Q^14Z^$
MRBIADW-SJ2J26MD^:G&#5TKQ2]IK;2:ULE;[2KSW2/BQ\-]?\;ZQ\--'UFVN
M/$.@113ZAIJM_I4$4^?+D:(_-L?!VL 0>QJM\&].\9Z3\*] TWXARF;6X+*)
M+MF;>WF =&;G<P& S9.2"<FO@SXR_!?7/'WQ:\5?&G]GR\M;/XM^ ;ZVGTLR
M.%BU*RDLK<7&F7F.MM<E"JL?]3.JR*058'V<EC3QE)5*Z=/F@GK]ENUE/M:]
MGVWUM8^7S:I4PL^6C:=I-.WVDKW<>[TNEUVTO<^^8_BW\.)/""^/3JT*:2\_
MV5+B3=&)+CS/)$2*P#/(9?W:HH+,_P H!;BL[3OC?\+-3BUMK?5T2;PU&LVJ
MVLT<D-W9Q,I99)K>15F1&4%E<IM8 D$@&OS4O;OQWJ6F?L\?M(:_H&HV/AC0
M_$>O:AXDTF:)GN=)?6([R&VN;B%03BSEF*3. ?*60R<*I(]_U#0/^%H?M]>#
MOB]\,&6XT3PWX0UC3O$&JVY#VMY_:$]L]C9"1<K*\31SSLH)\H,I;'F+GUYY
M72@WS2=K3=[JR<6URO3>5E9_WHZ6W\N&9U9I<L5>\%:SNU))\RUVC=W7]V6M
M]OJ_3_C7\+=6\"Z3\3-*UB*ZT#79((M/OH5>2*Y:Y;9#L*J<B1B C=&) !.1
MG?C^(W@27XAR_":+5K9O$L&GIJLFFAQ]H6RDD,2S%.NPR*5!]17YO?LD>$_$
MGPT\:Z]^S#XHLY;+P?\ !K6K_6-'U"<;+:73-70SZ;$LC85ULTGO8I1_RS,$
M)R,BO)_B'J/C?P?\3_AW^WS#%I[Z9J'B.?3]1^R2RO?S>'M>$5HBRP",<V/V
M:UN)HU9C&\<Q('SUI_8]*5:=*$]+-Q>FK:;@O626O9M=C/\ MBK&C"K.&MTI
M+71)I3?I%O3ND^Z/T_\ &7[2/P+^'GB>\\'>.O$UGI&HZ=:1W]W'=L8E@M)2
M56>1V 1(2P*^8S!-RD9R"*U_'7QS^$?PSTT:UXYUZUT^R^QOJ)N'):);-,;I
MV=056(9'SL0O/6ORE_:RL/BYXK_:Y\?I\!)H+F]N_A)I]DT C#R:A&-2O)KF
MSM)V)BBO'M)-T)>.95+HS)L.:]>_:4F^&.L_\$F/%6F_!*WF&DOX".C:/9SH
M_P#:"K%:B*WM)(W_ 'OVA!A#&V7WYXS5K)Z'^S7D_P!XXI[:<R6NVF[MO>SU
M5B7F];_:;17[M2:WUY6]-]=E?:UUH[H^\M1^/WP>T?P9JOQ#UC78;/1=#(&H
MW<ZO&EJ&19 TNY044HRMN8!<$'-;^J_%7P'HMAI5_?WQ']NY_LZ".&66YNL(
M9#Y4"(TS[4!=L(=J\G KXV_;S?3];_X)Q?$9O#^R[GUCPA/;6OV<"1[J62 K
M'''MR79B<*HR<]*L?M"^&_ _Q @^'WB+1O'TGP]\8:187E_X;\2)Y,U@49((
MKJVN(YSY,\<RO&QB+)(?++QNI1C7)1P%&<82DVKRG'O;EBFME?=ZV3LEHFSJ
MK8^M"4XQ2=HPEVOS2:>[MLM+M7;U:1]S^&?$NA>,=!M?$_AFY6[L+U!)#*N0
M&4^Q ((/!! (/!&:W*^=?V3?''Q$^)'[/GAWQM\6=$A\/^(;]+AKVTMXG@A=
MDGD1;B..7]XB72JMPJO\ZB0!B2":^BJ\S$TO959TG]EM;WV=M^OJ>GAZJJTH
M55]I)[6W5]NGH%%%%8FP4444 %%%% !1110 4444 %%%% '_U/[^**** "BB
MB@ HHHH **** ."^*J>)I?A?XCC\%:5::[K#:7>"QTW4&"6EY<F)O+@F8Y"Q
M2OA')! 4DU_.[\!M'\8>"OBE\,]/_8@\&_%[X<ZA_;5FGC7P/XD@OCX'T_2"
MK'4!#/J/F6Z.,?Z$UA.=YVC8%X']+]%:0J<J:L1.',TS^0#X!_!WXOCX]_ W
MQM;?"[4_"^HZ1KNN_P#"2:?I?@2_T^/1!J>GWZ>7>:_>/<76KF>5T+7"R-;\
M@OL+1 ^GI^POX.^%G[!W[-.MP_#O5?"7BK3[!;OQ'?V?@I/%!AU*XL65O[=T
M,PF[N\M))%'*!YMHQP"@;C^K"BM7B7?^O/\ S,U05OZ\O\C\;_V,O@U^VEKW
M[-'PTLX=7TCX+^'+.SGM-6\%+X9N)+J6V%_<GS8)[G41-IK75HT;);O',UHY
M[X\M?)OV>/VC?V@?V0/V0O#7[%]K\%O%>M_%[P9:+X7TL6^DW#^%]0:W<PP:
MBVKHOV>*S:/9--YCI,I)4INP:_>FBH]K>]UYE>SM:S/Y9/VH/@'XJU34?VC?
M /Q(^#VN>-?C9\1-<L[WX=>,-,T>6ZL[2W%I:1V7D:QL*:8FFW,<KRB6:$D'
M/S!LU]177[+7QVA_;DA_9@NM&N[SX-:[XGL/C)JNMK PL#JEC#Y=QIC.1Y8>
MYU>*UU'R<Y*&0XP&K]^:*?MW87L5W/QQ_:.^+O\ P4%_8X^$DYN=0D^-GBKQ
MCJ%MINCW/AOP+>I;>&H )#=7]]!8W.H2W2A3'Y40\HM(N,E2Q7Z-_P"";_AS
MX=^%_@5J%GX(L?%Z:A>:U=:AXAU3QOHMUH>JZUK5XL<ES?-!=10DH^52/RU\
MM%C$:D[#7Z T5#J7C:Q:A9WN%%%%9EA1110 4444 %%%% !1110 4444 %%%
M% 'RM^W5+Y/[$7QCF_N>!_$+?E83U_FP?\))_M5_J9:_H&A>*]"O?"_BFR@U
M+3-2@DM;NTNHUF@N()E*21R1N"KHZDJRL"&!((Q7S%_PP/\ L*_]$6\!_P#A
M.:?_ /&*\/-LHEC)QDI)61\UGN0RS"I"<9I65M3_ #:O^$D_VJ/^$D_VJ_TE
M?^&!_P!A7_HBW@/_ ,)S3_\ XQ1_PP/^PK_T1;P'_P"$YI__ ,8KR?\ 5>?_
M #\7W,\+_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG
M-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X
M23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3F
MG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V
M%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?
M\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["
MO_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_
M &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>
M?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/
M_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_
M (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X
M3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?
M^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI
M_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _
M["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K
M_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G
M_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG
M-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X
M23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3F
MG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V
M%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?
M\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["
MO_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_
M &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>
M?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/
M_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_
M (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X
M3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?
M^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI
M_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _
M["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K
M_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G
M_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG
M-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X
M23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3F
MG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V
M%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?
M\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["
MO_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_
M &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>
M?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/
M_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_
M (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _["O_ $1;P'_X
M3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K_25_X8'_ &%?
M^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G_P _%]S#_4FI
M_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG-/\ _C%'_# _
M["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X23_:H_X23_:K
M_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3FG_\ QBC_ %7G
M_P _%]S#_4FI_P _5]S/\VK_ (23_:H_X23_ &J_TE?^&!_V%?\ HBW@/_PG
M-/\ _C%'_# _["O_ $1;P'_X3FG_ /QBC_5>?_/Q?<P_U)J?\_5]S/\ -J_X
M23_:H_X23_:K_25_X8'_ &%?^B+> _\ PG-/_P#C%'_# _["O_1%O ?_ (3F
MG_\ QBC_ %7G_P _%]S#_4FI_P _5]S/\VK_ (23_:KT+X4>#_'GQN^(^C?"
M;X86$FJZ]KURMK9VL75W;DDGHJJH+.QPJJ"Q( )K_13_ .&!_P!A7_HBW@/_
M ,)S3_\ XQ76^!OV1?V3_AAXIM?'/PT^&'A+P[K=CO\ LVH:9HMG:74/FHT;
M[)8HE==R,R-@C*D@\$U4>%W=<TU;T*AP3+F7-45NNAY%^P%^Q)X)_8:^!EK\
M.M%,=]K]_LNM>U0+AKN[QT4GD0Q9*Q+Q@98C<S$_<=%%?64J4*4%3@K)'W="
MA"C3C2I*T5H@HHHK0U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXD'V. &V:.5HS] :UX"_;M^(G[%GQ0\+>-;;Q3'XJ\0^,;==+CM[_2K+6O\
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M-\.ZCJMJ_BB5;G1':)8(]7FG721 +AXK"20Z7:1F4&[>,22,L,BM+)TGA?\
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MIT[Z%I,-A-->K'=31-)EM1@MXXHA(9+EO+1F7<Z^N?M/?\%4_@)^R?\ &O\
MX43\2=-U:;6#:F_4V<:2JUI]AN[I) -X8F6XM5L(8P"\MU/&J C<5 /TWHK\
M@;S_ (*Z^%;5=3NA\-O$/V+3[>WO#?-<6)M8[2XU"XTQ+JZ=)W-I:M/9W)6X
MG58S$BN2H+;/5?VI_P#@J/\ L_\ ['_QB7X-?%NSU-;T:=8ZS+/:QI+'%IUZ
M-17[0PWAMD<]@ML0 6:>[MU4'>< 'Z4T5^$WB_\ X*G_ ![NM+\6+\,_AR]W
M/86R0V@F,,=S9ZSJ&OMX8L-/E@-V4N7?4K2^!G$MO&RJ@PJJ\AN?$[_@LOIV
MF^$M.\2>!O!&HP6]IJ,D/B&ZO);66.S72K6^U?4;:!$N%DN)6TO3)I8IHU,2
M_:+=CNW.J '[FT5^17BC_@K/HG@'5I=+\?\ PP\0Z.=--[%JYEN]-<Z=/IVG
M1:M<I(L=TS.L%I<VOG2Q;XDFF\K>2I-<8G_!;7X+>(_# \3?"WP1XB\31B74
M5E6-K2T$$-@FKW"SS-<3HL<<MGI#WF"?,2&YM=R!YD0@'[445^?_ ,8/V_\
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M6]!N_'^E>&]#UVST.^72]8TS4YK"T$X<ZBS6T O;J:"+4B9HKD1"6*V,;HS
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M\>ZUHGV2^:5=(DMM.?2[2VNCIPOEM((K.%DEN8-,BM%>621+6WFF6WCC)CV
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MPAIOP\^%6LW6F:REUI]M::)87US&T-RR^9&L!$HNY8)95X<O*C$AFSYU<?\
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M'(I(D6=8T9A( ;FN?\$N?V<_$,]FVI7NM>19W^JWZV\<\$<;MJ^K1:Q(C%(
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M/$OPY\,:CKGBW3YM)US4;G2+6:ZU*PN8D@EMKJ5XB\\$D,<<;QR%D9$52"%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_1_OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>moln-20221231_g2.jpg
<TEXT>
begin 644 moln-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH **AN[V'3K22>XFC@AA4L\DC!50#N2> *Y?P_\>_
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MC8RC.-:2<5RI\SNH_P JUT7DM HHHKL.$**** "BBB@ HHHH **** "BBB@
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MF&<DD=/L*N&OAYTI<LCHIU(S5XA1116)H%%%% !1110 4444 %%%% !1110
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M:W9L_HHHK\#?@?\ M)?$S]EW6(;WP7XJU33X(WWR:;+*9]/NO420-E#D9&X
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M9CV_QJQ^QA_P5B\:?L/?$^34/#=E;ZIX5U"1!J^BW<A5=11<X97&?)E )VN
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M5I6'3/E'TY\+!W]JK?UH8\"SK1S_  KH[\Z3]'\7_DMS]>****]L_L(****
M"BBB@ HHHH **** "BBB@ KY[_X*E_%:^^#_ .PKXZU+2[AK74KZWBTJ"08#
M*+F9(9-N>C>4\F".0<$8QD?0E>*_\%#_ (.7/QY_8P\?>';%&DU"33Q?6:*N
MYI9K:1+E(U_VG,6P?[]3/FY7R[GD<01K2RO$1P_QNG.UM[\KM;S['X:^%].V
M1KN 'ZUUD%FKVW0<5R_AN<&-/I766#[XSZ8KYT_BDY#QG:K:PR.VU%52Q8G
M %<1\&?V^_%?[)WQCM?%7P]GAAOK$F*;[6ADMM1@)&^&2,$;HVP.X8$!E*L%
M8;'[4&J/8>%(;2)BKZ@Y5B#_  * 6'XDK^&:^:9HRDQ!%?39+EL906)J=]/D
M?9\-9;R\N/;:DG[MM+6>_P!Y^ZW[/'_!R)\%_B'X=MU\?6/B#X?ZXD?^DJ+1
M]2L';_IE)"#+SUP\2XZ9.,U-\5?^#DGX(>#XYH_#.B^-_&5TH/DO%91V-K(?
M=YG$BC_MD:_#33+=92-U=#9:;$%'R+^5?0PRVC)WM^+/V*GQ=F<J?)>-^]M?
MSM^!^MWA'_@Y^\'WFMQQ^(/A/XFTK3V'SSV&K0WTR?\ ;-TA!_[[K[K_ &7?
MVY_A;^V+X+?6O GBS3]12U0->V<S?9K[3N,D30OAE Y&\90D'#'%?S0ZO9+M
M;@5S5S*UI*QC9XV8%25.,CTI5\MH[)6]-?S?^1IA^,L;0E_M%JB^Y_>E;\#]
MU/\ @H;_ ,%^_!7[,FIW'A7X9V]A\1O&$.4N+M9R='TU_P"ZTB',[CNL9"C/
M+A@5'P%KG_!>[]J+Q%JTUW:^+M&T>WD)*VEGX>LVAB]@9HW<_BQKXLT*R^TS
MY/:NL@M8XX?E Z8K?#8.DEI%?-)_F<&(XBS#%S<U4<%T47;\=W\S]&/V4/\
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M]3:T.;:!6ZLF8ZYC2)O+X[]:VX[C,=:4Y:&U&7ND6JABM<W>LQ:NBNY-T?\
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M &1R3D#G--_X)LZ':>,TO)O$%Y=:*DWF?V>;8+(Z]0C3!^G8D("1Z'FNC_:
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MSM[I5X5G3YA]#U'X5Q\<,BW%=%X># +]:J,Y1?-%V?D73J2A+F@VGW17\0_
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MH *\9_;P_90M/VQ?V=-6\*,T=OK$+#4-$NI"=MM>QA@F['\+JSQMD'"R$@9
MKV:BDTFK,Y<;@Z.+P\\-B%>$TTUY/^M'T/YTO#[/!(89E:.6$F.1",%&'!!]
MZZVR.46LWXP>'I/A_P#M"^.=#FPLNC^(+ZT.!M!V7#J"!Z'&1[&K&DW8:->:
M^>DK2:/XAKTG2JRI/>+:^YV)+^+?%WKG]4T_S0W%=1)'N6J=S8AUZ5)D<6VD
M8FS6AIMI]G_E6T^E+GIW_6H9K/RE/% %BQO1%@'K5[SUG7J#7,7=[]E?/I[U
M/H^O"0[6)^M %[4[/SR2*Y_4M.V[OK75+MG%5;W2PR_A0!P6H6Y3/'-9C,5:
MNJUS3\;L+7+WJ&*7GL: '1MFIEC+"H;7YVK4MK7S * *?V1B>E36L+1-_P#6
MK4BT@NO%6DT+"?=/O0!GB?,>*A:4;O?O4FHVYM:SEN<-UH U+6/>U:EG9;A6
M=HQ\XX]JZC3K3]T/SH KQ:?P.*FBTW<_2M2.R 2IHK8(.: *,&DKW%2-H:R)
M]VK%S?QVR=1Z5&NKKC ;\C0!DW^A! W\\5I?LY:X_@/]J3X<ZM$[(;#Q-ITK
M$'&5%S'N!Y'!7(/(X-0ZEJL8C/->@?\ !/;X-7G[0_[:O@K3K6$R6&A7\>NZ
MI)L)CAMK5UD(?T#N$B'O*/<UI1BW-)=ST<GHU:V/HTJ'Q.44O6Z/W2HHHKZ
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M&,$I5Y[1>R7\TDM;=$KJ[OV9\'>./V+?B]X0L)+^;PR=2AC&Z0:;<)=2KS@
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MT3Q-HT[M''?Z3?17MK(RG# 21LRD@@@@'@BMR@ HHHH **** "BBB@ HHHH
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MX=_"S2]0L?#'@'P7X<LM6C:&^M]+T2VLXKU&&UEE6-%#J0 "&!! Q0!\/_\
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MK?Q9&L6N11:%:HFLHN=JW("8F W-@2;@-Q]30!^-G[1O[-O@?X=_\$(_@_\
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MJPBLK=6/4B.-57)]<5C^*?V<?AYXZ\;Q^)M;\!^"]8\20J(X]6OM$MKB^C4
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MX9T/7/$4AFU74=/TN"VN]3<N7+3RHH>5BS,Q+DDEB>I-4/$_[-/PY\;>-_\
MA)M9^'_@G5O$@C\G^U;W0[6XOMFTIM\YT+[=K,N,XPQ'>@#\=?B7X97XB_\
M!N?X%\1WVE6NK:UX1\026-KJLMJDMYIEBVH3H8EF(WI$6,2D @'"#L,>Q?\
M!1OQ9X(UK_@EOX9L/@K=>$V\"V.O://\2+7P2+='@BFM<E[E(  &:1(@Q<;M
M\<8/W6 _3CPY\&/!_@[X?OX3TCPGX:TOPK(LB/HUGI<$&GNLA)D!@51&0Q)+
M#;R2<U!X ^ ?@7X4:#?:5X6\%^$_#6EZD"+RSTK2+>SM[L$%2)$C15?()'S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>moln-20221231_g3.jpg
<TEXT>
begin 644 moln-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'PK72UUHK6/FW_@EEXMU+PM^UO9Z/!<.MGK=K=6U[$&/ER^5$\J-CU#)P3R
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MWS?\YH\W_.: '44WS?\ .:/-_P YH =13?-_SFCS?\YH =13?-_SFCS?\YH
M=13?-_SFCS?\YH =13?-_P YH\W_ #F@!U%-\W_.:/-_SF@!U%-\W_.:/-_S
MF@!U%-\W_.:/-_SF@!U%-\W_ #FCS?\ .: '44WS?\YH\W_.: '44WS?\YH\
MW_.: '44WS?\YH\W_.: '44WS?\ .:/-_P YH =13?-_SFCS?\YH =13?-_S
MFCS?\YH =13?-_SFCS?\YH =13?-_P YH\W_ #F@!U%-\W_.:/-_SF@!U%-\
MW_.:/-_SF@!U%-\W_.:/-_SF@!U%-\W_ #FCS?\ .: '44WS?\YH\W_.: '4
M4WS?\YH\W_.: '44WS?\YH\W_.: '44WS?\ .:/-_P YH =13?-_SFCS?\YH
M =13?-_SFCS?\YH =13?-_SFCS?\YH =13?-_P YH\W_ #F@!U%-\W_.:/-_
MSF@!U%-\W_.:/-_SF@!U%-\W_.:-] #J* <T4 %%%% !1110 444A;% "T4T
MR8H\W_.: '44WS?\YH\W_.: '44WS?\ .:/-_P YH =13?-_SFCS?\YH =13
M?-_SFCS?\YH =13?-_SFCS?\YH =13?-_P YH\W_ #F@!U%-\W_.:/-_SF@!
MU%-\W_.:/-_SF@!U%-\W_.:/-_SF@!U%-\W_ #FCS?\ .: '44WS?\YH\W_.
M: '44WS?\YH\W_.: '44WS?\YH\W_.: '44WS?\ .:/-_P YH =13?-_SFCS
M?\YH =13?-_SFCS?\YH =13?-_SFCS?\YH =13?-_P YH\W_ #F@!U%-\W_.
M:/-_SF@!U%-\W_.:/-_SF@!U%-\W_.:/-_SF@!U%-\W_ #FCS?\ .: '44WS
M?\YH\W_.: '44WS?\YH\W_.: '44WS?\YH\W_.: '44WS?\ .:/-_P YH =1
M3?-_SFCS?\YH =13?-_SFCS?\YH =13?-_SFCS?\YH =13?-_P YH\W_ #F@
M!U%-\W_.:/-_SF@!U%-\W_.:/-_SF@!U%-\W_.:/-_SF@!U%-\W_ #FCS?\
M.: '44WS?\YH\W_.: '44WS?\YH\W_.: '44WS?\YH\W_.: '44WS?\ .:/-
M_P YH =13?-_SFCS?\YH =13?-_SFCS?\YH =13?-_SFCS?\YH =13?-_P Y
MH\W_ #F@!U%-\W_.:/-_SF@!U%-WTX'- !1110 4444 %%%% !1110 5'))B
MG2-BO'_V[/B?K'P>_8Q^+GBOP[>_V=X@\,>"]9U;3+KRDE^S74%C-+#)LD5D
M;:Z*=K*5.,$$$BJIQ<Y**ZETZ;G-06[=OO/5+C45B'6J,WB!$/WA7\O&H?\
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M=H[G_CTKTNS_ ."Y7[5'V9?,^*CL^!N/_".Z3R?_  %K;#<*XNNWR2CIYO\
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MW_D=RX(Q[UYH?>__ )$_IW_X2B/^_1_PE$?]^OY7_B'_ ,'#'[6>E7*0Z?\
M%XJW\9'AK1FQ^=H:YO\ XB)OVR/^BQ-_X2VB_P#R'7FU\IJTI\CDGZ-_Y'Q>
M85(82NZ$FI-=8ZK\;']8G_"41_WZ/^$HC_OU_)V?^#B?]LC_ *+$W_A+:+_\
MAT?\1$W[9'_18F_\);1/_D.L?J%3NOZ^1Q?VC2[/\/\ ,_K$_P"$HC_OT?\
M"41_WZ_DY_XB)_VR/^BR-_X2VB__ "'2_P#$1+^V1_T6-O\ PEM$_P#D.CZA
M4[K^OD']HT^S_KYG]8O_  E$?]^C_A*(_P"_7\G)_P"#B7]LG_HLC_\ A+:)
M_P#(=!_X.*?VR!_S6)__  E=%_\ D.CZA4[K^OD/^T*?9_U\S^L;_A*(_P"_
M1_PE$?\ ?K^3C_B(H_;(_P"BR/\ ^$MHG_R'1_Q$4?MD?]%D?_PEM$_^0Z/J
M%3NOZ^0?VA3[/^OF?UC_ /"41_WZ/^$HC_OU_)Q_Q$4?MD?]%D?_ ,);1/\
MY#I/^(BC]LG_ *+(W_A*Z)_\AT?4*G=?U\@_M"GV?]?,_K(_X2B/^_1_PE$?
M]^OY.?\ B(I_;(_Z+&W_ (2VB?\ R'2?\1%/[9 _YK&W_A+:)_\ (=+ZC4[K
M^OD+^T*?9_A_F?UC_P#"41_WZ/\ A*(_[]?R<_\ $13^V1_T6-O_  EM$_\
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MC_OU_,!JW_!?C]JNU/R?%AE_[EO2/_D6L:S_ .#@/]KG5M<CM;?XM/@M\_\
MQ3.C<#_P$J:F#E%V;5_Z\C&IX?9A"2BZD+O3>7_R)_4Q_P )1'_?H_X2B/\
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M;]9:>ONG]1G_  E$?]^C_A*(_P"_7\Q>I?\ !?3]J.RBW?\ "UV7_N7-(_\
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MU\6%MK5028_^$<T<N_I_RZ<?GFERJ]N9?Y>I7^H..OR^UIW]9:>ON:']2_\
MPE$?]^C_ (2B/^_7\MMS_P '!'[6^KH_]F_%)HU3@RR^&]'5?UM"3^54Y/\
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M/^"\G[4\<T2P_%F0EA\P_P"$;T@_^VM:1PDWV+EX6YJE=U*?_@4O_D#^F_\
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M4[K^OD'UR'F?UF?\)1'_ 'Z/^$HC_OU_)G_Q$7?ME?\ 19&_\)71/_D.AO\
M@XM_;* _Y+(W_A*Z)_\ (='U*?=?U\A?7(=F?UF?\)1'_?H_X2B/^_7\E_\
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MD2%T#.V%!9<D9%>8^*O%$9(3<J[SR<]!7]#7[*7[*WPG_8&_X*A?'+P/X3\
MOK6B^+/@/)XTT^Y7Q5<S16-B]RD-WHD!VEIHKATBE2[8F6-8@HW;V(^1_P#@
MG'_P2Q_9R_:A^%OQ>^/7BOP)X1T;PKI?B>/2=#\#^,?BA?Z!HF@6SP02^9<:
MNL,ES)GST$6Y0'*L#G((QJYU.I3?LH/E7+9O2]^G]:>>QRUN(*E6E)T*;4(J
M-F]&^;2WS[[;Z['X]ZA\0TO9Q;6_*_=+X^51ZUV'B+P[XH^&OPAT'QAJ'A/Q
M-8^#_$TDT&CZ[<Z7/%INKRQ.R3+;W#*(I61T=6",2I4@X(-?K_8_\$9?V8]
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M*D_']/VG;_XU?\+.UW_A8EU;G3GU4QP-&]H&W?9OLYC^S^0'^81>7L# $*"
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MYA"<^1&M7+YQASL^AO!6I6>H6O*@,HXP.M,^.'Q*A\"_#*XU2X5L68+@ <G
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M?B-XHT33$\$G^RI+[[3>P->EA_J9(%V^:G^OVJ=W?!Q^='B+QVN=L?S2.<
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MO9?E&>I8G_ 5:;Q(VOQ?8='MXY6A4!F+;8XAT )Y_+DUS_B&TNM/\Q9KC<^
MNR!.3[ _UQ^5<E:HX7J4Y-KNK6]%_39QUZCIWJ4I-I[M6LO)-Z?FS-O+V3[:
MRW5^S;>=L0P"?Y_CQ^%6(M>F^QK;V]PMMN_A1<L.>I)X'XY-1PS7+3HO]GS
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M-N33R :0CW]JD+C<5Z3^QNN/VK/AY_V'[3_T:*\VKTK]CC_DZSX>?]A^T_\
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MC?GRXRW/]YC5^71H=.3Y[AE:3DC=UK2G0>[6GG_P32CAVU>2T\_^#_P"$Z1
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M5Z1^QTF/VJOA[_V'K3_T:M95?A?H73?OKU/Z"/V??OP_A7VY\%?^/>*OB/\
M9]^_#^%?;GP5_P"/>*OFSZ4]Y\/?ZE?I6VG2L3P]_J5^E;:=* '4444 %%%%
M !1110!6OO\ 5M7S!_P5.C\__@GY\=(\XW_#_7ESZ9TZ>OI^^_U;5\N_\%4[
MC[)_P3W^.TS'"Q_#W7W)],:;<&M:%O:QOW7YFV&M[:%^Z_,_D*\1>$HBH\R1
MGR< 9K[G_P""&_A.WT'_ (*0_ TQQJC?\)#"3@<_<>OC+P9"?%^MK/,K?8K?
MY@6X#GM7MOPD^/.N?LZ_$?1/&7A#5%T?Q)X;N%N].N_(BG^S2J" VR561NIX
M92*_5<+@Z=2G5J127,FDWZ;^A^V8++Z56E6JP27-%Q3?FM_0_03_ (*:?$6W
M7]JB^\/Z)^U]\2OB3_;OQ3-AKGPWD@US2[#PW NI/)Y23R7!@E%M-''&GDJN
M"J2)MVC'L?QNNOAK^SA\//\ @H$?'7A'Q%\2_ OAWQUX2$VA7GBV]2\U5F2+
MRUFU.9IKK:)&#%MS.0@4$#I^,/Q/_::UK7_C'>^/=0UA9O%NH:Q)K]Q?>1$O
MF7SSF=I?+51&,RDMM"A>V .*]D^$/_!8;]JCX7_%GQQ\0=!^*5YH?B#XDSPW
M6OR_V%I<T>IR11B.*0P2VS0QLJ#&8T0XSG.37DXO"S?+1HOF<4K]-;Q>\4K;
M63M<\/'8*H^2AAY<SBE?51U4HO>*5M$TG;F]3[R\)?\ !,?]G/Q!^UGX;U?5
MOA[XJT7X=^/O@)JGQ-E\!7FL7:ZEX5N[66!<Q7)=)9%9'8QB?<I8,6!4A5\(
M^&W[.7[*?BS]F_XF?M7ZG^SSKVI^"?"^MV/@O2_A58^/-1DAM9V@26;6+_4L
M?:520R*B*JB-70KM?<&7YHM?^"C7QLN/CIXK^)5Y\0-2U+QQXRT&X\,:OJE]
M;6UTT^F3X$EHD<D;1P1G P(538<E=I))P?V8_P#@H)\6OV"_$]]K'PD\<:AX
M0U#6(UM[M(H8;JVO0N=GF6\Z20NR[FVLR%EW-@C)SA+*ZTJ;EB)<STLKNVCU
M7J^^K.>IDU>5)RQ4^9Z67-*VCU5^[T7-9L_5S]CK]BOX5?LX_MW^ _B!X&\-
M^*/!_@;XR?!;Q!X@N/!>J7)FU'PZJPA)88IY,NT3H08VEW,<%B2"%7R[]G?]
MEGX#_$O2_P!E_P#:+^$_PLUKX&ZA8?'W0/!L^C7WB"YUNU\4Q&YBE^V03W"J
MQD1D96$:K&"DPP2H(^%;_P#X*V?&[P]^TTWQH;XG:G)\47MC9C6)H+:;9 >L
M"6[1F!(>I\M8P@)/&2<YOQM_X*V_M,?M&_%WP=X\\7>.]<UW7OA[J$.K^&3+
M8V=O9Z;>1.KI<+:)$EN7#(O+QDL 0<@D'*M@YQDDFF[*]FVUOI9+7=*[UTV.
M?$8"<9I*2;LD[.3:^+1I+71I<SUTO:[/U:^'7[ /PK^-G[3'QX\4?%OX?_#[
M5$\6?'+7?#V@ZKXO^*UUX16\ O7$D&GVUK%(UU=*Y;"2%0Y( (VDGR+X*_\
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M %>.3?MJ^'8X?W>FZS*_HR1J/SWG^5<MXH_;8U&[C9='T>UL2>/-N93.WU
M4 _7(HEB*2ZD5,\P4%?GOZ79]%:OKUGX7T6XU#4+B.ULK5=\LK]%'\R3P !R
M37EVM_MJ^%;%BMI;ZM??[20JBG_OI@?TKYT\:?$WQ!\0G!UC5+J\C5MR1$[8
M4/J$7"CZXS6!LKEJ8Z6U/0\'%\35)2MAU9>>YZI\8_VI]2^)6C2:796G]DZ;
M,<3GS?,FN!_=)P JGN #GUQFO)]N:DV9I-N:X:DY3=Y'S^(Q=6O/GJN[&;#2
M[#3]AHV\UG8PYB/91MJ3;Z4FVDT%V1G@TUES4C#-'ETN4:(]OTH*U)LH\OFC
ME'S$>RFE.:FV\TWI4C4B$C'^--J0IDTW907<;05S3BF:;4\H[C6XIN,U)2%*
MFQ5QE(?2EH*^M38HC/6F[*D9<4VD5$8R[:2G%,FC:%J'8H:PS32N*>3S2,N1
M4C1'FFEO_P!=.*TF/PI6-- ^;VIA&*D--;%0Q#::4YIY&%S3,DFIL7$3;[BC
M8:7/^]3HH7N)0J*69N@ I<K&1D8K?^'7@N^\9>(H8;,,C*P)D ^X*Z#X=? K
M5?%6JVK7-K+#8NP+R,.-M?0?AKPGI?P_D\BQLU1E4;BJ_-(?K7J8'+)5&IU-
M(GS.<<24L-%TZ'O3M\EZGLW[(J&S^+N@V[RB66."16/<XB:OU$_9Z^_#^%?E
M3^Q^\C_M":;(ZL/,2;&.B_NFK]5OV>OOP_A7B\4)+%JW\J_-GTO!>-JXG+^>
ML[M2:O\ )?YGVI\'/^/:+Z"O:M$_U:_2O%?@Y_Q[1?05[5HG^K7Z5\X?6FJG
MW:6D3[M+0 5#=?<-35#=?<- '$^.O^/5OI7\=FI>+(+6+_6*./6O[$_'7_'J
MWTK^-'4OAO;^;NDDF;VW5K3G5C%^R5S]@\*IUXQQ?L$F_P!WN[?SF3J/BN35
M[GR;7YV8]>P'K5JU\-QI&&E422MRS$=ZMVNF0Z<5CC15V'C'I5V5MJUS1HN3
MYJKN_P $?JM'#RE>>(:;_!&'<:7&\@RH^7BJNI6L%M:L=QX' S3M<U=X[KRX
M4:1F].U3:+X;FU"1;BX;/=4'05RRM.3A!:G+)QJ5'2I1N^KMHOG^A@QZC]F3
M;;PY8]3MR:FT/4OL]WY\V[?R!D< 5U5UHHC7H/\ "FZ'IJSRLN!UHIX.HII7
M_ RIY;6C55Y^BM9%&?QPD,) ;)QP .M95GJ3>(M1V3MY4(Y8=&;VKM;OP\OE
M?=7\JYO5_#_[U64[64\$>E=5:C75G)W78VQF%Q7,G*5XKI:U_G<[+2KJ&&SC
M5-JQHH  ["J>OZW#:PMN=1QW-<K,UU96K8E'RCTJU9^"U=!=:A(TTN,A#PJ?
MA7=]:J27)"/^2.JIC:TX^SI0U\W9+^O0CTS6;<W;74VU8T&(\_Q'N:AO/&$W
MB#4ELK)?]8V-^WA1W-5?$*I*ZP08$C]Q_"*UO _V?2!LV@2$Y=CU8URTZE24
M_9)V75_H>2I5ZE18=2M'>4N_DOZT]2:W\&Z@D.U;SRXV.6VQY9C]36MX,L+/
MPS,S!/\ 27&UY9#ES_@/I6G_ &W!'%U7\ZY3Q#KRZK>+:V:M-<,WRJAZ?X5Z
M,HT:%JD=7TZ_<>M4I8;"M55JUM?7[M]?0[Z3Q)"J?ZQ*Y?Q-XV21Q#;G[1,W
M 2,;F_(58T/X;-/IRK?.TTS$EMKL /;\*T4^'4.DQ[K55@?U5>OU]:Z:CQ56
M.BLOQ_KYGI5(XZM37*E%/YO[MOQ+G@3P\NC:=]HN/^/ZZ :7G.ST7\/YYJ]J
M]\L:GYATKF]0U6_T9"/+\[;W5NOYURGB#Q7J&HR+"H%NS\!?O.WT'_UZBICH
M4*?(DRJV8T\+1]FHO3RW?Y:ESQ'=Q:K(T+,?+SN?:<8_&K7A6Q@AM&D"JJDX
M7Z#_ ":Y)].NHBJRLOE@[F4$_.?<UIZ0VH>)I/)MV6"W4[6E/_LH[_RKQJ>(
MO5YG'7HNIX-+&7J\\X/F>B75_P# 7G8TO$%U)=GR;./[1+_=4]![FD;P?(UI
MYEY)YDQY(7A4]A_C_*NN\->$[;0+7;"N6;[[L<LY]S_D4WQ#*EO:M7J?4KQ]
MI5W[=$>Q_9[<?:UWK;;HO\_ZL<+I'@UFN9!#-)&%;C'05/JWA"8KMGNYY%]!
MA178>!],^T6$ETWW97)7Z#C_ !IOBM5AB_A[UC_9]-4>8RCE=)8?F:T?K8Y*
M3P@MO9#;<W 0#[H( Q^5:$7ANSL;!2L*;L9W'DG\:2[U"-+*&%F"EU //2JF
MK^+8;H>3 V47Y<C^(^@KCE&A3UT,N7#4O>=KVT_X NGZS;Z/:/LW3W$AY"+N
M^@ING^*?(N&;R'DOIOE2,#[@]/\ $TXZW8^'M,\M2LEQ(<L%(Z__ %JS]*U"
MYN9II[>%67/+9P3C\*YI5'%J*EKV2V_X)$J\HRC",]>R5[?\$U(]8OM)+W$]
MNTEPPQ@8VH/3-6]!UFW^T"^NI$FNN2JJ?EB[<>I]_P!*YZZU*YU*XV20W$_E
MC=Y*+C/N3W'L*T-"U^TTJ.228@7$GW^VT#H!11Q"]I;FT7?\QT,='VW+SZ1[
M]^_K_5D7O$'C5=0NEC^:*'^)V7&?85GR:I%XCNUA93%:Q_>)^4G'0#_&JFJ>
M)K?4]15I-T<</.&&"Q[4R"\BU^]5BH6&,]_XZB6(<Y6YD[O[_P#@$RQKJSLI
MJ5W]Z_1?F:^JW%F8A;VJQ^<^ H3&<^M:-MX8LS9K]KFED;'S?O2JD_ABN;U5
M;>Q=3;E89"<87H:JWMY)<)Y?VIY#CHORJ/K_ )%5+$1BVYQ3_(V^M1A)^TBI
M>73^OD+XKGAN+U4MP!Y0VH%' %4(Q*LN?E5E'WF.XC^E.DTSR/G:=MQZT"R$
MN&B1I,'[Y/!->;+FE-MH\>KSU*CG)6?:_P#E<L0P23INEFVJOW0 !_C4B>'Q
MY'G;Y-V=P+'BH;:QGEG+,0P7D C[M27#7%Y)Y(8MZJ!P/J:[:*37O)E6CRWG
M%^0%9IOE::215Y*I@?G3XO,MU-PL:+Z;CDU''I,@@,?F;=S8P.]7_P"R?[)6
M.9G\SR^S'BO0HTI/6QFHROS6MYDEK=M#"9/)DEF<<G;@"JC6UQ?/G*L6." .
M!6@]_/J-JWDQK$N/O.?Z572RO-,1#YT>YAA5V_=KIJ0O9:M'1*[MNU]P)H4P
MFXDVJHR>.*['X8?"^\^(MTS0!IEMF'FS-Q'#_B?;^58.B:??:U?V-C#Y9>^N
M$@3)^\SL%!/MDU];:#X8M?@_X/M-"LU$DTS9EE PTKG&YS^7X# [4J<$FE%?
M>?+\5\1QRC#KV*_>2VOLO/\ R+'PD\+?\(E;QV]K&RV\*[<L/F?G+,?<FO>/
M <"W$\<[+UZ#L*XKP3H$U[IRR-'L1N>>N*[WPKJ<=E=K!MXCX!KU,+AE _G7
M,,RJXFHZE1W;W.LD90OS<#TIVE1QW#';MW>U4-4N&*\=Z;X1\S^TE9N$Y%>G
M'1V/%=V=+8V6R<,36_<1K+I$T3 2><A0*?4UC7^ZWF6./Y@XR#Z5<-A-$(V\
MPLJC/%;>ADMSE?CM\+Y-<^%&I1Z?(\-U%!YKH@!^TJF&*'ZX[8Y [9%?(<<-
M>_?&?]IAXI=6\/:?"WF;&M);AI  F1AMH'.<$C/&#7ACO':P[GD2-?4G%>?B
M:,M['Z_P;&K0PS]MHGJON*[/LJAJVIB"-N>U4_$'Q$T;1(F\R^A8CLC!C7G/
MB/XSQZWJ*V>EQLS2,%#MZUPU*?)!R?34^NJ9SAZ6CEJ^BU9Z)H=S>QR?:A^[
MCSA01]ZOH?X5>))I='A=KC9A<$[N!["OFZ,ZUJGDPF$+M4 D=*]9^'FD7&FZ
M/")G+%1D@'@5_.N=\68_$2<>>T6]$MM/S/U;+\DPDHWG&[MJV?1.D^*+:PT:
M2/SO,,O+$FO,=<@@.IR31XW,3WS6?8ZVUN7\W=M[<]*MVKPSV_F'^+GFOB95
M9SFW4>K/JZ=&E1I*%):(QM3M5DEW$=ZJ:QK+6\*)'MW8Q6O>VJRDM&P]0#7(
MZ_(;>^ 8YW<"MZ<8[MGCXN4ELADWB*]M8_NYSTXJUHNI?:/WL\G[W/W3VJ*6
MY2TM/WB\8Z^E>"_&S]HYO!FO-9V"^9,@&6SP*]+*<GQ&8XA8?!QYI[^27>Y\
MEGF<4,MH/$8M\L=O._:QW'[4GQ+F^&FDVM]:[?.F8IS]*^.?&7B>Y\::_<:A
M=,&FN&W' Q72?$WXNZI\4?)6^;"0DE5!KD?(P*_I'@KA=93A5*O%>V=[M:Z7
MT1_,/&_$\\WQ;5!OV*M9/36VK*HCYI&&T=>:GD0@U#Y?-?<)'Q<8V&,/SI%7
M-2;<#_ZU(PVFI 9MP*;UIY&:3;W[5+10Q(][ >O%?2O[.G[(EEXKT.QUG4+N
M2.1I ZHIP" :\,^&_@"\^(?B2.QLPN_&YF/10*^MO NIW7PXTFSTV3]X(5"D
MBOB>+\VJ4*2HX:=IO?O8^5XFS"M2IJEA96EU[V/:K:&WT$0P1W';: 3VK;.A
M)=6X;S@<C)->,ZMXCF6XCN@^=O8GM76>$?BG#.$A8DAAZ]*_':E&6]S\_I9;
M)N\7YGH%NL>EP,F/,&,[J+.?[8C-_=&:HV>O0S((UYW\$^E=3X;T9;E-FY>1
M7*U;5GTF"P:6Z,.UU_\ <7",GRA3\V*\N^*UVL=I]J7_ %*HP<U[\WPTN[O1
MI(X8=PF.T$#KS5[5_P!DS[1X*\G4%5%F7.-O->[D^2XC&5H^QBWKKY'UN7Y3
M3K5X^S5]KGY<6'PUN_B!XODMK.&1EFE8[@O &:^E_A%\ ['X::+'^YW7C?,[
MMUS7L5I\&M+^&0:.TAC#]"V.35'5'CBW$L.E?T5EN!5&*<M6?K.(PZC&R.=D
M@\JJ\K[0U2:IKD-OUYK)D\4H#\M>_3DCYG&*Q=$S$_Q#\*CU+0K3Q%9M;WD"
M31OU#"JG_"1!AD?J:7^W,C_Z]=$>6VIX=1ML\J^)7[&.A^(9I+FPW6LK#[H;
MC->'^.?V4]:\+(9(8Y+B//\ ",U]A/KG'_UZKW6JK,GS -Z@UPU\!0J:VLR8
M\R/SYU31KC1KEH;B)XG4X(88KT3]C2SDNOVI_ +1JS+'KMJS''0"05[%\<_@
M[;^-+6:>T5$N&Y^[5O\ 8R^"<G@SXO>'[JZVF1=1A9>.GS"O"K9;/WDMDF[_
M ".?$9E3PTH*6\FDOFTC]D_V??OP_A7VY\%?^/>*OB/]GW[\/X5]N?!7_CWB
MKX@^Z/>?#W^I7Z5MITK$\/?ZE?I6VG2@!U%%% !1110 4444 5K[_5M7RY_P
M57A6X_X)Y_'B-_N2?#S7U;Z'3;C-?4=]_JVKY<_X*L6;ZC_P3R^/%O$VV2?X
M>>((T;T)TVX /ZUI1_B1ZZK\S;#_ ,6.E]5I\S^1=?%<VFO':VL:R.YV(B]:
M]B_9L_92\0_M5?'KP3X#L]26QN/&6L6FEF14W-;+-*JO)R0/D4LW_ :\W\&^
M#O\ A Y&FF1KB5A@S'YB/IZ5]8_\$F?C-H_P^_X*0_!74]6N$M[%?%5G;R2R
M#Y8S,_DJQ] &D!ST'7M7ZI3ISCAIRKOWK.T;[:?B?M5.C..$J3Q#M+E;4;[6
M6FJW/7_!G_!#+X)^*/BI^TMKDOQF\1>!?AG^S]X@M]%.I:_X?/B2[GWR26SR
M.+4VW_+S$P4)"WRR+G[I9O-[+_@GYX ^/'[:7P]^$WP5^-L?Q,T[Q<K2:OXC
MD\'7FB1>&XHM[SN\%Q)F41V\;29#HI.%W*3FOK_P7^U[X5_X)_\ @[_@HA9>
M+'^%^L^+K;QM:MH_@[QRT%U!XI7^U+K)6Q:5)+I5BE2;"$[#L8XQ7BG["?[>
M'PO\,^"/VB_VGO'G@3X9VNO>++*S^'F@?"SP=JG_  B"SV5U#%'J5W:PQO+<
MVJ&%(V^TQJ29&G"NA8E?%CC'1YZ>';>W*ERZMQCJ]+O5MW<K=#YV&.EA_:4<
M*V]E%+EU;C'5Z<SU;=W*W0^:?VBO^"?MQ\ ?^"E_@C]GT>+XM:TOXF:GH$7A
M_P 86^F8AU#3M6>&.+4$MO..51I)!L\T;C"WS $$>T?M*_\ !"/PG\.?#?Q<
MO? /[1EC\5?%'P#0W?C;PH?!UUX=O+*U239,T%Q++/%,R@.2R!D4+U)*@^[:
MO^U'^S_^UQX+_9!^*OAU?"GP8U3X#?$[2/!EYX0UCQNNH7EIX=2\M;B*\\^[
MV3R6MN01O(VQ"24%L1Y7Q?\ X*W_ /!:S7/B-\9/CG\)?A7I?P5T7P3XJUN6
MRU?Q?X-T:+^TO&=C'(3&UWJ"RR+<!B2=\84MEAG:S \?ML34E&-26O;1:IK?
M>]UKI8X?K&+JRA&K+7MHM5)7O:][K7W6E\D>&_\ !1C_ ()Q^$_V&OVJX=/\
M+ZAKVO>#O$GA_3?%?AB]UV2*2^:RNX W[TQ(D9994F7*HHPH[Y-<O\0?V+_C
M%X%\+:MKFK?"7XF:7H>@QK)J>H7?A:^AM=.1E5U::5H@L8*NC L1D.I[BOI'
M_@X(\?VO@7XZ_!?X?[;F;Q!\._@UX:\/ZK;K$3-%=K'-+Y93J&\N6,X//S5]
MM^*/^"B2^)/^"QGB#1]0^-OA^3]GR3X22Z4EC)XIMV\-WE[)IBLR%?,^S-<>
M<SIDYE)^3IQ7H4<<Z.%A'#0YG9N7RMNUU:/5H9C*A@J<,)34I--R?I;5M=6N
MY^(_@S]E/XQ_%OP'>>,= ^&/CZ^\ 6;2F?Q+9^'KNYTV,1_ZS,Z1F)=O<EAC
MO7O7_#F?QI/_ ,$U[']H;2]%\8:Q/=>(I=-DT2'PG<S/%I,=D]RVN&Y5C_HH
M9#&6\H1@\^9QMK];/^"0W[2'P%^!O[,_P*%]\</"ZQZ=ITZ:S;^)/C-J&BW.
M@7\S2E[-/#BJME<VBR2-B>Y90H;>"V$Q\P^!?C_:_M/_ /!+OXA?!WPS^U#X
M0^$7B'PA\4=2O8[?Q#XWFTF#5?"+V4L0L++RF9KBV9W;%M&IC)7D#>N[AEB9
M\TE):J2U:Z.^B739>9YDL54YI*<=8R2O);IMJR5M-EKOJ?F;H7['?Q NM8\+
MZ/'X%\;0^(?&FGQ:IH.GIHES]KUVTE5FBN+6+9NGB=4<J\896"-@G!J/2_V$
M?C1\54@_X1_X:_%#7K&ZNI[03:;X9O;B-GMV N4W1QD;HLX<9RAZXK]E_P!G
M[XC? WXI?'C]C7XYWW[1WP7\%Z-\)?AUI?@S6/#FOZ_%8Z\-2M(+F':+=R L
M!><YF=E4*@(W!ACP;XB?ML:C\/?^"6NC^'_ 'Q070]9USXK>)[O5M/T#7DBU
M&XTZ2:0P/*(7\U;>3<2.B2 C.<8KOC4^L3CA:4==%+=);WO\DO6YZ4*WUNI#
M!48:Z*7Q)+65[V\DO6Y\#^'_ -BOXI_#GX1GQI9?#7QTW@=H_M3:[_8%V--V
M'_EI]J\ORBON6Q7H7[5?[/2_LQ?LN_ KXD3^(_[4_P"%U:7J.I#3CI_V8Z-]
MDN$@V>9YC>=NWYSLCVXQ@]:_;+]F;]HSX"?#W]G;P[I?_"Y?!^J:'<?#A]'B
M?7_BY>K>&X^R$26DWAZ14LK=1AD25V$F J@'()_);_@IK\7?"?BW_@GO^QWH
MND>(=!UC6O#.@:Y;ZMIUE?17%UI4DM]"T:7$2,6A9P"5#@%@"1FNNCF%=25*
MDO9Q3MMI;EE]VJ\O1'?A\TQ,9JC1BZ<(RMJM+<LFO-6<5U3OI9=?DF'X3_%K
MXK_#:Z\:>&?ACX\U3P'I^\7OB>WT"[FTBT"'#[[E8S$NWOE@ >"17L/QY_X)
M-ZU\,/!'PEU;PZ^O?$B]^)WP[A^(E[:Z5H,WFZ!;,?WHD,3REXH^-TQ$:C(R
MJU^@7[4'QVF^.7P1\+^-/@U^V5\/_@G\-]#^&JZ%/\,KKQ#-I6JV-XEDT,MH
MFF6ZL;II)&VBX56=,[XM^T&N@^"7[6_PAT'Q9^SOX=UOXH>"=%BUS]F.?X>W
M>J3:K"]EX?U:X";8;]U8BU(V-GS=I!P#C.:\WZU6G+VE?WK7NK/33;;?TN>1
M]<Q$Y>VQ/OVO>+3TT>C36^G2_P#G^*7BK]GCQ)HW@71_$5KX.\1MX?U[5/['
MTS5$TR=K34K[_GUAGV[9)NG[M26'I7K_ ,)_^"6GQ<\1_&3P-X-\3_"WXF>&
M[OQOJ4-E9S:GX1OE;RV.Z6>.*1$\Q881)*V" $B8EE +#](= U_P7^QM^SC^
MRGX2T']H/]GWQ5XN\!_&:ZU_5=4M-7;5-!TJ&6SE4N_E@320E'""=41!+(!O
M786%_P#X*H_MF>!_A[XA^ OCS1/CC:K\2?#_ ,1_[4U;2O /Q?U7QYHD&BSJ
M!?W0N)HTDLY'5!"+*+$0AED558.YKG>*M7;A3]UWMIII>SM]QR2QEL2W3I+E
M=^7332]G;ST^1^<?[=7_  3P\??L.?M6ZE\,(=&\8:^9-0DL_#5\?#5S:'Q8
MJ;09+.'Y_-7<P&(GDP>_->2>.?V6?C3I7Q*TGP;K7PR^)VC>)M</_$NT&\\-
M7EGJNK>T%L\8ED'!Y137[67/[3OPZ^$'_!7+QA\3O%/[47PQ\?>'?BQX<US1
MOAM=Q>++[7+;X7RW"6;1_:8[>2/^SXI2D\9-O/%(-H.^,N2F)JW[9 \+_M9?
MLI:'\3OC;^RWXJTWPMX[N]<?4_!_BW7/$4F@6[6LD>^[UW5[VX189&<[H'9&
M1H8"I9<A<O[0K5(*+VMK:^NC?_#K^GE_:F(K04'MRW=KJ[LW^FJ_3?\ '/XG
M_LS_ !(^#&BZ'<^-_!?B3PCINKH[Z9'J>DW-A'J*1E0YB>9%$@4LH;9G!89(
MR,\KJ/CZ\/\ HZK;VL:C:68DE1[*/\17LW_!1?\ ;D\6?M4?M)>+;[Q)XTUC
MQ=9V>N7\6D7%[?M<6-E:&X;:MHNXHD)54($0"MP?>O$?#5S9ZWJ,3[\VMN<E
MG&&F;Z>F>?PKVZ56]J=.?O/?7^G9>5O(^BHUKVITIVD[7L_^&=EUM9=B+3&^
MVS>2RW$,,GS274Z;6D] @/\ ^H>]=/J/CO3_  [I26\)#,JA(XU.68]!47B?
MQ'8R*MO"!/,_(1!G ]3Z#WKBKS3"BM)(?.F9B4A7Y549_7\:VJ5I8=.-)J3[
M]OZ^_N=%2M/")QH-2?5]O+^KN^YT%C\0)++SFCM6GO)L90'"Q#G&2?Q_^O61
M/)>>(%N));S[.K'!,0Y([@$_X533PGJ%S;M()8[>)_X(5Y_.H;73EMW\N:>2
M=@0L<6?E+>X_QXKSYXBO.T:J=O6WY:_UL>74Q.(G:-9/E];+\-?ZV1$FB->E
MEM_.=(05,S$!>G3.,D^N"*]R_9O^"VF>(-'BU:Z62ZGF!4J3MC3:2" !VR.Y
M->>VHCM],M-,MU\Z^NF$4<:#F21SPH_$U]9_!GX>_P#"O_ ^GZ;)L:X@BS.R
M_=,C$LV/;<3^%73P<85$T];7?EV1XN<4UAE#V4_?>KL]M-C7T+P=#;6\<<:*
MD<8"JJK@*/0"NJTO0DM^@IMC&$4=*UK1@!7JTZ:1\YOJ36UBH45.MH!1 ]3Y
MXS71%%D/E #WJ:W4>E1L:(WP:: TH4#U1\5>%[?Q5X=OM,N<_9]0MY+:7'7:
MZE3C\#5JSD^:K$KY&:U230+1W/S3U**UT/5+JRBC:.:QE:"3"%I&=20P'?@C
MKTS4<4_F(O\ H<D-OGYI<?,QKU+]J?P3J7A#XOZQ';PP!-;E^VV\GJLF2>/4
M.']*\_,UWH[)'=>3)Y(XBC[GH,DUY_LVGKMY+3^O0_3\+^]I1J=&D]%IKT_X
M8I27UK>W6SR9U7.,OGCWK13PY;ZK/&L)FMXVZMG!<4DMMJ%W"LS?9X8Y"2/[
MQI+AUM[509FDE9OF/H/:MHQ6\U^AVQBM?:*Z]+$AT6'3M0\FU>68[L<GBKUZ
MSN%B\N/Y!VY-9]K)&+I5174OP#FM.!$TK?NFW;N3CDUM32M9:(Z*<4TU'1$%
MM:AT\EE;!Y-.MXUM+M8]NT*01FKEAOO;@^7]U1G /)JWJ,T<<?F,BJJCH?:M
MXTURW-*DJ=*DZLW9(9J-R'??(R_NQ\M<GK^L?:[AEC^[TSZTFK:S)J4I_AC'
M&*HXQ7G8K%.?NQV/P'C+CJ>.F\/A=(=^Y!MYI=M3$9I-OO7 ?FG-?5D.*7;4
MFRDV?YS2Y0YB/;01MJ39\M&*.5AS$=&VI*3:*GE8<PSI0%_SBI,48Q4M!<C(
MVT,.*<_WJ3'^<T<HR/92[*=CBBG8KF8W91LIV*1NE3:X<S&'I3=O-2%*38:4
MD5<9MIC* ?Z5*U-,=9\I29"PS05J1EPM1MUHL4F,(I ,T_%(6J6C0:5IA'.*
M>1@T$X%9L"/92,N:>1N/2FD<_2I9H1T$9IQ(Q3:EE7&[,4E/Q28"TF41.<"F
MU(W--)]JFQ28VBB@BE*)04S9BGFM;PWX%U'Q1.J6MNS;N]*-.4G:*U)J584X
M\TW9&/'"9G"KR6XKU7X3_"1H'CU"\7*G&U2.M=S\+/V9EL-*2]U".,S*=VT\
M]*[N6SC6W\G]VA0\ ?PBO=P>5./[RK\CX?..)XSO0PVVS9>TN6"RTJ%/EC55
M' '04RZU>%,N,9QU/)-<[XJE;^S&2S9F9#R1WJFBRC1_WTGE[AR<_,U>O*LT
M^5'Q\<*I+G;W9ZU^Q?XFDU[]HO21\L<"+<*BC^(B)Z_6;]GK[\/X5^.O[!&F
MSVG[3>CM,^8VBN1"N<\>4_)K]BOV>OOP_A7YWQ')RQ*<M^5?FS]JX)IQA@)1
MAMS/\HGVI\'/^/:+Z"O:M$_U:_2O%?@Y_P >T7T%>U:)_JU^E> ?8&JGW:6D
M3[M+0 5#=?<-35#=?<- '$^.O^/5OI7\?>L!5:O[!/'7_'JWTK^./Q+XCC@8
MY9<**Z*-10A)OR/V;PDJ1A#&.7_3O_V\S=5OX[6YW,P4=\UEW/B)K^0QV@:9
MCQD#@>Y-2?V#)XBB6XN-T<;<H@[CL3]:LV5G#ID6V-0JKGI7GR=6;[1_$_2Y
M/$5)>[:,'UZOT6R_K0B73ULK0[CN?JSGJ373^'+/?I<+[?O*#7. '6[^.TC.
M-V3(W]Q:['[3#IUDL:X"QK@5U8.,;M]%H>G@8QYG);+0H:K&L=5?!%M]KU*Z
M8#*(0,^_^<5GZ]XD^T7:P6Z^=-)\JH.YKJO#EK#X=TE8]P:1OFD;^\QZ_P"?
M2NBBXU*UULC2C*%;$>Z]([_HB;4X5CB;Z5Q?B?4HK!HV9NIQCUK:\5^+X;-&
MRRYQZUB^%(F\0WLMU,FR.'"Q@CG/4_3M^=/$U5.?LJ>YACZT:E3V%)^\_G;U
M,D2WES.LK6\BP*=P!&"_IQZ57UOQ%?7#;))1:QXY[LU=7XBO8;"!N5&T5R5]
MI+ZE*+B6-E[JI["N#$4Y07+"3;ZG@8ZC5A%TZ<FV]7K;\M;?UW91LM2C@N6D
M(;I@9R6/O2'4I-2U&..,M&&;[W0X]JW[#15N(?\ "L_5M(^P2^<HRT9SBN65
M&K&"=]#BJ8.O&FO>]V]W96.KT;PNNHVZ^9YCCIRYJ_:^%K?P[<I<0PK&<X8@
M<D'UIW@/5X[JP!^ZWI6YJ%W&8#DK7TE&E2=-36Y]CAL+0E3C525^C-+2-0B:
M!3N6K5U=QF/[U><_\)#,NM+9V*^<\C?=_NCN2>P%;]YI.H3+A;R%1ZF,DC\,
M_P!:Z*>/YHM15['I4,P<XM0C>VCL0>+-8AMHW^9<GM7.Z9$LAEN)$42,=N2.
M0/2I=6T*'2)VNKJZDNIDY&[Y44^H'^)-8UMJ-YJDWV>&/R5;+EF')_#\NM>+
MB,0_:>^M>BW/!Q6)E[7]Y'7HEJ_5VT1H6&B2^(];^ZWV.-2&/9VZ8_SZ5N2>
M&'T[]Y;_ +MEYP.AIWAO5H]/@2%QM:-<8[U:UGQI:6ELS-(G3IGK751IT8PY
MYO4[*-##PINI-Z[M]C-O/'$VG;8Y(Y/,8[0 ,Y-58OMVJZ@DFJJUOIZ\^7N^
M9SVR1T'XUI>#]!;7;\:C?0F&./F")OO$G^(CM]/Y<5O:]Y(M6W;0M:PI5*D?
M:3EIT7?U*IX>K6A[6<WR[I=_7K;[K^C*TOC.PTVS"K+##'&N%4< "N4U?69O
M%EQY5NS0Q*-S2LG4>P.*R]6NXX-29X+7SL<*<84'Z_X5H-HJBV9I+YU\P OY
M8"Y]LG/'7WKDK8JI6O#HNVGX_P"1QUL95KMT^BW2T_%V_ ;I'A6'5M0_?,UQ
M#%_K'=O]8?3_ /56AK6C:3HMM\L,*-C /4_2N?MO$$=@9(X[CR[>$[5QRQ/^
M?UJ"[L[C4W6XFDN%7/R[_O8]0.W\ZX_;4U"T(IR.6.(HQIVIP4I?+^O\RE-+
M;VUTV=LC$Y"8X!/2NH\.74,5C'"O[ZZG;A$!9G8] !U/I4W@SP)'XG\6V.GA
M<QD[F7&<@#/-?2G@GX2:?X<MU:UL[>WD/5DB56/XBN>C"<)NR1Y-3'2P55Q2
M3?Y?YGFGPD^#]U;&>_U2V\J:YPL<+<M&@[GW/''8#W('8S_"/3Y9/.;3[9I>
MSF(;OSKTRS\.A5Z?I5HZ.NS;WKH^JIZL\"M5E5FZD]V>-ZM\(;&]D622QAD=
M1@,4R16#=?LVZ;J%QO$+VS$Y/E.5S^'2O=+S2%C./Z51%E\W_P!:HE@XWNT1
M"33NM&>36'[-NA6TVZ6S^T#&#YCLW]:\9^+'PPNOACXF:!'S8W&9+-V'WE_N
MGW'3WX/>OK^2RVK7)_%#X9VWQ$T#[+*1%<0-YEM-MSY3XQ^*GN/\!6%;!Q:T
M.[#U%&:<V?*,.CS[%DD+2>JGI6@MYLM3Y<$C%>.!TJ:Y%]:^;%)"(VA<QN">
M5(.#_*HXM3 LC&-J)T)/+,:*=.,=(L^NIQITU[C>JZ_\$A%^RVS)#$S2'EF(
MQBH4>Z@CW%%7=_%Z"M$75O;QK'N&YN7;LM/ANHK]]X^6WAX!/\5>A1HWTYC.
MK#FWEKV,U<O;KY;2239^\1@+3X;2:X)::Y;:H[G@&IYQ-?,S0+LCS@-Z_2B\
M\/MI\"F2X8;1NP!72HV5[;'$Z<GJE=+Y(;%'-;O'ON-JL<@'L/4U8NK?[=+A
M9))-HX=C@ GTIT+Q?8QY:M._5I&Z+4D6G+J:-,LCHJ\Y)P&/L*=KZ+4Z:=/2
MRU-;X=:?<67CO19(9I)[B&^MV2-.I82*<>@_^O7W"FF6-W ]](J27#$A2>=J
MCH!_GO7R)\&?#&I7_B6PN(8X8;?3V6YF8*=W!RH_$@?AFO>+7QM<6%N+8L&9
MF/Y5U4XQC)*W0_%_%2M3>(I4(?%&-W\]OP_,]I@U>2^^S6EJWE;AE]O&%XK?
MCTB2W,9A5F_VZ\U^&6L7'B/7O.6/RX(UVANS'VKW#2&6"P53W%>A1]YW/R&M
M[J0FG6[36ZK)G=[UN:3I2Q!6VXK,M=S7"KC:N:ZA0L%NN/2NR)QLDN$Q"D@7
M=MZ^U1:;K7FB:0R+Y,*%FR>%Q2:OXIMM#T"XGFV_NT.U,\N<<#\:^>_VAOC9
MJOPS_9Q\6:I;V>)[FW&GPR-D!'G81E_JJLS#MD"CFUY43RVBY,^(_C5\6VU[
MXM^)[W2;J22UO]3N)HY<XRK2,1M]N:X6?4YG;F:1OJQJA&-O\Z'<YJL1"562
M<NA[F,XFQ6.Y77EI%626R79?<3R7;2?Q-7:? _06UOQ1',?F2V8.?PK@2^*]
M>_9<TF:ZOY9MW[G=AN*^8XNE+#916G!V=K7]3UN#ZRQ6;T:<U=7O]VI]$^&[
MV-(7N'1>F "*[/PWJ\%SI"^6R[^<C->=WEZEJ@16&T53TKQ5)HVI+M8^7(>>
M>E?RG4P$X+GB?UUA\TB_=9ZHJB\D8L?N]O:M_P &_#[Q1XYTC6+SP]X;U_7=
M/\/P^?JEQI^GRW4.FQD.P>=D4B-=L;G+$#",>QQQFAZS]HB\S&[(&>:_0+_@
MBG;Z?K7[/G[5EMK&I?V#I%QX<M([S4?LSW7]GP-:ZJ))_*7#2;%RVQ<%MN!R
M:[<CP,<?B5AI.UU)W](M]=.AQ\19U++L%+%P7-9Q5M>LHQZ:[.Y\!Z)X*\<?
M%G6KO3_!/AWQ%XFO;6 W4\&D:?-?2PP@A3(RQJQ5064;B,98>M<O\,_A5\0O
MCMK%U'X1\,^*?&%U8*))XM'TN>_:!2<;F6)6*C)QDXYK]5/^"-_PX^"_@K]H
M#QO/\.?CLOQ2UQ_"-S'<Z6/!=]HOV6#[1;DS^;.Q5\.$78.3OST!KP+]@S]N
MGX7R_P#!/!?@==_&"^_9S^(S:W+J,?BA(Y8[;5RTA=1)<Q,IA&P)$Q=X\"),
M%P60_283A2BXTW5E[TE+1.+NXVLDTW&[OU?0^*S#C2K[2JJ$'RP<-6I*RE>[
M<6N:RMT6MS\\OVJ/&?B/X)64^AZYH^J^'M>C/ER6FH6CVMQ">0=R. R]#U K
MY]^(WP!^)7A#P+I?COQ3X%\;Z-X5\3-'_9>OZGHMU;:;JAD0R1^1<.@CEW1J
MS+L8Y521D#-?H_\ \%,/V)/C]\=/^"B'P.^%/Q4\5'QU+\0YK>R\/>)+&<36
MDFDQL&NI44(NUXH299"5);AMSYW'] ?VXOA#X@_;K_9U_:B_9WA^&7BKPWX9
M^#^DZ/>?"C4;O0KFVLM9FLK/=+#:3M&(Y</$;<8=B4N,CC.W]=X)RRCEF$NH
M-3DW=RLI6NDMKZ?/S/Q;CC.*V:8NSFG&*5E&[C>UWO;\O(_F\^'_ ,.O$'Q9
M\8V/AWPKH6L>)O$&IL8[/3-*LI;R\NV"EB(XHU9W(56. #@ GL:[_P >_L"_
M';X6>%[K7/$WP5^+?AS1+%=]QJ&J>$-0L[6W'J\LD(51UZD5[1_P;[S;_P#@
ML1\#Q_U%+O\ '_B7W5?5WQ _X*<_'?X&_P#!Q1K'A?1_B)XTUCP?>?$Z#PV_
MA.^U6XO-):RN;F*%XHK5V9(F"N2C1J&5@,<$@_>U,1-3Y8I;7/@:=&+AS3[V
M/R2TW2KK7]4M[&QM;B]O;R58+>W@C,DL\C$*J(HY9B2   22:Z/XP_ 'QU^S
MMXAM])^('@GQ;X&U:\MA=P67B'2+C3+B> LR"58YT5F0LC+N QE6'4&OVO\
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MR2#[3,L:CINJOH-OIW@_23<2*B7%P,L['<Y'8$GG\*[*^*J_PHI12Z]O1?\
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MG^%16?J7BV;5KU;>W3RT8@,[+]T>N*]$\$Z58Z+:'R6W/+@N['+.??\ PK/
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M.UV=T\/AJ5#EE;F?]?@/OM'BL]%#>6BMMXXYI+/1[OQ-J,.G:?;M>76 SHA
MP/<D@"H#J4OBEMJK(RMQ#;P*7FE/;@<_@.:^@?V7_@A+X*T>?4M4MC!J&H,"
ML3-N>&,= W^T<DD=ACOD5C.7/*U+;^OS/)S/,(4HVHVN[?\ #V+GP ^!$G@9
M)-1U0Q3:M=C;A/F2V3KM![D\9/T';)]?LM.5$^Z!VIEM;A<5>@&VNVC1L?'U
M*TIR<YN[8Y+/G[M$MB"O2K49RM.<#%=L:)S2JG/ZA98[5DRP;&Z5TFH1@UAW
M:;343PY"KI%&:+*FJ-S%S6E(>*JSKEJY*E$Z(5SR'XZ?"&3Q1$NH:7&OVZ,_
MOH00HN%]?]X?J/H*\9BLFBNF@EM6C^SG$BD?-GT-?6EW#N%<3X]^%]GXK$TR
M%K6_9<"5.C$=-P[^F>OY5R\B4KL^@RW-E3]RO>W?MY>AX#J,B7>1)&JQJ.%P
M,L:I_P!C*D*2;E3)!5#T'UJ]XDT.ZT;6&LY+.XAEC)#&7C=[@]Q[CBH8M-D2
M%II$AV=#D]O8U?,G+8^AE%57=*_F.M[Z2WEW,5=<85MIVK]*N6-W T_FR[I'
M .W*]?P["J][<R7,"LODQPQG "_Q5-I%M%>7&)X_L\:C/)^9ZVC4;=D:PC)2
M45^)#JYENK!O+C +$E4!_4TZSL5CLHW6-E$9^9SCBKFJ-'"S+:Q;H0N"Q;J:
M[#]G?X6K\4_B1:Z9J<>W3Q \PC$FTR[<<?KGCL#5NRDY/4Y<PK0PM.>)J7:B
MKNWD=)^S#J_]H0:Q9^8[?:KB"-)".%^]D _0@U[YHG@*RL7\F15:2=E 8CG'
M>H8OA?9>#I8(X88;2ULV!140*!BK<>M_VGK.VU_>^3@Y!Z'M7;1O9SGU/Y9X
MGS;^TLPGB8JW-T]$E^AZ'IVFP:2BPVRJ-HY ' K8@U2:%H]O:L'PL)(8/,N.
M7DZYXQ6M?WT5JBX9?7K77%Z7/G)+H>L?LT?!K5_VH?C;H?A'2YDM9M0=C/<N
MNY+2%%+R2$<9PH.!D;F(&1FOJ36?&_[,'PM\22>#_P#A!_$GBZWT^0VE]XB;
M472221#AGB19%5E!SR @;'1@03\\_P#!,W]HK1_@1^UIH.L:]+';Z/=K+IMS
M<L<+:"9=JRM_LJ^W<>R[CVQ7M'C+_@EU\2M/\=26OAC3K/Q%X>NY?,TW6(M0
M@6&6W;E6?<P((4C. 03]W=Q4.474M4E96TUM<3BU&\%=^ESA_P!M_P#92TWX
M0ZCH>N^&=0?6O _C"R-[HMS*/WL8 4O')P/F&]>< X.",J:^9OB)%H?BOX*^
M*M-UKRDTR33)VE>51MB"H3O^JD!@>H('I7Z*?M#_ +:VI_L*^!/"/PS\!:QI
M&K:IX7T]TUR\:$7$/VIVW>2G(QM8N3GD!E!P0PKXL_;D_P""_G[2GP'TSPU>
M>&[[PFMIJ3SQ7<DVAI+B10A0#YL#(+_7;[5I0=:25E?S;M?MT,:SI13YG]RO
M;\3\80,)3'7FOT=_XBE/VLO^@MX'_P#"=C_^*H/_  =*?M98_P"0QX'_ /"=
MC_\ BJ]#FQ'\B_\  O\ @'E+V'\[_P# ?^"?F\0<U])_L::(;SPM=R,!M\X@
M?I7T;_Q%*_M9?]!CP./^Y<C_ /BJV_!__!U'^TM;S[=8N?!EU&S??CT)(RH_
M!J^;XNRW%9CELL-"-M4]/>>G1)\OYGU/!^;X;+<SCB9N^C6ONK7NTI?D>9WW
MAJ.XMVCVKGU]*Y>Z\%361:4_,J\XS7W=X&_X.&OC9\0M+$^GZQX3:3&6C_LA
M-R_ANJWJ'_!>C]H:%F2/4/"N_M_Q)4/]:_ 98?!T9NE5JS36C3IV?_I9_15/
M'8ZO!5J-&$HO9JJVO_39\%>$/&O]AZ@T,C-Y+'\J^J_V7_V]X_V5O@3\9/#<
M7AA?$"_%;0QI'VK^T_L?]EX@NXO,V>4_F_\ 'UG;E/N8S\V1V.H_\%Z/VG8K
M:2:'4_".V,=#H2<_^/5SFB_\'#_[3VIN^_4O!L:*2,_V$F3_ ./5&%PV"P]?
MZQA<1)/5?PT]U9[S[,,7B\PQ%!X7%8:,HNS_ (C6S36T.Z1XU_P2S_;Y3]@/
MXU>*O%7_  BZ^+F\0:%-H/V8ZI_9_D;YX9?-W^5+NQY.-N!G=G/&#@S?\%"/
M@O\ #7X(^'?AS\5/V6_!/Q:M]!N)KVRU.R\1WGAO5#)(P+M<W$*R/-G 79E$
MVH@V_**]2^+_ /P<O_M0>!WACLM;\$M(Q^96T"-L#_OJN%/_  =._M:9_P"0
MOX'_ /"<C_\ BJ_5>$^':THTL;"IS4US6BX\KUWUNWNDS\FXNXBI*57!3I<M
M5\MY*3DM-M+);-KY]2]X9_X.4=7M_P!LO3/BQKGP<T/4K#P+X4N/"WP^\,V6
MMM8V?A19S$)KEY#!(UQ*T<*18 B41\  _-7C?[$W_!>7X]_LO?M3:=\0/%_C
MKXB?%KP_$+I=0\)ZUXQO!I]\)HW"E!)YT<+1R%'4K$<!-HP&X]6'_!TY^UI_
MT&/ W_A.1_\ Q5'_ !%.?M:?]!CP-_X3<?\ \57Z%]3DE;V:[?$_\C\Z^L1O
M=S?W?\$^9?V>/V\-'_9M_P""F]K^T%X?^'ICT73_ !#?ZY9^$/[;P+9+E)U%
MLMW]G^['YQVMY/1 ,9YKZBU;_@O+\(?#_P"T)K?QK\%_L;^%=)^-FK7,E^GB
M;7O'E_KMO;W3@AIULC#%&K^AB,9 S@C-5S_P=-_M:#_F,>!__";C_P#BJ#_P
M=._M:8_Y#'@;_P )R/\ ^*IRPM26K@MK?$]ON%&O!:*7G\*_S.!^'/\ P7C\
M>?#[X!_'BSBT?4C\;/CUJT5_JGQ-M-?:QNM,AB$216]O;10*R".(3I&RSKL\
MX8&$ +?V2/\ @MU\1O"OP5^+GPJ^+D/C#]H3P_\ %_2!I$">)/&EP;CP])Y<
MR&>"2>.Y//F(^T;0'@C8$'-?07[//_!Q;^UE\:==FAF\0>";6UMP-S)X;BW9
M/89:O7K;_@ME^T_I^O?Z1XF\)7%B ?D_X1V)6SVY!KYS,\]P>#J2P]5)32O9
M-OTZ+[KH\3'<38'"U'1J57SI;<M]_G9GSO\ '']MGQM\5_AW^R+/X7T"W\%^
M*/V3M*BLM/OO[7-\FO.EOIT):2/R8_)1UL"&CW2 K.RDX&6]N^%'_!6RS\!?
M\%!?%G[0NC_ V/2[SQIX8.AZSHL?BP&&>[\^V<WPF%B,,4MD1D\L[FR^[)(.
M[K?_  7M_:'L9_+@OO"TA]3HJ?\ Q5;OA#_@N/\ M!:S#BYOO"XDQU&C(/ZU
M\/B,_P"=+FK/1W7N+3_R8^7J<2*6KQ4KW37[F.C2LOMGYIC7I_#^O1_;%S"I
MPQ S7Z.:/_P78AO_ -M&Q^,$/PQ=DLO X\&_V3_PD.-^+PW/VGSOLO'7;Y>P
M^N[M3/&?_!=+]HS0-0VPZEX6\INA.B(<?K530/\ @OE^T!>,T=QJOA42 \8T
M9!_6N*CBJ$%>E5:V?PKIM]KS,<'6PF&ASX>O)7:?\-/6-[/672[_ %/!_"G[
M3*^&_P#@GQ\8/@A9^%8[F7XJW%O<-JXU'[/]@,3PM_J?*;S,^5UWKC=WQS\;
MZ=I\?P^TV;0KF2XDO+=-S'.1STK]7K3_ (+E?'Z9@3JGA9E/_4&3_&OA#XS_
M  =7QWK-UK\+JNH7 :28#A9,DD\?C7?@L[IT8?5W-RCTNDK/UNSHR_B:EE]J
M/.ZL;-*\5%Q]&I.][O?8\Q\+^*X8K&,77S #TK8;XLZ9I=O(O0,,#ZUYGJ:F
MT,BQR[I(B5>,GE3]*YN!+[Q+J:V\*LS9X"C)KB^JRG*UM3RHT74E>WXG6?$C
MXORR6_V>S=O.D'!'&*H?";X?:QX]UQ9KB9C#&=SLS<?A6_X2_9MDU9UGU261
M%)!* _-7LOAGPY8^%+);>SC\M5&#SR:_0N'^"95$JV*5H]NK/N\HPKI)-[=C
MH_"=M#X:TJ&WA 41J 2!UK5?7N/O&N=6XQ_%0USG@MBOT^.&C"*A%:(^QIYA
M961H:CKP"GYOUKE]:NQ=[L\U>N3"^=S,3]:HSV]NQX/3U-:1HG#B\P<E9'$>
M(O"7]HG=$H63U KF+WP]?V#'="Q7U'I7K2PPQ^E-N4A=.0K?6B6%3U/(]L^I
MXV+MH'VR*RM[U=@N5<+78^*_"]GJ462@5\8!4XKS&ZNY-%U!H9/EVG )[BN2
MI%TWJ;1?,=1#(M7(;Q8ZYNTUD2#[PJW_ &AO'!R3Z4XS%+179O'7U@%;_P &
MO%\4_P 8O#,#2$O)J,"A1_OBO+?%>J2:7IDT@9=RC.*N_LB7,VN_''P[<3-G
M9JD&/^^Q4UZC5.47V?Y'@8S,82E".'E]I7:]5H?LW^S[]^'\*^W/@K_Q[Q5\
M1_L^_?A_"OMSX*_\>\5?F9^D'O/A[_4K]*VTZ5B>'O\ 4K]*VTZ4 .HHHH *
M*** "BBB@"M??ZMJ^7/^"JT:S?\ !/3X\*WW6^'FO@_3^S;BOJ.^_P!6U?+W
M_!5"R;4O^"?7QUMT?RWN/A]K\:MC.TG3IP#^M:T;^TC;NOS-L/K5BDKZK\S^
M0RSDM4UCYC&J0J6/U[?UI-=\=+/+]FL5^T2GY0$&0#[GM77#X7Z?IMDJ-!'*
M0.6D&YF/J:R;[28].DC$2(BJP 51@=:_39X7$0ARMJ-][:L_8*F#Q=.'*VHW
MU=M7Z=C'T-]6TB*23[&TTLIW,RD8]@*S]<NM>U'<UPJ6T/9%.Z1OZ#]:]6M-
M,$=B-WIS7,>*+=0JJH^9I H^I.!3Q&72C2Y>=V_KYEXK*91H*/M)6[77^5RQ
M\/?$EOH^B10*OD!220W4DG))SWJ_XA^)MK90<2*S=E7DG\*J7=G!IVF@2;<@
M5R\/B:WL+V2XCMY9E4%%\M<[CG_ZU=%3$SP]-4N9+Y?H=53&5,-2C1YDM.VW
MR0MW?:AXCW7%PIL[-N55QB20?0]!]>3^M8=T8]3F7]S<:I< G:#DQQCW_A_.
MM;5[FZO_ -]>!+>'[WV<'?(WH#CC\!G-5[+5+R*!HX+*2/S&W-)+\BK_ %_2
MO&K6E*TV_FKM_+IY71\_B+3ERS;UW;5V_ELO*ZTW\RQ:Z\?"ELS+"9KJ;&XC
MV[#T JO9ZK=>(;HS:@LGV?/RQ1+E2/\ :;_#%6(]'^S6K23-YDT@RS?T'M78
M> ?#'_%+0S.N/-W./H2<?I75A\/6JS5.]HI7M_GWW.W"X2O7J*E>T4KV_P ^
M^YS/B;XAI:6FV&"25SQA4/'UK1^$>@1^(7CU*X&Z>0D!>T8ST'O2>-M+C@B;
MIT-:'P\,GA'3;=Y/]7( Y_V,UT4J<WC$Z[O%+ML^YUT:-1X]/$/FC%=M$]-3
MM[SPG#-;;2O:JFE:[)H4GD7'"KPK'N*N+XRMI(OOKT]:X_QIXWMIB+:W5KFZ
MF.U(H_F9O\^O05]!B*U*DO:0=G^9]/BL10H1]K"23_/R.TN?'%O'%DS1K]6K
MB]:\73>++S[)IW[WG+S ;HX@.N3_ $[FM'P3X'M[.UDFU2.UN)IB"(V4.L(Q
MTY[^O^36AXL\2VFBZ:>8XT08 '  K*M*K5I<U67*NW7_ (!C6G7K4>>M)0CU
M76WZ'#ZY?Q^&U6'?\S#Y=QY8]R?\\50DOI'9)+6SEN(83N\PC:LC=<Y/4?2M
M#3K:/Q/KL=Q,FV.WQ(=X^Z.P^IZ_2K'BOQ5#>2FUM5:;R_\ 6&/G8*\:>J<W
M*RZ=W_7H?/U%S1=1RM':*6[_ *]"J=%N=2TM;[4+HQLPWI'$=JQCMR1D_7BL
MKPN;&+49)Y$E9(6!);+-(P/!Y_A';L?YOU_Q'<:M&L*^7:Q@?*A.XJ/]KL/S
M.:S;)K1;=_M%Q<3-(V%CB)!E/? 7G\O2N.K5@JBY>G5]7^?X'#6K4_:QY%>W
M675_/7\/(VM4\;_\)'-)#&JV]K%RSR_+O/\ = ZUK>#+7_A(Y/M6I7'^BPL!
M! H\M6Q_$>^/3L?IUQ] U&PT&!Y&C+7,P"K#&A9D']T#U]:DL;NSCGGN=262
M'S!A+=CC'N<=2?\ /MT4:C<E.K)/NMEY7_R.K#U6YJI6DI/=K9+M?R\K7-[Q
MM<6>HO':VZQS7$C84 _=]SZ#WK3B^Q>'-#CL+-5N+N0!%2)=TD\A]%'))].:
MY+P=X7O?BKXB^Q^&]-:&.$@S3-^ZC0'NY'/X8+'TZFOK#X-?!>Q^&^@VJBWM
M)-46/%Q>B$"69B<GYOO;>< $] *UIXYSG*5-*^U^B]--3S\9Q13H3E*E%2F]
M+]$ONU_KYT_@/\-)O!/@Q5OEVZA?2&ZN$SD1$@ )^"@9[9SVKMKB,1"M+R_*
M7I63J4^T4N6R/S^M5E4FZD]WJ4YGW/\ C5BSCR:@@3S&S6E9PX/>HB9ENSBX
M%:EJF*JV<7RCBM")<'_/-=$45$FA'\ZL(<5"@XJ51S6I0\M@5&_-2!<BG+ 3
M3LP*HZTNPU=%O2&/ _\ K4^4"JN5->)_M0_#*TA9?$EO!^]D;R[D#NV.&Q[@
M'/O]:]S,?6L_Q-X=M_$^C7%C=+NAN%VMCJ.X(]P<&JCH[G?EN.EA,1&LMEOZ
M'Q39:7;:A))YTFU5ZX/%/OM+MT\M+4[GZG!SBN@^*_PT;X<>+IK63]["P$D;
MJ,!U/^?SKF+FZ72YA(@.&'*BMHN/+=H_4?[1P\</]8=N5ZW'RRM8(V9E90.C
M<UBZIJ373?PX[8INHWANYBW16.<56*[JY*U>_NH_#.,^.)5W+#867N[$97=1
MMQ_2I"E&RN+E9^32G=W9'L_SBC;4@3_]5!2CE9/,1A?:C94FRC91RCNB/91L
MXJ0I1MYHY1<Q'MZ\4;.:D*4;*.4=R/91Y=2;.*"N*EH7,0LM)M_6GE*-E/E+
MN1[*-F3Z5($HV4A\Q"T>*C*<U8/%-\NCE*C(BV&D(Q4A&#367)K-Q*N1D9-(
MPQ4I7%,VY.:S*N1;,TA&*E/R"F$5,BTQA7BFEN:<PS2$8J&KEHC9>,TQAD5*
M?F_E3'7FH+B0E<"F_P 52,F:;C;4FO,-(_\ UTT]:D/S&FXQUQ4-#(V!)IK+
MD^M2G_)IK=*FQ29&%^M!''-.W4A7-1REC<Y-&W=Z_P"-.6(NP ZGM7K/P/\
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M5R.Z7F?*XRFJV(3INZCW;L5M6P\JK-<--N/RPQ#&3[_Y%+NNB(X?,\N-L*$
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MM\41V,6M:;'=3?=2Z$3L2H.=IP/7E1Q[5Z+XM\8376KSZ7#'-]HA3+$@C<,
M_*._I^==%2I3I)J3UZ?U^!_*7%V22P.;U*%->[>Z[6>OX7M\CH_%GCJ:#48]
M/L[.6<R1[A)'\P!]"/\ )KF;+5]2O=&F/F+>7UO(3,%)5<9QA0?3\*Q]6^(=
MM8RV-Q:VLC:H@(F9F(!'&/7G.>U5-$N]0\VYNHI;A9+V9IG1GW1(22?E![>W
M KS9U,5*2:^X\>G'#*+N>E_#776O)7$ZM&\;[65NJD<5]">"OBSXBT/PX--L
M/$FN6>FL"#:07\L<)SU^16 Y^E?)N@V>HV44TWVB1II'WLQ_B/>MGPE\3M=L
M;X*S>=&"0 #S7LT*EDN='C5XZ^Z?0NL6!UJR:./Y)%&5ST)]*^3?V[?B1I.J
M?L\?V?<*#J5]J41LHR06A:/<9'^@4E/K(/6O:H?B#KFNZ)?06#&VOYK:1;>1
MN?*D*D(?P;%?F;XEEU*77;B/5IKJ;4+>1H9OM$AD=&4D,I))Z'->KAX^TES+
MH>-BJKIQY6MS."TI&!3MG-."XKNY3SXC E&TT\+D4[8#4O0VBC1\(^,K_P #
MZE]JL9FCDQ@C/!KUWP-^U\;1HTU>R>;G#2(P_E7B+I\M1F.OF<ZX4RS-=<93
MO+^9:/[T?3Y'Q5F>5:8.HU'^5ZK[F?87AKXIZ;\6+*YCT^5H/)3,F_CBO,OC
M/X:OO#7AK^U-.O':WW@'@CK7C&C>(;[P\S-9W4UOYG#;&QN^M>V_#/\ :&T[
MQC82:'XOAMTTY;?Y'$?WF7IG'<U\W@^ ,#E=3VU&'M%>[YM7\CZ7'<>X_-(>
MQQ$^1VLN71'@VI7LVKW#37#-(Y[DU4:/!KZE\5_"'P]XL^!-Q?>&M(A:ZD;,
M#@?O,!OK7S/K6B76@7[6UW"T,R]5/:OO,OQ%.K#EIKEY=+?\ ^%QM&K2GS3E
MS7UO_P $SBK*>E)FK")DXKN?@_\ !R;QGXNL8[^WDCTZ20&0YQO&>GM6F,QE
M'"TG6KNR2_JQY>)QE.A3=6J[)*YY]NW'CM78?"_X*ZS\5=1CAT^#; QP]Q(,
M1QCZU]4:O^QWX';RYH=-:,)U59FPWUYKNO .B:3X9TB/3[&UBM8[<85$7BOS
MG,O$2C['_88/G?\ -:R^YNY\GBN-(.E_LD'S/J]E]SU.%^$?P$_X45I++]I%
MU<7+"220# R.PKI+_P ;?:[Z.+9\JGYCGK6]K^HI<W*0L#M[U-#X TZ[C62%
M5\SJ<FOR[%XZIB:KK8AWE+=GR<JSQ$W.OK*6[':5I<.O0+)MVLO2MGP_IGES
M2;77]V*LZ;HZ:?I^Q%V[14-O<0VLS;FPS=<'K7 Y-['51P;:M$R?'L"WEC(,
M?,.A]Z\@UG3[J6\,T9V;3C'K7OEIH7]KHWR[MW3-<9XB\("RU=X3&OS#=71A
MZRCH?0Y?@U'W6CE_#WBPI9JDA.]!@U)XZ^(\?A[P->76?FCB8CGVJ'Q!9V/A
MV)I9BL8[UX-^T3\29+C3?LUGN^R3@J6Z9KV,IP+Q>*A2CLW^'4UCD?MZ\816
MESQ36/%-[K7B&:Y61UDNG/ /7-?0WP1\&1^$=.BNYF\Z\F0%C_=S7S[X,L5O
M/%%JC+N7?FOI+2]0\F!%!X  K^A\#1I0::2T/T2&!A%<R6VAWEOK>?\ ]=6!
MJN17(V6HY[GTK2BNB?6O?C4N925C9DU<BH'U5N>36:\YQ4,MQ@U3D+GL:#ZG
MD?\ UZK2ZP4;VK.GNB!5&YOB*S=2Q#U-PZ[@_P!<U$^M[JYXWK$]?I0)V8]3
M4>T8^0V;C4O/%<'\1M.:^M6DC'[R,Y'N*ZVW1I*H:]IY$#-MRO>LZBYHZE0=
MF>56.NNAVX.X<&M*RUFZO;WR(5.X]3Z5%'H;7NKW$J+Y<:FK^@R0VTY9CMQP
MS#JQKFP]%IIMGRF>9TI*6'IKU9H:SHN[2BLD@9F7D ]*Z[]DS04TCXH>'F;[
MTFIP[?\ OL5RNMZC'#8-)Y>V,C@GK73?LXZ^D_QC\)HK-M;5+=0/7YQ75BN5
M0D_[K_(^6R_VDJM-=.:/YH_8#]GW[\/X5]N?!7_CWBKXC_9]^_#^%?;GP5_X
M]XJ_+3]^/>?#W^I7Z5MITK$\/?ZE?I6VG2@!U%%% !1110 4444 5K[_ %;5
M\T_\%,_^3%?C1_V(NM_^F^>OI:^_U;5\P?\ !4J=K7_@G_\ '*1%WR1_#_7F
M5?[Q&G3G%;X5VK0?FOS.G!RMB(-_S+\S^5WQ!?1P0G++^=<.-0CU;Q'# AW)
M$X>4]E Y&?KBL;Q9XAUB\MW>X$=C @SU\QV/I@<?SJIH^DWUKIIF9V@$V6VN
MO[QO]IO0^W88^@_3\3F3JU>2$7;=_P!,_8\9FSK5E"$'9:OII\]K^?R/0/$O
MCBQT.S_>7$4?'<US>EVVJ>*IUO(%BAMU^:(W!*^83T8#!X[\]>U9W@OX8P>,
MKNXO-0>2X6WD\M%8_(3@$\?B/:NMOM'N-*@_<W#!5X 8=!50EB,1^]JJT.B3
MU?K_ , TIRQ6+_?5H\M/HD]7;J_TL9D_@YVD:XUC5&F"CBWA.R,?4_>/Z?C6
M5<VK^((_+TE8HX;<X,@3]VF/X1CO[>GUJ]IWA:X\;>(&M[J\G-I H:18ODWY
M/"D]><'I@UVFIV-KH.F+!;QQPQ1C:B*NU5%.GA/:J4K<L>][M_/HOZL%+ ^V
MC*27+#NW>4OG?1?TDC@?#_ACR]57[7))>7"G=N?[H^B]/YFM3Q)%%:6[D[5P
MO6J,_BJVTK4[BXE<?NQL11R78^@_*J%KK+>+-75KK_1;6$B0HQ^9^> 1V_GQ
M7,JE*G'V5/XF_P"FW_F<JK4*4?84_B;_ *;?^9/I#'5]3A6ZAFM]/7YG9QL\
MW'11WY_E7;7OC[3=-M%B6:-=J[51>OH  *XW7/%\.IW"V.GQK<7'0@'Y4'N>
MU.M6U3P_IS)':0M)(2S2-)@9/Z__ *JVH8KV7,J;YN[M?Y:&V&Q?L>:-)\W>
M5F_EI_2ZD=]KLFK:PGVFVG%ON^6-EP9F[#'7'?\ R:O:U'K&K_+(B6%C_&V\
M-(5_V0,C\SQZ&J'A/3;_ %>_>[>:,RQY4#R_E7]:M^);?4I(6CDNHXXSP?+3
MYL?4G^E9PYY4W.5]?17]3*G[25&52?-[W:ROZOMY(U],U30;'3Q"(X=L?7=\
MS$^Y/-96MS+&/^)5I?DR2'F80^2 /4M@$_AFJ>CZ)#->16J'$:G?,Y.>/<^I
MZ?\ ZJUO&'B^WL(?L\&V6?L@/.!6SJ<U*\[12[+\CHE4YJ#=6T4M%9:^B_X8
MS-/U+5A!+YE](5C."< <^U">'SJEHM]J-])#$K;ERVYF'8_-P/RS63;3W-_:
M*]TN+?<6,<38WGW;K^6*V9/!%SKEG'-<(L=LP5UB$C,Q'7O\H_(_45R4VZD;
M).7JW]YQ4[UH647+31-O[WY+[V:'@[1;&]DEN)I6^P?P*TK?OCW8\Y(XQ[_A
M3?$NOZ9I]H]KI,=NJQG+B!1M0GN<=S^9J22^M9I([.+23/<8V)&#MS@=SG'X
MFI+WPI)IEBLMXMI >=EM;K^[B]\\9/X <]^M=RC+V?+22\W;^K>G_#GH\LO9
M<E%+3=V>GE=VMZ:ORZG*W>F1O9O/)'Y-OG?AN"P]6_P-:W@Q]-TRVN+J;R(0
MV A;"_*/\<_I52UU#^W)88-NVUSMWM_'CKCVXZUH^'=$TV\UB2X8Q_9[,X4<
M89O_ *W]17)1I_O%.G;Y_C\D<&'IKVL9TK/IK^+]$@TC5+ ZV][<-''!"#Y0
M?@NQXSCTQGZYJGKE\OBGQ'#9V\$DGG$)&BH?,G8]%5?O$DUJ:?IR_$GQU8Z5
MIRAFFN5C,BKN"@'+'J,[5!8^@%?6GP?^"6E?##2!';K]JO9"6EO)HU\Z3..,
M@<*,  ?S)R:ESS_=1M:]V[;GFYMFZP\?81M*[OZ^OY6_$YO]F?X+/\,O! ^W
M6ZPZEJ#F>>,8/DC "ID<< 9/;)/7K7JD<0C3I^56#;A!4,GRUT4Z2A'E1\-.
M3G)R?4K7<FP5@7K^?+^-:VI2\5EV\?GW514UT,BUI]B73I6Q:6&S^'M4FEV.
MV-:V+;3\BM(TRDBG;VS8^[7MG[.G[ 7Q8_:K\)WFN> O"?\ ;VE6%V;">?\
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M\D7UUYYZ]:^Y?B-%O\ :ZO3.GW _\AM7PGBLJDG;E/F>*\ZQ%&A'"0D[2O\
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M0P0,W8?_ %ZY\5+V4;<_O/<YL94]A#E]H^:5KV_+R73]2.QN=0OY'&76$O\
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MA8KC -=!^RKI"V'Q8\)R71_?-JL C4]OG%<W([75F)II JL-P4>E=A^S8O\
M:?QN\,7##(CU.!4'I\XYHQ5G"3\G^09?)QJTX?WH_FC]@/V??OP_A7VY\%?^
M/>*OB/\ 9]^_#^%?;GP5_P"/>*OR\_?#WGP]_J5^E;:=*Q/#W^I7Z5MITH =
M1110 4444 %%%% %:^_U;5\Q?\%1W$?[ 7QQ8]%\ :\3_P""Z>OIV^_U;5\Q
M?\%1K1;[]@+XY0,S*LW@#7HR5^\,Z=../SK;#W]K&W=?F=&$O[>%NZ_,_D<?
MQ39KK!DED"QVJDDG^\>!^F?TK*O/%?\ PE%YY5JLP@9@K3[.%7N1Z\?A74:E
MX'TW2[=5CMX_EYRPW,3ZDGDFH/!NBQW&JW4I7]S&0H/8GO7Z?.CB)35.32N]
M;?Y_U\C]DJ8?%2FJ4FDF];7_ #_#;[C8TKQ7I?A_28X(66..)< =S[GW-86H
M>,IO&,DEOI-O+<%#\TA&R-?^!'^F35CQ>]G9MR(RV, =R:WO"&EVOAG0$+LJ
MSRCS),GHQ[?ATKM_>U)^Q4DHI:V_#T._]]6G]74E&,5K9:^27;[C)T34YO!^
MD^2\$LEPQ+R. /F8_CT'05AZMJVH>*B7>3[!91DAFW!I']@.@^IS]#6IXD\1
MKJ>J"SL]LTTA"_+R(\]V] *DN_!.DVEFOVN[N+B-.=C2A$)Z\[0"?IG%<]2,
MIKV=*7NQ\[+YO?UM^IS5HSJ1]C1E>$=-[+YO?UMK]YR5_H\=_:[XM\=K'P&#
M8:7L>>N.OUKL['PG;V&D+NMX5XS]P5B?VDM[J$7V6TD?3[=@<Q1$QD+T48&.
MP_"E\0^-=2U2>.UM+5H$8[3),NT#Z#J?T%84?84N:HU=[*RW]/(Y:#PU'FJ2
M5V[)66_IY%[P?I"WOBMF15\FWC.[C@,>@_0UL>+YX+.!L[>E9=AI6M>'=,9;
M?[*=YWL[9#,3W/\ GM63!H]_K^L,U[=;VA(<+&NU!Z<<Y_SQ73[25.G[-0?-
M+[D=BJ2I4O91IOFD_DCL?!FDKH6B%KC:LTQ,C#^[GH/RKG/%VH?VY>2V-FLD
MUQ(.D9 *CN<G@54\7ZCJ=M;".&>2:1FVA(P ?J3@\"KOA:ZT_P (:6SN^^\F
M&Z9VSN8^@_S_ $P3K*?^S+W8I:M_IYA4Q$:EL)'W8Q6K?Z>?Y&%-X.FT:SW3
M2,CGDA)6P/J?XC]:OWUI;:3ID:+&GVB0#*JHW$U:D-QXU22XVR6MDO"%EPTO
MO@]!^'-4;2UM[ 7%Q(SSW3OY:;CN8^RC_ 5Q^SA'^&M'LW^?^1PJC"&M)>ZU
MHWV[KUZ;(K>';*ZU>^426VZUL\9C##,C'GGV]N]=7K?CEK"S95LKC?T V@#\
M\UM>!]!BT+1F>X9?M%P?,D&?N<8"_@/US69?&V\2^)([-77RHVWS%3]T#G!^
MIP*]"EAIT:*M+WI>GR/4HX.I0PZY9VE+O:_E]R*GANXO-%CFO+FQ9[B;D,I#
M;%[ 9(_S]!6?K.MW7B&1I;I?L]K"2!'NRSM[X[?CS_/K/&GB:QT6P:,21[MN
M -PR:\Q;4H[@3/>M-,F_=%%""!D^XY].<@5CC*BHI45*_?;\3GS"I'#I4%._
M?:WS+&GPV[:L3<,TZQY A12VX]E"CKCO[T:AHDVH:U##Y;6D+YW1@@';UYQT
M_#FKFEW<OA>S>==-D$TB_*,C:B]A_C[UGQ^()+SSKJZDD69OE5(5[?EG\>.E
M>?+V:BHSW>O;3S;/*E[)14*F[=WI;3S;_([[X!?$/2_A'\0KB\O/ETO[,T4Q
MC16*-D%2,X]\X['Z5]'^'/VK/ .L0H1K@M3)P/M%K+$/KN*[<>^:^&;>19]0
M*SHRVR'=@G(8]?\ ]?K6K?:E)?P@6T>V-N/,8?R'^144,99-QMZ?U;0\*M@J
M&*E*K\+[+K\NWF?H1H7B[2?%MNTNDZII^I1KC<UK<)*%STSM)J:XX!KX#\ 7
MNI>"/%D=]HVH75G=0*2SHW#YQ\K#HR]?E(Q[<5]??!?XT6_Q,T&.&XG@CUNW
M7%S #MW_ .V@[J?T/X9]&A6E./OJQY.*RJM0A[6UXWL=%K$FTTFA0;[@'M2Z
M]$25;M5S0[;85^E/E]X\DZ/2K?*BMNVML=JS-*&$%;-L:ZX1-!ZP;1TKT?0_
MVE_$'A_]F'6_A/#9Z.WAW7M8CUNXN'BD-ZDR+&H56$@0)B)>"A/)YZ5Y\K4I
M&!53HQFES*]G?YH/4]"^%W[4WB+X.?!#QSX%T2ST:&S^(210ZKJ+PR'4!#&3
MB&-Q($",&<,"C$B1N1Q@_9P_:R\1_LOV?C"ST:QT35=+\=:2^C:M8:K#++;S
M1-D;@(Y$.\*[J"20!(W!R"/-Y>!5>5N:REAJ4E)-?%J_.UO\D3RH]!^.?[4/
MB#X_^#O 6AZS9Z/:VGP[T9-$TY[**1))X5" -,7D8,_R#E0HZ\>GFIDQ1(:@
MDDIQIQA'E@K(JR6B)3-@U!<WH05#-<$5GW=R6S\U5S,"T^HY-.M[S>U8[3Y/
M6K6G$NXHC(#!_:*\7Q>$_A%JTC-MEU"(V,([LT@(/Y+N.?:OC?97LW[8WC&7
M4_'%KHJR?Z+I4 D9/663DD_1=F/3)]:\=*XJ9:L_*^*,=[?&N$=H:?/K_E\B
M/9Q2;<U+LI"N*CE/F[C-F*-M/*X-+M7%/E CV4;>_>GE,]J'7%+E07&%:-E/
MV4;>,T<J CVXI=G-/V&A5S2Y0N1[/:E9:DV_+VH(S18+D++@5'MVU.R\4GET
MN5E*1#BG#)%2%*3;Q4210Q^E,QQBGLN30%!J;!<813-O-2$8-&W J;%)D3=*
M9MS4S+O/TICIC_/2I:-$R$\FF,,5,RY%1D<UG8TBR''^S32-S5(PIC=:SD:1
M9&W)I#P*D(P*85_*H91$1B@\\4]ES3*S9H1D8IK#"U(1N]J:1S46-$R.@C-/
M*BD/TI-%<PP)S7<?"CX33>-KEI'7;"A'6F?"_P"%-UXSU"%S&WV?<,G':OI3
MPMX,L? VDJD856QSSR:[\#@>=\\]CY?/L^CAX^QHOWW^!7\.:!I_@735*01H
M8P%W!1DFJ.M?:_$FK+(K,EJH[M5S5[]+VW;S"HV'*J*Y>P\0WNKW,R!&6&'C
M.,"O6J3BK06Q\31ISFW5EOW9K3>&H;2T\SSA&6.3SUJO>ZU]GC6&VW/(W' P
M/J367%XC%R[-(WF;3MC3/ZUGZOXHD-\MM&%1FZ@#DYKGE5BE>.AV4\/4D[2U
M+'B7Q*^B*G[S[1<2':JQJ2%-8]]83ZC;PR7CR0K,PR,$N_L![UU6EZ=#%$TT
MLD<*KP9#C<Y]%_QI+NRTRVCCNYG:YN=V^WBW=,="142I.6LF;T\1&&D5KW'Z
M?JDZ/'INGVT232KE53'[I!P2Q]?7K4/BG1H(M/D2:;[1,5PX+G&>_0&J7A>;
M5;S5KP6J[)KQ@LDKKM6WB4>O;))X[XK9\26]CI^F.L+&XE5>6;)#'OT_^O5Q
M]ZFV_P 3&7N54E^&_P ^W],P_AUX:^VZ+%)N:WT>Q9D6-FYF?<2_X9)&>3@?
MC6K?:A VHQK"MONY\H>2%6,_WL]> ">E<UHWBN3Q!=PZ?9Y\N/Y$B4=_XB?Q
M)SZ58\46,^G:C:Y61HY'$4C,RIG)' 7[W/3/O6,*B5/W/O.FI1E*L_:.S=[+
M_/S9O:E;OJFG>7&[+;O'N&P?OK@?WV/10>O)Z8I/"/PIDF@CDU198X+=/W5N
ML@S@L3EV[=N!S]*T/#T=]X@U18X(5ATFW93-<LFU9L>F?O#C  X'3Z]!KNHV
MCCR8VDF Z[6QD^IQS^M=L:,)>_+_ (<\NIB:D/W-/KJ^Z_X/XG;_ +*MX)OV
M@-'3=;?*DP"QKT B;OBOU*_9Z^_#^%?E;^R+:+%\>](981&-D_\ $3_RR:OU
M2_9Z^_#^%? <57^N)O\ E7YL_9/#U)99*W\[_*)]J?!S_CVB^@KVK1/]6OTK
MQ7X.?\>T7T%>U:)_JU^E?,GW1JI]VEI$^[2T %0W7W#4U0W7W#0!Q/CK_CU;
MZ5_&9)X@NK6*&SL8!'O^5-QQCW/>O[,_'7_'JWTK^,^P\/Z@[_:I%2WD(PJ,
M-Q0'U]_Y4TIO2%_EV/UKPMY[XF-.]WR:KM[_ %%.A)I\/VB^N?M5QG.&X1#[
M#V]3^E4+;4[>76!,[?N8>5..&;_ZU)K&D33RJUU<-)'G[@&U:Z73=%C33EVH
MJX'  HA2E.5HJR7?5L_6J-*<Y\D(\J6NNK?KK^IS_B'QHTL:I;1R-S]XJ0!7
M5> ?LFGZ:LF]&N)@&ED[L?\  >E<WKMHL;QKP-S8K/DU<"[6UL]\DC,$^3ID
M_I2C6E2JNI4UZ+_@!#%2P]=U:SN]DO\ )=ST;6?$-I:0EGEC4 =2:XF?5AK^
MJ1QQQ2212-D8'^L[X'M[],9K0F\'R2)'YGV-F4<O)NE;/KC@51M#_8.KK]G;
M[9?3?*N\[0H[X]!ZGK71BJM2<ESJT?Z_K8[,96KSDO:+EC_7]6L_4V+O3=8O
MU\M1#I]OT+,P9L>P''YD5E:Q!;Z5'Y=KNFF8<DG<[X]3_P#J%=%J$,T]O\VH
M)'D<[8\X_'/]*Y=(H1<20V+/<2?\MKB1MVT>G''X"IQ"Y7YOJW^208J*C+2]
MWU;7W)+^N[((_.FLU>YF6VLXQ@1@_,^..3V_"I+/5%TII'CM79VPD0VX_P Y
MJ31='A^T27%U(TBV[?(&/R@CDG%/&K6]]JB28+QQN-@49\Q\\ ?I7&KI)MV?
MXG'3C))2;LWM?5^O9+LE^9<T<W&E7)O+^/S)3_JP!D1?3W]ZM7^NZAK=N?L\
M8AA;@S2$8 [X'7^5+<:;J7B -OA^PP*."Q#.WX=OQ_*LO6K:2QA6WDNMMLF%
M8+\O ]ZZ)2E"-E?E^YO[]?ZT.Z3G3IVCS<O?9M^=];?TC.N;JZMY?)L[IV+L
M%D?N3T'\ZLG0Y(Y4AM6D>]N/E+;B6/J2?0=?2C0K236=5AAL8Q'#%E][*<#W
M_/\ /\*Z*TTIO"5S)=MFZF<8+OU4>@'I^OO6%'#\_O/;OV]#GP^']I^\=[=^
MB76W^9H+X-MK*V5FA1YE7!D89;\^M<?JVC)=ZLBC"K&2['TQ6Y?>.+F_MY/)
MBBCC7(9Y'QCZ#_\ 57$ZE))<;IF>9HVZ@?+YG_UJWQDZ-DJ:_0TS+$4%%1IQ
MNON_KU/2/"_CRW^S^1YFY[?Y6P#C\_PI?$7Q M88]J[WD;@*J')-<MX:N;'1
MM'\QY(U=OF?GI[?A42ZM%-J"W<D$WD0G,8V_?/K71];J*DHMJ[_!'0LTJJC&
M#DKO\$7['6O[":2ZO(66:3IQG:OI6+XN\4S:I<"-1Y:M@;>KMG^5-UW6Y_$.
MW;&88V;*A?F<CUI-"T"74M1=UC\F.$?>;YCN/]?Y<5Y]6I.?[JGL>76Q%2K^
MXHM\K_'O_6AZ3^R9I+W6NZY-*GS)'"HR=V,ESU_"OH:PL-N.,?A7C_[(VAK9
MW?B!?,:21O(8ENO_ "TKW>VLB<5MAZ'+&S/C\?3<*\HO^M!+:WP*O6\>*=;V
MIQ5I+;%>E1B>=4%MUX%6XH\BHXXL#BKENE>I1."M$$@S4T=K\PXXI\8W&IX5
M^:O0CL<,[W(I8 .W:HQ#D=*O20Y-1F/ JN@1HW94^S\=.:CE@R.E720#_*F9
M7/MW-8SJ6/6P^#N9YLR?X:0V/R<UI\$57NY%"GT_G7F8BJF>Y1RYVT6ISNKK
MM0_SKE]4;#5TFO2_(U<MJ3[FY]:\3$5%>R.Z.!Y%=GF7[0.J*EIIUK^\8[VG
M*K[<*3^;5P=CI]]JU\@LX9+R:08"JI<K6Y\2_$<FK>-[F.&UEN!"?LX*C(^7
M(('_  (FO9?@EX$DTOP]#MM_L_F+OF<CYW)ZC-?-\4<40R/"QJ<O/.3LE>VV
M[Z^2/OLLPBI8:$%VN_GK_P  \ U'P3K,48CFTW4HP268K;/S^.*=)9-IZ;9K
M>:)]FT&="O/T-?97A'P-;ZS<R/<+\L9PBXX_&M+Q!\(M'\1V,EI>PQS6[?PL
M/U![?A7QF"\8)1JKZQAO=ZVEK\DU9^EU?NC1T;-M,^5_"<]KXT\.6D/VM=-U
M*PD_T8J<+N'3/;FL;Q_\2]:T3Q]<,MTT>J6J"VDF7'RA>P[?US7MVO\ [*6D
M^&M;FU>&YO6MK5/,6W!^X1R2#W/' .:^:/'OCB7XA^+;G598([5K@(NQ3G 5
M0HR>YP!SQ]*_6N$,XR_-G5EE_O4TE?FC:47+6VM[K1[-K3?O_,?'V+Q.15JE
M"$4E7;Y6TF^7[7*^FMM];>9FWEU)?W4UQ/(TLT[F21V.6=B<DD^Y_G5>=U'Y
M4.^%_P \5#(2?2OOJ6'/Q"OC#:\)?%7Q'\/H9H]#US4])CN2&E6VG:-7(X!(
M'?WZTD/Q<\5VNIR7T7B?Q!'>2MN>=-1F61B>Y8-FL!CF@+NKMC0BM;'C5,3-
MZ7.\L_VJ?B/8P-&GC/7F5NIEN3*WYMDBN7\4^/=<\=3^;K6LZIJTG8W=T\VW
MZ;B<?A67LXHQ5QIQCJD8RK2DK-LCV_XTX+4@A)[4Y8#ZT2+A<B"9I^VI%@P*
M=Y582L=4$T0$4TCG]:G*4UHCGUJ357(@G/2K.GZ5-J5S'#!#+<3R'"1QJ69C
M[ <U)9Z?)<W$<,4<DTTQ"(D:EF9CT  ZU]+?![2K?X)_#>.ZN=/ECUK4%+W#
MRPE98^?ECY&5  ''<GZ8^=XDSZ&5X=5.7FG)V2O;YOR7_ /,S7-U@Z:<8\TI
M.R7ZOR/+OAS^S;J6L3M<:U9W^GV\)5A;FW;S[@=QCJJ^^.]?4.@?$ZQM=+AM
M%C6$0HL: +M"8& /TJ]\)]?DN[9IIH@LTV&((^[[?A6QXR^'&G^*[9I%_P!%
MNB=WF*.I]_6OPO/>(*^:5E+%Z1CLELMK^;OW/S3-,X>-J_[7'W5HK;+N[=?O
M,FVUO_A(KE=C9"MG@UNWVE6GB+27T_5;.WU"SF&'AGB$B-^!KSJRL+[X?WSQ
MS'S(U8[)0.'']/I6YIOQ%,\JHP'S<5X_(U[U-[;,YY8%S7-0VW5CS'Q[^P5:
M?VX-3\)ZE]C'F^:;.X!9(QUPC#G'L0?K74QZ!=64?V"1=LMNFS/J<=:]'AU_
MR'1U.0U9.M68N-<:[7Y59037H8S/,;BZ<*>*GS*.S>_S?7YD8C&8ZHHQQ$N9
M1V;W]+]?F>-ZK9:EX?U+S86DZXXKI/"WC.XNVCCN%*MTSCK5[Q//#=7NV,#Y
M3S5.TL$+;EX9><UA.*G&[6IWXJI3K4[\MI=SHY(HYAOV\^IK,\4Z]'I^F-Y<
MF7Z8%8NI^-FTE)$>1-HZ$]:\[G^(JZI>2;IE*QDD+GK3P^%J27NQ;L7A)58Q
MU3=CL&\8SZ):M-LW,P+9/:N&@77OB7KWF+)-#;JV3(3@ >U4H?&,WB3Q!%9-
M-&J3.$"KSQ7K?A_3X],B5(U554>E?=\*\+O$R=?$QM%;>?\ P#]EX&P492>*
MKPMM8]+^";0^"M.M]TSR3HHR[L3S79>+OB2=1M]OFD\8KR6SU9K9?E/_ -:I
M)]=9UY:OU.A@:=&/)322/U*,J4?>BDB/Q%'_ &C,S2?-DYKFK_181N_=K]<5
MK7NJ_+][Z5B:CJG7YJ[(44CEQ6+N<[X@TR,1GY1_C7$^0MKJO]W.17::QJ&X
M=:X36[[R+U7SU.*)12:/!K5;FM]I\LCFK=KJN&^]7,C5@XZT#5O*/7\:VC4L
M>54C<ZR35LC[U5I=4!/+5S4FOG\*C.KEV_\ KU7MC+V9T1O\]&[THON?O5@0
MZ@6J87^!S1[0EQ-HW_\ M?\ UJS]0UF2966%B ."PJC]M>[E\M&^I]*=K+K:
M:;Y-O^]N&&/QK:G[VI\SQ!F3H15&D_>?X(S[=4%ZTMQ*TTG9<]*B,0O=66:X
M^6&,_*OJ:?H_A^;3[:2XNG#2-R%/:L?3?$7VC6)&G4;;?.%]3572LI=3X^4I
MU92G?F:ZG:&+?9LT<(5<<<5YKKL$T/BZ#<K>5(WX5Z-8SRZI9^=(RQQ]A6')
MX>37]<7YV:.#+':O7VJL13YTN4QP=;V4I.0ZZO))=.80I\BK\TI''X5T7[,7
MB+R_C5X/M8VW&36( V/3>*JZSHS)HQA\Q;6/;@*!EOQK1_9/\.Q:%\</#DTC
M?:)KC5(5BX_U:[QDUSXR,U!V[/\ ([,MJ4W5B_[T;?>C]D_V??OP_A7VY\%?
M^/>*OB/]GW[\/X5]N?!7_CWBK\S/W8]Y\/?ZE?I6VG2L3P]_J5^E;:=* '44
M44 %%%% !1110!6OO]6U?,7_  5%N%LOV!/CA,W"P^ ==<GT TZ<U].WW^K:
MOES_ (*K+&__  3T^/ F_P!5_P *]U_?_N_V;<9K;#MJK%KNOS-\+)JM!KNO
MS/Y([SQ=-XQG:/38F>./.Z=LB(>P/<^P_2JEUK]UH.FQVBR11]5\P^IY)Q_2
MF>)/B<+>V6#3;62X;H B?*H^M4_#=EJMW=B_D2*2?!VJ3\L6?3W]Z_1IXERJ
M<D).4NK2T2_KSOZ'ZS4QCG5Y*<W*?5I:)>7_  [?H,TK3KV]G>Z5IFD7I=7"
M>6HS_P \TZ_CW]>U;OAC1I/%^LM#/)+-9VZ_O3N*AV[#(Q]?R]:S]<76KD8F
MEBMXP.5C&YF_$]/R-:G@[5[KP[I*KY*M&.=RCEB>Y]ZK#4XJIR3O;=WZ_+\[
MZE8.G"-54YJ7+N[]?E=_.^K.DG\#V.G6GEP0QVZ*,@(-OZBN;LO!47BKQ/;V
MV3-%&WG2^8Q90HQQCIR2*O0ZMK7C>:6&QCBMX(R%DFER<9[*!U/XBKFG6LW@
M 3/&IN))L;Y6/SMCH/3C/:O2E"C5:M#W%N[=NB1[$J="LXM0_=K=VLM.B7X=
MCK;ZTATZP\M%55C7  & !7&0V/\ PD/BB&./'E6Y\V5NP'8?B?T!J,^(-8\:
M2R10>59VR-MDF?YF]]HZ$_4\>_2L^_O'\'%H;2X:2:X(SNPSN>@Z?T%:8C%0
MG:5GR+^K(UQ6,IU+3Y7R+Y7MT1V'C'7+?2]-;<R@#C.:XW3=>N9(;B2WLV_>
M')FE;8B@#@>I_ =^U9FMK>:C.LTD=PL<9SYER0H!]DXY]SP*W?#OA235O#Z-
M=7$T,3;BL*87<N3R3C//7@BN6>(JUZUH)JW]=?T_X;BGBJV)KV@FDEIM^;Z>
ME_+RL?#;0I+R:XU"[D\Q6'EQ'& <'D@>G;/<YJ3QMJ-K9_NE**[< GM6;?Z]
M)IEU':1WBQP+P=H7Y%'I_*L\:8VNW4TUK#(\?22ZN"3O]E''TX 'UH=91I>Q
MIJ[Z_P!?YA*NH4OJ])7EUZ^O?\?O-:;7'?2H[>R@D%O"@!N)1L0_3NWX<>]:
M'@;X;0QZ8U]=*KW%W\ZL?O(IZ<]L]<#UKE=3NYIY?+NI_-$6-EO$F _U Y-=
M-HGB;5O$+O;1M#:K"@+/LW;?;&13P]2G.K>HFVM$M/Z7S886K2G6O63DUHEI
MO^2VZLS?'5NVF?NXKN?Y@<(),?J:Q=#NO[*CDD>VN&CD&(H8LJISSN+''YUM
M7OA!=:\3VT,LLEXY8-(SD851R>!Q[?C6OXW-O86JPP[6D8A50'DFLYX>4IRK
M/W5';K_7XF=3"SG.6(?NJ.BZ_P!?BCCY_#\>H%;J2-%:0@*NXMCTR3UK=GL[
M:^U.&U\R-5A(DE)/0 CC\:R7222[@AN9XX5C(W*C<1J/4_WC[=/?K3;N[TV6
MY\NTA;[/$29& +-*?3/5OUK"#A"^BUM>^C9S4Y4X7=EJU>^C?R_/LC5\8^*[
M6_NET^S1[B1CLQ'_ "STKG]?T.<2;[AMH/6-3\OX^O\ *M/0+RWAN7NGB8/%
MD11+&<H#W('<^G^15US4#X@F99@T$ Z@D!C]?3Z=:G$-58N<W=O9;+YBQ35:
M#G4=V]DM%;S_ *^1054)5E0R-@B-!_%[T]+&YOX-JM]F6/MC<Q_I_.K^C6=M
MI%NT[!5>3A<G)"]A_P#6JM>7UT"_E6YC\S^)QC(K#V:4;S^Y?U<Y?9)1O/KT
M7]7(],O)-'M5C5HVD8]2>3[FKVA:_>>&/$=IJ5K=>7=V<HF6;R\?,.PSG@]"
M #D'!JK'8FVC4A8]S<[4^9C]:TK*SN/LWVAHE!+99Y#DM[ 5=.G)KE[%TZ+G
M'V;V[:[?UWZ'U)\(OC]9_%*!;'4K==(UAE&V)GS'<GN4/8_[)YQW/./4M)AV
MA:^#_M37 :69I?/3 0)D%?? KZH_9E^.4/Q(TK^S;QFCU:Q0#]YPUT@P-X]_
M7\Z]*G)-V_X<^;S;)U07MJ'P]5U7GZ?D>R68VK6E!-BLV \5:23!KKB?/&@D
MWRT[SJII-QUIWG50$\CYJO*?QI?.R*:[9%(""0_SJM*>*L2#BJTE2T!4N#5"
M['!K1F&:H7$>,_RJ6@*BIN:K&H:S;^$]!NM1NFVV]C"TSXZX S@>YZ#WI(%R
MV>U>8_M8>-X],\%PZ)%*INM2D5Y4!Y6%#G)],L%QZX;THBK:G'F&,6%PTZ[Z
M+3UZ?B>#>+?$4WB[Q/?ZI<<2W\[3$9R%!/"CZ# _"LTC!IZKBEV\U/*?B-2H
MYR<YO5ZD>*,5*$]Z795<IGS$.*,5-LHV4<H<Q#BC%3;?>C91RAS$6PT;#4NR
M@)1RAS$.*",5+LS0(\_C1RAS$6*&&14QB-,>/)J5$I,BV4;#4GE<^])LJN4K
MF&;:'7BG[3377-9\H<Q%LYH*\5+@FD9?EJ7$?,5]ISFAQQ4I3FF,,BHL:18P
M+S3&7<:D88%-[5#+YB)AFF,,U+M^7O3"IK-HTB0E=@J,K4Q7-1NN36;1HF1,
M,]J1A3V&!3&^6LW$TB,88IA2I2,FFG@UFRTR,C::8XR:DV<U:T70[C7+]+>W
MC9V?I@5G:[LBI345S2V*=M:27<H6-2S'CBO1?AU^S_?>([E9+C;%#P>17HOP
MA^ ]GI&DB[U!-UR3D*QQBNX@O&T2X*K&L:] <=J];#Y>DN:J?'9GQ,VW2POW
MECP7X5L_!&E+:PL&D5>>.]9NOZKY4\G[S=(PP!Z4:AKZVLCB-_WDHRS'M]*P
M+C3)WW2,TC/)T)Z 5Z%2HDN6*/E*--RFZM5ZL71K1PS2W#-)N/*CM1K>MVZ6
MYAC'EKTVKU-+J>L1VEA]GC;&T8.#\S&N:\*6+ZCJEU-=;OL\/W<_Q&N24[6A
M$]&G2YDZD^A8\$^'EM[FXOKIE6!2?+4^]6M12-K>:_@MXXX^\KC+OCTHTZVD
M\073"XD^SV<7*IG;D5<U?4K>\EAL;7;-T5(U3*_YS41BE#^MS2I.3J7>O?LD
M.NK3^P-(%Y=.HN'3Y$/_ "S&.@Z\^^*QM"U>V@THZM=,S7FHLWE1Y^:- =OX
M9QUZX].IW==L((;=VN+B*29A@F0>8V?I]U?U-<CX2T*X$EUJ5_M7R7*6*)_&
MH'!5?ZXP,<<]"HVII+^O-E4%&5*4I/JOGY+]?0VK#5%U+4ET^QCQ&K'<%/\
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MXTU6)K69E:1CCCTIG[)'B5IOCGX?6;_6-J]O"F>PWC/\ZM:TOVNS<>5&JD<
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MT"XNKZY;3;2%#Y8 )EN#V"]E'N0?QYKCDU7^S/%TTTDRS38"01<L$8]7^N,
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M][X*BL&F61I)F*2;>40D@*,]/Q]?SKO]%UR;Q%=V^G6?^IMX]H&=JD <L?\
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M+45\/Z=(WV>1IIFW'(VA:4J-I*-1Z(<J/+*,:LM([F3K\'E7*M-)(X4\#/\
M2M*U&I26I9]RQL/E0M@BJ]IMUG5_WDB]07.?E4=<>]=+X@U^UL;=44[Y&X55
MZFM,/2B^:HW9"HTXOFJN5E^9S.DZ1)J6IR(_RK&=V$]?<U]U?#O]CO\ 8+US
MX9^%=0\;?M6>-/#OBZ^TJTGUC28O!.H74>G7SPHT]NDB6K*ZQRET#*2&"Y!(
M-?%%KJS:)9S2?9V\V;DDGI4>BZ3-KUY]JD:-/+;(#Y&?I71"C%I0CN>7C\M^
MLTXTJ524)7O[MMO/FB_PL?H):_L7?\$[])N-W_#8'C@R3?*H/P^U+^7V.C4/
MV(/^">5G/]HG_;$\<+)_#_Q0.H\?0?8Z_/\ UJW;3IQ(;CSKD\*$7A:KR7$(
ML2_EM-=,,&1CP#["NCV?+[K;T]/ZN>34X?FKQ>*J:>=/](;GZ!2_L4?\$Z=V
M^;]L/QQ/)V;_ (0'4FV_@+/C\:FLOV(?^"=Z:>SI^V)XV6%SEF_X0'45)_.S
MK\][+0IELCYR\,=V-^U?QK*^U?9[S$:^<RYQGA1[_05,HN.LK_U\C#^PJE-I
MRQ-37_!?_P!-GZ*R?L6_\$[[Z(PQ_ME>/%MXQ\R+X U(<?7['5'_ (8D_P""
M<*[F7]LKQNB#CCP!J7_R'7YYV.DZAXIUJ.Q@8,UPV&8?='_ZJ[;3/V7]5F?:
MVH6J1X.65#NKSZE9MV5SR\1@N2=IXFI?_MS\/</MB']BS_@G"ZK_ ,9D>.I/
M[N?A]J>%_#['_.H?^&+/^"<$,[?\9E>.O,;J1\/=3/\ [9U\2K^SAKD6MQV)
MRT,C8%P!^Z4=<MWKG_''P_U#X?\ B22QOVC;:H>-XP<2H>A&?Q_*L95)KH;4
M\IE-J,<34OO]C_Y ^^/^&*_^"<.1_P 9F>.FP>@^'FIGG_P#JU%^Q+_P3DN1
M@_MB^.Y/3/P]U, ?^2=?GEII7S59K=A&HX]S5]C]HNXP 5CR-V/2B-VKL]&C
MPW4:O]:J?^2?K _0NQ_8:_X)US*8X?VP/&YVG+?\4!J*Y_\ ).GM^P[_ ,$Z
M[5OE_:_\;C;U_P"* U)A_P"D=?!-YY)\M?):)!CYCQGV%21W/]LSK&BQV\2@
MX8G-=2IQVZGJ_P"JTE[OUNK?_N'_ /*S[ZMOV*_^"=\"^=_PU]XX96[MX U+
M#'Z?8ZGL/V0O^">,%Q(W_#7OC:1L8(/@#4UQ_P"2=? CPQV]S'O<S+$.,#Y3
M55KQO/D;8P\SA0HI^SLSJCP_5I[8VK_Y3_\ E9^B0_8Y_P"">L,32#]KCQ@O
MG=#_ ,()J.[\!]DJ*W_8]_X)ZVUOL3]KKQHWFMC/_" :DS$_^ =?G\T2IINS
MR&\Y>7=_X?H*;!J,Z7\:F-D@1,(0!GFMO9ZZLW>25DU_MM;_ ,I__*C]#8?V
M-_\ @GVP5E_:Y\;LT7.9/ NHE1^!M,4^#]CK]@.]O5N$_:^\;R22'8N/ >H<
M^P'V2OS[1/M2>27VJ6X'4FO?/A)\#;/3-$M;R95^VW $B*1]Q>U.O+V4.:[\
MEIN>1Q!&668;V\\;6;>RO2U?_@K9=6?H=\'OV//V/? >BQK:_M$>*]2CQE)+
MCPK>(0#SP/LXKNV^#7[*EK;;E^/7B38O<>$[UOY6]?''@>R_T:*"5=RQCK79
M-9QB'&55?2ML'@W./.]&S^;<VS>K4Q$IU)N3;W=OT21](1?![]EW48F>W_:$
M\41JG)/_  A]Z,?G;UCZ-^S[^R/%;/<+^T)XEF\[DR-X5O ?_2>OFOQ]>BST
MI-/C.TWH)D<=D'4?C_+/K7'W.J):PB)>% Q7XSXE9I2>,C@H4HUG36O/S63E
M9V7+*/2U[WWMI9G[%X9Y?B%@Y8V>(G151V7)R:J-U=\T)=;VM;:^MT?= ^ /
M[*B6:?\ %]O$&P 88>&KOD?]^*ZK]GG]G_\ 9CU#XY^$TTSXP:OXDU#^U8#:
M:5=>'[BW@U"8."D+N\(7:S  @D YQWK\_/#?C5=JV,AYZ(<]1Z5U.AZG=:?-
M#=6<TEO=6<BS0S1,5>)U(*LI'(((!!'0BOS7"YW0A6BJF#I:/^_T[7FU]Z9^
MJ8C*L35P\U3S"M[R:WI]5UM33^YI]F?1'_!0CXJ>)/%G[67C2V\07=X/[#U:
M:ST^V=R([6U1L0E%Z+OCV2$C&XOD\FNZ^/'CJ^\<?\$G?!WB3QF[W6K:7XLD
MTO1K^Z8FXN;,Q2[EW'EU#1E<_P#3!?3G#L_^"F?A#XNV5C)\7/@SH/CCQ-I,
M:Q+K4%\;&2["_=$RJAW>XR5R3A .*\9_;5_:[U[]K;4=)M;C3]-\-^$_#<)@
MT;0--7;:V*D $G@!GV@+G"@ 8"KDY]3$5,+"6*KPQ'M'732C:5U=IWG?W?=Z
M6;UVLCQZ$L95A@L++"JDL.TW*\6GRQ<;02?-:=]>9*RWNSP'QG\1K6X799Q2
M3S9ZXVH/Q_PS3?"/B.-8U6YQ&S<DGA:P?$MMY-_#%_>;MV]ZZ"P@ADL5CXW8
MZ&OF?J:4=9W9]%/&SE-NVAS7QN^+^G^ -%EN/.CED92(8PV3*_8?X^@KXXUO
M7KCQ'J]Q?7DAFN+AR[L?Y#V'0#L*^A_VJ?#]M/X+N+BX=8Y+5D>$^K%MNW\0
M3_/M7S4K;J_IOP+RG!TLNK8^"O6E)PDVM$DDTH^3O=]W:^R/Y1\=,VQU;,Z6
M J.U&,5**7=MIN7GI9=EMNR0O3HV^>HQSZ4Z+EJ_>7)<I^&^S;T+!:HPV30'
MXICG:*Y^</9M;DNZDSSUJ'S:#)@5/,/DN2[^::9.*C+<TA;%.X[:#_,I0<]*
M6QM)-2NHX88VEFF8(B(-S.QX  [DUZ1>_LK^--,T3[9+IT*G&XVZW*-,!C.<
M X_#.?:N''9KA,(XK$U8PYMKM*_WG'B,91HM*K))O:[2/-F# =*=8:C)I6J6
M]S&S+);R+(C#J"#D?RJ6:*2VE>.16CDC8JZL,,I'4$&HIXM_6NN\)Q<7JG^1
M3ES;['TZ-776-.W1L)!@,C*<Y4\BH8&8JRMP&]Z\T^"7BC4;;3?L\MC<3:;;
MRB/[4H^6,'DH3^/X9 [BN]?4EU/=-;+LB)P 3GIP:_F_-LAJY?5G2J--1=EY
MKH_\UT/"HY/7PV%=:JU92M&^\NMUZ=1-0\$?VH0RQNV#P5."/QK2T/PK+IXC
M"W%PK*?NNV0/TK9\&:\LD7ER+R!BM&_GCAN<XZU\[4NW9F^'S*<6HR1O>"->
MDTF';+R1WKMM+^,<UE\L;;  ?F/:O+8O$$4)_><#ZUQ'Q<^+L>CZ;-;VK;I6
M7:N&]>*X987VDMC[S)L0JDE'N?>O[,/[7<NG7L;_ &J/RXGXR>IKW_Q9^VXV
MIZ3M^UQD[<=:_)CX.^.YM+\+6;-+N<@L2#Q]XUW\?Q@D*X:1OSK]VX>P\<'@
M*=*FMTF_-M79^[8'+\#"C"T5>R^;/HKXK?%L^)KN1FD5MS9R*\C\5^*P VUE
MZ=:XFX^)BSK]X_G7-^(/&WGLW/7WKZ7"R;D5F^81A3LC4UWQ(TTO#C&369'J
M^]N6]JYJ;6C*_P!?>G1:CS7T-&5D?D.88AU9G4"_#_Q8IK7B_P!ZL!-2P*1]
M3XZUO[0\WE-QKX#^*HY-0XZUAG4J:=1S2]H'*:-Y?;E;FL:^N,]ZDDN-YJK>
M1EZSE*X<I32;JNXUP_Q#M_)UGS/X9D'/N/\ (KN!'S7+?$RSDETEWA4-)'\R
MC/7\:Y:D6XE\ZA>3V1Y[X@UJ2Q$,=OAIKA]HR,X'>JU_<PI#L5FN)Q]]F.5!
M[X XK&DTS4%UOSI6>YD:-DBBB8,2YQC'ITY/I79Z?\/=EA'#)>1)P#*(06=V
M[_,?_K_UKGHTYSNK'R6;9JI34H3:CV7XWL<';7'E/=222,TDS".-!]YN.@KM
MO"OPYNM7B4WEPMN-ORQKC*#W]*R-6T6QTGQ3;VMK;R?;&^999')"#NQ^E>K^
M&O#O_".:3YAD4R2@'S9A_P"@K_4UT8/#\TFI=#P<RQW)3BZ>CEMI\CD8?AWI
M>C:DJ_:;B9W<%R>%P.379Z9?1E-MFJK&!C>PRQ^E<%XXUZ:UUU1)*TD<QV!M
MN /\XKJ/!EZEQIKRM*L441VDGDL?0"NRA**FX05CR\5"I*E&I4=S-^*GSZ#,
MKS-D^IK6^'_AN1/"%OYTDC0JO"[MBRO_ !.3Z9R !S@52U>XTN_U!6N+7SH(
M#YK"1B?,(/ QTZD?AFK\VNR:RGG2?*F,*@Z*!514?:N;[$RE+V$:4=-;O_@?
MU_P+R):V,1FO+>QF5CB")1NSCJ3GD]O;K4EWJ5QJ,'S95 ,".-<!1V&!6#X:
MGAUW4KB[NG9+*Q(B"KUD/]T'MTY_#US707_B1[NWV6ZK;VRC"J.P_P ^M;0D
MG&_0YZE-QE:UWU[(\\^)EOY]DRLLR\9W$$8K3^ _A2?_ (1%;Z_\RS6[4EY6
M^5Y%!.U4SV.-Q;OD?A=F2&\O]UVTC6T(WR#)'F#/W<^_\LU?EEO?$UF;Z8BS
ML3S&7_C';:OI^0KEITE[7VGX?JST*N(E]7]@M-5K^B7GO\CJO#^FZ?IFFW$R
MMY5O+]XAOWEP1V)/\(_F>U0W?B)[B+R;...&%>RK@5R^JZMY]Q#9Q-^YM0J?
M[Q[G\>M;FGLJQ?A7=&K?W8Z'D3P_+[\]6SFO&WA\ZQ9S+*SMN'8U6_9,@OK?
M]I'PKINUI!#J4,Q?' C5QDG^7U(]:Z36UDN('$4+R#IGHH_'I5O]FJ^;0OC7
MH,<R*LU]JUK$,,&(4/\ _7KRLPHIQ<MM'^1]#DN)DIQA:_O1LOFM3]?_ -GW
M[\/X5]N?!7_CWBKXC_9]^_#^%?;GP5_X]XJ_,#]Z/>?#W^I7Z5MITK$\/?ZE
M?I6VG2@!U%%% !1110 4444 5K[_ %;5\R?\%0GCC_8'^-[2;?+7P#KI?=TQ
M_9T^<U]-WW^K:OF3_@I^(V_8*^-WG!6A_P"$"UW>&&05_L^?.?PK?"_QH>J_
M,Z,'_'AZK\S^3-H7\:W :W5_[/7YGGVD+(!_"I[Y]1T&?:H]*TE9/&MG;Q)N
M^8E@.R@'D_I6KXJ^)=K!"MO90SWL[<+%;H7;].@^M5?"VM+X9F-Q=6\C:E?$
M($!#&($\(/ZG_"OUUJBZJCS7::;?3T_X!^[-4'64>:[33D[:>GS[7OK<ZOQ#
M9QVMIR%&!7EOB*YDFGD\GS'C!P0IVJ3[MV ]N37H&MZ7JWB:/YF@T^+N6;S)
M,>P''ZUA:EH\=S=0Z39[5=AMW'^$#DL?\\GZUIF$)5-(JRZ>;-LTIRJZ132Z
M=V^R7^9R7AO3FUK4(K>ZF\NUC?\ >J6VK@<D >_3U[UTVNW&CZ1:K;V*PF0G
MB.$98GU./YFNL7P/9V&G"-88Q&HZ;>*X?Q7''8W(6UCB5HR7;L,"N66%EA:7
MO6N^N[]$<4\#/!T?>LV^N[]$8UWHGGW=NJJO]H7$@4'&YDR?Z UUMM\.VL+0
M[FN,MRQ\PC<?PJ'P+H1TG68]2U;=YF-T8 ^521W^@/3^?;IO$OCRQBAV0[IY
M6'"1C<Q_ 56#PM%0=6MH^W7_ (=EX'!4%3E6K^Z^B>_JUW9QNAZ?'IVMR0[5
M6,(7/Y]_S[UW7P?^":?$_5Y=3O%D;2;=Q'&B\+=N#\P)Z[1P..I)&>"*H_ G
MX4S?%;Q9=7&H1R?V/"-DH1ROFR9XC##G R2V".P[U]8>$O"5IX<TN&UM8(;>
MW@7;'%&NU4'L*X[\ZY(K2Y\5G6<I0>$H::ZO]%_7D9^D^!8;>)0(515&  .E
M:UMX>2+^'I6S&F*>%Q6T::6Q\ARF?%H\8_AJ:/28SCY:N#FI%/%:<J'RHSY-
M%C#9V"D_LM4'"X_K6F6R*:PX_6CE0<J,V:T&S[M>._M1_#F*?18=>ALIII+-
MB+M8!\SH0-KL!UVXQGT;G@<>VSU6E@CN[=X9D62*52CJW1@>"#36CNCLR_&3
MPE>-:'3==UV_KJ?!LFG3:M=SN8WMXU&[:>#^-#:=;VKPR1J/,4<L.QKL/C)X
M4N? 7CW4M+7#0N_F0\?,T1Y7_ X[@U@VMO#'Y:LWF2MU]%I^SBW^I^ITHTZJ
M4X:IZW?GJB)%D55W>8TC'JWI5F%/LZM'M4,QZD]*D(:\O,;=I[>PJO(CFZ9=
MRJJMUK;EL=48\I9CD:V.T2,T>>2.E*U_(7PORQEN<#J*GLX%;$.[<A^\0*MP
MVD<4[1;555Y.:WC3;V.B,96T8RXN/M<,8BC"[><^M5+V\:)?,D8-Q@$FB^E^
MR,^9%V^@KG-6UEKD^6IK+$8A06NY\?Q5Q92R^BXIWD3WNLL5VJU4Q<,[?,:J
MJ<'K4@?%>5+$.3U/YOSC.,1CZCG5D[=BPLE.$O-5PU.+U:D>"XED2<T_S<"J
MPDR*>KY%:*9G*!96;BE22H%;(IRO@U:D3*).9<__ %J>LF%S5<.0:>DF5JN8
MS<27S/K3Q(:A0Y-/W<U?,R>4?YK4>9WYIC-BDWU49!RDGF4JS<U%YE&^CF%R
MD^_-+N^M1 X%+O-"D3RDF\?TH+9J'=2[Z?,+E)0]&^HMQHW&BX<I(9/\XHWF
MHMQI2V34.0<H]Y.*;YE-8\4W?3N4D2;Z-]1^92AN/YTFRN4>3Q4>^E)R*8F7
M;:.23@4KARGLW[(OPR_M_P 32>(+V!C8Z3_Q[,PPLEQQCZ[1S[$J:^B+JZRY
MP:S/!_A2+X>>!M-T. J_V*+$KJ,"20\NWXL3]!BIVY/I75&/*K'T6%H^S@D3
M))DU8)RM58ZGWX%,Z!DW(JG*V*LS/UKJ?!O[.7Q"^)_A^35O#?@/QIXATJ'=
MOO=,T2YN[=,9SF2-"HQ@YYXP?2LJDXQ5Y.Q48M['"O+S4,K[JZGP/\#O''Q7
MU?4-/\*^#?%?B:^TG_C]MM*TFXO9K/YBO[Q8T8I\P(^8#D&D^)7P#\??!JUM
MY_&'@?QAX3@NF*02:SHUQ8K,1U"F5%#'Z5A[:'-RW5_4TY7:]CC)5S4#1<UH
M:5I-WXBU:UT_3[6YOK^^F2WMK:WB:6:XD<A41$4$LS,0  "22*T-?^&/B3PK
MXY?POJGA[7--\2QR)"^DW5A+#?*[J&13"RA]S*RD#&2&!'6I<E>P6?0P47 J
M0=>:Z;XD_!/QE\%[NVM_&/A'Q/X3N+Q#);QZSI<]@\Z@X+()54L >,C(S7,Y
MHC)25X[!)-/4DI6EP*@,F#37EPM7<DKZI;6UZRM/##(RG*LZ@E3[&O-/B??W
M'AJW#0@-I^<$B1E,9)[@'OGKZ]??T'5+O%<!X\F&I:?/;^3]H5QS'CK^?%<U
M:HTK1//Q^5X;$0YZJ2:UOM][_P SS[1+6\\:>)+AF$W]GV*KYB;R!)(<D*6;
MH .3SG'3KD=KX-TBS\.SW&H74EK"9E B$"\[1DD@D9Y..<9XXZFJ7AFWL_"^
M@R0_9]UQ,[7,R/)O2-V SGU;@#T&..F3G:W)-_PBCZQ/E5N<>0F>D8/^ K*B
MG3@ISUE:[['P.)E[:HZ=/2%TEW?YZO<ZJ]U*;Q/;/_K&A(.R)<G"TSPSHUGX
M+TZ3SH8YKZ:4RI!G<MMT R.F[C/?'US2:;=W.G>";6XAC6,3A67)_>7#$C:!
MZ $@=>N?6M>TT^7P_H<DJR1?:)LL]S(.7]HQUV^YQG]!VQC=\SWL>74ERQ=-
M;7M;O;^O7\3-\,SC23?:A?+YE[?2>7!"X^Y&.I(/JWKUP/:L[X@27&JVL,EX
MLQM2PS_"H7/;I^E)X/UE+F>;5+M1.EK)]FAC8?ZR0 9./0=?<D>AJ;Q=?3>)
MHV:=OE88V@\8K.4DZ5E_7FS:,7#$<S7S[>2]/S,_2M8?4[[S!NDEF/R*.3[
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M1%!'_0"N=U"PN;MWNKTFUC4YCB)&XX_B/^%9^F:^NAZFXA_TJXE.QY%7./\
M94?7_'M1K7VKQ+JL=J&FEDDZ1 B-/^!'DX^E36Q7M(=WV6W]>A^NUL8JD.[6
MEEMY>OR,V]9]6NT;#W67"Q*Y)#FMR72%T2T^T7$X6YZC:<!/8?XUH6?P_ETX
MK/-<_OE7"K$FU(_IFLP:$=0\56T;223?.2=QX  STZ5A'#SA[TE[S,XX:I3]
MZ<?>DU8T?#26D=JUW?21R3,V8S(VXHO]*R]=U"/6)&6,?Z/GEL8#?2M_Q'I-
MKIT.=JYQUQ7,1LL;Q^6_F2 [PA&$7ZUK6C**5-_/S-<5S4XJB[>?=^IT7A/P
MG%::"'FA56D);!'0=JRKPV4.JJ^%V0G)VKFG6WB6;6+IK>2X58D&&*<9/H*3
M6&MU5;6U4,S=<<X]S6WN>S7LUHOQ(J5*;I)4DK+ONV%OK45W?B>93]G!_=KC
M[YJ37;F1BLGRVT*]<MAG]JR;/3&_M +-,WEPC(QQBDU2Q:]'G,TGE1_=W'K1
M&I/D?<XW6J>S=UK_ %^!!K7BJ:4*MO;K"I.&8#YF%6O[8C%K%#':'[1)@+E>
MA]:JB_A$R%5:18^3@=ZU/"FEWWB?4A=V]J&CB8A1GH?>L_;6E[TM]#S9XJ,'
MS5)[Z>A#=M<Z?9_Z1#)(W7E_E_*G:9X$U'7S&8[6X:27'\)55%=U:_"^?6)D
MDU!MBH<^4G?ZFNZT[36A50J[548 K.M43E:.J/+S#.*:GR4/>5MW_6HSPGX-
ML?#UE#Y=K!'.J .ZH-Q/?FNGLV -4[>!L?XU<AA8&L$?/:MW9H0.#7'_ !S^
M&C>/?#PN+*-6U6Q4^5GK(IZK_4?_ %ZZR $&KL!IO4ZZ%25.:G'<^3K>"XMF
MVS(I\KY63& #[U<@AW6\DK8SG "C %>E?&7X6?V3=MJUAN:"ZD/G0]HW/\6?
M3_&O/0DL2M&D:9#99B<_A6L(Z7/T; UH5J2J0V_4C8W2JK7$/F-)Q&&Z+[XK
M4$T,JQVBPI$BC<[XJ*2T^UWOF7%PVV%> HXS0&:-MS;BK]"171&/*SU(WC?L
M2ZI;M+;;U_U"# XVBH] =YKB...%66,$YQU/K3=4NOMGEQ[RT:] .,TFEM-;
M)(T?[O ZFM5;VB:)E->UNBS>>8+UFD4EMW.>].GD%\/F5?,/"@'&!37EFN%S
MMW+'R3TR:FM+&9W^?9%M^?/K77"G=@YW'V,<FG7,<R[7D4C*D?=K[-\ ^&)_
M$%O8Z@_[F)K:,JG3C:,\5\F^!_#S>+]?CB7"JN6<^H%?3W@;XF_9[:WL9-JB
MW01@CN.@K''48.4(==S\=\5,SIPC2H0^)7?R>GXV/2M(U..PNU2+YD7ACBM^
M[D:YB_=_Q#BLJU\-"YMX_)^1<!LXZUNZ;:^4D<>=QZ5ZN'IVC8_F[$XCFG<Y
M'QKI]Q//%DG<D0Z?4UQVN:#,+/S%+;EKU+Q9;&WU%6DXCFC 7\,Y_G6#>Z>B
M(0?NFOY:XNQ#CG^*A)6:G^%E;[UMY']3\'4U+(,+.+NG#\;Z_<]SR6"\O(;]
M/E=6C;(;T->G^$/$:ZI#L\SRYE&&7/6L[4O#UL\;,!AO:N)O-2E\-ZP)HY-H
MC/!/?VKYK&82&*UAI)?B?287&3PK][X6>EZG:_V>9)N<$Y)]:X'Q?X]DMKEX
MX;@JV..>]=CI'C*S\7:;Y<KK#-LR5SU^E>)_%"RN!XU\JP99%!!9L\#U_P ^
MM<^'IT9KDDO>[&^+Q56"YX/W6=IX2LKF^<W5U))/(1P6[#VKS;]IWQ_KO@ZS
MA;2[N2Q0W B9D4;FRK'C(]NU=;:?'73? >ES'68I888  9$0N"2< 8'/]*\
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M2=,T32H;6QMFFCA'^MG;<TA[L>V?H *RK_Q')?ZN+5F_=PME_P#:)Y_PK?\
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M7MUOJ?*\39Q&CAYT*$OWLE96Z7W?EI>WF;'B;]G[P_XCU&V:]TC32MG)O3;
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M?:KY6CL+%B_EL/\ 72=0"/0<$^O K6O?%DWB"8^6S!,]<UQ,'C!KO35MU?\
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M=\CYRJ!<\G\SCU-=E:'LY1Y3X[#5E7A4Y][?<OSV.\O?%>ZY2YD556$9BB'
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M&&&&&#T(XZUX)XXU;5--MMOVI57'WM@R*A\#?'OQC\.=/ATS1=8O-/M]S2R
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M.  .2:Z:7PUJ$T:[U2WWG $C?-^0J[X6T33_ (8Z###)Y%QJVS=/<8W%6/\
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M]J/]FGQA^QK\??$GPU\>6$6G^*O"\Z0WD44PFB</&DL<D;CADDCD1U/!PXR
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M@5WJBOBJL\EXB7P8=?,RHOAMHV@3&;RXVF'.X^M2_#%8T_:#\&M"-H_M>W!
M]/,%-G$EZNZ1C\W.!5[X/6"K\;_";=UU6W/_ )$%<6/C%8>:BK:/\CU,GJ3^
MN4W4E=\R_,_6K]GW[\/X5]N?!7_CWBKXC_9]^_#^%?;GP5_X]XJ_)S^ACWGP
M]_J5^E;:=*Q/#W^I7Z5MITH =1110 4444 %%%% %:^_U;5\O?\ !5&(S_\
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M0&GUJU6^N([BS:<-( Q^95^8@CWQCK7IUX8]G[Q]S>I->8?%]_\ B5236_\
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M7%)+^WKXRM+QA;7$,ENO"K- C$_CC/ZUQ8C,*%+XG]Q^79S'#8#3VJEY+?\
MKYGW4T@/<57E (KX@?\ X*"^-C'A4TQ6_O>17)>,OVM/'GC:W:"XUZYMX)/O
M):@6^1Z$H <?4UQ5,ZPZ6B;/GIYYATO=39]S>./B1X=^']LTVM:QI^G*J[ML
MLP$CC_93[S?0 FO!_$/_  40T6WO)4T[P_J%Y"C$))+.L'F#UQAL?S^G2ODN
M:XDN96DD9I)&.2S'))]S3:\VMG5:7\-<OXGF5L\K2?[M<OXGT)XH_P""@VO:
M@"NDZ)IFFJPQNN)'N7'N"-@_,&O&_'_Q.USXH:J+S7-0FOID&(U("QQ#T5%
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M,I0:.LMY^E6XKBL*UU!7 ^;]:O6UT&_B_"NF,C+ENS563(I'NM@JF]YE>O\
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M_C)DE'RJ?85ZK:^&8[2%5C0*JCC K]AE-SES6_X!^D9EQ=SS?U:'DF^GHO\
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M5]N?!7_CWBK\?/Z./>?#W^I7Z5MITK$\/?ZE?I6VG2@!U%%% !1110 4444
M5K[_ %;5X1^V\GF_LR_$1?[WAG4A_P"2LE>[WW^K:O"/VW&V_LS_ !$/IX:U
M(_\ DK)6V%_C0]5^94/B1^(L6DK'_"*;<6RH.BU+]M)6JUU>=:_;-$>SL0RH
MJ54N6!%)<WO-5VN-U9MBN5[INM4B-S8(X;BKLZ[ZC2TW-6?*+;4^-?VK_$EO
MX"\;ZK:*5\Z1]\<:CH&4-^'6OG75-?N-6N&DD=N>@STKU+]NK65U']HG6HT/
MRVICB/U6- ?US7CH?-?&YMCJE6LX-Z+3[CQL^X@Q>-FJ527NQT276W5DFZC?
M3<T;J\K4^:L.WT>93<TFX4]0Y42ALT5'NYIP>CF%RCJ*;OH\RCF%9CJ*;YE
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M^P4\P^HPM1MSZI=6KZ-_==:IK78_3CPM_P %"_A;\4OCI^S+\9O%FH:+\/\
MQ1X#.HZ%XOT73-%O!9V>GBWNET^2W5$D'EKO"^6K,Z^=T"IFOGO_ (;#\%C]
MA+X\^#YO$%Q-XL\;>-[37=+M9;>YE?4HQ-NGN&E*%%8@ GS&5C@  X 'Q3>^
M,9-6GCLXY-R#YF?^\36E9VJI#[XK.GE]&+_=MZ6[:6DY)+3:[MZ&U;.,5*/[
MY1NU*]DU?F@H-O6U[*^RU;?D?I=\5?VM?@!\0O\ @HE\*/V@=+^)VI-J-YJ^
MEG7_  U/X7O$_P"$=@@LFBEE:X"D3'>D0"1*V,N=Q&,==\,/"_@_]O[]F:/P
MW:ZA\0M'@\!_%#6=92Z\.^![_7+'Q,U[=RW<._R0%@G2.5%$MR42($%L!LK^
M6'ARQFO+FXDA=(5C78TS#.W/8#UX]1Q3]-_:3^('[/$-W8^!_B-X\\+6VK3
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M^)OQ 6QUZ:76)OAXGAQQJD%Q*S2-;K?DFV"!SCJQV_QD\UU_P"_;C^$/BO\
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M%N6)@Y4HK7IKT1^;<?<63RW!J&%FHU9/3KIU?D9GQ*^(-U\2_%=QJEWM62;
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M[6$E(E;AI/H#V]__ *^+C*Z22_KS,ZD.5MR?]=D0^+-3NM37R+.&-)KCY44
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M>2,/W/F@-@#^+'3Z>GXUCWNH72:.R()6L[=2$?;M63N6_$Y-.\)W@U(^:YX
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MR7#XY 8HH^@!KR[XA^$='NK5ODDC;GYDD;/\\5Z%>!KE"TC%F/O7)^)=,?4
MT-M!+<2$'Y(D+L?P'-&+C&<;6-LMG.G-/F?Y(Q?!-XUYIFGZ;:J[K""BH/XC
MDD_UK0\:6UQI$2F0*FP[B-V378>#O 4O@+PJOV>T5=0NH]]Q+*XW*3SL']T#
M./<COQ7GOQ/&K?-YT+&/!Y3YOY5RRHNA046G>R^1W4\4L3BW*#5KO?=M[LZC
MX=^=XMN&6W;RX8E#2RM]U/\ ZY]*VM=O_+O!8PR2-#;G:6)^]6%X:U:/P?X-
ML]-L\M/(BR3'JSN1SGZ=/I4_A"SN_$OB-H-K!F<-(Q&-B]R:Z:<O=4%N]_\
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M\.UOKS5+?3KG1;S4+F"^TF*9YU6\N'-O]F6$+;7$C1K,UP(HC)Y)0JQU[?\
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M% M_SQ/Y4?\ "@6_YXG\J]9\85GO37WF2R:"^T? -WHNJ0PL5TV_9NP%N_\
MA6!?^&=9N[E6DTS4@ /X;63_  K]'?\ A0+?\\3^5'_"@6_YXG\JJ/&%1?\
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ME^^Y^07B'P9XLNT;'A_7.O:PE/\ [+6+H'P5\8>()9FN]&URSL(7[V$@DF.
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M$_E75_K947_+M?>>;/+U+>1\$3^'-2<?\@^^_P# =O\ "L^Z\*:HW_,-OO\
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MB?RJEQ542Y?9JWJ<[\/Z+DI.L[KR7^9^07ASP5XJT2=K-O#NNOSA'%A+R/\
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M2$DYMWR/TIFO_![7+M.+34F_[=7_ ,*_3O\ X4"W_/$_E1_PH%O^>)_*M?\
M6Z7+RJDOO?\ D<__ !#>'/SO$/\ \!7^9^/'CSX$^*A'(8=%UBX'HMG(<_I4
M7P:^#'B+2+N6XNO#^N1LIX#V$HS_ ..U^QG_  H%O^>)_*C_ (4"W_/$_E7%
M_K%+GY_9K[SUO]2X>Q]DZS^Y?YGY5ZGH_B:[E*KH&M8[?Z%+_P#$UE7W@#Q'
M,F6T+6R3Z64O_P 37ZT_\*!;_GB?RH_X4"W_ #Q/Y5M+BJJ]X+[SEAX?X>'P
MU7]R_P S\E/"_@;Q%8WLLA\/ZXOR\9L)?_B:=<^"O$VHWFYM!UL+N_Y\9?\
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MC_N4?\(O'_<H ^=_^%&I_P \?_':/^%&I_SQ_P#':^B/^$7C_N4?\(O'_<H
M^=_^%&I_SQ_\=H_X4:G_ #Q_\=KZ(_X1>/\ N4?\(O'_ '* /G?_ (4:G_/'
M_P =H_X4:G_/'_QVOHC_ (1>/^Y1_P (O'_<H ^=_P#A1J?\\?\ QVC_ (4:
MG_/'_P =KZ(_X1>/^Y1_PB\?]R@#YW_X4:G_ #Q_\=H_X4:G_/'_ ,=KZ(_X
M1>/^Y1_PB\?]R@#YW_X4:G_/'_QVC_A1J?\ /'_QVOHC_A%X_P"Y1_PB\?\
M<H ^=_\ A1J?\\?_ !VC_A1J?\\?_':^B/\ A%X_[E'_  B\?]R@#YW_ .%&
MI_SQ_P#':/\ A1J?\\?_ !VOHC_A%X_[E'_"+Q_W* /G?_A1J?\ /'_QVC_A
M1J?\\?\ QVOHC_A%X_[E'_"+Q_W* /G?_A1J?\\?_':/^%&I_P \?_':^B/^
M$7C_ +E'_"+Q_P!R@#YW_P"%&I_SQ_\ ':/^%&I_SQ_\=KZ(_P"$7C_N4?\
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M\\?_ !VC_A1J?\\?_':^B/\ A%X_[E'_  B\?]R@#YW_ .%&I_SQ_P#':/\
MA1J?\\?_ !VOHC_A%X_[E'_"+Q_W* /G?_A1J?\ /'_QVC_A1J?\\?\ QVOH
MC_A%X_[E'_"+Q_W* /G?_A1J?\\?_':/^%&I_P \?_':^B/^$7C_ +E'_"+Q
M_P!R@#YW_P"%&I_SQ_\ ':/^%&I_SQ_\=KZ(_P"$7C_N4?\ "+Q_W* /G?\
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M@ HHHH *#THHH CIK]*** &T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 *GWJ?110 Z.G444 %%%% !1110 5'110 C_=IE%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !0.M%% $E.3K110 ZBBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>moln-20221231_g4.jpg
<TEXT>
begin 644 moln-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0 !2@%*  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      %*     0   4H    !  .@ 0 #     0 !  "@ @ $     0  $:*@
M P $     0  !Y<     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ 1O_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K,UK4ET;1[_5VC\T6,$LY0'!81(6QGMG%:=<OXW_
M .1+U_\ [!]U_P"BFK2E%.23(J.T6T:NBZDNLZ/8:NL?E"^@BG"$Y*B5 V,]
M\9K3KE_!'_(EZ!_V#[7_ -%+74458I2:04W>*;"BBBLRPHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "N:\->(T\1_VKL@,']EW\]B<MNWF#'SC@8SGI72UY?\,?^9L_[&"_
M_P#9*WIP3A*3Z6,IR:E%'J%%%%8&H4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!__0_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***Y[Q5XL\->!] O/%/B[4H-)TFP3?/<W#A
M(T';D]23PJC))P "3BG&+;LA-I*[.AKR/XH_'CX2?!FS^U?$?Q+:Z3(R[H[8
ML9;N4>J6\8:5AGC=MVCN17Y*?M&?\%*?$WB26Z\*_ 5'T+2?FC;6)D'VZ<="
M8$;*P*>S$&3&"/+/%?EKJFJZIKFH7&KZU>3:A?73%YKBXD:661SU9W<EF)]2
M:^LR_A6<US5WRKMU_P" ?-8[B.$'RT5=]^A^S7Q%_P""J^AVKRV?PJ\&S7^,
MA;O5IA F1W%O#O9@>V94/J*^0/%'_!1K]J+Q#(YT[6K+P]&__+.PL(2 /0-=
M"=Q]0V:^%:*^IH9'A:>T$_77\SYRMG&)GO.WIH?1M[^UW^TS?N9)_B/JZD_\
M\I_)'Y1A119?M=_M,V#B2#XCZNQ'_/6?SA^4@85\Y45V_4J.W(ON1R?6ZN_.
M_O9]U>%_^"C7[47AZ1#J.M67B&-/^6=_80@$>A:U$#GZELU]?_#K_@JOH=T\
M5G\5?!LUAG :[TF83ID]S;S;&4#OB5SZ"OQ6HKBKY'A:F\$O33\CKHYQB8;3
MOZZG]8GPN^/'PD^,UG]J^''B6UU:15W26P8Q7<0]7MY LJC/&[;M/8FO7*_C
MNTO5=4T/4+?5]%O)M/OK5@\-Q;R-%+&XZ,CH0RD>H-?J5^SG_P %*?$WAN6U
M\*_'I'UW2?EC76(4'VZ = 9T7"SJ.[ "3J3YAXKY;,.%9P7-0?,NW7_@GT>!
MXCA-\M96??H?N/17/>%?%GAKQQH%GXI\(ZE!JVDWZ;X+FW</&X[\CH0>&4X(
M.00",5T-?)RBT[,^E335T%%%%(84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=FC59ESZ")L=S7X+45Y^(X?PM1?!;TT_X!W4,[Q-/[5_77_@G]>_A#QOX/\
M'^C1^(/!.LVFN:=+P)[299D!_NMM)VL.ZG!'<5U-?R+^ /B5X]^%FNQ^)/A]
MKEUH>H)C+V[X610<[98SE)$_V75E]J_:']FC_@H[X:\<S6G@WXWI!X<UN3$<
M.J1_)I]RW0"4,3]G<^I)C)SRG KY/,N&JM%.=+WE^)]-@.(*=5\M3W7^!^H]
M%-1UD4.A#*P!!!R"#W%.KYD^@"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_AC_ ,S9
M_P!C!?\ _LE>H5Y?\,?^9L_[&"__ /9*ZJ7\*?R,*GQQ^9ZA1117*;A1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__T?W\HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***S-9UG2O#ND7NO:Y=1V6G:=#)<7$\IVI%
M%$I9W8]@ "332OHA-VU./^*?Q2\&_!OP5?\ CSQU>BSTVQ& !@RSRM]R&%,C
M?(Y' ^I)"@D?S=?M)_M0^/?VC_$QO=:D;3O#MG(QT_28G)A@7H'DZ>9,1]YR
M..0H5>*U/VL_VF=;_:-^($E]$\EKX3TAGBTBR8XQ'G#7$J]/-EQD_P!U<(,X
M)/RG7Z/D62*A%5*B]]_A_P $^"SG-W6DZ=-^ZOQ"BBBOI#P0HHHH **** "B
MBB@ HHHH ^F/V;/VH?'O[.'B87NBR-J/AV\D4ZAI,KD0SKT+Q]?+F ^ZX'/
M8,O%?TB_"SXI>#?C)X*L/'G@6]%YIM\,$' E@E7[\,R9.R1">1]""5()_DBK
MZL_9,_:9UO\ 9R^($=]*\EUX3U=DBU>R4YS'G"W$2]/-BSD?WERAQD$?-Y[D
MBKQ=2FO?7X_\$][)LW=&2IU'[K_ _ITHK,T;6=*\1:19:]H=U'>Z=J,,=Q;S
MQ'<DL4JAD=3W!!!%:=?G#5M&?>IWU"BBBD,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>7_#'_F;/^Q@O_\ V2O4*\O^&/\ S-G_ &,%_P#^R5U4OX4_
MD85/CC\SU"BBBN4W"BBB@ HHHH **** "BBB@ KP7]H;]H3P5^SKX(D\5>*'
M^TWUSNCT[3HV GO)P/NC.=L:Y!DD((4>K%5;T'XE?$3PS\*/ ^K_ ! \7W'V
M?2]'A,LF,;Y&Z)%&#C+R,0JCN2.@YK^7SX[?&SQ;\?/B%?>//%<A02DQV=HK
M$Q6=JI)CA3ITSEFP-S$L>N*][(\G>)GS2^!;^?D>-G&:+#QY8_$_ZN5OC/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#__TOW\HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBBC&YW=V(554 DDD #DU_,Q_P $MO\ D[;2?^P7J7_HJOW\_:E_Y-H^*_\
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MK_Z*6NHKE_!'_(EZ!_V#[7_T4M=117^.7J%+X4%%%%9%A1110 4444 %%%%
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M6NC:9;E1+=7LZ6\"%V"KNDD*J-S$ 9/)('6O.?\ AH;X _\ 13/#'_@YLO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__3_?RBBB@
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M 8%VX)V8*U]PU\/BL/4IRM56KU^\^PPU>%2-Z>VQ_*!^T-_R7[XF?]C/K/\
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M0O<1I"#;LK*Y$S(1D?*0&XQFOS9_X:L_X);?]$[T?_PD+7_XU7T__P %)_\
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M*.P&22>  22 ":^Y=3_X)B_M:Z9X:D\0G0K&ZFA0NVGV]_%)>8')"K_JV/\
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M3](_FS#)?]TE\_R/X[Z_K8_88_Y-)^&7_8+_ /:LE?R3U_6Q^PQ_R:3\,O\
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M?6)/?"W#RH/P210/85\EQ=03HPJ=G;[_ /ACZ;ABK:K*'=?E_P .?;=%%%?
M'VP4444 %%%% 'P?_P %+?\ DS;QM_UVTK_TXV]?RSU_4Q_P4M_Y,V\;?]=M
M*_\ 3C;U_+/7Z]P%_N<O\3_)'Q7$?\=>GZLNZEIUYI&HW6DZC$8;NRE>":,]
M4DC8JRGW!!%?U>_L'?$7_A9?[*O@/59I?,O-*M#I%SDY8/IS&W3<?5HE1_\
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MC;%(LH4/ L8P2@#9!R,CO7S+HVBZQXBU*WT;0+&?4M0NF"0V]M$TTTC'H%1
M6)^@KP\KX;A34GB4F_PL>OF.?SJ-+#MI?B?U.?L[_'+0_P!H7X8V7Q#T:V:P
MD>22UO+1F\PVUU#@O'OPH8%65U; RK#(!R!Q7[9WPWTSXE_LY>,;.]B5[K0[
M*76+*0C+1SV"-*=ON\8>,^S&L3]AWX*>(?@;\#+?0?%J"#6]:O)=5NK?.3;-
M/''&D3')&Y8XE+8X#$CG&3TO[8OQ#TOX<?LY^-=0U"81W&KV$^DV:9 >2YOT
M:!=@/4HK-(?]E2:^44%'&I8?;FT^\^E<G+"-U]^77[C^7NBBBOU<_-0HHHH
M*L6EW<V%W#?64C0W%NZR1NIPR.ARK ^H(R*KT4 ?UR?"WQG%\1?AMX7\=PX
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M:P72?B7XVO\ 6=.#*_V0LD%JSK]UF@@6.-F'8E21VKXK#<!8E5$YU$EY7O\
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MS^@RBBBOS8^I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__4_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]S3VLN7DOIV/TN_X)8?\G ^(?^Q8NO\ TMLJ_?*OP-_X)8?\G ^(?^Q8NO\
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MH(R<%AP"<_JY_P /9_V7O^?+Q'_X 0?_ "37Y ?L;?LE6'[6>M>)M!F\9?\
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MC@8QGNK'#_\ !+;_ ).VTG_L%ZE_Z*K]_/VI?^3:/BO_ -BKK7_I%+7X!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@%S91(3]3LR?>O9O^"04S+^T1XIMQ]U_"MRQ^JWUD!_Z%7EO_!4'_D[O7_\
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M5H7PW\%:'X"\,PBWTO0+2&SMU[[(5"[F/=F/S,>I8DGDU_%II6H2Z3JEGJL
M#264T<R@]"T;!@#^(K^U?PCXIT;QQX5TCQEX>G%SIFMVD-Y;2*00T4Z!UZ=\
M'D=CQ1XA.7+1[:_?H+AJUY]]/U/+/VFOAUI'Q4^ GCCP7K%O]H6YTNYFM_[R
M7=LAFMW4^JRHI]QD=":_CLK^QC]I/XAZ1\+/@1XW\:ZQ<BV2STNYC@/=[J=#
M%;QJ.Y>5U ].IX!K^.>M_#_G]C5OM=6];:_H9\2\O/#O8_J-_P""97_)GGA+
M_KZU3_TMFK^:_P"*?BJZ\<_$WQ9XSOFWSZYJM[>L<Y&;B=WP/89P/:OZ4/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH __U?W\HHHH **** "BBB@
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M!7X(?\%8/V=M6TSQE9_M$^'+-IM(UB&&RUEHU)^SWD $<$TA'1)HMD8)X#(
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MB+MQY\&W;MSG)SGM7Q_#V+IT,93JU7:*O?[GV/<S*C*I0E""NW_F?S<_LO\
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M_P"6_P#_ 'PKQ.$\]P>%P\J=:=GS-[/:R[)GH9SEU>M54H1OIW7F?L+\*/\
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MJ9#B%4PL'VT^X_-\YH>SQ,UWU^\****]@\L**** .[^&?PX\4_%KQOI7P_\
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MH_DY_;5_9GUK]F[XOZAIZ6Y/A/7Y9KW1+E5(C^SN^3;$]!);[@C#/*[7P P
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M^UW;02>+/'NE:?K4";+?5DN/[*OHT[([WD:JZ G(616"\[=I)-?/NC?\$C_
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M -DKU"O+_AC_ ,S9_P!C!?\ _LE=5+^%/Y&%3XX_,]0HHHKE-PHHHH ****
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M(WP61R53VM>5W_6XEU_Q[2_[C?RK^'ZO[AF574HPR&&#]#7P_P#\.W?V+O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __6_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5%<*64,%8!@&(ST)ZUP=%%>K"*BE%=#S92;;;"BBBJ)"BBK-E97FI7D&G:?
M]S=74BQ111J7>21R%554<EF)  '4T ?57[%WP2D^-WQRTC3KZW\W0-!9=3U0
MD91H8&!2$]CYTFU",YV;B/NFOZ;:^3?V.OV=X?V>OA3!IFIQH?%.NE+S5Y5P
M=LN/W=NK#JL"DKU(+EV'#"OK*OR[/LQ^L5_=^%:+_,_1<EP/L*/O?$]6%%%%
M>(>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT/TW+L&J%)4^O7U"BBBO/.T**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Y?\,?^9L_[&"__P#9*]0KR_X8_P#,V?\
M8P7_ /[)752_A3^1A4^./S/4****Y3<**** "BBB@ HHHH *SM7TG3M>TF]T
M+5X%NK#48)+:XB?[LD,RE'0^S*2#6C133MJ#1_)U\=/A3JOP4^*GB#X<ZH&8
M:9<'[-,PQY]I)\\$H[?-&1NQT;*]0:\DK^@O_@H3^S7-\6O <?Q*\(VOG>*O
M",3EXXQF2\TX9>2, <L\1S(@[@NH!9A7\^E?JV3Y@L314^JT?K_P3\US3 NA
M5<>CV"BBBO5/-"K>GZA?:5?6^J:7<26EY:2)-#-$Q22.1#N5T9<%64@$$<@U
M4HH: _7CX'?\%0;S2--M] ^.NC3:LT"A!JVFB,7$@' ,]LYC1CZNCK_N$\U]
MGV7_  4._90NK<3S^+)[-\9\J73;XOGTS'"ZY_X%CWK^;BBOG\1PSA:DN9)K
MT/<H<08B"LVGZG[Z?$+_ (*??!/0+*5/ &G:CXJU J?*+1?8K3=_MR2_O1]!
M$<^HK\>_CI^T)\2/V@_$P\0^/+T>1;[A9V$&4M+1&ZB-"22S8&YV)9N,G  '
MA]%=> R:AAWS4UKW>YRXS-:U=6F].R"BBBO5/-"BBB@ K]=O^"7?P3DO-:UC
MX[:U;XM]/5],THL/O3R &YF7_<C(C!'!WN.JU^:WP?\ A3XG^-7Q"TGX=^$X
M]UWJ4G[R4@F.V@7F6>3'1$7GW.%') K^IWX<> /#WPM\#:-\/_"L/DZ9HENL
M$6<;G(Y>1R."\CDNQ[L37R_$^8JG2]C'>7Y?\$^CX>P#G4]K+:/Y_P# .VHH
MHK\[/N0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /_7_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_#'_F;/^Q@O_\ V2O4
M*\O^&/\ S-G_ &,%_P#^R5U4OX4_D85/CC\SU"BBBN4W"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH _]#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<OXW_Y$O7_^P?=?^BFKJ*Y?QO\
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M>&.E:<ZRW+?[,MQS''[B/S,CHRFOU[^'_P -_ WPL\.P^%/A_HUOHNF0\^7
MO+MC!>1SEY'/=G8L?6NWHKY7'9I7Q#_>2T[=#Z3!Y=2H+]VM>_4****\X[@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KR_X8_P#,V?\ 8P7_ /[)7J%>7_#'_F;/^Q@O
M_P#V2NJE_"G\C"I\<?F>H4445RFX4444 %%%% !1110 4444 %%%% !7R/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Y?QO\ \B7K_P#V#[K_ -%-745R_C?_ )$O7_\ L'W7_HIJUH?''U(J
M_"P\$?\ (EZ!_P!@^U_]%+745R_@C_D2] _[!]K_ .BEKJ**_P <O4*7PH**
M**R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\O\ AC_S-G_8P7__ +)7J%>7_#'_ )FS
M_L8+_P#]DKJI?PI_(PJ?''YGJ%%%%<IN%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__2_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M7\;_ /(EZ_\ ]@^Z_P#135U%<OXW_P"1+U__ +!]U_Z*:M:'QQ]2*OPL/!'_
M ")>@?\ 8/M?_12UU%<OX(_Y$O0/^P?:_P#HI:ZBBO\ '+U"E\*"BBBLBPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O+_ (8_\S9_V,%__P"R5ZA7E_PQ_P"9L_[&"_\
M_9*ZJ7\*?R,*GQQ^9ZA1117*;A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '__T_W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&_P#R
M)>O_ /8/NO\ T4U=17+^-_\ D2]?_P"P?=?^BFK6A\<?4BK\+#P1_P B7H'_
M &#[7_T4M=17+^"/^1+T#_L'VO\ Z*6NHHK_ !R]0I?"@HHHK(L**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KR_P"&/_,V?]C!?_\ LE>H5Y?\,?\ F;/^Q@O_ /V2NJE_
M"G\C"I\<?F>H4445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!__]3]_**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,CP?XGU%&.G2PW)N;.]DB1I)(CN1&ADVJ2@)</@C<&VJWZ+_ !;^+?@'X'>
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MF-C0!^H-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCJS <U^C= !17C_QP^._PR_9U\"R_$3XK:K_ &7I"S);1[(VFFGN) 2D4,:
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M^@6=Q?WDVTMY=O:QF65MJ@L<*I. "3T S7YKM_P6!_8\#$"?7B!W&F<'\Y:
M/U*HK\]/ 7_!4?\ 8U\>:O#H@\7R^'KBX;;&VL6DMI 3_M7'S0QCWD=1[U^@
MMO<6]W;Q7=I*LT$RJ\<B,&1T895E8<$$<@CK0!-1110 4444 %%%% !17P!_
MP4%_:\\7_LA> /#7B;P7HEAK5]K^HO9L-0,OE1)'"9"0L3(Q8D ?> 'H:UOV
M/?VL/$_[1?[-.M?&[Q3HEGINIZ+<ZC UM9/(()18P).I'F%V7=OVGENF>^*
M/NFBOQ1_8M_X*=_%+]I7]H+2OA%XM\):-IFFZM;WLJSV)N!/$UK \RY\V1U8
M'9M/RKUSVP?VNH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__U?W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX)>#?@7^U+=Z3\/[&/2-&\1Z9:ZW%96XV0VLD\DL$J1*.$0R0,X48"[MJ@*
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M_@K_ *O8?#']EKP?\)O 5I!X=T;6M;CC:QT^%+:U^Q644DQA$405%3SVBDP
M/F4&OR<_X)Z?M8>#OV2/BUK?B_Q]IE_J6BZYI$FGN--2*2YBF$T4T;A)I(E9
M3L96^<$9!YQBOU4_;VG/[:/[ GAK]H?X9:3<PVVB:A)K,EI=!?M::? US879
MQ&74['593AL"-6/48H _.3]A+]M/X,_LD>'=>D\3?#JY\2^+M:NSC5(9(%,6
MGK&@2W3S5+)F3S&?:</E<_=&/E3]ICXK^!?BU\<=9^*OPH\-R>"-/U5X+D62
MN@,5XB*)9D\D*J&21?,^7^(ENIK[*_X)^?M<?LY?!+PYK?P[_:(\$6NK6=[>
MG4+'6/[+M]0FB:2..*2"82#S/+'EAD*;L$L",$&OO36?^"C'[ MGX@TC1_A]
M\*(_$5Y>WD$(N%T.QL88?,D"[PTH\TLN<@",9_O"@#RO_@K?\.OB-X^^&?PA
M^/%II]S=Z3IVDF+6%1&;[!-?)!,DLJ@91'8,C.< ,J*>6%>0_L>_\%*_AM\+
M_A5I7[/?QU^'5OJ7A.R#P_;K&"&?S(YG+$WEC, DS9;YI%?<P'W&;D_K=^U?
M^WIX"_9/^(OA?P!\0_"][JNC>)[":ZGOK-XW:W59/)"?9I HE4\E_P!XI Z*
MV<5^&_[?WQ&_80^)6G:)X@_9?T:33/&-Q>%]3:TL9--L&LS&^X20.$3S_-V%
M6B3!&_>2=M ']-'P*NO@]??"G0+WX!K81^!+F.2;34TV,16RB65WE"QX!1O-
M9]Z$!E?<& ((KUNORB_X(Y:#XGT;]DV\O->CEBLM8\1WUWIJRJ0&M1!;0LZ9
MZHTT<F,<9!/<U^KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(R0<;B\AYX4'!H _?:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\9/%-CX)UJ#4? NK:BPC@DU40FPDF8@+$+F*1MK,3P9$13TW9(!^_?BI\5?
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MV6OAQ^SY\//AK++^S.T$O@WQ/?2ZNLEM=R7L+3RI'"X1Y7=E"K$JF,G*D$$
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MB6^OI(P"R6\.1NV[EW,Q5%R-S+D5_,#_ ,$OM8N]'_;@^'L5G(?*U#^U+68
MD!XGT^X8 ^P=5;![@5H?\%-OB7XC^*G[8WBCP_/,TMAX3E@T/3+;/RQB-%,Q
M '&Z2X=V)ZXVJ>%% 'ZB1_\ !;7X&MK2V\G@'Q$FDD@&YW6AN /7R/.V_AYM
M?='C?]MCX.>$?V:K3]JC3_MWB'P=J#Q10+90JMTTLDQMV1HYWB"F.165\M_"
M=NX8SX=X=_X)2?LE6GPJL_ WB/P[+?:_]E1;O7H[RXCO6NROSS1#=Y*J&SLC
M,13;C<&.2?!_VY/@7H/[-O\ P303X.^&[^XU2QT/6+5ENKH*LTK75_)<,6"
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MI]G8J;N"..SLWQQF-IV\YAGN80.X)K!_X(^3'QQ^R+XT\ Z_))-I\>O:A9*
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M4%IY"Z3++/P-D.H61C2X+'Y5$Q5W)X3=7[GJJHH11@*, >PH =1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY?\ #'_F;/\ L8+_ /\ 9*]0KR_X8_\ ,V?]C!?_ /LE=5+^%/Y&%3XX_,]0
MHHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#_];]_**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC:+:,TFP,TDDTTF-\LTKDO)(V!EF/  484   ]2HHHH **** "BBB@ HHHH
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M,[D* 68X '%?#^O_ /!+SX">(OCU/^T#>:[XB36;G6UU^2SCN;469O!.+@J
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M6C/^U38Z1^S%=7]]IP\36Z>&;B96%VZK<KY$C!51P 1NR55MO+ '( !]\_\
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M8_\ ,V?]C!?_ /LE=5+^%/Y&%3XX_,]0HHHKE-PHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?__7_?RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '__T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BN5\;^)AX/\*ZAXB\G[0]HB^7'G:'ED81QJ3S@%V&3V'-?&=UX^^(&H3F
M[O?$-RDI8L$MBL$*9.0JHHY4=O,+GU)KZ+)>&ZV-@ZD9)13MKW^7R/A>*^/<
M+E-6-"I"4IM7LK:*]KMMK>SM:^VMC[VHKQ?X-^/]0\7:?>:1X@=9-6TDINE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_  Q_
MYFS_ +&"_P#_ &2O4*\O^&/_ #-G_8P7_P#[)752_A3^1A4^./S/4****Y3<
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BD) &2< 5A77BCP_9@F:^B)!P0A\Q@?HF351@WLB93C'XG8WJ*\WU3XA6R
M(8]&A,TAZ/(-J#\.I_2N*N-<\2:@3YU[(@/:,^6 /3Y<'\\UV4\!.6KT.*IF
M%..BU/?20.35=KNT0X>9 ?=@*^>FL9[H@W+M*?5B6_G4RZ/Q]VMO[/CUD8_V
MC)[1_$]]%[9MTN(S_P "%600PRIR#Z5\^?V/WVTU+"XMF+VSO$WJA*G\Q0\O
MCTD"S&76)]#45X9!K?B6QQLO7=1VEQ)GZELG]:W;3XA7D)"ZE9K(.[1$J0/]
MULY_,5C++YK;4VCF--_%H>K45S6F^+="U,K'%<>5*V,1RC8V3V!Z$^P)KI:Y
M)P<7:2.R%2,E>+N%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_T?W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%1RRQ01//.XCCC!9F8X50.223T KP+QI\88HV?3/#+98_*9\<Y_V
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MZ@P37H-["<$5R-[&0:[Z%0\RO3L<?/$!6KI7B;6=&(6UGWPC_EE)\R8]NX_
MBJ\ZUFNN*[G%25I(\Y2<7>+L>YZ#XSTS6BMO)_HMT?\ EFYX;G^%N_TX/M78
M5\JN@8%6&0:](\*^.I+:2/3-?EWPMA8[ECRI["4GJ#_>[?Q<<CS,3E]ES4_N
M/7PN9W?+4^\]BHHHKR3V HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__2_?RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0@$8/(-?ES\6O!Q\%?$K
M6=)0$6E_(VI6I)R3'=,7<<= DN]5']T"OU'KYG_:;\(C5?"5MXMMUS<>'Y"T
MGO;2X$F0.6((!4=LFO7R7%>SK<KVEI_D?1\,8_V.)4'M+3Y]/\OF?+_P.U2'
M0/C'X>N906.IQW6F*!V,ZK/N/T^SX_&OTXK\F;*[N-!UG1O$%F ;C3[^V=">
M0HDD$+G\(Y&K]8XW25%DC.Y7 ((Z$'I73Q!#WXS\OR_X<[N,:?[RG4756^Y_
M\$?1117SY\<%%%% !1110 445EZUK.F^'M)N];U>=;>SLHVEED8X"JHS_P#J
MII-NR'&+;LC@_BQ\4]#^%/ALZSJ0^T7EPWDV=HA_>7$Q!(4>@ !+'L 37QKI
MG[5WQ,T_51JGB'3[.\TDMF6TMD*S1Q]_+8GYF ['.:\D\>^.-1^*/C&X\9:B
M#':H#!IL!/$-MGEL?WY" 6/H /6N4FFBMXFFG8)&@)8G@ "OM\%DU*%.U6-Y
M/?\ R1^IY7PU0I4>6O#FF]_+R7^?<_8G0=<TSQ-HMEX@T:87%CJ$*3PR#HT<
M@#*?R-:]?/\ ^S!IVI:9\%]#BU.)X6F,\\*.,,MO-*SPC!Z80CCM7T!7QV*I
M*%64$[I-GYMC\/&E7G2B[I-K[F%%%%8'(%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y?\,?\ F;/^Q@O_ /V2O4*\O^&/
M_,V?]C!?_P#LE=5+^%/Y&%3XX_,]0HHHKE-PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '__3_?RBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^2+=+Z[AMFF((!$8E92V"1G&>HK^?K_@E[_RD)^,O_8+\1?^GNRH_P""W_\
MR43X6_\ 8+U#_P!'QT ?T8T444 %%%% &9K&M:-X=TV?6?$%_!IFGVH#2W-U
M*D,,8) !>1R%49(')ZUD>%_'7@GQQ%/<>"_$.G:_%:E5E?3[N&[6,MG:',3,
M%)P<9ZXK\+_^"D'Q7\5?M.?'?PW^PY\&9O/AT^Y%QKLR$F+[8D9D992O6*Q@
MW22#G,AVXWQBLS_@AK_R%/C)_P!<=!_]"OJ /Z#:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*UK6]+\.Z=+JVLW MK6'&Y
MB"3DG  4 EB3P  2:9H6OZ1XET]=4T2Y6ZMV)7(R"K#JK*0&5AW! -?/WQ^U
M"22\T?1E<B.-)+ET[%V.Q&/T <#ZFN6^#GB)]#\5)IDTC"SU@>21_")U!:)O
M;/*<=2RYZ#'U]'AE3R_ZTF^?5VZ67Z]?P/S+%>(#HYW_ &=**]GI&_7F=OE:
M[2>G=WZ'V%1117R!^FA1110 4444 %%%% 'S)\3--@LO'K3HNTZO91S''\4E
MJQBD8^^QXA]!6#X2U<>#_'-CJLWR6&L*NFW;$X6-RVZUD/; <M&2?^>@/:O0
M_BTD4GB;PVHYF%MJ!_[9[K;=_P"/;:X"]TBTU*SFT^^B$L%PI1U/&0?Y'T(Y
M'6OTS+JL:F#IQJ[2C9^B;2MZ637FC\!SS"SHYI6J8:RE":E'U:4FGY-R:?7E
M;/K6BO"/ 7Q#DTQK?P;XYN-MSD16.H2X6.\7HD<C=%N ."#]_JO)(KW>O@LP
MRZIAJG)/;H^C7=?U=;/4_9LDSRACZ/M:+U6DHO>+[-?KLUJFTTPHHHK@/8"B
MBB@ KF?%WB_0_!.BRZYK\_E0(0J(HW2S2-]V.)!RSL>@'U. "1RGCCXK:#X/
MD.DVBG6->892PMF&]<CAIW^["G(^9N<'Y5-?-6H'6_$>KCQ+XNG6ZU!5*PQ1
MY%M9HWWD@4\Y/\3GYFQV'%?59+PW*M:KB/=I_C+T\O[VW:[T/SGBSCVGA>;#
M8&TZVSZQA_B[O^XM>_*G<S==U?6_&NN'Q1XE7RI$#)9V8;='9PMU /1I7_Y:
M/WZ#"C%7?!G@;6?B3=LNFS-I^A0.4N-0 !>1E.&BM@>"W8R$%5[9-7_"OA"Z
M^)&MS:1 S0:'I[!=1N4."['G[+$?[Q'^L8?<4XZD"OM#3]/L=)L8-,TV!+:U
MM46.*)!M5$48  KZS/.((X*"H4$N>VBZ0733N]]?5W;/S7A#@F>;598O&2;I
M7=W?WJDNNJM:*V;5MN6-DC(\+^$_#_@W2TT?PY9I:6ZG+8Y>1SU>1SEG8^I)
M/;I71T45^6UJTZDG.H[M[M[G]$X7"TZ%.-&C%1BM$DK)+LD@HHHK,W"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=17+^
M-_\ D2]?_P"P?=?^BFK6A\<?4BK\+#P1_P B7H'_ &#[7_T4M=17+^"/^1+T
M#_L'VO\ Z*6NHHK_ !R]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOR._:>_X*
MR_#CX1>*+KX<?!W0S\1/$MI*;:>X2;RM-AN,[?+1T5WN75OE94"KG@2$@@ '
MZXT5^ DG_!1S_@HKIEL/$FM?L\"/P^5\SS3X?UR$>6.2QG:5D (Y#%,=^:^[
M?V)O^"@OA/\ :_U#5/!TGANY\*^+M%M/MT]L91=6DMNLB0L\4VV-@RNZ[D=
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M,:B)&BQQJ%51@ #  '84ZBBOG3XP**** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]3]_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!]K_ .BEKJ*Y?P1_R)>@?]@^U_\ 12UU%%?XY>H4OA04445D6%%%% !1110
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MBCHOAFPL/%FK6QM+S4[>!8KFY@+K(5E90-^6126;+':!G %?E9\6_P#@F?\
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M9_V,%_\ ^R5U4OX4_D85/CC\SU"BBBN4W"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+#VK:MK#IQ6Y!8>HK*=8YZF).<CT_IQ5M=.]JZZ+3O:KJZ=[5SNL<<L4</\
MV<?2HGT[VKT'^SO:H'T[CI258E8H\XET_P!!65/8=>*]-FT_':LBXL.O%:QK
M'33Q)YA<6/M7F7Q'%QI_@K6[VTR)H;61EQUR!7OUS8XSQ7':YHT>HV%S83*"
MEQ&R$'I@C%=V'KI239ZF$Q24XM]&?2?AG3K+2/#>E:3IF/L=E:000XZ>7'&%
M7] *W*\>^!/B)M=^&NE6=V?^)EH*?V5>@G+>?8_N6<YY EVB1?\ 985[#7A8
MB#C4E&6]SY+&4I0K3A+=-A1116)S!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y?\,?^9L_[&"__P#9*]0K
MR_X8_P#,V?\ 8P7_ /[)752_A3^1A4^./S/4****Y3<**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \S^(MZ/+L]+4\NQE;GH%^5<CT.3^5<KI:D$54
MUK4/[9URXO$.Z(-LC]-B\ CZ]?QK8TZ/&#7O0AR4E$^?G4YZKD=E9#Y:UZR[
M087\*U*\VIN>K3V% S3P/2A1VJ55S698@7TKQKXQ?$C_ (0G2ETK275M;U%2
M(P3S!$<@S$#OD$)G@MD\A2I]:UC5K+0-)N]9U%MEM91-*Y'4A1G ]2>@'<\5
M^<VL:M?>+O$%[XCU/_77DA8+G(C0<)&" ,A5 &<9.,GG->WD> 5:;G->['\6
M>#G^8NC35.G\4OP7?_(R+6TDE<S3DO)(2S,QR6)Y))/4FNAM[/ID5/:VW3CF
MNEL[/(!QS7V%6L?$T:!F0V3'J,5IQV)QTYKI+;3\@<5L1:8. 17GSQ)Z5/"G
M%_86QG'2J\EBWI7H)TWN5JI-8#'2H6)-)84\XFMRO2J9!'6NUNK,#/'-<]<6
M^">,5U0JW..I2:,JBI&0BHZV.=E2ZM8[F,JPY['O7UM\&?B'-XHT^3PWKDA?
M6--0$2,<FX@SM#D]2ZDA7SUR&R23CY4I;/4K_P /ZK:>(M)(6\L)!(F1PPQA
MD;'.UE)4XYP37)CL&J]/D>_3U.W+\:\/451;=5Y?\ _0N>+G-9<T6<U<T36+
M'Q+HEGKNFG-O>QK(H.,KGJK8)&Y3E6&>""*DFCP:^#UB[/<_1':236S.:FBR
M#61/'743QXYK'N(Q75"1QU('*7$>,UBSKU%=/<IP<5@7"UWTI'GU8F5:77]G
MZA;WI) @D1SCKA3DC\17TU7R]<+R:^C=#N&N]&LKE^6DAC+?[VT9_6N3,XZ1
MD=>4RUE$U****\@]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH __6_?RBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC49K]P?#_B'0/%FBVGB/POJ5OJ^E:A&);>[M)4G@FC/1DD0E6'N#0!L4444
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +1K^E:B@#^:-O\ @B7\>OX?'?AH_4WH_P#;>H6_X(F_M!?P^./"Y^KWH_\
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M[%S=/BKI?XI<#^<53+_P4&_8R;I\5])_'SA_..OP8;_@CW^V".D>@-]-2/\
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M0!_4$O[57[+[?=^,'@X_3Q!IW_Q^IE_:A_9G;[OQ;\(GZ:]I_P#\>K^7%O\
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M\'?C9X TH:M\0?!'B'PWILCB(3ZIIMW9P-(>0@>>-%+'' SFO+* /[P/AO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\C^(8_XFEG_P!<C_Z%7KE>2_$,?\3.Q/K&
MW_H5=N _B(X<Q_A,R--7.*[:S3Y17(Z4,XKN;1.*ZL2]3EPT2^@XJU&N342K
M5Q%P*\]L]%(>!4H':FJ*D6H9HC\\_C'XC/B'XEZD4;,&F$6,?!&/()\P'/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\J_B
M:2?B)XF).?\ B8W7_HUJ]O\ AF!_PAME[M+_ .C&KQ#XF?\ )1/$W_81NO\
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M[]D7XVP_M"_L\>#/B@TBOJ-]9K;ZFJX&S4;4^3<_+_"&D4NH_N,I[T ?._\
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M/B_7])%E?>&?%>L76HQZ]=WT2QV]O=2F18I8,FYW0J1&!'$R':-I"]/Z5Z*
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M_9>&'%TZ->.58B5Z<O@;^RUKR_X6K\O9KE6C27TK1117YB?T$%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?_1_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2.+S9!SL4PL0/;)K]0OVI/V=M%_:C^$EY\)M>U>XT.VNKFVNA=6R)(ZO;/N
MVOP0>0>17??!OX9Z=\&?A9X7^%>DWDNH6GA>QAL8[B<*LDHB&-[!> 2>PZ4
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M:W)F^Q?;?./^C2R[0OG)@MC.>,X./V!H **** "BBB@ HHHH **** "BBB@
MHHHH *\W^+&JZOH_@F\N=&\Q)7*1O-&/FAB8_.XQTXXW?PYW=LUZ1171A*ZI
M58U)1NDT[=SAS/!RQ&&J4(3<7)-76ZOU_JWJC\TH=0TI-L45U" !A55U[=@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3>R-VBBBN ^B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTUBLFL,SW;KUAL(L&=^.1ORL0/9I :^NM-TZSTBPM],T^,0VULBQQHHP JC
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M>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /_2_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW39VY'T\M:WJ\BLVYMON?.8F3E4E)[ML****S,0HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@#_]/]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!;'@X?P2XJQ$N2I"%-=Y33_P#2>9GYSZ/I/B7QEJ*Z3X8T^;4;I^-L2EL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#_U/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM=:A/-;:/:37S0';(T:GRT;&=I?H&P0<=<$4UK'QK<'$.AMM'=YXT_0UZ1X
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M7J%>7_#'_F;/^Q@O_P#V2NJE_"G\C"I\<?F>H4445RFX4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 -=$E1HY%#HX(((R"#U!%?%/Q!\,W'A;
M79EA!-O(VY#ZJ>0<\?0^X-?;%<UXI\+Z?XJTYK*\&UP#Y<@&2A/\QZBO2RS'
M>QG=[/<\S-<![>G9;K8^+-/U-@1D\UWVFZEDCFN.\1>%=3\+:DUE?)MP<HPY
M1U[%3Z?_ *CSQ3M/N"C 9KZRI&,X\T=CXVE.=.7++<]KT^]W8YKL+*?=@9ZU
MY)I=WRN37H.GS#C%>%B:5CZ'#5KG?6[;@*T%7)XK&L9-P'O70P#<M>14T9[5
M-W(O*--,9K0*TTK67,:\IGE,4;:NE13"F:?,+E*F,45*PP<5$>*HD*,TPFDH
M G!S5A.0*J!AFK*.O S28XEE1WIS+Q3!(@[BJMS?Q0H3FILR[I+4@O"$!)XK
MSG6=0&\6\ +R.0JJHR23P !ZU:UC7Y)I!:6:F260[551DDGTKIO#7A@::1J.
MI8DOW''<1 ]0OOZG\!QG/=!*G'FG]QY\VZLN6'WDWA;P]_9$)NKL!KV<?.>N
MQ>NP'^?J?I76445Y]2HY/F9Z-.FH1Y4%%%%06%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_U?W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\J^,7A?5O%/A%8=$0SW=A<QW:P!@OGA%9&0$X&<.67. 6 &1U'JM%=
M6"Q<J%:-:&\7<\[-\LIXW#5,+5ORS5M-UYKT^X_-2[OK;3KDV.JL=/NAUAN@
M;>4?\ DVG\<8IPO+,C(N(R/]\?XU^D%U96=]'Y-[!'<)_=D4./R-81\%>#6)
M)T&P)/\ TZQ?_$U^A4^/:37O4FGZK_)'X?6\&,0I/V>)BUYQ:?\ Z4_T/SU&
MLZ4)E@6[B>5S@1HX=R3V"KDD_A7H>A> _'WB1RNEZ-)9P_\ /SJ(:UB'TC8>
M<WX(!_M"OMZRTK2],!73K.&U!ZB*-8__ $$"K]<N+X\;5J%*S[MW_!)?FST\
MM\&U%WQ>);7:,>7\6Y?@DSQ7PC\$O#VB31:GXCE.OZC$59#,@6UA=>08H,D;
M@>C.78=B.E>U445\5CLQK8F?/7E=_@O1;+Y'ZSE&1X3 4_982FHKKW?FV]6_
M-MA1117$>J%?//Q8*V_Q \)SQ#$D]GJ4<I]8U:W9<_1J^AJ^7_B#J46J?%"2
M&-MRZ!IZ0-[3WK^:X_"../\ [ZKZ/A:FWB7+HHRO\URK\6CX3Q$K1CE\:;WE
M.%OE)3?_ )+%FG#/6I%<5R$4]:N@Z5K7C#4+NSTJ[&FV6FLB7%R8A*[S.H?R
MH@Q"@JA5F9@P^8 +G)'T-:C%)RF[);L^(PN*G*4:=*+E)Z)*VNE^MELF]6CJ
MXKBK\=SCO6%=^#O'FBHSVDEOXBA!R%'^AW07TP2T,A_&(566XUF, 76A:C _
M=3 )<?\  H6D7_QZO/\ 94YJ].::]?T=G^![BQ-:D^6O3E%^:=O_  )7B_DV
M=DEU[U86[]ZXP-XLN&5-,\-W<A;_ ):7#PVT2_[VYS+^49KH;;P9XLOI5DU?
M5HM,@ YAL(Q+*3[W%PNTCV$"G_:KEJT:<-9S2^=_P5W^!Z.&Q5>H[4J4G\K+
MUO*R?R;9KBZ/:D-U4MO\-/!\(8W5H^H2O]Z2\GEN7R?[OF,P3Z(% [5Q%S:2
M>%=?;PZ))9K"YA-U8M*YD=%1@DT)=LLP0LC*6).'VYPHK*BJ%5N-)NZ[JU^]
MM7_PQU8J6+P\8SQ$4HMVNI-V;VO>*WVZZM+K<ZF:^2*-Y97"(@+,Q.  !DDD
M] *I6TNMZBAN+'2;@VY^Y)*8X?,'J$=Q(!_O*I/4<8-9!CBU34--TJYRT-W=
M(KJ.C+$KS[3ZJWE[6'0@D'@U[=6>+JJ@DN6[??L;9;AI8MR;FU&.FEKM[]4]
M$FO6_EKY:VE>*Y5)BT^%&[":YV?K&DE.MO!OB.[W-JFI062M_!:1&5U]Q+-\
MI_&&O4**X?[5J)>ZDOE?\[GJKAR@W[\I/YV_])2?Z'(:9X%\.:=)#<R0&_NX
M#O2XNV,\BO\ WD#?+&?^N:J/:NOHHKBK8B=1WJ2N>OA<%1H1Y:,%%>2_/N%>
M4?$KP=_:%H_B;18-VJV:9D1  UW O)C/JZC)B]_ER%8UZO16F"QDZ%15(=/Q
M\CGS;*Z6,H2H5=GUZI]&O-?\/H?$GVN*XB2XMW$D<JAT93D,K#((/H170^!/
M'K^ +G^SM19I/#4[$G&6-@['EU'4P$\NH^X?F'RY L_$CPNWA/73=VB8TG5Y
M&>+  6"Y;+R1?1^9$]]Z\ **\WEDK]8I4Z.+H:J\)??_ ,!K^KIZ_P UXFMB
M\MQET^6K3=O)_+K&2L[>FTDFOO6&:*XB2>!UDBD4,K*0592,@@C@@CH:DKXX
M^'/Q%?P'<II&K2%O#4S<$\_V>Q_B7_I@3]Y?^69^8?+N ^Q5974.A#*PR".0
M0:_-<ZR:I@ZG++6+V??_ (*ZK]&F?OG"O%5'-*'/#W9Q^*/9_JGT?RT::3J*
M**\<^I"BBB@ HHHH **** "BBB@ HHHH **** "N7\;_ /(EZ_\ ]@^Z_P#1
M35U%<OXW_P"1+U__ +!]U_Z*:M:'QQ]2*OPL/!'_ ")>@?\ 8/M?_12UU%<O
MX(_Y$O0/^P?:_P#HI:ZBBO\ '+U"E\*"BBBLBPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB*+O&237S_KY!1116!UA1110 4444 %%%% !1110 4444 %<OXW_ .1+U_\
M[!]U_P"BFKJ*Y?QO_P B7K__ &#[K_T4U:T/CCZD5?A8>"/^1+T#_L'VO_HI
M:ZBN7\$?\B7H'_8/M?\ T4M=117^.7J%+X4%%%%9%A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5^:GQQU1]1^-?B RGG3(;.Q3_ '!%]I_]"G:OTKK\L_C'NB^-OC??
M_P M+JT9?]W[#;C^8->_P]&]67I^J/KN#8)XB=_Y?U1AQ7'O7WC^S?8V]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "$ C!Y%8EUX:T"\#">QB^;DE%V$_BN#6Y151FULR904MT<
M+<?#[1)3NMY)K?V5@P_\>!/ZU@7?@/5;93)I]TMUC/R,/+;'H#D@GZXKUFBN
MB&-J+K<YIX&D^ECY\DNKRPF-M>QM!*O56&#]?<>XJ0ZJ2.M>YWNGV.I1>1?0
M).G8,,X/J#U!]Q7+OX"\/,2521!Z"0X_7)_6NR&.IOXD<4\!47PNYY@=2/\
M>JNVH?[5>L+X"\.@Y:.1OK(1_+%7X/"'ANW^Y8HW^^6D_P#0B:MXZDMDR%@*
MKW:/$OMS.P1,L['  Y)K8L] \1ZA@PVCQ(3C=+^[ ]\-R1] :]PMK.SLUV6D
M$<"^B*%'Z59K&>9?RQ-H99_-(\TT_P"'PRLFKW1DZ$QQ<+QV+'D@^P!KO+#2
M]/TN/RK"!85.,D#DX]6/)_$U?HKBJXB<_B9W4L-"'PH****Q-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH __]?]_**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN#ST8?Q*IXK[ ^#.L7&L?#S36NV9Y;(S69=SDNMM(T2,6/4E%&X_WLUZ7&V
MA*G#&TWO9.W7>S_!K[NQX'A)G56G6JY1735KR2>CBTTI*W2]T[=[OJ>I4445
M^<G[L%%%% !1110 4444 %%%% !1110 5R_C?_D2]?\ ^P?=?^BFKJ*Y?QO_
M ,B7K_\ V#[K_P!%-6M#XX^I%7X6'@C_ )$O0/\ L'VO_HI:ZBN7\$?\B7H'
M_8/M?_12UU%%?XY>H4OA04445D6%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXEABRLH:QG<=1C,L!/\ LC]X/JP]:\L\+>)6\,>(;+6R?W,3%+@ %B;>3A\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!__T?W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>7_  Q_YFS_ +&"_P#_ &2O4*\O^&/_ #-G_8P7_P#[
M)752_A3^1A4^./S/4****Y3<**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _]+]_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QO\ \B7K
M_P#V#[K_ -%-745R_C?_ )$O7_\ L'W7_HIJUH?''U(J_"P\$?\ (EZ!_P!@
M^U_]%+745R_@C_D2] _[!]K_ .BEKJ**_P <O4*7PH****R+"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\O\ AC_S-G_8P7__ +)7J%>7_#'_ )FS_L8+_P#]DKJI?PI_
M(PJ?''YGJ%%%%<IN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?__3_?RBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\;_ /(EZ_\ ]@^Z
M_P#135U%<OXW_P"1+U__ +!]U_Z*:M:'QQ]2*OPL/!'_ ")>@?\ 8/M?_12U
MU%<OX(_Y$O0/^P?:_P#HI:ZBBO\ '+U"E\*"BBBLBPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O+_ (8_\S9_V,%__P"R5ZA7E_PQ_P"9L_[&"_\ _9*ZJ7\*?R,*GQQ^
M9ZA1117*;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '__U/W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **HQ:IID][+IL%W#)=P -)"LBF1 >A9 <@<]Q5Z@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y?QO_P B7K__ &#[K_T4U=17+^-_^1+U_P#[!]U_Z*:M:'QQ
M]2*OPL/!'_(EZ!_V#[7_ -%+745R_@C_ )$O0/\ L'VO_HI:ZBBO\<O4*7PH
M****R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ.L_:"^'VB_%3X(^./A_K]LMU::QI-W&%?\ AF2,O!(/1HY51U/9E!K\4/\
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M6M1&Y%K<1&]A@D8%HX+BY\S/4A6$*;(N0@< 9ZO_ ()"_';XF7'BSQQ^R_\
M$B^N+]?"UJ]]8)=2>;)8-:7*VMW;*YR3&7E0JN=J%6V_>H _=JBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_AC_ ,S9_P!C!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#_];]_**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT=_*^R17H=6,H+"1HU?YE4  -P 3C&<&OLJBBOW+(\J6!PL,*IN7+U>^]_\
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MKZ0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&__
M ")>O_\ 8/NO_135U%<OXW_Y$O7_ /L'W7_HIJUH?''U(J_"P\$?\B7H'_8/
MM?\ T4M=17+^"/\ D2] _P"P?:_^BEKJ**_QR]0I?"@HHHK(L**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[]EC]G+XC_L=?#_QGX\^'6BZ]KNH_P!J_:+V[M$EGE\G5+N)-SD9.V-%4>P
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M/X0^)'_!935O!GCS2+;7M"U'5-4^T65W&)8)?)T.:6/<AX.V1%8>X!K]M/\
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MF<*1Y>1U/R\U^T] %#2]+TS0].MM'T6TAL+"RC6&"WMXUBABC085$1 %55'
M   %7Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]?]_**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J*6&&=0L\:R*#G# $9_&I:*&AIM:H****!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_#'_F;/^Q@O_\ V2O4
M*\O^&/\ S-G_ &,%_P#^R5U4OX4_D85/CC\SU"BBBN4W"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__0
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJC%JFF3WLNFP7<,EW  TD*R
M*9$!Z%D!R!SW%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&__ ")>O_\
M8/NO_135U%<OXW_Y$O7_ /L'W7_HIJUH?''U(J_"P\$?\B7H'_8/M?\ T4M=
M17+^"/\ D2] _P"P?:_^BEKJ**_QR]0I?"@HHHK(L**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS\5^(]-T6>9/,CCO;R&V=TSC<JR,I(R,9% '6T5YG_PNKX-_]#YH'_@TM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[(?A]XHEB@DNI3MA:UF8_P!GZH!]T%"3'/CA1YH^8HM '],]>&_M'_'?PO\
MLV_![7_BWXJ0W$.E1A;:U5MKW=Y,=D$"G!QO<C<V#M0,V"%(K\,?VC/&7B3_
M (*4?MF:-^SU\,;]Q\-_!TTBW%[ =T+1PL!?ZD<95N<06N<JQ*D$"5J]._X+
M.W<'@;X5?!7X.>'0;?0HI+UXX"[-M32+>VM;8$L26VI<.,G)- 'SE\/?!/[;
MG_!4#Q#J_C'7/&,GAKP)9SM$"TDT.DPRC#"VM+.%AY\B(P+2.2<8WR;B ?7O
M$/\ P3(_;!_9TM#XY_9I^*\VO:CI_P"]>RM&FTBYF"\E4B:::WG[YCD=0PX
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MST60G('[L?LK_M(>%?VIO@]IGQ2\,Q&QFD=K34K%FWO97\(4RPEL#<N&5T;
MW(RD@'*CK/V@OA]HOQ4^"/CCX?Z_;+=6FL:3=QA7_AF2,O!(/1HY51U/9E!K
M\4/^"'GB:_76/BMX.:0M920:7?HA/"2HT\3D#_:5E!_W10!^X_Q@^*GA7X)?
M#/Q#\4_&D_DZ3X=M7N) " \K_=BACSP9)9"L:#^\PK^.;XS_ !2^/7Q%UT?M
M$>,-4O["#QQJ6H?V:8KJ6..,:>8=\5LH8$0P":.-&'4JPR6#5^M7[?\ \1?%
M'[7_ .TOX5_87^#]SNT[2KY9-=NDRT0O54F9I,<&.P@W%AGF5F3&Y5KRO_@K
MY\.O"WPD\-?L_P#PU\%VWV31?#NF:Q:6R<;BJ-9;G<C&YY&)=V_B8DGK0!_1
M]ICM)IMH[DLS11DD\DDJ.37\Y_QK^*7[0'_!0G]K75OV;?@WXCF\/_#WP]/<
MP326TKI;-:V+B*XU"[\HJUP))2%@C)V_,@ 4EWK]_P#Q9K3>&_A;K/B)&*MI
M>C7%T".H,%LSY_2OPS_X(<Z':SZI\8/%,\8:[MXM%M(I#]X).UY),/\ @1BC
M/X4 >6?M"_\ !.[XQ_L6^"7^/_P4^*-]JG_"/21R:D;:*32[N"-W5?/3RYY1
M-'O($B-C"G)W*&Q^PW[ ?[3-_P#M2?L^6'C/Q)Y8\4:-<R:3K!C4(DMS J.L
MZH,!1-%(CD !0^]5   KW?\ :&T:U\1? /XDZ#?*&@O_  WJ\+9[![.49YZ$
M=0>QK\>_^"'&I7$OA_XOZ.Q/D6MUHLZ#MOG2\5OTB6@#]Y:_GS_X+5>,O%^@
M^-?AAI>A:W>Z;9R:?J$SPVUQ)"C2>;$N]E1@"P P">@K^@ROYSO^"W__ "43
MX6_]@O4/_1\= 'I%Y_P2,^/NF0M>>%OVA[B34(P3&)8;VT7=VS+'=RLH]PI^
ME>(^%/VMOVSOV ?BY:?#/]J*6]\8>$IG&3>3&]>6TW!3=:;?R?O)-@P?*D;'
M\#+$QW#^E>OR?_X+$?#[1?$O[+$7CBYME.J^#M6M)+:?^-(;YA;31@_W7+1L
M1ZHI[4 ?J+X:\1Z+XP\.Z7XL\-W:7^DZS:PWEI<1_<EM[A!)&XSSAE8'FOS8
M_P""LGQTN_A)^S3_ ,(GX?OGL=>^(%ZFGQ/"YCF2R@Q/=R*P(." D+8[2UV/
M_!*_Q-?^(_V*O!D>HR&5](GU&P1B<GRHKN1HP?\ =5PH]@*_.?\ :MG;]L?_
M (*9>#O@#9DW?ACP5-#8WJKS&4@'V[5FS_"Q51;G/\48'/< X;_@EO\ %KQ[
M\'_VJ+OX%_%.XO;5/&VGK&MI?3,WDWZ0B]M'PS,%,MNSJ .6+H#R,5_3%7\[
M'_!6KP/K'P9_:'^&W[4W@>,6UQ=FW#R(,*NIZ)(DD#/C'^L@*(!W6(U^^GPY
M\<Z-\3? /AWXB>'7WZ;XET^VU"WYR52YC60*W^TN=K#L010!_-?\9_"/Q$_:
M,_X*<>*?@38^/M1\-1:OJ%Q#!<B2:>*UCL=+-T$6!9HAM/DE<!EP6W<]#Z+\
M;?V#_P!K?]E+P/J7QK^&7QMU#78/#41NKY+>>\TZZ2V4C?(J&>:.5$'S2*S#
MY0<!NE><>+OC#X/^ ?\ P5N\1_%KQ\;@:#H6J7_VDVL7G3?Z5H\EM'M3*Y_>
M2KGG@9-?3?[4_P#P5:^&_P 5/A5K_P &/@%X:UG6->\<VLNB^?>VR11I%?KY
M$BP0QR2RS32([(B[5PS!LMC:0#[:_P"";G[5_B;]J;X,WUS\0/+D\6^$KM;&
M^N8D6-+N.1-\%P8UX1V 97"@*67<H .T?F3_ ,%()?'?CW_@H#X,^#>D^+;_
M $&R\0P^'])@:&:7R;5M3NVB:;R4DC#D&3<1D%L ;AQC]#O^"6W[,/C7]G7X
M+:MJ?Q)M#I?B3QO>17KV#X\VTM((]ENDP'W927=V3J@8*V&# ?GU^W%J.GZ1
M_P %6?A7JVK7,5E8V6H>#IYYYW6.***/4 SO([$*JJH)9B0 !DT =1\0?^"9
M'[6OPD\.7GCOX/?&Z_\ $>KZ/&UR+."6\TN[E6(;BMNRW,RO)QPC%0W3.< _
M4W_!+C]M;QK^T;HVO?##XLW U'Q5X4@BN[?40@22]L7;RV\\+A3+"Y4%P!O5
MAD;@S-]8?&;]NC]F;X.>#-2\37?CS1M>U"UA=K72M+OX+V\NI]I,<82!I"BN
MW!D<!%ZDU^4W_!%;X;>(KSQS\0_CE>636^CO9#1;>;&V*:XGGCNITC'?REBC
MSV&\#UP ?8WP,_X)[^,OA1^V;XB_:<UCQM;ZII>J7>LWD-FD4JW3G5F<A)V8
M["(Q(>03N95.%[?JE7\]/[)-S<-_P5T^+8:5B&NO%"G+'E5NEV@^PP,#MBL#
M_@K?XE\5^$OVQ/A+XE\$EVU_1M'T^]TU%0RYO8=4N'A BYWEG505Q\W3F@#^
MBBYU+3K.:&VN[J*"6Y.V)'=5:0^B@G)/TJ[7\_5M_P $D/C%\8_"5U\3/CK\
M4IU^*6M1&Y%K<1&]A@D8%HX+BY\S/4A6$*;(N0@< 9ZO_@D+\=OB9<>+/''[
M+_Q(OKB_7PM:O?6"74GFR6#6ERMK=VRN<DQEY4*KG:A5MOWJ /W:HHKA?'?Q
M0^&OPNL[;4/B5XKTKPI:WLAB@EU6]ALDED4;BJ-,Z!B!R0.@H X[XV_M%?!O
M]G/1M.U_XR^(AX>L=6N#:VLAMKFZ,DRKO*[+6*5@ HR20![YQ7L-C>VNI65O
MJ-C()K:ZC26)QT9' 96&?4'-?@#_ ,%@?C3\'OBC\,_ &G_#7QQHGBNZLM7N
M99XM*U&WO7BC:WVAG6%W*J3P">,U^JW@/]K+]ERS\#^';2[^+WA*">#3K1)(
MWURQ5T=85#*RF7((/!!Z4 ?65<IX\N[FP\#>(KZRE:&XMM.NY(Y$.&1TA8JP
M/8@C(KI;:YM[RWBO+.5)X)T62.2-@R.C#*LK#@@CD$=:Y+XC_P#)//%'_8*O
M?_1#T ?RO?L4_LS_ !8_;4D\:S6OQ9U#PQ)X2.GM(TYN;TW)U'[2<Y%Q%M*_
M9SG.<[NV.?T;\ _\$HOB[X/\=>'?%MY\?;N]@T34;2^D@6TNE,R6TRRM&&-Z
M0-P7&2#C/0U\/_\ !+[]KGX,?LK_ /"R_P#A;M[=VG_"3_V-]B^RVKW.[[%]
MM\W=L^[CSTQGKSZ5^RGP]_X*<_LG_$WQQH?P\\+ZQJ3:QXBNXK&S6;3IHXVG
MG;9&K.<A<L0,GCUH _06OY;?^"EOQ<\?_&G]JCQ'X*^&]S>W&C?"S3)(IX[.
M9DC1K-3/J5TX#  Q.WE,>O[H 5_2#\;?B=IGP7^$?B[XJ:OM:W\,Z;<7@1C@
M2S(N(8<^LLI5![L*_%__ ()%_!=?B1I/Q>^.WQ*@_M-O&S7'AXO,.;B.['VC
M5"?42M)$,CNK#Z 'W!_P3 ^.5S\:OV5]&M];O7O?$'@J:31+UY7+RR)"!):R
M,6)8Y@=$W$\LC5]S^.KVZTWP3XAU&QD,-S:Z==RQ.O5'2%F5A[@C-?ST_P#!
M-;Q#JO[,O[;/CS]EOQ9.4M]=DNM-C+_*LE]I+/+:S#/ 6:V,I7^\70>@K^@W
MXC_\D\\4?]@J]_\ 1#T ?RR?L2_LS?%+]M:3QQ/'\7=3\+2^$CI[.TOVF_-T
MVH_:3DG[5"5*FWY)W;MW;'/JWQ@\+?MN_P#!,_Q'H'C33OB1<>*_"&IW/D1M
M)/<3Z?-,@+FVN[*X=A&TB!BK1L6VABLBL#CTG_@B_P#$7X?> %^,;>._$^E^
M&Q>_\(^8#J5[!9B41?VCYFSSG7=LW+NQTR,]171?\%9OVN/@[\4_ 7A[X%?"
MC6K7QCJ2ZO%JEY>:;(+FTMU@AEABA2:/,<LDK3D_NV;:%(;EA0!^VGP)^+&E
M_'/X/^$_BUH\)M;?Q-8QW)@8Y,,W*319[^7*K+GOC->LU\M_L4?#+7/@]^RO
M\.?A[XFMFL]7T_3C-=V[_?@GO9I+N2)L?Q(TI4CL17U)0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<OXW_P"1+U__ +!]U_Z*:NHKE_&__(EZ
M_P#]@^Z_]%-6M#XX^I%7X6'@C_D2] _[!]K_ .BEKJ*Y?P1_R)>@?]@^U_\
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M\%"?VM=6_9M^#?B.;P_\/?#T]S!-);2NELUK8N(KC4+ORBK7 DE(6",G;\R
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MX8Z;/Y>J?$6^6!U!PPTZP*SW!!Z\R>3&1W5V'M4GAO\ 8U^T?\$O3\$&L?\
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MX[U'4;?PY&]U?)&QL=4M+:(;GF1X6"7$2J"95VH0O\+C./TG_P""<'[:-_\
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MU33[71+T6,\>JPPPRF0QK(&0033J5*MW8'(/'0GZ>K^;?_@EQ^V!^SU^S?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^/GPGO/#?QH^$-I;>'-$D_MF2YL[5$GMS912%I%/VR4X$;.& 0D@X'-?;_\
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MJ$5_+"C#,-A8[COD'4>9,4$>>NQSGY:\WN!_P7$UR)M/E@MM(24;6F23PTK
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M?I5X1\'>%/ 'AVR\(^"-(M=#T73DV6]G9Q+##&O4X1 !DGDGJ2222237244
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M7X]>"?V.K[X0?&?0#HNOZ4=5L-*@DNK>X:6QN8_-A+2022(N)I9(P&8$*HX
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MFAPL)+F10LEU<S.99YF Z;Y&)"Y.U<+D@"O:: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&? 7PYUJ:&XU#PKH&EZ5<R6Y9H7FL;2."1HRZJQ0LA*DJ#C&0#Q7IU 'Q?\
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MW.[=&<@ #[DH _!&;XQ_\%A+/1I+ ?"S3[73X+<Q[(K&U58X53;A56[X"KP
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MWVF7M[KNJ)>0_P!ES331K$D*Q_.TT,)#$@\ $8[]J / _P#@M?\ \FW>#?\
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MW$GD&OW/^$7P'^$7P&TN_P!&^$7AFW\-6>IS+<7*0-(_FR*NQ69I6=N!P!G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N7\;_ /(EZ_\ ]@^Z_P#135U%
M<OXW_P"1+U__ +!]U_Z*:M:'QQ]2*OPL/!'_ ")>@?\ 8/M?_12UU%<OX(_Y
M$O0/^P?:_P#HI:ZBBO\ '+U"E\*"BBBLBPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYB_; ^/\ J/[,?P)U
MGXP:5H\6NW&ESV<*VDTK0HXNITA)+JK$;0V>G-?3M8?B/PQX:\8:5)H7BW2;
M36],F*L]K?01W,#E#N4M'*K*2I (R.#S0!_/A_P_!\=_]$KTW_P93?\ QJM'
M1_\ @MIXYU/5K+37^%NFQK=SQ0EAJ4Q*B1@N<>5VS7[;?\,Z_L^_]$Q\+_\
M@EL?_C-?S9?\%,O"7A7P5^VQI>B^#=%LM!TX6&C2?9K"VCM8=[RON;RXE5=Q
MP,G&30!_5C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7E_P ,?^9L_P"Q@O\ _P!DKU"O+_AC_P S9_V,%_\ ^R5U
M4OX4_D85/CC\SU"BBBN4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /_4_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MR_C?_D2]?_[!]U_Z*:NHKE_&_P#R)>O_ /8/NO\ T4U:T/CCZD5?A8>"/^1+
MT#_L'VO_ **6NHKE_!'_ ")>@?\ 8/M?_12UU%%?XY>H4OA04445D6%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7\M__!5?_D^O3/\ L&Z)_P"C7K^I"OY;_P#@JO\ \GUZ9_V#=$_]
M&O0!_4A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7E_PQ_P"9L_[&"_\ _9*]0KR_X8_\S9_V,%__ .R5U4OX4_D8
M5/CC\SU"BBBN4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **X[Q#X_P#!_A6]33_$&I)9W$D8E5&5V)0DJ#\JD=5-87_"Y?AG_P!!V/\
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M0>W- 'NM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__5_?RB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP_ [X^:?!H?C:8O%87T"&WM[Z>('?;S0N28;G@E<'8Y!4*C;5?\ 8JOYE_\
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MO]V&UB6)!^"J* /PK_8^_;1_:*^%'[2B?LC?M=7DNJ2WMVNF6UY>E7O+2^E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5Y?\,?\ F;/^Q@O_ /V2O4*\O^&/_,V?]C!?_P#LE=5+^%/Y&%3X
MX_,]0HHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Z8V9H(KB6WTRPMWSY*W+0X>\N9-IP&!YW%1''G'LFJ?\$D_VE_A78?\)?\
M OXQ_:_$UJ/.^SQ?:=%DD<<E8KE)Y59B1@>9Y:G^(J*^^O\ @E/X#TOP=^QG
MX5UBUMEAO_%ESJ&IWL@^](_VJ2VA)/H((8\#H.>Y-?H[0!\6?LW>)/V@;S]D
MB?5/VA;>XTSX@Z;::M%+)/&L%RZVOF+;SN(\+O*J"'4 . 'YSD_@%^Q+^S+\
M4_VU7\;S0_%S4O"TGA(Z>SM+]IOC<G4?M)SD7,.TI]G.<[MV[MCG^IWXC_\
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MS_TUF9$'NU?R-_!OXW_&/X._%_P)^T?XJU#5+C2-3UB:::>:>1TU*"*54U-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OGKXH_LW>"?BEKR^)=2NKO3[\QK'*ULR;9508
M4L'1N0.,CMP>@KZ%HH ^+_\ AB7P!_T'=3_.'_XW7Y__ /"O?'__ $+.I_\
M@%-_\17[H44 ?A?_ ,*]\?\ _0LZG_X!3?\ Q%?4'P4_9>T_X@>%;K6?&LFI
MZ'?0WKVZ0>6L.Z)8XW#[98RW+.PR../K7Z844 >0?"?X*^$OA!;7J>'WGNKK
M4-GGW%RRLY6,L550H4*!N.<#)/4\#'K]%% !117E_P ;/%7B;P1\(?&7BWP7
MI5QKGB#2M*NY].LK6%KB:>[6(^2JQ("S_/@D $XS@&@#^9W]M#XT:I\7?V_9
M];\.^'+CQWI'PQO;6PM])M5DD%U%H\_F7:MY22$1R732*SA3E-OM7U=\3/\
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M7H'_ &#[7_T4M=17+^"/^1+T#_L'VO\ Z*6NHHK_ !R]0I?"@HHHK(L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OY;_P#@JO\ \GUZ9_V#=$_]&O7]2%?RW_\ !5?_ )/KTS_L&Z)_
MZ->@#^I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O+_AC_S-G_8P7_\ [)7J%>7_  Q_YFS_ +&"_P#_ &2NJE_"
MG\C"I\<?F>H4445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;EE(% '\_P#_ ,$-?^0E\9?^N6@?^A7]9O\ P4P94_X**? UW.U5LO#A)/0
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MUFXUZ6SU$W=K(LRW]P'@Q%'*TP++R0R#;CYL&OO;]M/X=^,/BQ^R[\0/AYX
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M7[7:[=O]A?8O]1YOGY\_Y,>7_M?=YH _9BOR[_X*]>!M1\8?L@W&K:=$TO\
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MQ]\:_P!E3Q;\._AEI9UGQ%J$NG26]H)HH#(MO>PS28>=XXP0B,<%AG&!DX%
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M@@U_.#X'N+7Q;_P6LO+[PS*KVUIK.IK-(G*AK+1Y8+D''<RHR'W-=98^$O\
M@L'\#_#[_ ?P1%_PD6A6ZFUTS6()+"X:&VP5407-VZ20J!]P3J&C& FT!:^L
M_P#@G/\ L$>)_P!G&^U?XQ?&>YBNO'^OP/;1VL<@N?L$$D@DF:2XR1)/,RKN
M*9"J"-[;VP ?K#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__U_W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=17+^-_\ D2]?_P"P?=?^BFK6A\<?
M4BK\+#P1_P B7H'_ &#[7_T4M=17+^"/^1+T#_L'VO\ Z*6NHHK_ !R]0I?"
M@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4^AJ***_.C]."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_
M (8_\S9_V,%__P"R5ZA7E_PQ_P"9L_[&"_\ _9*ZJ7\*?R,*GQQ^9ZA1117*
M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '__T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=17+^-_\
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M_MW_ -+B?H/A9_R/L/\ ]O?^D2/TJHHHK^8#^PPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KR_X8_P#,V?\ 8P7_ /[)7J%>7_#'_F;/^Q@O
M_P#V2NJE_"G\C"I\<?F>H4445RFX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!_]']_**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QO\
M\B7K_P#V#[K_ -%-745R_C?_ )$O7_\ L'W7_HIJUH?''U(J_"P\$?\ (EZ!
M_P!@^U_]%+745R_@C_D2] _[!]K_ .BEKJ**_P <O4*7PH****R+"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN<)<][<KD]K7O>,>_F7****^M/@0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_AC_P S
M9_V,%_\ ^R5ZA7E_PQ_YFS_L8+__ -DKJI?PI_(PJ?''YGJ%%%%<IN%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?_TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=17+^-_\ D2]?_P"P
M?=?^BFK6A\<?4BK\+#P1_P B7H'_ &#[7_T4M=17+^"/^1+T#_L'VO\ Z*6N
MHHK_ !R]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y?QO\ \B7K_P#V#[K_ -%-745R_C?_ )$O7_\
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M[_B-'$?_ $$+_P  A_\ (GY\?\,1ZI_T-D/_ ("-_P#':/\ AB/5/^ALA_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%WC6#PRMS++-%8RW,]A<6/GY\R"">))%E@.<!)-N%PIWXR0#[(_X*H_$?2?
MG['7BK1KJX6/4O&$MII5C$2-TC&=)IR!U(6")\GH"5!ZBJG_  2A\"ZGX*_8
MW\/W6JP_9Y/$]_?:O&A^]Y,KB&)C_OI"'7_9(-?%VC?\$Q_VJOCSXYTKQ)^V
M9\34U#1M+PHM[:\EOKQHLY>*+=%'!;A\#=(N\GJ5) -?N[X>T#1O"F@:;X7\
M.VB6&E:/;0V=I;Q\)#;VZ"..-<\X55 'TH V**** /./B=\7OAG\&-$M_$GQ
M3\1VGAG2[NX6TBN+Q]D;SLC2",'!^8JC'Z UX=_PWG^QU_T5G0_^_P"?_B:[
M+]I+]F7X;_M4>"]/\!_$Z2^CTW3=034HCI\ZP2^?'%+"-S,D@*[96XQUQS7Y
MZ?$K_@D?^RIX3^'7BKQ3I=QXB-[HVE7U[ )-0B9/-MX'D3<!;C(W*,C(XH _
M3_X7_&SX4?&JQOM2^%/BBR\3VNF2+%<R6;EUBD<;E5N!R0,UZE7X=_\ !$'_
M ))I\3O^PO8_^D[5^XE !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__5
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)P&:@#RE/V=]<E_83^*_[8WQ:WWWB[Q_>Z>=-EN1F46LVK0/<WA!Z/=2Y"D
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M!&C*K54_:7V35K6[^I>HHHK[(_. HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HJ*::&VADN+B18HHE+N[D*JJHR22
M>  .IKC/^%F_#;_H;-)_\#[?_P"+K6G0J3^"+?HC&KB:=/XY)>KL=Q17"_\
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M9))?V0/A(\K%V_X1^S&6.3@+@=?0<5#^W;_R9[\6O^P#=?TH _'?X0?M;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4/\ TG>OY3S/_=JO^%_D?VODG^^T/\4?S1^)M%%%?QH?Z2!1110 5^\&D?\
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M'%^'PN.I_5<'&,IM1;YIO1M=VT?O11117\T']9!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?__7_?RBBB@ HHHH **** "BBB@
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MZ)_P7$\(W&JB'Q%\)KZQTTL 9[75HKJ<+GD^2]O N0.@\WGU%?L?\(/B_P"
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M K^H=A7VY_P3,^ WACX0?LO>%/$]MI\:>)/'EG'K.HWA ,LL=U^\M8@W41I
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MI)$T[6NF:I:WDXB0A6D,<,CL%!8 MC )'J*]-H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KE_&__ ")>O_\ 8/NO_135U%<OXW_Y$O7_ /L'
MW7_HIJUH?''U(J_"P\$?\B7H'_8/M?\ T4M=17+^"/\ D2] _P"P?:_^BEKJ
M**_QR]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OY;_^"J__ "?7IG_8-T3_ -&O7]2%
M?RW_ /!5?_D^O3/^P;HG_HUZ /ZD**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\B_V^?^2PZ/\ ]@&W_P#2JZKX?K[@_;Y_
MY+#H_P#V ;?_ -*KJOA^OZMX+_Y%6'_PG\6>('_(ZQ7^(****^G/C@K]*O\
M@GC_ ,S_ /\ <*_]NZ_-6OTJ_P"">/\ S/\ _P!PK_V[KXKQ$_Y$]?\ [=_]
M+B?H/A9_R/L/_P!O?^D2/TJK@?BM_P DN\8_]@;4/_2=Z[ZN!^*W_)+O&/\
MV!M0_P#2=Z_E/,_]VJ_X7^1_:^2?[[0_Q1_-'XFT445_&A_I(%%%% !7[P:1
M_P @FR_ZX1_^@BOP?K]X-(_Y!-E_UPC_ /017[/X/_'B?2/_ +<?S3](S^'@
MO6?_ +::%%%%?N)_+H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\1=K?\ /A?>SY/_ (@;A_\ H)E_X"O\S^>/_A67Q)_Z%/5O_ "X_P#B*/\
MA67Q)_Z%/5O_   N/_B*_H<HH_XB[6_Y\+[V'_$#</\ ]!,O_ 5_F%%%%?CY
M^ZA1110 4A 8%6&0>HI:* (XHHH$$4"+&@Z*H  _ 5)110!%'!!$[R11JC2'
M+$  L?<CK4M%% #)(HYD,4R!T;JK#(/X&F?9X/)^S^6OE8QLP-N/3'2IJ* &
MHB1J$10JJ,  8 %.HHH **** "BBB@ HHHH **** "BBB@ KR_X8_P#,V?\
M8P7_ /[)7J%>7_#'_F;/^Q@O_P#V2NJE_"G\C"I\<?F>H4445RFX4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>7_'#_ )(MX_\ ^Q?U7_TDDKU"O+_CA_R1;Q__ -B_
MJO\ Z224 ?D7_P $0?\ DFGQ._["]C_Z3M7[B5^'?_!$'_DFGQ._["]C_P"D
M[5^XE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA?\ 0K)_W[GK\]Y&?IY]C45\<?\ "^OBM>';IGA6-BOWA]FN9?\ T%EQ2_\
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M **** "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCK7PMT247.KPZ%JEYJ-V@.+C5+BU8RR*.#M4JL<?&=B+GG-?FA_P3_\ ''[
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M  57_P"3Z],_[!NB?^C7K^I"OY;_ /@JO_R?7IG_ &#=$_\ 1KT ?U(4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME5I7]1U?RX_\$<?^3O=9_P"Q8U+_ -*K2OZCJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJC>ZIIFFIYFHW<-JOK
M+(J#\V(H O45YOJ'QA^%>EG;>^+-,5NZK=1R,/J$)(KC=0_:;^"6G[@WB19V
M!(VPV\\F<>A$>W\<XH ]ZJAJFI6>C:9>:QJ#^5:V,,D\S_W8XE+,?P -?-=S
M^U_\'8 #%+?W.>T=MC'UWLM>=>.OVMOAKXG\(:_X6MM-U4'5[&ZLED:*!5'V
MB)H]W^N)XW9Z5K147.*F[*^OH8XB4U3DZ:N[.WKT/RQ\0>(+[Q!?2W5RY\MG
M9DCSPN3_ #]36+#-+;R+- YCD0Y#*<$'V(I)(WB=HY!M93@@^M,K^RZ*@H15
M/X;:6VMTL?P5BJU6=64ZS?/?6^]S]'/V'?$#ZSXTU);DYN8M,E1\=& FA*L?
MU'YU^G%?B!^SCX^U_P"%VO7_ (BT/1SK,][:M;^3\_RIO5M_R GJ,5]B#]I?
MX]. \?P[)5N019WIX^N:_F3Q"Q5.KFU5T^ED[=6DK_CI\C^P_#>G6634'7O=
MIO7LV[?>M?F??=%?G=+^TW\?H7:2\\)6EG"0Y7SK*[3D [1EIAGD8Z5SLG[6
M'QMO,1P:?I5LPY)$3KGV_>3D5\M1R[$5-:=.3]$V?7U<;1A\<TO5H_3.BOS
M;]J7XYKUCT[\(5/\I*K7'[3OQVN GEW-E:XSG9;H<_7?NZ>U>G3X4S.?PX:?
M_@+_ ,C@GQ#@([UX_P#@2_S/U(K,U76M&T*W6[UR_M]/@=Q&LEQ*D*%R"0H9
MR!G )QZ U^66J?M3_&[1[4WE]K%LL>0HQ:1$DGL!LKS#Q=^TWXO\>:;%I'B^
M[6]LX9EG6-+:.(^8JLH.Y0#T8\5Z>"X$S&I5C"M2E"+W=KV7>V[^1XV8<>97
M0B[5XN5M%>U_GLOF?K[_ ,+&^'W_ $,^E_\ @;!_\71_PL;X??\ 0SZ7_P"!
ML'_Q=?B#'\0-#9L2VTB#U"@TC_$'1 Q$=M(R^I 'Z5]B_"=<G/\ 6M/^O<K_
M '7O^!\HO%K#\W+[-7_QQ_.UC]Y-/U+3M7M$U#2;J*]M9<[)8'62-MI*G#*2
M#@@@^XJ[7YT?![]K[X4>"?A]I7A?7(=16\M#/YABMT>,>9,\@P?,!. PSQ7W
MYX;\1:1XMT&Q\2Z#/]IT_48EFADP1N1O4'D'L1ZU^;YSD&)P4W[6#4;M*35K
MVZ_-:V/OLEXDP>/5L/4BY63:3NU_PSTN;=%%%>(>\%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5R_C?_D2]?\ ^P?=?^BFKJ*Y?QO_ ,B7K_\
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M110 4444 %%%% !1110 4444 %?RW_\ !5?_ )/KTS_L&Z)_Z->OZD*_EO\
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MHOA32[X:E'*\;?9Y9;.,06-E:NP42F (C22 8^0EL.X%?T@4 %%%% !1110
M4444 %%%% !1110 5Y?\,?\ F;/^Q@O_ /V2O4*\O^&/_,V?]C!?_P#LE=5+
M^%/Y&%3XX_,]0HHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O^.'_ "1;Q_\
M]B_JO_I))7J%>7_'#_DBWC__ +%_5?\ TDDH _(O_@B#_P DT^)W_87L?_2=
MJ_<2OP[_ ."(/_)-/B=_V%['_P!)VK]Q* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]+]_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M['G_ ";QX7_WK[_TMFKW\RXPQT\BCBU+EG*?*VM-+/;>STW/E\IX$RZGQ)+
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MM_\ TJNJ^'Z_JW@O_D58?_"?Q9X@?\CK%?X@HHHKZ<^."OTJ_P"">/\ S/\
M_P!PK_V[K\U:_2K_ ()X_P#,_P#_ '"O_;NOBO$3_D3U_P#MW_TN)^@^%G_(
M^P__ &]_Z1(_2JN!^*W_ "2[QC_V!M0_])WKOJX'XK?\DN\8_P#8&U#_ -)W
MK^4\S_W:K_A?Y']KY)_OM#_%'\T?B;1117\:'^D@4444 %?O!I'_ "";+_KA
M'_Z"*_!^OW@TC_D$V7_7"/\ ]!%?L_@_\>)](_\ MQ_-/TC/X>"]9_\ MIH4
M445^XG\NA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'Q!^WS_R1[1_^P];_P#I+=5^15?KK^WS_P D>T?_ +#UO_Z2
MW5?D57])>&/_ "*H_P"*1_)OC!_R.I?X8A1117Z$?EH5[9^SC_R7/P7_ -A&
M/^1KQ.O;/V<?^2Y^"_\ L(Q_R-<&:_[K5_PO\F>QP]_R,,/_ (X_^E(_>BBB
MBOXZ/[L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/]I_\ Y(;XE_[<
M_P#TLAK\BZ_73]I__DAOB7_MS_\ 2R&OR+K^>/%K_D94_P# O_2I']A_1\_Y
M$U7_ *^R_P#2(!1117Y<?NH4444 ?OA1117]L'^8YY)\:O@=\-/VA/!+?#WX
MK:6VK:(UQ%=B))Y;=EFASL<20LC# 8C&<$$U\@_\.I/V(O\ H2[O_P &^H?_
M !^OT9HH _#?_@LUH6E^%_V?OA3X:T.#[-INDZK]DM8MS-Y<$%D8XUW,2QVJ
MH&223W-?J3^R?_R:S\'/^Q,\/?\ IN@KR+]N']CR3]L;P3X>\)0^*QX3DT#4
M&OA,UE]M64/$T13:)H2I&<@Y/3&.<U]/?"GP,OPP^%W@[X:+>_VB/"6C:?I
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MW4LIR?O,,<Y !\J_\%N#GX-_#HC_ *#TW_I*]?;/[*/P"^!+_L[_  E\4O\
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M^T-X@^*VKGPMH1>'1TEV1VT66>1C\JAMOWG/H.!G:/XB?M/]EC]G!/A3I/\
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MZ5I6GZ'IT&DZ5"+>TMEV1Q@DA5ZXR23^M:%9-W ****0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8\0W$=Q<(#+;K)]INE/]TW$A91Z@ /C.,G&3]M>%O!_ACP5IB:1X6TV'3K5
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M//\ @GMXST7X>R)/X<T[PA'INFR0R+,DEE)'';1.LBY#AHV!W@X;.>]?-O\
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M2?[[0_Q1_-'XFT445_&A_I(%%%% !7[P:1_R";+_ *X1_P#H(K\'Z_>#2/\
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M&BW'Q'^'GP'M;GP/"9'^U#2]5OT$4>=Y^UPS11MLP=["/ QR!7WO^P[_ ,%
M?"/[7L6H>%]1TK_A%_'.CP"YFL!+YT%U;;@C3VTA"MA&90\;#*[EPSC) !^A
MU%%% !7E_P </^2+>/\ _L7]5_\ 222O4*\O^.'_ "1;Q_\ ]B_JO_I))0!^
M1?\ P1!_Y)I\3O\ L+V/_I.U?N)7X=_\$0?^2:?$[_L+V/\ Z3M7[B4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!D>(-'B\0Z#J6@3RO#%J=M-:M)&<.BS(4+
M*?4 Y'O7YM/_ ,$]]57<?^$W@VC/)L6''O\ OJ_3RO"?VFM>U'PW\"?%^J:4
MQ2X^S);AEX95NIHX'((Z$)(3GM7U/"^=X[#UEAL'4Y?:22V3U;LMUYGQO&'#
MV78JA+%X^ES>RC)[M:)7:T:['XI>.=!\.^&?$%QHGAO7?^$BAM&,;W:0>1"[
MKP?*R[EU!XW8 /;(P3!X.T?PYKVMPZ5XEULZ!;W!"+=FW-Q$C'_GH%=&5?\
M: ;'< 9-<K17]1JC/V7(YN]M]+^NUOPL?QNZ\/;>T]FN6_PW=K=KWO\ C<]!
M^(O@W2/!&N3:+IFNIKJQ' GBA,<;@=67+ME<\ ]\9Z8S]E?LC_LS1>(#;_%+
MXAV;?V?$RR:792KA;DCD7$@/)C!^XI&'/S'*8#<%^RK^SM+\5M7_ .$Y\9*W
M_",Z7,H6-P2;^:/GR\MQY28 D/?[@_B*_L(B)&BQQJ$1   !@ #H *_)N/\
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M J>BBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__4_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"GY5'3/)4'->V_"WX">+_C%JO_"Q/B[=W*V,[ JDV5N;M5Z8SCRH?0@<C[H
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M\NHJCA::2[]6^[?7].E@HHHKR#W HHHH **** "BBB@ HHHH **** "BBB@
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MM_\ TJNJ^'Z_JW@O_D58?_"?Q9X@?\CK%?X@HHHKZ<^."OTJ_P"">/\ S/\
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M_P""P_@+3[-MTMCJ_A1I0/X3 (KHCC_8P?QH _HWHHHH *\O^.'_ "1;Q_\
M]B_JO_I))7J%>7_'#_DBWC__ +%_5?\ TDDH _(O_@B#_P DT^)W_87L?_2=
MJ_<2OP[_ ."(/_)-/B=_V%['_P!)VK]Q* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD\8^+08](LW";%R$=02RP1^@7/SL.N?4YK[6@@@M8([:VC6*&)0J(H"JJC@
M < "OD-C[T>B)&BQQJ%50  !@ #H!3J**@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /_5_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAWZP&XFGB>X2T:\Q]FMX;="#+<RAE8 G:H9?E<L0H!^M=%?SP>.OC7_P6'^
M_AH?%OXF6T%SX8MMDEU"]EH]Q%;HYP!<)8!;F-,D!FW@*>"P-?K%^Q;^UEH/
M[77PG_X36ULUTC7]*G^Q:QIROO6"XVAEDB8_,895.Y"1D$,A)*%B ?7M%%%
M!1110 4444 %%%% !1110 4444 ?RX_\$<?^3O=9_P"Q8U+_ -*K2OZCJ_EQ
M_P""./\ R=[K/_8L:E_Z56E?U'4 %%%% !1110 4444 %%%% !1110 4444
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MS5^<'QH_:.\0?&#PO:^&]6\ORK6\2[&R$1G<D<D?7<W:0\5O?"[]JGQ+\-/
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M*** "BBB@ HHHH _(O\ ;Y_Y+#H__8!M_P#TJNJ^'Z^X/V^?^2PZ/_V ;?\
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M+_AC_P S9_V,%_\ ^R5ZA7E_PQ_YFS_L8+__ -DKJI?PI_(PJ?''YGJ%%%%<
MIN%%%% !1110 4444 %%%% !1110 4444 %?SD?\$]/@EX!_:1_:C^-?Q#^/
M&G1^(M6\-ZBT\6F:B!/ ]S?W5T)9)HG!640>2$56R@WCY20N/Z-Z_ 3]IW]C
M[]J?]GS]H?6?VG_V,?M5[:^(YY;N\L[#9/=P3WDGF74+V<@*W-K++\ZA0Q0G
M&U=BN0#]7?VI/AEX&U[]E7XE^"[G3+2PT>/P]?W$:11)##;S64#7%O*%0 #R
MI8T<8'\..E? _P#P3#\%^ /V@_V*I/!OQ>\,V7BC3_#^NZAIEN+^W61TA,<-
MV/)E(\Q"K7+A61@R] 0*^(_'OQ)_X*K_ +4^AR?!W5_ NM:5I6JLMM?+'H4F
MC0SKD$I<WETJJB<991(BL.&!!Q7[C?L6_L[2?LO_ +/^@_##4+I+W6=TM_JD
ML7^J-]=$&1(S@$I& L:L>6"[L#.  ?D=\'O M_\ L&_\%.-+^#?AG4Y)_ _Q
M(M0L44YRYL[L3&T5^<&6"[@,:R8RR;NF\BOZ':_(3XE_L[?'#XJ_\%/O"7Q;
MO_#4EI\-_ MM9+!J[30^7,MI!)=!4C#^;N-Y.8\%> "W3%?KW0 4444 %%%%
M !1110!\A_'G]AK]G7]I+QC;>//BKHES?:U:V<=@LMO?3VP-O$[R(I2-@I(:
M1N<9P<'H*\#U7_@D]^Q?;:7>7,'AO45DBAD=3_:MT<,JD@\OCK7Z<4UE5U*.
M RL,$'D$'L: /Y9?^"7'[*7P7_:?U'XBQ?&'2Y]3C\-QZ2]FL-W-:A3=-="7
M=Y+*6!\I>IX[=:^K?^"PGP'\6V.L^"?VGO %K*T'ARWBTO49;==S6)M9C/8W
M+ 9^3=(Z%R,*1&"?F%?M5X"^$'PI^%9OV^&7@[1_"AU0H;LZ58P61G\K=L\S
MR47<$WMM!X&XXQDUWUS;6U[;2V=Y$D]O.C1R1R*&1T88964\$$<$'K0!^//@
MO_@LQ\ ;GX<6VJ^/-'U>R\906O\ I6G6=LLMO-=*,'[/.T@ C<\CS,%0<'=C
M)^;/^">G@;QW^U1^V)XG_;5^(.DM;:)8SW5Q9NP)@;4)D^S6]O"S8\Q;2VSE
MA]UECS@GC]AKG]C#]DV[U5M:N/A'X9:Z9B[?\2R 1EB<DF(*(SSZK7T5I6DZ
M5H6G6^CZ'90Z=86B".&WMXUAAB0=%1$ 50/0#% &A1110!\9?MP>'?VI/$OP
MPT:R_9,OWT_Q5'K$4EX\=Q;VQ.GBWG#KNN?D/[TQ' YXST!K\D?&OPN_X+#V
MO@W7KGQ?XDN)-"BL+I]04ZIIC!K18F,XVJ=QS'NX')[5_1W7E_QP_P"2+>/_
M /L7]5_]))* /R+_ ."(/_)-/B=_V%['_P!)VK]Q*_#O_@B#_P DT^)W_87L
M?_2=J_<2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR%_:@^,.J?&OQ]:?"_
MP#NO=)L[I;>!(B/].OF.S?DD#8I.U">.K9P1CZF_;$^.C?#_ ,,#P%X:N=GB
M#7HF\UT^];6;95FSV>3E5[@!CP=IKBOV*/@4-&T]?C#XG@'VZ_C9=)C8 F&W
M<%7GYZ-*,JOHF>H?C]/X7PE/+,'+.L4KRVII]7W_ *Z7?8_(N,<=5S7&QR#!
M2M'>K)=%V_KK9=SZ1_9_^"6D_!;P;%IP5+C7;\++J-V%&7DQQ$AZ^7'G"^IR
MV 6('O%?,?CCX-^//$GBK4-;TKQ"EG:73JT<1EF4H @4C"C'49XKP+X=>%?&
MOQ'DOX],U][3^SUC9S-/+@B3=C&W/3;S7Y[C<94Q-65>M*\I:L_4,NRZCA*$
M,-AXVC%62_K\3]"]3U*QT?3[C5-2F6WM;5#)([=%5>O_ -8=3T%?$[G6OVA_
MB#L0R6OAW33D9'^JA)&?4>;+CWP/4+SRIN/%WBYK3X0Z%?C5(()Y'FN4=S',
M=V2[.W/E1]N.3R,_+7W%X(\&Z5X%\/P:#I8W!/FEE(PTLI^\[?7H!V&!7+L=
MIN:/H^FZ!IEOH^D0+;6EJNR.->@'\R2>23R3R:TJ**@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#_];]_**** "BBB@ HHHH **** "BBB@
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M8S:Q+':6-_?1I]LM[JY;;:[KB$^7<VTSY02?,58@^9L5@/U:_9A^(/@[Q/\
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M<R/G]X4.,=LU]D44 ?@3_P ,]?\ !8S_ **>G_@WC_\ C%'_  SU_P %C/\
MHIZ?^#>/_P",5^^U% '\MO\ P1L#C]KC5A(<L/"^HY^OVJTS7]25?RX_\$<?
M^3O=9_[%C4O_ $JM*_J.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBO!OCQ\:;'X2>'E%H$N=?U$
M,MI 2,(.AFD'78IZ#^)N.F2 #D/VCOCU#\.=,;PMX8G5_$U\G+##"SB8?ZQO
M^FA_@4_[QXP&\Z_9K_9\01V_Q.^(,+37T[+<:?;2DY3G<+B4'J['E >@^8Y)
M&WF?V<?@C=^-M3D^*WQ*A>[MYI#/:1W')NYF;<T\@/5 ?N@\.>?NCG]$Z "B
MBB@ HHHH ***^"_VM?VEE\'VUQ\,_ MUG79UVW]RG(M(G7_5J?\ GJP/./NC
MW/'KY'DM;'XB.'H+5[OHEW?]>1XO$&?X?+<++%8EZ+9=6^B7G_PYYW^UQ^TP
M+UKCX7?#R^S;#='JEW">)#T,$;?W1_&P//W>F<^G_LC_ +. \#Z?#\2_&UJI
M\0ZA$KV,#@[K&"1>68'I-(IP1C*+\N06<#SS]D;]F>1I+?XL_$>Q!4A9=)LY
MQDDGD74J'\X@>OW\?<)_2ROM^*,[H8+#_P!CY:_=7QRZR?57_/\ \!V/SWA'
M(<3F&*_MW-5[S_APZ171V_+_ ,"WM8HHHK\Q/UP**** "BBB@ HHHH ****
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MXU"(K+!'#&#U?;SEPH_I8H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#_]?]_**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVQOAC\9/V)_VQG_:_P#A7I+W_A;6;Z35'F6-I+:*XO%*ZA9WNP?NUG+2.CG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNLHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_EO\
M^"J__)]>F?\ 8-T3_P!&O7]2%?RW_P#!5?\ Y/KTS_L&Z)_Z->@#^I"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _(O]OG_
M )+#H_\ V ;?_P!*KJOA^ON#]OG_ )+#H_\ V ;?_P!*KJOA^OZMX+_Y%6'_
M ,)_%GB!_P CK%?X@HHHKZ<^."OTJ_X)X_\ ,_\ _<*_]NZ_-6OTJ_X)X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPC:RB:VT_P#MF[BM8WC#*C_9+F-84<!F *EL D;N36A9?\$]O^"F?B'P_:>
MM:\?MI_AJW@2TCL;OQ/>/8Q6\:A$C%O )5V*H "A, # KGM!U[_@L'^T-:1>
M-/"T_B*'3+X&2W>&2R\/VSQ]5,2RM:[TQ]U_FW?WC2ZK\;O^"L?[*$:>*_B;
M'JM[H%O(HN/[7@MM7L#Z++=6Q=XE;H"LR9/0YH _3[]A_P#X)O>%?V4M9D^(
M_BK6E\6>.I8'MX9HXC#9Z?'*,2B!6)=Y''RF5MIV$J$7+%OTVKXH_8H_;1\(
M?M@>![K4+6T&A^+=!\M-6THOO">8#LN(&."\$A# 9&Y&!5L_*S?:] !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
MT/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZD*_EO\ ^"J__)]>F?\ 8-T3_P!&O0!_4A1110 4444 %%%% !1110 4444
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M!_674-Q;V]W;RVEW$L\$RLDD;J&1T88964\$$<$'K7\\W_#\7Q7_ -$DLO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH __]']_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /QY_X*>_MP^+_@A_9GP(^"MRUKXU\16XN+V_A&^>RM)F:.
M**W !Q<3L&PWWD4 J-SJR_%GPT_X) _M"?%JT/CGXY>-HO"6J:LPGDBNDDUG
M4VWC):Y;SHT#GT\UV_O8/%>O>'M L/B?_P %I?$,WB:(7MOX57[7;PR@,BR6
M&EP10$*?^><KB5<=' ;K7[]T ?S@>./^"+GQB\'6,GB#X2?$:R\1ZO88EMX)
M;:31[AW7G]U,)IT63^[N=!GJPKW?_@G1^VE\6O\ A:=Y^R#^T[-<S^)+-KB#
M3+S43F^2ZLPS365U(23-E%9XI22QVE=SADV_N17X$?M_:-8_#_\ X*-_ 'XD
M:!$MG>Z[=Z+]N:(!3.]MJ0@9WQR6:W=8B3_"H':@#]]Z*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _EQ_X(X_\G>ZS_P!BQJ7_ *56E?U'5_+C_P $<?\
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M$_BSQ _Y'6*_Q!1117TY\<%?I5_P3Q_YG_\ [A7_ +=U^:M?I5_P3Q_YG_\
M[A7_ +=U\5XB?\B>O_V[_P"EQ/T'PL_Y'V'_ .WO_2)'Z55P/Q6_Y)=XQ_[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\3O^PO8_^D[5^XE?AW_P1!_Y)I\3O^PO8_\ I.U?N)0 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _]+]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4,X],B@#[*HHHH **** "BBODG]JSXWVWPW\(S^&M'N4&OZM%L"Y8/%"^5+
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MN7\$?\B7H'_8/M?_ $4M=117^.7J%+X4%%%%9%A1110 4444 %%%% !1110
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MM_\ P57_ .3Z],_[!NB?^C7H _J0HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "O+_CA_R1;Q__ -B_JO\ Z225ZA7E_P </^2+>/\
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M<1B<37GBJ\6G)W>CLNR^6Q_8.18;"8/#4\%AIIJ*LM5=]6_F]3> "@*HP!P
M*6BBO%/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#__T_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU_PK2+X;^(=1^,-G9WW@W3;.:\U-+^U^V6XMK=#)([0[)"^U02 JEL_=&<4
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M9_[M5_PO\C^U\D_WVA_BC^:/Q-HHHK^-#_20**** "OW@TC_ )!-E_UPC_\
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M***Y3<**** "BBB@ HHHH **** "BBB@ HHHH **@NOM/V6;['M^T;&\O?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>J_M@?%KQ/9-OL_[(U!48="+K5()$/''(C- ']&]%%% !1110 4444 %%%%
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MSQ_:_P#CXNGVTGP[\+W +L=MY(A^\Z\^7GIM3@MZMA>S"O?_ -HOXT6?PO\
M#$MC97&S6KZ(^65P6@B)VF3&00QY$?\ M<]%Y_,?X+_"_6OVAOB68KYI(]'M
M"L^I3J>8X"QVQHQ!_>2D$ G_ &GP<$5^M<!\/4Z-)YSC](0UC?R^U^D>[]%?
M\B\1.)ZLIQR;+M:M31VZ)]/\^R^9]%?L6_ E]4OE^,WB^ M;V[L-)CE!/FS@
MX>Z.3R$.53(.6RW!52?T]JEING6&CZ?;:5I=NEI9V<:0PPQJ%2.-!M55 X
M& *NU\'Q'GU7,<5+$5-MDNRZ+_/S/N>%.&Z658..%IZO>3[RZO\ 1>04445X
M)](%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7+^-_\ D2]?_P"P?=?^BFKJ*Y?QO_R)>O\ _8/NO_13
M5K0^./J15^%AX(_Y$O0/^P?:_P#HI:ZBN7\$?\B7H'_8/M?_ $4M=117^.7J
M%+X4%%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!^#/P:_Y3.?$7_KUO?_2&VK]4?VRO^33?C!_V*NK_
M /I+)7Y:_M,?\$WOVJ/'G[3GC#XX?!?QCI6A6WB*6.6"7^T;W3[Z)3;QQ21N
M;>W?@LAZ2$,,9 / \@U/_@FE_P %&=:T^YTC6?BQ9W]C>1M%/;S^)=6EBEC<
M89'1[8JRL.""""* /O;_ ((__P#)G=M_V'=3_P#:=?J17\V'AO\ X)=_\%!/
M!VFC1O"'Q+TW0]/#M(+:Q\0:I;0[V^\WEQ6JKDXY.,FO4/AU_P $_O\ @HIX
M=^(/ACQ!XA^+\4VE:9J=E=7<8\2:M,7MX9D>51&\ 5R4!&UB W0G% '[_P!%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\M__!5?
M_D^O3/\ L&Z)_P"C7K^I"OY;_P#@JO\ \GUZ9_V#=$_]&O0!_4A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?D7^WS_ ,EA
MT?\ [ -O_P"E5U7P_7W!^WS_ ,EAT?\ [ -O_P"E5U7P_7]6\%_\BK#_ .$_
MBSQ _P"1UBO\04445].?'!7Z5?\ !/'_ )G_ /[A7_MW7YJU^E7_  3Q_P"9
M_P#^X5_[=U\5XB?\B>O_ -N_^EQ/T'PL_P"1]A_^WO\ TB1^E5<#\5O^27>,
M?^P-J'_I.]=]7 _%;_DEWC'_ + VH?\ I.]?RGF?^[5?\+_(_M?)/]]H?XH_
MFC\3:***_C0_TD"BBB@ K]X-(_Y!-E_UPC_]!%?@_7[P:1_R";+_ *X1_P#H
M(K]G\'_CQ/I'_P!N/YI^D9_#P7K/_P!M-"BBBOW$_ET**** "BBB@ HKQ+XK
M?%V+P!,NB6EF]QJ-W;-*DFY52+>61&P0VXAE)*\<#KS7QKJ/CWQGJ]I/8:GK
M5U<VUR"LD3RL493U!7ICVK14[6<GH_1O[K_G8CGW2W7];GZ;T5^2'V"R_P">
M"?E1]@LO^>"?E7=[+!_\_)?^ +_Y,Y/:8G^2/_@3_P#D3];Z*_+_ $?QCXI\
M/V*Z9HFJW-C:(2RQ0R,B L<D@#U-?3_P&^)FM^(=1N/"6O227TR0R7<=S(P+
M!$:-"AXR>7R"3QTKD5'GDU3U2N^VBU[]O-G2ZO+%.>FWGJSZAHHHK U"BBB@
M HHHH **** "BBB@ HHHH **** /B#]OG_DCVC_]AZW_ /26ZK\BJ_77]OG_
M )(]H_\ V'K?_P!);JOR*K^DO#'_ )%4?\4C^3?&#_D=2_PQ"BBBOT(_+0KV
MS]G'_DN?@O\ [",?\C7B=>V?LX_\ES\%_P#81C_D:X,U_P!UJ_X7^3/8X>_Y
M&&'_ ,<?_2D?O11117\=']V!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Y?\,?^9L_[&"__ /9*]0KR_P"&/_,V?]C!?_\
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MR^$/%5B6G?0HIO*AFSRZV;O\BJ_\5M-F%AP"B@(0#W/]DK_@F=X%_9K\?_\
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M-=#112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#__U?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK^O?"KPY=:A,YDDE_LZ%#(YZM($50Y/<L#F@#\./@TOB[_@H[^W_ &GQRO\
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MRX_\$<?^3O=9_P"Q8U+_ -*K2OZCJ_EQ_P""./\ R=[K/_8L:E_Z56E?U'4
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MJ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/=+BW<J8]-L+A.5>"$_-+(A^[+*>" RQHP! !^J-%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** /B#]OG_DCVC_]AZW_ /26ZK\BJ_77]OG_ )(]H_\
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MY/L,X4 <5]U#,LMR&+6'M6Q'?[,?+_AM7U:V/SFI@<WXDDGB$\/A>WVI>O\
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M **** "BBB@ HHHH **** /_UOW\HHHH **** "BBB@ HHHH **** "BBB@
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M0C% 'WQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_Z*6NHKE_!'_(EZ!_V#[7_T4M=117^.7J%+X4%%%%9%A1110 4444 %%%%
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M-<%6 902""#T(Q0!]\4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\@FR_ZX1_\ H(K]G\'_ (\3Z1_]N/YI^D9_#P7K/_VTT****_<3^70HHHH
M**** /B']I7_ )'JQ_[!L7_HZ:OGFOH;]I7_ )'JQ_[!L7_HZ:OGF@ HHHH
M*]Y_9O\ ^2D3?]@NY_\ 1UO7@U>\_LW_ /)2)O\ L%W/_HZWKT,M_B/_  S_
M /2)''CO@7^*/_I2/NNBBBO/.P**** "BBB@ HHHH **** "BBB@ HHHH ^(
M/V^?^2/:/_V'K?\ ]);JOR*K]=?V^?\ DCVC_P#8>M__ $ENJ_(JOZ2\,?\
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MT28_&OUAK^9^-<II8+,:E&A\.C2[76W]=#^NO#[.ZV8953Q&(^/5-][.U_\
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MZ/7[#@,=2Q-"&(HN\9)-/R>I^'9CE]7"8BIA:ZM.#::\T[,****ZSB"BBB@
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M]&Z***_J _D4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#_U_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/R+_ &^?^2PZ/_V ;?\ ]*KJOA^ON#]OG_DL.C_]@&W_ /2JZKX?K^K>"_\
MD58?_"?Q9X@?\CK%?X@HHHKZ<^."OTJ_X)X_\S__ -PK_P!NZ_-6OTJ_X)X_
M\S__ -PK_P!NZ^*\1/\ D3U_^W?_ $N)^@^%G_(^P_\ V]_Z1(_2JN!^*W_)
M+O&/_8&U#_TG>N^K@?BM_P DN\8_]@;4/_2=Z_E/,_\ =JO^%_D?VODG^^T/
M\4?S1^)M%%%?QH?Z2!1110 5^\&D?\@FR_ZX1_\ H(K\'Z_>#2/^039?]<(_
M_017[/X/_'B?2/\ [<?S3](S^'@O6?\ [::%%%%?N)_+H4444 %%%% 'Q#^T
MK_R/5C_V#8O_ $=-7SS7T-^TK_R/5C_V#8O_ $=-7SS0 4444 %>\_LW_P#)
M2)O^P7<_^CK>O!J]Y_9O_P"2D3?]@NY_]'6]>AEO\1_X9_\ I$CCQWP+_%'_
M -*1]UT445YYV!1110 4444 %%%% !1110 4444 %%%% 'Q!^WS_ ,D>T?\
M[#UO_P"DMU7Y%5^NO[?/_)'M'_[#UO\ ^DMU7Y%5_27AC_R*H_XI'\F^,'_(
MZE_AB%%%%?H1^6A7MG[./_)<_!?_ &$8_P"1KQ.O;/V<?^2Y^"_^PC'_ "-<
M&:_[K5_PO\F>QP]_R,,/_CC_ .E(_>BBBBOXZ/[L"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/GQ_M(S+=?$""%!_$^IWJC\S'7S-=7O[:&L'%S#XK(?G;]GN(E_((H%8_\
MPI7]J7Q)-NGT/59)&XWW$R0GDXY:5U_G[UVTOHP9''7$9@X^E1_K)'+4^EWG
MLM,/EO,_^O2_1,X#XV?\))8>-[CPQXCU\>(9-(6-%GCNI+J#,R+*1&\F#QN
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MM3:5^MET78_$<T\<,SJXFI4H4Z:@VVDX1;M?2[ZONSX _P"&<OVB/^AZC_\
M!C??_&J/^&<OVB/^AZC_ /!C??\ QJOO^BNS_B$N5_S5/_!DC@_XC3G'\E+_
M ,%Q/@#_ (9R_:(_Z'J/_P &-]_\:H_X9R_:(_Z'J/\ \&-]_P#&J^_Z*/\
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M?YZGP!_PSE^T1_T/4?\ X,;[_P"-4?\ #.7[1'_0]1_^#&^_^-5]_P!%:?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]#]_**** "BBB@
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MAOP;+\(XK9->U*SL#+'K32/&+J98BZI]C7<5W9"Y&>F1UH _>.BBB@ HHHH
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M?VYJ1N9)1<&>6XQ$RJ%7?, W!!XZ<UXK^Q5_R2_5O^PS-_Z3V]?8% !1110
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M--_M+29/*L%,+7,/F0-L=I5RN\<$@<<U^4O_  3*_;"^$'[)[_$<_%<Z@/\
MA*1I'V/[!;"X_P"/+[9YN_+IM_UZ8ZYY]* /UD_X*^V]Q-^QS>R0YV6^MZ8\
MN.FPLZ#/MN9?QQ7I'_!+Z\M[S]AOX;"W(S -5B<#LZZI=9S]00?QK9^*4'A;
M]OS]B?7V^%[2O:^,K*:72#>1_9Y/MVEW9,2."2$#7%OL+9(VDGD5^0G[ G[>
MNC_LA:/XA_9__:&T;4K"QL-0FN+:2&WWW-C=-M2XM;B!V1@A9-ZE<D,6!!#
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M+72>3-+\@\Q@#GY3QVH _MFHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /R+_;Y_Y+#H_P#V ;?_ -*KJOA^ON#]OG_DL.C_
M /8!M_\ TJNJ^'Z_JW@O_D58?_"?Q9X@?\CK%?X@HHHKZ<^."OTJ_P"">/\
MS/\ _P!PK_V[K\U:_2K_ ()X_P#,_P#_ '"O_;NOBO$3_D3U_P#MW_TN)^@^
M%G_(^P__ &]_Z1(_2JN!^*W_ "2[QC_V!M0_])WKOJX'XK?\DN\8_P#8&U#_
M -)WK^4\S_W:K_A?Y']KY)_OM#_%'\T?B;1117\:'^D@4444 %?O!I'_ "";
M+_KA'_Z"*_!^OW@TC_D$V7_7"/\ ]!%?L_@_\>)](_\ MQ_-/TC/X>"]9_\
MMIH4445^XG\NA1110 4444 ?$/[2O_(]6/\ V#8O_1TU?/-?0W[2O_(]6/\
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M<?F>H4445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@#^7'_@CC_P G>ZS_ -BQJ7_I5:5_4=7\N/\
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M_8EOKA@-2\;M)&O( LBQS_P*?B@#[JN=6TJS4->7L, ;@&215!_,US]W\0O
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M1110 4444 %%%% !1110 5R_C?\ Y$O7_P#L'W7_ **:NHKE_&__ ")>O_\
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MKU_4A7\M_P#P57_Y/KTS_L&Z)_Z->@#^I"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _(O]OG_DL.C_ /8!M_\ TJNJ^'Z^
MX/V^?^2PZ/\ ]@&W_P#2JZKX?K^K>"_^15A_\)_%GB!_R.L5_B"BBBOISXX*
M_2K_ ()X_P#,_P#_ '"O_;NOS5K]*O\ @GC_ ,S_ /\ <*_]NZ^*\1/^1/7_
M .W?_2XGZ#X6?\C[#_\ ;W_I$C]*JX'XK?\ )+O&/_8&U#_TG>N^K@?BM_R2
M[QC_ -@;4/\ TG>OY3S/_=JO^%_D?VODG^^T/\4?S1^)M%%%?QH?Z2!1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_TOW\HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD(_[Y1C^%>U_\$UM-ETK]B'X76LW#/:WTX_W;C4+F9?T<4 ?<U%%% !1110
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M7B;2;NQTZT ,LS7$3!03@<+(3U]J_;_Q#KVG>&-$O?$&K.8[2QC,DA')('0
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MGZ$_\+;^%/\ T.>B_P#@QMO_ (Y44GQC^$41VR^.-#0]<'4[4?\ M2O@N/\
MX)[:L6Q+XW@5?5;!B?R,PJ^G_!/)RH,GCX*W<#2\C\_M0K-Y)P^M\<__  !_
MY%KB'B=[9='_ ,#C_F?;LGQM^#<6-WCG0SG^[J-LW\G-5I?CO\%H4,C^.-'(
M7^[>PL?P"L2?RKXP3_@GE&,^9X]+?32\?^W1JQ'_ ,$]+$,#+XZD9>X&G '\
MS.:7]D<._P#0;+_P!_\ R(_[<XI>V C_ .!Q_P#DCZOF_:4^!,"AG\9V!!_N
MLSG\E4U@W7[6GP M0=OBE)V!QB.WN#^.3&!C\:^=O^'>VC_]#M/_ . *?_':
MMP_\$^?# _U_C"\?C^&VC7G\6:MX9=PNOBQ,W\K?^V&,LVXN?PX.FO\ MY?_
M "9ZGJ'[:_P1LR5MKB]O3S@QP *2.F2[*<?A7%ZE^WG\/H%_XEFCW5T_I(_E
M#\PCU4A_X)__  ^4?Z1XEU1SQ]U8%^O5&KH+']@WX-VQW76H:S>'T>XA5?PV
M0*?UKKA+A2GNIS_\"_3E.:=3C*IM&G#[O^">4ZI^W[<'/]C^'8HO3S6:8?HT
M5>6:[^V[\3]2/_$O9+!.ZPQQK^KK*WY-7V]I_P"QM^S]9 "?0)KUAWFO;D=\
M](Y$'MTKT#2/V>_@CH9+6/@K3')QS<0+=8QTQY^_!]QS73#BGARA_ P;;\TG
M_P"E2E^1A/AGBNO_ !L;&*_NW_2*_,_(36/CM\7/&UQ]C;4;J\>0$"%&DD)'
M?$:G:?\ OFN:\4^%OBWIF@KK_B_2-2TW2IY5A$EU UM&[NI91M95SD*2#C'%
M?OCINCZ1HT30Z18P6,;8)6")8E)' R% %<K\3/A_H_Q0\$ZGX)ULE(-00;)5
M&6AE0[HY%]U8 X[C(Z&NK#^*T(U(4Z>'4*=U>SZ>222.+&^$>)JT9SK8R4ZE
MG96LF^B=V]&?SST5[WX]_9I^,/@+4Y;.X\/7.K6BL1'=Z=$]U#(O9CY8+)GT
M<*?KP:Z'X6?LI?%3XA:M;KJVE7'AS1@P,]W?1&%PF>1%$^'=B.G&WU85^ISX
MAP,:/UAUH\O>Z_J_EN?AM/A;,9XCZJJ$N>]K6?Y[6\]C]-OV5[NZOO@#X0N+
MR-8Y1!-'A5"Y2&>2*,D#&24523U/4U]!5B^'/#^E^%-!T_PUHL7DV&F01V\*
M=2$C4*,GN3C)/<\UM5_*69XJ-?$U:T%92DVEZNY_:N4826'PE&A-W<8Q3?=I
M)!1117">B%%%% !1UX-%% 'G%S\'OA/=ZC_:UUX.TB6\+;C(UC 6+?WC\G)]
MSS7H<,,-O$EO;HL448"JB@*JJ.  !P *DHK>KB:E1)5)-V[NYST,)2I-NG!*
M^]DE<****P.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGUZ9_P!@W1/_ $:]?U(5_+?_ ,%5_P#D^O3/^P;HG_HUZ /ZD**** "BBB@
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M17[/X/\ QXGTC_[<?S3](S^'@O6?_MIH4445^XG\NA1110 4444 ?$/[2O\
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M0?\ DFGQ._["]C_Z3M7[B4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"=4G[*ULD2^)I='%T[;EV-KPF%^5\W.-GVA?)#_ ///';BOS#_8$_;UT?\
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MS\QMV$VT8_B8(0/<C/'-?@17](^HZCIVDV4NH:M<Q6EI" 9)9G"1J"<#<S8
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QO\ \B7K_P#V
M#[K_ -%-745R_C?_ )$O7_\ L'W7_HIJUH?''U(J_"P\$?\ (EZ!_P!@^U_]
M%+745R_@C_D2] _[!]K_ .BEKJ**_P <O4*7PH****R+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^
M6_\ X*K_ /)]>F?]@W1/_1KU_4A7\M__  57_P"3Z],_[!NB?^C7H _J0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R+_;
MY_Y+#H__ & ;?_TJNJ^'Z^X/V^?^2PZ/_P!@&W_]*KJOA^OZMX+_ .15A_\
M"?Q9X@?\CK%?X@HHHKZ<^."OTJ_X)X_\S_\ ]PK_ -NZ_-6OTJ_X)X_\S_\
M]PK_ -NZ^*\1/^1/7_[=_P#2XGZ#X6?\C[#_ /;W_I$C]*JX'XK?\DN\8_\
M8&U#_P!)WKOJX'XK?\DN\8_]@;4/_2=Z_E/,_P#=JO\ A?Y']KY)_OM#_%'\
MT?B;1117\:'^D@4444 %?O!I'_()LO\ KA'_ .@BOP?K]X-(_P"039?]<(__
M $$5^S^#_P >)](_^W'\T_2,_AX+UG_[::%%%%?N)_+H4444 %%%% 'Q#^TK
M_P CU8_]@V+_ -'35\\U]#?M*_\ (]6/_8-B_P#1TU?/- !1110 5[S^S?\
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M_>BBBBOXZ/[L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KR_P"&/_,V?]C!?_\ LE>H5Y?\,?\ F;/^Q@O_ /V2NJE_"G\C
M"I\<?F>H4445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_ !P_Y(MX_P#^Q?U7
M_P!))*]0KR_XX?\ )%O'_P#V+^J_^DDE 'Y%_P#!$'_DFGQ._P"PO8_^D[5^
MXE?AW_P1!_Y)I\3O^PO8_P#I.U?N)0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!__]3]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP7<_^CK>O0RW^(_\,_\ TB1QX[X%_BC_ .E(^ZZ***\\[#\R/'W_ "/7B/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_CA_R1;Q__ -B_JO\
MZ225ZA7E_P </^2+>/\ _L7]5_\ 222@#\B_^"(/_)-/B=_V%['_ -)VK]Q*
M_#O_ ((@_P#)-/B=_P!A>Q_])VK]Q* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /_]7]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH _EQ_P""./\ R=[K/_8L:E_Z56E?
MU'5_+C_P1Q_Y.]UG_L6-2_\ 2JTK^HZ@ HHHH **** "BBB@ HHH)QR: "BD
M5@P#*<@]Q2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<OXW_Y$O7_^P?=?^BFKJ*Y?QO\ \B7K
M_P#V#[K_ -%-6M#XX^I%7X6'@C_D2] _[!]K_P"BEKJ*Y?P1_P B7H'_ &#[
M7_T4M=117^.7J%+X4%%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5_+?_P57_Y/KTS_ +!NB?\
MHUZ_J0K^6_\ X*K_ /)]>F?]@W1/_1KT ?U(4444 %-9T7[S ?4U^)/Q7^-O
MQ>TGXI>,=+TSQAJEK9V>LZA##%'=.J1QQW+JB* < *  !Z5XWKWQ,^(/BB2*
M7Q%XAOM1> %8S/.SE0W) R>,U^LX'PHKU5&<ZZ46KZ)MZKMI^9^*X_QJPM&<
MZ<</)N+:W26CMY_D?T,>;%_?7\Z/-B/ <?G7\Y/_  D>O?\ 00F_[[-2P>*O
M$EK/'<V^IW$<L+!T99""K*<@@^H->F_!]6TQ7_DG_P!L><O'2GUPK_\  O\
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M$_BSQ _Y'6*_Q!1117TY\<%?I5_P3Q_YG_\ [A7_ +=U^:M?I5_P3Q_YG_\
M[A7_ +=U\5XB?\B>O_V[_P"EQ/T'PL_Y'V'_ .WO_2)'Z55P/Q6_Y)=XQ_[
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MK^Q#^&PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_X8_P#,V?\ 8P7_
M /[)7J%>7_#'_F;/^Q@O_P#V2NJE_"G\C"I\<?F>H4445RFX4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>7_'#_ )(MX_\ ^Q?U7_TDDKU"O+_CA_R1;Q__ -B_JO\
MZ224 ?D7_P $0?\ DFGQ._["]C_Z3M7[B5^'?_!$'_DFGQ._["]C_P"D[5^X
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '_UOW\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (Q1_P -F:Q_T(Q_\"W_ /C%/_B+O#__ $$/_P  G_\ (B_X@GQ+_P! R_\
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M_+OX/_M,ZI\-M!F\.:U82:[:(X:US/Y;0*<[DR4?*DX('&#GUKUW_AMK3_\
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M]%?#'_#;6G_]"E+_ .!B_P#QJC_AMK3_ /H4I?\ P,7_ .-4?\1<X>_Z"O\
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M /&J/^&VM/\ ^A2E_P# Q?\ XU1_Q%SA[_H*_P#)9_\ R(?\05XG_P"@-_\
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M>\;2=GZJ+375'Y-GG@1GV'Q4Z6$I>UIK:2<5=>CDFFMG^!]ST5\,?\-M:?\
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M **** "BBB@ HHHH **** "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=17+^-_\
MD2]?_P"P?=?^BFK6A\<?4BK\+#P1_P B7H'_ &#[7_T4M=17+^"/^1+T#_L'
MVO\ Z*6NHHK_ !R]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***\^^)_Q4\ ?!GP==>/_ (FZ
MNFAZ!9/%'-=21RRJC3N(XQMA5W.YF X7ZT >@U_+?_P57_Y/KTS_ +!NB?\
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MC7[?Q%X$\>Z9>V%O;):N\TILV$R.\A CNA$Y&UU.X*5.< Y! \X_X6M\+O\
MH<=&_P#!A;?_ !R@#OJ*X'_A:WPN_P"AQT;_ ,&%M_\ '*/^%K?"[_H<=&_\
M&%M_\<H [ZO>?V;_ /DI$W_8+N?_ $=;U\D?\+6^%W_0XZ-_X,+;_P".5V7P
MW_:O_9T^$OCB/5?'GCW3K*UO;"ZAB>!GO09!+ V&%HLI7CINQG!QG!KNR^25
M1MO[,O\ TEG)C(MP27>/_I2/UPHKX:_X>4?L1?\ 14;7_P  =0_^1J/^'E'[
M$7_14;7_ , =0_\ D:N$ZSRWQ]_R/7B/_L)7G_HYJY*N8\0_''X.>)-?U/Q%
MH_C72)K#5;F:ZMW>]BB9H9W,B$QR,KH2I!*LH8=" <BLC_A:WPN_Z''1O_!A
M;?\ QR@#OJ*X'_A:WPN_Z''1O_!A;?\ QRC_ (6M\+O^AQT;_P &%M_\<H [
MZOT+^!O_ "2W1/\ MY_]*9:_+;_A:WPN_P"AQT;_ ,&%M_\ '*^CO 7[>G[(
MOP\\)V/@_P 6_$FQM=6T_P WSHXH;JZ1?-E:5,2V\,D391P?E8XZ'!!  /T4
MHKX:_P"'E'[$7_14;7_P!U#_ .1J/^'E'[$7_14;7_P!U#_Y&H ^Y:*^&O\
MAY1^Q%_T5&U_\ =0_P#D:C_AY1^Q%_T5&U_\ =0_^1J /N6BOAK_ (>4?L1?
M]%1M?_ '4/\ Y&H_X>4?L1?]%1M?_ '4/_D:@";]OG_DCVC_ /8>M_\ TENJ
M_(JOM;]JK]L[]F'XR_#W3_#'PX\?6>JZE:ZI#>21-%<6H6!()XV;?<Q1(<-(
MHP#NYSC )'P#_P )OX+_ .@_I_\ X%1?_%5_1?AKB:<,KBI22?,^I_*OBY@Z
MT\XE*$&URQV3.HHKE_\ A-_!?_0?T_\ \"HO_BJ/^$W\%_\ 0?T__P "HO\
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M5P_4HX;$PG+FCI&<6]^R;9^O]%?#7_#RC]B+_HJ-K_X ZA_\C4?\/*/V(O\
MHJ-K_P" .H?_ "-7]=G\3'W+17BOP:_:)^#/[0=GJE_\'?$L7B2#1I(HKMHH
M9X?*>8,R B>.,G(4],].:]JH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_X
M8_\ ,V?]C!?_ /LE>H5Y?\,?^9L_[&"__P#9*ZJ7\*?R,*GQQ^9ZA1117*;A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!FZIK.CZ) MUK5]!I\+ML5[B58E+$$[07(!.
M 3CVKQ3XV>/? LOP:\>Q1>(]-=WT#5%55O(223:2   -R37 _MF?LGV7[8'P
MWTGX=WWB63PNFE:M%JHN8[479<QV\\'E[#)%@'SLYR>F,<\?E7X[_P""+F@^
M#?!'B'Q?'\6+FZ;0].N[X0G1T02&VA:4(6^U'&[;C.#CTH [#_@BKXD\.Z%\
M-_B5%K>J6NGO+JUD46XGCB+ 0-D@.1D5^V'_  L'P%_T,NF?^!D/_P 77\K?
M["O[ 6G?MC^&/%/B*^\:R^%3X<O(+58X[!;OS?.C+EBS31;<8QC!^M?=W_#C
MCP__ -%?NO\ P2I_\ET ?MM_PL'P%_T,NF?^!D/_ ,71_P +!\!?]#+IG_@9
M#_\ %U^)/_#CCP__ -%?NO\ P2I_\EUY7\<?^"0&B?![X/>,?BE!\4+C5)/"
MNEW.HK:MI*0K.;="^PR"Y;;G&,[3CTH _H*_X6#X"_Z&73/_  ,A_P#BZ/\
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M@8_*\O<,*V[...M ']K'_"P? 7_0RZ9_X&0__%T?\+!\!?\ 0RZ9_P"!D/\
M\77\4]I\'(+K5?@WIIU5E'Q5@BFD;R0?L7F:Y>:/A1N_>8%J)>=O+;>VX_1_
M[!_[$6G_ +9EUXUM[_Q=+X4_X1)-/=3%9+>>?]N-P"#NEBV[/)]\Y[8Y /ZR
M?^%@^ O^AETS_P #(?\ XNC_ (6#X"_Z&73/_ R'_P"+K\2?^'''A_\ Z*_=
M?^"5/_DNC_AQQX?_ .BOW7_@E3_Y+H _;;_A8/@+_H9=,_\  R'_ .+H_P"%
M@^ O^AETS_P,A_\ BZ_!KX@_\$8-!\#^ ?$OC6/XKW-XV@:9>:@(#HZ()3:0
MO*$+?:CMW;<9P<=<&OD7]A;_ ()_:;^V-X1\3>)[[QM-X6;P]?168BCL%NQ*
M)(O,W%C-%MQTQ@_6@#^I_P#X6#X"_P"AETS_ ,#(?_BZ/^%@^ O^AETS_P #
M(?\ XNOQ)_X<<>'_ /HK]U_X)4_^2Z_.?2OV)M/U+]NV;]C4^+98[6*6>/\
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M\OA3_A$!II7RK);SS_M_VG.=TT6W9]G]\[NV.?T._P"'''A__HK]U_X)4_\
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ML'BV75H/&TNBQMJ;62PO;_VM?-9DB 2N'\L+O'SC=TXZT>(/V)K#0_VYK/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX1_]\BC[%9_\\(_^^15FBN_V<>QY_M9=RM]BL_\ GA'_ -\BC[%9_P#/"/\
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M^SCV/B/:R[E;[%9_\\(_^^11]BL_^>$?_?(JS11[./8/:R[E;[%9_P#/"/\
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M]%+745R_@C_D2] _[!]K_P"BEKJ**_QR]0I?"@HHHK(L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\&_:4^
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M_HH/B'_OBT_^-4?\.2/@E_T4'Q#_ -\6G_QJOVJHH _%7_AR1\$O^B@^(?\
MOBT_^-4?\.2/@E_T4'Q#_P!\6G_QJOVJHH _%7_AR1\$O^B@^(?^^+3_ .-4
M?\.2/@E_T4'Q#_WQ:?\ QJOVJHH _%7_ (<D?!+_ **#XA_[XM/_ (U1_P .
M2/@E_P!%!\0_]\6G_P :K]JJ* /Q5_X<D?!+_HH/B'_OBT_^-4?\.2/@E_T4
M'Q#_ -\6G_QJOVJHH _C6_;/_9C\,?LR_M!6?P?\,ZO>:OI]S96-T;B\$8F#
M7<CHP C55P-O'%?K_P#\.2/@E_T4'Q#_ -\6G_QJOAG_ (*R?\GP:7_V"-&_
M]'2U_4A0!^*O_#DCX)?]%!\0_P#?%I_\:H_X<D?!+_HH/B'_ +XM/_C5?M51
M0!^*O_#DCX)?]%!\0_\ ?%I_\:H_X<D?!+_HH/B'_OBT_P#C5?M510!^*O\
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MQ:?_ !JC_AR1\$O^B@^(?^^+3_XU7[544 ?'7[(7[&G@W]CW2O$ND^#]>O\
M78_$T]M/,U^L2F,VRNJA/*5>#O.<^E?8M%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>7_#'_F;/^Q@O_\ V2O4*\O^&/\ S-G_ &,%_P#^R5U4OX4_D85/
MCC\SU"BBBN4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ/Q]\(/C=X:LO!L.@:+%J<&CQ(6NK,SO:M"D\^]M[&"X#.-JD,<;4(*C]3:
M"O//!/PB^%'PTN;V]^'/@O1?"MQJ(5;J32M.MK%YPA)42M!&A< DD;LX)->A
MT4 >>7?PB^%%_P"-HOB5?>"]%N?%\!1H]9DTZV?4D,:>6A6Z,9F!5/E&&X'
MXHO/A%\*-0\:Q?$J_P#!>BW/BZ HT>LRZ=;/J*&-=B%;IHS,"J?*,-P.!Q7H
M=% 'FG_"E_@[_P )7=^//^$%T+_A);]94N=4_LRU^W3+/&8I1)<>7YK!XR48
M%CN7Y3D<5S2_LR?LW)I,F@K\*/"8TR6=+E[4:'8>0T\:LB2F/R=I=5=E#8R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!__T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"?\ AV;^W?\ ]'$O_P"#?6?\*/\ AV;^W?\ ]'$O_P"#?6?\* /WVHK\"?\
MAV;^W?\ ]'$O_P"#?6?\*/\ AV;^W?\ ]'$O_P"#?6?\* /WVHK\"?\ AV;^
MW?\ ]'$O_P"#?6?\*/\ AV;^W?\ ]'$O_P"#?6?\* /WVHK\"?\ AV;^W?\
M]'$O_P"#?6?\*/\ AV;^W?\ ]'$O_P"#?6?\* /WVHK\"?\ AV;^W?\ ]'$O
M_P"#?6?\*/\ AV;^W?\ ]'$O_P"#?6?\* /WVHK\"?\ AV;^W?\ ]'$O_P"#
M?6?\*_/#QCH_[4W@S]J.W_96O?C#K4^NW&L:9HPOH]8U'[()=4$!C<Y<2;4\
M]=WRYX. >* /[!:*_ G_ (=F_MW_ /1Q+_\ @WUG_"C_ (=F_MW_ /1Q+_\
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M_AV;^W?_ -'$O_X-]9_PH _?:BOP)_X=F_MW_P#1Q+_^#?6?\*/^'9O[=_\
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M1_R)>@?]@^U_]%+7445_CEZA2^%!1116184444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!G_ -DZ4+K[:+*'[1G=YGEKOW>N[&<UH444 %%%% !1110
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M5X5M;R15!):'#R12E0"6$<C,HY( YKXF_:X^.G[6_P"QU^TW;_&S5[F3Q?\
M!#7Q#8C3(5\NVM$ !>)ASY5YNW21SDD3#Y#A5V( ?)W_  4E^-7[3>F>+-?^
M _QVTVS'@'7M<M-6\/7MI$4B&FV9=#$LR@-*Y#JUPLGSI(,IB-DS_1OX6O/#
M.J>%]+O?!\UM=>'[BUA:Q>T*O;/:E!Y7E%/E*;,;<<8KYM\1>'?V?/\ @H!^
MSY$#*FO>%]>3S;2[BPE[IMZ@QN7.3#<0DX=&X(RK!D;G\D_@]\8?B]_P2[^+
MP_9^_:!,VM_"'6YGETK58D=TMT=^;JU')"@L/M5KDLC'>F<CS@#TC]L;]CCQ
M[^S=X]_X;,_8R#Z7-I;O=ZUHEHF8XHSS/-# O$EI(,^?;X^3[Z84?N_TD_8Y
M_:L\-_M;_"A/'>DV,FE:OITHLM7LF#&."\"!SY,I&)(W4AE.=P!PP!Z_3NB:
MWHWB?1K+Q!X?O8=2TO4H4N+:YMW$L,T,J[D='4D,K Y!%9_A3P9X1\":3_8/
M@G1;+0--\V6?[-86\=M#YLS%Y'V1A5W,QR3CF@#I:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG[-F@?LJ?!K3_A5HE^VK3K/+>W]\Z>5]JO9]H=Q'EMBA41%7).U1DDY-?2M
M!1110 4444 ?%W[;\W[55Q\.-(\-?LFVW_%0Z_J(L[^^5X8Y+"Q:)RTJ23,%
MCRP ,@#.H^X Y!'\WO[;7[).O_LK7G@Q?&WBH^*_%?C.WO;_ %2=0YBCFCD0
M;4EE/FS$ER6D<*6/\([_ -B=?SI?\%P?^1^^%G_8,U+_ -'14 ?T51_ZM?H*
M_G<_X*3^,/%O[2W[8?@K]C;P;J36NF:?/8V]RIR81J6H@2R7,BKC>MM:.A Z
MK^\ P6-?T1Q_ZM?H*_G*^&,QUS_@M=J=S?#YK;5];5 ><_9M'N(4_)5!'TH
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M<G_P5L_Y,M\0_P#83TK_ -*5KK/^"6W_ "8K\-?KK/\ Z=[R@#X6_P""WOQ
MU2WTCX9?"VUEVZ??S7VKW2#J\ML(X+8_11+-^)'I7['_  '^%6B?!+X/^$_A
M?H-K%:PZ#I\$,WE+@2W6P&XF;U>64L['U-?A#_P6O26U^,OPPU*92UK_ &/.
M .Q:*ZW.![X9<_A7]&L$\5U!'<V[!XI5#HPZ%6&01]10!_-1_P %(-&M?@%^
MW_X%^,7A.(6#:L-)U^X,8"*U[:7C13DJN,^9'$A?^^68G.3G^E2\_P"/2?\
MW&_E7\Z'_!92&/7/VC/A5X8MFS>7&D(NWN!<W[QH?7DJWY5^QW[0O[)WAS]H
MO5M)U;7/'7B_PDVD026Z0^&]42PAF$C!BTR/!-N<8P",<<'- 'R'_P $:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^S'X?_9.^&5Q\,?#6LW6NVEQJ4^I&XNT1) \\<490"/ P!$"._)H ^FZ***
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MY$O0/^P?:_\ HI:ZBBO\<O4*7PH****R+"BBB@ HHHH **** "BBB@ HHHH
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M^X^(NC07^F>/?#]A=W^GSIF(_;K:.=DP>5*,WRL"&4@$$$ U^.'Q%\7>*?\
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M>\+>$?"O@?18/#?@O1K/0=)MN(K2PMX[:!,]=L<2JHSWXKH: "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '_TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=17+^-_\ D2]?
M_P"P?=?^BFK6A\<?4BK\+#P1_P B7H'_ &#[7_T4M=17+^"/^1+T#_L'VO\
MZ*6NHHK_ !R]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH ****
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MFD/H* .'M+GXV?\ !(SXW&RO1<^+_@=XQNMP8  . ,;EZ)#J$* ;EX2=%[
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M****Y3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBOSJ_;N^,?[5'A*Y\)_"7]E7PE/JGB#QM'=&;6(X/.73D@,:X5I
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M_P!H?X >(=730- ^)GAC4]4D8(MK:ZS933LQZ*(TE+$^V*]AK\)_CM_P1O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 5Y?\ #'_F;/\ L8+_ /\
M9*]0KR_X8_\ ,V?]C!?_ /LE=5+^%/Y&%3XX_,]0HHHKE-PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
MU/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .37/%?_ &.5[_Z;M/K[2_;I_P"3/_BW_P!B_=_^@U\6_P#!%/\ Y-<\5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNU% 3]X+*RL]-LX-.TZ".UM+6-8H88E"1QQH-JHBK@*J@   8 X% %FBBB@
MHHHH **** "BBB@ HHHH **** "BO@K_ (*$?M)^-/V>?A%I=K\*X!<>//'>
MIQZ+HYV"4PO*I+S)&V5>0?*D:D$;W4D$ J?S:\5_L\_\%1OV<]''QZT?XHW7
MC:_M$%WJ^D1:C=ZD4C7YW4VETODW$:#(81 .HSY8Q\P /U0\ ?LGKX5_:]^(
M?[4VO:RFM3>*;"TLM*MWC(ETY5C2.Y7<25((AC$;+@[6=2.I;X\^,6H^*/\
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M\L@OV_2[M1%?V3/T\V,%@R'^&1&9"<C=N! _*[_@H#IOB/\ 8\_:R\#?MO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y?\,?\ F;/^Q@O_ /V2O4*\O^&/_,V?]C!?_P#LE=5+^%/Y&%3XX_,]
M0HHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP7SLQM&[IS7!:M^U!^S?H/B63P=K?Q0\-6&M0L8Y+6?5K6.2.0<%'W2 (_\
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M9- '9T5X9X+_ &G/V=OB+K,?ASP/\2O#^M:M.VR*SM]2MVN)6ZXCBW[W_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /_5_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_8/M?_12UU%<OX(_Y$O0/^P?:_\ HI:ZBBO\<O4*7PH****R+"BBB@ HHHH
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M ()&?&W[7:?:?%_P-\7W."#T<?W6Z)#J$*#@\)<(.V"(OZ OA?\ %#P-\9?
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M11Z*H % %K3]*TO25G32K.&S6ZFDN)A#&L8DGE.Z21]H&YW/+,>2>2:OT44
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M **** "BBB@ HHHH **** "BBB@ HHHH __6_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\;_ /(EZ_\
M]@^Z_P#135U%<OXW_P"1+U__ +!]U_Z*:M:'QQ]2*OPL/!'_ ")>@?\ 8/M?
M_12UU%<OX(_Y$O0/^P?:_P#HI:ZBBO\ '+U"E\*"BBBLBPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6_"?COQ]X:L_$5_X8E6\TJZ?)&&&]0VP@30[L.(Y-R;@#CKGW&@ Z<"BBB@
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M?Q;_ &+_ !U!X7^TO-.EE<7,UC<69G8F2WMYH(G22 YPJ2A<+A6+XW']VZ*
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M^(;B"XTZ&!95GBEA+H990ZJBM)$4#A2PR@P<#D X7QC^Q!\6/$'_  43TO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '_U_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .30!;HKS.Q^-/P=U3PA>?$'3/'6@WGA?3Y&AN=5@U.UEL(95"L4DN5D,2L
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MA_\ :W\#:KX^\+^'-1\/Z?IFH-IX_M#RCY\B1I*QC,3-D*)%#9Z'N><?#O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O'?C[\9=%_9^^$?B+XN^(-/N]5LO#\*R&
MVLHR\LKR.L:#/1$W,-\C<(N2<X /L55;ZQLM3LKC3=2MX[NTNXWBFAE021R1
MR JR.K AE8$@@C!'!H \"_9H_:8^&_[4OPYM_'_P^N=DD>V+4=.E8?:M/N2,
MF*4#J#R8Y!\KKR,$,H^<OVPO^"A_@O\ 9<\2V7PUT'P[<>._'E[$DYTVVF\B
M*VBESY?G2B.5O,<#<L2QDE?F8J&4M\$?M%_LZ?%3_@G?\5#^U;^RD))_ $\F
M-:T4[Y(;2&1P6@G4<O9N?]7)]Z!L G[K'V'_ ()C:SX9^/OQV^/O[4%]IACU
MS4]1M8M/6X99I;&QNA*QC5L?>*11H6&.$P, D$ ]D_96_P""HWPO^/GBJ+X:
M?$#1W^'/C"Y?R;6&ZN!-9W<^=OD),R1-',3]V.1!N/RJS-@'AOV[?V"-?\2>
M(4_:@_97+Z'\3]'F%]=VEDP@;49(^?M%N> MV/XU/RSC.?GSYGN/[<G[!/@W
M]J?PY+XG\,1P:!\3M,CW6.IJ/+2\"#*VUX5&64]$EP7C.",KE3\Z_L*_MU>*
M+/Q1_P ,D?M;B71/B%HDHT_3]0U [7O73 2UNG)P;@C'DS9*W"D<ERK2@'$_
M#7_@LUX:T7P-/H_Q[\$ZM#\0M&1[>9-.BBCMKNXBRI\U9Y$DM7W#$B['"G)7
ML@]>_P""?OP,O/BCX*\?_'O]HOPI97T_Q>\20>(K+3M0M%D$$=DTS6UPJ2K\
MH+3N(N/FB ;)63G])?$'P7^#WBSQ'#XP\4^!="UC7;;'E7]YIEK<72;>FV:2
M-G&,<<\=J]*  &!P!0 M%%% !116!XK\4:'X)\,:OXR\3W2V6D:':3WUY.V2
M(K>W0R2.0.3A5)P.3VH WZ\?^/OP?T/X]_!WQ5\)/$&U;?Q%9/#'*PW?9[E<
M26\X'K%,J/COC'>OQMUG_@IK^V1XU?4?BA\#O@L+OX4Z3.ZFZN=/O;R:6&(D
M.TMQ;RI&A Y81HPB/#LP&3^D'['?[;GPT_:[\-2OHJ_V%XOTN-7U+1)Y \D:
MDX\Z!\+YT!/&X*"I(#JN5+ 'P#_P3Y_; \/? CX/_$'X(_M(ZF-"U+X,W-P8
M8YCNGFM6G:.2T@3.Z62*ZRJ@=5E0#"J2,KP!\(/B#_P5&^*4?Q_^.]E/X8^"
MVA&:V\.Z/&QBN+^/=\V)0 VTLH,TXZL/+BP%9E\S_P""J7P+\-_"_P#:*\$_
MM,:EH/\ ;/@OQ5>VL7B*Q0M&LUU8E3)&70J4-W:+A<'.Z-V)YK^@GP1J'A75
MO!FA:IX%\C_A&[RQMIM-^RH([?[')$K0>4B@!4\LC: !@<4 ?B;XC_X)3_&7
MX.^/[3QQ^QI\5)M!26=$EBU&:2WN+>!F^;,MNC1W<:YR8I(ER!CYS7[A>';+
M5M-\/Z9IVO:B=8U.UM88KJ],20&ZG1 LDWE1_)'YC ML7A<X' K8HH ****
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M\,?^9L_[&"__ /9*ZJ7\*?R,*GQQ^9ZA1117*;A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_T/W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\E_^"S&O7FD_LGZ7IEJY2/6_%%A:S@=&BCMKNY
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M&7\DVH0E(9"-H/F,ZYW%FQM/D?Q._P"4U^A?]?FD_P#IF2OZ"]7_ .03>_\
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MKX:7[Z;)XO\ $>LVFJ3@D1)I<5_]IG:< @M&K0HVS(WN%7O7]<%?SQ_LC_\
M*77XL_\ 7YXJ_P#2L4 ?H=^S=_P3;^#?[,7Q(T[XI>"=>UO4-7M-/GL9H[^2
MV>WE:X"AY56.!'0\'"[R,$<G!SY1<?\ !)OX;>._BYXQ^+'QS\::MXPE\2:I
M=7UM90'[$EO!/(SQPRREII9/*4A$V-$H50 N, ?K#--';PR7$QVQQ*68]<!1
MDGBOYI/A9+\>_P#@J?\ '3Q<-<^(U]X*\ ^'E2Y73K%Y/*BMY9&CMH8K99$1
MY75&,D\A8@] 050 &=_P43_8X\&?L9W/@3XR?L_:CJ.B+=:@UN8I+DS/:7D"
M^?!-;S$;QD*X96+<@8."17[,^.?@%\-/V[?@/\,]8^+HO8Q<Z=8:[$VG3"V=
M9K^S1Y%.Y)!L._IC(P.>N?PX_P""@_["/PQ_9(\">%_$OA?Q=JFNZWX@U)[:
M2#4I+?F&.%I'EC2.-7^5]BDDD#< >2*_HG_9:_Y-D^$7_8GZ!_Z;X* /YM?^
M";7[(7PI_:N\3^/=+^*,NI1P>&K:RDM1I]PD!+7,DJN7+QR9P(QC&.ISGC'Z
M^?M>?!7P5^SW_P $T_'GPH^'PN/[$TB"W>(W<HFG9KG5X)W+N%4'YG.,*,#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD)(M[E>1Q&^>1+^WW[/W[0/PY_:4^'-C\2?AM?>?:3_N[FVDP+FQN0 7M[A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O+_AC_ ,S9_P!C!?\ _LE>H5Y?\,?^9L_[&"__
M /9*ZJ7\*?R,*GQQ^9ZA1117*;A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '_T?W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\;_\
M(EZ__P!@^Z_]%-745R_C?_D2]?\ ^P?=?^BFK6A\<?4BK\+#P1_R)>@?]@^U
M_P#12UU%<OX(_P"1+T#_ +!]K_Z*6NHHK_'+U"E\*"BBBLBPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_TOW\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&
M_P#R)>O_ /8/NO\ T4U=17+^-_\ D2]?_P"P?=?^BFK6A\<?4BK\+#P1_P B
M7H'_ &#[7_T4M=17+^"/^1+T#_L'VO\ Z*6NHHK_ !R]0I?"@HHHK(L****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y?\,?\ F;/^Q@O_ /V2O4*\O^&/
M_,V?]C!?_P#LE=5+^%/Y&%3XX_,]0HHHKE-PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]/]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QO\ \B7K_P#V
M#[K_ -%-745R_C?_ )$O7_\ L'W7_HIJUH?''U(J_"P\$?\ (EZ!_P!@^U_]
M%+745R_@C_D2] _[!]K_ .BEKJ**_P <O4*7PH****R+"BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH __U?W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&_P#R)>O_ /8/NO\ T4U=
M17+^-_\ D2]?_P"P?=?^BFK6A\<?4BK\+#P1_P B7H'_ &#[7_T4M=17+^"/
M^1+T#_L'VO\ Z*6NHHK_ !R]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P $?@C;_P#"3?&3Q-LM[2TMT^T_V;]IXCDDC&=\[Y!AA(]'<;-JR>N_L._
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>7_#'_F;/^Q@O_\ V2O4*\O^&/\ S-G_ &,%_P#^R5U4OX4_D85/CC\SU"BB
MBN4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /__6_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N7\;_ /(EZ_\ ]@^Z_P#135U%<OXW
M_P"1+U__ +!]U_Z*:M:'QQ]2*OPL/!'_ ")>@?\ 8/M?_12UU%<OX(_Y$O0/
M^P?:_P#HI:ZBBO\ '+U"E\*"BBBLBPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 0@,"K#(/!!K\9?VH?^"3VF^+O%<OQ7_9<UV/P#XF,INFTYFDM[#[1][S;
M2:W!DM')YVJK)D_+Y8'/[-T4 ?S[0_LJ?\%:O']L/AWXX^)S:5X:<&&>[EUD
M.98#PX+6J&ZFW#C;(0&Z,0"37ZI_LC?L>_#C]D7P1+X?\*,VJZ]JNQ]6UB=
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M%%%%<IN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?_]?]_**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Y?QO\ \B7K_P#V#[K_ -%-745R
M_C?_ )$O7_\ L'W7_HIJUH?''U(J_"P\$?\ (EZ!_P!@^U_]%+745R_@C_D2
M] _[!]K_ .BEKJ**_P <O4*7PH****R+"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O\
MAC_S-G_8P7__ +)7J%>7_#'_ )FS_L8+_P#]DKJI?PI_(PJ?''YGJ%%%%<IN
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?__0Y#_AXA\=/[T/_?VX_P#CM'_#Q#XZ?WH?^_MQ_P#':^"J
M*_8/[.H?R(_+OK];^=GWK_P\0^.G]Z'_ +^W'_QVC_AXA\=/[T/_ ']N/_CM
M?!5%']G4/Y$'U^M_.S[U_P"'B'QT_O0_]_;C_P".T?\ #Q#XZ?WH?^_MQ_\
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MZ'#6/^_R_P#Q->H44?7*G?\ !?Y!]6AV_,\O_P"%=:E_T.&L?]_E_P#B:/\
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M=:E_T.&L?]_E_P#B:]0HH^N5._X+_(/JT.WYGE__  KK4O\ H<-8_P"_R_\
MQ-'_  KK4O\ H<-8_P"_R_\ Q->H44?7*G?\%_D'U:';\SR__A76I?\ 0X:Q
M_P!_E_\ B:/^%=:E_P!#AK'_ '^7_P")KU"BCZY4[_@O\@^K0[?F>7_\*ZU+
M_H<-8_[_ "__ !-'_"NM2_Z'#6/^_P O_P 37J%%'URIW_!?Y!]6AV_,\O\
M^%=:E_T.&L?]_E_^)H_X5UJ7_0X:Q_W^7_XFO4**/KE3O^"_R#ZM#M^9Y?\
M\*ZU+_H<-8_[_+_\31_PKK4O^APUC_O\O_Q->H44?7*G?\%_D'U:';\SR_\
MX5UJ7_0X:Q_W^7_XFC_A76I?]#AK'_?Y?_B:]0HH^N5._P""_P @^K0[?F>7
M_P#"NM2_Z'#6/^_R_P#Q-'_"NM2_Z'#6/^_R_P#Q->H44?7*G?\ !?Y!]6AV
M_,\O_P"%=:E_T.&L?]_E_P#B:/\ A76I?]#AK'_?Y?\ XFO4**/KE3O^"_R#
MZM#M^9Y?_P *ZU+_ *'#6/\ O\O_ ,31_P *ZU+_ *'#6/\ O\O_ ,37J%%'
MURIW_!?Y!]6AV_,\O_X5UJ7_ $.&L?\ ?Y?_ (FC_A76I?\ 0X:Q_P!_E_\
MB:]0HH^N5._X+_(/JT.WYGE__"NM2_Z'#6/^_P O_P 31_PKK4O^APUC_O\
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M**/KE3O^"_R#ZM#M^9Y?_P *ZU+_ *'#6/\ O\O_ ,31_P *ZU+_ *'#6/\
MO\O_ ,37J%%'URIW_!?Y!]6AV_,\O_X5UJ7_ $.&L?\ ?Y?_ (FC_A76I?\
M0X:Q_P!_E_\ B:]0HH^N5._X+_(/JT.WYGE__"NM2_Z'#6/^_P O_P 31_PK
MK4O^APUC_O\ +_\ $UZA11]<J=_P7^0?5H=OS/+_ /A76I?]#AK'_?Y?_B:/
M^%=:E_T.&L?]_E_^)KU"BCZY4[_@O\@^K0[?F>7_ /"NM2_Z'#6/^_R__$T?
M\*ZU+_H<-8_[_+_\37J%%'URIW_!?Y!]6AV_,\O_ .%=:E_T.&L?]_E_^)H_
MX5UJ7_0X:Q_W^7_XFO4**/KE3O\ @O\ (/JT.WYGE_\ PKK4O^APUC_O\O\
M\31_PKK4O^APUC_O\O\ \37J%%'URIW_  7^0?5H=OS/+_\ A76I?]#AK'_?
MY?\ XFC_ (5UJ7_0X:Q_W^7_ .)KU"BCZY4[_@O\@^K0[?F>7_\ "NM2_P"A
MPUC_ +_+_P#$T?\ "NM2_P"APUC_ +_+_P#$UZA11]<J=_P7^0?5H=OS/+_^
M%=:E_P!#AK'_ '^7_P")H_X5UJ7_ $.&L?\ ?Y?_ (FO4**/KE3O^"_R#ZM#
MM^9Y?_PKK4O^APUC_O\ +_\ $T?\*ZU+_H<-8_[_ "__ !->H44?7*G?\%_D
M'U:';\SR_P#X5UJ7_0X:Q_W^7_XFC_A76I?]#AK'_?Y?_B:]0HH^N5._X+_(
M/JT.WYGE_P#PKK4O^APUC_O\O_Q-'_"NM2_Z'#6/^_R__$UZA11]<J=_P7^0
M?5H=OS/+_P#A76I?]#AK'_?Y?_B:/^%=:E_T.&L?]_E_^)KU"BCZY4[_ (+_
M "#ZM#M^9Y?_ ,*ZU+_H<-8_[_+_ /$T?\*ZU+_H<-8_[_+_ /$UZA11]<J=
M_P %_D'U:';\SR__ (5UJ7_0X:Q_W^7_ .)H_P"%=:E_T.&L?]_E_P#B:]0H
MH^N5._X+_(/JT.WYGE__  KK4O\ H<-8_P"_R_\ Q-'_  KK4O\ H<-8_P"_
MR_\ Q->H44?7*G?\%_D'U:';\SR__A76I?\ 0X:Q_P!_E_\ B:/^%=:E_P!#
MAK'_ '^7_P")KU"BCZY4[_@O\@^K0[?F>7_\*ZU+_H<-8_[_ "__ !-'_"NM
M2_Z'#6/^_P O_P 37J%%'URIW_!?Y!]6AV_,\O\ ^%=:E_T.&L?]_E_^)H_X
M5UJ7_0X:Q_W^7_XFO4**/KE3O^"_R#ZM#M^9Y?\ \*ZU+_H<-8_[_+_\31_P
MKK4O^APUC_O\O_Q->H44?7*G?\%_D'U:';\SR_\ X5UJ7_0X:Q_W^7_XFC_A
M76I?]#AK'_?Y?_B:]0HH^N5._P""_P @^K0[?F>7_P#"NM2_Z'#6/^_R_P#Q
M-'_"NM2_Z'#6/^_R_P#Q->H44?7*G?\ !?Y!]6AV_,\O_P"%=:E_T.&L?]_E
M_P#B:/\ A76I?]#AK'_?Y?\ XFO4**/KE3O^"_R#ZM#M^9Y?_P *ZU+_ *'#
M6/\ O\O_ ,31_P *ZU+_ *'#6/\ O\O_ ,37J%%'URIW_!?Y!]6AV_,\O_X5
MUJ7_ $.&L?\ ?Y?_ (FC_A76I?\ 0X:Q_P!_E_\ B:]0HH^N5._X+_(/JT.W
MYGE__"NM2_Z'#6/^_P O_P 31_PKK4O^APUC_O\ +_\ $UZA11]<J=_P7^0?
M5H=OS/+_ /A76I?]#AK'_?Y?_B:/^%=:E_T.&L?]_E_^)KU"BCZY4[_@O\@^
MK0[?F>7_ /"NM2_Z'#6/^_R__$T?\*ZU+_H<-8_[_+_\37J%%'URIW_!?Y!]
M6AV_,\O_ .%=:E_T.&L?]_E_^)H_X5UJ7_0X:Q_W^7_XFO4**/KE3O\ @O\
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M^K0[?F>7_P#"NM2_Z'#6/^_R_P#Q-'_"NM2_Z'#6/^_R_P#Q->H44?7*G?\
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MPKK4O^APUC_O\O\ \37J%%'URIW_  7^0?5H=OS/+_\ A76I?]#AK'_?Y?\
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M._X+_(/JT.WYGE__  KK4O\ H<-8_P"_R_\ Q-'_  KK4O\ H<-8_P"_R_\
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M:/\ A76I?]#AK'_?Y?\ XFO4**/KE3O^"_R#ZM#M^9Y?_P *ZU+_ *'#6/\
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MUZA11]<J=_P7^0?5H=OS/+_^%=:E_P!#AK'_ '^7_P")H_X5UJ7_ $.&L?\
M?Y?_ (FO4**/KE3O^"_R#ZM#M^9Y?_PKK4O^APUC_O\ +_\ $UP?@3P7?:C_
M ,)#Y7B34K/[+K%W WDRA?-9-N9'^4Y=L\FOHRO+_AC_ ,S9_P!C!?\ _LE=
M%+%3]G-W[=%_D83P\.>.G?N'_"NM2_Z'#6/^_P O_P 31_PKK4O^APUC_O\
M+_\ $UZA17/]<J=_P7^1O]6AV_,\O_X5UJ7_ $.&L?\ ?Y?_ (FC_A76I?\
M0X:Q_P!_E_\ B:]0HH^N5._X+_(/JT.WYGE__"NM2_Z'#6/^_P O_P 31_PK
MK4O^APUC_O\ +_\ $UZA11]<J=_P7^0?5H=OS/+_ /A76I?]#AK'_?Y?_B:/
M^%=:E_T.&L?]_E_^)KU"BCZY4[_@O\@^K0[?F>7_ /"NM2_Z'#6/^_R__$T?
M\*ZU+_H<-8_[_+_\37J%%'URIW_!?Y!]6AV_,\O_ .%=:E_T.&L?]_E_^)H_
MX5UJ7_0X:Q_W^7_XFO4**/KE3O\ @O\ (/JT.WYGE_\ PKK4O^APUC_O\O\
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M6AV_,\O_ .%=:E_T.&L?]_E_^)H_X5UJ7_0X:Q_W^7_XFO4**/KE3O\ @O\
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M^K0[?F>7_P#"NM2_Z'#6/^_R_P#Q-'_"NM2_Z'#6/^_R_P#Q->H44?7*G?\
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MPKK4O^APUC_O\O\ \37J%%'URIW_  7^0?5H=OS/+_\ A76I?]#AK'_?Y?\
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M._X+_(/JT.WYGE__  KK4O\ H<-8_P"_R_\ Q-'_  KK4O\ H<-8_P"_R_\
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M:/\ A76I?]#AK'_?Y?\ XFO4**/KE3O^"_R#ZM#M^9Y?_P *ZU+_ *'#6/\
MO\O_ ,31_P *ZU+_ *'#6/\ O\O_ ,37J%%'URIW_!?Y!]6AV_,\O_X5UJ7_
M $.&L?\ ?Y?_ (FC_A76I?\ 0X:Q_P!_E_\ B:]0HH^N5._X+_(/JT.WYA11
M17*;A1110 4444 %%%% !1110 4444 %%%% !1110!__T?S;HHHK]L/R,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]D_
M9T_Y.#^&/_8T:+_Z70U_5Y7\H?[.G_)P?PQ_[&C1?_2Z&OZO*^#XO_B0]#[3
MA?\ AS]0HHHKX\^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N7\;_\ (EZ__P!@^Z_]%-745R_C?_D2]?\ ^P?=?^BFK6A\<?4B
MK\+#P1_R)>@?]@^U_P#12UU%<OX(_P"1+T#_ +!]K_Z*6NHHK_'+U"E\*"BB
MBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O+_AC_P S9_V,%_\ ^R5ZA7E_PQ_YFS_L
M8+__ -DKJI?PI_(PJ?''YGJ%%%%<IN%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_TOS;HHHK]L/R,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]D_
M9T_Y.#^&/_8T:+_Z70U_5Y7\H?[.G_)P?PQ_[&C1?_2Z&OZO*^#XO_B0]#[3
MA?\ AS]0HHHKX\^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N7\;_\ (EZ__P!@^Z_]%-745R_C?_D2]?\ ^P?=?^BFK6A\<?4B
MK\+#P1_R)>@?]@^U_P#12UU%<OX(_P"1+T#_ +!]K_Z*6NHHK_'+U"E\*"BB
MBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O+_AC_P S9_V,%_\ ^R5ZA7E_PQ_YFS_L
M8+__ -DKJI?PI_(PJ?''YGJ%%%%<IN%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_T_S;HHHK]L/R,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]D_
M9T_Y.#^&/_8T:+_Z70U_5Y7\H?[.G_)P?PQ_[&C1?_2Z&OZO*^#XO_B0]#[3
MA?\ AS]0HHHKX\^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N7\;_\ (EZ__P!@^Z_]%-745R_C?_D2]?\ ^P?=?^BFK6A\<?4B
MK\+#P1_R)>@?]@^U_P#12UU%<OX(_P"1+T#_ +!]K_Z*6NHHK_'+U"E\*"BB
MBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBN,^('Q"\&?"SPG?^./'VJPZ-HNFIOFGF.!G^%$499W8\*B@LQX )
MJH0<FHQ5VQ2DDKL[.BOQ)O?C_P#M%?\ !0+QY>?#/]GQ[CX>_#.Q8#5-:.5N
MWA8_\M9(SE6D ^2VB<%N?,DV9V_LEX.\.MX1\)Z-X5;4;G5SH]G!:?;+UQ)<
MW'D($\R9P &=L98XY->EF&5RPRBJLESO[/5+SZ7\CEPV+55MP6G?OZ'24445
MY9UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^-_P#D2]?_ .P?
M=?\ HIJZBN7\;_\ (EZ__P!@^Z_]%-6M#XX^I%7X6'@C_D2] _[!]K_Z*6NH
MKE_!'_(EZ!_V#[7_ -%+7445_CEZA2^%!1116184444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445^0
MO[67_!0S48/$7_"B?V4T_P"$@\77\PL9=5MT%PD4[G8(;%,%9IL\&0YC7L&.
M2GH9=EE7%5/9TEZOHEW9S8G%0HQYIO\ X)^HEY\2? &G^-K'X;WOB&QA\5:G
M$\]MIC3I]KDBC4LS"+.[&T$C(Y )&<'';5^>/['O[$=G\'9E^+_Q@N6\4?%C
M50TT]W<RFY73VF&'6)V),DY!(DF)/=4PN2_Z'5&/HT:=3DHRYDMWW?EY%8><
MY1YIJWE_F%%%%<1N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Y?\ #'_F;/\ L8+_ /\ 9*]0KR_X8_\ ,V?]C!?_ /LE=5+^%/Y&
M%3XX_,]0HHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!$UT#_ ,%\/_Q-7FF<PPKBI1;N3EV52Q*;B[6/Y6*_J?\ V4O^3;?AM_V
M[+_T6*_FL^-.FZ?HWQC\=Z/I-O':6-CKVJ000Q*$CBBBNI%1$4<!54  #H*_
MI3_92_Y-M^&W_8#LO_18KQ^*Y\V'IR[O]#U.&X\M:<>R_4_&S_@IK_R<HO\
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M<\@X5LDJS?GO7TV$Q<*\%4INZ/G\3AIT9N$UJ%%%%=)SA1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^Q3;_ _PY!\5_B38AOB!K4.8891DZ3:RC_5@'I<2*?WK=5!\L8^??\ (/\
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M7J%>7_#'_F;/^Q@O_P#V2NJE_"G\C"I\<?F>H4445RFX4444 %%%% !1110
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M3DVV]3Z-))604445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4PL+*S_:8DN+4KYM]H]C-/@<^8#)$-WOL1/PQ7ZC_P#!/8@_LF^#L=I=3_\
M2^>O;S[$.K@*=1]6OR9Y&2T53QM2FNB?YH^#_P#@JY_R43P+_P!@JX_]'U^:
M?P\_Y'_PS_V$[+_T>E?II_P5>@=?'/@&Y(^633;M ?=)E)_]"%?F[\)+"75/
MBKX,TR!2TEWK6G0J!U)DN8U _6O7R5_[#%^3_-GF9JO]LEZK]#^MZOY0/CC_
M ,E^^('_ &,^J_\ I;)7]7]?R@?''_DOWQ _[&?5?_2V2OGN$/XE3T1[G$_P
M0]3^K^OPY_;Z_:L^)^F?&*Z^%OPZ\17GAS2_#,< N)-/F:VFN;N:-9F+2QD/
ML175 @(&X,3GC'[C5_+9^UW<O=?M,_$>5SDKK$\?X1X0?H*Y>%L-"I7;FKV1
MT<1UY0HI1=KLXKXF_'#XH?&*UT.U^).N2:W_ ,(]%+#:/*J"0+,5+EV5078[
M5!9LL0!DFOZ;/V?_ /D@WPW_ .Q:T?\ ](HJ_D[K^L3]G_\ Y(-\-_\ L6M'
M_P#2**O4XKIQA1IQBK*[/.X:J2E5G*3N[(_.O_@HY^TUX^^'_B#1/A-\-]9N
M-!DGLQJ.HW=FYBN6$LCQPPI*I#Q@>6SMM()RO.,@_EKXY_:#^,/Q,\':?X$\
M?^)KG7M*TNZ-W +HB2;S=A0%YB/,DPK-C>QQDXKZ+_X*07+S_M1ZM$QR+?3]
M/C'L#"'_ )L:^#J]C)L%2CAJ<N57M>_FSRLVQ=25>:YG;8_J7_90^&]C\+/V
M?_!WANU0+<7%C%J%XX&"]U>J)I"Q[[=P0$_PJH[5\!_\%%/VJ/&GA3Q-!\$?
MAQJ<VB^7;)<:O=VS&*X=I_FB@CE7#(H3#.5(+;@N<!@WZG_#74H=:^'/A76+
M;'DWVE6,Z8.1ME@1A@_0U_/[_P %&/#^I:1^U+K^J7L;K;ZY::?=6S,#M:..
MUCMFVGN!)"V?>OE,CIQK8V3JZO5_.Y]+G$W2PD52TV7RL>,?"/\ :;^,'P>\
M66WB70_$-Y>6ZR W5A=W$DUK=1D@NKHY8!F'1P-ZGD'KG^GSP?XHTSQMX3T7
MQEHQ8V&NV5O?6^\8;RKF-94W#L<,,CL:_D"K^KG]G3P_J/A7X#?#_P /ZQ&\
M-]9Z'8+/'(,/%(859HV!Z%"=N.V*[^+</34832LSBX9KS;G!O0_";]MWX0VW
MA+]JN^\/^'HUM;;QDUIJ-M&!\J27[F*7@= ;A)& '0' K^B;PWX?TSPIX>TS
MPOHL0@T_2+:&TMXQT6*! B#\ !7X@?\ !0SQ5I^G_M>>#-0!1QX<T[27N!Z,
ME]/<[6_X RG\:_=FO-SJK.6&P_-V_P CORFG&->OR]_\S^=S]OOX_P#BWX@?
M&37/AU:ZA-;>%?"<YL8[)'VQS740Q/-*%^^V_<J[LA5' !9LVOV ?VA?%W@/
MXP:+\-+_ %">[\*>*YOL1LY'WQV]W*,031!ON$N CA2 RMD@E5QX)^UQX9U#
MPK^TI\1+#487B:[UBZOX]_\ %%?.;F-E/<%9/PZ=14G[(?A;4_%W[2GP]L=+
MA>4V.K6VHRE.B0V#BXD9CV&$QSU) ZD"OK7AJ/U'EM[O+?\ #<^9^L5?KG-?
M7F_78_J0K^1>77;KPO\ $B3Q+8Q13W.DZJUW%'.GF0L\$_F*)$XW*2.1W'%?
MUT5_*!X/^'>I_%GXWVGPXTF00W&O:O);^:1N$4?F,TLI&1GRXPSXSSC%?/\
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MPVYB&7/56!4C@C%?T7_L@?':Z_:"^#%EXOUE537=/GDT[4]BA$>YA5'\Q%'
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M=I=3_P#2^>OA?_@J] Z^.? -R1\LFFW: ^Z3*3_Z$*^:R[_D:R]9?J?08_\
MY%T?2/Z'YE_#S_D?_#/_ &$[+_T>E?UX5_)#\)+"75/BKX,TR!2TEWK6G0J!
MU)DN8U _6OZWJUXP?O4UZ_H9<+?#/Y'\G'Q[_P"2Z?$;_L9-7_\ 2R6OZ1OV
M4O\ DVWX;?\ 8#LO_18K^;GX]_\ )=/B-_V,FK_^EDM?TC?LI?\ )MOPV_[
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MORI<DO'LC:-L%GX^3<"<<C]'_CO^V]\,?V>_'"^ O&>B:W=WSVD5XLME#;/
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MC^WSK?Q^^#W@SX9Z.LEBTMG#<>*G V"ZU"!BJPH!QY.Y!/CD$L@X,9S]T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^-_\ D2]?
M_P"P?=?^BFKJ*Y?QO_R)>O\ _8/NO_135K0^./J15^%AX(_Y$O0/^P?:_P#H
MI:ZBN7\$?\B7H'_8/M?_ $4M=117^.7J%+X4%%%%9%A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M02DV[L^U2MH@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O+_AC_ ,S9_P!C!?\ _LE>H5Y?\,?^9L_[&"__ /9*ZJ7\
M*?R,*GQQ^9ZA1117*;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?&'PR_;H^/7PT\0^)/%!O+7Q1J'BDVYNFUE)IE0VV\1^2L$L C&)"-J_+@#
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MC5KA7]#'_!,S_DVG_N-7W_H,5?SSU]D? S]N#XL?L_>!_P#A /!NE:)>Z?\
M:I;O??P7,DV^8*&&Z*YB7;\HQ\N?>N#/<%4Q%#V=/>YV9-BX4*W/4VL?9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;M4L'(&X @'O
M@]?Y4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O+_ (8_\S9_V,%__P"R5ZA7E_PQ_P"9L_[&"_\ _9*Z
MJ7\*?R,*GQQ^9ZA1117*;A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !35544(@"JHP .  *=10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYO0#G]_,\O/K\Q-?-_ZISMR^UT]/^">__K-'XO9:^O\ P#]O/VU_VW/ .G^
M]9^%/PGUB/7?$&MQO97EW:-OMK.VD&V8+,/EDE=24 0D+DDD$ '\+:**^DR[
M+J>&I\D/FSP,?CYXB?/,****] X0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]D_
M9T_Y.#^&/_8T:+_Z70U_5Y7\H?[.G_)P?PQ_[&C1?_2Z&OZO*^#XO_B0]#[3
MA?\ AS]0HHHKX\^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N7\;_\ (EZ__P!@^Z_]%-745R_C?_D2]?\ ^P?=?^BFK6A\<?4B
MK\+#P1_R)>@?]@^U_P#12UU%<OX(_P"1+T#_ +!]K_Z*6NHHK_'+U"E\*"BB
MBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O+_AC_P S9_V,%_\ ^R5ZA7E_PQ_YFS_L
M8+__ -DKJI?PI_(PJ?''YGJ%%%%<IN%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_T?S;HHHK]L/R,***
M* "BBB@ HHHH **** "BBB@ HHHH ***^S_V#?AYX+^)WQ[B\+^/=)BUK2FT
MR\F-O-NV>9'LVM\I!R,GO6&)KJE3E4ELM3;#T74FJ:ZGQA17]0/_  Q?^R[_
M -$[T_\ .;_XY1_PQ?\ LN_]$[T_\YO_ (Y7S?\ K=0_E?X'O_ZL5OYE^/\
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MBBB@ HHHH ]D_9T_Y.#^&/\ V-&B_P#I=#7]7E?RA_LZ?\G!_#'_ +&C1?\
MTNAK^KRO@^+_ .)#T/M.%_X<_4****^//J HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KE_&__(EZ_P#]@^Z_]%-745R_C?\ Y$O7
M_P#L'W7_ **:M:'QQ]2*OPL/!'_(EZ!_V#[7_P!%+745R_@C_D2] _[!]K_Z
M*6NHHK_'+U"E\*"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_AC_S-G_8P7_\
M[)7J%>7_  Q_YFS_ +&"_P#_ &2NJE_"G\C"I\<?F>H4445RFX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!K]@?^"E'C.P\._LV7?AJ>7%WXJO[.UAC!^8K;RK=R-C^ZOE $^K+ZU\I_\
M!.']J+^R;V+]GSQS=XL[UV;09Y6XBG<[GLR3_#(<M%_MY7DNH!E6(Q%+ .I2
M2=F]^WE\PS*A0J8U0J.UTMNY^=_Q._9]^,?P;L;+4_B7X8GT2TU&1H8)7>*5
M&D0;BA:%W"MCD!L9 .,X./-_#7AK7O&.OV'A;PQ92:CJNJ3+!;6\0R\DCG
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MVLK74KJ&'QVP2.5U4'3M.. &( YMJ]0^&?\ P4S^.7AO6;?_ (6.EIXNT=W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^0RW.JWMQ=RN3DL\\C.QR?4FOZ_Z_C@/4UX'!RUJOT_4]KBEZ4UZ_H?T,?\
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M]IPO_#GZA1117QY]0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?0GAA7]$_P"P;^S''\$_  \:^*;8#QEXKA228,/FLK-L/%;#T9N'E_VL*?N
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M!X+W3^3#GW587(]G^E?DC17S67\-QH5U6Y[VOI;_ ()[^.S]UJ+I<MK];_\
M /US_P""4WCW[-XC\;?#*YD^6_MH-5ME)X#6S^3-CW82Q_@M?KW\1/&=A\._
M ?B'QWJ>#;:#8W%ZRDXW^2A8(/=R H]S7\B-%&8<-QKUW6Y[7M=6_P""&"S^
M5&BJ7+>W6YI:SJ]_K^L7VO:K*9[W4IY;F>0]7EF8N['ZL2:^^_\ @F0RC]I.
M0$X+:'? >YWPFOSRHKW,7AO:TI4D[75CQ\+B/9U8U+7L[G]3G[6/_)M?Q(_[
M EW_ .@5_+/%+)!*DT1VO&P92.Q!R#4=%<6495]5@X<U[OM;]6=>:9E]9FI<
MMK>9_65\&?B[X2^-?@'2_&_A2^BN1=01FZ@1P9+2Y*_O(94SE65L@9^\,,N5
M()7XE>"?"&H^$O%VH7.FV-OJ&J:1>6DU^\,23&.2!XP'G(#;0#CEL 5_*)IF
MK:KHMTM]H]Y-87*?=E@D:)Q]&0@UKZYXV\9^)T$7B77K_5D!#8N[J6<9'?$C
M-S7B/A-JIS0J67I_P3V%Q,G"TZ=WZGW3_P $QF _:1G!."="O0/?][ :_8C]
MK7_DVGXD?]@6Z_\ 0:_EGHKT\=D7ML1&OSVM;2W;YGGX/.?94'1Y;WOK?O\
M(*_H2_X)C_\ )MLO_8<OO_1<-?SVT5VYKE_UFE[+FMKZ_P"1QY;COJ]3VEKG
M[+?\%:&'V?X7+GG?K)Q^%G7XTT45IEV#^KT8T;WM_G<C'XOV]5U;6O\ Y!11
M17<<84444 %%%% !1110 4444 >R?LZ?\G!_#'_L:-%_]+H:_J\K^4/]G3_D
MX/X8_P#8T:+_ .ET-?U>5\'Q?_$AZ'VG"_\ #GZA1117QY]0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7\3GC/_D<-=_Z_[K_T:U?VQU_$YXS_
M .1PUW_K_NO_ $:U?H_A[\5;_MW]3Y?B;:'S_0_7O]C_ /X)W_!'X_? '0/B
MCXSU?7[35M5EO4ECL+FUCMP+:ZDA3:LMK*PRJ G+'G/3I7MOBG_@CW\'[K3Y
M4\%>-]=TV^(_=OJ"VM["#_M)%%;-CZ/7T-_P3._Y,Y\&_P#7QJO_ *7SU]ZU
MXV:<0XVEBZL856DI.WWG?A,LH3HP<H;I?D?QN_'CX$^._P!G?XA7?P[\?0(M
MW"BS6]S"2UO=VSDA)H68 E20000"K J1D5^H?_!)W]HS4H-?O_V</$UX9=/O
M(IM0T(2')AGBS)=6Z?[,B9F"] 4<]7->K?\ !87P78W7PS\"_$,1J+W3=7DT
MLN!\S17MN\^">X5K;C/0L<=37Y$_LD>)KOPC^T[\,-9LWV,?$%A:N?\ IC>R
MBUF_\ARM7VT:JS/*G*HO>L_O77^NYX#A]4QB47I^C/ZQOB;X_P!#^%?P^\0?
M$;Q&^W3O#UE->2C.&?RURL:Y_BD;"*.[$"OX]_BW\5/%WQI^(.L?$GQO<_:=
M4UB8N0,^7#&.(X8@<[8XUPJCT&3DDD_T*_\ !5OQ7=>'OV61H]LV%\3:Y86$
MPSUBC66\_P#0[=*_G?\ A;X43QY\3O"/@>7(3Q%K%AIS8.#B[N$A//;[U>=P
M-@X4\//%2W>GR7_!_(Z>(*\I58T5_39^FW['W_!,\_%WPE8?%/XTZE=Z-H6J
MH)M.TVRVQW=S >4GEED5Q'&XY10A9E(;<HQG[+\=_P#!)G]GK7-#FM_ VHZK
MX8U8)^YN'G%[!O'>6&0!F!_V)$_I7ZA6=G:Z?9P6%C$L%M;1K%%&@PJ(@VJJ
MCL !@59KY#%<5XVI5=2-1Q71+;_@_,]NCD]",.5QOYG\87Q?^$_C#X(_$/5_
MAIXYMQ!JND2!2R'=%-$XW1S1-W21"&7H1G! 8$#]GO\ @DC\=M2UW1?$7P%\
M0W;W!T&,:IHX<[O+M)'"7,(/94E='4<\R/V%?I9X]_9I^!'Q2\9VWQ ^(G@V
MR\0:[:6R6<<UWOD3R(W9U5H"WDOAG;ED)P<9P *]3\.>$_"W@^P&E>$M&LM$
MLEQB"QMX[:(8Z?)$JK^E>KF_%E+%X3V$Z?O::]$^Z./!9-.C6]HI:=O(Z"BB
MBOACZ *\F\;?'GX)_#>];2_'GCO1="OT4,;6[OX(KD*>A\DMYF#V.VO@G_@I
MI^U9XA^#'A32_A5\.K_^S_$OBZ&66[NXF(N+/3E/E@Q$8*23ON57'*A'QAMK
M#\$_AK\*?BA\=/%C^&?ASHMSXDUN96N)0C*-J[@&EFFE940%B 6=@"3C.37V
M>2<)K$4/K.(GRQ_K6[V/"Q^<^SJ>RIQNS^IZP_;0_94U&X%K;_%#0T<G&9KD
M0)_WW*%7\<U]$Z-KFB^(].BU?P]J%OJEA.,QW%K*D\+CU5T)4_@:_DA^+G[(
M'[17P-T'_A*?B5X/ET[1MZQM>0W%O=PQLY"J)&MI9/+W,0H+A03P,FNC_8T_
M:)\9_ 3XR>'WTK491X:UN_M[35]/9V-M-!.ZQ-+Y><":('<CC!XVD[2P/HXG
M@NC.BZN#J\UO1I^5T<U+/9QJ*%>%OZ\S^L^JE_J%AI5G-J.J7,5G:6ZEY9IG
M6.-%'4LS$ #W)K/\2^(M'\(^'=3\5>(;A;32]'MIKRZF;I'! ADD8_1037\I
M/[5G[7?Q#_:;\874]_>3Z=X/MI6&F:,CE88XE/R23JIQ).1RS-G:20F%KYK(
M<@J8Z;2=HK=GJYCF4</%75V^A_1YJ?[8W[+6D7IT^\^*&A&96V'RKQ)T!]WB
MW*/KFO4_!'Q:^%OQ+\T?#SQ=I/B5H%#2IIU[#<O&IX!=(W9DS_M 5_*)\-?V
M2?VC?B]X>'BOX>^!KW5-';=Y=TS0VT4NPX;RC<21^9@\?)NY!'4&O)[BW\?_
M  D\:26LXU#PEXIT*;##,EG>6TH&1@C:ZD@@@CJ"".#7UCX(PL[PHU_>7H_O
M2U1XRS^K&TIT]'ZG]HVJ:KIFB:=<:OK5Y#86-HADFN+B18H8D7JSNY"J!W).
M*_F>_P""G_C#P]XS_:1M]1\*ZW:Z[IL6AV4:S65REU KB28NH:-F4-R"1UZ9
MK[_^%W[17BG]K_\ 8?\ BAX8N[)M2^(NAZ3-I]Q!9QEI=0$\1^SW"0H.'E*N
MK*HQO4D !@H_!/QGX$\:_#K6CX=\>Z%>^'M4$:R_9K^W>WE,;YVN%D"DJ<'!
M'&01U!JN$,F]CB*DJLK3CI;RTU%G>.]I2BH+W7K?]#]8/^"2/CWP+X'U#XH'
MQKXBTW0/ML6C^1_:%Y#:>;Y;7>_9YK+NV[ESC.,C/45^WVM77@SXD_#?6EM=
M=M;GPYK5A>VLNHV=S%) D+QO%,ZS M'^[^;))PI!ST-?Q[^ _A/\3?BBUZGP
MX\+:EXF;31&;D:=:R7)A$N[R]_EJ=N[8V,]<'TK^BS]F_P '^*O ?_!.N_\
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M.IZ%64D$'U%?Q[_&3]F7XX_ %+.X^*_A:;1;74',=O<B6&YMY) "VSS;>21
M^ 2$8AB 3C -?6?_  36_:)\9_#[XX:'\)KC49;GP?XQF>T>RE=FBM[MT9H9
MX%)PCM( CXP&5LL"54C?'\&TEAWB,)5YDE?H[VWLT98;/)^T5*M"US]H_P!L
M[XB^"M"_9^^)/A>\\3Z?I_B"ZT"[^SV4E[%%>2>;&RKY<)<2-NY P.>U?R95
M^M__  5(^$WQ/USXZW7Q$T7PIJ=_X7T_0;,7.IP6DLEI#Y3RF3?*JE5V @MD
M\#D\5^2%?4\'8*%+"*4)7YM7Y:;'D9Y7E.M9JUM/4_LX\)_%[X3^)9-/T/PY
MXUT35=2N8U$5K::E;3SR%4W,%CCD+-A02<#@ GM7R!^V/^S)^S]\<O&FAZ]\
M7?B2O@G4M/T\VT%NU[96WG0>:[^9MNOF/S,PR..,=:_,#]A+]G?X[^"_VJ?
M7BSQ;\/]<T?1;.2^::\NK":&",26%PB%I&4* S,H&3R2!7=?\%@_^2T>"?\
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M[O3[O^&/F-]/O(]/@U5XB+2XEEACD[-)"J-(H]U$J$_45^GO_!(S_DYC7/\
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M&=(H"\7RH" SLX )P Q#8>5</X*.%6*QL]^B>W;;6XL9F6(=;V-")^BNC?\
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M1Y-@6)H^0WRY<9/7'6OP>KWN#J5".$3HN[?Q>3L>=GDZCK>^M.GH?U'?!/\
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M_L\_&K7K7PB\UYX1UR^<16T&K(B0W$K'"QQ7$3NFYLX DV%CPN3@'\_?%_\
MP2#\<Z%\/[O7_#OCFWU[Q19V[3_V4E@T,4[HNXPPW+3DESC"%HE#' .WK7X]
M.DL$K12JT<D;$,I!#*P/((Z@@UUX3AS*L73DL-)W76[_ "9C6S3&49)U5HS^
MX2BOFO\ 8^^).K?%S]FGP%X\UZ3S]2O;%H+F4]99K&:2T>1O]IVA+-[DXXKZ
M4K\RQ%!TJDJ<MTVON/JZ513BI+J%%%%8EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y?\ #'_F;/\ L8+_ /\ 9*]0KR_X
M8_\ ,V?]C!?_ /LE=5+^%/Y&%3XX_,]0HHHKE-PHHHH **** "BBB@ HHHH
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M6_4?$C3C3:\_T/ZJOV"/^30OAK_UX3?^E4U?AO\ \%._^3O_ !+_ ->6E_\
MI)'7[D?L$?\ )H7PU_Z\)O\ TJFK\-_^"G?_ "=_XE_Z\M+_ /22.L^&?^1O
M7_[>_P#2D7FW^Y4_E^1]S?\ !'#_ )$_XF_]?^F_^BIJ_9^OQ@_X(X?\B?\
M$W_K_P!-_P#14U?L_7SG%G_(PJ_+\D>GDW^[0_KJ%,DDCAC>:9PD: LS,<
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MO(,X+SFU@;'J%667]2*]J^$O_!3/]F?XG:E!H>J7MWX+U"X;8G]M1I%;,QZ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH __5_-NBBBOVP_(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#V3]G3_DX/X8_]C1HO_I=#7]7E?RA_LZ?\G!_#'_L
M:-%_]+H:_J\KX/B_^)#T/M.%_P"'/U"BBBOCSZ@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OXG/&?_ ".&N_\ 7_=?^C6K^V.OXG/&?_(X:[_U
M_P!U_P"C6K]'\/?BK?\ ;OZGR_$VT/G^A_3=_P $SO\ DSGP;_U\:K_Z7SU]
MZU\%?\$SO^3.?!O_ %\:K_Z7SU]VW5W:V-M+>WTR6]O I>221@B(BC)9F.
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MFK^&GBI? GQ'\*^-W4NOA[5K'42J]2+2=)L#W.VO*X)_W"?)O=_?96.O/O\
M>8\VUE^9_:#I&DZ;H.E66AZ-;I9V&G0QV]O#&,)%#$H1$4=@J@ 5\A?'[]A7
MX+?M'_$"Q^(OCV;4K:^L[-+)X]/FB@CN4C=G1IBT3N67>5!5E.W Z 5]=Z+K
M.E>(]'LO$&A74=]IVI0QW%M/$VZ.6&50R.I[AE((KX!_:^_;[TO]EGQYH7@>
MT\-1^++F]LWO+]%OOLLEJCOL@ Q%,"S[78JP'&T]#FOSK*H8N5?EPM^?7R]=
MSZ?&2HJG>M\)]$_!']E7X'?L\7-YJ'PLT!]-O]0A%O<W,MW<7,DT:L& (ED9
M%Y /RJM?AA_P5@_Y.FB_[%^P_P#1D]?K?^RS^W;X*_:E\37O@[P_X5U;1M2T
MZR:^GDG\B6S2-72/;YRN'WLSC:/+Y )R,5^2/_!6 $?M2PD]_#]A_P"C9Z^K
MX9I8B&9M8J_/RO=W?0\?-ITI82]':_0^AO\ @C3_ ,A#XL_]<M$_]"O:_8#X
MW_\ )%_'_P#V+^J_^DDE?CY_P1J<#4_BPF>3#HI_)KS_ !K]@_C?_P D7\?_
M /8OZK_Z225YG$__ "-9>L?R1UY3_N:^?YL_C'K^S3X/VMM??!'P397L2SV]
MQX=TV.2-QN5T>TC#*P/!!!P17\9=?V>?!7_DC?@/_L :7_Z2QU])X@_PZ7J_
MT/*X:^*?R/Y-OVE?A%<_ OXX>+?AG(K"UTN\9K%VR3)8S@2VS9[GRF4-_M C
MM7[S?\$ROC=9^,/V9)= \0WBQW7PUEEM;B21ONZ<RM<6\K'LJKYD8]HJ^?O^
M"O/P7^U:7X5^/.DP9DLF_L74V4<^5(6EM)&QT"OYB$GNZ"OR3^%'QN\2?";P
MS\1/#6AD^3\0-$.CS8; CW3(6DQW/D&:(#_IIGM7=.E_:V6P?VKK[UH_PU.>
M,_J>+EV_3H9_QY^*-[\:/C%XM^)]Z6QKU_++ C_>CM4_=VT9_P!R%47\*_HK
M_P"";/P9_P"%4?LV:7K6HP>5K/CE_P"V;@D886\BA;-,^GD@2 =C(U?SS_LW
M_"2Z^.7QM\)?#*%6-OJUXAO'7@QV4(,MR^>Q$2MM]6P.]?V(VEI:V%I#8642
MP6]LBQQ1H-JHB#"JH'   P!7F\<8R-*C3P=/U^2T7]>1U\/T'.<J\OZ?4^>_
MCGX&_9;&CW7C7X_Z%X;2V)5)-2U6WMUG9MN%1)R!,S[1A51BQ X'%? 6D_\
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M_P %0?BMH7Q)_:1_L?PW<BZL_!FG1:3-(A#1M>B62:?81UV>8L;?[2-7LO\
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MI?FSW<#_  (>B_(****\PZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5_PK8>!?#GP'\$Z6,6>@:7J.GP\8_=VJ6$2\?1:\Y_X)&?\ )S&N?]BK>_\
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M_P#W>IZ_H=O$G\2/H?V^:=_R#[7_ *Y)_P"@BOY]_P#@L'_R6CP3_P!B^?\
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M<?F>H4445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ=6/P<E:->MZ:,_1S_@F[K5SK/['G@?[4^][%M1M0>^R*]FV#\%('T%?R_\
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M ?BK4[>RTSPO9OIUS;6-G900VGVJ[EB9(88HH@NYBQ&<#Y5RQP 37W&+K8+
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MQ8H\0?X5+U?Y"X:^.?R/Y'_C=_R6?Q]_V,&J_P#I7)7])?\ P34_Y,U\#_\
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M^NW_  2")_X9V\4CL/%5S_Z0V5?DE^WU_P G??$K_K^@_P#22&OUL_X)!?\
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MW>S_  /YQZ***^E/GPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ K^)SQG_R.&N_]?\ =?\ HUJ_MCKQ.?\
M9I_9RNIY+FY^%?A2::9B[N^AV#,S,<EF)AR23R2:^HX:S^&!<W.+?-;;RO\
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M6,:3I((\GD[,<Y/4DUY==W?CWXL^,Y+N[?4/%GBG79N3B2\O+J4C   W.Q
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MK/PN\17/AZ[U"#[/</;E2)8LY 975E)!Y5L97L1FOW\_93^)7BCXH_\ !/\
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M)W%$:>-RJY.<#C-=4N)L-''0Q5*E:*35M%>]]3)955>'E1G.[;/PP_X(]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 5Y?\,?^9L_[&"__ /9*]0KR_P"&/_,V?]C!?_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_U_S;HHHK]L/R,***
M* "BBB@ HHHH ]]_9Y_9V\<_M&^,6\,>$MEI9V:K+?ZA.&,%I$QP,[>6D?!"
M(""V#R%#,/UY\*_\$N_@3I5G&OBC5]9UV]P/,<316D)/JD:1LZCV,C?6M?\
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MT;\8?^"8\>D1>';/X,ZK?ZKJ&J:A]GO'U-HA:VEKY4DC7#O#$K##*% PQ8L
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MU[0=9\+ZU?>'/$-G)I^IZ;,\%S;S+MDBEC.&5A[&OT9_8Z_8G^'W[1GPNO\
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M[&S^TQ_P3FUOX8Z#>>._A)J-QXDT73T:6[L;E5-_!"O+2HT859E4<L BL!R
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MOAKXAU"6*_NW75+G41"\=I9I&6,B")(RTA8!%0GYB<DJ 2+'_!)?_CU^*/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5R_C?_D2]?_[!]U_Z*:NHKE_&_P#R)>O_ /8/NO\ T4U:T/CCZD5?
MA8>"/^1+T#_L'VO_ **6NHKE_!'_ ")>@?\ 8/M?_12UU%%?XY>H4OA04445
MD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!\&?M7_L)^'OVJO&.C^,-8\676@2:18?8%B@
MMDG5U\UY=Y+.I!R^,>U2_LG_ +#'A_\ 94\5ZUXJT?Q7=>()-9LELFBGMD@$
M8619-P*NV3\N,5]W45ZG]LXGV'U;G]SMI_D<GU&E[3VO+[W<****\LZPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O^&/_ #-G_8P7
M_P#[)7J%>7_#'_F;/^Q@O_\ V2NJE_"G\C"I\<?F>H4445RFX4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!__0_-NBBBOVP_(PHHHH **** "BBB@#[I_8Q_; ?]G#4K[PUXJM)M2\&ZW*
ML\RV^#/:7(4)Y\2L0'#*%6120<*I4Y!5OW.^'/[1/P2^*\41\"^,-/O[B8#%
MH\H@NP3V-O-LE]L[<>E?G3^QY^R-^R_\9?@_I'C_ %G3[W6-6#R6NIV\U])%
M%%=PM\RJMOY3!60HZ@L3M89.:QOVP?\ @G_=))IGBW]FWPXGV.WM_L]_I$$I
M,V]&++<1&=R9"P;:ZAMWRJ0#EL?"YC'!8C$N#;A/9O2UU\S[+ RQ="@II*4>
MW4_9"ZM+6^MY+.]A2X@F!5XY%#HRGL5.01]:^!OVC_V!OA7\3?#VHZS\-](@
M\*^,8HVEMC9@6]G=2*,B*: ?NUW]/,0*03EMP&#\7?LJ_#;]NSP[\2- A5=;
MT+PI:7D#:E%K$["Q-FKCSD6WG9MSLF54QKN!(.Y0-P_<F\O+73[2>_OI5@MK
M9&EED<X5$0;F9B>@ &2:\:O">"JKV-1/T_4]6C*&+IOVM.WK^A_'=<6\UI<2
M6MRACEA9D=3U5E."#]#7]?OA;_D6-(_Z\[?_ -%K7\D_CS6K'Q)XX\1>(M,B
M\BSU34;NZ@C(P4BGF:1%Q[*0*_K8\+?\BQI'_7G;_P#HM:]WBYMQI-^?Z'C<
M,)*52WE^I_-)^VU_R=/\0O\ K]B_])HJ_HX^$W_)*_!G_8%T[_TFCK^<?]MK
M_DZ?XA?]?L7_ *315_1Q\)O^25^#/^P+IW_I-'6/$'^ZX?T_1&V1_P"\5_7]
M6?SW_P#!0>=YOVM/&D;=($TQ%^AT^W;^;&O>O^"5!/\ PMOQ@.QT,?\ I3%7
MS]_P4!_Y.X\=_P#<+_\ 39:U] _\$J/^2N>,/^P&/_2J*O8Q7_(K7^%?H>5A
MO^1B_P#$_P!3]'OV[KE[7]D_Q_+&<%H;)./22^MT/Z&OYEZ_I@_;W_Y-*\>_
M[FG?^G&VK^9^LN$O]WE_B_1&G$_\>/I^K/ZW?A$2?A1X+)ZG1-._])HZ_GO_
M ."@G_)VWCC_ '=+_P#3;;5_0A\(?^23^"O^P)IO_I-'7\]__!03_D[;QQ_N
MZ7_Z;;:O)X8_WR?H_P T>GQ#_NL/5?DS];O^"='_ ":MX>_Z_-1_]*7KXT_X
M*P_\C5\._P#KRU#_ -&15]E_\$Z/^35O#W_7YJ/_ *4O7QI_P5A_Y&KX=_\
M7EJ'_HR*C ?\C67K+]0QO_(MCZ1_0?\ \$G?^1G^(O\ UYZ=_P"C)J^Q?^"C
M7_)K&O?]?NG?^E*5\=?\$G?^1G^(O_7GIW_HR:OL7_@HU_R:QKW_ %^Z=_Z4
MI1C_ /D:Q]8_H&#_ .1:_27ZGXY_LH?LO:W^TQXRNM/%VVD^'-%6.34KY5#N
MOFD^7#$IX,DFUL$_*H!8@\*W[>^#OV-_V6_A-I9U";PM8WHLU\R:_P!=9;O
M7^-_/_<ICU5% ZU\W?\ !*FZTU_A#XOL8@/[0BUWS)CW\F2UA$7_ (\DE>O?
M\% /A)\3OBY\';33?AHLE]-I=^MW>:;$^Q[R%491M!(#M&Q#!#UZC+!07FN-
MJU<9]7<^2-[?\.++<)3IX7VZAS2W.PO_ -L+]E3P)<6OA31/$UE<S33)!#::
M);M<1;Y&"##P)Y &2/XZ^NJ_GL_9B_8<^,OBGXDZ)K_C[0+GPMX:T2\AN[I]
M03R9Y_(<2"&*%OG.\@ N0%4$G).%/]"=>3G&$H491A1GS/J>GE>)K58N56/*
MNA_)=\;FW_&?Q\_][Q!JI_.[DK^G7]G_ /Y(-\-_^Q:T?_TBBK^9#X[6DEC\
M;OB%93#:\'B'54(/^S=R"OZ;_P!G_P#Y(-\-_P#L6M'_ /2**O?XG_W>E_70
M\3A[^/5_KJ?AQ_P4IU"6]_:<N[:1B5L-*L($'HK*TN/SD)KX"K[F_P""C!S^
MU1X@]K/3O_29*^&:^ERE6PM/T1X&9O\ VBIZL****] X3]C/^"2W^N^*7^[H
MG\[VOJ;_ (*/)=M^RWK#6V?+2_T\S8_YY^> ,_\  RM?+/\ P26_UWQ2_P!W
M1/YWM?JS\3?A]H7Q5\ :[\//$BYT_7;9[=V !:-CS'*H/&Z-PKKGNHK\YS6L
MJ>9>T>R<7^"/O,MHNIEZ@MVG^;/Y&J_=W_@E4;S_ (4UXL#_ /'H-?;R_P#K
MI]E@\S]-E?#VO?\ !-O]I73O%<FAZ+I]EJVE&4K%JBWD,$)CSP\D4C^<IQ]Y
M51\'(!;@G]K?V;_@AIO[/OPHTSX>6<ZWMW&\EU?W2KL%Q=S$;W"DDX50L:YY
MVH,\YKUN(LSH3P_)3DFW;8\S(LOK0K\\XM)'R#_P51\C_A1/AH-_KO\ A)(-
MO^[]CN]WZ[:T?^"6W_)O&M?]C+>?^DEG7S=_P5/^*5AJOB3PK\)-,G$LFAI+
MJ.H!6!"37("6\; ='6,,Y!_AD4U](_\ !+;_ )-XUK_L9;S_ -)+.N"K2<<I
M5^KO^)VTZBEF3MT5CB/^"KFH2Q?#KP-I08B.YU6XG([%H8-H/X>:?SK\.J_:
M[_@K$?\ BF/AT/\ I\U'_P!%PU^*-?0\-+_8X_/\SP\_?^U2^7Y']%/_  3:
M-H?V8-.%MCS!J>H>=_UT\P8S_P  VU\\?\%93??V1\,UC_X\S/JOF?\ 77;:
M^7^F^L__ ():_&+3H+?Q%\$=8NDANIY_[5TM'.#,2@2ZC4GJ5$:.%')&\] :
M_0S]I;X Z)^T9\-+CP/J5P-/OX95NM/O=GF&WN4!&2N02CJ2KC(X.>H%?,5J
MBPV9NI4VO?Y,^AI0^L9>H4][6^:/Y8:_>/\ X)6&_P#^%*>*1)_QYCQ!)Y7_
M %T^R6_F?ILKX>L_^":G[2L_B)=(N[;3+;3]X5M1^VH\&S."RQC]\>.0#&,]
M.*_<'X%_!WP_\"/AII7PX\/.;B.Q#27%TR!'NKF4[I9F )QD\*,G:H5<G&:]
M3B/-*$Z'LZ<DVWT/.R'+JT*WM)QLD?%G_!4_[-_PH/P]YG^N_P"$EMO+]<?8
M[O=^'3\<5[)_P3[_ .32? _^]JG_ *<KFOSR_P""G/QKTSQAXYT;X2^'KA;B
MW\(^;-J#QMN0W\X"B(XXW01KSZ-(RGE37Z&_\$^_^32? _\ O:I_Z<KFO,Q=
M"4,LI\W65_P9Z&&JQGF$^7I&WXH^%?\ @K EV/&7P^D?/V5K"]$?IY@ECW_H
M4K\E:_IP_:\_9I@_:4^'D&CV%S%I_B31)6N=,N9E)C+.NV2"0CE8Y<+E@"0R
MJ<$ @_DY\/O^";/[0&N^,+?3/'EG;^&M CD'VF^^UV]RS1#DB"*%V8N>@WA
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M!QE3CS-):>FYT"7W_!/V-UDC?X:*RD$$#1P01T(.*]?_ .&DOV>?^BF^&?\
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M>OE;]DC]GO3?VD_B/J7@;5-9FT2*PTF;41-#$LS,T4\$(0JQ4 $3$YSVK[K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
M'>+?^"D'[+W@GQ5K/@S7M5U&/4]!O;C3[I4T^5U6>UD:*0*P&& 93@CK7/\
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M"GU_KU*ISQ:E",TFNI^J=%%%?*GKA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_#'_F;/^Q@
MO_\ V2O4*\O^&/\ S-G_ &,%_P#^R5U4OX4_D85/CC\SU"BBBN4W"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)?B;X5M[JUTO6?L?DQWJ)'<+]GLX;=MZQO(@RT9(PYXQG!X'I_[%/[17@O\
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M;]6>C4XBQ,E967R-_P 5>*?$'C;Q'J/BWQ5>R:CJVJS-/<W$IRSNWZ #HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?AM_P %F/\ 7_"+_=U[^=A7U%_P2G_Y-4C_ .PYJ'\HJ^7?^"S'^O\
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M_$C7+?PQ\3-$E\ WEY(D5O=-<"]T]G<[0)91'$\.2>K(4 Y9U%?6O@']C/\
M9E^'GAV#P[IOP]TC5!%$(I+K5;.#4+N?^\TDLZ,<L>2%"J.@4  #\C_^"A'[
M"]MX!UO1?'W[/_AJ\GTOQ#,]K>:1IUO+="UNPID22%$#LL<JA@4QM1E^7A@J
M^MA?['Q=3ZO&FX-[2O\ \%_B<=;Z[1C[5R4NZL?T&@A@"#D'O2U\7_L#:A\5
M)?V<M&T#XPZ)J>BZ[X<FFT^,:K#)!<7%DFU[>3;* VU$?R1D _NZ^T*^*QF'
M]C5E2O>SM?N>[1J\\%.VX4445S&H4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\8A\#?V>?%WCFVF\G53;&QTW!PWVZ\_=1,OJ8\F4CT0U],5^!O\ P5W^,?\
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M#7[^U\CQ#EWU7%SIK;=>C_RV^1[668KVU&,NO7U/YH?^"K7_ "=4?^P%I_\
MZ%+7[E_L=?\ )K/PM_[%^Q_]%BOPT_X*M?\ )U1_[ 6G_P#H4M:OPL_X*C?$
M[X5?#GPY\-]+\':/>VGARRAL8IIGN!)(D*[0S!7 R>^!7VN-RFMB\LPT*"NU
M9[VZ'@T,93HXNJZCW/Z2:\!_:JUC0=#_ &;/B;?>)6C%B?#VI0XD(4/+/;O%
M#&"?XGE957ON(QS7XVS?\%A?C(T9%OX'T%'[%FNF'Y"5?YU\>_';]K[X_P#[
M5#V?A?Q7<1_V;YZO;Z-I%NT<$EQRJG9NDFE<9PH=VQGY0"37D9=P7BU6C*M:
M,4[O4[<3GU'D:AJV=7_P3BM+^Z_;(\ /8@_Z/_:4DK 9"Q#3KE6S['(7ZD5_
M5/7Y._\ !-;]CKQ'\&K._P#C'\4K$Z=XGURV%K86$H_?65DY5W>8?P33%5&S
M[R*N&Y9E7]8LBN#C',*>(QEZ;NHJU_O?ZG1DF&E3H>_NW<**,BLO6X;VZT74
M+;3'\N\EMY4A?^[(R$(?P.*^62U/89^*'[7/_!3KQ7H7C74/AM^SD;5(-+<V
MUSKDT(N9);I&VNMI&^8O+0_+O='WG.T!<,WS*WQ9_P""HVIVW_"6I'XU:U9!
M()(M$9(2A&[>L26P4KCG<%QCOBOEO]F_XA:#\!_VAO#?CKXD:')J5EX:O9A>
M6A16GAE\N2$2*DA"F6"0B10Q'S+P0<$?U ?#7]JK]GCXMK"G@7QYIEY=SXVV
M<TWV2\)/86]QY<IQTX4BOT_,Z=/+8PA1PRG&VLFK_P!?D?)824L4W*=5Q=]E
MH?C9\ _^"J?Q6\+^)+7P_P#M!0Q>(]#>40W-]%;):ZC9\[2Y2()%*%_B0HKG
M'#9X/]!-A?66J6-OJ>G3I<VEW&DT,L9#))'( RLI'!# @@]Q7YO?M-_\$WO"
MG[1/Q7'Q.LO$_P#PB!N[6.+4;>WT];AKNXC9L7!<S1A7,95&^5L[ >I-?=GP
MJ\!K\+OAOX;^',6HS:M%X;L8;"*ZG55DDBMUV1[@O VJ HQV%?*9]7P-:$*N
M%7+)_%&VB_3[CV,NIXB#E"L[KHS\,O$/_!1KXZ^ ?VG/$/ASQ7KJW/@/PYXF
MU*TFLH-/M//>PM+J6-(4DV!]Y50H8L#GDGJ:X[5/VTOVZOVF/%%_%\#K*_TW
M2[8DBQT"R%P;>-ON?:+QXV;>0.NY%)SM0=*^//C-X<U+QC^UAXZ\(Z,%;4-<
M\;:G8VX8X4S7.I21(">PW,,U_57\%/A!X3^!?PUT7X;>$+=(K73($6:94"O=
MW)4>=<2XZO(PR<G@84?* !]7G%3!8&G3J1HQ<Y)6TT\WZGCX*-?$2G%U&HI_
M/T/Y]M%_;U_;;^ ?BR+1_BNUSJ C4-)I/B/3Q;2O$21O258XIQG!"ON9,\[6
MK]Y_V=/VA? _[2GPZM_'_@MG@*O]GOK*8CSK*[50S1.1PPPP*..&4@\'*CS;
M]M[X!>'_ ([? ?Q#;W%I#_PD7A^TFU'2;QD!EBFMU\UX@^-P2=4,;#IDAL94
M8_'/_@E+\3K[PG^T:_P^:9_[-\<:?<0F'/R?:[%&NHI2/58TF0?[]>;B*&&S
M# SQ-&FH5(;I;-?\-\]#JIU*N&Q$:4Y<T9;7/W]^,?Q@\#_ KP!J/Q'^(%V;
M72]/ 4(@W37$S\1P0ID;I'/09  RS$*&(_ 7XC?\%*_VI/B]XH_L+X.0'PO:
M73E+2PTNU74-1F R?GE>.1F? R?*1!@=^2>O_P""N'Q3U#7?C!H'PFMIR-+\
M+:>EY-&#@-?7Q))8=#M@6/;Z;V]:^[O^">/PL^$GP=^!^B>-+S4=,_X3'QE;
M)J%Y=330"XAM[@!X+5"6W(BIM9E_B<DGHH4P.#P^"P4<97I\\Y[)[+^M_P !
MXBO4KXAT*<N6*W9^7NI?M'?\%(/@[#!XK\:7?B;3--=@?,UO20;1BW 1C<6^
M%)Z8RK>E?J#^Q9_P4'T?]HF_C^&_Q$LX- \=>6SVY@)%GJ2QKN?R@Y+1RJ 6
M,99@5!96X*K]Z:IXG^&FMZ=<Z/K.KZ3?6%[&T,\$]Q!)%+&XPR.C,0RD<$$8
M-?RQ?M)>$K/]FS]J758OA3J*?8=$O[75]%G@D$H@60)<QQA@3N$+DQ\G)"Y/
M4UT8)8?-8SHRHJG42NFM#*O[7!N-13<H]4S^M>ORA_;*_P""D=I\%?$5Y\+/
M@]8V^M^*]/;R]1O;L,]E928YA1$93+,N?F^8(A^4[FW*OVYXU^-5OH_[,.H?
M'S34&&\,#6[1.H,MQ:B6W4Y[%W4'VK^=']ACX+67[27[2=IIOCK?J>DZ?%<:
MYJZRLS-=K$Z@)(YY/FSRIYG.67=SGFO)X<RFC*-7%8M7C3Z=V=F:8R:<*5%Z
MRZ^1WND?M'_\%(_BK&?%'@^\\4:O8J6=9=(T8&T^4D%0;>VV/@\;3N/'<YKT
MKX-?\%1/CS\._%0\/_'VV'BG2TG$-X)+6.PU2RVMM?:(DC1RG),<J;F(QO7K
M7]#FG:;IVCV%OI6D6L5E96<:Q000(L<44:#"HB* JJ!P !@"OS5_;X_8<U;]
MH^^\/>,_A9%I]CXLMG:TU&:[D:WCN+(J3$\C(CEGA8;1\NXJ^"2%4#NPN>X'
M$U/8XC#QC![-;KYV_(PK9?B*4?:4JC<NW<_1+PSXL\/^-O"MAXR\(W\>I:1J
MULMS:7,1RDD;C(//(/8@@$'((!!%?A7^Q]^W=^TO\6_VC_!?P[\=>(X+W0M8
MFNDN84T^TA9Q%:32KAXXU88=%/!]NE?J'^QS\$_B-^SY\#D^%_Q'U:QU>?3[
MJZELVT]I6BAMKC$AB+3)&Q(F,C9V@88>E?S^?\$]/^3QOAQ_U\7W_I!<5GDN
M P[I8W1345[KMY2U16.Q-13H;J[U7W'Z$_MZ?&_]L3PE\2O%_@?X?:?J#_#>
M?2466:+1!=6X@N+7%V3=^2VT#+[CO^3!Z8K\E/V?_'7QD^'?Q"C\1_ FWN;K
MQ2MM-$J6MC_:,GD.!YA\DI)QP,MMX]:_K(^.G_)$OB#_ -B]JW_I)+7\]7_!
M*W_DZ^T_[ VH_P#H*5ZO#^8TWE]9^R7N+7^]IU./,L++ZS!<[]Y_=Z'W]^SQ
M^T#^UKK7P,^/'C;XUP7FEZQX/T)K[0)+[1ET\"=+6]E=E1H8UF"O%$2"& X!
M^]SP7_!/C]L?X_\ Q\^.5[X)^)^O0ZEI$.B75ZL4=E;6Y$\4UNBMOAC5N%D;
MC..:_3']J/\ Y-I^+'_8J:W_ .D4M?A;_P $E/\ DY[4_P#L6K[_ -*;6O-P
MD:&)P>*Q'LHI]++;3I^9U5G4I5Z-+G;[^>I_0[XY\;^&?AOX0U;QWXRO5T[1
M=$MWN;J=LG:B]@!RS,<*J@$LQ  )(K\ OC/_ ,%2_CEX_P#$<F@? :T7PII,
MLPBLW%LE[JUUD[5W"02Q*7/1(T+#.-[=:^B?^"P/Q-OM-\+>"/A+I\SQPZU/
M<:I?!25#QVFV.!&Q]Y2\CL0>-R*>H&.L_P""5G[.WA71?A8GQ^US3XKSQ)XB
MN+F/39Y4#-9V-L[6[>5D?(\LBR;V')0*!@;LYY5@\-A<#]?Q,.=MVBGM_6C^
M16,KU:V(^K4I62W9\ :A^T5_P4G^'.FGQOXDO/%6EZ4Y!:ZU315^R#<< '[3
M:F- W;IGM7Z._L3_ /!15/CGK\'PJ^+MI:Z/XLG3_0+VW)CM=1=1\T1C8GRI
MR!N4!BLG(4(0JM^IE[96>HV<^GZA ES:W*-%+%*H>.2-QAE96R"I!P0>"*_"
MS6_^"7OQET?X^7OC;X.ZQHOA_P -:9J\6IZ*UY<7!G@".LZ1B..&0D0R?(-S
M@E5!SS5TLQP&.ISIXBG&G)+1K3^O04\+B,/*,J<G-=4S]W**:F_8OF8#8&<=
M,]\4ZO@SZ$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]+\
MVZ***_;#\C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]0^&WQI^*/P@.HM\-?$
M,^@G5O*^U>0$/F^1O\O.]6^[O;&/6M[Q[^T?\;_BAH!\+>/O%MUK.E-*DQMY
MEB"^9'G:WR(#D9/>O$:*Q>&IN7.XJ_>VILL144>12=NUPHHHK8Q"BBB@ HHH
MH **** "BBB@ KWGP5^T[\>OAUX:M/!_@KQE=Z3HUAYGD6T2Q%(_-D:5\;D)
MY=F/7O7@U%9U:,)JTTFO,TIU90=X.QZ+\1OBU\1OBY?VFJ?$?79M=NK&(PP2
M3A 4C9MQ4;%7C/->=4454(1BN6*LB9S<G>3NPHHHJB0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ]D_9T_Y.#^&/_8T:+_Z70U_5Y7\H?[.G_)P?
MPQ_[&C1?_2Z&OZO*^#XO_B0]#[3A?^'/U"BBBOCSZ@**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH _#;_@LQ_K_ (1?[NO?SL*]&_X)
ML_ /X)_$3]FY?$?CSP-H_B#5&UB^B-U?645Q-Y:"/:F^12=HR<#IR:\Y_P""
MS'^O^$7^[KW\["OJ+_@E/_R:I'_V'-0_E%7Z%6JRAD-)P=G?IZR/FJ<%+,9I
MJ^GZ(^H?^&2?V8/^B5>&O_!7;_\ Q%*O[)?[,*,'7X5^&LJ<C_B5VW;_ (!7
MT+17Q'U^O_S\?WL]_P"KT_Y5]P@ 4!5& . !7\]?_!6WXQ_\)+\4M!^#6F3[
MK+PA;?:[U5/!O[Y0RJP]8X A4_\ 35A7[Z^+/$^D>"O"^K^,?$$WV?3-#M)[
MVYD_NPVZ&1S]=JG K^2SPCI?B+]KC]J6SM=2W?;?B!KS7%V4))@M7<S3[/\
M9@MU;:/10*^KX*P<75GBZGPP7X_\!7/'SZL^2-&.\F;?P#_;,^,G[-WAF_\
M"GPT_LR.TU.\-[.]U9B>9I#&D8&_<IV*$X7L2Q[U[I_P]6_:M_Y[Z+_X+O\
M[97])MGX?T+3[."PLM/@AM[:-8HHUC4*B(-JJ!CH ,"K/]EZ9_SZ0_\ ?M?\
M*NOQ3@ZDW.>$3;ZM_P# %3RBO&*C&LTO3_@G\4FJ^)-1U3Q1>>+T"6%_=WDE
M\/L@\I(9I)#+^Y )**K'Y1G@ 5_7K^S3\7[;XZ_ _P )_$R)E-UJ=HJ7R+@"
M.^@/E7*X[#S58K_LE3WK\^_^"L_P4M]=^%6A?&+0[14N_"%U]EOC&@7-C?D*
MK-CKY<X0+_UT8UXS_P $B/C3]BUOQ1\!M7GQ%J2_VSI:L>//B"QW4:^I>/RW
M '01N>]>GG<X9CEJQ=.-G![;V77]&<F C+"XIT9.ZE_7^:/8O^"PW_)(? O_
M &'9/_262OB3]A_]AGP7^U/X%\0>+?%'B34-&ETC4A8QQ6:1,K+Y*2EF,@8Y
MR^,#TK[;_P""PW_)(? O_8=D_P#262I_^"/?_)&/&W_8P#_TDAK+"8RK0R15
M*,K._P"I5:A"IF'+-75OT*P_X(\_"///CO7/^_=K_P#$5VWAG_@DG^S?H]TM
MUKVK>(->5<9@ENH8(6]<^1 DGY2"OU(HKY6?$V/DK.J_P/8658=?81P7PY^%
MWP]^$?AR/PE\-M!M?#^E1MO,-LF"[D %Y'8EY'( !9V9B .>*^)_^"D7QU^*
MWP$^%OACQ'\)M;_L+4-0UD6D\OV:VNM\/V>63;MN8I5'S*#D 'CKC-?HK52\
ML+'4(A#J%O'<QJ=P65 Z@],X8'GFN#!XQ0KJM6CS]T^OWW.BO0<J;A!\OIT/
MY9/^'D/[:'_11/\ RDZ5_P#(E>Z_LQ_MW?M6_$/]H'P'X(\7^./[0T76M5@M
MKNW_ +,TV+S(7/S+OBMD=?JK ^]?T*_\(QX:_P"@3:?]^(__ (FI;?0-!M9E
MN+73;:&5#E72%%8'V( (KZ>OQ+@I0E&.$BFUOII_Y*>33RJNI)NLW]_^9\,_
MMR_L50?M2Z-IWB#PO?0Z3XW\/Q/#;2W /V>[MF)?[/,R@LFUR6C<!MI9@5.[
M*_@]XH_9Z_:U_9MU:369O#VO>')+;/\ Q-='>5X H/!^UV3,J@]0&93Z@<U^
MHO[:/[?WQ_\ V??C/JGPM\+Z%HD&FQ06UU97MU#<3SSP3Q@E^)HXQB42)C8?
MN]>]?JG\)/B?X8^,GP[T/XC^$;I+G3]9MTEPC9,,N,2POW#Q/E&![BM\)F>-
MR_"TW4BI4I;?G:_^=R*V$P^)K246U-;G\X/PR_X*9?M2_#YX;?6-9M_&6GQX
M!@UB /)M[XN(?*F+>A=GQZ&OV[_9(_;-\"_M5Z1>6^GV;Z!XJT>-9+[2Y9!*
M/*8A1/;R@+YD6XA3E596(##!5FP_VV?@=^SYX@^"'C;QS\0-$T_3-4TO3;BY
MM=8BBCM[U;Q4)MT\U0&E\R7:GEN2&W8&"01^./\ P2V36&_:UTIM,W?9DTO4
MC>[<X^S^5A=V.WG&+KQG'?%=5>C@LPP57%4Z7)*'W=_1_=<QIU*^&KPI3GS)
MGU-_P67_ ./SX2?]<]<_G8U][_\ !.[2X-*_8Z^'J0\FYBOKASZM+?7#?H,#
M\*^"/^"R_P#Q^?"3_KGKG\[&O:/^"57Q]\->(_A$/@5JE]';^)/"L]S)9VTC
MA7NK"YD:X+Q G+F*5Y X'W5V'H>.;%T)SR*BXK9MOTO)?J:T:D8YC-/JOT1^
MLM?S6_\ !633[6R_:CM;FW.7O_#MA-+[.)KB(?\ CL:U_2#J^KZ5X?TNZUO7
M;R'3].L8VFN+BX=8HHHT&6=W8@*H'))-?RE_M2_$:Z_:N_:JU*_^'\+W]OJU
MW:Z+HD84[IHHL01N!U ED+2#(! ;D @UAP+1E]:E5^RD[LTX@FO8J'5L_0/]
MK?4M2_X=A_!E9E*FY'AR"3G_ )8QZ=.8R?8^6AK\V/V<]6_:NT)->O/V9K77
M)$N#;QZG)HUB;L9C\PP+(1')M^\Y XSSUQ7[P_MH? :34?V'+CX=>%XVO)_A
M[IVFW%FH'S21:/&L4IP.2WV82$ =3@=Z_++_ ()B?M$>'/@S\6=5\%^-;N/3
MM#\=Q00B\GD$<-O>VAD-OYC-A5202NA8]&*9XR1[V3XQ2RZM.E!2:DWROJKI
M_E^1YV.H6Q5-3E:Z6I-_PGW_  56_P"?7QQ_X)F_^1ZX3XBZ?_P49^+?AP^$
MOB/X<\8Z[I!E2?[//H\@3S8\[6RD"G(R>_>OZB5974.A!5AD$<@@U^<G[>/[
M;L_[-%IH_A3X<MI^I>.-1E$]Q;W:O-%:6 !^:1(WC(>5L! 6^Z&./NFO*RWB
M"=:M&G0PT.;TV\[G9BLLC3@Y5*LK'AO_  2D^%OQ8^%U]\2[;XB^$]5\,V^J
M1Z2]N=1M);42O UT&$?F*-Q D&['3C/:ORZ_9[":_P#MK>#)]73YKGQC#<.K
M<_O1=F4 _P# P*_>_P#85_:+^+/[3/@+6_'?Q'T/3-(LK2\2RL)-.2>,7+QI
MNN&*32R_*NZ-5(;D[QVK\$?C9HVN?LR_MBZQ=PVY63PQXE36]/5B0LMJ;@7M
MM\W<&,JK8[[AV(KULIK5*N+Q=.HDJCBMGV5OU1QXR$84:,H7<4_UN?UI45P?
MPT^)7@WXN^"],\?> ]1CU+2-4B61'1@6C8@%HI5!.R5"<.AY4\&O'?VO_CII
M7P"^!/B3Q7+J L]<O;6:QT5 1YLFHSH5B9%[B(GS7/0*I[D _F=+"5)U502]
MYNUCZJ=:,8.HWH?3U?RJ?\%&_P#D\[XB_P"]I?\ Z:[2ONG_ ()G?&G]I+XS
M?%;6+7QQXVO]:\(^'-,::YANEBF\RZN'$=NAE9#(.!(_#C.S!R,U\+?\%&_^
M3SOB+_O:7_Z:[2OT+A?+)83,IT9R3?)T]4?-9OBU6PL:D59<WZ,_J8T3_D#6
M'_7O%_Z *_E6^-7_ "?IXC_['K_V^6OZJ=$_Y UA_P!>\7_H K^5;XU?\GZ>
M(_\ L>O_ &^6O/X(_BUO\/ZG5G_P0]3^KROY5/\ @HW_ ,GG?$7_ 'M+_P#3
M7:5_577\JG_!1O\ Y/.^(O\ O:7_ .FNTJ. ?]\G_A?YH?$?\!>OZ,_=[]M>
M\N+']BOQY-; EVT>VB./[DLT,;_^.L:_++_@C]96DGQO\97\@!N(/#QCC)ZA
M9+N OC\46OVD^-'P^N/BK^SMXI^'EDH:\US098+4$X'VKR=UOD]AYJKGVK^=
M#]@/XU:5^S]^TE9W_C>7^S-&UJWGT3499LH+7SG1XY) <;0D\2!R?N*6)Z&M
M\A@ZN68FC3^*]_P7^3,\Q?)BZ4Y;?U_F?U2T5!;7-M>VT5Y9RI/!.BR1R1L&
M1T895E8<$$<@C@BORL_X*;?M3ZM\)/#>@?#?X8>))M'\::C=)?W<EE)MFM]/
MB5PJN1]WSI2I4=U1L\$9^.RW+ZF*K1H4]W^![>*Q,:5-U);(_5JBOSY_X)P>
M-OC1\3/@E??$#XP^(I]>_M+4I8=+-Q'$A2UM5".X>-$9]\Q=3N)QLXZFOT&J
M,=A'0K2HR:;CIH5AZRJ04TK7"BBBN0V"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N7\;_P#(EZ__ -@^Z_\ 135U%<OXW_Y$O7_^
MP?=?^BFK6A\<?4BK\+#P1_R)>@?]@^U_]%+745R_@C_D2] _[!]K_P"BEKJ*
M*_QR]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _D.^+/\ R>+XR_['S4?_ $Z25_7C7\AW
MQ9_Y/%\9?]CYJ/\ Z=)*_KQK[[C;X,-Z/]#YW(?BJ^O^84445\"?1'FGQD^)
M.F?!_P"%GBCXF:MM:#P]8372HQP)9@,0Q9]992J#W:OY'?!7P^^*_P"T;\0M
M0T[P5IDOB?Q3J9N=4NE$D43-N?=-,[S.B#+N.K#)( Y-?LY_P5V^,?\ 8_@K
MPQ\#]+GVW/B"8ZKJ"J>1:6I*0(P_NR3;F'O#1_P2'^$7]D>"/%7QJU*#;<:_
M<+I5@S#D6EIAYV4_W9)F"GWAK]%R*?\ 9^6SQK7O2>E_N7ZL^8S"/UG%1H=%
MO_7W'P]_PR5_P4?_ .@9X@_\*&W_ /DVL[5?V,_^"A.NV$NE:YX?UK4;*?;Y
MD%QKMK-$^U@R[D>\*G# $9'! -?U!T5YZXXQ"U5.'W/_ #.IY!2_GE]__ /Y
M%/V8_BAJO[-7[2.@>)M<62QBTJ_?3-;@?ADM96-O=*ZCJ8OO@?WT%?UT1R1S
M1K+$P=' 964Y!!Y!!'4&OYD_^"G?P<_X5I^T=<^+=.@\K2/'\ U2,@807BD1
MWB#U8OMF;_KK7[#_ /!._P"-/_"XOV:]#BU"?SM;\'_\22]W'+LMLH^S2'/)
MWP% 6/5U?WKMXMI+$X:CF%-;JS_KR=T<^33=*K/#2Z;'X,?MX_\ )W7Q+_["
M$?\ Z3Q5_0KX6_8U_9:N/#&D7%Q\,M%EEEL[=G=K8,S,T:DDDG))/4U_/5^W
MC_R=U\2_^PA'_P"D\5?U6^$/^13T3_KQMO\ T4M5Q1B:E/!X3V<FO=Z.W2(L
MII1E7K<ROK^K/#(/V-_V6+:3S(_A;H!(_OV2./R;(KV/PC\.OA_\/[=K7P)X
M9TSP["PVLNG6<-H& ]?*5<_C7945\'5QE6:M.;?JV?10HPCK%)!7\Z_[9'[&
MO[2_Q&_:7\<^-O!/@:XU71-5N8)+:YCN+55D5;6)"0'F5AAE(Y Z5_1117?D
MV<U,%4=2FDVU;4YL=@8XB*A-^9_)[_P[_P#VP?\ HFUW_P"!-G_\?K]A/^"9
M/P*^*_P.\(^.+'XJ^'Y?#]QJM]:26R2RPR&1(HG#,/*=\ %@.<5^GU<;\1-'
MU_Q#X!\1Z%X5U&32-:U#3KJ"QO(FVO;W4D3+#(I[;7(->KF/%E?&4GAZD8I.
MVNO?U.3"Y-3H3]I%MM>A\&?M/_\ !-GX:?'KQ!>^/_"6IOX+\57Y,EV\<(N+
M*\E[R20;D*2-CYG1@"<LR,Q)/Y2_$;_@F/\ M4>!#+<:/I%GXQLH\GS=)NE,
MFWMF"X\F4M[(K_CUIG[-G[9'Q0^#/[0\.M?'?Q#KVMZ7_I&D:Q;:C=W%S)9A
MW4-(()6;#P2H"RJH;:&5>3BOZ'M!_:)^ WB;1H]?T3XA:#/8R()-YU&WC* _
M\]$D=7C/JK@$=Q7LU\9F>6.-._M(6TTNO2^YPTZ&$Q=Y6Y9>I_,AX!_:4_:I
M_9;\2)H4>KZKI1TYE\W0=<29[;9_=:UN,-&&_O1[&]&K^F']G'XWZ/\ M#_"
M#0_BEI%O]B;45>.[M"V\VUW Q2:/=@9&1N0X&4*D@$XK\/O^"HGQ_P#A#\8O
M%GA/P]\,KJWUVZ\,1W8OM7M@&A?SVC\NVBF'^M5"C.67* N-I)+X_2[_ ()D
M>"-;\%_LIZ1/KD;P/XCOKO5H(WZBVFV1Q-CL)%B\Q?4,#WI<34J=7 T\9.GR
M5&]N^_\ PX95.4,1*A&7-%(_&?P\;)?^"DB-J!"Q#XGSX+=-_P#:[^7_ ./X
MK^IVOX\/CSJNH:#^T[\1=<TF=K:^T[QAJ]S;RK]Z.6'4)71A[JP!%?T9_LY?
MMV?!+XX>#K*\UOQ#I_A/Q5%&B7^F:C<QVI\\+\[VS2L!-$QR5VDLHX< T^,,
MNJSIT:\%=*-GY!DF)A&52G)V=S[!\2W%C:>'-5NM4P+*&TG>?=T\I8R7S[;<
MU_+%_P $\[6YO/VQOAS':,59)[Z1B/[D=A<,X_%01^-?J5^WG^WE\-M%^&VL
M_"/X1:Y;^)?$?B>VDL[F\T^99[.QM)LI/F>,E6F=-R*J$[,EF((4-X%_P21^
M!>IWOBS7/C_K-MLTO3;>72M+9Q@RW<Q4W$L?M%$/+)Z$R$#E3C/)Z$\)EN(K
M5E;G5DGZ-?K^!6.J*MBZ4(:\NK_KY'RO_P %,(KF/]L;QD\Y^22#2FB_W/[/
M@4_^/!J]'\$?\$K/C5X]\&:#XYT7Q;X;&G^(;"UU"W#RWF\1742RH&Q;$;@&
M&<$\U[I_P5R^!FK#6_#_ .T!HMLTVG/;)I&K,BY$$L;L]K,^.<2B1HRQX!1!
MU89Z;_@GK^WAX#T7P'I_P,^->L1Z'<Z+NBTC5+LB.SDL_O);SS$XB>(Y",^$
M*;5R& W>NLPQ/]ET:N"U<4DU:^RM_7D<7U:E];G#$==4>&_\.@/C[_T-WAG_
M +_7O_R+1_PZ ^/O_0W>&?\ O]>__(M?M'XZ_:I_9X^'GAJ7Q3X@\?Z/):HA
M>..SO(;RXN..%AA@9W<GID# [D#FOYY_$G[3W[2O[1G[1DL_PE\2Z]H$WBF_
MCM-*TK3]0N(H;>W7"1B1(6"?*@,DSE<9WL>*Y<IS/-<5S2<E&*6[CH;8S"8.
MC96;;Z)GZ-_MW^!=?^&__!/?P5\/]6N8KJ]\+W&AV%Y+;EC#)]FMY(LH7"MM
MW!<94'VKEO\ @C==6K>&OBA9*1]ICN]+D<=]CQW 3\,JU?H+^T-\"]1^*O[+
M>M_!H7\NK:V-*MUM;RZ8>==:AI^R6)Y7/ :>2+#MV#M7\_7[%/[2,G[)7QHO
MV\<65RF@ZJC:9K5LJ$7%K)#)\DWE-@EX'#*R'G:SX!; KERU2QF5UZ%/6?-?
MUU3_ !LS7%-4<73J2^&UC^J>L+7/%'AGPR+=O$FKV>DB[<QPF[N(X/-<#)5/
M,9=QQS@<UY;IG[2W[/6L:"/$]A\2?#S:;L#M*^IV\1C!&0)$D=71L?PLH8=,
M9K^?W_@H9^U'HG[2WQ+T7PW\-C)?^&/"BRP6DZHZM?WEV4\V1(V ;8-B)&"N
MXX8]& KYO)N'ZN*K>SDG%+=VV/5QV90HT^9.[Z(_?+]IF[M+[]F'XJW5E,EQ
M"_A36RKQL'4_Z#+T(R#7X;?\$E/^3GM3_P"Q:OO_ $IM:_2CP?\ !Z]^!_\
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MP#*<@]#2UG:1I5AH6DV6AZ5$(++3H([>",=$BA4(BCZ* *T:^;?D>H%%%%(
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MI\E1O;OO_P .&53E#$2H1ES12/QG\/&R7_@I(C:@0L0^)\^"W3?_ &N_E_\
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MM$>**&%N!(D:N[,XRC$KM)VY/S.5Y#7Q&(5%Q<5U=MCU<7F-.E3YTT^WF?T
MVVJ:9J]@]YI-W#>P,IQ)!(LB'C^\I(K^5K_@GI_R>-\./^OB^_\ 2"XK]GO^
M":/P7U3X4?LXMKGB2R>QUGQM<OJ;1RC;*EF(Q':*P[;E#2@'G$G/I7XP_P#!
M/3_D\;X<?]?%]_Z07%?59)AXT:6/I0ES)*U_E(\C'U7.>&G)6;?ZH_IF^.G_
M "1+X@_]B]JW_I)+7\]7_!*W_DZ^T_[ VH_^@I7]"OQT_P"2)?$'_L7M6_\
M226OYZO^"5O_ "=?:?\ 8&U'_P!!2N/AW_D6XOT_1F^9_P"]4?4_?+]J/_DV
MGXL?]BIK?_I%+7X6_P#!)3_DY[4_^Q:OO_2FUK]TOVH_^3:?BQ_V*FM_^D4M
M?A;_ ,$E/^3GM3_[%J^_]*;6C(?^15BOZZ!F/^^43N/^"PL=R/C'X'E<_P"C
MMH+!!VWBZEW_ *%:_4O_ ()_W5K=_L??#:2S(*+:7,9Q_?CO)T?\=P-?-'_!
M5[X(ZKX]^$^B?%3P[;-=7?@.:?[:D:Y;^SKP)YDIQR1#)&A/HK.QP :^8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]/\VZ***_;#\C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /9/V=/
M^3@_AC_V-&B_^ET-?U>5_*'^SI_R<'\,?^QHT7_TNAK^KRO@^+_XD/0^TX7_
M (<_4****^//J HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#\J?^"F7[-?QI_:#D^'4GPA\/?V]_8(U87H^UVEJ8OM7V3RO^/J:+=N
M\I_NYQCG&1GWK_@G]\'_ (B?!#]GZ/P3\3]*&C:W_:EY<FW\^"YQ%+L"'?;O
M(G.T\;LCO7VY17KU,ZJRPD<$TN5._6^[?>W7L<4<#!5G7N[O[@HHHKR#M/C#
M]O'P?\:?B/\  2\^'/P0T,ZUJ7B*[@@OP+JVM#%81DS2$-<RQ [W1$*@DE6;
M(Q7Q[_P3E_8K^*GP6^(_B#XE?&OP^NB7=M8K9:3&;JUNR[7+9N)0;664(41
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M8K]E?V,?V,] _94\.WMW>WJ:YXSUU$6_OD4I#'$AW+;VZM\WEAN68X:0@$@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\;_\ (EZ_
M_P!@^Z_]%-745R_C?_D2]?\ ^P?=?^BFK6A\<?4BK\+#P1_R)>@?]@^U_P#1
M2UU%<OX(_P"1+T#_ +!]K_Z*6NHHK_'+U"E\*"BBBLBPHHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]3\VZ***_;#\C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /9/V=/
M^3@_AC_V-&B_^ET-?U>5_*'^SI_R<'\,?^QHT7_TNAK^KRO@^+_XD/0^TX7_
M (<_4****^//J HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /F3]HK]DSX5?M/MH#_$I]01O#8NA:FPN%@XN_*\S?N1\_P"J7'3'->E?
M!GX0^$O@5\.],^&/@<W!T?2FG:(W4@EF)N)GG?<P50?F<XP!QCZUZC175/&U
M94E0<GRK9=/ZU,E0@INHEJ^H4445RFH4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7+^-_^1+U__L'W7_HIJZBN7\;_ /(EZ_\ ]@^Z
M_P#135K0^./J15^%AX(_Y$O0/^P?:_\ HI:ZBN7\$?\ (EZ!_P!@^U_]%+74
M45_CEZA2^%!1116184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '!'X5_# ZU_PDA\(:.=7\_P"U?;/[/M_M
M/VC=O\WS=F_S-WS;LYSSG-=[115RJ2E\3N)12V"BBBH&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E_P ,?^9L_P"Q
M@O\ _P!DKU"O+_AC_P S9_V,%_\ ^R5U4OX4_D85/CC\SU"BBBN4W"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH X(_"OX8'6O\ A)#X0T<ZOY_VK[9_9]O]I^T;M_F^;LW^
M9N^;=G.><YKO:**N524OB=Q**6P4445 PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /_]7\VZ***_;#\C"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /9/V=/^3@_AC_V-&B_^ET-?U>5_*'^SI_R
M<'\,?^QHT7_TNAK^KRO@^+_XD/0^TX7_ (<_4****^//J HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&__ ")>O_\ 8/NO_135
MU%<OXW_Y$O7_ /L'W7_HIJUH?''U(J_"P\$?\B7H'_8/M?\ T4M=17+^"/\
MD2] _P"P?:_^BEKJ**_QR]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_X
M8_\ ,V?]C!?_ /LE>H5Y?\,?^9L_[&"__P#9*ZJ7\*?R,*GQQ^9ZA1117*;A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '_];\VZ***_;#\C"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /9/V=/^3@_AC_V-&B_^ET-?U>5_*'^SI_R
M<'\,?^QHT7_TNAK^KRO@^+_XD/0^TX7_ (<_4****^//J HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&__ ")>O_\ 8/NO_135
MU%<OXW_Y$O7_ /L'W7_HIJUH?''U(J_"P\$?\B7H'_8/M?\ T4M=17+^"/\
MD2] _P"P?:_^BEKJ**_QR]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_X
M8_\ ,V?]C!?_ /LE>H5Y?\,?^9L_[&"__P#9*ZJ7\*?R,*GQQ^9ZA1117*;A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '_]?\VZ***_;#\C"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /9/V=/^3@_AC_V-&B_^ET-?U>5_*'^SI_R
M<'\,?^QHT7_TNAK^KRO@^+_XD/0^TX7_ (<_4****^//J HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_&__ ")>O_\ 8/NO_135
MU%<OXW_Y$O7_ /L'W7_HIJUH?''U(J_"P\$?\B7H'_8/M?\ T4M=17+^"/\
MD2] _P"P?:_^BEKJ**_QR]0I?"@HHHK(L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:*/[<Q?_ #\8?V/AOY$?EU_PZI^#O_0W:]^=K_\ &:/^'5/P=_Z&[7OSM?\
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M_P",T?\ #JGX._\ 0W:]^=K_ /&:_46BC^W,7_S\8?V/AOY$?EU_PZI^#O\
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MCH:_1RBBN/%8VK6:=65['5A\)3I)JFK!1117*= 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5GZMIT.KZ7>:3<,R17L,D#LN-P612
MI(SD9P>.*T**:;3NA-7T,_2=.ATC2[/2;=F>*RAC@1FQN*QJ%!.,#.!SQ6A1
M10VV[L$K:!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5@:!X=M/#W]H_9)'D_M.\F
MOI-Y!VR38W!< ?*,<9R?>M^BJ4VDTNHG%7N%%%%2,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>moln-20221231_g5.jpg
<TEXT>
begin 644 moln-20221231_g5.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^%W9&AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-RXQ+6,P,# @-SDN
M83@W,S%B.2P@,C R,2\P.2\P.2TP,#HS-SHS." @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z
M:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O
M,2XP+R(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIP9&9X/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9G@O,2XS+R(^"B @(" @(" @(#QD8SIF;W)M870^
M:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @
M(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/DU0+41A<G!);BUC:&%I;G,M,#,P,S(R+78P
M,CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z=&ET;&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL
M=7-T<F%T;W(@,C8N," H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTP,RTP-%0P.3HP-#HQ,RTP
M-3HP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#(R+3 S+3 T5#$T.C T.C$U6CPO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C(M,#,M,#14,#DZ,#0Z,3,M,#4Z
M,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL
M<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIW:61T:#XR-3(\+WAM<$=);6<Z=VED=&@^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XR-38\+WAM<$=);6<Z:&5I9VAT
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP
M1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E
M/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%<T%!1"\W44%S54=H=F1'.7IA1SEW
M241-=4U!0311:VQ.02LP04%!04%!0D%"3$%!04%!14$F(WA!.T%117-!04%!
M05%!0B\K24U716Q$43$Y455K.4=357A&04%%0D%!04U317AP8FTX0T5!04%B
M5S4P8VQ*2%%I0EE75F]G0C@T04%G04HF(WA!.T%!64%-44%!65=.>F-%,512
M;%%!04%!05-55D1)2$Y34C!)04%!04%!04%!04%!04%!04%!4&)704%%04%!
M04$P>3%)54-!9T%!04$F(WA!.T%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!4EDS0GED04%!059!
M04%!07HF(WA!.UI'5GI9=T%!05E104%!0G-D,U)W9$%!04%F04%!04%566UT
M=V1!04%!9U%!04%!56-L:%I79T%!06AG04%!055:,6A:5V=!04%I=T$F(WA!
M.T%!0559;&A:5V=!04%K04%!04%56D<Q=5I!04%!;%%!04%"=UI',6M:04%!
M07-104%!0TED;E9L6D%!04$P=T%!04-'9&UL;&1W04$F(WA!.T$Y44%!04%K
M8DA6=&%104%!+V=!04%!56)75FAC=T%!0D%W04%!06MD1U9J84%!04)$04%!
M04%-8VQ24U%W04%"1'=!04%G35HQ4E,F(WA!.U%W04%"1'=!04%G35EL4E-1
M=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U8VUL;F%(46=+1TUP241%-4]4
M9V=31U8S8D=6,&1#,5$F(WA!.UE73G)96$IK245.=F)80FAB;FM!04=2;&,R
M34%!04%!04%!045N3E-2,$EG4U561$YJ135.:EET36DT>$%!04%!04%!04%!
M04%!05,F(WA!.V,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04$F(WA!
M.T%!04%!04%!04%!04%&:%I7:4%!04%!04%!1'I544%"04%!04%28DU71FQA
M24%!04%!04%!04%!04%!04%!04%!04)95U9O9T%!04$F(WA!.T%!04%B-DE!
M041J,4%!041K1FA:5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L84E!04%!
M04%!04-39T%!05!H04%!=',Y:UI83FHF(WA!.T%!04%!04%!04):2E)536=A
M2%(P8T1O=DPS9#-D>35P6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-9V%(
M4C!C1&]V3#-D,V1Y-7 F(WA!.UI73759,F=!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!6D=6
M>EEW04$F(WA!.T%!04%!04%U4U561$E$67A/5%DR3%1)=4U30D5:5UIH9%=X
M,$E&2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#04%!04%!04$F(WA!
M.T%!04%!04%U4U561$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J
M8C)X=F1826=C,T)H63)59TQ30GI5:V1#04%!04%!04$F(WA!.T%!04%!04%!
M04%!04%!04%!04%!04=2;&,R34%!04%!04%!04Q&2FQ:;59Y6E<U:EI30E=A
M5U8S85<U;DE%3G9B;5)P9$=L=F)I0G F(WA!.V)I0DI254TR351K,DYI,'E,
M:D5!04%!04%!04%!04%!04-X4UI76FQC;59U63)59U9M;&QD,FQU6GE"1&(R
M-6MA6%)P8C(T9V%7-&<F(WA!.U-55D1.:D4U3FI9=$UI-'A!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!0C)A5U8S04%!04%!051P4#1!1D8X
M=4%"1% F(WA!.T9!040W8W=!0D)-3$%!3F-N9T%!04%&65=6;V=!04%!04%"
M34-664%504%!049C9C4R,6Q96$U!04%!04%!04%!44%!04%!04%!04$F(WA!
M.T%!04%!04%!04%!04%!2U!!04%!06Y.<%IY04%!04%!43%*54E'3C%C;EE!
M04%!04%!045!04%!04%504-G05!!0E%!1U%!94%#34$F(WA!.TM!071!1$E!
M3G=!-T%%04%244)+044X059!0EI!1C1!67=";T%',$%C9T(S04AW06=10T=!
M27-!:T%#5D%*;T%N=T-K04MK07)G0WDF(WA!.T%,8T%V041"04U907EW1%%!
M3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"1%%%5$%2:T)(=T5L05-S0DUG
M131!5#1"4E%&34%624(F(WA!.U=11F=!5V-"8F=&,4%8=T)G=T=,05I)0FUG
M1VA!86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"*V=)1$%G=T-&04ED06E9
M0TQW230F(WA!.T%K14-3=TI506PP0UIW2GA!;F]#:$%+3T%P9T-O9TMS07)9
M0W=13$Q!=%5#-$%,<D%V541!04U,07A91$E1371!>F=$47=.4$$Q;T0F(WA!
M.UIG3GE!,S1$:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%11T)"345)05%T
M0D1S15-!4E9"1TU%8U%2*T))=T5M9U-O0DQ917A!5%0F(WA!.T)/144X050K
M0E$P1DA!57)"5&]&4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8;$)F64="
M9UE70FEC1TYW6DE";&M'86=:-T)O=T<F(WA!.VY1879"<T%',%%B:D)V54A"
M=V-:0GES2%!19%!",D5(9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G>4-%
M64E79VAU0TE)26QG:7$F(WA!.T-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8
M:TIJ=VUK0V)O2GIW;FQ#9G-+15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R
M>D-W<TPF(WA!.TEG<S5#,45,85%U04,U9TQS079)0RM%3"M1=U-$0V]-47=X
M8T1(54UJ9WEN1$U!33)1>GI$43!.2F<Q0416;TYD03)/1&%K3G=W,V4F(WA!
M.T1F9T]%=S1U1&MK3UI!-2]$<'-/=&<W4T1U-%!#43AL1#!%4%AG.39$-5E0
M<W<O4$0K=U%#4D%M145-45E20BM%2G-1=5)$6$5055(F(WA!.T5X17A%53A2
M8E)'345A;U)Y4DAO16=C4TIH2D9%;5%3:$)+:D5S35,T>$U$17E-5%%X3FI%
M-$U4<$)01D4K555":%%N1D5K56%H4TPF(WA!.T9+,%5Z:%1W1E))5DY"5E=&
M6&=6;7A7.49E05=!>%EM1FMK5V)"85!&<DE7,6AB-D9X,%A14F1L1C1K6')H
M9E-&+V-91WAH04='55DF(WA!.VEH:79'3E59*VAK9T=555IA>&U21V)C6C-2
M;T5':6]A55)P,T=P-&%X4G)S1WA18D]X=&I'-&]B<VAV84A!26-+:'A32$AS
M8V]X>DTF(WA!.TA0561(:#%(2%A!9&U2,T1(97=E1F@U04AM;V5L0C8K2'5K
M9D5X."M(,FMF;$(K+T@K;V=&4T)"24=W9VU#1$5)4$%H2$-&24E856@F(WA!
M.V]32$])9G-I2GE*5DEO26ER>4QD27=O:D]#3FU)-5%J=VE0=TI".&M44U(X
M2DMS:S)I54I*5&=L84-76$IC8VPY>5EN2FQC;6AY83,F(WA!.TIU9VY'0V1*
M2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'2U1G<&%Y;61+9$%Q06EO,4MM9W%M
M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,F(WA!.V)I>6E,3F-T1$,Q0DQ8671Q
M>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](3"\T=TY40G--2U%W,GI%4TU5
M;WAG:D<V369)>4MJ2FHF(WA!.TUP<WDQ1$U.33!9>F9Z3S1-+T4P2WI2;$Y*
M-# R1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K3C)!,VY$9EA/0E$T541I
M34]-9S4F(WA!.T)4;$-/6#@U=D1N-4]J639D1'%Y3W4X-TQ4=')/-F\W-D1W
M;E!'53AP1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH4#)%+V]J+VDF(WA!
M.U%#3D%:14-M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP1&954$%204Y%
M4C!32U)--49%:U964EIP1C-K66E2;61'<3!B=U)Z5D@F(WA!.V4P9D%3059)
M4S!I4E-.9$I(56QJ4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P36-K>394
M44I.4VLR5%1D>$]*535U5')D4$%%.4HF(WA!.U0U3E S5D%N54A&474Q14=5
M5D)2;3%(;55J1E-F1DQ(57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*5T0Q
M6F-6<6Q7.3%D158U2E@F(WA!.S1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L
M<C%7,%9B;%9V;%A$5F-H;'I76%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%6
M9U8R0W$F(WA!.UE0>&A4,D=I6696:5-72V-9=D)J43)/6%DK=&M11U-56D]L
M;%!75U-:961M4%=A4UIU:&Y05V546BML;U R:5=A3WAP43)M86%F1G$F(WA!
M.U-'<69A=F1R5#)U;F$O.7-6,GEV8E%H=%E',C5B:$IU83(W16)X-79E1R]2
M8T-T=VAN1&=C5'!X;%A(=V-K='EP;DU"8S$Q>G5(454F(WA!.V1(0C!Z2%5O
M9%E6,31862MD<'0R*TAD5V0W3C1%6&AU94UX-4MN;4IE960V4FYQ;&5W4C=9
M,W9#9D-&.&=8>FAF548Y;U@T0F9M2BLF(WA!.W=N.&IF-%(O-5E"2&=+:4)#
M;T9R9V,R0TU)2U-G=E-$5C1/-FA",D5G251J:%5E1G$T64]H;DM',31C-V@U
M*TE"26AP:4TV2DTT;5HF(WA!.VEF-DM:27)+:7I#3&QO=CAJ1T]->6\P>&I:
M:4XO-#5M:G,V4$YO*V5K06%18G!$5VM4*U)Q2DE2:VYQ4S0U3DYK-V%524I3
M2VQ04U8F(WA!.U@U6$IL:E-7;C5C2VPS5U@T2FA-;4QI6DI*;5%M9GEA84IR
M5FTP2V)R-7=C;DEM8SDU,6MN9$ME44HV=6YX,F9I-2\V;T=M9S)+1D@F(WA!
M.V]B86E*<4M7;W=A:F1Q4&UP1F%K>#95-'!A;6U'<6%,<'8R;F)Q9F=Q1DMO
M>$MK,W%A;7%(2W%0<7=+<F1A=G!R1GES,$LQ17)B:74F(WA!.TQA-FAR>&%V
M:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ<G)1;'1*>3%%-U=+=&=',F5B8G=T
M,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4F(WA!.W4V93A)8GEB=E)7.6HW-$MV
M;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$5TU057A&2$5Z<U9,>&-J1U)S
M8D1X,$A(=CAG.7E,>DHF(WA!.T]S;35Y:FI+=#AS,GDW8DU.8WDQ>E183G1C
M-#)Z<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14>'122C%-=E94=%A2,6Q8
M5S).9&,F(WA!.S$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW1C-)<F1%3C)7,VAZ
M96]T.' S-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K+T]7135G,VTF(WA!
M.VQU8V8U-FYO375I.#958G P3W!B-G58<F-/=C<W26)T164R8S=I:G5T3SE!
M-SAZ=U=01&PX6$QX+R]+33AX;GIP+U$P.4U,,5506&4F(WA!.SEM,S(K+V5+
M*T)N-'%0:S0K8V8V5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O+R\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44$F(WA!.T)G445"055%0F=51D)G:T="
M45E*0W=G1T)G9TQ$06]+0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&8F(WA!.TAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H
M55)&4F]F2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T)!040X07=%
M4D%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!448F(WA!
M.T%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!04%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34(F(WA!.T%G35)"04%&
M25))>%%614=%,D5I8UE%54UP1VA">%=X46E00E5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%4F(WA!.UI(5$0P=4E)2F]-2D-H9UIH
M2E)&4G%3,%9T3E9+0G)Y-"]013%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95@F(WA!.W W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#
M:S535FQP95EM6G%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1544F(WA!.T)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%
M>6]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%,F(WA!
M.TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<# K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<F(WA!.S%U8C)2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$F(WA!.T%!=T1!44%#15%-4D%$.$$Y
M2"]58G8X03,R9G9(.6-69#E2=2]W1&9:*SAF,7A6,S%'-R]!3CEN-W@O6$98
M9E5B=CA!,S)F=D@Y8U8F(WA!.V0Y4G4O=T1F6BLX9C%X5C,Q1S<O04XY;C=X
M+UA&6&MV+TMN4'IG83%31B]Z175E4W%I*V]T=7EV4E%1,WA#-#-,*V\Y4U)5
M55-N,F,F(WA!.U945%1F>3,O041E<VUK:&LX.$YF865G2#%31V5Y:D5W2U12
M>4M:8FA8.58K4TEY3G94-'5L2T%+;U)V>3(O4&$Q,'EE1%0O4'E35#@F(WA!
M.S)K=&9R3VYW<U%#6DA-5%131S1E:%HP2$EQ,T5,<T\R2W939$\P>E9O9%!T
M;W)X+W).-4A%:5A.>E)6.5-25D%D*TLX5DA*=#9!67$F(WA!.VE0<4XS+W9S
M+V50-C1Q-S9J9"\W-U S:BMU2W4K;S-F*RMZ.30O<FER=G%.,R]V<R]E4#8T
M<3<V:F0O-S=0,VHK=4MP<F%O>5<V2W<F(WA!.V]W1S1X5E9X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS2"]-<GIR<E!L>&)23DIG
M:6UU2G54<TQH5SE.;$(F(WA!.T$T:&Q);V5V-%IS3D1P235B36DV,U@V,#14
M141Q.#EG+U!(.'A,:&QI8E-,1S-*86IY1#%(2VIV4F95-TA-,&1M62LK5&E4
M-U9L5S$F(WA!.U!:0G(X63AR9G U;S-:0EHO5S)I5E-',FHU;%%'<"MV3DIM
M:G=%:G5D,6AL>'A"-S-J1&8X-4)E8S1*0DA*;W1N3W!R4U)8:VIR5V\F(WA!
M.T=X6G%C9'%J355:4S52>$)N;C56+VU,<6YM<S-S3W)14E<Q,T-Q4W=X44DT
M6#!Y4W)66FUK0DE02'8S>65/9#@R1315=V9Z6C4X+TTF(WA!.S9Y,7$Y1FQE
M1WAH17!(,4]E0THO5%5K:$],36AQ2U4K9EAV:WAK075W-DM7<WE2:U%B1S9D
M+VQL-7,O35!69DU32%=(92LP>5%01DDF(WA!.SAC2U)X46M+5U9M2V]V-U-C
M9'HS>#0K23=#9S-A8E54;DUC*T9N+VYN54Y3<V1!:VPP-$]*,F1537E#<&E4
M9&DU1D1T.%!(-F-:6%<F(WA!.WIV9$A#17-G17IS.'A(;F(X>%=Q;C96:G%E
M:$5%3F9O+V0U:"]V=3AF2C-V-4Q303,P+W)B4%4O2T8S<71X;V-:,4]+5DQY
M3FU2;6TF(WA!.UAG,&<K,')5;TYQ3G@K:DTR4$QD,$=Q:D%:0TE'-'-.,695
M+WI,;'9V53!Q.6AS<F1K56UX=31&85)72#(K0E5/>B\V<#1N36M#2%8F(WA!
M.W=Y4VY0:T<W.#-Y4UA#83EE+W!&1%5W,TM7+V]2:6Q+0F%+;UE'<#-R6#(W
M-41)23E%>$I:1C5J=612='1$=DIT3VAA92M736E#3DXF(WA!.S(U365024-J
M5DLQ-55P=E1$9VI%>D%K841K65EX37=*1V<X2&PX,V9N97)S2612;5='<%=*
M1S K2C5!3UA%5DII4$EG:6QA;75D0BLF(WA!.U0P<#=V.4XK,3)K=$QH=FU0
M>#A8<78U5S,O;D,V,&%995HT<&9R2W5R45AC<6E->6]Y,$DY3VEL94Q,6' K
M,71M;S=1:&EJ265'4E0F(WA!.V=A=4U!4G<P>E1-0GA867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&5T<K9B]09FMZ>3@Q=F%E631M
M;5-C96\F(WA!.T]-2UA#>$-P0W4V=%5I<%5G14MC>4U/3UHS:6%A8W!H9%-&
M<TPP+SAZ=GEH:C%A,VMS1VUM;F1I44DW1T--46M.56QM84].=C)E6'<F(WA!
M.VLO9FPU>%II1%HK,7!R1$AC4DAY1#$S53<K,3 O5')M*W5Z4S)T;VUK;#96
M2W%+:T%'9TI0441-2T5423!(3655>F5:+W=!<4PT970F(WA!.SE8*V]S47I.
M8G1P.$1-5#160U-#<#=(;#E/6"]!36Y3-V<W3"M4=%(P2#)H;FYK5%AD0C%F
M4TI(,%=!,C%V8E1'1C1M:FEH4$QI<C@F(WA!.V=K2DLP4$QR.#AQ>31$:DY&
M=S@K2U=/6$1,;6MF;50X,G9);6XV;&,V4G%K,3%(2F)N:3!S2W59,EEB349A
M2G$Q56=G,4%Z0VQQ-%(F(WA!.VM9;F\U3TAS,TYK:4I21WA6=DHS-6ME4W19
M,5DV4&]K=#%.25%X:FYM.50P,S1J;#A0<71Z,U5%-W%-;&HQ34IY-%%W>C9$
M3&EJ>%0F(WA!.T9":V9M4'I*6F%"6G!D6%-34V@R-&E+14LP;$%+<S-%;&1L
M2#1K6DQ.;4=/4$57=E,V85=A9D1'=FEW=50X>B]!0U)C5').-E=O;68F(WA!
M.VQ2541&0E4W0V\Y64PQ>D0O;%!&-75Y+VM$561E2#5V461,=F)E*S V,W9,
M979O>GAQ-FAJ5FA58G$R-2M*5'-D*W5B0TUR1G5O>5$F(WA!.TU*1THU:#4W
M-6<O3V8X=$QB5F)N4CE8=3=U,FYT6E!336E*3C9B:TYX3$DY=5<R0G(Q;V1S
M,E$W3'I'26M">D9S1'-M6&M8.# O22\F(WA!.VUB5EIT1CAV>C-%,#%V13@S
M<51Q-G%Y>'-I='A-<#4Q+V5$<6\W-5AN,$=41D1J;'EU;%I:<E=O9F\W4S=M
M.31--6A3;U92>4Y384$F(WA!.S!Q3FA7<#ES,5=R>DA(:6Q-8W='55):95,V
M;#5O+TU/935D>&\R;%-W9VXP8FTU33A4041C97%O;%AI,5!A:#=(<%A162LS
M-FE,,U F(WA!.W4O83)N0SE!+TPO5V11,5!2839I:U,S:U1F1TQ93C9.1'-!
M:DY7=$-P-RM'8E1S>E=(4$=6.40Y:&$U>'!K*V).9S=&6%EQ-T9867$F(WA!
M.S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7<O>FXK5W5J*UIB<&(V
M6C5)<G!5.4IX1U5#>4E+,$1C;&)F8V(K1S-U3#AE8W<F(WA!.T9.3U1#2D<R
M3&%0*U)M;%)80BMV<D\P24%#:$I99T0Q-45G4FQT.75H2# U66182FE.34AP
M1W!E6#E.,4A1,S!7-%9H679':U%#<V4F(WA!.V%I36=O47AQ87%60C-R-S5J
M=WE'375)8S-*9U1(8V1(;3$O*U(Q;4IK*W)3,T5K44A&:5I),$Y+;G!61"MZ
M="]N5$UR.#=,=6,S*U4F(WA!.THK5$]F2B]K=E-03$U%-'-)-49L=2M(,6AP
M2$1K*VYY-$0T5E)D=E504F-X.'5A52MB:EIC,'!M>7AN>DHK5$]H86AC,TXU
M03 O<5@F(WA!.TUH;&%&6&I61F1I4S-(:VIB8C=E1V$R96=H26LW:'IC6&%M
M5T513FI323AN9FQ2;W5I,W-7;WE2>D<Y9UEV0UAM4FQ5:T5#9VI34',F(WA!
M.V4U3U-X84M%1%ES;')Z.6]:36<T5%%$2SEE.'4R1W11>'!D8VQE1W!I:U%G
M16-Q5C9H:"MY3S)86F-56FEI,&%F55-X1S1S5B]W0U8F(WA!.V%W:3A.16,R
M-T=P:TYW=DPO9V91<&Q(-4M(;35P-UAY:U9S>F)4.5!T3E!T171,4U P;TDV
M;%EW>DU!5UES9#)*4%4U;%)I26EH>60F(WA!.V1K>5-N3&EL=5AM;71F:TPU
M8G5,:39U8E(W:VTU:T5V,6-Z;VE)=T9$=U!P33%$=#%*>F11-V)Z4D%&4E T
M.39/37!V-4HO2V919DPF(WA!.S$Q0G%0<%-.<4YU6&%'4G!1=U0Q16%.9T9J
M:FA7;D9Y4&E">6Y5.7%:8S!E13!)*U-M5G,X>E=S5TDS*W)E6&YU57)C5'=/
M,&YO.%DF(WA!.V\T-D9G96AQ:#)Q8S%V:6%A-C12>B]M:'IH;W-P1BM6.#!W
M.&YE8G1&.'IA9DIC-E1*3$Q"8E-E:3=42G=B;'A$9%!K,F)7944T.6DF(WA!
M.S1U6$9+0F]P.6M'=#)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8T-RMD2#5R96(O2T]U,E9N;T5%1$0V=5HF(WA!.S5L=DEM94MB
M;5=52W))>4U#<%AB-&AV-#5L66-);$=Y-&5F54=%=TAN;'0O>FMN*V%&+TYB
M9C9$65<X84YZ;E<R:&MD-4989FHK.6PF(WA!.V5G8G!T=C=J3&AP;V5B6$Q6
M4V92=78V,C%L-5EU9%=T-#,U:4%006I)47ET3%%)6%)Q16-3=TQ!.7$U9U94
M;C-T8GEH4'IG."MW.%DF(WA!.U=T-T-C055&>$I(2T=91'5W5U)&<C0P55II
M*TY).4$S:4U#3V)09GEZ.#%A<G)T:&1J5F9I=DQA4E<Y4E9#2G=L53!553=Q
M>4XY1DTF(WA!.WE):VU)2F%J5C=-2S@S+VUP*UE';#9X94IO.7!:5#)58W!I
M.4<X4U0Q27EH2VLQ:FMJ0D(R<G5D.#)-9$9C064Y,&@W54EY4VEE:%(F(WA!
M.S-K1#AY4$]U<RM:23=F5S=E,VES<FES8V-6<$=X0W1W3&-M67,W8DUO0C=B
M;G=Y1V)3:45,-G,Y4#)G8VU54C9&;% U;"M93F(P;E,F(WA!.S1&,%HO479,
M:&XT,TQ)<GAQ55A:1T1"=G1&<2M.1D]9,$DS8C!E:7=X;D]P8VYL:V8U;"]N
M1DEY4GE4-F9#9VM1>5-*1CA:44%C;$@F(WA!.TE-=31"4%0X35)I:S=8*U0X
M23,S93-E5G12=612.'8R5C-D27E83'!X;C5G2U=E36Q'96=#:6IL95%P-#5'
M46]U:GIW15IK1&LX43@F(WA!.S%F;D(K871H-6AV23E+=#=1865S=D9B92]J
M0WE2,&-554U(:3565V<S<6$Q.7,V:E0Y;&%A5TU'4DXQ,&144%5Z0DY-:B]+
M;GHY*UDF(WA!.V5T95EM:#AX:4<T<TQG5$I&.5%H<$1"26=$<5AK3E-".$1R
M47-F:4EZ13=3,$]$2&IU1S!H6$TW:TYM1$Y/570K5#)(3D$U<GE8.#(F(WA!
M.SE+.'<R5CDU8V)Y=%HS57E4,WI.<6AT-$=U47%C;S9--31Y96U.,C,R>4=(
M431$6FM04&U7,TIR<S1O4E!L>4-F9FQ";TUU:F%*97<F(WA!.U-78W1K6DQN
M;4DU;&139C-A:FM053,W6DA&;7E:0F54;C=Q8UA$;GDU0F54;C=Q6C5L<F$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%DF(WA!.W$W1EA9<3=&6%EQ-T9867%H
M9%$P>7<Q0TE26&M%8S9Q4U4Y4D9F:5-#0U8U0G%':'!H16E/4T1%2&UL*VLK
M5#E%,'$U3GA9=VE+43 F(WA!.TAW<$5M=W%!4&=25#-/17I*-6Q!:4)Y0V1:
M1FMK9#,U33!#-6Q%:'1K:4LW9U)X=V=D4S-D1#-.8VQX;G963TQE0DQE1DE9
M+W-)2TLF(WA!.T14640U05I&54IQ96AA8G%)2G59;$QK04=126AE9S-'-TLS
M5$1B030T;FU!,W!E:C)M;5)M3S)R=V)Q0T9(978W2W(T-$5X:4)Y0TTF(WA!
M.VUH:6UI84M61FMJ8U5D1T%)23EW8U=13DI9;FQV5&MV5&5X;5-/8VQI5U)U
M3E-X<3-19'HQ>%-:2'9454-G<#19;U%T-W P3C)T2%HF(WA!.S!0.$%.1S-%
M-U9P=5!N:$)+,'5S-TI,4TE2<$I)-FI996]X66HW.$)+;VI&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%DF(WA!.W$W1EA9<3=&6%EQ-T9867$X
M=2]-=C@P=&8X=&$T=&AO.6Q$9$-/15!/;'ER:FMZ-V=O-G5V454O-&)W>6UE
M46<P1S)'3W=X87@O4#<F(WA!.WID4&57-'5D3'1)3$U/<'4S:D5K:FU0:T]8
M2#DU<U-T85I$>%-Y.$E06'9.3W,S=6ME6')R55E!:W-I2W9P5E9G07IK2W!9
M5D]W<FTF(WA!.W<P=4E:36=I-B]6-6II>&U1-79)2"]04#AX27!':6)2.5!C
M9V9$2T1+065N>%5-9S8W:6TR8EDY;5DK*U@T*T1R0C)R2W5N,B]R96TF(WA!
M.R]L-35U,418.49E9E5O46PO1$IX;%='3C%3:DM'1D-X24Y#4T]V8DYD<F1/
M355G0GE,;F%(5DA,16LX=U='96-F>F4X,6%6<C$W8F$F(WA!.U99,C Y;$$S
M;VA,;%A%<7-N=W,S=W5O24PQ*VEN5$U%6DEG:U-A<VUU26U2,$1V2B]W0V-(
M;6I69DU6<&$V<EDR.7995'5)=4YS<G8F(WA!.TIZ:T)#5EEU=S)F:EA98E9X
M3U-*2456>#8T>6U",$Q-9D]V;D163DEE0TQ48F1(;EE&,U<T4G5,0W9&47!6
M;#A#9G5Z1C%E;VQJ030F(WA!.U):96PW4#!C37A01V%(:WA/2#@Q9D]5<DMJ
M5T9P1TLP9#%$:VHU1#%$;48K9GDO>E$W85A9=6Y(.&-J*U!C.54P-CA7.3 K
M,G9&0E8F(WA!.V)I2DI1<#9J;6].33-%5%ET-6UC1$=20C9):D-X9&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&DF(WA!
M.W)S5F1I<4(Q4%).3#%.5BMU,G---V]#235*66\U5U=V6&HV:71405EG.#!G
M:TE$4B]*,FIA5F-I-70T25)/=%%K:3(Y=D=Y9V=I9V$F(WA!.T].1T%O861C
M4D5D>3A25'@P4C!:2%5-:D%H;$EQ0T1S45%C24Y-4TQ30V9Y3F]%<S9Y<F)X
M4D)46# P=#=B:G-A.31I97589FU-;C@F(WA!.S0O3718-6)(+TYJ.&=N<T5-
M8T5+47AG3$A'07%+04%!0C!!0V=$2VE39'DR9T%#9VPK<2M89$LQ3W(S3G1#
M,'A8:C8W47=Y4%1W<DDF(WA!.VHW64=-<U5:1WE!6&%.-69S9$I6:&)+;UIX
M4C-72T=)=%1X.4I%>%=/3TUE44%29#=95V0W2#9D,41(36\S6#%%5C9%.7=(
M1$1!440F(WA!.WIB67I-9'=A4WDP.'!A8F)86751161L8FY'1$)B:F<S5W%L
M67=W4'9826I(16-G1UIZ-4-+36HX,#=Y8E4W1EA9<3=&6%EQ-T9867$F(WA!
M.S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<F(WA!.T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8F(WA!.UA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<6MT>&944GEU1$YX05DP
M<5%.9V-65V9P1U@O9B\F(WA!.T%/23A++W%X5D=A9F-44U1L6&-S3TI.1&ER
M96\V,V)71GI"8GEW6$UJ6$@R2&=G:VQ18C K2FM"0R]4:VA',$5Q1VTK6G)/
M+W5H8G@F(WA!.S)T-T5Z06Q:2C=394M-,$9A8S)8:5!P=VU&2T-J<C8O:G,Q
M5FYI;6PU:V=#1TYP0TME25AP;$TX;D0P4'=B8V5->C9G93@P;S(K=%<F(WA!
M.S X>5),0F-Q6$,P9#=E5E5"659O5TLP1U%J;4).569K5V-T3U%,=5!Z0TMU
M-W%/,70R;FM74FM3;%9I:F56.7E"<VM96GHQ-T1,:3 F(WA!.TI!4%!M;49'
M6F)(53(T<U4T:7=U3U)P,T$T.4XK*U$T=WDT53ES8C)+.71)-W%*2D53559#
M5%)V1$E+1VA$4GE"5T<T.$UK0WA+5F$F(WA!.VHU=S R=W5N='!B5R]K95!L
M>6%+>7585#126%IW;D9Q*TE.34)L5$E24D=L*UER5%5B;')E3S)V24A696%T
M8S)S.$--06%':G5O1F8F(WA!.UDP3TEL84-%5G%7<%$R15-3>7AY>4Q)-&I!
M:&IA46=K13%93%=I+T0Q>5E&<U-5=6@X,C9F3$MK671B.65B8T]B5U9Y1D<U
M1E-E1W<F(WA!.S)Y6$%F2F)4=DE*9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<GIF>C5O-F%H8W=S9$-/<W9$-FA5+U<F(WA!
M.U!Q-G%E86M+9'AY-4%(=#1E3TMS87,O3%4P56QU<6555U-(:UAK5G(W:W%.
M23-P3T-#85-5:2]Z,WA6-GAP9BLY2B\Q5"]$1E=0.$$F(WA!.VY(4R].;6]8
M6D=N86AC-E9$17EE;E!B5FQ$<49*26%&5C5(-&U)4'AJ<&QS1$5C,D)T2V1!
M.'4K9DQ,5UE,<3@Q9E5.5%--56MG;#0F(WA!.U)15415*WE81E-6,W(Y*U-L
M2TI(2D%"4E@U9W U=&YV;V8P63$Q85%,2%-/4S$U:VQY9"MF<&LU<61937!)
M-$Q(=60W,EI,04%F14$F(WA!.THX+S!-67-,4#AY6G)I3EAV3E)L-"]:4GI+
M:59R5E-Z,30W2&8T<WA-8V114TXU1VY:6G V25).0TEV-',T+TU-96$W:GEF
M2DAP340F(WA!.W!E>FU-6$-7>G0V.&%5-78V8G!3<#5+1DY!86=N3G1K=71N
M;#0P2E!'1&$O;F=784YB,UAF4V%N16U/-4)O96Q71D-#3SE-;SE8;CDF(WA!
M.W)D569*-V0K6&M0;6TR.'-W5S)U>&-B=49M5D=L;#E34C1M26179&AZ<%1K
M5C1N8U5Z27@S5S=43W(R95-E84Q8.#5F,#-F5%=C=7(F(WA!.U<S<51L>D1A
M0V57,V]D;#E-<5=79RMF441+1'A8,6)2=S!N+T%/5G1R*V%K9FU0-C-R4#$R
M-'-84C1B:S9I,&M9:D1$:W)2>'E%8VHF(WA!.WIJ07%G-DA*62M+,DTK1VUE
M96-B1'I.97!(8C9B8WE7<4935&0R<$M323%2*WI69S)W-S=D93E$;5I!9V,S
M2&QB14EF2W8U:')C,C<F(WA!.WDK6615=3 U9VE.545#1D-+:W9Y9712=#A,
M53ES=#0T.7=9,%AQ<T13=$1','%E;DM60FM11W9&:4YX565'67I9=GA6,DMU
M>%8R2W4F(WA!.WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A625HO
M-S94+U=0-CA65UEQ:DY,+S-P4#A!<6XK1TMT870U63 O5DQP3&TU;G8F(WA!
M.UDU150P=W1R9EAD<6Q!4W=*:F=L:E%T=C%)<CEW>%92<V9+1VXR9#-$9%(S
M=7!Y=D)89VLK;S-K,%IR6#=C8VMR2R]8.6](1E4R=F(F(WA!.TMZ=G)75S!V
M255U3%=:94TP17%H,&1F0FQ/>$=+;T12+TMF;&Y26FYN,&Y3<E=W;6Q8:$I*
M8GA*1WI,5W9%;%%.<6I&55IQ5VY186@F(WA!.V%087I03DA'-4(U,C P='9)
M0W!Q2U-1<VIJ-SA64UDK4G1-2VQ49C9T43!R+W55=G$W2U8O=T(O94(K;G9I
M<60R1FQ&6E=Q5S!4>7DF(WA!.TEN26@U-5I*-4-767-E56MR3S4S3S(K=S)'
M,DMP4&1E4W1-=6)M5S1A.3%73G!885(P:3%3+VIJ0EDQ259%;4-O=F=Q9T%D
M<U921VPF(WA!.RM73$A48G(V>D1C,SAS;D5P>'5B-C=U239%058Y3U=2,#5F
M1#EQ;&-64E=P-E)A-FHV2#%I4S14-G4T:U0V=F-45SE33WHK:39C,3(F(WA!
M.RMY,5)I<5=*-4DP=$%!=#=Q=D5.>6]D578R-W%A8GI(8C1F,2M/2W-G>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W4F(WA!.WA6,DMU>%8R
M2W!$4"]F4V8V>"]8:7%Z1E5:<&8K.4HO,50O1$9596)Y>D1&5%!'1UA:;$QR
M554X9"]B1%-R-%HT2C U=WE,2VQA8VLF(WA!.TE95BM9=U5R<%HT26%'5U)9
M=WAO=DYG=%0T0W5.2W13.'1(;#E*2C0R;%!334UP8F(R<EA$4W(U6EEO;S)K
M;&19-#%&5V1I06](=50F(WA!.VE!5'E61&Y69$Q!0DXU04%4>$(Y4DM%:G0Q
M-C5,=S5D>%=K54-#2V<Q2&E-9W%H*VM,1#%$1CE::3E1359+8S$U8VQ&5T9+
M.5%.>FLF(WA!.R]$;'IO;S1G=F=U<F$T1EE*:VQ!-FQ'1$19,#=92E))-6A1
M8F1.8S(X04)M;%-)2&]864Q88T1V.#A!:51Y6D%%<E5V<DHU4%13-&HF(WA!
M.V%3;DQG2%5N:C0P0C995$$Y>3A*5G-I:#)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9.+U!7;VTQ=F(F(WA!.V50.$%X175H
M0U%Y17$P2WDK;T%W<5%Z1#13359387<X=VQ,;4<T;C@S>#-6;F)U<EAI0S T
M07%Y:%%R3BMY0W=*<B]41E=E*U8Y8S F(WA!.W)66G!8,"LT5S5716-:0V=/
M>$\T1S1'2W-(,74T.'=Y-FLY-7!F;"]2-VTQ=49%:WAV-$A3-7%4.&171$%/
M;V)C:T$K*UI-87)C;'(F(WA!.TMF9FPQ96%Q<W0S8EAT;' Q=DEX0D-A5$AW
M:'%O<CAB;G%26#,O6&M-;SDV66Q%*V8W:E5:66QT8EA4<DLX=311:S!36#AB
M5%<U1&PF(WA!.VQA<DQW2T5C4G97;FIG>"LY6DU2,#8V.#!X87AA>C9J;VUG
M5VQ*=55R5SA,3F1&=U,S3DML+UDX9V9P<G1L<'%T:5=,3B]Z23AW2G F(WA!
M.UAK<2]V6DQ)6$5B27%#3S5J5U=(-'HQ;&HU5DMJ=SAC;C)F:#A434)D9F8X
M1S9)<W9N=B]!2E=4<7-C8E)F-$HX=%-3;%$P8F96;4LF(WA!.T9M2BM+:GE#
M;U!Z<FY39GEF4#A!,5-F*VU456YV4#5495DW;E8O2CA,5#99=&IC5W-S:T4P
M1G)'<TYS0U-*5DU+;'HX4'!Y<E@O2W(F(WA!.VY09' T4$1Z15AX5TPS,U!X
M4DE0269/;FYF5F]03G0X,FYE53E%=FM-:G%Z86IB05A+.&U+=4=0<7AH=S19
M,4\O=T%23V1"<&1'1&DF(WA!.VIE4UDR+VA/,S-/<GE:9E5F4T=39FLO-7(Q
M;6)Z4DQ&9658.4XP,C%V16MI:D]J5W=10C!54TPV>FAM,DAP=74O=T,Q5$U0
M=%A44D<F(WA!.TMX3U5I4#5X*S<W4&<R869)94QK0C=M4V9N0C5J97=I<V]5
M,&DP=G)I:E-)=7!1*W1&=5%T15I'<7 R,RMJ34AS>D%:,F5)>#EX<#,F(WA!
M.RMI=VU12G-J,U!.53@O83A:,#4K52],.&-H2C5U;'58;#<P0R]V1'8R>F%J
M4B\P-3$W+S)/5TY+4GIL2W9E*VM,0S=3.7-B93AJ5FLF(WA!.U,U:5-:56-C
M5T%D47=$03E$=G9N3%1J=WE)-VY44VI2258X:7AD:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G,F(WA!.U99+V-X>'1/-5I1>$1.46M6
M<%4W-'%P:4M)0V=244YT<41T,'A61V%01D9(8T52;W%!9VMH44%+:S%*,GA6
M0S-F;&)66C=M9650>DHF(WA!.V91*W$W4$A%24Y09$EG>')X6&YA<WA#:C12
M>5EM;G9V:F%P:F\R;#,Y9W-Q,U=Q5&%I<FM'2512,CA9:4$R-' V16-7,RMT
M6$96=70F(WA!.S9096%L-D%T.59U9$U%4F(Q0F)*8E V;DE!1&PY6FAN<'AP
M='AP,4YF6E9,-V)Y=')513!B+S1M=E=22$102#E8,#5E840Y:&ET<T0F(WA!
M.U-L96TK*TMP;G)E;#-7<%=I,CEV<44R;F9&5U(T56=K.5)#<%5X<W,X8W$X
M5%AW<FE$4W-C4#5A;R](;G)%=T-H06]3>#!L865M2TLF(WA!.V0W3G5N8G<W
M6F(K67EF>FHX>71S;C!U>'5B3S--3GAE>5AZ8W%P2DMK4V-60VA1:6E&27A4
M-&$W,4Y39#9507%623=R>6)Q5GIC4WHF(WA!.U U9W5A4U8O9"]69$]C3'5E
M1D=K=&YF-$%D<70Q.71S:TIY2$EO24-),')Y=G%7;C-34V8T9W9*-UI7-4Y:
M3D)94GA054554&\R,&(F(WA!.VIF9C171T-5:65A9TMN;41Y-W%'<7IO.$=S
M>C)%0TM0.4=J9W,U-'I)<$I%;BMK=WI%2#1Q8DA%4TDU36=33U-84F51<G5'
M4DI94$TF(WA!.T8Q0DMT4&II=$Y,53!(.'1,4&%V535)-5I(;5-K>FME6EI6
M0DA*2$)(2$I+6G!%54LX>D)16$E'-T5+1E56.6AK1TLO1EA9<3=&6%DF(WA!
M.W$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5H;B]V<% Y62]R
M>%9::7%-,'8O96LO-G O:&EQ831Q-T9867$W1EA%:%$F(WA!.U=9,$$S2E!1
M1$960T<O<UIQ*VIC>%-5-CA(5G5T2V1$-VI*1T5H>D-Q*U)65&$U=#%K.4YP
M55=4*U%S069U>5!%3U9S:$$Q9$MG25 F(WA!.U$Q<#%Y5$9O>4E$>$Q!365X
M3RLU<&EI,FUL:54P6C%",S)*2%E64#19<EE867!D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U8F(WA!.V1I<G-69&ER<U9D:7)&9%@Q<E-.3FY),4,X
M:'1427I&0DY)<6-G1'94:U(T-'%O5R]M2%%R:6%/1T,O=#5:6FE6:5)*1EES
M479-9U4F(WA!.U X=2M+<#-P;BLY2B]W0E4O=T%-5EE0-6DX,6533DTQ6FAF
M5S)R4$IE9G9%;71:2C)G8T]39F<T>7%+.61L2#AC>4EX:U(P87E1;E@F(WA!
M.VM$>DHU9'9O-VU,5$QA*W-9,5!,:'%44'E9:G5I>5-3,$)R,C8O4FM-:U-/
M8DM*0THX-S9T;TU&:W-U;WA8;'I&86M3<W1G,&EY<4<F(WA!.TI535%J>&MI
M<2]29WAG.49K5TMA5#4T.&E83W,R,&QJ638P6C5:3V$S56IZ<F)R=5=O>$UX
M47%F-6%%2'!L<&A+=6I(:410=DY(;5 F(WA!.U-.13!+-S%(54-*8F%*1'IG
M5FLU4V-T=4%$<W%M=G5E;5(P,D=74UEJ2&TR9U!N=51Z:"M3>4Y.3WIA=D5X
M2'%',$]M-F)X0DI)15DF(WA!.U8T4W150F]+;C9C-DQH,5A+;R\V868V,30S
M=F9K8GI8;TAM4'DQ86%L;WEF5F)$-&])<DYW:V)W:49V5$-&15IL6#110V]"
M*WE2;E F(WA!.S9V0E!&:TU:-WDU,S,R9W90+TXO-6UE454Q<31I=G)E.4QX
M3C91=7)31S!M:FPY3V\U0C5$6"MY;6%(4%!&2UIU-TAU9#EO.4YQ0FHF(WA!
M.T)J5DAV2D-D+VQZ*UE8;$A6=%-M,'9364HT2DA1>2MV9%(R.$IC>&=$,'=)
M1'8X0416+W9Y-U-:361M368P9F]C8G1$5%I99U-M4C<F(WA!.V=39G942#AX
M+TU8;'93<D9$<4YS,3-*8T0P>6)D67!:-#0Q26)M16MQ1%)U>'I.:T%D:C%E
M93%C-$-H26)L-35:9FU.*U<V4W$X3FHF(WA!.W%..4DU0VE#-G1B0EEZ555&
M6%5C;$90-6-4:$529'5(94M/*S4Y+T,Y=C!T-THY3G1:3$964WIK:5(W9%5!
M0VA'2$IA0F1U:'E63S(F(WA!.VA80TLU26Y&:S=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867%X9E9.2C!U*W5E5C=A43-,4D]415I9
M,6-Q83$F(WA!.S(U031Q:&)F>3=O3G1-:S%V<#EV1$Q'86\X8V%Q46%5<G-0
M1$95.#!V+V5K+W=#<68T67%K175I*UEB96$T:G-D0W-$6D)I<TDO4TTF(WA!
M.W-B4V]$.$132V).*TIP+VQM:#)"-S5,:DM/1DY03$]L6&-%,7A09C9B1EIZ
M;'8S8W-D-4ID;5%%54Q-2&EH0TAB<T1I6D5Q03=Z3G F(WA!.V5O5#-&=F,V
M8G!T<F581D-K<S%Z9%-7<E)H5'E4:'=G=6$W;'0Y:5!F<VE20VM*4VUJ*UDU
M8FU!,U=G5V9!4V9V2$=Q>E551V=A4E8F(WA!.U<P5&LQ3S(S5#-X-'EV0WE0
M>D(U6C!F6'1';3!F55E3,6Q-04-Q16]14C!+:V1X;&U$4$Q&3&EJ>EI!,'=S
M+VM(-4M01#DO9CAK0T0F(WA!.VXV,&1313AF,V1.*R]W0T9-,E@X=#4K-E!Y
M+V%Y-'EZ5%%F3$=I841:=%HV6&%R0D,W*W)*56QI.&Y&535S5THS-'AR;71Z
M-FEE5U@F(WA!.T9-,E=*3G9/=%@O2W%E.3%'6C0Y16=J:&QK.5%S;7%V1V=O
M>F9:4G)+6FAY5VA0>&5W;TTQ,#E$:FMB<'I99&\U66ER5%1Y4BM8,S8F(WA!
M.T@Q2TLT=3E$9VIK:C5.1F9F<$(W=#0R2W-P2'!M,G16,T1E*U1X85=%1%E'
M-UAM,75424MK9&LS.#DK5UIT6BMP:413;V(T46@K56HF(WA!.UAB5V-K6DI8
M:49P1$]R2S(O2W4T-UID2TE03C$R8E1X>695>$M(.')R>4,V16@P0S)N:494
M=V96-4%$53%!64Q9<#AT;3)Y4&A284(F(WA!.S)F:C@S<4]K,FMD;G!L<F)2
M,C8R:5)226]T:UEU<UI!,U5/849Q2#ER=C%Y>'I)>$52435)<D9K-T9867$W
M1EA9<3=&6%EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<3=&6%EQ:TTO.3E*
M+W)(.65+<DU64FUL+S<P;B]64#A-5E181EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T8F(WA!.UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1E5H;B]V<% Y62]R>%9::7%-,'8O96LO-G O:&EQ6%@F(WA!
M.V9M3%9O8BMA,U9T2D-":4E"3&5M3U5J:U9(2D]"<#E&8W-%4EA6:F%..'5A
M,4YQ56-W;FUS2EIO:5 X06IN,U Q:%%$+U!65C1K9E0F(WA!.V=N1VMG<75T
M-C%&<"]P24QM,&AN:W%E3C5.-DDT04AC1V@W-6I:<VY$>7(T;6Y*=UEE3SEP
M140K84Q3*S,X,6\Q,45K=#5P4FAK64PF(WA!.U-+.#5Y8FUL46]7:#,Y+W!Y
M<4]C:V=%>#,X,C97:SE*244Y=C9/>61A<F5R639D8UA:94M-46]71'IT=VI"
M-V-M05!F36]U=7E3-%DF(WA!.VMS6E!N9&I!<G)F-D5'<'EK6G122$5!9U5/
M>61Y5"]81'=4-VY(.&569G=F-EIK96DV;$AQ5VUX6&E345,X-FAN=%I05VEQ
M<D5(:3DF(WA!.T5R,#A-06-J2%!I:F8S2DIE*V-O-V953&DQ5S@P;&919F=Y
M6$8V25I64&=52VXY97@R,W!I0DDX9S!3>FUY0G<O3D4K6"]-<39L97HF(WA!
M.U=B,U=M>GI2;UI!;&AD9E=(0VAG<#5R>$90=$1V.4=.14AD;FEY;5)O.%!W
M2V8T5SDR2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DLF(WA!.W5X5C)+=7A6
M,DMU>%8R2W5X5C)+<TLX>6581C%E-5)M=C=Y>D5,3E9B4UEX0G=7<5$Q069$
M1E5(<%AL2#9H4$9+,G)8.3))<$=L-%@F(WA!.T4S34U3:%%"=&AS=&$P>%9L
M96UB,T)(*U-F-%EQ.#,Q>GDY-5)U<C9C871B6%8S9%%69VQV9C!B<5%&55EJ
M<F)W0DIL2DYA.&TX46$F(WA!.UIC37A(2FAW36DO3'I1=$5T<$QP=$U6<F5.
M5'AM=&AB6&1Q<$Q!9$=U0D@V9RM(<49Y33AN16M2<'9Z-S5,9E542F8K;W)7
M:TU237,F(WA!.TQ,2S=Q14<U:5=&2EI'4%A:4EA.9'%T2V-P-74S-U W4D=N
M0C(S-S)*95=V26-6-W%4=W=43D,X04Q3>DYB6#!62R]$.$)U65E9,TXF(WA!
M.V9"<3DX>#AF6G9#8G5N3WHY=6E9<6E2-3 Y13@U-DI*9BM6<FTR3C--<VMA
M3$DX:4I*2U@Y4&-J,%E1>DY5:71&53<Y<S):1FEN;'0F(WA!.U1I.%-*03)E
M1D@X=#=+4S16:VM.6DMB0W<Q:%%+;FEX+W="-'=&;T)896U!8V8X04]D9BM3
M>3DT+TAW93(O;#,U9513=DQY>%(S<S F(WA!.SA->FU73DAH:W1J2'-&6E!4
M;$-Y1#1K4#)L2'EY55)18S=4651J:E).=DMV3U U9'=383-E:31U<$HU:$HV
M;G)V639K-TU(;U<K3T,F(WA!.S)L4B]T9G-S9#8Y3CAJ56=44F-+5VAY5V%)
M6D0K5E!K;4A49&)3.6AV2EEP23!D;G0O<60W0VMS5$%P4G!,<4M#;$1X8FE+
M;F]C244F(WA!.W)S;'0P*VMN1UA&279936LW0C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<$10+V939C9X+U@F(WA!
M.VEQ>D956G!F*SE*+S%4+T1&53%X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F(WA!.S)+=7A6,DMU
M>%8R2W5X5DE:+S<V5"]74#8X5E=9<6I.3"\S<% K<68T67%P>BMA<D='-6QT
M,G1B,'9#4T=:3%-::V%H<#A$2W!$5E F(WA!.U-M5$5#:3!8<$]R=V%N13AK
M54YX0G=)0E,U9VMG8F9O4GI!<5!L9VQ';$)63"]527)*1F533U=136%!47AT
M25(X=V\R>4)L5$E#,4<F(WA!.U!7-V%3-45!9W514S-$,41B>6A!83 S8FI3
M;G8P=V-A.$M-=5IX0D)*355E45)G<U5J57,U<"]+;S9N2D9J23!,4V=E8F)%
M>$-15V0F(WA!.RME4DMH4F%41G1Q9&=V.$%L6D1J85!Z27)L3#5&3G)3-6IU
M<F1*-#%D16-60WEO,&)I:'!U:FA71U-"8F]Y<U=L=#,U;7-R5S5N=#4F(WA!
M.TQA.%IR9FE794\Q;61'-55(=TUQ:TXQ-V9W>7=12E1A23!R5W)F56A*-E5&
M>D$P9$]3,U9V3$%31S9&5$EO0BMG-$I2<%%59FM5=7@F(WA!.U8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9H6&U196%Z
M8V].1&%Z5D-Z0S1.,DI#4CA7>%AH-$,F(WA!.W5+<&9P+SA!>7-,-C5B+W!!
M-F0Y535N-C!)4DQY-%4R-$5N-U9F2$976#9:6#9W861E2G K1TMS2S%B>7 U
M=C%#.2MS>#9Z9C983U8F(WA!.TA/,7-P,DU,3W95.&$X5DI!.2]F3'A/239.
M9$9.+TDO;#=8=$QM=4)E6'0Y9%)3-R]73#9:2EI4.$EP.%!X.%(W2"MZ235*
M07!I0W@F(WA!.R]W1$UF4R]/,7AR9W5.364W5T=/4#!R5V5X6BMA:FIZ9%I&
M:3-5;&HT0V]#.6-O>4-2<FAB24=J=4Q9-7!7:F9M9$YF5S W=G%.>DHF(WA!
M.V%/3&E'3R]K:T583D-'2#DX-G%F9F9P:UEW;41U9'9F*W!S;$UD03E-+TU/
M>CAW,VYL;5<P,'EK:S@W2TIO-'9G:SE.45A0<'-7-C@F(WA!.VQ'=T9C;$\V
M,F-$5U)M659&-#8S;&HX,W!'93-E+S%X<F0Y=4QZ>E5#:U8K26QQ8D1R:#A7
M6#@P3T)E9FQ2*S$W5#5&<V9-3FPU8W0F(WA!.S=45FEI,T5$3W$W*W%X:DQC
M;#5-1W!T57)19&=-63-7-W-D3$=564%3-7-D.'AE5V9.=7 S+W)W-G9E859)
M3U-.2%EZ3C95;GA&;%HF(WA!.V\K431-5C)"<64Q9D$U15IX2%)T24M/.&ME
M6%!-3VLV;$Y,93-T.69X4VII.'5O5'$W0V]R5TY15W X4VIR,BM70V-G47-1
M5V-:4WHF(WA!.V1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<5%Z+S,P;BMS9C$T<7-X5D=A6"]V4V8X0590.$$F(WA!
M.T1&55!C*U%V2DXQ4%!08V%$65-Z,TQM4S1L83)I3'4W2&MZ33-'<$IB8RLK
M2V\S4V9,,FAA4#8S-DMS24Q,-G=1,"]O27%C,D9A1G$F(WA!.V14=FEQ1W9V
M2F9L2R]U>F58=6HR;'AD<R]Q1V531D=C=E)6-59)-C!29"]B1E5.3"M84&M+
M5U%34V58-T(R0W%I9S(X6D%696=#,&\F(WA!.T]V8D959'%(;&)Y,W%.;&)7
M3CEP;')C,E9M071P8E-223!C459E24-+4E)11C(R>%9!=BM86&M.=U$O;"MW
M87)M56LR.%I03FI5;70F(WA!.TLW,'A6371).'9A1F]Y=75K-F9B,DMY:%))
M3&5.62M157-60C1G8D%U>$AZ4&II<4AU+THS;$\W=34W>38P97IM=3=O8V)I
M-&5#3G F(WA!.TA&3TY'8VIK87)S8U98-E(U5#AS-DY/."MK-EAB5TTP:3A(
M:W0T;&I:;')7:$MG8F)9<6UU2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7@F(WA!
M.U8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A625HO=T,K:R\Q:BMV1E9M2V]Z
M4R\X065K+S9P+VAI<6$T<3=&6%EQ-T9867$W1EA9<3<F(WA!.T9867$W1EA9
M<3=&6%EQ-T9867%K,VY+>#%7*SAS,SEN<%A(-CE/9U--35%!45=(3F%N6593
M;WI(,55*4WAK4C5L36%V9#@K4V9L3BLF(WA!.V)93%)16&5R<&%33'@K<DQF
M9TE&2DAW54UT3TY25V@K;DY:2#AY04)W;T]'0E!-=F%V>7,X=F599DPO;# V
M9'),2WI*2GEG4%!N248F(WA!.TMG34I#2W)7<3$R4&,U;C9,2$]%86XS<$YD
M1UI:;4ED:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6658U:SAW='!.>6E,<'0U
M9FUD;4$F(WA!.TYP1TI!<$1505EK:6QA-'%G.4TX,FTO;FEJ+U)';U<V>7E'
M37901'A#14QY1%!U84MA8DA&5U8V66%80E K4V8T67$X-3$S>D9/3E<F(WA!
M.VYU8DAY.61A<&)805(R=31.4FUT;%AL,5(T>CA-9E$O1E=N,S5K>&IT>BMX
M<DI:0BM8;7$S6FQU-U<U,'%45$I#45DW3C=X-W@O:$8F(WA!.V%K>79X5W9,
M<T)8.55-;RM+66QI6#5T96)R5W@X,5<W9F]I9E5:3E!H075);S<V-7-N1$U$
M279%=W-9;4%$<5161W)7;3%$;59P;VXF(WA!.V<U,69K0S U3713<&EE;&9M
M1EEZ87A9=BMG-WI48E964T,Y=6TQ9E5,:&AB<GA1.$574TI24DYW0T1V-S5D
M2T)O-V<O-6]994YU.7@F(WA!.S@X82](<#-L<31N:FI-<W,Q26]&65-):DTQ
M5S-:4VI!8U9*,D]91VUG6E1&3')S=VAI2E!86C0K,S5R,V]I:W1F.$E806Y5
M8E8Q4V0F(WA!.S U-V(P5D9*0C=!3FUF=UI,-F8V54]Q.&)$=SEF.4Y*-C<U
M0S$R3%4O3#985$I);'@V<DIC>$@Q<%%J<E%+03!H:U Y,W=0,G9(34@F(WA!
M.U5X35HP9C%/,#!'451X,E!J=50Y-T9V32]M3V505TI:=$XP2S0Q84M1;S@P
M,$XY3&%M3C17-&=.1E0T4CA!,S)'*R]F1T5D='I4:VLF(WA!.W!H*U@R=%A5
M=7%81G9E85<K:FU69C-6=DQF4UAJ37=53G-'67%T14A:4C1936<R-3)M2F5G
M6E%Z9&ER<U9D:7)S5F1I<G-69&ER<U8F(WA!.V1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7%25$LS<E-B2#=2+UAI<7II,V=C5E)E;4%I-4Y2*WEF-%EQ
M;'1Z;VYM,#--<VQR96$F(WA!.U-K260O<6MC;6YZ1FMJ63%#=38S84)J5')2
M4E4W*S)'>71)+WDO<&5P5U!R+UAV<4(U=%=(-FAB4&)52&8Q3V-S,TTW1&9B
M16ML85$F(WA!.U!M<GEI*W1854TX86%E9E189S5V3%=36C)5,41!4$A.05)S
M9FAR6&ED+VQ+3U-595)94WAX4$U*2G O-6(V:EEZ*W!#;6=%5D$K3%0F(WA!
M.TQL>GA"+UHY4SEC2U(R<&A/85HV;T=+4&-Z6%=,13,R;7HR<6E%>5-+4D5B
M:5 Q67<O6FU136A.4%IH:TEY24YH;$]%6D-P0W=W<R\F(WA!.VPY<EIL1#AT
M0W%!;TI/;EA24'=G0W10<F](6&9**TY0*V-F;30O-4Q$+TY$3#E#<V(V>7,R
M:'9$6C@K9DI&<TQD<F%)2U9!,U)P2G$F(WA!.W1Y0DYA:F)B=%5W2DHU=5)'
M26E+06]*8F8V3C5N:W5*<$Q/-S!Y3U Q03EQ:S%J3$EY<658<4(R4S5J-4TQ
M4CA103<Q2&9',E9):E(F(WA!.TY*,6DP=G!:8G@Y3V%",6%G<S=/4T-9>48V
M:&UK965A;S0W16-E=3E2,'A*2S!N94)867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%DF(WA!.W$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$F(WA!
M.S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6&Y0;DQZ<&%A4G%X
M6C=J5U=H:T9&+U)S9'9.8F\V;FAX8FU/871Y2%0S>2LF(WA!.T5,2%)G4VEV
M26YM=$Y2=C4T4V1915A!8U P=DA$2%9V.&=2;T=R="]..4=$2D=H,"M#>$MC
M96,Y6FAS.4M:;&UV27!5+V4X3$95*W,F(WA!.W5Q+T-1:7I$:2\R<6M:2$=,
M2UI&9W1P*UES3C%C=V96;CAZ37=C251,8C)Q46<Y1#9R8UA(5W1F1$QJ:B]Q
M<V5*-G!*<61J2&)'-&4F(WA!.UI!:7)Y3E=59E(Q.3AW32M966]'6C521&%"
M6EE29CA!-6XR14]P4U%M>3%H6EE4=TU6=F)X4WAV4G9T;U-X3$MF-7,P63=6
M:$]P.%4F(WA!.V\W8W946#)T,T)7,5=Y<E%036QT<2MN:3=A2C=%<V%#0S1+
M<DE"44=P1F9F3G!O=&)(54%K9G=M;7%585DY-6\O3513-T,Y87EC,V$F(WA!
M.WAW=7!&,UEI2U%--$AX4FXQ1'AO2S K64]2,5=R:D$X2C1V:%1T9$0R8E!,
M2&E(1#=P6#@Y;'9L<CAY=$MV<BM$5%4K='5*>6$S;#8F(WA!.TEO<4UW*T)!
M<V5X<5)4-6Y"<'1:1U(T4GA(>DY-=%HR5FMX>$UZ=VEU:V)0,W!Z-74X-C9B
M-6$P.4QY6E=U,F0K0S(P1$M:0V]"3',F(WA!.T%4=GA!*RMG>E!*<#4O4&Y'
M34,K<GHK,B]05'EZ0F-44WAN5V)X;EIU1G)01F%R14,U1E!I5G510R\U:DIE
M2%<Y=4U.4TDR8FMF:SDF(WA!.U!S=&9S8G)Y+TAR:6YJ85-19E='1E%3=$9Q
M>4=M,TI45F9N9VE,<75R;&I,17<T*VQ7.# Q1#@K+TQI6#!D=F,R=7(R9'A!
M>C@T-V4F(WA!.TM#4T=116Q64$HS5FU',C-W:DTP86558D)!4'IC1#@W1UE%
M9UI2.3%-,3AI*V8X050O3CEV8U17='1,865G45)&3U8U;$=,2T=)56TF(WA!
M.VTV2'@K95DK6$-95F96>3E0<5)L2D$V2S-N8E=99$TP,%1'5S96-%=%>E)7
M2'!T8T]G*T5G2DI13717<61X,'=9-#)7*U)94&%F;4XF(WA!.T)D6&QS3%DK
M6D-F54ER3$)A<$(X5$5K4TYX9C=0,F9A;G1L<'@K-6IX4%5:.5-T25E';F0V
M47%/4FMO,T=N*W13;5DY3FIY>34X+U$F(WA!.U=6-6-737,S;65A85!L1GEH
M9W1*1F%J2T]C5$)F:4<S,G%D.'E/0SDO4S$X6'9:,35,,3)0561%:FYK:W5!
M,TEH4G%(<$QC8V%$:GDF(WA!.T5A;U!W<FQ/4TY&;$5O3'I:*UE';39/-G=.
M0F54<31A;'I:3$<V:&LV<5-Z1#E7879,<DE3:V-9:UEK9%)4;%)W>4%%<5<K
M5W9Z2# F(WA!.VY68G!B25%8<TQ%1FAD6&MC8V-:.753=%-V8G!H>&%Y04U9
M8UA%5#$R+U%I5T=613%62G(U;#@R5T]I5V%80E4S5$\O17=W<W!K0VHF(WA!
M.S=B060K4&AM5FYZ1$A'>7HP;6Q/869#1%AV-4U.<R]Z5C!E1U-S8C9P9'-F
M:%='-&IT,6HU361I6%-R9T0V8S$P3S!)03@U;C5/-7DF(WA!.V1I-4-/5T]0
M=4UM9C)M=6%D8V%81G%2;5-/0U-%5'1Y9&9G6&I69S%$*WIU1&TQ:DMX8GHR
M5U!H:V<O=W9-9%,O4$AY-TI/<V-W,6HF(WA!.U1P67E62S(P5G9):D1E:E9K
M2G)88CEN8G0S3U-J2&E&9S V=S9U37AD>4AU<&UF:V8X=W1+.#-F5VA:=WDR
M>E<S16A,:F=*2%)I5C4F(WA!.V-63%5O5C,K67@V,#5/2%5$25-",%-N>G8K
M8FUH*UA,=30P*S=T-S$P0V-$93)#>%-&2E13<3!D;$%P>38Q-F=I;3):3U!"
M2VA,;S F(WA!.UID8DAI3U!E*SA59R]+9C4P84AQ,F\R5VM7.79Q1"MV4E=V
M<CE966E#-31O2U)L9S-X55@K=4A*9VMB;%%$2$9R26=I1FLS=%IR.40F(WA!
M.S!Z358R3'-69&ER<U99<F4V6G)3-FID4&%A3%EY5S-X3D9/8C972U=5=4-7
M5U)"8D]Q9W546#1Z,DE'4S1I:6Q4>3EP;7!*<414-FHF(WA!.V\Q=%IC52]C
M>G<S,'0R,65N04DX34-O=$=.2UEM4E=K9#5J<W(R9$QE4W@P*S$Q0S12*TQ,
M9'IV8G%K8E5*6E=32V5P<7$W8V-!2D,F(WA!.S!K56UM95IP5U54*UAR2U%!
M<'I987104F=/<%EF5E8U;&%F1'DO1$1X1F%:5F5786Y3-6)71S-J;'!%5FAT
M<$=+4G-W2'=+>FA86E(F(WA!.U=N>$)34C%P;%=82$A*17AK3$)31%1&,'-0
M3E!(9U!,.6I%1W%31C%754MP-#=&94YM0W!A<%4P2#,U<5 U03 S8V9M,BM.
M2E O3#$F(WA!.V<Q<%DP:W-9<D-D:5$P34UZ,TLX5DHT2#%(4TTQ24YA53)Z
M639F4UES3CA!<3)%<$4X,DYE6G9*,3%D-FI04%DV6D9,2$M+<R]W0F4F(WA!
M.TYU6&1U5$UZ26)7-$$K3'=B=E=L97!Y86%%:EIC=D1R.'5-541S1E!Y-35.
M=F)E+VEF561'=#!H1$(O5T=O=F-.1U5"2S!J1G!B:&HF(WA!.WI#-T9Q52LT
M<TY,0TIU;'DY;UI::6E5-S@W*UA2<E=L<$9(67A8,7I%.5EH3&-.849!9G1-
M<VEX6$<K=S)+57DX9TAM-GI.9VIK1E,F(WA!.UE/;C586&=F,7HU9G0R8FU7
M84)T66LT:V)5,T9H6'AR*W9)949(=6-F*U0X9FTY1W,Y03 R1%)6,#EB0T=+
M27AS2'1667-G85-P9%(F(WA!.TM12$DU369I<%@R>3)*<FLU47A2-&5'=E,X
M.&XO3&962FU,2%%R94YW>#1C3EAF9T$Y86XT<D%T.$\Q0E0U-S5K+VY-;F4T
M4#AL668F(WA!.U U<S(X;RM7-V93;UI*1S V2WAV1W)'5VIU1W5I,%%.5G$W
M4G<X9F11=F)Q8W!Y6G!4*V]U5F<P=5!&.4E24&U$5#=M-64R93(P*S(F(WA!
M.W981&-*5W5:,V=-8V)%5EI/154S2G9B8C4U045H=DE32U13=DUK,W K=C5E
M<TI#:$I*3W$S1D-654)786QO0S%E;2]Z.7-01U9O370F(WA!.W5,4THW0U,P
M5TI8:CE->'!#>$MQ44)12U-+:T0S=U=L:5HP-WI5:6Q9+TPR;F-',S1*<6LV
M0E=O45-0.40K13<W1F5V96U(:4M+5#,F(WA!.WEZ<#@Q;EIU2CE09S V6FU!
M.4LS=4AU9U9!0D)A4U-/13$U1FA3;E1E=3E!1$EL44M3<E8Y4#A!341A:$\Y
M;F]T<%!!>#52>DA56DDF(WA!.T=C;6Q3.&8Q5U5+9792:C(K:EA:=7DX3U-2
M:U)U6$EJ<5IX1DLR:6%4<4)U;&963DMT-UE2:C%)<$ER,E,U26M"1D)W84,S
M2%0Y<78F(WA!.U=U,V9(1C)89VA)4T$S2&UM5W!M4E9Q+VY(4DID53 Y0F)7
M:V0S9'A.*S=%;'<Q<GA6<49I<FE+-49F:$=X5#92;5IK>%)M2TM-1V\F(WA!
M.VYI3GA9:$@U1S%T2GI**V<W9#%$8V=J-G-W1$-V46AB054K+S9C<$=J>'55
M93%->$971V8R5VLR8U=J<G!R5WE25S=X36LY<7)T26<F(WA!.SE52#%&1'-&
M6FA6:G5137E9>$%&0C$K5U)Y16U7.79.2E!Y=79*6$IF46)E3W)N:C9E<GE&
M5E9U<$A+>#5F1#%!-SEZ:U!#:31"-U F(WA!.W@K8DPO2FYK*S P;4]74V)3
M64Q+-E W<U-*8W9E1C0Y;4Y794M$:CA1-TQV4W!Y66E">6(X5VYH:C5$9$QV
M3F9K9#E1,4-A93 P:4,F(WA!.U9*1D%A45AZ5W!9;%15=$@Y5W5&1D-!3FTW
M:S!R;5)$57II2T(R86,S6BM,2DQI23-54$Q0:T=3,79O,C%$47):24$T:SE8
M.4EY6$PF(WA!.U)L0E9/368Q5S-6=FI58D9Q54I0<U=7<&Y)551S:D@R9&EG
M8G%Y.41Y:'IN+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X
M;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S
M/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HV-44V,SDP-C@V0T8Q,41"
M039%,D0X.#=#14%#0C0P-SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F)F-6%F8F0R+3<R
M8C,M-#-A-"UB,C5C+3)C,#!B83(Y,3@U93PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB9C5A9F)D,BTW
M,F(S+30S830M8C(U8RTR8S P8F$R.3$X-64\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI
M:60Z.#DR,C)C93,M-S(Q-"TT,#AC+3EF.#8M,F5F83(U-S0V,C5C/"]S=%)E
M9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX
M;7 N9&ED.C@Y,C(R8V4S+3<R,30M-# X8RTY9C@V+3)E9F$R-3<T-C(U8SPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C8U138S.3 V.#9#1C$Q1$)!-D4R1#@X-T-%04-"
M-# W/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z.3(S9# S,3 M,&0X.2TT-&,U+6$T8C M9#<X835A-#(S,V9E/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#$Y+3 U+3(P5#$Q.C0S.C0W+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#0R R,RXP("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IB9C5A9F)D,BTW,F(S+30S830M8C(U8RTR8S P8F$R.3$X-64\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C(M,#,M,#14,#DZ,#0Z,3,M,#4Z,# \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R(#(V+C @*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/&EL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E=E8CPO:6QL=7-T<F%T;W(Z4W1A
M<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B
M5&]O;#Y!25)O8FEN/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#X*(" @
M(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q-BXP,SPO
M<&1F.E!R;V1U8V5R/@H@(" @(" @(" \<&1F>#I#<F5A=&]R5F5R<VEO;CXR
M,2XP+C \+W!D9G@Z0W)E871O<E9E<G-I;VX^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_X@Q824-#7U!23T9)
M3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P
M35-&5     !)14,@<U)'0@                  ]M8  0    #3+4A0("
M
M !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "
M!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD
M   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L
M=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/
M" QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H
M8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2
M<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N
M,0
M        6%E:(        /-1  $    !%LQ865H@
M %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                  !D97-C
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(                             9&5S8P
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$                                  '9I97<
M     !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M    5Q_G;65A<P         !                         H\    "<VEG
M(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W
M #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0
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M>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>
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M.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N
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MPV2$Y$75Y>*%)^.UQ49V*/_:  P# 0 "$0,1 #\ ]_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MII$4FL1I%:3VTM.NMI[>[@X7J/4<^SSQBQ12:S2)XQ/?,=DQW.!7_&TZJO\
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M_I@=/O\ V5W'_P!*YV__ %?=&_E=U^ZI_BW%_P!>;O\ 1Q_-;^^/^-IU5?\
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MF8_'J[<^FCKJZ>^J9J6_ <FGLV:QP.J*K;O,H:>RY:V&)J.FJ;=#'5UELO\
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ML\4VG%CR6K$SIKI$Z<=(B-?DAV/;9+9MO3+;3Q6K$SIR;S&@O
M
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MYZ>H@D9-!/!,Q)(IH98U='+%+&Y'-<U51R+JAY+,3$Z3PF'9XG7C')5(
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M^CC^:W]\?\;3JJ_],#I]_P"RNX_^E<?ZONC?RNZ_=4_Q9_7F[_1Q_-;^^/\
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MWB..O=,]DQW.F?\ XVG55_Z8'3[_ -E=Q_\ 2N=]_P!7W1OY7=?NJ?XMPO\
M7F[_ $<?S6_OF>[5_.,ZFLYW0VWPJ[8+L33VK,,]P_%KG46[&=P(KA!;\@R&
MW6FMFH9:G<^KIHJR*FJW.B=)%*QKT17,<FJ+K;SR)TC;[/+N*9-S-\>.UHUM
M336M9F-?X..'#O68NL[K)EK2:X]+6B.4]L_K/2>>3NS
M
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MR?*/_1>H?_I1[)_J>\L_R^^_=XO\2?Z[&ZG_ , -OO\ VE9'_C6/_NF/KO\
M]D^4?^B]0_\ TH?ZGO+/\OOOW>+_ !)_KL;J?_ #;[_VE9'_ (UC_P"Z8^N_
M_9/E'_HO4/\ ]*'^I[RS_+[[]WB_Q)_KL;J?_ #;[_VE9'_C6/\ [ICZ[_\
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M\'G.XVVXVF:VWW>.^+<5GC6]9K:/?$Q$POSE5   V^_RM;5_YS-OO^V>.?\
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M9K$1'OEFIZ4X<
M
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M6'J5_P"7NN?] W7^*/\ 6!V&_P ]NT7_ 'DX;_Z-#_3_ ,B?]M](_P"F;?\
MQA_JP]2O_+W7/^@;K_%'^L#L-_GMVB_[R<-_]&A_I_Y$_P"V^D?],V_^,/\
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ML
M
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M3'_S'T'_ .$-I_C3_6IZ8/\ :/V%_P"^#;W_ !B'VW9_RN+]U7\I_K2],?\
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M[-Y/]6O3OSY>,'EGJFWS;Z8_B+^+#GX1K.F++%+WBO;:D6K'>Y(&V]&
M
M
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MZKT[JFUB-9OM-SAW%8]\XKWT[M)TF)X3Q9B<2[,
M
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M5RGF'J%T_2</5*1S_@[?AM2?WT3/NAV+H>?Z^WG]:/Q3^Q^%Z CS-V$
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MT0 ]M_1)_5#Z;_YGL&_O'2GSYYA_SYN_Y^_XW>-C_0\7ZD?B<HSAVV
M
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M_P#5_6\L5C3#E_A*_P!MKXH^2T6TCNT=SZ7G^/LZZ_6K]&?DY?@T<_CK+D
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M2<,VW1O\\;^2K8S^<'(_XN1GHGIW_3-S_-5_?."Z[_$X_P!:?Q/-J>KNL@
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M)\YN^@
M
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M<//GH7YJIYE\E[F8PWFL;G:9)M.UW>*)^IFQQ,?2C6?AY:Z9<4S,TM$6M6W
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MG\<.Z0_I0?(8
M
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M6UIXVF9XL?./<H[N?EA?R2;@?SBO_BS8C[7^[+_X2W__ 'C/_$XGYX??#_\
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MXO\ FF?][#YP^]3_ /$ES?\ /MM^^L[_ ,^^7YC
M
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MYXZ?2I,S:EI.O#^I_O\ ?X!5?_7J$=2_H&7]4]=O_B0]?_YA;]]5XZ3H;\?
M     -S]IMYMS=CLJI\RVMR^[8E>X5B;4.H)O%;[M2Q2)+^KK[:9TEMM[MKW
MIJL%3%)&CM'(B.1')=@W&;;7^)AM-;?C]\=KL_E3SEYF\D=4KUCROO,NTWL:
M:^&?H9*Q.O@RXYUIDIK^;>LQKQC28B7J!Z(NNO$^JZQ2V&]4]!B.\F/T3:C(
M,4@GD6W7VAB]U%-D^(+5/?4R6Q9WHE12/?+44#GM:]\K',F?W'IW4J;VOAMI
M7<1'&._VQ^3L?ISZ)^N?2O578SL=Y7'M/..WIKEP1,^#+6-(G-M_%K,TUGZ>
M.9M?%,Q$VM6:WMS].3>^('*O_27R3_S#>/[WU!AD^I;W2T.J?YLW/\QD_>2\
M*!YP_#(     #U\?+K_J7[$_^8;_ /QVR8[UTK_-^/W3^.7ZZ?=X_P#B,]"_
MF,O_ ,TYG-4Y![0X"==?6W9.E'$:>T6&&BO^\6744\F)V"I>DE#8Z!'OIG9=
MDL,4L=1^K(:AKV4L"*UU=41N8CFLCE>SC.I=1KLL?AKI.>W*.[VS_9Q>">N?
MK7LO2KI%=IL8IN/.&[I,X,4\:XJ\OCYHB8GP1.L4KPG+>)B)BM;VCRR[B;DY
MWNSE=RS?<;*+MEN3W:59*NZ7:H69[(_$Y8J.BIVHRDMMMI4=X8*6GCBIX&:-
MC8UJ(ATS+FRY[SDRVFUY[_[/P/RZ\P^9.N^;.JY>M^8MUEW?4\LZVODG7AV5
MK'"M*5Y5I2*TK'"L1#!RMP8!7I*NJH*JFKJ&IJ*.MHZB&KHZRDFDIZJEJJ>1
MLU/4TU1"YDL%1!*Q',>U4<UR(J*BH3$S$ZQS68LN7!EKGP6M3-2T6K:LS%JV
MB=8F)CC$Q/&)CC$\8>@/Y=?S%+GF-SLVP6_MY=79'7.AMNW6XMRFC;47RH;&
MV*EQ/+*J5S5J;Y4JU&T-<Y72UTKDAF5T[F/F[/TKJLY)C;;F=;S]6W?[)]O=
M/;[WWY]WC[P^YZQN</D+S[FF_4;S%-IN[S&N6=-*X,]IYY9Y8LLZSDF?!?7)
M-;7[PSL3[<
M
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MZGOK^/>[CIVVRY+:17Q7R8:7O;2L16-;3,Z5B(CE$1'!EAQ;L(
M
M                                            V^W;_DIW-_F^S/\
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MI9@
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MMGV^'<TBF:/%2)UYS''Y)CO<7/\ A8]!W^8K_P!2=O)_I#.8_P!,O,G^4_\
MR/%_>-3^JMA_)_W5ORIG'?EH=$N*9!8LIL&ROP%]QJ\6R_V6N_RC[M57P5WL
MU;!<;;5_"UN>5-'4_#5E,Q_NY8Y(G^'1S7-546O+YM\P9L5L.7<:X[UFLQ\/
M'QB8TF.%->7<RKTS8TM%ZT^E$ZQ]*W9\KG8=<;X
M
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MRTI::S,6B+1%IF)FLQKIK$QP:V]S6V^SR[BFDWQXK6C7EK6LS&O+AP[W9?\
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M;1$Z7K/&EHFL\8E\=[W9Y^G[O+L=U7P[C#>U+1[:SI/OCNGMCBE3GFLZ>_\
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MT>9\?4-W32*Q/U::QK>W='"8K^E.O9$Z=K9^]#YD
M
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M;K5\V+/GFLQX<%*1-J4OV_%R:Q:*?FX_I3]:FO<J?8KX'
M
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M88B+6X<(^+2:9M(X1\33L<LC>>K@
M
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M]O\ =>_V2KY/>^/P?!9EMS<M/=^#Q>]_5V857N=?&GA\?A\7'371=-+#Z_\
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M;5F.R:VB8F.^&8G$NR@
M
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M_P""?=^1VEG3G*@
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MWP5W[L\>MUW_ .S3[=XO^31E^%[/!]37W:_3_LT=JC9?_.CX.G\)X?%\O/\
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MXOB9*YO#$^*]>'AK.GT;1'.9<#U7>[G;9JTP6\-9KKRB>V>^)=87_%.Z\?\
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MQ=FV>]Q;RGBIPO'..V/]SVN6)PK;
M
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M)?\ I58S_A!9O[XTQV[R!_X[Z)_WOL__ )HQM#JG^;-S_,9/WDN^4_JK?$P
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MZAO[SDW66VMIG\$1'96(X5B.$1$1">.U-(
M
M                                          <*>OK<:; ^GR]VVAJ%
M@NFX5QI,)@<QVDK;96QU%?D+O#HJ.@J;-;Y:23731*I.W0\7]>O,5^A>G^;;
M8+>'==0R5VT=_@M$VR_)..EL<_KOH/[LWE3'YE]4=ON]S7Q;/I>*V[G7E\2D
MUI@^6N6]<M?YONU>>X_/U^HKZUKGN:QC5<YRHUK6HKG.<Y=$:U$U5555X(3$
M3,Z1QF43,5C6>$0](G27L);]B=K+70U-'$W.<GIZ6^9S<'1-2J_6,\/O*6PI
M*J+(E#CD$WN&L\2L=4>^F1&K,J)^C7I/Y#V_D;ROBP9*1_7FYK7)N;Z?2\<Q
MK7%KS\.&)\,1KI-O'>(CQS#\F_6_U+W7J1YSS;G#DM/ES9VMAV=-?H^")TMF
MTY>//:/',Z:Q3X>.9F*1+E$>GO'  !@6YFVV*;M89><&S&@976>[P.:DB-C^
M,ME<QKTH[O:YY&2?"7.@D=XHI$14YM<CF.<UW ^9?+?2O-G1LW0^L8XOL\U>
M?#Q4M^;DI,Q/AO6>,3[XG6LS$]E\H>;>M>2.O[?S'T'+./?X+<N/@R4G3Q8L
MD1,>+'>.%J^Z8F+1$Q@?3_T]X5T]XE_!_&FK<KS<%BGR?+:RFC@NF0UL:.2/
MQ,:^;X"UT?C<E-2,D>R%'*Y7/E?)(_@O(/I]T7T_Z3]@Z;'Q-[DTG-GM$1?+
M:.7#6?#2NL^#'$S%=9F9M:;6GLWJ=ZH^8/5'KG]9]6GX/3\6L;?;5M,X\%)Y
M\9B/'DMI$Y,LUB;3$1$5I6M*[\G>WFC@O\Q/^K;<_P#"_%/^M3GAWWAO_B<9
M?^=X/WTOH[[J_P#\5K#_ ,QW/[V'0 ? S].F7;?_ /I>83_A=C?]^:(Y?H'^
M?=E_SO#_ ,95P7FC_P -=1_YCN/^*N]7)^J;\5  !Q-ZN.G*T[\[>UTU!0PQ
M[D8O0U-=AMVCC8VIK'0-?4SXM6R?A6>W7G1S8D<NE-5.9*U?#[UDGE'JSZ=;
M3SWY?O?!2L>8]K2;;?)$<;:<9P6GMIDXQ77ZEYBT</%%O;?0[U7WWIKYHQX]
MSDM/E/>9*TW6.9GPTUTK&XI'9?%PFVD?PF.+4GCX+5\YLD<D4CXI6/BEB>Z.
M2.1KF21R,<K7L>QR(YCV.145%35%/SNM6U+32\3%HG28GA,3'9+]6:VK>L7I
M,328UB8XQ,3RF)[8EH,63O5^6SG\V2;,WK"ZR99JG;S)I8:)KG:K#8,F9)=J
M&-=?Q?AN\=QTXZ(S1$Y'W)]W#KU^I>3L_1LUM<G3]S,5]F+-$Y*Q_A(R_)I'
M8_-_[VGEG'TGS]M_,&WKX<75-G$W]N;;S&.\_P""G!K[=9[78D?0SY7=3OS(
M-AI*^GL^^6,V]\U92NHL8SJ&DADEEGI9Y&4N,WQ[(T5/%3U3TM\KEU<])J5J
M<&*?*?WC/(EL^/#YWZ9CF<U9KAW,5B9F:S/APY9T[K3\*T\Y\6*(X5?;/W3O
M4JNVRY_3GK&6*X+Q?<;.;3$16T1-MQAB9_2K'QJQRCP9IGC:''38[Y?VZ>Y*
M4E\SU9-L<3E6*9K+I2K-E]SIG:/_ .A6![XEM;9&HK?>5[H9&*J.;!*T\[\D
M>@7FCS)X-]UW7IG29TGZ===Q>/VN+AX->6N6:S'"8I>'JOJ+]Y[R9Y2G)T[R
MUIUCK==8UQVTVN.W+Z>:(GXFG/PX8M6>-9R4EMOUD[1X9LGNI:L'P:FKH;1#
M@EBN-1/<ZZ2X7"XW.JN%[BJKA63.2.!D\\=+&BL@BA@:C?PQMU77KGK%Y2Z-
MY*\TXNB=#K>NTC8XKS-[3>][VODBU[3PC68K'"M:UC3A6.+MOH)YYZ_ZA>2\
MWF+S'?';?6ZEFI6,=(I2F.M,4UI6.,S$3:TZWM>\Z\;3P<33RA[:[N?EA?R2
M;@?SBO\ XLV(^U_NR_\ A+?_ />,_P#$XGYX??#_ /&_2_\ NK_ZXS.RX^DW
MR,  -B-\>G3;7?RRK09C:DI[Y2P.BLF86MD5/D5E=JY[(XZI6.;76U9'N5])
M4)) [Q*YJ,D\,C>B^=_3ORWY\V7P.L8O#O:UTQ[BFD9L?=$6T^E37GCOK6=9
MF(BVEH])].O57S=Z9]0^T]!S^+IU[:YMKDF;8,O9,S77Z&32(TRT\-XTB)FU
M-:3:=.?3UB_3QA;\=L\S;O?KI4)6Y1E4M&RDK+Y4Q.F;0PI"DM0^EMMLIYE9
M3T_O7M8Y\C]5?(]5J]._3[IGI[T:>G[.8S;_ "V\6?/-?#;+,:^&--9\-*1.
ME:ZSI,VMKK:97^JWJEUCU3\P1U7?UG!TW#7P;?;1:;5PUG3QSKI7Q9,EHB;W
M\,3,16NGAI6(Y!'?WE[9'J3J<=I-@MWILJ]PMF7 <B@>V=(U\=QJJ"6EL4=/
M[U6L2ODOLU,VF75%2H5BHJ+HITKU(R=.Q>0NKWZIX?L?V#+''3Z]JS7%$:\/
M%.6:>#]OX7H?I+AZKG]3>A8^B^+[?_6>"8TUX8ZWBV:;:<?!&&,DY/VGBUX/
M,,?F4_84 ]6>V]MJ;-MW@5HK/$E9:L+Q:VU2/3PO2IH;'0TL_C;XG^%WO8EU
M35=%[3]4?+FVR;/R]L-IFU^-BV6"EO?7%6L_AA^*_FS=XM_YIZGOMOI\#-U#
M<9*Z<O#?->T:?),,T.9=?  '5QUM]9"XHRX;/[2WAO\ ">5L]%G&66Z75^,Q
MN1(Y,?LM7$OA;D,K5<VJG8NM W][8OQ*N6F^7_6OUAGI<9/*'E/-']9S$UW.
M>D_Q,<IQ8[1_PL\8O:/XJ/HQ_"3,X_LG[O'H)'6K8O/?G?!/]3UFM]IMKQPW
M$\XSY:S_ ,!'"<=)X9I^E:/A1$9>F!5555555555555U557BJJJ\U4^-N?&>
M;[^B(B-(Y.872+TNW+J RM;G>XZF@VPQFKB7)+G&KX);S6-2.>/%K1.W1R5=
M5$]KJF5B_P#1:=WBU222%'>O>DOIAN?/_5?M.]BV/RSMKQ\:\<)R6X3&#'/Z
M5HF)O:/J4G76+6I$^$>N7K)M/3#HOV/ITTR^<=Y2?@8YTF,5>,3N,L?HUF)C
M'6?XR\::32N28]"MJM5ML=MH+-9J"DM=IM=)!06ZW4$$=+14-%2QMAIZ6EIX
M6LBA@AB8C6M:B(B(?H'M=KMMCML>SV>.F+:8J16E*Q%:UK6-(K6(X1$1PB(?
MEQO=[N^H[O+O]_EOFWN:\WR9+S-KWO:=;6M:=9F9F=9F5^;#6
M
M
M ZYOFD;N3[8=*>1V>V52TU[W6NU!MQ3/C?I.RSW&&JN>5N1GA<CZ:KQZUST$
MNNB(E<G'70XKK.><.RFL?6O/A^3G/X(T^5\[?>@\VY/+'I7N=IMK>'>]5RUV
M==.?P[Q:^?Y+8J6Q6_G([='E+.E/RL:F,=(YK&-<][W(QC&(KG/<Y41K6M1%
M5SG*NB(G,)B)M,5K&MI>O?H3Z7K5TR[)66VUEO@;N7F=)0Y)N5=70,2N_6U3
M![ZBQ=)E1TS;;B5+4?#,C\2QOJEJ*AK6K.YJ=ZZ;LXV>WB)C^&MQM[^[Y/QZ
MSVOUS]#/3#:^F?DK#MLV.L>9-Y2N;>7T^E\28UKAUY^#!6?!$:Z3?XF2(B;S
M#FH<@]H  &U^\FS^#[[;>9!MIN#:X[E8+]3.8V5K(?UA9KE&QZ6^_62IEBE^
M!O-KE?XX9414_28]'1O>QU.XP8]SBG#EC6L_@]L>V'6/./E#HGGGR]N/+7F#
M%&389Z\^'CQWB)\&7',Q/AR4F=:V]]9B:S:)VPZ6.E+;KI2P3^"N'L6[Y#=5
MAJ<SSNOI(J:]97<(4>D/CC9+4);++0)*YM'01ROC@:YSG.EFDEFDIV6RQ;+'
MX,?&T\Y[9_W.Z'6/2WTJ\N^E?0OZKZ1'QNH9=+;C=6K$9,]XY<(F?!CKK,8\
M46F*Q,S,VO:U[<GS<>G.)'7A_4_W^_P"J_\ KU":/4OZ!E_5>3>NW_Q(>O\
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MZ!SL[[^
M
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M9_X;)69^SX[1IBQS&:=<M\?P>ZH^/GZB@
M
M                           !M]NW_)3N;_-]F?\ %RY&UL?Z;A_G:?OH
M5Y?XJWZL_B>"X^D70 #>G'^I/J*Q*RV[&\5W\WJQG';13I26FPX_NGG-FLMK
MI&N<]M+;K7;K[34-%3M<]51D4;6HJKPXG'Y>D]*SY)RYMMM[Y;3K,VQTF9GV
MS,:ROKN=S2L5IDO%8[(M,1^-,_ZVO55_M,]07_?-N/\ XR%?]2=&_P DVO\
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M)Z9U/-L?S:7^C^K/&OR^&8U]KO6US_:-O3-VS''W\I_"W\.,;
M
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M9T;/\7:_"GZU)T^2>,?LQ\CME.E.7   #;[=O^2G<W^;[,_XN7(VMC_3</\
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MK6)]UG9^AX9KAOFG\Z=(]T?[L_@;W_.!_J97O^<' _\ KU4<?Y&_S]7^:O\
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M/GSEPEWEJ
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M'EW%,M9[+4B7GGJAO;[3RCFI29BV?)CQZ^R9\<_/%)B?9+MQ/Z"'RT
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MYE\\] \Z9]_EZSU;#\3;\=)Q3\2F.D<JZ1$7K6(XS:U(B9UM,ZZN59]Y/,@
M
M
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MC+@C7A6OBQZ_!I6(BF.F2N/2(B(C337E6>IO%@
M
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M?'3!?-IP]N&)X\.'?H]69W5^J0
M
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M?M(
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M-J_[UVSHMM=GIW7F/P1/[+MD.E.7
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M';OI6?P0W?-%<
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MF+3/8"?K2\,
M
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M-X,N&L?1VV:T3:LXXCZN#)I.E>6*\>"L^&]*U[&CZ)?*0
M
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M7T=Z?KH >?KYV/\ Z5'3Y_YAW$_OAB)U?S#]?%[K?L/@+[Z?^<_+_P#,;O\
M?[=T;G77Q [:_DTO8WJ@SE'.:U9-A\H9&CG(BO>F?[82*UB*NKG(QBKHG'1%
M7L.<Z!_3+?S4_OJOK+[G,Q'J=OHF>,]"SZ>W_E6RG\4/3$=N?I4 =.?SH%3_
M "$[5MU3Q+NTQ435-51N'9*BJB<U1%<FOI.!\P?T:GZ_[$OCW[Y<Q_H+TN.W
M^MH_^9\SS?'4WYRN>?RQ_P"O#LE_\<G^B+/CD^C_ .<<?]M^]L]W^[/_ /%N
MZ)_^.?\ S!NGK:.[OUE
M
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M_P# O6O^Z=Y_\SY'B7/V+?RR 'KTZ&?ZH^PW^ M+_P!>KC\J?6C_ .*GUO\
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MG;0?+C]$P
M
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M'.BN9
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M?3737PUFVFNDZ:Z::Z3IW+,./XN6N+73Q6B->[6='>1_P)__ )*;_P!0A_\
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M #K+^_L[WL_Z)B_FZ_O8<@CC&P
M
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MO;9[O+M+_7Q9+4GWUF:S^))G--<
M
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M*_NF?_$MR?\ >NX_XO X '@3Z==W/RPOY)-P/YQ7_P 6;$?:_P!V7_PEO_\
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M'Z?OQM
M
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MY8]59W1^IP
M
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M&O=+(SCW-      8)NC_ "9;B_X"9=_%^X'->6O_ !%L/^>X/^-JZGY^_P#
MO6O^Z=Y_\SY'B7/V+?RR 'KTZ&?ZH^PW^ M+_P!>KC\J?6C_ .*GUO\ Y[;]
M[5_2%]T__P"ES\H_]TT_?W<KSS!]"@ #SP_.)W!HKYNSMAMS23QSRX!B%VO=
MS;&C-:.Y9W74&E#,_P#YSWZ6G%J2H\*_A2.H8J<7.T^]?NF]!S;+ROU+S!EK
M-:[[=TQTU_.IMJV^E'9IX\UZZ\]:3$\H?C#_ +2SSEM>J^HG0?).VO%\G1^F
MYL^733Z&7?Y,?T+3S\7P=KAR:<HKDK,<9G3IZ/K!^:SEOT(8_+DO5WL3;X6O
M<ZES),@?X-45L6*6JY9/,YRHU^C$CM"Z]Z<-4UU/+?6S?UZ=Z5=;SWTTMM/A
M?+FO3#'X;OHO[I'1LG7?O'^4MGCB9G'U/[1.G=M,67=3V3PTP\>_EK'-Z[#\
MK']'@!LGU ["X3U'[;7+;3.FU4-OJZR@NEMO%M2E2\X_>+=-XJ>Z6>:LIZJ"
M&J=3234TGBC<CZ:HE8J:..X^1/._6?3[S#C\Q=%FLYZTM2^._B^'EQWCC3)%
M9K,UUBMXTF-+UK/8\L]8_2+RKZV^1\_D;S9&2NSR9<>7'FQ>#XVWS8YUKEPV
MO6]:WFLWQ6UK,6QY+UGZSBC9_E7=(=LH(J2MQO,<BJ(_T[I>,XO,%?/^%K?W
MV/'UL5L3BU5_!3,XJO9HB>G[O[S'JKN<\Y<.XVFWQS^9CVV.:Q[IR_$O\]Y?
M/?3/]G]]V_8;2NVW6QZGO<U>>7-OLU<EN7.-O\#%[?HXXYSV:1'''J+^4MA,
MF+WC)>G>Z7^U93:Z*IKH,"R&Y,O-ER)*6*29+59KK51176TWBK1JLA=5U%53
M2R>!CU@:KI4] \@?>DZS7J6+IWG['@R],R7BL[G%3X>3%XIB/'DI69I?'7G:
M*5I>(UF/',15XEZU_P"SK\K7Z#N>N>B^XWFW\P;?%;)7I^XRQFP;GP1-OA8<
MMXC+AS7Y4G+DRX[6\-;3BB;9(Z"IX)Z6>:EJH9::III9(*BGGC?#/!/"]8YH
M9H9$;)%+%(U6N:Y$5JIHO$^XZ7IEI&3',6QVB)B8G6)B>,3$QPF)CC$P_(#-
MAR[?+;;[BMJ9Z6FMJVB:VK:LZ36T3I,3$Q,3$QK$\):Z.LJ[=64EPH*F>BKZ
M&I@K**LI97P55)5TLK9Z:IIIXG-DAG@F8U['M5'-<B*BZF.;#BW&*V#/6M\%
MZS6U;1K%JS&DQ,3PF)B=)B><,]KN=QLMSCWFSR7Q;O#>MZ7I,UM2]9BU;5M&
MDUM6T1,3$ZQ,1,/8KTJ;POWYV VUW-JEC2\WJR+19*R-K(VMRBP5=38<@E9!
M&JI305MSMTE3"SFD$S.\_)KU-\IQY(\]=1\N8M?LF'-XL.O'^!RUC+BC7MFM
M+Q2T_I5L_I:^[YZE6]7/1[H?GO<:?UGNMKX-U$1$1&ZV][;?<3%8^K6^7';)
M2O9CO1R%.AO9@
M
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M*ZJO]F;J"_[F=Q_\6R/Z[Z-_E>U_PM/[Y/V/=_R63]S;\A_JE=57^S-U!?\
M<SN/_BV/Z[Z-_E>U_P +3^^/L>[_ )+)^YM^1MWG6U.Z.UTEMAW,VVS[;N6\
MLJI+/%G6'9%B,EVCH70-K9+:R_VZWNKF4;JJ))5B1Z1K(WQ:>)-=O;;W9[R)
MG:9<66*\_!:MM->6OAF=-=%63#EQ:?%K:NO+6)C\; 395NT/Y26]R[5]5%MP
MVY5OP^,[U6F?!JQDLCFTK,GIU==\*K',:]OCK)KE3RVR#5':+='<$U\3>G^=
MNG_;.C3GI&N;;V\<=_AY7CW:?2G]5RO2,_PMW%)^K>-/EYQ^3Y7K//%';@
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M'((XQL   !M]NW_)3N;_ #?9G_%RY&UL?Z;A_G:?OH5Y?XJWZL_B>"X^D70
M#W8=._\ 5_V+_F=VR_B59#YSZK_G/<_S^3]_+ONV_H^/]2OXH=?7SF_ZH=L_
MGBPS^\68G9_(7^?+?S%_WU''=:_H<?KQ^*7E4/974W./Y;']=_8'_"'(?XC9
M2==\V?\ A[<_J5_?U;_3/Z=C]\_BE[+SP9W0 \:'S)_Z[^_W^$./?Q&Q8]Y\
MI_\ A[;?J6_?V=+ZG_3LGOC\4.#AV)H/47\DO^JKG_\ O!95_1QM0>/>H/\
MGG%_S6O[_([5T/\ HEOYR?WM7<.=%<R
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M]F;J"_[F=Q_\6SC_ .N^C?Y7M?\ "T_OE_V/=_R63]S;\A_JE=57^S-U!?\
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M,_XN7(VMC_3</\[3]]"O+_%6_5G\3P7'TBZ  >T[Y?O]3'IX_F^H_P#K]P/
M?,W^?]U_.S^*'=^G_P!"Q_JN8AP3<8SEF:8?@=GJ,AS?*<=P^Q4C'R5-XR:\
MVZQVR%L;5>]9*VYU%-3HJ-3EXM5+L&WS[G)&+;TMDR3V5B9GYH87O3'7Q9)B
MM>^9T=%O7-\V6P2V&];4=*UUJZ^YW6*:VY#O%%!46^CM=#*V2&NH<!BJXH*^
MINM0U5C6[/CBBIF:OI/>R/CJ(/1?+ODK+&6N]ZS6(I7C7%SF9[)OIPT_:]OY
MVD:Q/!;_ *O7PSAVD\9YV_)^7YN]YYE57*KG*KG.555555555=5557BJJIZ@
MZX^ >E#Y+G3U6XI@.:=0^14#J:MW)<S$L%69$;,N&6&O=+?;K&U$\3:6_9/3
M,A8CE1R_JGQHG@>QSO)_/W5*YMSCZ7BG6N+Z5_UYCA'OBO'^V]CLW1-M-,=M
MS:.-N$>Z.?SS^)W6WZ^6K&;'><DOM9%;K)CUJN-\O%PG54@H;5::.:ON%9,J
M(JI%2TE.][M$Y-//\>.^;)7%CC7):T1$=\S.D1\[G+6BM9M;A6(UEX5]\MTK
MIO;O!N/NQ>/?,J\[RV[WZ*EGD]Z^VVNHJ71V.S-D5S_%#9++%3T<?XETC@:F
MJGT7T[9TZ?L<6RQ_5QTBOOGMGY9UGY70\^6<^:V:W.TZ_DCY(X-JC=4M[+%T
MT=1V46>VY#C73_O;D5@O-)#7VB^6+:G.[M9[K05#?'!6VVYT%AJ**NI)V+JR
M2)[F.3BBJ<?DZMTK#DG%FW6WIEK.DQ.2D3$]TQ,ZQ*^NUW-ZQ:N.\UGMBLZ?
MB2W^J5U5?[,W4%_W,[C_ .+97_7?1O\ *]K_ (6G]\R^Q[O^2R?N;?D/]4KJ
MJ_V9NH+_ +F=Q_\ %L?UWT;_ "O:_P"%I_?'V/=_R63]S;\C"\WV2WFVRMU+
M>-R-H]SMOK175K;;0W3-\!RK$[=67%T$]4VWTM=?K304U16NIJ:21(F.618X
MW.TT:JIL;?J&PW=YQ[3/ARWB-9BEZVF([YB)GA[5>3!GQ1XLM+UCVQ,?C;8F
MXJ<P>@W>Y=@NJ;:W-*NM^"QJYWAN$YH]\CHZ3^"N8N99ZVLKO"]BNI;#6S4]
MSTX_CH6KX7:>%>"\R=/_ *SZ-FV]8US17QT[_%7C$1[9C6ORMW89_L^[I>?J
MS.D^Z>'X.?R/:B> N[.KGYP/]3*]_P X.!_]>JCN/D;_ #]7^:O^*'%=9_H4
M_K0\F9[4ZBY!=)7]:KIF_P!X+9G^D?&SB^M_YFW?_-<O[RS9V?\ 2\7\Y7]]
M#W('SP[TZ-_G.=-?\)L(QKJ5QF@\=YP'X;$=P?AXM9*K#+K7._@_>)_"FKOX
M.Y%6NIW+HKEBN2*Y49!P]$\A=6^#N+])S3_!Y?I4_6B/I1_;5C7^U]K@NM;7
MQ8XW58^E7A/N[)^2?QO-J>KNLN072YOY?>FG?#!]VK+[Z>FLEP^#RBT1/5K<
M@PZZZ4>269[/>1Q/FFH'K+2K)XF0UT,$RHJQH<9UCIN/JW3LFRR<)M&M9_1M
M'&L_/S[XF8[6QM=Q;:YZYJ]D\?;';']G:]N6+9-8LTQK'\PQ>XP7C&\ILULR
M&PW6F5WP]QL]XHX:^W5L2/:R1K*BDJ&.1'(CFZZ*B*BH?/>;#DV^6V#-$URT
MM-9CNF)TF/G=YI>MZQ>DZUF-83Q6R=&_SQOY*MC/YP<C_BY&>B>G?],W/\U7
M]\X+KO\ $X_UI_$\VIZNZR[!/E8_U\=BO_CG?T-[AG6/.7_AO<__ !O_ (VC
MD>E?T_'_ &W[V7L./"W<@    =7/S@?ZF5[_ )P<#_Z]5'<?(W^?J_S5_P 4
M.*ZS_0I_6AY,SVIU%RBZ)?ZWG3?_ #Q8+_?VD.'\P?YCW?\ ,7_>RV]C_3,7
MZ\?C>W ^?'>'F3^=[_6 VF_F=B_CKE1ZYZ>_YLS?S_\ O*NK]=_I%/U/V9=+
M)W]PCOH^1A_Z5?49_@]MO_?+,#S;U%_B-K^OD_%5S_0?KY/='[+T5'EKLC'L
MN_\ 24R?_!Z]?WMJ2W!_'T_7C\;&_P!2?=+P''TL\^ /<ATE?U5>F;_=]V9_
MHXQL^=^M_P">=W_SK+^_L[WL_P"B8OYNO[V'((XQL
M
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M,&_RX_J6WF:8]TY+3')FYZ<X8
M
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M\=K6UTT\-:S,ZZ\.4=O#O>MD_6-^(
M
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MXFGZL?B?M]Y5_P##'3?^8;?_ (JC/2USS!<]W/VZVMM$M^W&S;&,*M,3%?\
M&9'>:&UI.J+HD5'#4S,J*^H>[@R*!DDCW+HUJKP*\N;%AKXLMHK7VSHX/KWF
M;R]Y7V<[_P Q;W:[+:1'ULV2M-?96+3$VF>RM8F9GA$3+H Z[_F8Q[MV6Z[.
M; R7.VX!<FS4.8YY5P36RZ9K;GM\$ECL=!.R.OL^,U;57XJ2H;%65S%]RL<,
M/O6U'6.I=7^/6<&UUC%/.W;/LCNCO[9]W/X%]=?O*U\V;/+Y/\@SEQ]!R:UW
M&ZM$TON:3PG%BK.EL>&WY\VBN3)'T)K2GBC)TUG /CD ]47RMM@JS9SIUARK
M(:%U#EV\M;2YI602HB55)BD5(M/A-#4-1-&.FM]1/<4:JJ]B7+P/1KVN:WN?
M1MM.#:>.WU\DZ_)V?E^5^I7W7O(6;R=Z>5ZKU"G@ZMUF]=S:)^M7!%=-M6??
M2;9M.<?&TG28F([*SEWTD <)?F#[X+L7TPYU=[=6)297FD3=NL0<URMG9=,H
M@J8KC7TZM_%'/:,;IZZJBDT\+9XHT7])#CNJ;G[-L[6CZ]OHQ[Y_)&LO%?O
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M2L1"<,F\ =<OS3MM)=P>DC)KI14ZU%QVRR'']PZ>.-%]\ZBHWU6/7U4<B?\
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M'9GWN
M
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MO]G!O<^[] ]Y@RZ_#VWF;=XZ<_JSM=CFG3N^GEORX:ZSSF7:6?-+[]
M
M                                                &WV[?\E.YO\
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M5?T<;4'CWJ#_ )YQ?\UK^_R.U=#_ *);^<G][5W#G17,@
M
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MMU//)DG^VG\K::^9'D.3UBW');]><AN#DT=7WRZ5UVK%1>*HM57SU$ZHJ_\
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MW_3-S_-5_?."Z[_$X_UI_$\VIZNZR[!/E8_U\=BO_CG?T-[AG6/.7_AO<_\
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M;_=]V9_HXQL^=^M_YYW?_.LO[^SO>S_HF+^;K^]AR".,;
M
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M9]K66(
M
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M&\KKK3G'V2MJS$9(K:9OD\46C'?Z%)K:<T-Q_F)_U;;G_A?BG_6ISL?WAO\
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M9:>IAV]RBGI9T1ZOAJKC:JBVTLL?NT5S965%6U6*OX6N1%=P13IGJ+O;]/\
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MF"NOTI^+7PYLD=L1BQ6M/BY1DG'$_6AZ,#]$7Y3@
M
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M-NIC3CN,NEKQK'"WPX\.&MH^M7'6>URE-QZ@
M
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M/'QC769YXGB3ZX
M
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M''7P5_6MQM,>V*\/[9P77,_AQUV\<[3K/NCE\\_B>;4]7=9;[=,6T<^^V_\
MM1M1'%+)29=F%MI[XL*/66#%K<K[QEM6SP*U4?1XU;JN5O%J>)J:JG-.-ZOO
MHZ;TS-O9^M3'.GZT\*Q\MIAL;7#]HW%,/9:W'W<Y_ ]R\$$%+!#34T,5/34\
M4<%/3P1LA@@@A8D<4,,4:-CBBBC:C6M:B(U$T0^=YF9G6>,R[W$:<(Y*I
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M<7_-:_O\CM70_P"B6_G)_>U=PYT5S(
M                                                     #HW^>-_
M)5L9_.#D?\7(ST3T[_IFY_FJ_OG!==_B<?ZT_B>;4]7=9<P_E_?US>GC^<&C
M_P"HUYP7F;_,.Z_FI_'#=Z=_3<?ZSVGG@+NP   ?GVGTV\\ /9;\M?\ J0;
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M55Z9O]WW9G^CC&SYWZW_ )YW?_.LO[^SO>S_ *)B_FZ_O8<@CC&P
M
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M%::WQY*6IDI:.=;TM$6K,=L3$2]<QY,>:D9<5JVQ6C6)B8F)COB8X2H&JS
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MXG'T_%K\/'KKIK^=;LF\]O9$<([9G>P^F'3P
M
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M5QK/9DB(B(B(B(B(B(B:(B)P1$1."(B'TM$:<(Y/D.9F9UGFX,?,3_JVW/\
MPOQ3_K4YX=]X;_XG&7_G>#]]+Z.^ZO\ _%:P_P#,=S^]AT 'P,_3H   -3&/
MD>R.-CGR/<UC&,:KGO>Y4:UC&M17.<YRZ(B<54F(FTQ6L3-IGA#&UJTK-K3$
M5B-9F>41WRY![==*N_6Y\L"X[MW?*.V3Z._7^2T[\9L:0KK^_P -9>&TS[C&
MBMT5*1E0]%_<GH'EWTM\]^9[5GIW3L]-M;_A<T?!QZ=\6R>'QQ_-Q>?8\O\
M-7K1Z:>3Z6CJO5=ODWE?^!V]HW&;7]&:XO%%)_G9I'M=J&P?R]\$VZJ:')]S
MZVEW&RJE6.HIK1\*Z/"K35-3]+X*K3XC))(G<625;(H.U:;Q(UZ?4?D/[OW0
M_+V2G4_,UZ]1ZK728Q^'3;4M^K;CFF.R<D5K_P"[UB)?&/J9]Z+S)YJPY.C^
M3\=^E=%OK6V7Q:[O)7]>OT<$3'.N.;7_ /?:3-78BB(B(B(B(B(B(B:(B)P1
M$1."(B'T-$:<(Y/E>9F9UGF^@ .(O7=_53W4_P#Z'_I'Q \E]=/_ (E?5/\
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MCP8<%9F<>#''*E=><S/TKWTB;VXZ16*UKO,=R=!
M
M                                                    6]724M?2
MU-#74U/64593S4E91U<,=12U=+41NAJ*:IIYFOBGIYXGJU['(K7-545%12)B
M)C2>2O+BQ9\5L&>M;X;UFMJVB)K:LQI,3$\)B8X3$\)CA+H<ZP_E/UDU?==Q
M>ER&F?!5235]VV?K*J*B^%E=XI9Y<"NE9*RD6EE>OB2UU3XDA_$E/,YJQ4S.
MM[_HDZSEV?RU_O9_8GY)['PGZO\ W4\U\^7S%Z7UK-+S-LG3[6BOAGG,[6]I
MBOAG^0O-?#QC'>8\..O1WDV*Y-A=YK,<R_'KWBU_M\BQ5UER&UUMGNM)(USF
MJVHH+A#3U,6KFKHJM1%TX'7+TOCMX,D36T=D\)?$74^E]3Z-O+].ZOM\^UW^
M.=+8\M+8[UGVUO$6CYD"8M   9_MSM5N/N]?XL8VRPK(<UODBQ>\H[#;IJME
M%%,]6,JKI6(C:"T4/C146HJI88&Z<7H6XL.7/;P8:S:WL_LX.?\ +OE7S'YN
MW\=,\M;+<;W>SIK7%2;>&)X1:]OJXZ_M[VK6.V7?WT=_*MQ_;:LM.X_4/):\
MSS6BE@K[+@%$[XW#<;JXG,F@JK[42-8W*[M3/:FD/@2W0O1=4JOP/9V?8=%K
MAF,NZTMD[*]D>_OG\'O??'H_]UKI_EO-B\Q^H4XM[UJDQ?'M:_2V^&T<8MEF
M?X_)$_FZ?!K.O\;PM'<DB(U$:U$:UJ(C6HB(B(B:(B(G!$1#GGV+$1$:1R<2
M>O#^I_O]_@%5_P#7J$T>I?T#+^J\F]=O_B0]?_YA;]]5XZ3H;\?     <B=J
M^DSJ,WGJ*9FW^T>87*@J7M:F17*V2X]BL;5<Q)'OR:__ *MLLBPL?XW1QS23
M*W]%CET1=K#L=WN)_@J6F._E'SSP>B>5O2?U%\Y9*UZ!TG>9-O:?XV])Q8([
MY^-E\&.=.<Q%IMIRB7<MTS?*&QC%JFV9=U'7VCS>[4[H:R';G&W54.(4U1&Y
MDT3,AODS:6Y9(UBZ))2PPTE*KVJU[ZF)RHO/[3H5*3%]W/BM^C'+Y9[?P?*^
MQO37[H_3.EY,75_47/3>[NNEHVF'Q1MXF.,1ER3X;YO;2M<=-8TFV6DZ3W16
MZW6^ST%%:K304=KM=MI:>AMUMMU+!14%!0TD38*6CHJ.F9%3TM+30L:R..-K
M6,:B(B(B'8(B*Q%:QI6'V9M]OM]IMZ;7:8Z8MKCI%:4I6*TI6L:5K6L1$5K$
M1$1$1$1'"%X2N ,>R[*+3A&*9-F=_G2EL>)V"\9+>*E5:B06NQV^HN=?+J]S
M6ZLI:9RIJJ)J89+UQTG);ZM8F9]T./ZMU/:=$Z5N>L[^WAV.TV^3-DGNIBI-
M[3\E:R\0VXV<WG<W/LSW#R!_CO6;9->LGN2([QQQ5-YN$]<ZE@7PL1M-2),D
M434:UK(V-:B(B(B>>9<ELV6V6WUK3,_._$SS%US>>9NO;SS#U"==[O=SDS7[
MHG)>;>&.7T:Z^&L:1$1$1$1##"MPSUM?+8VG3:GI+V]^)I%I;YN(E7N=?/$U
M$?*N4^Y_@ZY>*N:B8=16W\*Z:/\ %P155#O'2<'P-C77ZU_I3\O+\&C]9?NW
M^5(\J^D_3_BT\&^ZCXM[E[Y^/I\+_P"5ZX>'?KR<\SDGNX   <$^N3HLQ_JR
MPNFJ;9/18]NYB%+4IA>3U+'I1U])*_XBHQ+)70-=/+9*V=%?!,C9)+=4O=+&
MUS)*B*;C>H]/KO<>M=(SUY3^Q/L_%\[PSUO]&.G^J_1:Y=M:FW\V[2L_9LTQ
M]&U9G6<&;3C..T\:VTF<5YFU8F+9*7\K.X^V6>[199<L'W(Q:ZXCE%JD5M3;
M+K C%DB5SFQ5MOJXG2T5UME3X%6&JII):>9O%CW)Q.F9<.7!><>6LUO'?_9Q
M][\L_,?EGKWE'JV3HGF/:Y=IU/%/TJ7CG'9:EHUK>EOS;TFU+1QK:88(5."
M+FBHJRY5E+;[=25-?7UU1#245#102U596551(V*"FI::!DDU143RN1K&,:KG
M.5$1%4F(F9TCC*W#AS;G-7;[>ELF>]HK6M8FUK6F=(BL1K,S,\(B(UF7H:^7
M5\NZX[<5]JW[WYM/PF;P-;5[?;?5K(I),166-R,RC)X_%(Q,H=%)K1T2Z.MG
M_.3?]+\+*3M/2NE3BF-SN8_A/S:]WMGV]T=GOY?H/]W?[O6X\N9\7GSSWB\'
M6Z_2VFTM$3.WUCAFS1QCXVD_P>/GA^M?^%TKB[JCL#[0
M
M
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M)EW\7[@=<\M?^(MA_P ]P?\ &U=[\_?^!>M?]T[S_P"9\CQ+G[%OY9
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M
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MB9B4,P
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M/<XYP[C<Y\F&W.MLE[1.DZQK$S,3I,1/O94VVWQV\=,=*WCMBL1/SZ-XC07
M    Q;,,&PK<.ROQO/\ #\6SG'9:BGJY+#F&/VG)K+)5TKE=2U3[7>J2MH7U
M%,YRK&]8_$Q5X*A=@W&XVN3XNVR7QY=--:VFLZ3[8F)87QTR5\.2L6KW3&L?
MA;3?ZI72K_LS=/O_ ',[<?XMF[_7?6?\KW7^%O\ WRK['M/Y+'^YK^1*63IF
MZ;\9N]MR'&^G[9''[_9JR"XV>^63:G [5=[5<*61)::NMMRH+#3UM#64TK4=
M'+$]KV.35%13#)U?JN:DXLNZW%L5HTF)R7F)B>R8FVDPFNUVU;1:N/'%HY3%
M8U_$WN./7MLLXV4V:W-N%)=MR=I-LMP;K04:6ZAN><8%BN67"BMZ3RU*4-)6
MWZU5]334:5,[Y/=,<UGC>YVFJJIN;?J&_P!I6:;3/FQ4F=9BE[5B9[YB)CBJ
MR8,.6=<M*VGVQ$_C85_JE=*O^S-T^_\ <SMQ_BV7_P!=]9_RO=?X6_\ ?,/L
M>T_DL?[FOY&>X+L_M+M?+<9]L]KMNMNY[Q'30W>;!<)QK$I;K%1.F?1Q7&2P
M6RWOKHZ1]1(L395<D:R.5NGB776W.^WN\B(W>;+EBO+QWM;37GIXIG359CPX
M<6LXJ5KKW1$?B;BFJL4YH8JB*6">*.>">-\,T,S&R1312-5DD4L;T<R2.1CE
M1S5145%T4F)F)UCA,'/A+8'_ %2NE7_9FZ??^YG;C_%LY+^N^L_Y7NO\+?\
MOFO]CVG\EC_<U_(?ZI72K_LS=/O_ ',[<?XMC^N^L_Y7NO\ "W_OC['M/Y+'
M^YK^1OE:+1:K!:K98;#;+?9+'9+?16BS6:T45-;;5:+5;::.CMULMENHXX:.
M@M]!1PLBAAB8R.*-B-:B-1$..O>^6\Y,DS;):9F9F=9F9XS,S/&9F>,S*^(B
ML16L1%8CA"0,4@
M
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M4MI/.-:S$Z3V\6)?Y)=J_P#-GM]_V,QS_P!#3H'^H'T(_P#)/E'_ .!^G_\
M5W*?Z4>9O^T=]_TC+_?G^27:O_-GM]_V,QS_ -#1_J!]"/\ R3Y1_P#@?I__
M %<_TH\S?]H[[_I&7^_/\DNU?^;/;[_L9CG_ *&C_4#Z$?\ DGRC_P# _3_^
MKG^E'F;_ +1WW_2,O]^?Y)=J_P#-GM]_V,QS_P!#1_J!]"/_ "3Y1_\ @?I_
M_5S_ $H\S?\ :.^_Z1E_OV1VO%<8L:HMDQRPV=6\&K:[/;[>K4\+6:(M)3PZ
M?@8B>A$0[CT+R+Y(\KS$^6>C=*Z=,<OLNTV^WTX1'#X6.FG"(CW1$<H<?N>I
M]1WO#>;C/EC]ODM;]],IX[4T@    0=_QG'<IHEMV26.U7VB754IKK0TU='&
M]R(BR0I41O6"9-$T>SPN14144ZQYK\E>4//739Z/YSZ9L.J=,XS&/=8,>:M9
MG\ZGQ*V\%^6EZ>&T3$3$Q,0W-CU'?]-S?:.GYLN'-WTM-9GV3I,:Q[)X-@+U
MTC;,W9[Y*6V7K'W2*Y5_4M[J%8USFN159%>&7>*-$<OB1J-1J*B)IIP/DOS+
M_L^_NW]?R7R['9=2Z3>^LS]CWN32)F)C6M=W7=UKQGQ16*Q6)B(BOAUK/>MG
MZI^;MK$5R9,.>(_E,<?AG'X)GY]?EXL8_P!2?:O_ .#^X/\ [5<<_P 5#I/_
M -S.]"/^UO-W_2NG_P#Z+<C_ *X?,W\AL?W&7_',RQ_I1V9L4K)YK%79!-'H
MK'9!=:FIB1R:_B?1T26^@GU1=-)(GM\VO$]'\I?<*^[?Y6S5W.XZ7NNK[FG*
M=_NLF2NO?;#A^SX+Z]U\5J]T:\7$;[U.\W;VLTKGI@I/\E2(G]U;Q6CY+1+D
M#;;7;+-10VZSVZAM5OIV^&"AMU)!14D+>U(J>FCCA8BKST1-3ZUZ+T+HGEOI
MN/H_E[9[78=)PQI3#M\5,.*D?M<>.M:5^2'1MQN=QN\T[C=9+Y<]N=KVFUI]
M\S,S*_.54  "#O\ C..Y31+;LDL=JOM$NJI376AIJZ.-[D1%DA2HC>L$R:)H
M]GA<BHBHIUCS7Y*\H>>NFST?SGTS8=4Z9QF,>ZP8\U:S/YU/B5MX+\M+T\-H
MF(F)B8AN;'J._P"FYOM'3\V7#F[Z6FLS[)TF-8]D\&P%ZZ1MF;L]\E+;+UC[
MI%<J_J6]U"L:YS7(JLBO#+O%&B.7Q(U&HU%1$TTX'R7YE_V??W;^OY+Y=CLN
MI=)O?69^Q[W)I$S$QK6N[KNZUXSXHK%8K$Q$17PZUGO6S]4_-VUB*Y,F'/$?
MRF./PSC\$S\^OR\6,?ZD^U?_ ,']P?\ VJXY_BH=)_\ N9WH1_VMYN_Z5T__
M /1;D?\ 7#YF_D-C^XR_XYF6/]*.S-BE9/-8J[()H]%8[(+K4U,2.37\3Z.B
M2WT$^J+II)$]OFUXGH_E+[A7W;_*V:NYW'2]UU?<TY3O]UDR5U[[8</V?!?7
MNOBM7NC7BXC?>IWF[>UFE<],%)_DJ1$_NK>*T?):)<@;;:[99J*&W6>W4-JM
M].WPP4-NI(**DA;VI%3TT<<+$5>>B)J?6O1>A=$\M]-Q]'\O;/:[#I.&-*8=
MOBIAQ4C]KCQUK2OR0Z-N-SN-WFG<;K)?+GMSM>TVM/OF9F97YRJ@
M
M
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M_P"+=G_UG^I7_F'KG_3]U_C3_5^V&_S);1?]VV&_^@H_T \B?]B=(_Z'M_\
M%G^L_P!2O_,/7/\ I^Z_QI_J_;#?YDMHO^[;#?\ T%'^@'D3_L3I'_0]O_BS
M_6?ZE?\ F'KG_3]U_C3_ %?MAO\ ,EM%_P!VV&_^@H_T \B?]B=(_P"A[?\
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M.HX]?!EPY+XLE/%6:6\-Z36U?%6UJSI,:UF8GA,PVY_U?MAO\R6T7_=MAO\
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MVPW_ -!1_H!Y$_[$Z1_T/;_XL_UG^I7_ )AZY_T_=?XT_P!7[8;_ #);1?\
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M(>*;C<;C=Y[;G=7OEW-[3-KWM-K6F><VM,S,S/;,SJN2U2
M
M
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ML3VUK-:]FFD0Y$FT]#
M
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M-U:Q7<%>U.)P?5?O.>EVPQS;99=YOLD<HP[>U-?EW$X=([^<]T3R=O\ +?\
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M'#2N/%CI7A6E,=(BM*Q'**Q$0DS6;X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,1/NGE/R-G'GPY?XNU;3[)X_-S9Z:ZT
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M3DII9]AO-MQSXKUK';I.GS\OPMC'N,&7ACO69[M>/S<VYQJ+@
M
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MUM$Q:)TF)YQ+;B8F-8XQ*X(2
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M$_-+:K:MX\5)B:^SBE3!D
M
M
M
M
M
M
M
M
M
M
M
M
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ME$Y<?\)MXXS,<XCVQ^S&L=LZ.9VW4<.>8I;Z&6>R>4^Z?R_)JYE'".0
M
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M.;;JN#-I3)]#)[>4_+^7YW.TZ^Y0
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MC<$UEH
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M4ZCN]CN=C?P;BLQW3V3[I_LGO<[@W.'<U\6*=>^.V/?#=(U%X
M
M
M
M
M
M
M
M
M
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M)9$8-T
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M$P9:9::\]/%CM:NNDQ.FO:R\H<D
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M9(I&N8]K7-5$Z-EQ9,&2<6:LUR5GC$NQ4O7)6+TG6LITK9
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M,NVRSAS5FN2L\8_LYQW2[/CR4RTC)CG6DLH*F8
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MD<T3@G(@
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M=SGL=><J
M
M
M
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M,3&L3PE6,U8
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M:VWW-+8]Q2TUM6T36U9CA,6K.DQ,3SB8UA>F2H
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MC^ S^*W*E*WGP9K=\8+Y8CO<XS9>L@
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M,66]^^L.P8V'LH
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M-?!K,7K'#6^*V2E?%6+6BTZ.8IUEZ@
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M)F9Q7OX8XWBO)SB.IO7@
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M5O!\4T3T<B^<\\O2^.\X\D3%ZSI,3V3#L];5O6+5G6LQP2)BD
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MQEQ9,.2V++$UR5G28=NI>N2D7I.M)CA*;*V0
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MWX[6T_N9[O=/9/R3[>P;#>_:*_"R?QT1\\=_O[_G]W.(Z^Y(
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M_P!WO=A1UMRX
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MHC6:9:6QWTGE/AO$3I/?HESF6F
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MMJS$UM$S$Q,3$Z/+<F/)AR6PYJVIEI:8M68F)B8G28F)XQ,3PF)XQ*L7L
M
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MMOL]?M_E&UXC'O<59B(UY5W&/6TX+]D3,VQVX>')-IFL<SSOSP
M
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M/NW>=/26]NITUZGY/F?H[S%28G'KRKN<6MIPSW7B;8K:QIDB\S2.=AZ"^=@
M
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M'1J]<\K;FNXV<SX;Q]7)BOVTRXY^E2T<XUC2T:6I-J3%IWQ+G;@
M
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M"UHUBN7'K.G*8B]9MCO-;?#O>*S+DD6N\@
M                                           . 77-\PC:;HEQJDAO
M,?\ #C=S)*1]5AVU=JN$='7ST+9)('9+E5R]Q6MQ?%65,3H8IGPRU-?4-?'2
MPRMAJI:;N7D_R1U;SEN;8]EIBV..8C)FM$S6DSQTBL3$Y+Z<?!%HX:>*U(M$
MSXMZP^MWECTCZ;7[;_ROS)GI,X-G2T1:T<8^+EMI;X.'6-(M,3:]HFN.EO#D
MFGCWZCNJ+>_JQS:3-MY<NJKRZ*HK9,<Q2@=/083A5%7/B5]LQ+'5J)J>VP^X
MIH8Y:B1TU?6) QU543R-]X?7'E;R9T3RMM?@=+Q1&:T1&3+;CER:?I6[([8I
M72D3,S%8F9E^4?J-ZK^;O4GJUNJ^:-U;)6MK?"P5UK@P5G36N''K,5X1$3>9
MMDOI$Y+WF-6QM+0ZZ?AT3NXZ'=\.W]CR#>=1GC&O%.QT"</P^C73L[5T.1IM
M76\O4YTGBD(J!%[/H^TVJ;6.YQ>;JDQVKIU$G<B=GEJA=;;Z=C3IU&T\=96C
MZ->[VE%L&O8WL?4([96DE(C455;]?J[TUXE-MO$0W<>^\<Q$2C)Z=J:Z(GLX
M&GDQPYC;[FVO-#S0Z:Z\N1HY<?8Y[;;CMAJL]ZON*WJUY)C%YNN.Y#8ZZFN=
MEOMBN%7:;Q:+E22-FI+A;+G02P5M!6TTS4='+$]CV.1%144XO>;/;;S;WVF\
MQTR[7)72U;1%JVCNF)UB79.E]4WO3=WCZAT[-EV^^PWBU,F.]J9*6CE:EZS%
MJVCLF)B7I>Z!/G.T>5U=FVBZP:ZVV/(*RIH;3B^]T%/2VC&KB^2G2!D.Z,"3
M0T.-U\];&U$N]+'';%]__P!*BHHX7U,OS)YU](-STFM^I>6)R;CIT>*U\-I\
M6;']*9B,<Q77+CK6?#I>9S5BD3:V:;6M7]$/1/[UN'JV3%Y8]3[X\._M-:8=
M_$13%>=---W&L5Q7FW_#5B,4^+Z=<45F]O0^Q[)&-DC<U\;VM>Q['(YCV.1'
M-<US55'-<BZHJ<%0\3?<43$QK'&):@D
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M)CG$]DJQ#(
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M?PE8^G[8[+>^.WV>YR/3-UX+?9LD_1GZOLGN^7\?O=O!TMSP
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M'LG_ '?Q^^7=:=%=E
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MALK[#=6P6XUYUGOKV3^Q/MU=JVNXKN<,9*\^V.Z?[.7L;Q&DV
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M",GY_*8[I_W><-^CCFT
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M7,H^W'B@
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M9]OQM?8ZS]:LS,VR;;6=/%/T\/"+S>NMX[:CV%\6
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MV/AL
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MWPWG\ZO*;XKS$SCR1''C6T5O6U8YNESU4
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MAF>-\-Y_ML5OH7UUI?)V#FP]F
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MHV,;]G=&Z-L>C['%TSIN*N+98JZ5K&OOF9F=9M:TS-K6M,VM:9M:9F9E^/\
MYI\T]5\R]6W'7>N[C)N>J[G)-\F6\\;3/#V16M8B*TK6(K2L16L16(B(^GHT
MX*J</0=CQ8/8\^W6_G3FR&EI4X+X>'J3RYG*8<,<HAU?>[V>,:IF.E\VGI^[
MU'(4P. R[SOE)04?)-->6JZ>KV&[BV[A]QO^>BO)2+Q_#]7YBVVW:^/?>U9R
M4J)V?=ZN'F->^"/>WL>]F><K&:GT:NJ<_LX&I?%PX<G)X-UK;A*#J:;37\/
MX[+AB9=BVF[U[4!5P*G%$X<=>'$XS-28=FV6XBT\90LC-?5Y(<?DKJ[%@R>%
M'RL1%\O::MH['*8K_,]"/RFOF=5F)5^,]*G41?W5.&5CJ6P[-[C7BI\4^&UC
MW,I[7MYE%?4/UFPVK56P6>KD57V>564CU6WOA6V_//JCZ<4\.3S/T#'I:-;;
MC%6.$]LYJ1'*>W+6.$QKDX3%_%]X_=H^\)EV.;;^G'GC/XNFVTQ['=7GCAMR
MIM<UIGCAGA7!>>.*=,4ZXII\'U"GSP_0L
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M^9WZ6@
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M])G97^T8(UVEI_<SW3[.Z?DGLU[!L-[&XK\/)_'1^&._W]_SN;)P+D0
M                                                   #XJHB*JJB
M(B*JJJZ(B)Q555>"(B <%]^/F2=&_3Q+5VW-MXK)>LIHWK%+AFW[79SDL=0U
MWADIJV*QK/:[+41]K+A5TB\-$U7@<]L/+/6NHQ%L&&U<4_G7^C7\/&?DB6CG
MZCM-OPO>)MW1QG^SWNK7</\ :"<2@EJ*?:;I[OMX8CG,I[IN#EU!C_#1?#/)
M9<>H,B5Z>)/^;^.8JM77QHJ:':]MZ=Y9TG>;FM?92LS^&9C\3C<G7:ZZ8L<S
M[YT_!&KB7DWSX>K&ZS/_ (.X=LQBM*Y6JQB8[DM\K8_#HBHE5<,L93.8]$XZ
MT^NJKHJ)HB<SB\@='I'\+DSWG]:L1^"O[+4MUO=3]6*1'NG\K '_ #KNN&25
MTS<HV_A8]ZO2FBV[LJPQM5=?=,=,^:H6-$X?BD<[3MUXFU'D;H$</!E_=RP_
MKC>Z\Z_-#<.Q?/8ZMZ!?#=L5V0R&'QO>KJC%,IMU7X71-;'&R:VYO3TK8V2-
M5W&!SU\2IXM/#IK9/('1K?4ON*S^M6?QT_99UZWNXYQ2?DG\K=Z@^?\ [G11
M.;=>GW;^MJ/%JV2WY?D5MB1GA1%:Z"IH;L]S_&BKXDD1-.&G#5=*WIWM)GZ&
MYR1'MK6?V871UW+VXZ_/+%\Q^?IOI<J"6GPO9W;/$ZY\3FLN%UN.096D+G(J
M>]92H^P0N>S5%:CE<W5.**G MP>GO3ZVUSY\MZ]T1%?P\6-^N9YCZ%*Q/RS^
M1U"]0?5KOUU+7?\ 6N\NY-]RV.EF?/;+$^5EOQ:S.=XVHMJQNW,I;/22LBD5
MGO\ W2U#V<'R/YG;^G])Z?TNG@V.*M)GG/.T^^T\?DY>QQ6?=9]S;7-:;>SL
M^9Q*KJWQ>-%7777BG?\ E.3T:_N;P;8]7N^FSE13Q8[FE?><?@1K),0RR>JR
M#''T[555@I::JJ&U=F:J\5=034KE7])53@NANNE;+=Q,Y*1%_P!*O"=?V?EU
M64SY*<IUCNGD[@-@NKO!.H2A6BI&IC.=T-*E1=L.KJEDTTD3$:V:X6"M5D"7
M>V,>Y$<J,9/#JGO(T:YKG]4WG2\VQMK/TL,SPM^7NEMTS5R<N%F^]95*Y5X^
M7I-6L,IEC\LWB5>.O/0LB-&&JQD?S,H_"A:.=S[C+E[V*@KE74G0U:24 &E>
M9C/-C/-\(0  -<4LD$D<T,CX9H7LEBEB>Z.2*2-R/CDCD8J.8]CD145%145!
M,1,:3R.7&.;TA=+N[O\ EIV;QO*ZN1),@H$?C.6Z:<<CLT-,E35+I^%JW6BJ
M*>M\*<&?$^'L/,>K;+[#O;88_BY^E7]6?R3K'R.Y;'<?:=M7)/UXX3[X_+S^
M5R%.-;8
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MR5GC']G9W3VNSX\E,M(R8YUI+)BIF
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MW>QF]8_AL6MH]WYT?+''WQ#D>F;F<&YBL_Q=^$^_LGY_P3+T"'G3M@
M
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M)$XX^(^K=.S](WUMIN(GX4S/P[Z:1DK';'&=+?I4UF8GE-HTF>RPY1H
M                 &B22.&-\LKV111,=)))(YK(XXV-5SWO>Y4:QC&HJJJK
MHB%>;-AVV&^XW%ZX]OCK-K6M,5K6M8UM:UITB(B(F9F9TB.,LJ4MDM%*1-KV
MG2(CC,S/*(CMF7 +J.^93TP].*UMKN^5IFV94B*W^!N$O@NER2?FV&LJT?\
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MPK6\&FL1,6TF)G28B>#B=QM=SM)TW6.^/CI]*LUUGV3,1KR[.?.'(8VU
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MMHG28F)C28GC$\)7!LJP
M                             '7CU^]7#]@,-I\$PBH8[=C<"W5GP-9%
M4PI)@V-*KJ.IRJ:!DOQGZVKIO>4]H16MA6>&>=SU^%2"?S/U(\\5\K=/^Q[&
MT?U[GK]#A$_#IKI.2==8]E8GG.L\JR^H?NS^A5_5;S%;K?7\=H\B=.R1\;G7
M[3FTBU=M28F)TTTOGM6=:TFM>%LM;1YQHHI:B5\\[WS2S2.DEEE>Z22621RO
MDDD>_P 3GO>Y5555=54^2<N3)ER6RY;6MEM,S,S,S,S,ZS,S/&9F>,S/&9XR
M_7.(V^SV]-IM*4Q;;%2*TI2(K6E:QI6M:QI%:UB(B(B(B(C2.#(:>G1J-3PZ
MNT[D7SE7-Q>;-K,SKP3E-3\N''S_ %F,_@<5N,^B=BIN":-U7T$?B<-DS\>,
MI2&CY:IQ]9&K1R;GN7SJ1$:B:)RY:>G@-6I&XUMJLY*9.Q-%]GV#5LTS3VK%
M].J:\.&GW$^YM5S1*(J($37EHOT$\_>Y+!FE 54.GB3L7AY=Q.NO%S6#)KI/
M:QZHBT54,X<QAR:\43(WBJ=Y,N0I*BR22&2.:&1\,T+V2Q2Q/=')%)&Y',DC
M>U4<Q['(BHJ*BHO(SQ9,F')7+BM-<M9B8F)F)B8XQ,3'&)B>,3').?!@W>"^
MUW5*9=KEI-+TO$6K>MHF+5M6=8M6T3,6B8F)B=)X/1_\OOJY_P O&&NVYS>L
MFDW:P&U1255PJIO?OSC%89H:&FR7WKOW_P#75NEJ(:6Z-D\?O99(JELCEJ)8
MJ?ZV]-_.]?-/3IV>^M6.M[>(\?9\2G*,L1W]EXCA%M)X1:(C\@?O-^A5_2GS
M)'6^@8[3Y%ZEDM.'MC;9N-K;6T_HZ:WV\VXVQQ:GTK8K7MV,GI;Y<
M
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M<NDWPSRI/BQ:5BN/Q]H1ZP^0P
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M_.?1O/WEG;>:.AW\6TW%/I5F?IXLD<,F')'9?';A/9:-+TF:6K:=\C)VP
M
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M>L1\3%:8TU\.L6K;2OCQVI?PU\6D<E2QWH
M                                       ;1[\;U85T[;19SO/N%4SP
M8M@MF=<JN&CC2:XW6OJ)X+=8\?M43G,B?=<AO=93T5-[U\<#9IVNEDCB1\C>
M0Z5TO>];ZCAZ3TZL6WN>_AK$S,1RF9FTQ$S%:UB;6F(F8K$SI.FCK/G'S7TG
MR/Y9WGFKKEIKTW9X9O:(XVO:9BN/'2.4WRY+5QTUF(\5H\4Q768\('41OUGO
M5#O'F&\FX==//=LFN$WZHM"U+JFW8?BT$\W\'\-L;4AIHX[3C]#(D;7)$R2J
MF62IG\=1/-(_[@\H>6-GY7Z+AZ3M8I-ZQ$Y<E:^'XV:8K%\LQ-KS'BTB(K-[
M^"D5QQ::TA^*?J7Z@]9]0?-.[\T];O,Y\]Y^'376N##$S\/!CX1]#'6=-=(F
M]O%DMK>]IG:^DI^7#[_5S.\8<7*.UX]O=U,ZZSP9#3TZJJ</5H<IBQ:^YU?=
M[J(B>+(J:FTTX)YM=#EL&%U3>;O77O3L%+KHY?+D<G3#'-US/NYY0E(8$X:(
MG9V?DX&[CQ1S</GW,]LM4D"\>'ER]9E?#W,,>YB9Y\5C)3(NOW?8:M\3D<6Z
MT1M1!X4T5/3W>8U,N*/E<KM=Q,SK$H"JB3BFGT]GM.)STCYW9]IFTTEC=5#^
MEY>KU'$Y\?:[;LL_"(8Y41^%RG%Y::.U[7+XJQJBY4Y^7EP-"\:2YO#;6L:+
M)VO-.Q?MX%,Q$\)Y.0QSP]KV%_*$ZZ)^I':R79C<N]NKMZMH+321Q7&X3L?<
ML^VYA=#;K5D4TKE2>OON.2OAM]UF>CI9_'2U4LDL]3,K?D?U1\E_Z-=5_K#8
M4TZ+NK3-8B.&/)SMC]D3];'R^CK6-?!,OU/^[%ZPV\_^6Y\K]?S>/S;TO'6/
M%:?I;G;1I6F:>VV3'.F/-,ZS,SCR6F;9+:=R)Y:^I0
M                                                 <2>L'K9Z?\
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MJ9+SWD'D#[!
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M$R:GJ('/AFB>G%'-545#J=JVK,UM$Q:.R7)1,3&L<ER0D
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MNGSN9Z-F\.:V&>5HUCWQ_N:_,[J3HSL@
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MV^]I-;=D\ZVCOB>W\??#M>WW6'=4\>&=?9VQ[X<B#CFP
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M*S(&4T"O2-OB\#&^)4U75>)NTZ+T>G"FUV\1_-T_(JG=[NW/)D_=3^5DV/\
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M^.$_A;PFDV
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M]5>^1[U5555555=5.WTI3'2,>.(K2L1$1$:1$1PB(B.41V0T9F9G6>,RIF0
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MTXWK'@XS%(CMY/V9?'(
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M$;QG,.E@
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M])WNQSS3Q1$Q7)28B^++772?#EQVIDKKQB+:3Q;K'+.H
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MCRXZY<5HMBM$3$Q.L3$\8F)CA,3'&)CFKD,P
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MI@S^*8BN/)K,8,^LS$5BE[>#),S%?A7O:8F:4T]LIVQ^JH
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MG96]<E*<MSK;TH
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M/,W0MGYAZ7;Q]/WNWQYL<\-?#DK%O#;29B+5U\-ZZ_1M$UGC#/S5<P
M
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MRC*[CLODU2D;9[1G]*YEMBGDT:RG@O\ 1,DI:R1TFJ?AC\*(J:KJJHGGN_\
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M
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MJ:*L@>G)\;W-7O.FY,>3#><>6MJY(YQ,3$Q[XGBY>MZWKXJ3$UGMCC":,&0
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M6',@
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M<U*Y8R;;I>.TVZ?LO#K\.;5F*QO=W2)GQ;O/2*Q>UOL^'!32KT':WV/1=O\
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MWD2OE_J\>8^F4\/2-]>?'$1]'%GTUF([JY8B;UCLM&2(TKX8<X#[R>$@
M
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MCCX^&T;+=S'.<=_%?;9+=GT+_$Q6M/&?BXJ\JQIWKGT0_.$
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MF.'BR3'9I'/\V7L8
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MKWJ'C;['
M                  ;<;QMD?M%NHV&1(IG;<9PV*5T?O6Q2+C%T1DCHE<Q)
M$8Y456^)-=--4-K8Z?;<.O+XM/WT*=Q_1\GZEOQ2\X..(BM8G#1--=-555X<
M^Q>!Z?E=2HWML<*.:S5.6G<GTHFG,X_)+9JW2M3$;X>?TK]AIWE?5N/;%_1]
M2^7<:MUU99W0IKX?5V_D->W!=#+Z)/T>SEY<S7LLAE5(Y-$]/9^?M*K+(9#
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MX^_\Z/R_C]KUF[.;X[1]0>$V[<79?<#&MQ<.N;(W0W?'+@RJ^%G?&V5UOO%
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M02QS12(B*K)8GH^-Z(Y%:JM>U%XHJ"8B8TGD1.DZO6,>/N^@
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M-5(G#AR=L6M'SQ$_L.<Z);^$R5[XB?FF?RNX<Z4["
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M6I>LZ:UO29K:LZ:QK$Q,<)T7YR#7
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MC]6)UGC.FD3IQ^W(^<[T2X31.DQ;),UW9N*QRI%;\)P>]6N**I:U_N65UQW
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MO.GLSTQSWO7L?<C\*0
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ML>Q5:]JHJ*J*=#O2^.\TO$UO69B8F-)B8YQ,=DQVP]7B8F-8Y+@Q
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M4C]:+5_?UJHY#^T3]&=JI??6RS95<JC21?<5-;;:=NK$:K4\5ECR6IT=JO\
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M"\8KQ$=]ZYZS/;ICCLB7J?.POT&
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M+S+V*'R:_5T
M                    !'7BUTU\M%TLM;[SX.\6ZNM=7[I6)+\-<*:6DG]V
MLC)8TD]U,NGB:Y->:*G RI><=XR5^M68F/DXHM6+5FL\IC1YDK!!4T=3/0UD
M2P5-'/+35,#FIXH:BFD=#-$Y473Q,E:J+IKQ0]6RS%H\5>4NFTC2=)YM[K&]
M/ QO!>7-/0<?D[VU7N;EVQR?AU1/8:EU]6X=K<GX>/=W_P#S*&K>%M6?T+DT
M3O33Z?8IK675932.TT\O+D4RLADM(_EY>=2JT,X9%3OY>7EQ*I9PDN9@R?0
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M[_[I[UT1$1."(>DXL6/#CKBQ5BN.L:1$1I$1[(=?M:U[3:TS-I[6/%B
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MQ^[^(A9+[OQ^%GC\'CTUT37N0\AM'AM->Z7?(G6(GO79BD
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M98O"FFBM\-&_5=>"Z=YU?S3,?9<5>WXG[$_E<ST6/X>\_M/V7="='=D
M
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M4?;CQ4
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MMR^3O/.V^#OZ:VQ9:3-L&YQ:S%<VWR3%?'CMIVQ6])^CDI2\36-^SMCS,
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MC=TYATT
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M<8F-8F-)B9B7U1M]Q@W>"FYVUZY-ODK%JVK,36T3&L3$QPF)AFIK+@
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M>615=%%=L'9]"&<59Q17]QR_#V&7A9>!42#3L3R]1/A911]2!?S?E'@/ U+
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MKCCY<OP_V-9X/<F=Q?K0
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M=SXIF+6ZEBQ<.[-,X;?)-<DQ/LU>\0^'W[<
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M/5,>2.]
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MK^P[8#J#G@
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MNGYTS'@GWA.EUW/E;:]4B(G-M=W%=>V*9:3%M/?>F/A^1VYG[)OCP
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M&^EK3QF>=IF>Z-=(TC2',$[:\>
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M)\*?"K,A\VGE[28AE%5PV-.'#5?+U&<0SBJJB&40SB%1&JOF3O,F2IP8GEQ
MY\[*7Y;WM]:6O>KI[-)462=57BC:-6R4;>?!&6Z>%OJ/G#S[T_[!YES36-,>
M>(RQ_;<+?/>+2^2O4[I?]6>;]Q:L:8MS%<U?[?6+_/DK>?E;KZHG-=#ICS]]
M  -=>8'Q5T34"BKET77DO%?R 6\KN'J^O\@$5.O/U_1HB 8Y7:+XN/KTUX:<
M. &'U^FCN_CK]@&^'0_5S4/6QTI2P>!'OZ@MJ:1WB3Q-]S<,SM%#4:)JGXOA
MZEWA7L713E>B6FO4\<UYZ7CY\=HG\#T7TAR6Q>J?EVU.<]9VD?);/2L_@F7Z
M AW5^RX
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M_P ];/\ X^GX_P!E[YCX4?N6
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MI6/EY_W,2W.G8OB;RL]E>,_)R_#H]"9YL[8
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M6.L5_9G\,S#L_2\7P]I$SSM,S^Q^*',TX-R(
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M/WX?!@
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MKBO.*>?'6)I/B[/%KIPT<I#M3R4
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M]B
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MOBF/=IK#[!^Z_P!'GJOK'T'!:=*XMQ?//_XOARYX[^=J17WSV<X]RI\5OV@
M
M          -H-^]N6;K;1YOA3(F27&XV>6JL*N\*>[R*U.;<[&J2._YIDMQI
M8XI')Q]U(].2JAN].W7V/>8\_P";%N/ZL\)_ U]UA^/M[8^V8X>^.,//=8*Y
MS7I%*CF/8OA>QVK7,>U/"]KFKHK7(J:*B]J'I&6O;')U6DM\\=J?%&C?%W+I
MP3UZZ\5[SC\L-ND\&YMMDXM75/4GW&I==5GUMD7\/'7EIS^U36M"ZK.Z)_!O
MH3M[O4:UEK*J)==/44V60RRDY)W?:4RSA-P_H^7>I7+-6(2 =0?SC,XDL^R&
MW6"4\RQ2YMN#)=*MC7*BU-IPVS5#IZ=S?"K5B2[9!0RKQ14=$W37CIW7R1M_
M'U#+N)Y8\6GRVG\D2XGJ]],%:?I6_%_[8><D]/==  #FWU_6GY +.:/M[/+C
M](_$E%U$?/R\M22$%4Q\_9]9#% U,>FO#L)$!4L3BFGTH2ACM2Q./EWDG8@9
MX]=>"\R90AY8]57U_3V!'L1\D2]WE^0<^?,6ZQ+W?4.*%)8W)V 4W1]Z:+Y>
MH)4E:J>CO)&D     *D::K]'M R2WQ)^'5.Y?R:\S$;@VMB-1O!$73V"4LXH
ME1$:J>7#VF+)E5-)R377@1^),?@3$4B=_'GYO3ZP+MLJ=_'0)?5D3S@]ZD]Z
MZ?5IZ! CI7<_9[%'-"(J':(OW^D3S.U"3R\^/TDQP8HN6=.(2C)I_M)]Z$9+
M4\^)(BYJGGQ&A[D5-4<^(U[$(J:HY\1IVH1$]0JZ\?+N])/XT(Y[^_BO<$J!
M(        56JB-0QXZ\$Z&NKN'=I]I/'M0U:IWH-1\\3>\:FC2Y_+3UCF/GC
M7N&@>-?,-!\\3E[?8-(#\2]XX'$\+NXG4:D8O:HXCZC$](XBHC.YOF(X(54A
M<O/R]I(KL@_.1[Q<-A7L31!J<E7W*>OUCBEJ]VB)HG/Z/8-!H='PU7\J#3N'
MJ=QNI?=<;Q^Z2>-7W*R6FO>LBHK_ !5E!3U#O&YOX5?XI..G!5//<D17):L=
MDRY*.,:I&6+37AR\OI(B4:+&1G#EY=YE$H6+TX+YC*.:%DY-%4RCDA\)0JQN
M<BZ(OV_7P(F.*82D*^+FB<>":&$LH3-/3J_331>]-./9V%<RRB%Y-;E<S@FJ
MHG+3_P!=,8NF:NVKY=6VBV3#,LW*KH%95Y=<V6&S/D9HYMCQ]TBUM1 ]%T6*
MX7FI?$]%3@Z@0Z;YFW7Q,]-K6?HTC6??;E\T<?E<[TG#X<=LT\[3I'NC_=_$
M['SK#EP
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M=%U]HY0A%33Z:\?+S#FB91,]3S1"80BI95=S7\GY1^(6;G:\N7UDI:
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M<$1.'(\MR7MER6R7^O:9F??,ZR[A6L4K%*_5B-/F2A@R
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MY5_[TI^\NZ-ZG3_]@'5(_P#P6?QU=\1_0L_/\
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M>]^!?F'JM^O=?WW7,FOQ-[O,V>==-=<V2V2==.&NMN.G#N9>;CAP
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M[:-QY2G+VX=SCO\ /XL?^_<X%>B<W+KZ43T<$/G]\NB/5$T^L#6U^O/1 -8
M"W5VJK[?0GG M)>*+YU^Q?2!#U"Z:^=/L0#&JR3151>/#MUU[ ,.N,VGBY<=
M>W3V\^\#M1^1_MX[->NNVY7[UT,&T>V6?YMK[CWL=55WJCI-LH+>LOC;\-(^
MFSZ>H:[1RN;2N;IHJJG/= Q3;<WS376E:::_HVM/#Y9K%H]VONGZ9^Z;T2W5
M/5K'U'72G3=AN,_+76;UC:Q77LG3<6M[JS#V:G;'ZA@
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M%%9_6?2GW?.AQU?SE_6.:-=MT_#;+RX?$O\ 0QQ[XUM>/;1U*U,?!>'?[%/
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M,O"QF[5X/03X88^)J\"$Z>Q'B??"G<3I*-9?=$)T1K+[H3X0T,HJ!/A0$Z1
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MC7G#U<GS(_3(
M                        >?3J:PA-M^H3/;13QNAM=YN+,NL[=/=Q?!9.
MS]93PP,1$1*>ANLE33,1."-AT/2.E9_M73<=Y^O6/#/OKP_#&D_*ZKO,7P=W
M:L?5F=8^7_=1V,52*L:?A5%1$YKQ5>Y5^XG-!26[UNDT\/JY:_D-*T-BK<"U
MOU5O/3AVZ)]!K770W"H$54:B\$[->?WFK9=#,*%NNGJT*++(9A3-T:WT:E$K
M(3,::-0PGFR:R$@'GX^=!>'SYWL9CZRL6.V8EE]X; DOBDC??;S::)\KH-?W
MMDS<=:C7Z?C6-4_<</2/(M--ON,G?>L?-$S_ +YP'6)^G2O=$_AT_(Z5#OCA
M@ !]3M]'U*B_4@&AR:H3"8[D9.WGY<OM(["4)4LY^C[/L)0Q^J8JZ\1"&.U,
M?/GQ_+]9/M$#41KQX>TE'O0D\*KKP^HD1<E.FJ\-/+UD<6,PM'T^O!$7V#7O
M%):?3]S]?WJ(T%-U-IV>Q/+4D6SZ;BO#Z/N7B@%C) K573V?<$+1S.*]BDI4
M@   !<0)Q;_ZUKY>P#++<G%.78G).\@9W0(C4;Q^C0Q9LLI7<&HBD#(*>714
M]&GE["!),GTYKP\NPE.JX;4<OQ:^M=/I!P:_B/.GM)XITCO?5FX+Q7V&(MGR
M(J>TGDA$U+E34A"!J7<^SGY?09([$#42::ZK^<0=B'GG5->.I/XQ%35'/B3R
M0BYI^?$CC*-47-/S\O+4>Y"*EF5=>/Y2?=S%D]_;V]@]@H<R4@
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M6@
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M.O>8-S--G&&.>2WX(X_CT<GTW%XL\Y)Y5C\,\/Q:NWDZ8YX
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MV2QF-&I4U)F$0IJWN*](91/>>%1I"?%#6B:$Z2QF=7TSB.Y $ 2
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M8]WT\M>>D=G/1Y=ZTYZ8_3G?4M];)?!6/?&?'?\ %67=:?O ^&@
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MQ>2_1?JV6+^'?=1Q_8,,=MK;F)KDTGLFNVC/>)CCK6--.<>IT^R'XQ
M
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M:9>I;F,6*9K_ ,#MO%%K5M^C?->]+1'#7!&NND:=_1S#[&
M                                                  .E/YX>P;=P
M^F>Q;T6JE]YD>PV3PU-PD:[1\NW^=U%NQ[((FP1T\DU74462,LU4U5D9'3TD
M=6]4775/7?1KKL],\T3TW);3;[['-.>D?$IK:DS[X\=(]MH?)/WP_(\>8_3>
MGF?;4UZAT;/%YGMG;9YKBRQ$1&LS7)\')SB*TIDEY/:"HU:B:ZZ+IZ47E[#[
M)V^7A#\ANI;;PVF694C_ !,;]QSV"W"'0=]C\.28CM3L"\$X]WJ.5PSQT=;W
M5>*<IG<$X_6<CBEUW=53$2^?R\D.1K+@LT<4C#V<?+@;U.;B<\<)2L?)/+O-
MNG.'$Y>:Y3DAL]C6GFIKVF%XUB6<+:5NK5-:T=C;PVTF)=6_6Q>5J\\QO'VO
M\<-CQMU8YFO"*MO5?.DZ:=CG4ELIG+YE0\,]2L_CZIAVD?5QX?%\M[3K^"M7
MW5]VKI\8/*N\ZM,:9-SO/!$]],-*^'^ZR9(]^K@Y4L^U/;P/+LM>#Z=P68]5
M1\%]:>OCH<9FKVN;VUV/SQZZKIP[?S&G:-8T<SBOV=J-5GA<ODFAJS7BW8MX
MH?4YH9(GDNV+IX2ZC7MVI%G-OEV%E6G;M2D/V+]9LXVAEY)&'[$-NO)QV1)P
M?N3:HT<O:EH^2>HVZM"_-?)R+:M65PWF9UY*;<E4V*JVA_VE5^;.JT?R5"BW
M8V*\T54>7L^PU\C?PH.H3GZ30O\ L.3Q2AIN:^KZC1R<W+XN4(N5?PJOEVFO
MVN0I''1%2\5]' U[S])O4Y*#N2^@JMS6QS(TUT3O4FL%YT2M.S5473@FB)IV
MJ;5(:&:W!D](Q$1/1Y)ZCD<%8T]K@-W:9G1/TRHFGJ.2Q.&S1JF(EY>7EQ-F
M.3CLD+MB_>71/:HM"Y1=4+XGAHHF-):'J5RRJH.7B5]BV.2WD3CK[2N5U$;-
MPU[BF[=Q\4;*O8:MIYRW:1VK&5W'T%%N3:I"SDY(:]YXMW'"RD7@OL^TUI;=
M(6:E=FQ"SD75=!+9I&D*#ET0IMHLK&LK95U74JF>Y?$:*2JJK]A@SB-%:./7
M[RRM?G5WOHD88D7BJ<$Y(;-8TCVM/)?L[4K#'R73CV?<75JT,E^SL2L,?!.7
M+ZS=I31Q>;)K/L2D,7+AZ.9M4HT,ETK#$B)JIMTJT,E]9T7S(TX:^SL+HAJV
MO/8O&Q\$\OH+8KI#7F[5X/03I#'Q-7@0G3NA'B??"AEI*-9?="8JC5]T,O"!
M/A0$Z0/HT@!K #6!\U0QF\)TEI5R&,WGL3X9:5?Y*83=,54U?J8S,LXJTJ[N
M,9GO91535Z)S4CQ1V,XK/8I^]3B8^*67@:%>J^@C6&<5B&Y>S5<ZCW7VYE17
M(K\SQVE_#HJ^&NN=/1._2X>%6U"Z]NG+B<UY<R?"Z]L[Q_E../W5HK^RZ5ZC
M;6NY\A=8QSII'3=Q;]QCM>.7MKP_"[J?'Q\OJ/I*+1+\UYQZ0JMD\NPSB=%-
MJJK7\3.MN]1>G:K-=Y]2S\:B:JNI.LL%*3M(E918R\E]*&M?ZOR-W#S0E2NG
MB\N\XO/P=BVG&88C7O\ TM//^<Z_N[.]],Q\FWEUE75=7)VZIJB<OR'5-[;G
MK+U?HF*.$1'![)_E";!/V1Z-L/O5VI$I\LWMK9MW;RLD--\3!9;]24='@E E
M7"Y\L]$[#J"DN+(Y%1:>HN4[?"B^)5^&/5#K4]:\X[F:SKM]M_ 4_P#C<SX_
MGR3?2>V-.Y^UGW7_ "1/DSTHV>7<T\/4^JS.]R:Q&L5RUK&"NO/2,%:7TGZM
M\EXTB=7:*>>OH@
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M=E;#),KVKXFN9X-==4TT.-W-IC':(Y^&?Q-O#$3:->^'?H>=NS@
M
M+*Y6^DNUNK[57Q)/0W.BJK?6P._1FI*R!]-41.\TD,BHOI,JVFEHO7ZT3K'R
M(M$6K-9Y3#S1.M53BV3W[&*Q%2MQR^W:Q5:+IXDJ;1<*BWSHOA1-'>]IW:H>
MI^.,V*N6/JVK$_/&KI^G@O-)YUF8^:6]N.2N=$U%7CHW@J)JGL553GVG'Y8X
MMFG%NO:E7\&G-40TK\^+8KW-R[2QR^%53@B:J:E^Y?5N!;H7.\.B<.?=]:\3
M6M*VK.**#P-373537M.JV(3T3/"WSK]17,LU4A(!C&;0S5.&9=3T]2ZCJ)\8
MO\,%6QGO'4LTMJJV15+8U<Q'N@>Y'(FJ:JFFJ%NWF(STF8UCQQ^.&-_J3[I>
M'0]_=)   #[V)Z5^P"E(FJ?0.Q,(N=O!?7]',':@YV*NOEVDRA U$:\> 0@:
MB)55>!*$/+3JNO D1DE-KV<_N LWTG'D-136EY<.XG@*:TJHB\/3Z>T&BBZE
M\WV?0-$+*2EUUX?1Y(1R-$7-3*FNJ$H1DL"MXI[ +1S/-HOT$BDJ*G,#X!J9
M^D@D3="W]'LU\E(&;V]-$UT\VH9=C*Z5RZ(8B=@DT1/4OW$)23)_+N[QH>]5
M2I_%SY>6I&DFJNE4FNFO9Y=_>.(^K5)W_3^0:#4VIU3GKZ5&O>D=*CD7C]*!
M"*J%UU\NQ28Y':@*E.?K^TE':QRJ54UXDB!GD754U]),H14TG/B1$(14TO/B
M3^(1SWJOI^H<_<A;O7L3UDI4@       /J(J\@/OA=W#4:O!YQQ&I&)YU\O,
M/>*B,=R1-/+N0@56P.5>/T$H54IO2OL^\A*HE+JG!/J^X"HE-Y?F4=@JI3?\
ME/I_(#@JI3+W</1^<"JVE7N^O[-". JMH]53A]?U*/D%PVD[]5^GZ-!QDT5V
MT>G9Q]'Y!Q3I"X;2^;AYQP^4T5OAO-Y>TE/]G]G!I2G7R\D![A8= <5%T:IV
M ]ZBZ/7TD:0C3N<\/ES0Z]05:FG_ /;O)%[O_P!YXZAPO79_Y%'\Y'XI7[:/
MX3Y'>3+3^8ZC$MV81%3!P5-/J\E+(EC,(21GE]A9#%8R1\^!E$_.Q6$C='&4
M(4R4+F)>7H,9Y,F3T"-5$35>2)Z/J*K:LZZ-TK#%#(L:<=5\*:\%71%T[^'!
M32RS*^KM0Z'*:GI:+<5K6HVIGEQ65ZJFCI*=K,@2)-=?Q)%*]^O#AXTUYH=1
MZ_,VMB[H\7[#F^G1$1?OX?LN>IUYR8
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MZ^R7A7W@=W\+REMMI$_2S;^LS^K3'EF?[J:NV8_91\?@
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M,3]')O,U*7RS$Q.EHP4G'@X_2QYHW%)TXNW,]6?'@
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M;4Q1,1$>.U8^GDF(X>+)?Q9+]]K3+=LQ=B
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M5K6.$16(TB(CLB(X0O#!8
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MOMM.WSS&G\',ZQ^3Y'8=OEC+CB?SHYMW337@
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M2*6-S7QR1O:CF21O:JM>Q[5145%5%13J$Q,3I/-S36
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M.7WB;7CI_2Z1_%SFS3/OBN/3\$R[.3]87RP
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M72-=,F2VG".'9')R-*7'@
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M63-F_ML.#+EI/R7K6?9S>Z(YM^MH
M                                  >+'YO.V<>VG7;N14TE*E';=SK)
MB6Z5NA;"D;'/OEM=8+_5,=_Y9:[+\7N4[WZ?\Y(Y.;5/M'TDZE_6'DC:6M.N
M3;VR8+3[<=O%6/9IBR8H_#VOR,^][Y9KT3U;W6\Q5\.WZEML.YB.4>*:_"R3
M[=<F*UIGOF77U;7JO@Y\4TY)]Y[+M+:OB+J^.(B>3*J9>ST'-X>QTK=Q&DRR
M&C370Y;%$S+J^]F(U3L+?,<KCKV.M;B_&4W31Z(BJ<ECKVRX+<Y.R$BQ.WN-
MS'72-7%VE4,V"DO-2)9QR:')JFB%-Z\."REM+:RZ9.I2!\>]N?,D8K'+7VZ1
M$<BHJLEL5JEC>FO[F2-Z.1>U%U/F[SK68\S;O7GXJ_-\.NC])?1?+6_IETFU
M)B8^%DCAWQGRQ,?),3'O;!2MX*AU.T/6*6XZH:HC3C]/H4T\E7)8;RA)X57A
M^94./RT[G+8,T<I0D]/Q37O7L^@U+5F)<MBR\."W]UY?G,%WQ%5K4:@XS[E<
MVU74+>WO7ZBRL*,D]B3B3@GGXFU2''YI[$A$G!/.IM5YM"\\4I$BZ\#:I$Z0
MTLDI.)B\/:;,0T,EE\U.TM]C6M*NU.!;"JS671R8-#^7K^\JOS9U6C^WR[37
MMR7U1D^FA1=O8N:$J$Y^I31NY/%/)$3I]OWFCEARN">"$J.2_P#K7VFI+E</
M/Y$=)R\N\HMS;E.:U?V>DJMS7U7,2<RVG-3D2],O!OH[C9KS<=FCFFX'::>G
M3[?M-W%.KB<]4Q OV*;N.7%Y82\+M4T-RD\''Y(XKYCM4+8G2?8U+1I*Z8O+
MV%L=RFT#NU18A1,++%N_GZU,.Q;583]OK^TINV\2)F3BOH-.[D,<\$9)R=Z#
M5R.0P\T;*[3ZC4M/%R&.-5A([1"J./%MTC65DY>:J86LV8CL6SG*Y2F>]?$1
M"DY=$\Y7+.(?&IVDUC64VE>1MT3SJ75C5K7G6?8OX6Z)YU+M..C4R6UGV)2%
MO!$3T%](XM+);O243=53S</RFWCC2'&Y;).)O;ZD-JD<8AH9)[$I"WR]1MTC
MM:.24C&B(FO:I=7FT[SQT7D:)]!?31K75C85A$SH/@U@#&;)?-=##Q&C2K^X
MB;,HJIJ_S^PP\4]C.*J:O]1C,QVLHJT*].UWEZB->YE%9[FE9&IY_08^*644
ME36;N^M"-?:SC&I+/YS'6&<8E-9T[^/I_,1-X9QB4G3F,W61B45F77GY>TP\
M:R,7!I67@1-^'%E&/BT>/RU(\4,O"U))YU'BCO8^!]20F+:(\#)\,6:7+L5C
MIW*R=^1V-D#VO5BMF=<Z5L;D>BHK%:]475.*&]TZ;SU#!%?K3FII[_%&CA?,
M<8Z>7]];+&N*-GFFT::\(QVUX=O#L[7>:DGES_*?3$9'YB6Q1/)4;+Y>7$SB
MT2IMCT7#7ZZ?>6UM,-2]-)5D?Y>7,OK>)4VI$KB-_G+:VT]S5O56\6J:&4S$
MQ.G-5II*SD4KELT1=5V\^79Y<SCL^FCF=I/N8A<V:H[@O%%TY=W Z]OJ_1[7
M?>C9-)CDYA?*Q;;V?,/Z=77-U+'3I7[C>!U:^..):]VSNX<=I:Q9G-8M5)=7
M0-@:GXGSJQ&HKE1#PKUAF<7D3J7AU^):F&.'/3[3@\7R>&)U]FK[O^YWGPSZ
MU=%C--?AVC=Q&NFGB^Q[B:QK/;XM(KVZZ1'&='MD/AQ^T@
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M'>,E=89B4LP
M                  ?'.:QKGO<C6M17.<Y4:UK6IJKG*NB(B(G%0/.?G-]C
MW WBW%RZWJL]!?\ -+[66N9&,19[5^L9H+1)HSPHJOMT<2\-=55>*KQ/3=OC
MG;;'%AMPM7'$3[]./X=74LEOB[B^2.4VG3W=GX&[V*V&>5D+&1/>JZ*KM%1N
MJ:\$;HJJK=..FO$T<V2(ELXZ3,>UR!Q_'?AT8^5-'<-/$GA\/!%1?!IJKN/;
MIIW'&9<NO"&Y2FC<^@I(X4;JFJZ)YM?4FOWFI:TROADU.[731.'V%,LTFR33
M1.7U&,PR5D?WD:=PUD)?0 'DJ^8IMO-MOU<;IPI3^YMN;5]-N1:)/#X$JX<Q
MA^.O%0C41$_#E<=QB5>/B6)57BJHGLOEC=1NNBX9U^GCCP3[/#PC^Y\+JG4,
M?P]W;NMQ^?\ W=7"(Y]I  !V)Z_9P3[ /B_8$PM)$^Y1VB+F8O'AY<47UA"+
MEBUU)T.2PD@3EIP\N9"%F^GY\/+ZB=>\6ZTVO8O>!H^$XZZ?1Q TNI->SZ A
M2=2<.7EY@:0M7TG#EZT)-%C)2<%X>7I B9Z7G^'3U$B*EI.:Z#7O$3/2IQU0
M(T14M)SX+^?Z%)U0LG4R:\N7F]'H"'UM,B*U4TX+Q\M/,!-4E,[5$TY^7J3[
M2$Z,EI(E:B)IV>O7\P9)R)-$3T">0N4=H1K$IF(:'2Z=HT1^)1=.B(O$:)U:
M/B$1-=?/W#1#4VI10G56;4)KSXA'!<,G7O\ +ZPG1<)/JG,C@AH>Y')WC41=
M3'XD7R_(9#'*J'GP^HF.X]K'*J%4=KIP7GZ?R$>QBAYH^?#O\O63[!9+'Z4'
M%#0L:]VJ>@&HD:]B(GEYAP2UI$Y?3Z/S$BHE.Y>>J?01J*C:77O7R\VHU&I*
M;CR\O8$*S:7S?6H]B59M+W)]'YA(K-I>/+[/N(%=M&JKRT]>OT<1\@NFT?F5
M>_RT)XFBZ91JJ\$]'DA"=%XRB\W'MT'#1.B[CHN/Z/9]I.HN$HE_N5]G B=1
M6;1)VI[ ?B5DHT[N/F3[D JI1][?H_,(%5*/_DD:P*S:+7DU/+UH-2%9*+3C
MIQ^_U@:TI%[OK0:I5DHN"JJ<=/L ^)1Z_N?H(&I:7PIIIY?0!:OI]%7AVJ3K
M*%L^GU[!J+*6#3D2<EC)#IS!S=FGRO;4^;<G<ZYHC_=4>#4- _2)RQ^\N-^I
MJB/Q3:HV-_AM3_"U457IJJ:>%=>N>9+Z;?'7OO,_-'^ZV]I'TIGV.Y:H@\.J
M>GN[]#J<2W98[5Q<^?;V%M95RQFKBT773S+PYHI;#"43(S\AG[6**J&\_N]9
MG#&49R+&+7&O$B4PF:-VCTXZ<=5*YY,H;B6:=&/9Q71=-=%7CQ3NUU-;)'SK
MJ2WSQBY/BDA<S]RJ.YJG=IRT5>1QV:D:<6U278QL3O*^BAI<=O\ 4.FM*JD-
M+4JUSG6Q[E_ FJ-5[J1[E5'-XHW])NGXD=UCJ&RUF<N./I_C_P!UR^VW'YMO
MJN;;7-<U'-5'-<B.:YJHK7-5-45%3@J*AP3D'T
M                                             ;!=0.[5!MMA];24
MM<UF7W^CJ**P4L*M?54OOF.AEO,D>O[U!1>+\#G<'3>%$1VCD3Y<^]-ZY].]
M)O(N?I73]Q'^GO5<%\6TQTG^$PTO$TOO+1KK2N.-8Q3/&^;PQ6+5IDFOI7II
MY+W'FGK5-SGQS_4>VO%LMI^K:8G6,4=\V_.B.5-=9C6->IZFB1=#\0L=7V5>
MS(*:!%T\N!NTIJU+W2S($[C9BD->;+R.F3NY%D8U<W55A\WT>2&7@A'BEH6#
MCIH1X$^)J2GT[/+VD^#O1XVKW6G)%]1/AT1K*HV+O^]3**(F>]YXNNC!'X3U
M'YE(V'W5!F45NS:VN\"-25MX@6GNLFJ?A<JY#;ZSCS[^/$_3K[O77*]?]+MC
M69UW&QF^UOQY?"GQ8X_P-\7[#P#SKLYVGF'-,<,>:(R1_;<+?W<6<1$30]RK
M73DZIHJ-3M[BZ(1,JA9$:, #XJHAC,Z)B-5%7%4W9<(4G/T^XHME(B9]R@^7
M3M]1J9,^GN612%H^;S^PT<NXB.U96DRLI)^S4XS+NM5U:1"@Z;SZFK?<3WK(
MK*@L^O#7R]9K6W&LL_!WM:3%E=Q$<&,UF%PR5.2+ZON-O'FUTAC-=5XQ^NAR
M.+*HM71>1R<?/]:'(X<G%5:-5\U>1RF.VL*O8KHI=KIPE@^F0
M  '8AH<O883/:SB.U3U*YEDTJIA,Q'-&O<T*Y$*YR<2*S(CD7M$9#PR^Z^<>
M-'%J1Q9%TZM:/\Y9%SA+6C^\SBZ)KW-2.0SB['PR:IWH1J:2:IWC6#27SQH1
M-HA/AE35_DA7.1.D0I^(JF^J=9?-=5,)OJC3ME\\2)VCQQ'O3I+5J9>.$<8?
M?$91?6=(3JUEL2E4:NOI,H]C"8T:BSL8AA9+3KQ4C\:=&E7=Q&L)BK3J1-F6
M@BJ@\1IJ^^)1XH1X8$<H\4'A@\:]X\9I#2KO.8S<X-/B,9N:OFIA-T:RTJIA
M-C1I5Z(83DT9166GQJ5_$UEEX8/&I,W1X8$<NO$1;4FJJBE];,&M%+HG3W,H
MG5J1=%+(DE50RCN5OCDX$VY)KS=\7RX[.^V].TM8]G@;D&X&3W:-VKU]ZR&B
ML=B5^CVHUNDED<W1NK?PZZZZHGYO?>EWE=UZFQ@B=9VW3<&.>7"9MES:</9E
MB>/'CW:/<?3W%.+H4WG_ (3/>WX*U_WKG%5-X+P]?EYSYGRP]!QL9JV\%]'=
MW?E..R5ANXY8M6,Y\$_/V'&98[&]CEB]6SGP\_WZG&Y8;V.4'.WGY>7 TKPV
MJSQ<O.AW)X;-NY66&I>C&9;C-PH:5%X*ZZ6N6"\0)XE7@W]7TE6FG-7*GK^X
M?N >;,'0_6C/Y>W5HC'UKI6;%C]N?!:FYIQ[O@X]QP[9FOR^+>O/2K[[R=3J
M&*-;;/=4O;]3)$XY_N[8_DU=NY^T[XV
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M7Q_#VV/>Y+X.&D3MLUIR[>:\(C3X5ZUGP\(M%J_FN31V)YF
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M0
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MIT\5=:S69WG.,=K
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MO8Y%:Y.QR*AUNU9K::SSAR<3$QK')>$)
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MG^'5O8U#J^]V_@M\2O+M<O@R>*/#/-O\<>V0
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MN_C3<[?)-9GLM'.MX_:WK,6K[)C7BRL[BX@
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M;WI>]R]-ZEBR8.H8,EL>3'DK-;TO69BU+UF(FMJS$Q,3&L2FBUJ
M
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M'"F#),\MQ6-*X[3_ $B(BL_P^DY_0(<J^S
M                                       !Y%/G?[MVW<#JQQW;VR7%
M*^BV<V]H;'>(XY&RTM'F>47"KR*]00OC>Z-TT5C?:8I]/Q1SQ/C=HZ-43Z@]
M ]K>>B[W?3'\%DWG@K[?A4CQ6B>V(M>:3W7I>)XP_+/[ZGFW;]6\_P"WZ#M;
M^/#TK916^DZQ&?-:<F2([-8QQABW=:)K/&NCJBM-*_PHNBZZ(B)HOK=Z.P^G
M=CAM,:=[\[>N;S'XIB)C3M_)_9Q9[;[>]R-5473ART77GV\NP[3M-I>VG"7F
M?5.J8ZS,1,:LOIJ%41/%^%.Y.?EJ=@P[?P\W1]WU"+3.G&4Q'$UJ(C4\O.IO
MTQQ$>QP>3+:\ZV7*)H;41HUYG5])X(#&8A(0*3N9$LXY.OSK@Q=ZIA&90Q.5
MC?C\:KYM/PL<[_V:6B-7=BOTK5X]QY%ZG["=-MU*L?1^ECM/]U3_ '[ZY^Z_
MURL3U/RWDM'BGX>YQQVS_P %EGY/X'YW7NY.!Y!,<>+Z\K/%9RQ=O9]7Y"JU
M6S2_SHR:+V&O>FK=QY$;)!JNBIKZ#5M3BW:9=%JZ%?3]!5-%\96A(%3L3ZC&
M*1#.<TSVM;(M%U5/1YS*M./!A?+,PO8XEU35/47TIQ:U[\%_%'Q0V*5^9J7O
MP2#&JNB(GI+X:EK:<5ZUO#B6UKIS:MK*[4[2R(53/8J%L0Q?3-"B]?J->RRJ
MT?\ HJ4VYMBO-&S\E\NPHNW<2&G_ '7H-&_-R6+L1$_+UN-+*Y3 @ZCDO_K7
MVFI+EL//Y$?)^CY=Q1=MTYK1_+UE-N;8JKQ\_+SF=>Q5?DD(%XKWFQ$M3+"9
MA=R\N9LXYXN+S5X2EX7</I-ZD]KB\D<4M"[BG$V\<N/R0DVKKHIM1+2F-."Z
M8[5/09UG3@U[1I*JJZH9L(C26A3"TLH6SS'L756\J:IY>7:86Y+L<\45,WA]
M)J7AOXY1DS>WOXJ:MXX-[%9$3MX+YO/W<C1O&DN5Q614Z<E*)<ABGL6R\E]!
M79='-:KS4K7QR4G]A7*RK6U>1E6>#&R\:O)?07TG@UIA(1NX(I;'-IWCCHDH
MG<E\_P!9?2>.C3O"1B7BGF4VZ.-R0D8EXZ&Q3L:>2."2A7EY><VZ-+)"0C7B
M7=C3O'!=L7B6Q/)KVA7\2&:OPRIJO:JF,V91#2KB-991"DY^G-3";=RRM=5!
M9%]!CK"V**#I=.TQFRRN-;/F\Y7-U]<:U?-QY]Y3-]>2^N/@H.F7\_EH5SD6
MQBA06?\ Y2^HPFZV,7L473=W'T\RN;]\K:XIE3]ZO>J^7J,9O#/X7L:5E7O7
MVZ?:1.31E&&>Y369.6OUK^0Q^(SC!/-\]XG]TGH(^)JGX4]S4DG#\IE%Y83C
MF.9[SRU)\<H\#6C_ %$Q;OY(FJNV3L4S]RJU.YNALU3_ !>ZVWD2(B^#+K'5
M<7*U/^@UT5;KJG:WX?73MTT.;\O1\3K>UK/9GI/[F?%^PZ5Z@Y?@>1^K7Y:[
M#-7]W2:?[YW.LDX:=I]"1;5^>%\7%<,D+JVT]S2RXUVQY?66CDIVKAK^1L4M
MKS:F2O!=L?P+JRT<E>U<(XV:SK'!K35J5=4YDHB-)6LJ:MT]9K6XMG#.EM4+
M5-U1>'E[.9QF>O8[#LLFEHF&)5T**JIISU7R[#@=UCC5WKINYFM8G5R>Z,NM
M+<KHIW+3),<6HR+;C(JBFAW)VWGJG14&16^)WA;=;4YWCAM.66F)[EI*M&Z.
M15AF1\+E1/&O4?T\V/G#9ZQ%<75\43\++I\O@OIQG',^^:S/BK^=%OKS[OOK
MYUOTEZU&3'-MQY<W%JQN=K-M*WK'#XF/7A3-6/JVY3$>"VM9X>TG9K>/;_?S
M;;%]U]L;W%?L/RR@;64-0B-BK**H8Y8J^SWBC1\C[=>K16,?!54[E58Y6+HK
MF^%R_$G5.F;[HV_R],ZCCG'O,-O#:L_@F)Y3$QQB8X3$Q,/VF\J^:>B>=.@;
M;S+Y=S5S])W6/Q4M'..RU+QSK>EM:WK/&MHF&Z!H.P@
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M CE541LT+/$B<D5B]KCKF_P>'^$CY7*;?)K]&7)4XQM
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MWFD]CE:V\5=4\5L@
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MW]/IYNV%/^5[6L4SQ$<;89GZ-^';BM/'A]2TS,Z8XAVF'Z[/DT
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MQK')^5<Q,3I/"8?0@
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M3&6(M,9K5[M#D7U4
M                "UK:VBMM)45]QJZ6@H:2)]15UM;414M)2P1IXI)JBIG?
M'#!%&U-7.<Y$1.9,1-ITK&LRKRY<6#';-FM6F*L:S:TQ$1$<YF9X1'MEM)=^
MHSI[Q^2IAOV^VS5DEHTC=617?<_"+;)2ME9')$ZI967R%T"21RL<U7(FK7(J
M<%0W,?3>H9M/@X,U]>6E+3K[M(XNN[GSKY-V4VC>=6Z9BFFGB\>ZP5\.O&-?
M%>--8F)C5UM=7/S==F=LL<NV,=.=SI-Z]U*^GN%OMM[L#9*C;7$JML;H8[U7
MY5+3.LV5NIIG>."FMKZJGG?&K9IXN#9._>6?1_SWYLS5QX=KEV'3[3,6W&>D
MU\,=OP\5]+9+_H^+P8M==;S,>"WR_P"LWWR/3+T_Z?GZ?Y9WVWZIYH\,UCX5
MHOAP3,1X;VM&L9N<6K3%XZVB-;VK7GY:ZRVY-E^2WO,\UO%1>,ER:ZU]^OET
MKI'5=?<KQ<ZF2KKJRME>Y5EFGJ)7/<Y7\57M/N7RCY VOEKI&WZ/LH^'L=OC
MBM8F?%:9XS:UYYWO>TVO>\SK>]IM.LS+\9_.WJSD\P=0W'4,ELNXW^YS6ODR
M6F=;VM,VM;Q3QUF9[:]_&-(9;0V6EIT;X(O$Y$T\3]'+SU31NB,14TX:(AZ1
MM>FX,,1X8UGV_P!FGS1R>*=1Z_O=U,SDOI69Y1P_#SGVZS+)(:=&HG#R\YR]
M,<1R=5S[F;=J\:SN-FM.]HVM/.59$T+56NH0!($  X+Y<"1M+O=@B[A[:9-C
MM/%[RY_")<[(B(BO_7%K=\91PQJJHUJU_NW4RN7@UDRKS. \S]*_KCHF?94C
M7/X?%3]>O&L?VVGA]TR] ],/-4>3_.NRZQFMIL?B?#S=WP<OT+S/?X-8R1';
M-(ATGR1N8YS7-5KFJK7-<BHYKD716N1>**BGS):LQ.D\)A^FE+Q:(M6=8GE[
M5!6^M"N8UYK8E;21(J+IY?D*[5[U],DQS6#X$XE,T;=<JU?!YOH*IQKZY5-8
M/,IC\/5G\5J93]R<?)2:X]6-LR[9 75IV->V5>,C[DX=Y;$-:U^]>L8B)Y<2
MVM=/>U[6U5T;WEFBF9[FLSB-&+Z61'! )Y"A)V^HU[+:+61>!3/-L4YHJH7G
MY=OY37O+?Q0AY_W7I-*_-R.+L14__P T:67DY/!R0E1R7_UK[35ERN'G\B/D
M_1\NXHNVZ<UH_EZRJS8KS58^"M[OR&5>3"_&)7\*Z.])?7DU,D:U2L"\-"^G
M-Q^6$Q [EY<S>IR<3EA*PNX)[#;I,?.T,D)2-W!/I-JL\&C>O%<L=HI9'%1:
M-5SKP,O%P]JG13>XQYRSK"@JZB9[EJF]=>'M,)9U[T=*G,U[PV\<HV5FJ+YO
MJ-6\-[';BB9F<_/K[>1IY:\?:Y/#?@B9F<T[N7EJ:LQHY+';M6"IWE=HX-J%
ML]-%*5]9UA25-4,;,X:6KV&-9TEE:.U=QNX:%U9TEKWCM7L+D_1+^S5JY([4
ME"Y.7=P+:SHT\D=J2B<B^7:;>.8<=EKI*2C7]%>/8;-.YH7CG"3A7BG$VJ3K
MHTLD<$BWL]"&Q#3LO&+R+*\FM:%15T,M=>3"(U4U4CDSB%)[].1AK,^Y96NJ
MW<[O4QF5T5[EL]_G\O,5S;1=6JU>_P N[\I5:VG-?6JT?+ST7UE%K][8KC[U
MFZ;BOE]!5-FQ&-;OF\_EZ"JV2(;%,,SV+=9DT^]2F<K8C!"W?4>?U)]R%=LD
MROKAT[&A:A.]?I(\<SQEE\&6A9^Y.'EYS&;SWL_A/GOO,OT#4^$U)-Y_+Z"?
M%*)QM;9=>"?7^4GQ,)QZ*J.UXZ\3*ME=JQR5VOUX<E+HLUK4T5D=WED3W*IK
MW-_>FBB6OWEQ+7C%0_K>XRKPU1*:RW!(%35CT7_I<D>O+@JZ*BZ':/*&/XO7
M\$]E?%:?DI;3\,P\O]8,\;;T_P!]$<+Y?A8X_MLU->V/S8M^335VV1R>+MXG
MN=+\>/)\)Y<>BY:\V:RT<F.)C5=,E["VMI:%\:\8]%312^MNV&CDII*ZC?V*
M;5;:M')36%VQ^O#N+8EIVKI*KJ6Q?O5Z*3UT]GU\"J5E.:+J&\_K\QI9JQQU
M<QM;L>JH_$BKVHGV^KM.*W%-8U=IV.::S$,6K8/$CN"<=?+VG!;G%XHGO=XZ
M;NII-9UG3@[#OEE=<UPZ0=WF8GFMVJEZ?]T;K0T>;T<[WU%'A5_F2*WVW<NV
MT_XY*=:&-(X+PV!/'66QJ.<R>:CI&-\"]6O(5?,73YZIL*?_ #[VU)F-.>7'
M'&<<]\QQMCY_2UK^?K'W/]UKUTR^G?F&G0^LY9GR7U')6N:)UF-OEG2M-S6.
MR(X5S^'3Q8HBTQ:V+'#V=PS15$44\$L<\$\;)H9H7MDBFBD:CXY8I&*YDD<C
M'(K7(JHJ+JA\=\N$\WZ_UM6]8O28FLQK$QQB8GMA4"0
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MSJ.+33)\D_L.4VU]?HRY-G%ML
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M1V-S3UAU4
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M'L+XS
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MO+TZH!I<[7Q)YT_+]($=-S5=._T\/7IP A:ANNJ:=^B^OT]@&.U47!=4[_N
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M-,N/76<.>GT<N*>WZ-N-)F(F^.:7TB+0Y(F;O
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MYEW,GE#ZP
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MV.+8;:]D:_-Q;^WMI>/>[&#K3E
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M<S[*VC)''MO$.S$_5E\M@
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M*;K#2;6TXQ%8RX*WB\Z3-K8L->3UIG9'Z-@
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M<X]T9\2/VJ
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MDO8@3R6$C]=5\M2&*.E7GQ Y/=)G3#?NI7<2"V.;5V[;['9J6OSW)(V/8D%
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MS$\I7TM,3K'-V\G37.
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MU8K[IF'?(?T2/SZ
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MMFMVQ\:.R8F>Q ],?+X
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M%Z6^6LQ*<(;8
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M]'\P[BWBW6\Z;M\N2>$?PML5?B\(X?QGBY:>Z&_)H.X
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M,8-S@W-/B;>];T[XG7\7_M:MZWI/AM$Q/N8A\7KVIY=W NU1K+6VJT[?+Z.
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M^@_H5^[=ZD8_5/T=Z/YER9(R=8QX(VN\XZVC=;:(QY)OW6S5BFXB/T,U?<^
MO47R[;RQYOWG3JU\.TM?XN'NG%D^E6(]E)\6/WTEO,>Z.D
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MZ!AR^7^@>::\-QAW>;:VY?2KFQQFKKV_0G!?P]D>.VO.'>N?2#\UP
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M=O;PX_L\WZ_>@G6)ZWZ0="WEOK8]G]G]O_)<E]M']SBB8]DPYV&Z]>
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MB>Z8YQ/_ +8X.#RXLF&_@R1I/X_<P*)VOKX_>;7:K737)IW$\^1SY-9"#RY
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MQ>)5?)(K(T19:B>15?)*]722O57/<KE52J9F9UGFLB-.$)\@
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MX79*#&\2L=KQVPVR)L-#:K11PT-% QJ(U7)% QB/FDTU?([Q22.U<Y5<JJ=
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MX?QN9V>6,F&(_.KP_(Y"G&MH
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MK,UM&EH:C)
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MX]UZ+4S6C6VWZQM<E>,QI,X\^+7AS^CDF-)UCCKSB)CT>GU<_)<
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M7;)QY\$YJFOJ77O0"Y9-RX\-?K\P%TV;FG#OYZ]WU@7+)]>U$5./I0"X;/\
M\KTIZ%X<@+J.?S^OV\^S4"X;/VZ]_F]7:G8!7;,B\=?4NJ)S\X%1LS===>.O
MEW*H%PC]>>GI I2/14<NOF]"=W:!%2.XKKR[?3Q A:C5=4Y:Z_3K[ ,>K6ZI
MKWZ:>S0#V6_(XR"6\]!UBMDC4:S$=S]R,>@<DC'K)%4W"BRQSW-9#&Z)4GR=
M[?"YTCE1/%XD:J,;WCI%(ITW%;77Q>*=.[Z=JZ?@U[.;]1/NF[NVY](\>&W+
M;]0W...7*9IE[N_)//6?;II$=P)R3Z8
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MCR1];@
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M^3FYS#N,>>OBI/'MCMAND:BX
M           #;FX;P[26FM6VW3=+;FVW%'I&M!<,WQFCK4D5W@1BTM1<XYT>
MK^&GAUUX&7AMW2C6.^&<6VZ6R\4D5PM%QH;K03IK#6VVKIZZDF3@NL532R2P
MR)HO8Y3%*,R[(Z/#\5R3*Z]JOHL;L5UOE3$CTC?-%:Z&>M=3QO5KD2:H]SX&
M<%57.1$15X'6_./F;9^3/*74_-W4(\6QZ7L,^ZO772;5P8K99I$Z3]*_A\->
M$S-IB(B9X.1Z/TW-UGJVVZ1M^&?<Y\>*LZ:Z3DM%=9]D:ZSRX1S><&ZW.NO=
MTN5YNE3)67.[U]9<[C5S.5\U575]1)55=3*]RJYTD]1*YSE7BJJ?S-=6ZKO^
MN]5W76^JY;9NJ;S<9,^;):=;9,N6\Y,E[3/&;6O:;3,\YE^E>TVN#8[7%LMK
M6*;7#CK2E8X16M(BM8CV1$1$+,XYN/@1/)I)8/H(? +B'0RKS8WY)B!4\O2;
M-&O;FR.B5.''M0Y##HT\C+Z+[/L.3Q=GO<?D991]GH0Y/$T,C*J/L]7W')8N
M#0R)N+DGH^TVZ-:R4CY+Y=J&Q7DIGZS62R  'WL7TI]H1VO@2  /B\O2OU?G
M)864G)VF$IJMWMT74KF.QFL)F*NNG+\Z%%XU6UGM[4?)#S*+475MW+*2#5/7
M]Q3--5M;K-]/_P GR^LIG&SBZ@M-KIP[4[/M,/A:L_'IVM*TB=WT:$?"3\1H
M^#\WTK^0CX.I\2'6]U6]"]/G+[EN/M#24MNS*59Z[(,118Z6W99.[\<M?:I)
M'LI;7D$KD59&.\-/6/=XW.CE\;IOJ?T;]=LGEZF+ROYUM;+T.-*8=SQM?;QR
MBF2(B;9,,?FS&M\41X8B]-(IYMYK\FTW]K=2Z1$5WL\;X^5;SWUGE6_?'*W/
MA.LSTUW.R7.R7"LM-YMU=:;K;JB2DK[;<J6:BKZ*JB=X9:>KI*F.*>GFC<FB
MM>U'(?<^TMM=_M:;W8Y,>;9Y:Q:EZ6B]+UGE-;5F8F)[)B9AX[EC)@R3AS5F
MF6LZ3$Q,3$]TQ/&)6/N$[OJ-B-K'<K^)#2L'F7ZR)VL$7@]UI^8B-OI/L3XX
M:DC\RED8H1XU1&?F+:XN/!A-E9K>Y#;ICT8<URUNB<C:I5C,_,N43@AN4A3*
MHB%T1K+*(TA*6JU7.]5]):;-;JZ[W6OF;3T-MME)45]PK:A^O@@I*.ECEJ:F
M9VG!K&N<O<8[G=[38;:^\WV7'AV>.NM[Y+12E8CG-K6F*UCVS,04QY,V2,6&
MMK9+3I$1$S,SW1$<9<T,#^7YU&9K3PUM?9+)@5%.C7QOS6[NI*U\2HBJY;19
MJ2]W2EEXJB1U,5.[Q)QT3B>(>8?O)>F'0;S@V^XW'4<]>$QM<?BK$_SF6V+'
M:/;2UXTY:SP=KV7D?KV[K%[TI@I/\I;2?W-8M,>Z8AOI3_*US9U-(ZJW7Q:&
MK1C%B@I\?NU33/D5/WQLE5)5TDL;&._1<D+U<G-&\CS_ "?>ZZ!&6(P]&WEL
M.LZS.;'6T1V:5BMHF>^/%&G?+F:^F^\\.MMSBBWLK:8^?6/Q-N\M^6KOU8X9
M:G&[EA&;,8CECHK?>*FRW:56J[PHD.045OM#/&W336NX.5471$\2]FZ+]ZCT
MZZA>,75,6_V%IYVOCKEQQ\N&]\DZ<?\ @N7MX1H;KT^ZUACQ;>V'-'=%IK;^
MZB*_W3A-FVW>=;;W3]39YB=]Q2XJCG107FWSTC*N-JHCIJ"I>WX6X4Z*NGO(
M'R1Z\-=3WKH/F;R]YIVGV[R[O-OO-KVSBO%IK/=>OUJ6_:WBL^QU#>;#>]/R
M?!WN*^+)W6B8U]T\ICVQK#"SFIYM0(2 !V(4G)Q4JM"R.,*2H46C@CE*QE3[
MCC<\1Q7QR1TC5[CB,V/5L4F.2,F9S\O0<-N,;8I/8BI6<T7R4X+<8VU2R,?'
MIKVH<-EPZMB+,TVXVMR[=G*:3$L,MRUUQJ&NGJJF570VZTT$;FI/<KK5HQ[:
M6CA5Z)KHY[WN:QC7/<UJ]*\W^9NB>3>D7ZSUW+\/;5G2M8XWR7GE3'7AXK3S
M[(K$3:TQ6)F.8Z/TK?=:WE=CL*^+)/&9GZM:]MK3V1'SS.D1$S.CO5V4V2QK
M9+#Z?&[&QM5<JE(:G)<@?$D=9?[JR-6NJ'M5SUIZ&F\;F4U.CE;#&J\72.D>
M_P#.3S]YWZKY]ZY;JG4)FFUI,UP88G6N'',\HY:WMPG)?2)M/=6*UK]+^7>A
M;3R]L(VFVB)RSI.2^G&]N_V1'*M>R.^9F9W>6-R'1_ Y_P 33X7$:63XH?-7
M]WTK]Q'$^B?C[OI7[AQ/HL/S?;_$=R+'-CF:V&BOMKF\3F153%2>CG<QT:5=
MNK8ECJ[?6,8Y4;+"]CT1537151><\O\ F/KOE?J%>J=!W&3;[RO;6>%HUU\-
MZSK6]9[:VB8[=-6AU+IO3^K;:=IU''7+@GOYQ/?68XUGVQ,2ZQ=V^@3*[(ZK
MO&TUR_A9:V^.9,9NTM/0Y+2QZ>)8Z.M=[BUWEK$15_$M)-R:UDKN*_6WDC[Q
M72-_X-CYSQ?8]WPCX^.+6P6GOM3CDQ:^SXE><S:D<'C?7?33=[?Q;CH=_CX.
M?P[3$9(]T\*W_N9[(B9<$KUC-_Q:Y3V?);+=+!=:9=)[?>*"IM]9'Q5$<L%5
M'%(L;]-6N1%:Y.**J'TUTKJ'3NK[6N^Z5GP[G9WY7QWK>L_+69C7OCG':\OW
M6VW.SS3@W>.^/-'.MHFL_-*Q8WBFG8<[BQ\FG:?G243>7F0YC;T:]Y242<CF
M,$->>22B3@GI.7PQ*B>20C1>'I.7PQ+7MS2M)!/4RQ4]-#+45$\C(H8((WS3
M32O5&LCBBC1SY)'N71$1%55.2C)3%CG)EM6N*L:S,S$1$1QF9F>$1':HF)M:
M*UB9M/*(<Y=E^@G>C<Z2EN.342[7XK(L;WW'**27]?U4+O"KOU9BGO*>X.D\
M+D5%K'T42HNK7/5%:>'^=_O%^1/*=+[7I63^M^L1K$4P6CX-9C^4W&EJ:<.6
M*,MHGG$:ZNW])\D]7ZCIDW,?9MMWWCZ4^ZG"?W7ACNU=R6Q_33M7L+;_ '>'
M67XK(9Z=8;GF5Z]U6Y)<4=X72Q-JDCCAME ]T;?^C4C(8E\+5>CWHKU^)?/O
MJKYP]1=QXNN9_!TVMM<>VQ:TP4TY3X=9G)?G]/)-K1K,5\-=*QZGT?R]TWHE
M--I37/,<<EN-Y^7LCV5B([]9XM]Y$Y^T\SM#L%>2R>WGY^13,+(E#5;%XZ?4
M:>2&S26.U42KKY=AH9*S+<I9C=5$J:\^WO..RUEN8[,;JF*FOEZ#C\M9;N.4
M%+XDU31?+M\YHVUB6U731'R*J:\/+O*+3*Z--&S>>;';2[DOEFS+ [%=:^9/
M#)=XZ=]LOC^"(WWE[M$M#=)$9X4\*/E<U.[BNO;/+_J%YT\JQ&/H?4=SAV\<
ML<S&3%'NQ9(OCC7MF*Q,_)#B>H>7.B=6UMO]MCODG\Z(\-_W==+?A<6,C^7A
MMC<GOEQC+<OQI[U54@K/U=D%!%JJJB11/I[97>%$73\=2]?.>Q])^\WYNVT1
M3JVRV6ZK';7QX;S[YB<E/FQPZ7N_2_I&29G9Y\^*>Z?#>OXJS_=2VJK?EMY(
MR1$MFZ=DJXM7(KZ_&:^W2>%/#X%2*GNUT:JNXZIX^&B<5UX=\VOWI.FVKKN^
MD;BE^ZF>EX]O&<>/V:<./LTX\%E]+=U6?X'>8[5]N.:_BM;\:-I?EO[DO?I5
MY]A$,?A71]/%?JJ17<-$]W+;J1J-5->/BX=QR]OO/^5JUUP]-ZA:^O*TX:Q\
M\7M^+Y6G'I?U37Z>YV\1[(O/^]AN)8/EIRO?$_(=VHV1I[M9:6S8DY[W]LC8
MZ^NOS&QZ::-<M._7754331>/W/WJ*5K->F]&F;<=+9=SIIW:TIAG7VQXX]_;
M&SB]+K1_2=Y&G=7'^S-_V')'">@+83&GQ5%ZI\ESFI8K7JS(;RM);FRM5-'1
MT..P69[HM4U]W/+.UVJHNJ<$Z-UG[Q_J+U2LXMA;:]/Q3PUPXO%?3VWS3EC7
MCSI6DQV:3Q<SM/3SR]MIB^>,N>_[>VD?-2*_-,RYCXCAN)81;6VC#L:L>,6U
M%174=CME);897M14]]4)2Q1K4SKXEUDD5SW*JJJJJGD'5>N]:\P;K[;UO=;C
M=[K]++DM>8CNCQ3/ACV5TB.R':]MLMGL<7P=GBQXL7=6L5U]^G.?;/%FL;N"
M:^7G-&LK;1P722*FGJ[2R+?,KT5/>Z]NAEXI1X84UJ-/1]?T$?$GL3X%!U0O
M]TGEZ.17.1E%%):I5[>7GT^PQ^)[67@:5JM/W7M7\A$Y-$_#]BDZIU_=>7TF
M,Y-991116IY_BUU\O483DXLO LY)M5XJ56NLBJS?+Y^'E[2FUED5U1TS]=>X
MHO.J^L(Z1>919;7FLGKQ*9Y+%J]-44JE;')S2Z>NK6X;>P4.&9^VJO6&0>&G
MMMVA1U1><:@541D"QN=K=++3_N8D5)Z=FJ1*]K60GWI]VG[YG4O37;[?R+ZD
M1FWWD7'I3!N*ZWW6QKRBFDS_  ^UIV8^&7#36,4Y*UI@CPOU(]'MOYDR9.N>
M79I@ZW;C?'/#%GGMG7\S+/;;ZMY^MX9FUW:?CN26'+K127_&;M0WNSUS/'35
M]!.V>%^GZ<;]-'P5$+OPR12(V2-Z*US4<BH?KSY9\T^7?.?1<'F/RKO-OO\
MHFXKKCS8;1:L]]9[:WK/"^.\5O2T36]:VB8?)G4NE]0Z/O;].ZIAR8-[CG2U
M+QI,=TQV3$\XM&M;1QB9A-G/M
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M<^O'X[@
M =(WSQ^I^HVBZ<;3L?BMVEH<TZ@Z^MM=X6BG6.KH]JL>;3S9>R26FJHZFD3*
M;C6T-K\$D;H*ZWRW&)5_ Y#CNK;G[+L;:?QF7Z%?P3>>,3$Z5^C/&)B;UM')
M\J?>P\_7\M>2,?E3I^2:=4ZS>U;^&=)KM,>DYM9B8F/BVMCQ:3$UOCG-7LEY
M!:2'EHG=KV_;W'1GYG,HI(N7+S)Y>D#)*=FFGFT3R]*@3=.WEY+W:^Q )J!O
M+RU[5^@"3B3EZ?J D(NS_P!:^X"]9S7T 54X\ *Z\$5?,!:O71/2!:O7L[$Y
M^G\@$=._GQ5/+[@(B:14UX^WS]GFX 14TZIKSY:>7;R CI)_^4GGY_3V@6;Z
MG371W'L\N0%JZM5%\/C]*HOT<]0*D=;IIH_ZT\W;P^D"\CKEY*O+EQ_*H%Y'
M7*Y=$=KW\>[[$ DH:M>_VKY<P)".NX:([N]*_F0"[;7:<UT5>6G/3[0*J5VO
M+37NY_3R K,J7.[43T:?0!<)/V:JO).:I]?,"JV1RHO9]/TZ 8IE. 8KE\$D
M=WM<'Q3VJD=TI6,IKG Y471[*MC/%(C577P2(^-5YM4Y[H_F3K'1,D6V6:WP
MHGCCM,VQS[)K,\/?72W=+LW0?-W7O+F6+].SV^!$\<5IFV*T=TTF>'OKX;=T
MN#F>8%=\#NSJ&O:M10SJ]]LND<:MIZZ!%Y+Q<D-5$BHDD2JJM7BBJU6N7Z#\
MN^8MEYBV4;C;SX=Q72,F.9XTG]FL_FV[>4Z3$Q'U-Y4\V=/\U]/C=;6?!NJ:
M1EQ3/TJ6_9I/YMM-)Y3I:)B,(8FJ^CC]QV%VE4>NB:=X%NO,QEA/-2<NFJF#
M">:PE7SE=E5I1LR\U[D\OK*9461DKDT7RX>2%5I46GBBI7?I:)R\WU^LHLU[
MRBY>7M^PIMR:]N4K!_U?4J?D*E*UDY>CR3ZC&6$J"<5,><L(XRKL;HFOL\O.
M9,ES&FJZ]WVF4,X7L?-/26PNCDO8ET7ZC.%E5TUVB^7:61*V)7#'Z^GZS)G$
MZ*S7Z>CRU0RU9:JGO?+7\@U3JT^\5>7M!J^>->_ZOL&IK#YXO.OTC6$:PT*[
MAZ/+1"-43*V<[7RY&,SHPF=$C9;-<<AN5-:;5 M165+M&IKX8XF)QDGGD5%2
M*")O%SE]":JJ(NAU#J&UZ;M;;S=V\.&D?+,]D1';,]D?L<7&]4ZIL^D;*^_W
MU_!MZ1\LSV5K';:>41\^D:RY78MM+C>/PQ3W&".^75K6NDGK(TDHH9>"JE)1
M/UB\+'<GR(]ZZ:IX=?"GBW6?.G5.I7MCVMIV^S[(K.EIC]M:./'NKI'9QYOG
MOS!ZA=:ZODMBV5[;78<HK2=+S'[>\<>/;%=*]DZ\VY"MCB8V*)C(HV\&1QL:
MQC6IJNC6M1&M3T'4+6M>TVO,S:>V>,NAWO?):;Y)FUYYS,ZS/RRQ:^8UCU_C
MDCN]IHJQ7M5$F?"UE6S5$36*LB\%5$O#]R]#?V/5NI=-M%MEFR4B.R)UK/OK
M.M9^6')=.ZYU?I-XOT_<9<<1/U8G6D^^DZUGY8EQ;W VJK,=26ZV19[E9DU?
M/&K?'6VUNOZ4J,:GQ%*U/_*(U%8GZ2:)XE]4\N^<,'5--GO_  XM]RB>5;^[
M7E;]K,\>R>R/:_*OGW;=9TV'4_#AZE/"L\J9/=K]6W[69X_FSK/AC9E>]>&G
MYOM.ZO0UNOU$2B6DQ8C28*KV)5U3T+]YG"RO-*P+]:<?3]G OJV:I:%>*><O
MJV:)-B\$]'+Z2Z)7UE<-=HGK3\IFL?7/XKZ/S_0!OKMKM#/>_<7S*(9:6S*C
M):2W.\4-3=$=^)DLRIX9*:@<BHJ+P?*BZIHW1R^;^:_.^/8>+I_2+5OON5K\
MZX_9'9:_X*]NL\(\E\[^HN+ID6Z7T*U<G4>,7R<)KB[XCLM?O_-K//6=8CE9
M3TM)04\-'14\%)24[$B@IZ>-D,$3$Y-CC8C6-3T(>-9L^;<Y;9]Q:U\UIUFU
MIF9F?;,OG[<;C/N\UMQNKVR9[SK:UIF9F>^9GBI2KQY]NOMU1"I2CI>]>7:O
MJ^Y +&5-45'(BHNJ.31-%UX<?-]8Y<8YIB9B=8YN/&?[.4MT6:Z8LD-ON"^)
MT]K=X8J"L=Q<KJ943P4-2Y4TTX0N7^XXN7T/R]YXS;.*[/J_BR;;E&3G>OZW
MZ=8[_K1^VX1'J?E7U&S["*[#KLVS;..%<O/)2/VW;>L=_P!>/VW"(XNW2U7&
MSU<M#<Z.>AJXE_'!41JQVFJZ.8OZ,D;NQS55KDXHNAZIMMWMM]AC<;2]<F&>
M4UG7Y/9/?$\8>U[3>[/J.WC=;')3+M[<K5G6/=/;$]\3I,=L(AZ+STX<OK+5
MZ@K4[4,=&$QHI.;IW:>E$^L(:-/+7[B-#2&G12-$:2:!&C4A+*$]8,:O62U2
M4EGHI:ER*WWT^G@I:9%7@^IJ7)[J%-.*(J^)VFB(J\#0ZCU38]*P_&WN2*1V
M1SM;V5KSG\4=LPXOJO6NF]%V_P!HZCEK2O9'.UO96O.?Q1VS$.5F#;9VS$DC
MKJIS;E?58J.K'M_>*/Q(J.901.35JJU5:LKOQN3EX456GD'7_-6[ZS,[?%KB
MZ?K]7MMW3>>WO\,<(]LQ$O"/-'G7?=?F=KAB</2]?J1/TKZ<IR3'/OBL?1B?
MTIB);H(JHO ZHZ0K-5W;YU[.'F310+AJ\O-IV\?/WZ 5VN3AR]'U)WJ!6:_3
MFOGU[OH NV.Y+Z0+AKN&OFT4"NUVO#DOU@56OTY^I>[\P%RR3S\.]%^O0"JR
M77@OY?R@722JJ)QX)SUU\M40#2^1.*:IIS[->&FO:!8/<GIX:^S7[P(V?MXH
MB\]?O^L""JT545..G9HGK[E ]7O[/SFUEN/35O'MW#+(N1X?O7)E5TIUCTB9
M8<\PO&;;C]2V57JKY*BXX'=&.;X41K86KJOB73NG1,GCZ?6)T^A>U=->/9;6
M8[-?%,1WZ2_1S[FO5=KG\B]3Z+6?^7;;JOQ;QV?#W&#%7'.O?-MOEB>[2.]W
MVG+/L                                                   \R/S
M[-_IKCE6TO3-9JU/U=8+<_=G.H:>IIYXY[[>'7#'L)MU9#&SXB@KK'9Z:YU3
MHWOTFAO%/)X$\+'.^A_0WH59^U>8LT?2U^!CU_M;Y)CYZ1$Q^VC7G$?GM]]?
MSS>VYZ;Z?[2_\%CI.]W$1,<;V\6+;UM$<8FE8RWF)GC&7';3A$SY\Z./54\W
MEPXJ?3&"G:_.C?Y9B)971QZJG#EV_7[#F=O7DZ5O\VD2R*G9Q3\QRV*.&KJF
MYOP3=.U-4]AR>.O8Z[N;2G(4X(<EBCM=?W%DBQ.">7ER-W''%Q&6>"1B3EQ\
MO)#<HXS-*_;]2>7U%T<G'9)XJJ=AL5Y0JE57DOH,^Q7'-;/-?)S;.*.*R>J\
M?7]!1:=(;V.(F45.[FO>OT&AEMQT[G,;>FNB(G?HB^TXW+;G+GMOCXPA)I//
M]VOG-#+?2-'/;;%KV(N6H5->6AH7RZ.:P[:)1TE6B<^?EZC4OG[W*X=C:>2Q
M=6.5W#DG<O'4UISZSPER5.GQ%>/.6MM:]//Z3*NX[V%NG5GEP5X[BU.>K5\V
MNGEZBZ-SHU,G2[3RTF%]#</$J<U3T_6G(OINM6AGZ9X([-4K#6HG)53NU73[
M3?Q[J-/:X//TZTSWPD8ZUR\U14\R^OGV*;=-QKREQ>781'#3BO&UW8FOJ^_T
MFQ7<SII#1OT^.=HA=,J'._=+Y>@MKFM/&6IDVN.O8O(Y>_7\IM4OIQAQ^7#Q
MTA<MD5>2^7U&Q7)-N#3MBK$+R+CIQ538IS:6;A"K645%<J*HH+A24U?0U<+X
M*NCK((ZFEJ8)$5'PSP3-?%+&]%T5KD5%,[XL>:DX<U8MBM&DQ,:Q,=TQ/"8:
M^#=;G9;BN[V>2^+=8[1:EZ6FMJVCE-;1,3$QWQ+K,ZA^G&JP:>KS+":2:KPN
M9SY[A;HD?-48M(Y?$_5/Q2S6-RK^"5=5I_T9%T1KW>,>;?)N3IMK=2Z96;=.
MGC:L<9Q?LS3NG\WE/#27VMZ/^LV#S3BQ^7/,^2N/S+6(KCR3I6NZB.7LC/\
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MC9:VL=$W7PM:R.-K8V(UC&M35M:;3K*^(B(TAN,0D
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MVK'\+BKS_A*1SB(YY*<.$S:M(T<N#[/>.
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MG]OV 1ZU"ZKJJKQ[. 'SXI->WV\/IX :DK?#Q1VGF14^K3B!>PUJ<.?9V_D
MEHJ[DB*OMY\M$ DHJQ=->">;O]"Z@7T=5KS7N[>&J: 2$50G?Y?<!)1RHNG9
M]GHT7O OHW(NFJ]NOEW@7\2HNB<^/T<$ O$YIZ4 C;]8+3DULJ+1>J2.LH:E
M$\3'ZM?%(W7W<]/*W1\%1$J_A>U45.*<E5%WNG=1WG2MW7>["\TW%>WLF.V)
MCE,3VQ/XW)=)ZMU#HF^IU'IN2<>ZIVQRF.VMHY6K/;$\/EB)<)]P=GKYA3Y[
MA1-FO&-ZND;<(HT6IH(E7\,=TAC3][\"</?M3W+N:^!51A[[Y9\[=/Z[6NVW
M$UP=4Y>"9^C>>_',\]?T9^E'[:(\3Z>\G^HO2_,M*[3=37;=9Y3CF?HY)[\5
MIYZ_H3/CCL\41XFS;UU<OL\O6=W>BJ2F#"5&1>'I_.8*Y1TJ\5X^2?E*[*K3
MP1DJ\%]/I^GU%,J)1LJ^GMY)^7F4RU[(N3DOH4JLHLBY.:^78A1+7MR?*6@K
M;E514=OI:BMJIM6QT]-$^:5VG%51K$54:U.*JO!J<570U=QN,&UQ3GW-ZX\-
M><VF(CYY_!WM+=;K;;+!;<[S)3%MZ\[6F(B/EGMGLCG/*&[%HV0OM9''->;A
M2V=CM%6GB9^L*QO)?#(D<D-+&NG#5LK].[L.B[_S_P!/P6FFQQWSVCMF?!7Y
M-8FT_+6'FW4_4_I>WM./IN')N+1^=,_#I[XUB;3\M:^]FE/L5C36+\3=KW,_
ML6%]! U7<=5\#Z*I54XIP\1P%_4'JDS_  6';Q7VQ>9^>+U_$ZOD]4NLS;^!
MV^UK7]M&2T_/%Z_B65?L12*Q5MF05$<B)JUE?213L>NGZ*RT\E.Z-->WP/T3
ML[3;V_J'FBVF[VU9KWTM,3'R6BVOSPW]IZJ[B+1&^VE+4[\=YK,?):+:^[Q1
M[VUF0[>Y/BS735U$E10M_2N5 YU31MXZ)[Y? R:F1RJFBRL8BJNB*IW7I7F7
MI/5],>WR>'<?H7^C;Y.,Q;^UF?:]#Z)YOZ'UV8Q;3+X-U/\ P>3Z-_DXS%O[
M69F.<Q#$FKV^?4[)#ME>2Z8O!/-I]2+]IE#.)7+7)Z_OX_09,XG151QE$LXL
MJH_R[?7WZ&6K+5J]YYOI_(#6#WG'LT^D:FI[Q/3Z51 :P^+(O'E]HU-84G.(
MF6,RO;5:KA?*^"V6NEDK*RH72.&-.2(FKY)'+HR**-J:N>Y4:U.*J:6]WNVV
M&WMNMY>*8*1QF?Q1'.9GLB.,M#J'4=GTS:6WN_R5Q[:D<9G\$1'.9GE$1QF>
M3F7@6"T6%6]R*YE5=ZQK/UC7HB^%?#^)M)2(Y$<RDB<O<CI')XG::-:WPGS)
MYBS]>W.O&FQI,^"G^^MWVGYJQPCMF?FCS;YLW/F;>:\<?3L<S\.G^_OWWGYJ
MQPCMFV<.?PX^=?J1/K.M.HK&1_?KPY^ON]H%G([5%]7LU M']RIJBHY%1?/H
M$MD<SVAMMY6:NQ]\-HN+M9)*5S52V53U5%5?#&CGT,BJO%6-<Q?[A%57'>NA
M^=MUL8C;=2BV?:QPBW_"5CY?KQ[YB?VW8])\N>HF]Z;6NTZO%MQLXX1;_A:Q
M[YX7CV6F)_;::0XUWS'+WCLZT]XMU11N5WACE>WQTT_-=8*J-703<$U_"Y53
MMT/4-CU38=3Q?$V.6MX[8_.CWUGC'RP]DZ;UGIG6,/QNG9J9(TXQ$Z6K^M6=
M+1\L>Y FZY%]:3":KN->*>;1/J5?69PLCFE(5\O+TEU6Q7DE8EY*OEP_*75;
M%$G$O#U_D^PNA=6658[B>0Y34-I[);*BK3QHR6J\"QT5/RU6HK)/#!%X6KKX
M=?&Y/T45>!QW4NM=-Z1B^+O\M:<.%>=[?JUCC/OTTCMF'%=7\P](Z%A^-U//
M3'PUBNNM[?JTCZ4]VNFD=LQS<J,)V6M&.NAN5_?%?+PU6R1Q*Q5M5%(G'Q11
M2HCJR5JKJDDK41%XHQ%34\B\P^?-[U.+;7IT6V^RGA,Z_P )>/;,?5CV5G7O
MM,3H\*\T^IG4>L5MLNDQ;:].GA,Z_P +>/;,<*1/;6LS,\IM,3HWFD7DGK^Q
M#H#R];O77AZU M)%3CQ[%3V:\ +&1>?/EKS](%@]>S7TH!:/1%U\_%47AY^U
M ,;ON.V7(:;X6]6ZGKHFZ^#WK=)H5=IJM/4QJRHIW+IS8YJJGF-[8]2WW3,O
MQMCEMCOVZ<I]]9UBWRQ+DNF]7ZET?-\?IN:^+)VZ3PG]:LZUM'LM$MAL@V)C
M<LD^-W98D555M%=6J]C==%T974\:O1J=B.B>O+5W:O?NG^H5HB*=4PZ_M\?"
M?EI:=/FM'LAZ=TKU4O$1CZSM_%^WQ<)^6EITU[]+Q[([&TMTVQS:UN=[RQ5-
M7&FOAEMJLN#9$3M;%2J^H;KW.8U?,=NVOFOH&[B/#N*4MW7UII\MM*_-,N][
M+SMY8WT1X-U3'?NR:X]/EM$5^:TPPNIMMPHU<E705E*K4U5*FEG@5$73BJ2L
M;HG'Z3FL6YVV?C@R8[Z_HVB?Q2[#AW>SW/';Y<5XG]&U;?BF5CX=>>BE^C8T
ME)4MBN]<J-H[1<JQW8E+054[ETTUX0PN7]TGM-3-O=EMXUSYL5(_;7K'XYAI
M9^H].VL:[G<8,<?MLE:_CF&;6K:3-;DYJNMC;;$[36>Z3QTZ-U73\5.Q9JQ-
M$_\ H1P6[\X= VD3IFG+>.S'$V_#.E?[IUG?>??+&RB=,\YLD?FXJS;7^VG2
MG]TW9L&QEHI',GO]?+=945'?"4S745%KVMDD1SJR=/.UT7H4Z9U'S]O<T3CZ
M;CKAI^E;Z5_DCZL?+%O>\_ZMZG=1W$3BZ3BKMZ?IVTO?WQ&G@K[IB_O;S4%K
MHK93,H[=24U%31II'3TL+(8D[W>"-K45ZZ<7+JY>U3HNXW.XW66<^YO;)FGG
M-IF9_#^+E#S;=;O=;W-.XWF2^7/;G:TS,_//9W1RCL7R1Z<-./:FFJ>?L14*
M6NJ(Q>6G#SK]X&M(E7\B*H%1(U3O^CTZZ=X%1&+V\/1S K-:O#3@G?\ <!79
MPT;JNFOT_8!71>>B\^8%5B\-->7+R](%1'*G("JV3CW?4H%='HJ<>'U>H"LV
M1=%XZHJ?2G%->T#2YZ:]W/0"W<[73OX_E^@"TD75%7CS_-J!%SMU14].FO/S
M <X_EQ=8DW1;U&6S-+TE75[69I1?P*W6ME'[Z:>/'ZRJAJ;?E-!2,5[*F[X?
M=8F53&^[?+/1.JJ:-6.J?&WG_+^\Q8-U.UW-HIML^D>*>5+QKX+V[?#QM6W'
MZ-;S?2TTBL^S^A?J=/IAYWQ]1WGBGR_NZ? W=8UG3',Q-<U8[;8;Q%N4S..<
ME*Z3?6/=-CF1V#,+!9LJQ6\VS(L:R*V4=YL-^LU9!<;5=[5<8&55#<+?74KY
M*>JI*JGD:]CV.5KFJ=NRXLF').++$UR5G28G^S_VOULV>\VG4=IBW^PRTS;+
M-2M\>2EHM2]+1K6U;1K$UF)UB8X3":,&R
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M<UXWQ<:WUB(O?LL/-7O8
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M+,8<_#+V3W^SW_C]_/L6.LN6
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M,DI433UHGJ7B!-P-\W/3V+^1 )FG1.'H^]?I4"7BY>I/IXJ!(1IZM$1-/+T
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MAMDI76(FT3P<Q#9>G@
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MWF/M3M,_AIQU[#E,-^4]CKF[Q]J9IW:JG$Y#'/%U_<UB(E-0<T^[RT.2Q<G
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MGKI->M>5=YBW>PGA,UG2U+?H9*6TOCO^UO6)F.,:Q,3.\9K.T
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M].WLYH^!EG^%B.$]\?EC\,<>]V"'6W*@
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M+-2+TR8[1>EZVC6+5M69K:LQQB8F8E+AL@
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M=WVU]=(GA/?6>4_L3IPUB8[';=MGKN,,9:\YYQW3VQ_9V:-VC37@
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MZ@JHVR1JK7-=HK7HYCG-6:S-9UCFB8UC270)O;TT[F;(76M9>[/5W;$VSO\
MU9FUJI)I['64CI593+7OB]]^H[A(W1'TU2YKO'K[MTK-)';=;UM'M436:\W'
MLS8N4>PO2CN1O;<Z*J6VUN+8'[V.2XYC=:.6"":D\6LD6.TU0D3[Y6R-14:Z
M/_H\;O\ G)&\&NKODK7WLJUFWN=^F(XG8L%QFR8AC-"RW6+'[?!;K=2,T56P
MPHJNEF?HBSU55,YTLTKOQ2RO<]VKG*IJS,S.L\VQ$:1HR)4145%1%145%14U
M147FBIVHI ZH>I+H)NE=>+CFVQT-%+!<99*RY[>SU$-O?2UDKU?43XO6U<L5
M M'.]RO6BG?"D"HJ0O<US(8[Z9>&EE5L?;5U[7#8_>:U5KK?7;4[B0U;51$C
M;AN03ME\3E8UU/-3T$L%3&][51'1N<U51412[Q5[X5^&W=+?S:+H=WEW$N-)
M-E%FJ]ML6\<;ZZZ9-3+37I\/B_?(+;C,KXKHZL5O):IM-"FNOC54\*X6RUCE
MQEE%)GGPAV&=0VSN+X-TGW/#L.M[Z>VX1/8;Y3(Y(IJVX5:7JEH[O=KG4JV/
MWU;44ESJ)Y9&HU$1J,8UL:-8GR%]]_H,]>^[MUC<5B;;CIV?:;ND1$3]7<X\
M.2>/**X<V6\S''2NG;+U[T2WT;#U"V>.9B,>XQYL4S[\=KU]^MZ5CCWNGD_!
MF'W:KL8J_>6Q"N9U7T,6NGEJ6TKQ56LEX:=7=G+A^<VJT^=1:Z_CI>]/+TEU
M<:F;I&*A1S57PZZ^;N]1L5PZPIMEXZ/KK<KD71-.Q/+AW$S@X$9HA:,H-%T\
M/)5[/N*HPZ<%DY=5XVC\*(NGG[N!9\+2%4Y-4E!'X=/47UJIM.J9@=IIZOI-
MNDZ->\:IJGF1%0VJ7:UJZIN&I3]'7Z?6;E<D<FM:DI**H3O+ZY(4VHOF5"<M
M>1=&2.2J:2KMF1>WR^TSB[&:J[9>6B^Q2R+:L)JKLD[^/V&<2PF.R5PCS.+,
M?"UHNIG$][&8T:M24:R^ZZ\!R3SX2:#5/A@T&IX8-!J>&#0A.D/HU-( D
M/BA$\FDE@ :D$LJOI#("-(?-"=4>%\T"-) A\'(?435= *Z< /H  !\ I$+
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MM5_S$>+XLRV\7K_T):%\DG![G-;_ .S&2HX-1&]NFJJJ[.+ZBG)]9PH+6
M[Y^@-]2[IRL:3^]]U'DF5,H_>(Y&)3+<W/=[A51$=%\8^754U3Q^).:*:N7Z
MZ_']5L/\S>X5L=HV>M<:O_5U9<LVN%4B([W:UMMI<8IZ!7*GX$>D%VJ?#KQT
M5=.TRP=K')V.I V%0  [5_ED7"M]_O!:E<KK<D.%W!K%1RMAK7/R6F<YBHO@
M:M3 U$=JBJ[W+=--%UU\_8MQ]KEUUJWZNQ_IMW$FM\CX:BYQ62PR3,D<QS*&
M]7^V4-SC7PIK(RKMLDL#FZHBME775$T7#'&MX9W^K+SW&VUP !S1Z!<BJ[-U
M&X_:H'O;3Y=8,IL5;&U$5CX:.S5.3Q*]%<GA5E3CS-'(BJFNG)RJ598UIKW,
M\?UG&CYANJ=96\"]Z[?*G_=9@Z?8?&OJM2:>>]Y:=-+5PS'^ QUX^W6)^31^
MS7W3\],WH#T3'6)UQ7WM9U[9G?[J_#V:7CGIQUX:<9XH4?%/+N0\XGD]TW'-
MD5*OX4U\WG(GFX3=1W)R'DGK,9</DYIBG7@GK#C\W--T_+U_8IBXS-S7S.PC
MM:EDE"GEY>@CL:625VWM(CDHLK)V>7:1VJ+JJ_HKY_R_>3V*(^LM7]_G'8W:
MK67CY>@F.2^G!$S_ +KU_83#D,78@:AOZ7I,H<KBGDA)D354])/:Y3'*#J$3
M1W#M4GM<OMYE SMU:O+M[#*.<PYC%.DH61G/UF43I+DJ61\C5126Y28F%H[7
MCW^7(>]?&C4Q5\N\(M"^B?RX_8.?!JY*I"-_%%,?9+3O7L34#OT5]7:I':XW
M+7G">IW?HKK]'Y#'O<-N:IRG7BFGEY:D0XG+'!/TVNO#7L\N\Q<3FTT3M/P^
MK[2'%9DDSE[#&S2LN&<O5]HE1DY+A>2>7F^P-517ZE(74GC[U)W,F6Q5:3:J
M3V+\2,D3GZ_I)[6]245.WFI+?Q3V(6H9Q5?49=CD\-N&B&J&]OEYQV.1PV1$
MT?,RB7(X[H]S5377BA,QVPW:W6SX]5Y$ZQVMBN72/:^>#AHGL)U8S>9G66GP
M>8:PGQ*B-T[")EA-GU4T(U1KJ>+1/M&G$TUE\5_#GZR?"RC',R(_SC2&4XN*
M#J\;QFXJKJ_'[)6/75/'56JAGD377BDDD"O:J>)>*+JFIQN7HW2<^LYMKM[3
M/;..DS\^FKD]OU7K.TX;7=[G'7NKEO$?-$Z(O^ 6#?\ IJ6'_P!IM-_\P:?^
MB_E__),/S-[_ $G\S_Y?NO\ "6_*O:7#\0HW(ZEQC'X7HNJ2,M-![U.*.325
MU.LFB.:BHFO!4+\70.BX8_@]IMXF.WX=9GYYB9:F?KWF'<1IFWN[M7N^+?3Y
MO%I^!DD38XF-CB8V*-J:,CC:UC&IKR:UB(UJ:G*4I7'6*8XBM(Y1$1$1\D.%
MO-[VF^29M>><SQG\*KXE[S+65?A@U4C5.CX-9'Q7)Z1HG1H5W>91#*(4'+[5
M,N2VL+=R\_+D1VMBDZ*2\4(GO7Q*@YOY28E;$J#F_D,O:MK915FO81R619I\
M"^2!EXEY"WD)X0ULEDG3?I&/9Q<=N)UA-TJZ*GEVD3QJXG/'!/TZ\-#&>,.)
MRPDHW::><B&G>NJY:_R^\GG#4R5XM+G?1]),]R:<%!R_28]K9K':IJNB$3W+
M(C53#-0?S]I*VJBY-?M)CN65E15NG$G19$ZM)#)\(\/<&B#3O-9!X81J^HB^
MCTF45T83>.QK1FOWJ3PA7-I5$C\N0U83=5;%W^7VD:JYNU)&GEQ^LC5'CEK1
MB:<$&K'Q/OA\WUD:HU/#YOH&IJ>'S?0-35J\*A&L'A4&L'A4(\3[X?.-)/$>
M'SCB>(\'G'$\33X5[@GQ-*L[T)U3%FA8T\N U9^.5-T?T]Q+.N284EC\OSD3
MI+8KDUC50=%WZ_9]0XQR75NMGQKQ)B8E=6\+&2-6KKH93Q][;I>)64D7B_,(
MGLELTOX49/ NG9[">7N<EAS1/O9YL_O#N!L+G5MS_;R[.MUVH7)#74%1[V:R
M9':9'M=66#([='- EQM%:C$U;XF302M9/!)#4112L[#Y;\R]3\K=1KU#IM^'
M"+TG7P9*_HVCY])YUGC#I_J1Z;>5?5;RUD\N>9L46C29PYZQ'QMMEF.&3#:8
MX3PCQU^IDK'AO$P]073AU$89U*[=TN=8HR>VUU-.EJRW%:Z1);ABV11T\-14
M6]]2V*"*Z6V>*9LM%71,8RI@<GB9#4,GIX?L+RSYGZ9YJZ;7J'3K?2C2,F.9
MCQX[?HVCNY^&W*T<8[8C\:/5+TN\R^DWFC)Y;\Q4BU9B;[?/6)^%N<.LQ&2F
MO*>S)CF?%CMPG6/#:V_QV)YNV5WUWRQ38;#),IR)'U]=5RNH<=QVEFBBK[]<
MT9XUBC=+JE/0TC51]54*UZ0QJFC7R.CC?E6LWG2&-K16-72=N3U@;[[CU]5*
MN:7/#[-*^5M+C^%5=1C]+34SU5$@J+A0R17>YJZ/A(M1.]KEUT8QJ^$V8QTC
MLXJ9O:6W5CWZWKQRM9<+3NKGL-0Q6KX:C*+M<:.7PZ^%*FW7*JJ[?5L;JNC9
M8GMX\C*:5GLA'BMWNTCI7ZVG;EW>@VYW3BM]MS&O7W&.Y+11MHK7DE4UFK;9
M7T:N6&VWRI1JK"Z)6T]4]?=,9%)[MDM&3%IQKR6UOK.D\W8P4K'#OK,W_K-D
MMOJ6AQF=(,ZSB6LMUAJT2-ZV6WT3('7F^I'(U[7U-.VKBAID<GA2:9).*1*U
MUF.GBGCRAA>WACAS="%5555=4U%;6U,]965<TE355=5-)45-343/62:>HGE<
M^6::61RN<YRJYRKJJZFVH4 ,RP'/LJVRRJUYCAUTGM5ZM4\<C'QR2I35U,DL
M<D]LN<$<D25UKKDB1LT+E\+V]RHBI$Q%HTGDF)F)UAZ0-HMR;5NYMUBVX%I8
MD$-_M[9*RA]Y[UUKNU-(^CN]K?)X6.?\#<8)&,>K6++&C9$1$<AI6K-9TEL1
M.L:N,G7_ +@UV&[(?J*U5#Z:MW OM/C55)$Y62)8(J2JN5Y8QZ<?#6?"PTLC
M>3X*AZ+P71;,4:VU[F.2=*Z.B@VE   [=OEL;A5U=9L\VSKZB6:EL,U!E&/1
MR/61*6FNTD]'?*6%')K#3-K8:>9K&KX5EJ)7:(YRJ[7S1QBRW'/8Y1=:-=56
M[IEW2J*.1T<TE%CE"]S5<BK2W3,L<MM=&O@5J^&6AJY&KV:*NNJ:H5X_KPSO
M]67GG-QK@ #E=T1U]90]3.W+*-'O;7KD]!60L_\ *T<F(WV:57_A<O@I9(&3
MKR_YKBJ)J5Y?J2SI]9WYY%;7WK'[[9XWI%)=K-<[:R1W%L;Z^BGI6O<G<QTN
MJFK'"=5\\GEGK*.JM]754%=!+2UM#4ST=92SL6.:FJJ:5T-1!,Q>+)896*UR
M+Q14-UJK8D ,WVTQVKRW<3!L9H62/JK[EE@MD?NT55C;5W2FBFJ'+X7HR*FA
M5TCW*BHQC5<O!%(F=(F4QS>H,T6RZ"NN+;&X8#OG?KY\/(F/[B/7*[/6>!RP
MOKIVQLR*A=+HC%JZ:[^.9S$XM@J857](V\5M:Z=L*+QI;WN'18P ,EP[$KWG
M>4V+#\;I'UU[R*Y4]LM].U'*WWL[OQSSN:UWNJ2DA1TLTBIX8X6.>O!JD3,1
M&L\DQ&LZ0].>(8Y2X?B>,8E0N5]%B^/6;'J21R:.DIK+;J:W0R/35?QR1TR*
MO%>*FE,ZSJV(C2-'!/K^V,NN?8I9]RL5H);A?<#IZREOE!20^]K*[$ZAZ5;J
MJ%C&NFG?C]6U\JQM3_F*B9_[C1;<5M)TGE+#)76-8YNE,V5(!D&*XM?\VR&T
MXKB]LJ;O?;W61T5NH*5BODEE?JKGO5/PPTU/$UTDTKU2.*)CGO5&M54B9B(U
MGD<^#TC[*;:4NT.U^([?TTL=3-8[;_[-*V)OA97WNOGEN-YJV:M;(L$EQJI$
MA1^KV0(QJK^$T[6\5M6S6-(T0/43L_3[W[5WW"?>PTMW\4%YQ>NJ-?<T61VQ
MLJT+IG(U[HZ:M@FEI)GHUSF05#W-17(B"EO#;5%H\4:/.?D./7S$[U<L<R2U
MUEFOEHJI:*XVVNB6&II:B)VCFN:NK7L<FCF/:KF2,5'-56JBKN1,3&L<FOR0
MQ(NJ&AK;G6TEMMM)4U]PKZF"CH:&C@DJ:NLJZF1L-/2TM/"U\L]1/*]&L8U%
M<YRHB)J0/03TB[&5&Q^UT-#?(XVYGE54S(,J;&]LJ6^5U.R&VV%)HW.BE_4]
M+K[US%<Q:J6;P.?'X'+J9+>*W#DV*5\,>UEO51CE3E_3+U#8O0TT%9<K]LEN
ME;+53U+XXH7W>JPB]QVA7RRJD4/N[DL3D>Y41BHCNPQBT4GQVG2L<9GV?(ZE
MZ@[;+O/(76]IAB)S9>D;RE=>'TK;?)$<>SC/-^=]1N3\/=PX\>Q#S1^*3*J5
M4U3\GG R&GY)Z_J]0$S!V>7[D"8@Y-\OW($Q'PX_\K[@+Z/M]7V@2#.2KY</
MS@73?T4 JQ]H&J7FB=R)]2?<!9R?NO0OTIJ!8R_HZ^GZ4_(!"U":Z^E?K5/M
M A)V\^''RY^M (2H3GP\E5/O @*CM\NY5 @YV<]?+L_*!%2-Y\-.Q?O]8%A(
MB^?S]R=RZ 6JJ[7CS[$^X"YC5>7FU]"_<!?QO\NY?N D8'\>[C^?Z )VF=R_
M)]_I GZ9W+BO9]GY0)VG7E[/K0"=IEU5/3]K0)N)?PZ=R)]* 7;5X(OEP O(
MTU=IY)R UOXHJ^?4"B!;.X:]Z:_0B@1\VJKYNSU>2@14R<_1]2_<!#U#>>G:
MB^9=->/L A*AFFOK_*OGX@0E0W77GV\._P!@$5*WS_9Z>7)0(^1O/GKV:)Q
ML_!Q55]6B<?H[ -*M1>]W_RO #XC-/W.GEW]B :O [\NJ?8!\Y+P[%^H"KXM
M.?#7L[O3VZJ!I5_<G#S@??><DT3O77\R\ -?O>&G!/+7AV?0 ]ZOFU7N7[%5
M./J U>]\_P#[=P^QH&I)/9YE^P#[XTT\_H_*!I5Z]B_0GY0-#G?W2^7H0"DK
M^[AYP-.J\U7LT]0%!SM5\R 4G+P14[?8J<0*#ET3O[%]&G$"DOFY=@%)_>G!
M>2Z=OF I@?4YIZ4U\O0!>,73V_3YO4!*P+P3CKV\.S1?/P FJ=VB)]W9KI]@
M$O"_BFO#BGW=B=J 7['>Q>2]WG J^/\ !Z%XIK[$] %%7+HNO+G[ *#EU7Z@
M*#W:\$Y=OG H/7FG?IW^2@6KE5%7BOV:>OF!35-?-]WV@4E31= -#D14U77A
MW<P**Z>E//Y*!\1$3D!J1%7D@&M&=_L3[0*B,UY-^C[0*B1N7R\D K)!P37C
MY^//Z *C8.WA[-/JU J+"GF^E/J ^I$B<E^C\H#W2=NGGX(!J\#?/Z/S ??
MWN^E0'@1>2*OM U)'_R?:GW@/=Z_N?L^Y 'N^/Z/W?<!I6/MT5/H T>[3S>?
M@!3=#SX+IYN*>P"DL'F^A4_(!06-47EZ^W3[0*:Q::\].?!> %-T:JFGEWZ\
M0*"QKV=G?V?1W@4'QKS[^?G[^SGW@6SXM47GJGU_E LI8M>*<NWU =L7RR?F
M59'T>YC0;<;G76[WSIHR6ODBNEL1DERJ=K[M<ZJ)[\WQJEC@J+A-:F2^)UTM
M=,J)41RR5,$4E6Q(ZCG.F]7R;>*[7/I.VUX3/.G/E/Z,SQF)UTGC736WB^C?
M0?UUW_IKU.G1.NY,F;R+GO,7I]:=K>TQKGQ1I-O#KQRXJ\+1,WK6<D:6]HU@
MOUDRJQV;)\:NUNO^.Y%:Z"^6&^6BK@N%JO%GNM+%76VZ6VNIGR4U905]'.R6
M*6-SF21N1R*J*=MB8F-8Y2_4;9;S:=1V>+J&PR4S;'/CKDQY*3%J7I>(M6];
M1PFMJS$Q,<)B=4L2V0
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ML9*1,S;X.:(FV.;:Z3%\?BO;':T\Z#J+V
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M62@_FI,\H0LY4^OR^LRA")J4UU]?V_>9PQEC=8S]+S]OI^XMK+"6,5;>?/\
M/Q4NJKEB]8WF7582Q.MTX]O,NJKEB5;KH[1..G?YBZJN6%5KE77[^9L5568C
M6KS]'=W%]5<L4K%7CZRZK"6*5B\_O3N+JJI8I4.Y^7ES+H82AIU37R^\LAC*
MP<NB*93W,>W50,D-;.9C;DE<,YH3*8Y):#3R_.5RRA/42Z.U7EJ56Y,H972R
M\O+\I3:%D,DII^7'NY=Q3,,XE/TU3R_$5S#.)3,5=HK=':HFGEV=YA-66J8B
MN7A3@OXOJ*YJRBR0I[LYFJJO%>*<>:^WD8S1E%E_'>'ZIJ[GVZ]_K,9HF+)>
MEORM;HKN*<$U<B:^U4X(A7;&RBZ:@OKE757\>>JJGWF$XV473T5^\4;?Q\43
M1>/=Z^XJG&R\3XM\\2\'KHG+CV]_/5%)^'P3XE.INR.;XO$G%/R+[%%:(FS&
M*NZ:JJ(Y/+L^@NBC";,=K:_QQKQU5.'9KYN*^DMK7BPF>U@5PJ?$J]VJ^7!#
M8K&BF98?7R>-KD].G/\ )V%]85SQ;:W:/Q>->';]6GGU-NBFSFM\O?=Z3#]Q
MKEM7=ZN1N/;B1NJ[+'*^9\-#FMJ@5\:PL=5QT=$R_P!DBEAJ'I%)-/44E%&B
MM:U=>"\R;+XVUC>4C^$Q<)]M9_#.D\8X\(FTN1Z5G^'FG!:?HWY>_P#W8_%#
MNJ.B.Q                                                ><?JWV
MW=MCOYGEGAIUI[-?+B[,\=\-##;J1;3E#Y+B^EMM+3JL#+=9;L^JMT2L\**E
M&OX6_HIZ;T;=?:^G8[S.MZQX;<=9UKPX^V8TM\KI_4,/P-W>L?5F=8]T_DG6
M/D<;3DVD        ?4)A,+F-.7M$]LLUVQOF(3^->1QZJACJG1?QQ</88S,I
M74<'+AV^TQF66BZ;3Z\DT]GW$:FBX2E_"G#G]_K(\2=%1*-=-=-%]'81XDZ-
M*TGK7T(3XD:*:TOF\OH&IHHOI-5Y=W/4G4T45HD[OH_,A/B1HI.H_-]&OY!X
MD:+1:/S?1HGWF7B-&A:%5[/HU)\2-&A]"J:?A7M\NX>(T6[J14UT12=4:*:T
M<B_N57T\/KXDZP:+5].Y.;5]FI.J-%NZ'N)U1HTHQR.33[O43J+^%SFJFNJ<
MN/-.??YS"4PRRWR_H_1JNI3:%L:MQ+-+^AS]IJWA;5NK:)?T>"]AIWAL5;HV
MJ75&FG>%]9;BVQR+X>SEV_=R-6ZZK/[:FOA_%P73O7[5-:RZK,J9-50HE9"<
MC31J(5]K*%VG)?1]J(8I4'MXKKV\B?:?C6_AU5$7GS]G(RU[4>U1?&G%>?$:
M_,A;.C37@B+Z3(470^;R^M!JA3^%5VBJGE]Q.IHTK1ZKRU3\@\1HI24?<WR7
MV$Q9&BSFHN'+L\N)E%B814UO\6JZ*GKX:^M%,XNPF$)4VU4UXI[%1/M+(NQF
M$#44*IKP[RR+,)A!U-'HG+L+(LQF&/U%/IV?G+8EA,(.>'37R\N)9$L9A$3-
M1-?+SH9PQY(V1=/09L5C)*J=OEW&40A:OJ-.WAZOL4F(1JH+5HU4T^[G]1.F
ML(U:DK?/]*CPZ&KZE;YT^L>%.LM#[BC45$=Q]GTHH\"->Q;I<_QZ^+GHO/N[
M"?!P(LD*>Z?BY\E[_,BF,T3%F66VZ>)T?XDUX:\].*)Q[=%34IM19%N/!N%:
MZ]5XZKHJ)V:)V:<_2:MZ_.MK+<>U52*C-57T<U\M5-6\+ZRW&H)O$D:HJKJB
M<_8OTFK:%T2R.)=45/-K]OV%,LWUW)28YDK9_(F.9VH^;DIE#%!53=45/7Y>
MTLK+&6,U3.?E]I="N6-5;.? MJPEBM:G/NT4NJKEB-;HOBY>TOJKGDPVXKX>
MW@NO!/-]7,OHKLPVM=SU4OJJEB=:[GZU+ZJY8G6+SY^2\2ZK"6)5J\?;^3ZR
M^JJ4!.[GV\_IY%D,91$J\?660QGDM7\R80T$H5F\D,8YRF5[ G'7S_:1+),P
M=GI3ZRN63*:-_A1.?9]GK*;0SADM)-IHO;HFG'LXE-H9Q+(J>HTT7547LXH5
MS"R)3T%4C4157T=^I5,,HE+TU?IS=P]/H,)JRB4FVZ*NB(J^%.7'1=>_TF'@
M9>))-O+M$:CE5$T775.*Z=FJ]AC\/M3XE]#>U8J.5W!%X\?;RX\C&<;*+)V&
M_N5/"Q_#M5')]^NA5./O91=-TE^5KDU>J(O!>/?R[M.)A.-E%DDZ^^%/T^/9
M^+\IA&.)3XFEEY\2.:K^+N//M35?I03CXI\2)K+KIK^/R^CL+*T8S9C4]R75
M55R^WU+I[2V*,)LQ.Z5BKXM%UY]J_D+J55VG3@P6MG55=QYZ_E[38K"J6#7=
M$<BZ:\=4YKZ^S0V:*K-M+C&^.5LL3G12Q/;+')&YS)(Y(W(YCV/1R.8]CD14
M5-%14U0VZ<>$J)ANKOKF-;N;?L<W0KT8ZOR_#[%3WV6&-C(_X58G2,Q:_->D
M,$%-#-6K:X+BV!B*D%+<(&ZJ>>;[:?8=W?;Q_%Q.M?U9XQ\W+7OAV;!F^/AK
MDGZVFD^^.?Y?E;(&HN  'H6Z,,9KL6Z<-O*:Y0K!5W:FNN2^Z5BL<E'D%XKK
ME:9'*J-<]:BSS4\NJIR?HFJ(BKIY)UO+8I&E7'OYDF!UMXP7!\_H:=\T6&WF
MY6F\NB9XG06W*8Z#X6MJ%1O"EI[G9XX$77A)6-31?$JIGAG29CO8Y(X:NFTV
M5(  [I/EPX%6V#;3+<YKH)*=,]OU'36M)$T2JL^)1U]+'7Q\?^;EN]UK84Y+
MK3JO)4-;-.MM.Y=CCAJY?[X;;1;N;59E@#I(8*J^6O6TU50B^YI;Y;JB&YV:
M>5[&NDCITN5'&V96(KO<N>B(NNBUUMX;1+.8UC1YL;Y8[OC-XN>/W^WU-JO5
MFK:BW7.W5;/=U%'64LCHIX96ZJU5:]O!S55KDT5JJBHIN1.L:QR:W)%$@!V[
M?+IV9N-GHK_O-?:62E3(;>[&</BF8K9*BT-K8:J]7A&.3A!55UO@@IWIHKDA
MF7]!S577S6U^C"W'7M=HA0M=0?6%T<Y%#D-ZW7VIM$U[M%ZJ)KKE>)VV-\]W
MM-UJ7R37"[V:@C8LMQM5=,OO9H(O'/3S/<YK%@5?<[&/)&GAMS57I.NL.L26
M*2"22&:-\,T+WQ2Q2L=')%)&Y6/CD8]$<Q['(J*BHBHJ%ZI,X[C.0Y==J6PX
MM9+ID%YK'(VFMMHHJBOK)/Q-:Y_N:=DCF0QJY%?([1C$XN5$XD3,1QGD::\G
M>#T?=++MD+74Y=F*4]1N3D5$VDF@@D944V*6=\D=0^ST]3&Y\-7<*N6*-]9.
MQ5C18VQ1*K&NDFULF3Q<(^JOI73C/-S=*F;;_<O;#"]W,7JL1SBT1W2USK[Z
MGE:J0W"U5[8Y(X;G::U&NDHJ^G;(Y&N1%:YJJQ[7L<YJS6TUG6$3$3&DNK;.
M?EL9M25T\VW6<8[>K2Y_B@I,K2NLEX@C<_1L+JBVT%UMU>^)JZNDTI$<B+I&
MBZ(M\9H[853CGL1.*?+:W/KZZ/\ AEF6'8[:DDTF?9G73(KJ]C41RK#1ST-D
MH6I(J^%'.JM6KJJL5$1'3.:O9$D8Y[79_LUL=@.QN.NL.%6YR3UBPRWO(*]8
MI[[?JF%BMCEN%8R*)$IX/&[W-/&UE/#XW*UB.>]SJ+6FTZRMBL5Y-X#%(!L9
MN5TV[+[LSR5^981;ZB]2(B.R"UR5-CO;W)P:^JKK5-2NN*L;P:E4D[6IR1-$
MTRK>U>4\&,UB>;:FU=!G3A;:V*LFQJ]WAL*^)M%=<GN[J)[T5',?+'034$TJ
M,5/T'/6-R<'-<G RG+='@JY78]C>/XE::6PXO9;7C]EH6JVDM=GH:>WT4/B7
MQ2/;3TT<<:RRO57/>J*][E5SE5553"9F>,\V>FG)-D !\<UKVN:YJ.:Y%:YK
MD16N:J:*UR+JBHJ+Q0#$X\ P2&M6Y185B45Q736OCQNS,K5\+O&W6J;1I.OA
M>FJ?BX+Q)UGOE&D,M(2     !BN<XQ!FF&95B50YC(LDQ^[67WLB*YM/)<**
M:FAJ=$15\5+-(V1-$U16H=2\^^5<'GCR1U?R=N9K7%U/IVXVWBGC%)S8K4K?
MOUI:8O&G&)K$PY;H/5,G1.M[3K&/6;[;<8\ND=L4M%IK_;1$Q/O><VKHZFWU
MM5;ZV%]/64-3/1U=/)HDD%332OAGAD1%5$?%*Q6KYT/YGMYLMUT[>YNG;ZEL
M6]V^6V/)2>=+TM-;UGVUM$Q/MA^E&'/BW&"FYP6BV')6+5F.4UM&L3'LF)U7
M4$>NB+Z?O(I75C:=$Q3PZ]GH\O.;=*:M:]D[30=FG,V\=&K>R8BH]=$T^@VZ
MXM>#7MD3=/1<$X<-.Y3;IB:U\B^;;M6K^'G]G+Z2WX"J<W'FL);=X55R,U_$
MNO/AQ]!3.#2==%L9M>"BM*O:W3R]!C.-E%VEM.C>"\#'P:)\6JNUOA\NPRB-
M&*Y8[PIKYBR)5S'%=QS^%->7W_061DT8335?1UFB:Z\O/]I=7+HJG'Q5FUW'
M7Q:_1^0RC,QG$O&5W#7Q>CR0MC,KG$NH:[5>?/S^S4MIFXJ[8DE'6><V*Y5-
ML:0AJ4=W:^G["^N2)56I,+QDK5\WE]!=%H53"NCD7[#/W,9C1K,^<,6HA8
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MVKW@73&<N[L3M4"^@8OBX_9Y=X$[3-7A]OEWJ!/4Z::?9ZU^T">IM.'W?D]
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MM?M1TWJ.RZOT[!U;IV2,O3]UAIEQ7C72^/)6+TM&NDZ6K,3QB)X\61%3=
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MU>Q^7-_&WW,[7)/\%EY>RW9\_+WZ.)ZMMOBX?C4^O3G[8[?FY^[5T<G?76
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M[%+JPPF6$5[]4?SUU73D;%55N+D[TR;:6C?O']S-GZJLEMV7V^CHMR-N+M)
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MBV-V#&J1R,1U+8+/;K-3.2-OAC1T%NIJ:)4C;P;PX)R$S,\TZ1')/D
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M6B9=O!)KXXENTD4ER6%=5_![WPHG#303:T\Y(K$<FY!BD
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MG<NO#DOEV 4GNUX:^G[@*:KIQ4"BKE4"@YW8G+O[P-&NG,#0JM75>:IYP*0
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M_OKO>EV^-M]><[7-;Z=8TCC\'/,S,VF9TSTK6/#1WXGBK[2
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MO55B+XO%KJB=Q/BM/.91I'<SHA(
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MB](GW>"^GOEV9GZM/EL
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M3N7J3["6%>:@].'JU(AM4Y*#OT5)CFNKS1,W-3)OX^2*G9SYDM_%9%SMU:O
MRAO8K<4+.W5%$<W)XIXHF6+Q<T_*3R]SD\.32-$7)$K570G2)][D:9-864D2
M*(GLELTO,+"2)>*:<#)M4R0TMC7DB#VLIO':N&1+W>7WCWJ;7A=,9IHOE^4B
M9[(46MJDJ=O)2)X0TLUN"8ITX^7(CE#B,TIFGY\2.QQV;DFH%T<GH0QGFXS+
MR3$3N*><CFX[)"2B<1SAI9(7C7:$1Q:F2-87/B0-;PR:M7@$:3#0YNB!G$K=
M>?I$\&S6VOO6<K.9/M;>.RRE;HJALTMJCYHT5-?L);>*\PBY(]=>'$RB6]2^
MB.ECT7D2W:7X+1\?>GEYR.38K=;.BT,M5U;ZK5S!,:\87ULM)(R8GLEL4NL9
M&>6AESX-JEEH].!$<);%9XK-Z<_+GS^DF6YBG@L)5T0F.;<QQQ63G$S^%M5A
M15=0LB-&E%[AJG1K1RIY<1[F,UU56O\ .3JPFJLU_G&GSJYJK-<O>8S"J:JJ
M+KZ3'E[F$PU:JAE&DJK5AK1>U!R5S#6CM0PF-&H( '@UXZ \32K/2GI&B?$^
M>[5>SZ/S#BGQZ-21>7 :(\:HR/B3R86OP72-1"N9U:\SJO8$X)S,FMEYI*->
M7J,(YM*\)&)W!$]0EIY(XJVJH8M>T:R^^)-">+#3BT!F^*NGI)B$Q&JFKM.:
MDLXUGAV-"NU(91&BFJZ(3#*(:#)FJ(B(8ZL)F7U.*A"JC>[VCDKF55$T,6#6
MUO:H8S/9"JUNO'V$JYE<M83P4S95:S\XU[E<V5480KFS7X4(1XI/"GG!XI/"
M@X'BD\*!&LOJ-3L3[1J:M2(O+0:HUA42-5\O)2.+";JB1#1A.16;%Y>7$<%4
MY&M(O,-6,Y%1(T]@XL?')[ORXCB>-I6'7G]/+ZN(U3&3N4W0>8,XRK=T'=]/
M+[@MKE[U%8=.&@F6Q3*M9*=%XHGV>7 G5LTRZ+5\"IYPV*Y8E9R1:IR\OM')
ML4R:(^6'0GW<VYCR:HF>+354,HXPY#%D0U5$FGB[^8C\+E]ODGDO\"SB^;79
M]B6X>-2I'>\.R"W7^@8Z:IA@JW4%2R6>V5SJ.:GJ9+9=J9'TM7&U[??4TTC%
M71RG+=%ZGEZ-U;;=5P?QF#+6^G?$3]*O'LM76ORM#SCY7V7GGR?U'REU#3[+
MU#:9,.LQKX+6K_!Y(COQ9(KDK^VK#TE]1>QEAZK=LL2SO ZZF9D?\'Z')<$O
M%7%-1TV18UD5!3W>FL]R2:..IHHZZ">.>G?*SQ4TRJUS6MDD5/N_9[O%N,&/
M=89UV^6E;5GOBT1,3\TOP3ZKTS=]*ZCN.E;^OP]_M<^3%DK^CDQVFEZ_):LP
MZ0LPPC+MO[W4X[FF/73&[S2N<DE%<Z9T*R,:Y6I44DZ>*FKZ.335D\#Y(9$X
MM<J+J<A$Q,:QR<7,3'-B[6N>YK6M5SG*C6M:BJYSE71&M1-5555>"$H=CO29
MT99'DM^M.XF[%EJ[#B%HJ*:Z6?&KM3NIKIE=9!(DU&^NMTZ-GH<>CD8V1Z3L
M:^L;HUK5B>LA3DR1$:5YK*4UXSR=SAK+FE[&2,='(UKV/:YCV/:CF/8Y%:YK
MFN14<UR+HJ+P5 .N?>/Y>>'Y?<ZS(-L+['@-=6/DJ*C'*NA?7XM)42>)SEMR
MP2Q5UABDD=JL;&U,#$X11QM1&I=7-,<+<5<XXGDXY4GRU]X'U:,K\UVUIJ#Q
MJCJFDK<HK:M(_&B(Y**;&+?"KU9JOA^(1$7AKVF?QJ]TL?AS['.G8+HVVZV1
MJH,CJIY<WSJ%JI3Y%=:..EH[.Y[5;(['[*V:JCH:B1B^%:B66HJ$35(WQM>]
MKJKY)MPY0SK2*\>UR^*V8!2G@AJ89:>IABJ*>=CHIH)XV2PS1/16OCEBD1S)
M&/:NBHJ*BH!M7/L+LA55OZQJ-H=M)JS\7BEDPC'')(YVNLDT2V[W,\O'@][7
M/3AHO!#+Q6[Y1X:]T-S+=;;=:*."W6F@HK9;Z9JLIJ&W4L%%1T[%57*V"FIH
MXH(FJY571K4353%*]                                '13\]KIIFW*
MZ?\ %^H#'*%)\DV%NLT&3)3P1?$UNVN:5-NH*^HE='$ZMK?X+Y+3T,\4>ONJ
M:DJZ^==$1RG%]8VWVG8S:NLY<4^*.?+\^-.7*(M,SV4T[7R1][CR+;KODW;^
M<ME37?=(R3&72(UMM<\UK:9X>*WPLL8[1'*M+YKSIQEY+J%_!/-HO-./>OM.
MDOS:951OU33AQ3S^E.?F GX%U]?E]@$W3KR3SI]?Y0)F+EZF@247/7SH!(,Y
M>O[$ NP*\?+VKZTU^X"F_FGH MWIQ10+69.&OEKR^I0(:9NO9^7AQ]',"-E9
MYN'V?D BYV<%]'HUX?<!"3LY^7I]/% (J6'GZ_9Q^@".DBY^7M[T4"PDB\WW
M_E0"S="NO#O^OCP[0-;8U[$]O-?M N&L7DB*B>?Z_.!=1-1%3@O%?SK] $O#
MP1-.?#[]?:!+P_N41-/)?H4"9A7@B:<--=/6GU@3$#M$1/+5%U EX%3P\/5Z
MG*@$@QZ<=./+[_J O(G\>*Z]VGH N/&GG^C[P/B^%_+@OE[0*$B=Z=FB\N'%
M +21O=VI](%C(W@O#S+]_I C)H]5Y>GRT[0(J=G/@G'Z?-Z0(J:-=%[N7G^S
MD!%RLY\/3]_H L96=O/Z>7;YN %F]OFX=B^K0"U?'^?[P+5S-5U\D5 +=[/-
MQY:=^O!/K LY$U5WJ]NG#Z@*#DT5?/HOMUU^D"U=S55[-?+1>T"BJ]NGXE7A
MYDTX+Z0-*KIQ50"+VHH'W73EP U([AW+]"^;3D@&I':\^?9Y_P H&O77R[ON
M ^ZKW@%55Y@?4<J<.: :E?JGI I@ -*M3GIQ\VOV :5\SG:]VBZ_8!I\*]J+
M[43Z]0&GG;Q]*KZ.&J 58VZZ=GV)KR3RX@74:(B\.'V^;CQY@2,:\O.B<O,@
M$E&[DG<FJ+R[>X"^8Y-4X\%\M0*J*B\@/JKVJ!1<Y5]'<!0<[7@G+Z_R 45>
MB<N*_0!35=5U4#X   :V-UXKR^T"X8WM5.'8@%PUNO%>7U@7#&:Z<.'8G?\
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M?YNR>5/5GH^ZUG[+NMQ&SRQ$Z1--U_!5FW[6F6V/+/\ -P]TA\7OV7
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M#5=43\:NX=J]!\T5\/48GOQ5G\-H_8=DZ1.NUF.Z\_BASZ.N.4
M                                      V8Z@-IJ#>G:O)\(J(H/UG4
M4CKAC%;,UFMMR>WL?-::EDK^,$<\NM/.Y%15IIY&]IO=.WEMCNZ9X^I$Z6CO
MK//\L>V(:V[V\;G!;%/UNSV3V?V=SS15-//1U$])51/@J:6:6GJ()6JR6&>!
M[HIHI&+Q:^.1JHJ=BH>HQ,6C6.4NF3$Q.D\U$E      'U#*&4+N/L]!'8R2
MM.G)?+D82RAD=+&O#R^HJF6<,CIHN"%4RLA.TT"]J>HKF640FH(-=.!7,LXA
M,P4W>WRY\2N99:):.D1S>7T&$V9:+EM"G!-%37R])'B3HJI0^;Z-"/$:=S4Z
M@UTT;ISX>SVB+&GSM#J#1%X(B:#Q'A46V]-/T>?;Q)\3&8D=;?$Y$1.?W((N
MF:RN([7_ ,GEYB)NGP\%RVV?A7\/81X^*?",M"*NKFIYD5.WO$W1X?F7*6IO
M:GT?=Q,8NGPOKK0URHNG#C^Y5.7+1>WF3XSPK.HLJ.:J(G'GR^Q.),9$>%!U
M5BT8Y$8B\%X<^.GG\_H+*Y&,U8O4694U_ FGH_(71=A-4/-:GQ*CO#HFO%$5
M>U>&FB::&<7U8>'1)T;5;HBHJ::</)=%,+,H9=;]4<WAKQ]'/V\RFW%9#<NT
M:?@X:>M/:IJ9%]6Y=J<W\.CN[RX<#4NNJW&M;TX<?;P]AJW7U9O1KR]/U>HU
M[+(9#%V>A"J5B^3]'V?4IBD ^:A JHG:-)&GQIYQH-#I=%TY$Z"FLOG7ZB=$
M:JB/73O(X=J8]C4CU541=!P%1."HO<I"6B1/H40A8RMU1>"+VF<([-$'5,Y\
M"R&$PQJLB;HNJ=_G+:RPEBM:Q$\6B)K]I=5A/-B5:G/SK]1?55/)B-:B\>[C
M]1=5A+$JMO%=4[_M+X52QZI1./K^W[BR&$L;JU1-=/M+JL)8O6/Y^7H+HAA+
M$JR;P/7GQ37A[._S%U85SP04]2O:J_061#"91;ZO37CR,_"C59R5BKV^7IX*
M915&JFRM5%TU7G[?.3X4:LDMUQ=XF<5X=W!//P75%*;59UENI8Z]SE9^)43A
MQY=W-$133R5;%9;VX[7<&HKDUX+R77L3GHB<SC\M6S26\]BK4\3/Q<4TT^S3
MM0T,E6U26\=JJ4<C.6CD3M[T]&G TKPV*RRV)VK%3T+Z_+4HE8IRJB>P1RT$
M;-)S3T^7<9PQ8]62M3Q:K^?CKR\Z%M6$L2KJK371?H+JU5S+"[C4I^+5=//H
MG$OI"J98#<:QJ:Z.3MU7AV:_2;5:J[2PBY5J+XD1>/:J<N)L5JJM+"JVIYZ+
MV\%UX?>7UA5,L3K)TXJKB^L*YEB]5-KKQ]'EYRZ(5S+&:N775->'$MK#"98_
M4/U5?+D6PPE%2K]JF4,96+UX&7:A2,D %=J*J)P4QY2F5Y&CDY\/-Z#&67:O
MV<-/81*8Y)2)^B)W_9P7@82R7L<VG:NOTF.@K>_5$Y^KUD:)?%J]$Y_2/":K
M1U:J*O'7VD^'5&JUDK5XJKN?MY><RBJ-5DM?SU77CR^[7L,O"CQ*+ZYSN7#R
M]!,0C7N:&USTU3FNO8OH[Q-4^+N5X[DYKE5=>*>2Z:H1-8F#Q)&&YJNNJIR^
M[AZ#&:)\2_9<]-/Q)[=.1AX&7B7D=U56JB/Y]^NB:?G(FG'B>)0=7NUXO\_,
MGPDRHNKW:JB.1=477CYM2?":\-%A+4*NJJ[BOG,HACJL))UUY\3+1&J,FEY\
M3.(8MR=A'N3?;9=S7*W_ /2QMVW5JZ+X79?:&/;JG8YJJBIVHNAJ]1C_ .=^
M?7^1O^]E=M?Z5C_G*_CAZ;#REW(
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M=5T3N)FTSSF4:1')FY"0
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M0MEUS!&F#>[3#GKPT^CFQUR1PXZ<+<M99R5.6
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MGOO/XH<^3KCE
M 'F]ZL\9@Q+J+W7M--&D,$V2?KZ.-K6MC8F56ZARA[8VL<YC8VR7AR-1-$:B
M::)IHGIW1\LYNF8;SS\&G[F9K^PZ=OZ1CWF2L<M=?GX_LN.YR33      ^H3
M"87L2:JGJ'8L3-,Q5T33N^LKEE#*:2->!3:5D,II(M=-?L\Q3+.(9'2PZHG
MJF6<0GZ:FY*J?D_*5S+.(3L%+JJ)IW%<RST3L-)JW]%"J991"^CI/-]!CXDZ
M+KX%$_<IP]"$>*4Z/OP2Z<$3AZ]-?/V#Q2>%H6B5>'AUUU[!XC29]SY\%HNG
MAY<.2_>/$CPRJ)0?NO"G'S=V@\2=)T5VT/;X=?41XD^%>0V[Q+KX=4]!C-T^
M'M7*6SN;]!CXSP_.NTM/X6_ATX=O/5>*IZB/'JR\/:NF6?6-WX>?KUT]'+0C
MXG'BGPJ/ZE\3E3P(O/@J+]G--1&3@CP(>JLBM5?P<=5[-$]>NFB%D9&,U8U6
M6?W2K^]*B\4UY\^/'BI;7)JPFK%ZRUZH[\/8O9YBZMU<U0Z4/A31&KSUUT]&
MO'0L\3'1*TD2QJU=%5/)#"T\&4,YMDR)X=$T\WW\>)K7A;5N+:9D[T3EST37
MGRU4U;PNK+<*VS?HZ+]*?8:UX75X,\H)U\.FO=V<36M':MJGXJA>'XE^DKF&
M>J2CFU3BOM,)A,2U+,OJ[^0T2INF1.:I]?TDZ(4W5#4[4T\O6-#526L3DBIY
M>D>%&K0L_B[=?+TDZ&O:U-?VZC3N/8N6O3EJG+Z3'FE]1_'F.'9S.'8N$<O#
MCP'#Y4Z*SN*>EOU</L,8YBS>FO'V^@RCAP$15,3CP\N)G5A+'ZF/5'+^7[BV
M)8L4KHOTN/F\N)=65<][#ZZ)./L\N)?654L0K8N>B\=>Q"^LJY[F(UL:IJO'
MZN/DA?66$L4K->/!?+EVEU5<L4K'+^+@OT^WGV%U5<L5K'IQ]?;^4NJKEB=:
M[5?;Y^?K\Q=57+'JAW/R\N9;#"4),[1?+R["R&*Q?)SXF40A:^]T<BZ_E)T^
M=&J7H:KPO3C[5X</M,+0RB=&Y=AKM/!QY:<M45?9KJ:F6JZLMZ\=KE\4:^+7
M5$1?TDU]?+0T,M6U26^&/UFJL7AQT5..G#7AKVZZ''9:MJDM[;+5_@8B\51$
M_=:\%7MT5.W4T,E6S26>052.:CD7GV:^?N-::K=2>9$XJO#ZQ$)F4#5UB-14
M1=%_/Z5+*U83+%Z^NX.77V(7UJKM+";A<?#XN?:JJOWZE]:JILP:XW)5;KJJ
MZZZ^;3AZ>)LUJKFS Z^M1->*=WEP-BM5,RPZOK$T5==?7Q]1?6JN98=5U6JJ
MNO:;$0KF6-U<Z+K]O'O+:PPECU3,G'B61#"6/U$B<>);$,)E#2N155>\SAC^
M-8R>%?SJ9PQ6;_"FO!-/;]9/XSV*!DQ5&=I$\T]BY9R,9YI7+.1$I[5PUW%/
M+CV$<S31=L?V_1^4Q_&G56;+HB]WER\Y&B=6E]1SX^7TDZ$RMW5/;K]/$G1$
MRL7U*ZKY<C**HU6KZA5YJ9:(U6ZS+K^4:#2LCE[?+UDZ(:?&[S+Z?R(-!];(
MY._Z/L&@JMF7M(T-5=M3I^Z\OH(T3JN&5;DY+V=^G<1-4Q/<^NJWNYJGM(\*
M)DCJ5\:<>_ZE]!.B=22H7O$03*V][YU,M)1JM9'JY>9,(;K;!-<[?79=&M5R
MINQMV[1J*J^%F76ASG:)V-:BJJ]B(:?4?\WY_P"9O^]E?M?Z3C_G*_CAZ;3R
MEW(                                              &+9MA]GS[$[
M]A]_A2:UW^WS4-1HB+) ]R(^EK:=5X-JJ"J8R:)W9)&BG4O/?DSHOJ'Y0ZAY
M+\PT\?2>H[:V*_?29XTRT[LF+)%<N.>R]*RY;H76=[Y>ZOM^L]/MX=WM\D6C
MNF.5JS^UO69K:.V)EY_;YC]RPW*+[BEX;X+ECMWKK16:)^!\U#4/@6:)45?%
M!4-:CXW(JHYCD5%5%/YP_-/EKJ?DKS5U'RAUF/#U3IN\R[?)IRFV*\U\5>^M
MXB+4GC$UM$QK$OT2Z;U';=:Z5M^K[*==MN<-,E>^(M$3I/MC728[)B83=NEU
M\*</9Z#5P68YJLPHW\DU[OR^LY3%9QN2.UE-([@GEY<SD<4\&E>$[3K^CY=Q
MNT:ETS$OX39A1*Y8O)>Y?M+H53S4YDY^;[%,+0RKR1DK==?-J:UH7UG@AJF/
MGZ^TU,D<&Q24#4Q\^',T<D-NDH.>+35=%_/[32R4;-+(2H8J:\%-/)66U64)
M4,Y^7V&EDAM4E%RKHB^7,UK>U?')8R.T]7UE%I6QR?(ZE6\%71?O%<FA--4M
M2UBM5/Q</+N-K'FT]S7R8]644E?HC?Q>7/[#DL6XT[6CDQ,OH:]'(WBB+PU^
M]#EL&?5Q^7%HRJEK$7PHJ\%Y^7F.4Q9NQH9,:<CDY*BHJ*;E;-6U=$C&_P 2
M(GL]?87UG55RGV-9DR   !Y?D"'S4&L/BKH.2->YH]YZ3&;0:2T.E1/+4B;I
M\/>I>_\ +5#'QI\$/J3IKH(R'@54F;Y>2&?CCM1X9CDJHY%[3+6#7O:D[N_Z
MP>T"0#22KE\ J,YJGF J@      TNY+Y=H3'-3(9@  !6)5@      -+N2^7
M:$QS4R&8 3FGI")Y*Q+    -#N2"4U:"&8   5$Y(2KGFU    "DO-?2I#..
M3X$@  GU<?9Q")Y-!+!2D37AYBNW<SJLW-]I5,,XG3FH.:B^GS%<PL6RQJO)
M/7W?05S75G%I@2GU[/M$8^\FVBK\+KP7Z#+X3'XBHVG:G9Y?291CAC-U=(.'
M+GY=IG%&/B:DA\WU$^ FTOBPKW?4H\!XI4)8N&FAA:K*MOG1DT2<>">SF:]J
MKZV1%0Q$1=$\YJY*MBDL=JF\^7E^4T,D-NDL<J6Z*IHY(;E)0=0J)KY>7,T[
MMJB"J7<5-+)+;I".<O'T&O*Z.2V>Y-54KF>QE$:J/B7O,=6>D/J.[QJCPM:*
MB\E)B>YCHUH]4\_I)X=HJ(Y%^[[B>,>X5$=WDQ[&,PY4=&S7.W[QE6M<Y&6O
M)G/5$548U;#7,1SE3@UJO>B:KVJB=I]=_<<K:_WB^E6K$S%=IOIGV1]DRQK/
M=&LQ&O?,1VO)/6R8CT]W43SG+@_XVKN?/W4?$(
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M>W35RQ.%>D@
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ML_//#\&CE.<0W0
M  '07\P&F9!U)7^5KG.6MQO$ZF1'::,>RTQT:-9HB+X5CI&KQU755/1/+MM>
MEUCNM:/PZ_LNJ=6C3>3[:Q^)PI.<<:(FI*8C4T4:2:2 "$ 'U.9,)CFO8>:>
MA!V+$]2*FK?2G9YT*Y90R^B:BZ*FGT_<:]EL,NHXN"<%Y_<4VE9#*J.GX)P*
M;2SB&24L"KHB(4S+.(9)34VFG#N["J961"?IZ;Q)IX>SNX%<RRB$G#1ZN3AR
M\O6839E$)!:+_D]W8O<8^).C4E!JW]%._EIYAXC1I2@U7]'AYAXC3N?/@>.F
MG;VH/$:=\+A+?II^'L]1'C3I"O';]>'A\OH(FQX4K!;=-/P]W8G<83=EX5^V
MUZN1/#JBZ>;5.TQ\;+PI-MIU:GX>2_68>-EX4A%:$1/#X43AQT^G34QFZ?"U
MMLNB+JWBOH7ZN1'Q#P+&HL.KE=X-$Y]O%>WLY*OH,HR(FC%;E8M%54CYIV=N
MGF]A=3(KM1@=PLGA\2I&J+_ZSP[>XV:Y%4U8E/;48KD5%U1>[314X<RZ+JYJ
MLVTZMYIJB>GL,IE&B:I%1OA373EJ5V[V42S:VS-;X>/8GI->\+:RSRWUB)X=
M%]?+[C7M5;$LWM]<O!/$FBI^7D:]JK:RR".O1-.*>W\ZE4U9Q*^BN/%/Q:)I
M]?+Z3&:\$Q+4^X<TUX]Z:?>/":K5U:JKQ<GGXHB_09>'N1JIK7)HFKTT\RZ^
MCL$5-6AMP:NNG9Y<O43X35J9<-7<]$X\.?+MX$>$U^9=1UBJJ+JOM\_JXD>%
M.J0CGU7G])AHE=M>FJ*BH0GBOF.U1#">>J=5VBZM\NW@OTH0R4'-TX$SWHY\
M$;4LYF<2QE"S1ZHJ:<T7R]2ED2QEBU;#KXM=$Y]GL["VLJYAB=93-X^LOK*N
M88K64R<=$[^XNK+"88E7TJJU^B<=%^CCRYE]95S#"JVF=QX+W<NPOK*J88E6
MTR\=47R]1?65<PQ&MIEX\^U>W[$+JRKF&(UM+^EPY:]_MX\.)?65<PQFHIUX
MZ(I;$L)A!STSN/9["V)83")?"[SF<3VL5LZ!W-=?+ZB8DT7%,UR*G/5%[/IY
MD20SVRR(CV(NOIU7FNFO+7N-;)&JVO-O9C\R-1KM5X:?NO/V\-3C\L-JDMY;
M!6:*SCW<W.^XT<E6S26\-GN2->Q%=HG!O#CYN:K_ '7$T;TUAL5EN+27)J-1
MNO8JIQY\O.:MJROB6N:XHK%771./L[/K(BG$F6,5ES1NNB\>>J_=Q+JT5S9A
MU;=O%X_Q<N*:\>'KX]A?6BN;,$N=S1=4\7'N1$3Z4-FE%4V8;67'@[\2\/7K
M]7<7UHKF88;75JN555WJ\N)?6JJ98I5UFNOXN":IZ?KU+JU5S+&*NK1=41>_
MZO7J75JPF6.U%3ST7R^\MB&$RA9Y?.9Q#"4-,_77C^3O+(8H][C-'XY6;W?2
M3'X$+1Z\=#*.]#02A59R([4]BLQ2)3SA<M5$0C0]S6COQ>I".PU[U7WGF(3J
M^>\4&L-$DNC5X]WUH3$"R?,J\UT)TCL1JME>J^7$RT[T:M/%?+B2&F@ (
M !]153DH#Q.[U ^I(K>.O+[>!&D):%FU7751H"2:\$U4:0/I*'*#HSQS^$W4
MGME3/;(M/:[E<<CJ)(V>-(/X/66XW:C=)^)GACENE+!$J]BR)P7D<3US+\+I
M>6>V8BO[J8B?P:MWIU/'O*1V1.OS1K^-Z)SS)VT
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M7_\ %O\ ZX? _P!_CZOE/_\ >G_]N=UI]!/SM
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M41BZIZ?;ZN0%TR/EW_0@%TB<D0"NU-$1.W[0*Z.XJB+R3GW]X%1':)P[^'H
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MNX])C7H^VMQ_;XJW^:?%K'LT<N3AWI@
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MA6(TCW0E#!D
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MO\EO;#L./TL?-X
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MO7_+O2=9\6#9[K-IV1&?+BI$_+]GGYH=T)[J^!@
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M7Z5 D8IT7EP7GIJG'T+V@2$<FJ(NO%?I NF2Z\%]GF_(!H<YO%%X\=.'F I
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MOWQ\H](OT#RITSH.33XFRZ?MMO.G+7#AICG3A'#6O#A'N;J&F["
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M1^6=9^5VW98/L^WK2?KSQGWS^3E\C?\ .-;0
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MB:BJ%70W*WEJVHDXY55-/8;-;:J9KQ5VNX\2R)83'<UF43JQ:PSCD!(
M'Q>*:]WU?D)83':TD60I+S7TF$K(Y*;W:)S,-=>/8RB%D^;12JU^+.*]_-26
M=/5YU4P\;+PJ/Q::Z</3JOWF'Q8U9?#:DJF]Z>HGXD(\"HVJ:O[I/;Q,HRQ/
M")1X./)<-G3^ZUX=_P!Y9&2&$U56RJO;]1G%F,QHN$?KR4S\3'PQS5$=KS,H
MF>;"8??$A.LFDJT?)5\O+B90A4   /@%(A8   &IJ=I,,;*@8M*JB<P-/O.]
M -2.:O;[> 'QW(2FK00S   #X[L3S?7^0EA/-I" 3[1I5[4,?%$)BLRH/J$;
MR,+9.YG%%C+6(WBYVB>=5^KCP*+9=.:VN/7DC9+E&W5?%SUYZ)[-.)KVW%5U
M<-I1LMU3CHJ(GF547U+P4U[;KYEU=OW\T>MRU77Q?2:\[G7M7_!:?UCJOZ7E
MWF/VCCH?!5DK]$XN^E/+4R^/HQG$TK7]RJ/M!&+O:5KUYJ[1$\_T#XZ?A0L9
MKAKKQ1?SE5\ZVN%$3UK5[O/IQ]AK7S1+8KCE"5-2BZZ.1/3ZC4R9(ELTI,<T
M#4RZZKXM?0O,T\EFW2K'ZF;L-+);L;5*HN23GY>I#6M9?6.U8R/7CY>HIM*V
MM=5#Q*5ZK?##ZCD]!.J/#+43JAJ1RDZPQTAK1=1QAC,:-:.5">$\^:%9FKU1
MK45SG*B(U$57*JKHB(B<555,JQ:UHI$3-IG2-.,S/Y29B(UGA$._W8K 5VTV
MIPW$YH_=W*FM;*^]HJ-1Z7R[O=<[K"]S57WB4555.IV.[8XF\$Y)_1?]W[T[
MGTM](.B>3\]?#U3%M(R[KEK]JW$SGW%9F/K?"R9)PUMVTQUX1RC\\?/WF'_2
MCS=O>KTG7:VRS3%W?"Q_0QS[/%6L7F/TK2W;/973@
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MUOULW>TQV\6/IFRVVTB>S6*3N+Q_:WW%JS[8F.QV%GISY<
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M,CCC8B(B(B(B)HAZ!RX1R?MY2E<=8I2(BD1I$1PB(CE$1V1"H&0
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M[3-EBW&LX=OKGRUMPF/IX\=J1$\)M:([7O9/B)^V8
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MV>WU>58[JQRCW]L^V9=LVV"NWPQCCGV^V>W_ '/8W;-->
M                                   =<7S)L#J;[MAB.>4D<LRX#D-3
M1W%&>+W=-9LQ904<E;-I^%$9>K500-U[:CV]G\K[B,>ZOMY_X2NL>^NLZ?-,
MS\CA^LXIM@KEC\R>/NG_ '8ATI'>76@#69LP   T+P,98SP:V+HHA-93U!)J
MJ(JZ<>_[#"T+(9M;W:::*B^7J->RZ)9Y;7*OA]7+5/M->ZRK/;<OZ/!5]6OV
MFM9;5N!0(U=%3S<T7[C5LNKHS2@C1?#HG9Y_+0HLMJS.AB_1_#Y>Q>!1:5L0
MR>FI]=.!3,LXA/14VK4X?1^<JF640O(Z77CI^7Z2-66BK\+QTT\O:1J>%K^%
MY</+V#4T7+*3ARXKYD(FR=%U'2ZJG QF4Z+]E.UO9ZC'5.B[9$G<8S*5=L:)
MSX?61JE5T3N0C605R)]W:-!I5Z$Z!XT(T%O4PMD8JIIKIQ33Z==4,HF8)AA5
MSH4<UZ(U5737L1=>:=FA?2RJT-K+Q;_TE\/%->W5>/H-REE%H;:W&F5KW</O
M-NLJ+0Q:HUC<J>7<71QA7/!8?$^#FO+R3M,M$:OK*Y._3V)HGW#PGB5TN353
M3QKHG9JGMY$>&>X\32MR;_=+[2?!KS3K[5+];-153Q<O/KS]/+SCP=W)'B:'
M7G143Q\^&FO<G:3%#Q'ZXTT_$G-.2]RZ_8/ >)(PW3QJB^+AV(BZ^OAP[3":
M)BR>I;FCD15<FB<$X_7HJ]I7-&<69-0W'77BG!>_Z>PJM1G$LNH*Y55./#3M
MXZ)SYZ]NA1:JR)XLVMU5^)KM41-4[>.G;VZ<37O"VLLTII.*<>WTFO,+8XL@
MC=JB*5>QE')=+Q3TII[/R$)[%H]/N,HYZ"S>W75/+RU,H1^-1='JBHGTDH1T
MU.JZ_4B:F42QT1-12\%X&<61H@ZBEUU_#KZM?L+(LPF$'54&J<6IP^WV=I9%
MF,QWH&HMS>*^'[NTMB[":H.JMK7(J(G'FGJ]'F+(LPFK':FSZZ\$1._C]7#R
M4LK=AX4%4V1JH[\*\4T[=-?0JEM<C&:L>EL2N<OX%T1=%X:<>[M+(R:,/"LY
M;&G]QP]'#3V<C*,B/ AW6)?'X/!V\].SOX<.1G\31CX&O]2(B:(SZ/NX<1\3
M7F>!JI[/[M^G@X)Q35NJ:+RU$WU(KV)3]6\.#?.GI,/&R\.G!?04RMTX:<$^
MTQF4PD&*K/J,4\FF2J5O;IZ/S:B*FJ+GN'!?Q=_-5]>OK,XJB98E<+MHYZ>/
M7NXHNJ<NSD75HKM9@]PNRJKN/+737V<]?8;%:*ILQ2JN;E_#XM./>O+[>9?%
M%<V0,]?S_%]/Y2R*L9E&S5O#GSX\^/WF<58ZK%U7KJNOTF7A1JMEJ/$Y./#5
M.W["=$/CY?.-!;/E\Y.B/<IH[5===?S#V'O?%=VJ3PCA'-'/W*3G:IP$1QXG
M)37R^\R0^@?473B1*8:VNU,9C1/#L:E<B$ZS/)&BGXEXZ=JDZ#3Q5>''S_=W
MD\CFUHSO(UUY"LC>Q$]0X)TE(QP^%K47L3CV\>:_283.J='U6+V(0<X]J@]A
MES%LYNA,3V2C\:EIV]NA'L0HJ9D\VE7(WF$/J*B\E ^@ /BKHBJ!H8U575>:
M\OO O(H5<J<-3&93HR"AH5>J?@[EU[=?1P*K6T9Q#G[T1['R9IN#3Y]=Z1W\
M%MO:N"Y0/>DK&7'+XO!46.DADBF@D_\ 9/+X;A*J*]J.BACD8K)U.N=>W\8-
MM.WI/\-EC3W5[9^7E\LS')RO3=M\3+\6WU*?C[/FY_\ M=T1T9V$
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M&+WK,?5EW7'[J/AT
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MR]0U^V[_ 'F7<7XZZ3EO:_AB=(X5U\->$1%8B(B(X,R-]P0
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MJ7[I?E&_7/4>WF+-69V/1]M;)KP\/Q\\6PXJSK^TG/DKIRMBB7L9.V/TW
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MXR1K'&/%7%CK:L_6KFK/)Z0SP=]\
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MGMCL_A?PV3Z_9'='Y?Q1^#G>=><F
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MNZS3GS3K>?FCV1[(=EQ8J8:1CI]6&8%"P
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MGGS=N_.OF'-UG<:UV_U,..?^#Q5F?#7]:=9M>>V]K:<-(C=H]B=/
M                                        M*^AI+G0UMMKX6U-#<*2
MHH:VG>KFMGI*N%]/40N<QS7HV6&16JJ*BZ+P4JS8<6XPWV^:/%AR5FMH[ZVC
M28^6)7[7<Y]EN<>\VMIIN<62MZ6C36MJS%JSQUCA,1/'@\;648S<L'S#*,+O
M"Q)>,0R2^8O=?AWK)!^LL?N=5::[W,BM:KX?BJ-_A54153L0^#>H[+)T[J&?
MI^:)C)ARWI.NFNM;37CIP[.SAW<'[^^7NM[?S/Y:V'F/:Z3MM_LL.XKIRB,V
M.N2(X\>'BTX\8TTGBUT;^'/N7GR]2G'RG<5XLIHY>")P^ORY$3#K^[Q\=60T
MST14UTT,>S1PN:LS"?IGM3FIBXC-692\3]%YD./O76$DU_!%]1&FK2FO'1<Q
MR:>CR]A#7R4UCVKI%1?+ZPU-)@ ^*FJ!,3HI\^?,CDNK93<TGFMB5-45.9&C
M/5H5FI,2RBVBDZ/S$\%D74EC\ORDZ+(NI+&G<1Q9Q=36/S>SRU#/QM*L\EYD
M\$Q9\\*C2$^*'Q6Z=A&G<G5I5$4<83$M*IH3$IB=5M)P52875MP6$O/U_:3V
MKJ+.5=$T,H;%(1SW+JO<&Y6JBKT0+8J^>/BG+VCB>%=Q3JB\PHR8HF$M#-RX
M\/+Z")AQ^3$E(9==./G,=&ADQZ)!D@:EJ+MCT4CGR:]JS"NFG88JP(:5:A.K
M+66E8T7R\D)U[V476DD6BJ&QCR?,M7-\N]!R]S<K*SFCU15\O02V<=])1$\>
MJ+YC*)<ABNB9&:*J?1Y@Y"ED;-%])ESANXKHF>+G]9E$]DM_%D1<C-5&OA;U
M++.6,SYMFEUD]GFXH1R;-;?,(WO]@)LJ(BJ&,S$*K6#357:RYC9YA,Z*+V72
M)IP0KYRIF5>-GF,^2F]E[''RX&,SHUKW736&.DSS46LNV1D^[DU[7736:<C'
M51:RNUG=[0JM9<)%R"F<BLV'7LY#W*[9%=(D0:JIO+6D?<GEZ!JHM;VJB1+]
M0U5S>&ET:]PU91=;/B147@3$KJY$?)'H&W2^JRE;V]W!?03'<VJ61LG#43S]
MC=IQ6$OE["R&W10\1.BSPOJ.]0T)JJ([SZD,)JK,4BT*K0OHUY&,<FM>$A'R
M(GFT[\TC G%?4.QIY>23C3BGH,9:-YX)2)$T(EHWF=5XQOW$:\&M:5RQOY0I
MM9<M8)G13:RLB=QCS5S/>U>%1HQU@\*C0UAJ\*$\$>*6I&^;0B98S*HUO=[2
M.,L)LJHU$\X83.KXKD3S@BLRIN=Y?8B$>]L5II[UM),C4XKIYB6Q3'-IX(V2
MI5=>.GV$MRF&(63ZAJ+HKN/E]A+:KAG36(X*7Q+/[KZ_NT&C/X%NY\2I8J\U
M3TZA,X+1"NV5%Y.10JFDQSA4][Y_I3R4,/ ^^]7L7Z4^HCYCX</BRZ)Q52="
M,?<M)*E$[?RC1L4PS*.FJ>"JJ_;[3+1N8\'9"#J:G775?0G ERF#!V1S8_55
M2Z+RU[/RD\/D<UMMMQXL3KZQ>*)Q5?4B^?APT0SB'8MKMH[79;\KW8-^=[F7
M'>[(*-TF,[7RNH<<2HIXIJ.ZY]<J!R(Y/B()HI%Q.SUB5:^'W<T-9544S')X
M%1?:?1KR[?>]8OU_/3_D>TK-:3,3I.:\:<.&D^"DS-N.M9MCG3C$Q\=??3]2
ML70?)^#TWZ;DC^MNK6KEW$5F/%39XKZUBVD^*OQ\]8BL\K4PYJSPGCZ"#Z=?
MER                                                  =27SLMLV
M9_T'9C?V-G?7[29M@>X]##3L:]]0U]V=@%T9-^\R/2DI;+G=35R>%T>GPJ.5
MVC5:[C>K8+9]C>*5\5Z_2]T5XVF/=77Y->W1\X?>JZ#_ %SZ1[C>5U^+TW=X
M-S$1'&8FT[>\<N44W%KSR^IKV/%M2O5-/-P]7'Z>!T=^63)Z.3E^3U</,@&4
MTTNJ-X]B:Z>K4"?IY$X<4\N?'7S@3L$B:(FOYN"=_,"5B?RX_3](%VU^B^;L
M\W=Z= +Z.7L7R_)J!7X+Q0 !3>WM3U@4P*;F=J<^X"DYNO!>?U 4U9W<0*:L
M3M31?+B!35B]G$"FK$[6Z?1]0&GP-\Z>@"DL?>BKW<57[5 T^!$YI]8&AS=.
M.O#S\P*+FIQ5/8GW 6DJ:IV\OJXH!&/X([V?8!83+]B?6H$;,O'S?=^<"/DF
MTU3RU^U0+;WZ<O$OEY]> &ME1HNFNOF5>'9Z0)6GJ.7/FFGF[=/0H$[!4=R^
ME.[Z%X 3E--XDT1?.G'7U>M% DF2]B_7]0%TQ6\-4]"@5DX]NGG UK'JFG/T
M_8!2=%IW_6GW@4GQ\..BIW^7>!9R1<T[D33O7\H$?*S5%[T\D4",F9S^[S?:
M@$/41\UU\M/R 0U0S37AKY^ST@0T\?-?/Y=WJ @ZEG/@OL33S^P"&D3BO#L[
MT15]7/4"QD3N[^[@GMXH!:ZZ.7EZ]5]F@%9CN[VZ?5R[@+EJ]FO!>[3CZU N
M6*NJ<^'8B\/9V@7<?'3@G-.SGIW\ +YC=5[/,G=W>;L O(TY?4GVKR](%XQN
MOG7L\WY0+AD2KYD\N:\P+MD2<.Y/I]0%TR+M]GEYP+ID6G?KZOK]0%9(4[>'
MK50*C8%]'U_3Q K-A3LXKP[.T"JD/>OEY><"I[A./!?9R HN@YZ<4[O+B!8R
MPZ:KIZOK]@$7-%IKW+PX]X$/41Z>).]/S=X$/+P:J>GZ$4"P>[PZ<N/>!I23
MT+Z.\#4CT7GP7Z -8%U$[7R[>\"4@75$X^GV?>!+PKP;Z4^P";IT3PHNG'1/
MM F(&IP33U>?70"9A:GX4]"_4@$BQJ+Z$ NV-1$1=/R>@"NQFNFO;R_+P ND
M:B)IHB^H#[HB<DT ^@?415Y :T9W\5[D\M0*[6=_!.[RY 5.#4[D\O:H%-7]
MB>T"BYZ-_+P]'I L)JA&ZIKQX]VOL7L CY*G375=$\Z_3Y: 6BU2<5UY^?[^
MT#1\4U/[KVZ_4!J;4(NO%?4O;Y^*@5VS)SU1?7HOW :_?\>?_N2?5R ^^_\
M.GM1/L IR5/G\O+T@6$E3IKQ\OM^D"-GJM$5-?3]7G[P(&IJN?'ZO.!C=;5Z
M(O%.U=>"::*J]X&(U=0^5W@9XG.<J-:UOB<YSE71&M:G%7*[AHG,F(F9TCC,
MIY\(YO=1\LCI(3I%Z7L8QF_4*TVZ.?OAW#W46>*G2LM^1WF@I646(.E@=.JT
M^%VB**C<U)I875_Q<\:M;4*U.^=.P3M=G3#/"W&T\_K3SGWZ1$<-.$0_7'T$
M].9]./3_ &^RWE/#U_>S&YW>L1XJY+UCPX9[=,-(K28UF/B?$M7A=V&FZ]J
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MO-LF28B-;VM.G%NB:CL(
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MVJUX*9E#23JJ\]?+Z"S1AJMU>Y?O3\JDZ#22@('Q4]/M5/J4D-/3[5 ^A($
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M^5SC. <D
M #J3^8EL)(RHI=]\9H%=#*RCLVXD=.QR^ZFC]U16')IDU=HR:/W=OJ')X6M<
MRFX*KY''<?+74(TGI^6>/&:?CFO[,?*X#J^TX_:J1[+?L3^Q\SJA.WN!"0(
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MKQY:(:MH75EFE&_5NFO<466Q*:B7@J:\T\O8I7+*&I6HO,C4:59W*3K!Q:?
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MB3U9]3LOG+>_U3TFTU\M8+\.<3N+Q_PEHG32D?\ !TF->=[?2F*TYA'V@\8
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M8J\ )^CGXHG+5>_DH$Y$_P 7!5_)Y(!(Q.U31?+O KM=IPYI]0%VQ=4T[OJ
MU*FJ:>6H%#37AS\N\"VD;V=J<4\Z 6$C..J)Y=P$=/'PUY=B_8!$31ZZ^O\
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MT]7Y0/O@3M5?J^\#4C43LU]/$"HC%7S)Y=@%1&HGG7O ^JY$^X"BKE7FO#Z
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M&+?_ %1NZ:6II';CV\Z9+S/T;9/!CTO7XL5]?1VE^E0
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M2L^=-_CB,D<)^S89TM&WB8X3>;1%L]H^CXJUI76,?COVWGG+Z:
M                                              <!NMCI=?NY8F;A
M8-;DDW(QFB=%5T%,W2;,L?@\4B6]L>J-EOEJU>^C5$]Y/&YT"^-?ATC[%T+J
MWV/)]FW$_P#);SPG]&>_W3V]W/OUXKJ6Q^T5^-BC^&K'SQ^6.SYNYT8/8^-[
MHY&N8]CG,>Q[5:]CVJK7-<UR(K7-5-%1>**=^=7:20(     58GJQR*A/8SK
M++;;5?HIP^M?I52F]5L-Q;/4<$37DJ*FJZ<%[D\RFM>%U9;E6RH5?#^)>SDJ
M?D-2\+JRW(M51KX>/=S3[N)J7A?66X=MG_1Y+R[S6O"ZLL\MU1KX>*)R\YK7
MA;66:TLOZ/J[>\U[0MAD=+*J::</+7L*IAG">@E1>?<5S#*%UXD[S'24GB;W
MDZ2-*O[OI&D"BY_'O4GG[CW*3GC2(]Z%!S]2=.]'XUM),C=>2^LRT1JC*BJT
M1>/E]1E$(F4//6?A7CS+(JQF47-7+HG'[_:9Q5CK\ZV6X<OQ<O+T$^%$2OH+
MG^)J>+LT\_'0QFC*)2SZQLK$5RIQ;IJG?YS#PZ2G75C]P3Q,=HNO/314]':6
MU8RVQN[4U?P3MYZ?8;>-19M;>6IH_@G;V:IQ]1N8YT46;5W1NCWZ(G'M1>'=
MR73N-RC7LPFN<Y->7;W?>;%54L2JYW-=V<?/H75A7,H2:I>NO'R[N19$0QF4
M7)5/1>?K^OM0SB(1J,J%[^/I\E&B-4S25.FG%/+VE=H9Q++[;5+^%-=>7)-5
M*+PSK+<.UU#E5NJ+V<E-:\+ZRW&MD_%O'1>&G9Z^WD:MX75;D6N=?P_B[N6A
MJ7A=5N-;*C]'15[.:Z>KSFK>%U9^9N!05'!O9P3M_)VFM:%T,LI9]6IQ\O;S
M*9A9$I6.;5/J*YAEJK(]/+\G$C0:O$WO\O0-)'WV>7T:!+0K->/)/03JA36%
M/,-3136'S?1]Q.J-&CW*:\4X>78!I=3-7EP]).LFGS*+J1%[/7R'B-%%U$G]
MS]*_D)\2-%!:%./X?M^CD3XD:+9]!HO)?+@9>(\*FMO<O#P*GG5%'CA&G<^?
MJQW;]>GV#QF@MM3_ )2^7H'B3X=5-ULX+HWCIVZKY*3%T>!8SVI/!KX$5>?+
MBFOJU,HNQFK#KQ;_  )P335%X:(O%-.U.':7X[*[1HVKO5+X6OX<]>"Z)P^A
M3<QRHM&C9N]QHU)%TTY\_$OT&_CXM:[87)$1'O7Q(O!>'A5.2KYU7B<CBY-2
M[:NL?^)=%7FOLY&Y')1,Z+!.*F6NLL-=9:B63ZC54B9%PUGFT(]_-+2L?%>"
M\U]8UE#ZC/\ D_0.'>-7@73L] U@?%B\R#6!\]UYOI&OM'SW7F^D:^T?%B\R
MC7VC[[KAR7[1K[1J2+S)Z^(U&M(_3[-!JGWJ[8^S3U)Q(]XNHZ5SM%TT^O3Z
MC&93IJE8*/3CIR^[F839E$).GHW/<C6M5554Y=GG7GWF$VT9:.3>T_3)NANI
M%%56"SLM-@D<B293D3IK?:'M\2M?^KD2":LO#FJQS56FBDB:]/"][#BMYU7:
M;.=,MM<GZ->,_+V1\K<P;+-GXTC2O?/+_=<X<2^7IMU11Q39QEF2Y36HW62F
MM24F.6CQ.35S%C]W<[G-[M>#7I4Q>+FK$UT3@,WF7<VG3;TK2OM^E/[$?@ER
M5.E88XY+3:?9PC]F6[+.B/IE;&UDFW,E0YK='32YEGC9)/\ E/2#)X(D7_UE
MK4\QI_U]U7LRZ?VM/[U?_5NS_0_#;\K"<E^7ST_7N.5+3!EN(S.1RQ/LV12U
M\4;U<YS$?%DD%\DEB:CD:J)(URM3])':N+\7F3J6.?I^"\>VNG[W17?I6UM]
M7Q5GV3^75P\W*^7%N18(9Z[;C);3GM+&BO2TU\;,8R!4T<ONJ;XFJJK)6*U$
MT5SZJE5RKP8<WM?,^URSX=U6<<]\?2K^6/FEQ^;I&:G'#:+1W<I_)^&' #)\
M1RG"KM-8LOQZ\XU>(-%DMU[M]5;JKP.XLFCBJ8XUFIY6JBLD9XF/:J*U5144
M[)BSX<]/B8;5O3OB=7%7QWQV\.2)BWM0+8U4LU8KAD*KP1%7R[S&92OHJ!\B
M\O+GW<2)MHF(2<5J>[1$9JJKIW^OMT1#";Q#**LCH,5GG5JJS1%5-53L]2+K
MV%5LT0RKCEN;8-M*ZYS0P4M-+(^1R-31LG!?Q:JY=?"U$\/:J:(:F3=UI&MI
M7TPS;A#FKM;TE7*ZLI:ZX4;(:5Z(KJBY1*V!S'\'/@:YKUJ? J+HK?$U>7#3
M5. W?6:UF:UGC[')X=A,\9Y.P7 MI,3P%D,]!1QU=XC8^/\ 6\\+62Q,D8D;
MXZ*!'/CHXU9JGB173*U[FK(K5\*==W&\S;B=+3I3N_+W_B<GBP4Q<OK=[= U
M%P                                                      $;>;
M/:\AM-RL5[H:>YV>\4-5;;I;JN-)::MH:V%]/54T[%_2CFAD5J\EX\.)E2]\
M=XR8YF+UG6)CLF&-JUO6:VC6LQI+SR]473G>=@<VE@@BJJW +_45%1AM]E_?
M5]PB^\DL5TF8QC&7FUL>B*JM:E3%I*Q$U>R/TGI/4Z=1P:SI&YK'TH_9CV3^
M#E[^I;[9VVF72..*>4_L3[8<83E6B$@0   2! DZ*=6/3U=_V"T<%M99Y;:C
MBQ>[PKSX=_IT-:]5U9;F6N=-&*B\T14TUY&K>%U9;CVJ?]'GV=Z&I>%U6X]L
MG7\/%>SN-6ZZ)9_;Y]/#JNGK-:T+JRSNW3HJ)^)%UTYFM:%L2RFEEY<O+UE,
MPLAD5--RXKZ.)5,,X3#'HJ)V</5YS"89-7B3O(TDU?/&A.G>-#I//H.'8**O
M\E)T[Q1<_P _$GW(6[GZ<54G1&O<LY:C371=/7Q,HA"(GJ]'+Q3U*9Q5CJB)
MJU4<OXONY?0A9%6.J/6OT<J^+377O^SD9>%CJ17+PK^E]/;K^435.J9I+CXD
MT5R<E3GWJBIS*[5919\J96R(NB^KRYB(T)XL(O#>#E_#R7DG'CZN9L4U56;6
M7=NGCUX<U[4-S&U[-J[RS]/GVZ=O/7FAN4E19MO7*J:_B^C\IMU4RP^ND<GB
MX]_H+ZQJJEC$]2Y-414]/'4MB/G83*)FJ'KKQ^G7RT,XB&.JR^)<JZ*[ER[#
M+1&LKN"I_$GXE\VO>1,)AD=%5<6\53R\Y5:K.)9W;:G7P\>[BO/Z36O"ZLMQ
M;5-^BNJ?1K]IJWA;66X]KG1?"OH_/R-6\+JMR+7,B(FOF7BNGTZ&I>%]9;AV
MRH35NCD3S>7 UKPNB6<451IX4\2>7H[#7M"V)9%%-RX^7YBJ89ZKY)47S^A?
ML,=(2U(YOEY:$:#[JB]J#24BHBIV+Z/RA"FL6O;]&A.HIK#YO83JC136'S>U
M!J:/GN$5./WDZR*2TK5\Z>S[=!K,&BBZB1>_Z/N4GQ(T4'4+5[/I7\Y/B-%%
M] BIP;V=G/VD^)&BV6A_Y*J3XD3$=K3^K7KQTT\VGY"?'"-#]6]^OJ7\A'C3
MI+Y^KNY%]?'[!XD^"%"2UZKQ;JFG=PU[N1EXT37L0]9:D1'?A1$X\DTT54U]
MJ:F=;L)JVUNM#^DBHY.?8G/UHAM4LIM#:6_4Z-5VB(O-.*<>'J-W'+7LV5R.
M-$;(FG8NOXD3Z$5.)R&)K7;$7ER^)R\>:HNO-/5Z3DL;4LP][E5RIYU+>2J9
M:4^OB3!#Z2E58SS<3&>/N%58_P /+MY)[1KW"FD?F4?*-:,\R#@E]6/7N4C6
M$-/NO-]).L![KS?2-?:/GNO,-?:/GNO,HU]H^^Z\WTC7VC6D7H]2#5*JV+S>
MTC45V0J[DFOU$:P>Y(0TFJIPUXF,V9:)6.DT1$T3S^2K]AA,_,RT9;CF*W7(
M[C1VJSVRNNUQK9FPT=MMU--5UM7,[54CAIH&/E?^%JJJZ:-:BJNB(49<U<59
MO>8K2.<SRA92DWGPQ&L^QSSV]Z!LSR&&GN&XF04F$T3T:]+';(8KW?UC5%UC
MJ9VU$=HMLJHJ*BM?6*G%',:IU[<^8L&*9KMJSDMWSPC\L_@<GAZ7DMQRS%8[
MHXS^3\;E#8N@[I\M4;&W2TY)E<B(GCEOF3W"E5Z^!S5_#C2X^UK?$[Q(G-%:
MG%4U1>)R>8>I7GZ%JT]U8_WVK=KTS:5CZ43;WS^31+UG0YTRU4#X8MOJF@D>
MFB55)F.;/GCX+Q8VNR&MIE5%X_BC=R,*]?ZK$ZSDB?[6O[%893TW9S'U-/EM
M^5L-F_RUL$N$<T^ 9WD>.5:HKV461T]%D=L5Z(ND,<M)'9+A21.X?C>^J<U=
M5T7@B<CM_-.XKPW&.MJ]]=:S^'6)_ U<O1\5OXJTQ/MXQ^Q^RX!;L=(F]^TK
M:BX7;&OX28[3_B?DN'/GO=MACXK[RNIDIZ>\6R-B:(^2HI8X$<J(DCM4U['L
MNM=/WFE:7\.6?S;<)^3LGY)U<5GV&YP<;1K3OCC_ +OX'&-&JO(Y75IJS8N_
MZOL(F1=,IW/Y(OI(UT3HD8;8Y>*M\N\PF[**I:FL<LSD:V/@OFY^A4Y)P,)R
M1$)BNK-K5A<\RM3W3E5=-&IXU5%77FC473AQ->^XB%M<4M_MO]@[WE-7#%%;
MZR1KU\360Q3RR2,8KE>K6,:KW(SP+XE\*HU.*]QQVYZECPQKK&K<Q;2UY=A&
MVO2=:+*D51D388VHUBNI*7P25=3X4=X??SR,?%3-XIJC4>]4\2(L:KJ=:W76
M,F3AC<IBV5:_6<P;39[78J&&V6:@I;;04[42*FI(6PQHNB-61_A3Q2S2>%%?
M(]7/>O%RJO$X6][Y+>*\S-F_6L5C2L:0DC%(
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M5MK&+7Z>68G6+9IB=)TF-:XXUI2=)UO:(LY5'UN\E
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MXWMQB=SFB.'Q;UX5KK-<5/H5UM;)>_-8] ?/8
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M=9M:9UM:UIFU[3-K3-IF9S(ER@
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MF+CX)M?2\=YAY(^P
M              !UN=7G1;'N ^OW-VEH:>ES=R2562XK%[JFH\P<J^.2Z6US
MWQT]%DNFJS,56Q5_Z6K*A'+4=GZ-UV=OIM=Y,S@_-MVU]D]]>[MCW<N&ZATW
MXNN?;Q_"]L=_MCV_C]_/IAK:*MME956ZXTE5;[A05$U)74-;3RTM91U=-(Z&
MHI:JEG9'/3U$$K%:]CVHYKD5%1%0[Q6U;5BU9B:S&L3'*77)B:SI/"T+8E
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M#2S,5$T="R->'I.+S;S<9_XRTZ=T</[/E;>/!BQ_5CBW(-5<
M                                              ,(W$V[Q/=/$[IA
M>:6N.Z62Z1Z.:NC*NAJV([X6YVRJ\+GT5RHGN\44K?.UR.8YS77[;<YMIFC/
M@G3)'X?9/?$JLV''GQSCR1K6?[-8]KH(ZC.E[-M@+R^:ICGO^!5]5[JPYE34
MSFT[G2(Z2*UWR.-9&6J\M8QVC7.]W4M8KXE71[(_1.F=6P=1II'T=Q$<:_LQ
MWQ^+M]O5-YL<NTMK/'%/*?V)[I_&XQG*M(   &BDFD@&MCE:J+YQ[&59T9;:
MJG]'55[-.*\BJ\+JSHW+M%5^BFO+3AXDUY)IPTU1.)J7CBOK+<RU5"+X>79W
MJ:EX75EN3:YET;W>;7ZN/::MX7UGM9[;IOT>/=S1?N-:\+:L^MLZ)X=5[NS\
MB&M:%M9U9?33<N*=GV><HF%D2GZ:9>''N*IAG$IZ&35J<>7G*YB&>JNKR-.\
M:5?Y]!I IN?Y]2?<>Y25Z]Y.B-86TDR-)@GVHV>IT[?+NYF40QF47-5<%X^7
MH+(AC,H&HJUU5=>W7AKYRR*L9E U5<C$<OB75$54XZ<N/?YBR*L)E U-W1J<
M'Z+V=O;RUT7L+(IJPFRV=>O#I^+3BG'[T1>/ GX9XDW17ECO#^/]+314]O88
M6QLHLGG5R*FNO/BFB]_T%?A9:HJOE;+'KP1=%37SIZ^>AE6-$2VWN[?TM%Y]
MZ:</I-NG>HLVKO#%7Q<4[3<QSWJ+-L;DBM<Y%7VI^4VZ<5%NYA%?^Z-BJJ6'
M53E:Y57M[TT+ZJY0D\NFNJ^7L[2R(8RCED7Q:IR,]&.J[A>J*BZ]J<?,8S"8
M9-0O3\/JX%5F<,YM4OZ*:&M>%L3VMQK;/IX4U[NY-#5M':OJW&M4RZMT5%Y<
M.'V&K>%M9;B6VH_1_1[->/Y35M"^K<*V5'Z/Z/9V\C6O"ZLLXHJGEQ1/7]!K
MVA;$LFAG1=.*>W7Z>XIF&>J2;-JB>7(QT3JJ)*OG]I&B=6MLI&@K)+YU^L:)
M:TF3\VI&@U)*B^7'[!H:M?C;Z/+UD:!XF]XTD?=$7N&LC3X$\XU2>[1>_P O
M4-4:-/ND\WL)U&CW7FU]8U'SW*^?VH3J/ON?/Y>P>(XGN$\WEZB-31I?!JG#
MZU)B4:(:MIM6KHG#1>U?.9UEC,-M;W1HU)'<4U5W<O'FOFT-O':5-XELAD42
M?C3@NJKW>WEPT.0Q-6[8/*&Z>\3GST_$J^Q-3DL+4NV"O:*CWZZI^)>''1>.
MFOG.2Q\FI9ACT_$I<IF.+ZB:KH3R9*OAXHG8GV_F(_')[5S&Q5]9$_@3HNDA
MU1.!&J5=E*O'AV:$:IT54I/-]OJ(\1HT.I$_N?8-3126F5.SVI]I/B1HTK3N
M3]S^0:FDM/N5_N5[^6I.IH^)$JK^BOL_(-33W-7N5Y>%?81J*C:9Z_N>??H/
M$E>142KIJBKZN'H]AC-B(2D5%X4_1XK]7U&$V9:).&C7@GA55X:(B>KLX&,V
M9:-U=K]ILGW3RFBQ;&:/W]5/^_5E7+XFV^T6]CV-J+C<9FM<D5-!XT31$5\C
MU:QB.>Y$73W>\Q;3#.;+.D1R[YGNA?AP7SWBE.?XG=YL[L;A.S-ECHL?HV5=
M\GIV1WG**R&-;K=)/PNEC8]/%\!;4E:BQTT:^!J-:KU>]%>O0M]U#/OLGBR3
MICB>%8Y1^6?:['M]MCV]=*Q]+MGM_P#9[&\QHM@    &Q>XG35LANB^HJLLV
M^LK[O4OJYY<@LT<F/7Z6LK(T8^NK;G9)*&:\5$3FH^-*[XJ)KTXL5'.1>0VW
M5=_M(\.');P1I]&>,:1V1$ZZ?)HULNSVV;CDI'B[XX3\\<_E<1,B^6GA534)
M)B6Y>26*G5?$ZGO]DMN4.37FV*>@J\45C$7EXFO5$YJJ\3FL7FG/$:9L5;3^
MUF:_CBS0OT?',_P=YB/;&OY&V%?\N/<*DJ)DLF<X3<Z9LRMIYKJR^V6HE@1S
MO#+-3TELOT<$RM1%5C99&HJJGC71%7;KYGVUH_A,>2)]FD_CF%$](RQ/T;5F
M/;K'[$M5)\O?=6-[5J<DVY5FJ>+W5UR9RHFJ:JB.Q&-'+IV*J$6\R;.>5,OS
M5_ODQTK/VS3YY_(W>QSH)DIX&R7S.[?3U3951:>VV"HN=,Z%O@5KTJZNYVB1
MDSE\2*WW#D;HB^)=51-++YBUG^#QSI[9T_8G\:^G2](^E:-?9'_L<@L1Z4=L
M\;?'/7_K/(JAK='-JYTH:'Q:?ILI[>D54Q?$NNBU#FKP147CKQN;J^ZR\*Z5
MCYY_#^1MX]CAIQG69<B+59;18Z=*6SVRAME/HQ'1T5-%3^\6-OA:^9T;6OGE
MTYO>KG*JJJJJJ<;>]\DZWF9GVMNM:UC2L1$)0P2
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M^K77Q7GV5B9]CG=M9T!W>L6GNF[=^CL]-K')_!;&9H:VZ2-U=XXKE?7LDMM
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M\KX;S.WV6.T^"O=DS6X?&S3&GTK1X:<8Q4IXK^+F =V>'
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MY_Z;/6OX49OZDMX)B)_I6R\6D_M?M/BB>^--8[8<9-Q^E+JDVAI:RX[E]/\
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MD:5K'.?;-K3,VO>TS:]IFUYFTS,YF2Y0
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MB/DOTIVL7Z3B^T^8;XXKEWF6/X6_;:N.NLUP8YG\RG&8BL9;Y9K%G.XZJ]B
M                                                           !
MQ;W_ .DS;??J-]SK6.Q3.8XFQ4V9V>EADJ*AD;6QQP9!;EDIH;_311,1K%?)
M%4QHU&LF:S5CN6Z=UC==/GP5^GM_T9_8GL_%[&CN]AAW7TI^CE[X_9[_ .SB
MZ6]Y>F/=K9&IGERBP27#&FR>&FS*P-FN..3,>[PQ?%5+8F3V>HD5=$BK(X7.
M<B^#QM3Q+WG8]5V>_B(Q6TR_HSPM_N_)JZWN=EN-M/TXUIWQR_W/E<?3D6H
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M
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M:3]>>?Y/D;]G'-H
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M57/131R9&YCH@IIU55_$:5[Z\6U6O<C99?.46LNK7L[%LJZ\2J9U61&CX0D
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MAICQTK2E([JTK$5K'LB(AT/-GS;G+;/N+VR9K3K-K3-K3/?,SK,S[UR;2H
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MH9.K=;W.?=]3S6\5\N:]LF2T]\VM,S/LXZ1RC@R0V'&@
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M*GL^M +J-R+]7K[@*P'Q51.:@:'/1.6GI7R0"@^5$YKK]7;W(!:R3^7#A]B
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MZ>^G5L>^V>WG>]?II/VK<Z7O6W#CAI$1CPZ6B9K:M9RUB9K.6T.QDV7M@
M                                                 1=\L=FR:RW?
M',CM5OON/W^V5UFOEDNU'!<+5=[1<Z:6BN-LN5#5,EIJRAKJ29\4L4C7,DC<
MK7(J*9X\F3#DKFQ6FN6EHM68G28F)UB8F.,3$\8F.,2U]WM-KO\ :Y-COL=,
MVRS8[4R8[UBU+TO$UM2U9UBU;1,Q,3$Q,3I+R'?,D^5WDO2_=+MO#LG;[IE/
M3M<:IU57VZ-U5=<BV>JJAZN=;KZ]6RU5SP9\KO#;[N]SY*=%2EN"^]2"KK_J
M;TY]3\/6Z4Z/UV]<?6HX4O.E:YX[/97+WUY7YUTF?!'Y>_>"^[;OO(N?+YK\
MGX[[CR3>WBO2-;Y=E,\ZWYS?;_R>;C:GU,W&*Y<O4!#4<M%X\/)#W#'E?&VX
MVO/6."3@J-.U3;ID^=PVXVL\]."8AJ>6B\>WCZ/K-ZF;YW!Y]I[."2AJU3@J
M\%XFYCS=NO!Q&XV4<XYI!E7W+]OER-JN=Q639:1K,)"&K[%73S_?Z#;Q[C3@
MXO<;'7C"=HKAHJ-<[5JJG;RUX>PY/;;O3A/)USJ'2_%'BK'TF305&J(J+P7R
MU.;Q9M>.KJ&XVWAF:S'%)QSZHG'4W*WUY\W%Y,&D\%PV1%\Q;XFM;$J([4G6
M)4SCF.35KYR=9[V/AGN?=3+QVACH^ZF47A&AJ3XZ@3%HGE(*IC>>&A"U>OWE
M,KZPLI%*[3P;5(6,BZE-ITAM4B5E/P0U;2W,-4/4.T143R[32R3P<I@IK*%F
M7FO<:>2W!R^*D0A)W<57S&AEMV.8P4X0A9W&CDLYG!BF914K]->\U,F3LAR^
M+!,K)TGU>;\A1XFY&W4_>>?M\WY!%D7VWL7U//HJ<?J\M4-G%D['%[C;SQX<
M&44<VJ)QUTT.4PY/F=;W>#2>+(:>;]%?/KY:G(X\G9VN#SX><,@IY==/-Y_+
M@<CCOVN"S8]$U#(CM/+@;V.W'V.,RTT2L+TU0VJ2T,E4G$O#R\NTNAI7CBKH
MG87UC2-%4RJ(B::&3#7CJHO1./F*LD1S65F5C*O/UE,MK'"*G77M[^!K9/JM
M_%"!J>W[M.\T,O/Y'+86/52<_7[$-'+KX9T<QMYXQJQRH=^D<;EESV&O<@*I
M./M-+)/%S&"L]J*E])JWER%*+&37[2N9;-:\5MKH[3V&.JZ:SHK-=Y=QE$J+
M47+'>7>9Q:846I&B]C=R4V*6U:=\<\DG"_D7TLT<F.4E%)R0NK;2=6EDQS"2
MB>G VJS$QJT<E924;D5$\QL4F-&E>)2,6G#CW?D+J\VGDU2<2(7PTKKV).7G
M-FL<&K>4@Q.1=CCCJU+2O6-\O,7Q#6M*Y8PLK&GO46LN6L_.9PIM9<-:91$S
M/M4S*JC54NK6(C1A,J$K-4*;5T64LB*F/AKH:V2NL.1P7XL7KF<')Y?7YCB\
MU>WL<[M;<8877IHGM^WS=AQ.>.;LFTG5A58NCW:=QQ67M=GVT:UACLSE\7E[
M#1F7-8J?1:$=[/,8ZKXIPTA4:[BG'U+Y<!J?#2D"\M=.)92VC4RTE+4Z\O+V
MFS66CEHFH%X&S6=.+C<M(3%.O+3ZC;I;C&CC<U&04TB\$X>CA[#D<=W!;C#S
ME.4[^2:>?GY<C>QWUCVN'S8DO$]$1$U_,;M;:\8<;?'K*^8[SI[2Z+1+4MCE
M=,=Y:_09Q*BU)5?$GDI.OO8?#EI5Z)S5!,_.RC%*DZ9$[=3";1'-=3!,\EI)
M4=B%5LGR-S'MNV5E)-WKZO2:U\O<W\6W]B(JZYL+=5\3G*YC&,8Q\LDDDKVQ
M0PPPQ-?+/--*Y&,8Q'/>]4:U%540XK?=0V^RP7W6YO6F"E9M:UITB(CMF78^
MC]#WO5M[BV&PQ7R[O+>*TI6-9M,]D?CF9X1'&=(XO1#T#?*IM&/P6/>_JLL4
M%]S.>&GN>%[+W:&.?'\$9+XI(KKG])[R6ER?,IZ9S$;;I4=;K2UTC)65-2J/
MIOA3U2];.I>9=U?I7EK)DV_1*3-?B5F:Y,W#29UC2:4G68TCC->$S$3:+?MG
M]V+[E_E_R'TO#YI]3-MAWWFS-6MZ[7)6+X=MQB]8R5MK&7)$Q6?#:/#2T>*T
M6O%(P]Z[&,C8V.-K61L:UC&,:C6,8U$:UK6M1$:UJ)HB)P1#Y]?H'$1$:1PB
M&H)   #B9OOT,]*?4E)5W#=C9K%;MDE9+%/49M9(:C$<YJ*BGI/@:62ORW%Y
M[3>KS%24J-;'!7RU5,B,;^]KX6Z<[TCS1YCZ#PZ-O<^WII:(K$Q;''CG6UO@
MY(OAFVO'Q3CFT<=)XSKYKYS](/3CS]-LOF;I6VS;ZTQ,YZ1.'<3,1I'BS8II
MDO$1RK>UJ<(^CPAU'[I_("P^J?4UFR74!DF/HVFUI<>W.QFVY4RIKEF57-DR
MO%Y\3DMM"V%R>%/U/6RHYO%SO%JWU?I?KIUC#K7J^SP9XX:3BM;#,1I&LV\7
MQ8M,SK/T?!'&(TC3C\P>9?N1=#W%K9?*?6=QMXTX8]UBIFB9UY?%Q3AFE=.7
M\%DGAQF==8X;7WY$O61;/&^TYEL/DD7[ZL4=%E^96^L<UBL1B2PW?;ZBI(Y)
MD<JHB5#VIX5U<G#7M4>N_E^N*+9MEU&<VG&N.,%H_=7SXM?FCEQT>3[W[EOJ
M9MYF=GNNC9Z=FF;/2W#OB^VBL3/LO/+GRUVKG^3-U]03SPQ;>8A6,BFDCCJJ
M?<S#&P5+&/5C:B!M5=*:J;#,U/$U)(XY$1?Q-:NJ)RN+UL\H7QUR6C>4O:L3
M-;8ZS-9F-9K/AR6KK'*?#:T:\IF.+K=_NA^L<7FL;396K$Z:QNL6D^V-9B=)
M[-8B>^(EG^,?(SZU[_205-XN^R>$R2)(Z6WY'G%_K:^G]W.Z)K'KA^%Y/;9)
M)HVI*SPU+F^!41RM?JU-+-ZY^6*7O3%MNH7TY6\.**6Y<M<WCCGIQI'&.[27
M-].^YCZI;JD7W67I&UUYUR9\MK1QT_X';Y:S,QQC2_+G,3P<OMN/V?JC;+:J
MS=[J/JZJ!'0NO6.;;X/#0RJWPL6HAM6:9/>;@QCE<KFLEEL"Z(B.6/BK$ZEO
M/7;J62LQL.G8<5XM.ELF6V6)KK]&9K6F'PVF.<>.T1/"+3IK/JW0/N1;.EJ9
M?,_7;WIP\>/:[>*3[8KGS7O[HF=O[=..D=J6P/RU.CGIT=17+$MIK7E674,M
M+4PYYN<L6>91#74%5+5T%RM;;K3ICN,7*CDE1&SV>WV^5R,8KU<YJ./,>O>=
M_-'F/6G4MWD^RS6U9Q8Y^'BFMM-:WI32,D?1C3XOCFNLQ68B9B?I+R7Z">EO
MD6:9^E=,Q9^I4F)C<;K_ )1FBU9F:VIXX^'BM&OUL./',Z1KK,:N>)U1[$
M
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M0
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M]\/%]GQS_"7CC[(_W>7NU<EL=OXK_%M]6O+W_P"X[.CJCF
M
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M$1$31$3@B(G)$3L1#]=HB(C2.$0^2.?&>;Z2
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MIMU_J._WUIG69W&XRYIF===?X2]N.O'W\6=F\X$
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M1K&,:B(UK6HB(UK431$3@B&;MT1%8BM8TK#4$@
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MJ@
M                            !A&>;;X+N=99;!GF,6K);9(CDC97T_\
MTJC>[36>V7&%8KA:ZK\.GO:>6*33AKHJH7[?=;C:9/B;>\UO[.WWQRGY567#
MBS5\&6L6K_9R[OD=-74?TF7S8F:7+<6J*K(ML9ZJ*/XNH1CKQBT]7,K*>AO7
MNFM9544DBM9!7-:QKGO2*1C'^!TO>.E]8Q]0CX.6(KNXCY+:=L>WOCY8]G7]
MWL;;;^$Q\</X8]_Y7'FT5^O@5'=R_5S30Y*]=&K66YUIK6Z-U5$^CN[5X&I>
MJ^LMP+?6*OA75-/-V?E-:U5T2SFW5BIX>*]GEQYFO:JV)9I2U?!%\7E]!KVJ
MLB4Y3UNJI^+N*YJSB4]!5ZL7\7EIQ*YJRB59U7P3CYR/"G50DJN7'U>2ZDQ5
M&JVFJM4Y\R8A&J-EJ43F[[^TSB$:H>IKDT7\7>G-.SUF<58S+%ZZX(B*GB3C
MZ5X?5V%U:JYEB=9<=6NT<BJB+S^CAW:%U:JYEMU>KM[ICU\;4=HO->7;IS3B
MOI-O'353:VC9O(+\[PJ[WBKQUT15X\%5-=--3>QXVM>[YAVW>Z>ZU1)%M[A=
M_P E9%(L$U=24Z06>GG1&K[FIO==)2V:DF\+D7PR3L=IQT&?<[39Q_RG)6GL
M[?FCC^ QXL^>?X&MK1^#Y^3?1W0[U-+2K5)C5A6;35+?_"VQI6_I^#P^-*E+
M?KX?Q?\ /Z>'M\7 X^.O]*UT\=O?X9T_+^!L_P!6[S368C7WQ_[&RV78-NCM
M174]/N#AM]Q;WDGNJ:LK:=L]HJY$\7CCHKW0R5=FJY6L35S(IWN:FBJFBHIO
MX<^TWE9G;9*W]D<X^2=)CYFODQY\$Z9JS7\7S\F7XYDC:F*+Q.3\2)HY%7LX
M<>.G'0HRXM)64OJW$;<M86?B[%3GYS5\'%?XM5C/6MD145VJ\='>COXDQ5CK
MKP8C<'HNO%.WL^W4OK"N6!W+F[E^4V:*K,-K$Y^OR[B^JJ6(UK41W/G]_P"4
MOJKE"R)]99VL94TX+J2+R)>*=FNB^7J,)Y"?I7\N.O(KE9#,+;/HC57A[/N*
M+PLB89K0U"<./TK]A1:%D2RVCJT141%3AZ>THFJR)9-2UZ(Y/Q<M.WOY]W<5
M35G%F0TUU_$GXN2:<_.B]ZE4T619,07?5[4\?!%Y:]J(NBZ*B<2N:,HMQ9)3
M7CL\?8NO%>:)V\40JG&SBR7BNZ(FOBY<N*&$T919)07;Q)Q=VZ?;I])A-&46
M[5\RZL1R)XDU[=%XZ:+YC&:<$^)56YL_NW+Z_P A'AD\30VZ,=^Z7GWIKZR?
M#)XH'79C%3\2ZJJ=J<$7AKIIJ/!,GB?5O#--5>[T(O+7V:#X<GB4TOL:_NET
M[%UXKW<-$XJ/A(\2[@O;'_A5^G'3AHO+AS5?L,9QLO$E(KDWAI(FJZ)IKI]>
MFIC-&7B2D-RT1?Q<ON0PFB=>"\9<]>2^WEYNWM,9HGQ+R.O5>;N'=P])C-4Z
MKGX_CS[NWS(1X4^)42N[W>I!X3542OUX(OT_;V$>%/B4IJ[1%_%RT[>TF*HF
M6(72X*B/U<NG'EIK]9=2JNTMFLBN"N\:-5R:ZKV)IZU7F;^*K6O:9;&9)6+H
M]O#CKIJJ>2Z>@Y'%5JWEL7?7ZJY.?%=>WO[SD<?>U+MMZO\ YQ>/->6AM0IE
M\@8JZ>T3*89I9[6Z3254U\2?AX\$354U737GV%&2^G!96O;+<>WV9?"B>'BN
MFNC5[>6O!#4M=?6K,*.R*UJ.\/']SJFG/FO;SU*+9%D423+.Y5T6->/:J(J(
MG?KYM3'QI\*LZS>%-&IIIZ=/;H(R)\*DZTN3FU41?,FGU$>.$>%I;:-7?H\$
MXKP\NTGXG<>%\?:>WP\=->7T^D>,\+3^I^SP\$Y\.2]R<!XSPM;+-PX,U3LX
M=G:OM(^(>%799=5X-X)IQ5.WV+P1!\3ME/A7C+-Q1$9RT55TYZ<N)C\1/A2D
M%G5>#&>)W:J)R\VJZ:)]9A-^]EX93E#C<M1(QC8G/?(]&1QQ-5SI'N=X4:U$
M17*KU5$33157@5VRQ$,HIK+LHZ?]E(L H$R6^T[5RNYTZ-B@D;QL5!*U-:9K
M5_0KZEO_ #R\V-_>TT_'XNK]1WT[FWPL<_P,3\\_D[OG<MM=O\*/';Z\_@<E
MSBVX
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M.6>>1ROD>OXGO<KEXJ=1R9+Y;SDO.MYES5:UI6*UY0F#!D
M
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MX=JZ\_R&CDR:RVZ8].,HN27GYS6M9?6NJVU55U7U>8KF=5G+A 0D
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M"'Q!>]\EYR9)FV2TS,S,ZS,SQF9F>,S,\Y5"UB
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MW=JSQIMXF9QX/9.>\1>_*T8\=:SK3-,3WC'TB_/<
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MO,!]\2=_+U ?5<G:[Z=0+>1R<D1.6GY>\"RD?IP1>SL[?+4"-E?V)RY:?;Z
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MJE8\P[G^'WEHTU^+>.&+Q1-M:X*:8XTM-)O&3)73XDN=1>]B
M
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M:UIXS+/#1<^
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MQ34TC5572-ET[]TO?QU/;S-](W-.%H[^ZT>_M[I^1UK>;;[)ETC7X5N7L]C
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MO^)R$..;0
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M*5I7PUY,@*V0
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M]4WN3J/4<E\V]S7FU[VG6;3/]FD1&D1$1$1$1$)8Y=J
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M;W-.3);E&L\(K6/S<=*Q%,=(X4I6M8X1#.3><$
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M-?:UL/W7?1C'F^+?IN;)3PZ>"V[W45U_2UKEK?7L^MI[-4]_P=OER?[.R_\
M>[OM_I/.;VNYKM*>#%M]C-9K,?3VFUR3I/MR8;SKW3KK'9,.2K]VWT4K&D=#
MI\NYWL_CW,MJ,]^1OT-Y73SMQ6W[G;653FRNI9L1S^MO-/#,[QNA2>FW#I,U
MEJ*6-[FHYC9HI'L;HDC7+XRK<4Z7NZZ;G8[;XD\)OCB^&T1PCZ-<=JX8GMUG
M#:->,Q/)USK/W4O23JE)C98=[T_)QTG!N+6B)[-:[B,T3$?),]\3Q=074S\G
MKJ,Z;Z&X9AMM<X>H+;&W0NJ[A-CMGGL^XN.4T;6OJ*NY8)\5=_UM;*=TB-6H
MM596S(QCYYJ:FA:YR=8WOE_37)TVUK5_D[:>.(X_5M$1&2>'+PTM,S%:TMQE
M\K>I/W6_.GDS!DZMY>O'6>AXX\5OATFFYQUCG-L&M_'6/TL-[VTB;6QTK$S'
M6135J/1-5X\%3LYIP3L7Z#K,Q,3I/-\P))DZ+V\>]-/S$"Y;+Y_6G!?6G "I
M[WSK[/)0*K9/SM7\H&OWO_*7V:_6!]][_P KZ/R :_><.STZ\U MI)?2OGTX
M>CN LI'\^U5Y_<!82OY\?3IQ331>'>!'RO\ 4FGT?>H$34.3CWZ*OV@0=1(J
MKS_+JO'7U(!"5+^:<T @ZAVFJ>SCYN[U@1DCM=>/!/K[5\X%KK]6G:O:!\1=
M?SI]BJ!]1>U%\NY0)&GDTTU5->"IS3[->($]3R<OI3V\N/>!D-+-R3M33V>L
M#(*:?E^+3L7CS^D">@E7@NO-.?EP4"9IYN6J^;OU]?8!*1RHNFNG#O[NSLT
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M
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M%8YUV^.=/J4GC>T<<EXUF9K3%%.R$\^?0H
M
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MM9'JFOAUXG&9<^3-.MYX=W8VJ8ZTCZ++"EF
M
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MFABIZ>%C8X8((V0PQ1M31K(HHT:R-C4Y(B(B&A,S,ZSQELZ:<(Y*I
M
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M%@RZ=OPLEWLW0_-/EWS)B^+T/>8-S$1K-:V^G6/VV.=,E/[:L,%.@.?
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MF;);-FM:^6]IFUIF9F9F=9F9GC,S/&9GC,JQ>P
M
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M.M-OBF==-=(\>6^D3ERS$3>T1$17'6E*\GCM+R@
M
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MS:(FB_9P5?2!+03\N/F\N0$K'4<N/F[/.!>MJ$TXJOJT7[.T"Z94HG;]*_D
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M*UK6L:16M8B(B(C2(C2$J&P
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MB95&NX^2F<7T57V_#@NFR:%GQ5'V7M73)41$74SC)&G.%%MIK.BO'.GB^_\
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MOVJGFKZ7
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MO]:9EG%:UY0E3!(
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MQD<;&QQQM:QC&-1K&,:B-:QC6HC6M:U-$1."(4\V;4
M
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M/'EO^WR6M>>V7B'5^N=8Z_NOMG6=SFW.Y[)R6FVD=U8Y5CV5B(]C)SM3B@
M
M                       !U-_,GZ?I[E;*'?[$+4LU?8X(;-N73V^EA]]4
MV!J^"S9?4MB6*:I?8)'?!ULJMGE^!DIWJL=/1/5/$?67RK]OZ?3S+M*_\JVL
M>'+&G&V*9X6]^.T_N;3,S]&(?9OW1O4FO2^N9?3CJ^338=1M.3:3:8TINJU^
MGBX\HW%*QX=)_C<=:Q69RS,=-T-4CN/BU[E3EZ#YCT[GZ%Y<$UX3"4BJE\*:
MKKHFG?Z/H#0O@XKMM4G?IR3F1HHG!*Y94JNO'7TC25%L&BJE0O;Q7TD:*YPP
MU_$Z<^?<-&/P>Y]6H33@@T(P\5K)/WK["=%],7<L7U&NJ(I+:KA[UA+-VJHY
MMJF/L1\DW-$7R_.3PAN4QHF>7GHIE$=LN0Q41$TR-5>_M\PY\7)X<.L:H"JF
MXKHO->S[S..'O<S@Q<.+MC^6#TR-RG(JGJ$S>SI-CN*53K?MK37*B22ENV70
MO5*_*Z9D[T9/!B"-2&DE]U+'^LY72121U%O73WOT<\I5S9+>:=_2)I29I@B?
MTOS\D1II]'7PUG]+Q<-:Q+X+^^AZOWV.VQ^D_E_--=SGI7-U"U)XQBGCAVLS
M$ZQ.33XN6O"9Q_"C6:9+5GOD/HE^;8  ZUOF1]-2[M;9-W3Q.V,GW"VLHJFK
MK$@93QUF0;>Q)/77NV.>YL<M94XY(Y]QHHUE71BUD<4<D]2Q#S#U0\HU\P]%
MG?[2FO6-I6;5TC6U\?.^+AQG].D:3/BB:QIX[2^JONI^L-_3OSO7RWUG/-/)
MO6+QCR1:VF/!N9TKAW/'A2)G3#FMK6)QVK>\S\"D1YW::=4X*J^8^2M-?>_7
M#-BUXPFX)N2*JF//WN*S8>V$]3U")IJOW^GSF,QVPX;-AGL3,%2BZ(JI]1$Q
M\[C<N&8XI:&H5-./V^2$-#)BU2<50B:*CN?9Z2-&CDQ3/.%ZV=$[5(:TXE3X
ME._R^D:,/@RMI9^>BZ!?CQ(R:JYHB^OR[S+31NX\';*/EG7PJJJ.?!MX\7'@
M@JJ?55X]_<91#E<&)!SRZ(JKZ$,N?!RN#%K.B'EF1/SD\9<KBQ<$?)-JO#R\
MW$RX0W*8].:DKU4+(K$-/B7O^H)TA]1RIY:#5$UB51K_ #DZ]ZJV*%5'^?[/
MR#@KG$K))V&.G<JG%*JV33MT'%A.*6OWO_*7Z"-4?!CN7"5"]_V\?L'!1.W5
M&U*=O(C@QMMN[FN8ZA-?PNT\OJ'%1?;SIQ2$52J*FJ\/RD<)][2R;?@EHJGD
MFNOK[S'3O<=DP^Q)Q5')47U+]Q'&&EDQ=DI&*I[U'-I9,/<OVU*=_P!.GWD:
M-6V&5PVIY<_2BZ_1P(T56PJ[:EO:H4SAL^25#>Q?5Q^G@-$TPSW(Z6H:B+JO
M?P3C^0G3O;F/#,\F/U=3IJO?RXF3E]OA[&,5=4JJJ>+AQU^[O[#*(T][G-O@
MB-)TXL6JI]55=5\Q9$?,YW!BY0BG.XZKQ51,N2I3@YX=('0WEG4I*W+\CJZS
M#-HJ&O\ A9K]% S]>9;-33.9<+=AL57#+2)'2.C6&>Y3LEIJ>H7P,BJ9(YXX
MO4O(?IKN?-$1U/J4WP=$BW#2/IYM)XQ37A%8Y3>8GCPK$S%IK\K^O_WF>E>E
M$SY9\M4Q;_SS:FMJVF9P[.+1K2V?PS$WRVB8M3!%JSX=+Y+5K-(R=_>U'3ML
MKLE2PP[;;>8]8*V*&6&3(74B7++*N.?PK41UF4W1:R_34\SV^+W'OTIV*NC(
MV-X'TSTCR_T7H.'X/2=MBP5TTF:Q].WZUYUO;^VM+\OO.7J/YY]0-Y.]\X=3
MW>^OXIF*7OIAI,_R6"GAPXH]F.E?:WJ.8=)<=]XNE38C?2GKG9W@-I6_5C'Z
M9I888K#F<%1\*M)3U3K]01,GNJT4>BQ07!M91HYJ>*%R)H=?ZWY6Z!YAQS3J
MVVQY+Z:1?3PY*_JY*Z6CW:Z3VQ,/1O(OJUZA>G&YKF\I=4W.WV\6UG!:WQ-M
M?O\ 'M[^+%,SK,>**Q>-9FMJSQ=%'4Q\O_=G8>2X9+C$-7N;MA"Z>I_A!9*"
M5U_QRABIEJYG9ACU-\1-1TE''',C[C3+-0^[A26=:1TK($^<?-WI5UCH,VWG
M2?%O.E1QX1_"TC]O2/K1^VI''C,UI#]*_1_[V/DOU!IBZ-YLG%T7S;,1&E[:
M;3/;EKAS6G^#M,_\#FF)C6*TR9IUF.",50J=NO+CYCRF>Z>;ZJOBBT:QR2D-
M5IR7AS^@QF&EDP:\X7\=4B\UT]"D:=S4O@E>,J]-$1R>2$?(UK;>)YPKMK51
M.Q?6-/>IG:5GL?'5ZIQ56IYU_,HT[TQLZ]D*+KA_R]/1H-%M=G$<H1M1<]-?
MQ>KQ:KQ\W<9:-[#L=>QR7Z>.D7>7J2KJ2KL-JFQ?;Y]0UMQW(R&DGAL;*>.J
MJ*:M;CE.Y8)\NN=/)1S1^YI'>XBJ&)'4STR/1YW[RCZ>=:\U7KGI6=OTK7CF
MO$Z3IIPQUYWGCSX4CCK;6-)\1]7/O >0O2/!?99LE>H^;M/H[+#:)M69B=+;
MG)QK@KV^&=<LQ-9KCFL^*/0YT^=-^VW3?B3L;P6W.EN5Q=%4Y3E]S;#-DN4U
MT3%;')<*QC&I3VVB1SDI*&%&4U,CWO1KII9YI?JCRYY9Z3Y7V,;'I6/373QW
MG2<F28_.O;2->W2(B*UUGPQ&K\J?4KU2\W^JO79ZWYJW'CBGBC!@IK7;[:EI
MU\&''K.FND>*]IMDR>&OCO;PUTW].P/.P
M
M :7L9(QT<C6OC>US'L>U',>QR*US7-<BHYKD7147@J#EQCFB8BT36T:UEXG_
M )E?29/TD=1-TH;#;WTVT6YZW#--JZF**J^!MM'+6-_A#@2U4T+8UKL(N54R
M..-LM1)^J:J@EED669[6]0ZWLO@;C[3CC3#EF9[(B+\[1$1RB>=>%8TUK&O@
MF7Y*^OOIA?TT\[Y,>QQS'ECJ'BS[28B?#2LV_A-OK,:>+!:8B(UM/P;8;6GQ
M6F(X"0U6FG'\OG]9PCPY)LJ//V^K[?K KMJO/Y_+FH%PVHX)Q[//]P%1)_.B
M^;A^0#4D[5[O+T:@:9)NY=-?NX\]%4"PDG^U/9V 64DR::KZ/9Z (N6;55](
M$=-+JU>*>GCQY]J\] (:>3PHJJOT>ST)J!"U$NNO%/0B\]>(%&T6:]93?+1C
M.-VJX7W(<ANMOL=BL=II)Z^Z7B\W:KBH+9:K;0TS):FLN%PKJAD,,4;7/DD>
MC6HJKH9X\=\N2N+'&M[3$1V<9]L\(]\\(;.TVFZW^[Q;'8X[YM[FR5QXZ4B;
M7O>\Q6M*UC6;6M:8B(CC,S$0]YWR^>D"R]&G3KC&W[Z2W2[DW^*#*=W<BHV-
MDEN^:5\*/DM4==[R9U39,/I9&VVA\"LAD;#)5)%'+53>+T';8*;3;UVV/ZM>
M<]]I^M;E'/3AK&L5BM9F='Z]^C/IKM?3'R5@Z/-:3US-$9=YDKQF^>T?4BW'
M6F&/X+'II6=+9(K%LEM><9<]8  'CC^<]T2?ZOF\L._6W]GCI-H-\;M5RW&C
MMM'-#;\)W3]R^X7JSO5L;J*DH,TACFNMN8V1JK-'7PLBCAIHE?UGK^TF<GV_
M''"VD9.7UNRVG/Z7YTZ3]+C-M;Q#\ROO0^E7^AOF>/-_1L45\M=6R3-HK68K
M@W>DVR4[HKFB+9L<:QQC-6*Q7'77I>AETT3R[$X\3K;Y83%/,O#OY>?V@3L$
MZ)HFNGV=OU 3E/4ZHB*OL[$\VF@$S!,G#1?I^WD!*Q3IRU]/I^KF!=MJ$[]/
M1R^Y -3IT1%XZ^OT@1\U1SU71/LX\E[@(J:H1>W7GZ.Y5X]V@$35SKHO'U:\
M0,;J)%77CKKZ?S\5 A*B3BJ+V>?EP\P$5*_GR\_)?KX:@6;EU77\H%%5=VIR
M_P"3JG#MU4#0  U-3GV^SZG<0*J</-Z."?6J:Z@5VKKV\M/5]" 5VO7OT]>G
MMX@5V/5%Y\./'A]?I N&RKIS3FG%.WM7U@7#)]$XJGK]J]N@%[%4:>;S^K[$
M4"4@G\_#EQ[/+4"6AG[=>SO[>?GU E8JCE^+SZ\_M[ )2*HT_=>7,"\94<M4
MU[$]NO;H!<LJ/-IQYHO#AZ@*Z3IWIV^7!=.(%I+4-7M7U_GTX 0U74IX5[?6
MG=PYZ]H&(5U3^DG<G'BBJGY5 PROG\2*GB7CP7AQ^L#&9OQ*J<>]>_U]V@$K
MC6-7W+K_ &7%L7L]QO\ DF27:WV&P6.T4DUPNUZO-UJXJ&V6NV4-,R2HJZZO
MK)V111L:KGO<B(BJ68L63/DKAQ1KDM.D1_NSPB.^9X1'&>#:V6RW?4=YBZ?L
M,=\V^SY*X\>.D3:][WF*UI6L:S:UK3$1$<9F='K>Z#_DJ;7;4V>Q[B]5EIM.
MZFZM13TERBVXK)&7+;/ :ASJ>ICH+G1Q/=0[AW^D:Q8:M:I9['J]\<5/4HR*
ML?W/9=)VVTKXKQ&7<=LS&M8Y_5K,>WZUH\7")K%)UU_1?TC^ZUT#R]ML76_4
M/'CZAYAM$6C;3/BVNWGA,5O6/H[G)'*_C\6#C-:TOI7+/>I9[/:,>M=!8[!:
MK;8[+:Z:*BMEHL]#2VRUVZC@;X(:2@M]%%#24=-"Q-&QQL:QJ<$0Y2UK7GQ6
MF9M/;+ZTVVVVVRV]-IL\=,6UQUBM:4K%:5K'**UK$1$1V1$1"2(7NL'JW^4[
MTM=3UJK[C9L6MFR>Z;H97V[<#;BR4%KHZNM7WSV_PSPRB_5UBRJGFGF\4TZ)
M275R,:UM8UB*QVMN]GMM]$_::ZY9_/CA?7ASG\Z.$1I;7AK%?#,ZO!/4;[NW
MI_Y]V]\VUV^/I7F#2?#N-M2M(FW'^.PU\./+$S.MK?0RSI$1EB(TGR>]5/0K
MU']'-[DI=U\+J)\.GK&4EBW2Q=M3>MN[\ZH=4_!P1WUM-$MDN]2RCF<VVW..
MBN"LB=(V)T/@E=U+?=)W.SUR1_";:/SX[(UB-;5XS3C:(X_1FTZ5M;1^=GJ'
MZ1>=_3/=33S#M9GIDVTQ[O%K?;9-==(^)I'P[SI/\'EBF32)F*S72T\1HJA%
M7FNGLY\U]&IQ;S%)1U6B)V+PY<N_Z$ OXZK3]US[_0G$"\96>?\ +V<P*OQZ
MHG!?IY?E INN'/\ $[MX:_>H%M)<>"_C5.Y%X?4FH&JR6[(\QOMJQ;$+%>LI
MR:^UL%LLF/8[;*V]7N\7&I>D=/06NU6Z&HKJ^LG>NC(XF.<Y>2*68L.7/>,>
M&LVO/9$:\N<^Z.<SRB.,MO8['>]3W>/8=.PY=QOLUXK3'CK:^2]IX16E*Q-K
M6F>41$S+T4="/R2;A4U-GW5ZT864U''[NXV38.VU\<M552I,UU+/NA?K9-)!
M#2+$Q9/U-;IGR2>\C2JJ8E9/0O[5L>B8]O,9=YX;YHG7P\Z1[YY7G7LXTX?G
MQ;A]O^D/W4LLWQ>8?5"(KCCZ5.GUMK,SKPG=9*SI$:<?@XYF9UK\3)72^*?2
MU:;3:[#:[;8[';;?9K)9K?1VFSV>TT=/;K7:;7;J>.CM]MMMOHXX:2AM]#20
MLBAAB8R.*-B-:B-1$.=F9F=9XS+[LV^WV^SV^/:;3'3%M<5*TI2E8K2E*Q%:
MUK6L1%:UB(BM8B(B(B(C1($+@
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M2L5QUF9\%*ZSKR7.!=^
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M?Q1P=FVVTQ;6GAI]:><]L_[GL;ZG'MD
M
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M3T]/"QK&,8U&L:B(B(B'3+6FTS:TS-IG69GM<]$1$:1PB%P0D
M
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MF9\4=G"(B(B(B(B)HB)P1$3DB)V(A^J41$1I'"(?+7/C/-])
M
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M9F9F9F9F=9F9GC,S/&9GC,JADP
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M$^#Q12)^K6')$O=Z
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ML48O*G2]GLK>&:SDI2)S6K,Z^&^>_BS9(UTX7R6TTC3E#?PXEW(
M
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MIN=UN-WD^)N;S>_M[/='*/DAS6+#BPU\&*L5K_9S[_E9P:ZP
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M:UJ:\CK-[WR6F^29M>><S.LS[YER]:UK'AK$16.Y?F*0
M
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MOR:?*YG;],P8?I7^G?V\OF_+JYM(B(B(B(B(B(B(FB(B<$1$3@B(AP+DGT
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M/_<^1R(.,;8
M
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MT7:;?;\]=?XG'3GK.O?K+JV_Z[UOJO#JF\W6YC_WN7)DY<OKVEDYVIQ0
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MS$\8O:\3$1S'/MAXL
M
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M.MHMN<TQ,QVS$WXSQGC/>W(.2=>
M
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M<<;$1$1$1$1-$(Y<(Y-ZE*XZQ2D1%(C2(CA$1'*(CLB%0,@
M
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M/>(T\>:^D>*>,^&L16E-9BE*Q.CD><([T
M
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M[<HU5P
M
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MK=\S,S^%LUK6D>&D1%?9P2Q@R
M
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MXGS)YL\_>9O.6;Q=8SS]CBVM<%/H8:=VE=?I3'9;)-[\9CQ:<&\)[2Z8
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M,SPCLB.$1PB(A,G-M(
M
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M@\W;S)N^H6X5\7"F*FLS&/#CC2F/'&O"M8C69FUM;3-IW6.6=1
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M9F9F92Q:U
M
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M1.2*6^''9D;;W8
M
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MOI73.B;#'TOH^WP[7IN&NE,6*E<>.D:S,^&E8BL:S,S/#C,S,\9EDY4WP
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M$16L1PB(B(B.$)$Q7@
M
M
M
M
M
M
M
M       &#YKMK@6XM*VCS;%+-D4<;'1P3UU*B7"D8Y5<YM#=(%AN5 CE75?<
MRLU4Z'YY]+_3WU+VD;+SUTC9=2QUK,4MEQ_PV.)XS&+/3PY\6L\_AY*Z]KG>
MA^9_,'EO-.;H>[S;:TSK,5M]"T_MJ3K2_P#;5EQ(R[H'VXNLLU1AV3Y'ALDT
MDKTHJEL&3VBF8Y=8H:6"JEM]W\$6JIK-73.<FFJZZJOQOYS_ -GAZ8]8S7W/
MDOJG4^B9+VM/PKQ7?;>D3]6N.N2V'<:5Y:Y-UDM,::SKK,^P]'^\'YEVE*X^
ML[7;;VL1$>*NN#);OFTUB^/6?VN*L1QX:<(V&N?0!NC%/X;-FN"5U,BOTEN<
MF06F?PHJ>[7X>ELMZCU<FJJGO?PKR53YZZK_ +.?U5P[C3HG7/+^XVNL_2SV
MWFWOIV?0Q[;=1Q[?I\.R9>@;7[P_E6V/7>['?X\O=2,.2/;QMDQ3[OH\?8PM
MW1-OZBJU*'&7:*J(]N24_A<B+HCFHZ!KD1>?%$7S'1;?<-^\)$S'V?I4Z3SC
M>TTGV\:1/SQ$N<CUU]/YX_$W4?\ QF?[Y>6[H7WTK9)&5,^$VAK&(YLMQO\
M62QS+XD3W<:6FSW25'HG'5S6MT[=>!O]-_V?_KWOLEJ;K)T+95BNL6S;O+:M
MIU^K$;?;9[:]OTJUC3MUX*-SZ]^0L%8MBKOLTS/*F&L3'MGXF2D:>Z9GV-S,
M>^7M?9T;)EVY-KH%:Z-7TF.62KNR2L7Q^^:VX7.KLJT[FZ-\+EI9?%JNJ)HF
MOJGEO_9O=>SQ&3SCYGVFWF)KKCV>UR;CQ1Q\41FSY-MX)CAX9^!?76=:QI&O
M5NH_>,V%-:](Z9ER<)^EFRUQZ<M/H4KDU[=8\=??.O#DGA?1?L?B3XJFNM%R
MS2NB5CTFRRX?$TC941%?X;3;H;;;)H'.1=&5$51HG!57F?4/D;[CWH-Y.O3=
M;_9;KKF_I,3XNH9?'CBT<]-OAK@P6K,\JYJ9M(X3,\WF76_6WSWUBLXL&;%L
M<$ZQIMZ>&VG\Y>;WB?;2U/=#E-06^@M5'3VZUT5);;?21I#24-!30T='2Q-5
M52*GI:=D<$,:*O!K6HA]9]/Z=T_I&RQ]-Z5@P[7IV&OAQXL5*X\=*QRK2E(K
M6M?96(AY1N-QN-WFMN=UDOEW%YUM>]IM:T]\VF9F9]LRNS<4@
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ME?P//=]U/J/5,WVCJ>XS[G/^EEO;);Y[S,_A3)S;2
M
M
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M4#U&S_&\X]4W.\Q1;Q5Q3:*;>D\M:;?'%,-9TX>**>*?SK3/%OH<\\_
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MAYPZENM]GUUK&2W\'3GPQXJ^'%CCC/"E*QQENN<PZ<
M
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M.$+LA8
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M*G$SQ9,F')7-AM:F:LZUM69B8GEK$QQB=)F.#3W_ $_8=4VMMCU/!AW.RO\
M6QY:5R4M^M2\36?EAPIS/Y8'07GEPFN=ZZ;L.M]5,JJYN&7++MNJ!JKVQ6C
M,BQFT1:*G)L")YCMVR]0?.FPX;?J.XG^<F,O_&Q=Y-U?[O?HSUO+.;>= V=+
MS_(3EVL?N=MDQ5CYG'VY_)&Z&J^MFJJ:U;HV:"5R+';;;N'42T5,FB)X8'WB
MV76XN:JIK^^3R+YSEJ>K/GRM8K;>5M,1SG#@UGWZ8XCYHATC-]T;T;RY9R8]
MOOL59_-KNKS6/=XXO;Y[2G\?^2]T$V9(_P!8[?YCEBL75RY!N7F-,LOXY'Z2
M)BURQI$3PO1OX4:OA8G;XE=K6]4O4"V:<D=2O&.=/H1@VOACAIPGX'CX\YUO
M/'EI'!N;/[J'HKMM/C=/W.XT_E-UGC7W_"OB_!W>_7E9M;T-](>S#Z6HV[Z>
MML[3<Z"NBN5OO]UL$6893;JZ!6+#/;LLS-^09+;W0OC:YJ0U;&M>GB1/%Q.N
M=2\R^8.KQ:G4][N<V*_.ELEOASS_ .#U\$<YUTKQCA/"(>E^7?2/TS\J6KDZ
M%T3I^+<4M%JY+8HS9JS'*:YLWQ,M=-->%XX\>;E8<(]%
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M            <)M]_F/=#/33<+G9-YNIG;/&<DLDON+SB%JN-;G6;6BH^,IJ
M%:6Z83M]093EE!5LGJVJZ*6C9(V)KY5:D44CV!LOA7SH/EB9_=%L]BZM,.H*
MM/<?OV:XIN;MK:_^DU$=+'I?-QL'Q6RKX99463_I'[U&BR/\,;7.0.QS$,SP
M_<'';7F& Y9C6;XE?*:.MLN48A?;7DN.W>CF8V2*KM=[LM56VRX4TK'(YLD4
MKV.145% R4            ,&W$W.VWVAQBJS;=;/L,VUP^AEC@J\HSS)K-B=
M@@J)FR/@I7W:^UE#0_%U"0N]U$CUDD5JHUJJ!UOY!\[WY6^-7>KLEQZK;-4U
ME%[CWTV/[9;VY9:'_$TT-7'\)D&+;:7FPU_ABG:DGN*F3W4J.C?X9&/:T.5F
MQW7-T?=2==#9]D.HS:G<#(JBF^-@Q&VY50T&;2T:0TLTM6S"+VZV9:ZFIDK8
MF32?!>&"5WNI%;(BM0.5H
M
M                                                         !@V
MXFYVV^T.,56;;K9]AFVN'T,L<%7E&>9-9L3L$%1,V1\%*^[7VLH:'XNH2%WN
MHD>LDBM5&M50.M_(/G>_*WQJ[U=DN/5;9JFLHO<>^FQ_;+>W++0_XFFAJX_A
M,@Q;;2\V&O\ #%.U)/<5,GNI4=&_PR,>UH<K-CNN;H^ZDZZ&S[(=1FU.X&15
M%-\;!B-MRJAH,VEHTAI9I:MF$7MULRUU-3)6Q,FD^"\,$KO=2*V1%:@<K0
M           <)M]_F/=#/33<+G9-YNIG;/&<DLDON+SB%JN-;G6;6BH^,IJ%
M:6Z83M]093EE!5LGJVJZ*6C9(V)KY5:D44CV!LOA7SH/EB9_=%L]BZM,.H*M
M/<?OV:XIN;MK:_\ I-1'2QZ7S<;!\5LJ^&65%D_Z1^]1HLC_  QM<Y [',0S
M/#]P<=M>88#EF-9OB5\IHZVRY1B%]M>2X[=Z.9C9(JNUWNRU5;;+A32L<CFR
M12O8Y%144#)0
M
M
M
M
M
M
M
M
M
M
M        L[C<*2TV^NNMPF^'H+;1U5PK9_=RR^YI*.!]14S>Z@9)-)[N&-R^
M%C7.731$5> '4S_QVOE4_P"U/_ZA#J._T0@;_P#3=\SCH>ZNMPYMJ>GG>[_*
M#GT&.W++);#_ )-MW<3\-@L]3;Z.XU_ZTSC <:LKOAZBZT[?=)4K._WFK6.1
MKE0.>8
M          #9#J%ZCMF.E3;2X;P[]YE_ /;FUW.T6>OR+^#V591[BXWVK;0V
MJG_5&&6/(K[+\55.1GC92NC9S>YJ<0.OS_CM?*I_VI__ %"'4=_HA YJ]+_6
M5TW=9N-Y+EW37N/_ )2,>Q"^08WD5P_@AGF'_JZ]5-!%<X:/X3/<7Q:NJ_'0
MSM?[R"*6)-?"KD<BH!R=
M
M         'YO'SH?[3OJT_PQQ3^C'!P.(W2%_6RZ7_\ >(V4_I*QH#]4
M_+7ZWOZZ/5Y_O0;_ ']*^6 <B/D^?VEW2)_.54_Q2R0#]*       '!7YG7]
MGGUF?[N^YO\ %NL _,A ]H_[+Y_5^ZGOYX\6_B3&!Z@0/(%\]3YM^?VK/\DZ
M*.F3+KGA=MQ1GZKW[W'QJMGMV27N_P!93,EJ=L<<O%-[JKLMCLU)4-;>JFFD
M;4UM6]U%XHH(*AE8'DT  >IW]FSZ<>H&X[@9MU)Q9[FF!].5CAN.(38925DT
M>,[X9Y4T,<3FUEDK8Y[74VS;ZDG9.^YQ1LK8Z^2&EIY_!\<Q ]E8    \=7[
M4C_*!T=?X';R?W[V] \I@'ZN6Q'\A^S7\U.W?\4+.!^=K\X/^TNZN_YRJ;^*
M6-@<1NF7^LCT^?SW[4?Q\L 'ZK('$_K:ZM<&Z).G#/NH+.:=]UBQJF@MV*XM
M!4?"UF:9S>G.I,7Q:FJO<U/P;*^M19*JI]W+\)0PSS^!_NO X/S?NJKJZWXZ
MS-T+CNKOQFUPR>[S35C,>L,<L]-A^!V6JG2:/&L'QY9I:2PV:G;'&CO#XJFK
M>SWU5+/4.?*X.- &?;68)GVYVY&#;?;66F[7O<;+\HLUBPNV6-TD5TGR*NKH
M8[;)2U,3HUH/A:C29]4Y\<=+'&Z9[V,8YR!^H+TH[5[B;)].VTNUV[.Z=_WH
MW'P_$:"VYAN-DE4ZON5]O;O'4U<3+C40Q7.YVRSOG^"HZJN66X5%+3QR5,CY
MG/4#D*                    #9;J/W?_U?>G_>G?3^#W\+?\D&U^;[D?P6
M_6WZA_A%_ W';A?_ -3?KO\ 5EZ_5/ZR^!]U\3\'5>Y\7B]T_3PJ'F$_\4__
M /(*?_;._P#WO('<O\KKYEW_ !)\/W9RS_(K_D8_R7Y+CF._ ?Y1_P#*+^O/
MX06NON7QGQ7\ \$_5GPGP/@]W[NH]YXM?$W310[30
M\W?[3E_4NV1_WH+!_11NP!X>P/TH/D^?V:/2)_-K4_QMR0#LH
M
M                .ES]H!_LQ-X_\,=G?Z3L: _/: ]MG[,-_5-Z@?\ >(?_
M $:X0!Z7  'F[_:<OZEVR/\ O06#^BC=@#P]@?H&?L]?]FCM_P#SE;M_QMG
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ML=?)#2T\_@^.8@>RL                     #HD^99\Z[_ (=_4!8]B_\
M5H_RO_KG:_'=R/X4_P"67_)_\-^OLBR^P?J;]2?Y*<V]]\)_!7WOQ/QC/>>_
M\/NF^#Q/#@WAG[3[_"_,,3Q/_4?_ %?_  GR6Q8[\?\ ZROQ?P/ZZNE+;?C/
MA?\ (!3?$_#?$^/W?O(_'X=/$W75 ]7X                    /RU^M[^N
MCU>?[T&_W]*^6 =CG[/7_:7;?_S:[M_Q2G _0,
M                                                         >:/
M]IY_JF]/W^\0S^C7-P/$F!^A+^S_ ']F)LY_ACO%_2=DH'=&
M                                                /+7O?^TK?Y&M
MZ=WMH/\ 4M_A'_DJW0S_ &W_ (0_ZQGZG_7W\!LKNV,?KG]4_P"0BZ?JO]:?
MJOW_ ,-\34>X]YX/>R>'QJ'([Y>OSU?]?'J7Q_IV_P!5K_)5^O<:RW(OX8?Y
M;OX<_"_P6M,ET^#_ (/_ .2'#_?_ !W@]W[SXYGNM?%X7\@/0,  \#'[1C_:
M-5O\R&UW_K^2 =#P'ZOVS'\CVU'\VN"_Q7M8&Y0             /.1UO?M
M7^IKU2;K]-7^J5_E'_R85N,TG\-/\O/\$/UY_"/"<:S'WG\'/\C.4?JWX/\
MA%\-I\?4>\]S[S5OC\#0Q/I3_:*?]9SJ-V<Z?_\ 4]_@1_E9SBU8;_"W_6"_
MA+^H/UFZ1OZR_4/^1&P?K7W'@_YGXVF\6OZ: >F,
M
M              \&/[2+_:&6G_=WVU_C)N"!T"@?K+[=_P G^"_X'8S_ 'DH
M0,Q
M  -ENH_=_P#U?>G_ 'IWT_@]_"W_ "0;7YON1_!;];?J'^$7\#<=N%__ %-^
MN_U9>OU3^LO@?=?$_!U7N?%XO=/T\*AYA/\ Q3__ ,@I_P#;._\ WO('<O\
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M@
M                         /'5^U(_R@='7^!V\G]^]O0/*8!^F]\L7^SS
MZ,_]W?;+^+=&!SJ
M              +.XU?ZOM]?7^[]]\%1557[KQ^[][\- ^;W?C\+_!X_!IKH
MNFO)0/)/_P"*?_\ D%/_ +9W_P"]Y [.OE?_ #@O^)%N3N5M[_J\?Y&?\GF#
MT69?K?\ RM?Y1/UQ\9?J6R?JWX#_ "98+^K_ '?Q/O??>_GU\/A\":^) [J@
M 'YK_P X/^TNZN_YRJ;^*6-@<1NF7^LCT^?SW[4?Q\L 'ZK(
M  'EKWO_ &E;_(UO3N]M!_J6_P (_P#)5NAG^V_\(?\ 6,_4_P"OOX#97=L8
M_7/ZI_R$73]5_K3]5^_^&^)J/<>\\'O9/#XU#D=\O7YZO^OCU+X_T[?ZK7^2
MK]>XUEN1?PP_RW?PY^%_@M:9+I\'_!__ "0X?[_X[P>[]Y\<SW6OB\+^0'H&
M
M                       !AVXG\G^=?X'9-_>2N _)H [^OV;K^T,NW^[O
MN5_&3;X#WG
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MO(OU38[%^M;BS(KW0MJ/U1C5LLUBH=*6CC9X*:EAC_#KX=555#F\
M
M                       !^;Q\Z'^T[ZM/\,<4_HQP<#B-TA?ULNE__>(V
M4_I*QH#]4    _+7ZWOZZ/5Y_O0;_?TKY8!R(^3Y_:7=(G\Y53_%+) /TH
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MPZ:<TR6XN5MOQ[$]]=KLBOE<YNGB;1VFSY365]2YNJ:HR-V@')4
M
M      .ES]H!_LQ-X_\ #'9W^D[&@/SV@/;9^S#?U3>H'_>(?_1KA 'I<  >
M;O\ :<OZEVR/^]!8/Z*-V /#V!^@9^SU_P!FCM__ #E;M_QMG [O (V\7JSX
M];:N\W^[6RQV>@8V2NNMXKZ6V6VCC?(R%DE775LL%+3L?-(UB*]Z(KG(G-4
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MX#.0
M         #S1_M//]4WI^_WB&?T:YN!XDP/T)?V?[^S$V<_PQWB_I.R4#NC
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M9VJ*^X?DE@RNR3O='#>,:O%NOMJFD8C'/CBN%KJ*JDD>QLC55$>JHCD[P)\
M          8IF>>8/MQ8ZC)]P\SQ3 \:I?>_%9#F>16C%['3>XHZJX3_ !%V
MOE90T$/N:"AGG?XI$\,,+WK^%CE0-GL+ZP^DC<B],QO;OJEZ<\]R*2)L\=@P
MO>[;/*;T^%]72T#)F6JQY/75SHG5U=!"CDCT669C/TGM10Y&    #C3E/6?T
M>8-=/U)FW5ATTX?>OAXZO]493OKM=C]T^%E?+%%4_J^[9325?P\DD#VM?X/"
MKF.1%U10-S-NMYMGMX*!MUVEW7VUW1MCX9:AEQVZSK%\VH'T]/6S6V>=M9C5
MTN=.Z&&XT\E.]R.\+9F.8JHY%1 W*     #;O.]WMIMK:::LW.W0V[VYI*>W
MONL]5G>:XUB%-!:XI'Q27*:?(+G;XH[?'+&YKIG*D:.:J*NJ ;'P]?70G4S1
M4]/UJ=)=145$L<,$$/4=L[+---*]&1111,S)SY)9'N1&M1%5571 .3MBR"PY
M1;*>]8S>[1D5FJW3-I;M8KE1W>V5+J>:2FJ&T]?;YJBEF=!41.C>C7KX7M5J
MZ*BH!+@  $;>+U9\>MM7>;_=K98[/0,;)776\5]+;+;1QOD9"R2KKJV6"EIV
M/FD:Q%>]$5SD3FJ <8:WKTZ&;;65=NN/6?TGT%PH*F>BKJ&MZBMH*6LHJREE
M?!4TE733YA'/35--/&YDD;VH]CT5%1%0#D-B.=83G]M_7."9CBN;6?6)OZUQ
M'(;1DEM\4]/%50-^.LU76TNLU+,R1B>+\4;VN3@J*!E0 #\M?K>_KH]7G^]!
MO]_2OE@'8Y^SU_VEVW_\VN[?\4IP/T#  '41UI_)=Z7.NO>J7?;=S/=_<=RZ
M7%;#B+K=MSE.W=HQQ+;CJURT4[:3)MK,ON:5TJU[_>N^,6-VC?"QO'4.)?\
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M'HNK)')HJ+V@9$
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M411S03PR,EAFAE8CXI8I6*YDD4C'(K7(JHJ+J@%4
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MZRR0T=3'>,*R>R93:WT]QIVUEOG9<+%75](Z&NI')+"Y'^&6-4<U5;Q S$
M  6U;6T=MHZNXW&KIJ"WT%-/6UU=6SQ4M'14=+$^>IJZNIG?'!34U-!&Y\DC
MW(QC$555$0#C%6]<_1+;KO4X_<.L3I8H+]1W"2U5=DK>H/:6EN]+=(9UI9;;
M4VV?+F5D%PBJ46-T+F)(V1/"J:\ .2]KNMKOENI+O9+E07BTW"%M107.UUE/
M<+=6T[]?!/25M))-35,+M.#F.<U>\"_
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MKI?:.G2.=\,LDDZ>!KFHYS0[4@
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MYN:Y5N!F%WE?+<\GS*_7/([Y6O?++,J3W.[5-55NB;+,]6L\7@9XE\*(@&&
M<_NB?YE?5/T+91::O:W/+I>MM8:YDF1[)99<:RZ[;9!;YJQ]7<X:&T5$D[</
MO5;),^1+I:DIJOWRHLRSQ>.&0/T)^CGJWVKZVMA\4WYVFJIFVB^?$6W(,:N,
MM,[(,&R^V>[9?,1R*&FD>R*X4#Y62PR)HRLHIX*J-/=3, Q7YB>4Y-A/0IU9
MY?AF17W$<LQS8C<2\8]D^,7>X6#(K#=J+'ZN:BNEEO5JJ*2Y6NXTDS4?%/!+
M'+&Y$5KD4#\[W_B ]>7^VUU<_P#JR.\G^.8',K;3YU/6;M7TNYMLE9]V-Q<N
MW2S[<6OOM1OONAFM_P!QLQP3 9<6Q^SLQ+;NMR^XWJJM5QN=WH:FH?5/=[JV
ML<Y])%\75+4TH=3&2Y-DF9WVYY1F&0WS*\FO=2ZMO.19+=J^^WV[UCFM8ZKN
M=WNE157"OJ7,8B+)+(]ZHB)KP M[)?+UC5WMU_QR\72P7ZT5<-?:;W9+A5VJ
M[VNNIW(^"MMURH9H*RBJX'IJR2)[7M7BBH![2/D7_-LSWJ4O,_2-U-W_ /A/
MNK:L=KK]M+N?<%BCONX=EL,:U%^P_+EC;&VZ9CC]G\5=2W%K/>W&VTM2ZL5:
MJG6>L#TV =:?S+/F6;6_+LVMI+U>J2+.-Y,XBKJ?:K:JGKDHY;O+1HUE;E.4
MUK&RRV3";)+*QLLK6.J*VH<VGIVZ^^FI@\%O5AU^]5O6ED5;>-]MUK[>+%-5
MK4VO;6Q555C^UN-L;*R2F@LN$4=2ML=)2^Z8U*RL^+N4ONVK-4RO3Q <-0
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MV/;&ZF90[3VZX;E*M8DS)(74T]5BT4*L<FDKI4C3B] /TK0
M
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M^^A8]7)X9UD;PD [R
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M-G;6*QC'+4P-RQL*M?J^)L:1JOX .P\
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MW)=L/S[>O<G,,6N<EMV@SFYVZ2X8_D.2W&TUKZ"Y4D51 LD+EBGB9(W1S45
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MH@%4
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MRNYJ!N\
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M5URK)7S2L8C8XG*KG(G-4 SS<[IRZA=DZ2AK]YMA]YMHZ&YS)36VMW.VOS?
MJ2X5"ME>D%#4Y58[5#5S*R!Z^&-SG:,<NG!0+GIWZB]W^E?=;&MY=D<OK\/S
M;&JECV34\DDEJOML=+&^OQO*+5[QE+?L:N\<2,J:29%8Y$1[59*R.1@?I$=
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M]E__ *MW4I_/?9/XAVL#L<^=[_9;]5O_ )FVR_IMVT _.0 ]VW[-/_4 S?\
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M/P2*[5>+6@>K0
M                              #\WCYT/]IWU:?X8XI_1C@X'5\
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MMNU%8;[DMI@?+<K!,^)(:Z='0.8KE:Y7,:'EK_:D?Y0.CK_ [>3^_>WH'E,
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M2P*X1VR]MA9=*6?^"=JM$%:VJC@:WQ3LD>QFK6JU'.10Y)
M
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MFMT<DDK:2CA5SW,B265SEU555SE55U4#,P
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M6H@$B
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M',Z2)'*CT;XFM<@<J@
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M5TCW00UV9VK)\9RB5D;I59$^6'!K2BJUB>/P_B7@U .>/[0]_9L9?_.MM/\
MW]G _/\ P/T#/V>O^S1V_P#YRMV_XVS@=W@'YG7S6/[1KK%_GORO_P!?@ W6
M^2%_:D=*7_GG<W^A+<L#]#[<3^3_ #K_  .R;^\E<!^30!SV^6QT47+KVZJL
M0V/_ %E7V'"Z6@N&<[J9+:XXY+E8MN\<GH8;HZUNJ(*JDAO-\NESH[712S1R
MPP55<R62.5D;HW![U\+^5G\O#!<(9@5LZ/\ 8B\6KX&2AFO&:;?V'.LWJ4FM
M\-NGJWY_EU)>,SIZZ2*%)&RT]="L%0YTL/NY'*X#Q6_.BZ#<-Z%.JFCLNT\=
M32;-[NXHW<+ [%6UT]RJ<,J672LL^3X2RXUTT]SN5LM%PIHZFAGJ7/G2AKHH
M)99YH)9Y ZH\4R:[X7E&-YCC]3\'?\3O]GR:QU?A\7PMWL-QI[I;:GPZM\7N
M*VE8[35-= /U@\*R2+,L-Q++X('4T.58S8<DAIG.\3J>*^6JDND<#G:)XG1,
MJD:JZ)KH!^=M\YGJQNO55UV;L3T]W?6[<;-7FOV9VRH8IW2VZ&VX762VW*;[
M2>%4IZA^6YG!75K:AK4=)1.I8E5S86. VU^6-T(77Y@?4W:=HY+M68SMYCEF
MJL[W:RFW-B6ZVO"K964-O6WX^M53U-"N2Y'=[G34=*L['QT[)):IT<S:=T,@
M>\+ /E<?+SVYP^FPJS='NPE[MU/"L3[MG^W.-[DYA5O?2PTDU14YKGE!D.4K
M-*V%'HC*MD<4KG/B:QSE \ROSS?E*[7]+F,VCJLZ9+)48IMK=\JH<4W/VPAJ
M:NX63"[Q?8:E]CR[%*BXU-57V['+Q<J5U'5V]\LD-'6U-.E(D=/)[F //!L[
MNOF6Q>ZFWV\>WMQ=:LUVURVR9CCM7K)[E;A9*Z*L925T44D3JJUW&.-U/5P*
MY&5%++)$[5KU0#]3C9O<ZP[U[2;8;PXNCFX[NG@&(;@V6)\K)I::W9?8*"_4
MM'42,:QJU='%7I%,GA:K96.16HJ*B!N0  Z<?F'_ ";MFOF![P;6[NWS-;YM
M7?,<IGXWNE6X?:;;5WK<G"*5DM18*"FJ[G[VVV+*+%6ROB@ND])<&_ S+%)3
MRI#3I&&]&S?RA?ES;)VBGMEDZ6-L\WJF4\D59?=Y+/#O#=[G-,VC;/65#-PD
MOUGH:B3X%BM;0TE'!"KI/<QQ^]E\81?4-\GKY?74%A=TQF3ISVXVCOLUOEAQ
M_/-C\5LVU>08U<_=5;*.[)18;26?'<D^'?6.5]-=J.MIIVHWQ-\<4+X@_.RW
M:V]N.TFZFYFU-WJX:^[;9;@YGM[<ZZG9[NGK+CA>1W+&ZVK@C][/[N&HJ;:Y
M[6^-^C51/$O,#TE?LPN\]QM6^'43T_U-9,ZR9KME:MU[91ROUI*:_;?9+;<6
MN#J-CG_O5;=K3N!&LWA;^^Q6YGB7]Z:!Z>.O[J>@Z.^D+>[?]OPTE_Q#%'T6
M"TE7&E13UVXF4U=-B^#0U%)JCZR@@R6[T]161MT7X*"9VK4:KD#\QG*,GR#-
MLER#,<LN]=D&4Y7>KID>1WVYS.J+C>;Y>JV:XW6Z5T[N,U775U2^61W:YR@=
MWGR6/E56#KPRS*]V=\/UO#TZ;5W>AL558[35U=HK=U,YGI8[I-B#+]0R0U]F
MQ^Q6F>GJ+O-2R0USVUU-#32Q.DDG@#V(_P##3^7S_!EN)_ZF'37^JV4T=(E5
M_DAPO^$RQ1S-G:]V:?JG^&+ZE7MT=,ZO69S-6.<K55 .H?)_V;;IYK.JO%-Q
M,4S2[6/I;9-/?\VV&K:F[7/(7WB@JJ66UX?BN<5-3-<V;?7YKI$KY*V>6\T<
M4"Q05,KJMM1;P]'F-XWC^'8_9<4Q2RVO&\8QNUT-DQ_'[)0T]LL]EL]LIXZ2
MWVRV6^DCBI:*AHJ6)L<<<;6L8QJ(B =&W49\@#HXWUW0W?W^R[<KJ9MV8[DY
M'E.X=]MN.9EM928S27J\2U-UJ:6TT=SV:N]T@M<=0[PQLFK9Y49P61R\0/ T
M!W$_)O\ E\;,?,,W;W=P+>G)MS\8L^ [=6[+K/4[7WK%++<JFY5>345FD@N<
MV5X7FM+-0MI:ESFMBAAD21$57JGX5#T?8+^SA=#^W^;8=GMFW3ZJZF\81E6/
M9=:J:YYQM%-;:BY8U=Z2\T,%PAI=C:*JEH9:JB:V5L<T4CHU5&O:NCD#T @?
MGA?/N_M2.H3_ ,S;+_T);? <1OEP_P!?_HL_WH-D/Z0[ !^G77T%%=*&MMER
MI:>OMUQI*B@KZ&KB9/2UE%5POIZJEJ8)$='-3U$$CF/8Y%:YJJB\ /S$OF$]
M+M;T==7^]>Q3J6H@QNP9547K;JHG<^7]8;:94B7_  >=*I[G?&5%'8ZZ.BJY
M$5=*ZEG8NCFJB!G/RL.I3_54Z[=@MSKA<?U;AUQRN';K<665_AHFX+N*B8M=
M[A<=$]XZCQBJKZ>\Z,_$LEM9HCOT7!^E^!^?7\_CJ.7?3Y@&7X=:ZUU1B73O
MC]JV?M4<<K7TLF24KILBS^N2-CWMCKHLFO4EKF5='*VTQHJ)H!UO]'O3I?NK
M+J9V:Z?,?2IBEW(S2VVN]7&DA6>6PX?1>\N^;Y(D>BM?_![$K?6UB-<K6O="
MC-4\6H'ZBF)8K8,%Q7&<)Q2VT]EQ;#L?LV*XU9Z1%;2VFP8];J:TV>VTS7*Y
MR4]!;J2.)B*JKX6(!TJ]6OR)^G?JXZMV=262YGE6"XWDEHAEW8V\P2CME#5Y
M_FUM?3T]OR6ER:OCKX,9CNMIB;#>&14$TU:^%LT4M/42S3N#F3MI\JOY=>U-
MECL>.]'^QU\IV4\,#Z[<O"K;N[>IUBFJJA9Y+UNBS+KDRHFFK'J]8Y(T5B,C
M1$BBB8P.,G6]\ECHIZ@-ILVFVVV9PG8;>"TXW=[G@68[162BP.SLOM!;6ST-
MJR7";!^J\)O5BN]1;H8:E\E$RM@8^22GJ(9))72!^>F![1/V8;>>XY'L=U&[
M$7&LFJ*?:[<'$\]QR&H?XTI;9NG:+Q;KI04'B>KV4=+>-O'5+XT1&-GN#GIJ
MZ5P'/;K ^2'TI=:^^V2]0FZFX/4+8,SRFVXU:KA;-O\ *]M[5C$-/BUBH<?M
M[Z.BR/:?*[K'--14#'3*^MD:Z57*U&-T:@>"GJ+V\LNT74'OMM1C=5=*['=L
M-Y-S]O+!6WR>DJ;U5V7"LVOF-VJJO%3045MH:BZ5%#;8WU#X::GB?*KE9&QJ
MHU Y8_*RZ1=MNM_J]Q?8'=>]YOC^'7O$<YO]5<MO+E8;3DT=9C-CEN=!%3UF
M28UEEK9333L1)FNHGO<S@US%X@>HC_PRG0;_ )VNKG_MYLW_ *! /0-9;;:,
M#P^TV=M:^&PX9C5!;4N-VG@22*T8[:XJ5*VY5,<5+3(]E'1^\FD:R./5%5&M
M3@@?F3=?O5AD76EU6[K;[7BMJYK%>+[56+;6UU*RM9C>UN/U531X198*:1D7
MPLCK8OQE8C61^]N574S*U'RN W(^65T"9%\PKJ-H]K(KM68IMOBMI=FF[V:T
M$4$MQLF(TU93T,-KQYE9'+0297E%SJ8Z2B29LD=/'[^K?%/'2OAD#W<[??*R
M^7CMOAE/@]GZ0=BK];X:9:>:\[@[?X_N1F=8^2F933U=1FN<T5^RB.IF\/O$
M]Q50QPRN5T+(^&@>:;YWOR?]O.F?$F]6G2U9*G&]KUO]!9MV]KHJFON5JP6M
MR.L=36;-<4JKC45=9;\4N5\GBM]5;GR/CH*NKIOA$;3/=#3!YE:2KJJ"JIJZ
MAJ:BBK:*HAJZ.LI)I*>JI*JGD;-3U--40N9+!402L1S'M5'-<B*BHJ ?I6?*
MJZL*_K)Z(MHMV,DK&UNX=JI*S;C=&HX>\JL[P5\5LK;S4^%58VKRRS/H;S*U
MJ-8Q]Q5K6M:U$0//]^U(_P H'1U_@=O)_?O;T#RF >N/Y-?R4]GMR-G,6ZK^
MKO&Y<\_RB4\MXVIVCKJVLH<6H<0]]+3VW,\QBM=32UE_N.2)"M1;Z%\R4$-O
M?'+/'/+,C*4/1"[Y>G0A_P"RU]+T<=,UIJ[/<;5=K7=,?V4V]QN^45QLE9!7
MVVK@O]@L%MO398:NF8]W_2-)M-)$>BJBAS$
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M-13T]93STE7!#54M5#+3U--41,GIZBGG8Z*:">&5KHYH9HW*US7(K7-545-
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MM\-/14%'3QHC61Q,:QJ<D G
M                                          'YO'SH?[3OJT_PQQ3^
MC'!P.">Q.#6G<_>_9O;6_P!1<:2Q;A[J[>8->JNSS4U/=J6TY;EUHL%QJ+7/
M6TEPHX+C!1W![H'RP3Q-E1JNC>U%:H>TC_PRG0;_ )VNKG_MYLW_ *! '_AE
M.@W_ #M=7/\ V\V;_P! @#_PRG0;_G:ZN?\ MYLW_H$ \8W47MY9=HNH/?;:
MC&ZJZ5V.[8;R;G[>6"MOD])4WJKLN%9M?,;M55>*F@HK;0U%TJ*&VQOJ'PTU
M/$^57*R-C51J!S$^3Y_:7=(G\Y53_%+) /TH /*!\TSY^V1;=YOE73OT/U%F
M9>L0N5PQS/M_[G;Z'(::FR"WR3T-UL.U]BN=/4V.M_4U?&L4U[KHJREGE9(V
MDIW1)'62!Y:-V>ISJ+WXJ[A6;S;Y;K[FNN<S9JJDS//,DOMI;[JLGN%-3T5C
MK;C)9K;;Z&LJ9)*:FIH(J>F5R^Z8Q. &QH%:HJ*BLJ)ZNKGFJJJJFEJ*FIJ)
M7SU%143O=+-//-*YTDTTTCE<YSE5SG*JJNH'?I^S=?VAEV_W=]ROXR;? >N3
MYG7]GGUF?[N^YO\ %NL _,A ]H_[+Y_5^ZGOYX\6_B3&!Z@0/R-P/2Y^S#?U
MLNH'_=W?_25A 'ML Z7/V@'^S$WC_P ,=G?Z3L: _/:   /T;_DA?V6_2E_Y
MFW-_IMW+ Z0_VI'^4#HZ_P #MY/[][>@>4P#]7+8C^0_9K^:G;O^*%G \#'S
M[O[4CJ$_\S;+_P!"6WP'$;Y</]?_ *+/]Z#9#^D.P ?I[ >1O]J?_P#K%/\
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ME1%T1'T]RM<4C5_<N:B]@'Z80
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MTB_VAEI_W=]M?XR;@@=-'3M_6!V+_GCVQ_CM9 /U90/(W^U/_P#UBG_V3O\
M]SR!Y&P/U0.D+^J;TO\ ^[OLI_1KC0'(@#\WCYT/]IWU:?X8XI_1C@X'5\
M[B_D(_VI'3W_ .9MZ/Z$MP0/T#-Q/Y/\Z_P.R;^\E<!^30!ZCOV7C^7#JH_F
MIP?^-]<!WP_.]_LM^JW_ ,S;9?TV[: ?G( >[;]FG_J 9O\ [T&X?]'FT('H
M2 _(W ]+G[,-_6RZ@?\ =W?_ $E80![; /R\>O\ OUPR;KHZQ;S<Y72U4_4Y
MOC3)XG.?[JCMNY&1VRVTK'.57+%16ZCBA9W-8@&T&RF_&[W3GF\>Y&R&>7K;
MC.8;7<++%DM@6D;<8[7=4A2XT;'5E-5Q-BJVP,1ZHWQ:)IKHJ@<P?^+K\R?_
M &OMUO\ WHL7_H(!BN<_,^Z^]RL-RC;[.^J'<C)\+S6Q7/&<IQVY365]OO=A
MO-)+0W.V5C8K1%*M/64DSF.\+FN1%X*B\0.!H'O$_9LLDJ+[\OC);7-XO=X;
MU);CXW2:HB)\/58;MCE[O"J.<KF_%97+Q5$775--$15#T"  /R\>O^_7#)NN
MCK%O-SE=+53]3F^-,GB<Y_NJ.V[D9';+;2L<Y5<L5%;J.*%G<UB ;0;*;\;O
M=.>;Q[D;(9Y>MN,YAM=PLL62V!:1MQCM=U2%+C1L=64U7$V*K; Q'JC?%HFF
MNBJ!S!_XNOS)_P#:^W6_]Z+%_P"@@&*YS\S[K[W*PW*-OL[ZH=R,GPO-;%<\
M9RG';E-97V^]V&\TDM#<[96-BM$4JT]923.8[PN:Y$7@J+Q X&@>\3]FRR2H
MOOR^,EM<WB]WAO4EN/C=)JB(GP]5ANV.7N\*HYRN;\5E<O%41==4TT1%4/0&
MYK7M<Q[6N8YJM<UR(YKFN31S7-75%:J+Q0#\]+YXW1KM=T?]7[H]H;Q8*7$=
MZ+!4;I1[7V^J9^M-KKC<+S64=UMWZLBA9#;<+OESAFJ+$Q')[J-E12M8V*EB
M=('3*!ZXOV9K8KI^NL6\'4%59)0Y%U(XK<5P:WX551)%4[:[=WNWTE1_#.VQ
M2JJW"KSZN;56]]9&G_0J>WR4Z*WXJ5'AZY@ 'A)_:6/Z_P#A'^Z_MY_2'N\!
MT;[,?RP[4?SE8+_&BU@?J_  /R\>O^_7#)NNCK%O-SE=+53]3F^-,GB<Y_NJ
M.V[D9';+;2L<Y5<L5%;J.*%G<UB ;0;*;\;O=.>;Q[D;(9Y>MN,YAM=PLL62
MV!:1MQCM=U2%+C1L=64U7$V*K; Q'JC?%HFFNBJ!S!_XNOS)_P#:^W6_]Z+%
M_P"@@&*YS\S[K[W*PW*-OL[ZH=R,GPO-;%<\9RG';E-97V^]V&\TDM#<[96-
MBM$4JT]923.8[PN:Y$7@J+Q X&@>\3]FRR2HOOR^,EM<WB]WAO4EN/C=)JB(
MGP]5ANV.7N\*HYRN;\5E<O%41==4TT1%4.C7]I%_M#+3_N[[:_QDW! Z7]@Z
M.EN.^NRUOKH65-%7[M;<T=93R(JQU%+59C9H*B&1$5%5DL3U:OF4#]6X#K\^
M:Q_9R]8O\R&5_P#KD 'YG0'M'_9?/ZOW4]_/'BW\28P.NG]IGR.XU_7!M1C4
MLKTM..],N*UE%3*_Q1I<;_N5NFZYUK6^%ONWU--;*2)R:NU2G1=>.B!YX[#:
MI+]?+-8XI64\MYNUNM44\C7.CADN-9#1LED:W\3F1NF151.*H@'ZRF*8S:,+
MQ?&\.Q^F^#L&)V"SXS8Z3Q>+X6T6&W4]KMM-XM&^+W%%2L;KHFN@$^!^6OUO
M?UT>KS_>@W^_I7RP#L<_9Z_[2[;_ /FUW;_BE.!WQ?M,=^N%MZ%]K[-22NBI
M<DZG,/IKKX7.3XBCMNV^ZUSAI7M1?"Z);C3P3<>3H6@>&$#G3MY\S+KRVFPC
M&=M]N.IO<7$<&PZUP67&,:M,MFCMUFM=.KEAHZ1LMHEE2)CGJNKG.<JJJJJJ
M!F?_ !=?F3_[7VZW_O18O_00#B/OEU";T=2V94VX.^VX5]W,S2DL5%C-/D61
M.I'7"*PVZKN%=0VQ'45+21+3TU7=:A[=6J[65>.FB(&_GRT<DJ,4^8/T872F
M\7O*KJ2VCQMWA1'+\/F696K$*O@YS4\/PM]?JNNJ)Q1%7@H>T7]H!_LQ-X_\
M,=G?Z3L: _/: ]]7[.A9J&U_+DMU=21,CGR/>S=&\W-[6(UU170+C^/1RR*G
M&1[;;8:>/5?W+$3L [W@
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M)+&S=ZV536N5R(E10VRZUM)+^%476&JIV/3LU;QU3@!^EH!T"_M(O]GG:?\
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MWY774Q-:YGTT]U9M7C\\\;WQO2VWO>7;ZANL**Q45S*ZVR2T[VKP='*Y%UY
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MA@GVRDO,C(V(QKJ[(\IR+(;G*J)JBOJ+E=)9'+^Z<Y5[0.R4
M
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MS/='&+%?8\FM%FR62V24M!?HK?7VJ.YT_P ';J25M0VWW.>+BY6JV1=4UT5
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M)!.Y%1>:*!^KV
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M6R)E/;;#LGM59K?!&Q(XX:&UX+8:&DBC8FJ,9'! U$1.2(!O8
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M7$#]9?;O^3_!?\#L9_O)0@?G"?-U_M)^K[^=:H_O%9 +SY/G]I=TB?SE5/\
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MVB\Y;<,/VPH;O:Y7QMIZ^TR[H9+AWZSI*QDS9*=\"2-J(5]['XH]7 85U/\
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M/[+U#$[??JDJ%8U9HMI,,ACD_=,BGS&H?,Q.SPR/IF*O_K* >S\
M
M           _-X^=#_:=]6G^&.*?T8X.!Q&Z0OZV72__ +Q&RG])6- ?J@
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M5QBN2;;;X;/;#VF6\8GD6*;F;:9Q8M\M\,JLS;WC5VH<DQ3([8M3NS>,;O\
M1T]SH()V-ECJJ.H:WPO9)&Y6J&]_S.O[//K,_P!W?<W^+=8!^9"![1_V7S^K
M]U/?SQXM_$F,#U @>!C]HQ_M&JW^9#:[_P!?R0#J!Z=OZP.Q?\\>V/\ ':R
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MX8XI_1C@X&-?**_M)^D'^=:G_O%>P/TK
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MD>(71R-E9%\;#3MFHZE8Y%H;A#!4M8Y8O"X/TM-A=\MN>I/:# ][]J+W%?\
M!-PK%37NSU;? VJI'N5T%RLEWIF/D6@OM@N<,U%74SE5T%5!(Q57350W> \*
M7[2]1U4'7QMY530O93U_2Y@,E),J(L<[8-RMX:>9&N151'Q2L5'-71R(J+IH
MYJJ'0_M=<Z&R;F[=7FYU#*6VVC.\1N=PJI%1L=-0T&06^KJZB1RJB(R&")SE
M5>Q /UC&N:]K7L<US'-1S7-5'-<UR:M<UR:HK51>"@?0/S7/F\[0W/9GYC/5
M/8Z^@?1TF8;E77=JQ2\%I[A:-V%;GGQ=&]K6M=##=+W54ST1/WN>GDCXJS4#
M#/EJ6?I4RGK"VOP?K+QVDR#9#/I;GA=;+<<KRK"[9C^6WRC=#A%]NM_P_(L7
MNE#:VY&R"DJ)):ME'3Q5CIY_WN)7-#VR?\"7Y5/^RQ_ZF_J._P!+P#_@2_*I
M_P!EC_U-_4=_I> AI_DC_*)I;[;L7JNG:S4V37BWW*ZVC'9^H/J AOMTM=GE
MH8+O<K=:)-Y6W"NM]JFN=,RIFBC=' ZHB1ZM61NH=@'3)TF]/_1S@=WVRZ<,
M!_R<X/?<NK\[NMD_A5FN7_%97<[-8,?KKK^LL[R/*+O![^T8Q0P^XCJ&4S?<
M>-L:/?(YX>+S]I%_M#+3_N[[:_QDW! Z:.G;^L#L7_/'MC_':R ?JR@=?GS6
M/[.7K%_F0RO_ -<@ _,Z ]H_[+Y_5^ZGOYX\6_B3&!PJ_:>]M;C;.I/IVW>2
MCF;9LSV3K]O4KFP:4K[SMWG%^R"IBDG;P6L6W;E4_!^CEBC3PZHU?"'F5I*J
MHH:JFK:25T-51U$-533-1JNBJ*>1LL,K4<CFJZ.1B*FJ*G #]4CI?WUQKJ9Z
M>]H-^,3K*:KM6YF"6'))XZ54TM5]GHV0Y1CU2Q))DAK\:R2"KH*AB/>C)Z9Z
M(YR(CE#=7,<NQS ,2R?.LPNU)8<2PS'[SE63WROD]U16BP8_;ZBZW>YU<G'P
M4]#04LDCUY^%H'Y4F\^?NW7WAW7W2=!-3.W*W*SK/W4U3[OXBG=F.473(E@G
M]R^2+WT2W'PN\+G-\2+HJH!VY?L]?]I=M_\ S:[M_P 4IP/2;^T'[0W/=+Y<
MV57RST#[A5[+[E8'NU/%#HM1':*5+U@=[JV,\*NDAM]KSV2IG1%3PP0/D7@S
M0#\_8#V._*3^7U\JGK<Z/<*SC*MB:3*-[\,EJ\+WRB_RQ[XV6YP9;25E7-:K
M[46#']T;3:Z&UY=CBT]72R4M)!1OE2H@C_?*:9K [.?^!+\JG_98_P#4W]1W
M^EX#1)\BGY4L,<DTW2XR**)CI)99-\NHQD<<;&JY\DCW;OHUC&-15555$1$
MG-HOD_?*XQ7)-MM\-GMA[3+>,3R+%-S-M,XL6^6^&569M[QJ[4.28ID=L6IW
M9O&-W^CI[G003L;+'54=0UOA>R2-RM4-M?V@'^S$WC_PQV=_I.QH#\]H#] #
M]GA_LV,0_G6W8_O[ !WD
M                            !YH_VGG^J;T_?[Q#/Z-<W \28'Z$O[/]
M_9B;.?X8[Q?TG9*!Q&_:>?ZIO3]_O$,_HUS<#Q)@?I<_*9_LW^CW^9RR_P#7
M+B!V'@?DT;B?R@9U_ACDW]^ZX#TB?LO_ /61ZE/YD+)_'RU@>U,#QB_M0_\
M+ATK_P U.<?QOH0/+B!^LOMW_)_@O^!V,_WDH0/SJ?G0_P!IWU:?X8XI_1C@
MX&-?**_M)^D'^=:G_O%>P/TK .@7]I%_L\[3_O$;:_Q;W! \&('Z4'R?/[-'
MI$_FUJ?XVY(!V4 ?E-=1/]8'?3^>/<[^.U[ [E_V;K^T,NW^[ON5_&3;X#UC
M_-=IIJOY<?6)% QSWLV4R6I<UK7N5(:)U)65#]&-<J-CIX'.5=-$1-55$15
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M*5JJBHJ ;P_M//\ 5-Z?O]XAG]&N;@>),#]+GY3/]F_T>_S.67_KEQ [#P
M
M                  !X,?VD7^T,M/\ N[[:_P 9-P0.@4#]9?;O^3_!?\#L
M9_O)0@>&+]I%_M#+3_N[[:_QDW! Z:.G;^L#L7_/'MC_ !VL@'ZLH'5]\Z'^
MS$ZM/\#L4_I.P<#\W@#WS_LYW]G+1?SW[H_^N8V!WP@?FI_-U_M)^K[^=:H_
MO%9 ,E^2]_:=])?^&.5_T8YP!^BMN)_)_G7^!V3?WDK@/R: /4=^R\?RX=5'
M\U.#_P ;ZX#V= >)/]IY_K9=/W^[NS^DK-P//;LQ_+#M1_.5@O\ &BU@?J_
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M\NVG5Y8V5,3KK0YSM1=JFC\3??16^Z6#,J.AJ59KXO=3U-GJ&(NFFL:@>JL
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MNDK7< /+Y^TB_P!H9:?]W?;7^,FX('31T[?U@=B_YX]L?X[60#]64
M
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M5RV(_D/V:_FIV[_BA9P-U@
M                                ,.W$_D_SK_ [)O[R5P'Y- '?U^S=
M?VAEV_W=]ROXR;? >YW<3^3_ #K_  .R;^\E<!^30!ZCOV7C^7#JH_FIP?\
MC?7 >SH#Q)_M//\ 6RZ?O]W=G])6;@>>W9C^6':C^<K!?XT6L#]7X#KP^;-_
M9O\ 6%_,Y>O^N6X#\T8#VV?LPW]4WJ!_WB'_ -&N$ /VGG^J;T_?[Q#/Z-<W
M \28'Z7/RF?[-_H]_F<LO_7+B!V'@?DT;B?R@9U_ACDW]^ZX#TB?LO\ _61Z
ME/YD+)_'RU@>U,#QB_M0_P#+ATK_ ,U.<?QOH0/+B!^LOMW_ "?X+_@=C/\
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MU.#_ ,;ZX#V=
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M]M>38MD=HG6FN=DOUEK(;A:[G13(BHRHI*R!CVZHK5TT<BHJHH?H_P#RP/F
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M_P#>*]@?I6
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M_LQ-X_\ #'9W^D[&@/SV@/T /V>'^S8Q#^=;=C^_L '>0
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MO\6]P0/!B!^E!\GS^S1Z1/YM:G^-N2 =E 'Y3743_6!WT_GCW._CM>P.Y?\
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M-X_4/C]W ]<GS2HM]+)"^1CGT'Q4C4?[IS%#]' #AU\P79&_=1W15U)[,8I
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MZ7/RF?[-_H]_F<LO_7+B!V'@
M                                            #P8_M(O]H9:?]W?;
M7^,FX('0*!^LOMW_ "?X+_@=C/\ >2A \,7[2+_:&6G_ '=]M?XR;@@=-'3M
M_6!V+_GCVQ_CM9 /U90.K[YT/]F)U:?X'8I_2=@X'YO 'OG_ &<[^SEHOY[]
MT?\ US&P.^$#\U/YNO\ :3]7W\ZU1_>*R 9+\E[^T[Z2_P##'*_Z,<X _16W
M$_D_SK_ [)O[R5P'Y- 'J._9>/Y<.JC^:G!_XWUP'LZ \2?[3S_6RZ?O]W=G
M])6;@>>W9C^6':C^<K!?XT6L#]7X#KP^;-_9O]87\SEZ_P"N6X#\T8#VV?LP
MW]4WJ!_WB'_T:X0!S^^=)TL9!U7]!6X^,X1:);]N%MC=+/O1@]EI:5U5<;Q7
MX5!<Z;(;1:8HWMGFN]QP:^76.C@C;+)55:Q0,8KI&J@?G*@=BG0]\T?JQZ 8
M+[8]E;_C%\V_R2XOOEXVNW+LE9DF#2Y&ZCBMZY'016F\8WDMBN\E%3Q1SNM]
MRI8JUL$*53)_<0^[#*>M+YN?65UVXW3[?;H7_%,.VT6MHJZMVSVCL5TQG&,A
MN="L3J"HR*:]7_*\JO[*6KC2>*DJ+E)0LJO#,V!)(XG1AUEUM%66VLJ[=<:2
MIH+A05,]%74-;!+2UE%64LKX*FDJZ:=D<]-4TT\;F21O:CV/145$5 /03^S3
M_P!?_-_]U_</^D/:$#UF?,Z_L\^LS_=WW-_BW6 ?F0@>T?\ 9?/ZOW4]_/'B
MW\28P/4"!X&/VC'^T:K?YD-KO_7\D Z@>G;^L#L7_/'MC_':R ?JR@>'3Y^'
MRU\FV7WDR3K&VIQRJN6R>\5Y=>]S66FDDG3;7=:\U$C[Y<;O#3QO6EQ?<"X/
M^.BKGK[MEXJ:BGD]W[RD28//+A^897M]E%AS?!LCO6(9ABUTI+WC>3XY<JNT
M7RQW>@E;-1W&UW.AEAJZ.KIY&HK7L<B]G)5 [Q]M_P!HV^8=@>.TMAOT&P^[
M=52PP0,R?<C;O((<BE93M<Q'54FV^=[=6>IFE:K?>2/HUD>K$<KO$KE<&V.^
MOS[?F,[W6BZX_1;BXKLA9KS$M/6P;%8M+B=WCIG4<-+)%:LTR"\9?GU@E?-$
MZH^(H+K35;)I'(R5L7AC:&-_)_\ F"97T<=6UOGRBOR+)=I^H.^6C#=Y;5"R
MOO\ >*J[7:ZSQ8ON/2TL3*V[WG)<6OM[FDF9$V>JKZ"LK(8XY*F2!6A^B@
MZB/GC[#93OY\NS=FWX7;Y;ODFV5TQK>2EM%/!+45EQM>#U-2F6,HHX55[JNA
MPZZW"L8Q&R.F^&6)K?$]JH'YUP':/T3_ #?^L3H2PRJVSVNN>"9MMD^OK+K:
M< W:QV[9%8L7N5SEFJ+M4XS68WDN'Y):X;M63?$3TB5[Z%:GQ3-A;+-4/E"W
MZROF^=:?6]CD^!;EY=C>$[7ULM'/=-L-H[)78GB=\GH?AI*=<AJKM>\FR_(*
M1E;2MJDHZRZ3T+:K21L+71Q>[#K  ]6?[+=_*!UB_P"!VS?]^]P@/51U(;"8
M-U0;&[F;";CTRSXEN9C%98*Z>*.*6LM%;XHZVQY';&S(L27?&;[24UPI%=^%
M*BF9KJFJ ?FC=8'2-N]T4[VY/LGN_9:BDK[35U-1BV40TLT>.;A8BZJFBL^9
MXK5O5\=5:[K!&BOB\:ST-0DE-4-9/%(QH0?3-U4[[](&Y='NOL!GMQP?*H:?
M]772.*."X6'*;%)/#45..Y9C]?'/:[]9:J6!CO=S1J^"5C)H'Q3QQRL#MTRO
M]I%^89D6,26"SVGIWP.ZOIE@;FV*;:Y)69/#*M#/2)6QTF<[@YGABU*5$S:K
M1]H=#[^)J>[]RKXGAU>;4]<O4[M'U,4O5O9MT\DR#>M]QDJ<ER+,;C6Y#'G-
MGK'4[;IB&7T]34M6Y8E<:.EC@2C8Z%E&R&%U&M/)3T\D0?HG]"O6-A?73TYX
MCO\ 898KYBR7::ML.4XO?*2L:['LRL:Q0W^U6R\RT=)0939HII6OI;A2>*.6
M*1&2M@JF3TT(<F\VQ*T9]AN6X+D$3IK#FF,7[$KW"WP^*6T9':JNSW*)OC:]
MGBDHZQZ)JBIQXHH'Y8/4%L?F_3;O5N5L9N+034&6[:97=,9N*RT\E-%<Z>DF
M5UIR"W,D5SI+-DMHD@N%%(CG-EI*F-Z*J+J!NST9]<&_O0AN=4[H;#7RTT]9
M=[9'9,MQ/*K;+?,)S:R0U<=?!;,DM-/6VRO_ .BUD2/@JJ*KHKA3^*1L50QD
MTS9 YS[Y?/R^8CO5)C+;?F^&['V_&[Y9<A?:]C<=O&,QY'<;#<HKI10Y-=LH
MR?-,GN%CJ)8DBK;7'7P6NY4RNAJZ>:-SFJ'M,^7[UJ81UX=->&[W8PM#;,F=
M$F.[J8335"S38)N/:X(?U[95;))+4.M%<DL=?:II'*^>V54#I/#,DL; _/B^
M8]_7_P"M/_>@WO\ Z0[^!RY^0C_:D=/?_F;>C^A+<$#]#T !^>!\\;I+;TN]
M=><W3'[6VW[;[_Q2[T88VFIT@MU#<\AKZF+<''Z;P2/AC=;<TBJ:J.GC;$RF
MH;A2L:Q&(U5#IV ]97[,WTENK;UN[UFY3;%2FLL3]F=II:F"H:DMTKX:.\[D
MY!2.D]U"Y*"VOMMM@FC29KUJZZ)58Z)4<'K^ \Y_[2=L-E.Y'2+MSN_C%OEN
MD&P>Y$]=F$%/!++46_"]P+;!8*N__O:N_P"B6[);?:HIT\"^&.J657-9$_4/
M#.!W&=*'SS.N+I)VMLFS>,U&UNZ6"8G2,M>%T.\F+9'?;CA]CA2-*3'K->L/
MS3!;I466W(QS:6&OEK?A(7)#"K((X8HPXV]9_P R_JUZ[YZ*CWQSFCAP>TW.
M2\6/:O!;8[%]N[3<G_$,AKEM:U=QNU^KZ&FJ7P4U3=ZZXU5/"Y[8Y&^\E5X<
M!0/;9^S#?U3>H'_>(?\ T:X0!Z7 /S+/F9],>0=)O6MOGME=+944.-W+,[UG
M^V=:^G=#1WC;7.;I6WW%Y[?+I[JK;9XJB2U53X]&MK[?.S1JM\*!L#TV]2>[
M_29NYCF]NQ^3NQ;.\;2LIHIYJ2GN5IN]HN<*TUVQ_(+15M?27:RW2G722)Z(
MYDC631/CGBBE8':)OU^T#?,*WQPNJPBVWS;;8>DN,4U/=<@V%QS*L6S2MI)O
M!^\4N797G.<7K&98W,U956:6VUK=53WVBZ >JGY0?S#;=UZ]-U%+E=PH8NH/
M:6*VXGO%9HW10SWE_P .Z/'=S:&D8NC;7G%+22.J$8UC*:[T]7"UC8$IW2!Y
M9OG4?+$R/HYWFOF]>V.-33]+N[>15-TLM3:J=TE%M5F-YEEKKEMY>60QHRUV
M>>L=+-8)7:124:_"(YTU,Y9 Z;ML]SMP=FL[QG<[:S+KY@F?8=<XKMC>4X[6
MOH;G;*R-'1O1KV^**IHZRGD?!54TS9*:KII)(9XY(I'L<'>#;OVD;YA=#B$.
M-5-GZ=KQ>8J3X9^X-QVVR:++ZB;WGC^/FHK1N':\";5^'\'ACLC(/#_Y/Q?B
M Z6=ZM\-V.HK<:_[M;V9S>MP]P\FEB?=\CO;Z=LKXJ>-(:2@H*"@IZ.TV6T4
M$*)'345%3T]'31IX8HV-X =C?RD/EK9?UY;Z6F]Y-8KC1=,VV5]M]RW:RV:*
M6DH,DFHU9<:7:W'*MS6)<;[D:,C;<%IW*MJM<RSR.9++1LJ _10I*2EH*6FH
M:&FIZ*BHJ>&DHZ.DACIZ6DI:>-L-/34U/"UD4%/!$Q&L8U$:UJ(B(B(!X.?V
MD7^T,M/^[OMK_&3<$#IHZ=OZP.Q?\\>V/\=K(!^K*
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MU115M%434E91U<,E/54E53R.AJ*:IIYFLE@J()6*U['(CFN145$5 .?/0_\
M,QZIOE_U.10;'7[&[EAN75<-TR/;3<.RU618+<KY3Q04L.0Q4MMNN/W^SWK]
M7T[::6:@N%+\5 V-M0DON*=8@Y"=4_SRNO'JKP:Y;:WK(\$VAP?(+9)9\LLF
MQ^.WO%Y\LMM1\0RLH;QD63Y5FN60T%QIJCW%5345?1TM53M]W-&]CY4D#IZ
M[^OV;K^T,NW^[ON5_&3;X#W5YCB..9_B63X+F%II+]B69X_><5R>QU\?O:*[
MV#(+?46J[VRKCX>.GKJ"JDC>G/PN _-K^9+\OC<GY?V^]XPF]45TO.T>2UU;
M=-F-S7TCOU9EF,.<V=MHKJN+Q4]+F>+-G;27.D=[N17L;4QL^%J('N#AWL]O
M-NET_P"XF.;L;,YO?-O=P\4J7U5CR:P3QQU=/[Z)]/5TE535,51;[K:;C2R/
MAJZ*KAGHZN![HIHI(W.:H=W"_M)OS!UQAEA3&NFQMU;3PPNS5-N,R_A/))'4
M,F?5OI';G.PU*BHC:L3T;:&Q)&Y5:QK]'H'4[DW6MU4YEU!V+JHRC>[-;SOS
MC%VI;OC>>3U=+!+CSZ1TSH[58+!14E+B]CQ>5E5/'+9Z2BAM4T-3-')3N9-*
MUX>^SY5_S$+5\PW8&7,:_'*O%-U]NJNV8GNY:*>VW%F)5&1U%N2KI<APZ\SQ
MRT4UHR*")\_ZN=425]JD18IT?$M-550=G('YEGS,^F/(.DWK6WSVRNELJ*'&
M[EF=ZS_;.M?3NAH[QMKG-TK;[B\]OET]U5ML\51):JI\>C6U]OG9HU6^% V!
MZ;>I/=_I,W<QS>W8_)W8MG>-I64T4\U)3W*TW>T7.%::[8_D%HJVOI+M9;I3
MKI)$]$<R1K)HGQSQ12L#M$WZ_:!OF%;XX7581;;YMML/27&*:GNN0;"XYE6+
M9I6TDW@_>*7+LKSG.+UC,L;F:LJK-+;:UNJI[[1= /53\H/YAMNZ]>FZBERN
MX4,74'M+%;<3WBLT;HH9[R_X=T>.[FT-(Q=&VO.*6DD=4(QK&4UWIZN%K&P)
M3ND#R3?/N_M2.H3_ ,S;+_T);? <1OEP_P!?_HL_WH-D/Z0[ !^GL  \//[2
M#TEMVMZEL.ZH,8M;:;$^HBR_JO+WTE.D=+2;K8'0T-OJ:J=8Y/<P2Y7ASJ"9
MC4C8L]505L[G/>^14#S>@>A']G7Z2W;T]7%VZ@<DMBSX+TS66.[VN6H@J%I;
MANOET=;:L/I8G_O5-,['[/#<KI(J/>^GJH:)5CTE:]H>[<#J(^>/L-E._GR[
M-V;?A=OEN^2;973&MY*6T4\$M167&UX/4U*98RBCA57NJZ'#KK<*QC$;(Z;X
M98FM\3VJ@?G7 =H_1/\ -_ZQ.A+#*K;/:ZYX)FVV3Z^LNMIP#=K';MD5BQ>Y
M7.6:HNU3C-9C>2X?DEKANU9-\1/2)7OH5J?%,V%LLU0^4+?K*^;YUI];V.3X
M%N7EV-X3M?6RT<]TVPVCLE=B>)WR>A^&DIUR&JNU[R;+\@I&5M*VJ2CK+I/0
MMJM)&PM='%[L.L #U9_LMW\H'6+_ (';-_W[W" ]BH'Y\OSZ^F/(-A^O;.]P
M4ME1'M[U'14VZ6'WAM.YM#+?WT5!;-QK&^K:GN9;O097!)7RQHB/9276E<Y%
M5_B<'4;M?N=G>S&X>'[K;8Y'78CG^!7VAR3%<BMWN75-LNM!)XXI'0544]'6
MTD[%=%44U1'+355/(^*9CXGO8H=T6X'[17\Q#.,"FPFV2[)[;7*IH(K?5[B[
M?[?WR#/9F)2+25E3#-EN;9?BELK[AXEE=/16FFDIYE\5,L'A:B!WR?(D^9;6
M]6.T];T[[V994WKJ)V:MD=3;LBR*Z5%QR+=S;'WS*>FR6ON5PJ)ZZ]9=A]9/
M'07B:5SIJF":CJWOFGEJWL#K!^?U\L3(\'W!R/KFV3QJ:Y[:YW4LN6_5DL].
MZ:HP//*E[8*G<.2C@C5[<4S:9627&H_$E)>7R2RN1E8Q(P\Q]DOEZQF\VK(\
M;O%TQ_(;#<:.\6.^V2X5=IO-FNUNJ(ZNWW2U72@FIZZW7&@JXF2PSPO9+%(U
M'-<BHB@=Z>WW[1G\P[",,I\3O$6Q6YUPI:9:6'.]P=O<@_AFK$IF4T$E0_!L
M[PC%ZVIIO![Q)9[7))+*JK,LNJH!U3]4/5KOYUC[D3[I=06>UV:Y&VG?;K+1
MI3TMJQO$K&M3)4PX_B>.VZ*GMMFM<#Y-7*UCJBI>GO:F6>=SY7!NQ\O[H1W4
MZ^M]K+M?@U!7V_"K74VZZ[N;D_".=9=O<+?5HRKJI*J5GP=3E%WACEAL]N\2
MS5M2USE:VF@JIX0_2JVTVZQ#:';S"=K< M$-APG;W%[)A^+6B#16T5DL%O@M
MM!'))HCJBI=!3HZ:9^LD\KG2/57.55#R0_M2/\H'1U_@=O)_?O;T#RF ?JY;
M$?R'[-?S4[=_Q0LX&ZP
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MEX_EPZJ/YJ<'_C?7 >SH
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MU9![U\CZBJI:RH57*'25=/V8[K5AO%3!9=Z^ERX6!E2C*.YW3(]V+/>)Z/\
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MV,WBW5,=;9LIQ.Z5U!<Z:UY%9:V))(9)*>>"1BOAGBFIY9H9 Z5?_#*=!O\
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M\:K*YE)54:17BCLVSE@NE12>ZJW*K8:RG?XD3\6FJ*'>
M
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M<L=72P56+8GAMN;:XZ3&*=T;'4CI4D?(KI'-5K6!S' \ZG_AE.@W_.UU<_\
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M2M;J2*5B)$UM&U[6_I.<O$#E6
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M5QQJSW66."":HH[KN'>IX\BFM$M8Z2%\=#;+9620,21E5!))X(@YY]07[/\
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M5$S:.HJ\SW@HJJ>E;(Y*>:IHX=CZ^*DJ)8D1SXFSS-C<JM21Z)XE#F5L+^S
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MTL<UXK+/:+#:ZBL<Z=?$Z"CIV*B)HQ -Y@
M                                                      !U)=;7
MR9^F#KSWEI]\-W\[WZQS+*;#+'@T=OVVRC;VSXZMIL%=>:^CJ'TF3[79A<EN
M,DU[E25Z5:1*UK/#&U457!Q!_P##*=!O^=KJY_[>;-_Z! /0S9K53V.SVFR4
MCYI*6SVVAM5-)4.8^HDI[?2Q4D+YWQ1PQNF='"BN5K&M5VNB(G #JDZVODS]
M,'7GO+3[X;OYWOUCF64V&6/!H[?MME&WMGQU;38*Z\U]'4/I,GVNS"Y+<9)K
MW*DKTJTB5K6>&-JHJN#C-AG[-[T.X-F.)YM:=U.JVHNN'9+8LIME/<<XVBFM
M\]PQZZ4MVHH:^*FV,I*F6CEJ:1K96QRQ/<Q51KVKHJ!Z!@-A^ISIYPOJNV)W
M$Z>]Q+IE%FPS<NVV^U7VYX76VFW9/24]MOMJR"!]HK;Y9,CM4$SZVT1->LU%
M.U8G.1$1RHYH=)G_ (93H-_SM=7/_;S9O_0(!V[]%G1MMAT*;*Q;$[1WW/,B
MQ&+*K]ES;CN-=,>N^1K<LB2A2M@=5XSB^(6Q:&)*!GNF_!I(W5WB>[AH'+0#
MH_ZC/D%='G4YO?N/OYGNY/4M:,PW0R!^27^VXAF.UU!C5'7/I*6C6*ST=YV<
MO]TIZ3W5(U4;-65#_$J_BTT1 O>F/Y#72%TH[[;=]0FW>X_4C><SVTN5PNMB
MMF:9?MC<<8JZBY6*ZX_.R[T5CV?QRZSPLHKO*YB0UL#DE:U556HK7!W0WFU4
M]\L]VLE6^:.EO%MKK54R4[F,J(Z>X4LM),^!\L<T;9FQS*K5<QS4=IJBIP \
M\W_AE.@W_.UU<_\ ;S9O_0(!SUZ#/E2]/'R\,JS_ "_97,MY\GN6XV/VK&[W
M!NCD6#WJAI:&SW&6YTTMJBQ/;K":B"K?43*DCII9V*S1$:U>('9L!U;]=ORD
M.G#YA.X>'[E;SYKO=C%]PG#$P:U4FV&28)9;346E+Y=;_P#$7"#*]MLUK);C
M\9=Y&^..>*+W36I[OQ(KG!PXQG]FRZ&<4R3'LHMVZW5A-<,;OEIO]##6YSM!
M)1RUEGKZ>XTT57'!L533R4TD],U)&LDC>K%5$<U>*!Z#P-F>H;8[$^I;9/<G
M8;.KAD5IQ#='&JK%L@N6)5=MH,DH[?5RPRR36>LO%HOUKIZQKH$\+IZ.H8B*
MNK% Z.O_  RG0;_G:ZN?^WFS?^@0#M)Z$N@+9SY>VWF8;:[,9+N9D]BS;,US
MFZU>Y]YQ:]7:GNRV.U6#X>WSXIAN%4<5N^#M$;O!)!++[USE]YX51K0YQ >?
M;KO_ &?K8+JAR^_;M;'Y>_IRW.R2IJ[MD]II,=BR+:S*[Y4*DLUT=C-/7V6N
MPZ[72H\3ZRHM\TM)+(Y9EH5G?+)*'4)'^S&]:2W]*:7>WI?9BWZV6%UXCO\
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MHY:FD:V5L<L3W,54:]JZ*@>@8
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MU9![U\CZBJI:RH57*'25=/V8[K5AO%3!9=Z^ERX6!E2C*.YW3(]V+/>)Z/\
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M6IHB!D
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MB5DOEAKK9CE/+2T4,;F4<4+71PL:J:,:B!MG_P /[H-_V)>D;_U6[9O_ !,
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MZ>HIYV.BF@GAE:Z.:&:-RM<UR*US55%30#B9_P /[H-_V)>D;_U6[9O_ !,
MW2VNZ<.GC8^NNMSV5V&V8V@N5]I(*"]W':[:[!]OZZ\T-+,ZHIJ*ZU>)V.TU
M%PI*>H<KXXYG/8QZJY$1>(&\X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
H                                                 '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>moln-20221231_g6.jpg
<TEXT>
begin 644 moln-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJNLZS9^'].GO
M+^ZMK*SM4,DT]Q((XH5'5F9N%'N:^3OVA?\ @L1\.?A2UQ8^%8[GQYJ\>5W6
MCB'3T/O.P);V\M'4\_,* /KNN8^(_P 9/"?PDM%G\4>)-#\/QL,I]OO8[<R]
M>%#$%B=IX )X-?DO\;_^"IWQ>^,RS6\>N1^$]-8D?9]!!M78>\Y)E[<X=023
MP.@^>M4U6ZUK4)KN\N)[NZN&,DLTTA>21CW9B223ZF@#]</B-_P5Z^#'@">2
M&TU+6?%$T9 QI-@61C[/,T:MCCH3^->1^,?^"[>EVURR^'_AYJ%Y"0<3:AJJ
MV[*>V8TCD!_[[%?G'10!]R:Q_P %T/&TK_\ $O\ !7A6U7G N)IYS^89.G/U
M]1WR9/\ @N%\53*WE^'/A\JYX5K.[9AQW/VD?Y/?K7QC10!]F?\ #\/XL?\
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M"?\ D7_AX/\ MPO#_P"W56[/_@N3\2HW'VCPKX(F7'(CANHSGZF=OY5\544
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.I?C[_T(?_E:T[_Y(H_X=2_'W_H0_P#RM:=_\D5^RE% 'XU_\.I?C[_T(?\
MY6M._P#DBC_AU+\??^A#_P#*UIW_ ,D5^RE% 'XU_P##J7X^_P#0A_\ E:T[
M_P"2*/\ AU+\??\ H0__ "M:=_\ )%?LI10!^-?_  ZE^/O_ $(?_E:T[_Y(
MH_X=2_'W_H0__*UIW_R17[*44 ?C7_PZE^/O_0A_^5K3O_DBC_AU+\??^A#_
M /*UIW_R17[*44 ?C7_PZE^/O_0A_P#E:T[_ .2*/^'4OQ]_Z$/_ ,K6G?\
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M2;A8$"@Y;S=FS:!DD@D8!YKAF0Q,492NTXP>HK^AHGYJXWXD?L_^"/B^L?\
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MX9?T>B^[US0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:ZDR_9-5B7_EC>1@"3Z!@5<#LLBUZM7Y4_\ !&[]HT_#7X[7/@G4+C;H_C9
MMNK?=BOXQF,CTWIO3W;R_2OU43I0 ZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1=0N%US[).(UN;J&!RDLJ%FD6UD.(PV,=N 0KE/UBHKX)_8N_P""R>J?MH_
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M">B^#_"_AWPE>_$CXM?$BY^R^&_#-G+Y9E^=8_-E*AGVEW"HJJ3(P8 J%9E
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MO_!<7]CWP[\*=>TKQCJO@?58]6UV]T*Y2]@L[5+V&YDC>6,E 5@M9V89RHD
M.-PK[Z_:R_X)'?L]_MS?$V'QE\4OA_\ \)1XDMK"/2XKP:[J5CMMHWD=$V6U
MQ&G#2R'.W<<\G@8WOV3_ /@FI\"_V&M1O+[X6_#G1?"VI7\/V>:_5Y[R^:+(
M)C$]P\DH0D*2H8*2H)!(!H"Z/AO_ (+!?&GX/_\ !2?]FKXN>%O#_P ?-2\"
MZU^S_%J-SKWAZX273K?Q%>PAA'9RPS^6URHGMFB7RP^R25#M8E VC^Q/_P %
M/OAO\3_^";/PA^%OC+Q)_P *%\:?%CP[?^'= NM!L+BQL;*.">XL4O+6Y.8X
M)"8>-TH996[ JQ^G_P!I+_@BW^S1^UM\79/'?CKX8V>I>*+ID-Y>6^I7EA_:
M!485IDMYD61L 9<KO( !) Q78_M#?\$T?@;^U+\&_#W@#QI\.=#OO"_A&,1:
M%:6H>P;1D"JNVWDMV1XT*JH*!MK8&X-@"@+GP%_P;RZ]9_ W]MC]I;X#Z+>Z
M/X^T;1+T:Y_PL&VCW7VMR"41&&ZG\QA*09I"FW@.MRV6WYK]=$Y7_/->0_LA
M_L*_"G]@[P/>>'_A7X/L?"MCJ,JSWTL<TMQ=7SJ"%::>9WE?:&;"L^$W-M R
M:]>086@).YXQ_P %%O%'B;P1^P=\9-8\&R74/BC2_!FJW6FRVW^O@F2UD821
MX_Y:+C<O^T!7\_GC']GGX&^'O^"!'A3XM:/KEI9?'S5/$=W9:C=1ZS)'J5^D
MMS<VUQ8-!YF!#]B:.1ODRRG)XE*G^F:YB6X1HY(UDCD4JRL,J0>"".XKY#M_
M^""W[)=IXTU[75^#6BM=^([>YM;F$W]ZUK MPCI*;>#SO+MWVN=K1*C1$ QE
M",T I'A^J?&?]JC]F3X _ ?PS^RY\#_"/Q*^&:_#'1+I]6U"\6&87KQN9$ ^
MUPY!C$$I.PY:=N3@@>(_L'?%Z/\ 96_X. _C5_PO.;3/ OB/XJ>&+:\T^YU*
MX2"Q\Z5;.X:TCG9S&5^26-3O(9K0IDM@']=O@K\'/#O[/WPJT+P3X3L9--\-
M>&;5+'3;22ZGNC;0)]U!),[R,JC@;F.  !P !YU^V-_P3K^#/[>FG6%O\5/
MFF>*)-+!%E>>;-:7UJIR2B7$#I+L)Y\LL4+8)4XH#F///A=_P5Q^$WQI_P""
M@=Y\!O!,=]XPUR'23?W7B;0S;WFBV_E*SR0S7"R;LINC3**ZB6;8=K U\1_\
M&V?[0'@/X)^ /VA/^$R\;>$O";2>/))T&L:M;Z>6C6-@7 D=<KG/(R/QK]'?
MV._^"=/P9_8'TS4+7X4^!['PS-JX47]Z9IKR\O-O(5YYG>3:"20@8*#DA17C
M5_\ \&\W['NK^(;C5+KX/QW%]=3O<RR/XHUIA([,68E?MFWDGIC X] * 32/
MDW_@AYX3T?\ :X_;C_;D\:0Z:NL?!KXC:M<Z.&DB9;+7X[FYNW< \$DV\FY@
M#D"Z7."172>"_!NC_#O_ (.C+'0] TG3M#T;3/A<(+2PT^U6VMK:,0<(D: *
MJC)X  SVYK],/@7\ ?!?[,?PYL_"/P_\,Z1X3\-V!9HK#3H!%&7.,R,1\SNV
M!EV+,W&2:YK_ (8M^&?_  U?_P +P_X1O'Q0_LS^QO[:_M"[_P"/7&WR_L_F
M^1T_B\O=[C% <Q\ _P#!:7_@JMJ&H_%1OV4?@SK'AS2?'7BR(:=XN\6ZSJ,.
MGZ?X8LY8BTD N)2%$QA8L[C<8U8*@>9P(_1_@5\4OV;_ /@F%^Q7\.?@18_&
M:SAN/B*M]HNG>,]&)NK>?6)O+2YO/M4)>"V:&6ZA($DH\M/++$@%SZ=\5_\
M@@S^RC\</B9X@\8^*OA;-J_B7Q1J$VJ:E>R>*M:C:XN)7+R.%2["(-S'"H%5
M1@* H '1?\.;_P!FW_AF7_A3[?#&QD\ +JKZY#I\NJ7TT]K>NBH\\5T\S7$;
M,BA3LD4$9!!R<@71\*_\$2KFQ_99_P""OGQ\^!>BZYIOQ:TN^TM/$4_Q"/\
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MC\*Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDF(2KC'._&1U'N]5=8TV+6--N+.==T-U"\,BYQE6&#SVZT ?SVCD>OOG.?\
M/\Z*UO'OA*;P!XZUK0;A_,N-%OI["5\8WM%(T9..V=N?QK)H *"<#^'UY_#]
M.GYT44 ?K[_P2%\?MXV_8LTFT?!D\,ZA=:2S;BS$!A.N<]PLZCZ 5]/U^>O_
M  0G\9M+IWQ$\.R-\D,EGJ,"[N[B6.3C/^Q%R!CU[5^A"<9^M #J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBFNVWD^G- ')_%[XRZ+\&M$6\U
M660RS[A;6T0S+<L.H'8 9&22 ,^N ?E'XG?M;^*OB+;:C8K-#I>C:A"]N]K#
M&KDPL-K R%=W*DY*X_+%<]\;_BI=?%SX@WFJ2LWV97,-E%_#%"I.W\3DL?<F
MN0 P.Y]Z ,!/A3X7@7;_ ,(WH3;>.;"(_J0?YTO_  J_PQ_T+>@_^"^+_P")
MK>HH P?^%7^&/^A;T'_P7Q?_ !--E^%/A>9"I\-Z& P[6,2Y[]< CZCFN@HH
M [3]G+XU7W[-&D+H^AV=F/#[7+W<MBR8WNX4,RR#Y@<*.N0,=.:^ROA+\9-&
M^,FAM>:7(ZRPX%S;2C;);,W0,.A!P<,"0<?4#X!KL?@7\4[GX2?$*SU*%C]E
MD807D><+)$Q&?Q'WA[@=LT ??*?=IU-3[M.H ",UE^)_%FE^"])FU#5KZST^
MRMUWRS7$JQQQCU+,0*J_$?QOI_PV\%:KX@U:Z2STW1K26]NIY#\D$42-)(Y[
MX5%8G'.!WK^?C]OC_@H!XN_;9^)5]->:C>V?@NUNG?1]%1BL,,8X264#_63%
M>2S9QN(7:*#:E2<V?M+XF_X*?? ?PCJ36E]\3O"*S+PRQ:BD[*??R]P!]B<_
MI6>/^"M'[/9S_P 70\,?]_G_ /B:_GK/TQZ#&,#MQ14\QT+"Q[G]"G_#VO\
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MI#6J>7&2&4X+G (SUKD_#G_!%&7QGI-]KGP(_:&T'5O"]Y<-+8020?:$B/\
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M?[.7_12-._\  "__ /D>OP"V-_=:C8W]UJ.8OZK$_?W_ (?-_LY?]%(T[_P
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M^&?CCX-M/$'A76+'7-)OEWPW5I*)(V]O4$=P0".X'2OYQ_C_ /\ !,O]J_\
M9D^$^L>.-?\ "O@?6?#OAFU:\U,Z5JGG3QVR*3+-LRIVJH+-M!(&<+Q72?\
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M "L'XJ:C)I/PR\174/\ KK72[F5/JL3$?J*WJYGXT?\ )'O%G_8&O/\ T0]
M'Y\YW<^O-%';\** "BBB@ HHHH */QHH'7_/O0!^B'PQU*36?AMX?O)O];=Z
M;;3/_O-$I/\ .MRN;^#O_)(O"O\ V![3_P!$I724 ?+?_!9?QC=^#_\ @GE\
M0#9MM?4;6&QD/I'+<PI)^:,R_P# J_G_ !7[T?\ !<'_ )1Z^+_]^S_]+;>O
MYW_CS\5S\*?!RW%NJ2:C>MY5JK#(4@9+D=POR\="6&>":F1W8=VA?8[@C/7(
MXSZ@^O\ D\5Q.M?M$>#]#U5K.;5T>93AO(B>9$/^\H(_PKE[/X ?%_QGH:7%
MWXAMK)=2CP]I/.8Y(XWZ@A$(4G.2O&,D9ZU:\2>#?A;^S5X1ATGQ)9CQ-XDN
MH_-F6,,LA![@Y B7L,$,V,C.3CY>MQ=@(U%2P;=:I>W+"SVW;;T276]C[O#\
M"YM.A+%XZ*PM)*_/5;BG?9123;;\D-\8_M2V=KK$.F^&=-F\27DQ'^HW%<GL
MHV[G/T'%4],_;#TV"VN$U?1M2L=1MVV&WC4/N/?.XJ5(YX(KTS]D*S\+ZAX0
MOM6T'PS)X?>2Y:W=IY3-),F%;Y9'_A.[[HXX[]3<_:7_ &='^-^EVO\ 9O\
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MF_\ @1'_ (UX111S!]67<]W_ .$CT?\ Y_M-_P# B/\ QI5\1:3_ ,_VF_\
M@1'_ (UX/11S!]57<N>(W63Q#?LC*R-<2%2IR"-QJG114G38^FO^"//BFZ\,
M?\%#_ *6S;5U7[;87 _O1M9S..>V'C1O^ UXC_P7PU/Q'X@_;!^)\EDT\T,?
MB 6UYY /F"WBMXXXEQ_= 5<\CH,\9->M?\$GO^4B?PN_Z_KK_P!(;FLG_@I8
M2/V^?BQR1_Q/Y<8//W%_^M5=#*4;RL._X)J_MH_ ^S_9\E\$:5^SO\/?''Q*
MT^PB718I-/MX[KQ'=M(B&.ZFN@Y#G<SAE8JX38BJQ13]!6GP?_:X_P""COC/
M0_"&J>&;S]D'X!:-;,=2T_P]<QP7^IR\!HP(RLA#-G V+$JY9O-?:M?DE\0K
MZ;X*?M0:+XHL7O-!MQ-!<M?VV=HE#99EQT(PIV]<KN]*_6OXS?\ !R/\._$G
M[*OBG2[.37M#^(VK^&[FPTJ^T?R+R.VU22W*).@\Q&1%F(8%LE0.[#:?0P]:
M,HVJ.WSL?-8[ U(U.:A!7ZWZ>>[/;M*_9)_9O_X(8^$=0^-$.@_$;7-=N(ET
M&]UD7%SKVKWB3NKE6B#);JI:($R;$(V ;LMAN(\>_P#!6OXK?MJ_$70_!W[(
M'@B\DTJ[CC?7?B#XQT*XM-+T(,1O"++L5FB7DD[]S8"(PPQ^(/V$_P#@X"^*
M_P"R+\,;7P]XT\,^)/B%YVIR7\^M:]J%W=7TUNZ(JV\+.?W00H6R?,!WGY1W
M]<_: _X./_BG\>/A]JF@?"WX/VOAF;4K9[>76_$%[]M$*.I5A%;LD<;.0Q W
M%QD\H16WUFGR^X^5>F_S.&.6XAU+U(\S[\VGW'MWPR^*/[;'CJ36-0^%/[1W
M[,W[3%OH;A;[39+&+3;R,N6VJ!:*B*"5<*TDZJ=O5N:TO#'_  78\7?LV_%#
M2_!O[67P6UGX32ZU*8;7Q-ITK7FCN00"Q'S;D&Y=S122E=RDH!S7YT_\$E/^
M"D__  ZG;Q7:ZI\(=2\1:EXJGA^W:A#</'<B*(-Y4,7WHM@9V;A26+\N5"JI
M_P %*_\ @HC\3/\ @IM\1='DOO!NO:5\&= O(+NV\))J,=K<7DJH0\\LFTMY
MA621%8(RQH3C))8S'$Q45*+:?9FLLKJN;C."MO=:/Y):/YG] &G?#3X:ZU\)
MM66RT/P>O@GQEISSZD]K;V\-AJ=G-$2TDK(%5D:-R=Q/*L23SD?&-O\ \$E?
MV%?V[/AQX@L/AEH_@W[9H[FSDUKP;K<K7.C7+!O+=U\QHWR58J)$99 KX)QN
M'YO_ +?G_!2#XN_ML_ [P_\ #GPS\/9?A'\,?#5I':7.@:=KXN9M:CB"I'$[
MF.,F*-4XB965B-S;F"BO>_V//^"Y7PY_8T_9T7PKX)_9;\2>&O$D4*B:VLIQ
M+!JMRJ[1+=7;QBXD[\LK%0Q XK26*IU'Y&"RO%TES0;YF]O+I?\ X![E^SS\
M<_AE_P $I_@'X^^"_P"T9^T=X:^+%JOVFTB\-P6-Q>WUA:2QND^GR8:1F,H8
M?NG*^46?YN21^3'P&T".'Q=XQU;0M/U71/!.J7DTFA:??R^9<);&1VA#MSN9
M8BBE\D,>[=3K?#7P!J6H^-_$OC/Q9;V8UWQ7J$NHO H\U;-Y97E<[FR02SD<
M$\ <FO0)N8)#GJO>O/KU^>T4M$?2Y?ERHIU&WS/>^GX']./[.6M7'B/X#^#]
M0NG\RZOM%LKF9^[R/;QNQ_%F-=J*\H^#/C.T^'G['WA/6K[=]FL/#&GNP7[S
MDVT(51[EB /K7%'_ (*"V(9MOANZ*YX)NU!/X;:Q"6]CY;_X+K:/%#\5_ NH
M*D8N+K2)[=W &]ECF!4'O@&5L=LDU\)]??T.<YK] /V][NU_;6U#PM<)YGAU
MO#J7*,2!<?:!*8CURFW&SWZU\]_\,31?]#(WT^P8Q_X_02>!T5[Y_P ,31_]
M#(W_ ( __9T?\,31_P#0R-_X _\ V= '/?L&ZG_9/[9/PVE\SR]VNV\&?7S#
MY>/QW8_&OW!7I7Y"_!?]FB'X2_%_POXH;6GOAX=U2WU'[,+,)Y_E2*^W=N.,
M[<9P<9Z5]V?\/!;)A_R+-SR,_P#'X,?C\G^<T ?1U%<I\&_BM8_&/P6NL6,<
MEN/-:":%SEH9% )7/?A@?QKJZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N:^,PS\(/%>.O]CW?_HEZZ4]*XWXR_%'PW\-?"5U+XCU"&UMKJ*2)8,[K
MB[^4Y2*,99VVY.%!( ). "0 ? M%"LLBAEW;6^[D8X[44 %%%% !1110 4'C
MMN]!_GZT4 9_D>><4 ??GPDURW@^%/AB-I%#)I-JI!.,?N4KH?\ A(;7_GHO
M_?5?GE'XP\10Q*B>)=>2-!M55U"=0!VP-_\ *E_X33Q)_P!#1X@_\&4__P <
MH ]8_P""VE_%?_\ !/3QEY;!MCV>>?6]MZ_G._:C\ 7_ (O\+6-]IL4EQ=:+
M*TIA0$L\;!=Q _B(*@X]-W6OVJ_;#UK4M9_X)Z?%P:AJ>H:D(WT@QBYN))O+
MS>C=C<3C/&?I7Y2@94\MZ]?3T^AJ96ZG?A[\GN_\-Y_(Y'2_CSKW[0_PHN(_
M!LT.C^,]/>)[V&3'SQ_-N:%F!4!F ^]R <9Y!+O@+^S3J-OXPO\ QA\0!;:E
MKEV^^"&0I,L!_P">C8^7<!@*%X4*>A( XWP.6\#_ +<4%MI\GEV^O1NUW$PP
MA#0/*0/^!(I'N2.]>V_M)>,=8\ _!G5M6T60PZC:^7LF*+)Y0:15)VL"IX..
M0<9K\,X@PU;*\;_8N6\E.->S4M>>TGK'FU:C?IVT/Z?X1Q6&SK+?]8\[<ZDL
M(G>%_P!V^5:35.Z7/;SLVBM\8?VCM#^!NM:;8ZI:ZA)_:",^^VC5EA0<9()'
M7&>.0!GJ0#XKINE>,/VO-<U/6IO$%UX5\*V<ICL=Y;RRW90 R!F (W.3P6P,
MXP/</@SXBL?C1\)-'OM4DTO7KSR$^V;H(V\J< %@8R,*1@<  'J.,5Y9^W!\
M2_#A\"1^#]/FAFU*&\C9H+9MJ6@0'AL?+SNP%ZC/M7#P[:AB?[.PN':Q*;C.
MHUS**O\ $HR22T[[K;4]+C&3Q. >;8_%*6":4J=%?NY3=E:$JD)-RUU277T*
M%QJWQ?\ V8X/.OI%\7>&[;&^1F:<1IT^\0)4_'<J^_?W#X-?&C2/C9X;;4-+
M:2*2!A'<VLV/-MG(X#$<%3SAAU]N@D^%FDR^!/@WHMKJ]S&TFEZ8INYR^Y$"
MH6;)[HHXSW"UX?\ L?VH\3_'KQ?XDT6U;3?"K1R1)&W";GD5D&.@P%=\'[@.
M.A-98R&'S7"8O$5*<8U*/_+R*Y(S=[<K6W,]U;Y^?1E]3&9#C\#AJ5:<Z.)W
MHU).4Z2LFW&6_)'9QEMNK]/?/%?PK\,^.)O.UC0M)U*;8(O-GME:4(,X4/\
M> R>QXS7D7AC]G;6O@[^T=9ZEX3AW>%+^+9?1RW(_P!'0_>C.3N8@@,IQ[9Y
MK)TCX@>)OVF?C\O_  C^J7&C^$_"LRRF:'($P!."W3>9,'"ME0@/'+9V_P!M
M[XCZUX1L?#.CZ+>R::VN3S":6!MLFU#$JJ&'(4F0YQ@\=P&!O+<!F>'Q-/*/
M;)NO#WH2<G&">JNOAYK:JVJ?WF>=9ID>+P57B&6&E%8:JN2K!0C*I*+L[2LV
MX-Z.^_34X_XYZ;:^%/VQ=#N-'G(O=6$+ZC%&V0&8LAR.J[T .#R3SWK].O\
M@@ES^VAJ73_D6;GI_P!=[>OSA^%OP$A\!Z_-K6HZA/K>M2# N9 5\O/#8R2=
MQZ;B3@#WK]'O^"" Q^V?J8_ZEFYQQ@?Z^WZ>U?N63X&>#P=/"U)N<H))NR6W
MX^GD?S'Q!F$<PQ^(Q].GR*I+FY=&E?NU;5[O3?H?,'[5/_)S_P 2/^QIU/\
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MI%3@T[GT;_P2>_Y2)_"[_K^NO_2&YK)_X*5_\G\_%C_L/R_^@I6M_P $GO\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36X;\*=7,_%/QP?
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M8U/YCU0_"W0?^?!6[X\Q_P#&O-_B;HUOH/BN2WM(Q%"J*0H8GJ/>J)\::O\
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M*Y>RG6VO(9&#,L;JQ"]< @_TKT[_ (7KIO\ SZ:@>_\ !_C0M@J2FG[IS/\
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M 4444 %%%% '._M5_P#*/3XP?[^C?^EM?ECV_"OU._:K_P"4>GQ@_P!_1O\
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M2O\ Y/Y^+'_8?E_]!2M;_@D]_P I$_A=_P!?UU_Z0W-9/_!2O_D_GXL<;O\
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M1110 4444 %%%% !1110 4444 %%%% &+\2/^2>:_P#]@VX_]%-4]]_R*O\
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M]FO_ )%.'_='\A7IPZ5YC^S7_P BG#_NUZ<.E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'
M\2O^2>:__P!@VX_]%-5J^_Y%1O\ KW'\A57XE?\ )/-?_P"P;<?^BFJS?_\
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MCROLMSWS]C3_ (*6?"/1/V4?"FGZ_P")K7P_K'A+1H--O;">.7S)3;QB,/$
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M_>=G\)_VG?"'P)_X*(_$#Q3?7KZQX=\37-[;QZE9H["W6>X28-LVAG5-OEG
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M8B>(GHY-NRUM?S/U;(\IIY;@*."IMM4X*-WN[*UW96??1G[+^/O^1?\  O\
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MSM\=:OK/P$_:'\-_%32+/^T8](8?;(2I^[L:*0$X.%>&1E##[IY]*[/]J?\
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M^*7^LD^M>+^)_P#6-]: .7N_O?C4-37?WOQJ&@ HHHH **** "BBB@ HHHH
MYW]JO_E'I\8/]_1O_2VORQ[?A7ZG?M5_\H]/C!_OZ-_Z6U^6/;\*F1Z&%^ ,
M8'Z5%!:16A9HXH8RW+%% S^7>I:*DZ [=Z*** "BBB@!KQK,"K*K+W#+NS0J
MA5"JNU1P!CI3J* "OMS_ (((?\GH:G_V+-S_ .C[>OB.OMS_ (((?\GH:G_V
M+-S_ .C[>JB9U?@9\P?M4_\ )S_Q(_[&G4__ $KEK@&. ?;GGO7?_M4_\G/_
M !(_[&G4_P#TKEK@&&Y2./F&#4^I:V^2/04^ TSHI&I1<CC]T3_6E_X4)/\
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M$/0]/M=4U;PY;0O:P709H"\MU# &;:0=JB4MP1G:,XZCSO\ 9/O?#G_!6/\
M82\&^+/C!X#\%ZY-JTM[BS\KS8[-XKN6VWQ,Q,D#NL0+!7W'CG!P/)<Y5?WM
M1/EZV=K>7S/C*E25>U>NOW:TLG9+T1\:_M!?MT?&#_@JQ^UI_P *J_9G\2ZE
MX;\!Z;:^=>:]!)/I;W"@?O+J>;:)XH@S+''$JAV(R1\QV1Z_X2_;[_X)N0-K
MMMXAN/C-X/L3ON$EN)O$"K'W:2.7;>(F!RT3%5 R2.M?8W[6>@?!_P#X)Q_L
M&?$:/PW8Z1\,K?6M)NK*Q.C 1ZE?WTT31PB-F)DDE4N#EF(15)RH7->9_P#!
MN>_C2[_8EU6^\47VJ7NBW?B&4>'EO)7D,5LD4:R^66R1&9_,X'&Y9#W-;^UB
MJ;G"*Y.BMK]YV_6(1H.I2IKV<;*S6LO.YV?_  3L_P""S/@/]NC4[?PGJ5G+
MX)^([0LW]D7#F:UOR@W2?9IB!N( +F-PK@!B-P5B/JGXJ_"OP[\</A_J?A;Q
M=H]AX@\.ZPJI>6%XA:*XVN)%SSP5D1&!!R"%(YQ7Y#_\%U-#\+^&?V\/ANOP
M;@DTWXZ7$T4VHIHT2QYNGEC.GR.J<?:F)<L6ZQ&(O\I6OMO_ (*X?\%)V_X)
M^?!2PM]%2PU#XD>+MT.DP2?/!9)'@37CH.6520J*2-SL.H5E.53#\SA*E]KO
MN<]?!1E.$\-=<^MNW_ /./V_/^"$_P +_B1\#]:U#X3>%8_"?CW2K9[K38+.
MYE%MJK)\QMG1V959P"JL,8<KDA2:Z#]D#X2>//VC_P#@DEK7PZ_:%T;4/"-S
M#8W.E6UYK \B\-A!&DMK>SQL=T;0N-IW@,R6X9A\Q)]5_P""7-O\:+7]DO3[
MSXY:E+?>*-0GDOK,704W]K92!7CBNB !YH;><8RJ,JG!7"_D?\?_ /@HI^T'
M^WKXF\9:!:^+CX>\!75S):R:':+%;6Z6V]@L4DJ)]HER%PX9]K9(("G;6U*-
M6I)TW*]FM>QUX2CB<3-X>Z?(UK_D=U_P;G:[=WO[='@:UFD+6ECJDLD()^X7
ML+LN![94'\:]1_X*6#'[?7Q8Z_\ (?DZ_P"XE5?^")WPXL_A;^W5\*]-LV:=
MO[0NY)9F&TS.;&X!; R!P ,>@^M6O^"E?'[?/Q8_[#\O_H*5[6MM6?>T8RBT
MF]4>(VTK07$<B[2R.& 8<<<UV'_"[]78?ZC3S_VR?_XJN-HJ3;E4M6=E_P +
MOUC_ )]]/_[]O_\ %4?\+OUC_GWT_P#[]O\ _%5QM%.[#V,>QV7_  N_6/\
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MVO3ATH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^*GB#3]0\'S16]Y:R3,Z86.0$_>KRVBFF5'#I.Z8F<U]N_\ !!#_ )/0U/\
M[%FY_P#1]O7Q'7VY_P $$/\ D]#4_P#L6;G_ -'V]*.YI6^!GS!^U3_R<_\
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MCDJ<XKZW'QR\'?\ !:[_ ()>>.YM'T)KK6AI5];Q:#>LDUSI6MPV[26IC?\
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M ,^=Y^:?XT:!SXCL<K_PI_7O^?:/_O\ +1_PJ#7@/^/>(=<?OEKJO^%YZ?\
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MN^)W[02_L^V4+-XVL]3DL+UQ/N^RK$?WCS7";ML$>,LP&2!@[B0I^F?VI_\
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M?^Q/T?\ ])$KFJZ7Q_\ \B_X&_[$_1__ $D2N:KB.Z6X4444$A1110 4444
M-E^Y54_?-6I?N55/WS0!-#]VNWT?_DG,W_7Y!_)ZXB'[M=OH_P#R3F;_ *_(
M/Y/0!]:_LU_\BG#_ +H_D*].'2O,?V:_^13A_P!T?R%>G#I0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!C_$/_D0-<_[!]Q_Z+:I+W_D5/\ M@O\A4?Q#_Y$#7/^P?<?^BVJ
M2]_Y%3_M@O\ (4 ?.OQ2_P!9)]:\7\3_ .L;ZU[1\4O]9)]:\7\3_P"L;ZT
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M5/WS0!-#]VNWT?\ Y)S-_P!?D'\GKB(ON5VVB?\ ).)O^OR#^3T ?6W[-?\
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MU<JJ\ "9L ?@:2-*T'+8]I_X071?^@58?]^Q1_P@NB_] JP_[]BO&/[<OO\
MG\NO^_S_ .-']N7W_/Y=?]_G_P :?,<_L)=SV?\ X071?^@58?\ ?L4?\(+H
MO_0*L/\ OV*\8_MR^_Y_+K_O\_\ C1_;E]_S^77_ '^?_&CF#V$NY[/_ ,(+
MHO\ T"K#_OV*5? FB'KI=CU'_+(<UXO_ &Y??\_EU_W^?_&C^V[W_G\NO^_[
M<_K1S!]7F^I)XF@2V\1ZA'&HCCCN)$50.% 8C%9\W^I;Z?T-22.TKEF+,S<D
MGJ:CF_U+?3^AI=3L6VK/V7\??\B_X%_[$_1__21*YJNE\??\B_X%_P"Q/T?_
M -)$KFJL\F6X4444$A1110 4444 -E^Y54_?-6I?N55/WS0!-%]RNVT?_DGE
MQ_U^P?R>N)B^Y7;:/_R3RX_Z_8/Y/0!];?LU_P#(IP_[H_D*].'2O,?V:_\
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M172O_1=M7XYO_JV^G^%?L9\<?^4?OBK_ +(KI7_HNVHB9XC>)^.?3IU/^?\
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MH4444 %%%% !1110 4V;_4M]/Z&G4V;_ %+?3^AH _9?Q]_R+_@7_L3]'_\
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M1UD<G17H'_"AI/\ H*+_ . __P!E1_PH:3_H*+_X#_\ V5/E9/UBEW//Z*]
M_P"%#2?]!1?_  '_ /LJ/^%#2?\ 047_ ,!__LJ.5A]8I=SS^BO0/^%#2?\
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MY@MY+RWM+JX RSMN<R+;6\:KN9G )R". Q%OX3?L!?\ !/\ ^,?[=OA?X?\
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M\V][/Y'X^$_TXKIO"?Q.NO"6D_8XK>&15<ME\YYQ7,T51URBI:,[K_A>E_\
M\^=K^9H_X7I?_P#/G:_F:X6BG=D^QCV.Z_X7I?\ _/G:_F:/^%Z7_P#SYVOY
MFN%HHNRO8Q['=?\ "]+_ /Y\[7\S2?\ "]+_ /Y\[7ICO7#4478O8P[&EXL\
M32>+=6-Y+''$VT)A.AQG_&LVBBE<J,;+0^AO^"3W_*1/X7?]?UU_Z0W-</\
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MNGZC;KJD<3*0K[I+=B, D9[%A]*\X3X&>(M?NK6#7=:CNM-MWW#;*TDC#C.
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MF?\ PH \H_M9?[U']K+_ 'J]7_X=A?$;_H8O#W_?F;_"C_AV%\1O^AB\/?\
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MJ7%-<LNIK']"?QQJ+_$N]:Z\11VFO:@SK+)?7]K%<7LK*  7N&4RM@  98X
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M\T__ "7_ "-N?-?Y8?C_ )GLG_$0%^R/_P!%:/\ X2^L_P#R'1_Q$!?LC_\
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M'_$+#^S_ /\ 0Y?&+_P::;_\@T6R;^:?_DO^0<^:_P L/Q_S/9/^(@+]D?\
MZ*T?_"7UG_Y#J.7_ (+_ '[)+?=^+7_EKZU_\B5X_P#\0L/[/_\ T.7QB_\
M!IIO_P @TT_\&L?[/X&/^$R^,7_@TTWG_P D:7+D_P#-/\/\A>TS7I&'X_YG
MP9\9OB?I7_!5+_@NUX;NO!,,VH>%-4\1Z59VLS6S6\UWIUBD<EU<%'^892*X
MD7<%8($#*K BOZ'X%VI^.37R?^PE_P $:O@S_P $_/&EUXE\)VVNZ]XFGB-O
M!JWB"XBNKFPB88=8/+BB2/<,@L%WE25W;25/UDG _&N?-,=2KN%.@GR05E?<
MWRS!SHJ52K\4W=VV'4445Y9Z@4444 %%%% !7C/_  4$_9\N_P!JC]C3XC>
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M)Y5@\=B*JQZFX4Z<YVA)1DW&UES.,TD[ZOE9HC_@OK^R4NX?\+8Z?]2QK/\
M\B4Y?^"^_P"R3C_DK'_EL:S_ /(E?1>,9^G6E!XKS?KF.>JE#_P"7_R9ZZAP
MM_T"XC_PII__ #(?.G_#_7]DG_HK7_EKZS_\B4?\/]?V2?\ HK7_ ):^L_\
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M+6?_ ,;H/_!.SX!G_FBWPK_\)>S_ /C=-YEB6E%I:>I$<KR--M.K=_X#LO\
MAY1^SQ_T7'X2_P#A5V7_ ,<H_P"'E'[/'_1<?A+_ .%79?\ QRN-_P"'=GP#
M_P"B+_"O_P )>S_^-T?\.[/@'_T1?X5_^$O9_P#QNE_:&([1_$T_L_)>]7_R
M0[+_ (>4?L\?]%Q^$O\ X5=E_P#'*/\ AY1^SQ_T7'X2_P#A5V7_ ,<KC?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG&*5M[&U.4I-MFO5?5_^05=?]<F_D:L57U?_ )!5U_UR;^1K$ZJ7QKU/G/\
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M[E8Y(E??;RQL<)+*,%L?-G' (]1HKB3:O8\KIJ1VEE%86D-O"OEPP((T3KM
M& .?0?RKS+6_V+_AKXA_:HT?XUWGAOSOB=H-@VEV.L_VA=_N+=HYHRGD"00'
M*W$HW-&3\_7Y5QZC0>/7/;W]OQHYG>X^6-M3R/\ :S_84^$O[<?A^QTWXH>#
MM/\ $T>E,[V,S22VMW8%P-WESPNLBJ< E VTE5R#MKQKXA_LJ6'_  30_8_\
M51_LJ_!?3=7\9:Q)#;O9FYDFN+M&)5Y)IYY?-D2)2S+&), G( R37 ?M1?\
M!P'X1_92^*OBSPOKOPA^+=Q;^$]2?39M:@L(4TVY96V!XY&D V,3\N>I('>N
MQ_86_P""SN@_MW?&'3_">C?"OXH>&XM4L)=2@UG6+&./3WC1-PQ(KD'>& 4C
MK6ZC52OT,6Z;=EN<=_P1W_X)A7GPB_X)H:Q\+/CSX1TF]_X3CQ!=:U?Z!=R)
M=?9HWBMH8@\D3%5E'V82!HWW1[U^97!4>Y?LJ_\ !)?]G_\ 8M^(TWB[X>>
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M5_\ D%77_7)OY&OG/_@WS_Y1._#7_KOJ_P#Z=;NOHS5_^05=?]<F_D:^<_\
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M[1SWP:L_LT?M^_!O]L/6M3TOX:_$#0?%6I:+'YMW:6S/%/''G8952159XPQ
MWJ"@RO/(RN6>X^:-['HMO\-O#=IX&;PK%X?T2+PRULUF=(2QB73VA8$-'Y&-
MFP@GY<8/ITKF?@W^R5\+?V=]5O+_ ,!?#KP1X,OM079<W.BZ);V4TR[@=I>-
M%;:&&0N<9^@KSGQ1_P %:OV;_!7Q7D\$ZI\8/"%GXBAN?LDT+7#O;V\V[!CD
MN%7R4(/#;G4J00>0PKQ/]I'_ (+<^%/@-_P4Q\&_!2XO/#MGX-6TEF\7^([J
M261].NFM[AK>RC10 CF1;8F0^8&6XVX7!8D83;LA2E#<^N/"_P"RW\-? WQ3
MOO'6B_#_ ,&:3XTU0R&[UVUT6WBU"Y+G,FZ=4#G>?O<Y; SG%4=(_8T^$6@?
M$[_A-;'X7_#VS\8)+YZZS#X>M([Y93DF03",-O.3E@03GFO'_P!C?]I'QM\4
M?VT?CUX4\1>.OA_XB\.>"K^.'1](T99!JFB(99E*WA:)%+80#*N_S Y/.:Z3
M0O\ @J_^SAXF^+$7@FQ^,7@NY\133_98H5NV%O/*21Y:7!40.Q(("J^2VT#)
M;%$HR01E!JYZ_KGP6\&>)/B/I7C+4O"?AK4/%^AQ&#3-<N=*@EU/3XSO!CAN
M2IDC4^9("%8##MZUTZG=^>/\_P"17E?QO_;@^$W[-GCJP\-^//'F@>%-;U/3
MY=5M;;4I6A\ZVB#EY-Y&S'[IQC.21@ D@%O[,?[<OPE_;)CU3_A67CK1O%TF
MBLJWL-L7CN+?<2%9HI%5]C$$!@"IQP34RC*UV5&4=D>K57U?_D%77_7)OY&K
M(_#VQ5;5_P#D%77_ %R;^1J3:E\:]4?.?_!OG_RB=^&O_7?5_P#TZW=?:%?%
M_P#P;Y_\HG?AK_UWU?\ ].MW7VA7L8'_ '>G_A7Y(Y.*/^1OB?\ KY+\V%%%
M%=AX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?$?C'_E/A'_V0$?\ J1-7VY7Q
M'XQ_Y3X1_P#9 1_ZD35Y.<?PH?XHGV_ _P#%QG_8/4_0^H****X>_P CS H)
MS113CN#V/AG_ (../^42WC[_ *_](_\ 3C!7L'[!WCG3/AC_ ,$KOA#XDUJZ
M6RT?P_\ ##2=2O[AONP00Z9%)(Y^BJ3^=:?_  4;_8O_ .'@/[)?B#X6_P#"
M2?\ ")_V[/:3?VG_ &?]O\CR+B.?'E>;'G=LVYWC&>_2N6^,G_!/?5OB9_P3
M*TG]G/2?B(WAUK/P[I?AF[\1KH?VA[NVM$B20"W\] GG"+!!E;:K,N6SFM8R
MCR13[F+B^>3\C\$O''QK^%7[6/@3]I+XC?$KQ%-I_P 9O&FN6VI>";#^S[B=
M+>".5FEA:9$,:JUNR0*&9<&!6/&*_93]C3_@J?8ZG_P10;XUZY<QWNO?#?0I
MM(U>*9_FN]5ME2&W1VR,M<E[1S[W&.U>[?LI_P#!-_X8_LQ_L[>$? ,GA3PG
MXHG\.V"VUUK%[H%N;C5)R2\T[!@Y7?([D*7;:"!DXS7QIK'_  ;;:A#\)?B#
M\/?#?QYNM \ ^.O%-MXD32/^$1\_^STM_M0BM2_VY!)\MQ%N?:FXVL;;1T7H
ME4IS,8TYQV/R?F\??#:/]D&U\<1>-+S_ (:@C^(;^)G<6-QO^Q$ C_2-GDF4
M7""X^]T9AUS7]+G[&'[2>G_M??LJ^!_B1IOEK%XJTJ.ZGBC)*VMR,QW$()Z^
M7,DB9[[:PW_X)[_!U_@:? /_  K_ ,*?V2VAG0!,NDVXO!#Y'V??YNS?YFWG
M?G<&Y!SBN/\ ^"5O_!/C5O\ @FQ\"=3\ 7?Q#_X6!I-QJ[ZIIKMHG]FMIOF*
MHDB ^T3;E9D$@Y7#,W7.:SJU(S6A=.G*+]X_/O\ :.^ FM?M,?\ !R5XJ\&Z
M1X]\2?#F'5/"MN=3U;P_<"WU1K1-.MV>""4C]VSL$!89^0.,-G!Z3]BWXO\
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MP?J?AJUNKY-*U*?R[6&.PMYV$, D6-7DF$89E()5I,E@2K>X_ S_ ((8>.O
MOCCX?P>-?VEO&7C+X;?"^83:#X8M;!]*X!4K#).MPY\H; I4 Y0LJF,,17NV
MA?\ !-8:+_P50UC]I8>-/,_M?05T,>&SI&WRL00P^;]K\XY_U6=OE#[V-QZD
ME6@GIV%&E)K4]U^ ?PPN/@K\%/"OA.\\0:MXJO/#VEP6%QK.IS/-=ZI*B!7G
MD9V9MSL"V"QVYQD@5UP.#0#GGV';_/\ G\Z*X3M"BBBCJ@Z%?5_^05=?]<F_
MD:^<_P#@WS_Y1._#7_KOJ_\ Z=;NOHS5_P#D%77_ %R;^1KYS_X-\_\ E$[\
M-?\ KOJ__IUNZZ,#_O*_PO\ .)WXC_D2UO\ KY3_ /29GVA4;G:>>_2I*CE'
M.>O'2O</C#QW_@H@?^-?OQS_ .R?:]C_ ,%T]<=^P$#_ ,,(_!3_ +$/0_\
MTWP5V/\ P4$M9M4_8,^-EO:PR7%Q/X!UV..*-=SR,=/G 50!DDD\ <FOBW]D
M#_@LK^S7\*?V3/A?X9U[XC?V?K?A_P ):5INH6W]@:K-]GN(;.*.5-Z6Q1MK
MJPRI(.."1S7S>:5J=+%Q=5V]WJTNOF?I_#F2YAF7#<Z>74)UG&O=J$7-I>SL
MFU%-I7T3ZGWY7Y"_\%N/@9I?[3'_  6*_9H\!ZU>:QI^E>*-):SN+G2KA8+R
M%3<W#$Q.RL%;Y1R5/&:^PO\ A^I^RM_T5+_RVM8_^1:Y?Q-_P5D_8B\:^/\
M1_%FL^(O"^K^*/#Z[-+UB\\"ZA<7^FC).(9WLC)'RS'Y".2?6L:6:86#NZJ^
M]$5/#_B:2LLNK_\ @JI_D=E^R#_P2=\%_L&V_C:\\%^)?B%XCOO%ND'3I(_$
MFKQ7<,>T.RF,)#%M)8X))(QVYK\H?V6/VP?AW\,_^#?GXT_#'6O$UAI_Q#U3
M7KFWM/#\K%=0N!-]BVNL?78!'+N8\ QD==H/ZJG_ (+J?LKX_P"2I,1[>&]8
M[]>?LO/?UY/M7F%W^WS_ ,$\[_Q9K6O7$/PWGUGQ(DL>K7LOPWNWGU%)=WFB
M5FL,MYFX[]V=^><\ 53S;"V]^HOO1F_#_B6_NY=7_P#!53_(^(OB)X"TGXI:
M5_P2[\.Z]80:EHNL1+:WUE,H>*\@-]8;XG'=6 P0>"#CVKV?QG\+E^&7_!P#
M\0-%^%^DV/AO4M6^$%\VGVVDVZ6L(OGL-L3(D84*QD2(D@+\RYZG(^C#_P %
M-?V##)X3D.H>!RW@/_D6F/P^O?\ BGN5;_0S]A_T?YD4XBV\J.F!6HG_  5J
M_8D_X6E_PG/_  DOAD>-OLOV+^W_ /A!]0_M40<#R?M/V+S=F /EW8XJ_P"V
M,+>_M(_>B?\ B'O$UK?V?7_\$U'^A^;_ .PO\:OV,?AO_P $M]:T3X[>$;/Q
M%\0;+Q,S:OHT%DT'B>^(N4\DP7.Z%UCCCR&43(H E5AF3#^I?M#R_!KX7?\
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MC"7M[1?>A2\/.)[?\B^O_P""JG^1\T_M$_""Z^(G_!4;]@OPE\6--CUK5/\
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M'[//_1</A-_X5EC_ /'*/^'E'[//_1</A-_X5EC_ /'*/K%/^=?>@_LG&_\
M/F?_ (#+_(]MP/6C ]:\2_X>4?L\_P#1</A-_P"%98__ !RC_AY1^SS_ -%P
M^$W_ (5EC_\ '*/K%/\ G7WH/[)QO_/F?_@,O\CVW ]:,#UKQ+_AY1^SS_T7
M#X3?^%98_P#QRC_AY1^SS_T7#X3?^%98_P#QRCZQ3_G7WH/[)QO_ #YG_P"
MR_R/;<#UHP/6O$O^'E'[//\ T7#X3?\ A66/_P <H_X>4?L\_P#1</A-_P"%
M98__ !RCZQ3_ )U]Z#^R<;_SYG_X#+_(]MP/6C ]:\2_X>4?L\_]%P^$W_A6
M6/\ \<H_X>4?L\_]%P^$W_A66/\ \<H^L4_YU]Z#^R<;_P ^9_\ @,O\CVW
M]:,#UKQ+_AY1^SS_ -%P^$W_ (5EC_\ '*/^'E'[//\ T7#X3?\ A66/_P <
MH^L4_P"=?>@_LG&_\^9_^ R_R/;<#UHP/6O$O^'E'[//_1</A-_X5EC_ /'*
M/^'E'[//_1</A-_X5EC_ /'*/K%/^=?>@_LG&_\ /F?_ (#+_(]MP/6C ]:\
M2_X>4?L\_P#1</A-_P"%98__ !RC_AY1^SS_ -%P^$W_ (5EC_\ '*/K%/\
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M'[//_1</A-_X5EC_ /'*/^'E'[//_1</A-_X5EC_ /'*/K%/^=?>@_LG&_\
M/F?_ (#+_(]MP/6C ]:\2_X>4?L\_P#1</A-_P"%98__ !RC_AY1^SS_ -%P
M^$W_ (5EC_\ '*/K%/\ G7WH/[)QO_/F?_@,O\CVW ]:,#UKQ+_AY1^SS_T7
M#X3?^%98_P#QRC_AY1^SS_T7#X3?^%98_P#QRCZQ3_G7WH/[)QO_ #YG_P"
MR_R/;<#UHP/6O$O^'E'[//\ T7#X3?\ A66/_P <H_X>4?L\_P#1</A-_P"%
M98__ !RCZQ3_ )U]Z#^R<;_SYG_X#+_(]MP/6C ]:\2_X>4?L\_]%P^$W_A6
M6/\ \<H_X>4?L\_]%P^$W_A66/\ \<H^L4_YU]Z#^R<;_P ^9_\ @,O\CVW
M]:,#UKQ+_AY1^SS_ -%P^$W_ (5EC_\ '*/^'E'[//\ T7#X3?\ A66/_P <
MH^L4_P"=?>@_LG&_\^9_^ R_R/;<#UHP/6O$O^'E'[//_1</A-_X5EC_ /'*
M/^'E'[//_1</A-_X5EC_ /'*/K%/^=?>@_LG&_\ /F?_ (#+_(]MP/6C ]:\
M2_X>4?L\_P#1</A-_P"%98__ !RC_AY1^SS_ -%P^$W_ (5EC_\ '*/K%/\
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M//\ T7#X3?\ A66/_P <H^L4_P"=?>@_LG&_\^9_^ R_R/;<#UI,GMS7B?\
MP\H_9Y_Z+A\)O_"LL?\ XY1_P\G_ &>?^BX_"7_PJ['_ ..4_;T_YE]Z%_9.
M._Y\S_\  7_D>V;BO\/ZTY&W"O#C_P %)_V>]X7_ (7C\)N._P#PE=C_ /'/
MI7JOPW^)&@?%OP?:Z_X7US2O$6A7Q;[+J.FW:75K<A6*MLD0E6PRD'!."".N
M:J-2$G[K7WF-;!8BBE*M"4;]TTOR-ZBBBM#G"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "J.N\Z9<?]<7X_ ]ZO51UY,Z5=,>GDMQ^!J9
M?"RZ?QQ]4?F/_P $8/V-OA)\6_\ @G#X!UWQ1\,? 'B+6[R74A<7^I:#;7-U
M,$U&Y1 TCH6;:JJHR3@ #L*^IA_P3L^ 8_YHO\*__"7L_P#XW7D?_!!W_E%S
M\.O^N^J_^G.ZK[ KY:C3@Z<;KHOR/T?B',L6LSKJ-6>DY?:??UL>-_\ #NWX
M!_\ 1%OA7_X2]G_\;H_X=V_ /_HBWPK_ /"7L_\ XW7LE%;>RAV7W'C_ -J8
MW_G[/_P)_P"9XW_P[M^ ?_1%OA7_ .$O9_\ QNC_ (=V_ /_ *(M\*__  E[
M/_XW7LE%'LH=E]P?VIC?^?L__ G_ )GC?_#NWX!_]$6^%?\ X2]G_P#&Z/\
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M'LH=E]P?VIC?^?L__ G_ )GC?_#NWX!_]$6^%?\ X2]G_P#&Z/\ AW;\ _\
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MVIC?^?L__ G_ )GC?_#NWX!_]$6^%?\ X2]G_P#&Z/\ AW;\ _\ HBWPK_\
M"7L__C=>R44>RAV7W!_:F-_Y^S_\"?\ F>-_\.[?@'_T1;X5_P#A+V?_ ,;H
M_P"'=OP#_P"B+?"O_P )>S_^-U[)11[*'9?<']J8W_G[/_P)_P"9XW_P[M^
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M_P )>S_^-U[)11[*'9?<']J8W_G[/_P)_P"9XW_P[M^ ?_1%OA7_ .$O9_\
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M *(M\*__  E[/_XW7LE%'LH=E]P?VIC?^?L__ G_ )GC?_#NWX!_]$6^%?\
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M=5-<_P"0->?]<6_D:4MF:4?C7JCX._X(._\ *+CX<_\ 7;5?_3G=5]@5\?\
M_!!W_E%Q\.?^NVJ_^G.ZK[ KYBC_  UZ+\C[KB+_ )&F(_QR_,*"<FBBM#Q3
MP3_@I9^W%I__  3U_9(\0?$:ZM$U+4K<I8:-8.Q5+R_FR(E8C^!<,[8.=D;8
MYQ7YR?L]?"+_ (*&?\%"_A+:_%^'XZ6/P^L=>\R^\/:,[-8QW,)8[&,,,#!8
M6 ^0S&1V #'((8^_?\'0/PSU3Q__ ,$UK?4--@N+B'PAXML=8OUB0L([<PW-
MKO;T4/<H,]!GFO</^"3_ .UGX!^,7_!.CX9ZAI?B+0[=/!OA;3]&UZ"6[CA;
M1I[.VC@F$RL?W29C+*6X9'5L@$UTQM&ES'/+WJG*SP3_ ((T?\%1/B5\9/CE
MXT_9Y^/MM##\5/ JRO!J"0+%)J"02>7/'.(\1M(N]'22,!94R>VY_HG7_P#@
MLA^S+X7T;7KV_P#BYH-O'X<OO[.OHC;W)N(KC]Y\B0B(R28\M\F-& [XW+G\
M\O\ @G_XNM/VPO\ @Y-^)'Q.\#M+>^"]'M;R234+<?Z->1I9PZ<KEAQMEE4R
M)T+ ;L !@.4_X(.?LY_"?]H7]O/]HBW^(_AWPUXLU;3;B9]$TO6[2.[@,3WE
MRMU,D#@JS)BW ;&Y!(<$9K6I2BFY/LC.-5\J2\S]2/'_ /P4\^$FG?L6^*/C
M9X7\::#XB\-Z%;2QV\L9E59-0V_Z/:3)M,L+R2F-<.JD"0-T.:^4O^"<?_!7
M'4OVY_V+?C5'XJ^(7ASPK\8K'3-?UG38X+&:WM?"^E164"Q78*QR,T4%Q(6)
M8R2G'1A@#Y"_84^&OA:3XV_M]?#[0['3]>^$>E>%M>OM-MI\75G'<6-S+_9T
ML>[<I:(&3RY.6^52"<9KTO\ X(U?";PHO_!#;]HWQPOA_1_^$R;1_%NCOK0M
M$-\UE_8\$OV8RXW>7OP^PX&X ^M$J,(IKT94:DG))GV5_P $Y/VNK/X6?\$Z
M[[XB?&3XZ^'_ (B:;I>O36]UXQM([Q[6%7:".*W*R6\4VX/(!Q&1EQSU(]!O
M_P#@L[^R[IGB;1='F^,GAE;S7X(+BTPEPT*QS(KQ^=*(_+A8JZDK,R%=V#@Y
M(_*CX7DG_@U9^(W'/_";PYYZ_P#$PTWI^/\ 3UJ7]K_]D+X;_#?_ (-V?A#X
MVTKP?H-KXTU34=/O[S7Q9QC4KHW(N3(CW&-[18V 1DE0$7 W"CV,'*S[D*K)
M0NNQ^LVH?\%:?V<=+^."_#J?XM^%U\627:V(MT:9[99RP41&Z5/LX?)"[3*"
M#U&0:Z[]JK]NWX1_L3Z98W7Q2\=:3X3_ +5#_8X94DGN;D+C<R00H\C*N0-V
MW:,C)R:_&7_@JG^QW\./@=_P17_9?\5^&?".B:7XKUU-)EU76(;95O=3:]TB
M6[G,\N-\B^< 5#,0J@*-HKVK]O+XJ>!/B9^W#\&/!/AOX#:;\;OVAF\)Z<5N
M?$VO2QZ';QFRDN4AEM'<03A8WEG??L'(_P!83A9=&._K^!?MI7L_+\3])_V5
M?^"@OP;_ &W1J ^%_CO3/%%QI*K)>6@AGM+NWC8X#F&XCCDV9XW!=H; )SQ7
MQQ_P0M_:Z^)G[27[47[36C>.O%^K>)-,\'ZQ!!HUM=[?+T]#=Z@C)'A0<%8H
MQ]%'6OE__@DKX7\1?#C_ (."?&6C>)-'\"^%]>70KX:II/@J,QZ%9.]O:S&"
M!"3MV,1O'02*]>L_\&WYS^V3^U][Z[;'_P GM4HE3C%2MY"C4<G%^I^N:]P.
MF3BBA3Q17&=84444 %%%% !7D?[=G[6VD?L-?LJ>+_B=K-N]]'X<M5-K9(VU
MKZ[D=8H(L]5#2N@+ $JNYL$ UZY7PW_P<5_#/5?B1_P2O\:MI,%S<R^'KVPU
MFXB@4NQMXIPLKD#^%$<R$\@",DX -73CS229-25HMGR+^S/X;_X* ?\ !5#P
M!)\6].^-.F?"OPSJEW,^@:=%OL8+D([)^[C@B9_LZNK*&F>1V*YPP(8^Q_\
M!)O_ (*;_%[_ (;%\0?LM?M(+;7'Q"TB.9M)UA(426]:*/SS#)Y06)U:V/FQ
MRA%)13NRQ%>R?\$*_P!J7P/\6?\ @FKX!TW3=;TFWU;P'I?]E:[I\ERB7&G/
M"S#S)%+9$<B8</\ =.3SE3CXJ^&WCS3?VU?^#HJW\5_#RX_M;PMX/@D-[K-C
M^\MY8[72GM9)=X)!C:XD2$."0RN""00:Z]).46M$<=^51DGN?HEX@_X+(?LR
M^&-%UR^O_B[X?MX_#E]_9M]'Y%RUQ'<?O!L2$1&27'EN"8U91CG&Y<]=:?\
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MDE_H/@.+R=&L V@W#QQ! 2JR;1'(^TD%B6YW$D6'BXN^Y7MG=);'UM_P0O\
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ME_VX_A?H?CC_ (*??L4S>*O#>CRZA\3/#OA6\\:1W%HA77;N:X$4YNAC$K,
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M[3?B]X,L[R./7=/N#)=P6QD9442++$DB0M(P17B=2&905 .#G:!X\TG]A_\
MX.=_&&I?$2XCT/0_'"3+I^KWY$5O$+VUB>&7S&(41^;&]OO^ZK9!("L1]?\
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MECTFR5#)&P*N!YA;:P()4<'%<_\ \$\/V*_A?\1?^"_?Q]\):YX*\.:IX/\
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M5_\ D%77_7)OY&OG/_@WS_Y1._#7_KOJ_P#Z=;NOHS5_^05=?]<F_D:^<_\
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M)JVCS&SFB6XN-36>/$B,DD;JD6?EW *-K*&8-^^!Y'<>A]*\-^+?_!3#X"_
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M4-%FBBE1)=GF1NLD;HRDQ1MC 8%3@CYE/'WO_!#KX5:G_P */:X\3?$>23X
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MZ^4__29GVA1117N'Q@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/AGH>O>9X@MM+U;PUJ5_=BQ2[BN0#(DMO)%-MP4D4;AC=M._&3@?\$@X0/\
M@W4^-QVX:33O%[,?4_V7C/Z5\O>%?^57WQ-_V4V/_P!#M:7+'HM4PC*26KT:
M.J_X+8_%OQEKW_!-7]EW3=(\':=X7^$>M^&](U-7L+V5DM]1-G+LTT+)*TC1
M1P[75I YR!ER0<_1UG_P6.^/7[)_C/\ 9_\ #OQH^%/A'P?X1^(WD6%Q?QW,
MDEQ;0K<)"UPK+/)& L,MK(P.3\[<#@5Y!_P5M\(ZEKG_  ;]_LJ:E9V5Q=6>
MC6V@O>RQQEUM4DTB1$=\?=4OM7<<#+J,@D9]/_;XUGPK_P %>_\ @A_+\1O
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MVP?BY\$_A7\$_"OC?Q7X-U_4]-T>07CVT$-I97DUO)<WKR3(ASMA  >(;I,
MD[5/EGA'XC:E_P %MO\ @M)\,OBA\/?"?B+1_A?\'HK)KW6]4M_),IM;B:["
ML49D#RS2K&L0<MM#.< D#S+]E#]OO2?^">7_  6-_:F\7>*O#OB+6?!>I^*=
M?TS5;[1K3[1)I#MK,KP2/DA0CLC(07!^88SC:3V<.D;NRNNP>TE_-;5Z]S]
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MX=\(_$+7/AEXKTC4H]6TS6=-N)H<ND<B-#-Y3HYC=9#R#\K!&PP!4_"/CO\
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MU\I_^DS/M"BBBO</C HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\
MRD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[
M&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O
M]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+
M/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG
M_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_
M */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"
M_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!
MS_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */.
M_P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!J
MC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#
M_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,
M1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\
M[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&
M;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_
M\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$
M>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT
M/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[
M3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_
M !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7
M"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C
M<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC
M_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\
MRD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[
M&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O
M]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+
M/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG
M_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_
M */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"
M_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!
MS_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */.
M_P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!J
MC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#
M_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,
M1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\
M[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&
M;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !VC_A@O]JC_ */._P#,1Z1_
M\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT/_"7"_\ RD^+/^&"_P!JC_H\[_S$
M>D?_ !VC_A@O]JC_ */._P#,1Z1_\=K[3W&C<:/[&PWG_P"!S_S#_B(&;?RT
M/_"7"_\ RD^+/^&"_P!JC_H\[_S$>D?_ !V@_L%_M4#G_AL[/_=(](_^.U]I
M[C2.&;I1_8N%ZW_\#G_\D#\0,UM\-#_PEPO_ ,I/B>3]@[]J2:)HV_;*\Q),
MHX_X5)I'/_D7_.:]U_X)_P#[)47[#/[)_ACX8PZ])XF7PV;HG4GL_LAN6GNI
M;AOW6]]H!E*@;VX .37L++E,-]34D?W!Z#I710R^A0ESTT[^<I/\&VCS,TXJ
MS#,*'U7$>S4+J5H4:-+5)I7=.G!NUWH[K4=11178?/!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>moln-20221231_g7.jpg
<TEXT>
begin 644 moln-20221231_g7.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BJ]MJ-O>W-Q#%-')-:.$F16!:)BJL P[':RGZ$58I
M1DGJAN+6X4444Q!1110 4444 %%%% !1110 45R?ASXIVOBCXD:MH-KL?^R8
M$>60'JY)! [<#'XUUE88?$TZ\7.D[I-KYIV?XFV(P]2C)1JJS:3^35U^ 444
M5N8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!\Z_&+XFW7P/_:1.H*LDVGZM:PR75NIQYH \O<,\;AM_&O>O
M#7B2R\7Z':ZEIUPMS9W:!XW7N/0^A'((/(((KYI_;PT\I\0-)NOX9-/$7XB1
MS_6N;_9L^/\ /\*=>6QO6>;0[Z0"9,Y-LW02*/RW#N!["ORG"\3O+,\KX'%/
M]U*;:?\ *Y:W]'?7MOWO^IXGAE9GDE#&X5?O8P2:_F4=+>JMIWV[6^RJ*AL;
MV+4K*&X@D62&=!)&Z]&4C(-35^JQDFKH_+6FG9A1113$%%%% !1110 5Q/Q\
M^*,7PI^'EU>ALWUQ^XLHPV"TA_B^BCD^O XR*[2218D9F8*JC)). !7Q7^TS
M\66^*7Q#E\B16TO3,V]GMSAQQN?GNQ]AP%';)^3XQSY9;@&X/]Y/2/EW?R7X
MV/J^#\B_M+')37[N&LO/LOF_PN==^Q)JDVH_%C6)+B3<UQ9-,Q)^9W\Q?TPS
M?D*^J*^-/V/;V2T^.6FQJRK'/%,DF>X\MB,<?WL>E?9=>?X<UG4REI])R7Y/
M]3T/$2BJ>:W76$7^:_0****^\/A HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<_V^;+:GAVX_OF6/\ +:?Z
MU\WU]4?MVZ:T_@+2;SC9;W9B//.77(_] -?*]?SSQ]3Y<ZJ/NHO_ ,E1_0?
M=3GR:FNSDO\ R9_YGN7[*G[1G_"&W<?AW6[C&DW#?Z-/(>+-R>A]$8DY[ G/
M )-?50.:_.4'8<BOI#]DS]HC[0]MX5UJX(<@16%Q(W#'@+$3Z]E]< =2 ?IN
M!>+N3ERW&O3:$GT_NOR[=MNUOFN.>$N?FS+!K7><5U_O+S[]]^]_HJBBBOV
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M^<>)M&V+HU.\6ON?_!"BBBOTX_,PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*HX>KAJD96<EHT][=O0^M\.<+B<-6KTL1"4;J.Z:VOW]3'HHHK\H/U4****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17XY?\$+/^"A_P 2?VT/^"A_CK6OBAXR>YM5\%W#6.F>:+72]//V^RP((,[
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MN2_X-2OAUI]I\ /BCXM$$!U;4/$$&D--C,JP06R2A<]E+7#'CJ0,YP,>S_\
M!Q[^S[J'QL_X)S7FJZ5;R7-U\/=9M_$4T<8RS6HCEMYSCT19Q(?18B:^)_\
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M34H8=<30].N;C0O$5A($<G>5$*R&)\JS$-'(,=F!_H/C;>BMAER,X/:OA?\
M:4_X. ?@Q^RS^T[KGPQU[3/&&K76@O%;W.IZ';V]Y:I<,BLT)!F1]T>X*P4,
M0P*XR#7W%IEY_:.G6]QY4T'GQK)Y<R[9(\C.&'9AG!'8UX^<5Z];V=6O3Y6U
MO_-MK_7<];*Z-&CSTJ,^9)[?R^7]=C%^,'_))?%'_8(N_P#T2]?SI?\ !OA_
MREH^&/\ UQU?_P!--Y7]%OQ@_P"22^*/^P1=_P#HEZ_G)_X(!ZM:Z)_P5<^&
MES>W5O9VZ0ZL&EGD$:+G2KL#).!7H9%_N.*_P_I(X<Y_WS#>OZH_I8K^7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"3U1^EOPY^(>E_%+PE:ZUI$WG6=VNY<\/&>NUAGAAW%;U?G3^RS^T=J'P
M\6+'=>?)H5\P%S P.(_]M0>_TZX%?H/X=\0VGBK1;?4+&9;BUND$D;J<@@U^
MZ<+\24\UP]WI4C\2_5>3_ _FWC'A.KDN*LO>I2^&7Z/S7X[E^BBBOJ#XX***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA\(^.=6FL=$\4^'=8OK?B6WLM2AN)8O]Y48D?B*X^5]CJYD=)1114E!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAYO^R>7?_H^2OG?_ (.P?^2O_!W_ + ^H_\ H^&OHCPI_P JP\W_ &3R[_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 5K(U32<K]VNOEM@!]:S=0M<QUA5H*QU8?%M,^@?^"67_!0*^_96^)]KX/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;QN%>'KRH-WY6?08/$*O1C62M=!1117*= 4444 %%%% !1110 4444 %%%%
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MY]ZHR79IK77O6+Q!M'#EXW&:3S\U0^T>]'V@UG[8OV)>$_/_ ->O4OV4)/\
MBOKX\\6#?^C(Z\C67%>M_LF1[_$6K3?\\[9$_P"^FS_[+6M*I[R/ XHBHY76
M;[?FTCZ#2?FK$<VXUF1SX-3Q2\UZ,9GX'.D:2S>M0W'S1FFQR\4YSE:TO=&'
M+9G.^(;8R1MCTK]Y?V*_B5IOQ6_97\"ZMI4L<EO_ &1;VLBH03%+%&(W0^A#
M*>*_"?4H=X->U?L%_M_Z]^Q1X]6&4S:IX(U28?VGIN<F'/!GA_NN!U'1AP<<
M$?FOB%PU5S3"*6'^.FVTNZZKU[?=U/W/P:XXP^09C*&-_A5DHM_RM/1^FKO]
M_0_<&BLGP1XUTOXC^$=.U[1+R'4-)U:W2YM;B%LK*C#(/L>Q!Y!R#S6M7\TR
MBXR<9*S1_<U.I&<5.#NGJFMF@HHHJ2@HHHH **** "BBO*?VS?B%<_#KX":I
M-9LT=UJ3II\<@ZQB3.\_]\!@/0D'M0!Y_P#M!_M[Z?X7U&ZT/PWI]GKTD>Z"
MZN;H[K3/0HJC_6#KDY _WLY'@]C^TPL6M"\N/ /P]N/GW%1I13\!\Y'Y@UYC
M16RBD9W/T,_9L_:1T#XY:']ET^W72-2T^)?.TPXVQ(. 8R  R#@< $<9 R,^
M<?M_?M 7G@^QMO!^CW$EM<ZE"9]0F0X98"2JQ@]1N(8MT. !R&(KY:^%'CRX
M^&/Q'T?7K7<TFFW*R,@;;YJ'Y73/^TI9?QKTC]OE)O\ AHF[DD8M#-8VSV^3
MT39C_P!"#5/+J5?0\7H!(.1116A)]Q?L)?'F\^*/@N[T75II;G5=!V[;B0[F
MN(&R%W'NRD$$GJ"O4YKWJOB'_@G%-,GQSU!(_P#5MHTIE&>,"6'!QZYP/Q-?
M;U8RW+B%<O\ &'X5:?\ &?P#>:#J3/''<8>.9 "]O(O*N,_D1W!(XSFNHKSW
M]H?]H;2_V??"R75U&;S4KS*V5DK;6F(QN8M@[57(R?< >TC/ASXL?L[^*O@[
MK$MOJFESR6JC='?6\9DMIER1D.!\IX^ZV&'&1R">5T+PQJ7BF[^SZ9I]]J,Y
M.!';0-,Q_!0:]*\9?MJ_$/Q;JLEQ'K3:1 W"6UC&L<<8QZD%CZY+'GICI6G\
M,?V[O&W@?4U;5+I?$FGM_K+>Z 20>Z2*,@\?Q!AC/&3FMM3,]Q_8W_9+N/A!
M))XB\1*BZ_<1F*"V1PZV4;8R21P9#C'!( SUR<>V^+O!NE^/=$DT[6+"VU*Q
MD(+0SIN7(Z$>A'J,$56^''Q$TOXJ^#[37-'F::RO%) 8;9(F'#(X[,#^'<9!
M!/"?MG?%.\^%/P1NKC3IGM]0U2=-/@E4?-%O#,[#T.Q& /8D=\&LM6R^A\]_
M'?P9\$_AMXCO+.TD\3:AJ$1.ZSTZ\C^S6[?W#+(C'ZX+D'@\Y M_ _\ :[\"
M?"6]6.S^'LVDI,GESW\.H"]NW''7>B<$@$@,!GH.U?.A.316O+W(/T\^&WQ0
MT/XM>'$U30;Z.\M6.UP/EDA;NKJ>5/UZCD9!!KH*_//]D/XL7?PM^-&EJDC?
MV=K4R6%[#N(5U=MJOCU1B"#UQD<9-?;/[0_CF3X;_!3Q)K$!9;BVM"D#+U26
M0B-&_!G!_"LY1L[%IGD_[1?[>%O\.-<GT/PO:V^J:E:.8[JZG)-M PZHH4@N
MP/!Y !&.><>*V7[?/Q(M=8-S)J&GW$)8G[))8QB$#TRH#\?[WYUXPS%FR>2W
M)/K16G*B;GW=^S5^V;IOQLO%T?5+>/1_$!!,:!\P7@'_ #S)Y#?[)SP,@GD#
MXV^,^N3>)/BWXDO;@L9)]2G.&ZJ!(0%_  #\*PM'U6XT'5;:^LYGM[JSE6:*
M1/O1NI!!'T-=G^T!X3NM,\5P>(&MUBT_QE NLVS(#Y8:4!Y8QG/W)&8<\XP>
MXH4;,1PE%%%4!WWPZTS4/%?P>\;:?;-));Z:+766A'(S&[1,1Z?)*2?4(/05
MP-?;7["?P'D\%?#?4-4UNS"W/BA57[-.@.+4 X#*?[^XD@]0%KSSX[?\$^]6
ML-:GO_!0BO\ 3[ARXT^241S6V<G:K,0K*.V2"/?&:CF5QV/FBBO3Q^QE\3&.
M/^$6N/\ P*M__CE>U_LT_L'S>%]=M=?\9- ]Q9OYMOID1$B!Q]UI6Z''4*O&
M0,D\J7S(5F>Y? #PG)X'^"WAG2Y]RW%O81F96ZI(XWLOX,Q'X5V%%%8F@444
M4 %%%% !1110!^8/_!U1_P F3> ?^QXB_P#2"\JS_P &K?\ R8?XW_['VY_]
M-VGU6_X.J/\ DR;P#_V/$7_I!>5\>_\ !''_ (+3>!O^";_[.7B#P7XH\)^+
M->OM8\22ZU'/I9M_*2-[:VA"-YDBG=F!CP,8(]Z^PP^&JU\E]G25WS?J?*UL
M13HYLYU796_0_H K\K_^#K+_ )-9^&/_ &-4G_I)+4__ !%7?"/_ *)O\1_S
MLO\ X]7G?_!PK\?=-_:D_P"";7P'^(6D6=]IVF^+M;.H6]M>;?/A5K28;7VD
MKGCL2*X\KR[$X?&TI5H-)O\ 1G9F6.H5\)4C2E=V_5'L'_!!'_E#%XH_Z_=>
M_P#2=:_*+_@D-^R?H/[:'[>_@SP3XJ6:;PRWVC4M3@B<HUW%;PO*(=PY57=4
M5B"&VLV"#@C]7?\ @@C_ ,H8O%'_ %^Z]_Z3K7P!_P &W'_*4'0_^P#J?_HF
MO9HU)0^O3@[--V^YGDUJ<9_4XR6C2_0^DO\ @X[_ ."?'PG_ &=/V9_ GCCX
M?^"]%\':A'XB3P]<II4 MXKV"6TN)E:51PSJUKPY^8AVR3QCWK_@UVUNYU7_
M ()UZ]#/+))'IGCJ_MK=6.1&AL[&4J/0;Y'/U8^M5/\ @Z<_Y1\^#_\ LH5E
M_P"FW4Z7_@UD_P"4>_BW_LH%[_Z;M-KSJE253).:;N^;KZG=3IQAG%H*RY>A
M^-%I\>=>_9B_;8UCQYX8:U7Q!X=\0ZE-827,7FQQ2L\T8<KD!BN_< <@D#((
MR#Z[_P $C/@MX-_;L_X*,:;IWQFU^]OO[8-SK1ANI"[^*M00B4VTTI.5#KYL
MC'JXC* @L".;_99^!.@_M,_\%6-)\"^*([F7P_XA\:WD-_%!*8I)HEEFD*;A
MRH;9M)&" 3@@X(]?_P""T7[$E]_P3-_;>T?QQ\.8Y/#WA3Q%<KKWAF:S&U-$
MOX'1I;9.P"2;)$7H$D"C.PU]16K4W/ZK%\M24-'^GYO_ ()\[1I34?K,ES0C
M+5?U\D?I[_P<$_&*Z_9V_P""8.K:;X;F71/^$JO[/PG$MJ@B6*UD21Y84 &%
M5H('C( QL8@5^3/_  24^,_[+/P&G\4:W^T%X8OO&&MS/%;Z)92:.FI:?;0;
M299&C9PK2,Q4 LIVA./O&OT:_;.\9-_P66_X(;MXS\'VJ7'BKP_+!K6H:/;J
M9)(+^R5EO+=%&6SY,LDD8Y9T:,8RW'YY?\$@/VJ?V</@G+XG\/\ [0WPZT+Q
M%8:I+'>:5KUUH2:I)I[JI62!UP7$;85E* X8-D?-D>+E=+ER^I2<9.2E[RB[
M2Z?UYZGK9E4YL=3JIKE<='+X>IY#^VW\3?A99_MBMXT_9Q76O#/AF.2UU:P@
MG@-K)H^H(VYA -S%8PZ+(O.%+E0 J@#[G_X.2_VI=1^*_P '/V<]+M[B2UTO
MQ;H)\:7UDAQ'++-# +<G_KF'N0.?^6AZ\5YOXJ_X*.?";Q[^U@OA;X/_ +(?
MP:\8>$]5N[?3M#M[_P -"VUK4IWVJS$HS1HK.3M!C)"@%B,D#Z(_X.9OV1M3
MN/V>/A+X^T/1;&QTGX>P/X?U>RTY<P:7!,L MO+^5<6\<D3Q X&#+%P,G'3*
MI'ZUAHUHN+ULY--[:7\[_B<\:;>&Q#I236E[)I;ZV\K?@>A?\$3O^"3_ ,&?
M$G[ WAOQIXY\#Z#XV\2?$*&:]N+C5[47(L8/.DCBB@#<1?(@8NH#EG/. H'Y
M*_\ !4/]E[2_V-?V\?B'\/=!,W]@Z/>0W&F+*Y=H;:YMXKJ.(L22WEK-Y>XD
MD[,GFOOO_@DG_P %]OAW^R[^Q]IOPW^)^G^)([_P6)TTJ\TNT2Z34K9Y7F6-
M@67RY49R@S\I4*2P.:_.#]NC]J6\_;4_:R\;?$Z\LO[-_P"$IO5DM[3=O-K;
M11)!!&S=&988HPQ P6!.!TJ\KHXV./K2KWY'>U]M]+?(SS"IA'@J4:-N?2]M
M]M;_ #/ZN_#?_(NZ?_U[1_\ H(K*^*WPI\._''X>:KX3\6:5;ZWX=UN(07UC
M.6$=P@8-M.T@]5!X(Z5J^&_^1=T__KVC_P#015VOSOF:=UN?>63C9G\OO@_X
M(^%=1_X+*6_P[FT:WD\%-\7GT Z46?R38#5S"(,YW;?+ 7KG'>OTH_X+[6V@
M_L$?\$Y=!^%?PIT>'P;X?^('B1QJ%O8R2;9((X_-E3+$M^\D$&><%4*X()K\
MX?BI\0H/V8O^"U'B3Q=X@M+UK#P=\8;G6KR&%!]HDMHM7:<F-6(!+1\KD@'(
MYP<U^C'_  5,\6:3_P %E_\ @EQ/\3OA#IGB*[7X6>*9I)K.]M4CN[FWCMP+
MIDC1WX5)HI1R&*QO\N<"OT#&\_UG#5*E_9Z7[7Z7/B<'R_5\13A;GUMWMUL>
M<?\ !O;_ ,$J/AC^T7\#-:^*WQ,T"U\823ZM+I&D:9>,QL[6.%(VDF9%($DC
M,Y4!LA0F0,MD>&_\'!7_  3K\'?L)_&[P;KOP\LVT3PS\0+:Z<:4LKR1Z?=V
MK0^88F8EEC=;B(A23M97P=I"KT'_  1+_P""U?AG]@?X;ZY\._B1I>M77A>\
MU!M7TO4-*A2>:RF=$26&2-F7,;>6K!E)(;<""&ROF'_!77_@HI-_P5E_:3\(
MZ;X#\.:ROA_P^CZ7X>L9H@^HZG=7,B>;*8XRP4N8X45 6($>2<L56J-+'K-9
M5)M^RUZZ6MI\[_J9U*F#>6QA"WM-/6]]?P_0_;7_ ()$_M#ZI^U)_P $Z_AG
MXNUZ^DU#7IK&73]1N9/]9<36MQ+;&1SW9UB5R>Y<GO7TG7B/_!.']F*Z_8W_
M &)/A[\.=2>WDU;P_IS-J+0'=&+J>62XG53_ !!9)74-W"@X&<5[=7P>,E!U
MYNG\-W;TOH?:8535&"J;V5_6VH4445SG0%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUB^T'PR+A;6?598Y;N3SKF6X?>T<<:'#RL!A!P!U.2<O]MG]B3P/^WU\$9_
MGCR&^73FN8KVUO=/DCBOM.G0\20NZ.JL5+H<JP*NPQT(]>HJ57J*I[9/WKWO
MYC]C!T_9->[:UO(^.OV%?^"*?PW_ .">OQCD\:>!/&7Q0N+RZLI-/O+#5=1L
MIK"^A?! D2.TC8E7574A@01W!8'[%HHIXC$5*\^>J[ON*CAZ=&/)25D%%%%8
MFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW';V\;S32L%1$&68UW'AG]G;7-7D#7JQZ;#GG>P>0CV5<_J1]*]6\#_"W3?
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MY.BMK(@_0C]EK]I*W_: \+3>?''9Z]INT7MNF=C YVR)G^$X/&25/U!/JE?
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M28'\+1SV_/XSC\<5]#PGRK.,/S?SK_@?B?&^(7.^&L;R;^SE]W7\+GY!:4G
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M6(/V2\"[L ]8W'=2>?4'IU(/R-XC_8F^(_A_4)85T'^T(XVPL]I<1O'(,XR
M2&Y]P#ZXK]!J^-_VQ_VN-5U+Q3?^$_#=U-ING:=(UM>W,+[9;N0'#J&'*H""
MN ?FYSP<546]B96.7^''[#_B'7M=CC\376G^&+(-A_.NHI+F3V1%8\].6( '
MKC%?;7@?PAIO@+PI8Z1H\*0:?8QB.%5.<]RQ/=B223W)-?EU+,\TC,[,S,<E
MF.2:]#^!/[2OB+X':Y"UK=2WFCLX^TZ=*Y,4B]"4S]QL="/09!'%5*+8)GZ
M?$"=K3P)K<R,ZO'83NI7[P(C8\>]?EW7ZB:!K6G_ !,\#V]];[IM-UNT#J&^
M5C'(O(.#P<$@X/!K\Y_C5\(M0^"GC^\T6^5V2-B]K<%-JW<)/RR#ZXP1DX((
MYQ2IA(Y.BBM+P=X0U#Q]XGL]'TJVDN]0OI/+BB3N>22?0  DD\  GM6A)][?
ML474EW^S)X9:5F8JMPBLS;B56XE 'T & .P KU2L/X:>"X_AU\/]'T.)E==+
MM([<NJ[1(P'S-^+9/XUN5SFB/A?]O_X<W/A7XU/K7E_Z#XBA25) /E$J*$=#
M[\*WIAQZ&O"Z_3KXG_"W1?B]X3FT?7+47%K(0Z.ORRV[CH\;<[6'//<$@Y!(
M/R=\1/\ @G=K7A:.[OM/\1:%)I-LID,FH2-:-&F?XCADX'<L!].E:1DK$N)\
M[5[1^SM^S;??%OX2>-M4MQ(MPL"6VFKCY;F5'6:1?KA$4=LOSTJG\._@-X/D
MUV'_ (2GXC>&K>UCD'F6]A(\KRC/*^:5"+_O#<*^YOA_I^BZ3X+TZV\.M:-H
MD,(2T:UD$D3(,\A@3NR<DG)).<\TY2!(_+^:%[:9HY%:.1#M96&"I'4$4VOM
M#]K3X9_"6^U::[\0:Y'X9\1W"!V>S4S22]@TL"@Y^ORDXZ\5X?X2^$WPHU/6
MXH[WXGW2VY?#(=$DM6D'M(Q=5^K _3M34KBL<K^SW\)[KXR?%+3=)AA:2T65
M9[Y^BQ6ZL-Y)]^@]217Z35R/P<^%GAGX7>$XH?"]O#]CNU$QNED$SWF1PYD_
MB&.F.!G@<UUU9RE<I*P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O,_VP_@TO[0/[,7C7P@55IM8TQQ;[AD"=,2PG\)$0_A7IE%;
M8>O.C5C6I[Q::]4[HYL9A:>*P\\-55XS3B_1JS_!G\V4%O-I=[-:W,;0W%M(
MT4L;##(RG!!'J"#6S9/Q7UE_P62_8LF^!'QB'Q!T*R*^$O&,_P#I)C'R6-^0
M69#Z"0!G7W#CL,_(VFW&Y17]9Y!FU',,)#%47I)?<^J^3/\ .WC#A_$9/F-7
M 8E:P>C[KHUY-:F_9'(J];]!6;829K2MCQ7U-)GP&(5F78A\HIS')IL9R!3I
M/O"NOH>?U*DP^6LV]3<:U)ER6JC<QYKGJ([*,K,Q+Z*LF[@S707<&XUG7-MC
MBO-JP/:P]4P9X,5''#BM6:US42V>#7&Z>IZ4:VA7@A^:M6R7%5XK;!J]:Q8-
M;4XV.>M4NC1LC@K6O;/D5D0':*OVLNVO1HNQX>(C<U8&RO6GO]ZJ<$V:G$W-
M=L971YTH.XR=<51NH_E/Z5HRL&JM<19%14B:TY6,2[BS6;<P=:W;J#FLZ>#-
M>?4@>O0JF/)#BJTL=:LUMS52>'FN.5,]*G4,YUVFH'X%7;F/%4Y^%KGDCNIR
MN5]V*-V!32V!^--!P:P<CIY259=O_P!>GB>J^<GFG*U-2!Q)O.I1+FH@V:<H
MW-5$<HLF*81FG,OZF@)F@9&10$Y_PJ58C2",FIY1\Q);\&M&T;C\*H(,5:MV
MP*VIG-6U1I1R$#Z4DC[C[>E01R<4YY*Z>;0X>74<[XJ%I,'UIKR;FXS2?-[5
MFW<T41"<M_\ 7H RW%+\WM2Q+S2*'1Q9J>*+)_K0BXJS%#M&WUK:,3"<AJ08
M-3+ 2*ECAQ4JP<UM&!RRJ%?R*/(]ZN>30+?_ "*KD,_:E06]/6V'I5M;?/\
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M!(9T>-#LMIC]^-CT&3EATR"0,[37B-?(+5'Z@%6)]9O+G38+.2ZN)+.U+-#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFMU"[^;?^1_:G@#AIPR:O6EM*I9?**O^92U_P]8^*M'GT_4K2WOK&Z&V6"=
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M_P 4O"L&KZ'=+=6,WR\#:T3#JC+U5AZ?3L0:W:R;NS1!1112 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW0;C5_VD-+N(HPT.F07%Q.3_  J8FC'X[G6OOFL9[E1"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBFRRK A9V5549)8X H =17EOC?]K_ ,%^"+MK
M>2_:]F5=Q6V7>!]357PC^VKX)\5:B+9KJXL9&^Z;B,JN?0GL?3/!I\K"Z/7*
M*J:/KEKK]FMQ9SQSQMW4]/KZ5;I %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?TZ>2W&PK*48J6!^\?Q^Z/Q/>OJ2OSQ_:RDGD^..O>=)*Y^T\;UQ@8&,>W7
M^M5'<F1YO).TA//#$G I%E:,Y5B.U)16Q)['^S5^T[J7PO\ $UK;73_:M(F;
MRY4E;_4 _P 2GMCTY'TQ7WA9W<=_:131,LD<RAU93D$'FORNMSBX7A3SSDX!
M_*OT*^ OQ#M;/X">'[[6KZ"S9;=8F>>49) XS[X'2LYKJ5$],HKA[/\ :1\$
M7\[1Q>(M/9EP<;^Q[UV5AJ$&JV<=Q:S1W$$HW))&P96'L1691-1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;O7O'P%_X)F?&3]HB\B-GX5O=!TUB-U_K4;6<:@]U5AO;CD87!]:_2S]A_\
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M6!J=YO[UV7PO^ 7C[X\W\=MX1\)ZYKQD;;YMM:L8%/\ M2G"+^)%?=_[(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#SO\ :=^%/_"VOA;>6<1VWMM^_MFV%CN';CU%?GGJVES:3>RPS1R1M&Y1
M@RXPPZBOU0KS#XV_LK>'?C'%)<&)=-UAAQ=PH/WI["1>C#WZC/6KC*Q+1^>U
M%>X>)_V#/&FBR2"UAMM156P&BDVY'K@\_P!1[UJ?#W]@'Q)JFI'^W#;Z;9QJ
M2?WF]W(Z8QQ@GOZ5?,B;,\E^%'Q4OOA+K_\ :6G[?M&PH">P-,\5_&+Q%XQU
M*:XOM7OYFF9FQY[*J[CD@ <8K.\=Z+#X>\57UE;R^=#:S-$K_P![:<']0:R:
MKS [KP#^T5XJ^'^M175GJ]YMCP#%(_F1R#T96ZC\0>.M?87[/7[6.E?&N-;&
MX1=/UN-06B#;HIO=#U_ \U\!UO\ PS\7W7@CQE8ZC:RO#):RK(64D':#EA],
M9ZY%3*-QW/TYHJGH.I#6-$M+I>EQ$LG3U -7*Q+"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H*[AR,T44 <
MKJOP-\%:[.TM]X/\+7DK')>?2H)&)/7DJ:T?#'P]T'P2C+HNAZ1I"MPPLK..
MW#?]\**V:*UE7JN/*Y.WJ<\<)0C+GC!)][*X4445D= 4444 %%%% !1110!3
MUG0+'Q%9-;:A8VM_;L03%<PK*A/T8$5S:_L^> 5N/.7P/X/$N=V\:-;[L^N=
ME=A16D*U2"M"37HS"IA:-1\U2";\TF5M,TBUT2RCM[.UM[2WB&$BAB$:(/8#
M@59HHK-MMW9M&*2L@HHHH&%%%% !1110 4444 %%%% %'7?#>G>)[,V^I6%G
MJ%N3N,5S LR$^NU@17/V_P !/ MI-YD7@OPG'(#D,FD6ZMGZ[*ZZBM(UJD%:
M,FEY,PJ86C4?-4@F_-)D<%M':0+''&D4<8"JJ+M50.@ J2BBLS?;0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9=ZX
M/>EHH _/G]K;X777P[^+&HL\>VSU"4W,$AQAPW)''I7EM?I1\7?@CH?QHT3[
M+JT++-'S!<Q'$L)]NQ'L>#7Q[\8/V+_%'P^U/-C:MJ^GR-A+BV';MN7JK?F#
M[5K&1#1XS72?"?P/>?$#QOI^FV2YDN)E!9A\J*""S-_LA<D_AZUJ:#^SMXNU
M^_\ )@T/4&.[:2T)C /3G=CN?R]:]8\4_#J;]DKX.74LCF;Q)XB;[&)D_P"7
M*WZN$/\ >;IGZ>E-R$:7QF_;8NO"TK>'_"KH(=-VP?;Y$W&?:,$KR."1U]!7
ME]O^V%XZMKIIAKEPQ9@P5PI08]L?7V->83S-/*S,?_K4RCE079]I? ?]NG3?
M& AT_P 4"/3[YMJ+>(,02L> &'\!SWY4Y'-?0D4JW$2O&RNC#*LIR&'M7Y5P
MRM#*&'\)SUK[F_8;^+-Q\0?AS+I]XP>ZT=Q&& Y9#]W)Z9J91MJBDSW"BBBL
MR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKP?\ :;_X
M*7_!/]D6\;3_ !EXZTV/Q!G:FA:<'U'59&(.U?L\(9TW8(!D"KGN*^;_ !%_
MP5!^/WQYN%3X0?!&Q\#Z*QR-<^*-P]O+(,'@:=:MYJ'CAB[J2PX !-55BJ-/
MVN(DJ<>\FHI^E]_178J/-6G[*A%SEVBFVO6VWSL?H16;XE\7Z3X-LEN-8U33
M=)MV) EO+E($) R1EB!T!/TK\U=;^#WQ]^.<1'Q-_:4\906<P8MI7@.S@\-Q
M19ZI]IC4RS1D#HXSR1]<?1?^"5_P3LKG[5JGA>\\4:DPQ)>ZYJ]W?32<[N0T
MFSEB3PHR6/KBOG\1Q9DU'3VLIO\ N0=OOFX?@F>_A^%,XK*_LXP7]^6OW14O
MQ:/MKQE_P5$_9S\!S>7J/QL^&OF E62TUV"\:,@X(80LY4@]C@]?0UQ.O?\
M!<;]E/PYN^T?&#1I-N<_9=.O[KUZ>5 V>G;V]1GR?PU^RU\,_!L6W2?A[X(T
M[@ FWT.VC9L# )(3+'&>22:ZC2?!>CZ!M^PZ3IMEMZ>1:I'MZ8^Z!Z#\J\N7
M'V7KX</-_P#;\5_[;(]2' >.?Q5X+T@W_P"W1.FTC_@N[^R=K;JL/Q>T]-_3
M[1HNIVXZXY,ELN/Q[<]*Z[PQ_P %<OV9_%LZQVOQL\!Q,Q !O=0%BO)QR9@@
M'X]!STYKS/4?#VGZPK+=V-G=!OO":%7W<8YR/3BN=UWX > _%$3)J?@GPCJ*
M,""MUH]O,&!&#PR'MQ]*4>/\"_BP\U_V_%_^V(<N \:OAQ$7_P!N-?\ M[/M
M+X?_ !L\&?%J,OX5\7>&/$R@9+:3JL%Z /7]VS>AKJ*_+GQ;_P $R/@3XQN/
M.F^'>DV$W:32Y9M-*_00.@]1TZ4S0_V/_&WP6EAD^$GQ\^*7@>*U=I8M+U&\
M&O:2'.<G[-<<8)/.2<]>#S7HX?C#)JKLYSIO^]&Z^^+D_P#R4\ZOPAF])7C&
M,U_=E9_=)17_ ),?J317YV^$OVU?VLO@*N?%W@_X?_&[1U=BTWAZ[;0M912Q
MP3'*# ^U<?*@#'IDXR?7_@A_P6B^"/Q7\8Q^%=?U'6OA7XT8A3H7C;3VTN;<
M03Q,2T!!P0I,@+<8'-?18:5/%1<L).-1+?E=VO5?$OFD?/XFG5PS4<7"5-O^
M963]'\+^39]9T5';7,=Y;QS0R)+#*H='1MRNIY!!'4&I*"0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB*CJXB;E)[MMM_>S[[#X6CAZ:I4(J,5LDDE]R"BBBN<W"BBB@ HHHH ****
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M3AZ^%K?5\5#DGVZ-=XO9K\5U2/1J***T,PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$$>[='?ZL5/SY 5HXE(5>""02TWT!I>EVVB:;;V5E;P6=G9Q+!!!!&(XX8U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/Z_I7O5<?\"OAP/A9\,].TEE59XU\R?'=VY.3W/J?6NPK"6YH%%%%( HHHH
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MC^D'P;XOTWX@^$]-US1[J.^TK6+6.\M+B,_+-%(H96_$$>XK3K\X_P#@A?\
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M4^#_ !->>9X[\*VXW2RME]7LQA5GSWD3*J_<DJW.X@?8M?SL? ;XUZW^SO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5S7QC^*>E_ _X3>)O&6MNT>D>
M%=+N=6O"N-QB@C:1@N2!N(7 '<D"NEKXC_X+F>+;C6_@#X'^$=C)<1W/QH\8
MV&AWIA8(R:;"XN;M]V>,".,$#EE9ASD@Z48Q<U[1VBM6^R6K?R5S.I*2C[BO
M)Z)=V]$OFSQ/_@G3X5U8_ FX\>>)MC>+_B]JUUXUU=U4J-UXY>)5!^ZHAV$*
M  NX@=,GWRH=/TZ'2;""UM8HX+:VC6**.,;5C10 J@>@  J:OP/-LPGCL94Q
M<]YR;MV71?):(_>LKP,<%A*>%AM!)>KZOYO5GA__  4._:<7]E']EKQ!XBMY
MEBUV]7^S-%'\1NY00K@=_+4/)Z'R\=Z_!R>XDNYY)99'DED8N[N=S.3R23W)
MK[C_ ."ZW[0+>/?VBM+\"6DQ;3O ]F)+E5/#7MP%D;/KMA$('H6<>M?#=?TU
MX6Y"L!D\<1->_6]Y_P"'[*^[7_MX_G#Q+SQX[-I8>#]RC[J_Q?:?WZ?(****
M_2C\\"BBB@ HHHH W/AA\2-6^#_Q#T;Q1H5P;75]#NTO+63MN4YP1W4C(8="
MI([U^_O[-7Q[TG]IKX)>'_&FCD+;ZQ;AI8-VYK.=?EEA;W1PPSW&"."*_GFK
M[@_X(H?MA_\ "H/C%-\.=:NO+\/>-Y0;%I&^2TU( *F/03*!&?5EB]Z_+O%+
MA?\ M'+OKM!?O:-WYN'VE\OB7S2W/TKPSXD_L_'_ %.L_P!W6LO27V7\]G\K
M['ZZ4445_+A_2P4444 %?C#_ ,%?OVP_^&D/VA'\.Z/=>;X3\"O)96Y1LQWE
MWG$\_H0"!&IY&U"P^^:^_O\ @JU^V'_PRK^SE<6NEW7D^+_&(DT[2MC8DM4P
M//N1Z;%8!3V=T/.#7XE$Y/\ C7[QX0<+W<L[Q"VO&G^4I?\ MJ_[>/Q'Q7XD
MLHY/0?:4_P XQ_\ ;G_VZ+1117[X?AH4444 %%%% !7Z)_\ !!W]J5M(\5:U
M\)]4NC]FU96U;0P[<).B_OXE_P!Z,"0#H/*<]6K\[*Z3X-_%#4/@I\5O#WBW
M2FVW_AZ_BOHAG DV,"4/^RRY4^H8U\_Q1D<,VRRK@I;R5XOM):Q?W[^5SW>&
MLYGE>94L9'9.TO.+T:^[;SL?T85SGQ?^&UG\8OA7XB\*ZA_QY^(M.GT^4]T$
MB%=P]U)!![$"KW@;QC8_$7P5I'B#2Y?/TW6[*&_M)/[\4J!T/_?+"M6OXQC*
MI0JJ2TE%_--?Y,_KV4:=:E9ZQDODTU^J-G_@B[\;]9^*_P"Q)IV@>*I&?QI\
M*]2NO!.NAF!;S+-@(6XQD&W>$;OXBK'FOK.OSM_8J\6CX"_\%8_&'A$>8NC_
M !N\*P>(85$;%$U33F:&0 XPN^W)=N>6"YQD9_1*OZ"CBHXJG#%Q5E4BI6[-
M[KY2NOD?@=3#2PU6>$D[NG)Q]4MG\XV?S"BBB@D**** "BBB@ HHHH 9/.EM
M&7D=8XQU9C@#\:@_MNS_ .?NU_[^K_C7Q%_P<9?\HKO&'_85TK_TLCK\4?V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX(H_%K_@IG\/]0^)UYXKL=!TG4KF6.UU/76GO+S79T)6208RQ0."AD9LEE8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN/\ XFCZ[A_^?D?O0?4Z_P#(_N9VW[ G[.R_M1?M6>%?"MU&TFCM.;[5<?\
M/I"-\BD]M^!'GL9!7[W6MK%96T<,,<<,,*A(XT4*J*!@  = !VK\R/\ @A#\
M%-9\*?&/QSKFN:#JVDR6^C0V5L]]926^\2S!W"EU&?\ 4IG']:_0;]I'QW<?
M"[]GKQUXDM6*WF@Z!?7]N?26.W=T_P#'@*_FWQ4S">/SR& I.\8*,5KIS3LV
M_P 4OD?T-X98"&!R2>-J*TIN3??ECHE^#?S/S$_X*X_\%$]3^+?Q"U3X9^$M
M0EL_!N@S-::G+;OM.M7*'$BLPZPHP*A>C,I8[ALQ\-T2RM-(SNS,[$LS,<EB
M>YHK^@\AR7#95@H8/"JRBM7UD^K?F_PV6B/P?.LXQ&:8N>,Q+NY/1=$NB7DO
M^#N%>A_LQ_M0^+/V3?B;:^)O"M\\,BLJWED['[-J4(/,4J]P><'JIY!!&:\\
MHKT<5A:6)I2H5XJ4)*S3U31Y^'Q%7#U8UJ$G&47=-;IG]$'[/7QRT?\ :3^#
M>@^--!9O[/URW$OE.<R6T@)62%_]I'#*>QQD<$&OA/\ X+V?LV6\NB^&_BII
M]NJ74,PT/6"B_P"M1@SV\C?[I#H2>3OC'85L?\&_/Q NM6^%/Q"\,R.SVVAZ
MG:W\ )SL^U1R(P'MFV!QZD^IKZ2_X*8^ I?B5^PW\0=+M[.:^NQ91W5O##$9
M)6DAGCE 51R2=F..H)K^7,'3?#G&*P])^[&:C_VY.V_HI)^JN?TMBJBXAX2=
M>JO>E!R_[?A?;M=Q:]'8_"&BNL_X4%XZ_P"A+\6?^"BX_P#B:/\ A07CK_H2
M_%G_ (*+C_XFOZA^NX?_ )^1^]'\U_4Z_P#(_N9R=%=9_P *"\=?]"7XL_\
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M*QTX/!4L-!PI;-W"BBBN,ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\S?#.E'X:_\%2/VF/#+
M;H[?7)=$\5V"$;?,$]F4N7 P,_OE"[ER#CD[N*_3*OSU_P""C'AY?@Y_P4\^
M"OCZ&&1+/XE:!J/@75KAB/)CD@9;VS'7_6.Y=1QR%P.]<6;8=XC+<306[@VO
M6#4_RBU\SNRC$+#YEAZ[V4TG_P!OIP_.2?R.^HHHK\$/W8**** "BBB@ HHH
MH **** "BBL[Q;XKT_P)X6U+6M6NH['2])MI+R[N)#A88HU+.Q^@!JHQ<FHQ
M5VR9244Y2T2-&O,_C!^QM\+?CY>M=>+? ^@:O?2##WA@\FZ?T!FC*R'\6XK\
MH?%'_!7?XL6_[1_B+QEX;UR6UT/5+G;;:!?(+BQCMD^6)3&3\KE0"[QE69B>
M<8%>^?#_ /X.#I$LHX_%/PV22X ^>XTK5=B,>^(I$)'_ '\-?J$_#/B7 \N(
MP6LFDWR3Y91;W3NX[/31NY^:P\1N'<;S4,9I%-I<\>:,DMGHGOOJE8^M?!__
M  3$^ O@74UN['X:Z)+-&=P%_+/?Q@_[D\CK^E>YZ=IUOI%A#:VEO#:VMN@C
MBAA01QQ*. J@< #T%?GIKG_!P=X=@M"=-^&NM74^.%N=5BMTS]5C<_I7SW\?
M_P#@M7\7/C!8SZ?H+:=X#TV<%6.EAGOF4]C</ROUC5&'K1#P_P"*\SJ+Z_=+
M^:I/FMZ*\G^ 3X\X7RVF_J5F^U.'+?YVBOQ/V5HKYS_X)C?M?+^UQ^S=9W&H
M7"R>+/#6S3=;4GYY7"_N[C'I*HR3P-ZR <"OHROSO,\NK8#%5,'B%:<&T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRK 4\#0VBM7W?5_-_=MT/X_SW.*N:8ZIC:V\GHNRZ+Y+[]PHHHKV3R0HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<%'/EOCU5\MV0=*_J'A3Q&R.MAZ>#E_L[BDE&7PZ::2V_P# K/U/YIXG\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!X0I8 D+&N2 <YYK[!HK2G6J034'9/?L_5;/YF=2C"=G):K;NO1]#\]?$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>moln-20221231_g8.jpg
<TEXT>
begin 644 moln-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"]!@8Z"N2IEU!*48M\RCS=+>AI&O/1NUKV/T:HHHKQ#L"BBB@ HHHH ****
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M6!84444 %%%% !1110 4444 %%%% !1110!_/_\ L*?\$[/^'A_QP^(6C_\
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MFX*$I2E+E<59*ZMY>;VT;=2OAY.LM;JSM;?H<I_P5=U;Q#^W5^VW\38?#/\
MIN@_ OP[*9\$^6D=K(GVUQCC>)IG'J5@[!3C](_^"17[1_\ PTM^PGX/U"YN
M?M.M>'(SX>U0L=S>=; *C,>[/ 87)/4N?J?RA_84^,_Q\^#WA3QMJ_@'X,WG
MQ(T_XE VNK:M=^%M4U1+A5\T2Q)+;2(GS-,^\<DG&<8 KW;_ (-\_C+J7P:_
M:6\:?![Q-;7VCW7B&W-W!I]_ T%Q;:A:9\R(QN RNT#.S C.+<=*^@XTX><N
M'ZF!I\K6#4'!IIR:4;5>9+5:WEKO8WQF'O0<%;W+6_4\K\2?L=?\-S_\%?\
MXK^ _P#A(O\ A%_.UO5K[[=]@^W8\J3.WR_,CZ[NN[CT-=Q^RC)XR_X)F?\
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M4A0,,RFOBW]F;PCI?P5_X.&]8\,^%;"WT/0&>_@6PM%\N"*-]*^TE%4<!/-
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MA%8?!8^$<'+W&I.:3NDDKI[NW]=SD?\ @KOK/B3]OO\ ;K^*4'A7_3O#_P
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MXU\<?#+7-<E\1:+X>MOMNFW$EPUPMJ4G$+K$[<F%]RL!G VY &YL_*7[%'[
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MH+:TK6;DDG>[TTLMS]5J***_#S\I"BBB@ HHHH **** "BBB@ HHHH ****
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MA@@AC"1PQJ %55& %    X %?-O[;G_!*SX>_MZ^/M)\1>,-9\9Z;>Z-I_\
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MVJ?^"<7@G]L/XIZ!XJ\7ZMXLW^'(4@MM-L[JWCL)%64R-O5H6<E\A6(<955
MQC->^7-E%>6<EO+&DD,J&-T9<JZD8((],5-17D8C,L37I4Z%6;<:::BND;ZN
MWJ]SS:V.KU:<*523<87Y5VOO;U/F7]G_ /X)7^ /V:F\:Q^&]<\;&S\>:3-H
MVH6=U>6TD,<4F0'CQ;JPD0,X0LS !CD-79?L;?L.^$OV(/"FM:/X3U#Q#J5K
MKMTMW<-J\\,SJRIL 7RXHQC'J"<]Z]HHKLQ?$.98J-2&(K.2J<O-?[7+\-_0
MZL1G6.Q$9QK5')3MS7ZVVOZ'SU^S?_P3:\#_ +*?QNUKQOX/UCQ=9R:\LT=S
MH\EW;MI0CD?S BQB$.!&V-A+DJ.,D$@V?V2?^"=W@G]C/QQXDU_POJGBB_O/
M%$8CNDU2Y@EBC D,GR".&,CDGJ3Q^=>^44\1Q%F5=5(U:S?M%%2O]I1^%/O8
M*V=8ZJIJI4;YTE+S4=K][%'Q#HT/B/0;[3IVD6&_MY+:1HR X5U*G&01G![@
MUX+\ _\ @FKX%_9T^"OC[P'H>K>+;K1_B-9RV6I37UU;O<P))!) 3"R0(JMM
MD8C<K#('!&0?HBBN/#9GBL/2E0HS<8R<6TNKB[Q?R>QS4,=B*-.5*E)J,FFU
MW<7=?<SQ[]E']BOPM^Q[\']8\$^&=0\07VEZU?3:A/+J<\,MPDDL$4+!3'%&
MH4+$I *DY)Y/ &=^Q;^P)X._86M?$47A+4O$VHKXF>W>Z.KW$$Q0PB0)L\J&
M/&?-;.<]!TYS[E16U;.\?5C6C4JMJLTY_P!YQ=TWZ,UJ9KBZBJ1G-M5&G+^\
MUJK^A\E?'3_@BY\%?CEXUNM>-OX@\)WU]*T]TF@7D4-O<2-U;RY8I53/7$84
M$DG&37K_ .RS^QA\/_V.?#-QI_@G2&MIK\J;[4+J4SWM\5SM\R0X^49.%4*H
M))QDDGU:BML5Q'FF)PRP=?$3E35O=;=M-K][=+WL:8C.\?7H+#5JTI071MVT
MV];=+A1117BGEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !117S;^VU\>;W3M0A\#Z'-);S7,:3:K/$Q618F)VPJ1R-P!+$8.TJ.A85K1
MHNI+E1%2HH1NST+X@?M=^#/ %\UG]KN=:O(VVR0Z7$)_+/H7+*F?8,2",$"N
M?L_V]_!SWT,-YI_B33UD(#SS6L;11>I.R1F('LI/M7C?P[^&,<L$>Y-Q!X"\
M+6QKOP>CNRV8(_KGI7?]7H+W7<Y_:5'JCZC\#_$'1?B3HBZCH>I6VI6;'!>(
M\H?1E.&5O9@#6S7POH][K7P$\>P:WHKR'!"W-OOQ%=Q9^9''YX/)!Y%?9W@'
MQ[IOQ*\+6VL:3/YUK<+R/XX7_B1QV8=Q_,$$\N(P_L_>CJF:TJO-H]S:HHHK
ME-@HHHH **R_%7C31_ ]A]JUK5M-T>U)QYU]=);QY_WG(%4?"/Q=\)_$"X,.
M@^)_#NMS+DE+#4H;EACKPC&JY96O;0+K8Z*BBBI **** "BBO._C=^U=\.?V
M<($;QMXPT?0)9%#1VTLIDNI%_O+ @:5EXQD+C-5&$I/EBKL3DDKL]$HKY>M/
M^"QW[/MW=M&WC*ZAC'25]&O"C?0+&6_2O*OV@O\ @N!\*%N&\/\ A^\\17%M
M<@+/K,6GF.W53GA0S+-]2(R<< 'FNN&78F3MR/[F92Q%-*]T?6'Q*_:D\(?#
M&9X;J]FOKJ,X>"Q02LA]"20N?;=D5P]K_P %&? TES'%<6/B*UW'#2-;1/&G
MN=LA;\E-?'>I?$:S\<6,.I:;=0WMC?1B2&>-MRR*>X_SG(K FD\QZ]&GEM.W
MO7N<DL5.^A^HW@7XBZ'\3=$74=!U.UU2T)P7A;YHS_==3\RM[, :VZ_,?X.?
M&+6/@EXR@UC29F&TA;FW8_NKN//*./?L>H/(K](O!/C"R\?^$M/UK3G9['4H
M%GB+## $=&'.&!R".Q!KS<9@W0>FS.JC651>9K4445QFX4444 %%%% !1110
M 4444 %%%% !117'_'3XL6_P8^&]]KDJK-<)B"SA;_EO._"+].K''.U3WJHQ
M<GRH4I)*[+/Q'^,/AWX3V4<VN:E#:M-_JH%!DGFZ_=C7+$<8SC [D5YG)^WU
MX4CW-_8OBMH@<*XMH/FZ]C,..GO],5\^>%+'4OB=K\^LZY=37NH7TA>:5_O'
MT"CHJ@8  P !TKT.Y^$L,NGQK]G5N.IY)_*O2^JTH:3U9R^VG+6)[G\+_P!I
MGP?\6IX[73=2\C4I02+&\C,,_P!!GY7..<(S<?C7H%?#'C/X0G3K;SK</;S1
ML'1HV*NA!X(/4$'D5[_^R?\ '^3X@:*- UZX4>)-/7"-(<-J$('#^[@?> Y/
M#=SC'$85*//3V+IUFWRR/:****X3H"BBB@ HILLJP1,[LJ(@+,S' 4#J2:X\
M?M#_  _.J?8O^$Z\'_;,[?L_]LVWFY]-N_/Z548M[(+I;G944V&=;B)9(V62
M.0!E93E6!Z$&G5(!1110 445F>+/&.D^ M N-6US5-/T;2[4;I[N^N4MX(1T
M^9W(4?B:-W9 :=%?,WB/_@K[^S_X=U)K7_A-SJ#QG#O9Z;<RQK_P/RPK?521
M6!\2O^"U_P "_!/AAKS2]:U;Q/>-A5LK'2IXY%)[LTXB3 [X8GTKKC@,2]J;
M^YF3K4UU1]-^.OB5HGPVT[[5K%_#:*WW$Y:23_=49)^N,#/.*\BU3_@H?X*T
MJ\:,Z?XDFC7_ ):1V\/S'V#2CC\C[5\>I^VSX?\ VK9;[5-)U">:\!#7-I=K
MY5Q;@]!LR1M[ J64=,]AA:C>M=2,?4UZ%'+(I6JWN<E3%O[!^B7PD_:J\%_&
M6Y6UTO4FMM2?D6-ZGDS-_N\E7/LK$UZ/7Y.P3O;3))&[1R1L&5E.&4CD$&OO
M+]B7]H>;XS>")]-U:?SO$&A[5ED;[UW >$D/JP(*M_P$]6KFQF!]DN>&QM0Q
M',^66Y[A1117FG4%%%% !1110 4444 %%%% !1110 445Y+^VO\ MA^%?V%_
MV?M6^('BMWDM[,BVL+&)@)]5O'#&*VCS_$VUB3C"HCL00I%=&%PM;$UHX?#Q
M<IR:22W;>R*C%R?+'<]:J&"]ANI)%BFCD:(X=58$H??T[U_.7^U)_P %&_C)
M^WQXANI/$'B*^T3PG<.?LOAK29WM]/MXS]T2;<-<,.<O+NY)V[%(4>&ZG\,_
M[)=9H,QR6^&CD7Y61@1@@]<U^X8'P,Q4Z*GC,4J<W]E1YDO5\T?G96[-GLT\
MEDU>4K/TO^I_5917\_7[ G_!;_XF_L=^-=.T7QYJVL?$+X;NZPW5MJ,QNM2T
MN/@>9:SN=QV #$+L4(&U=A.X?O9\/_'VC?%3P1I/B7P[J%OJVAZY:1WUA>0'
M,=S#(H9&'?D'H0".A (Q7YOQ=P5C^'ZT88JTH2^&:V=NGD_+[FSSL5@YT':6
MW<V:***^/.4**** "BBB@ HHHH **** "BBB@ HHKR/]M+]L[P3^PI\#M1\<
M>-;Y8X(!Y5AI\4B_;-8N3]RW@0D;F/4GHBAF;"@FNC"X6MB:T</AXN4Y-));
MMO9%1BY/E6YZY17\U/[6G_!3[XU?M\^)[QM:\3:EX<\)R$K;^&=$NI+6PCBS
MD"7:0UP_3YY=W/W0H(4>-^'_ ((+#-%<1JR3(PD1@3O4CD%3Z\ YXK]WR_P%
MQ,Z"GC<6J<W]F,.>WDY<T=>]DUV;/8IY-)J\I6?I<_JZHK\"?V(/^"P?Q:_8
M6\3:?IOC/5M5^)'PS:00W=GJ5P;C4-+0_P#+2UN'^?Y1@^5(61@-J^63N'[L
M?#/XDZ'\8OA]H_BKPUJ5OJ_A_P 06D=]87D)^2>&1=RG!Y!YP00"#D$ @BOS
M3C+@7,.'*T5B;2IR^&<=GY/JGY/Y-ZGGXK!SH.TMNYO4445\6<H4444 %%%%
M !1110 4444 %%%% !1165XW\9:;\./!>L>(-8N4LM'T*RFU&^N''RP00QM)
M(Y]@JD_A50A*<E"*NWHD)R25V/\ %7BW2_ OAZZU?7-3T_1M)L$\RYO;ZX2W
MM[=>!N>1R%49.,DCK7S5KO\ P6F_9I\/ZT]C+\2([AHF99)K31=0N8$(Z?O(
MX"K ] 4+#Z5^2G[9W[<_C/\ X*+?&"\O=0N+K2_ ^FW!70M!$A6&UBR0LLJ@
MX>X8<LYSC)5<*,5Q]I\*8I=+_P!2=W\3+QFOZ&R;P7PE/#QGG=:2J25^6FXI
M1OT;:E=][))/NM3XK%<5593:PD5RKJ[Z_)-6_K8_>']GW]OOX-_M2S+;^!?B
M%X?UG4&D>)--DE:RU%RBJS,MI<+'.R ,/G"%3S@\''L-?S-ZQ\+9M$E6]LFD
MMKJU=989D;;)$ZG(9&'(8'!R.1^5?J__ ,$8?^"G5]^T-IC_  N^(^I"X\=:
M+#OTK4[AL2^(+5!\RN3]ZXB R3]Z1/F(+)(Q^=XV\*5EF$EF655'4I1^*,K<
MT5_-=64DNNB:WU5[=F4\1^WJ*AB8J,GLUL_+79]M3]!:***_&3ZH**** "BB
MB@ HHHH **** "BBB@ HKY_^-G_!5']G/]G;7)M+\7?&7P%IFJVLS6]S81:F
MEY=VLBG#)+#!O>,@\$.H-<3XI_X+I_LF^%/!-QKLGQK\*7T$$)E6UL?-N+Z;
MT18%3S-QZ8( &>2!DU[E#AC.:T8SHX2K)2V:IR:?H[6.>6+H1=G-?>CZD\4^
M*]+\#>'KK5M:U+3]'TJQ3S+F]OKA+>WMUR!N>1R%49(Y)KYKU_\ X+5_LQ>&
M]:FL+CXI6LUQ;ML9K31M2O(6/^S+%;LC#W5B*_&7]LW_ (*FZM_P4^^,%U)!
MJUQ9^"=+N&.B^'-YB%M&.%GF3@23,.2_S!-Q52!UYGPI\,8[@>9Y:L 1CWK]
MRR7P/PU/"JKGM:<:DE?EARKE\FY1E=][)*^S:U/D<9Q3555PPT%9=97U^5U8
M_?S]G_\ X*'_  5_:@UG^S/!/Q!T;5-68GR["=)=/O)\9SY<-RD<D@&#DHIQ
MWKVJOYL]8^%2Q1Q3VS36MQ"RO#+$VV2%U.596'((/0C!'X5^HG_!%?\ X*5:
MU^T*-0^%'Q&OVU#QMX?MC=Z5JLQ_>:U9*0K+(?XIXLJ=W+2(VXY9'9OE>-/"
MV.6X268Y54=2G#XHRMS17\UTDI+OHFM]5>W=E7$'MZBH8A*,GLUL_+R_4_0B
MBBBOQL^H"BBB@ HHHH **** "BBB@ HHHH **** "F2RK;Q,[LJ(@)9B<  =
MS7S5_P %&O\ @H#;?L9^%+'3M(M[75O''B%'>QM99 8K"%3M-S.@(?:6)5!P
M'*/S\C"ORJ^)?Q>\>?M'ZP;WQIXJUKQ!B9IX[>YN#]EMF;&?*@'[N/. ,(J]
M!7Z!PSX>XS-J"Q=2:I4GLVKMV[*ZTOI=M>5S[;AW@?&9I36(<E"F]FU=OT6F
MGFVC]ZHI5N(E=&5T< JP.00>XI]?S[>&9]=^&WB*/5O#>L:IH&IP@K'=Z;=2
M6MP@8%6 ="#R"01G!!K[V_X)S?\ !5C5M=\9:?\ #WXJ72W4VHNMKI'B&0"-
MVF.%2"Y &&W=%EZ[L!MV[>O?GOAAC,%AY8G"5%6C%7:MRRMU:5VG;UOV1V9U
MX=XS!477H3]HEJU:S^2N[V];^1^B=%%%?F!^>A1110 4444 %%%% !1110 4
M444 %%%% !4<TRV\;22,J(@+,S'  '4DU\X?\% /^"@6E_LA>&%T_2_L.K>.
M-20FUL9)<I8QX_U\ZK\VW) 5<J6YY !-?DM\:_CAXX_:5\0R7WB_Q)JNN22/
MN2&68K;0>T<*XCC'LJC^M?H/"WA[B\WI?6:DU2I/9M7;]%=:>;:\KGWG#7 .
M,S6DL3.2ITWLVKM^BNM/-M>5S]^(9EN(UDC971P&5E.00>A!J2OYX_#OAC4O
M"&H1ZCH>H:AH^I6^3%=V-R]M<1=_E=""O3M7WO\ \$X/^"L6N77CK3_AQ\7K
MX7QU25;71O$4J".;S2=J07.  P8X59<9W8WYW%E]//O"S%8/#RQ."JJLHJ[7
M+RRMW2O).W75/LF>AGGAGC,#AWB,-45515VK<LK=TKN]O6_9'Z2T445^5GYF
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$WQ>M&N/VH
M/%TEXVZX^U1!05QB,0Q^7V_N;?K[]:^V:^7_ -M#PDOAWXHZ'XBBW+'K4!LY
MPO3S8B"K'W*MC_MG^?9@9)5&NZ_X)SXB-XW+G@4(D$?'Y"NR:T24=.M>?_#Z
MX>ZACQNZ]SUKO+V[_LK2)KAEW_9XFD*]-V 3C]*TJ?$$+6/@G_@IA^V3<>'?
M$]UX%\%W M[ZU&W5M4C/[R%R,^1$?X6 (W..03@8()KXD^"W[4/Q._91\;W>
MN>!_%FIZ7=:@P:^BD87-OJ&.GG12 HY'.&(W#)P1FKWB77[KQ=X@U#5+Z0S7
MVIW,EW<2'_EI)(Q9C^+$US&NV*E-VT9^E?:8?!TZ=+V35^_F>5.HW+F/H[Q+
M_P ' '[05[H@M(%\#Z;<!0/MEMH[M,<#&<22O'SU^YCV'2O$/%/_  59_:(\
M6:Q)>7/Q8\5022=4LI$LX5^D<2JH_*O)M?LF9VP":P)](D7YJJ&!P\/A@ON(
ME6J/=L^U_P!E_P#X+X?&7X-:W;P^-+JW^)'AT$)+!>QQVU_$N>3'<1J"6Y_Y
M:K)QQ\O!'T-^T[_P<<Z3?^ _L/PA\+ZU#XBOH]K:EXBAA2'3"1U2&.203..<
M;BJ @$AQE:_)=XS'P?6K&CP^=?*/>L*F4X6<U-P_R^:-(XJHERW/6]8^(7BG
MXZ>+)O$'B_7]4\1:O=-F2ZO[AIG"]0JYX51V5<*!C '2MFPO)M$N(Y[>:2WN
M(6#I+&Y1T8="".0?>N>\-SQV5L%5>U:%Y?+)%P>:[>5)66QGYGW;^P;_ ,%D
MM3^%FI6_A?XL7]]KGAF3$=OK3*T]]IG0#S<?--%UR?FD';=PH_3;P1\9O"/Q
M,\+KK7A_Q-H>L:3(N_[5:7L<D2C_ &B#\I'<'!!X-?S9:YJ[0EOFKE=6UDR9
M^;/]*\?%Y'2K2YX/E?733[CHIXR4%9ZG[K_MN_\ !:/X5_LIZ-<6/A_4;+XA
M>,F4K#IVDW2R6MLWK<7"Y10#_ NY\\$*#N'Y:_&7_@LW^T-\8==FNE\=77A:
MS9RT-AH$2V4-N#GY0X!F;'^V[&OEEWWDTOS>U=.%RG#T%MS/NS.KBIS\CZ!T
MO_@J+^T%96$EK_PMKQDT4PPQDO/,D';AV!93]"*\NU[XE:MXQUVZU36=4O\
M5M3OI#+<W=[<///<.>K.[$LQ]R2:Y -BGA)&Z*:[X480^%)>B,7)O<Z/_A*V
MC7JOH:S=3\0/=C[WL*H+;2OVJQ%H[L?F!K0D^H?^"<7Q'N+Z+7/"MQ,TD=NH
MU&T4G/E@L$E ]BS1G'3);UKZB(P:^*_V MUA^T5:PC</MEC<0MQUPH?G_OBO
MMR^A\MJ\G%QM4T-H;%>OO;_@GYJMQJ/[.-G%,#Y=C>W$$!(ZH6\S_P!"=O\
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M24&]6HRM%OTL[?*R/R_,.!\MG5=5Q<;[I.R^[I\K'[/:W_P=E^'+;69(]/\
M@IK5U8AL)-<>)(K>9ESU,:V[@'';>>>_>OIK]BS_ (+\_ ?]K[6+70;K4+WX
M<^*KHK'#8>(_+BMKR0Y^6&Z5C$QX  D\MF+ *K5_-RZ,*;7'CO"C(*U%TZ,)
M4Y=)*4G]ZDVONMZHX,1P7EE2GRTXN#[IM_@VT?U1?MV?\%-_A1_P3Z\'RWGC
M37([KQ!(@:Q\-Z<Z3:K?$]"(]P\N/J3)(57 (!9L*?QU_:%_X.:_V@/B9XCD
M?P-%X;^&NCHQ\B"WL8]4O&4@?ZV:Y1D8@Y(*11CU!ZU^<Y;<>>32A2:TX?\
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MDU]9?LS>/6^)G@Z&XN2OVZSE\FZP,;B,$-C_ &@1[9S7Q58DEAG_ /77T/\
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MAU+[9:ZEY\5E(6%S=Z<J?+'M/S'$A+*AY*HN,_*#%^QS\%_'NC:)XV$MO?\
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M0NW]U6!PS>PR:XKQ7^U+X3?P[>+IEU-JUW)$\<<,<#Q!F((&6D"@+GJ02<=
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MJ=$EI8^&_'__  34\$K=R26.M>*+6)CGRC-#(%_W28\XZ=<GW-'PX_9T\)_
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MOX=^!;KQ]J2K'NALU/[ZX8?*H]!ZM[5ZIJ?P!T*[TGR;19K6Z4?+<%S)N/\
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M1]IC]Q7RG'V(HT.',6\1LX.*_P 3TC^-F<>/DE0ES=C]I:***_B4^/"BBB@
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M]O\ #OBV-K6,,_+#\J^5O"_B5K0QQQB6660A$1!N9B>@ [GVZG-=Q=>*-?\
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MX8MZOHO2[T5[7>BNS&6)A&:A)ZL\X@E5AUJ5EWCZ5Q.@>-UN[:,AU;@5M?\
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M!R3"&D:.;H?EW(W0*')Q7Q_J&D>-/AEJTNFZ]X4\3:)J5KQ):WNF3V\R_P#
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\8_\ !4__ ()':/\
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M]?FK^9^@Y3XC9E@Z*H5$JB6B;O?YM;_-7\S\9/@/_P $C_C1\>[ZSFUG25\
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M:)QJ$-O);QJ_FF1I1&(MZK$5,2,R@?..D_\ *-K]NW_L?M,_]/<5>N?M<_\
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M /=OVF?^"B'P7_8\URUTOXB^/-.\/ZI>QB:.Q6VN+ZZ$9SAVBMXY'1#M8!F
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MRZ=>VUG;6]YJFN7\EY/'&%DNF238I=NK;44*,] *^ZZ "BBB@ HHHH ****
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MIE)_=4 ?=NB?\%9/V=?$?Q=7P-9?%3P_/XBDN1:1J([@6<TIP B7AC%LY)(
MVR')X'/%>Q_&'XO^'?@'\--8\8>+-0_LGPYH,/VB^N_(EG\A-P7.R)6=N6 P
MJD\U^'?PI\-?#37OV8-)^$GQ1^+GQD\)^*-'U)_M'PRM?!+7$UO>"5F$T&(,
MDE'+DLZR8WC!&-WZA_\ !5#2I-"_X)0_$BQDO+G4)+/PU;P/=7*E9KDK) ID
M<'D,V,D'G)- &GX._P""P'[-OCWQQH_AW2_BIH\VJZZ(_L:2V=W;PNTGW$>:
M2%8HY#D#8[*P) (!.*Z#X\?\%*?@C^S'\1[KPCX\\=VOAWQ#9Z>NJ26L^GW<
MF8&SM*O'$R.QP<1JQ<XX6ORU^)/Q4\'_ +2?_!+OX,?L\_#/PWJGB7XQ">SO
MY].M=!N(&TDGS#+>/.\:H4D\U<RJS)M<LS* ,_0X\"QO_P '"G@.QU]+?6+[
M0_A[!(9YE\T&[BM)E\\;N=V[<P8\@G/!YH ^O?B)_P %//@3\*?AEX9\7>(?
MB%I^F:)XRM1?:,9+*[:[OK<G:)EM5B-P(\@C<T8'O53XI_\ !0_X8Q?L4^)O
MBUX9\>:?=:#:V<EO9ZG:VTEPUMJ$B;;>*6#RVDCD\UXLK+&,!@6 7)KY8^-?
MBS3_ -A__@M1KWQ@^,5CJ2_#?Q3X5CT_PSXF739KZUT"Y6.V1XB(E=HW8Q7(
M^52V+D<;6<B#_@F[\+->^*WB']K+XA^%/#NH^'?AI\6(+B'PA8W5N;-=8D:.
MYQ=11'&V,^:,,!MS,5!.QL 'J'_!&'_@I3%^U[\%&T/QQXV37OBQI*7FJ:K&
M^E?85@T]9U2.0O%#';8 D084EN<D<$CUOP3_ ,%7_P!G?XB_%J'P/HWQ2T&\
M\17$XMH(_*N([6YE) 5([IHQ;R,Q("A)"6/ R:^"/V"/BQ:>,O\ @EUXZ_9A
MTB;6M.^.EU9:ZJZ#/IMS;N!_K#"\S((HVE3?& [J=V0<97/COPH\._#'XB_L
M\^#_ (5_$#XQ?&C0/%VBZ@BGX<6O@EI;G2;T,V9X=L&<!7:0DN)=I;*DX! /
MTKN?CYXSM/\ @K5)X%D^*?AM? \?AHZFW@C^RICJ8(@YN/M/V'R]N_YMOVO=
MC^#M5N#_ (+;_LN7%K9S+\6+$)?3FWC#:1J*NK#',BFW#1K\P^=PJGGG@X\&
MN+22P_X.!Y();B2ZDA^%YC>>08>8BWP68>IQD_6O /V%/!^E7/\ P;Z?M!WL
MFGVDEY<ZM>-+,\0:1S#!8M#DGGY&9BOH68CDG(!^R6F:[;^+_"MOJ>BWMK>V
M>J6BW5C>0R"2&>.1 T<BL,AE((((R"#7Q#^P/_P43A\*?L7>(OB5\=?C9X;\
M=:9:>+3HL'B#1?#U]##:DVMNZVK0+IUM*S9=GWB%EQ(!OR"J^T_\$G9&E_X)
MP?!TLS,1X=A&2<\ L /RXK\?_ O_ "KZ>-/^RQQ_^FZSH _8KX2?\%0_@'\=
MOBU%X&\*?$G1]7\3W!(M[5;>XACNF"[ML4TD:Q2MC/RHY/!XX-?,/PS_ ."N
M%O\ !S]O']H#P[\;/B/;:7X#\*ZA'9>&+-])5Y(6,C!E06L!N)<*!DON XR1
MFN1_X*)^&=/\'?M&_P#!.Y=)LK;35CURSLE^S1B/$"76B[8^/X1YDG'3YV]3
M71?\$Y?">E^(?^"P/[7$E_I]G>2)+]E5IH@Y$4TS"5.?X7"J&'< 4 >T_MY?
MMH+J/[ \/Q.^#/Q@\)^$;.[U2VBB\3WMA-?V@C+,KP-"EG=2+(6VC#0 J0<E
M>_D?Q@_X*6>(_P!FS_@HQ\)_#OCCXC:?I_PGO_AS!KGB.3^S(C#?7K6][B=&
M%N+D;Y8H=L:!<\#8,D5\0_#69Y?^#>7XA*S,RQ_%F)4#-D(/LFGG ].23]2:
M^B?V@?B7X6_9T_X*S_L[_$7XB-)I?@71_AE91R:K+IL]W;Q71M=06(*(HW9I
M [QD;02N0W&,@ ^Z-6_;B\%_M%?L;_$SQM\'?B1H?G^&=!OYQJ\]I/C0)X[>
M61)[BUD@>?8NPN 8'WA#M5^E?$/[3W_!5CQ]\%_^"9?POU32?C-H_B'XP^+]
M7N;K^V]+\.8M=4TJ&YO8)"L=U80QQ^7(D$9#0HY*$KN4ECG?!CPQ?_%BZ_;I
M^.7A_0]6\._"GQIX UFVT3[;8FS77)39.YNXD(!*_NY'W8ZW6/O!@.-^)7PX
MUOXA_P#!M'\*I-%TV[U+_A'_ !+=ZK?+;Q-(\%LNHZM$TI"@G:K2ID] ,DX
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M\W[:7[8FK/9V[ZG;^-GM8KIHP98HGOM29T5NH5F1"0,9*+G.T8_2*@ HHHH
M**** "BBB@ HHHH **** /@__@JM^WKX\^!O[1GPM^$?@GQ'H/PV7Q]BXU#Q
MMK-G'=0:9&9C$%19OW.1M);>#]^,90$M7MO[+7A;XV?"2X\37_Q:^+'A'XF>
M"([%;W2-4L_#RZ=J1 !>221;?]R(@@.%02L^0=Z8*OP'_!2O]I'X$>$?%F@^
M!?C]\/=<UCPCJ5K)>)XGF\/SW&EZ3.Q$8B2XB'FK,RY+>1ED!BSG=E?DO_@F
M/H>H:?\ M&?'>;X.R>+I/V6F\-WXTV;65G2SN;KRE"FV$P#,XD6Y&<!A%CS<
M.5% 'V9!_P %M/V7;A--9?BOIX&JRF*#=I.H*4(8+F4&W'DKDCYI=JD9.< D
M97[?'[1GBWP)^T%^SC8^"OBYX2\'>'_B%K:V]U87>G2Z@WB^%KFP"QVLT5E<
MI'F.<J':6!3YZD/@%D_.3]E/]I/X:^$O^"/'CKX3R:-J>L_%7XD:E=QZ5I%G
MH%S<3:J_[A8;A)EC,;B J3M#EU*'"?-D^K_'_P"%7B3X(7?_  3/\*^+EDC\
M1:/XD6.\@D;<]H6U+1W6!CR,Q(RQD#(!3CC% 'T=^SO_ ,%$=;T?]M7]J&P^
M*?C>UL_AC\*9(WTY;BQ@B73(S,R8#0Q":9F^50I+LQ( !)Y^D[O]OGX2:7^S
MQ;?%;4/%T>D> [XD6>I:EI]W8M?G!($$$T2SS;@"5\N-MP!*Y -?CC^T]^RG
MXN_:/_;7_:OUCPG=+<2?#751XCN-!D@:>/7%CE(*^7G:S1Q^:P5E8L"4&-U>
MS?MY_%R;]NCX(_LW_'/PY'K5AX"\$WLUIXRA\.V2WD_@>]5K4M,(&!78BQ[D
M+@*%\K)'F 4 ?II^S)^V_P#"K]LBROYOAMXRT_Q,=+(^UP+%-:W5N"2 S0SH
MD@4D$!MNTGO53]H;]OGX1?LH>-=)\/?$/QE:^%]6UNTDOK..XL[EXY84W!F,
ML<;1J<J0 S L<  D@'X\_P"":GA[X8?$[]O#4OB%X+^-?Q*^+/B1/#\MKJNI
M:AX8ET_3;J',2""6=H8LS)^Z=58'(48)VX&'_P %:?%_AOX?_P#!6S]F_7O%
M\32^&]%T^6^O\6$E]Y21S3/YGDQJ[N$8!SM4D!,]J /MGX$?\%"?@W^TUX3\
M1:UX'\<6.N67A.V>\U91:W%O<V<"J6:4V\L:3,F%/S*A!(P,GBL#X/\ _!5?
MX _'WX@>'?"O@_X@P:YXB\5-,NFV,.DWZRR&)79_,W0 0X6-V_>E,J,C(()^
M)_AU?_\ #6G[>_Q\^.GP[TG4K3X2_P#"M]1TB37IK&6QM_$MV+18SY:NJESN
MB).1E1"I8*S*#W__  1L^%MYXN_X(O>*M-\(K:Z3XN\81:_:07\:B.1[MHW@
MMW=^OR_( 2?E H ^D]2_X*V?LY:/\5O^$*N/BOX>CU[[0;5L1W#6,<@R"K7@
MC-LN"",F4 'CKBO!?^"PG_!3N^_9,^*WPM\+^#?'"Z#J,VI0ZAXLMQHZW@;1
MY'4*X>6!UYV3<0MYG'3E:^5_#GQR\"^#O^"2>J?LQZIX%\0Q_'ZXOI[1?"I\
M.W#7U[?M>F6+4%D$94[(0JYW;R(=H!3#5Z?_ ,%(?@WXS^"?[#'[)-_XKL]0
MU!OA3J5@WBJXMT:Z;2T6.$X<KG*H(C'OSM+*HS\PR ??.J?\%!_@WH?[.FE?
M%B^\=:=8^ =<:1-.U*YM[B%[YT>1&2*W:,3NX:*3Y1&6(4D CFJOP]_;@^'?
M[5WP1\9:U\)?'VD:E=:'IER[7#V\T4FE2^5(8IIK:6+S1&&4D$Q,&"' ;I7P
M#_P5(^)VG_M:>,O@C\=/!.M>,+KX.^$=0O-.U7Q!I&AS/<>')Q)$_P!N%M<1
MC]V5"$2%=O[G;D/M4]1^Q=X7^&GC[XR_%[XB^!_C%\2/BKK=QX&OK/6-4U/P
MR^GZ9? Q( C3&*/=<1[(CM902K9!8!L 'MG['?\ P47T?X:?L.Z/X_\ CM\9
M/#_BM=<\27&CVGB32M"O8;69PI9+<PK802*5$<I+M"%_VSQ7LWP)_P""E7P-
M_:8^)TW@WP1\0]*USQ+$'9;);>XMS<A 6?R7EC5)MJJS'RF;"@GIS7X[^.[=
M+O\ X(0?"6*1=T<GQ8N$89QD&WNP:^X/V\_#FG^%?^"RO[)2Z996NGJEM+9J
M+>(1@0QEUCC^7'RJK, .@!(H ]E_X*X?';QO\!?AQX'O/!/Q4\,_"NZU7Q M
MA<W>LZ5-J$>HJT3,L"+%8W95LJ3N*H,#[_:NY^-/_!43X#_L[?$[6_!OC3X@
M6N@^)?#MM'=WUE-IMZY1)$C=-CI"R2L5E1MD;,V,\?*V/F?_ (.-?^2&_"+_
M +'ZW_\ 2>:JOPFT*SU?_@Y1^*$UU:PW$VF^"(+JT=UR;>4VFF1%U]&V22+G
MT<^M 'L?[8W_  4)TOQ#_P $R_B#\7/@3XXL;Z\T+[+!:ZG!:+(UE,UY:HZ2
M6]S&=K&*;[LD><.".QJ#]BW_ (*Y?"/XK> _AGX5\2?%#2;KXKZ]HNGKJ4,E
MG+;QSZE+"GF1>:L*VJRM*Q7RU8?,=H7.!7Y^^%[2/2?V$O\ @H!I]K&MO8V?
MC.PC@MXQMCA4:PZ@*HX'"J..RCT%=Q^WWX8T[PU_P2:_8UN-/L[>SN(;W2)D
MEA0+(CSV1FF8,.07E =O5@#V% 'VEK7Q\\<VG_!5J[\"Q_%/PVO@^+PL^IKX
M(_LJ4ZF)!;G%Q]I^P^5M\SYMOVO./X.U>%_\$Q_^"W'A>^_9\W?M#_%BQ7QU
MJ'B*>VLO,TCRREF(K81F06=N(HD\QI?GEVY^;)PO&KX@4O\ \'$5\J@LQ^&L
M@ '?]R:^.OV3/VA? /PT_P""5?Q8^".L:-JVI?&;QQK-S'IWAF#P]<S:A,6M
M[46\S-Y6T>4Z22!=V\;20N6R0#](/V]OVCO%G@;]H']G&S\$_%WPCX0\._$/
M6U@N;&[T^34&\80-<V 6.UFBLKE(\QSE0[2P*?/0A\ LGB/A/_@M%I-I_P %
M7/&7AO7/B3M^"<>GIINB6_\ PCSG&LC[)&Z;DMOM7^M^UC+GR_0XV&O)?CI\
M(O$?P&F_X)H^$_%HDC\1:3XG(O(9""]H9-4TB58&QQF)'6,XR,IWZUZ/\5/C
M-HO["O\ P7=\:?$/XE+JVC^$?&O@N*RT;4(=-GNTOKA8K%/*01(Q+[[:1<#.
M"R;MH;- 'VO^TM_P45^"W[(&NV^E?$3Q]IN@ZM=()4L4M[B^NE0YVN\5O'(Z
M*<'#. #C@UJ>(_VW?A5X7_9Q?XN7'C+3IOAU&8U;6K**:]B#/,L"KLA1Y-PE
M8*5VY4YR!@X^!_ /QP\*_L%?\%*_CEX\^-]KJ<7AWXK6D%]X-\6R:+<7EK=6
M3J7^PH4C9E8Q&&,HP&/LOS;05)\7O/A1XD\$_P#!&']H_P 2:AH6H^$_"7CS
MQM8ZMX6T6]A^SR6UG_:4 $GE?P*RF-!TR(01E2I(!^J?[.W[?WPA_:R\::CX
M?^'?C&'Q1JFDV2:C=I;V%W'%#"Y4*3+)$L9;+@; Q<'<"!M;'L=>0_L ^'-/
M\*_L/?"&STVSM[&U_P"$.TJ8QPQA%:22TBDD<XZLSLS,3RS,2<DDUZ]0 444
M4 %%%% !1110 4444 ?G#\1?VUOB]^TA_P %-?%OP+\&_%+PW\!]*\(0[+.[
MOM#M=4U#Q%<[8B(TCNB%8OYI=5C*MY:;OGR<?4'@WXM>*/V-OV5[[Q1^TUXZ
M\+WTVBW8CN-;T/1KE8A!)*D-N9(HT+/*[L"QCB1%+[<$*7;Y:_;Y_:+_ &0_
MBM\5O&'A7X_> _%/A?Q#X>C:STOQ)<>'KNUN];1%!'V2>%2[JKL=GGCR2&#9
MPY%?->D:1\4-'_X("_%J/Q\OB&'PZVO:5_PB,6N;A=QV8OK4/M5_F6$L!L'W
M<[RO!R0#]+_AG_P5B_9X^,/Q/T[P;X=^)VCWWB'5BBV<#VMU;Q7+N 4C6:6)
M8C(=P CW[RWRXW BO-?$7[1WQ TW_@I;\1O!\/Q8\,R>%=#\&3:O9>"4TB7^
MT["9;*!A<M<-8B)E\UF?;]K<XD V<%5^+?VA/B#X=_;4_95_9E^!/P1T;5KS
MXH>$6TF[U">#1+FS7PL/L($\DDLD:#;),Z3F5"RMY(;<25S[5XB_Y3S_ !H_
M[)3/_P"D-G0!WW_!.G_@JG9Q_L(Z+X\_:"^($)UK7O$]YHNGS+I.ZYOC&(RL
M<=K8P;FV[^6$?!=03EE!^EOVB/\ @H+\'_V3]/T>?XA^-+?PS)K]NMU96=Q8
MW4E^\1Z.UK'$T\8SP=Z+A@RG!! _$7]C3P=XE_90\!?"[]JJXMXO&'@?PWXN
MN-#U+1Y8#,VBQLJC[1'N)569I9"K *$E2+))D&/IK]KK45\&_P#!42X^-&O?
M$CQAX!^%7Q$\*VDOA/Q_X;TK^U+>!3;6R&U;]W(8][),Q"+O_>+D;78@ _5G
MX)?';PA^T?\ #VT\5>!_$&G^)/#]\2L=W:,<!A]Y'5@&C<9&4<!AD9'->1?%
M;_@K)^SY\$/'7B+PSXJ^(UKI&O>%9D@U*RDTN^DDB=\$!-D!$W# GRB^T<G
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MU#1OA[JG@U]/AUJ.PFNK?[2(YT,)\I6._(7Y0"0)$8X4D@ ^U/VE/V^O@_\
ML@QZ9_PL7QOI_AV;68O/L[;R)[NZFBZ>9Y,$;R!,@C<5"D@C.017E?[;?[:%
MOX@_X)^WGQ.^#/Q=\*>&+<WUK%%XHO+*6^M;8-,J20R0):7,JR'<%VM!N7<"
M=HYKXN_:\NIO G_!4:Y^,GBCQYX_^%_PS^(7A:T?PQXUTC07NS8?Z/;(UE-&
MT3O Q:.=F4)Y@,BY&UV(YWXN?#3P'X/_ ."1'QVUCX=^,O&WC+P_XD\7Z3.]
MWKVA-I4%Q<+<QL]S:J54/'*)$!^564Q %5&W(!^B1_X*2?"W]GKP1\.-'^+'
MQ+TNV\8^)/"%CKKW@TR[6UU56@)DND9;=4C622*4K&RQN?E41@E5KT/]F+]M
M;X7?ME:5J5Y\-?%UEXFCTAT2]C2":UGM=^[87AF1) K;&PVW!VG!.#7YW:EH
M5GXB_P""K7[#]O?6L-W;K\*].N!'*NY1)%9ZA+&V/59$1AZ%17I7["]I'I/_
M  7?_:>M[6-;>WETB&X>*,;4>1FLG9R!QN+.Y)ZY=O4T >Q_M(?';QOX1_X*
M=_"'P3I/Q4\,^'O"?B/3?.O_  ?=:5--J&NNK79>2*X6QDCC&U$&&NHCF)N.
M06UO$W_!9W]F?P?<ZE#J7Q0M+:YTG4)-+NK?^Q]1:>*=-P<>6MN79 5(\Q04
MSQNR0#X5^VQ_RGM_9E_[ 5Q_+4*\I_X)N>#=)U?X'_MWWEUIMG=74]QJ]H\L
ML0=FB$-^X3)_AW'=CU /88 /?O\ @K'_ ,% ->^"?P:^#?C3X3^.-.M/#_C3
MQ)'#=:I;P6M[;WM@4+-\TR.$ P<E=K*00<$$5[]^SW_P4@^"/[57Q!O?"O@'
MX@:;KWB"Q1Y'L_LUQ:M,JDAFA,T:+.!@DF(L OS="#7Y!^,+./7O^"/_ .R[
M8WB_:;.;XCZA;/$Y)4QM<S[E^AW-^9]:^S?VO]&M/#O_  7Q_9G;3[6WL6D\
M.S0-]GC$68U3445/EQ\H4E0.@''3B@#&UG]N7XO^%?V3_P!J[Q1%\9O#/B[7
M?AWK5C9: VDZ%Y4GA</J3PRP3+<Z?!',QC(3<// ,;$,"0S>\?L2?\%9_A/\
M8/ ?PU\*>(OB?I%Y\6-:T*P.IP26DELD^HR0QF2,2K$MJ)3(Q'E(P.[Y0O:O
M@?P=H=[XD_8[_P""@EEIUG=7]Y/XVLA'!;1-++)C692<*H). ">!T%'Q7^(W
MA?\ ;K_8F_9F^!7P3T^^U[XG^%9M.FU:\L='GMX?"["T=+LRSO&B@/<.)6=&
M*,;<L6)VY /N3Q'^V#KGPJ_X*:>/]+\5?&#PS;_"OPCX3.O7/A!-$NI-3TR-
M+6V9[IIDT_;(N]W?8ET[8D V<%5X#_@CO_P5<?\ :>\=>*O!?Q"\>_VYXPU7
M7;A_"-G_ &)]F\W38H6E/SP6Z1C"HQ_?,'.,<Y J+X:*T?\ P<@^.E9S(R^
M(06(QN/D6'/'K7!_\$DOCMHG[*GQ5^,'P7\;76K>%/B5XP\;S#1;632+B82"
M1'1+C>J%!$&53N<A2'5@2NX@ ^SOBK_P5;_9Z^"GQ1F\&^)/B=HMCXBM9OL]
MQ!%;W-U%:29P4EFAC>*-E/#!W!4YSC!KJOCU^W7\)?V8K3PE=>./&EAHMCXZ
M+?V'>"">ZM;]0(B7$T*/&D>)HCO=E3:V<X!(_+_]GOXU>#/V+OV%_CA\!?B]
MX5UJW^,WB2[U"&'39=&N+N7Q?+/"L=I-%<",JRI*"ZLS 8P\>YF(K-^.'P!\
M1?"_X(_\$_\ P/\ $JQ9]0F\6727VEWJ[VM[6YU*P=+653_=AD560_=Y7C&*
M /UL_9N_:H\!_M=>"+SQ)\.]</B+0[&_DTR6[%C<6J_:$1'95$\:%@%D0[E!
M4YP"2"!Z%3(84MH5CC58XXU"JJC"J!T %/H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !7SI\ ?V!/^%&?MP?%3XR_\)9_:G_"S(8X?['_LOR/[-VF,Y\_SF\S/E_\
M/-.OMS]%T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>moln-20221231_g9.jpg
<TEXT>
begin 644 moln-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0$ J "H  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0P!I4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM5;@6=TP^<^B/T;Z<'VH ](HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH JZIJEKHNG7%_?3I;6ENADEE<X"J*^0/B_P#'#4/B%<R6-BTEAX?1
ML+ #A[C'1I/Z+T'N:U?VBOBM)XHUN3P]ITV-(L)-LK(W%Q,.I]U4\#WR?2O&
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I58HP9258'((ZBDHH ^C?@A^T%))
M-;>'O%$^_<1':ZE(><] DI[^S?GZU]'5^<E?5W[.'Q6D\4Z8WAW5)O,U.QC#
M03.WS3PCC!]67CZ@CT)H ]MHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+
M^,/C)O _P_U/487V7CJ+>V/?S'X!'N!EO^ UVE?.?[76LL(_#VDJ?E8RW4B^
MXPJ?S>@#YQ+%B23DGJ:2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M
MKP;XFN/!OBC3M9MB?,M90Y4?QIT9?Q4D?C6+10!^BEE>0ZA9P75NXD@GC66-
MQT96&0?R-3UYU^S_ *RVM?"G1BYW26P>U;Z(Q"_^.[:]%H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OE']K.4MX_TN/LNF(WYRR_X5]75\G?M9?\ )1=._P"P
M5'_Z.FH \5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^M/V4
M93)\-[U3_!J<JC_OU$?ZU[/7BO[)O_).M1_["LG_ *)AKVJ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^3OVLO^2BZ=_V"H__ $=-7UC7R=^UE_R473O^P5'_
M .CIJ /%:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /K']DW_
M ))UJ/\ V%9/_1,->U5XK^R;_P DZU'_ +"LG_HF&O:J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KY._:R_Y*+IW_ &"H_P#T=-7UC7R=^UE_R473O^P5'_Z.
MFH \5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^L?V3?^2=:
MC_V%9/\ T3#7M5>*_LF_\DZU'_L*R?\ HF&O:J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KY._:R_Y*+IW_8*C_\ 1TU?6-?)W[67_)1=._[!4?\ Z.FH \5H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^L?V3?\ DG6H_P#8
M5D_]$PU[57BO[)O_ "3K4?\ L*R?^B8:]JH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OD[]K+_DHNG?\ 8*C_ /1TU?6-?)W[67_)1=._[!4?_HZ:@#Q6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ/_85D_P#1
M,->U5XK^R;_R3K4?^PK)_P"B8:]JH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOD[]K+_DHNG?]@J/_P!'35]8U\G?M9?\E%T[_L%1_P#HZ:@#Q6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#ZQ_9-_P"2=:C_ -A63_T3#7M5
M>*_LF_\ ).M1_P"PK)_Z)AKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3O
MVLO^2BZ=_P!@J/\ ]'35]8U\G?M9?\E%T[_L%1_^CIJ /%:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /K']DW_DG6H_]A63_ -$PU[57BO[)
MO_).M1_["LG_ *)AKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3OVLO^2B
MZ=_V"H__ $=-7UC7R=^UE_R473O^P5'_ .CIJ /%:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /K']DW_ ))UJ/\ V%9/_1,->U5XK^R;_P D
MZU'_ +"LG_HF&O:J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY._:R_Y*+IW_
M &"H_P#T=-7UC7R=^UE_R473O^P5'_Z.FH \5HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^L?V3?^2=:C_V%9/\ T3#7M5>*_LF_\DZU'_L*
MR?\ HF&O:J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY._:R_Y*+IW_8*C_\
M1TU?6-?)W[67_)1=._[!4?\ Z.FH \5HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **T_#OAG4_%NJ1Z=I%G)?7C@L(TP, =222 !
M[D]Q79G]GCX@@$_\(_\ ^3EO_P#'* /.:*T-<T#4?#.I26&J6<MC=Q\F*9<'
M'8CU'N.*SZ "BBB@ HHKI/"7PY\2>.EF;0]*EOHX3M>7<L: XSC<Y SCMG/(
MH YNBO0;OX ^/K&UEN)?#[F.-2[>7<PR-@>BJY)/L!7GU !1110 4444 %%%
M% !117L_[./PXT#Q])K[:[9M>K9BW$2"9XP-_F9)V$$_<% 'C%%>T?M'?#G0
M/ ,GA]M"LFLA>"X$R&9Y =GE[2-Y)'WSWKQ>@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HK['TG]G?P&^CVAFT=YIFA0O,UW,&9BHR<
M!P/R&*^2/$-A'I?B#4[*$L8;:ZEA0N<G:KD#/O@4 9]%%% !1110 4444 %%
M%% !1110 4444 %%%*JEV"J"S$X  Y- "45Z';_L_>/[F%)4\/,$<!@)+J!&
MY]5+@CZ$5)_PSO\ $'_H7_\ R=M__CE 'G%%>@W'P!\?6J%G\/2, ,_N[B%S
M^2N:XK5=&U#0[K[-J5C<6%QC/E7,31MCUP1TH IT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45UOA7X4^*_&NGF^T;2)+NT#E/.:6
M.)21C(&]AGKVH\4_"?Q9X+T\7VL:/):VFX(9EECE52>F=C''X^WK0!R5%%%
M!1110 445U_A?X2^+?&$:3:;HMP]L^"+B;$,9!_B#.1N'^[F@#D**]GA_91\
M82+EKS1XCZ//)G](S5;4/V6_&EE"SPG3;]E&1';W)#'Z;U4?K0!Y#16UXD\%
MZ[X1F\O6-*N; D[5>5#L8]<*X^4_@:Q: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#ZQ_9-_P"2=:C_ -A63_T3#7M5>*_LF_\
M).M1_P"PK)_Z)AKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ4 ?/%%=WJWP-\;Z'IEUJ%[H9AL[6,RRR"ZA?:H&2<*Y)P/05PE !17<Z/\
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M.[B.4FA8JP_^M[58\1^)=3\7:M+J6KW;7M[(%5I& 7@#     'T% &91110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]8_LF_\ ).M1
M_P"PK)_Z)AKVJO%?V3?^2=:C_P!A63_T3#7M5 !1110 4444 %%%% !1110
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MT>R]U(_;)O4!A^[7\%P<>I-?/?[07C+_ (2WXBWD<3[K+3?]"BZX+*3YC?\
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M#TH ]%F_:^ NF$7A<M;[N&>^PY'K@1D ^V37IGP_^-OAOXB2"TMY7L=28?\
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MWJ-N6'H1VR:^/*_0W7H4N=#U&&1=T<EO(C*>X*D$5^>5 'H_[.__ "6+P_\
M]O'_ *3RU]6_$'P3#X_T>UTNZ<I9B[CGGVG#,BY)4'MDX'T)KY2_9W_Y+%X?
M_P"WC_TGEKZX\;>*K?P3X5U'6[E&DBM(]PC7J[$A47VRS 9[9H P/''Q.\,_
M"/3[2SG4B3RPMOIMBB[EC' .,@*OUZX.,X-<1>?M.>%=;\.:Q T%]97;6DJ0
MQS1 K*Q4@*&4G'..2 .:^9_$7B"]\5:U=ZKJ,OG7=TY=V[#T ] !@ >@K.H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^3OVLO^2BZ=_V"H_\ T=-7UC7R=^UE_P E%T[_
M +!4?_HZ:@#Q6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6H /VP/^92_[>_\ VC7S_HL*7&L6$4BAXWN(U93T(+ $5] ?M@?\RE_V]_\
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MZ_&_I0!QE=Y\"O\ DK7AS_KLW_HMJX.N\^!7_)6O#G_79O\ T6U 'UC\7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNK6#;H)UP\;?>C?^)&'J#^?7H:^ :Z7P/\0]<^'NH&ZT>Z\L/Q+;R#=%*/\
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ML?\ _,V_]NG_ +6KYRKT3X0_%]_A3)JA&E+JD=^(MRF?RBA3?C!VMG.\]NU
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MSW3K%9W:M9S2-P$#X*D^V]5S[9KA=2U*ZUB^GO;VXDNKN=M\DTK99CZDU6H
M_0#QIX4M/''AF^T:])6&Z3 D7JC Y5A]" :^4=:_9M\;Z;J#06FGQZI!GY+F
MWN(U5AGC(=@0?T]S6Q\.?VF-4\+V<.G:Y;'6;&(!(YU?;<(H[$GAQTZX/N:]
M$;]K+PKY>5TS6#)_=,40'Y^9_2@"'X1_LYQ>%;R+6?$LD-YJ$)WP6D?S0PL/
MXV)'S,.W8=>3@CV/1=<LO$%K)<V$RW-NDKP^:G*LR'#8/<9!&?:OD[XE?M$Z
MUXVMYM.T^(:-I,@*NB/NFF7GAGXP",?*!ZC)%6/AE^T1)\._"T6BMH*ZBD4C
MNDPNS$?F.<$;&[DT <_\?_\ DKWB'_?B_P#1,=>>UO>.O%DGCCQ9J&N2VZVC
MW;JWDHQ8( H4#/?A16#0!^B&D_\ (*LO^N*?^@BO@CQI_P CAKO_ %_S_P#H
MQJ]KT_\ :WFL]-M[>3PNDLT<2H9%OBJL0,9V^6<#VS^->"ZIJ#ZMJ=Y?2JJ2
M7,SS,J= 68D@>W- 'LG[*OB:WTGQAJ&DSL$.IP+Y+$]9(R2%_%68_P# ?>O;
M/C5\-9/B7X52UM)4AU&UE\^W:3A6.""A/8$'\P*^*(+B6UGCFAD:&:-@Z21L
M596!R"".A!KW[P7^U==6-K';>)---^4&/MMFP61L8^\AX)Z\@CZ4 ><-\#O'
M2W/D'PY=;^F0R%/^^MVW]:]G^$/[.Z^%[F/7?%30RWL&)(+-6#1P$<[W;HS#
ML!P,9R>,7)OVL_"RQ9BTO6'D_NO'$H_/S#_*O(/B5\?-=^($+V,2C2-(;AK6
M!RS2CT=^,CV  ]<T ?7^H31W&B7,L3K)%);LZ.IR&!4D$5^>5>\VO[54UOX:
MBTS_ (1N-IH[46WVC[:0I(7;NV>7^F[\:\&H ]'_ &=_^2Q>'_\ MX_])Y:^
MC?VB/^2.^(/^W?\ ]*(J^3/ 'B^3P'XNT_78[9;QK0O^X9]H8,C(><''#'M7
MH_Q&_:/?Q]X1O="7P^NGK=&/=.;SS2 KJ_ V+W4=Z /%Z*** "BBB@ K9\%_
M\CAH7_7_  ?^C%K&JUI>H/I.IV=]$JO);3),JOT)5@0#[<4 ?H9=?\>LW^XW
M\J_.FOH:Y_:[FFLY(T\+1I,R%1(U\64$CKM\L?EFOGF@ HHHH *]N_95\36^
MD^,-0TF=@AU.!?)8GK)&20OXJS'_ (#[UXC3X+B6UGCFAD:&:-@Z21L596!R
M"".A!H ^U_C5\-9/B7X52UM)4AU&UE\^W:3A6.""A/8$'\P*^7V^!WCI;GR#
MX<NM_3(9"G_?6[;^M>C^"_VKKJQM8[;Q)IIOR@Q]MLV"R-C'WD/!/7D$?2NL
MF_:S\++%F+2]8>3^Z\<2C\_,/\J *?PA_9W7PO<QZ[XJ:&6]@Q)!9JP:. CG
M>[=&8=@.!C.3QCVS4)H[C1+F6)UDBDMV='4Y# J2"*^0/B5\?-=^($+V,2C2
M-(;AK6!RS2CT=^,CV  ]<UU=K^U5-;^&HM,_X1N-IH[46WVC[:0I(7;NV>7^
MF[\: /!J]"^ '_)7O#W^_+_Z)DKSVM[P+XLD\#^+-/UR*W6Z>T9F\EV*A@5*
MD9[<,: /L7XV_P#)*?$G_7M_[,M?#E>W>//VF9?&7A74-%C\/+8_;$$;3M>&
M7:,@G"[%YX]:\1H **** /K+]E774O\ P'=Z:77S["[;Y,\B-P&4_BV_\JJ?
MM"?!K5O&^H6FMZ%&EU=QPBWGM6D",RAB592Q S\QR"1T&,U\^^ ?'VJ?#K7E
MU/3'4Y&R:WDY29,YVG^A'(_,5] Z;^UKX>DMD-_H^IV]QCYEMO+E0'V)93^E
M 'D<O[/?C&S\/ZEJ]_;6VG06,+W#Q3W :1U1=QVA-PZ ]2.E>:U]#?$3]IZQ
M\0>&M0TG1M)NE-] ]N]Q>LJ[$8;6PJDY.">XQ[U\\T ?>7PM_P"2:^%_^P;;
M_P#HL5\@?&3_ )*EXE_Z_&_I7H?A']J.7PSX9TW29/#:W;64"6ZS+>F,,%
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M-_Y)UJ/_ &%9/_1,->U5XK^R;_R3K4?^PK)_Z)AKVJ@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *^3OVLO^2BZ=_V"H_\ T=-7UC7R=^UE_P E%T[_ +!4?_HZ
M:@#Q6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ
M/_85D_\ 1,->U5XK^R;_ ,DZU'_L*R?^B8:]JH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OD[]K+_ )*+IW_8*C_]'35]8U\G?M9?\E%T[_L%1_\ HZ:@#Q6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ/_ &%9
M/_1,->U5XK^R;_R3K4?^PK)_Z)AKVJ@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *^3OVLO^2BZ=_V"H_\ T=-7UC7R=^UE_P E%T[_ +!4?_HZ:@#Q6BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ/_85D_\ 1,->
MU5XK^R;_ ,DZU'_L*R?^B8:]JH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD[
M]K+_ )*+IW_8*C_]'35]8U\G?M9?\E%T[_L%1_\ HZ:@#Q6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ/_ &%9/_1,->U5XK^R
M;_R3K4?^PK)_Z)AKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3OVLO^2BZ
M=_V"H_\ T=-7UC7R=^UE_P E%T[_ +!4?_HZ:@#Q6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ/_85D_\ 1,->U5XK^R;_ ,DZ
MU'_L*R?^B8:]JH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD[]K+_ )*+IW_8
M*C_]'35]8U\G?M9?\E%T[_L%1_\ HZ:@#Q6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#ZQ_9-_Y)UJ/_ &%9/_1,->U5XK^R;_R3K4?^PK)_
MZ)AKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3OVLO^2BZ=_V"H_\ T=-7
MUC7R=^UE_P E%T[_ +!4?_HZ:@#Q6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#ZQ_9-_Y)UJ/_85D_\ 1,->U5XK^R;_ ,DZU'_L*R?^B8:]
MJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OD[]K+_ )*+IW_8*C_]'35]8U\G
M?M9?\E%T[_L%1_\ HZ:@#Q6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#ZQ_9-_Y)UJ/_ &%9/_1,->U5XK^R;_R3K4?^PK)_Z)AKVJ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^3OVLO^2BZ=_V"H_\ T=-7UC7R=^UE_P E
M%T[_ +!4?_HZ:@#Q6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#ZQ_9-_Y)UJ/_85D_\ 1,->U5XK^R;_ ,DZU'_L*R?^B8:]JH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OD[]K+_ )*+IW_8*C_]'35]8U\H?M91D?$'3'['
M2T'Y2R_XT >)T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHK0\/Z'<^)-<L=+LUW7-W,L*>V3U/L!R?I0!]?_LZ
M:2VD_"G2V==KW;R7)'L7(4_BJK7IE4]'TN#1-)L]/MEVV]K"D$8_V54 ?RJY
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'QG\>/A?)X!\3O>6D6-#U!S)
M;LHXB<\M$?3')'M]#7F%?H-XH\,Z?XPT.ZTK4X1-:7"X/]Y3V93V(/(-?&'Q
M/^%.J_#/5#'<J;G3)6/V:^1?E<?W6_NMCM^6: .(HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OI;]F+X7R6,9\7:E%LDF0QZ?&PP0AX:7\1P/;)[BN3^"/
MP'N/%<]OKFO0M!HBD/%;N"'N_3CLGOW[>M?5\<:PQJB*J(HVJJC  '0 4 .H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJVDV6N:?-8ZA;1WEI,N
MV2&5<J1_C[]JMT4 ?-_CW]E5P\EWX3NU9#S_ &?>-@CV23O]&_,UXCXA\"^(
M/"DC+JVCW=D%_P"6DD9,9^CCY3^!K[^I" P((R#U% 'YRT5^@5YX,\/Z@Y>Z
MT+3;ESU::SC<G\Q53_A6OA'_ *%71?\ P70__$T ?!%%?>__  K7PC_T*NB_
M^"Z'_P")H_X5KX1_Z%71?_!=#_\ $T ?!%%?>_\ PK7PC_T*NB_^"Z'_ .)H
M_P"%:^$?^A5T7_P70_\ Q- 'P117WO\ \*U\(_\ 0JZ+_P""Z'_XFC_A6OA'
M_H5=%_\ !=#_ /$T ?!%%?>__"M?"/\ T*NB_P#@NA_^)H_X5KX1_P"A5T7_
M ,%T/_Q- 'P117UUK&CZ%9?&#0_#D7AC01IMY9M/*ITN$MN F/!V\?ZM:[W_
M (5KX1_Z%71?_!=#_P#$T ?!%%?>_P#PK7PC_P!"KHO_ (+H?_B:/^%:^$?^
MA5T7_P %T/\ \30!\$45][_\*U\(_P#0JZ+_ ."Z'_XFC_A6OA'_ *%71?\
MP70__$T ?!%%?>__  K7PC_T*NB_^"Z'_P")H_X5KX1_Z%71?_!=#_\ $T ?
M!%%?>_\ PK7PC_T*NB_^"Z'_ .)H_P"%:^$?^A5T7_P70_\ Q- 'P117WO\
M\*U\(_\ 0JZ+_P""Z'_XFC_A6OA'_H5=%_\ !=#_ /$T ?!%%?>__"M?"/\
MT*NB_P#@NA_^)H_X5KX1_P"A5T7_ ,%T/_Q- 'P117WO_P *U\(_]"KHO_@N
MA_\ B:/^%:^$?^A5T7_P70__ !- 'P117WO_ ,*U\(_]"KHO_@NA_P#B:/\
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M_P#@NA_^)H_X5KX1_P"A5T7_ ,%T/_Q- 'P117WO_P *U\(_]"KHO_@NA_\
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M^A5T7_P70_\ Q- 'P117WO\ \*U\(_\ 0JZ+_P""Z'_XFC_A6OA'_H5=%_\
M!=#_ /$T ?!%%?>__"M?"/\ T*NB_P#@NA_^)H_X5KX1_P"A5T7_ ,%T/_Q-
M 'P117WO_P *U\(_]"KHO_@NA_\ B:/^%:^$?^A5T7_P70__ !- 'P117WO_
M ,*U\(_]"KHO_@NA_P#B:/\ A6OA'_H5=%_\%T/_ ,30!\$45][_ /"M?"/_
M $*NB_\ @NA_^)H_X5KX1_Z%71?_  70_P#Q- 'P117WO_PK7PC_ -"KHO\
MX+H?_B:/^%:^$?\ H5=%_P#!=#_\30!\$45][_\ "M?"/_0JZ+_X+H?_ (FC
M_A6OA'_H5=%_\%T/_P 30!\$45][_P#"M?"/_0JZ+_X+H?\ XFC_ (5KX1_Z
M%71?_!=#_P#$T ?!%%?>_P#PK7PC_P!"KHO_ (+H?_B:/^%:^$?^A5T7_P %
MT/\ \30!\$45][_\*U\(_P#0JZ+_ ."Z'_XFC_A6OA'_ *%71?\ P70__$T
M?!%%?>__  K7PC_T*NB_^"Z'_P")H_X5KX1_Z%71?_!=#_\ $T ?!%%?>_\
MPK7PC_T*NB_^"Z'_ .)H_P"%:^$?^A5T7_P70_\ Q- 'P117WO\ \*U\(_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#R;Q'_P G&>%O^P:__H-S7K->3>(_^3C/"W_8-?\ ]!N:
M]9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \F\1_P#)QGA;_L&O_P"@W->LUY-XC_Y.,\+?
M]@U__0;FO6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /)O$?_)QGA;_ +!K_P#H-S7K->3>
M(_\ DXSPM_V#7_\ 0;FO6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)O$?_)QGA;_L&O\
M^@W->LUY-XC_ .3C/"W_ &#7_P#0;FO6: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)O$?_
M "<9X6_[!K_^@W->LUY-XC_Y.,\+?]@U_P#T&YKUF@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#R;Q'_ ,G&>%O^P:__ *#<UZS7DWB/_DXSPM_V#7_]!N:]9H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!XG_ ,*)\8?]%5UK_P C?_'Z/^%$^,/^BJZU_P"1O_C]>V44 >)_\*)\8?\
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MB?&'_15=:_\ (W_Q^C_A1/C#_HJNM?\ D;_X_7ME% 'B?_"B?&'_ $576O\
MR-_\?H_X43XP_P"BJZU_Y&_^/U[910!XG_PHGQA_T576O_(W_P ?H_X43XP_
MZ*KK7_D;_P"/U[910!XG_P *)\8?]%5UK_R-_P#'Z/\ A1/C#_HJNM?^1O\
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M!XG_ ,*)\8?]%5UK_P C?_'Z/^%$^,/^BJZU_P"1O_C]>V44 >)_\*)\8?\
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MB?&'_15=:_\ (W_Q^C_A1/C#_HJNM?\ D;_X_7ME% 'B?_"B?&'_ $576O\
MR-_\?H_X43XP_P"BJZU_Y&_^/U[910!XG_PHGQA_T576O_(W_P ?H_X43XP_
MZ*KK7_D;_P"/U[910!XG_P *)\8?]%5UK_R-_P#'Z/\ A1/C#_HJNM?^1O\
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M!XG_ ,*)\8?]%5UK_P C?_'Z/^%$^,/^BJZU_P"1O_C]>V44 >)_\*)\8?\
M15=:_P#(W_Q^D/P7\>6?S6OQ.U"9QR!<>;@_7,C?RKVVB@#P]H_C5X/R_FZ;
MXLMEY*84/C\HV)_.M'P[^T9I<M\--\4Z;=>%=2'!%TK&+/N<!E_$8]Z]?K&\
M4>#M&\96)M-8T^&]BP0K.OSIGNK#E3]#0!J6]S%>01SP2I/#(-R21L&5AZ@C
MJ*EKY]OM!\3?L]7K:GHLL^O>"V;-S82ME[<$\M[?[X&/[PZ&O9?!OC72?'FC
M)J6D7'G0D[7C88DB;NKCL?\ (H W:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /)O$?\ R<9X6_[!K_\ H-S7K->3>(_^3C/"W_8-
M?_T&YKUF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KSOXR?$YO .DP6FG1_:O$.I'RK*!1N*DD#>1WY( '<_0UZ
M!<7$=I;RSS.(X8E+N[=%4#)/Y5X9\(K*3XG?$+6?B!J,;&TMY#:Z7%(.% '7
M'^RI'_ G8]10!UWP>^%*^![%]3U0B\\3W^9+JY<[C'NY**?KU/<^V*])HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X;\=U_X1#Q
MUX+\:P_NQ#<?9+MQQF/.<?BC2C\J]QKRK]IJQ6Z^%-W*1S:W,,J_4ML_DYKO
MO!]ZVI>$=$NW.7N+&"4GW:-3_6@#8HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#R;Q'_R<9X6_[!K_ /H-S7K->3>(_P#DXSPM_P!@U_\
MT&YKUF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#Q/X]?\E"^%7_ &%#_P"CK:O;*\3^/7_)0OA5_P!A0_\ HZVK
MVR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK_\ H-S7K->3>(_^3C/"W_8-?_T&YKUF@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/X]?\E"^%7_84/_HZVKVR
MO$_CU_R4+X5?]A0_^CK:O;* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S?]HK_ )(]KWUM_P#T
MHCKI/AK_ ,DZ\*_]@JU_]$K7-_M%?\D>U[ZV_P#Z41UTGPU_Y)UX5_[!5K_Z
M)6@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \F\1_\
M)QGA;_L&O_Z#<UZS7DWB/_DXSPM_V#7_ /0;FO6: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$_CU_R4+X5?]A0
M_P#HZVKVRO$_CU_R4+X5?]A0_P#HZVKVR@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* /$_CU_R4+X5?\ 84/_ *.MJ]LKQ/X]?\E"^%7_ &%#_P"CK:O;* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /-_VBO\ DCVO?6W_ /2B.ND^&O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S?]HK_DCVO?6W_P#2
MB.ND^&O_ "3KPK_V"K7_ -$K7-_M%?\ )'M>^MO_ .E$==)\-?\ DG7A7_L%
M6O\ Z)6@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \F
M\1_\G&>%O^P:_P#Z#<UZS7DWB/\ Y.,\+?\ 8-?_ -!N:]9H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \3^/7_)
M0OA5_P!A0_\ HZVKVRO$_CU_R4+X5?\ 84/_ *.MJ]LH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /-_P!HK_DCVO?6W_\ 2B.ND^&O_).O"O\ V"K7_P!$K7-_M%?\D>U[ZV__
M *41UTGPU_Y)UX5_[!5K_P"B5H Z2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /)O$?_)QGA;_ +!K_P#H-S7K->3>(_\ DXSPM_V#7_\
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M"#3JX']G_P#Y(/\ #?\ [%K3?_26.N^H **** "BBB@ HHHH **** "BBB@
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MX^(VJ-IOA/X@>%O$^HJAD-GHVM6UW,%'5MD;DX]\5V] !1110 4444 %%%%
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M#1J ^/[KAE]J_"3]H;X(:[^S5\9-=\#:Q+YEWI<RO:W\*E%NH& >&=/3*D9
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M7O;I@/-F;ZD  ?PJJKVKU.BB@ HHHH **** "BBB@ HHHH **** "BBB@#\
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M445^:_[<W_!33XB_LV_'[4O /A+PWX7NM/T^TMI7NM:AN9Y97EB60X\N:,*
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MS17DW_"ZM;_Z)_JW_C__ ,:H_P"%U:W_ -$_U;_Q_P#^-4 9GQZ_Y*%\*O\
ML*'_ -'6U>V5\S^/?&U]XP^(7PX^V>'[O0OL^J+L^U;OWNZ:#.,JO3:/7J*^
MF* "BBB@ HHHH **** "OSL_X+9_\F_^!O\ L9U_]))Z_1.OSL_X+9_\F_\
M@;_L9U_]))Z /FG_ ((J?\G3>*?^Q,NO_2ZQK]J:_%;_ ((J?\G3>*?^Q,NO
M_2ZQK]J: "OQ3_X+2:P][^U%X<L,D0V/A6V 4@??>ZNF8@]>FP<_W:_:ROQ"
M_P""RG_)V]C_ -BQ9_\ HZXH ^H_^")-FB? WQ]=#/FR>(Q$W/&%M8B/_0S7
MZ-5^=G_!$S_DW_QS_P!C.W_I)!7Z)T %?GK_ ,%L-.CD_9M\&WY_UL'BV&!>
M!T>SNF//_;,5^A5? '_!:O\ Y-9\+?\ 8YVO_I#?4 ?'?_!'/4FL?VO)807
MO/#E[ =IP"!)!)SZC]V/QQ7U;_P6TU9H?@+X$TP%MESXE^TG@8S':S*.>O\
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M62Y/X;X(_P Z /R3U;5O'?[9'[0J2W$AU7QEXPU-((4)(BA#':B#KLAB0?\
M 50D]S7[A_LT_L&?"O\ 9O\ #=E%:^'[+Q%XI$8-YXCU>W2>XDDQ\WE;@1"F
M>BIC@#<6.2?R$_X)T_%WX?\ P+_:,B\:?$6_DTW3-/TFZ6RGBM);AOM4FR,
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MVG0R2M-<3O@<#+99N2<(HSA17U/_ ,%J_P#DZ;PM_P!B9:_^EU]7T1_P1-\
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M_P#%G@_Q)\)]:O&NI?#J+J6C>:V76S=]LT0[[8Y&0CK_ *\C@ "OTKK\)?\
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M[1/(#O6)LD@ AWSNRJXW_I>O[)_P63P^-$'PH\&_V;MV^2=$MR?][=LW;O\
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M(ZU] _MT?">?XT_LI_$+PU8PM<:I]@_M"QC3[[SVSK.J+[OY93_@= 'Y5_\
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MYFZ1P3H4\PGLJ/Y;GV0U_1!;W$5U!'/!(DT,BATDC8,K*1D$$=01WH _*_\
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M8L/_ $8:^TJ^+?\ @KK_ ,F9ZM_V&+#_ -&&@#X _P""0?\ R>-9?]@2^_\
M04K]T:_"[_@D'_R>-9?]@2^_]!2OW1H _,__ (*B?M]:]\+]:?X1?#?4FTG6
M_LZRZ]K=LV+BU610T=O"W_+-RA#LX^8!TVD')KX,_9M_8O\ BK^V!J5_J?A^
M&.+28[C;?>)==G=8#,2&90V&>63!R0H.,C<1D9S_ -NFXN;G]L#XMO=L[2CQ
M!<(ID&#L4[4'TV!<>V*_;']@&RTBQ_8W^%*:*(A:R:.DLIAQ@W+,S7&??S3(
M#[@T ?$6F_\ !#6^EM0VH?&2WM;GO';>&VF3H/XFND/7/:O /VVO^"=G_#'7
MP_T+Q-_PL#_A+O[4U0:;]E_L7[%Y>8I)-^[[1)G_ %>,8'7K7[O5^8G_  6P
M^)GAN;P1X)\!0ZG#/XJBU7^UI]/B.Y[>W$$D:M)C[I9I!M!Y(5CVH \^_P""
M(/\ R4WXF_\ 8'M?_1S5^OE?D'_P1!_Y*;\3?^P/:_\ HYJ_7R@#\5O^"U?_
M "=-X6_[$RU_]+KZOJK_ ((J?\FL^*?^QSNO_2&QKY5_X+5_\G3>%O\ L3+7
M_P!+KZOJK_@BI_R:SXI_['.Z_P#2&QH ^_Z*** "BBB@ K\@_P#@M]_R4WX9
M?]@>Z_\ 1RU^OE?D'_P6^_Y*;\,O^P/=?^CEH TO^".?PA\"?$[PO\3I?&/@
MGP[XLEL[RP6VDUS2H+UH%9)BP0RHVT' SCK@5^C=G^RW\&-/N$N+7X1>!+:=
M,[98?#5DC#(P<$19Z$U\(_\ !#O_ )%'XM?]?VG?^BYZ_3V@"GI.CV&@V26>
MF6-MIUHG*V]I"L48^BJ *N444 %?D!_P4P_X*#>)M2\?:U\)OASK,VAZ!H\K
M6>LZII\ICN;ZZ4XEA613E(D/R$+@LP8$E>#^O]?R[_$*XN;KQ]XFGO6=KR34
M[EYFD&&+F5BQ(]<YH ^A?V8?^"=?Q4_:BTF/Q%IZ6?AKPE)(536M:9U^TX)#
M&"-06DP1C<=JYR-V017U3:?\$,YWMT-S\:(X9_XDA\,&11SV8WBD_D*_2WX1
MV6D:;\*O!MKX?$0T*'1K-+#R,;/($*>65QVVXKK: /Y]_P!N/]B7_AC'5/"-
MG_PF?_"8?\)!#<R[_P"R_L/D>2T8QCSI=V?,]L8[YK[A_P""(G_))?B1_P!A
MN#_T0*\6_P""TGQ,\-^+?BMX(\,Z/J<.H:MX;L[I=5C@.Y;:29XBD3,.-^(R
M2O4 KGK7M/\ P1$_Y)+\2/\ L-P?^B!0!^D]?@Q_P5B_Y/8\6?\ 7CIW_I+'
M7[SU^#'_  5B_P"3V/%G_7CIW_I+'0!^E/\ P2A_Y,C\'?\ 7YJ/_I9+7U]7
MR#_P2A_Y,C\'?]?FH_\ I9+7U]0 5\V?\%'?^3)_BG_UXP?^E4-?2=?.'_!1
M>"2X_8I^*BQ(TC#3XG(49^5;F%B?P )_"@#\D/\ @EQ_R?9\,O\ N)_^FN[K
M]_J_GM_X)MZ];^&_VW/A;=W+HD<EY<V8+M@;Y[.>!!]2TB@>I(K^A*@ KX7_
M ."Q_P#R:+;?]C+9?^BIZ^Z*^%_^"Q__ ":+;?\ 8RV7_HJ>@#XJ_P""-?\
MR=O??]BQ>?\ HZWK]O:_$+_@C7_R=O??]BQ>?^CK>OV]H *_"[_@KY_R>->_
M]@2Q_P#07K]T:_"[_@KY_P GC7O_ &!+'_T%Z /O_P#X)%?\F9Z3_P!AB_\
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MU*WM9;:RMTTL6$<)D7:[M^^E+G:2 . ,D\\8^X:** /Y[?\ @I)_R>Y\4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW@M_%_A/0_%4%N2T,6MZ;#>+&3C)42*P&<#IZ4 ?G1_P0[_Y%'XM?]?VG?\
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M[=LXXK]6O^"8O[%^I_LT>!=4\4>,8!;>.?$R1J]CN#'3K1<LL+$<>8S'<_)
MVH.H.?I?X7_L[?#+X*EG\#^!M$\.7#)Y;W=G:+]I=?[K3',C#V+5Z+0 4444
M %%%% '\J]?U*>%?^18T?_KSA_\ 0!7(2_LZ_"B?7FUR7X8^#9-::7SVU)M
MM#<F3^^9/+W;O?.:]#H R_%7_(L:Q_UYS?\ H!K^8+P=_P C=H?_ %_0?^C%
MK^I&O/+;]G7X4V?B!-=M_ACX-@UQ)OM"ZG'H%HMRLN<^8)1'N#9[YS0!Z'11
M10!\ ?\ !:O_ )-9\+?]CG:_^D-]7RK_ ,$5%/\ PU+XJ../^$,NAG_M^L:_
M9+Q5X0T'QUH\ND>)-$T[Q!I,I!DL=5M([F!R.A,;@J?RK+\#_"?P/\,_M/\
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MM/\ L"_!SQ%\"/V6?"'A+Q9!'::_#]HNKJTC</\ 9S-.\JQLP)!8*P!P2,Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$_CU_R4+X5?
M]A0_^CK:O;*\3^/7_)0OA5_V%#_Z.MJ]LH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-_VBO\
MDCVO?6W_ /2B.ND^&O\ R3KPK_V"K7_T2M<W^T5_R1[7OK;_ /I1'72?#7_D
MG7A7_L%6O_HE: .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \3^/7_)0OA5_P!A0_\ HZVKVRO$_CU_R4+X5?\ 84/_ *.M
MJ]LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /-_P!HK_DCVO?6W_\ 2B.ND^&O_).O"O\ V"K7
M_P!$K7-_M%?\D>U[ZV__ *41UTGPU_Y)UX5_[!5K_P"B5H Z2BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/X]?\E"^%7_84
M/_HZVKVRO$_CU_R4+X5?]A0_^CK:O;* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S?]HK_ )(]
MKWUM_P#THCKI/AK_ ,DZ\*_]@JU_]$K7-_M%?\D>U[ZV_P#Z41UTGPU_Y)UX
M5_[!5K_Z)6@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /$_CU_R4+X5?\ 84/_ *.MJ]LKQ/X]?\E"^%7_ &%#_P"CK:O;
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#S?\ :*_Y(]KWUM__ $HCKI/AK_R3KPK_ -@JU_\
M1*US?[17_)'M>^MO_P"E$==)\-?^2=>%?^P5:_\ HE: .DHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \3^/7_)0OA5_V%#_Z
M.MJ]LKQ/X]?\E"^%7_84/_HZVKVR@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \W_:*_P"2/:]]
M;?\ ]*(ZZ3X:_P#).O"O_8*M?_1*US?[17_)'M>^MO\ ^E$==)\-?^2=>%?^
MP5:_^B5H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#Q/X]?\E"^%7_ &%#_P"CK:O;*\3^/7_)0OA5_P!A0_\ HZVKVR@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-_VBO\ DCVO?6W_
M /2B.ND^&O\ R3KPK_V"K7_T2M<W^T5_R1[7OK;_ /I1'72?#7_DG7A7_L%6
MO_HE: .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \3^/7_)0OA5_P!A0_\ HZVKVRO$_CU_R4+X5?\ 84/_ *.MJ]LH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /-_P!HK_DCVO?6W_\ 2B.ND^&O_).O"O\ V"K7_P!$K7-_
MM%?\D>U[ZV__ *41UTGPU_Y)UX5_[!5K_P"B5H Z2BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/X]?\E"^%7_84/_HZVKVR
MO$_CU_R4+X5?]A0_^CK:O;* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1145U<Q6=O+<3R+%!$ADDD8X"J
M!DD^P% 'BG[1$I\2:YX-\&0DM)?WHGG5>JIG8&^F#(?^ U[<JB-0JC"J, #M
M7AOPECE^)7Q/USQ]<(PT^U)LM,##'&,9'T0G/O(:]TH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@#Q/_AK+PG_ - W6O\ OS#_ /':/^&LO"?_ $#=:_[\P_\ QVO;** /$_\
MAK+PG_T#=:_[\P__ !VC_AK+PG_T#=:_[\P__':]LHH \3_X:R\)_P#0-UK_
M +\P_P#QVC_AK+PG_P! W6O^_,/_ ,=KVRB@#Q/_ (:R\)_] W6O^_,/_P =
MH_X:R\)_] W6O^_,/_QVO;** /$_^&LO"?\ T#=:_P"_,/\ \=H_X:R\)_\
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MUK_OS#_\=KVRB@#Q/_AK+PG_ - W6O\ OS#_ /':/^&LO"?_ $#=:_[\P_\
MQVO;** /$_\ AK+PG_T#=:_[\P__ !VC_AK+PG_T#=:_[\P__':]LHH \3_X
M:R\)_P#0-UK_ +\P_P#QVC_AK+PG_P! W6O^_,/_ ,=KVRB@#Q/_ (:R\)_]
M W6O^_,/_P =H_X:R\)_] W6O^_,/_QVO;** /$_^&LO"?\ T#=:_P"_,/\
M\=H_X:R\)_\ 0-UK_OS#_P#':]LHH \3_P"&LO"?_0-UK_OS#_\ ':/^&LO"
M?_0-UK_OS#_\=KVRB@#Q/_AK+PG_ - W6O\ OS#_ /':/^&LO"?_ $#=:_[\
MP_\ QVO;** /$_\ AK+PG_T#=:_[\P__ !VC_AK+PG_T#=:_[\P__':]LHH
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M_P"_,/\ \=H_X:R\)_\ 0-UK_OS#_P#':]LHH \3_P"&LO"?_0-UK_OS#_\
M':/^&LO"?_0-UK_OS#_\=KVRB@#Q/_AK+PG_ - W6O\ OS#_ /':/^&LO"?_
M $#=:_[\P_\ QVO;** /$_\ AK+PG_T#=:_[\P__ !VC_AK+PG_T#=:_[\P_
M_':]LHH \3_X:R\)_P#0-UK_ +\P_P#QVC_AK+PG_P! W6O^_,/_ ,=KVRB@
M#Q/_ (:R\)_] W6O^_,/_P =H_X:R\)_] W6O^_,/_QVO;** /$_^&LO"?\
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MLO"?_0-UK_OS#_\ ':/^&LO"?_0-UK_OS#_\=KVRB@#Q/_AK+PG_ - W6O\
MOS#_ /':/^&LO"?_ $#=:_[\P_\ QVO;** /$_\ AK+PG_T#=:_[\P__ !VC
M_AK+PG_T#=:_[\P__':]LHH \3_X:R\)_P#0-UK_ +\P_P#QVC_AK+PG_P!
MW6O^_,/_ ,=KVRB@#Q/_ (:R\)_] W6O^_,/_P =I#^U3HEQ\MAH&L7<A^ZO
MEH,_DS5[;10!X>WQ6^)'BS,?ASP*^G(W N=2)P/<;MB_SI;/X$:YXRO([[XA
M>))M1VG<NGV;;8U]LX 'OM7\:]OHH S]#T#3O#.G1V&EV<5C:1_=BA7 SZGU
1/N>:T*** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315556592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLECULAR PARTNERS AG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">V8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Wagistrasse 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">8952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zurich-Schlieren<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, CHF 0.10 nominal value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">36,044,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001745114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember', window );">American depositary shares (each representing one common share, CHF 0.10 nominal value per share)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American depositary shares (each representingone common share, CHF 0.10 nominal value per share)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOLN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Wagistrasse 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">8952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zurich-Schlieren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Patrick Amstutz<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">44 755 77 00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314398192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG AG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Zurich, Switzerland<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314166720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Financial Position - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">SFr 7,235<span></span>
</td>
<td class="nump">SFr 8,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">7,506<span></span>
</td>
<td class="nump">8,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short-term time deposits</a></td>
<td class="nump">161,198<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="nump">5,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">25,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">87,946<span></span>
</td>
<td class="nump">71,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">254,752<span></span>
</td>
<td class="nump">164,191<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">262,258<span></span>
</td>
<td class="nump">172,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>Shareholders' equity and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">3,604<span></span>
</td>
<td class="nump">3,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Additional paid-in capital</a></td>
<td class="nump">360,323<span></span>
</td>
<td class="nump">355,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury share reserve</a></td>
<td class="num">(981)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Cumulative losses</a></td>
<td class="num">(127,780)<span></span>
</td>
<td class="num">(250,950)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders' equity</a></td>
<td class="nump">235,166<span></span>
</td>
<td class="nump">107,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">3,637<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">4,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">6,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">9,841<span></span>
</td>
<td class="nump">18,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">7,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,501<span></span>
</td>
<td class="nump">9,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">6,409<span></span>
</td>
<td class="nump">28,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">17,251<span></span>
</td>
<td class="nump">46,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,092<span></span>
</td>
<td class="nump">65,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total shareholders' equity and liabilities</a></td>
<td class="nump">SFr 262,258<span></span>
</td>
<td class="nump">SFr 172,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312889488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Income - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and other income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from research and development collaborations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 189,556<span></span>
</td>
<td class="nump">SFr 9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenues and other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">189,600<span></span>
</td>
<td class="nump">9,754<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,749)<span></span>
</td>
<td class="num">(55,718)<span></span>
</td>
<td class="num">(56,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,238)<span></span>
</td>
<td class="num">(17,454)<span></span>
</td>
<td class="num">(11,595)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72,987)<span></span>
</td>
<td class="num">(73,172)<span></span>
</td>
<td class="num">(67,670)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,613<span></span>
</td>
<td class="num">(63,418)<span></span>
</td>
<td class="num">(58,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(619)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
<td class="num">(4,816)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net finance result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,240<span></span>
</td>
<td class="num">(365)<span></span>
</td>
<td class="num">(4,449)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Result before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,853<span></span>
</td>
<td class="num">(63,783)<span></span>
</td>
<td class="num">(62,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result, attributable to shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,853<span></span>
</td>
<td class="num">(63,785)<span></span>
</td>
<td class="num">(62,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to profit or loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of net pension liabilities, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,334<span></span>
</td>
<td class="nump">8,012<span></span>
</td>
<td class="num">(1,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that are or may be reclassified subsequently to profit or loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive result, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,317<span></span>
</td>
<td class="nump">8,009<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive result, attributable to shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 123,170<span></span>
</td>
<td class="num">SFr (55,776)<span></span>
</td>
<td class="num">SFr (64,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic net result per share (in CHF per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 3.63<span></span>
</td>
<td class="num">SFr (2.06)<span></span>
</td>
<td class="num">SFr (2.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted net result per share (in CHF per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 3.54<span></span>
</td>
<td class="num">SFr (2.06)<span></span>
</td>
<td class="num">SFr (2.51)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 18</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315886544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result attributable to shareholders</a></td>
<td class="nump">SFr 117,853<span></span>
</td>
<td class="num">SFr (63,785)<span></span>
</td>
<td class="num">SFr (62,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation costs</a></td>
<td class="nump">5,088<span></span>
</td>
<td class="nump">4,085<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Change in employee benefits</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Financial income</a></td>
<td class="num">(1,859)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Financial expenses</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Change in other current assets</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="num">(4,445)<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Change in trade and other receivables</a></td>
<td class="nump">25,264<span></span>
</td>
<td class="num">(23,374)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Change in trade and other payables</a></td>
<td class="num">(5,339)<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">3,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities', window );">Change in contract liability</a></td>
<td class="num">(25,190)<span></span>
</td>
<td class="num">(10,651)<span></span>
</td>
<td class="nump">17,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses', window );">Change in accrued expenses</a></td>
<td class="num">(2,434)<span></span>
</td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions', window );">Exchange (loss) gain on working capital positions</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(646)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities', window );">Other financial expense</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash from (used in) operating activities</a></td>
<td class="nump">118,566<span></span>
</td>
<td class="num">(90,953)<span></span>
</td>
<td class="num">(28,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities', window );">Proceeds from investments in short-term time deposits</a></td>
<td class="nump">199,219<span></span>
</td>
<td class="nump">67,876<span></span>
</td>
<td class="nump">52,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities', window );">Investments in short-term time deposits</a></td>
<td class="num">(299,417)<span></span>
</td>
<td class="num">(88,876)<span></span>
</td>
<td class="num">(73,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(933)<span></span>
</td>
<td class="num">(1,451)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisition of intangible assets</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(374)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(101,121)<span></span>
</td>
<td class="num">(22,237)<span></span>
</td>
<td class="num">(21,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of new shares, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,493<span></span>
</td>
<td class="nump">113,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Investments in treasury shares</a></td>
<td class="num">(631)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options, net of transaction costs</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="num">(1,189)<span></span>
</td>
<td class="num">(1,179)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash (used in) from financing activities</a></td>
<td class="num">(1,570)<span></span>
</td>
<td class="nump">50,581<span></span>
</td>
<td class="nump">113,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange gain (loss) on cash positions</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="num">(4,464)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">16,133<span></span>
</td>
<td class="num">(61,907)<span></span>
</td>
<td class="nump">58,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at January 1</a></td>
<td class="nump">71,813<span></span>
</td>
<td class="nump">133,721<span></span>
</td>
<td class="nump">75,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at December 31</a></td>
<td class="nump">SFr 87,946<span></span>
</td>
<td class="nump">SFr 71,813<span></span>
</td>
<td class="nump">SFr 133,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment For Exchange Gains (Losses) On Working Capital Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316075664">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Equity - CHF (SFr)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Treasury share reserve</div></th>
<th class="th"><div>Cumulative losses</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 54,139,000<span></span>
</td>
<td class="nump">SFr 2,160,000<span></span>
</td>
<td class="nump">SFr 182,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">SFr (130,870,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(62,764,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,764,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,514,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,514,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64,304,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,304,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of new shares, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">113,613,000<span></span>
</td>
<td class="nump">727,000<span></span>
</td>
<td class="nump">112,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">840,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,220,000<span></span>
</td>
<td class="nump">2,915,000<span></span>
</td>
<td class="nump">299,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195,174,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63,785,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,785,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,012,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55,776,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,776,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of new shares, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">51,493,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">51,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,289,000<span></span>
</td>
<td class="nump">3,229,000<span></span>
</td>
<td class="nump">355,010,000<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="num">(250,950,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,853,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,853,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,334,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">123,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of new shares, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of treasury shares incl. transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(981,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(981,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 235,166,000<span></span>
</td>
<td class="nump">SFr 3,604,471<span></span>
</td>
<td class="nump">SFr 360,323,000<span></span>
</td>
<td class="num">SFr (981,000)<span></span>
</td>
<td class="num">SFr (127,780,000)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 18</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See note 12</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315243248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure Of General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">General information</a></td>
<td class="text">General information<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners AG ("Company") and its subsidiary (collectively "Molecular Partners" or, "Group") is a clinical-stage biopharmaceutical company pioneering designed ankyrin proteins ("DARPin") candidates to treat serious diseases, with a current focus on oncology and virology. DARPins are a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics. The Company was founded on November 22, 2004, and is domiciled at Wagistrasse 14, 8952 Schlieren, Canton of Zurich, Switzerland. It is subject to the provisions of the articles of association and to article 620 et seq. of the Swiss Code of Obligations, which describe the legal requirements for limited companies (&#8220;Aktiengesellschaften&#8221;).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc. is a wholly owned subsidiary of Molecular Partners AG. Molecular Partners Inc. was incorporated in the United States in the State of Delaware on October 8, 2018. Molecular Partners Inc. is based in Cambridge, Massachusetts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These audited consolidated financial statements as of and for the year ended December&#160;31, 2022 comprise Molecular Partners AG and Molecular Partners Inc. </span></div><div style="margin-bottom:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s shares are listed on the SIX Swiss Exchange (Ticker: MOLN) since November&#160;5, 2014 and on the Nasdaq Global Select Market (Ticker: MOLN) since June&#160;16, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of General Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315211216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of preparation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the IASB. The accounting policies set forth below have been consistently applied to all years presented. Unless stated otherwise, all financial statements are presented in thousands of Swiss Francs (&#8220;TCHF&#8221;).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4 &#8220;Critical accounting estimates and judgments&#8221;.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Group's cash position at December&#160;31, 2022, the Group deemed there to be no material uncertainties that would cast doubt on the Group's ability to operate on a going concern basis. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements as of and for the year ended December&#160;31, 2022 were approved for issuance by the Company's Board of Directors on March&#160;8, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to rounding, the numbers presented in the financial statements might not precisely equal those included in the accompanying notes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Subsidiaries</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Transactions eliminated on consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New or revised IFRS standards and interpretations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new or revised standards that became effective during 2022 did not have a material effect on these consolidated financial statements:</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Onerous Contracts - Costs of fulfilling a contract - amendments to IAS 37</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Annual Improvements to IFRS standards 2018-2020</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Property, Plant and Equipment: Proceeds before intended use - amendments to IAS 16</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several new or revised standards have been published that are not yet effective and that have not been early adopted. No significant impacts on the Group's consolidated financial statements are expected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Segment reporting</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group operates in one segment, focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The executive management, acting together as the chief operating decision makers, assess the financial performance and allocate resources on an aggregated level, and monitor the Group's operating expenses. Accounting policies applied are the same for both internal and external reporting purposes. The Group derives its research and collaboration revenues from research and development collaborations with third parties. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation / transactions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are presented in thousands of CHF. The presentation currency of the Group is the functional currency of the Company. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assets and liabilities are translated at the closing rate at the date of the respective balance sheet;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">income and expenses for each consolidated statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates at the dates of the transactions); and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all resulting exchange differences are recognized in other comprehensive result.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment, Office equipment, IT hardware and Leasehold improvements are stated at historical cost less accumulated depreciation and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful lives are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT hardware:</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 years</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements and right-of-use assets are depreciated using the straight line method over the shorter of their estimated useful life and the lease term. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent costs are included in each asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. An asset&#8217;s carrying amount is written down to its recoverable amount, if the asset's carrying amount exceeds its estimated recoverable amount.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost and accumulated depreciation related to assets retired or otherwise disposed are derecognized at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of retirement or disposal.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are solely comprised of software. They are stated at historical cost less accumulated amortization and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Amortization is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful life of intangible assets is determined to be two years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, the Group assesses whether a contract is, or contains a lease. This is the case if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets (threshold of CHF 5,000) and short-term leases. Short-term leases are leases with a lease term of twelve months or less that do not contain a purchase option. For all other leases the Group recognizes a right-of-use asset and a lease liability at the lease commencement date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. Subsequently the right-of-use asset is depreciated using the straight-line method over the shorter of the asset's useful life and the lease term.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments required over the lease term that are not paid at the commencement date, discounted using the Group's incremental borrowing rate, as the interest rate implicit in the lease generally cannot be readily determined. Lease payments that are included in the measurement of the lease liability include fixed payments or in-substance fixed payments and variable payments that depend on an index. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequently, the lease liability is measured at amortized cost using the effective interest method. The Group remeasures the lease liability when there is a change in future lease payments arising from a change in index, or if the Group changes its assessment of whether it will exercise an extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the lease liability for each period. The Group does not provide residual value guarantees and does not have any leases not yet commenced to which it is committed. The Group is presenting right-of-use assets in Property, Plant and Equipment, whereas lease liabilities are presented separately within current and non-current liabilities in the consolidated statement of financial position.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Impairment of non-financial assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount exceeds their recoverable amount. An impairment loss is recognized for this difference. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial assets at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents / short-term deposits / trade and other receivables (except for VAT and withholding taxes) (and when applicable accrued interest income) are all considered held-to-collect items and are labeled under financial assets measured at amortized costs, with the following definition / accounting policy:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at amortized cost are assets that meet both of the following conditions: (1) the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They arise when the Group provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities longer than 12 months after the balance sheet date which are classified as non-current assets. Interest income on the short-term deposit is accounted for on the statement of comprehensive income as financial income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, financial assets, except for trade receivables, are measured at their fair value plus, in the case of financial assets not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset; for the Group these are considered to be immaterial. Trade receivables are initially measured at their transaction price. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent measurement for the financial assets mentioned above which are classified as measured at amortized cost, is based on the effective interest method, reduced by any impairment loss. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets measured at amortized cost, a loss allowance for expected credit losses on the financial assets is recognized. Measurement of any impairment loss is based on the &#8216;expected credit loss&#8217; (ECL) model, which is based on a predictive model. The loss allowance for a financial asset is measured at an amount equal to the lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Group measures the loss allowance / impairment loss for that financial asset at an amount equal to 12-month expected credit losses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trade receivables, the Group applies a simplified approach which requires expected credit losses to be recognized from initial recognition (measuring the loss allowance at an amount equal to lifetime expected credit losses). This takes into consideration past history, combined with predictive information which accounts for the specific circumstances of the customer (e.g. credit rating etc.), and other relevant factors such as the economic environment. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other financial assets at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables generally arise from transactions outside the usual operating activities of the Group.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial liabilities at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables and non-employee related accrued expense are measured at amortized costs and classified as financial liabilities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash includes cash at banks. The Group considers all short-term, highly liquid investments convertible into known amounts of cash with maturities of three months or less from the date of acquisition to be cash equivalents, provided that they are subject to an insignificant risk of changes in value. The cash flow statement is based on cash and cash equivalents.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share capital / Additional paid-in capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds. The Group has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Treasury shares</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the consideration paid for the acquisition of treasury shares, which includes directly attributable costs, is recognized as a deduction from equity. When treasury shares are sold subsequently, the amount received is recognized as an increase in equity, and the resulting surplus or deficit on the transaction is presented in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include current and deferred taxes. Current income taxes are recognized on taxable profits at applicable tax rates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are calculated using the balance sheet liability method. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled based on tax rates enacted or substantially enacted at the balance sheet date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized if it is probable that sufficient taxable profits will be available against which the deferred tax assets can be utilized. At each balance sheet date, the Group reassesses unrecognized deferred tax assets and the carrying amount of recognized deferred tax assets. The Group recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. The Group conversely reduces the carrying amount of a deferred tax asset to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or the entire deferred tax asset to be utilized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of deferred tax liabilities and deferred tax assets reflects the tax consequences on the balance sheet date of the Group's expectation of recovery or settlement of the carrying amounts of its assets and liabilities. Deferred tax assets and liabilities are not discounted and are classified as non-current assets and liabilities in the statement of financial position. They are offset against each other if they relate to the same taxable entity and tax authority.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have to pay income taxes in Switzerland in the presented reporting periods for 2022, 2021 and 2020. The Company&#8217;s accumulated taxable losses may be used as tax loss carry forwards to offset future taxable income over a period of seven years in Switzerland. No deferred tax assets have been established for these losses, because the Company does not have a history of sustainable taxable profits, increasing research costs are expected to be incurred in the foreseeable future and future revenues are highly volatile and uncertain. No deferred tax assets were recognized on deductible temporary differences on pension liabilities for the same reasons. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc, the Group's US subsidiary, is subject to US federal and Massachusetts and New York state minimal tax.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee benefits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Postretirement benefits (pension plans)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides retirement, death and disability benefits to its Swiss employees in line with local customs and requirements through two separate plans, which are both accounted for as defined benefit plans. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first plan is the compulsory defined benefit plan which is funded through employer (60%) and employee (40%) contributions to VSAO, a Switzerland based plan. This Company-wide plan has been in place since inception of the Company and all employees of the Company are eligible to its benefits. On retirement, the plan participant will receive his or her accumulated savings, which consist of all contributions paid in by the employer and the employee (net of any withdrawals) and the interest granted on those savings at the discretion of the pension foundation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At that time, the plan participant has the right to choose between a lump-sum payment and an annuity, or a combination thereof. The annuity is calculated using a fixed conversion rate determined by the pension foundation. The VSAO&#8217;s plan assets are pooled and the Company&#8217;s share is calculated based on its share of retirement savings. Additional funding requirements may be determined by the pension foundation in case of a severe underfunding. Should the Company withdraw from the plan, the withdrawal may qualify as a partial liquidation under Swiss law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second plan is a voluntary complementary defined management benefit scheme established as of January&#160;1, 2014, in which only employees with a certain management level and / or above a certain salary level are eligible to participate. 33 of the 33 eligible employees participated in this plan as of December&#160;31, 2022 (2021: 32 out of 32). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This plan is set up as a collective foundation with Swiss Life, a Switzerland-based insurance company, for which contributions are 30% funded by the employee and 70% funded by the Company. The purpose of this voluntary plan is to allow higher savings opportunity in a tax effective manner and risk benefits for senior management. In addition, plan participants are entitled to a lump sum payment of five times their annual base salary in case of death. This is a fully insured Swiss pension plan that covers all investment and actuarial risks, including invalidity and death.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VSAO pension plan accounts for over 90% of both the Company&#8217;s defined benefit obligation and plan assets. The liability recognized in the statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligations at the balance sheet date less the fair value of plan assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows. Pension liabilities are determined on an actuarial basis using a number of assumptions, such as the discount rate and expected salary increases applied to determine the defined benefit obligation and an estimate of the fair value of plan assets attributable to the Company. In determining the appropriate discount rate, for example, the Company considers the interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. In determining the fair value of plan assets, the Company adds to the participants&#8217; savings a share of the pension plan&#8217;s technical and fluctuation reserves. Additional information is disclosed in note 18.1.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and past service costs as well as the net interest on the defined benefit obligation are recognized in profit or loss in the period in which they are incurred, and are presented as part of personnel expenses. Remeasurements of the defined benefit pension plans are recognized in other comprehensive result.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has set up a 401k plan for its US based employees. Under the plan the US entity matches the employee's contribution and provides a true-up in matched contributions at year end. The 401k plan qualifies as a defined contribution plan and the associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has set up a defined contribution plan for its UK based employees. Under the plan the Company and the employee both contribute into the plan. The associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group operates share-based compensation plans that qualify as equity-settled plans. The fair value of the employee services received in exchange for the grant of equity instruments is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the equity instruments granted, which is determined at grant date. The fair values are determined by management with the assistance of an independent valuation expert. At each reporting date, estimates of the number of equity instruments that are expected to vest are revised. The impact of the revision of the previous estimates, if any, is recognized as part of share-based compensation (non-cash effective) with a corresponding adjustment to equity. When the vested equity instruments are exercised, any proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bonus plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group recognizes an accrual where contractually obliged or where there is a past practice that has created a constructive obligation. Bonuses are based on a formula that takes into consideration the achievement of the Group&#8217;s goals.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a guiding principle of IFRS 15, revenues from research and development collaboration agreements are recognized when earned based upon the performance requirements of the respective agreements. For revenue arrangements with separately identifiable components (separate performance obligations), the revenue recognition criteria are applied to each component. The transaction price is determined as the consideration expected to be received from the arrangement and is allocated amongst the separate components based on their relative stand-alone selling prices. The corresponding amount of transaction price allocated to each component is recognized as revenue when (or as) the Group satisfies the performance obligation by transferring the good or service to the customer, which generally is over time for upfront payments or at a point in time for milestone payments and development option payments. Payments received in excess of revenue recognized are recorded as contract liabilities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include fees such as upfront payments received in connection with out-licensing of products and/or access the knowledge without transfer of a license as well as in connection with discovery alliances, as well as fees for maintenance of patents, R&amp;D support and services, participation in Joint Steering Committees and other involvement in collaboration agreements. In exchange for these non-refundable upfront fees, the Group does not immediately transfer a good or a service to the customer, rather the upfront fee consists of an advance payment for future services and the right to access the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input-based method to measure its progress towards complete satisfaction of the performance obligation. Accordingly, revenue is recognized over time based on the percentage of actual costs incurred to date relative to the Group's estimate of total costs expected to satisfy the performance obligation. Estimated costs are reviewed and updated routinely for contracts in progress to reflect any changes of which the Group becomes aware. The cumulative effect of any change in estimate is recorded in the period when the change in estimate is determined.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues could include fees such as milestone and development option payments received in connection with out-licensing of products and in connection with discovery alliances. Upon meeting the set milestone or upon a development option being exercised, the Group obtains a right to a non-refundable payment and the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations for the Group. Consequently, the related revenues are typically recognized at a point in time, either when the milestone is met or the option is exercised by the customer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue could also include reservation fees that will be recognized into revenue in case of successful development of a final drug and exercise or lapse of the related reservation right or, alternatively, in case the results from the research will not justify further development of the drug. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable to a customer is recorded as a reduction of the arrangement's transaction price, if it relates to the same arrangement, thereby reducing the amount of revenue recognized, unless the payment is for a distinct good or service received from the customer consistent with IFRS 15.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of the accounting policy, based on the type of payments received, are set out below. Under IFRS 15, revenue is recognized as or when a customer obtains control of the services. Determining the timing of the transfer of control - at a point in time or over time - requires judgment. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Type of payments received</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Timing of revenue recognition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of upfront payments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of milestone payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of payments received for development options exercises</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition for reservation fees</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses as disclosed in note 16 consist primarily of compensation and other expenses related to:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development personnel;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical studies and clinical trials of the Group's product candidates, including the costs of manufacturing the product candidates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and services performed under collaboration agreements;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development services outsourced to research institutions; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">attributable facility expenses, including depreciation of equipment and amortization. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed that will generate probable future economic benefits, and when the cost of such an asset can be measured reliably. The Group does not currently have any such internal development costs that qualify for capitalization as intangible assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its internal research and development activities, the Group is also party to in-licensing and similar arrangements with its collaboration partners. The Group may also acquire in-process research and development assets, either through business combinations or through purchases of specific assets. Intangible assets are initially recorded at cost. Intangible assets are amortized over their useful lives on a straight-line basis beginning from the point when they are available for use. The estimated useful life of intangible assets is regularly reviewed. The Group does not currently have any such externally acquired in-process research and development assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group charges all research and development expenses, including internal patent filing and patent maintenance costs, to profit or loss when incurred, as the criteria for recognition as an asset are not currently met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932344121600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial risk management</a></td>
<td class="text">Financial risk management<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial risk factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, uncertainties regarding the effectiveness and safety of new drugs, new and unproven technologies, development process and outcome of clinical trials, rigorous governmental regulation and uncertainty regarding regulatory approvals, long product development cycles, continuing capital requirements to fund research and development, history of operating losses and uncertainty of future profitability, uncertainty regarding commercial success and acceptance, third party reimbursements, uncertainties regarding patents and legally protected products or technologies, uncertainty regarding third party intellectual property rights, dependence on third parties, dependence on publicly available scientific findings and research data, lack of experience with production facilities, dependence on third party manufacturers and service providers, competition, concentration of operations, product liability, dependence on important employees, environment, health, data protection and safety, lack of experience in marketing and sales, litigation, currency fluctuation risks and other financial risks, volatility of market value, as well as limited liquidity and shares eligible for future sale.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is developing several products currently not generating constant revenue streams which results in volatile cash flow from operating activities. Currently, the Group&#8217;s revenues stem mainly from irregular and difficult to predict income from product out-licensing, milestone payments and fees from R&amp;D collaboration agreements. This will likely remain the same at least until the first product reaches the market on the Group&#8217;s own or through a partner. This results in a lack of regular positive operating cash flow, which may expose the Group to financing risks in the medium-term. Furthermore, management has taken actions to manage financial risks, such as foreign exchange risk and liquidity risk.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners conducts research and development activities primarily in Switzerland, the European Union and the United States. As a result, the Group is exposed to a variety of financial risks, such as foreign exchange rate risk, credit risk, liquidity risk, cash-flow and interest rate risk. The Group&#8217;s overall financial risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Further details are disclosed under note 25.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital management</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is not regulated and not subject to specific capital requirements. The amount of equity depends on the Group&#8217;s funding needs and statutory capital requirements. The Group monitors capital periodically on an interim and annual basis. From time to time, the Group may take appropriate measures or propose capital increases to its </span></div>shareholders to ensure the necessary capital remains intact. The Group did not have any short-term or long-term debt outstanding as of December&#160;31, 2022 and 2021.Financial risk management<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to reduce its foreign exchange exposure, Molecular Partners may enter into currency contracts with selected high-quality financial institutions to hedge against foreign currency exchange rate risks. The Group&#8217;s primary exposure to financial risk is due to fluctuation of exchange rates between CHF, USD and EUR.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s hedging policy is (1) to maximize natural hedging by matching expected future cash flows in the different currencies and (2) if market conditions allow to consider hedging certain of the remaining expected net currency exposure as the need arises. However, due to market volatilities, the impact of negative interest rates during most of 2022 in Switzerland and uncertainties in the cash flows, a 100% hedging of the currency exposure is impossible or not appropriate. Molecular Partners does not engage in speculative transactions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Group did not enter into any forward currency transactions. No forward currency transactions were outstanding as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table demonstrates the sensitivity to a reasonably possible change in exchange rates for the Group's main foreign currencies, USD and EUR, with all other variables held constant, of the Group&#8217;s result before taxes. There is no direct impact on the Group&#8217;s equity.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. exchange rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners earns or pays interest on cash and cash equivalents, and its profit and loss may be influenced by changes in market interest rates. The Group does invest its cash balances into a variety of current and deposit accounts in four different Swiss banks to optimize interest. In addition, the Group does invest a portion of its cash into risk free money market investments in line with its treasury guidelines.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group strives to optimize the net balance of interest paid and interest received by monitoring the interest rates applicable over the major currencies the Group holds as well as the offered holding periods. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table demonstrates the sensitivity of the main currencies used in the Group, to reasonably possible changes in interest rates, with all other variables held constant, of the Group&#8217;s results before tax. There is no direct impact on the Group&#8217;s equity.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. interest rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHF Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk on financial assets corresponds to the carrying amounts of the Group&#8217;s cash and cash equivalents, short-term time deposits and receivables. The Group has not entered into any guarantees or similar obligations that would increase the risk over and above the carrying amounts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and cash equivalents and short-term deposits are considered low risk and were held at Swiss banks with Standard &amp; Poor long-term credit ratings as of December 31, 2022 of AAA (Z&#252;rcher Kantonalbank), AA (Luzerner Kantonalbank), A+ (UBS) and A- (Credit Suisse) and therefore any impact resulting from the expected credit loss model is considered immaterial. Analysis performed included assessing the cumulative default rates by credit rating category and applying these rates to the cash and short-term deposit balances at reporting dates. The calculated loss allowance based on the ECL is considered immaterial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group enters into agreements with partners that have appropriate credit history and a commitment to ethical business practices. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk as of the balance sheet date was as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Credit risk</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total credit risk as at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">250,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group&#8217;s liquidity risk is considered low by management due to the financial assets at the reporting date, giving the Group a secure source of funding for its research and development activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Risk Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932317715472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical accounting estimates and judgments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_CriticalAccountingEstimatesAndJudgmentsAbstract', window );"><strong>Critical Accounting Estimates and Judgments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Critical accounting estimates and judgments</a></td>
<td class="text">Critical accounting estimates and judgments<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s accounts are prepared on a going concern basis. The preparation of the consolidated financial statements in conformity with IFRS requires that management and the Board of Directors make estimates and assumptions which affect the amounts of the assets and liabilities, contingent liabilities, as well as the income and expenses reported in the consolidated financial statements. These estimates take into consideration historic experience as well as developments in the economic circumstances and are further based on management&#8217;s best knowledge of current events and actions that the Group may undertake in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates are subject to risks and uncertainties. The actual results can deviate from these estimates. The estimates and assumptions identified by the Group, which have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in a future period or have a significant effect on reported results, are discussed below:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuation in revenues is common to biopharmaceutical companies focused on research and development as the revenues are often linked to up-front fees, reservation fees, milestones or license payments as well as income for delivery of drug substance, which occur sporadically. Depending on the complexity of the relevant agreements, judgment (for instance in regard to the performance obligations recognized using the cost-based method, where revenue is recognized based on costs incurred in relation to the Group&#8217;s estimate of total estimated costs to complete satisfaction of the underlying performance obligations) is required to reflect the substance of the arrangement in the recognition of revenues. Under the cost-based method, the Group&#8217;s estimate of total costs to be incurred under certain agreements is for example, based on actual project-related contracts and history of similar contracts of other collaborations as well as industry experience. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is required to evaluate whether any changes in operational and/or technical collaboration and project requirements could lead to a change in the timing and/or amount of estimated project costs, and how such changes, if any, impact the recognition of revenue. Other revenue related judgments with regard to the determination of performance obligations under reservation agreements relate to assumptions on future production costs and market prices. More information on revenue recognition is provided in the respective accounting policy. Additional information related to the Group&#8217;s significant revenue agreements is disclosed in note 5.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_CriticalAccountingEstimatesAndJudgmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Critical Accounting Estimates and Judgments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_CriticalAccountingEstimatesAndJudgmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932317630992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues, other income and and entity-wide disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenues, other income and and entity-wide disclosures</a></td>
<td class="text">Revenue, other income and entity-wide disclosures<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group assesses and estimates the progress of its projects with alliance partners at each reporting date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">License and Collaboration Agreement with Novartis in the Area of DARPIN-Conjugated Radioligand Therapies ("Novartis Radioligand Agreement") </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;14, 2021, the Group entered into a License and Collaboration Agreement with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology. Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. The Group will be primarily responsible for the generation of DARPins for tumor-specific delivery of radioligands. The Group is eligible to invoice Novartis for its employee-related expenses associated with the research activities. Novartis is responsible for all clinical development and commercialization activities. As of December&#160;31, 2021 the Group recognized a receivable for the upfront fee of USD 20 million (CHF 18.6 million) payable from Novartis in trade and other receivables and a corresponding contract liability in the consolidated statement of financial position. In January 2022, Novartis paid Molecular Partners the upfront fee. The Group will be eligible to receive milestone payments of up to USD&#160;560&#160;million, relating to development, regulatory and commercialization activities, plus tiered royalties based on commercial sale levels from mid-single digit to low double-digit percentages of royalties on net sales of products commercialized by Novartis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group identified one combined performance obligation consisting of the license and the research activities to be provided. Revenue related to the upfront payment of USD 20 million (CHF 18.6 million) is being recognized over time in line with the progress made over the duration of the contractually agreed three-year research plan. Progress towards completion of the research plan is based on the cost-based method and is measured by employee costs on the related research activities as specified in the agreement relative to the total employee costs estimated to be incurred. During 2022, the Group recognized total revenue of CHF&#160;9.8&#160;million of which CHF&#160;8.5&#160;million related to the recognition of the upfront fee and CHF&#160;1.3&#160;million related to the recharge of employee related expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future milestone payments and royalties under the agreement will be recognized as revenue at a point in time, when a milestone is achieved or any subsequent sales by Novartis occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option and Equity Rights Agreement with Novartis for Ensovibep (the "Option and Equity Rights Agreement")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Group entered into the Option and Equity Rights Agreement with Novartis, granting Novartis the exclusive option to in-license global rights in relation to MP0420 (ensovibep). Under the terms of the agreement, in 2020, the Group in 2020  received an upfront, non-refundable fee of CHF 20 million for the technology transfer and manufacturing of MP0420. The Group committed to utilize up to the maximum amount of this upfront fee for the manufacturing of the commercial supply for MP0420, which is required to be manufactured by Sandoz, a division of the Novartis Group. All such amounts paid for manufacturing performed by the Novartis Group is considered to be a consideration payable to a customer. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant inter-dependencies between the upfront fee and the manufacturing activities, the manufacturing costs paid to the Novartis Group are offset against the upfront non-refundable fee from the contract (see below, as well as note 15). As of December&#160;31, 2021, the entire CHF&#160;20&#160;million has been utilized for the manufacturing of commercial supply for MP0420. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensovibep License Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, following positive Phase 2 clinical trial results, Novartis exercised its option for ensovibep, triggering a milestone payment of CHF&#160;150&#160;million to the Group, which was received in 2022. Relatedly, the Group was eligible to invoice Novartis CHF&#160;13.1&#160;million for other items related to ensovibep..</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the exercise of such option, the Group entered into a license agreement, the Ensovibep License Agreement, with Novartis under which the Group granted Novartis a sublicensable worldwide license to research, develop, manufacture, commercialize and otherwise use ensovibep and products comprising the compound in all indications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is eligible to receive a 22% royalty on future commercial sales. Molecular Partners has agreed to forgo royalties in lower income countries, and is aligned with Novartis&#8217; plans to ensure affordability based on countries&#8217; needs and capabilities. Novartis is responsible for all further development and commercialization activities of ensovibep.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In early  January 2023 Novartis informed the Group that it has submitted a request to withdraw, with an effective date of January 25, 2023 the Emergency Use Authorization (EUA) application from the U.S. Food and Drug Administration (FDA) for ensovibep. Ensovibep is not presently in clinical development.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reservation Agreement with the Swiss Federal Office of Public Health / Bundesamt f&#252;r Gesundheit ("FOPH")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2020, the Group announced the reservation by the FOPH of a defined number of initial doses of the Group's anti-COVID-19 candidate, MP0420. Under the terms of the agreement, the Group received a reservation fee of CHF&#160;7.0&#160;million which resulted in a current contract liability of CHF&#160;7.0&#160;million, as presented in the consolidated statement of financial position for the years 2020 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Group met the contractually agreed milestone specified in the agreement, resulting in the reservation fee received from the FOPH becoming no longer refundable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Group and the FOPH entered into an amendment to extend the term of the reservation agreement by six months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment also allowed the agreement to be assigned to Novartis upon its exercise </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the option under the Option and Equity Rights Agreement. With the exercise of the option by Novartis in January 2022 and the subsequent assignment of the agreement to Novartis, the Group recognized the CHF&#160;7.0&#160;million contract liability as revenue in 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreement with Amgen (the "Amgen Collaboration Agreement")</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Group entered into a license and collaboration agreement with Amgen for the clinical development and commercialization of MP0310 / AMG 506. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement the Group received a non-refundable upfront payment of USD&#160;50&#160;million. The Group was primarily responsible for performing certain clinical development, manufacturing and regulatory activities in the first clinical phase and the Group assigned the full USD&#160;50&#160;million (TCHF 49,625) upfront payment as the transaction price to this performance obligation, based on the Group's development plan and the Amgen Collaboration Agreement. The Group recognized the related revenue using the cost-based method to measure it progress by reference to actual costs incurred in relation to the Group's best estimate of total expected costs to satisfy the performance obligation. This cost-based method is subject to the assessment of the management of the Group.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;26, 2022 the Group announced that Amgen, had informed the Group of its decision to return the global rights of MP0310 following a strategic pipeline review. With no remaining performance obligations under the Amgen Collaboration Agreement, the Group recognized the remaining balance of the Amgen contract liability as revenue for a total amount reported in 2022 of TCHF 9,653.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the years ended December&#160;31, 2022, 2021 and 2020, the Group recognized revenues as disclosed in the table below. Revenues in the table below are attributable to individual countries and are based on the location of the Group's alliance partner. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues by country</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands, for the years ended December 31</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues USA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">189,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Analysis of revenue by major alliance partner</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands, for the years ended December 31</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis AG, Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH, Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc., USA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">189,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income </span></div>In the first quarter of 2021 the Group entered into an agreement with Novartis to facilitate manufacturing of MP0420 drug supply at a third party supplier. The related agency services earned during 2022 amounted to TCHF 44 (2021: TCHF 424) and are presented as Other income in the consolidated statement of comprehensive income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932317634512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use assets relate to the facilities the Group is leasing in Schlieren, Switzerland.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79__IAS16_g73-79_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315293008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text">Intangible assets<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Software</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Software</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128__IAS38_g118-128_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315207648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text">Financial instruments<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets at amortized costs</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">250,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above mentioned amounts were neither past due nor impaired at the end of the respective reporting period and were of highly rated quality. Please also see note 25.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities at amortized cost</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-employee related accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-employee related accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14,848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of financial assets and financial liabilities not measured at fair value (except for lease liabilities) is a reasonable approximation of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932317775088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock', window );">Other current assets</a></td>
<td class="text">Other current assets<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Prepaid Expenses And Accrued Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315293008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and other receivables</a></td>
<td class="text">Trade and other receivables<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value added tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Withholding tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables are denominated in the following currencies:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in trade receivables for 2022 mainly related to the License and Collaboration Agreement with Novartis entered into in December 2021. The amount invoiced to Novartis in December 2021 was received in cash in January 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932317630992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and short-term time deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock', window );">Cash, cash equivalents and short-term time deposits</a></td>
<td class="text">Cash, cash equivalents and short-term time deposits<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total cash at bank at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">71,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in USD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total short-term deposits at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">161,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">61,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The short-term time deposits denominated in CHF at December&#160;31, 2022 contained six positions with three Swiss banks, the short-term time deposits denominated in USD contained three positions with three Swiss banks and the short-term time deposits denominated in EUR contained one position with one Swiss bank. The short-term time deposits in CHF at December&#160;31, 2021 contained one position with one Swiss bank and the short-term time deposits denominated in USD contained three positions with two Swiss banks. Please also refer to note 25.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315494128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text">Trade and other payables<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social security</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value added tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables are denominated in the following currencies:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315045872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Accrued expenses</a></td>
<td class="text">Accrued expenses<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.924%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued payroll and bonuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,975</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315163824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilitiesAbstract', window );"><strong>Contract liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract liability</a></td>
<td class="text">Contract liability<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group expects the contract liability to be recognized as revenue or, in case of consideration payable to a customer, reduction of costs, as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year one after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year two after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year three after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year four after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year five and later after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year one after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year two after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year three after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year four after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year five and later after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the movement on the contract liability:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at January 1,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recognized as revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Offset of costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,191)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at January 1,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recognized as revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Offset of costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">45,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,330)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,904)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License and Collaboration Agreement with Novartis entered into in December 2021 resulted in a contract liability of TCHF 18,584 (TUSD 20,000). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, an amount of TCHF 19,904 has been released to offset a corresponding amount of costs paid to the Novartis Group for the manufacturing of the drug product to establish the commercial supply of MP0420 under the Option and Equity Rights Agreement entered into in October 2020 (see note 5).</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFR15_g110-129_IFRS15_g110-129_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315494128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional information on the nature of expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Additional information on the nature of expenses</a></td>
<td class="text">Additional information on the nature of expenses<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and development expenses</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research consumables and external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,342)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see also note 18</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and license fees, see also note 17</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(50,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(55,718)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(56,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see also note 18</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,604)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(72,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(73,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(67,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development non-cash effective pension and share-based compensation costs were TCHF 3,856 in 2022, TCHF 3,045 in 2021 and TCHF 2,612 in 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative non-cash effective pension and share based compensation costs were TCHF 2,329 in 2022, TCHF 2,113 in 2021 and TCHF 1,573 in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315129360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalties and license fees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock', window );">Royalties and license fees</a></td>
<td class="text">Royalties and license fees<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until October 2021, the Group held an exclusive perpetual license from the University of Zurich on patent applications and patents relating to the DARPin base technology. The Group terminated the applicable license agreement with effect as of October 2021 as the main patents under this agreement expired in September 2021. For the years ended December 31, 2021 and 2020 the minimum amounts of CHF 50,000 were payable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group currently now only holds a non-exclusive perpetual license from the University of Zurich on patent applications and patents relating to Phage Display technology. The amount payable by us is CHF 10,000 per annum. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Group entered into a research collaboration agreement with the University of Utrecht regarding the development of the Group's COVID-19 program. Under this agreement, the Group paid a fee of CHF 250,000 to the University of Utrecht in December 2020. An additional fee of CHF 250,000 was accrued as per December 2021 and payable under this agreement. With Novartis exercising its option under the Option and Equity Rights Agreement, the University of Utrecht was owed a further CHF&#160;1.0&#160;million that was expensed and paid during 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Royalties And License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314989472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PersonnelExpensesAbstract', window );"><strong>Personnel Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock', window );">Personnel expenses</a></td>
<td class="text">Personnel expenses<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,737)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,909)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,525)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation (non-cash effective)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social security costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other personnel expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(39,889)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(36,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(33,634)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Full-time equivalents and head count</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average number of full-time equivalents</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full-time equivalents at year end</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headcount at year end</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.1&#160;&#160;&#160;&#160;Pension costs and liabilities</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit pension plans</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial assumptions</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate at January 1</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future salary increases at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortality tables</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVG2020 GT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVG2020 GT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of last actuarial valuation</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.12.2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.12.2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of the amount recognized in the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of plan assets at December 31</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net defined benefit liability at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of defined benefit cost in profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost excl. cost for managing plan assets</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit cost recognized in profit or loss</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof service cost and administrative cost</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof net interest expense on the net defined benefit liability</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of net defined benefit liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net defined benefit liability at January 1</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit cost recognized in profit or loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions by the employer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net defined benefit liability at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of defined benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at January 1</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expenses on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by plan participants</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits (paid)/deposited</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost (excl. cost for managing plan assets)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit obligation at December 31</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">52,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">54,461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of amount recognized in OCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in financial assumptions</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in demographic assumptions</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss arising from experience adjustments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excluding interest income</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of plan assets at January 1</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by the employer</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by plan participants</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits (paid)/deposited</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excl. interest income</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of plan assets at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">47,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Best estimate of contributions of next year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by the employer</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan asset classes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt instruments (e.g. bonds)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate funds</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value (quoted market price)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">40,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">39,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value (non-quoted market price)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">47,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof entity's own transferable financial instruments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof property occupied or other assets used by the entity</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sensitivity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with discount rate -0.25%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with discount rate +0.25%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with interest rate on retirement savings capital -0.25%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with interest rate on retirement savings capital +0.25%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with salary increases -0.25%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with salary increases +0.25%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with life expectancy +1 year</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with life expectancy -1 year</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity profile of defined benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31 for active members</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31 for pensioners</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discount rates are based on industry benchmarks related to benefits with a 20 year duration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In liabilities for employee benefits, as presented in the consolidated statement of financial position included are also TCHF 307 (2021: TCHF 257; 2020: TCHF 255) for accrued sabbatical cost.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The sum of these two positions represent the non-cash effective pension costs recognized in the profit and loss section of the consolidated statement of comprehensive income of which TCHF 846 are research and development costs (2021: TCHF 837; 2020: TCHF 1,039) and TCHF 250 are selling, general and administrative costs (2021: TCHF 235; 2020: TCHF 214).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the most important parameters which influence the pension obligation of the Company a sensitivity analysis was performed. The discount rate and the assumption for salary increases were modified by a certain percentage value. Sensitivity on mortality was calculated by changing the mortality with a constant factor for all age groups. With this procedure the Company could change the longevity for most of the age categories by one year longer or shorter than the baseline value.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the amounts that are reflected in the statement of comprehensive income for the periods indicated:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of defined benefit cost in profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on defined benefit obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost excl. cost for managing plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit cost recognized in profit or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,080</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof service cost and administrative cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof net interest expense on the net defined benefit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of amount recognized in OCI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in financial assumptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in demographic assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss arising from experience adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excluding interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2&#160;&#160;&#160;&#160;Share-based compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2.1&#160;&#160;&#160;&#160;Employee Share Option Plans (&#8220;ESOP&#8221;)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;ESOP 2009 established in December 2009</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;ESOP 2014 established in July 2014 </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ESOP is an incentive tool that fosters the entrepreneurial spirit and performance by way of financial participation in the Group's long term success. It gives employees, members of the Board of Directors and selected advisors a beneficial opportunity to purchase shares of the Company. Each option entitles its holder to purchase one share of the Company at a pre-defined exercise price. The number of options granted to each participant was determined by the Board of Directors based on a participant&#8217;s position and level of responsibility. The options generally vested quarterly over four years, with vesting of 25% after one year. At the end of the 10 year option term, unexercised options expire without value. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, an aggregate of 282,105 options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, an aggregate of 318,902 options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the initial public offering of the Company on the SIX Swiss Exchange on November&#160;5, 2014, no further option grants have been made under any of these two share option plans. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2.2&#160;&#160;&#160;&#160;Long Term Incentive (&#8220;LTI&#8221;) Plans: Restricted Share Units ("RSU'') and Performance Share Units ("PSU")</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2018 established in March 2018</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2019 established in March 2019</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2020 established in March 2020</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2021 established in March 2021</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LTI plans 2022 established in March 2022</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LTI plans, members of the Board of Directors are eligible to be granted RSUs, whereas members of the Management Board and other employees are eligible to be granted PSUs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are contingent rights to receive a certain number of shares of the Company at the end of a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIwNw_9040953b-cb8b-40fb-a37f-f83b25c57861">three</span>-year blocking period. The number of RSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each RSU as at the grant date. In certain circumstances, including a change of control, a full or partial accelerated vesting of the RSUs may occur. RSUs vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxMQ_05ecdaa7-ecd6-4736-951d-8a9dde75aba2">one</span>-year period from date of grant. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSUs are contingent rights to receive a variable number of shares of the Company. Since 2021, PSUs granted to employees (except for members of the Management Board) will vest in three tranches of one third each. The first tranche of the PSUs shall vest on the first anniversary of the grant date, the second tranche on the second anniversary of the grant date and the third tranche on the third anniversary of the grant date. For the members of the Management Board, the vesting schedule remains unchanged and PSU's will vest at the end of a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyMg_8b946c45-4517-4e69-84b4-4b2d7403ff98">three</span> year cliff-vesting period. PSUs granted to all employees under PSU plans prior to 2021 will continue to vest at the end of a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyNg_6be1f36f-6243-4b7f-bbee-a9ede8c3610e">three</span>-year cliff-vesting period. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of PSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each PSU as of the grant date. While the PSUs are designed to let the beneficiaries participate in the long-term share price development, the number of shares to be earned in relation to a PSU also depends on the achievement of pre-defined corporate goals for the respective year. Accordingly, the number of shares to be issued based on the PSUs can be between zero and 150% of the number of PSUs granted. Even after the determination of goal achievement, participants may lose their entitlements in full or in part depending on certain conditions relating to their employment. In certain circumstances, including a change of control, a full or partial accelerated vesting of the PSUs may occur. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LTI plans are issued annually, which allows the Board of Directors to review the terms and determine the targets on an annual basis. Employees generally receive the grants on April 1 of each calendar year, or for new employees on the first day of the calendar quarter after the start of their employment. Members of the Management Board and the Board of Directors receive the annual grants after the approval of the ordinary shareholders&#8217; meeting. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 604,800 PSUs and 96,001 RSUs were outstanding. As of December&#160;31, 2021, 547,485 PSUs and 95,635 RSUs were outstanding.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.2.3&#160;&#160;&#160;&#160;Conditions attached to and measurement of fair values of equity-settled share-based payment arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the conditions as well as the inputs used in the measurement of the values at grant dates:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:67.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.301%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.935%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU/PSU, conditions and assumptions</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nature of arrangement</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant of PSU/RSU</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant of PSU/RSU</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant date RSU</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 13, 2022</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 21, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant dates PSU</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan&#160;1 - Oct&#160;1</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan&#160;1 - Oct&#160;1</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of RSU granted</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of PSU granted</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price (CHF)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.55 - 18.88</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.90 - 23.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for RSU (years)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full contractual life for RSU (years)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for PSU (years), Management Board</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for PSU (years), employees excluding Management Board</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00 (pro-rata annual vesting)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00 (pro-rata annual vesting)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full contractual life for PSU (years)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Shares</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on Common shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.69 - 76.84</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.57 - 61.69</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / CHF LIBOR / Common shares</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.54) - (0.71)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.58) - (0.61)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on NBI</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.89 - 28.16</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.21 - 27.01</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / USD LIBOR / NBI</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.58 - 4.78</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.24 - 0.34</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on SPI</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.57 - 17.02</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.96 - 16.15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / CHF LIBOR / SPI</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.54) - (0.71)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.58) - (0.61)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend (CHF)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of rights granted (CHF)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Latest expiry date</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sep 30, 2025</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sep 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation model</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monte Carlo</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monte Carlo</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional comments:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility: Historical share prices of the Company have been used.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The indices, Nasdaq Biotechnology Index ('NBI") and Swiss performance Index ("SPI") are used as inputs in determining the fair values for the 2021 and 2022 PSU Plans.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movements in the number of all issued RSUs, PSUs and share options are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share option / PSU / RSU movements</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU/RSU (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">915,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">382,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">533,104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(145,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">962,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">318,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">643,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(252,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(218,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">982,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">282,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">700,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance adjustments indicate forfeitures due to non-market performance conditions not achieved</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forfeited due to service conditions not fulfilled</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF 22.35</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     (2021: CHF 19.87)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2022:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise price<br/>CHF</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options / <br/>PSU/RSU<br/>(number)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remaining life<br/>(years)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thereof exercisable options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.94</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU/RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">700,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">982,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">282,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2021:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise price<br/>CHF</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options / <br/>PSU/RSU<br/>(number)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remaining life<br/>(years)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thereof exercisable options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.05</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.94</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU/RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">643,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">962,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">318,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash costs for share-based payments recognized in the statement of comprehensive income can be attributed to the Group&#8217;s two functions as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Employee Benefits And Share-Based Payments Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PersonnelExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PersonnelExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315104032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income and financial expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial income and financial expense</a></td>
<td class="text">Financial income and financial expense<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:58.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on financial assets held at amortized costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net foreign exchange gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial expense</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:58.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative interest on financial assets held at amortized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(619)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(556)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,816)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315576416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncomeTaxesAndDeferredTaxesAbstract', window );"><strong>Income Taxes And Deferred Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text">Taxes<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 the Company generated a taxable profit whereas in 2021 and 2020 the Company generated a taxable loss in Switzerland, all of which are reflected in the Company&#8217;s cumulative tax loss carry forward. The Company did not have to pay or accrue any income taxes in the reporting periods as the 2022 taxable income in the period is fully offset by the utilization of accumulated tax losses. Any future taxable income will be subject to Swiss federal, cantonal and communal income taxes. The Company&#8217;s applicable income tax rate for the year 2022 is 19.4% (2021: 19.4%; 2020: 20.8%).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc., which is incorporated in the United States in the State of Delaware, is subject to statutory U.S. federal corporate income taxes and minimal state taxes for Massachusetts and New York. </span></div><div style="margin-bottom:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, current income tax expense of TCHF 0.3 (TUSD 0.3) was recognized by the Group's U.S. based subsidiary for estimated U.S. tax obligations of the subsidiary based on intra-Group activity (for the year ended December&#160;31, 2021: tax credit of TCHF 2 (TUSD 2) and for the year ended December 31, 2020: tax expense of TCHF 11 (TUSD 13)). The tax expense amount comprises of the sum of the minimal taxes payable for federal taxes and for the various states in which Molecular Partners Inc. is liable for taxes. The applicable income tax rates are 21% federal tax plus 8.00% state tax (Massachusetts) and 6.50% (New York). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net operating profit for tax purposes amounted to TCHF 124,020 in 2022 whereas prior years generated net operating losses of TCHF 58,632 in 2021 and TCHF 58,631 in 2020.The remaining tax losses as of December 31, 2022 of TCHF 88,198 may be used as tax loss carry forwards to offset future taxable income over a period of seven years, with the amount of TCHF 29,566 to expire in 2027 and TCHF 58,632 to expire in 2028. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred tax assets have been recognized for these tax loss carry forwards, because as of December&#160;31, 2022, it was not considered probable that such loss carry forwards can be utilized in the foreseeable future. In addition, no deferred tax positions were recognized on other deductible temporary differences (e.g. pension liabilities under IAS 19 for a total of TCHF 2,245, see also note 18.1) due to the tax losses carried forwards. Income tax expense has been calculated for the year ending December&#160;31, 2022, based on the effective income tax rate expected for the full financial year, being 0% on December&#160;31, 2022, given that the 2022 taxable income in the period is fully offset by the utilization of accumulated tax losses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the facts above, as well as the fact that the Company incurred no significant tax expense in the reporting periods presented, a numerical reconciliation of the effective tax rate is not provided. The primary reconciling item is the effect of unrecognized deferred tax assets for tax losses and deductible temporary differences.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the expiry of tax loss carry forwards for the Company, for which no deferred tax asset was recognized:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total tax loss carry forwards as at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(88,198)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(212,218)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncomeTaxesAndDeferredTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncomeTaxesAndDeferredTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315004560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text">Earnings per shareBasic earnings per share is calculated by dividing the net result attributable to the shareholders of the Company by the weighted average number of shares issued and outstanding during the reporting period, excluding any shares held as treasury shares. Diluted earnings per share additionally takes into account the potential conversion of all dilutive potential ordinary shares. <div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares used in computing basic earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,469,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,005,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares used in computing diluted earnings per share</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,265,567&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,005,171&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000,652&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the number of shares that are dilutive, is 795,610. For all comparative prior periods presented all potential ordinary shares were anti-dilutive. The number of shares that potentially could be dilutive in the future were 835,422 as at December&#160;31, 2021 and 794,377 as at December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315075328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group leases office and laboratory facilities in Schlieren, Switzerland. These leases generally have terms between 2 and 10 years and contain extension or terminations options exercisable by the Group up to one year before the end of the non&#8209;cancellable contract period. These terms are used to maximize operational flexibility in terms of managing contracts. The options to extend are held by the Company and the termination options are held both by the Company and the lessor. As of December&#160;31, 2020, the Group exercised the option to extend the lease on its facilities in Schlieren by five years with a new lease term ending on December&#160;31, 2026. The earliest contractual termination date for both the lessor and the Group on the major real estate lease is December&#160;31, 2025. For information about the right-of-use assets please also see note 6.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below are the carrying amounts of the lease liabilities and the movements during the period:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.924%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as at January 1,</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions / new leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as at December 31,</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as at December 31,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="15" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the expense amounts recognized in the consolidated statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:58.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation on right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total amount recognized in profit or loss</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cash outflow for leases for the year ended December&#160;31, 2022 amounted to TCHF 1,232 (year ended December&#160;31, 2021 TCHF 1,232; year ended December&#160;31, 2020 TCHF 1,275).</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual maturities of financial liabilities at December 31, 2022</span></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1 year</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and 2 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 2 and 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total contractual cashflows</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying Amount lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual maturities of financial liabilities at December 31, 2021</span></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1 year</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and 2 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 2 and 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total contractual cashflows</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying Amount lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315099552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text">Related party disclosures<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs of key management, which includes executive management and the Board of Directors, are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term employee benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-employment benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316539472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Capital commitments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Capital commitments</a></td>
<td class="text">Capital commitmentsAs of December&#160;31, 2022 and December&#160;31, 2021, the Group did not have any capital commitments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314989472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial risk management</a></td>
<td class="text">Financial risk management<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial risk factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, uncertainties regarding the effectiveness and safety of new drugs, new and unproven technologies, development process and outcome of clinical trials, rigorous governmental regulation and uncertainty regarding regulatory approvals, long product development cycles, continuing capital requirements to fund research and development, history of operating losses and uncertainty of future profitability, uncertainty regarding commercial success and acceptance, third party reimbursements, uncertainties regarding patents and legally protected products or technologies, uncertainty regarding third party intellectual property rights, dependence on third parties, dependence on publicly available scientific findings and research data, lack of experience with production facilities, dependence on third party manufacturers and service providers, competition, concentration of operations, product liability, dependence on important employees, environment, health, data protection and safety, lack of experience in marketing and sales, litigation, currency fluctuation risks and other financial risks, volatility of market value, as well as limited liquidity and shares eligible for future sale.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is developing several products currently not generating constant revenue streams which results in volatile cash flow from operating activities. Currently, the Group&#8217;s revenues stem mainly from irregular and difficult to predict income from product out-licensing, milestone payments and fees from R&amp;D collaboration agreements. This will likely remain the same at least until the first product reaches the market on the Group&#8217;s own or through a partner. This results in a lack of regular positive operating cash flow, which may expose the Group to financing risks in the medium-term. Furthermore, management has taken actions to manage financial risks, such as foreign exchange risk and liquidity risk.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners conducts research and development activities primarily in Switzerland, the European Union and the United States. As a result, the Group is exposed to a variety of financial risks, such as foreign exchange rate risk, credit risk, liquidity risk, cash-flow and interest rate risk. The Group&#8217;s overall financial risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Further details are disclosed under note 25.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital management</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is not regulated and not subject to specific capital requirements. The amount of equity depends on the Group&#8217;s funding needs and statutory capital requirements. The Group monitors capital periodically on an interim and annual basis. From time to time, the Group may take appropriate measures or propose capital increases to its </span></div>shareholders to ensure the necessary capital remains intact. The Group did not have any short-term or long-term debt outstanding as of December&#160;31, 2022 and 2021.Financial risk management<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to reduce its foreign exchange exposure, Molecular Partners may enter into currency contracts with selected high-quality financial institutions to hedge against foreign currency exchange rate risks. The Group&#8217;s primary exposure to financial risk is due to fluctuation of exchange rates between CHF, USD and EUR.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s hedging policy is (1) to maximize natural hedging by matching expected future cash flows in the different currencies and (2) if market conditions allow to consider hedging certain of the remaining expected net currency exposure as the need arises. However, due to market volatilities, the impact of negative interest rates during most of 2022 in Switzerland and uncertainties in the cash flows, a 100% hedging of the currency exposure is impossible or not appropriate. Molecular Partners does not engage in speculative transactions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Group did not enter into any forward currency transactions. No forward currency transactions were outstanding as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table demonstrates the sensitivity to a reasonably possible change in exchange rates for the Group's main foreign currencies, USD and EUR, with all other variables held constant, of the Group&#8217;s result before taxes. There is no direct impact on the Group&#8217;s equity.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. exchange rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners earns or pays interest on cash and cash equivalents, and its profit and loss may be influenced by changes in market interest rates. The Group does invest its cash balances into a variety of current and deposit accounts in four different Swiss banks to optimize interest. In addition, the Group does invest a portion of its cash into risk free money market investments in line with its treasury guidelines.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group strives to optimize the net balance of interest paid and interest received by monitoring the interest rates applicable over the major currencies the Group holds as well as the offered holding periods. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table demonstrates the sensitivity of the main currencies used in the Group, to reasonably possible changes in interest rates, with all other variables held constant, of the Group&#8217;s results before tax. There is no direct impact on the Group&#8217;s equity.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. interest rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHF Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk on financial assets corresponds to the carrying amounts of the Group&#8217;s cash and cash equivalents, short-term time deposits and receivables. The Group has not entered into any guarantees or similar obligations that would increase the risk over and above the carrying amounts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and cash equivalents and short-term deposits are considered low risk and were held at Swiss banks with Standard &amp; Poor long-term credit ratings as of December 31, 2022 of AAA (Z&#252;rcher Kantonalbank), AA (Luzerner Kantonalbank), A+ (UBS) and A- (Credit Suisse) and therefore any impact resulting from the expected credit loss model is considered immaterial. Analysis performed included assessing the cumulative default rates by credit rating category and applying these rates to the cash and short-term deposit balances at reporting dates. The calculated loss allowance based on the ECL is considered immaterial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group enters into agreements with partners that have appropriate credit history and a commitment to ethical business practices. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk as of the balance sheet date was as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Credit risk</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total credit risk as at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">250,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group&#8217;s liquidity risk is considered low by management due to the financial assets at the reporting date, giving the Group a secure source of funding for its research and development activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Risk Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315117440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Putative Class Action<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract', window );"><strong>Disclosure of contingent liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Putative Class Action</a></td>
<td class="text">Putative Class ActionOn July&#160;12, 2022, a putative class action complaint was filed in the U.S. District Court for the Southern District of New York against the Company, its directors, and certain of its executive officers. The complaint alleges that the defendants violated federal securities laws by, among other things, making misrepresentations and omissions regarding its product candidates ensovibep and MP0310. The complaint seeks unspecified compensatory damages, as well as an award of reasonable attorneys&#8217; fees and other costs, on behalf of persons and/or entities which purchased (a) the Company's American Depositary Shares (ADSs ) pursuant to certain offering documents issued in connection with the Company's initial public offering of ADSs; and/or (b) the Company's securities between June&#160;16, 2021 and April&#160;26, 2022 inclusive. A motion to appoint a lead plaintiff and counsel was filed on September 12, 2022 and is still pending. The matter remains in its early stages. The Company disputes these claims and intends to defend itself accordingly. The Company expresses no assurances as to the ultimate outcome of this matter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 86<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315054048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events after the balance sheet date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory', window );">Events after the balance sheet date</a></td>
<td class="text">Events after the balance sheet dateNo events occurred between the balance sheet date and the date on which these consolidated financial statements were approved by the Board of Directors that would require adjustment to the consolidated financial statements or disclosure under this heading.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315797904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">Basis of preparation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of preparation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the IASB. The accounting policies set forth below have been consistently applied to all years presented. Unless stated otherwise, all financial statements are presented in thousands of Swiss Francs (&#8220;TCHF&#8221;).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4 &#8220;Critical accounting estimates and judgments&#8221;.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Group's cash position at December&#160;31, 2022, the Group deemed there to be no material uncertainties that would cast doubt on the Group's ability to operate on a going concern basis. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements as of and for the year ended December&#160;31, 2022 were approved for issuance by the Company's Board of Directors on March&#160;8, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to rounding, the numbers presented in the financial statements might not precisely equal those included in the accompanying notes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Subsidiaries</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Transactions eliminated on consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New or revised IFRS standards and interpretations</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New or revised IFRS standards and interpretations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new or revised standards that became effective during 2022 did not have a material effect on these consolidated financial statements:</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Onerous Contracts - Costs of fulfilling a contract - amendments to IAS 37</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Annual Improvements to IFRS standards 2018-2020</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Property, Plant and Equipment: Proceeds before intended use - amendments to IAS 16</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several new or revised standards have been published that are not yet effective and that have not been early adopted. No significant impacts on the Group's consolidated financial statements are expected.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text">Segment reportingThe Group operates in one segment, focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The executive management, acting together as the chief operating decision makers, assess the financial performance and allocate resources on an aggregated level, and monitor the Group's operating expenses. Accounting policies applied are the same for both internal and external reporting purposes. The Group derives its research and collaboration revenues from research and development collaborations with third parties.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation / transactions</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation / transactions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are presented in thousands of CHF. The presentation currency of the Group is the functional currency of the Company. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assets and liabilities are translated at the closing rate at the date of the respective balance sheet;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">income and expenses for each consolidated statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates at the dates of the transactions); and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all resulting exchange differences are recognized in other comprehensive result.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment, Office equipment, IT hardware and Leasehold improvements are stated at historical cost less accumulated depreciation and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful lives are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT hardware:</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 years</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements and right-of-use assets are depreciated using the straight line method over the shorter of their estimated useful life and the lease term. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent costs are included in each asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. An asset&#8217;s carrying amount is written down to its recoverable amount, if the asset's carrying amount exceeds its estimated recoverable amount.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost and accumulated depreciation related to assets retired or otherwise disposed are derecognized at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of retirement or disposal.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are solely comprised of software. They are stated at historical cost less accumulated amortization and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Amortization is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful life of intangible assets is determined to be two years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, the Group assesses whether a contract is, or contains a lease. This is the case if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets (threshold of CHF 5,000) and short-term leases. Short-term leases are leases with a lease term of twelve months or less that do not contain a purchase option. For all other leases the Group recognizes a right-of-use asset and a lease liability at the lease commencement date. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. Subsequently the right-of-use asset is depreciated using the straight-line method over the shorter of the asset's useful life and the lease term.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments required over the lease term that are not paid at the commencement date, discounted using the Group's incremental borrowing rate, as the interest rate implicit in the lease generally cannot be readily determined. Lease payments that are included in the measurement of the lease liability include fixed payments or in-substance fixed payments and variable payments that depend on an index. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequently, the lease liability is measured at amortized cost using the effective interest method. The Group remeasures the lease liability when there is a change in future lease payments arising from a change in index, or if the Group changes its assessment of whether it will exercise an extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the lease liability for each period. The Group does not provide residual value guarantees and does not have any leases not yet commenced to which it is committed. The Group is presenting right-of-use assets in Property, Plant and Equipment, whereas lease liabilities are presented separately within current and non-current liabilities in the consolidated statement of financial position.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Impairment of non-financial assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount exceeds their recoverable amount. An impairment loss is recognized for this difference. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets at amortized costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial assets at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents / short-term deposits / trade and other receivables (except for VAT and withholding taxes) (and when applicable accrued interest income) are all considered held-to-collect items and are labeled under financial assets measured at amortized costs, with the following definition / accounting policy:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at amortized cost are assets that meet both of the following conditions: (1) the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They arise when the Group provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities longer than 12 months after the balance sheet date which are classified as non-current assets. Interest income on the short-term deposit is accounted for on the statement of comprehensive income as financial income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, financial assets, except for trade receivables, are measured at their fair value plus, in the case of financial assets not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset; for the Group these are considered to be immaterial. Trade receivables are initially measured at their transaction price. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent measurement for the financial assets mentioned above which are classified as measured at amortized cost, is based on the effective interest method, reduced by any impairment loss. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets measured at amortized cost, a loss allowance for expected credit losses on the financial assets is recognized. Measurement of any impairment loss is based on the &#8216;expected credit loss&#8217; (ECL) model, which is based on a predictive model. The loss allowance for a financial asset is measured at an amount equal to the lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Group measures the loss allowance / impairment loss for that financial asset at an amount equal to 12-month expected credit losses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trade receivables, the Group applies a simplified approach which requires expected credit losses to be recognized from initial recognition (measuring the loss allowance at an amount equal to lifetime expected credit losses). This takes into consideration past history, combined with predictive information which accounts for the specific circumstances of the customer (e.g. credit rating etc.), and other relevant factors such as the economic environment. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other financial assets at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables generally arise from transactions outside the usual operating activities of the Group.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities at amortized costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial liabilities at amortized costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables and non-employee related accrued expense are measured at amortized costs and classified as financial liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash includes cash at banks. The Group considers all short-term, highly liquid investments convertible into known amounts of cash with maturities of three months or less from the date of acquisition to be cash equivalents, provided that they are subject to an insignificant risk of changes in value. The cash flow statement is based on cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital / Additional paid-in capital</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share capital / Additional paid-in capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds. The Group has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory', window );">Treasury shares</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Treasury shares</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the consideration paid for the acquisition of treasury shares, which includes directly attributable costs, is recognized as a deduction from equity. When treasury shares are sold subsequently, the amount received is recognized as an increase in equity, and the resulting surplus or deficit on the transaction is presented in additional paid-in capital.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include current and deferred taxes. Current income taxes are recognized on taxable profits at applicable tax rates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are calculated using the balance sheet liability method. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled based on tax rates enacted or substantially enacted at the balance sheet date.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized if it is probable that sufficient taxable profits will be available against which the deferred tax assets can be utilized. At each balance sheet date, the Group reassesses unrecognized deferred tax assets and the carrying amount of recognized deferred tax assets. The Group recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. The Group conversely reduces the carrying amount of a deferred tax asset to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or the entire deferred tax asset to be utilized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of deferred tax liabilities and deferred tax assets reflects the tax consequences on the balance sheet date of the Group's expectation of recovery or settlement of the carrying amounts of its assets and liabilities. Deferred tax assets and liabilities are not discounted and are classified as non-current assets and liabilities in the statement of financial position. They are offset against each other if they relate to the same taxable entity and tax authority.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have to pay income taxes in Switzerland in the presented reporting periods for 2022, 2021 and 2020. The Company&#8217;s accumulated taxable losses may be used as tax loss carry forwards to offset future taxable income over a period of seven years in Switzerland. No deferred tax assets have been established for these losses, because the Company does not have a history of sustainable taxable profits, increasing research costs are expected to be incurred in the foreseeable future and future revenues are highly volatile and uncertain. No deferred tax assets were recognized on deductible temporary differences on pension liabilities for the same reasons. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Partners Inc, the Group's US subsidiary, is subject to US federal and Massachusetts and New York state minimal tax.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee benefits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Postretirement benefits (pension plans)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides retirement, death and disability benefits to its Swiss employees in line with local customs and requirements through two separate plans, which are both accounted for as defined benefit plans. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first plan is the compulsory defined benefit plan which is funded through employer (60%) and employee (40%) contributions to VSAO, a Switzerland based plan. This Company-wide plan has been in place since inception of the Company and all employees of the Company are eligible to its benefits. On retirement, the plan participant will receive his or her accumulated savings, which consist of all contributions paid in by the employer and the employee (net of any withdrawals) and the interest granted on those savings at the discretion of the pension foundation. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At that time, the plan participant has the right to choose between a lump-sum payment and an annuity, or a combination thereof. The annuity is calculated using a fixed conversion rate determined by the pension foundation. The VSAO&#8217;s plan assets are pooled and the Company&#8217;s share is calculated based on its share of retirement savings. Additional funding requirements may be determined by the pension foundation in case of a severe underfunding. Should the Company withdraw from the plan, the withdrawal may qualify as a partial liquidation under Swiss law.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second plan is a voluntary complementary defined management benefit scheme established as of January&#160;1, 2014, in which only employees with a certain management level and / or above a certain salary level are eligible to participate. 33 of the 33 eligible employees participated in this plan as of December&#160;31, 2022 (2021: 32 out of 32). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This plan is set up as a collective foundation with Swiss Life, a Switzerland-based insurance company, for which contributions are 30% funded by the employee and 70% funded by the Company. The purpose of this voluntary plan is to allow higher savings opportunity in a tax effective manner and risk benefits for senior management. In addition, plan participants are entitled to a lump sum payment of five times their annual base salary in case of death. This is a fully insured Swiss pension plan that covers all investment and actuarial risks, including invalidity and death.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VSAO pension plan accounts for over 90% of both the Company&#8217;s defined benefit obligation and plan assets. The liability recognized in the statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligations at the balance sheet date less the fair value of plan assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows. Pension liabilities are determined on an actuarial basis using a number of assumptions, such as the discount rate and expected salary increases applied to determine the defined benefit obligation and an estimate of the fair value of plan assets attributable to the Company. In determining the appropriate discount rate, for example, the Company considers the interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. In determining the fair value of plan assets, the Company adds to the participants&#8217; savings a share of the pension plan&#8217;s technical and fluctuation reserves. Additional information is disclosed in note 18.1.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and past service costs as well as the net interest on the defined benefit obligation are recognized in profit or loss in the period in which they are incurred, and are presented as part of personnel expenses. Remeasurements of the defined benefit pension plans are recognized in other comprehensive result.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has set up a 401k plan for its US based employees. Under the plan the US entity matches the employee's contribution and provides a true-up in matched contributions at year end. The 401k plan qualifies as a defined contribution plan and the associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has set up a defined contribution plan for its UK based employees. Under the plan the Company and the employee both contribute into the plan. The associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group operates share-based compensation plans that qualify as equity-settled plans. The fair value of the employee services received in exchange for the grant of equity instruments is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the equity instruments granted, which is determined at grant date. The fair values are determined by management with the assistance of an independent valuation expert. At each reporting date, estimates of the number of equity instruments that are expected to vest are revised. The impact of the revision of the previous estimates, if any, is recognized as part of share-based compensation (non-cash effective) with a corresponding adjustment to equity. When the vested equity instruments are exercised, any proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bonus plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group recognizes an accrual where contractually obliged or where there is a past practice that has created a constructive obligation. Bonuses are based on a formula that takes into consideration the achievement of the Group&#8217;s goals.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a guiding principle of IFRS 15, revenues from research and development collaboration agreements are recognized when earned based upon the performance requirements of the respective agreements. For revenue arrangements with separately identifiable components (separate performance obligations), the revenue recognition criteria are applied to each component. The transaction price is determined as the consideration expected to be received from the arrangement and is allocated amongst the separate components based on their relative stand-alone selling prices. The corresponding amount of transaction price allocated to each component is recognized as revenue when (or as) the Group satisfies the performance obligation by transferring the good or service to the customer, which generally is over time for upfront payments or at a point in time for milestone payments and development option payments. Payments received in excess of revenue recognized are recorded as contract liabilities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include fees such as upfront payments received in connection with out-licensing of products and/or access the knowledge without transfer of a license as well as in connection with discovery alliances, as well as fees for maintenance of patents, R&amp;D support and services, participation in Joint Steering Committees and other involvement in collaboration agreements. In exchange for these non-refundable upfront fees, the Group does not immediately transfer a good or a service to the customer, rather the upfront fee consists of an advance payment for future services and the right to access the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input-based method to measure its progress towards complete satisfaction of the performance obligation. Accordingly, revenue is recognized over time based on the percentage of actual costs incurred to date relative to the Group's estimate of total costs expected to satisfy the performance obligation. Estimated costs are reviewed and updated routinely for contracts in progress to reflect any changes of which the Group becomes aware. The cumulative effect of any change in estimate is recorded in the period when the change in estimate is determined.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues could include fees such as milestone and development option payments received in connection with out-licensing of products and in connection with discovery alliances. Upon meeting the set milestone or upon a development option being exercised, the Group obtains a right to a non-refundable payment and the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations for the Group. Consequently, the related revenues are typically recognized at a point in time, either when the milestone is met or the option is exercised by the customer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue could also include reservation fees that will be recognized into revenue in case of successful development of a final drug and exercise or lapse of the related reservation right or, alternatively, in case the results from the research will not justify further development of the drug. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable to a customer is recorded as a reduction of the arrangement's transaction price, if it relates to the same arrangement, thereby reducing the amount of revenue recognized, unless the payment is for a distinct good or service received from the customer consistent with IFRS 15.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of the accounting policy, based on the type of payments received, are set out below. Under IFRS 15, revenue is recognized as or when a customer obtains control of the services. Determining the timing of the transfer of control - at a point in time or over time - requires judgment. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Type of payments received</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Timing of revenue recognition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of upfront payments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of milestone payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of payments received for development options exercises</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition for reservation fees</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses as disclosed in note 16 consist primarily of compensation and other expenses related to:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development personnel;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical studies and clinical trials of the Group's product candidates, including the costs of manufacturing the product candidates;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and services performed under collaboration agreements;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development services outsourced to research institutions; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">attributable facility expenses, including depreciation of equipment and amortization. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed that will generate probable future economic benefits, and when the cost of such an asset can be measured reliably. The Group does not currently have any such internal development costs that qualify for capitalization as intangible assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its internal research and development activities, the Group is also party to in-licensing and similar arrangements with its collaboration partners. The Group may also acquire in-process research and development assets, either through business combinations or through purchases of specific assets. Intangible assets are initially recorded at cost. Intangible assets are amortized over their useful lives on a straight-line basis beginning from the point when they are available for use. The estimated useful life of intangible assets is regularly reviewed. The Group does not currently have any such externally acquired in-process research and development assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group charges all research and development expenses, including internal patent filing and patent maintenance costs, to profit or loss when incurred, as the criteria for recognition as an asset are not currently met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.
Effective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.
Effective 2023-01-01: The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]
Effective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]
Effective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.
Effective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]
Effective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]
Effective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.
Effective 2023-01-01: The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]
Effective 2023-01-01: The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Basis Of Consolidation Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315903680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Disclosure of Useful Lives of Property, Plant and Equipment</a></td>
<td class="text">The applicable estimated useful lives are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT hardware:</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 years</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock', window );">Disclosure of Timing of Revenue Recognition by Type of Payments Received</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Type of payments received</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Timing of revenue recognition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of upfront payments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of milestone payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition of payments received for development options exercises</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition for reservation fees</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315164640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues, other income and and entity-wide disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Disclosure of Revenue by Country and by Major Alliance Partner</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the years ended December&#160;31, 2022, 2021 and 2020, the Group recognized revenues as disclosed in the table below. Revenues in the table below are attributable to individual countries and are based on the location of the Group's alliance partner. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues by country</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands, for the years ended December 31</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues USA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">189,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Analysis of revenue by major alliance partner</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands, for the years ended December 31</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis AG, Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH, Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc., USA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">189,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315083616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Disclosure of Reconciliation of Changes in Property, Plant and Equipment</a></td>
<td class="text">The applicable estimated useful lives are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT hardware:</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 years</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lab equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Office equipment</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IT hardware</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge for the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315166304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Disclosure of Reconciliation of Changes in Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Software</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Software</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge for the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315074624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Disclosure of Financial Assets at Amortized Cost</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets at amortized costs</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">250,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of Financial Liabilities at Amortized Cost</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities at amortized cost</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-employee related accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-employee related accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14,848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315075328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock', window );">Disclosure of Other Current Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315054048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock', window );">Disclosure of Detailed Information about Trade and Other Receivables</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value added tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Withholding tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables are denominated in the following currencies:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Trade And Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315174400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and short-term time deposits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock', window );">Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank in GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total cash at bank at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">71,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits in USD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total short-term deposits at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">161,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">61,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316539472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Disclosure of issuance of shares</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:74.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt 0 1.02pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ordinary shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21,601,192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to capital raise in July 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,528,089&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to Novartis agreement in October 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,739,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to vesting of PSU, RSU and options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">278,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">29,146,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to June 2021 IPO</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to vesting of PSU, RSU and options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">32,292,648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to creation of treasury shares in August 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued in relation to vesting of PSU, RSU and options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,058&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares in issue at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">36,044,706</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315019008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock', window );">Disclosure of Detailed Information about Trade and Other Payables</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social security</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value added tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables are denominated in the following currencies:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHF</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Trade And Other Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315104032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock', window );">Disclosure of Accrued Expenses Explanatory</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.924%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued project costs and royalties</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued payroll and bonuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,975</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312324800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilitiesAbstract', window );"><strong>Contract liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory', window );">Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group expects the contract liability to be recognized as revenue or, in case of consideration payable to a customer, reduction of costs, as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year one after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year two after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year three after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year four after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year five and later after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year one after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year two after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year three after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year four after balance sheet date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue recognition in year five and later after balance sheet date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Explanation of Changes in Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the movement on the contract liability:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at January 1,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recognized as revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Offset of costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,191)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at January 1,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recognized as revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Offset of costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">45,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,330)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,904)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock', window );">Disclosure of Current and Non-Current Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contract liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOPH</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">35,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 120<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_120_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Current And Non-Current Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316539472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional information on the nature of expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory', window );">Disclosure of Attribution of Expenses by Nature</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and development expenses</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research consumables and external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,342)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see also note 18</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and license fees, see also note 17</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(50,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(55,718)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(56,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see also note 18</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,604)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(72,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(73,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(67,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development non-cash effective pension and share-based compensation costs were TCHF 3,856 in 2022, TCHF 3,045 in 2021 and TCHF 2,612 in 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative non-cash effective pension and share based compensation costs were TCHF 2,329 in 2022, TCHF 2,113 in 2021 and TCHF 1,573 in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of attribution of expenses by nature to line items by function in the statement of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316332176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PersonnelExpensesAbstract', window );"><strong>Personnel Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock', window );">Disclosure of Detailed Information about Employee Expenses and Head Count</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,737)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,909)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,525)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation (non-cash effective)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social security costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other personnel expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(39,889)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(36,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(33,634)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Full-time equivalents and head count</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average number of full-time equivalents</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full-time equivalents at year end</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headcount at year end</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Disclosure of Net Defined Benefit Liability (Asset)</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit pension plans</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial assumptions</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate at January 1</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future salary increases at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortality tables</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVG2020 GT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVG2020 GT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of last actuarial valuation</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.12.2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.12.2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of the amount recognized in the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of plan assets at December 31</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net defined benefit liability at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of defined benefit cost in profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost excl. cost for managing plan assets</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit cost recognized in profit or loss</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof service cost and administrative cost</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof net interest expense on the net defined benefit liability</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of net defined benefit liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net defined benefit liability at January 1</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit cost recognized in profit or loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions by the employer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net defined benefit liability at December 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of defined benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at January 1</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expenses on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by plan participants</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits (paid)/deposited</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost (excl. cost for managing plan assets)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit obligation at December 31</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">52,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">54,461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of amount recognized in OCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in financial assumptions</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in demographic assumptions</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss arising from experience adjustments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excluding interest income</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of plan assets at January 1</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by the employer</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by plan participants</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits (paid)/deposited</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excl. interest income</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of plan assets at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">47,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Best estimate of contributions of next year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions by the employer</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan asset classes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt instruments (e.g. bonds)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate funds</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value (quoted market price)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">40,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">39,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value (non-quoted market price)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total plan assets at fair value at December 31</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">47,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof entity's own transferable financial instruments</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof property occupied or other assets used by the entity</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sensitivity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with discount rate -0.25%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with discount rate +0.25%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with interest rate on retirement savings capital -0.25%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with interest rate on retirement savings capital +0.25%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with salary increases -0.25%</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with salary increases +0.25%</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with life expectancy +1 year</span></div></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit obligation at December 31 with life expectancy -1 year</span></div></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity profile of defined benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31 for active members</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average duration of defined obligation in years at December 31 for pensioners</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discount rates are based on industry benchmarks related to benefits with a 20 year duration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In liabilities for employee benefits, as presented in the consolidated statement of financial position included are also TCHF 307 (2021: TCHF 257; 2020: TCHF 255) for accrued sabbatical cost.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The sum of these two positions represent the non-cash effective pension costs recognized in the profit and loss section of the consolidated statement of comprehensive income of which TCHF 846 are research and development costs (2021: TCHF 837; 2020: TCHF 1,039) and TCHF 250 are selling, general and administrative costs (2021: TCHF 235; 2020: TCHF 214).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the most important parameters which influence the pension obligation of the Company a sensitivity analysis was performed. The discount rate and the assumption for salary increases were modified by a certain percentage value. Sensitivity on mortality was calculated by changing the mortality with a constant factor for all age groups. With this procedure the Company could change the longevity for most of the age categories by one year longer or shorter than the baseline value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock', window );">Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the amounts that are reflected in the statement of comprehensive income for the periods indicated:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of defined benefit cost in profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current service cost (employer)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on defined benefit obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative cost excl. cost for managing plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined benefit cost recognized in profit or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,080</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof service cost and administrative cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereof net interest expense on the net defined benefit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of amount recognized in OCI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in financial assumptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss on changes in demographic assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial (gain) / loss arising from experience adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actuarial (gain)/loss on defined benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return on plan assets excluding interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remeasurement of net pension liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the conditions as well as the inputs used in the measurement of the values at grant dates:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:67.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.301%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.935%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU/PSU, conditions and assumptions</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nature of arrangement</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant of PSU/RSU</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant of PSU/RSU</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant date RSU</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 13, 2022</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 21, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant dates PSU</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan&#160;1 - Oct&#160;1</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan&#160;1 - Oct&#160;1</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of RSU granted</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of PSU granted</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price (CHF)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.55 - 18.88</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.90 - 23.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for RSU (years)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full contractual life for RSU (years)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for PSU (years), Management Board</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting period for PSU (years), employees excluding Management Board</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00 (pro-rata annual vesting)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00 (pro-rata annual vesting)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full contractual life for PSU (years)</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Shares</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on Common shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.69 - 76.84</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.57 - 61.69</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / CHF LIBOR / Common shares</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.54) - (0.71)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.58) - (0.61)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on NBI</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.89 - 28.16</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.21 - 27.01</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / USD LIBOR / NBI</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.58 - 4.78</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.24 - 0.34</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility on SPI</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.57 - 17.02</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.96 - 16.15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate p. a. (%) / CHF LIBOR / SPI</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.54) - (0.71)</span></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.58) - (0.61)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend (CHF)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of rights granted (CHF)</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Latest expiry date</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sep 30, 2025</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sep 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation model</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monte Carlo</span></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monte Carlo</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Disclosure of Movements in the Number of Share Options</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movements in the number of all issued RSUs, PSUs and share options are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share option / PSU / RSU movements</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU/RSU (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">915,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">382,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">533,104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(145,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">962,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">318,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">643,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(252,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(218,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">982,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">282,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">700,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance adjustments indicate forfeitures due to non-market performance conditions not achieved</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forfeited due to service conditions not fulfilled</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF 22.35</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     (2021: CHF 19.87)</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Disclosure of Movements in the Number of PSUs and RSUs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movements in the number of all issued RSUs, PSUs and share options are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share option / PSU / RSU movements</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU/RSU (numbers)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average exercise price (CHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">915,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">382,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">533,104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(145,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">962,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">318,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">643,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Performance adjustment) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Forfeited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exercised options, vested PSU / RSU) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(252,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(218,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">982,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">282,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">700,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance adjustments indicate forfeitures due to non-market performance conditions not achieved</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forfeited due to service conditions not fulfilled</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF 22.35</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     (2021: CHF 19.87)</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock', window );">Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2022:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise price<br/>CHF</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options / <br/>PSU/RSU<br/>(number)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remaining life<br/>(years)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thereof exercisable options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.94</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU/RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">700,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">982,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">282,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2021:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise price<br/>CHF</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Options / <br/>PSU/RSU<br/>(number)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remaining life<br/>(years)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thereof exercisable options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.05</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.06</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.94</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU/RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">643,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">962,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">318,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock', window );">Disclosure of Non-Cash Costs for Share-Based Payments by Functions</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash costs for share-based payments recognized in the statement of comprehensive income can be attributed to the Group&#8217;s two functions as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Employee Expenses And Head Count</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Exercis Price, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-Cash Costs For Share-Based Payments By Functions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PersonnelExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PersonnelExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316433168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income and financial expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock', window );">Disclosure of Detailed Information about Financial Income</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:58.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on financial assets held at amortized costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net foreign exchange gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock', window );">Disclosure of Detailed Information about Financial Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial expense</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:58.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative interest on financial assets held at amortized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(619)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(556)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,816)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Financial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Financial Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315370496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncomeTaxesAndDeferredTaxesAbstract', window );"><strong>Income Taxes And Deferred Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock', window );">Disclosure of Expiry of Tax Loss Carryforwards</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the expiry of tax loss carry forwards for the Company, for which no deferred tax asset was recognized:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total tax loss carry forwards as at December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(88,198)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(212,218)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Expiry Of Tax Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncomeTaxesAndDeferredTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncomeTaxesAndDeferredTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315237536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Weighted Average Number of Shares Used in Computation</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares used in computing basic earnings per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,469,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,005,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares used in computing diluted earnings per share</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,265,567&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,005,171&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000,652&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314144672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock', window );">Disclosure of Movement of Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below are the carrying amounts of the lease liabilities and the movements during the period:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.924%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as at January 1,</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions / new leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as at December 31,</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as at December 31,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="15" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory', window );">Disclosure of Expenses Recognised in Profit or Loss</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the expense amounts recognized in the consolidated statement of comprehensive income.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:58.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation on right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total amount recognized in profit or loss</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Disclosure of Contractual Maturities of Financial Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual maturities of financial liabilities at December 31, 2022</span></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1 year</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and 2 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 2 and 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total contractual cashflows</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying Amount lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual maturities of financial liabilities at December 31, 2021</span></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1 year</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and 2 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 2 and 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than 5 years</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total contractual cashflows</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying Amount lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information about leasing activities of a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 59<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_59&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Movement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315290880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Disclosure of Compensation Costs of Key Management</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs of key management, which includes executive management and the Board of Directors, are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term employee benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-employment benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total year ended December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312823568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk', window );">Sensitivity Analysis to Reasonable Possible Change in Exchange Rates and Interest Rates</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table demonstrates the sensitivity to a reasonably possible change in exchange rates for the Group's main foreign currencies, USD and EUR, with all other variables held constant, of the Group&#8217;s result before taxes. There is no direct impact on the Group&#8217;s equity.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. exchange rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div>The following table demonstrates the sensitivity of the main currencies used in the Group, to reasonably possible changes in interest rates, with all other variables held constant, of the Group&#8217;s results before tax. There is no direct impact on the Group&#8217;s equity.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in % and CHF thousands</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incr./Decr. interest rate</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect on result before tax (in TCHF)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHF Positions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USD Positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR Positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureExplanatory', window );">Disclosure of Maximum Credit Risk Exposure</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum credit risk as of the balance sheet date was as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Credit risk</span></td><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in CHF thousands</span></td><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total credit risk as at December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">250,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity&#8217;s financial assets and commitments to extend credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Risk Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315083616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Segments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316026736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Applicable estimated useful lives, property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Applicable estimated useful lives, property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Applicable estimated useful lives, property, plant and equipment</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932318463840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Applicable estimated useful lives, intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312371568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Employee Benefits (Details) - employee<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems', window );"><strong>Disclosure Of Detailed Information About Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans', window );">Percentage of VSAO contributions in total company's defined benefit plans</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=moln_VSAOMember', window );">VSAO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems', window );"><strong>Disclosure Of Detailed Information About Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitPlanEmployerContribution', window );">Defined benefit plan, employer contribution</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitPlanEmployeeContribution', window );">Defined benefit plan, employee contribution</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=moln_VoluntaryComplementaryPlanMember', window );">Voluntary complementary plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems', window );"><strong>Disclosure Of Detailed Information About Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitPlanEmployerContribution', window );">Defined benefit plan, employer contribution</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitPlanEmployeeContribution', window );">Defined benefit plan, employee contribution</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated', window );">Number of employees that participated</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitPlanNumberOfEligibleEmployees', window );">Number of eligible employees</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DefinedBenefitPlanEmployeeContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Employee Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DefinedBenefitPlanEmployeeContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DefinedBenefitPlanEmployerContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Employer Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DefinedBenefitPlanEmployerContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DefinedBenefitPlanNumberOfEligibleEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number Of Eligible Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DefinedBenefitPlanNumberOfEligibleEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number Of Employees That Participated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Employee Benefits [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of VSAO Contributions In Company's Total Defined Benefit Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=moln_VSAOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=moln_VSAOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=moln_VoluntaryComplementaryPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=moln_VoluntaryComplementaryPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290594544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues, other income and and entity-wide disclosures - Narrative (Details)<br> SFr in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">SFr 23,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 23,710<span></span>
</td>
<td class="nump">SFr 521<span></span>
</td>
<td class="nump">SFr 23,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from research and development collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,556<span></span>
</td>
<td class="nump">9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,191<span></span>
</td>
<td class="nump">9,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">28,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,312<span></span>
</td>
<td class="nump">6,409<span></span>
</td>
<td class="nump">28,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">11,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,659<span></span>
</td>
<td class="nump">6,409<span></span>
</td>
<td class="nump">11,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember', window );">FOPH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember', window );">Licence and Collaboration Agreement with Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember', window );">Licence and Collaboration Agreement with Novartis | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from research and development collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RevenueFromRechargeOfEmployeeRelatedExpenses', window );">Decrease through recharge of employee related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember', window );">Licence and Collaboration Agreement with Novartis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PotentialFutureMilestonePayments', window );">Potential future milestone payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember', window );">Option and Equity Rights Agreement with Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from research and development collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_UpfrontPaymentReceived', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_UpfrontPaymentAmountUtilizedDuringPeriod', window );">Amount utilized during period</a></td>
<td class="nump">SFr 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RoyaltyIncomePercentage', window );">Royalty income, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember', window );">Option and Equity Rights Agreement with Novartis | Commercial supply of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from research and development collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember', window );">Reservation Agreement with Swiss Federal Office of Public Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExtendedPeriodOfReservationAgreement', window );">Extended period of reservation agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue that was included in contract liability balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithAmgenIncMember', window );">Licence and Collaboration Agreement with Amgen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from research and development collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 9,653<span></span>
</td>
<td class="nump">SFr 9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_UpfrontPaymentReceived', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 49,625<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ExtendedPeriodOfReservationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended Period Of Reservation Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ExtendedPeriodOfReservationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RevenueFromRechargeOfEmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Recharge Of Employee Related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RevenueFromRechargeOfEmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RoyaltyIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Income, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RoyaltyIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_UpfrontPaymentAmountUtilizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment, Amount Utilized During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_UpfrontPaymentAmountUtilizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=moln_CommercialSupplyOfProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=moln_CommercialSupplyOfProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithAmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithAmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315652752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Country (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">SFr 189,556<span></span>
</td>
<td class="nump">SFr 9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CH', window );">Revenues Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">179,903<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">Revenues USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">SFr 9,653<span></span>
</td>
<td class="nump">SFr 9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290547424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">SFr 189,556<span></span>
</td>
<td class="nump">SFr 9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithNovartisAGMember', window );">Novartis AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">172,903<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithFOPHMember', window );">FOPH, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithAmgenIncMember', window );">Amgen Inc., USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">SFr 9,653<span></span>
</td>
<td class="nump">SFr 9,330<span></span>
</td>
<td class="nump">SFr 9,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithNovartisAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithNovartisAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithFOPHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithFOPHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithAmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_LicenseAndCollaborationAgreementWithAmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290186512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Disclosure of Reconciliation of Changes in Property, Plant and Equipment (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">SFr 8,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">7,235<span></span>
</td>
<td class="nump">SFr 8,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,986<span></span>
</td>
<td class="nump">1,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_RightOfUseAssetsPropertyPlantAndEquipmentMember', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">6,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">6,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">20,887<span></span>
</td>
<td class="nump">20,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">21,932<span></span>
</td>
<td class="nump">20,887<span></span>
</td>
<td class="nump">SFr 20,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">8,754<span></span>
</td>
<td class="nump">8,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">9,646<span></span>
</td>
<td class="nump">8,754<span></span>
</td>
<td class="nump">8,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | IT hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">9,616<span></span>
</td>
<td class="nump">9,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">9,616<span></span>
</td>
<td class="nump">9,616<span></span>
</td>
<td class="nump">9,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(12,741)<span></span>
</td>
<td class="num">(10,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge for the year</a></td>
<td class="num">(2,088)<span></span>
</td>
<td class="num">(2,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(14,697)<span></span>
</td>
<td class="num">(12,741)<span></span>
</td>
<td class="num">(10,662)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(7,164)<span></span>
</td>
<td class="num">(6,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge for the year</a></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(7,660)<span></span>
</td>
<td class="num">(7,164)<span></span>
</td>
<td class="num">(6,602)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation | Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(653)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge for the year</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(687)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation | IT hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(1,012)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge for the year</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(1,172)<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation | Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(3,615)<span></span>
</td>
<td class="num">(2,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge for the year</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(4,815)<span></span>
</td>
<td class="num">(3,615)<span></span>
</td>
<td class="num">(2,414)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge for the year</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">SFr (364)<span></span>
</td>
<td class="num">SFr (298)<span></span>
</td>
<td class="num">SFr (273)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_RightOfUseAssetsPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=moln_RightOfUseAssetsPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290553744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">SFr 331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">SFr 331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">2,122<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(1,574)<span></span>
</td>
<td class="num">(1,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge for the year</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">SFr (1,851)<span></span>
</td>
<td class="num">SFr (1,574)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314199008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details) - Financial assets at amortized costs - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">SFr 250,344<span></span>
</td>
<td class="nump">SFr 156,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=moln_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">87,946<span></span>
</td>
<td class="nump">71,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">23,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=moln_AccruedIncomeMember', window );">Accrued income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=moln_ShortTermTimeDepositsMember', window );">Short-term time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">SFr 161,198<span></span>
</td>
<td class="nump">SFr 61,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=moln_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=moln_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=moln_AccruedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=moln_AccruedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=moln_ShortTermTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=moln_ShortTermTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290578832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details) - Financial liabilities at amortized cost - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">SFr 8,570<span></span>
</td>
<td class="nump">SFr 14,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_TradePayablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_AccruedProjectCostsAndRoyaltiesMember', window );">Accrued project costs and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2,167<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">4,850<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_OtherNonEmployeeRelatedAccruedExpensesMember', window );">Other non-employee related accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">SFr 556<span></span>
</td>
<td class="nump">SFr 537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_AccruedProjectCostsAndRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_AccruedProjectCostsAndRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_OtherNonEmployeeRelatedAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=moln_OtherNonEmployeeRelatedAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290575808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepayments</a></td>
<td class="nump">SFr 3,910<span></span>
</td>
<td class="nump">SFr 5,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets', window );">Accrued income</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets', window );">Prepaid expenses and accrued income</a></td>
<td class="nump">SFr 4,589<span></span>
</td>
<td class="nump">SFr 5,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued income other than current contract assets. [Refer: Accrued income other than contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and current accrued income, other than current contract assets. [Refer: Prepayments; Accrued income other than contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932318368512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">SFr 521<span></span>
</td>
<td class="nump">SFr 23,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Value added tax</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Withholding tax</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">SFr 1,019<span></span>
</td>
<td class="nump">SFr 25,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315477840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure Of Trade And Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">SFr 521<span></span>
</td>
<td class="nump">SFr 23,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure Of Trade And Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure Of Trade And Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure Of Trade And Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">SFr 361<span></span>
</td>
<td class="nump">SFr 19,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfTradeAndOtherReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Trade And Other Receivables [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfTradeAndOtherReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290136704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">SFr 87,946<span></span>
</td>
<td class="nump">SFr 71,813<span></span>
</td>
<td class="nump">SFr 133,721<span></span>
</td>
<td class="nump">SFr 75,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short-term time deposits</a></td>
<td class="nump">161,198<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">67,611<span></span>
</td>
<td class="nump">44,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short-term time deposits</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">7,685<span></span>
</td>
<td class="nump">20,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short-term time deposits</a></td>
<td class="nump">4,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">12,520<span></span>
</td>
<td class="nump">5,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short-term time deposits</a></td>
<td class="nump">46,260<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">SFr 130<span></span>
</td>
<td class="nump">SFr 1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314188288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and short-term time deposits - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>bank </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>position </div>
<div>bank</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfShortTermTimeDepositPositions', window );">Number of short-term time deposit positions | position</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfBanksWhereDepositsAreHeld', window );">Number of banks where deposits are held | bank</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfShortTermTimeDepositPositions', window );">Number of short-term time deposit positions | position</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfBanksWhereDepositsAreHeld', window );">Number of banks where deposits are held | bank</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems', window );"><strong>Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfShortTermTimeDepositPositions', window );">Number of short-term time deposit positions | position</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfBanksWhereDepositsAreHeld', window );">Number of banks where deposits are held | bank</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfBanksWhereDepositsAreHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Banks Where Deposits Are Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfBanksWhereDepositsAreHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfShortTermTimeDepositPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Short-Term Time Deposit Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfShortTermTimeDepositPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312794304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Narrative (Details) - CHF (SFr)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in CHF per share)</a></td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TreasurySharesNominalValue', window );">Nominal value of treasury shares</a></td>
<td class="nump">SFr 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IssuanceCostsOfTreasuryShareTransactions', window );">Transaction costs related to issuance of treasury shares</a></td>
<td class="nump">SFr 631,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IssuanceCostsOfTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs of Treasury Share Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IssuanceCostsOfTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_TreasurySharesNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Shares, Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_TreasurySharesNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290189568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Classes of Share Capital (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>CHF (SFr) </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr) </div>
<div>vote </div>
<div>SFr / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 12, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 235,166,000<span></span>
</td>
<td class="nump">SFr 107,289,000<span></span>
</td>
<td class="nump">SFr 107,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 54,139,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,044,706<span></span>
</td>
<td class="nump">32,292,648<span></span>
</td>
<td class="nump">29,146,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,601,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_MaximumAmountOfShareCapitalIncreaseAuthorized', window );">Maximum amount of share capital increase authorized</a></td>
<td class="nump">SFr 807,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 457,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 428,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares', window );">Maximum amount of share capital increase authorized, number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,573,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent', window );">Maximum amount of share capital increase authorized, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseDecreaseInAuthorizedShareCapital', window );">Increase (decrease) in authorized share capital</a></td>
<td class="nump">SFr 378,641<span></span>
</td>
<td class="num">SFr (350,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement', window );">Maximum percentage of total number of shares in a placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated', window );">Percentage of share capital registered accumulated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 250,000<span></span>
</td>
<td class="nump">SFr 267,000<span></span>
</td>
<td class="nump">SFr 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_ShareOptionsPSUsAndRSUsMember', window );">PSU, RSU and options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,957<span></span>
</td>
<td class="nump">269,552<span></span>
</td>
<td class="nump">848,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3,579,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,792,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=moln_ConditionalShareCapitalMember', window );">Conditional share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AuthorizedShareCapitalEmployeeParticipation', window );">Authorized share capital, employee participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 136,296<span></span>
</td>
<td class="nump">161,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesAuthorizedEmployeeParticipation', window );">Number of shares authorized, employee participation (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,362,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation', window );">Increase (decrease) in authorized share capital, employee participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">SFr (25,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AuthorizedShareCapitalFinancingTransactions', window );">Authorized share capital, financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 226,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesAuthorizedFinancingTransactions', window );">Number of shares authorized, financing transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3,604,471<span></span>
</td>
<td class="nump">SFr 3,229,000<span></span>
</td>
<td class="nump">SFr 2,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,044,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AuthorizedShareCapitalEmployeeParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized Share Capital, Employee Participation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AuthorizedShareCapitalEmployeeParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AuthorizedShareCapitalFinancingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized Share Capital, Financing Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AuthorizedShareCapitalFinancingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncreaseDecreaseInAuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Authorized Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncreaseDecreaseInAuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Authorized Share Capital, Employee Participation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_MaximumAmountOfShareCapitalIncreaseAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Of Share Capital Increase Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_MaximumAmountOfShareCapitalIncreaseAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Of Share Capital Increase Authorized, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Of Share Capital Increase Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesAuthorizedEmployeeParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Authorized, Employee Participation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesAuthorizedEmployeeParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesAuthorizedFinancingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Authorized, Financing Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesAuthorizedFinancingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preemptive Rights, Over-Allotment Option, Maximum Percentage Of Total Number Of Shares In A Placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preemptive Rights, Shareholders, Percentage Of Share Capital Registered Accumulated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_ShareOptionsPSUsAndRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_ShareOptionsPSUsAndRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=moln_ConditionalShareCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=moln_ConditionalShareCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315652208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity - Shares Issued (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract', window );"><strong>Changes in number of shares outstanding [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares in issue at start of period</a></td>
<td class="nump">32,292,648<span></span>
</td>
<td class="nump">29,146,992<span></span>
</td>
<td class="nump">21,601,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity', window );">Issued in relation to capital raise in July 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,528,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity', window );">Issued in relation to Novartis agreement in October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity', window );">Issued in relation to vesting of PSU, RSU and options</a></td>
<td class="nump">252,058<span></span>
</td>
<td class="nump">145,656<span></span>
</td>
<td class="nump">278,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity', window );">Issued in relation to June 2021 IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfSharesIssuedTreasurySharesEquity', window );">Issued in relation to creation of treasury shares in August 2022</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares in issue at end of period</a></td>
<td class="nump">36,044,706<span></span>
</td>
<td class="nump">32,292,648<span></span>
</td>
<td class="nump">29,146,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued In Relation To Capital Raise, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued In Relation To Initial Public Offering, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued In Relation To License And Collaboration Agreement, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued In Share Based Payment Arrangements, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfSharesIssuedTreasurySharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued, Treasury Shares, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfSharesIssuedTreasurySharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932291264160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">SFr 997<span></span>
</td>
<td class="nump">SFr 4,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Social security</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxPayables', window );">Value added tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">SFr 2,143<span></span>
</td>
<td class="nump">SFr 7,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax payables. [Refer: Value added tax payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316343232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure Of Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">SFr 997<span></span>
</td>
<td class="nump">SFr 4,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure Of Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure Of Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure Of Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure Of Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfTradeAndOtherPayablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Trade And Other Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfTradeAndOtherPayablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314405808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_CurrentAccruedProjectCostsAndRoyalties', window );">Accrued project costs and royalties</a></td>
<td class="nump">SFr 2,167<span></span>
</td>
<td class="nump">SFr 3,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Accrued payroll and bonuses</a></td>
<td class="nump">4,763<span></span>
</td>
<td class="nump">6,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">SFr 7,501<span></span>
</td>
<td class="nump">SFr 9,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_CurrentAccruedProjectCostsAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Accrued Project Costs And Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_CurrentAccruedProjectCostsAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290484544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contract liability - Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Disclosure of transaction price allocated to remaining performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liability</a></td>
<td class="nump">SFr 10,046<span></span>
</td>
<td class="nump">SFr 35,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Expected revenue recognition in year one after balance sheet date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Disclosure of transaction price allocated to remaining performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liability</a></td>
<td class="nump">6,409<span></span>
</td>
<td class="nump">28,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Expected revenue recognition in year two after balance sheet date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Disclosure of transaction price allocated to remaining performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liability</a></td>
<td class="nump">3,637<span></span>
</td>
<td class="nump">5,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Expected revenue recognition in year three after balance sheet date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Disclosure of transaction price allocated to remaining performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Expected revenue recognition in year four after balance sheet date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Disclosure of transaction price allocated to remaining performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_LaterThanFourYearsMember', window );">Expected revenue recognition in year five and later after balance sheet date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems', window );"><strong>Disclosure of transaction price allocated to remaining performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Contract liability</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 120<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_LaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_LaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312639328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract liability - Explanation of Changes in Contract Liabilities (Details)<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at beginning of period</a></td>
<td class="nump">SFr 35,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 45,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseThroughAdditionsContractLiabilities', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="num">(25,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities', window );">Offset of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at end of period</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_AmgenIncMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at beginning of period</a></td>
<td class="nump">9,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseThroughAdditionsContractLiabilities', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="num">(9,653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities', window );">Offset of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at beginning of period</a></td>
<td class="nump">18,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseThroughAdditionsContractLiabilities', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="num">(8,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities', window );">Offset of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at end of period</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">18,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember', window );">FOPH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at beginning of period</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseThroughAdditionsContractLiabilities', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognized as revenue</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities', window );">Offset of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability at end of period</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Offset Of Costs, Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DecreaseThroughOffsetOfCostsContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Contract Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncreaseThroughAdditionsContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Through Additions, Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncreaseThroughAdditionsContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932291693088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract liability - Additional Information (Details)<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability</a></td>
<td class="nump">SFr 10,046<span></span>
</td>
<td class="nump">SFr 35,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 45,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities', window );">Offset of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="nump">18,584<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">SFr 19,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities', window );">Offset of costs</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 19,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DecreaseThroughOffsetOfCostsContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Offset Of Costs, Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DecreaseThroughOffsetOfCostsContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Contract Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312265664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contract liability - Disclosure of Current and Non-Current Contract Liabilities (Details)<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current</a></td>
<td class="nump">SFr 6,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 28,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current</a></td>
<td class="nump">3,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,237<span></span>
</td>
<td class="nump">SFr 45,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_AmgenIncMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,653<span></span>
</td>
<td class="nump">18,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current</a></td>
<td class="nump">6,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current</a></td>
<td class="nump">3,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">18,584<span></span>
</td>
<td class="nump">19,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember', window );">FOPH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems', window );"><strong>Disclosure Of Detailed Information About Contract Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liability</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 7,000<span></span>
</td>
<td class="nump">SFr 7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Contract Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_FederalOfficeOfPublicHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932291727616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional information on the nature of expenses (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">SFr (39,889)<span></span>
</td>
<td class="num">SFr (36,251)<span></span>
</td>
<td class="num">SFr (33,634)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(50,749)<span></span>
</td>
<td class="num">(55,718)<span></span>
</td>
<td class="num">(56,075)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="num">(22,238)<span></span>
</td>
<td class="num">(17,454)<span></span>
</td>
<td class="num">(11,595)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="num">(72,987)<span></span>
</td>
<td class="num">(73,172)<span></span>
</td>
<td class="num">(67,670)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense', window );">Research consumables and external research and development expenses</a></td>
<td class="num">(17,154)<span></span>
</td>
<td class="num">(26,342)<span></span>
</td>
<td class="num">(26,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">(28,101)<span></span>
</td>
<td class="num">(25,647)<span></span>
</td>
<td class="num">(25,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="num">(1,971)<span></span>
</td>
<td class="num">(2,016)<span></span>
</td>
<td class="num">(2,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IntellectualPropertyExpense', window );">Intellectual property</a></td>
<td class="num">(957)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="num">(492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OccupancyExpense', window );">Facility expenses</a></td>
<td class="num">(854)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_OtherResearchAndDevelopmentExpense', window );">Other research and development expenses</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RoyaltiesAndLicenseFeesExpense', window );">Royalties and license fees</a></td>
<td class="num">(1,010)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost', window );">Pension and share-based compensation costs, non-cash portion</a></td>
<td class="nump">3,856<span></span>
</td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">2,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">(11,788)<span></span>
</td>
<td class="num">(10,604)<span></span>
</td>
<td class="num">(8,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrativeExpense', window );">Other administrative expenses</a></td>
<td class="num">(9,965)<span></span>
</td>
<td class="num">(6,242)<span></span>
</td>
<td class="num">(2,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(549)<span></span>
</td>
<td class="num">(568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OccupancyExpense', window );">Facility expenses</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost', window );">Pension and share-based compensation costs, non-cash portion</a></td>
<td class="nump">SFr 2,329<span></span>
</td>
<td class="nump">SFr 2,113<span></span>
</td>
<td class="nump">SFr 1,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity classifies as being administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OccupancyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from occupancy services received by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OccupancyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IntellectualPropertyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IntellectualPropertyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Consumables And External Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RoyaltiesAndLicenseFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties And License Fees Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RoyaltiesAndLicenseFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932291756192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalties and license fees (Details) - CHF (SFr)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems', window );"><strong>Disclosure Of Detailed Information About Royalties And License Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_CurrentAccruedProjectCostsAndRoyalties', window );">Accrued project costs and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,167,000<span></span>
</td>
<td class="nump">SFr 3,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems', window );"><strong>Disclosure Of Detailed Information About Royalties And License Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">SFr 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RoyaltiesMinimumAnnualAmountTotal', window );">Royalties, minimum amount required to pay in total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_UniversityOfUtrechtMember', window );">University of Utrecht</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems', window );"><strong>Disclosure Of Detailed Information About Royalties And License Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_LicenseFeesExpense', window );">License fees</a></td>
<td class="nump">SFr 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_CurrentAccruedProjectCostsAndRoyalties', window );">Accrued project costs and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=moln_UniversityOfUtrechtMember', window );">University of Utrecht | Reservation Agreement with Swiss Federal Office of Public Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems', window );"><strong>Disclosure Of Detailed Information About Royalties And License Fees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RoyaltyPayable', window );">Royalty, payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_CurrentAccruedProjectCostsAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Accrued Project Costs And Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_CurrentAccruedProjectCostsAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Royalties And License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_LicenseFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fees Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_LicenseFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RoyaltiesMinimumAnnualAmountTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Minimum Annual Amount, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RoyaltiesMinimumAnnualAmountTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=moln_UniversityOfUtrechtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=moln_UniversityOfUtrechtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312732112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PersonnelExpensesAbstract', window );"><strong>Personnel Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries</a></td>
<td class="num">SFr (27,737)<span></span>
</td>
<td class="num">SFr (25,909)<span></span>
</td>
<td class="num">SFr (23,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation (non-cash effective)</a></td>
<td class="num">(5,088)<span></span>
</td>
<td class="num">(4,085)<span></span>
</td>
<td class="num">(2,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Pension costs</a></td>
<td class="num">(3,192)<span></span>
</td>
<td class="num">(3,059)<span></span>
</td>
<td class="num">(3,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="num">(2,399)<span></span>
</td>
<td class="num">(2,535)<span></span>
</td>
<td class="num">(2,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Other personnel expenses</a></td>
<td class="num">(1,473)<span></span>
</td>
<td class="num">(663)<span></span>
</td>
<td class="num">(1,704)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">SFr (39,889)<span></span>
</td>
<td class="num">SFr (36,251)<span></span>
</td>
<td class="num">SFr (33,634)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PersonnelExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PersonnelExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316407360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details) - employee<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PersonnelExpensesAbstract', window );"><strong>Personnel Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AverageNumberOfFullTimeEquivalentEmployees', window );">Average number of full-time equivalents</a></td>
<td class="nump">167.4<span></span>
</td>
<td class="nump">158.3<span></span>
</td>
<td class="nump">142.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfFullTimeEquivalentEmployees', window );">Full-time equivalents at year end</a></td>
<td class="nump">175.3<span></span>
</td>
<td class="nump">163.2<span></span>
</td>
<td class="nump">145.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Headcount at year end</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AverageNumberOfFullTimeEquivalentEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average Number Of Full-Time Equivalent Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AverageNumberOfFullTimeEquivalentEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfFullTimeEquivalentEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Full-Time Equivalent Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfFullTimeEquivalentEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PersonnelExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PersonnelExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932287840112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ActuarialAssumptionsAbstract', window );"><strong>Actuarial assumptions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Future salary increases at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract', window );"><strong>Reconciliation of the amount recognized in the statement of financial position</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 52,529<span></span>
</td>
<td class="nump">SFr 54,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,284<span></span>
</td>
<td class="nump">47,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">SFr 13,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract', window );"><strong>Components of defined benefit cost in profit or loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostDefinedBenefitPlans', window );">Current service cost (employer)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostDefinedBenefitPlans', window );">Past service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseDefinedBenefitPlans', window );">Interest expense on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">231<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeDefinedBenefitPlans', window );">Interest income on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans', window );">Administrative cost excl. cost for managing plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Defined benefit cost recognized in profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,192<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans', window );">thereof service cost and administrative cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans', window );">thereof net interest expense on the net defined benefit liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Reconciliation of net defined benefit liability</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss', window );">Defined benefit cost recognized in profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,192<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(8,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Contributions by the employer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(1,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfDefinedBenefitObligationAbstract', window );"><strong>Reconciliation of defined benefit obligation</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial (gain)/loss on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(8,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract', window );"><strong>Reconciliation of amount recognized in OCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain) / loss on changes in financial assumptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,222)<span></span>
</td>
<td class="num">(2,303)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain) / loss on changes in demographic assumptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,432)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain) / loss arising from experience adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,546<span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain)/loss on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,676)<span></span>
</td>
<td class="num">(5,508)<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans', window );">Return on plan assets excluding interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,342<span></span>
</td>
<td class="num">(2,504)<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(8,012)<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfFairValueOfPlanAssetsAbstract', window );"><strong>Reconciliation of fair value of plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Fair value of plan assets at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,483)<span></span>
</td>
<td class="num">(13,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Contributions by the employer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Fair value of plan assets at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,245)<span></span>
</td>
<td class="num">(6,483)<span></span>
</td>
<td class="num">(13,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Contributions by the employer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Total plan assets at fair value at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,284<span></span>
</td>
<td class="nump">47,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets', window );">thereof entity's own transferable financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets', window );">thereof property occupied or other assets used by the entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined obligation in years at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">15 years<span></span>
</td>
<td class="text">18 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IndustryBenchmarkDiscountRatesPeriod', window );">Discount rates based on industry benchmark, period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_AccruedSabbaticalCost', window );">Accrued sabbatical cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 307<span></span>
</td>
<td class="nump">SFr 257<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories', window );">Actuarial assumptions, possible increase (decrease) in longevity for most of the age categories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost', window );">Non-cash effective pension costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 846<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost', window );">Non-cash effective pension costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 250<span></span>
</td>
<td class="nump">SFr 235<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IndividualsAxis=moln_ActiveMembersMember', window );">Active members</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined obligation in years at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">14 years 9 months 18 days<span></span>
</td>
<td class="text">18 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IndividualsAxis=moln_PensionersMember', window );">Pensioners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined obligation in years at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">16 years 3 months 18 days<span></span>
</td>
<td class="text">19 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Percentage of reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.25%)<span></span>
</td>
<td class="num">(0.25%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Percentage of reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 54,524<span></span>
</td>
<td class="nump">SFr 57,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 50,672<span></span>
</td>
<td class="nump">SFr 52,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember', window );">Actuarial assumption of interest rate on retirement savings capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Percentage of reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.25%)<span></span>
</td>
<td class="num">(0.25%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Percentage of reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 51,699<span></span>
</td>
<td class="nump">SFr 53,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 53,383<span></span>
</td>
<td class="nump">SFr 55,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember', window );">Actuarial assumption of expected rates of salary increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Percentage of reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.25%)<span></span>
</td>
<td class="num">(0.25%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Percentage of reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 52,253<span></span>
</td>
<td class="nump">SFr 53,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 52,768<span></span>
</td>
<td class="nump">SFr 54,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember', window );">Actuarial assumption of life expectancy</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod', window );">Reasonably possible increase in actuarial assumptions, period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod', window );">Reasonably possible decrease in actuarial assumptions, period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 53,090<span></span>
</td>
<td class="nump">SFr 55,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,961<span></span>
</td>
<td class="nump">53,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Quoted market price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract', window );"><strong>Reconciliation of the amount recognized in the statement of financial position</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,391<span></span>
</td>
<td class="nump">39,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,896<span></span>
</td>
<td class="nump">9,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets', window );">Equity instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,754<span></span>
</td>
<td class="nump">20,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets', window );">Debt instruments (e.g. bonds)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets', window );">Real estate funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,793<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,748<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Total plan assets at fair value at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,391<span></span>
</td>
<td class="nump">39,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Non-quoted market price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract', window );"><strong>Reconciliation of the amount recognized in the statement of financial position</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract', window );"><strong>Plan asset classes</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Total plan assets at fair value at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember', window );">Defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract', window );"><strong>Reconciliation of the amount recognized in the statement of financial position</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,529<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
<td class="nump">54,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Reconciliation of net defined benefit liability</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,461<span></span>
</td>
<td class="nump">54,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,676)<span></span>
</td>
<td class="num">(5,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,529<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
<td class="nump">54,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfDefinedBenefitObligationAbstract', window );"><strong>Reconciliation of defined benefit obligation</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,461<span></span>
</td>
<td class="nump">54,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest expenses on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">231<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost (employer)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions by plan participants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits (paid)/deposited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets', window );">Administrative cost (excl. cost for managing plan assets)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial (gain)/loss on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,676)<span></span>
</td>
<td class="num">(5,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,529<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
<td class="nump">54,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfFairValueOfPlanAssetsAbstract', window );"><strong>Reconciliation of fair value of plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Fair value of plan assets at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(54,461)<span></span>
</td>
<td class="num">(54,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest income on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions by plan participants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,317)<span></span>
</td>
<td class="num">(1,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits (paid)/deposited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Fair value of plan assets at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,529)<span></span>
</td>
<td class="num">(54,461)<span></span>
</td>
<td class="num">(54,512)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember', window );">Plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract', window );"><strong>Reconciliation of the amount recognized in the statement of financial position</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,284)<span></span>
</td>
<td class="num">(47,979)<span></span>
</td>
<td class="num">(41,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Reconciliation of net defined benefit liability</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,979)<span></span>
</td>
<td class="num">(41,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Contributions by the employer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(1,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,284)<span></span>
</td>
<td class="num">(47,979)<span></span>
</td>
<td class="num">(41,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfDefinedBenefitObligationAbstract', window );"><strong>Reconciliation of defined benefit obligation</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,979)<span></span>
</td>
<td class="num">(41,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest expenses on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions by plan participants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,317)<span></span>
</td>
<td class="num">(1,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits (paid)/deposited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,284)<span></span>
</td>
<td class="num">(47,979)<span></span>
</td>
<td class="num">(41,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ReconciliationOfFairValueOfPlanAssetsAbstract', window );"><strong>Reconciliation of fair value of plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Fair value of plan assets at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,979<span></span>
</td>
<td class="nump">41,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest income on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">203<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Contributions by the employer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions by plan participants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits (paid)/deposited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excl. interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,342)<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Fair value of plan assets at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 50,284<span></span>
</td>
<td class="nump">SFr 47,979<span></span>
</td>
<td class="nump">SFr 41,089<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 18</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of administration costs in the current period related to defined benefit plans that are not reflected in the return on plan assets. [Refer: Administrative expenses; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets; Return on plan assets excluding interest income or expense, net of tax, defined benefit plans; Return on plan assets excluding interest income or expense, before tax, defined benefit plans]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount cash and cash equivalents contribute to the fair value of defined benefit plan assets. [Refer: Cash and cash equivalents; Plan assets, at fair value; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount instruments representing debt (rather than equity) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of the entity's own transferable financial instruments that are included in the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Financial instruments, class [member]; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 143<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_143&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount instruments representing equity (rather than debt) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 147<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_147_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 148<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_148_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from administration costs in the current period, that are not reflected in return on plan assets. [Refer: Administrative expenses; Net defined benefit liability (asset)] [Contrast: Administration costs not reflected in return on plan assets, defined benefit plans; Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense (income) arising from defined benefit plans. [Refer: Interest income (expense); Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income arising from defined benefit plans. [Refer: Interest income; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount other types of assets not separately disclosed contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense (income) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount real estate contributes to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from the return on plan assets, excluding amounts included in interest expense (income) arising from defined benefit plans. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 147<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_AccruedSabbaticalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sabbatical Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_AccruedSabbaticalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ActuarialAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ActuarialAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IndustryBenchmarkDiscountRatesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Industry Benchmark, Discount Rates, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IndustryBenchmarkDiscountRatesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post-Employment Benefit Expense, Non-Cash Effective Pension Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reasonably Possible Decrease In Actuarial Assumptions, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reasonably Possible Increase In Actuarial Assumptions, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ReconciliationOfDefinedBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Defined Benefit Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ReconciliationOfDefinedBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ReconciliationOfFairValueOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Fair Value Of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ReconciliationOfFairValueOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of The Amount Recognized In The Statement Of Financial Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service Cost And Administrative Cost, Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IndividualsAxis=moln_ActiveMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IndividualsAxis=moln_ActiveMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IndividualsAxis=moln_PensionersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IndividualsAxis=moln_PensionersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932291681584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract', window );"><strong>Components of defined benefit cost in profit or loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostDefinedBenefitPlans', window );">Current service cost (employer)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">SFr 3,137<span></span>
</td>
<td class="nump">SFr 3,097<span></span>
</td>
<td class="nump">SFr 3,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostDefinedBenefitPlans', window );">Past service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseDefinedBenefitPlans', window );">Interest expense on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">231<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeDefinedBenefitPlans', window );">Interest income on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans', window );">Administrative cost excl. cost for managing plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Defined benefit cost recognized in profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,192<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans', window );">thereof service cost and administrative cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans', window );">thereof net interest expense on the net defined benefit liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract', window );"><strong>Reconciliation of amount recognized in OCI</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain) / loss on changes in financial assumptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,222)<span></span>
</td>
<td class="num">(2,303)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain) / loss on changes in demographic assumptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,432)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain) / loss arising from experience adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,546<span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans', window );">Actuarial (gain)/loss on defined benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,676)<span></span>
</td>
<td class="num">(5,508)<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans', window );">Return on plan assets excluding interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,342<span></span>
</td>
<td class="num">(2,504)<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of net pension liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">SFr (5,334)<span></span>
</td>
<td class="num">SFr (8,012)<span></span>
</td>
<td class="nump">SFr 1,514<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 18</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of administration costs in the current period related to defined benefit plans that are not reflected in the return on plan assets. [Refer: Administrative expenses; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets; Return on plan assets excluding interest income or expense, net of tax, defined benefit plans; Return on plan assets excluding interest income or expense, before tax, defined benefit plans]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense (income) arising from defined benefit plans. [Refer: Interest income (expense); Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income arising from defined benefit plans. [Refer: Interest income; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense (income) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, resulting from the return on plan assets, excluding amounts included in interest expense (income) arising from defined benefit plans. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service Cost And Administrative Cost, Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315683136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>tranche </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="nump">282,105<span></span>
</td>
<td class="nump">318,902<span></span>
</td>
<td class="nump">382,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of PSUs and RSUs outstanding (in shares)</a></td>
<td class="nump">700,801<span></span>
</td>
<td class="nump">643,120<span></span>
</td>
<td class="nump">533,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_ESOP2009AndESOP2014Member', window );">ESOP 2009 and ESOP 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage', window );">Cliff vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="nump">282,105<span></span>
</td>
<td class="nump">318,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfShareOptionPlans', window );">Number of share option plans | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_RestrictedShareUnitsRSUMember', window );">Restricted Share Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod', window );">Blocking period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of PSUs and RSUs outstanding (in shares)</a></td>
<td class="nump">96,001<span></span>
</td>
<td class="nump">95,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember', window );">Performance Share Units (PSU), Employees excluding Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember', window );">Performance Share Units (PSU), Employees excluding Management Board | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted', window );">Number of PSUs issued, in percentage of number of PSUs granted</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember', window );">Performance Share Units (PSU), Employees excluding Management Board | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted', window );">Number of PSUs issued, in percentage of number of PSUs granted</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUManagementBoardMember', window );">Performance Share Units (PSU), Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUMember', window );">Performance Share Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of PSUs and RSUs outstanding (in shares)</a></td>
<td class="nump">604,800<span></span>
</td>
<td class="nump">547,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments Issued In Percentage Of Number Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfShareOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Option Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfShareOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Blocking Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_ESOP2009AndESOP2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_ESOP2009AndESOP2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_RestrictedShareUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_RestrictedShareUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932290056992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU and PSU granted (in shares) | shares</a></td>
<td class="nump">340,152<span></span>
</td>
<td class="nump">260,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price (in CHF per shares)</a></td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedDividendOtherEquityInstrumentsGranted', window );">Expected dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value of rights granted (in CHF per shares)</a></td>
<td class="nump">SFr 17.08<span></span>
</td>
<td class="nump">SFr 24.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_RestrictedShareUnitsRSUMember', window );">Restricted Share Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU and PSU granted (in shares) | shares</a></td>
<td class="nump">33,015<span></span>
</td>
<td class="nump">29,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUMember', window );">Performance Share Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU and PSU granted (in shares) | shares</a></td>
<td class="nump">307,137<span></span>
</td>
<td class="nump">230,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUManagementBoardMember', window );">Performance Share Units (PSU), Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Share price (in CHF per share)</a></td>
<td class="nump">SFr 6.55<span></span>
</td>
<td class="nump">SFr 17.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted', window );">Expected volatility on Common shares</a></td>
<td class="nump">64.69%<span></span>
</td>
<td class="nump">58.57%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted', window );">Risk free interest rate, common shares</a></td>
<td class="num">(0.54%)<span></span>
</td>
<td class="num">(0.58%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted', window );">Expected volatility on NBI</a></td>
<td class="nump">25.89%<span></span>
</td>
<td class="nump">26.21%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted', window );">Risk free interest rate, NBI</a></td>
<td class="nump">0.58%<span></span>
</td>
<td class="nump">0.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted', window );">Expected volatility on SPI</a></td>
<td class="nump">15.57%<span></span>
</td>
<td class="nump">15.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted', window );">Risk free interest rate, SPI</a></td>
<td class="num">(0.54%)<span></span>
</td>
<td class="num">(0.58%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Share Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FullContractualLifeOtherEquityInstruments', window );">Full contractual life for RSU and PSU</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Share Units (PSU), Employees excluding Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems', window );"><strong>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Share price (in CHF per share)</a></td>
<td class="nump">SFr 18.88<span></span>
</td>
<td class="nump">SFr 23.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted', window );">Expected volatility on Common shares</a></td>
<td class="nump">76.84%<span></span>
</td>
<td class="nump">61.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted', window );">Risk free interest rate, common shares</a></td>
<td class="num">(0.71%)<span></span>
</td>
<td class="num">(0.61%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted', window );">Expected volatility on NBI</a></td>
<td class="nump">28.16%<span></span>
</td>
<td class="nump">27.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted', window );">Risk free interest rate, NBI</a></td>
<td class="nump">4.78%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted', window );">Expected volatility on SPI</a></td>
<td class="nump">17.02%<span></span>
</td>
<td class="nump">16.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted', window );">Risk free interest rate, SPI</a></td>
<td class="num">(0.71%)<span></span>
</td>
<td class="num">(0.61%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ExpectedDividendOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ExpectedDividendOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility On Common Shares, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility On NBI, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility On SPI, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FullContractualLifeOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Full Contractual Life, Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FullContractualLifeOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Common Share, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, NBI, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, SPI, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_RestrictedShareUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_RestrictedShareUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312671504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PersonnelExpensesAbstract', window );"><strong>Personnel Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement', window );">Number of instruments outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">962,022<span></span>
</td>
<td class="nump">915,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted (in shares) | shares</a></td>
<td class="nump">340,152<span></span>
</td>
<td class="nump">260,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved', window );">Number of instruments forfeited, performance adjustment (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement', window );">Number of instruments forfeited (in shares) | shares</a></td>
<td class="num">(63,990)<span></span>
</td>
<td class="num">(66,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement', window );">Number of instruments expired (in shares) | shares</a></td>
<td class="num">(3,220)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement', window );">Number of instruments exercised (in shares) | shares</a></td>
<td class="num">(252,058)<span></span>
</td>
<td class="num">(145,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement', window );">Number of instruments outstanding, end of period (in shares) | shares</a></td>
<td class="nump">982,906<span></span>
</td>
<td class="nump">962,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement', window );">Weighted average exercise price of instruments outstanding at beginning of period (in CHF per share)</a></td>
<td class="nump">SFr 2.35<span></span>
</td>
<td class="nump">SFr 2.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement', window );">Weighted average exercise price of instruments granted (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved', window );">Weighted average exercise price of instruments forfeited, performance adjustment (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement', window );">Weighted average exercise price of instruments forfeited (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement', window );">Weighted average exercise price of instruments expired (in CHF per share)</a></td>
<td class="nump">5.40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement', window );">Weighted average exercise price of instruments exercised (in CHF per share)</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement', window );">Weighted average exercise price of instruments outstanding at end of period (in CHF per share)</a></td>
<td class="nump">SFr 2.05<span></span>
</td>
<td class="nump">SFr 2.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">318,902<span></span>
</td>
<td class="nump">382,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved', window );">Number of share options forfeited, performance adjustment (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of share options forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of share options expired (in shares) | shares</a></td>
<td class="num">(3,220)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised (in shares) | shares</a></td>
<td class="num">(33,577)<span></span>
</td>
<td class="num">(63,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">282,105<span></span>
</td>
<td class="nump">318,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding at beginning of period (in CHF per share)</a></td>
<td class="nump">SFr 6.87<span></span>
</td>
<td class="nump">SFr 6.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options granted (in CHF per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved', window );">Weighted average exercise price of share options forfeited, performance adjustment (in CHF per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options forfeited (in CHF per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options expired (in CHF per share)</a></td>
<td class="nump">5.40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercised (in CHF per share)</a></td>
<td class="nump">6.85<span></span>
</td>
<td class="nump">4.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding at end of period (in CHF per share)</a></td>
<td class="nump">SFr 6.89<span></span>
</td>
<td class="nump">SFr 6.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of PSU and RSU outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">643,120<span></span>
</td>
<td class="nump">533,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU and PSU granted (in shares) | shares</a></td>
<td class="nump">340,152<span></span>
</td>
<td class="nump">260,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved', window );">Number of PSU and RSU forfeited, performance adjustment (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of PSU and RSU forfeited (in shares) | shares</a></td>
<td class="num">(63,990)<span></span>
</td>
<td class="num">(66,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of PSU and RSU expired (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of PSU and RSU exercised (in shares) | shares</a></td>
<td class="num">(218,481)<span></span>
</td>
<td class="num">(82,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of PSU and RSU outstanding at end of period (in shares) | shares</a></td>
<td class="nump">700,801<span></span>
</td>
<td class="nump">643,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of PSU and RSU outstanding at beginning of period (in CHF per share)</a></td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of PSU and RSU granted (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved', window );">Weighted average exercise price of PSU and RSU forfeited, performance adjustment (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of PSU and RSU forfeited (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of PSU and RSU expired (in CHF per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of PSU and RSU exercised (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of PSU and RSU outstanding at end of period (in CHF per share)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise', window );">Weighted average share price, at date of exercise (in CHF per share)</a></td>
<td class="nump">SFr 22.35<span></span>
</td>
<td class="nump">SFr 19.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Exercised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Expired In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Forfeited In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Outstanding In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PersonnelExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PersonnelExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932287657472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems', window );"><strong>Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="nump">282,105<span></span>
</td>
<td class="nump">318,902<span></span>
</td>
<td class="nump">382,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of PSUs and RSUs outstanding (in shares)</a></td>
<td class="nump">700,801<span></span>
</td>
<td class="nump">643,120<span></span>
</td>
<td class="nump">533,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments', window );">Weighted average remaining contractual life of outstanding PSUs and RSUs</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of PSUs and RSUs exercisable (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement', window );">Number of instruments outstanding (in shares)</a></td>
<td class="nump">982,906<span></span>
</td>
<td class="nump">962,022<span></span>
</td>
<td class="nump">915,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement', window );">Number of instruments exercisable (in shares</a></td>
<td class="nump">282,105<span></span>
</td>
<td class="nump">318,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeOneMember', window );">Exercise price, range one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems', window );"><strong>Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options (in CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_ExercicePriceOfOutstandingOtherEquityInstruments', window );">Exercise price of outstanding PSUs and RSUs (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 0.1<span></span>
</td>
<td class="nump">SFr 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeTwoMember', window );">Exercise price, range two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems', window );"><strong>Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options (in CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeThreeMember', window );">Exercise price, range three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems', window );"><strong>Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 6.06<span></span>
</td>
<td class="nump">SFr 6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="nump">15,450<span></span>
</td>
<td class="nump">15,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable (in shares)</a></td>
<td class="nump">15,450<span></span>
</td>
<td class="nump">15,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeFourMember', window );">Exercise price, range four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems', window );"><strong>Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 6.94<span></span>
</td>
<td class="nump">SFr 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="nump">266,655<span></span>
</td>
<td class="nump">299,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable (in shares)</a></td>
<td class="nump">266,655<span></span>
</td>
<td class="nump">299,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_ExercicePriceOfOutstandingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercice Price Of Outstanding Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_ExercicePriceOfOutstandingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Exercisable In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Instruments Outstanding In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=moln_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316105312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation (non-cash effective)</a></td>
<td class="nump">SFr 5,088<span></span>
</td>
<td class="nump">SFr 4,085<span></span>
</td>
<td class="nump">SFr 2,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation (non-cash effective)</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation (non-cash effective)</a></td>
<td class="nump">SFr 2,078<span></span>
</td>
<td class="nump">SFr 1,877<span></span>
</td>
<td class="nump">SFr 1,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=moln_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312407216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost', window );">Interest income on financial assets held at amortized costs</a></td>
<td class="nump">SFr 1,142<span></span>
</td>
<td class="nump">SFr 99<span></span>
</td>
<td class="nump">SFr 367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Net foreign exchange gain</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">SFr 1,859<span></span>
</td>
<td class="nump">SFr 191<span></span>
</td>
<td class="nump">SFr 367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from interest for financial assets that are measured at amortised cost. [Refer: Interest income; Financial assets at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312356704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign exchange loss</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="num">SFr (4,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost', window );">Negative interest on financial assets held at amortized costs</a></td>
<td class="num">(562)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on leases</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Other financial expenses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="num">SFr (619)<span></span>
</td>
<td class="num">SFr (556)<span></span>
</td>
<td class="num">SFr (4,816)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Negative Interest Revenue For Financial Assets Measured At Amortised Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932318205168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes - Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=moln_MolecularPartnersIncMember', window );">Molecular Partners Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="nump">SFr 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="num">SFr (2,000)<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="nump">SFr 11,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=moln_MolecularPartnersIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=moln_MolecularPartnersIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932318113632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes - Deferred Taxes (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NetOperatingProfit', window );">Net operating profit</a></td>
<td class="nump">SFr 124,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_NetOperatingLosses', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 58,632<span></span>
</td>
<td class="nump">SFr 58,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">SFr 88,198<span></span>
</td>
<td class="nump">212,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwardsExpirationPeriod', window );">Tax loss carryforwards, expiration period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset)</a></td>
<td class="nump">SFr 2,245<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">SFr 13,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2027Member', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">SFr 29,566<span></span>
</td>
<td class="nump">58,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2028Member', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">SFr 58,632<span></span>
</td>
<td class="nump">SFr 58,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_NetOperatingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Profit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_NetOperatingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_TaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_TaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_TaxLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Loss Carryforwards, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_TaxLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312609056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="num">SFr (88,198)<span></span>
</td>
<td class="num">SFr (212,218)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2023Member', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,976)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2024Member', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,766)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2025Member', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,767)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2026Member', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,446)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2027Member', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="num">(29,566)<span></span>
</td>
<td class="num">(58,631)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ExpiringIn2028Member', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="num">(58,632)<span></span>
</td>
<td class="num">(58,632)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=moln_ThereafterMember', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Income Taxes And Deferred Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_TaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_TaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ExpiringIn2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ExpiringIn2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=moln_ThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=moln_ThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314418320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares used in computing basic loss per share (in shares)</a></td>
<td class="nump">32,469,957<span></span>
</td>
<td class="nump">31,005,171<span></span>
</td>
<td class="nump">25,000,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares used in computing diluted loss per share (in shares)</a></td>
<td class="nump">33,265,567<span></span>
</td>
<td class="nump">31,005,171<span></span>
</td>
<td class="nump">25,000,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare', window );">Number of potential future dilutive shares (in shares)</a></td>
<td class="nump">795,610<span></span>
</td>
<td class="nump">835,422<span></span>
</td>
<td class="nump">794,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312746736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems', window );"><strong>Disclosure Of Detailed Information About Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow for leases</a></td>
<td class="nump">SFr 1,232<span></span>
</td>
<td class="nump">SFr 1,232<span></span>
</td>
<td class="nump">SFr 1,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=moln_LeaseFacilitiesSchlierenMember', window );">Lease facilities, Schlieren</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems', window );"><strong>Disclosure Of Detailed Information About Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_LeaseExtensionTermOfContract', window );">Lease, extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems', window );"><strong>Disclosure Of Detailed Information About Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_LeaseTermOfContract', window );">Lease, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems', window );"><strong>Disclosure Of Detailed Information About Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_LeaseTermOfContract', window );">Lease, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_LeaseExtensionOrTerminationOptionPeriod', window );">Lease, extension or termination option, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutLeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_LeaseExtensionOrTerminationOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Extension Or Termination Option, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_LeaseExtensionOrTerminationOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_LeaseExtensionTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Extension Term Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_LeaseExtensionTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_LeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Term Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_LeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=moln_LeaseFacilitiesSchlierenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=moln_LeaseFacilitiesSchlierenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314187808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Disclosure of Movement of Lease Liabilities (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems', window );"><strong>Disclosure Of Detailed Information About Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities at beginning of period</a></td>
<td class="nump">SFr 6,039<span></span>
</td>
<td class="nump">SFr 7,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseThroughNewLeasesOperatingLeases', window );">Additions / new leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases', window );">Remeasurements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Recognition of interest on lease liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">SFr 24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payments</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(1,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities at end of period</a></td>
<td class="nump">4,850<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
<td class="nump">7,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">4,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">SFr 4,850<span></span>
</td>
<td class="nump">SFr 6,039<span></span>
</td>
<td class="nump">SFr 7,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_DisclosureOfDetailedInformationAboutLeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_DisclosureOfDetailedInformationAboutLeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Remeasurements Of Leases, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_IncreaseThroughNewLeasesOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Through New Leases, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_IncreaseThroughNewLeasesOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316588160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Disclosure of Expenses Recognised in Profit or Loss (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation on right-of-use assets</a></td>
<td class="nump">SFr 1,200<span></span>
</td>
<td class="nump">SFr 1,200<span></span>
</td>
<td class="nump">SFr 1,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short term leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_LeaseCostRecognisedInProfitOrLoss', window );">Total amount recognized in profit or loss</a></td>
<td class="nump">SFr 1,243<span></span>
</td>
<td class="nump">SFr 1,253<span></span>
</td>
<td class="nump">SFr 1,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_LeaseCostRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Cost Recognised In Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_LeaseCostRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932312595696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total contractual cashflows</a></td>
<td class="nump">SFr 4,928<span></span>
</td>
<td class="nump">SFr 6,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Carrying Amount lease liabilities</a></td>
<td class="nump">4,850<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
<td class="nump">SFr 7,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total contractual cashflows</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Between 1 and 2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total contractual cashflows</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember', window );">Between 2 and 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total contractual cashflows</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total contractual cashflows</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932318691600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Disclosure of Compensation Costs of Key Management (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">SFr 3,159<span></span>
</td>
<td class="nump">SFr 2,423<span></span>
</td>
<td class="nump">SFr 2,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation costs</a></td>
<td class="nump">SFr 5,567<span></span>
</td>
<td class="nump">SFr 4,410<span></span>
</td>
<td class="nump">SFr 4,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932314144672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures - Narrative (Details) - CHF (SFr)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Related party fees</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 13,000<span></span>
</td>
<td class="nump">SFr 45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_PaymentForTermOfEmploymentRelatedPartyTransactions', window );">Commitments made by entity, related party transactions</a></td>
<td class="nump">SFr 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesReceivedRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of services received in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesReceivedRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_PaymentForTermOfEmploymentRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Term Of Employment, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_PaymentForTermOfEmploymentRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932316093056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details) - Currency risk - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent', window );">Increase in exchange rates</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent', window );">Decrease in exchange rates</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if exchange rates increase</a></td>
<td class="nump">SFr 5,904<span></span>
</td>
<td class="nump">SFr 6,633<span></span>
</td>
<td class="nump">SFr 2,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates decrease</a></td>
<td class="num">SFr (5,904)<span></span>
</td>
<td class="num">SFr (6,633)<span></span>
</td>
<td class="num">SFr (2,976)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent', window );">Increase in exchange rates</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent', window );">Decrease in exchange rates</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if exchange rates increase</a></td>
<td class="nump">SFr 1,252<span></span>
</td>
<td class="nump">SFr 2,019<span></span>
</td>
<td class="nump">SFr 432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates decrease</a></td>
<td class="num">SFr (1,252)<span></span>
</td>
<td class="num">SFr (2,019)<span></span>
</td>
<td class="num">SFr (432)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932315228576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>bank</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks', window );">Number of different Swiss banks</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Balances Investments, Number Of Different Swiss Banks</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Risk Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932318187328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details) - Interest rate risk - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent', window );">Increase in interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent', window );">Decrease in interest rates</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates increase</a></td>
<td class="nump">SFr 888<span></span>
</td>
<td class="nump">SFr 323<span></span>
</td>
<td class="nump">SFr 683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates decrease</a></td>
<td class="num">SFr (888)<span></span>
</td>
<td class="num">SFr (323)<span></span>
</td>
<td class="num">SFr (683)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent', window );">Increase in interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent', window );">Decrease in interest rates</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates increase</a></td>
<td class="nump">SFr 294<span></span>
</td>
<td class="nump">SFr 234<span></span>
</td>
<td class="nump">SFr 149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates decrease</a></td>
<td class="num">SFr (294)<span></span>
</td>
<td class="num">SFr (234)<span></span>
</td>
<td class="num">SFr (149)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent', window );">Increase in interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent', window );">Decrease in interest rates</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates increase</a></td>
<td class="nump">SFr 63<span></span>
</td>
<td class="nump">SFr 102<span></span>
</td>
<td class="nump">SFr 32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax', window );">Effect on result before tax if interest rates decrease</a></td>
<td class="num">SFr (63)<span></span>
</td>
<td class="num">SFr (102)<span></span>
</td>
<td class="num">SFr (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932287825488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details) - Credit risk - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">SFr 250,344<span></span>
</td>
<td class="nump">SFr 156,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">87,946<span></span>
</td>
<td class="nump">71,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">23,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_AccruedIncomeMember', window );">Accrued income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_ShortTermTimeDepositsMember', window );">Short-term time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">SFr 161,198<span></span>
</td>
<td class="nump">SFr 61,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_AccruedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_AccruedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_ShortTermTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=moln_ShortTermTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>moln-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:moln="http://www.molecularpartners.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="moln-20221231.xsd" xlink:type="simple"/>
    <context id="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">moln:AmericanDepositorySharesTheNasdaqStockMarketLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic0d265762d384de3bc912a8791ed2b7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8aa95d3bb3ea49f38b656b59881a996f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia354966cf31e42aaaa6b703a60e1341a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8af2f1be9ad44d51b81ad6f3e39f3917_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ec7c73caeed425b977de2350cb9e35d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id66ad877b195477caaa63da51066504e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dc9a065301142489cf73ad6591f13da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cc7f91b995e4a8e8339b8aec0df0032_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id00f48490e1649a289d5d3945dc00e92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i535054e5b34d4a6aaeb7b886535df3dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fba67aaaf88433581c2a71e67a97f3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15e5ef472f264809b3c22976835aa54a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae7e5cc7cd4c4a6ab9342ae37f83b666_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeb7fef9acf84e13bae5ef3655a07afa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35d2bc98f85c42efaf80ceebcbf879d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97c02508d8664ebaad3f69a80bf22ab3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79a62605a2a64c89a0a34d7bbc035e7d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7c118ee100384a299e971a96bc0a67db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida1ef664b85047599beb657c0edeb373_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c9db8103d514df6aea83be7bdf65bb2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4566f4cc772449408ec24a9a58cbf560_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42ec354c9f8f4c9a9d165067d15652b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e80d6a46f79433a9f1419880a584236_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58f89c5d3edd409a893e4a981cc24bd0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib359265a93b948b2b6a8eefcd3139fe8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e1e929b08e148649e795b949412ce45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i134827d19330412b856f8be3015f6a0b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">moln:VSAOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">moln:VoluntaryComplementaryPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia75b3bef6aac446986fe84984a05f946_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">moln:VoluntaryComplementaryPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56649e20c0b0463da822d9678ae13d6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7afdf7fbdcd3403f9eab53aecc3a73dd_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="i86479feb060c435da9376e68efd6bae0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie09ac87f9d574f82a6928c8d06b64069_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36fa71d491c847329fa6c34d14edfb51_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74229b204f0a4e65a5b4572fda04aa7d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cfad794c98341a992833dca18dfb48a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">moln:CommercialSupplyOfProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:OptionAndEquityRightsAgreementWithNovartisEnsovibepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc6153f573e54a3eac1c9d6b41928f25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81750a7eb8914110a2c5e64c43bc2de0_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0215c4c9fa24e1aa58a4a62c6f6dcac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9358dea0732b40a194894bcf6ddddaec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i11c7f8788e1743f68a27f638c26a39bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28fa8e94c14b481ca8ccfc64c63add77_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb6f6a0e23734f59bbbb2a62cce89125_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccbcbcc25f484b88a862620fa45229ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3059de8c6f0f4f34a718c2a08e7fe684_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c93a9c3be2d4ab1aca8bcaec0a3ece3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f2f00f6e1d34d28bc572c7a3716463d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithNovartisAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i98b9c15b3a534e53bbe14f8fb49c9c04_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithNovartisAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69206f52bb344692804141964f0b8919_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithNovartisAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03d96b78adfc4421949448ba38c3278e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithFOPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie43e19cfc5e6468284394d74ddd1c6b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithFOPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d6429be12154d0ba42dc47086ea5532_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithFOPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9455742d8ced4b6aa55b012e2998f544_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7779c743611545a1a5466aeccce603f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LicenseAndCollaborationAgreementWithAmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i039f8aa8b8604b2e883f7b3401f7a929_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7552852e9d984715b1fdd598bf43ceef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd82706cc4f64d05a8031db8ac29d402_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6bbe794bea748fba48087bb12f33b68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88e0b443e7594af9817dff19575a130a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id866ae6d346e441aa470d04134f56aea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f4189b498f848ccbfe85984bfc5754f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3fdd67cc72964dfbacdf60557d1afe8a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i929b7236fc1c4b00a1fbffece5751b1f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0bfb7ab39c194903bc349d24d15bdff3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i449ea807ec98486b91b11b3611579b53_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i721fcb345fbe4680839954bebb736c75_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae809b4cb3c34e5e883367b1b36f9a41_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i700c3d4d5945423fb23d62d557025628_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i442e98a6f284460eb60903633206fee4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied5bd6f58f8f48858390908d4e2a3e7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62a4b7bf00f14853a994219c229c2c99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67bd3877ed504b9aa0d90579b46a85dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8209c15b7f84b6c9ad36754465a7bb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c56aac02e0548818298a1b40775502a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad0b882b89ca4bc19848d14f02c8a322_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87deb100db7642138360f124b7b83f30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07001daad34a409cb04dc3e2f9fddf5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6db54fee24e4009b68217ec1b72ecdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75365a982a614edc804e839f45c5b05d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i078bf95a5a1b404484fa9d710b87ffcc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice16a04c397c47bca71d3d2d60a51120_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b1102832e1f4e1fafce024fd7eb6448_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e85bbf49b974c1ea7e5b7900e92843f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i70c79a462ea7412a93e68016da430184_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id7021179595f4067925348f27617f344_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56b61e3a808b46ecb5fd9e84efd88fb1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd725be5cb634d3ab32c12364784d95e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i623979330c12419785c4e5ddc7af24af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8693395446c5444f8dea66e3b926bfc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id42028a51dd041c8adf064ec5e6ff3ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3eb97834871d4133bebda22f171f379c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4515285a8328425c8e01df63e4618b0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad950054a9b34e23b44f9eadcd5ac579_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc0b75f40939487cb5f179a9d998733b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbf076ebc35b49ddbe4032b44413da3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54edf24cb9164d1dbfea8b8935a712b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea606ad4acc0477bbea8cec093c5f28a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ca2744f82cc4290b5c5196c97ed6050_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26412b3157954911862c5a447f325fd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18bc5a3445ce443b98c1b2827a0abbf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacafa94802ef4385b1333762542ab2f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i610b20f353ba4dea967f7adf9a040527_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib96855ceb0f64121a493479e560bef93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9417e12bdb64e3bafac232b9b8e7099_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id2dba62e38a349b5bd2d7fb9c9475d34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa9d4dcab9014ff6a5667ed415cacf65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e266b3fb54b46679c03b9f807b42f18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic872fe1c5a64452688768d06a4b4096c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i400d3c0abd194c8e869aa1b7e6a16268_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74f28cfe913d4066ba37fda6c47ac60d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i337a906d7c4e48bc876b5ed46aa717c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1742ca85635d45afaa2bb5e7b5c34750_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8ce32bfd0d64572b4c65f93443e740f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icab5d29cfc93414ea6aba3b898a8cf72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica8eaf81db894ce0b611d7d987fef5f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15f9aad96b06470c9ded02ebad46915c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97000304b6a7470ba15cf385bc4113c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd1b6d0b84ef47739e20d7569c9e7102_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c236926219843fc950064245dabb01c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7da99d7da3114dd5a669a798631979bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d43267d2666482cbd65715b80893cc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab1da6a1258a4f2f824c654908d097f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcab65890a354c7eb8e9eaaa6083e002_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1330a3506b934eb6a59f96f40d105eca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">moln:RightOfUseAssetsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60ae0c8e6c1242e094cae93b6edbc064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i322fcb8657fc434286b60a943aabbd22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a000e55273047dba1042898c89c120b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40f2da050b044a43bb1f4bbaaedd6819_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14e65b8ceef04aa9a9e140cd7cd7c323_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i137ae661167d42648f19a81509b45e09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib61e00b45a7c4b488678787526592c08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0a2cc30e5c64038a201d238fbf11978_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9c8f0e30de34329b9dd662589d2625a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf6e38e9a01048c6a7e34827d9d57b9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib278e099451c4b7e9229b48c30d76025_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8bbbdd9cb75406c8df9b0ed579152dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ef84e56318a489a8550043d9384b54b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac28997728a9430bb0713563ae32e639_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7a6529b985e46fea5bb9ea34f1efa71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08f2c57f37114335bb14a01f1e265d33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5978b0e87e0e41418a1eb6893998c62a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bef516c67454da38f24cc8f5ef7b00f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd992de4c1764c598225f05b506bb29b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i829b948cf2c94f18aebf743811865ac2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id32257a4e4494aacb101dba09b0114a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6313d1eb0624defb28c64aa01dea0b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9789cf293a2a4a9b8bb9f043c05612a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61b9f00779e44405b197ec74e74a0439_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie27040b2af4143aab5074a6b04e2ced4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:AccruedProjectCostsAndRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i587a7a797df14da6b6b0b353a5dbac42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28fffe2b94ca408ca522a3764d0a9a7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:OtherNonEmployeeRelatedAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideda6d7323e8434683a468cdbdbfaad9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i304edf7fc9dc4af086181703ec172bbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i786fc55946ab49a5b3e6894295ca6683_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:AccruedProjectCostsAndRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff33ff9bbe6c47fdacddc7317235393c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f4ee1fc220b4633b70d08183faf0864_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">moln:OtherNonEmployeeRelatedAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bddec936def48f8835419a973c2564e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if10f3857f8be428ea614cef6b5f0cfdc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b566efcfd8e4616a1184a3238a19919_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3dd2f40888e4d59961b586143204f41_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib18995551c1f4e4f88287c5b9130f130_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd1e5f5e6ec145b3bceebef0cf07f8db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee446437d91845ccb79f71155459c929_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i150e9865322b40bf976dd456472c9667_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1e6b625e94e4ef8b99a049db65e38b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i297e474b905f4802b3fc5c84517b4244_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if62d6f3c76c74566abf3f5f15fb7e4a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b4cf686055c46f0990c5475b479feab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92a813a501bc4b9b8b3d48933008d151_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="ibdf5c6ab807f470abff7a20928b54739_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95512f09473b4296a07c0bf49732b9f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36e31ef12d534128ba81206be595d4b6_D20220413-20220413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="iffee4313ed1e4200a7baafdb5092cc29_I20220412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="i226a1800b6a24a9ab618c75812acf641_I20220413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="iaf0473678da046f9afdd55eced60e2d5_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i76a78a9b245d4218947bfd4a0acbd239_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">moln:ConditionalShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13a375d0b11f458fbd6bc7e1aaf8675f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">moln:ConditionalShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ddb4cbe7d484358b5bf5ba0089d4386_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">moln:ConditionalShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b22ff48cfa44ceaa5de97b4809b8b54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ShareOptionsPSUsAndRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i23a22766f4574cdab095ce240d4ab462_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ShareOptionsPSUsAndRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie47af3905cff436a87efc3199975fdcc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ShareOptionsPSUsAndRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46461ef8c2bf4ad194fcc5da61eb4790_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i859523f38bfc4cef886b0469de3d3c27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i918edbfe84d34f33a0b487a26eeba31e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4738c29a9abd4ebdb07a22bac9da094f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44b7ff2364ee43b4a7559bda1f8cfdc7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:LaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6592e0e0184441c58126d7e24b37d82e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if56ff0ffb76b4ef7bdd5f9a0f0de46ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if631f991ae9c444c817903110fa5596a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16a9cc51038a4f4d95c67fe474148918_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9a4c1ad6eff4eaa80acba6bc1f1a654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:LaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9c25c613d894005a9d3a3b959ee5252_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie40be771ab47427dab17aa01b8815550_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5e790e4d70ba47b7811ed9628565b55a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25f724f166614126b409c627fece74f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i11110b5c186941989d4682d8c5456ae1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id871d1f18f9746c1968f95282a63c920_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i092e160ceafe420685da4b0eed564d63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:FederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">moln:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">moln:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc53d874499145cdad911dfc92439430_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">moln:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief90048dd4494347a75a5ce67581ab00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if164200b3a3a403cb3987f2f289dfaab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66792e0d15a34af9b27cee6aec9fbcae_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfUtrechtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e3f5143278948b68b6427ace3f8dade_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfUtrechtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46ac96852f4042b3a422b02e00b4ff71_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">moln:UniversityOfUtrechtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i477f396e4168445ea6fbd216e6f8a944_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2698db5ae60649b096fe74b1692909bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b64a6fd6d004538825e688a02e1881a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26558c7e2e90408aaf310a75bba70d80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3319cb244b7e4172804e14694e32ba95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9e07ae88ae04fad8ed31f5f90d82653_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76d575c9c1d347f3ade30668167c5c96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifff310e7d99a4295bb708e767bfd827a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59e9a73043d041f097d4b73f09999ed1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie370090677a545b69199494d00542b66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87a252953f884104bde7e1a0d7c46591_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcf864ef90754f278e13ffa37235877e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">moln:ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8202c8045424e74acc574ebe5b785fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">moln:ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8670303e14b477492db59a0f50b6eec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i345d907a04bf4819bb7da74c7aa2c045_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90d91352ae9f40a98d596b751938d675_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfLifeExpectancyAfterRetirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdef4a2f3f49473fa1da77464227f8d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfLifeExpectancyAfterRetirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87e47e2a1d2f42d6b887d22d3f1fda3a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:ActiveMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5c53ee898715434fac2e14c485a6b3ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:ActiveMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied315fa7934d4ceca93243eef84aeb2b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:PensionersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i718f06d2648742acbc789cc2611558ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="moln:IndividualsAxis">moln:PensionersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ESOP2009AndESOP2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76a79e3fe3be49e5918a663e53a05813_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ESOP2009AndESOP2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16708e73e7aa4355b85eac7ce415b78b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:ESOP2009AndESOP2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib5fa38f116e34565a5e36d42a37700a5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieffd03daf5f049beadb8aa9b7a149884_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c649c507ba24f33a40832e35ce5a3e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1c7b494d350479797a5d1c4c82ccba2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97a4f932a6df488d9cc6ed653efcf1f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied19b6e08547434f9cdba0fd054a6b2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72a85516e9d14b69b127030c7418be86_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91457d4200b443229b7716268dcc0131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c84992c462c4044bf0e6a6000d7fa91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73b1e70d913e41eb90a4644426c8401b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia48dcfaff35049b2936b8df362cf345b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb4215e729f94983af2861f952675797_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58ac6f2ae72f4533ab1243a7f02391ee_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie860cc1afbd34f37b81b8c5b43ca86a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4d5712930e540a9b8c8240c3972c7ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">moln:PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id45b9f3adc9745569f9195e24eefccdd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf36213d4e434ddab3aee4d16f583fc3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69ed7f76d9f64feb954d4407df356caa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ab6a4e5dc284abeadf7a60e68289a52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f7c058068224203b33c7fcd1f1b017f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f487997ebf84760b436351b9cd07415_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18556d3232ec4e46aaa9d8f104201d8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2287ef5f8e94d59ac113037e7dd05ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09f51f1fee3243008271209344707ab6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4eea0ffff4540458374ebbc176fc17e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f264b7c466b43e2be89711f4ad6b777_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">moln:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">moln:MolecularPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i601f0ea0b2a5490cade7bed682109126_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">moln:MolecularPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ced05873ca5491bbfebf6675070c334_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">moln:MolecularPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia07c5697db104aff83e8133bcbfd34e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0b15b456e71466f914f4fb77e4fbfc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9e4c0c2414646e3920288a6e3d93b50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a33d4e0e53241cb86e82f186e53b0d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i448b10a8ed3a4b459f511c18fe6a4023_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i309bd18113fa4d088977cb2d88cd4092_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia64fa509207d47efa0e81300d9d73cd3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9273a8f19ab4459a81e57dbd2f441d17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i875b50cd70744049a9efbc6796621651_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2651abe27944dcdaf65a2279954b10f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf748a46ec9a4ba8b9feba532a6b4da2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfae2f7fb65743218e1d395982995a0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ExpiringIn2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc42f5752df44c938ff23151446565fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia11f395ed16342c5ba81005541468e8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">moln:ThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4de6e75b42b401296433bd018ede76d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaac4cc8da2f54efab0f4f0d53dcfdf39_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie5811d9f19074f96a9cbb5482d36febc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">moln:LeaseFacilitiesSchlierenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie87b69197a5e41b68d889d5a9f94133c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20e09613a3fb4d9ca1c6817d2d362664_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fe3972176af4d07b4e1942adcf6c075_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f6b2661b6384f1fa68e0f05fada4e22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4735c93b327e4729bb263ba18457993f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc9f9f10e83045df9c56d3e82d087d4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i075b63d9ec7248cfaea163eaee0d8389_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fcf3db326314fe697ed5cd42ecbbada_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfcf107f070c4e4881afc0cfb8a17695_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i535d9072a4a54202a9a35ca03151f8e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6257911404da432da8c7b7b86e6e80fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:AccruedIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2714f74d10b649b4b454a1f1bde37423_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5431eb0aa5e34ad0b9389372b7ea9eb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">moln:ShortTermTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i001bd3a832b04bf5bbcaa90c5bc76c16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f458970fd1a437482bffbf1e51aa71e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="chfPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>moln:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>moln:employee</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="position">
        <measure>moln:position</measure>
    </unit>
    <unit id="bank">
        <measure>moln:bank</measure>
    </unit>
    <unit id="vote">
        <measure>moln:vote</measure>
    </unit>
    <unit id="plan">
        <measure>moln:plan</measure>
    </unit>
    <unit id="tranche">
        <measure>moln:tranche</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl8xLTEtMS0xLTEwOTYxOA_38da190d-2a08-42d8-938c-2c5ef5f9e1d9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl8yLTEtMS0xLTEwOTYxOA_2582f81f-7c78-40e3-840d-8e31fff4e5d3">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl8zLTEtMS0xLTEwOTYxOA_92bdac7b-5410-479c-b156-dee15392ee19">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl80LTEtMS0xLTEwOTYxOA_cd066924-9294-4c0b-b85d-5574e400b09a">0001745114</dei:EntityCentralIndexKey>
    <dei:NoTradingSymbolFlag
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV80L2ZyYWc6YjQwOWM3NjFjMWE0NDBlNzljNTdlOTcyYjVmOWI1OTAvdGFibGU6NTYxZjU5NmIyYWU5NGZiZmEyYmM3OWRmOWFkN2YwMmIvdGFibGVyYW5nZTo1NjFmNTk2YjJhZTk0ZmJmYTJiYzc5ZGY5YWQ3ZjAyYl81LTEtMS0xLTEwOTYxOA_124437ce-630f-4851-b79c-6c2d1b1d0c4f">true</dei:NoTradingSymbolFlag>
    <moln:VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod
      contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIwNw_9040953b-cb8b-40fb-a37f-f83b25c57861">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxMQ_05ecdaa7-ecd6-4736-951d-8a9dde75aba2">P1Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod
      contextRef="ieffd03daf5f049beadb8aa9b7a149884_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyMg_8b946c45-4517-4e69-84b4-4b2d7403ff98">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod
      contextRef="i0c649c507ba24f33a40832e35ce5a3e0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyNg_6be1f36f-6243-4b7f-bbee-a9ede8c3610e">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod>
    <dei:DocumentType
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAz_b44e5f8f-7771-49d3-ae3b-176a5913026c">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YzQ4MThlMGViYjE2NDk4YmIwNzA3NWVlNjE1MzJlNDYvdGFibGVyYW5nZTpjNDgxOGUwZWJiMTY0OThiYjA3MDc1ZWU2MTUzMmU0Nl8wLTAtMS0xLTEwOTYxOA_3f391e6a-1dfd-45d9-829c-09827bd262e4">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YWJhODI0NjA2OThlNDA4Nzg5YWI1ZWNkODUzOGFjMjgvdGFibGVyYW5nZTphYmE4MjQ2MDY5OGU0MDg3ODlhYjVlY2Q4NTM4YWMyOF8wLTAtMS0xLTEwOTYxOA_7354047c-823f-4458-99f2-4a72d7b28144">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV8xMzc_22c4bfc5-e9b6-40c9-84ff-9d6e9e7109ae">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV8xMzc_d19a5df1-5a22-4002-85e0-70289fefbd3d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6MTgyOTE4NmNlYjg3NGQ3OWFkNzUyNTdjNzZmNDE2ZjEvdGFibGVyYW5nZToxODI5MTg2Y2ViODc0ZDc5YWQ3NTI1N2M3NmY0MTZmMV8wLTAtMS0xLTEwOTYxOA_9e26e913-4ba1-423a-b53d-3da8e5109b13">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6Zjg4YTFhNjk5OWQ3NGVlZDg2YjViN2IwYjZjNjA1OWUvdGFibGVyYW5nZTpmODhhMWE2OTk5ZDc0ZWVkODZiNWI3YjBiNmM2MDU5ZV8wLTAtMS0xLTEwOTYxOA_8f1aec91-e18b-4a7b-baa4-52b00485c277">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTE3_aab14802-a6a3-4c00-bcda-7468d20958f4">001-40488</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTE4_625e0649-9766-4403-b68f-da825a879df5">MOLECULAR PARTNERS AG</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA4_9c491deb-02a6-466f-8808-ed5a8ccb34dc">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTEz_d7636496-c7ae-48ac-bbca-05b9813d0446">Wagistrasse 14</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80Nzk_fa937c97-9bc7-4d32-8017-2581efc520e3">8952</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA0_a221be1a-3574-4d1e-9ec5-511642e5d82c">Zurich-Schlieren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA5_7a80fd54-9e0a-4856-9dac-850ec666ff4d">CH</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk1_05d33968-df11-4ae0-b0f8-e29c8b91da9f">Patrick Amstutz</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA1_7b3ce974-1b35-4458-82b9-30393ee2a343">Wagistrasse 14</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV82MzM_7dbbc48e-845c-4842-8ace-fd8de2eda1e8">8952</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk5_4e9554f5-8231-47fc-bd50-a9a5f9386153">Zurich-Schlieren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAw_304bc077-633f-4b5c-bb42-35bbc802e593">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV82NzI_7e8a2f50-16d3-43e5-b7b6-fbfde3b4a3af">41</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibb81756c2c60468f913a6406d67e00ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTE2_d87b90f7-8bd4-4883-a78a-7359cff4daf7">44 755 77 00</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8xLTAtMS0xLTEwOTYxOA_a13d0220-17b4-4ab7-8dfd-e7256367ee74">American depositary shares (each representingone common share, CHF 0.10 nominal value per share)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8xLTItMS0xLTEwOTYxOA_8a2ca305-ade2-44a0-8de7-676cdbef081b">MOLN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i109c54c95b934c2f808300b94b50ae27_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8xLTQtMS0xLTEwOTYxOA_e118bef4-a651-4a73-ad96-982a424078a7">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8yLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjc4NzljYzRjYTI5MDQwYTBiNzFjOTY5Njc2ZmNlYzQ4XzU_91428dae-2df9-415b-98cf-803eb1e5f334">Common shares, CHF 0.10 nominal value per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NjIyMjkxOTJkMmQ2NDQwYmJkMWMwMzI2MGU2NDU4NjUvdGFibGVyYW5nZTo2MjIyOTE5MmQyZDY0NDBiYmQxYzAzMjYwZTY0NTg2NV8yLTQtMS0xLTEwOTYxOA_89f01ce0-d581-4fb4-af2c-edc1d4cb4625">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV81NDk3NTU4MTk2NzI_5cd5e58f-9b82-4901-9e0a-6fea6b90b158"
      unitRef="shares">36044706</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAx_42d9474f-d10d-4b11-bb83-b732e7a1c7f1">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTAy_685ef6fe-4386-4e6b-a367-bfc2721b741a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA2_5c72a816-d43c-464e-af27-d68a79461597">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk2_6fe98727-cc78-4c37-b4d0-c51d2fdbd481">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YjNkZGQ3NDIyNWRjNGI0OGFlYTY2YjFmYjBjZDIzODIvdGFibGVyYW5nZTpiM2RkZDc0MjI1ZGM0YjQ4YWVhNjZiMWZiMGNkMjM4Ml8xLTAtMS0xLTEwOTYxOA_8960f2f3-4900-4c0f-8fd5-f8a69164df5b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6YjNkZGQ3NDIyNWRjNGI0OGFlYTY2YjFmYjBjZDIzODIvdGFibGVyYW5nZTpiM2RkZDc0MjI1ZGM0YjQ4YWVhNjZiMWZiMGNkMjM4Ml8xLTYtMS0xLTEwOTYxOA_ea9d5f14-bc62-4ad3-a2ea-90c9764811f7">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MDk3_888a3555-9797-434a-b39e-f6d778713944">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTA3_6b6343a7-79f9-4615-a01f-501900484608">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGFibGU6NGRjNjc4NWZjM2RhNDk1NWEwNzRlOWQ1ZWMyMGFmOTMvdGFibGVyYW5nZTo0ZGM2Nzg1ZmMzZGE0OTU1YTA3NGU5ZDVlYzIwYWY5M18wLTItMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjNlZjNiZmVkM2Y5MTQxYmE4Mjg1MjE1YzBiZDRhNmY2XzU_d0d48105-39de-496e-9e80-abfce5ec7025">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xL2ZyYWc6MmMzZjI2MWExZTk1NDlkZGFjY2FmNmFhNmIwNDc5MDEvdGV4dHJlZ2lvbjoyYzNmMjYxYTFlOTU0OWRkYWNjYWY2YWE2YjA0NzkwMV80MTEx_a1d241b5-7543-4682-a4ba-b4d101f07018">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNDEvZnJhZzo3ODc2OWJkZDJlY2M0OWNhOGM0ZDA2MTBlZWFlYzA1NS90YWJsZTpmNDk3NzkwZGVkZGE0NWY4YTMzMzQ0M2UwNWNlODA5OS90YWJsZXJhbmdlOmY0OTc3OTBkZWRkYTQ1ZjhhMzMzNDQzZTA1Y2U4MDk5XzMtMC0xLTEtMTA5NjE4L3RleHRyZWdpb246OTNhZGNlMGIwMjc2NDQ4NDhmM2JmZWMxNzc2MTkyZGNfNjI_2198439d-ed9d-4b08-b8b7-8184eb413442">3240</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNDQvZnJhZzplNmYwMjQwOTlkZWY0NzYwOTRjMmM4N2EwMTI2OTI2NC90ZXh0cmVnaW9uOmU2ZjAyNDA5OWRlZjQ3NjA5NGMyYzg3YTAxMjY5MjY0XzUzMTE_f0ebfbea-85be-481f-b60e-55ee2c522ef0">KPMG AG</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNDQvZnJhZzplNmYwMjQwOTlkZWY0NzYwOTRjMmM4N2EwMTI2OTI2NC90ZXh0cmVnaW9uOmU2ZjAyNDA5OWRlZjQ3NjA5NGMyYzg3YTAxMjY5MjY0XzUzMTM_9b9942c2-dcc3-4270-b03e-09d6a1b5b301">Zurich, Switzerland</dei:AuditorLocation>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMtNC0xLTEtMTA5NjE4_80821b77-b0f9-4330-b5da-e1cc4fec2436"
      unitRef="chf">7235000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMtNy0xLTEtMTA5NjE4_cdbffc23-4a7e-4bc6-af91-560d66671ca0"
      unitRef="chf">8146000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzQtNC0xLTEtMTA5NjE4_bcb9aa44-a4a2-41a6-9577-d5b449b8ee0e"
      unitRef="chf">271000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzQtNy0xLTEtMTA5NjE4_0f076513-58aa-428a-ad33-e2cb4f01b645"
      unitRef="chf">331000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzUtNC0xLTEtMTA5NjE4_dc9015d5-1690-4477-8721-2d3c69ec6e80"
      unitRef="chf">7506000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzUtNy0xLTEtMTA5NjE4_0cf17505-402d-49c7-809e-eaee6585a17e"
      unitRef="chf">8477000</ifrs-full:NoncurrentAssets>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzctNC0xLTEtMTA5NjE4_1f5494c4-fafa-4367-9175-d8a0a8b174cf"
      unitRef="chf">161198000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzctNy0xLTEtMTA5NjE4_4cacc76d-f1e6-4187-bcb2-1cb84c0dab56"
      unitRef="chf">61000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:OtherCurrentAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzgtNC0xLTEtMTA5NjE4_ae13e406-f8f2-4027-8c7e-455c3488ef70"
      unitRef="chf">4589000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzgtNy0xLTEtMTA5NjE4_a6a777fc-bb05-4772-a08b-eb60cdab91e8"
      unitRef="chf">5728000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzktNC0xLTEtMTA5NjE4_ac584565-1f2d-47f0-a848-2dd5b3988acf"
      unitRef="chf">1019000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzktNy0xLTEtMTA5NjE4_70b1f396-8452-42ad-ad00-9b41cb764abd"
      unitRef="chf">25650000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEwLTQtMS0xLTEwOTYxOA_639d63de-cd06-47e9-a3b9-441b54ce9bc6"
      unitRef="chf">87946000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEwLTctMS0xLTEwOTYxOA_4134f6bd-fff8-434b-a9c4-276bc8873978"
      unitRef="chf">71813000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzExLTQtMS0xLTEwOTYxOA_e8d95164-9684-4d5b-bd13-c48168c7b515"
      unitRef="chf">254752000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzExLTctMS0xLTEwOTYxOA_e02b3723-4ebe-4582-9c35-cec481625fa3"
      unitRef="chf">164191000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEzLTQtMS0xLTEwOTYxOA_996f710b-d494-4c6c-950f-5957131bef10"
      unitRef="chf">262258000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzEzLTctMS0xLTEwOTYxOA_4a20bdf0-4085-4422-9171-7ebaaf54751a"
      unitRef="chf">172668000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE2LTQtMS0xLTEwOTYxOA_0f05f07f-c676-4da5-bda7-5f827dde2bfb"
      unitRef="chf">3604000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE2LTctMS0xLTEwOTYxOA_f27bb330-15b4-4f1d-9da1-6b254d0a665a"
      unitRef="chf">3229000</ifrs-full:IssuedCapital>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE3LTQtMS0xLTEwOTYxOA_c9c90f6c-e7fe-4c17-a0c5-9915b9bedc0e"
      unitRef="chf">360323000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE3LTctMS0xLTEwOTYxOA_87ae71b7-cc7e-4a8f-992d-0dc98831a2b8"
      unitRef="chf">355010000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:TreasuryShares
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTQtMS0xLTExMjQ5Ng_15c8f3fb-8ddb-44f0-9423-2b90799e0e01"
      unitRef="chf">981000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTctMS0xLTExMjQ5OQ_864b9785-7266-4783-82c6-dd68f6f9ec30"
      unitRef="chf">0</ifrs-full:TreasuryShares>
    <ifrs-full:RetainedEarnings
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTQtMS0xLTEwOTYxOA_d6f52072-f95a-47aa-85c4-6933e4d4c418"
      unitRef="chf">-127780000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE4LTctMS0xLTEwOTYxOA_b9d7b17f-632e-4a16-a5d5-6c6fe260e14e"
      unitRef="chf">-250950000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE5LTQtMS0xLTEwOTYxOA_6b588273-6090-4f0c-877d-472392c08805"
      unitRef="chf">235166000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzE5LTctMS0xLTEwOTYxOA_df8d5891-6860-438a-bcf1-09e8675469d1"
      unitRef="chf">107289000</ifrs-full:Equity>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIxLTQtMS0xLTEwOTYxOA_40a3d5d9-38bb-4e8b-9897-2e3a19dc1f30"
      unitRef="chf">3637000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIxLTctMS0xLTEwOTYxOA_bbbb5c48-9958-4ae0-b425-e51b33a75037"
      unitRef="chf">6925000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIyLTQtMS0xLTEwOTYxOA_86449c35-c370-477c-9def-537172ec2418"
      unitRef="chf">3652000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIyLTctMS0xLTEwOTYxOA_a771a6c8-07f6-43d2-9251-0d1bd35bc1a6"
      unitRef="chf">4850000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIzLTQtMS0xLTEwOTYxOA_09465c86-3d6e-4736-9715-0a8a24822dd7"
      unitRef="chf">2552000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzIzLTctMS0xLTEwOTYxOA_a85571b8-ad2e-4b68-acca-3b78d9140068"
      unitRef="chf">6739000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI0LTQtMS0xLTEwOTYxOA_2962e55a-2fbb-4842-b299-6db16136b274"
      unitRef="chf">9841000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI0LTctMS0xLTEwOTYxOA_595f6eb4-2afe-451e-8c93-b002360c4077"
      unitRef="chf">18514000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI2LTQtMS0xLTEwOTYxOA_d60e9c21-8a58-45d8-9b5e-a5dcb51b2e3d"
      unitRef="chf">2143000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI2LTctMS0xLTEwOTYxOA_1f731b2d-e95b-4e3a-8aa1-13c44b1bbfb9"
      unitRef="chf">7389000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI3LTQtMS0xLTEwOTYxOA_f2874694-979e-481b-b120-2baeab0177c7"
      unitRef="chf">7501000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI3LTctMS0xLTEwOTYxOA_dec0e40a-3cf9-4c5c-aa0c-49a20bc63b5e"
      unitRef="chf">9975000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI4LTQtMS0xLTEwOTYxOA_e12f3f24-11cb-4f83-9de3-c51ab8ca280d"
      unitRef="chf">6409000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI4LTctMS0xLTEwOTYxOA_7a321736-5c29-4c4e-b21e-8d1b3e7bfac7"
      unitRef="chf">28312000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI5LTQtMS0xLTEwOTYxOA_e5e0759e-108e-4ce9-b595-25412bb754ac"
      unitRef="chf">1198000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzI5LTctMS0xLTEwOTYxOA_151e54f6-b62d-4163-9715-402b12e7a6bb"
      unitRef="chf">1189000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMwLTQtMS0xLTEwOTYxOA_a56d3a9b-b479-4b90-92eb-73157d721fff"
      unitRef="chf">17251000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMwLTctMS0xLTEwOTYxOA_510b5b6f-3214-4024-abe7-2afa3314b556"
      unitRef="chf">46865000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMxLTQtMS0xLTEwOTYxOA_4cfbce7b-64c2-4e3d-b00b-e8f2b2f025d7"
      unitRef="chf">27092000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMxLTctMS0xLTEwOTYxOA_b3f71b34-ebba-4fb6-9b02-0ce767c3b90c"
      unitRef="chf">65379000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMzLTQtMS0xLTEwOTYxOA_2afbfb54-0d0e-4ddd-9fbd-82e2bc498973"
      unitRef="chf">262258000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTAvZnJhZzpmZWE3OGY4ODc3YTg0NWJhYWRlZTI4MjdjNDhlN2FlZi90YWJsZTphOTJjNDM1ZWY3Yzc0ZmNhYjc3MzEzMGU4ZTM2MmIwZi90YWJsZXJhbmdlOmE5MmM0MzVlZjdjNzRmY2FiNzczMTMwZThlMzYyYjBmXzMzLTctMS0xLTEwOTYxOA_91020095-323b-474f-8390-cd3d090db543"
      unitRef="chf">172668000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzQtNC0xLTEtMTA5NjE4_e3baf974-0ec2-4a8a-a7e3-f4e1fce7f5a9"
      unitRef="chf">189556000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzQtNy0xLTEtMTA5NjE4_7a1edd25-c974-4cf7-8b3e-f8e472612ef0"
      unitRef="chf">9330000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzQtMTAtMS0xLTEwOTYxOA_37438ba3-95c8-4ce8-af59-4cfb5899cd10"
      unitRef="chf">9344000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:OtherIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzUtNC0xLTEtMTA5NjE4_006dc753-b00b-4134-8326-d7426d11a401"
      unitRef="chf">44000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzUtNy0xLTEtMTA5NjE4_155eef06-cb43-4077-a984-fb71dab10cbc"
      unitRef="chf">424000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzUtMTAtMS0xLTEwOTYxOA_0f7db0a0-e3db-47ab-b691-628949e354cc"
      unitRef="chf">0</ifrs-full:OtherIncome>
    <ifrs-full:Revenue
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzYtNC0xLTEtMTA5NjE4_7234358f-1dab-43dd-a4de-1a6eac544c46"
      unitRef="chf">189600000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzYtNy0xLTEtMTA5NjE4_12e07976-f641-44cb-99ba-3515abbe7a02"
      unitRef="chf">9754000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzYtMTAtMS0xLTEwOTYxOA_8b1a861d-a89d-4aa5-8f90-0a2dc5bd6892"
      unitRef="chf">9344000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzktNC0xLTEtMTA5NjE4_a05f88f0-0f0b-48fa-b25a-8bf1b6def125"
      unitRef="chf">50749000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzktNy0xLTEtMTA5NjE4_940305fc-640d-43a4-84dc-d49c39a41fa2"
      unitRef="chf">55718000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzktMTAtMS0xLTEwOTYxOA_920f372d-d3c4-4984-8d29-16e58cf18b2d"
      unitRef="chf">56075000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEwLTQtMS0xLTEwOTYxOA_4bad8fb3-3a4c-4eb2-9f9b-5fbcd829d028"
      unitRef="chf">22238000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEwLTctMS0xLTEwOTYxOA_74b040e1-d5e9-4e78-a522-e8a0202557de"
      unitRef="chf">17454000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEwLTEwLTEtMS0xMDk2MTg_59898afa-1eab-4db3-a832-532069b77fb1"
      unitRef="chf">11595000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzExLTQtMS0xLTEwOTYxOA_8e7231ae-b412-4866-98e7-0d9403c7d10e"
      unitRef="chf">72987000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzExLTctMS0xLTEwOTYxOA_6b09888b-8979-411a-9c0a-bcddb95500a3"
      unitRef="chf">73172000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzExLTEwLTEtMS0xMDk2MTg_0ff4a6f1-7d82-4285-8f8a-a905a49dde3f"
      unitRef="chf">67670000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEzLTQtMS0xLTEwOTYxOA_eb3f4cfb-f74f-41ae-b46e-8675c3cf2444"
      unitRef="chf">116613000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEzLTctMS0xLTEwOTYxOA_4d24e67f-c048-460d-bad2-66768d2614c0"
      unitRef="chf">-63418000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzEzLTEwLTEtMS0xMDk2MTg_e9a2187e-c8f3-4a2e-abf2-a87252140857"
      unitRef="chf">-58326000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE1LTQtMS0xLTEwOTYxOA_2a18b2ca-3ffb-4e19-97d4-47af686c2b83"
      unitRef="chf">1859000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE1LTctMS0xLTEwOTYxOA_bc49e657-ed9f-490e-8df5-438d127fbbb3"
      unitRef="chf">191000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE1LTEwLTEtMS0xMDk2MTg_3e3615fc-0164-4eb9-a36a-673b626eadb8"
      unitRef="chf">367000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE2LTQtMS0xLTEwOTYxOA_e0a91baf-1528-4091-8671-7a19fb08f2c9"
      unitRef="chf">619000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE2LTctMS0xLTEwOTYxOA_dc9ffb33-ff01-4be2-83a0-3a3d9015a0e7"
      unitRef="chf">556000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE2LTEwLTEtMS0xMDk2MTg_477a320c-5838-4ac3-ba30-0d685f3e8416"
      unitRef="chf">4816000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE3LTQtMS0xLTEwOTYxOA_3c7f77b8-36d2-446e-a75e-3260b04a272d"
      unitRef="chf">1240000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE3LTctMS0xLTEwOTYxOA_0e239acf-dbda-40f4-b912-50cf371fa107"
      unitRef="chf">-365000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE3LTEwLTEtMS0xMDk2MTg_96114c03-c75e-4310-95d9-d41c58fee5d4"
      unitRef="chf">-4449000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE5LTQtMS0xLTEwOTYxOA_a99be057-50ad-41ca-982d-0af3b6b474e3"
      unitRef="chf">117853000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE5LTctMS0xLTEwOTYxOA_8ab0f1c6-7377-453b-bd05-cc8bb3a90b99"
      unitRef="chf">-63783000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzE5LTEwLTEtMS0xMDk2MTg_d9ff90ee-49b3-43be-8cef-3ab4b48feb41"
      unitRef="chf">-62775000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIxLTQtMS0xLTEwOTYxOA_617e3e00-bd85-4f8c-accc-81c39a8f593d"
      unitRef="chf">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIxLTctMS0xLTEwOTYxOA_52005751-4bdb-4a71-b6a1-2e35a3f88156"
      unitRef="chf">2000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIxLTEwLTEtMS0xMDk2MTg_1dc0a622-2571-4f8b-a2d3-6fd8239d0c2e"
      unitRef="chf">-11000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIyLTQtMS0xLTEwOTYxOA_e8d94d38-c465-42eb-8305-440dbca3c061"
      unitRef="chf">117853000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIyLTctMS0xLTEwOTYxOA_15d320bc-5c4f-45e7-ba68-5443949e3f03"
      unitRef="chf">-63785000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzIyLTEwLTEtMS0xMDk2MTg_5f474f53-da44-44c2-bad7-91523c9866b0"
      unitRef="chf">-62764000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzI3LTQtMS0xLTEwOTYxOA_54638c24-280c-485a-864f-c4f5247cac07"
      unitRef="chf">5334000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzI3LTctMS0xLTEwOTYxOA_bec696fd-2663-4f14-8352-77eb78309156"
      unitRef="chf">8012000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzI3LTEwLTEtMS0xMDk2MTg_52dfd530-d33b-4a39-a785-bdaba2352f38"
      unitRef="chf">-1514000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMwLTQtMS0xLTEwOTYxOA_4b35fec1-d700-45bd-8eca-70939eb9d373"
      unitRef="chf">-17000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMwLTctMS0xLTEwOTYxOA_08dea2dc-2ac6-402c-8358-c76b6954a372"
      unitRef="chf">-3000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMwLTEwLTEtMS0xMDk2MTg_451b0a8b-c309-4f97-b527-c445a3bed032"
      unitRef="chf">-26000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMyLTQtMS0xLTEwOTYxOA_37e8bd2c-14bd-4768-966d-815dbe034e24"
      unitRef="chf">5317000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMyLTctMS0xLTEwOTYxOA_e485f48d-8892-4b3c-9aa7-7c1658483765"
      unitRef="chf">8009000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzMyLTEwLTEtMS0xMDk2MTg_e1876538-e017-433e-8cc9-53e32993a968"
      unitRef="chf">-1540000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM0LTQtMS0xLTEwOTYxOA_13eb5fa5-00f8-4552-8949-22127888f38a"
      unitRef="chf">123170000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM0LTctMS0xLTEwOTYxOA_c3c0caf6-c6d3-49e2-8c52-cd2ea4e31a02"
      unitRef="chf">-55776000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM0LTEwLTEtMS0xMDk2MTg_f178e19d-0d2d-4f9b-b50e-a77eeebe91e8"
      unitRef="chf">-64304000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM2LTQtMS0xLTEwOTYxOA_bdb586b1-c688-46bc-b471-e9af7f8d5fbc"
      unitRef="chfPerShare">3.63</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM2LTctMS0xLTEwOTYxOA_56ab0a8c-ebbf-493e-b40b-4a21ab64ec00"
      unitRef="chfPerShare">-2.06</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM2LTEwLTEtMS0xMDk2MTg_d066d430-e9f3-49e8-822d-1debf7cbf253"
      unitRef="chfPerShare">-2.51</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM3LTQtMS0xLTExMjUwOQ_421fae4b-d41a-44aa-b7cb-b8e934b238d1"
      unitRef="chfPerShare">3.54</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM3LTctMS0xLTExMjUxMg_0e6564db-4cf3-4e92-bce9-a7368b239eed"
      unitRef="chfPerShare">-2.06</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTMvZnJhZzozNWI5NmUwZjIyMTU0NmZmYTgxZGZhMDUyYTE1ZmY2NC90YWJsZTpjMjg1MzM3OGYwY2I0ZGRjYWM5MmExYWYwMjY4NTcwOS90YWJsZXJhbmdlOmMyODUzMzc4ZjBjYjRkZGNhYzkyYTFhZjAyNjg1NzA5XzM3LTEwLTEtMS0xMTI1MTU_70e58c45-4793-43da-a2e6-86407031f348"
      unitRef="chfPerShare">-2.51</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMtNC0xLTEtMTA5NjE4_4305ccae-2789-4868-8d9b-2de8ca44bea9"
      unitRef="chf">117853000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMtNy0xLTEtMTA5NjE4_de58d8eb-94f3-4469-815c-273a5c9340d0"
      unitRef="chf">-63785000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMtMTAtMS0xLTEwOTYxOA_403685cd-414f-4032-a59e-7082462844c7"
      unitRef="chf">-62764000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzUtNC0xLTEtMTA5NjE4_603103db-84ff-46a5-932a-b52ff613d364"
      unitRef="chf">2388000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzUtNy0xLTEtMTA5NjE4_2cc454b7-9175-451c-9413-e9e213d35a67"
      unitRef="chf">2565000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzUtMTAtMS0xLTEwOTYxOA_5eecc022-d6ec-45a1-82da-bf37260adcdf"
      unitRef="chf">2887000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzYtNC0xLTEtMTA5NjE4_d551a3fe-4b77-416f-952e-1c9e6ee2e870"
      unitRef="chf">5088000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzYtNy0xLTEtMTA5NjE4_64c8abc0-0f6f-4044-ae8b-14727775a866"
      unitRef="chf">4085000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzYtMTAtMS0xLTEwOTYxOA_221fdf25-14a8-48c5-8a62-88d9ae93e23a"
      unitRef="chf">2932000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzctNC0xLTEtMTA5NjE4_a0571fb8-25d2-40fa-9c1c-b46140171f19"
      unitRef="chf">1147000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzctNy0xLTEtMTA5NjE4_2d723ee9-a101-438c-b4f5-c81ba0f82edd"
      unitRef="chf">1073000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzctMTAtMS0xLTEwOTYxOA_dfe37a4e-fd45-46d3-9380-ec76c44ac5c6"
      unitRef="chf">1268000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzgtNC0xLTEtMTA5NjE4_096b202a-af88-4705-8bf8-56970c08bc4d"
      unitRef="chf">0</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzgtNy0xLTEtMTA5NjE4_f5fcf05a-6c1c-400f-b07b-35085b49da4d"
      unitRef="chf">2000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzgtMTAtMS0xLTEwOTYxOA_fad74f4c-7142-4e82-bc43-7f4d2d261dab"
      unitRef="chf">-11000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzktNC0xLTEtMTA5NjE4_58376ee6-0e2a-4ab8-a334-f410718ece9e"
      unitRef="chf">1859000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzktNy0xLTEtMTA5NjE4_7e71f6dc-0c02-4f11-a371-891e9b88d345"
      unitRef="chf">191000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzktMTAtMS0xLTEwOTYxOA_0cb327d2-d0b9-4430-8bca-73a119cd990b"
      unitRef="chf">367000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEwLTQtMS0xLTEwOTYxOA_d6de0e83-2dac-4ea4-afb4-2b042d7b8b8a"
      unitRef="chf">619000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEwLTctMS0xLTEwOTYxOA_4016e562-09a5-4f08-8bcc-116aa8ad3c84"
      unitRef="chf">556000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEwLTEwLTEtMS0xMDk2MTg_9a3372c2-ef2a-49da-89b5-d1519f6c512f"
      unitRef="chf">4816000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEyLTQtMS0xLTEwOTYxOA_90c233dc-7c41-43fa-ab54-0e5913504423"
      unitRef="chf">1787000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEyLTctMS0xLTEwOTYxOA_43056218-71cd-4e87-9ee0-39fca48cdc01"
      unitRef="chf">-4445000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEyLTEwLTEtMS0xMDk2MTg_d1110e58-0dfe-4e86-a7da-31b187507bc1"
      unitRef="chf">1040000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEzLTQtMS0xLTEwOTYxOA_02218164-3607-4826-b9d1-cb856ec5927f"
      unitRef="chf">25264000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEzLTctMS0xLTEwOTYxOA_99b9e14d-cf7f-4faf-94ba-a0f63104a58e"
      unitRef="chf">-23374000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzEzLTEwLTEtMS0xMDk2MTg_61be0e1c-5755-42e7-bd5b-0a2eb11769a4"
      unitRef="chf">-552000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE0LTQtMS0xLTEwOTYxOA_b2545eda-7e5f-46d5-903f-d066c01a07f9"
      unitRef="chf">-5339000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE0LTctMS0xLTEwOTYxOA_87021b82-207e-466d-94ef-2e4605b3b301"
      unitRef="chf">1656000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE0LTEwLTEtMS0xMDk2MTg_8201d7c6-50c4-4730-9172-f4d8919b4560"
      unitRef="chf">3395000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE1LTQtMS0xLTEwOTYxOA_e27a0ec4-d5ab-4d5c-98e2-b9dad1225a52"
      unitRef="chf">-25190000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE1LTctMS0xLTEwOTYxOA_6dd9e4ba-5ca6-4c28-aa70-027777f75296"
      unitRef="chf">-10651000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE1LTEwLTEtMS0xMDk2MTg_a4492a1b-19ed-4f6c-ab69-519591a15081"
      unitRef="chf">17560000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE2LTQtMS0xLTEwOTYxOA_2733d90d-c012-4f62-97ac-2ea2f30c98bd"
      unitRef="chf">-2434000</moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
    <moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE2LTctMS0xLTEwOTYxOA_1ebeb90d-36c6-4963-8c22-af1a58f61f75"
      unitRef="chf">2290000</moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
    <moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE2LTEwLTEtMS0xMDk2MTg_47575849-984c-4da7-9e3a-bc4e22250ae3"
      unitRef="chf">1037000</moln:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
    <moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE3LTQtMS0xLTEwOTYxOA_eb5f9d85-2fbf-4790-b872-561ae784225a"
      unitRef="chf">98000</moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions>
    <moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE3LTctMS0xLTEwOTYxOA_f3389e2b-a2c4-49e3-9912-b83c3e1d34f6"
      unitRef="chf">144000</moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions>
    <moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE3LTEwLTEtMS0xMDk2MTg_d93c2be7-8c2a-49f3-8dc8-333bf505e6ee"
      unitRef="chf">-6000</moln:AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE4LTQtMS0xLTEwOTYxOA_6ece472e-e343-4454-bf39-b032bfa9a840"
      unitRef="chf">646000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE4LTctMS0xLTEwOTYxOA_3e2fd3d1-9199-4720-82d4-3b45ebe64512"
      unitRef="chf">583000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE4LTEwLTEtMS0xMDk2MTg_f14f7a37-02e8-401e-b68a-ce8f5793ed1f"
      unitRef="chf">219000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE5LTQtMS0xLTEwOTYxOA_f1cca18b-b988-46bc-be2d-64506ccebc10"
      unitRef="chf">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE5LTctMS0xLTEwOTYxOA_31434e16-27d8-40e8-8560-e47c37e28d9b"
      unitRef="chf">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzE5LTEwLTEtMS0xMDk2MTg_9133ec17-370a-4d4f-84f5-bfa6815cb382"
      unitRef="chf">2000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIwLTQtMS0xLTEwOTYxOA_8e3fb290-f608-4d50-ae92-e9e569247467"
      unitRef="chf">-14000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIwLTctMS0xLTEwOTYxOA_d42dbfe4-7bb8-4957-ac8b-65433982ed55"
      unitRef="chf">-8000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIwLTEwLTEtMS0xMDk2MTg_f8e629eb-eefd-4352-aa8a-1779114230d8"
      unitRef="chf">-9000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIxLTQtMS0xLTEwOTYxOA_066c0623-66a3-46ac-88ca-3ac83dc55c3c"
      unitRef="chf">118566000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIxLTctMS0xLTEwOTYxOA_b6995ee5-2a22-4f11-8187-b5b750f1d51c"
      unitRef="chf">-90953000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIxLTEwLTEtMS0xMDk2MTg_fe78dc5a-449c-4220-83c4-513be85f8bbe"
      unitRef="chf">-28983000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIzLTQtMS0xLTEwOTYxOA_7ee61164-50b0-4cec-8928-1c12ae0d8e81"
      unitRef="chf">199219000</moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities>
    <moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIzLTctMS0xLTEwOTYxOA_a117daaf-6a93-4bb7-9227-b68320c7812b"
      unitRef="chf">67876000</moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities>
    <moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzIzLTEwLTEtMS0xMDk2MTg_d5b575ed-4d75-4ff1-8eb0-e9c5cb38efc9"
      unitRef="chf">52765000</moln:ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities>
    <moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI0LTQtMS0xLTEwOTYxOA_40517ae5-0137-430d-958d-973b51bac31e"
      unitRef="chf">299417000</moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities>
    <moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI0LTctMS0xLTEwOTYxOA_ead651ae-0290-48cf-a19c-232f2cd3ebf6"
      unitRef="chf">88876000</moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities>
    <moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI0LTEwLTEtMS0xMDk2MTg_0b4a0353-27d6-4bfa-b5d0-05709e981ac7"
      unitRef="chf">73397000</moln:PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI1LTQtMS0xLTEwOTYxOA_2ea5cf33-fa45-44d5-a09e-7e673555719b"
      unitRef="chf">1177000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI1LTctMS0xLTEwOTYxOA_c5bf64cf-4a92-41f5-b749-ca9bb001d58e"
      unitRef="chf">933000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI1LTEwLTEtMS0xMDk2MTg_c14a7d3e-ffa3-42f1-b07c-53a2fb4a2a3e"
      unitRef="chf">1451000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI2LTQtMS0xLTEwOTYxOA_2fa3574f-a46a-4059-82df-76dbecdc1a86"
      unitRef="chf">240000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI2LTctMS0xLTEwOTYxOA_28d5d7ed-65cb-432f-b58b-0370e6f8cd6e"
      unitRef="chf">374000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI2LTEwLTEtMS0xMDk2MTg_3daacfb7-8b50-40e5-bd27-ffb27a762cda"
      unitRef="chf">232000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI3LTQtMS0xLTEwOTYxOA_186bc2a7-5c7f-47e7-b12a-19dd434fc641"
      unitRef="chf">494000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI3LTctMS0xLTEwOTYxOA_be049d3a-0021-4b7e-903e-1df8e99d11b1"
      unitRef="chf">70000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI3LTEwLTEtMS0xMDk2MTg_1c1f33e6-8773-459a-ac1d-d15954cc7f87"
      unitRef="chf">569000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI4LTQtMS0xLTEwOTYxOA_b33b117e-4bfa-4654-bf5f-8a29c978b6a1"
      unitRef="chf">-101121000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI4LTctMS0xLTEwOTYxOA_d1fc9f2a-54b2-4e39-92e2-ec69e4386766"
      unitRef="chf">-22237000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzI4LTEwLTEtMS0xMDk2MTg_0ccf2923-2dee-4d5c-8540-c7e516fb1a17"
      unitRef="chf">-21746000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMwLTQtMS0xLTEwOTYxOA_9b9ce15b-7805-417d-b6ea-803674e8f7e4"
      unitRef="chf">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMwLTctMS0xLTEwOTYxOA_b6ed4673-bd4b-429b-af6e-8f8d78221c89"
      unitRef="chf">51493000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMwLTEwLTEtMS0xMDk2MTg_00a3ddbf-56c0-440d-83b5-62bf7478bc1e"
      unitRef="chf">113613000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTQtMS0xLTExMjUyNQ_37c3bcff-e576-4a37-9aec-9c5473e4d0c3"
      unitRef="chf">631000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTctMS0xLTExMjUyOA_1f76d408-cc32-4d59-a793-0f9e68f17726"
      unitRef="chf">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTEwLTEtMS0xMTI1MzE_7f5d73bc-e472-4ca0-a16e-d044238bf4d2"
      unitRef="chf">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTQtMS0xLTEwOTYxOA_e09cdf70-30b7-48ed-891d-4f26824cac2f"
      unitRef="chf">250000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTctMS0xLTEwOTYxOA_3b9f859f-c18e-45da-9cb3-905f51295ce7"
      unitRef="chf">267000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMxLTEwLTEtMS0xMDk2MTg_e20c6f94-41b8-4831-bd54-3c31cf0eb7d6"
      unitRef="chf">840000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMyLTQtMS0xLTEwOTYxOA_9070e256-b243-43bb-9969-f4db4532ca32"
      unitRef="chf">1189000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMyLTctMS0xLTEwOTYxOA_eb89a0d8-17ad-4c4c-9a80-9962cadc631d"
      unitRef="chf">1179000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMyLTEwLTEtMS0xMDk2MTg_1ddf5a28-f17e-49af-9a35-39a791730374"
      unitRef="chf">1251000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMzLTQtMS0xLTEwOTYxOA_fc976e86-5d75-451d-b283-9975dbf01ee4"
      unitRef="chf">-1570000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMzLTctMS0xLTEwOTYxOA_b792012e-ed44-425d-a26b-21512ca34759"
      unitRef="chf">50581000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzMzLTEwLTEtMS0xMDk2MTg_4ebd997b-66af-487a-8c68-cc86af5212f5"
      unitRef="chf">113202000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM1LTQtMS0xLTEwOTYxOA_333fcb5f-b4cc-4825-b237-4cbf8b9b7786"
      unitRef="chf">258000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM1LTctMS0xLTEwOTYxOA_780a09c2-7b78-4440-8d52-44e95e85b4e2"
      unitRef="chf">701000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM1LTEwLTEtMS0xMDk2MTg_d6bb726d-aaa1-41e2-b630-8b4f820a6383"
      unitRef="chf">-4464000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM2LTQtMS0xLTEwOTYxOA_536f47ae-ed3c-4085-95e2-7e21a9eabb52"
      unitRef="chf">16133000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM2LTctMS0xLTEwOTYxOA_e4e8d8db-faca-4c89-94c0-edacb28c3091"
      unitRef="chf">-61907000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM2LTEwLTEtMS0xMDk2MTg_2f27d838-ebb7-49a1-8497-a23bf47446c6"
      unitRef="chf">58009000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM4LTQtMS0xLTEwOTYxOA_d0793833-f878-4f05-9326-c3d562bfc63f"
      unitRef="chf">71813000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM4LTctMS0xLTEwOTYxOA_87981db1-9f27-430f-9fd5-53bc3e255c8d"
      unitRef="chf">133721000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzM4LTEwLTEtMS0xMDk2MTg_c91ed266-311c-4c17-b6b6-ce2b1b10c569"
      unitRef="chf">75712000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzQwLTQtMS0xLTEwOTYxOA_8c7108d9-bf3b-45a1-bd84-330e405f9896"
      unitRef="chf">87946000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzQwLTctMS0xLTEwOTYxOA_9a3f4d00-1994-4827-8473-aa26aa2ba404"
      unitRef="chf">71813000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTYvZnJhZzowZDQ2MzhkY2MyYjQ0Y2Y1ODJjNDZjZDFkNmVkN2VkOC90YWJsZTo3ZGY0NjhlM2JhY2M0NjA2OTBhNmEwYTEzYTNjODhkOS90YWJsZXJhbmdlOjdkZjQ2OGUzYmFjYzQ2MDY5MGE2YTBhMTNhM2M4OGQ5XzQwLTEwLTEtMS0xMDk2MTg_8d5a33d9-ef06-484c-8a4a-63eaac8fe867"
      unitRef="chf">133721000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity
      contextRef="ia354966cf31e42aaaa6b703a60e1341a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItMS0xLTEtMTA5NjE4_409bb373-26a2-485f-94f5-e597300da200"
      unitRef="chf">2160000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i8af2f1be9ad44d51b81ad6f3e39f3917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItNC0xLTEtMTA5NjE4_77e511b1-66d4-4ca5-b81c-eaf723ee266d"
      unitRef="chf">182849000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i0ec7c73caeed425b977de2350cb9e35d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItNy0xLTEtMTA5NjE4_b4668b67-be56-4a86-9325-60265428d99c"
      unitRef="chf">-130870000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzItMTAtMS0xLTEwOTYxOA_0591dc2c-ab31-4bc6-a58c-e4225a5a86d0"
      unitRef="chf">54139000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzMtNy0xLTEtMTA5NjE4_59eedfff-e627-44a1-90ad-19ea66989635"
      unitRef="chf">-62764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzMtMTAtMS0xLTEwOTYxOA_fe07bb36-1430-48a1-9dfe-96b968cf9748"
      unitRef="chf">-62764000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtNy0xLTEtMTA5NjE4_b7151253-29da-4569-86f9-977d9f4426c9"
      unitRef="chf">-1514000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtMTAtMS0xLTEwOTYxOA_0ac734fe-7da4-46b8-a08a-45fa65d58b36"
      unitRef="chf">-1514000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzUtNy0xLTEtMTA5NjE4_d305efb4-6853-4429-a6b7-94d14890cbb4"
      unitRef="chf">-26000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzUtMTAtMS0xLTEwOTYxOA_091b54d8-66fb-4164-9f8c-1c5bfdaa5be7"
      unitRef="chf">-26000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="ic8cd3aa0747447e291a096b54c7459c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzYtNy0xLTEtMTA5NjE4_999902db-a300-409c-b0b7-a6043e815001"
      unitRef="chf">-64304000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzYtMTAtMS0xLTEwOTYxOA_9b1a2388-c99f-41fc-8c6c-c8815987b533"
      unitRef="chf">-64304000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="id66ad877b195477caaa63da51066504e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctNC0xLTEtMTA5NjE4_a97d247c-d856-4e0f-892e-d1533f366f60"
      unitRef="chf">2932000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctMTAtMS0xLTEwOTYxOA_81e9a3f8-57df-4400-8006-52fd92ab8808"
      unitRef="chf">2932000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="i6dc9a065301142489cf73ad6591f13da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTEyNjA3_af072b3f-1e50-41b8-b6b8-cbf670de7fcf"
      unitRef="chf">727000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="id66ad877b195477caaa63da51066504e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTEyNjEz_ed0190b7-f838-444c-ad0f-70993d1b3c88"
      unitRef="chf">112886000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTMtMS0xLTExMjYxOQ_e38e3c45-1c18-46c4-be93-cd9e2b526228"
      unitRef="chf">113613000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i6dc9a065301142489cf73ad6591f13da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTA5NjE4_b6b1c5dd-2641-4163-8598-f315946fdfca"
      unitRef="chf">28000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="id66ad877b195477caaa63da51066504e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTA5NjE4_7379f947-28f2-4610-af08-490f855bfdf0"
      unitRef="chf">812000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTAtMS0xLTEwOTYxOA_4c6651d5-7f01-43c4-9e46-404640a69305"
      unitRef="chf">840000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:Equity
      contextRef="i5cc7f91b995e4a8e8339b8aec0df0032_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktMS0xLTEtMTA5NjE4_df743f3d-951e-4c25-9052-d9d0987de894"
      unitRef="chf">2915000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="id00f48490e1649a289d5d3945dc00e92_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktNC0xLTEtMTA5NjE4_7f5670b7-80ef-4b5c-a8fd-e42b244392a5"
      unitRef="chf">299479000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i535054e5b34d4a6aaeb7b886535df3dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktNy0xLTEtMTA5NjE4_3e54ff40-358c-4ead-bde1-529ac8765dd3"
      unitRef="chf">-195174000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzktMTAtMS0xLTEwOTYxOA_a58dc30c-f86f-4e8b-b84c-1132730d4438"
      unitRef="chf">107220000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEyLTctMS0xLTEwOTYxOA_c05f3ff2-ebaf-489d-b1ff-e95871ed6660"
      unitRef="chf">-63785000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEyLTEwLTEtMS0xMDk2MTg_1844d52c-1365-4895-869d-80edcd534abe"
      unitRef="chf">-63785000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTctMS0xLTEwOTYxOA_3a27d870-a318-403c-ba95-cbcbfffae1a7"
      unitRef="chf">8012000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTEwLTEtMS0xMDk2MTg_7ed81ab2-ad36-4a94-9833-448ac1b7a03b"
      unitRef="chf">8012000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE0LTctMS0xLTEwOTYxOA_09cfad7c-367d-4713-9b21-de40abf4413f"
      unitRef="chf">-3000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE0LTEwLTEtMS0xMDk2MTg_bcaadd9b-2409-4b6e-af96-0cbfa6e8750f"
      unitRef="chf">-3000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="i79617737b6da422193eaa5e52fe6dc2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE1LTctMS0xLTEwOTYxOA_c09f1c2e-ac3f-4e25-b55a-1274e50da75e"
      unitRef="chf">-55776000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE1LTEwLTEtMS0xMDk2MTg_5635ab28-5ee7-4ee3-8bf9-baa5cb7949c3"
      unitRef="chf">-55776000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTQtMS0xLTEwOTYxOA_527836ae-cfb1-442d-8184-b9f6a8fd7dc6"
      unitRef="chf">4085000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTEwLTEtMS0xMDk2MTg_2f807717-1707-4db6-ac76-98e239d570f0"
      unitRef="chf">4085000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="i9fba67aaaf88433581c2a71e67a97f3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEtMS0xLTEwOTYxOA_38d8992f-68f1-42ef-a115-51091c077c82"
      unitRef="chf">300000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTQtMS0xLTEwOTYxOA_202d8e85-7a71-4acd-82de-993522c1a6db"
      unitRef="chf">51193000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEwLTEtMS0xMDk2MTg_8aa88b7e-551f-482d-9c98-dbd1fded96aa"
      unitRef="chf">51493000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i9fba67aaaf88433581c2a71e67a97f3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEtMS0xLTEwOTYxOA_cec4ceeb-2c61-4b37-adb3-ebdce63e799e"
      unitRef="chf">14000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ia78e787fa13840a39b08edd73e533b87_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTQtMS0xLTEwOTYxOA_57613203-4c3d-4e30-a631-9b9fe3296547"
      unitRef="chf">253000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEwLTEtMS0xMDk2MTg_e49fe919-6ca9-47de-ba92-30a2f9e66e7b"
      unitRef="chf">267000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:Equity
      contextRef="i15e5ef472f264809b3c22976835aa54a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTEtMS0xLTEwOTYxOA_74a4480b-6df6-4ba4-9e04-616a6acbf170"
      unitRef="chf">3229000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="iae7e5cc7cd4c4a6ab9342ae37f83b666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTQtMS0xLTEwOTYxOA_7f7bf8d0-2ee5-4547-8cf6-13366eaa1e7d"
      unitRef="chf">355010000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ieeb7fef9acf84e13bae5ef3655a07afa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIwLTctMS0xLTExMjYyNw_c1390445-8f4b-4166-a811-a35b1be90639"
      unitRef="chf">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i35d2bc98f85c42efaf80ceebcbf879d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTctMS0xLTEwOTYxOA_cc89f0f5-a272-45a5-a90c-268ab7ebdbaf"
      unitRef="chf">-250950000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE5LTEwLTEtMS0xMDk2MTg_49b56ac0-2665-4464-8e13-7ffc2d8e3339"
      unitRef="chf">107289000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIyLTctMS0xLTEwOTYxOA_2dbb8a92-9e0c-47a9-98a7-8a4df4b493d3"
      unitRef="chf">117853000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIyLTEwLTEtMS0xMDk2MTg_6081a502-af3e-48c1-bd4f-11700fdffdc0"
      unitRef="chf">117853000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTctMS0xLTEwOTYxOA_118e40e9-7c10-4528-8c2e-3f7aad743281"
      unitRef="chf">5334000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTEwLTEtMS0xMDk2MTg_a87347bb-4fa7-441d-9b78-40752564d044"
      unitRef="chf">5334000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI0LTctMS0xLTEwOTYxOA_deaedea4-e831-4279-94c8-23dc70860b85"
      unitRef="chf">-17000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI0LTEwLTEtMS0xMDk2MTg_802c9ec2-a534-4bce-bc9f-d074e82be74c"
      unitRef="chf">-17000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="ib8593897957647fdb19ea4f4192e2387_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI1LTctMS0xLTEwOTYxOA_2610354a-5464-48ee-94a0-03b095e5858d"
      unitRef="chf">123170000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI1LTEwLTEtMS0xMDk2MTg_cbfa059f-f16d-47ee-a976-fe620005f674"
      unitRef="chf">123170000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i97c02508d8664ebaad3f69a80bf22ab3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTQtMS0xLTEwOTYxOA_2287db37-eedb-4c7e-a09c-1ecd05f3c8d0"
      unitRef="chf">5088000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTEwLTEtMS0xMDk2MTg_6c785a61-4fb9-4251-8527-22403d85ed74"
      unitRef="chf">5088000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="i79a62605a2a64c89a0a34d7bbc035e7d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEtMS0xLTEwOTYxOA_670a7f4f-b6e2-42bd-a261-d268e6320676"
      unitRef="chf">350000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEwLTEtMS0xMDk2MTg_0d64f99b-c9bf-487e-8e5a-831571c9a9d2"
      unitRef="chf">350000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i7c118ee100384a299e971a96bc0a67db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTExMjY2Ng_b52e114c-bb80-4f50-87bc-744a4b0672fd"
      unitRef="chf">-981000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEzLTEtMS0xMTI2NjI_8da5f5ce-3d30-4198-b089-9046a41774a7"
      unitRef="chf">-981000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i79a62605a2a64c89a0a34d7bbc035e7d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEtMS0xLTEwOTYxOA_427e864e-e104-4b8b-968a-31771e944e2d"
      unitRef="chf">25000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i97c02508d8664ebaad3f69a80bf22ab3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTQtMS0xLTEwOTYxOA_3538464b-a523-4092-951d-4e0aed8bea48"
      unitRef="chf">225000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEwLTEtMS0xMDk2MTg_f95e8681-0fd4-427b-9667-19e15823a877"
      unitRef="chf">250000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:Equity
      contextRef="ida1ef664b85047599beb657c0edeb373_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEtMS0xLTEwOTYxOA_0bde11ac-1c1d-4d94-b7a9-933e92f0a740"
      unitRef="chf">3604000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i4c9db8103d514df6aea83be7bdf65bb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTQtMS0xLTEwOTYxOA_9fb73987-902b-4660-add0-a5dae928a80e"
      unitRef="chf">360323000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i4566f4cc772449408ec24a9a58cbf560_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzMwLTctMS0xLTExMjYzMg_e58af3a2-225c-44f1-b11f-bc66dc3658e6"
      unitRef="chf">-981000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i42ec354c9f8f4c9a9d165067d15652b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTEwOTYxOA_4e879f11-0e55-4067-b2f6-4a53f1980a85"
      unitRef="chf">-127780000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEwLTEtMS0xMDk2MTg_c6dc082b-5ebb-4f30-b768-b3ad71a4febe"
      unitRef="chf">235166000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjUvZnJhZzo4MWI4MjBiMGRkMTM0MjhjYWFlMTY3ZjBiZmJjMzQ0Yy90ZXh0cmVnaW9uOjgxYjgyMGIwZGQxMzQyOGNhYWUxNjdmMGJmYmMzNDRjXzY0_bb335957-e042-4040-8b4f-d9894283c9e2">General information&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners AG ("Company") and its subsidiary (collectively "Molecular Partners" or, "Group") is a clinical-stage biopharmaceutical company pioneering designed ankyrin proteins ("DARPin") candidates to treat serious diseases, with a current focus on oncology and virology. DARPins are a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics. The Company was founded on November 22, 2004, and is domiciled at Wagistrasse 14, 8952 Schlieren, Canton of Zurich, Switzerland. It is subject to the provisions of the articles of association and to article 620 et seq. of the Swiss Code of Obligations, which describe the legal requirements for limited companies (&#x201c;Aktiengesellschaften&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners Inc. is a wholly owned subsidiary of Molecular Partners AG. Molecular Partners Inc. was incorporated in the United States in the State of Delaware on October 8, 2018. Molecular Partners Inc. is based in Cambridge, Massachusetts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These audited consolidated financial statements as of and for the year ended December&#160;31, 2022 comprise Molecular Partners AG and Molecular Partners Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s shares are listed on the SIX Swiss Exchange (Ticker: MOLN) since November&#160;5, 2014 and on the Nasdaq Global Select Market (Ticker: MOLN) since June&#160;16, 2021.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2MQ_d8598488-84be-4c3d-bab7-d21343d2436c">Summary of significant accounting policies&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of preparation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the IASB. The accounting policies set forth below have been consistently applied to all years presented. Unless stated otherwise, all financial statements are presented in thousands of Swiss Francs (&#x201c;TCHF&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4 &#x201c;Critical accounting estimates and judgments&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Group's cash position at December&#160;31, 2022, the Group deemed there to be no material uncertainties that would cast doubt on the Group's ability to operate on a going concern basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements as of and for the year ended December&#160;31, 2022 were approved for issuance by the Company's Board of Directors on March&#160;8, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to rounding, the numbers presented in the financial statements might not precisely equal those included in the accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i) Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii) Transactions eliminated on consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;New or revised IFRS standards and interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following new or revised standards that became effective during 2022 did not have a material effect on these consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Onerous Contracts - Costs of fulfilling a contract - amendments to IAS 37&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Annual Improvements to IFRS standards 2018-2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Property, Plant and Equipment: Proceeds before intended use - amendments to IAS 16&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several new or revised standards have been published that are not yet effective and that have not been early adopted. No significant impacts on the Group's consolidated financial statements are expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group operates in one segment, focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The executive management, acting together as the chief operating decision makers, assess the financial performance and allocate resources on an aggregated level, and monitor the Group's operating expenses. Accounting policies applied are the same for both internal and external reporting purposes. The Group derives its research and collaboration revenues from research and development collaborations with third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Foreign currency translation / transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are presented in thousands of CHF. The presentation currency of the Group is the functional currency of the Company. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;assets and liabilities are translated at the closing rate at the date of the respective balance sheet;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;income and expenses for each consolidated statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates at the dates of the transactions); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;all resulting exchange differences are recognized in other comprehensive result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment, Office equipment, IT hardware and Leasehold improvements are stated at historical cost less accumulated depreciation and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful lives are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IT hardware:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements and right-of-use assets are depreciated using the straight line method over the shorter of their estimated useful life and the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent costs are included in each asset&#x2019;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets&#x2019; residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. An asset&#x2019;s carrying amount is written down to its recoverable amount, if the asset's carrying amount exceeds its estimated recoverable amount.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost and accumulated depreciation related to assets retired or otherwise disposed are derecognized at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of retirement or disposal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are solely comprised of software. They are stated at historical cost less accumulated amortization and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Amortization is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful life of intangible assets is determined to be two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, the Group assesses whether a contract is, or contains a lease. This is the case if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets (threshold of CHF 5,000) and short-term leases. Short-term leases are leases with a lease term of twelve months or less that do not contain a purchase option. For all other leases the Group recognizes a right-of-use asset and a lease liability at the lease commencement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. Subsequently the right-of-use asset is depreciated using the straight-line method over the shorter of the asset's useful life and the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments required over the lease term that are not paid at the commencement date, discounted using the Group's incremental borrowing rate, as the interest rate implicit in the lease generally cannot be readily determined. Lease payments that are included in the measurement of the lease liability include fixed payments or in-substance fixed payments and variable payments that depend on an index. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequently, the lease liability is measured at amortized cost using the effective interest method. The Group remeasures the lease liability when there is a change in future lease payments arising from a change in index, or if the Group changes its assessment of whether it will exercise an extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the lease liability for each period. The Group does not provide residual value guarantees and does not have any leases not yet commenced to which it is committed. The Group is presenting right-of-use assets in Property, Plant and Equipment, whereas lease liabilities are presented separately within current and non-current liabilities in the consolidated statement of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-financial assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount exceeds their recoverable amount. An impairment loss is recognized for this difference. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial assets at amortized costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents / short-term deposits / trade and other receivables (except for VAT and withholding taxes) (and when applicable accrued interest income) are all considered held-to-collect items and are labeled under financial assets measured at amortized costs, with the following definition / accounting policy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at amortized cost are assets that meet both of the following conditions: (1) the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;They arise when the Group provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities longer than 12 months after the balance sheet date which are classified as non-current assets. Interest income on the short-term deposit is accounted for on the statement of comprehensive income as financial income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initially, financial assets, except for trade receivables, are measured at their fair value plus, in the case of financial assets not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset; for the Group these are considered to be immaterial. Trade receivables are initially measured at their transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent measurement for the financial assets mentioned above which are classified as measured at amortized cost, is based on the effective interest method, reduced by any impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial assets measured at amortized cost, a loss allowance for expected credit losses on the financial assets is recognized. Measurement of any impairment loss is based on the &#x2018;expected credit loss&#x2019; (ECL) model, which is based on a predictive model. The loss allowance for a financial asset is measured at an amount equal to the lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Group measures the loss allowance / impairment loss for that financial asset at an amount equal to 12-month expected credit losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For trade receivables, the Group applies a simplified approach which requires expected credit losses to be recognized from initial recognition (measuring the loss allowance at an amount equal to lifetime expected credit losses). This takes into consideration past history, combined with predictive information which accounts for the specific circumstances of the customer (e.g. credit rating etc.), and other relevant factors such as the economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other financial assets at amortized costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables generally arise from transactions outside the usual operating activities of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial liabilities at amortized costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables and non-employee related accrued expense are measured at amortized costs and classified as financial liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash includes cash at banks. The Group considers all short-term, highly liquid investments convertible into known amounts of cash with maturities of three months or less from the date of acquisition to be cash equivalents, provided that they are subject to an insignificant risk of changes in value. The cash flow statement is based on cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Share capital / Additional paid-in capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds. The Group has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the consideration paid for the acquisition of treasury shares, which includes directly attributable costs, is recognized as a deduction from equity. When treasury shares are sold subsequently, the amount received is recognized as an increase in equity, and the resulting surplus or deficit on the transaction is presented in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes include current and deferred taxes. Current income taxes are recognized on taxable profits at applicable tax rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are calculated using the balance sheet liability method. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled based on tax rates enacted or substantially enacted at the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized if it is probable that sufficient taxable profits will be available against which the deferred tax assets can be utilized. At each balance sheet date, the Group reassesses unrecognized deferred tax assets and the carrying amount of recognized deferred tax assets. The Group recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. The Group conversely reduces the carrying amount of a deferred tax asset to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or the entire deferred tax asset to be utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of deferred tax liabilities and deferred tax assets reflects the tax consequences on the balance sheet date of the Group's expectation of recovery or settlement of the carrying amounts of its assets and liabilities. Deferred tax assets and liabilities are not discounted and are classified as non-current assets and liabilities in the statement of financial position. They are offset against each other if they relate to the same taxable entity and tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have to pay income taxes in Switzerland in the presented reporting periods for 2022, 2021 and 2020. The Company&#x2019;s accumulated taxable losses may be used as tax loss carry forwards to offset future taxable income over a period of seven years in Switzerland. No deferred tax assets have been established for these losses, because the Company does not have a history of sustainable taxable profits, increasing research costs are expected to be incurred in the foreseeable future and future revenues are highly volatile and uncertain. No deferred tax assets were recognized on deductible temporary differences on pension liabilities for the same reasons. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners Inc, the Group's US subsidiary, is subject to US federal and Massachusetts and New York state minimal tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Postretirement benefits (pension plans)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides retirement, death and disability benefits to its Swiss employees in line with local customs and requirements through two separate plans, which are both accounted for as defined benefit plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first plan is the compulsory defined benefit plan which is funded through employer (60%) and employee (40%) contributions to VSAO, a Switzerland based plan. This Company-wide plan has been in place since inception of the Company and all employees of the Company are eligible to its benefits. On retirement, the plan participant will receive his or her accumulated savings, which consist of all contributions paid in by the employer and the employee (net of any withdrawals) and the interest granted on those savings at the discretion of the pension foundation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At that time, the plan participant has the right to choose between a lump-sum payment and an annuity, or a combination thereof. The annuity is calculated using a fixed conversion rate determined by the pension foundation. The VSAO&#x2019;s plan assets are pooled and the Company&#x2019;s share is calculated based on its share of retirement savings. Additional funding requirements may be determined by the pension foundation in case of a severe underfunding. Should the Company withdraw from the plan, the withdrawal may qualify as a partial liquidation under Swiss law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The second plan is a voluntary complementary defined management benefit scheme established as of January&#160;1, 2014, in which only employees with a certain management level and / or above a certain salary level are eligible to participate. 33 of the 33 eligible employees participated in this plan as of December&#160;31, 2022 (2021: 32 out of 32). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This plan is set up as a collective foundation with Swiss Life, a Switzerland-based insurance company, for which contributions are 30% funded by the employee and 70% funded by the Company. The purpose of this voluntary plan is to allow higher savings opportunity in a tax effective manner and risk benefits for senior management. In addition, plan participants are entitled to a lump sum payment of five times their annual base salary in case of death. This is a fully insured Swiss pension plan that covers all investment and actuarial risks, including invalidity and death.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The VSAO pension plan accounts for over 90% of both the Company&#x2019;s defined benefit obligation and plan assets. The liability recognized in the statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligations at the balance sheet date less the fair value of plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows. Pension liabilities are determined on an actuarial basis using a number of assumptions, such as the discount rate and expected salary increases applied to determine the defined benefit obligation and an estimate of the fair value of plan assets attributable to the Company. In determining the appropriate discount rate, for example, the Company considers the interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. In determining the fair value of plan assets, the Company adds to the participants&#x2019; savings a share of the pension plan&#x2019;s technical and fluctuation reserves. Additional information is disclosed in note 18.1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and past service costs as well as the net interest on the defined benefit obligation are recognized in profit or loss in the period in which they are incurred, and are presented as part of personnel expenses. Remeasurements of the defined benefit pension plans are recognized in other comprehensive result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has set up a 401k plan for its US based employees. Under the plan the US entity matches the employee's contribution and provides a true-up in matched contributions at year end. The 401k plan qualifies as a defined contribution plan and the associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has set up a defined contribution plan for its UK based employees. Under the plan the Company and the employee both contribute into the plan. The associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group operates share-based compensation plans that qualify as equity-settled plans. The fair value of the employee services received in exchange for the grant of equity instruments is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the equity instruments granted, which is determined at grant date. The fair values are determined by management with the assistance of an independent valuation expert. At each reporting date, estimates of the number of equity instruments that are expected to vest are revised. The impact of the revision of the previous estimates, if any, is recognized as part of share-based compensation (non-cash effective) with a corresponding adjustment to equity. When the vested equity instruments are exercised, any proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bonus plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group recognizes an accrual where contractually obliged or where there is a past practice that has created a constructive obligation. Bonuses are based on a formula that takes into consideration the achievement of the Group&#x2019;s goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a guiding principle of IFRS 15, revenues from research and development collaboration agreements are recognized when earned based upon the performance requirements of the respective agreements. For revenue arrangements with separately identifiable components (separate performance obligations), the revenue recognition criteria are applied to each component. The transaction price is determined as the consideration expected to be received from the arrangement and is allocated amongst the separate components based on their relative stand-alone selling prices. The corresponding amount of transaction price allocated to each component is recognized as revenue when (or as) the Group satisfies the performance obligation by transferring the good or service to the customer, which generally is over time for upfront payments or at a point in time for milestone payments and development option payments. Payments received in excess of revenue recognized are recorded as contract liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues include fees such as upfront payments received in connection with out-licensing of products and/or access the knowledge without transfer of a license as well as in connection with discovery alliances, as well as fees for maintenance of patents, R&amp;amp;D support and services, participation in Joint Steering Committees and other involvement in collaboration agreements. In exchange for these non-refundable upfront fees, the Group does not immediately transfer a good or a service to the customer, rather the upfront fee consists of an advance payment for future services and the right to access the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input-based method to measure its progress towards complete satisfaction of the performance obligation. Accordingly, revenue is recognized over time based on the percentage of actual costs incurred to date relative to the Group's estimate of total costs expected to satisfy the performance obligation. Estimated costs are reviewed and updated routinely for contracts in progress to reflect any changes of which the Group becomes aware. The cumulative effect of any change in estimate is recorded in the period when the change in estimate is determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues could include fees such as milestone and development option payments received in connection with out-licensing of products and in connection with discovery alliances. Upon meeting the set milestone or upon a development option being exercised, the Group obtains a right to a non-refundable payment and the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations for the Group. Consequently, the related revenues are typically recognized at a point in time, either when the milestone is met or the option is exercised by the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue could also include reservation fees that will be recognized into revenue in case of successful development of a final drug and exercise or lapse of the related reservation right or, alternatively, in case the results from the research will not justify further development of the drug. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration payable to a customer is recorded as a reduction of the arrangement's transaction price, if it relates to the same arrangement, thereby reducing the amount of revenue recognized, unless the payment is for a distinct good or service received from the customer consistent with IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The details of the accounting policy, based on the type of payments received, are set out below. Under IFRS 15, revenue is recognized as or when a customer obtains control of the services. Determining the timing of the transfer of control - at a point in time or over time - requires judgment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Type of payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Timing of revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of upfront payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of payments received for development options exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition for reservation fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses as disclosed in note 16 consist primarily of compensation and other expenses related to:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;research and development personnel;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;preclinical studies and clinical trials of the Group's product candidates, including the costs of manufacturing the product candidates;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;research and services performed under collaboration agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;research and development services outsourced to research institutions; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;attributable facility expenses, including depreciation of equipment and amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed that will generate probable future economic benefits, and when the cost of such an asset can be measured reliably. The Group does not currently have any such internal development costs that qualify for capitalization as intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to its internal research and development activities, the Group is also party to in-licensing and similar arrangements with its collaboration partners. The Group may also acquire in-process research and development assets, either through business combinations or through purchases of specific assets. Intangible assets are initially recorded at cost. Intangible assets are amortized over their useful lives on a straight-line basis beginning from the point when they are available for use. The estimated useful life of intangible assets is regularly reviewed. The Group does not currently have any such externally acquired in-process research and development assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group charges all research and development expenses, including internal patent filing and patent maintenance costs, to profit or loss when incurred, as the criteria for recognition as an asset are not currently met.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:StatementOfIFRSCompliance
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0Ng_c0beeee7-b16a-44ed-a0fa-2a22455bf772">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of preparation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the IASB. The accounting policies set forth below have been consistently applied to all years presented. Unless stated otherwise, all financial statements are presented in thousands of Swiss Francs (&#x201c;TCHF&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4 &#x201c;Critical accounting estimates and judgments&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Group's cash position at December&#160;31, 2022, the Group deemed there to be no material uncertainties that would cast doubt on the Group's ability to operate on a going concern basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements as of and for the year ended December&#160;31, 2022 were approved for issuance by the Company's Board of Directors on March&#160;8, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to rounding, the numbers presented in the financial statements might not precisely equal those included in the accompanying notes.&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <moln:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Nw_043232e8-bb45-47f6-8b3d-2933f9d5d7b3">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i) Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii) Transactions eliminated on consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.&lt;/span&gt;&lt;/div&gt;</moln:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Mw_40ea66a2-3ebd-4ce4-b10b-a81aaeb8f939">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;New or revised IFRS standards and interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following new or revised standards that became effective during 2022 did not have a material effect on these consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Onerous Contracts - Costs of fulfilling a contract - amendments to IAS 37&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Annual Improvements to IFRS standards 2018-2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Property, Plant and Equipment: Proceeds before intended use - amendments to IAS 16&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several new or revised standards have been published that are not yet effective and that have not been early adopted. No significant impacts on the Group's consolidated financial statements are expected.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0Nw_79f1b29b-7153-4cd0-a9e0-2ea96bb86532">Segment reportingThe Group operates in one segment, focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The executive management, acting together as the chief operating decision makers, assess the financial performance and allocate resources on an aggregated level, and monitor the Group's operating expenses. Accounting policies applied are the same for both internal and external reporting purposes. The Group derives its research and collaboration revenues from research and development collaborations with third parties.</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <moln:NumberOfOperatingSegments
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzcx_d0fd6cf1-0da1-468a-b5af-3f223460ffd5"
      unitRef="segment">1</moln:NumberOfOperatingSegments>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2Mg_d4eac75e-5924-4ea5-b309-f0a417872f28">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Foreign currency translation / transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are presented in thousands of CHF. The presentation currency of the Group is the functional currency of the Company. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;assets and liabilities are translated at the closing rate at the date of the respective balance sheet;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;income and expenses for each consolidated statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates at the dates of the transactions); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;all resulting exchange differences are recognized in other comprehensive result.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2Mw_71ee2e09-d5ef-4066-a362-51c4833c2022">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment, Office equipment, IT hardware and Leasehold improvements are stated at historical cost less accumulated depreciation and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Depreciation is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful lives are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IT hardware:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements and right-of-use assets are depreciated using the straight line method over the shorter of their estimated useful life and the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent costs are included in each asset&#x2019;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets&#x2019; residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date. An asset&#x2019;s carrying amount is written down to its recoverable amount, if the asset's carrying amount exceeds its estimated recoverable amount.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost and accumulated depreciation related to assets retired or otherwise disposed are derecognized at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of retirement or disposal.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2NA_cba1c10e-b34d-4e38-b7ab-ba4547a77c42">The applicable estimated useful lives are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IT hardware:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;IT hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,315&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;624&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;21,932&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(4,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(14,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;IT hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;20,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(12,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i2e80d6a46f79433a9f1419880a584236_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90YWJsZTo2MmFlYTRhZjAwNGI0MTdmYjY3ZWU0NmNkYTY4MDA3Yy90YWJsZXJhbmdlOjYyYWVhNGFmMDA0YjQxN2ZiNjdlZTQ2Y2RhNjgwMDdjXzAtMS0xLTEtMTA5NjE4_b8d0a3de-bdb1-46ee-b1a1-4af287e143d4">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i58f89c5d3edd409a893e4a981cc24bd0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90YWJsZTo2MmFlYTRhZjAwNGI0MTdmYjY3ZWU0NmNkYTY4MDA3Yy90YWJsZXJhbmdlOjYyYWVhNGFmMDA0YjQxN2ZiNjdlZTQ2Y2RhNjgwMDdjXzEtMS0xLTEtMTA5NjE4_0a68fab3-4e83-4880-8c92-ce85ae43fc04">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="ib359265a93b948b2b6a8eefcd3139fe8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90YWJsZTo2MmFlYTRhZjAwNGI0MTdmYjY3ZWU0NmNkYTY4MDA3Yy90YWJsZXJhbmdlOjYyYWVhNGFmMDA0YjQxN2ZiNjdlZTQ2Y2RhNjgwMDdjXzItMS0xLTEtMTA5NjE4_329209fa-1b51-494b-b07f-a78e86eccff9">P2Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1OA_f164076f-ca28-4d0d-8217-0753157d7b24">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are solely comprised of software. They are stated at historical cost less accumulated amortization and any impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Amortization is calculated on a straight-line basis over the expected useful lives of the individual assets or asset categories. The applicable estimated useful life of intangible assets is determined to be two years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="i7e1e929b08e148649e795b949412ce45_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzExNw_1e7ebf23-4f7f-4a15-b05c-66fce7ad9387">P2Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0OA_278e26ab-f84f-4e44-8106-9f1df317cdce">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, the Group assesses whether a contract is, or contains a lease. This is the case if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets (threshold of CHF 5,000) and short-term leases. Short-term leases are leases with a lease term of twelve months or less that do not contain a purchase option. For all other leases the Group recognizes a right-of-use asset and a lease liability at the lease commencement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. Subsequently the right-of-use asset is depreciated using the straight-line method over the shorter of the asset's useful life and the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments required over the lease term that are not paid at the commencement date, discounted using the Group's incremental borrowing rate, as the interest rate implicit in the lease generally cannot be readily determined. Lease payments that are included in the measurement of the lease liability include fixed payments or in-substance fixed payments and variable payments that depend on an index. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequently, the lease liability is measured at amortized cost using the effective interest method. The Group remeasures the lease liability when there is a change in future lease payments arising from a change in index, or if the Group changes its assessment of whether it will exercise an extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the lease liability for each period. The Group does not provide residual value guarantees and does not have any leases not yet commenced to which it is committed. The Group is presenting right-of-use assets in Property, Plant and Equipment, whereas lease liabilities are presented separately within current and non-current liabilities in the consolidated statement of financial position.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM0OQ_5ceee685-cddd-481d-a934-b89c6a39d1ce">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-financial assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount exceeds their recoverable amount. An impairment loss is recognized for this difference. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1NA_f1fb0e2b-b7a8-48f0-936d-414e0ae53d7d">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial assets at amortized costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents / short-term deposits / trade and other receivables (except for VAT and withholding taxes) (and when applicable accrued interest income) are all considered held-to-collect items and are labeled under financial assets measured at amortized costs, with the following definition / accounting policy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at amortized cost are assets that meet both of the following conditions: (1) the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;They arise when the Group provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities longer than 12 months after the balance sheet date which are classified as non-current assets. Interest income on the short-term deposit is accounted for on the statement of comprehensive income as financial income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initially, financial assets, except for trade receivables, are measured at their fair value plus, in the case of financial assets not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset; for the Group these are considered to be immaterial. Trade receivables are initially measured at their transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent measurement for the financial assets mentioned above which are classified as measured at amortized cost, is based on the effective interest method, reduced by any impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial assets measured at amortized cost, a loss allowance for expected credit losses on the financial assets is recognized. Measurement of any impairment loss is based on the &#x2018;expected credit loss&#x2019; (ECL) model, which is based on a predictive model. The loss allowance for a financial asset is measured at an amount equal to the lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Group measures the loss allowance / impairment loss for that financial asset at an amount equal to 12-month expected credit losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For trade receivables, the Group applies a simplified approach which requires expected credit losses to be recognized from initial recognition (measuring the loss allowance at an amount equal to lifetime expected credit losses). This takes into consideration past history, combined with predictive information which accounts for the specific circumstances of the customer (e.g. credit rating etc.), and other relevant factors such as the economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other financial assets at amortized costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables generally arise from transactions outside the usual operating activities of the Group.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1OQ_6d8c3ae6-66cc-45de-98df-2eb847868efc">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial liabilities at amortized costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables and non-employee related accrued expense are measured at amortized costs and classified as financial liabilities.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1NQ_c5b5dcd1-bc70-404f-bf80-a8856353f837">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash includes cash at banks. The Group considers all short-term, highly liquid investments convertible into known amounts of cash with maturities of three months or less from the date of acquisition to be cash equivalents, provided that they are subject to an insignificant risk of changes in value. The cash flow statement is based on cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1MA_43931c05-2957-4b82-91d4-93043b00dcb7">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Share capital / Additional paid-in capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds. The Group has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzIxOTkwMjMyNzEyNzQ_595c3ca0-9c24-48bd-abe8-71f5d5e5205f">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the consideration paid for the acquisition of treasury shares, which includes directly attributable costs, is recognized as a deduction from equity. When treasury shares are sold subsequently, the amount received is recognized as an increase in equity, and the resulting surplus or deficit on the transaction is presented in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1MQ_b1d8561d-d3b9-4c90-bf81-97cd0374aa80">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes include current and deferred taxes. Current income taxes are recognized on taxable profits at applicable tax rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are calculated using the balance sheet liability method. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled based on tax rates enacted or substantially enacted at the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized if it is probable that sufficient taxable profits will be available against which the deferred tax assets can be utilized. At each balance sheet date, the Group reassesses unrecognized deferred tax assets and the carrying amount of recognized deferred tax assets. The Group recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. The Group conversely reduces the carrying amount of a deferred tax asset to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or the entire deferred tax asset to be utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of deferred tax liabilities and deferred tax assets reflects the tax consequences on the balance sheet date of the Group's expectation of recovery or settlement of the carrying amounts of its assets and liabilities. Deferred tax assets and liabilities are not discounted and are classified as non-current assets and liabilities in the statement of financial position. They are offset against each other if they relate to the same taxable entity and tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have to pay income taxes in Switzerland in the presented reporting periods for 2022, 2021 and 2020. The Company&#x2019;s accumulated taxable losses may be used as tax loss carry forwards to offset future taxable income over a period of seven years in Switzerland. No deferred tax assets have been established for these losses, because the Company does not have a history of sustainable taxable profits, increasing research costs are expected to be incurred in the foreseeable future and future revenues are highly volatile and uncertain. No deferred tax assets were recognized on deductible temporary differences on pension liabilities for the same reasons. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners Inc, the Group's US subsidiary, is subject to US federal and Massachusetts and New York state minimal tax.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2MA_4e57a332-1b34-4824-a9e5-15c0a495fc4f">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Postretirement benefits (pension plans)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides retirement, death and disability benefits to its Swiss employees in line with local customs and requirements through two separate plans, which are both accounted for as defined benefit plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first plan is the compulsory defined benefit plan which is funded through employer (60%) and employee (40%) contributions to VSAO, a Switzerland based plan. This Company-wide plan has been in place since inception of the Company and all employees of the Company are eligible to its benefits. On retirement, the plan participant will receive his or her accumulated savings, which consist of all contributions paid in by the employer and the employee (net of any withdrawals) and the interest granted on those savings at the discretion of the pension foundation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At that time, the plan participant has the right to choose between a lump-sum payment and an annuity, or a combination thereof. The annuity is calculated using a fixed conversion rate determined by the pension foundation. The VSAO&#x2019;s plan assets are pooled and the Company&#x2019;s share is calculated based on its share of retirement savings. Additional funding requirements may be determined by the pension foundation in case of a severe underfunding. Should the Company withdraw from the plan, the withdrawal may qualify as a partial liquidation under Swiss law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The second plan is a voluntary complementary defined management benefit scheme established as of January&#160;1, 2014, in which only employees with a certain management level and / or above a certain salary level are eligible to participate. 33 of the 33 eligible employees participated in this plan as of December&#160;31, 2022 (2021: 32 out of 32). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This plan is set up as a collective foundation with Swiss Life, a Switzerland-based insurance company, for which contributions are 30% funded by the employee and 70% funded by the Company. The purpose of this voluntary plan is to allow higher savings opportunity in a tax effective manner and risk benefits for senior management. In addition, plan participants are entitled to a lump sum payment of five times their annual base salary in case of death. This is a fully insured Swiss pension plan that covers all investment and actuarial risks, including invalidity and death.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The VSAO pension plan accounts for over 90% of both the Company&#x2019;s defined benefit obligation and plan assets. The liability recognized in the statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligations at the balance sheet date less the fair value of plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows. Pension liabilities are determined on an actuarial basis using a number of assumptions, such as the discount rate and expected salary increases applied to determine the defined benefit obligation and an estimate of the fair value of plan assets attributable to the Company. In determining the appropriate discount rate, for example, the Company considers the interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. In determining the fair value of plan assets, the Company adds to the participants&#x2019; savings a share of the pension plan&#x2019;s technical and fluctuation reserves. Additional information is disclosed in note 18.1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and past service costs as well as the net interest on the defined benefit obligation are recognized in profit or loss in the period in which they are incurred, and are presented as part of personnel expenses. Remeasurements of the defined benefit pension plans are recognized in other comprehensive result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has set up a 401k plan for its US based employees. Under the plan the US entity matches the employee's contribution and provides a true-up in matched contributions at year end. The 401k plan qualifies as a defined contribution plan and the associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has set up a defined contribution plan for its UK based employees. Under the plan the Company and the employee both contribute into the plan. The associated expenses, that are deemed immaterial, are presented under operating expenses in the statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group operates share-based compensation plans that qualify as equity-settled plans. The fair value of the employee services received in exchange for the grant of equity instruments is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the equity instruments granted, which is determined at grant date. The fair values are determined by management with the assistance of an independent valuation expert. At each reporting date, estimates of the number of equity instruments that are expected to vest are revised. The impact of the revision of the previous estimates, if any, is recognized as part of share-based compensation (non-cash effective) with a corresponding adjustment to equity. When the vested equity instruments are exercised, any proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bonus plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group recognizes an accrual where contractually obliged or where there is a past practice that has created a constructive obligation. Bonuses are based on a formula that takes into consideration the achievement of the Group&#x2019;s goals.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <moln:DefinedBenefitPlanEmployerContribution
      contextRef="i134827d19330412b856f8be3015f6a0b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzIyMg_6335e948-488a-4532-a621-9929078afa60"
      unitRef="number">0.60</moln:DefinedBenefitPlanEmployerContribution>
    <moln:DefinedBenefitPlanEmployeeContribution
      contextRef="i134827d19330412b856f8be3015f6a0b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzIyNg_7a657408-3e6f-40b9-a435-d0b6662ab8a7"
      unitRef="number">0.40</moln:DefinedBenefitPlanEmployeeContribution>
    <moln:DefinedBenefitPlanNumberOfEmployeesThatParticipated
      contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI0OQ_da5b8ac5-5a74-48c1-8a6b-5d330a5fb313"
      unitRef="employee">33</moln:DefinedBenefitPlanNumberOfEmployeesThatParticipated>
    <moln:DefinedBenefitPlanNumberOfEligibleEmployees
      contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI1Mw_8f335008-c287-43e4-84ef-fc74c2037f1f"
      unitRef="employee">33</moln:DefinedBenefitPlanNumberOfEligibleEmployees>
    <moln:DefinedBenefitPlanNumberOfEmployeesThatParticipated
      contextRef="ia75b3bef6aac446986fe84984a05f946_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI2NQ_d63dbb44-e4a5-4e83-9897-93e407ce496e"
      unitRef="employee">32</moln:DefinedBenefitPlanNumberOfEmployeesThatParticipated>
    <moln:DefinedBenefitPlanNumberOfEligibleEmployees
      contextRef="ia75b3bef6aac446986fe84984a05f946_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI2OQ_2527a6c7-bc48-4bde-bc78-63130cc1910a"
      unitRef="employee">32</moln:DefinedBenefitPlanNumberOfEligibleEmployees>
    <moln:DefinedBenefitPlanEmployeeContribution
      contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI4MA_84d2f8fd-c536-4626-8805-7cfb9ec493ec"
      unitRef="number">0.30</moln:DefinedBenefitPlanEmployeeContribution>
    <moln:DefinedBenefitPlanEmployerContribution
      contextRef="ifc8eaa268a7944f08798bc5f16ec842e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI4NA_bbd87785-9251-4ac4-b3f1-830f589c8484"
      unitRef="number">0.70</moln:DefinedBenefitPlanEmployerContribution>
    <moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzI5MQ_a655a61c-6290-4eda-a9ce-85c98b1f26b7"
      unitRef="number">0.90</moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Ng_3b75df64-94c9-4f65-9544-5a6816442c12">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a guiding principle of IFRS 15, revenues from research and development collaboration agreements are recognized when earned based upon the performance requirements of the respective agreements. For revenue arrangements with separately identifiable components (separate performance obligations), the revenue recognition criteria are applied to each component. The transaction price is determined as the consideration expected to be received from the arrangement and is allocated amongst the separate components based on their relative stand-alone selling prices. The corresponding amount of transaction price allocated to each component is recognized as revenue when (or as) the Group satisfies the performance obligation by transferring the good or service to the customer, which generally is over time for upfront payments or at a point in time for milestone payments and development option payments. Payments received in excess of revenue recognized are recorded as contract liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues include fees such as upfront payments received in connection with out-licensing of products and/or access the knowledge without transfer of a license as well as in connection with discovery alliances, as well as fees for maintenance of patents, R&amp;amp;D support and services, participation in Joint Steering Committees and other involvement in collaboration agreements. In exchange for these non-refundable upfront fees, the Group does not immediately transfer a good or a service to the customer, rather the upfront fee consists of an advance payment for future services and the right to access the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input-based method to measure its progress towards complete satisfaction of the performance obligation. Accordingly, revenue is recognized over time based on the percentage of actual costs incurred to date relative to the Group's estimate of total costs expected to satisfy the performance obligation. Estimated costs are reviewed and updated routinely for contracts in progress to reflect any changes of which the Group becomes aware. The cumulative effect of any change in estimate is recorded in the period when the change in estimate is determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues could include fees such as milestone and development option payments received in connection with out-licensing of products and in connection with discovery alliances. Upon meeting the set milestone or upon a development option being exercised, the Group obtains a right to a non-refundable payment and the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations for the Group. Consequently, the related revenues are typically recognized at a point in time, either when the milestone is met or the option is exercised by the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue could also include reservation fees that will be recognized into revenue in case of successful development of a final drug and exercise or lapse of the related reservation right or, alternatively, in case the results from the research will not justify further development of the drug. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration payable to a customer is recorded as a reduction of the arrangement's transaction price, if it relates to the same arrangement, thereby reducing the amount of revenue recognized, unless the payment is for a distinct good or service received from the customer consistent with IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The details of the accounting policy, based on the type of payments received, are set out below. Under IFRS 15, revenue is recognized as or when a customer obtains control of the services. Determining the timing of the transfer of control - at a point in time or over time - requires judgment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Type of payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Timing of revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of upfront payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of payments received for development options exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition for reservation fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <moln:DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM2NQ_a69b7ec4-80e0-4109-83cf-5dd688b95da4">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Type of payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Timing of revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of upfront payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments received in connection with out-licensing arrangements are typically non-refundable fees for which the Group does not transfer a good or a service to the customer, rather the upfront payments consists of an advance payment for future services and/or an acquisition of the right to the current or future access to the underlying intellectual property of the Group. For such arrangements, the Group has determined that the promised goods and services are not distinct and are accounted for as one performance obligation. The Group recognizes revenue for this performance obligation over time using an input based method to measure its progress towards complete satisfaction of the performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments received in connection with out-licensing or other arrangements are typically non-refundable fees entitling the Group to a right to payment upon such milestone being met. At that time, the customer has typically acquired the right to use the underlying intellectual property or additional knowledge about drug candidate(s), without any remaining performance obligation of the Group. Considering the uncertainty surrounding the outcome of such development activities, the revenue is consequently recognized at a point in time, when the milestone is reached. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition of payments received for development options exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development option payments received in connection with out-licensing arrangements are typically non-refundable fees entitling the Group to a right to payment upon such option being exercised. At that time, the customer has typically acquired the right to use the underlying intellectual property, without any remaining performance obligations of the Group. Considering the fact that the exercise of any option is outside the control of the Group, revenue for options that provide the right to use is recognized at a point in time at the effective exercise of the option. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition for reservation fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reservation fees received are typically non-refundable fees. The timing of revenue recognition depends on whether development of the final drug is successful. If development is successful, revenue will be recognized when the related reservation right is exercised or lapses (as the exercise of any reservation right is outside the control of the Group). Alternatively, revenue will be recognized at the point in time when the results from the research will not justify further development of the drug. At this stage it is highly probable that a reversal of the cumulative revenue will not occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</moln:DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNjgvZnJhZzphYjZhOTQ1YmNmNmU0YTZlYmVlZTJiNTk0ZGM1ODBiYy90ZXh0cmVnaW9uOmFiNmE5NDViY2Y2ZTRhNmViZWVlMmI1OTRkYzU4MGJjXzM1Mg_961595b7-1bcc-4af2-b499-5d1884afab1b">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses as disclosed in note 16 consist primarily of compensation and other expenses related to:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;research and development personnel;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;preclinical studies and clinical trials of the Group's product candidates, including the costs of manufacturing the product candidates;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;research and services performed under collaboration agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;research and development services outsourced to research institutions; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;attributable facility expenses, including depreciation of equipment and amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed that will generate probable future economic benefits, and when the cost of such an asset can be measured reliably. The Group does not currently have any such internal development costs that qualify for capitalization as intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to its internal research and development activities, the Group is also party to in-licensing and similar arrangements with its collaboration partners. The Group may also acquire in-process research and development assets, either through business combinations or through purchases of specific assets. Intangible assets are initially recorded at cost. Intangible assets are amortized over their useful lives on a straight-line basis beginning from the point when they are available for use. The estimated useful life of intangible assets is regularly reviewed. The Group does not currently have any such externally acquired in-process research and development assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group charges all research and development expenses, including internal patent filing and patent maintenance costs, to profit or loss when incurred, as the criteria for recognition as an asset are not currently met.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzEvZnJhZzo1ZWYzNGJhZTI3YmI0NzI2YjU5OWVhMGNiNzJhNmY5NS90ZXh0cmVnaW9uOjVlZjM0YmFlMjdiYjQ3MjZiNTk5ZWEwY2I3MmE2Zjk1XzM1_6975d309-63a9-4e48-856f-2d40d5a1f923">Financial risk management&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial risk factors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, uncertainties regarding the effectiveness and safety of new drugs, new and unproven technologies, development process and outcome of clinical trials, rigorous governmental regulation and uncertainty regarding regulatory approvals, long product development cycles, continuing capital requirements to fund research and development, history of operating losses and uncertainty of future profitability, uncertainty regarding commercial success and acceptance, third party reimbursements, uncertainties regarding patents and legally protected products or technologies, uncertainty regarding third party intellectual property rights, dependence on third parties, dependence on publicly available scientific findings and research data, lack of experience with production facilities, dependence on third party manufacturers and service providers, competition, concentration of operations, product liability, dependence on important employees, environment, health, data protection and safety, lack of experience in marketing and sales, litigation, currency fluctuation risks and other financial risks, volatility of market value, as well as limited liquidity and shares eligible for future sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is developing several products currently not generating constant revenue streams which results in volatile cash flow from operating activities. Currently, the Group&#x2019;s revenues stem mainly from irregular and difficult to predict income from product out-licensing, milestone payments and fees from R&amp;amp;D collaboration agreements. This will likely remain the same at least until the first product reaches the market on the Group&#x2019;s own or through a partner. This results in a lack of regular positive operating cash flow, which may expose the Group to financing risks in the medium-term. Furthermore, management has taken actions to manage financial risks, such as foreign exchange risk and liquidity risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners conducts research and development activities primarily in Switzerland, the European Union and the United States. As a result, the Group is exposed to a variety of financial risks, such as foreign exchange rate risk, credit risk, liquidity risk, cash-flow and interest rate risk. The Group&#x2019;s overall financial risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Further details are disclosed under note 25.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Capital management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is not regulated and not subject to specific capital requirements. The amount of equity depends on the Group&#x2019;s funding needs and statutory capital requirements. The Group monitors capital periodically on an interim and annual basis. From time to time, the Group may take appropriate measures or propose capital increases to its &lt;/span&gt;&lt;/div&gt;shareholders to ensure the necessary capital remains intact. The Group did not have any short-term or long-term debt outstanding as of December&#160;31, 2022 and 2021.Financial risk management&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Foreign exchange risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to reduce its foreign exchange exposure, Molecular Partners may enter into currency contracts with selected high-quality financial institutions to hedge against foreign currency exchange rate risks. The Group&#x2019;s primary exposure to financial risk is due to fluctuation of exchange rates between CHF, USD and EUR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group&#x2019;s hedging policy is (1) to maximize natural hedging by matching expected future cash flows in the different currencies and (2) if market conditions allow to consider hedging certain of the remaining expected net currency exposure as the need arises. However, due to market volatilities, the impact of negative interest rates during most of 2022 in Switzerland and uncertainties in the cash flows, a 100% hedging of the currency exposure is impossible or not appropriate. Molecular Partners does not engage in speculative transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, the Group did not enter into any forward currency transactions. No forward currency transactions were outstanding as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table demonstrates the sensitivity to a reasonably possible change in exchange rates for the Group's main foreign currencies, USD and EUR, with all other variables held constant, of the Group&#x2019;s result before taxes. There is no direct impact on the Group&#x2019;s equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in % and CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Incr./Decr. exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effect on result before tax (in TCHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;USD Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EUR Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest rate risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners earns or pays interest on cash and cash equivalents, and its profit and loss may be influenced by changes in market interest rates. The Group does invest its cash balances into a variety of current and deposit accounts in four different Swiss banks to optimize interest. In addition, the Group does invest a portion of its cash into risk free money market investments in line with its treasury guidelines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group strives to optimize the net balance of interest paid and interest received by monitoring the interest rates applicable over the major currencies the Group holds as well as the offered holding periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table demonstrates the sensitivity of the main currencies used in the Group, to reasonably possible changes in interest rates, with all other variables held constant, of the Group&#x2019;s results before tax. There is no direct impact on the Group&#x2019;s equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in % and CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Incr./Decr. interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effect on result before tax (in TCHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CHF Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;USD Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EUR Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum credit risk on financial assets corresponds to the carrying amounts of the Group&#x2019;s cash and cash equivalents, short-term time deposits and receivables. The Group has not entered into any guarantees or similar obligations that would increase the risk over and above the carrying amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash and cash equivalents and short-term deposits are considered low risk and were held at Swiss banks with Standard &amp;amp; Poor long-term credit ratings as of December 31, 2022 of AAA (Z&#xfc;rcher Kantonalbank), AA (Luzerner Kantonalbank), A+ (UBS) and A- (Credit Suisse) and therefore any impact resulting from the expected credit loss model is considered immaterial. Analysis performed included assessing the cumulative default rates by credit rating category and applying these rates to the cash and short-term deposit balances at reporting dates. The calculated loss allowance based on the ECL is considered immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group enters into agreements with partners that have appropriate credit history and a commitment to ethical business practices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum credit risk as of the balance sheet date was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;161,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total credit risk as at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;250,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;156,599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group&#x2019;s liquidity risk is considered low by management due to the financial assets at the reporting date, giving the Group a secure source of funding for its research and development activities.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzQvZnJhZzpiMmRmMjI2OWY5ZjQ0NGRmODljOTQxM2E0M2RlNWMwNC90ZXh0cmVnaW9uOmIyZGYyMjY5ZjlmNDQ0ZGY4OWM5NDEzYTQzZGU1YzA0XzIx_7b9a07b2-ead2-4d0f-b820-c9ba27bdb8ba">Critical accounting estimates and judgments&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group&#x2019;s accounts are prepared on a going concern basis. The preparation of the consolidated financial statements in conformity with IFRS requires that management and the Board of Directors make estimates and assumptions which affect the amounts of the assets and liabilities, contingent liabilities, as well as the income and expenses reported in the consolidated financial statements. These estimates take into consideration historic experience as well as developments in the economic circumstances and are further based on management&#x2019;s best knowledge of current events and actions that the Group may undertake in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These estimates are subject to risks and uncertainties. The actual results can deviate from these estimates. The estimates and assumptions identified by the Group, which have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in a future period or have a significant effect on reported results, are discussed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuation in revenues is common to biopharmaceutical companies focused on research and development as the revenues are often linked to up-front fees, reservation fees, milestones or license payments as well as income for delivery of drug substance, which occur sporadically. Depending on the complexity of the relevant agreements, judgment (for instance in regard to the performance obligations recognized using the cost-based method, where revenue is recognized based on costs incurred in relation to the Group&#x2019;s estimate of total estimated costs to complete satisfaction of the underlying performance obligations) is required to reflect the substance of the arrangement in the recognition of revenues. Under the cost-based method, the Group&#x2019;s estimate of total costs to be incurred under certain agreements is for example, based on actual project-related contracts and history of similar contracts of other collaborations as well as industry experience. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is required to evaluate whether any changes in operational and/or technical collaboration and project requirements could lead to a change in the timing and/or amount of estimated project costs, and how such changes, if any, impact the recognition of revenue. Other revenue related judgments with regard to the determination of performance obligations under reservation agreements relate to assumptions on future production costs and market prices. More information on revenue recognition is provided in the respective accounting policy. Additional information related to the Group&#x2019;s significant revenue agreements is disclosed in note 5.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzM2Ng_bb0b0d50-084a-4a83-94c8-341fa9d09ec3">Revenue, other income and entity-wide disclosures&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group assesses and estimates the progress of its projects with alliance partners at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;License and Collaboration Agreement with Novartis in the Area of DARPIN-Conjugated Radioligand Therapies ("Novartis Radioligand Agreement") &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;14, 2021, the Group entered into a License and Collaboration Agreement with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology. Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. The Group will be primarily responsible for the generation of DARPins for tumor-specific delivery of radioligands. The Group is eligible to invoice Novartis for its employee-related expenses associated with the research activities. Novartis is responsible for all clinical development and commercialization activities. As of December&#160;31, 2021 the Group recognized a receivable for the upfront fee of USD 20 million (CHF 18.6 million) payable from Novartis in trade and other receivables and a corresponding contract liability in the consolidated statement of financial position. In January 2022, Novartis paid Molecular Partners the upfront fee. The Group will be eligible to receive milestone payments of up to USD&#160;560&#160;million, relating to development, regulatory and commercialization activities, plus tiered royalties based on commercial sale levels from mid-single digit to low double-digit percentages of royalties on net sales of products commercialized by Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group identified one combined performance obligation consisting of the license and the research activities to be provided. Revenue related to the upfront payment of USD 20 million (CHF 18.6 million) is being recognized over time in line with the progress made over the duration of the contractually agreed three-year research plan. Progress towards completion of the research plan is based on the cost-based method and is measured by employee costs on the related research activities as specified in the agreement relative to the total employee costs estimated to be incurred. During 2022, the Group recognized total revenue of CHF&#160;9.8&#160;million of which CHF&#160;8.5&#160;million related to the recognition of the upfront fee and CHF&#160;1.3&#160;million related to the recharge of employee related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future milestone payments and royalties under the agreement will be recognized as revenue at a point in time, when a milestone is achieved or any subsequent sales by Novartis occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Option and Equity Rights Agreement with Novartis for Ensovibep (the "Option and Equity Rights Agreement")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Group entered into the Option and Equity Rights Agreement with Novartis, granting Novartis the exclusive option to in-license global rights in relation to MP0420 (ensovibep). Under the terms of the agreement, in 2020, the Group in 2020  received an upfront, non-refundable fee of CHF 20 million for the technology transfer and manufacturing of MP0420. The Group committed to utilize up to the maximum amount of this upfront fee for the manufacturing of the commercial supply for MP0420, which is required to be manufactured by Sandoz, a division of the Novartis Group. All such amounts paid for manufacturing performed by the Novartis Group is considered to be a consideration payable to a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the significant inter-dependencies between the upfront fee and the manufacturing activities, the manufacturing costs paid to the Novartis Group are offset against the upfront non-refundable fee from the contract (see below, as well as note 15). As of December&#160;31, 2021, the entire CHF&#160;20&#160;million has been utilized for the manufacturing of commercial supply for MP0420. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ensovibep License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, following positive Phase 2 clinical trial results, Novartis exercised its option for ensovibep, triggering a milestone payment of CHF&#160;150&#160;million to the Group, which was received in 2022. Relatedly, the Group was eligible to invoice Novartis CHF&#160;13.1&#160;million for other items related to ensovibep..&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the exercise of such option, the Group entered into a license agreement, the Ensovibep License Agreement, with Novartis under which the Group granted Novartis a sublicensable worldwide license to research, develop, manufacture, commercialize and otherwise use ensovibep and products comprising the compound in all indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is eligible to receive a 22% royalty on future commercial sales. Molecular Partners has agreed to forgo royalties in lower income countries, and is aligned with Novartis&#x2019; plans to ensure affordability based on countries&#x2019; needs and capabilities. Novartis is responsible for all further development and commercialization activities of ensovibep.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; In early  January 2023 Novartis informed the Group that it has submitted a request to withdraw, with an effective date of January 25, 2023 the Emergency Use Authorization (EUA) application from the U.S. Food and Drug Administration (FDA) for ensovibep. Ensovibep is not presently in clinical development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reservation Agreement with the Swiss Federal Office of Public Health / Bundesamt f&#xfc;r Gesundheit ("FOPH")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;11, 2020, the Group announced the reservation by the FOPH of a defined number of initial doses of the Group's anti-COVID-19 candidate, MP0420. Under the terms of the agreement, the Group received a reservation fee of CHF&#160;7.0&#160;million which resulted in a current contract liability of CHF&#160;7.0&#160;million, as presented in the consolidated statement of financial position for the years 2020 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Group met the contractually agreed milestone specified in the agreement, resulting in the reservation fee received from the FOPH becoming no longer refundable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Group and the FOPH entered into an amendment to extend the term of the reservation agreement by six months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendment also allowed the agreement to be assigned to Novartis upon its exercise &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the option under the Option and Equity Rights Agreement. With the exercise of the option by Novartis in January 2022 and the subsequent assignment of the agreement to Novartis, the Group recognized the CHF&#160;7.0&#160;million contract liability as revenue in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreement with Amgen (the "Amgen Collaboration Agreement")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Group entered into a license and collaboration agreement with Amgen for the clinical development and commercialization of MP0310 / AMG 506. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement the Group received a non-refundable upfront payment of USD&#160;50&#160;million. The Group was primarily responsible for performing certain clinical development, manufacturing and regulatory activities in the first clinical phase and the Group assigned the full USD&#160;50&#160;million (TCHF 49,625) upfront payment as the transaction price to this performance obligation, based on the Group's development plan and the Amgen Collaboration Agreement. The Group recognized the related revenue using the cost-based method to measure it progress by reference to actual costs incurred in relation to the Group's best estimate of total expected costs to satisfy the performance obligation. This cost-based method is subject to the assessment of the management of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;26, 2022 the Group announced that Amgen, had informed the Group of its decision to return the global rights of MP0310 following a strategic pipeline review. With no remaining performance obligations under the Amgen Collaboration Agreement, the Group recognized the remaining balance of the Amgen contract liability as revenue for a total amount reported in 2022 of TCHF 9,653.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, the Group recognized revenues as disclosed in the table below. Revenues in the table below are attributable to individual countries and are based on the location of the Group's alliance partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues by country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands, for the years ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;189,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Analysis of revenue by major alliance partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands, for the years ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis AG, Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;172,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH, Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc., USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;189,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other income &lt;/span&gt;&lt;/div&gt;In the first quarter of 2021 the Group entered into an agreement with Novartis to facilitate manufacturing of MP0420 drug supply at a third party supplier. The related agency services earned during 2022 amounted to TCHF 44 (2021: TCHF 424) and are presented as Other income in the consolidated statement of comprehensive income.</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTEwNA_db90b115-89ee-4f3b-a104-a34b79ad5490"
      unitRef="usd">20000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTExMA_1256b448-f0bd-4e9b-b98f-b0adc3e9d684"
      unitRef="chf">18600000</ifrs-full:CurrentTradeReceivables>
    <moln:PotentialFutureMilestonePayments
      contextRef="i7afdf7fbdcd3403f9eab53aecc3a73dd_D20211214-20211214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE0Ng_3fbad312-a081-4b5b-b8dc-cc8c34164481"
      unitRef="usd">560000000</moln:PotentialFutureMilestonePayments>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE2Mg_db90b115-89ee-4f3b-a104-a34b79ad5490"
      unitRef="usd">20000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i56649e20c0b0463da822d9678ae13d6f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE2OA_1256b448-f0bd-4e9b-b98f-b0adc3e9d684"
      unitRef="chf">18600000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i86479feb060c435da9376e68efd6bae0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTE4OQ_226b0abd-ca89-47bf-9ef0-ddd2dc438d7b"
      unitRef="chf">9800000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTQwMg_764904cc-b3ea-40cb-bdc8-83cb937facc1"
      unitRef="chf">8500000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:RevenueFromRechargeOfEmployeeRelatedExpenses
      contextRef="i86479feb060c435da9376e68efd6bae0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTIwMQ_e2686274-a039-4188-91ec-a4ab1ec8a3dd"
      unitRef="chf">1300000</moln:RevenueFromRechargeOfEmployeeRelatedExpenses>
    <moln:UpfrontPaymentReceived
      contextRef="ie09ac87f9d574f82a6928c8d06b64069_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzQx_d220b7c9-2177-4d78-bc92-550c359ac041"
      unitRef="chf">20000000</moln:UpfrontPaymentReceived>
    <moln:UpfrontPaymentAmountUtilizedDuringPeriod
      contextRef="i36fa71d491c847329fa6c34d14edfb51_D20211231-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzQ5_cbcb3524-41a6-4e13-bc62-94998cd5656e"
      unitRef="chf">20000000</moln:UpfrontPaymentAmountUtilizedDuringPeriod>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i74229b204f0a4e65a5b4572fda04aa7d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk3ODg_ba3181e5-1352-4261-b98b-2e9a8e5cea63"
      unitRef="chf">150000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i4cfad794c98341a992833dca18dfb48a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk4MTI_96b5ddf0-45bc-4338-b41d-c9cd908f2047"
      unitRef="chf">13100000</ifrs-full:RevenueFromContractsWithCustomers>
    <moln:RoyaltyIncomePercentage
      contextRef="i74229b204f0a4e65a5b4572fda04aa7d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk4NTA_43aac4f6-3078-4013-b72e-422f1e7ba0fe"
      unitRef="number">0.22</moln:RoyaltyIncomePercentage>
    <ifrs-full:CurrentContractLiabilities
      contextRef="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5ODM_788278c5-2553-4b35-948f-a709ed82895a"
      unitRef="chf">7000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5ODM_85f40d64-3c0e-499b-b630-2869ff85f6c5"
      unitRef="chf">7000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5OTI_788278c5-2553-4b35-948f-a709ed82895a"
      unitRef="chf">7000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2Mzk5OTI_85f40d64-3c0e-499b-b630-2869ff85f6c5"
      unitRef="chf">7000000</ifrs-full:CurrentContractLiabilities>
    <moln:ExtendedPeriodOfReservationAgreement
      contextRef="i81750a7eb8914110a2c5e64c43bc2de0_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDAwMzQ_a92e34b1-1a06-44e9-b526-91556db4ed5e">P6M</moln:ExtendedPeriodOfReservationAgreement>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="ib0215c4c9fa24e1aa58a4a62c6f6dcac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzU0OTc1NTgzMTQxNA_007e88b0-5188-460d-9f91-653e0323ec9f"
      unitRef="chf">7000000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <moln:UpfrontPaymentReceived
      contextRef="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI2NDQ_e3629a1c-2a8b-408d-b456-56155c6feec0"
      unitRef="usd">50000000</moln:UpfrontPaymentReceived>
    <moln:UpfrontPaymentReceived
      contextRef="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI2NjI_e3629a1c-2a8b-408d-b456-56155c6feec0"
      unitRef="usd">50000000</moln:UpfrontPaymentReceived>
    <moln:UpfrontPaymentReceived
      contextRef="ifafbd9dabaca4bf39c486951b25a67f5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI2Njg_53a31a15-8042-45ea-85b0-2c819c4fb8f1"
      unitRef="chf">49625000</moln:UpfrontPaymentReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i9358dea0732b40a194894bcf6ddddaec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI3MzU_e9f5978e-e9fb-4fed-a1d6-66cd709aee32"
      unitRef="chf">9653000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzM2Nw_30250abe-fcca-4166-bd51-07aeed53d6c9">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, the Group recognized revenues as disclosed in the table below. Revenues in the table below are attributable to individual countries and are based on the location of the Group's alliance partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues by country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands, for the years ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;189,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Analysis of revenue by major alliance partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands, for the years ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis AG, Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;172,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH, Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc., USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;189,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i11c7f8788e1743f68a27f638c26a39bc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItMS0xLTEtMTEyNjgx_b885c4e6-3030-465c-8854-e2844bf8b645"
      unitRef="chf">179903000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i28fa8e94c14b481ca8ccfc64c63add77_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNC0xLTEtMTEyNjg0_67339144-e2dd-4aec-94c0-2b66621926ba"
      unitRef="chf">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ibb6f6a0e23734f59bbbb2a62cce89125_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNy0xLTEtMTEyNjg3_bdd09910-4b63-4d70-8751-fb441ec18b81"
      unitRef="chf">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="iccbcbcc25f484b88a862620fa45229ea_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItMS0xLTEtMTA5NjE4_0c319448-d5dd-4cbc-9517-b6ce4ce2119b"
      unitRef="chf">9653000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i3059de8c6f0f4f34a718c2a08e7fe684_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNC0xLTEtMTA5NjE4_d8840ff8-3e9a-4f83-8b3c-17aac6572fd7"
      unitRef="chf">9330000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i1c93a9c3be2d4ab1aca8bcaec0a3ece3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzItNy0xLTEtMTA5NjE4_da898e12-33e8-460d-8f78-0f8112196681"
      unitRef="chf">9344000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzMtMS0xLTEtMTA5NjE4_87d6c20c-892a-40f5-ba12-019c3e1b32ac"
      unitRef="chf">189556000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzMtNC0xLTEtMTA5NjE4_d8212d48-66f6-447d-b348-55611606c697"
      unitRef="chf">9330000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpmN2E2ZDk0MWYwMmM0NDEzYjMyYjE0MDU1ZWM5Mzk4YS90YWJsZXJhbmdlOmY3YTZkOTQxZjAyYzQ0MTNiMzJiMTQwNTVlYzkzOThhXzMtNy0xLTEtMTA5NjE4_833c0194-fd82-40bb-9961-645a110a7366"
      unitRef="chf">9344000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i9f2f00f6e1d34d28bc572c7a3716463d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItMS0xLTEtMTEyNzAx_d3eaad92-c437-479f-8a00-58cdd7fc0770"
      unitRef="chf">172903000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i98b9c15b3a534e53bbe14f8fb49c9c04_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNC0xLTEtMTEyNzA0_79f5238e-0a4f-4db2-920e-078b2860ef83"
      unitRef="chf">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i69206f52bb344692804141964f0b8919_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNy0xLTEtMTEyNzA3_3e8a3e02-8372-4e5d-832c-9bcfd0b30b63"
      unitRef="chf">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i03d96b78adfc4421949448ba38c3278e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtMS0xLTEtMTEyNzAx_0f852cc9-b560-4da9-9af4-f16bff4ce899"
      unitRef="chf">7000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ie43e19cfc5e6468284394d74ddd1c6b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNC0xLTEtMTEyNzA0_efada4b7-9fa8-4f63-ab2d-f6d7e6a7dbb0"
      unitRef="chf">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i9d6429be12154d0ba42dc47086ea5532_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNy0xLTEtMTEyNzA3_e29d8ee5-e15c-4051-bb08-7e9f266730c0"
      unitRef="chf">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i9358dea0732b40a194894bcf6ddddaec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItMS0xLTEtMTA5NjE4_e9f5978e-e9fb-4fed-a1d6-66cd709aee32"
      unitRef="chf">9653000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i9455742d8ced4b6aa55b012e2998f544_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNC0xLTEtMTA5NjE4_34b7f875-de2d-4891-a433-29ff07f0e30e"
      unitRef="chf">9330000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i7779c743611545a1a5466aeccce603f7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzItNy0xLTEtMTA5NjE4_ea9e499d-7dc2-4dde-af52-9d6451670120"
      unitRef="chf">9344000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtMS0xLTEtMTA5NjE4_55acdbb7-051d-4a44-9a25-46d3fb2c6127"
      unitRef="chf">189556000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNC0xLTEtMTA5NjE4_7b5af922-2dde-459e-a519-a6e782794e17"
      unitRef="chf">9330000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90YWJsZTpkNGE4ZTc4ZjJiNDI0OTVhYjk1YzkyNTIzZWU2MWM5MS90YWJsZXJhbmdlOmQ0YThlNzhmMmI0MjQ5NWFiOTVjOTI1MjNlZTYxYzkxXzMtNy0xLTEtMTA5NjE4_50953119-1827-48a1-aa97-aa69c43fac7d"
      unitRef="chf">9344000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:OtherIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI5NTI_006dc753-b00b-4134-8326-d7426d11a401"
      unitRef="chf">44000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNzcvZnJhZzo4OTMzOGQ1MmRjNmE0MDk5YjA5ZWFiNWVmNWE2ZjljOC90ZXh0cmVnaW9uOjg5MzM4ZDUyZGM2YTQwOTliMDllYWI1ZWY1YTZmOWM4XzEwOTk1MTE2NDI5NjQ_155eef06-cb43-4077-a984-fb71dab10cbc"
      unitRef="chf">424000</ifrs-full:OtherIncome>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90ZXh0cmVnaW9uOjAwOGQzNmY0NGQxNjRhYzM5NzkxYzhmMTQ5ZTgxNzY3XzQw_f7769d13-3bd0-4002-a24f-769cfbe0179c">Property, plant and equipment&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;IT hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,315&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;624&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;21,932&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(4,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(14,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use assets relate to the facilities the Group is leasing in Schlieren, Switzerland.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;IT hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;20,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(12,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i039f8aa8b8604b2e883f7b3401f7a929_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMS0xLTEtMTA5NjE4_d4cdde50-93f6-48ff-b178-bb3e306daff0"
      unitRef="chf">8754000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i7552852e9d984715b1fdd598bf43ceef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtNC0xLTEtMTA5NjE4_257f8977-92dc-4c6b-8e32-5d31ae4c9b20"
      unitRef="chf">711000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ibd82706cc4f64d05a8031db8ac29d402_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtNy0xLTEtMTA5NjE4_ba4610b0-08f8-4362-866b-c86d6009cab2"
      unitRef="chf">1199000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia6bbe794bea748fba48087bb12f33b68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMTAtMS0xLTEwOTYxOA_3781782d-e236-4be1-abc2-05dd0fa3cf14"
      unitRef="chf">9616000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i88e0b443e7594af9817dff19575a130a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMTMtMS0xLTEwOTYxOA_43402806-0185-4d6f-8848-6d4991240e7b"
      unitRef="chf">607000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="id866ae6d346e441aa470d04134f56aea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzMtMTYtMS0xLTEwOTYxOA_6b94c9bd-4aa3-45d1-a1a2-1d67ad6050e5"
      unitRef="chf">20887000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i8f4189b498f848ccbfe85984bfc5754f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMS0xLTEtMTA5NjE4_193a6126-1931-472c-ad65-2a55f867fc26"
      unitRef="chf">1019000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i3fdd67cc72964dfbacdf60557d1afe8a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtNC0xLTEtMTA5NjE4_f0c2fe71-c15c-4709-ac8e-3145b5c78cf3"
      unitRef="chf">20000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i929b7236fc1c4b00a1fbffece5751b1f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtNy0xLTEtMTA5NjE4_7ef5b083-e714-4d4c-a1be-9eb6d261ff8f"
      unitRef="chf">121000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i0bfb7ab39c194903bc349d24d15bdff3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMTAtMS0xLTEwOTYxOA_99268bff-b2b4-457f-9911-c51370302718"
      unitRef="chf">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i449ea807ec98486b91b11b3611579b53_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMTMtMS0xLTEwOTYxOA_e0e92447-ba77-477e-a4ba-000733a35d21"
      unitRef="chf">17000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i721fcb345fbe4680839954bebb736c75_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzQtMTYtMS0xLTEwOTYxOA_9500c96d-068c-4e2d-bed3-60f7b1762e70"
      unitRef="chf">1177000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i8f4189b498f848ccbfe85984bfc5754f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMS0xLTEtMTA5NjE4_1f960984-4783-4983-80b0-22c8943d3439"
      unitRef="chf">127000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i3fdd67cc72964dfbacdf60557d1afe8a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtNC0xLTEtMTA5NjE4_05b0a16d-1993-4b3c-ae8e-3801c755b1d0"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i929b7236fc1c4b00a1fbffece5751b1f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtNy0xLTEtMTA5NjE4_b7efb31b-532b-42b4-be6d-0bf08054c4e6"
      unitRef="chf">5000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i0bfb7ab39c194903bc349d24d15bdff3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMTAtMS0xLTEwOTYxOA_689dd451-b46d-4851-8200-c468d3baff8b"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i449ea807ec98486b91b11b3611579b53_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMTMtMS0xLTEwOTYxOA_86b23f1e-9ce4-4df9-8ebc-124b5a79c08f"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i721fcb345fbe4680839954bebb736c75_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzUtMTYtMS0xLTEwOTYxOA_cf86fd32-b5d7-47ba-adda-778ea2138413"
      unitRef="chf">132000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iae809b4cb3c34e5e883367b1b36f9a41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMS0xLTEtMTA5NjE4_7c420aaa-b909-4d61-bdb4-24f6cf61e040"
      unitRef="chf">9646000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i700c3d4d5945423fb23d62d557025628_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtNC0xLTEtMTA5NjE4_a86442f1-7a19-4417-97ba-4861bfb0c49e"
      unitRef="chf">731000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i442e98a6f284460eb60903633206fee4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtNy0xLTEtMTA5NjE4_719ee655-21c7-4348-bc62-e6b1de1392f8"
      unitRef="chf">1315000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ied5bd6f58f8f48858390908d4e2a3e7e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMTAtMS0xLTEwOTYxOA_3b82cffc-5226-4409-9e7f-cef181985f22"
      unitRef="chf">9616000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i62a4b7bf00f14853a994219c229c2c99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMTMtMS0xLTEwOTYxOA_dd409026-8d4e-4b7a-b4d3-af1cc0ffb10b"
      unitRef="chf">624000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i67bd3877ed504b9aa0d90579b46a85dc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzYtMTYtMS0xLTEwOTYxOA_91fd2ff9-5408-4709-b8f7-4ee0760a864f"
      unitRef="chf">21932000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia8209c15b7f84b6c9ad36754465a7bb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMS0xLTEtMTA5NjE4_e2db9bd2-6804-473d-a77f-f452dc1322cf"
      unitRef="chf">-7164000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8c56aac02e0548818298a1b40775502a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtNC0xLTEtMTA5NjE4_72db48ae-4cb9-4df1-b605-b939559c8fc2"
      unitRef="chf">-653000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iad0b882b89ca4bc19848d14f02c8a322_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtNy0xLTEtMTA5NjE4_7b4b9400-04b0-4af7-b1af-5fbbf4e9a561"
      unitRef="chf">-1012000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i87deb100db7642138360f124b7b83f30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMTAtMS0xLTEwOTYxOA_f5544574-9497-4793-bc65-f0d07e7b8705"
      unitRef="chf">-3615000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i07001daad34a409cb04dc3e2f9fddf5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMTMtMS0xLTEwOTYxOA_5ef5249f-911f-4c22-b74b-19225f66cf7c"
      unitRef="chf">-298000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ib6db54fee24e4009b68217ec1b72ecdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzgtMTYtMS0xLTEwOTYxOA_1094b690-0e59-421a-a8db-e4788892acbf"
      unitRef="chf">-12741000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i75365a982a614edc804e839f45c5b05d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMS0xLTEtMTA5NjE4_c841c39b-a52b-4b9d-a7e4-aad69303e54a"
      unitRef="chf">623000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i078bf95a5a1b404484fa9d710b87ffcc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktNC0xLTEtMTA5NjE4_02a71cb0-658f-4f2b-8948-a02108e761e3"
      unitRef="chf">34000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ice16a04c397c47bca71d3d2d60a51120_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktNy0xLTEtMTA5NjE4_d83bde6d-521d-4bae-a719-33e72352e85d"
      unitRef="chf">165000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i3b1102832e1f4e1fafce024fd7eb6448_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMTAtMS0xLTEwOTYxOA_e59de82b-56b0-48df-a50f-d3c1d6a3d27f"
      unitRef="chf">1200000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i6e85bbf49b974c1ea7e5b7900e92843f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMTMtMS0xLTEwOTYxOA_e46b0fa8-9754-4519-8e9c-679b48d7760c"
      unitRef="chf">66000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i70c79a462ea7412a93e68016da430184_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzktMTYtMS0xLTEwOTYxOA_4f5f362a-7102-4f31-be30-5cdac2abf42d"
      unitRef="chf">2088000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i75365a982a614edc804e839f45c5b05d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTEtMS0xLTEwOTYxOA_197dc206-d62f-4118-a034-7754d02380a2"
      unitRef="chf">-127000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i078bf95a5a1b404484fa9d710b87ffcc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTQtMS0xLTEwOTYxOA_8c7254eb-b190-4da3-b234-9465f6a5281e"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ice16a04c397c47bca71d3d2d60a51120_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTctMS0xLTEwOTYxOA_c3fb4200-1ad3-4300-a04e-72fd528297a4"
      unitRef="chf">-5000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i3b1102832e1f4e1fafce024fd7eb6448_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTEwLTEtMS0xMDk2MTg_4c546899-ee7a-4ac4-8556-921e4ae77514"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i6e85bbf49b974c1ea7e5b7900e92843f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTEzLTEtMS0xMDk2MTg_c8651b3d-4c04-4017-bdd4-68354ce70870"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i70c79a462ea7412a93e68016da430184_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEwLTE2LTEtMS0xMDk2MTg_cf657a00-d7da-4fd8-8b7c-339652cd3533"
      unitRef="chf">-132000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="id7021179595f4067925348f27617f344_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTEtMS0xLTEwOTYxOA_653796db-e514-436c-bfd8-415b312b24d9"
      unitRef="chf">-7660000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i56b61e3a808b46ecb5fd9e84efd88fb1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTQtMS0xLTEwOTYxOA_acfd0d3a-471d-43e2-a4eb-d916becbd3fb"
      unitRef="chf">-687000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icd725be5cb634d3ab32c12364784d95e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTctMS0xLTEwOTYxOA_1eecd969-58b6-40c0-a740-211310a2ac07"
      unitRef="chf">-1172000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i623979330c12419785c4e5ddc7af24af_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTEwLTEtMS0xMDk2MTg_953c7631-3be6-497b-9067-61f433ce1dfe"
      unitRef="chf">-4815000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8693395446c5444f8dea66e3b926bfc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTEzLTEtMS0xMDk2MTg_606a8a53-c78b-41cb-b959-e11d0cd4eaaa"
      unitRef="chf">-364000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="id42028a51dd041c8adf064ec5e6ff3ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzExLTE2LTEtMS0xMDk2MTg_9ef3b8ae-13cb-4dd8-af3a-f88a01bf73ff"
      unitRef="chf">-14697000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3eb97834871d4133bebda22f171f379c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTEtMS0xLTEwOTYxOA_caaef95e-76c2-4cea-94f0-65f34c604285"
      unitRef="chf">1986000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i4515285a8328425c8e01df63e4618b0e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTQtMS0xLTEwOTYxOA_69ca4d95-7a9f-42cf-8e2d-0539a9033766"
      unitRef="chf">44000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iad950054a9b34e23b44f9eadcd5ac579_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTctMS0xLTEwOTYxOA_67da88ee-3205-4f4b-a95d-80070c0889b8"
      unitRef="chf">143000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icc0b75f40939487cb5f179a9d998733b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTEwLTEtMS0xMDk2MTg_b91b2a03-eb0d-4416-8232-6d11ff0befe7"
      unitRef="chf">4802000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icbf076ebc35b49ddbe4032b44413da3d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTEzLTEtMS0xMDk2MTg_449af92e-96b5-4e29-a1d1-60f61f43ed77"
      unitRef="chf">260000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTpkYjQ1YWYwNTUzYjI0NGFmYTE1YWI4YzA1ODNmYmU4NS90YWJsZXJhbmdlOmRiNDVhZjA1NTNiMjQ0YWZhMTVhYjhjMDU4M2ZiZTg1XzEyLTE2LTEtMS0xMDk2MTg_d44f78a4-da6a-45b5-ae7b-451000047916"
      unitRef="chf">7235000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i54edf24cb9164d1dbfea8b8935a712b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMS0xLTEtMTA5NjE4_9cf82d8d-2298-4477-a2c8-f4f2c100422c"
      unitRef="chf">8337000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iea606ad4acc0477bbea8cec093c5f28a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtNC0xLTEtMTA5NjE4_4de6a7e7-5a09-43e5-8f35-af5874e1e6ee"
      unitRef="chf">660000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6ca2744f82cc4290b5c5196c97ed6050_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtNy0xLTEtMTA5NjE4_3dee1d69-48a6-4b36-a992-799c1e824eab"
      unitRef="chf">1119000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i26412b3157954911862c5a447f325fd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMTAtMS0xLTEwOTYxOA_a6f4953d-16b7-4c29-8171-073d006de18f"
      unitRef="chf">9616000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i18bc5a3445ce443b98c1b2827a0abbf8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMTMtMS0xLTEwOTYxOA_a5c7a144-dc28-4ac2-9a2f-ad3d86775c00"
      unitRef="chf">317000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iacafa94802ef4385b1333762542ab2f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzMtMTYtMS0xLTEwOTYxOA_8638bb47-bc9d-4f59-99e6-39e779a56b67"
      unitRef="chf">20049000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i610b20f353ba4dea967f7adf9a040527_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMS0xLTEtMTA5NjE4_5d5fd567-8a20-4b62-b453-984c07ff613a"
      unitRef="chf">438000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ib96855ceb0f64121a493479e560bef93_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtNC0xLTEtMTA5NjE4_a1712fda-16d8-47df-9f83-0f9ac1b1ff0a"
      unitRef="chf">51000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ia9417e12bdb64e3bafac232b9b8e7099_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtNy0xLTEtMTA5NjE4_ab4563f6-0e1a-42d4-bd82-3dd79a4440c9"
      unitRef="chf">154000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="id2dba62e38a349b5bd2d7fb9c9475d34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMTAtMS0xLTEwOTYxOA_fe1f402f-1538-40e1-bf4a-53baed49a4ad"
      unitRef="chf">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="iaa9d4dcab9014ff6a5667ed415cacf65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMTMtMS0xLTEwOTYxOA_40423e82-4ff0-4e49-8409-cf0135dd817c"
      unitRef="chf">290000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i9e266b3fb54b46679c03b9f807b42f18_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzQtMTYtMS0xLTEwOTYxOA_3d5ea0e5-ee2b-43d2-8f9b-ca9a68e557ca"
      unitRef="chf">933000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i610b20f353ba4dea967f7adf9a040527_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMS0xLTEtMTA5NjE4_b5bc35c5-a4fa-4599-b063-b19a1334e73e"
      unitRef="chf">22000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ib96855ceb0f64121a493479e560bef93_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtNC0xLTEtMTA5NjE4_535bad18-ef66-4200-b582-50b1d89736b0"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ia9417e12bdb64e3bafac232b9b8e7099_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtNy0xLTEtMTA5NjE4_4f3ee8f6-ae7d-48e0-86fe-6753c19cc6f2"
      unitRef="chf">74000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ic872fe1c5a64452688768d06a4b4096c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMTAtMS0xLTEwOTYxOA_8407dac0-925f-4794-88ec-77151dd191b3"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iaa9d4dcab9014ff6a5667ed415cacf65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMTMtMS0xLTEwOTYxOA_93aa4a0d-4601-45a3-af5b-a11548393582"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i9e266b3fb54b46679c03b9f807b42f18_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzUtMTYtMS0xLTEwOTYxOA_298772e8-f45f-47bf-8745-046bb36745c6"
      unitRef="chf">96000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i039f8aa8b8604b2e883f7b3401f7a929_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMS0xLTEtMTA5NjE4_163d88a2-f9f1-4cd3-82c3-23c0847ee860"
      unitRef="chf">8754000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i7552852e9d984715b1fdd598bf43ceef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtNC0xLTEtMTA5NjE4_639d02eb-bc52-4727-bba0-c4c9394f98da"
      unitRef="chf">711000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ibd82706cc4f64d05a8031db8ac29d402_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtNy0xLTEtMTA5NjE4_39f2da1d-79d3-4875-a9f4-93635315c49b"
      unitRef="chf">1199000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia6bbe794bea748fba48087bb12f33b68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMTAtMS0xLTEwOTYxOA_e22a94f2-47c9-45f9-b1de-2c1d0d04a554"
      unitRef="chf">9616000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i88e0b443e7594af9817dff19575a130a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMTMtMS0xLTEwOTYxOA_2b0f9300-e527-4714-bb36-f0fe07469aa3"
      unitRef="chf">607000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="id866ae6d346e441aa470d04134f56aea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzYtMTYtMS0xLTEwOTYxOA_4d5c6459-3431-494a-9bb3-e56e7acf9eb0"
      unitRef="chf">20887000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i400d3c0abd194c8e869aa1b7e6a16268_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMS0xLTEtMTA5NjE4_0bf92e63-ecc9-4680-82bc-8ffded7963c7"
      unitRef="chf">-6602000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i74f28cfe913d4066ba37fda6c47ac60d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtNC0xLTEtMTA5NjE4_d4aba85f-5d9e-4e95-87b3-726c42797839"
      unitRef="chf">-617000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i337a906d7c4e48bc876b5ed46aa717c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtNy0xLTEtMTA5NjE4_1d8b53fa-0e4a-4d44-90d2-fac74034728e"
      unitRef="chf">-757000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1742ca85635d45afaa2bb5e7b5c34750_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMTAtMS0xLTEwOTYxOA_158f137e-e6f9-4608-b76e-1bce4cefcd88"
      unitRef="chf">-2414000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ib8ce32bfd0d64572b4c65f93443e740f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMTMtMS0xLTEwOTYxOA_ec7acac9-6a43-4d1d-8a4d-3c03efb39dde"
      unitRef="chf">-273000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icab5d29cfc93414ea6aba3b898a8cf72_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzgtMTYtMS0xLTEwOTYxOA_0a5b54c1-8fbf-4584-b42d-7772f06cc8e7"
      unitRef="chf">-10662000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ica8eaf81db894ce0b611d7d987fef5f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMS0xLTEtMTA5NjE4_c8caa493-4aac-46ab-bc59-3b2c4a17daa1"
      unitRef="chf">583000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i15f9aad96b06470c9ded02ebad46915c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktNC0xLTEtMTA5NjE4_03d5367b-1034-450b-ad24-c298ed2cc35d"
      unitRef="chf">36000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i97000304b6a7470ba15cf385bc4113c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktNy0xLTEtMTA5NjE4_aa0c8ad3-5928-4123-9978-768ed9ee60e8"
      unitRef="chf">329000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="idd1b6d0b84ef47739e20d7569c9e7102_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMTAtMS0xLTEwOTYxOA_25c16f61-3b0f-4438-9aeb-43941ca4b809"
      unitRef="chf">1200000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i0c236926219843fc950064245dabb01c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMTMtMS0xLTEwOTYxOA_85348138-e641-49af-9477-d7b25a66d384"
      unitRef="chf">25000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i7da99d7da3114dd5a669a798631979bb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzktMTYtMS0xLTEwOTYxOA_199893f5-d15e-462c-a08b-5e41dace3786"
      unitRef="chf">2174000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ica8eaf81db894ce0b611d7d987fef5f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTEtMS0xLTEwOTYxOA_3c35320c-657b-4457-ae3c-d6ed86d38960"
      unitRef="chf">-22000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i15f9aad96b06470c9ded02ebad46915c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTQtMS0xLTEwOTYxOA_4a58f099-5961-4857-91ac-cb0c84ff0856"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i97000304b6a7470ba15cf385bc4113c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTctMS0xLTEwOTYxOA_0f2dc528-65d7-4e73-9f20-729b7bf71ad7"
      unitRef="chf">-74000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="idd1b6d0b84ef47739e20d7569c9e7102_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTEwLTEtMS0xMDk2MTg_b148ee08-3861-489a-a731-1bba0c1a454b"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i0c236926219843fc950064245dabb01c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTEzLTEtMS0xMDk2MTg_d329b6a0-1847-45e0-87f2-ecee12cc5d79"
      unitRef="chf">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i7da99d7da3114dd5a669a798631979bb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEwLTE2LTEtMS0xMDk2MTg_c597192e-8191-435c-a064-93fcab7c2a68"
      unitRef="chf">-96000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia8209c15b7f84b6c9ad36754465a7bb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTEtMS0xLTEwOTYxOA_01e861d6-d2ac-417b-b007-dcd5281c1c71"
      unitRef="chf">-7164000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8c56aac02e0548818298a1b40775502a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTQtMS0xLTEwOTYxOA_c828882a-1272-4eeb-91f1-b5df89c7ce1f"
      unitRef="chf">-653000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iad0b882b89ca4bc19848d14f02c8a322_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTctMS0xLTEwOTYxOA_a545588d-cf59-4a38-8d3e-446205a2b3bb"
      unitRef="chf">-1012000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i87deb100db7642138360f124b7b83f30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTEwLTEtMS0xMDk2MTg_49da6d7a-5193-4f5e-9aab-3d3585427d60"
      unitRef="chf">-3615000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i07001daad34a409cb04dc3e2f9fddf5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTEzLTEtMS0xMDk2MTg_c4df6b47-2fc7-44a1-8fe9-0aa4cdce8948"
      unitRef="chf">-298000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ib6db54fee24e4009b68217ec1b72ecdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzExLTE2LTEtMS0xMDk2MTg_124b4d73-523f-4c03-a18f-da07275d3374"
      unitRef="chf">-12741000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1d43267d2666482cbd65715b80893cc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTEtMS0xLTEwOTYxOA_48882fb3-0560-40ed-89d8-27db713f9f9b"
      unitRef="chf">1590000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iab1da6a1258a4f2f824c654908d097f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTQtMS0xLTEwOTYxOA_8b39c143-7403-4922-a755-63c28232e5d5"
      unitRef="chf">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ibcab65890a354c7eb8e9eaaa6083e002_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTctMS0xLTEwOTYxOA_6211cd89-1a98-4780-9453-c53a77b7150e"
      unitRef="chf">186000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1330a3506b934eb6a59f96f40d105eca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTEwLTEtMS0xMDk2MTg_0fd7f143-5c70-473d-b3c7-47d350edba7d"
      unitRef="chf">6001000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i60ae0c8e6c1242e094cae93b6edbc064_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTEzLTEtMS0xMDk2MTg_4ec01da6-e139-43c2-8e9c-8f4cb3603023"
      unitRef="chf">309000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODAvZnJhZzowMDhkMzZmNDRkMTY0YWMzOTc5MWM4ZjE0OWU4MTc2Ny90YWJsZTo2OGU0MjA3ZjJlYzc0ZmIwYmE3OGMyNjM4MDJiMzc1ZC90YWJsZXJhbmdlOjY4ZTQyMDdmMmVjNzRmYjBiYTc4YzI2MzgwMmIzNzVkXzEyLTE2LTEtMS0xMDk2MTg_18d24150-75a3-4372-a29b-3e3c1a3135da"
      unitRef="chf">8146000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90ZXh0cmVnaW9uOmNmODhkMTE2MzJlZjRiOWZiM2JmNjQyMTg2ZWNlMDMwXzEz_05a7c547-489b-45df-87b1-5ad9e3470cd6">Intangible assets&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90ZXh0cmVnaW9uOmNmODhkMTE2MzJlZjRiOWZiM2JmNjQyMTg2ZWNlMDMwXzE0_d46444e7-51e8-4e29-923b-4587f6ce99ed">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i322fcb8657fc434286b60a943aabbd22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzMtMS0xLTEtMTA5NjE4_db2f0b06-1bbc-4d92-81a4-9387de0798e3"
      unitRef="chf">1904000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i2a000e55273047dba1042898c89c120b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzQtMS0xLTEtMTA5NjE4_7a0e52c7-dfb1-4824-8d5c-f3d7d8440868"
      unitRef="chf">240000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i2a000e55273047dba1042898c89c120b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzUtMS0xLTEtMTA5NjE4_509812ac-a182-4f45-9840-af9406ecb099"
      unitRef="chf">22000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i40f2da050b044a43bb1f4bbaaedd6819_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzYtMS0xLTEtMTA5NjE4_e0ce944d-a746-4510-8923-389752d43387"
      unitRef="chf">2122000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i14e65b8ceef04aa9a9e140cd7cd7c323_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzgtMS0xLTEtMTA5NjE4_ab599e5c-1034-4a8d-b1e6-196d16ce1354"
      unitRef="chf">-1574000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i137ae661167d42648f19a81509b45e09_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzktMS0xLTEtMTA5NjE4_5432010a-48dc-4d11-9598-d0517fc876aa"
      unitRef="chf">299000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i137ae661167d42648f19a81509b45e09_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzEwLTEtMS0xLTEwOTYxOA_8e561c45-13dd-4450-8cae-655030ff6db9"
      unitRef="chf">-22000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ib61e00b45a7c4b488678787526592c08_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzExLTEtMS0xLTEwOTYxOA_8238ed11-19aa-4b92-9cc9-fcde8d71b1a4"
      unitRef="chf">-1851000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ib0a2cc30e5c64038a201d238fbf11978_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo3MjIwZTdhZTU4NzQ0MTkzODFjMWI3NzZlODcwYjMyZi90YWJsZXJhbmdlOjcyMjBlN2FlNTg3NDQxOTM4MWMxYjc3NmU4NzBiMzJmXzEyLTEtMS0xLTEwOTYxOA_3ebd2231-3e9c-4e59-911e-b7d4c15f8ad0"
      unitRef="chf">271000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="if9c8f0e30de34329b9dd662589d2625a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzMtMS0xLTEtMTA5NjE4_10f43fc5-4fd8-4639-91fa-6fbad95a911a"
      unitRef="chf">1530000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="iaf6e38e9a01048c6a7e34827d9d57b9c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzQtMS0xLTEtMTA5NjE4_a8e27e30-a623-485f-bb34-c35bd7c006aa"
      unitRef="chf">374000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="iaf6e38e9a01048c6a7e34827d9d57b9c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzUtMS0xLTEtMTA5NjE4_39c08f3d-0b46-459c-a186-0805201afb4c"
      unitRef="chf">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i322fcb8657fc434286b60a943aabbd22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzYtMS0xLTEtMTA5NjE4_9fe68a58-f2f3-46a6-8cb8-10b731592f43"
      unitRef="chf">1904000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ib278e099451c4b7e9229b48c30d76025_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzgtMS0xLTEtMTA5NjE4_5b04a528-7dbc-4b13-a4ef-ecc04c7f7458"
      unitRef="chf">-1183000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="ia8bbbdd9cb75406c8df9b0ed579152dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzktMS0xLTEtMTA5NjE4_1f5342a8-764f-4a83-a3a4-0a3ff48fcb88"
      unitRef="chf">391000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="ia8bbbdd9cb75406c8df9b0ed579152dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzEwLTEtMS0xLTEwOTYxOA_2a3d2449-d1bc-4f1d-8bc7-b2f5afbd8daf"
      unitRef="chf">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i14e65b8ceef04aa9a9e140cd7cd7c323_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzExLTEtMS0xLTEwOTYxOA_21290e9c-273f-49de-8d8b-6a4741b89f3a"
      unitRef="chf">-1574000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i0ef84e56318a489a8550043d9384b54b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODMvZnJhZzpjZjg4ZDExNjMyZWY0YjlmYjNiZjY0MjE4NmVjZTAzMC90YWJsZTo1OGM0ODMxYzhlMjI0OGQ0YTYwMjJlOTlkMzU5Y2E1Yy90YWJsZXJhbmdlOjU4YzQ4MzFjOGUyMjQ4ZDRhNjAyMmU5OWQzNTljYTVjXzEyLTEtMS0xLTEwOTYxOA_c976360d-6d59-4848-abcb-482071c0f229"
      unitRef="chf">331000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90ZXh0cmVnaW9uOmE5NjU4MDcxNzk0YzRhMTRiOTJiNmExNjIzNjQyNmUwXzIz_7f81f168-28a0-4ded-ab9f-000d94432c7b">Financial instruments&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets at amortized costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;161,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;250,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;156,599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The above mentioned amounts were neither past due nor impaired at the end of the respective reporting period and were of highly rated quality. Please also see note 25.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued project costs and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-employee related accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued project costs and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-employee related accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;14,848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of financial assets and financial liabilities not measured at fair value (except for lease liabilities) is a reasonable approximation of fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90ZXh0cmVnaW9uOmE5NjU4MDcxNzk0YzRhMTRiOTJiNmExNjIzNjQyNmUwXzI0_f1f1b94c-ed6b-40ed-8b24-ffa4b8ed8167">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets at amortized costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;161,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;250,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;156,599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="iac28997728a9430bb0713563ae32e639_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzItMS0xLTEtMTA5NjE4_0cb13c15-28a3-4e9c-b170-13a28ba3702e"
      unitRef="chf">87946000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="id7a6529b985e46fea5bb9ea34f1efa71_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzMtMS0xLTEtMTA5NjE4_25e4c455-bc41-4c85-9683-646798f764f7"
      unitRef="chf">521000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i08f2c57f37114335bb14a01f1e265d33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzQtMS0xLTEtMTA5NjE4_e54c82a3-e12a-46af-a158-4dc648d2dff8"
      unitRef="chf">679000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i5978b0e87e0e41418a1eb6893998c62a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzUtMS0xLTEtMTA5NjE4_831f1cb4-f130-444c-b087-1120b23c450f"
      unitRef="chf">161198000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i9bef516c67454da38f24cc8f5ef7b00f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzYtMS0xLTEtMTA5NjE4_b614a088-d64d-4d47-8a92-29ddf3919073"
      unitRef="chf">250344000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="ifd992de4c1764c598225f05b506bb29b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzgtMS0xLTEtMTA5NjE4_a87adb07-7fbd-42ef-8052-0cf19f9d1966"
      unitRef="chf">71813000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i829b948cf2c94f18aebf743811865ac2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzktMS0xLTEtMTA5NjE4_1bc21463-1ea0-4a4c-b357-5d8d53213400"
      unitRef="chf">23710000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="id32257a4e4494aacb101dba09b0114a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzEwLTEtMS0xLTEwOTYxOA_e0393618-61ab-4bc0-b1fa-a3969dca54b3"
      unitRef="chf">76000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="ic6313d1eb0624defb28c64aa01dea0b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzExLTEtMS0xLTEwOTYxOA_839b31e9-3fbb-41be-bded-68bb9a99bd0d"
      unitRef="chf">61000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i9789cf293a2a4a9b8bb9f043c05612a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpjYTAwYTBkOTM3NWQ0MGFhYWY5N2JkYWI4M2JiZGQ5NC90YWJsZXJhbmdlOmNhMDBhMGQ5Mzc1ZDQwYWFhZjk3YmRhYjgzYmJkZDk0XzEyLTEtMS0xLTEwOTYxOA_1e623582-0ee3-4919-ad17-9d37359f2160"
      unitRef="chf">156599000</ifrs-full:FinancialAssets>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90ZXh0cmVnaW9uOmE5NjU4MDcxNzk0YzRhMTRiOTJiNmExNjIzNjQyNmUwXzI1_30d2ae15-b76b-4a64-8c87-6cf0abf78654">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" rowspan="2" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued project costs and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-employee related accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued project costs and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-employee related accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;14,848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:FinancialLiabilities
      contextRef="i61b9f00779e44405b197ec74e74a0439_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzItMS0xLTEtMTA5NjE4_59a1b763-02cb-4114-9ad0-7a1cbdfef64e"
      unitRef="chf">997000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="ie27040b2af4143aab5074a6b04e2ced4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzMtMS0xLTEtMTA5NjE4_b5bc85b7-67d0-42db-b1a6-e83d195ef382"
      unitRef="chf">2167000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i587a7a797df14da6b6b0b353a5dbac42_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzQtMS0xLTEtMTA5NjE4_340d6fd6-7002-46e3-8fa6-e91778270fba"
      unitRef="chf">4850000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i28fffe2b94ca408ca522a3764d0a9a7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzUtMS0xLTEtMTA5NjE4_fddbb4b1-42b2-45c3-a3f0-f8585434e58f"
      unitRef="chf">556000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="ideda6d7323e8434683a468cdbdbfaad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzYtMS0xLTEtMTA5NjE4_10ece931-0e18-47ab-9574-b9d245989adb"
      unitRef="chf">8570000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i304edf7fc9dc4af086181703ec172bbf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzgtMS0xLTEtMTA5NjE4_bab1c094-a602-4e2a-a9ad-14313ad64af3"
      unitRef="chf">4862000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i786fc55946ab49a5b3e6894295ca6683_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzktMS0xLTEtMTA5NjE4_73435e0c-a2f3-4ce3-993a-2f3d7d2d1eae"
      unitRef="chf">3410000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="iff33ff9bbe6c47fdacddc7317235393c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzEwLTEtMS0xLTEwOTYxOA_839474a6-76ba-443b-a543-5a9983c1779a"
      unitRef="chf">6039000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i5f4ee1fc220b4633b70d08183faf0864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzExLTEtMS0xLTEwOTYxOA_fea76590-4a00-4a96-aa3b-bd8a25d6e843"
      unitRef="chf">537000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i4bddec936def48f8835419a973c2564e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODYvZnJhZzphOTY1ODA3MTc5NGM0YTE0YjkyYjZhMTYyMzY0MjZlMC90YWJsZTpmNzc2YTI4NWYzMTM0ZTJlOTc2MzhkMTEwODljYWRkMy90YWJsZXJhbmdlOmY3NzZhMjg1ZjMxMzRlMmU5NzYzOGQxMTA4OWNhZGQzXzEyLTEtMS0xLTEwOTYxOA_77c07ee8-95fb-4dc8-962d-33d7e06e2059"
      unitRef="chf">14848000</ifrs-full:FinancialLiabilities>
    <moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90ZXh0cmVnaW9uOmZjMjliZTUyNWFlOTRmNzU4MDdmODQ3YTEwNmM2MTc3XzE5_aaea3d8d-bd61-4f34-ab75-7075529dbe5c">Other current assets&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock>
    <moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90ZXh0cmVnaW9uOmZjMjliZTUyNWFlOTRmNzU4MDdmODQ3YTEwNmM2MTc3XzIw_26b32305-37c9-43a6-b61d-b14b50e4c492">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzEtMS0xLTEtMTA5NjE4_9bf5224a-bcb1-46f9-8030-52633f7b6fba"
      unitRef="chf">3910000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzEtNC0xLTEtMTA5NjE4_413cfe8a-5717-49a9-af7e-0d4ac09ec97d"
      unitRef="chf">5652000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentAccruedIncomeOtherThanCurrentContractAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzItMS0xLTEtMTA5NjE4_5daacd73-2bd0-4a71-a14d-c5693ec894d2"
      unitRef="chf">679000</ifrs-full:CurrentAccruedIncomeOtherThanCurrentContractAssets>
    <ifrs-full:CurrentAccruedIncomeOtherThanCurrentContractAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzItNC0xLTEtMTA5NjE4_a06ebd44-9ec1-4cf8-9986-070ef611133c"
      unitRef="chf">76000</ifrs-full:CurrentAccruedIncomeOtherThanCurrentContractAssets>
    <ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzMtMS0xLTEtMTA5NjE4_634c7335-2118-483b-8d14-04748083f60c"
      unitRef="chf">4589000</ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets>
    <ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yODkvZnJhZzpmYzI5YmU1MjVhZTk0Zjc1ODA3Zjg0N2ExMDZjNjE3Ny90YWJsZTo5Y2U1Yjk4NzI4YmE0MzY5YTViODRkOTRkMGQyYTExNC90YWJsZXJhbmdlOjljZTViOTg3MjhiYTQzNjlhNWI4NGQ5NGQwZDJhMTE0XzMtNC0xLTEtMTA5NjE4_25b5d011-a48e-42e4-a94e-bb9be9ea801a"
      unitRef="chf">5728000</ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90ZXh0cmVnaW9uOjAwZTNiYTczYjgyMzQ3ZTVhNGI0MjU5OTQyZTEwMzBjXzQ0_3e360874-eea2-46e0-95c2-c22afdf64ed2">Trade and other receivables&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Value added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Withholding tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;25,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables are denominated in the following currencies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;23,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in trade receivables for 2022 mainly related to the License and Collaboration Agreement with Novartis entered into in December 2021. The amount invoiced to Novartis in December 2021 was received in cash in January 2022.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90ZXh0cmVnaW9uOjAwZTNiYTczYjgyMzQ3ZTVhNGI0MjU5OTQyZTEwMzBjXzQ1_3da8b6b2-71be-4fb8-b32a-7d7de5f012d4">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Value added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Withholding tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;25,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables are denominated in the following currencies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;23,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzEtMS0xLTEtMTA5NjE4_09cc10d2-58d7-4364-91fe-152fdffb6d34"
      unitRef="chf">521000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzEtNC0xLTEtMTA5NjE4_30ce7643-fc88-4f9e-8249-74910e007c7b"
      unitRef="chf">23710000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzItMS0xLTEtMTA5NjE4_813634dd-76a7-4944-86b2-da529956c367"
      unitRef="chf">250000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzItNC0xLTEtMTA5NjE4_08b91915-1adc-47d9-8ff8-6c3817ca6df9"
      unitRef="chf">1770000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzMtMS0xLTEtMTA5NjE4_b01c0a93-b460-47d6-b92f-a7d7aa6bc434"
      unitRef="chf">173000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzMtNC0xLTEtMTA5NjE4_2d04b67d-ed21-487e-a3a3-fa090b9c122e"
      unitRef="chf">24000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:OtherCurrentReceivables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzQtMS0xLTEtMTA5NjE4_0b74f371-92a9-4d20-b706-baafe9d840e1"
      unitRef="chf">75000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzQtNC0xLTEtMTA5NjE4_d8f014a9-98aa-4280-ba11-984eb974969b"
      unitRef="chf">146000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzUtMS0xLTEtMTA5NjE4_f04bcdb6-0066-4ebe-9557-0dd4a6d0f114"
      unitRef="chf">1019000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTo1MDAwNTg2MjQ1ZmM0ZmJiOGUxYTQ1MmFiODYxNjQzZS90YWJsZXJhbmdlOjUwMDA1ODYyNDVmYzRmYmI4ZTFhNDUyYWI4NjE2NDNlXzUtNC0xLTEtMTA5NjE4_3931eea3-3229-43c8-a288-2748fe89c43f"
      unitRef="chf">25650000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzEtMS0xLTEtMTA5NjE4_980d801e-11e1-4037-9962-b792e73c5997"
      unitRef="chf">160000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzEtNC0xLTEtMTA5NjE4_f6f1ef66-2741-4d41-8204-3de36963488e"
      unitRef="chf">958000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzItMS0xLTEtMTA5NjE4_2c8e216a-24ba-4633-9469-0e2b7a0c9d73"
      unitRef="chf">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzItNC0xLTEtMTA5NjE4_fcb07f3d-e206-4fbf-94bc-fa3665c202bf"
      unitRef="chf">3127000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzMtMS0xLTEtMTA5NjE4_9bc7619d-7903-4827-b4ef-2956d5d68905"
      unitRef="chf">361000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzMtNC0xLTEtMTA5NjE4_20245feb-70ac-4a57-9cfe-f6a914dd5423"
      unitRef="chf">19625000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzQtMS0xLTEtMTA5NjE4_d1104317-ae6e-43c0-8869-9fdfc972b093"
      unitRef="chf">521000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTIvZnJhZzowMGUzYmE3M2I4MjM0N2U1YTRiNDI1OTk0MmUxMDMwYy90YWJsZTplMmMxZDBlYWJjOGM0NDVhYWVlZWZiZDZjNjI4ODlmNS90YWJsZXJhbmdlOmUyYzFkMGVhYmM4YzQ0NWFhZWVlZmJkNmM2Mjg4OWY1XzQtNC0xLTEtMTA5NjE4_391b79b7-d3cb-4dae-a904-5d654cf427b6"
      unitRef="chf">23710000</ifrs-full:CurrentTradeReceivables>
    <moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0_7c86ee19-7297-4d19-93a2-4ab90a8488a0">Cash, cash equivalents and short-term time deposits&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total cash at bank at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,946&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;71,813&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits in CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits in EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total short-term deposits at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;161,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The short-term time deposits denominated in CHF at December&#160;31, 2022 contained six positions with three Swiss banks, the short-term time deposits denominated in USD contained three positions with three Swiss banks and the short-term time deposits denominated in EUR contained one position with one Swiss bank. The short-term time deposits in CHF at December&#160;31, 2021 contained one position with one Swiss bank and the short-term time deposits denominated in USD contained three positions with two Swiss banks. Please also refer to note 25.&lt;/span&gt;&lt;/div&gt;</moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock>
    <moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU1_14a644af-2eef-45a3-8b19-2895e588618e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank in GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total cash at bank at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,946&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;71,813&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits in CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits in EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total short-term deposits at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;161,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzEtMS0xLTEtMTA5NjE4_3147ae58-67f4-4534-9ee4-11eec58f461f"
      unitRef="chf">67611000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzEtNC0xLTEtMTA5NjE4_77e20fdf-b95c-42f7-a309-c6d997560c6e"
      unitRef="chf">44621000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzItMS0xLTEtMTA5NjE4_101eb846-5d02-4f43-9e8a-7925878a4eda"
      unitRef="chf">7685000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzItNC0xLTEtMTA5NjE4_69229f1d-09c3-472e-af4b-7bb1fcb4c602"
      unitRef="chf">20313000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzMtMS0xLTEtMTA5NjE4_58b124c8-3d96-4733-9ee8-8d8b297b2bda"
      unitRef="chf">12520000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzMtNC0xLTEtMTA5NjE4_55adb384-df3a-43d5-b7b2-47307a7265ba"
      unitRef="chf">5821000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ifd1e5f5e6ec145b3bceebef0cf07f8db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzQtMS0xLTEtMTA5NjE4_d279fa45-6e72-40d8-ab86-8def7f26f01a"
      unitRef="chf">130000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="iee446437d91845ccb79f71155459c929_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzQtNC0xLTEtMTA5NjE4_989d3b54-958d-47e0-a309-d5434c85c35c"
      unitRef="chf">1058000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzUtMS0xLTEtMTA5NjE4_319740a7-3ec2-4b81-8cf5-6e8b6044e1fd"
      unitRef="chf">87946000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzUtNC0xLTEtMTA5NjE4_13057b77-f90e-489d-b786-05b735281cad"
      unitRef="chf">71813000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzctMS0xLTEtMTA5NjE4_2220eac0-b7e2-4be9-882d-4732b410e76d"
      unitRef="chf">110000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzctNC0xLTEtMTA5NjE4_41a28201-cd5d-4bc7-abb6-4d94e93ccb4d"
      unitRef="chf">20000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtMS0xLTEtMTEyNzMw_6b445bbf-4d1c-4e0a-902d-0efe35950c9b"
      unitRef="chf">4938000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtNC0xLTEtMTEyNzMz_f232b5fd-1b0d-414e-a416-e7a6f8425d61"
      unitRef="chf">0</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtMS0xLTEtMTA5NjE4_c431faef-8719-481a-96eb-922e024fae91"
      unitRef="chf">46260000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzgtNC0xLTEtMTA5NjE4_d5d0d166-ff01-41f3-96d7-0c8a2eca8f18"
      unitRef="chf">41000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzktMS0xLTEtMTA5NjE4_f851f675-053a-4050-ac6a-34e780984d4d"
      unitRef="chf">161198000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90YWJsZTo1OWNhYmE5ZTg5ODY0OTE1YWJmZDgzZjBiNTE4MmM0Yy90YWJsZXJhbmdlOjU5Y2FiYTllODk4NjQ5MTVhYmZkODNmMGI1MTgyYzRjXzktNC0xLTEtMTA5NjE4_07537003-90b5-46b0-ba2d-de5166a54e7f"
      unitRef="chf">61000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <moln:NumberOfShortTermTimeDepositPositions
      contextRef="i150e9865322b40bf976dd456472c9667_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk1Nw_496e8fe0-f11b-459d-b2be-aa5f2301d05b"
      unitRef="position">6</moln:NumberOfShortTermTimeDepositPositions>
    <moln:NumberOfBanksWhereDepositsAreHeld
      contextRef="i150e9865322b40bf976dd456472c9667_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk2Mw_ded9d2e7-a6fb-4f26-922d-08fc9ce51cd4"
      unitRef="bank">3</moln:NumberOfBanksWhereDepositsAreHeld>
    <moln:NumberOfShortTermTimeDepositPositions
      contextRef="ie1e6b625e94e4ef8b99a049db65e38b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk2OQ_d48b83f3-f430-43b6-8fb8-162e615af340"
      unitRef="position">3</moln:NumberOfShortTermTimeDepositPositions>
    <moln:NumberOfBanksWhereDepositsAreHeld
      contextRef="ie1e6b625e94e4ef8b99a049db65e38b2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk3NQ_39e198fd-edd0-434b-9347-961152bf1408"
      unitRef="bank">3</moln:NumberOfBanksWhereDepositsAreHeld>
    <moln:NumberOfShortTermTimeDepositPositions
      contextRef="i297e474b905f4802b3fc5c84517b4244_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk4MQ_c6ed3146-6107-40b5-b698-c59eda184b68"
      unitRef="position">1</moln:NumberOfShortTermTimeDepositPositions>
    <moln:NumberOfBanksWhereDepositsAreHeld
      contextRef="i297e474b905f4802b3fc5c84517b4244_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzEwOTk1MTE2Mjg3MjI_371ec1cd-45ca-4356-a478-afa7a584ae5f"
      unitRef="bank">1</moln:NumberOfBanksWhereDepositsAreHeld>
    <moln:NumberOfShortTermTimeDepositPositions
      contextRef="if62d6f3c76c74566abf3f5f15fb7e4a0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxMzk5OQ_0f39775a-986b-4201-93dc-1235de1a881e"
      unitRef="position">1</moln:NumberOfShortTermTimeDepositPositions>
    <moln:NumberOfBanksWhereDepositsAreHeld
      contextRef="if62d6f3c76c74566abf3f5f15fb7e4a0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxNDAwNQ_84a04cb8-728e-46c4-b3bb-ea3740cb5182"
      unitRef="bank">1</moln:NumberOfBanksWhereDepositsAreHeld>
    <moln:NumberOfShortTermTimeDepositPositions
      contextRef="i7b4cf686055c46f0990c5475b479feab_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxNDAxMQ_6e43514a-8baa-4f25-a860-9b30d040286c"
      unitRef="position">3</moln:NumberOfShortTermTimeDepositPositions>
    <moln:NumberOfBanksWhereDepositsAreHeld
      contextRef="i7b4cf686055c46f0990c5475b479feab_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTUvZnJhZzplMzJhNWU5MGNlZDk0MjFmYTM1OWM4OTMyNTEzYzVjZC90ZXh0cmVnaW9uOmUzMmE1ZTkwY2VkOTQyMWZhMzU5Yzg5MzI1MTNjNWNkXzU0OTc1NTgxNDAxNw_d7b6affa-3cc4-4f26-89a9-ef38e6fbad36"
      unitRef="bank">2</moln:NumberOfBanksWhereDepositsAreHeld>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i92a813a501bc4b9b8b3d48933008d151_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI1OA_ff7df3f8-69f4-44e7-a1ed-8cfa815f67db"
      unitRef="shares">3500000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="i92a813a501bc4b9b8b3d48933008d151_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI2NA_d967de99-e585-4b40-bfea-5f1a25803be2"
      unitRef="chfPerShare">0.10</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i92a813a501bc4b9b8b3d48933008d151_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI3Ng_ff7df3f8-69f4-44e7-a1ed-8cfa815f67db"
      unitRef="shares">3500000</ifrs-full:NumberOfSharesIssued>
    <moln:TreasurySharesNominalValue
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDI5OA_44a40820-c2cf-4509-89b7-360ec8a22b23"
      unitRef="chf">350000</moln:TreasurySharesNominalValue>
    <moln:IssuanceCostsOfTreasuryShareTransactions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDMwNA_6107347a-01bd-4e41-a1c2-e708fac7fa4b"
      unitRef="chf">631336</moln:IssuanceCostsOfTreasuryShareTransactions>
    <moln:TreasurySharesNominalValue
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU0OTc1NTgxNDMxMw_44a40820-c2cf-4509-89b7-360ec8a22b23"
      unitRef="chf">350000</moln:TreasurySharesNominalValue>
    <ifrs-full:Equity
      contextRef="ida1ef664b85047599beb657c0edeb373_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzU3_c5e85fcb-7b0e-4cc2-9950-5d14b675e777"
      unitRef="chf">3604471</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ida1ef664b85047599beb657c0edeb373_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzYx_fdf6a476-6edb-4982-9b75-18524d1367fa"
      unitRef="shares">36044706</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzY1_4bb43c96-8366-4918-875f-1250f34073d3"
      unitRef="chfPerShare">0.10</ifrs-full:ParValuePerShare>
    <moln:NumberOfVotesPerShare
      contextRef="ibdf5c6ab807f470abff7a20928b54739_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2Xzkz_163dac0f-9770-4ae4-9c5e-ae7950e5a1e6"
      unitRef="vote">1</moln:NumberOfVotesPerShare>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzIxOTkwMjMyNjQ1MTI_5c357942-054a-46b5-99ef-c71f9dcb6797">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt 0 1.02pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares in issue at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;21,601,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to capital raise in July 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,528,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to Novartis agreement in October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,739,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to vesting of PSU, RSU and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;278,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares in issue at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;29,146,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to June 2021 IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to vesting of PSU, RSU and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares in issue at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;32,292,648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to creation of treasury shares in August 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued in relation to vesting of PSU, RSU and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares in issue at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;36,044,706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ifcdf9dd73ee04977b7cafbf9acbef678_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzEtMS0xLTEtMTM0MTk0_ca733041-fa0e-43b5-bc7e-5ec8d82784af"
      unitRef="shares">21601192</ifrs-full:NumberOfSharesOutstanding>
    <moln:NumberOfSharesIssuedInRelationToCapitalRaiseEquity
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzItMS0xLTEtMTM0MTk0_0e744fa7-1e19-4fc3-9b87-3ca9649c074d"
      unitRef="shares">5528089</moln:NumberOfSharesIssuedInRelationToCapitalRaiseEquity>
    <moln:NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzMtMS0xLTEtMTM0MTk0_e702815d-4250-447a-a5b2-ea1b3e697243"
      unitRef="shares">1739130</moln:NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity>
    <moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzQtMS0xLTEtMTM0MTk0_ceabd18a-6007-429f-b2ef-cd14512b88ed"
      unitRef="shares">278581</moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzItMS0xLTEtMTMxNjA0_a8fcbcc8-9458-4bcc-935c-b4135b56b828"
      unitRef="shares">29146992</ifrs-full:NumberOfSharesOutstanding>
    <moln:NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzMtMS0xLTEtMTMxNjA0_9db348d7-611e-41ee-8394-f32969d9c02b"
      unitRef="shares">3000000</moln:NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity>
    <moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzQtMS0xLTEtMTMxNjA0_1632d346-5480-4c79-a919-3d9bc0e19b71"
      unitRef="shares">145656</moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzUtMS0xLTEtMTMxNjA0_790f416e-0672-4d8a-a386-301adce93c2b"
      unitRef="shares">32292648</ifrs-full:NumberOfSharesOutstanding>
    <moln:NumberOfSharesIssuedTreasurySharesEquity
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzYtMS0xLTEtMTMxNjA0_c3517173-22d5-4483-8904-67f2c6f84a9b"
      unitRef="shares">3500000</moln:NumberOfSharesIssuedTreasurySharesEquity>
    <moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzctMS0xLTEtMTMxNjA0_8e7ca176-97c3-4444-b1bd-03a5cb9e67ef"
      unitRef="shares">252058</moln:NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90YWJsZTpkN2Y0YjExODVhZjI0YzRhYmM2NTVlOWEwOGViZTQxOS90YWJsZXJhbmdlOmQ3ZjRiMTE4NWFmMjRjNGFiYzY1NWU5YTA4ZWJlNDE5XzgtMS0xLTEtMTMxNjA0_4637e177-b193-458c-9528-78db7c1e6c66"
      unitRef="shares">36044706</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="i95512f09473b4296a07c0bf49732b9f3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwMQ_fe18e0cd-6b91-4916-9a32-599a64924b2f"
      unitRef="chf">3579265</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i95512f09473b4296a07c0bf49732b9f3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwNQ_e35ef410-d149-4ff2-b7c3-b47396376f6e"
      unitRef="shares">35792648</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOQ_3d75aa8f-fb1c-4327-8a65-c8648321d60a"
      unitRef="chfPerShare">0.10</ifrs-full:ParValuePerShare>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorized
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMDY_56bb8dee-f8c9-46ee-838b-0969383952e9"
      unitRef="chf">457316</moln:MaximumAmountOfShareCapitalIncreaseAuthorized>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMTI_6754a41e-52f3-4f53-bd65-2cd36b3dc1b2"
      unitRef="shares">4573162</moln:MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares>
    <ifrs-full:ParValuePerShare
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMTg_b859f619-8fe6-48a2-b24c-53ad031a3597"
      unitRef="chfPerShare">0.10</ifrs-full:ParValuePerShare>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorized
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMzA_56bb8dee-f8c9-46ee-838b-0969383952e9"
      unitRef="chf">457316</moln:MaximumAmountOfShareCapitalIncreaseAuthorized>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorizedPercent
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyMzY_48e43d46-ae6d-4c6e-98cb-9fa8bb5cdcf6"
      unitRef="number">0.13</moln:MaximumAmountOfShareCapitalIncreaseAuthorizedPercent>
    <moln:IncreaseDecreaseInAuthorizedShareCapital
      contextRef="i36e31ef12d534128ba81206be595d4b6_D20220413-20220413"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNDg_5e82de81-cde3-4a37-9cc0-7a984dadbacd"
      unitRef="chf">378641</moln:IncreaseDecreaseInAuthorizedShareCapital>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorized
      contextRef="iffee4313ed1e4200a7baafdb5092cc29_I20220412"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNTQ_956fae05-548d-4f46-87bd-dc59e6f3ff84"
      unitRef="chf">428675</moln:MaximumAmountOfShareCapitalIncreaseAuthorized>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorized
      contextRef="i226a1800b6a24a9ab618c75812acf641_I20220413"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNjA_9eb1bca8-6771-4335-8e7b-102976eb30f5"
      unitRef="chf">807316</moln:MaximumAmountOfShareCapitalIncreaseAuthorized>
    <moln:IncreaseDecreaseInAuthorizedShareCapital
      contextRef="iaf0473678da046f9afdd55eced60e2d5_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNjY_3aa8c6be-7bde-4533-980c-b4a83f248b0f"
      unitRef="chf">-350000</moln:IncreaseDecreaseInAuthorizedShareCapital>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorized
      contextRef="i226a1800b6a24a9ab618c75812acf641_I20220413"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNzI_9eb1bca8-6771-4335-8e7b-102976eb30f5"
      unitRef="chf">807316</moln:MaximumAmountOfShareCapitalIncreaseAuthorized>
    <moln:MaximumAmountOfShareCapitalIncreaseAuthorized
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzEwOTk1MTE2MzYyNzg_56bb8dee-f8c9-46ee-838b-0969383952e9"
      unitRef="chf">457316</moln:MaximumAmountOfShareCapitalIncreaseAuthorized>
    <moln:PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI1NQ_51cd63d8-9db0-4951-bbd1-64ba3e77e964"
      unitRef="number">0.20</moln:PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement>
    <moln:PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI1OQ_f24299ce-bdf1-4b9f-b714-8278f1fbf4dc"
      unitRef="number">0.15</moln:PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated>
    <moln:AuthorizedShareCapitalEmployeeParticipation
      contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI3Mw_d083bd9d-5812-4055-ba76-f1caf5f2dd7a"
      unitRef="chf">136296</moln:AuthorizedShareCapitalEmployeeParticipation>
    <moln:NumberOfSharesAuthorizedEmployeeParticipation
      contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI3Nw_80a819c1-7c60-45b9-8b88-a75d6f5b3623"
      unitRef="shares">1362963</moln:NumberOfSharesAuthorizedEmployeeParticipation>
    <ifrs-full:ParValuePerShare
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI4MQ_9aa6eec6-8bc8-49fc-ac8c-b3a5e3461153"
      unitRef="chfPerShare">0.10</ifrs-full:ParValuePerShare>
    <moln:IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation
      contextRef="i13a375d0b11f458fbd6bc7e1aaf8675f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI4OQ_222c9aa7-e944-4108-8b86-28a4f4caef15"
      unitRef="chf">-25206</moln:IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation>
    <moln:AuthorizedShareCapitalEmployeeParticipation
      contextRef="i9ddb4cbe7d484358b5bf5ba0089d4386_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI5Mw_bffe0ad4-358d-4ee0-898f-933ba618a934"
      unitRef="chf">161502</moln:AuthorizedShareCapitalEmployeeParticipation>
    <moln:AuthorizedShareCapitalEmployeeParticipation
      contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzI5Nw_d083bd9d-5812-4055-ba76-f1caf5f2dd7a"
      unitRef="chf">136296</moln:AuthorizedShareCapitalEmployeeParticipation>
    <moln:AuthorizedShareCapitalFinancingTransactions
      contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMwMQ_41029f86-515f-4269-85f7-b3bdac49417f"
      unitRef="chf">226087</moln:AuthorizedShareCapitalFinancingTransactions>
    <moln:NumberOfSharesAuthorizedFinancingTransactions
      contextRef="i76a78a9b245d4218947bfd4a0acbd239_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMwNQ_70b0a1e3-a835-4c75-bcf2-8293e4e23cba"
      unitRef="shares">2260870</moln:NumberOfSharesAuthorizedFinancingTransactions>
    <ifrs-full:ParValuePerShare
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMwOQ_7353ea4e-695b-44a0-9898-e1cca5c92635"
      unitRef="chfPerShare">0.10</ifrs-full:ParValuePerShare>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i5b22ff48cfa44ceaa5de97b4809b8b54_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMyMQ_471f11b6-90f1-43d7-a0a4-ea021d874e34"
      unitRef="chf">251957</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i23a22766f4574cdab095ce240d4ab462_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzMyOQ_338fa3e4-0023-4315-a75d-6284c73f6135"
      unitRef="chf">269552</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="ie47af3905cff436a87efc3199975fdcc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yOTgvZnJhZzo0OGU0Y2FmNmZkNDU0ZWMxOTU4ZmQ1MWFjMTBlYWY1Ni90ZXh0cmVnaW9uOjQ4ZTRjYWY2ZmQ0NTRlYzE5NThmZDUxYWMxMGVhZjU2XzM0MA_b2901e70-914c-45f7-9355-4718037f4341"
      unitRef="chf">848340</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90ZXh0cmVnaW9uOjU2MWZkNDYyNGQ2ZjRmYzQ5NTYwNDcyMDE3ZDk2Y2EzXzE3_cb251fad-a3d0-4714-9bb5-358625f025dc">Trade and other payables&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Social security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Value added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,389&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables are denominated in the following currencies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90ZXh0cmVnaW9uOjU2MWZkNDYyNGQ2ZjRmYzQ5NTYwNDcyMDE3ZDk2Y2EzXzE4_e8877a62-c44a-4d44-82d6-949f391beafe">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Social security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Value added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,389&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables are denominated in the following currencies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzEtMS0xLTEtMTA5NjE4_a469c290-ea4c-4c9b-be23-f93f2d06dfaf"
      unitRef="chf">997000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzEtNC0xLTEtMTA5NjE4_5efb7a8b-76bc-466c-9c16-fa8454ac1c81"
      unitRef="chf">4862000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzItMS0xLTEtMTA5NjE4_9bf27f57-c715-4871-b6a3-ff1f99cb9fda"
      unitRef="chf">1146000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzItNC0xLTEtMTA5NjE4_fc17a486-6386-4ae1-820e-fd3babfdf771"
      unitRef="chf">1672000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentValueAddedTaxPayables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzMtMS0xLTEtMTA5NjE4_cc86718a-b631-4499-b762-c2b57997107c"
      unitRef="chf">0</ifrs-full:CurrentValueAddedTaxPayables>
    <ifrs-full:CurrentValueAddedTaxPayables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzMtNC0xLTEtMTA5NjE4_47350678-37f2-4f9a-9ffa-a66e21f56abb"
      unitRef="chf">855000</ifrs-full:CurrentValueAddedTaxPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzQtMS0xLTEtMTA5NjE4_a073e553-05aa-4e57-bc0c-411ee0379af5"
      unitRef="chf">2143000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTo5YmRhYmQ5NTU4YjM0MzJmYjI0MTgwOTE1MWI5MTZjZi90YWJsZXJhbmdlOjliZGFiZDk1NThiMzQzMmZiMjQxODA5MTUxYjkxNmNmXzQtNC0xLTEtMTA5NjE4_9ff78de3-aeb4-491a-8e19-e1ce1295b9b0"
      unitRef="chf">7389000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="if10f3857f8be428ea614cef6b5f0cfdc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzEtMS0xLTEtMTA5NjE4_8bfb5f89-6e39-4f2c-be41-ac0345995713"
      unitRef="chf">790000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i1b566efcfd8e4616a1184a3238a19919_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzEtNC0xLTEtMTA5NjE4_6713ce10-cef4-485f-9d82-c557214aad58"
      unitRef="chf">1464000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="ib3dd2f40888e4d59961b586143204f41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzItMS0xLTEtMTA5NjE4_76c01a50-6125-4d43-af2a-16974f00ad94"
      unitRef="chf">104000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="ib18995551c1f4e4f88287c5b9130f130_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzItNC0xLTEtMTA5NjE4_8039146d-bcc3-4ac7-8a81-5a64dd2bf938"
      unitRef="chf">3250000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i99c5fb5d04a14802a05c3f4bf6dee734_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzMtMS0xLTEtMTA5NjE4_927e884c-4355-44e2-bc40-58cf3735aa1e"
      unitRef="chf">103000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i98e8fb4cae3d43b89d65720dfc7d9357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzMtNC0xLTEtMTA5NjE4_8af994ec-b525-46df-94c1-538bad4cbadd"
      unitRef="chf">118000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="ifd1e5f5e6ec145b3bceebef0cf07f8db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzQtMS0xLTEtMTA5NjE4_24062f5f-bdef-4731-b5e1-e71fe9290755"
      unitRef="chf">0</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="iee446437d91845ccb79f71155459c929_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzQtNC0xLTEtMTA5NjE4_1b10e5c0-e81c-49c2-882e-31c396405d85"
      unitRef="chf">29000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzUtMS0xLTEtMTA5NjE4_cb167ca6-1f80-44c4-b694-9124443179fa"
      unitRef="chf">997000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDEvZnJhZzo1NjFmZDQ2MjRkNmY0ZmM0OTU2MDQ3MjAxN2Q5NmNhMy90YWJsZTpkNTFhMWNmZGQzMjU0ZWVmOGMxNmIyZmM4ZTIzOGMzZC90YWJsZXJhbmdlOmQ1MWExY2ZkZDMyNTRlZWY4YzE2YjJmYzhlMjM4YzNkXzUtNC0xLTEtMTA5NjE4_eff9b995-e76f-465a-b787-4a648f805aa5"
      unitRef="chf">4862000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90ZXh0cmVnaW9uOjViNzBjZGRiMDkyZTQ3M2U4YWQyM2E2N2VlNDY0MTU1XzEy_78df942e-36c6-48bf-a5f6-1b1dea15df90">Accrued expenses&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued project costs and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued payroll and bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,975&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
    <moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90ZXh0cmVnaW9uOjViNzBjZGRiMDkyZTQ3M2U4YWQyM2E2N2VlNDY0MTU1XzEz_2df09340-b7e8-4cb3-8193-a66d55bb9ad8">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued project costs and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued payroll and bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,975&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock>
    <moln:CurrentAccruedProjectCostsAndRoyalties
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzEtMS0xLTEtMTA5NjE4_5294e1c8-965e-487f-a9c7-abd664895d18"
      unitRef="chf">2167000</moln:CurrentAccruedProjectCostsAndRoyalties>
    <moln:CurrentAccruedProjectCostsAndRoyalties
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzEtNC0xLTEtMTA5NjE4_c3b22def-f873-48e8-99ea-5bd0b605c150"
      unitRef="chf">3410000</moln:CurrentAccruedProjectCostsAndRoyalties>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzItMS0xLTEtMTA5NjE4_a59faf88-7b8e-4e81-8764-5a65703eb14b"
      unitRef="chf">4763000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzItNC0xLTEtMTA5NjE4_4aade9ed-35a0-4db6-9d0c-4b49c94ef3d2"
      unitRef="chf">6002000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzMtMS0xLTEtMTA5NjE4_732db787-2def-4222-bfec-7b34fc490195"
      unitRef="chf">571000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzMtNC0xLTEtMTA5NjE4_ef3c92b5-745c-425b-90a1-9923b022e71f"
      unitRef="chf">563000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzQtMS0xLTEtMTA5NjE4_25700f49-6732-495c-a163-facb1172ce20"
      unitRef="chf">7501000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDQvZnJhZzo1YjcwY2RkYjA5MmU0NzNlOGFkMjNhNjdlZTQ2NDE1NS90YWJsZTowMDIxYjNlYzI1MGM0MWVmODdlNDU5OTVjNzU1NjViNC90YWJsZXJhbmdlOjAwMjFiM2VjMjUwYzQxZWY4N2U0NTk5NWM3NTU2NWI0XzQtNC0xLTEtMTA5NjE4_1c627d64-6464-4016-9671-1a472ede597e"
      unitRef="chf">9975000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzc5_6277c3ee-66b0-44f5-b090-aba5501613a5">Contract liability&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group expects the contract liability to be recognized as revenue or, in case of consideration payable to a customer, reduction of costs, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year one after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year two after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year three after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year four after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year five and later after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year one after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year two after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year three after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year four after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year five and later after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the movement on the contract liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recognized as revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Offset of costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(25,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recognized as revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Offset of costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;19,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;45,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The License and Collaboration Agreement with Novartis entered into in December 2021 resulted in a contract liability of TCHF 18,584 (TUSD 20,000). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, an amount of TCHF 19,904 has been released to offset a corresponding amount of costs paid to the Novartis Group for the manufacturing of the drug product to establish the commercial supply of MP0420 under the Option and Equity Rights Agreement entered into in October 2020 (see note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,637&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;28,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzgw_2b23c3dc-d0c6-40bd-8fdb-1e0354a053c1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group expects the contract liability to be recognized as revenue or, in case of consideration payable to a customer, reduction of costs, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year one after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year two after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year three after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year four after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year five and later after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year one after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year two after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year three after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year four after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected revenue recognition in year five and later after balance sheet date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i46461ef8c2bf4ad194fcc5da61eb4790_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzEtMS0xLTEtMTA5NjE4_74e09c35-0ff9-4b5f-8a02-632be26ad020"
      unitRef="chf">6409000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i859523f38bfc4cef886b0469de3d3c27_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzItMS0xLTEtMTA5NjE4_c5b6d1a5-98ae-4218-97ad-15a1d4231698"
      unitRef="chf">3637000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i918edbfe84d34f33a0b487a26eeba31e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzMtMS0xLTEtMTA5NjE4_fbf462d7-9dea-4a87-be4d-168e27e8f45d"
      unitRef="chf">0</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i4738c29a9abd4ebdb07a22bac9da094f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzQtMS0xLTEtMTA5NjE4_4594fe0e-9784-4a92-b5db-1b5ef3f92660"
      unitRef="chf">0</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i44b7ff2364ee43b4a7559bda1f8cfdc7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzUtMS0xLTEtMTA5NjE4_b150cb82-a283-45cd-926a-d5de475c8979"
      unitRef="chf">0</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTpjNjZlY2I3MzU1MGQ0Y2VmOWQxNjRkNzJlZmM4YzFiNi90YWJsZXJhbmdlOmM2NmVjYjczNTUwZDRjZWY5ZDE2NGQ3MmVmYzhjMWI2XzYtMS0xLTEtMTA5NjE4_50583090-ab47-48f1-bec4-eb199c165794"
      unitRef="chf">10046000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i6592e0e0184441c58126d7e24b37d82e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzEtMS0xLTEtMTA5NjE4_f501ce41-336a-459a-8597-f8b1c97d33a4"
      unitRef="chf">28312000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="if56ff0ffb76b4ef7bdd5f9a0f0de46ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzItMS0xLTEtMTA5NjE4_a7486895-1b5a-4644-a6bb-962852412beb"
      unitRef="chf">5798000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="if631f991ae9c444c817903110fa5596a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzMtMS0xLTEtMTA5NjE4_0a8e689c-ae9e-44e1-a832-04d649af5984"
      unitRef="chf">1127000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i16a9cc51038a4f4d95c67fe474148918_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzQtMS0xLTEtMTA5NjE4_bd63276c-cd3d-47d1-a1d2-39899a3ba77e"
      unitRef="chf">0</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="ic9a4c1ad6eff4eaa80acba6bc1f1a654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzUtMS0xLTEtMTA5NjE4_0fbaa059-0b49-4728-8991-9c0beadf2948"
      unitRef="chf">0</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphOWViOTYyOTNmMTk0ZGQ4OTRjYjY3ZDNkY2ZlM2ZmNy90YWJsZXJhbmdlOmE5ZWI5NjI5M2YxOTRkZDg5NGNiNjdkM2RjZmUzZmY3XzYtMS0xLTEtMTA5NjE4_8e35d122-a010-4d14-9e30-87a066c93455"
      unitRef="chf">35237000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzgx_9abcb5a4-6eeb-4681-97ab-b42ba78146a4">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the movement on the contract liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recognized as revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Offset of costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(25,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recognized as revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Offset of costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability at December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,653&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;19,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;45,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:ContractLiabilities
      contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItMS0xLTEtMTA5NjE4_6a61f981-ab6d-465d-9ab2-ad47642999dc"
      unitRef="chf">9653000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="ie40be771ab47427dab17aa01b8815550_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItNC0xLTEtMTA5NjE4_3512db37-57bf-4116-998b-258e140f7633"
      unitRef="chf">0</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="ie40be771ab47427dab17aa01b8815550_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItNy0xLTEtMTA5NjE4_513696ac-0696-448e-ae32-b20a19b31ac1"
      unitRef="chf">9653000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="ie40be771ab47427dab17aa01b8815550_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItMTAtMS0xLTEwOTYxOA_8263f15e-ebc9-4496-bd60-4a57ba405b19"
      unitRef="chf">0</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i5e790e4d70ba47b7811ed9628565b55a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzItMTMtMS0xLTEwOTYxOA_86b59d17-3a55-4d2a-b93e-a399fc0d5b1a"
      unitRef="chf">0</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i25f724f166614126b409c627fece74f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtMS0xLTEtMTA5NjE4_a03cc1a4-26ea-4d9b-8e17-fce92bdc2c86"
      unitRef="chf">18584000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtNC0xLTEtMTA5NjE4_dc146720-2f72-4d7e-bab4-3497b11d6218"
      unitRef="chf">0</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtNy0xLTEtMTA5NjE4_eb7a78b2-9f69-499d-b43c-5a870623d6fb"
      unitRef="chf">8538000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="i541403487eff40c4bfdde6eeb766b311_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtMTAtMS0xLTEwOTYxOA_51a283e9-504f-450a-80c2-f8f57e0f758b"
      unitRef="chf">0</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzMtMTMtMS0xLTEwOTYxOA_fd135142-a596-497f-a586-abcaa3a1d581"
      unitRef="chf">10046000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtMS0xLTEtMTA5NjE4_3a10ff36-1264-4294-9dda-9e383eb3ae15"
      unitRef="chf">7000000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtNC0xLTEtMTA5NjE4_28141207-1118-4218-9a13-59cc82071aad"
      unitRef="chf">0</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtNy0xLTEtMTA5NjE4_54e10340-c0ca-4062-a373-05caf0019ed8"
      unitRef="chf">7000000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="i5c31655620614bf9bef6d5a7044bfc27_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtMTAtMS0xLTEwOTYxOA_f020218a-ae37-4333-90fd-91c92750fe56"
      unitRef="chf">0</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i11110b5c186941989d4682d8c5456ae1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzQtMTMtMS0xLTEwOTYxOA_0e17ecec-0826-4257-af2e-df6fb2478e9a"
      unitRef="chf">0</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtMS0xLTEtMTA5NjE4_5e04415d-0934-48be-84be-7ae8b75d0a4f"
      unitRef="chf">35237000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtNC0xLTEtMTA5NjE4_129a0b4b-4889-44f9-a091-7538808a2f1f"
      unitRef="chf">0</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtNy0xLTEtMTA5NjE4_261e374d-99c8-4bea-9283-b837928b6ead"
      unitRef="chf">25191000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtMTAtMS0xLTEwOTYxOA_2c1e0b47-d042-465d-8ae3-dd2ac5126cc0"
      unitRef="chf">0</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTozNGY0ZWM1MDc0NTM0ODVhYjEyNGFjNDU2MmExYWEwOS90YWJsZXJhbmdlOjM0ZjRlYzUwNzQ1MzQ4NWFiMTI0YWM0NTYyYTFhYTA5XzUtMTMtMS0xLTEwOTYxOA_0640ee6d-43a3-41cb-be24-a506bb9b7693"
      unitRef="chf">10046000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="id871d1f18f9746c1968f95282a63c920_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItMS0xLTEtMTA5NjE4_dbf64ce7-d71e-4b96-9b2f-81aac29df67d"
      unitRef="chf">18983000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItNC0xLTEtMTA5NjE4_4d99face-2cee-471f-a4ec-8c7ea4cc71ae"
      unitRef="chf">0</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItNy0xLTEtMTA5NjE4_b71e982d-b1bb-4f56-9274-c34f1babd988"
      unitRef="chf">9330000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="if664c2fa84d54fba8b00571c067277c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItMTAtMS0xLTEwOTYxOA_61ce8981-707e-4f2b-a9f9-28c6410eff9d"
      unitRef="chf">0</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzItMTMtMS0xLTEwOTYxOA_81b8c2f1-9941-453c-b507-76a4c6f5cba3"
      unitRef="chf">9653000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i092e160ceafe420685da4b0eed564d63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtMS0xLTEtMTA5NjE4_a4f3121d-701e-4f69-a2e1-681c5d09de42"
      unitRef="chf">19904000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtNC0xLTEtMTA5NjE4_53da3e56-30d2-4782-9e82-91871fc3e32c"
      unitRef="chf">18584000</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtNy0xLTEtMTA5NjE4_ea2d5d25-2f77-4073-b00b-7756e171284d"
      unitRef="chf">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtMTAtMS0xLTEwOTYxOA_411b0f06-8bed-4467-8f2a-3b48cc4a1ac5"
      unitRef="chf">19904000</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i25f724f166614126b409c627fece74f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzMtMTMtMS0xLTEwOTYxOA_11798456-1627-406b-b1ba-36bc95d9cd9d"
      unitRef="chf">18584000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ida8fa2e1fb2f4e16a9fe9d78dfba780a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtMS0xLTEtMTA5NjE4_4217694d-14df-40ff-8635-cce6224c8d9b"
      unitRef="chf">7000000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtNC0xLTEtMTA5NjE4_fdfd0e11-2ade-4c26-8c3b-4c2fd7a47651"
      unitRef="chf">0</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtNy0xLTEtMTA5NjE4_fbdd8992-0955-46b6-b0a9-dbb1853c3e7c"
      unitRef="chf">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="i1e57d2d5123946c1b18cb8002fc61246_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtMTAtMS0xLTEwOTYxOA_9793f80c-5263-4123-9bd4-210f356a0dc6"
      unitRef="chf">0</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzQtMTMtMS0xLTEwOTYxOA_33107334-bbd4-4221-92ab-a68eb47f09a4"
      unitRef="chf">7000000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtMS0xLTEtMTA5NjE4_b9664695-fe74-46fc-bf28-d6a244deeb1c"
      unitRef="chf">45887000</ifrs-full:ContractLiabilities>
    <moln:IncreaseThroughAdditionsContractLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtNC0xLTEtMTA5NjE4_ac04206a-d7f5-48bd-ba88-f85ce0b801c2"
      unitRef="chf">18584000</moln:IncreaseThroughAdditionsContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtNy0xLTEtMTA5NjE4_ee93a9ad-f3fd-42d9-ab00-0c38142ba6df"
      unitRef="chf">9330000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtMTAtMS0xLTEwOTYxOA_f3c9d6c3-fce6-4c8e-97ca-606a555bfbdf"
      unitRef="chf">19904000</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplZTBmYzM2OWZjZmI0ZWQzODIzNjcyZGI4MjE3YzdkNy90YWJsZXJhbmdlOmVlMGZjMzY5ZmNmYjRlZDM4MjM2NzJkYjgyMTdjN2Q3XzUtMTMtMS0xLTEwOTYxOA_6bd9c00d-8ad9-48d4-a517-1ad0e09ed9f2"
      unitRef="chf">35237000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i25f724f166614126b409c627fece74f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4XzU5_7c823c5b-9b80-4d69-8e8f-f7b4e5cc3648"
      unitRef="chf">18584000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4XzYz_fe3777c6-8696-4f4a-87fc-f74da631a3f7"
      unitRef="usd">20000000</ifrs-full:ContractLiabilities>
    <moln:DecreaseThroughOffsetOfCostsContractLiabilities
      contextRef="ifeb503f7e6924d8d8a491a31d7b72fcb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4XzU0OTc1NTgxNTE0OQ_f7978675-29a8-465d-ab4e-ff1b0964ecec"
      unitRef="chf">19904000</moln:DecreaseThroughOffsetOfCostsContractLiabilities>
    <moln:DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90ZXh0cmVnaW9uOmUyNzBkNjhmMTFlNTQ3NjJhNzAyM2EwYzdjOTExYWY4Xzc4_fca51629-d698-4805-870a-265976533cc9">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,637&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,046&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FOPH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;28,312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;35,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzItMS0xLTEtMTA5NjE4_47adf00c-8d74-4f53-b368-8f55eb5d2798"
      unitRef="chf">6409000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzItNC0xLTEtMTA5NjE4_e2e633b2-fd26-4558-bb19-a28cbc058ea0"
      unitRef="chf">3637000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i2b9e249b02224f78ac1a5ec8a5b3180c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzItNy0xLTEtMTA5NjE4_f50c5494-c912-44db-8271-0be61c0c0a13"
      unitRef="chf">10046000</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzQtMS0xLTEtMTA5NjE4_89388ec2-b0f8-4c52-badd-dbde94653313"
      unitRef="chf">6409000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzQtNC0xLTEtMTA5NjE4_4f88b97a-553e-4eec-87ef-eb7652bdb7a0"
      unitRef="chf">3637000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTplNzQzYTA3YzMwOGU0MTQ3YTdhMmVkYzJhMjJmZTViYS90YWJsZXJhbmdlOmU3NDNhMDdjMzA4ZTQxNDdhN2EyZWRjMmEyMmZlNWJhXzQtNy0xLTEtMTA5NjE4_f693ceaa-2894-4b11-9ebc-2f4e30d2948b"
      unitRef="chf">10046000</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzEtMS0xLTEtMTA5NjE4_c5deabe4-af66-4c0c-b097-39fb8be6d5d3"
      unitRef="chf">9653000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzEtNC0xLTEtMTA5NjE4_47030331-e936-4825-8eb7-cf00ee2c769e"
      unitRef="chf">0</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ie9c25c613d894005a9d3a3b959ee5252_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzEtNy0xLTEtMTA5NjE4_b4a394fc-0d13-4fdd-9ca3-191e7eff5c6d"
      unitRef="chf">9653000</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i25f724f166614126b409c627fece74f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzItMS0xLTEtMTA5NjE4_0bf5a028-7d3c-4443-95a1-284dec7e8371"
      unitRef="chf">11659000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i25f724f166614126b409c627fece74f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzItNC0xLTEtMTA5NjE4_55fba5df-bb1f-4ff7-9d26-6c04556bd7bc"
      unitRef="chf">6925000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i25f724f166614126b409c627fece74f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzItNy0xLTEtMTA5NjE4_36f66bb0-b10f-4863-8b6f-033002d8fd45"
      unitRef="chf">18584000</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzMtMS0xLTEtMTA5NjE4_0c93af43-5c68-4715-8c77-a1cffd347b88"
      unitRef="chf">7000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzMtNC0xLTEtMTA5NjE4_907f34ec-0346-47f5-9ac0-62ebbbc109dc"
      unitRef="chf">0</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="idc6153f573e54a3eac1c9d6b41928f25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzMtNy0xLTEtMTA5NjE4_88c4ff90-b1c1-4b07-9de7-525b93ace2b3"
      unitRef="chf">7000000</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzQtMS0xLTEtMTA5NjE4_d55d18aa-63a0-4693-af66-385f914f20a0"
      unitRef="chf">28312000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzQtNC0xLTEtMTA5NjE4_ce502e71-bcbf-4d6e-ba5c-99c8a273fed5"
      unitRef="chf">6925000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMDcvZnJhZzplMjcwZDY4ZjExZTU0NzYyYTcwMjNhMGM3YzkxMWFmOC90YWJsZTphNzk4YmJmZTYzYmY0Y2Q1ODExYzFlYWRiYjhjYWI2NC90YWJsZXJhbmdlOmE3OThiYmZlNjNiZjRjZDU4MTFjMWVhZGJiOGNhYjY0XzQtNy0xLTEtMTA5NjE4_c82f6421-c910-4e8a-915c-b79462746a0b"
      unitRef="chf">35237000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzYz_49e3629a-7153-43b6-a3be-154eb859e9ae">Additional information on the nature of expenses&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research consumables and external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, see also note 18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties and license fees, see also note 17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(50,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(55,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(56,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, see also note 18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(22,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(17,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(72,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(73,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(67,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development non-cash effective pension and share-based compensation costs were TCHF 3,856 in 2022, TCHF 3,045 in 2021 and TCHF 2,612 in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Selling, general and administrative non-cash effective pension and share based compensation costs were TCHF 2,329 in 2022, TCHF 2,113 in 2021 and TCHF 1,573 in 2020.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzY0_7a511043-05d1-4470-b97a-8df4eca298b5">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research consumables and external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, see also note 18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties and license fees, see also note 17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(50,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(55,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(56,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, see also note 18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(22,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(17,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(72,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(73,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(67,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development non-cash effective pension and share-based compensation costs were TCHF 3,856 in 2022, TCHF 3,045 in 2021 and TCHF 2,612 in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Selling, general and administrative non-cash effective pension and share based compensation costs were TCHF 2,329 in 2022, TCHF 2,113 in 2021 and TCHF 1,573 in 2020.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory>
    <moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzItMS0xLTEtMTA5NjE4_e44bd2b4-e155-4711-9bfa-7f29284f9e1b"
      unitRef="chf">17154000</moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense>
    <moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzItNC0xLTEtMTA5NjE4_2c7af06c-7377-4eee-81d1-763e788323a7"
      unitRef="chf">26342000</moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense>
    <moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzItNy0xLTEtMTA5NjE4_49f44d85-8bb1-4e70-99c5-8d19dc7d368a"
      unitRef="chf">26599000</moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzMtMS0xLTEtMTA5NjE4_9695218f-17b4-4edd-a289-d400359f27fd"
      unitRef="chf">28101000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzMtNC0xLTEtMTA5NjE4_1c583fd7-ba53-45eb-9bb7-e91199446a2b"
      unitRef="chf">25647000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzMtNy0xLTEtMTA5NjE4_dff0fd1a-aac8-4395-901e-c8e9ae41363c"
      unitRef="chf">25251000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzQtMS0xLTEtMTA5NjE4_429a317a-4ea0-497c-9abc-5984a2dbc019"
      unitRef="chf">1971000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzQtNC0xLTEtMTA5NjE4_ad25f186-788d-4a87-b463-6d655b44566c"
      unitRef="chf">2016000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzQtNy0xLTEtMTA5NjE4_436b3d41-75b0-4027-83dd-fc36a6d2bedf"
      unitRef="chf">2319000</ifrs-full:DepreciationAndAmortisationExpense>
    <moln:IntellectualPropertyExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzUtMS0xLTEtMTA5NjE4_c8f11bd5-b5ac-43f7-a5fd-4196378ee485"
      unitRef="chf">957000</moln:IntellectualPropertyExpense>
    <moln:IntellectualPropertyExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzUtNC0xLTEtMTA5NjE4_942df570-fd41-434d-9cee-77dda60fa7e5"
      unitRef="chf">636000</moln:IntellectualPropertyExpense>
    <moln:IntellectualPropertyExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzUtNy0xLTEtMTA5NjE4_9624d49d-8cc6-4230-af37-967a2760ff46"
      unitRef="chf">492000</moln:IntellectualPropertyExpense>
    <ifrs-full:OccupancyExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzYtMS0xLTEtMTA5NjE4_5140d9a2-75a6-477b-9d20-4843597a7b75"
      unitRef="chf">854000</ifrs-full:OccupancyExpense>
    <ifrs-full:OccupancyExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzYtNC0xLTEtMTA5NjE4_8c34b307-03ad-4517-bf00-b588eac199de"
      unitRef="chf">758000</ifrs-full:OccupancyExpense>
    <ifrs-full:OccupancyExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzYtNy0xLTEtMTA5NjE4_c272c09a-5ee3-4c3a-a6ef-73e109d5c1f7"
      unitRef="chf">683000</ifrs-full:OccupancyExpense>
    <moln:OtherResearchAndDevelopmentExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzctMS0xLTEtMTA5NjE4_a7747c98-92d8-4ed4-9f2c-e72cab42bba7"
      unitRef="chf">703000</moln:OtherResearchAndDevelopmentExpense>
    <moln:OtherResearchAndDevelopmentExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzctNC0xLTEtMTA5NjE4_f07a9d62-af7a-4a8b-9407-8bf2e122f683"
      unitRef="chf">259000</moln:OtherResearchAndDevelopmentExpense>
    <moln:OtherResearchAndDevelopmentExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzctNy0xLTEtMTA5NjE4_aaed2ec5-a545-434f-a391-35291f829bdb"
      unitRef="chf">169000</moln:OtherResearchAndDevelopmentExpense>
    <moln:RoyaltiesAndLicenseFeesExpense
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzgtMS0xLTEtMTA5NjE4_5b4b3807-e36e-46b7-8df8-da71ec9a70cc"
      unitRef="chf">1010000</moln:RoyaltiesAndLicenseFeesExpense>
    <moln:RoyaltiesAndLicenseFeesExpense
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzgtNC0xLTEtMTA5NjE4_aab03222-061b-4125-9074-a471689a7211"
      unitRef="chf">60000</moln:RoyaltiesAndLicenseFeesExpense>
    <moln:RoyaltiesAndLicenseFeesExpense
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzgtNy0xLTEtMTA5NjE4_be2b2c5b-f948-4454-ad5a-76605a1a3e0c"
      unitRef="chf">562000</moln:RoyaltiesAndLicenseFeesExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzktMS0xLTEtMTA5NjE4_65e59a40-366a-4f77-b1f7-120a6ab30a9f"
      unitRef="chf">50749000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzktNC0xLTEtMTA5NjE4_af35379d-d82c-4187-b0e5-805172674ae9"
      unitRef="chf">55718000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzktNy0xLTEtMTA5NjE4_d5a8087f-5cbf-4525-9057-5c41f3804813"
      unitRef="chf">56075000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzEzLTEtMS0xLTEwOTYxOA_651db15b-a380-4f98-bd38-b29ce00106fc"
      unitRef="chf">11788000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzEzLTQtMS0xLTEwOTYxOA_6b847969-4d3f-4d7f-9567-885e61a6abeb"
      unitRef="chf">10604000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzEzLTctMS0xLTEwOTYxOA_ccc195a2-a8a7-4c11-85ad-cd15c2ca31ac"
      unitRef="chf">8383000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AdministrativeExpense
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE0LTEtMS0xLTEwOTYxOA_c8d1fa2a-d189-431e-b1fb-8e3019da2f0c"
      unitRef="chf">9965000</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdministrativeExpense
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE0LTQtMS0xLTEwOTYxOA_41e9b3af-fac9-485e-9611-3fe5081f54cb"
      unitRef="chf">6242000</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdministrativeExpense
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE0LTctMS0xLTEwOTYxOA_00e7bb61-e209-4a51-8a4d-cced24db33cd"
      unitRef="chf">2587000</ifrs-full:AdministrativeExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE1LTEtMS0xLTEwOTYxOA_96e5e696-4f95-4cbb-ba79-b24e6d1b1be9"
      unitRef="chf">416000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE1LTQtMS0xLTEwOTYxOA_c13a7919-93e4-4218-afad-6c51586e27e0"
      unitRef="chf">549000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE1LTctMS0xLTEwOTYxOA_6a9aa1f1-ec05-40c3-abd0-6d2f96e79b55"
      unitRef="chf">568000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:OccupancyExpense
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE2LTEtMS0xLTEwOTYxOA_51d3c25f-0630-4fba-82e7-ed0c603ee700"
      unitRef="chf">69000</ifrs-full:OccupancyExpense>
    <ifrs-full:OccupancyExpense
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE2LTQtMS0xLTEwOTYxOA_a3ed564e-5753-40cc-a268-301de76d3fa9"
      unitRef="chf">60000</ifrs-full:OccupancyExpense>
    <ifrs-full:OccupancyExpense
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE2LTctMS0xLTEwOTYxOA_1ad96ce9-fa05-438b-baa7-69afa05e8b34"
      unitRef="chf">57000</ifrs-full:OccupancyExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE3LTEtMS0xLTEwOTYxOA_ff5addd1-20c5-40cf-abd9-53a29778df00"
      unitRef="chf">22238000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE3LTQtMS0xLTEwOTYxOA_0d329f04-7a19-41bc-af32-89f15d941d4a"
      unitRef="chf">17454000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE3LTctMS0xLTEwOTYxOA_7801354b-9cfb-4a8c-a23b-6ad1935be30c"
      unitRef="chf">11595000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE5LTEtMS0xLTEwOTYxOA_4d547dd3-c895-40bd-92f1-05a666fc389e"
      unitRef="chf">72987000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE5LTQtMS0xLTEwOTYxOA_4d0a58c6-b775-42a5-9dff-6fbea4c29316"
      unitRef="chf">73172000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90YWJsZTplYWE1MmU4M2I0MTk0ZWZlYWJjYzZmYjA0MGQ4NGI1My90YWJsZXJhbmdlOmVhYTUyZTgzYjQxOTRlZmVhYmNjNmZiMDQwZDg0YjUzXzE5LTctMS0xLTEwOTYxOA_c5abf255-4206-4e71-a7b8-6df3e037a1b8"
      unitRef="chf">67670000</ifrs-full:OperatingExpense>
    <moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzE2_85e82184-76d3-4b6c-9cb6-e7ae217c94db"
      unitRef="chf">3856000</moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost>
    <moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzI0_95633b23-e42f-43f2-b9d8-b4dd6acb4042"
      unitRef="chf">3045000</moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost>
    <moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzMy_7d8d8b08-3639-41cd-a95a-628ddecb59e9"
      unitRef="chf">2612000</moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost>
    <moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzQw_6591a417-69f1-4945-b84c-d008c608311d"
      unitRef="chf">2329000</moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost>
    <moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzQ4_da33a6a8-950f-4c27-ad49-565fa8237551"
      unitRef="chf">2113000</moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost>
    <moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTAvZnJhZzo4NjMwNWVlNTgxNjA0MDZiYTk0NWM3NTczYjRiNDU1Ni90ZXh0cmVnaW9uOjg2MzA1ZWU1ODE2MDQwNmJhOTQ1Yzc1NzNiNGI0NTU2XzU2_8f0b6689-589f-461e-9530-c30b27d3231b"
      unitRef="chf">1573000</moln:PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost>
    <moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzgz_0201971b-fec6-4f14-81b8-c8faa76745b4">Royalties and license fees&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until October 2021, the Group held an exclusive perpetual license from the University of Zurich on patent applications and patents relating to the DARPin base technology. The Group terminated the applicable license agreement with effect as of October 2021 as the main patents under this agreement expired in September 2021. For the years ended December 31, 2021 and 2020 the minimum amounts of CHF 50,000 were payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group currently now only holds a non-exclusive perpetual license from the University of Zurich on patent applications and patents relating to Phage Display technology. The amount payable by us is CHF 10,000 per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Group entered into a research collaboration agreement with the University of Utrecht regarding the development of the Group's COVID-19 program. Under this agreement, the Group paid a fee of CHF 250,000 to the University of Utrecht in December 2020. An additional fee of CHF 250,000 was accrued as per December 2021 and payable under this agreement. With Novartis exercising its option under the Option and Equity Rights Agreement, the University of Utrecht was owed a further CHF&#160;1.0&#160;million that was expensed and paid during 2022.&lt;/span&gt;&lt;/div&gt;</moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock>
    <ifrs-full:RoyaltyExpense
      contextRef="i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxMzk4OQ_41d06b78-5c0f-4a69-be9d-43e2661e7c84"
      unitRef="chf">50000</ifrs-full:RoyaltyExpense>
    <ifrs-full:RoyaltyExpense
      contextRef="ief90048dd4494347a75a5ce67581ab00_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxMzk4OQ_b4cdc3e3-8998-46c5-aacd-6be7a17af3a1"
      unitRef="chf">50000</ifrs-full:RoyaltyExpense>
    <ifrs-full:RoyaltyExpense
      contextRef="if164200b3a3a403cb3987f2f289dfaab_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxMzk4OQ_dc99d2f4-0192-4c54-bce3-a41c65cb5533"
      unitRef="chf">50000</ifrs-full:RoyaltyExpense>
    <moln:RoyaltiesMinimumAnnualAmountTotal
      contextRef="i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzU0OTc1NTgxNDAzMg_079eb0c3-43a8-404d-af43-d7ea60f8ab77"
      unitRef="chf">10000</moln:RoyaltiesMinimumAnnualAmountTotal>
    <moln:LicenseFeesExpense
      contextRef="i66792e0d15a34af9b27cee6aec9fbcae_D20201201-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzYw_fca579eb-ffc7-4361-b9a8-72178db03eda"
      unitRef="chf">250000</moln:LicenseFeesExpense>
    <moln:CurrentAccruedProjectCostsAndRoyalties
      contextRef="i5e3f5143278948b68b6427ace3f8dade_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzY4_21eee2e7-d3c6-408b-b7b8-ad7d96bb9094"
      unitRef="chf">250000</moln:CurrentAccruedProjectCostsAndRoyalties>
    <moln:RoyaltyPayable
      contextRef="i46ac96852f4042b3a422b02e00b4ff71_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTMvZnJhZzpmMWNlMTRjMmRjZDE0N2I2YTRjZWIwZmRmOTkyYzc5ZS90ZXh0cmVnaW9uOmYxY2UxNGMyZGNkMTQ3YjZhNGNlYjBmZGY5OTJjNzllXzc2_02420dca-596f-4fe8-a055-2084908e1381"
      unitRef="chf">1000000</moln:RoyaltyPayable>
    <moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1MA_62cdf938-6ef9-4ba9-a72e-de9ad7c7c0c1">Personnel expenses&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation (non-cash effective)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Social security costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(39,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(36,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(33,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Full-time equivalents and head count&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Average number of full-time equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full-time equivalents at year end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headcount at year end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;177&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;18.1&#160;&#160;&#160;&#160;Pension costs and liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actuarial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rate at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate at December 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future salary increases at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mortality tables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BVG2020 GT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BVG2020 GT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Date of last actuarial valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.12.2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.12.2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of the amount recognized in the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of plan assets at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net defined benefit liability at December 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Components of defined benefit cost in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current service cost (employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Past service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative cost excl. cost for managing plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit cost recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof service cost and administrative cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof net interest expense on the net defined benefit liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of net defined benefit liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net defined benefit liability at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit cost recognized in profit or loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of net pension liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions by the employer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net defined benefit liability at December 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expenses on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current service cost (employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits (paid)/deposited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Past service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative cost (excl. cost for managing plan assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain)/loss on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit obligation at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;52,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;54,461&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of amount recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss arising from experience adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actuarial (gain)/loss on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return on plan assets excluding interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remeasurement of net pension liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of plan assets at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by the employer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits (paid)/deposited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return on plan assets excl. interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of plan assets at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;50,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;47,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Best estimate of contributions of next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by the employer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Plan asset classes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt instruments (e.g. bonds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Real estate funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total plan assets at fair value (quoted market price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;40,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;39,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total plan assets at fair value (non-quoted market price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total plan assets at fair value at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;50,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;47,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof entity's own transferable financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof property occupied or other assets used by the entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sensitivity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with discount rate -0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with discount rate +0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with interest rate on retirement savings capital -0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with interest rate on retirement savings capital +0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with salary increases -0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with salary increases +0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with life expectancy +1 year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with life expectancy -1 year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturity profile of defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average duration of defined obligation in years at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average duration of defined obligation in years at December 31 for active members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average duration of defined obligation in years at December 31 for pensioners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Discount rates are based on industry benchmarks related to benefits with a 20 year duration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In liabilities for employee benefits, as presented in the consolidated statement of financial position included are also TCHF 307 (2021: TCHF 257; 2020: TCHF 255) for accrued sabbatical cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The sum of these two positions represent the non-cash effective pension costs recognized in the profit and loss section of the consolidated statement of comprehensive income of which TCHF 846 are research and development costs (2021: TCHF 837; 2020: TCHF 1,039) and TCHF 250 are selling, general and administrative costs (2021: TCHF 235; 2020: TCHF 214).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the most important parameters which influence the pension obligation of the Company a sensitivity analysis was performed. The discount rate and the assumption for salary increases were modified by a certain percentage value. Sensitivity on mortality was calculated by changing the mortality with a constant factor for all age groups. With this procedure the Company could change the longevity for most of the age categories by one year longer or shorter than the baseline value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the amounts that are reflected in the statement of comprehensive income for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Components of defined benefit cost in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current service cost (employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Past service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative cost excl. cost for managing plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit cost recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,080&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof service cost and administrative cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof net interest expense on the net defined benefit liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of amount recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss arising from experience adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actuarial (gain)/loss on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return on plan assets excluding interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remeasurement of net pension liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;18.2&#160;&#160;&#160;&#160;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;18.2.1&#160;&#160;&#160;&#160;Employee Share Option Plans (&#x201c;ESOP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&#160;&#160;&#160;&#160;ESOP 2009 established in December 2009&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&#160;&#160;&#160;&#160;ESOP 2014 established in July 2014 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An ESOP is an incentive tool that fosters the entrepreneurial spirit and performance by way of financial participation in the Group's long term success. It gives employees, members of the Board of Directors and selected advisors a beneficial opportunity to purchase shares of the Company. Each option entitles its holder to purchase one share of the Company at a pre-defined exercise price. The number of options granted to each participant was determined by the Board of Directors based on a participant&#x2019;s position and level of responsibility. The options generally vested quarterly over four years, with vesting of 25% after one year. At the end of the 10 year option term, unexercised options expire without value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, an aggregate of 282,105 options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, an aggregate of 318,902 options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the initial public offering of the Company on the SIX Swiss Exchange on November&#160;5, 2014, no further option grants have been made under any of these two share option plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;18.2.2&#160;&#160;&#160;&#160;Long Term Incentive (&#x201c;LTI&#x201d;) Plans: Restricted Share Units ("RSU'') and Performance Share Units ("PSU")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;LTI plans 2018 established in March 2018&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;LTI plans 2019 established in March 2019&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;LTI plans 2020 established in March 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;LTI plans 2021 established in March 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;LTI plans 2022 established in March 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the LTI plans, members of the Board of Directors are eligible to be granted RSUs, whereas members of the Management Board and other employees are eligible to be granted PSUs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are contingent rights to receive a certain number of shares of the Company at the end of a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIwNw_9040953b-cb8b-40fb-a37f-f83b25c57861"&gt;three&lt;/span&gt;-year blocking period. The number of RSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each RSU as at the grant date. In certain circumstances, including a change of control, a full or partial accelerated vesting of the RSUs may occur. RSUs vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxMQ_05ecdaa7-ecd6-4736-951d-8a9dde75aba2"&gt;one&lt;/span&gt;-year period from date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSUs are contingent rights to receive a variable number of shares of the Company. Since 2021, PSUs granted to employees (except for members of the Management Board) will vest in three tranches of one third each. The first tranche of the PSUs shall vest on the first anniversary of the grant date, the second tranche on the second anniversary of the grant date and the third tranche on the third anniversary of the grant date. For the members of the Management Board, the vesting schedule remains unchanged and PSU's will vest at the end of a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyMg_8b946c45-4517-4e69-84b4-4b2d7403ff98"&gt;three&lt;/span&gt; year cliff-vesting period. PSUs granted to all employees under PSU plans prior to 2021 will continue to vest at the end of a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIyNg_6be1f36f-6243-4b7f-bbee-a9ede8c3610e"&gt;three&lt;/span&gt;-year cliff-vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of PSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each PSU as of the grant date. While the PSUs are designed to let the beneficiaries participate in the long-term share price development, the number of shares to be earned in relation to a PSU also depends on the achievement of pre-defined corporate goals for the respective year. Accordingly, the number of shares to be issued based on the PSUs can be between zero and 150% of the number of PSUs granted. Even after the determination of goal achievement, participants may lose their entitlements in full or in part depending on certain conditions relating to their employment. In certain circumstances, including a change of control, a full or partial accelerated vesting of the PSUs may occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LTI plans are issued annually, which allows the Board of Directors to review the terms and determine the targets on an annual basis. Employees generally receive the grants on April 1 of each calendar year, or for new employees on the first day of the calendar quarter after the start of their employment. Members of the Management Board and the Board of Directors receive the annual grants after the approval of the ordinary shareholders&#x2019; meeting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, 604,800 PSUs and 96,001 RSUs were outstanding. As of December&#160;31, 2021, 547,485 PSUs and 95,635 RSUs were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;18.2.3&#160;&#160;&#160;&#160;Conditions attached to and measurement of fair values of equity-settled share-based payment arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the conditions as well as the inputs used in the measurement of the values at grant dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU/PSU, conditions and assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nature of arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant of PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant of PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant date RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April 13, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant dates PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jan&#160;1 - Oct&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jan&#160;1 - Oct&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Number of RSU granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Number of PSU granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;230,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.55 - 18.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.90 - 23.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vesting period for RSU (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full contractual life for RSU (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vesting period for PSU (years), Management Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vesting period for PSU (years), employees excluding Management Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00 (pro-rata annual vesting)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00 (pro-rata annual vesting)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full contractual life for PSU (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility on Common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.69 - 76.84&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.57 - 61.69&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate p. a. (%) / CHF LIBOR / Common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.54) - (0.71)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.58) - (0.61)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility on NBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.89 - 28.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.21 - 27.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate p. a. (%) / USD LIBOR / NBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.58 - 4.78&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.24 - 0.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility on SPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.57 - 17.02&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.96 - 16.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate p. a. (%) / CHF LIBOR / SPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.54) - (0.71)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.58) - (0.61)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value of rights granted (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Latest expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sep 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sep 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monte Carlo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monte Carlo&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional comments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected volatility: Historical share prices of the Company have been used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The indices, Nasdaq Biotechnology Index ('NBI") and Swiss performance Index ("SPI") are used as inputs in determining the fair values for the 2021 and 2022 PSU Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movements in the number of all issued RSUs, PSUs and share options are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share option / PSU / RSU movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU/RSU (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;915,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;382,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;533,104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Performance adjustment) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Forfeited) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Exercised options, vested PSU / RSU) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(145,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(82,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;962,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;318,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;643,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Performance adjustment) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Forfeited) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Exercised options, vested PSU / RSU) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(252,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(218,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;982,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;282,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;700,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Performance adjustments indicate forfeitures due to non-market performance conditions not achieved&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forfeited due to service conditions not fulfilled&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF 22.35&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     (2021: CHF 19.87)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Exercise price&lt;br/&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options / &lt;br/&gt;PSU/RSU&lt;br/&gt;(number)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Remaining life&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Thereof exercisable options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;700,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;982,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;282,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Exercise price&lt;br/&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options / &lt;br/&gt;PSU/RSU&lt;br/&gt;(number)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Remaining life&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Thereof exercisable options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;643,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;962,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;318,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The non-cash costs for share-based payments recognized in the statement of comprehensive income can be attributed to the Group&#x2019;s two functions as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,088&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,932&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock>
    <moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1NA_2b053c93-b572-4e70-8537-cdca803dea98">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation (non-cash effective)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Social security costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(39,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(36,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(33,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Full-time equivalents and head count&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Average number of full-time equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full-time equivalents at year end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headcount at year end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;177&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEtMS0xLTEtMTA5NjE4_4141df67-be65-476c-a8e1-67fbfe2afce4"
      unitRef="chf">27737000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEtNC0xLTEtMTA5NjE4_0781f697-b564-4760-8743-1451a447a01c"
      unitRef="chf">25909000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEtNy0xLTEtMTA5NjE4_356efa23-c78d-4646-bea5-1fe8f457e713"
      unitRef="chf">23525000</ifrs-full:WagesAndSalaries>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzItMS0xLTEtMTA5NjE4_f0241507-9427-4245-9908-bcb5e1d5b825"
      unitRef="chf">5088000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzItNC0xLTEtMTA5NjE4_e109cd55-05d9-482b-a88d-ae87e5e8349d"
      unitRef="chf">4085000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzItNy0xLTEtMTA5NjE4_5ec3cd35-8279-4aa5-9317-5c1f8c5f42dd"
      unitRef="chf">2932000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzMtMS0xLTEtMTA5NjE4_f46f46a4-cff6-4d39-9886-cb1c849ad97f"
      unitRef="chf">3192000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzMtNC0xLTEtMTA5NjE4_652c01d8-200b-4bd8-8ffb-bfd2208f19c9"
      unitRef="chf">3059000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzMtNy0xLTEtMTA5NjE4_10980168-1d30-4c9f-b281-3c52eafbf97f"
      unitRef="chf">3080000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:SocialSecurityContributions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzQtMS0xLTEtMTA5NjE4_fcbda96a-7db7-4e44-99cf-d700b89b886e"
      unitRef="chf">2399000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzQtNC0xLTEtMTA5NjE4_5e57c4fb-af43-45e9-8235-2aed5a99f571"
      unitRef="chf">2535000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzQtNy0xLTEtMTA5NjE4_f52b1b4a-ede1-4993-900f-f9d8923af7d5"
      unitRef="chf">2393000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:OtherEmployeeExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzUtMS0xLTEtMTA5NjE4_dda0d4a6-e7cd-4430-835a-46b28c30995c"
      unitRef="chf">1473000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzUtNC0xLTEtMTA5NjE4_73cc9c9b-1f91-4dc2-b01e-a2598ea3fd4c"
      unitRef="chf">663000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzUtNy0xLTEtMTA5NjE4_f06eba62-8531-404f-a32c-b48d5691c343"
      unitRef="chf">1704000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzYtMS0xLTEtMTA5NjE4_1bbfc146-5f63-4f3e-8c7a-0395ff401da9"
      unitRef="chf">39889000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzYtNC0xLTEtMTA5NjE4_c40494f0-1e58-42a7-82a7-529b5ea73e5f"
      unitRef="chf">36251000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzYtNy0xLTEtMTA5NjE4_dc8d7f83-ae1f-4b85-93dd-31e8765c3a7f"
      unitRef="chf">33634000</ifrs-full:EmployeeBenefitsExpense>
    <moln:AverageNumberOfFullTimeEquivalentEmployees
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzktMS0xLTEtMTA5NjE4_a051e47b-84c4-4126-94fb-6e8424aa78cb"
      unitRef="employee">167.4</moln:AverageNumberOfFullTimeEquivalentEmployees>
    <moln:AverageNumberOfFullTimeEquivalentEmployees
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzktNC0xLTEtMTA5NjE4_40161d90-c6fa-4b94-9c1b-10ddf423da6a"
      unitRef="employee">158.3</moln:AverageNumberOfFullTimeEquivalentEmployees>
    <moln:AverageNumberOfFullTimeEquivalentEmployees
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzktNy0xLTEtMTA5NjE4_0341f3ab-0b98-47b9-8134-5b8f7817515c"
      unitRef="employee">142.5</moln:AverageNumberOfFullTimeEquivalentEmployees>
    <moln:NumberOfFullTimeEquivalentEmployees
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEwLTEtMS0xLTEwOTYxOA_2b5f2406-2fe7-4805-bb1a-e52ed550f76c"
      unitRef="employee">175.3</moln:NumberOfFullTimeEquivalentEmployees>
    <moln:NumberOfFullTimeEquivalentEmployees
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEwLTQtMS0xLTEwOTYxOA_d9f26100-045d-4087-94cb-75d395d7a8c6"
      unitRef="employee">163.2</moln:NumberOfFullTimeEquivalentEmployees>
    <moln:NumberOfFullTimeEquivalentEmployees
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzEwLTctMS0xLTEwOTYxOA_b5cc9769-29d2-4448-803f-af8fffd2dccc"
      unitRef="employee">145.4</moln:NumberOfFullTimeEquivalentEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzExLTEtMS0xLTEwOTYxOA_b1a4c71d-895e-453c-841e-209bc08bcf43"
      unitRef="employee">191</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzExLTQtMS0xLTEwOTYxOA_9a4ce4a4-9181-4321-8edc-726361f1db9a"
      unitRef="employee">177</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTplYmI1MmYxOWIwYzI0OWQ3YjNkOWJhNDg3OWFlMTExOS90YWJsZXJhbmdlOmViYjUyZjE5YjBjMjQ5ZDdiM2Q5YmE0ODc5YWUxMTE5XzExLTctMS0xLTEwOTYxOA_2ea22f84-712c-489d-bc11-cd907acea328"
      unitRef="employee">159</ifrs-full:NumberOfEmployees>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1NQ_772a7064-bcc6-4cb6-8692-e101360a1dd9">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actuarial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rate at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate at December 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future salary increases at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mortality tables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BVG2020 GT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BVG2020 GT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Date of last actuarial valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.12.2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.12.2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of the amount recognized in the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of plan assets at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net defined benefit liability at December 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Components of defined benefit cost in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current service cost (employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Past service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative cost excl. cost for managing plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit cost recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof service cost and administrative cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof net interest expense on the net defined benefit liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of net defined benefit liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net defined benefit liability at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit cost recognized in profit or loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of net pension liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions by the employer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net defined benefit liability at December 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expenses on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current service cost (employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits (paid)/deposited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Past service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative cost (excl. cost for managing plan assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain)/loss on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit obligation at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;52,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;54,461&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of amount recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss arising from experience adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actuarial (gain)/loss on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return on plan assets excluding interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remeasurement of net pension liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of plan assets at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by the employer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits (paid)/deposited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return on plan assets excl. interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of plan assets at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;50,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;47,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Best estimate of contributions of next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions by the employer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Plan asset classes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt instruments (e.g. bonds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Real estate funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total plan assets at fair value (quoted market price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;40,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;39,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total plan assets at fair value (non-quoted market price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total plan assets at fair value at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;50,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;47,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof entity's own transferable financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof property occupied or other assets used by the entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sensitivity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with discount rate -0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with discount rate +0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with interest rate on retirement savings capital -0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with interest rate on retirement savings capital +0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with salary increases -0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with salary increases +0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with life expectancy +1 year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined benefit obligation at December 31 with life expectancy -1 year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturity profile of defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average duration of defined obligation in years at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average duration of defined obligation in years at December 31 for active members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average duration of defined obligation in years at December 31 for pensioners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Discount rates are based on industry benchmarks related to benefits with a 20 year duration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In liabilities for employee benefits, as presented in the consolidated statement of financial position included are also TCHF 307 (2021: TCHF 257; 2020: TCHF 255) for accrued sabbatical cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The sum of these two positions represent the non-cash effective pension costs recognized in the profit and loss section of the consolidated statement of comprehensive income of which TCHF 846 are research and development costs (2021: TCHF 837; 2020: TCHF 1,039) and TCHF 250 are selling, general and administrative costs (2021: TCHF 235; 2020: TCHF 214).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the most important parameters which influence the pension obligation of the Company a sensitivity analysis was performed. The discount rate and the assumption for salary increases were modified by a certain percentage value. Sensitivity on mortality was calculated by changing the mortality with a constant factor for all age groups. With this procedure the Company could change the longevity for most of the age categories by one year longer or shorter than the baseline value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMtMS0xLTEtMTA5NjE4_0373a5d0-0a45-455c-a48f-576e9285bc20"
      unitRef="number">0.0040</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMtNC0xLTEtMTA5NjE4_7ec13401-7924-441e-a97f-39a9b7b21842"
      unitRef="number">0.0020</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQtMS0xLTItMTA5NjE4_dcadca12-b6a0-4cba-9a28-c973f3d3f054"
      unitRef="number">0.0225</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQtNC0xLTItMTA5NjE4_47b083d6-69be-404a-a843-a9a85f62278d"
      unitRef="number">0.0040</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUtMS0xLTItMTA5NjE4_60da7700-d7f0-44b6-ae49-41cb6a18fd78"
      unitRef="number">0.0200</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUtNC0xLTItMTA5NjE4_b21cb5d6-db55-439e-b91a-6c93dbfe3b15"
      unitRef="number">0.0200</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzktMS0xLTEtMTA5NjE4_52f9a14e-806f-4926-b103-12d6facf8dcd"
      unitRef="chf">52529000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzktNC0xLTEtMTA5NjE4_67ff5aeb-56b3-4e8c-a91a-313dd31133f6"
      unitRef="chf">54461000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEwLTEtMS0xLTEwOTYxOA_7e94570d-4743-4b4a-8474-d59477643cc6"
      unitRef="chf">50284000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEwLTQtMS0xLTEwOTYxOA_5e5127a5-f2a5-4a4e-b85a-ddf3ecc3c916"
      unitRef="chf">47979000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzExLTEtMS0xLTEwOTYxOA_a161e82c-ba49-4d66-8082-60a4890e4a14"
      unitRef="chf">2245000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzExLTQtMS0xLTEwOTYxOA_9ef51b2b-2f1c-455e-82ef-37e16626beda"
      unitRef="chf">6483000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEzLTEtMS0xLTEwOTYxOA_a037f677-cbd2-4672-a9e3-a14cdf3977f6"
      unitRef="chf">3137000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzEzLTQtMS0xLTEwOTYxOA_d087b850-3a06-464d-b93c-ff02a6bcc54d"
      unitRef="chf">3097000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:PastServiceCostDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE0LTEtMS0xLTEwOTYxOA_066a7544-b20b-4295-a299-09ec47ebb1e4"
      unitRef="chf">0</ifrs-full:PastServiceCostDefinedBenefitPlans>
    <ifrs-full:PastServiceCostDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE0LTQtMS0xLTEwOTYxOA_0f8a6dce-46e7-43e4-a5c8-feeef5fb84bb"
      unitRef="chf">-94000</ifrs-full:PastServiceCostDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE1LTEtMS0xLTEwOTYxOA_10b023cd-62be-40e2-82d8-a2b509f686b5"
      unitRef="chf">231000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE1LTQtMS0xLTEwOTYxOA_8a54d606-687c-4d3c-aa29-9ccc77dd902d"
      unitRef="chf">114000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:InterestIncomeDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE2LTEtMS0xLTEwOTYxOA_a207d6b7-58dd-4ee8-b0fd-d889bec158dc"
      unitRef="chf">203000</ifrs-full:InterestIncomeDefinedBenefitPlans>
    <ifrs-full:InterestIncomeDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE2LTQtMS0xLTEwOTYxOA_8b4033d6-6bbb-4cfd-9a7c-b3f17d5a91fd"
      unitRef="chf">86000</ifrs-full:InterestIncomeDefinedBenefitPlans>
    <ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE3LTEtMS0xLTEwOTYxOA_fa86a5a1-541f-4b79-a206-97a1dab16744"
      unitRef="chf">27000</ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans>
    <ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE3LTQtMS0xLTEwOTYxOA_ff4b582a-982b-45d5-b5e5-cd10cd38b25d"
      unitRef="chf">27000</ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE4LTEtMS0xLTEwOTYxOA_a01d23b9-5b24-4fa2-8b24-fa65ddf4745c"
      unitRef="chf">3192000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE4LTQtMS0xLTEwOTYxOA_c57249ee-1934-4c76-825f-ea9b97333b1d"
      unitRef="chf">3059000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE5LTEtMS0xLTEwOTYxOA_bacbe7fe-7c47-4bce-9de1-39444d83f520"
      unitRef="chf">3164000</moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans>
    <moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzE5LTQtMS0xLTEwOTYxOA_c7c48849-e4e1-440e-910b-96a34d44c9ef"
      unitRef="chf">3031000</moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIwLTEtMS0xLTEwOTYxOA_bbd11a7a-b8b1-413b-9bae-3ced9b3ef0b1"
      unitRef="chf">28000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIwLTQtMS0xLTEwOTYxOA_27792bf7-11e6-498b-aea6-3b6af34f3a6f"
      unitRef="chf">28000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIyLTEtMS0xLTEwOTYxOA_e9f287c7-2d82-413d-9c54-175ca773b27f"
      unitRef="chf">6483000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIyLTQtMS0xLTEwOTYxOA_9e64fc68-a17a-4758-adce-e987e5084c23"
      unitRef="chf">13423000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIzLTEtMS0xLTEwOTYxOA_f1e95922-3810-47ce-95e1-99ddc059324b"
      unitRef="chf">3192000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzIzLTQtMS0xLTEwOTYxOA_53eac376-79f3-4ff3-a07c-8e4a0662b238"
      unitRef="chf">3059000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI0LTEtMS0xLTEwOTYxOA_845e2274-3834-493e-bf20-f97fd800ec76"
      unitRef="chf">5334000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI0LTQtMS0xLTEwOTYxOA_f2b18a98-bb20-435a-83a3-cf7f057fbd29"
      unitRef="chf">8012000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI1LTEtMS0xLTEwOTYxOA_cc323f3b-ae38-4abe-8b20-81c72d6b58e1"
      unitRef="chf">2096000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI1LTQtMS0xLTEwOTYxOA_d72a25cb-f2c5-418f-bd90-08e33f58d041"
      unitRef="chf">1987000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI2LTEtMS0xLTEwOTYxOA_9bcc46fb-ec98-4555-ac56-2402befe88aa"
      unitRef="chf">2245000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI2LTQtMS0xLTEwOTYxOA_f9e2702e-1894-4af6-9c0f-b8a20b56f370"
      unitRef="chf">6483000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i477f396e4168445ea6fbd216e6f8a944_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI4LTEtMS0xLTEwOTYxOA_5ed83b69-3a98-4d24-9bc0-8f001e0747d0"
      unitRef="chf">54461000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i2698db5ae60649b096fe74b1692909bc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI4LTQtMS0xLTEwOTYxOA_89f7d991-8e55-4b97-9874-5140f79d4c83"
      unitRef="chf">54512000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI5LTEtMS0xLTEwOTYxOA_5d9bc0ea-b827-4a7b-98dc-2238ebed3f28"
      unitRef="chf">231000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzI5LTQtMS0xLTEwOTYxOA_45db47de-29eb-4ae4-b15d-3405efe55abe"
      unitRef="chf">114000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMwLTEtMS0xLTEwOTYxOA_d567ad92-5a05-4f05-8a2f-ae5811cc5e67"
      unitRef="chf">3137000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMwLTQtMS0xLTEwOTYxOA_0ebbe5a7-d0ae-4d73-b04e-2683a2ae6253"
      unitRef="chf">3097000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMxLTEtMS0xLTEwOTYxOA_d9a09e4c-813d-4a2d-ab7c-76bd54f4ab5d"
      unitRef="chf">-1317000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMxLTQtMS0xLTEwOTYxOA_d807296f-dc34-484a-9987-4308fb518686"
      unitRef="chf">-1246000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMyLTEtMS0xLTEwOTYxOA_09feff73-3144-4633-a703-b66d169e42b3"
      unitRef="chf">-2032000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMyLTQtMS0xLTEwOTYxOA_77109b1b-55b0-4c99-9aeb-a1dbb77a356e"
      unitRef="chf">-1067000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMzLTEtMS0xLTEwOTYxOA_1e257495-adf9-4ab9-b86f-fb07cd1492ec"
      unitRef="chf">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzMzLTQtMS0xLTEwOTYxOA_b28708c1-5c50-43fd-b6b8-b352bf25d76a"
      unitRef="chf">-94000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM0LTEtMS0xLTEwOTYxOA_2cec4de1-389b-408d-8758-9613ce9d5536"
      unitRef="chf">27000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM0LTQtMS0xLTEwOTYxOA_d05bb6b8-d9a5-4b6c-8c31-cab1878b0935"
      unitRef="chf">27000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i95956f3137454e5b8d8cbd8e523fcd28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM1LTEtMS0xLTEwOTYxOA_697b877e-1cff-4774-b967-e17735765c26"
      unitRef="chf">8676000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i76382ebd83bb4b008d3413f21ccb1209_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM1LTQtMS0xLTEwOTYxOA_fcc3de30-e0ea-4561-9465-b427fefc1a84"
      unitRef="chf">5508000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i3b64a6fd6d004538825e688a02e1881a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM2LTEtMS0xLTEwOTYxOA_9887f539-211e-47db-85f2-ec4b82d7f1c9"
      unitRef="chf">52529000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i477f396e4168445ea6fbd216e6f8a944_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM2LTQtMS0xLTEwOTYxOA_e37becb2-0830-4fa7-ba7e-19914d03eca7"
      unitRef="chf">54461000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM4LTEtMS0xLTEwOTYxOA_f964a3a2-42bd-4d29-882b-67e32fe096cc"
      unitRef="chf">12222000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM4LTQtMS0xLTEwOTYxOA_9aedd531-7331-4e35-bd0d-f6afab139464"
      unitRef="chf">2303000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM5LTEtMS0xLTEwOTYxOA_fcaba9a2-8ef1-402d-954a-800322966395"
      unitRef="chf">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzM5LTQtMS0xLTEwOTYxOA_3e5177f3-41e4-4310-838f-a45c2a738040"
      unitRef="chf">2432000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQwLTEtMS0xLTEwOTYxOA_cce17613-7b73-45f7-9050-dea5d4371e32"
      unitRef="chf">-3546000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQwLTQtMS0xLTEwOTYxOA_4295f8f3-50ad-4d15-9937-0db1ad91b159"
      unitRef="chf">773000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans>
    <moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQxLTEtMS0xLTEwOTYxOA_e8ed03e6-e2de-46b9-a88f-f3f13088e392"
      unitRef="chf">8676000</moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans>
    <moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQxLTQtMS0xLTEwOTYxOA_6f39fd2e-5c9a-4415-a7cc-c7107006a2c5"
      unitRef="chf">5508000</moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQyLTEtMS0xLTEwOTYxOA_6586dc3d-2aff-4aa0-9bf0-1449e8dcbfa6"
      unitRef="chf">-3342000</ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQyLTQtMS0xLTEwOTYxOA_1ca6fe24-7062-4da8-90e4-0bad9307ec4a"
      unitRef="chf">2504000</ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQzLTEtMS0xLTEwOTYxOA_2041f829-7c08-4d31-abcc-c3195aa8df1b"
      unitRef="chf">5334000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQzLTQtMS0xLTEwOTYxOA_0ebbeba0-ed33-47b0-bb48-2609d5686afd"
      unitRef="chf">8012000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i26558c7e2e90408aaf310a75bba70d80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ1LTEtMS0xLTEwOTYxOA_440ffff6-330a-44db-9218-bdafb409f538"
      unitRef="chf">-47979000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i3319cb244b7e4172804e14694e32ba95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ1LTQtMS0xLTEwOTYxOA_20c195d7-6c7d-48a9-afae-a43829c508bd"
      unitRef="chf">-41089000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ2LTEtMS0xLTEwOTYxOA_f61aed05-5360-4283-870b-b4453c30aef8"
      unitRef="chf">-203000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ2LTQtMS0xLTEwOTYxOA_829d28b1-4306-4987-be25-d4a21ac2417b"
      unitRef="chf">-86000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ3LTEtMS0xLTEwOTYxOA_0ee47338-9930-42e3-b54a-7748c9056419"
      unitRef="chf">2096000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ3LTQtMS0xLTEwOTYxOA_13efbaa4-aadb-405c-9401-7ddf315b417a"
      unitRef="chf">1987000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ4LTEtMS0xLTEwOTYxOA_60129b86-70c8-4d22-b7d6-504e9fa02f81"
      unitRef="chf">1317000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ4LTQtMS0xLTEwOTYxOA_f8d0f06a-124f-486a-b813-d9c8d1aa656a"
      unitRef="chf">1246000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ5LTEtMS0xLTEwOTYxOA_360af30e-7282-4a2e-8a49-6bb17813b8e5"
      unitRef="chf">2032000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzQ5LTQtMS0xLTEwOTYxOA_0d096052-b302-4380-8744-985cb305b750"
      unitRef="chf">1067000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="ibb550d50086748f2bb1fde126eaa00af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUwLTEtMS0xLTEwOTYxOA_73501053-7ae4-4b54-a9cc-5f5d9cbef887"
      unitRef="chf">-3342000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="i1cac2503a0a84ffaac3db28bd213dfd9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUwLTQtMS0xLTEwOTYxOA_ec0f092d-c911-460a-b24e-ac765cf5d006"
      unitRef="chf">2504000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="ib9e07ae88ae04fad8ed31f5f90d82653_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUxLTEtMS0xLTEwOTYxOA_e546cb9d-72a6-491a-bdc5-5a731866e9d2"
      unitRef="chf">-50284000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i26558c7e2e90408aaf310a75bba70d80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUxLTQtMS0xLTEwOTYxOA_9acb23e1-ce99-49dc-8110-4ecf0ad61bd6"
      unitRef="chf">-47979000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUzLTEtMS0xLTEwOTYxOA_e22b4b95-b7ab-4d50-8b57-c5c6d1f1572f"
      unitRef="chf">2231000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzUzLTQtMS0xLTEwOTYxOA_098a1dbb-38ad-4f13-8e58-704caaf30ae5"
      unitRef="chf">2060000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets
      contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU1LTEtMS0xLTEwOTYxOA_9067f954-917d-4740-a38c-20e940f0ce22"
      unitRef="chf">7896000</ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets
      contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU1LTQtMS0xLTEwOTYxOA_20284400-22f1-463d-868a-b1e156f1cfbd"
      unitRef="chf">9581000</ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:EquityInstrumentsAmountContributedToFairValueOfPlanAssets
      contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU2LTEtMS0xLTEwOTYxOA_2044d38c-3176-4750-ba51-bda4d9c69bad"
      unitRef="chf">20754000</ifrs-full:EquityInstrumentsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:EquityInstrumentsAmountContributedToFairValueOfPlanAssets
      contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU2LTQtMS0xLTEwOTYxOA_5a77e96b-b34f-45ae-8a5f-edac6616a687"
      unitRef="chf">20246000</ifrs-full:EquityInstrumentsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets
      contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU3LTEtMS0xLTEwOTYxOA_f3069cd5-166a-4ce3-a9e5-fd66f00a5e48"
      unitRef="chf">8200000</ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets
      contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU3LTQtMS0xLTEwOTYxOA_852b9a23-5605-49ff-acda-9dac31e86164"
      unitRef="chf">6130000</ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PropertyAmountContributedToFairValueOfPlanAssets
      contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU4LTEtMS0xLTEwOTYxOA_02ec1b0a-64bc-4097-83f8-37ab53306f36"
      unitRef="chf">1793000</ifrs-full:PropertyAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PropertyAmountContributedToFairValueOfPlanAssets
      contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU4LTQtMS0xLTEwOTYxOA_9a8e99ce-f343-426c-b741-ea56109407ba"
      unitRef="chf">1612000</ifrs-full:PropertyAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU5LTEtMS0xLTEwOTYxOA_7de4cbac-ff5a-4600-955b-75170e72a474"
      unitRef="chf">1748000</ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzU5LTQtMS0xLTEwOTYxOA_1cfda344-575c-4216-a416-44e1ff080fd8"
      unitRef="chf">1547000</ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="i76d575c9c1d347f3ade30668167c5c96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYwLTEtMS0xLTEwOTYxOA_cc6edd7d-24e8-48e1-86b9-532921b268da"
      unitRef="chf">40391000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="i7062935e4e5c41c3ab66bd99f93a6e70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYwLTQtMS0xLTEwOTYxOA_1eef52a6-8ff3-4b80-a020-a7e86282a5f8"
      unitRef="chf">39116000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="ifff310e7d99a4295bb708e767bfd827a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYxLTEtMS0xLTEwOTYxOA_4a88c765-111c-4e06-8db9-0ce8461f806f"
      unitRef="chf">9892000</ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="i59e9a73043d041f097d4b73f09999ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYxLTQtMS0xLTEwOTYxOA_4b13e50c-36b8-4aa5-8104-d6735eae07f4"
      unitRef="chf">8862000</ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="ifff310e7d99a4295bb708e767bfd827a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYyLTEtMS0xLTEwOTYxOA_aad5deab-3d82-4239-be2c-50cf87605fb4"
      unitRef="chf">9892000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="i59e9a73043d041f097d4b73f09999ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYyLTQtMS0xLTEwOTYxOA_4aef8557-7ff7-4280-9614-00e033664d27"
      unitRef="chf">8862000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYzLTEtMS0xLTEwOTYxOA_e89d7aa5-23c7-4be0-a266-2a6c59e13f60"
      unitRef="chf">50284000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzYzLTQtMS0xLTEwOTYxOA_3de6e4ea-e29e-41b4-9eb7-9bd79990279b"
      unitRef="chf">47979000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY0LTEtMS0xLTEwOTYxOA_ce8bab57-4ecf-4a25-9c28-c4b0ca01cf88"
      unitRef="chf">0</ifrs-full:DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets>
    <ifrs-full:DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY0LTQtMS0xLTEwOTYxOA_6430777a-933a-4d6b-af6f-5a05a6c53f62"
      unitRef="chf">0</ifrs-full:DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets>
    <moln:PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY1LTEtMS0xLTEwOTYxOA_c35dd4d3-e756-4ea4-ba8f-9839acd7085f"
      unitRef="chf">0</moln:PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets>
    <moln:PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY1LTQtMS0xLTEwOTYxOA_bf25344a-c0cf-420f-a0c2-f787d6dc3494"
      unitRef="chf">0</moln:PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ie370090677a545b69199494d00542b66_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmY0OTdlMGIxMzk0ZDRjMTJiYjJjODE4YzgyNGE0YTYxXzY1_2c10a6c9-4925-4c94-b43b-2fcf154dfaed"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmY0OTdlMGIxMzk0ZDRjMTJiYjJjODE4YzgyNGE0YTYxXzY1_49f15a45-8a60-45ff-9efc-90ed7bca151a"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ie370090677a545b69199494d00542b66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTEtMS0xLTEwOTYxOA_3ce4a0bf-93fa-4f52-91fb-076a83aaecd9"
      unitRef="chf">54524000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY3LTQtMS0xLTEwOTYxOA_bb92d81d-1f4c-4d77-9ccd-6595e43f69ba"
      unitRef="chf">57066000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ie370090677a545b69199494d00542b66_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmE2NTgzNzFjYjU4YTQxNzQ5YmYwZTM5M2RmZDFhMmMwXzY1_29daf00f-7441-4fbe-9929-d59f49914c44"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmE2NTgzNzFjYjU4YTQxNzQ5YmYwZTM5M2RmZDFhMmMwXzY1_ae2e93ef-3913-4c19-81e0-44a914167835"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ie370090677a545b69199494d00542b66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTEtMS0xLTEwOTYxOA_cb43dff5-9237-426f-a16c-bf790758f07f"
      unitRef="chf">50672000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="i87a252953f884104bde7e1a0d7c46591_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY4LTQtMS0xLTEwOTYxOA_7665d5f2-a975-4c0f-8e10-37693776b840"
      unitRef="chf">52054000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMzZjlmZTUzNjVmMzRjMjE5NjlmNDY0MDVkYzAzMjFhXzk1_5b718a93-5362-422c-94ff-623870b367d8"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMzZjlmZTUzNjVmMzRjMjE5NjlmNDY0MDVkYzAzMjFhXzk1_d508d1fc-1994-41d4-a476-d8934a030902"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTEtMS0xLTEwOTYxOA_716a1d9c-bb74-41d7-9696-a2d656a0be78"
      unitRef="chf">51699000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzY5LTQtMS0xLTEwOTYxOA_c81d057a-ecbc-42b3-b236-1cf31f0b5617"
      unitRef="chf">53576000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM5MjgzN2U0ZWZhYTRiZjI5NjYwYTRjZWIzNzQxNDY4Xzk1_67eaebde-08d2-4970-9953-35b32253be58"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM5MjgzN2U0ZWZhYTRiZjI5NjYwYTRjZWIzNzQxNDY4Xzk1_b0793946-7b78-4bc7-b396-01b6f7ca9999"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ib8202c8045424e74acc574ebe5b785fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTEtMS0xLTEwOTYxOA_0494c1a8-8ac4-42c1-bf06-327f0e9a1cc2"
      unitRef="chf">53383000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ibcf864ef90754f278e13ffa37235877e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcwLTQtMS0xLTEwOTYxOA_517b0709-de8f-46bc-a3ca-acd025146a79"
      unitRef="chf">55373000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM0NzQ0M2E0OTFjZDQyY2Y4Mzk3ZWNkZTFhYjE4N2VhXzY4_2c5b278b-cdbb-4713-99be-16df5ce0187f"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjM0NzQ0M2E0OTFjZDQyY2Y4Mzk3ZWNkZTFhYjE4N2VhXzY4_c6462219-925e-4f8d-b9cd-13d8e06641cf"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTEtMS0xLTEwOTYxOA_507bc1a4-0b40-4e53-8161-34fcd5bafdf6"
      unitRef="chf">52253000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcxLTQtMS0xLTEwOTYxOA_d0df930b-ff53-4c12-a429-8be1f4c03758"
      unitRef="chf">53993000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjEyZTg2MDViMWFhYjQ0MDdhNzJiZWJlMzk1MmNiOTJmXzY4_479bf9bd-cb45-4109-9e3b-0a86cd56fd0b"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjEyZTg2MDViMWFhYjQ0MDdhNzJiZWJlMzk1MmNiOTJmXzY4_fc007c9d-1b12-4283-a96f-ae2abf77c961"
      unitRef="number">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="i345d907a04bf4819bb7da74c7aa2c045_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTEtMS0xLTEwOTYxOA_36ff9586-83e8-4702-90f8-fee8d11dd3ee"
      unitRef="chf">52768000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="ie8670303e14b477492db59a0f50b6eec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzcyLTQtMS0xLTEwOTYxOA_927182c4-ce00-4c50-9934-64c646a1d768"
      unitRef="chf">54947000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod
      contextRef="i90d91352ae9f40a98d596b751938d675_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjNmOTIxNWUxNDAwODRmODE4NjJhZTUxNDkzNWVhNmU1XzY4_84517c98-675c-487a-9a44-89b0814a7d4c">P1Y</moln:ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod>
    <moln:ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod
      contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjNmOTIxNWUxNDAwODRmODE4NjJhZTUxNDkzNWVhNmU1XzY4_90086918-5022-4d8e-a8e8-a06d84e10c01">P1Y</moln:ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTEtMS0xLTEwOTYxOA_bf2162de-0bc9-4bbd-a06c-0073ab26698b"
      unitRef="chf">53090000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="i90d91352ae9f40a98d596b751938d675_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5XzczLTQtMS0xLTEwOTYxOA_fc62beed-2b3c-4c30-9ed4-ff6ca62bc78a"
      unitRef="chf">55283000</moln:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <moln:ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod
      contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjMwMWQ5ZTIwYWFlNjQ2ZGI4OWZjMTJmZTY5NjQxMzJjXzY4_b27abe48-85eb-4dcd-8b21-5aa1c3de5e1b">P1Y</moln:ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod>
    <moln:ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod
      contextRef="i90d91352ae9f40a98d596b751938d675_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTAtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjMwMWQ5ZTIwYWFlNjQ2ZGI4OWZjMTJmZTY5NjQxMzJjXzY4_c9b261c1-fa39-4cb6-ac56-bfa537d68ba6">P1Y</moln:ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="icdef4a2f3f49473fa1da77464227f8d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTEtMS0xLTEwOTYxOA_370fa8bb-3845-4441-a12f-bfa82817ad07"
      unitRef="chf">51961000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="i90d91352ae9f40a98d596b751938d675_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc0LTQtMS0xLTEwOTYxOA_1554b47d-18e1-4724-8f2b-4109a309a49b"
      unitRef="chf">53569000</moln:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc2LTEtMS0xLTEwOTYxOA_676db116-0225-42cb-ace0-c9bb1f70876d">P15Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc2LTQtMS0xLTEwOTYxOA_cb092f01-38fc-4443-8614-5af7f61e4dd3">P18Y6M</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="i87e47e2a1d2f42d6b887d22d3f1fda3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc3LTEtMS0xLTEwOTYxOA_8ae3b577-c98c-408b-99fb-318d8630e73b">P14Y9M18D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="i5c53ee898715434fac2e14c485a6b3ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc3LTQtMS0xLTEwOTYxOA_02b8f6ea-796e-4668-ad12-64e349564c7f">P18Y3M18D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="ied315fa7934d4ceca93243eef84aeb2b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc4LTEtMS0xLTEwOTYxOA_b2088d77-dbd2-48b8-8664-95efffa1612d">P16Y3M18D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="i718f06d2648742acbc789cc2611558ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowNGZiM2U2YTI2MWU0MmU2YTUyNTBhMTJmNmY0ZWZhOS90YWJsZXJhbmdlOjA0ZmIzZTZhMjYxZTQyZTZhNTI1MGExMmY2ZjRlZmE5Xzc4LTQtMS0xLTEwOTYxOA_1dd79c97-1152-43c2-8d2d-6088b917695e">P19Y7M6D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <moln:IndustryBenchmarkDiscountRatesPeriod
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI2_f4a202f1-b044-417b-bf05-c99d49968343">P20Y</moln:IndustryBenchmarkDiscountRatesPeriod>
    <moln:AccruedSabbaticalCost
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzMw_5ba9013c-2274-4fc4-ab46-04afde555a72"
      unitRef="chf">307000</moln:AccruedSabbaticalCost>
    <moln:AccruedSabbaticalCost
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM4_5daa3cba-7861-45fe-8008-c3e4283cc60c"
      unitRef="chf">257000</moln:AccruedSabbaticalCost>
    <moln:AccruedSabbaticalCost
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzQ2_eaf482b0-086d-43fc-b079-96d4a90a1bfb"
      unitRef="chf">255000</moln:AccruedSabbaticalCost>
    <moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzUw_e8292bfa-7d04-43e7-9403-41109b25d858"
      unitRef="chf">846000</moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost>
    <moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzU4_68f0217e-9dfb-49c0-9fb0-f801540a85db"
      unitRef="chf">837000</moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost>
    <moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzY2_8f1655ec-652a-4018-90bd-827a55504e84"
      unitRef="chf">1039000</moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost>
    <moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzcw_73270677-9acf-48b6-b1df-18dbbf78d6d2"
      unitRef="chf">250000</moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost>
    <moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzc4_cb735f31-9fe5-4fa3-bb49-e74655d6eaf8"
      unitRef="chf">235000</moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost>
    <moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzg2_fca7fc69-684a-473c-83f9-70dc4de96642"
      unitRef="chf">214000</moln:PostEmploymentBenefitExpenseNonCashEffectivePensionCost>
    <moln:ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzkz_68781a81-9380-4639-b1a7-4d99c0d6c3e4">P1Y</moln:ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories>
    <moln:DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1MQ_1ef444d5-65ef-4232-ad92-82ebbc1f256f">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the amounts that are reflected in the statement of comprehensive income for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Components of defined benefit cost in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current service cost (employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Past service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative cost excl. cost for managing plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined benefit cost recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,080&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof service cost and administrative cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereof net interest expense on the net defined benefit liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of amount recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss on changes in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss arising from experience adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actuarial (gain)/loss on defined benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return on plan assets excluding interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remeasurement of net pension liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzMtMS0xLTEtMTA5NjE4_a037f677-cbd2-4672-a9e3-a14cdf3977f6"
      unitRef="chf">3137000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzMtNC0xLTEtMTA5NjE4_d087b850-3a06-464d-b93c-ff02a6bcc54d"
      unitRef="chf">3097000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzMtNy0xLTEtMTA5NjE4_8998ca09-02f9-4062-bd89-1b1819842ea5"
      unitRef="chf">3033000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:PastServiceCostDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzQtMS0xLTEtMTA5NjE4_066a7544-b20b-4295-a299-09ec47ebb1e4"
      unitRef="chf">0</ifrs-full:PastServiceCostDefinedBenefitPlans>
    <ifrs-full:PastServiceCostDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzQtNC0xLTEtMTA5NjE4_0f8a6dce-46e7-43e4-a5c8-feeef5fb84bb"
      unitRef="chf">-94000</ifrs-full:PastServiceCostDefinedBenefitPlans>
    <ifrs-full:PastServiceCostDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzQtNy0xLTEtMTA5NjE4_b5a6c0bb-9288-4c91-82b6-a8fadab4ef4b"
      unitRef="chf">0</ifrs-full:PastServiceCostDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzUtMS0xLTEtMTA5NjE4_10b023cd-62be-40e2-82d8-a2b509f686b5"
      unitRef="chf">231000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzUtNC0xLTEtMTA5NjE4_8a54d606-687c-4d3c-aa29-9ccc77dd902d"
      unitRef="chf">114000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzUtNy0xLTEtMTA5NjE4_676efcae-cd09-4961-9083-56b4ef8a9c4c"
      unitRef="chf">103000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:InterestIncomeDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzYtMS0xLTEtMTA5NjE4_a207d6b7-58dd-4ee8-b0fd-d889bec158dc"
      unitRef="chf">203000</ifrs-full:InterestIncomeDefinedBenefitPlans>
    <ifrs-full:InterestIncomeDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzYtNC0xLTEtMTA5NjE4_8b4033d6-6bbb-4cfd-9a7c-b3f17d5a91fd"
      unitRef="chf">86000</ifrs-full:InterestIncomeDefinedBenefitPlans>
    <ifrs-full:InterestIncomeDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzYtNy0xLTEtMTA5NjE4_76dfc071-d894-4019-9f94-2b2e7a373305"
      unitRef="chf">80000</ifrs-full:InterestIncomeDefinedBenefitPlans>
    <ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzctMS0xLTEtMTA5NjE4_fa86a5a1-541f-4b79-a206-97a1dab16744"
      unitRef="chf">27000</ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans>
    <ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzctNC0xLTEtMTA5NjE4_ff4b582a-982b-45d5-b5e5-cd10cd38b25d"
      unitRef="chf">27000</ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans>
    <ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzctNy0xLTEtMTA5NjE4_e7532241-e619-4e91-9a45-d44f497babc1"
      unitRef="chf">24000</ifrs-full:AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzgtMS0xLTEtMTA5NjE4_a01d23b9-5b24-4fa2-8b24-fa65ddf4745c"
      unitRef="chf">3192000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzgtNC0xLTEtMTA5NjE4_c57249ee-1934-4c76-825f-ea9b97333b1d"
      unitRef="chf">3059000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzgtNy0xLTEtMTA5NjE4_32649527-2cdf-4ee8-a7d4-ee1642b0b285"
      unitRef="chf">3080000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzktMS0xLTEtMTA5NjE4_bacbe7fe-7c47-4bce-9de1-39444d83f520"
      unitRef="chf">3164000</moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans>
    <moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzktNC0xLTEtMTA5NjE4_c7c48849-e4e1-440e-910b-96a34d44c9ef"
      unitRef="chf">3031000</moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans>
    <moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzktNy0xLTEtMTA5NjE4_9123af97-07e6-4cc0-a5f4-b560d98303cb"
      unitRef="chf">3057000</moln:ServiceCostAndAdministrativeCostDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEwLTEtMS0xLTEwOTYxOA_bbd11a7a-b8b1-413b-9bae-3ced9b3ef0b1"
      unitRef="chf">28000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEwLTQtMS0xLTEwOTYxOA_27792bf7-11e6-498b-aea6-3b6af34f3a6f"
      unitRef="chf">28000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEwLTctMS0xLTEwOTYxOA_7a13a011-4b07-41cd-b52c-8ff3feb1bb5c"
      unitRef="chf">23000</ifrs-full:InterestExpenseIncomeDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEzLTEtMS0xLTEwOTYxOA_f964a3a2-42bd-4d29-882b-67e32fe096cc"
      unitRef="chf">12222000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEzLTQtMS0xLTEwOTYxOA_9aedd531-7331-4e35-bd0d-f6afab139464"
      unitRef="chf">2303000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzEzLTctMS0xLTEwOTYxOA_844f34f9-3cc0-44a6-a427-b775af11c43f"
      unitRef="chf">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE0LTEtMS0xLTEwOTYxOA_fcaba9a2-8ef1-402d-954a-800322966395"
      unitRef="chf">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE0LTQtMS0xLTEwOTYxOA_3e5177f3-41e4-4310-838f-a45c2a738040"
      unitRef="chf">2432000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE0LTctMS0xLTEwOTYxOA_05ebdab0-155c-4acb-bd69-bbf282d3b93e"
      unitRef="chf">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE1LTEtMS0xLTEwOTYxOA_cce17613-7b73-45f7-9050-dea5d4371e32"
      unitRef="chf">-3546000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE1LTQtMS0xLTEwOTYxOA_4295f8f3-50ad-4d15-9937-0db1ad91b159"
      unitRef="chf">773000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE1LTctMS0xLTEwOTYxOA_1e55999c-503f-480c-b97b-5f9656f67ea4"
      unitRef="chf">-335000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans>
    <moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE2LTEtMS0xLTEwOTYxOA_e8ed03e6-e2de-46b9-a88f-f3f13088e392"
      unitRef="chf">8676000</moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans>
    <moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE2LTQtMS0xLTEwOTYxOA_6f39fd2e-5c9a-4415-a7cc-c7107006a2c5"
      unitRef="chf">5508000</moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans>
    <moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE2LTctMS0xLTEwOTYxOA_4b6ed920-4b26-4d0b-9c87-14e16dbc7883"
      unitRef="chf">-335000</moln:ActuarialGainsLossesNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE3LTEtMS0xLTEwOTYxOA_6586dc3d-2aff-4aa0-9bf0-1449e8dcbfa6"
      unitRef="chf">-3342000</ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE3LTQtMS0xLTEwOTYxOA_1ca6fe24-7062-4da8-90e4-0bad9307ec4a"
      unitRef="chf">2504000</ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans>
    <ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE3LTctMS0xLTEwOTYxOA_64e26fa0-6386-40fc-8b7c-ca07271175e4"
      unitRef="chf">-1179000</ifrs-full:ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE4LTEtMS0xLTEwOTYxOA_2041f829-7c08-4d31-abcc-c3195aa8df1b"
      unitRef="chf">5334000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE4LTQtMS0xLTEwOTYxOA_0ebbeba0-ed33-47b0-bb48-2609d5686afd"
      unitRef="chf">8012000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZToxZDk5NGM4ZTNkZTc0MjQ1YTllYzM1NTI5NjE3OTZkZS90YWJsZXJhbmdlOjFkOTk0YzhlM2RlNzQyNDVhOWVjMzU1Mjk2MTc5NmRlXzE4LTctMS0xLTEwOTYxOA_a836888e-d8a9-469a-afbc-57fe3aba8689"
      unitRef="chf">-1514000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE0Mg_8791729a-c4a1-468c-a8ea-85243519ab1c">P4Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage
      contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE0Ng_9c49746d-e2c4-4262-b248-71eeddfbf251"
      unitRef="number">0.25</moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage>
    <moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod
      contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE1MA_0b600d4f-20a6-49a1-a27f-26ccb8b32bd9">P1Y</moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i76a79e3fe3be49e5918a663e53a05813_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE2MQ_f2309263-f0f8-4ab0-ad9e-0efd2f581ad7"
      unitRef="shares">282105</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i16708e73e7aa4355b85eac7ce415b78b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE3Mg_0b685d2c-21f6-47e2-9b3a-eed912b29d5f"
      unitRef="shares">318902</ifrs-full:NumberOfOutstandingShareOptions>
    <moln:NumberOfShareOptionPlans
      contextRef="i029630cbc287400e8ebdacf4da90e321_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzE4NA_d824e7cc-ede2-4337-a00e-f6bca8546634"
      unitRef="plan">2</moln:NumberOfShareOptionPlans>
    <moln:VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches
      contextRef="ib5fa38f116e34565a5e36d42a37700a5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIxOA_bacca4cd-76b4-4482-ab31-31358dbe27eb"
      unitRef="tranche">3</moln:VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches>
    <moln:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted
      contextRef="ie1c7b494d350479797a5d1c4c82ccba2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIzMw_ead708e1-2a06-49cd-85dd-90b76cff8ebf"
      unitRef="number">0</moln:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted>
    <moln:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted
      contextRef="i97a4f932a6df488d9cc6ed653efcf1f7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzIzNw_ed254c71-e137-46e3-b104-2dd1b0651cda"
      unitRef="number">1.50</moln:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ied19b6e08547434f9cdba0fd054a6b2f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI1NQ_f3477044-bbac-4593-b7b5-ba741171002d"
      unitRef="shares">604800</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i72a85516e9d14b69b127030c7418be86_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI1OQ_35921681-1e2e-4fff-a2f0-990922576d2f"
      unitRef="shares">96001</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i91457d4200b443229b7716268dcc0131_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI2Nw_50834197-9e17-43f4-97b0-ef2ee08d305b"
      unitRef="shares">547485</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4c84992c462c4044bf0e6a6000d7fa91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzI3MQ_674a812d-bb49-412c-aa82-aa5617413cdd"
      unitRef="shares">95635</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM0Nw_9df37919-79b2-42db-ae2f-5da40399aad8">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the conditions as well as the inputs used in the measurement of the values at grant dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU/PSU, conditions and assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nature of arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant of PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant of PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant date RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April 13, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant dates PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jan&#160;1 - Oct&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jan&#160;1 - Oct&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Number of RSU granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Number of PSU granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;230,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.55 - 18.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.90 - 23.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vesting period for RSU (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full contractual life for RSU (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vesting period for PSU (years), Management Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vesting period for PSU (years), employees excluding Management Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00 (pro-rata annual vesting)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00 (pro-rata annual vesting)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full contractual life for PSU (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility on Common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.69 - 76.84&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.57 - 61.69&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate p. a. (%) / CHF LIBOR / Common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.54) - (0.71)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.58) - (0.61)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility on NBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.89 - 28.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.21 - 27.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate p. a. (%) / USD LIBOR / NBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.58 - 4.78&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.24 - 0.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility on SPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.57 - 17.02&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.96 - 16.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate p. a. (%) / CHF LIBOR / SPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.02pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.54) - (0.71)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.58) - (0.61)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value of rights granted (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Latest expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sep 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sep 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monte Carlo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monte Carlo&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzQtMS0xLTEtMTA5NjE4_032e56e6-b576-471a-8df2-80b27d595320"
      unitRef="shares">33015</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i73b1e70d913e41eb90a4644426c8401b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzQtMy0xLTEtMTA5NjE4_306f069a-a3c3-4ba4-a67d-4827c2df24d6"
      unitRef="shares">29519</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i0c649c507ba24f33a40832e35ce5a3e0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzUtMS0xLTEtMTA5NjE4_af35ac15-f799-42a4-ad8c-8269e47ba2e7"
      unitRef="shares">307137</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ia48dcfaff35049b2936b8df362cf345b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzUtMy0xLTEtMTA5NjE4_a985c538-4da6-4447-8bf0-7c4e67a9c358"
      unitRef="shares">230536</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzYtMS0xLTEtMTA5NjE4_a6c47541-e261-4643-9661-2e8a0fb290d9"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzYtMy0xLTEtMTA5NjE4_5f3cf399-0e09-4a45-a16e-716ba0f0de62"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMS0xLTEtMTA5NjE4L3RleHRyZWdpb246NDEyNDFiYzZjZjk1NDUyYjlhYzZmZjNhNTUzOTcwYjRfNA_966fc4f5-948e-45e0-82aa-214015367345"
      unitRef="chfPerShare">6.55</moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMS0xLTEtMTA5NjE4L3RleHRyZWdpb246NDEyNDFiYzZjZjk1NDUyYjlhYzZmZjNhNTUzOTcwYjRfOQ_f00b0e25-8b20-4b19-a051-a264a9cf6791"
      unitRef="chfPerShare">18.88</moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMy0xLTEtMTA5NjE4L3RleHRyZWdpb246N2RiMzVmYzA1YWQ1NDUxNDhlN2U5YWY3ZmQ3MGQyNTFfNA_e9eb5e2e-f2d6-47de-a406-b5c1bea23f2c"
      unitRef="chfPerShare">17.90</moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzctMy0xLTEtMTA5NjE4L3RleHRyZWdpb246N2RiMzVmYzA1YWQ1NDUxNDhlN2U5YWY3ZmQ3MGQyNTFfOQ_5f7a218e-58c5-429d-ab2d-0001113eca8e"
      unitRef="chfPerShare">23.25</moln:SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i09aaee2b2f7442b0ae3069eec0c34c3c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzgtMS0xLTEtMTA5NjE4_0d49c45e-4f7b-416c-837e-b263f3f8e16e">P1Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i73b1e70d913e41eb90a4644426c8401b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzgtMy0xLTEtMTA5NjE4_2f55b4ed-a843-48d7-b3a6-48c3e7a88f7b">P1Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:FullContractualLifeOtherEquityInstruments
      contextRef="i58ac6f2ae72f4533ab1243a7f02391ee_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzktMS0xLTEtMTA5NjE4L3RleHRyZWdpb246YmY1ZmFlN2NhNWJmNDljNWJhMzdlZWNjMzUyNDNjODZfNA_897b4eec-7e93-4fe3-9a12-2e8c87ba3674">P3Y</moln:FullContractualLifeOtherEquityInstruments>
    <moln:FullContractualLifeOtherEquityInstruments
      contextRef="ie860cc1afbd34f37b81b8c5b43ca86a4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzktMy0xLTEtMTA5NjE4L3RleHRyZWdpb246ODE3NDQ0NmE2ZWE5NGRjMmE2MGU5NjU0YmFkNDM2YTRfNA_3b5ace30-bb75-478d-baab-2a54a9ebd660">P3Y</moln:FullContractualLifeOtherEquityInstruments>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="ieffd03daf5f049beadb8aa9b7a149884_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEwLTEtMS0xLTEwOTYxOA_4e7cd230-596a-4250-a6e1-230a9bd44074">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="id4d5712930e540a9b8c8240c3972c7ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEwLTMtMS0xLTEwOTYxOA_a84c537d-1476-4095-bc0a-5c03f76aeb48">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzExLTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmI2MWUzNzhmZjE4ZDQxOWVhNjhiZjI2MGQ5Zjg1MDMzXzEwOTk1MTE2Mjc4MTU_93461b59-e9f9-4278-a8d3-42a9be4f7d95">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzExLTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMxODQ3NTVmNjgwNTQ5ZjU4OWRjOGI5NTRmNDBjYWUzXzEwOTk1MTE2Mjc4MTU_df6592f7-ac6e-4649-ac5d-e7bc085dd4d0">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="ie1c7b494d350479797a5d1c4c82ccba2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEyLTEtMS0xLTEwOTYxOA_364407b9-97ef-4e2b-a406-ddfd380cd35d">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="i35aebd2363304f5ebbb7c0186cac9c37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzEyLTMtMS0xLTEwOTYxOA_1d8f6b5c-70a6-4c39-ba46-7c1e3d3f1381">P3Y</moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMxZmYwY2E5YjZhOTQ3ZmQ5MzI0OGI1Y2ZhNDExNjM4XzQ_937384cd-bfe6-4a2e-b79e-92d6b37f55b9"
      unitRef="number">0.6469</moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmMxZmYwY2E5YjZhOTQ3ZmQ5MzI0OGI1Y2ZhNDExNjM4Xzk_8a685cc8-fc8d-4c3d-97b2-0d136358f0d6"
      unitRef="number">0.7684</moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmIxNmMwMTNlZWQ0NzRhZGE4NTQ2MTcyMWEyZTA0ZGIzXzQ_3596c371-0192-4aba-9e04-17931a93a5cb"
      unitRef="number">0.5857</moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE1LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmIxNmMwMTNlZWQ0NzRhZGE4NTQ2MTcyMWEyZTA0ZGIzXzk_97a89ffb-7753-463e-b7b2-6596e2a065a6"
      unitRef="number">0.6169</moln:ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjlmNThjODM5ZTdkYjQ3MmE4YTY2YzkxMTk4ZDcwODgwXzQ_e26332e0-5856-4f3b-b3d7-48f350dd35a2"
      unitRef="number">-0.0054</moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjlmNThjODM5ZTdkYjQ3MmE4YTY2YzkxMTk4ZDcwODgwXzk_db4d750a-10d1-4d91-833c-7a1d53ec9100"
      unitRef="number">-0.0071</moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmNkNmY0YzYzNDA3OTQzYWRiYWEwYWU4OWExYmQyMmY4XzQ_83e45b1d-569b-4eb9-b446-579f37d1d79d"
      unitRef="number">-0.0058</moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE2LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmNkNmY0YzYzNDA3OTQzYWRiYWEwYWU4OWExYmQyMmY4Xzk_1d8bf81f-3c90-4eb6-a96f-c3c1801b4e2b"
      unitRef="number">-0.0061</moln:RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmZhMTQ2Mzc0ODhjODRmOWZiY2IxMmQzZTFkNjU1MTAxXzQ_64c5a00a-81af-4c82-9f98-45ccb31b399d"
      unitRef="number">0.2589</moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmZhMTQ2Mzc0ODhjODRmOWZiY2IxMmQzZTFkNjU1MTAxXzk_b633b632-2265-4a94-b40b-1acdbc311dce"
      unitRef="number">0.2816</moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRmY2JkOTVhMDE4OTRhNzE4NTkxYmMxZjM3ZjE1ZWFmXzQ_8f8e5fd0-42a9-45e1-9100-4585b60fba32"
      unitRef="number">0.2621</moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE3LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRmY2JkOTVhMDE4OTRhNzE4NTkxYmMxZjM3ZjE1ZWFmXzk_0d7bccd4-e7b7-496e-a867-841d4a625167"
      unitRef="number">0.2701</moln:ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjhmMTA1NzQ1N2ZiMjRjMTc4YTIxODI2NmVhNTYzMWI0XzQ_fe792cda-f891-40ed-a7a5-5fbda27136f4"
      unitRef="number">0.0058</moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjhmMTA1NzQ1N2ZiMjRjMTc4YTIxODI2NmVhNTYzMWI0Xzk_ae07f8d7-ee2e-4f5d-87b9-066169fa0556"
      unitRef="number">0.0478</moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRjYTI4YTY4YTQ5MTRiYzVhMmYwNDFhNWNlYjUzNWJhXzQ_538f342b-0f49-4a38-bc89-c16c0b6bf1db"
      unitRef="number">0.0024</moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE4LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjRjYTI4YTY4YTQ5MTRiYzVhMmYwNDFhNWNlYjUzNWJhXzk_472025a1-bc00-4db9-827e-0c2e1bffb2df"
      unitRef="number">0.0034</moln:RiskFreeInterestRateNBIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmFkNTE2OTg3MjNiYTRmZjJhNmFjODNiNjllZThiMDg3XzQ_0d26ec49-e9fe-4d34-ba9b-7ad06af470fc"
      unitRef="number">0.1557</moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmFkNTE2OTg3MjNiYTRmZjJhNmFjODNiNjllZThiMDg3Xzk_1aa660de-9e8b-49fa-8073-9570061b565b"
      unitRef="number">0.1702</moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjc5MDAzNTQ0MDA3NDQ4OWJiYjUwNmQ1NzNjYjVmMTJmXzQ_1d5fa597-e110-4f34-8fad-06fa8ce10488"
      unitRef="number">0.1596</moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted>
    <moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzE5LTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjc5MDAzNTQ0MDA3NDQ4OWJiYjUwNmQ1NzNjYjVmMTJmXzk_75174eb4-59c6-4e9c-9b19-82b1532d4f72"
      unitRef="number">0.1615</moln:ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted
      contextRef="i1786db0207c341b2b410b411876b4fe2_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjA1YWE2NzdjZmFmYjQ2YzI5YzhlM2UwY2E2MDMyYjRhXzQ_3ed27653-60cf-4b82-af95-2b4cdecce694"
      unitRef="number">-0.0054</moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted
      contextRef="i347aa02a21ef40af9b7f9408e9016422_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTEtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOjA1YWE2NzdjZmFmYjQ2YzI5YzhlM2UwY2E2MDMyYjRhXzk_57a1684c-5902-4fba-9fab-e6e24e17415c"
      unitRef="number">-0.0071</moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted
      contextRef="icb4215e729f94983af2861f952675797_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmU3NWFlMDE4OTRiYTQ4Y2FiMjcwMTRjYzczNWNjMjE0XzQ_cb279c0d-2ee1-4635-a54e-e751aa52b7d2"
      unitRef="number">-0.0058</moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted>
    <moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted
      contextRef="i9b8948e8c2f6412aa966401d4c9ea61c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIwLTMtMS0xLTEwOTYxOC90ZXh0cmVnaW9uOmU3NWFlMDE4OTRiYTQ4Y2FiMjcwMTRjYzczNWNjMjE0Xzk_bded6ed9-5b95-4f66-9e0d-a7faaba52c9b"
      unitRef="number">-0.0061</moln:RiskFreeInterestRateSPIOtherEquityInstrumentsGranted>
    <moln:ExpectedDividendOtherEquityInstrumentsGranted
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIxLTEtMS0xLTEwOTYxOA_1554a52b-bdba-4600-8fa7-1e580f0b0932"
      unitRef="chfPerShare">0</moln:ExpectedDividendOtherEquityInstrumentsGranted>
    <moln:ExpectedDividendOtherEquityInstrumentsGranted
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIxLTMtMS0xLTEwOTYxOA_c5693bdc-535a-4cd2-ae70-122d49b753ae"
      unitRef="chfPerShare">0</moln:ExpectedDividendOtherEquityInstrumentsGranted>
    <moln:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIyLTEtMS0xLTEwOTYxOA_363112df-c978-457d-a56a-1c03087bc5e1"
      unitRef="chfPerShare">17.08</moln:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <moln:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTpkN2Y3YTM1MzRhMTQ0Zjc5ODE5YjViMWZjNzFjNjExMC90YWJsZXJhbmdlOmQ3ZjdhMzUzNGExNDRmNzk4MTliNWIxZmM3MWM2MTEwXzIyLTMtMS0xLTEwOTYxOA_2a919820-092b-4c6c-bb1f-13ab7395f007"
      unitRef="chfPerShare">24.56</moln:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM0OA_5cdbda59-85ce-4a24-8b61-727bfb294183">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movements in the number of all issued RSUs, PSUs and share options are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share option / PSU / RSU movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU/RSU (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;915,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;382,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;533,104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Performance adjustment) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Forfeited) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Exercised options, vested PSU / RSU) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(145,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(82,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;962,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;318,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;643,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Performance adjustment) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Forfeited) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Exercised options, vested PSU / RSU) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(252,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(218,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;982,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;282,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;700,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Performance adjustments indicate forfeitures due to non-market performance conditions not achieved&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forfeited due to service conditions not fulfilled&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF 22.35&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     (2021: CHF 19.87)&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1Mg_273617d4-fbf2-43e9-b189-2ac8781105b9">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movements in the number of all issued RSUs, PSUs and share options are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share option / PSU / RSU movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU/RSU (numbers)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;915,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;382,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;533,104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Performance adjustment) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Forfeited) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Exercised options, vested PSU / RSU) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(145,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(82,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;962,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;318,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;643,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Performance adjustment) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Forfeited) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Exercised options, vested PSU / RSU) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(252,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(218,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;982,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;282,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;700,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="51" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Performance adjustments indicate forfeitures due to non-market performance conditions not achieved&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forfeited due to service conditions not fulfilled&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The weighted average share prices at the dates of exercising during the year ended 2022 amounted to CHF 22.35&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     (2021: CHF 19.87)&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMS0xLTEtMTA5NjE4_6b943928-1a58-49ec-bea1-f94ae6451f07"
      unitRef="shares">915163</moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtNC0xLTEtMTA5NjE4_b2d0cf73-8e1a-463e-86c4-bd0ce04e2371"
      unitRef="chfPerShare">2.74</moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtNy0xLTEtMTA5NjE4_d140c382-f1cf-4ef0-8fd1-94a501008e71"
      unitRef="shares">382059</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMTAtMS0xLTEwOTYxOA_61227059-b430-4b06-b4b4-11299a94a45d"
      unitRef="chfPerShare">6.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMTMtMS0xLTEwOTYxOA_8a8c5393-8b22-449d-b43f-f56140f82f3c"
      unitRef="shares">533104</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEtMTYtMS0xLTEwOTYxOA_940d50e4-f66d-4a9e-b678-4682ddc2bf39"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMS0xLTEtMTA5NjE4_3e37c165-aebd-49d7-98dc-4fb11b881e1c"
      unitRef="shares">260055</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItNC0xLTEtMTA5NjE4_0bac546d-5506-4072-bf3b-977a567282e1"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItNy0xLTEtMTA5NjE4_af9f991f-6dc7-455e-a7ab-9bfad10c9898"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMTAtMS0xLTEwOTYxOA_212f3028-1af0-421c-b977-47af4a1cb476"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMTMtMS0xLTEwOTYxOA_1af26d5d-6deb-4737-9bec-05405f7c541d"
      unitRef="shares">260055</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzItMTYtMS0xLTEwOTYxOA_6a0e81c8-745b-4149-ad79-4d1309cdf264"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMS0xLTEtMTA5NjE4_8a727a20-6ef0-4650-8fb3-8f2f12f9de05"
      unitRef="shares">1022</moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtNC0xLTEtMTA5NjE4_0a74c39e-231f-4cc1-a166-f28b7de2920b"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtNy0xLTEtMTA5NjE4_0b38481a-7d4e-4afe-af7f-60f55dd70792"
      unitRef="shares">0</moln:NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMTAtMS0xLTEwOTYxOA_d8b46cc7-6244-49ae-96ab-9e5f695f951b"
      unitRef="chfPerShare">0</moln:WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMTMtMS0xLTEwOTYxOA_7b6883ea-a183-41a6-9937-fe8d7906fb32"
      unitRef="shares">1022</moln:NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzMtMTYtMS0xLTEwOTYxOA_3be3408b-40be-4b59-8b65-cfd6de3041e3"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMS0xLTEtMTA5NjE4_37e135b3-dd5d-406d-9db4-ae8653463f05"
      unitRef="shares">66518</moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtNC0xLTEtMTA5NjE4_b1d4651c-e59c-4129-8a09-21daaa368165"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtNy0xLTEtMTA5NjE4_3479d6a7-ea45-430a-91aa-4e14945fb33d"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMTAtMS0xLTEwOTYxOA_54255fc2-2833-410a-aeec-bc2e4e206ff0"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMTMtMS0xLTEwOTYxOA_e9895286-2b97-456f-a246-8d20807340ee"
      unitRef="shares">66518</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzQtMTYtMS0xLTEwOTYxOA_c7b96cbc-f9da-4528-8d70-b1f9c42ddf44"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsExpiredInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMS0xLTEtMTA5NjE4_22741e7b-e62d-4a95-8275-8926c2ef4e7d"
      unitRef="shares">0</moln:NumberOfInstrumentsExpiredInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtNC0xLTEtMTA5NjE4_c34d2300-bb74-480a-9d58-72529d03c711"
      unitRef="chfPerShare">0</moln:WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtNy0xLTEtMTA5NjE4_10cfb562-f413-447a-8580-9bad651c1bd0"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMTAtMS0xLTEwOTYxOA_17cff91e-ceba-4099-9109-8fa47cfb6f62"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMTMtMS0xLTEwOTYxOA_24b7fd69-817e-453a-bf38-3e954a1b38e8"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzUtMTYtMS0xLTEwOTYxOA_0abff26e-5a40-41a4-abfc-5fceba7c15ef"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsExercisedInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMS0xLTEtMTA5NjE4_7c60a109-a8b4-438c-80fe-d029bcfa6105"
      unitRef="shares">145656</moln:NumberOfInstrumentsExercisedInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtNC0xLTEtMTA5NjE4_3f064121-9bed-4de7-b1c4-2371ce9505c2"
      unitRef="chfPerShare">1.85</moln:WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtNy0xLTEtMTA5NjE4_099bc862-b990-4e2e-9470-789381c7b52b"
      unitRef="shares">63157</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMTAtMS0xLTEwOTYxOA_05c1f865-6dd6-4a2e-8405-8e6d4bea2348"
      unitRef="chfPerShare">4.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMTMtMS0xLTEwOTYxOA_8e9a2a6f-7f89-4080-a779-89aa4d38ef44"
      unitRef="shares">82499</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzYtMTYtMS0xLTEwOTYxOA_0c6dd91d-7d41-4007-9fc3-9ae109a8be32"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMS0xLTEtMTA5NjE4_ea22c0b6-f916-454e-9ae0-7bc5b3a8aded"
      unitRef="shares">962022</moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctNC0xLTEtMTA5NjE4_6cc9e77e-6fab-4b47-b018-c200c9a1c7e2"
      unitRef="chfPerShare">2.35</moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctNy0xLTEtMTA5NjE4_c6df9de5-4ac6-4ea4-b3fc-e778b64e82fc"
      unitRef="shares">318902</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMTAtMS0xLTEwOTYxOA_d097e238-c6a6-45e9-a301-4397b1a36a55"
      unitRef="chfPerShare">6.87</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMTMtMS0xLTEwOTYxOA_e96499fc-01de-4149-a343-809b7a366822"
      unitRef="shares">643120</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzctMTYtMS0xLTEwOTYxOA_b76ac5ae-7529-4338-92c6-d8060ac0c1f8"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMS0xLTEtMTA5NjE4_af51e9f5-0000-4f19-9d72-a62ba1f3fc0a"
      unitRef="shares">340152</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtNC0xLTEtMTA5NjE4_b958a69f-1829-4cdb-a707-43cc5874961d"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtNy0xLTEtMTA5NjE4_6cab9c61-1931-4857-87ff-6aadad3e5011"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMTAtMS0xLTEwOTYxOA_9e5f87a0-edd8-475b-81e0-d6755696771b"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMTMtMS0xLTEwOTYxOA_5dce6ac1-cad2-4e19-8214-71b185d81229"
      unitRef="shares">340152</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzgtMTYtMS0xLTEwOTYxOA_58a29192-c5e2-4249-86f1-28c501876f40"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMS0xLTEtMTA5NjE4_ca8b9f49-d33e-4c50-bd02-e166a652b5e8"
      unitRef="shares">0</moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktNC0xLTEtMTA5NjE4_b50b3f26-2bab-4e07-8e2d-bf7d72665114"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktNy0xLTEtMTA5NjE4_308b92bc-b4d4-4825-81e6-06d22fee314d"
      unitRef="shares">0</moln:NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMTAtMS0xLTEwOTYxOA_9720a92f-cd89-435c-bc31-dcb541b23fbc"
      unitRef="chfPerShare">0</moln:WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMTMtMS0xLTEwOTYxOA_848bb28a-e481-4904-8557-87a44c73ee67"
      unitRef="shares">0</moln:NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzktMTYtMS0xLTEwOTYxOA_98cb9858-4ca4-438c-8b9c-b751e2e5c7af"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved>
    <moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTEtMS0xLTEwOTYxOA_10dac0e0-4417-47cf-b4a5-18a75ae10fb2"
      unitRef="shares">63990</moln:NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTQtMS0xLTEwOTYxOA_86360a92-a51f-4e6c-b2cb-32a2843a45de"
      unitRef="chfPerShare">0.10</moln:WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTctMS0xLTEwOTYxOA_ce68ac92-b309-4192-8d21-ffb7ce663512"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTEwLTEtMS0xMDk2MTg_41cf2a39-72ce-4ada-8814-3ab1553abcd0"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTEzLTEtMS0xMDk2MTg_4a7feb68-c724-45b6-a563-859e29ff9a5c"
      unitRef="shares">63990</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEwLTE2LTEtMS0xMDk2MTg_1ef1b03e-9e95-43a3-9e0a-c7b7e20831fa"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsExpiredInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTEtMS0xLTEwOTYxOA_4e58b13f-4528-4239-b368-a0040e853d6f"
      unitRef="shares">3220</moln:NumberOfInstrumentsExpiredInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTQtMS0xLTEwOTYxOA_aebb7251-1f4c-49c0-b4d2-0d84b94c2192"
      unitRef="chfPerShare">5.40</moln:WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTctMS0xLTEwOTYxOA_456dc3f8-ed67-427e-99bf-422b053f1b32"
      unitRef="shares">3220</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTEwLTEtMS0xMDk2MTg_0162a0eb-a29e-477c-8034-a63843b6f81e"
      unitRef="chfPerShare">5.40</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTEzLTEtMS0xMDk2MTg_f6d9b821-7315-4d26-a28c-a2c4db787ac4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzExLTE2LTEtMS0xMDk2MTg_173c4ac4-a339-4dc4-b88f-d3495851a6a7"
      unitRef="chfPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsExercisedInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTEtMS0xLTEwOTYxOA_fd68a07f-aef5-4d2f-a942-1892201098bf"
      unitRef="shares">252058</moln:NumberOfInstrumentsExercisedInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTQtMS0xLTEwOTYxOA_5998fcc7-6989-4716-958b-abca1693df96"
      unitRef="chfPerShare">1.00</moln:WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTctMS0xLTEwOTYxOA_5bc4b277-71be-43ba-b570-85a097e5b4b3"
      unitRef="shares">33577</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTEwLTEtMS0xMDk2MTg_a7218890-2607-42f8-b9f3-7e57342aa3e6"
      unitRef="chfPerShare">6.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTEzLTEtMS0xMDk2MTg_949f9848-6ee4-4f47-803b-dc9710769f60"
      unitRef="shares">218481</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEyLTE2LTEtMS0xMDk2MTg_5a1d24e7-1b0d-41c8-9c5f-e589c8ad8f5c"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTEtMS0xLTEwOTYxOA_9c345de5-c7cb-41b9-acbf-5408efb01492"
      unitRef="shares">982906</moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTQtMS0xLTEwOTYxOA_54e83d93-c5a2-4d21-9780-7c5425de453e"
      unitRef="chfPerShare">2.05</moln:WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTctMS0xLTEwOTYxOA_9996dc0d-fbeb-4806-a800-2ecef71039b7"
      unitRef="shares">282105</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTEwLTEtMS0xMDk2MTg_fab73de5-75d1-4af5-9ca3-a14c27cb74b4"
      unitRef="chfPerShare">6.89</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTEzLTEtMS0xMDk2MTg_b5d7f32e-fcd8-4f12-b38a-681a185e4707"
      unitRef="shares">700801</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTphZWNlNTlhM2E4NTY0MTRhODk4MDU5ZjJkOGM0NzBhOC90YWJsZXJhbmdlOmFlY2U1OWEzYTg1NjQxNGE4OTgwNTlmMmQ4YzQ3MGE4XzEzLTE2LTEtMS0xMDk2MTg_a680db0b-e943-4bae-b071-3df6d1adb319"
      unitRef="chfPerShare">0.10</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <moln:WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzMxNg_10cbe746-a4b6-4b80-86df-803b449ca86a"
      unitRef="chfPerShare">22.35</moln:WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise>
    <moln:WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzMyNA_ba3524eb-fae0-4fcc-b921-e9463cbd5927"
      unitRef="chfPerShare">19.87</moln:WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise>
    <moln:DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM1Mw_e4a0bf06-746d-4488-8f57-e2b5d2d4eee8">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Exercise price&lt;br/&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options / &lt;br/&gt;PSU/RSU&lt;br/&gt;(number)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Remaining life&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Thereof exercisable options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;700,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;982,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;282,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table applies to all share options, PSUs and RSUs outstanding at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Exercise price&lt;br/&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Options / &lt;br/&gt;PSU/RSU&lt;br/&gt;(number)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Remaining life&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Thereof exercisable options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSU/RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;643,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;962,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;318,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="id45b9f3adc9745569f9195e24eefccdd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtMC0xLTEtMTA5NjE4_0934500b-5141-4069-bf32-554a525c3b66"
      unitRef="chfPerShare">6.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="id45b9f3adc9745569f9195e24eefccdd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtMS0xLTEtMTA5NjE4_69203454-692d-405b-b101-f3128933ae92"
      unitRef="shares">15450</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="icf36213d4e434ddab3aee4d16f583fc3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtNC0xLTEtMTA5NjE4_602a2ed2-7d77-4de3-95d5-d4acfb6e3273">P1Y4M24D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="id45b9f3adc9745569f9195e24eefccdd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzQtNi0xLTEtMTA5NjE4_46524f29-dd41-49fb-8e9d-c890291e0095"
      unitRef="shares">15450</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i69ed7f76d9f64feb954d4407df356caa_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtMC0xLTEtMTA5NjE4_12af9d38-37e4-43e7-b596-8b14f2a9e604"
      unitRef="chfPerShare">6.94</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i69ed7f76d9f64feb954d4407df356caa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtMS0xLTEtMTA5NjE4_e0ced487-950e-4d37-a407-9e46b4d88627"
      unitRef="shares">266655</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i5ab6a4e5dc284abeadf7a60e68289a52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtNC0xLTEtMTA5NjE4_f7f3e522-0c73-4d69-b8ba-44930168cc39">P1Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i69ed7f76d9f64feb954d4407df356caa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzUtNi0xLTEtMTA5NjE4_12e5696e-5a40-449c-a511-de7baba76230"
      unitRef="shares">266655</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <moln:ExercicePriceOfOutstandingOtherEquityInstruments
      contextRef="i0f7c058068224203b33c7fcd1f1b017f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctMC0xLTEtMTA5NjE4_e2b5b0eb-8322-4b99-8ce8-dd06ae1ecfc7"
      unitRef="chfPerShare">0.1</moln:ExercicePriceOfOutstandingOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctMS0xLTEtMTA5NjE4_bf4da345-4252-4a61-b427-e4abd83e5f8b"
      unitRef="shares">700801</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctNC0xLTEtMTA5NjE4_ec3485ee-f4ec-4768-b370-0d18c17cdc63">P1Y1M6D</moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzctNi0xLTEtMTA5NjE4_4bfb14d2-8541-4bf2-aec8-060e9d3e1f7e"
      unitRef="shares"
      xsi:nil="true"/>
    <moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzgtMS0xLTEtMTA5NjE4_e34d0316-55ce-4156-ab95-664dd4a2ea14"
      unitRef="shares">982906</moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <moln:NumberOfInstrumentsExercisableInShareBasedPaymentArrangement
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo4MjlkODE3MWU4ZDU0NjI4ODAzMDVjYWU3Njg0MGU2OC90YWJsZXJhbmdlOjgyOWQ4MTcxZThkNTQ2Mjg4MDMwNWNhZTc2ODQwZTY4XzgtNi0xLTEtMTA5NjE4_380acdf3-1717-4ebc-9e6f-13c1d92ea117"
      unitRef="shares">282105</moln:NumberOfInstrumentsExercisableInShareBasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i3f487997ebf84760b436351b9cd07415_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItMC0xLTEtMTA5NjE4_bf62dfb6-d186-4f09-927a-1040dd1da0f8"
      unitRef="chfPerShare">2.31</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i3f487997ebf84760b436351b9cd07415_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItMS0xLTEtMTA5NjE4_a85dde1e-1612-42c0-8cac-ca2d8ddc0b6c"
      unitRef="shares">1160</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i18556d3232ec4e46aaa9d8f104201d8c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItNC0xLTEtMTA5NjE4_e9465b65-85b9-430d-8ead-83141dc72905">P0Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i3f487997ebf84760b436351b9cd07415_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzItNy0xLTEtMTA5NjE4_6a9816cf-75e1-47f9-aa34-aa980cf1f166"
      unitRef="shares">1160</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtMC0xLTEtMTA5NjE4_4cd09695-c21a-45a3-95f5-e5a7f98a5cec"
      unitRef="chfPerShare">6.05</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtMS0xLTEtMTA5NjE4_c8bac9e6-11ec-4fa3-95f5-e6b613376a85"
      unitRef="shares">2815</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="ie2287ef5f8e94d59ac113037e7dd05ac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtNC0xLTEtMTA5NjE4_1c037e3c-a4c1-4786-be05-637e9d584971">P1Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i1f6cba3d5e7a402aa655f3c73d59a136_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzMtNy0xLTEtMTA5NjE4_7d19dcba-86d5-4b78-9121-4876cd5f7f97"
      unitRef="shares">2815</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtMC0xLTEtMTA5NjE4_cc5448e7-7919-4c74-988e-cfe4a46c1cf8"
      unitRef="chfPerShare">6.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtMS0xLTEtMTA5NjE4_8b903621-4257-41dc-9cb2-32b98a347740"
      unitRef="shares">15450</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i09f51f1fee3243008271209344707ab6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtNC0xLTEtMTA5NjE4_f66ce897-004f-49ad-a9eb-67feefbf1639">P2Y4M24D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ifb328ed053f743d2aa1a4c81bf6b9340_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzQtNy0xLTEtMTA5NjE4_dfa308a5-1e65-499d-85ea-130fdf2f19ad"
      unitRef="shares">15450</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ia4eea0ffff4540458374ebbc176fc17e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtMC0xLTEtMTA5NjE4_3b573dfd-4779-4243-b8f9-612953ddd6e3"
      unitRef="chfPerShare">6.94</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ia4eea0ffff4540458374ebbc176fc17e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtMS0xLTEtMTA5NjE4_46ab86d6-27e7-41e2-8040-9976ccb2bbfd"
      unitRef="shares">299477</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i2f264b7c466b43e2be89711f4ad6b777_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtNC0xLTEtMTA5NjE4_3dccfb15-51a2-45b2-983e-9ad50e726285">P2Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ia4eea0ffff4540458374ebbc176fc17e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzUtNy0xLTEtMTA5NjE4_dcf68790-e052-44ee-bf47-2c13eddc96d9"
      unitRef="shares">299477</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <moln:ExercicePriceOfOutstandingOtherEquityInstruments
      contextRef="i3f487997ebf84760b436351b9cd07415_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctMC0xLTEtMTA5NjE4_8ff2148b-6fa8-449c-b667-3ed73f0f4713"
      unitRef="chfPerShare">0.1</moln:ExercicePriceOfOutstandingOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctMS0xLTEtMTA5NjE4_2b31238a-bfe2-405b-9493-95a74283e78a"
      unitRef="shares">643120</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctNC0xLTEtMTA5NjE4_05bae8fa-2187-4645-8ebf-6a64219f81bd">P1Y2M12D</moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzctNy0xLTEtMTA5NjE4_ef129133-9efa-4fb0-93d1-55c10de10883"
      unitRef="shares"
      xsi:nil="true"/>
    <moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzgtMS0xLTEtMTA5NjE4_df1cfe2e-8e69-4c33-95e4-19a9535bbf3b"
      unitRef="shares">962022</moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement>
    <moln:NumberOfInstrumentsExercisableInShareBasedPaymentArrangement
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTowYTJlOThmZDkzZTI0NjcyYmFiMDgxMmE1YjMxYjBiYy90YWJsZXJhbmdlOjBhMmU5OGZkOTNlMjQ2NzJiYWIwODEyYTViMzFiMGJjXzgtNy0xLTEtMTA5NjE4_bdb3e215-b2b2-4130-a835-8a64042acf6a"
      unitRef="shares">318902</moln:NumberOfInstrumentsExercisableInShareBasedPaymentArrangement>
    <moln:DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90ZXh0cmVnaW9uOmU5MDRjZjc2ODA5ODQ3NjI4NzQyNTI1YTI0NTg0ZWFiXzM0OQ_47f92baa-234d-421f-a602-40a5863f8897">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The non-cash costs for share-based payments recognized in the statement of comprehensive income can be attributed to the Group&#x2019;s two functions as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,088&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,932&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzEtMS0xLTEtMTA5NjE4_6c836c16-9a91-4cca-88c3-828bae112ce3"
      unitRef="chf">3010000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="if8a7b1edd6fe45eab0c6b8008c033e82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzEtNC0xLTEtMTA5NjE4_4696666c-b094-4684-8460-b60d23a338c6"
      unitRef="chf">2208000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="icc53d874499145cdad911dfc92439430_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzEtNy0xLTEtMTA5NjE4_2fd6111d-6e8a-4629-bfd0-8dba427454ce"
      unitRef="chf">1573000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i13d5e5d068794e57b6e946bb440fbea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzItMS0xLTEtMTA5NjE4_25bdb6f6-455a-40a5-9ef5-c16c8997226b"
      unitRef="chf">2078000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i0f2fe0f87d384af2ba1d3012e41e0149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzItNC0xLTEtMTA5NjE4_a7377ad7-28cb-41fe-b8dd-52d0ba799dab"
      unitRef="chf">1877000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i8240ff4b46164dfd899074105b6aa15e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzItNy0xLTEtMTA5NjE4_3f00bbe4-6260-4d74-9ac1-0f6e80f02283"
      unitRef="chf">1359000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzMtMS0xLTEtMTA5NjE4_863597aa-b849-4874-9c72-3ea4c8e7b9e7"
      unitRef="chf">5088000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzMtNC0xLTEtMTA5NjE4_f2ed8813-fd77-4a83-9f06-1a53912ed863"
      unitRef="chf">4085000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTYvZnJhZzplOTA0Y2Y3NjgwOTg0NzYyODc0MjUyNWEyNDU4NGVhYi90YWJsZTo5MWVjOGM4NzRhZTg0MjNlYWQ1NTQxNmVmOWVmZTk3Ny90YWJsZXJhbmdlOjkxZWM4Yzg3NGFlODQyM2VhZDU1NDE2ZWY5ZWZlOTc3XzMtNy0xLTEtMTA5NjE4_6088fa1c-da79-47fc-9cdf-2950f1ef1d87"
      unitRef="chf">2932000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90ZXh0cmVnaW9uOjViY2JmMGE1YTUzODQwYjc5ODBlMDQ4ZmNkMTFkNzc1XzIw_5e05796c-0a63-4a6f-b0d7-ffe0adbf44ea">Financial income and financial expense&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on financial assets held at amortized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net foreign exchange gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;367&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net foreign exchange loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative interest on financial assets held at amortized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(4,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90ZXh0cmVnaW9uOjViY2JmMGE1YTUzODQwYjc5ODBlMDQ4ZmNkMTFkNzc1XzIx_ac370d5d-9a97-45c0-a279-ac2afd79c010">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on financial assets held at amortized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net foreign exchange gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;367&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock>
    <ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzEtMS0xLTEtMTA5NjE4_7150d3ca-8165-43dd-8d92-1af4ae5ab3db"
      unitRef="chf">1142000</ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzEtNC0xLTEtMTA5NjE4_af8521f5-28fa-426e-95e2-5ac5b9ce2d7f"
      unitRef="chf">99000</ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzEtNy0xLTEtMTA5NjE4_a74edc72-95bc-415d-a49f-c32c52d409e2"
      unitRef="chf">367000</ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:NetForeignExchangeGain
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzItMS0xLTEtMTA5NjE4_91f5980a-c8e1-45f8-882b-27b52b19f349"
      unitRef="chf">717000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzItNC0xLTEtMTA5NjE4_2d942ed6-85d4-4161-9922-5b538f29d797"
      unitRef="chf">92000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzItNy0xLTEtMTA5NjE4_5b08ec60-6dcc-47a4-8559-0d89da15386d"
      unitRef="chf">0</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzMtMS0xLTEtMTA5NjE4_413f637b-b5a8-44b2-988d-aed4240d4241"
      unitRef="chf">1859000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzMtNC0xLTEtMTA5NjE4_8e14015a-f947-47f1-9236-f89f43cb0de4"
      unitRef="chf">191000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo1NjlmODQ2Y2FlNWE0OTg0OTBmZWNkOWMwZWRhMWM5Mi90YWJsZXJhbmdlOjU2OWY4NDZjYWU1YTQ5ODQ5MGZlY2Q5YzBlZGExYzkyXzMtNy0xLTEtMTA5NjE4_6775caeb-61d3-46b9-8374-fab830e4c9ec"
      unitRef="chf">367000</ifrs-full:FinanceIncome>
    <moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90ZXh0cmVnaW9uOjViY2JmMGE1YTUzODQwYjc5ODBlMDQ4ZmNkMTFkNzc1XzIy_d73ac9f8-6f01-4039-bdf2-75dbfea7be2b">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net foreign exchange loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative interest on financial assets held at amortized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(4,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzEtMS0xLTEtMTA5NjE4_2d8794bf-c1d5-4026-9fcd-6ef95ea9d17a"
      unitRef="chf">0</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzEtNC0xLTEtMTA5NjE4_503eadb4-4a7c-4bb8-be42-299b1958df48"
      unitRef="chf">0</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzEtNy0xLTEtMTA5NjE4_606f6c90-f5d4-4964-a559-441218e158e1"
      unitRef="chf">4512000</ifrs-full:NetForeignExchangeLoss>
    <moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzItMS0xLTEtMTA5NjE4_44cb8b81-9b65-4712-9c52-1e3b701db1aa"
      unitRef="chf">562000</moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost>
    <moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzItNC0xLTEtMTA5NjE4_af671ced-8f77-4a5d-ac68-3256c359f944"
      unitRef="chf">495000</moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost>
    <moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzItNy0xLTEtMTA5NjE4_e3c1969e-9971-4bc1-9054-19792fad5426"
      unitRef="chf">271000</moln:NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzMtMS0xLTEtMTA5NjE4_96a1060a-e697-417d-ace0-c051c6ac5320"
      unitRef="chf">43000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzMtNC0xLTEtMTA5NjE4_29f9b2d8-2b2a-4533-bbe8-3bb3c8ddbc90"
      unitRef="chf">53000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzMtNy0xLTEtMTA5NjE4_048e8f01-ae1a-47af-96a5-6ac294acc4b8"
      unitRef="chf">24000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:OtherFinanceCost
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzQtMS0xLTEtMTA5NjE4_aa19e989-e839-4784-b421-1e785b0a78b7"
      unitRef="chf">14000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzQtNC0xLTEtMTA5NjE4_d32f9d10-d43e-4b71-a417-017f53fa9899"
      unitRef="chf">8000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzQtNy0xLTEtMTA5NjE4_53fdafc7-1613-4c4f-8da4-5aca3b1db9b4"
      unitRef="chf">9000</ifrs-full:OtherFinanceCost>
    <ifrs-full:FinanceCosts
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzUtMS0xLTEtMTA5NjE4_44e8882e-8ff5-44ae-8392-07a10ccebf11"
      unitRef="chf">619000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzUtNC0xLTEtMTA5NjE4_a4fc90af-3da2-4418-8ef1-0cb44d9dbb2f"
      unitRef="chf">556000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMTkvZnJhZzo1YmNiZjBhNWE1Mzg0MGI3OTgwZTA0OGZjZDExZDc3NS90YWJsZTo4OTI0ZDE4YmFiNzA0MTMwYWVmOTY0MjQzMzRhOTkwZi90YWJsZXJhbmdlOjg5MjRkMThiYWI3MDQxMzBhZWY5NjQyNDMzNGE5OTBmXzUtNy0xLTEtMTA5NjE4_c718809f-44cf-4edf-8b82-d905aed4acb3"
      unitRef="chf">4816000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE3OA_ec42e320-e297-40d6-b97c-1d706c18502e">Taxes&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022 the Company generated a taxable profit whereas in 2021 and 2020 the Company generated a taxable loss in Switzerland, all of which are reflected in the Company&#x2019;s cumulative tax loss carry forward. The Company did not have to pay or accrue any income taxes in the reporting periods as the 2022 taxable income in the period is fully offset by the utilization of accumulated tax losses. Any future taxable income will be subject to Swiss federal, cantonal and communal income taxes. The Company&#x2019;s applicable income tax rate for the year 2022 is 19.4% (2021: 19.4%; 2020: 20.8%).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular Partners Inc., which is incorporated in the United States in the State of Delaware, is subject to statutory U.S. federal corporate income taxes and minimal state taxes for Massachusetts and New York. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, current income tax expense of TCHF 0.3 (TUSD 0.3) was recognized by the Group's U.S. based subsidiary for estimated U.S. tax obligations of the subsidiary based on intra-Group activity (for the year ended December&#160;31, 2021: tax credit of TCHF 2 (TUSD 2) and for the year ended December 31, 2020: tax expense of TCHF 11 (TUSD 13)). The tax expense amount comprises of the sum of the minimal taxes payable for federal taxes and for the various states in which Molecular Partners Inc. is liable for taxes. The applicable income tax rates are 21% federal tax plus 8.00% state tax (Massachusetts) and 6.50% (New York). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net operating profit for tax purposes amounted to TCHF 124,020 in 2022 whereas prior years generated net operating losses of TCHF 58,632 in 2021 and TCHF 58,631 in 2020.The remaining tax losses as of December 31, 2022 of TCHF 88,198 may be used as tax loss carry forwards to offset future taxable income over a period of seven years, with the amount of TCHF 29,566 to expire in 2027 and TCHF 58,632 to expire in 2028. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No deferred tax assets have been recognized for these tax loss carry forwards, because as of December&#160;31, 2022, it was not considered probable that such loss carry forwards can be utilized in the foreseeable future. In addition, no deferred tax positions were recognized on other deductible temporary differences (e.g. pension liabilities under IAS 19 for a total of TCHF 2,245, see also note 18.1) due to the tax losses carried forwards. Income tax expense has been calculated for the year ending December&#160;31, 2022, based on the effective income tax rate expected for the full financial year, being 0% on December&#160;31, 2022, given that the 2022 taxable income in the period is fully offset by the utilization of accumulated tax losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the facts above, as well as the fact that the Company incurred no significant tax expense in the reporting periods presented, a numerical reconciliation of the effective tax rate is not provided. The primary reconciling item is the effect of unrecognized deferred tax assets for tax losses and deductible temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the expiry of tax loss carry forwards for the Company, for which no deferred tax asset was recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total tax loss carry forwards as at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(88,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(212,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzYx_f2331bd2-d43f-47c5-9911-57da8047c74c"
      unitRef="chf">300</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzY1_c3739f58-a7a6-48c8-9423-843866bfb063"
      unitRef="usd">300</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i601f0ea0b2a5490cade7bed682109126_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzc1_9f391459-55ee-4219-9413-32e0c4df89bf"
      unitRef="chf">-2000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i601f0ea0b2a5490cade7bed682109126_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzc5_10e1f131-a9d6-44ca-a22b-c99a4f97ce48"
      unitRef="usd">-2000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i3ced05873ca5491bbfebf6675070c334_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzg3_491b53f8-a5d2-4dc6-b4e8-de7343c52455"
      unitRef="chf">11000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i3ced05873ca5491bbfebf6675070c334_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzkx_d04c8d99-9657-479f-8d8c-a60774635f19"
      unitRef="usd">13000</ifrs-full:CurrentTaxExpenseIncome>
    <moln:NetOperatingProfit
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzExNw_9f057846-b552-484e-8021-4e3738dbd604"
      unitRef="chf">124020000</moln:NetOperatingProfit>
    <moln:NetOperatingLosses
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNTQ2MQ_e91fc7dd-eb32-4645-a157-1f888f9e92eb"
      unitRef="chf">58632000</moln:NetOperatingLosses>
    <moln:NetOperatingLosses
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNTQ5OA_fe929ea7-60c8-4bdd-adb8-345e62c17542"
      unitRef="chf">58631000</moln:NetOperatingLosses>
    <moln:TaxLossCarryforwards
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE0MQ_be806e52-b064-4404-a283-427f423a5a7e"
      unitRef="chf">88198000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwardsExpirationPeriod
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE0NQ_63364d82-d49c-4f63-81b6-3a5845024872">P7Y</moln:TaxLossCarryforwardsExpirationPeriod>
    <moln:TaxLossCarryforwards
      contextRef="ia07c5697db104aff83e8133bcbfd34e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE0OQ_ef132c27-c92e-4796-b6b0-fd1cb8efc634"
      unitRef="chf">29566000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ia0b15b456e71466f914f4fb77e4fbfc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNTYwMg_29056bec-7d61-4569-95e0-77f55d6f4b8c"
      unitRef="chf">58632000</moln:TaxLossCarryforwards>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE2NQ_a161e82c-ba49-4d66-8082-60a4890e4a14"
      unitRef="chf">2245000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:ApplicableTaxRate
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzU0OTc1NTgxNzA5MQ_9ba8b94b-4b32-4398-b3f3-eec02ed812ed"
      unitRef="number">0</ifrs-full:ApplicableTaxRate>
    <moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90ZXh0cmVnaW9uOmIxZTljZDhiNGRiNTRlZWFhYzU3N2RkNDViODQ4M2NkXzE3OQ_0b1f8c24-6a21-42a9-8707-2ecfaa62be12">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the expiry of tax loss carry forwards for the Company, for which no deferred tax asset was recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total tax loss carry forwards as at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(88,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(212,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock>
    <moln:TaxLossCarryforwards
      contextRef="ie9e4c0c2414646e3920288a6e3d93b50_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzMtMS0xLTEtMTA5NjE4_f99e675d-9cce-4c16-b8aa-a6c525b23757"
      unitRef="chf">0</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="i5a33d4e0e53241cb86e82f186e53b0d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzMtNC0xLTEtMTA5NjE4_f03977a8-90e6-4ff0-92b4-a47d9e6781bc"
      unitRef="chf">15976000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="i448b10a8ed3a4b459f511c18fe6a4023_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzQtMS0xLTEtMTA5NjE4_1fdb8dd1-6994-42c1-b43f-5dbd839cfa0f"
      unitRef="chf">0</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="i309bd18113fa4d088977cb2d88cd4092_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzQtNC0xLTEtMTA5NjE4_244198c7-8e0d-4dae-9f3e-0e2dc32729aa"
      unitRef="chf">21766000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ia64fa509207d47efa0e81300d9d73cd3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzUtMS0xLTEtMTA5NjE4_a55f3283-3ee8-40ac-ab5b-9c440c8e6dd0"
      unitRef="chf">0</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="i9273a8f19ab4459a81e57dbd2f441d17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzUtNC0xLTEtMTA5NjE4_87e1d8b4-aff3-4c97-b409-5e0af05659b6"
      unitRef="chf">23767000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="i875b50cd70744049a9efbc6796621651_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzYtMS0xLTEtMTA5NjE4_7ea1b8d7-78a4-4a81-8d37-f6f26f862f16"
      unitRef="chf">0</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ic2651abe27944dcdaf65a2279954b10f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzYtNC0xLTEtMTA5NjE4_417d3cd7-fc1b-4327-87f4-2062071aaf22"
      unitRef="chf">33446000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ia07c5697db104aff83e8133bcbfd34e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzctMS0xLTEtMTA5NjE4_ebb9af83-d09f-40f2-9b99-011a6d6b5dc1"
      unitRef="chf">29566000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ibf748a46ec9a4ba8b9feba532a6b4da2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzctNC0xLTEtMTA5NjE4_fd6ec585-261c-4e17-8ddf-3ddc20a3ec84"
      unitRef="chf">58631000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ia0b15b456e71466f914f4fb77e4fbfc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzgtMS0xLTEtMTA5NjE4_f78d4427-9449-44ba-9f60-6b7f740b715b"
      unitRef="chf">58632000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="icfae2f7fb65743218e1d395982995a0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzgtNC0xLTEtMTA5NjE4_b980491a-bea1-4efa-8ed3-dd30e86d9c36"
      unitRef="chf">58632000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ifc42f5752df44c938ff23151446565fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzktMS0xLTEtMTA5NjE4_5f2e7218-cfcd-4a36-b213-5c5a17ed6c0a"
      unitRef="chf">0</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ia11f395ed16342c5ba81005541468e8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzktNC0xLTEtMTA5NjE4_a41a0b4f-67c6-47f6-9041-d136499d76b8"
      unitRef="chf">0</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzEwLTEtMS0xLTEwOTYxOA_c9ce1dc7-d22c-43c0-a222-57b3ee30c4a4"
      unitRef="chf">88198000</moln:TaxLossCarryforwards>
    <moln:TaxLossCarryforwards
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjIvZnJhZzpiMWU5Y2Q4YjRkYjU0ZWVhYWM1NzdkZDQ1Yjg0ODNjZC90YWJsZTpkMzU3MWE4OGM4MmY0NDYxYWUzZGJmZThmZThhNWFjMi90YWJsZXJhbmdlOmQzNTcxYTg4YzgyZjQ0NjFhZTNkYmZlOGZlOGE1YWMyXzEwLTQtMS0xLTEwOTYxOA_71ec72f0-92a1-4798-b3bb-bb7f46840c58"
      unitRef="chf">212218000</moln:TaxLossCarryforwards>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzU4_e1738639-85c4-4740-8708-fa9b992c4915">Earnings per shareBasic earnings per share is calculated by dividing the net result attributable to the shareholders of the Company by the weighted average number of shares issued and outstanding during the reporting period, excluding any shares held as treasury shares. Diluted earnings per share additionally takes into account the potential conversion of all dilutive potential ordinary shares. &lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares used in computing basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,469,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,005,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares used in computing diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,265,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,005,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the number of shares that are dilutive, is 795,610. For all comparative prior periods presented all potential ordinary shares were anti-dilutive. The number of shares that potentially could be dilutive in the future were 835,422 as at December&#160;31, 2021 and 794,377 as at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzU2_636720b0-cb64-4af6-97d4-1750396b8993">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares used in computing basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,469,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,005,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares used in computing diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,265,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,005,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzEtMS0xLTEtMTA5NjE4_e3197fb3-7497-4e65-9b54-1f15dcb7ffef"
      unitRef="shares">32469957</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzEtNC0xLTEtMTA5NjE4_5d4bac1b-bd9c-447a-9dce-2fb03521b367"
      unitRef="shares">31005171</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzEtNy0xLTEtMTA5NjE4_51fd6cf0-6ca4-4377-8232-44fa7cf80dd6"
      unitRef="shares">25000652</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzItMS0xLTEtMTI5NzI0_66886844-0b37-4ed5-8297-3eb2d0e948bd"
      unitRef="shares">33265567</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzItNC0xLTEtMTI5NzI3_f177326f-71a9-4c15-a2c5-59fa204f7dc9"
      unitRef="shares">31005171</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90YWJsZTo2ODdkNTNhZDA2Yjk0NjMyYjQzYTIxNjhkYzJlMGI5YS90YWJsZXJhbmdlOjY4N2Q1M2FkMDZiOTQ2MzJiNDNhMjE2OGRjMmUwYjlhXzItNy0xLTEtMTI5NzMw_873ed1e5-8bbf-470a-aeb5-e47f673e83db"
      unitRef="shares">25000652</ifrs-full:AdjustedWeightedAverageShares>
    <moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzM1_fc856eeb-5dd6-4d91-a5ad-1de4ba298014"
      unitRef="shares">795610</moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzQz_b883cf75-3665-400c-952a-3abb5a800f3b"
      unitRef="shares">835422</moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjUvZnJhZzo4NmM1ZDJmMmM5OWM0NzdmOTUwNTdhYTMzNDU1MzdmZi90ZXh0cmVnaW9uOjg2YzVkMmYyYzk5YzQ3N2Y5NTA1N2FhMzM0NTUzN2ZmXzUx_24764bba-9460-4ee1-9d7a-6f5a92233752"
      unitRef="shares">794377</moln:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExNw_1562a2fc-f576-4dfe-b830-788ed8ebb122">Leases&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group leases office and laboratory facilities in Schlieren, Switzerland. These leases generally have terms between 2 and 10 years and contain extension or terminations options exercisable by the Group up to one year before the end of the non&#x2011;cancellable contract period. These terms are used to maximize operational flexibility in terms of managing contracts. The options to extend are held by the Company and the termination options are held both by the Company and the lessor. As of December&#160;31, 2020, the Group exercised the option to extend the lease on its facilities in Schlieren by five years with a new lease term ending on December&#160;31, 2026. The earliest contractual termination date for both the lessor and the Group on the major real estate lease is December&#160;31, 2025. For information about the right-of-use assets please also see note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below are the carrying amounts of the lease liabilities and the movements during the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions / new leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,850&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,850&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="15" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the expense amounts recognized in the consolidated statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation on right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total amount recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total cash outflow for leases for the year ended December&#160;31, 2022 amounted to TCHF 1,232 (year ended December&#160;31, 2021 TCHF 1,232; year ended December&#160;31, 2020 TCHF 1,275).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contractual maturities of financial liabilities at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 2 and 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total contractual cashflows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Carrying Amount lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contractual maturities of financial liabilities at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 2 and 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total contractual cashflows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Carrying Amount lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <moln:LeaseTermOfContract
      contextRef="if4de6e75b42b401296433bd018ede76d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzE0_fd752879-2c21-490c-8ce0-172205078332">P2Y</moln:LeaseTermOfContract>
    <moln:LeaseTermOfContract
      contextRef="iaac4cc8da2f54efab0f4f0d53dcfdf39_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzE4_f3243d89-fcbe-4a0b-946c-f3a875f969de">P10Y</moln:LeaseTermOfContract>
    <moln:LeaseExtensionOrTerminationOptionPeriod
      contextRef="iaac4cc8da2f54efab0f4f0d53dcfdf39_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzIy_30c3baf2-39cd-401d-bc21-419cfa96a637">P1Y</moln:LeaseExtensionOrTerminationOptionPeriod>
    <moln:LeaseExtensionTermOfContract
      contextRef="ie5811d9f19074f96a9cbb5482d36febc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzMw_811f8afd-0649-4d1a-93fe-aeeeccd832db">P5Y</moln:LeaseExtensionTermOfContract>
    <moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExOA_de62a082-04e1-425f-8f8a-5e01f113b6e8">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below are the carrying amounts of the lease liabilities and the movements during the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions / new leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,850&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,850&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="15" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEtMS0xLTEtMTA5NjE4_72d4db79-9ec1-4897-b6fd-506c7d110ba8"
      unitRef="chf">6039000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i8aa95d3bb3ea49f38b656b59881a996f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEtNC0xLTEtMTA5NjE4_7fb0208e-d879-4369-8e49-31f7f14fb3a6"
      unitRef="chf">7218000</ifrs-full:LeaseLiabilities>
    <moln:IncreaseThroughNewLeasesOperatingLeases
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzItMS0xLTEtMTA5NjE4_652cf571-9fca-48b4-9249-0588e3832526"
      unitRef="chf">0</moln:IncreaseThroughNewLeasesOperatingLeases>
    <moln:IncreaseThroughNewLeasesOperatingLeases
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzItNC0xLTEtMTA5NjE4_9662e4d9-f1b9-4ded-baac-81ffba9edb7d"
      unitRef="chf">0</moln:IncreaseThroughNewLeasesOperatingLeases>
    <moln:IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzMtMS0xLTEtMTA5NjE4_27f5225c-57a4-4b71-81d6-e254117489c4"
      unitRef="chf">0</moln:IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases>
    <moln:IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzMtNC0xLTEtMTA5NjE4_7c4b1858-21fb-4f16-b61a-44d18c5191ab"
      unitRef="chf">0</moln:IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzQtMS0xLTEtMTA5NjE4_ecdca11e-0e3b-4b3c-8306-b0bce71839d9"
      unitRef="chf">43000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzQtNC0xLTEtMTA5NjE4_48a56737-4154-4c9e-9bf5-3bb2948b5c2e"
      unitRef="chf">53000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzUtMS0xLTEtMTA5NjE4_eed6d847-899a-4742-bbef-65f291515a54"
      unitRef="chf">1232000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzUtNC0xLTEtMTA5NjE4_4e9e5956-e34e-453d-ba4a-e98449770f6d"
      unitRef="chf">1232000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:LeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzYtMS0xLTEtMTA5NjE4_4cde766e-22a8-43a4-986f-a45f6bce430b"
      unitRef="chf">4850000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzYtNC0xLTEtMTA5NjE4_3aa26eab-d537-437d-acab-d01ed36b4ef2"
      unitRef="chf">6039000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzgtMS0xLTEtMTA5NjE4_18c49f60-386a-4ea8-a9d4-ea31acd26bba"
      unitRef="chf">1198000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzgtNC0xLTEtMTA5NjE4_5f4b3884-9163-4921-aa62-95d0641860fb"
      unitRef="chf">1189000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzktMS0xLTEtMTA5NjE4_afc0c0d4-4ab5-4f30-9f4b-51a8dc8561d0"
      unitRef="chf">3652000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzktNC0xLTEtMTA5NjE4_c6a2d81e-ad31-4c75-9c06-d7e180e49db7"
      unitRef="chf">4850000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEwLTEtMS0xLTEwOTYxOA_f40bb559-7c0e-492f-ac07-d5560758c39d"
      unitRef="chf">4850000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTpiYmE5NDFiYWZkZjI0ZTVjOGY3OWIzOTBiN2FmZGFmNS90YWJsZXJhbmdlOmJiYTk0MWJhZmRmMjRlNWM4Zjc5YjM5MGI3YWZkYWY1XzEwLTQtMS0xLTEwOTYxOA_7bd882f1-b8f4-46a7-94f5-9312d78274a0"
      unitRef="chf">6039000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExNQ_5789e782-192d-451b-be37-174023d03ba2">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the expense amounts recognized in the consolidated statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation on right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total amount recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzEtMS0xLTEtMTA5NjE4_fc9a5c0b-69de-4540-9c55-2e3243243f16"
      unitRef="chf">1200000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzEtNC0xLTEtMTA5NjE4_d527c733-fbce-4226-ba71-cf8a92eb5c50"
      unitRef="chf">1200000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzEtNy0xLTEtMTA5NjE4_3c5484da-f1a5-4250-bf4c-1c062fcea901"
      unitRef="chf">1256000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzItMS0xLTEtMTA5NjE4_4b3cf030-f5e5-4572-b800-7466d85972d3"
      unitRef="chf">43000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzItNC0xLTEtMTA5NjE4_088c8c29-0a6f-45cc-bd5e-f6dcaf3b2956"
      unitRef="chf">53000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzItNy0xLTEtMTA5NjE4_90cbd60c-d79c-4257-882d-7c58b33ea25b"
      unitRef="chf">24000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzMtMS0xLTEtMTA5NjE4_87185449-c61e-487b-a349-1abf15a26c32"
      unitRef="chf">0</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzMtNC0xLTEtMTA5NjE4_277f71a8-0df0-40f8-b3d6-63523d214c9f"
      unitRef="chf">0</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzMtNy0xLTEtMTA5NjE4_990a0971-028f-4f48-bc21-cc98dd9089be"
      unitRef="chf">0</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <moln:LeaseCostRecognisedInProfitOrLoss
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzQtMS0xLTEtMTA5NjE4_95f11ae7-b03e-4eec-b901-a4d94c58a4ef"
      unitRef="chf">1243000</moln:LeaseCostRecognisedInProfitOrLoss>
    <moln:LeaseCostRecognisedInProfitOrLoss
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzQtNC0xLTEtMTA5NjE4_99f93a2d-bcd8-4208-b4a2-0b6cefe680ab"
      unitRef="chf">1253000</moln:LeaseCostRecognisedInProfitOrLoss>
    <moln:LeaseCostRecognisedInProfitOrLoss
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4ZTNlNWZlMmU1MmI0ZmVhYWFiZjAwNDFmN2ZjMmZiZS90YWJsZXJhbmdlOjhlM2U1ZmUyZTUyYjRmZWFhYWJmMDA0MWY3ZmMyZmJlXzQtNy0xLTEtMTA5NjE4_761f0a26-af68-469b-8d95-2ddac524d96b"
      unitRef="chf">1280000</moln:LeaseCostRecognisedInProfitOrLoss>
    <ifrs-full:CashOutflowForLeases
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2Xzg0_184925db-b5ce-4119-a00c-d10a86ff435d"
      unitRef="chf">1232000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2Xzk2_b858f4ab-85a9-4112-97d0-facc35902999"
      unitRef="chf">1232000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzEwOA_859fb679-1e2b-46c7-ac87-5840c9755952"
      unitRef="chf">1275000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90ZXh0cmVnaW9uOjQxYTZiYTE3OGMyNzRiNzk5ODcxMjk3ODcyMWMxNzM2XzExNg_af4c47be-af64-4535-b0d4-cf894aecd995">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contractual maturities of financial liabilities at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 2 and 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total contractual cashflows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Carrying Amount lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contractual maturities of financial liabilities at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 2 and 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total contractual cashflows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Carrying Amount lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i46461ef8c2bf4ad194fcc5da61eb4790_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtMS0xLTEtMTA5NjE4_4ec7e113-d755-436e-82c0-fe12b6530612"
      unitRef="chf">1232000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i859523f38bfc4cef886b0469de3d3c27_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtMy0xLTEtMTA5NjE4_6f37c091-736b-4063-ac61-e244c3656de9"
      unitRef="chf">1232000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ie87b69197a5e41b68d889d5a9f94133c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtNS0xLTEtMTA5NjE4_7a9cf37c-3d14-40b4-bd17-cc99fcd9ee55"
      unitRef="chf">2464000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i20e09613a3fb4d9ca1c6817d2d362664_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtNy0xLTEtMTA5NjE4_c7eb243d-ac43-4590-a34a-c73e58112862"
      unitRef="chf">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtOS0xLTEtMTA5NjE4_73f41b0d-1a0b-485e-a360-d3d15f9b0b72"
      unitRef="chf">4928000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="ic0d265762d384de3bc912a8791ed2b7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTowOTI4NDkxYjcwZjk0NzdkYTExOTg4NmZkYjdhOTk5Yy90YWJsZXJhbmdlOjA5Mjg0OTFiNzBmOTQ3N2RhMTE5ODg2ZmRiN2E5OTljXzMtMTEtMS0xLTEwOTYxOA_c12379e5-627c-425a-8e9e-160fe3f29116"
      unitRef="chf">4850000</ifrs-full:LeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i6592e0e0184441c58126d7e24b37d82e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtMS0xLTEtMTA5NjE4_13dceecf-7dcf-479f-9faa-4aa7bcb46f17"
      unitRef="chf">1232000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="if56ff0ffb76b4ef7bdd5f9a0f0de46ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtMy0xLTEtMTA5NjE4_3ea80005-ef49-4f71-935b-888533b687ea"
      unitRef="chf">1232000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i6fe3972176af4d07b4e1942adcf6c075_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtNS0xLTEtMTA5NjE4_081e9641-659b-47c3-aed2-2e1d5fa2f829"
      unitRef="chf">3696000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i6f6b2661b6384f1fa68e0f05fada4e22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtNy0xLTEtMTA5NjE4_092d90b6-a418-4ed6-9f0a-1dcdf9e178ed"
      unitRef="chf">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtOS0xLTEtMTA5NjE4_4249e343-900b-4936-bde8-4430af5235d0"
      unitRef="chf">6160000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i45ab5095fb4e4ae7a889842f6c1990cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMjgvZnJhZzo0MWE2YmExNzhjMjc0Yjc5OTg3MTI5Nzg3MjFjMTczNi90YWJsZTo4MjZkNjM4YmJjM2I0MTE5OWJlMzM2YjBiZDZhMmY0Yy90YWJsZXJhbmdlOjgyNmQ2MzhiYmMzYjQxMTk5YmUzMzZiMGJkNmEyZjRjXzMtMTEtMS0xLTEwOTYxOA_5f99987a-d3bc-4ca4-97db-44d0a46e99ea"
      unitRef="chf">6039000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzQy_12169646-ff94-494b-9a84-626980ce99c5">Related party disclosures&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation costs of key management, which includes executive management and the Board of Directors, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzQz_39683149-0c0d-4b63-b539-750f492a8f65">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation costs of key management, which includes executive management and the Board of Directors, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total year ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzEtMS0xLTEtMTA5NjE4_9e912bfd-2de4-4969-be9c-06a0d4f9df81"
      unitRef="chf">3159000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzEtNC0xLTEtMTA5NjE4_f5d703fc-46b2-4d60-b009-1301b190a4a9"
      unitRef="chf">2423000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzEtNy0xLTEtMTA5NjE4_f1a4677f-5987-4db7-bbbb-d0f8fa8b65ba"
      unitRef="chf">2408000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzItMS0xLTEtMTA5NjE4_b0329695-ab60-47c3-8e06-9abbae38d668"
      unitRef="chf">297000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzItNC0xLTEtMTA5NjE4_607ee237-4adf-43d2-bc89-f50be755bfd6"
      unitRef="chf">203000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzItNy0xLTEtMTA5NjE4_90553a76-f4b5-4c93-b851-4b77a12cb831"
      unitRef="chf">205000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzMtMS0xLTEtMTA5NjE4_7baae529-8366-4590-9f13-d9012c883cd8"
      unitRef="chf">2111000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzMtNC0xLTEtMTA5NjE4_68d6358d-9a42-4c2a-93f5-fb8f41c76b84"
      unitRef="chf">1784000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzMtNy0xLTEtMTA5NjE4_6c1942ae-bf24-4c49-a411-8fe664da994c"
      unitRef="chf">1601000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzQtMS0xLTEtMTA5NjE4_1c0f34f6-3e17-48b2-b557-75e2d84ab3a4"
      unitRef="chf">5567000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzQtNC0xLTEtMTA5NjE4_b00c76c1-10a1-404a-a06f-3ab73cb50d09"
      unitRef="chf">4410000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90YWJsZTowMDFiMzA3ODczMjM0NDQyYTJiNTcxZmRjYzRjMDUzMi90YWJsZXJhbmdlOjAwMWIzMDc4NzMyMzQ0NDJhMmI1NzFmZGNjNGMwNTMyXzQtNy0xLTEtMTA5NjE4_39be0dab-2b8c-4934-a9e6-0c71d8c15336"
      unitRef="chf">4214000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzEwOTk1MTE2Mjg1ODk_cbb10263-5241-4491-b4e8-5922c7c24d09"
      unitRef="chf">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions
      contextRef="i7ddc731055fd4747a1a7ce539ee83aa8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzU0OTc1NTgxNDY0MQ_c4ac91a6-44e6-4744-af7c-8093f92b618e"
      unitRef="chf">13000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions
      contextRef="idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzEwOTk1MTE2Mjg1OTI_b44e0e7a-417e-4c10-93ce-5d97bce0f9f7"
      unitRef="chf">45000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <moln:PaymentForTermOfEmploymentRelatedPartyTransactions
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzEvZnJhZzpmYmZkOTg1YjA3OWY0MWVhYTBiNzI0MDk4MzA2MDY5Zi90ZXh0cmVnaW9uOmZiZmQ5ODViMDc5ZjQxZWFhMGI3MjQwOTgzMDYwNjlmXzU0OTc1NTgxNDY2NQ_67751612-1f6e-4aa3-b285-1f2d1aae4564"
      unitRef="chf">21000</moln:PaymentForTermOfEmploymentRelatedPartyTransactions>
    <ifrs-full:DisclosureOfCommitmentsExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzQvZnJhZzpkOTYxY2U0ZTY5MTk0ZmE0OTQ0OWVhNzIwOTdhN2E1Mi90ZXh0cmVnaW9uOmQ5NjFjZTRlNjkxOTRmYTQ5NDQ5ZWE3MjA5N2E3YTUyXzIx_1a4fa5ff-c336-46c9-ab06-06ec866f021b">Capital commitmentsAs of December&#160;31, 2022 and December&#160;31, 2021, the Group did not have any capital commitments.</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90ZXh0cmVnaW9uOjE2ZmUyOWJlM2Y1NDQzYThiODU5M2QxNWI3NjIwMzczXzc3_b5b3ae65-af10-4e63-88c9-baeb528c2252">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table demonstrates the sensitivity to a reasonably possible change in exchange rates for the Group's main foreign currencies, USD and EUR, with all other variables held constant, of the Group&#x2019;s result before taxes. There is no direct impact on the Group&#x2019;s equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in % and CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Incr./Decr. exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effect on result before tax (in TCHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;USD Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EUR Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table demonstrates the sensitivity of the main currencies used in the Group, to reasonably possible changes in interest rates, with all other variables held constant, of the Group&#x2019;s results before tax. There is no direct impact on the Group&#x2019;s equity.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in % and CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Incr./Decr. interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effect on result before tax (in TCHF)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CHF Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;USD Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EUR Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;+0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzItMS0xLTEtMTA5NjE4_3bd29b07-bdf6-408d-a3af-386b3d400713"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzItNC0xLTEtMTA5NjE4_85441b83-1fc2-4ee6-8c97-d25575f75115"
      unitRef="chf">5904000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzMtMS0xLTEtMTA5NjE4_c5bdebb3-f84c-47b1-8a67-11307be7a82e"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i5b28054be9b44082a6b93131b559d39e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzMtNC0xLTEtMTA5NjE4_77bdb23e-73a4-47f6-9a4d-51df9bdd8a9e"
      unitRef="chf">5904000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzQtMS0xLTEtMTA5NjE4_f22bea8b-c8a0-4711-81a4-6bf7c6ac3a7d"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzQtNC0xLTEtMTA5NjE4_98fc1607-d52f-4cef-b787-2f5ff2e83ef3"
      unitRef="chf">6633000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzUtMS0xLTEtMTA5NjE4_9bb51d1f-d825-40bf-8c0a-da00fdda0b6a"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i9d2d050659db44048b1184a39cc7d287_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzUtNC0xLTEtMTA5NjE4_c65ddb2e-5938-40f6-9a84-758408a3162a"
      unitRef="chf">6633000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzYtMS0xLTEtMTA5NjE4_e14dbe9d-4434-46e5-ae22-aec18ada3b46"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzYtNC0xLTEtMTA5NjE4_0612c886-666f-484e-b1e1-86594f08647b"
      unitRef="chf">2976000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzctMS0xLTEtMTA5NjE4_4e859b3f-b865-4f3e-b819-1e7964d56a89"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="iaf21ac53aa214298ae5dc0970247644d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzctNC0xLTEtMTA5NjE4_bc6e6084-ddc7-47e9-8412-aab8451a8978"
      unitRef="chf">2976000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzktMS0xLTEtMTA5NjE4_639017af-655a-4155-b9b2-e8baac24cd92"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzktNC0xLTEtMTA5NjE4_32845329-9a88-4c94-884a-4e5b998a68de"
      unitRef="chf">1252000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEwLTEtMS0xLTEwOTYxOA_c81398bd-266f-4214-966c-3dd1d0f5fae1"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="ib0ebb3f5e6c7436299746a7a8dbf0932_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEwLTQtMS0xLTEwOTYxOA_32b13255-2647-4abe-bc6f-ec19eb498579"
      unitRef="chf">1252000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzExLTEtMS0xLTEwOTYxOA_b9267f07-adac-4168-be4c-ae112acdfa55"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzExLTQtMS0xLTEwOTYxOA_aaddcd22-0d78-4eb3-b6fe-a2cf6dfebdba"
      unitRef="chf">2019000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEyLTEtMS0xLTEwOTYxOA_e1ccc80b-c56f-46f1-a223-d1ce40b64fcb"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i55c55679da5d4a8fae9f0502845b16cb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEyLTQtMS0xLTEwOTYxOA_57a43284-1172-4c2c-bcce-28018a9c0e39"
      unitRef="chf">2019000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEzLTEtMS0xLTEwOTYxOA_a9a5b28e-4f3f-4d5f-8302-349e42680b3c"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzEzLTQtMS0xLTEwOTYxOA_1dffc1d2-847a-442f-9465-ce2b1a59b5c5"
      unitRef="chf">432000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzE0LTEtMS0xLTEwOTYxOA_d175abd3-eb9a-46b9-9783-f314a684569c"
      unitRef="number">0.10</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i30fdef79743b4c7d92b9f6c09614aad3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTpmODAwOTMxOWYyMWY0YTAxOTFhMWE0NGFhYjg3MWIwOC90YWJsZXJhbmdlOmY4MDA5MzE5ZjIxZjRhMDE5MWExYTQ0YWFiODcxYjA4XzE0LTQtMS0xLTEwOTYxOA_e05b632d-e7c4-4cc2-8ecc-06b611669836"
      unitRef="chf">432000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90ZXh0cmVnaW9uOjE2ZmUyOWJlM2Y1NDQzYThiODU5M2QxNWI3NjIwMzczXzUx_22cab5fc-44b0-4ad6-a35e-6a8d9eaddb87"
      unitRef="bank">4</moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzItMS0xLTEtMTA5NjE4_3b7bf98a-39a2-405b-a8c3-2c82cbda8fea"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzItNC0xLTEtMTA5NjE4_77618f8e-37ef-4b57-8797-c3576ffacc6e"
      unitRef="chf">888000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzMtMS0xLTEtMTA5NjE4_7258ab1a-365c-4616-a80f-9fd75c85e5aa"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzMtNC0xLTEtMTA5NjE4_4ba873f9-42a3-4fe8-be00-19bc05758a7d"
      unitRef="chf">888000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzQtMS0xLTEtMTA5NjE4_477922ac-6237-443d-a90d-260c45ba567b"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzQtNC0xLTEtMTA5NjE4_e23aecdc-890f-4bcb-bd2d-c9d02b29f2c5"
      unitRef="chf">323000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzUtMS0xLTEtMTA5NjE4_547de7d8-c9d7-4273-bea6-50e20757d176"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i4735c93b327e4729bb263ba18457993f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzUtNC0xLTEtMTA5NjE4_52437581-6063-413e-90b2-323863009922"
      unitRef="chf">323000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzYtMS0xLTEtMTA5NjE4_061af2f6-8d85-4296-9941-b87ccd2481ed"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzYtNC0xLTEtMTA5NjE4_8df49456-52db-4813-a265-a2beba4bd5fd"
      unitRef="chf">683000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzctMS0xLTEtMTA5NjE4_bc212912-b225-4724-a64f-459cfdb2442f"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i1bfa06945a784465a596b7c48b03dbd4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzctNC0xLTEtMTA5NjE4_303a22ba-4171-4395-b5c2-bb29dea202a5"
      unitRef="chf">683000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzktMS0xLTEtMTA5NjE4_c5989fda-7695-43aa-8282-aaffa578ce12"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzktNC0xLTEtMTA5NjE4_d2d92c4e-8cbf-4162-931a-acb61037eeb2"
      unitRef="chf">294000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEwLTEtMS0xLTEwOTYxOA_5b4b1a08-f0ec-4a29-9015-1799d86585e6"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="ib2fff12adec440c6b2a8131723062b4d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEwLTQtMS0xLTEwOTYxOA_db853c1e-7077-4107-8f0d-6164d0bc7e9e"
      unitRef="chf">294000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzExLTEtMS0xLTEwOTYxOA_6f0ad1d5-5206-4a66-bec5-b49a53329280"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzExLTQtMS0xLTEwOTYxOA_c443c952-a4ca-46e3-a8b6-2e377a5de130"
      unitRef="chf">234000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEyLTEtMS0xLTEwOTYxOA_2ce36ff1-07c4-4c95-b020-7dc07b5c945a"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="ib47973cc7ad643f68354a50ec39d60ff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEyLTQtMS0xLTEwOTYxOA_4036476e-fd72-41de-85ed-d1a49c7d6783"
      unitRef="chf">234000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEzLTEtMS0xLTEwOTYxOA_f5004416-1ac3-4691-8527-f161b4189d04"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzEzLTQtMS0xLTEwOTYxOA_67ac8355-ce59-4c40-a436-8f94e09fb769"
      unitRef="chf">149000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE0LTEtMS0xLTEwOTYxOA_5e735c18-8441-4922-ae60-b8021d0af13c"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i0e7fb979efbf41febac9a2716613befd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE0LTQtMS0xLTEwOTYxOA_ccb14483-8fdb-403a-aba6-a52c626cb806"
      unitRef="chf">149000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE2LTEtMS0xLTEwOTYxOA_f285ac56-1d82-4cae-a8c8-e1c5fb11d0d8"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE2LTQtMS0xLTEwOTYxOA_1cc33b9a-3ff9-4938-930a-027403fc446a"
      unitRef="chf">63000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE3LTEtMS0xLTEwOTYxOA_03ca2ec6-7d1b-42cf-a817-06b909a68e13"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i6de0721c579f420c98f2e3a79c194d7b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE3LTQtMS0xLTEwOTYxOA_179878ed-a310-482c-b3a3-7bd24f166a6a"
      unitRef="chf">63000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE4LTEtMS0xLTEwOTYxOA_7941fee4-d1ca-439c-93c0-f324281de7cd"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE4LTQtMS0xLTEwOTYxOA_87d98923-d819-4463-92a4-52a6aeb586b5"
      unitRef="chf">102000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE5LTEtMS0xLTEwOTYxOA_caa70c42-dd68-4b79-8ae5-8c3a618b00e4"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i8b7a6880db994464a3d6a16057cc8c48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzE5LTQtMS0xLTEwOTYxOA_89d19629-39d2-42f2-8d5d-b204d67a53df"
      unitRef="chf">102000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent
      contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIwLTEtMS0xLTEwOTYxOA_6035c6b4-8f06-461f-a4bf-6b5d381dd2d3"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIwLTQtMS0xLTEwOTYxOA_6c1ac547-8dc0-4a24-9d7f-9107bc648d82"
      unitRef="chf">32000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent
      contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIxLTEtMS0xLTEwOTYxOA_bccb924b-a9d4-4b73-a60c-4b5e0f6180f4"
      unitRef="number">0.005</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent>
    <moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax
      contextRef="i56de654af20844f7a8c3b8dcf11bd65c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZToyNDdjMjkzOGY2ODc0Nzk5ODU0YWRhNGM4ZDU3NzQ4NS90YWJsZXJhbmdlOjI0N2MyOTM4ZjY4NzQ3OTk4NTRhZGE0YzhkNTc3NDg1XzIxLTQtMS0xLTEwOTYxOA_d5dfeec5-da0a-44f6-b038-39b939373e53"
      unitRef="chf">32000</moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax>
    <ifrs-full:DisclosureOfCreditRiskExposureExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90ZXh0cmVnaW9uOjE2ZmUyOWJlM2Y1NDQzYThiODU5M2QxNWI3NjIwMzczXzc5_79f60f4b-8639-47bc-9da0-1813e98e81a6">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum credit risk as of the balance sheet date was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;in CHF thousands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;161,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total credit risk as at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;250,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;156,599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCreditRiskExposureExplanatory>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="ifc9f9f10e83045df9c56d3e82d087d4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzItMS0xLTEtMTA5NjE4_46d7fb33-52e6-44d5-a0ba-fe49f00b3f48"
      unitRef="chf">87946000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i075b63d9ec7248cfaea163eaee0d8389_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzItNC0xLTEtMTA5NjE4_59a25227-ae5a-4239-a6e4-57625e0399fe"
      unitRef="chf">71813000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i7fcf3db326314fe697ed5cd42ecbbada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzMtMS0xLTEtMTA5NjE4_b5e90694-c197-4049-94d3-c4a17ec85289"
      unitRef="chf">521000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="icfcf107f070c4e4881afc0cfb8a17695_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzMtNC0xLTEtMTA5NjE4_0a5dbb36-97d5-4702-a2bc-cca79afb8a43"
      unitRef="chf">23710000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i535d9072a4a54202a9a35ca03151f8e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzQtMS0xLTEtMTA5NjE4_453de71f-2376-4df2-ab20-f2606ca168e1"
      unitRef="chf">679000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i6257911404da432da8c7b7b86e6e80fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzQtNC0xLTEtMTA5NjE4_25620a12-0da9-4d5c-a00f-ac1e5e2c1740"
      unitRef="chf">76000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i2714f74d10b649b4b454a1f1bde37423_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzUtMS0xLTEtMTA5NjE4_e818c332-fdd6-4ddd-a4d3-199f0ff8bfeb"
      unitRef="chf">161198000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i5431eb0aa5e34ad0b9389372b7ea9eb3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzUtNC0xLTEtMTA5NjE4_c602bd06-35f8-43c3-9a24-331e96ecfa65"
      unitRef="chf">61000000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i001bd3a832b04bf5bbcaa90c5bc76c16_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzYtMS0xLTEtMTA5NjE4_30f70880-9073-404b-acaa-22c9a99b54f0"
      unitRef="chf">250344000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="i4f458970fd1a437482bffbf1e51aa71e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zMzcvZnJhZzoxNmZlMjliZTNmNTQ0M2E4Yjg1OTNkMTViNzYyMDM3My90YWJsZTplZGVlZDkwMzk0YTU0MmJhOWYxMzlkM2E4MzBiOGU4ZC90YWJsZXJhbmdlOmVkZWVkOTAzOTRhNTQyYmE5ZjEzOWQzYTgzMGI4ZThkXzYtNC0xLTEtMTA5NjE4_1b1a8bbf-6cdd-419e-8228-d021e98e7d43"
      unitRef="chf">156599000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8xNDA4L2ZyYWc6MTRhYjE0OGRkYzRkNDE4ZjhkN2U3YmVjZTdiODlmYmIvdGV4dHJlZ2lvbjoxNGFiMTQ4ZGRjNGQ0MThmOGQ3ZTdiZWNlN2I4OWZiYl8yMTk5MDIzMjU1NjEx_164395de-1982-4b9e-9b76-5d32d80a9de1">Putative Class ActionOn July&#160;12, 2022, a putative class action complaint was filed in the U.S. District Court for the Southern District of New York against the Company, its directors, and certain of its executive officers. The complaint alleges that the defendants violated federal securities laws by, among other things, making misrepresentations and omissions regarding its product candidates ensovibep and MP0310. The complaint seeks unspecified compensatory damages, as well as an award of reasonable attorneys&#x2019; fees and other costs, on behalf of persons and/or entities which purchased (a) the Company's American Depositary Shares (ADSs ) pursuant to certain offering documents issued in connection with the Company's initial public offering of ADSs; and/or (b) the Company's securities between June&#160;16, 2021 and April&#160;26, 2022 inclusive. A motion to appoint a lead plaintiff and counsel was filed on September 12, 2022 and is still pending. The matter remains in its early stages. The Company disputes these claims and intends to defend itself accordingly. The Company expresses no assurances as to the ultimate outcome of this matter.</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory
      contextRef="i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8zNDAvZnJhZzo4YTI0NzYwMTg0YWQ0N2EzYjExN2U1NzUwMjM5MGNjNi90ZXh0cmVnaW9uOjhhMjQ3NjAxODRhZDQ3YTNiMTE3ZTU3NTAyMzkwY2M2XzEyOA_f97c1b41-cd95-454c-abe1-578bcdcba771">Events after the balance sheet dateNo events occurred between the balance sheet date and the date on which these consolidated financial statements were approved by the Board of Directors that would require adjustment to the consolidated financial statements or disclosure under this heading.</ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtMTAtMS0xLTEwOTYxOA_0ac734fe-7da4-46b8-a08a-45fa65d58b36"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtMTAtMS0xLTEwOTYxOA_0ac734fe-7da4-46b8-a08a-45fa65d58b36"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTctMS0xLTEwOTYxOA_118e40e9-7c10-4528-8c2e-3f7aad743281"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTctMS0xLTEwOTYxOA_118e40e9-7c10-4528-8c2e-3f7aad743281"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTEwLTEtMS0xMDk2MTg_2f807717-1707-4db6-ac76-98e239d570f0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTEwLTEtMS0xMDk2MTg_2f807717-1707-4db6-ac76-98e239d570f0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtNy0xLTEtMTA5NjE4_b7151253-29da-4569-86f9-977d9f4426c9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtNy0xLTEtMTA5NjE4_b7151253-29da-4569-86f9-977d9f4426c9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTQtMS0xLTEwOTYxOA_527836ae-cfb1-442d-8184-b9f6a8fd7dc6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTQtMS0xLTEwOTYxOA_527836ae-cfb1-442d-8184-b9f6a8fd7dc6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTctMS0xLTEwOTYxOA_3a27d870-a318-403c-ba95-cbcbfffae1a7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTctMS0xLTEwOTYxOA_3a27d870-a318-403c-ba95-cbcbfffae1a7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctMTAtMS0xLTEwOTYxOA_81e9a3f8-57df-4400-8006-52fd92ab8808"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctMTAtMS0xLTEwOTYxOA_81e9a3f8-57df-4400-8006-52fd92ab8808"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctNC0xLTEtMTA5NjE4_a97d247c-d856-4e0f-892e-d1533f366f60"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctNC0xLTEtMTA5NjE4_a97d247c-d856-4e0f-892e-d1533f366f60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTQtMS0xLTEwOTYxOA_2287db37-eedb-4c7e-a09c-1ecd05f3c8d0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTQtMS0xLTEwOTYxOA_2287db37-eedb-4c7e-a09c-1ecd05f3c8d0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTEwLTEtMS0xMDk2MTg_7ed81ab2-ad36-4a94-9833-448ac1b7a03b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTEwLTEtMS0xMDk2MTg_7ed81ab2-ad36-4a94-9833-448ac1b7a03b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTEwLTEtMS0xMDk2MTg_6c785a61-4fb9-4251-8527-22403d85ed74"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTEwLTEtMS0xMDk2MTg_6c785a61-4fb9-4251-8527-22403d85ed74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTEwLTEtMS0xMDk2MTg_a87347bb-4fa7-441d-9b78-40752564d044"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTEwLTEtMS0xMDk2MTg_a87347bb-4fa7-441d-9b78-40752564d044"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See note 18</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtMTAtMS0xLTEwOTYxOA_0ac734fe-7da4-46b8-a08a-45fa65d58b36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTctMS0xLTEwOTYxOA_118e40e9-7c10-4528-8c2e-3f7aad743281"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTEwLTEtMS0xMDk2MTg_2f807717-1707-4db6-ac76-98e239d570f0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzQtNy0xLTEtMTA5NjE4_b7151253-29da-4569-86f9-977d9f4426c9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE2LTQtMS0xLTEwOTYxOA_527836ae-cfb1-442d-8184-b9f6a8fd7dc6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTctMS0xLTEwOTYxOA_3a27d870-a318-403c-ba95-cbcbfffae1a7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctMTAtMS0xLTEwOTYxOA_81e9a3f8-57df-4400-8006-52fd92ab8808"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzctNC0xLTEtMTA5NjE4_a97d247c-d856-4e0f-892e-d1533f366f60"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTQtMS0xLTEwOTYxOA_2287db37-eedb-4c7e-a09c-1ecd05f3c8d0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzEzLTEwLTEtMS0xMDk2MTg_7ed81ab2-ad36-4a94-9833-448ac1b7a03b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI2LTEwLTEtMS0xMDk2MTg_6c785a61-4fb9-4251-8527-22403d85ed74"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzIzLTEwLTEtMS0xMDk2MTg_a87347bb-4fa7-441d-9b78-40752564d044"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc4_0723b4bb-2efc-43da-a0d3-2a9560c80c08"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTQtMS0xLTEwOTYxOA_3538464b-a523-4092-951d-4e0aed8bea48"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTQtMS0xLTEwOTYxOA_3538464b-a523-4092-951d-4e0aed8bea48"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEtMS0xLTEwOTYxOA_427e864e-e104-4b8b-968a-31771e944e2d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEtMS0xLTEwOTYxOA_427e864e-e104-4b8b-968a-31771e944e2d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTAtMS0xLTEwOTYxOA_4c6651d5-7f01-43c4-9e46-404640a69305"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTAtMS0xLTEwOTYxOA_4c6651d5-7f01-43c4-9e46-404640a69305"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEwLTEtMS0xMDk2MTg_f95e8681-0fd4-427b-9667-19e15823a877"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEwLTEtMS0xMDk2MTg_f95e8681-0fd4-427b-9667-19e15823a877"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEwLTEtMS0xMDk2MTg_8aa88b7e-551f-482d-9c98-dbd1fded96aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEwLTEtMS0xMDk2MTg_8aa88b7e-551f-482d-9c98-dbd1fded96aa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEwLTEtMS0xMDk2MTg_e49fe919-6ca9-47de-ba92-30a2f9e66e7b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEwLTEtMS0xMDk2MTg_e49fe919-6ca9-47de-ba92-30a2f9e66e7b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEtMS0xLTEwOTYxOA_670a7f4f-b6e2-42bd-a261-d268e6320676"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEtMS0xLTEwOTYxOA_670a7f4f-b6e2-42bd-a261-d268e6320676"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTExMjY2Ng_b52e114c-bb80-4f50-87bc-744a4b0672fd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTExMjY2Ng_b52e114c-bb80-4f50-87bc-744a4b0672fd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEwLTEtMS0xMDk2MTg_0d64f99b-c9bf-487e-8e5a-831571c9a9d2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEwLTEtMS0xMDk2MTg_0d64f99b-c9bf-487e-8e5a-831571c9a9d2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEtMS0xLTEwOTYxOA_38d8992f-68f1-42ef-a115-51091c077c82"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEtMS0xLTEwOTYxOA_38d8992f-68f1-42ef-a115-51091c077c82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTEyNjEz_ed0190b7-f838-444c-ad0f-70993d1b3c88"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTEyNjEz_ed0190b7-f838-444c-ad0f-70993d1b3c88"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEtMS0xLTEwOTYxOA_cec4ceeb-2c61-4b37-adb3-ebdce63e799e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEtMS0xLTEwOTYxOA_cec4ceeb-2c61-4b37-adb3-ebdce63e799e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEzLTEtMS0xMTI2NjI_8da5f5ce-3d30-4198-b089-9046a41774a7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEzLTEtMS0xMTI2NjI_8da5f5ce-3d30-4198-b089-9046a41774a7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTQtMS0xLTEwOTYxOA_57613203-4c3d-4e30-a631-9b9fe3296547"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTQtMS0xLTEwOTYxOA_57613203-4c3d-4e30-a631-9b9fe3296547"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTA5NjE4_7379f947-28f2-4610-af08-490f855bfdf0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTA5NjE4_7379f947-28f2-4610-af08-490f855bfdf0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTMtMS0xLTExMjYxOQ_e38e3c45-1c18-46c4-be93-cd9e2b526228"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTMtMS0xLTExMjYxOQ_e38e3c45-1c18-46c4-be93-cd9e2b526228"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTQtMS0xLTEwOTYxOA_202d8e85-7a71-4acd-82de-993522c1a6db"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTQtMS0xLTEwOTYxOA_202d8e85-7a71-4acd-82de-993522c1a6db"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTEyNjA3_af072b3f-1e50-41b8-b6b8-cbf670de7fcf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTEyNjA3_af072b3f-1e50-41b8-b6b8-cbf670de7fcf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTA5NjE4_b6b1c5dd-2641-4163-8598-f315946fdfca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTA5NjE4_b6b1c5dd-2641-4163-8598-f315946fdfca"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See note 12</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTQtMS0xLTEwOTYxOA_3538464b-a523-4092-951d-4e0aed8bea48"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEtMS0xLTEwOTYxOA_427e864e-e104-4b8b-968a-31771e944e2d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTAtMS0xLTEwOTYxOA_4c6651d5-7f01-43c4-9e46-404640a69305"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI4LTEwLTEtMS0xMDk2MTg_f95e8681-0fd4-427b-9667-19e15823a877"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEwLTEtMS0xMDk2MTg_8aa88b7e-551f-482d-9c98-dbd1fded96aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEwLTEtMS0xMDk2MTg_e49fe919-6ca9-47de-ba92-30a2f9e66e7b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEtMS0xLTEwOTYxOA_670a7f4f-b6e2-42bd-a261-d268e6320676"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTctMS0xLTExMjY2Ng_b52e114c-bb80-4f50-87bc-744a4b0672fd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI3LTEwLTEtMS0xMDk2MTg_0d64f99b-c9bf-487e-8e5a-831571c9a9d2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTEtMS0xLTEwOTYxOA_38d8992f-68f1-42ef-a115-51091c077c82"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTEyNjEz_ed0190b7-f838-444c-ad0f-70993d1b3c88"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTEtMS0xLTEwOTYxOA_cec4ceeb-2c61-4b37-adb3-ebdce63e799e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzI5LTEzLTEtMS0xMTI2NjI_8da5f5ce-3d30-4198-b089-9046a41774a7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE4LTQtMS0xLTEwOTYxOA_57613203-4c3d-4e30-a631-9b9fe3296547"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtNC0xLTEtMTA5NjE4_7379f947-28f2-4610-af08-490f855bfdf0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMTMtMS0xLTExMjYxOQ_e38e3c45-1c18-46c4-be93-cd9e2b526228"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzE3LTQtMS0xLTEwOTYxOA_202d8e85-7a71-4acd-82de-993522c1a6db"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTEyNjA3_af072b3f-1e50-41b8-b6b8-cbf670de7fcf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90YWJsZTo1OThkNmYwMTUzMmM0NmExYjQ5Y2YzZTczYmE2MTc2Mi90YWJsZXJhbmdlOjU5OGQ2ZjAxNTMyYzQ2YTFiNDljZjNlNzNiYTYxNzYyXzgtMS0xLTEtMTA5NjE4_b6b1c5dd-2641-4163-8598-f315946fdfca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjYwYmVkNGIzMDE1MzQ1YzhiOTBhOWJhNDE5NGE1ZTkxL3NlYzo2MGJlZDRiMzAxNTM0NWM4YjkwYTliYTQxOTRhNWU5MV8yNTkvZnJhZzo2OTIzNmYyM2VhNTY0ZjQ4YjYyNzk2NmEwODg3MGRiZS90ZXh0cmVnaW9uOjY5MjM2ZjIzZWE1NjRmNDhiNjI3OTY2YTA4ODcwZGJlXzc5_01b5ce3e-de31-42cf-9021-9caea2b94f8e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>140
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M^%W=:+$T!\XW0FN1F\L%HPF3Y0OP_:T0>GU3_D#]+PC#?P%02P,$%     @
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M2V-+W$]+VU-!.0>[?Y#2G QW0-^EL[]02P,$%     @ *X!I5K9[NE4G!0
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M4U0->H4]'_ECL@9<&'K0LH; 0=O@%7%39P&QY0<@NJR>ZF6DJLO6+(G'^FM
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M(FIP3]];'8*=2W697%5272"J5,$7>T47*; 12&XI[.Y$NF*%G5=RX@"9N'*
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MD-[;F=.==W!FG[%B4WXLD5 '^UQ5QYO-T^:#S&WY&:+S?(JOY]CR_!.)KV?
MP?8F@3?EMQVO;;KZ,O2%%AN>2Y2R-73#OTH@9$7UL:6Z46)7?DU8"*5$5EYN
M&86"U !XOQ; N;[1#32?O";_ 5!+ P04    "  K@&E6+_RS7_0'  !S(P
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MNMO;_@F/_H,2A^Z9AZU02M3=VSUG!6^-0/]_)X1Z_6 N,#YGL_XO4$L#!!0
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M@@?H^VU+UEC_P 1W;?>.E_?-_P%02P,$%     @ *X!I5AZ$P+YR#0  \"(
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M,OFQ+M/+/H1 P^.Z)+05M\"VWY0M,3_DXKN&4%?6XFN=H($>XXXJ\-8#^I$
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M_2C!T+_OT*%\8-P.OO$90WO4%K?HPY.]V%>B*X;EDXDE.%$T.GA)0ON</V6
MX@8.F([0:(.G?]]9[VC?A^V3WJ\0*F67_%L+,@D!"3](:)^V/^>X";]BZ*:'
MWX+\+"WV_G"06N#5\>CB["!\K$LWWJSY-PUSX[VI^'*ED,>6)F!\88Q/-[1
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M[ 5N:3[=X]*?Z%J^.RU=Q$V,?U8@I_:T .]+ASSS'PHP7*8O_@902P,$%
M  @ *X!I5EZ-;ZDK#0  IB4  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&ULK5IID]LV$OTK**4V.Z[2:"3-X7%\5(T]OK;6\90=)Q^V]@-$0A*R),$
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MN'U@!XWC81TQDNZ<<4;APHROJF!5@.,X [:':=O'%JE1,R(R[2D<EW0XIGL
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MAM:?D,1'?V@$E/AY2&%=%'W3U\SP$J\,3'@AF+N4)H*;I3Y)HC.8)7&(OS8
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M-;@<#CS0;1=N%U:53>=;*4M]M)EF]'"A=@9TOE;*[A8N0/<4SOX 4$L#!!0
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M"4GCCU,Q]XCI:41[7:YTRPI<>G0?-*I']%;??A-EX0\7^*8CW_02^M<7YG_
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M:I= ZY52]A"X N,3FOT!4$L#!!0    ( "N :58:L93V+ ,  !D'   9
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MU Y [U>*$MT-G$#_)S/]#U!+ P04    "  K@&E6T2>W1<,"   L!@  &0
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MX+ ?T*3*D:IH L<>YH("^0#>_.V;<!Q\V&'NL#-WN M]SZ#LQ.BW<!N8W.=
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MFR[ID)J\Z#NK#C8N$QC-I;TR*8PM;B!WK^AFNUO9B;N,K,7=E>Z*RB7#FE1
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M6*W?LL$H)]=%2IK9"+'>REJU"C\](ZQ",F5>D6:5GK'?D'_['B;*. W ,?Y
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MJ_*: 0*/K01"G5EAXHK7>-X1^(0WVBC[]APK#@/Z(3&^DI?=Z/5$V@M;7-;
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M/, M7H?CBW+C.E'A)J*;X- ^8;3]_KOY,OWQ#;*+B>SB+?1O+,E_Q=@))RO
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M=_N^=]O9_0^\:YJ/3&\YE:_ DD+CZ_$P -TUHFYA5>/-OU&66HF?5M2[43L
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M8D[2$'Y=!7I3UT0?L G4D/.>(,UC@TIVT?]^PE+Y4ZD&RH?*H.2I@%P-M18
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M$\8HVYUBQUUFI<)W!B8;/31#YIM<<VZUW*I#[?11)# 8K$<@!"#W92!&Q+R
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M8GDC@EC.G1W(16N@Q8<4:O(&.65B45;!85?!+RSO^B!B7NA:"^_I,N5J/@F
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MI^O+JR=GM*E+_][;%DH&2OMMQ58-4?([0AE[#/$47Z^,H3>7AO2 82*SU@"
MF5K2U>/LO:%+3&N9)7D$P?IE59)E5L@Q@#-!Z0-AT' 6?!_P-;^'[_E=TF#
MH46S9\#YYR9!$B7)/]!UJ-SOUI6X'72C5G?<C:_\W?CJ*..^-P*16H?7IWC_
MGD-\\/!#$0*CSJ8F,"6/+HCSR3(&"RD!@)P@7.F@"SJ?JN$#9MH2Q]B]TIH%
M7@N:E#][F)OS4:ZJ7&#DLFSVVYS,_97I!7+1"$5/U!9Q37!TU?-H :8NV+<
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M/E#B4<0KMEO=@B;$)S,_1EW"H3+'>_-2< '.6L:)^+/FY<*;)LO#P!^N.1^
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MM'F%&M,I2(F1FP,UDV4I\VNV\TXJ5]9EXO0@^ 6&.SQ"D50_"(O0L2\/7+Z
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MZ !-66BO@M8D92\$C:(PII^'P4(7CJZRLFBU@5Z#S%1WC4<OU%E_P=!7XS8
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MT'@'VE]I[7:&3[!_+&=_ 5!+ P04    "  K@&E6'K&/#$L#  !O"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R=EF]OVS80QK_*00.&#5"C_Y*=
MV09L9T$+M%C0=-N+82]HZ6QQI4B5I.)DGWY'R5&=SO;:O;%)B??<[\A'.LWV
M2G\T-:*%QT9(,_=J:]OK(#!EC0TS5ZI%27>V2C?,TE3O M-J9%4?U(@@#L,\
M:!B7WF+67[O3BYGJK. 2[S28KFF8?EJA4/NY%WG/%][S76W=A6 Q:]D.[]'^
MVMYIF@6C2L4;E(8K"1JW<V\97:\RM[Y?\!O'O3D:@ZMDH]1'-WE3S;W0 :'
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M7).S\R("/;3H86)5%]KB6EG79(/9N%<-M0>X_8U2]FGB XSOY.(G4$L#!!0
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MGD8LD8OBKHR6\S0>D.O$;VD.Q9'[J.%>14*?E<6"M0YA;8XUC)+_1?:U8.^
M@!:*,/+]'5Q]S4K<2(0!^29PDSJL$N(EW4!X6[,=BZ-8"D>_&BZV%W*VU^L>
M],=KZVW<L ,C",)CG@F.203>$=1BP!(,5W^/I>X7OKXE^!%+GE 0DO_:&.6"
M\:Q":-Y$:/%@6KR 7YKP^YAL".\P&<\0U]WP(L[HB-"$4BIRL2JWZF4!OA9
MJ*'F!J9X@_LU!9] HY72;\O0?->A XGQM9S6@\<CJ=_I8EH@KAZ+0+,0E7K
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M=P/D:^Q2>/-10?(N_W)XG$^<>VU07[^M0QE7"LB'Z  TE48&J!P!*[4H&E?
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MOM^2)37 \UE1U.T%#=!]4?OR_P!02P,$%     @ *X!I5LY(J,<? P  I@<
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M*WI(T08#6E\8XW>#$*!]FF>_ 5!+ P04    "  K@&E6^%=7%>0"   T!@
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MR37L#ND6537^5(J1:S=R+*2A <:).4V,J.P&LB^E-(UB [0SZ.P?4$L#!!0
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M2],AHK0'S'XNA%Y/K /?<X[_ 5!+ P04    "  K@&E6T:2"=&$"  "Q!0
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M,(W\^$A^?)$1+[9Z, D3W^C!8"I]64,"TUA+CJPE(X]XB<U7$ILSA"/((E6
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M.]15!1::3IE:5="KN!="46^&H*()+#2]!=1BAE[FA@BU[XA0/XXCLQ^[POS
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M0/W_QSROOKUH3G!\].'=_P%02P,$%     @ *X!I5C"DCN0&!   WA,  !D
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MS@:*A)?;Y'(@66%VFC,FU;[57"Y =<U<!ZCG<\;DTT!O7NL_*^)_4$L#!!0
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M8ZNWPP(O8Y F +\OA="O$]/ON^L]^0M02P,$%     @ *X!I5H_7[88- P
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M&"B$)5Y3.6/;*R@:\C1?P*C(/M&VJ+4,%*R%9'$!5@IBDN3?^+$PH@*P3U\
M. 7 >2W +0!NUFBN+&MKBB7V1YQM$=?5BDT?9-YD:-4-2?1MG$NNKA*%D_X=
MQR$@G(2(R0BXNC,!D U>4!#H*YH2$5 FUAP06Z*\=E:IF$+"E"@L(40D03<9
MQ63-.23!$_K^F%*L+C+^A(ZF(#&AXEBQ3JXNT='\DA\C]:%Q=Q%;"Z5!C$RI
M>M+*S*#0?Y'K=U[0/X7@!+GV%^18CM, G[P>;M?AIG*RM-,I[70R/O<EOF?#
M;G:&G2MS<V>JUOWYH:#H6D(L_C:UG>]SVKR/_G&?B10',#;4KU< WX#A?_YD
M]ZQO329T1%:SQ"TM<=O8BX15<M74;4[1RRCT/\_&]_3]V%2;.*QQW+YME54U
M=:>ENM-6=2J+37I:06]UOR.R6G]>V9_W08'TNK2D([*:);W2DM[[ YE3>)6P
MJ=WW GE8,_0&S7'LE]KZK=J^W\^:U+2"WNI]1V2U_@9E?X,/BN.@2TLZ(JM9
M,BPM&;X_CL.#J.V'\;#"M9U^<QIMZWDZL%K%W<^GC<_D5M1;W>^*K=YC90*R
M/RB3Q49=V=(16]V6YTG&;IT*7I?+@J/Z4'9[^P_NAB)[V'.\O7":E2E6OT+\
MQ'Q%$H$H+!7..NFK</-\*L\7DJ798+M@4HW)V6&DWF2 ZP)U?<F8W"WTK%R^
M&_G_ 5!+ P04    "  K@&E6."?T%VH$   .'P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6S-F6UOFT@0Q[_*BI-.K=0&%LR#<[:EQI"F4JM&<7+W
MXG0O"%['J,"Z[-KN??O;!0(&-IR1)E+>8!YF?I[Y#SMFS.Q(\Q]L2PA'O](D
M8W-MR_GN4M=9M"5IR"[HCF3BRH;F:<C%8?ZDLUU.PG7AE":Z:1B.GH9QIBUF
MQ;G;?#&C>Y[$&;G-$=NG:9C_>T42>IQK6'L^<1<_;;D\H2]FN_")K A_V-WF
MXDBO*>LX)1F+:89RLIEKG_!E@*?2H;#X,R9'=K*/9"J/E/Z0!U_6<\V0$9&$
M1%PB0O%Q($N2))(DXOA90;7Z.Z7CZ?XS_;I(7B3S&#*RI,E?\9IOYYJGH379
MA/N$W]'C#:D2LB4OH@DKMNA8V1H:BO:,T[1R%A&D<59^AK\J(4X<\.0%![-R
M,,]UL"H'ZUR'2>4P.=?!KAR*U/4R]T(X/^3A8I;3(\JEM:#)G4+]PEOH%6?R
M1EGQ7%R-A1]?+$.V_8 BL47DYSX^A G).$-AMD9L2W/^D9,\15S<&T+^'66Q
MN/@1^3&+$LKV.4%T@^Y(1+,H3N*PJ+TX4U+E%@4=ZJJ@WDOJO:3ZS]1W/N%A
MG+#W@K^\N4;O5M?Y>R0V*,[0_9;NF7!G,YV+K&7L>E1E>%5F:+Z0H4^B"V3A
M#\@T3%/AOCS?'2O<_?/=#85[<+8[GK;==5'INMQF76ZSX%DO\9K"?>\5[ON+
MA?LT5+B_OXHO05\X2=D_JO*4$4W4$<E&>,EV843FFNATC.0'HBU^_PT[QA^J
M8D'"?$A8  1KE=6JRVH-T8M57*RN[D)6U:-$.05*_HX<%IX[G3@S_7 J=-_*
MQ1ZVVE9^WPI;EBL7RJE9H(#9+C9KJU;2DSKIR6#2JQ?ZDRKGDF2?QNE@//4Z
M2??-'&P81B?IP;#&WC9 L):"=JV@/7S;W%RKQ!IT&KM@(6$^)"P @K64=VKE
MG3?7AQW(LD+"?$A8  1KE=6MR^K"]6&WWVQ<T90Z+:EO-9DXW0;K#X8U5D$@
M6$M!KU;0 VOJ7K^IRV[=:=?+OIG9M_('PQJK(!"LI>"T5G ZJ&#P<*<2:]!I
M[.J'A/F0L  (UE(>&\TP9;RYMEZ%!%194)H/2@N@:.WBGDS*&*ZY5ZS3KN,Z
MGMUI30HKT[!Z3]G#@8V6$8C6EK&90/'@)#2JPU>HUJ_?U.H^M2NLNMU].*;1
M"K[&K(>;80\/3WL/*U\IUJ#7Z$8 2?-!:0$4K:U_,W?BR=OK\I!#YQ*4YH/2
M BA:N[C-2(S_9R8>U>7M_B.H:9O=)U"%F>WUGN&' QLMXVN,M[B9;_'@G#6N
MRSO]+N^83D]%A9GBWYGAP$;+^!KC)&[F23P\4'Z^NE4J!CGO+4%I/B@M@**U
M]6^F4>R]O58/.8HN06D^*"V HK6+VPS*>'A2'M?JIXJ_NGLM2F%DV%ZW0X%.
MO%"T4D3]Y%6B?%/\+<R?XHRAA&P$WKAP1?O-RY>OY0&GN^+MXB/EG*;%[I:$
M:Y)+ W%]0RE_/I O+.M7X(O_ %!+ P04    "  K@&E65>*1BF0#  !J#P
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M9L$7Y(DK@H<T7.$($LX03GS$ D+Y 0<:(R[>G$C.DK!0/#Q 5YA2+/.//DV
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MHY-KD+@@XE19IW>WZ&1^RT_'KE0,-(Z;-J==V=." Z?Y ;IG5.8"W= ,LGT
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M[:">+QF3VXT^H/VKD/P&4$L#!!0    ( "N :5:Z'GO[30@  #A.   9
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M35K+;EATV5\!V9:39FM+-[5^D U:.Q]*"U T64I=ZH!.7&9_OKAL7$W7OTM
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MF@.1'>I-K[YE0F1)_7'/V9;G58'R^Z<L$Z\'E8/39G&K_P%02P,$%     @
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M2HYR6$M(YVXHE\6:FK[I"%KI*G=%A:R9=3.3[R!@RD#.KRD5^XX*T+VLIC\
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M7YR>@<H"\7Q*"%\OY/FL.(\[_P%02P,$%     @ *X!I5F;M>OR> @  !P<
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MB$H!\3PDA&\VTD YB+I_ 5!+ P04    "  K@&E6\TVP0F<$  !T'@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6S%65MOVS88_2N$5@PIT$:B;I8R
MVT!J*4B ;@V:=7L8]B#;M"U4$CV2MIM_7U)2).MBQDHX) ^Q*/.<0YZ/)G'
M\0&3[W2#$ ,_TB2C$VW#V/9*U^EB@]*(7N(MRO@W*TS2B/$F6>MT2U"TS$%I
MHIN&X>II%&?:=)R_NR?3,=ZQ),[0/0%TEZ81>?R$$GR8:%![>O$U7F^8>*%/
MQ]MHC1X0^[:])[RE5RS+.$49C7$&"%I-M&MX%9J& .0]_HK1@1X] S&5.<;?
M1>-N.=$,,2*4H 43%!'_V*,92A+!Q,?Q7TFJ59H">/S\Q'Z33YY/9AY1-,/)
MW_&2;2::IX$E6D6[A'W%AUM43L@1? N<T/P_.)1]#0TL=I3AM 3S$:1Q5GQ&
M/THCC@"F?0)@E@"S#3!/ *P28)VK8)< ^UR 4P+RJ>O%W'/C@HA%TS'!!T!$
M;\XF'G+W<S3W*\[$0GE@A'\;<QR;SG#&"*\62.)H'B<Q>P0?01#318+ICB"
M5V"V(P1E#$39$OR!LX]/[0KZN83&B(*+ +$H3NA[\'!#0)R!/S=X1SF4?@#O
M&NVQSOCXQ2CT13G63\58S1-C#=#B$ECP S -TP2SVQMPP47>]Q#-AA!]>PC
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M>+7D[ EPC5;>]$$=S-I:T:>5SON]Y.I?JNSDZBK/J4X +@"MFF6DTZ$^<D=
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M3/"&CG6$@'8>#NT>JK*M\Z==-V?H/+UU,?8(N$'K=?S%<$\2J=8#8B2)542
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M)4N+RQ4E$>5Y _7[@C'Y=I-W4!>+3_X#4$L#!!0    ( "N :5877[ERM08
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M>(KY0_KRB91 7M;?.HU9_A>\E+'.!*Q/C*>'LK'(X! EQ?_P1WDA:@VPV](
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MR*BV\E R'OR ![,I)3M 4VN!EO[(R,Q:B_##),W[ Z?B:2C:\=D=IHPD"8X
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M_W[7AK!\T*R3^@+^N.=PSP'?RW@MY*,J #1YJDJN)DZA=7WANBHKH*+J5-3
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M!D@3@/L+@<YV$_. _K<E_0-02P,$%     @ *X!I5J*]M\27 P  3A,  !D
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M09D VI]+B5O#'- .[^@O4$L#!!0    ( "N :5;59Z2Q^ ,  +$1   :
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MC,@Z5E.^^82YH*[A"W@LTR=L<EO'@F M%4]RL!Y!0EGV)MO<$0< MW<&X.4
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M0<SE6B#P"!A1IJ3_4,"M,K-$-YJ?60+1+\H6$ F>0%3,*LJD$FLSH21\-^1
M%2;RWZH(=)J,0)-D?D-DI0ATBPAT:W_<SRS0"4VF:PONUA9AUI8J'V9<_93+
MY+S7L=/2L^_UT#47V/CU-B4AO4)(KU:(GM&_(*2>Z\IU6H[SQW55Y-^-]-^#
M++GBIG#%32W50Q3IO _IUD'J# USU%L8!$6V0*,C[VA_98ZK<E/63^\@3MV!
MTSD*^*E1K]=N'T7\U,@;W/2J0]XO=/9_1R=E"O4'E>L,\;S._LGH/E8(K;"J
M4%IA=5[JH) ZJ)?Z/*W/+[7P7UW=FB3S&R(KN<UU]ALPYW^38?*A-!2$1MG\
MIMC*83C8![L-IIF<K#[/7&+D_\2HK,;;J_$:S#4_(:M+-N^'^N^"EOVQW_RZ
M];O?YA).WM'AZNEZ7>\X]*=6GN,.CF-_:M5I>V=BO]^QNK7;L0:33MY1*5-4
MB:TPJU);878JUSXXRR8H%NF=@(2 KYG*SFY%:W'O<)>>MH_:[\U]1'I&WM-D
MEQE?B%CH51-BC#2ET[K1FSV1W0]D%<57Z8EYSI4^?Z?%)9(0A3'0WR/.U:YB
M.BAN:<;_ 5!+ P04    "  K@&E6RXZ,P34"  ##!   &@   'AL+W=O<FMS
M:&5E=',O<VAE970Q,#0N>&ULA53;CM,P$/T5*T@()&@N[18H2:1VE]7N0U'5
M"GA /+C)I+'J2[#=9OE[QDZ:+5*WO"0>>\Z9,^,9IZW2>U,#6/(DN#194%O;
MS,+0%#4(:D:J 8DGE=*"6C3U+C2-!EIZD.!A$D734% F@SSU>RN=I^I@.9.P
MTL0<A*#ZSP*X:K,@#DX;:[:KK=L(\[2A.]B _=:L-%KAP%(R =(P)8F&*@OF
M\6PQ<?[>X3N#UIRMB<MDJ]3>&8]E%D1.$' HK&.@^#O"+7#NB%#&[YXS&$(Z
MX/GZQ'[O<\=<MM3 K>(_6&GK+/@8D!(J>N!VK=H'Z/.Y<7R%XL9_2=OY3C%B
M<3!6B1Z,MF"R^].GO@YG@/C3"X"D!R1>=Q?(J[RCEN:I5BW1SAO9W,*GZM$H
MCDEW*1NK\90ASN;W3%)9,,J)9F:/S!*O HMNR7LR+TOF2H>'C[*[?U?(-W=@
M*>/F;1I:5.!XPJ*/MNBB)2]$BQ.R5-+6AGR1)93_$H0H?="?G/0ODJN,=U",
MR#A^1Y(H2?!^Y/X*Z7@HRMB3CO];E+4KRO*Y*#_G6V,UMM*O2\EWK)/+K&Z\
M9J:A!60!SH\!?80@?_TJGD:?KVB>#)HGU]CSKP>Q!4U414I65:"=VDW+C/%%
M,9?D=H0WGM -[S&?I.'Q7$-XUE@"],Z/CR&%.DC;]=BP.TSHO&O,9_=NO)=4
M[Y@TA$.%T&CT >/J;F0ZPZK&M^E666QZOZSQE0'M'/"\4LJ>#!=@>+?ROU!+
M P04    "  K@&E6']P6\G8$   R&   &@   'AL+W=O<FMS:&5E=',O<VAE
M970Q,#4N>&ULS5E=;^(X%/TK5E:S:J4M^:*4=@&I;5I-'T:JRG3W8;4/;K@!
MJXG-VJ:T_W[M)$T("2X@/\P+Y..>8Y][$M^+&:T9?Q4+ (G>LY2*L;.0<GGE
MNB)>0(9%CRV!JCL)XQF6ZI3/7;'D@&<Y*$O=P/,&;H8)=2:C_-HCGXS82J:$
MPB-'8I5EF'_<0,K68\=W/B\\D?E"Z@ON9+3$<YB"?%X^<G7F5BPSD@$5A%'$
M(1D[U_Y5%'@:D$?\16 M-HZ1EO+"V*L^>9B-'4_/"%*(I:; ZNL-;B%--9.:
MQW\EJ5.-J8&;QY_L][EX)>8%"[AEZ=]D)A=C9^B@&21XE<HGMOX.I:!SS1>S
M5.2?:%W&>@Z*5T*RK 2K&62$%M_XO4S$!L ?[  $)2#8!O1W ,(2$.X+Z)>
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MF. N'J0)P.MK(?1^8O:)S?\"X7]02P,$%     @ *X!I5N\=XR=+ P  SA0
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M(10CZ\34I318$3BS,9&%8F(+C50$KD3+9>F(,D8&BH]F(+LD<,:N!F7:F,A
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MT>9XSLO\5K'N1W\N/XRZ_83S=5E>FF-?Z\\-+[9_,V3[]TX^_ =02P,$%
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M5>\,T#NKWAF@=U:],T#OK'IG@-Y9]<X O;/JG0%ZY^:P($#OK'IG@-Y9]<X
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M$U!+ 0(4 Q0    ( "N :58'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ *X!I5D-M%UOM    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ *X!I5IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  K@&E6Z9XMKJ4&  ".(   &
M        @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ *X!I5L6,UAPT @  L04  !@              ("!YPX  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "N :5:V>[I5)P4  *<5   8
M              " @5$1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  K@&E6_R*33C &  #^&@  &               @(&N%@  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ *X!I5B_\LU_T!P
M<R,  !@              ("!%!T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( "N :58T?7-X*0<  $TQ   8              " @3XE
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  K@&E6L1Y?
M?+P$   8"@  &               @(&=+   >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ *X!I5N%J@WQ@)@  8X$  !@
M ("!CS$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "N
M:58>A,"^<@T  / B   8              " @258  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  K@&E6@KMIT#T&  !8#P  &0
M        @('-90  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( "N :59>C6^I*PT  *8E   9              " @4%L  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ *X!I5B2P5=D@!   5 H
M !D              ("!HWD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  K@&E6-?]D/L\"   6!P  &0              @('Z?0
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "N :5:>$6%P
MPP,  -T(   9              " @0"!  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ *X!I5J.),55E @  3@4  !D
M ("!^H0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  K
M@&E6&K&4]BP#   9!P  &0              @(&6AP  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "N :59QN GM0@,  -4(   9
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M970R,2YX;6Q02P$"% ,4    "  K@&E68+]L8/T#  !L"0  &0
M    @(%3G0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M "N :58Q;OJ7*!4  '-!   9              " @8>A  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ *X!I5C1-F_/F @  [08  !D
M             ("!YK8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  K@&E6WAL*F" '  "S$0  &0              @($#N@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "N :5:LW3*L:P,
M $((   9              " @5K!  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ *X!I5@T7D,1;!0  TPT  !D              ("!
M_,0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  K@&E6
M,N+Q4,4"   9!@  &0              @(&.R@  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( "N :5;$ZXX9'P(   X%   9
M      " @8K-  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ *X!I5AZ$P+YR#0  \"(  !D              ("!X,\  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  K@&E6^O@AIED$   R"0
M&0              @(&)W0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( "N :59!3!\,C0(  /P%   9              " @1GB  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ *X!I5A;]$MR/
M)P  S(H  !D              ("!W>0  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    "  K@&E61SUH0?T'  "R%@  &0
M@(&C# $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "N
M:5:;<%#I0@,  , '   9              " @=<4 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ *X!I5JF^5$]/!   C H  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( "N :59<-P6_^@(  ,0&   9
M  " @54I 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M*X!I5D(P<.?] @  ,P<  !D              ("!ABP! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    "  K@&E68AMZ&.H"  !%!@  &0
M            @(&Z+P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( "N :5:$1))JF (  (P%   9              " @=LR 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ *X!I5L*-Q_4_!
MB X  !D              ("!JC4! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    "  K@&E6G5_U_2($  #&"0  &0              @($@
M.@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "N :58A
MX=>DFQ   %T[   9              " @7D^ 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ *X!I5LY(J,<? P  I@<  !D
M     ("!2T\! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N :58D\ULS< 0  (\*   9              "
M@<]? 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ *X!I
M5AO9-=)# @  XP0  !D              ("!=F0! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    "  K@&E66OT.#=L"  !_"@  &0
M        @('P9@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( "N :5;1I()T80(  +$%   9              " @0)J 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ *X!I5@ZTF]V4 P  3 \
M !D              ("!FFP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    "  K@&E6S]FW-.0*  #0@P  &0              @(%E< $
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( "N :59I'NUW
M3 ,  .X-   9              " @8![ 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ *X!I5MTC'[&R P  A!$  !D
M ("! W\! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  K
M@&E6&V@+7&T+   &<0  &0              @('L@@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( "N :58PI([D!@0  -X3   9
M          " @9". 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#
M%     @ *X!I5HP]-MZ! P  ?A   !D              ("!S9(! 'AL+W=O
M<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  K@&E65^QSRH0#  "X
M$   &0              @(&%E@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM
M;%!+ 0(4 Q0    ( "N :5;&1N.??P(  &8&   9              " @4":
M 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ *X!I5M$.
MCU_0 @  Z@<  !D              ("!]IP! 'AL+W=O<FMS:&5E=',O<VAE
M970V-BYX;6Q02P$"% ,4    "  K@&E6C]?MA@T#   G#0  &0
M    @(']GP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M "N :58X)_07:@0   X?   9              " @4&C 0!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ *X!I5E7BD8ID P  :@\  !D
M             ("!XJ<! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    "  K@&E68[IJ-M@"   V"   &0              @(%]JP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( "N :5:Z'GO[30@
M #A.   9              " @8RN 0!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ *X!I5CBN^6JQ P  90T  !D              ("!
M$+<! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  K@&E6
M^\(=#KD"  !!!P  &0              @('XN@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( "N :59P-<0T00,  )L/   9
M      " @>B] 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ *X!I5F;M>OR> @  !P<  !D              ("!8,$! 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  K@&E6UUUO?< #  !\%
M&0              @($UQ $ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( "N :58*-_OI.P4  #,A   9              " @2S( 0!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ *X!I5CPYQ.=9
M P  E X  !D              ("!GLT! 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    "  K@&E6\TVP0F<$  !T'@  &0
M@($NT0$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( "N
M:59SGY.H:P4  ! :   9              " @<S5 0!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ *X!I5KU;?7)&!   5QD  !D
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M=#@U+GAM;%!+ 0(4 Q0    ( "N :5:40A>/&08  #@N   9
M  " @<__ 0!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @
M*X!I5A=?N7*U!@  H2<  !D              ("!'P8" 'AL+W=O<FMS:&5E
M=',O<VAE970X-RYX;6Q02P$"% ,4    "  K@&E6Q3/H6L4&  #G*0  &0
M            @($+#0( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4
M Q0    ( "N :59ZU96$208  .4M   9              " @0<4 @!X;"]W
M;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ *X!I5FZ^I[6' P
M; X  !D              ("!AQH" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX
M;6Q02P$"% ,4    "  K@&E6A&;QUP(#  "+"   &0              @(%%
M'@( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( "N :58J
M#/^&1@,  "(*   9              " @7XA @!X;"]W;W)K<VAE971S+W-H
M965T.3(N>&UL4$L! A0#%     @ *X!I5AAFV=O\ @  LPL  !D
M     ("!^R0" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N :583$,-1K ,  -,-   9              "
M@6TW @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ *X!I
M5E3C9.$) P  )@D  !D              ("!4#L" 'AL+W=O<FMS:&5E=',O
M<VAE970Y.2YX;6Q02P$"% ,4    "  K@&E6K@/]D,T#  #Q%0  &@
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M:&5E=#$P-"YX;6Q02P$"% ,4    "  K@&E6']P6\G8$   R&   &@
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M @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  K@&E6XPVLQ_\"  !%/@
M&@              @ %78P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  K@&E6H4#6(VT"  #_.P  $P              @ &.9@(
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     <@!R %P?   L:0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>342</ContextCount>
  <ElementCount>424</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statement of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition</Role>
      <ShortName>Consolidated Statement of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statement of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity</Role>
      <ShortName>Consolidated Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - General information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Generalinformation</Role>
      <ShortName>General information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Financial risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Financialriskmanagement</Role>
      <ShortName>Financial risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Critical accounting estimates and judgments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Criticalaccountingestimatesandjudgments</Role>
      <ShortName>Critical accounting estimates and judgments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenues, other income and and entity-wide disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures</Role>
      <ShortName>Revenues, other income and and entity-wide disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Financialinstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Othercurrentassets</Role>
      <ShortName>Other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Trade and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Tradeandotherreceivables</Role>
      <ShortName>Trade and other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Cash, cash equivalents and short-term time deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits</Role>
      <ShortName>Cash, cash equivalents and short-term time deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Tradeandotherpayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Accruedexpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Contract liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Contractliability</Role>
      <ShortName>Contract liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Additional information on the nature of expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses</Role>
      <ShortName>Additional information on the nature of expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Royalties and license fees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Royaltiesandlicensefees</Role>
      <ShortName>Royalties and license fees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Personnel expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Personnelexpenses</Role>
      <ShortName>Personnel expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial income and financial expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Financialincomeandfinancialexpense</Role>
      <ShortName>Financial income and financial expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Taxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Relatedpartydisclosures</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Capital commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Capitalcommitments</Role>
      <ShortName>Capital commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Financial risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Financialriskmanagement_1</Role>
      <ShortName>Financial risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Putative Class Action</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PutativeClassAction</Role>
      <ShortName>Putative Class Action</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Events after the balance sheet date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate</Role>
      <ShortName>Events after the balance sheet date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Revenues, other income and and entity-wide disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables</Role>
      <ShortName>Revenues, other income and and entity-wide disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Propertyplantandequipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Intangibleassets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialinstrumentsTables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Financialinstruments</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/OthercurrentassetsTables</Role>
      <ShortName>Other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Othercurrentassets</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Trade and other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TradeandotherreceivablesTables</Role>
      <ShortName>Trade and other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Tradeandotherreceivables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Cash, cash equivalents and short-term time deposits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables</Role>
      <ShortName>Cash, cash equivalents and short-term time deposits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Shareholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ShareholdersequityTables</Role>
      <ShortName>Shareholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TradeandotherpayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Tradeandotherpayables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Accruedexpenses</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Contract liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ContractliabilityTables</Role>
      <ShortName>Contract liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Contractliability</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Additional information on the nature of expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables</Role>
      <ShortName>Additional information on the nature of expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Personnel expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesTables</Role>
      <ShortName>Personnel expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Personnelexpenses</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Financial income and financial expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables</Role>
      <ShortName>Financial income and financial expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Financialincomeandfinancialexpense</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Taxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Earningspershare</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Leases</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Related party disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RelatedpartydisclosuresTables</Role>
      <ShortName>Related party disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Relatedpartydisclosures</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Financial risk management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialriskmanagementTables</Role>
      <ShortName>Financial risk management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Financialriskmanagement</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Summary of significant accounting policies - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesSegmentReportingDetails</Role>
      <ShortName>Summary of significant accounting policies - Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Summary of significant accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of significant accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Summary of significant accounting policies - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails</Role>
      <ShortName>Summary of significant accounting policies - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Summary of significant accounting policies - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails</Role>
      <ShortName>Summary of significant accounting policies - Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Revenues, other income and and entity-wide disclosures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails</Role>
      <ShortName>Revenues, other income and and entity-wide disclosures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Country (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails</Role>
      <ShortName>Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Country (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails</Role>
      <ShortName>Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Property, plant and equipment - Disclosure of Reconciliation of Changes in Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment - Disclosure of Reconciliation of Changes in Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/IntangibleassetsDetails</Role>
      <ShortName>Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/IntangibleassetsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails</Role>
      <ShortName>Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails</Role>
      <ShortName>Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/OthercurrentassetsDetails</Role>
      <ShortName>Other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/OthercurrentassetsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails</Role>
      <ShortName>Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails</Role>
      <ShortName>Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Cash, cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails</Role>
      <ShortName>Cash, cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Cash, cash equivalents and short-term time deposits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails</Role>
      <ShortName>Cash, cash equivalents and short-term time deposits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Shareholders??? equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails</Role>
      <ShortName>Shareholders??? equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Shareholders??? equity - Classes of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails</Role>
      <ShortName>Shareholders??? equity - Classes of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Shareholders' equity - Shares Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails</Role>
      <ShortName>Shareholders' equity - Shares Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails</Role>
      <ShortName>Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails</Role>
      <ShortName>Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/AccruedexpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/AccruedexpensesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Contract liability - Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails</Role>
      <ShortName>Contract liability - Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Contract liability - Explanation of Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails</Role>
      <ShortName>Contract liability - Explanation of Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Contract liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails</Role>
      <ShortName>Contract liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Contract liability - Disclosure of Current and Non-Current Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails</Role>
      <ShortName>Contract liability - Disclosure of Current and Non-Current Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Additional information on the nature of expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails</Role>
      <ShortName>Additional information on the nature of expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Royalties and license fees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails</Role>
      <ShortName>Royalties and license fees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/Royaltiesandlicensefees</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Personnel expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails</Role>
      <ShortName>Personnel expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails</Role>
      <ShortName>Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails</Role>
      <ShortName>Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails</Role>
      <ShortName>Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Taxes - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails</Role>
      <ShortName>Taxes - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails</Role>
      <ShortName>Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails</Role>
      <ShortName>Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/EarningspershareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molecularpartners.com/role/EarningspershareTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Leases - Disclosure of Movement of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Disclosure of Movement of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails</Role>
      <ShortName>Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails</Role>
      <ShortName>Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Related party disclosures - Disclosure of Compensation Costs of Key Management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails</Role>
      <ShortName>Related party disclosures - Disclosure of Compensation Costs of Key Management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Related party disclosures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails</Role>
      <ShortName>Related party disclosures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails</Role>
      <ShortName>Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Financial risk management - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails</Role>
      <ShortName>Financial risk management - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails</Role>
      <ShortName>Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="moln-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails</Role>
      <ShortName>Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: moln:VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod, moln:VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod, moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod -  moln-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="moln-20221231.htm">moln-20221231.htm</File>
    <File>a112022_aoaxmpasofjanuary1.htm</File>
    <File>a121section302certification.htm</File>
    <File>a122section302certification.htm</File>
    <File>a12organizationalrulesofth.htm</File>
    <File>a131section906certification.htm</File>
    <File>a151auditorconsent.htm</File>
    <File>a21-depositagreement1.htm</File>
    <File>a23-descriptionofsecuritie.htm</File>
    <File>a410psuplan2021formanageme.htm</File>
    <File>a411psuplan2022foremployee.htm</File>
    <File>a412psuplan2022_formanagem.htm</File>
    <File>a413psuplan2023_foremploye.htm</File>
    <File>a414psuplan2023_formanagem.htm</File>
    <File>a419restrictedshareplan2022.htm</File>
    <File>a420restrictedshareplan2023.htm</File>
    <File>a44licenseagreementdatedas.htm</File>
    <File>a45molecularpartners-novar.htm</File>
    <File>moln-20221231.xsd</File>
    <File>moln-20221231_cal.xml</File>
    <File>moln-20221231_def.xml</File>
    <File>moln-20221231_lab.xml</File>
    <File>moln-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moln-20221231_g1.jpg</File>
    <File>moln-20221231_g2.jpg</File>
    <File>moln-20221231_g3.jpg</File>
    <File>moln-20221231_g4.jpg</File>
    <File>moln-20221231_g5.jpg</File>
    <File>moln-20221231_g6.jpg</File>
    <File>moln-20221231_g7.jpg</File>
    <File>moln-20221231_g8.jpg</File>
    <File>moln-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="1044">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>146
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moln-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 45,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1044
   },
   "contextCount": 342,
   "dts": {
    "calculationLink": {
     "local": [
      "moln-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "moln-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "moln-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moln-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moln-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "moln-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 674,
   "entityCount": 1,
   "hidden": {
    "http://www.molecularpartners.com/20221231": 4,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 135,
   "keyStandard": 289,
   "memberCustom": 49,
   "memberStandard": 41,
   "nsprefix": "moln",
   "nsuri": "http://www.molecularpartners.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.molecularpartners.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Critical accounting estimates and judgments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.molecularpartners.com/role/Criticalaccountingestimatesandjudgments",
     "shortName": "Critical accounting estimates and judgments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails",
     "shortName": "Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Related party disclosures - Disclosure of Compensation Costs of Key Management (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails",
     "shortName": "Related party disclosures - Disclosure of Compensation Costs of Key Management (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Related party disclosures - Narrative (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails",
     "shortName": "Related party disclosures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i5b28054be9b44082a6b93131b559d39e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
     "shortName": "Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i5b28054be9b44082a6b93131b559d39e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "bank",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Financial risk management - Additional Information (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails",
     "shortName": "Financial risk management - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "bank",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails",
     "shortName": "Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i59a66968bd8a458385cb5a8b56142f45_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCreditRiskExposureExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i001bd3a832b04bf5bbcaa90c5bc76c16_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:MaximumExposureToCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails",
     "shortName": "Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCreditRiskExposureExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i001bd3a832b04bf5bbcaa90c5bc76c16_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:MaximumExposureToCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenues, other income and and entity-wide disclosures",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures",
     "shortName": "Revenues, other income and and entity-wide disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property, plant and equipment",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.molecularpartners.com/role/Propertyplantandequipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Intangible assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.molecularpartners.com/role/Intangibleassets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Financial instruments",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.molecularpartners.com/role/Financialinstruments",
     "shortName": "Financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Other current assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.molecularpartners.com/role/Othercurrentassets",
     "shortName": "Other current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Trade and other receivables",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.molecularpartners.com/role/Tradeandotherreceivables",
     "shortName": "Trade and other receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Cash, cash equivalents and short-term time deposits",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits",
     "shortName": "Cash, cash equivalents and short-term time deposits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Trade and other payables",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.molecularpartners.com/role/Tradeandotherpayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Accrued expenses",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.molecularpartners.com/role/Accruedexpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.molecularpartners.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Contract liability",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.molecularpartners.com/role/Contractliability",
     "shortName": "Contract liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Additional information on the nature of expenses",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses",
     "shortName": "Additional information on the nature of expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Royalties and license fees",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.molecularpartners.com/role/Royaltiesandlicensefees",
     "shortName": "Royalties and license fees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Personnel expenses",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.molecularpartners.com/role/Personnelexpenses",
     "shortName": "Personnel expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Financial income and financial expense",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.molecularpartners.com/role/Financialincomeandfinancialexpense",
     "shortName": "Financial income and financial expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Taxes",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.molecularpartners.com/role/Taxes",
     "shortName": "Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.molecularpartners.com/role/Earningspershare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.molecularpartners.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Related party disclosures",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.molecularpartners.com/role/Relatedpartydisclosures",
     "shortName": "Related party disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Capital commitments",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.molecularpartners.com/role/Capitalcommitments",
     "shortName": "Capital commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statement of Financial Position",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
     "shortName": "Consolidated Statement of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Financial risk management",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.molecularpartners.com/role/Financialriskmanagement_1",
     "shortName": "Financial risk management",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Putative Class Action",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://www.molecularpartners.com/role/PutativeClassAction",
     "shortName": "Putative Class Action",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Events after the balance sheet date",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate",
     "shortName": "Events after the balance sheet date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Summary of significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "33",
     "role": "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Summary of significant accounting policies (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables",
     "shortName": "Summary of significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "moln:DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Revenues, other income and and entity-wide disclosures (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables",
     "shortName": "Revenues, other income and and entity-wide disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Property, plant and equipment (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.molecularpartners.com/role/PropertyplantandequipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Intangible assets (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.molecularpartners.com/role/IntangibleassetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Financial instruments (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.molecularpartners.com/role/FinancialinstrumentsTables",
     "shortName": "Financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Other current assets (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.molecularpartners.com/role/OthercurrentassetsTables",
     "shortName": "Other current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statement of Comprehensive Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome",
     "shortName": "Consolidated Statement of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Trade and other receivables (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.molecularpartners.com/role/TradeandotherreceivablesTables",
     "shortName": "Trade and other receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Cash, cash equivalents and short-term time deposits (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables",
     "shortName": "Cash, cash equivalents and short-term time deposits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Shareholders' equity (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.molecularpartners.com/role/ShareholdersequityTables",
     "shortName": "Shareholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Trade and other payables (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.molecularpartners.com/role/TradeandotherpayablesTables",
     "shortName": "Trade and other payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Accrued expenses (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.molecularpartners.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Contract liability (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.molecularpartners.com/role/ContractliabilityTables",
     "shortName": "Contract liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Additional information on the nature of expenses (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables",
     "shortName": "Additional information on the nature of expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Personnel expenses (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesTables",
     "shortName": "Personnel expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Financial income and financial expense (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables",
     "shortName": "Financial income and financial expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Taxes (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://www.molecularpartners.com/role/TaxesTables",
     "shortName": "Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statement of Cash Flows",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://www.molecularpartners.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://www.molecularpartners.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Related party disclosures (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://www.molecularpartners.com/role/RelatedpartydisclosuresTables",
     "shortName": "Related party disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Financial risk management (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://www.molecularpartners.com/role/FinancialriskmanagementTables",
     "shortName": "Financial risk management (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Summary of significant accounting policies - Segment Reporting (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesSegmentReportingDetails",
     "shortName": "Summary of significant accounting policies - Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i2e80d6a46f79433a9f1419880a584236_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Summary of significant accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails",
     "shortName": "Summary of significant accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i2e80d6a46f79433a9f1419880a584236_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i7e1e929b08e148649e795b949412ce45_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Summary of significant accounting policies - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails",
     "shortName": "Summary of significant accounting policies - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i7e1e929b08e148649e795b949412ce45_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Summary of significant accounting policies - Employee Benefits (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails",
     "shortName": "Summary of significant accounting policies - Employee Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Revenues, other income and and entity-wide disclosures - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
     "shortName": "Revenues, other income and and entity-wide disclosures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i56649e20c0b0463da822d9678ae13d6f_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Country (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails",
     "shortName": "Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Country (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i11c7f8788e1743f68a27f638c26a39bc_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ifcdf9dd73ee04977b7cafbf9acbef678_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statement of Changes in Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
     "shortName": "Consolidated Statement of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i8af2f1be9ad44d51b81ad6f3e39f3917_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
     "shortName": "Revenues, other income and and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i9f2f00f6e1d34d28bc572c7a3716463d_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Property, plant and equipment - Disclosure of Reconciliation of Changes in Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
     "shortName": "Property, plant and equipment - Disclosure of Reconciliation of Changes in Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i3eb97834871d4133bebda22f171f379c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Intangible assets (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.molecularpartners.com/role/IntangibleassetsDetails",
     "shortName": "Intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ib0a2cc30e5c64038a201d238fbf11978_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i9bef516c67454da38f24cc8f5ef7b00f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
     "shortName": "Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i9bef516c67454da38f24cc8f5ef7b00f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ideda6d7323e8434683a468cdbdbfaad9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails",
     "shortName": "Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ideda6d7323e8434683a468cdbdbfaad9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Other current assets (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.molecularpartners.com/role/OthercurrentassetsDetails",
     "shortName": "Other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails",
     "shortName": "Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails",
     "shortName": "Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "if10f3857f8be428ea614cef6b5f0cfdc_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Cash, cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
     "shortName": "Cash, cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "if10f3857f8be428ea614cef6b5f0cfdc_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i150e9865322b40bf976dd456472c9667_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:NumberOfShortTermTimeDepositPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Cash, cash equivalents and short-term time deposits - Narrative (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails",
     "shortName": "Cash, cash equivalents and short-term time deposits - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i150e9865322b40bf976dd456472c9667_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:NumberOfShortTermTimeDepositPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - General information",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.molecularpartners.com/role/Generalinformation",
     "shortName": "General information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i92a813a501bc4b9b8b3d48933008d151_I20220831",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Shareholders\u2019 equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails",
     "shortName": "Shareholders\u2019 equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i92a813a501bc4b9b8b3d48933008d151_I20220831",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Shareholders\u2019 equity - Classes of Share Capital (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails",
     "shortName": "Shareholders\u2019 equity - Classes of Share Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i226a1800b6a24a9ab618c75812acf641_I20220413",
      "decimals": "0",
      "lang": "en-US",
      "name": "moln:MaximumAmountOfShareCapitalIncreaseAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Shareholders' equity - Shares Issued (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails",
     "shortName": "Shareholders' equity - Shares Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "idf47a840ebe6464b88b9919b66cddf6c_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "moln:NumberOfSharesIssuedInRelationToCapitalRaiseEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails",
     "shortName": "Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails",
     "shortName": "Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "if10f3857f8be428ea614cef6b5f0cfdc_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "moln:CurrentAccruedProjectCostsAndRoyalties",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Accrued expenses (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.molecularpartners.com/role/AccruedexpensesDetails",
     "shortName": "Accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Contract liability - Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails",
     "shortName": "Contract liability - Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Contract liability - Explanation of Changes in Contract Liabilities (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails",
     "shortName": "Contract liability - Explanation of Changes in Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "moln:IncreaseThroughAdditionsContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Contract liability - Additional Information (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
     "shortName": "Contract liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentContractLiabilities",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Contract liability - Disclosure of Current and Non-Current Contract Liabilities (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
     "shortName": "Contract liability - Disclosure of Current and Non-Current Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ie9c25c613d894005a9d3a3b959ee5252_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of significant accounting policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Additional information on the nature of expenses (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
     "shortName": "Additional information on the nature of expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "moln:CurrentAccruedProjectCostsAndRoyalties",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Royalties and license fees (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails",
     "shortName": "Royalties and license fees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i7a203c5105214474a5a6e65a376ecbc6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails",
     "shortName": "Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "1",
      "first": true,
      "lang": "en-US",
      "name": "moln:AverageNumberOfFullTimeEquivalentEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails",
     "shortName": "Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "1",
      "first": true,
      "lang": "en-US",
      "name": "moln:AverageNumberOfFullTimeEquivalentEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails",
     "shortName": "Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
     "shortName": "Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Personnel expenses - Additional Information (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
     "shortName": "Personnel expenses - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i029630cbc287400e8ebdacf4da90e321_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "moln:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
     "shortName": "Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "moln:ExpectedDividendOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chfPerShare",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails",
     "shortName": "Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails",
     "shortName": "Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Financial risk management",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.molecularpartners.com/role/Financialriskmanagement",
     "shortName": "Financial risk management",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails",
     "shortName": "Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i87e1420800e8425c9cfd768d4f41a8c0_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails",
     "shortName": "Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NetForeignExchangeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails",
     "shortName": "Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NetForeignExchangeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Taxes - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails",
     "shortName": "Taxes - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i0d4f4b9eeead491d9cf2cc19fe9ead53_D20220101-20221231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "moln:NetOperatingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Taxes - Deferred Taxes (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
     "shortName": "Taxes - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "moln:NetOperatingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ic0d265762d384de3bc912a8791ed2b7f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "moln:TaxLossCarryforwards",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails",
     "shortName": "Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ie9e4c0c2414646e3920288a6e3d93b50_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "moln:TaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Earnings per share (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.molecularpartners.com/role/EarningspershareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashOutflowForLeases",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.molecularpartners.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "ie5811d9f19074f96a9cbb5482d36febc_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "moln:LeaseExtensionTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i45ab5095fb4e4ae7a889842f6c1990cc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Leases - Disclosure of Movement of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails",
     "shortName": "Leases - Disclosure of Movement of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "moln:IncreaseThroughNewLeasesOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails",
     "shortName": "Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moln-20221231.htm",
      "contextRef": "i04204c7cbed9404ea3c8a49005d5af3a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "chf",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 96,
   "tag": {
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Revenues Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Revenues USA"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "CHF",
        "verboseLabel": "CHF Positions"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "EUR",
        "verboseLabel": "EUR Positions"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD",
        "verboseLabel": "USD Positions"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r48",
      "r289",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates [member]",
        "terseLabel": "Actuarial assumption of discount rates"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases",
        "terseLabel": "Future salary increases at December 31"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of salary increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases [member]",
        "terseLabel": "Actuarial assumption of expected rates of salary increases"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the life expectancy after retirement used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of life expectancy after retirement [member]",
        "terseLabel": "Actuarial assumption of life expectancy"
       }
      }
     },
     "localname": "ActuarialAssumptionOfLifeExpectancyAfterRetirementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [axis]",
        "terseLabel": "Actuarial assumptions [axis]"
       }
      }
     },
     "localname": "ActuarialAssumptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [member]",
        "terseLabel": "Actuarial assumptions [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 2.0,
       "parentTag": "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net of tax, defined benefit plans",
        "negatedTerseLabel": "Actuarial (gain) / loss on changes in demographic assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 3.0,
       "parentTag": "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in financial assumptions, net of tax, defined benefit plans",
        "negatedTerseLabel": "Actuarial (gain) / loss on changes in financial assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 1.0,
       "parentTag": "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from experience adjustments, net of tax, defined benefit plans",
        "negatedTerseLabel": "Actuarial (gain) / loss arising from experience adjustments"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      },
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidinCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      },
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidinCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "terseLabel": "Weighted average number of shares used in computing diluted loss per share (in shares)"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other current assets",
        "terseLabel": "Change in other current assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Change in trade and other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Financial expenses"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedTerseLabel": "Financial income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "AdjustmentsForIncomeTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in contract liabilities",
        "terseLabel": "Change in contract liability"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in employee benefit liabilities",
        "terseLabel": "Change in employee benefits"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Change in trade and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments for:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation costs"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": {
       "order": 5.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of administration costs in the current period related to defined benefit plans that are not reflected in the return on plan assets. [Refer: Administrative expenses; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets; Return on plan assets excluding interest income or expense, net of tax, defined benefit plans; Return on plan assets excluding interest income or expense, before tax, defined benefit plans]"
       }
      },
      "en-us": {
       "role": {
        "label": "Administration costs not reflected in return on plan assets, defined benefit plans",
        "terseLabel": "Administrative cost excl. cost for managing plan assets"
       }
      }
     },
     "localname": "AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdministrativeExpense": {
     "auth_ref": [
      "r34",
      "r75",
      "r216"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity classifies as being administrative."
       }
      },
      "en-us": {
       "role": {
        "label": "Administrative expenses",
        "negatedTerseLabel": "Other administrative expenses"
       }
      }
     },
     "localname": "AdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r16",
      "r133",
      "r143",
      "r144",
      "r162",
      "r200",
      "r201",
      "r202",
      "r208",
      "r230",
      "r253",
      "r256"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails",
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r61",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "negatedTerseLabel": "Amortization charge for the year"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Applicable tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r14",
      "r122",
      "r123",
      "r124",
      "r189",
      "r192"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "auth_ref": [
      "r278",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]",
        "terseLabel": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic net result per share (in CHF per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_CapitalCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital commitments [abstract]"
       }
      }
     },
     "localname": "CapitalCommitmentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r41",
      "r45",
      "r84",
      "r88",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r158",
      "r168",
      "r169",
      "r311",
      "r312"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r45",
      "r88",
      "r92",
      "r94",
      "r95",
      "r158",
      "r168",
      "r169",
      "r264",
      "r265"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r12",
      "r104",
      "r119"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at December 31",
        "periodStartLabel": "Cash and cash equivalents at January 1",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_PlanAssetsAtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount cash and cash equivalents contribute to the fair value of defined benefit plan assets. [Refer: Cash and cash equivalents; Plan assets, at fair value; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents, amount contributed to fair value of plan assets",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r97",
      "r106"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash (used in) from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r97",
      "r106"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r106"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash from (used in) operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedLabel": "Payments",
        "terseLabel": "Cash outflow for leases"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]",
        "terseLabel": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]",
        "terseLabel": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in net defined benefit liability (asset) [abstract]",
        "terseLabel": "Reconciliation of net defined benefit liability"
       }
      }
     },
     "localname": "ChangesInNetDefinedBenefitLiabilityAssetAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in number of shares outstanding [abstract]",
        "terseLabel": "Changes in number of shares outstanding [abstract]"
       }
      }
     },
     "localname": "ChangesInNumberOfSharesOutstandingAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r199",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]",
        "terseLabel": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r168",
      "r171",
      "r173",
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]",
        "terseLabel": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r168",
      "r171",
      "r173",
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]",
        "terseLabel": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r199",
      "r210"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]",
        "terseLabel": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]",
        "terseLabel": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of plan assets, fair value monetary amounts [abstract]",
        "terseLabel": "Plan asset classes"
       }
      }
     },
     "localname": "ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that are or may be reclassified subsequently to profit or loss"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that will not be reclassified to profit or loss"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r2",
      "r29",
      "r109",
      "r111",
      "r116",
      "r242"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Comprehensive income (loss)",
        "totalLabel": "Total comprehensive result, attributable to shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "IT hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComputerSoftwareMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer software [member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r126",
      "r129"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "periodEndLabel": "Contract liability at end of period",
        "periodStartLabel": "Contract liability at beginning of period",
        "terseLabel": "Contract liability",
        "totalLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContractLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract liabilities [abstract]"
       }
      }
     },
     "localname": "ContractLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer",
        "negatedLabel": "Contributions by the employer",
        "terseLabel": "Contributions by the employer"
       }
      }
     },
     "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants",
        "negatedLabel": "Contributions by plan participants",
        "terseLabel": "Contributions by plan participants"
       }
      }
     },
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]",
        "terseLabel": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [member]",
        "terseLabel": "Counterparties [member]"
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r251"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit risk [member]",
        "terseLabel": "Credit risk"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r184",
      "r203",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AccruedexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AccruedexpensesDetails",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/OthercurrentassetsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current accrued income other than current contract assets. [Refer: Accrued income other than contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current accrued income other than current contract assets",
        "terseLabel": "Accrued income"
       }
      }
     },
     "localname": "CurrentAccruedIncomeOtherThanCurrentContractAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/OthercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r17",
      "r112",
      "r242"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Current",
        "verboseLabel": "Contract liability"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liability",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r18",
      "r114",
      "r242"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current payables on social security and taxes other than income tax",
        "terseLabel": "Social security"
       }
      }
     },
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/OthercurrentassetsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/OthercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/OthercurrentassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and current accrued income, other than current contract assets. [Refer: Prepayments; Accrued income other than contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepayments and current accrued income other than current contract assets",
        "totalLabel": "Prepaid expenses and accrued income"
       }
      }
     },
     "localname": "CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/OthercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current receivables from taxes other than income tax",
        "terseLabel": "Withholding tax"
       }
      }
     },
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentServiceCostDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": {
       "order": 2.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current service cost, defined benefit plans",
        "terseLabel": "Current service cost (employer)"
       }
      }
     },
     "localname": "CurrentServiceCostDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase in net defined benefit liability (asset) resulting from current service cost",
        "terseLabel": "Current service cost (employer)"
       }
      }
     },
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax expense (income)"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r218",
      "r220"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxPayables": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current value added tax payables",
        "terseLabel": "Value added tax"
       }
      }
     },
     "localname": "CurrentValueAddedTaxPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current value added tax receivables",
        "terseLabel": "Value added tax"
       }
      }
     },
     "localname": "CurrentValueAddedTaxReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_PlanAssetsAtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount instruments representing debt (rather than equity) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Debt instruments, amount contributed to fair value of plan assets",
        "terseLabel": "Debt instruments (e.g. bonds)"
       }
      }
     },
     "localname": "DebtInstrumentsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through performance obligation being satisfied, contract liabilities",
        "negatedTerseLabel": "Recognized as revenue",
        "terseLabel": "Recognized as revenue"
       }
      }
     },
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, at present value",
        "terseLabel": "Defined benefit obligation at December 31"
       }
      }
     },
     "localname": "DefinedBenefitObligationAtPresentValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]",
        "terseLabel": "Defined benefit plans [axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [member]",
        "terseLabel": "Defined benefit plans [member]"
       }
      }
     },
     "localname": "DefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r34",
      "r120",
      "r187",
      "r194",
      "r215"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedTerseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44",
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "negatedTerseLabel": "Depreciation charge for the year"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": {
       "order": 1.0,
       "parentTag": "moln_LeaseCostRecognisedInProfitOrLoss",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "terseLabel": "Depreciation on right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "terseLabel": "Financial assets at amortized costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "terseLabel": "Financial liabilities at amortized costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation / transactions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of non-financial assets [text block]",
        "terseLabel": "Impairment of non-financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]\nEffective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for issued capital [text block]",
        "terseLabel": "Share capital / Additional paid-in capital"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.\nEffective 2023-01-01: The description of the entity's material accounting policy information for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]\nEffective 2023-01-01: The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for treasury shares [text block]",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of the entity's own transferable financial instruments that are included in the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Financial instruments, class [member]; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's own financial instruments included in fair value of plan assets",
        "terseLabel": "thereof entity's own transferable financial instruments"
       }
      }
     },
     "localname": "DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "New or revised IFRS standards and interpretations"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted net result per share (in CHF per share)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Critical accounting estimates and judgments"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Criticalaccountingestimatesandjudgments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accrued expenses and other liabilities [text block]",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Accruedexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of additional information about leasing activities of a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of additional information about leasing activities for lessee [text block]",
        "terseLabel": "Disclosure of Expenses Recognised in Profit or Loss"
       }
      }
     },
     "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory": {
     "auth_ref": [
      "r278",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of attribution of expenses by nature to line items by function in the statement of profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [text block]",
        "terseLabel": "Disclosure of Attribution of Expenses by Nature"
       }
      }
     },
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [line items]",
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]"
       }
      }
     },
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": {
     "auth_ref": [
      "r278",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [table]",
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]"
       }
      }
     },
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Disclosure of issuance of shares"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Capital commitments"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Capitalcommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [text block]",
        "terseLabel": "Putative Class Action"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PutativeClassAction"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureExplanatory": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity\u2019s financial assets and commitments to extend credit."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [text block]",
        "terseLabel": "Disclosure of Maximum Credit Risk Exposure"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [line items]",
        "terseLabel": "Disclosure of credit risk exposure [line items]"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureTable": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the credit risk exposure."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [table]",
        "terseLabel": "Disclosure of credit risk exposure [table]"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [text block]",
        "terseLabel": "Disclosure of Reconciliation of Changes in Intangible Assets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Disclosure of Reconciliation of Changes in Property, Plant and Equipment",
        "verboseLabel": "Disclosure of Useful Lives of Property, Plant and Equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentTables",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Disclosure of Revenue by Country and by Major Alliance Partner"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Earningspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Additional information on the nature of expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Financial income and financial expense"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Financialincomeandfinancialexpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [text block]",
        "terseLabel": "Disclosure of Financial Assets at Amortized Cost"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Financialinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r164",
      "r171",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Disclosure of Financial Liabilities at Amortized Cost"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Financial risk management"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Financialriskmanagement",
      "http://www.molecularpartners.com/role/Financialriskmanagement_1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]",
        "terseLabel": "Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Intangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]",
        "terseLabel": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [text block]",
        "terseLabel": "Disclosure of Contractual Maturities of Financial Liabilities"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [line items]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [table]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [text block]",
        "terseLabel": "Disclosure of Net Defined Benefit Liability (Asset)"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [line items]",
        "terseLabel": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [table]",
        "terseLabel": "Disclosure of net defined benefit liability (asset) [table]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [text block]",
        "terseLabel": "Events after the balance sheet date"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of notes and other explanatory information [text block]",
        "terseLabel": "General information"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Generalinformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Disclosure of Movements in the Number of PSUs and RSUs"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Disclosure of Movements in the Number of Share Options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Propertyplantandequipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Relatedpartydisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenues, other income and and entity-wide disclosures"
       }
      }
     },
     "localname": "DisclosureOfRevenueExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Revenuesotherincomeandandentitywidedisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Contractliability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Shareholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Tradeandotherpayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other receivables [text block]",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/Tradeandotherreceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]",
        "terseLabel": "Disclosure of Expected Revenue Recognition Analysis for Contract Liabilities"
       }
      }
     },
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [line items]",
        "terseLabel": "Disclosure of transaction price allocated to remaining performance obligations [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [table]",
        "terseLabel": "Disclosure of transaction price allocated to remaining performance obligations [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Disclosure of Compensation Costs of Key Management"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedTerseLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedTerseLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Summary of Weighted Average Number of Shares Used in Computation"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Exchange gain (loss) on cash positions"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r34",
      "r215"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "negatedTerseLabel": "Personnel expenses",
        "negatedTotalLabel": "Personnel expenses"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r14",
      "r22",
      "r108",
      "r110",
      "r122",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity at end of period",
        "periodStartLabel": "Equity at beginning of period",
        "terseLabel": "Equity",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity [abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total shareholders' equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "Shareholders' equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_PlanAssetsAtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount instruments representing equity (rather than debt) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity instruments, amount contributed to fair value of plan assets",
        "terseLabel": "Equity instruments"
       }
      }
     },
     "localname": "EquityInstrumentsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimate of contributions expected to be paid to plan for next annual reporting period",
        "terseLabel": "Contributions by the employer"
       }
      }
     },
     "localname": "EstimateOfContributionsExpectedToBePaidToPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price of outstanding share options (in CHF per share)"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "negatedTerseLabel": "Share-based compensation (non-cash effective)",
        "terseLabel": "Share-based compensation (non-cash effective)"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": {
       "order": 3.0,
       "parentTag": "moln_LeaseCostRecognisedInProfitOrLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "terseLabel": "Short term leases"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Explanation of Changes in Contract Liabilities"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0
      },
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedTerseLabel": "Financial expenses",
        "negatedTotalLabel": "Finance costs"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Financial income",
        "totalLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeCost": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "totalLabel": "Net finance result"
       }
      }
     },
     "localname": "FinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r163",
      "r168",
      "r169",
      "r173",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, category [member]",
        "terseLabel": "Financial assets at amortized costs"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]",
        "terseLabel": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r177",
      "r178",
      "r199",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]",
        "terseLabel": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r181",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, category [member]",
        "terseLabel": "Financial liabilities at amortized cost"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]",
        "terseLabel": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r177",
      "r178",
      "r199",
      "r210"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]",
        "terseLabel": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income",
        "negatedLabel": "Remeasurement of net pension liabilities",
        "negatedTerseLabel": "Actuarial (gain)/loss on defined benefit obligation"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r197",
      "r225",
      "r246",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]",
        "terseLabel": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r197",
      "r225",
      "r246",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r41",
      "r84",
      "r93",
      "r96",
      "r158",
      "r169",
      "r173",
      "r252",
      "r311",
      "r312"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r141",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "terseLabel": "Total contractual cashflows"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r32",
      "r36",
      "r37",
      "r38",
      "r76",
      "r121",
      "r188"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedTerseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r103",
      "r235"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedTerseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from administration costs in the current period, that are not reflected in return on plan assets. [Refer: Administrative expenses; Net defined benefit liability (asset)] [Contrast: Administration costs not reflected in return on plan assets, defined benefit plans; Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets",
        "terseLabel": "Administrative cost (excl. cost for managing plan assets)"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss",
        "terseLabel": "Defined benefit cost recognized in profit or loss"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Exercise of stock options, net of transaction costs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation costs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Issuance of treasury shares incl. transaction costs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r10",
      "r88"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Intangible assets at end of period",
        "periodStartLabel": "Intangible assets at beginning of period",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r89",
      "r233",
      "r248"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible assets other than goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/IntangibleassetsDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpenseDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": {
       "order": 1.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense, defined benefit plans",
        "terseLabel": "Interest expense on defined benefit obligation"
       }
      }
     },
     "localname": "InterestExpenseDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseIncomeDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense (income) arising from defined benefit plans. [Refer: Interest income (expense); Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense (income), defined benefit plans",
        "terseLabel": "thereof net interest expense on the net defined benefit liability"
       }
      }
     },
     "localname": "InterestExpenseIncomeDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)",
        "negatedLabel": "Interest income on plan assets",
        "terseLabel": "Interest expenses on defined benefit obligation"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": {
       "order": 2.0,
       "parentTag": "moln_LeaseCostRecognisedInProfitOrLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedTerseLabel": "Interest expense on leases",
        "terseLabel": "Interest expense on lease liabilities",
        "verboseLabel": "Recognition of interest on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": {
       "order": 3.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income arising from defined benefit plans. [Refer: Interest income; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income, defined benefit plans",
        "negatedTerseLabel": "Interest income on plan assets"
       }
      }
     },
     "localname": "InterestIncomeDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from interest for financial assets that are measured at amortised cost. [Refer: Interest income; Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest revenue for financial assets measured at amortised cost",
        "terseLabel": "Interest income on financial assets held at amortized costs"
       }
      }
     },
     "localname": "InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestRateRiskMember": {
     "auth_ref": [
      "r184",
      "r203",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate risk [member]",
        "terseLabel": "Interest rate risk"
       }
      }
     },
     "localname": "InterestRateRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as investing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as investing activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issuance of new shares, net of transaction costs"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Key management personnel compensation costs"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Post-employment benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresDisclosureofCompensationCostsofKeyManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r208",
      "r253",
      "r255",
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "More than 5 years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r208",
      "r253",
      "r257",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than two years [member]",
        "terseLabel": "Expected revenue recognition in year two after balance sheet date",
        "verboseLabel": "Between 1 and 2 years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r208",
      "r253",
      "r257",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three years and not later than four years [member]",
        "terseLabel": "Expected revenue recognition in year four after balance sheet date"
       }
      }
     },
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two years and not later than five years [member]",
        "terseLabel": "Between 2 and 5 years"
       }
      }
     },
     "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r208",
      "r253",
      "r257",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two years and not later than three years [member]",
        "terseLabel": "Expected revenue recognition in year three after balance sheet date"
       }
      }
     },
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "Lease liabilities at end of period",
        "periodStartLabel": "Lease liabilities at beginning of period",
        "terseLabel": "Carrying Amount lease liabilities",
        "totalLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]",
        "terseLabel": "Lease liabilities [abstract]"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      },
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r61",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]",
        "terseLabel": "Quoted market price"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Non-quoted market price"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r61",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r14",
      "r122",
      "r123",
      "r124",
      "r189",
      "r193"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset)",
        "negatedPeriodEndLabel": "Fair value of plan assets at December 31",
        "negatedPeriodStartLabel": "Fair value of plan assets at January 1",
        "periodEndLabel": "Net defined benefit liability at December 31",
        "periodStartLabel": "Net defined benefit liability at January 1",
        "terseLabel": "Net defined benefit liability (asset)",
        "totalLabel": "Net defined benefit liability at December 31"
       }
      }
     },
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "auth_ref": [
      "r278",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Line items by function [member]",
        "terseLabel": "Line items by function [member]"
       }
      }
     },
     "localname": "LineItemsByFunctionMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r16",
      "r133",
      "r143",
      "r144",
      "r162",
      "r176",
      "r200",
      "r201",
      "r202",
      "r208",
      "r230",
      "r253"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails",
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "auth_ref": [
      "r170",
      "r213"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk",
        "terseLabel": "Maximum exposure to credit risk"
       }
      }
     },
     "localname": "MaximumExposureToCreditRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset) [axis]",
        "terseLabel": "Net defined benefit liability (asset) [axis]"
       }
      }
     },
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset) [member]",
        "terseLabel": "Net defined benefit liability (asset) [member]"
       }
      }
     },
     "localname": "NetDefinedBenefitLiabilityAssetMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NetForeignExchangeGain": {
     "auth_ref": [
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Net foreign exchange gain"
       }
      }
     },
     "localname": "NetForeignExchangeGain",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "auth_ref": [
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss",
        "negatedTerseLabel": "Net foreign exchange loss"
       }
      }
     },
     "localname": "NetForeignExchangeLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r17",
      "r113",
      "r242"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Non-current",
        "verboseLabel": "Contract liability"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liability",
        "verboseLabel": "Non-current"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r18",
      "r115",
      "r242"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions for employee benefits",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r15",
      "r143",
      "r144",
      "r208",
      "r253",
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Expected revenue recognition in year one after balance sheet date",
        "verboseLabel": "Less than 1 year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfEmployees": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of employees",
        "terseLabel": "Headcount at year end"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "terseLabel": "Number of instruments granted (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r157",
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSU and PSU granted (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Number of PSUs and RSUs exercisable (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedTerseLabel": "Number of PSU and RSU exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments expired in share-based payment arrangement",
        "negatedTerseLabel": "Number of PSU and RSU expired (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Number of PSU and RSU forfeited (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of PSU and RSU outstanding at end of period (in shares)",
        "periodStartLabel": "Number of PSU and RSU outstanding at beginning of period (in shares)",
        "terseLabel": "Number of PSUs and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r147",
      "r152",
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of share options outstanding at end of period (in shares)",
        "periodStartLabel": "Number of share options outstanding at beginning of period (in shares)",
        "terseLabel": "Number of share options outstanding (in shares)"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Number of share options exercisable (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedTerseLabel": "Number of share options exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "negatedTerseLabel": "Number of share options expired (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Number of share options forfeited (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of share options granted (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Shares in issue at end of period",
        "periodStartLabel": "Shares in issue at start of period",
        "terseLabel": "Number of shares outstanding (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails",
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OccupancyExpense": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from occupancy services received by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Occupancy expense",
        "negatedTerseLabel": "Facility expenses"
       }
      }
     },
     "localname": "OccupancyExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r78",
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Common shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_PlanAssetsAtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount other types of assets not separately disclosed contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets, amount contributed to fair value of plan assets",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAssetsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r28",
      "r33",
      "r118"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "totalLabel": "Other comprehensive result, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive result"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r19",
      "r33"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Exchange differences on translating foreign operations",
        "verboseLabel": "Exchange differences on translating foreign operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r19",
      "r33",
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans",
        "negatedTotalLabel": "Remeasurement of net pension liabilities",
        "terseLabel": "Remeasurement of net pension liabilities, net of tax",
        "verboseLabel": "Remeasurement of net pension liabilities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans [abstract]",
        "terseLabel": "Reconciliation of amount recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AccruedexpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEmployeeExpense": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other employee expense",
        "negatedTerseLabel": "Other personnel expenses"
       }
      }
     },
     "localname": "OtherEmployeeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceCost": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance cost",
        "negatedTerseLabel": "Other financial expenses"
       }
      }
     },
     "localname": "OtherFinanceCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r74",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as operating activities",
        "terseLabel": "Other financial expense"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Par value per share (in CHF per share)"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails",
      "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PastServiceCostDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": {
       "order": 4.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense (income) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Past service cost, defined benefit plans",
        "terseLabel": "Past service cost"
       }
      }
     },
     "localname": "PastServiceCostDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost",
        "terseLabel": "Past service cost"
       }
      }
     },
     "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan",
        "negatedLabel": "Benefits (paid)/deposited",
        "terseLabel": "Benefits (paid)/deposited"
       }
      }
     },
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payment of lease liabilities"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedTerseLabel": "Investments in treasury shares"
       }
      }
     },
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible decrease in actuarial assumption",
        "negatedTerseLabel": "Percentage of reasonably possible decrease in actuarial assumption"
       }
      }
     },
     "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible increase in actuarial assumption",
        "terseLabel": "Percentage of reasonably possible increase in actuarial assumption"
       }
      }
     },
     "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets, at fair value",
        "terseLabel": "Fair value of plan assets at December 31",
        "totalLabel": "Total plan assets at fair value at December 31"
       }
      }
     },
     "localname": "PlanAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PlanAssetsMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets [member]",
        "terseLabel": "Plan assets"
       }
      }
     },
     "localname": "PlanAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "auth_ref": [
      "r290",
      "r295"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense in profit or loss, defined benefit plans",
        "negatedTerseLabel": "Pension costs",
        "totalLabel": "Defined benefit cost recognized in profit or loss"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense in profit or loss, defined benefit plans [abstract]",
        "terseLabel": "Components of defined benefit cost in profit or loss"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlansAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PresentValueOfDefinedBenefitObligationMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Present value of defined benefit obligation [member]",
        "terseLabel": "Defined benefit obligation"
       }
      }
     },
     "localname": "PresentValueOfDefinedBenefitObligationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of stock options, net of transaction costs",
        "verboseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from issuance of new shares, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r3",
      "r27",
      "r99",
      "r109",
      "r111",
      "r189",
      "r191",
      "r242",
      "r260",
      "r263"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net result attributable to shareholders",
        "totalLabel": "Net result, attributable to shareholders",
        "verboseLabel": "Net result"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r159",
      "r215",
      "r216",
      "r258",
      "r259"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Result before income taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r232",
      "r287"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating result"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_PlanAssetsAtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount real estate contributes to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Real estate, amount contributed to fair value of plan assets",
        "terseLabel": "Real estate funds"
       }
      }
     },
     "localname": "PropertyAmountContributedToFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r9",
      "r45"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r46",
      "r233",
      "r248"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails",
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Acquisition of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Acquisition of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r125",
      "r155",
      "r202",
      "r243",
      "r244",
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r125",
      "r155",
      "r202",
      "r243",
      "r244",
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [member]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]",
        "terseLabel": "Related party transactions [abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedTerseLabel": "Research and development expenses",
        "negatedTotalLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Cumulative losses"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r7",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Cumulative losses"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, resulting from the return on plan assets, excluding amounts included in interest expense (income) arising from defined benefit plans. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Return on plan assets excluding interest income or expense, net of tax, defined benefit plans",
        "negatedTerseLabel": "Return on plan assets excluding interest income"
       }
      }
     },
     "localname": "ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense",
        "terseLabel": "Return on plan assets excl. interest income"
       }
      }
     },
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Revenue": {
     "auth_ref": [
      "r30",
      "r117",
      "r159",
      "r186",
      "r190",
      "r195",
      "r196",
      "r198",
      "r215",
      "r216",
      "r242"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue",
        "totalLabel": "Total revenues and other income"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]",
        "terseLabel": "Revenues and other income"
       }
      }
     },
     "localname": "RevenueAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues from research and development collaborations"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyCountryDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue that was included in contract liability balance at beginning of period",
        "terseLabel": "Revenue that was included in contract liability balance at beginning of period"
       }
      }
     },
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RoyaltyExpense": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from royalties."
       }
      },
      "en-us": {
       "role": {
        "label": "Royalty expense",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedTerseLabel": "Selling, general and administrative expenses",
        "negatedTotalLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r278",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount of expense relating to selling, general and administrative activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense [member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sensitivity analysis for types of market risk [text block]",
        "terseLabel": "Sensitivity Analysis to Reasonable Possible Change in Exchange Rates and Interest Rates"
       }
      }
     },
     "localname": "SensitivityAnalysisForEachTypeOfMarketRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_ServicesReceivedRelatedPartyTransactions": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Services received, related party transactions",
        "terseLabel": "Related party fees"
       }
      }
     },
     "localname": "ServicesReceivedRelatedPartyTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, not classified as cash equivalents",
        "terseLabel": "Short-term time deposits"
       }
      }
     },
     "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/AccruedexpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits accruals",
        "terseLabel": "Accrued payroll and bonuses"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SocialSecurityContributions": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Social security contributions",
        "negatedTerseLabel": "Social security costs"
       }
      }
     },
     "localname": "SocialSecurityContributions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of IFRS compliance [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "StatementOfIFRSCompliance",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables",
        "totalLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r219",
      "r285"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r11",
      "r20"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      },
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade and other receivables",
        "totalLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r167",
      "r172",
      "r252",
      "r281"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transaction price allocated to remaining performance obligations",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r77",
      "r221"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedTerseLabel": "Treasury share reserve"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares [member]",
        "terseLabel": "Treasury share reserve"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfContractsAxis": {
     "auth_ref": [
      "r247",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [axis]",
        "terseLabel": "Types of contracts [axis]"
       }
      }
     },
     "localname": "TypesOfContractsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfContractsMember": {
     "auth_ref": [
      "r247",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [member]",
        "terseLabel": "Types of contracts [member]"
       }
      }
     },
     "localname": "TypesOfContractsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r161",
      "r165",
      "r166",
      "r203",
      "r204",
      "r205",
      "r207"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r161",
      "r165",
      "r166",
      "r203",
      "r204",
      "r205",
      "r207"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, intangible assets other than goodwill",
        "terseLabel": "Applicable estimated useful lives, intangible assets"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, property, plant and equipment",
        "terseLabel": "Applicable estimated useful lives, property, plant and equipment"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WagesAndSalaries": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "negatedTerseLabel": "Salaries"
       }
      }
     },
     "localname": "WagesAndSalaries",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average duration of defined benefit obligation",
        "terseLabel": "Weighted average duration of defined obligation in years at December 31"
       }
      }
     },
     "localname": "WeightedAverageDurationOfDefinedBenefitObligation2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of PSU and RSU exercised (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments expired in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of PSU and RSU expired (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of PSU and RSU forfeited (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price (in CHF per shares)",
        "verboseLabel": "Weighted average exercise price of PSU and RSU granted (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price of PSU and RSU outstanding at end of period (in CHF per share)",
        "periodStartLabel": "Weighted average exercise price of PSU and RSU outstanding at beginning of period (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of share options exercised (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of share options expired (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of share options forfeited (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of share options granted (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r147",
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price of share options outstanding at end of period (in CHF per share)",
        "periodStartLabel": "Weighted average exercise price of share options outstanding at beginning of period (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of shares used in computing basic loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.molecularpartners.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 License And Collaboration Agreement With Novartis, DARPIN Conjugated Radioligand Therapies",
        "label": "2021 License And Collaboration Agreement With Novartis, DARPIN Conjugated Radioligand Therapies [Member]",
        "terseLabel": "Licence and Collaboration Agreement with Novartis"
       }
      }
     },
     "localname": "A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_AccruedIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Income",
        "label": "Accrued Income [Member]",
        "terseLabel": "Accrued income"
       }
      }
     },
     "localname": "AccruedIncomeMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_AccruedProjectCostsAndRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Project Costs And Royalties",
        "label": "Accrued Project Costs And Royalties [Member]",
        "terseLabel": "Accrued project costs and royalties"
       }
      }
     },
     "localname": "AccruedProjectCostsAndRoyaltiesMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_AccruedSabbaticalCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sabbatical Cost",
        "label": "Accrued Sabbatical Cost",
        "terseLabel": "Accrued sabbatical cost"
       }
      }
     },
     "localname": "AccruedSabbaticalCost",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_ActiveMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Active Members",
        "label": "Active Members [Member]",
        "terseLabel": "Active members"
       }
      }
     },
     "localname": "ActiveMembersMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumption Of Interest Rate On Retirement Savings Capital",
        "label": "Actuarial Assumption Of Interest Rate On Retirement Savings Capital [Member]",
        "terseLabel": "Actuarial assumption of interest rate on retirement savings capital"
       }
      }
     },
     "localname": "ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ActuarialAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumptions",
        "label": "Actuarial Assumptions [Abstract]",
        "terseLabel": "Actuarial assumptions"
       }
      }
     },
     "localname": "ActuarialAssumptionsAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories",
        "label": "Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories",
        "terseLabel": "Actuarial assumptions, possible increase (decrease) in longevity for most of the age categories"
       }
      }
     },
     "localname": "ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans",
        "label": "Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans",
        "negatedTotalLabel": "Actuarial (gain)/loss on defined benefit obligation"
       }
      }
     },
     "localname": "ActuarialGainsLossesNetOfTaxDefinedBenefitPlans",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment For Exchange Gains (Losses) On Working Capital Positions",
        "label": "Adjustment For Exchange Gains (Losses) On Working Capital Positions",
        "negatedTerseLabel": "Exchange (loss) gain on working capital positions"
       }
      }
     },
     "localname": "AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Increase (Decrease) In Accrued Expenses",
        "label": "Adjustments For Increase (Decrease) In Accrued Expenses",
        "terseLabel": "Change in accrued expenses"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInAccruedExpenses",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Shares, The Nasdaq Stock Market LLC",
        "label": "American Depository Shares, The Nasdaq Stock Market LLC [Member]",
        "terseLabel": "American depositary shares (each representing one common share, CHF 0.10 nominal value per share)"
       }
      }
     },
     "localname": "AmericanDepositorySharesTheNasdaqStockMarketLLCMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen, Inc",
        "label": "Amgen, Inc [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_AuthorizedShareCapitalEmployeeParticipation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized Share Capital, Employee Participation",
        "label": "Authorized Share Capital, Employee Participation",
        "terseLabel": "Authorized share capital, employee participation"
       }
      }
     },
     "localname": "AuthorizedShareCapitalEmployeeParticipation",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_AuthorizedShareCapitalFinancingTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized Share Capital, Financing Transactions",
        "label": "Authorized Share Capital, Financing Transactions",
        "terseLabel": "Authorized share capital, financing transactions"
       }
      }
     },
     "localname": "AuthorizedShareCapitalFinancingTransactions",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_AverageNumberOfFullTimeEquivalentEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average Number Of Full-Time Equivalent Employees",
        "label": "Average Number Of Full-Time Equivalent Employees",
        "terseLabel": "Average number of full-time equivalents"
       }
      }
     },
     "localname": "AverageNumberOfFullTimeEquivalentEmployees",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Balances Investments, Number Of Different Swiss Banks",
        "label": "Cash Balances Investments, Number Of Different Swiss Banks",
        "terseLabel": "Number of different Swiss banks"
       }
      }
     },
     "localname": "CashBalancesInvestmentsNumberOfDifferentSwissBanks",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_ChangesInWorkingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Working Capital",
        "label": "Changes In Working Capital [Abstract]",
        "terseLabel": "Changes in working capital:"
       }
      }
     },
     "localname": "ChangesInWorkingCapitalAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_CommercialSupplyOfProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Supply Of Products",
        "label": "Commercial Supply Of Products [Member]",
        "terseLabel": "Commercial supply of products"
       }
      }
     },
     "localname": "CommercialSupplyOfProductsMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ConditionalShareCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional Share Capital",
        "label": "Conditional Share Capital [Member]",
        "terseLabel": "Conditional share capital"
       }
      }
     },
     "localname": "ConditionalShareCapitalMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_CriticalAccountingEstimatesAndJudgmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Critical Accounting Estimates and Judgments [Abstract]",
        "label": "Critical Accounting Estimates and Judgments [Abstract]"
       }
      }
     },
     "localname": "CriticalAccountingEstimatesAndJudgmentsAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_CurrentAccruedProjectCostsAndRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/AccruedexpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Accrued Project Costs And Royalties",
        "label": "Current Accrued Project Costs And Royalties",
        "terseLabel": "Accrued project costs and royalties"
       }
      }
     },
     "localname": "CurrentAccruedProjectCostsAndRoyalties",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AccruedexpensesDetails",
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_DecreaseThroughOffsetOfCostsContractLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease Through Offset Of Costs, Contract Liabilities",
        "label": "Decrease Through Offset Of Costs, Contract Liabilities",
        "negatedTerseLabel": "Offset of costs",
        "terseLabel": "Offset of costs"
       }
      }
     },
     "localname": "DecreaseThroughOffsetOfCostsContractLiabilities",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption",
        "label": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption",
        "terseLabel": "Defined benefit obligation due to reasonably possible decrease in actuarial assumption"
       }
      }
     },
     "localname": "DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption",
        "label": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption",
        "terseLabel": "Defined benefit obligation due to reasonably possible increase in actuarial assumption"
       }
      }
     },
     "localname": "DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_DefinedBenefitPlanEmployeeContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Employee Contribution",
        "label": "Defined Benefit Plan, Employee Contribution",
        "terseLabel": "Defined benefit plan, employee contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanEmployeeContribution",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_DefinedBenefitPlanEmployerContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Employer Contribution",
        "label": "Defined Benefit Plan, Employer Contribution",
        "terseLabel": "Defined benefit plan, employer contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanEmployerContribution",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_DefinedBenefitPlanNumberOfEligibleEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number Of Eligible Employees",
        "label": "Defined Benefit Plan, Number Of Eligible Employees",
        "terseLabel": "Number of eligible employees"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberOfEligibleEmployees",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number Of Employees That Participated",
        "label": "Defined Benefit Plan, Number Of Employees That Participated",
        "terseLabel": "Number of employees that participated"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberOfEmployeesThatParticipated",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Basis Of Consolidation Policy",
        "label": "Description Of Accounting Policy For Basis Of Consolidation Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits",
        "label": "Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits [Text Block]",
        "terseLabel": "Cash, cash equivalents and short-term time deposits"
       }
      }
     },
     "localname": "DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/Cashcashequivalentsandshorttermtimedeposits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory",
        "label": "Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of Accrued Expenses Explanatory"
       }
      }
     },
     "localname": "DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Current And Non-Current Contract Liabilities",
        "label": "Disclosure Of Current And Non-Current Contract Liabilities [Table Text Block]",
        "terseLabel": "Disclosure of Current and Non-Current Contract Liabilities"
       }
      }
     },
     "localname": "DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory",
        "label": "Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits",
        "label": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits",
        "label": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Contract Liability",
        "label": "Disclosure Of Detailed Information About Contract Liability [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Contract Liability [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutContractLiabilityLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutContractLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Contract Liability",
        "label": "Disclosure Of Detailed Information About Contract Liability [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Contract Liability [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutContractLiabilityTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Employee Benefits [Line Items]",
        "label": "Disclosure Of Detailed Information About Employee Benefits [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Employee Benefits [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Employee Benefits [Table]",
        "label": "Disclosure Of Detailed Information About Employee Benefits [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Employee Benefits [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Employee Expenses And Head Count",
        "label": "Disclosure Of Detailed Information About Employee Expenses And Head Count [Table Text Block]",
        "terseLabel": "Disclosure of Detailed Information about Employee Expenses and Head Count"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Financial Expense",
        "label": "Disclosure Of Detailed Information About Financial Expense [Table Text Block]",
        "terseLabel": "Disclosure of Detailed Information about Financial Expense"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Financial Income",
        "label": "Disclosure Of Detailed Information About Financial Income [Table Text Block]",
        "terseLabel": "Disclosure of Detailed Information about Financial Income"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes",
        "label": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails",
      "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes",
        "label": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails",
      "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutLeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Leases [Line Items]",
        "label": "Disclosure Of Detailed Information About Leases [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Leases [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutLeasesLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Leases [Table]",
        "label": "Disclosure Of Detailed Information About Leases [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Leases [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutLeasesTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income",
        "label": "Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income [Table Text Block]",
        "terseLabel": "Disclosure of Other Current Assets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/OthercurrentassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Royalties And License Fees",
        "label": "Disclosure Of Detailed Information About Royalties And License Fees [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Royalties And License Fees [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Royalties And License Fees",
        "label": "Disclosure Of Detailed Information About Royalties And License Fees [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Royalties And License Fees [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Trade And Other Payables",
        "label": "Disclosure Of Detailed Information About Trade And Other Payables [Table Text Block]",
        "terseLabel": "Disclosure of Detailed Information about Trade and Other Payables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherpayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Trade And Other Receivables",
        "label": "Disclosure Of Detailed Information About Trade And Other Receivables [Table Text Block]",
        "terseLabel": "Disclosure of Detailed Information about Trade and Other Receivables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherreceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Employee Benefits And Share-Based Payments Arrangements",
        "label": "Disclosure Of Employee Benefits And Share-Based Payments Arrangements [Text Block]",
        "terseLabel": "Personnel expenses"
       }
      }
     },
     "localname": "DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/Personnelexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments",
        "label": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]",
        "terseLabel": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments",
        "label": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table]",
        "terseLabel": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table]"
       }
      }
     },
     "localname": "DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Exercis Price, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments",
        "label": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table Text Block]",
        "terseLabel": "Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments"
       }
      }
     },
     "localname": "DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Expiry Of Tax Loss Carryforwards",
        "label": "Disclosure Of Expiry Of Tax Loss Carryforwards [Table Text Block]",
        "terseLabel": "Disclosure of Expiry of Tax Loss Carryforwards"
       }
      }
     },
     "localname": "DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfGeneralInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of General Information [Abstract]",
        "label": "Disclosure Of General Information [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Movement Of Lease Liabilities",
        "label": "Disclosure Of Movement Of Lease Liabilities [Table Text Block]",
        "terseLabel": "Disclosure of Movement of Lease Liabilities"
       }
      }
     },
     "localname": "DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Non-Cash Costs For Share-Based Payments By Functions",
        "label": "Disclosure Of Non-Cash Costs For Share-Based Payments By Functions [Table Text Block]",
        "terseLabel": "Disclosure of Non-Cash Costs for Share-Based Payments by Functions"
       }
      }
     },
     "localname": "DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]",
        "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]",
        "terseLabel": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]",
        "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]",
        "terseLabel": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Prepaid Expenses And Accrued Income",
        "label": "Disclosure Of Prepaid Expenses And Accrued Income [Text Block]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/Othercurrentassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits",
        "label": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]",
        "terseLabel": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits",
        "label": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table]",
        "terseLabel": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits",
        "label": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table Text Block]",
        "terseLabel": "Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Royalties And License Fees",
        "label": "Disclosure Of Royalties And License Fees [Text Block]",
        "terseLabel": "Royalties and license fees"
       }
      }
     },
     "localname": "DisclosureOfRoyaltiesAndLicenseFeesTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/Royaltiesandlicensefees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies [Abstract]",
        "label": "Disclosure Of Significant Accounting Policies [Abstract]",
        "terseLabel": "Disclosure Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received",
        "label": "Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received [Table Text Block]",
        "terseLabel": "Disclosure of Timing of Revenue Recognition by Type of Payments Received"
       }
      }
     },
     "localname": "DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moln_DisclosureOfTradeAndOtherPayablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Trade And Other Payables",
        "label": "Disclosure Of Trade And Other Payables [Line Items]",
        "terseLabel": "Disclosure Of Trade And Other Payables [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfTradeAndOtherPayablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Trade And Other Payables",
        "label": "Disclosure Of Trade And Other Payables [Table]",
        "terseLabel": "Disclosure Of Trade And Other Payables [Table]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfTradeAndOtherReceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Trade And Other Receivables [Line Items]",
        "label": "Disclosure Of Trade And Other Receivables [Line Items]",
        "terseLabel": "Disclosure Of Trade And Other Receivables [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesLineItems",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_DisclosureOfTradeAndOtherReceivablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Trade And Other Receivables [Table]",
        "label": "Disclosure Of Trade And Other Receivables [Table]",
        "terseLabel": "Disclosure Of Trade And Other Receivables [Table]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesTable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_ESOP2009AndESOP2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESOP 2009 And ESOP 2014",
        "label": "ESOP 2009 And ESOP 2014 [Member]",
        "terseLabel": "ESOP 2009 and ESOP 2014"
       }
      }
     },
     "localname": "ESOP2009AndESOP2014Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExercicePriceOfOutstandingOtherEquityInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercice Price Of Outstanding Other Equity Instruments",
        "label": "Exercice Price Of Outstanding Other Equity Instruments",
        "terseLabel": "Exercise price of outstanding PSUs and RSUs (in CHF per share)"
       }
      }
     },
     "localname": "ExercicePriceOfOutstandingOtherEquityInstruments",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Four",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "Exercise price, range four"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range One",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "Exercise price, range one"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Three",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "Exercise price, range three"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Two",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "Exercise price, range two"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExpectedDividendOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Dividend, Other Equity Instruments Granted",
        "label": "Expected Dividend, Other Equity Instruments Granted",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "ExpectedDividendOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Volatility On Common Shares, Other Equity Instruments Granted",
        "label": "Expected Volatility On Common Shares, Other Equity Instruments Granted",
        "terseLabel": "Expected volatility on Common shares"
       }
      }
     },
     "localname": "ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Volatility On NBI, Other Equity Instruments Granted",
        "label": "Expected Volatility On NBI, Other Equity Instruments Granted",
        "terseLabel": "Expected volatility on NBI"
       }
      }
     },
     "localname": "ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Volatility On SPI, Other Equity Instruments Granted",
        "label": "Expected Volatility On SPI, Other Equity Instruments Granted",
        "terseLabel": "Expected volatility on SPI"
       }
      }
     },
     "localname": "ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_ExpiringIn2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring In 2023",
        "label": "Expiring In 2023 [Member]",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ExpiringIn2023Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExpiringIn2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring In 2024",
        "label": "Expiring In 2024 [Member]",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ExpiringIn2024Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExpiringIn2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring In 2025",
        "label": "Expiring In 2025 [Member]",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "ExpiringIn2025Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExpiringIn2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring In 2026",
        "label": "Expiring In 2026 [Member]",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "ExpiringIn2026Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExpiringIn2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring In 2027",
        "label": "Expiring In 2027 [Member]",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "ExpiringIn2027Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExpiringIn2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring In 2028",
        "label": "Expiring In 2028 [Member]",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "ExpiringIn2028Member",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ExtendedPeriodOfReservationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended Period Of Reservation Agreement",
        "label": "Extended Period Of Reservation Agreement",
        "terseLabel": "Extended period of reservation agreement"
       }
      }
     },
     "localname": "ExtendedPeriodOfReservationAgreement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_FederalOfficeOfPublicHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Office Of Public Health",
        "label": "Federal Office Of Public Health [Member]",
        "terseLabel": "FOPH"
       }
      }
     },
     "localname": "FederalOfficeOfPublicHealthMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "terseLabel": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_FinancialRiskManagementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Risk Management [Abstract]",
        "label": "Financial Risk Management [Abstract]",
        "terseLabel": "Financial Risk Management [Abstract]"
       }
      }
     },
     "localname": "FinancialRiskManagementAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_FullContractualLifeOtherEquityInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Full Contractual Life, Other Equity Instruments",
        "label": "Full Contractual Life, Other Equity Instruments",
        "terseLabel": "Full contractual life for RSU and PSU"
       }
      }
     },
     "localname": "FullContractualLifeOtherEquityInstruments",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_IncomeTaxesAndDeferredTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes [Abstract]",
        "label": "Income Taxes And Deferred Taxes [Abstract]",
        "terseLabel": "Income Taxes And Deferred Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesAndDeferredTaxesAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_IncreaseDecreaseInAuthorizedShareCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Authorized Share Capital",
        "label": "Increase (Decrease) In Authorized Share Capital",
        "terseLabel": "Increase (decrease) in authorized share capital"
       }
      }
     },
     "localname": "IncreaseDecreaseInAuthorizedShareCapital",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Authorized Share Capital, Employee Participation",
        "label": "Increase (Decrease) In Authorized Share Capital, Employee Participation",
        "terseLabel": "Increase (decrease) in authorized share capital, employee participation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Remeasurements Of Leases, Operating Leases",
        "label": "Increase (Decrease) Through Remeasurements Of Leases, Operating Leases",
        "terseLabel": "Remeasurements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughRemeasurementsOfLeasesOperatingLeases",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_IncreaseThroughAdditionsContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Through Additions, Contract Liabilities",
        "label": "Increase Through Additions, Contract Liabilities",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IncreaseThroughAdditionsContractLiabilities",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_IncreaseThroughNewLeasesOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Through New Leases, Operating Leases",
        "label": "Increase Through New Leases, Operating Leases",
        "terseLabel": "Additions / new leases"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesOperatingLeases",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_IndividualsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individuals",
        "label": "Individuals [Axis]",
        "terseLabel": "Individuals [Axis]"
       }
      }
     },
     "localname": "IndividualsAxis",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_IndividualsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individuals [Domain]",
        "label": "Individuals [Domain]",
        "terseLabel": "Individuals [Domain]"
       }
      }
     },
     "localname": "IndividualsDomain",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_IndustryBenchmarkDiscountRatesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industry Benchmark, Discount Rates, Period",
        "label": "Industry Benchmark, Discount Rates, Period",
        "terseLabel": "Discount rates based on industry benchmark, period"
       }
      }
     },
     "localname": "IndustryBenchmarkDiscountRatesPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share",
        "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share",
        "terseLabel": "Number of potential future dilutive shares (in shares)"
       }
      }
     },
     "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_IntellectualPropertyExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellectual Property Expense",
        "label": "Intellectual Property Expense",
        "negatedTerseLabel": "Intellectual property"
       }
      }
     },
     "localname": "IntellectualPropertyExpense",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_IssuanceCostsOfTreasuryShareTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs of Treasury Share Transactions",
        "label": "Issuance Costs of Treasury Share Transactions",
        "terseLabel": "Transaction costs related to issuance of treasury shares"
       }
      }
     },
     "localname": "IssuanceCostsOfTreasuryShareTransactions",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LaterThanFourYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Later Than Four Years",
        "label": "Later Than Four Years [Member]",
        "terseLabel": "Expected revenue recognition in year five and later after balance sheet date"
       }
      }
     },
     "localname": "LaterThanFourYearsMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofExpectedRevenueRecognitionAnalysisforContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LeaseCostRecognisedInProfitOrLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Cost Recognised In Profit Or Loss",
        "label": "Lease, Cost Recognised In Profit Or Loss",
        "totalLabel": "Total amount recognized in profit or loss"
       }
      }
     },
     "localname": "LeaseCostRecognisedInProfitOrLoss",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_LeaseExtensionOrTerminationOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Extension Or Termination Option, Period",
        "label": "Lease, Extension Or Termination Option, Period",
        "terseLabel": "Lease, extension or termination option, period"
       }
      }
     },
     "localname": "LeaseExtensionOrTerminationOptionPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_LeaseExtensionTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Extension Term Of Contract",
        "label": "Lease, Extension Term Of Contract",
        "terseLabel": "Lease, extension term"
       }
      }
     },
     "localname": "LeaseExtensionTermOfContract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_LeaseFacilitiesSchlierenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Facilities, Schlieren",
        "label": "Lease Facilities, Schlieren [Member]",
        "terseLabel": "Lease facilities, Schlieren"
       }
      }
     },
     "localname": "LeaseFacilitiesSchlierenMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails",
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LeaseTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Term Of Contract",
        "label": "Lease, Term Of Contract",
        "terseLabel": "Lease, term"
       }
      }
     },
     "localname": "LeaseTermOfContract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_LicenseAndCollaborationAgreementWithAmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration Agreement With Amgen, Inc",
        "label": "License And Collaboration Agreement With Amgen, Inc [Member]",
        "terseLabel": "Licence and Collaboration Agreement with Amgen, Inc",
        "verboseLabel": "Amgen Inc., USA"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementWithAmgenIncMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LicenseAndCollaborationAgreementWithFOPHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration Agreement With FOPH",
        "label": "License And Collaboration Agreement With FOPH [Member]",
        "terseLabel": "FOPH, Switzerland"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementWithFOPHMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LicenseAndCollaborationAgreementWithNovartisAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration Agreement With Novartis AG",
        "label": "License And Collaboration Agreement With Novartis AG [Member]",
        "terseLabel": "Novartis AG, Switzerland"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementWithNovartisAGMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_LicenseFeesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees Expense",
        "label": "License Fees Expense",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseFeesExpense",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_MaximumAmountOfShareCapitalIncreaseAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Of Share Capital Increase Authorized",
        "label": "Maximum Amount Of Share Capital Increase Authorized",
        "terseLabel": "Maximum amount of share capital increase authorized"
       }
      }
     },
     "localname": "MaximumAmountOfShareCapitalIncreaseAuthorized",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Of Share Capital Increase Authorized, Number Of Shares",
        "label": "Maximum Amount Of Share Capital Increase Authorized, Number Of Shares",
        "terseLabel": "Maximum amount of share capital increase authorized, number of shares (in shares)"
       }
      }
     },
     "localname": "MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_MaximumAmountOfShareCapitalIncreaseAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Of Share Capital Increase Authorized, Percent",
        "label": "Maximum Amount Of Share Capital Increase Authorized, Percent",
        "terseLabel": "Maximum amount of share capital increase authorized, percent"
       }
      }
     },
     "localname": "MaximumAmountOfShareCapitalIncreaseAuthorizedPercent",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_MolecularPartnersIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Partners Inc.",
        "label": "Molecular Partners Inc. [Member]",
        "terseLabel": "Molecular Partners Inc."
       }
      }
     },
     "localname": "MolecularPartnersIncMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Negative Interest Revenue For Financial Assets Measured At Amortised Cost",
        "label": "Negative Interest Revenue For Financial Assets Measured At Amortised Cost",
        "negatedTerseLabel": "Negative interest on financial assets held at amortized costs"
       }
      }
     },
     "localname": "NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_NetOperatingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Losses",
        "label": "Net Operating Losses",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "NetOperatingLosses",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_NetOperatingProfit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Profit",
        "label": "Net Operating Profit",
        "terseLabel": "Net operating profit"
       }
      }
     },
     "localname": "NetOperatingProfit",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ContractliabilityAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/ContractliabilityDisclosureofCurrentandNonCurrentContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/ContractliabilityExplanationofChangesinContractLiabilitiesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_NumberOfBanksWhereDepositsAreHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Banks Where Deposits Are Held",
        "label": "Number Of Banks Where Deposits Are Held",
        "terseLabel": "Number of banks where deposits are held"
       }
      }
     },
     "localname": "NumberOfBanksWhereDepositsAreHeld",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_NumberOfFullTimeEquivalentEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Full-Time Equivalent Employees",
        "label": "Number Of Full-Time Equivalent Employees",
        "terseLabel": "Full-time equivalents at year end"
       }
      }
     },
     "localname": "NumberOfFullTimeEquivalentEmployees",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfInstrumentsExercisableInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Instruments Exercisable In Share-Based Payment Arrangement",
        "label": "Number Of Instruments Exercisable In Share-Based Payment Arrangement",
        "terseLabel": "Number of instruments exercisable (in shares"
       }
      }
     },
     "localname": "NumberOfInstrumentsExercisableInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Instruments Exercised In Share-Based Payment Arrangement",
        "label": "Number Of Instruments Exercised In Share-Based Payment Arrangement",
        "negatedTerseLabel": "Number of instruments exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsExercisedInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Instruments Expired In Share-Based Payment Arrangement",
        "label": "Number Of Instruments Expired In Share-Based Payment Arrangement",
        "negatedTerseLabel": "Number of instruments expired (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsExpiredInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Instruments Forfeited In Share-Based Payment Arrangement",
        "label": "Number Of Instruments Forfeited In Share-Based Payment Arrangement",
        "negatedTerseLabel": "Number of instruments forfeited (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "label": "Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "negatedTerseLabel": "Number of instruments forfeited, performance adjustment (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Instruments Outstanding In Share-Based Payment Arrangement",
        "label": "Number Of Instruments Outstanding In Share-Based Payment Arrangement",
        "periodEndLabel": "Number of instruments outstanding, end of period (in shares)",
        "periodStartLabel": "Number of instruments outstanding, beginning of period (in shares)",
        "terseLabel": "Number of instruments outstanding (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Operating Segments",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "label": "Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "negatedTerseLabel": "Number of PSU and RSU forfeited, performance adjustment (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Other Equity Instruments Issued In Percentage Of Number Granted",
        "label": "Number Of Other Equity Instruments Issued In Share-Based Payment Arrangement, In Percentage Of Number Granted",
        "terseLabel": "Number of PSUs issued, in percentage of number of PSUs granted"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_NumberOfShareOptionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Share Option Plans",
        "label": "Number Of Share Option Plans",
        "terseLabel": "Number of share option plans"
       }
      }
     },
     "localname": "NumberOfShareOptionPlans",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "label": "Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "negatedTerseLabel": "Number of share options forfeited, performance adjustment (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "moln_NumberOfSharesAuthorizedEmployeeParticipation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Authorized, Employee Participation",
        "label": "Number Of Shares Authorized, Employee Participation",
        "terseLabel": "Number of shares authorized, employee participation (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesAuthorizedEmployeeParticipation",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfSharesAuthorizedFinancingTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Authorized, Financing Transactions",
        "label": "Number Of Shares Authorized, Financing Transactions",
        "terseLabel": "Number of shares authorized, financing transactions (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesAuthorizedFinancingTransactions",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfSharesIssuedInRelationToCapitalRaiseEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Issued In Relation To Capital Raise, Equity",
        "label": "Number Of Shares Issued In Relation To Capital Raise, Equity",
        "terseLabel": "Issued in relation to capital raise in July 2020"
       }
      }
     },
     "localname": "NumberOfSharesIssuedInRelationToCapitalRaiseEquity",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Issued In Relation To Initial Public Offering, Equity",
        "label": "Number Of Shares Issued In Relation To Initial Public Offering, Equity",
        "terseLabel": "Issued in relation to June 2021 IPO"
       }
      }
     },
     "localname": "NumberOfSharesIssuedInRelationToInitialPublicOfferingEquity",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Issued In Relation To License And Collaboration Agreement, Equity",
        "label": "Number Of Shares Issued In Relation To License And Collaboration Agreement, Equity",
        "terseLabel": "Issued in relation to Novartis agreement in October 2020"
       }
      }
     },
     "localname": "NumberOfSharesIssuedInRelationToLicenseAndCollaborationAgreementEquity",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Issued In Share Based Payment Arrangements, Equity",
        "label": "Number Of Shares Issued In Share Based Payment Arrangements, Equity",
        "terseLabel": "Issued in relation to vesting of PSU, RSU and options"
       }
      }
     },
     "localname": "NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfSharesIssuedTreasurySharesEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Issued, Treasury Shares, Equity",
        "label": "Number Of Shares Issued, Treasury Shares, Equity",
        "terseLabel": "Issued in relation to creation of treasury shares in August 2022"
       }
      }
     },
     "localname": "NumberOfSharesIssuedTreasurySharesEquity",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moln_NumberOfShortTermTimeDepositPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Short-Term Time Deposit Positions",
        "label": "Number Of Short-Term Time Deposit Positions",
        "terseLabel": "Number of short-term time deposit positions"
       }
      }
     },
     "localname": "NumberOfShortTermTimeDepositPositions",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Votes Per Share",
        "label": "Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Expenses",
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_OptionAndEquityRightsAgreementWithNovartisEnsovibepMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option And Equity Rights Agreement With Novartis, Ensovibep",
        "label": "Option And Equity Rights Agreement With Novartis, Ensovibep [Member]",
        "terseLabel": "Option and Equity Rights Agreement with Novartis"
       }
      }
     },
     "localname": "OptionAndEquityRightsAgreementWithNovartisEnsovibepMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_OtherNonEmployeeRelatedAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non-Employee Related Accrued Expenses",
        "label": "Other Non-Employee Related Accrued Expenses [Member]",
        "terseLabel": "Other non-employee related accrued expenses"
       }
      }
     },
     "localname": "OtherNonEmployeeRelatedAccruedExpensesMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Research And Development Expense",
        "label": "Other Research And Development Expense",
        "negatedTerseLabel": "Other research and development expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PaymentForTermOfEmploymentRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Term Of Employment, Related Party Transactions",
        "label": "Payment For Term Of Employment, Related Party Transactions",
        "terseLabel": "Commitments made by entity, related party transactions"
       }
      }
     },
     "localname": "PaymentForTermOfEmploymentRelatedPartyTransactions",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RelatedpartydisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PensionersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pensioners",
        "label": "Pensioners [Member]",
        "terseLabel": "Pensioners"
       }
      }
     },
     "localname": "PensionersMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of VSAO Contributions In Company's Total Defined Benefit Contributions",
        "label": "Percentage Of VSAO Contributions In Total Company's Defined Benefit Plans",
        "terseLabel": "Percentage of VSAO contributions in total company's defined benefit plans"
       }
      }
     },
     "localname": "PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units (PSU), Employees Excluding Management Board",
        "label": "Performance Share Units (PSU), Employees Excluding Management Board [Member]",
        "terseLabel": "Performance Share Units (PSU), Employees excluding Management Board"
       }
      }
     },
     "localname": "PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_PerformanceShareUnitsPSUManagementBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units (PSU), Management Board",
        "label": "Performance Share Units (PSU), Management Board [Member]",
        "terseLabel": "Performance Share Units (PSU), Management Board"
       }
      }
     },
     "localname": "PerformanceShareUnitsPSUManagementBoardMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_PerformanceShareUnitsPSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units (PSU)",
        "label": "Performance Share Units (PSU) [Member]",
        "terseLabel": "Performance Share Units (PSU)"
       }
      }
     },
     "localname": "PerformanceShareUnitsPSUMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_PersonnelExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personnel Expenses [Abstract]",
        "label": "Personnel Expenses [Abstract]",
        "terseLabel": "Personnel Expenses [Abstract]"
       }
      }
     },
     "localname": "PersonnelExpensesAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost",
        "label": "Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost",
        "terseLabel": "Pension and share-based compensation costs, non-cash portion"
       }
      }
     },
     "localname": "PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-Employment Benefit Expense, Non-Cash Effective Pension Cost",
        "label": "Post-Employment Benefit Expense, Non-Cash Effective Pension Cost",
        "terseLabel": "Non-cash effective pension costs"
       }
      }
     },
     "localname": "PostEmploymentBenefitExpenseNonCashEffectivePensionCost",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments",
        "label": "Potential Future Milestone Payments",
        "terseLabel": "Potential future milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePayments",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preemptive Rights, Over-Allotment Option, Maximum Percentage Of Total Number Of Shares In A Placement",
        "label": "Preemptive Rights, Over-Allotment Option, Maximum Percentage Of Total Number Of Shares In A Placement",
        "terseLabel": "Maximum percentage of total number of shares in a placement"
       }
      }
     },
     "localname": "PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preemptive Rights, Shareholders, Percentage Of Share Capital Registered Accumulated",
        "label": "Preemptive Rights, Shareholders, Percentage Of Share Capital Registered Accumulated",
        "terseLabel": "Percentage of share capital registered accumulated"
       }
      }
     },
     "localname": "PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities",
        "label": "Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities",
        "terseLabel": "Proceeds from investments in short-term time deposits"
       }
      }
     },
     "localname": "ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets",
        "label": "Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets",
        "terseLabel": "thereof property occupied or other assets used by the entity"
       }
      }
     },
     "localname": "PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities",
        "label": "Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities",
        "negatedTerseLabel": "Investments in short-term time deposits"
       }
      }
     },
     "localname": "PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reasonably Possible Decrease In Actuarial Assumptions, Period",
        "label": "Reasonably Possible Decrease In Actuarial Assumptions, Period",
        "terseLabel": "Reasonably possible decrease in actuarial assumptions, period"
       }
      }
     },
     "localname": "ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reasonably Possible Increase In Actuarial Assumptions, Period",
        "label": "Reasonably Possible Increase In Actuarial Assumptions, Period",
        "terseLabel": "Reasonably possible increase in actuarial assumptions, period"
       }
      }
     },
     "localname": "ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_ReconciliationOfDefinedBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Defined Benefit Obligation",
        "label": "Reconciliation Of Defined Benefit Obligation [Abstract]",
        "terseLabel": "Reconciliation of defined benefit obligation"
       }
      }
     },
     "localname": "ReconciliationOfDefinedBenefitObligationAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_ReconciliationOfFairValueOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Fair Value Of Plan Assets",
        "label": "Reconciliation Of Fair Value Of Plan Assets [Abstract]",
        "terseLabel": "Reconciliation of fair value of plan assets"
       }
      }
     },
     "localname": "ReconciliationOfFairValueOfPlanAssetsAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of The Amount Recognized In The Statement Of Financial Position",
        "label": "Reconciliation Of The Amount Recognized In The Statement Of Financial Position [Abstract]",
        "terseLabel": "Reconciliation of the amount recognized in the statement of financial position"
       }
      }
     },
     "localname": "ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moln_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Consumables And External Research And Development Expense",
        "label": "Research Consumables And External Research And Development Expense",
        "negatedTerseLabel": "Research consumables and external research and development expenses"
       }
      }
     },
     "localname": "ResearchConsumablesAndExternalResearchAndDevelopmentExpense",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reservation Agreement With Swiss Federal Office Of Public Health",
        "label": "Reservation Agreement With Swiss Federal Office Of Public Health [Member]",
        "terseLabel": "Reservation Agreement with Swiss Federal Office of Public Health"
       }
      }
     },
     "localname": "ReservationAgreementWithSwissFederalOfficeOfPublicHealthMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails",
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_RestrictedShareUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Share Units (RSU)",
        "label": "Restricted Share Units (RSU) [Member]",
        "terseLabel": "Restricted Share Units (RSU)"
       }
      }
     },
     "localname": "RestrictedShareUnitsRSUMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_RevenueFromRechargeOfEmployeeRelatedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Recharge Of Employee Related Expenses",
        "label": "Revenue From Recharge Of Employee Related Expenses",
        "terseLabel": "Decrease through recharge of employee related expenses"
       }
      }
     },
     "localname": "RevenueFromRechargeOfEmployeeRelatedExpenses",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_RightOfUseAssetsPropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Assets, Property Plant And Equipment",
        "label": "Right-Of-Use Assets, Property Plant And Equipment [Member]",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetsPropertyPlantAndEquipmentMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PropertyplantandequipmentDisclosureofReconciliationofChangesinPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Free Interest Rate, Common Share, Other Equity Instruments Granted",
        "label": "Risk Free Interest Rate, Common Share, Other Equity Instruments Granted",
        "terseLabel": "Risk free interest rate, common shares"
       }
      }
     },
     "localname": "RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Free Interest Rate, NBI, Other Equity Instruments Granted",
        "label": "Risk Free Interest Rate, NBI, Other Equity Instruments Granted",
        "terseLabel": "Risk free interest rate, NBI"
       }
      }
     },
     "localname": "RiskFreeInterestRateNBIOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Free Interest Rate, SPI, Other Equity Instruments Granted",
        "label": "Risk Free Interest Rate, SPI, Other Equity Instruments Granted",
        "terseLabel": "Risk free interest rate, SPI"
       }
      }
     },
     "localname": "RiskFreeInterestRateSPIOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_RoyaltiesAndLicenseFeesExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties And License Fees Expense",
        "label": "Royalties And License Fees Expense",
        "negatedTerseLabel": "Royalties and license fees"
       }
      }
     },
     "localname": "RoyaltiesAndLicenseFeesExpense",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_RoyaltiesMinimumAnnualAmountTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Minimum Annual Amount, Total",
        "label": "Royalties, Minimum Annual Amount, Total",
        "terseLabel": "Royalties, minimum amount required to pay in total"
       }
      }
     },
     "localname": "RoyaltiesMinimumAnnualAmountTotal",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_RoyaltyIncomePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Income, Percentage",
        "label": "Royalty Income, Percentage",
        "terseLabel": "Royalty income, percentage"
       }
      }
     },
     "localname": "RoyaltyIncomePercentage",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_RoyaltyPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Payable",
        "label": "Royalty, Payable",
        "terseLabel": "Royalty, payable"
       }
      }
     },
     "localname": "RoyaltyPayable",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax",
        "negatedLabel": "Effect on result before tax if interest rates decrease"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent",
        "negatedLabel": "Decrease in interest rates",
        "negatedTerseLabel": "Decrease in exchange rates"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax",
        "terseLabel": "Effect on result before tax if exchange rates increase",
        "verboseLabel": "Effect on result before tax if interest rates increase"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent",
        "terseLabel": "Increase in exchange rates",
        "verboseLabel": "Increase in interest rates"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Cost And Administrative Cost, Defined Benefit Plans",
        "label": "Service Cost And Administrative Cost, Defined Benefit Plans",
        "terseLabel": "thereof service cost and administrative cost"
       }
      }
     },
     "localname": "ServiceCostAndAdministrativeCostDefinedBenefitPlans",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_ShareOptionsPSUsAndRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Options, PSUs And RSUs",
        "label": "Share Options, PSUs And RSUs [Member]",
        "terseLabel": "PSU, RSU and options"
       }
      }
     },
     "localname": "ShareOptionsPSUsAndRSUsMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement",
        "label": "Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement",
        "terseLabel": "Share price (in CHF per share)"
       }
      }
     },
     "localname": "SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_ShortTermTimeDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Time Deposits",
        "label": "Short-Term Time Deposits [Member]",
        "terseLabel": "Short-term time deposits"
       }
      }
     },
     "localname": "ShortTermTimeDepositsMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_SignificantTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions",
        "label": "Significant Transactions [Member]",
        "terseLabel": "Significant transactions"
       }
      }
     },
     "localname": "SignificantTransactionsMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_TaxLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Loss Carryforwards",
        "label": "Tax Loss Carryforwards",
        "negatedTerseLabel": "Tax loss carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "TaxLossCarryforwards",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails",
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_TaxLossCarryforwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Loss Carryforwards, Expiration Period",
        "label": "Tax Loss Carryforwards, Expiration Period",
        "terseLabel": "Tax loss carryforwards, expiration period"
       }
      }
     },
     "localname": "TaxLossCarryforwardsExpirationPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDeferredTaxesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_ThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thereafter",
        "label": "Thereafter [Member]",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "ThereafterMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/TaxesDisclosureofExpiryofTaxLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_TradePayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Payables",
        "label": "Trade Payables [Member]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "TradePayablesMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_TreasurySharesNominalValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Shares, Nominal Value",
        "label": "Treasury Shares, Nominal Value",
        "terseLabel": "Nominal value of treasury shares"
       }
      }
     },
     "localname": "TreasurySharesNominalValue",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_UniversityOfUtrechtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Of Utrecht",
        "label": "University Of Utrecht [Member]",
        "terseLabel": "University of Utrecht"
       }
      }
     },
     "localname": "UniversityOfUtrechtMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Of Zurich",
        "label": "University Of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_UpfrontPaymentAmountUtilizedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment, Amount Utilized During Period",
        "label": "Upfront Payment, Amount Utilized During Period",
        "terseLabel": "Amount utilized during period"
       }
      }
     },
     "localname": "UpfrontPaymentAmountUtilizedDuringPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Received",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moln_VSAOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VSAO",
        "label": "VSAO [Member]",
        "terseLabel": "VSAO"
       }
      }
     },
     "localname": "VSAOMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Blocking Period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Blocking Period",
        "terseLabel": "Blocking period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Percentage",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Percentage",
        "terseLabel": "Cliff vesting percentage"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period",
        "terseLabel": "Cliff vesting period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moln_VestingRequirementsForShareBasedPaymentArrangementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Percent",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Percent",
        "terseLabel": "Vesting, percent"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementPercent",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_VoluntaryComplementaryPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voluntary Complementary Plan",
        "label": "Voluntary Complementary Plan [Member]",
        "terseLabel": "Voluntary complementary plan"
       }
      }
     },
     "localname": "VoluntaryComplementaryPlanMember",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/SummaryofsignificantaccountingpoliciesEmployeeBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement",
        "label": "Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement",
        "terseLabel": "Weighted average exercise price of instruments exercised (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement",
        "label": "Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement",
        "terseLabel": "Weighted average exercise price of instruments expired (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement",
        "label": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement",
        "terseLabel": "Weighted average exercise price of instruments forfeited (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "label": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "terseLabel": "Weighted average exercise price of instruments forfeited, performance adjustment (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement",
        "label": "Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement",
        "terseLabel": "Weighted average exercise price of instruments granted (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement",
        "label": "Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement",
        "periodEndLabel": "Weighted average exercise price of instruments outstanding at end of period (in CHF per share)",
        "periodStartLabel": "Weighted average exercise price of instruments outstanding at beginning of period (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "label": "Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "terseLabel": "Weighted average exercise price of PSU and RSU forfeited, performance adjustment (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "label": "Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved",
        "terseLabel": "Weighted average exercise price of share options forfeited, performance adjustment (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted",
        "label": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted",
        "terseLabel": "Weighted average fair value of rights granted (in CHF per shares)"
       }
      }
     },
     "localname": "WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments",
        "label": "Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments",
        "terseLabel": "Weighted average remaining contractual life of outstanding PSUs and RSUs"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise",
        "label": "Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise",
        "terseLabel": "Weighted average share price, at date of exercise (in CHF per share)"
       }
      }
     },
     "localname": "WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise",
     "nsuri": "http://www.molecularpartners.com/20221231",
     "presentation": [
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails",
      "http://www.molecularpartners.com/role/CashcashequivalentsandshorttermtimedepositsNarrativeDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails",
      "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails",
      "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails",
      "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails",
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails",
      "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/RevenuesotherincomeandandentitywidedisclosuresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molecularpartners.com/role/ShareholdersequityClassesofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFR15_g110-129_IFRS15_g110-129_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "59",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_59&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r222": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r223": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r224": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r225": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r226": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r227": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r228": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r229": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r23": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r230": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r231": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_21_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r232": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r233": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r234": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r235": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r236": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r237": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r238": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r239": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r24": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r240": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r241": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r242": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r243": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r244": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r245": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r246": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r247": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r248": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r249": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r250": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r251": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r252": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r253": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r254": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r255": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r256": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r257": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r258": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r259": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r260": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r261": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r262": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r263": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r264": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r265": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r266": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r267": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r268": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r269": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r270": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r271": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r272": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r273": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r274": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r275": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r276": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r277": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r278": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r279": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r280": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r281": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r282": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r283": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r284": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r285": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r286": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r287": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r288": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r289": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r290": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r291": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r292": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r293": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r294": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r295": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r296": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r297": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r298": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r299": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r3": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r300": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r301": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r302": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r303": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r304": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r305": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r306": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r307": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r308": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r309": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r31": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r310": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r311": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r312": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "143",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_143&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "148",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_148_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>147
<FILENAME>0001745114-23-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001745114-23-000003-xbrl.zip
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M^M?3OY[^];3NT/[U]*^G?SUW^WI:<"=]0'^KX=W3X=&711C/=@LQ[B+^OOL
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M_W,5O>/F+,TD#G8SVXZKG0[IK,!V<<\R#B_",49JX%BPQFI._?EIC9FPQMR
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M".*8%!\E[$6(]9#LGEG^T6!:^CQO:2@Z&1@BXQ.#N?H>*1L[0/\?,?A-.GQ
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M4B.U%*]\,6LH)S6Q'M M2VI)6AN# ^/$%K01L0VH1*4Q28WHIMBTIL2Q26S
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MJRB;/6A$VQ-JT]IH4V(H:!C!S>.[UZ*?2QC6 AR_TJU4S$W%KQ@T1'!'XCY
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M0R2/G$@$77M2)JV)S8/?\$<&_L\=SOX$4$L#!!0    ( "N :58L$JGPV <
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MRDODT:0\>>D[^X:X/?F-?PH0_BCA[-]02P,$%     @ *X!I5I_,0L.'+
MU1\" !X   !A,3)O<F=A;FEZ871I;VYA;')U;&5S;V9T:"YH=&WM/6MSVDBV
MW^^OT,W6[B15&!O\3K*I8K"<4&6#+\:9G?OE5B,UIB="8O6PP_[Z>\[I;KU
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M\CKW:J(:=7Z],HW!I=$=]$=F?_37ZQ7/P?Q*F)3GA\V3UOF+FY2P]V?%=_Z
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MS]C"&'/#YWOTL2AE<-$%F7M-HR=O5.^DMS+UB2"S'I@%%F&CZ ER*]E\[@G
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M!MR*?&ENA3ZS:U?L*[AB,9^ /TKG@M(YI$\)6V< C:CTP(S?(MTZHRKPV#9
MM%N47*(H5<A%2((&W7LAQBXQ4H>4))5S4N 85DX$H6=],Y0KE71T[>_67FS;
M Q&EXR 9G^*]CSXG>)[T8H42_.KH1/G/&YE'D-"3>@G5,0<&=0<M?M>*8$EY
M/(]*"P$P(.?$NA^,DPA;4 LB"8D_J&#H ;8+V>U<]::;BCD5W0AX0>8G]EZZ
M6=QSLAQV)V9]4L>L=]0M#+PPF&!E&EA; C OR+E0L*&?@P6(:!Z#")US'U@@
ML49MOU%%]Y@RVN$>4&_@'B]9(7X$&8$R+I2BTM11R6EEG0Z65=POY-DX@OW<
MI).?!Q^V+:$3]1:!*"%(-3((/":3<<<\?.3<7<K )7QYHK[1>,NRG0%UCU$_
M=VN^64^#K'_0&K T-6]>9I(H\%7(Y:.B@54)66P=-;0VO08U'J<"]+5'+W(P
M4!M$#M7:: ,)H8R^/OJ;6:!%2:D(,&]('T.:<9#[ 4O^G(4Q%BJDK)D$J06D
MH=,OO-RB +'TYVKOA%IW,E'FV8.GR[<HGY5)=J9S6[%]J?'V<<JEVD?O3]70
M6%_-,'AI356(7JN,8T1YC%[2G]C[ JQM6VF@6H-\% %_UTC%-:D.^77+!"M2
M\W-2FIH?\\K\W(F+?7&T:Z__V>C<C;X,AC1MO&"KM]RJ*E<-ATGZVM#5V9V%
MX2S,"@*LUD930$5N$H-UT#^;MV&SQ5[H[<$_T@N8BJH4)J^F6V2%7B5"EF6I
MJLIW<T&8+#6/T(E!*GK2?E<%")0E:)QI99'?ZL/G-(0L]WZ7I?9WE?LNO^U'
MU=GVHQ)M>T$WVOSN'[]K5&'GCTNW\TL]9_,[?_+NF>90N2%P4B((Y(W5_-:?
MON[0B8KH^J=ET?6O31,'8M<5_B]<X9]IG@@6<S E1T'2(FO,C4@F%8.Y8GM&
MX$G;9$EI5>Y_:8MH@R5I0/G 7:X[1*Y+1Q83THG!XG=5O3BF /D"DTU@/3S.
MT2? DF>@(P(S9U5>/":=4V<1CS+4>1!2MYE'C.C*%HWJ);#5!W/@,OC&*7>D
M*Q,,J_G4<^G[,5KO49X]6%VNQ2MA"95%#^][H>IP&6-%W-?I'K05%_O;8991
M:+0.T(P-L-^R[/)#I9>Y_E&N7$^N@5UE)IZO"BM!$+@V:QH]UXC\>Q0)%B8O
M-:CYFUQ%=>4D-$"S#$/2\#BJ")W"0H!Q\@%-HP-8'N,>=L(308I$,&48':_Q
MRM@D0U)(+A65'/6I6](?13XLIN+?ZU 2L5PV2X*E=:%JTD=/;Y!\!/ZBZ*U^
MC,5<^&35U9H^'^EQO$B\"NL72[WRZW;)VS6CJ3=),[B8C4E()UB"Q3:.@^W+
M$X:M"" :@ZVERP[GRM=J\QF1B[?45596D! ?U9%X+W)MV1M61OSU:\045P=G
M/YU6,#A;3*%_*3%*IJTUA9C+  ^7Z.@:'),,&DNHG%4YTEP5RS:!'6MQ0L#
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MYQBQM7([10?8'I&6OUN.P>,8W;%Y NMP(BJ*?;+I8,F/?(>:U!C.':M,KSY
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M5SJI&\$0Y+$3281"?]&P,(W0["+C#NAA\(0/A?,CC 6V,%3;$[L)BFJ4Q34
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MN,T7*4<B"Y "\7=C7*J(RW7,NQR@/-NONAQ@X]J0<-GZ6:9GG-".-(MD4(F
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M<;BA,0\C%CU&D^!S9M"-C9]X_,,'P"5%LAR&ZZ,?L>L!L*+0A3-:;@OURN8
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M[-:LW0%9W(9/FL?"L@)+I8?F#4F>#A/G*H!@'(&V2\O#QT>!Y(9IZ@R.$8V
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M](L-S.:+_BN%*XN&T)3/P':JR"P^.^&B=3N>I+@O6G8*R46^Z_BW9S96RFO
M<GH#OK(H%L.]C7D%U9QO&)6)<N6Q0Z,E05BTI>FR#28U#UK8:.% D3WA."C#
MA)\2JG3(?_?(!%DQRH$Q]W_V:O%V%5#5E7.N-;/B*P[:CXXZ-DLW5?@CW[RG
MQF,P2#5>%!1JB#,+$53QTOIR5?XP1Z/)IY76BGI6#5$MN3U4XTBJ>!T1V4F4
M+ Z]-&_+YG'#0>&Q<[\=JUY#@KWPB*YXED)YF)+,$-/O?N[!_1N0D&GOTR!1
M,!-75SYV%\FODQ2@(M@3'IARBV%RU,H):M$)#Y8!ZKI<($TG:7'YRFOAAA1@
M@H>RL)*W"RGCH9I^D4;8<8>6!MUP2N#-(8R\R"! 8(S7.U9O/U@;A<_17\/J
MHLGM6&3Q<"V1Q</=P8H==B&C[PH9;2I1I845$Q)VH9).GQ;%: KYU&/[_MJ(
MX-'V' '(:&W!UHL-!T.*-=-:]WBMX9ME <*ZF6]<G<TH#$\J%XG2NVA@%PWL
MHH$/C)9<(0BH!?3QHW[W>_=]PWQ=:ENEMM]TJ>W&Q=FH:+#$1S:$?Y>&?7W?
M_^XXK_GD[XKL_H#(:[A2B'=Y"#E7;9L;@\D.GE%S0)E1!%W:3O&\>\5_E7+D
MH9!+^<V:D %G6A-*/@;C%2VM1X2K!EBS89SFM^[<2<^V37KUR*4O'+VW(M*^
MUQJ^!%X,PTS5U\M<>G1N8'=/&'FS."*@&;>Y*%V^"R"[X,BH&<- 0E+JCV.)
M",U%MS^DK2#K=\XAFX3[=]2K,<%K^C%89(DCQY__W3,Z!5X:T6IL^J,GHFC)
M<2ZK1VP;(K++(KD_(IAIQ96,@*::4Y,/TAS,W$)G>[BISO8E*R&*KSQ=__JL
M?O.J;D/VO=MTZDTU[KT=BF^_6OQWMXI1*P_C.RYN@[<IED7M,*PE=M&26<LZ
M&>XRR9]TYBEO9=7/+.!^MM!>C-P/<9,M,'R?1O.RB>-)DR]^@Y6'Q1R&<@VI
M>K](RB_,\R.T>C*'T@7NHH%-DDACIA'?&+KQ&*VR@:#WX]Q[3/6-V/PXGMDF
MSO?J=XN1DKB6H7U=4CG@>0S2^\W7T)@3 ?,E09-3F&("Z@TP/=?T/. =ZJ;F
M+#XC$R2_A??&:%/OC0\@A]W%@1>'ZWB:;" SR2S;=C6L9EX?@>!00!--X>M8
MI=4\KL2JSQS6ZX18TZ3"TW C0:A^-UJ0_+OD=<SYUC6Z@\NFS$92,!H)/22T
M=7KGOU^XVSG?,:C=[Q$]D"= ; JGWNV\>^DFWO?D53IA!CW5GDMHSAP)YZ$Q
M0%X:&C1!RL(L-AHD&.K<:"1JW-8R3<Y.$O5N$--/@)!8L^JX^#>3*]G.5-2&
M8)Q5JX1\^P[7RHVJZ^GK(RQGM(K[]MJ*"'5S%)L.NN=(O]0+^@%01DE=U+0R
MPJBJ+$S5S&JJ/%&J%P.:F4^@(85YGF4:QWZ7TX)*E<J6_A)@V3="VEZ.1E+=
M6PU[P]%,YC$$,69Z1F)J!'*DJ*F&LG&]]U35IKO8HYP+A2F!!6L"/R4FO;DL
M$.>!6. 2+CNM53AR"2ITPD&: BI =;>![7B+0XGQ,_2%*G<_[STW2$%5&-W@
M>#5O\P64!5J%J6@.8W4ZUC(;=K3E=-3R?QJ@2*NB/!^U:$A5R/?7DH/DP:,4
MH/B@S3+R.) ;D[/C0NT(K%W'O0YE0M I8UQ=W,K-;K7>8*EXZ[^;B"ODF5.D
M&%[B?$6DUT*MYT9V?>2VVDVB,]AKY[_[=MX[4TUT*2AY- Z>=RFHQL613"KM
M](C?SZZP5#16K\%_>"(&YX.K4@O\J FNC60 \Q61T3Q3Z2->R"VT7Z_6A TV
M/ ]E3'XK+A@>AG%"VB)?ZF>5;(9AZ6*+'$H(>LW&.A&L-HCUF$CB;),&QCGB
M.U2YZ4TYGDT^3LO I9O:X-,N0_Z(6W0%^:43K##0N^=!G6Y0I?+V'(G' YL^
M 'K2"_!2)"D&G'SDG)[V#/<28*5=8]""KU1,[XSKBI= RIIJ.!OA9-^#(5O]
M9??$C]T+"Q3:B1"Y/MX1JKC;"GFC!L /++K1><U\ 0<#6D ^)KK'FV=L&_4V
M87R:D3U;J-\>+;_OUV^NG+;LKA2;AC[TMC)46JXNKY2C1:8L<2QEJQ^,#8"R
MM'%W3E(.V;0 F]24R+7INM0HREP?X'KE-:%UPS:RRY4),PE=/C.Z":9W'B_#
MXS_X$KF$J1]1)U@#:6,7.28]R4&O]E'!E(J \Z@.'NF[\JA*DGORZ=BTIZF5
M2TW;K>#TN=MG1F,P9"3OUG %GV[%;/HJ&X(+:F3)9:M&]I5C*W-OK(@B\D>W
M,!;W.%@#O26^M8T=A_%M3<9CW7GI^Z-UEL!T6B]]&Z-C?9]+_K_Q"C9&]T.@
M.M[KMQ9A:HK"N/=P,\ZGC?E4->BR60/)RD-F0430-(9>+/ ,_!G^47IA-,T8
M&</^A1/!'<.F#7 4;B].!J'55,SJ$Z;48OTBLI])WX<D0EOOI,? P+A(RT;.
M: <78'4[VU?T!TUP!HV2FJM.->VA0/MPR%26&= WALV9JEOQ"+'?%(IK@&SI
MK)W=Q'D+E>EXO<K4WW19* 7;75;A[^_#2VB_J@$K89D,%FP%<^==TD8E;?:[
MI$WCXIA!R.]#W&0RD0^?60JLT6BL@K4@O,!1@UNHI/1ZOMR*H"YNQ@7'Y^%J
M;Z! ?!='A5!,[_-BMA$QW77(2G#I:XN*5[-0N,<@"N) G_UIMUDMG0R(=X7)
M#BT:&UK64 9)ACW2"'PT<SAXZM'/!GM"N^U.V *0-7@T"GTT-"S*:QQK]I_Q
M FXFA"R1I;["?!PHCLP4R:YH8M3BR1#\C%+\+QC50D4D$PSE>DM\5/=7B,5.
MZD/P&/GUTL0&>(=ZMFP)P6:N-4IWD/XV!Q[EZ%WCK5:&KS94&5[$8P!%K9GB
M8+U:[<R%H*ITC\JUJJPMQ0_EFGERNRTL&MO/C4%+$S/3@;T4DL8/IR*]?QG+
M15M=V4JE&?%#K@W]'$E-4*,EH)Y(^A7*]VZ)D!"R8&E'SY42&;+N^IZI#,\4
MX;)8'CIA\B@\A@"G5$VCY1+'%>ZA7F"U.^K8.C-7EYX:B='(1T,8S8VJ]?SF
M9RE6+GEVW45M2'DEF5#H"^8BM&X_>9$X%V&3,#FB)YM1U6960,]46">C:.PZ
M@F&XM;U&U,5X#A;YWK\SF"[<TX\"NC%H[909=6#X.6JS:K%3.E^E4F,\94A6
M)H-(S<E0"%>)OQ9",4ZP27F].Y"*4MTW[D0PE)7S!D81<Q%7 +55>:$1Q&*@
MB/NBI)";&@&7DW&UL[96\*M#[81)I2G'U5S:52(U*'SN)?-W,MX:$*00IC3:
M9WE/7%30GL0SN? X&(H0TLS&"M14(J$A\ZOFU-@'HYQ%'HAK."(V5;2(&%9O
MJ(^:7B9IJAV(.=6!:^L74P88G P@P78C'$Q]P.'3)8 )).2U+109C?]G45:2
MF&:B^$/)-GY6Y<\0EP!V,EH51G6=,<Q63BD;UD^%_&6#AZ$MJ==JJW]L>JO6
M\TO<G6F5B%_J!=+WZRHS4CW:Y*'9: OVGB4KFT*B:<E$*X7FJ[50:+[:'0K-
M5QV%YG?Y@*\WU <\T<DI(5WON5[P!-1E-KI[NGZA!09<'A*1&5MW 4.X"R!3
M!6X9-SLU(+\.WS$]VVH\I\Q+6?U4!\?+;JRL8?]G,;XV35MC\(#>EKX)"*N=
MW60312=;V$J!LCL.5EM%8HRW0/6D$J\RF>-I"V=71X5V-E4:JR;^H5Z[IM;+
M1QSC]L5KMX]U9MK)\MYKPD;>T6 @PP5VCX(UW]!(2;OEBG))]@PT3\W&J?EF
M[^,XN!Q-X_$"N_U4$?P[X Z!0ID.ODZ3H1CU.[_%HP \O::.?E;;7>/KI;2P
MF_O\.=Z@T6P0;H;H&DYKE[)3*;N#+F77N#A[I.O8;:*^]B62]@VA&@7;%AQ/
M)L(:XBB5K0-Z^$VAXLB^D&PM$\[NC5IO0Q_PP0P!&;"U&@\9!S] 'CCAP>H*
M'SAU'-HJMU3!<@2DI3CJZ'3\LQJ3*7_&J!A/ W-EU 2.98**$ESUE.D1H<B7
MT  8R]=-MDTK5('@Z#E9/[BL)4YX%W7R!.XGL0'B:(_URM6N)/5&:(=<C&7Y
M&CQ:;"B7 ,URX:@8E -&\L< ,$I'51$DP)"%>ZTN9$4BM]'69R, S@4@Y;;-
MH<NUX"^<\U)K:@0#9022Z[^H3COFP*BZ(L2B"I.=DN5B=<'YENNM(8^82;_&
M&Y&/6,/Q1J&*%F*K"ZX)PVHKPG\:VX?"6W^SAG$YP+!Q7":%8H>$WC/@DX9"
M7F[!X@OY]<Z8Q*RM*D>-\8M@7,(MWLX3PD6F: [ZM8RRZ<CP(7=.69GLY1MJ
M$QY7,WY4B([M/-N<XV]^(W2.P8D.=)< 1"&3=[+,+S^>XL_ZS-6.*J]!J>O;
M)S(+H\<:MLPR 9:=C$A%55#$:"KN1J=@8OD0HBVRC6-DNLNCO*RDZ!(5F?Z;
M< Z2W%N%&RK>VZ0<0? 2Q@PY%GVHC96OSR%SKQJI9ZFED_!8[K<B1@V-E1OQ
MP2MK)VL/[V[:7'&CP[4O$T%"LL'C&JF@.F;Q7+9M]XE6LVTU(XR'M(Q5X6V1
MUV!/>Q=NK@/^WFMP$?96NTM[*LYC8!CX@E-V>-TMLAL$0?GL1JNL92&5-QL:
M4GF??(4#1U@2$U;;15,PM>2]9>3)M".]$[64D<6S[^0VI338+>G$M[Z%@;]&
MN;"G@*EV]6:HB(B\\1Q@'1[VE&M!BKD>D5E @B(*V/SD"T'G&KA05$&D&M(,
MXEVCE5<6>;KBN**EQ>$+US@9)95:.*BHC-E_$7KU:\)I%6])/<W=CWH M3C&
MD=4&-DF@>,=DH@2E"7>&N!^I=MX'G+P6'A^?B4QF!L+:!-B;*Z7!:01QJDJR
M^WB&])75JCYK>_ +B*(?/'^[/B%J4SAK43-^2<=UVG_;:Q9)\VHRX';37"<R
M5^J+$:J4D805H,LFWVLR)=SDE28-D@8OE8R1%.AGL2F%=[BT84KT#MRQ2'%R
M90?Q,LIKQ)P_YUA"_J,:FC))<"7DHKC(0QH&JH=Q73$TZ(.V+@/^]%8[N3MP
MSJ=YB06.I8O(KP$HM/ X^2A;^^Z17=[#8*:CTITFHCI:"@9QE&7"U!EQHT,Y
M<!GTAJ^[X[>03 :PLIB#/,D= I<3H5&0T,*H!-<E.8.#@?/I<!X0H6-<-LZY
MUS=QM'9$7/E(-NF8V=NTFA;YXGJJ,^$T(4ZU^:A0FH*R(;GN=6DL9:MXW&_X
MY7!10KD8HFY 3?PS+[X$LO3*7>AO%6+\$PNJ*="K"EYH!6M,L=MJ&W?_^88:
MN7_F;#YXC_G3M72/2W$L\\S5DE0#;V#(_-:8$#U-L;7,>$5:0T/*A/20'PK1
MDQ7L.4PM+GG)$CO)E7X;EV=>L2U&IAS3G2_S9+A[3=3CR(TJ^3#JUXC$NV)X
MA"$*LE3<F1RK_RR7H3Y) "#YF2>+ E4M:_M$8BJIF%A?4'6PG@]N*X&]U31!
MCK-#B>RU;BL)MW57L[9ZYO+VPL F7%$P$ 9%<0"# 19BQI_[PFA XO<N%:=3
M<8==*JYQ<<3IP90RVAGQ5W&MNXWDEQ8:__+SB]=O,2A@7>V3^V@-<K,C@W1-
M :;4^YLL&G;(734F<9Q2NX8N4Z(+9:A;;0U&%[Z-:J7P8V>9-"$-]T@J+[\]
MF$O^"!G5]-O6=(_HK^ITB#+1RL5,G"6QXPCX BR)6)6LPK2/HTA[(54/& !N
M4Y,9[=RUVP4_6ZZ7'@*\*THR@_YZ%4PEGA':4Z7.B!4*H<8C. 7#(HDGQEG0
M0V.=KWB,FRQ.F95$&-LV4OA^#VR30R7'IQ?^O('30P2S+J0%&.TLW!CDQ[A>
M4+:80D!\F#AI0NEF/B%EE8^^Z/RK*B:I),0:S!SAWDGZES2)%X2FLG-'M,62
M?%[=;/6"CX:2LV\(B!&9]%(+JLX;IUM=J>J?J))C+JU(@./7D#\J#H-)>QW:
MYQ?\V/R6_";QXE@Z3GIU\L)VJ?1?F%N([)F]S6KZ&O>OUVK;(S"LB"<QY&J(
MQB"XC8=(9,6B)56RU05!;@,7D=-G1Q7_"9>:I'-.45;["9O=R<R_4G\NT:I<
M3V77S[D46U9)#!;]5O$U5.*W _&;V]L2U[A$,JAH1R,)BHX<6A-AW<G7"?5(
M3GP&?E,71;$]T0UE?\M\$A4U7Q%9HXI94L',B,+DFPV.[S0VFJ[FT'(X&S*=
M]/>6\!\:'25%38%_&<RYWJJWOL];;+K3M_$:7[ENAE+45( IS[SOX%+ZJ-$=
M54AC%A"K_0ULY;@?+&.!<5#1?'8A%6/2[]BEM1J#P,8:CQT.9':_]]&!@P0/
M]'KPAMJM<VLP"6%D?(&&:\N1]2Q_"+9++%XW7Q3E(LK81Q@WP6A].V,J*M@<
MW J#;@QTE#(!K$(-KHSP !/M9Y;>]]H:D<X0U&E@VH&:OWM-YSK^AE?U!YCR
MSK/1%4/8EO$5:'^#]7MZ5;0>EBE4LJR<S@Z\J CQP""-7 \OE2K%?:"8N8KG
MI4T&:'23!5TQCU%A<"B&;$)$GAFE@&CN0MK&,!D-%:QT:M/1@4A6%3,[9:D-
M.2BER<:1%?!WPS[O<D#UP9TI#' HE]Y*G=CHVL1I&1O^#8F%_P)&+Q1)0F7,
ML%X4KW9$'5L\!DV>ML6D[!,T3SS0$RKU/M[2!8W&BDZX"L<%W(1"4JM9K7O_
MM<C_?_;>M;EM)$L3_BN,[C=ZQ0B8;?GNKIB-4-ERE79=MD.2N[8_38 D**%-
M AR E*S^]6^>6^;)"T!*99<H2QL[,RZ1!/)ZKL]Y3K->$(K,.3S>H;R#YN:V
MI^(F7F\0TT4<03HVG"N'4J5OE6^YK6.9;0-=X=CSBFAUY0C)(+ YTT598^LN
M"NUB0Z)3;?'9"D@W!TBU D$VGUM5WN(WNP"3U9JH?&G0]Y]Y:5LG)_L[-(6J
M.LC83R;->E.LB%\G';)3'.@:9XEK(JVP\NG4[%C+9R<U>T6XC=5"5,H?"I*X
M=/LAE&Y#Z<_N0BA]5T3:Z36[K?0U6R$;2D,_Q3:RO(G(LRTNU SN)L;1$1/N
MF3K\?(HMK9LJ;<[&_=VZDO-9(BVWTQIH8\)^?T<3]F\POMI"<10,MH/GXOXF
M[C]3_=&50F)6-0#7B(/47*.+?+X&I.%R7JX>K9=94!4%BMSH]JG%@3G,H;E[
M<^@Y,5,51YUPR;4,Q/PJ7V)T]#_\BJ:HF[.\LO^]*)HS<#.B5TNQL'EI 0K4
M[KF.^%"*F6N'L:B!*GZ0$^/*T:MRNL0U-NL,(:2(^FQD?P8A+W*ZO7J1C+P8
MI,5A"%<@+SQ3.>NQE=F^]Y,4GIV"P3/0WT;%(+T\>'67B:)J11V<B*I)L,RU
M?/-2A%M'Y]CJ! 2D*E5P7#=!I2Z.WKDD7E##"^BK#C+!XL8SQ2HH!M5*_TT/
M=7B-(W_-X[Z]H+\E-?S-KF ZFQ;VJ['>NE0JJ3+Q3"Q^GT/.V9_1"?0*MF.G
MQ_4NR%0)Y\+BZ02J_XT;24"N/F+;H>XYKH.09ZIW-*S=NKOLP!&RY2H4BEV/
M*G:2%&H\:.(:I3.A3JHTYEC!O2G(WU W3M(*[&YBC2PF."C5*300 CZ08@*B
M#X9(3L>&):B/B#N+ZH[<3]47CG5;NA/)BF/KX KY; ?O'KV P4)IY=0[D LS
MR3*B.12I!V^] "K]N6L][&J' ::@&+5@F.PXB3J@PCF0O30'/!L70[(-%:NA
MW3':-%WE%9!38859AQ,NH^YP@+/!O^NR6NE25N_<VI5-+^?V:TG<.^:.4=RP
MA8#QQ*&[8#F0F >34\?4C- +;<#/H*G[68WW-B!58FA[0IOIICB0B9.N]EC,
M-K\*PZ1MO4"$+>RN33)_<PDF730\R=4I!L(WB%BXN1R0PM&;2 '7XR"QVI#,
M_QX-+>#Q^$TD,9C/ZXFTI/0X8VK5S,+1B'R[;A*Q_-[0L<&9<AJOVK5ZWX4)
M0&4/ BJ9Q *:VR*K.PVM29VH3<AX#Y:B@[U0.>;EB+R.&J==4<<QU7B:B90]
M_13"&NV5I-O[NRATGM_-7/B\TNGFKI8)?\8%KM8),.>L;F'04(*]B29?=62Q
MU;7(KV^+8\76YLZ)32*4_NE'H-/??[*C484#>U*.*M!<^(7[&T30UH7?7QN/
M*1;D&ZU@'#)HM@01[@0B[E NR\$$C;Y,]Q#///(!X<0PUV.V;BJHWIH0M)+?
MT:;,$!0W;6&_PF%&08M-%:>M_<W_:BW6:>_R\G+4%I/167TQ%"97>$!9H<%5
M3+D(:0GI6,;>LCYT\"FCIN$.@]N^,./E%(W+OXG))&)XS^6^!!&?-).'\$:S
M'8-WQD S?S-^T8?1X2@;_)YC#FQEGOEV]&8T>/+X^;/7=ULJ/-U1J7!,!^M^
MRX%T\:53K43L0/0-U"9"P=6!G..3I:?Z""%YZ3-.=Y9NV&*QKCC(TNIF]AR_
M<T4A\$<+*<P"I(FVR;G/!3!G&YL+C<;N@%_FA_LRRV (@=."TL\$X*';NO [
ML\< ,V>!L*F)19@NR^$9)NY!;8_>#U+Z'::6697ZH>[%)>N>WX5DW>W5O2 Y
M?]V$5UI9RP[-B^?2:N/SHA)5'5>KI=R#YZ,7=UM)/=M1)?6^I,;&O&/W5UE]
MDG8^Z'@+R$R* $)$5!(?(\8GU @!MFB.Q6!DL2%S"[C.4^RNS#*_RA?8$XB0
M%QR5 &EN-)4K1:]G.@1UM^_!\QV]!Z?YUS_1:TN?P4@K V2!(E,(7NCL')*!
M&77)H9\@N6FY95N2P:7S4,GN@2\0644KAHG\/.#VM>V"/3!$^EWBDU%4R2)&
M\Z^^2Y9DG"N)4 <YY\HB:L@5V%LVWZH@_&H@, ?'F&@-1\Y^:"RK<277%(TL
M( -4(:%%2! ,#3DL@S4UQ4FR6'<U? LRJ_[S*2'+T\> JX04>X%CF+L,H;(Q
MQ#E<I,Z07B3>HHPV'L=50*.23\VB<6+@PE'J Q$,4O?Q[F.KEXQ7>VJ)9AB_
M!]^!Z'"];B9%8K5QJ<>X D#6NM4BAGF0U",##O*JPR0? ;5![JA%7,[9IJQE
M<-D&M)](=XY1.BI%W"L&'<'_S2R0WD<(93X9J#'((.&$2[C,KZ!V896OUKC4
M+6;5*5<W=B.I<23GY1+C"FX9J<ZU^%I,+*NN;F(GI\=%3VTVGN'7*+*(:%<
M'=C?B$Q&!PG1P@A(69FQT+7)ZSN$-B7@46=Q?@"69CV?E1&%J<V<A,]S'UAD
M:^* F0.58O).Y*2E+84"RB+CIHK:HK5+M3],SBEE64UT8%R'$%G&2)P3QV?T
M9]50/>>R!<O]@]=-B=V2^HY9OK:>\:A[?5ZX*\F9(WL1'?=Y_W60YEC38E'%
MK1JSV/QR!\'V[D*CJFPT'^14@/[9 ,I%ZJL"#2[2#?!#2Y/=2E>LS%IA1"0E
M7OMYWBRPWH(J7A$E-<_+!39CZJ%/C=*PH$@RFRMG[/%7J >O\KE(+LMVF3<E
M8G(AP5-+3TP0HGS7"R5,&XX):J&JI*EDD&!S>,-X#^]D9YZ@:^&>H,UF2O\/
M[5I(H4](;(CJD+I!^039K/ ;?U\Y9Y@1'@Y:#%II!LN:*&CP:10?JHG]:F*C
MI!;+P72]NJ)+P%"C =Y%=V1;8Y$!BM=\9YCJ(HEM(*FS!99A4H+[C)HP0?0.
MX :V96NJ'MX)S'P,=XU2T'UGP':+H+-03C-*5 2 ^(Q+%+[:K/Z>RN6RTI9.
M?#&17%JJ("K)R 'F3T9!!?E7AA(C?F)K3$ 7IY!O(5H+Q8@[*:;(V*+V>$Y(
M_.OU,;\H5Y'&5<L5ZJS2)R\H8P\\_9:^&*=5TT&]I$TPNW22[3RIU);E2&",
MHDV^X-G"FLZ((<_SB89*-ZIA"UD5YH=4/T;\4CAKKK+T-X; +SPHO7(;VWXF
M=D3;@=<N=85<>VGC^@C3X?0\J\@;V1,3LROX3_X(,0_('E8]PH,(=PONG^UK
MF2JL3+S3?E96$\#ZP'.L@78'%6)PX$NQ7R,JK]3Y3IME]M3' E*D&KD90<EE
M#Y@#P0X!A$'L37@>UH(9V8E%THCD8!=)H7(V^595 ,(Q1J%S=CP GTL7I>"?
MT7B,<H>>B-!U-O2I _NC78^-VU4:\PVP0=2!50&N<V'3_00@8=4TZZBZ,&H#
MQ8 ">SW9_PFI JR@AV=,S;1521_>A2.P&P& >0QXN#4,;UI8V:?06P3?Y#Y1
M>$Z&6[;ZN'^)H!=W(1'TTY^_7.EP[\'QZ=&;]X>#?UY7@N[ V$]_/1R\/?ST
M\>3H].#X7]D _OO-YY/3CV^/#CX,#CZ\I;]\_.W3P8=_[;*&Z(_$/Q_M:H76
M;SDV\19$L$WZ3P>GTCSCY[K^8DTC 2,W]S=U];E: 5M%S# >H^<3G J@JQ!I
MF_GK:?$:!$L2)?-S3>3+YA6_Y=4Y]-ACBH$WV"MF9MF1,X0NN_U36">Q#BWV
M6Q417$ED-!,PK;%X\4O49$:AZYDV79ZFZOUA9M,FOX0@9Q^G:Z.A[*"X>4"M
M7^33NM8M\$F]&/-*DP$BE4&:RUU<&]W/VUA>:)1 U9?1]%@0$#1GH5JJFI6S
M>VT#_T$O)BRPJT;RK((.THPMZK#NJ+T;GM<O1;$<C%%"N/8P_B;C&C/$AR@M
M5!9CA0.T[DR]+*H$2"G,I8PC$G%;OI8I3]9"[]73M!-J76X[*^NBV$[(6>J\
M*Q 46[+)L<@EML%%S$P[(E!SJPBKJ=H6H\MEO^&'W%Q$$5O(<UN) =J"$>V@
M3S4AA_W.'SMP3HA3%1TB45)T!+M*<#*OXQ@ 5^.L#Z)DJ&VZG^+(I^8N$_P?
MXRJ 2:]K$+"4^$LV#.%NUZ)7L>_5&H6QM?\Q$L%(574C0BQ$< 88WDN!)XR_
MM<R,)L;&R]&KO?PN,O@=V38*FH 34[X5(9_J)N3NI-3UVLP$K\#_K&MF.6FO
MS(\7]@IZ;7T[ "7<H=.=M1IS45"E92Z;]V<]H$G]2$1>(]R+WT/-M7^:DKM-
MVR[[DPSE]!%,=9#FHC&-F$<)[QU!/F[<<-0[*_[YL/GG17W!H/4<@Q>K<@7I
M7S2ZY+]:.7])GA=(CML8N\_GV$TI),D^JU/HTG%>>2&M"OF].V^I;/*[=K6&
MY?!K#?CB6Z]<N=7;]JU(HS<Q-GJIJ["GZK3&?!+I:Z%B(I,)C3NBJJ"@==6"
M2C)OOXZE3^GE. B[%_-:8RR4[KK6YN/AD"K XU:=03XAL!:C_+Q TV0EE@V6
M\9+X-PLP+J?3HA*2:;C(#7UFO,7\"O<C,RO&+/F\:(K"RJV;S>^@!%3LD2S'
M^HD"F/88N]>QA+(K[?Y0""?_;+V"K$=$!"[/#[2_9@OS.%-0DPIUT$Q]T-VJ
ME5\&B3[O[[Z90D_TPN3+&K8=HNB3IK2<+Y/RHIS[T 3L#@UA 6$U[UB7+%X1
MBWS=FI&7E\-;[%J3__NUW@&-3#2XG!+SO]2JH)8*QW&NCI_5',:KFJ&$<%R:
M>KZ1+&)6P@QG\QH:SA9YLSK_GW7^!6VBILJGM3G!ZZ8Q"K&"O[7KRL@PR.DM
MC?M0ZNY- V-VK:'&=&H,_18[]9$AIC@XS,^8!(!82*1[JNK=;48)7:K,SB\A
M. W)]J;\@E8?[NJZ:I R@Q?ETI@'EL=Q"O0E?%V,),#<@!E(8\Y3NX"T[P7$
M[ID-9&PL2!K48FQ4<(U6W'*]8M@2;KQD N&D41E<6<V:G%"*\(%;7;^F!^F
M5IPGHH<,O<?!MVNH+39KBY9KM39'"TIP)U=CRC:.RWIR7BS,$P%C- %KE(EG
MS"&;P@=F[,L2_Z4KK8&O'%';95M@=;.1G/,YNL)LB\'BK9D>J:G'#(N%/ ^R
MJZZ-3C)G9%;0V\QY0% <6NN<"35WZ0(K^.V^#<H%./8HFO*>JRXR8K$L",-)
MZWI>F+MZ[KYJ*Y+LFID%K;A@@]8U)98&[XHI%CH?FTO<&%G]<UY]4=@%B-/#
MQV/S9T0_HL6)!^7MZ1O]1=@,]8TAUT9'EU/US< QJ]IN^2@3 (^P)=O@"@5I
M^C3>M06/KTL?\F$V'_;R+N3#;FEQ/.645DQ4Q"\Y;Z;AP",JE!P0;3&&&>BA
MM1#Y0]B'@C>UCYS%V!$UK6(ZD$ST>DY@6H<S5=T$N'?F#(TI'&:F,!KT[PBE
M0<$-D"O0,$?C?HE5$=K#9[X-PV\V.H+JJE-!*Z+%<9+,:X@H$_=FS=0[-I-0
MB2A#F=F/,Q'L8Q(0"";*K&A0R1.OF!5D\CMK@F-AIE?YMHFPUKR#"5<R1:ZV
MR?:,WQ.TJ\R0-JCG1+&$M:(8#,)BM9J3>"3!/-@3)"W16)3+O))NZS.WU(EB
M!A7/)9:*"W6^+7X";4L0JT:U$S@W7^1GU -!-+^QA!"G!]@?]XAQHY"X&U9K
MIZ,#V^!V,FUSSF%1Z :UF0*3T?7T,= >4JSC&:GRF 8;VMK>LNB%&5]@PJS@
M.9$F6D9&B0=+TVD;%[;]OQG&'UYYNN3FO6NP?[B(P)&"0[B0[$V/))^=6@#U
M(R\C@2T;['*RRUN]*1"TJ[0%)Q#\8)K\-T9#W-^\^FE8,!7@2=O6'/, 7.>W
M:,;V<E[//!=MZ:'65+&DUN<80LZZ6*F9/SMLZ+G?\S(Y='@3\[!AE"F*R^@B
M&.XJ,4'R >A2#>VRSWN-[0##C!,1C[DJSLRS"4%K=&K.-L!.7^;T"?D]B@&(
M5E+L=.E88!8& ^D/764L26U0-U896,GMFLWXB$^S&4;S8[3,"-.6*KO0\IL5
MK/2%B[I=ETJ8,QT8]X[5K:K2''OD:26Y$MELJE#_"*<=**"RNJCGT(9D15RY
MU)NU5M528"S-J?LV%@BM8D@[E%PS_!<;3/%3E&UA>=^,N3=>-ZU+G[#93#P^
M[HJ:]70L!5C'#7HOCVOVT' R@B"!ATYNR*6YHVU= &5FLM&]6W2+4V'V,\]=
M=Z\C>"ETO4A5-]S%W&L 'P[,%D_$*LAYP @'(:$KK)PB"+-/SXY=9MR-ZXXB
MBN4;=@""WU*K&J"/:JWD8P)AOB34:,D'@=@,ES/5:TLUV@;.$16 1\*SI[W2
M!@OY9MALM:[FG6NH-0/.3)]T+RJOJFV?Z(B,3]6G>)E"66Z,TE=V';7+:[0J
MTUFGJD/(I]6C"%I.\I[24VDR$YMYQ&PTA^NM1^N^;M'93=E^ 2.@GI281Z"
MX 1$@FK6AS";LJN>V$WV(I^74X[K7:)^[>0%\GZT+OJ%<;0A-*5*3TG 0%7G
MR_JQ^02*=XAX#VI/LI^##5:M],V*ZCT>X2I8V!&.X+PT=BFSL^.PYO/Z4I(
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M@D/VX8#" ;5@)CJ?$#BA,YJEN;@R7L\9Q!S]/ K$)NG_2L@SLP8P5Z6Z'L1
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MBY"-S4/#TLIJ&UA"F]!\78PY;"=,XB;WS#D,D3E_A_@/X.GFX U.)L;H78,
M6JUR^#=;&O",VSL+?5?F\.MY.38*_N?;/*JCP8'9-;B]=C]D']K:+C[7!!GU
M33P :*!$U:H+(/0D8E';329T9IG5BJH$BH).H'E\YC-M5/P.XC:M\?]FV-04
M$XY4E61M4!W3217"R$TT8\VLGLM)MR:GGO ADC E8 EPQY ;&G5SWNYWU+*Q
M;>02LS2.3)6/P*+!$\T*\X@'K9QX\J7JBINT6++#7=9SG?&3>#-F=6,9C#4@
MW;)!6FKJE(PC9 4P+'B"Q)K:)-@6ULM$V6:.OE^#H\&!B0,DPVK)&.QX1:?H
M3#U2SZ4E;&/PE;!.2(T1(YW<[\;YTG%0X:+,X6L2[3SI41G1MG2L:]!:!UHL
M.L5B%]G"$>,@3.(!D"CQ?AXL8#H4$L6A$WT>!]0-C&8BI&G=,Y$6$-0.&MM'
MTJ,5VB+UEHZ:7(2\3==2=,AMNU0173P"9",4E"<[4B <1VE!YB, ?(DMXA%^
M""WIL2%34> )30G -C%9^.TQ,K\-W@) P<@=\W<*0"6(V()#'&@0JON@PY@O
M8(4[WAA/LPUT$_J71M?*47%HGFDT"D1:^2-QH2&L1/&$3+!<63C >+VNM4CV
M-$(;1_0WA5+17Y+D.E@>7?OI%IH;ZW$=('<T>&=>B-<,:?]6Y\3 [<F)I)#>
MO(BIX[;U"/4XX&$/.1F;DWGRD)/I7!P^7R+<10GZHK6]MH@&M8H 0KS#\+C(
M8'5YQ<3+5NNF&BBN1W>[_0NL+QF//8YE:ROFBG %<(&3HLZ+W[.Q(1GWUMUP
M6W<$=[1#U\/W2&JDG4/+GDX)<-\L,I.)#2_UB\R)74)YMMJJ@WQ[!6##IF3I
M(W_.*Y(\])&;D'I(SY32TV&8Z:9IN*_97]J"[3L8\0Y\%:( *!?8[-?+F<#R
M3YB^QN9AL/EI AV<ZF=\#/?LK,D7GF[<@D1Q?"6U)KKF'BJ 5-+"WB61 ?U#
M\*FH'-\!X:>(^:0BY')$KM'9'3P2#JD<)49+(B.=@LV!+,@X=**W(^ "("*0
M]>I1/7NTK"=?BI7=G"Q!L!MXRX3JZ1K[L=]!&5ZGNC/8$6>>96)'2Q :>$$L
M,[?Q\;M7>S3X'-(7XB.ZZE'8.2*F;8N;M:NW<0Y!(Y :=$?!/75@Z1;FDIUS
M/EH_1H.I_-PR" VQ^(#E4YR-'P:.%_0.Z2\#XQ!B.CYUHX2E<93:(/OL.HS
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M)W.("S&7MEWA+!I/_+H@4,,=Y4!.(T678@'1B9KD9(.'[UU$1ZE#DN/!\:K
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M )2RRL\0&+_,2R)(R/&OCVJX0X4,;UQ_'3B!P\74E;=HW/',)3Z@\*=1S=V
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MUA%QZ6/6 J*Q:-:9*_)>PM26&-#84Y#((:<&.,9^E45*7T_(E1/+."]SA
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M%6<_RR=8'\S.D;0EPMH5R5[;CM"YX/$!Q-S.K[Q&?.GR"Z#6**1H,:A5? !
M.0#4RP< U'46K+/4OU.WV[H45S:S%7OCCR0%IL.47>/<*K&OWW%'I#?8K6K"
ME<K4:DF$ 42SS4F<>MV7.&7?W;O3<>2H-[84FQ5I8M9^C\HPI"L1I@);+(/
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M]IAR\&_!;.U-P$>'.-!#!)BEPY@OA*XW\<9XFFW"NIVM 6='1\6^">A.@U&
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M#3BF:R@\5R483"(M]]4J0OL;L_.7>3.-4-2;=XMO;%/,BPM 6WM3X=JJE1G
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M8^U[[5A *N,+RZY>#E$@K M%TZ'8^F.JW?Z>HA79?^G3BO0%6<F5MN]4_:B
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M[&E3S.K/\T1:SP>Q\^U2,SW^QU$L8+$:!JZX+UZ[AJCD0EH6-#<7)&D1;=V
M+>),-Y7/,&R%02$-V1,/VW(U!'964CDM?S.8O\AFV5="D9EK5>0"QC R;(V>
M$Q(G=X@O._Z;*'J$1JG;0Q38YC_:+USX*>PLDWR93TJL3V(-90Q^%@EA7W2%
MU6!$!<$C'*0">R&:<=JNC)XF2]D4NOLZ@3*DN#8 7FDPA0)2,&CM.XJM,,8A
M<022F=OA)(Y2Y#>NPHBDA3M2R:NXG<)ZUD=>/J!65JA<SE1O:=;@ZOAO^[(>
MC=YQKLW_U)>>EI*+T&%TLI@!CY9;MNSQ!53.8CXQVVE.X?PJ?7$(_">7!X%
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M?LE?--]'U^Q*\F<T%,)_+B;1..2$_0BL&XQ:8I\!Q<$%4]LTK;Z.)@-1]QU
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MKQN^K?_E8?=E[7?'1]WC=_5?-P^HZ;N3H[=KN.LZIN!=]_!H=V;@S<GQH\_
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M:A^28:D)@EA(L.X>']_OU0:1.X1[=!9A'/[ UY\&XSR: 1TSK@]W=*9FH[)
M*OPAI"KG^EZ@D?P!](HY=&F%]JB3)2U7Q5;C1L]\(]7UG<R!!RAHV=(;-X[)
M3DYK63D%I"NX3VMYVW$=3MI8DF[61^Z9?LH]TTE20"OX:D5]W<Z;-*S6F?*\
MJ38!%-<@43B<9/J).>7%Y);(%*,HZ!_8 JKC.G0X%R?@#2RBZJ=>?4ZGZUW"
MEFT>L>\8LCI5Q<Y<H)^I=$AY4O9H8]QVF!D/ JFH=-%$ 44Y0\6X*%ZDTQ?S
M=/P]++1,BR,5YF*B^=KUFAHK;36@7RYWN$-G\_@>Y!<WZ)AG'(@#J*@2VS"G
ML3X$K&,Z"_^UB#(JSL%5@B?MR4J!0:-DD7>M^$>:\YE479Q*&LTO'X/VN5>G
M(H!]=TXDU]M$6EAOZ@<CL2G8EH'MS"(.2B4H\(W1G,&CS&7DT%XC^F]U*(W"
MXBYDRF#91%NVW'9E*EN\X\_B'5]M(=YQ#?3-&+9Y]%E^N1K;[X^;:"1LKI/N
MX2H;=K-#Q38D0B']3B=,9<"KK,2NXU77T+#U3??D]7K FJLUP-SJ5I7NP9T\
M=GN8AP0@T1[ACR"FNTT4UF?]KQ>7@RNO]]NPWX<F\ZT@MH*XMX+XTA;$HY<;
MD42W_30BJS28I<GUBG;)\6;&[]8D7RX^]T^_?>X-O:^]X=5Y?W@IE,IVOT@-
MBU"#Y[DMDWTZN!I\Z)W_C^^==WM=?R>G.3<=W)U\@QW8*%>?^MZGB\]G*([G
M9]Z'_GG_X^!TT/OL7?R!0GKQ<>M?HO>E/QR<]LX]ME9ZPS^]RT^]8?_2^SD/
M;J-O,[B\_-8_\S[UA_UOYV)A6HNKM;CVU>)ZMPV>3T,3>.P^,_6POQRV ?.]
MHY='*X56U."?5B;?O>N^/7Y7)Y*-PO.V^^[E7ZE%/&[8YDT[Z2';Z'%[JSUY
M#+OWX7-?G*C>Z<7YE7"FZ[M [;9N/SE>;1\]Y+LC,9S5E/#FQRI.M[<_-]8F
M 3T\[KY\]^I93\&;D^[)JZ.]GX)F.3@^6@\;P1Z8..VE&[_46</R\QVF-X=/
M[@VO!J?BN!X(M_+CX'QP-;@XOUP!^MWP@IANVZH>VH=5V/2C]AS?HE6N:QU$
MH(C#[N%?6]O&,JE-M<7&1M0 &!Y2438X-=S5>)/5*J6P3"M,>R=,1WLK3!*C
MV(I1*T9K%Z/CO16C:ZQ*:46H%:$UB]#)WHK03/Q\'"0F&E^8>6$T+P[R#LN6
M[RDC<*@_120!?U'Y22N.K3BN3QQ?/2=QE(VA'&)'W:-:D5O7:QVU(B=%[O7>
MBAR,*::RM$$R3K,YE[*W8M6*U=K%ZLV^BE6Y@*^5IE::UBY-;_=5FDYA4$*<
M N:M::V^-;[6<56@:I%HS[$"\W5IV;>A K.%.K50IQ;JU$*=MA;J]#P-LG=[
M:Y")8WL4)-];*^P)K;#G*D6'+_=6C-(9\X.U@M0*TOH%:6_A><PYU$I1*T7K
MEZ*]Q>4I\K-6CEHY6K\<[2TP[XQX7AV(!?ZF/:A: 7L" =M;V)Z#F[V5IU:>
MUBU/>XN[TW"[5I#6]5HGK2 I0=I;-%V56+\5J%:@UB]0>XNC<[4Q:46J%:GU
MB]3>@NG. /N3Y8[HQ'^TDM5*UOHE:V]1$6=7IZT$M1*T?F*(O05$" FBOLCC
M2+Q.&]9KI>D)I&EO41%]V1BL-VY%J16E)Q"EO85&5-L<MN+4BM.ZQ6EO$1(?
M%W'L]9,B*F)J(&A1JRC"%<=EEVXJB,J5)=J(5E!;05VCH.XMTH*:TK9RM,;7
M>M7*D9*CO4588% C6.7,<U]9<^RY+FY/OE9BGTYB]Q;*\36+$HA"QM[%=!J-
M6Z[:5IR>0)SV%L@Q#*^CO,B"E@FIE:,GD*.]16\,0R%%T9B(D%SVHW5!C=EH
M7(/68@NI:H7R"81R;X$?ICRU,,56IIY.IH[W%@JB!:E-7[?"]#3"M+=($+3R
MO-8'6_MKO6ZE24G3WH)!6I^I%:*G$J*]A8!<WD5Y[GW,@F3LB%"<?OK8RE<K
M7^N7K[U%;GQ+QBUK>BM3FY"IO45Q?$NH%+D0(N4JH/S6O>RV(O:D(B8'(:\\
M(O+[QQ*[)[AT_YJ]#[S>UZ\7@_.K+_WS*^_BHW?6_WIQ.;CJ#?_\]9=7[]Y[
M'R^&7^#S8?^T/_AZ=4F?\E7PQ>6GWK#/'_?_MW_Z#1K'>[WS,W'1Y\'O_>&?
MOG<U[)U??NP/\>/+;\-A__Q,_&7<]J^IH1T1@.=XQASM8:/YWGR>1DF!$+YT
M:G1 [+9'22M)ZY.D_8O2?4RS&5IE5YFXRS3,@E$41\4]B)5P@_)6H%J!6J-
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M/_W_?._HY=&A#VV=(.04S-+DVCN(.MZ7B\_]TV^?>T/O:V]X==X?7HHW\;U
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M1*@F$"8<JZI/M<AAOXT6A9>DPL84&R^[B_)0'L0^:Q@OOP''[":X#7%SSL(
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M'A9%3"E1*IKA(_%^5S869':V?]_49Y)_:HLP9J"Z+PRSA!WXIK76B3,-S@(
MO;KNA7B%ZVA4Z?BQ8T9 2Y[2<+"53.*-SU0YA!7E-7A^N":DXJ)<\:FR$9L'
MLQ!M]RIQA,$J0=2<0B_B31]",[%BXG4GI:4E;E@F+<'6&8+KS"_YS2TG5BYE
M7[4WQ6Y+SY87E%2C)%N0I=VHPBGE2YSE?7+CCH/\QO!AYF50LRR-JP:)JH5Q
MMAFK#+#5I<FLCT._A.F)8)"J3,[F0])UB6^['E "UP%>X93$EY*<D[K@T_UB
M-2C\OX)Q7X9 M@&^CC<1E@-65&I M8FF%E_YR-O-@3BB8 _II7)A SN,ZG()
M@@*FRA?NFJ]C HWKX,51OBN ;S7=.ZV>W^R*>G[JJ,C.*&@CDJ1#]D:XI$87
M:Z%U&OG-JMCM@"CEX:Y?VFU!:2&0]4*:QG&0;33JM#.!\__8AEF2G D036.[
M2'@[TP7DV[),=N78,P3+NU: :P7XZG3C<V/[[X8%"]2A5YDXK8R:=>W-8S\-
M<=[<I NLC.%26F8?;0SV(N&5/B?%#XQV03;XBW OQ,?JEY+ZTJ0W,Q13(#E%
MX$T$&(.DJ;.;0<H%;"I CEJ-"S"PK &[N@,B>-1B)IM$T-PO&Y^G*HI";-<@
MX5I[-O.@XP*G5=CA4_DZXYJ.A-VD"<([9FG&_9SH767%44[A9)B)J2IL$[_S
ML?"(2O0G,HLD_;'<#DI@0 (M7I(EJ*PK3:VC+"]H(>$F)/QH%R#AFVIQ7RF%
M' !U=7F/<:BEKK!1N53C+)Q$3&P+(659?!<4=!*D]N6V8Z93E8['&Y79B _S
M22[+5Y8*,JF?&WRDT&@J#HTQ-*PH(NOQ7XL('#PO6!0W:<;]6J%!9J4LNCP%
MR)BQ\BQPSG[5%\]3?F.'[/M4#RWN'\X+S& Q%R6JIBD^''ZB-!(4H1(72:Y4
MG2)U*.@\5WRWC;FQ%9FY?%Z1@Z1*3^*%/P"R$!&)YHS_C304:;Z 9I2 T(LT
M2(^ @=9R! F':L6DW'>,2MS*NE-I;D!7JECA2,P+1$$=U>&KLHS!ZK/7@6E)
MK@,-<C9\<JA#=RWN79AQ5;JSAGJG3:,67]] F,DE&KWQMME%54_!2)*8XX:M
M>OCN^,3BVWH Q=8N;.$61U^[A3\*DU=8=MXIAU<V/E%5\UY'?O!\$$>),* I
ML+?;V_)XNP."'Q=B%?J L.?HQ%.V'VI,<FQYFR;'Q#U=\7US=FCKH]"5N7O:
M;BO;7J*N:!.,%+ZCQZ]-H7"TVVJRQ8362@MY&UM%[*&L3V)SPJ8KR.DD_'V@
M0;(!S :'SQ*0] $'LQ62GDC!DGLK3EUN%0&>-KMDKN!:3<R$?[%:J(0J"TP&
M*,GXQ($-IK7:2#RCC!EQ#9-0.56")IX%)RV3U;("^)@6=A<+Z'_P$#HFZ8^O
M3LE$(=9F6B8)7FK)F)Y(5;_:;N,"0S9!:]0^WMRU=NU?F+[6M'WNINWKUK2M
M%1C%@G"!+ @;GZ@2';RN<BQWC7$!D2N<#E4#-RBDY540N3SF%Y GA:"/A57+
MD5&#X]P;+7(QX#PW:%DGLRAA0\]7AE2A&2GJ4SS"Y(U3,N'$#X[?OO5^$]\E
M=S"NRT+\4UP#D_IGFGW7__+$-!T>^]ZW[F6WM]L2V39H:&BIS9[7QF>HZFPZ
MJFF!:05\1@1H26HAV: AD7(HL?8IT1 +R?@2)#?0LDW(./A%I^!NB8_UKB<I
MU=+60#B"C9[(Y\)4+*1?<U\5#$MDB/@TCI4WQ-ZQ!&6IED1FO8%L*HCQ\?1%
MILK+FT93Z:/8U=XT))%U>-W^H>J(FH6S]%958TIBE+SIH5T/V_(9]>\-C]'W
M6<H'H^>?V4\P17]-)2T%K^P=Y+MT3PM3V6*>7?$ \(-UP2H\AG\Y"E5JN9PR
MWN/:TJ,65=Z@"*%1W9AH=9_.>VQ4B%ON/5I3MBU,Q%OO-!JS1K4TVS!K?\%;
M.]EME=CB]%?:J5M!$N2P$TF$?'?=L#"-T.PBXPX88G"'CX3S(XP%MC!4\Q.[
M%8KJY\5E *KG%L'V>L+2C"/$X&!# [3^@C&7]T._THB87?7GLASV-HUO)<1N
MOA@)NP/L5L(8HYT"'#"ZDZ5XO4"8)7$T$U8.W4=7QADOB[ ?^C1;0"\^A@D6
M1@9"<MW (V1]L9C$\(>X#4H[&= 97$@S ;\0_Z-T1P[_A2P VEAB0.#'3A<)
MO1ZR'9$AJ&:GTO^/1L!#,-Z2?I?QCB.C.?'PS35/P6IT"19[*#;\AA\%L&NR
MD)I*Z"9I<LJ,#H9;D2G8A'@U=6[4$TGGP_7"\&T TZ,-: ,C'TI,&O5O*O>2
MI8ZS+,$M)M[ Q!^WF/C:Z6E4]:!61N3EL3^.:6AL383>I-1DAL<J_O\ZA555
M[@=!1SCGMYAO9>V)R5#L#TRJ6CKN>#WV-Z4X'.B^40>T[6Q>Z /&NIP=7^[F
M.'4I^;K2+IU77>E0Y([7'/24IX&1W!8&O>\Y;8#=!C\?MW5AM2:?O=4V/DT/
M@#]KU//Q'J.>CUO@?OW>M4DY-SY/)="S4/-=B$I>^]['8)1%WV&4>1YZAR]]
M[^3UX8GWZ==?CH[>OK\6&S<%PN\:\OPE?/F5WL"R=K*)=<RX0S7P*\_" PI0
M8[=C-IN#VS2B^B-QDTFZ&!7.MHY\AXZ#_$/\=QQD$.)?<#)K(8N:=0!</DX>
M;/45RSLMW&U)0[-P;UOPP=C:\.WAF_= ZCZ;$3 0=RKFD0.J5PYB[S:(%R@K
MIY\^>B^AK0^X0SY\'DWB>^FS(YIN41C5>.(@6P"+_#R(Z.M9<.^KRC6= X%R
M1/!MQ0&(QB&0Y"QB"ASH&D'ECLN4$S/C*O.7^GUB]('Z?=+\__K+JW>;9"-J
MVB$RH[91U,MV3@T4:FYT6H07E:1BD^D<']-(/7#_56 9NC07Q ,RC.,;X.&;
M9Y M%/]D6+#P<%!RQ$DA":QR_?LY!(/FY,(1G%5&PN%,F:;D*=%MI*3>!=$M
M>9:R4>ZDE8Z=E([I(H.5WBR+^79.S4UZ%VZX1\6V3LVF=:H\_"&,CAHU'0M?
MF+ C%'-%I4MF1XH5^&1]^%XNC//BQ6)._)NIT&?X=CXHVUBX) 3XQT]D !<O
M%3LAY_R&T:T'E?HDS,=9-*(:!$US>GCH(/=C!5S.#"AF3;9#I<5A6EWXOFC8
M*(;56? CFBUFLI9@+NX0%>R\"._&UYR:5%V@/ 8C3"V^%S82^C7@GV ,#-^K
MK1KX:5^F[?Q3[\O<"3/?^PA-PC8^1[N F!"^TC;,TVHTAD8D9;>#$6V%9NV&
M_&;7Q6T/^.E9M6$_;CME-.Q0(TVR\5G:A4,&RARV8:)J1!C,\NM$<I:!' \5
M!L.[A&B&\/!GB_@ZL /WLLET'63HP1K@2?$1;A70&UX-3C_WO<&@=O!;,]2O
M7R\&YU=?^N=7WL5'[ZS_]>)R<-4;_DFQHH\7PR_P^;!_VA]\O;K$3[?^I?@M
M8."7GWK#/@W;Z_]O__3;U>#BW.N=G^W@MCKK?Q[\WA_^Z7M7P][YY<?^$%[$
MN_PV'/;/S\1?QD+M[KDICOTG.C8?JH%[1KV&;BC\9,V>W-.VT3.!:I5DE5.8
MA0 XHEG**\4O5B&A3)@Z6I[ 22SO1=03_PZI9HD0GY4[,RW%0^@F+8/S(62-
M.9<6,4T%]HF'O\L4&%5FS2>GSBQS?S@I+0$M9M%:6JR6?XG4DCN%CE2%57G=
MD-I4J*$L">^% A);%+H5X<M2LB2](T]V$L8AV V^P4 "/V86$AR!\'>#[U2:
M)IO_250S=JR>S>/ :'/SH/> IT[2>6'=79@SXW"R@$AA$D+(CK<B0"(@_8)Y
M57TOX8E; Z4*,%)Y065+,U%*GHI? J%I%N*%4!$'BVD\,<7J.^Q-!.C "EIA
M:1?UQA>'Y0^P/9SD%I632C5J<(&8WG&\R"$Y-0EALP QM@JFTD@CEFMCJ%@]
M7%";^AUV\XZZ3P6*^ F2Q1E.^A4#38-1%'-=Z=-UQ5UR:K5@ZMZ+XY-= %-O
MB^#!B;6] K=1H=IHN.G4B#AN159J(\(,UIVRNR1H!$TI1,%'B.$ .[)<T!\F
MUUEP"_7VP-I1P#^$LKY)Q:?S&\)QB*-SLAB3#8-G,24XF;U,&!&2YQR.]@D9
MH"6$I#SKS5)Y' W_E,W/ILYF$;1.H[RM45]S#V1[PG)(%K,1$=41"?G5#;^N
M>E$LX1<&@C"5XWMICD'-EFV4;V=2O4_]I+W>1KVN.GH"B>9+[BV;,$IRD$VQ
M5KXW2R<J>\ZD>!R!*Q4_P7[2/1-6,Z&Q2PE7+5)VNUM:?"AQ!#(8L;NQSH]C
MAKQ+Q<PL" P@7 $LWPOQBJ  -G_89]YD$1MNX82_AIY(CF:<5,B'K0L &?#8
MCS)((='3B6[+G(R:6M)@B^01#"O@8:O.!LHX)7<'B:VB[U#"=9["].*W2>JU
M"I@4L*%V"XXC&%H6B= FY.C>R[ZSS;T<Q?*(GR*N#N%TB5BP<8B.TI0=>?:R
MA.H- -'N8(>QH"14;2B;-0S-F#IB^/)42@GM6K^TB6'%]4[;#A#(9E9["%&
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M4SZ_$4_Q@ .@DATGF5)C4"<M\F"B&1[?RY?RE83;*7H(63M$^\#5=T>_%HN
M.:\=S6I<V;AD<$69O'V^POW'<22]WLJCA($$J3+(*H+\X#: #H6:D(Q<X9PV
M@^]N'@*WU:[>$O@W;=2#RI[ X/,T<AE1'2\7.S*?EC]7_I09VV_R.<589PI+
M;;TUO3 VYL O^;5]!]N#)<!HC2H6.0X6.RCD9+JTO*"@D*TP*VWHB+:NDGL)
M!*]3+$KA=1J83+?$!=1 Z*=B5'BH*R@W#A2_/R%+VS;6ZY1"L0^K)V$ OY$^
M\Q572F8Q9/$Y7J7',OOP.)E[5=>?B4H?<5*(XVH&QV-)<W'-!%B?8BB [AH'
M\V ,I[K0"C*JY7O,&50)")DQ,AG-JJ6)%Z\F-_ZK[IN.;)\&IB82%N-KIIEJ
MY2O/)SOV8SP. ZLV0:CL->SC23R.A04P095MHC34[W*YJ*?2S!/F'5XU*>]_
MHXV4'5PE1S..TSLQO[_^\DJXJ@>]#IZ%:]ZV>,=_0-8Y&J^PD4M+QZ]E>@/B
M;0PW/3<*JPQS8_IDB.TZCJ023M,5TR;,&<;$N5T>4'X38A;/T6",.)_R\G,R
M?.<7+D%X48@XR9F_6>#M36CX#^(PGTM#6[P_MY\ $Y*U$Z7I"1NZ*TLQ(=U"
M"V$DXM5N)#@$UB:"^MNL^ !>(I(.CC2<5ABU#<XUU:B!RTU5PW7CU#.Q"6$A
MF^J2ZTZ\WB:U<$DD2=%#("[+PMN4[F@Y;1H#JMRU<;#(0[,5A8;QF2T$]!LB
MNOI#AWZB94DYA?/@GI2,:>F"WP$U@SH[6\Z/*?-\&BI4# '"QV)8UW!V8SFL
M80<067_3XU9/>6PHLF7.1UX$LSD60QHP%D3\J)Y^O$(CX-^\)XYH!"MV##24
MZ2Y7\E2E#5-3"+P2_,IAKAV<=MR<O#PF<)RP@6$1PF8%UXN*KAWV%D02X%"E
MTFQ2&QXH/ @1R/"0?2^ UN@<*42WL?N$4=&226^O+M G!R(MF51;BN+USCIZ
M_Q%,2;S[O?.<-,&>%"^7R%,Q6K'*K%' 8\O#N$-R"V:3!ESAX7T+0#E#;(5(
MTC$F\X99J)/<B$:+[+6L0YGY9;S:-73U2&!MA6T;7".A%_ EF>3J>-CTERXR
M6'3 ^:XK1PAO*U.YVA19-G>5'2L9:S'FJ9-*P/XR+PP[V++J[6RYL;Z@D260
M$6=0JCB';B5<GAD'P"505+T $$822'+K)^3P!+'AQ!@>"WDJ<\E*8 <.F-O]
MQG!3U$W00(NC<"%3]9Q7!E=]EF !KFQ#%9A825TA]< 99P-#+;HQ=<VA-9[\
M5$X^ASS%5_?X:VV4376/*] 08E9^W'-)V@]$0&(@5\JF'IH9\KU-47C9-ZRE
MW90E%:K.7L8^%^(9<9WLK_"VY>[8UJE,L3$,PK6UR6;6Z_4N9+V>'@[AGJ\_
M3"-*HH^4(J$3NZ$/NC,'(,W#TI[%P$*J6RI5?@<7?$_0DX_!,L6DOBG(R/T!
M W0&8KR#\ ?^(B@1: C%;3;7["!J"%D^$LB[$3^$I52-#YV@8+S!N -="-2A
MKW_M_ D=,I3WH /2; D'4"L(T+!S"=]Y=^DBYHAP!MI(?&^,2]73.0(D8A)L
M#2@3(*7@B30\9-B&T%YUII[OR0*9U>V4BN97-HD1OI/Y,CE8HZH,[VZ$>EC_
M\Y5E&[8$_G/ X*VF+#+!4+&.M/6C;:-&TV:43JJ&#<TI)P#UE(#-1E8HI:RX
M_FZE8&2Y@R8;7->A9B\IQ0/'.K:2Z2B==C*O48S',5>DL8VFCGM.\%*'33JD
MC$Q99K5QDUFING.RZUT2"W3E16GO<M$&?"YM\)&82:A-@*PS96?&WO4BP$6A
M]*V5MY.SM,B2*+^I=MOA.2$O<XLF9IM1="L<&Y8F@]8.UREZS,N5O$O'-Z7/
M(+0+*ZAU+:V&13RN*VEL6)>^<=47M1D<5;DK.ATUS0=!$4:R52'WOC"5D6MP
M,JT*CY3O&U'"DQU03&^4:]?-TXMRLQ^6SH/Y") HPE?AD7(;I;&LN*E.A=&V
MU5O6OG1%5=OU/H+E7>)U4CO%0Y,=SR'GEBG!+C2 P$2QRE#1'0($<0IP6G%G
M(:0"_S3+*^N#$'JKFL$/F;Q%LX$Z7( "$+8(YWXKNA[S^&8]EU1L5@2M-*\'
MK/1=T1;CY(4XR^06'/,.FU8N:3+A26J_@ (N*-4MPQ@V#H,K<@M4&3 A= M2
MG%$V7LSR@NO\*49DC&MD9M*=MX]D< 4LFF ,2&TD M-S\/?<&7<PMG=ML^)=
M;J1YU'TJAO"']RTW5"!LB,M@&GX/PSD3K;E,WN>;L[YR:;$:KP@5&=8&F3E2
MX]B2\5D$'>KH@19LW8),W?1 G0A.7\14@JSNO<'O'L5^D#WPFM+!ZM9<5)Z.
M.=D7C-);0\XQ;R![@E@MJ*NW<N</(;+:E$%$:A.,9O/37.F/J32\=/[$YB<Q
M0C'0\C=/F<JP]C?C(-%)YYB,2O0;:!G#'_,PR<O1*1C&W0U;ZJ5COO/P.(]"
M<HFKJ5ZFZUY6=5K*SL/E>Z<4Q#3N;P#H >=CPGQD_-OATEE#*C_$[D=>@24V
MUK[ZZN@1QL\XA$U199JL^)3TWI+),7165!4W\(\P9F8@ LW5T0+YLC#H@+%P
M=O=/E?$VPJ$YI98PGIAJ,)6,=0B="J9_2N.I4LCZG*BM;E?G2O],K)"NLTO2
M)8B/J3M6Z@!43M" _5.:2?<@2FE)N87HQ<%#,CPHOI]QN3NH(I6*@=C4-Y'8
M7$25&C!.W&#.^Y&2Y0@%63_P>DQ0@$]JAM56DCZNQU0W:*/C5)Y*!_NIG$N2
M!&O\)>-9Q;:7S1J8EW'LW*H6Z18B4Q\FY:O.F'ZB2LZ1?[0:%[*S;2Z7J#@K
MS,OF>\W$NT7H9R'=;>C>"-V_V870_8:FIP'[;P>6' 3E#Y?/U643W<,Y4CTC
MJ$"!)SBQ'E J'B^QW$ (9OJ4NM60?U66/:I4.[N/E!II1!E$<\P,C=<4(I#%
M49W?W?8EGZJ7ST-]R8%!NX)J=YM\M9N XT96G:G#Q9I6S% FPXF ^Z>2".%X
M%2)KF-^M@G$]B"1FP_&E2DE4PE@&G-V7X45I1CNM' <TX1&<$EDJCFVZJ?C=
MJ"0B=[94L9)F5<TDHV#LOK@0;@X@W,IP-X(UJBR4BNUIU]::'8S#&629VLL#
M*P*IB(2?)^%#A$D@QTG5(S'.B(%S-B=2.E767 D]I !S"MW(Z1.H"Y'@.(G_
MP2T!E4SB?0$F+NV=, Y_^-[E'X./5]X,<EQ(^.1+[S6+\N\$@'.ZL:S/#2<6
MH=R:L% %&:"C$BZ%>."XR-(D&I-/S42M7>^;VOZW*FG''!<ZIZ4S,N7]ES]V
M$0"'9# -5V^*NE ;8@@F6LSRDO7. $'24D4OJG&J5?7@,%>?+3T,K8UP5,:+
MPH;J83UX+FR/*('R)6&O3*<PLT/2JV38NP U],V_%N3+20HIO5P&"E2N?6T!
MK^(?*]TC$MKNY,U[$'GI</E0QE&-B$BS@RTE5]J<]A.C5!U!&'0S,-J/#JOC
MO$"O5^QO^)XZN 2YNVOAJ^X[O'J[^:L_;-1*(&1\1T&\BN 'S[&% Y +!E\@
MYE@LL53\0E4E/.-H3EB0!WD*Z/BG#8SCK\N,==0FLY)VXN[526PA#0BQJ!C/
M<U.T*KXR^\F&4-B_+=MNNV@@O]Y2 UEV/_'!&!HQ:SUE7;C-.$W_<#M2++NS
M]-O;B$,N^?-F_-%FOFP,S6Y#634BU^<!TUE4[3>35<[R%@SW8RJ9+!01>ATL
M\>!'!_) XS!6'' YF\UDHB1B!O##D@F!C'6U=@0F-N#!%IT.QRAS?J(;AW=P
MW^$:F\*:-?1 %>LZ6]ER<.C#_+LCTXRE;Y>;M4886=:)B3,##1L%Z. Z3-,L
M5WZKPO)QE2;#8/#IVN?"/-^96=&EPU68UL0$5KG1@>S)9H>W.BY#N\:$5*!_
MW@W@S""RA^PKM?D*"9!7.)X<F: F.-S2RS@) L% ?!!#H%E K#G<#1B<H^(&
M,PM!-C$A$T+_"@\K@\=!3&X<=K0[W/@:9NY5_&):P8@V4BT:16D64*-CN-68
MM= NFBK7T@:P;SJJ\"Y(P.4*$RH;S;CA$G,-3&-D#&[-X[]F'AM;/XB$^[-=
MY:/.>GK#,]OD%*X0V2BU]?2;(Q[IM!+T*#?+,="+1J>(8F<;'&XO\;]IQQ.?
M'EGRW^:MP5=K\.7*V<D #:@F<'OM/VE$5"I!.?*$\2"%;="&85H (7\8*BQ
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M'.M,?'&S.PA('K#DN$A Q+E,*]+""0PXP;L63E [/0ZM8+96<@E9QY)1J\.
M(:+&N>CTBQZNQ+C2EJ/>::*3;-3A0E7:6L6T34)L"2.TBS$*=)%O6-746F6S
M#SB6YD .GUR_B,,IS/C;TDGU G;1QC/1;[<T$_U9L9AB%]4^YDFDPI:FJN_I
MNJRP&'>E[?7K+Z_>O1<[)H?59D.OYC=;D;G>1AMGU\JU>KH3PY!R<9@4?+Y@
MWIXPW+5'#52 XW!BU#:'-2)%FM-F/9-%KIJ-V5<P2]]& AO.J(H>")FD^TX,
M/L5RFPUVT1/9\:24O(?+ZTC:FICHB H5-P1:N;+"6YFK7.^;EACCI2VI'3JZ
M0MP2+7?@"\D7,_$_.+(BGM@LC&:C12:.F*A032B$^Z.#GXX4I:(]%V,>?[<(
M%ZV%$,Z89W=V)5R;F>-69-K\4.,)U9^G=4R6::;SPU1A+:>M&@]RN(@5/S#7
M)$)M[O5A&415U"9F<+)0Z1/Q%Q@Q):K_2+)>PP^(4K@@-_PZ3!;B[@GVU^76
M,PH.8=$IS@*TH^K:-1QW#\W41)D36-*!4_U9:;N;=-1E;D:W.E*5!6FFA)!_
M<+<4E4;#E#W,C%R'.8XJF:5,!DK:&] @PHP4OXR$(\M^,\A"0R,MDP;[%H/2
MSE34*LPHNV@E;&W5CV$E&!;F\S42(+@<E<B_5/\+/@]RXV 4:B3,A.=%G+..
MZ^;8R%I(5R9_PH1(.5KCV%:0SVB#(*7V5UDX7>3&;RITK%8%.C%J&#>#X1$I
M^@/OIPGW]!M77V2RR.29*ZR1*)U TUYFQ6QJU5ME4PIL/BWXNDRSI=OW(D&?
MT3Z,D^I1+FDM=?L4;%$F=!-E9&H[!<IAB=F[3L5K3 .AVGRS'S&UX &3";,I
M*?UW%'(X?\H1;F5XPT=">;$-P]J62'SUD5 Y(+!I"Y7ML,.M&H1HK1[^$)9&
M KQ9LD^<"O6E:O_ ;,4157A!IE?Q[2]OH:3W1EF'(_=P28W7WMRW$ECUF77B
M@#8FTIN%H8S+FLQMI4V$*V*=W'3"^1H0Q82QD.')K6[3;[IOA2>WBR?+>%M/
MEB'M<C#$9"NLYWVT.-(A*PJ?9OJ6MAX8HQDJ2L62FMGX>IT!31>%>J9B!V-;
ML3YY$.1Y.HX"2>-/ !9#_4FX!#(XH<LE!B?LXQ2&1>"9G+)VU'Q:*&J9SG(?
M!;5:V'$\RAXA5<8J;H>(!)4NED>E2A@:K[TXE>0Q70S]]10IR#6R%F.A@?0G
M<[_&_(?Q?^M>=EDYA5#1^F!7H-'0KU>C"F],VM!NBB)[5>%)7O9M!IH#UQMT
M>]V#6)5>_$;'OWD)[JB/T#G]XXO7Q.$&I[#S2MD-=H860_4$W44=K(/'[[94
M%W].A55*-6C;$N+=A 8&A >A8CC=K)(F,^%IX^[W =M69.D]_%/HK *MD;Q(
MX[#"^>DUL$#*FG0T^Z+O@,* AHSNGARRI&C]L>2_ULP^T/-$'OPF%Q-@3<KP
M)8Y::$4L3D"*FBB\H35F@CA:&>]"0F-2ZKBYY4M0VI]Z>^*2;%2\9(=F7@XL
M?W&M2+V(T;;"G+,I&1K)2J5TXK:<YV\J#.)TIWZNVB^5S3(*X7 NWPH>Q<2X
MR,;,<$I-"Q&,=9%3(,R9)/"F$5%?BR?E$/%'6^+&#/@2QHC.Z7OBEI<MK*VX
MM?&YN/-DQ5[W8/I!=0H3=G)7%0A&8+M(J++*9@"!,X.6.*>JCVG9@>(0H<XA
MM8@* U%Q\K)%5-1KK]D\S=U%@&JK:_R][M3I:X#[LNZ]4T.GD)6)6B5G$W]J
M C"&=(1#P2[X2F/L3U$B.2>5H\J&-#!S%Q"SRPS4PY=;:J&>EC%H9WH]T>,K
M4?\1HN$+E(N$B0S6#JF)[?.U;WMQ3-DA$^)7E1EE]M;3,W6]4_D=W=#L-FK&
M&; / G9G*?+&OK@8U/-NA<Z>4.<\<>*.0RHCY[BY QF%01(J&*E02$=YJ5L*
MVQ4\8K.\01V^%1@IU1OEV$*7&GQ-/6K5QC8*WJWK]2AMGQ/>"ZJI-9P?6L-X
M!]ME-X;=ZXWN1="T6;JXOI& 3R1H.+LZ[>CMQ]%YM0M5LL!8(0PA.?'D%<:Q
M#T&,FN#4J+&2'98G"^/"THU,83F09Q%>%]*^FM_<YQPID5NLYGF[';XX/-S2
MTZ&?CV_"H  ]\GR5.Y>GA+>4%K\7VG8<!Q%(T%S"55V10U\I4ID/B51W1B%F
M0KHT)-#*^;/[0ZZ.?)1-:B>-)T*1\_%0J0(L72P5PR)?$.0G2<*XICR&^^J%
M/^:13DJ6 #?0[GR!YB$G'<U9"$;B5=+$G"2(OPH#D_84F8:.J>2QBWN%M]#%
M2';<BMP<&7"MY!@V2WG5[XE16'Z\1_V@#X^V5&M\A;RWV&%],E?0"@&!:%6(
M4B%&<EB#W2B'#+$6-O3P1S+IJJ0XE<VGA.TD1.8%IEML!*,"^87&$F"YCQ?,
ML ID$DVGXGXF_E!6MX$Q(.ZATCZRQB8C-M+I L[CZ2*YCD )'"SQ)PD&9A1>
M4A]F^$%'2W#-LP\:OA.+%U-GOUAXM> W'KU\OYT(OH]BRBQIH%?:Y);$^3I\
MK[QOGF1<$+TWC.VSY5/LTCE;,\N=F@P&B+HF2K *K4#JO?J7$@(U#[) 9C^P
M?F[,LERSVPRZ66?+M/J"=J-/D%5+VC \75;7,%"58K7N6CM\80&I9G+JKJ??
M+@=?V;&@\.W$B\/KD-+NP,"@,$B('Z[ 9D;W1BNL&DHW3BF;/95E20ACQ;V#
MG9,.JD\Y>?/^Z9H%+5=%6SV+E9VY;5/H&^UNX_M.UQM0>!7]^P9I'8G7G87U
MDN=67D$':]YTID;9)Y\T3JQNYQ$6''Z^].(A12'2^3S-BD7"O8U53@FEM/:7
MX((YU@TR\I!SK-&^)I5+T\1%":M0H[@6_FQ6P6,H1/\>FIA)A'^CA:40DVCG
MS=);&I[4G'CM*"SNP#>4U)BU;P^/8]HNIHM)@.LPF1B'@7.\UJ_5CV&)N\O[
M0]>NN=%[KA3-1.M87UY[&YK'%<;@E%4'(ZJ$4;D&4+.*70SW&E#[59N-TM/A
M&,%'+ETU.2[L%<65UF*;-"^6C^T"YGAE&5Y4W$2Y9SJ0RT.[N%'1[V>Z0_(K
MC%W+J5&]<9=Y!$;O6/TC?:*FF(PFR!TJ""91J1HKSI>1X+4 ICU7-P&,DYAV
MF:*6.JL2HF<XLY1OL'PF# $;A?)O$-0&K:"H/@#,%U7CZ\KK4<4<$NR&' :3
M!=PDA/2OG">JH%&M?1N%@P(W)HF*I=YV/.9QO*4Q#R,6/4&3X%MB4(Y-GGG\
MPP7!)46R'(CKHB"Q*P*PIK ,:+3<%NKIS0$,*W]!W6*4I4\/VVHKM+JQ#O+.
M%AB?*I1 (ZI,,]8L;/WLGF[EW I3_@^PX:6G"E,M4ZCPMW-/M&@A$RUTV**%
M:J>G 3Y0X_R!.H56USB*46A&E*13(LG+<XLA.U65;FR]*U>+87+FMF86(JLV
M+K_/A4U+CAU XXI[FQU=]Y8TNYPO; $Q?D'OKGZ$_3\LWT@9G.8UI7<JW;XR
MKJY#0DO8CA)I%!QN)J4\- ?3WHNI6JW9B4Q2UVJ!1P/-:]=TQ!VC]>U#U%AP
MRG!2<S9(Y FW"@LSXB@$AJW,*$+B,L 0> DP\8=/T[5S;@RH3!;2L>[8@$@+
MCDD_V-16=(!R?B[M"!/@T/9RUM#I*N[G9%Z(P0)R4[ZU1?4(>_Y'Q\E,B5.#
MM)1$?:=+3:HV#;V%<@F(H:!$-^9<%]RM]QU5GQ0EZ*,0\6P4(]AU6GE5E8K&
M*AEC[:L7<D(XJMU.@.*IEU7%0$;#7;)8U<?#SUWB@WZ.U#:316B67DV=]S(*
MN9J:05CBKTLO.0=>@3GC'<5^M/U4$W)9NVT"ZDF DL);Q! 6L?TU3S/@GTML
MLJ[74UT)5I,R3*II4:.@V/*<0(FGO+JY@XK3:Y,7E.><>#(71-8" ;)R2R9<
MDTG'K PK+Z.D_U",D+:.MI'HCHTNE8)3731I<*YNG8G/LPA+RE!H\6 DSWTL
M/A5#>*BZX4@.3B=L]"25Y8CR*" (/YTC#)H:2=<'_U)P7N=;,4S>K2!9[!^8
M+!KI.D.<>45M36_HHM@-\@>>S[HSM47?VO :=,("<J3,?/Z@0Y+VET$!3FU&
MU"",9TTA.4U*G- QT1@!,QQ>5,!(9R6!!N_ &SA0+\;6+D_-;<<E>@[_&%?&
M#H0UFP!>@!K.[$VD)=JI"4ANL>B0")G$L)E^^0=S?M;]3@46&:RH2B+N[1BY
M7*V:U<<:$[$J4W@G?CT+E@JB%4AF%J<VFZ1H\8@-.Q5S7I0)?AMUI%.-E55L
MP[.)7#>81-"Z5%+)FRD67$3%+WC B]\D"6O"$I= PW78XE*)\2)!5FB< ?>@
M(\JPT40H(_/G11@F*7*)B.\J:T9NL$K]L_C?(L;=RS:4R5SB%!PF=Z68E6(N
M(U/91ZQ:P-JEW+S!:?))'C$R4"+DMAB'T5S77,C6!@SL=QJ<(%FF7!G4U[Q3
M;T'/D@8'AE?=9/DAOB)L.#G@)0H&]N)T&F6S@%*8[ *-*]N(Z\:03!H7HI[]
MU_BE23!:\K<,%L[\[VYS4\F%$EP9EW[=/2H%:.I^48>P:,Z8R.V5PR:&?Q8&
MAT;N'75?^=Y)]PC^SS'\GQ/X/Z^\Y]PE[J1[>.@DKQ82"UK.(%^?A+2Y4:]2
MT-BU_L*G48RT%2?%EYH,H]IW41[:A?YR'^L#WS@9)$Q7/KUR]\?*.-:(G"/'
MZ#!6'Y19/%Z2620P4,;6A"/-J!*,8' I(\.\PLB5+3$1'I)%/*:*$V&_ 0)N
M'"HW>46"$+HQA[A[,[%YQYK!^/]G[TV;VT:V-.&_@NB.Z%>,@-7>EZZ8B5#9
MJBK-N&R'I*KJ^VD")$$)UR3 !DC)NK_^S;-EGEP 4K;+(FU-1,]UB2267$Z>
MY3G/ \^#1XCY@63-S57DVWC@R=\%A5VS; +%]F:&U!)CJ]J) >D/"7MBFF,[
MH9XF730H'%?)EW4;;.CA]*0IG&N\,M.$0H,=IR&XI@HNHF),V=9X'OK@6G#H
M\"2772W!,F8;6"_$+*8+=K#N<^0J1_[X/D?>.SQ"#L>I"N;RT12F2#F33M#=
MN.BA:*NN5!">8JM\BZ9#CW;G*!U61-_+U>?!";)A^[O&13-.;3.?2Q&*/B!"
MG:%MQB\F(^CGR-1[@F_&R7_^3F)$][O7Z^F.(AB$+&P7P IW3D49MT/Y5/XZ
MT1AQ*CI_I0_/(R&E37JJX-*66=2$G'D5+M)\@^0>442L;)>(#?^<4A$"R9$3
MTV:IH'<;$LV=%<KMO15<&KML+:TEG=;AZ2P\(>KF.]XPH%]Y9_H$#K,_*)]C
M@_D$JXH$N))#@:.'%+BB=V*1BV"QQ?)(%BN77+JL[A(N7EEK\5VE.A 1NGI
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MD*0GD.Z:\[>>K!?CML!T&>.8;^S!Z+R)1=.N+HJ+,F*P=J2+&Y^C;E;./EJ
MB&-)]=[]NK)])7E/2\1!#Q^7.50T%N,';CRS5(^#<X-+U@HNPT@OE^54UHE+
MR&M]*$V0&'C>ZGY1CVF@H!RWFXJ4\9G98_\R%MW<Y3 [VR)K[A_N^I'BDUOC
M/RU'0Y$@GY3V;;O7N001 ?S% Z=NF9.92U.'CPWY3S_7/ROF7:E:>#R?.A7
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MJ^+VR_OB=N_P[%0^6#"2/0G@C8G?U.^_.-.KK_Q%N=VOD'O-MTKR;DXB-U;
MN3>='& :'1.4SB.X!G?*Z-TJ VS-(S\*!96?;0L9=.9LH; RJ%L,2)"88 WP
M9N-RWER'[TZ6=NBEM\]=IA+2!UNB[4>#"4Q@QU".JCM@EA+3A:G= ^/F+<J"
MP&8L=]&%K!= ><&Y49W%0%I2TLGQM@B]BY-!I*D@_W?)29N*=3SBCDR(F[X.
M'EFPY/C?_QHIQ< SE:]&\1_W(I:>'-]E^YQM3TYV4R[W:Z0SO<R22FG:=^J+
M0OK3F7L8;H]W-=P^8R-$&98?-\(^B4]>JSKDG[M]JUZ;\>3IT'[^T9(^NVV6
MVL887W!P*_:F4AK;X;$V^$4;WEIZ95AMDK\9O*><RE;7+&-=6Y 9HP#$G&1K
M3.#/BV77Q_3D*!@_P\O#A@YE7'/JX&^K[B.S_1BK7BVA?8'5-% LB2SFO. 3
MPPF0T2@K%'T:ZSYBPF_$YY?EPG=QOM2^>[R4Q+@,,G;5*@#08YH^[;[FZIT(
MG"\T34%SB@;5*T ]]_7\C6=H6)SS6(TT4'X/SXW)KIX;;V$?WA\<>'"$@:=F
M!%D(O^S0T;"=>_T4-@ZE--$5OBAM82T12FQ[S7'<*\269FXBC3 7A.9WIS=2
M>I:2@3F?NDHE7,2955FPF!@[9*SU_"9]OK#J.9\Q:-UOD3V0%6 FA8OO?N6]
M"TOO!W*4SIA'S\IT&<O9(.T\R ,TG;*@%1(7UJ6225#F7 F*JM-:"N4<))&"
M@WG]"FB)';-.B(#3C,E^K2)Z!+56O3;R_5M<6PM6QP7LI]C2Z#7X'0PU$CJ)
M%)\4>A3L?K$+[@+02DEJ:LX885Y5FE,=OYIM413SHL"9S0QD*?1ZED*.?Z]
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MF [6N<3NF6C'^4X-/.>$3U$;J/=5>79Y.6T"F.ZJT*??BOP>I^@<*DROL<O
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M2LZC/;5T+HR1@^] ?KA9MY,R,=HXU&,< >!$W6H0PTI(ZI(!V7?=XY0? H%
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MN$%C9R9\$1$1AY" ?^,,!IT)>NS[Y'I!7@L2%):O,4G.B%[6*OD<W!Z5:T4
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MHPU5 A'<KFNK[LC\F28NURY-P':<]"W??8;BD<]CBH,#WN1EM82G_R?4LS*
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MIMKGK?ET1[?F<%G7G&4?R)'[CW]_]NJG[.>*2KO'.&<_[E8^WPC\C1-%@=J
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MLL84I?H*.N-62UE$F_#'F+1D=]>)Y4:M\7FO O,^KL3QW:[$8Z:(QC-D$Z'
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M9=.Q@1=K0*MDSL*4*1'P+7:U&4/IC>*<6$2!8G5'"4U"E-CR2/OH6(QWU;&
M^;SW)9POP5G3@PZEARW,$+KDOJXS\5F7WN!8\(.;UT"RJ^11MK5GP=QPH3?
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MW$7_.\&4&-=WIGSVW$T8?QW>R-JWD37<'!# XUY[FZ%WV/50K^@)<E+:\9Z
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M/M&\D%=,7E6B<UA2D!ZHA)P]=-JL'F/J$6PDH.($I&+67HD5L/:7F%,;7M?
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M:MM=[_0.;EK![B*;[&81R+Y'"(7]+C;I<9C\"*NH2L>* 25>(&'XX4_(3HD
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M\V'R]O#3QY.CTV3_I^/#PU\./YQN<B*T#W'Y?%,1EV]MKS.(+[SU^#>*,CE
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M,(<QRTGKYO5%W1Y@,BW?Y&1:HQ.>FIX0=BN29=LH</)7(I)M98>:^CB8^G"
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M1+;=<QT!HBP:N7%4]YNAM,#2CVM7XLN) U=7W!M3Z/CIA2+!G4(8C+QPQ5W
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MX;Z:2H#>KED-W+GD=="ZQB13\BZ?H/]Q;.YQ;63WCUGYF^KM!.H?/CXS?\8
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MEWGS>.CYJ+4P#(90\ROV,;J<6QSIQEI90;ERM6RN0 K^S+I^F8@1-+'PJ'-
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MXK#<-=84,9;4 4595T0<NAY8=3?9UU[2"ET5F*$H5_O +F \7N2SR2!4UE7
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MM%/]^UDUN3;_<]'.9__U_P%02P,$%     @ *X!I5NG0P3/ HP  EHP$ !X
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MQ^CD^/0$MC98DC!EERIK0 I!<=$EO(L/)OSS\R6,*H$]\PQV!UC9>*<W=*=
M49T_>U,9!15'6L&V*?4*KL*=#SJER'5K)+L'<AR]ZHZ_7^/B2 +%BFH+=TQ=
M*C1WXVC2X,[.-JB1DB+/147#!EOPEH,;TD!Y!^+[H"9 S?A255/U1_135DQ@
MD&] M\(#?E'E.UT/;[U[+6XT.[@0.&NP"+LGRELG69*HVBPG168$Z)=7/[\\
M%@GZ\B8U/(#IC/'/=Q%*<LWH8#A(#^F319%-T0Z"CSK[!#=Q"M?!8IGK8$>U
MKJ)ER3;X5+Q?T=15#;_$?]M%7NALB@?W!2B8B<K?12^/SX_)9)E:G7"O-\*
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M$NJ=:^/LVJ,Z[45NV\_$4C !_Z*9:YA4;):62Y>R=H.F2>5T7M$_]_CC MM
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M@I%X@18<YFYF98KQ77-='/TO>B=Q]+,&QP+-R9_3R4;%T9MFJ@2>[=_S3='
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M**B'U0E%'@$K$F$**IW=AR"F.\^P0]N1C"1_)DQ(E])/WH2N]N$^WF.G(,J
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M=%$(6CO!RW8(:WA]F0JTWD[^.9H)=VSQ4=O/TO=MZW!;&-HR9'-(BA"E_VI
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MQY,-&M&!E&'HFF, W",]]X>'=ZZ&!D!-U-FB)]0TO)F%$^T<,X6W">N+[?'
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M%WED:6A794-NDKT'-T*PY:ML[E8IO)<J6T#?+V+&1;QV3[HRT><%5]V2JZ;
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M<]^9[(L%X2Y,I1IO7R<Y<B0F][GBJS? <"V8"ES<@//F(X3*./86&!%JV@$
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M#J0'_T1YA5$=.S1Z76!65]0F0^/[<G2OT X7-\A_:EI9[VH+6);U=&=X%,<
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M<C</_A=DP4H*J&,;QF(FDXSR%0+;DM.IWPXD\ G!&XQX3S#T0:%:/)]I'D7
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MZFH U$5@MB,VUB.PC^JJK*P\OOQ2( C-!MG$"!$*7U,M<VH[@XJ9$\_$I(+
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M<W%O$>T,4!@VS(I;GR%#8[58)-3YMG$+,QZX%E8+2KA5M7:X"0Z3$>A*/+)
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MJ39O<*\>V=Z_O(A$RYN2DN3R[KR>DY%Q_4NOJ:,QZ*WFD29 P]26!B&/?4U
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MCOFW@O)OBQA=$WE"RVG 3>2#B!GZC^P-V5/&IX[=.N^3.)_KK_<Y4V<JJV2
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MG#D9#Y7VG"6[<#F/9#6>P489)NZ2D"J]AVV[=%'@4A3XM(L"=U'@+@K\4J/
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M4M=V2I<[?FJ@)@41.Y.H8@2>XJ2Q,P%)FI!FH!<2L](C7X$=E4!6OD@Y)QE
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MF!*^0R1(@D6N-R9%BJFXIJ!WIM-N]79MO$@-+\=-.56 5T25L_L%YJ;]:F5
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M_++X\6G'C]NQ\]OGQUWM6Z.U;T'JA7&:)]+Y0_XK#Q(Y8TR5CO]V_+?COR^
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MO/MABE9%4^MEAH$B)1^D(!0"';@DLO,E=D"P]%&W(F:0'%#XV'D&FV<L*'F
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M.?A>#\)=T^?@V!+EB8R3"?"G?ZM$9!!1$^IEXTTE%QQ;2?0NF:QQ&/CJ[C
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M#*1 LJQ/EOP..G:<M82_O\.,Y<])G''2Y<XKDJW)!OQY@3UF,!47(5)* $W
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M-5#";Z?X=ERXX\(O@@M?=%RXP2_YD_ZZ1$;<,=X6'+^.\7:,=UL%%H..\[9
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M)I E 7N82T%1Q$2F#AQ_X!YP]_:/NC);^SM/"^.VT,(_9B 2K'V/Y00Y/@I
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M\/BN:TJX*\>W-2&#CR6?+?E)SJX*!SAO8E(\RBL.?!BJZ&#E8)F@IA)M.$S
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M;W--G,?*(0*;4X*A%!_8V4#?-T$T3A$G_0%)8Z$3?7BO)GE*U0K+TKN_9T5
MJ5:(7-&1XZ/OF UK)Y3WB#^,_W!5Y&8F Q/@2<1<9U/E/&._1Z^GM(85?H+D
MV</'_3216!F KYRRH4\N!LWU5,,D?%M/)W5QP:Z7I53^#]LO57T'?S0R1= Q
M<OP5G5&A\-4\="DH7 E^8HQ^%DKLLF%:]G0-"Q7AL@-%%=KF2&UTSI(LOL-X
M1+$$6+O3^!T,)[S/Y^![/0AW39^#8TN6QS**I\"@_JVR=T%&3:G#@SN37 =K
M%;GTR#T6!;ZG[@Y\X)W*\69UQ["U@#(,@LD>*F03B++FP&TVR>6KCN#]+++$
M?Z .5Y5$1Q?(ED4Y5OS2\>038W\,YW)R*W*[!S052245TV=%"E?GY-N_P\Z1
M*D(@(IO*IT+& ^:DM3F%<>?2 534X$X50PEGQ3Q:@5 LVG-6NP82$":Y TA0
ME8WB"/DI*0"P8LX<^G"5X6A$D&>ALZ[,J+.>GM]Z,MM((:MRY(S$WG>Z XUO
M@38'*F$C2)O2YTICV5"-25[AK:.,W]RKM@@O47D&;:R5E4E2 J]2]<;8;<%N
M):W%3]W1!GT*YO:]$E?CU*5-"U/AK:EE(7S/I.^IX@QKDS<C'7@J"NZXB!A4
M!=W3/(KSFA)=&^))U_=DHO'2-:!ND'$\,S)XY:6(7I*'[74C\@) ^J,PO%NK
M(;0IU\4*84^CR',F@DJ-5I"OK)8V1>\%I8E22#FI4S)( ^FQ3LK:B!=)U@TF
ME"2J&[PAMM<4W1?4$,N@/&%"!!#LZGO1#B!P"_K!\X!"$TO/ "4]]+7ZOS*M
MGM);,-BDF\!$CJ(21/.7(@:]QX OI)5) !R[?ZI$ #XWZH %PI4:-2K_3$S$
M!5T,-PECW&29*[< ]=4C*Y>4=PN0). EA<W%3U(KQ?X /\T>Z&3WLH/E%UVP
MO N6=\'RKC:^E9EIF/(?5@K5'+/J 3GH8.HAU;=E8Q2N*?NUR'E,G2B->$?-
MOUZ\;U<^8N^&U%8I O^+7#<]UCA)DBOX+J61Y$T]$@NF<8W )0DK/+AAK635
MX$<N:\S"-,M=F>+NEPPVW2':)(\8\,;W=SL&#;#JK>-Z?4_U7>YA]"06A#6/
MR$J$U99?A&/%,'+&AU[G4R\YST$Q\-,#1 -.%K BT62"M\S'!NO4&'>F\KYG
M50=/G$CEC>8(9";@;6Q$'2+" !6C4A:9#16/T2$"?D%5^63V]?)!2Q]O]IE3
M3K0N3[VXL#0_Q."]YZ.N:4-]%=IL97D+(V,PL]^<#GAH<08LEC)0(G;D;:$:
M 5AI 6E"/>-#3Y57ZXSP.^$'Q$Y+F&+$.<-\"NSM9P@15NE-<0E/B",""GF9
M<=;8?+$4?LKH00JQ ,H*=K8559P)@D6V??56!9^>/P75%%>6"A379X->M>NQ
MELO&M4"?P3J4]YH,YK79RT\E41AN;FWBM4K:\$S[]94"CAQLL3I)^SMH"]%T
MEW#-W]]AT<7G.$HYV7OG/4&M20W\>8F-3+ $ #%&"@A'P%S9$6TEWI."5%"8
M@D#EWQ. / (#)HF&"=0(\Q[N7AD?_H%V ,1H>#KZE*W TV_2;[U8WUJKK6KD
M%X7N:#(P.#A9B"$CTB+PIP+;-7@UP@/NXQ-(OQ5^9FYPRS$PH?$W,\MG);#(
M""<,3\F\*3M*&OYJO,LW,A:G:Z-G5&)@&#E#X60'LX88O@8&WN/DB'U]$21
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M4TLB9^C)XV&+4LU'U8+($W@)*:KJ@GB4<!>95>X3HN&=<Y407\"DN?2K^20
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MC0RPZZ@N!77O;3P1*9G#^E\%.!/L6R)=/H^+V^H4P"A(TLSJBXQ1,*)*UQ8
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MK1$.T9(.",*+J"?WMH^W.+:U:T%.!953*Z.-@*;<K;*Q8C;5" ;+)7 N$9%
M#\.(6D42C""(E>E_8[MA(TNBH(">J,%G=Z30"E">FF)J"VNA2T)W2>@N"=TE
MH7<T"1U,I]+'4CB=:/@&<^FCLBM4E! U$V:55:ITC05%V+!#R7./1)KF4[8Y
M1&;K0H1E(^M%58"'<80H;I3X"WB&&-V:H/#Y.Q5+J!B)#)-,D X'M%*UBK;%
M$?1=Q$>I#B_F\0&9^,(!6Q[Q9@%X4*Z'2MQ /98 >JGY%OO+J+K1ZL#5U0+4
MC,,-J,. H[),G2I?:TB6 A]%^0 AA)A8(N&/(EAR8<[O"7 XAO$=1S:X3<71
M4>H'N-IS4?*U;4\:Z7:M3UG?XLU1&MQ:S[F=QS6GK49)1U0[@?%N+'Q53T)8
MK13)%@]N5FAM[+KI(7HZ=OW6C#>AHO$XW'FYTIH@]:^55C-K++"PQLIX?.[*
M4,=@*$L7C$4G4G7;491KI&2 ;C3BPHT&,0]6$L\6(\EDKSV$:$LO2U%H.RDY
M:)J2+WHG9_C0W.188&9A3T%$&=<I%IC9-0=JXJF:G0M7C"DLBZ5Q:G0V7FBR
MH#CBT04MB<W=X8([U/2_7$WQ/.27:B%*]1566P(76#BE"@O:<6+0P\Q80;S[
MZ='?S/9UY3;#^:O?+VNY*AJN'B/+V62>W&TP3 (3OYK*A':NOP1ZO;AZD/6V
M0P3;.,6>*55.*0"@-(HO>4'BY5/,@7M2 1V;<LL'TBH20RCRB 0N]I;B,#HU
MT'U%3LLJA0)[4L9WE'\T-4W/FQX:)XC3WA$I8Z'+E?A5C8K"L"6)I5_^GI7L
MM9&S XQ)L\T,!NL< <T)#5QEGB8R- FJ5$QU35@A,O9=NCU9M$OB!*G3Q9^#
M"R&QZ!AO.68;GKP'+?34J#2\FZM+T[@1VL\S@E6 UR]5YPL_-,I$,#$*7!M=
M%J(0FGST%I2IS;\82FPGP]HQ&_YF3W?W4'LR^T:J!;G >B(V2_/D#I,CY>9H
M[=[R/1CF>)_YX+DRPEW3?'!BJ?)$QLD8Y-._50TRJ*@QC8SQ)I([A*WZ>9<\
MWS@,?'5U&(#H](4&S]3C=FPCH HO84J@2H43HFHX\/A="L$H%IQ/8DO[AXJY
MZA0Z1GRWK,FQ%YK8DSG&?ABN2+TC$\F>#4_M8VG-]MF.PM,Y_?;GL N]RB!J
M**:*K9#O@(5UF\\9::VWUYYR!A7%NU-]%L)9\HZ60-C*[IPU_\7@4E!0$TA0
M@[G#"@67E&!=L? /PS/*;S0JR+<P7Y=VU#E/3^\\F==((60&/2\BV:3VGND;
M:/P5:&^@%E"C.B2!HBC4*5/TONNH_[?.L*X ;]3RH(UAL[1)JD)6IMX0IT#8
M(^:U^EG%VF!/P=ZZK&^7]>VROEW6]UNSOKND<!K7.#K<8/ PM :9B< WU<NJ
M[<P2_)NI$_A5'-YQSS*X#WGB32B1G13=<KKKS9=>X,M43V;0,+UASNG+V$Q&
MJ"3PTB*UKF>-E48QK)\6L"M>0YO*Z4S!HW#&<>P[(T%-E$LH@];<O') DZKD
M*8.<KG(\R"MQV4]E#\6/)?L+([1/S119Q%$<8T23IFX:1#TL6@""7;XOQ@8(
M"H@^\'V@T-3R/<!QCP(=$EC:EJM\&12T>A)5["@JP;DA4B3@"QFH&ERR!A"6
M4O76*2:2G/7(+_5D; @NS7RC&"P4GM08>\5C8A\"J E\29C2IFB="A72\%Z*
M?)%#;\$WA7RD\'+QD=1)<8PPR/*'C<MM+5NUIJ0#>PNB6DHO8+?N)4XLVJ%V
MNGR())]Q!(K"O#2$UC =VNBKF6Z[5(LX[9G-Z&'P1:[;'NL!XB\%0:;D1 '@
MGUI0DVO80$V0A O6TKL&</)8CPDS)WMIB[M?Y='T<'A3Y6$ *-_?[1@4P7)<
MC?$!?#5RW<4\1R((;1_A50AOKO@2V(JA\$RT>U7TNQ+F!D<OR X0#SF=P8G$
MHQ%>,AT:O%9C<IE.?]=J1AXYL2K>*E#43&;:6&XZF8.I)$;6+ L;ZF@C)@)Y
M02@ 9(RYQ:*5AS?OF6M#M(:E65P(!1!AEMT/T%>WX<I*8[;R8ER),6,YPDT,
M'EF2 =NR#'2)G2.;J5$(5OX^2VG8+ VJY49LKJ6\$T%(XK0"+$22,RJVP'%Y
MABQA16OZ5WA#'+M7V-.,%<=&A:6&J?0&*<1"*2I9OU;^;R((&-J.JEL]A'K_
ME/Y24EDJ8-^ S6PUFL,Z+AM' RWY=3CW*\H(UY80/I9&8<B\M=6/JKK"UV2]
MW+E1 $;65TH^@\$89RV1[^^P7/ES$F=<<;GSAF1K:OA^6> H%ZS#14R3$J(2
M"%<.&5O5KV0@E0RF,%1%L 2AC^A@::JQPC3&OH]OKXJ0?\] !!(TO!W-94L
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M,D);BE:S2D4YMZ8>R5[1TJ_$*91O6[J*@:^45-!U<01*A $Y1B>*4S,GA(H
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M=&WM?6MSVT::[O?S*[!V32)54;1(W:U,JA3;R7HK<5R1LG/V?-EJ DVRQR#
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M\I+?N4M^9Y;<@$'=8T-#?%6S?.9%N1&H8-ZG['?-Q */B5P1(#(6VP6IX-O
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M>"D'5U!CAVJF,FV NC<IY>M=[Y'XMDPFU<PF2D"+5I>6*QY$U=FKD@85R\N
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MEE54_VM=S7K<" [5H%CN>S=W<<W,7#U3-Y)ZH@N6HVHA3H"/%,X6#VXA:&T
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M : T"G/Y*O'S&2;"?2Q'P<B'K>%^(*TB,80BCTC@8L^F (];#XU>D==RRJ'
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M+-UY.[(UM8H_+7 4#+9:('Y+"3T*A"M'QITB7S*02@93&.I:7X+@1VC%-#5
MBP:C/\#3JR+LWS-0@00-+\=PV1+ _R9SZ<M]Q"NM58.JH_$Q;4D(9TM+26W$
MJ@3Y5!*[%@M(!"!]%(TY</+A+ UN."DG#()I[@31!#9SX8+A5[(87H^:AM\:
MKU)6Q^)R76226GP1JV<HO^UA&1-# \&-][A:8]]\"1H@DQKJTL%"XNB?&8Y!
MCUHZQ\H)I#TW\%R>WVF FC0.[$RBA:%\+4AC;P**-"'#P.PC-N]$@08[*H&L
M?)%R3BJ $$#'.G(*]$1;$")\^#.(8;<FR_WA/E'@4 T:C,B^90&@RZW*3?SZ
MQ_7S!O&"^OFM][#KG@7WZMF^2A>'EIZ*(^@-GR&9(EH06#9J0K77IH"[Y^E4
M&T+P%7![^^@4WR<5M'WD[$P5YY9*1\8\D+8L/&LV$)C\GWFBTD#YSC &+AZY
MAM?\-UBU)!A8%+G7&D&T LNXB\9WT?@N&M]%X[<>C6^MXW/>$L?G5SG1CK"N
M',>T+3C76:*5P,Y;.*UQA3Y)I?6IC11%6I526(2 ?:D4AY#Z39S#UHO"IXBA
MR8$B- G*"MCJ:EMSK6T?JM:VG0E!S]7ESP TH346[*<8NS0FY8%5:BEH9V)J
MI;8!-LK(%L08JJ\M232K5(3I.TXC*(RK%@"HE6KHB$"LP#2\Y<I,>U_W-Q2-
M6J:>Q"!":EL7';[E[I:[. \#V^-"$#Z*- ]YA+!N&:5D%(_!SL7_@LU)97!Y
MVM.DG"S5=Y?P<%>.>_A81].T*/QW*:Y@#-1B+HBMQ':;B$OC*^Q-4[WM\-N)
MF>A2'7>QX1["BXQA3TPU%$%XVX/H>15(8AN1#L5=ZDID$P3GS=<-&72WO[[A
MI584MX/"H/66(]NPVS7(OMHYQ^B!^\0U]>WX"_WU*(Z_H%N%4^47\.6, L*8
MA)/$.8DN:"TA_[8"]? G\* P:OP%J*:!_M3]GA/#*@_!*0BY.J YRD/6]K>Q
M"@C[A^Z!E5F])7=SS[BV121HWV1*%<^0Q=%L;FS=X*' $Z;Q726VS_2E1\&8
M) '<*%0RMR[INM=Y!MJJ-36#:]#8=5Z"\,1U$DHC;5L9-1(1I>WO)-(31RH,
MA+(!C%:<\; _YC@;)>' 75%S@R.U;A:3B</HIA.+BH5Z@:3R[D?@6E/R@111
MUJ-  08_0^N!)7P-TL#_RF%3QRB8$3=)DP%%F3E'6)2,E+)EOU/65>-L.Q-*
M+2F6I=7.G[1LRTFOMJ4H9 HZMP(KP?4LJ4X;VXH7"FN62LR(F3627%:&L';0
ML.!7R^4TZ13MFUY=9T-Y>%M/T]M"4YM>"[ZI;B/EI#P:8YI^5Y*OBKC=.F(;
MR%BXMRH.C<:ZAV2]D#QH6D?*C:JZ^J>R'$O5I;'@6C=B%0:.+<48=O&Z=GH8
M8Y11WMUWEV,786:./8.4\$5+(B-7F/FWB.L.'OMNU?Y8H#L@1%V O[J@KD"F
M0RI.YY*C_6+&[=XV'[JFL@)L?-(+W!%._BPP\CCG)@ <#9AFE$CE7%W?0[4C
M K#U@"$D& +Q#)QBIQ.!*V?<,=.\LE0S@+#G!/_6"4#3V$0%)J[/)VISN)8U
M=;6=PY=:H$VI1M4I1,'Z)*=BU1V.U&.L5*I]-2EBOK9(3YJ*GEY)]>T^]PX/
M6\*]UUB(J3%H=XAA,86O(E 8H-,R<GZB.#J0$2A:7SJ0NI2;=)!R"O53KEQ@
MRL;:7<$HF+IFS=Y^Q:V-4JF[J:V)HWLSVBRRR1BM-;H;2<PNY]?E_+J<7Y?S
M>XD=. 9;VQ'GKC1U8BUD)5"5UM)5C*2M+2+3.D'0Q%CMP1C%<6K'YE&=*!P.
M5;;NZ:?N.S?<^6X >&8[C(M?$&N+\%)^U>,%_\M)!.Q\G*(U&=.;4@4F56NM
ML]XG="S$33W;5YPEN<Z8^EC*9[-5[ ;9;H%;R7D73!4YZ=&=/\O69$>O> CF
M/,?J4#.VC@.#\8J!=T5]:764)M]E_:_KRW4ML<#)4ZF^$P:#AZ1("'6%;7Z<
M)UEJ@E,!BF05RFH&=H^A5;%'Y-J?A@K;M'K>.R POM/_@SO[TU(&?G_WQ?*6
M9^2N%,L?*(M(R=F?T0W9(;_OBN<-,#JUL'A.=3,8JLZ=Q"0IO[5VODB*_282
M\-'.>V05_D4YMMH6Z]RZSJWKW+K.K6O:K5LOFIJ4]_4 YU=@K0!]KESQX[SH
MZ5.^Z+UZ^@2-@_<6(V"7>J9!'5/S5+F4#S,!NA6:)_?,JD"+;ELME7.6O];@
MS0_!1GS2(]R,5I>-D ;&HU6&&(S,FH*BGZ=DBF]J\;1@?ULP[*!*L@9EO("H
M<.?CGIB)*SNTQ[\_Z12+^EVMT"Q73;Z+ SKKWYWN2L0_F5&-\"Z1K?9Y&]W7
M6FO*M/:EN8\-;S'%"-R$K.\._5T&6N=ISR(U?;2!1/@'=VIP3?9<E[-RHGO'
MCK&FO*5Q;OE9(EI"Z"Q)3(2*T@SKCK&-\;92F@,'\"NW1S!EZ@+Y3R"IJ 1H
M>(B^\."HYYRLYCJ'/C8%-6W!R?T2P_8T=4X;JHI#K2IV:%>I I* K]N]MSNH
MA;DIN%'1@G]Q>Y-!2NP4<3I=U<U;X<8$,-D91Z_J1GF+*B\R+Y18^N5,(7!F
M+B65D00$YEH[O(E^%93*ILRDL[!0T+OG!?QZ\]&[]K&6YYT3UFFK"[![<GVI
M]+=Q"Z=26I_%<T85\>17L&DI)3FSB^YYJ@^R/IMBYI\_3FB*B5M&3&80X2W^
M4T//KRY@WB6]L1GD5KO5]='.<8S3'=2LJD&5PNV8H1G@@[0-Q#\KJ2'$&C4=
M0MR_8N<!U2(W&:0W&^+;I<.!Y;9=21@#=8<D33T:4-LERY[<WSWI AS9[GT=
M[)Z#52?FVKW)Q[NWR;H7OMW[>K%[^UH:.M;NW3W?W=VU Z":VN&1WE^S#F?N
MU'*5YK+'V?65= 5(70%25X"T]0*D%LGPSS38N.7NW_G#7))MU7=U1:R=#NET
M2*=#GD$1:P,5J\-OE,$^=2ELJ_+TZ*0NX5,7'"&RO.^=@+U(^YNF$Z*RMP<@
M?NI;<K95JGI\^#?=(R?L"ST-,M[*5AQ<@=W-K1HD].A]3'?Q%!R;1W,*. J[
MA.< C3A5/9+9'<*LUA>/[>%-MK^+323U>0][&_>JT>Y]]_IB</DDRZ3[;(2_
M2 O_)&:RYUWQ9+3M[QOLP]%E4]325&[.<-V*ALLUNK^IC0*AO_5<F>$K&GWR
MX)J45JN;=TX'!'<[8*-$CV8](LP,S82$[Q"@D="*ZSU&D6))K6V^G9GR67-<
M&V]2P]MQ72ZUX!W1K>=! 87IOEH99Q7W:;0PR%!PFT6<5[I&,)6]OF6D0BFZ
MT?QQ#$WM\)6;NH^HX[8-7N#%4?_L].Q;G$#8I4,R%!_7"3R]@ 5M=MO'=0)G
M*@A"N<YW1WY9(6/X6(?]HV6Y,V2G\+[.\\&@?_QTZ 9+PIT<_T^Y 7=$'JGQ
M]>HW=B3\+Y,DSJ/@0*\ON,#_N]SZC@_[PP=L^+8DVZ$V;P:7\,?IT?"23)U5
MKO0W$; AH54[NCT:*MR%#:(0'>5TE&/?\W^D(-EC(/-U=+XCHRV3T4-B>>VR
M'F\,9&@!=&[JW],T]GGL@9V!047Q=F(;_@ -;C/A#?>  <<BJQ5UI0H!B9F.
M)[ J?;HO9]K=08O:0'6'!MC4_(.&W];D\4L/,-,<RS7O&*[)],!@C;ECAC%/
M8A&F!2XR#\/$N!>%\_:(5(HQDNQ6H"&=2APUC\/4V5O_[O5@>'SYA"&,-<?-
MQ!;@0$G:K[<\)AJN>O6CR#+A3[7;E,4E<M^BQ]J'XY&(W@V$)8OA*O;<]&3!
M%+LF+9&YPZ(JKH]!"D7:@QLS*C"/C0'*\L(X30WB*/6+A'H(3('N[UE0^M1.
MB\:#Q8[9^["]7:@GUTES078L295JZ,4,9'.6VJ&K2[?6W$!3":9Q""M-OX?E
MR,R HN.W"]0/A+[SH+$5[1)1/RT88(B'F0/+V6AOCP^"AON69_#8Z0VU<L"]
M1VFR+@^Q_>@,00]B+XU[WIR)$B,&>BY.EB=1]591["%FNYYE R?4FD"E:UQN
M.SX)N]B:?<" ;5/[@'1#$WU1_LP7Q*1 OPD.3I(/@B9I%W]2^J<\M0,^&$F"
M&P&!6<RG+8;XV!D+!."..Y-'1HJ##G(0W2N8&F1>%'$LVC]W3E8QEJ6W>BJ7
MMD#T[;6)LF+LEX-?C<.T@+GS.7Q/@L<82S0-VLYFEM5(HA[+E4A?8D>5@6 O
MUE2LP.G?WV&)?5,6BT^)CNE]&ZCC;J(Q-G>LPS4E%X/3P\OE/Q\;5ZKA=__?
MRO]6O?9#_]STOEO?EXO[MF4P(-N,T@*/M1N/]:=>UFH1VM7F=;5Y76W>0V5"
M5YOW6+5YVXIB8A;PBOQCR:4S5*9EHP?N]$4P2![1,[I7?=#2]M[3G*=KPK8"
MHW>_E&3>WA9Y536,_\/C\Q[G?W2K):VR3N-L,\Q=^_+;65!]6H/"!5SMZ02&
MZPHG:Z+RC6QL_7O4UG\6\JZUZZX$Q>DX,%K10!AG1=;]B<,X*\GRJ"X/M-')
M-7^J.IMU/CPZ_(:WV#SX4,[N/68AT(-"'<_4DG\SBH,%_&>:S<(?_S]02P,$
M%     @ *X!I5L+PDP2[*0  R<(! !\   !A-#$Y<F5S=')I8W1E9'-H87)E
M<&QA;C(P,C(N:'1M[5WK<]O(D?]^?P5B5W:E*HH2*5'/S59I;:_CU*[7M?8F
ME_N2&@)#$A$(,'B(9O[ZZ\?,8  "$F5+!&@A5^>U27 PCYY^_KK[AS^]_NW5
MIW]^>./,TGG@?/CCIU_>O7)>'!P>_N/XU>'AZT^OG;]^^O47YZ1_-' ^Q2),
M_-2/0A$<'KYY_\)Y,4O3Q>7AX7*Y["^/^U$\/?ST^R$.=7(81%$B^U[JO?CQ
M!_P$_I3"^_%_?OC3P8'S.G*SN0Q3QXVE2*7G9(D?3IU_>#*Y<0X.U%.OHL4J
M]J>SU!D>#8^=?T3QC7\K^/O43P/YHQ[GAT/^]P^'])(?QI&W^O$'S[]U?.\O
M+WQ/GA\?3RY.SX].CTZ&IV?G9Z/AX/34F\AS>7HZ.OO7 "9Y"(_S;Y)T%<B_
MO)C[X<%,XOLOST_Z%Z>+]&KI>^GL<G!T].<7Q4=%/(6GQU&:1O/+H_[@!!Y.
MY>?T0 3^-+S\=Y:D_F0%/TK%.)#Z9^,H]F1\X$9!(!:)O-1_N?+\9!&(U:4?
M!GXH#^A'5\67C. -MS).?5<$ZBWT0OXZGVG_B&>;QO#_GGZS^KI/7QVFWOIW
MYZ/^:'!1^S6LL?:[NX8=#/O#\_J?VL,>TI1YVK SR4*$?WEQ_$+_8"$\#XCF
M<KCX[ R*VQW(R?KF1 L8>!(!T:D!8,PHOGQY1/^[PF\.)F+N!ZO+[Z]C7P3?
M]Q(@^(-$QOZ$OT[\_\K+LSYN/?U[R=1Q<G3TXL=?HT"Z62!BYX.(TU#&B7/]
M]KN7H_,KYW>9I+'O(IU_G(E8.A\"$2)-#W\XQ''RO;ACF4>XR,+6'!)95!%N
M@5#*M$@WZG&V8G"TOA-71+'JW@Q.D!+>?)[Y8S\%+C*X,"NF23]PZODUXD'&
MN OV>-_VE1P<]<^'3W E^Q<7PT<?=732'YW5?_VEPP[/^\.CS?9@0_Y1N%B;
M/5I/L*>/1; -CK3!1CR(YW[AS+Z6-PWOXTVC$9#*=R\'IT=7F__9LN-[[$TZ
MJ]RD2MG6LIUHXTA?>SJG]YW. $^G7KUP'GRQ'TW+^(HM[4;J1MK:2$^N 9\.
M[Y R+=N,W1M)[?)HT"=1MHC807$9RT"D_JVLM=BU79#_1(R3*,C2^I_<9U%L
MW[ :5%E3_.<LSEG[5!Z,8REN#L0DE?&E")9BE;SH?!V=K^-;]W7<;^LT*3ON
M5;Z/4;W[1+<HFCBOX%$9ILES<GE<#/M'Q\>/[YSHGYV>-78Q[R8W->0!_OYR
MV#\;69^1B-$?;DJ79U*XWLDCZS3\=D^Z42Q(?&8A$!$^!9,0SBR6D[^\>+F)
MY[WIV=9R+)"NHC'7R)-0PI-HMT]&"5N?[7'-@7<\X%OG 8,^'?U.S;G>IMRU
ME7S(8K#"9,=N.W;;L=OGP&Z'';MM<"6OY<0/R>>5."+TG'=@5L:+6*;T9,>%
M.R[<<>'GP(6/.R[<K-MA 1S8'_L!\&+)K/C:FP-K3M*X8\7-7\B.%7>L>$NS
M/>E8<8,K>0/TRWQX15P8@UJ^ZR\Z)MS\5>R8<,>$MS3;4<>$&US)VU@ P483
MY_>/?R0=TWU>3/>D8[KM./FMS_:T8[H-KN1]Y'R4;A:3!Z)CNAW3[9CN<V"Z
M9QW3;9;I4BK]1,8=R^U8;L=RGP/+/>]8;H,K^;L$R@VGY-U]+0,?+LP*?0T$
M^.T4WV?&A4<=%V['R6]]MA<=%VYP)7_07U?(B#O&VX+KUS'>CO%N*\'BJ..\
M#:[DD_BL$&8?(Q?>H[V^*THJC?UQ1G#@CA]W_+CCQ\^"'W<9;XVF8/B)&T1)
M%DOG=_F?S(_EG#/[._[[G/CO:<=_VW'RV^>_70I<DROY+9W)V/EM#'0L.!$N
MFCCP60[]Q9K2'3/NF'''C)\!,^XRX1IU3LAX[H?T,>%_J70?\.29O^AX<,>#
M.Q[\+'APEP+7Y$I>S40X-54&XRCH.&_'>3O.^RPX;Y?WUBCGC>(%?BR=-[>=
M#[CQZ[?UV9YUC+<=)[]]QMOEOC4:@Q.I<#[$42K=KLY#X[>OX[L=W]T6W^W2
MWYI<R2]R*@+"HL5RF@4BC>(5_)6+L'<HM,;OX]9G>]YQXG:<_/8Y<9<5U^1*
MKN<R]*@--W)C*PS7<>". W<<^%EPX"XCKLF5?)1P1P27GNR8[O-BNA<=TVW'
MR6^__467#-?D2MY&<$="S$+^12Q)]?U;%ON)YW=^X.8O8\>&.S:\+3;<Y< U
MN9(W81JO'#],(^?G*':[]F\=XWUPO^?3M7,[[Q]7GQ%_Y,/[P_3R0#WWHKU]
M[[_V>#9K+GT=AO*SK&\IK1X>#?HTX")*J''894P@_5M9VR5>-Z'.?R+&211D
M:?U/[FM?39=P6U?M!&<W+)&G]><LSEG15!Z,8REN#L0DE?&E")9BE936!@M3
M0Y^?]"^0;K]T&W:PB_?YJ#\:7-1^_:5=O ?#_O"\_J=/W<;[$>CPK#]:)\07
M/_X:!=+- A%3/F(HX\2Y?OO=R]'YE5/;K3JGU?NEYA$N\L47\-L',[_[QCM:
M;.U&4QMYXG?.@/?2:H2X*<MN9KY#GB^H27/5(<&Y7HK8<ZZGL:32 4['P2LY
M^'''P3L.WG'P)^3@3VH1G=RGQ Y/_DRM%._;T2]:1,ED&/2'HT=C__>JYR>H
MGJ.'@E>PK7<6S:F!7K-JT5XO9K9IVFQB>;[X\=-,.@LU;:KNX"<&9@:4DA"E
M+)!2]AYSD\N36]MDFAQ2Z%.^M7I+]AW8@S1R8!> 6?C)S!'.)!9SN8SB&]@A
MD3HR1#:24#&,5]$<V,\*?[&(HUO?DXX+;%3XH2.I91[(K@6P-JR?L?13'.U6
MP"SQ\R "&@)9.G?\T(7[ YH&CN-&JMP<_0M?,LE2+(.49*XK$ZY1!R]+8%PL
M3Z?*<NB9X+?PN[%,86B': N_]V/T(TD\7363=&:.O?AK'YZ@HY]%@8=L>;QR
MIMAZ"N,!:XSDCQ"?WY/"Q<5MGTQ TVN"2OAHYOVOO.YWN5RVX]X8;I=_'J_Q
M3[WF^WJN[PQ7?246?@JO_R_<$;S>B9,E\%<_9 9+DA?N5Q X,X%7'J[?7 J*
MMB4R=291#+<3GMXV6=^)@V.C</LWK;_K^LEQ6_23C;IIMY67;48L>V)_ZY>F
MN-FG_<$Q+OJ3N>DS 0)4RM 1"]00@!&0C$V2#/X*DA6O_T\1>BI %+_V8^FF
M4<R'0P)9 U 3)XJ=4"X=Z?E6/2[]&O4E_">BPEVHM26*S<1</Y%>Q;,00?VK
M^\ZGZBGQ8&.)O,D%V<_%$'A V(&>DP%]P<O<:(Z3-M5J\#5A9.K7X,K@D84,
M$_X G_=!6S'*2,6[&] _WQ>G_,J>\BL]Y094CQY+#/'9GV=S)\SF8SANU124
M%=2Y6.$QD<X&1$9L/">5-JLL&U[S<7NNN70VHI/\\L2:#8,% **>#M.?+P+R
M4>;#B )C-K7W\*KCUSS<7-S(TH4CXX681@^^42PA5;AUF0^"GT;P!/ )%R:0
MLDU0Y"\%7M)WWC%E>3*04QBKIPB+S(4,C)%;/X'?]39;4<\!OKB4L CX+U%J
M8HB8WPJD'.(<YQ(I/+F#.<!#42AQO@F!10/[70UQCVM[!@UPB6_@EKO-W_+3
M"UST=;@JD^A&=&GNO!']]?)^+-!&@*L"6^[?^EXF@K6;K=ZT&</!KY9^$-!%
M0U<#_M<RZW--0',A,9W&=+.!?T09=YHN"&H0(%&6)BD,3?(>5N9&(;,+&(?$
M?Y*YL\K7 /\ 40^K9!E%+^37E'>GX'OP(M!4PRB%-]W*6+E#D&M84P0I!^Q&
MH*S+UU"8N5[B2@J2E72:S*G0\9(RKZ)CS;TRA1&43(VEE[GY5#<["M"7B$E&
MP/(]/W'!IH4'-K9L6GM!O>8O*(OA:U)R*?*&%Z4',LHE841_3?.L+=:K_8)G
M(8&S]>3#3C2*E;:KA"%^^Y !X%*&3D%$H!\VR;"_.WF6E*[60]=@D'G<F*UL
M#:#(]F*Q%$%BB!I6C%ZYB1^J#.*QKVYK%@;D/;S7 '#49;'OX?? [B0Y ,E%
M3/:$M_L4+%M#P>A#ENXLQ  <'H"M+:&32"0W9'=%8<C%.+035^ESBC\A?XZR
M^,$L2AUY#.1\BT18I$U4*9$H@5 6(DY7H&>!MN?>$>MXWB'UDRZDWH74NY#Z
M$X;46^#F5_$^T 1D?]HG]CD6X8WE'3,<&C2^@AG/K?T:#)K1X7]43/R#6D@3
M5NJN>_=/VN+=?T/19LJ2)3EONC1T?OU'U=- @7;B+  -_G[[GQQUH%$1UP7-
M+<F"E+P(K*R!?2ESE  B",R9R4*TD#WRVJ9!)X&T3ILQ&W"7I:<! YL;,0]T
MM?7NT!)WWQIHC5OY/1P+V5KK(6.-,D%KD!1;1JN4L29H0< 3RG]+'SHA?$B2
MB'\=F=8N91 (#$BV)+NZC&>J$&RBD9=^(I$X]>?H( J#%=J8 :@].*$*FT4X
M\RS-8#%@1P !P."(UA6$UA4&K=N S[8"--P$M$3,T5MG'\A>V3Q[&T?90G^]
MSYB?F2R30<])LC&ZZU*?=IO(B:(.<T>D*2@?L/=PC!+M.U 5&4C-W(9HBT,$
MKD0+E&B!:5"X;IS!VSZ[09; =\&*&0_BB=913[.(< [HRL!?@KDA0M<H1\;1
M03%2+PM8?-T";_ "!#=-8'X<,R6TA*(8KHV69C'^0\.;C..T"OVMS&&SA1ZL
MP,.[T* 69G=2:J_NU5I^W9H P=MB<*""8Z+%E;M^1;RRHGCDW<[YLN60KE *
M%!90AR-BZ[.%K?+U+% A/#66H9SX*8?R;*^B^FTEZC/!$.(4KA$Y#I60"&0X
MA9N+__)!?Q%:NB#.81'+6S_*DF"E( ]!$+GDE^>XG@XH%GSNI?!T.>RX\U3:
M&B_Y>^DK;4_1CR;8'JD&^#%H<F$R83R!,E(KG8Y%G02^Q]^00QPIV.)KN9["
M3D0,UO@A0E_L'D9*+X!'"X)MYZW#45NLP[?V<>]^9+@UYF")\9N KZT:Z>C2
M4JQJ,M,4Y*I*:^$1<U@H8:F*D!_"4RG,N3+G"'3*.*O00HM1;)9N?M]Y\]F5
MBQ35/J/)FU 9@U5%U81ZI85JC)$R/*V;GSB3F"%=[ W[!@ )K;$/?PN96F*Y
M0-,?-UL40O%E'2*+X1 0[1\JYZ.C0O",RPM0W\YDP3W)-)G3FA('H+\S@HFT
M!W7LZJE;4"*TK,^Q#T8'( %@RP82&/@CBD^"K?)OD#+P6$]%:<OF GL?ZJC;
M4K:4.51!O]\ %;9&ZR6G%*JE.O:<'[K%21XQ#,G^M!2#G-J6K>*9>_C%]JTY
MEK&O84/:!?=ZWJ'841>*[4*Q72AVZ]G-S1M?IVTQOMY'SD>@A9BR;G8HCXVM
M"Z#/4#D.E H8$M!:+XAR0,!RO_%#=LN&40'_J8(4^!L?IB;,)ZR%*B^T4B3Q
ME:QX%BP)Q+%R9"$:DYU3\8*]W*=U&Z4,F/,<<@E+=!;34_O*2>%B_*'"V]%S
M?%I-3ZF>EHY;KW9:L'P:7>95VPR,#AUIH,<@6F 3/9<6#X)A5 K-?)_HK^C=
ML&35&N\A>-*V7MBS%EW83XHT=NVZUN3\W&42T45D)ZZ"C(91>*#O!LJ4?O$V
MYE[K,?V0='>ZPHE$O+D7A90>L@BD-T6H:X)!FT+0$'WA"RO]7&/J<XPA<98\
M.$W.98I\>@3F5NH_1\<UL!P&\Z1@YW3!TNPA R938W!, 2]TAG H:[$('MG/
MN-T<;KHYYTW?'+WFO[,Q3U3T6@9@7<0KRWFP\[9W:QR/?S"8.[]0!;M8WWJ0
MB2HJ1)JH'UKW8-_)K]%]CC[TT>AG^8J"(HUY*3%G5$S 4(F6OHI:%Y(LZ':2
MXQ&O:$^[>]3 D0MJ!$?*],@B#)%L$A&;TA:Y9=V4;:_INC'KGBJUP*\C#RM[
M+#&X5MH9S>'MJ=H.&3A5?J"YW?M "VAQ#8'6\IW6>)X_&N4530#%2F!Z0&/
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M #\&2R[.AEPUH)S4I:'%JDT"W^,U%/9&"K;D6FFG<*@04S)AC 4N]G0]91?
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MI31VNT-OI8*K6I%+M 98-O\NTC +0H7;954D?@1!_E]P[\D:8CO*_JTVOQJ
MW'8^(+?M"6LZ(/>+'"D'7I7T8LXE5?SE0$(?T@I[KV8W6A&N6%$^.D0$;C;
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M?,FGE2;Z"GX^/8">V_-.E-T$>N(L!95.>^%"8T;ZVL.LGE'G9ARW[X6@<<"
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MZFGF6\:?SN2HS#G!0\'2S6L(?SBE3U$'0_;(U/O1A0/OA[5[EF4G6&49NOA
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MS5GKC5%F9X[5!T_]R4"YT ^H3P;W*LUF)%OX95;C8GH?+IL55T>UTP+^K.!
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MNY[=HWY4=9%[(H*(JOOQ'(TP6Y'K!EP/T'E'#J3Q;U<2/P4]Z#8Q=1165-E
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M@X@E83FX,G%+WVTK+(V\C%=&\&KA.T5C#= _BIQQ'8W.GU2IA9AO8,/U6<B
M"G=0AE;V4Y/O.DK]=I1:@8FX1:^1!7)R.Y'<!C C3^6,E!8T]>P&VW9HVH*^
MI"1ZRO7#PGF@5*#%T.?T8O;ASBB%*I FXX2BQU.L.[PKC/V]^>"N</2RK=4A
MZ?OARRS PCQ%]EL)KKQZOM\USK8$DNQ;IUO4 PFCD29.KD^^*Q7C(3 K7Y"8
M\95)&7<@('7I&>Z=21<BV3DZ_^/T6.^R0X<1\* *V=6:T-DDJ;(,,^9+X"H.
M[1'9M^,((F'YZC*.RD6!T.4K43)2)=Q(A)372UF?.1=V!:+,^2G IS%\5WC%
M;8HMA=-$W$09_)K;)R-F2<.)&M#-5_W+JYVC](^=O8Z"'Y>"0="Z0+4HMAQ9
MC^CI>&&[O)$U4HJEU+A +RSWM\ T9DL#A"G_H?N-&]%L"@S':&(D2!L[49Z7
M()W560 G1X&RG$N)M#J.$CF95R4+F?<7J"<YG &DN4S26S 20.++))UB9CI:
M+%O#;1+CI+DAQJ\]&"P6OHER^%/$.1DZ\,I2_Y:70Z"QHE0?:[_N +D"R1<Z
M%43/J#95 C!3M0[\<JQ32$RQA:5\X3.V C54"_+Z2U<*KJ$TFJ3U?8U%*-(Q
M6XJ4OH)#@.L0/TA?D$EZ*?V5R%M:K$SNR,]BJBH >'U %$RKU8-W$-^CRJJ'
MB75;&#0=T;F=\\2QF4.21PJ210T8"(EW#[895J83'H\J/#BW*KV)QD!>:( _
M.6^MTT$-3I8Y[+WHHAH;PS*JH;H+_,%'+1I#IF(:LS&S2)*P/>Y?7D1(@R\.
M7GLS-6ZO,$:XCQ7.>8E5BL;H(I.=#3;T<[3F7F(%6AB%++@K0\DVZ7P/;HFC
M_^#WM6'$T3 3620-7D,A@8FG<%>LO@M31'OHVGP\+M6>'[G3_8S(UF<MPT)/
M$-Z"'\.W+(M&70=:^DRR"J:<(C!Y.1[+7%4\1UCJ[%<A/06W++UT!H]J@5GT
M;4SF./J$M:7T)+S_DT2/ 8,I<HEH7@;DHB/H$VS9M#!^\F',$$,=U5^%'8X/
M(B<$/60DHE@Y[E8\0PQSPETOQ"=6\7"]N,I=*6JJW!A]=6E6X\M<C&0!S"Y'
MJ&T%R/866RO=*S!P[2JB-<:D;(17896O8\='94<E)IWA1O;3U:4]4/4PPH,B
M"BK)GYH28N4BQZO28L*.YV<'>\\(.AG_VO>UI0;BG0A<A%,L R]TKP 1*["
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M19;/:55HC(/$H';F>3TA2R!:JM5X?,O"+W(S6:F!]?)\O=!/5E=A6EE:[T7
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M8./'<Q;*)NP-^@N0>F1@K;1-<0$?J/@$4XJU]!;)IWE&B<\S*2C#M9#P44^
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M,.+2N60T/>(%93D0(4:9S026U0)D]\O/!R]>-\:14]4ZKY[U,(8P5C/ M]Z
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M8?5R1N2G,M>'VD-=/=0K5J/WD5L[+PQ8 3Y01RBUBJ*\A8P", 9.*1I<@BQ
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M!M&SF=V-&C@PP38Q&H$9RS7^MU$1DZHP6QDC7K)_F3B$]SLA-['!)5*W(A\
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M^1>#N5,0HX%8($DJ_ [$Y=D(;)5P>-&/P8M_2?-\,57%5;"'-L_<^2#+P7J
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M1"EX4O!0M#Q@@PZ!9^;WT>40R&6"/:;MVC?6&@P,)]!PPL.QN(8-KW3[ TX
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M4A.>(%=B$9>6=:-0TOI9[X+UXMJ=4:]5X=JO<"9>#ZF0X6()TST'#1P1H(:
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M T*3OCAX_7*UB/L5#]BS7\#'"88A[2P!NXT)*/.9C@XXIIL#L>"H HH3C#2
MS(AS+;Z,P(J"V[Q(8_ \%'6&2.LRP0Q^P53LSZ8J*C"8IB70GAB*NKD2H4MB
M)PM[";?GN$#P(8VR_="V#3,M^:Q$"YU?FD:^.&*_DZ^4G2N-Q$Z;XE=_;_LV
M@\'E8"_!P@8)B\\65.5J1*7J$=QA_QUJ?)E2I6G(Y?9EGL9P7U@J[@Y'\&$*
MH2VP@+M/,VRW+!@40/@^<\?NY.$@-OE(+Y2J= .NNN0X(\.\?)2R:>/ )Y;
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MQ&,W"9FE\#4.9)4CJ.$#+GR8BU_TB'%L!'RDEM-P&RN_[W$/KU2&5S<.^9J
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M_I4RP _."6D:40DT-*JV;;J(Z?_H=/&N_0!_HF,?-O8O%]18JBS7+"!V;/K
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M@W$*OZ0! I.W8A@KR>;X*$W*XM*GH\Y)2K=!@L>WWM'IP9AX.DC6Z3G %\B
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MK\9M1N'D8FS2#NJ:@ZVHYZ1:C\Y-<VR^56&Q7YRPU$_VVHF5=8FM/,6,-(;
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M^;&]_#]S>"H!SW!A?0.1T6D2JOG /8Y:5TCLTL/"8;DJ[!"TF;_IQ&]YF'"
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M[G5'FF_U$%>DR4+R8,^DT0AN0\:V1P^/=UN7R[U5;PXF=_ PY;^&R#7&!5S
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M3U]V[OC32X70XCIQ@M+1#*L?4A5?*7\JR11)IK69F*BNKL$NN4Z6,@9).\U
MEH$( /.'LE)PJ+ZFM_?@)>4 (?YMRB8/ ?ZWBD@#2&CPH'0C$!A_I9'&)-89
M-01G23$A2.%TYG$ DL1EYFU01&V(4>Z^I/-"9?.-2HO ,S!=E*KP>^_HV@[3
MMYA'E<X#"4F5N(CFE2EE<J</L1KSI"@Q;3J5Z9\3<PR)7(=99!7QX=?D-0=O
M7 Z/GHJ-RV2S57-;#.<=GF$YYFHV.*Q62G)&=:"A,9U,?7[P9J/:!\LS,B]&
MPO*Y+I647BY4&)1WBVF>@E0OHEC!]OTD_Z2O4:ZF^56N42-N06T?;Y9&(Z(@
M+S48-VPJ+KX3,;X:&QDAG+,T+S'OOU;WUE:-[T/P<BY$SM1,SBGRDS.<5,92
M6D2XN3<A&5.X:XP57"H30U#%6RP:!FA)73PMFNG7!R\V6B^!$H&\75T)1XUL
MY9PD95FK]LEMFIY4O2V(M%N#^F7PKAS14!\>7>2M/E//4Z?+8,OG"1W'B M,
MM8!I (^E=#SOHY'[$L'18>;"F4_3_!:?I3ZK66VQ<YU/=4SZICDO\]J854'Y
MD0",J@H6!:YF-#6JNF'NYO'GZV0*WN^&FT4T096>0]*M\Z9*P[EB0X%47<M*
ME9:9T-<G%']9*FG^ZF]$[6JMX<_SAFJI##Y/H)'DM'#(P2&T@+TK!67NH#IC
M"D.'EED!N/ERHF%.U".5\](=_R.IP,:8K3%C&YRL?_Q,QV:' 5R! 7S]$&MS
MAP'<80"_$PS@L,BS2*7[UL.""U9GLYH*^*+21"B)*<A)]W"EW)S2$MF,2P.U
MV\P%?]9I1JR[6\"7Q7Y_5IX&*OC:8C]U>!7I:U<!-8'OPS)1&K9<N%%Z'1.;
MQZH-]K$\#TO:&W=ZKM2]&/P81-V6F*LH<G 5I9+VOC9)>-M.MO85C9-6-24.
M![K:0^"7Z60LYYS-EZ3VFW&-YK[XY@E^[$8!SIZIC"LKS*I;/G3+B^]FFXS+
MRHQT1F\@[4U=,)0"N:-V[LP7[!XG$FS #QZBPG;50<E"J(P\T\MUSP;:YD1Z
M/"2U>MBI5_W,])-2IIL-C'AA8=SV)CWOID%,!(UR/MRTS\?^4#T*?.O8I$EE
MSY%+,C!R.'&XI.4J!P\KPV,4X3&]JE,K4SUV C!RZU29QJ(%S.]5!F^+/F$^
M^X2YG.LHNU($7+*@-"+2<D9F7@=DKS^:<-58UG\^Q[2%6MZ@I0B)@ZJ#9LVA
MWFAR7 AO*,4T40>$8M!GE;R-E+_*6]@W(RZ_)I2I$4:T8[MSFW72+2VMJ),Q
M]!P)Q\E02!13E0X8*M)P*0V$LH;N(OJ<+.J%YB0%5<;,26($&RQ8PMO(UY&K
M(JQ1V:S<[7MQFAQW7=!IJC--GT@Y$8VJ8S^K<.=<(]P:4QZV?#&CQ%-80DD%
MT!0D&4V!N0E5V'.%OAVPDT Q45_AR(FL:8KF"-+<I9J]\"#X0](?]-2.X+AS
MSBT"T&/><6/-N.$\A:D99SJOMEC$>Q<,*7VOE-WVDEDHP^ ",R%\O'3BB?,C
M8KC[N9)0,KPPD=&L(FH66B),1B-OS (SV0+DPQL:8\"\ ,CANDAX)\#;CN7L
MDHDOF8$],Q*1!-B]=)K'=_M23VXY?ER9DD:WWUM1P)OA%07\.CX=GX].N-;J
M DL#MKUHZ,UP:@)TT= (#M(5J=,AE0RA71+1R$BO%W#K>:^;3M0L2'6.-Y3@
M@D._O<K#]W+27MIY%?N3Y?$&A\3TKV-[<3.O(0EYI'K3.7K4^IE"PBS\=I$S
M17H#$.2^_GU)>.+ZFW[]:X(>H,HM,"= 3]PQ9QCH:"0"85]>EV#74_0?*C9L
MZ$-^@6D-ZA?]/9+QI6(;1_/N=3Y4V%\M, *T !A-5TC*7D8I,^JCB6C_Y#N'
M/E/<>A/&Y'$\)4V:R[XN"*3VN$%-!]N_(9&+S'D]"$:XY ;0P-\H;=\(P2!-
MF[.-9 KY8GBUE=MJCS"W:>082?*4.$".00'2SR)-ADM<@U'JC)*Y$NV>VV=;
M.<M;(W?J[UW6?3-2>( M'C2<^CP+8'LHF#C_7FR8P79$'\/!$5@_U%B"-WD2
M'P0.9FD-[$#8-VOFKM.$G5]JKXEOG61$G,.WGZI,S1.S?;31JY$FS#/H]T<U
MIX3%0W,&'U;I^#05Z&!PSUJ!'K%1"JMXE#.7Y_B&B<\T.S9:N)M5KIZS308W
M!MWL;H^"UEM0?%3S/9' :@@E^)EGLK<:D%B8%@G+U#" ,JEK^X&F:8QITH'D
MEN1W"B?DY752&"+.&=KS>$L,=:!\'$H?F1&-3!6#Z!ZC^4I1$C)GJDUVBN3A
MVNM V.+UZ*7OS'6^<-<9*[KRXA,%),0=!#VJ*G+IIJJZ1?B4=QNWM.T \R[<
M@>W!NT/[B8TQPH#P^?@-E9E%(+93A1$+*6RCUS!O@("Q8%%+1Q4**7"Z('32
MNVG$^QM=_;KDNG43$$E@LV'B2/.3MXX_ Y6[8R%9'&(QFQG.=;2CTEH)HWFS
M@]'L8#0[&,WPJ;10Z&HW03A-59\8=',&3R$%].+@Y<:+ \A=1.$%:HL\[$2K
M<'0V^OK7ASV8""3AO.'0JNBQ2[UHL<5&2$UXZ.M<KM4V#AT7Z[#K^6!6W5"C
M[9T\4%NC"H(CE.I14/"XV6KN-0/6"UB#$C21ES%CW2.ORX]Y4,D##LDK'>UX
M:L$DZB0@W/XS.)9]&TD0"O^48 SWW3'FA:)P>*R6BMRJ]&Z5E^GRI2<94>G$
M>MK,4DT^\.R,,1V +X<?B+5TJ>O'L!D5W=Y4T'M6O/6IM]^-'$S3=NU&CC'O
M1CD-S,":W3H 4N#5/5HH7QC;S\I0;S+X5[)88!N*1$E+ S<0=05"K-([N;LV
M@R.8O='+@V"$<2Z;'^: C4%HWI>9E#@9U<-+1P]R/JQHNR^JB.8[%8SP+-@H
M&7:VT*G4J!3X:-?HS--M<4E/]U1&IE(?E3O=5&XN<5]V2$!(25[,8E;]XD^T
M>+@W"8:(OX-C/CRN?)#_A00Q-WNV+Z[S&DMMVSF"=3/%L/5G^0*5T@WL :K:
MK3.%\8698I0S-OY98&R6H[<(WX";]QYX$SC%R'I5U)R"3YIH@^ 6F210(U)0
M@Y+S0M*OHQU\6&)^[GU/DU,5T,"Y"P[Q2(3F=CHV2ZI8BK238AW@!>4PD@I<
M;XD+K)@N^X)1P)?06#JO,#7/&,TAT&RF(K0-L1A?ARHL% !$<\+L>I63L9#7
MVG("VC>#(O]G MKCI%SBGCA7%)?9.&&C,#ETX9PNK;/Q(8WTSC.'A^%8;%$.
MVI<+#E\.H,:[Y>XPD \W0QF**P$36B;2J""92QS3CZ[*R0U-=P_,26([[D17
M8I,A&4K7DC9POMO58/="=_2D1IV*J,92R5N!L\5X-RR )6,B7.6ZZ#IQJ@'P
M*\05B[@$[1T1]Z97*.B+)?:=Y+^- "2E&9KGRE@051YJ*Y!_T=57I3L>&^P-
M(%\@PF (Z0+1SY2PQ#72.1_-'(? ?2?S[\,H&:!'Z21)"3A=%DT=ATX[B5V
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MZ48PQ(!(+CQ5%ALN/WNW[^$@#J=(0!_$>E%SNC XQR4< /I7UZ@1Q0/'2U?
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M"U=L_%B6">Q]V.TTZ;#GX9\B.$#G?*SLSV #Q#N6$[@W'H=I?K49D$D:7,U
M]]J;725I&DPEZ&Y0V<&I+*4HX/N#?+Y E[@,-AIW*1<R2B9)%$S@UPL<'I\
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M6-&Q#*(T+U4 PZ 0L.QC+,E;[6"L@7L<B/FX2& OA<%' 6Y3-*O1UBY7R^<
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MIS(679LE;&&6_2;*,Z[O53'(1A<E;GC3LQ7JC4'(J]1N/268H!ECD6Y7);,
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MC3UBCBC6/SAPWB729X!-F"[;040RH="XPJKCFIE(5+DH&9V*XQKOK5N5FO>
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MRF/@";H;E+IA.92RKU7(/N[O]TG".MN"*0S]OPV%,:LI^FYAE1V1EU_7ERL
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MJ^VQD6RN.DHSA#"DBK"+R(U$.6,R+UQ6@KL\F5E8/0U:BA'*F!#V@QNILIO
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M>:5$&)TNCG;C7:G/ G@*\SR6>,-8EB"4WHOCIDB3"Q/3UW3:NJ_$P-RVWNV
M,:$* YL'L C3O'A$]I16DZ]'N]>JR0%W.N!.>X<[W1YPIP/N=,"=#KC3[PAW
MV@][I\RS/E@XMI(GR="4CVN1AA@9JC(8XRQ9A& 'SXG>Q_0.X6XVV3+$.-(<
M[7KN>49Y0E&6>93HI&$!*PT&=^8U1LN+*=A1.D6JJQXQ E\-J;'URAF1 1T'
M!QIQ<(['1&_DKJMET\)@"RQ.HJSJ>&E:%CFM0\!EX^)\T]IC421S:BU+K3<Q
M[XRD&#.!^1$8\;^)[0';A(J)1-;D*D]E87KBD,\+%\]%E%_ V.%85MP<G""B
MRG5!&9#YG!,/<:[HEM 5A<\H+32I"26%XTY,EY(R*I(QUQ?O; <'H_>CTU&
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MF!5W8[!Y/DC#?4B#&V8_E1AM>VRB\7RT_>Q:=J,!'3N@8WN'CMT9T+$#.G9
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M? R/YD(B+15*,@]W*)J^+S'M$3#C3JIK>U!=:Y<)#GCW011895WE11I?)?&
M\%CO2C?;0?1GQ:DQ7R%%I6%!R,_'OIH&1,QJ>"96>DO!K-LQLH#%LAB$9+U"
M8C@@^R,>N/XGLBA1&BQ9@-,=$JN)+$K,X(,&T;@GT0@.\K@7^+ [V0X#SO<>
M)>(XFV ^G$SZQR89KT9[0WSM'F5#M=!]9&+! ;;=T=X@&.L4# ])VP>1Z =-
MT^]G?9@+:XY[RX0VU?X<;AT)QN17RFO4W$.+O"PE\?4.N<IUR\5A'P2C+YOD
M_U$#>L@Y<79)*JXF=1I$=5%PTY..:H'A^%BG"/PW<L %!ZE(>I%W85%030ZX
MD46$8U,L:4E9(LX#562=R2\+[#?F8=FYW&PCV:3^N%E><:U4(2_S"Z[=FF'C
M3O@QUI)$DH$E=;:@>Q"4#JY),J+&X_81L8R24D=.B(^ILKW&_$X];DT-%IU+
M&EAW/[*<NJ%)D>J'>@/FKV#$F&!0\7^L&,-@?GXEN5\P7Z3R!$GSG2.D6T^Q
M&PK>(R[$%5;6C.'B/,-/D>4/IY;^+;.$IT?$JG4&$]OIF: &I<Z<8<>KO)YB
M[H/6!&OSM^07X93;V0<49KZPGL=IIF&7MF,1$>L;+"135/'Z>$2RW2O-;[WR
MM?'9$QACFF)SDS^9 P"7.:,WSU1'.L04<=LE$=DN=)S<R7(U\?@LG"/B_6NL
M HU%#Q[7*D4"1(JS^%EI4^DC19'"\5]A 9!$L+1".1'G;?OM:>I*[NO\M?TG
M=KJ5(G^49$C[^&9+7?= FG)[M/-P6K(!1-X>T3P<9V"U+0I9B8?&P(R"XZR1
M!42=1B)GR^@P1YE,$FPP_/S5V[\L+R^[L90M8=E[.&&!<^/AEJ,A++MJUZBC
M7E4KEOJ\0Z7A?06_]'UKHDFQJ,ETJ2L>52F$[<*INOZD"6APP1[W\]=/>Z''
M_5GHG=&+76>A\T(O(VQ+793*%9W<,0HV)#4\W5 _@,6DSM_FAYMZ"S,-9(;S
M[FQGU6Y5(6>?]"I'_5GEQG9&P'$^"?52.Y\F6=BQQ_$;W*?>=U?$7H2\ *H9
M53+'^J>0%4"7)D<_" R<,<D%6"PUVVO4VXN).SU$B* *KQEB-O%Y:"LA15*V
M!,,"*R)J?"@U82L[(277ZY&AWFJHM^I=O=7SH=YJJ+<:ZJV&>JO[J[=Z#)93
MW!_+J6$?8V]8W]%I6C,FJ5B*N<TLH@'#G4/1K,&OT7S2]A7=B<R51ES[2:ZN
M[,_J:KM8@XB,CXK9K07B9"FH*$KL,")EJ?M$>>6 BDRH)%<IJ3#*B)5[8[!W
MP6*@F!TM.%FR8*7BO77G#?*;G[J[.^G/@N^-]E[R@J,W4BLV,?HG-O1,:".;
MQJ"93N4DCJ-1$C ^]S<^^2JV23$Y,Z*ZS4-T=S#EQ2CMP,I#+!WB-.IAOU21
M5XRIXT/PO^B=T?&-0Z)FIAPPQM!V)B+%CBHBI)NE7J;,CHJ]R=D9QZ&L:%MF
M>Z,Z-S3.U=/VWZ?]$5M]"K'/#;.35YIUI(1_D"?L-Z$EVJ^T+C"_ V?/)5(+
M(AVC<'QW<Q^4A:FD"N1&*UOX-W_Q/01L9OU;<%S&HR^S9)P@?_19-)-QG4JW
MTY.H*A'-> L3PQ8&1PP9W$*JO- U<1)%2ZUT5]D1B?$C.M<']D(C/,U;KGX3
MYQV^ S%+^B-FST?/7FDQFTG![>Z39E:&J,<GE&"V3(9YEBYI\5AC<":33L0$
MU(4;.';S32NB=$][P?_LWX(S<7JJ#@)O":>@+C*R9IC0&;5'8Q'':#J(4B\G
MFD?,.[M /EAE?DQRE?.'J_DQV+<I8JY[X<9PHU24%$D6U.D.! R>IFQME$C+
MLO&DQ>2B/V+B'C_H&1' #W<LF[4$ZP#OB+5WA.UR*[*,.\Z60FJ/J4[I7,KD
M%*P.P3\8R^H*C5OO0<2Z0H]IGT*NHF'3&_3,1%PB5&-"1OL4FX)57"U"3EU3
M6@-8<]76D,$*]E(6RF3AMC(#F8:/5VBO^T!U?1NAW+D5SLIVN+E?F;P%?N&%
MFH?3H[.C_=.#7X.#SQ\^[+_[?-H1%7M$ZW!;(,EV;Q9B>T0N]&=P)RX3N#^Q
M1?N--AX4T3T*#BTIH]>D(E38@Y8S?'N%%GJJ"L.!062Z&Q( R@=*E:P\G($L
MU!0%&\@\"4/J Z2VAZV7^-3'R=40$I[['LS6@=O/L@=3M1DJ6GW-X]"04-/9
MM]5-M!WV(3I411.Q8J?X#=PV-/?Z6(*]MQG:ZS1*,IHE\I+K:U)5:P4?^_O$
M;0APH'L@D]/A#&@4'#FCPZW:>B%^X;$=) ;GZ!U,BZ7VEC2=(?&6MNU 68__
M5+.B:\1V1]N$ 87K&O5!ST-^M(W_8[BW8&!H;IX5ZC?EAWDM&72%5.PL#[G'
M8)_ &^ BY0S-U'2U;&-K7=<]AV=FT@_ASY&EI)V+9:AI-VBPB'P%&S_17/:(
M9H7OHKSDR99?%CB\,* [<D?N"UJD*U'$G?/U?+3C3A;\_2*D]]&MLE:\LGI!
M]!G@;EX3ZXQ1Q*V6$8_7%'N,6%(R 3Q%\,!G_CG%&A),N-@>:PM24#TY-?K6
M!773](<X5O.FZ'8(PTXA.45.B6JS?,!&;[P-8VR81UO]#3>?@*M^^%G%%(/]
MAQ6__6S9.!?Y1&[XL'1$Z  I5@'0.6E:H*J\TD(6&&CCV GSDY-["M\FJ(I
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M']?GVA2[3J>$-N@#FNK-Z\?5DF:+.[#"G('D7.9(9F(SS1S 8!PARK!#M/X
M4WB+EB<'#\H'L4%ZY\%#%,>\CGV(3\"44-969(I I["4H"4'FDE3*; #G.6Z
MTX;AUFRJNQLC:]WZSB$>O>GH%XV#_Z:>;RV,AV($Q;@<031X!I;NF[(YUMG[
M1J6N(]5[!$V*2LY]"$G;.MF0H^DH9.-)(7GQ>9X><-Y\,W0:L3A4."LNY_C>
M%=)TJ)O+N &7(1(!AQG/?U-GL9$ I</B'#4QV0O!AR0L"KC<-;$JS<%7K72.
MGA9:"?N*!*C5I9K)E+%5D4P6E4G,JWL\X:/O6V7D[V"N>:Q7O,!EHZX9)86D
M1C%:9'JER %HZ 63$7;507=P^Q68 JT2 &.#(:77I-&3IUW!C;E?9ZC2\AN#
M(Y*GEZJ:0+T993+BA&!QJGJ<+JOUN[D7A\VM)+)E\VV=G(7W')-M68C$9RQ3
M!$ 9B&1;.Q[;HU\QI+O3^(0WANS3QJ!]<=X^\MAU,/F3V$O,NVL\QX8X;F^I
M6[4KM>0"3O;E5B><03"T3$YF(]=,DDBIFU/;\Y9GQD5CA"AI2:5@E*DH^)4K
MI\^6W>ZKMOAXTT)?FW<>K0AY=!@4.I7ES+ZWJ] -7( 9L:71XLH YT9Q*I<9
MS3#[UEJWQN'K54+18F&[,=S\L,TNMNI%)\"E%>"Q>3;S+ *9(./AI2QF4L1F
M0# (FB#OT:.@P_OU=*-+@]@HQ5KIC39DFK& 5WF=QJ[(P4CE-&?'!C3D+$_C
M<L3A?VHHJ"P _H5)GN*OT-: &6@E#F&DS/QK;L@RUY(VFE)1@R(3%-O&>KL<
M>VY=2H-.MOYY6UA=\DHVZ6(]/Z1T_\47PFV-$%]WC*V6ZU&P7[G^80>%*RYV
MD]%RI8BW0GVM?:\/%=C=F?1^Z_!'-G]%XH%@=[5G4-/H3AO=Z'+N.&##(TC+
MUJ'!+*77#L[&DR<Y>=T;L) B.?G/++_:^C6_"LX5V.])UZ(]Z.KWJQR-H6)F
M\[?DP%=H"C7ZL,)Q0XC-#[&&_KD?TOO  8O3H$C<"3.9E2JNUA$65A4YD=L(
MQ8EZ4* .$;P>W+P]I9E$C4P5+H5;5P=^QZ1.:6#F%':*=Q..D+@%<Z*-X_6Y
M=YMPHB>]GWI4S[8S>K%[_7[J]=;AB$JF+#DCC&0BHNQ9W#-'71KLE-V%7AN:
MG[E!RNSU)MKT!'B +PWPI<<#7WH]P)<&^-( 7QK@2]\+?*G!XKWWN&SL1DDZ
MEC1E]01SD(4D7A[;\##YMZY_==DHFMBD?(P%480]*4Q]%,?'# O6ONZ\.,D-
M$L7I/$&8+3#EB>DH[([Q>KU#@W.G/T#.,P<G75;C<YFMH%%_B/:6ZHNF:@X;
M<4]8L%41W078A[?!TU!$D2O#;A(!9$!(\]*'WWCM7L\.<%*0\*#=QQ+#>O;.
M;3&@N"7V#"FYMXW\0DU9,1V2<.!0JM8R:ART]B;>I^73$4!,*R.$(O)'3)W(
MLDQ9P;12E'%VH'VQIE32^4TSR@FGL[A(L*MSK*D/)"( +J[K*!4DF" ]]FD[
M>KTB"N# R4&./&[BX?N$^=F-VPNPXB:)):(FJ*['<+W=1;A16MO;\%H!O[-P
MNSIXO%3OR'TB^'A0V1)^TUN_HF+84PB5.6IL30=GWVJ5KC8,>9I_Q$9JGG*Q
MZ_:SONS$[1?D)O[PLV91ZTFDY;B]=]I1.[<Y)AW.IM0^0JJ,)#.LDJ:/N<OY
MT9<"NEX0V-D^I>?4>B:2L ]A3]O)K14]OQDN&$X$T&6;4"DJW/=.)>=JEA%%
MWA_]J\8V;&#K*!UFH&+GWK.<9F8X$NPYD4KU^ ZT9_N1E>JIX[V8P<.# 0LJ
MC3NN:GZ4A.,'B@Z%PG(85$Y8OW48F>TFJIJ#:*K5(MEB5Q(O+.V/IG42*^*U
MB6INJM[#3H"V"DU;%@,[4_?)DCE<9VA750=R>A>8W2@IHGK.)UC)#3-@@?!
M45B"60T3J'\>;?J-2\!,7/Y;QLA,>RDQD2XS4,&2?DN]9V*FEN'M!:\FORR0
M#RI=VO2MRORNJME53X[])^L=K1\DXD8;%8R,(L8<GH'LN#P 122*RYW*2XR*
M$@I0BVKG$$R#< 896!-7LP'A >PD:NWYZ3;UD9N!*!!/S\*/#[)0C>:NHG6#
MM;D2!1[<W.Z7)XY.W3G].L0GHD<%+P42F1"S*D(8DBK#*SFCL<##.D)6/KL3
M"UO]:@A2['5AUVO8=HN%Q('0"Q=ZA('IFM8IHF;AP*(@3E?\Z662I\SN!K+
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M+[1E1\:K.@]HGC OG/D".[%@\=17Z,>_^+Y/?.?UBA/W>M/ WU^ANQ$G-58
M(N7=5KWPM^5?V(<*:^TPAC;[\#5U>0>7D1-.][B9OD*>'HNWTIO ]TIO14O
M(_160K_6R>X/SQA>VUXQ#WMG<L3NMG'*$E971;3H^.^V?;KPZ[23'C*L]_1W
M\6[?=O&9%E6I6D>RB7UFJ0OA)P^ZHY^TI=##(,)=%*@^ [H4*28C2BM=!F7G
ME9@F58/XL*.'G; E!X%@,B[4D%0W7G!O75VU/L=2B 56]208Q&8?E[,<A00K
M5ZK:6]=@:?)_JL0[)5DH"63ZJ-JWL>_@C+C1(787,ZV"4_BMLO*[>Z0#7G#
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M*[#6_E?JC/(_I*1O^^.N:]>V1?Q']2/'S&< X3*8K;(/&>:GO0][R.;0S(N
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MQ[9ODV[<(@RWE^,9U:SPO^"NJ3S-Q?&+"@(8J'\/?]-FR#3Z!./&+20 ,^R
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M]$ZR&:]GA3Y-/5V.W*?XFIC_(1[>D7-_!%@^&(#ED\<CP'($6(X RQ%@^9T
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MWA!1,7J*HB^55 VS[NR-K!0W.=%7HP3<9)5"#$BI#6+)J+9V6CL08X(PQ'$
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MX6XHH0#^%GD207URO3R@$LQ-'?+%+ TZ+D*LL01F5615 B%'XS,A2B=$SQX
MP8-_L=Y^98-=)VE79$OF?)NT83V4U&RA9MH7XL,,M)@P0CEO'F^2;H!714]
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M0#;::3,5D2^>Y5A@3V&CS D]46J;V&G5%[5:XQS-05$O]$349.ZJBD/X;N+
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MD3(B4D9$RHA(^540*;T'.2!L31@?TG*47:24 ID1GB$?8ZYM;8KMF0;6=F
M)P'N+TS>&$GN!A);4X;OXM8SH*U,:4<<"R8Q;/($?OR7'AY".5#-[K<S.<#2
MUG;L0 !')A["01:*JT Y'$57]7*F"@B!L]S&;HUK6EM\"GMZ> _;I-9+*,?:
MUL9P#('&,>.MI0&@/)"Y;H&BVO$-,9.3:-&4F*OR!Q>ZK@D:SL1W7(6Y9JYR
MJ[JKMFT .61(*9G]HIL]PTO>N9$AVAYN\%&/7;O@X*M*6$M0/G1(5QP5I;AE
M;0>,14890M8,+WMK$=M1*5-T9#:MJGGANJ=S Y$&%O_1>,0]=U9=&,C]VQDG
M'6M"+>&W*3?DA2+< K-4<Z.G%3:Q:7+#1.UX_/Q)3T\]&:5E#+=X,A1";A*N
M?^XR6N^WCAIB37*+RA^AEAF5HTDQ*%'-V["+OCS!KO%NV2H*NB$6+R,(D,B?
MK7([OCA+[969P7]:2B958X1 &H[OMW@LAB,>Q]/CYUZZR-;H&*8@U'T4_+]1
M$'ZO0A2:EI"J*N89IA-0-9#E8[JJD.T3AMB\V#@$-%%8@F :U##G@<PMG)A?
M)QM(7=2)4X4*4!!IB.5"35"I<RB/CBR,]BEN)8&M%D'9F]><7VGQLPR=_@$@
MV"AG#WQ#\G[7!9[;446^&!Y5Y-D?%Z=OWYZ^NOBDW9@/Y^\_G)Y?_"LZ/_O;
MWR_VG2WR<'ALD>]O<FUS7&5KV)IG^37!I49$S8\[77X6HF8+&1#CX_=;7OH"
M16&WBW]*;GL2]-<6Z_3%]/!@-B$LLOO9?*(5O/998FSB:$2:P9$LUO8D,,C#
MS'EQ/$/%:N^WJ<N&.T>XO^7(P:<<;?N/-5%S4*-)P%1ZV!YF#*0D'1S4<-0Z
MPT3H/'\]H_1U.Q$JJ3LLW75Z%\OG2KLXQ:T"!'AR256^&"&Q(!'JC3>'-X@.
M!H#W^%@0 QA-PQ!@'Y1G%;P[+=M?18:YR8YU,X!R7$"Y$-HFW6LMH.PI5RPK
M'1GP<,4#9J![/RRDV-OFD4.0E_\7)GAH @.0[X-L8IO*IM2E26N%O18(^. @
MRR:2OK(M=BO"HH.W00H1K?M@\3P4@VT=1ET[02\/1MYD80<@;K",@YD7;\D'
M,#FQ^+*9WG^WQK#P(_E^PT3 $!' P#J1+.&56R04[H_N<AV  W5TC'LR?1:[
M#?V,W+M C#7L1OWD6)X/H,RR:"ZOHE6SK+,UP/$R;>> *50!@2)N0$ODJ7WB
M9<%8CM96@TL[%@T-'JP-:;0Z$##07TV956DVMQT9L9X7^<_J6P> B+1RVMM6
M"H&#$.&&>QN(B#-C^QU ^EEXXRU,?%.UN8+HM#)%F!^620W)M=W:^F'/1->@
M3R9RQ@B!C_MM.FDSUCOFM&_U&[,L"V8!BQEY)K2IYVD&Q),Q]2W=B.X#7@9D
M'GIZ/_M^BD":_,!K<)12A;4]21D^3 &QK+S?\1T;&B*9CU+LCE:;>)A?.&#U
MX+"+O:-(#*.KE\&2S2_AOV1I\EA2(@KEKK#&<83*C(NLF' Q,YTY@YD]L'5K
MY@Z,;3;]/-&(H,1<FJST3# ,6N5J@1Z25E-P ^8\7D-9!%S S0&AE!6 @B;5
MY ^!7<I@7$8WIZ#4TW;IF^^RX"U:U_3FM \$]H@HN;ZK'+C=!*"79C_4IADN
M839S6I3*]+QVSB(CJKS>>)CY%?H)A%K7JFZ293S"Y$:8W ."R3T=87(C3&Z$
MR8TPN5\%)I>5I;HN,$T:8_]R0QX04[_W1Y#JC*4WS*-%"03C-T6Y3&^0J@0^
M6-Y:NY-8G,@$C<$L@')#;A)CO$8T#P.:#-?#[3" 8P.D$@"^_H$V 52UWR[@
MSZJIND>6)W0!C>'WN]'XT86:7^7(C_R0'</ S?E*QW#S_'R%NVANV.,NSCUW
MT7I=.W,7 P=[2W?1^KF_O+L85MEU>(OA)=_N+,JJ?;VS: 2UY2PZK=$<9W'G
MIY$9\,;3:/[+GD8_"Y1]CX#D:RK6;LJ=MAV;1J]M'\%SO?&34F]H:"C8$:(7
M]*-7:-Y*E7DGC,O9A8Q-9N^GYOU1==,MJDR_8Z(55C%OZ"RRS3!%"])C"!40
MMZD&1(\$IP1_'+=/ATVI0+>BVE=U'F5XLJR*B(E$[2PA8MU4,S-XG2M&\6;N
MM.&^M,=$YI5P]@YBOW?MSX(IW\.&_*!*O:"Y6D;O;=/R'>.%8)N*5+-0]\LT
M]P!%F>.]8[.$FZPL?=R!2((<ZH/K\X;.*;&M?IY# ])\;L@LX)<QPH_0FH1-
M;(T!/,_(VK!SZRB0__ZOIR]^ V@!1;[,/C/=2J@_D-PP-GC9VY@P_Y6C:<#&
M6B[U:S?$, L\0+>VU"1 XN)\!89H,$-Z="]_<P  ;$9A5R1X,=[ ][\QZDV]
M:E=$K&)::-UA,7[K7)CWD1>:%_ %:2*N.M'ON$[$E(71 PF4OD$%1"KX(11N
M:/< \6.(5*:*,]. &1'6M9#1R3]I?DP1BHO)EB[%W_A>!-:XEK6RLHWJ?,YX
M,UZWF*EA\)_:%\J+FZ5*+TGB4FWK+C.'@T$L*WN&>9S%BMHX\Y'K2#K- )MC
M;:MT&IUQLPV][ZJZ*+BD'[[GCM+&!>O<5(G9I3G\ BQI!)H@AP#P?2I+']&B
M^=IWLK\7@^J6U48FGV,)#,G(ZZ1.ICOESP"(5ZI'P:P8/#3V)PW<@5&#!J8)
M1PR1%]_%[CK7CX1(NLO#692W]IFNQZ?/.U!+O+V<J\U><@TH'!AUP+;>*B!F
M_;J(O1?W(?6](LN*=/\;/D4^N*?(.WN*P!]YPE$)8C;Z6,/R[SABM]>&^  A
M^^?H;549$V[#UC<BP^<R2HW^+_PM()< [P67O2(&R"X\V&X-^\[@E=@%-J[S
M)$:XK5]GIG^C[3%EK3$ROU8\)1[PIV-.P(S]BCMV0>I,B-F[7<Q-# $W5RFT
M;Z5F;WZ%A,1.B+-H:HB9VHM+88%<RF<3HO74)X\_:B#CSST_O,!)U5-'AJ"M
M5,<6J_ZOA729HYD QX6B]+RP=X$/_1_QB*9=]T)"P*!WK*T()Z=?I8) AL+P
MIC*QUPWKY=6@)WH(:\0EZA-2(74_= NHDQQ]//#)FISM:Z=OY268T6@JPL%K
M>-Z!-E!_;ERX[E$PD5OX:ACR0.)K_YM4VYFIHC[4"/84D4)"4)8H8\ZVQ2I<
M*,.\!E1O_E=.Q^P>LECCK2;(E\^T7ZE*4MB5,"1R;:@M :H=:GM+(:"ND8SH
MH1$]]'#00\]&]-"('AK10R-ZZ%=!#]5(YK#&9DU,,M0R=I.J:E;<5<GZHM;F
MY:"F&&==-HK'1AV[@(V-]OQ^^Y(#K VYIR^)HK)+UU"+Z2ZKW6B+D*B3^R$!
MM0?I/+=V?H^#VU/1Z2 R_#M)@;!\.I@E&T!IXL1PE-TOR- I:+] *.'K'>BN
M&1NZ]_P#CN?N:?C: WJ_"5H&"-U]551U1;OLE:2A=\MW0#P'<QB73\&E=4V#
MQ?M</LW-C) 0T6S3RE-K1.G8&5B+MPA^T7<(A>H2<X?SI2AS95@R:6!#:76S
M,7@/(QW"J<5L*'<-E3$V76NAUZB]H'@X!.@6C!2'V+I[Q(I;(>*?%!UVGQM"
M8KSAF_8>.)+/@IZ@PT+@1]RHM9+SI6<4G2"1(#Z-GQEB27=65\DM'32)=[AC
MGUH]%34C^:"SB#0'H2;,<$Q!>C*86OI\T06.7!C(57@W%Y;B0&X(+ [3=0F(
MCT6"-++4OI+!^EK0]82ZC+OU5D+*^LD='B"XD0^6%T'&9P5B&GU:<TOC.Y]@
MZG\-;R_@5:A%L&D/' [!YR?>[DUN9%+<YC$5]-,UN*.Y/35@,N> X9M;@!$,
MZ0XSH@7<\J3+6I@S60OI'555)#]L&:T102B'AGDQ!S DJ$^S6;SFXEM-R7Z'
M$ :(YF9Q .!T= H%,=7.[9,._Z--J:T 'H<R!'X7ZB<&X8'UBVPP1<EG 8#7
MY-50H>K=H%@7:Y&O>4/-(9"] (6A")\-BILV$!3G_+O)KJ$?3@??:L^3MWN4
M4_]C'Q&[L$*\KWV#UN-=:%#[_.RCB\EOF2X&D7___5_'SW\C&!(J%VR#Y;:D
MZ_)WML\*H^I< ">@VS6=><G-A'DKM=7L=4Z> W#WSQ]S+(7>JAQ)\-9U,0WJ
MIUS$/+5S;#4)C(VB5M)0P+%<>C6\IR #G('5S&N@-:QK$\*SU_BZV (W[=/%
M/#%JW 7HAWY[L,K[#R8;7*-DWJ:G#MH8D9-J 5;'"!3[A8!B?V![@@&4:#A=
MC4WI L?<6G8X(N.-1^B58L:1=HKTB5(6:^V\T?EH$._76;$TO3 2[:UF9>K=
M4RQ9HYD#.[;KE.N)*\#AOK#M*69*ZW\(;-P V$O P%#]RH]D0K:@3%/K[%=Z
M,JCAA7W2,/@UW?D[<]9@"+$(<ACUC"%63UPLK/95\R5490 &^J\FO60ROK5
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MY&#3VR N!&T;9,*<)Y6*-R]01B\SPSY5-=F*,G7FJ;V'6>=AV&&+]LLZUDQ
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MUYCE>I,&U:9['#<=$.S*222@D79-(.PV3B.KO*W_]06X^E!_F]PP:".,H]L
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MQSP1%Z?G[Z*3/UY'\(^S/SH\^0>T#%LF_A\/I]O4X;/I$2Z#UKZ[9Q"6XO)
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MSSW6!^_PF3!YA;3/,>U!8JA?T6I^UD@:G-LUBO%=>31*UF)JC\?EU)$F:K]
MUG. Z S+ %M9V"ZLCR'!$QE$Q+A\)I0?L7 >>"9R:\$76D(H27>::Y]NQJ8
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MT5U$TS;6NH-8*[/I$$09G$U6.$@772SO!U_'AJS2#[C(BHTN4&F05CP><KL
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M7\282,*MC:N'*)>@[B:3EX7@*KB K"G)B7K5X]>("+_^BM4;2\SX$/^X.'E
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M#L]0TA<:]SHG5?5]QGVGXCH8NITQ:4+"VA;9\.I!5V=#*ILID4) A*L:H1%
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M\SOTL%:W:W6[IZ?;O6IUNU:W>V3=[K\G:;22_[M=SF?_^_]02P,$%     @
M*X!I5NE,*E@AU 4 4;4V !$   !M;VQN+3(P,C(Q,C,Q+FAT;>R]:U=;.;,N
M^GW_"D[V.&>O/<::'5U*MZQ^LP<=2)K>P21 DA>^9)2D$I@8FV6;!/+K3\E
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MWNX?W;V/R>P_VS-[;U[J_:/5\[V>/WN^NS[>W!'U[P];_,RMU;?:9Y1!L =
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MRG.*6*+#J$.J,^Y"QZ0A9 59FL@!1,OV8;DO))UU"#M[W@($0B\<)=:CWL;
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M9X/6!G3!6RV#"S&VB[M+JMQF?)1!*^NRLM:"5REF:YPTT0L?=$JN%3OHS$_
M>SM;$$:9T:)4QB,45;RJH[U0-Q47P96P2!C-9KYRBCM2)8S6^"!0&TB.HJ=
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MBD<7)>5LV2\:PBB2K3V9\=::?+OR/5L(^DQZ>DI&<W@!$(($DS+F(&4N'%6
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ML?B\F&(Q=,&F0:/7*@J(Q<28$(-()B9GD[1ML!=S ,CT.BH4,#XX4;)DA^[
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M+E*Y($P;#H&9AK&(?3B3\*!@B;B>%E(2)4D#^)-D"/<O1]='WD^GIV\? +;
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M%KK'J,.OWGD73_T8[.;$/-X#[*C#\+$.S4Z]!,[%'7UVJ>%K>@3?:@,:K?4
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M4[2-E_N  ]3K8.$K7>!%I/=3 @N.8 +9J-)#4Z4H"8TJW:!*_]&HTD:5;CI
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MW7.JO\DW#2*GY]>\85:)9Q8%#T<L6F6TW0B4SE Y,F*7+I)15WNS?3O4C(1
M >NH.B!S\&=2U(A+PKRZ=C7)$)V7(82%$SR$J!#4;*#QV%=P(>\56^4CA<K>
M\Y:G7Y-<=[86^L<R53CCK/EFFI%P&4E#OD#L9OVC\[:[&!JA3ME4[$KU<X*@
MX^7A9, E!=@9Y<]P4@TS:KZ@/E8T7UQ%T>!E>,@@G.+C8M(WY7*[&F&-&Z5
M[M@WDE*A-X3_G*RXC6(#UOTTHWY7O(E%SQLW"\L$(E;-NWCD5[!XNMMW4W/-
M%NURU!=,V U\.6SN\D%-P!6.O%=YBF(Z3U))8(_-+U&X"/CKZC(M59+B?_LK
MW?6OU^_(NXA!OD$PM.K"O@?T!@2U(SOG0@&\LDVOW**U<5JFN95%_<YM"\ 5
M;\"2^CB.]ADL^8U5%1A);K]2@(T4PP\<XKG"HYU3,L<VG+/3:A+T=+Z$/\-^
MHG+;$P4IU!-%Z2)PA2%< ='')A9X 5 L8D[M]-B1%D74<4\V8"D^8L\+7 LD
MAY\*2_LY_-,'A90O LYP;&JP ;4RD_3$HJA\8E@UIWG-%+)H)$I6*#RW0.%A
MP@0OH6I9I.XB<;?W/;<% R2"^_N*-0@G\?-B#<;T+&_5GHP=?-CK.PTC)G&0
MBFR1+>!]'97<11$QMD/ANI149-A4STZ#6+K6J]3 5]+ <"VV:1ARD2V[4R_&
M_6HD=G_ =;!A"WNTDWM- <\3S]!LY93;3%<%<[?GHG%AL[*%5C):5T-.YJDN
M09<(2C>[%7HIIXC%X%2%TS*:+,*84\$,6P;K(F_1YF4Y:8@C[UW%9IFNU'Q1
MZC M])7F9-Z4.255<+\WQ<G.NQE(I6??C:%![HT(2D;ZPF ,X9%"+EC3MUT5
M4_FYDCW=JT=X)RW41]Z;O+!T1>83/J6)80PPYX^.DX)+X)&*\4B!!T>]B&&,
M:FFEVI(2[".[#4%,*+V+KH\NR12:<\UF.,^^9D/">"95<Z_Q5A0QQBU6<%/^
MFCH)DE\'-PF>E[":I+!- .8<DP<$8/MQ;K;N!U?9=A!-H9:*,PHH1-(7F56N
MV!$\4>W,I)O,5]G:<;I/;PU=$-8]B6#G!7(<3+ B/JWT9Y/\F39C^ "]QMIM
MNE&5]1R/!;FI#-29>0;Z00J2A)"Y< *YD!3YPLXB7(\,.AIC%X%;$*SWY6-'
M[?"\2-J7;.D/D@6N;!YC5HT39O0Q;E3AJ#V &\*#OUKR%!#)$$]!S?$-,U?>
M(<"![0(_X M8'?H/9W4P;-/[P.KPR^7EZ=6OWIM7WM7%];^\5Z=G[]Y<7>\]
M=<,;%W,(@2;R?SAQ%V4F(#2;LF.K6#V2*$KNT-2KQ 7Y%-C4@;P)Q52\K=@8
M9H)*%[#-UE,7?<DG(3A, .<G(V\''!34[D>>X[?Y\ 0,EE-*73$A9*'.D^!?
M2V$_]1)CBD!'_1D<'I!P\*2VRJ\X?(0ZY7"$_T":3>]B"TL+T7ZLC -EN4,N
M3%#&3NDN-+ SV"VG0(F/C+^TN['F\3<\,AI?TGQE'$$!>"@_23\OPU(U%GW-
M^IM%5_XAQ_Q6;]B'W,Y%QA08XR6)P[2E[PA&.<K9]DL=+?F?LQ1P^0!^3>ZR
MCH/(M\!MT5MB,Z:P\O.$D]M@9JSX%X[%#T\3FK>7>5(%S=.&%6Q93AR1KI**
MDBPCO47E>BI,8#!*MM)$+[RK\&O]=839<SP$^B=, MT"P^Q&!KVQ2),IN CJ
MC*C6PGP!OBJ*S$H2K=1[!N A8I-XA#&;B#JO!FV%(I4&+&7:X:TT=;#^VKI9
M[@BD.HRH!F" 7G2X8HG'&:,NC32]0ZH4?$[)[\K _YPSFC(2JY;6#"GU#('Z
MAN?3[FSI"0I]* XS@]7H#_%=OT7QX '4LWMT* 9'/'FP$;OO5>SV%%C*8H<$
MA)+\,/+?9N#Z@:F5BY# 'A4X"-C+!/_;P$+\) 79O U3V'\+$8%]1A)S= /O
M,+( U=W2C$+%O@ELIYJ%L.&4<T,2.[(-QD>I.)36?=15T(*/:A^7I:Q"/L,'
MHP@8(;*P.XE)7:;-M[=WH;3W=WV02.L?-X4(K7/'^UR(:-3'%ZB/]]P*"6KC
M-L2<L\Z2Z 2H"D*TUF<R?=.^2GZ<I@US**!J[1/$K7=4.&$(BT;>ZEQ<'NM,
M:2'PT5<LF\-:FJ,".Z!YR(0;@%+B2"\XJV3MR/L,2"MF23%DUIG1F4CG&.;N
MN25[TNB+4UO$J.NA90)9UQ[ MMX*"!9R#(1!]Y"0FK\Z?LF1=V8^3?.;@LL2
M8E0?R?AF.6,)YE8QS"_"4_BZ^=/)(F,1$-^HA!$Q3$PDZ.5&P V$#3:@!FFO
M>?-"0CT*?6QD"S02;*$'J0AB88;MBV\X@T^BC2F@=6=.B;8]=LII-"5#A]'%
M$$NU=,4ME9@5YD)JX2K%,[IF-S'OQ NY4H4*4T]M:7>"2K2E5%/A<.Z[7_FD
M3^-;YZ#5'1HC]SB+0M7#W0-L?ZV9 $G@'#VL=&^2JK#I%A-5BL$.Y:CLX2FQ
M*/F0CEQ4^ZOJ)!AOR*"\$J5*6A)=#;W[+.&EIZ03B[3,_+3*32\CI!LQWJ48
MDZM]:\OL5*Z22M=68XOU!NC.5#UU0(W^TH2X[Y&FU5*LNNGT"%/G:Z,8PH)P
MVFMK@Z']**K"(7Y;H5@6M6]:2]Z)_*ST<ZNUEY@22"4-F*!<!.+F*I=4&=C-
M+Z4C3,L>7#W*TB-ZW*+EJ'/[6C5'F30&5M>H/U>=ZW7'FAJ$JK[CFK5MCN+N
MCJ(M6ZTY83.16;9B+%SHO$9+E94Q-ZQRR>OBD>)..U794!%:.T9*\7\S6;9*
M/E>?RE3!ZLI>C;SL3E[>4S6M&*_IQ@>%>:%M9.\DS(B%IQ"%D@( &4(P/2N!
MD%2GFH_#%]-2!D*'R2O57E$O0-K;!8V?^^QF2\R48GXT:)3'#H7A3;'?T/:0
MI=+)66C$CLE"MUP6M58EO6[-B)(2K1I4F(76]HW[3W)5,6?)I:<0P6/9LM >
M9Z8#*&-9^(+V#UFIN'7U38'. POWC2#N5BL1."S!2OC24@#0OF_D>')HOC;Q
MA('T*J-F*<-:>C(@UKZYE'J#4.>6)@M#B4;QGJ*86O8R&:NF:25V*N3W9R!S
MDFFLV&!FRVA54T!JF<JKN1/[6?P:NNY.KR<"^0>"  AWP-$/IM[*Y(BL<G4/
M5)@VH=#7DEPL%&%^U,BMVU7HB!U]QZ&KNY,T/PY1=P1&4R 4[7G59+1,/6@F
M,)_F1WE&UM5FKU1S#@W[0L6G&+E^R\&#GZD*DORT"-5(L6L<&T:HP5ZGU_7^
MJO#MY '$^H5JYX?]K>7IN:0Z8Z4R:::PR6?./*9^2$OR81T$[XV_3/1C''FG
M6.5PUY2?V7H1IDD3#QXMXJRPM'XD8-?I%0G4IW:FY1S7;6V$]GS9/3+Q8!(W
M3NIN#Y5;3<0-4R,W],PU2B++@&G]0>O>F%8 14)I*06K?(*M#82"X69SPR9#
MY:2M!;C3T4P1%>T[^2HC<C5YJYJ*D-'=-&"P^CB@^G4WC*_P:7@2&&V0H>=6
M0$N 1P-7]94U#&B,MK:8NO'<J ]8@QC1;/0S'#D9DJG1F0@[^D8/2?!59PEU
MU83ES%Q62<TUO6CF )XT)>#O4X6]UQ&4EGX7(NH8JVR5@1%6@31E+I6[:%IC
MU3?*_I\]36KD&SBA("+^#'T%Q/_A%;!)H.6XTG#RTWSAXD;0N,&Y1T68885.
M-9+89Z739TMC+@1D07R/2]0ZI#L$J3"B2$ H*>8F"WT[7 =,C)Y"Z#TYL<4
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M4"!ED2*EZ]:1Y2T#1-CP&</+?D@4M54;9E3%4RL]HWAW8!FR*:,E]$J#)_=
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M?HY3+R4-5R2YJ()W]+,TW'+E4DZ_*>5LQRTW66%5P?)VIC@I!!WV\E"-*AA
M<7+8HZF!V 5&(8NV<4OCS*K*!UQANJI4%(R6X']Y<WQ^&K.',TTG[J"A6>)I
MM*:IR<RDB)8S7S#$#:LGA.I8"V[9]/:6N$#S^Q<:TIDS0SVFP!IYQG!]YL6,
M%!"7*TQPP,-ERV8';0Y!I^(B56*;RCAP>'TJ#.ZVK?T>X)SBO%!\'45%<S^Y
MNW<*ZTCHEYI$K0[[(7+CA#)K:\/L0#F"+"."8"LF!> Z0SCYY'DVA4(JFY)R
M:E0V#W:NB:^U*,W""5PK_[_LO5MWW,:U-?I7>N2<?+;' !5)MI.=[2=9MF/M
M'<<:DO/E&>Q&D[#00 ^@09KY]:?67)=:50":I!W:Y'&_V"+9C4M=5JW+7',2
M3VI8-B0NZ^Z#XLEQ #?4=>F@3Q2+$^"S\'K--"N*['2F>3*Y2^%2B.YT<S N
MVP;(-+_-G6]9\O&T)V=010QNK&->^/MT&EA7,LF'>_G+]-JTG81TFFXQ#DNE
M7*AFI@N<E[>1_R!9+%3BQ62#IZB-4XC^D/&@M I2<FX'!R*U&"83:AG3:<L"
M8ZA^'/L;+8/%7JM3T^&#-AT**0H;EMP$:P6SY7V75U <EI#J<=,OG>;N(>=.
MTJ)RQKJJ)M4J";2H!]II'AYT'K@;,3I68:<,U>'0*!4K,X3%3M[3;#SD;)"(
M 7#PO"TB>OFC@:5?-" QF/II/AZ48\ YH+NNK0#=#@<.)0VIQC5[TJC'>)J:
MAYP:];O#.5XV8)@V;X UQ(4;Q>>I&.*]ZX1<Q:N&GR;K(2>KZ3@42@4(D\+V
M4RB</&E^(H:7Y0 #@R4?30)D6-Y'GRBWW S2"LSK$*)[ZB69%-U=L6 Y7Z3Y
MF#010Y]U>0G)2%4_$8('?XR71OTA'.8 0A-]=8L,1_737H_TZ6>]!(XG=$CY
MRB6+" RL**_,<(T:&^]R0NM;S:I?SRI%VCC./"B24@Y*35ZED[^=>S60TVD?
MLLX,Y7Q(!F'+K (Q,V+, V5?#Q5GK1S.8HE<AMW97EI]);U"RD?H6SNXK"2C
MVEL\*1S>.*O0J,.LLA&;^4RA>E>52T*!#,>P;]AP5(-R)2=SYPRO8?AN!Y0D
MP@2B$WNV>L_II])(4;0)>5,-Z[X^I^;U<VKB Q- H<3<MTO%W@HW?R35L?L7
M+15H<7<\N36VT_C^LP7(]/U!J!,BWS;^/=3A/<K^-I+M3"DM*ATZ097',<"W
MEA\)[;4TID<&SHEVMZNOQSXL+-/WC 06IA=,\2C47+DX,D229!OJ'\=@"3;B
MO7%C9$;7 ^,>QSI_6GD+6.J%Y_9Z]E-Z*VUB,;D@AEJN2U*ONP90^9?=G4NS
M!R9^A[AYSRV-. RZ!DS@-:_E&9,OA:5L)O1]8'NC9@"6YUY:@%D#KS%*6;X0
MW\S!*41:DH"A8XML]\?U)PS\,[E%OHP<(7B<9^^?.1A_TNFX1]OFNOHB7$BN
M),.%(D1"_&$#&G-'J$EMT7QXT:(521IP:$70?<)5_0,JDTW4\H'D.R*),"M"
M<R)%:&K<;,^H4X .@+UH%[L%0OV[ @>G'_6J@_'[NZ]QD[4U_\99H9*/#);(
MSU?Q>;7=>OY1;(=X52$2#CIF6GY_%?#/3A7P.^-:95520//B+U\,4PW:>9R4
M;\(#L'D[T[_#OL9$]8HC]G'@DG9U>+;Z#MU"TP/VO(-&!_,]R#ELML\_6HZ.
MINVHUU/S$H4V$E%@9[X8 D@(,H-6SYU$8OB=Z4)/OEK[6UOLHS6!FW<'!^.&
M3?G$MU@\:.3QT[-&E33B"_O7,B'*^S[:I@O7=JX/!I^>$0'5==;=D!K<R(*K
MT KA.]#)<M S2HZ> 9^Y4T 2X]I+%?C;9KJ\32EZIE'BZM9.>7H1%G1(#EI0
M0E1EC"&G. )YN:7A?0RNWSU]ZQ\B&#)!]0OT(;:4)=HT"GY?UD9BE[!J+PZ7
M9($HZ9W.JX+5&A+($ EPNIAG^$$O:.Q)B%U)$I#./?BQX#]9.AJUIB0SK$+Y
M*&;R5@X@C*IGJ<X56^>TK>XP=>"C<U,2QNS@1(5)CF+@[L^;L%TXJ\2WIL@5
M7=>%$T6;-J1,6U!XIW-KZ;@/.\W:(Y8:3%U*GUBC>NMN.60KVNMUI2U4MM:[
MIF8M[ @+5N[]BEY<@IP=M5XD3P\S'<E?2 0QF0 R1\+1XD3S0BC?,[2QG"[3
MZ2F==R711:]0P=AUX8I9!/4O0V4>XJ0L;90C>D$3JQG&B!@]-@J/, Y6[->9
MM%HKK68X+*J?ZL$SL<R#N*:@)::YK:H/GI@AI:'!1@9QWK)9> )A^8+Z(^=]
MMF7=2.-=Q1U_\Q.*7<D9O,F6L1UYPB(]<&/#S]=Q _'Y1*U;N]G[* *2X!HG
MX-699OP%F6 52^SHJ"=(?[4YU=!^'8KUZ,YLJF#)6;1%0Q;.GY=K?ZK]_&4E
M>-.IJ:>>Q');$<%RSZ<<PRA%:4YZYLFR$.Z1$A+=D(C_G1;+0QL3E\>?:]RE
M<WY751QR-G1 LDAT#,@C">#:N8L+NJ=W7U/P'^3L.:V"W]1D+.SNCYP3&<DX
MH^*3EW@2@<FGH?3TI&?S/^T@<-$Y5Y./"20OT*F*N%/V2Y9.B%I3HCP8' *?
MP2$W 42:P04Y0K]^6D /O8 PO=3&PXSNL[6IXRP?LZ7M* 6-"'M7#XIA+%=?
MUDQ5.:S^SI'@ZE4L+B%:_O+OM*H[GV$4"75WJ?Z6_,URN8OKC6$.PM_X2E4S
M5$C4GKKM'[7!(JEB0B9CH:V9_?  -FB-:WW-,J-$CHE(^OC:X!Q;)AH^HSS$
MC?L2I21P>:/597'-]2%E_9UH2M!JKDXZ1K_*>IKDWEC)V[)OOSSD0=[(*X=I
M(@YL5LP"%KX;9JG7+O8TK4?X(+.-WME=3@[__LJPGY_*L$>3]"&^EB+(#)E4
MI!NG%>Y2[D8QJ/2I><&6(\)IL8O,*;(^1X]8H "9T_HX6M07ZM*]1&62I)S"
MT)U)I4&8P([7&W*N?Y_0CQ6W9/ *J1@0V2MSQX.3H@,WQ>%ROI762CZ6%[\#
MG%*U?JZ)TB <$%<.R?&S'3#IVPY.$0KE5DZ]W3,[6MO1MYD,@!9R'T<:_/[P
M/ZWI:<G!B@+$UGY&A_L'29)&>G^F3[M%9ZI ;<LA937!SE,2+\D+KHJ+8=,9
M!S!]3_G22B603_C_D]GHJZLZC)4[4=)5[=CVA<(.J1V"U]677;<1%CW7HS\A
MO].WF,+)'L<*N V?>-_Y9KPKAO7.4R_H8Q!C@I%5$'J1>M8)-)7 'U,]DGI2
MZFUU=KB$/ !LCT$'N4-UH$GCN6R[UJQ"EWL8:0['4TW00F(R51:4VE4'0]>U
MX)7T_?<T.D( C*>GV(L&:C49*!;28K,^[,/-H2Y ,!V"--R8$6<YK;X+:]K9
M8C6M)'C1P2I=]*0L GRRNPM=A@@BW&Z1"4V))]2>EDZ.9#Y'S1S!?'Q,;B?V
M$\>IKGR>QA"E=E?U>86*H:I]O8@P/9&9)31-\D(UX97"0=4!1Y]L>MM:2P.\
M]+)J*)R0S*RM,%,P8R;X'%7"IA;<K\C+T,O@BYO@+N1U;O^VVEVU\/CTFO5!
M)V:(6*;D,X2@635=<*9[/9<XH>Q02YY,(WN],,:[1P&PN.<YI)[ $MY\T>'"
MHG!P$X6FA1'L$'N<-]8SS5$IXZ<WTU.CF,4Y>9D?EZT3#8Y<@N,.O4&.P<4+
M :M.>:+L9+UW DZ 8^EZ^G&DS>D*AX<KI8\?FTMS 9[U8X'.#<F?N)'&-K(N
M@Y(GF(K=$-.CCXJQ[3BO^WS86]XQ\#5BHN$VU_Y(HJ5P39?[8"! !E?001"F
M^GP4;\C+YPGC,/NRX8&8UHT^<1 /U_HUH835]9L/5<7R0L03TQO]&-$,\T]Z
M#.O#S^R?J,Z%!2F[:6')*-]2LHRT+2LF*.&U2S$D+O,]<8A'9ZHF%IZ==SWV
M+$[G-:82/:FXI;&Z:]3BL#[7?_ON+6^=O[U^.UA$DL<2W&@5&V'P1-' B*=S
MFW$0BX#;@7E]EJW8F@DS'J@) ?6<U)D]J1V4RRTZ1CR<"XZ')],\D(__8N6Y
M E/=X-R9W"$Z5^^7!?XD+1V;/.#5V?@AM=2* 7<+9)OQ/ M6E4;?.=>F A=Q
M%V\OR7'_;)Y7;!C[JRJL9\8+=]233D)/4OBWM5=1 %BNK4MLAC/[T1NTOY?,
M>Z^ZCN#S"T=9<*6!Z!3NIB63G1Y0-KJ9>&>X:'H$# 0'0PZE#_Y(F-!P3-R(
ME)G<8#EYS#"J><LH*>M1N+1N/ZF*=#<6 MI3-2!BLSK!L1XPV9PX*&),$B:!
M=*J/)<,2FB*_'\WC%><G7/6J:T96".1;;'AE9&P'I[+5KSCS.O;>CUFQ!E;!
M&1IG]R,/>W[V+Y?0EV?S]U<7^//3J N<=M5]=]66LOT0WG72O6%+773]A:'[
MB:Y8>!*5*J10\L954QT.8"L-!K(^D.Z,_(8^?MDU+"YUHM/_-2WE=AR62PKW
M@)G&0CZU<DC>63$BF&"4V:.1-;\^^=RV;CBA-,IW2 Y=X2-A175KPSE9W'%:
M(;\"2]-0U?^&G%N/VEMKT!]=0DCK]!18@J<&T;PD:_"O)XL8>]*<049[2APD
MDGO,"$X?/VO3D]Y Q"S;KLT*ZN88:M-DJJ]J+A'U=?!XJ":HZ=''G[6DJA&X
M:OI*6#LH.\2I04J@X$UN)O0V.PA6,;'UT3S44A5]1D/+48JG4%:DOA(80Z1B
M-!I&9I1%9<Q?R6Z2\0<_FHKZ\9RR3]O5M_&$UX.K B2R')84=IE=5:?@Y.Y<
MDG8I@^\*'9.L+54Z8BV2P[C&THW5H-&W40 *#Y/12RF/?EAGXX%+O$D:,]8;
M"P><=^ +OKB4$9%I-)4-1['BNR@HRQM.0<&#"&Q%KFP]G?8]'4Q5O5TNV'-&
M>(YKW4D7X<DIYQ5N"@:7?2][C<IYG/NL^T2CSS!PS*6.7#AQG0QH_['6L_2)
MB3R&M3[Q=OH ]GYT - VHTMHO?K'<<.1@5?XW78C,Z<!^V.CC81SM]V>\=U&
MY-RN$\T:M[3\7C;&L+AN8OH^Q)D,.RU%OGE5409_+<@*(H-PVD$PTN&18)BT
MARZN<=HZV1.B.UCD%FYL0--W#.:>X,M]<Q-?-[W.3(G,OV$P 9XE:5MMB/-G
M=4%YU1:1%Q7M&]H\-%LA')-#!3M-3Q7$;T:89@H1O,J:IKJH-O:H[J7I&G3Y
MJOVQ W(*&5:O,<%9L*J]8.T@ J39V]EU4H !4O_(SE+;(8];O![R%P3+0"IF
M8/'A=5]Q[H6\S+)EL9MXM(X$YS1\0[5FV:_$4DA6AQC5@ =%=2 <78>2@H['
M?]8NM F#GJ0IAX%?F> ;AM>?@]33C(JH[!:JIVO0$36\ D,4GE(1E@3NCXG.
M,(,\E12OLQ0L?X*8I;B:S2@%K6S$*EF>N\?>@9 TI]63KGBZ@O:VR7QJC"@O
M%6XZ_R2,:J$5AN+> ?3P20!*M6D?=<)>\.O"?'@#;"1A6#.FP9S+P!23TW*Q
MFO!L]<U\(8$?/X'RS90V(V8@+_>Y8'F;83ZMRB$X)<Z#&D=X13+2\55<^9*M
M!O<?]_70L;VA@;D*JTRH!1_]UODAXT'R,(:Y?(9\,&+4'9T#EFV$6C@K[$\1
MU4)IR[6S<.12BG1SH6787HAN[JFP^L;055'6UR86M!E"VR 9ZTXRV>!M".L
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M!#<QG.)H?!*VKC@Z1AI4Z[O'I&:UGMUC,^ALA\SC'23H>&J=VA,=7^.2H[P
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M \6<5"#B<NWJ3<O=H9QO0[V+LLHTKL11IO5_+DU*>IRS<-QJB,R]=8":#@4
M+[$F3)*E%QSU4BU;26. (==/G1J;?JTC1>OA9%YY:;@$B.2QS05_T[;=52DM
M(Y0!D:\,Z7?^3[G;?Q&_];[JKRB>0V7@]7?O"Z.HK^5ZU$M0WA@N8. O4,V\
M!OO(KMN@<$+T9=?5TM/%W'Z6#Q'VD23.M-9(^=*C+L*]>,DPV*0^9;"V@GHU
M:I2T:3Q>A^U%%(0"G+^D]@ MGFG^R>DR2L+]V>I?ES65@^3;0/H#1TFZZLQ_
MU%>70MP4 OR*]#AC>;6PUH(0G9,R'.]^<5BF^D?Z)%S[B.$>Y?[C.U(C!>)W
MT)A)V>B'\J?5ZU%J9/_3G0^N_/07TW^C3Z&L)611 ^/3N=3 P2&_!46!43/G
M?X*+0?P?+PJZW%^YBA8>\HQ;:) WWFBSF>8.=?%R><;*9ZACM/-)O\O.B-,,
M1BMDD#1H4M8QWVBKM)C,KLEX>9+QL[85*D>C$:"OME4O;(/"40PC]/R+^ #"
M;5(]PU]>?#%E'GSY_.5S2SOJ)A%>L2JV<5!/3E,SI&5Y'%]*-3(,R)G<>:,/
M];K<$*726I\DC#4-VF58^6<HR5=A[70W57\FS)?59C(ZI5.QWE2P'709]$HL
M/=*+@I$R\?'3JMN ;%>XS+/5]\)"2:N+OLG%7E+2?C_NJ088=LW8@Z*$D#05
MNHITWPF'"3@>"7'> \NDV8F+4>XKM= 1W5S*T<"Z"@1W)7/6$\'4N2#'CDZK
MCN4UFMMXD=.BU,W];/7-2#UG?4%/]VJ\(.S8BS_C[5X6J[?A,SCU!4HLNY!N
M^:;=-EH!1LG'%W_INV&!OGGWJK MJ]''7.Z<<WN#EF(W().N-]K7Y/?+?@Q>
M ><Z)U556P9AK&@8N<2S#VL*_7^LVDU9'MXPX3D_9T,2'C1; \EVV73M2+CG
MQL8SSTK%"&RO:=E@$=M6.JGH3C3L*0=W(T++#'.RN(@R8#\A@1O"&@J^]MV:
M*E78 ]P+5DF&E9-J/BF;QWR*Y$Z5'76=S;1[V@E"1_32 9+H-^HMPHHE]5W@
MP^'#Q2]$V+<KJ7&)FJ31!ZX%'@&MY\!P>OA2X(_&8/Z8#^YI(R_O  ]U46Q+
M//7VJM?&W2K='CV6=2N-CYA"-/4Q8#P%@<0-_1)'F/#F?DGMG >:VT/?->[$
M?#%?UXJGYL4%H?O0JBT['I-F.T ./P:7<A:AQR=>_I'.B=4VK,VPCFCO13)'
MN](U]P)2KD!P.^'Y0Z31R G\*5OQ#6-PR$" %NZ0HH4(MF(/@:ZSX&F,ATII
MM7=\_NH]B,*F"5?_]$7X)QIO':("ACW= Z+G%U8[B>BVSU;_A"'@SOE#@C(#
M&C;L2H!:U4+Z^H,-%QX-@K" E+[XHYB,E_0.XY[^^]D?;<])%Z@-I0BI#*M!
M&C'["5^LHH%>V(%WQ+"_VE%AJ"2[/JS#8+\E>QDM^XN)0<]L)@\X8;7F2CX$
M8"YTO!J@WJC620E%=F7HL['Y8KGNQ*%B6*(-M3L2+%<Z6!!($)J4A*?W\:^H
M=!7.+J=>P&=\NLOO>,=\6J0C$CS),&GA$=X1O_+6[9V7V(>9DRH#-+^MMGSN
M"FAI,[^+U).VU+AM*T^F>-D- (4#2\3=NVN)QG!<T-G8.SIT^:,(=0L0<I/L
M%@+A.1)/2<9I]LU!)%C2EK']X3_S)D#:3DGQC'#KM%$A//VXT4F(M=Y5:UZH
M"@H<E/ T[!K^9$5S'H>$O.1U'[PVZOZ\JBQ?V7+/ES*\^LPK;0*I=,H0&SXE
MMJ82K%P[:+&M<YBB+I8>CSQGO>J6$K_:L)4<+MKA.(=5C#:-6<2E"V1N59_#
MG]EUA,#R(#G"O6L]%X&Y8/4.EPQS%%K1'.Z39FV-4EW:77EQ7M9[0N%?\WF)
MRPO8UMN,F!UF% <7I^& N-6LSEM?U;MS:M;:,1&"5BW5(<73!3-[2# 9@L4
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M2I##8$3#Q)[P#X9_^/SWCG\X.CS98D[P=,=7=8(4O)O5-0M+]LLW*4/6_G$
M%NZ)%OF7@@=0:<VV9#G=NEI3UPIM0X2#3%U%!=H2A&W[B@P.=?^#M+&M&O$.
MM;Y[YQ[R08>>[#SZW"[8=4'H,(Q<]U[@4GD<$W)T^?Z+L&TX460%BF%WF T*
M:_M2"7QYY!7OX2" &B^7395^?<J!'V%F/T3JG!FLD);4<I C@PB(C4R!N/3!
MM3)USBE.> >_ /X?*T%ZVK;AM#8\9DHZQWR?.%V I/7S3$YBO28@WFW<=4]@
M)?S0^=YZ91,QO$9DHM#=,#?,ZW+/GJ$Z621CT1V6:!D2E(NG-E9XL]$#YWV2
MN_)'TD1,H=RN\T7RIBEL%WVV*DBXW,S#5 D@Q*V'#ZI*0LIUE[#5UY6VHA-.
MY?[CDBZIVU@/R9D6@3\AJ96^AX1#)3[&;;>W&=60@'W5N&=3\V<U(,)@U: !
MKV[9_I.]=\0 )&YH<-3[L;8J+IH,\(-<%MK+H/HR/AE\KMXQUZQO&Z:)8LR]
M+\KSNQHI!:/SF2.EO5%"30P'T170UYDRR?B NS7Q-JIAXDX=C.AU/,9#P!'.
M\6 JN<5W;/5HJL'I#;[_C4SFE+5/&2 9;96QKUPK2VA#N2R>>J&K(OYNILPC
M(L5!V+J)9')F2NQ<)-8]8(MB-V7=0FPN!V3=[8@42N$3\.@!LR>\)EP$+ONF
MX!TCK@[SVFCAA[%D'+'ICCZ^,DY)SH=.<L8YI$YES$7T5QTW$3M#] O4>8>Q
M]&T;;F:=8AL3K%#3P3EW_&38Q-/L/O3L(C!!^5>E%RDV\6P3YQ4SJ+&Z0[8
M/%:5VI-'\#64N%Q%BE1H'!RLVF^(:=>D7XE#@<Q&[-:.")WV":A^/NF%,%)%
M,)SS52LM0B73)PO'LPHY2Z<B(:'%^R%H(:# ()FX): Y%2P>'&V*R;,^%'4S
M.;I!\0GR6=PH2GT D!#BC3T^!;DK#B)^5E0RMSHCD:8/LBQ]Q>V':!H0B&#T
M:Z^UVYJ]V^N*&:$U.0XH!>%Z?1>KT@-8.H!J/R%D([H49@"QL/TJB]5A7X.M
MKH2RY3B)=J0.D-\K*0*B6+S$KOR !H]$EBE"^36DC/WND4TPXR;4:SL>!,I
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MXE="R)NI0@EWM$TV_U!D-.HSYTL\T:/;4;J-.OD*$/+XEB0Z=U5U$'ZT+>P
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M>>(_3)C&'!'5B$0^_>+'T?ZZ#D%9""ZJ5M4MR)Y:-:"IO4[VD:;5E"5K6G:
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MUA"LG>$ZY<R(J/XX6X7M(?&%;ZEVS8&3MFI_V$1\GS^I%.HG+4#T-F3[*;B
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M&3 S]2SN9$O_JU?OWM+9'9<JWJLDM.AU,E&EY$BEB4(OW?59W0I)S5&;,IF
M"JJ\]VGY>>P>XCW/<4&? %S"H U=JU%LB<*'L1]&K#HDT<#C*1,TW4/PD(RF
M07OCD8N-C2OA+TL7&-(K# F8#CXEIYDP[QW#]:QE5+5EU:W$KJDONV[# JA8
MG8]CJH[Z#4N'8WI,S1^5T7=O9XY-^M[RT(.D1(IK?A(H[<IJ;2[_?@B#5<%O
MCI;0=B<9E8LNMN-C#=7L3R22]0Y+=G1)2"DY7Q@-YMGB88R6SKXG<%?7B(]
M'2[*D@K!0=1(<?IQW$\SOX"O:J%7S%GBU9_51:K,=_ZU^3&(BX'S]6V";A/[
MM-CH\0MGT\SG#85\\&;B6P3#)V_VM+*.7EV4R\CA341K7&.UZ7*(ZUBGB6F+
M[F#I;*F3:DL;',WA<H7;H=N,6YD0<$=6'&<FM4\H.:24>$-"56%5Z6[*AA(N
M62%[70[*W(B^X(,<8+$1*QQEP>D-)H(*C_1>O)RE?WL@OL?;&3+X34[X8)</
M??E[SX?>T\UX7_57-0-1!8@G+OT062/<K\S9,H!I6@(FDJ;A )HB+D2KH&>"
MB@G_$FR[<N(RY#(5"*RU79'%>2YI8QSQ Q-N8X84CH\:.7B7MHFY*$P!T G8
M3MNQ&714[5W(!\>,:$G):!Z8MHXKS(9K!E\14;]9AU(:Q0$W0ESTX?*4+]Q1
M*$WLI7PKE+RK2C W@CJ8F7=Y1CIBW_9=L,6[P5<[%SXL]?FP'>&Q7-5*LJ2]
M%\)4XLCE[$^W"7*Y&WF%6HE?&'B!0R-$;.,\V3RGPHCG15K!)=SES#J(H-*U
MKWLIH5MNPAWCG_0JPN44?^$:E)JRWFG';10J SBCI4#Q"2QR)@LU*H7RVLV7
MF93(Y)>P2LQ!B2E=HNW!1PC,5<PYDARZW1&L!]S/0C,>U+*#,@;MK:8Z$^]T
M;(/M"5/!<B\.-RYZ<+T0G;W^_O^^^>KLQ5^#<6LWM+G +0$7=F-" VA"E$<0
MBCTETP@KC=B#]I$+M0EG=W_#01-+SQ%(C+!Z&5UILKUGM%XSXI7K"GPI<'AE
M2A*<$I8W\P.M2'X%L+4M  8*9^.J3]YGZ/.@@F7@4\?+/LWQ.RY-H.2^Q,RK
MV'FZ?N+-DN+RM1:7P_REV0FV0<E%BNP*.!+MV1D>#TPOLR"2[\AY"^01B0DE
MEA;Y\NF HCQ)%I-YU/IXJOI6CX2\2>,=>?>LI[)8>-3PA7%P>'YB[O19..EX
M<UFFG&E/8\N/XY?$.'U26&$KAL#.=P6'#/@PO4.@NZ2P%*+DQ/0/.4)L_;?O
MW@KTQ7I$E_R1@B%HYS0$1'I/ !F$N_6P'Y'A?M-&:->Z[M?C;D#.;%A*80F:
MNEP19'3<XX4:4<^Y<D\=1UUM1S]S:D36?3(2-7?[A%7?ZG'BZ/4=+\-M#L_<
M7O&(R+M<-4FG139X%LAY'&?*S\ND:<K3I3 UQ>YSKU$&;5$"K9"^GG-M579Y
M$OI/N7=D1=P:,$A\YQ%HE$-__-PF__'1FQ\\QPLM%VEN$NI;'M5GJZ\%J[E0
MY[FVN-FLJV;?'<+:L6B?IYIX<EI2@FEYDHVES\^VGBU&^L/U@!FHJOCFRJ[4
MW2?CK]!FIOYVI43X"WB<&_-UIX\_,WMR*-QC I5/6"F3(SER)H05@TK1<12<
M04\GF7/\I^/)9G$"Y 8L\7HVH<;$B.'$8O!:#  XP=?+!QK6]35HKD^N/9G-
M"*"&Y<_^,Y-ZVZ[,S)MCG$"VLCI(7FN14OKG+'=VV:B$EAW'6NRB7AH2WO-C
M,+M@9\V%MQ9S[V\N0G 6)Z:(1T#RFJZT+.[DU-IH]\CLQ;C&JR#3<J>68E,-
MZ^!4*Y++=; N.<=I;35X</U%I2PF*0!)PHF(Q:GG0H3MSS-4FO 52DS>Z/DB
MZDS%@._N#%HAR+S[&YEH7@IG%=G?7JTONX[E$6S_W&8H%]=3$AS,KBI'630-
M.!(@2&^6ZC]SYV5;]OO+"7]ZR@G?U6%^\7EL:O52KLJ*P(4(XH%%'20RR?M(
MWO<UBHGFUD:NK$GC0B=(UAJGQ9&V('^7--GFJ3*I\VQ=&=<:8E4?^VC+ZI2,
MQSI9/BGXJ0]4U-7^)F0;0%,ZA=FB*).Q&[M0*B%=!RS!=S\^:F\#ZT#XF9#V
M!?6E=?!%)3UP!S0-]*7%T68!4RCY2&)504H%LW =^O!06XK]"<W4="Q=\Z$2
M*DYJ$2JT"4WZ8JO"<1W(%7;U09B++VFY?DRN7->&*>!&MW)P.?%/I"],Q6Y\
M*JHE@W:5M/;Z4Y3:'HFL&3)B3.JY9<@7 7DT6J:KXKDVD#?O*Y0<@M7#V(R<
MG@[/0$<9GB .7'!JNO' !VXL@6@E,2,4F70\\O[2=_")2.['I1VGX@Y:("BG
M/: <GAI5V^(6GE>/T!0<]RLEG'TDT<!$3H8^MJ;H JV\O7:8B1QQ,W]CD%#7
ME6M_DK<7(DIG)>"9L7&0ODI[=0*H)2N!$_NXCB#.J\NRV1H[6=)+[>0UINW<
M\O*CYF&387"Z$DGK6M(RJ^_-5W)-XG0NA9$.#A4Z]/!A_Z%;KX5DSN2)8TN!
M"7^X]G W@+)2L3,6!G-A]_"3G>GI,/]Q"0LYH]GE;+^2[)^RM<3Z?-?GC,_?
MOGG[ZA6$N<L==X.'B?[VS0]?O_ZV$-6M(0(PDFRG)R7BU3/IT$<"FFW0,%CO
MLW8=.GPI7+[I[!BYD+B",_,G$:Q/%R>Y5VL<X%[46!$3P%REUTXM!M;3)QX/
M:H?\[*Y+1F:$[@&&]MGJJ\HA9&B<R">79L+9C&J:#,E:3(NC/:;2]T6&'15(
M>3<Y3SBSBX/D7K/ B5G)R#*B4]J\(TL%>RFB)X0E1"__J(_NEU192[JF:79>
M!^<OO'E;EZO7NNW?RHR_HG,VO.GKUV]?Q=WA+2KZCX(YJ*+_$ND0_ =-!^Q\
M/%@KM$+D2)^(L^(H4^OND\D#$64=+1=9N[6"7 F'CV^Y]PB?QPP/L83(T)ZT
MJE3WJ<F7NEQX5T#,K@6,I?('0LX(YOJ$].;C<4]7_'__4GS^_#E=4BA+PGM_
M(N<7WAWDY.)'XH$B-H\1R_*PSK)#5$'[$0[Z=-5/Q)L\<+W2G^&>5*&E,&N&
M5:&(UQ%N1.Z,<2\4F12GO(,WTWS#(4J7Z.%Y+42I"&?AQ<Q-3U)GS!>CKL%W
M/'6OF)CZY?.7SWE)OGWWJG"L!O\3@G_RQ%X4])E/R8.@PNI@;^L/'Y+:V.!?
M)50(>#:V F)5DFK$''U?,?^]7RTYPTDU$!B ZYUZR8S_GSL"Z PRW):$)GC"
M<+H&EXP=3V9G00HMV#FTMR9N%[.,4-:"RD3)Z?9_:S(S-6'AL!KP\KJKOZ*+
MO(TG.G8W/<AK,C[EIDN_);]+;$&P7Y>Q0JY\RYY:@@8_G&*7=:.YG4$\),+U
MNMG@7"56\B]8R$.5EA2U<X%7\YJ=&5O8TK53Z*[DE<]$1^"*$#A=NA$$A:=D
M'.G9"_3[]26=KUPF?\;C/'MH8N8BUH\\?]!#2=)?'#%QWO@I66::I5U6F5A*
M6L2[TZL__A/J^_& 5HP9'[LT]7$PCYE*Y4QTP1.<QQ71E3R2BD@VU,%K6H?'
MZ=K_\__\U\L7?_EB6/V-VR0GV^J=ZX0,E_KZGZN_??7V721SD9?ZW_ .FVX7
M+X</A2_\\W_EWZ(!*\Q!$V%*YV]GQUCR!J-J4L4G<>D1,U.)["SQ\H?=W]\P
M%GP+N0%:M24?^5G<6*@UHO_S*4DR0C@57SY?[0@3$KY5A7&$U_[9'QG>UU+X
M>]%TYP##H]5#EC3IJI#3):AP)_H1NX4M,S[-S?B#_FB,!SSO ;X(,@3G-\D)
M %^%[-0Y<%6#L)"JFN2/BN2:BY<R 03';T8 ^&LN0 I/DIPOB'-)@"!GMPDS
MMZNPVN5P0.\X5&PE=:QZ")6IH3-@QW%'4K+E0%X5,A)"2@,==9]9$WX1MCID
MKE2M7KDKV4MZ?QT"G-4W$CF^XK[L;"=@-7]EMKYD3))&3S%T5'#2TC0="1N3
M:/'\QJT.M CP,1*>]?#OJF_";0IA,E)7*PM(9J_0B4$*C^6NQ,,0W@ZP+9AS
MTL 92+1!=[K\8@7>&'G/&FXH_YX3:'1KKF4A&<XMW^P9O">U=LP[CM53ZMY2
M]Y_]WE/W1\]0U9TAGO)AHP(Z4X\2VUR;!HR\;AW,]$ <_YN)7Z\96CER4PS1
M!](KGZ"*N_BEQ&W&7;(G_-@$LN0KO715< 9Y<M1Q<![LZ@5 =H:/#/:2][G
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MEG_BB*6]L6J$>KT%$G_"3HTPE8R*]= JN=1^[%5;5R6 F,0(U3%&S*UK[?X
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MO:5\KGH-IQ2BCC>4Z'H]*ZUPQ*AE0Y;,8<:+3[2)P5NI*97&;J%858C/";R
MF=(D!5^(Q2N<)2O87;EZ5]<:'26^#\OQ(N.F]-&I[XTWE>-I%6&,F5+4 C<P
MBS><9O1T)EQ\9,$PE#DN^U5Y$WRR832_DBSN>@B/(M]>/C'-!"R'NODGL_U'
M<F+#[40"5A6D2>RO<D'B!:9>74*SXY;6.5E>93X,8!RR/,%:K3F]K5+ZG_S/
MPTS/18R!9M54!6TU%P_ 8F?^'/ >;1=:/LBZU#&F#Z-)UD <$C$D:8R#(DS%
M.>0CE61B#IEUTZVG'H1\N"3%N06D6MQ$4<4F/+L,OS]HV^!F1R$%?L?X:&N8
M<M[,;D.1500)%TY2"US'EQM$3<$VF+8+AA4.N^:VV=7>&FC-&T*C\H[8D4R0
MV;E-ZW+S;CJ(4YG+^N><1/@=9&G9[2B9;3,638.=K]GK&($/^9P1/;%R!^/#
M69>(FQD[#SV*/=.4^Z_KLT&'[="([V=("7_P..+V(.VCIH4(N>7W(1OO@LX"
M0D,8=-4,O .9+AG^'81EPAX4JJ?;\I_ 7 YCN0/ZSETS[%?^I<,399='+IQN
M<"9\]@?+LBI4':1L@.8A?,(R4_U WW-7DJH.9A88;%\.X;-78.##=.&!$=R8
MYDV1VVI3$NBMC&9 &)TD&Q\NC_ -Z''T8XA?A N*+&MU'^<SZ!A21IP%7G@5
M8.,5EKE?%FY(*<).)7M?:P(9<D;P-NS4OP/_Q45)X3X=;S/U.]ZC)>F;P;JN
MIV9':[_K-IB"\*D</[^88ZS?B?@-#-X'!IF:I*AC-,P$-M@*1$'7$.9]V!Z3
ML4+R/%N- 5>.)^3BG;"WN8S:G//>IX <&2T>I'JW&QPU/RA;LIH!_BW,2OO.
M>'*@MK/'4V)_)>&$TM5J7>R6%4: VS,\L^O?R1#P0<RV"AOY6(^D_.<?=;WZ
M2PF=$EOZM=DX@"28A@\+&+837D0U<NL#71[:VL:?WK E(5O;'<+[,ULL7%DM
M?^<>4H:DGN#*'G=D<;F(FPR"8FP PZS8\8O"_3 \X([#I_NT:K2(.-V9'[Z?
M3YCF&)0&7N_+D\.,)HI(\&5,?#')6O)]*6E&\AO"2G3W-2880KS?0.EN(.8
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M7QM0A*IJ19[R0%Z#$23,AU^% UN.U+P0X543<B-P4#&<!(Q G]26+V%'/,B
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MC)M\3K\*%_<1CY"I83ZQW4CK) A"=3%9<J^@6D*EF1^RY4R[Q.B_JMR'-<A
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M2<.U6$?6 2)]9S,;(D1'I?VES';<=_=4?XFH#"CY@6WL*F(ZJTQA,@S;NO2
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MQ^8&P6 3:$P%JWO?];L+.8"/-W8F!,UQ@8-Y6M'S+^6XN;WZL?PI#&+U.AR
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MKT<\4O71Q:L0_GK'J$Q&;57>ESUB,8B+I_"^7B1= -J/81*W$S#B;#8=$LS
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MB_KSS,9FW70' %R4FWHB_<9PM*=A[,$<W74[,"QA F_=5;1A4FJ.7&..I&9
MS T24(<YO()^Q&DOPVC:VYH1J5J_O5ZY;<6P!==U*#LL 7]&%;:(4#6E3HT)
M5M4SRK'Q*3(O)MP1)@:BY1NF'BG*A)@GZJG=9E,_PK^6[TY%?R[.!2$2]C_J
M\O9X]<,>S/'K/>CCEJMO6C)<KS>C(H=>?_.Z0 J+NBT18)-EEDVDCUZ^+&+
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M/^DI]53'5WIPK>TQ0L]U":%<0N/>>3SX#R0SFG;UPABU!)G20:;D@)CC96[
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MI!+%B\V X6</LWSH.NP$R@XNN]7RO?&X*M @'[R)?X:P!]&(+@,NLZ.M4!2
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M4"]]Q:FV0_A#H[R_[7:U ,G@,IX%ZJ)I.SHO0(QPTZ\F*'MS9H%_0&AAZ!(
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M_/(]2@CZ-7<1P3;/(FYX7/?[)<S&(Z./UW$^QB[^P@*L^:5>9%+NA948$[_
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MJCV_)X-U#FM ZB<]&:A)[SA%_^5_O/S\Q1<S8M%//R]>?/99\6\O/I\]'.)
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M5P,"&>H-4!1$IYM4<BE!VU&"8?)GT;NHK^&7".# ?B DB@M.L$M01,J""L:
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M^Z-=UTEMX61FDOWK'*I&=\4RZFV&,]2/^N7> XR>UQQ)79<6&HXZ\GF.NP=
MG9H4I&@8A_E>[T^2+_';>6A;+D70UQAB8GC>=A0N 8L,)RWD%M;\0?Z0GKO1
M%UY95R?[VA=AQAYYAOYO\ J5]5Q=-01T1]2[8O=.8U[59V%6):R?\7,B/@2!
M(>:HKA%8IA$T4%A?!ESCI#GXTT] $84\]\H,W[!VP.NVG5 M4G075/,AK=I[
MXY\4RR+(]FS.DK4:QW)S:V169^YJ7Y@\G<G,CXXX6>A&RI2)42,E-YPL6/QZ
M]6;D7M)Y#]3B/-#WH\US2:!U/PU[[#A&31EVT()S]-,QJVED3U52K'SWS@FV
MN>O5G^Z@?;C+(\O VH;Y!%^E5 S;MNQ#_(<-=MC03("$,3*:W9S04=+:Y?".
M6LMN:]T8PNZ5V4 IJ)F)WL!6T"4&,0)STQ=JM4 #(<,@-1V"7TOBG)R&9NH-
MATC&Z9J9)SHT4*8_*(U(N!^'<0:Z9D6=$+:%[VA!)V+@EYGDT:M*!L2H^9BI
M-,$$-+ITA(.!:BG337$ECSJ:50Y<;\*KM9ALY*:LFZF$5JB:?WX1Z(!1U@EC
M7;<HNV0-#)NR_24/?(1^C"4_-?M+>R'W]M24B;6X*LF=XEYB'OB3:ZF&,4N"
M&@^;'0%AA)[Z Y.HJY@5Y0__,77]M">DJ&)#M]9):B3KT<:!'K 6T_Z6?B&^
MG^9 @C,%9Z!A>_/[N.<G<@4Z,8@2"7>$7-A(-03FABXL^%,+MS_2>U8M6M*/
MOT1V]YVQ",'=^8FT?R&BE4[=JW\/YJK"-K6PJ33-7'$UXL08,S1NMCH?@>":
M8];W6QA1JV6S4YZ+$)".=7:+,++>G2=8+OP"6XK95YJ!LE5V4V9*%1&94GI7
MY2@?%JZK&^<NI0.7\Y2_--B/..JO6;M2#?FHP6K :0+@_V/O39O<N)(LT;\"
MTU1/D];(5*ZD)+[WS)*+2JP62VR2*KV>+VT!() (,1"!B@ RB?KU<_WX<OT&
M LA,%2F"I1P;ZQ(30"QW\>O+\7/0,%AHQ\V&0R<G+=U[(DZ@Y/1D)S&OIUU
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M55B4OFU!)AIJHMS*/[JF$ /!!R]0 '%C-D'H]PY#0%@9NPGU5H/9TVZ 9U/
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MA8)+$JO?:8:&D?^ZTUJXRP"Y=1E-1QI3W+P:AZY;#X,XR<.**X4F"4=_R^(
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MJAZZ]];VW:QGP3B=#AZ*8FNL@JUE<.G(?R9C0JF]#K4O72SSDV'A"YM>F5_
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M5"-$C<+'X!ADXB90 #T4$PWJ879D %0\'+SXL&386R22X,U5YE?4JLS.D?8
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MR:KWZ_!<M-!S)N9?YD7%U1Z^%(#(97W=2OJ#6]*7N7\%[D<F:;#@W@SF.3E
M13MGLG.C9!V\^NF"TND1$\3^T <:.0+?CYGR 3HI7\!)).,CBZ$*;F4IV4 J
MF3?4N82!&35U!H^OR198&9X3R'&'4NZ?6U:R"'GOU(Z#9;KB%!B/%<V6$-,L
MBU$]60OM@+M;FRP,-VM(L"(U&PX]SEV7++7&9]&BR0W0VRY7$VT:ZV"M$YGA
MB@'5'XHY*Q>>#,^/CL*11;&26LEXWWJ$WDS5.)N%P:7#5I0IB5HYDJ*%,.N
M^H<0)>[WZD!R_,<<I1R%1F_N2X'3VE:4!O3M^XJVCY%G*6,]KI$R3I&' RYP
M'?9D[=4" ,&U:<1S( O#A$K%?9I?.QYQD FUS'\8C)FP""(H$ZL4\=)A>88O
M' XNH*<AT%W_]$,;ALUWC:O"HP=')27Q189JJCVK%&*BSRJR:QBY$+,:TM_#
M90DVLPJ>%+XL?<T$!OIUU5*!H9P>E,44(JC!/D^4%H4#,S)QQ!4P"89QQN$I
M,X+CO:8YT*24^8<:"X*MX"M,Z[*HP0P!D [Y^@HZ][- U&D$B]K_(L\O'76$
MGL6,&L_&&EP7.6@,R2QN6]L[3>/@DB2VI*CCJ!QN8R?5'#JWK,]T]EK+^^RY
M9<^_^:*RY[\W QX=JZ^+14Z?[/,^WI(HT4[(A;R"XC+#7KZN!^_S-6M_?A?=
MS0>C<I4_3+S.P0/JIB!:+==1K(QFU*Z77^,(1-?TJHH= (M9,"?EW"Z2K1_V
M;+W_[_\IYI>#MAF'@:S+ZH *L,<GI\?_<WE\^.OB\BMJDMOV4;IK3\^.%A^>
MI+-Q'D:.*O1PXGF_8>OQQ[)$'QV=+3[08G8/M:M6LV?SSLT[]78/D'APPLPO
M$S,<C[=*6OQX[2R)!XX<.;3>RQ7]#^?U)(.AEF2(=$1/])PT?T#Z3S6IK&M0
M_QQ^6^738AEU-<H\:RH5IJ(R=2&* '0>  XI#<O?W<$Y?+*@-5M='I3Y-*R1
M1^$O6 $%N/>^._A=@N/^B4.%]]&GKGKL>(1T;([/#H_/:3 HK204 =-B1.$:
M]9"+QU74E9ZM"/F^OWC-1#'JLDWTF\Q</ A3,1N\>GUT>OQ86?ZLQQ=_CG6?
M^]G\!+/YBO;C@?JH2B.7717!DJ\/)@U<L):5+J[$ 1O51.BP7,TIL>Q^.14(
MWL682+5>K?.R+B:#'_/5^WQ>9%RB>O7C,%H@FN'STU,@R>]G^1/.\K-:@/X4
M8Q&3.6GG .IIK((5S2_Q^5K$Q+MY1!P";7U5C/(%?O/LI[^]?'YP_.T=]N7G
M2]3AA#-T)_&#9B-EP<[(<V$8#H*1O]97=-"U7NK%1"&MSR9> [R!>S0(_3E6
M.EW?Y=E\CQYTZVP!#0 2#<Y H7@]6DNUE**W.HJ!=()0]B/:O"IJKZUL"5#O
MVT:<XD)DK0$O&]<'?'/*,6#E>*S7HBD ";2>IR(F8H>VQH;(_&FSI+6@<^M,
M?CAXA=JSO<0RS(S<BC-A8<W).UC!%L5!K1>5Y0&)-@,,G$\2(A#KW@DN6O5A
M.'B:$;E<1A7O9E*,AX-G>4D)M6&8K?$L_$]<\.$)W^5MUM1=IAA@YVK)[D3@
MH8UF#]QP\_%)'6LT^EN1#QY<E&5.)&8/P^,5]26! .PI"+X0_E%#]06.W@63
MJZ\'?R;=#WEN?MKL?3[)!@]>%>&"556LYH/72>X]S.#;L&OSOJ!BWU;^!:>/
M&"T3C/.8R=NTBCDK%H(I3JP7:,P$'M'DG34]%)X+A;5'R@9KMW!..V?<VMYZ
M<EBOM:1^A=M6&\Z4CLA3S(#NB\F^IH/CQT?_,? B?/#EJU58)5+G&(=0@,H_
M NZOE)!3F4QF2#A"UX:;,M%AA&P::>K2W(]!'X=>O^FJQ(8"]1)\2>W"R]I%
MH5(6OXCR04&I2^HTYPZE%2GRAH/S/OMCV9]O[[,_.X8'>6\(8M9AA87%6<RA
M^2$*$*6:/LO"P\D8TS'0#*4CCE8=T+O$DQVVCR,2X/YZ.20BU:1@P=4)&T:)
M+M9&"B>G,!Z ,=P>A_+;K-!)S?IC]&7\0H<MP%3+9D6FIZJOHBH >8:,B9@5
M%38Z]R2C%[!K0383O)&+,,7[4U\N"+#D7%>UR'$NQ(7,MZBQA(Z>PIS"<3F7
M(W0! >V6"Z1%;1S8HNO.3(#^@<6<Z'RQ0@NH-?,ECT)X8X9=2I%D6C>=^>L6
M:??J>-GN ;XE.$E^N;Y#E.7,$)5+BNGZ\];;"018+&5EEVEUS4L#=(L3X=NK
M"F4DT;K01OVBFK%,*=8(.AYH6<CO!4PD/#]:V$!/%VWMQK8+U]_"3BCDN[I>
M6)$7H194B9A 51:.K";G7Z["";KDW8DH+">VT_^D+"P.MZC'+E-I;?2@&*BI
M1A_N]>4GOZ";%QFT?O^[=V+HH\/3QS0.;\(,3UC0,)K )N9.!N\.4"\$)7R$
M>@PER3'L,287KW[DBGBX]P'8,E\]?WLX>,UDAJ >(_W1&:V7XT[='9:?Z,]0
M;-20@&&/V3076\@5<ZF=A5T"X)&QZ2'5*H8:>E3%/.6P2;U$HI*AC5>R^JQC
M>=0G(PK1E?A9+Q7>&GPDD!435;U^$7WIB#S"E8N%'E@C%1.+YX.HF9\<G9S>
MQ=;NY]J&/1M]KK6]D1_Z]O QTD,_LWWD6JT#X\!1+52$()K.?B"+X^\+2Q>:
MS9A7,:@ AF0A@*,FK'8SIJ<_:(DB0=$,/=Y!=11-J(+84E@>3'^=,*)SGQBB
MH.#P,,1.NC4IZ,P]$ ,A.W.>J(VE/EP,#EI;,S[[F8&*!FBV0E.<-M!F:ZY#
M1V$G%"?6=ABU1A-3R7!N4.?UE,JY2 V"%Y1=(EVIGR2BQD:[8FOH4']".("$
M3]8KJEU+?%9_X9P\'I?S\-P(+9GA@62&#>L%:+48.G1Z;N25Y4[JN;J,H^47
M[X"&V./]/=Z;_6UGURME0,P&33TB\(M;FSSCMW"IRF+4L-X@>.5A+?@CP5'T
MF8[#@<?))=@> +CYOZOP\CTK'T\\#W^FE,0T:V?FU3. D)]!72J^_9J0ST5K
M./<<1!\*7S0=7687&5/QNK-8-SW *?B8K^U&J(O+^3KX^ZH8OX^,M&NI8H5!
MI;MK> - T<2_FT8XO6!.5QY]27S.3;LJA,:^#=,7IA*\!:YI%H1JAD!*O .Q
M;(D7Z[Q7Z=ZO6H,MLU@;CU,K:3^RBQ)\HO6:2D#,[([0D.O"RFC# T050H*L
M_HN<VY.]V==Z;C_3T-I.+#Z3<<XR8_3!K*9B+2V1L $DI9A/?((Z[)=M(=)T
M1;0WANKJS[P/F3-SF?-^H)D2[3I$2[SV.(&I;5P$Q^O?[IS#1!F P,Y82$/A
M6TK= !8HJP9).EQ/43[W-UE^@Z<YN\[61M86R6Z9G,T]7^16+-<8(D8KSUG8
MA'Q7&6C.P5"CN&ZXF*F5.&\;-+S(E5FL.Q21 B%NLI5C/\!^TWUF<468JX4)
M3C"]&3)4$'5M!B+$[(L3XVP1N9C0R%*#Z5A(Z9.0DW A_]Q^1NXOV<_!J_]\
M.[K8FQW-9@WGEOF>A*I4Z68^O' .Y"+8Y?WPF+IKC51B8Y<R#0;S#)%<2@@A
M'7BU_QARNQ![@)WG:C+L9O94%X-S=E([Z,7&HKJ:1-%OLDGXNW@2[_!:Z\%K
M>VY 1%*KDJDFFJ^()$7<)U;HV%+]M7:;GRL^0-E%?9J+WC,[LQ]UJ3\Z_.;\
M\ZWU?5OLOZ@(-B@V\OQ]K^6,=M+QST9+#&W5F!Z7E+KE_JXIT+JFXBH'0=&0
M->+H*"OGB,!GS'<G/. 46"8=.\Y0LG EJ^<QX*W8F0K^P]6.OCVZKQW=D)*7
M=:5V;H_*"-L;;[NY]>NLE20.57PI*[Z\#O]8#];!Y ;[?UEK&L]A*S9*U53\
MO19"S<KL-0Z098^)YD;_P\TP[5KRZPAL\TE7H8[O:8^A\&=B$@<EPK1 \8CN
M!$:J[4T"DJ#B7AR2,N;&I4ZLQ_JHW(A0"!VN[V/@6+@;?-KK4-]=+?JA0LW4
M"C%<+F1:U8I:8B W0Q)]$SOT?<6PHLB47%^=-#K=E)B3$U?1M; 2& %PU[7R
MNG4:SM)^B7<S >UH[.CN?LU847'L>THSUD[H-#B3-A&LL$*BUK(8D[@IXHSP
M"K*V^I?'1VO ^IQ]5W^$IJO[GJN>BN=]S]7>G-@H2#[E=@3.^ETD!>-Z\S#G
ML_"=,YT75OW8IW>]Q?++M1-C&_!2JPS_ I7GD]\;PMW75[8%PGT1Z=BWVW,Z
M)3@S9$= WH;()=?$5^OC_\]58J=AAK?^"_E[C(B"W6<N23XSN,R'E^%B<&)+
M#'$Q9!9VSFUHLC%8^H).R'%./U1Q,;Y8<)0B9[X,#B34N"1&[,W;AHXL,4"\
ME Q$2BT*$9E^>%*M5*]A3D<?NYU+TXE85V%@QUK[;'ONIZ5"F5.VRM281VY!
M7<%#</.) U-O[7?JYD*AP85;2&2?*[#/<-[(Y35-@L>85=V!0%T$@)CI8&D%
M@ ]S*-W>8B0IJ+#[)3P3N?+)"R?!EN6N%)YLJC(2BU8<F(R:]CMTK)<P72@-
M4M0!R9>T"MBM194CSC'G":QPNG&I%E+0\Q'3OM*Q6>5;)P$#/F7E'?LT3<MC
M56R?1 ++3?(Y*C6L"KG1Y3$<:!J#Q#T*$@(G?V&L52JXF0#Q\@QEK;\B]AWJ
M.5:KW7R,?Y'JSN>U^SM:=[)%-I9-QQ$JB*.E_AEN+%5/JB.\K^IKM1;MYZ11
M@G7_N>W$7FG!A$"KHK#-_64;^PG64PU-\FZ0\X*72^9$!#C"6HU8#8=.\JZN
M*TLG!,\"/0T/!^.Y!2QALA\6I4L*4R(?)@L3B\*2M,RYEB4]M-0X=Q L13WF
M1 'M+K1"A"=Z=W$1K&)EI9<^8"VGIK6U5L. :^:WZZ03>,#$ /@"<%[-<$ F
M,6@PI,&G#V$;-_>Y<U2XS$CI)=P@JW)NT727GS5Y+K,D+P1SJ"^I@#=IR!EJ
MKI9^$>PE,>;-L@DSG,464&8.Y]7./4%D4G7TDZ;SX8#3I'3LUF@K</JA-$12
M_7KQZO7%NQ_^6V!U)UW12FHNMGZW:Z20[!N":7*X&76"(T6US^\P4+0S(]TB
M7T[<<\FX)BUZ*VC=.8@=3J-[H_M)C>[W9?ZA ,"B"1:!I&Q$OPO@3DZ_(1_B
MTAZ#8CXGMD\XLI_=^+[$PQR(_N D.LS0!E->T10(EFGFRE:SO))F3O@,"G=B
M^\#@E);2 F,F+!NI^36UJA#QCM\O:J+$IP03M'DS]68(N##)<T8'3%:LQ<$+
M'"3Q81\OM(%!TE&D>"S%_8;%N(;V,+=)FQ32VWE?JK%2S?&74:K9-&.?J_''
MQTL:%- Q'E,\83/=:BL ;J-X<3AV,0SUY@1K&\E:]G#2NV&QBS=@:#LZ@ #<
M$G]C@X!!-KV_S5"J)4+EAHJIM/YW;87\C 5*)7BG(QZ(/=QQZ%"QWO'(KH@5
M@'](R<<DX1U?-":D8\/NUE!H*!C5"%=]# =C7*ZHORDZB!VCW1UG;L:R@(^
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M3!YV:4P8$?)CI="$U^0Z=QV0E-.72M\NC>BLRVH@B""I(@\>! ?K89=3?NB
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M.ODR:EF?:5\1S$ATD3N$-\9/1SW8W.3:$J'>JLP?_K.(A]W[;Q/E<'_"_.N
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MX441+)3U]6!2K\)+'_#?PN%"J>[LDNLK\18UD0HO<55\8JD)3=WQ/&L##'W
M:?U1\(<J^*JV?(20O?.LJ,)T+\LEZ\N".$ZT6AV^B!_ F:5<'M(.RMJ\I-IF
M^,J#[*'PO5FV3_8D>LJ1%^%4<4Q&<LJ#[SP</!B%*X3[<LD#*77^AMW]P?AA
MS_7=7#NM@7WR=K:(/"X,]O3B[RL*"]ZP7LNV0PXZJ9J;WJ/7VZH-_5-PM*B
M2 "RG@-KZ[DTC 7B>%0QER"F-^\7E!:-/%&]*2HQ#_R]/C(;L?LW3X0_M"@[
M;,50=X)=*_OAD=.--E,Y1#FYR:<A1F9E"S:=P5JR33M);=M].<Z5X\[NRW&[
M6\1D8481 .+SG^:-:+GXNEH]E:U@YYX_AX/C%([(7$Y<8 "R#\6<&+;F=!SP
MNB>B&><!Z -LW$C:/>W865GABA]!\23P8$3%G")E?RG&H[P-+U+_@PJ)A"MJ
MG?4W _'GIEXMOH \=P<MR[M>(+/'G%D@)R1,S%;;,,LF7-J0Z9ILGX)=P[]7
M@]5_1D8-<8T)S2;OT;-O/0!33SJB.#J"J"==A7O&K[3.^<X_T"R""(!\XH7)
M]KEB=?CMY:5 E3<]Z>2T.3[O+"G1]Z8"&>_):XBXRCG&!]O)H>9)2E9_@6R]
M-Q\;\4Z\X>GA<7K'J6K*A3?*YTE.Q]YIGYRX;2DK+TJOLP2?F5Q7GJB=P7KT
M(&0/[UCSPXY'")R83EBLT=KG&<FO\YW@=%S733FY)N$1O3W"'(XNAQI"^4;C
M?)@$3Z[(#RG 59L[W7B7KDPYXK3M?X72!<)30HBJ/,K>SW+/26DPD,')R;])
MX 9P,]>(N^&6A)DTD5CB8?5?UB[>"Z,2UA'TEP O,(SJT.@AX(II6D"G6* D
M)$DA8+L*A7+&8"N8V 6L<EG]716>1XH]V8*_?JOL@LJ^W26Y0+OBSEO[V\\F
MQYW:[U.?;*3L=(YD"$KW!;=NA;TV+Y:T 3/X,Q09DR)6F*])DUWSY@ZC<YE7
MX_7@9]K8#/J1D7KPXN>+APFDU%#$!/M+K/VA,Q/AD0B+@)J7M.7W9G\._R][
M;][<MK6DC7\55F:S:R!%B]>DWK=*\9)XYCI6V<F]4[]_WH)(4,(U"? "H&3-
MI_^=I[?3!P0IR8ECZH93,Q-9(H&S].G3R]-/ XT3WI&^PC^5M+Z.MW*095N(
MQV2G'&_1Y@T;#N\I_S<8_<1Z?@C:JQV]+B; ;8_>(9]+2ON4U.7HIR(<RXO1
MMZ,?H&';?!X,W7__EZ/'1]\WHQ_#W5Q-PLM6+9"O,]6OVKWR716$^'S9=G+-
MLQW+WCZ@.TMJ(Z9!3-T1A<QM7G]F'7QW^E/&P:I),2VA *LEP9)1Q('NE1#R
MNBVL<R@B!WLOWOWUS<N]P^<Q"IR9U7LK7S[Z\,G(^V[[T_W4D-K^N^Q-3"G$
M3()6I&"U5Z,T85$F='Z&P=S]W8WG[>R::.KF85 7@@:,#Z-X:P[S220D?H^=
M0(8V\'T931[ %&$#>UL+WQ:;>&F;>YNPSM;KL5NGPD[FX5JY9\)W^.PWI;%H
MRN;ZWB'?45OYY;>CD[<_CAX?/#'KFQ^Z9JFWRF,>7N&![%I/G?4"D1K)<6[B
MO_:]0P%C.DPD+Q-J72PF:\Y%IN;PWEEP+$HT%$_=$-UA/JNQ*R0;H@KU&B@U
MYOTZ.GC2[U><^BC^PV%OR?0F7W5]_F]1-##J2M=$;TB@^AQ,>+?/-45;5Q&C
MG'O11RW@[V__'8%;/:S53,)/3[B>NW^G!\N7Q0#Q*&\42WGEI!ASJ([<I;!B
MO"1IF#Z>Q1@>R4>$Z"G.@RFP*!<%!BC5*]NT=L,:^T=DMQB0]YXE0T_0J>38
M3J1R8(NFLH;4#Q&$L[(.4MO,\S&EU=%),KCR@%"3!  ?0UB X1(JR?6&\_]W
M 8P+?C_VZX;5-'*KYBHA!A\Z>I!W?+;8?,RX0(V6>%9C@)2&?2A 20DR[?(I
M,9_R>)=/V; ^L3S81)4N#!)65"8$<_;<NI<&?14K!=,X&E\82)#3'9C<'-GH
M'TO&GQ+HM@Y2',OZ@ND!G7>. L[QQ_R<KU!4"Z)6/5SE=3/9^U@4"_Y,4\]K
M#C/FDW"*.@JZ9=18H2G/EE(*6K=!^K1F*4RA#,^+5QC55O(HFX]%IW\H/N$/
M?)+F]&/0UZL:P8)^%/3,6RDSDL,?FV4++^$JHI$J'\]<W5@LJ@J_!A4(EW]K
MH09JQV?7,E@E^!B"9,ISZ+GA1H.>4&(1?V]S2.:6;]('F* $]:45X!F[H(D=
MP*(2Q4J+.YQ2C*I0(DIA*<L@VSDU9*]RKH %KRG5 .<:> *5ZIKI!VF8H?SI
M_(*)1!2]SON(DC3M+S&F;L .HY-Q\06\+^"=\%EMBQUY$:0JG9&Q'*"<3-".
MF\>3CZ#DFISS4U>H.T>W#P&51"R5>UI3S(D+!<]@;&LI! ]2;R0NI!)?4@;A
M3*'9;CN=#(O M^;AAD5O$9NK"!&SF)4H+6%_(A&2Y&[)Y&(A=@K9??QAJ6(6
M9V&I3$7#H+Q.B6CQ<BP]YM:5\T(8#:LP!DG[!.D9;PE4EY[X7=F%+1S?PNXA
M6A\U<5XZ'^R4MVL;IG23;[JF!AQ:2/5_.^KI/M(R)2&V$U48 Q$:YGI=UY-L
M]!*5[>S.M_,"0,63<4S^O'[YXH1?FH8B/Q3-)6)D_K.G/WTXR52PRP8GFQF,
MW7&@_$IR:A E&SHT]_6HC%[GY8QJ VL>YG4,\[IZ>!)/>9_4T7 E(3U\LK32
M9;V=?!A!UB[>T9Y\EY%J\?;&S:&JG2D-9JQ#$=U(Z3%JL"5,2LD256/9+LB;
M_1,J<S91JMW4_,B5\@3^?(N5JO4*-1XM7Y6967 _?):96N*X\^BF7M2S(*E7
M>4-",BM T=UFMC0@99C-:/+Q>8[SA/5O_'Q;E/\;=@BGB4@1J'*YZ1B4T"ZX
MG%<8P_$%^E>3&#!A_G]?5CI=Q('CK$FFSZ,#H65,] GF\"83*#SOO&[.I:,[
MRC O2QK,N"FYX#<,A?-Q3"DF9H'?):GD9$=%N<VQ/U1OFH/.O* 4/IEBR(Y2
M#@6YMV7O(!KD9=76R0<TBEHDFVV>2$6#7/SLLF#DG/G6.ZKF+TDG1OJGT!AC
M55=VHB2:6%,58"N1KKPJYS@#W9+HHO(Q#'L)>)V'R\)_:P&)+KD*MAG]^)=3
MS0Q'%9=H-PV+4I=$3M0#1AP?R"^G0RS*Q#_)=/0=2EYV G-G@:&4<:M!,M4"
MK)G?_/Q2P3CB'A$R("9E15EP'\P^3P-KB[!!NPW\DAOH64"8]XP(-7 ]O*GL
M[@E_?\_D.S_4>3.A(_SF_0_TWZ(+6TQP&0(/%+!+B&##=A1]$9UO*ABQDK\#
M]VVRV^,ON<>2&R#K%T=S$O2L!AS1^6-/0C@H&QD^C(EFEU/>)X$16T_XQA*.
ME)9O@YA%2.^"%W87P&:)_4P&[P/'TQCFPL.U^J)%&$81^V3"J;A@_\-59!('
M3;C#PDU1MFQGM_FT4!I#Y/+S<20P#'X"Q2@&+!J,J22HOG!0A5MJ)\I?Y[X9
M_2#[TPKL$-)ZXOLRA,WZX2\G&>W::H1% E+LI;2)^Q8TWZ20P\.2$EP#*H1G
ML:5:YB QY#\(]+5O/TD4E9-]Z>G:2<P7E9BP^RWS.5V/4OLVC!#2<\+\$=>C
M%W:%<:Z.&;K,JER_3W_"%,R3^Y&"V1V8+W!@RHJBV:Z()045A)^$ [C1GREM
M0%%\?'S@*D5]+OVH)D.+$$,_;#?^\>UI)G\W.BV*#]AK,F'D4P88LFR$,E0-
MGS[!RNIXS+AAIA5H^K9KB%@N9KY(]],]L%/A7]1^-:X08@]=3DJC1O57+,(0
MUP,7K/1E)UF1$GD![!%G#JBZE@O-#>+7P4KX'L_9;>H7W%3.29!/*6$@-L."
MSF!XE<3194.V(J.T<:%_$ ?7#+WK(3WGX+R1TV<]^2<[.)+&666L)!N@E3\6
M*\9FB\)\)+72/U%JM:W[/EK_+)61?[3P@;<B;--2_+T8\QZ-+\ @U3774-"?
MN/&M)%%B!T#7:[(7/(Q*GV9C1]ZY9I*5]JY9NAX<GPXZGWYMG^K-GJ-1/M4B
M&:#$D^54CW- XW8A>"FOZBD:0/+@7> %7$VAR KU"09'A!4[+RB(2>/I,<EZ
MUS4/CO$U)^Z@O3+VF8T[-&+^H-KH+'50>)I^SZ,_Z[SQNJO'0' XEPH437E4
MB6]^?KD_^H#PW9"<(5:'F[:LED$FP;W .27Y)J$!M+:$%PZ_S9?AP.8TEYG2
MDK8N/'A\$&9QK4P*! !== E;[;*:J<"0.LF)P2R,9%PT%46&J8A%4G6>AFEU
M%332@3M]EH\E[\#[2BT?DN12I#4/E\KQP5X8*"?BE)G[3258$J*HSVPI5$0,
ML![&3>*"A. ,*1A0[RX[XSJUV;@ 6D_L&!@1E""O+3TRC(?..",LTL&W/*%-
MVBE)+LJ;D=%BB>POFA1?RE'UZR\<]&+$A669VJQY9.UJVLX%@%$6!+@0APF-
M#Y?- %]Z),M9,:^SI*ZI.$(_E^2I]D<G&M&24M AGE87;+"(-H-?A)]=,E@T
M',5^]M>&2@'"WF1*E H6T#$6]7P9?DD\QVTD9,T;E 3(ZUOJ$Q(9?;N"A8H?
MO?U7XHO>6DA*CU/;+I,<'8F-,@FS70-\$9T0C#=@"W2;R#@G0AEP3(;#?YYS
M;Y68661ZPQ(%AT16SUQ&)!^@]X[5-5ZIFT<@+L7^J#\[:H'-=P^1YDZXE3+I
M5H")N[QD4-PZ %Y-.??R,O8J2(4ITSZYE(&=<$9:,_4M\33J61!4.[*[34D9
M70-:0*_GP4<BPX'J5*@_>_A10'7QD1+KBC=?V]6+!>$NEC-K/\*N6-[72H82
MPW>X&88BTRVW?$E[V5Y0!KH>CY?-_NB5D'/3NL6PL);=M'I+V4<4>Q?+%V^X
MQ_H;IP^(FT>T$[P:@@8C=1$=T1MBX+YP^,<7IXDAT>_OXOXF"\H*IA?1IO87
M$Z46+,BU;:FDP^@:TZP+[X+.C4UM;=;N4(K]I,_['Z#[(06$V,$HZ;EES ;A
M ];29MVVVV("BD"/1<+G(F@F+0%V)-!X3K +I[F8*1%;SP_E'D3E(M?8OK8U
M$\0F5^#G%&.08Z54BU35K\U\VOBDSIICK7+$4T>=\*LY71M:O]P4>5M7VG+$
M<_,@3DS/Q)(&-3,M%>I'RTEU8KSDBF8 :;N$)XK*I+._MRP/)M]<3!;V;&BC
M]="&G0._"?X3UD$;.DEM+:-V2+KQ4#WP ]NX#%.::?@'FTC&GV7ZR;00UX":
MGV##!L0)I+J+5"T#)]404?UY< '<O=QSY$7O9E1/4W%?%+)JQ<QP$. S3DJR
M3,I!:7L6 J+^*AUDF'14IH$WP=*8 W(4/G,%HOT<Z"DL-^UH<&S&8#HM(7Q6
MB1XT MF>M6DU&IQAB&(T H^_R&?=T#*7J#3!W4 7O*I4QKN63%57X4V+CN1.
MI@[)I@G)ICL0!+,8T[W 2.8*A49AK?Q-JSDNDM'&L<<E#@\CDJ*:$H@U ?"J
M\SHQ=DPP?/2%ET"=']S># D4RMMR2W"B&TV8GX;SH0UU9Q/7)=X;I$_0VEAP
MAZ663#F>?JSJ+%]@RY@@_PQ%P3M<T^\ [+U#^(F):PZ_9NGY/E>G_;(V("[5
MX82%ZS0X3D6FG-2^EO2W:0&R\(+-*X1*K"VL[0P<44IALAOO:!A;4.D7'"Z8
M%GL08=0S4I.WX(YPCS6"L/-PJ&,-'KG+B,6,V-/[FA'[2KJB!POM:E@4N(Z(
M H1"B 34 +R(I$X]1IAW\0@$CW*)[GW:MDPI%?AH:(0*%M&T(U)0IZO5N-[U
MJ/T:RO=HJY6O1+FU&&@6G(&.&U*5A*BO%\OH '"6<'IM?:YZ\&E6S<YZHY O
M8JDS0FY32;>^D:L)5F%(!CFRVJ,.WA1&I5J:;X Z&I2(& 25$WXW*QJXKQG3
M3C/G"/Z";TA8H0V6[F1YIX90N^/PNQV'XZ]Z' :C6:Z-)RB_A#++Y)0E*(O6
ML0IMII"HS,M]*7P+87J3X9-$"=KZO,D7JO.#8"]PCH9SNN2_M,/^NV'R5L!^
MU#09,19X410!(X]]1/Y1_[P))1R%7E!MHA "[O8\=<VJM.AU^WV:TZ24MK=X
M7#O9T?MZ"4*6TT>KWY KW,7/*&6C5_$JV&[3QFDT\IPCA88&I;A!27D <[([
M&*K*^F&A,HGJ1 EPI/J1MB]SG:V%5A3M4/>(%4A$ELM.]L#+^E((,V;FT8&=
M=)!BHU^86Q:Q4BRR!_1*F G6(.YU0G\?:W&S-+V7#6$=DJ W0F^5]!0Y;[AF
M!UZ\BT8/Y2=7H/@; JS[H[\U^!TG1_2&D[?H%U'AO8!5-QRBE;AT,G3Q2YJR
MEEZ(RXH[2D*ZDO QIT"G):7+I(B+8R&6Q.:T+R@*!\M'MNF*^.;_AF&&[6[J
MK]MY3>QF242=GX,+,$\JJBT(Q9:VGCYK4*A2!/?52K;+:MQ04QLYHXWU$->]
MIJQ7LLWA"P(VNRRDU^"L;%T%F64" ,=V0C0Z:^KQQ;(!!(+=_<P(:XG/A._=
MP=(3;8ZH 5#$TQ#PFRYG@AJ@Z^QZI8$!@T8IBA_3L1)CU>2OP,8W13.E"G,@
M [B2:/&IVK!*ESDOI$4"70M9/281.#< G6^0G*2X_R?.D3.+6A*(%%0]9,"_
M@$/N9277ACN+RTKY<<OY?%G5K).O-94Y^L!L 3,R&2AL/J;(QM "&%1H.K@8
MC,B/V8IR2*LIZ23/-/$*AW(]84 NU^."I-C*M:E+D&H2SW6_*8I39BKW*,KV
M&<[M-R->U-5XV8B_SO#,OF' 3#O4$;Y=2JR4#Y2_V7WPF*X,BD4;/5;\H&^K
M%33YDD78NM4ANQ1419A-V/QQNR&G[&!(*,EF8N"$ER&%X'B+L$S:I@1K$/A0
M8<KHBP[PJHF\!)6 T,5L$7Z+>)XEJF(*J',UQ%-2@O0"N@?/8W-$*8@<J-S/
MK+@>J>T@@V%VG'=2/<RE#.D4):WM35JDTP >R3LN8P:VQF 2P $%KQ,V.M-:
MLK9+'ZHK:AE6</1R[Q;*X+4=2P^_$-]0;.U9WJ'GVUJHUXA:VZW+I"= +!4D
MQ053)9'=;\4FB*\Y,@[KJT,BP1E8_SX5B:<:,#J<:%-1VEZRC!*[)9^I4^YC
M/1VK6>K.IW8<&'HCB&)2%ZSYR+D[KU.]3H&#4GD#Z<(M*4-?S*84'-X*M?0Y
MS![O(]94^<N4V:/8?FZ/$\/3I8C\ONE"5^+J_F=L:"<7YP]_.3&98D(-REX3
MU,LIN.B\K56G?/+Q/(>8HD=KBM@Y& /T%%EJE_?KRC.-Y<JEXF\!:>/D^-Z5
M3E%3"#T-DD7HGSKLD1(^=KMW[^#9^?JM/HF&<^\&63^X5;GZ.9')J)(Z!E+(
M=GJQ4P2BX&.I &A26]-2!YPQSC+8'M24/!M99W$;7;_S.8'^,*C9-8<OO*FZ
M]2<@\H*>!FD:-R6SXQ(;S:_AF:/71627.7WYZ^L30AL3;@CK0Y@)+_.XJ]DZ
M81Q,XMPL\<1I4403/I_\?=EV?(_2X^TS#*?$_Y*O34N[+Y]Q&,S6?8;\\7QN
MW6<&;O%]FM!5CD9]9&:2P2#89(BY87YAD @$89>/B_FX9_<C'_>U2 +3QO3>
M1V29,U9QS[7OFB4Q,6SR5R@B.4ISA+#.EBTP+2OD;%7MS@[),@'_646%(]JF
M1JB#XN0X"<&DK4:3<.[;! %NMKW#)K5"%RQ?BL&_[==W?^,0PQ,!P4=RV125
MW-LBS_<%>Z>5BSX)O,7L$,./RJ3<V3MI#G,N7$)\*;7X6KR04MPYL1H16A<2
M07<2AJ"=)B8%L'K4)H1?(F@L[GM,U $8.:DVN1(YM#'U4U=@E?:I&/82!?M
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MI6#QJ1=H;6^,M&WCBV+\<5&7%(0F\B3"+RI4V"Q'0E9(G$U7/*8]^62=::G
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MH#0G[<7#K'N>Q*&4OFJ?RCFW)SG*'@<WPG@J6JK1@YTV1=B%\B)$+FI#J<_
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MW/#2KISUKD-DK5R;M,$!FEX;B87%(S9!N0K>1%'UNN;XKC V=B'T&AJ<=-V
MPZ:L,%-N.XSX[A@+RPDK8EZR#C!,H]6NKA=+"P5_;QI5YKOSL5G/]E];,!E+
M6T@4KNRPD:((WY?MQ]%KYHQ5A;@+(\<P\J.M"B.O_\@6WB%_*<>(+8H[^R)Q
M_4_,#MKF:1P\M6D4FR;1"U_(=7,2!((,B^!_O_EY+URB?U^>$X?A^WQ2UD&Z
M*>!CM)P/OK$G^ _86[YYN/TF]KNJ9T?!9#0[CHXR*7AQBC9/N+>LB)P(01B'
M-- 669>T<0_P 7<7]29DB 0U[X&W\J8:_5=>+4'_9H:H<T6JNMH+5R;<-%A
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MK$J0%PA]1: P-OFMD3,[0@S/2T3 ^B!H+C#L!EZ?3\,;)DK)[SPC>:Q^CPH
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M^7U!]<7HK*'<'A]D88,YZ*-!RG!E+^^'7Q\;) 75$[8<79CJF29;_S#A.;U
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ME<W=1;T,CYFT=U/%GR'1NU7<K>+GK.)-?D@^_GA./;3V9+CC<5%,IYN6  F
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M=&]IV]&0\_51T'*<]B;?BC;F3W5Z1X"!83MA^ ,A)*1-#"#[Y+N<)H0;EW+
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M "#>.#@=6^E/H8]J$9S^UH$%<=3E/V./B[OG KKQ]7*D].>+J[<7_ZWK7+/
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M)NBOQ11DF34@0B 4&4I-O/Q"ZT\B.T4W@+R\2PRGC\'V$PX#J3_AA97&;LK
M?31GW\<!ZE\+, _U>,QF#S4+)^Q/XV?7'Z//GZ/::7RB+:9*<6*:I>Q%P57A
MC;EE_O%$&207I%0P;.GX4/H%,"!XX"J2]$ D@-  &T\F=9-B#E@6=@@%T9#]
MH_Z"W)&2P)G(AD#]1U#!K3*A@6AD0@\(%K8R96P+GP5! U=-"9=2GBG)(<R
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MNE=Z<QU@!>SHLB#"0VYO(G,B(A4?IWQDHA=7P">H9:VFBR2"1=V6I6 D@E!
MTDQ]U_&U\(F9GQ2VG#,0PZ0022E+GG048&$8!^29U,?NI+A!D% C7HT'D,,*
M]ODE'9&C-T'"_;_Y]*; 9VD-=:_;FI_-%)H:3>HFDZ)(-4,@Z6]ZB]]?RN$1
M^O #%,VKR ]SOF'<J?+3?OV!+9:OWF8.$AE72R=P8$V"6086*@S3NK);FM/L
MCKB*=.=J%@Y.]!%A#"'O4_>:"'P0<K5HV.: 30WO?G&%81VY6+X2SC@D \OS
MK[1:RB^.Z0F+Z@)NG(LVR[GD;;D8;NK1LX9PJX%Q 8U..8U;H$E.)'T35W:X
M1)J5%O\OSI2K:"5NCJ)RM$;J@Q(QD,CWKRG:!]SQS;LOBK.*:PA$<B/F"I-\
M]M-0*C&3)*@B/)[S>,:<EO%>FF1M%;E%'DK,+ 42,X@6$_^ SEK>)Q$@0T6
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M)>5OG,%+F?1.*!TIC3]17%S58B I$E>%VZ.63!A\!MFZ4I"6PXAPOKO2D%X
M@37@(21^!C:YS'O?E<]'ID]H*!900#B9QC?4B9<NDP^DZBT@X&?N_;5:\*P#
M?Z/Z6%8[2F5\V3<EH$DA4!3**ME?&A\A9&KE3-\HO>.]K_I17#'/GZ:I UK'
M&YF(CT<L@*ML%B(>3]\KNR8!40.J$>G 3"4C<[RD@0GVXH 7O'78S /V!;=*
M1JFLT6A@G(E4V4)4,@/,C-@%.9^%@Q+=Z@:+:(-RP3'9B0T,AODJA*TPXFVO
M R!&MJ!?_0YJ99IQIO+:1.8\0._L/0OP=3(5/TF0R\8S2+M*@AK$PI.\NL^
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M;H@Q#YSW?@!_>DB)E'CX,0SC#:.G&]K;C?;^E^\VV/PH:.ZM$]JN'V)GR,O
M)[\ZJ'>B /6#3]X P2%_8;<-)3X2)7[V&T)<,X%\]$]\3D)T=P_V7J>Z8Z&J
M8@B>/S%1;3/;Y)F1;O%U?L\7S.7;C(MY#.98>W!]:H"UBZCPSHS7CL>"U5/!
M[/GPR6*0OG4PRS8RI.K#,2HPX0\<&389X?\>"5%BPSCCXTL)..,C!J"<J)Q
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M;BG5/FU5D[;L"^=P)53I@K:L*68WP6NQ!L$0S5+6Y@&;HHO$A_=&WSRW>B8
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M!N:=T>/3Z,[L<DK_4U=V63XR:B>(YH!P+PHL F2-&&;OO%*0JSJXSN]W=?<
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M<Z._8+V*36BM"R 5_ZH8^"I__:P'#;(Y1H@=MRIVA0E]2^-?#/;OL(H)N[H
M\4',ZIAUA?O-KCMFB!VU=H5VXV].Y(/QZ/J+,7?=^W&L1KUJU*LGY5C'#+&C
M5J^08WUR[#GCKO$;"VW?LX%K\?O%%AI%JU&T&D6K'FRKYNH!]AZ:>3SBQON
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M$L)G*H87!)+JB"7 YK#]'PK#:DWX**E"3AIQ_HSD*FY]TC7I_OLO];8]E>!
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MY9_&%^Q$,K]S.3<E-3O)+2P<5Y)5KY&M P2*[>^%*2F:&6N$U02PM0#V>7D
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M@YT(UKAZ]\98QD$8,] 1(Y\^4[@R+NRH9=0,858'$=8]%,+@]<4(>PV:Z<0
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M!A# A^ KZY0TX@^X._%LBSU?17D<K"+8W*?3=9_]%^^EHM1)$EQ(^FD&W*V
MGG-][@5?1;VF9!+?G90L$?^IXHH-3\9SK0.<Q)(R%$D-!]J1Q^K49]0*S@/E
M[$0GR@<_QG.2+T+]OX&D@&>O2Q!)!2DN,(EX"?_B;XW/_FST#>:U^B<=#:+^
M$XG 9(T_D1J!G$F?IZ0VJE$B 96L@^@NBA.ZKLSMI/2\M;1RIXJ+B58@YS_2
M9&&$\3#0]PE,F 6 A*'A(@!63$VYFRE;@RLS*W$^E#X+PC<J]74*7P0+B-]Q
M1M3O<AYMK--K&IFZ&/A$"ZI>89/7S@1U',ZR2Z.EPE5-\^R#DA)])GN2)8J#
MZC#EYCKL["@399[!E]*LU-,SS_&<9"J2WFQVF)*S\)ZF;^*FE'&K%R:>_^>S
M^'0(E^[Q=#(<G4R.3V;GTXMA=#&-CD<7Q]&)NAC]WV@X>;:5=N64</XAE0)G
MK;+FQT'0?2]O*(#K@6QA-.FF"H62!?B94I%4>D,YWD:Y3Y+LG@2*JTV1O$56
M-T 182M*1#IW26^9Y8IY9F)DA6MB2*B^@'%RHBFMPL0@T1?([B)[* , 9DSB
MG5+#"QI,JW!8)X DV:?3:*>FNA[W!E;QP@/?>&FV]8W>UCZLJE-/:%_G2[!)
MLS5E@5SF.=H"M.@^K&1S;UK#%B#OB2V VF8@ &%H8!]EEQ753M*Y>YN<0=<-
M2%CG)3')*/\N"A":)"BB!#]"]SK;6LB[*8TTS5*P6;(5VEX5W'=KJE:Y5PEI
MM<0 :#^1W@^\3-/@_$@[QBJ)TK:I2+E-@EH O(/6U?R.3&:LW1;+6>6HMVHW
M0Q%_!/9.R]L-WOC^4N=K4#^6J:E*#QRN[,-J'D^A<6U!=>)44F7DB? .K)]!
M<*T4&_1JIL_[ 0< :P5H$XLI^[I4R^!T\&-P1#EE"JX2'$KP$MT_4=5!0^;)
M@S_'2SA4OH/@T9_C: JW@B3]UD_QEZ@L<?YB#_?^)%^G1;:(<M)]:TM!H9#(
M8NE>S.,"KTKK.KBVE^;EK-0ZVPJYM!2OAG-7FQL:QH5G"MQ/,%S+'*Y[&K=H
MU/G#%-1-1JET**D*/ .K-DR52@5B #^&!H'VHZWBU! -NT:*"A/X:DO$7,";
M*$Y!MQ1GQ"J#_W^-VZ$^HK'BI*'75DL:-B4$@D: 2D:5*IS+3*&AT"V1OL/@
MP60W@@<]4<=<MUKOY0>*:5?<'I.X_;$"28&YU6_N5'X7JWLC2H$2"_8:7 ';
M1],LK]]^STCP^,@A-Y$49&+H0^=JOUGY;[(#^"4(M+MXJE:!_IAYP#@GS1#O
MHGD,#'^#/]C'Z!3T,X_1YY_"%]^@*7+F=%N+P5N2<+TG+*UB1/-LA2N)K*%%
M=X=K&VJI35= H4HJ*!%C$2Z.F9I7Z%/0U<+:R<.70 @#(XF*%Q6X3M07U(#1
MAW.';A.P\R+[#OLTNJ8#-/,*[[@J!V'->>TT$YYDEB*(Q\;E4(JZ\P=XW-HO
M-!>Z+N!+M_$J#*A,?!W@1O/7"M!80(OWYN2-4=0'@9_AEC,V+FO_Z_H<02Z%
M$J3#JB!0^_&ZUVH_#FL&H9+.)0&?Q.E=EB#*C_HX4VI>!'\:F1PTFUA?@6G!
MU@:5WX&67_%W9EC^+-OJ$3*/BV)AYJIR>,H%2IV9BT(#"D7%")*I&%!*\8E7
M21GQKMJB^YRL#OCYCM3;Z9IU3S[!07!9WQ@\,-@NNF57.28G$"F*=H.;:U4=
M :G*>=&H2J'['P:1!VQ$1PHAZ("]C340.%'A!;Q :":5HC"CWMD-C^BR!!D-
M8S<.IB9Z"BD:RKN2\)13_:^0GT;UOS!JEU_VX%=ST(;<@(I#*M-RRTFQ(W.6
MH&>0(2.(P(G<1:&3^=(-<_8<N)RDT?/@@UH+. 5Q#9]4BA4\UB7LFR&% J4Q
M=U]J_7CMP\5_\">!]YX;QG$HP9Q<1!4F2&PQT?GV>P>40B4JW8>!_F9X4,BQ
M&7<T>G1"N$M2E,+SHO5$+BFCHQL8QF3:M)Z5NX]VN86%>;";2YOZCZP&RU8O
M]T%#T!F'"(:O  <MI':J<:JYI\XUNQ9"ITOO-V-:L:@)^53S#"^2N7='R/84
M8@79N(4$I3LO%['22/0ME_04G0_L/ <:(MC9.2&!P3^L+Y;O0@NQ=PE'SQSR
M*D[)40,[3X8?AO-S((_%IF?LW7J?51C^04ZAO\'YPV1PZ>SL1Z-MI2B[+IAF
M\[6^3Z<9:(7X#T-H()E1TM1W"4.F*,XW;LO]+6QCEL<W&!B%A=?V)]HTL 2T
MX:U'G ,L,R,_LOD2_A4XA*]5D!5B12_HKD85A7;2TT.V.0L,,DG<S;K.D.==
MS_7:][7S-'2$)A*)LI+70[S:,:(F^1T8$9.T&7:"LU5<9J$D(K&H*[3\DN@4
M_R/4@L#?*ST@*U%28L<T"O)V9F.$KIX4.O5Y\(1X$;2$:;Y P\+)RSI470O#
M(U/YTDDP1%4CRK6$I%?H 1LAQ%2.G)(=#)30#!VKS'=T;U:IR?NXC?/YD9P
MDX.\;+04QS4:RC9H\?<?G$JP1(;EHVTKU7;6Q!''35S)!R^\SB*@I+C<!G67
M=H<4R 1E&8GI%!&(9G$^JY9XY<T4*:!("ZROBH8%%,:I"]KNTB=(%Z.03=M-
MX4$T<,23]WK3XN:*/<@V)^@FRX#!(OAPW^V\+O<=EC'';"3<4Q9<)U?SG<*>
M/.7XV_$<Q.?.J*H@)BH0IVL!1DVB>TYG(44_81,C*HIL%D<BR6P4P8_?Y57"
M>SU#U6MF2;09V',4+** AG WUKOU%EM.^.$1A_<$^=M;>LK(D7+ZO"\9W*/C
M 74&^)V%%REG[.J'SV!*&BF2G/M2\V'A.3DGVGY=^XZ=./?M..!G^R0'J!;Q
M1Y29"G,_<_X;F2P@[3'[@GYA$0<&O[7BW; 1DCY<K?_0\E%Q'BG[I@V) <D_
M2A[L2>JS26I#5+-&3%TRX-.)! 9UWG(^CW-$\<B>BP#SB]<JRMD#D*K[B,*M
M4>O;E+^#E%<4,08$W !?^ZSH<V+QN#0K 5 8+,[F_,%E]#%>5DRZ9E+[D(,-
M.1SO1LAA+SD^7W*D67I$-T<9M\:=MQ4=DB../$;48+1[)^6 !FB15$V!8EQ4
M]>F1SZ^,/N"UAVX;Q[G1.3W6RAU)5-YGQ/2%1<STO=>K*)Z+0-PT@>; &')G
MP4++SRAEF6/NLUK$G(TVLC5HO@^O(XDPT@I3>XQW9L\BCV21G[,H)>/W\W1J
M[2FZ 5V]1.>C=:;?*H;GP7 +)M+AN$NJ/D+WA,VA P:Y026O-,$ F4J2H1_^
M8\F>)C%4?0)JF6V6MT_4I)0*$8^'#)+Z-2F8LABB-2<%:\,GSN'7$LYW3]]?
MD;ZO'?W]UG$D4I@&3U'I2@C?0W#/5P?1<XT].@P4.==62@"MJ#S*X5,Y_]MX
MG:9JG0GY9[-9Q?EP.#U^("AFM_ &^4?I@N@<:)ZY1#WZ/**VHA?K \DC!<_J
MHI1"E67"ER9[8+@R)"ZLST0R]&?930KG-^>\=7+'+55YF\T_)QG[=)>2L:]P
M!QW7U,N/B.]<2%)#E18J>93QZ*SJ],G"[;^B?WRU2F("0VV;_[9G>;%+9TDY
M*^<#\14B,;]V$D\^>1-&XUW:A,M!@$7ZV)DK,C4LK$ C3;\A#T_K#NU LKNW
M,KL(9XV[QJJ8KC]S5[4PJRJ<D\OI9F0%"_0TNL>HF4!+'FV(;^9T:T9X2]RH
MX-71R%019?D*\[1@( SKQ"G?! OX[W36*BMZ1@,O,%2/BW\1%V4>3[DRE1.A
M^C3[S9E0J<*8_5S-$@+N)?TSYG2#N2R0(E9ME7<4YU):H\ 4!$K4QX#=FA,A
M:@-(WKY3%N.D$A1*L=Y;89(.7H=%J:(Y(PNDJ-2C>@4J#1;)4SI$E*=4-H>:
M<L5)$9RGZV9;J8^PNX6#(3"5-$(WU6#!*4% JP1@P#4"G!>UT E?JSR&;\/J
M7UR^>QM3@&)>@<(XPYJ?.=?S."U,8JI2ACEB'@3,8PX;G60KSBF<5C%A@ ?5
MBH;'X,I1057D,S@K;$OHOH #A '\.\6J/@S9V>+>^%^R5IU2/0@N;06YGE+&
M'>O:3E'7YTGJ%:N3G>?"T;N8%<+.4C]0GA4&<NA,2.OK13'%0U$O:BPIY$1Y
MYLP6='Y TY:@0RE'=QA_2;6$RLMH\#)3!/8=7;3:Y<D)+,@26?N&NK6M(FYU
M!YD.@V1 A5<M5@<:*9+SX4V\@7X1Z>07O5K)%/.?\=9..G]Q2](C1_8K)34+
MKH0IH5<0R X2);*,PXQ^%?L6)>S]IZ,K?_=,U2G;]\(]NMJ@J#!&%'.G:ME1
MXC;81S+7*&J_PDR-#&B2O'/!0;\JYW]2]W&:WL&-GT<W3UD\?\AI#@I+H_W=
M1";**4LPPW*V[+[)OT+5?&B4=T"E16C3A@PTHAE1+C,QE&U@FYU6"89.IE%"
M60+%+98YPZNKB"N:J'%?/J<?.2^?HN$S24)(HGMQ$\]=3L$ISTA5LE\S2Z+T
M'?T/-^2^*;K>,Q*ZIF6I]$FIAT5GA*D>F+N&\AQT@D4,(H\S=41^HO"-YDI[
MAEID+5"9)_K]6@.;C^8(0IOJ8]0:_'A&>4*9N%_H;)<NE@&3SU4V)\?+/E9G
M8W4GNQ&K>RIS;XH%*E)^N$"0+Y!UDR$VSQF-N%T<)VRRIG/UALVV#2*%/(!U
M!<I3FC0>D9^O6Y5<]R "C.X[K0]0\KK14WHFL][QE$&DPUK_FV<,9FP")/6T
M<@SK0(H:BM+H[+G1&$FRZ60\$6*M&NE=5M9T4!9#H!07A5>V(IF?#Y\AD,#F
M"[IGAPR3C0.PD!?__F_CD_'SFRFJJ_KDGU;7.9!K@0)>I9L5H@_UZ@W<::^J
M'%UMB%@1.KP(5JM52C?QH/FK:_@5"-RB*W$*;Q2B)E:-6(>E?"YMU^C1!L$+
M,Q6RCCV+1)?/;D-1>"!4Y(,T51E;C6'@3,2]C1]@],S@B>%5R.T0:0&L< EU
MRSKJ\WS4- ]@YZPK_- FV2/DE+7N-O$MQMU1"TD(L8=2Y:)Z**5K#&/+V44/
M BX,</(QZ6U6Q7#=B5.C7L\!-@/"7K-&$F.3]3M.&_+.EXN>J-FT0,N!'FP?
MM:<4YW2"O++9+*^4KK!"1Y-4AEE=6*X3;1"WD9;87$W/E9^PQUNP4',:"&>H
MC?4R^AA2K&Q5(NT_S"[>J3/@@%2R\D?>1Q^#UTNB ]Y8O"P)F/.OSHF-G:>O
MW!0,_^=7,N/?G1G#*QHVCS,UJ R V\]HB$E^&]9&+E]0*]'EZJJI<X\Y.1O3
M9U'S+VG^9<MO6GQ,Y))R<,#^_=]&I\/G$Q^R9[X5'Y'OKS4# -'F)N.S<#P^
M#2_.QU0!P+5(^,L(@>WX%RXV3.#]I"GE*-Z&SQ^?&X12>AZO+4MCO?="7#[6
M0[.=?X8L$'0OHB! OPR92Z@C('"&F$L&M8U\.-S75\:;P1=B2=-=(BDN*JZ+
M,361I&(65&\[!W%#:8RD=>B9Q4X3XD=YCAA8MA[8;_&GU86H_IO]F,PE[ KQ
MDXIU0\@TC #AP,VT#630((@Q"2H$I_Y3]"]5LBR^X@7A9B AED0K# Z(E0*U
MS=6[OR;G$QZ;*LI0RU[,\V*(&Q/ZQXH1F:O4+V/HOUA$EAIR[;=?Z]043*ZF
MTQUX,9"BF]KPR#R'8',G=!''MN)YAV6LNV7ZIFKS F^Y=5P@7B^K:C"*/%TX
MD"OH7L21M3-*(G/DCJ*/>Y \!$>"%,LMJ0O8_F<4\AX-!S\.@E\4Z)I F=62
MZ//2,1<O'0^4]ESH;_T,WWJ'F"?+P;/>2U<3^_,.D;)OJ+16O.44,0F-ZF*B
M;*RCQB2MA+BQSS S-) +",-2[S;1[1QA+?*F%J81O'L5+NT.,+=(2J=ZBERR
M5 #BEJ4;15. F#AU%0/+OA&QP0PH;N%RPAK45G. '?&BADN:D[8+^++0CCM1
M=3%\5_I#F(ZH].Z=TNJ\X>0'HC9-7PE0QC\K6"2"B=J*&#0W8(FD</=)!VF/
MD/],*M9;Q,I0W/&X1U-NI])7J'GBY4J6(/[OO2ZR!)5"6=@)K$NDY:V<Y<$Y
M33W#0I0?#7(5U^3[#/BW,.CR.C ]>$=W1")M1.F-JL3/AP&&>-EO1Q8\UW5@
MN1Z(#(R +U=P8R,#56A>SJ**AY^KA8'(L5EY\'VIG\6WY;IPDA&1F*M\IEPK
M #4"+(KN_4F^0=1RX)W16%L9$2@X)7F\ _)@!:+<4)L!N+*Y])H!T-V.":S;
MP+9>P6[8K/YK.!38D=3^#KMG6@1KWX!38AI2?:F#74;27M0%>!=_[0!8=.8(
M[*]NE%7Q^&SG!)1R%V=<IJEU)2?3 NYR1!!NK[)><N+^,BZ,MT]4)SIY<BSA
MOZSV$C/08RT# H2T!DK"%W]Y.YR 4E!; 2@,'U#[(!."JMI-LBD&MN;1$@BP
M\% @D<3OY>[ ?@A9ROX=H+$\56OCYE@HCUCW\1 ;#SG=QT,V[(](0@0_4+=1
MLB"WG\ ) CW]);/PT**;V(;R!]&AR^8&,^82##:$-PE>*"(8E/C2E/B L<%=
M9$(K"'1[AFQ6:<\:H9"W53S?/J*1_7.]DH/I(1OW5CI,57F/WDB_T0/I[ZL\
M3H(Q_VG,.5,%< F6*RXSAJW(4%'*2#K!K1C- ^;T>+$0C9;REQWQBOJ_6I6<
M1*XEM 8_+$K4ES')$)N6D/!8$@"F^ P*#>>D(E2.*&U*Q*0NYL?^\U7).F5A
M?!"<>%CJ6!0+3AQ)P8%S8!Z^F*S]L31D(SHR"94^)^0!@@9@;S&VHB#X>+FF
M33HD3_O34]A')[N4\0NVW[6#Z7/%C5(>-DV>-O&5'&6SJM#Z3T>O%U=!T\&3
M189MP=F,?B9 A5ZJM]CSFI*.$,APT,0Q;#-XMZ60\UVB$-JC"V:O-RB=B"5_
MYB8CGU$>,![MTBY<#IJ+ASL"I'_R.&#(7O#/&]U$S*+GZO9B#W85<UQ0Q7HY
MS1+MQ_OES<^_:@^;=$IR+Z8!&)6"<^3]G2)8N1(()7T/ECGW(I):PD6F?29O
M6K)ANU9Q_?K_$U?-RX\L%@AR!OX</F(5OV9W?.=1OZ71L;.0^D];KZ41:_ET
M-CK>)38"2?HVB4AFN][GW>.@+U8E-3[;I?.[&H@4V N]K82>S<#:1F:AO/H,
MN?3)-#@9[A(-OL#H$0/%7WM)]+M&D%],ADQVJH712_3.)=^[W)_L5*7SJP$5
M-Z<"8HWBZ34Z.+[G ]R]\F9TZUX*2.##Y;M;[L/QKE4XTZ417'%L_5LDX._7
M7W[6[2]_#$5;#UZ?O.P]X:"MLT5VC[5J<#(2Z]()2>C7A__ C#>59/<:T=AZ
M#@LV[LM;[7M\1UEL4M=L< 9,JZI71Z/@X!4BM?Z:#8+)9'(T/CDY/CZC_J.;
M>CH?.ZY^DY^B%@O!>9$D.>\5TRNZT>ZYT!;&"S\%R1.3&[."*'@"9HGC@ ^U
MJ?*EQOY)<C%^L;D8KO+_Q;_W=P;A?X?4\>5']_/H&5;#R\;[XE^D?AD+AK3B
M>-87_\3KE)&&^/T?L^P#+^\=I7E^^>\AJ55)@>'GR]D_JYBOJ^)Y<+E:Y5&,
M)7]?Z?A^U"E1IE?F5UA<ND@D/T%C#(7!+S;/PVV \J4__C:/TUF\2JRR7V^1
MAW]K[H(!>[,=].R,ZUM$DB*/"YDDN6DQGQ#'> %:RCW.&O[@]I.75U]R=S6-
M]?"W:GY#05?]:%P\C%72P[NIL\RI_2+N3L;L<YX/-:7"/!^O!? DQ,RLN. ^
M1)PGL\Q LC/"F(ZS1R1A"DLP?MKK@4W']G^@OGS+KU6G-GY\G1KW6?]0QBH%
MW@$91=F\L/0G*D^C^1P>MN0,@[:74;E4HNZBE%K,$&RC/JT[I7<WFL^Y36(M
M72E;Q;,B# YBSKC0QVK17H!7,3\(4Z 2]3&6GIJ2I%UFLP_F-.&-_RA,6O24
MROP/8AD8^Y.G-_!?:3-9,\CI)C ":I5GI;VK0&O/.*>"AH/Q-,'I8#+NAL%6
MHOQA6.E?4"CGU:RL*&-C"6O [F(XQMVA0X$W6"C!'0C\'J<>7A_G'13! 6T>
M]N;![2NTFNEL@0\\0L-*XAH6/15%8^C8.)D;VPG?>Q.]O#KD$V]6I[LUQP=7
M;P[9H7UP9[<(KX_L"#L*E 2!P^?=HYI0HFTUN!D\)6^%F$U,A.CEZNGZ1&PM
MA4 ]'EP  QRA/DVM&EBYER3''*2:[H)24&M<;+1#64ZA!VN/:H)V^#"F,39+
M;Y8&9'61/#KDF/\&>8IY/T[>K!!$VR<9C$- 8R49$^]D*D#GOG$5F#&A?*V%
M3'5%D&L47=F"H7?R<W,=$VXW8D V,/%IJ6QG]PZP#8K;Y#>1EE1<E%1)HSQF
MJ539N:1 )^X5)F4[4=MV$ -KW&:0%@,U0,.LC)/:W$_@#"YMCE,-5DLC YG;
M$9?%I"-E!IV+*V7.'TM=]_L@1-%O-#]N$68_9,-8ICVCZ99HJUL?&)Q+LF95
MGA-N5L>DI?A,ZL^$;$F@DN5+I&3:SG .&=,IC*^WR#77#SX>DLF.I:%DT;-H
M6Q_ZRJ.K-6I-4I@PFL(BC\RO<]VBVE3.]=$!H M;"M_9H6\ZZBN4S1V_A]^*
M&7B^1NI?1ZQ.MA*KO4AI?ZS>[MIC?9C_YE0[(F;=L5T7 P>V#ACI7))=_:JU
MJ-BFPM-8F$!AK-K\+ZA3V'P4WJ?RX/ $RX!/CP?G0^G,6F@A,CD)SR[&X>GQ
M>2.^3HR#D/<(VI\(BK%4' \'HR$M2=<X,Y2*N2^^_I).A\?A\=EP<#H,&FLZ
M#8?'Q^'9\/03U]1[DF((@PWW4RB;&]M+01>[,,ZIN24OW"-KJ53#'I95>0O:
M_;_XZM>V1DLY,M9K8F\_+" B^ &0DM3.G;.I1Q/ZUG$HO1JD[TI75?OQR5DX
M&9T.QD.L_LVJ&Q;C2%:DLL-C6#&+$!]H[J;!,=#Y)!R=CN6T0]V$EYHBTCT+
M\\<,5JJ^QE+$(^RA]IE$\1U&B<[W514;(3690TC')=4<>8-HFRLV";0&^U&R
M?=#"=;?2@8];V%+6OA2,<N'Z>L60\UGJUN%J]D#KW&W!]<CRTMZ+OXY-0U&%
MU:B^O$+NGJ.Q!^*(H%T0F/!(+5?L>1&O1N$T^B6E%(_&D7WB!L!2-:D$ 0D"
M,_M@6VY8(\R!M7/FXLM*K3=K:]0V&1"1#MHX7X)B\6P6O4FT*N1^PU%!V%%/
M'#0KJL*:$<U=8ZKQEUG;-?@G;QS[?1J;)]\N0)IC_V^5505L#DE5,G9FCT\4
M^.,):W*AZV ] W)T82Z?%LV-3,!*-SIQE)X&\L[GJ3T4<KQ''J4">],34DR.
M[HZ-W^'==+$#=Q,'01@#SNPY@@@>(6(4LM,/^C^>8U%7$JU_B%-:+;WTW!_N
M!.:&X GH/91#H//@G^VT!T.>>IG#_YOK+\O/ _KI+^6\^=OY9# 933I_!AVI
M\[=-PXXF@^/AZ2<-N_FW\_/MWOP+;01O!NPW'N!_/IL\,T<2S3[<Y%CM="3D
MNZ#_TYUT?ABO/@8@6 +ZW\%P['>SQ3X[C6/)5KVQHE&X&:J5K3*[<+K]+@QQ
M#SYY2V<SI?J[I9OU/,? =>1[W7_ZB;O<MC&T(8'LD;LQ=!/W9V?&([+ AZ=C
M;^G?&+\]@).ZP.H'P;]HO>PMG8S'HFL0["*61GE6+LSH,?X+K80<(& +=Z1>
M, SAH<'B@.FB[UPKE]S:I*;AC,XUZ!_8&2;GU=,[OX3\^ 3*YHOMB4YV='X<
MGDQ&GT?9WZ38J]//=RGXQN/S\.1B\BT+OD<K&N/A7M'X^HK&)^[RGM_ZSF]?
M4-$8,J'T3-&XV"L:+2<[.1L#95]\UXH&D::@'\-2$B4I!5GVP703*VTB[R=1
M<2:8:>>:-Y@6.UVW,;#8'-M\)6M+\1O=>OX'GDA*/RDMGX0G(*>'YY])S3LL
MIU]_CJ!EI R,#!3!6WAQ&067/R%=O9F5&0K2<8UX.P5IV$V^':1;_\3W*(I'
MX=GD(AQ-AM^U,-[*ZOL>M=#S\/ST/#P>/<HIT%,J>+QQ-]KBP/<VW)8VW#:;
MN>>>WG+/%S?51OTRU;;0,!XA#79-#1B?G8<GYWO7;U.(<8;?9/B]RC!0#H]/
MPXN+,3?Y^=8EF3%F"(JORH/?KH/7;]]\NOGMXN]^'?O;^<)C)53?Q=)$]VS:
M"Z8'K9/O3S9-QEHV?0-2Z?'6R;CSP)N+]:R31SRZ9[6F(=.][WM&VP%&^^*&
MS+AGALSHBQLR?5<36#4='9^$ITY?C+W\TO++K6'[<M*K[U0!4FO,%8#?NM3J
MB,!0,7U.T!,F7Y\KQ+)[Z2_\2P8BABH[WD9YF5+!]>MT-MC>PKFL;K YYOA8
MR\*O8./4OM%)P2>MISC<#1?,)#QA6Z?%T+:YWFWD.=Q^87NA:!T[CR:JK39F
M5ZC-E$=O)+='T<*>#K^$';^GQ-Y18D\)[O$N@\G>9? D+H/N?=_S])ZGOXYW
M0@-@],P[,?YT[\1.J_?CDW$X/-G,#WNEZFMX/+X[X6M0@IY8^/Z%2KKWQ?O/
M_@N.80>*]Y^D<0#!4_P5;B\$ZT;P7MO$5KNUBC[#:]@V\X^$UU!WA)*HX5((
MFX6 ;1953NBX%K>%(0@)YXF!,>8;<,C2>2CP/-A:/-D>RX->H[M^AE LGX?L
M\1@0;1$X1WBY4/L*%C8QZ ]I^</15VEH4>?;=I.)4,-/C03]XTFKMC?'@Q/<
MBS?- FN&.?-) 3'E+(#R=$T:W>@\/#Z9H%K7A3TF9<"/5A$)\ZE0MHO=G&%Z
M-+4]H/:Q:GF//3)9OWR8]GQ<5+T5CZT%#PDMVK3Z@[EGW(),T_8#$*7!K4KF
M;CW!*3?=PWE&!,\*6^<NV[C"->H1#%BML!2"T.'8"]QY//SDL<Z,<=%OMSVM
M@SI:'$SE4,[P30U[SX>7IN,AC%>$D[+PLS@EL0@,Y*UWNGMY\ ?) ZF#W%H>
M3,["\<G%X**;X*1:;_?D@6S%8TLV]_)@+P]V7QXX99E;RX*3DW%X/CS?) Q,
MN>/GB@.B'%\4=,:,OQ _<BKW^$+2_1UV3#?$JUN9\N3T)+PX/WV *3$?Y2(\
M/_W"3-D&02NK&C/PIGLVN,^K))IIQ'#L!A&7E<B>.+U3!8-,;EV+K#N%:2A%
M& :WO(Q@5+3B6I 4$2?ZHP 9^]CQ>_FRD_*E7CN[O?UQ-@DO1I/!AAO-U*1^
M!1G3K6[L+WU[Z;?)$-G']H)M"D>DJ?3-X6_#UJU,OPQLL5&N#2KM3:X8FI<[
M?^#V<%.?&:)#3C7[$S[PG4JR51@ )5>+"#OJL)O$*H! S::+ XPWKT HS."1
M&.&!J6W!7Z2M".RYVLN<794Y]0+"K67.^"P\/SG?Y/.0^K==M7%&CZUUW-LX
M3VKC?(<!D-%N!$#V@OF3C$VG!G$KJ?R5NRUNI$6Z$<[#T^/1P$)Z/$74J-OC
M9@3=SAK9NA3E<XSL,SRELY,';H6S<'Q^&IZ=_!%&MB04Z%UN/2?9[@=-Y"TM
M9&Y11Z,E:S+$;]T/7X*"$(.R"U<\W0JH%' 3YP"WM!2K7[2#10[WV'V6?]"G
M*J7-NH\O-KD1"O@U*N;1/X.?DFP*D[]6DJC_2Y1_4"5W8=W6M?"]*MRG*" ?
M%.PM"@"V$SZ:#%K0[Y%)<8#^W08G@[-)NYX^WMXW<!R>G)Y@YZM.UP#7>.VJ
MGCY^;"G?7D_?QR*V5+'[)A!$/7QM*VU(%-P;A<04/!'_P 'JEC(E)J\(:0A=
M()OP[^R<<O4;)I6BFNIT&?0DM=:V46D;7*A>%1R^&,_CB-./G)M0=P!LR=^)
MDJ1S^C0G8CML=54KOZM_ =>RJG+JU2J_,6D:KD)!202\2E0:%[<D2U=91@I%
M?7BYEM'[A=V1M+!95.0UPV&BN,!_IW-*]YDEU=QD$_ON.^K!5Q[!ZT=+OO.+
M"-ENE6<WH$70)F]0/N#FCZ8)S)>E)(6C*#[1;U[;XLH>C7?SRJ9Y/W1E^UT3
MMW&MG83CX<G@?(-KC1.?=^[*UEOQV/SV_97=KRN[#_57U)#XTMF&2]O1M \K
MV;(GZP-MN/O;:K7??5;[<M#[]IY?>8/W[3V_L?:>WV$<9[P;<9PGXO W#:UY
M&:V12]OL2+Q)/(4Z"@YL"U22ES;IJG Y[QF:$J/QUS8E.A6<]L5O6<7S%.?R
M+$1)%<^K*#E\4&D834[#\<7I8+)M?_91.#D=AQ>GDV9)C:M I(J%[B<J$*$W
M&Q:$*.; 'N;_=B>HO\\I. 4^UR(!,2=&P=-@T:<E3PZ>2+*UXKP9L%&08@M=
M.-1R>47H\4B2@-T4SO.HQ47SN[A DJ 7X8J^?M2T8!$P\M1XC.)4C 3VC)";
M C0+&(3.@B^R>,67P2H!>M')/ZL,2!BID;=?Q@.6ZUI5VOZUFC7C*+^[H-X%
M:/Y;3;TIJ/8"J9<":3P^#8?G9P_8\.-P?#H,S\^&KB4./SVN'XOS"?41/20%
M,QAP1$2;:?]*>OP=L#M1%"B85)NHF1ND6I2C7,'70<>*4<$4!E]P/IYVVJZT
M>T2FZH@CSS-";\7 J\3I**(2X?\6!^8T(R<G2&I'X)A)T6 9U5D6EC3@;V2:
M8)HAAFRGH'%%3.S #14]0#%2%H=8/KU"5Q(0$"86-D5 //_/9_'I$+3SX^ED
M.#J9')_,SJ<7P^AB&AV/+HZC$W4Q^K_1\?FSK3RB\A=T-GZ52,.#U;J<0#$(
M?@$BS=$\O)+M>I3YY:[C],GD8> (1&T+Z=-WS2J5%.K^EC(IT.8!6^HR39$\
MWJE5EI=AK74]RM2B6L(28[XDB*^6>L/T%\A88>5 T3L14?7:\$9YGP7H;D27
M.VB.<RV"V2A>M,RD_U<0N9+ND=E@,9<Z";CWTWXM*4X<D87S(A.,%!(X18RU
MN.NRR<TDA_XV> O\DN4W\)QS"_W\\U487/_]Q^!G!9-*/^ ?2.VXRNY5*O]%
M4:*0GZ5Z;""% D8F^])$D\S7*5V$/BIFN2;KRQ?7<%V#%$42I@KP-";OSJH"
M$3>#@18XB9M!\+MB/Q<M0HSWN5JF\6+=^!8\%&'*ATF^3N)H&B>T/C>ZY/Q9
MTF)P)&<O+F? 1>3TR:QKB'QMJVB]I#+YQK=%7<DQL3SGF2ZC#\2C>O%XH: =
M[WR__RQR35&VW>$-76MFHA]U]J"S]A?%-(K$[S,$7?AH3-3,J&"!^ KD$L8!
M\7^CDNAX'H.45B3!F;)@ RC,-GP>L=^'@Y?TM]'S$"_PR_>_A#J,J4TOHWC!
ME5X4-M0Y R8HK(KUI]%P.!@&L(T)JOSD!:VOC2L:=#!6QYI 72.C)%J3>PW&
M:BZ?>)P_'=W 4"'=!?P'U#AJFV)9"59DXK+&9N(93P;#/VLY45^ENS[2:FH?
M(('A,*R_T/;5(_NB4 AF%>C>2QS-E5H9FV1:"XNM$#,J'5E>+'+B660*2%R7
M,>]QP0J=E3-DG9F9>**KA=:^H/ BL8F3;/D,1PUNQ;:EL,5-3$Y.E&0EB'K0
M4,GI#1L.8@M6;:.4M=T-B?S)GXZGV'8HY"SCO 7&0#K7 =U[D>SDNHCFBHZ<
MB:O[C'LO?EZA1CXWL= X!999,M5D?-4U-"\XWE5"[NA"*2TM7I=J&1P/@B/0
M"KTAG'2-4*2(]\XIOO/">J6O58I8:[]$*? P$2(2QDOM53%CX%_=<<X&/^)(
M[]!Y# 3PEG3!]XZYK5_<5O7;TO0X&>V2Z?%B$+P4.Y--CRS9@3O]/5D/$:4B
M!-?W<!<$-QD8SBG2!P5![H%RY@JN,C9"04Q7B8A+ND9 @(+T0S4)O5)HC:?*
M(6T0"Y5$1-1'I >RB9?\7PNG0ZH1:\C\&%:-;U)CN3.'P(Z&;&G#=R57 >[W
M"%1$B<;OPR$V'#+9AT,V[$^N,%ZLW50Z>.OX7JQ^GP%OI$?D$U/BGL$_S( B
M_J52NM" <\I_J3PA!>(V"] M1"*^IKBTN2*VE8;'NR0-7X(.%GUD]_.G1[\[
M>QH_'50QR\A7:H[")Q1P,08WP\MX6>$_7J=$4!7])^C8"C=#'N$4(^7\L)O;
MT\Y6OP)CO!-.X9"*>$A[O<C-KGKMXEVPL\(8#5JQUUYLX/O(Y/3)%L"=Z,H&
M\J !*4AB;<&^!7@3[M@JUWXTN)?4';JG2V$A\K:%5DE6Z4UT(U$G#'S,R=,\
MK0J8/%#G#$R86.?YL=,\H@R9*,4YF018T@'AQ47\$9ZF<AE<I1D'[KPJDAX8
MFU81'*!A1PX-SRD>4;HQW.0IW2V8-Z=R\8A(-DXGO1RB_0NCXG*GY([_AWB-
M4#]@+EQH+IRY7#C37!@SA^%,82>LB,>'M-=_%F'>,GJ=CCZ 3896NTW_H:*Q
M34=^8+46YP9!@^V?%9;XBT'(IBQ]MLQF'^RSA\'! _OSPCP:UN;&J9S5"HU0
M$RF#ERL.-!RTA9#Z*#!4FMZ#G9O_^[^-3\;/9Q_^%=TF%:A\Z5,M8.-T#RDN
MC.$KR?)%NLCOM"-(GX.71;8S9_&.UX+5D$7PW[P4(,XDZO%II)[/R=8A(M^2
ML:"/A'PJ<%P$RF%RH-'+8'4^X#"MZ1MQ?P"F.(C>[%Z!610&SW;D+#T])?@]
M+F]1L.+N.!I'KP[SF>"L<(1J+6JU%?/D#]6+$*%NQ>.N:IF=G,A7XML\OD-M
M\=M0I?@\'>5(J\F%M9J $>.<62]"1S"O/RH*57Z.HK%Q1P]I!#=@PQ>[<_^&
M@6XOL+^&GYZ0]M=PST[#*1#LN(HY;A!3C5*1U?3S7)55SM$43E(PVOXG:/IH
M(*2*K2>,:,FO.GNA:5UQ.KCK@_14;\OZG-VX9_\>$-R>_?MS&H/@JJ9D%U5"
MMC)'QS?IV=:OHGTGG\[\H0['8N:?2M:AK>7("O13Z$_ LT=S9E(4$"@9-NH'
M@^!:J9U1_5_ =A1E/"-_I%22MNF/O2*B%NV?4LVTC,9Z\I*#EJL5[(/)5>A4
M*4/VJRW(NV/N!\?SAAG&"2B6'-<&/?'9*L\6BM(AJ)S(1,OG8#4B&3S[IHR,
M;>FDEVO=C*-EO.R2LZ&]\9[5H!VVVSIK1;H\//0VKF#'\^OV-@E;C:"(@Z4/
M^'KK']#UY)'.B-YF4S9.^8MXD\,6+WAC;VKF&-;(WZ2(INIH97M-[.DY;:^)
M]>LT,!\[OF-YT&V-L23S=#8LY64EZ?$N4F/:R3V+8'*<8/20S?49%I\17U09
MH46;IPP65OYQ3F[89AZJ*$]A<[CT@WQ+M4D*KD^T;%='J#X:=1*NX:+IFVP!
MX\"J^;J^J%["NA/61K$^';:"6/:0P6),D($=C*->LA,<$EY">(RXTT D%%%(
M,!(@\5?$$>0TD3BUK-6HWCDPWA%]S[HN2EV\42AI8D#NAP>T,["Z'GK$Z"&6
M/X#45M':R5)727QCC""#80#\&JO%S@CJ'U6I8E@(W)-%-/U7==-+<B*XGGV&
MFLU0.][)#+4GIR.GB.2%E]2P5XB?_G#V"G&_3B-^*#+!H&8,YK+TK6W61(T!
MR]5GJ5.L(O"#IF Y*@-,WR\9J\$6X_3:D_))"9#M>8_:=_H[:$OEK4UZ%*+?
MYSKV8)&?MJ1N[WR[?:;-GGNF!(K,V5P<^.>N,L4GY&O0SGR[SM;/7[NQ4UPC
MN>D"I)J1=L]HC=S8ZP#/U20X9Y&T>P;('1MS@>)G$'G3OR"_'OC195S!8<-'
M^^!.2=4JJ/!42.B53M8^2-AM239KR>#]3-.QU6'3OD4.QY,_2:9H_KS%<@R(
MJ+L>_JQ=3Q\*K3ZGDJ K0Z^W]3/6\C#%Q+I- U!)89R'&WR0;53TJB/7KU5#
M?CIY_W?TW<QN4W0X%*6J5/Z4B#V'!$T:Y *_,3GYL]Y^KJ:VD#UN7@N[-?6A
MQ84G;?7^<^GMQC1,$^/7 Y,$H/JJ(#8X#_[QHF9X.0>C'2U6J1)Z\=G6ZZX8
MJ;MGB^Z.R?D'\MP#^2IU1NG')?4@"NR#.=>1972M+^4*<?LEV8XPOBCS=F-2
MC495B1[21<*V*+F-') VY\"."T!WA6'D.<)_L.+HE]/@:.AQ!_Y 3[T336I)
M2BST'RG((H'H6GD.#AB713,"!F_K !//U&2O[  ]7';69YGP 8,=RTEJ9&;>
M?WWA;)W%KYTU,[RN. ?(.20)J<U4,S$#L9U]X*-@&B-: 7Z00G46O"JZR^*Y
MJ?O-*LHCTF$]1G]Q<D TWK,AK\)@]\BX* :6JAP$UXVT].*6P#5AFZ+[B!$Y
M->)O-H.KC/!CT"Q.HGBI]T.&G:I4+6)*>9<I$+B,N:/QO6R*\" ,N\];?A@L
M\?CPD_,8D9,H"$O"7O:4<(SH/P<!(E2HC]%RE:#]T\A@B9V\*CG*WP;7 [.3
M9OOEQ\:63U5YCW#)YDT"(G%V%\&?W?A35*,<7W&I4TY,^ !HU\D#(U!\Y-.H
M"X4:\&;>*!GX <RQP^"?P/ 89.53,#NN,4?BPIPQ3,D^#,3&SY*DPE8M>5VW
M*I[#!^ +^+50P#NQK8N%1,7LQ 3GSC"M%@KG+N-&:U0IZ#=EH4%AU'FF.%&'
MY[1F";A2*0'Y%+-;I855"=]B,82@-C=^4+[6W:5^? P$<A#?.1]$-L >QL:B
M?D1&$&IT]10K@S3G6051R?H(2TGB*]@C0RE$2D5-%J%<77\%(F(MV<DYE,$I
M,%S09BZU,%S$B>XWMXW*ZR#S4=K&RDQR[FK27O[$W&C " [$.$2V/ U!/.@0
MF:H<6&>33TD@E=0KQ(=/G8%:!5=XSK_%K<CV]^1Q63]P>7V'@<R3G0QD]L7U
M<5W"%83\H7;8"WH)-K0DB>B$*"E\88!.T$BB] .CM#;20SB/IYD%B;\LXM1!
MW6K?.($IG'';!=*-ETH:A^7D.!,$3S'&':QDRC<*72-&HXZICX1]C2J/N4<Y
M:>GAJ31L(F>QJ%0CQ!")7^JIXCO]C!^#8>*& Y3(F=8,4U1(1'Z2:6NRMG"W
M^Z%3/Y(;7N-YI9'@A%U6"$Z'YI"!DX+%N]!?< "XT;_ -?DY@8,_$(;Q5SAO
MNHBX<]7H./2T@ )$N.*+[A<L'-%Z"*H]BCS#E]Q, RC809SC&RHN;%<K 4 /
M3C6]O'EY]>(O5R 69C%UI7M9Y=D*F-&YA^^HN!3^038!%8^D!MHO9FZB)E"(
M0)\6U*V.$#]CNOICU)Z7&D)0VAC+ 2KG !WX-\&P OGP\LUKUB\T&UUB6@?S
MU^=1A?<-YDG/0(+W9M3 QO04HX,YX^GHEW#].$@"S$EMF&,+D-U<N/D<[N4<
M@>MK48?>DZI9.Q*5XO:#99Z!RM4$0=&:KU6;#< CF:Q+EY+M3Z)/VD<QJ\"+
M/H5(A%1];%)P>>>Q&P*<%0*0*U1 9S':D< 4(0%])['M!L!&9@QDOTJXZ0+B
M-T8),-!!/% #:6SDD(^FU3DILUF:D$9+C6ZHB+J@^!G,$A31-8II):8I&;!Y
MS-#M9)4SX E>A(><WSL'71EE^CPJ(_RYY#S'_M/#CUJPT 73<:*TQE8JT-J[
M815"[8SNZY!AOC34)U'P?OFHP: -P"E3]RN)9?IA1=W%@I):L'\'UWJ04PI$
M#*6&E]3#0K!+02+$'% +J:=$)>0[Y[Z9!IP?]'Y&D.XJE$$R90N:Q9V-Y+KE
M)'"&+W^37ASL)1.,_$@;7?3'7I#&IRFUT0PQ63VA^+I55)(9^TJ #B]YZTF$
M7UEF!AF\NRJQ2R+HH;-B+4I92?6@)FO@Y&:+\+;2FZHZKIY7E^^O+FNB56YK
M)T!IZ%NG?-'X7(]>&-\?^BH-ESE]X]DW@;#.25;8'F4\1U1E14=!'5?%I.*;
MA:#>ZKC19"*!^"^X*?!21>Q=Y-X-XF#@>8G.7<PR[E+7J< ,/)W 1= BG5]R
MSHV*0OB9,CC8VTK<HC)=+3V*4D76V6]O"KHE'C6]QH5&_H6:$]:>X$,.Q$'P
MQC8C/=>J9=,ZT1I@M$)+!C= NH:PVS%5-UD9"ZBI3WSH:,'5&C>)])ED)]X1
M B1K+.@C5D.Q2RFC@4?ZO]D"]/PX[M5+F?_IUI%2H_BF9$JYJ-[^E;Z!0/MA
M)VT4IZ:/!\M)V0X'3O$*B12K,V;BP*4'__J9Z51_I*II/7 H52K&8=?=/?@\
ME]XNZ!B*$Z2:N;O 7C8D53YZ\DT7M_%*IX>[I5N(8T<N5RT(-=#A@>-WF"J8
MX:%T;G1FZ10\>>^2K*7$ 9VB9;JG"H*/P>TE]SP(7[CS21ZS;T$7U!RZ@@5%
MH_0COI9&.J/Q>.3=I&(O(>PT6'#8GSV;DS :79R?<NB-N_D:TP@?:*[,M2?U
M4R%_XKWN:?[. 4&&18!B>,-92<CH%#[0"K8YI[:02$J:US7>:T5=M)E9OJ<7
M0]&D?;D*?_H'Z'YR4\'Z5[G26/:LY2VX(SQYA0+%0,FR,!)_TLZ,!D_(1&;A
M4DO.T?V3@'Z*>*I;4<+'\BSB%IL\=G,[3>@@FL]SLB'X,S::] !-$T69EAJZ
MC##3B/0SG_X(+1\C8/P)A)NQ/41G<3ZKEGP3%=*&TWO;6;$83$ZA'X>%NN8,
M:GUP0&8"TKRXT-KU"-39@8S$WR =FL)@FF<?5(Y8ZL.+YU+9QR8$%GWSVOR&
M4 )4+/I+#14;<]-E"USG6Z:3UHW$;%F,+4:$?\F,V!W( 5^:KQ-=HH9VH<8&
M]PKC]G$")TYP^KW'"3;NC\,+6(-,<42JG#6T5.95@3:OX2_0=13RM4;B-ED"
MI=$N/2D;6FU?X\TU01:D]P&*V?D\4?7>"K:SG.='KSU5K%/X.CKLA/O6IDM"
M3K+Z)J]QBC\W4\CM)SSC'L%*N=^=AB@/?1G =2IZ(@M0?<6)R,KKS,Z$Y >%
M"HTXGH-.@EC#WHB@1P0V;&U#V'Q'202XM$U0*)PMK2_]L#9WWX;?3,V,5D-"
MDVIL>PN G50M2:38*FU4K#&%HTMXA<'UD3M22"<K>I 'V:M%&05E;'Q<HOY<
M>NV]NXW(/'0*@%>@\XCTU+MDQ2>;5GCXF<AVO#PVOI+E3?(U6EQ+G\$6O)#P
M4Y [LJI$IFIC)Z=M0^?(OK>H19DDH8_G@/:DOI.;>RQ*4E.CP 9!3,KXD#LI
M#=Q&S;;%R\7I ]KUA GEB4#ZR\8;@\G30Z2_HC<WEE!A<!,O: .C1'SVP("H
MJ6'GS/I 1K$S&@::9NP0H%2 RO:]T<KN\<GH8&I0]DAO[;V!<UFP]U@7M]OS
M9MT88Y1:1CE*F)9-[ V)6C-MB-Y)0,1%N*4B<S Z9+>3R?23%*=(7Q_N[=%Q
M>1R,#RG5T$B7X !3J)!!UZ[4\)_93FS,Y'74Z[ C'T%PQ#0KVP1).X];YD8]
MD[2+C#5_(31.K&;_\16H2LLI9DT>3&A#5&'=:I+EN+"1-4<A[EH!!F[S>2(9
M-.@Q+D FS8BY#HX/20C!K1T<?#QL-  46P,STO+2-?A\TPA/2>"^3(O751X3
M3EA1@=CACEL!195Q!I&?9T,2V>G&[(^N1:IIAQ698*-N^I<EVFRA]553M"$H
MTW$./%SH?M$'ZT-] V-B&RQ2Z2YE3@*1;TIZ_70R=M0Y=#37N;&\B=N04O]%
MP^N%)"1H[X1S*2-),C_YM[*_+>[+V[$77I:%*!I;VYZN/X6$A]%$G0P/=HS.
MU4KRBDF1I,(%DO) 9!5?7&0IQ[JS'%WW[4O5<2/'=)4%#P+,,]GPJJ2<XBJJ
MI"1R1>6-[ACN>"X,JQV:6^V##[D7\PQQ;'T.IE4></XM)6AO=#U1JD;OR?3]
MK7*U%'*%H1NK6KI!A7H/06DS:'-V))+FN+4I%SBOE!RT#.2V=.Y^E9("UZ(R
MS;V@";OG.12L\Q!;.L6S08'7;P'DY#I S-U*8UE7@B.4MF$V9%&38HD+JS5O
M-#NF=-V]\"4G/=%TX5TT-=*,X*DT.I53<"!I^+I$*/62+6@1E"']</NEGKF]
MWV*P!"XB'1A\;66.+M5R'=\]6D]G@V(AI+"F%EDMI].^,.==$_Z\1;I)G".6
M9[HO,9S]VU>OK[;3#CEM.%V;DE,O!Q;FO2A%_Q)!J.68:="991^.M+W&"GQ=
MU9'/$O^R)]S1)F+,U2,33P*'I*UJ,(DSSG_#A[F>3\8"M4CT9[TC_$/H>!I0
M8T7^8,0J.^;)T(RI$PGFBOMW2BH5)I?G)59M<K0NM.V_W5VB?&U>$$FR%:?+
M!/Z4^)I2UM'/"2J93F;&$F[OA4'PUA^ 7X(EZZQU*YX$JQ\%R#+#*(&X-;CF
M9FX!(\E%#J02!GFV!EM-7$WD0<&#822\!F:Q*UE,R(*]K=3K.D=]E#I"^RNX
M;-F6Q^Y#<YG4L@@(!6OBX@6/!&QQG^4?4.#J< M>]%%<Z"91M6[:H7B!Z1RM
M>SATG!?NH:+[O?U@!\%/-IX3IX:(J(OLK>*1ZK:U*P7( F-6I=P@K-5";U4I
MM<-:LVCE'RX(<T?3>>LQ.:V*[MH+PPE1, ;^TJ01',"-1+ZI0TI^BSZH5$J*
MV$3O5EN^0W_VV=Z?O2GQM<J-^J^IW#,6Q$0 8L>L4L%-J(=H'<*W#X?>D_B;
MYT_5L5:YOR1ZY@AXO+-@E]C$0"6,X @I_4-"QQ(E C-[9GA0Y[.+<R")/ZC$
M&,DQQEPQ5R<!68;I?H>F9).[UU&:G)I%5:%$N=7]HF6U6EZ0,Z[$KM!TN?"^
MM5_1N*V+"+^7U,:3/M+8B)A:Q.H;7'%A$,W+O\AJTW-L'HSM^<Z0.] I)3W4
M#;I2*^L9?#4SS=9ITF@T<+S/&E]X3K0R)I%>J::;LB%)WR8B2Z-D[:3QM%&@
M3[5;D+A61NXQFQ#,F#NIFKQ'6!.?&AJJ"*=I.T5/U%]\C-:--.]Z/-D9"CNB
M/'"Z^1Y%:$V%Z6GIC&_X2I1BO-(*E6!K9G2EDV,]R%9P?^L8@J/"UD=J8\E!
M\*K*<3O1T1:R*Q)GBO(GS9P)&K/W];MK%HIDRO)'\4N<+<A^O;SE<2Z]GV'I
M'A:<KS%'(4D4Z6GPNJ:Q :56&H/R@7TK-FR<ICF= H8!DXK(VMV '?!KO%[4
MB3QMBE9I1ZH]M)Z7 !2KNB=-?IKI@N<DCDQ1[YPKISG4(4$<HV_!J>4WJG!\
MW&+3T,RD--,%MI2D.FWCD#@B<\E_BMA2%A'Y2Y/( 1A3RM9*CL:VRLA82]S'
MWH?5I('%/P,FGT+]'42.+BBUA(!&:(@J>G&;H2'5V"U<PNCLN766"":V)C3C
M%.&X YP0^4(<WP?9:6BFA(Z1TH+478O3)6J.R3RU6[TN!=U+?:II90 &NCZH
M!TXHU++/)-![#\&':#GWFF0<]004$H%ZTCZDUE=!Z8\P&8FKR;;?7*X4HV1A
MK@WV<*5<'O?HQJF<:"N2=2<X@P$*'7^AN5(QO3ZX0^/'HX% R>)D)'QZ$>=%
MV>Z)J+&M<8Y$']DU8KQ=<J%BS-SZ(=O6U+T+)J!J";K^01;(MR!9D)%9NB'X
M \=L3+K9(G,!-@H7KYWO,@\5(_3]=H[U3RJ;P6?7LY+$N+0N44+'<O;=UR1I
M3'=W9 ),&M!K VEER0!16W9/G.M[^2$Y[H9$8(0E!ICLIM78W_/ T6>F:YOM
MJ7+^*G=GE/(?H1IO!O4+@^=@Q5"54B01Q8^*V*VR5$I[V@G[@L]MD375FOK@
M2[#>"YL),T=/^9SDI;X]*$C7INOH&0V"UPOV.YE'8[X#FI>?)B'Y#B81*D3"
MT7&BN)3E1AK&<!'%>0U$-I4X+YS%/#)MD.C?G3)!0U,XI\.!HOI]0:XM%L5V
M+VIL76TOW[40LZYYJ36PGV0!TR:7\6+@,@"!SK&1ARFY>S!":B,$%L6AMJBP
M[>@W27__6T ^N9,2ZVKP7^(0S&#NAFM2ZM8([/Q,]89A/XFB4*H:'9'E&?0E
M<\,"BMJP5<53V5TQMJU::L49$V;);V,!AF3$=;@AE?7!KXURR&T]>"9R\4=
MZ/<F0[>,%4N@PY!9RIV+%:,M$0S0GT41\]R=0N&. ]+OJJFIL&T.'GKI(_D8
MB;^&'+]^X$OP!G&A<977XKO;S)@<V.4MA4P:^\=*(?>BHCQ([2C'JT4&QB"
M/^_,[RPX"%Y&M7'Q8#$,SN+9C9([$?*B%B*O!7W,EG*@1PSC&FVY49W=X[VP
MQEJN)'*\$[AGGT%F1HWW#!J^*A=-FM"W.3!'/-=W.EZ>FK0R^0^^4!M7_-YQ
M;QWWYWO'_8;](0NDTG;B9=!-9)Y6&-U%<:*MC)K+)!5P*H=L=?0-@;X&FEK?
MZ'1>+<SK3^(%DF"4DS&LT7._I! TL)8M6OHU*N;1/X.?DFR*X"PTR^ 7GK)N
MN<699QC?I2QAK#BR^> 4RN,<5E@9Z#8V"3FUL;/1">I'1L47?$8!DI+X,6G0
MT;9[:,S&N@BJW:@8F//B<F&; 6S,1D^'<*N/_BH0DZ@J^#A@+;KYPFD8(=:O
M>'D;9FFK3^(_\/;Y1T4'Y:F_#G[-^S:C@I21]B5'J5TUZ>&M:ZXOD),D-T[%
MK*#53O&77W=R<\=LG<Y-#S+"MSQK)\)*#U;1J;LXJPH;YR:_A<X>N%.YOTP"
M3<*HN=:WN>>P_L 6U+:E9>(QH]TRPA@EKB+P9)/D0$?@7&B?.C=CO9&*M963
MSVW'UYG,TN5"<K33&@]Y1IXU(+>9D''MF>PQ\FVY'Z%1#QI$HC'T-^P5)VML
MI)M#;1K"Y\D0<\I1\</]5\RVNWN,>L8@B+";)@%NLP$EQ$"OBE.GDDQ"N5:L
M&Z_N(:%\<V-O=E.;;X8RFN.&F=/)=^O2)AI(*#620499-3-R#FEG)T=F:L&?
MJ*9/-IQ<GZS;MFU.J]GSR 7@WN#8A*CDI>S69-8V9.+&%?I/^N]ONXJ!6:PP
MQ<1UKX'\B!=F$P17C$:IL(?'IAEF,BWJY@Y%FD610[/#6!W6R<.[BBWN*RG6
M_I^7K\+:9GO>\RW\H*:8BT-D;2(;"]T)CZ-.SI*HQ382S,53JSS8X*9&Q/F)
ME%UF+UU$R.TB-[#$*?KBYVCA_,PC1L2;RKV6RP4S%.-'?P<6AY>#W\#6D>WX
MA[!6F*+C6YP[KZ>D35!R$.%M&R&X+1;H&R[7#:M;=NW6:$&4B@_[[/=M-2=6
M)[#68ZK+D$J*>GRCF3 /IVOX58/Z(]'8/0;"P6ZQ<6DD3:ZZ;LFN79?#L>+/
MGZ?QS4RMUN=BC?!H]=QR$O7:K6M<+DT/,,;^4NT,0^"P1 M4G?:J5] Q/^,*
MFZO6C]$'UOH+SCEKX\DM+Z-U;K]G+6>-M4"<([+YN/4&A#;2VZ)/BFO.MRU%
M/^S4"JU.3_N"$I7 ")3',?IS*&%,T#YL2D=-O.A9!8)R%Q5:">:ZC#1J)_J_
MV3-(.:DZ]X#%8UW<6:7$)KLVI&8T9VM,Z[T<26T.Z.0.]?_F\R$I_((>ML<Z
MG)5P,O@_[HDXS;F[@#!::-:4V/+EER(H8$QE+74JUCI%&TN@6,1<YV8(QH6>
MD4F3'*V/RO9",]C>R$:Q1>1=03E7M4.?[AQK^#U'KI3Z&+5 PBJ-%)<HE2QP
M MGXX)3:KZJ<@*+T.K13IRV1JJMFNVLSW5U'T5K_%NF3<LTWYDSFJL@0([*9
MY[LEVFZHB:_)_\%KI-*GM=U'+V!,\3)?6-7D&L:_=;A!5W:X>%JD0E;BHZEK
M6"3B611;9/JCZ?K(!:KG"XBR(#DE#N[E[(.+I,:9&CY:W.MWUWCB/N)]BP*!
M%UM9@IK"T27:#87W&N;,[;W?UOM]L?=^;]B?5PAK?'XZ'M6Q15U>,(C@HA))
M:##E%CKV.=,()V2GN"@-W"FANZ2<&^^DI._ LYJ@5R863]C+AF&(0WYGF_HO
MF,PJ@E;G>-9G#Q(71#O:(=PPHB8K1:K[++XP>D0S%:;-TX+ 6QS>U&FPI$W6
M4V#O)?]BG@5%1J)EPY-DIK!2I5)7JV^S.VSVXZ/2XCR/";VIV]E(&4&5UDSC
M%D6P\\KK_X7R2.T+UF82%VW%4ZH)M5"B35B%S'A%;;PHXMY'189YF&)4^N C
MDICJX(L88#)GQ"UTO3[O_V@,^V]C]@S,X,$1QA:3[]"F:N@2T"QWLF(PP=?$
MC-S6ABA[R,1L2BL1//!?>&4:0:AKNJDO3T70F_:=R%$1#:K#"X4G0"6ICE[&
MFL,"3IVRQF4J]4_A64K$0)8;>Q43*Y5R[:))?"*_>>&D)U!.'#=1(.0;%]K4
M8<H.^=LG'FT428].Q#?8>7F0,N\B-[#?%6U*T/G7HA=]'/C0?P1X6.89RKT
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M4*YIO'[!<^SX>#\X8FM<8('MH<74]X?.LL(J6\&]<4[([+56Z<7O7)"^  2
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MB/)(VS(O0(5)J2OV-PJ%L^T![U3+13[@XT'P"]BS.=HROV1STZ/:V#J,1N6
MW9G.!W3VO['=\%;Z?'_JZ3\M5%J- G9N"3_N_A*N=G\)+W9_"2\'#8;NO1$#
M5NG?*K#TQ\/QB(#)=8\C[/Z(YAX,RYD)V+K^Y@;[@W%$=((-SZGI.9D?IJT$
M/FY_:Q37HT9IAKV/#+0S=D.Q(1,5N9TJ: 8P27^P$+W.[B2IUP2.\:?Q:#"V
MV7*4%6RF?I-G!.;*)T0K0V#8C_$2?DW6P9].)X/SP#1D>$]0V*7[%7D31'R%
MT1TT",2-A[^3.7Z?<]X V+LS!C%F;5-WN*/O_NEX<*(_Q-DIMJ#&?,YHU?C"
M9'"L7P@9W[<V]Y.3P84_=S,0?AP[3E'V/IWYZ(2PAT><5!'/"109=6/8Y!*=
M3-1-1)"(*:'&YK\XN=MR@)[CR\#\\RS!&ISS=#A>@";JW(FL>UGEMA6U;GSS
MZF@4'+S"7)!?LT$PF4R.QB<GQ\=GAW2TTK/64I2WN/ZSX-\&;T&-R/*;*'4A
M<7_^^2H,KO_^8_"SPJ5]P#\P9EIVKU+Y+VE>1C^1%QF6_X\LQC;>6?;A**]2
M F5?HN$OCM;2(8K^;XYF/\-U9(-Y1VX;UU:%]FM*-A CT3-X/:)/*_$YR8-N
M0V8MAF+D/O@:&955<\OJ[48I.W>+EI:&Z4YWA2Y_)9&[D&8 I2<R?9Y#%E]%
M\5P:1G-GY#@U_Q)X==U..M0MIL/@1J4*VQP(9+<,31Y$UJ!C;+%<9#/,P\&N
MEN05+C!P0!YP.'3XTXR$11XL,\8@I]9_2528J2K&E+;R*Y0O4+$(/V/2?3;<
MVM^A?^SLB\!Y7MC>@GWRJO5$<61C\F0 \H)RCUB*O#61NMVR"X=G J%MNK-U
MK:O_/GZW_S<E20T1-U,O:^8NRP960WIR])POF(5N:?^NPD8!HTET-#HY4)SK
M,3J9R[]L%,>Y3+S6]2"G1A>38[JWHB4V69^'.DO%?5 Z\G)XK  1PE<@:)'4
M3@=_\SO^VM $QJ-Y>:[WEK4[ZBLL#3 4]_O%)AG<"+&]?[U$D1"!=![R!A5T
M\Q;5$AMK_:O68YX;S,L7R<\*PCW.X,K!VSA>Q/:>OGYY95H&Y;2QE#0,JY*$
M*_AT-)M5RRJ)2OD,:L 5-B<6I0"E/E (2"$.C]G2"OSEZC96"U@.G ;IJV_X
MSJ*1_OXV>$7-*12?AM-9 B\5:J6#\X>[;PX39XW?;:TL6VYI:1"\J<W&1NQU
MZ-TDPS]B=K<P/747)14OVM7 =;,-@IQ]D*B# Y^:O7/>2-J'D@C2Z'DR"'Z,
M"K9'R"TO\R3C9OLULOX'LY8>ZTBA8=<GPVU72SJ-V:K=$L#:J_6+H2;#*HTN
MPZ]1N4"5]TJGO6) \I7IO,)/(M'V7E;[#,2RQU:4H1YOJM(IVD3Q5I;M].\Y
M<"5R<*RWQ- &[8G3A,SLR<$&";_PV&!QV"$C#[7@XK@ZR,>BT VJ.]FU/L7.
M&0Z"W\Q7BVJ%H7Y31O%I N8 Y%R*#R>(C2,_BCY_6&=-YV$[.?UPZ)X6+US-
M'[>\8$H"Q-31+'*X&.^S_ .>1H.TC^A/-]R$^Y5Y]& \'$T.:WFL9+F5I2)[
MXAJI*"-;YPV:Z?&_(I.AAP^_QZQ_4%U=>^_@ZLWUFT-'Q%&7;WN^8>WZ(4GM
M2[%'[@6Z/JQ[13(RW9Q[6&!.QY*H.Y5T2N4M&1T+4GUIQW]Y(N[_4<VBBKVO
M,:6HW7(#O"1>4KM@.*[P$9N)05]TAZUR2=A!%U^)<68\8-/$,M2IS'#"MNRH
M?=?M_<\' \;F-*;^6%@-TS(''8N&.0"+&NYL:Z8Y""Z3(B,=ZQ^<7E]H0]C>
MJM0BT1,G6(K-/02UHH5:(^AT.(B.85$[*Z)'(Q Y3V6&#0!A,EIP3NT1."V!
M;8A=M%6AS+FBF#H^C"[GN):FB)T18\XE<JYE_#"> Z:W8 +MSEW+5W!2(%8*
M)DES$;MN4'*JOJW@HIK!!4'N8Z2&5W&^[/T=_!Z%G*]DS#,8'EE)MT+#0(*S
M!;G9 A1WCE]YQ5L0V2U8P!;4V.CSKD?3R1JS5]22.Y.9VD&Y"O[VYL=KTG))
MA5BJG/I-WN39/=8/D0OV,R+W3QMRN[)\VK@NWW1H@D_9/+7_6NC[6VJ[&!7L
MDDXS!ZGV<;39HEPZNF67-LF*PTPRL$!J:DYA"0^?I7Q9)NX&LTK'1!2TG-:
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M4LTY)V@1%W!,P5I%>9 JK.Y$=!9; HD!3'R9B^VIPH806U9Q*I@(5&J$U35
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MREON)4S..@9'[?-%CBAZG&]@Z@#FG!T'\PN\95B;!:S-3H/,L#976!O1)FU
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M,6X&&" +4 1@N>" .LV <5H %B06SGEL@MG8(@T.Z8HEH60(J&U&6H: .4+
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M&NHL U/$)6>%C*?Y:L7*U#(^+$$%PF0 D8%@2B 8\5>P:$0RP5)1@C. :H&
MX3J>DR=,DR E8CQ*Z=6Q2#+WUZ\D_5Y/14:!N:# J'<".0LUQQA@%A$@Z@,&
M:.P(X,%)3)2#%J>)F:O6GV)E*];O+TX8%"4T"MWO=TMSVM>F%6W.3M%KZJYO
M=EK.=Q\7QZY9,=BJI=#5)<B=/<4SQ.*+<37A,IZ:(Q)8RJ-IAKT!DL#XBD)G
M;#Q+R-%*Q+:G9=1GJF);?)+6&J);_4+F&>=FBW,CEB=BCF!H+& V3<Y@7@"C
MN02,4J*H\B1 ,HR4SV "<T:9C#(U#,!GE)DMRHP9]![/D09&@-.41B7*XC2A
M0@"%&"962<X-',3=.<TP,Z.(_:3.L[KD1>=US&8=:^9/V>\W?3<^Z/%)US=]
MNU=^?U+3AV7(R<CKR'"9UY'A\C%P^;[OCWM%OZG[Q5G9:A7M3JJBBHAI6[K7
M*T/I7?)$GU3:<='I%JVH(6<D79-UK%FVWT=_['7OM!O_:D=B#T7;]XL4Y$QV
M::O4IFQ54\0:U0?Q\[X^7YNL0"0W4<X+K'OD?PYQIDJC?GU;H1ZD .SY_GXX
MT.?O=-GN)<>)[^VW?V"AWG[8\2$^COO-M^.+_H>6OIM#F/TK3_*OC.NLQ2@G
MTF(*L(064,DTD)P&8&E@F JK;>HTPQJ$C'I7ECMW(,-)_0?99#BI-YR,#LKQ
MEBL>',"<$T #HD 2AH$0W@A)H*K2$64#HM&4Q*6#DZ5@X/&[FI&O;JV=[PTV
M90RL-P:."5EA%QPC$#A"4DXV44 +R8!QVF@<X3 0F;J5,O24B-7B\6\21RK-
ME:)Y'>OK._JI(U5W??*4'NN+$5=J[]3T_/^=1B!O7<S(K[H,3O6\CC4),HQ7
MN]Z<VZ9N?_6%*T/P7=^V\=Y1^^IWXTU;NA\?*2DP\9)VT;DN(JE]E"&//YF!
MM_'1.O(54>W<T-1^^^"*HCKMK/9.I?;NGHWQ)%)#6/ 6 1>%'J#,.""]U4!
M190WRA&1>KJ-#LU<VM$H&2-J6(B<,:(^&#':UUXZK[&S &O+ 878)O>@!%9P
MPQ6+IK+ &UM/::R6(6+%(6*1KK8,$3.'B#%3UA@R4$L#+($*T* $, P+8"EE
MFD3M$9*($7CU1JSE',2\CNP>>'3*]D2)5MD=L+HU[O=)[QSPFJ'('E?Q3H27
MQD5='M%H]%/!)5"<1_,?,6<\)-1C6N40C3'^EZ_>?7%58/>.H<F0]1R0]8SY
M31FR9@M9(XX(3R4+5$:,D@H#:H@%2FL!A$6<22J)X*S*4X*C4ZTR9&7(RE7P
M&;R>"[Q&720>R8A/1 (/D0"4D-2+WBK B"=8*:(5'R08C1F'O Q>DD>!1_:B
MC+_'X@>FKN\BU\PY<]#IZ]8]SIG<KW"YM(S%^G*R6C%?M0*.<>,@X@T+F@$(
M@P24,0RDH@JD$Q-2RD"DCEH%)@TD1O6*Y;.*EK_73X:YE6E<F %O[H WX@2R
MQ$*K P>6.P*H\A'P;$0]Z[#7U!.D(=[88JPAQ RBS1EN,MS4QG>3X6;N<#/J
MM@E(2(^4 ]!AES);## ,>J"%\#Z>LD)>;FQQVB PMS+,'IV\CIP7,[$)])ON
ME;;*@!DX7(H3WQWX6(I?RG;Q^M]O1P#D";M2%R%[STS"Q_4>JIE#J=;:S?3-
M0C[X[J=$CK/U'>%1U:;BA#>ZVXZ;5]7%W_SR4(>!68>91(?!8WQ$QADFN4'1
M9)(24&XL,%0@X)4.(DC'@K$;6V23C^;P+TWH.@/ ?!+Y[T& )WI5\ -63H:"
MV4'!Z.1!KE.>O@7>F "H(CY" 4S]+C#2AE-O(8RR>!.N4*9^1H%YH< 3G1T9
M!9X'!4:=&@YR[BB!404(E1-5 HFQ \AY$Z)>%S C"0;8Z.S!I86!G]F6#Z2O
M+*M]N5.V3OO>/=W"G&)OZHURDUF9DSSN)"+F2??!TV__DHB:6EB<0][((N;I
M(N9VB]KSW:._SO;__$(Q"MI3 QQ%&E"J-3#Q^("17A%J,)$.)9N33=NA=EJ8
MGI&HR9!0.^USCC9H!H=9@H.]#0[GNU^_0,\9IRZ:G3:IGUYA8*Q/#1<)EQ$;
MX@FZ::W0C L9%^9NE69<F"4NW+)+#]ZCN+XO GHF+66 "A6!@3@--/8\=;>'
M A(4")73VJ7+ @R5??JB2K6.?[OR^]:_JC_FQ';5'5^6_?A(=@)&_.1]H6W*
M$M?MB]3.K]WIISDI9\W2-JLDE"(NLXQL^+6K6\6)[@[*^IN^YQ-[5D^ODS$:
MRK9NVS)^J=>/;U0]CS>O#^_JN:^>^%AWOY;MJWV4U78-OFJZ+[;NO6RX=I$L
M])-.KTPD\K+K4\>7[_[56>GZS;@7E3%RZZKAK\";2[2)"X\L?^\EMVC%QB?Q
MW04!Y5M ?]R,VW^F]5:8Q&$TH*@A$#%"F8W "+4RFB)%-?,*?<&IT_OPJN9U
M$L>)_NJ!Z7K]#>@0G_&E;IWIB][&BQ^/*I[3[7V_NV7W']Q/3AWQZV.?W;;R
MGZ5^$177_?HVY7ZZHM=$V:]UKUF\;77.>A/2[N A!J44/X)$?)B6/NGYEU<O
M7KFR=]+2%R_+=K6DZJ)7/]Z.G8S@4D6+@X]O-G\3#@Y@Z/D:_O+PX\WJHSN(
M.?B,1925[-Z/X2:Z][.';ILL/O&HNS[\&8>/O7(>=WUH!Q#<9$K.8;$*YRW(
M6Z#P9'>])T\//Y2G=Y,,B"=*3ERDBUQ-E-H;%9>DHQ077G<+WW81Y7>\]<?&
M=PN"&@_5N'4C]$]A?:7'F'P#JXU;L(DVV0[N13UP<I_ZPX_^4#YAWNY!  -B
MG+?[.;=[BHC1/+9[U;83_K"=CY!"RREH!L'6*&LZI_$N[O[JZ=$'G<!]^-2O
M/DT9>$0E$I_1??)ZGF<]=;C/FA4'[-TD;3RJ#4-=TN5RRET]I_Y^J"83I1#&
MLA01'E[%-<X^[_R)=R^;WP[Q[L7AT9_P$!^B_9W?C_9V/A]]WGG[;2^M __G
MV_YU7*-#/K\[A'M'S=8N_KT9KXNOMW%:V][QF_A[;RX/#_:.]G>:WT;B&D?N
MV^>C/_'^N[\N#X_?'AU>QM_>.62[[][@PWC][L%><Q?OTOUW?Z:X1G_O=17K
M[.\>;+.]HS?T"R606:L]P$(J0"670#IE '9>6DVI\5IM;"$D&I+E#/QU!(*Z
M]#/(D# G2+BX PG.,^FD-T#1E !!N4I]=VU$"**9581"!S>V.&D(R58G S>#
MP3+-U<A@,!\PB" P,H4+$BZ9=8 B&D#\%P::*0\$E)AR+&E4_2(<X(;@,^@Q
M4!<X6-GYH>/Y>ML=G?;Z5;I#XJ>7<YWN79=[+'M#@CKNZ1.'/:^+_V3'GW2C
MB*IF/!6Z[0I]W(FKNZS>F%E;A3KXWB?<$/Y"U-Y9M)HJW6(=/;<$S]M.]S9;
M;+?==L44O>J?;\Y/?+NW-#VEED'=^VO4'<1AM-Z),T#2$)4]KAE0!.LT+RT$
MCH@CG&YLX0:1,CN#,E@\\W"3#!8+!8N[CB)L+674"*"08( R9(&BB "O/$Y0
MP307"2P8'_439;#(8#%;7U$&BSJ!Q1A'$O/>VJ@6 L>]C7"A$9#81=TB$($Y
MU,ZZD.!"RM&A;LL-%VOF3*I*SH#1/>^JT0V1NP:&KNWT^H_+"1B_(?6&/R1K
M[T5[2.Z,V?+5DSMSMV@K7JA8X8.^J-[,<F9V<N9PU()UC"%-@@=1,16 (AZ
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M^@"PIQPR0PR!53B!Y_3PC!FU:X:<,>,9,&/4@)3Q])RP'#!H*:""P#0I&H-
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M\:(F>#%J\R%*J$<<8.&2KA<5/LDX!)X*2X3'TBF3\6*=\6+AQM]C ",#PY3
M,&;.*2+$6R0 $5 #ZF@ D@8&3-!<(F8-D:E5P.J$\=<L5%<U?RI"-3NXU*VK
MNKT<M%L+-]T\&[]4E/6^'5J=L][^:7_P=WBM>\V,V[/$[?=G8PQ Z4DP6$$0
M.)2IPPL$VBL,O/*,*QS5>"Y2_M7J^.XR.-0PE)?!H0;@,&+M.8J="9X"84P$
M!\4$T%8:P!DE1$GL'6,;6T])U<[8L.+8,,_Q%AD;G@\;QH3]I.=8>0.BB>0
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M&@3K@G).$.]A-$2%$58'$Y2VQ@<N9$(#I#(:U 4-1ET*5B'O,.> (&0!M4@
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M(@EIKD@B&24TYBEA7HKHDK,XDE'*P_C18<H3<V>_^2ITW9.!+/)<56HBX-Z
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M8UOJ!R9N>@E_;YK^\8'3]K\>G)]\/?KSDPI3%0H:$5_X(.-C00E764B$S%3
MHR . BWCPV'LAX],QM]1-8''%G+QYJNJ1%%KEJ:>EN+SH+S0].AZHF8;XS!^
MBJEY$JS\?3 UJUEYM^6.\J,+R\3WT/Z#)(ZK.15S7T12DB"F/N;)A22-LI3D
MH1]E-,YE+MC.RR!]9#Q[[YK; @ZG!X'[9G!<M]<PR?*,)B1(\P"T.]\C+/=
MS\N\/(TP83;W=EZF_F/SMO4HT,=B]$O=+_537.J-#+OI9?O/<S=+T314@ KF
MRX@D.:P0#04EF:(QH1XLIL?B+/0BD.YTN>WK=N/ '<72;%X5R-6Y<'O3 9PF
M->:J&H3^<(!'\8=J//8-9R,ADCSS >4B15FJTC#,>,J4\$ 1]L( &\[>#.=Z
M>OJN(>[S,H<A\X2&>2A)%OF*4!%$)/.B@,A,>EF:2)5F5(<+^E'?;?;..?-[
M;ZU]%^ZU)PQFTO-RFH(IK_R89BQ(,QG),*.1%)ZGLA[,'A3,EKF8/(H3C*9)
M/943RB-!6)I+[)W- TK#+&"@K059-J1)WSR[A[-' 6=;6T2HW[W][KU5%9(H
MC+R(JHB'5%(6,Z9XPM,TAK]+4&'E>FF\MOA(+Y;O02PO5B$*543SG'HDC%)!
MJ&*2<*E\$@49$VD21U*&.R_]+!KZR1V4&^EQI<>5VRCY*6,9:/6<AXK1+ ]3
M'D<QC[(T]5F6Q7FOY#\H8[%,RK(HE2+T!,G3&-1\E7+"4RJ([X=!$GH2-'T,
MJ/.281 L$[.]HO3/ YJED]V=[9R$^H+5#[\%+O:7]I?^[*77^#MD45^,V!7B
MB/K^W?LK^RMO?^43:[IVJ*:#2M6ST;1OI+9]ON$^1J1?ZGZI^Z5^BDM]&[HR
MR6(_2<*$QY+1(/"S4#$6J2C(52Q%('7HE^]"O_Q;\9;OJC(OIM@LN&<;[HYM
M>'/UQ[%89!N$%^5AG@=$<983FF:2<#_/B<JB-/&5C&.LK!B'PR1=#I'8VHY(
M/1S<.1Q(*9+0]Z(HES2A"?-9(E049DJE(6-I#P>;" =O+K4K R#AX/5GN.?I
M)S^E5$:!('X81X@'$4EC (744U+(**2,J\>'!WWM])4 \%Z-%:MGE<(ZAZ;F
MVG2 %=01#$8%X\6HF!:JGM<-MRB%]Z=*J6]O?8:^%$>_U/U2]TO=+_66+O4_
M:Z??MHOQ[ZR8U*BN8_?B.1VB/LI?JQQ>1_ZF)O##]-V(]563[U2K_[;"R ]9
MD,@T\0@+L4:/%PK"&6CV@@L..C%38*SMO$R'WL_G<?=P\LCAY.?M_!Y.M@M.
MEDF"1,G49SP@3(8QH2RC)$O#D%":,N'SA'DA?YQX\L1<V6^^BC,V.54#6>2Y
MJM1$P+T!('3]+C2T)Z=XV. KDT%YH2K=6:WNW=[;QX#UC'B_U/U2]TO]%)=Z
M4]S>URG"3AJ_;H7QT>38B>)RTNNVM]-MO16FLI>)G,E$D#!.)*&)'Y*,!SZ8
M#]1C/*?4#_.=E\N%;+?6]=5#Q#:YPGN(^,<A8MG\Y8+!#LXX":B7$<IC15B>
MQ<03/&>Q2I/(>UP8\>3=XZNS\([+*1L-1/<T#D9E?3]=QVX(5(/>H;VMW%+/
M5?=+_427^I'5_NBWV39MLTTQ_U>H];TKZPYU>7]E^'N6^R( !5Z$F&P?1(1'
M$2-^D% 5>9(ED=IY&47#)%EN4'?KVAT]+CQ:7+A'F[_'A7O'A64;/XK#B/$@
M)9%2"0"#"DG*\XQP@'O!DXQF(GQ\P- WM%J)!!^PS3C!N'&IS7TXBFR[>U?]
M5.#[]M*XO5/OR2SU+80W2U*5I$G._#"E'@LS[J5*RB0$ 1[R-/F!F+8U70PT
MD&@<><>N,(+MN&V$U\>MW:50#_XX_G-1V8^") UCIHC(N4\H#21)_902GN4Q
M5M)-I(AW7M*AMR*UK8>,QP\9O73HE[I?ZL>VU \;W-XK @^O""Q;]T&>>DGB
M)\1//+#N)8\)$TE,LE0%82:CQ,.VAH]1$WA 5[Z]!<'K7W@Z^/V!( $[Q+.)
M4":E_7)0XVG\3G?J+33P?ZHY]39PMC\-]EG.69PPQO(TI6$8I;X(6.(K^%N6
MY"'_$;"'?:6.<E<HN0?JVP!UZ$"ZF[B8RC3+@IS$:0X66Z!RPGP_(I'O9;X
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MG%W +8IZP 8"'JYU01!YIVK B_+BC,%T"S73.N+ "M;!!4RI@K<! 2L5NCT
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M(^"@! "&G5L-WH& FJ O"BRGX1R\_O5!:XR%+!@&H15UU],#'^8*"1Z39G(
M,PL -$/<-=B& STIJ\\&T0;C8E*,,3:.?>U##6X7:N!O>*C!M:$#"Z$&R@ME
MI@+)PR"G6<S3F%'N<2ZI'_HR"1\ZU.!M6;VQ43>_V4+_3YK+"M"'IZ*$A6%
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M'5"["]DM6 1*D)@VSI&E=&4-&BMA;4TM,0<,30?[-:#8@IEUWN)^NH #8P2
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M%?++L-!\%>';B#!L?/C"N<K2FJ77H[$$M$O$QD1)"(&'/%TF:+>T:E?,S19
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MG>>$RA!H0N$3@Z;R(FO7!:DXJ#@8PX$QD3H $;6T@,GFA1528E9JB4Q0K);
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M5A5M%V:KK*FLF1/6!*,41A4$J C $$&7G9()2#*_,!O65+5GEB!J>=$@2*]
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M[TN%X:1!FK)U,B-J"MFB,JZFD-V7>&A<M@6"]4Y+H,J;D*RC,4AMF>0AW.<
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M4+T@"=6T)E37A.IA0O7>)>+:6=4UJ;HF54]V"Q_AV?U]PC636K%BC5.M;00
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M0FD$[X:_,0!X9W&9M<FDHA*9>6HN4[WT23@KF'4OS)HB.HV=XHDI@@RU!O%
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M;=G6Z=)CUZC<\/4P5GI(]N!@T(<Q@G\#_-QH';UJ69@MCMS?0 !G<L?6<U-
M]-W;PM8.UY&SP"6R40;$O8S(:.^0258[)WSP22XL$C9A!O_GS&>)OUHC'^8*
MTZV$VBKS^ E@XDY&M+?7RSV =V,O#N"_W1A'SD]O"B2-B?6-3#HK<IVY?M4%
M[HE/3$9&8B(T",8)U<YJ8/K216%$X$Z.4Q0X8>CLE]_H[(QO!%R$ZK^KO0NS
MNVR4!:/N8I?-Y=T=$34-41/D 1H0MTPAXSU&RAI "QN<]6%AD2E=EWR*7$$5
M#+FG1:0482X0%@.)G&)LE;,VA9QL3;VG9JP$",925JSGM(:-]1TC9+(1BUSM
M 2B5 *^T<@$%+TR4B:6D.:Q8%*Q!3=GGN#][H51:HC%VTE)NC762:*\$0(0%
M0.3DW!9^ PK%%F9O"^VE'1,=<=YJ))4BB#,FD([*(8*I43(ZAI-86-1X.GOY
M4)LF8?S;52:+D0+G >I027.%(_^@!<<FS!632@>+N4P&H"4($>%D$D=8A<8+
MCA[GQ$U5'!VV=GM 7,K:\X06MK63RP0], $$$!,1%XP!)\*Y28+5+%&N'4Z_
M$>AZR-I3\&8^K>%T]9%X4SSGMV,+NX_UG,-1/)-&^4V)SESLZ]RZ&?=W/PN]
M9"GN2K6R/QC6K@:0X$%#/(R#+AQ^'L^.-7#T?(15]^2@"D(>C%*WX0]P@V<N
MY5GDNYXG1JB$68;G>VEGFVAG7S[(324/LLQ+K4HON]A<R[*^(S0>A<'.=9V'
ML+X/!B.?M#JFNMDS.9J1S.:4Y\O2R:.'Z,%[')\)B$ WYKVY?M:P@7D=XN!X
MT*H<6WN1D)Z_9VLN"^; <]A>'ZZ=GZ<%%SFP@\.3LQ#M!=N ,Z:<IE4]YO#\
MUL<&=-7MWNMW0A93[U\^9RN.I'6FOZ6I[OO9>?8L?-'%V(,Q[+6RW/&@!O<\
M_E/N4'TV#.'/&]_7A#T<9&O(8YV5M$>[V=4=9TOIG9SML8:185R_X1LOT[4G
MXS-/><I*>_OB:79A0/(.NCLZK)[G_"GR3<1?!W#2?$=PJNJL'>OC^.V/SY<W
MH+,.]\\<\+ID4"-]\)&=3=[%'6Z@GI.LQ]+=EZP>;B8KA<.51AK>([L9BY4/
MS_836UF("-[HV:".%$!?,8ZDHT'UH%?MY[+1G%O,5,N^8LP5'O1KMM/I^PP)
MU<NLIM&EF?)7[0_[YSG(6/^_1ZV1)%0^G:^V=^%;]>KKPRM_RW=3G<2W#BI,
MAV_=<)Z#01_<A\-*W/TP=CKPP#D@!G\& P8,@*,ZH]ZYXW.T>CE#H (0^%(;
MOE]=[NST8Y7R'$,;P-NY]$]X!4?^BCSL\'QST8X,^TSJ?&3!]=H?[N+YQP:6
M/W:#OLT@ &<]M_?1FZWDTP];AP!6OKKW*3KU%A[H/,5A/%?@L]#OYLP'/WX8
M,(IL?'V_#Q/"[V70S#?D_ZRUTO6UXUR ^P*#P6#.EYK*-8-7 ?,A[YV.T7(\
ML<:+SQ]A]*3GTPA.64W,"K1AI'[& <KF,GKSX^R-/W+[XMYPKQ__O,.6[-28
M]XSKHKZ<F_[7RO+7X+Z7SFY[K;KK,1$<Q[[M;EQ+&WU@@==*JGI+7\Y,XCW'
MQU=)<WU'$!\D"QJ9X##B1A#D7"!(<F=95"H:R1<6Z:3G=QX2/\QON#:R@$MV
M#]/CRM0;U(;PHB]]86RL%VL,'%*UX\J6"M-B.%[BSTD&_!NL.69KAF$_KLSW
MR@S-7*.6$^</)E'15^8^FK,>X">O4M49O#_J'HT4R,^/@ ^J!X#I&8?5A)DK
MR_]VZ<DNV_IEQ^?K^:[XTL43OF]K7UO?29138WQ$+B1P;UUN@*L(1UG^)I'D
M$@]^89%,1E7/K?WV&H1I>7?C@S\"ZH[6QNTC .>]>G54_^C<&H$/ [,;%R-4
MN705,;AJRK5#NQ]1ANTQ:08JD:_9"Q>;3Y-$HYZGQQ_ISYO37]^CJB1[-:J2
M+_&"S@A2 (;1&Q&DG.]7\;@<2\YN?>R-'*:#_F%6R06KS^996:=KA?KU>O(+
MYW0*%P;0K_R$RP8]G@C7T-S'@\-1NMC()W!VV!K[/[><.^6ZJM'"=>D^\V7<
M.<6L)%Z3;0VF77TN/(U[9J)^//.Q8'A>5RKJ4K7\WE"Z=2D9]88BL;RED;GM
M<3P;XBO;Z-F:1]FIV30JK]A'^.B>04PEK=+6.,I%X)1HPY5+@5MLO0N4F;L$
M,:?O8ZQT#SK]DQB_7':Y2@CSAB6>-8YW M;,!1-0WD] ' N!G%42)>)M$HF&
MH&S.\9!U:IXX)_5A9O'[?A 79E),XUZFT3S>T=AJ8CQ!RDOP=80S2#NMD54B
MR"0<D[02B8'_UHV<S *ZEGA:LDU?Q<CSQOJ.L5;&Z"6,M]?@Y2:/K-<>.69%
M9%P2(MBM":97L"%4Q&(4!QK_?ADNSL),XS8Y%4&:"-V=A4?SNC.>S'!(MUKI
MSD/64Z@,G.S2EW(EA@T_6\/^X*3F\K>''VK+1[F5]:5-_]_EDV4'I+H:4"A_
MB2F<?3O3P+,;O!K\J_VQE/\%?CUS9S<\_DMU;TO#81_H5/[JGZ,DN>SO'W4.
MQYD(/VVK4REMW_.R^?X?GIQ F&4PY;$C)'&ADPLR*Z$2:Y.62J1;W'/\N-2$
M@MOWFKW@M5-*/<Q@A:+A''&"=<9MB:BV/'%O8R(B=]ZITRF-)QZ4H6!"<-R[
MJ +7G GMA(/UP6*L3>!,R^EM1PNAF_7H"R!T+J6(;> (QB$@'B-&VNB$#&/.
M2@($BW%8M26I"SRE6.3^*0F%S<_)X#<?R^9?0:WW*GB@8;3T35NH\\;L7#FM
MU[V3Z8;^Z6QO;N/2EEPQ].F&WLCM37C.L +Z@001"7$JP3<120%#=<%Z;CA1
MN;L<E76LU6MV6XMIW,LTFNL["CML263(:B9R]W_ 0)\HTM2PR"-EW@$&TCJ5
MN*[5M!S-XK:^PI$'XJN8R.IS$4DC'.(P!9$![H,B\=X*;ZADXGYNZT4^&?B0
MMA?L8?8:+V>9P<C^!,^R6H_.TA/._-@Z.%XYRVNTG=N"Y1"L9^S,GNT5Y)0N
M/V@=G&6!C,WMDJ_[^QPNV^GWX@WY%0Z\1/"08=F[Y%N?WU1ULO&&6?1'.2UM
ME*^2C74PVK6H]5VGM3M*7,EK:?]B;VX41YYPG7_C$U]DH%S)/*FZ9%S-7+IP
MD_UM;C+XM5U;I78<]49O/\S%CL-M+.8BU.#M,*>%]3,I&5YT:KEL9"/#/ N.
MW*='3([S4_SO+]\VJ]_(O^_6+^813=Z$HS0EKGVRG/MHK0C1*,<U-@X<0WY[
MM& "YL;OYA.\FI7Q6UE+HQ26LA3>!(@GF24ID@AQ$AF<]^]94 AH"4?1@CL>
MM.(Q^X)4D+H14UA2MA3;&86_<D9;)V:3.+?0R\3I4L+5'_ZFW;,_7X>#,>J!
M] :G)F664B5EXD)Q'ZS#1OA(.0:VZKBDM\A?E:DYJZF9F[,QG2SP480Q93 U
MB:CV59"D&B@K2Y)DK@)^35V(*6&:]SLU\9N<FI$KFYC!PL/:R21X S%Y1HPQ
M2J3@;U.4+U-S1E,3-Y9V'#681 7. ^$>\1Q6,$R *ZF(QDS!^'"RL*BYKC,^
MQ9-XEJE9C8O$+@;N&":"<>&U,]@:9SDQW(IHR Y\LO B$YK>J2TZ81]&&2J3
M/_]SI?'R#-)%KT^/Y=;0=_K#HT%.>LYU)4N]L):]D"_V)&^Q#5=^Y;9ZE</W
MLM,@G_-L&I!F^Q.8[3IMM+_N-[M;>+O;P# -:&-YG37:<"ZZ+IK=YE[CY/HT
M@._\R%-GZZ3Y>9UNM[]VMT[ANQM;Q\UE?P+78-O+^W2+KIS^]W2%[7@'M##9
M@"P+.)L^1\8YD7<5)!4)4Q'\",-:O:,8E@ZK;2"IDC!>!(PY3LP9JR0.C"FJ
M+=-JH18!60YR2N/@*"XL5N_]LO\W?O63;;<OFS]\-K[L:'.S&IM;+[WX1!95
M!>\N&]-R/+2M3M8@&4$LW.*2ZQ\=3C6RC?QS ^[C[T[?[[\_.^,[46NEK*3(
M<VX1#SQG%P?P6+B!]9"X:%.\;C>W85G5O/V:S#!@6L<>#.-?9[_\.[2&,,-/
M_FKU*F2J#OKWU=.)@XF&]%4R[NCCBY35#WB4MCH6"1E?>?SQA^JC:VWT1Y\I
M.%*8&S_&'\B-G_WNM(1\4((^Z+2__TP;]01G5?SF1YF[5V#PW6[V-M&8"Q4M
M.O?",.9.JWFK5Y'>G* /9PDW:UW)![R%ZNE?6.SE;J_AM_(W]S2 *\(4[^H5
M7E7S?0XISQ>?97>MBZU(TP55*AJ=MZHLS:J-!F*3?L056O?Q:#"(O<-S=M>O
M/OUV='#0:<7!\-RQ9J^4Z8UTE?IBJYMUE#*KVX1K@--\^D]WJ[V*&QN[QVL;
M<+\_5D5C8[N]W;JFJ]3NM+8_?VH! R3@@,.]KI\VNMNM1AON;WD)C@&'O+W_
M"Z[7!79X25=I233;P!8ME\:#>XZBS:ZY-PZY2!E*AB4:L S)IH5%8R:#V>]5
M?/-9+U! YW>@\S!Q]L>#SEU"?061[H9(S8_7$$G$Y& D'5+2 2))Z9'Q1(*Q
M:2ZX]<1KDKMSZRF=N=\K)MV;SJ7J?Z^5L7WK5]7-XR2+DP=1MBEOX.T!Y.Q8
MV35,7.N-QN#;> @ .C?L+_A[QL^-/=M;[?E^-\+?"EK.#BU7)_F;<8FJ)!3R
MB@C$M2+(20O\+9%DC'<FA9R?7"=\,COYGFCY&\QX*D"\=LD'\;"[GN/=@\7L
MV%0!B[D BPEJE3Q1EFN))(,?,,8$:8HC2H$YZU)(2I$,%E(]FEK-&5@\--[U
M2@E2E<2<ZSIRZH3]]9B8UMO&O)D3I.K-+^47#W!V!H!782VU?L6 3N.@7Q#M
M7HC6F*0_WFNIB+9 >AA!G!N#G,I[G]0)98PB6/FLOZUA#/\](W?Q!3S"602B
M9A%K>MM@,',"= ,8E$E_KTD_06.X8@)+I1%3B2*>C$4F)8NLE)&2)*1U;F%1
MB\DN:J][PM]"8L[2+^"!X^\O^YJ_^=!0USBH-LY#N37.=V=Z=V/F#/F0DUW&
M?ZMVDS](\0RIOM-W@/^VG2I'TAZ>][*JL?,]X9< YMJ-F8I7>],]P$^_SUC/
MW3(V??SF;BNVN.JS6^/6I^S+8L6B$ QA82WB42CD//:($Q(C9LK8K(-!ZX1/
MMHEZR5G]L##!/<'Y.<((=[VEQ\0D'WV-@H5SL4-<L'"66#C!]X'<*YV%"6UT
M''%#+-*1F%R%'@DUPAF'%Q95G6E3L'!NL+ BZO^JDL#GN 3N:O)?+5<)A=CK
M=UN]JB/[6/'CHN&[KV:^SQ(6]RKO*QGT)8.^9-"7#/J20?]J7V')H+]I$84Y
M5M+F'^2?)((3TT(E[2*G.EI)N(]).I&P3\&7M/G?N"0'^\V-3WN-'\WN]F=P
M*=JYAOU[=^US UR)U1,XGF]OK)["OT^W/UYS2:H:]Y5?6W1[?WNY<9)KV+=_
M;/&MTQ6ZU0:WYG2OTVC#?9\V]Z>FS6N78(BT03(R@WBB'L$ $F0]9EP8(Q1A
MX)*8R6KV]YJB6M+FYP9TB!-2Q@3XHB.71%I"-+>,,FV),<24M/GY1Z2)((D$
MQ/&18 3+!T=<BX1,T!1Y(10EW-H@=,[MXI(73'J?:?,KFU]+JOQ-H.A8"#1Q
MK#6 8H E7 ),:J!CC&*>SC3A"Q-[4=R;D@"OI,?$"HPDH2*WNV#()FH1D4;Q
MA+$-)G=GQX]&O3G+:"WI[[,& **!MPM!/$D\\J0UU<H+9PC#"?Y?6-'\H\,$
M*]*8&<)E0,Y[AKCU"FFK"1)6<L![EPP#5L3J5#S:4YLS?'AG&>^;WY9+EON-
M:C+&B^1$P-P2KC&U6'B6N$LRQ*@8+]QF#M!K2G:[H2IJG?LR5-T2>:2 8QPC
MH7UBB@EK2<S<9C(%Z'4GNI;,]ED#@(XZN:Q4Q8 @.VV"%(KBD+P*A@GU5-RF
M ,"] &"2OMAD#(\>.9&=&QD2,MP#?6':V< ]_ @  $2_,0!X9X&9SW]_*8&9
M&[?( HDBB2BC)UPXYL!N7,S;8U@E'=Q3D9<W7;+W7)@V);.9<BQI$@FY$!/B
MBA% MTA05"1%0PU60LRL9&_.G+(2M)DQ.,3(N>0,6 S17'COE$F*$"&X,!Z,
MJ1";N0"!"6)#',%1>(RB)N#>&$^1UC0B1CPSDF,1="YOF,SG?=WS_Y%)0_?*
M"9XKWO.0HK1'[.J_TVJ'TH3S%:#AYI0N!HY(Y:U$)&F,./<<.6DX@M'CG#,"
MBYJ=WH3S%94W/ +*GB=QX&E*O69UC0)^<U'J5?;OGA(9)W@BF+5QQ@CP#B4X
MBU)8Y)16B%O)-8"EL%;<U RT8.-+8>.4TJ\) 9IKHC-7"JC&KU)E_GK0'U8B
M3G\-8@>^^3->E#C]GZOM%\;WB"\.L0YN]NCPYD,NO3H/DSP.7LCC_80HO];V
MX-+/^\A3\86SH_8&9T]Q8'<C<H-H]Y%-\)!_V<ZQ/1DN_.MJU5JKARZ_^.OO
M;/1F%O_C!O]:G':O\RB'Q>=##FO)^\%1#"N_#F)O&(=G2\O_M*QK=2J5X'G2
MQEH_7RJVVOYXBW[=WVHOB49W$S=/FYVUSY_V&^WF7K,=.ML;ZQ2N1YK?KFL6
M?6\U3_]N;W^&:R[OG\#W6(-N\JT?ZR<-ND*;]'NGN;R%&QN;Y+^G*R<[2H=D
M>/;_I9>(:Y>0%0GXL",A6B+@4WQ=&XL(SBEG'D8%6#*L]BX*RF"LN(Z<D@F-
MH_$@U.)X%'ZOB76+-4^5S+KUCIY-,FM,6FZPN_&GT\UOS@2TGMT83W=H2-@P
MCH%I1(VX=PQI8EAN+Q6$<,[8H"<$M%Y-?:\T'SAY6!7J;XM;Z0?,'UK ^MOB
M5OH49U7R84>^T"O@I;ZWU/>6^MY2W_LR[LD9=3H8]-O1'\+[&!Z.])\'_1/;
MR0RBU/^^2,2^8GY7V=Z7T2!]S&,$C._KV0B]EDC5PQC?N$G1<6-Y]==6.U]W
ME30^-W C1ZJ6 S"\3;&V\;W=/-TDS<P(KT>JVDO'C?:G5H-^;S?:F\=;I^N_
M<J2J2>&Z&_L"[IDU-S9I\\<JGEH1+*CAD7B-C!0Q"S& "V.\0M8%*;DV(A!=
M-6R314JKU 3/'1 ]-GI>@.B%@&@B9.Z9HS2G5B6M&  1^+#&1(N$"]A)+#P1
M.)>\<%*:$[S3?--S/F=/!OU.IV)RKM\[&CZ0Q[V+5+/9)5=\V^L/#@_CH+O2
M/>CT3V+\._9B:@%*YG&!PPI"S@XAIY0,6V&235HCY310M:@)TDKR7!0H%&;1
M$>[RIJ*2CRZLF;/\LY)_.F>TJ8#""X'"I*B$M2&:&! 3%B,>G$0FY(;;CAL/
MKEUB@2XLRCK&11OK55<*5UM@I5;XZ6G.#7N-!:KN!553RH(5HZ'*@JK</$XI
M12Y%#W2&\>2YP<2(A46AR!NK"BQEP7/+7LI<G\U<GY( R;RA3B#%!9 1*APR
MV!)D#&4.@#A7S<%<?[RG,F=S_9EDGN:/M#QYI4S1!7D*W<\[IUH5-VYV>#FM
MNEB ;21ND 26A+@!T+1$,C X[PA1U$=::84(/,F.7E'"^!O3"BFZ27.&CS.7
M0BWX^"+X.%EX[25507(D.?S@F$ADI"*(6*YH#%$8%1<63=VH2?74@H_SH:5T
M:RG-_<M&U,+B')=QB/DHX_@:?\;>4?PTZ'<_PH7RM!C^:!WN?3P:P@N*@[FJ
MXO!C?#KH- "?MI>W^'9[Y=?V1L:GK9.M#7^<\0FPAVV=[O]J_/C47?MX+7&^
MNWG2//U[O]G>ZS8V/G6:&^NLV89[.UW*B?. /:&]MK'R:POPY[^G7NP LBC/
M8D12NES&G 1RV&!DG17 MR1A5EROXH@R6$Z#<=H&+@2WVDFNM4N6$8+91!7'
MV8NO=<9+QLGOZSBF%FK<?M&K-^F"MQI\;<HPY5%H!]^'OUCJC#/</5UAQW0[
MW!C 9!IA\A>X6ESJ=/H^RY5M]+_&KFWU #^^Q$&UCH+3N.8 M:JG?]<&NGN\
M0QUEG@6/ LYE1M@%I%-PB$3,P JP8)Y,5':<E[X]]Y*WL1=KGV$).:A*E@!K
M*BDZ/S$!:H?]FHNU0?3]W1Z</]3L$/Y5856M/ZAG$3MOA_![RD</6[#^C";#
M6/8NG\#6_!C%ZG!L.!HQQ.J(X>&PGD\Y$L%[J[IWFG\P5#^)Z)LJHF^E*.39
M7\.TE;+4-TP7QJCP%8#S##7'6#IB#+W:2;2#6K\7:U7Y=,V-@['#O1@/:P%6
MWE+]\+ H SBA)";MJ4O<!O!'DO<B6/BCX\K@>_4K>B E>BWQAH?1I7$#CW:S
MO=W9HJNL<;I)&I_7\1;]WEW[L?ZKF9N G,)]=',3CD^MYG7MYFZ#-KO?VUMM
M?]K<V(3K?FUO_]@2V\LKM/EYG36ZWW,3CW;CQRJ=6A:A>,3&,X%P2@9Q)Q+2
M%E,D&7612AMPCL?*.L>/[O56LI'?,/H>'O=GB[[O(CU1"R,H2PQ<6Y]U);4&
MSYQ+$R(+S%-5 /9U >R49&8OG S$"F2TC8A3HI%1-B B+ D<1E::2N%$LD?7
MG96\Q?F'R;U!?!J:^K:!TA =@TM1\\!X8LQBQ[6R5,;H+"/Q^8%R+EN.OP:,
MG)(PF<"]D#0H! N?1=QJE=5Z 2.ECEEB)7$19M9R_(TD4KUEE$S]HT%AD_=W
MUQ4#5]U88UW@T06' 2$IO P3+ ;?O8#DJP')*9E37, 01AR!/FH.(&DH<B)O
MCC@1$TN&2HG?JBY#H9)30++U,U:5P1V;@;)PRGO#)7<J)<HDCY$SQZT2PKA@
M2=(^!?\"SG>!RP?"Y92>[8X([)VFR%+-$!<^((!(BX((D2OAM5&F<,IWG)Q?
MK_VV+5M)07U.,8L2NWQQ#-V:TC,+"\U&&6)<(:X3 ;_<<Q0=,<83&/V1=GL=
M<UFR4><T&[5D 94LH)(%5+* YM=@2A;07/O)4A@:<<1$<\Z)%YI0&52DW#$5
M-(WW$NXI1.]FH@?W\!WN9>MD;:/9;6SLX^W/ZQS.#P1NBVTO-_>WZ':G0;>[
MS9/K1&]%;/]8!=*V*AIT*]_3_O;R+CQ+L]5LA_T&!>+7W3S=[FZQJ5E 26#B
M(R>(,7"1N3 6:6$42MH1;U1@S +1H[K.R*.[ZY0TH#<,OR4-Z$$2VD*FA%-R
M2CH>DW(AB&0L3CA$+N/]I-$*PKXXPD[K::BXEMJ(O%T#""LY1U8ZAXRD6E!.
MJ(MN85'4E=%E[^;-[]V4-* ' J5D)!E#;#0>R*C71!F<:P*3%<)(6X#R=0'E
ME%P@;'4$H/0(QC@BSB-!5C.*, ^2&YN$T3GF6"=T5GWZ7_NNS5L&RI()]""<
M)-(:[P7!3%N>>##"2Y4B5YQP;8A^?IQ\>UO;SP214S*!7)",*NF1#RP@K@)
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MI;W)((L-04HPK;&V-)'T)CAIP<:"C??&QOM$_F<&CB7R/\\ >CWR3R6)3/&
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M6+E.N<[,D\=6P;SOG8>\ 72/GW?>^#*VY1F8]OO7XU\VX.EOP'R"$<\\9\D
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MK7=:>Q(9))E!DH'%&5B79CH)5R>XLYS3W-@:K:?]MZ::?_S"R*-S;B[SMK1
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M$7;Y2&M=HRET%RSL4]AG>NPS@Q(\A7UFRCZ7=]B'<A&B(12<5![2' K(J9N
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M%6T-&,5HDGY&\2@(D<I/QU9<%=9X83ZS-Q?#BWYH#4PG.\K:7=</24@-[JC
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M]FPJHQ,T2#1*&&XP<(8C,"LU)%DB0*?-R!N+A60YD+M)I[O%J=%\IT8!^((
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MGG'SW[;_\^:D;[TS02/\<B6LXTE;1&08\MQ0BCT-"!M)F#5BQ%;I,\%O94K
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MK8"U5I _1^37K#7,>3Y&]8!5P, D8: BL55LE*'I_YD>^6FX>'9AN.:=K8T
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MJNT!^!2PFQ_+M1\PW5T@C5D,;#AHMIN]?K?B8_?;*7"B*>*D5;;A;:+.DL
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M158A'@P82D%F_^C2NTX[#NL^C(6A*C'IUK(R[()<QJRW=N"8&<')4-['2D;
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M!GIUZTU0@LJL/G(MH%>=E&#$ 0&_:'@.&[]_7?^G]O6XV>O5/OP:5%//[S3
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M+^>D^9(U%^R9$77VW>%1D O2#/+1[0\_-R9+]5MXO:^8J(N/-)R X9.=7WG
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MTXG95>G$[\_-:MOOVQPIJMR@ (=C!7O/7;S53ALKF(*;ZH,I'P86R[ 8RN$
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MXA"1B=HA#D8*TE@Q9(3".)<ADL)5?5\P+9&9N8O,%/UZ>/VZB2MZ45];/6W
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M+,CXXI'Q<:CC>?![Q!\O0-_%V':AB ^*@B=C*!@(QYYIBA+)-8QBRN>% T'
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MK;HR*^8\%MK>Y7YF8J?#"]R+@+XV1'J>VD]71\$OHU2)@#\,$$U$P#%(ON!
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M@!R:8X%TE(&[:"GC>ND=7R&\L(Y7"!YSQ#JN\EH/X6*C^W?E0BL\Y"GQ9")
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MDX"/C1M^'#=\E-IZP W'L$$\9X_J0 E*R2EX3S)!Z$,?KRG0\2*@8WYRSV?
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M-M4"&^W2TCLJZ#(6NF03E6RB.0V)W1)-"F#<$3 F@F+"&)V\5TB:7 Y($8F
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MK@@71QE-V65J@3K%)YVYO7&8>T;.Q%$6X5;GOWD1_MNTKMEJ#IJYX4H!LP>
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MS[1^\4>SL=8XJ!^NTZU/7P[K[:^G.X>M@W\NUJ<43C%B5'(,*6X4XE$*9)P
M0SX1$;Q3*<6TM,KH,I=FV8A)THK'G>'?6W5>Z(#_7N-Y2O;/TQY0P.@'8/3$
MQN<%C%X#C":RB43@(-_$(1=RJUM81F2"CX@FAYF@Q#&I (S(,FPRRT1-5G(5
M,"I@]/I@%!)(KN8XNBBYY$YK9PPQ3DH?0I*^ B-\"4:X@-%<@-'Y.!B1%*1/
M&$F?27&84DC3W)^0)]A;DL8A9"HO 6"$EZ68+,UXKV!T__C2 N8^SLXC#7>>
MF-W')WW7 #M[U_-C.#SIPVH4H'UFH-V\X8)NBL;%)MZ34FNI.4?8L>R"!@%
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M*#Y#2^,"BB\*BA,>J3'),$L#F)%!(]COP*#DEB+LI(\I2HVM&^8Z%5 LH%A
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M?I["YNEQ8CQ)Q")1B&M'D1-"(24B#9I;QRR86&)9R,GCJTM->HVM_W'AL,?
MW3.'R^X[I*<$V9_\C *-\^B.%FB<)31.>)\.8W Q/4$$6X)@P[/(8ID0LTXQ
M[P0.V.3V9)Q,<M\4:"S06*#Q]3SO HTSA<8)'F;C(@[6(>JTS[1@'%D3)0+
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M"D8;RE#0Q"#P/$.&6HX$!886G=#2B;5-@NERH%>G4ZV$3O5 -.ETJJ7$#[&
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M.L!4;OG^L#HI["$\L6[Q[AD48 =GZPUPA;**'L9"O=[NVP*" +_,]^:K\3T
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M(K=GZWKDAN$,_CD:]WN;_P]02P,$%     @ *X!I5@0Y/3MW(P  _K\! !$
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M:"Z#.$K[TLF\R_5MR>!#TB(4$<Z]VI174=X 4JKR[S :E*X<&"9S=_GTC*/
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M.5OKQ'-*89%NP>WZCMR\X\7R[.1D_:%L0BB[^/NJ(!N 8C5ON/KG(B:Z#\?
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MT@!&G>)0O,9ILCE&+9GU()B6)C,/@,P([3!""1I2=\M^@\AQ^7I#Z9Z#1#.
M75LN<;4\BD+E6$QDL9I4'4)AT23/DL@>44@('77*-=*&4:;O,>'D\_E6M5D:
M'E-AA9-L-3GP#+P@TCS/](O O3=/JD^O$#M*]V\/#.VF3?>54L-M<I6<#9\I
MD"+0)C A%5'B \7LF?@,Q4AN#$30_1+'M^D;I0O7!"('RJ*E\H3E,6&U?JLY
M@<\P)9+(Z*.4+I,J#PC$GC-$B*%@Q;D"4)0-P?9+MV^G<90^61-T-)!)0X1\
M.)XO5BM<G+S&TWJ<M?QEOGHUA>5R4B:87RYODFD ;2[>LV)](7]16!8= !,E
M)JEC!)'Z0>>1Q(_2<6N"J2&EV#+C?\ZK*"&",\A\YH;\T^@92&N9=[D$%;T,
M$/HE^!MY;]?%28QH5W1D0O/ -/W'?!+D%(BD )4JQ8S"3WUJSVP/1-R=+7G\
MTC?$]B_S6;I&A\] 'J"@*,G2/M;@D46PCD7O7%!(VRWW<]=O4C<NYZL)"@X2
MP"! N)85]AI< ,F<)SJTD84!:766G8W*2:,)FD^ AJ:G%E<^]F;R(#NA1<T6
MY 2Q>C>!>1XXDT5I$"3ODOO%(G?3.2[E>#B2[MLE!\EHD/WRZV+^>5(K"Y<_
MSQ<_G9Q.YU\1_X8S+.31'"G)467RC1.ZZK,0W]XJQ027F0O'>8C]SG]W)'I<
M:G98/+63WB#@VG94)YV*UI"KP)W*9"&")Z?;  -M!0]"88KV"2"UYW%JOW!X
M6" =*JDAG3KA+!03'+DHDGR*G,D[\3DQU!)%X=+&CN<3]SMU^_!+>_@4%ZNO
MOTZ!/G26:\QX6JM>CUSAVDLKF"\(3'->6'#5F>(A(<\FZ-B/\3O)'*O]W@,]
MMW=(&^&T+."<K6#V:1*G>,[?.N_Y\1AF?Y_/\^\3>@>I@VBB+A2+.4&Q6-VQ
MBI0#.F>S#4%:!?V*.A\B=ZS6N@EZV@JK(8K.B]4(SU?UO>9&B42\%@V<$7RA
MYLN!&,84>([>F'[ATC8*#^?[*KM@4_$V.B: .Z:E=XR$(5DVSI-%+46G?NFB
MT<9#!R/E]J[85PC-\7^4?33TX%!O*R5Z.N?,"VZ8+>3Y1%-,YOVJGK==\WAJ
M?3B ]/=8^H:"O\J'R2 "EXH5FQ3I]A*)!(K"O4(C2+N+V-&]&BHI=#56L(A8
ME*7X3Y#' HI\%^4%RXF"Q&!\B;[?;8\=TF%/K?KVQ<J]": ]Y3%L;;=5WJ)(
MEFEW?C256" -S((%<F=M5M+W2_.,O?"T'2P.E,0-3/SEQ<WE>4L_#W7%]-7\
MY'2!QSA;3C[CFQF]':_3== ETVV?WN.:Z8-<-;MH2H%EF:S>SI?+OV&9+_ C
M?#E2'GPN&)DHF0RKHV #LI&$ +*T4@?-L6N\?Y/ PW7/^37>S<J^FB]71T+)
M()5RS(IU+6P6+ *73*@@G) >!/0S2K?(&Y=!.A0SMS708?)H:)2^L?8S,?[N
M%!>T)+-/+]-J\OE<,R:O "PF5DH]*=%0":O^I_"%UD!Y4I-/L#GN('=<)JL]
M<-K*JRN0"-):BJB8 HEDL]<GWF2XC;$F)V%0Z-$"::\JU8L/W5QI.4K*Y)*=
MKJ&7KG61DD&TJ=:K%T$QF!<=XYZ;U(WLZG];.&TI6SU$.$UO_G[&V1D>!1>C
MQIB8$)Z<4!Z1GLP3>;4B)4VQ><](8$/46'7I,(C81Q*#Z,\CA0BE]O+QF=2X
M#B4S$/68HQA,5@K C@<)W^AJR>,W<\A1:Y%KDR-=2X$3T'(;\$SE*$I$X,K@
M>'SO\7BBCT+)?7[$?J)H>K)6G6 B8*.*ZY'X9'9&>WNSR2ED/%(ETM_27N0R
M2O)JO&.^1-K;.3DC-5&L9<?#M8<I?J3R[&=/#P1.<VDU1-+MJ"K$&%V6M<JR
MMGS)TK* UM1Z"D09,\&]WT'# U'NP1P?N8 %0C!,0!#GCDP$89E!%;35W 35
M[R#Q&FGCTJ*'X>2!:/Y14F@/_LK.\DAH+S3XP&3R1(-!8D44PZP&0_\'TNO=
M<;^F;&1J<2 D/%X( X04D5N=0ZV> *2()CO.0/%,YIQ;3G;=%=?/C=P:4NP5
M5==2CLU.4V1)M 3-1"A8777.8@9!_K_"(%SP7O2[=7"%L'%INWWP<,<]SSW6
MO3VP:_AW43:Y_&VR.GYUMEP168OE$8 4$I1C&%*-Y-'3CLNUJCMI'<!Q ?TN
M[#U([KCBZS8P:2NCEJ>OMT^8CFJ5ET2B0J(WA./BB!1)I&2MK,J@8^[8%>BN
MH[?#;\IO85UHRY.6Y/\;3E+@%.:%ZK!+D3P*+Y6P_5S%NZ@<EQX]%$%WW9T_
M4#K#Y*"*M^@C!Y9"J:<4'BD^5(D9290Y7Z30_;;&73FHIU:9[1&QIP2:]];8
MPIBTY  7HYDI*3,=8F#!)*0H!S0XX3&;?B'%;AJC)?^_X.I=^0A?_@Z3V;(*
M")?O9N_Q9-U<>%W%L'Q77F.I720W%X%J[?KR*(()GB?+8LSD+$DD9\GEQ%*2
M*9L2HRG]?)+6W(U+0S?![NYJN@LD.FSM"SY^^I*.8?8)7T]*P052'$O\?%P0
MQ><R/?)*1%Z3A@DTZ39GR2R!#@RE+P*,+<7VBR@/Y69<IN2)H-M4Y"VA>NMX
MUJF4O!0LJ&B9CCZ3-:RY%(=&&PA!=+R]>/_9^3[\?L I_?+3WTE++&#Z<I9?
MYI/);+)<U>=\QHM5J,VU +QE0)B@53"98C.(+*>2$CJ.)?3SVG>C>606XA!<
M;6E%TUYL3?,E2Z0/J@V87E-8/IVO+]!=$(6&E\*-8<I)6^N$B#Q3/(.L/>KH
MC"K]&M/<2^K(-'5;"+43TM.6)</R^.?I_/=ERV+DR\_L4H*\G8-FA<=D>.LD
M$GR-Y]_?S.YHCF:B+2 5,,5Y/3\B[Q"P0B A:1%=0C3]3-VN5+=IW[=>_YH[
M_.<2\YO99OC0M2(?PX/&Q&D+6*^9-A1I>T<*U7+C-2@??,<SSMUH'I<)' 2'
MVSO_-19GRWN(Y.XF<H$O_-_WI 9>K?]%_N]=30N)%AY+8$H%(%WL- LR"!;)
MA L?HA.AWVG3'@R,RXQV@N'0@F[<O_3&CGDS^XS+&U6.!DV,*006E2%G$FA1
M0(;$--I0ZPR*UOW,PVXTCZNAR],IP$/%.2S8MI74VB0-(!B67<3S1JT@@,)_
M'H+R1+?)_<KN=J-Y7(U/GPYLAXJS/]@2&LM#K!=QZS 96Z] *8DL""RHO"I<
M]"L%W@=L^ZS-R_ROL^5JG2S^>;ZX7C_D%*D"P1F719)JD(YY'VME4HS6DIN4
M9,_9<'?1.2[W=@"L;1L?UT1H3><+7J7H-9XN,$W.I3#++T_FB]5DN?[Q(K.0
ME4^F-APMRA.=N38 *6"9$$$GB5D@]CO@?2SUXW)EGP!RC04\&!!OF[]K(R6^
M3>;!VH\F*!8K1'04P" ZRY++*9/-(E_HJ53=CBR,R\=] D@.(>K!<'F]8MM(
M=$02.5N!G"&=-*=E@,*$DQ3\Q8 ]SS7O(?21KNW0Q=-/9VKWD-N MO8"[UMQ
M?W5<CLS>6/":2255G545Z[@<P62B*)"CL\5TG 6P)Q>[@-!\SXIN((%WM,';
MFLZJ8#!:3\HXU;K#2#Z#]Y!8Q"0=AY"<ZW<[?P\&=H&E_9YAV5[,!R.RGO1=
MH;*VRMZD8:^53/TV7_R;UF4S@_O7.M-E?8M0*,C<><NLB)76>A,;,;*4(U<V
M&Y7SC4SG[:/%PTC8!53NNS"X'44UQ-5A7-8Y[N^QG,WRU5E VY;'@Y96*DL.
M@ZH-4C)G(4G#A$8 ;5!9V6\\PSX<[()*_UV@LJ.D.YK?&_,"KJIGD90J1F;F
MBS%,UP;S4'O+FZ!X=J5(*YXJ*_,8/G9!:/C_RQ@W$OI@,/UP# N,1&JF2/WD
M_$A"66V%4RSK0.&51\&"=<!B+6E*7*4D^QW^/$3M3EEH_CUC[D )#JD KW6,
M.!*1' (HZKS!G<X4'\6D!..V.!M!29'[-0"_G]:=4/5='VX<)+V.29<M<V@A
MJ!2\$2S5X9):RD K4!)#)50$"&#*4R65=Z%_)^Q]YZ<<C:4\S%U)T%! U+'7
M26JRWQ:(@MJF79CB E (Y/JE]1YW5U)\9T<2>TJE=:9CNPOX,J7%&>:-(JW]
MZKPMQDHFN:[6F=2IM]ZS6%+.")Z'?"/E]F!^8Z<'[P2,CK.!NV4UVHNE[8 A
M7.!R5</;AP);(9Q)06B6H1Y\J#HG1Y)S5XJP$HV42?8+$Q]!^$[(,]]=ZF(8
MP;:^&?IF5NI2O#M;G7]?WXAXB&"EI(\%)4NQ7GY)6;,0>60Y1XP1K"1%VPV)
M>[.Q$RZ_L].#/C+O7Q^-J&5R6.=Y*5Y'8M,6$DDP$RQY G4X1.C7V'Z?^NB]
MO-&S13HF:_:NW#DX[ZI4MZU;X$IY#)ZE8H#BNO4H<1L)3<EX@<E Z-CQXV!^
M1M;/>@#P;O%^^Z*@C==,I";$O%Z8<XK6KMJ;V8?C^6+U$1<G'R<GY*Z=UL.F
MY4/T@R#OK"3'L@)?.^<H%FSBS!'U 554PCYX';$]6:.O5VR%Q2>6:,OX_G(O
MW1PF^1#!*JN0%;<L>Y?K@%**'Y*2Y-)I)()SR*%?VGQO-AY9S_B=Z<\A93Y
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MJ><]NM&GN%M%+SUX;#6]-]>B657O8YVU[)(2WCN65<A,8SV+"3$PR$@.O+.
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MQI"@ZH+.IP!!'P=NS1+F^HNO^=*EN>;=U+M+Q/VW^J9Y^3_X]1\P@T_KN/X
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M9&T.9P2TG<WKU-I..>ZP?O3-#': ']F<LN=>LIH?SV@/4&04Z,BD,]:K .!
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M'W )]>SY+<RG-0'U&A?'G*02M8!<K/]HR2(4RV)062(F%<IP<>K=&+]R=>A
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MUK0ZU[H.05A5,SRTR2%9I\Q3OOKC0QS":.^4BUGG@NS% ']7R+G';5BH- ^
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MF- KT];#*<..$&@7E=WJ^=EUWVW/D:M@"LNA=A'07C,(PC!R%%3T&H4NPW6
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MO\Y[N^UT=& %>#GW=O^*L],Y7)R1 3<YJ=465Q9_=K8 V6;,8M),QUP#DF3
MH2.-BYKL?3Z<,N^$^%7'>/92E7NZVIZR7KSP>[ VK0D: !L\FO, V$,%<SJ@
M]&DU:<''H HC:;D6R0-#6RMN"F<8$"QF8]!>>@0(_#@5Y<F@S9!ZL@\-'>I'
M6GMHHS=_&W&4TA5+QJ"JF3C>)!8-YPQ0:AYY,(8_=HZ\P/2GT]GG[ZZ?N,Y
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M.8?<&RD 11A,T?8$_[HUL$^FN\ZX[DATUVT^C$TK^"9GPS2$R+RK<3.TPML
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MNB,O )BR)14..=\K>G0L77-;T;>OZ(;NFDM^TAS2<C*&.)Z,EU>W8UQO?[_
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MI\AI73:>00#B+FDE )*W8<C3U9<<ANU!-_:1?L^]<;QT(1M=-VA-4-RJ,!<
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MZ+'+RW_TWHG,QRN%T*;U.H)0E :+P9(FSR;T>,\1QYM(JFWTPB<'I32145Y
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M@M8]V6H[*$] >@[ D_'4U*J][%+VW]7?\ QGWU9)85=4DTI0B]90:\)O:E&
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M:(GV-O.M([OZ(+<_/O)XECV)/>V14GW[FI<%1]=@HJ\NEJ @H8Q@V->%D$F
MK5*3J5X%UZTT\/:7'R_/]J+1,*[<XFI R(75/V'[_H=OO^*"[_R/TX^?Z73V
MYGR2E_1M>L8C*YK,VL6Y5C!/5K>YK)X1VZARB,&;$3, MD3_Q VID=@Z2-/9
MGU=%0#]\6P%;6?@=H(T>8MD(]V 1ED$Y?C?JVRN[ADE!V0BQ9AV<)P5*EP!&
MI 3HG6J.(_H8LY1UO-Z1(TO2PV&78Q&D;;C4MQGZ@>;4<AA>3<I/+;]A^D=[
M<KBDQJJ*1AD2RCC(L4V)UB:PL978%*@ZUNJD-JEKN[,'%SO$6T]/G)D.2-9!
MDHY^HS/^QT__Y+MYAF<,]57YPN1N;7N;Q?T]6JPYY,!^5O DP:!@H.T-U%"H
MCBPQ/<9[T-X&^>.7J!$XME&M_)]_W"(;;^U?RW]8_GTCRP>J_]9^__W#VRL2
M_OGGGW_G@T#Y_ QG?^!LT5R!O^?IEW\L"?F>?YI.)G1&EVKW52G+K[>VXG4Z
M^W+1YXH6>'HV_Q[C_/3+'V?TD+K9;H%_7&_H^XU>KO*== RW-?IK09-"Y6__
M=EK^_6^G;>ZUD*I$0V2B:[&'(+/460G=6B:=;+=4G_T#/M+LR[R-$IM.+E9L
MH9//.*.$<RJ7HW9?S68X^;1\PKXZ#R>><JJ^2G"8/)CV;HY%"J!@170J".W&
MJ]?N94M[7;__2?,%'^@/]-_GEZ_]\S?3V7+=']:O>_F_N&R4)(IR05M6(C+Q
MR5;20XR*P&E'+#=9!NQV->\)Y- =0<81R.^N^#%9U_<3UO;8?SP[K?5Z Y>M
MHT\R99/;.PY)U]+ZV8U?SDJQ1C%=)65AN[U8]H7H11#'86;??LC>FU@>*4W9
M&R0@4]N1<K8Y:!9R<%D+X4K6>1QI?%&)HS!QD&2+7\\;F=_5=^>+^0*9>)-/
MRRV\N\@":&G^5#%ID*A:5I)'0(H:;"7GC#1>U/&F-3X ]GD)X3 \[#N98H7M
M!J#E>/N3C+KJUNL256F@T$#$2!"M0!0E>F=")_6U:87G)0W]$;OOM(OM]>0/
M_+_]U[6.U,ZG+*T&$AC!.!$A%D*HKK*36(4JMV<B]G;1?8_D&4K4J,SK,0*U
M(_C5 ?K(?Y,_T_Q$1B=%U094:>,1K6,KL=7TDC99**.#23B0[-W&\B)]0S/P
MKOSMUUMY>_B7_LE)%5D;Q3 =&=T>3I=UE97EBG=AG16R=$NRV!G"B[0-Q*Z^
M1SY>&7]M6N"=<?)OY_/S-BKPOEV\G=P<CW7QO7_RORZHG$2)[?W5 K&JAE;6
MTH8H5]#H5:A:D+_=<?(!*VT0F,]06(^'[8/,D+Q_>S<<G<L];B#TB4<V?2-)
M4)IB:R;6;%[4H%/4JO#I##A>3D!/FWI>TGY8F1AD\.0^Q+Q((]/1QR"\ 2N:
M/R>0K1I9'3AA"*6(:$9LL[+W=@[3OOI08CPN]X^GP?5'_B\?V-Y%SKL7;+(7
M=AF]#>UE7DMV&2O+GLW25Y]"S>,)=U?4QY&#.H(\W9'G0?@Z2.K@O1!7>8X=
M0(Z>EMH!^*$25(?A_MU<H(%8=S Y$[5D%"U?":FT]$H#"54!GXEM$)E4UB-F
MF!U*OAY,6STB\=J&8WT'C%__]NZ]$B*R:K_XHS2KO+=HDG<I0C*:C=ED%02)
M$9S%ZM%ZGWWMY*!O7.(0[D;O_)CV3LR^LU0^$+LRIZTZ?[GYWYG(\P^__7Z)
M3,<H5:H1?,W$FW4:4C(!5-'!UYJ5R;83F^]=YLFQNC^B]GVBW]-LF;0XR70-
M[?UOOU\, B.:O_XKGYTW;_87G.!E:&6*L[+J+VNDBREET$*T?&KE +5($'+.
MIK(GZURWH-B>0)Z<R(S)F!XS.N[%OAZIMXHIQ" CZS?6=A$AJ21!,DPTP15K
M.T[VVV;99R,P^Q.][UR,C4@O2S2D-U&8RO+*@$Q('F*B"B6Y*KS7U#7.?O\Z
MST< MB=KC[D7UYO_T':Z-)*KJ2+QLN"6G7^5-( ^*<@18Z :8M)A-*?C"M;S
M?3K9C3.#Y $NH:R.0A<THS^"W$1XJ->.'1FVGO'[4'N0=XOO4#GVHRT6"PQ"
ML-K*R_K/T":M5,NN=1&Z/B'>/_@2,0CKMR%RCRR?SQ8GOS#9OIQ_6;6SK"JE
M:!U(=H=;.TMJ>Q)06EVFS\9X+/=PN^(\+2G,7UXR^A]TMIBWGY;FP9*;=Q8]
MA"&P._6G?9"NQT>#)1#\ZP80X7Q016:PRK?QXE4 5EG:C'&J,F<*Z/K@X<U%
M'R\/=R;=H:M'KXV6:;TV5G!2WD[^.%_,?V=KA4G[F7XA;/]1LU6FE7^^ZN0_
MQ\4RS^.GU@6RS[+389 -6J\Z C%O%;JZ5)(PKEI2T40=,8>8R15'+MBH_-U"
MUV$P[N%'?M?U9IF4P7;S?]'II\\+*J^^THS]WM=_L2%^.J?WL]/<7O#7)VW\
M?#TCNC@,CC(49W-KOA380ZYLQZ/SE*P+07?+>!P 7'_I3#?S5=:NN4K LIET
M<QS92S2LUJ1$2)6="YDJ%2>0)6<\ZVM;]"-W\CJT.&[.5!J$W8-TQ[B/7)NH
M=0G^_FPKMHGBB172VD0.L,UJ-,(CQ.00:@A669D$W:[U&5":!]WJLQ?]XQ&D
MOB,V2W!;[&-#VNV)5XKXLG? OWFF+Q:((5;@\UY3%$()[-9[OR= SU1D#\;3
MOH,^^[9FD$7IK$HK0=:U5<ADOGM"A9 H2U4\^U'=VN<^FJX:QR>'8_*P[ZC2
M&U;[[)8L9MB:O9^U[N[KZ72B@W*A2,7'@A*84EL5J@S@3?8F^B2->M#IW&[)
MYRQ3P_"E[^K@U4B*_YR>X6+9+?7=Y,?IER_3"X7[@-ULHK6>W69PJK53M;5
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M7@+> \O(-CP8.>"MLG5"ALK6I6#K,I"%&/D7R\ H6;*B=&N]^V@"WELQ8XN
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M18R@9>N[X1RR)'MDF59DBO52YO%LUXZ@^VANOB3_ZLL?I]>KG6AF*N]<0\7
M%XF@!-&Q^<E^B46)9+,<L]?Y1J"'CD7V)57K6ISWPYU!^L_>3X(+E\49(TI
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M<>WN4\$^)-\V*'[YU^V7A'/ZO__K?P!02P,$%     @ *X!I5@4M9GE'D0$
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M&#!O'I2)A46*8A\F3:6NZ*8W?PF6)F3G0F*6LK6@MN:VD$)Y6ZO9A-&?N$_
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MFM:(5.&NVV?Q^O(7'_3EWAH^4V&U?FARZD<\O?AMN)12[GABBM-_"W2L(V<
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M^;>=+;0VW,5(3F\DE,[?$O3+$7MH@<>??:MQO?M0]_VEM;@[&A_N9]7]03A
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M>HRG\.?IJ0#'5Q;#:I\0BKG(>EN;8U!%73-9^EE5=*';T"RNM3SHL#5CRYN
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M#:"'7.W)#P6>OI5]26+PQ-CDU%;&70B_IGB4(?CIB,I+V=YM(=96RPP2)CC
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MGSO0[/Y(3=^PCY1%A#'[VNG+?L5+\/@BUC7$9N[@X<AF#JB,KVH!NEGWR&P
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M30K__O[!'W] ^;&%\(=2U^%JUB(:R%C/X+.BR@= /OY74ZJ?;GC\9=/C;W]
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MQ-Q9+'YL]YA%AE7:0K%^TG1K/F]P%G\KP8<$T,*1 ))@XD]RWL]08 4;AY(
MPZ8D0&<:(6S<&K83X/EO55D.KH+F@J1/3[#P0U!2#3:"<YT8=T*T@!.."HA\
MVF38RB>0 .DU)$"H..Y\?M)QN\+_*L-RRD#L[8:-P?M)@#?X4%B?R"SP" P_
M(-/T_2(@FEI^D,"VCV^"X;Z#YR198%7S+?]:U(($^!B%X:4AAA*E\6/K.W\:
MX]=^6N-JT#<X;*."!$#<(7:[%!"\1N'_4M^#>!M4BP(?[J-AFS @^-\/H?,?
MA3;%T&@!_[V,?(2H,/)CP^)( %GLSS^-\2=CU%J0'\*RP?M?"WF0 "GTNZIL
M>!P>?/I?4J[.S^4LV+_4E\%'PVQ7X5L(<M(S0E2'_X=1DOZ]HFMV+\>"9G87
M_U>QCJ^:./KS)( Z"<!&=$8[KN=A%7C7NZ'"*.]($@ 9'%I"9-JSLQ8>(>=2
MSL[S^"KU ]S(("8%D5<?'.(+AP5 K4LF_B13B=%?^Y(:0,5&!:@-3*8']I<3
M\1/6[8+V1E>[6PUNA*COUX?^UVQ3[?WOY@.S]_^GBCK^TQBO_N.4A/W1:$QL
M<4+\:Y47$H ?^#]LVM?_JL8X%Y*@OT9L1940V=+'=JV!=Z8[R4]^\3,$L:>\
M_^X  W.EZP3/M7@M!0:_[EI,/_J/ZO\^^3?M$R?CUBHGF._(-V[$8>W;8[U+
M NPUKW9_DFP+!9N.-RW]V:!P,I%>?0U"W85%(5 &1I&<\ BY4&<BTQA34.RN
ME=O3G06:J^DBSQEN)I\V>"1>(8M1:?=Y=Y""&E[RT#0C88VVETUOO.]1!UA?
MZ%0PP/:@0Y(*=^=>P['WH:T6BVE\X#_Z4@SX=Y_(C2+^4K1Z\34)\&&&!&"!
M*]A&$,^#M$[/_S8]^*>[A_TFF_G3/O-_26;^Y,C6[^G70*@Q<JZ3$BF\:D/V
MBHG_2D+S#WZ4I"]_S3D274TN9CJ?>W$^^I[9ZM,SJ4:U')67T=J9I9_MVGO*
M[..4A[KB];H.#@PGXR_IX_,@K-6QL8"M#;1"SJ4]M'5.^V'S1  NRR]>V^\D
M4N:D=2"@F7M%<')Z099GYE%LML6(]NTP=?J,,$7NKSX-6[AG3=[&-]EEL"^-
MTF\GV+>=__0\R[SK=#[9X35*^4'VD95,3^U5);QQ\3"G;IWU,Z3N:/8J?OOS
M==I@;M'//I$]V3* HX?W*&^LB$P^XA@Q#7HDX>.LK,08H\1KH[?@\WP(]G(_
MK/$[Q*!$LQUBZNR%WVO,Z=Q<6F?,)B#C0W_XY%0EAL4"NKV97+?W.!)WQ/H-
M)9T$^#6 E,/=7(F^2O.'A"Z+:+Q>R3"_=MWRV8V;HY6KD-V/U^\&<9=]?BK%
MCC1C_J %\*O#%ABDRZ78M9_I2<E2[CZ=SG9@/U!ZD+U.%Z%D=X:KG].M0#EV
MG[HH46)+^*R,,,7PD(KA-67I@U"429N8"$5>1M_"$Y66_H" _<^+>HL_/#_+
M<(RML ^N;'$LS/D%O30R=1D)-#<1\W&7X6"ZB%6WN;CDES(PEO?C[#1Y]#\&
MUPS4S9GD$[^QB5WP=*;8<M)(M>_:,/0;?SQ(W?5Z':V=)>'*WQ] $2&@X!=^
M6*'T4>;KXQ+E 2[JQWT4X\8WN7>""@P>.LM8(Q_6]6=_7=467 T.%G8=H!0B
M&G523Q;]QJXWJ$4HSG?HE50T.JE45K J-;V.CSD' 4J?\U+^N.X\=G+&30!]
M-4\BAG/P"4T:A4+#\\.&*T,RJ[XERM_>VT?\87C,<N;SX%J"@MF$5NPN);6V
MQQ;EEHE/LOU'I*%?O (+,OJ<-XMK>?RF>(=8NE)#=O;%OFQZ:<$]I:ZO\*&3
M;HMOI6\O0<',KE]^(%CG%^$JGL+>K2U*?<Z@('M@2+:SN^WHFH&:=8',LJ-9
M67]EGX.NP.IID(#/9QTN==A[&A/RZ.OPR\<5H?I(HY@G.'']X9CJ)UGOUZ/-
M;.Y:%R;J3D/>0]Y82I2(<]=U7N2;]&UZ>@XJ,NF8(&A6W?6XT.GS8ZB_,\<%
MU426+:5>6T/V9\%&"0$S)_ +'9;.@=1+_5)QT"1F+98=_L9+U*^W4D6L& >&
M'!*X"JZ7"3[U])1&ZDP3C67!7$?@LL\ML7+3VGZL*ZSZW.:?#<_9&5)FI 9D
M_^$+_HI;K;KQ&PGMW^;7R5VS[,M\VJYMW_:I[D&<>?3'9)WN Y3V>G:B H0$
M>'PY'\3D>O QI3+P9NL]67<EH,IUVI>\E&)^N7&12B;G]LD38/>W8FG_']?_
M[W/]#5 BE*\6R*S.H)RXQ8#M/,XB<'HD9UXHOS3>L E2ZK)*/Q/]47MP_+<S
MV33RKZM5[3+@WG=$-A*@:*0G:?#!+ G@&1,.C)$[=="=47EK5<K1E$V?\^:"
M7A)%FO*85B^W^%G[I'Y.C[K".-:Y2RSQ\Y_I/U>N7QE,Z<G>8O<0[66@U]+R
MR<K^'PP5_Z3R 'Y5:PGRQMG]@1'W!R_[O7S._O+YQM><$G;NC%-UK+CA[T+
M-Y&WM)?15W.KQU__J*]\N#9C=UV0$07I8'R_)9"0!UHZ7YK4EPFI%W3G^2+U
MD';A,^7GD7#!P>>?LK?RD8FLSU6F[E$.V[#-2(*0Y:KVE;MY0VVHO(A\K0/!
M0TW)F58^Z<L(&3;7+N=']^=O!H8U'7']SLBST4%@HN')( @CC'U  NC[+_R:
M:[.86#(+IR?P7V6'/?\Y3 +<<09)QS1^"_2.W=U#Y#2_;%E:S+:3S>N02?KP
M6;:I=O-WTE0\C5U7O&;_N^EPU^>W;O?+VOX=QL7ELJ^K4>5F:Y]]'PLP/5;M
M>-FX3I%* @@CSKM.8+,,HP*PU9^73Q==54)'6P<$E'&][+BE=15+GO,L9\)^
MBUN,O\,LX:=D3+3_7=@]J_@[P']"!K5_2GN [M_.!YG?^A%E?OXSY9G?87Z)
M_IKG#9[%M7:5P"W/PKT3A2WV^*U]6OM]O_@]CR=D4CD";G \NB'<NVS8@W8(
M5)= >[2V)/Q@]E@@8,8[K^R\]^::57E)UR$U,PC_+7?)H_V;[9@CY)3$H@JV
M^2_%&[LCVJ4__G.Z-N5H'1O^C4#*OP6ME?QG_V>F_K?-5) R<99S+[T,)P0Q
M:&I.1%KL]-SHX<M<,'O(X2%L^Z%0ZR% =,FJ],&S/J8S/\O_FH;-D],PXY;#
M?WWU,S9.U&GY9YC6^]&1?Q*%58"Q<O/V>I?%:[E%.1JR@3GF QI) A'*GZ_-
M/8B\POC;>>#^RR]/?\-FHA1CY(X#X@?]T^Q*+C<PIEQ)"M]831A4YO8X):Y*
M6D[=NT +%9S<2!$P^_'<]ZW3S&/U  >.JZJ7'FZIL=$^KJ1*!+&XU@^D2IC^
MH71?UED)=*,A/IQ7A]HOV[:VA/:F&BLY /\SVGOV_VN:JOX4.U9I80,QPRH[
M4QOR0&Q#7@HR:</;OS2]4G*Z5R+\8Q7?NVE5(W\L^=]<H/5ONL?^O_UA@43J
M4.D4'%W0&MAH=XR@9&EZ($FHG":XD0#=)D('H#]@O/K?"1DD0 F7!5&!!&BJ
M^.G7[;;T1LB1!# J^K5E'12MGCH'=N_#NEH2;9'D$\7R2BP0NW%%6NLJ),"+
M%2;T1F3)NB4[[7"!GK./QRQM'56\S]WN?%=J[O(?'&J#5SL=L.]60Q"1LBXR
MULM%" PFQK&*3TM\HV@[_:*OX9WUERN=_;/0:\3A-K8]-7^<Q1SV!.>E;]T2
M<(.N."N8Y=!:QZ,V7T\./<AT%=T:+1$0?V8T*'# $[QJU$\"T&+!_>,0G?K)
M8T^N'@MHCD^1?C&BL2K8F7&9\V,R.]1)1=-K$:&TV1DE.M8@9)(T\Z&P[+W.
MFS8#>>.242YMJH,2=Q5+D]8\HZ2U2XQ#CE%]H9IS/8UN!AK:'19IK$)#*I\J
M,U1?IJV/A@A."<R&8^-0+0^Q,'3S^NJKMHC&V7O+W2[20K;>WFW(>Y$!OK?$
M]D]CE !.;< XT 4^;.#JCG0T+P=:*"/F*"3GUKI>ZMJ,LBWCRJ)8>_EI>:>#
MHQEKRO62A7;O!3).8<#8+/3+A]@A^K[H_2=[=[8G]!HK#&Y@N X!C%K7$LVK
M^LY,:U[_H6(HLU(/=S&*!])Y@YQSZ)&7DM;IL88U1Z%6HX7+-**2E[(*HE7K
M/ 7TN1V_!ESL$W&\GQ=2_+1V?E.]9LJZ)""U/$=9"YRQ$OC8I+%J1CS$#_1D
M=0!5_$@39VR3)V&50Z7=Z+!;\D.PP+AEE&N?8]C]0#H87T&HG(*YRP='89J
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M[61#+*R,,:B;'RJ /WV/X1+@,KK#0R7D(W&7J^68X )=- 9_TNF1QHJ,X5E
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M)Q[%GAF+3 W_$)9]58L7&8$,!FSI: __""=',C.2NCEV9$R&J;:Q!'4FK.6
M.K\+\-YT8QS7<'&3GL"S4561'_;F-U,>^*AH/NOZXQJEO&SAVDO'6^59KKQQ
MO_9PO_N';[S^IA_?I]DFC7?? MLFA5]+K*;Z/EL/3"^JR_7)-CU40640+S$0
MWJDKXT&MV"94$D83'1C3(6TO\65IV\*PT)L_8?7>@?20[3!_K>"EQ^X_[Z!/
M\-&9LX0@*Q+@6W/-X2(A]F@?*W;2"\,*ML2!7*7G:M:\,<[/CM0"C3EG(SV.
M<$Y3]@FVX7N*7Y:&SJ4B&9/;"J/M;SO;:%1WR"M]DAQN6R$!WHW:%.9/).4.
M8C9P .@*C JT^@[1D /?8T15T^1<GY<JGFSBHMGK]$_;:RL8XKJ>6MDNJ&/*
M_NF:H.BGI/JC'#^MV;?N59<.:.;28MG"M%(T+[U-$W1>@,=FY=@3J<91X<2+
MDD@0)5YMNL.SYCN0N<.<T\TB("7$N=CM:51TNCQ.*P=?W^O#^J'0G=;LH8F3
M,8UC>(-I)K3_AG,__1R<2)V$%NX"TT"8O5'%1WBQ&7^-U1S%/OHU,[O.ID:<
M5OZ2E8I2ZOK(H] 2/@K\>U/^,N2#3=?%$$B,663K@P-0C=%B%J9]'&17,P\;
M@#5&?$Y7U1<.]]SS$IK@;[-T=;1L?UTU*W7?(/RZU[EWGY="9F/QBH0/4"&(
M$38<)7L;A>BAL_.FPMNA0DMB]R'&+)N6=&?V);ZVZ^M];%D4V+A_;7%]*,5P
M91#;!)MOP!BB3?&,7/W %G@"WC80AMZR0M,L6AE=K1)8LM*_6L#M[:S6KA<#
M&;9:D;V>\7EFN?$/8@%>,??G+)%:C00XM]4ZR<>F*(.GK'>QE:S5N_)E_U/U
MCWDECKU'QRZEG55@U.WR \^ 2;0S1E.]J,32NK=D:4F'^X2KHW2^*W!QUD4U
M.W#P3CMXZQW*;W5K%XFS^U433AT$Z[X%]P!%MT1APK[X&]Q:-TSW?+#;,+^T
MT,TR<TW+S8RIA;E!DW=ZX?DM;9:!:0*9975?49? 6_[:DWIN#FN !JV_.ES&
M9AE/%.G'5>3?/9&QM!H]WW$@LY'K'K2>DGVPT<*D-VIK$<7_X>?<0II7H'MP
MWIF@12)-'CI6>L%R#;R[CA+&.*&%^X8ZV=T:7-O2-F-*WUAZ^*JZBD9(%#H<
MTGHV!<JLQL]^4\0S5Q"I;5'>1&I))%W 3O=3IW=(;U;LK0T/O";R@_6M%;.[
M&V&Y,IW7/^ZDEG>GI*48RF)/R$]9BWV#0B!K\*Q)&$0'-F&-3O%FY'K?XU.C
M,NM^MYKZ'T?-D^(B*KZRB6]JZ E)9!J9%(6@)P%6"T$MTG@6X:Z&_C*(!*HS
M; \S_"!+3>>A:=20KA-0(.O-V]<"HGP=75W(YRJ&\1:N.@_3.YNO)YA;*YQX
M'X.,57W(H7 <*[ *PXKVY^&9TP][ZX>Y%]*J8WS64B#Y*SR&/ZZ,=V-@(NE]
M8SSM+9D*K5[J-J&3Y!R:?)U2%I%J"-@[;"V+W)OM4]-?DRKR*9HW-T?0*-]&
MG?*Q^ITCVM^9//\(X+>32>0I1"$&28!H6.U^'/3J#O L/K@L:+V/*$,"1+R"
M"EM\GZ4P2)Q84>8T6JD4/KDR[*/\2J]187)<%EQ-CG1C"Y:6A ZXL]&<T7I2
M;XZ%)%>_C0A:?.'#:HRC <@FTE(\.+NO*]*L^M7'TE[:K*#N*M[+U#XFD\XG
M#'5,/AFALRO0ZB!+(DW3&I@*[XYR[OE5C2X8'=@=9\0#+LXJWN$L[ PM>Y^2
MQA:P$P)+EJUY?:_N9G?L6B/T5XT@#Z(8EA(SC-[:=4<I8OQG.T6W5\XRZ ?Z
MY&^#5#3D[@UMOK[\^7XLIZ-1IR_T?<V@433T$B$?2*0>1#5@;,D@OX WF%(U
M1KJK?&P"G]N^X5E4%9E4!A[B#Q;UV="D2K QZV.FJ^*ON\=A#U/XP$M_@;B\
M\JO)Z ET8B%PEV9MGSX(U.?S/4"Z=#DHEL+G7+J-=JZ"=O[*.E-PQ*4[SY\%
M[^G/37[8;>[\L4A [CDW_5PLPH <R%D/5F(@ V<$'84Q=PI#Q+#&:^)),2#J
MJRW-TT3@G8!M:?F135:S'#MGE0#]S0O/K3D53.Y=&SP.7QWKX[%?\^XQHL;?
M0GM%@2+DO1F^*SQ-F(EY.M\ZN=D:XY"Z<K><"54G,FAW0$]1!!,'-0KCF677
MV'8UR7/Y/:$"JDS\0I2+&H2QJ(M+Y017@2TTOR[<%I@J2*XT?R@QH2<KFY-2
M>H;5^%8J0LH=>%95"&<(G0>BC,:>(1B$/T3U$@6PP*+>LJ*(D?34)0O-DI4Q
MH=9T_FJ!'/N#(FH-F0: MM^];P_2EFPRB=2;L97KCD(U>"[@DG]D0<EV\W!(
MT1C/B&2R8$QXV975U3"="]6F!_OD![/ !N=#1^"H!TD+PQ@]K+'D=,DS"$@]
MQ[_XNY^5G@]/0YV'YW59&3[!.>N8@(?6N_T:-=O\K6Z]J29WOY6H.P:$Q8I4
M#O_?'RDKPE:K,_C'B%1;Z NKV9[$(8*_N :X[U-0C'6/-X4PA_!9>*,15O+\
MV!S93S/SF+S\$N#D?ZLKG,2Q*O5HH3B;VVWQU<T;LZ,N7<Y4>:]+!<_Z?&&Z
M$#*[3V2U5TLW-@$=8< _;]-_A?->1U3ZG*=:)%KUPS;N1.VNO,2)X:]B<]ZZ
MA:_"$KS\Q1&7W&YHOX&5(BPD;FA-97;D,\RD"G3,17PVMU$;>59+4?0X$[C;
M;;=@C8CU'V->'"T:SM]^FI[JR?]:/T0R,>UJ06-4='3:M><GJ^^7&+92AHCC
MB*:6W:8U[\BGIF$D@).!_@"4I055%A;*IN<NKF)IVDF;[[[87NKMD*N?;K A
M.'^ BF759T9)9>$T(";C3]SAE[X1Q::KY' X6V<_3[K=(=J9[03VF'$K<6W&
M^5O)INZ,\<Q@G><#F_ZN=PP;$E9B]?R$'-N-FWY^JZQ>:[X/YGFS$2Q$C8KM
MU38Q]<HN7%U>B5%62+7Y4?WCDZ?;*G$=ZXCBZH.Q0,]AL]85H_:O!#_A,>R]
M&VYX^,[\AT,'(J=\0B(KDD'[.=6KAG-#"<_VZ'>5<8_4FTJ"?'LUFCYT3M4X
M33*)6QL.^-$=,>CY8@Y?95=>C\Y/:?YH^B-E-O84@7$E%'72X%6Q[FLP -ZN
M;JKI8I.D\\V9*KM:W065I-U@X>N+AF,2GIQW7WHR77&R>?\=G$]'AL0[A-='
MH3<\%35;9K_&X2Q.'C3&TC'K3ZPVQN[?A=?K^UM:/IM@7_G.49+R)OM"%_N9
M^A%9_&:"6TI/]QU%2$O<8KI"PWVPV\F'FG$,0@3)R]UG6VK$]:C'Q&HF\P.A
M\#3K?EP3<MC=9D$A=W\KAP;#22B'&)4.%7V[(90V G=UU_>5=P=D^.9+I(:^
MR5REZG-;;8VOU4Q3<OQ#F4< <Y^0?PP_)]Q'H\8D6)NZO&]\M;,I<J-RS2[)
M]TKJHXS=;QK+4LO/-3SVSLW.DP"U5QM0L_T(^DY&B ZVR$\^!]Z3HV/NWUD_
MY6'7T-22J>EK6,1]T._#<:EO\*M@IR]#">7S]4 @ZB$HRA1$(_>1W]-ML.^I
M=(0#JL/D\D) .L:4Z[ZN[7OWTY1]^P=<3F:,CT=/S!QC-B&/LN]T?#-^(?1I
MPCM=OW)63VV*'/;;0U1^!%13(.=LR^Q\Y,4T<R6+1B\CV@V.7T#91+476@^6
M+1\&L>W1H33[@!10%7A7!4WAK+<#CG]!OD)'\.70DW)6U?>%+X?]^,0$[-\G
M5,5?$VY^B1$D5%RHLL^WP/J*EQU3MD;0=;YSEO,9<^7(=!%*$19E&>),/_CJ
M:!_^[+'/!I 1YE$3N8=S#X)AZK">KC!_;W>?HFW3GP'%*3>'_5W*N,=OH8=$
M7#X-4.MV6_IQEP#R0L;A7B3 O"E2YP5><Q7V K,B!F]&/_K<5&ZUM)VRJ"/9
M-(UYXV_O><Z5IS=**R1_\JXYF/I:PD2[V]9\Q[6C1TJB1BE^-M+FEI8+^NF+
MQYL?TI(4DJA0!"L;H9G2=;V'D')9BUL[Z;,OLEO39@WU;4R5% DI,)<-M .4
MT9I_?L%::7OMU)]+>U(K=6A#;@!E@'F<;Y0<?G5OR;Z(3+DCY0@E!6C_D[":
M1O$0_0\*-/IQ;Z3DN92J["T)"">@B^L+H<V%6U=\!WED;-[A)/!>*,5![V<H
MZ,>6]-D)H9:(ZJHF&7>UG*:C60I+7&B[*PG@EJE4,E=_1NZ^ZEWMM:SFPQ7H
M#+BQ9C=W5A%<#^O33_ C,A(X9WM-%18BGV$R$Y9,VQS#+?5=?4>O:_!179T4
M]+UF_IQ,FR3>5\B;145N)$QCXKS3Y%[MC4TK_CBUV;=OXSZ?HD_)[:PZ99%0
MHU3T>?WJ=\0\(3UMJ[G*MR8:E4Y()LJ[R;CDLGWI4($!8[T,ZV<QLX?SBY;Y
MKDRW4]ESMLZ=.SSC=_6++VU(QM6Z D(BS-45H@^*S-!I CK7-T]9'#>)RT\N
M+*!75 (MFU_?7'D2_2VVVJP^5TGI*"D.@7H(C("S.DTU2>^&FO2L'?82)<?M
MXB\6/KHQ8:GI8&$D;QXVZ)T5WL*7] GXTMJT"Q231P8!MYKY&=#\F''3M%!<
M[T^%!+H%,VLSBVWI8.>0LKN\R])7$T7W(!6U]0VZ-32 '@6K3/".E)]V6)4-
M8VQGB\'!BI'E8>&$B9XKE$!)+'K\0X %A;5XF=6T[BHTLGYQ00'C62)JW5)5
MY>ZOSH@M00*Y\)?1F^]0PVN/WD[Z?Y 8D*KJ^+AQ,%)76:XX,!(ELAUD'[]>
M%4P"X 7C"$B;(C)(<6#?K)( ;- %=>49"%6I3JGKK1!+%R_^5W<3/3UMGZ.O
M"*KSL'N=BQS0$,C$9A&9'(F$4!/K[(=5$046U2]?V2TLC!8N-'\P"A_%>J4#
M@=&]R,4G2&5M:9V@,KF<Z9=MVZDZ7X"HE' %1=/M&CS3+$85#=XS1\?2<R.:
M!G+(0U]<UO0+AM'(W=?WXV#2\3X7JW%)EW:W1*9$F78H;U1Z;A+CB7V)<\'[
M3T+I\,H/.(=Q!&W"JT:%R[HW4YV_9SN(26F?\/G*9I( -VN>(2B@O,3/0.HG
M2>%P6DGUH<)OJ.BI; ZGY(/#.UUT$[KS3NHE    R#9H]1C%[ORB9_ADTI($
MD "#32?WO]7\-(U88:N<Y>#NY0%BW Q<\0<6I3\E-T[\/7W@?VG3$)^KQ_]\
M(X:VLEQ7Z\IE@5K!YV.M_9"MORQ_X2E8\3> 2-A/J[&=GR >(S"A67A#>'<,
M=PUOB:J)[Z!<VX]K.\L!D7Z[L]"!^'[Y( ^K!]&$;7X*]TA(3YP/H%+?&KEV
M>J$-$0&OWQ^ G2>./;U<10)0*48W)G&XWO!?*0!%'@T/"T[NR[O';'6ZE#C'
M&JPX- 1+#3\NJZ6]ONX/S3"VTC&2!0GN@^Q!L0P0":PU"M;=7/=='PFFW-D\
MO">KS:BJ5VY&HSOWPEX >'UM39._XLSS0V>.D9G.<]!Q$ N$ CE*HX^Z#:7(
M0 Z&^^=(&R2&#+M:G)A,/3G\(^Y,2ZI6XK*&J^I0;(/RW;<+%G#PM[?*;TX9
M*7ND%Q[TF[;YG^#%XSQ5=%"FO?,0E7<N/S^_HX@;;A]HB?PNI)#:\HISXFQ*
M\MSI<Z=S]37I;HAZG3VZM9I(FRNH#7C4L<B1"LTRP&7!J26T9'2-2FZ8:L%]
M^.+^FNL],L_W=LM@JJ7-?D8/:GUXO]8/2$_\B+B(#T8:P/I)@,N=0HO;F>3D
M)(9S8H;&T_E>U+T/ETVHB99+:N\9J#B*7E)'-!>?L7L*44;Y=</920"7I$C%
M-I,L)+#6!<:D&K0BTXY^L&RY2_S4W&F.3."GQ^0UVBWSQWO,,>PCAEAQSP5]
MAKFTQ")_E:?4H*PKYU1/* P*T6_Y<D2CZ^%1Q:!U_D.'.XMQ_M%#K3,/+W71
M/KAD?_ !Y@2.NV'4!;KDOH\,.@9>5NRC1,_&RFGX>-4C8J2DK&V9,@YX5LVO
M/#%-YI.Q5^ZJ4<36($'<W\!LE2!7Z>A,K83(DAILC=&4I"I'<.E"MWQ_>GC)
M4E?JATGXO/HLUU+H6YW-/>K8]F&1P;U'OIW2*.DP]2O?[6^C?R385YN+QYSO
M?.?-,Z(QJ#W/7__5875=[FP*=@NG@I=$1^U)KU?0)T&%4'N54.Y9=3ZW7,%.
M1@/:F36U2V,XT%W UV!<->U$<$J9MIAEPJ>[N4*$;)@;C"=HDP?8U\9;*E$#
MO6*YP[G7WT3,<GVWY'K-AHH_J(I/U$^N\^'CTP2?-Q12VH?/0*Z->RI&X[M\
M$XVO!9J:FK4216SOI0S$7F-]]!A \8SR;/4][JT-Z3"X(SB&,RJ2R.,*544=
MW1LMQ9X\0,\FT!B<R[5:7=9WY-H+8#Z[?W9-#1G@L&JJO)8WO[,>,1,%*]O)
M9>C\\-(*W=FR%OCRUK3D[C%!S+9Y5C]WQEQ8W_2!VPL#KKHNG[2/5Z"=XS?]
M9+?VY[U[8 RJ'"AIS0EUB85Y"VS1C&7"0[-^6CVAD8GV-]PW*YCO;FN\^>+I
MJLB@JUSSUB4_S"BKXZ\U],&*?[/ABYQ2]X&14<049EK%+H(C^=1K_^DK[_]9
M!=?6P%@1$F#W>SF9+M1N]>4]4P=R-:D%ZCG56NW1ASCS6UN^4PLWH!;%J-'?
MP;G%KL=GNA:X:NG)_<S;[$5)8SZ@9KN]YW*EYTW7A#HR Z,AY]%Q=] YFSF/
M(W@//JW(>OI?D"$V4]DGQ/+J"B:UN<_#5RM!W!V@M:0D$H#SUSJ,'8^E%O:#
M/;(JL&>AJ)5)(\36DZZ1J:?R#8V$]+D4W80P3H7[%-RF&$J<#3G]YX/9@A;M
M;3(&X&P=5SU5]91XO1H*1CR\!0<YDDME/OD,.&C+;\$:A/$,6T2J/9Q44.38
M "\W:AD1<^RI %;_O-47J(VU'!X<X^:S;Z$_2,KZM-RU%7OLLHXTM!F7])A=
M:5+-?$W],JG!TU('IIE+3OSIH)\Z50FO8*MYG%)QZ!LK^G2!_2TGO(*Y \8Q
MD@+M9NMABCRO>YETNU;+? L=.-^A>C$1<6NT1.HI6S0FH<;=1F2J<F\?SUSH
M9M%H,9W-EM#LZD>H$]5JN.7EZ-QHMB#X1U&@^.R>+ONJ"2BJ0RT_R$BS$34;
MN6=?7UL78]L2QM<DD'"!]6$ P/1LGYZRGA>.AP0PM:I+N@T5P&L2RO8@DN@'
M?>H<#;,FLN]V2N[&W6R?KGYI\CZ2@TGX#V"?C V]7'JJJ*E^$#Z_NM,!U@%R
MQ,9U(R[+U\397$7!>^GTAVI1H\UOKEMLL_T<:4"H;;V>$&DSN"_XXOQ-EE.F
MU>SDIZ;?)%F-6!\4P((DY&X4G0#3. <JRH(4,3534(Z@]C5!!0OKI9_7QALI
M,TQ#;3#B6RY%.-6XRC(?9KK)NY(Y_#?-TQ[IR= @XFJ029<A#R,)_%\Z9->R
MECGDDIK<O0/]G9U#,4:R>^"%\AB!LB49CVV9;(;'\(I7QL?E>2-$U,]&%>GW
M>&-",5%]&W%!71J;A-Q,*1LLTBHT7Q@KMG1;6.X9*Q^2T]8^B"?RU;VJ)@&6
MZ?EG?-F9#Q68.G/1>1%$23)A8)2GI\ #IV -E@:HT=SZB@JPNRG,K:,C=>/R
M&<&G1;41E,EG?.N!>4KKE$>W8M6;'K3CNFW?!3[I7$<?8K*QO20 M>;:N5RF
M*8BE*_*A-3_-'+/I3/5&^N::D>S(0YQ.M%S/QPB6,RQ^S+FZ2A8$(ZQWE6*,
M.L\W7OZ@KS$U1SN6J:DQYV(=8RQIKQ*^V68S"H_E??CLWIC?4&;Q0$\O@_J.
M9".+L9:#VS_^YOYO&B*7E9*I;#KS]XSA3IK7"Z)L@H[<?\3',R:'<)Y.8AP)
M27!GX-P^\M%@-W!^ME?O;9#%]G;(?"7OYMJI34C:P^2,]G1GOC06UN66Q.S,
M(UB"15Z_)Q>2+<;?^_E3_]R:=15/A34#IL%[,*F9M=-[K^W36HJGG+OL/SQ6
MB27:-^UCQ6KPEW&]L*;-.!S=-H*RD[ND#\S@ZETY;T[3NL#6J/4FCF/@W499
M?T>>J =*3<O3,+LX3QQ_M]Q0QK41VE:#9[0G4N71]XPQ0"XW8EU2@IS[VN(Y
M/RQ'3\M?3E3!.:;8YRZ&3H:F]=SY=I?7[ D?.^L9'7N<.AD#A."K>;#ZL;X/
M-.O +N^H(20)P!+D.['V:?)>G#$\T*7Z19QT;JI58R!MCPE7L8XCUZUD1@6\
M\J_E56U"62<5= YQ%N8(6Q370 6&127B92O<.V4^6&:8R974$2>".K(R6ETN
M"[ 62FS>PDJM"\1#1R#<A/S.L] O*YRMZ*2N/(YOG=(3E877EI9=V<:M!\\]
M\UKD2\BR]SRMG5/:*E)NJ[-H<=X4$?/\EC9^>EP%ZZ8!K;XB\J&A[>N>EDC6
MN&5LM*Y402(&P_7$U=*OJ4-F23!@UTB3NG@EKI$YK_0H"2M,1N2DM_B[6&]T
MG!XJ(VT-],*"!<J)RD$L[EOB0/JQ5)+I0,D2F='H(G_$C2%AY>7DBWN=;- Y
M$J >_*M1^3)>$:N,ENWE%9W=#6]<"$@K7[1>BDCBFM/ACA\I-^1XQ5 2IE$)
M9H N@^K $:HZ/N1,@ EO@8J(K'+]U>[$RGRLRD(0M0U(4SC0=EQ*#;LHUL6@
M32^77?Z!"Q8]Y5IU7^=7*R[X:AP)@+J+2 2R"V-WT )(QS1$=(V7P<;7Y&7K
MA<5E*R:J5'<7X41*)]O60^ ^E=")P^QW:$R^RPK'N*>J,G)8UT..H,Z^5^7I
M66#V+HS]E9@.IPAU:3G@$0!PX3SD0R5Q!5$G'-4IHMAM$+@V^Z(2;Y8!M@T5
M\[29E[J_$X#@2QY*R_!9W,A6_R&3*]Z,C<&90LGA^6*'3C!9H%@X(T0>665I
M5,>9,YU>5KYH8:7I,,)@B![FKQ^PBKBD3<-P9J@LHS' <$-**Z 2HD4.PA?#
M28!S'["+:) E=ABMB7PVK:JWIO+=GT=[=^=&XZV0-UE^\ S6[=OM,9^G;W:&
ML_XP1: ,Z.?<3C N;80D6VRHLRUJD[@MOC,J8/2^M8[-]%I]FYXJYE#'1_;"
M;>54D\_]E'S::B BUP,,"/P"@^#YBBU ZN)9 P,D^&>!IDT&:M6?T@]4,<DZ
M6YXF5Z]K/J/G-GV'Q:V/==-'F#X]']6'8'?IY,WK-Z5QS1\L16AZ+,3O/KRX
M]R*QV%GHR_F[>:^?QGKY/S& ]]V1.W85L.\A Q>1%RN+](_J-J+[?F\QR/3N
MQ/JX9^.*#4MM)-_9GL!4\]M_B"[I"91=[:1%P?&,""+5V"KB4I!ECSH/]BG*
MM9,:38$MN?V\J<KD4>-T(<.%',CP@ 3]_+L1+PO5ZH"-+!48ZE'2(ML@HM9[
MUV@-O&"/3,\JV5X8B/,OT:!K+JV7;Y#<F'JL;,L\<$K]-?[:5K465 [;2Z21
M)+NC 2$-?WZ5? UF% M$/L'JK7-X/)N"J$ VT0)3?+(] ?+3W:8R9Y$VURH?
MOGMB1V<MYB]8PP9_PRILH*+G^15* D!G@+6(W1K<8VR(+FIP3P<ITF'L_M9:
M?C,7.NGG*-_QN=VL<":U5\2$?2D+(_-(D*G\]J\-('9)\P6K6X-YC-#)/'J(
MBE!>(M[2_E).Q?:D&UN+K[7E8N6=V"$?U93(LQ</MI_/59O'2!B1_8H:OOH.
MSJ N".NV['#$G=,L_BZ]6D79K4 4J9NV-8<B5%O.=C]SNLX>[V!=QQZO2#-F
M10BVQ85 ^S)K^EFQPL5D#WM%E BIJ:U.XZWQF)7T;_=.9M ;:>\$2T!P[P?<
M+$HSI)I;-N\_]B(866#W4-)(\)XT*LL<RX5NN4-<1+5$"^CZTTBKNWLK"Z0X
M&F_>1']Z_^1!VN.@P;NS4=_ *"/X/',OF%F=&V(WKBKP-2@)R1N9R_5OL'%7
MUZ'%#-+\G@P;Q2F!G^OU#IT#;@I\E801:61P<EA[(C5/&;&7*#)]9$"CA\(D
MJ<V4K%4],&MI:>0L5]65^];+T.GK#;NF^KSWG74V,YA,-KO50*M5<" )X#VV
M".N'T>&E\NB?[$= N:;DN<S^P#VI#RHG3LP[,-A8:E\]*'J>]^GZ^Q?\XGLF
M]J/WBQYI?4A?\Q=M%6H'V4&YH!_!#? >8"+T.J&0R!L4@@,-P!EN:X*GH+-^
MT@M][/.X-XY!]@.4/TLGU0[!>K,CN2R$)IC]/@_^+N@"A!6MWY,)CZ-@'TAQ
MKE@8#?K<*A''I&N><U,H3<-Q\,HC$ ]Q*:\NJH?@=Q\UU@>+)3)^:9+DW*81
MQ^GO.<U0[7E):;@49"HFRWEL%SW[0_V>Y=NK]3Y93XM=LN]_^9D;>RK<#VX9
MVU5;]2N5CB-*8Q4-/87O>8H="\_L,>[MOTK^HEML51D7WJI[_J;@*H7U%4(]
MS.$EFNT.]G8><X?$BLBL75BHRAUKF^GJ'P5MCX)HC6,40=GQ50SW[L;ZMG)/
M?,WX8]-ZK+ T/S8U+%;D+?TKD)?W<R@KH1#N,,8-X457C1**<TK-:#(R[EZC
M>?L3$A/,8-28]N)'*BNM8-!4F<!(DLKL01:1KX,0#?OFA480*5U) 'QUS33]
M(GQ-H1U5@M%#UR2HRJ7O!_,4FL1*O=./#D,8\534Q=ZT]RT3%:L7Y_M#L4+J
M(5&<!.C=@KEZ_SP39$\"G*F&GTK![R!Y>=8D>L^(M:II<;KY&JWHKVR$[\T7
MH),8L&/A]?&?V;WX"S?,)^/SI[@_S(H65F=NO]D!HNFV?KU^T@Q,),<'%2,2
M8,/_[XX%@_#J@9AT$N M6R0(Q4DF:JG?2("HS\0)Q-%9U""1PAIV8!T*^IDT
M"#P\A:VZXY->D #114@8@4*?#!^@0S7[OXA=\%=%"/_EGD#4*6+!DOC,AIT$
MZ'*O(>H7$'36DT[Q<)0\48-,%_7)P/GS0@:1&K;Y=!"O&8QC( &^+*_#\9<F
M28!3:YV_'K(A"T2?0RB"?SN/3,)?:",!OK:!D(?PQA8"H$.&!'@V"\9GZ/P_
MDH03^3,B2( C.FD\"PDP<IR$C3S$\)$ []H'85B>$A+@H.UO#G7D$8$J.'W8
M%YI>();.GP08>@+[L\F2CH&)H*T#LF"SIY1X+6D:$N ;)QA+SI/_-QL&N WB
MAHUMD #/:P[HL;$V;&2%R,%_;>*1G0&M<8W-11$C]\G9RFI '@GP:?MO#AW
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MKY7/%$Q=9P%+P; A\&!:NW24!C,VHW@#R BA6I*Z?;CD&Z4AI/<Y*,G-]5:
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M[N05A=W]HZ#<E#%1-^%WG'!D'/Q 8%1B@WOG&W1^"QH#SI Y 7,&]A$?>FI
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MJQIA=T>?L+A0V$5+73PX\I76$MBX<G]Z?<J"!(B/BM?-[V]H@M/"AG\?([N
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M=0%XKPEWTBG+#YWEA377"BQ]&E!?'RF3ELFL<!E:N0C:@U!8;MQ'+'[L1DI
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M)7H:0MX.;DZ!!GUW<LQ(GJB1%\]_>*S^]'N=?->EMP?8> _!58,)!:U[[FZ
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M>=<P9J?N5U4@?#SF#G!7SIF'E:T)LI8VT>QQ/&A^%D/<SP1T1FHBOX,I1YB
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M"<?JV'\H(#_ZMNO:="O%P\J1"=#Z/BDPT5LJ%9XRT\W):<_M<UR9RD92HPE
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M8/GMZ>WO43K[QBO)_69T7HO;)0VBC(_'=) 9$SHQ,,AU<X8P/%>/STU0 L>
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MD'%^2SZOO+S"FU9W_9^6V)^ /.9O&9:C4W3KD@V?GI&YJC17$<<;*YJX49U
MTS:FGH^TC]\'TQW=H8B.#LBLL#"X@UE7T1/O#*7YSB86,]^SFM#^:0>/B]FH
M&"EGI?^:]-S<O+E_>"Z1G QX+[/PK0MQ^"Z([W;;L0/^*G&9_4?B*SI)&/A1
M1@4Z!/PEQ:3#05;6H\JDZ9UB%GZV]L,V: "0PR\!UQ<3CWB0*=U"G/NVB,=
M;97]K[D]'#S?>KAX3G&JO*(AN1\5X'PUSK]%V=X]\Q;E>\'">?K,AQQD72)/
MWS!GL"=I:?,<2=\/S 74XQ,CJR@:^"#FA_#;$*:C8ZW''7")YAB+F6K'<>C]
M^M8<WC:LDJAE\@-$V?XP(+G57D&Y ^"6L5%Q^;80I(0."[[U_9OD>?>6AFS4
MQ>Q2J6Y[)H38SPGEAE>A+R3'MGR3U4.$C@Q0G2:A@M3!#HWI8*%20 LR7:FN
MC-B4V]X013,JJ3&?-693^O#,4-5&;]!)V%2DUY%CH9/7HYX31"D8 S^1 Z[[
MXX9?=UP 'N%+<TWK@:N?W .K7V?O&P:(3N[#!_FHQTK\M8K?JLF>[DAISR?O
M(ZY4.;V5MGL0MVFG#-"4(/WCB3;+<]URY\6Q%U0?+<!:-(;*9&-*@;3Q>U-;
MTG:'*GK5'A6%S>R_F<3QSR.EC.X4WN3-OY;K/$^3#!9MMQT)_ A&^V ETN7
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MDVM=:G)0A([3WZ$)_E^G]ZMB*1^F:7E#U=*98-YJQ1PUXE9M(1)BC#'V)#!
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M-]2L*[F*N-9GY(-/W*@O=.L \^E&N;9VC.?7OUOX=?@F1Z_VR'S._J[G59N
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M6.>%GZY?9@W^6L\DR,=BJT+[L?7@&(I[J!@R';\4J23$E@M6K9Q*@BMM'SZ
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MZ?-!/Y?^B33E?,)6ZWT&3/,2]8AE_MP(DV E8AW2@:SFYJ48,;I)_Z9V9N!
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M,/O_"U0ZE6*$X/\71\.+I/"Z"0!02P,$%     @ *X!I5@GZI8WAVP  :>L
M !0   !M;VQN+3(P,C(Q,C,Q7V<R+FIP9^RZ=5B44;LO_-#=)1*#DH* =#,@
MT@*"A+0(2$EW"PA(2TLK(2 E,2#=C'2#='<-/3+#\(WO^^WXSME[GWW./]\_
MYYZYY_I=S[/6FG7WO9Z9N]]WJP"YFI*J$H"!@0'XH%_ W1KP4-''[BT :&@
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MO[;])SK7_H?-,&B'_NW:?S3..1\ Q"_1NOGT;]?>9 ! 0S@ W)O_MVML7P"
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MOL;/W:G\XZV*A:8EX<- $A@1BE  =G 5>3H!=U</M%&?=A(+3)/1F7MH/%'
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M?5@6,**)<+HZ9!X1A43+LL..$F*0,H&%^_I[OL7[7F=&2W)W@)=MCEI-MOM
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M)>YZ&U4<FA Z&VENT^'P,F]J0!6PN3)T8B5JV[I! K%1'T6&-U,%35P [ET
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M-+'@Z4D-24JK--T,Z$A>OH%S(9Q!"1SK.YW3E(#VJ* (\IC*SXK"::G^%W^
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M9TPLF:7V8*,NOAO7@&Y) ?7.@MV];G/0?HY.?G!G/YZ[#GUHC$QJ9AUMXSO
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M"N;G=1;GZ;E;!N>#Z:Y^_WIC)6-0,?H72ZIKRH B$ WS__;&#L,+9XMXES=
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MC_T?BS2(R$ 0<?1A9\#;N5H<L'31K0H*3KA[!EZV%?4CCW[OR19;/QT29&(
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M$$[[[?S(XU^@WD#/%">C;WI%%OO *M26GBY_0:&2!:;L9N'+)MW=^WAI).2
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MSV:WT7>\:]]S?6&S<%+20P26Q!>7:??P"2.-;B$I&*8P":XL3:_<I9LQ:0A
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M[FR? .IX)3$6M'_HE.6+98XK&:IR5H_0E4(MKA'U>=TD@R4V(>/Q3M*1ID6
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M8S-?+%>YCW7IAE3O$+OE#G3Y6@Q\_86];-A88K^XSNS#$Z"_5\C"OE#-/Q<
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MNU)"4ZF3_7.;LF=8Y,U&=]58,^SZ4ZY4A_:#JF^QBBQ+E8YB43M6;-T[DQ<
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M=53TZ=D.3/WW5%V^=GHLY3AJ=GM@B:H=!MGM4Y$Z(\0"- \7<B$=F:B@]4<
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MS>$XL%=\HY4#C<0_O4S::M/3Z9'1,8RU:3#T%3!P\T$$_5WX$!RQN6N<J].
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MGZ+48N/):J.BUN.%J:)YXP>4&C4_UM->-_((D!N-[\DFEUZXY4(0N8IGO F
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M<[-"YHR=I_!<H:&V2NF8XGV&^$>B++=5>J3D[ 0C@-7TGV'WQ8NPX[UL5.A
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M^U]L#?P[_AW_CG_'_Y?@8<_]!U!+ P04    "  K@&E6U\DVXX<. P!0.0,
M%    &UO;&XM,C R,C$R,S%?9S,N:G!G[+IY/)7?NS]\F\<(F6DK91Z2,=-N
M,B<90H2$T#;/X]Y%48@B%+++T XAPS:S,T<A<TCF>6AOX\8>GEN=[_?[Z7/.
M[SGG=_YXGM_SO,[*JJO[7FO=UWQ=[_5"_D:>!([J:^MI Q04%$ 0^ <@3P$G
MM8)<[P" H2$@ 0  /?B.': "*0KPSZ]!GF:VU+MTR>Z:B9&VWA4M< $ ,.M>
M<?7PI#P* .X>?CXF.A>%+&]8"=%U Y0  T +R & O8.OEZ&IMMGA"7I:EX1\
MP47 'V-GZ/<7^J5UKPD) ?][@\W!R\</9/(:2,L[.ODZ@/0#D'8+]/,Z?(X%
MZ6.W88<T)?4A[0,R"-(\A[3S;UKJUYK?]/E#VM'=PQ&D#WGV<G1W/*1;0/I1
M@+\32%-= >FH %>G0) > .E3;O[NKB"-/]SK[F3O"P#4S(?/_9P<7$#Z#$@S
M^YB97 )I=5"US,Y_H6__A?9S"O([%.J2IU>PCZNSBY^0F(.XD-RY<RI"NDZ!
M;DY^?M+7[!U@]CZ.0I<\W;WL/8(!X+?,OP;[H6Z%0"4KR9U34I(^*R/W%T7]
MW[[\+XY#V_ZF-HU_V8R"Z\N_GOU'ZSRS $!E&]3-TW\]N_T2 "H? @#/Z+^>
MG7H- *R@W2IZ_B(/UZ&_N/CY>:G*R@8&!LJX.CG('"KTG^,_7?!?&'_YGLSA
M<?]4C]!EISOV_FY^0H=Z<_!T\_3W$?+ULG=P$I+^NQ/_MS?^QWQ(F3C=<?)Q
M\@!WF(->YNKA#)K;P]'5S]730\C5XW]EQ/_FMK^-WWX-#HX<$G#,3@8XVG,,
MH%K[ E!S, %4-S/!-Q3_M-L5!G/@,/(L( N__?[7H/CWIU(F'/[EZ^K\:]\E
M$S,A!W^?@-_O#L,2H $8 5;@&, +' >$ 3% &C@+* -JP'E "] 'C  SX 9@
M"S@ +H [X ,$ F' ?2 *B 6> LE &H $<H \H @H!2J!.J 1: ,^ U^!06 ,
MF 3F@!4 "^P !V"RHZ,X0L%!P4L!H3A-(4EQED*%0I-"B^(*A0G%#8I;%,X4
M'A3^%&$4D12Q%(D4:11O*/(H2BBJ*1HI.BAZ*48HIBB6*#8H]BFI*)DICU$*
M4HI0RE*J4%Z@-* TH[2A=*;TI@RA?$ 93_F",HOR/64%92/E9\I!RDG*%<IM
M*H"*B8J+Z@25-)4*U24J(RHKJCM4/E1PJABJ%*HLJB*J&JIVJGZJ2:I5JCUJ
M6FH.:B%J:6HU:EWJZ]0.U-[4<.HXZC3J=]05U"W4_=13U%AJ$LT1&@$:21I5
M&CT:2QIGFD":*)H4FK<T:)I6FD&:.9H=6EI:+EI16F5:7=H;M'=I0VGC:%_1
M%M-^I.VEG:'=IJ.CXZ63I-.@,Z*SI_.CBZ)[2?>>#D/71S='AZ=GHH?0GZ77
MIK>B]Z"/H$^ASZ=OH.^C7Z _8#C*<)I!E<&(P9$AF"&!(8>AAJ&'88[A@)&-
M4911@]&,\2[C?<87C$6,K8S?&3>9F)A.,IUC,F9R9;K'](+I ],GIBFF/69V
M9@GF2\PWF?V9XYE1S!^91Y@WCQPY(G+D_!&K(WY'XH_D'6D^\N,(GH6#189%
MC\61!<&2SE+!TL>RSLK >IKU JLM:PAK"FL9:P_KZE&&HR)'+QVU/PH_FGZT
M^NCPT6TV#C8Y-B,V=[8XMGRV#K9%=CIV$78M=D?V!^S9[,WL,QQ4',(<ES@<
M."(Y<CA:.>:.T1X3/:9W[.ZQV&.%Q[J/83G9.14XS3F#.-,YZSDGN:BX1+CT
MN-RX$KA*N8:X]KD%N2]P.W$_YB[B[N/>Y>'G.<_CQ!/#4\PSR+//*\2KQ0OC
M?<9;R3O.1\TGP6?,%\B7R=?*M\I_C%^-WX$_AK^4?U2 4D!"P$0@5"!;X(O
MMN!Q01U!+\&7@LV"J\>YCI\_?O?X\^,-QY<@'!!-B"OD.00#61;B%+H@Y";T
M0JA%"'M"X(3N"?\3;TYTGS@X*7KR^LF(D\4GQX49A56$[P@_%VX2QIZ"G#(\
M%7:JX-3H:8;3*J==3J>>;C^]*R(J8B$2+5(ILBC*(ZHG&B):(/I=[(@85,Q;
M+$ML0)Q67$4<)OY*_*L$I82BA(M$ND2/)*6DDJ2KY"O)7BD:J7-2'E)94L/2
MS-(7I .D"Z2G9+ADKLA$R%3*K,N>DK62?2;;+DLZHWC&[4S.F3$Y=CE]N0BY
M&KF-LQ)G'<ZFGQV0/R*O+8^0KY+'*4@J."ED*GQ3Y% T5(Q6;%(D*BDK^2@5
M*2TIGU*^I9RA/*QR3.6:2IS*IW,TYRZ>0YRK.[>GJJ3JIUJJ^E--6@VFEJ^V
MJ"ZJ[J2>HSZC<5+#7N.-QJ2FD.8MS=>:D] 34'MH%G3ZO/!YQ_-OSR]<$+]P
M]\+["^L7SUSTN8B^N'M)]5+XI8^7J2[K7(ZYW*W%KG5=*TWKA_9);6?M FVL
MCJ).J,Y'71I= ]UGNL-Z@GH.>GEZ6'UE_7#]%@-F U.#-(/I*Q)7?*[4&%(:
MZALF&7Z_>OJJQ]5*(\!(SRC):/R:Z#7O:[7&M,;7C-.-YTWD3,),VDTY3.U,
M\TUWS"Z:)9B-71>[[G^]R9S5_*9YGOFNQ66+1(M)2UG+<,O/-_ANN-ZHLJ*S
M,K=Z:[5MK66=;#UW4_%FU,TA&U&;()L.6SY;-]MZ.U8[>[NR6S2W+&[EWR+8
M&]EGV6_?UKN=<1OK<,DAU6'%\;SC<\<E)PVG1*>%.QIW$N\L.FLX)SDON4!=
M4EQ672^YIKGB[NK>1=[=A1G!4#"RFX5;L3N]^RWW:@]V#YA'B^=QSR#/7B])
MKRBO26]5[V1OK(^!SUM?"E\;WRJ_8V S]<5?S/^A_U2 9D!Z #[0/+ LB"W(
M(^A+L$3PX^"%$.V0W%#J4(?0IK 38??#IL(OA+^!4\!OPYL0PH@'B+E[.O?>
MW6>\#[O?%7$F(C%B*](BLN:!X(-[#V8>ZCPLB&*)\HD:CE:+1CZB?N3ZJ/NQ
M_..7CTDQCC&=L6=B4V()<0YQG4_DGKQX0HZ_$]^=H)20^93VJ<?3H6?09^\2
MV1)#$F>2#),JG@L]CWF^E6R7W)&BD(),94SU3YU\<>5%U<M3+Y^^)*2YI VF
M7TPOSA#(>)RQ^\KQ55_F^<PBI" R%KG_VO7UMS<Z;RJR1+)2LFFS [+G<\QS
MVG-5<O/>\KV-?4M$>: FWYF\:\E3SLO+%\A/** L\"]8>G_S_=?"RX551=)%
M;XJYBF,_ !_\/RR7W"H9*C4H;2I3*2LJ/UV>@>9 QU105 178"M=*B>K;E3U
M5NM7-]6HU:!K96I1=2?JTNLYZQ,:&!L>-) Q(9CMCUX?5QN=&V>:[)K&FBV;
M!UJ,6[I;#5H_M6FW-;=?:,=\TOA4UZ':4=VITEGY6>ESQ1?%+^@NQ2YTMU)W
M18]R3]77<U]K>M5[&_J@?8W]E_O;!O0&/@]>'>P=NC[T;?CF\.0WQV^+(VXC
MN-& T8.Q>]]IOL>,'QU/^2'P(VM"?*)X4FFR?NKRU)=IT^FQ&8>9E5G?6<+<
M@_DC\RD+D(6\Q;.+=4O:2U^7K9?G5KQ6#E:CUMC6,M;%ULM_GO_Y!6N)G</Y
MX,@;<9N\FZ@MA:VF[6O;/W;<=PYV8_"\^'=[*GOM^Q;["P>!!#K""Z(XL89D
M0/I.=B>3R6/ )8"2@N+PY]\&%0W5X:"EIJ:BH:,%RQ4XZ1F8&.CI&>GIZ!B/
M,#(R,8.#CH&%]0@SRR%]>,CA]L-=X \S/1T]\__V('\$V.@I3]">H:(X"5"R
M45"Q49!;  C8T]!0_!K_:&@H**FH:6A!EAB9P 7HHR#[5%24(+,TU& _0Q$.
MO@>HV6C83\A=H.4PMJ<[Z7WL[/UG;^B%+Y8T<IKT8D_)W_:)8&#DXN;AY3LM
M(BHF+J&@J*2L<D[UTF4M;1U=/7U3L^OF%F"CY>#H=,?9Q?6NKY]_0&!0<$CD
M@X=1T8\>QR0F/4].27WQ,BTK.R?W+>I=7GYI63FZHK*JNJ:IN:6UK?U31V=?
M_\#@T/"WD=&IZ9G9N?F%Q:5EW,;FUO;.+GYO_U N"H"*XA_C/Y2+#92+$K0!
M-=VA7!24@8<+V*AI3LC1LE\PIK/WYCAY]C[]L8O/WI0T,@C+FV Y;_OT,G*=
M4I@ZC3L4[9=D_S7!(OY;DOU3L'_)-0HP4U& QJ-B Z  D9 5(P;\S_P_<&)D
M$)/YNPA78K$B-1E ABOUR7<C[E5.[1:L(/ B[6N"D%8R,#*O=N3J&K1"G:O
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MK(^_93W;^:&\%++&VS0PHS#>;YPJ96:-[K,867WU:K4H6+;5""]BGHX]V#%
M\&D5W^7 IS4;Q9K4W6]BXM9FM%6@"(S(;V>VC)+<M5!W@7>3@>/;Q3%(K%%/
M+!PR5(0:$,'&IQ6X^\JG/AW[4EQZMCWI0]-'CEY+EGL6:M,0+G@?AJV!_1*V
M:.7C_L2WZ^R=!D.]\U&P%UF-EK/5MT^,;;S[?L:2Q7)V881PY(#W+K)L=U44
M1V7@<FJPSF&Z@#9E_D>3TJO[UUO,<0]Y?6HS$NFD%G@!CB !ODR9ZS[Y'"@M
MX\2\+VGSJ5+OT>,_Q@(.-KKDZ8QDGS ?<%ZM.&GY0C\V-M8[6MUCRR!%/=_
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M^HO&I^%UJ[3TU9)H,1)^ R-1=*GD/I*2LH(0J*E64B4N^0!GX?W6/ UV)^#
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MO[4<]V*\YQOIIM<]);7&>AR&>JG7"RK&XMS27V<BLN@2?P'R&$1@CJ<P]6?
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MN7-PYB6LE_4?WE,_9C :5G7(-O5[S?>X/3M$MY)^Q1/:,V.88V+TN(S4& %
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MU[%';$[=E?O1'::NMC][GJ]!ZRF-QI.(BXM203,Y2E7SNHRC/TXK8YH>].W
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MSK;A$C?(1-L5KEK W6-$%C-% 9_]V6D[WU:29KNML9-2I"'FJ8O9'5OCG6N
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M]Q'!0E+;V[.+;R!G/^4;C#P<)<'+\1JV#E:#-.[8+5V=//6GMIF+ZC2JVI%
M\H7HA3T5(';54_<*VZ21>66..@H.!BK9*'^6WF4\.2VQ>4J*;#G.4:)M*J0?
M3^Z)O:-"A.KK.K*RT#'ZILB-^%NVA5:7SK4EJ_VUJFUZ'YTB:'/9:LH !(^,
M.O*[X?\-GSQ]H$HNJZ%]<WT+_O8L!U9P,;8[XBQVG5^T_4UC=>AJ%&R/:M</
MH=G$.J9=?5K>5:'QL<-C8E<=D8;/&JVZ:GF&JPJ\JZVM'^@C;NP_GE!DF.]2
MXGXA/Z50N6I!Z*-[UM(.M41XT1&E:CX+1C*J,WWZ,9;:66[L_;W#J9==X$V\
MSZV_@=< OI%QH1*;V.UJ.-.;]AN/D.=GXM%WM9\'(=>FVRFE7R5XK:("FTR/
M]Y:-1\35/H UX5W1MNYA9FOOMK"$8SB.O";2FVPW+PIM>W<Z'R^:.<&:<61\
MYL,(282Q3XN):HTE#"F,6_1UI.8^/5RP8=PO 1:6%AHMQT=K-0A"C@JD8NVY
MR.OS$4F(EA=-6&]ZA,!,\]MB_L_UWLWI_?ZB+''")]< >;BPP;@WI<I:3]RJ
M(^>"#8<KY,<848K9J"MEWGF#0YUQH:.V]:EJWW%Q)I_Q=]P#'Q6:\M'.L148
MJ>T&,<3=)UC>#7R/+/(\ME7A$Y76ATWP:Y_40&$V/@PEO.8KEWT\K2.]BVAZ
MI>2_[74T\@OHP'Q\N9<[1C/0HJ1?VGV=OSC#05'!>P^B G^@G<Y697&T,>E_
M#?A=[B=M.ZHPVI3MTW?'(L]0-I9$F37YM,>52W3I:9]G[(H*[(#$+;*=L8>E
MWAO7&#=!GHH[U'('CDB@G7+O4A>>70.HKP&&;R!(R3X2WXLSN;I@O=SE@CKH
MUASQ+K3 I-U/ >T<[K-J$OLD.*2MO@_.SR*K*E*1;6CF.5O'U$.G66];:1L=
M6!QS56[$,XRZ-Z4CJ@ESE'KW->C+/N+YB?2CR.BY>?N(HNW%Q>Q^ N)]"[*Q
MW"47U_0UZJ X-[Y5;1TX)!Y9'Q8>6Y<(^O3R%@-WAIAO\MV5'J_>?I_M*)\S
ML:4LW(3FF8&+6;Q_:4"\1^57O1HC#X-?*_8:O*;_[.'0:P @G$7G\I6R.\KF
MQZIL/7F\VZ,>C]E7I1R[\S[%UF+Q7L8+1[>.><*V3.,VGN,F*]6Z1Y[W/4+/
M\Z="JY*&QM*!U:F.FN-GQ,;(BW1!^9Q2CA@N9K[TU2;A^;D(NXI]^5R-AJ -
M5@?LU6<_PL45&?*9Q Q8:^ 16Z*H/]+_*N-](SXA3[QX+]74,:R"EGXBU" *
M^B&S\4"W%Z9@YU_7K@%%9<2K#"0F"!07-Z34 JA0ZQ:,>.K%'4\=9[@+[<:2
MX4PX7TS[I/&7"U!.T%V\)EN8=X)WX&/?1S<E&GBF+T!C,EJ=Q<;\4VW9U9]:
MC9KZ6<$KK#:'%%/1B3+-?=1,I=MX)MUAUV-9-*JQ.A6S"&QB[M9-WA?KG#]%
M%EX#G*#AU0I"^\I=#<ZNY9LX-8K^W!0KTE5]XJYFX+N+U/,@;BU?E=BG&ROG
M>>YCP3ESQ0*O1?G&[GXQW+DP_);&BAKNCYMD]+7[RGP#Q&[+CZE8"@K]A__F
M&O;O^!D3!6(M[[U:C9_F&Y'?7*W(;T 'E&"G0H8TYA.- KT*X8Q'L^X6[I=*
MSEU]"RMMR-[1,L4!GP?3<@,6O@=S:HT'YGD2/HZK BY-@W[T)?S616\CJA!<
M-*O;[G:_G(:HG[W]\2MUTBD(Z^MZ1B=KX&HG=;/)>7YM>XGN6]629Y$ M)'C
MW3US=&OLY"P&1^^&TO1._;!+/AUYFDO3%);GKD3Q,2<F4@*[VJB%CM'<3'F?
M6GUH'DS-$4&0K[R8M7^\5V6I8WDHAVUOJ53Y8A7HVF)G0IX>KPH^Z6L)9V2N
MO^VC-XE>*5X*VS"N9KQJ*LUJR+-,GJU?*I[:E(&LSYA$9",'W4VJ94H2-5#O
M<4?VTU8>'TCHZ[V*E'F68Q/_C3MR\I,?M:I+H&:36V7EPA+G,HCR4A8REIK<
M>N7SN"%^\4ACD#,BQ.T#MH&( W<NA]Q-HHGN]] *EUI_[KR(!F9 KA9V96FB
M>L\/]%8=JZ"F0FM'R&\3%$+W))9;T8EB:>9"EVS9;!1 -QT2?/VIFAM)5UH-
M$UB/S&G'M<5Y"+"1G>(=%@QCOF'YFWP[@C_Q@C$DC8/*O$7FLL4NZ+7SB^TA
MW LB.36,A>](97^\,2$XASW:HP,@2<%,CF];5*FK<V3>M>>$!NCE)>QMJ=T?
MP^'(=]]HI15RB.VT+.O6<.?#?ZGHI4%3\SZ.13;JVBC2Q^D[X@R[$%YE4QTC
MW3,WH[!:^R$++FN=0%HE&S>*>-6?MN^D="W-'5M(Q:C#U6].K/^]0AGPIB2X
M*\!2S_NWOCFL[$VB!B2JKP$O5H\R.7)#4_-='5&!0IDPZDM>XB!8J^!3/>R[
MV*0P=US,?219\\DFX]!VY_Y91_+!D$N!ORN53U$;%.$+I83%R\L)Q!5&)?P$
M1>):]L.2BIXGZ #M:V/3J6Z!5J3ZSVB,&N'2M7,YKCT^0-Y.>ZGBB63SL5]N
MJ+0*\Y*/"K)7L4$\!W2M;),'$^WYLP+OE+P?>D14JP:<,RWI;.LO_B-!U)Q=
M,]Y:XHI6GA_N @)CQL\HB,+-^Z<YU36*R59=[I@:ZF^")TVBFOZ?!R@[;%GH
MWS-CC4P[?D\_0IW/7P"'=P-2+'Q3;$_=@XYGJP.NAKS/V7Z)ONR&[ 7I,_AD
MCH\3]/?/"!P*,A@!0Q]$T]BWW+]WI$I-.B%HE9PB$O&QJU*VQL_I/D[+;Z;'
M[!/T1!=3*L6+J#*^BF'%]GD9/!5!?Z-B>!O4Q;EQ9&A,?BAK[S%R8D7DTI @
M_U_M/_C(IOL_3O>6Y4TBZS7@OUYW>]W DF+?-0O8\:/_7P: Y0/B4 N$K:UY
M&L]_#6 ]  U"7P<._;^) -9^_\T->'NK,"<2\.R_#?$_PG\=/-_M1>SI7?P,
M1_ $@:2TG"!V/A L^3_7V/!\&@+0,FHT5\*5J=\M"\ICXB!4O)H)/USC?9Y!
M#UQJF\&NAG!;<.%ASC:DHFQ9-!TS?C&7G1X5.#1[QUH*TR<2K]32N*S)FA1.
M]TIAH.PJW ^H@6D6\L.@VXAW_WH#'SBGYK7AT#HCV\L-=76>PWI2K7:NU(!'
MEKDV< ,/E&->@^#D19>M165B.<W#6(?=04V#ZEBMF[RE*091U=3<N<,N=+K)
M?:,[4X(8>Q923'/\ 9#P<&D)%!HDAD/_4+A',![97HQ_EM\X)L=5:&K:==A=
M_CIL]DE68\RWK/1*F<*>)T9"39>"?M> !0QT41JE$S$K.KQ-H'.G+&@2G(WP
M=&,-$YLXM*ZW>_G$7Y(2SCTR23_H')-I.:1@-Q*+F(,E=Q]MV 8=Z?_*R1T9
MW!NY4C ?$JG>-[BODK^HSMFE6=;#G9K)&.E/7/PRQPS2<D?1[9<&+%F&M_FG
MY!FBWZ0>%UNMCVILL'::";'&@]39DXH69+W"?J0P3?G2C.'MVR1P=K]JPY]-
MAFL_-J0.:Z8^D$3',B@D+@"IMIJ?U576)!$7I]1'5YI2WGUSC=>+XW\>32JP
M;*6JQ[<+1<[Z57: 7;]D;9SA5AM*S- V,,=Z[X89\SDSM5:.\&<_Z>)5K6D,
M%074  ^=Y<3-.,W@LOP.-E\1H5^2GDYRY??OW9\$MSZ.LHE%GBE+W'#)6]]:
M_6#$'R]BV*@[/T2S/LLQ)C80J-Z\OUN4.Z/NZ ]S,D*Z^#O+?3!<3.*YD>OU
M3M'H1NCM^R+&X,Q0=V]/8IHO9]I''^'>EB7CH8=[.[SMP?5!_4[6RU-PC<Q+
MR9R3/3P+W9>JVB#5HJOL7$K[.Q^-@TKGL,Q8K1+YF R[5J-G8U2162#Y!20U
MOKU#X3'66YC"#]3!>!JWP/2^'H,4:Q)UAIO3TLKJ::9PZ)5EOWMISW>7?L"S
M_G4"OH@P %YTL/+L$"&DL.X0Z8MS?^M'GOY;BK-7='/7 "HC-K%<DFU>(:<,
MBYZ YKE H6E%]T6&M$M1[ [_/6NE6KXO6.94E^10(0'ZZ4U*TI3!B1PV]F =
MSPM0(;Y]P?Z;PBT_4/N9Q=/]V&]R/'GXU'XG1JZNH@(M>ZKR#Z_BY!MZL[08
MJ"(":&^+'G4CQ>H/4OV@1J::_H8V=N<KZ%[X'-32B4^O':Z=5Y=WJKX1(HQ_
M"@YGE$/Q#:6ZO<],/CP^.OD[A0]>6&FHJ4V)\Q'+$PJ<IQAKYMS?*<X>: 1&
MDF\+R]$@@F3Q5EE^D6?M%[-I"SH/&):&3P+A#-;EXZFDDU*??=XFT,^M!']-
M=*6BIAD@F.W;_VB\L=@03-TQ2W] %^9]KT\-198U?MQ38AN/>?G&,Z>W&"P)
MV+%*=%7CN=.PPO=XO=A7V[)HPR"),8E5+$U;I^#B1&YW<7=V<+GKMXG)M[>-
MA@.OS"5Z!\"'*HGU5GE2-L>#O.@_F"1/6G:CN$/-9-D8YVP\:+]@"6TABAKU
MDF=[B_4>T%B4E9?I'21MJ&_(&*25LGEKDO$=P/=9?;$QTHO?O$M#YFR]22:3
M4D""?5<TRO!R,_YX"\^<_^N2NT,F<%4GGKZQZ<>09SIYN63HGJNU8VGUE B0
M[Z5[Z*X[IDGU3TME333!_8"G(U4YXC,!%%SD1\4$1]XWGMJ@>VBV7O1AUKQ]
M1J403!(6PRE*0C9!^=F9J;,^K"G=U%=87KJTV(_1LV!%#Z2Y<B1;N%(%4Q\L
M*4W6>G@RNH]!/YAOH33O_+C'[.S.[*K"O!S;@=4IQ/]X.YK%>P55F)=J-0N1
MV9:C63 ^SKC#P4Z\L%I5HWZK(T60,0!CXKAAP909&8TUH&0]@>>*Y R<*1,+
MN@;O*Q^^!'AH!1AX8)6H=WMR,>TKHNU6((%TK\-K $>_F+SU;K#E8&.-_>\5
MJ^\0%QA6H1%"XVG:.%8*TW=W.PWDD@Y)9Z /H/ B;(T1G"\9".^O,H,$W1>1
MW]A(B3QXX5?AAC6F5YYM-;C@/-<U<D:3' .*B3]FR\0OG_X*<1Y *E@71=P*
MVB8[H/S:JN]DJ3W'O+;B5A9&BDA()*8@EK'),P41L6$:^>+:XDP>$,N@QN8=
M,4X76<OQ8SQ6!Q4^>#.7FG_)X507VA<Y8$GNU,,W*;XXA7YZM1S'W'TU9 $M
MY1\6UZ$QV4A*<>10OE5WL^X:P+C>S+?/G9+CG%H3%J1>L-$L$+HK!_3V+QAP
M<RMI0Z!6:^+&.,N+GM"^>LF#I5FW>;:P@1J2F$-J]W",HM^VC3CCQEQ:9!TG
MN>;VI*Y\VU(AL;[TJ>KDL/[.Z>IMJO.ED1JQD&\[))D<D5:,4?P5VZH7CZ*(
M-/U;J=K9B+DV[$/1'EY %]3+%UU4.K6HT^KVS?+.\JA+D&'6YBQ-@E'Y#X-*
M+=,WJ2.F?=*B'+7?N0SG'NVX5% 4X3YJ4_H?.VEGJ,OHKEA$[AW(]=+ -$HR
MR#R0G*77 !8!SP!8+%).J?B>RZQYK?2O I/RC<P?4+V06T;B(9$>ZHXL!1D/
MBVS*'[-"7]8!1S+<Y^^Y/U07P^J=?Z75NS1L><*'_B;F#*3,L\/0/XFWOE_V
MMC$0JC&53/\KG]>T8<NU>RZ!.5=ZT*=Y#U'/-4Q?MHX;#2D0[?I;-"OZCY5!
MC8XO/$%I[;CC ]5@SJ1/2R+9=AV0*VE@HEE:)\;CFQ=^A9)\7I-;M3<7J0"[
M& TR.2#ABI0-?+:<I!"6RZ"[D_DK4$[.>BHM1*%E_]:DE14ICVZ#_S^[.O3*
MR09?TS9G,V*TN/6V-G[QS4-?%]W,/R$76]Q=AYJ_,3BF25KQA0X;!];):P#Y
MCO=06"HRLIFM-%_.8\!KL((KG=ST ^<[5FF!%] W;$[SR6W)C%QS\0/RR.!X
M553$FH66/_$R]5?PC,SF->#16K'UQCAR(-QB=\@H[7(R8*G]8W"1QH#H04+$
MH$)*06<VGVGOG%.*]1H]Q/1@R\ N[':^UG*4&0'MMX'74Z,(U9/:XS9;E+,U
M"#PMF=Z8)4!CSV\5:>P40H#++AM@[Q+1UQ5JAS3GZ2^"OLFC7T'JX#(#UX!3
MPA9+/3(9ZTGU7*J;+=I&<0&3[F)['TZ1R/;BT6;'"1R#\YRDO0:HA:0'4*+_
MAL29_UI1L- V%6H9E2?7*^KIZ7'XAV*)(Y+E-ZGE(3:#X^>SI28.PW.QPO9)
M\+Y'F&2=$?OH\\,EP:&SW^/G7@Y>R^>[#&!MM1E,%4QQ%Y,9LJ_U;&$*%#\Z
M1*0FW'R4]_*+\YN!P<=VI2%6B+_W'$(U8E/F0K5K]NM;;4[S4[[^[OWLF1K?
M96R#<JO2>:$Q36/!7R$V CDL7U>)!&M+$!LR0R]E9B6^+-'ON IQW+RX8YRK
M>Y9N50?<#4?F5C55/!FBM'SB /JB9E2O3I&L6\:[PC+ 0"H]A H<:KT&1&-F
MN6M,S364:QKU49Q![$-$TF/Q848GK.K VOF;92)*TYP&L^-_#8#:8%W^DJ>A
MWM;4+2' ZA7\KV/C7D\54D9&L8SM?B[,WIQ^:Y$[H\$D!ICT+^QX RZA/[-!
MJ241QI]]FM+\(.&8R7]@C@PE\(? +9YKNBC0)K;@T,JLR_/4'GP]WM$!H3%U
M.Y:"$*PET_L#U\99YE&A[&25<MQ1(^?S.FC"682AV=*MZ#\G?SJP)87M:47M
MOVURPW(VY4\U^P^&[F_56/!B74_X-\#.#1M@1[,S:X\0:L4)0_D6C01;$O[5
MU.82PJR^RTS<=JZM>D7TKSJEE+@/8F'RQ6Y"GVOSCJFLZYB4N=OU*ERS\L69
M?N4I1XU80\OTAGM!(JS/'8IX)<A_KC)4_TS7G[!I$9LV.(Q9T@:G1<;')')P
M\&O9=JK]275DR+?.Z1[2<'QSY:3UBZ93*[*.M5>%'C8:5*]LYB(>(<[=[UN0
MR<?PVJ][-;IQ)"'AY>W(>_</E!_KW<N1N*T/<4K]W7ZGDE<D[=GD@$PDJ><D
MT&XNMF4_HH_J1U'W-< JKKIK+8X!.-(<Z3RQMX-Q,%9GBH+?PC3?O_TE_4H$
MUS1Z:HD?.=#&L<(_%DB@)V<&)2[MFJ):F*\!7R37W^2.70R=OK5SBZG7N4P(
M62] CKG]KU1]E7H;=6<H!JQ/E<;]/_$-V-S_QC>@BSIG^42:\\JI/N"7HW_(
MM*/S!7JP0_<7A'* ;F(W+/CW/8GR.1?DIXC_*=RS-O1Z7*=!4PWJD_2)/'QK
MES$UN_XR_),4]+^B]+E1KYUANY8*ZO^>7U96' I&C-27E:U^N$INDPDZ[ R9
M@E[Z?PE^!\=4L)(\N@8TF%,AV;.<EKP1WA_V3/Q=94%"HKJPO1<G<MX:7B"Q
MF;C\C[KW4UOF$>(6=+7 P^$8A<0N!"$U<03-O;XTJ!V(M2_8PIP:.81^+J:P
MKMM'9<ND[[VW">W0A^OCO,P' J?43CW-JIM_=M*1-Z9[P9PM9,/2^B*\HM=S
MRM8^+QDW1+]W*5 Y?\OZ96Z_N--Z0=@GLT1D8E._D3=PJ+L\>/&9RV,E^B.F
M6P!?Q!SI).*[\_>4-R.Q]3)/8,9^1C@,]EN"SW]^U%2)^B%<P7NX8GLZX*C]
MHN J[V0[:D$#Q;-3/'FJ"3M/2]W[-E]58V>G&[IE3&0L<V-RLK"_:)#U(4DC
M!C"OW4QH5[ACKC?@6JKT9N0AR'V)I1:16%/[5_^#C9=2@52GC_YI(CC#T.%T
M;].1'H/@,JJHDJP8;[&8^XZ![-+_V3%6X!@S>H8K=R/8?]1 ,XN*Q?XDU>A+
M5AQ#J8.=SXV>!9P_F^292-U!Q-2OY#.U_)FC2_$4TA!Q(=X;WY:9Z_ YC1;O
MB,JR=SK",I1L9;@&ZQ+F*B4G6Z?O+D& ^0[KS6PU21<J(EW#;8!E^SLEEKP8
M8:.N'B/UY055JY@\J**%IZ$MBWECLI'?",SBXUF^[;#@%+&>X=3G(O;'DF"=
MRTXK_R=)$3BLK09L6-!M1P;?3!G:L@C-PH/EJ37"9UZ51W_45CC8=1*TGGPH
M]+F)) G'/,ZT>B*?ZB\L(+U9O8KYA\/CS:IQ5_&!+#[2W#,?#6N\-O @[SR_
M7OKY=BOC@%1D_L8MPP,G]D)^QB0W-XTM5X*@VPKDD'YBJ3YRI76!3S758#9Y
MTS9Q!<7K.?ACY,J;X"O5<I^@%17+?6.U&TU/FF^Y'Y/-DEBI]>)IJE(21]8Q
MC6HG(PNJD>>#2!=-2]C+4F\$=^//3J=,.U(!LQV:/KTF)V]_&'S#AN]WB3+Y
MH'?PVC#7/\MCK@CK;"'BHK'A\@$[F%+_R4]W4\?*Y&B=]N)UM"=GO(ZL?9*<
M4##I-:"TR/@JM[TZS 9U'BMP?LO]K!C\J\9H:0>D']9ZKJORZAIPLL6(2D\6
M5_;%L_-;[S85L$LZ6SZ[NFS9\)7)JXU5&?X4]TM-T9K:VK_3KF]A:T?_Q</R
MK@EV!=_G9_+%L5\Y8M^.*8Q_W)%0F/^YQHHOQ6V!:JI1T\;DF'0;"^;182_9
M,D)M<=")6*QR,&'NG!E>D.\O,YD40]*E\%(;0"@Z,IG#0Z9ZO^=,C963NBL4
M5(F93A0TQV^D!+740\?&=>[C"\:1#\"**&UP68:4BMPN^!B;I?$XE]1(WS=0
M]I@?_&. 7"7-:4"LT<TF*C#0X+3<[!^AO@:H)[[6C1XLE%+X(GY/'AU9<+@T
M=_N=JP#D@&WT("]6J;&Z-F:0*;H8'4\Z$+,F/M!+['4%IK%+#BM*4IO/K1)M
M)ZND3EBT9?VT.R]':*3^L*W12,"R3"=IPJ?./-5:%4GC@S=SUK&IYFU3N.Z&
M5;DZ!K<BL1H9DO'H30%?2JZQ?CI/BCBHC@8V6=7/^3R 15YH8VM\ Q9_)&2Q
MGA0@H.%SCM5[=W/NQ:-UX,7XB,EZW#I. VX#F4O;,B,$"&+#WTM20,8YJ,P'
M3>3#0&/B\(9)FYB-:!2<T &W30\(!!E*JR1.14/=CNS-9<IR?9^9-"5OSK:O
M5=@VNB@:B'ZI@4G]FWLL^%1!J*:FYCP%% N&>2]>,@6*U\2N?G!1&_?0$HZH
MVG)VL,L\L#KBEK[7_H%M":R?++"CCA1=[^%+RN5:FZ3A.1!L;@ABJ$:4"-;6
M 8-B/AF!OA,LW0J[K;_QJ^0RAS </\[D;T0U0FG76U[8/'G'&+&=5#9!\JZA
M',NBY6[089#P4<N_LJ=#NZHN*Z]Q+N0I!O.S]?V.B)'C'=._@49ZWX76GD_U
M+RHLAY 5F6J8/+$1@MBU478LYE:E5)5U9]UO.M(=G$DP4DTTD;3ELL7_H(&>
MLHR4]\^&U?&%#$%0V<+?2DL?=SZ6E3>_A- \=,2"?QX5Q F.!PA),AM^ETO3
M)%ND\*WKD9KN:N!5T;78_6:PT<M;&%A^[GSQ"W'<!S>X!&66#&2:R 1+%S=[
MZO#TCYB]\/[3AAG#$H,[/IX_)!OV,Z-.+38W,Q,;ND2%N4<EQ).\V>@4]KD&
M?,M7N0L6G%J]!H@6]^Y.:>1!['NIMG^2&$O\$#!-M7NO&Z,#?CA(HVQ$R9FA
MONNT4YTY7+P;;:CS)M-=G]%EUU$C+4!>^_+4"J\("P)A4'=1I"G;7OE:!W"7
M(Y/*L*&WSV%2:QN6H""&_<<2J;V(L!S<1G4+IWLGZT0"EFW69CH]'?L5@I8Q
M/R&DCN?P3&YSBTC_^JAHWOKI[$DL;,G2WH^Y-7O=Y[2\JSC[57%H3VFZ. DO
MV)RZ2VKM>0>:24 VN1YA.VJ+3\48W:.0,IPR!X5Y7P.V3PU=540&/)-]SF95
MMOP26#Z:WJFP+L=X\QR>(FIW5PY#GEI<T8E!++\MCYVP* IZJR0_!<\NBL9W
MJ1B&TC^).:<YHMYAV/= +R!.\E=_'3*Q*,Z\$?+UIWC^DG+L2P(V+N:J":JX
M7P C&8G=H>60@U-$-BRQW1NX2E7)MW<+=H2FF-_^#LTN3>G:/)7H.9)^!R_(
M6#PS'_II]8&Q[OZ=)OY%V)\^%Z!B_<&=:)X$%U>E:1/U:X! Z+LZI8UX*7GY
M0-#O/Q/B:P:)*-5M!B/V3*'4HC?5N;=BCA5>C72TW_P.=2#P)^E]N @0TS-Z
M&CE9RC51MUIO_F@A"%?,'X3VE>=_T?8"+520W9(8;+K_HOW"?#7QGIF8YJ^E
M)YXF1_J1WGQ5\;L"KB\FT#,@^WX(%]XFL& *6JG2C_ZLMF$<$-+.P)YBM)$V
M^/M0Y,QY:X[&3T)>0SUUP&J*=E='8W]&2=,AR#3BW=3=#<NA1MM,4-<2S^,=
M,EF5F0;"T+"?_3WU!1M#A"V<UX%($_%Z-.EA=AKS>R.?ENS@<A]8WRZ_6T=J
M;!(#:,^+?N?-*$UTP7O+WQ=8]+ '.#-&(MTB(FT+2"5, U:SFUY*MT;Z"0H)
MY%HI^/+0EQ[V8L]6TO(-L6+KG8?U)#-/6@&@[),"K !*P:Z41L5L^._17HP;
M];=FNDT1,^7$:,FB8_%]PVU3H16+UD&@S!5C/:IFS,55[/);U^3/HMONEJ0$
MY_T<O-*B4='[AJ#:-9>L - .ZV.;W,MMCCEU(<PD]"L>%9JQOD2+ZR0Z++NK
M]/X4"GQ;9%GQXL#;O4$ZJY1/JU'?S*[27?RUR^RG!F4I+B:^#^!$%(=5NGZ2
M*"B2TIN--+L<BL8Y;3)IU:7XWA2E%H]VRAQ,*W*>-!M$N-EKC05,2@3?N"3;
M>.A(*Q/6#I;I7?BXW02?%BI->(O1M;^,](Q<EQ/.FIHRYL.I,M^OH,P1OUDX
M[6>8/?YUX+(U\P3/[9@2[$DCIV34HK0_K2)M<Z#?(=XW\'=#3EKF][C5)__@
M%Y$SL8KLEM(Z\_POVL\>*;E*%(>1YKL(U0_#^,,OO)$/\_>R#2HVZBQ(Y#5?
M5QT\G1(E]'7-2]\I/V&C%@[CB->ZS%&>23"M<75U 2L;@3;=9VO=(G%3P' A
M!*V1">?W3^(&KLNYJS[#?\9&>"<MW?2/UI8DBN64#X2-&RUH-8O(T 5+9L[*
MYA)-[_YN@FXT6U=(Z""YL_?1H>+4C)O#N(F7[_WIA<N0ZV8"+F1M\@]5C^7E
M'L(TGIMR)L][1E/)CFFGJ9X@D<V/(>@ BS#R 43QS."?AQD&H"SS(,!^\  R
MWBO-T,R&723.8D>@N&1\2NUH2S41"EVVSI5WWA+^'E+.DED\(!'!^5&"NAM]
MLY$:W7(C2'G_*@4I,)FM'[WN2]Y5?0<A_-W!0T-M\7FPXTWBKW.;PW3X30;'
M,$^S])Q51N4 T+9/[54QY#\1B(#_B4#XU[T!Y4'0ZK$X^,+>500">.R$,830
MK9M+[B'U+\BNH! ","RX;A]$E%]$?KL&V,_]1S#E&D1S#8CU@Z\.Y<NOM<]M
M@C9,'4?*Y>2)^9#$ZHQG-\9TE0&/_]N,_E?K3TJ@D0$"B7?/#T;DED+:K_P]
M-S)D BX@EU>FH+Z6?4/9V(J05GFB[!OT/;;VF>">XZZTC\Y@VM/R%N_S-"O$
M3C9DZPCX$_G 3X,]MS\.R@.P:UZ[!GQFPFO/*?X[_B10BG05SNW_;-,F!;IO
M+0G?>15DB2@YX@^.G%LEJ:4*!%43./%'I9#!E@?'.@Q^2@;F;!V93+6F33)[
MW9$AE1I9GZ:XC%0V_6S96PS;YC?&8$9Y>F8]>7,%Q(B=WP+-B6##XE:N ;K'
M<ZES?Z]N_WMC:I!RC24NY[+]@F<G^(!_4>=TK_.%56F09#REIV;9_O2](KE,
M/1VNUL^Z+F+N79D:I>1YWVL<T.4$UWJ\\Z54D-R_9X2RL?BI=E@^)-Q;F&/Q
M4]/*MO"K/A$6-WK_H\\$)9WJC,A1H3#UE"9[?%\&\IR@<U6 0H0LL>S%>E-:
MV1VX9I>H(Z<M_1\(IP0=I> L!0U47O *5CVSF+@5>:KS%;AO[(;+70CIA#('
M*?Z%\%HX0)[@$^0DP826";#9\*:',GT,+\7#*3&1BJPNF]=2@YX)%MK"]R3[
M5'ZLNFM<B3=:'&A,F<B:[1],\,7&A[.:#?):&K(8Y)Q%&@V+9=0UZ30V_J.\
MM]%7Z03%2Q.\&VB\F14/5\;[+NU]2H5U3 :1^)>8E^8OF#:8O#/K]##GBC-A
MB;(.[C46>6<09DF&=[F4AO1"!*[2B-R0\0OH]A'2"7)WO[G&9KY)>,$P-E:<
MX2DJ(TO=#B-\(A"<KZ?$GL-7&&U.OA/<FKSZPQ+_#-O5%QN3R8]/]#^XI3?6
MZ+XD>&>IG;&Y*-C%Q6MT(V%>W2&NATGUMOVMFS1:$5P^\>JM5[^O ?-94-J6
M=RV/YIS9[LJY%_HIO<5PF 961=*[(I"OUNQ3W&34[U7LNI1TF_A*D/4,/NS=
MTDA+8C<;TN1O<#BQ0#:7K!4E@!)Y! S.,Y/,1JIC#2%[R@-V0^-#$UNG_'C#
M2RGB#/$6/G3>C1*?VTJ\@^_9-^U@?5*[;U'D83<6) ,G4[>*]!?=>91]1R+9
MDYF6\S--4,.I[U42Y!9!<^0:8/N?BH\+P+8!YWG7;*N#LY?['R[$S[X)>3=8
M/NYPM4[>^:GSL;CK]7M;*\:2=WGMMPLY%DRO 7A^^ZX]:LBHUD%V,X^31Y!N
MH(V=^/>LZK3WI"5W78=_/V2%]1FWW=1AX)%N80J91[14H7>8#GQ;9^4.?&-.
M!GPM\(&%2G#\^SX;>S?[@MG7FQL?J[\_-$VF^-'7I0E0[.9DAK];8^!,=>T]
M=4$U)VF:CS1@M6*"5&ZZIVJH-W!N+^/P58Z"7HZ>\EY-I4/CR C+,NJVEFAH
M%1H=^SC(%!^R?VF@0QOD@0V2S]IL%L8CO!=H&F^>=/QT/,64JV%!&BME\314
M:H#H/"C[?P*>MUNN$H-(+\TA(YEW\9_J>;Z+6][T*^A3VP^/6QIBL?235 KD
M_QUTL.J4]%%6_&__M_(R;D6R-D)_W_Y:JQM> +MCN^]/L.=.//AA,/+TX+32
M<Y'2&L,BT?4Z\#)"5$=,>1YH*[1MDC35I^>.OEF"IR;>*[_4#*+&%RVYT3E
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MWI@5GG ]O#_T2WNY2>%M>O_U"=X>R/''LDYY[M S0 5J:Y4DI4>2(++@N/^
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M77$!91S;1WV%'>[L5E+7]5^YK"KXN8=+"F6_2;VTDD5\A-X:70!.BE/IIA:
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MU']:C/8?NJH5'FU=$0:V9E4#(YK 0=Q'T[:ZE8;)D;RW=61K31^HMVAN?YY
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MP;M-]KA';ZNOQY1>^\I0)_R3Z(47-B:8E#AC9*K:WFW1=[?%(@^XPYH$\LG
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M-?;*B<#\/'=$;N$%I7M5\UXYF3=STDS)UXN6D;G&-K"H"54V\H>OK<_>9WP
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MWB/&#E&X"='TPLCQ>R6=;&8\;S+8X[0I7V!24&,-X (WT86@8E/9T)#Y5Z>
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M,0$%@\'O^T<$=%,WK8W PS'R*X<*C_ZVM:87R99O'TE"%-UE?M3*\R3VV]8
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M*+_0CKXP-M^2-A@;$9BW=IQ%)\W13+>"[3-/ZQWRK,#J#D<LM[6[=G)&:L?
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M$(&7%#2ZUR[5)?O:+<JC1\4T'Y^E+T34%(FX5/"7&&=2!+77IFX";0)#BO=
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MHQ2(YP'ANHE!,V17=.H%)/)>33.9*FS4@ 3XCOU" NS^BB4!(I#R:0\(D23
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M$,9WU.RZRP^72%/,J\52^,ON]B95C8K!: U[Y!R2OS>SFZ@.M,1]O/-#J0E
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M62J"7FP[-F[&4VVC28!;6Y>9FS;[<XV[E6'#JU<JH5UOYRMPKOIJ%1]54 E
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MH_)CW--SU?FV8)%#ZB#@XW;:50VM7#J>!L$!P3KPQ@IH#MBJ4O]PKMUX:;(
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M_I,)Z!@X*GR:-*14'Y=F7P5@>&PMRII->R)4.2O"F\TK*71^KB]2VXVT(MH
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M6CRTN55+?5@!-G*1]$D_0G.:"A4KK:U/-+]250WF;)1A5_4+3-FY4<(/<II
M-]NT%/*WSO(!,TS); H7G+&]@DOP Z?;UTM2!"P0-$1UGO*5X-2EVN1%9>@0
M>4Q\RJ.P2\!UGI:4Q90PKE&B(M7,U:Q'MSIPKGL%Q6 '<>JT*ISMW84B"G^W
MDW;J]I!P)8)@.[^9XPN_IK.KX0/L4ZK_DAO0_[R&\7WZBSNUO/H0OYS%G>BT
M40<)_!&:\2*+_/!(\L3T4PBE>]EL[RG%0;='=!R0>11'UB[$T>DG!K+N8)W8
M(0H"7P=#Z7"I(HS<S*5;C.[^Y?G(/DF'#5_HOY&1:E?Q5=C=8<B*'A5(Y:06
MXRMP%S@2E2F\A%%L*'/G(&I/U.AQ6(K-203EEU X\5B&Y 13+6 E=Z8O =OY
M>7B(189IQ-IQ>;GA@(4'=(D53NW= UAK=<3MQ7'C(Y=GLDS,.&LA[Z,K=3WH
ME&.RUP'>/:-HT-*]%9'!+',[TK%$TEFNDVJ_!22XG'VP7'J/V-,SV:RK"LJ_
MH\IMU6HRZIZRX]6:/A/JNF8_;Z4)\Y7L/)"HUEW39(LSG\R$ZS60?*W]]<]>
M[X5? A2,Q&A"!?:*WPYW"JQ0(N^&&.,X.O[9QZM@)15YY.',QG59N::<[S78
M+LY'57#>77Z-F2DC 8C.!_-:,]D^8_;FC-FK'^U_,JZ];RJMDWA26[EBU#FX
MX=U<?5$"Y9QL&RF,.5XSV;1K$$.M33UI@-'B3RUQ8R2WVK+-])JLV#G,(&JC
M/A-*EU(=)6K*[!E7S/B[)J]LAG.&)+%8^^A3]MCJ^_.1)TM>C](*=XKI[Y'[
M)YEI]1@]?'G34&/]N/BW(8@3 4HT]GJ4>50J!TV2RO=F?:8BU'G RN59;&^S
M32;)G8W@'NSTZ&)-U!&]\X4YV=[F#T ..[I 5E,*^P"C7&ELP*S&@\9H6SKZ
M[YK;K*_&)R0!KO5X05//YKF&<Y*6QG6MG?JF!&;6B"G$&P.#WKX?"S)M!OGD
MN<_1G/VMK*3!QN1*>4N(B?]Y:#.WF46&W^$NF6=<22M^#_SZ'\?#,E>?>E=Z
MR4_*T<R )N4W;ZA'D2&\V+]-=4X%GP4Q;S]S[A*@=)4K(I',L*B==-5+@&HC
MKW]J;O'I,;+]</X1,MW$H&N#<3NY'W+6= J4&!2/C"TE83E\'<NK=G>P>V*N
MM6B\1H6IC:V PT<+U+1QX>>:%,RQA7RH\M#;R(B 3Y\7PI!R53];\; 0W$!(
M[WA<W_.EGJ-SD[4,'.TP?^ZU0T]K(*?UL73=P'KRK4'OUS.^-@,AP81;()@;
MI5Y[4,ID3\9:AOQ[<TXVCQC9GDJR+:M70;?&O\'>)/CUNV6(;WI.M+"SP7I]
M?&4IS>7&4^NQS#M08[N;V)R88='Z1H_"*(18W.#>82C4]IUHZF:4:*=VFKK]
MZ1$:G+825)Z<OW2A/1B>MQ4GD+>/BMD5GI;9I2WU&9(;WWLX3#F^.]EVIB>I
M._J+PLV:*7#PK4QQ]XZS_W*)8;DNL2[%.Q?^=(WEY' 3(MXE=Q0$39VW3(.F
MTD47XZ=JOB6POYR6>SC1O O[7%IBK=EH)\#$)1R$Z5ARU@RN=.M:XC81'9>V
M^>G../P#5#,C+7Y]2K$T(LQW[TO0:6J5#F5CW:M/B]=VC')P,?-<N)LF.A+.
MB3+/2X?IMJ <F!7,$Z-88V/U_- %\OVFSCYL9_>(1> EH UHM^A":\<;A:1P
MM1DEW:U1(L>4G[XZT(T2V^T\M$J);N7*4EMP3]=C1')7CZ=/0:] RD0Q+]8<
MFXP<^_?&:22>6P(.-(@I5I^/THCOU+\$. X,\@XFIJ\AC\S4]N:06+KRX!(B
M.GC#+#VN&+M6T:NOL=KU;M>[]1&&\P'B&RS64TEY>A,]-Z3JE]Z=4^];\="B
M]4#$^'!L^8LJ3_SM6HOT!:>#WK7RZ<UZ]Q;+WO&/<364%K\58<S3DH*!QIS>
M98DFO81QD-7KA_VFDCRM,/*8S=692P#2>">F)6V$A7CD=O2#@&@QN[]YJ^0M
M+&R0_4_*0\>%2T#M53_*+E3,X79VX9]O?&@ONJC=73T8:2T<S2IKG'9JU4'O
MN3':X,J+"=,(\4ZFQ!PZM<13Q&(,P?=%T.BL%D9SRGOTARC%G+E]_=G;&&+I
MIM,Y,'(-LY-WM8!&I1_K.?=@0E1/8M^I9:G-A"R%ZAB/5J48KJSRC7\KA-HW
M9N5$AV9(>(1;>G8%5C3=_(-OI/P];Q2+-\TU&Q8N=EC7Z&<-#7_;M_07>]QU
M-I7[4= /"78N4U7R:7CEX=OR+>^OW.:!IL_:_<+>TD,M=8YP'W UP^=F=*PU
M=6TLBDGR\PT;3$!)XU!,7RYC2%=MO-OUL&0B1/U$;W\;Q-!#3:7#&?H#$FM
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M@:DX%U(,@O)^#$!U&@8T=9Z>Y_?0+ QA'F2&W]S/_?<,2#[(>3N[-,JJ>>P
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M"I7]>IC.>EG40D7/@Z^9^K!(92EWQG+ZMI%JU^5XZJ=;"[J@D"\%_+3[7KJ
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M?H5*8<W&W2X!2ZR)H$,AVZ@3<]LI5ES]06Z53:WQU.D;P'/*\PET#6K[:C^
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M-X3>*=NH<WC*8!28YJR3>ICG+O2\U]!<+FMY"%>5JS-HO"!5UNJ9D/=:]'T
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M1*6F;EQM)6>*[<(P&1#? ]D*# ZH&A;-FKW3-X",\SQ9SFE&R86PW,/W%WY
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M%FB!3_P23;#*73#:!9=@:\V&:@@B</K?BVQNE<S;SL$KM;3];Q.T(DC_!>3
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M%R1_.!P6_H.$0@=P1^1WUJ-E?+*P;GIU=3412O0OEM_<_4IQ30]PRZ/9GO!
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MPW-<&.F$?&"NU"FK(40/ZJN:JD2M]VU"OF"EHNNT&,'!>3JMZ5LU1V$O5,B
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MJ4 R@!:F]:<&83I_YCX*#4L-DET]&SO/@$61&D0EIEQ;0<OJTD5QSKZ/V&6
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MVA*U@&-WV[WG[BV>PF (K%U/XZS^O3:OY*)K(C"DQ9G@H;H-V1:^&GNUY]U
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MX,L:=7#\B5_K2+UX2C5UT> UY;_W829Q'0JT$W(:91?9;WK:LO?&!J8-,J:
MRX07-^3.*I5P#P^KK9>F#O8-S\^GKZA,4QS._](3-UGNJ "80AS%#33:\R5E
M338C*XIZ[:373&K<\YMTCEM.F]:::;K\O(C#CP7*%OPC!(9/>=*W:@_N./,?
M203HPS]/4,P!DTRU[J22]LP^U$]D4R4FKB>7+8N/W-^-2,HS4'IB:_FM:]9@
M;23$64Y[R5$<LN--&DF0B+,!MQQ]7G$T\^J]+1NL3/?7% >C2/];.W;W88^7
M;IY5GE]+89#QRLBMX<.67BF,^7@4QZN9)6_@S@K(_>,YR\.IS[(&KG")[DF'
M?B<3)2#WP7%/, P;OIB%[&YCE[RP'!?T0!];5Y9*X7GB<C;&@2GVHP?B@5L)
MV^AUVAOB.J^[!FTM.QC)@/L*=04R@K)@Q8/J(+5NE E^= Z*1 \A[F=6^X]9
MJ+*M;9?,7NH-^KM!G'[.=-HD*Z9XB/W4#G8CILYX,.9?1$-&H85YU>,&!_JQ
MC^^UY*PW>T75#YW7AJQ-[ZT[*UNZ>$56N>G&I1WW%W8Y_%4\\UOYEBSG6J[.
M:]B56)O(-S2,<G-2FN"<6$]8HK/6/OJHQ=Y"S(3:YY<HS=MYSE]X[J7IMU:%
M:N\8Z.Q95]EAJAIT&E?'MM*O5*SS%0P\=N5J&4_Q 6%>7X8<L_W2?C(P>:?7
MH$E-ME^X8+9%/Z60VKDG<.-'[%:2=:]/I4%IN'+8$*'HIG7V>E'"L]T*Z^#0
M-"55:W1M$2-729W$,\)K;>.RQ-\&C)(G;.,I])\G?!81WM(2KN:& 5?O+HJ/
M/4TKW;E7$]<69U+BH20E1W6NT/7^65/_MB1>VR#*5:]>NI3CR99^=T8$:'X]
M,\&0"N$I=A$5T9A!FXYVS3MWRQ5 V.A.7)3N\,@[SC05,0(Y!HP>O4=UV;>]
M3*=_&]EN9:9^QV'NW46JQ-.@"4_&HUCJR&^2;Q3;\PV6$1FO_)7IAWD#HAO$
MTTK7[^N\(YP618C-(U!)1[QFFISS]FW,VQS<U#P9>ED] QKK@7]MBM]^GYLN
M^K#&(ZPANC&6.\Q<I9X:E!]ZK+3O^*G$UU.;UTE!V[@Q_P\O:V/^,.7W7.:2
MF7;P6)Y@#_.F!Y"?K4]\>%P,JYU2LG[?P*BV ;+SVV5E735+6[F$YWK[^IAX
MJIQ4GLG6V8_RMFC>F_\>^10#[(\J(Z%L_[JU/]U\7FE<Q^Q%6-4&NVAQLZ"_
M7]9,#RR7<U-=%*>54+6B5/L1KAMEM[#SZ4=6&1Q[Q9P9XA^#:@AM3JW'[AK^
M3FU#F08>\:J/#^Q& O(X<4[9J_NEL6D2@SPE^<KBJ[%U%A[#NLH/)41GW'4A
MWVW>OO49<S5P"0DHC4Y0+K 1/]:PD1)(L%#)B'P^PP+4-?<TBJ H:K/"P=4;
MJZJSM^=YTC6:9!F"LMHWK[P\27]44X-?;+DQ@],;//E\^VALI]^;#!#[U-K<
M7-.<N.=!4SV3DZQL0;> _Y&-#']I?*E9EEX^L& &O:#=OT9XZW?-25U0F?1H
M1CVJ7$W5>>7+\ZF5]3>Z#<>"\:@$&K6Z7$?X^\B)$[SY(8;CR;+KQP:L"ADP
MW\'C, +N;/).U' .ZE*C['4:FZD^-MQ7+74H,@DU,0W2F-"&6U5.M@"=5BVF
M:\LU90,W8I=>I?G,M!](OOI0JK(+D*/948X,4@_V7VZ)$6*(L77H3AS(+_/!
MVF!_LZJ<K(XKT,<J86_T.8KV/_L:)SWIU%G$G('\>2K;MI-=H#+@8[[KHYTG
MXW4@55#IAI,'%3K%6$$TK*3M8E\H_*&87@)V]C6Q^MU >II7P 614\F0X4D&
M,<+O#&3X.!$V8K)F@S-['55J8:9UYJ HULT T<#!6RX3Y$6I30Y]\IL'S,$:
M?%W7XQ/'SSN+":"[FWF\2@9P\/8&/;OXMF)ZQDP@%%Q2^XUKON7ZS/36CE_?
ML^5; JDD@=.5Q'V(U64O*Z^O^-^R:%&;1FV!\ 6W-R3OT/PAU [UF:R[F[]'
MH;CC?2KW#T.[ <>?2"J%?I\#75CS'-,#.UJ$V6.JJ#RCS__((TI%U00S=0K7
M).AF-L@ *N_;*E[!<HR%MQWU;)Y>5SX8.3><\D1)=.#P.D=[;.JRL)/0B\1U
M.SO+O]82?QUS6<4%]W]T;A_MO8YR(XB$K;J>][G"3=*U:,M_0&8^(EAX'OR;
M>9WP0.OG"O;20^]\Q3[G1> 87-1LX3-4Q;LH7/FC'!>^%[QW[VM'LV_BC1?]
MVK$?*/>B\=A8F"(ZKQ:U8)0(L?BSQUJ:V*V&_,<YX%!97L3P=(_[6!O5/E'\
MMK[SY7?#M:J=.&S/AVQZ_RLGD'K"[V,U"D]_!Q=PCS51W)NIY+G1YHDN&7S6
MR]\?D)5JHC!&F[D&K0X6G B =3%C<LUPGTQ>59M)>5#<PYU42'L;)UPNO&GX
MVO\ANO,%._/T=&HV8 ?=5F06IW%(C#1]->H2_<%8:O5R)5:K$KQFW'ZO3C!H
M;*:?I6'RSEO7P2H7J_T^QM5#$(NON%YGDX:02T!2^-!CQZ876ZBB(=?XP_W)
M3A/VP5*)%B?GC/R-#U'$^+_!6M!  ^'05MU;R>7^DK^[ ]RI*0;H@OI^SWWJ
M>"J\]"V8OV!B3WQ'APQP3M!XM8A/BH%^!*Y#AN7>)FHLF_++,NO'>#.'1CP2
M(=A_RH1E\TY"!V:CW)#K2O>%D*+%\VT^%CX7K(5Q;OXK4?U"G%8_7;G6+(^>
MDHIFR(!)';]P[:@N^L\# W:P%RD^SC;9\!2Z2693V&V<SSQ&5:Z_W/HN@O!L
M3K7O/(+SD@;=ZM8[SQL?I#-FQCKX[()Y"U/Y@!@M@<M>]Q/'2IA$GAL,-AT@
M?QZ)(UE/"O7MC%926ZYUKG/O@,O(@/\)B1U8F)K4"5?#-2W-"8%.$WK$:Z3.
MX?U6,"'X2W I^'_*?%[V*XB,)&T3IB_)@&O]@\(9D+V6X-'_U\#9#WCK_\?
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M3:Y'"[^TBJH3PU?\B36^'P.259D3WU(K-:JIG<9<OKY++18>\](S#2^Q^,W
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M.E0DQ/9F]A9XUWM[1,6L;&FPI7E* AG73Q^BZ51G8JFSM3YZ-/P8Y"5V\S5
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M8H>1<FP&]>H/LK8Z3I1&"VVU;%84)<L,G<XL>_U.;PD)\G;)5]Z48S?"462
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MYYY0,,FPG+(;>^IP?FU+OJ?$"Z;4N(\<QV"#;E;7N52^:7/_Z\Y^VKLP;"?
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M[LN)9%NU V.=J/LTT\QXA7\X4/4S1.Y= ,J[G_F4*:CR:">Y< FR.1CPV%P
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MLUZ+L/KZT!&O9>-@?:A:UY;=DSB>N#V>M@J6L_NEY3R";EHV3M@G"1TKMTS
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MPB4A@J&VGW.,VT^)ODB'0&#GK,_$:=&<-$+,A3*[J-@B[ZK$D2>[74HNXQ<
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MH,^38T%4BS ^].?LYB#_?"P<O<=O ?52<(U\HO@V.& O,.A=\Y_$EW6WMMY
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M!ZK:CW0+_U 3_/P<3@4_NW[9DKZS]#8K!LA2<@OCI.(L)'(1X9#1[F126G.
M^E9QO8X(_W1+A=->VK?[SL_U)C-,]\YDK7R'Z423)JWO:M-(_$$%\^KJPAUK
M#\0D1X/'^LS"&7ZV>&4CB^==A51(]=-BS_V"S,8RG:J6.V#AR^YRZEYV4=@>
MCK)"2#?'0%LHW"GCUD#/WWE8!@=C4>2;-B5S-5- %I"+4Z%;*1X=('@!X!-9
M<H^&W,K'E1?C_4?>5E6?SWD4/8^3-/^D.+7YPYSSM?E@88A55)>@[D'^R)G&
M)=3YD6_J0]:+0R9!5E5.BZ1/3P@*ES2LQ/VTQ H10;YZ^0D.'VP>%]>ST*0Y
MWSBY /R6"T&<3YQ 6D$:*4N+I%MP<A1TU^8"\#'-[P(@LMF/]2+?-,L^%0;]
M6WSSOXHC7!'W>(1;8/]=GG42U-"R3Q#<!)*$%@G\[N?,0#3J G!%Z@) ?E)P
M 0B3OA0 #CK4!UV:#23*,=3I5=3C4-NQ=CUCJWT0B@QHJ3SO_/?_ZC8$N<NL
ME9;9MT'.^Z1K_^8LBEX6)-T:"%Z, B(<+L6_K.&357H )C_TLXOZ<AE^[5\)
M>+<Y2(Q$U%)V?MXRB'1K6IR4Q("&_V\1BKJQ>>2;GAV4A$RB008.6O6?2CZN
MP8S:;E3[Y^D86O2Y,7W STF^+. QKO?JW[]LO8.B2B(X?NP2[<\RL42\T>7P
M?9C92CZ+47YT_JM0Y32/&)P4D;"8]%5Z7][O=_:T40>'E"M5-%GN ;VR^5/'
M&*JQ'03N^V=N-6T$$OG)]PL;P+L\4<TE5J!-=E),(N;,:'D&><N@4W^]^-HN
M8N\"H!]B$(>)G$I+S]%93T=BH+F*6E@:/!-V/&=/T8NH=CE]QMC>9ZJ1-::"
ML-7+#CM&/CEB.?F$_I7OM?O?C>K"_TBTMBZ9QEUJW'CI:!;46$?,+-*';=,,
M<K7?##WOI(6P,93\'1QYFG+8>@'XQ($365]L)-]6WB [9,=AA)I S>$%>49-
M%F67B>Y!X/+@(!B)YSSN..CJJ#]JQ2'E\TWU,J\+0/Y$:MY?JTI4!'ON!>#+
M]DH'^;._*-#]S_EWX,!4M'0#>O- )'A!RV-*YI]^WVY7+]W!>RM.(V'-P-,L
M;>#7^T,IU65?"NS.IPA!W0NHFF38\@7@WZ.L1XKRJ.L^=+[;O^517PNC+1J;
M7R,/4$/,8K["'\.2 *=/[EH?;PQ EA+\0NZ-@=XWLRP^(^IM-L2PWBQKJW^H
M5-*V*I57U"\PF'\!8*0@5/B+SZCA>W&"._6N)4Z^AH$Z7TF"Y5Q;:?0PAG0G
M[P^W*\C;26R"E.H4GK6LW- .'8*P*SYU252O/9M>F=M?<QD<N&JO].Q$O;4Q
M2;V+N>V.]DWV=L;$FN+UQDE).N%QG)N;8F10L7+F/;S&,<JO?EMOZ-%)3$[:
M2UC1SG>]PEQR5Q^#';O/NO-44-93XE.+36560@ZFI\802N19-&Z*Z^[O6KSS
M"J/X-CZV;C/>7"V,9,9'L4OI5[ZS%+R% \6":LC96+(! E5G&'_0)OO4[TZ@
M+PFKM!TU!G)KYEF_'GMWXH'O^>1#OK +@.#2N<MP47M]N'!ZQ^L<098339T4
M2/Q$_&CW.\S6Z,\YVQ--K;- H"K)G-#M;XN,6]S]!@/#J($+VL&R?T6F03:#
M+KJ7(YDP>FA>Y^)B;'3BVS?[#+<()#><0O%@W Z$S54,$1&^THO,WL$V=\T/
M?V3+H+_M*<\TY+*@J "323#(<PLM"(EM ],<!VHRQT)1P;RS@Z>GWL>S9^WM
MI)(XX-46Q.W",W>[C8W3$*L<(/9/@W+2LI4 YX\1 _IQJIQ.L!_Q-5@?VLE*
MM];;Z,63U+L ?MJ<0)?ET!_C(]VSG:(%)N8K5%OEG%L@^I+B3PA<8DQ7 D;G
MLQQ6:#1CG_36/!X\-4KW3UD>.*EW8I^:-D)N>91<WS3O0E#W!+J6-\@%0A@Q
M]C-5?I6'"Y78XQHA#A=?[V\\ 4,N0:TG[EZ.+0Y]6Q_:1QO@+)M]?7-&TLO3
MRH,^'U"[1KY ^N)!,YLE22X=^?%MJ2% V1.(CS&>(;G,46=O>Z&H\L @N^G%
M@2M/$I-FEM"4X'J)YS :9I9:I5'04V)$ 9HL>&2K[PD>7^AR\<R('WOF9<@M
MJ<6(^9E362BL\BK-P*+F)\[ 1L*0P[:V/R[K^%[__J!HZSR]L_B[>O<2"80L
MDQ.F#G)[\\QU[!I*ET\K>_[DVYF1!4;IZ?M<3QWGPPXH,<@L;6O+ACOS%W6Z
M?,^&'/!C][J(F($0OTWO<"64[@NXJB8K&I6)*J-NJ$2.>&OD5"*1%4CKS%\_
M64X$ZT\4QX$WO#?O5*:2+PG&7*]T*_#176(EO-PC6SO@K]""G/&>=VJR@@^Q
M23+!]!?I?D73I'=ZD*R17[*I1MR'O,P\P0IT'JYD_?Q,LS9B XQLZ]/:.ZZ?
MWF::/GWQW+D*?K)V6KT_&!!>=P"*NX.HJ@T'(FN['%>X;!*,H<N 6T$>EJD8
M.F$%D3=E 8?T]!U+(8C092B]B=-)@LOC%#IO8ZG73Y&.O#&5<AO?5*\K' ^)
MO'K!+W=_Q^93,?5KKXE-NQ9XT6GB=MI@5G11-WTJS4"?+WM4L@/H'/+4M$%1
M1AE8&P5*V-9/IY."'M[X<?"$6_9X"_*R-X%,[#@[K_&M)7:(HJB5U2\ #<9'
MK^E!PM!NO^2L&R,"!X?2XS$4YNIS!P%HA9!"6-94\0C$E)W(*F:JZ;=Q>LI]
MO7A%0[Q<J[FTM!:'RSA6VLJ<^%^$?6=4DTW;;105'U10I".@5.G2.Z@(" A(
MA]"D2R)->DML@'3ITD5Z"9$20@=ID=X)A-Y""2V4$""$XW/.^YVSSI_O^S%K
MS<^9-;.NO:]]S[UWOUC1X*F[@=?K8+G](T9E]G"#<=YX SOKQT:N(GG$B"/%
MHYW! %CCT%WUKP:C\X]3BWKK!EP9^36RW;W2]:/YMC=AR V/;*[QA^ERC.^S
M!0<DS42D.-AK,T">ZY#]^R=VKTC](>$VP;&KIB7$!O5QV\3!2-ZA]W(<,:+M
MK5>G_9GST?!QG9 0]AG__+4W47(]QT(>&C\H6O5$$(PFI=IN\#\G^\0ZV_T#
M5RN$ Q)-IC3\H:U=QBJ[(YDE;]MT_0X2K+.KB<MN21XAZFF$MP>"]4J^+QAG
M\/R:/C"M<O [YCKN<MY4YJNK=X'3 S7-FXJY7IM_SVX*44DKZUDLZR,V7>@N
MN9K7WRV>;0O*7%')"I)<;GD,/N7"@C5)]&RIUGM_!M%2././,^ZWH&U7*FBZ
M,/1A"+I/5LJSX93?/NIM6F$+ELK,*/M\^%8%$_#<'':1ZN8,:C;O6%:[U!![
M>:-]:TR([9G6_B5E.J*(-LW]!7,7,#?8PSAK"D][&UUGH5/H;S"NX<P2T&9;
MP"6T7C\0T/H9T3GJZE88XZ4TMG/2=@DX1KLN[5%:6;<C3=\'@#JX(M?;N@S#
MA:7@J[Y."!Y@D9*S8U&9[Y9&*1C)>.!J\@X)H#[FS=@?/31G=UQZN[(E'HC6
M^$FT[NV!3&[;]*F(!"W_G&AZ.X9,O?O \Z/55B2QM+K'/R*8R>=0_"?1->_M
M?>:F.HSMX K.@"1F-D;XO ]^+AVW$^3Q].CPNK0GS]9N?-S X'5KHM*;,GQK
MN^N<C\5?;(V_[FF_0A^>'ED;=Z#T*CN?7*\SGKP@3AJ:A/^W\=Q\*KEQ ?]E
M152N]U_N1  ?.OVGU_\SZ.&M$XC@YDO =?VO0W\Y%I&X'=F81F;';3&BR3S(
M!_^)>7#ZRW(R^VLO ;^@W3T<NQJ+2IX9L1UZV;4=^5M=RKA#^2?QNDWW=ULE
M3A].5KB_RQ4H[?"E'(2\8.\C\\*?E6NZ7_.8P6 N<C]\>36GS?ZD%?V *L.H
M);S++T=0&!;-=Q)["0BX^%!L\^I<L2S$_0$HPW?F!H>$<_1R*W -I/O:SV9B
M&[+2QR,C\+[A0AY!=MK-69Q2E.X^V]I2**D]Q-+$>Z'C#H]*,3L[)Q&NMH@Y
MMO0Y66.J)[^50NH&G%S:.80+FY*1+Q8X/]?G0_)79J*IDW,+0(1:X)W.><M4
M1@/:(>ZL^TJ,GF359N]N?<_5N$;V!AS9V0'T7)_@>6(WUM#2XH?SG']4@XSD
MJ)RI?EG)M\?J.?69[=QYIOF-1M%I>J=ZP$R%&9)'S_;C^!$3TV^5[*8<QW M
M&ZD4B\W!Y<K,TOO#@1YBNZ GWXB@?L1 HU)_CI#64TS>^$$ V2;+T4#@/=87
MN;9J"[R769^5,'(JTG.:HT;NXZ@)EH85$B7,; 1>#JO:>ELDU)]R)4%OL4?%
M-MVF0&\RB43"(,XO^[B$$C37(LQHR\8/9\9PUBO['(3JIOW;K=.8ACF0O/33
MF/XP31@D(ZZ_67:(H\"8I<\IV,DUWJO7>+^52+/5VK>K_(>1-51JP1><O1\>
M^Y<<L[CHS[L@!3UO??!?2IV*[:YE6.%L0"JKZR?9""5_KXJ.S/-D .&45_2U
M9*C":6_7KV# REC%R.ELH0GFG8LR_A>)M >B&0LPYS_U[H'S=;5W,"5]CMFS
M)L$Q']4GA9 KFZ;QA-?"DX_V=BPO 9WN$8$J[<U7$,(@W/;D>:UZ:6-^VMF.
M,9L>Q[,%>J"ZXNC(??['%2X*7#D7!601T79HF(QAUY,XH_$KB$I+TLS0O"=Y
M.7.]T#?V>+]1X>5V?U=:K*;2@/<"L_)CRV +_ 4!+O&J]D!YQHRMFN ?3O7#
MFS(ZTT-3JL^-_F!JVQE94MCG?JC,)=D=8@=;V8<QGI*Z?B9ZY'E4*&2_.5:1
M$EEZ-<!:8OG/X^)-HZ72Q*MJ[PQV_U)E%J<E+=@ ,%Z:5_V4OPV;.W<PEK1<
M8R"QQLL!C*>AMU364506V%6-D,],#W"_!%B9F/XN41S6L32GYODP3>>.S:.-
M-/;0,>X_U3PQN-$ET?^C!30>L<:[T)#JHZ;N:=SOW*N9;A!07*WN<DC)+U_K
MXN?UNGM*<N>H/M3NU4AZ=,O;>8&_4RT9KU=S\9HM4;']"='C06<CC21L[)MJ
M[@'FXLX/?D5/83Z/U4R<W-H_!J;6Z'!:!9(5_*OK!V7I]SCN0*[/;+RVF)MC
M<!%G^J0DD+J]N?]3&SRUY[9LS/J^L0SC(XT,?>&*7'MP'4C8EY7,V^&KWY<C
M!_ 93KT.])&@SB^[%SLJ]9Q2V(C1*$%;SMJE-C/^H[Z.A# II^E@YXR64@L)
M9LN"Y06 L1(.GSH^@9%IR-Q#Q5*![;YLM<A!.09>)Z?V$K)H(+L]*P*5QI'U
M3_?-4ZYCR0'Y6U$]:X<9[\ ]J&L3CPI5&?(/=>)X,NY9E,P.[89HEKOM>%6J
M60^='7"-BXI(/0;JB6#)&MP/]9+_MF)P4JCCUOVAI=P[B*9Y=XQ>0C!"$<G]
M(>AD\V(E<;1! Q%1<*XVSO[JC6O8C6\EWRX!B VE,BK"UJVHVO39YV>?1)2'
MC81,-(<7CY6S(C:[=>P-1(.VO$<2 BWT.OIVR15=P\$,0B*[</@#H3'.3Z73
M5)_YL(H^2A_7*8IA[C?]Q\XA!\MLQ08<25JP;]OR\&>)L;J4S!7V^F/D&7MI
M'.ZC.XL;<S?VFG,0^X?LETQ\3$?E%\\)=P35$1;T;QUJG^KW!6_=/._\6PRK
M- 'V.5Z6!PF1(^809V2RO8 M[EP;&<2;,DFN5>(R'I\<I/1S--9/T -A?^"]
MY<L9&>_V?-V9Z5.M(0U%XX^N0>SJ,UIIK?VK7X;2[5A]'DC\X:3X%THF8?XB
M/0AIL(6Q"^W$R]F5-];Y*4.O,L_)QIF. U+V<P->ZP*&!9KF[Q8L?(Y:YK95
MVE+%]7@F.K_5C I%1S&O]"OYW=^XPA%1D:J%%W2Q4UWM(O3%I674:(\\O=!;
M,6_AK4..!<N["BMN.E!<?\,:C%+2>Y -U4(LS6F?L^K<$^*_R.4;DHA/9 A\
MJ-S!IK .IQ_1W0]&DEO[B;V$$D9EJ[- 2)A>%/.QQ8Q/R[D!L.PTUC>9^H;N
M<,B925+Z;'H_U939(V-,O$9[:>RG>IL(])CJU3E-KJKV\^_.2*F2169#\_TS
M&_D!29T<$=EQTM2?/O:..-1,BV=)8 7EBPW,%Y!22HYX=VIA14')+'_=N52#
M1EH^A9 Z9..$C^.#BM80GBT4]57,)7=SSW/UF]]MAY5&L3;FDX?&?6S9#R<A
MO2.PF";GP?KIF*X;  HV3>Z5T49A37=RVR_,3&&.4]G7D047BEF?(73ZJ.3X
M,IJD0J)@^1ZNY7)\. W-.-@.@$8JWH&YL!A)"'GJ>.>G?'2TB8?D?] ;BX._
MT[OJ'^OJ;ID]B7>JB1V0&4C&=/RB4&XZ.Y+:%%X<T.ZDK9VV/5B1#0#:)'N=
MD9^7N[3\,QS,YHUF=S@+G;E]GY_=3+DTKVA95S!K<15;P,9HD:7?_Z-$WNND
M8'1.10]7$NY9/FMI]FZLW.%<X!-%:<(_9R<5ZGHWP1"9B5!8NA /Q*4@A_^!
MYFSB[-F5!*BXPH[K0A=C']B1D)QMD^RQ\'BE9,C62B:\20%<--51U-[GY\GB
MGJY^:C_DJ]R4?;KS$=@D@_!UU\.]L'_@-Y$W0%>?$P)Y=WAO/TKO5V/8!+QP
M7*3 EA;P\77ERNZ!CI\UR[Y2>/L Q;D(9EG-_,& 0OT=H:+96+HK;8 '- :Z
MOA5[WNYWI#>$=S!XZ%K=5[>AD):<)4N.Z&.+/4:<28JO:V4AMX)8^\]C(<@'
MB!2D.YDFD-_K7;E=)5.T3:.<U)TY4L/4A*OV:V)HJ0Y]Z<?;T( >@?C8:975
M],)+ '5>8N<DF&?1\6/G09(N'3_E)[T*2MWC$6T?SX""*"OVB;Q*!+O9MX\/
M'&+_&<++>$5G3KA?W536+?(+*-6FJ]W?N2II]R):W#>'$'#M#+]GLEFBR0\Z
M/Y*("7@NW#&GZ=IX>IJ!S]+NBFQY!78L[);F'J0>S?M !V4\."G?T?N=@G<[
M]/G'P?WU1XU#*>F"%;^)?'YJWR.FQ2M&F'GMCVE,.=T-CH];I3W&8E[B]BNZ
M&1"YJ&O.O75SVWV6D\E+Q8@AVFZW%@L+":R6RCK\Y_I"*\*7I2(S0QETV$J'
M*WHZ 9PS*Z[;4 OPSS:K6:U1VJ91>K%""8M[,='DTR0DO1'!<J>TK+VXP@2<
MG&J-2 ^62>1+SYNEB)S=Y^L@).IJ#YAGS_,#'*)4%#^/GT'EAXB)PIGR#A'.
M=)Y5%Z.4?'B8@%<O^RC4,X7-(,;&7MLZ)@EM+G\)^)KK+*>>K*YRSTHO2E'K
M#+:0 FL_ABL0W?,7B+GIVF:7 #\G/QVNK-+OZQPVH,E1A'&VZ?O91+.1\E,W
M\LC8U_8NHZIS03>T_ 7+0TZ;WAJ19!/YWV-2CE>,WNLQ533J[7>?VTH1[$V8
M7QZ>A#?[C3:EA,=_#4YHBHF;PN)9"3^&5ZS-4'_I\D_K5DL59_B_]IS)EX"J
M9$2338URS)IZI#%?-^6%>.#%Z_^$? =TXCV[N2\!_Z9XYWPHY5^#P;'0)+W_
M(?,@2WEJ0J]1^V6.;\H'JG_C#M+__2[R03:'#8HJ"Q$DGNQOW_PE@7)=UR89
M(+7([?\W[(#PJ,2%Q:"[C*.WV1==DN+.KQR^G7T/-=^E":N7AT:O[]:4[7AU
M#G=@74^CZ W;KM8H&N;- LWIP>&8LC]SQB1&WER^KR(%3K=[FQ*:J/PBW$00
MKB^>']S8>))WM4%IR $[UI1V-FY/8\\_/?^J?W^K)TRC/D'6,^M'-HB040R<
MGE= XCV^'$:&K>B\?5UN;FQ?4Z^('"T8WX:MQ#R*)LVH+PMFS$<><6;)/0OT
MDY:L37\]:B[04T<Z4.%(MOA[?O'?4Q)6J?TW+><J\GQRY34. Y3,J!&-4EN6
M%MWQ[5PN<D.!FT7FLC/PX\I-VRU^]3DH+*Q+[/Q!](@;1%=/#:YZD:)HRQZZ
MPORP(:0D@'V"#RVU#F..I1'1]1P<]B>!$-FEWB6CR_R*]7?7/#&520A3+N8P
MX^*&]T%YNZLUYO8F3 IAS_*V&]7%K)_MBQ+2$!-'=4*(M)]A;]N>\<O.'<.=
M*L==I;Y>2T'>'83-/9#R'DO8@(!C^[:&$Z/10[G7/+:EG&CI#+.%6*)C$ NZ
M!7$W"N[HW )_N/YJ#" H-%"C3[CHN($D_*9B25UM,AN?T#Q6-#:OB+!&/,<Z
ME?.95X_FJF-8.-PE?AGWV.OE:#1D*_VV8"I1O&?7$);+Y+:#LSY9HOFL#VZ0
M>!F?PC5:J3.P82+!JG>']<\I1S>[SQ<WAS^OP;<Z(+3N#+.[;WMBXH3F /!B
MDN>YA&I0H5+G< ^R?Q-GV0F]F:@V!K&9_> 52;K5R2YO+*"(I.1C-W51JD!O
MA%P";N_CRO1PB 27LOSWTARWO$,>JN_/M(]>&2^NB.OP!;M['PC$,K()IN%;
MZOF^F'O,).&/RJTH5[P93A0<XI5!I%(CL+'UF#F$KQ'H_;8OT;ZI&6TL N2U
M:OD1>0#%)':GVWQ2I!U;N#IY*!;]Q3(QWBJYNY6ZV9,0^D[09_U?I9<1PN$"
MI26Q\80>G'[[-6C\J^TL<JNM5!(W5A+1RIF K26TJJY+N+N:TAADL\SN*%OL
M0"4.P=8-87O AO0YK9D>0<DW! /_TMRR4N+<_@J9WB9N3Q+A!/9YM.2T970@
M81E9"S[GHH@HLJ&A&K=:X4Z'F*A$5DX!:\3NYUH!]5U5C(YY!I=TK6F ,:Q7
M4T-\#A]D-B3L]A25V<=.4#U@\7@W,>O+I][MTI'^54F@]OKK@!2*-T:U.UU&
MICTX S7I,2/G7LMHTL3QR?;$/KJ=D'.S'"&7BTP_>S]XT."8M/X#_IU,2[P!
MC8!((<;L3&8>]<5/JX4,+.F%F2C?V?>IC;_M7DN_I6<0B%XG!:2K9S$MV?+F
MSV&L$+/$>=%N]7MA[.(@G;D99!K?%Q\EI'A(BDQJ-$7D=DVN=![#M(SZ?-(0
MI8OOF>1U^QBZE?0%9&.4[TXD;$L0OS7:.$R<L@W)A]/96RZP"4>+\SO9ZKL
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M"NSD<Z8D2VA7PSJWVB.K!4L#[?- 8N\H/A31*6X!IZI^&JVW$DU&='WM?VQ
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ME>@?&J\MEWGA<>%L6F'T^Y5B-L$&H[6> 1GPNSA,"UQ&+SL/4:NN6R\Q%Q7
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M>@9HV:7B^V^WHG<"GWDN_N(Y-@-F,S.S.8+![-S>ZS^0>:['30/2@1H<"OU
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M=ADW7JVI@T7\C]F-+'VJV*)/$/"^#.D^QW+XCCZ>$L4";5<)@W!-U+3>Q,D
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M9D90X,HN4[PAA%&,J;<$!44VZIZDG+LI:SE68^[8!A(VN_!JT^@4&#I]> U
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M!K5RCEIP\,JH[I]:FD3-R"W\K.0J4_+3+LD=M2.%DGP@GK3N"ZE%K.2DYST
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MZ5J;_X>QN]1OZ5I/;"L0+FN&SB?/WRZ7)UAP+./H6.MBLI*,YY!%;.'6-82
M;E6B89#>%Q-315$&Z1/[L$$I]4MO7RTG' @\J.$NT^E(78]B /B^?3L<7CKL
MY:7>?GKTZ^D%P4<"X<K7\8L):]1SB"(LFE7C4K]@O^E]ZVN8I%??J#9(SC4K
M:Q[DHONB6W5?F5AIK%$6%"Q^IFMV]?&02L6LND>>5YP#EXSE]WY/5JV;S'$M
M-SB;5]".0^#)=.RA7GV#@QV_ ?[PCQ3I_90;!1\MUCSL3 :5>+]CY^'CGW;
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MY_<I0.S_^HK%<SY5CH?'_ODXX5?T7G8+2.%4;(B?^GGG"3]_K_[2<46,FNZ
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MGY"_Y@?AS$U&N^JK?_@ *?]A0%!P'Q #W9&8:!K'.U'&D0[> &TC7H:/SW+
M:\]C3K6*5H_'![B..-\[9OP@W MGL7" 2T1B*OE;/$U!<\+#EQI,094(>\J
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MUUI6Z$B"Z<&OU?TM#37JX.YF0M:5R3.+ I)BX2+%5G;]<*F0&YB^UGB:=3+
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MREA[I_WR[VPY+W]= QZ?-[4^43EL;:UFH374IUGLK<OC;C-C\)#7Z@[7W3>
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MG&DZA?>\4]-/U%OHI3$9]A!\/#IFFU/,W=Y.$QEG1"/;PD#KAS1%+G;A=LE
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M#5E^JQY^+,5M9Z^?V"&^BQ1\]J/M]XNT>;29Z%T!W12P)6K.SRDH=92GM'C
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M96!;,C H"\6P_S<=5A^-6'0S'P1]N-B-F);:(\8O-*%*XG\[DDQEYE-/PL@
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MX=04SHV6'K$.VL[5(9HN]G(9U)<.U(O.J![F;483[-THZ"(YW^WP^*EKNMP
MIV1=96Q/F\J%@-=S"GMTI]IDNRW!RU?H46EU)Q1.%68-@]RMPY>C40+Z<74.
M&5F" I#,BL- 3J,SP<2O5Q;R!#;ZOGQ\]-L=9F.L5&YO=AZIUF[.>?H'^.9)
M/58FT@_!#T-88JI?>:3LW1PI6:JL#:_3NBUK+3(EPFXQ#-Z]C65H]<6S=Z5+
M8/1ZCK[A$1;U0^-DH,G#V;4:KND+&8M%G$-4Z)=#T>SQ$$[5:'X;A5+_$Z-,
M?P+R=(U7,6@&$.VLN7S=9Z5 ),7 DT?'I]7>7# S2GX[/O9/8,^/3T^['7I!
MQHW[I^PT>G@H;&TU4)YFG?$[<L-W/C!F'O\:,]LFHAD)0"<\2C;D]@W2I%S,
M\2Q<>6N0[R,(0Q3&7)%3NY%P'N\^8STK'>\=^M \1*'MQPN,$0_[ XA4QS!W
M%O.G3TUD .^X5O.PI/"'\-@2&6 +K=;C 3>+/OY[*H?\6?6H0('?:MCJDX!!
MU/Z")Z3G*N(V)?JS1Y<\!1%C'O)DP$SM@%@^MC%%1UI1Q(*Z17G;$5T.&447
MUFW]EQ/RI]TT8O0%ZV4=F+*N6AK^+I(]I.6$C.QL"F/Y27R0S:*YJ]9N(3V]
M<OUK_%>NW#_V%?2;"K65,B #S\%[&P2_/]WT< 1!#RK/"K?/>U5RWC__<N=.
M57-N !EH#D]!Z:/FXD4YM4ZXN\@ TW;.\F!PJ/,(T[H,I'PJ896GB_WDP*+C
MS=V/59=?[9<3]A$9<]:F,B8\:]K5!I6(EKLD<42K(D'S+DQDPKY:^]+(@]=#
MEZ?='FH/G25*W358@/S2B_@45'@3AU,2>!0GFW=?TX#6XWSL_AU+!/.)$27+
MJH@WR,#+^(71UW,L;H&3>)"QKOC*MOVZPHI15X,\%3(-X0R)G)V<92-IA%RO
MB0]%A8=(G.>LTMX:S9(K%"(#8Z=S16/],5.4.21FJ8%26)H_I:XZIAF-=EPN
MS<@MQI-093OC2)+IT+S+252:*.E-&Z3K%,)QMAQ"_)#7VD?@50&=G(UHZ.-
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M3'3HST]YP21%?N:]O(C_R -5&TX[\OS=)O!I.,>^]<=W4FP#!5;3W3_YJ*6
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MF/'\V0Z ;QR5X5\("S'/8J=O]GE)I0/LG< 5,)/J4#\@V@"*\'4(33X*5<0
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M>@R$0<7H4LA.$]':KPUOQLIM[_FX^8H(#!\*<4OD-K@;;U[)Y&.I,1#ZTZR
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M?#0!?YK."<4G8;\6>2X ,0WY.=JCSY8?.2)AD659\=%7'(X/7>\X-3CGN/H
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MYP);YSY'B=<=Y4RS>(J]F[^HFA\V$Q;0- .(8+!4IH&.S>0'R/YOBYLFE*=
MSSYV;96(L?C%DJ$]DVKG#"O5?YUYAQ17OB&A8D":KZDX S_V6N!5)44,&)E4
MI+TO\Z- ]9F)K,&>V;KRI2,25RXG'.E3KOGP2/A#_8O<XU^8 OB2]I^1:PF0
M&6P;A$U_&A-6I>Y;_JE[X8[N)>6:^A/G0QZ*Q=9+OGNIS<D>QS4G'P.>CJY
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M(FX(D.3TVMRXQ9Y&\KQD,S_#5]\.3MK'4+EG\34JZ1J\;57G)[[ZQ.&%/OJ
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M39<'?M%4Y!KR3B9HUOK?"K^(45__7YJ'10W^SVT4<7D,KA>-+FEK$AU5O#E
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M/N8.O4Z"K,A"P0@XL^>GDI&L'^KDO]&S_AVYU_^<T\LAZA+O(B=1+'H02K<
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MJ_>,PQ=<D6&E@ITYMQ87^1,JO_JR/(&-0=L6XL7)J:C[4";*! 8<5/.JQC'
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MK4/[=J$\/]&N..+@_(A+Y?*RK?Q .0^K;R.JW&$K).=[>YR5*5]V3%4V7!*
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M^$070U4."X7H4U#Y99M=*(DGCV)NTX<A:-BB?M*3(\![^]2UG0"$B:J(NTW
M!^Q$1+]6;EV5H3]KI]:S@9KEMU\'IS4?L-;>[)<50G2[9[%&<A-AE/%".G(-
M1=@!H0K$1K[QG.<)?ZKU^HYGHZ'01JA+KB3=!-?;6[43F6W4..4<!>7&/$CG
M""WKA>#,_99D^Y$LN6:1SJ,[OTOR>97'0-[,#[,\5L)LDE0FRY^<BV%%*!(9
M0N\0;/%Y [N[T/^#O?>,:C+0TH6C5 $!Z3TJ*"A-Z3TBTD2,@/02%>D"TEL@
M]%X4!*0(2A&EA=XA(+UWD- )O2:4$""$BS-WK>^;,_?.-S/KSCUSSG=^[#]9
M*ROKS=K[V<^SWUV0G;J:(,70EM4RXX*\LO+:!KJO4_)M[XH1MRRU&HEHG6<9
M$7FPJ6RL,L[\3!@J.]'$BGN\=&8Z E5R$YP]QO8JOK<0^?5!SN=-*,]^Y$V2
MI^G+RQ_>*_!A+K5] M81PQR^-@$57;KNT<HD*<(L Z5K=2)^=&1@YIFJ"]'<
M7O9&10+PZN>UPI<>0YD976HS7^:7D>1'-U*Q7N1@&=PW9+I)*0#G&:IL;8C.
M,%9)B[W"]S2PQO*<]KQ*S@[%24:X]NU,SE/CB7[<8XQ*2HYJP;-\BI**LD@?
M:Y8/[[D45ZE>K0K5=('>;D'0JK IL ZZ*FJQEW*0UL:#[64RG>:/5C>'R>15
M5"]+K8CQY3/<(&R\4?NU^T:)Z6[3G]ITQ:;1)? /AB'($!8(LEE3Y05!6362
M5$L=07RJ8[+CU8'U'RR_OJH]TM7>97?LJ7\$DO5C] 1C^28;N'--\(:8O4B\
M\-)+D>)L1[M<11_+"T #3+ H5V_N:WOY^X_7:.J!0OS'081K&\6P%@4HR[$"
MQ7D:7L\-R+KE!$>N3$P8V^L=O9E9D@H>5J*_#^TSKR9></"=5J()1%ADAERF
M1T=:_)41<<>8N7L!<JX;HIM9QSKUHVO5G^I)(BD]I[2?O*3037PKH,YS ;A*
M<#&T,1(EC$O(J&ZWN\%\\VCHC?-"'>[J,3L4.#<]B6;4:B9VZ-:U;[@4Y0#?
M/S"6@7,JM(942 1@> Q+AAMTLEH!M43+DE5T:F4=ON0AWUYG?$UW%=^>+\/^
M(<:YF.J606I@9-W=B,5YMHVJ!\A-C&V"V>/1V4<!7*O2<BWLA<M>GW42>7YR
MN)QY86 +U:W"<0K7,YMAC!5\XK.W+0]N\/1T$S<S&GY-)/?,>=%&^ICZ&MG-
M#S"!2@3NMF.S<4&+4  J\\8&MFTE*W,[F9<K<HO8 *_T@LSW3&8+AGYFKX0-
M'H'>.Y/Q]![8ZV0:,IE!VC)AJT.1]%16?=<$ARD1O;Q4D2JBH:1UB.@+0(4'
MGOX,I1K3H'XFYS><A9S70L?,) 7:.Y!6AC\#''#UO@B)4@KRG\ZX_7N]6?\K
MH0^"?@[WGR^;CTSNG*-/TYV4>_Y!W2&Y[LNO!R%W61)Z0LF7%&N<DJD?\9*E
M+L*LX;@[\&8PDK+3*+.M<UP<1ND99?A!PWM"1%FP<'^'XJVU94QD+<#*/#_A
M$D53 00WF-W@52@QS@F3NO;X/ UJ-">$3JD,1>UPO?IL-"L+2GF73)%??I]/
M19\H9EK=4AM\M',F.^^9IH,C0D]J8]+CA!K=%AMO&Q]_2N">:4S7Y%<#W^FE
M,YX71R>W7 !P/)#M071G.U.&(.;ZQ$]45-HU)FO!2NG;&HSQ$C/1Z!8VUO>/
M3DR1HL,?+N'O$8"4Y#]7>_T[ZNL0O/3I$=P:&H&%GF<)X3TP+H8R7&%"(5YO
MJZ\BE[9$>\7KL]Y5Q>HO<W/L-'?RYL(,FR31?A$8RI;4/?\&#7;-',_8CK7G
M#4_L8R>.G<2T21P790T6L'*3*SJP%D:816!;'(-GM^*V<,4VS>#SKS3)L(4<
M&/H%<.H8!6]Y@E-$A_K$T<U!;)DFG>>[K01S&PO=<].6SY[R%/$G5+P&4!@+
M#H/_% :?X&!+&AJ0"!@]_&;\=1JM,](4&^ZK=$L^+@+EB4?[01VBHT*J+^PV
MXRZS5 L0\19(N?D0LAD!]\R]?:LA!JRE'!(N?1*2+M&G6K7-=71JO!A'B7-I
M,2*)"X%R?S=>1RJDL(0B!T;NA)*; W^%^U\9Y!V+!XM=:81TJ?Y[J>^YS^1
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MO$(.(!1R7[]/6GN.J"+EXRBO3G%R9'LOZ]"]8S9XQG?)XI1!;VE"8>5AK8,
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M.GVHWXZ8(LA5FR81),9UR:P^/(7MY747&N]=WSK-^GPTR+@E60IL!$Y_#Y7
MOHT)_+BM;,%1ZI:Y,&"]K-54J3]SB;U^5J-S4CC$ A#PH')27,Q7O7.W4/!
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M2+6#G499X%D5]O0JZ-TTZIC%,TI?47 5^YOJRHB;H>*'!D,D6H<,5_ XO]_
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M@N1@B]_F@;58^ ZC6(3WODYE@E>>V3,]0YZ6&,YUK+YU$;7U&L\ J3<)]F<
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MK]F$A7W=1QVAY(D(CI]'@E]XAEE.!LN=4?.BN(M_HX] 1Z@4UJO9T2-OD\,
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M5=N9I<M<Q'TM&&X'IH5WK&#$GKQ'W =)C%*!Z)_]CG\,#"?Y<0G&['TZ].
MZH3"M):W)Z$"3DEK%LZX^!)>0R)C"C)7)\ XR#3 ^C*)*%FX9.UTC)QG.<3'
M<:D63'?-&5Q^=QK!<E 9][6OS-D7?UF<_]6/TUNK2:L0G=";%VD 8%$Y"[Z9
MI=]Z"_!?!N?8I7!N-?;DG#+K:=^&SR,A+-' HI BR-U@93MW]BU5 $U@HN+3
M>Z"*@%2EWFM'#ANT/P<A1-LE:!S?XTT1QMVL8EYM%OU>(E<@J@(U1!UJW'K
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M'L;XUR]*,^D^6^PM['P6?4*EJYC4RKN+AU.,"JP(CZ3L3NXDOE*'+PZ"FR,
M[__;S:WQ;Z\<%E6*]38-XT%1;A?<#-9VV&T>O&V')W221X>7P+HW#/35/I8T
M]JGZ*)QSH(RWP@V$&G936J8/#]CK0>;;PK>&9"K==:,!I04 #ZLI.)L6OK09
MJ!^=EI:,?.4^UJS-Y?:9):989?Q\,Y?WY;35R<^+-L[,H3=?&HQ"E$@O"?44
M=L%.)<Z7L[5EQ+Z'E]^9>NS^2/I=0/_4V+Z?Z>$G351F\?5AVTF2X=(@+8W9
MQ,L:P2_)'9.*H%XE^DD[1J?9UMJ](.'03!*Y85ST2#ZJ]5^W@E]Y+?@G<S,/
M.P3> U?OQSJYB.@59MP8C:W):CREJTR4YKO$6Y#I$RQ5[,(KBNV[7N@LH58V
MROXWB4((1FQ:I17O7JUP\M>!:2?N@@E+=Q\KK<L"/[#T*9063_LIG&:#P!0K
M*;&?IT.Q)_7TLQE+I?'.85M]Q'#>52#VEOI^A1!H-FHQ8K(##8IY5><GP_OV
MGL1FK@MM.H9M&N;1+YS*CER=:%M>$(B72[;L)C>8H\>.7"7,:Y)>C(D6M-1_
MM+>+"2\AJ0KL6&1(#7(5OW[;_N/WP $7$=H"9H;1FA_N/A75K 3JQU4$2MH%
M^3M'Q?EG=/#RHO@UC[0O%V>*&A@4#*AL54P BSS8VIAJ[]FD[)^:1FFL-'].
M!>ZE=P>IY0'U+:WV?1 V"4ZN7IL/ITL*TX8%W*_/;@ZO;8*ES8,+"M"6FE?I
MN]DYM[SUXH"L"CQWR!EF<D?Y/O432/^5(.K4"#+I9BN9:M2N6VLN_UJA#YDX
M<N4LG33(J"R> =V .4(N^\]O*5XU,AGQ07&;_TFNM_1YV#=*"4^>;R4B[B#O
M'%E<=2$\9]/@\;R\8QRE9B!KPA/=SE.V01^.K!4XCG03:>'!W=VL].ZCZW8J
MZ1M(9N[H?0N+YGTWK-2XI1#OJUVL2-],0OXZ&4!%M*+ 5P^23F#IE.+YCX9\
M*;(%9C8O-Q89GORZ=7P)#GD<K/R_T@H+@H\0"<(X.9P!+),H$=:-UMJX:["N
MH:[3GH53%M]%4'0B=R_A^:]QL$SE[*"2OF7B1XG8/5?FV*VN5EU+2>T-F3+]
M2IUG96#&MT+#;PX->"]JT3H[QR8[<^2#%"B/"/&$*(QUH7[-I4^J\<&,2;?@
M#[G/ .,&I%.;QNW')QYF%%&K-GG<'?C2I)CZJOQD&?-^4A$T3S<E@EW56X.4
M66&F6[LJ@GY-KGE55C,NT&Z9N<3WAL$EKZH1G>B24NN6V,0B/&PU[F9D>[>)
M&%34'2"21GDT))0?9;B,D,*8?$$KGK*GV;:FKVI(#6PQ)^:F*6\5)K4.VEHM
ME&PYWW\U:S_9=3=^[JGU99:>>>T4%^O3;=E*DS4#7:'I/)JN+J-&??3=@H(*
MEMF _5?&;N>FG2>E,MYV2_;)P<*],@A9>1V]T2L_W'_.#B '8HES1-2Z8+B;
M_5@;'\%MC3E<@-PB..?@P06-=SET&@Q&,*L<?\_P.:W9\3>!-68'@48YQH_*
M@Y+-QW/K4CT#>K\@;GP^9+G&E8?:MAQ<,+22FEDANV0V;;F,Y >D)?JN^" ,
MJ,  =[]93SL,)DDE,:)-?ZTSL%/*;_[F[U4+P1:TDS;-;3/V/N?2$'X=_K-*
M0K,1]O^#E9%_^]"?C?SG7B791V"<!#&",3&R9X"8!!0EP1E_!HA\">O@LM\;
MH]+^'@0#X?,90("Y:P'/^$\ H<)Z"3M,>=8/+$>>/BJ;+0R^*^^WY?=17_5-
M0+OJS1<7+=#RKD^GM.5K%VX67 ,->\RV)!XL518V7##]H\K/C[43,*5_>XX6
M2RJ;^5;A-/7QL4R5/YUQQ5"]K-XU@CFZ<[0F_:"RB-WI42CML5$@3&YK(S_?
MP-//097S43'+9:%;B*1@JX<_<&HE=[*3:C4*LLE3O8>(_!:KY03Y3H;:!ZK=
M1/H4!J]:O+CMEW69K:# I/1D4??*=)G)XA\_WK(8L3KX*0!H^5,"Z7K>'#[$
M!L'S%VI:RRR"A<;M7R75]GO<.@THAQ-%@D(\YR^/@);8L)')7QZ>UQ9R''ON
M+;XLSGCDJ>,CA1F<UX$'/.7^'A],[<\E4O]GV*(2W*,DBP5WMC*2M)?)T,[.
MP&=NR75K15XL13\";C ^3ZFN7%.\Y.E(DT-HP,4M]?Y$7/P3K$(H*[].KUR7
M?L^N\>'@VV>ICR?T>9HT;_.?WN\U?&<%#%-P64J*IC".*?@M-B^5.)KOMOCY
M@A\DL:=S7#*NURC=3I[YR#@2ZK(/HM#%$96#KQ!BB();UIQ8VBX]>O]4<*KQ
M>*&%HK117?./^]SOFR]CDC]%\.C*(/S)\6< )\1,;P>R&ME)?\,?CDF*E$RP
MT!T5R6NL;9X27OP1IDI[G]]3B\/4[P*-,K!0TD3M'>8Z;7>@%#R:].@;VOE4
MMX ]<W9OS"AWWA]=T,MO5W;_Z$+L@=BL8(_T GW;N6!UW%":8!HLS]_/N*7.
M+<OM=EUR/NAXVAQ LB$CS@#ND$0@&T5"ARA,Z5%;D[5M2M6%ZX^_%3NZ^JUF
MO:*V%^C0$.7BEF.F20<9,*4<FNN1&(LQB'C)#9(F#KRL']XM#="^(_#Q]%NB
M"<?MRK7F=W/-3,Q_F/5A[8P4KDVVIJ@N1%QF0O5PR72<R-V>UZOYFEVI5LN*
M"V_X_"S/RS%#2N"UP-T^(@@Z !6MPDIWNVKA4>")-X;ZL?(6]T7!.V/:_ ^Z
M,T*UNY9Y_(<]/M /+83#:\"DFUQX;<+R8H6T"N[- H,2RU9F1<77TJH_+7C\
M%),&JY- 3;/KU$ZT62>ZYMJW:[WR]"@0UEB,R3^\$U@U'(T(EBZQ=/*36-C\
MKE!?72O.GKOD=_?P=GT]@$\AD?["5''G,.%^[TX63KJ7$]BY<-TE,'22I.K'
MDO )KIMY;Q[C.\/$UGZU-?J%'H?"!]E*=0K=PAG@+J3R## -IG+RL7?*P"0D
M5G=A5AT#:A^>!;7/"G9=]WJ1T;[ 5,"J)H3^+- @XB74[N0=Q\=BT* ?\)ST
M2CL<,ED$NW\&X&RC&RR!M<M2 -!1S@MO,BBLKMI:$P)QM[N+IBK\!,HCHFZI
MO*6+A]WL0.;]G6%;?@.J%=O!+0['7K_35A#RNOXTL_+2H-K$B31(C#ITM+]1
MEN__5092>7^['LAQ4&61;6?)RWY)1_7P+ZO_O$>1TX'RJF 8MWOSCX1(NH]Q
MQZ\^AB$>/%P!KXC]L_0(NUD[C/9[@DV*JZMX3B[3F;@^ES,Y42U4-IWUJ>O;
M@-J3Z6F^!YW9C-:C1.6!,T #A'03J4P0M.OYVPZB?_W8KUG7YN&T-+RTD;*9
M_D+DW&::BB'IQK,XRE5IS+?E%]$9LQN :X"+X8OGE(&C(C<-K=)N-F<_B$_=
MN B LE(U?HITH]).#Y*!WHP\WC(30\^@\'W&V3PB="Y$Y&CHL>G,]S. B9'X
M24HEM^PLW1N;>:<OL';>-B7_7NVD[@5FJ-C7+$SS1[-,&IZ>8G[/'_W"#0D>
M'/.M[/D_!&7X7\*%S@!AQIO))#MR0PL8Y]#]-JZ__^IUL'7"PMK,-V<V_6XD
M+3)#87I8)1QU"5DL!R"])\<H<5/F(( V.2O2'0*JQ)+0L/2QR:J[N_(;ZCK,
MZ29.P48@,J!*0?C)RY=O;^[_+KP^N>^^"\+9+I\!=C.(#O.47\ K)#W!B&"1
M JOA8JW;.4NQX/'17/S63G?=ZNQ6'[<L.LV:AC60$N=R\IW< *4+#B GPYS[
M$6C@XE%YAOF- N@I FT3-1SY>VM3R]H"HM82[?"'\&'7H-KU&C_'%WHM%'+Q
M YQ;B=T"UF%/! 4[I*]W^RZT[,_>KS43\.C;W\MKA%\+$@IMJ[P([=^XCJ-7
M(6>7 S$LHTHRW[&U#D8_$C["=S7*HW*7ECN8UR_)ZF4H(-@1X<C7,((0J)T^
MGMG4'XPI%UQ:B!75>L;_ R:A^2/MQXGHCX=["AA[8VO:3SU(K;8[5&^&8&YB
M^#UKO'G!\_)#10!,&%BEMS.,L\5/I/;4F)/,)A0>";Y/S!V37%L[_).COBLH
MR\;H*H3WREZ7;[:%CR(!U.:_UR9* /5:\^!<UWO1S=.2.FICIQJL8YO/^US%
M?X]&2A=>;_=(N2$Q@NH\ V"U_\ZN+_;N4%W:53$*Z^[N7#&)GSH>%VR((F5_
M]HALZ. YM-*>PF%/X,$FI!I.#ULL!E7#NA:X'6'T"F+ESCKE_K%[0EQ26;J9
M,K,!:#OG(4\V8>6^Y:E0T!/'?_L+[,DWPC]GMEUH(9>U"5 FE,10A\GV(4MP
MEFTV\_C H[E#;9[6UHFOJK&FXFY^3PO5+GB(\Q0X71T_!>>'@N1!]DF$N_^L
M4W;NY/)/BO0F*KA>0E$F)FP@=V>?S ]-I&M\#Y1G^\";>*X;&C/Z;T@T.(&
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M3%O&%(:H06@\)Q^0P0WLYE76/.J^(3X"CA^LK"QF++0#O#'W7AKL]>:7QJ?
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MS1A)&'+\]2YQ$D38!$ZUJOT0BWZ1,78K1_WT,PJT]YWO!-/TW:#.R-.V(-!
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M.T)1;E-H=V;QUX%3AVF^>N",49RN8<$)KF@K:H#=]3Z'2"?5V&.\(&W7W3\
M2$[9:*7D;_J^MJU5-8^BU6BH37;S2RIR10OU>ULOME61]07=B1BK:\#*_ %9
M=\G<_4,0C JF8'@-L+-L*[5B>F*B&I5+ AN-OZ'1#-DS B..5TA&N(<88*;K
M-SZFA[II)]-"5S,23X?V\>%=X9Z:X>I]S5$4#F\31/0A<0]-?]YU0XB<9 2J
MWK?JJVK7$K@\K;:MUZW=!MV78BN@D*)NGDPTPET,/8A5<W]!X@1K&5NNXNHZ
M4:'0.<C:T3&8ZPY=V*VN#Z<*_=CE1L7R?:6%S92%O*^T_?:QPV0EHVJT6Z+E
MA3L66^CQ?8^^TV(?GM\ 2K(]VD*>?4*ZF\FA?A2'HBJ=W;JS7'2Z:@78LA++
MLRIVC7FRQ8H__#XNCAT[Y%HO5;A,:9)7)IS)RV^L[1L/13^K/7&8!+)AK9LH
M/.:F?C.&0=XL#Z?^08Q2A63PMXW!Z.EVFYC[AEH2INZ <[BPK86-3 >FGDA4
MR7?O]^PW>I83]/WY6XNC%#49[*[O%%_+:2-+.-&QL;CZ9SCZBA,+$"^^Z-8B
M(A1&GT<RJ2!R5\0V6(K=J\G?E)KK(B ,+VS&D_5N"]35I!IJ$H@*=_NU#2AK
MC0V6TZO2,U+7M:\A*='XR &3Y&)PWNR 1U6S%^D>Y(0[C/08E"K6SO!(C1N5
M\G!\O61:+==&?=*@^+R816_85[\' /U8-V"W\7 &97\IZ?$6T[[4%<<8JE+U
MO0OW09+8B0AZYY7?)04X1YF&D?5A-JNWK.@9\_DIW:<C[L'(.PDG+!EG]>#5
MVHLABT\).@[Z74[1<J51Z>%$1:Z_)U+-9T4-<"^SI^,G<3]T0L.YJ\2W"]^C
MA%WGZKBRMXUFA[=-3BDQ.YU[3A)[&9!,/2,;W< O[XV[K?H%V(CR)<L?4LD[
MO2B>7T0&\ I]R4+K?LG !X^KWWF[8F"X[F3X9+-[+CJJ =?JV./AK0RFP2QX
MML@D+CK%*4@JYRJ(OFE:(I QO098C]:E^-XSIAL4'LDN.9A3.CR>Y4O;7YU,
MD>*+YU9QC\QO_"/RHV$B-K%WCJLR\Z2N5)92MQ>1>=N3K[,YI/D ;N5_J:@.
MQR70*XLN>&84&-:"6A\OQQU6,90.%6D8>S#:OI76F\@\ 8\CXB;3[!R__>XV
MS0GJX.I27JL7GLS)]Z4[;[9W2:SJ=0C5<GO-3"+(+V9A.OG-_^X)5?-"D7$#
M"$W8;I ?4&7XTXQ7[)=[0/_Z'\729J)MJ !&ST.KJWDJX0N%"IIW\X5&4.2%
M0)+\6S)AARO/]]> J 2E7<H)W7NI!W.3"C7;WVK#PW7W7#BU.M4UH]HU0-UR
M3:K;*S#@LI5N?VEDJMJ21BRTH4@1I,@EZ>8&4MQ(#\42X$;^P=*VBK7_RV+7
M_)?%#GE%.3[V=V6A(BL?QY.GR+;V5N#ALPW@*=E-X!Q6_LNQ]W=%(78DNG^,
MPX?]AI3WE/Q'RT3D#1^ \&'.#KHO48@^SLM;3:^N"M_'%&*%7? .EV,W[^TF
MDI,C8-^6T44EUX#_IQ#D0=/&=TZW=@U ZEX#?H\TQ2)C&H!+%@?%>:SI$_,V
M1T^LJO8GP\NJG .N9J#"F]OHA-]1"&7'XV_ JV^Z171<0"J#E.0ZZ?Q0]"JF
M.S/N://H\TX?K*V0K0M(AFBV=I$)#;D&6%+Y]'1/*I=N"^DF\G4.D8CJ%2=N
MTU\#Y N(T;IMMN-KX$+8@@ICC_2W>J8X6<\+K-J!LYFH:K,>X@)?AV9)WG\:
M]T'LHI/]1GFPU]&4)YK5Y-KQ/J[XO&>7J9<>;I$:"6!:0:78@*D:!*SI1%B5
M-^\N<%(:728"HEKHT6 *3+\N^DW&KLK*]).^%X$[3+M7:V<@/\J488?TN=7]
M+TQLU6B1XEB]/9&$WE)B$CN6U>1'<AZ,%[K#X#)$R(Q(]5*2>M!323'#FZR8
M$!O5OH(DPM@?Y'3 R)&).S')QKPBM[R[M4I]M4%-F!T)QQH_66@4QK+=2RVP
M0AE,ME%*6\1#0QR7\$%5__O91Y:XB_?O=>^PYE=&9?:5V">I[$1,L:?7D*7_
MIS1VSH'E_-E*0)KEMB2*'#KT+#LA6L;[.')L@Y-5-Q87,-8+#+I'/,<,;^QJ
MR4,WEGY7*%"RB#QX&MGV[!I -)Y>K&U^]K&\XUUB)RONHSF<-XKS6VS7'9V%
M@)M'&>1 CVIM!FSCI;JLEM;8G]M^\JG&*FQ)%XSEYA =A348ARA3Z9 >Q,EW
M,7%C8$68>[A)2=]FA8_$IUE&0F]2\ 0C_8[OCTHKL%C O?'])5&3B=0'QJW/
MBL8@W,\YY.7H=&XR:, 8.?C)M@2^!ZBC6H)H3R30<R*\FZ6M.WY(JP0=9S)(
M0[M5K&_G*X,OZ+JT"/H*9=/(J5;:.U[;-''-:5;:<]DDI(HW-PW]NG'A[%(<
M[5(LJ9J8Y5HJLG*G(3],:WV[ZQ?F[+3&^O$H5MQ)E5GT(=]RN?#165"E,)[X
M,3(?!.$C52GT$;#],*Z_]GO-,)S/:JB?&?B^ ;4^%"+UAI)M &SV31Y!%+OI
M?%S,F)V_NLD;@1R[#&BOJV,'PQN]5="WY +N@VDVTCC>$1^A8/;+#_+.MN/(
M/]NF?7S.:;OC>[L(\_41J4$#?J=77XF/:)'Y%E3@-MF0B?@2F.K._:.)/U+X
M;[?ZG1+2NIF7I374DHYT>W%\8_@W,C?'H[K#] P[5WDTB'25R?*HFMBRB-4A
MRF^(U5L 2"LBJ_M+3L<1^2LUO-INOF&7>!A2>PJLM0Q/_'/+Q0)KRV??XJVS
MM8AXO>XPG$6=04[WM )9FPRO8F3N]QX$+)H_V(HAF*@LJW9/*XBYK!FZ_($8
M;$JM\\T+Q4Y_*=TF#_N643;LT[R ^.)8;%=:&[A.Z-$]"^;#B(K[RM:A"'-+
MUNJN7IE4MML(NA9SWCT\*)7J!I?5HTVJ<WQ HWJ%\/;GLW4GP6W<=/.1<MC"
M%Z?6>,CBBEF)(862ZE$A3(?(1$]I5RC_K=P6Y'T,5W;$JTLP>FP[SI6]M((M
MQ7#Z\%?(B+Q]\BQAEO<5=UMQ/GSS_!I@0"R&W.?DLL+9P^KMHS5DJ=;3^'4'
MK@$5S>V]/H8+"6C6*-(KRW;#XB4BP9&6C#.T5^SP2B[NP.#B5;3?2P)S^OG[
M7^(Y0S.]'GDPFN=J1UC9-1?X#'76)P:?J7H^"([4ZR7\$WIEBGGISOOS(+E5
M]VBEUSG=NJS*:\_;Z@\NNUFJB1O[! T*\+%P7]PGL=::VYP:RZHH)Z)^(YAF
M^D%FK\UCR YRW-\&I_>P;+L !2_9]F9.3D]QG#R0*[W1UY&H8<OQ18EW,R87
M".O./W7:_,>IHM[U2&48V+'Y)C'W _]WFA_*1=Q1):_^&VG[S:*A;$O"(FX-
M'_VTVBH_L'#TS2"G8N>)%)E\\MZ126).;SS5FM,TS'SKS #*_R0Z"+C#=).S
M'CVM+Q+\%(0THV+8BF*XQR6CX[9YQ"ZT)*!A*'),)4ZU4HYBSJ90$S:1ZQ3R
MTWW_4H>.T%\:L@#[RD1L'S+'+C!9+!3QVB4AL&JII@L3Z7E^;UF\+Z97'%G?
MKTN,IFD7P-2WZ5ZH):X9!3XW-+,R=:1]QJ_W0-1W!%;7G09!]0DTM14W$P]?
M Q ]:.<4P@D.:S2/[KG/4)A9M(0_I]*ZT/3L1JUP4R2MN>[T(+7E.CI^^!E=
M>JC_Z%_Q^-/-#2"@U%#OY^P2M (DJ(?!.ZHKQGR4"Z<\G.4U>%:Q_F*M/?BU
M'[L4M-7U(TD!;%2JN M]<V7(.^OL)/^GCV^$G /5BY58#X KLA)W'\O+1##*
M\&YB& AN!L\_>.V;]MS_R<WOC2:.7Z@&1/](<?S3LYAWU#C7?[$1F=*,SZUM
M(GM0-'\RGA:U,$^TB2,^F$6$N.PGV28**H;36=B9O+HG-C.SS(8/<+CMHIG&
MT;'V(Z9>=[T\.24E\\1RTR&'5E:.LY>*13A&?%#%1LD#N_W4>:(R.SR?-E%>
MO-AILV[B:M2UV&:S;JV1GOV(Z_G#%50A5J+\T,432>OLS-%Z\H9!'B==UQ#L
MI%^5RY+FYZ2(S!""D.T,<$ZT1_SNPC?[:5<(HX"'=[EE9\P4EJ5NB;L)W7 V
M-)G'/VO0[;^&ZY'_H\L3_U047NDJETQ4G!\WJCX1KFS;=>TE''O0?EN/D>K]
M2X);=Y]6L.<'SAA\,X8_S1(;Y*7059-#:*WI%14?%UPV$JM'*SOGU+QF>\W]
M5E26@Y:6NT'DCF@P_F?C1P4N>3X^/(E=T14>1W.M!$WUU+J'Y9@D <PX@^XF
MV&/+6\DQ=V(#ZR2D3724GCIFJ#R:,\ #3!J?JE;:V$5D.8D,3=5)ZDOH?@W]
M?%+KJU5<"8V'ENQF;AHJ3 =#V@H8GN\X'#6HQ=QH,QX1B I8#OW0WS2-K=)Y
MTD1DSN\:T$!7>BR\#%?-O2-C<^F^Y!Y T0TE:QRFN+6#)UP0%U'>W7?T1Y33
M]RMRX O?WB=>\[(&N>"EV2EQ\AIS%S$+YC'R '#I@;''T@%3]^YKM;AQT.@*
MC N##,A+6">CLI^=T%6[[#50/H0]W]B5U .0P>NV;1WPS@K6)7G< 3[COSN7
M2,@:C?4:(JI+UU<;##(>#3DE@L^A)TYUD35T:@,FCGQ?FDP,:OOW'Y@#X3G$
MT?4[)F9='-W.,/T)O$'ZAA"C<;S9 4EME*CE&E)T[$1PQ<\3V=CGE&9H!7W>
MT: XY.H,TJH3K%5W!F<VER':DQJ>+=1*J>6_,6M&WU.DTC.-'7^^&NEEWPMS
MT!UI<K]*:\(S\9C D=%[-,UT+EZZD9&HBC>Z2I' AAY#T3B^.LF8"Q. .I4<
M8 $/C,"D=KK,@G8:GC<U79J +??'3ROK$96^0"F1P@)8H1AF6BZ/K:E._,)0
MX4REL7!*O"U.SUUMHI*7!?"A]C)/X@@<L;B8=Z4=46!A]G2S#O4(:>-V(9?L
MF3\+RRO_N@;39-;L(',.)_/:+,X<\+P&?-DUF[ [!I,J]]E,Q=<I-,*Y?%&:
M^#O]][1P)[XBQDJ\$(1=4Y@N!HB?NL1&[W0*HQ@!+7G)^DS+Y_N('UP-A?@\
ML[3-XXQ0W7>=13_:*R9+>CSDD+D#/GU'ZE\?RHY,Z%AZII.9W^^V!PU*7/@9
M_)-$&A3,\>QP?_VO?-VR_5<B$5/[RD2J]LA#[NBU#KEQ1/F4DOQ%P??(C>D_
M%(?5ERRA&/OVB6J3)VBYKXO-3]+'&#3\C*=%'[ZHBOUJ.2?A]_/ND$^X*]4%
M2']XX^*MQ+>Z,1UUUI\2=U=J],;>;DAPB3%\H66D .O'.+XI<;&4[3J;D%&=
MN*R"\8E ;;MDF%X+=8YTROD4Z:LI'\E*;D[N(2>WR^0B*#7 K-#8?V E_9AY
MW)M&&*[U#'S!49#[#XUO#'YCEK=DP4$A_J 5Y=^@'2#D&I">4!>ZBOV[OC<:
MX.7$7$V,^@V_BS']MQRN^%^!$3C*ARS+Y^7!,?Q._L #;I;0=X &33XYNE,6
M\IF'TML5Z7"W<0KV/*[G"_7(2<MNQ[ZE48W1["_ ;^5]X?)Y8.[/QS,0$;7)
MQ"4E1JX_O7OEU2<OP3_&=*X!^C'K#?DQY^-L.XMH69G=K(84R[! ;&VG9MRI
M-Z8$X2ZO")JM#;CHX3H.#849Q/"Q9\TBDD9\[F&0P+G?C$>1K)^;O\7+J07
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MC]50VFU\J.PV4,>U:FQV^AEE9Z* %<V0M: Y4(&NZ9/5^C^DA,TO'R/9)Z3
MRR#RCM_;4ZN_T.)K[ J5(808I?:*LDM)8=]@"G\!K8D"#; W5NAR"L3W"VO4
MGV<B9M67<;P*%N6!VG!?,G0T/\32+.H;C&J-:>QKN_LF "QK3G]9Q_XXY:OT
MW6[S>8E&=-*OV1[?E0NP:5F3GQ1>''KKNY%QUIVT(^L14:ANV/6T.N+#RTF
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MUEO6/?=W?N6/R3]9ZWGVGCWSF<_L/7L>[Q$]<\);XUS\)>F1/K?^J,+5[;U
M\ _\C:0$K1,U=08UFZ  ^*4_94(/J9(C+#=87G93C^L^,F^T?2<T&V68DQ1"
MS</JJ]*%RX'S^LXV9Q$M*?IDS\TK^\3HT)BW3>FD3!K 8JU>F+]0:'Q*%SE?
M1@/4TH,OY'KPXK]ME<1A.9B-\=<3?+,WBASGUY_IMS@_])?.5FW/!?0%G>&
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MKVP4U8Z;L!1@7OEUYLR]\#J$.XIX>34,BYA>NND3;A7CAA?&*C>EPW,]O6F
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M_BCW=-M,JNZZF;ZM#OCI^T7=P;-,$J%O!H+_ JP71#I!8^G>(A7#I,8+%[[
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M3I$*=S"YZ_SR85_+X-6;(EP."V3N->H]"TP:I0NQCP^R5]F6))V'[I&H+#1
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M:V[<DWCR<V+\AI6D@25@Z5R\] :2*"5%9U5FU+_JBYGC]DW.$A%N[7&NDT_
MU6$K)=W/-=\?5=3K.WTL.+D4<&I2^SYX($3!%E1]N(7$'V*!9%X33%W7[FFH
M_0)12J<9-]&YDR.W+6[M-.9S9THUVB#UL=DI[?OJ#7(FO R;6@)TK6I2>\1
M389E1K";V&NZ',L;0M$R3QE(A5OO9FN!B RM@^,'&! SU*)%3+02EQ!R+<8!
MJ#.6[/(]\Y,ANP+*XJWV*8/EK+PD XED!TE>!C*>VD,#[*5!8L '1U@419H7
MT6H.7B;!F6F J:PX&J#PX^9ODY]C!$OBGT4?XJ6U#I]XQ\NXU@J<5M5SE*%;
M44:C#;\+NAYXZD*\Y0=^1WUGX>=_'HZ08/"^!3&X$GP2S4*5@%W'M4YJJ'ZV
M6Z^ S,4T6I]LM/,P_V7P[6**Q/G'SWX^4/VM"/T,_!E-A2(6L_HJZ'9NHJ6J
M=W:FN%D&P/F:X\5"-#6B!(\DJ%)2FC7(LI0FJBSY,7XAG//C(@UP)N$,PFV!
M/@R=[MD#:V\O0B<OZLINE"&LI_%Y>/M#4^:M3I@;R9GZ ZY)*8"I8P9 +4AN
M;ZJH88Z#D<;NTV2UN=(BOMM'2BV^@DSE!B"%=8BKF38H\EB S-U.>#UZ\!UL
M\8V27V/SN+H^VDTG>I_?^I<"((/L_ 92]U?#KXOP.?2>&YH?O<7H1Y'^HT1E
M42:IDEF)C20U:$P'DH?,ED=$/JC%/UC)LU(A]%[[XIUZ75'FT0?G2P&BKP^<
M(*6@FH3_QMY[1S49=7N#041Z$:E2HM*E*46D!D6:B%CI$)4N B("04(B(+T)
M" @H00%!*9$N-4" J(@H56H*37JB&!Y(8>+[QZQUWUG?S-QO[LS[W;GWC[,6
M:Q%XGIRS]V__]CEG[U\T_"I%FQH I!# '$ZL".G?NI01'. 3M"3O?N^+R0V\
MZDF-X+'G@M=4E^P !7Q71C*F?GF=40,S)#'CX9 J/)"[=35^MN;8!\5Q&\.S
M-P=</IU(;=<XDUVDG7K8%'P3.$*]S2CJE( E@\7AQD#$:P#IW&R9;CA@>);T
M4NSF%-&5+^VSU=E5;AE^Q"EDMX>)@K\)!$"1UZANY$M!%7.]W_&#?IQ?1E:=
MLQD%_=+((7/;A<A+JGNBZ%YP#*I.?(.;A >4,Q*1?L@,=PGF)_(2"HFL\,NR
MCO!_H.2+FWSX,>=XSH+L#2E/OL_%$OWW+RNS/R&+]PX!JE!LT$%?B&"[*MGC
M4JPE>3&M$^6;YAU'+_3MO>N:0FQ)E/3&R6?/=?+74C)P@I.Q5#P9CX-FR(J9
M\(XU,JXV!ER<DN<^V&3P+",(03GY27E!I[JA]C@91L+4M-(;6<Y2BOCDKL<H
M,Y$!7%P NY(TGWX3D<Y,C@\%4F&%=NUV>-#O=M^+UM*7V +C*$,'V:\S><;4
MKC/['HV2SV;IZQHKY#Q;=+I$^*O4J$J"_BAD<F?3C.D(QHMV20H*5X!*M$#7
MO#2=F79V=S'S828A@^]&WYAJ*%$1SF6L[-99' +M1<YS=N&GH"0,_8@E%LD5
MBN1MP(CHC(U4;^J,1/AZ^NH,9(L\D/PR9V/H(O_@U&_M+,LY4F<](Z93'%@F
MX-8+"7;Q>.&'^/6,PROLU_3L.^]=WX7ZC=8$RAVR<IN7QYW(;DS7COUXXK'!
MWWO!=0Y==I-OID(!.V)BE>9FM],?R<F:H,7S(>^'5-3>=NT>N>OI61.!+OWO
M&M__BN-?7./+N8S;D*$9P6*6>_7<C<DRV:M"JP<_1?AQS>J$@#M.*#DX&#W5
MZJX+CL4-(;@!7HIV?T&[\R/?9@.W)H)B:WL<(5EATX)<]I&YNK#'8D.U#QV6
M)3/B':4MU$D1!;:S???PV2M(P!]<O\#46WIN=*!;V>):<H/GUL-6MWM3*P >
MK4\$\ZX4\9+'7Q(#9"Y.^7WG>H9JQU4:(AN^V(!#W&1$''X^?&MQ^$I,G;.F
M&67=/&+L[<E&F47%Z:CIOT*4SA)Q".__0W'2]N=."1;.I,#!0!)E@ H=-V(G
M-UL;S&%TJ:A@F8H""5[<P>[2X\NPD>,1W?>*)HVN< Y"R9>W)CVH#X ,F@P<
M0D%EF,CXME+;*O9!=QFOJ9O?%8J@2C?:DO3T)0T]S*^N@]#?,?&L%&.K&QR[
MES972V[K/NH0MX5^+61G'/?.3#[S$']MOD78)FC^C>FVZ +DO4///DB:+L'(
MAG.3ITF7"QF9).-C=RU6)P:30\2G0E4+$[NSQ&&?3G\L7_1()?SB0E>%ZJ,#
M&J;;TL[@-\*#S>7,N&\5W4LN?1UHI#$?G=VU9@K^@J&+M/45:3'*]D$!_'H$
M:,_&&3OA&9C&-,UDO$>8JX@QLI'7Z_6,OZ)2^D5JA%+!7CHX T)V5(WTK(\E
M?,V6/GPLS<-%A*>BA,U4'  )G'8#TX^44XV +4)01J<^X]4^R,^-G2;G.GKB
M TT\/R3@P>^YN]GY01J<DV5YWF-NL<&2PB]\.,%-+,92QNPU4:;@UPMIX2L(
M(0!=HO?$BQ*)]+CK'/FXMJ>U:;(J^?;+,&[Z4X'Y1MX#(06, ZP%FMD'?9(&
M6!3V]@IF.V=UARXJ2-4 6BAM_4QNH(TL>#[  UK;' 6Y9A48L*%PH3E[J/ZE
M<\0)OIM%-^6%L=P_@L>0W68F;,SO^(;F]7ER$0Z+$&9^HS0^:=HIH*)D9DNA
M7BVYN'NK=39:%U:SLS!MWG^D0TRE!==IK+RF@/&\/92<0-SIQ1]9E95OPU @
M"=O5]IL_H"ZXNTJ=#>D18J=R*Y5-OYZ//7XL5/XW]"WKC_9!/JA83#TF00H+
MX:+K!KV:'HP-UEIRJ7SC2BS_\+0ART/)UWNJY;BI]$W,Y$Y/ZW(TX@!<EVR7
MM-'WIIZXQ?=S*G3]^/@YT<&R9U>^%'ZK.S-Q3:LT=E18=:*"?5%P.HB4@(7&
M0>KMTG11R6>"[^YYO_72R#^4+Q=@$#<[I84]D/GYQ>( >O!HR=E%<Z0RAEW>
MCI7"B7:*T/V 9J(*FBX8CJ32D/J".1$<+_JYO1,:T@*4!=^3O[RK_M4,:<(T
MH==Q-'OF#TBC8 )<(?S5F22R"S8+*_*HN*/AY/<OE0H;RY.];SRT/3XE\<$#
MKH55&CI,0AOQZUY$2#JD7@W*23]<WOWF+H*O*=V.9Y[KJ8T_.+>I;\AJ.34B
MT+J?5'?F(@]H3YN$R/2AY!$T4W3 O&[F2/_Y#'[HM./,A>[7^;JJ>E:>%C]O
M/GD<NP*-A9#-MY(-?&(1:K#?!%SB;%4C6,S%Q=5)'J\8V)!]JH"_''6ZY'F3
M\8E X.]I%*"(BF6YHV <AB<4\@338!</MJ@EK_^<XOC2W-1\S;BC.ZS@1TI$
MV?%C]R5Y/9+.I NQ_=H';92SUJV=@DSIE)N%1S!RT<21T+4U5/.<GSKDQW/H
MYEQ@5:"%F%[X[J3;,\X!U5\B( 1I],#29(WSH)?9_629DAF])W=,[W28R@L)
MUJ*7L;:C&$*S(HXIM-#0RA\-GE:R91^\(1=$CSJ-?;0U +D?DDQ#4;D83Q&G
MX=P3[5!*R/Q.2D(BW7\>=BL>ENNG>50D;F"S8-554EZ?1]2BEYVM4,Z7<WGK
M,691+QQ*%1F'_ %_0/_LQQ0-I?_M>;,Q3<1/(WM9>4S>^AH1%G0I+RBD;%5Q
MYR*7V"INO5[5!7\Y[8-JJ\SW>:.W1D=_3,!9.3O'&Z"Y?( ($5U]"D!M,/;)
MX<F_+>IW)6YM%MK^UC"5BQ'Z97B%,P[9?9GN([BA0O. V1!\L/;,X;9OYITQ
M[EJRVF_Q7X]Z73O;>]+#20#F=3^X67<%0[9/ \^+)YHHPTT #R**9^TOO3'2
M?#T]*_\HJJRWUC9<OLY,8_=VVJC5^Y[DEH/%WL=N[](BJ;(L3_<'?*C0L0E2
M4$:C5;L3!=3_O5O^=$[MR(7*)KOZW5AXUGN%2U^$-A1NBJNY_!%[# $]9"VW
MBN:&$G&(VP6P-&,\KVFHEK*M<U'U]8B]YKBQ\3ICP/Q*P(<;IIPF.>2@=5Z:
M'=R>4=@H*&E-QA#+<+W>%.&53Z$RK:[USBG>J(%]4 :LK#M[\):>(''>:.(/
M]MTYA?'\\ "N+]EF)Y17!E0.8(XA"<]0=7A<T.1G&BD UX_D PLHMA9<"G.I
MV0B$S]\-_/*!IE.WP;M4KIZZG$H@L,\/ <K\^R"Z*AA0@6 AR04D*5MC#%%\
MW,OG9ZW3G,3RM4=>%Y1,\O<<MHNJJEX]6Y ])\.%_LKZ8LH.ZQ?W08U#T=MM
M^R"NV7/EL+6>>(_;"OWVO&T1[[T:<T:%6[SLT\CGF\Z!]&_O3A =6%,X #<D
M/P0?VH8(#NF^C&NIK>_(IFDLP8Y!<PZ&HT]?$X59/*U7[I+HZCKDTVL],0^F
MBWE<J"6O1K4*\MW=NV.U\OGM=W6QI87:GT8M5[^QS.GT:#(S7?47BLD]3SL(
M%%)#QD)1J?BCFO.CB.- O*1Z[VD;:EQ=?,3!^H9LU)_F(P8U2ZYQH,>#[04,
MQV+![']3I4,IIQ]V8-IZ]$&H^GCD2MME]#?-J4+B/BB1>9+Y%2/$E '.RZ-<
M)AHB"_W/EH:F>;[,4XZ;YFE+G.(58F,Q#'\RAF#7#094T>MX(N_0 ;@<^<51
MBPQDE&+)29MPXO0;VJ5:<]ZS$35NCR=Y^ 3.?M6R!2'/840Z%6 NA+]W&Y$D
M:)J&>4T&<<TZ\(T^&^K6YSX)^< LBYX3.W<XD! \V4J0=PTEA/'+2,3(H F>
M=?6U+4[@=XPVQU:GF$.0R,-]*F=7<KYJ:8_X(]^CZ"(>U+KQAM^TZ["E"?/O
M:J4:)W)A&@>=)#0YT@O$)DMQ4B^_S0-MX$E,- K4?H2F29>S2X!R;R]]$/-3
M'VC?3 EY"]7Z+?^+Z!"2<U.:PQP$ A4+=F4 *N$I1EXT&^;4T: N3-S4O2*%
M#V2W9FI4]1/YP\:T\FG-Q %EJ:OV^OH2O^QT_TA#9)&$]_;43SZ<W2\5SYXX
M=[2_25GTJL6!QYIDD/2=5@B@9+<>0<%WX<'P$)H9<[B5DVK14F$>3-746II:
M7&X?4]*:<Q6LM]$8?-=VB*2E</:K .2>,ONN#2,1?G4>,ZE'W1JF'Z= +8*X
M!DA49O]HPPZ;1UQH0+V3"-9@_<CN,1G<7;&#R[I['"Q(:=D'9>F3MYC8$>2*
MZM@6<!*\[L;"MO T^A%*.$'VR50_QB-P#U'Z=&9ZZF)2D!+*QZ#AUP6)2J-W
M5@KQ1][/OV.9<#R<G5&"\0N:Q!&-,^+I"HQ7\_[< 5NZ&R:&;5:= R'JZ9-C
MGKF>26-*"LBPP=6S2X^->8G-Z[HT+?H]%J!*N_C/<0QO#P:YD -3M-><0TOM
M"Y+G[,I[EA;?)*KD?$F(C&B+?;')J=CY][S+EWZ%DK$^S5K#2NH9(!.&M1NM
MV=P(* DSN>3<D>ODE1#.DW=?965G* =@KC*'.D4GC'C)1XCH&+A=H+HN2A#F
M8S&"OBU0QU43H/8ZWG,N+K.I-3-'7K8X$YJ%)U\)^M$VCT^&^$%X$</@>K%H
M1F7EDX8BVD!K8Q-,5UW#G*:+C7KC&,Z9:('2"%Z4^3&CQ;:-IHMBF)<P;JRT
MJB9G'U1VH/,X(PE#R(?4XW%;DP/=*$EZQ%O@R=V]E5'^P<:RQ88SR)]Y.V(5
MHK:5%[4R58+F4(7RMVX)?D<#RN(]T&2D+,9S '\0X#S'(CU>LU_S'^X]<NV6
M'1%)_OUN0!LG=6\9Z+P77)0SS>R&\M)#R!Y46[(2-BC)((AJF;@=_5:J$GI&
MA8YN6'70.QPKKT')\LBTGL))=B\<-I5!=D$F50E*ZR,!!G0E<J^]^,ZMJKW4
M]0F]7Z_T?_@\R[U!@"<U:FDY&$WTXLE.Z%V=625F?S5D'V0=I/KG#<800R@'
MLS.5X0C&RWMP<7+V!0-F8P!Z$F]<-\310C.ZXMJ_>91D]8U8ZL[N\R*ZNY@'
MR0U9%+N"G-0;Q6S'/-JM9'*E[8/D0TB:C(3B?=#P#70S0IHN!T2_1G1]@XN,
M/1R2ZS?K%F\]5ZM]_D=GT;#CL)Q62\K6!X[F#=D/2^V:3&XHS8A^FU%D(@$,
M70!PQ-_$:8:+8_K2E%A+\P=-'I=WXH,-6152T1+RL@8>!:#?2$ ]1H7Q BZQ
MP(_M>PJ*)/QP]]GE81QD9& 61A&"R!]EKY$K(C=_L4BJ' '<AYHZ0@B/IZN2
MD>=,CH\U;!TVBS)NG7&9KINN+OMBCG6U%GYAE'Q*(.+K*6[P'>8@\S"%\S'2
M!Q\_QTEQ:_[16,V.;75+6Y<:MCNY-#=^=M&6DFLQU95:*10IK%\L:$WQ3@LG
M07C63&3?8[(OMHRIU:C?:4\P\6K([O]8K\CS\GOVAP?Z,N8(%1;V56!\@_;T
MJZ\SZ7CDKRC$TE53L#;STS[H0+L3S0C.^D1<U#Q$RA6@7=7;$4=-B:N>K,.=
M,GU?D>M4>'=#:<M##;:)>/XZ&<3T.T:&/#&11W9[Z08=@OVV:IIH4+>\,6;R
MW2M<(I<;_E+ SV,F(;;I@KTLX2BC81\4?XSQ=!_T,Q,6L@\"R>V#>.C[('+&
MWQW42RSWJYAA?MOI%#]--]9K3?LXAICTO8$++AGPESU^)&)7^^PUH_;T\L4E
MC-]/]@6[:552$XJFR_QLHD[13'CRR*NOZ$6K11+?,8M:UUFV@'LGKCX^R /O
M*GE<6T _Q$C(II(!&Z+Q=9+@^@CY,[[7 )*6ZCN5MM$ZN*2!DJ_=>%+XW.JJ
MW-E  4<!Q%5H!8I\8Q\4C6EHWCC\!N#L@G# 3X4."4ZZNN)7K_$.N-QJ+K27
M"A@(5O/AEOKRH#BCL%::F0D7 _S>T*59CP''M=J/QV(- AHS0R6$!XX*GKF^
M)5_X@E9;++C43)T -^^#^J$'?@!MU'3 )>CU3P2'G\_1N)S67K+"O/F1)*[6
MY\^\'7_'$1Y;=^G2;%A4]/O?:P.\A=1+Y'J\W;*_K" _D;;^HNG>3<17G-'+
M\<'#:H^:MA[1E$A*,3I!28@#%''LD- ;AEYO0=175'"_5?K2F=0Z5OQNJRNO
M!4TLA-.%]T'4^XR*?]Q9ZS0AX_J@?$AO0-.YP?I$AWA3-D[QE=>9CY>N]FE_
M%//URDSRA'YX]?Z^,CL1\I_U*@'T7]7F^K^P%F=%6;SDJ!JE*EG@?M=A5'_9
MZ_CX0N=BUF^$_M6ZN/]A59?_K97XO_KXMWNCH_]<I.MV Q,'R8RS2X=HC[+\
M=?%_>77?_PP#\M_2>?\OC?]N!_O?X]\S_N7M8&%Y.$QJ*[(;ROZ))'G"I>/R
M!G/H]CW< >O$K\LX0Z$'/]9Z%L0.810TD7<%TW=:/XWO@X@:K3%NT[G*,0JM
MZ0,+&S]89N(K')D-]<.^X$_Y\M9@="HUS!;OL.C)_$TX6]E[3^"ZT^W5<I4.
MY[0&]W!_J.: V<Z=Y-U(J@>CF+,?+3 SN98D@TEZ>!]SU[%_M$B)Z&V^\1&;
M_IB0>@@490;5SE]L?)^SF%!3K8QR>[;4</H'[,[[34HN?H$^_H5ECT1CH=?)
M0V.A :KG1Y;&&MM^/*1)W6YU24D24RXY.*^V>3XZBU/QL8XR6IN5-8V1@Y@)
M@^S[H$.Y&/J#IFW!1 2(XK;FURE&.9-?-?M:\JB4X0\-^<,Q;'=JVX2*GW+W
MZXNP_?AN'BP./F(B-05DPJ5"21V*,E&S=]STMXI=L'*$=UR\NX6%<NR!EV'%
M G/)JE)N%' "7=.#\984<&W"JF[FR%#[2W72W*PX/,Y!29KOVZ%!T64AN =@
M'G*R.V ^C<=)FGA3U]#^CMVM@_GH"\F.RVF*<;V9']E553[>BO@KD 6*^D>L
MO/%@0+3=SFBS%B>A]J67XZ9TEC6!S53XJKL1ID&OBW-T'U3K0/*)%RAV"9J,
MK_?TGGWA,? [W,?(0W2MUD:$(O_WH/UOCUS[ZQ^/I7/IL"F(]JXAA9G2,/\K
M44J]"-7AAY4_>^I=9O'G#KZ3\+*VEG$\H"\=<OE[ISS=@"(S/ F+[#.P?WL?
M=T#5Y:?B@Z@<Z0+0QC]8=-6@A_/W=L,W0U5 #)-?VZZ1K:RE->=X_"DK4'OZ
M^8I/[-GC=4::\^B# $EETTB<)&,(31Y]]WDO:D;/7_+>AL =;Y[+ MH3(FQC
M5\UAFVC:!<00$SR&,IWH5(1YV([.WTGS#ZF:-#/XL/I&[]DIN6_)(.K)DV5Q
MC/2W/@(E;UQQX7[W7Y$*Q)WD,NTL[*^=XQP]VFS*(<H_.-B8T]Z<EU4J9)HF
MGV75??6PA5-^!HCMDU)9Q!!= QV+W#;Q!0,Z+,R;?\:V\LS>)(TDP]X;UO\;
M._6RYFW@*;[<>OF5(;M\;M%:UO0[' ZF:!,[T$GBW<WNJL.W)V;'%4:*]CC:
MM4QXBA]C\EOJ3IU96$X&;?Q\71NZ)0R+[!F'3!4IC:D_3#$F04Q^/6Q.B7SH
M]DO4]<5?&Q@37?I.]P+.:2<2*5^?;,Z 6E^^52(+.[SN4[O>F]U%LEI@RWD6
M4U7^])RTD.^!BR?CW[Y;>22+.E-=[6Y6_F.:?W@H^$2?B/\+KY<?KVA%%A F
MYBV[)VXES7=P/-]FO]XHOP]:N C:;CU9G;-15.(O\_>(=*P!JZ)V24;B4:7*
ML8RR!V AA"+<&+ K%A2AVU!$,^(?YN:KCR\Q'\:<R<=J]9=]G%E0%2I1 A4]
M_L898GX;\.^=DZ'DQGJ04-QWP_;Z,]Y:*#:U->1XQ_@.65B>OY$^(]L>6OWY
MG_*K%DTA@-;5*?PA>:@/(3?RT&G)3NOL5M#QIO!+\P^J4DM34SVO<+J81Z#^
M:3UR9GRGEE)(Q@;J4.Q47.?;VR9;&J3Q&T7B4Q>;)L[?(,0("!Z\\UA7^4U;
MJ=7PY^[#;&J]!)!!EG\J>:@7E>"NTXZZ3 Y/?E@=MCH9/L ?MRU^S>)QW,S
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MZ?9]DZLXY:*]O(W&0H#C7Q/\3=Y28ONT^X]NSJF+#:L(SG$;NEN?V@=%2Y1
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M.H]29%/F!056$&KDV2GHBL%@E5YNWF'&IX!-(6NIU-_Q]IP%]+_:"77PAVV
M->UOQ8L2D;9<.]%YS/T-ZDC/DG[69SZ[\!/OCQ$>/VTRM''+H MC>B>8<HSD
M=DG9DN,YVTE_I [>>0"OJ%GP[=X'A;HJ4P]@]/=!=R>GJ3C6/\Z'&1+X\_40
M$N0;WW[,O?LM:<4YW>@]1*Z]*;8,Z9.0W@$1,83<?9!8>R092:UH \0IETG4
M,:. \BI_ORAMO6S$TY1I2ZPVA]9T?05[KL;C7Z>A(Z)(0S#9'LV^!CZ$]$7&
MXQOUHN?%)L2]9XP23U6^_9DE_U1['KQV3/EQN&,:8@^N3_F:1M'K,I$!DH@3
M^#= GEW3J/KNIQLM:9X\^ V-L/?KYT38Z!-T'W)&K]V4-I,GF(2*/F-B,@K7
M%4-7N)IQ?,SR([%8E V+17$4'&_85;@O>=\EW%CP-3V $;L/\D=.VG3MY?5C
MXJ%2H?QA@OP7 M%9<Y&#!BOJS])^G91<2K]Q[K=5%7:1DZW5X06L;5XPELGV
M]WIKNR7%']=/\#40>XND9ON+O]3;L\]0:(B\KHJ:N]BR')T-M66RLGKR370\
M"\!-1/WW08=,V&#^3N.Z6])3 Z]W=YH^B?B)[NT*JPGAY.L&=1+7$]L<^+KK
M?DR9FDRQ9C\0,<949 $E']Z5;OIK@1+TI&:\?V])WG%X4_\(7/R0+E'FL=?]
M8A6OF6+V!H0GZYVL%"CX#"2AV(0/T"L%FECTKH["9P(>ON7KG?>I,>#RQFN_
M]F=9IQ8D]0X_=0$%2GML&S*Y VBG@ EJ**!>>1<I'""01[*3FC-_1!7,.#,\
MS$5U*>V*FK0.#[M<(:%Z.Y9M]P\M^*X!(I,5&IP A\J[$Z>='"?OR@H412R'
MIBN_SKC"MR57R_/N';>W/.B0+2@4+(0DY(,;T3UV NZP+<)._]H^Z/#JGE'
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MB!@X-SN%[+%CI%$UZZ8ZOF[51C4/SM9OS@]=\D&;Y-!4R#M,GA":$MV6TI]
M_MVSUU\ZA4NL(=76.S6LE*25OVRRJ%H^_J"7K\C8EWU;#).+!U2"^H; =#_&
M.R-+ CI^1Z_YJ%[/H)95>?I7;ZOO5:-#;]W.\H%.&T9<>L3\R08=%NS')TWY
M=".?(#2 MY4;_DB^E6;Q: F"C9;&\023NL\W.=MXZ% 6;IG3Q:%)1^WZMM+Q
MPL7,D2 I75Q"RA?]#^GK424WE$8O#E_0,JP4+/Y;G'Y),-T!<A3C%744[](1
MB1>"G?33L9G(&1@X<?Y@;MWI.XY+G!=F[-32H"' *G7-EFR7&"HER:=WIC5T
MIM;@CZ654T["!SE=^C;+8G3;S=XQOV":AC(@7ABQR]?P;EEKMJF8SW50/[5?
M4U^TNYRJ4\N0[6Z<Q>B?>B0(/7M(!/GCY,X^Z((Q"*F&JM5<'Z384,>S<4=P
ME/#KY(9.88-(0QMJX>^'4QE3EZUI-Q0N%B*L9]O"[X6LXB6,U&F!K(=JTRV+
M82.7@<Q@$H;K;KC)A0#YG2,KOR\];FEJJ_L0=K@A4:+2HJ\I7O7$^[/;*.#$
M/J@7FC '@J8&S&..K""DQ#'DC.<"99$<SY^9,TJ6[OU^&7YOIJUV1,[8G)62
MV0=-S1.V^B!LL$B"0T_:W8E^@ZQ5RMV\O()[,4O#L[?B'>_$*6:<'I"OUH>T
M>4^)Q"_&@1!3<&Z@MHP> D"(D!1G(\5Q?._XZ9GG$@M8/14=IZW%SU4M6ZD3
M51,#R%I+K'H(86<=35XF;B55%PPYC&S/Z\ZV,0"EC@*;EA/WD,(Z95;KYE'6
M_[%'QO\LZKJJFD?!T),>[8,8L9N8[>OV#29G]S(=B+?_2=.U!7D0^3&O&/G#
M9&(?9*X>*N( +*Z*=(J(7#7W=/Q_?-6@']^LM''5GZ9(/])"J7YQ& \K="BD
M&9HW/66NS[9JYY>!%OIXWGJS;\F\S9G-I-HB]:%D%\TCA>@4*"]=$K&ILZ%G
MW8*Y+<OBJN6NB:7'A-D, RRT? _8Q4+>;VWHTAX ]^"!C!+FR;O.&CDD4PV=
M-4NS!SMGOFK5*[S/E8ITE @Y^DX8NS0E4JDWAZH37.>G<%)M@>9PDBHT.1M
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M,.)T,QB6FZI[IXL%E\%48U;N;L@<@#1(0^N"-LPC@B-*;"($<JN1D"GOX9K
M XQ<QT"G=)J^V9L;3:,6 FUA=<W;P=#!9;K8 +8 D4V)).+2=/XXZJI?MVZ)
M\9/;]0QZ_[7Z2*WT0D0O^P2[3#S$&7,7,O5FFAK"R"T!*L/E'P#E+N^;FK]O
MS CB[X;?YQ3XU._Q)# '!XJ;?NIXA7-IARX22\(D8_R&TIE2C 03OL%E;/E,
M2EJ8IWP?M3?UXX"*>ZUC=ZLUI_[3C7Z@SQO9S8]<4*%D,S_\A.R)_HE<IA]A
MI_J.MH/);;W0AN7>9UG+_2CAZDW%QMQE=:-'GJ6?6<:^U9&]4Q7QF>LKPEN4
M@"2;07=YX)[[H!H#069<E*GL&,L+8(PRNAO!F!T+KM_"NEGXRWCT?U+X6C&>
M>FUAA49_KO[]63QOB.9S*0DU.94=I^@^())E1DZ @Q*6]VRG(JS<*067%]9C
MD_]P-X#9[?=@#:5R N949O4)>SK39EZUW@@&WBC]#I0S>7!DC"GFG$+CFU=$
M7@M+28<DM!@Q3S9A\ 2FI #$#(80BO9!ATWDF9_Q36?J:9*P?= U_VK.:VUM
MM5;YA>OD5:'^";&)L%7ZZ]G>4S?8VKZD-I]4W3-$+^U0BQ-HXDQ>7H++AM&]
MPJOC]&._,OLW]D$^34'T^ _H%9[')I<9K9/95!.@Z4H.Y(>X6?K98P<@AZ'Q
M>++=%J"4T),Q-4'H;Z1(X4R.CV^G65Z>J'GX?'ZD:/+6:3-_?X,V[N+,E,"7
MT5BVQV>_6C-PC#;DPA!"'?GCT-J>0S^*; [=U<T0V0?]6([:![W9,'ALHLUX
M!2$4H,19C&WPY/P\9ATWWV%YM9F\$!0*SZRM'5-7?RU5Y ES5.B]6)SO<%<(
MTS-_EJ'$LO'[B*F_!!J*';0THZPDP:,(^R %S=(D>QU,4^$)U<;4^^@<5:V*
M*2F^,PD\F)+F,^,[N;^FW'KKNPVTK*4J/!_>CK?GC.$BQ(YC"J" HCJ&?@Q%
MO@*5@4F9P_UJG6&QME/ERM\FY_H]C/<BS#CQ:!TVQE%@J]] $XOA\)\SID@7
MV><1IZ5>GE]L2PSP\(-*KEJYLLU0H'UY21.DY52+1MJ=K]5\X@B-TXU[IV?%
M:L\&G!,S.26F>S7=PN0*!_(<GNQHEP8A/T9\M4?R/9RD=UPGJ?_J6A60\!OG
M\/EP[,^2G:*68>5[ZELC/=I15O+-_0C!I9M!OVGP)A5NV1RTA6QZD0+<,4D_
M4/86,LN)OB_X;2L:(M*PE8;BA(,I+C93M; \VYB5[P(7'#C"AL2B[CPW (>B
M/R,!]8%3@#:9PF9X&7-:KO;$=S+R^A7D_USP1#[!DZW ,4@1DT.LV"E)024^
MG WJ0\B.Z#H="E!LC"?M#>O/J+F?UT]S^@@:>!%Z[[<[/^TX;)FTLPZE/<B8
M5.U]1"_ Q37R7WV8DF+O(]:W=<+I7E# ?-3<I739$ZOE?%4W4VX[AJ/X]T&$
MVD>"/:QU[Q0  LK@6BVC?^QX?)W#,JE)C?(Q<TYJ =?P@U/O#3>\;:=A9^?O
MK]EC;@VQ7@SB#YFZC)S&D08'7SC;-I6I?Q&:OICZ&S_=?RR&(\YI3B) Z+AL
ML$"WAQSLSC;;3CA=M,E)CI'2;EJQ:&]K=]$>1#A%N_BW'[S@* ^=P7B*(>1!
M#NV#?/&3)3U(";@YZ27RX@3\O*Z@EJI#XYG,0INUE!NJTKE+YWEZRZ*SLRZ?
M.L6)9T5N^WW0KA8CG-G3ZL!\QK.[#Z(*,EHP7ADQR-J=Z'9^BBKNJI_[L>_]
M;ZF5HO4='_+Y]EZ.4C)F3%?#+4\T<[(;90Z"X*<]HB@I3&XOFLL*XD!V[["_
M.^?8U/ JZ7"KH9N9=5O.*S_GV?QQJ>?.>E@5>5%:GT0L+8H&@W,!UI0UHD;A
M*_IMRCI$0*=:Z6;R+_YK2Z0Y+O[N>,<G&H%%.@&KZZ9\4G+I6H(DA]XM\54D
M^3IR.@\KAN'7<2*2<]-DRO(+%L_H/+I9NA4<&A[24-?OJ6707]C"F"*O^V^C
MF+RZ^R#%PE*68X^5[X-6U!=!440:!*9)W.JVF]P']3!%R F)K\;H<L0-_;(4
MIPBB?P3!.S(I\-)'^"M)M:$/9[YUD+7= C+Z4;&MY4\T38ZM%!E\"S+2+/_X
M;6;U_=VPNA]F)^/N9+E6Q2O<DK2^UO7K[()#'_[?E'C2G1F/(1ZH(X@)ZL14
M4 K=-KP4KDS.+0ZL4=OPD@T8?QO*H\IU-58^8*$W>NGA'1$.4^L[Q> 1\&.D
M+S@:);(U?1$(GF<(]N:M?2ATD3G/O7FF7&WN8DM4,5)L)G("/?'K;U;)<8"1
MN@WYD7V-K-</?6RP5%[NX@;5 =F=C2Q4/\_Q^U4N=^:5G(<.GYNL5$?C6=9J
M">8T"M#K13]!< $I#Y*DYY2_Z\Q>NY"QJ3KG8JE]<OG%@=XKG*7V[BV54S"D
M^:CNAEGXY,/IB$"O'UISKLIN[\]^ZCHKTCI>^P:(M,1,_,GOJT&].:<^]N4+
M]V$LCWCF1]"+DS$P2?3@%AC9?1EY)R"HJTCN^\.A1$W=169A1! /TO-N2JO3
M;4_S >?'6E:2\FQSCTUR&;G[(']-%CEOQ,0U9HC1]6K'=&ANPMN.0[*5?*<^
M>YZNBGYZ3F?U1F7XK0>",MQ[CS"%2$ !MQ%-,T8,[H/XC;R(^-0BI0"6&]B/
MS;<VI3K.N>T^K6[M=PEMT*K8C9:XPX]8H_,S2DWX$<,&)F4U]*,3^Z#FJH:D
M\:F5P>K!5^D.;JMG9OJ."#E\.!CVU9=]QG_W!<NSTV :.%(0722O&\S_IS"I
MNLKHBI%VJ:V:?$2M6538[; ,F!??Z_,.QU+_',*\,6!ZL3"AI%.O'F#]P'&<
M[-.;=G[*9@#*(\A_=^3<X0/6'K6MVG7' ]E/G3\$^[3TV(3%2Q,4F4.H;2-8
M"9/&RD<6G!GRC!<F(,"%Z@U<+Z?+DT/_+)6]6?GM^K4>+S$5'IGO;#_T++.&
M[2Q8\QPT#T^FH9] MB_KXNE<C?L@4N4?*$&I7T9N?J='DY\._79/0Z<-+&PF
M7SOM%J!MN7B)_/[.D[<#%E;'?G'IL/W6I(O4S]O153(FM?NN_1A:6)/5Y"72
MI*7/K"W>OH^5CFD:4#GX,*!SC+['_%PPE(KT&)KR)PIFM(>(4P-3YE-4_<L5
MTC_I&/L5_;!5-"6=N6IR"$$J M"M&$+9U&89S9HY">%CQ5 D[]=^_I,NOF@^
M^*[#HWKY[(_8%RF1NM;:TR&ICVA*=#$I@D"A9I<=!]R:7)8\C2//^6[G"Y^.
MELV!O>4S16WVZ02?2)^[72PX[<ST^3O!)ORU (HUP8ID36Q V!),!W]$D&_E
MB#4[F\X5J+N$YVEQOE>/,_,?E 8NQ XB1A$LHS^*),(1 W-<E,89)@(=X*LS
M>"D[CQ:(HB7)L!*(G)O>>V?1_>CI^=X"I5@DH0+%FCR2?UGM]VU#%#?>?>:4
MMV- -?I)W<?S,;TG5>1!=M('6"9BHH;L%FT'>Q%Y&=<)J+0_WA3U9[:ZU34U
MZHOQJU;]1*%<KF+?_,2>3FGVU-0'!F! 7G/C*H6== .A /!3E*ZC7%!8>[^*
M%0>'0,^6].]>CDK-F=/+H6D+J?V.6<4Y7[\51^[T!P$G]T'KM03DH;L.K-<R
MG3M#L<PB]?=/?5U5OK1>/N"W7'0V\XY]=U354'I*P>YU)A>.;-E'U3/18;QN
MM_4=;SKZY\/P0USF1>-OVFH[UT\\A3R4D;MY&WOJELE*L>!<P;^DWFKXO^:%
M7?3GK6DY+$:R$9)$FK=I&-.DGPUX)69S)]N:[UXE[=N T#$KU^PL+0=V>0W.
MU331K?M+CWZMVXW+<:@?K?^]L02?$"4OA+@JC7E=Q=[8;&\U6?M32Z<A>\0I
M"<S'SCO, [-(BF[WJK-[>8F[R<LJ9UN/<#$]K%& 2,H'3R_' UH"EC*J>^;H
METQ]Q"!3 )B6UINH-\FLF2K/$]U6EFZ(.F\C*??EBK7<TC5!LYAS#+.3%'?A
MJI+DL@'.,?^@G":(S%>XZ-NC C"#KR%N,CG,</R$&?EKVZQA-U3DZ+#^]DM.
MQS/-(*LTCFI<[FJ7T.>;]\])=,N8(]+A)HS8]M-$Q@,9:/_>&BR>UT<@-WB:
M421^\H'1L-N YKNTEDVKC^C.J\+RCJ^O)#[FN'(*) ,2G2Z"E<67*4A+1[U>
MG1W>=7/]#81T5]WT_0S;I2E]5]7[75_';#(19"1N!Z48V*-([/.^Z&H=%2-4
MK5D%IX-V#,DB2?Y_%QG@!$=<-4?HOEQ"2R47*?19%K[>;J;KT[8$%BHUN['<
MDBW*>(?.&A8KZC87<<B*M/QMS1E-/TZ18_*J5,*T<07F31VO[AJ\>4M-4?W0
M^]YFX6>(C>R"D4S=B?<[H(F-<OIISO6$?="%%"P*8 ,##LO[H/]197@E=>!_
M5!DN>Y-BV#\G"?"2_7ME]7/G5&VENITOU&/])0[CFL;5S@4=3>68Z?8P/?OI
M ";/[M_=6AA/O@YFA5C9SE-TMD; @ZR$W4#;5JTV;56><'.9%JUKXC^IN7<A
M\Q"_0>]E;KF_O86]___;6Y@=A^* J]#,_JJ,&=F2(_MW]'(+-##OH%&OW4RL
M2"W0.C_!AX6RCHOG\I+,O 3_L9.Q.A$-(62QZ'%,HV' M7V0[5B[/;5&WO%/
M"H%<ZVX*JRYI=G#]8\]A=Y[KHXG4O[NI\,@W#GY-FQ$=8X-IR^\!Q]^_KTN[
M'3,WIYLL47(N[L(%MILW[H- ;- A/%U,O*_S,)!',23BNS39?F)=@3R?4\*#
M@2$Z-F\#7 (@[/'_&WOO&=54VZZ+3@0$Z;V*4:E*DZX(!/6EB8B*@( 2!9$F
M("(])!0!Z4W@%92 B* @$6E2(QU$>I-0DM ["25.2>'$[YP]QEEK[;%.&6OO
M;X^U]H\Y!C]FGLESU^MZRGT'.SS^ZK/O['[<=(S20V*^37J4@/="VA)/)#>?
M),F^26JO]\X;?L?I'U!R34TS7?VCH@&3; Q;"/4% [$Z^23:\W:BA1"CT.KD
MUP](+W=_'#P4'/#Q/U77V%/7Y.PC\R+7NK'$2N\H\B7K%<,34O_H"AF!Q[ $
M+7?ACE#MWI6GD-BLLOLBYY[8!&=8<F5+!-M04IB]L]W$[S^<H7_R'&6D\5K'
MHZ/^EK$0;L2IJ;\&/ FTJX> Y5<7\4E:L= MX[X5#3?CD(<1HXG%FQ,4;NKC
M;'+T(-1]>U+TJH[!R;R@K7V%DU]KJH.T)&^]OU@M*O!7<D;)U-DC3[^;'Q70
MAMZF6A"7!L@O0 X]-M) V_RUW Y[ZZ]C5>!2LLWGYH=VDMVO. M"@V.<?;\*
MY.^HL[-E(+Y!1*HL$W!? MLVS:^^-@LDT+1QET>E9<1/-XR<=@C )><YG?V.
MV?BZG4-1>OW4\W<%Y',Q50A"UB>-%Z(1WP]Z)JH:<!F;(H+8SEW#=R]%<\)^
M[[R:J+BI('[QSL/X3?\_M-06C8T<#)*?\V80$O; :#1@_CXKE%M77-I;RB7E
M^HS_.>FRQ]HG8H68?K%1A7.69G?)"N/>GV3-"-E6PZ^DQ-0_:R3RF;#8!C+D
M77<(9 C]@9F^*)J>XP0WQ0S1[:C7S("LR%5,I6IK#4P(C&I+6W47_9MD)]GF
M>2XX7ORU"<3&A5?^4E)'/56*F$V8H(J8X&O;9A0)EFTI/%.K)Z2&J"2/%%]"
M0TS"ID:/[RE5I9V+C\S$=E^[,H<K,).ER3W@$.$0B(!69B?!W3]-LV\]&EG^
M/%+ Q9(M^BNMZMQIYAYL7Q/I34G9SSF,)!*??4*"81:6D[WDYR -3]-U:'*F
MJ&WLL0\+:EB&%CM8/IDZ#51]3;]C>,/ B6,GY)DVBFBQ/04EHTC5*0F8QTA(
MEXNSYTZ5F5Y@=AS_X\: 08>/DY<PQ^LSHB)ODN)IH^ #XD +B@W.5@C7!I'%
MY:\*W)Z\\)ISO+-CMY!6WYBNIK(1_$@F!Z [0A^F). @4!=+_J#"3A*<8QSN
M,H<2(LB.;F]JL2_%GUZRNQGPK?W5N[;N]L5X=,& ."4$,7(("$/=S1G^.T""
M$MIQO ^)5-MUCPS9[Y)%]6Z<:>07\Y08+4H=99J,7I_%2&+PI; O$UU(K(X5
MZ.I'=&YC:[^YXKM6,9O94%6S8[_XZ9H=Y=K00YTL:KEOLF]:*N]C6C;2S2<!
M5UW<AHLSX ,3B*W+!/#+\*W^SN L@L ^&O\U+A,Q).2LMG$K(*,M<3Z1RLU0
M_1624<VK><L$"*]/[O=1+4Y]=?IYV&)8/;RR#<J6)[%T+DSQ0/!SW.:&5W[J
M@_DDX>9\P)-H2T[Y8QOT8<@QC)MY"M:*K/CRVJ^)]+6CK>+YD6N=<_@,7XFN
MIS;'-A\JM9ND7TZ/9F=ZP;8^L&DYKPQEZ'QCAJ314?^R5"C $3)JH][%5"X7
M41!A@%9\R^L'RV;DS;]\.&!WX$I@VKS9)O:BEZMM967,Y7,RVGP:S?J7<U,U
M1BY(74)SD09:(>#9XLW<H[G$]7D>%&\T7)9K5?E'1JZYHLTS/3--FVV9W9<+
M;UDG\X+./Z D4?2H?,2!C54BL@W##E>4OHMU>_(Y?<F(4W;L1[]+WB/F][_%
M4NLNVG*F _F\[O^=D\=(8RVPYT\(IJ49&""&Z'+$HQ@BK*UG3J'*TWS*LYL^
MY>Y&K$HW)M4>W/U<J@B8?#=C>7K4"$#T3<RS444\YTUB]R!1NI 6SM (U1=Z
M5B5&2"6%MG,_[VQ=7) R>:5VZ43(AA\JJW$6CVSQU>K.M<SB]#HE*VG_,*/M
MZK<37Q\&BX7==AVN00#(%@6X<RG5!):(K+&,=R8YOO46V;%0$7_7J)/Q@14Q
MXZ]>OB#6$BT4(R;9NFCZY_[J%T7YC4*&OI>&]7SFW1(%5D.T#H$X^4C+M->S
M9K)]9>?73OP5E,'VIB\J.8HD2;[81*L^39J(1[JK3E*^58!3UN.RC16C6I+=
M-FY92UNFVRK:1_,$9)QN5(BWUER<V()1A1H(Q5W(!$SE/JH5%]Y\0G=^[:"H
M;LPY>0D[X9+TL:JD<%/@KW?BX](MYZ=&V*2Q2*>4"%M89?'&)($W!MM^S =M
MPCF[UF('$_V5Z)+)67!V]H8BGXL,7WBDB2836$BQ^M. XIJ! 5R^D8CK3'FN
MG35[?$B&/IF^U#\F$.KG(A3]SHK<<YWE,2'\LNGYXQ-3##,R44V"$E\C!NJ+
M6\.NAAUDMTW-G;KU%#>)C0M^N]XS=>Y-V)'-$YD'FWI\]R[)5O_P5-(X8V+"
ME)D9PWZ2>.DX/RP&58'>B*"8TGMA->--R >$+)_G.;7DHHC1OLW24R/)WDHR
MYX([_132SQ=*]W9/'P)MZ88&82-P:<*?'B$MKEJ6'."4<27I:$+81P^46\6H
M\GQ]3>[WP?=I.AUGOVA/6+MT$\*E4Q5Q4/Q[Z&=8&Y2+>B9W_M>W%-XKA'NV
MK4^-5#ZXOE=-\]'/^'I%]S)*Z:GA1MFU!Y<L.KY8^TZ )F1+D/(>V7+;&^D6
MBN/\FWXB=\9XP0/E6776^>O08G4*7UPC]=7K,R<<3:QV=F$5)Q2)_4GS,,XU
M.@])Z,CZU8G'RQ4-+_;2.?_^\51UKLP(@%LS#&2!5NB#=,---EP=TS,/\M&S
M);@[F(R]\WLEER[,S=KFFOXH^F4EI.ED"#6#$0/B@A2O@HP_6)6(.FV?0LP*
M1O1NS8H-E^?-9+J:JI93XR2T_?UYA'MN68>?[Y:./RBF'^MA(*M1Y!?,)M-\
MF&"G 622.&]7G<.[>2K8@S1MZ6+PV%M ;,D](FCV4G6J,._N_42;V$U]!K,/
M Z,8WQ$$O4@-K2=$=>C'AGP:M7Q#2Q(:3,?%]J:&M/J=TEW^?GDI59AG*R&C
M P@9B&8 @Q3D%[;8;8%U*QA?4!)_5+!NS-L$20"Q2I'1WHS"+0TT(3*#3%IF
MA8ALL8\;I?%)IR>N##U;F/1Q=15HX_(<)? QI0?+?Y!)-Y.9,#,"D'K(+U!J
MT<3<  T15'H(7.V $&^G_#; 11P"^\N%R-6ED -!\K,_%?Y!23K'!9+D?'8\
M_-QC.&_9M.?PY)K<UKC1*Y\MYI87A9GO6;/3Q8].PW]J(G"0+[5=J$1<-;H5
M&0?A;CSGG\+C)G+PV/:7T]8XD_<X]F6M@+=9D1G[G=?:UM=#N/(8^=,)DP<!
MY;^4(8E6 \DW.[4_HA, YGSFN[5SF((UJBLM&>GBDP+E1/I $Y!BC8&$J/=!
MT';I=LCDKZ6M\9N^9)J-9&Y8A9'B]X:Y6SAUE>D'GW\*,5'48!J(8=P7GU8D
MML%T2-,G/@%^FDC=F;9OBOY6^V2DQ(3KZOF3T5*5:1/EB%<,\OTW+W@&NJ%/
M="#?)II$P<V(-1:W9SQ#$LG9G,AGV>S.IO".LRRF5X[H^T:-O(=>ALLR+"R6
MEKZ/YEBI[UL'8S=%R383 EZCSIS-=\:FF+OQ#TDP>_I/!BJ.P3R&<+J=$"-!
M7JA0]9HA3:'=BU7Q%Z[E/40X2"N].;_ AV2&V:SDW-8527CPUN&BF0C*1[A>
M8]Y/R91/,)$K]4(^\Y6A#?C%MZMTR/!H4=XK'^$RCA]VSV_D_\6:(A/-G#'^
MV>!?G!J><+T[D;@WU>3<<K"5=K]@"UVFDA]GQL&5WOZ]4#XBW40N'/H&"DIO
M?V.P,:BX20<:M&_F'X%;TU)H463H)J<_JIMB,D6=R8V5I%;-K#-(QI9.#/*A
MSV1"2STM-KY1F=AU:40K3,4Z;WR-4V'\CLMUZZ&*MC,+_-UZ\: \_=@ERCGX
M4]IKJ[D,N!NQA[A,E5%^^^F%9ZE#AL[/YJEER)Z["U:T_YI(IU_G$U\*LR$D
M'DFT5TUB:\-P,,:^>!4EFG>N43=ZY\SRAF[P"?MS>^F$S.Q904=6HJKCG_IR
MU",@K!"N OH3/7HT]16NDK3&WNJW)_DI7M]6Y!SM%?&C2@-,R8I8NCJ]&U8E
MOWF,X6TBPPCIH/6V$Y:M/KSWW-=9UV?M&Y^Z'WB$%7_?^>L]<B_A[9I)%KO
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MM_$RVZU+J%+E\D2U1SQM1?VF33Q]GRHUYL9&#,^:G'K?R[U29Y7'*\3$NS'
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MIM<G!A4=#1:5"^E\(1D'G_58]!O)&K2^.LCO(>C;<8DY^!$QY<'BV1_"O>!
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MI=NRIKJ,#1>-(D)1'-+6^O558CX#MV\Q/Y]V&)9-["A)&#:\I%^FX,"WP]5
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M;8[NNE/^I=V"8?5:8BW7RFUF7^4.#LUX=%^??G3H,T$+=>4_NNSZ_[8LLX%
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M^=G7SB>77DLI!KA7Q_Z"^8%_)A6$L2!&I L2_H"$KVQ@1O8?\S%)H<9#,&R
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M+"G7IBM",M]+HMONS)0=/G_X2*OXDU,'!)M3*3A_A@)):7M?;3)W9S8#]7G
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M"M#K=A^,82E>G&OM+1GM822_B!4@BY@%7.*QBDNXZ6+M\I*!=T)\(XPF>$N
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MNDOLN-@,6ARL$2DRUC>&Y*CGEJX^D) +Q(O48Z5X;G9KB"F$SM\J@.R+ *\
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MN&6YQE6\?_7VI<MAK_9EON- ^;E#HFFU*O_\Z.U_C^,/U7./P<?M,?A8&M]
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M:D1RL'V#RG,_9CR1^+*K#O\S 1SEYH1'3WE[BB9ZX]1VTAU9%VT I!1.&_H
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M[U]X#H@/'U,"+9;8E_N<M#Y3+B'.]JWZS-G 3:Y'; P]L;R6O<5/90#(892
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MLVF'CS([)VPO,M_P!NW3EKRT]=<!F%V8=DEEY(.T VPO/(0$Q_'\V1=8QU-
M?>+HN(HN8>G:9>I"#?VQ7L$-,'!2YJ<8Z&E0/YUX4X_Z?;::0U;VZZ7Y&DG"
M37&>JVDC.J]_F8^>8Y\\7MB0.E_^C:*"\>1:K1;3[IF1-8Y48(,N4UAZ1Q4I
M!%1C#8S\HE?9SJW^[<@\V0=V1_&!I\+!49W18[>39*2%M[!/TU[44TL9P,N
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MMN1$F#A1;O5&V>>!1=PNN<69RY#UXK;%Y3&>K;#+@*V<6,'[<#9U\X9?O99
M1XGTA%!R5#;.LW63=<(O"XRCU.0Y)RU09NR?OF@_,;[E(-ISI<A[WH+OP@X#
M,Q'1CCX%Q^13 >7:$1*-,Y"&ZM'$')?"BK%NX;!SL:P_7UVWGK61RI?@=S@E
M\GD^F)'[,)8&/7L'8=U40"DE%-=L7&TTX_BT\B"[!)ZO.G:-_Y12T'6](VV%
M_O=K/BL%T>T+X0(:*FG"[$GB6C0BJLZGWC(DL>-%AF5,;GFO]*[?<.?>;TQB
MJ6)U/7>AL^;CEO2!$*H#' DOK6QGCT+C[FP>AUJA<<-)R!,D%G?[SRY896WK
M;F>&9)W;"A2/1?]+B*-^@,H;YC]G_@840"/PJX33Y%2XLSS?E-_V0G'DD\ B
MRXGV^U^FYL!N)VIO;8F\B0U).*VWRM_8N";=L LABNVM0]QS9JT;Y^MT[:/X
MA<"$HH%FJ01V^;CR Z^;#N:WX^BE63G\&83;@D!)$*)X^WH.#D) #L-$6O$1
M1L@[B&:O[_*//L]\<^&:4>E/]DWHN@<\_SQ-PP=5\.OC$AW)RJZ0*$%(PQTM
M+&*,D%T8W.5W'WMR+\4BAJ J<PQV<U"=5Y3YVGWD6W.L>5 ]!_0\T<QS:CXY
MM S.+&2<4:-N&L.C!Y=^UJ?4J3O-&>#.&%RUR*\R9SUE93MEY.A_"NRIKNRM
M+Q*NK\?GX*#)H<\@7$9'W,:@B3+M#0+(")Y)%$(YT+:[S=B2"LAQ'GW6+5L[
M=ET!UJ=A (CM$^UI-'[L:R>QTD>4R VN]3V\"QM/DR"7P\Y\EW7/O-?GX_5H
M_7AP^?'7ZZ,$7*E=CY61VW+$C -"30(Q[HH<;R;<K!FQLJPBZL\G53^2F\/+
M!.G=^Y#PD%E4\Z HD#O'6=TL+-=J[4#HC;I/6";3?&5E[(-P,2'NDP!3^GY6
MXV._O-) ?MBTL!#YDZ81KEGO"_FU_!P8?_=YRVU;35\>0LOWA=G'/ZM7ET!U
MBH)L?GV77;?TV] L:,QG0OV)L6(H9,$H4EFR4 YI?"??.>;TP$,[M<E<KYZ
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ML>!W^!K#T<#=V<%%AY</A@K1X+X3.:=,#:;HY]MF.8O,_M$R;8'$Y@RD5]W
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ME!_WJV4KZA0YK9ZS%1<Z7XZ(*#ZIA_*A).95ITY\?<6:_F#$SIC#+C1DYEM
MK&O;NX.VA:_.<&;A=7,C.32HJUT>@!O^0@)J!;K>W?LXNQ>H;0.=TF8D(O!W
M%M@0BT6>-X9\/MTOK_AJ'Z=RMREO[9BYRD(UY&5Y'<\HH=NP-F%42)?!EX6_
M_6WTAR//%U_W;[&=\('PP)>RB=&4^KD#\]2Q;K' @3W0>G?F]WZ_*S]M#73J
MJ[_Z6=[6?B#XP.!R &L"^-//?KOOECCVB5**83=\;)T*.& V1X_>GJ9MQZ?_
M:L_2/^\E&_OK>\F:Z[5@O<CC<&<P([R)%V^G9Z,W>>Z"Y70;M*#[$MA"=H7>
MFS.XRKL0P)KM!8FS5:4)&'"C/@D>/L=585$CE'10D5I]S7:J^,P;1NVJ,%=S
M0B\Y#^[B&44%E(O-?0&M)_OXYG1F,L1MN&L-3JZL_.SB!(O.E CKUC+-^TD:
MA8N52#*R8.0G70G#Y!?:DD["O.12^WH\.TV 3JG%HCQ63Z<TH"7]L2C1.=':
M2\>,?,6^;.6S2'.P_F0GBJBV'D\],U(O^5W!2AK>+2 =V<%8I>?4!C^YBQI
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MXGZXWVF_R#-[+=EX)J<N=:3K1*;%0\7D:(EDW6FEU!H=NN= XKD^FBK"^RZ
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MZ9=WL?#UE/X%U?< EA694"F%KG8&#TK'',YH+GRN5#ZVB"+QDW(VI5WX_-!
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MCK*<SM-B*7.#5TOOT%_&@\)K+1Y6YX:5N]Y\]*U!6NL-?OJ:SMK5MIY<D"6
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M "KUHT@T+I,_HF H7OA-\D?EFT?B) 9<6&I4_4/$6"E:=K<LUTW?CRZAI=&
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M8%L8VXKQN(I4XT@]VR<%\E[#8NB^$\_^M'BB;D, HY'*%R5CD78P44QR';7
MQ^[;R%.<@^V%)M"QFNOD3[/OI3A7:%)/D9>(RFRG'19(%"I9=\%DK$A6D#D>
MX09?ISCN]FJHL6.[KZ5>FI?\:G%E'?"9Q$85QQGDF'J!3^J?YGXIQ;W*.L=U
MWFA$R*=:\F*%%^:DVVHQE_YS1]J=#.I!F ='HBN1&T&?*9.@\^_MAW:UEVN=
M$\/$ET?X@>5FD],AW3HF)G)J-V]K\"8>@(?8;(C(UBE@Z*XYF,4'JELU="-3
M18JM,B]7F^YLAY*8V[O3.1.G)_Y),O-%FU7D2<]P^ZWBIY:^\]V;\8E</*U&
M_R9L808\KI7[]B3]-8:#6/K[">@4N\I23VS$NY*K2 A"YW/[&_L+SROLK.J+
MV,@!RS^AG241(@NI;;/.K80AH4-DUM"TLH/ D]1EDPP^_NM>\0$R Y'X7]8I
MF$?!=$Z7$X*_?!+[T1D(X$W45[/*XJ;*%W1<T8W4$<'RV$-W[LUMU02-0F]M
MY>(VH$=2XO.<I+[.%O"Y*;@\<="A9-K7^[J3(3I77#2(QS78,<?+-=0NQ&V\
ME,_Y\%NQL(F%6/'!LAY'@,00,N,^12(%JL,1%YFS:?CY8?*M#:\&B42$Y@R:
MMO AP9$(=0O = %)EQM%/6MUP3FMS/>,6<'[STW3ZDC3;O$3FXUL)+F11H&G
MVW M8C@_AC'[1_!5>@[Z\K-^=^M/6L50?C5C&WG,??0[_-:S5(B9F$R%S7AM
MOH;VQ1JGB1<28=NE)3006D%R%LKE5]9E7%4]-^C,:I79RVJ ])0^[S2]6@(/
M+_ >Q:+/C?.MKB^FH#U?Q#NG;+W1'#2AR,[#&-+ZL-GZ8WIDV:CE'FQI3S[P
M](E/3;R JXX?ZA_._D_?4__7[[>'_PF4_2I1YI/3H2:)W:$C@3@0VMA0._I^
MV,R0XUF9:8%:\.S4B'2QTB; LQUYNY)82R4(U\AAR@%XT78Y9$7G^@%ON4__
M_5B:3Q-3M9&;\Y,>,%_'IF#72T:/KC#8&^EF*RTTWL=QD-B!A$BB^7D?>2PR
M:*->O\ I9E'W<F?:A]6+0=]G+K[" C<%])_KWZ ABT)V^JG_H3NZ#B),$ 4=
M%LI*,)8JXE(_I>)-[Z>_=[Y[TY>9\R; M_6$TDZOSQ:%R0$/MA@6&:;PP!6&
MZQ4#GLNI>_CZ"W\:3,&Z=WR=O@K;W.SJ?] :4GM$C^A$\C;*D/RJR25(IPE)
M\7?E]=R5GT:PVS!9777%ZM>JM]^XO!.P5#%Z6'E.5FK9D7[WSE]2[3/M[0UY
M]=7>[H77;Q=N:ZVSL5ZP+3_?!'#77E$];P"-055JDMC0"\NM9VY#Z4F LBK\
M9J7KD:LG5V9' LOP][;!9/^4C5HN&]ZS6UTEC2@;=,S4_@;/D9*/#E;DU;IX
M1:\^].AY^EP_,CY\B.#_X.$/>UC:$V;WSD1'VI5(T>\(.;@]3KX)&/ZMLQW\
M,E77)6>%@=&DR7=3V*/JBL!MC16A)R>"57E3!-0$\>[#E-,A1XYPTPP#*MEQ
MR YB?=K(.?SSRA#/&1U(PG.9RN6*Q#GP]6*6IM#H?=X!^JU>M@/($1NR66>W
M9 K<X3"_WW8, (J$P+UZKE:>K:O,6YL.'K[]67)+((W--/29Q=FBG5,T^A/(
M2M &F*HJ"(9$)Y$V2=Y7DL)9^N5.4YZU!FX!+QY]51=ON13T31MXNB$ML@ 0
M(*B.!!L? W /8=.M'=SBG6W(B&R:#5<XD#&!,G*CP9A,9[#L>V0AH\[SK'FN
M19G9_63 UA$+U;*JP@6/K-H_^4 -AE +5(,<!ZA-;])95O-TJ1'4=Q$X/:%A
M!^1A+EYL5>@&@-Z/0-J15;"-TGGPQ'Y+E;Q?0Q(QI%UI"?_1B?6>@+28#_K&
M=OS<HVM:7*=__'A>$/@#E28/Q3V$3L^UMK[":QP#YHW>\M-XGH]:'O*TBUI?
M]TG:"$=>$>!E9/;77EE1!0T8L>'[UUV.['QX",TX]:7:]Z:-$1CQ,]@HXR&[
M^'L#7&I2/1<")=.8,TQ$V8Q/FK#QGE]$5FV1+LBT@,OL1K.#=L4%*>?0_*L/
MHL)*=^ %_@J\R;$ZJ0]^F';=O&20 DCL.IT"('-_0&5GVE!.>QQYP>4J*O#Y
M[25![-^@H:Z9<KT2:5]6ZD+(HQP/>\2>]JEL_JI=_XAZ? RPATUI-B$K)5O6
M]%\UTNV(#W2-58_)Q#N4UD>?P'57A_.8FG(^[VJ:Y_T$.&3YCX(H%SLI#%3&
M+.)?2#79I9^1*T9Y2(-14@UU&7B1/[<\LX_8927)URI*5I7^3N!9[-"A(C%
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MF/OUN6F+VP?30C)7->]$\THGGG$<5 4!0,3+_>M7?(\!851]GIQ)U?E)CL>
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M%(G)GZU,1*%/S<A'U\,O"V5DO%((ETHT.24 P?'O;4 K)#MU]3OG+J5VGV+
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MORJ.\M\=A*8DL>K9+<< 9AT;.[=RL\:7!W;/S1A>3=EVJ#'[LAX#*OO5EW=
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MI5^-^<\N)5+\&( S0AZH-,A0FK^)4&+\*+FB!S J^!10P6=O)9MP9A"\ZSQ
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M/LJIYL@Z3G:9:U#'VU]N7ZK ^8T6G$RU%L-L3%;6^3;V#33<Q3E>;';84YB
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M)^@L^?8 4%S_Q+/1 9LVH$DC6Z%4^.1WG6M/>GF/>ESG/D@&&_NQSV]AF=%
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M(%$:H!KX$W2[#SW7Z$@#5*73%0<4 Y/[W^6WP-/40>2VI@7]'U^1IP@I0W;
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M^/*6H=6RT^GY"VJN+4=O=)Z:?_/FH1KVL2"L(H> .(&H1-K#0P*6H\C>C_!
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MWD&9+XK8WL61Z!!#2XK,62_/EAIVG\A;]3@"VX"WW>&Q5)$7- YA]TVE2S=
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MJX=A-0Q"(DT9 &=B-O@E$B3"EU%JD92(,B2,8+D9  "'UP,*E/L!L'6?:&8
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MQM>T9T+V+0NXY=-T8WP,\F;W+8K-ZP=77JR&,576Z?4N<'%_M\72--+(!QC
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M)JT8>65@O>QM!5,:[_FSULG?T1.G2<[@!&&<QB%,M,1CGR*DY)+G_'S@O'3
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MKDO2-M,<#$NP@4\ZXG?B@O2@)#-0F8HI\(Y15IYYO5YT;R'M@:FZ7??A.\(
MCA.C=W3\$_([A&!SQ+@+*EC2Q$H;0AZQ/!#RTNJ+T)F=4\6$"YE]=R6J1DL&
MO?,\;PDZAB':66W8@L+O,J)W';1YBSA)36V"7'SGT"6X\73[5]#*[N"='7X?
M+WFCE)T3G,9'MP\I;F[1..&$+<L!77?"\+QD#$_EJ*876H/<C=^5R&EN4RYX
M4LI^1S8U.(CI^GUF #+PYR:8WSXI'$G1^AB"Z1!^6K0LJEPYGAG,)RYC91#U
M\]ZVU</ ,%B[OFPYM5)?%40U8WB;F"@F PW2>;ZS(D,;_GZ:$FK^[\*FWC?L
MRL+43)\H_#KP\^:'^5?CO9#JKB>8VVLPTGX5FC7GSGE\U&S]Q^G^>4[L88?X
M:W*YGAJ!#I,GGTQ!LL73%J&80U^EI2+T ;!,-;GI+.(ZZ$WV J=[BY:1YXBT
MW/P0Q\OIR=(7ATL%"F+0ZB:6%YA0F@2;=,C(<]09AN+;Z((\=>C-;$8?F47V
M/^QO<U)MD3Q>YB<YM'AGY:'?)6_!Q-I-?E\_*Z;=IF@,BL8#CK=C>/4EO&CJ
M1-23=<J13[_-U7*-FN[*=KQ)\DR\^-F&[>'[%$1^M(A('K?I_UJ7MWEZ/IC"
M3\8OK<'(IKZ2BB!N?E=9G]\[_2(UIL#.S'FNXV=>JHT(RYG5_GI$@:GT_<Z9
M H0-PWB% ]L;AY&S< &*9H%44IOIH.:4>9"'DNU1S7B% 2'=-$%C^1*4J2!E
MB>&):JB%XQ 1U*H8'DK5FQA@VPCHP$ F$2= 1_S&T\RR4 +H:-8PDG#Q\8FJ
MJ +>Y."3PD1T,QR41:\NX/HG+3MINM0"I,Z$?'QV#QWHJ7ELE>BO[!^DTS!]
MHU_;]'E*>_%+WD<WOIJ*V*#'<T&%([V]Z%5OHK,CO&E2QP@UG68W2 >(0[X_
M^\'CDP:8<G1LMHI3 QSA1@?"5L\ R!=Y7-PTC@]D281L.<A]C]B%ZXI:U54K
M#3%;''&F QZ.QMZ",XG3WVY?2KWP,5$FT%1,<5XJ^(!)IUX R8!:I'^\G\P,
M7NO25GVL"8F3E"?,3(4\\.44L5%QBQO]&G=KM=0RT__6X3OFDI97?7_U@PH.
MEQAI#-7A<H9A9/</(C1";2QZ)0'V+9=@=-0SF60U-GM[-;.C9@U"QKB67Z,#
MR<P&$&=:/QVHY.Y QS?)CMR'QT)8_F"B;6UM<[WBR-=J[6_59GZ_OBEXR?KU
ME%UU*,X"84&^A>S!U%BV)W.$]%AHS6M(RA%>]@:%"T<UM6=;9W2>$_4J3NPH
MCW[U$<@S:]8![!_]1)8B# :JZ  _*-RN+TXHK:2)CU7I<+[T5;ZBL279LV@W
M<>N5E/3=Q-C;;IX2Q@Z4[V/ZPJ@6V!_T86>$>@,8,_=@>.--F#W"(/7&Q0]B
MH:R=4JY5O 6%[")V+6PI<[CWS+-T8.XU_"A"A!A/<AI0:>#'U5)D_7#>;@-%
MPS<?9!PJ54Z5]8PS97]@;^N>DBE;<YK50_I>>#]<$]F=6^'QB'P2(3I,$_3*
M7/MTI>);& JQO!#^D13^9MHXX\<;:UZ8S)IUVA6+<,7_>VQ4&#FUA1R%0;@T
MDH\@NZNQ1*N5O=@*3!,L^IR2DH.\\DG3TP>3E0!UH"]_'?C)2YFE3<'+KV#(
MBLXA:@@_?#X>(PCVS9+HP/77%U_D9Y_C\3-UU[_=GBE;<*<PF9#$8*^O4=IP
MP@W(+J1)"/7C- -T!P>MV+9M('M5>QRT8.A< >T4,6!-F>P"*I+.$/P+QNH\
M<O42&WM>O3 J?/](*5/]Y/S#*0=M'FWT!M#B"A\41_T>_Z6XVP.ZJHU#YZHF
M7_<2=DNJPOVL).^1_"3Q I3GYR%F )5M%#J7GELNB&WS)#CGYDU/^,;[+G3A
MF4(#=]XN^;-LB*2OKG(&NFZVNDH]>,6[RV#>+.7@%WSN(Y2HOCRMUUDG(W2[
M5P5[O8$L<_Z=5Y7%$9*3<H/KAVQ!Q*-O1U-@VW[P/K86.]%O-$[CTC:W^N/I
M#D3I'K8+,L/^;K?NKDBQK6P80-X[ XQ\DD 1!1/G_;B;'ZI&(5Q]4>B9#D^6
MFH<GXF9DLB(_F<MG3_'P9]P6Y_+]#4_$B.JRDZ$4K=$F!<2E1J%LVXS<DRJ'
MQT]7(SZ%"*0VV7-S:'/9QUJU/^Q BM+&4 >A?MAX!@PJ29ZJ!VT"B/RXX,AU
MI@$-[S\E^M\LOU GT_6^7W62*>V5Q\)L6!2NN'Z]R7U[OU8;0HFXWHB'Q**J
M8SI\I0M]X<)%ZMX/9'AN#F5;:D!U5]-YBQTCY,X^WI1AQ< ^X38>P06@?F@^
MD#1\ 9PBF%L0M)Y<YA?1%'/R&2+B4_E/O6TYO*EV&*O*&7&N-[SM+ZXEH&D?
M4+)=W[U=:]BQ>N?KP*4NI@4.LQ.Z-X6:5^"]F,[<"7E2/=A-Z.J"5@FO1>$?
M#"X0.C.#P@I#'JJG:;BSVK!8ET6.J62UA.9"&MH0HU3%\1Y(C24EBPYT8,C"
MZPQ=*PJ -;1#171 [@L>0Q9'H[9GBL8'L82KD&2'W&;(Q#VG,5W-$)*D-%%I
MT"O;C2AN>CCS?([W]22;M-ES9I\7X-YL9]&O4'-QJ$W?'$4&XO3LT &+R? [
M<()C[X40FA!"8V@$N3CO4)^5[#<P=1 ^9)3'%49C9^@QEGGP]#PZ4A35"4]^
MJ!.2?XT8FX;O''*,CP^YO?JXTJO]O(R'J<>DVW1[1$(>,/5T%TKJ D\QQ.,5
MU"0CFPHAF?OONN?]=M]8]7//PO:D#8ZJWG8PDOT9:5)X?BMMRNVDJ6(M';B
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MYM2AN6JH(5\OF+H,+Z,#3 P*D,O2Q U:XI"/?06+M;ER64Z'FC]2'FOVEPN
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M'\\=&V ;A9<7+C32@=4V0M+ZP&-^T/P"LT3<C]9"U(%#%,7-3S3.QZ&W<UA
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M0_3"4U9PQB> F,O 7B475Z(FEL,/+G3_Z6-7$\Y2Z3,+6Z<9E'$O$YA1.M*
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MCWF-"3=5">%0]@^XU*MP7_PZKVY_$9,L-^^\S[VWF6.;^?]M3SN1AK496TX
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M=S^?N1N!"?UH(G\58?TOL.\?0\+/$T FB-A\ G"GK%"CP +_';%RDOE_Y"D
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M@/!&?FM--I8'@G8I&S)UD)<CVB&J0@F_.8&Z3W=^Z SJ('H+%[0(RWAPS G
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MLZ0],];KM8O&^W+9LNO!*[QUD>^?K4:8B1\: >!ZA6= Z#P@SMHR*5O@&7@
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M;6^ %ZD(PW-93*ZWI%),4ORJ S#)J$S_*YSI \;?X'W!H]B1E/(!BC1RR/=
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MO'(TTY'&F!>>-?'R_\6A]/+Q\+@_*-,F)?*(S9Y))8*!AUB\4@_NALQ#"89
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M[0^,=T8F#2V9B?)!L .(E2XH(YP+8V\T3Y]2[-WD]>5"$V&\CV&M$8BDJN'
MA"0?F*%Q[8J+VZQB/E&>UF.3_?/IV@-U8CYN\EYT#Y1-1Q;+;,MI^/ZGAJ9I
M=XD"3CP:B-8'CWCNMF)0\92_[9@+MMI9 ?-W&MG8FK-2+\OMODOTK0R9CYR7
M4>(O@[ZT'0BCW1WV'["Z<3HB:]42$ _LTN5#>WQ88(__8S\6_RJ@4'TJ]+>.
MK_NC4!9W4I;/V>>Q5S2BUU6K0WG]_/5,\-J4V] WR-GUK!/06[>:367;$U"Z
MQ1[Y ?6S@1H-0/7(=/> 1BR4EZ2$[^_:??)GSU^')]15+W^]5=LP\+U"9]'U
M G&39H4/6GR!-YTXB,[((0<$)W+V!/0,==#4B$+'HGYS_KV-PV-V,M-Q'=*/
M_<@\K<OR^ 2$RZ7D?&,0QFZ<@&+_Y@65]&*-3D#Z.).4:J.O<;^NJGT)'EKR
M%*)K;+5Y4 *X0!UL?X%W _%=BX10<@'I/M[\J_64GS^+@(L&^\MWWQ%;<_X0
MF$*R<-PA3YH/($]A!N.T*5QID7:6?;I2*XARW/&>_[#,49[%%+]+UJ6UHT?Q
M\3L?1F'K**5V%<ID@2JYG@)&C!76*\>US?\A!DI-VB@)NH]6NFGP9M:',ONQ
M3%Q"\[] TA2QNY%?MS,Z>$%P-Z!IA0W2">+>ZDB1>U^JGD_\*-7@#95='SBW
M3R3F=];/#E%E"_U;[.U(S;>&R!\,)G/Y.Z&(#@##%8 J:#H\OKP;R?)V1+G;
MB3^JB^4I?PY#@F:35GWZO;00B=ET9*?@"6AMO!JUXSZ%/+!H!,'B2%0<UCUS
M"&;7XP,J:_9VU,V)DH$$9='4*Q#M(&@ELAX97PUW).K"+^(M#@K\9ZHP*0);
M'G]R["^]LB3!7I$JJ7)>]KU@@"O!-,?-=[PZM&]IL?YE,[/H"NX81>4CBA!#
M+7>.P3O]N%RSEEM9"X#E53/KELI"E_A/$..!(O;P?\$]9]J3F?\_]M;_?QC_
M^EOB_*^.L>G=0.6&BD5%+7S#=FN\6ZI@J5%&4<94S'/QJ$JK](X+G7WL/*N0
MAO8O^-QN"!W\=C6<9L)YIBW0V[]]:#GPQ>J#?2>9%G,YD\\ER>G"3\&:2X$Y
M$.>5Q;$KY'=JJNA H?@&2**=A)O3/,</R6.C[J5%\8=G3D YM<&& T=:(/AE
M7#TA!Z"R-#H2L!N.@Q"^3 7JW$1;<GXW"W7'\MN9YZ2-(E_]YGLX^JT>?) '
MSTE(76.XE'N016@B9R+.(:C"9U%4\J_>+<+3\:YXXP[C_0E#>9*.FZD_"S5F
M'*+TI?F77Z]IUE'&H?4UW6D+OIC>C>["^!F$VRT/<^V!#CX;/OVS61UK#[I+
M9(\<'U:>40=,B/*(V79I\C.$"BR-8 =,OF^.UQ/:?-*V\&#JO*UKZ5@;%O;\
M1_N8LJ*"4+9V@4YZES[[&XBK\J)R/ZK^!)1FLN-.=#]Z94W(/G]OLV5D]<=-
MR[,&.OT)BJ7GB+I]#TK.; 0P(19]*4*XP\2#035+[I\A+7WY\L9[_F&G'*Z,
M<"6(NPI%/G\>S%*:>H;NH?P@18P$ L#X;GM<82HI E,!X8 "+M9M$]6%$O=C
M_[!^C%33_HB]K"F%9M/:6/("_>SXJ]DUA7KJB&DP#=(SW^3J!$(95L=*O]_#
M9E0I==DSR_F2JNG'DA?8[[^/4D]MZ.#FCME0-%3 4H.D??P%W$^A)9>K"ZLX
MNG8_,@\LAJ5.7';2D.52^UBG];IOHL<]+?2[K>EO1I<S#+_&8G5L,6F"7CG+
M4KB0*N]J;[Z*%N96V0DL(\.'07YW/=)L!F4<5?^WNE4HIG>ENR:^*2^C7C'E
M0#_B0]?VN7MHUV^IR>4_@H<^_J-F<S<38OP$=*I*@7*)REYT*5(.VQ3!6<4W
M4V\FI7(N!2@IOC60L%]-CTC<7[M,QAIW%[_W^6/Y#(*S(1:R^*)P52B_0EHG
MF#RT_C[W<4Q9Y5#\DX#/'W,/\<D/[<2E=DCO3H/@G40-(+<'C#,/7 AW! *)
M^C^_+G/C>ZP,>%$!U=]>**XAS_]67VOP7><I4/Z3L2$> D+^E+:85AMQO=XT
MTY#WJ>8Q<2X3IB06G,E_/\-0(G[K6EU=N@$#W2.H(OP:CF%GEQ@.Y\LSCK.I
MPVND!+U4"';4N).S:M&V^'L@;L]$=!-_23#6>G82=XC)W;$GZAL0#4:((B0[
MO$FR'YQ#,F6D-YL2]TA^,_.>U%TSB5NH+*&'K_N&HP95Y;*=%]_1+B,]DR($
M[U##9P=)?YK"-) KPA$K;.QXR_=VWL.)A:YFY(4C4W^K-=<H8]M(**IQ'[DS
M2Y2#BY&SX;)!F+28&<Z$1GH3U%2@D$7$$WS4V>'S'V3NT.U>M38:%'MXM[#T
MGSTD8$YX_H^4=1;RBW:Q32BKCO.L74[5.QW+=TD\G*Q2$X&?=3M&[Z4:GDGG
MF\_IEQ&B73H!^4#B6V:[H/,K6'!/(!L[D.=EISY%\#-&YY[6,!(3[E)E$/_$
M<W1$-?E&<KX>MP\25$F!P.K-&_&!J3J/0M\-AR'?]S77+<8'_(@>,I3QKY+.
M<<^@$'./$JR*$/F^=H&1E$MP)=0X99JW$6,IZ/UP\8@P(=^OFW]@I-FS*I[M
M5Q%R2=<(P489@O#K_#T,M H<UB"&H V&#2(,LS6\&S>F\\XO,.0>!D'%=")>
M_;"V"4 ^_CFJ,:@/=J7,41'A=7 <F.^@M5"(Q%C;B(/T"%[P3)4WXFT)*=[>
M]\M4HW%^4=BJ0K./K&00RTVCBB<<L4A1FM4Q"B+*("9WE0KQ@@:A#9._:OJ&
MD_;JDW7+!@._/'[J+D'U>H.#DGT_(2Z*?\\!:%?<X_7RL-K<-)2O8(F]=4DT
MU8#G'Z4)P@'A\I\%@KB-74]T'*4/GQO3**AMW_H.$BHQSJOH?5F\<F92[EE
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M=5T[;?.72ALMS76IQYW^+O$#^/=7[]%J2]S<=>RIQEI$'%'U)039>1GEMI(
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MWU@<!/38\C0).<56COTBY_OI^FXPH4\C237B!?]QNWC?]_X'CA\>&#-4PPV
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MI: 5GC=*M7X+W*\HF6Q5#/,+6!JO8;'/5GE35^<7>H]EOT=GC,H#N^1JO?-
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M(Q\KNCHV]6<CP][:+3E*+>=Y9&H$)0>-"5=,/ 4Y/S@-4OQ' JX-0R+IYAM
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MV;%S_8R:V5UG)8Q(23V8O*;W2P*IY'4MT*+MXM++P"5=5T($H(H%QUR <\W
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MW"Q>Y/;C0VS(7E]*4XDU9TEDK/C4(XS18BA'M &G<2@*X($<7L(R!NEB;)"
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MFSW?-ZX[W=>B$V0#1]9:XL UK$2NIUI8AI#K2$QZZVL)AZ9Q5'NK:#TD=:
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M[[,R]HM&#TIL 96D=RV>X:7A,5'I*W76/$\S :3//@9F><G:>:$G1(3#QMG
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MC]@_8O^(_2/VC]@_8O^(_2/VC]@_8O^(_2/VC]C_R]BW SY7YPG^0.V;]DI
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ML.'&\27V%KN]GV6\59)Y-8N;H";;5>M!0=G4B>;H;KF^8K1R8EP=<<$,/,E
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MK&GY]*?I_,VSE;QE0@7'GT+5K)EB.)B6#63KY+QY5=?A'0Y&0A#T8(1O[--
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M_#XPW<)1L-V/Q<.JR$FT=HA*T3S')_4L[L,^JOSI*\:83>\O'V,&*$!%<\X
M.8;X"3G4 $\YM:NG3D;+BXQK.F%TV)HS9TU3/)ATEFJB9YA:%14UT/Z"S'77
M33?XTEG1O]%I4MG-)9CD'0J@S2;:XNKN5^05G?)!V2BFX.@Z+<R+G8A8F#__
MNX4#VY7I=G(GR4NHM+3)B4%0X;*EV3YU<J!$RH#GL"[LAJ3*]F"UT;3(IQA)
MIK^[Q/C_^3*CI9;^G=&#(+[]9KL)Z1F-O"<KH2]L+R;Q/DP=#K$R5P^]XK[,
M.4I]G$"QNAA27Z;7YC'NXFB7X]FJ4]70IH<KAEY42_GQ2P&*]LB\I[R:UW,B
MWC*)0^<QH&E7C'5T"R# Z]"WN6$&/7A^=L"GWN8X7:&<A88]!S=3_^;##VWG
MQ2,(>*1G*Q?K*)^ J*R-@8K34'DX=G,4_@[@\PEZ?.X3LJFP!9B;25 A)L(7
M$"00_C3H<\!.]YO:J!;AO/*^T3LEM?Q9!JU5?H5M] L>BLF<KI<%0^DVU"X%
MW?S,<*];^:57V>F3R6R4-$+@G?.!J$-WZ(@Q29#(3ODY#J3O9@0M/&Q>"&K_
MA*<3IA#.K/88G#EI)';UZSXDF3J%#-!L=^)[""[A<AP9F6@?$1#@-9^;GN*^
MEAMW]M8M7LN[UP!G7M$9E8,S70+#<9;+=L'PL\- RX@.O53E.UI4,9?+J#_\
MW;;YGQ7RY+_4!Y&&>!!.XA[^!DZQ \6N]&+/=6@[S256 [IFPYEY,2@PJ?)2
MD*ORRMB]'XQF/FG?OYAT%<H.$_V@FO@PM&F,(\LH]/E"\3)JQ->@HWOCZ.W^
MDR7'XHO U+>[],@,F#*L'41%4H'LX1O-(O<Z3I9G>.KK1Y8-NOH1BYF2YK=D
MU_NXWNUV3B[ V^43X5PMM.[/W$',U5,OENI$?ME]M2UUG2$#M"YXW\WRY@4L
MO'@(?KD&QEHBHZTF^H'1FASY[AP)2(C2X2LRH!4\N(I#1A1VX!NX!+$5HQ.#
MJT.GO*[OW(>6._6Q#=IC> <R@.8WGAH[[UB-4SXZC(I!EF0_CE!6<U(I[XN2
M(MU6Z!8,F[ZY01H(KL6 V-8<68>03:88R%K5K/3MZ(+ZNHR:/)\/O6*D5^<-
M6P')9V%2[O-8R\'7*3,-3V"T(YNKTA%!L=';G*J%]W8-A6=0_/C81?DM-=S[
MQ<8\;="DG8G*I5EAA/NGN0$;P4@%B?F'4WDR'>5Y%4PN%]TPS@6E)'33!L--
MYH>+R/R6W0(*_/ A78.ZX"0ZE:R,!7K#52YW0,2SZ]C:ZOQ<+.<Z*A6VP.4(
M[&TO8;?,H]98)(U,G[+\N77%J"@0:&J')5NP;M_UJOPX!$O5S(*.Z@(+0X5P
M]X2OXH.*>O/7K\3'63-S#G.DQ3R9D5KSOB8:>H97A&U_*NU>\</F<*7JTEUM
M^)EW#3:)'EI>J.\D2BIR3YSRI]"+JOD(&:7^QKU/&R]E$F4C\+$_Z,4!QIQ)
MVR:]E\8E:+BDZ!=%\,#-#<I*D[#P5CA'#TZG9^ZB*>NZW97 K1OA=E.VJ189
M\T'E?C>22[HLM0\9SD3UV^D3N" 8Y9:LKQLP^I$=KYNO7"(QD!>RZTY>2J0S
MQ2NF"8B:^>[!A&EHB]"X)WH(JJ5 7$%\EKZ5(O]0,VY +&S\&6N.WQ(3=)M#
MZCNG=MER/TLZ>NQ(02WM;/_,ESDP".]T\L#*^NZ:CC13J!J-, ;U5CX!M MN
M$8'_'"PB WX_33U4 F+O(::IYNBW1CM(O-+L$7Q5S3\XG1#[TX13G'7T 9 '
M7VN#R_E<WA-<"K[OSB%SO<18^7NI=#B33013#R#9Y]?DQXYCW:=**^N^^L+^
M&2-(WJ)@EHU#5!IPNI9TQQ1C2HR2A^\_1!91?JS&81@U$)N(OT\&S.13TN2E
MR58$JZ9'$<$ UU*[..MW^>&8\FF]EX2QKW/$X]1:UIC-34Z_?HYM]P#XY=+(
M0DG+FB^!<VY&3:+\P7P]DP?1?QK>>FGQ7A0N-9%(!N296>_Z@S\*,_\YU$IX
M@=4/?V%*Z_82&'6I8DC&HT0D<,N+WRIF0CSZW-LF2QE+/8.[BD.,ZQBFFK)+
M;/%R<2O?</MK1G<*++(IWX^E/'D,'T5JVM\A7C+"NS3;+^IWLW! ??$A03A@
MU\1$6F;JOO<MW,^\I%9N^DY(M7.R52^UA$S@_F]'"\<:VKC"X7#Q!D-A%Y6B
M;+<?&BJ#<Q26**&ZQ9,;,(@>1[8YO%S3P8 9NS>>5'P=6([$]"ZO%E\_WVTV
M3/5U<""Q"/4$/)6+GM\"HD\]I+LE93]_+.!148\OI,+\ZHW?B.QK4!FNMPD*
M95$FU/^>3OB8!YY9SS09J[&N2:CHT)0;[A>,>5:2D,?U()!&,(9(@P^DT !Y
M/!%]3FP4:G8>@<'G F0FDY14KY]_U7M&UU.C@EO+\. XJR-JO6C>IKU1:VMU
M*?@\G4;>[R FHZ%3))J'P&&,]N\8Y+8/J.S*G!V,$S!]8^+AIG3.XZF8.:-2
M4=G6I1'%^#;#TSY]KB-0YV"T(RO><&% OP>FVFPOJWCG9H]88(IA6 7OVZ06
M?4VIQ,)6FL0>#U<28RV.&S.0.Z3)DO_S5VIK,@83])9YHQR*Z/>%,N""%E%=
M\@DOVR% =N5Z91:1VJFMM_2E'F&^;#?K+,4 YP0K'W@ZW<=]*W^7&6-3_P15
M*ONQ\<>5*I'%R 3DR<1)!I@7=LF=#.!MN100AKE3I]F8[;G45^YZD?<>3:1(
MP+<$\7N#4!?41_F?N8ND;!QJ83O#*QA:&5#9X=WC7-3><U3B)'"Q7FTY_-N'
M-$&O7QK6>_K@+W,TQ!"X.\M9[7B<*EH^;C_6^+CT4WVD@6>9R/O':\CR,/LJ
MSW#!J^52LUTOC[>YP[]T9RWE>D41$N4O=4[$V]Z+NX]$'2,*R  @ZC$R'%%E
M/[TNK!BZTF%;82HEJV_Z(F:I*_F6N9<AVQ"[ 5/]_>R\QRN@T/E*US;Y*;\1
M^QWF2 >=>\D"$N/*AF;;^:KL%W4]XXKY+R>;?[AX6>;G#^\ZPB&^^-21-(.H
M3!V(BM26=-,6SMDQK[TZX_C>+_V'S0SDJ\IH#^\#GU2%N,>"#V*PH @@+TR-
M- :NHM#Z<!RL4*60-K%DQOWFCUD:%;\W4]\NI9G*7>&)N.\%+?_F\"O$\:QF
M,>>:LE3Q5-Y<PJGP^.W^\\42_/"FE^XE\%NIA"[8 $EU1%N(--$BB'-IUO2;
MAO)WC7&8R+-UIL<JE_MIA1[72WSH-C4B92)W2E_TG\LV.NCT.TQJ&E%8*^1/
M<\*? ??D'_0[SOUR5+5="F09CU9&,@Y;BMJQN"2?;KMVIM:+&QF_F"$D;DJ8
M?:T:W]_(OGH [8?\S.'C%/1,T)7J$!WC)X ;*0YL'I!-<!+ST[Y6F=A>*BDI
M\\9@.K3]SLUWD1==J./G'M"5#1]!5@?#$-B[J 0PH])E3=DOYTQYW*QBRF?B
M#0P/WUV\$<)O*B I16=Z14T0<)T7:8\S)7"98G+R"YJ1$9KB^6NU5YF"/[F)
M-SW^MAY[FC_X>:%CC+]$SN+=P_S+0^Z#98@OY7QI=&R<&Q*^H^ AXEN\-7:P
M T1'H,Z#JF/#GV:Z)+'=<J-W$_=_M&M\ 4"UO6FS<.8'A>N"9.$+)9E"BQW8
M^<ZD;KN)2V-;XE#O"@/9I3B.]3;!Q",3Z$-L_^$:_@ [VJDMAKO15(W3^XA)
M\?1\;VOX^9[*3"?,J$V&2B&:?AHE!VCE+2 \)]:V7"8-.=*1 >%TW2?"85Z/
MY!XU&I:4;IMCU!XRG=%+6['DLW(&R=]\:?53,)%#GX=_Q*T,.>[N%/?CRH'W
MCV03[=CAM>!42G)[/R%["\[^@LZ[5NQWND'&\IO@CX(A:WEE\#FN$^E3/2CM
M,/P)*DH>2P;8CKF,^#GH!)T=NUS!NQ)^-?Y;)ZUY66M<0OT@%V&(((&O742&
MYBC4X@8[*%GSZ_J5W%OHMYJ*[4L\,8\UKRH %D/IF?*NT,"BW?X!-I)L E_6
MAE05OY\_WCC;B=4E V S UX$6 XDY9&CQ 8O7#[%\5/_\_OJ':>,)+AB#_R)
M?+@*HIRN&QZ520:$*$LW.RPDR)KE-?W,>7PXR20>?<M=I1NW9<[@M"?\\LSI
M#'8>(Q$!DPZ0-\:MAGE.[-T>O\@N2>-)00 )DH#3"KTI*\=.ZSWC4SW8J*,J
M,=^W5-$2%QR?D"T<DZ+KQIRLOF48D[8GK/]L=4D0J[[ -$'7AI@6Q0RV.N@9
MST?9]=O-W*_9B.6+RG95Z[Z*K17X"IAK! MZ]G"-QO=*89[<&(,W@:,C.50+
M;E:-\6S/+\!*")3(%>JT-J>,R]^)A?$'9&BJ>15]'QTL^#7#]S'&EK?RG;"*
M^1?#;W&%,T-7[I\Y'&QEF9IOFS^CS5?047HMWFF+O7J ./[=2'O2>T'2B4^&
MBZJHZ/,=P%*R(2B] 4S@>HYA4OFHC*#Z[>]_P=OQ7,;64&U9-WM6D"<!T@N[
M!&\S(($"=FZGZ&&Q%5B/I@]1Z7?T(346A(N!&37P9OY<>+4C=/=[7Y4E?^*L
M(V1_;#ORX:M\":O,\6/0I$XAY=43\ 5HQH#!VW@?BMF?:'W.S^.IF_#:/S6X
M\/:7:E\:4LPH[UVWW77#-F?!JTG@3$NQBGY-I.;VB*$HM\LC8T6.9$/-9%,+
ML\F?#[X6Q5\>O7.H;<\3[>NN'F^'!@_U$#@4228%I$7K^1,F2\+>Y!20&N3)
M$@NL/ HA ]  K&?J)\??%/26MA-,X+EJTO+@8^1:V2,'U.6>?L3+A4%O2P5.
MK6RM;;_'/^ONE@Y:0("/R8 VNP:H-!E0MTKZ.;D:]8\:J/C_7@,MV&([O0>]
M0?P,0@.%-4;W&UGP^MKCA_#-GZZQ\!G-4I)KMN943W*C3VWACX">."@(5U:*
MG>^>!B:^N(Q^?W=(#M,4(L>5PYW,_8NZZ*J"Q3P3RT?.70+G[P5B>(LTJ!L=
MW]4>@/(0*D.= T[&PP6/P+@#U=,MPL9^'.7-+%!/KBJ0 ?1D0$0/L<&1#-CU
M@$$T,H3R/$L,0?$^WH?6ULR#6R]GL/63.2M*Y8(Y@W\F09]P4/3@#.^MKB5&
M[J#VZ2&K% PB;7J"B$#M0.!]?2T*>*Y3+Z@U$0%EG3N#]4S_-/=[RU]VA7CS
M7,8EEBN6#_@%WJ5[?5/8745J2;\A?J2L)^(UN*IAC6&Q&63\55A(56_^5(4/
M,WN(DH9GK)JJ^"R5_?)8?YZC$,^44^5#!MCX+3<2+)1+,\W3SOV4C^G?TQ_^
MT]SL-2VMA[===-!'(^*V(SY'+S)<A$ R>&54)G&AQ4U99VW'PF5S^"PTV?6W
M)3KEH^;8\(4+1)W6.=5R!WW]L2&9\N1[H7E7U=47BHL!EB$+D[N28">H +$!
MI@T5&-UJ CD7ZF"$&(=OZCH7?7QW*^Q3S]6*VQ_.<QFG.O8G2*ZJ,:V/'>X+
MY1/=(U)=S0I,?TY81Y\PN%*"6P'>A^5UVN%>=V;VCY@R@4W8+4.-RVK3DX"D
M;PM)K-KOD",[+ 'P=M1YJ+@;>HMV3DC@^E#IX:WW-5TT;%2&KL]GTER<DI_9
MK%Y""8#0&Z1KIR*F^.M*.]7P0=,:DV4R8%Y D0Q(G/R&$$ ]12: A#:7AC6-
M"WORUZX&$U5OZ]76IM")#L@,BGUX(%2V_.PJ)_]>0<HB3E:?39:G8"EA;:5.
M1MTSW!<^:5%);$ ]Z0<FPCD?5F*KNKT8 \S$JLM3\)XN22%U]>##^T5%+XMH
M%\JY3IK_I360@+&>1IV%>^[$SE-!S[AA5]OM[D0%?K8U5BKO#?9Z+G:<_3WN
MG.YS]@5VG]W57Y.5F<[G;6S0:R_@*X&V?D]RHU-?SEH? TTH1FD#7W+'^Y,!
MCG91I+B8&C)@X1T*J/3^7+#Q@GRTY\0T9@6-W'=)>L5>^85C1@X>N\Q^D0S@
M!@^Y[IT>1A _-P6>&KGSJ^0O%C.K=#N<E_STRJW<A+WB1]\ ZD?F(P,IA5 0
M__'AR/9Z^[K !E_.W,KLA$%^?(RZNF"Q-!-K:URH&FU5_MOG#]+XRQ(/ZKD4
M=06=.BW&X:V@0L2T_*$_%KX%7(C (J+SD]NW^W1\'L(9(].F'^6;]OFTJ BJ
M/_9L;6,Z ^0FG*/XB-M/PC5\4D' 1@],,K9399KSMZ^KZ]GBFQ6#;+,</WYL
MM5]A_DI=%Y+6?0-_A$82. L6)T-?4):$0]=I42" \^( %"FT0F<R>JL5)&2<
MJ[!ND[4Z>@#&2ZUV&I8>KN70CI1>ZIFKJ\M!/]^HUDQ)]!A'6_0K2EUYX8;R
M/49.W@OB^.[-];AHS''W@ R(!)F#G@C,A\XQX8.+\:>8N;"\]8DTUO($Z5,;
MB>3U1;?=#[$#5N)+HM1":DZO&( #B1V(F,RH#F2<NGY7J=3(Y4NCU:(O/63'
M=%E21('J<\IKKX<K]7+Q-PZ+YWEAVH1[^)UBW2*HP40.4=98 &(SI@-Y"OP2
M(P:@N@XH[W]#:S,9/]G\]C&I_6VNV6P_;&(S8.JSVU:1I(65L>?JP>("2"C
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MRG\Z0.=)MYKAI+8C\(EDL1U0,-B@&/L5JT^(?DE'#-N"[YM/FMU'A8*6C(=
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M7XU*CLO>5HDABA!SR("%K'EV;?'@]YUP+G[P6;S?[6LA;^!NORZ0-DTZ 63
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MG:DF#I7%ZH:"9GYU<N'O6],!O?=8]8&1E_#;&5I;)1ED>,NM-?QZTLM6SNE
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MR1]S/F!:T^23Q#9GRG'-+Q(?8R,$@[MJ.UET -0+S_23[LA>BF,QRK"87I.
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M.U^-WEHZ"[P&$+]<EJ1B2+33J"D&)(*!$4!\$&SHT#;)2S[E&7;Y\K!#]T$
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MS7/I>]*;K235P$+"5_S*81CD6HF-&V>QV_BZBNV\7*V#HV_L(T;&#-<4:)S
MWEM.>#BFO'4L0Q;>$>!AEVH\A+0;O77T3<K,S 'O!K,!CH';O6:[",&4SWXR
MD)N8$8M0SFYU=@M1%<M$CTKIBZZ'BLF2RCP1D5;J2[EU!#L8/XA+\_02*!S-
MY0<^%5AZ?0*B@VG^G/3K)R:3^[ZJ\57_IO34ZXN+$1WP?SY4ED.2[CJH5JF=
MN(Q_N+K48\_SR7=>U^)F2/I9(;:,PQ3E2A,K+N1=N2ZLL6"44%8W)G>1'GXW
M=Z9V!O?<S-.*S*WUYLT>WX=8;7_*FJS[&NBEWX(Z($WY;JF;Q*[]_-GH+?*H
M1V!N=+N;Z=%-2=3J6C)LL2R_QO+=@4%M_CD;=S'%JWA"F7 @IM9%Y#S<1_*)
M2'#,8-[GK#T3HFP"#2#:8OHM, #3T 5CW0C.C]2L_ZT67W%]W#WF\D?MJ8L?
M.BO"^'I3(B!?J\5*Y?;8"-:4.*HX=4),]H^OMTJ@B<$O/M 6V\:0JW^2@<$N
M)NF4H[+^W8R+U9&G)</-U.>=<D#O,@2Q^+2)ZA E[8;0Y/R^5?-TL./=6_G%
M!"#N*>Q=M2W3;S)SI4U'GKV@QS<(K DI0 /TE>V<Y%'5P3J ,]<%TS#U/U=?
M^I>LFGR;+Y[>*316IIIRBS)<Y$_,O7.1FX676$!Z".NX1KZ/D\#D%>$-NZ J
MR3T60A<-E#R*JJZ;?E7<$$Q5OOS):<9&_MPXOZ03'GR&S(K?KL+U+?%'M'@7
MS+56]&:6S#1_>-Z\Z'9JA,>QU$#0R6&.Q[X,DX/@OVO^6CG OIG@MNY=CN+1
M_1)UR8OB"ZIAQ2$2$;7)'<CIC0?QCXD%\+[B$=^BBO+",^ZS[\^Q)#$.\3*'
M;[UC#N]L0B2 N6OS(Q!L+49X#6NP,JJK_LG<45!'QJ/K/>>U$E)Y;X?P@/MV
MNM&QT*O$UJ5$2RQ_TDX6#6#YI\A-\KEQ/PHD^?B*M)-W<OJ%UP!X%B9/Y'@_
M9UWC3N@60>LA2O6XZ7%<RR=220E=53VC<G0%/Q^'<%7.ST3U9<M9=ZZ$WF61
M),=;UD%DZ2"4 QV&<1^\V-=ZL$OJ"'B#<0SUE,'6!6A%=BL_B$VV>NBX@+@!
MY81UR&C+0.[BC#+CR>[8;/"9D9+.!KY)CI>HAE,W+ZBZ0 RYNX?//0COT3T-
MF'Z,"^BC =ZVW:#D0,7GR#?Q,]V'5[AM9VUG4W_9S0SJ&Q3*\U;]M-*_>'ZP
MZX?T^A4G05WQ)P5WH<>;Z(W"([&'>_(>DJ5F20G4G]!+1!K@#M%M4<$+J]TF
ME:W_RT.R-7]SL%I_3%<=*,_WJ#LI_ZK8 ;F).H<0@_"0="&O3&+L 7&[H@J^
M93;B#6.2RD<_6LK1LIH1GB+/UG#P-IC##C!P@I!&R6R[#!T2RBM$6%9-"'$(
M$0Y#[HNFCQ_1I^:^RZSGH@>S0E7G]YFWG$.P&24"% _>_(/GI/+V)7AMULFM
MUD0=N/QP$U)2?#/(L.>8&'$J6H+1483 S.;L^V.J],.ZX6&\UXU_WUV(/_\4
M"MX/2=[3_G;R08KZYZ2,N?,L4M0(+XY^D@LQ$,NI1T_C]+0Y"AJ5$)"J)>V7
M2X([.=[Y])# #/$B^N"C%Q76>FV$-4K(0#_'$@.MNN6STJDS_4.\G:IWIL]A
MA-^R/0M724#MZ9 4J?UYMRAEKGA),98_^_,R1&</(9_OM8.2_%&/LC4_+O];
M$5D3U549@9+)MXAJ6,ZWP!_;S;CB'O[ZIJBBPK_VXFZ7:Q2?.?@02E!N*8\;
MK0 W'_=KE27'XZ;T;+*4*1L?3.TM:( H]0'9R>4:>ZSQ0@,-$*U]GOY7P4E^
M)&P,2-<%C/[YY!1P83X?Z"7B':@FLPO!2"RV'3\ $74U#3V$W**-:A/'SV8P
MI@I\M<P R7_,7GZ<Q]7DF+]<BBCQ2L@_ \($4SNMO2(\+NX=Q(,Y_@5G9 "&
M0NL'QR3O@8,L(2 ]M>+S*P+!O#(A!@:]QJ.[K2T#0]?^O-0MEC4H*DJQP;B2
M+T339=M/_.G[1"_,WX-L!1/[C[.S!J'N%RRHGI/.NGZY_8JZ?XZ,GX;U69.V
M$3$T .=&4W%D'46]NTFR=_;)N*)#<_T'OZ20 &[=KCEZ:)R&=2;'6(-[8%%Y
M@L24PF?6Q+A.MO:W:T-!YP7%I2?5YZ+GA/"--='_%N>D=<EPHQ : )PRF^;R
M!#XBE%T80_F,>(&(!M>8O'M%=L:+5F9-/&JQD;E4'>O2F&JA]_Y]PM_KI05S
M/KVWU^]#T+@=*JL529O\"#\:C3OLG F( 5O@F>8L_*G.">)7=W,\WS2PWY4Y
M^KB(N:-5MJ="96W%1U!Y3)*"85VBMT*/ ]YN=@XS#.;>)<I7[R]NQ=QM*VC@
M?&SG1>;66T22)6'<=31 HG6Y<#E9RHL@?,:A ]'Z1-)9N\IF^PGH7VG69E%7
MX\L@KTD\_VK=9"L5^*LW*-?J>6NB%OSDTQ:>.-NG?9[HC2E#"A W+!K&5.VT
M=$S\WI D[/I>)C\9UF?]S&W0SHA:1<<C%BO0-;VQ,&\'3"Z/'5ZH4]_FXV+4
MS S8=Z^(AX&Z_R"T;!5$E'T @1'#\&+(KEO =VH;R=$+ O6)X]B9P:!R3Z]O
M=KNC2.YJZ); O>:C)Y)][.ZKG--*A%-XU):Z8TE@MND?!(8#MYK]VH.IFY#H
M[>W]IE1P7(:M9_?S196:MRSM[#H.*[:@\"3>YU4UZ"\A_K,V\8*?GHMZ.=Z5
M_EM))^],X41U']\4]P56U*N+SQE2S]3_E,M;>9CR6BLIM&Q?8[%ABPF720C[
MY82B\FV,K<>^NCLW^^/J_*R*ZZD7P'.?%[=>>;P2_;J(VILEV<$ZM%L,24J!
MNA-8CN0X<;Q]F-JXU6CO[VE;&P,91\$KJ\.5T9YL9QBO 17/N8_"GH'$-L1.
M4\HTS\YX#'5YP>DDUFGA7OE=$X[UCYV-HG?['_<5RJA-QV%R."#R50*"6CP[
M'K?<2R)%4%S&U44Q-OE5B ;4ECNNN=V> P_?/*CH*%&/T[S_65\A3T#"_0ZA
MQS<9$F7N,)B#.:>U<50"7P 2K_!OAB[1 #%BXG1=\F)+PG+BXJ\6]<\]:S/&
M>_$-?"YZ:<^>9FGK0'YZIZ%$W7'!K=OGBN[>N/>WN0$?I"'F'W0KJ:&M]M]?
MV&,T(YTL%Z 9J"K$G=M$4XR<EJ>"^U,KB7?S,SHB#!6+0?D^Y=MZ0\*.K$%]
MD]6(5[ $8!4-T 47>A%LN26\Z((WKO(I_E2^9G>+#:DX-;A1 ZGNU1LM?\T@
MLM8*F2!=.6EA3%6 <!/7,,#X-G'\Y>C0;R^^K1H\JPM)TV#+-GCVZ(L^UQNA
MV\9/7W,$1I/Y.*F&>N&P33#HV%(-\HU?H</D6J2\/%HNWJ.XXF#C4&S$UCP0
MXWQKS!+AF04L %8A>I!3)*QZ@MH&YS2R0P%CYS+>X=R27DM\-5S_S=RN )OZ
M$$-(/:=U'QIEN8>FPQG=FU,'EI)) "5J^GVP)_W^'M  +[4<%V%=S9S1;4Q-
M[B#>P&D7TP">#UF]G0IE\BDI@P-7O!2OBP+\&95+*MG14A]JE$K'/!9F&J!9
M&\N^BU7_'$+KC+0X7Q"72,'041A#G7 ^9V"T=:8-GBG[5?;#<7%^E>[Y24L7
M?0F'>>O;2Z2Z72^RMC"&?_8A#!>^@7#:DO[DO@I#(U2 1 J4-_!TNY@JL6;)
M"-1./3.Q,NE'>7[W1^=7YQBF^?FIMZ6E;"K7   #M6,WNE9C?$><]<)$_:[0
MM/IBM^$F"-L\V!L3?#O:W>ATVEN3H[\LKYQ9;=_O1H!LITP7+RCHT)_,-X3:
MT6Q<#1Q$I0O\1506;WBUY\_:$*"4 L\)79Q]X^2MO83*])+/=2VOSYA\4%=]
M\YY!\M[F;<;WS&H'B; +0@NQV)VHMJL_?QU\5_0%<A&A&TZQC3W>'CYL3KS.
M-QG/LU;GWRT64*.HT9V(!G C[<QH8$0FVQ0^&BX!SVI:!"=$1/A=B#-J'1,]
MK<_U!T]^,?)6@ &#EV;38V.*Z6KNVFV;.= K2%_=+F]-O^\FBMSB(+E#@)1/
M+8^+ PVQ"O5E:MLE+DI?KO.-C0C$].,=XD<$.7YR"F@Z9L5C^+>&<&Q+G%&:
M5DNB*H]^XJC)BP4O9Q)[:T3\OW_9&]GUYTTU6DF0/Y7\,0? (HZX EO\ =JU
M;1&F 9YC3Q1;#]0;<AG'V0U*T):O(M[!'3C];,;S#K\1=KR4-.M7K7^_FP;H
MY#N[8-H8?MN%E>45T$0)HZGPBMU]T%BAK"%4'86[>>WFR(OGHJJ5S<!F>R5Z
M%&V",(_579&'2&-&W+L?W9LB6?177'H?_#E]^",-$'J!9/F#?(Z^6S(5"1*J
MVP"?;4'E<:&4<NY[G"F/>3_WH(]-Q))+X]OJ*"#-P;%S>1&(1//33?8BV:<
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MK0N5O+2#Q"T)+R+@K8$Y=)M)CM1=<Z(R3*:B0:$N]:Y]E9WMKK,!2^!4!#V
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M6_DS;)NL/F@ESB+,M<L7.JSMT>R?<?@"5\_&=L=\6*J,U,I;YYJON=#Z,DG
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M@&C0R2O&)>3W_U):X__-1I76=*4!)**::0#P(?A8K8SD",?Z],)V;[@C#F@
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M8(OT_!3,&1YW&_8+$7I\S_V(!2[710,<!N<A"J:[\[N3"RAM;NA=SCH:H-*
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MZUTFE24-!^LEX#T;<;[^ROK$T5F;Q<E=SEY3SA5P\LDWZ)1X,QH 7D(#[#O
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M>#*QXY>E[/8[EY'1$=R=O5JO4F)?-OF%\7X@RX3[H_TJT=DZV@YMWD?@P4M
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M8X%JX*S\7!VPM%W3F==.^\<>UGM^/#2\Q5;\]XUGSM-$0W C&$/:D**6:*'
M"QD72U/$<I"D?FO,OH'D]:$=NH'<<NZ/'_VHI2D$$C2@B:315\<ZA[>8+,,
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M #.KL)M(B,ZU'%O,:42+(EI<A)NJL\FD//[[W"6@I+;J@S@*=.H0)Y+8;KH
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M0T4ZO?)'AP=J1S]&Q.5TM?:/NC^7[N:S:]OZ)LIS%W9I\6^X_5&[3>HC RY
MI"WT&&'U$BZ!OK=Y;=J#Z4=4HV8TJ_09E;5% X/%T)KJQ R@.RALCL^-AQ;G
MUZJDNM4) ^K^>KG@S4!UN!"O\1Q?)37> ,&#SPV3Q%R@EU2 MIB?NY)@>V:C
MH*K'#CXA_&S)<W>O9=J+EG8W\694SZDQ* -^5!5H_(2DDRYC?_B/1]:+#KF-
MVY^.$ N!SMW[DQU+,20&O"YHXZ2,?E9Z%;.F[;K3767XE8I/.OD5@($:0/T"
M/ DJF$<;&S"]/ NG>+*+_C;];EL<:E_$QY_4[[)ZPT3ECW@U++GC&-^=6F*U
MB%E'\U,&2VIY"^[/S-,?1[5HIS]E>G2]IV?0@.8679DA%1-3!A99^WL9/LIO
M@W(WB&VG^)2I/ U8$&/*=^0H',:#UH=>(=S":2\91"I!8SV.V8]N7W>L3AF2
MU981O74^Y:'FE:8F9)?K5M/RIAW?JO8L?SIK2,%#'3F6ST_562:\0YF?WC__
M[PSN3KP2M+.)0+&C93D4FS*TX796CUQE_'>+<])2''!K>#8V0Y*@>$;Y11!W
MT/W_BD/0L$)<^/V!^NQ2U[>U?O"Z;OSC3@;BK]GJ /9VC=?#?#^!BR]P]*0P
MZ[]:_A89L+2-22712Y%0BZSXVI/#'\A^4/!\F4+'/*SQBIHJSC??PNHE&>"2
M,J#].I#YLL-'$3 _UX('M?!<8[_DXCLYK_@VDY(_F2<V[IY0_N;6M=%;YH.A
M:F[0!*(1M+D)S4J\7.M,NO"(#&BC8#\][6_0D?0F',?.2 :P@GJK"4K;V%]D
MP-<[%*<3<AO8#L/YCN]2(.V^M0(EMPVAL6ZDDE4*VK.A& ^%\<^8R  UGN,#
M8+Z>I-6@[Y\Y=R;#ZA'^B-VWU<F"= ;W!"\UE>@0T!1D?DOJXV%".?.<\T>J
MX^#N[FX!Q:Y/K>ZGG-"_QG]?O*C+O.!PQ-[/\X04/MZYQN9O5"+Z9KTGU6:]
M+*Q I$E'I[_,Z(S4H5N92 8\JXD;FA+W3'$V&_3VDNZYSR[ $#AFDK[43^^F
M +0?DDL7VXZY<;#P*\[T]];;HK]G>Z!H4U ,=*+Q/+J_Z:9T4+4:/QQO8&BL
M$JW\J(K&EC@I+!A>+X>C^'*>I3L->$6"-QK:JCL=4**1*5'9V_/XZO!F*H9:
MB/:U1$5=_%FRJGJ0O&FS=.LBI*S?:=_1??=P+\"L?M.H9.?4HZ(.^*-+M"3V
M. MA[UG@<BC15C+C(BN=W:7B#>CJ"@R^R#M:B!N#>76/RC6P/HH4'D/N'N%6
ME(U+!;62T]E_W[DOS!+Y;X*2 D*;>9X*J)TG W[LP,]T!2':8#IBO)H\:3"-
M(6?)((PCJ&0V+M5;0L@M^M?NG\]?DZBL5F*+%3=!]LGH7HX)XZ@2RP10-3PP
M2TA2+D,LD.W1%_CH.$&<AXJ;-O)-/^%R.!D07=*K;#%8Z66IC:INH!]I$M6&
MX5?22$X&A.N4?* &3M2ZD &_/O$LV]AC&+$2Q"(UZDW/Y5G/%M8;M9"TRXFN
M'-8SID(3##^!DRO2[5]]O;,U?:SO+KYBGI=0L7 _@WY)ZMUNLWENC4+RGW5\
M0YT#OC"8WN[PPAUJX<0P2+-4F\'C4Z/^)R-(MDX_E[=D@+B4KDBW+G/)Q_.=
MCG8H^9X/^'V07/HJBY=Q4#(H:>_=9_%78BU95.K,II_>_GLX\$_#QX\DA8Y+
M]1,,0Y2:3<ZTQ6+T?)B][]SG%^VY^(<7YKHI=OJ'6 =T,IBB[IBO!,6I6"^@
MJ%RGQJ*_9]Z;GIV:_G+KDR9B^C'>#.H[^ D?8M.GG3+<9OQFZ_F*M@T9()>_
ML=BQE*=!9PB31QR]NOB"7?_!RC5SI?T(61[Z31\WB-!(246LTH2397IGXMS%
MCB+M6\8\D44<SZ4M-]]Z/:ESB&,;#<^FHV(A4'"W29TDY8]:2MT50?KS67Z!
M/T0'_1F6G:81:!<R?BI;1WM%/#&%LRPSV[32YE%BO;N?GDZG6)6^?9S9._!8
MG?.1F"->#])G$3ML;D9XBFX=+FAO&WMU8( '-IRB+H_G6>/&FZJ8TBUWWS5/
M.=+I:/M>OWN96N369^X'-.]"T@C4:!3ANN1R6+9]OBN$#\,=CE!9$[GS*B:5
M4?QIV?F!/_&?I,__^2WH,UC6:P^9(0-^4FQ(/Q=D9$X.H_D!3%6X=<:RCWU9
M65-1)4E=K.1;\80EG$<L1^2(KR$"33J7YZB3(JPK/Y?),>S;,#_S6J7C&IM/
M7ZKQ&7QPX-9[1T7:>'4)PZ'LQ'G=\F#':0&O]F+5BX87BXXQ,2</HV[G_I<N
MF/^;MNE_MZ$\_VY#H?YN0R&)S*,EC'%JN<8X,_]_ZIM>"FKB.1#<X,'^;1\Y
MJ&NMSD)2?!<J&4K)._,;_W]OP?WK -]<FL>)T.XT+,!9W-0NCU=::Z@:/&CX
M-;R7+'MJ;1)HSB%R[@<;)7\O;EN1 0153JP6A0G:$13XGD0UH\Y!E#>AT]!*
M@U95UMX#R/RRGL5\SW2=<_KWKO2J%6?V/FF9;5 I$+TN>0XZJ#6"0E_@(2F"
M<NQ^BA==H?.\IB@L"-U^M'9[C:WK9V)N4O7QS!DKB3L6+P =L']&R?Q7\XN:
M_WK-QG=D0+BB/Q,I2B./#'A_EPS = $7^VQH*#%**( N7 82O']!2A*@_9T0
M("%R<->'<14TWD,,&_)5MG;3+1\3UW9SP]EG\6E<TGZNE*C,Q9V<;6YQ(^E"
MR#>7,Y;RBOC-,8PEOYJ"=/,'JGN_.ZDSZ,J_N]ZPT OM*RIX4C66\EIE6&>=
MGNMU@;.3ZGM $NCZ4,.WP&YW@V22'&D:"(  <&U@6@R3<4VXF?S@;(5)U4\K
MFCBC)NJ?ER\H^U277E1M>P=ODHQ#,0!? B]V+WN&F?8'Y4_/:CM+IC,]$O=I
M+UPUYTQ(]N4]N8!*1;+T+@.G^;'Q&)N:Q8TT]T>M5PJV;I3=$\C+2G<3J$)G
MO/$48HX,9.4?:ZRBO!U# @61/THNW\E#IQK#G;XL%P6--<&Z:F,3*R)CT"I_
MGD0%EM-P)Y_@2-?R="^L7Y@URYTBD &@7Z<]\KZ*XT_=9MQSH1J4M(" @VYA
M%%KA?[_YGD;G='"@6OK9MOS0VTH"WS@_136;/[4J_-7RO6DQ7&>18BDVYG]J
M$B_( 0DW>DDLN!"\/QG0.0O6I7#31^B9 0LD<0..UN*A=DV3"$-(MKJK<Q_,
MB7Q1C[EWX?'E^SV9%]R.E&INF#X,%?WUI5,QEV)G(;":PZ<]4KZB^LR)8.39
M5I R#X&%":OQEFYJ+8?MV%T:#'F?AD6%S5?!=MHP]D_#-=!^L%=PHYH7"19S
MXE5,6NO?-*JU63]W_'@XB?SP=Y7TGK](?#0T\EVP@MT46!QX2Y0,4"(<$$N
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MI<S2RKS)[1L"E94$J?YK_#2YA3>U;\8QZ@P4E]!KASP8E"7234YIO=GV+TF
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M",&X$Y9NWEGBU-U>=XO6]8M],;SK6)]9?J4UYFT+?<:KE1C36L(U8@6)AC0
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M=;BL;OZOE BWDL?!CC@.Z  R\QQL]4M%WG\T&O70QL%+N*$\(F?I@"3Y.W3
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MM*F?(<P+<%X2CJRM,U%K+5>Q10=4*TTV_["G]*-DG_L=ES'M@'\A*:(B G3
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M\5J.9E9?/KT_4K-WWGOU&"E.HZ^C7;]E,D)?^4+O@>]1!<2)M:/L#7G8WQG
M"&JMR'D&H5D1XTC5Y$<D%CL"MC.4[='(M7)YCKYVPUN2\?;-;HV+L8;7T#+;
M">:1RSO"97@]G$M"!70 77>],H"UP4;CYI+YQ/[!LWO][EZGM^H'9_GZRIQ0
MBY.Q!U69XS)+!-]UL5*U<H2S][A0X ]=KA=]O#[&!PU4-Q-[8(=QC",KJ6FA
M1;%GGFG,::PFP50\29B/)R'Z=%[JW=OB]UZM!IFU(86I2)JZ&QB .D5*Z7J]
M?G+(OJ4VLT?GCEZ61+XZ=TQ22'3,GOW^^:(& ,W5X)RIG\6IEC];3NM%MC<C
MBN>C1L<II;#_2+9%K3&,Q!7B1BU *4(L)^0@/C@/JD>[EM"H@,='KS3IYOZR
M*/:9W-3W/]0X0!<5JYE%E?'U_YHJ+;M_G;=?_)^!(MW7AKN^!WJ#+J1:.Q:!
M)$M[;#ZH)(&3=F<">+##2WLK>V1)&J<#)->60&01-/'(X[AD&+3,^I0.<"3
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M\D5#Z$]8FP/J)AW@1)+M #+M-Q!G2>%.I>OGBY+<W!_>B0<UB<U\#.G0HW
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M4V%'2N^$2M8E__RS9YSA6EU9DR6MY1J?ZI:M>K64LUK\8SB7:ABL30QZ>CT
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MF.W XV,%$B+ODSOI:.!EW2$Y5;X<)V4OZSG+R_\XM"R-<0Y4'6SK(U%2-M)
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M\&(()48'8++K:6EWP1D(O)[QD12,';;)[4H'Y$]_ZV.,T(^F WCI@*MN<70
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MY!B2^EX:VH0.<$9.@8C>!/#F!GZG$R5&"BIPMZTHRK>UMY\=.G/DG'9_]N>
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MH*29CGC1 I1JI>R' S%/;@#Q<,>-.I[C8@M8E;X?A[TGK''>Y E),_$64HR
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MWHR>+'[LC1 M&?MDX(NL,S:WPV<_E(,[Z^#IO .U9H?YW[4IH12K51IV,QG
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M*9Y,DT $YQ@@VTGL:W BG+B$?H[=5'$>3\,P0(*9OR]">2=<!SSZ!OL3:*2
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M>Q;CQ\!FE21#VG,DB.' F%+E-@*0W9?'7/%GVE@$LHI->ZNCFS%4,"Q(85M
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M^22CB[).]![#>;U;RG-CWQ53$?J'.<!I2P'!G./Y*C[D^:X'R;1R80*6]&%
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M,CP\Z_&Y7;L4\F$XT)^"^3)AO*J/&$C["A]B7^E%["DL\1UY/TDR_;$$72)
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M]XP''$T@:!HGOY?[%> ^NH<Z4!_V196.L$IT#-8GX'NUX,QF ZVF+V&2H!_
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M+E78QD6"IJ"@2I!**@/1<&$LA,6"HQ@#,&9?/[(%$V#@D7A\F[9E(C@\MD_
M/ZQ(. 1FM<EV],4)E8&/MZ"%/#6?[4V#&MS]:4J]@JV T-RM*(HX$(1EJ6!P
MN5FFMP+-6B+7!\A6:F!<A0')@H,U04%$WT .TA]I1II!H:./S)-;C&:6D:SS
M8:,9E# @B:.0LN%Z$5_+,J,@+*0X3"IF</T#0KT-A# D F[S6"@8@M'/I.,H
MO3&:("9.RU)",$JF.DPUZOC (6*Y+QA.T=/54I%"K,1RK#PSQPB4(*U!?":3
M[HLV*"$VMR TE*\U!Z+\6'0BC>9O\L48D7 AR2<,*0'!PS@B?P-Z=!ZB4#P0
M7@U3:-Q5,AE%IX,0PK <.D%&@;!@7+K,6\ D0JD<G%+"#<*2M3I3J)1H,W/=
M@3"X%A8FE>O%* +;6\7@,R'TT8T>#$?RP4PLT0?I[:\4F[ADA!C!H&I0?(P)
M+4;[$Q%(N"\$2F: R AV$)&@,".T1($9#U$'RK2!)&]PJ#P #3,%0(UXRNCK
MTPPSA0L60ZA@,"XPR P-D!F"T$BLD0)24D4!+")7[P\FN4-XI, P%!CLCR;S
ME/[N+'>)/S;(G?;QJUL<$"3&^0GUUB#YZ.\IZE @&ZIG,PP:-M:FU5E F9(I
M_F@<B.EL&<7$\-?A.!J]'YY+<^=0)% X5$D42;B!UG_O4/=WVID61()IZ7P\
MDO;+;\Y2F$3 I-EL;2G<GP:T?)R""KTU3*4$VTQZA58TZJ?0Y00A2",7*%56
MK%S&@?@:$#">CRQ(2Z,QD$ HSJ(G@"P@M4C-"M""V$:-#US/LKE0_  ^ V\;
M*8$.1D%BQ'P_N8(W>C >H-1:I$#;,U-0/)Y(',26P(UD%IT+94 PW@%X?V^:
M3ARJ94N%( 6)2F>(:!RZV1Q (1+5(#@?(>-8@6I?I<2/Z0TDCSK@9(75[ /B
MHNEH 8D&58=2>5Q$&(X4(+"R660_&%1IA6JD?A8ZB>;'EP9 ."805QE("?4/
MX(;*"1:"?ZB"ZL?U5?N:3+K15]T4:"U7@4'I?37>842JBDT+,$E\]0':,#Q;
M3 3Z!P %8J4["$[&@/PQ9+2OCH^PZ*"A1@P7!103L3JR4,LCD)C>,)J:.+I)
MZ2T^_CP9GZ]GF(A$N(&&(TA)MJKY8H0_7"4W$-5D*A)LH09 O-$:.41&)E@T
M(K;&!VJS1.$4" T5Z(V$X,4X*),@&_W0P)\(D8*-:B[?C*;R?" \B0Y)I?MR
M+%A$J%(N$O'"W)%^ I$!30.;B22P2N3SG[[M_/_ESU\>!/W+'U6 BFQ5\W@T
MC9F+E+%8H7(L%D33"8W^?)OA'FKF*ZD\O04?!+.,;@%^9#Q-0I<:"2JEWI]F
MA+O3A1P_MK<@ &S$8_!,(TI""\-I]2!_- Y#Q(6"@;YFDD D0'-#=6@25Z$T
M$M0,D A%QC* H_ZR00/R#91:,5(05"/GXG%D$A<KT:N!')T_1& 2,U4H*\4D
M( 21^5!-H 2-06@%;#Q++\:093*01B<B(FSB%<KP?)S[Z*=A7&^IUN+/8HAI
M$#3*1 %R.&$X+IR&X?EP.32;$0170?VH:GJ@T@()Y7*"3!2FD6^FFXTTHSZ,
M;B:3Q' =F(-DAE+5J-'?4\*0 F.033W ?%@0ED4;&$!1Z#5 E13)(R+]=#Q?
M7W>2EN 3B%-CQ6)_=9B>CV=XR\4FI5+#X''0'S_I"Z(C?=$\BP VNI;-)H,:
M"^-(28$4=[R9IH)@S&$D,)!#I4%86IDWBNAN# W2"S%0?@ 9+\5CD&HV"JTP
M*K0HBYYDU (Q00R@WD"T\&"*T1-.0IB&8@+Z>.M$9IMV@:M\U'HNCN9.LYDR
M_A0]%\J4F\T4JTEJD/,#8&HKW(!"(/AP'AA-MG!9!J@0Z L%8TA<WS ?\JA0
MO(.,9F\@4&(-(*KAH  5CN(+U%J!4%! D,7J(PBBFU4LOEG%-6"U 5B>UL\7
MC@V0,@V!OB"XC"C"L] &BC^= .7+Q?+1HZH G<V?YVLM(+Q6JI+QZ(%B%@X;
M2-=C-1:<$D8,8HI5$BE98] J9&0_DSM0P4*!(1@4$$26LL%"HP!JT$*%9F\K
MRATY*F62S>T-]%,P X@PIA('A9ED%#!/Q.#[> =8!1@4$L?QDW!I: @%@I("
M;5(/LLW(CR\6Z?5DGD@22,-2F7"%;;+A"(S1M^Z5"+P9*.( V;X<IIAI00=H
M: JB-X($4_%9'"$%# ["L1!,=Y:?E<;"J_4"J@3H)R$2 REZED9H!ILX[E 6
MD,8)X(F5H^<V/D*V0D?F +F^8IMW3?;AJ7U007YRNK]9C R BGDJO4)M!L)E
MY@"&36GJ"1R<2H@(U%!I\C 83@74TY4<M+_,8H&C0/_X*9,)%[ H.IA2Q.,%
M*+"64(F>B.7)2%1!D(]8BH-!-4*4A>J+!M$A*+:1"X&3;5850^@G4\GE!F\8
M(92FP:O) INU+QM][\N/%Q9@TBIL'@Q6X1=&MG*!MET=0468_'U$01IWGL+*
M)>,0H7*$AF[%H%D\(UE+H,L%'#E'+J0%*6@FB[>?A@5D&:WXT8,@%9.OYA,"
MV3JR'S94R)8+! (NVD#7TXU\=:B99_&F< 1LOR (%!0H9>&8?A F40M7H* L
MJI1E,\ 8L" JR,^F_]5RW]&3=B3?6P@,"%4R558,'F>Q@I4**D_LBV$;X11_
M'<C*!(MP=)OB5PMMFQ4+YR[30VRJ6BAET[42#$(  7_\QA0%5\&I<,L_]F6X
M+Y5%#3!0E&*HTL 3"GALK(:FI%-]Z7Y!>HM0+&'+F!((!F@U8)00&<G,MT)9
M :%R"<ADI CIH "\!4FDZ@0FR&@/@]0<"Y,$!3.-!!E&)&/*B5HV'ZWBZV%4
MN@POQ4K "!/"0#$++7B#6BF6BVUF*PD%$[-"N28+U,J"^86291(BGB9ECAYB
M")AD1A@3!N28$6 X%<_ $.@^8+K*:@3RE38KA6QP!P.1>B0$["O B*"^9CJ6
M&$37@(4*;[4% 4%(I$HHEQK@0PHEAXT*A2ODXZ74 !$0Q9" ;-H-S,-KH&%0
MEIR%-FHP0".-9=2B.1RI+]P]C$132&!F!AMHP!,E<KXB$(/':@D2*58.TW.U
MZ-%??,!6FW-+_M42UXH07"T=(1,&\'ADCH4%,_MCJ7P$B\1B&'Q9+)H/GZJ1
M&(+8[E8H 4=WETH501:T6FE3VI@@Q.@8AD'T7 $#)+":8& ]%")2>1-0%-\P
M/<Z?Q%'26'(A7*:S+7^RB&X& R$07W<:D$P66HU\C9S/(')9=))(K=$@!0)O
MXN@Q"UC.4"I%7#6+$01D:TF!WFHKAZ</H$FH:HZ8:5OX/#'& L)@S%@>EREB
M\51T.)^%@\D4:C]FJ%Z-(]%T)KR)9 UE<T<W>I;*[$.G0=0*%AN/)_J9Y60?
M.B8("]8%^ ?@)0%DM,P/IZ%C(2P&2>V.Q(K\E;YJGIH!QL/@F@"X-QAF,U6@
M0']B (@\^LNC!*+F@.4ZCM97* T$4RA6& G%)+KC(7@Z!4+PYS&@5@Y"3+=M
M@BAO#=1/[8>"^HNX1B($(D3( @(X""Z6C">1=""3SZ@^]#>PA88@BI7 9[G;
M3#(3W\A2B-06'L]/QA48,5J4@<+ Z+ !%CC<W\@7@6Q.AA"G!X=B?$ L7)A1
MX(]C^)# ,JR:'_J/5W]]D5@- ^BN\R?[$@T*"SJ,RY5*&4@4$LBF:5D*-1;/
M,;,A5C\T)Y0L\.=AO<5ZBDYJ9N. )BB)84%)\$J$U5\BDV-'/Z+D4%5P-ELB
MAECA8CV4KV3Q?/0<N;M-A#!L*-NL!1H)(BS>(! #@U!B)1JG0WN#H1@:$XSF
M^^)(!+,.KV=R=!(>72T<%0HI$$^ 4\12-1MJ@1*U<GB@F>8NPAGI*)0*1!8S
MB4HR/E K\C>9W07^;+'$&\U3N6N]]2@JQ"<(CH3+02J*2N0>@%)PQ/]XWT8'
M184!;3X8/8Q+Q($1)+,1I\6Q9 :<00H.]&=JD#032BP,M,T\@=K"50<!PPQ,
M"=@0@$43: %*3!!2"1=!15 P</0':R,;(R"R#%R8A"+@^S&Y5#\&C&CD\^%P
M;[]0(X%."J(;*7*8&FB$BW1$WU BD:J!87V9#!\63Q'F"Q$I05:T+@#'#*.,
M'F(8R'0BTI<.9A'9,C3%K+895YI GT 2G23'P$PLA90+1EH94@4'1(:J!#B8
M.U$C1_BPP@+I 6@,T ]IFYI&D1(O)9&"1M],LUC5*(AM'R>B VR:BJOT1I-@
M!KQ!PO3V\>'1Z50_"!P;2E<%V8Q8;PQ!86M)RT0'H+PI&%XH%:T*TZL#O,UP
MFA7/X(Y^-(03*!5TE/CC2A 9:3(H4,;F&BPH*ITFIQG8!)F&:\:2H%)>D,;'
MH! S_4EZ)(<F@Q#4!*W-SB;(?; ^)IXO#!^$UHR^C\TRP,1X+)0M"270O6%X
MI9*E5M*8&I *3R,*&6"T#]^F(&!"LS\0Z:<P0;1FI@8KU4I)<*PX%&<.0M"4
M7+F9IB21*+C1DR65U-_,"<7#<1 ]T4JT><E""$8@D2%T)HRO,3"4[\T @A "
M-4YF-C!$$(H9R\*);=H2*F#)M&HMRT)C(<T4.5JCU1-&_RMF- ,/P=K6%C>4
M*3,$4BP<LS?6!P)DT2Q^2IN.M:UZB\%(9!/%@7P15:N2(41:"Y;)-*CQ)#-<
MC(%X(]%6>8"OU-T'.7IT;P;RR2"B2@X$@Y54%IU/YY!)B "DCDX4&$58=[32
MGR4B862H0"392%=;.%(?"Q_%4H7*X!@AV>@OE@O1@1!?G@@,EH[J0R81Z\T+
M9%M9:HXBB*''HUD&+-;7YHPCY6"MDH9A6*4D'RA/ .,"R42RE !C!) #Y#@Z
MQ!@&A6 "M5R"M[L<S49__";YEPII"A\FE6*3LLU'EC'X-D5!#-"Q6&H5@1&D
MD^&A0JF$K[&@,990JPJ$EGO^%I)@--[ '\(L_ =1+_XRCL/&7Z*H>-!$*J'T
M8X 87P5/I]NDUH:%B3\&!OFEY!_S_U">JI5*I"J> A,F,'R,%$/ ;#(8I$(/
M!-P/ 4.#$2B$+Q8"P?AX(_R@&!0*Z>OG[>OC#D;^6O^?E/]#&Y_DV2ZL%]JJ
MYXOA/#%?"'5#0ODP-W<8S]V-#X4+W* ",)C/@Z(A*+CHUR;^JZH)*IV>IQ*(
M_E&U]#^L^I/B?^RU2"LUBH18;9CRWPR(L?&7\#0>TC_V"86&0J$"$<S6)XB[
MFSL8)7!#BU$(-ZA(S(/"D>X(6P<W@OY0_,]J%_YQ,/^3VH5_-IB_U1[VWYX.
M?UG^SYK1_N6L_=/\WRV(?Q7.'R6'E^KT85K+GP0]H8LT_S-!3WZ)'^3!$WSL
MXR8=S]:5CUW_Y-I?%_J3Z8&&PH1@& 3L!A:BT&[N[@*X&\^=#W83(E$\.,\=
M"H.)1;_6_U?3XU_:,(6*5)N@8 C:#0QW@X*#(! /=YB'.](-[/Y+Y)A/[OKK
M2G1A8KV)IQ5Y2VR"_)/0.KZ^RZ"PWT?7^;.B?]V$()2GDHB$FT"_%OSUPK^G
M,O_OD-Z_IW#^<^G]9=R?_Q'I_3$PTO]1T8U>_=?U^.OB_N/ZW?A)#"T/NIZG
MU1O4 =HPL50AVL02\3>"_HO\OZCE'R&@Z ;^:.0H BV,+U7]:TV_N^>3FFRZ
MRL/6@- @$&G_,;@!&.PRA92OY6DMRR"VP85M!/W+7?]:VOQKY4R15O=QRD$A
MZ\'KP;^4^4/>KS'A0+\+"C<:<0[TCY!SFR;;!O#7>'=_)KG_>>R-V!NQ-V)O
MQ-Z(O1%[(_]7-3+YMXBY-F?*<[EIN=>FD>=3V01?WY  &A5+(/L!'!P @*EX
MLE05-N8S $"ITFMI.)]E; YWV80RP!C ),!X  0 X ET:@H=&_0Q<"_!SW>9
MSG83X%_HK0$X?/RWR@T?L&P9X#]CID"MU0, #@&V-$QH,VYLZ:]M:85)K_YX
MO=.6GLV7?TR/&?LQK;5UT):>_S$M&4VO^^6>T?07']-"I4IH2W_LLUJH%'Y,
M7[>EOS4:1+:T(]F6WFV4BDRV]'U;>J7"H)3:TN\_EE6*>#H 8.S4C]?U(D&H
M+0VVI:=J@VB^MO1& &#B5,DG:?XG:;W(K/_X4+YA:HOV8QC+9:L%:Y9!T&C4
M,KS(I!#I]6X!-J'PM,)EOF%*-4]E 0!&G_D79GT<VV6V049 T B; [\>\LE
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MNQPB'6(<CCF<<DAQN."0YW#5X99#A<-#AV<.+0YO'0;&.(Z9.F;VF,5C7,:
MQJ#&>(\AC0D:LV6,9(QFC'7,UV.BQAP=DS@F?4S.F*MC[HRI'O-T3-N8'D>
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MNC0M=],QC]:6CE3QV6*'6\D7Q1=^;-V747#W5')64\9NE]-)*;F^B[>(LD8
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M@GROL.2@!JVI8D=R#RX<U)^A/MM]LS:M7=>^9G?/&695\L23$8M^/M \_3H
M,.&(U^\WC[S77K\IN_SS_^&**ZX_D+MK54/9B=X2T\7)B^;DKKRG-''K,J;#
M*2$X07+LGI6%G&?*HF,MNBNU-Q:E9-S5Q1#C&$+6VK7+3]/O#C27SB"WYN6@
M7*HBG:]CZ@CQ\+V-9S#&/M\?7G<':W*2Y"US+QFU+S?UK2A;DY65MSFC1FXP
MU'>I$[.Y2OWA>5-.5C8QQDW+?^)-<'J9EI&9D1JS5D8DLE?H7L3@X-\)&(S
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M2KHO4YQ_]X%_N_V]2W%HFZ**E&*LI $&3UZN.^JBF>IVUZ%AG@8S>WT6I\I
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M:1H681XM-DUT6;CN7RX_21<!7&DHKF\&C%)C5$B7$0'2!WQ/Z&(,VR[HM C
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M%&1],_=,^":M%K@1K&_FC"7G/N*H(3G=0Y@D^JJ+B\NT\\D !;NCWS5"#?9
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MIL:\X<;%=\]F+@>38---<BIS.E4IKH4_CK.A52P%3_]'G/&5]0,3+R2/J3%
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M]-<4VWOBMK)9T<R%>SWH5;"V".#S$TZCSQ+"+3?QC&IS5+.(@W@:6C"UW\?
ML5,X!?\NS^(QF2BV8XR0= K'7Z$LRU)/XB+Z@R9B8:UX]WI*\711@/-I8*X%
MTW1!U[O"M%A&TCC,=\E/KW@!5OR2Z'9'M^6)[MAT;6UWTJCQ'19!/M$N+#F&
MF\^V-]CCS+B? !?T[RW2GR0I)^OL(A6RK9.DAB.!5V(S F8?NMSGD:^/1&Y1
MU')H9G=:4H^S4K_#35&UKBK(1-16M#_F!_:T/!)L?]-_+T5+0GY&T=!$[7QX
M2?C4_%/4E?"X3-=XASP/BHKUV0L^.S'/LEFIG.2'/"M"Q1P^!PNOF5Z %34)
MK&F#PC_&^H6(A#S^&;[D+ GW7PM<W@@=3QM2G/[;)!(O<,WQ "6TRCSMY34\
MY:,XKGQ,Q-/K/CIX@Y?ZORP6,*9FJY6"7[_QIS2]:O<R=Z-JO+E;G)&WC,&Z
MS-PA1E\4[SE(J,JGAJ[?V3=B+T>6Q")/R_JXK3[D,(<<Z9'#,D5%I967;",W
M224Y)1N+D$N5547_5V3$YQ4PI/Z!2S-J[(H5W^O5D:.#"% = 2MN8I5*>0M5
M%+8<EQ*PIMX4K]X3&,R+CC0OE3;G926\2RCA]Q*$H3!9_43(T3RLD8V,O]@)
M 'QVPD;9=^U]/@<>]N7]$2[&-<^!R;?DO>N:$P'2(.9H7[K+@E'PD6P*DQ^U
M%F296#.P?[IKZ3YCEML;U$&O+QI-!M=@)QR]C8&+80M+,<_O*&>YS#0[7+AF
M.%S0WG",?I:-C(F@TJ5':_Y\V/1%@H-UW$A+<K86<4HCD'.G9^' =AJ8OXEU
M"UM]7[X>6>N2<_"HP330:8%;NKK<[Q*/LG[:;W<]Y+>K(?#\C+XDQ7O9;S>D
MVNCD)&A(6?#J_6O-B?(G/R43]4KN4.>3:G?62!NM6]4>P/C"+WN;FJV :7.-
M!6%8EW0\<#HCOJ!  .GP N5KP8V:8)9R2N40@H>+U[CF(0S!:8<4,($7'>X\
M42(]6PQ!I)4I)BDJ^A?D8;IBXLP*R6\85R.B21G!WHH)(;(&)/ 2).?\N=^<
M'M^EV;]8BF%O?.2Z;WQ+4M]_;&6'=DTV5O6O"+_\VUM"O'B/G,&SA)5=B Y8
M=J6+X1V[[T TPT 6E],FU:237K\?>VWF*=!B36.ZC[@N^-#6$/^<J1LX&NU9
MXUTK]UI,>&%C:-:?L[N6CO=JD2( O5?.?Z[>RNEBX4"I"&![&.S.Q*>5YI6
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M42G7=MQ!MP\W0TU2=FVR9!ZNA<N^\1ZTAE+]E.Z!2[)5__1'LDK4['I89A+
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MGD22%PTI4]1AS2N;0O>LD+82^,E]Z'/CQ+-V04_\?WR<?ZUL^[)9OGI[[WS
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M"AWJFM=:--]E(PYG9A+V$VDU)R9SX8(]#=K( .P"PKUCR6Q_[J2^8:]#?(?
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MX.40';/F*>9JB8"_SY$ZST-<L;F-$I_X(SKGR\=S#_<D@%%P,V)E:Y>Q:S"
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M6PBL]RZW9 NT;^QW!G<(,KJ2@UH+=:> /RV^H5O.%";DE,^8FGOF7P7_AR'
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M2;$S9-K94J!6!YGFR,_N0.S6$1F%B"08Y*M= L5AU-[E.).]:IU^D2MFN#M
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M1(9'&=Q]M57/L)6-[E)SQ*0/F%<UB+*S/23!=M^56N]>K;;^.94>-T\_N58
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MN8\8-A[JW-H]<O])O[MHG-_GX _\R'H$";!PMMQJ.8\"F:SX)"^W]P]B^R=
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M>H=W\OS< L0[$TCTS6V(U!4W/MS8828V/52E9P>]EI\8NM8FU^##\^:?1!S
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MT=A,++P=<GS ]/Y4*3LV#?>)%I5[3B.@KJTL@4Y I!8H#5'8<<YD7SD#'<I
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M?X3>HX<=<$$]0B?T<LG.7;&'G@F\VR'/UF/0>FO-C"D)V3V>0MBDT<776S7
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M#J0U0_&1MD9)K^Q!9G+?"[2_%@6!3 -1Z(_<SGUM,&75^"XK;MM_]!0[M!?
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MVGXVGU-.*FX40NG>O5:2"!7/>NVB%TV.^M!&2$/J4_;1PKQ>'PASI87QM>5
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MTD<X]<88OV.PS84$R'"Y@BZW7*G_W99U17'?;DG.O4[&;LD#Z<X59[EIQ^Y
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ME;;+8TQ^G14*UB0'#U5FM)BUZ7+WCTOI\PUY&%]R;+\:/@N,*3A$+<5WN"J
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MN9<QKL?5&?W]0Z"'QEY1D@^>TZ*<VO(MJ,D18TVV:IFJ2A/R!KEE#M\^)CC
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M.CD]^\P8= ,Y7)>0U404E>+Q_EPN=]X[!JO$Z%LVNQT4&$@,*Y467NI/^\;
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M.6L7'O2#ZT2*WMM[@Z4D@G(L4^I&W)_X%Y.Q$T.@#,4X0@I\-(I]OH2KW R
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M#[?N"\2^5.D0@"_#9_3#3QK(7Y9+#&@8T.X\L6'(E^6V9[WU7_..CO_DMNN
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MW4J/:'&X*8G1O %;D\URFV(BQU F-_:D/'LG=#K^JD4<+>K1/S6 FU"HB(@
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M D0Z&>92WX3-AQ3N&@GM+X5I5:4'IYN:;EUX'3P>]G+BDKD2UQ+$$DM [B/
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MU4G1'#45=L&=J*]?-E I"V!;MX&P#MMJS(ZYRKX_0>,*@.S "E&U=?TM,E:
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M8JXHU??SL&KM0J'9,.F>$TL9B]65L9KHT+96Q4*A3K#V,\8^?&YXN!NZ<R[
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M]=*P,JK-W79BCOG+7$SY9VRZ2=MAZ]YO+5NSS"?LK+5M^HF<UFXA_X_$RRO
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M6IA)VX\I,!*S?FR/K54T6FW-NRKUAPZ^A_[=U);YI]YY>O?P"P(X.L;'XN=
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M]Z]YO,8'_,4@F0_P"DL[N#)UY,*K.[;D [H-0WGH$_<HAJCBMB+R5(KY@,9
M;3[@!_.#/\W9'0J6(MYQ^8"9OO]M;8GK)[,^J&A<TJH"GI>L90:68,@L&.G
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M8Q;9"U3W4;X3)D*O*%F;0DCNX4%\0+>Q2*U1K%;W".N9&VL&4ENUI83+S=+
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MI170?4/YCB_C-FCXIF^#XR 8'SHVEV'Y>;-K7!#14^&Y2ZE=J,NY]88,0WP
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MEG\NJWW("B/ -P?NJ:^-;4-EG5V8:ZZTF"QGR\>VXF19I\7H,S%R*/:/@.;
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M!!9[%I+F.AN24OHA994Q[%(^P>5KNF%J0Q$^L+0Y$5MLO3!MM:SQ5R4^N>4
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M%&.5)>\%::&.'-E*J@\:^1JTIRV%T_U:.(\N YL/?6IP31,J.PYL"9]NM.F
MI<MC)Q%Y7.4+T$:,O?%.L&K!=M_(P;KVEC&-KVMEZ]U9QV*V>3(+86H=,IY?
MLJ6O1FA0(,]2=%L6F4>/_Q/Q8[D7)O/S+:4$][G#D3T*9" X\Q8Z> .:/4N+
M&9>5TAGZM/>^;5XJ!H1$-7'^"!M088)AK4=-^G9VPR3@ _\'=C%V#'O3J@-'
M#&]9I2::'(ROG-C+A_Y>^C1]';M_/5]I.@84U+T69#NCO5>31(S%)R8\L-!8
M\YUTA<58+ +7/R47F9.=5W ^"0Y U:3>&O:+4\B8ARCX$9T'10+G9Z8F7;[_
MX'-!OQE?Z?WXN[?1,X=OZMF3KPEH9FS&LTN^3R#NOH^Z(ZG?__>:=6C/Z.MS
MH?*3;H4$*F7YO^[X9VEJW;^'2'.?#<M8,C$*23+ER:>!OFA?8FJ67</DQ[WB
MVB>--54,M5U)W>>I UXKG#WY<:.7!>$V@KY(%,XZ8O#!\ITZZ;$3?>SKH-8,
M6JXC7,=4/037ZHAX^]LD/%S!3.<9OJR0*J?7*>ND\8B$]$Y_PK*\D1HBS6JK
M@49VNSH]7* HD0 ]3B//.)51"Z7NF=5RVA8!7_@I!M*<U0!"DEAN>[8PP;7R
M4$6#NN?!&)V[/E;(JZ%_@CUO5F)2'6_>A=;.ZDG6;"HPR"ZS^;1)73%3 JOE
M=!+&L1CZ5'_6%=,V>+T24>[$>5;$*AI+&S]LF8(Z$GA$6%9SA!T0:!>'[+1Q
M/2@LOW>@'05L#NNSD)&?764 9XD(96%KO2F2<X,TVQ]*,OI/L,!=//) 7A:T
M[^9<R]-3:+(33AE?K#2I54JNNR0A?V'$:'(_DC%A%Y B@U\G;3.3DU9L_0)?
MF1H?@)Z.UW]Z8^MWY]WW?9\9?H^OXQ(_>6@M/7J3B"$E]RF"W3P90QT&KO:_
M3OR[+]]P634>,)Q4+KIF@SJ2+VANTJ["Q PT-8]GQ3B;)G5$HHXD0IOS@?\=
M_0WDHO![TV\.#K^!AQUH0!,7<SME@,\]H#I'0]2!_)"J4\G[*:MBR0!M!OB8
MG)P<W^_<D':U6*Y.W*;5$VAEA;I?>&^RP>S4KBY\S>-O*U;$@P95Z7?0VG=#
M3SAY$Q#QCZ4M/]-C;TY#1&Q37^.I!J@3_S=.MZ\_X:-D5\''IC-H%N,X3[!O
MZWV2N;8J<75]0G&C-DY*>)L>U]Z^O!^2R!<\^9+7+NDX4SV%RKA48"99Y5BU
MD.K5YOI7E"SWMJR8"_+NF_!DW4KQ]O8GF&@<\;58=]6GQ>;8(;I:OA)*^N-I
MT4?&Y/(&_47!L5OP@M:-31UAP2R>2Q^:3)I(\*69B41KXO@NM(_)& 75[ +K
M"2 1 C]%>8CY-Q,CZYSQ>5Y(@,=K[3WY,9?O:WS^S]ZP<JB=KYSH]2@APP3H
M+O><YK_/K\Q1,:@X@?FX@>WO6EIL?8NUEKLBI/!8HWZ+9F>K]*?MUV\PM]]%
M%V??]@PVU/%,3V;3[R*@BJZ?GS[FK]RD5/GTOC<AX9'#"%#@E*YV6%^0XEA+
M"JPLFI 3.?EQ"N-<,;O9FX%O,A!8!K[0,@R%RHPRR+[#KCUO5U A):<9,U".
MV0G&[TWLFZ'C\54!5FIP@!%^+B1M^ WD3%S'-B;6\5PHO&W,CC79^$7$_<\D
M] H09T-KG+*7\H.K[R=EG!R/#2A.J@V)2TEOHGZQA]>9N=G_?(B:MTMY.N:X
M!M[T1SML>AB>SJ'$=E@LSB&Q7T(298&]7TBY[()L2@')Q&AU4&H^HPD3=AJX
MQ=>/S<ZJIX>N&&(CA_K3;^N".@TH#%R>JG"*9-<@AG4HE]5JFDEX"E>;(G2W
MNGX\>W8+()&56W,QTZ-5MZ2TE<T)JG!?B,YT!&4],B_\@21LYR$9R P%X3#$
MGFG?<R'__3\IH(U(L[XI< 5DD%/0J G,8T6P9[OW&$ZI<G*C98U<0"J@",1M
M#[=IPP!X4X]A#>PZ*55,K(=81RI2D)<&@ZH8/6QE.4WS36<\1S7Z9)GIKH%:
ML-*UI- -M=T;?7ZI6UKHFB<8]-GB]9]X<6L_;;-<MP-3%P<S7\+G"A7S-><-
MBMO2M<K'BWWUX)\2L;UT!)R#FFR6>B#<RM-KS=.8U\#I!Q$#N(@D->FA&]P9
MQ6]..AH4N[!*BM^ >-B[4(^)Q<!6.\F&<%F@?8,)HW&^ZFQXR$'?;F[%[3\P
MHI1LN$AY;>RP;O1.48AOK(#JR(@_CON</XN?"]T<J#92$RN!S%/77%S71:@J
M%$9VE<2LDR3!.=K'YX7)YJ-[4 5=XJ:.*!*J^EIOV>Q<"&(RUTA"G@O=[^(X
M'>2%G3Y^PG :@;R4&XF@A2:E!!J^[1HD)VW0+[0>-W13*)U55F9+;+D9]T'=
MZ2:O!G?' [-KNC"][:3=)E*31-[5P?F83J@K2SY!MN[C$;B?>B-$MH9D&?5'
M>C&>>_=L5K1Z?A9H;/AR*VZFY1\C=>=&7=QRW+"6O7!G-"6/KCE+,'6K;M!(
MWAXYC+UA95HWFY<8>2X$WE$=*GPD=^P:H=58<BB9/I>XCEE\8Z^^2DQ&8L6W
M@[-[_G0,AMZ<4NN;*OF18FC6U9>:L6B&?!=#.@ ]X8!_T=@1I"<N,(4G<)65
MNSF_;HOEG PSYJLB_>+J> 8*+$PWO"8@^HV]/\.YVPK4)N?ER *P *GN=E3N
MU.,R@3QD=,.7(R@&8'S*2#/FBX8273:9,\6N2\Z_?R%>5UL'M?S@>].JD?F^
MFBY7DD>C[\M5.%=U#1/O1-MZ_^7C-H>[RP2$/M>IQ$-;?]M&&$9U<--PVK'R
MV.9I>ODBPY$&&[0>*-FI)'?>UM(BHBJ3A\6[Z[JETMY%/NZ?]FU/>+=:)U"L
MR8Q(NZ:-Y?9%UN@.U<)_F)-V8I\)_\S]Z\/[_I=R61@2.2<*XQHX)=LB]\>M
MOH$/_OEXU?@GD.E%$]O.#GIW;-!GE!K^;$827WX\%:G8=27/WM82H]=VJH]#
MN1(%+&)@#BV>T6V8=MD@K>1T6E<PIYA9@P@[=AY:FJ^N<S?(),R7VE*4(] Q
MD9JF+<2UL0PDLNX:Y\C"Q[;S*E+%+*A0;,C.]L^)^>"XX[OZ8G%GPPAP<*#<
ME&KQ8<@U1FU3T'J(QV*;5JY,7$=GV]K9NJ%=C8&6RW1)3-L.1=QL0#O8=M_*
M-)#2L.5QJ;9!#+?!Q_^"_G4AK#DVI\O!02$B6H.1QU _/:%N1(861![9*!N9
M^3BQ9^;;SH6^P4ZY#AA<WCG#') $Q/4!?:.0[S%E_*'H!]SY>)C<%+A'7$<*
M#/1JKRWV 3=]K-5,4"@IL[VD^EI?F*1AS 8RP=B)N'I5M@%ENE$]((;<V.-8
M&.P](9C;FU??*;GY&4)M1LYP680QC,!7?Y<C.%V(R9/;&1HEL>(TFYYSI==O
M7G;A=#..K_:\/_E0-5_^[N7]"1X44P\NZUW\O:?L77FP4H92L)V3BF;*JW1%
M&1# Y5['F;Q,D^2H S0J(:=]PHQ*IW2\'(AUH.5$BI_$'%OODIY&#&:FP/(1
M&.8(]19F)A+N*S<,[:+)$G:OMV1/CS_RYKJ!F)V';_M>J.J7.%*<O4MMI?P<
M.\5-TTNYA"V/__"_\JY+\BS!G MIBH6DUX"&EX9_\<,%TR46LEQBT+B:#HFX
M;])+F;_U*30)$\"JKPW+/I>G)2NV1;5LG_R*F7>[EL;<M$I6/M0V7@Z.XZEF
M0H0[+;JM#M8C<Y-'X.J.6^="#Z, R]B73@/6;>$<QY.U^D'+H-S$LTLP5\90
M6GQV=6A>/H36TQR5'-4;H<"5C\=GXV_A'^ AB]X[NS>V2;6=^B+&RV8:ZJ8+
M(:Y,4!,^.>7=KBDGA#*]1EK7C'R0 \G.:E.U-*F,<I9AMBD[828HA"[6L+K(
M9ROI"_;J2;CW?JFZ,CL[]]]Y1G+RYO\.[Q3YX!G1527V_HN%<K;(O@V^YF']
MYY!W1=32,8;$H.8C".3T#H,KR.<Q#J)-;K._5^&Z5Q9P($-ME@X?%[!IJ!O^
MZ[+58-K2N9!A:-S]N8/(Y7FD)=CY&8&>,JZ%-;PT%-/5O[G!FK#!KJVL3QT/
M4M\'>H6\)P2T5J'/)%M6F447OSMRZ+ 1:>P3KB$36&\+9>6L0J 'S9=F#*O"
M.RN:*V4&:\-'/+EZ<B5_;^(&_#HKIL1_)E%AT5!Y?-LH3<-P3T=@S[+^:B'*
M>&6,^O5A2O]T!'\:TF.$Z-,8-R'7B,-NH*-@=XK\DW(W79P$(]I&=JA'.ZH,
MHCEEM^<?2GH1,4)&M6W2V'O2.0+V*2_MFKA5-_6*G5M$!&Y;6N[OCE\.D RW
MF&FW95LF[S \)M2#_G-A);T?LWWT+;,2-7'Z5ES+P0_ 2,O@]M-!90UQEOF6
M%>E&0;O^-K6]+7E89AU7.';1I@-_))"[63L2\CD+K\C%+A[L?]M4F=Y*+=MZ
M?']^'>$U0-0\6?5PR!]FD&EU:WMVBJO7LR.K-ES_@-:,F0PZ9W_('+7VMFCV
M:9CT1FI8D-\^&@'ID.X&9GF"NP6SB^WZARE]-Y,#0JSWU/2?SW"]<ME.B4GS
MYMCQ4I9? SCC*&?%MEP:/TNU::^MD6X!C+1,M9HJ#_A9*\[7FR48P,:MF*W&
ML-F-?M[.!8:8"\=^]-6-O2=E5G="Q.GW;"Z@:G"A;+-."UXSAJ"[?"YDEG:O
M./E66<C\D]F:U^\_'C[@7-+T.U5>.!?Z+<HL_\$MQ9.+X.1^SM5R-T]Y:PA<
M1EG<RJ9 63+"RBSI$,67GYH9Q/ZY3#DVB)U9E'"7E=X7]94!++IU&\"U5<=%
MU /"9F=[-/,((?KK0U_JR-KYHT1'CAT#V&P!6_/;*'JN +F+'6@(TZUH=QFD
MKJ%QE1\5#::L;E5CP_L'Y"N]<!@CB<J_*AU+85$>^3&[PZTER;+AZCD5[H :
M<:L(G#87UG]J 1.'J:FK[\+@RN64J,<K1H5MOT];-QO(PA8GP1M+TTO5U*M^
M\?4TX=+E 6'=$UTKDX@8R_D4D-]?;4=\B9CFQ(JJXH^UWZGU*_@U_?AWD+D"
M//>(<3QTP[K-0 X9:/E;(DNQT$EVUER$=N-A\8']XKIZY'R_-+257>&#"0#,
MOI0FTR0]O6CB_ Q/3SGYNYQ.W0-]-5TCNS:UG<N,./,-1M!(&*EE6]0+O1\B
MVE-$*[_SNK.C@7@[\0VP>JD.9[G  -\N:5!]736[LR?_C+$;?6$_G;#I08//
M81H22M*69$$XZ^6&9.OL<Z$/E;/&LXN37IH0C\A2?I6SBSVF!"D8%ENS(U05
MG@OYUC*/VNM,HS)MZV'K9APOJL.= !.@QW45@7C:#[SU^E2 *=-%A(1Y+A!L
M[ZWXW S\-&,;'4[QJH O<^=X.5<;^J K\&"@9@T_84H_W%7EJ$KY2I81@2!B
M,29317@Q):7'KYBR#/8Q)"3C-((+Z_IB0_G3X#X11HC5&BXV6Y$?$+9\V,QW
M*HP<@1EL;1?9M=W9X3-3"?/;IH,DI@Q5'/&0FX9,BT_'V5[IMJ#[ZC-[T-I<
M1ZS*X9$COQ/>G.0L:;$N\5!J#*DX(Z?X'!^0_0;M[),%E?NP_D-T6>.3MP2X
M\5N16H4Q9^X/&I7)6.=,;M']J)3A&*8CI_\TORILMO44$:@'$8[8@]Q,&V:8
M%_4CG S7ID-WLO=XH>S*0T._E76UIYY!_-Z6 N>)YT/(.7CR1'>>S+8&.DSZ
MQ>'8%WKU_TE$MDZH<4Q&SH7^=(-3%*]FS#B%M;FO T8I?2;%S,#RC)K9D&;7
M*I\7Z!<SCRU%%C$0]X]SJ?AE!1F%UQ+5+(X/I:=U>H&>X)><W;8>;?+  @0@
M$V%6_\[_':A6%Q86[U_9#F<U#)G7 \12FU=Z.99N2K%G,R[4)C>R7S$:<<'J
MT4"#(_R#'-V1%PF2[PQI[3X*;\I0WPTE$9"7_T9>J[.RUP[+%.N1E)O)EVRR
M70[K)NU$6OL.JR88.!Q/G"@NKF!S1BBY+,K,(HY$E/*#QP^7<CNMFN9@1A:R
M5^CQZSIYK!!LX*!'Y%"XJF*[[V'V+\!-<$R*;*.#JP"(,"U]3E\OC\[ HC.^
MT52(BDC_T_Y#-TWDMH3S*%\GQ&<(<1/FS$H< 12&IOJ&HE=8GR^2'M\CT77,
MUH[18&1@0]- "R^RW&6Q+[)M;5S2U^^5V2661G*7"4Q8^/N7/M?EBN4]G[L9
MOBB_147/U!0EO#AL4E7Y6U7J%QP&U_S<0\OOK\OAP]SCM]O/MSQ^OSE8LD2]
MH]6 QOQX\]'(863X'[>5#$5- BN6:BJJ@28FJPYN]B8F<G*>2+3(=V'SPWZ#
M(A77,-#51E\>:'*?X5-<45Q:0?%&;H,"Y>[XQVN-M!Q<SF:/'D]4W/\K-!#-
M1")-)$K*? PT*#L9YIF%$[N3!V?H=5?R2,196)V:;O]9.,*HC,ZW,@;N%)6U
M1\;I1$K(J>0M75[@G8&3"-:/)OR"XM,[#ZZP"GT5Q2$I2A,8T /+9TGY!O"=
MT]&P0>0O_WTJL.E=<M )U%%:?]=HW&WY.)H>^$^Q;K2*I2?!6TOQWJ FWH"
MT0C8:,K\E?MCAH[4^/O AP+(YL,)N?:4!G-!D=<.K"<V<HM>(27>%M++P0@T
M0PPEZ,R>Y-/Z/G1LEK+DO./(<%FE9BFM/,:R\ LK>*?)0,UC$VKS6EA-"7EB
M+12I)9'5.V]_590ZA2A^O0O(8C*S5).Q&>@,K+RY4JT.(345K&,G[)";E#>B
M@Q\JNL:YNJ^7SY:>D?)ED7&*SBQ2=37,)ETT,2DO+S<QD>4>H3MUN. UUD)L
M@0P/W%-Q2>_<!/6N;5"?FFE*^57"?O?B/;P25BO?HE99'I,)R&)_\TM P#^
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MUB)/!Z/,R5S_Z(JM5P.D 6,\)[*G.G)2E81PTN^I 6B97:F^]^':S:NF1(?
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MFO2J036YNH^/FXY$]36E@6E6AUCX072WSUA?\V,CXX'X(F0'K>;)61SE?>/
M$Z#U[@9S9W#K]*,/A3WQ>C3M#-3T_=@K/_EZ=(K-TBS%LF_&S-13<,58W]RH
M1.EFM'/[YU=\=)M:H\AYT4+F*:B4RH]M5X4]M:)6B%>-OQ?P>KEJ!G3UATL5
MQ6#>U)'S\O+FO383/":WY"*'007F4JIYZ'$T']^LZ-9%A\O%KS9^TRGG*#\$
M=^%(F__/H[SIY26)\QAD,JW^_7XU-G:^:<E^RASNX[ID@EW3NVF:Z>V&+SIM
MI-\&4?/(D#%1D]GS4Q9]W?)<46-$8I;HXJ8T^WYR<*A$3UYW__(EDXXFB07N
MD95N9T:B7*1%W8(GMA#XRCM^>8$<]2Y0M:Z\HYU<.F62=_WV'V__ 1O_M7NE
M1%9D@7@#L*8M+R\O\$KO?Y7X6WYBFF=6[^VAPN7KMF.P%1O$K8EIUV%,*.'(
MP=C(]J=GR17I(2JF4?4?&2N!QH\>O )J# G)OSK\LBSKP:OAS&:JD9T:.A<;
M@JK4K A%(F/[CL,K@.G\.\72KKI"5,^O"@-.787,8EPNV#J>?6MW7# *^R)9
M8N:<$Y@<D%S;.N0"]^7.8VXL$(4VV0Z,>DV86Z !X$#&U"2Q&AMZTNQ3I+&[
M4,ES4JQG:5E1!-PXG_E5FN-]\HQ-_)4/\&2MK5.]$O+C=W^,2,@^VYJOK&_Z
M)M-:.BQWHOOZ/9GS62/&%[^/3FF&7?SZT^C[).)MI<;?[FXZF[07D;:X%V]_
M,AL2"(^\DRL^\"?OB+JMS3;[)/I/_TIS4:,ML FR,\U?D#G%R#F YGL3&)%)
M4A=&>6S@D_>-148/RY,VCEG 20VAFD\\KRJJ4+)YHJ+ZWWX8FD8=25% 'KCP
M:I""2_"N46<=M,@BJXR;E.:&3,B(VF9&ZW 5;ZL$WT"+,F1&]O,Q"87\@^$[
M2XFGHVWZ2+@7P<3,-;L!.</IK-+I6$OP_'%ZA05_Z8-S,&]'$<BFDBXA/8%:
M,&7M2\G8.*&>RK9QN;&/'SK$0ZS$7Y1<,S975>YL9_>9-:T7"M8G[^)A2*B+
M]DJJF9D9_*]=)0D;US+.5VAM%TO%C05:HN=.YCVZV; 8M'Q&EY1(QD14Z+Q.
M3IJ2<8$CN7A/.?0?$$S(]="0\I?9'V=>6?T,'/2*;9K#@25 O/Y?9QUO>>4G
M]]:_O\^>75[B\A56RS,J*]N+.WO4WLZIQ[=\XHFJ'YZ0:82KDQ\?,^98J8I!
M\#?.;OY\"AGO.V]";-*)R$H?IVE+1LOL+VDQ/8WDVD\\7P- 4A''DAUR9>&5
MY"D)50+Y_.-97R3+7_O -$)E0+,D"E/?=RYE8E';1G6@]RRDXU_R[_3P[@="
MG.GJZ2]5.014$N_0.4C#>^UTN.'$/,N:5N*U_<U:IR?C\V[^M@9_)26]7[_#
ME2V]TY0JZI1XCA25D"K2\<%XW<&5ZUNX%EN/3:_\5XUW%AK=?1;\;]USY=B@
M_1_XBTUF' /WF!8B_WZ#3DD^.>_X[;Z/%_W]HO[9&4\/W(N>_CDS'0_.!7XF
M,U&\-.57I&YY9_H"VV[L/E KNYU8&7A<WNB"YTJW-(\KO7I\J,9V;Z/5_%D=
M9RM@O\TGTB=$:?3W:!NHG3*,<D8JB.80$9X3+%$ZKQ>;5[%O20EXT/G@Y*7_
MLJ724I&+J7\TE-R(VR&#LL\WP@@D$K+2/J]!G]+FFAF)>1?9/G[N%/FC74N\
M=F5[@T=X]X$5 SSO0*H3\H3L.IXFLI_+BAJN5556%+O%^:S*RJSIC,:<W)TY
M2E$$'=<4WEA'T7"AEL'=%/?N=;X)%A\P+_\B9I]-G98>Q<ALGM-&8GYW9^0'
MF'6SOHSLCC*SRZ-#;M7ZL$R.=R=S=Y@]98$VM3.__:<4$S;J%!Z+"]YL<!CF
M;@F8[;B-*^0S99N\V,8$=<?3I+E&^]TS&XL@B6CF_7:&-<T:R:1\!BLFY#Q>
M,/HP\Z@\N'W;:4TCTM("YX1$7PIU#W8'YN<W=)OUP.T+'=VDW&I5RCBEN!/*
M4+3TATN'F8@:@B.<'AH..TQDPR=A<NFBDJ]F%4W!HL"\=('2'H +#/1]"&^G
MP[:--B7/7VJ>::G#DFHR/RWY2%*L;GQZW, W="[>Y8MX[%V*HJ=__)!!ZN-[
M@,UWK\90K$ C>ENW?XB >B[%I"24;;IE179;.&<3$]BP/!Q$OGN2*Z8@(5&/
M/)81H @6C(@GQY2?OF1$_\2UV![2\>-J<F=B1(&,IA^[J5WOTG^/OA%2#!R1
M.MQU)S>V5X1V9&)R;W>.#6[?#0A$,=/]PZRUUD'W;NIH82MOVR7(I AVK("G
MMTHDPNMD?1"J<VA$L*;O71?KB%:FZ_X&?\OJTMYB8'"7R'20[E;$ST_N\L4G
M%A=CLIZWIO,'/3LY4F$I//EW6WA$X$$^Y';0#61>_DH/]*&R8F?8N,\L7T9/
M"TW8ZEJ<JLW^442:65/I4F"K2_?@^G>_89,T*C"6G@T+02.Z89Z3,+HQ-.27
MR]S<FM$ S=W#5K\!O:_B-:W$X_H#(KQ+29N!QS5")4L6,:[.-Z_W9B[OL!Q[
M4Z3A0]IW-N>L 7SO(S1O!'5-'M[9^WV])*8LM,XE;ZJ55=-8XZ6@FM$3T&1!
MF:K?;([[R,([\(\T/XD\V]*4FV^<AD5J.9P'DY[TR1^HR,48'1CUQ:XR;2_?
MC%M;I+0T#+E)QH.*-M,G^ YJ]TZU&, =LT[KRPW7-RSJI1-&[N!\1D]MORTD
M7:"2XQ=**_<N0"*R1#CIJL/U*AI[CK )A<I Z9R.\O^\<_ZK&_TF<H+SB:=$
MM-GYJA,&(1\F5W!V;9IT[RBLT1YE;WVQD)VAY12J_E,@KORH813"RU<#AY0K
MW @$N(>A'I=FY:]&7ZN*>(ETR7DOQZ>R3XS889<%L)'4KY:TC(2=S.7X0**2
M5'3,:@PFV.G #[^KO+)#?<^:QRU.>39X"T$I(E$ %3%05CF@FY),4[''?(?D
MCAD:,PQWW9W:\SQRY*9G]FI')G"APD,Z[P<2W49U@0U0M6^\L%C1+^IF;PQG
M;-,IUK:J)&7LD"H*0FK+7IK)6MK*3B_?'Z _+.6X[@(+W=NX;1RNG9Y:BY&8
M?R\5?'ZT3-6)R I8Q@"?4A.D+%^GBU9'LM\EU^O>T#@/$#*X,DS:,XB(4[L<
M8:-'/7<L3?:8\44:8FDO$95WJ,C+TO=NGBD/XG/U?;S?@2B ],^JMM0+)F$>
M2I:F4^B.V8;9GI?M[[;"VN:51"6#S:U=-':XA?OO:EX.M#? *8\AROG:O'R6
MZK>;;Q;,HYBB66&Z!UV_[JV<W$R>SUNZJ;T%0]H^$5<^;8HV#$BVM6!/RHMY
M[''3XQ[XZ>!O/==N.-.32:NU#-+R@VG;U5NO%65$2Y'-M/;\?YWF@#QN6QEA
MM>.K*?5[0:/LO3F&:JXV>=8;T),,MO)!G<LLC^F^?#FUV5XDRJPXN*G*EA=:
M,CAUE.:'*&YQ"7Z'GWBT1[2,?D$+46F152?*(<TN;>,W/<W.L@(0=@L;EWKF
M#B]=9=UK,CM_G%SSR<,GF;K(L3.S_5C1UF C [8#-!,[;6V"3]JNJ*F*I>CB
M3Y31KFLAZ]K?]$2Z<A]T,U03*87&#0S)U@<&1'L4[WR;879RUT'-%F9=T%)S
M_WK$':+[[LG+\KFD=TBSH?I-";?:A6+5W<UE;Y2G?2&;K+DS5)W)G?EI\?:;
M?__G-+_"-?2M2I65K?1?[AWLR6 ?-DP03!.@N^8VI #KR5H$(M#TWQU;#^+C
MN:')V(7Q_?-;N% L80P\<FK'VBA6%]-,W)T$V1VQTL5]#;-/1"TC<ME^Q/#3
M6BVC%CWY=3VY6_56:^/'2IYNTCX7Y1,/XYZV"OK8^,>I+B=A@Y;>14A[EV<Z
M"<2OLF1(AH3$CE?TB7<WM?M/NY[A7V$3QW:X= M1S,\%S&Q2?*S?2\M;;:!)
MXF0\J3P$:OC4F,\QJ222:3']C8+<4SV1R-IO#CS*@/*Z[H=>0(MDB^<"=VSV
MMK>%7HL#A13;^"8F/03UWPL17L:WA!U&ZXY\J/\Z'N#@9^23/+;/J5RR4<#G
MF=M[C# 2J30F1E0C2 E_7%- )G-]Q\3&TMI"Z/1E]8!9NW;L.&[:]_B /!_Y
M0=%NX&')]/4*7(M+C3?^<.VQ4#6.))"=:4VGU][1']O29[_^\&OA#,TL0*WA
M4!^N &=( -$6N*-'R\*D,W^DAR%#]Q-/X9*:3UEU(T1>0(4MZ"@<IT*?'C#_
MP_;GL]0Z RGLA$S54MPJ)MY<0 "I-EOBIW[W7#L/#QCT!H!@T.F!E9RX1H%R
M$H68K U-N!,XJX@IAHV%J)U9C&R/YEQ4S'[-ZXU0%UK+*WG7^/7N<7:U?ZO.
MJX_V>](_HZ5';-1^@ 4YO]&S?9Q5%O&RKY503%A_2G#!^!HQ*OM88N-LT?8M
MY-.QW16Z(-MD:7L#TZ?W<E=[ EYP2-H(U"3H!SF/&0&' GU0/A55555M_*O#
MB/W_H0S:6H_J=73<ZF"M$\WV.9-LA''F-U/H]9NB!B->WZF;&CTEJ<Q,[\FE
M"*N YZN^KZJR"915>>3O^68FY$;G-0_4B3)2,K<C0A\)<Q. 41/\(6)P _CF
M1>**GF2IZ.G%ZXO,WDI"W?Y*0S-L@]&]=FI?+S*#;PV)QZ4:DF=#2([?Y1SD
MS>*YFLX<F77O#8&O1O7'!/KQV]JW+<.:W91& YD"X=%"%-3,>/Z\/<8W?+[+
M<[VI9C_TH- R:B=] M.]UAD0$Z83Y:=Z<-UC<*>]G#PJ <@9:GJ'Q[3U,M3T
M^/PF6KE.ZY[90M@CY0K5W6;;-#=)WG8B8A'UO#%Q=^0$/XNT7"#&ZWV6,L!0
MG]#%E]1NI _@+N\(PUL.UGT^\3S(!!^ .P%:89+HG+3A_MU56O3:P-F@W?7L
M.MG0XZ+J,H1/>+ ?FE]?TV?_5@)*E4#WWQNI/UYPY';,F.T.9!U9?]6BBVTI
MA>;8A3SLQ&=,'I?Y[?I)Z,PHRBT$ND<2VLOI(UH61:&ML3O!EP>I?F%Z_1 (
M ],_"U)?EF8LWY,/G#A%39G$4Z3;CZ.26U(4RR*Q$G(0T^Q?9I[N:.+U:;RJ
MRP5*5TTY)_)6S)U)=OH8HS.^_GIUY\Q(N'OC &6W>8(4"^HH#W#PKFY\=(-U
M02?UXHRQ,M78'=\<NS5&NTL 6:&_=\E0"J]/!D:9=$C+/K/X+&SQ5FZ!5&B^
M\M/.OLAS>MDGGN#I'L81<#Z'U!!%/]'[K!&%OO1KE_(/'A4$H3[Q.-0UI[GU
M7$<X_?%JW_[ W'I:Q'4K0:T\TS=28UJ^0(6]^"<R*RMDC*\B1$DJ).UW"S/;
MU&-)<I'G$E&O$*S0N,8RFS6DSW4VYE('5FB37XAZB/;FH%MFP>8N!F ^Z7)<
M*5JVP#'/W9)/JK+J.37>"UUD-61K\*AZDHP;0O )HOH"_]I[%^C\Q_^X(:2U
MN"Z\'$>_9A0,OFY^)%TYA9CX7YR]9U1;U]8VRCE)[,0&'(RQ34_ @.G!=)#@
M)*8WA2)ZB1%=B-[KB1UCFH0!TP0(FR) 0I(I$B! '(Q!%J*8)@$"87H1O7>N
M\]Y[_WS?K_.N,?;8?_88>XRYYYK/,^>>:SXIVH)/FV*D/N3,):;@'E(VGYPW
M)?,'=-7D&/IF+0B,#\*OM&3E^/ &&XG"?9>V=<[*9A? ZB!SH^SJ34@IQ4IT
MGU<_>HS$<ASQ[2DX@!SY-NZ>B]F1L:>X2(]QL&'?:$B_-XNG$1N_4,U2)-9B
M&ERD*CR^L5$H^!F^07LRZ1VH&%&'J3'[KL#!T/R6MG-<L^D>P73-^D&5GM*R
MOMZ%[V(6UB-'?;2$C@N*RU\)KW-FBR0.TY<VRPJ6(R=%P]:&LHJ1T:5P*GZ!
M8$18BTIT*W'X]62HMZX &'/2(6+T%U[?>6^85EX=]QBD]:6.7BZA/&\U. M*
M^HM/41QG"QZGT2+&$\4:K,+>-@/!R0_4/&C4$;XG*34$\&Z24MP^V'UPQ$C%
MP0F#@4ZTJ^]'Y7XCB*D!@Q>&/*P!$W3+7)F.^6BZCS%\1EZ!R5)W!3/HI=Q8
M ;"4A1GE0?VT\[(V!A<O@O#*#*O_A ,;?CC FUGI?K24*0%)_#VU-^B:2R=P
M_>Z+9(TKW28ZR+C(T1XU633UA\?MGPD)5LY0G(C<"I#4-A8*W)7@;"UZU0=L
M1\^[EU(F77R+NX?N[=:=ZW;LG@HWT18(Q$ZHS+S';V<M[VJK;YA'MY?J13R6
MSS--_9P@Q<6EIJPJ^ SPX:L#Z/Y\&A2DEF])HT6Q\>]HP0,;"+++SV!C]2<B
MWN*_+W\<_QK@G;'W#JVR:6<>/$)R2JFU#, 0*;/8.:B" R'E;C6?DQ.V?"M\
M=I9)@DM^#.#NU7*G*CFW0O>G_Q['>:4BB2WF_SXXSW]J;M-TG+DT-L&#-?FY
M%KK0^0C[FF3?OWBLTLE?28 WJHNL5B<$(.7^)JFZP4V'<I85SI"S\+VP*XZ5
MZ%233K['2V*3,:-Y.*N@[,OX<%YZ[A5,;1B@?W4+G391G4SS=:G3#!@P2D/7
MKEB)8M$EA\,\"CD3=9J>0U:=+W;P2$U+_GJ@G_]B?L^SUOM3AN!@7Z6>B]0
M=SI67#=$<>P32LR]21TG[ZD[.<[-,TQ&DZ.E4:Z64+-5;S7<8EH7X).M3^@/
M J_<A]Y2[=:F/[_?7?QKW8^4DX<E\ +/$BL_(B5ERIGNXK^6.&5VBV#>K9R
M$PWK??BYW1NF$.,)0 XZE?+RMPER*S:(<)^9!!0DZ/FE'4H4.VYAQF' K:'Y
MP,%C/Z2,*%_D A[;;;40+WH G<(+;),.-Z[HW:KA_>397Z..9=7UU'_;9A0!
MG8&4QVZB^6G26'1*1:Y,C8G_>/)>6GD)@PIMFQELD56U.IT3U]\P:MSP]R'*
M'K:V--=WZNILE46+(0'1,$(TKH#L<-(H+\4X-0;%X^ N6YX=CKB0T7%6';//
M$3E[]R(P>USEKG;D<2@VFIR5NS9&NN;ZX)6^+:$'+]<R;O MH=*Z2Z+JIPYU
M-X,/(*ZV@_H^NE4<930%$_44:]G1O&7T:?F-DWHYYC%C 9IKIE LA'._.[5G
M?F_PA.X=>+>\'FS]^5/M?+IQL[%R[J%20<>:;AIKVU^]V6L?5T&1:=X][B9N
M'CM&V^W.E2:6UF^_DN#5_C__"GV#PU?K!2;>.VAV"*'NP>EN'X8V&W60C4&D
M=&2Q^J>: (B3(!"XO)AWM*$I5E=1E#I9"]UZ<SBP6TZZ*:%MVQ Q)!>)K^5+
MB+D2^^'BHLQ(SV0$IG-D80^96C@6!?DWE_'@YCLC8ZZY6D\B([+:Q9OT.YS4
M\NR$^1H*-:9=*N$[A@E#2M&*W;0$4]T2.EQ*M*,% 0S(.[BZCP/LS#A28PK8
MNG8[QXD%U<4*<2Z)Q=(NT?82><<@1M/Y?,#<WN$TXTHZKRX^9FC#>"%$7.&T
M^O"\;,Q<?:B6NX_.C0@O,OYK!-("!/"$@S&?*GL"CS!,S5VY<IKJ= ;-UF#T
M_=P>H6#'*(]EPV9!@V<MFI3'FID+VHIBFY*[&H.$.CV\<H.&2Z>=Z&\.V@("
MV0/M\<]?&U >3F!YY)_<L/T7P80UOZ-"D;)T ,\'C98?Q(6@F<%\%S/Z$K4S
M6YM#TJ 9T)+7Q#67XZ6SHR^BG#6&/WUB4G8O^\)]U4?3I'#5O4&S&Q31QO@7
MW$%Y/OC5AX,OBW9?C*S2AO>,"J8V#XX@=4F/4ZS;9NQCO#J'E,"PE8%J? *O
M<W+J3'K"44J1I %QZX;RLXZG\H[I")CAX*RQ[Z>5X]KJM$'\;LBXP .PNWSX
M(OO/%L1#7]%J4G[A!3\N^1N?4H?XK/UVZ\VLC;(/&P1O2D(^IJ@&5WS-U1BI
MT0O<2,<JL&ZGN_[A"[?&6BM)OJ:;6W/_N!]-;@5)$)-O"]@:1R8>5S>G%A]L
M[.H3:4+)D>+L[NQNIF1^G/\F8;&L;RO7DUP]H52Y&=2ZP5YR?#+Y1UH.<Z)8
M=;/5LC;+TIF#5HE ((Z-A59K<G3$(Y8,#<)6JXW6125K#MI.-"=P)ANHR++(
M"L>R,@>5%Y$OPH7FFD"-S<MAWR^X_%]QT3.6$OT2AE</[V^^K4 -*;$:^ :C
M5"1F&_.V?K+&$^IZZ4MH&0)9,3L>4F[$M >[\QBZ?S>A<7JL#>%EYU.<E@32
MBD[?O=RVB-Q=+,1!2.[A.D.GQU.;ZIH*=RJ$@5)7Y5+Y.8UQ^^9@T'K,$K1,
M>+$KI(\Q,C;=_GWJ*@<_@/@N3"Z!NV[G$P4^G/ 2^M&78X^DZK]R6K@D5A20
M.\D;(;J49CY5R\IDF'Z]>*.^ZJ#]>C!E,QAO:UVT?6-N2?=E]IB.H7F*>22*
M^"8PVQE?U?0YI@C6P&+-@7C417ZQK><WJO_Q(!%-]7_?_3 J9BU+),I>7V2_
MZ&BPX<N393J2#2 5NTRQ>NV/,&LS5%MOCWFW*KJ!P6ZH>\+)3Y^/L-1P _"%
MJ]K2H1_?K;0(YO%3 \XOF'-\35F:M@3AWI[E]])VXI'C?'Q3T6M'9Z;:OPV6
M+^(])71'9X;^;527A">".ZLPU;[-C>VE-Y2_>K@AV/V:BX!*>P=HS0PJ3XQT
MB[E++<Z_E#@$NC3$VJK4(4BF4=V/\=#@7SKNVU&5PDE:/]'\D*D-CRQV5/+J
MFZ_"2@%^3%-^OAA*U7LX6S_-Y)KKC;U6/(2<_"Q( ?7#2%)=VTBD:R2WU\XG
MVKN\S!Q!SS#3>]DF* U3X0D,LWXS3$XNQ,ZV]J/_AUC2X>\1)?R?K<J>W,<G
M"\A8)GZR??(OKCL9G](6TQ9'/#]R<=W!A1<NM^+M6S$(*/+KE1UIK&YK:&AH
M=>LF&O[GM,,69>@/IQF#S/REF/H>@=U^KU#UR>_0_G7'3-+W12(1NT.1;_--
M)N &@<%!)6K@O<$*TKG8L31;#P?KG@% =LS)FZH)B1U/AK01>B=S^B_;I7/_
M^.^!_>O2&5V_YJJ]U9G1NK'UC<>6TUV=+-W.SW;J(V;'C68E9NGEWT6W>GVU
MU'>T@3#3;8 =?J?"%W+-I9AT5A;',Z/ITFF8")B.D3<Y<7.(3M]5]2\\2]07
MX*C.I7/FV ,^R@N[,,6Y]"W9Y.I+P0/ZO?F>%= O"[L6EXIX>>KWJ2CA#(/]
MHI44:;51BWI\R[+.07GS+JB;WMS<V7+1T_,B8PW0&B-346&I'6JEY]X8U=*B
M[BLC#N&L18R#OUTP<'L \*@D"QUC/?.?6@W=4LXY&S#O]FQ Q/EEK-JZ?R9K
M?:!=7!K:+Y/:D1,S$4\?IZ@"'.H;W?AN0V]M*LB':=K>F)+_YZ)VS[(\[ EV
M\M>G=Z4,V;NVPM:S-_V:U0?R\5]]<]"#6R4F>P0(OS .V<O*N>A><:\257W[
M1TEKC.4V0&6^[BK*?*\N^G_J;BZ@FS\P=&:M5HO]IP^YLYVCC'6=X['NDQ=\
M@SZ2&36;&QS=T&/MPRA79Z>C:R[N/(\[7<X8U^GG'"M,:D8,Q? +4MILS,U_
M#=CO_@#[*.)3ZL*6\D]Q-Y>"Y8R UUP.N+@"-[A,3T[G?Q;*+AFR#&E(PRG
MGB$QGIF $EZ^HQ_ICM/H:BQB!<HT-!YLBI/:0[/&\=E4TUTM_T=*41@R!K..
MP6(PA !"4'7+(@LJ9*^EH^#AKCH@F^G5>I\GJ=GKA#B"'XXCVG4[&+H8JS7M
M&ZH#ZH=N%S]21AB19<NA4\NM!(01<<.^%1<6+F:S[U!XJ<^9N* M95YSW4Q&
M2)/2LNX#6C8/=Y:I^L;2\A\3Y5@DB7$DF]@$W3[2U<,22U%G% 55>@-4I6\<
M%:HRNV=5KWK';N;;B_5?,J\0=.*EK7WW*Y_A)SF3T&F:4.T?GY; W@!+&NM;
M$Y9EUY ]Q['W H"2T?'Y+9OLGT3?2Z[5^_U03#ZCVE+'MUCQ XN[.17M$C5(
M!3;A'9LNW4BF^'F9U87,73&9@LA@I4/>;-5<TZ'W&S3'!<=K+K:]5F]9M1"S
MLYLV.X-?"^Q@K6X=N<"_8X^'/M?!)@XRG4 >P?BJ/("UW3!CQ%11W>*N9H8[
M51M3\F9S,M2[*R?D;]&MQDK&L(H*<)2_5X;]I=P3XKAP>Z_IWUS_R/0NPO_\
MYY2<\B3:TK,G<*S>4HTI?#F"8)IE/E?/MT.8M9:;5AG)W%#]>"Q7_O? "&8"
M;7E6_E07<NF]C'_7N'8NR) ///7/HOK!$Q[.C]ZGY<08ABYDN(^J.#-\/&5>
MKW7(U!Y^M;O/6GP"*W.FWFR@"7%N8917%S4U*I#Z]9&?QZY.$S;/M*?2L(J%
MWE&F'05]=L/U?QQ85E 7"_Z3L<64ZKA0N)7=3[E9%T*O?@FN6=PY:=?%)BZ2
MU=BAL?I5P6=Y$6F9Y_"XI*FIWD:^W;7$ PL0C^^S>ZC(#FS/]!$;M07E"R*0
MNYI1.J/B%Q6/0E=PB@_54 FJ Q6D>H"H9Y#,Y@_!+_O0#8J8"5Q#C^*(!EK'
MK(2]E.M3X)=C$&8[A@T</_'NR!VMR ;C$7[LY?7:\A.K@M9#YICE^%YBV1VS
M*5B#83DQTZG1IX=PJ]^7DA#3X%XRSY@R5(2I4]%$E W*:N]*CMD#8[CF%3)\
M#JJ4J[60]KD!'X^-_ L1]LR,M )"*:A?:?/WM=5H\_N]Y=%99KK2#-C%5^H@
M:4UYX!4E?.E\3@S"[9JU,]UB_+NH&#'T0'LR4S !..LSL3;H>U'@;BNPTB?9
M[%1*VSLNB!C1B#B^L+B<'5S;/!Z*RGXX+:[567AA:RAYEH*HRLPF) )8QO4#
M*3[$3]A[^&J6GXP).ZW\1(SJ3[..*3XXA(SYE?HFWS^RXFG>>)9V(2=#!]X\
MO;.UEYS YM9=><>TTE8(ZK2#:7SY;<;&9 _6Z1)>9;AI&E+,D-EBLWMV,-'E
MI;GHL\D5GJ:>Z E2?%TB>61BNT_2D:A\+XVA7AK:GRB;FIIUYY5YZ))27NX)
M(2T],9^A3TXKZQ:I8!& &A5'+W;/^M+C%#EK9RO>:?O_HNWQ-/<]Z^BY!PJK
MW,>KOQZ>JC9X2=868F7BH^_-_>?0'<[Q>!.7'_QRG'0^6#1/<QZ98D:G$TL]
MF0-Q#C<"&"4R%KJ!QTW0JLC4C,@!9N[Q"71^:I%:;%)46%@25;21_G$ JW,U
M=9BZO;79]BSIV8Q$I-"ZF6C'S+FHM+E]IM&SUNHLGC[@_JA=);J<D@"48F,M
MDWF^/4P0PN)3JVLC2J^Y+/9OR <!VLBL[1VF4]D+_Y*\NJ3('7?9%JH5QZO'
M;$A4YB_R,L>W;8+5W=Z3$'?4GRAX9%CAW'\NX>/*U'#^SU>(6RC[W<UV@VGI
M.&[UM#76FSRC$)C[I2Y[K,&\HZ\JNQ+^]=UITIB<:*(U35@RQ]L'#Q49 X/D
M]PE8X.V^XMI5H*:8%6'%M,XR2M>_CIVM$Q/<1M>9GYPK]4R2]L]PUD^GYD,^
M;'2(]YUOU69M%J';@G+YJ1HFI3(4%2;'N[FA1"*)B!5Q?Q;7=EH7;'4U-AT*
M;\,16*(M3I7ITBXRSA:H70NDI!06A\[F^._Z(8RZ%/*XH\A6#&U/T -V1-8O
ML2SUN%>U;<B@7</RD[.@.P)Q03_ I0$1I<H4FIOZ23%!0,(GZ;Y(R%9;0C%O
MEFGW9Y5!W;6JY@<CX;.=IHB'4/V*+-/"T9YXG>I\)]]\4W2.*1II3%<;Z1@Q
M5VC0]GB48W+H0#'N^/_ZPG4392TB,F/FY<T^&A@89?.)2$A(OC'V4O/Q\75:
M>(+V^FI1F?I__,#UIM%]^^'F(&+_62O3:8MQEHJI"=)8+_*7EPWX([NA6XW_
MP[*I2+;)QW#P SL[0VVK7 :9\"N[]YJK8H76/&/@C_/]BQ'+."R%QH%6;'8#
MIK0LS."]K!L<\0_3-LJ(>)E=:B"(I-6VLUJP(OQZ8AWF$CX.&!=43#%\GL(B
M__C;6@/4&5O,K__7L#%5LARJYF"1=M8E(+(4:3O]B;5YY;YO;+"?R?1NR01J
M]N]_J">\\B<W1THG5_@T>RL&OXB=,Z6J.H.LUH'B>KTR&G?NNU6&;W9(7AY"
M*'IOHCA"]!%>U5S(9.GST3?S!<513Q$>?O,MSLKVR!HL[/B6=N2.)<CZ=@FU
M7!O#E+FILFG?RO>IIOB\%+_@W4)A1IM#IA=(^;@*T[2MPJO!8P$7^^'Y.HZ3
MU9M'_R_I^@?,P<DT&(TB43#(= 12/1^-Q\?4UM;.!Z^9 O:ULPV%X\%]J2EE
MOZ\#]2LW&@Z5L&6\K.IGE2QIUV8\((8CLAG/]B3610V@)>Y_Z2J+1+8E$I5S
M@2MFC'H-8C590KVHS.LI!E][%90(B#B7&A+Z6*JQ%?2=L)P_8RAK3 ,U$-CR
MR.RUU/SN(Q \L[IV=/8_L]SK@PJ&AL8R+R)!;C*U_7,'G&I6(@DY)5D3A#Z'
MO7'I5G'Y0E4[MS^23])(9\)>2$$LX@=5_+:%08\N>)29C;TBV2H7-X!/? J9
MF>Y3%P!5E3Z?,/?&P_J0D82+P^_V?3@W$Z3PS9]]:,2'<(MQ<U[-YE 2T^9-
MWJVA[Z22+)85]^9VUH1BQ'*>5K242]0NBT*CEX.?,/R7*;7DF2_% Y2A5U?&
M380,R] +D?N913O4%.FF65^VI:]3!E15=3(J)B[8LC3.AR4F_]$@P?R:ZW9^
M!-,\9IO?V25+L,M"YS@LLBBAC1TFM(8O."<.'H>71J(6H@G85@<+BHRN4P#'
M&UD.^GCHKN0N5_U-!CJ0'/7]U,&%UGM819[*2%-=/-8Q-:NH-;$WX51/>OZ(
MEA,/4_4ORX_,!YQ$'B);-?:?]"E.$W/$E4VK<X,&E=G$1+V.E+PCK.=96)YR
MQ.HTL]Z52K3^'P&'5JWR\O+U]'3KA\$INP7W!OYNF/Q;S5,$+:WUD9KP9->P
MPMS TG<Y7!B2](>;Q\$F4#)J.VYOQ7'-_3CYVP8R<_EA"2Y;,C#STC1;,1&H
MG)8M(5E[29^D?JC!5&,.]%TN#589.]O'ZNOG^J*X@.#Y<#:#Z$F^Q"M:;ABJ
M9=B*!$'NN3B51&4X*S*/4?:KQ9\8A5<W+"74>PXDU$J3T+E96;)%U1E6;+[J
M1%'%B_-? 'B7(.7Q&P)7H*U&!;NAH9W>\>EZAT^U]_RM(ZGK'M;1Q%ZRGJE7
M-;(ZO<+I1@GEWWM96(K1ON\+WS8Z\ &>99(9C^TAM2KJ&!4>9SL[B/1S]$09
M *TU(>.I)RYE9NM)X/5XGK#-A4U=O\U*_Y@LF!9GNW+*]^#9[."#DCD6'/%Y
MJ47,TIL>VI;KVA1=S),([$TQ;C3(OTG_9F9+;FV:(O@L6U !-$Z NJ:_J@V.
MTATL;2&-)J>?1*NON!A\/#_93]LHG /F< 0Z@CT$I*7K:L;^CF&WPNCW^$P!
M>\;<O_2>^B =2%KEZ1K8Q1Q3L9I>HUX)# 8C(1%0%1LVWY4^N3_5U&4V@(-:
M&$(=X3Z,HCD^OEZ?&(/0?+NJ!F=9DV+WT4J#T**B)3[11J5*'<8I<2/+LLE!
MP?8?K<-!]FN*@.%??_5&Z;2!4>]VH=R'>8'';T8D8I#+'?0M,-ZX7B[ASE^G
MRD.SL<K-"2#E,Q4+H'&RSJ@,F,8/U(0"T%%G_D!C=8@3+F1H$AI\Y^.0CLN]
MLS*#@[TV1_PUUZ ]9?;.#_B11O2*<F""52BI<H<1?*'02Q%)J-MG1IXBEXN
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MO(NHE5P+J+#70Y$G0](%_\B/]V;/JC4158@;X5^*-HW5P2(ES%\Y\;/*D:Y
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MZM6A,*.U#1)<L#X:SC?IF/6NK+MR$*A<M9F>5Q9X;UQMO&GL\$WDC^ 1<)>
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M81K@$1&8%D.5 WO]"4&L^=?N4,.:QDR8VO7@#XAP>VWK]'JSG@B;<B7$KOI
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M/2O/V=1 (P </%=B!;K9H2-=_YEK%6O/I91 ?=1X+8>%AW1]FR/MBTN M-J
MICB77A AB;5XY-K\=GC[%.-^P<AA.=Q5]S_=N,*IQRF)-;R*6S&P>ST^+TC-
M$+LF.Z4V$=ZI(L!)29SU)@<!GN4?]JSTJ/=@ 94,RZ8[+=TUA]*$*_OU2(V
M> F1S'U!&[Q-J>8&<9NFUQ?LU\&V</>;%I!>)KMKXKU6DNYH2:W^:SR(:JK7
M5%K5DLM4O/(I0NQ[I_M_.9AKO1)]LSW.&B."I,^B\2)'X1Y"R0SY4'B"RCZ6
MP=,+:!+;%;]]L6G28OVNB;R/<UAF'>$C!MLEFB7&E:_RPJ<$OV=MK0SES6N(
M^#3*ZCRKR20>B8"BNXCJN5KL/LXK&PUK:)W<TYGC2QC?B2@A<FK3@N&]XXJ=
M9M7].6Q"&A9KI)[@-[!I%/Z%#Z(04Y\&-F\NNO5RR6[,%"'#5""ZJEYI?MAW
M&_>(>F: 74_IBZXGLGNL'!HY<?I35/,YW\&8K70%B1SR\B8S+9CL3#>,.2O[
M\V_,YAI\]\XH_^VYM7<]Y9Y#[\DOGD;WO1J',S1F=-_13X;J&B[]29) '//7
MI*'81GVC3W9@>>]#CL1USO%8&%E);]_M_'@Y_Q#XU8:'C5:QN_SPV<,("'&]
M(:RXAO(*IRG9!@:+B$:V-*;3HJ5L^ 6R1,K6&;^O'%@:M=D><+@[;481BJ>W
MCBF(_I"8\H).H#ML\T9UXXJ0J/_N3R3!LWN*CYT]H9G"=30JZ$:(FVOR,H.R
MHJ*RDBX'<[[ #,??<W*O(C4HYAY'7VAI'E0<(&/K^Y:K47-QN)GTR;>P-A^P
M&[&4\Y^%9>] >\-G=8%X!Q<IOQR'_CWGZ]\4)[\VH]HFSL7&3>!X,\N4U/FC
MYGAQHU>$M/H@]IFW/6]K(N'2];^W]% J967&+N,V][UF8T*1)3N%@W>N)QD\
M5R#]S%X>OST05O2--[+0*.:#3^NX2[F_O'P[Z%92S?YUR?WT8JN#>;'^N^?B
M0N?#%[V4G _T@[9HGQ3R?\=@%!EG&:7<],@[NNJ$DLUB.(J H206PT*$5KAB
M>:%8\Y;HXE=;COF3/<CK'''?K5XF9U]=$W>>:9,JMK2TA"]%M\7.$QI2LP6<
M.,C?"G_SYN.[)*I;LD'Q)/[.'"H97+"D9]S!RY$2!WU0VPXK;:]&[YXO.36*
MQF21':);C>Q,]1S9M>,#)RE/,QQ04E1=^U/TEN$8KG)FKFD(CSP%^;%*!W))
M:Q%)$%!*83AR@%,6GN"M[[4_LENX\0!-;.^_]1^&:Z24I[R]L_;[6?LU:9UX
MER"P/:;HSP(;C&!. ,:S?=[EKE#A3*;>G.4,06U!;RI6XHUNE'GR2*&4X8F1
M[O@>U C?<)=*BB"$D^5LYR/<^C=\<TYNPRN*3]<.='2+RU]X7)]-"D >BOP\
M7/,+$#BN\9FQN7R#LKX(IB86=[3E5^5,W"^79*^?'D=><]\CQT;^T*;\@B=[
M:Z#PUV_6__ 0']S1USV\G^7IL#D*^&NFVB(M<.=#**;9K48NJ(LTX7I7]GG=
MI76B/'ZP3CGM[QYE1:=&:T4:EL<LM@3VGBXYT>FH"<RPRQ0777&]Q-[X25US
M(-=^X"Q-(K;G@6G[ 5'FXN>9[!=2V:K-CWJQ)"JD 8G+T@1K 7E]\NA*D-YF
MJ4E?EE+;^H*IG Y9K3O!WB^/& WWRBZ>WD]SL(37:YPK+^1ULDT%*8#B-?'F
ME?R($VHVRV%&'IY>>NQ=_YP5T&H#!@Z^K:FNJT9D&C2DKQ.AZ!AYR6W]+DW1
M5E5K45JA#X8- %3VM@O"7.@JYBF8@YY?%+S_&P'^U02G3BH/A+-?=_VV</5C
MK^;$WY,);76#]8VVX%GQ7G"$0>'XK:Z.!07MX$1D:4QQ!W]=]2H%Q8U%@E[A
M^A!Y!Z8_'([=/?:]N3K[A,GH*QQW/+CH#2O+_'CXR*@YYGWK:UHDLN0@#S W
ML^YF>R7T=7^=4GNOA#0,$0QVJ<FZLFH;49G#+U%EK%$/NLPN5U'FO=\[A.=*
MGC]0 CCL0?<X.V.7>T\[K&\9N?>YB\1:=39U&P:I'94\VG+@?+?/*Y@<;8VS
MIG$TB":&VFR JY#(BHOP49:26^@H-#3JE,YFF9J*6F3)USTK%2(T!W8D?7Q/
MWF[,4VKG!!I]AU#6DG-><(]_36_\G'Q>X@KL0DS%>\;<1,OX@9E%P-+#>9S"
M5>,RT92T3V83ZN?&$ +)++/V1"4LT^THS\$?I91!$?M&%"+B:LM-3Q"EV,\]
M@ ?%P':LRU+X'^R:'+]Z--EG>\E!A"*=V2:(Q0[>8%EWV"0@*EMMP8\MBG5T
M4A,C=Q;NYT]$YAN%\1]EBG ^@W[Z6NF4.'V&$0N X:>>IC"B=\H-8,K9O>YM
M)BIC3M.$,(^)=#;.=,V22W%(HR6CZS;0J**OD6?P"]\DSX.&KSBP9]1Q-RG2
M8R3)A*<DS;*9'X[_?*Q:JDM,S^O0%3KR*62U-#V0<:[3XTW*H*3QO0S9KF/9
MWF*!)(-P[K+AGX'AK_&''CN]]4A\%S+,Z?C7;]X@]B\\[UCI3S;K);U8M"K!
M 7Q[6QBW RTA<L1M7>'BW#+I7+D_&NOP-A$>(AWNTMOE3AF#XNY]AO?(\ L\
MYU3@IT"ZUL'B4O(A4)<W%_^.T!._U>A.J(C8[1QN^),;=WGE6&:48QS@U+4F
MXH>?M&ZAJ(,8:?>>OBH,ICYH#-04$4O7%]%WY-$33"0U#L=@0Q.#1<H0G@\>
M:SA-PW-JJ80D!H6CI9X32_9O]Z?=<G,8-GE.!#?XGS\YJ+\#_J"]^<'@/W:!
MGM"QS_]NZ&<S>]-_B7.>_Y'<U'Q9I8%*8,N9&:"=%+[P7:YK)UC'9_S^,TTP
M=;4..H+8G-(),:DQ7Z,):EAI9Z4L)9:Z.91%"ZED.MB=#>B<_K75_O9\+4^/
M&;-]9<YYTKLH9'OO34;!S(A+,BV:Z9L-'O>)*W4L,^$(F/PQE' #71H1C\6_
M=KI0,JPZ/CV-CT_0@PKBZ[.GUIS;'*:2!,OI68^.+GWD0]A-I@#[L;**OW]5
MYIP#!:1P[H,OJ/]5,2,+X:+J,R1QDR2=.)T]\^DH-GII>U/D!LL+D^T&%F4[
M/']6URDR<ANAUQ%3D<-&49S.LJ\-CH=&OW>1" P\DC6:S?.^Y!CVR__+WL!2
M%[AH6GGRJ2+>:]]<*"1?LSQU1!H&BO,EF*0'#ITO@GH'RP-J!>7K"R>-^DNE
M7W$\,N,/+SJ6]^ #(1.(]MQ[:_/X6WTMS: )YE,,T&^./:KDV.S%'&:?:9"D
MHRNN;AKBV1*9T-6M=CU2A56LT)#GM&2,=\>YI?M4B;Z3SOD/VZ.EVGG6D^JP
MG$WI4KE_.)CKH#,*SP&/AN5YW*AK$'1SL-U>$U/)VLV6'I[W_6>2P_!N0>ET
MZ70<-EO:GNCPRJLQC_KHV:0=3'W_,"Y)SE)?-&Z'9]Z2T5T(F9XE>7D"()?E
M9''--2^ =E3*,#B6+:Q8A?>B*9J4%^HH7!VR'&Z<J;2*$8TW654'IHS12ZG.
ME W<]L92/:V0?257;:>@%U PWNAR.GE-H_'V#!@LK170S?DIO1\0.?(IMVH$
MG!X4I:7F=/=S,RZ^Z N?M1^J/8,773QFNT>F*F,WY,!'C@C'6%D14_(LI+MQ
M;)'%>(6;T3&5)T\0KDK./1P1?S83$P9=(N4MS,M]O5G&P<Z9<=?4NO5\=7\?
M(UQ1F5,L;%(84::Z*>.#[/O[Z+HB@5*NZ*M$ADEJXZ./MN7K=*VT/(=.UT.=
MS1.%%0_Y<(^[>QUQ$N\6Z\5*I#("N4',98+>_%R3/NEKM.#GWRT#;S#G&X@M
MNW$Q)"B"AARBZP!-HRBZH[C>:8DBL%X$P/*TV&XLEC47S-&\^-8JW(&U]$[&
M*.46\(&',M5QXM<26+FJO[O"QG(P,SVWZ;>I:BO1C^RTU:LT"?.<1STMQ_MN
MY)_-.SF^\RN;&E_XKJ%-#<2TB(3)X:P9?[EQ?NKXX+<7-X$\R-_['@JQC#4C
MY:<HT$:3>\,XF]^9&J%9/(46RX^R,1+.Y._.W[$.N)F!3L(S3C)R3AP>%5"0
M<K"VLM'J3 &C%A2M+("<2#T!/3#0/CLZB1N;?N"]<.:[BVN33OE);5F=?W(E
M_RIP*\Q%D9N5>LL[TNRK2KW8:'YAAD(5J!MYB'RQL?:7_@?!RBT856MW3&C7
MK+I#VS;"*GBF\22&!:5LA#*JN @T[2"6*>9E>)M#WB<Y@R88TTY=G;.KLUM;
MC"!.2H$F8^O:KZ5392+><>1;72[U/%NIHJ5M!UQ6C!S!FG[Q)JQ%1V1FTD!R
MO_!)_89O4W,'U#4GOT7/WDBW0$'M(>. UDS&,WQ;TLX4@/V.);)- @("<P!]
MSW@3.O>Z8Z=J@(:,L<DZS.3'#/#OY#9%+&G<%??C,E3T@-KCW4(!!Q_NX-&+
MIHW)G6MOCC/H75;Z>*T/9;5+<_O"UMF$:6-"V])<SJ!5L_>1\$7N4HA7QFB'
MZ2T_]H75KL2CY,Y(>@\AG['DE]]CCCP9-6_(F$.J!*WGF<4]1)PK_:S:)<Y.
M^'=MZRCIY(>FV56)5]6>T,74.F8&"@G.J>L#!_ZA@X1FVMA$ (^_\ U?=,2^
M6O40H@XR7=T]V)%TP_&V(SCIG4;^HO:V?2".Z2R7@_->Z.UOU$;K/NP(Y\K&
MP*O9>6B?KD=SIF?B1D)B'2!. ^ .CHS#,X?CW^S$G,UO544Q:I@KQKM1!(%?
MA\KT:[^*/?4DU['&F8S^]#QK<MJ^1++201Z(@Y/[YW_@7)?ZL/(Y:D.-3LRU
MZO_Z1%H-B<S.^8=!6FH>XZ\+9./%#?5_6WP=#1UJW105*U*QH>A%3P=N9L"H
MY1&OM=&W><##$85]["G\J,&@)9=,?CB-\LM[.L4+:*]H)+O(^:_<"__L43E3
M3YGJ68+G/,Y['NRAXI_'\.G)OD/A0(]@6HQ#(1.J]4_QTB"H+>1LCN2ZIU8]
M-I4R>#GE^Y*^+F]JX^N55\^RS&2\/PX<^:0/'*VD;WF_#@T-$Z>9:@S.IP9P
M4"%-L[81^$Y>4,B,DLN$;PN&? ];[NGIA?/T='2'9F4_['7.%O7T<BQ#Z%UF
M,U<C:%QKRW=XK],40UCBN#1 [<?9Y)4AS/@$%3^<BIQSLM%WV!33LUEX9^SP
MC4/25_D:))6?]*RF8TS$VUW=;+^-CW>#M!V,S=RKPCDG/ QQW9VKP :=-5()
M DO,WD]=G/B&+;F7</1B% 179NCV9O#72@*W=,;G%!85*AVA-6S\=(0'CB=B
M+9OKXQJD"0]0UZ-$;UW:2#G*$408YE#/K78R'F&LH4&:3G!H;G9NYN=Z5P#4
M8T$;L/V9\:)^2Q\_&3RV[?X3_@"4& \-SIA[^![CL0KZV.]FEI,[6MERD9*Z
M(/!N<*7]*3[ XP/:/EL1/^TONHH>-[KBFE:^7I=<%];%!N6IT[7:8Y"B6(&Q
MZ;&%GJ1[$ZZ(O=(JT>V%[7@[V<#=W]?#?GB76Q]X2 Z%Y/>%1Y[)9W%S[*VY
M5W)>>\Y@=Q\#W%>/(A!8D[KR=N!2A'OM1D;>@4V F]&U+WP)G9B$6TDP?^ V
M(S&0,7TP/WJGVJO]128SQJMF=6*:D_3]G;/->;G3UPD"<H?"<#?+"+'=[H&&
M/=K4H74^L'5$G9/U[?#NI<9#WW+4G[Z$&:7=MLSH<3"O<[?W:#9ER6L<C,K=
M;_CMY-7J40M3<[7DFW?.T:QI]U NSH%XRIS(8?9NT]L#)(0Z/(M(TQP]\9R/
M1/<"A$#GO&F0X_8BYO2WWN&%A:R+.YS^]06CV=?<\!WYCH9@7!')(1Z#R,@B
M<NS864*#DD,;L<+V1W<YDRE2.8^%HUDI@F ;8EWAW'7*N02ER*@Q/+#SMZ?X
M:GH^'9:U.R;KFELPF"?3I2?[T/F T]Q"<!D9/93KFYT/?)8NA5,0HV$@@IA(
M8T])O?S[P_C_VK4 >?[[Q@^_\\E,^]U? "@>5@X_%XT]E0ER:6*D3I7$]_G6
MT*'08MHKV.W9IKJ^(&(OS3B>^,"Q7]J676E+/8UZ<W;>O%%DZ>ZV6VV.Y='O
MX1<LH0$VPL;!6^$90I82%=E(2Z,6<G>);5WX0V-4%+6"#1)A?2;$H>>"CE9@
MWKO[U.:B'H++VBN7J&\"5/U%BT3: +7<6H]%-,$>7K-2R(A^%Y^C22E1\_$G
MW;$1=%[MK%N?);?C]Z\5M;,++L;:,< 13UJSI7->Y;D+JP/J,C'>K^247P:O
MMQ]_MC@J9YZR"#"@BF7-4HW_3T?8F:OK"TK$*5?=M<(@F8O4D2""S8C]0)VL
MV6K=H3]=2LI?@PM$($VJT\/F5[:!@S+V)ES-?8')BQ?L5::XV$@H##'6GI)>
M!OI #B%V6)I>C4>*JA?P?&:_XCO9K)F,O!"-_"QVB5(TWYY%)VOT47D07MC"
M*P"9A5_+@;@%0O)7A&?TR_;QN\"Y^$KE*%=;&+H>'H7_4?_C?>/[8"6-K7.S
M-&G+7);ME?P-[>H_9Q2<JH#)AQ6E Y7.SR[@&P9&]<>L6E.W?1&EL,=M7K+,
M*E8S$_6Y0_=,!^^K(#(W)^G7USYFAG&GGQJ*WIQHN#^SX#4>^87/:QU<. -=
M'&QM!OI1&NC)I4:7;HXIVI6$)Q_E=FPJHV1H0_7_]"JA.:1^938P>*FN+NP.
MFFRV3,=@7$? B ZR"")V%+W/>85>Y*CO/*$5N^#L*=??6>D%LL"9/I?NCW4U
M,TCT.WVK!D/*J%W)$[R&4O/2J.H?<]MR47EOZ8/X5YGQ*TWL_<\[^X5.FL0#
MM;1#K,R+LF],-9E3+82MT/:J('S40J4B3N1@VD?#W*> IWJ8Y":=VW6[<T+5
M./:#"R3+_N\U#?$]K^E/A2K1^XEFE5$=(*<]+CV^:SG5:]W--W>#]#"%^GE:
M!9 =*!#H>ZI(Q7QJ:=(LMA5B+A<0,FXAO61BO_ Y[= IZ-ZMW]A)-1?%IE>"
M5[*Z2L3GA9#"UL5R4V/ +WP M^Q-!8G*JN99R&_GDZAJV":6V&[?/]2VBI1!
M[$?W ><W]T>$6[0Z/Y8CW/2<5\+$;JC&&':PVT?35JVSQ;UV<E>U.J_Y2NY6
M.AC.4+_P?=?>@QD5.3#&%SNI\SP'HV/B=_W:V<P,')?]:61:?S.:6]7NM4V^
MEYSWI!+_]V^?&<'OW0A-D]YW#CR03^G^S^84&:*I7&-_E(G:7B>S;C6%V@4>
M%^X-RXGYE8X865.1C]&"BHRI[U^M[OD.GXH(R,'B+..#%&//+ E;U;HSU.D;
MRT28Z4:GE^(2NPC1QA4]$RQ()<=Q]B'B3$M3_*3'HP7]:[F:V!QZ">8<TMFF
M?T_QT<,GZ<\ LI:ELGUJW(CT="B$J9 @X@EU6URBN0L?7<HG[8!'EF9.XB;"
MMKA#6BY?^,0I@1(M]5?LF9^;)-XA1)R93>IAR-WW>P>M>X.,P_ ^B<$G5$/S
M VNS_ ^.91/8G>'XEQU?^/;U=NTV"+5OL%]?=V&9>:D6WG$[]ZKBY-WWZ!Q>
MGU,T*,+#2=IZW$GE4T&'C<0B^,'?B+ZR$?>W/J]+W^TK=II"A-),*&+Q(U0(
M  #XPB==A=4Y4\/0F;/,=H9'Q;-/6Z=7PK=>>5S/BZ0Q?:CF(VH\+36QKAY+
MTQZZ3O_EIRF<E(C>3(H^#J2W7 BI#,>-*!0?^^2:*OS3L:(>OOPUQ+BBOZI!
MQZ"Z.W_3]9\!79Z2DE)FR4A^?M%R21W(("I;"0O!HUQ =PI8Y*Z9K,2KZI\B
MKY(8)EA<5)B9JGA/#OGY3>>/'=Z&L/<+Y!?/:YO/7H]=&U%3_#=;;.WR8(-C
MWY"6R4IMDZO\W?-3KZB4]_0'(A.EQ *'O?("''"/)DJS>C2Q<6&_'N\U8TUN
M"-0\[<3TGHLV8YL9+4V I:IVK%.:J7=OBV:G:11UYRPPUV6)LN"4SU@0K3;(
M_C =-'C6!V5+ES?"7A40A(WM?V\;U7@H>NNVC6UW]GSCU(2N+OV(X21=[BC:
M+[>(RIR]M7K=X)P>V8:.?[?\TVZ:UIU36;CE1%Q^DW5+PS4PA952&@.Y#ER?
MK_3!,"ZYH%++AB;4\P]F,KOCFMP,<O*@K9'@5+\68?VRJR1FJ)X@W :RI=G&
MM+F>+DPFE4;&WZG9_-6<7^:Y+^Y93CC<N>/Z7[&,O).N/-U7)PZN3)^9?=&P
MO=HL]1(])8$A6HE<3^PP?;R_Z;>]\_HO?(%=']Q&QV1"GQ#N82Y^Y*0@ITID
M]9Z^J=*-BBN#])UIDC-FCIK7.XOUHG_LCSY'Z["/M_] LUQ<RGVK691.*Q>6
MA\M;^4]KE'5UW#@!.>R.$XNP$A@?V]@M#G(F-$Z_!AN7-UQ_2EY&1^9^>EE0
M?!03_^#QQVE,>^PZ 2$]%F(>N2N-.9SV%32_P:R3RW0#P_ML.,]+(:)K\B-@
MSQP>U6)+_*['-WF]^YEDSO79, :&]"[FCXNBXS*CC)'S*U?CKW(AQ478Q$8+
MYX@"GO?,#.2%3"L4R82#4G>SJ+PN[#RP(>^D(R:CVK9G0HM1)@J,$W7:HWOJ
MH7,E88Z?F[V3)TBWP_YS.KCX__"70-?EN'EK+[.' +\54 M]W$!NNQ,>Z//
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M(W*RCFS400(,H+Y$S?Y711UJ_K-!&4??V<7B? 8#\II/ V,*RG(]?/>N*\=
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M>.OK1@EI/;>IC)FW&VE"F/+R#8DG+=E1@",(O;1\C; ?<VW2EVJ-/@K2B-#
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M1A,C3N/A#2[^/5$'J07O'_<HCE3@MES#WY.Y"HV$21ULZD4-$D$?$UBUUY@
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MN"?_<L'!3+@@3!MU0MP+G]MH3DJY>7;]GE]7?P.I='M$[[SHH#-_HW<?TOQ
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M@ENFSKXZ_7ZXU@E[I(X,3D7+8@FN[XZ#EAZ]R^K#Y;J7XBSC067)?GAV0N$
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M'4L /V39PB[6\[W$= B77NG%1*ZUK<X8Y6&/#\='-'J8M3&OV9!J-%SUI6R
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MO#K'Y0^W]N?#H936XU?)SJP,3'!P>)Q'F7^3E6.%+5M,UV9[\L#T6T0$#%:
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M+MYRC8(VJS*B3RQ-AG-.\+<U745V=_<D_IKG._P /(H)+Y0%=^.B@\%5N.K
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MDBJ9NI9/= /DL)2W'OB7$,LG<WX&)(W.A=V0=+I,0%HVS?&/NCE@*?1+;R2
M=VIJWQ9KK-HQ5*BZ$-\3;#UB(GS;>@[ >1WW),'4=7]]J*0K(QNUP K=]G+X
ME@(I5#6\*%N9]UKZ(&D(6/@L[\>?.28LC[N(K5W4;>F$B&?%9%]G9Y5V*_N:
MY]P90QYG09::?TGKGC<SMQY*4D1U  GZV?TF7M3$Q2Q2,R%YU]:!W)!0=T;4
MD.1DHC8[W?@7?)'/(^/\>$.NK1YDZG@R@M,<E)KJ%R1SW'@VZ"%[)]S+\ SO
MQSIH.L9Y#[KX5N;<%LEITQ?'E'HNNF*>.#OK5@[,_)AZDG=Y\]''5+1T>-U1
M)3;&1.JT[HL +/+Q[+33"HW_J)LK^[9JC<Q)J(2[#6WN#A&F0E%X2V.<+\EF
M:"L,K#Z<(91>,P+;!L0XFTVPUD']2.^.=4AU8')AO\],@NM^=CF\7+:4G=BT
M=IUYXT/W^.X1@.G%^5 PUT:#'="G\'!S#JBQBP\@.K5=*7/].S!2Q7FG.M"A
M<<)Y0C5)X^A.F<2KI99\A4YL'"='3,[7<$^\=UNI*R>I(<_AV)B+7@WHNCTS
M]$7@.W@<>+T0&;M/U_&^M9(F,5_E\$5 %F8I/2O-NU&<RM,Z&]1\=9^F;6S
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MJEVST+57C%0!L@YFKI+^7A[2US2<2YD/BR?<T$<KOY7D[TXU68E\B@W7*"(
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M>+U*:V=_^G(?&8FFZ(2"/]B[);;EO<)N#;6"F6]9TT%1BGT1V;R(2(EUT&*
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M/FB9;?LYSTT7HBP=[E=2/>LE\@I1;' Z&9IXB;-Y6!F10RNZWJ2\6QU^-!_
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MR9[)Y5#!)M$M(,7D=,YW9^-<9<P;O\8[&10>*:>Y9L*W,9NSP9CFNV N[=P
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M:6L_.*HB"\]'-,Q;3Q-3[>;3:K4[Q1\[^M5:P?D9RNH)5\>0KK-Z *Z["<E
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M;[0ONZJY.=:@_ K CK5R%G*"77Y7)406TUCM3WKHNKA&:*!L CK?B_()BVZ
MF$]62$0H!5%P1:04I-A6-PABJ""!*E()UI8LU1<Y_(Q_>_@EJVG;A"DK>[N*
MJII3Z!)I&(/;A+V+('373EG+$_I31L@>F97PO/&Z]9S<^)#B=VZ*8TCAY,7
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M*'7(O>8!V;31&63@7IG@"5DZN:7S1*^@_^?RP\=TK,2S[&EI4.&;:/!+EH)
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M7X(0S!'=[B*9G,UY^7EK*(UO^78-($Y[)!L"K(Z5N>AO&K:U@R)E_3^;M"<
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MVE4B_+AMK2S+@0_/L/=3LJ[?$+CH*6>Y;;V,_*1F36WO7Q=.TC4R'XY7"_[
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M;@7,80P]IA7]0LKP/ J*<]$*?)WA@H2O=2FM0.W]"N.>U/'B0YF^14_TWND
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MW<!8A)'-ET>"P_N%GVH$!;WO_/@7'APZ[%%]LY%9@<@N\HDI>KI3#SU$2!6
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MZ!N9)L\CT%J15Y6L5.F'#L2]^F@J*KD"/1ETP*MJ8]C5XHO>!C:^D0?KD[F
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MB+(XFTT.FUZYUL>T>YJ<53VW%!79R_:3C*:[X(2'2# .RM_$/MFS4I;=IX_
MRPK-]L *C,%'&?[AX9KX:#ICW#S$.HP.-J5%;M:1E]&]8W5C _TD$:?3PXO.
MR2VIHP=S,0>*A::.F3^MJT2K,YS@3&?F+@;@%-$=A@R9G1 +%.7(IEBY)6T9
MCQV,-VKC4@?S=+),1847Y2_&+1+VI5'UW]J@);%@T .' D4FVE;K+EWQC#)>
MF.<BRAW7A7ZMEP=X-;Z\O;LW^N^Y%PZ48ZL#<)?"4H7-\::;+KP\CY$K,$\O
M3RW/CC/   G=73U)[B^U*'W_)261H<+6B>??WM.+PJQ65$&LM];%W8+3O>8I
MIEJZ60#07J<_*TNXG(0,0RR,T^_"V=5$1AIJS?%GST;4ZJ;A9!@AS,=]D3@
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M"'91*@]>^!NG1*L:I? 5N>7PM)^CG"%J;N=*"Z=$AZ4L##!:1!XD+>J'G76
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MBCN^8'^TG%[5V_FJ\YF#,:5,I9R\"ES_VEA#HS.Z=,2'W,AUZ$C/MPA:W%8
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M^QUA<6UQU:2QZ1"&B*3+Q2]7_L5(=2&FE>X#+XW3],KS)KXCWKGYJ4C"S-C
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MHID?%'70G@_(]XD8_=?C><VU_R9X07_V_H+_^J4R/WOPP_G/2%QI9P16[Z^
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MO*D U%88'C\%IW&P"!&F28O_F&INK&V?_TU9(,MM=+X[%@J0NF&II!#\3U"
M!Z69IB;IU]PH#OG*B3#T]D06HC>I 2;W-.;CP.R1T2N4B.I7$H%0%?_>_3>!
M#SJ=IMV[/$NV<"R5/R3ZX!L5,I/A2N44C4XERU%Y?&UQC#I$31W*SSG4$ (M
M&_E\N/F<D?@F ?9XOS3$9PNW/-0P,4U&IQ[KK4V65XSX7@K#8>S'7AEIE13B
MJ2AC:5#UL\M[M2Q.'I?OQ[.KQTMM$T)PDUGRI)A."*.B=XEO16Z!W4S%T3/U
M$Q;WKATC$[,1?$B*NN[TA!\I2!9[_TE:JWED*?AIU*A4J1ZUUY2++Q#5@E3,
M6VK&)%U45NYW@B//Q4@N>H82#.P*ILHYVI%S\]VA3+K'$\.BDQ*^?_Z7/+Q!
M-Q7SJ+/!*C!KJUROFZ?3ZT*3J]7-)=Q\(HRP6)O1J/0F>2 0.H:?PY5ZS8=$
MSR:4>7JHNMDV]0W7C?F=HX:5[Q&Z+2X)HDSQK??%RPYCL6GRTCN??/[8>R.3
M^29-4M/MO2A?ZC!T6E0>_+I%J0GWB.@RZH;9NM*E<ZX281;J<I^\?,[<T25N
MWCY33O(.CUND:MJH<W%1<SG^F>9&10=7MQ*_J7QU;-=+H8X>19N&F*>%T*(&
M/KD&M8P>-]\)!KKY6F5]$3\;JT!8@1TJOW&ZA107-I..LZM=7&P7+HTY/DRL
M=@M23.1BC#MXR3(0 Z-R? 1O?,0=Z^E.J2EE:&LBCA\ZY:7S@@P35\9QQO&;
MNY]'JR%2[9P^+'%'1W3+]RRDYKRW+<]OHHS:NAIO6]"*+Q8V[<.B_%?7AO$9
M S$S%\U%AXGR?.8"N29>6;%:>R23:LV\%$,B;7&^NMH@B%('4?8]F(&AEX/;
MD&7()_,JWT8==WM;-(+O3EYBA]FSGP-A/"M-%XTQE8#]4<+R@KY:0.[!UF&V
M,*]/1,T<,?%M4;CL[M;YR24_1V*<U6V+,'HUQ1.OE>,LGXW\^E*YAT,:D4OJ
MFX= :@6;;;?1 >[. *T?PVS8AE LHD+L>P]%@ZE&4RI,NYT(_Z5K%'F%Z4)V
MG*OCI#Q.7;YQ/W*7$6;]U/DZ.5^P,*<B?R)/DR=_8?/P4S4]2\5D'QT\R=3L
MWK(5;6F1#<3EP=*&<).'/12I23T+&89.93*JCWCN;PNT\%VQ.VE?T_BLJ6IL
M@YGM@-YGQ&GZ>^56-W?#I*YI\C9 CH0>N^78CY0<EQ[1GZ11,U<DONR1QR%G
M-B=4>S8CWTW4>P%_ADFHTYI?D 'T?7S1DK<*+EJ4V'=/7X@I_--/7*(QSMK5
M7+=M^X_")?\OFPGM >3%0I^E/,O!L09'7O'274.'""]C.D][UF2SF@Z42'A3
M>'!T45SFAQ9,OZ'O,H]U$^6'\W1+?*+<Q@S11Z!ISW6H8:#2GOND@N,_9:A-
MUZ$F)DD%*'#7P/ZY*![BR),=:4N*1SHD;UG63W@8-5H$:31Q(E:$DPN'B)6Y
M29A*VE$U7T)E!MZO8L31? N.%,^-AZBI'68^CI4EF1X/Q^3/V2&R9#E=X%!1
MUE1LBC"=G'CUCG2E671\7S"W6K[^8@9J9*I4MC=U15#6JIV^01.NR9OH49?(
MPM!=@()6MGBXP"O+G*USG=ZH^PN0#WN$_L[^,QA(,WKG6^EO *>W>]:1MC+V
M#"7@V'M!VKLUI3EY'$"[6#K^[& UI$@3O3)(8D]RM^8$TQ3/:)RGTZP 41Y2
MM.G-K<I?,U10RM>KCO$20@KAO:A/UOLE]@PM%.O3^E+5.916LA#8&_,J\2IN
MJ>]-3GZQ6V?9,4UW8@D^CH&[P<?P%%!?TZ"P-5E=79.KL*C(4XG/0;Y\ HZ=
MD+BZ8O/JJXE&F16/^H\&A,SS\3?.3L]PPRJ<#TMU#]@1HW'#49ZBY097"!>(
M0POI2RVO/KZ4<DJR^_G<E&R=UYA<Q:=@TJNLY .6 Y",*O-+7V\=7;V,]CQE
M2?NBPUXL11DDV00KK3S-8=WNGTJS;U?1_9#%W/=S17Z9*K4P=JB<X.(=5MZY
M%3;YLT5!L^:>]U[KE\"(J'D*$ ]1*_I49;T]4KG(+ N94MHJ[TAA%,@0(ZX>
MM#SWT3ET36E<QT2F3;KLOX[,,24(.I<YCB/5S):"%59_)N?UY_BN*5MEA]P_
M0,6E2ZT\N3"4<US,MX3]8]/P4]6Y[L=$6?+G5U8NR=ZCY\'T(BX?,N(^1#$9
M&QD-M[5IJ-]29"#$(-R1A@P/!A33Q3&\58OIM;IZO;T'Z>FC#L'[EZOMT4SW
M(-\^5%I+E9H2XA@8(X>XN*NX9%_N?OOK?Y"UO\HL<Z_#VQ0%WMA11&S&9'VJ
MW).=.^B!*!Q'C[/]6^:VR([Z?8GU!H4K%X"!/ Z^WUXH0ZUX/8_M-&,D+]@0
M'!OV3@K(';PL60G<*8:R[OJ G.SNMJWTI5;X!?TU375;])P:&<7/8>?'ZJH]
M6&^Z;;YJ?80X\?\5AC*:51O(^V;(B>8[$3]/Z]K<P'S'Y[!;[NF'#!M0WZCY
M5>-U7L<6C<PW@:"72M:QJ&S3[[:QNUS\;L[6_:437VEN?-K)YI.BDM^PPQ\;
M>'L:KXR1O;LH)]Q!C^#,NB8&(?B!QWU%92;Z#-ZQJ*N5'Q=HS(>5FP>CJ?';
MN:&VWXXRKFF80X-"^-4[__GRC(;#."/ >./&+-,POXI16"Z>98!$>I?(Z1@+
M82:1/MI]R& /4KR@B4G-EMW]PUQ;?WG_3'O$4OZ7Q+6L& (]-DWJ&WBI$9Z_
M0!JYQ3QT^C<A%8.]O\OM6# ,O9%^D@ 8]KI0AFDM=JJ9C#0@3\Q(,%LN:1T?
M VU<9O7^(U$F9>K:"KC[*SW[S8.W@08#;5E*'(X_7C[UH0N2]YR;7%E9OO<I
MQ8@JM+OXTCA!0<U C6ZT#^=\AXE0-#<0CW$WJ$!#OLE>7MP%(4[*&&0_?J@=
MV3-0#OG+[ 2K,GSZTMOD>*(.6[<?)E(X.'&*>/0>[_!+I0K &3T.8-5#KR76
MPTPH.=E7B9PQGU8@"QOG#Q/8CS89^MCP#Q85C/*U?BOYOK0)*]FXL2X1:/9"
M^;Q%]M^L@69-AC+N:YI$8G/(T.V:6-(W!@"I]R%EVV8)-Z.%G["W88XZC1PQ
M<Y'T&H[ N-VZ:RV=V;=T^)MGC_K5BGY0TU?KVGA,7O7.H.;SJ"K#8ZYS$ />
M&^+"X051;'X?5QC5EP?;#@Y2X63[9>;N@/-@/;*\%@+G2:0Q65JTY@Q6<^I/
M:\GH=^YGB@L6RC[>^=<T215%2*X\9V_PX-82;NQV2P1L^S_M>R/KZ/:'M$CP
M\C[U[4LM8_6YI>.XEWU[*.(['Z;XV,"WFP%)$SV"SM22-[/9T:P_MK:9'P_6
MJSSVU(RSLN!FR[U*LB:#M5=8,M6V/?4\3U(O/)>$.5XJ_>C!<PX^+N=)@_MX
M>-G(>9S3E8CP/N!6$<P*N2U\-_UK#V],[E2&$"ZK,G*&-L>Z*T=;VUA!DQ_#
MS<+WE%!HHDDP:Y8+,8;NUE;][-4A5'8_JE>Y,[?G-9_3AT()=BR7$ZDS<GZZ
MU2SAVCESHVL<KRC0+>^:0YE(ZT/O(=U[+E$*<3G\PGGE\" #V!1IWHU''1I-
MG#3XJ=B!_=:[P9&TZ,M&-"?%\1_D9?KI@V;_%R8<M+=X>Q^RJ;MN*<D+6_#Y
M^9>9YH(8'>OU,$(X9Y8GV+C"X@T\#AT(,8/ =-9&,[U[GZMTMP5-J=B29208
M&KL9SHPRVQ<"VJ**Y\#?LWS4H=.&M/MK)8HNBU7#]>M]#&:8O F\T^O4/LXF
MINC A#)]YK8&+X.[6_KZ+..5EG5<X_^94S/SX[\)KGM;$BA>ZM3S3S0A4#$I
M7:^G"_HDG^8VFCO._.?CTG]O"]'D\01QL"8T,U; QQ9-F^,1JT5-C'?$)'K]
M/4E[IWLBU0+M"()EEB-7\\(1;0G^_!S44S@M73(;#SE.)IVGG@$2=DXD-=Y(
M];%6F&-S0-Z9E&\HG'=O4*\W(9+F03-Z#59,\V.1_)B/X4#F?5,];N9/58,^
M,]);Q4&E5>=Y"(74K44A_%'\B0*]>1[V.OGBY%%XTAIA^6\K4?Y,M'R&ZLLA
MW[7E%U*B_/<%!R+$NU[4^H@KLUMK,QD9\;.S9;>M<Q46'B#760>?H3.2<M!+
MQ>R'OVIVP.*V II$7L1J,1[EEYC":.?G?/A;<0SXD=-+0+($'H\B#G:+],0G
MO4+K<N-L&!0;W_/D>SJAV\+$'@5++2QM<"IBE?G5*5 .C;=  J\9>PC,_%\Z
MF&'_%);$1:C@]D_?^0O5YL4_4];FDF..:^JD_T/=1 :;F.A;.5'K18F7?-6!
ML,BM6%DZ\G@4]IA46+P*KLGI>Q65X /97^8/XYX@0,C:2S<%%#(26!.'M,YS
MC\4_T_^_/$)%=H\VA-9PO1FI]\5H#+3C\II&F]M2[6CS#^0;VI+<R[_-7,33
MS0:6BN^:V<MD;H'_H4L=NJ;IGCL,]'_KW0."'*&NAD!45LBDYG@G:0P,4#?)
MVU&G<MV7!PKS<HBQ3ZO(L:$'+6ITIW'#U+C_"PGP=DCL33V@4 %'&B+%U!"'
ME@VFF]+KJG=AS\[Y#DHP%)3%S9W]AJ\R=NY6CJ^YTUIQ_.>0R6BVS[#!"R=O
M(/^?HCP1D2.#2!Y+3W /6$KA]U/G5YW&+>G"B^IFAEL&JL;WHXK0PE590@E!
MVN?YQR"POL*A\;N#F[UO2K9('%%]V37(Q,##RS2_]R 5Y3NOT*ZK[_$1V =Y
M^^FCYKT2W0N#/1GNYU='8FC*S'?#?0F]7//<=18<AUR61$IQ(F,N+&^+RU;D
MP]M?NA=/Q3EB>R$.[M,BGFYT$_@F8_ #1O4CONSE''.8MA>I,+8M@K9G-I6H
M;E^XI7]6OG&F4]EV:L4+<FM4\\I9UQZ+\\UHG)9;1>-SQ6W6&YT'(G0N_;/A
M^T'E9HZI$C_C!7VK61/Z6+U4N7FC3*6U"F+[@CPUJ'GI/&Z($F@GP=#0$,+X
M>!T  .0?>.G_+Y+B1J'-?,OPD@(N<Z9H\7@DA7DBRM(B 6XZH(]\;5KDB!ZL
M[_5^KJX69[=QDE94TFE\2CU:Z9T,E3WK7E9YMB6Z,+ZTCA*,&BS$M+_7)RIH
M9/'5%@I-5$\" (HP7Q0W[O4:^ZNU\WN#<WTVS2Y."]_'0=U.V8%V+A+*8W]]
M;B_/4B10<R"6C:)E!SSIMR.SY$Y1T?-1#A,'IB[*S6$=TL]]>HR=LHCQ719/
MQ@S R)W6TU^V,D<ENXI3\JH>7&_:4'"XD?3#_LE8'WG\=O8'#XWG?BG6 ^R^
M@NGV7]H22CT7TI7.6GE<D1/+RH,^)77U<6\J$C7JRW&#AOUF_ @\MG(&^M.L
MU%L)8UH!=*U-\U+;77@J,;JG*!4WTQ491&AN5;"9L:G9S4*)PJ8FX-2']&ZH
M@:'L/L$J/"?!\IB+N]FB;$<\4FW RR+SX>U\O6-ZVNV%IW6! OB,EGXS9!M_
MF*"\VD4[4]_#;#[3G6S P65AH7Y'S#Q6?GQ8//3S4.W<:U,3&QF5)@IQA9 ,
M3TW&#%3\L+4^*_0HD08K1[T9E@F\6_I]68X9LVSLQ6X*L#'3]VV*7;>"& /H
M/HC;$BS4\PBO*O_6<U).FG^[V_;[B_]O4'\/?/C$0@C1%'S3?3 UBX.Q1Z/R
M[A '2"*31_U'6@T 2/#OWE/EH#.2>]PC@HX%QBQ$,P\_NS$7=O ;S8O?]B /
MT6EA;7HUPI<: %_HDRVG/>2$[3QE*NT'?SO>,L';6&!;;1^A;N-]4*PHI9$%
M["WICE[+,O@8\9W/YP:;3W+8.C"AE";Z-X';'S\ZW0A[$%44AKR=.%2Q+9$I
M&75<7!*UW#U'+Y_FWSA8FA%K*]\]SRY*#U/4@<MH5(U$.5KH@>&&=I83#9^4
M1P'T#A[=M&ZJ=*U"QPIMIX[\US3_6#>>3K6$ MRY#UIV[#FN:1BD8<=B'%?.
M,TH5PZ$'[+!3<LO\GMR>R<A\4'$JYYI4*LAT9&'\U.<L3D7$/75;SHX0L]+Y
M>4&R-92U,B-Y@=2RS^IJX#*A _1>H08:CR"@+""O:YJE:QI6W9"I8@C+SKA3
M)SPV"(;F2JQ=74M@*8\B!QFN-[@/*@P,8:EN\%9ENP-3*V=JU&:M(50Q2)KT
M)=.9;6(T8\#Q_I6*7/"\B__:I5C"A?5RW_.=J(7A7;U&.15SF,C_X*JKI.6?
M?TM'/)L0)1>^[ID\BCOX&PHK8=$%&\:.%JK&<0.Q<9:D;&E5[[UZE/K+MD/_
MEK)FNBVE.R[+BI!X=,U4T+VD_N%X)9<@K\U"A?FFD%K_TY"=\UC4C&_.Z_6K
M;%<WE3O!-;%7,PUJIO6^HX7T;<A^MTSVX*8V7V.D\XZ/KEO2H?="+O7T8F(]
MHA>P%8)V7>O#&%?8QNQ%6/0!=1#I/D8*K XA>A_251Y@,,[O(_L4C3[+0*@/
M%_;[/Z;:!;=)B0OG+\JIZ@R7$9S]_DHFZT\3XT7_^- +YG\84&YV5=9J'D6\
M8SK#NKQQ NE]-Q,#,2 CE"8"P()'&@X2;^#5[9@]>/"M536SK6R-85R4A-UI
M(86RI]D[ISILW#5WF&W_5"I(%RG?ZL<V"'IX8+)_P#S4K\IDT*VNTQ^DI(*J
M!$PL2HS_!XA-(T&(?/EN?C7HU.="O:YAPC7K36A9'$:RA&3%LZO58>R03?'
M/1 ;OMT\Q$ -B&JT](-**#8+F#DC)R!Z3T!U"3$'MHJ=G@R]<0C714?644U0
M?C:Q:FR1&%D<&-2HFY<4$KF6].[L:FB"*B/!M;A(K+9C.5RANX/CT'9!26]T
MNVXC5_D)+C!N/A1&ZV565%E?<8KP[[O[^YL"31Y.]G&"6I0=@7\? 'Y6\0/B
MZJ+XL0FQ)YQ:4X)[+ P1_R<(JJ/GQ9T1W7AO[HWHXM(I2#*\1J-[<FER66S3
M=="1TQXE[12?,IUC6>S"6:=E)3?!)!Y)=EU!MFM'VC",T_FUD#9?=L4RC>)I
M\?EED8/Z9I ?:3N.#!-%'=13A*8T4\HPR]+2%-S9T!E:V< 7[H(TJ&H.#Y?.
M=M0HU^4QSXHJP#E#VV8$E^=MG8> E!PZ*O\41)&SV-F:(/6R.(4I&Y*1I<3W
MJ-PR\@7-@XS$)),=(% 7'/TE&Y"WC,_':7[%##P"Y..TG?< N4&B0M<T//S?
MTTITFE7DD^;LYU)3$N[N%@H45IVBG P^]@L,[BC^4B.*%OZ/LX50P8LG#J8:
M$CP'YT$$[N_Z'$$!U--@535_;X0F;IE;^\-SL]>!0HO7-'Q/,-<T&::AP<B!
MW(L$E<OHK6#*-4ULXP+62%AEK?::YK0GM-VP(7+'8J(F0B,-B8QH#B/;5#'@
M_'A-<QNAOP@$/=PRT>0/"5O%J=_9Y?*_V(H)&GWN"8.-L7RIKT2^$\O8F"A\
MM5*;U%Y[W$_OF\7<F]V@ %4\$BEI//P5%RCI'H9'#<UEB[\!)::FU\2%C-GY
MG2>+Z@..KFS>1(AV.RQ.VQA_G%G/AYB0(6<5@$,9:<5 5.' S8W:2;O.NDYY
MYPNFGVSN\W.=X-D]2BWLG0TL&%OB4W9-8S'=UG$0VC+M6M4V$*W76'HJ\Q1N
MPVTC^;HVBSOBM:>G5,'_=%YVXV!OP\KISS&Q\N-SQ*K3PC]5"^=HWXH. ?@Q
M<3OZ 8GE-CS"D##,I0Q^WR%^F"#\)2^KW<3F?MUR7];66=U$7ISHLM"VL+R:
M6K\^7"R!M<3ZB*05M]["H@3=;P_"KIN9K\J6/)Z SUB>E #7K.5J^J(J*U87
MNBTO8J/KNO'.Y0VXI64?3*:DI0]%_4PIZN:2C"/F^(7!RZQF)-7]=\O;N;XH
M_J7?=:3WP99OW6_=6B:F_)Z,;AT@P8S>CE(W0*$]3.8MUS2,2:M1W&M8P="Y
M,NR!Q,D2]4%"R^Z'UM/("\])08MOQLVR*%1<R."W\2W@=Z9<L2 5%8^* (*;
MR2TUZY,0N.F1\TR1A1V,J<%]H7,;M 74-24/62I-H"Z:U20@R*"V-LFH\CFW
M82J3FF@IS[R!@(WY&]-'"9Y@L:'U QC46=987XG#PUL<KR$:K/YC#/\?P.KS
M\(]%']RK&,>R0#O&?#IBO[Z;R[QGQ@#:TE1F?:!ND'71Z"-8#5VU^'=C]=P?
M2$5,TZEL-ZLX5SB4_3@(V1BD_EL%/)Q;-2H0]EF&*XZ!0?Y)'XC6*G+)S_$.
M6/U@YP'29V)LAJ?!<&,4/X;]=I^53[;Q0[F@YI#$,Y)#8@IZJA$SO-1+;,H$
MY="-*K2TP#X9;XF$?ZY7G[6_-^^O+)"LDY3BC\O<L%'.8Q*Z/UR'^8R&"YQZ
M_\#WN/4QBS548#STZT$[W<Q"IX'*^^F&]F%QFV#8E+%DKB/!EOOH,-C>2ZA,
MV*Q%/_ J_UDZY/E$3> Y #ORUW='2$-YX7,1/I\@3KK(R24<YKEL> );]$GZ
MUOZLA;F5N?;W-FJP_2#=QET!%GSNP?["(;,IR^.P4OWY'*CUOVE&WXVD=\'B
M8K?(X4=A82Z+.3_K)JSHYIECP.)%59^K/C=H\*'Q'L/QC.>]HR#/V;]IALK5
M#BK<'Y,W9M!+*W\&F8F'CA_]5F"S9H@'.9NA.&-(3ZL-\A&=;4,5!H=''N==
M9"!)IRLGM/AV(1XIG@T@]6M\[C1WLFA9"F3>YC9N*ZSFQ_V*>-CYGMLSZY2<
MJLC%C(?- )D,6,T.#KC;XH'QS0M+%9\[397Y?P;DA(J;DY4%@_=P :@ C2)R
MRNR >I_[)?,US7)6Z/F6EH=22.AI:_,O)#E<TT17AQVH7=-0GX^$+BO$GY0T
MLN_MZ@?**>SOZ3](XP 2>*('WIT&RKUU'V=^=QKB+@RZ+-Z\R/X;HLG]]\BM
M:LR[*]>_U"#\*C"W M1OD=;^PB=4WPH_L;:=&VDPX3=B[^5/WQ^N(1I>=!>5
MGO)I9LBQCC9.4V;]I<%I8PX:]7WDP=?2ENKJ^I &_YH+?K=]!YVMX\:RJ5"V
M>'BJ\$Z?U"3LFB;!H7M_E7I-TXC1;R4KO5X=\V,H5[1X[G U>?]>O;,*[X8%
MU2LP5ZYNX[_/T+X3S9'9/]Y9F^V[K:[/*V0XZ2??C79-:6#ZGE Y0+2R^:N%
M+/'SU+Z<M!>8O!."/4B4DR. :X)YUF&C[%H3EL/E^LU5?]6<>TRVFU.=H_D$
M+I0JN@::=U*1@TI6TVX29JUUZU9O%-+B#.<S+D22MBA\PI:.1'L*F;!.O!]D
M;*!]G$.JJ:V(;"#*1N;HX=,#E>[(1%0.U7D ]:J 4A35U': Y/KY>"19@2ZH
M4SBN.8[PI>6I_K!F+E=Q-[SBS1?1?H,NK4J%P-A>GR&0AV^*JC2M;I]6JD?W
MIVZ\4[A,Q7TZ01?1TH;7ZT9W.IOK#WCL*DDPUP2&KB)\]QO38G@ \CR=.T".
MF<!LO+PC/PKOG6Q&G90<!,FO7O(>PD3=UC#:!#X^92:MN9]/]]LZNR4D=MX\
M+ILM\E%0'15TE?^$YS90 7_25TSQ-'<3T)Z#S)VFW%<15<BJO3?8\RII>$\_
MD%*]"A*U0'N.5>W.UAU#85G?_-H@2,,BV8%ZZTG(B.C6#NR7]^3Q4'_QZ^[*
MO(L1:XCSII9:%J"_D(RJ$5<T2N#:^#J1;_!QJ%M0-JU)J;!75947TV<P]!-N
M.50^,FM%6SIJPYHFI8*IV!%JD?:Q5*DCU5#J>(\TP(7AS&YVRV%%!B$%4JZ+
M>V >M37JY7*<N><7_G>/\A*O:39@SL5B9@]4$MCXQ<7VH[U<C3/(ESF))5XP
M2*]V;VW6R*+NL/CM,X78C ./\;P,USO..!RX;DO&PZ"<7\GXH?A8X;:<!\I6
MG(Z@3]\#OL.1*%N1MO6JEE^;"A(%ZJQ%D\:LV'I<;C2:F(<#Z$2L6K!E>@I,
M9%L5MXHMP4:W1WROYXGO#;9567<UM+MGWIMQ?VSM8Q&N.8O5!3-SQH',M;8>
MXF7W7(9 *4F8C.+PTO'(32NYGB7!G*,]!EH#&T"_F<@\!S [?Q24/&&64*=V
M4.P#-R6L6%#%YUS1*T9;LJLCW2Z.8\GA30R 'S"M^:%NU\-D?;)Q7^M^IO^"
MED?]FR1T,S%?NIC5#OB4OU*0+JA98YJ;D)=H))'+A9PH("\/-^T-HH#\/V#Z
M0(JI-&.8WJHR_5_W'+J#**H/&/)T6KZ@J_^-*P<VG^V!X;*_K!'X<[;2W#+:
MPRT_3%%L8+JZ8WW!:P3J\K:RH/WC%%!FX\9+$+4Z!J&KDM5I[O@D>=1[9V'M
MHDU_+LO.R'OYN4\"6MW!!G4:J*>(Y&:^G8)Y"PAAM=!0%F57$=7:4Q6G,])>
M,9R/HRK?&?F85ANY*QDDX8 1:X?C/*O\%GVE7U";S<O2*?*F'8L!0L*,%28V
MQE$LT_)N2JHWS38,$,X[>QIQS+T><3FPGU8BR"AI5.%@81,W&V%NLK6:,(/0
M7AK8Q^II:"[S5JKMF[PA0JWUY@>%7.+56V'E6)2+R[.19JF4UZ$8C.39#*]^
M\:,OL5>>$Y-@+],CTSU$QE.]MK:U/M,,G7YUX=0^!A^;IE-?E)?LYIG3LF_2
MMAVS-")NMLG0>VGZZ\;D^B4[)7AU7"IM<9FYI[V6&M1ZYN/3-U(Y7!"RX,]F
M>;* 1DY7-T:P%91:9(V*FF#,7HP!L>B#$H:B<A/5[\VVZ>V+!@5SE'G+-'B$
MDO+P^_9]?SL?*N*\9=L/>^^,/ B7HLQ-R'@ UW#1FX'H4J02492KN6&-H<,[
M\+4R:\C0_Z#'_BUL+A>=GFE//VPMW[I7YM-QE-*7K ]FF=Y)=^W<\DD=E?<E
M3$C39I#.A!6U3WX:$#E^>$PH5GP(4=;OO=09;MWO;;L2N!#C+IE19I/0E*MM
MD7(^%_MMSM3">BQGN;'Z^V@NOGXMKTF9XP$;@^Q:Q8U*5TG5Z'8SWLI21*%)
MG&;G]E@#8LL8BL@B!RDJ(<<\Y#Q; ]*6FJ5+])Z!6/*\W=A90ZE+)O-X)^B!
M: 9% ZD[&\OP)#(G1*A%6_U+6=BBP6ZNWZ6ZUZ8]76'WAL1Q@2%KE,;[5UIW
MK+ @T2\8N36#K>#<PF#UUC=5I:'2B)=D[PUD(-XCLX>+GR,"E]<5(@9=-CII
M\?2-%W#-<QL5CALN\!QRWK]TN@ -+WE,&W/$(Z7C?-*P8]B._=F A5(:&GX5
MW%C&W[_'1$9/*3R*2\<7+XV??F?P>EZ3\WI/4_M^?HB4R+\72!W2ZS-5X%:^
MYOR>.+0Q/M#2__"DIA@G+EY*JZO=B<E^:<*FO;Q_%.94G9K"_#F!18EK[T*9
M^)5S)9\"O;G.S9\_#/T-R+E<L%ST4_QSX& W^QGL?@.N@F2D_KC08'&?&N9,
MUQ/@:LG/2VG<%[APIJKRY+\UM"SIQ$KM[W G\R8,U^G_;B0*O;O.;0.@U[E4
MT+SIOFGHW3TC)2=0]A)17/$GQZ.,M58291D(Q-=^4KC"]@.^N8\?+<Q3*(OO
MU;RL)7T67XQ6G7S,#KR5WSVO_O!/Q*>5UE5U'JI$0Q'$L N]LK0Q-Y.?^PJ@
M/F"ROZA4I$%45DP._)A?NLT::"#*OF48J@G^:Q8QFM#8N K[0N]\ ]-"FOCW
MEKB?92I_ J^8U7[I[Y!!O+>)B^2Q^_[F["V'H>-"8L'YB]()-YG!TZ_E$^K0
M 7')_3^MJZ*'2:3/.4KH0<\>L46;X+O'-]07O:V_!-1P[V6(9:HO PM\)\3N
MG@0"7@E+1_?A"I3[;T263O#HRP:<7,Z:NO!?8$O1C$;Q5V!,37H"I";@:@6&
MB%5W^'%-TPVV2\!#'L4:O^._N;_)(&!J#ZQPQ-5M  N*1P+$5ZF_'0F<0Y3_
M]C!.S.R;Q&$>BG+<24.$ER:O9NSR:'8_2 N,#^C7JF%0D3O)J2RM]:E>&&71
MS5@6+2>]J9.+#^0)9(KZ0&N/7(R%),J5,$65S99T';#\[$P<W4G'YEAW9*B]
M##?1[B21$B1$[&,A;=$5O+,V%K;/.A?CU4VVP/E5*C=N!O7..OZ1+-4W.)'>
M>@O &4CW)?=,08_W&6G+36VWO$#&PL)U6<X"%ZZHDX&J/T,%(YR62AP2ESZ,
M.)HI&FUH>M21Y>_:FL 3(,&]NRV'_^2P*4I^/[KD4:<0I&P>S]5E!CCDCPY^
M:WXO,N03X3QFX.C6]V;/VEGJ0T'DJ)EA29,!#FL@U.EN(;AH KMQN&EBPQH5
M833P84Q\+L<F#LFVP.OSP<ZH][]'SIU.N5)DSC&WY8B97+\)TG*T$+\BM!H9
MB6Y_<8#-^@F?HI^?LFZ8*5&Z=4TC11RU7-:08 HTVWCZ3XUVGJ( _MS;0YS>
M!P(5:@+K3RYDUW8RL;@3/-K +08J$69&W6[17XA:2]+92M/8MXUC91]0%G1/
M 3,EN24U)J[%%3==H_!EPW$9>U)>KR-3^^7U.@E=K*%L)][P)7VV5O C_R!%
M!L,@(*)\8;(PN_,I1JR)LU[':>J,5FM.8SVC'+U,&<FX7"XHDR0^!2D0AM7F
MJ(])4ID\PVI+1T]Z)4TUCQ-P[J,O82]^6RQ9%JP]<&DQ8\'1&I]GNKK ].N9
MT(K*-TLB)"(6*AC_&%$#MZ9T>J#-XM%VOWZF*(>T%#OBVB#VE+*V$'_S7%&1
M^QQ+A_>Y%_K SW7#X_2:9IK\G1OK3$/CRU\Q_DWYJ[+X&(!.&[!M.,&U;+<W
MM]3.//HP.E74AU\U\;L6(#5+L?YC>.;:Z>[^&9K29%4FW1P]<SL^;*$<J_E0
MJB$).O /I_9(EAP*]39?%*;=BBF[*V7>K?W-'Q7P IV#P<X-CVA%I29EK()V
M&)X/X=A><:N9U&2=B*^</<Y^5>4CB21A,@=7_PAVD>0B&!O0=9+ SP FR?UD
M@$$(-/]<RR F-9$7P>4\OD$YN*W=E:0&?I'S<HGM$["MT [()I:=IQ;"RVP0
M&=WFE&VIS,D H@Q,2:D:(PQ?^IBZO$0.1&K>:N6'7M.(E_*K?P?CO;C? =D7
M/?UBU6ST0GA@XEVO)7J*4+MGZ+B%B4ZA3R:^#>[0$&R79F44N]/I[L[^4=(F
MDRY'P9W'4B+(:7S ;T4)%79<*%3$34*^ 0R<=_!(B%<!DU-\R%!4-&$32"'U
M%8T@=%P5FYK?TO85' 0CE-"F+N*>P1QI6J434$7BP)>W-C6($A(8VJ+)L$]7
M.'B:$GA1PX_.74M&E'Q38M=ZZ0V5C.[KK/M/J]IJ8UQT_"HU.']=[!$ZM![F
M^#N_H46-]D3.UQ#>UWD&V\JOSS_2%FO._,P[^.-?+&D#OY9.B*) BLU.($X+
M@9H%'$?+Z.V:?.A.V>UB4QTQ6GR6]SG-2?(O;JW^B;"$T3KC,#]NE:P=0N8F
M\C<$K)2QT&]%5:GT<H\\S;OO9WWK&\?U4$=.Z_B]RIWBCTW\0?0W#M$DCJ8O
M/XOQW'OZ>&F9$Q?P+L$0LH8OS&&DE*,2SUSV*,0#%:G0ALD)S:%TJD)JT?M6
M?$!@XZ%\EJZO^9:U]2F5RC0*(3TMB5:G@"5WEZ.L[O$"N%4XL80HH4]-5SL6
M61+)CEP=HAX5CWB?I>?YQAO(>Y!U5I($7'DSO.'C[=XVH$&S^,?;%&,KGJ"-
M8M&##C%PE);UP!1>(0/GFU4#6?08+P9ZN!C9Q+PQV"=& :U]KVE>K94)%=.+
MZA#Z?2JW85\S\B#;^8$IAGWSL9=\:R<)T_"B-X1T4IPR=N&:QH>T5<>1Z89?
MGK2F@%C)FJ"N.&1&49D7!*2N;D ;%7%SD>/%?TVIWS[;O-@FWYZT/:I))O0Y
MP$+SBG(_&WTO"X:($^&?4@]X JZ.;C%'[\I-L<F$,[#E)2A;GP\'K PW\^V+
MA:0,'S-<Y1Q9,[?7=&I? >C% ;H[HL -G858^.,!EN7==CMRH79%08#S8G-G
M1@!91FYOX(A]8N]-+;;$&3TJH1DT>9 K9VSC (H-R"E$,ZONT;'![*&][S)N
MVBA^8:DI+-.=%ND"?!F/4H6^:8I+5ZAGT@!Y^4 B^@Y1G)AW#/.IX>_C,AAF
MP>ABP</-?6K2[(YF;,FT<S?S"#A"#2D4&]VR8RR0RQ<XX]^P^HTC[(@C76LL
MF'S;GK%1NK;Q:ZRVE?];Y^TJ!#:\IYZ>6!VO?*4('JYHI%A7P X;X1;9?BQ/
MB:,7J"#!/7C\KDS[^0.:@_)^WQS;/HE6=J>8A,LZNE _)@\&@.I4B8V<?&%4
MK,',_&J8'IY)S>GKC7D\9TP_.I*L;@V1L?_^..M2>3[:GHLON.<!QN"G87&2
M<LY2@I:ELIO*YT'2E\@M"TN]TGQLM7$,J8'LX_SPG[6FLXRZ*7! 5VF1R-DN
MA32*M/(HK=[U(^2WITRIN<-!:=:2)HO1Z^>Q32C"T),^'ZC$V:JG;%41P1NJ
MR<^A,AK!'<'/:!IKU@?5%(R;^%YAUR#X"R"I#PK_WQSY;>Q#A+AMV !2-HZL
MI+-L(85/TVOSTFCNHUU\6=_=%M4;N0@=?/K@'G%CA5W* Z')I#Y<8JG2;\$L
MJVNITM0OAJ[P,I*[-[\9)(G(7M4H3$1D+YA+80: #-*1X \FY"LM,SE _DML
M)-X-[X/I\S&^2RP:KH4I:F7G=3+L&"22BS%Q#!T<01J&P8Y:!F7VE8(FB(TU
MR7CXW5A@M,*3#TRZ!DTF\1W90,AT&_)N5,VZVGCJ.Z%_]H"(\WG#^3#_OS0%
M]OXS][ZC>:'#F5YH1RYF:G9X7B(S@XBPE=&H&L+;2DLYF^4^,=!_JFZ/ZR@(
M!5C8_^J=WS<X]Y:U88_!11N/%PQ^\ZWL<0,_V$L@VS+!VZ@K$?*J1R&%*"<+
M<-6ND F"B2DH;#4KZ)I3_5D^NMX&^\9.- =O<.96CJ6<*16-KO$F] TVU.UN
ME#?DAK@%K_FE3 =D/N'RR:[3_Q:'<D^OM9YPI]JC%SKC?>,]#H\?SZ\:HZYI
MP@8"0V@IEQM9$/W9)J40J-=RT.=#UC<.94W,@]/3IP8*O+:-<>8$N-PN>&#,
M(QU>V1QGWFPEMWMP>9;E:NX&3V;=6EE:^CK4)%VB:-VTZL?_H:\Q)16(R7N:
MNB!#"S2!TFX4E)N+/^1'F[T/-1N"%&:1>W):OH3,LK_Y]N/2:6!IBYPK<52>
MDLFDXAK$5+B<%4B\K]1Y?SSC@BBZ,:!#/.\>67^29_7FV*2YQ9C'0.YJ>^Q*
MWZ816[,3^_=_+X-\^@YT.[B:#S]Y=K&W)[HT3RDU]@B:CRKMB]25;/CV.W:,
M2OP\>*SP7BK>3-BR*VT%V:H^WT3Z?%6[[V:]EO,D$Y:_0@*<J=CM[BS#:T&Q
M^90(%::D?#W22##]QO 2UDH1-\IW8 VCI/G61F9S7=.,0KJ'A2W0:>C([N:"
M>?Z#$@"#=%3;Z5)M/03P VOIB[UC<>[1'(E.==/N5N*P#=OWT>]U=C[&K;%T
MPDIVN"M;M_G?\[[- !7C[+R6_YKSG+1(US?NS$7B!@\_+CR'66A5MCAB2N-"
MEN-T?5\6O?JQN'4O-Y!#H>DLK30:*<;G8Z937FGGDQ7T;+ID#1,=I"S4(+OD
M6M2"AAC%>@^_\Z6R6ZS'R677#LC8>[Z.GU9WO-SX&4P[P$"6.0^9=-F;/)9)
M.PX)I7JXO]U2#*DZ<ZCZG$YL$>--R>8EQ!D.:19[&\1.P-3>_*#F,HU.!&9^
MV1=ADMH>WA$C$Y@Q;0YA5U)]!!.U;<YW^WR72](+HD&)+7;N:D)UT@6X*"H?
MHGAI_?\F<XW_V;'VR:1F2[AP7R@'P9]I^(>)A.G)]DL ZT@V:=21CCMC5'V6
M6-6U2,P:]%SK'*9B.OFH4M[=WX)#8-HN5FD%C/R\^YO2W$D?<:#HJZ&>6GQ=
MZ/AQNF]Y,8>XN)Q2P6F%'51P:44HM6SAG0;C!12:6++OO!AWUYSR#DAU@CYZ
MV!@_?)PR T1QAD1_>UQN64V[!6LJAU@">\UK&C&E:7J""I_[F5Z&H5O)1T]%
M\O/R]4%@;6]/UT$X__AQJED2(G(<A3%.\N/@S<<ZP^VB'2NF',UMS*T4TC&(
M]1JAU7=/-:53"_%Z52DD8TPF:8.[4KW #^CQLMX0-=MHARADRN:L<!YZ) &2
MY50[KMF1;'+ &L*0EJ35FC.=;7(W_C0[W!<Q[IX5M9*1OHS/^OC='/SL3TH-
M;X'-E $Z<L>9]^-M["- KG=J>.AS@1(!/#:>I"I.IT*GT[UV1OR4SR?PHPH7
MBBG-?MK^V$:FM$=8F!N8T;>$!\PZ/IDPA>R<:^^J\4D4"Y-1>Y)#G*_-- >>
MS&+IYE5^Y.\JBA/%)5@9YA1#+./NA!>S;0'^2//]3]706JULAI^1:6BP,&8H
MF'XQA]ULXKSBFN:I7R<T;_B:IMKFFN8@^9HF.L_'""8NQH^87:U6)W%4N)6&
M2Y='=6WOD1+KXY9,&_OESLD3#=_GV,'UQ2#G .IQ@DCQ=]/$PJ+BM7-5SZ3\
M5K:RZ#:*+]X#W!MES];OZ!)ZK]/+=<<[AZ\>&#T_&'@(I9NN"/63[,)XK5G%
MT^=!P>!IEI74OM:U3$?7T;4F+XO/C=*, 1]THE#X-;<Q=5;9YC[AIS>F:@8J
M$L=2/E:IO8G6-0:0I0*$+DE+8M4&+4O3.)-H_ZJ?]S0,Y'M?5PQV \JKC^8=
M0 L2$DH5[?'F%Y\RNXB%1U@Q&$?K)'QFD7@?J+95;>FYM=S$)75B5N;8^EV4
MJ6*Y7LJ7/_U_H!/-C<Z5@:2[$>P;+ ])SK9OW+=O]RR R/MY#IHF,(FI:*%.
M!.NQ'''N:KM3TP7A;S.OKP(P5!0ZNYB.DCSU*MC!6?3IG3?7-H^M48-.Y@,)
MQ!7%-K"RO"=FF?+S03[%>?T^"6\D%?M3OR+*?X\HDBZX?99D\#-1;@#,-.WC
MYO= Y[(SBZAEGSSE;=#/X?C74T9N6=R#@=.CWP.R,];6EY9F;HZ(#()@HH#-
MWX^*<U$4[-CM?P1*(,R]3<19*3S_XTWJ;Y2X T-1OL7%P1)#%I%#B(N)F9"<
M4%F-5WU7N8W/<;RGN)V0$/^--7$>^Y,KTPFK6@+!\=QJ0N6QZ@;6P*MCH3M0
M6&T#5+"A,K'8#-]5"\HZJ4UT6,W.4B02%-0:LS\Q*H V+ZYR,U4M?T3DL/G,
MK0D0+"FY[/Z@S:U]8R@9"8V6>=F,U8X(MR;O<4-GH&Z]4E(V:C.*]>[GRN\%
M/D#"8D2AVT'$Q-4/[;;\ $9OL,RB6*EXOF^!K=WN7&_#Y[%2GCPWGN'A]64K
MNH7$+;FGW[L61[-BYK(\K642 ^[J3$]=(N B]B[\CJ5E1I*ATRA43VGNJO/P
M87.+1HM%A0/A1W5NB#B,7*P^4:>JEP51K <>(Z;9N-QA;I@B/*HX!PE9ME4D
M#X!Z=?]]/B7K.=[HC@=8!4LY9!JLC#-^IJ".V*=T*R?9Q>)U$'<"_(^# _Y-
M;^OC%000U*C!ZN34=OZHTY+RZ!D+NKR,K6@\?Z7>7)87PE PI?&:1CL89O2P
M7?TBN<-<I\-D;A566MZS&9,B>^9_&DCKTET6HI5>?V67*5 E%/)3)SC\T6A*
M-$4-<IBBDRDRL\40]*4XK"2EJCBF,D?_M@@P(^,T4/L#)'S3N5VQWE,D_.-'
M=%/P+4(X.2Q9?U Y<>+[V7<CIEQ4@"Z>6/SDWY/+%D%O::&D^(R D*&)BMR7
MH(6UEV,VK!A]HZZ4E!0WCDS*Z;WT&N$4U/D?MSRI^/.70$@P%/:"#!"/VC$$
M)CEDZ_G8XC.: 75C&D5D]6$N/]_CXKA2'R.+QI/3 '\&O*(.4B:U)2T>\+0A
MJ7!A  P;+XY'QTRK.Q@@6LQFX/.V"RF\V/Z<GSV::':^<.S YDN0)EK;'JPR
M>*I%CD<?S%S!JB-']MB/5%0<2V,-2U::A[<VSTT0B+/$4^3I7;)\U<5=ZXO)
MAQH>)MUOXDT@P[OMGH4)%^>&,= [#,MT[0'WJ8Z8<<_. 5TU67&I&<&EG$_2
M2U21O8.%&LTY#-R92YSW"-5L_>HT86_2"H8_%O^+6334#>$%E@G]A[8O@=E@
M0,5Q\?>E>)/AEL3+Z*W?JU2@=%O+.5\%Y$*U%;N/KEYQ"UFU!ZT-1'QZT;[]
M,#</HP^H2\6:I=U7\Z9OK&W^>\/XK[KG?Q;A\CL$GS^M#$ILJ(7]'T[.,ZBM
M9 W3S(SML8T3)MG$,3DS!)'#V"8GF2 P2=AD) 2(#"*, TF ,!E$&HL@$$$F
M)R'&Y(R%$")C$#GG#%[?_;,_=FNW[G9UG>ZJ/MU5W7WJ.>_;U?7YO(14;M],
MVGHW[9E:+9KUO:![H5=-3=/(L(BJ"6PCM&I,&]V_-'%VX'J--LII6@/$'(?H
M% S[:N%-#TT'V3T%@_-)Y\O'E(JVYLS.M+$<40,$TL[3/2V/U/U4C>\:[RG8
M(M/8:O_7_XM:_UM2J;N\AI^Z!>1CI\O+8Q<D$4[)-+*J2MC9MX4S PL1_QYD
M[HV8A/XE<]<F7./D,;?Q^?VF+%_Q[:$@AUE-6O.I =SR!QTR/@P(/4C?(55U
M@\N_U9]K=_363CM0ZPV"A%W/ +U*(14H&)A_-\#G/*' WVJX\2QGC "(#:AF
M,]^8;8E2KT<91;34WS+5?GAC?G7!!Q%LL/?3ZJS$N^@ZFGT366URS696NZ9E
MM".#^DL]ZAFX)@RZ!AD8'BT*@V>[;R9="U/@1=GT5TC%C_=%9BSL7 V,XNDG
M'3Q,ACAUCOS<0F\=SJS/=@/JI^34_6+ZD#&\S^JK>O#VI=DHB+Z+CY\&!$(Q
M!% L5H9?^1_$#@3T7E:(6"_C/US1#EFWCT9%FP_)GO5E'4-4GX9.M=[LY"S=
M,QF-/>K';JZ>A=&!K2/)?,)J&FJEB58E[7HY]QP?#)GM]K79W<"GY7T:;6$?
MK^(1B (/*:&#I(X;#12;^9UK9II$@M5Y4HP485KA$/3SC?V#)YT"06+9I=$+
M9O-+<UMBY8(@16DM=-\+!0I(.5&EQ9GBAKT#/Y.&)"-59>>QX^XC+?'L,\+T
MLH:^\L+W[Z51W[^0_6[-4%8KJ6*ADQ-1&\$HTF/)N5Y8W'C7$[ CMEX3P+^_
M)5QM3R EGX7>9/58>#%\@7]>F)S7MUCISR.XM"7KW6AS6PFE_X.N/!0' 6XJ
MNJM<:X3DY2]-&X?!FGRLU+\434\QVW1.+2T-5&6/+NJ:5D3GNK _&AED&^[)
M>C?-2#EASRCL6/E(D+AB/F*O26=-4BS\!PP&V\1/ZB?TW[DE@;0='ZV!TM?A
M'_?DWA50 #0GR@Q^]#$Q91>S;LV,LE\O%S#B MM&!"R.=PK%9'6ORNYKRS]#
M!?(4&JJ (X#VZ" .U%/:[9+K6:YVHVW]QW).M,\6#@$<8H7@MBP?]Q%E,P.Q
M6MWIOHEN?G-!/C&\ $LJ#:$J9&=DZ*:K%5/ZJHHP&4#5U6W'DLX&T;+>&Y@7
MS$9<[1!"MK].2IQ>;J><FXJ?V^+'%-%>E>9X'/!6FHY.%T%6 O683(#;:A%:
M(BBYXHBV1@_<'$!J]!M(@U&U-YIB.'STQ.!R$X/3.^!F#1ZF?]':8J!B/-XG
M.EVP9JP8]D)@9G,!?6!-!!_]F>7:U#!J[KASWBJ<@&314C3UT_8^"XYS/I>)
M$WF0-[Q&.^M;X1GOJ+>\7"_T26[6),5@YX)#B]04=X!MKK[]JP>XC,&+"2T%
MUY/2*^K(A\Y[EUS=PT'X[5HN!14V?[6+SNN-M1<JKP)Y&TYB?[Z@XI5P(P#
M%XMG%*K1$_@T)+>&+Q[>=7T+9*IV?C)@7&U>W\F7CA.0:FJT&J7T#X(8'@ +
M#+&XK5(.YX GAU<SMM#!:ANP^7J0M%=A<-B",P+SYZQ+<O-8_U>%,_\\G<X%
M.W1 >\$N"'JI!7>+,0[VEW@J:)_%3"Q7)H/:[2;.6I^YZYN/DKRHKD0/YT[Q
M,K?)T5ZP:$H W*-E70#G'9KG]G@H^ORCI@>Q8DY"*\TU)B:*MY:PD<^.CV>N
MF!]OR5;TV5* #?) )6;(,@96O&!Z,5&YGKI\N)?M2(?MO2"Y.:<QCK[>/6'1
M$OX&AQ,11+9L;67;Z9SJ37OR1>8"Y;$.^%CR=^&5,/=5A> 3[>G#LDNI;2DK
M]%K9F+,"F+?.3<D*L!6-F"O*]9D]4Q]HYI9R%R\Z<&CL1N>0%798=J?2:NN2
MK;L(4)F' 2WJGG4W1]-&%MA;Z^6%2MT5#9N>0HK-S8FT>#L,4K9E(7T\D:V&
M6GK3)^=&+_:]F=;@8^(=^\0?=+FV#@6>3:PF_2--\0)9!+D1ARI$.?A\4A8]
M[*Y_?F,?F-TDF$>HK#FP^*OWJ5+8!H>UH5^=\MKAGB-J(&.K',:!!3+[E8VY
M! U)3?[[_R%0OS38PM(RDA#E?>^G?JV( ;15Y:+X[1BM,;JF?.Z@/=62830V
M*-4-,902DWFL59QE3H!)/6H3/8ER$X<Y;",*Z^66=7;HN>VR:++QB/3N_-?K
ML=FN*Y+- 3>NEQ IQ&;QI>L*CNKM\E:>DNDW^+$6WJ6$OBGW;AQG;;?PNGVE
MH=>09]F[D9%)=R:_1Z2!G7_'$)=I*_<%U&^$[6N=CBBNE&BM+[?]H+N+@;U9
M4RZK9DPV"#RBR0R?2)5=WTZ E&4-F,6+EI?/<*<%A@U7CGG8N?:??% NGU;M
M;#1IM[;@>&0MYK^8%BQZLR@3O"[*K-17!G*2*4(LI29<G7_>UVWO+IG\LOBU
M:JIK"L8XC_)164:X7 UM<:BN)</3?)QS51-G. =[J\:WS!O&>_Z $I3R;:4!
MLTP^B>=R<I6?ZO?@%'8\EW.103IA0YJ86AXD@PYNF,(N&-T9+\76)^*E1/V
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M/\+7%")8$T,Q)O3S)HGWOJJOM%ZHB'[[GX,>G38GAX62N"$"RO!NH4]@I-(
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M!IT%7'56]M:C&(!@YPYO3VKEFY_S<$DOJ"K'E<\=/_6O*%V$ "$>S?%A;<V
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M%R:WO;/K=_/ B#U'HQ]TQ7EW0QZ3=QC[#QCG@>\U/@6:?@_=PV9-J@CM]M*
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M+>4CN'\=FYSAW*[(:QMD2 7X[(*,J-!!^[50>=B1E&;YG&?AJ6#4X*-OQ(.
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M8)T9!E8DW$CI0%-ALW9ALJ!1_KT3XQ3$3<1M^?5R_!L?#F3QLIJ\U*:/A5E
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MNE%=F=_S?BVUVQ2OT&*TR[&L.&;W)98I2KP^7(:9[-V#V65Z4Q:+M@1?@_I
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M^W\6XGJ3/CO>EK@K$P9RY?WB_7/.M;G*YZ_?R$-$W/[^9'O[$UT47YSFJK*
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M^Q/NN8$KI\W9<J$U9BW]HN=8NYV+@4-I9;YM)F"K$.H*7UHK<GW[F4W759&
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MU<D]QJQ&'4LGIHF)/>G\RB:UNF^CXLFG4V-RL\(=?JU+-,2ONB]#8\^M<@"
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MQ DIF=I_4\K]/D#<ISCK@..?N?.Y7W5/?B^T< NS7 !F.:I8SNF^9F/[[MW
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M\[@29^9N>4?JNH5]C^G!H#;P6/3L*ERYL3G;Q-XBU=0*=JFPTNA_IGS+D0@
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MBN\=I3;3MOT6-);0^RV_=FNWSV[\I%7;4-.F^#:E9]O@_/A-V2BM)FM==VD
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MQB-V;U-,.[Z*.Q<7MM6/]C@/H?"=?6*Q45J=Q10#,CT*S\*85@\>\CE^DC$
M1P_XR<1"7-=J-3?$2E;H%&_Z!-0XP_=S;F7%(+BU?');306U0C?DZH[+!L"<
MN7(@)&QUR^^>AD$Z(SXC+R8NRLOS\@>]YZM<LGXP&$V?NQ2&I0ZJ!;8B\/Z=
M^]>S Q^6&]4;-F9(G9?WG.#.W9*#8R\?HI?.I<;/FAZ/K2H9Z'?OF:EI+GA
M:-LCE(F2M?F]UN>[Q!;4:4#V@\D(BZ@>Y \&T14YFX[%?-L]>9& M,%03D6
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M!]B"@[V$RADY@&Q!1W?LUH1\6#KI)J7PB&;%N)4!T-K>P<T+8;V_%C5I YN
MX)M!UFW*P&\I1X)_A^S,:;N"7DI*2JJ/LMP,4K[Q',&*X,'\7B6F27LM.?@<
M^CZ*(RDXY$.N,@U+V,32-&8WN.[<6C4D.1$UK]]--!&NTAA0:_HB !%.#56+
MCQB\!BZ:;5,XDSU_UE5:-?6#(7*:B8/IE3*E@>^%IGTL"W7S-YB4,IDSZQA8
MP%%O+.G\PK12@P[=?_6_#')*8&(I;!3]D,ND/!X6\>JKTHOGW;&]+[TV%)[4
M@8TE*S.Y!K8ME>PUST-3'COQXX_#%XKL^ X!)C*DW\.HQ[^+?RPD?H'07KX$
M@<U&S(:>:6MJ:M].!?K[^TM7<X; 8$&P4UQQGE/!@W9,[1980Q,BZ"C*@C1*
MC5F>U'X8@_;4SKUS4,!KK, _=L?"\+<:2X4B;/J?\,>9)VVY;*FL0?'B!DB
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M\PFI+EIDC\SUDH[C1I6O-I%K/3\8>*HA+9!9<*S'ETT!-74OS&Z0";>X*I,
M*[$MDNE%^,W*:/^RW&X?[4'ZOX/## RJCPY(;T;<E[YN]BGZOSH8<:@:0FSY
M[15D U7-=+U+FHH$7G#CZHL_X;YT_!X_H"(1:Q*T1L0E^5.HMN5%?F[]B'I5
M[\GXTD_=Y6<62,\)),0ZP)^5N83,ED'OOA6T]P=(J[TD(2_>69A0I3E_^SX
M4 MS0$T_<E$IXHBW0XSZ6;D_83B+(13'H A$#, ; EF(R25\#+FVTN$L>I3L
M6 QH,E6+$^XA%E(E4Y([OA-JM*'&QH9.54. E2-]73><?47[@O8+$Q-1-J!K
M5J;X7,T=_55.;1[W_2EX8[4'=MHA.S+ 1U,_"594B")^W69_/<\X7U(UF<V#
MW^;VJ .]4)('[X8V .=L+';Z2K# >!YW7PJ'T(0;83O:X6C,/9T*U/]8'+NR
M&(T1A[BLKPCZ/D@-6%NI2KJ9E?>0ST?R&ITE0%"<LT.0TMJZ*O97BAI&A
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M'-;9Z*[<I<V6DG3TI[' VX01R-Y0])-5:/X]1=5!)P/YK:+ ^XQVV5"/B8T
M5]C%,7]\@NVSORH*"CY/B' _^F[U^F18\4,!68=/5\C7*C&(M^TP I> W:18
M"7E[L)%J&L,3)V:HY/+JKXK;N"5MQ1!DM7G)"3UO),'\B7"IF;[ -?$RFGN!
MK:;^,\]/KU(.4CY+ 7<Z;DL!62 0.! "4>D>DTS;3^;OF::5]+OU[/MF:=J*
M<@'8#V^/F-J:/!%!1;(W>339V.LS 9_U:RW2F?$;<&C-EPJQGQS:Y!E@+69:
M==(?P4C5V!"+>W$S]AD8MI#(-?.K]\8\X4S]UC%[V^S;8?--S<P+?UN2&F\F
M2ZR;O0WP&7AL>L%Z.AVLB8"MQ/8&N5+B?M+EDA#,T *=K9%MN8V-H[X>T3Q:
M?Y.@_)V;A8QX0L2)R](0TRJ'TKNN'88<WUY@]I;R$"E2F0[WJ.(O:[N':UYC
ML&7S7X,"<$Q^&\*4HY(2>>D1_:TT(!WB-V*MM#KQ"1],][>I->L0-:$DM^ \
M2='11;/AEKCW4X(?B5@\-@L6@G(!Y&5A..H4;8IC-Y,>VB6BT';SB<R]/BZ8
M3[BT1-<>8V%K?0.C\MZ)+IK5]_]S/X+^@P'6H*DK>S@A&6T6)/S=]V'>%-[!
MFEMC<V"S37@Q?EPZ[]H ?2T_=@_P%V&X.D#WU/!X\;QKL3]?'<.CVSL[/I^!
M+OU2]&5ZMV.#M<KX%C2J)L2;?*$<G#6<N9J\EO"B0;Y(.*%ORB-KH<I@4VI<
M0</G9)]E0J4\0 .9_+Y/D01[M[B_]D>J@-7^+W?_,8O+!"[%A8,I-ZF]QX_
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M!I>:]&:-3,DB\44FV;YC*_$I$U&;E[:H?JU2G\M3S%^>\YSZMU /!#<I^!M
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M#27.BK.I-$_B\&)<:<Z]:<U_*Q%RDE!+50W;Y,;)^4;#7UG"[F5UEC7L6_I
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MULXF_K3I&[D#1"]OY5]X9WKW?UP M!BJ23D[2:,0B(T12.S,@0X3UB&)$0J
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MBF40="J\G+)O(,7$^9+>/!LE<& DS2YW:)+>B'L8+7BG-39D?H+C.OGNE]T
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M1?IM'M;O)/>X]DU=K\..<,!%D0T=R6-#VM^YL">',>R6M2-*( !10 M>%#6
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M7WP3JNS2]VU$XUHT(P8D&1#_3)+SC;04U#3L&V97XC]I(K>(*!@Y'/TAXWE
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M-?$!'[NDVT353BFJ68*(^#-&,V=(YSM7;LBY8HF6']JB[SQS_YF0174DG*K
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M<ZY\31<$3F97D<)*'?^S8B.@2M%X1RP[FC4W_S^,O6=0&];6]^N3XR1N.,&
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MZ*5'UE?#V7'>GQGH/^BSWJ" 5P@5IW,_==%8-2ES[N+[T:SIRR&@Q.I0X\T
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M8^S&#$^34F.9B1+[:7FMGI]H836CYPSR_4Z+=V'\3;KF+BDDZ<4T@QDOZX"
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M7^B9_U[I!Z0:LJVQNDO\;U.K)^J+6]F&#\E8A0=%KQBHQWV*IKV0'>.^6KD
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MZ9 2\[[&UKPK1[LC2<!WCJV@8??3&_=0N)0?_@DN[90;J;,V+D"69SW&]OC
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MW79*V4\;KIJ2O=<!7].US+F3G#3;T*#P9X_,TSYPXH3/B''(A7G"+TU_G%>
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M&/<T23XN\KPT&-0YBBNIL0:/#+,%*H?MTGML5]22T%0P/*#RX<52<'I3K6U
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MW$J&YE8J8GY=N\HY92(7I^MX=NN/=UU[YM#,P'H*>];_">G'2E.&Z_2C6MB
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MV3[3T>1,W]1W/=HY"/ZVQH&B,EOPY=HKWHD.PS4R_.#R/Q"#%<S^\DU;!2[
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M%GTKH?0)@H+55I]W?;DVI&F0"G9: I_'TBMSH;F+5T4-\>CI\\BE^BI $5_
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MA(:H,)T%:1TFSH(O/Q CL5MN?DH[LY7@S^OG7ZY)>Y;&2%NVH:I.Z^<"TB*
M?7.GSL<?SGJJ)MV2&W*JHFX/W4M*<81=L?(#[(XZ9]C<=Q_;#-LZ^JP]]G]0
M]P!<6]UZ"VU:[H8MQV8F%2^@'SE,B*?BQ\L3$8*P5ME![3KT8L*(*\PDX:B#
M^:3I4W.'\R#CL*>!HL\8RT&SI#,Z:3_^B?]T!S_9'E'I<&"SGT5M1:@2VJNU
M*(/234[M&#U+4\_Y[9> Z-W3JP_SJ,5PH&C1FLAC;=V.:868UM3YOSYM1.VN
ML[3_*+K]>V.7)ZJZ]Y=&K>!Z>_EEJ*!?-8A@\T<3'M%BH_CE&I[X2D'T <E"
MY](FOJCE5^IN-R7V-O=0@/0(67>;X'GB&$Y_$ T?&B/$]!_K!Q:YP17'+B96
M[J8N<?U;3(OBF&2T$XY77.C1[=X@Q"!6_D;Z*=IO?G_]OQN"B!>O.U[^9=A@
M E]?,B3Z,1K^FR#IYY8,[%RB&RKJW? =)NH_9Y)C+=DA+02_^N&.>J2?SK[>
M!+?0+[LS.5$]8]H38W*C9P6M&3NEXFLPK/L3450$*WR(S^[8IQ4E-;!B'#B.
MI\+$ZYA]?;E8[['>V?AX>Q/V^AF7[_NE5X-XM?W#"H-\E,8LV_?+-?C.95?)
ML097BZ[JXRQ-K8'[U86;^N@FJRJ;$Y'T7U%!)')FM0$.=X*8#Q0V*MTXR]36
M2KQ47_*:\SH&;EA6;81NRT?@"1'!"BG8Q:MO/1UA#4*AQTR[D5@_^Z10./;[
MF_N#N?OY'B:XJF6IE]X&8%?VPC$DQRZA,I,O6V>KP K2GF1^FLGR(7J*_[-]
M4=/*ZF<'7*@*(W5KD>OL/?C6VY8#45 D/XC@NL9SI#.SN>(4K-M?\!476<IB
MY=QIIFB?1(VE4CRV,*OL>T(P:)0JP=-^L-SCFDE,4\,&89XPMLVLZ8[ZU.)\
MX(^1JMJ-^]9*\W5^B<.$?XN?(:7439- *80NPDK:;CZ;8VE(%6 L/0F'H J=
MJ0?_%V/O&=94]KT-,\49NS]$1&F.5"D!$8)T9AQZE1(""67HD!!Z#X3?Z(@0
M! 2D!0DC((&$!"E)))"@M- 92@B$)KV7T$+W=9[_^U[O]3R?GOWAG'W.V?O3
M7F?=Z[[V6O<.J3^2N>]JWI_1D)Z%[KR$UO"IP&C]FW")C0*^_OQC4(Z3Z\)
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M$US3ZTQ!Z5^QG=26BH<:G!RB'-J<&8YTNZ<GTXDU[KR$'T9'B T/WZ5*P[-
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MLLL"3SS3[#NG1150<8#*\3I,;)+\EV?XG&B8/\P]K1A3AC6RO& @H%+SNXZ
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MJI^9S?HB7SGBJ+L:,E D4/R5+SPQX2>D='IKVI+&06[< 1L)R')^J'VB 'O
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M>QI\Y>N4Y^HL51U'?9CNI>K*>")H6#TQ_6=U)R6I^N3DJ@AQYL(-1RVF,3J
M-@]%#LV9I,!/=27'_&>RK-9Z( E6]ULFJ &[SO*F^JY.\E"C-A>E.@1DW&Y\
M=IO<#?U>\\V:Q(Y7IVC1CK7L*L-U34QX2&1=B*0\E/[>])RC840?*CVY9Q!^
M3RLFJ.=-^FIOKVR(_C:XZ"?';^;6SHGLU0$=?!!22@H>Z.6L]?I]Y?M K:X&
MO7K+_@?J:HD/A>A3!WCYQNIM#H]VW-QB L(21_3@!4;:<1VR$"2 1)F3*6<3
MU93";:+K%?>O#UZ.Y"[R@-?-O3],[5\MNN*-/@I%C<B$\_H?I ?T/"%^Y7-8
MH2L(M:]J<F=PONCH?EH39&HY.>?48_QR93@H_P74I2SMS#HH(WQK&\0N2VEQ
M$1VU&[B_(B8RU&W1CB+'2Q8UEYY?<=5$>M!. #=4UE#EAL7CJ#_3/+_R(3/U
MK\D=EGWE XCLF\/?D0>9AHB2LG>ER6IIV!R9WX65DM!;5X2QL@W6K0NL/E=Y
M/*X<H=[@DG-Q'*'"%A<^<)"0G&YYVQ_0?W<C-W=I:C.J?BFLL3.N?J-O)#__
M5#=C3+2D&E2MQ'!.34>*>*4*6:18><$GV!2KA>;?1"OC;-L[/3)(7ADFK7&A
MP)69L'\K-WI#E=!HC-R+%8LW;V,D .9&60+"K<SPUMT7JCF'&T*EO:$&:P("
MI:W, &N-G'9?I*1IL!=51TNC7&% <&<LNU/L@AOL5*#PT,_7M5W^)#?8@!<K
M7U40D]X176NP>2QJJ+K[%K("197VLXHX/8?(1JV0O2+%V-PB_]CUQL_JW74+
M=^NGFJK&8T]0C2''$R4IY#K!$7Q]N9):UH##KU_Y?AS>5Z')>4;Y$&,E",YO
M;>SL0T,,[75R]:Z.!U ^?R168&I+1P9*F0SIC0;$R'@\E;3FFUFO?I#JP<K+
M*\K1OQJ69EO,7ED&+M)J,:N5[).K,C*"O2#^SF5)!W&AZ7N%J(S/X@+,);?2
M__<J-"U4U+TFRC_##^HS(@MN_KM_8P@*RWTF(1$&LO5,OY@FEX=FHL/1K8^_
M\@51;!GKRTICX:'C"+=$1X0\";W@.N67+??YX-@WLGA%-<M^X*UHK&S.Z<OZ
M:<NH0@] BG>?7!>/=_XB_BN?F><;HVK?-T>UPX6D9LIH^"42@G?G;2-W:!_Y
M"'J2M$6]$TK#8'.>Y5R6EX^N\)?S\%+;VU:I;KEJ82G<,3IL8&"@6Q!$;:&T
MN#"FJBUNI4I(J"6]_&NQNR@".U[8NY&ENZ$*AT3DYR^I FY$-EXI"T\$D=[:
MW^ON;DP*\%RLR:5VUV%'-FYGAO+WQM^V/D'MZG>,X<57_"E3<D6&$>_*JMZC
M\!^&6\>$4]KXN7@<6DZDZF>@3>=H6=F6=]WT3"%C5^R1.[;;B(;TI,B._ZL,
MFS$61(W75PN,U%1.48L<"3^296C/1B1O)':Y'<CTVU=A/X>6DW4CHII!9/B*
M_GR-)HC+:A[> -.\M6[8[FWYYGSC![T!#F<B9_(GQ1, _BUN]P#-K:+AE/_.
M,4G8MVH%O.PVK5(Z$C]P"P%B^H:A+X2V_&X>GMH8O\"@"(*LU8!PTZ<+N\ T
M.]SF:<:B&*76 M1MLO&^&.5'31PZR8WFQ/ZY0!\V;NV,$\+VO"EB6@NB8A)5
MU>_FVM;;QOD<#UM=/N"L2:>XW2Q+5GS*D ;9SS#1(?/!8S19IQ;A>4Z@!'!I
M>PO77Y;F>2\O]GHT^_8N0G62*R>P:]%Z?L$Q)"[?SH 9A"?@?JQS%D2APZQB
M@VS8UK5+['W D>#\FHNX1M\6@O]T0Y_A'4FD]"M=3L6U*2N"HE[<KLD>65S#
MP3<5S%JM6WK!OWO>RZ&=STF!Q?M#!/3?FY;&\;:9,\':6YHQ4'^FTC?+4\$M
M0F>M>]/; .P/>[NY[,J@AA'.>C )JW["="8(8[@.G\V_O$<E?^5;N!@VKF]%
MFYKUB(ILHY8U1A2),4Q(Y*+)EG?[;@ZG3=_<NW5;4416[<N6TJ]\" 3BWI>%
M#@MSSX<!$1[EE>^S)*L\2NC[,W>E1<28;F$!GK89D(JQQPQ[>Y;@==[@Z<M_
MCN/:+=M\P[#:H?&6\6_2A)& N1A9MWWMGC-7V=M3W%I.OP_ 8U=\(FN/?&;]
MHW7 X^I4KX" $')E:BK\3CM0N%VE8@8N/%(L"1FVY!?(O#^I !FLAK0:>J@E
MI=GP=]U??%S@NHOLZ5WT\?%]U=,?T#U7V#*PGV_697R!,+FP)%WM"-5$7ES2
MJJH$%'$,PEQ 6>,+$V4A$YQ*(DNG<5%5V(K@X=#O0T^TT5U;0]SN2^]=.,B'
MT:B0[BM>WW@,<#TTVIE)%F7*AOZ+H[4B@_D*P$:#0:1L^CEKKQ-8).CC,3 N
M.OH^\+N7SB WIU=.]R1SP6;=\3H"NF , Q)IJ) [B \>3P?LB?5SQYV%>2/5
M3D=KI=V%XS%5/=H:VQN\AKS2T.1.N &R>$CEWJ.;EF_'*\*Y<S:R+UUT)YNW
M;NCM)]+1FRYEKXZ4NP7Z$?=D+*K/SSKMAO4?S[%;Z%3QTV@<=Q#\ 6$T_6E+
M-)K^0ZZ]BRP$DW,N!M*_8+%3:W4NBC276[@!F"L2C*QCC\,Y>OYU+5!E["D[
MAR$25-.*U &> BO-E:B>!W"S:(1#"J)>S7XP,1&35:3K<+$$!-I@Y_=LT% M
MOF<"/RG:G4 <:@\E1'_:)42(G:XQ)GQZ]:ETXLG*F^8G6&=42Q#XGJ9PYH\;
M!\$G+Y-?+6S">28,M]?IMU0.LZZ9WBCH7I9LN_@VU?]>[J)D:WL@ZXO!IJCW
MJTE>,S9"UM1S+K'4:EY<_$ U&K:=;V#PL*#?TU;B_@.N-=P6QO"XT\OI<;3H
M(4MFZ\Q7Y[&(8ARTAOFEQ+I0_A(QX8PIE(&?\:6G&7%TJ0.*_Q5PF$V@)7K'
MJ:?_IG*"!!SP*G+@A@ZDF!QOL,,SSVS):E'Q\Q;QI&D_KQY[?SV!DKM2^?A8
MAJAK#B+8^3,XI3ERL'4G0>*FEQ < '\'8\@J>*&-:ORD$HLURGPC=WRQM/Y,
M7F1G-69AY:A,3WU:INF*\DM'XD<+RT=#;4$O<VIODVJAT=73,MI[-T"ZO^SX
M5I[=+%3M><-0JJ"F6+%C$A5$"LE5P((VGP'8]'6W"Y[J5S,"8B3(==&/YMIR
M[Z'$M.+:#A*B5C8H5X_+<OUY-XT,K76O[1#OOG2%AV>+R>B^&4;28 :%$O#,
MG(7M6G6G@A^5"0Z5I&/5DMB*A>NUL#D*-("J?MK;GL&O.X!18_K-O?>9OLXN
M.M1:^\\I>__&9L4J]76)$@].K8(L.QZ>E7C?)I_JH'(L2WL6F3HZ#J\2[HE)
M6H99BVE?UQ7<=?P_D_/N+()R9P^!.3B)'N61QM!.$V( 3X'L;/]F11&K'&%]
MLV,^PM!^E64RFRJFF/*9"/IB\:\*66=>6J#8%,.]4(]#<,A).0S)?))9FE 9
M\'%21\UL6@!36Q)ZA8ZN]S (;-H5UQ54@Y'*<^)$3N[$F5$] V(_C)ZQ2<]Z
MTQ:(5"]!^9$ASR.@(D4AVSG=1>3"C]GR:]Y=%1SE+366@'FQ_&'XK&= 9)6>
M:<J(<_I#K^_:]-[3RMN.47_C*$R3G@+]AD$B"">,,&X9&K#1W'DRWGM<D9II
M!KN0(TMYD,?"5*R'02IA>@Y.%F$)85<@"EL1DKD16<-6;DY @X(7;FF#]-5E
M0'2JKKJ^L5%;J.;]Q.*<QRY+'O)AY?C"XV"N_R>&RJ"VH.6&G(4($?OW-FU4
MNJ)'+!\J? "P+'KX_MF2F+EP4IL!S:@+OJ"#O1;N8'\(FD[N39"VTK+V24[A
MB#6'GPP[W!N^KJG;WBVR?B3][A<?4_2(52=^(],JS02V(B_<D3GGAT>*9EB]
M\LSH=>AHUS9P00[ZZ\0 B,53O%]>W=5:67N.OT+AM%F3"Y#!4)1;#+5F)L-M
MI? KGP53D66%E'M ' 0F+%,)!(^P$=#9#J:@>5%"SW$^;=V>&R\W3SH8^DOK
M#VP,W@=35N8/DY>7SHQ9PAIWJ^V:[6<ZE>48ALWG&-<[+VF"0&"0NGW%=WU6
MKVDX!L+5TN]SZ%HE:]P]CI@X_:4J?_ KWP\*"M(F,[1Q[^SC(:=S"0,()_QL
MXPXI/]64OU/:2>YVJN>:ZOLR6=/Y+4>6Z]I<%7VO'G%P#S[^"D(SN_I2[UD-
MM#="E97M</KDPB$DZ8\,//NS[CEQ\T^I0/SKW[6C-7M#7="T?G3,D\:<0;67
MIHE=KZ^F\W>'7A62JO/^2.Y"6AXSG001#,J%V3%)M[9; Z3JX4'[=H+H/W0Q
MT6K-GE %T-/DI+S!&'ZMD%CSL=Z.XDEZ;6O43V@9NX2+@&3I" '1*L2%V31_
M! ]S6[.K*ER-:N8$%2DL*;H)[$J>5=L0%_$;JUP3IC014F>)8ZF%M*GU+/6K
MN/M$7)M*/DO'JKBJ_C>0#2@"KG%^%$ >L):R"E7TM]O,X!0?NFBLS5*R.H4*
M)3F[W6J#P^:*N]U2N_V2BQA_[(HTQDFT*M/)*[9^QU1R K\DC\>3\(' X4_?
M32T]*1@(F014$9@U6IWPG?B/%>]JA\'VNE[XCYZL?RQ.(VM(OB@Y@H29,!I,
MCT".6[#I?<@) N&;RX>+OH^7=1R,J?=_NS R\?.USEUS!B&P;3U7A&41$/K(
M+.>?(5.U\&#-#J(9>@PS6L+2Z-A[4J)DYLX,&).UB*CLZ0\W@#\Z75 5;=[_
M.-;G_5%3VIP0JKBEV%&K?>8Y)AI(H'OQT..3(Q4#S>U/F-8NSCR"XS ,_IG_
MALZD5QFBSV)TUE-LRS\)VY&?G[2Q(#Z&$ME'X6AK+M"(D2A*P584\E5^#009
ME'- 7WIY7;VNJU R^G'BVP:=AG_>,1^9V5OJ^F'?S_XX<6TW;&BT*8,O'V<P
MLWS"7GDJ/;NP:HU#_WE?.+;.P%*'SN?6-O:5K_+LDTMM;M7ZK_*U>UGL_>]
M7_G>K;@U;'[?;CC+\#H!?KL/#:,9KI\D8$)%M>O'PQ>U7H8=')V<EWY__=W$
MD%L_+@'W]+YLE)Z>6]Y%_WE[=GHFO)OS8UCIEIOM=[\-ALT51T66WW*PDL-=
MWT#^2D/[RKQ-D,V/^V1B^'03OKRT\.G2 SSXF<31IYQGWBX:O)B0O=4?)[6/
M8F+)QWRY:&O]J*4M%E_VBR[\VWA7.E_.\V<2O/BS3V[?N0C9&WX_9^#@-V]H
M:"DH"#2TU+\IKWSM1ZNWGA@/'UG'Q='*?@^N<\:N R?A$%+?@>?IH6\SQK1/
M'.!!:3)/EOR/GS+4V&!-DEW3GOY3&M,\Z3/]*U_VAN0>SB)#O)N;SX, )@7^
ML[>E%%O!I@'AE-5[.Y.O@@=W57*JUSM+>Y@UW,!E3$OJW=L]2WDGI4B$%=T6
M"&X!>X'!"@5M-BX&K[P_HU.73@;)^C2[82U?;&/#<+%$6-S5H:-ZU$N>FVU\
MD;F;YQA-OT+/?I4K6-B*H H<Y3->\F+[- _B ?&O.9 .WS+DE_)$2$P)Z]ZM
MGCC;ZLF^U&4VV:[O):S,S+O4J\V/+/NFM;7UI$QL)#]DD7GW(8?*U"F3D9&=
M5&FV>11BN*><>\\T-6]23%FY9)RY+I]]VZAWO*5V2Z[6M6OD-/(D+NK9@'_5
M1Y3RY4Y+:\DO'FNX+;*PU'_*Z*10&9P08S5>'\=,01:(ZWL3A?MIC4OSR<&3
MYI7AI%PW(9L)CY9U<C% ;_7,_T@"6N0^2B":C^F90P5KKD%([XK#Y G8(IKG
MDD&$F!9/DZ!'[PC7JUB]WG_+2B\[+73^3'L-@MP['N%9OUB,]V4!$N^\=1$2
MK%U8I\_ZFQRTH>CTH2\\:E<W>I2+]L;5/C6V2#,PQ0LYP58%!>R=5J6XIC(I
M;2)X(#TI*:;*=O7L=X+W8<-Z5KRFL3Q[TG%&_#QL_-&.$I$=BW/NY=)RH&Y6
MH 7(.='S+^11?T#7$P-7N18TCX</W?H]->1&JL=J(4W65VKQ0KB'/Q/]9_ K
M^&AE&&21+DB"9SG4DRP%15/P"L[80(/67E_'F8=Y^95M!"V(IKF7*@+SC+[K
M7*V6B*[@,*#:+(GBPE.67^G99=F&]"WX"3NT6B"])":A7U-]P 7GQ/5J$964
M"JE#U:'"D9XK48?8ZH4$V] -!9=T-Z[79U%)M1"ZYP&WCWOB=QQ_+A?217O&
M& ))"W:E%:-)NKH+NA96: /K"7KYO+6(:/+GSG])O?V^+F4-T=@BDDI<R[JZ
M@^FK_LI'96@RX1P*<A+W]+,(,<?,>WP\FZ"BLCG3]8ULOHHL+_D8&S>)#E@=
M3P;!]ZS.-_L_Y)@E?>53NN>QO9]5B7/2085;0U%M-I68[JU4[0$4UO7/;]VE
M5,V#6*&QECH87)FAMO7;MU<ZK9%;][NG.OV_0$1LJ[9R82.Z;U:GQ)7_2MGN
MA,J&/C:"?^[W'SF>QL3Z&E8. 1@RN[5B/L!S3HR#[BFRV,6XQS5L^=RU<@AX
MKOZ5S^I.A8KZMV^VNJ?A"TZAW0(MZWD1EX>@]\'#/2-QB'8O.'[-=4IN-E8V
M\<&=!;>K 0/$W7I0]YR8+VGK>#$AI8&21]CWO^=0O;Z%/;&^>V"4<4\OYGD/
MW;H'693*H.3!5;\P76^5(B4I0^/^<WH=@Y+28?OL>DU>R+H&V U*GV3\96T\
M=:&$%6'O.GP<\3WK]$SN8/5"9=HLH=]28.O[Y_5KTW_?SK8?W@]F7"Z_C\=E
MZ#P:&C;HG,F@]Z.-ZM.LS6Y[=.=>FY,1@>1+OAGQD=$=$G68Z2T(RE3]@UZ1
MHPFI_;8$>8/N9';JWZU*L".Y=_C:G@70R/0CY(M(C$P=&8"5(6N7\'QA8S%L
M(L)#+F>X/TW?2N-\E6;%&(=MTO6']1^N%\MAAR<\TA<4]IHBG"I[3A"SB#/7
M-F?($HK49&-5E-+,675:$=2 #8=]B8<I%\;)+:]K*XT/ ^I6#H@4L_X-P.U3
M@9G3! 7JAJ[=6%\1@N-=R1MD-7VILUMD+Q@J=?O8X*7@?D7&RG<(I3 _-$V;
M=^PG9"P1&\>42^\OO#P-G6-/FYREF.>WK;KE;+5/^^&N<XQ[]Q#Z&<K&-3%O
MNP\+?7 L&UJOF\1R"F[N*U_)H!7CUL'1JXVES><F,W<W-DM1O>\09U8[(QK'
M*O5-U[N^32:Z=?1M0+]SDZ\.S!<4TTZXD?SF5ABH?GH2*%6>F7QWT>T'^L_W
M/N[+(MR6"^ <Y)9?U9=**)=);PND.W-L9=2U=7*QI[E$_0L>QR?D=&1TR :F
M&7%Y#.8/4P[#O9C2KNPX%)Y?FBDM\]95Y1!.\J'W6;QSY-K)*,:#'GFX5"OJ
MKT^C4)(/1F K=.OA*M7]BQCW3DN2W'J;"^"DP9(HL%'):KSU86B@N2O6\7X9
M+KE\] ]<ZNL6$;LL3[0Z^55@85)2A&A^J$_C0B_<36HW/S^_**[_;KC%6&W@
M(ZL 'GD7$E$ ^<; QU4KNQ8V%Y@-Z;K\VG1OV!OGK39F(JV*4,U'1AY6); F
M+C0<Q9ZW?=]EZ*J'L.LO(^S#+A0,41M6OUGCZ=G*WG<!B[QB/\8GP 2VR2%E
M??'"SX_')FC!^U47?C!^H;;0DENP.7P#>VOG%)WT7]WI_'B3IL"_82;D]:$A
M_'=5D[(%7_D0O^J5(JP[B[\]KC$-3SX-9ZR,)B^Q=_\D?*+CL:Z?@%*H[+V8
M!\*-%XOJW4JO^;7MR>;^(3R0/,Y<_L%60O87O?^'L>]^:RH)VV:+NVM!100T
MM!4$% 1$"+VL0N@A4D(H$E8Z"45*:"&PNDHO @(2("B=%"(EE-!6.H:RE"00
M.J'WWL&/?=\_X'N?ZSJ_G#/GF6O.S-S/<U\S<Y_7>U HBAD%8)VW[9]-0?46
MFPK(F<\E\Z.R4I_?* V1S-V7I1<)YU^17,,8-D%N/M08\S=9U_PB[01&'6.B
M^VC+/SX)ZF=MSN/"I?]8-?\<GI&VYP^QXWW<F>Y;I5E5A<@L'8:7WC+3[#.U
MG$LNW'AM+WC)Z2.]W: I%)OM@)VT+ WINNH:8M'!.@[,<!5B-&CAS?P\EP".
M77:B,@_.A-2?L-E$Q_I6AH.FD#%JRW)B9TF8C'/=I?8/>@M[;Q>0Y#TI:]-9
M?NHNHZ%8V^GNOKOYK>QJX3Q;2((&TK^:&0ZV@X]:G17T?O:RYA&ACP<,2B9(
M_3(U,MR>AQ<42S",GJHW,\NMGH"R%DKS7*.Y!O+2FWV'E3+MF%M\L9# AT=%
MB:N!QDT@#:V]OSO#"AQBCOP"N89F&J4\_70<QQBB68?B+D\LE8/($2,/[1S$
M^]4%6A7AN/_#@:^W7>0AY5*E]\Y\*A<TC1U@1#F>UC!> H,O<>+>Y$[#@" C
M[/[@5T$-M:P# O3.$+3?7ZYR0DH^H:H1K&PIXN*ID<3%)2\OWRPBXN+Z 1AX
M4F^GY9@9CG-X/-46FI:1+2)EV%/H@A;59VLD]NH^="E),XR>6)+ Z?4H))X]
M%$NEW4\,B,J"[T'M58[%*MJ,E5=B;[LGI$9%K4?%BVCJA_VX9\R@I8WX0F+%
M2/+RD_+MKG-I8-W)9NR![V[6_&_9+P>4F/'.R0.%\28 @?8[TX+K.0V502GO
M)6[(_(;W#<J++?4J*@,:Y\!\.AT25&LXA_INM\+M#3H=C[],50LP5TTTX781
M\UIX]I-OND)]L&'/P>6:[K&YH,G**K5[>>%$_(1+MR0.['UV>^<(\\:*B1TP
M,9H;1O0ISLOHC]3*$IE-2F*1'^XMP*7FA]CRD%\U*%%_#-4E9LUL=_NL!X!)
MRK_CA=O0_\Y4V$8D=%'REWZ33-_1V39/H'G)=%5V%$:IIF_:Z^6-S"N/I3%C
MR];<\=(#P3U&-L[=CFU7 _4))2]&=>D^'0_,8%L[J>##*JD8?SI<:;%D+]UR
M_ N=EF@?HOL0JM /8WE<4#ZUF)X(M9=BMZEDGE7%K0E4?^M""]>MS,(D]73S
M]VVN=A..:R:#6A%9J%458Z4YC83:N@Y61E$ /LM$6V +==;C(&+^W ]21]-.
M;NOZQZM WB0+J*)NFH^8"I3?K;2O6)5-F'^7VG^UK -IYFR?$EIW-=4O[==,
M3P9?C84!*-UQ5\D_/M$3:!'GKP20!<@00+Y%_M#*SE+[6Q2RKHJINCY50 NZ
M)*A$8,=I:',^T7/:IH1;]N=W=*D&UMFGA;+G[1]XA0W.K4W8U;,<VZRR?28A
M@QV>[EZ+&:5E@*7'TR[(?OE3<^B?=VW5)4O] ^(*)43*E.N::?0JOL/#<U[*
M;G1N6 HS!N<Z=*; M-TE=>QG.)Z=.6X-3LH6JE<<9$237AU5O]24,4]'JI]5
M1-YOS[[(NC&IJSY_BRTM!%T ?ZHR:( -"$I-O?.=H[:I0]Z&&C3"@S?$UNSU
M^WLDR:V,=RZ>3#X(CG5UWUHCAVRQ$XU6MBU=)M5U3H38_1CX[@J1(?UWR51+
M&&N!^7-KGU.O%4EBTM9&@Y1;PP[FH8(BV'\V/#<BOW,@49AF77A@J84EY">!
MV&E?61G#2'A/^<3+8Q4?YX(&2F68<@AO'W$W?DY3O ]514MLS'!W6YBT-0XP
MNFL8O."7%W'7)03X@ABCU+F+D 1";5IA(B)XB0(337>T26IT1L*"TI:/0U2C
MD26%F=6M$[J=FOM/!9J&';443GF! H=:I$EE;>7!6O)RI!ZF/1@Y'#W,*LXR
M3^26]._-RXD0N$M:+Z@\VD6X[BBE!W#)-TRN;H55>?AH+D975:A+O/69&J/=
M,*HCH*WR:VP7Y; &W*T5<,*,]:E@(^"J=P?]"3Q$T;)MP<)$0C2RZ\S51W6.
M]&JP<1!P2F>$&?33#R:^',D7M1&J:"F!6(DT21/L><,IS\=]AL>LXKV!M!N)
M5-7N-#SY<:E#7D/WJJUS1J+)P^\<?Q1A#6/>(3;/]@-U=Q>$Y;]XJF=_8?4E
MHN1S)*H7F0=RJGTT>:$.'"K16O4[AUGTUX$2<!H+[1 F;IW(_!C#/+$!Y97W
M:C_URJL>: %YYQ=]SBUT ('U]'ZV&*K<RMU,^.UW1Y'H*$)7<53 G19C_QA'
MHF62@(BH?J*_^G%@;;6*J^;,?A=VA\@:5*SL"^WN[NZKLGC1J^J^MO^A!^@Y
MJ/A^:)@B3U+[,#NF(YFGG.M>-&1[F[WJ/JK0;5SZ,2N%UNMAJ>!3ZXL8Y>P:
MJ3?R<Q\P^B!3->F0.-X_JW#-P;*=L3+UIEQ"RJ%F0.1\!BPTQ!QOP.+)?'15
M7AK!_$7_U)B>5(?RP?D'M,3LQP!OJ> =TI&1[-_N;K1!%U05?_>A1"-2?<G;
MXU5.+ZDRDJ/B+*E/<6L'8NN)F6AO0V>$571(0[GO(0H3R?'$PUC;>ADP9L<,
M&/B+QC$BN,-\>\-L*46I(4Q\\F(0M^=4):".@@*-&U.W^XKAMCL@9*QWVF/4
MW<%#@0J>^CZ4A/UUDW%U><7!> (<G+<E$=P<E#UI8&' HSYO&L"MCS0(;8>+
M"U\[:'PYDS+=>#*T;A9JK[(YMW?_Z<Q!WE<IJJ1-7;RQ@N6Q(?[X6^0)-<10
M,AB!+PI9+N[\\W5B&LPM"QM3\'$E!<@6>I#IA#.]""_K43-Y/IF_#')6\Q,&
M>2>22"0T",DUJ9@1E9A*XZ0L(0Z"4!K,5V+)7Y'V/Q/+!C42&J'5=J:IR;D&
ME_!\U6#S@V_Q0$25A(]:D<%V0.C.76I6K[K]9V$XYBPU$8=)DKVU$T@<5WO)
M.Q(,+Z-.^$3WN'ULL?=T?#O[\9R152B^];4W4S"!%F>S1*PYHZ;1D?F(?(4/
M1,LR'O\M ]&QTK3<8!Y@:+)*7\B6+WY+@]^[^FME"S^&XO 1^4WT1.6@>RN]
MYTR[&'6]HJ'I^7*&=V9P6$#E^6]1TU8)WUIU=%Y%O8W-*<FB70O:G<F=.PXJ
M(0=[.B9(Z=6JUW_G\ %E'J(2?0= "RL/ZY+;5 U[5CK,;8)5'OGFSN[?[@Y0
M+%'U?>X;@+ZR!I]@M#V1BST7BW/F0A,COKK7BRC]PV3^.S@$X48Q#V+2RQ /
MF7"&"M[=2S'3L]N]IL.HHTHDS'U!6!2[-.Y:LDL+HH:Q%>\R[:3<HW)"D?FG
M9=)9M;LME,"'0L<((WH\O+B1'SR^[@C+K.>L:T$A36G#6=QE7->%SF%+UIZ[
M4J&AX8J3DZ!LVJ]X303+3%1LTW7PR-CG.\?$@O"^G^.-I1MW_*,JCSR/'WSG
MJ,$F3ZKM722D6W%%7C'85YL?85VC!CEYF??UJJ2TRC@O0AQ^(*?98W\GW)G,
MM6/2%"\'&OCE,1E91-OH2X2T=A:O;3:@4X7V>X=T[(^D2FHCN_A5/L:Z=LFM
MQK3\-7$\35^QDUL-V/(ZHLQKN@UN51M^';B@:*F)I#=G8?U:SU:"_.4D=Y@M
MSD656CKK,$GW/O/RU?J,?CEW%5%Q>T953GU,_2CQ>'0AOMLFTW8MH'',BI)S
M;N11=B@0T?:%J,T5.<ZVFL/1"%R)V(B(WY;G70C-N12;Y6_9:K/HA)5!:D#+
M2VY^=>6MWIQ,+F[-HP6M1[2VT)9YR&/4*4ZFHG[,*VB%"\URYSZQ04Z1]RD1
MKSI\MW=/KL,K\JEA-J4":Z;J#9?2LE^2>68JT?7U<[[#^3ZVM2CSR[.C45.Y
M>].?00O0RFE5HA,8&EJW^Z 2,2LWJC]%@:MSHK5=JFPUU.H_E+ZL,$);"/2@
M%?;N@%$'Y+@400*LS'">*EOJC4BO@\+5ZQL*-7G2QI8 3]>[3P%^IFI_CZ^,
MS*V*2Y'%N;%HF[/^]-?V[6E5K<ZW-V >%9-?345,UD+KV^'7V\S33<#PC9Y=
M[JD(K;LDD1W,+W#>BU< #0-'P;]OEF65#R4%'F&<%IM]C>SK(/<!<ENTC=?J
M[[/O;QDM V_F7"MCV$1&/#^9AL])M&@4,SC5VTU7C::$3:$_JE""F#6TM@>;
ME'P<1D.G[7/BZSU[/')\]FUW>Q3)/Y7'3C,//C;JCY.4M?^"MZTI0(H$44P&
M[<5>)$S*1@3E.;M0<XM"!,(0/@'2A6P3.77+RE0^?N"W-SLNY-+*<1+TPP&_
M,V,$9OK4MVKLP;PS2!!U"?4H"6K*,!O2'1%)4P*NHDU[+"Q RAA&!V^(K9!-
M6YE-!2^QU=C8V/V_K<7B$@;1TX_7S_B[U7JS<X067-/%!>?50"4A-L@05@71
MIHK8RNA7=W!P<"P;3S2P5],8&[U$F1XWLL4'IO_Z6B3?Q?O9A\K,$I<"1Y$(
M)8:1Z-*CH];G>K<(:>3ITB<-ZZ&4\M(XS5<[Y-PRM'UQ\#-ZP5'OZ/UN,_0Y
MKS7#77VW4!]KW*W7VF:%&5G2FQ3NQHA.^Y.?;XWB_6L&-/OU8]:7!$3$Q\H6
MHA('-IUQ\AYIN!O&:O>:3IX.!?!!<CP8/FX]/B/P#WM>GT/?VSU*79[D)P5S
M)E>IHBDQL^U%T??P$4J:&O==8Y2 *SOM!\X-2YEUN^<%D>*3F,05Q_H@3T!W
M*P1%D.>>;G 9JM>MI.3%[FI]T_3?[L!1P2',U,"/U>C+T_+6 T/5BTX%E8UJ
MYXR]Z(]L0&MK[Q:V]]__BPC%?Z;.0IG_F0E8E@@D#;8F:1;)UTRRAI+*D=>M
MAGVQP:'@-"<0%K?-)*! WK'-)$31.PVM?*>X!B7.O/(DX=ICK2]+=<M!2ADB
MX4;V.8FK51RS-G_]KV-.@\YO*D\2#(DF@"15FIB.";(H7Z]R?BB.F3.@]QL/
MOW F"_B!0K39Q_QMKOLN.O0[A[5JGO:XK&^\L[34E?VB_A) \^VS@4#,_64%
MJBQL  C@B3$IC%>]** -D] (2_IGYH3]ZE^$@7J2'K=E?GIOR>ZG?^FF8NOV
M7^)OX5/PDCYP'3<$-:'D>?M+53*;N'.F:7.GQQQODEP1(QL+AG5I%"H2'J29
M@NP.4V"R10/U&.IM%D'$>JV*HN"58"(9C4>'ME.6JR0LV2P$Q=('.M<1(U&"
M GI#Z6FS%XEG"WER=POH?76Y;U'L3+@7P>)MK5"]JR)#&#9UL[U&C>ZD!F["
M]4VE[JEQH]:ETIXGQ<?.KVZ<Q+F66\O _D9M3Q]U!V=]=E:([8A,_]=9,$JG
M-V:^#MZG5/0Z2^0YSTW\REP?O'DX[=8[7 8,_IU#;]CZ5HN.PE#(2HN]=&B[
MCXNJR.PG$/14/6757B[+.JY98W_<CAQ9#;>+[JBAM2=>445Z4<^%0KDC9YF5
MO3(=S65IHWV;^TN=WV0NGMD&GJ;..+-UZ(+2M<%XMZSP>Q<NZ'S2MT0VO>\O
MC.[>;4O*_;I+E=P\UA#Z6]IJ\=.B/]QH6<+";7!*9_77.T@3 9VDJQ$&N9MR
MD :TP'+TD?Y'8\-S20H8N+VVX_82Z(RW!$R\0#<4<EO:D$=]=%_1>3!:*97M
M;ME!B)+COG-3H=M!V!&_4_N"OD@M^V'U1[GCM+2Q/0L(GS0:=?HM1N^UZA;8
M_ 5_;MC]51-)ZH'L]8%:O$,W-IG"8PH$*S#K$D4(4">C!WDE3! SH='F-HM7
MI]Q*H'3S^&:A]<Y!X6=F<\G\<<U9Q*VN$E.^G%N7;1N49=-%9?H=)?VVMV>=
MKSVGN(].'EV5;+>BV_\,UWCWI=FJ 5X/6][]3[0GIA*NV513112+M00J'Y_/
M+!/2[KV@@WR1+8D!A"59?*T#RM-$76UW>S?=$DKC)7IK"MG_C\B(Y28S7>3X
M2YJ$]>C^?XZHV7SP2>]LHY=O/RUS*1\%;#Z*N)40+J_5XT"QK_Q@9*M2_&%?
M)N]$'^>^;FPN*RNS7>M\#3NQ_G#I8:5\E*OEP=(T'=9/3O\)?M[V;X^;BWW+
MKCLY&;#_+NG1S*1%O.Y!D<-18P7\WZKR'NF]1AXP##H]6Z]\VX8@]6C@S=2:
M*71IN-%IL.)?4P0I%D%;DJGG;IY=9?<QAY$]O* ,( \=;?_5'(ZAND] $8]B
MG]R1B6Z!0G?0:M\*XV:ZK%9&1/V9()V-^=B+J.8/B3;8X[0?]]G#_-P*R,5/
M=.22H]72$].H&2UW'5)QU[6B-0A]VQ>-_L+?ZM8HYA43NWCR?*3C";Z'3/T#
MOR"3?5JSM2?BH_104AI0U?B=P\-I-82@G"M[G\DLDO<6W$WE(RJJ[CGKGK3I
MUFK=JL5'Y^861I,="F,B11-%+>D!<_W>%D!TJL&YD=*5Z8V=$YZ?%LHF5EP<
M$7Y2T@ 1(T&C?$MJA5BE=EZA7Z@9?8#B&J*R-:2_GL$, 0=4G;BPM&89.#GA
M3/E#@D;V8$O5O=[=M=7YQ-=IX>^BIC6VCAPW.X0._HRT]?WT?\!,@3]6JN@&
MODN)FL7%^8;83&F7>Z@JK8,VC*#-W+Z:'<B6*T$':@3N+50*2K*)2Z(5%L=D
M,=,W$'LO?+CS;:2YUQ*O];&C?,[,RM2DNG>BHQ-QHEO&]<="<<M__&\%/_J)
MJQ2J4'*1_W1A&[,C ":%)#C/NKB_ D+_]'T\.IDX?-H"WRIXN8/1"LLSU^OS
M;PR7?:F*%5J")<OD(R<[^\$O-R"?S9< GXO&@QM"4HH+R_#!F'RLPJ'@&%!8
MP3?P./*GJ 2+M?^D@BP G/"=P36  <'&:&'_;-9-,I\V3%C;X<J%9IB57$ J
M6M ENU#S]G)C0O6N.7Q0^*JT^5!J+UCKUN;.40"/#3'7^ETY">C-AO<*V<TI
MO:.D3=LL]T/K@\2CLH*PU>1>:OD8S0[RRY9]F6:C>,$TRKDFX%N\:;W_]NX]
M0I#]K=[B^]!^]8:(AL\>\@")E2)!PT?E=T%:O$4N!4]Z;_7+^:]N[]U!MGV0
MS?/"^K)S[X@+WP^+J@<.?>1*T8#! 9BQN,^_(0HEER\FA=@/IK]0-^<F%T\+
MRAZ)WZ3?QFX-5M#J>\7BFL41TB@Z87[09+NS7 '4XT7GXJH_ ^P??/Y@_;:Y
MW=9[ZDP(T1#-BFZ)_F ?(UZ\,*JP%2:TWJ>:T=8_;67DN=!27?/M D03TL8:
MQK]S?.R5WLG3<6*<<<<@9ZEW04E W2[=Z)%)VN#N?T#:3!]B^3Y#.>87$VV0
M7PV&N+@NZRP3.]R[V]*%V@;%!DWNNR$:$XI D*Z.T8F7C[^)27"ZQ/9%X%Y<
M<R'FFB4Q1<3QZ_!P&7$A7E.I#[6%T7DU[A-Z?VUIGE=\Y_B@+A'#=XWJ%M4H
MJZ2P^VJ/2\%Y9JJAL&9YEHYBY@C1S>]^OM59(M4?[-YB@MQ%O+,D**=!#& S
MNHN$C@I[[ZQ"NO6M;\7S,/<B:?6:_1+PYRS#@!SH($3Z>:EULT&PQ*>OR2G8
MZ,*W'8*F+$JJRHE!@KYN;Q8?K=OUFM4:S%MF8GO8\9%+V5B_)AGVL0H_%PM=
MIAZ]DB%<=MCS7)A;D+D Q]0>.H]Y3!&] SYS@87WK,91)X=\4(LR1'M8.MF^
M\@(H8RQSQ1OCC?#-5JFN@OX0F0U3S 6.$J8("_N^_U)YOOV8AST.VV:5X?2M
M@TNR'J]9-WVA401C[,[MWG[VG6BY,TNC8'[<DL/I2)2,19&831LGMTN[IS-L
M<;'3Z[L7<=S.XY6KPJV\T <X+_6;C$I$E1C6%L_#0RAMS"&_!GUV,HF;B2'1
MIG7FEB#28#34PTCA4XV*S1!(9PZ_S>S..@3LYPY7*'RNE>+B@F?Y6X QU,VI
M=[SXSC0(V-]WZ3#%9-9.K:% 'I3D<G$#I+M\KNK#'F757W&YP,UBF?CI-A@C
MNF7[(_AN6[HWP:&PN)XO^=C806+.A*#BZK",+8R=G"TTO=7NG, XA+7ACP)X
MZ7%E5_^VFJ\%LCM,!*DAM>F#4/.N*EA4DU$$CJ1U*HI(SNVIJAW,S4LR#5H9
M.?A<;9"JF+#?/9N&"JDS>4 X^R;!&;2UF7E8RNBR@]4!ZZTC(<%U3^(\UTD5
M,)*&N'U,GQJ[:K;JHS,Z*;%?B&74UB">M,M#0N87)&T@\M\;J7/KGCC_7>)Y
M?AW.EP"L]G3==T [5H_(<7,VLL69$JU%@#[EC42:8,H)H*5I]89*^X'$K7*7
MFE1?V#"Y,MK<2#+W2=!]9#8GE-/CP<(IL/D-7JE%/83\QE)2!.]&6."/;[0K
M1?[9 W B?N=PZB@/;JF<H1D/L\55&.6OQWN8;8J.EVM=CCRU1_7TB075HTOT
MV%>-=LMW18M)O,,3\Y0]H-!2KR]Y.H974P\OEV!12LDT>=_K(@),-^ G,-(.
MUL$80UM?PY[&#DN]4YY83@*.:2IP!1]W]O*].5&)\$Z;W7]_P*IDC$IXZ2#Y
MN>(%BEQET;,FG5&U$;!M(\DNK?8JG1X<ZO@J>/JXB<8_2GA1UO/SWO;@T+-2
MA&2Y;FU,,;;H)UE.U_([AZ1)F8YCIQ7J]/N)-71X ^2S81WQ7]O5X#6%FZ-Y
M:=/RF3Q (5/0CWI/;[1WSSI*/1RY9MI@D]P>#S-F><?J,PA285T!:<\I;[T4
MIQSK[-Y-5A +/_]9,?R D6NI-VV#964(##_PK)1KZ/:@, %==Z_IX^.WM&!2
M-C&S'Z,KEP3ZY?,1BS^ACR]@:*L.VG@4B*^<B55+H[]EX><C.D#&';7NYQI)
M)V1FH#@%A0%KOV@$!M9YF"[Q!ZP8,I3]3)'@VII]E[8NSICE<-\ U24=&FJ@
M].3=R7Y89;-7JF\/,BVU#U2,R1XXF?LREHHEB+WF2@B1:' B02Z_*[%%CU@.
MVOLU==]0ZC@0OOEE_I!BQK#:!O!:]G?.YXE'=QZT0$%0@$H7CV=C^</?,[!X
M1:NQ*'PT?MG8V"2E)]2DC/C02\C;?=1#^$$O&4NJOE,)M1-_E^CDRS#B-OT0
ML!S8=<@/]24EJP91IC?N>^6*MJD^O6CP#HK*GYWF->^(ZO$]/J"/R7!K3;L#
M#DXOI;&2-88"D,8W_)*QD]K\]=(FLDD3#^_#.@\:1E.)E@H1]=W=*](-3[3-
MA0XG1D3]/NZKD!V'YY##^WBI%TR1_Q$7XE'.?3W!]ZSAZ8MJ"%?-5,:[KP?7
M:)?>8 UMLRUBQ3#?.7BSOW/<@$"M#B2IA8TTL_@BG'/_0,>CZR&-T*1U.@UR
M;46@ "5-=%<?Z^GUM=KLEI*ES<6+)_*T;1SQ3P?@4Q2[$(3:1X;QEK68C98@
M?Q#(+HBG%2EW;=X_'OXG.9V ,PBI<U+"UTJ5'M!2/5E+MI(K8E!,<Z$AM7:R
M,"KVT7:MO\GETNA_QJ,&%"+*'[W_Z8.@X,+>(>]WCJE8B#JIVOE _S&Z1U1H
M-J8J1PRK>C7$<,B.;VK#NR";4'0IT<2P(%C4QDC2)"T$ .2_(6-]AO$<5.OQ
M"M0"O"A5\3*P?V7@Y%$>ZFDW7Y5+GC!LIR1K37:NO8B*(K3=G$BXR<!YZ'_@
MP( L+"R@(-#%QY*4]+6 M_VA833#0^%[!.&K8>B7TYGL*D-6"2PKE<>2Y;Z0
M%+P56BYYW'-W6E71,257DTJB^]N!75.!<JK*7KO*J/;7RS'1&O>M4#$#1[9X
M$2DS*E->&8$M0Z.TD7Q#[Y2.>^^E/>;X85$K%^WL22[$5,<T390;UFP;9=TT
MQ*)CI-*L0PFY!R]@5O@29T]M6.3I5DGZ"LTA!]HFFY$@9GM?[67VTZNSU8.:
M)[$O%G0[B85X_*$:*2/!5[(]AT<0Z*V 6.%;IYRJ3.->M=SW33<O;/[$(=A[
M6E5FN )GN=0Z6_BV0%+G%(8"&)U1<<7Y[<7VMRE?7M'[-:?]<9?LPDVRNW+=
M\2LN.#E!6ED'I^T:P^L'^QK;'])-67^FE:XE&&A_?&[VC*EIF%]FN/!B)D%1
M-#_->PC%8Q(?#_)/II!TZ,8^O>G.00RR1L3H"XY?%AV&01-Y5QN]))_*>P00
MD[LB3_:B5SA![3N>#7;S'KZY0:CJIZ[OQ"!C)"?[\7N;-TYTE]#']P;%D^1Y
M=DQ8C '@9L=P2"H*M[AE(VH]36SU^XC>&!]P4%^C,AS$0^#ZB1ZGF,HEX?O&
M)Y\+ (3%#2T>>S=\GOD7'6[)'M=,Z*,HF*+=DTMV0.F8QYG/UBK'3!6VU]8>
MQ2%.$=\Y+I=FJ:FW^T0GMO:;&(*0%)WI_3NCO"E$7^>[P!?:PJ*J]'=%\X:#
MU7H2#OS*; /D1- 30U>)Z^+G*H.ZV>Q8\;PPK.^L[QWB0->U-&R8O5YZ<%/"
MFA1=X^<Q+I22>P )GYR0ERZHX=+F^Y#"5Z)8,KK[T,/.@@$8<-HX+33U#X*:
MSK9]%C8H$< -/A@ NU(.GB-O?/Y=O[[!?>_AX_:>G]U:A6Y:B#@F_E#T#\YG
M&A(#N7+C\DS2'5S2M$G%,'W:9%9"7S-EXYWZQ-?\I_G[C8LW?LO/==1]']E?
M^+DPW_UR/!H Q7F_%.*VCNS[,;CC[9;!U--I=;.@FT&0V[C;0MQMLO'>B"2N
MD<L92''16!Y+">_T(2?)BP3]ROU''#^86.7B'M[#*L_'Z$K=C[%4U)]U3.7J
M1@O%,"GF6$DW5Z-)P9G#>610]G^GY7.<OM3K, W8G$4-'HI=L[('U=GYHR%'
M],XY?.;5CD9I_RTW)K1\XENZ/$R2 #WG@;L%C*<7XS!+95/#>Z4EB<*+[2M*
MD0?RP:6-XT"?#%59O1[5.=;:FM=WCDB[, SPI<D27V&'QHLZC<CE!:E4?B.S
M]F4"/L_J6[ZC[5A45)1?V8H6WA2@9SL9MEQQZ$*RWNY(7_C.42(7.GADSNC-
M5/SQ6QGU;Y>J<>%;2N-@6-1(J7D[,3":[ SZEESJ\BWAC*76L:#<LX'7S-N8
M<?1AJA9%!+<%JKASD\O3B.ZK@Q!'QQM_+ 8U%@YZ$P,'*@YG;(N\RVT>?2!]
M+F>M[6-Y)0D/UCY8#-TF0N=)1?DQ#VP(BZJZ.\'URW>+-+]S*+X86=@IMV%6
MGE9EY#3/E3EV1#1> Y(>"B9Q<>T\RZ]<7(,MGO1<=:27V>Z+YN>;S,0ZV+V(
MJET\+(V>RP4<M Z7ZCA57J$N8P'[7Z4(&8+2O\3FBFPS5X!KD:"]'A8%<R/#
M<.%*Y[<JU)7O'+X-XY/P K]W6<ZVC9$@L%5)2]W@;FKO=77K=JO^HJF4D]1]
M[LV\6BU>FPR=*&R0<M(=?YTY9DSY\]+H0V61HO$QUTW43+OO21!Y)@\N'-D_
M?V)$B$%_&!4Q! CM'S?.*DJ] Y?G_YZ_X[N#>;?;6CC"_7C@T']Z>7O*DRD4
MCW2R?W+]X3_4RAF\1U."@HF^/4^_<6_CW#<EG2?]<=_RS"M[[[TK*K.+'AW?
M.]=6E$TTT?S 7#WY>9MW?1[VB)T<.XJ7_.BNZD:S".W>"0XSBX6B7"E\"@^*
M2XK^14Q@R:1*;;!^5A"FO6!+VZ66B[L_=QD;_+ D%!PSJ]VEBZ<&A38\0)@(
MJ2J*2ERJ*_9G1DX6C<&4[[9#F[ZZ?>?H7YAGTEY'?IVAS6S:*:970&2MG1RF
MFGVE.DRBLFIVIG("?_S&'KAC<UR:^>/F=%'ZEZJ'K&8OJ@= '(]- Z'I/778
M>D  ]_2Z7HS%V+BRK'M\1NMR>9+_L\Q'1%%G*'NN+X/L;@>WR44(%M:C>XQH
M#N_CD[7A##LN<JW3D<K1/>,1#SU?AD'HN?U+*+%7:N+S1GV]KJ9XF/#+#6CH
M>;FZ+A:(GC1(CP8([0Q^8M;T$UJQ?M,+$FVB"]%J[>5 A#&$XW?SE KF_@_&
M'!PJ:P-*IF:.J4-JUEAF+COP[EG[PP!"4O@^R+<DZ1L-9(R/_<Y1GIFJ@]59
MD!136.^'C3=8:O5[UP9.>,NF'D=,#@AK>HF>\8W-;OJ?M1N<1^/VLQ69U4>:
MZ-Z/\RZBO]BZRV^2Y6,7FJS.@&3SKRD]#3>$OW.H;S'MVE4[MBJ)X7>Y3@M$
M-#_H,8FOCJ$#8ZBCOQ: M3*GT)G>$K\U-8P+Q<;-';M/S:Z^2F],_+V.(0<H
MU2G)9'\J2D^^Z L '6P3]L],O!09/>N10JI\]8KRUZ]#%X'X(A[;F9J_R2T2
M ZU:_#0  6?T!+!774;G#@R$-08:FROY5$MX:-*>-"$RJ7UE90XF@@1B[ IV
MM$R$)$JS%!3( )N79=:,,AG!T*[ *U7,F#]//)\^7_S\C4 HO_:ZK,%F:>UP
MIYA=V6\\9'>_H*26046!($>L!W05WI<)\BXJ$A$)N/C4WSG4.H]"O03#["N@
M-0V, @1B?_MX1>.GB>\< CT=7A9K-:R7J2_FDLS2"#-3L?;-PR*._%^QXJ4V
M2YYH)CO;47<#Y5T+';4ML\;L]ST_-MJC5]90$O 21',SF'V!34C,L!@B;P;_
MJ;*\,.C%.+1"ESZ%Q3LF-$JY#V?VIM(7W*'_8S H= 9/Z(&BH>#VNBD.-?"1
MIY==B-T.N+"T)!GI4=4W7?#FH1/4F=-.S$ZP] ABD@#MEY$;>UBXJ:0#*D)7
MTGNA><!@:R^5U8"2)/L'/G%A)\EC8\0J-@.9O3VUO^7GYJE@SJ37EDP,/QPK
M-N4B+ET-]@E.&GNT?%(;7*B=Y91Z';?R?LR%E-JHI"FIBK*_Q%.5TM;VP9*E
M6/Z;;8]H/)".,@\0D0)HV[A:TR-N_77=;5>6RA3X-<3S3GVJ6?@O@4*ZCNFJ
M$AJTJ][7G7H[9.1 ,\A;I6HQ!4H7HS.+KG5!I@S+F38KH]>65$VRDS?RZ?!%
M[U+P?*V7S-KX%Y9A5V:4)P5EHJ7GC1SKE"PW!-EXQ*R97Y&-,"Q&CHH)&%(/
M[_UM>6AI#62UV4F1/8KK5U0#M-^)$3F44EY6!VQ<C/\_N]<&^XYK4^6>._,.
M9S5>;9>'JAOX?T[6"+T%%O P6**S\E%RNFM\(%#[WA9,AQ$J3QAXI[Y)?\KY
MOW(@=Q;>N#';!+YTMW?=CO-]Y7??,<D4;0H6IY6N-U7/K[UF[\>36M=OC9)K
M*9R@#E%R0:H#*;?5S-I-)*\P*2;YG]4W57?S0N,M+-Y@];]S;,>4!$@B-1_.
M7=FV-;FY]&K$[(>/?UI/&%75.F?*MY9>N FP*;1X*BJP&X$7OB4&;FP45XF&
M>I$CK8JB:7ELWZ)+_6;B(OWYV\;&K2LW#/F=<;9*:AQM\J-&EJJ/<'U@GT-4
M8/P0-"<&-^>5M!B5;.19JRVMEI4EL$@W?UW@MMF;/!S- #H(_N%]Z7K'VKL=
ME>((25J<5\1@O*UX2+D:3L_'P.P-%H2@T""0VT_H)A>IO?O2K"XY]IF[/4\E
MJ*@%4+\\;XT#U]P5I$G1UO<"Z]88@1"8K>5WCENY4JF.A8715&T];6/Z9LO/
M8"=3.2X20L3-2T='-ZF++$]6?*S?*>=!N-?LO=^=QU-G:2U;%9,&??["+7_3
MZ':<'301D9=;7)A!+;=R0LZD 2TU2A'X1\8Z[2F=<UV+D46<"X63X-)*E^LQ
M5XSV%,JMG] P3VI_S^MT$WVW=Z/0<>Q(-+=F$,)C(0W3<'3J M3V.J:B9.TY
M*U<]+$--R4CT"J%X[0,T7>J=L8+E"48:A$(Y&\?'X)(3DOGZS,W52RT\7GV]
MYN675<]5C/^SZU^(>3;466TRC%QAC200,^VUS0ZE%7\32\M@+B[-0V,.DH$Q
M;?@2_$5R5&(_$Y%4/*3C'W5D7VWL8\7>^V SJ+G 973GR35[J:['!+J07O3$
MNO+9^L1N<MJ<1TDR]G-.=*D_Q%+V38A[Z(-DD(CJ0_Y#.!UD(>(@KH#3,>Z0
MP&#$47>%SJ:AUQK$@#+A,=) <5,C$T;+I6^ B(8'3R2O^$/UIVK0Z>5!H\V
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MW__/>O!/B>@*^O6>U:&-JKE@28;3(X3&<*/*CW#O,F"/7C7;(<'*S=,$+9"
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MX\=L">QPMJ/5"_B&XIAO3T"G+- XM])J+96)+G#"GE!M,55I-M^^1>:*X*L
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M?>QEJ<]*N&'!U[F\9WK) -!^*HTN\_56 :NN[X9IA"UYVN4/E2#H[L:Z;&+
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MR^^E]4909[(P1#+P*P+(707ZS);N^6Q5J3^;NNLUUVA[8CQAQZJZ,I!V\7:
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MU;.6VY5F,RZQ"K(:L^;"SWJMST:+'CXQND'%P5[-C=U%OC.=_-L;&[9XZG'
M,W6P<V9K3#RWFN=[)!DQ._[1]>@(EA)5BS(A*UW8IU==07]GXHTA/>R 57KG
M*.RBZ-<^6P27D!;(*Y;E_L %#N1:>HFN6*$MH[2ZST0*FY./AL8A26'"-CV.
MR<6V$<<I+X+JWG+\.;#L,2-OZ;5(]V@B"87F7JX33?QW%@9EO_<E(V_)+?$2
M)%3/<G@P4K\LCW/(565L(9&+Y*4 ^H=I,Y7>^M)\3($BV0_[D)(K-\'@ 50\
M,&+!#B!T[0UX(B.C%^F-4S '8X,*98*@IHW\FI=*IE,B5T,T^9[7G4TO<Y=_
ME)^]P)*M&354$/\IRH9.0M_+1879=9">K0S1=>^YFO,W3C8LQY&6B2/3][2J
MWX_(AU62+3>/^N:6DF8V& HX*JH6/150!ZZ>&@:.F'8M8V+-5RO L(G/?6!8
MJC84*R;:P%H.XT9-)FO]P],820IVG7=#MVP!#C+T05U>FQV^1R6.M?KQFC '
M;+,=<Z+Q?\ 6-M]?Y:Z@&^YG13_I X_V>46]E>RT&W6/N0YYPH@9[->^I1D^
M!2^K,8JHL<,*D>BAN;6/!D)JIJ#V#T:O-Z->*4C4W0,']FRYOI+FWM]3ZX?=
MN6P?4)GTP&.V#F!1M%:NW)8A^G?*,]>$[;[K,VR5^IVZ#TQUZ$[SR4E: ;R=
M_&@T6DR, VLX7]^OF0DI\U0DIJR\LX-Q)Y34TD2PXFL/SHQ@^9L>XP)9-Z +
M%ET;=]OFZ%IS6KVZG L>!.%0-;[ JHUWQ&'Z.-)LV-M86XNF]^&5#LC,,2.D
MFT=S?9\AT[!-G12C(Q^-&+=;#CIY L4J\2E>GEFJM@*KA.+ >=7)*3'7B?.>
MB1O2(3+AY;J*-;J!Q'[R29XY5M.7:%&K)!"[Y%&A0](7.PGN6H EL^.A.-[1
MRGYHGQ<@UX&56::(5-L?9<-)% S<\QKQ2YRND(I&7C.L$"_/C!,(V/>4*JW]
M!O&B;B%PN**A9.XXDDX\6G('I>( FL]K,Q;=I4V>G"S_8(JURN!)I*48"<&S
M1@V1JP< YJ\?!P<TG0N@SW"SNLHX<SRV'*2E:[A(<-:[NT0<O^CS#/ZCLGZM
M7!'<T*WFV"JY]3?!$D.>P3HXUBIYL[]%/M /5?4^E-\AIFT?358X*FT%E!)+
M*.45R/:P1_^T_WV/LP&BL$Y>'Q",<GEMLRIMRB]0==TV74%E8C*'ZP2[!AK&
MU^/N_3_&WC.JJ2UJ&^58CP4]&(KT(U6ZE-"+1WH7DU " >F02._58T,(34!:
M@*!T$B"T *$$I4,(""&$CO0.AM[4J^=][QWCCOOCN_//6GN/-<8>>ZVYUWKF
MW,^<\W,I. 5?V@O0HHC.4)=4[Y(=0NJ*J%]<35@GQK!"7;B@J#:BT!#,-ZRI
M!+T/]N,5]P<\-A:5!NUS'<3W?B;[>LMDU^N^K+!P')O1B(&Z/U-L2:,ECKM!
MRPOPXZON6_N/C],[^2=-C;E\RJI;((.A>2W;$+]4",1(R"5X4#[4O5?^X1]T
M,F)BF5"R3&"I^&_VBY TOG4D,K:3H6/ATP,]A/D2*TN,M@\,B$ODK)'!ATO2
MZZ%%0P4;<Z'PW-B7=&&KG??N-VM?__L+*5T1RU[XRR7#!1(#5HJ+%>C>'K4+
MXQ/+,A5L0\+=X/Y:$/H3,K^3,0!L_G&D^6S)AB=X5]=B-W 980,S+?:4GQ%9
M8,X>*S>8;85"'>C%=U$=[6FK:B!AK8TPDZI$*^*D3Z)DTB1S+13QO5:KXVS&
M#[ZZ[G& -S\=LS.UT@2I<<-440+OP!2#8]<H+6VP;J<8"W9%\P0]\ZP>IA*6
M5>Q5^LQZFFCMV*N_\CNMS6@$OM;(M(ZW\*[?_-33HI7+>6.^YA)6"2!KG2KI
MS8P<B\>Z%='$W&:DA;E\#H#YV\;XZNY>EG]1.6)<Q?BJ2S:YV1\^TQM=<C D
M=\K8.$][93L.\-^W ;QE5'D_622$WY7*\J1BCT.^9Q.39__%^/DL5Z9-ST%\
M9>TZ&O?FNK^ %.5R_'\I]M>\6NS$M&K+%=GX][#"VM69&Y^Z/^>%0[%X(J]D
M^_WXNQ66.]<1R^(Q%M*=05P_F&GIL_NL.L9WC8%VNE9Y")R4Q@3,IE$T.QR2
M!>NV8VW5792)ZW>]0T^= M)#5=_5R8IE&Y8@\+;AYS_(ANY9R"8'?5VK%7FQ
M5..J@GNEND&(M;,;&\F"D-('S4[E=@KI7V"L;T#75Q?M*@>GNAQU:M2].TO>
M_/N_N)L#G.K79L=P^D*:7!+UE('A H<%*KDMA(B?X2%'/(4?H;V*=_\P4\R3
M"OUCGX%!W2VG=_-*M5O.IXB+A@2I=#<C/]"]3,S1:_6+>G*/ G2C>,W5_,]T
MXH+;'W4O'S+-O3XNU/^R,;[U "43&U0J?FUZ:5WZ5[=4F5=22%;'S/V)I473
M^$E<^,UFXQM7LU8?J5Y%<K!>VMT%L><YD'D6R =,<\[SA^@YIK#F4^'IDF\\
M0K6OWH9(ZZ@K@I]Q]S@S:XU[CP7[FM8.W._RD"D9"\[4MB2G#LMIG<7-EPF1
M;9EEAGA$(H2-_SIE%(24Q$P@B39_%.!?&)@,VHU=EE%]<"E8YZVP.T>@3-GA
M?4)T<])-(?9U?#@C#>DCAM)4K.T&8M<H#1B?FMBRQ0*(+>/F ?,D:W.:CK9@
MWIX0L8;W5?<$:5ZD,?&MX,&]N#EG=JT"+1/-.?>KB1:#;[5@_IN[V[RW@*J@
M_)U&DT6>2\'O>3D"A:( YCX:RGWF;K&XW'616K>Z&HQH/FD5Z$F,#J&A<S8V
M(4#),0R//X1F)R4(E )(H :B2QUHN>F+0 ^8Q>B$^/0U\) 3%)QS6PU$VO@U
MKW2)Z=N^D7:U;6X#XD65)\TM+K)ZSO.IP$3RUJ+NO[%R9>Y3Z#95$;H<%M#T
M2(C]46[3WD<.+FV7:"SN;[D[_^G #>4-)[;H.U$AF4;C3HF?P8>$_H*4SCF#
MM_BX9%U=#J5PMQ$+,18S10P/]2C\P-IOE89I41@P0_QD )V;UNR4PIZ_'G=%
MT52#'1 +=1(B#9U6M>9^7SOG3Y4;O7+/RQ,'>,RG]D.BS^S>SC^M_>$)UR(K
MKBEK-RPT=R"86VKG.Q4N(OS(E83(<K+TQ)F!WJ)U!&5:.:\S],7F4>6HE=1C
M_BV:@=4<.%3\B1(TFR?>5ZGT.\M6O4K$\G7/NOH*8Z*!-A;>;P2MBT9-""D:
M_1;OC,A0I\Z46_J=:4($,5D H,W!\77'F8.EP ,R2 Z\3S=4W5.KTKPD3;0J
M3%J/=_+1Z?!;#)MJY.,3Q:17!HH-#VJSJYN&U[J&$9QS>=LE4O^:<JNR[E1N
M#R$)O3V:L-S8JN$S?%990$84&43)0TLHTU71O6H;[KUI?'(X8&K!(/OB=@33
M_RT +2T3O9BQ:(2D1P+=PURC>?)YV*==;ONH!4[7NJG\^&KPN!08+3SIN4_V
MRUR(D!L )Z&%PE9Y!0P6=3&9YA2K42;I,K>]Z:8LP09KD<BTWBPKE^(7>WHD
M\W\,>D6ESS8EJ&34N.^11_R.):7CF/=K2:Q=5U=60"T4&-4\ZICE;O1N=BMN
MC>1]-'ID;/JT;M"S,[_442HDIPWEMEFW'JCQ([G/RF94?BM AZ_ OQ+3U%5^
M%,L,KQ9B;397W'.&DM&O*L7Y>2?#U3^_=M@G&3IVN[%KZO1RT095FDU1F,8*
MG3IY$LR[+$U_)118LN;DF\<GR@<W(A=;+1/Y]8;OA$BJN)&J-D:EGA<X1Z3_
M76<.E7R?"/$BYE6\V-_#)WHM1+E4G5;K8-05\I0P"5IF@((-+HIJL.I>P&4*
MVKV2(*$MT9>,67EK#M'+&+!G5$E[.6>THO;EB8U ##=+XPFS,3@M9YWJB[?C
M1:IQ>0S3@P_Q6U8X0G>*O'@Z4_MN^.YWS3@'5H.S[X<+?+K&7O5MU;US=""N
M).?\7D'^JZ[?%>W>=<QV' $5_R.^\/';FOQD.+4>$_5X-=DU 9^][.*<9'AY
M4KJ!\N,^:YVB39^*&C,R>LUC5*\P[.[!D'.:OO-0*9]T8WIK0L#F,W/BW4."
M: D2B8S^G66X%",J)0?>TG[@M*J"34!)A2EEP&3"&*M#XW$]%7=&)SR9WXF5
M^F":7@\;G+O,)V'3XM]7$ZQU^?>=O@5#$ZPX^81F5([S]4_[)&#"8W,$QZLC
MVA M+0@$Q@1 8G "6EN0B_7;KT.=F^?]?C*DA9]. ZLWK+Q0B5>KS#N./9GE
M%/Z<9@S4]"Y.XA04.-CWM!1Q".7_P://L[QZ/$(C!>?FWW"'J;]O4KD/7:O!
M): K1E4Q-:'TV+#UJO D]]8HZ:'.>9NPOQWOY7L,%,G[.-?]&*V"R2-'S8^'
M=?G(=U0<6>8=VU5'%BM2L.4O#YYR5:[)%F,K#ET/3S?BB8$>HU)VIMY]GGZ:
M8F[;IH7A 0_F]U."[R@C25G-UQZ/$K@O\V<?@'T[$G&"Y]);SM -]>X/^6:5
M&QK+[-5LJNA!EYF;\"CH>K_!K&"Z5&%1S/#(3X8KD7SP=4Z2HT-PCJE366F.
M*(1IX!GP&M^QXYMMP\I)_6^#\.;4+?_U9Z4,/?2;!C\9<ISJGNFRU9/\6^VP
M>1_JS=IR"\61F).BE'V1-1$'1"'*PJTGSQ&]I(,'QV1$CX8P<7P+?3(!:_DX
MD5/?(?]CEA_.U[4E_62$6B<7@Z?I+R8WTKV?N457U1$W('(]5"HT\==R&%L8
M4.9SK*4Y=!*4#TBUZ1(#X[2I,F9<>4_@CZ^;:%3"GZ-0S)E&&\GX>5Y!? DN
M^6,MB1MD.0T3;@OF2 A#Q:+%@CVZWU<U(VZ]8<0S,*@,K7*Z2W*&U!YD&A\F
M[5NTD,KSFZO3W*99M.Z2&Z_-==\I3)A/+#N>0'4]W[]><J 56 )?JJNC5+,-
MR\6'39Z-N$R/;!>17!M@+3&"$\0O$QL"S]]P Y>[K8S#ZH:KMN<X:%3K29.*
MS6=8W,7KIE%#(K4(#M4)0^9W^@*R.L<N;W:0EH6.^<DB_+Y5])[NO%^&:])_
MH8",HTT/&50 )_Y;G1$[?CC.%#75LFI[<S@I0!":G\6MH_\\IC:^,+X/?2TY
MK><TO3\:4U56B2E>>)0].DSD&;=*4%Q?:"5K<!;7!,AZ-E$TO]HT/:/'DL/+
MXRU3;$HD,UGE=@#G)OK.">,.!=HPSOQPD6)&B\6?#%:'\I,GQ3Q[5MEA\>6N
M<8,WGGCH1R\HZR19S14@W'. HZX';[?U1^D[W^]/[\<,*W#>*D^3B]>()2>R
M&D#]HW-<?C*P-@?DB''Y#_/C^H0EH]%.JB^G<=AZ::YQ;F%^GI5K!)/VBIBE
M->ETQG242U;R5>XLE&=N>KI/;"R9'#DP:#>A&V;>>S^<F*S"8<5FO,5?A7,.
MW//Z$+U,ZQG=&3(UG3X"J*;2-B1F)]>XXQO+G4PB;1T<DT_YBI:)U=;')_=$
M.1J;TKUF#%,Z5=_YU6N#1'P;BE_>"?0S^:&U.[_D#;LF*P<QV75M(<W756%X
MS-VP:R!A_H2)MC:]@WUVK6_#UF!B+/O=4DS81<\T*KULT]3-N*PI04-OD=9"
MBW-!W=V0[2Q'P#-?8/-!IA]!20 -_:XEM$QN$>W;#V;I+>_)'!7*.P0F)"CT
M3Q_V$)GKGNZ36V?]SATN)H\:0T)&WK*E\K,#>HL#IMS;2?V.8[3>7M\6="+I
M,'G$S):ZGT!]5U"*N=+IC!#UWMW=%%*2%[G?"T!&;0GRJFA</PF-\72H9Y;0
M##"QT^57]+7TR!,RA_._2NKV8$KN'O^H/K8\U>T?_F[O(%.K7B3)I>K^,*=T
M</B1)\>C<.\OI1\!-_,"PO]V\WDO@WF5LR*[2,2/1B!O/_>)=:D%6;$U1T7^
MZ7Z$?O[A_?&EE,%^@+96JDZ9R[O19)Q7>IF/O>(<1&!ND/2E.0;R#$JR2"3]
M\]EF(7TDQ:XI>OCNL9QJI/\C_U=M7RKVZ#?S,$ZR9K;*)QU[5ES,)X "@Q[T
M<JHFCPW[Z*D?R/STMX-U,(91=&3WJTGI<;SHK$S*Y_=.;UR$HAT'P(MU-7D_
M,N6"TC5ZA%,,Y3:NA08,1?PN,J,@,"6Y]$MO-GTR[84ZY_;?#=7ZV !G;'WM
MRY.;[;AVGN:V=546XMP!GZMLH2*8]0+QZ*%O@L8@V&-25?9]*<&_ZI1*,7 G
M\EY;SF=ETGP>(Y-\AONWDZYWW=T2;K,#^991LAX0CL$!G49LEA@P^C5B"N.!
MR1/V9<*RHP]KO8+GNSM&HG.B3>)<_I<.O_V;#\_1OO/FGU\77&;S$3HA?\\;
MYYJA[3MYA'!!2QWN]^G$ K4?=H^U%L./#)=.8M0%;ES_>,DI*M=_^RMI_A&J
MNUCN[$I<WNEAK9B&-)=5)TI5;:V(:/L"TS=N3(>_[L"5[T.5@2:#;L/",\1Z
M*D) KZ19E?@"($V.D,I3U_.G&IW4BZ38WA#AUZ:]#.E9:K,&-X\&O';:/V=+
MBR4EJ;8,&-[R"*[/*K[UH?H'ZDAR.LNQFF3E7))\_2:-Q;_"^18D0;QQY(D>
MZEAD>\0XK*B>NEI15$KI2'RSIRGEL>N%4N !;5B>1FFPU 5F5,"UOH?[J?K'
M^],M<@*VXH'1F2&M9<34?9S%>6H6Z:RD.[',,=9I?"5CX:VJ+J,+G\>W:G=F
MLB4-&G$_ID6D&-,O+-,==)NIVR_.8(&%QMGG(1>4I>UOPVI@T).LE1"<&NZ/
MK\59:)M='!(LSDF,7Z7A>W+=MA2L(PYI/$?N;L1)";Z#6E_4!##FI'B6&]=!
MK!DZ34P_K5OY>!!G_IDJG[GS5E+%K\@H$#6AZ)WS&Z)V=*4 I*4EXQO7!S?V
M)+ZWCN>J8ET^E994Q6K+$,A(I;1D]$(81@]2CG M:800%320Q/M\"_G0F%Z'
M>!'<LP;$0)WW&/[?RZ%P%%(4%=JGM%R(+4"+HJ"H$%[F_8._],:?HMDMR\-!
MFF),9%]1,0C3X]M&9[(HXX8LR+\N>%O>A!Z?,(C'X*?X9\_+LTPFPNJ;$,'R
M4J./27,F7:M1O_/%RR.4NRI*(IT.@*8S-O+Q.Z%#_]29KZ.":7;^$YAFK#BR
M:G.3WLO"_.>.+-3N[?I@B[G)<_Z*W:6G#"HU)Y[4T<'J3&VYU8K\CU/8,K",
M6%*X^AE7)P;NCIKQ<'K2EXR86$MOBJKS*M^5[#Z(A.#ZWW+B"!Z2PDE/I(>'
M%Y3>>Q#RH9C*)S-;5/"[7S;E4&4U\4][VUFNK;TXV?TBM2B].6RAH[,>PZVA
M2*LQ,CCSRHJ+:<SFQ_R:\:H,(3^;I!&(#=:YD=H):/UG)S^*>J$G>R*EYBPO
MCM)VSU/=3Y)\9'JY:(K<V%^I7,I^T3?L<D0=&F-.H _9\/*VX&DM\>>F'I?[
M[A>9%[,%R]TO.W81=.JJRN__81P_\VWS)3W6*?!D*XC$$J%=MZ+YF/KL'9C2
M MVY_B.NTF":ESD>XE1%P#E@;9!-5=+29;X(WW^2&0+M=M<FQ.))#YJ\6 :2
M+<6#EQ@]7G&@S8/O++R#\3]C4UJS680DHRENX>_Z2J)C!:W-*B!.\0:RUF_?
MXET4%[ --3"_DH':4SUB)+')BW5L BZYSQ9CYTWVB756*6Z8]/0R9?'4?U;P
MZY /(,[O6R'X'6'B ,*>VRKZ)X//?_[%:BRECML&(RJ:]TM62YI96)3RBAT^
MAA9"0T.1A+G"@I=P#";3ZK(:4-44%;*<VM,S%W5W8DTP31?##QWY!3G_NC6G
M++CV:._E:'=34[IG0#U_,M+MP:9+>?SQ)+=:&PNRXB0P,;9DFPI^HORG>^H3
M@V#GE!F\@*^\Q#,"7V1\B&2A_X)D_W5S^?; P]B;,W$ZQ;?)]V%J_#.IYAOQ
MHM5BY0F+781W4^40TP2MJ$#\.@U/]O?M6G*<6*Z(@M3^VD!^!S($7&MX+I6S
MT>7)<N.U_%!#FG9X0@$Z8>D?^Q9=DQD)PS?59Q:Z>A.)MYV!$--8$P[18^-H
MLM7*9Z.%C,5VGXHWIXD]H@LO<;<_=JYQBSDDKR0MFENNV=,^SX>5>@#3PVJ3
MJG T<Y :F[86U>QQ)DE/E34PE1*D/Q;UN>ULA*K_?ILQ0'1X=#&%4L!<-^$>
M+HF>3C13&E9.O@8I21[DSS%3%E8<P]XQ"T^)Y(X5T\.UD/CJGG+]/;W]JB[=
MUY/%8C,PE%S7(V9[@IFU+R@NZX:O"\R?9M()3@4):%=1>*FNF3YG*F0 @5[R
M\?"=:!:.>Y#MHVH347]>M61 ]LSJZ'XL?7KL<6R8:65V1PG4OE#2.\O(.37-
M9G=S-;9=>]F9_CTNDA<_$)^QUHZHDT19V!_&P+VHWH+ =O&67NY(3:L+!%R$
MK"C[3>;1=1$!1\B7X<X; N9 )UU"R6(%#4_8=65![B[/IEQYR"G2%*&V97X(
MZLKL4NSUK/U2KG;+$)Y^X**KS8HICTF_:[E85A0SX%M]O0C\L%MI0(<_%=Q7
MCP^11G42&F*E2(8>:55V5^96F+X$'QBXNY?)F@L\GRKWN__TC=U/!K&Y(=7.
M7(ZPCXGM;^\'OBW\GCNNG^73L0FP<'+GG/_!LIAZL\ENG#GIK-1*7\Q]S>.P
M-8*#4"TAJ*92@$BM@'A&9T /Z]6-\JJXLE\_<*K'%KYL3"M"EJ(/415H.#3Z
MW-2U^66>@K:LJ@\A6;:;DPJ$_]+TO"1I (>I8(@/2%W,GL2QT.)2PX6/B1=2
M]%F:.I_T#8=NO%QF-V>*?&E@N,R9/.MC314O-S<T#.RNP)O'QJN6@75E]!#W
M9VA\=&WCVVI3\_'$%:$_,VJ?'%94]?EGQD?"@)$<!^JY#6MJAC[#]3[ Z:V:
MQ<Y@M$]X$ JJKA_S!FH[J#OVAI'5T+173?+T7]1;ZN1!X!^R5VFXL4NUL-Q3
MVM3E\W" [=+9OZVN@J:2&ADW:A?1KT__+1LP7+NXV%I$A&$NE\5TAJ^UCW]@
ME8E,?,X#.V?^,X:2FRY'V[S ^E'I)##OQ=7'L9VJ*:B0LX>O<[+/SEL8'@T,
M1,RF;%\0U8F8>6_+8$G4P+X-*KL!3*0+XZ@SEUUDQR=:OL*DLYN: /B'Q!>Q
M\PN'(4$O5(RH<X<G026 D;6B7-?RR"_"I;5S1Y&F#P'[T^B*[?WMKY?Z#7M5
MAAB:7*4LV>B1J)# #QRYIV+KIY\^5J!": ]%#% ^F[;/GWQGT#7(9GO+O+"T
M,?)G+PAY&OGF I__"LY5PT[=IN'%#64$[M9/!J\E\ 4>2TJBNOI@SR6;JN.&
MO-#@"/>Q2^%5N/29['_QYL)P49^5[KT_/CINV^FN7$A\ UPZ^/XPW!C:;!$5
M6[RTMWI9_3YV=N8R,%0XMVF'UL H^IW-EB<B),A[=^NB0>\OC1O)^<E@\.)H
MQIN6Z*I^[>!OWHB5FI%6[U]-UECS"*/>HJU=^NZ+<@&[[99&Q#[]XGQ/Z6!:
M2T_IQL65&+:$TB)B8MEMM-#1BX\#5("I)7-VH] 'L[W /XPM\&S#2.S!?>9/
MPT2[-Q9O@QCD)&._=P_';H[<COG<2TJ45%[;'+F1YK=THJ%XYX&4P'Y(!(-A
MVY9:=LN?C;L7H,*(XAS5=-J'.XQ!@C3P&5L&R\'<LJVZ[1>1E@DA-'[_CW^V
MY_("OS\T@PP!+[S*F6@L8<XN6=P:N7XG\&\.%DC(BV^,ZE>.(OX._R:<2QJY
MTJ+RU_6X>$CPF?HWR<P[01&AH0P5<? 0[\,_('<Q.=&7M6)M?S*8"IP]I&V#
MR/O_'JD[[:^W9E_H)+T,3=]8*N%(%C US;<K?QA6L$49NU(07[J4]Q_KO>PV
M<4N#8%=PF[@1162A4$X>GK[#_%C9L,,^EA-7=SYE6[^03#F"H]_#& I6LU&[
MX NO%O;<U[]>9M.<WO<Y57JA/71"H,^-8?=?& ^YH2/4#&<'TSY8JTN&J]F<
ML;UCW8DU;2*O;5^@#OF91!J@OX@+QZ@0WY\2]BY^N=JK@8/GM))60]6F#:E:
M&4(!_BGGR&E)%K?3< VU1HAZR#>7<LTD]S*K@V<[R0F*TW/(TY\,-_C\*F1(
MO/#5K)\,,7:5RQGT42%WV4FF+G>U;$5R "4*/QKYQLXU@OK]::ON.GB?TL_N
M$FJR(_ ]ZA!]-X@UQ_4JC^41:R9*RR0)[8_L7\%CUU<W;W_Y^G]D"7Z]C8W'
MICB>%LWF5 3<V!JQ[%IVBDU\8BSN9S"E? 0E\#"I)O]39G#:K+ZC*;,:#[:2
M,\>;07/]3BYB0-@34_N6@O[^K0W#7R"QOK-"/*4[(2746G])NJ"CWR>2YY2\
ME'5B.!*)_Q(.,%)4CK+JYA(^YJJA>_ONM">G[![*N\2;F2D>"KOF]X=*7DNX
M?6G6/ #-%5P=ZJP-]]D\2W!E1>DDY#3%T/O@E[^BG<Y,3-D4;*<?>6:&R2G=
M]-TXP^P9:8\O3?D"%[_Z[=EU-(<W-S'V15APIMWQD4I/_S"1<,26CEI34;N\
M?TIFA[A.P*YO'O\06UKA"RYJ3ML-B1"JK:L2%](>"B<P+WI]S:#>UICRR208
MHB?6,*S%J-,!!;%*CY!'MSXV%A5SHX"9U+' >LIKOT=@:<5OBOVIFX'<Y2LP
ME;]2:EX6![:^7ZBQP(\=CBL9\%F>H"PJF@F$9J5PL:O=18VA9 2D=Z$7QT/%
MYAL_SG/O;#6:U38KW]14IFKOP@E.D<.K%>6JF1;[FPN+162Q_+BIQ='2B4"Z
M"5<3<2&YT_;Q1E;3GBD(KW$[-Z;7_JW5U$QP7VBF8E&C>[LMKT_?7 (3MFR[
M2#CE[Z+E68L)WP;_@)Q9@7Z;%CO[WM'@]A>DB7=QX]CXWMXP7@W=E3-&E*_;
M; J(P,ZG5'H7*N2HYU+(Y[V[__V-[ T190-EI^W[S4KBYELZ/=/A38PJW<.^
MX%:X:. &QF</[NZ,3?X<(?>HGPRDLI%V.91$QE8>N,1\1:+4G_^3'QIHF-:>
MU<(I$+HQ.WG": W2][7<<Y_\S"VN>BSU!3&14SG3G0.O/*HGC=I_3?W)X 8*
M=YOY##3V,QJL\BP'BZ'J^.CJAV],AF-IIGZNW,4PUFU;L:GLR/E,+\<W3;E%
MS1&VL$[SN@3=6VKFVRF)M:/X(ILT<54.M?D,XR9KIBA>5;C6#'O77>J! 'CW
M*]]I5=U=A+[1_'#>F",!4LW:>39!:Y\JW5']R6"W+$YOAWJW[R0.'G[,-HAU
MI%0==:\^"8  PR%F9?F?&:]CFGL=\PUP#CX<,M%;J<!M:4JUN7:1DHB4;VJ_
MNY@#A:QOO4P;=<SK(>4;%!?^^:TZ+GFX?'=1SID>L:7.(]*?>$,JMLW"YR3T
MF'6X&6KE-9/\(DR5P!F\H.]]EH50+ERC:9E*F&CR*OS1.!SPNL-D:56!;LK-
M=2MX.<61$"$T[:K+E(;IP3S3:HOGL&F\]Z9\?"(CWGS;=M#= CC$C3&!W71-
M)#@]2MZ],P"D:I,^56Q@93'H0A! IJ;CI)2#H^>O2U=L>>BE'!A7%EJZ@-%J
MQ6A(8)J6^_5R9Y)5>V7?/>,RS-CY#.5^3"HH  P/->3GO0)P1^B<U,H@-=EK
M+%X8U3K.OVK+-PT-?QP,#C9EYKFM2!E+!.PTV0EP_+/P=C9HZ5-X#QU? #T,
MB=!:[?*D;C?/FBGSSP//T%Q1<>I2;*.?EX7;!9;" S2R2!L JRTC9W=H "6=
M5Y_GVK9IU_R'5185U18=@)XUN[WV%ZF@])(*GT&''M*-H$<M,[:1E_VLWE![
M;P1I+XOA^4+J?)8V'_NI4&A'J*.B^*D0%?/!M[!@J8*\ VJ//7DN-2Y)RH$C
MO0*](OU*(;QLE@-G7Q@>&I8]>G.J&.RLI4IK<W/)K]Y4X%CC( @/Y8+&A?5@
M#^?.FER@C661RE%C"IS<A>>(]QY+$YCT8VU$PE7(EW:)X:1W,HT3U7T]^81A
M4*,IL]ZARD#SR9)1)'Q5*31<VS'",NMK[4"2#3[F6\<$'X6Y=:1UJ"XUEUEK
M D^956,_4(A82\R1)SI.DLLK1Z4]JW3/)2?V>.]4 8 Q+?YQ&?B,Z%Z#C?UP
M,W5Z%1>.=U#:R%6A8]O,5OI9-V_-DN+TQ!5C+@45EA^SI@&UM$YN+>\1K;[&
MZR6+.CU=:D0)KA$P6)U_\)7\I-KA))(LN] \2D4'X%T<J+G/C(Q,\6=FE- $
M$G9_D]NZV"FN12,@*M/'%CA\O&LN9:C3:))6UD&/1JM:,8'\_W]QR?^<)*,G
MWTU(IG&2!0(.8Z<;ZRC^'S-MD\RM*^2&GY@_Z5F=ZN7H75OV@T"7"4 J"UM,
MJE1X4-S['"FKF)CMC,4N:OF&7#U'O[N4'.=L+:T\=2K[[85F7?"QFR@W)'%:
M5&3TBAT=0W"VUE[/ 5D*&$3G6Z[H91]J6C!_P3;[* %&ZCC[P[;*@Y@I5@G2
MTYYCYSGT@L-&EQ4OCSKW3L\!T"QWRO><9DXC3^#_<-*OQY#5A$"]3E)SL) S
M(]?D)](*,-7E.[TBEZ 81+%&;9?S@_<)4@KI4_8RO?PLRJ+"MZ6L7I,DV(:>
M'/'A;NWT.<KDL T-"]_BM;@M'3>N?$-[^5!X1E4'::B-VXYH]5'GU\%1?S*\
M"?:A-"2RA<RE7GW\O)<:<<56P'WLH^"5V"+4=QM""JO<8^AE2OH7I&D, #!6
M5"NY:9IO6A*<Q'+GQ?;W'OHC?U! O;9=.PZ[6ZHN%PPV?_&\X?0:'7#]CG5J
M+^Y%,!RUUFX;WIU8Q<.;:0_$RP5]'?*G)",^#4C&O'9*H_F YPZ_[7^3C97.
ML*[.)'\M/^W-E+-KOP./+6:F)'HE9_07L</JNY!4\-QGQ8BI/LGJ\OY:_5,N
MMIKFD<;U>I-!(2+S0J>:34M1SAF-2D@KCD0BIN!V8\3RWCJ-_0A;FR_4QM/Z
M"V]F7Z 3ZW=1H]8WTS*#F4F*>C7)&8-"!@G?:;@!K3MU8-H+V?[T3J^Y+V&/
MZ_T"0/?*DXJYPV?=N71: T>6#AE=\<H\.Z1_RHXX?C>[_-K V'Z@')1DDAU\
M[[V!G/:@ 3+V\\UYR]67I?DK&%;MC'[IQ@D81[/<+J5UP-K*_D$GYL/*T>^L
MW0J0Z_2#PTB'U33 33A&T-AB-\17 GO-\4"DJ%GN?.E=Q>.45F-P];VX/*&L
M7(!BE'+>4BF8IJVI^!I>!1T0PQP>L1];'J-@WCK%:^L%P8SVKH(DNVEA-8N8
MW!<<9;.^"Z=V^NJW_LSR!GE0M$R[)XO5M\"Y?\R;?ID.2,J-"<X+/-K5%L4K
MRI9GQ;H1CK-C*AKY_ )1/@O3RT O"+[&;_.(%V!]G-+TEF7(HCYQ#.Y4S-KI
MW"0/Q?MV-7Z;JXC!K7DOX'PYK.Y%.!/\[\"G64(..=+>?,O6I@/9"/Z']$<$
MIZ+]+2$E;JP^(%.ZES<5\"3[O"GV7MP'T:S/P1%$S\%_G!ZD25NB@F/A;9:I
M\+TAE1_#I]BT>S:+Q@%S@[E>GH4'%N+R1*]AREL-2>V#-T_:$#FG-FSUK1OR
MHA66\0A* G9]97T_G0JN$ATW ^Z>DK WA2SCGS4>IYM<PQ3GOCR[L7&],,[D
M1V3UF/W]F/1,)VDKM6 WYXF$3IG'HP,4=E.'>8UA(3W#1XWN*Z)ICS,*@IAW
M]^Z]^9@MHR@PQ*3&FX&QSQ::R]72HE'&+![T"8HP0HL9PUN* #?QMG4U[<4\
M8K/C!W>/09B#^DMP./;$@KPL_:VX,Q_D&3M/M="BD/[Y"K0I'.?(ANT73^B^
M(JA+TL:\H!JQZ8FYI.:8+NV46EJ!Z;1HT \)I="^%4[%:H<;&W;'9A/P[.!?
M7[5+=$L7(/X]+'2RR>+(SN"''^^5N.;'F'H/:/E1=#-5D:ZUM?-5]U\ZGRMN
MY9@R49AD#KCOOD%!!E,28M9 BECV-* 5.#MX8\-D>)WZF@0H*S.& $R]I.P#
MX!7.T39%VI AN:V#0+9A1;',1U8R8FGWWCN>.*-T.@.[I *;OE?KXJMU)LZT
M_5GVL>)>NC*6+0?*P:A%<T+C;_>550JWGWT=YW?#48<("H=T^7)Z7.HI-2/C
MA.=C67V6B[9+[2(KM&%CDS;I?'F9 @,X.4'J2#GBD%H6GSH773''TL*<1"T_
MZ**NCY;MU12G0KKMV*Y.>EF_49"1=T:0\D1]F6TS0KHLK%#H:<__>3O_@S;;
M?\.I<#!P.=>W#$P\$YC4@\,E'W=R)980[%.E'+=+1I *Q[.)_3$P++4L(54T
M!T. 4C<C;6:[9OU4;%+.66UM28'AYRVGBNCRNN.&2*!ZB]*98_WRRC9UJ'<6
M]O1_'G/Z"UXX0X)30>DA '*RB8!N2)SS>P'[>'";\X.T*!X>Z ]C(R$K+8&\
M5Q"3*[+B>6R;128+C*"\4V5C,\60T..[_<7:M,\_>&"MSUWM>016BVHCO2IS
MV0 ZKS_2I:3R[01Y^/Z.N"K))7?6'</#TOC%&_(MCT\XZ$ZX#JI\^E$+:9.J
M_SOJY^.0A=8IH"'CO;N$QH7MN?G7J\I3F&D(4\ B*@)1$AO$PW+5FJKAC1ZL
MSY1V<BNJO4'Z//CVDG"'6TWR>%%C?2+STN26D!26][I\F .F(G[S-"S$5S8V
M7\MOE:>3ELLRU[TA0W\D!TG@5A1U$S*^LY]T;(,*4_QVVK<EGL<^7=PQ>P5;
M+/F302$_"1> ]\S)(1T_9PNZ:+*%K#<8_LGPQ50F$,=;1FF6POJ6PS'Q8(H)
M%PUY>HQ*AYDO3$ "O*AKQBKQ"!Q6KA ,8PRQNM9 >_$?P7WUE+(.8C7PVA2N
MXL:H\W:6)"S$:E+6A)3<$AV0.J9,=M,*Z.P(.Q\N4 '/UA5BA_NVVFS:*[NG
MQU6A5UJ6D;=?L"@6IV=GI&B_KEWK?AGBNP6ZGZ;,)^K.%+R*CKR<).YR][LQ
M?_"W1SV_]EMH70[3@+%JZE^-U6WV<=3VP<JZ7YUXJG91\XT\"(F[U 7U32+J
MSK\E<[ATAS3-:YJF0JB]\U_(O2=*)@85 3S7\?DS4X=L7CJY_\/3Q0=FV5]R
M[IG;>'KM6[ZE6?)*$4H)-#A_WG8?7I6\-$B/$#+3"DZK(*PN_Y"<5CKZ)O.-
MOZ.QN#$2> Z+Z;;=&7"4,[*.E:J=?G[C.8?WIFW$$EM>WW@C:Q::N$/WHR"E
M!"B)ZJIJ186KQ#K/'!0!0C9E"Q(PZ=P[>4_IA1RD;8QC5'WJ[:8P@>LQN$"T
MGPF]H$Y,N28T*#\).VA[I;FMQP;CI\E<CLYF)M5:&F4S]]WMN_-1Z?3LK/6>
MDW2:FOG(O-5-0>3HX>GY;#81LY+R5[EQP![B,!UB\^,*M\TB7*7^BYVEA;@H
M41L6?/2]J-,>7#E!VY@WCLA64_Z=P[P#X:1%][.3JB1BEF)&^YLC?S)(/&ZL
MK+!,=<3;:?#6[$AA" \'MB-GJV[<>YW/VS]8%5>>&@ 1NA8N>'VMIPL@-J:B
MIF7PY N.]=1@*>5>89#@6>3KK64+\3DU4TDT-##B#>CFG!2WJ2#M9>BQWX,,
M9XR)<HO_ FEPZ>/K=@D+,YH/!4P!VPGPM\$)UNEOY+07)HNI1QG'0-/8*G,5
MW*5SJ*CP(L#DAS[=;?1LT$'CK1=O_2/5JS'/C4.I  MA7J6X!2,K%<:#$E09
M"B>A"JT@XF'75S@U[IBE%X0"9]0@H(2*H'*EM?[VN6JZI'6@B;L0RF>E?6WH
M9CA'<>=4/LA7ETXO0J**66 !B\WZY4SRCTQMLY]S!'Y'^_9@N1\'!)0EL82'
MKB)SGX]:0?L?9%*1YE1IX'S.C,VO$VK9LM#90 VWU+ZZ^62]_5H:D^UWL_,#
MJO_B,PBD@:!"$9J *NSP3I%S,65IT^F3JZOU_)Z2PP^3H>5X?QE9'I*;9[+T
M3P86;B&==$X5GB2= ]/7^@UE$DC;FN5P$'1^6@=]-[/@B+Y@EV48OFU1,&E%
MY)GF&SHN7AE5=^6MO_K,KZ6,:)JX$CS=]=D.,#,F4/IFH'[*T6&-;IZ5;:O,
MF2/6Q'LS40L&W>)"QE#SAMQ&N9H[NJ\]=='SRRV2C-^=_M)B+9/SJ79*NKPV
M'\4QSNX3!;]1]'0,/<[N@1_NW<9\Q4/XW-7@^4P.D&?75S!$95RR&(?NJ"O4
M:&]Q1QZ-OJYWK[ PZG==<,?B7Q+_7UWP9][M-Z7Q_]4%YQC%,W%$1\=\Q+1P
MOK,4/X$D;,0O,C,?&0IN1^5-^M6/U'<R0KC!GDC+Z;S\L9T;>,1$R:$2$QGL
MRY<GK#^JE-+]JN#[[JJNK[=*J@?-PPT1=/M&TJZQX>6+[/(P]Y@!B =W %KJ
M)NU-#%>\T[YXTO!J1;BTM_9$!710_4[>2,92%Y>VY[BG(?;)U#1Q@-O;XJSV
M@Z=P))2:Q+E@+BCZ..PG ^^K!#2W_[S5?$)H5YQ_NK2\\(>M=O*VOT+.<![V
MDW>/<T)H;(#K2_&ZHQL\"0$LP'H+0\<$)VW'9:R.(:_\H^\!!N5I_&^"2<K#
MKKG" 8'60"QWK;6XO/+U,&?TH*:Q1YUU*?OV6LFJV_PSYI%O]1"[2S[2  @$
MLHS!8E 4Y8$:LJ_1+6DOFH&U5ZLR3-*CI*M&SWW2V#C=*N\-5;;S#O_38N)C
MPZ\O#XPO@G2"<U@T.:)'C4;AU(%,"5,_3G.)'>];*[N4J55L.&O$IT\;6S\.
M0/,5/HNLJ%F_[G;A3T\F=AZ'4>>PZL):/]8,B< P!\BYDE?%\'EC%1=\03]L
M^F:27V:IP#.ZH_F$DH?E0E%\S^KP$DA\=PK'O%HZ;YDD<O?@7(9_?!Y16>>.
M9OG:)]V-J)J 0N&B\%!EY6"1^VM_(].2D]/NKZV5NI<N/'L,HGP&6#$_T 0P
ME3F:<8SF\0F]$6/Y],=K)T[7>G9GTRYGZ^>OG:CA&FM65T3LFT=^,(--9[?E
M6&2^Z4IFA^G'&OEFZB2I4EAO@M@Z17)T8QT#;\*3>CH")%X.>M: E/B]HN3\
M6=?A;JG\7E>^?<U^W3\HM\;4J_[P_PLLN$4.LNJ&GS9]AD46%EMNAD7U^D)%
MK#DG;WB)\?/UEJJMX]DE+#;8ZJI-;Q%9+61M12/O1ARU/.A=Y(4J<#]W3T!\
M4>VU]JJ"BDE;3FVPS#K2W9D0Y^[QY/TEV*A:,&F;5^N<;-NZV!^A(8&?W1^/
MDX\//E<3\K8VZ3OF\^EJ7F')?EJX'%L<Y)H;L\NJ4 9+HNC.:U'J26E%/Y37
M*<VK/6OV6F"[1[L'>PKT88Z@&H'B-RQ,_GM!OF?D<W]:K,FAT><KF.B8CHE"
MCM%&6V6(>?'E0[B'!>^5YL7Y,\$K)8WU$-^@P.^+D[>:>TC=+SL/MP]W=[_D
M>8O']9RL#F$K<G6]['6,H&'I%D)8MO;BT)!:$;R<-2OU'_*W4G"[H& @TEZF
M3_1+#5\$$9JD,*3.6E"R=Q+!/\]SI1;[;16Y?:,S),1/>'XU\2UF6[1CKINT
M(U%A:?',71$+'%+5WYIOB2+[!8K4J2D6B:RGO^6.B(1%S:B6(Q8,N\TJ4%+I
M)9,5QM##/!-V,Y!Q2!9S==:C+>X9V)T*>!G2>1#)%\:K^??_K--%5(16.Z<N
MXJ'#'V51/LHO?MUV?V+_AD"\Q&#AQ5J<O_[URH??XZZD^]I)?LE8+M)\P, @
M6BRP?Z<BA/CBVVWD*,ZUYE\.<WG<TL(1X]^C4',IW1&==PB)&VQ9:Z:UB3>%
M.R5NW,Y:_1*3%P[=<S^Z_^I3+EOED4C)MR"TE*-%D\G.A]R;/&*B LI!$;F/
MD>WLM22H[HK6?LB]M'=1N LA/P:;;Q-9CR):+2\;,_E?2X [R?ZN,<8GZK.P
M)OAZCR5FY6%4[H5#T3\^0EM*CY@^#,T]DC-%@J<&?NC(WIP'FZN%Q0F5T@C&
M0VOCQ93##+*5%NE1-\Z!:<XTOGA:V#<,G'@)?1]D&5Y[9A0NGO>E:+5V:?_N
MKU&EXJ&!$1QWR:#YU((X2F)R*I15Z\A7>R"VFT3*+ \X6'Z;B2':PKIRYJJL
MMK1)O.H\L)D:*-7.ZB2I6GN91FIMIN&!,&OQ61/LY[^*W&7JI/X:^F;K.:!Z
MCN?_NIZ+#&>-;E3H5[]&!Z?%IM^:V9&\ GB3WODD@BUKU%$1Q&Z.R]?:I*47
M5/B(QZ'*[0Q_,@AOGA)2!^1] K!K^WMN$,5]*[9M:"/P$0'GVU.=,N0/WI(>
M2@=>8/B#8_72O[\6;+NF,+LBU_M0BKNHL5KL_?$\V-XB&+[V=X!X>57!K=J.
M2@(OMZ%5PLB7XYG#_%Q1)0O(N>$9[4AI;^G\9%5*OVYY+[)X6.B[K-RQ0]5/
M!D'D=S2_:7D126A4(B0:7QV\/#$XG/NFQ7;5[,OY05-< '*K/M33G:/_)P,G
MKB.3ED; INLE,,'D*.^]R$VL71(LURS<N\7E^PH0&:GR&]I$Y,>[BV"_)W!X
M<,$W INVL3]H7<TEI)FD9_H7 T--@W7Y$5QIZPC*H9)SV5!MVIBQ+>UZGW+T
MR;%P4:G3NSXR* 55<H6F6\G)SNBU<;?NN0<[!&M#*P(DG)7,#%ZHTRM-FZG]
MTD?3028Z,LU(6, @$%_Z)-%L#N>O8(M&H9/_+'7_.RH-=47^OLC:O-,#34Z
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M NFMJR=JWQ[W]P%G&!,7(!4+Z A!>XVGVD:"I;"-:8O:R\O"PS6M#<#-$9;
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M/XXW0^U:'DS#_$E]/J660TJG?+OR\A[9P^J2EEN#TZA98NT__UV#]%N&](E
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M7["?*<WV.Y<V%]>O4Z"6UGQ9<UFQY_3#<Y2KBWB[?\97EM<MFC_6CTZ68P[
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MVMRLQ8I]$G7\*-+BDG%$Q^_P\CGE%!V@J_\^AR3WEB@Y)"BKQT%3O\_L983
M2[Q\E):!(* 6YX)Y?*<DVN[*@E6[V.U7F66_93EP;$[*\EZ$EK_4K*K97\-B
MUWA#8Q>LW%N\V(,C!-]2VG-5H2DHU98$W6TQ7:@^_W/_U4=JVKFG:/;IB6E[
M30<->7"VUL&>A=@,O37O:ZFOK+-1F*#Y1"QM9B\T.NF1I+!T!&[@X?:*5A@]
MOL[O5%1#H2,RJ-ZZR?A,X IF;V950/Y3!=6 %\.F=K:Z:*\</V4V SV#T+3
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MDP[H_I0>#Q>M01.DWX(V1B%PLE\99?SO&9=ZE.S$K!_=$FS:F%0,W,^BQ@[
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M3#L_U5HY[+$@BS7 5PK*N^DSJAXOS1+5^ 6L&9K])HA8V^E@^PDG4^;$4=H
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MATG^;:$] : J[!W^N+9LWK<\N_:2#V.[-=U4U=V0SA"=DL9>7N.SN+Q[@5O
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M9!LJ%#)S:ZPIV@H\O4X[:6UQP3EJ,KVIR2_6\'+.WG>FPW^ZFD8N=-^>A<Y
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M^ON,7,J^6C!;%.93\FV]_5AF%1EL B]I$\/[Q.]#<[JPAM^/O0-?.M,,*"R
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M:2^5Z<:"V835$NFT+J@+?DLPUJ0[#9$$?)RD;L3G.7,.KO:,8G%@2%WO_3/
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M+Y1P>/5JBMB]MB%/T+^3MH1K;=5YMFX 9$IF6%(YA_2J;*Z%LWSJ0 \Q.Q%
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M%+=IO[0^#B] M<QP6!*AJF]E1BM,*9<_$WQNDIP2QZS1V=E9UV?(=D3@XXQ
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MUI_9+H;;RY]X>EXTKL.AB2E/F^=5(3W,9"/.=%,ZV=T7<IA?[D4@]J_Y>\_
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MG@T>[RI7PZJLO(HK&_T3N>$Q>0$;LZ/8IU@DH;S^YI@ORA30CJ<4AOJLS6*
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M)M[0_[5=DS'AC0$97\GCQRPO;^9R->.(8?R>?K6'B#-3J#DC(230[SX^@(?
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M<Y4WX(E@Q*Z]-_/7AW(5>N+[3*%D;)2PO9!XE07@CE1\^FQ[]>VDTA#D+\V
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MO@54"?$UE^[L6D,$*$=ZZ^%#ZZ0U2AO_@:U^1S(35IR<AB@#],H8XA:A@@J
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MAUX:YVA6/DTPP9(I_F9IZ?<?XJHJ( 8CPV+T#-_@8K01IU/&NN\6U-C%):#
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M*OOJ\/D>2@3?QIDJSPX8[[RA?$#A/WI*!'SOQ)F2Y*<65?([TO"UJZ>&UI_
MC"QOX:(E%:.!2UE^RRE*19<K[6_BK>,754V!PR4X'!XC(N(#8Z0*!H6$6D@,
M9\=WJA:88KV;F+M>&?'[Z':_R.@3[G_I:TE=JPMCML+L&2=AQ+"P?X>[C><C
MU%A;ZMK4IV7AU_V?-7XC(2]*PRS)%LM?5(4+(G3"O(J&E/:N@LDU"ZUZ<8N
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M:TN@[8MCX6KMCM&5]N6;S_N$; A@6<&13?&T6[E1#1!IL7:].\ GFA;\1,"
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MO2UO@)^_QQ7BJ5,'Z3.GGA?54'>6H3R[.3CHY[\BDCKRY\%_&EF%N)5,,'8
MIDMJ:.]AL:0?N::_>74?8NV!+3=[N^#J>=.EG"-1V% /3]I;83Y_RJ9%4"N#
M49P8D3S!V--(&L@U/R"^.DWPKR7A@E+>WFVC '0YL6Z^A*/?*OXD^J$$<FT)
MKT0*F2;RE-'! ;]A9P2RTU3IP:8(1M"GB)RV6/8I1L&>8F14S\[I/[@ A[8\
M;.TM^WWZ;VZ\>W1!\I79T8 DRE5E&?9_64U_=AU>+!A>J=4EC+4KOP_FW%^>
M*3MZS\?#3W__I'-AC!Z\<2W,92%JO@<_=BU;G 963\M3N:(7NXOB%>0IO$F-
MA>;5[+P5,QT#RYYXO+JT1N@]PLCDYE5X$W4$@&\$O5(\PU[83YXPC,>H[+_7
MX\3T20?^<7,K&A?4>H/12T7WE:&:4Y>??_.K!B<Y@LHV^?+IZS+KKES); V4
M#@Y]Q\DZBVZ;_\+\2&K_G[T2C_<'7$0J@4#^S/G/#ZS*_HGO>XTAJL779^10
M):"R8.F-OMQ,(#:^)/T/G(3G\H%_R-_B&QDR>^#\P'\Z-U<7MF&MR&OC/ZBS
MNGMN D07!5'E$9W&P/CP!>?*-T;YHM1^FIQ+HEGT@O._Y5732Y5>P^"'2K?8
M]UYFNCA_N2CPCF>/<#&I=6*1=3)>=E7(4Q/PWEI=:ZD8D?!/&VA5PD^4="0%
MMW[[(%K<QA.=6+OGV!$>9#K\8)%KOL!93_6:WK=K[AVWQ:N?6D;%QCU%Q9;V
M+L>]X)607K;B_2\)1 9<%V/I._/7A');)4<B51Q9N'AY9534;90_V_Q_*'%E
MSM349.6#":5L-36C_]3?-D+F24E@"KKR_0ZB25"X"F2$!E[;OK)P6=32Y,ZT
MRSA,J<O6[PYK$I$7IU_RN*L<6C9B3+1FGS<O%;8AQD!4EK^Q*UL1N(KU"L%2
MQ4J12W[)=XNZW&,".8H3.!,-E@_-7%*O%P#4^);J" 9J*U8>1&FFC%S'4;ZD
MQW\R_(;CZ.YV^7W%4+8>-#V#.'$/J)F#Y;U*AF8D2CE9VY"RG$JWDSJ[JU@>
MG&2/Z7(ZH&W9<?Z: E7R/QZ0M ,9HZ#JGE54.U%6+Z#S%\,9H9*VMDPC81&!
M(BVJ:E\R06V%B(WE7,7>AVEDS?GWRX.VW="\_V\2N)2@"8"J/[XEK3.\4/=L
M\IH<G,MPJ@F2B*C>7W!VZ14='9MT0X^#RF-Q[ _-QZK-36Z[[';W%^9*CT"_
MCTE44"WTNYT @]5&PVD[NG36,JB!&][M>6&9X,9F+EC>2W,,"FR$FCI6>&_>
M.TY06CLW!4GODY1B0ZT4N<UQG5\&P%=KOL4O-AR4<-80]FP947'";_($PSDW
MD&EJ8ZF5E88(O]64X535I37A/9&,C!S[+.G(..WT?ZX.J5-_FRBC; 6_M/'R
MDKJ_#X77WYD.PB)S;U2R"XZ:B<NX'V]L<-P#0YGK.$1&GP2F\!YMJX [ T@H
MF=6VP+;IKD*SPFW1Q9U=UQ?N6%%I/_H:YW&C;E+)]U\,(3?MZO]:!YC\8DBZ
MP'@OQ9T%R2LRG?#U[+?,C6#O+\\>\%B[D$]BQYR^6ZM9JPH@H[[)_S3-WIXZ
MS[E5NI01E0K1_L4P(C, N$<QZ]>M[BTKU '@MV6<7T1Z!X\+Y7CKOOJI-4_G
MJA1Q>K1F/F.0S;\44AKI.FXNYNR)ID3WC+D8><=:ECD82OP]ND(:5;;R<MC>
MCW 1#F>/Y1>7==?W]*9?V'IRF8&J1]_@1'"@U''YM@<CB.-FI,L;LFB3G5F3
M(OT@>9K=$Y%A5/DI_MHAYV$/8+ YWKW07<\XJ(^\)IP-PV\V1*T65@GZSIYH
M"]['5H90#-X8[#L=L'8KRJ<.^8_L6>F$?+?+]NMA4WKX$=JL(Z4"M\RV2C'(
MB]Y07Z71.4A<AZ5MT/DKAS3)&'=T1M^W_$%"7 M3YGI/C^0W'6T!IARV88N0
MCOOC;(E*WTNACDL31=[A@O@U\:QG%9Q92G>""X]7'PR)B?2B6;R6.^LR.$^>
M#_<F1Q3$91XYM(.O(C) >4[J8F),QL5D].E@$QP>^%I C+RD9+@ !]P;WUT?
MSPZKRG7+OXD@CIG*ZU'M[Q4?^OO[I PX#-69-D8 8);!SG6)$EGZUC--:<9M
M(!T_3E)QB]E$M=,M(2N=^R0<*/9A.LW1QOS+.N;K6"MHE;Q+5AWD28W(U?21
M<>9HH#SU7UHCD_/S$[.]/ .#3AT^Y60Z'7%F"&&OBW^2'[XOOZ43>)()+;%I
M#'H8%:G^YGNT7J_U4*V'SWW3V'/_ALV)'[GQIBG'T"%O%;A)LD%KS&H&1 >:
M-V=[/ZX;D&%2AM\0[)CJGD19>G72SK0PX)R2I&>5$_- ,>(S9&VU#4P<D)?V
MN:XVP]&F[U9$O0&BZEL/N2T[99K#Q4EBM"\!5K71$KT)4Z#>;F37B=<!B568
MR@#1BWP0W1V@AI>UD\X2YR@/4/06[[\H#]!9WLLTS.NG:,R*D0UWNWNVD:UJ
M->;)&Y,'9,.55*Q7IH?@XJYZIX%Q8W[8J&6VC5F;8@=3.+%I5(W2@P?W6CK
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M'$4Y+THP CR=%(9,H;&$E0B]&T3G&J?IPPR'+@T;4FXA909QLB.-HGR]6YD
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MVI;/SK*33K(S7K#O5R\0%9$[J29S6=^LZE9)I)Q>[I\<UBMS@U&$///1'O4
MZ>+S[YFAF\#K&VOTN"QH$'>G*:9?IGC\.96OKID2PLNPZ%T"R'NJIBN,_"GI
M>=6K.':71.%=G22$&H]V>*0'Q+HJ%\MZ%4>N>VK*+[G!D/+#Q1<^1)&@:YI
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M^4P0]K2RSC-"W6I752ZCLIZA+D:'R?Q=?Q6I&M5R+(KWZ8O_R?&[?@QJ?,+
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M.(H2=_FN !X)ANK5VU,XQ!<7IB,Z(.NSGTRT?W+PG8>US;[6:_QWI7;][*\
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MV?;65G_QBQK#NC*@/1?>/233ITL)U=9K-.;3:"(8/5U-JM#_0.="W3"/+$I
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MW"<I(X%N^QVAZY]+>Y--(4A@HY=EJ8*\Z<<^AI<Q&E03=LVTS:&M+2<AFI!
M!)O\Y/#\?Y2]]U=3V?L]CHZ.HJ*#$=!(&4% 0&00@G1FE XA4D*DA9$.H4CH
MW4HU8>@=-$ ""1 IH80 HY30$0()O;?00PD=O\Y[??Z U_>N=<MSS[D_/.N<
MN_>SU]KKG$2)]KF.G:K'IHL.OI6K&)E$]C'X!+;F.DE&&K;*/-J4^3)6VNC?
M\#D8/?V!(CY9]I+0\IYE7T!R VUJOU'^%U!TI/N;.M<OFB*ZH-"M3UO?_%)3
M4"KAK4>Z6^*M,KE,U<EOJI=B"NV>JG*RU.^KZS=Y"_[2>HD\U\6<5A6/!9X
MP^UEKJB"=2<XHS5[2[4MO9\2[N)X]L[IPZ\TYA%C4$EPEXY#I3!UF\@&!J,.
MQ=!X5V6CVKB#[M&0\[D5\"7K?=Q![3Z;6#6S,](Q$_WWT/8*@=K7/5,YTFE'
MX"U.@[F6_=1Z;9.!-<7\O _(^,-8\<P)^0^#B*YABVOBB6=YNPTN[B8@4T_#
MMRE*R,7<=R'\S\S7,A.4O+<'Y[VU4?_GH/*V):RO*_$_[V_O*#9]&^Z3T#)
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ME9XP:'A$%BU\*^_G,QX,P:I[QDOM+;?65^>(!Q0^-NR[8E0YW;%1TMU:7XR
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M@N2]/!P[[0M$').T'I!J:UAS=-Y5&2$9BZC8$/J)M'UBE=SR_%QS5Z^% 6O
M\O + LZY8I$4B<?'=4&WY[WL*)"&;YY_=",AI@88G'>[2?\W:^W0L!/:5M=7
M/M, @6-^(^M07_WF1^1'3<ECA?4JP#L2&*,G04$H?)^]]AZ\K2E@W(H+\8V,
MNV#B:!:@+NRF"5"^*6<F9D^2KXX^%)DM]"\K)=LXBBAM29#\4'?-*A[Y^]A^
M&>@ AVT8\.K28GFQZJ& D6$W.%KGNAD_:P>LF%DGU0P3B3WQ>VK4&WH<(5&8
MV%!FRK/WIUEE;&8:BK_LZBOM!N[GF.\3)4PI3JMN1NJBBGX<:&%)^)[[B&]?
MN^'3+ O_;Z,M3$R<A8_0XV%H$/VFL7^0/V\_+M'$F+?9:$=J.2FA\@4*6"<M
M._H/B@*2+K6S#*C:AFNWV/!]=]<$$3WX6+**O'0R*Q?\,$/>5I821["Q#*!T
M;BON*4B]B"S=J'6'PZT-9RM5DWNU_%L7I3^&K>"$Z^T>QK8@H4I\7%'=SCPI
MYNV#*V%Z6[)E'KS(?RF!/+:"C>S6QQBW>_U\:4(6N,1LT#I2$8EX:%=]7PMJ
M-!'6$'4W-5.[S,LCT4FQ7+]-9G:)2%A5'"]O[5M?[T"#^VJZ3/7'LWO5=8?\
MT68[Q:6J8^4V+XN))_.MA1^'+.Y#+!PL>7I$_6YB*; =WI:5_/M&,>0 L9B%
M[I&26DJ_!-GY260CW >9Q'_,[QD\\L2H=/V)E.RVXL^F8?F9!796^BYC=/:G
M>GK7_.\$%9O+N),&E] =]3"7CT2MU=L;[B)&80]RHFWTF6U!11GFQU=YWG,
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ML_KJNLO +V4T@^+S*\>M6D/<-W%#N*NV"+F]<LTY.KTYQ&I]4^_T&75),$E
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M=I7 5NQ028NY_4<CLJ'\MA]7Y-TVU;HMQOW>!$!P2S=5<<#9)BSZD(F7L-W
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M)G<8>!>K+U/<':-LR47K/2@$X'X[W3TP.F2-_AUO:^C5SQE+!RVC;?Z<E^'
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M,T+R=[G;9T>56:%F9^>' N1EQK#RJMECKK(PD[GX,C1789[)7.4!TI5=GNL
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M[O>4(DY$8G1E!,G!KJ.4%,E1L*_[((ZWHED6Q4Z:+8EPF2>XWT,=.CH6#8=
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MDD*"/+9;^FYSTH>N![0G->F:9T52[<:/S9[FG0U$&FRVP9I,=HX,M\0_#Z4
M6$H9I'"VE-63%%2?>J*CH.&&YJR54B8S];7\_YF'*T1>&HA*%-GOVTEF06(M
MII7CNSM\6^4MP&"3N/GAYQ'1;;:2>CO%97+SL-:NTNEEB/J6 X45*F"7(>1-
M;A@2*\4R]5:',<3FO*!9MJIP!WQ1_K6H5^6E.28LO@/>^ZCVR9>U8 YR#;0
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M8?%7LMZ:3/R A;%<06AF9FZO!;STP(65'QZ+16&S[[?>OXG=-),45"E.&-)
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M_ZYEUA +G3-,U)=*64QHI.Q""4'XYDBSEM1S\KC5'FFH.HD=LK4QRY;OS_A
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MI!8U5&L[#A>T;6\LVBXK-#JD1H)<NRH4NR1>[[OW1@V>7+2+V"YKY6H-9&
M5#0O=J\Z9!MIQ?-EI%J?H&<PR)?P@24ML'&]0:%@4^75Q*W"9'G[2RZ]:<-Z
MX(C%X]U8X1^K4Q$7:>J*F.=$DZ6=$R/66/L<!;'.4X N"7#98N8\!;(\(QO^
M<G.,,!X9V-D028CRKDDS^SE:?!A7B4H](6A/?"R//YYI[W.[U02>C\\' IT4
M7B)UE\02,3T"6/,;,_M10.J# PU!:];:L[Z+ZTV4G0UEI/)&8-9JUZ.?M!N\
M,<<!$F*4?F=<@UB!!&F"/6U:"S._'JTG]])M#N:#D?8DFI>ZY]ZMIDL'@)S0
MW)KJ4UU\S\QT,0K.60A!>1](PHE7NC7$UGSFL2*]TM'<)V@'-UO0CO<GOQ4^
M?(#F(_2$[P$W%+,"PBL"C U%Y=^K^!N]3[:25%"0>^FU0)4I2FVZ.DA6R2Q.
M)>RGB M?L^M5DF_@.<I1WSXL7$AO'3/Q^V@P_#5I;6=3Z4#M#1UX<W/$MK>?
MZ:8M6"/-N1H1)]'R=KPPM5WP9_A=B09)O<\#ZB_2.XWHUJZ5V#<'Z=P3<FO!
MC,3N(6\WDGOUH+YC_/.OI;WS&O<D8%BL?/Z[5Z;>Y=3 $]WYF+NDY]O(YXTO
MH",V^O_H-XI;?UG14,<79:.RS993D7Z.85D!J"#C(T9R'L(@50[FO.&DKR:N
MO[-W?\=[1L390!I)4_AU3LYD[F6G7L';6[)9+<')0:('?PZW:'R@/UYX 1V&
M*KG^ RA#PFU]RC;%S,!FXG:"24R#M"^PIQK+"9V&#X"V=K-(#! 2;"6QJ&GZ
M2$8<.*)+D1#$,=.U7V4$-VRSRYN2Y\94J^E__$Q*A0=NS1UD @/C7D_0WRL>
MS_1;]^;61X+9-_3X\G 1+SR^G*#F@<MA$B[O*HT3F+$"H:)O2#76F_3>.N33
M\K%3\?![4V=PT3!*Y>L$Y#5U<3JRB;_WLV'P;L!XQ4$([J^<M'.<=EV(>E]=
MVN?^;HO(QKYP];.L(<5A#@V-_ASD-?-3X':&T5A#R.%QD)A!\V>0C[P#&._-
MC4UH(UF.OEG,GQG0?I+2,+5/.F=4Q0VI.$"J0V7=RC:<O#)32A%^>SZ4R!$(
M<7=]0\ D5'BF\E&6K_RXV^EZ70VDNFTVS21CQ ;'";$/!3U+=/EL<C/4%+O1
M\F2<]X>**LI]1G,2&/S8>I#8JRS0G-.3;S=]3"+1<3XLXR@?]!H5*<FQCVK.
M0$Z8&LJY:S)*\D.7HS/##=5R- \RMT!__'@U3ZZ>IJAL"MA(&/)-&SR#:C)/
M3#EV^[=J<D*3UU5_2O8=%3$#J.HD3CCX?SK*%LNL(1KVRD&^< (P][WF\CEA
M]=;]MF QL90T:]-#0(J^ 9XYI8;WU31OYS<;LY2J;G]9YC(N5*53I5S*#._'
MN8?U;C?V3;NL7/BOGK8JPR=;^4G^0>:FF6P!VM4RE]V H8I[U)=SQC84)/?-
MA>DWO_P/V8QEP-KS&(K>T.3HSNVM5S_@'=C_E6)K^N%(+G8\<]2Z 81XO./.
MYZT58IG6+_E D-EAIP<GI'!,:\IV;>HE4HO"5OGB4U3H)L"N?%IH$!9.,SG7
MW!6</H=A@R?'=R8<7(_N<S#T&0T";V_IP;FN3KG<9+2YGGSC'[93:T+Z-;8Z
M2+OUB;*FU,8O76$ZS&=6=;S6/B[I^DXW7WYSGE"9<B0TXW.O/V]%!V@=7AHY
M6!3]TR^34>,ZO#0!VR('(<J2V?3NXM!$DNT6;%W?,A)] 0UF7"G-\?!G7'?%
M!8L09=1L@Q_ZV3E><@G8E'[4\.4=D<;,?(G/,+H3E^N](:$XI.ECU:Y.R0L_
M(I,;/V!5C@$'E,_GC*C[U)SY&=QB-^AV_@V_0PM(C,DW9NZOG3 1 %!,VP2[
M^V*@]Y(+T;A^D3[@#ZLO'\J_Z1"5/ I3W#O(<4PO.@U\W;0ZI;DJE'[;N#5D
M1E]&P/ %OK=^FL::[/56GDEM?1$.T5[O]#W-HV28^Y07YW#35OU5MOHV'WXR
MXM3>3@=D8C/5ZDL653V+$ ^Q+QD*R:0 <W1C>4X><F(>=*U%O>4A\ VJT#&D
M_'[^E,>M0JCROW=C:5,F0^8$HY1,H4U0-]6HK8Z"E:RRWQ!3,37L5I[AZ1SF
MM]*3+"_4]/]4Y_[0-RBN1*ZB]OE*X_NQ]7R$[CSKXR"%7$*J_ZV -_3<UP<?
M'#]20K&QZ4MV6<)@,'SUW:-J+4YTQSS544I,>DV^.E+/9I#[@62<PBTY947[
MH4FWG5J"'KQ5,USY1_,R]BK5;CF,U>D?9X1;$G+)G?BQ=GM4S^36IJ^HKT]P
MJ2G5[MY(R9Z9+>H'\P&O-BW^9<V^C@Z.]LS3Q]F:"O[">_3=G^4=% I&<_E'
M<[D(FY&K:SN_2M> !D;._H(=MNZ@Q\FC/\T@+KEDEL]^AQWF:NEH[OXJ5X0>
M:HE2C]#ZO3+U[!0<?O[W*^.+R"C- #,5J-"L8<\EEZ777M3*%;,7Z:CHQ%;/
M;^(O3=;K)6XSAG]_;MV*"?KEORM".,(::W%C_^T#,0H#=>7DU';@A_)6FSP2
M\Z<.2(QF5.)?4?KK^CL;OS[V6J";@0&SA'[=_K"W.B!)A6*=IKK#MW\.]7=K
M68$\2F^^PT0[)9EWLFB<[R*NV;Y;[=<X?O.KA-<BFWC<N+]_\!\IP9(&&/[V
MQ<9 /U>]D4!KNO[I[T/'5N:"Z-ZQ*XY#RTD')UKP[Y2,  PP@S;=XO?+LY'Z
ML$/R+0!C9(I<>C/D$YS1#-\_?(L:)@:P.\,"#\(_7M68SK6M0BGH>;SY>4>!
M=XZL0D<5]/V0LT\O(&U^-W+)5<QNYWR_"C@K\!?^6T;-#(&NL%K9^&Z.&-\4
MU?PWM&N=FS\_5^OWYI3I5B7<7TY?]A@[._1?'V,S-"1OJ6R>,;>^>RZ%B*P_
MSE!_*W.3B>"IJJ+W<WV,C8;&R MAEJ^46NZ,1!>4P1>N)%N2%<BMC;\^?I1!
MPD9%1%3/_[#J!OK:I)O_BXT+LXD^B#UWM C_#T0X5YVS?O)WH78*O8!W?3<T
M:/BJ=[9#836KS2J_Z>SBSZ>K[V>*5\T =*APE.WO]\6[S+0=$6=GIY&3OWR!
MB1RAP?.$*?;8CWI**PL;"_F.U=\5^3* 8#9^<>.?:R\?8"5C!L?)SBL_G/)7
MK9W^7N]RVG02H2/UU]VG7PEX?P5YHS:N;'RJUHB5-7N%W7$M2YP]TUY;NSQ_
MI4/Y6Z@P6:6W5E^[O[1FIJ45%J'U=Q,27]N!><-J YA/P>=_B$F8H_6._>5I
M7PV$2NTI5/UY3\B.AKICWD*9;^)"8:HP,,[.?$$8-QB\[@(/VC/?G(JPN'?[
MX,(L[X;U!I^%S\HI7 [\\^P19,!P+0]9DVUWVPGC0!2ZV?A6U'38KE1=WU4>
MR5RD=%N$PW PUCDTI8"R9UZ@#CM8VSX3+UP&[L9GL<)1$T .!"'ABQ>P.T!/
MN0SV[D/.=4QW^:20V93N2ZY'5,\+-1V/;QE_"76EHTM'--(.Z\N'^J/XW"#W
M=._)_X -+JXW:D0G-,A<Q\)RLOS0$9KN?VA93%$>W&BY]<S(YZM$O7E*A!EZ
M8M88YA>N+SNH*.$;(>?]'.D+@,A,;?(T'YL,^ZN$ZP68[)T==%>2M1](^")=
M,E-Y-.FG1N3[*7"ZX8>(VL/0/<;(14&.B,,X'<;PYU&97E^U]RC;F_/!&,9I
M SFE;@FU<?:C>]NF357[4G1=SEY.7?IO6AF_4-M>=9,495N8W5,I[IEAKJY^
M=78K;D@U)6+J4$7&QT O"T,Q)E(_9:M786KZ^>XEE]$NS0A92%]JJR_M#'I=
MW3'#>XHW Y35#VUS\Z6$V\O97SP\F5NVS8GBV]5O:EUTC-;)!_$>-!*!9[=&
MGV2-#F<SVB-@W&A>/!5)%U@U<6D^D)<N"D5GXK%T[1WT._=Q3G=$=]T;)P6_
MV/Y 8-UD3C@CC6C<6O#6(\%T;L/:2"-$*A?Z&EQQ2$3T:T6V5.DEC3-)<R\V
M4;5._FEWDM8D[P$>)^&5U;LAZI]S':WS+_9E:HSRN;O=%&6+4@$[<P?WF">J
MA$25^:IORG<+-F'GYT(ER[\\=J*! 9LQV:U)-WNDL6;<82?]VK5K@8V13Z03
M-(Z]XX0R3^JG:NZ)F^S/>[IUM]%\WWCU_P>LP NJ9BF[SCU=U]'S+^VLGHW/
M-/?@3Q>CK-<P.=/30B6<WIC0D:'R?WPNYOQXY0 F3U;EZT85@\L^.ZP4PPJ$
M=&BBQB&ORH)>=FG8,Q/C,RQXK=+R/$C'^-[S&W$V4[/MZ6:1RK[^^$A+0!.U
M1GK/2>;$=\E) TC+U+0Y1"3*S>5F;=L'V"#*,IT51\,"*7/=@GBV/V-:Q,MD
M:@*W1BQ/L>"?G&><\:LW+B]XXVINRDA_5?C:H)48J5K2@-W6U[P0L=9.RI'\
M@O^UR,%I@(JI."6Y))XU+&^>O]@8606!)J+P ?\$3?"'R#;Z'%YR_12G:UHP
M6:?WITN]L!"BSB4<_NXPR34D,<YRJO2!$+&A&U$#5M[CE*N2<N^-#(-O,I(>
MNSCF4</'-VLFFBSJQME4M+^?33%VI !.4N;9,>EHH#U?$9()2L?O0UI\:RZY
M!#F1X5X^X3(ZH\7S-0F''4^LNG%Y4S.Y2V_8F\&0"WI^<BS&>K:D!=JRF]F.
MKJ+00Q%V*<ZO_[0RZ]4W"]Y<.\C-E_USU2&OFJJ>QU.]*[W<L+TKB-0N4/Z#
M]D[L/?7*N?8)%K8"I<<(@_*^>$QPE(O>F.CK8J+R(3BVTF%00+TJ\^ QJ^!=
M@"H'_>J@6N&/1#9%.!H*85>DFM6L*^18+RV*,HZSK:X MPU-%)0M#QF3TYUQ
M]<*'AX0RG[P_IW&/Y:SVP<!OPY,YSPX9JY[_G1@AT7"H@"YB5;K&!^7X*#^Y
M3FAL:=$+H"YTXR5U:B9@_3^H-/%S=M94%-!.07GME&SZ.PG#7:@[I;+](V[B
MX_/^ 094S\@)9>=T$"7V[H\,:Y2@Y*SG\,C.^AG.PLVFG=@(8;.[36#IS:1(
M3?G["[))AB[0([?PA\GS_0ZOUZ"*7QM"$#=(:0(';4^;4DX4[C)GC&89W;6C
M_(,]"?B[8]W3PS4,Z*^M2-?9ANV=W4R&?"Y" ,VDN3Y^78 6CKKD"J>8,G<6
M_^FOIE<EFDLU6J'":TT;3B?](*VN7^P%W@\"G+RJ')'*\DSX2T,UN7OCY= +
M,\&<Z/TS*]BBJE=ZC89*Y6^#8>,96E$% <%NL66?GS=Z0'?&OA(GHMGM'HSJ
M :7G.;]E_8KY9&O-Z!VSC?RS5GB*VT*U#*KK9$1 2U20TMK_2%:4YE!LO3I_
MGJ^"C(5DJ<2_MGW K0U9(=%ZL]L]:A^$-&<^&=+I4ZK4!ULO)/P]7SF1W%NU
M'O#F_<.ZNG^:C^HGU>$?#(XE/O"U( UOCWI4!'<"@8"R3,$6G8^' 38^"8LO
M[O>3>7>KLU(>0=("S+6;FF/AO7>QIW;Q"ZVQYHZVP[XNW>2?>.LFMMB=@"M3
M3;\N!"PFP*>Z1L.#3-LT%="?IZCI2V^R#ZJN>>('>5!W%*HG<9['CN:0\LH6
M9"$-CRX:+_?[MRU&R$ZZM&UK[RY?E^>Q?2TSE/J#?Y(U/:& &H_T+G0A>\Q:
M13F3-YKU0R8]&W+N.$\;-^O!B8>2>M6XT%NE""$/])7@D88 6S&K1JB>'Z[<
MC!99#VGYXO$!5EI6-LQHPAYZ=E8XZ-,>=0<^S!#*;'>NLJ %-D'E#P7B.4]\
M:WJNV^A&$'L:"/9=BB5$(N'3WW"_VFI.CG;.^J(QBSE?RARM?1+/.L^KZE%O
M;,V,+!ANN.2R:ALZ\7NXM/(PF8+3#D[(@1[DR;R*'W5W#P<:/D#P'0<$B\.6
M-WV]Y>NM^29P9WY" '&#V1E.D?%RP&FPR3;?5#-5QA&C2O-*G3YH>&5QE_5F
MU%!CJ_WE6 OW/@_-@:P%3^@7E@[.55:,$]REUQR<-U>S>RKV7)!5_I,*C=1/
MC7<,F@CW#RU0"KEJ&4E^50;IO$CX!"M/MU@R95TP$ K(QM#O657RT J>__X_
M@?K_J=NJ^\\J[N4LU5;],Q0SN.OS.H.1+$JY>\7(SQSG/>PR$FAM<B7 00F(
M2WSPV$[@XZ[2 T;7F(V4AGGZL!S]4%>*]>Y$GS5^ CW9/>BJF"CUV@RIJ.\L
MBGD !9SE<RZYX(/W[MHPRWDS<\KDP#4<GU)"K6.)S.M,3.6[EMA0NLV@#=T\
MM1=D:V+%D_W8SUL#Y8W%2@M_4'0853!**.JJ4.QQ#C=%B(\ZNU?-U:K["96S
MCAR.Z''^256MM6__78ZI2I0A*GS@[L9Z3=!V! ZPR[7"-X=F D<:PB@+#=A#
M7&QS2:5XNI5C]7PY<#_#[$%'\6S#A<3R.K=Z=(S%OV_IB:[F$TX<JZ%1)Y_>
M6RCZ=7YDZ.C!.R,ON3+N]3Q)J/WAW62=AC;4L86N<%W[I7UC(O$B[?#<I+TV
MP16<W',=]@Y+%E&;6IZWXW69=ZY]2%04*D1#-<N;FF\P(<8R.:K,S4CK"'Q*
M-_:X>F3R6W"E6GEG'3VA_'D_4RC=[P#N/''V_/Z* OHD6Q3I79\#>N:/Q<<:
M-Z:,SEENWNU\X?/IG5&1 6#7:.[P#?4Q#:GFD*,KESD]D3NI.*IKE_\5Y4.[
MO7$</_\E:[- UIFZOW2J?IK_(:3*MV*]Z._MM3L"'\H^55HH:6(ZG2MQN_",
MNR9E.XV=CP>.>LN\6VS5.DH_E+\L-.CH4FSQ;9IRF]Z0J^O=+]-N+*P4&^<^
M]DBBS+:;WB_DU0!&[D[HR;Q)<?N+2S4N\B"1UMP8@&@K+S?V)F#0LH$KA'D'
M"="+FQRO>E+D'3NI5'J+0": >V?(3$9@4>/KP<;>^?K!0^*&U#?P:ZUJLPY<
M)GXN#'K7F*N<.'DJV8"0/-42CBFW*45Q?25GN=OYEU2YOMKWGM@(.7F_U2)E
M/YSV8"Z5U\Y*W\%,3!*?#P@&W]M1>CFYJ%/N9%BV[1=@J_L@R:4:QG.>5]'C
M4AD&XK?):I$9T$XMG@\KYFR4'*AU7.BL-,%9XP>\_2J9%FZ:B1^B240O\FW=
MU)]-/TF+SS:9B-XWK3A>'+%=W^/K>)KM0O$?$9IJ7[:6B[T;FPK?+R].[4],
M?0)]WB"J4+CRXIK;-?4"[/T^<04C^5SXSGZ6J7+L,Y 5-F@1_+1'_+\9R[0I
M21&]VP,LD=NEV![S1JR&2FB,]S*IW?P)4?OJMDAY=9 ]>1:S2FT<:RZ<RQ??
M52@H/-H_LW\#49>\M[O[0B2VMRL?U^HY?0>B,ABVC"%?69_/-5X203RI],.<
M8R4W<_G-S:'B02D?(0I"IV SQ[Q<#2]R13CO@&HT8-<_V8P7@BM(LH9V;# P
MJ5OT^:ASA, !^6**7,%=HBN8K^/F*P\<Q<43J(FB9&%M#>PN1(/G?J.%VO-1
M-V&^>FY.FPI4ZK1<Z$R%,63G*.N^%A%9S*UBQVU5BVQ" ,SL1T!V/J]?:ZC+
M/?BX!7ELQ@UPZJ29TPS#E3^(<,OHIP< C6P[&J2)\A@8U5Q0_?Q'OHX>^=ZR
M<%$="\>%$&(N'!@8&A$,\M+?EBT;I_"N3LN7I>H(X)JXN>% \,$.8!W5[&/W
MD3Y5#;-PHB62"T&:JWTXSP'97'SCSIDC#VWYA/(4HYRD,![*.'0"C;Z>!24$
M3WR1W*@[# \4:]N5[&APFXII&.1!QC>%P_JZ O"=1,WRHT7LQ='"GD;XX8,N
M567W1T'-6G^S@S%$7,(\&/)S2]8<I)3I,#(^5'_)A=K"-?$<FG"@[:%"*C F
M\S1'*Y)\2(Z0*!D&,[;?@,T7S#0>CJT60H<F-#F# X&K[<B\E=S4\(,<^ >^
M3'C5J=7'38D GR\5QOJ8&DJOA9.#F' UGY;V72#S=&K('5NL<^NN:=?VF67_
MXS==R,R78^M1&[M\5'^-7= @TF)">9Q[O:!7^8NX^\R/9ETOJ2]9>N^TV,MD
M;U4\]_BD[DS<O(IL['7/0GC7TF,+\8'SP"TOB^"&8<42SHI[!/E#P]$CU$N6
M045)PJ)#_Z+O03@-$T9[LA:_@5IC#4!J?[R)B Q ";XY4U[/9 N0?N?RS0RJ
M/LH/80S;#(G_L-HVEWCXRRC5FCBZW#7:^>7A>R.L1)IDDP$N&7&KK&57=>:#
MAWTH:"U4JOM=MCKM1FA=19I/"#B%-/.#R&IC$"]8QM<G>$A,G9R(_0 @O;4?
M'NE)B?0%31%ZG6?F>P<B53<*>H9KF/L'[?X/?PM<*4^QTJ?K,S"P\F8"]E/5
M-CCLWLQO(Q8Z,_-@<_NMD[H[";O"/W50U:-C$Y;G23-X[FW0=XO:OF'2!ACB
M&_-^]2AO(%O[1B;+<V8HA1?1J).8:QJM$!@MG,OXF-4T8J5_3V7'3(7L\ZN^
MH'^:G5M0:JFKC[?&CLX A)N;%VR=T,^;XI'F(M@;6I&":G8\XYED3O#>76Z1
MKCM?_P(<Y!197UW4%.F:$MK,XTD53(S?F_5BSPSERNR5'>G&?&UI#,^/?-1M
MZG2-6G&53T;GKFKXP[F2.FL9=S+!S"(X,]A%H"OZWADW)74%<P2?#\@.6NC7
MG X+#5$E(*M1V-[K=O^_P#NMH6_,<)W/-7L#8#ZS$Y/ON"H!EP-H??J#IQOG
ME%Q:W2R:4/UF0GY:0UINF2I:(98O$M+U["%[,^].R7GM3^.5M#.\H.'!")MG
M$VES+ E5QCNN/+1K2Y^G'Y% _3K3G+5C1"ZT>G)P>MUB4CU\S]QD30,V6.R@
M)C 39("5)RSN86KPSD=52G\U2!_94JG6T)G^O['#=GSNU@QY)Y23?7A_./;K
MQSTUT'7)>3.$3@-O_X/.M.I#IR\-C0--\-VH6+Y"!1Z'#<=++GY=QY>)PO+#
M/@R=&'AO'/J*E3I6V]$&S"\O<%2/:[YPM.YY@N(1*JDC$B_$3Z(OYL>(]977
MR]F%_!UL\^B6&2,WK\[D\7<0_Y>CC=N>N<'Z[%[*PYE/5:;>9>YCD,V8YM9M
MSAP#K \>%)K \X(95GY91R64R?EEY=]PW9O=+=E1-RZY+%C[RL]JAS,^)L,!
M&V>T^&+RUT%I@.&0BZ4HU?B@:P'>"5Y+TWBR%_J?1>'"^P&77+:S!7-R(N8N
ME5HRY[7^ZPB5JE0.PDGH@IZ^8CAR0(OI'E\_U(K4="C@XOJ^9*/QX'IDR,'Z
M?L<3Z*K.2MAODP("FC:5#_6GNF\!^$#%FI2[F2?LE\3)1;5VQY14&F(%W39Y
MUCSL(J^W<K:[MRKRW*-&"[:)I'G<IGX_?%!E$H47&2DH6\N_Y$+73FR^L7EW
MR-J2?IF8F*O.*2>4-R@(:^:]&YOTL5,^:7OL?.28&\Q +<AL+?=:FP%[J6#&
M*"[@IMOW8,T UGYX2.;HOQ>GW>;8;'*XV^OWO8(E(60G/9%/-UPR2\5_:P);
M]]\*N$"CLQ+$,,:2RR6QUXRH$HD%N5VOT?4Z9GH?>,RUFQ..$W$/.G!8$A!X
MYIB^MLO;;^=-K 7"K+;E6_QB7FU)=A1-]&"CT?+[+'+HW<BKVS(O$'04"G27
MB!?N1QP%#G\3ZXZ/N)8+.? 9&F@6OMQ\$?2 .E;P\+_OSCL)K#46%3JRU)O&
M:ZX:X+K ?R$HTLF#*6_P&L-D#*@&!+^W'27S!H8SG'H_O6>!4@).SN,Q86A]
MUDD$;&7K.*[]XQ$3$IU"("?I+]' @UIA7M0Q74':]U01:4V?C(>DC&[."!B,
MJ"-F&PA_==&XOV\#*DHD*3@'0D? UF8 B#H?X\[MFQZ2W@*FI.WMG#@ <) ?
MJAFSH0N7/9+5E>2K<1-H!J"K; -FR\!GVH#-Y[K7MA_P2IAO?HF_F/F"P6$.
MRG,M+'C#PH\R)F[*)E4AHI\C818]H\3E>$)O?C/S4YD/3'3M"W*--.=T5^'*
MH 6"OY9&T"^IE/WZ6U.HUC\8#OOO_[MB*M9(!.B)Z.DQJ!3CQ>0FDQH(G3*I
MHQV_%<G9EK<+NV!/(HXE/U/G\!TDN3E[VG$GHW9MC_M^=RU,J+3YY;I]6F.M
M4T=38_5P3=U8?TYH5!-6++VC81L(#-4K3*4@$Q7<_X%N1"BNE$-LH=.PL=S3
M6VO!,&;_7XU@4I/)/#@(;<;S+DK858UP"V%R(V]5;)! =6J=Z&A1E\Y76KOD
M^C20*;4#BIT6ZJ34('Y065X3[82()#Z<\I4EIBWP7P_%Q\+,;@&CKWOF)F8H
M4VB!B!)F.ERW=62)KU&N^I+KAA[4I5+/0*=J8DIX?*X_> J%NK# Z*(6J3&U
M4^?Y%[/F'Y?^YK(?';28)$A^JK.DCPZ"#2JLAT:>=W.64B;'92T!?0BX61A>
M"0:SB01G)SV7$'4Q8MU6=M=1G\"G.<0^T/*<9MLV]#K)3)D05QI^'27JAG&K
MS FVJ("=CKNPGH%UFGE8;0V6DT_0L<NI3K]ISLLEU&+ R?K;&5G #9,P"OC7
MWGF;BJ&J5^*#8, ['" *\ *N/T^M5Q?\H'9_QZ Z*POFP$O:+P2ZE%Y/H;=3
M:VW(O.L;LQ[;W+,6%W?"T$ZAO>@KK.F&XY:*;SPK5&RV!?U(;()OK>+]FMZS
MC^.QZUG,Y8+F0H>9.2=YS<.LLU=B E4!ZWHW7$9LXZXL<?8D2U#Q!3\%25;X
MLJ</%>HI$Y*EUI#'J64^UMOD#S10C*U,(>ZM8[+3=8WE)2^L=P.OZ^10:MGB
MH[P L_H7?V;5=-J7B-RR,;(2&GAUR777P7/H98G P=?-[WHMO\4UL$VGLR@I
M\F>L!IB_(]<6V=O:7-B>J((\7KI8FO.A^[]B^<D=O;LJ]3HQ'W.?P)ES<8F]
M*N;ZM/.AE4'EDT*#2E6 AJBHJ "/LG+I=N8 Y@W2N.A_Q]RO!!RN#)^?5GG5
MF^#MG'8=XQT_KL+3+@-.TU>Q%,M^'*@(YB4F)L;6'+I5K6B9-M[^E"0<A?0)
MP9F&R_ 7<SR'1IK_O7PZJ/SO[3I!<7?!\9!C6,$/9:;#U6:^=EE96:QOGYV_
M!4W-L9E^=(X?+.9]V)J56:PC4?MZYZ@M:[]*)N,CX*YT@]$326MK?/:D10PB
M@G0FG[[-VC0\?-//4;.XY#*)+#;-UM&9=J.W=XV.+5;W=3UDNOOZ\+.VE":2
M05L:<FI;3@HC%SGA%_F>$Y=<X'T3FV8$+YSQT;THJ,GP:A)U:50/6C$W*D-5
M'<9N,Y;/J%^YTRDK56!K@OD(2,$+C;S?SVL9[*0PX,;O K VLFH%*>C&0A^;
MV0\YZ:%+"GA$?@K:;-I-G]>^T[([D#_(TE9>UUG*TRGL^'<C<A<E$*GT3Y5D
MS'#!QX3Z>Q_XS1,FV!RK:XWJ6"5<E5D89VEG ;;04Y,UUORE+&Q[5Q+-J[YV
M[# 6\-GA_0HYE'?G11PMRJWG->[/+H]T\-),.QVOC&S.J28"-N9):T^RCQE
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M>_*"P8HZ,-R>IZ0 :&)G_^,B!T +&%7I3TR#3B!Y_)48G@5UYGD/CUSWO,%
M3^T7"G[#%Q?'C#:_BPUDRN8G2_$UGX6F>!?%M$ BMGK*ZT+,A8X(7$@Q..@F
M73&#^)^E[;1_(/EKEU$V?_O+#WG/#85<B&6:QR,S8OH:'>3^,,'4WMWH';'X
MS7]H%FWT]7"D'H'HN%\PFH1/LXN(@&S]1O(9MBRI<4/HW_*$1)!'D5&L<D-8
MS7#FWGY>S5GK6M.4666DOWLN[OA'=;^/U$!;6"8L0R)<K<:HP3>LW+9E7F.0
M(F>>+A3A^H"-_NUAJ^$(8(6TMB\O"G9Q"4'Z(S)M=G8LS3[KQC[[G2>+RK'<
M.SB)_4NV"D6SAG#'(KPK>49W=W;#@O>"%KY>3?1D6&K%3+O/7VH,QLCJEWUK
M+_@AI ]OJ7,*F#NVN9V6K:/0HU?R.(*;\JPM\O"X ^ES^<_ZP!4T>F>;9O.S
M#WH7M&.A'7WR0RIH:(@[ B[ 'KT1A7'R*F[3)9[R<<7G3VHHQS4 ]2_-7_)-
MV:MM[\R['KYSHL%"3R=?;D@//8DS=D8_ :"5(&<MP3\Z6#M+V1S<Y\ML&-AZ
MHC36@9!'EF U?P@5;I$-][]\PGN]U^2XM?F4J]V7&+Y[TO&=ZXE W1!KB41;
MM=1YDOXF;F0!)V5P5O!:[J81,0JPQV&DZ?TM75J2DS( U"\L4?K5Q%")&+@T
M-;YV\G=&LL$<B35;</[$21VTM;^6C(R-_F_M>/'Q2&S'KW:^TZ$0[=SU]?],
M1)[E6D[///EE7]6+!$45=Y;DW0T-(5:W>Z^=A/QXK=FDEHB+8GV.;OUO%V8&
MTUKB+P8^V%WI_KG<IQI_$-GZ=_N[XO:DY=W(1D:B<,EK&/^Z7_'3U8,NZ.'M
MP+5Y8ZG&9C&^# \^;DG)Z%K.YS2FWZ.&+EZ_H+4B(9K3,]2P;LZNDG)J"K_#
M*P:0UY;JC)0T_N>1;5I6?N@4&"(:?QB3H=D[\Y,C5;2MCD[M![AI=@(+OW,1
MU%0FFV1='R?X8^O+Z-J(0$)DK>Q3"<->0W?(1=]OEGNI @C$K+NH?IQ:4?K;
MQV_J:LAO)@S@GI;B"L'5D<K#NE=X/=G%LE7KGX *GA,K7?949D9V/,58-B-@
MCS7MH]5_(1B!YMT!XA+O_#54*I-R$ #:>ZUXZ:SYN*WE!P518R4]/[*& +;2
M0@-STNC<T'@=95,:=JYPS$7'Q\95KT.>?#C!:96&XU8,_S/A0\<+=.\!*R)/
MJ,_OK2DECD+XA!)3AB)V3GB^_3>L:F?JV-L# G&SM1B?$H;%/J8"D.O'GICB
M7>9F:ZN]1W5J=E['@SHS8""Z9^8%B3J)4U$0HKF--@8I.LC$R/[!@LC.#_J%
M!Z+N4J!.S'#S0SL"'"9D$%#"&Z.X:OPAQG@4LJFL<IP@NATIP&_AX0EF1OH
M15XVYC6Z,,!+0T(&WKX1&QP):MK85'*/>^^#G/?^PHW,&HT#?=^/]6/K.<D:
MB@?5NJ4,,SX^XCCL0P5"WD?^FI"&/:^*$;U>8R+51^+>1 F::8%BO,*3ZL86
M4*(Y(J$HG9 :VZP*%P4PO:[<%I_XCU$DU/ZL]/W?LJ0(;*T!%2V+&?K0"4-
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MU=13+&Y MWRJ?2K>9&3P$^W+$>HM?72ME7QB^.]C,Y7[YK0>/-IW-W\=ZP+
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M3^L?CM)3U$O=P/5=+*2>)GQSVGME0Q,0^;V#VF+SB\I6C&Z=N'L?OXQ\!')
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M1%8WZ%\7ST((X"O]6V$TBDE1M501J,:S*-02G5OEP0&.?':N=MKR/?7<#DJ
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M/:J%1-7O6@M#,%+IH!>:?:0OM-D2<.25\^)I9(ACWB'R0ZC%E@/9/JGH+O1
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MHV0Z3Q*:IG*+%GDR=21G=.XU-$[X-9VV.8@BM)>GE_L<(UC/"IT.VWJ@IG1
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M-3/.."HZB(C2G $!Z2*]!*X9Z56$$%I@)%)#0$JH :ZQT22Y .D0-)1 *#%
M @021BF1&B&0"*$(H04(H8:.KW._ZUGK7>_7Y]X?SUKGPUEK[_W_[;W.V6?(
M^!UO+3!C4FX'#_,M6#MD-4,K9??Q'5)7?NR)'KC80]K_J8GQ6?.2>@^L=VL
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M5.S]"Z<IY& ;+.\1G(;WQ8_41/ESUJ$._5$LR_%:!\-(QB>U/*,+Z\L+ED-
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M+2YZW2N*6W)))OZ5*O (&G^&9E%RRWDM(?&Y@ZK'X^G]:- >5B"'2BJ9>LG
M+DYQ$]:\ *=-&ZB)17X,I*4XX!G/U?1'K:>075W)Q]:2.&E'"4/R\L/>V.MD
M_I/D](9E+\%.-LC R?0B0LTL. HPS _OZ-N*N5[LLVG9*/?:LNTSX1'M*?J2
MDXC/^O+,\!#\C9#F%.J7[J8+@2N-ZS[2_8%SD67""I:/23-<3,+)A7W:N>$B
MW)TI?O0T4$0,H33UHK5IZ;V)JAY1[=B]X,1. R5CQ9#W'>%E)DMF3OQD)JT[
MBS[T?&H+09N/CW(.A<]FZ*/09K_O-W2NM^:8N9S\HO<LGRA1TP]9.W6^=25M
M'L5V5=SDXN>"9JO6^8=DQ\: KT(0F+*)EZ>X=B;"0(;KI',CTZVF\5+05IN3
M%W7+M>ER;7YO-4_?0!*C* P'3J*T]LXC=;I,Y3NIS@ YV&PRVE1V/F-QY-TN
M?FML1D]]%:W;!FGX6)>E]2$-V\YD9; ?;QH5G6E<IU1X#IY:Q(&N)=2:-@79
M1976.33IE>69^DH245%AC%#= X5*MJ1?/^;./&3I8P-H*MLPO[<[F Z@[D75
M$Q/ZO-"*<DH3M])B=43-[(TID3B_.0-_.0%![$13Q/1%HF'2<(EOEA:OL(QF
M:" 20)@(GSQ?'WN*9OF2_L"]8]<)CFS]?K"I3JT5D[]VU[D7EVD?%1RA/[#0
MES=CG%?L0_7W3XJ#,8D5L4$B8H(G-C?N"?T+ZGG?/**\IF4J2"GTFM@[6UOW
M^YZ.8D!IL/:@VQ*VIJHT^[[Q54(_2Y/GVB9N_@<4^G D>+ '$VL7^=S.O-R:
M<W6UN'KC.30PH#7 2-3F" >J(^:#6_?K;=(=+Z@VT5,='WP5.G)1-P/)MZWQ
M/6KFL%'H.U\"GG"3'M5C=$__B$([)?,[J8>[2W-ZB?=\ ]19^;!DQ87#]M)P
M78Y[**YH^@FVYDT]!FT3WZ_\V;\*5UGS8D#J]9[V-B'G=V.'X/*"74N=N+<3
M)V)$!+R@B!ZBG^G?H?;!'2!V_%2Y\VD@67F--EC3<Z$>12@-1:?\NGBP!UQG
M3=;2MW,=%,*CZF+&@6:@K25*R:&BSI?41_J,>:O&KT)S#E<U?EB>GULRVZU)
MZ?+C>#IF1=>>3!?ABQG+]UZ937_O^5^*1'5VX**#H7KJV/K>2F5N]X?0]Z'B
M>/&,+>X0'.AC*AY(7@UA2=2ZO^S3 ??C))3U ^KK<(6O=YO'1JR=G)R,Z5;S
M+\_+0BOS@KRKF001+UQUZHLC<[D>0W/($K WP(JC/F@8LG*53/608B4I/7[S
M)JRUCLAC*UBPO$36K3'YJC55^3185; !^9/%0DTD,60CY>^5BE6*\R"\SN%R
MJ2'[]6RC*:AS=J#=.WPPY,AKN%#/2ZZQ,[]]FDYAOY"6_C_OXEZ^?(F^8*BL
MK"];55%>497VCO%PE/$'\[ZCH^-%B5[-3 M"=6IJ:HH=L8JAVSPX&>!>R(L<
M$1&I>)+J]<M__[=%'X9>X^66P34-Z^(7YZKJT\ @2+N<<:1'PRM(\;6/:>45
ME:6U&\L9X%L2FR,\2/&"-_'H]T^)@=L.82IPF";\@MWB9*BO#I4=+J+IN<^6
MYJSXTQKR*S9']RK7)D]*EX;X.4=#AFB6YY>R\GP9LH5=I#%D(G#9-MK#"*J;
MQJ6KTO@%NN81/=LVEI^FZW,2:LJ!H/O&T(,O=16%'F-H9(.\9?>N8_?X?"H9
MDW0YCMUW!MGE#TEVWHG#_\ [8C(47XX,M]1M57FYCAK'-H)L.1W?$/1&&E..
M=Y8Y'I]<8.BO7C_*OZD;!ZUS#'&$P:3SZC:;HQT107?<5G-\1EDL&NK=FMC'
M!5AF1&X05W#=PO7696 A$!\<U]$,MN/(_8S!]LA&;^V>^2;)FD@^=-E<7E[>
MW?DC2=98V/1:QGN3W.-<R^[G)SJ*XYCH,Y_J#Q%/[" /X"!AN$\M[^2E:&X)
MQ-W:M00>8R)UH3[7+_SM:O"NN3V"R@$IN YIOE'&=5B_3QA!Y+2.#N2XP2!5
MKY(PH4G>5H$SDR0NZ%=R+)=Y2A7' H&&N*&_/+!0C;COY8+M048>K+,JPO&2
MX<V-AYH?&P$>*S60",#*LJ'^PE' QL1^X,Y/>.F(F(2: <+N?D"./7-#UMA=
MK<)Q@D2]4\0V[NZ>V;E>=<'.>POJ*6.,#E\UK0&8?BR^]2*CJVSP9FV#JI:Q
MBA15 :S?(QMG00C)D9'@BD!!9,3]R[WOC,Y=UDR;# IA>B88WWWXL,D<@32S
M#L9519"#R9,O0AOMY4IO(^=QV(V './<Q63'#DK+-CY'$$L"7(&!55!2D85'
M$_<\X"2[E@+FH88N93FSRN<7.)HX=O)^[![< 5]TN#^AF%D_(9U;%U$/V8&Z
MI:8N7BK@J:L*"5V"W.T*+SEZ[_EJD93N.9Y'J>'7!!>1:2I.,ZNXO&B5@/(Z
M+$B9INT0\@KXI<-EE1JU;9E+N;\M2%8^I 5D)'[:%]DES)C4E_M<MHO.5$.I
MZ116V=B'N2\:^_5'A1+'C3O'E,8-3:!?9CB+P0(:#";Z81P].:F@2)+6@O_$
M0/Y.V'=D1CE64V%[_34C'AH-8>D-TRHC/F+8WZQ\D3=4FLVMJGQU)?):NL<@
M)TY:FU^%^'+[CW9NO94&'3$@(<5?A1QBW!%&B6.];7<G8UEA'>E,8@-89_-Q
MG87Q'CZ=8'M <.:5.5#LN#/QDZ?YQJ"?"@C.7@6=NEM2VX^8_OZ=E>[,L<)1
MA%,E%C6VAQ!%79;)69)X'&^^4O*R7MN<E?U;FUT'H!X*L;[ODD%S$11?&[@
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M!G_!4%NK2GR?G0 4 UJ,^,&;;)_.3&OGUL#B>[;$]&&K06+!OY$G]F(^4 ,
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M>S6^%#RV1[-]^+Z16%8%WM(\L+PN 9B5)#^NKY>^J4<":U7#I;9(W(-[2_1
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M^7P!4V<Y\MN>HP0>]B\LKK3 %THVM[ &&)ODF5T)ZX+<96;BH.[KX#2,> W
MAV&S::0IW_3[9H*W9G#$8&E:F:M)E#=&P1LCKT#J]UM+*$.&!<:?,?9 &Z"A
MA:E=1N$3\#C1]VCYTZ6;'>T9[Y?$T:=FCOGFI"8?W6]4YF^'PB?&(NS=/H-
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M-1JB$+:7^YZ<V5ZH':IF(GS0Q@/GNH",/I<NX+GRJL_=+21'J>+J,GW:9H*
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M,H/*:H/34,T/BYE0/R7_WX_\B)G&6<*JK845FGTSEP^T8]#/&A*5.EL<*47
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MT-"P9)?$/T.[4]AFY -]BUVZ>W;B_'"BPN-IE7*?(H]U+?:E@$4LU<VHLV,
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MP_5Q"XP)GH;SLD&]I'SD9"2RTCIS*'1.6*5_,5XAJFR(; 9TRB&X'';,B-.
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M]PLG*2<#)CVG\J+);AC2T=&I8-*T%H IJVNBXN)&D49W7G2](W3D#]=G5YM
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MP\&#2N6.AO+]*C+"3R9LA-SG6CEO"1SYWX9,AW.$['V*19P*]F]F4K@S+Z*
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M2" "W9I\&12 \ \+))#SZOFW\=9UGPXA:66V5./'*M?SJ%GD"XD1I _[#<\
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MJB<$F8<HGL9$GNCR=5JFL)JQF* <\8^= O877? G;EHNS#RL:,K.SVW!Y%)
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M1H8W9@SJ/9_BXK>1%Z0@Z10X'9Q2)%\B%-B6\MC[;4>NML"Q_03B^)K+KMU
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ME]4(.$H2#^\U?N2E=4^3JT]CJ-VX03&@2RRWVQ;\Q3N_U#L'_NC%2*@:K-2
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M9'BZW0L]&8U R\Z##[ML;_+_<]?X%M(A#*=(R%3.#I,+<@[2=8:X=)1RS,L
M'\;OZQUSX'SY6(#A:20+8.788LFLWA<)V=1F!]*B'>6"&1J2PH^T-TU9@*VS
MD+U^%H#>^'2BI9NRY, "_!:M'1HXL"7%U-?NBC6&.K><8IJS -URE('9T\CF
MQ<T\GF.V+]I6T3<^[VM.-Y31<V6B3?!ZG'B=_QC?=MC1 Z?A!A?(U+,OC$N^
MGX6%/S-N:IGFC14.W=CVMC@&=P'6_O,Y_?.HV3/R1=;:IK0W<.Z0HC4/K@$/
M+G!>#0?#(O+I27_%LP#Z=3K"&8!32^M['UK*0T_DM.GT\\.;DT\T-)\>GHD=
M<-KSH+( VVD-D(ZQS[2-[\<\-8/;2X'4WL(S:4?>QRX3%]0\5DF'G]><MG%H
M;9SW51'X34%3BC?<7J#@P0<%6GY-5MCDXX[R?,SCNEH>D7,V6>XJI6IO^=K+
M84U]IE^JFU&\1K"\,+FO9JT:3/:C2K;GV[%D.!RQ3U$(EE6'MUQ!M=YHZ%-R
MEJ><#QPPB9\)M2T?\MBL$!&V*2[Z-%9.$O18YTHH0:S11QX.F"UWS\SK7-DC
M_)FYM^RKSX$AV7@V.-(%Y+JE"=*R8\[!*0XW.N'PCU#2=9G[#Y(\M'@+#?,L
MEW%"T@%8]Z;7SA^>'C[;*41%O:J.40?+$GW[5Z?IA0$;Q_K/2.]]E0TMR4=I
M>WOK0B;V]^N&=7GZEWUJFB'/"F%(&U^>2[6;719B2T'#G'\\ 9P1JLOK8H8P
MV5VFIXQFM,6?:!K$]N"V9D<,MBV>LP "E"?4H[T7VC4&_MH?$$5,Y<_LRTOL
M*.TQ"!,Q:031W#.=$ZK@>I ?\=,!.9JT?60%20TVQXL[!'VEUA5J ]>GYN>!
M-:1JXTEF=6;J,!6J&EY"!X;:"66E?D0T6>+OC6>-8[")[9<N6-[ZI)$%8!M>
M7QO;F1_FP/DK^!;-#03=YRJ5$E01_,/G5FJUQV;.QH"DA_.KOHIJ*YPFLF0,
M,_RV.FQB+BFMBMC%(:/!Y((^9J_^])\K:^7MDLWV2?/$0\QX-1-/FBAYJ^5P
MV7MSLI-YB05(=]J";$Q75DLW?SG,WKUQ(-'71/\*.1VSWG;LK+G<LG%4LJ]A
MRLDQFU=[="S7*Z]ARC!@ 4 LP*];=KSJFRP 16H3PG9(7C4&[P^\8 &N7IKF
MWICFGJ?';FF+Q)MRAXRPC>S_IX"T96(Q+<AD4-[ZG9;IH69K=N>\&B*CF 0Y
M'J=-;QKY:^M\_J_WT:FEY+U<",S/='K]PL *486M[;W(1[FU$R5R$^^'Q*FW
M,VZXY(?I_U/'U$"M0ZA2D!3$ZB0UGP5X.#TK<B Y>9X% +, ?VE3KASF[=(W
M!*0:G$60D!,3\B:QE-Q"R(,Q6(#6:!.#.GHN5]2-^(Z/G>L9E0,@1G1D!NXP
ME 4 5FX!#^G\/8%RL_$'ODS!8[D-6_QU_ P+<%)X"_%<=!9 :(8>NSV?24-M
MACMU<IU<E@WY(WWM<26[XTYP&+,E]=2W#1'X7B]$C&1^/#[3TAYE+?#NWX6]
M$-)TI.-$]AX1I^R,,,N=%D6.WUO-*^:UFFYM'U]@1!R+?0VHP$U!V+4[^\T/
M,2??_)<31REN.&H@:%W)+_GSM[9#"T9!WNX'LHJ[&H0%L)B>,3BPZ9>Q]MO
M,/YL^:NE3-L&J\^L9N@R[_J((&)PSYGN\YZ-MLRL4ZNO_^LI_/=PG=&N361\
M3,^CAY&<YL5GGGZ[*5+1/,D"W-B7VQ=ZS0)$W-3IU?DG#LCFBDT^^?ANS"H+
M$!F&W]<\EF$!K@DX9=,,-NQV,6216;X-%:&Z$T]C$=O L(ED6!SVS,00VXZ%
M0/6;X4WXG8VRB+]8@'9M%J!3@@4@J;, 4UOL@2R 5&5FV+'A!F.L1[NS\N R
M"W#]0%85>LQ^<-(O-ULJM?_BQ1YE=$2#-KA^9MALY+&=I)96.!6.VE0QN:1N
M F!?-!DF[J:0N0[6)R'SB\><]L=YVK4-1:;+DJ7[Q:FG#O_=^N><>I(3^2@F
M!M) GSZM!P31&F/7IXX5N;(G]T^**/R8W[M@M?(Z6Y<V\R1"YAU3YM@TD_Y&
M7>W Z7BF94ZO7CT-TT+>9.I#NI:X]#)C,2?!.RUR[^(ZG,I]\N"Q;,>9?[;
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MHE(F0G\)V?'^Z]2J/T#8]\2T]AQF^"0??;/6+D@:96L=%<EW7]ME =R@TRR
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M845QJJU75H0M%K46E+6PD._T]Q\)>G"PEMYW1\AJ?9V7 #:1KGAV#Q9VPS]
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M0[NQD4<Q(=)]!GH6!C;&UVI/:@L5XCVZK-35I=/,]J)%?IU\BI!W5+D.V8F
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MV$&J(_@V(SUQXA@\=1!06#N^JB5>(&D$2:@#]9D:FF[RA%QL&Q# X\3&AT>
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M\FFE2^CV _TX$@.7 %K+QO=\Y'0TP;BXI(&,![J U*LM^$ 0!*.<?HZS<P(
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M\J4\TCVKV0](<9:34I2.N=V7]M:F$2@67IK!)W 8JI]:DV6^NLCR'?=96QJ
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MP3(%%.T8"4,-X&\[YZ_'3]]#EFEI<EV?6%J+3X==SBCA^UNJVJMA;Z!B3W(
MQ_ @A0=K/U\,9T4@66&UG*CHM E1_@:*P,V-JU9@Q0!]0E$1)4GL[=;K>'M
M8O34[:%7%^Y&3_$.I>]!?^X,Q%ZNSYW.D'KO1355[JSJ>:YGTQ7T.NNOKM6E
M!*\*;,[-M[.(+)11RCC,IM(C9_()!<R&J"#T%M+.M"FM4HR]6V[,GY/*3.+
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M3Z/@DI'P6GJ4./V(Q_[<S]E3FVV\8B+\?+VV >)\Z]86O"STX#G5MX<;',(
MH+I]J?)0.A9,0<H8'3<XU7;6FB#V4P05LHY(W:UGM\$I;GOG7\"2;0YNPRS.
M(*J7F>F^AM?'&CJZU"#O4*R\'EC(@LJYPUM()E2K/*_VOI'U+QW\*/DI]\2^
M;J,;RWN;3W&2QH\DM1\VF 3/-^R-5Z]QA.RH,@L@[6)X$//$4'AC%3N>W[S\
M8@-#39]%1$[ZMZS)E7@_2.- &):A6:WSVM?ZGDWG'OX%>!)-'+(WW*W4[SC4
M?;8T/O,[7<61QF=R_H(X.;/5*!>VW.(UQ"^])MVUJH^RSW"_9N?+?H?EI[B6
MD\@8:DO38RP+4=U4U7&I$C7 ;[W[F!X;SO/$ZR!_F:QC[ '+-ES?^L@@U8!L
M,H;NNY"B_;GA'NCQ[V;/-G^7 L9.V#DES,D'$L'S!":VE$L0U@R\-XHP,391
MS-C2UKESX9'A?T>2"_-ZKA_8S87E:<&@A*@C'GE)X(:KS ASJZ?N3]9!>U>@
M1!*DU<38Z$GAYU+\D[,CVK?.^)LI7"-\[%>4"JJ_/WC3XILL?JOKY*D&8$1;
MV)=%F=F U#!$ZI62+UB,E/)U^B,@W %%!ST$'DRAE;1I]SOUZTJ&,<-L/+[&
M?MN9*WRKW@(H),3#6\-%#?5(1>_*=%6\,];M# 33%^+S*^,92$[K+5?KJ-J'
MVL [-E$UHV%[A:88-7*69C3EL,2]K-I>9TSM:XO!:^P_AC=?WU)N75NR.=_C
MSVBY<.O5G!W_'9N$<5QO\%O1LA^OYE?\(]I5^P4Y;-G8,]@%:6@"_GNMUFT7
MGJCP7+4H@EY;\^X\F\'_)>S'G1)I+M-?J*'KB\@F^;4NC*AE*:-0!X[FYE[5
MP]!,H#*>!2DNMD1(&JBIRVA\+["^=FQ@0CR7L,>HW[L8^*]A<AW#QWZB&)%_
M#Y-7UO\R&T)LL?JO87)O3/G[)(SVSV'R:9-3$G$8'S[UW=!%$IY_[(AG"8I>
MHUL"$>& \="0GA$XP7DWAC6Z!^UAN*)'Y"&XK3_$RBA.3J-BHXY@B8J[0\97
M8':UPL)6)_MKA% 4WUP= \,\@:@LZ.9J3%^-I*6G=IR*B!F,#$\78T D;[D*
MBGCDMA@;:!'4ARR2#AP?QWVG.@U_0#GFO:S8OQ'JR#Z)L<@CEW;Y5.&.>%@1
MS8'<U$%3@(0.XUU<LMM*)S[PZR.';*FFZ7.).,R6@@W(6_[!2D.O'79LZYKV
M;X(S(Q?>DYJ+EL@"BX\0IAJC2SGRWNXY=6?J![_:@!WO[/PO]MXSJNGM:Q?%
M/W_$K0+; BI5I2A=0$!*1#<"TD4($4)D2R>0A-Y"V>(&!"0(2&@"2B>!4).0
M $&E=RD))0D@G5 BO<-QG_?3/>\89]Q[QKCO&'?<]_=QC=^']6&M^3S/FG,^
MT]Y<[_TXOW/U+(V@&;ALX%V,*0P!="Q2^?WYX*<<=RL^XHMQUU0<U&G)[5'^
MZFZUW1 7;*W2UO6BS;'R^PGH);\J"U.)4L?>U??Z!UD)A8E^*D/YRW<M*JOS
M,M]JK7*VVO=O8G**=SQP]2ZW:D4,V#2J@X^G_N2$1)L:/4C]PMEV^X#R#I5T
M#X7$ZID;_+CQY02[^TG*-C1%I+B#@T97@BEG2<+G_53_W,BUOI'YL1CK1NOY
M(+1(7;HU\,./7=%/ZOKKB*[U'J0D <(.HH;E[:9UNY ')F$?D@>[3:W;G_=U
M I/SJOH>B6LN[4?Y<X_09JC.617OA^GW/&!]N##RV++\M^*]"\2=A;+*P4)Y
MP4+MP)[/6\^#9!% I5!G<&HO]+%)DN4?PJ%+W1XL]9H2D:2Q S?G[,/<>J&(
MR*<=']\AW7W>849<R[.=?.TZ' KSL<F@CEGKMC;9M,B[8IC9>\VF%ZVVUO7,
MS<VO>GW]MU+UW5?14N*WX^ZF)SAYZ[?EJ9:\?1N;]_^>JV1^Q+@.ZTZ)2$*?
MIF7!F.G6!""GL*/*=*2D0YI ]/6%4(HIPV#<WGWK??:]Z<#Z)X$:)>+8U$JR
M'S+/LT(?(Y[V;%/O/S]*S1)[Q.>_#IM#TL:J#CY&;A/K?_.,2XYKKB48%]1^
M(.Y:?!5^/B>4 FC\KB+; :?*^>NZ%^ZB#\%VH^[I"P1;S%^L+[RN?N"1M&?'
MY^&JHM[5^_Z.<ORJ6S4+0O:!6&PIO?<;L:4,!36);DDNN&1'X<>*J YFB]<-
M>!P.E[0;"C7GZ-S+S;GS'/"2"?46R:UW%M'P5)'.,JK+D7U/2=3LF90P@3F_
M#,X<>Q[=N'4%X.04$'?C)O$P9@_ZO'QQ3%#DYIDD!YMPF[]F SXV<W4IRRDJ
M5%H=P>*E6RH"Y7S%JVE(TJV]>M.U?DL#7Z+5889=?_#%LHBHKLQ%#'==1;)8
M;XKDLB#3?ZF^!'H G?AT3\Y_3$ I6TTPA!O>=PF1DQDWN]S*?]_K67OV]"#M
M$9ZOV$/(YW/:Y&%1MRE0[O.B%U]O+N8E.83>3LYB*7_]<UD($R\2UTXYK/^_
M5$"K<][ZWY5 JY@E/_1J?.DWD@$_ZY_.%MW<Y@8%C9ND7?SJS3/+//[25RG$
M&QQ"<: &A+)6'3I]9#]8*JCH0K&^0D:C4$P8:_!P[U9)IG6,O1:S*:MS.#S8
ME]&[SK#+]?$U+JM^"*88>B47?GAF>+N#[HRB"^I!V\MJN\BZNKI<  F>J8[Q
MOV#G1+:V;FS.L;@+&O$]:O5^JR.B>>LL.6NW'3.[^INEL-VS79_] 8#J?F0G
MYJ$,&TE_4#(I3HOM"W.6^<H/D/C^:'OW,772"N#NKTA["+9$(TY83L$I.B_Z
MO:H=?K-1K4=4\06S\Z.S+GUSFT4UN\!4);JY6R3,<24)JJ4YP?S]7MYNO$Y^
MB)$8BV.>A:T;.9VNZIK&5W!>M#FZ?2 .5T[7/DD[2>"'*)C&2YKX&=L#^&5?
MQ2V9O8?<'3OE4+(0E$WZ>G!_ZS55E)-F;PX.'%9@*D-EU1"PM.T< -A"Q+3_
M]ZYRH#)=.=1L2<[B2XK5F,+6H('PR9H4=4@.*.?HF/&7E]@"GG286JNCR"A6
M&0]K[@MHNE?,:*S^5-RUPY9O^F$C=U5UMS0/EQ=]F& GG_:T5-;AB6<5P<HI
M86K6BK/YE./H4<C&*0<,AXO8=@I,.?+E9( ZB+Z!=P(?OMQ[Z$X^?/,1'N (
MJM/*U0.BX:(VX;W*T$RM<', @$M2[U"B@@21*LI[?>E]VQ(PJ>H^]+879]TS
M'8!.!L(VVW$J#+EM$_/GL<VV2K3#@[6?LX2>"(%6]1F_=89/*^SUSP*!0U74
M0*H%7?[#O;R*R+NWG6 CD6=($7=P52$DQF3Z*8?)GMKLMOEPP-0/]67"C_;0
MYLT$-H-1(]#0KE<K],8W#[6:.%D=<FC:^B%-YB[TMN'G$ -MDR2R1KD57\ 8
M4T]/E"\#.&BN*@]4D$[ZGT/S]F2D63=KK8TO_C2]DB6AHBMNT>L+%!ZY+:/P
M*=SQ/W53\OZY-;29LRQ6;,<=+H\'$TF'O77UV?!O9?7!'Q#P'\[(?)=Q =L[
MG7-=REE<*:H-$Y_3Q.LL[9;^+'KSK4M:PM$5:T@W%I'[0>.=@Z-FV%+V?OV[
M]AI=Q"NJC49+"C9JKY 531#6I<%N%6DZR"LG<.C[$"40F1G4\/LCZL^V-N(3
MSG/1[J5%<7DY-NXLZ3F4VYUH@];[*D^V0I^WRO)7H%Y,#/^#\ORJCP"@T/?A
M7EKY-N2@0/ULBWG@_II*3D]/H#-17:8\+  2[]QI%NM(9Z#VGR]8S]:M64KH
M_.:14SHT,L"8B\Z:,#14N?P6$/?ZRV0ZR#[+9F-O[#>BCE;LF-2K]\-6HX1B
MST4/\8(&5]*3>ZURJ[8Q!CJL,D>QZ#S->'SK0&-M)>7!Z!@4(_TI79MC.V+S
M'"N_G)%'WFRL3PTH:9VTD=2+AZYWQ=4+C$P/GQS7#%G:KAN%I%F"K 8/"7?:
M&1"P3]J7R>!G[ L6G']/P7E'U]H6/'&0Q[DPT8@T&,'5<Z V6.%:!,F1Z/)U
M_>JVLH4IT+.D.,R94 1]00NQ:9R[O]CB^<XWZ,PJ?79D,RZKK)_/+%MOV':5
M:30&XP_4]I#-+_I</4;,:7:/36;DBF!2I1=AR"C7PG4KZH!%2Y=MUX,Y3'&<
MP%=MBYC/OW/\_\P=@5N)8Y.^Z;\_# [1Q%0LL8M&7BBO%<P6)>Y!DAA3SC/\
M8U!;5A!&VJ&,*$XW?;_& Q%>S<R)!,E+-J)0T#83%$SB]71,$)$>'/*F&[/9
MN,;HZ?=3[B*Y)L'WHW8(:P=25AJH,)&<Y&#KR%8/UWH/QX*\N!RT@-(_/>BV
M;X7,SK(]^W[1<%>S?2L-0CL<!<.3[OL,&:JV\S:!;&U\8+=[:K>(W:'*)V4=
M\KU[&9?</3Z7%"&=?#3B4%;/=C<W I8-2D7Q!]YE_2%OQXMF5-&R]7(/VM;H
MTDLK0;3MH:$C*Q 83[R,I .AN';6)V=5&% <XEJ&"4THVN6+A+J]Z;3OL2\W
MJ_IY0CH@?%L7+3O(:*U<YCV JZ):8V>RULD!)B[=SH5-UI:6-JMJ0BY 8P^B
M[=+2$+/=_*))[+NCN\-F''Y[9Q=6PW?8#SOL<('9:&9O_[A0*RL*W=TZXK&Y
M4L%!@I1762ECM,+ZZJ_6VT*QBXZ8A&HU:;N]P2<&MZ&9KWLH.9JKRY&[38="
M+@W;*53(1'_@A$@- 0(#/?Q,#*#0?0DC\P0CV^6P;]%8132:$$U @PSDGJL.
M= JEXO3TK#BW<)S?0'W-V+ZR@.)Y'4J0VHB_SK ^_95:O-F@H7OS3Y%EQD<=
M 8*AS_A%P07OY,G$F3%Y\M"3@\-4._R5,B^\<PZH8_77@>15V+I 6[#93P,?
MBT\'1X#"S.=>X(R'7?I?;,BY2DPR:13'W4/Y?JUJ"T;9+E:U7PY#A, "SQO:
M7]W:;)=XWC;GD5D.? 1X'3K[,^%GAZ8H0WNW&#;,3, PF"BTR!@,/@07=23N
M"J>=;U_"Y#&$PS?5Q/V(QOY$BVF\+W,ZS@J9C!NYK-1CT)'(=Z[I/W6W/V^J
M*1Q1F&,7UD>$1$S"AOH"C;7;H"N'^,A9<%KFY.9''/826<\X=E[M*6Y?[]N<
MOW/:]8:!<>C-UY)^INA-K:0R:NBKI47>R @W];)W_47AZ?=X&L=-3CEDZ=EC
MDR)?$VJ#U2XD,=:U<?W$PT 1^5TY#-XI0) LNUH$78G\X?@YHKG[6LO \'#+
M;AET;Y9/>/(_;=%]4G+YFI4UY0TB[!&;]P=\]UD6J3%ILJ:QXALQ-\CW E[[
M 4[IL1]AM4\+1G'ESP ^O"(P"YG.(><M\6C-A%'(T38.J=*95+X[Q_"CH8.?
M+*1"S[W5P7X?2&YK>5H60<-_%$))7O_+<<=P594J<!BME3&D9RE@F,HHD;WI
MY^_9:&6EE&J!:?_W.5K;%]84A\B[+?%-;1;BT]&W?@6>=$@U,Q?\]X4T3SC0
MKZQNBHBTPANK#NPQ):U2>;[ZQ-+%)_F[QD=?[H_WQSM;\?CQ\@W<*2[?I:\5
M[8#AQ$D/G"+IE5 *:LB^7"&[#$5AZC2@X]83F3_B#!V**8Z!&-NX\Z.CNU6I
M5H/B+W?R-'3;%/NYL2AL0-:\-'E4G[JM,:PP_@J]8@G%R.^A)MGZLZ_J6GGT
MVN'K!_2_MP(N^DH2QDM=<.49FR;S3T:,91F[,B3@H\V14,K+:@_JC$2GXC63
MF-L=\+0+<R?_F!X"F16@;NHX#GI8/KWN7Y&91Y[S(X&L#%7UG@P^M"E$YNS*
MI@)UQ>F]O8SL_,[23=,2AO"DIZ^@$90L8U>#4.[>N99B:<&X91MR8(3<4;>'
MD75-P?_"2B54YTLX+,Y:37'?;/I/J8>B@$$:S8Z ]5Q3%R1G'D:%3[Y*Q5.I
M-=U &[ -$ 5V+?TE'[(WS"TM+;51H<F KMW&7X'>BO?\4?=#9S!D8W6<#)Z;
M3Q:>"=ITL7Z^^G)XB''# # !M=[S4/Z85QHKKY=VKJIK1\U]3&@!6XJ4+J5C
MNE4?!(FRB+B)4LV!+J@/X) )/M&%V::9.].7G8&FB9Y*3X]"FL^J1PY82:+1
M;OD>XF%^*R4DJIJ4O*D)&_J ]];K[-6V1;A^_YR51M_P0D8 PT5MXJJ-VI7W
M3"7LL)+<][X#!$T@#F,;>W<!G1TOQ^?[.>W;VQW2@S,KNG/\FSTDQ 3PW58C
M31*2E^C'QA77P.";@\\M;6#U22$^C;5[T8&>^:B<?L=>G/8-6'D^*C-R6>$#
M+EJP-8KZ=6F+3[JI-F+8_)F6T$>_8L/JK*4&), XR2&KPN*])0P^/U\?9AY6
M0H3\="O?G'C5P@YXN^;[S  D^\IO<??)V,L$*P.%S_/Q_^LC6D=_>DRO901Y
MKTDR<B&0_">=V]'V^GIY 9XAQL\_CZ,+W\U 31OJ5^E^< 9N5Y:;*#U-S*M5
M7>(1!RZI I_Z1QD:6T* IGH&_\:KIJ;^/C@X]$=K,C0N,U;HXN]Z0A9V^\ZI
MB[0\;^ S'6N%W( ^GK31A+1Q0;>\:/F*\?*F+]I*<F:.A2W>8&!<,/KI]8XB
M=%[(M:?[EZY, +K6H&?9_P=:^JQ(76[GB?\)M]/DA-&4CM1?6@?'616K%^LC
MZBES$3?4]OA\ZV./<A?LIP),CV=QG!MNG"$!NR6F]/'L.N9Q&;V'W'2E57TB
MZRH!_L:3[2\Y)-&^_EL%]?Z#EK2G'\<SP5Q=Q3>31LXY6&L2'M#_C;(-[+_X
M5?*=7RF5%Q:CY7VO+XO(5J#O-,OKUI0YNA)Y3SEBU'+..91F!CKME 7@.MXW
MFZM(^#:><D25(>VP>7FO*__R%7<E'[.Z7ZG)>A_XC"=,=%2)5#)8F2%9K93(
MP$):"T40_7+Z:X59R,@KS^Z\['?UFA.5W2\ZKN>H+2LV\&JO4@;6*!LO)]^M
M_B)] BRGI"$*SB0"]K,AY4%CN[&01+)1VGA5/&RP\<,*ZAKI9=6>A2 &FW?W
MJOH5#Z*ZF\^U::TJHLW$R)SWT&.PE%)=.NIQE)-<?NFZO"IXA21/&?.!J1J\
M#KTL]Y)[D2SS^KVGR_Y:FBF],!:AT.M,%%;1:590&AF'#U]6))?$6\%@F9M/
MYO; ?8#@PG7+D6?#JEO;5FP_'U7;3^$9(OS; -1VXA#OH/\EU%=SQ(F8(RQ%
MO'*H9S_KG0O-%A,OX($2+QPL'-XI0S.?=[E+>HA9&JRY#C7+ G4+$L>#3TH;
M=2(:='7R[1A\E_]$[(0UT-G#U:MGS[R'^-BM94%_"ONZ$Y (S_NJU&&"G*\P
MWG+ P#AQQIIFU0T*;2CD:V'(#"13J1TT?-_3F\71O\<P>3^2H\8$M?S;0]3$
M@@G1DT&EMK)Z 8NP<,1? TQ9H:LUY&2F9>KHZCV0%>&<Z#;JCL9BFX;?P%6>
M@D\5.#S(PFXU%1] 3R7@<BA,[T\EF2AR)!GE8O7<>@ X1-&,LR7;OAW?FW7,
MW &4S&-D;K_N?EBBN<9**8/R4&K9)TN035F%L9F=>E%5YP'TH4DJX3 $C/&5
MG>._$RF[$XR,;\$3H07)&'.A]%:4Y.Z?L'GIP6(KC0GAXY:O!_#)AF[$3'31
MYWV:= T])NE53W%>%%XUI>E.K2,>K=]L:+:5#)([N3Y:LB!SFW7V&PGG^+$=
MWXNT*_>UBQM1[84(CZCZ6?G(>#_2FMJ_=M3BRYNAB6K1#.SU@6;F9!/9=_-;
MI6H@T (T_2^XBYY< ,-8I?)P[D79]XD*1!%AP@(7G6EK&PTTQY;D6?&%3H5#
M(]3M5^^P#O=I)2?K-AP-^P\CW .?YO8!S=>-)3BW/G%^9H\KG?393BXT>31M
M][SGX^0(CVFZ);9"7&*?<FBS#;;H=3?]E@^?ZW1Q&_RZG!L1X3N_0MY?/I;>
M1/'2EW6!443&:]+.#MQ_.G/2J6W=[GEG6)=,N<"%B&:Z7%#1E;=CTFM M4.1
M^HGVJ\\L6Q9Z+61Z58HP.39.%SG]U.X@=_[ C.DV:JF3ZW7!(<5AD)Q$/[5-
MA2\RN.&JIWM.I03+N8!X$_S6>K=0YD)+(E2#G]__D=I:?U"]XX@'Y.2K7]TH
MFZ"5P#_='5)#&Z8KT)#XZB(9NO_@B'<>6K [K&W2YH)D9%!.IT-J@J\=ZLDS
M'3V^%',[(J6.K$NP)YXG$7D6QL%#._U^\(<_/O1ULMP6W7$/VGP6;R9\J+)R
MVCE?I%8E_K-JQ,B(6/W@<ZC)H]4K2MWKV4TM&W;+]QN?S:1'BSB09\< )PLR
MS8B:%YX?+.W@1,W.2SA?]\62TDGQAKL+,NI/]""_\_7USP=O&C)13;LRJYZ?
M21->$YE5V)YRNBDF&F/T O?, O!]T%7H#<]]RO1N.O.2R'WOCFI+FQ]I/TH;
MS U9F#?E%U6X>HEBMS^UJ&WR=M7T5"_+WL)/[[D  KN493\,&@HKM3YVKAH$
MV6$E0P>KWHY.^V _QO8^N[CI2_9A77-:NNNQF_5J-\MM$>XKJ4H@^A*:U+^4
M*O"?'WOY_MGPG+66E:JO[,V0/4??['QALM<SA9! EF+@ 8CIZ1$<8*!8T;SI
M"2U,=!K>,)3$''KZ55&:A+KD7ZY_(*Y V<)/NS(-DU[,/D$"DZLUKHL5&#P"
M.$^+!&SU_LUN4S'ER=RT85>5M[<XE!BE-JN+MG,I_D2U= +9:+!G)XC'GVQX
M'^WA[*PUZR'A._I]_BV'IM7^VNHIAY6&JYYZ0U8Q3T>W=[P^$SCB!/[QUX\-
M M67 2E+CJV$8-#'CX64KQ9\35:WMK;]41H=_0]#WY;/V*H=>*"C<\&Y>BZD
M[OO8"NU@&3^^!#)_#,/3I?_G. @6"<PES\_#+^<S3*4.]VPY>;>- -:LGN@!
M.9-_;JG26O4R,D1T#!J?]R<:PH^]179$<P-=P/?1N3%[3;1W9)7+_A?*)W\[
M9#<9'%8$[C78>G.^&Q'R_];O55'++)&5#P1#G('D!<^ZP7X]+Z+=W>(P51A7
M&+_Q[=*"LH+2_VE&ZS&#!.*>6%EQUMFG%/?$*"UB2^3L.;N5;;MR,H@(2<),
M5GP" UN4W!MEQ[8T\"2LI<9)%_@)0+M%G+Z3UZI4C*.*-&Z(V]^_7_&WCJ[7
M \Y-X>7E,_O(%1Z7)2<_B]E]F@%(3:6V/B35_H*"?9J\+$9,/G3%H%<W;J:V
M*U5=LP@/K"KS4MD]>&L[=;2B^9Z%0(;4, YIJVR";T"O3WWMX)$$4*6;_\TU
MO*9>F)IZS NP>/D>3>N/C^)%11X6['5CV<(<0^>@5W37&J'F1G7->JD^F/X<
MO'=^\H*,QZJ0:^3<#69?7(Y5]D _Z'&\[1K>[WO'N#L_#BE(?<K,.^'__G#-
MNALAVF,G72[47$O/P%^SI34.!_1V?57^*/##>G2Z*,? TL)9  LQ646=[W@Y
MYP'2-VI]R0O_/%K<R7;1[&>:8:OH:4^#LS>A]!@K.DZK@@R/SJO@;/_9"15C
ME^VG1AN*URY8.BFURED?7CP@XP+*.E@!EITV9J)9.NY<$N9I8:E2OF(R_A<(
M[K(S"0/Z^U=N,,2$\F,'319'%Z E5"3U2C2VA^_L7QQG5LUW['\QY,#GN?UA
M*7LQ'IQ5_=GL'? V^)0C@]!] *,_TM'@ -##>W6V.7I/.2;>>)URY/=^_B>V
M<BT!F#K^1&\FF*OFQSW>$OE4H50]N=_;^?G59K[W<A']RM_M>CKFVMCX928?
M:C$Q%&/6XIPUZ7=-PU9EY-JE#X[!18K>F0,I#NJ'#\U1S-(&G4L>E%&%^[M@
MO38^(;O^,#VO I0U*RY'JJB$F^4]I+_[XB!YZ93#E3@C\C2/ ,\Y@W)>-KAR
M/&T+#Y0YASYT2)K04"VIM+]AJ:<X'9!L25)]^2<<!?XP^M,3)-7K$[)8'D03
M2YSP^1B]H'X.1M,.IUL&U(.,&I.>/WMN*-[0R[E!82D&L[.?L/O8["+]$=T
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MW*+3Y=7\QH-EK,L']<A7?[:2/FQWRBR.EZRMECI%-!*>)%SZ%'1M/V4KWG2
M[X56824-G.H\<Y[0"^T*8"WYHF_@:J9(862A7C2*+7<Q*H59QI?I 3-9NBH-
M5+U2[.E=;5W%^:]%'1\<4I<68XR,A?HF>T:$J8WADXCV_$#4>@I]14.2$_@
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M4Z)O?+_MK>>G<5%=,"H0T7K;O1EXH6E<F;6Q61VFY #0>A6H49ZA8YDFRQ0
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MPF'<[HA@,;L(3NL2C88JM$2J^2'0FK"7<__M1(VT[W5<?NF8>"9F47<&C.Z
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M\-Q3<I<"7F!C^.-2J\M6!Z<\F!DC*5.5XIYZB>Y\YW[(VEW W ;;1PT4%(Z
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MEG*,C*/V&>[(%_H^^TL$&[IH2WQ7/!&[:81X,E!P;%MB:T@7O:RM4BTX!JF
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M9T5'[.)]'BUG@Q@8EFANK'%)')Z7QE)\8]LTPY[W\5 A]>P)(!6/#V,N=)T
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MCNB;IQF>63+;HV,[O?I>KQ&4M@U;RWE3HXO;E6GHZ&&\BOM#Z?(GVTX5_A=
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MOF+^7&RONI5C$*FQ&<>.*=&YUY/P4@\JXB'2,9E=TZ]#U\^I691O!>YG$$\
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M7J&.*3T%H&39YWHKT]O/(H^OSDU.DJ>TA(X[>82D]E,9P*E=*\8H]!VIMW]
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MY/QDK3Y 1? 420AXC<+=T>GQ^,[Y7SI6P_4A;R:L3)]CQBLO#*#*<Q_&IHY
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M]37I1CA!MPF_8M(I5;L1_:Y3$U3/Q4'2TAY_\[ EB/-[3,*4V(K:X,O##[@
M^/@%*>LL6/J[=A;DG >-V3(0%"APV1C,HP=/Z/$N_.$=+>D<]9< @+C_B9L'
M !>?_T^:=#)A)">JTKX^B6YMT]"'J8$JMZ/ERBBGWCH_OQS"F>$P5_')#Q.
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M]!1XEX 1/\P/"F8#_:\PUORU-]\":?/5HITQ?3 E]=!#L]K8\.8C0.?N\A%
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MCMGKTPU0Q14*51AXSOJ]IWF ^D47#5L:L,S#]GJFY&?O,O0WO)1M$OTY;L-
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M<\V"JZYKI.VXKZ>)-[O65[%R7>L3=W7L-QJY#]"%[!1KA28&?A7,9>(L(-@
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M\_P0[?!N7'254M^-MTTCEE%PM)?4=S5;=.A1<W&4B-1# .@O,!ZY>)@?YUX
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M.M$()$( 7K&NFH8F PBT;TY=1F+<(8%J N%2BZ;[O[%<ME;]6)??\Q%W0AP
M6N[W:ZEWRC6%@EW1.K;>>/7,*1IFHBKXN\<B'#\#$?.J+"I2MYQG6Z[>X5J5
M"U*[0"7N45R#^021LP[26!48:CK,O!4(Z>1M\#L0B; 6@A67]_G4;^M=F(WG
MZS*R*)Y"E.>B(-I.:@&T]%B"P>#"].<"E9N'C1#;$7'2 I X)PWCOU!.[3*G
M*YL@9CSI& A/Z=C/^ >).)1;ES14+/:BP,3;,%7/D](-$F.<9B PT++F<,9B
M8<1'S-T*I3 ^)_X94W4MGXF>K_,#(;_T!%OZOC#_.'!%BY. 3F*)+#ZLW9T8
MF]4R>^9;]LV:$KJ'YTY8:\P+\BVD'%L=7>WZFGNY2"/VKAP_C%3830;H!&,P
MA2[]/AD?NQIX6%M,R.WTJ2.P?=BJJ%;([)9/PLR+#<X.!]$2-+:\TW/-+9.!
M^IJMOU:8!<3;TN!DV3TRC5<MG"YB;;QF98"^>V]]9,5P1Z%T-<XUVV>O<^MJ
MB$K+'O29[/5ZG)ZX,7G^JIHAC!(L7:2G.KK/:X SG^07-7LY#1'[K@^X/*2A
MI76Q++?,TTM*'%E45 2YA8HHB7YGI%ACW2>#:[4[%,_8  =E@<'68-:IL/7C
MXX;BJ?ZKFGB58J'-#>55&RD&1>YQBX72X*=0_#Z[$[:_K+"J?,O"<5\@@^=5
MIL1\NLC+S69(0$X:9W9L"!5X&"E.+=A.P8^[/BUC;!+L?,,M@P,>T4"M_=&R
M-=VAPV76!,O$C.<K$Y!H7Z\^7^OWHU$5;I%)QDT.[EFPSXZI[I-*WQ=2EFU<
M]R9>.I$!12%ES62Y<=MN7UYB/G<W/+6B!!.?[EM1;:\8>*XODE;/6+;?'_[N
MY/BK<#XPXE/@T-1^')MK(\_LNK*$CA#R3</M%M-%/.&!98:\T)14A!2#N5EU
M,Z.!VVNE1U_TE>I^GI-5ZA%'G[]=@H31DP'YE#WQJ&<D$6Y\*F+,VKWY 570
M89#[54CZ@S&>NULZK-L?:.S..[%Y856!^#L!'K?>]H6.2!.<57B0* ,/;/"W
ME]+5JA>:,Z7SQ?/$Z_4O?(0_",H#BC_RT[&TOS>#2OW^E3K[AXI:>;"RP*%G
M.89($<6Y-J' ,.3A'\OC#[T6:A+(F;:>=%C6&<LWV^Z,3; 9>,A.\MA<62I1
MP3/OEZ"":%*LHSR ]I(?UJ;2'JI)3:/*-+,SH@01L_*OM]73$I=XAN%"N8Q7
M+H=E)OYUHX97=:#>"!*[?6^./8>]QE#S@.F>SE"CQ9'.CNHJ.0<,PXY9Z*/F
MLP<PU)D:R(RZ/ :YX!*3I](A)7#H4@D%;% "#X@NS, >)1R.3ZM=S5#HR=>V
M99$O#LO![&UA#'SOJJP*L*7%VLZ7 FK:*(VT?9<*]*)N:FYC[U+T3)!DST4$
M>^O?Y!"YY7H- !,E#5SBI^"%,>&3X*R"KN9\35^='5]<0YEA3"<T[*/5E *[
M21NB=-RG $ 8F;#!21NB;_@D<[AJ#""L\ ^/KRK5W-L('#DRG(FA5(^^4LJ+
M&&X]+<N5"U.:9S12\CDZ6T\EU*G@#J?9*&!AYFK%S"^ESW)OQ@)"P)PLNWH[
M3^@U52VQQ9=FC%9K\ R&C^2%$3_EY1GMQH/J/?'T#XK\#\*/_1T4*#':&3@U
M^!H$\EO/:[+HLW0O*;;P@G=)$PU[: +SBVXLO76>?(%X8QH ;]'3!]N;I(X,
M#XA30!]D7XYH2T%]&L9X</:,=Z,RP5OCFMC\84R6I7\\=?__F^E;S-O8Z#,6
M#=D$OU;Q$+-,7Z2<4Z71'S3A<Y0:J#UJ &K4-"SP#XSKS03EMV(KO$A2EUYC
M=TP"&CXN)F?:HJ_>UO#6,:]+,K:)?9(%.P6GNU_7U [[M'/9F*D=UXF#7@C1
MP>TZMT*E^,'W _$3PR0UN"W!]OG00!"8SW*#M54F:.]%[!.\AK*,PX+OVHYL
M2X?O <^T1CH,=SM(TDOSJIH+T= P9>5@_*=&WMZ.@@<X<87^)9UGSL.*G+DJ
M$[%A?I6P@>[&I*AWT+*H)LB#.K65Z.92)?6;967NS84-4[#0 TF@LCJ0\..F
MQ=#0APN*P(F/G\!@TZF?_Y(9=I=OAW$(6[0'PZJ?5@)?=2VW,4-[)FD,?F$Y
MG[(0';H_/NOEA,-BX3N+CSU2LA#9:V%5E9C"HC30DJM2B$O  >TJBI_U8WU&
MS^5,;44_N UJ=0FNVYRI)RI4'1THWXUPGOP3QL^UGOKO:R]7<B96'MFD%?^
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M2\S-:CZ*YBO=0=Y;(_KLJ_N'>JMWAJE[*]"7+Q8\F;B+G9RU0(R3$E=\,&D
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MF8VUBX/ XF -1.*?::)N.!NI7[+^E#<([PPS,QZ6E4'M,Y8[PI4DQUU5;D%
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MH47EI9CC2H K96']\24)Q4(Z8GUG'&M;!Z+L'0RWIRY\&FMF>&:,^"5V?%*
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M+]^%CGX7.E+Q=E7N%VG_I=XB[G4*X]ZX*PY?4D@?VW1&I-^"C-/'Y53>&K3
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M2$B#-)%PRQ1'5_9E6=P,RU9'HU_U'U!^KHTM"-=Z_@.4DY1+&U4S;V(/VW^
M\CJF"/]=R,6KO*P$<E6-.A+1?EVMVS/N<BBK[.ZP43,@W=I)AO:,M=IU8<9@
M,*I+*B7U8M?I:1JOWY,N1_Y8]Q0A)ST<@JAH:+6"=,/1P*.2"/="_YJA]4X5
M3<3EFG8KD# *JW.D)]+[?S8<9IZC@C>+I0ND374>,6;1>CG/QK^D3D&EV)U)
MG!LB+>]B$NZ.N)*!;^)3#);[G5K:+P9X%+[E%'QX7Q?+RMR*J/5=:51)?<#Z
MH=\1E?FU'D]!G_"*#H5$?'M PJLJ1_1&U^*N:\M'8Q./W/4/[1<,4PVS+RYK
M$$\F#YN..:]<-:K. DT_U:IW=D.NN[RO>+RO])3G#/R9YKX#(YN[Q\8VAG/K
M*%"%TE*DT<G)Z'S=P-BS_16:;7/Z6F$P(V]P?D3^*+]Z+!P5J%M$;J,UZC=I
MBWXT">^F9>,[[4,_44X$F4.+ZFP>P!-IC/QA:Q=$8KIP+!YGWT0VO=NJJ'.D
M?DWW^&@4IVL^-4!P4G^4^&T!;6T>,:K?*]^#LL6&3_@H\&_2X;1=EZCJ0>YG
MTLA^C*?DO-+UDW!A;,@,_.Y08)*_4IJVH.!D2BO011@%N7K OQ[1P)%T,TMT
M6W]"JDU(XX_Q .@&V7B<XD)A00NM_!1#Q=,2CV+XV\E*$>JOZKW7"SL2'?$T
MO%[+8_;<WY]W)+]^X;U]Y;@F32!>KQSB1RR)4T8)2%!0?,+-U\ZS'6MU;"Q4
M<F"HIAO^H/'RW9>$+:M/>>SC_]([4U\W*T;>6NI=H_%$HD?5E6B7J".LZRI)
MHQ1N+2+2W!%5B/7QR%YW]*YR0* E,(%+4X'B@<NV=_I?'MO\/Z+\_U:4ZZ;L
MO@S'_6"2?X&^"YW\YSZ=-Q.9\C[\KK$N"Y9YL)>QB;$%5P\B.CDE <(RG#_A
M!BU:6BWU0=BE-WYFTD:25>L4\9.&.E;+S>@$\^!L::6(T"=MRB(>DKB9M#%M
MX,G:SLL[S&FO"FY0[ZW\9Z\F)P.0IY6H+M8,/U&/K]W[ZK?2H_=A;7L5$V;>
M[$4%'T5%6J>/BKTTM!>-O74Q.Q^S5!U<.MV&KP(Z+%P*#]3JA'B^5KL"L3UM
M_OFESMS0F>7O0E_5AB1G1[6U*$MU^S9RZ 31UHN?M* "VEGR!%<ET_":5Z-R
M696CJIYYZO"@Q9)*_-N)&E9*&">YMU^BXR^WP-8-J84313+;O/H\K56_O>2Z
MV3 ?_VH7N%W7H"H/@%&SM_:O</';Y03G5RQ_TT'C)*U=9@).2XU(IU )!-(/
M[E![0TUY]<@GNO')-JWO0GY^,$G$WY"@!83.>:54L ]R6Z^['@(;LW1!E6$<
MKIH" 9Z)W*=3Z8EA$N4PYV>SM:6]G#><5VR!?_L>>!P\VT&A>=G2$0%$D_O3
MDVFH%+R6I7D2Y (9D56$X5G=(:=H.<N\MC77 R7H^S$E?U_*+]_V#)V'@(#R
MP<\+%^.OVM[CZL;7]3Z5)Q07P3$6(80GDR-[.Z6*<G&G>N,JNT9&"4/)\S@Y
M40A<=?D#YPERR!Y9M)=6VL MG1!;7$O,:<:V+0K4J@)T*"NB+M:^.,5K]U(_
M7K%VD,V^6W=:/?\,H>+9 K@8E[6M463)S.<>1O-RCHVYBY<C+$&:^'-7&6YD
M'^' 5>:,]MZ"8GF6P<83=YB,O8NU?CL  ' >&6FYJ3TDJK8%&1!M1A.I$OM&
M#;>(Y2,'U%_]*USYZ<(TR,Y]8VEU8\N42?I,,0%-6+62)GLDK_>:@T[DBMP3
M^R!H^KS16_M=B/)=B'GSC&)6T,E2R_*.LHW1LU6!>@V>'6N ]*/DNXL3LE!D
M-:3<WP<Y_)MYSL^(@"?S!27PE+NE_VD9^2*,0AIY'2\-2^]?7UFUYIV)X8!5
M5!DD7@(RJF;8_'& DB35#=Y>!C SMU)65\^MN SJ2-%RE)YQ;V)WG4\(%=^U
M^5K<=Q/9@*#&SF4C68B?:?NT#:1X5;!SXZ1B=@, WN)3LB!?EHG(SG.>U=65
M"F(-W9[$D/'$#ZP_6D*7=HT#.9O'1I?!:$&.]H2T]^4F7UV#.EH_ @-\YEA6
MR7E"$7YQ)9[ R%'DW1M@  N(%,>1N58;<:"8[)U$:4S \Y@AMTJ#OL2C$+E
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MH7LCV4/A*7KV\OYN>:NI2?=R_X,Z.ARZ':P[$9ZA6/LY.+>NE+[B:D47O(K
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M(JB$EE8KDWLL^XMHCQ^1. :MWQ(^([*TX)\A@PXULPXL:!.XUV])E$\HV5$
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M,':J]L-9OTQB!$HMA4.J1Z\NQ3K.E_F%+B"\E"AD9K.%%=@Y?87@(-=9Z,Z
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M'[U8O'PL^?7I<IXZ^1U-K*#-*C#J&NV7"TRO3(N&S$[$IZ)X)D34PPM]!Z:
MM[TY^OJOEZ-6=OX\TD['OL=+"DSE(HM*W]"<RE0F"_/?Y!<^2U])M[-+7\1@
M,],RL1#RY1$6*0FN6Q87]QN<4%!89SW,)>JD#Z]M;OK.X<L0OR;@,%0,[ERS
MK1G,4E\IIB2GY(!<EV($-,4=IZIZ7L[JWV,&E<E&3S+;.]@NJ BU*NZE&ADU
M@9*D3#V&C0P]2EMEY\@ZY%E;&H7@6Q=#<Q*?@0T,,Y8[M+'M!M#.N(:;XP$7
M4*$]R 6>BT\#=P[%RBT&&XEVLX.+2BMIS@_A4V@I.^@0U+K'$F9F>V@XS431
MN8.R&U221PK"ZC]9?IT8QR>WKTKWC5'#OZ.].J80:R;G".\( W:PB.(8(N^9
MO6$TMUY?8.61B96UN";9U'@%G&!/A51=;C;;TG;9QQRVM;.LV[[/;A.]K6UA
M"'N-5%-!>"08,U8R-/-'1E59MD.ZN(X*;2-57=C;M7J3,\'LTI\BZ3(]S-)#
M_PQ;5"M-0BAWY^?(QFD16+A:8<:'A'"'A7,%937W9J!Z=_Q/5Q0X9AC;[4Z&
MJFN2>Y?B6/N5O>2/(B(UE6_RZ?TLK@;:[J4:LCNM(&8:55D:2XYMC"7+,(<'
M[ ?MM,S#<>:XQW_>>^<.TK_^1V">VHA\NN-<WQ=:ZX;,DD:0V B"A2J_:.1'
M<]9JL8^9W'>;B;C/++_I@U5,*UFJ;NENW:$RPE)H;S=PG17[LT-'^==Y+K\A
MS#DV)9R&N0S_B(\=J..F&HGFXZTD!>:/SXS^@"%5X?/@''L+I>!>58-^"GZ+
M68RY*<#>?4GW*QOEG^J$^8F]YX4&@\I+B"1D"!]YD3\NZE=GHU7\ATLYR8F"
MI;[G]MA00T+<WU&L(K]>&50K"J^%+/U;^NMZ[R'='O JM"?N098@\5CK<D^(
M^NM3[9<2C1J;,2-('6N(K)I+9@^\M(@Z*ACZ@W)2\N]&<M:48[)#-\_=Y*BO
MS],>T/-:;44G!.4M>K:R"0YP]95L:(DJCB_ON>AIZQR8NWC(ZDD;ZL7-UN15
M^U&<X_/;>%G&_5E=P])7_#7_'9?O(0.H$]O^]_1=S);PQ=LF,4*OM$F$,70H
M8D-E$/F^.4QZ58A,??+M;S]\&M"1WFCRDXO@T.DU]!/G6ETX]%,ZB--P#&S5
M"FX*7#?(W%1RMS7[FXWF]_,=D'>DE2[MP>@VK4[RI6.N)+7"@##YFMQS-?H'
MXID?Z]6IM:[L*9VE]2[W=X%\9$Q"0;G39%14R\<S"4[%W9X_15[ARM&4XY4R
M##OQ?I']K@S;'Q7T,WSIG47F8PC\69B8/9-<&? ED< 6[2&2;!4]DK/%O0UL
MS6ZE=X]Z0\3Z@DLJRF+%()>+D@GP,R'#J.WL\:=S1$DIBOZ+8>143AHY$U?
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M/@9)X?C48X^>-GS\S[X= P
M
M          #X7Q']D_-?4$L#!!0    ( "N :5;91*A'/(0! )// 0 4
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M_YIG<NF*F'MX2,3?SOW9E@ MP BP =R  " *2 "R@!*@!F@!>H 18 J<!VR
M*\!5X!K@#O@  4 ($ G @;M $I &9 ,/@4*@!*@ JH%ZH EH [J 7F (^ A\
M!J:!>0 -? >V "QP")Q0@AT8Q +B @F (" ID )(#:0-,@29@BZ +H&N@JZ#
MO$&!H' 0')0 2@/E@@I!ST#5H$90!Z@7]!XT#IH%+8-^@/9 OZFHJ9BIN*E$
MJ*2I5*BTJ8RIK*BN4+E1>5,%4]VA2J3*I'I$54;UDJJ5JI?J(]4T%9IJB^J
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M'A3!E^'V:FT%RV/)'SJ6G4=W'@5_(U8@\Y;JX.ZF0.QC,L#6CZ>L<O:H'T4
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MJ&=E"+\5A"1BC$2/[Z;4(GTVRU"VK0Q1>$>0HD2N4Y.Q'DRH0,]16T);X!.
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M57PRYLS,-9[/5P=2*NX?;CI6)_1[DPRFBE!1ZCDE#T,$NXN)22CTHT51XN.
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M1M1JX4DRB7[IQ!G9Q[3R)BOISL!(ITV*I/H/9AO>HT=KT"-/N]YUYCCW-4D
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MO95&35=S:2/"TN7[_5PY>Y[FO._10KGOXI7XTEO(P#S$!@\^,85#VO'J./#
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MZP:N8% EF:*7!U&Y<WT&R@J]]9L.>@'ET2)<GBT#OOU6IT87AO6+Z;10'F0
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MD?Y97\V757:FEV,H#7)#_&L4K_./GQ[-^0[YBYN?LEB^NYY]+T^W$I(\]U4
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MU??0OU66/7=@-??JX\>/BU*\O+QN6DK>_?1L6NY=6:JL9*:GY&_'_=H33;@
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M91X]*A"52 9$ZG=VX$HK8\Q;? 6PS9WK4^RN6@)DX,J@!R0UE108G)K[82]
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MQ"V2UR([,,(*' :?R6FH2K;"N]=)VJQ-2PD,^D/E<F"IS[[>=7PO.?_)'<0
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MR![2*N;!Q)6QTMSZQ@RUX #+X+Y5ET*AH]X_*D6J*PV*/*LE9!.2$EEOBP[
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MD^5Y_F.C-B2_+QW TW[I<;+4S6D*'6 %V!$OQ&U?_'.C3YMYW?2_/TK7V%T
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M-0.!"#P$&H/=<:(#CJTD=PM4V*??R^&@Q=B:<7<&?P3![.@ A!X=,#8*3=5
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ML!9.,J1@YT$1:!Y-5A<?%SC/I+3;3HWX74LW]B_OBU2>W(O66DUZN'?T\$:
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MC"]S'YU5SWHE]24&I<%7M/J)@[#/I\DY+*>^G28$28<[+'E<"[Y%2=(4D"-
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M0;H[:\PC6HNBG3@<'*^K]JPU*$^)U5D$N;376G2HN7<V^FW GAENDU0&Q$!
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M_X&I=D5]6([K,(YY'M;$G3PVZFW:9*H)-9[))R7\UE5SG<7.IMF(8/EC]T\
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MK>H>3H9BOJE@GB&0(Y#&]?AW^5,PZ$N@CD:X;O/7;$5PCVZ3G006D-^_QQ0
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MQ<- X2B23J_0S3-)]:P:U8/5W*?ZW@JD(=!X&IF1E[+3U5@R$8XMVL".XP6
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M965A<7YW7[F2\$^Y24E1*=M3"^0+)X!P*P]9O5<5UH'%Z-Q4^.7M3ZZ)(L_
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M%!!9JRF=X3JY9[J[0_3F0"]:L\,::E1;,5IM_8"4?B/&8-- =M9!R%SK\84
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M35%Q/]>SN;'\T65/:AICM>-T2#&5*#M7:E-_$?;>6U8WS1(>R9D2&=G1GJW
M*9T.&T9\&9:^;:,T<'I LQPS,65/']P';[+[^%[C*@_W38V!]ALO>P5 62<
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MMV'I6SHV8S%0=@A\0C 8][Z'LL(B'IMU-AL'>FKE"<\J[ EH1ZJ#3=@S&-:
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M7=8YLR10$#G\N0.:3Q:T>IZN;..5%ZHJQ!0?#FWE13C/LA$H[3!^2%8Z6&6
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M"_(64LB1#89;3INNLL!"T9O*6#.4@S!3^ZE%;$+N>OF)U/CX]V+=MA2^"\\
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MF<T)T8)GJ(HL80D&+RVE*5;KA/ME#B+4+X<@V.]V3E%4]/UI;[E7=\;#]7#
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M@"*]9TX^=),66[-''$3I:7;<GDO&\YZGQKSE!#);V\NW^ YGRBHJD/8 Y+=
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MJVLSZC^6JN\KZKTN^,1.UTI:=^#6_A[M B.@D;C5BQ(_@KC!&6A4,2MV*6@
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M*JO%//@)JBFQ1X_8'U?UW=/ZG(=P369M7Q#FV^7,NB&UL3/"BS&VT,]^?7:
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M%\T'#^N8[H_]QB/JKCA"1#FRLIZ(I'W%&<M=?AV 2:;]/P;&J !R1G21E<L
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MW[=<=>32]Q&YFKYDP]/2\$X#=EX.!IIIK2/&#PPW:6F=(078782*N(.2L<Y
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M]A:U]U]BBD%!9?+;(TCQER/(L&$)BC1+,?<M]BVFB+#1+/-TA-H#GCZ!H#;
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M^@M?_UN9O_"=/]C>P].>@/_8[&WO8?\'=Q'PZ\  !P(F>4C 48$N#D$$/$[
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M#T$7;RS 2\ %L7@K0J06SM#P5L.Q+/PKWL@?/IL#.>BO6W64Q"^US2\7_*0
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MP(V_RPM<EBQX TO6I@>7\R:WKOW!&/*MAH]OX@IP.>TP#D@=C7"_WHL5,#2
M13GMOZ$!0F[BIT0K@7$E:J;I(T,@A72/#)-4R)3UPDS#@2:L=GKPE/4O2E[C
M ]@WG?J8=!NA_M=2ZX-L]N#/[$V99 O<W@>A?6RUL-91>^00]3L E>*(>IP1
M8@'3!/\\$3,.5; =\1'1 ?X>UEJE]R/K]K:V_6\J]-[<[KA#IU^72'G7@O-
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MN7N^@WV-R*AU3#76=Y;+$,_1@;I)?-<RS]&H>3ZVNMCDSI:T5,X#M\@'"FX
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M,,BP,PD>'E;5*CXYW#\"(V&&2^[N%G;R_KLM<W"O#31VKAG^1HW->+-K.7^
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MG")^'(G;;O._F9=[.W9NULLONA+TZ"$7<PN'T&O%M-[TSE.5QL@*YV3&OJ>
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MQ@_.[>0?.\TS]8\?819V:Q"N]_;GD*;$]MND*&@J2=N?J2!GLS_W+EM[YI\
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M<B?V!5Q=#I+Z&AKC,R\/0TQY<)<BJ0" A_>_5W$]+8ZZ7ZIU X.86UU9[^E
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M%TFX2]-V4T![I[<?YBIUF^MJOU'AM:[+DP'!ZE-[7KT$6KPU7]M!6(-.2)Y
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M3FPZ!ROK5.-DV1SZR8#P@F/L!^_:Z4_#&5\\[B2H[(0\'M(V;)(C ^[MP\@
MJS$RX-^].@2J!/=M'&J+F#WHXF.J'I!0TQ\/%'.4W'<I?<X=:=@@=%-1=%-2
M(:';:<.&7>2^FL\OY9 W^G'2-69I,$Z@BVXXZ!)$R/=-FY4 U@KFLLK([6B,
MLDKZU?[ZM+)/*>3)PNKK'ROST&F-:M\GE%^4@/H7XRXL'5*0F#>^D">+9D[L
M9CQ0)N#R ]GHWE.T+5<$RIC7W/X'?WMPX\<[=*OII&C@>_#<3CNPA@S8G?7
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MMF3 ]P!\+:G_R@$IHPIU5&R8_#HIW?4@ U&TH)-IG6EV8R U!S_F@-VT(OY
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M&X9O]X[") T!Q8 +&(E!BUCDQ4?)531 ^Z>2BRM:E@^Z&JYC\TX2>=3$*U\
M:H5)]1'U5+"SC_Y8*_#*?\^-V\&\I&G:97 H)>SXVA <OKI&C;4358J4;$%/
MZ^)DD(4KD;H_Q"4FKZ@2'?^3C5^ \1=P:0,\R_VFCIBMS(R_>#'F[.P)B_@#
MC#@)D)#WN)I*/0"H.209=36YO\12!8>*6]!E>O;_AE2'QWRL:W9>FPAP@"J2
MA)4<:L,[%0RT'0*$4L[G^M'!_T"8EP=X"GMN@S%#6A>YL06Q@8P_\7.=L)LY
MZ;B559-J]GO=C KJ*U& ^5>'=]YO4Z5X#%\./A,C ZZ\(*96(?_.X+#X",RI
MRF/HNW^G\?,.W\12/[J4N:PTQ-[K3%PT&UK?%TBJ%$Z_."!=%Z;\"8?WN9 D
M]:# '=#(<V@D/Q+S-DNZ9$AR3#+)H,;/ZD-,\(?#=57W4*"(WN\_\HAAQKE<
M7%X3L1KH]( [4*>I@C1$!GS)/[&MK5IH0LV]8E:A=E[@3.'(I7O6]DZ'1K.I
M+%;VR?DX J(6 '(YKNT=>5CTQ5=4/]<UZ($+;IH,>'S>B$$3OC5 B0%J9,#/
MJ'X\'%/0@>2!\#JVW,+:)8/A>!_SKRI!-O+6M]NOTE?MW3G1\^7/<\2#2:\6
M@*3FW/_JJUDBAL_2?<QA?K:K=M '+8QX_F5+-1*M"!BS[\*UJ'M%KFMSE.&[
M*2'IG8S'M5#YA=J!2_Z;MW>.<TFT>RX_26U\&!U+FF50>Q8OWU4\=(4FDL>1
M#?=(HT:=/VXH^5%G[8' 3?M,UN=U=]()R_@B[ W&V6\D6OT577;?D/&34J7;
MV/!-LZ9P%KZ/B2@)RP(AF?>7)/C$$B_U;M+(G$M1?/P::Y=$^4JEC%@+7:SB
M,D/:BE@UWG0E[7?Z,&Z*O[&^-G:>-E]]#!VF\>N[.T<I^'#S,O)9]Q'1GMX@
MCYB=N@=)51:F&3@)?/7$'&;N4VO.2T&PJSA*D(@J<Y#&H%0RB"CT+6E:$(>&
M,EPRX;=#:G3W\/03 ]E$NU=W-/@?)U^J8!%Z-F#K"R;PL%*RP0[&9U<82V&*
M!QT#LF-*C[&745O=WRN:$K9.O>&,/][;":;(F7_]:J S;=*&>H[XK[:R%J7M
M4WA[' T>7!:HB$_(VS&Q8F^:Y#89/Z$79<EV$LEB$@Q7GTV5JDTIY=2X6WOY
MFC/B![3-$KKT*PG:9@IU %[;:J'";%2T\&'.E5.7=SA_,19N^Y@\$LX0B7W4
MIO5C^=6SM\&\&@.L9KE:O)6FAAF0 :L&,U3@P7G:9%&HG[,U;8#V4W 0E'&4
M6$UIRTO2Z'G!GL9_QN#M5_;\S[5?6*5W6P+UZY.('SJG:YGG.'E.[=\F]^U;
M9)\<9_G&$6Y%X-XW$&/(@/>Z$4@&+^':)&,,*7.HL(K&\_VVGVU=%@5[;IH*
M>M'/WW_"V17@%<C[2,]K8XL@YWW<$H&R-ISB$,V8!4VCPECT+3:?_;_>NG0%
M1+@=YO6)#&!KH6^=:QG@32A2@F2@/E)!HI(O'$"92(R[W*Y6"6D<5I$2LQI'
M]W>@< =V8U]2<M\E1WM<*W^X")>B)V_#_8+EQV[(BTF/75N97*W;.F_FC$Y+
M>(V]-(T>>D3+4?3E8PJNA7KO.;^C..F-+]/>-;E;H.V1@!X-9)4P!>_C4T0O
M($@8'_Z>&H'-0X?X>;=:-X)B.-Q+\2"B86@3%Y:W%W^4/UJF&99TJI8:KEVH
M_N;[!W'6VAKE=6(9<&D=&D*BQFL50ML+&R8)7JN* QZ\V14.J6RRQLP5F5J*
M%O?8KGWROI>U9N,>\M;+SE19\NWLH4JU$"I(9O_<?'!CX,A9_%/"9J*.B%##
MUOKTYAILS]!F'+A4VJ+L0HT%8PU.X++8&I7B^DMN?Y6?]3B;S),!&&]A0C)C
M"!F HYT"'KM4!U("@/H=,4%)X\(3VJ;B";SI*+7HR,48>O*18+(28^!6_R%!
M\/&K6^47X[H*G]4,LIV@UQ%%_Y?"J^>:R?<JE9Y2[Z]R@C:02WQ '6:_(/\A
M4TU--)1P:PT=#,+HH><8<2;$9$^.P%N%>$0'&7#M&/G4L_E5$[N#6SXBS4-,
MDPWGI,9(BC^,M7WBC.!H;:O 4J"/PEZNP/#KR_^%I[+LMRZS>1&!AJ 6.-3A
M]]\Y!J4>]>^J<4(,ZE%RWXL3+QD](?Y7-945#^GI@F'4P.%<5D4?G JW&L+*
MRL%>3AXW4[B_HHU;C-6,E[^'J%"_BR+\5[F?TLUMREY@O!!X#\PZ$VX[*4Y@
M7[D^7+Y,K\EI:OO']M.0RP95@D1C,FJV3S6FLN[/K5 *V_Y6\OQAM*BPF.:
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MLJ+!\^%N]+N'? ]>)^KFC>GO%;L'2-H/H,Z#N@*X DD3R1X^-4B_(]T.$%Z
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M<YM:V'8CLK\H<4-0W]&\Y/F.WKK]6A''5A%"K5;C.UAAK8)OKU__;LAZ4_'
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M,*? 77=(M<>,4)1]'JFN4K*DX_7F0:C4964Y'MP+-NQ6_SZ]FTF.=A1F]E-
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M\^,SCND%*I.8VF>H:<<_I)19H7Q?OM:1KF_(L>@K-H<GQ%@L=^\"5UA]S6*
M#\WLB P5]T*/2[/CUK6L%"V'-0V_D)8^MW#P8F]C<OK2Q&N9^PF;R^0?]5%*
M7]-UKEQ^*DY5OE?\PEU@6"QJ:&"@F^OGGY038""P"AF&(@5_KT:,UZ;(2EUI
MIO/'TT2._!B>^^S&,6+UH%,O>XH[X(O?BW3$7T0]$+5].*6Y#3KXA\.RNSG
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MF/HX)H&/6?Q^STGO<$9/I)WS;#X#T$Z/6B1"2&DM*^V,&ZOH1DU\4 >#^)(
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MG=L5K\8.G"K9]LZG'2]Y-J$5P[M7^<0!X,TJ"]*M1BOB,,Q_'-=N-@<440E
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MP[I]T>=)P$ \7>L)(N5I5=S"L[.?X-^_A';-;H:W0R(*7)P@)151940:$[D
M-':H<98^'TTWF#:VC92U/D!QD%13#O4)*GY2L<_Q$F]3-I\\I0*2P(A"%BH@
ML-IQ;<WPMTY2J\?DDXW&@8H(TM752X/^#8?'[%YHIP;P[[D/HWT629.4,7O5
M\FKG-U6>+9^N63 :.TR"H [VC]6[U?.[D"=#'2K&=FAG.#VYVG>6A\&7"N!@
MV"<N3T3!PECTVU[R($_U(A[^\8'>TKXZ=0?##\YDSI/\_7@+FN#9T=?!@SS?
M:TU,.>0GE'CAZ>>[JD,6Z:O[IW1X+EH!I]O7DC_K3&3$:S3^]YTI_SM"%]Q
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M6)'8'!5X%-^CUVL/5%B=)S2)_]A<4?4@]E<3%VC28O=!#Z:1MTX,UBH'G4Y
M3XO]76,&Y<I;K'B\QKI!)SKGKJZTS  )2'R-KL6305C05JGT,XZBANL=S, R
MK]TOS$%/%R5&*0S(!J=Z!I(%/AK!.7H@Z#H/C>$)5^6.*3T<6)[24K]G<%.K
M@?'>RPH>@='^Q]E&G-Q2HHLFTL=V$P=0MN,L.$4\S5;.I*7QX23EV5,RJ)%B
MB+;J-YFT;0OT$.C['==T-4)79ZHPY[V6H%;N%='_TS.=_W_YYQMO3[_TB:US
M7:$""%<D7N>,( 0L75CRHZM]_]REU[;@]PZ^6&>D!;UI)LNRRC5SI=]=GMB\
M)^W^/BLJ]2F?JP[]4J;D[3#MX*.VV;$H<QQ'$E_L&]%AW]22M$CK8*]1YK"=
M4[W@K1:8[8GT<-Z5.%Z1YZN"^NC?(VM377GVXT0P'#Y .;LV,=S=79O$G>05
M'GEM[$PL^O/.FGWP/##,^BAZ?Z,S3XUW8J9=J5/D$H/<('V=]Q$K?V"R'$DT
MMK2B#_A% 42XXAB5@[6HJ!B47F#6-)+"@J#(@1KT:Q#.^*Z?W4UK6$:W6\:'
MGQ7^QPX@X@9YUNOW-OB//N=;%9"D($-V1X0_XIM3T!;ZG6^E1RGQNX>T#+>O
M=W-#0L1(H47C;%%;6SM%D# QJU\=IR=?9_Z8/3?^M(1[3"_H-]EU^WT 8X])
MD5XXAXGIM?]E@B^I-5NHD_U5SU\_XM>MWZ3;O__;>GGWY&1>>JO@LDEBG)Y
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M&V$4\&:4!*^L3Y1^CO>E476W96X ;YMULL_$Q_PZ(?Z]+R9F[4BIKV YS$M
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MIC+Q3W23N]>$@MJ8MY+JOB0T72&@14A\2-UUP>ZVY;!,=OW0@<$[F>UM,97
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MW7C%>_ L:@8K@S>@98I2[YW"/FA=9L#R_&%2YP)4O@*BC^M]!RG!4P$/\JF
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MW&#]S8UEPW$V(R_!TF=9?C'TYL]_<22.OI^1='H6:US+%LT/2H!+4P'T@E1
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MON889J<@O.:DL1YI[5WA@$Z)L[&]S2M#A$.WQXV6\;)8=Z@.0YTK8.U4L7;
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M\N_P0_>(AW^5TH$$1@9[>WH]%!!WE1"05U=7$S!P#_=S?_A0QM39U=<YV$U
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M U#@"1 /I #/@1P@'X #)4 %4 ,T *U %] +# &CP!=@#E@&UH$M8 ]  V<
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M*M?7,++AN&0P/6+OF+#1WHCOEH9?'(/ (V\PM4C%'4C\6K-)'Y8AX1$I"\X
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M3%SE1*4M7-&#*&=\,D!&JJ.V<:P,@WEKQ&!G4!R":M/#V->ZON5:R>WE9/V
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MUL5,(%AJ-"/?[:6Y0ZJ6JS<YT-^2/"GG&XR)JQ29RX-S3*<4Z<.IU]C,K=^
MSNS=-K?B+)^]ZW[[.T;,3+=99,I!:MGC<_;WA,9#ONJRY6^KA&GDX0AK-YY
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MQAA6[L[#&'$@5/=]V]M*%W*ZL\C9[UUPR*=404_*TL11+0ZNO52KCW"TWML
M[)GI178/&!HR6[W$)SMI'-NOIX"KW^6H_]VF74#]>\:N3"\RC$^;===(<;(M
MG,E*H_S1U%NUJ=>QSTHEC'(&;:0J(R.[F_QG:Q.RJYH[&IM;?P3#T18K=@/@
M5JN#UB,5$*'8*?L!)L9I2,!)?WOS526=+7!N1.1[\I<^V&?=^)6!IV+#ZE\"
M_48Q?3$,L[(!,3/5$<&*R /3^F^KH774J<.=FN0<PJ>R,>7'"6>LF,FCD_7S
M.$W_2@S%^OCV0!H89:K2T5(=CO2_=]\HSDG)B-G(_XK8V(S6T8@8UQ!0&T;P
M-Q2OL.M$CO"&<$/YCY2;SS)"43PAX>1P&(EVD/][6\^QQ*%UA<X;$V.4$S+#
MM__0*R&W94$53\H_S]-I]Y:]R3=K=G1KMEVU/72%>O#_XF7K'K4[U:P=@-<O
MX%3!.+9+ (5X? D@KQ#HH]/$_*GO86OTTX.OQR43:W)C&34_.]M^*7^+^:P0
M,8JG>D6(J/M?>NAV>C2<.".<;!&M,Z$\7C3ZO@+M3CD%WSH3 ZYXT!W7JW&*
M^3+9@Y,N ==&; C!L4Y:TA%T?[D=9?MKV[G:N*,Z;(!FA6+CZ(G07D%GV[".
M0RN.R8A@&3P+H;=>ES$2E#BOH',DU)<41)%@:2CO(^MRPKP9)Y676:B!\HO[
MVJ!"):[?FN]2>)%CR?8!:Z!#P_XC6*I<Q/W>VSUW?W.,><]9SYQP=[;QBGAM
MV%K:)5#)!ELOO02(8<ARV'IS^4?P$N(K#/U"]I7GV270&%V^OUBOM[)U:+P6
M7H:<K_!%T.(B"6O8^*(=2E3Z8U43PA(!&V2 7%]I,FM^8QO7E)THENY[3SBY
M]LFQ4>XFL;IY$2%O(I#GR7A)@@*^)@E0AAI8GRIJQ>+A)Z5QDX-LFXMTI[K"
MM>]]M$D?A22IOG>?G#T@Y$*!B%V3)2DC3,+1"4H$D1[0Q)-84WWP;E9.60*R
MRLS-='UPNCAQ*AY:5\4)$(KOKM^>UG[L9L_271,SZG*Y58LVQB5&AD;*?6N6
ME^^^?H7UZGL17=*]ZE#=_B4B;QW63U.+D=5%)(MB>C>A>E&)8B:DL#Z)L.46
MKU%.T!)/5X&SB48YU^)\SW,"B8@MA)+/:+JC#HA/4*)O72LCV&I8;&-_?OZY
MME]+BEJ]KQ\1.]9G2<U^9:OCO5 ^)F\0<=S(3P@(/\0IG_(0O@\&X(2PVK!>
M/ZUKUIA1G1F<;MF/1_"D4"]IR+I=BHVG@[/@/6$_ZC8:C3=7A=2N5V[6?]-X
M-HCT=E&4G!/A5KMFP=;.8N4?+!?D$!9P//_3Q#6WC%\A.4?O5VRTUD'&C-,B
MXFP18X-U$#G'22$XK2.2_97(.UH9QWU#J+,??^?*%%XL4"5;SE*O52#HDA^Q
M??8,O?8,IUB"(_OB?\ISR.)@Y/K>YZ9RUK;!;Q*]O>\NG%./GW.Y?3)GI564
MJ$V!>4 H=V!DL'5DMVN_%EM=ZY=?Y%$8]KXI:-N5M%^U32\L>$E/;CSH)B<'
M/@[OE@\X):]R8,#ORBI0A\Q>_.PSPB_M1%9KW^NZ!AS7>3 EY.08,5;=F#"X
M]\-W,R2UEB'S>YM/FV3,*IO$4)6S60C4>]%0[]N\SQ^;Z^FV31MZ5?8<"MY*
M\%>_ER\!\C^X\*/S(0@KSC%E"*]X9)7"<\=8<7^O<G=F3:18<95*LUZ(\75+
M3=B3Y\5?K'9R8G0($=<%8X=*K?]=<6S[RI.$8-7K.9+^8U&3"8&][X?(5LKG
M'MT*V]VGK;&]Q6/*DN=D!E](1K!>_9#!M&":(&T;5U750[FZHGHPJRA^C.++
MS8\Q$"]*QF&0_]G_'N"W\*\T>*K&2X!!&'-RQ$-8VL]F\(P(C)Y-+?1P/^,
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MDP%DB+WM#68&>T&25%:O=Z!/!U0MY[_XJ.:7+#WMT[DAUMYQ*XCYZF0NVU.
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M9V\VYAQ 1/?#HF'+ZSZC;+)W#=5:^>0\6GHZ]J%VZ(6-A0-EPNH<).@4AV%
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M+<B$07.I!U00:_&@^ZN$H7)QDZWO:GB4U]O)>T2I<5P>REXG9K=+K#K91#O
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MR/ \FT>GS<-U28D=[=EJ+4-,$Z(3N)UA^67 QQI3D PST[CP,F)*AAS%\'/
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MG@8>'RDFS?;,4O5[4+Y@Z]1,DUD8O@!)3EBD!+Z(>H+X"GS__W+____*!8Y
MIU&3ZU- H&^_QJH]K[G-]EV=3W&&+[F#B[A#H=^--ESVDG#KV&44\M)CD,;)
MJSC=H/8K]BQ:@NE#A^Q?+;QQ,Y02<,^BP(AOCRTP3O$CI#C3Q%125SO6!T@;
M$)ZI2;N:$#@.5M/"QTYGJLZR'^4@U20 ;D:47V9QTNZ!"F^;O=C:7^S_P+_:
MOL.8ES!#K%-;,ZV 6*49O9Q[UM;842ZM0]576+AEL*\H(TF+_!MU'<E#O"K$
MEZ3[N(,]!2N:U&'/5N\I*M-MPTUJBNW[+Z\ *=&9(0_C7%75@?3TI <R*Z#3
MD,?I;LN7>A@0;ZGW!U[ON?)<RLSN>/\SC'IY63ECW.Z-Z=;49>FBX<I2COV]
MM(D=QB>]H_Y^<6(Q"X7#[12@I:^9CZ9/6&SQ!:V%6_(.%>*F]F7.(OF<O>MO
M(K,LL[8L4'A^\AU]'$(7%U0YX205*'*I?Z>([SA)W92#2>VQN-)S@Y&B;6 R
M;L"OKL]/T:"YV:66/CT3/%3\XR.?PI'IA$J)Y/L4)-8("2,\'NE&A*'+K@#6
M8ZMX8%H9I+E5#-+[85A&A5QI.@GX#?-%_;3CKE3K;K_G0.WBL@2[A^E#LB,<
MT<,@XK93Z05J7VLDE*?)3!RQ]D[^+(31X+N E=0BS79^V7AC3$6TQ[+E#(I\
MATC?86Y(?X]0HAFHV7TO!F.J*F,Z\X!D#(+JJ'QFSK!>#I]:>$)P6<Z*:;N7
MI(('IM_*_W@%$+]U;AU$5'0&6G_8OMW7)W<S1*0Z/YI)P<CI@^:*SNXY\$AT
M%"7U:J)4Q/M$0$S74)&[-PNGP9(W::%#ZSMK56V57#^Y)Z-QG_B']5K[02@\
M*Q2&4VO^IP3IMH)@T?"S9P^>3ON$^#8>KR*8%._Z (B%^Z,A&NK\W&U"E(/N
M 5''!V%<XEKO<P[FLR ;T^4%,@RY>.AM'NWT $[F8"#7)NPVA ><[>ORNGZ\
MIED*:'8W+N_$AI_O^YD-;^8JZ@;Q.4D$U]X[0@^S]2U4JYWZYTL2=9T>V-TM
MB2,ZS")$5E9V]5Z/_Q1ND7[2B!++(LW#-;4^\:VQ$5$\QI<?'T:"70%N3N)>
MS?_ABZM=B7[W?:-?0N6AY9E&O.P6BG]N#(<]]<1E_=[3<I$L?>HB]00VM;!-
MQY\FKE#T^ZV+UQOPI@N'>LE033S<S[GQ\3EF&XPIM,C#VDL$ZT;YLZ%%XYS)
MX\UY-B,6,+83EW TKOFP&P-U_L&ZTB*JY50-]UE@1+5UEOA\"(>>Q#K8PZD*
M>38#+"FV@/_4G&='"RD@7O7BU3K'"C$R,[WSN6M(!^PQ=[1P8:B!<]<-;\$\
MG1BQQ8[*/J5(^HR/+7\5KY[0UGJT&CM^PJR9T,@==CST8<]SWE3MUA\OP>+O
MRGX/G*C7ZZ@%@QOGW L#[AO= %[B$*>@BO%V6TP\I6^:G=>M25%37;_=[RMH
MO:*H,041W[<<R1US73?9SE$KS!'"M>H83P?E;77N[XA?H/?M46= 68)?8/;B
M:V>1%@F!EPPQ&C;UKI *C9V:W*+C-[GULBL5IX5[/(4>KZ1$10R]+*_#/HG2
MD6YEGJ[WFNZI$M^$[QYI^;X)XG+7-7@+H&.6&_:.^REHV@&KA@61N7R3:V.Y
MNZ:]_:/O&SH=\'_3]JB08-3.@_QR0VH+-N2T8*J+8DS^%8E%)G-G&'U(LILS
M*I= <4WQ_8_&?<NG?XF[CM>=[(D69H<J<<P0W^KPSQ]?GS.0KV&.$*6"&R#"
MD[.NZ/@'$/%QDK(CFPY!=9_3^:[56EA@E&6YKV?,^^NNJ[AKY64TB0BF0;<[
M3<[('O;(O)RH"ZL_W!QPUG,/(R<I8K2<C& 567(>B-SC.BEF#C/N];X"G&Q;
MHW2WM<#XQX?W<X>3[#AO?*PO XKI,+#[N*N"1A@'YWQ?O20SW8Q;*1U8UDA1
MFOFPU:,2PVHVKF:\TNJC2<A>9A]BMJBNGY0<6,4(B3_]L\_"L?;NWE?5V[(]
MD-:5 \+CNDJWXI8%FNE=E[+5CP-.18U1ON%G*B7)L.([%C/H3Y,<(MCC\HGE
MS'Q)(X>R;B=9N<?E4OPO+=*Y$L?5AMO^4KW@MQ!M/%,VAT\2P4.SCOQTK<7>
M56%95X-_9BD@ZB)^&4FZ'[","%7D6R-$>HDR;">*'CA;K&O*3EX!)F17/@21
MCT"@Y(#4KIUVX'Q@C_<#M38IBVXC.A[Q;@WTZ?'H=N$+:E/N[[!:6])]GW=C
M4JR(-JY!=&]F=U+!?'^QUYTKP$>54*^+/9[+\MK#MEPB!TF]9I+MCB+%RJ*8
M-O7C5 FUK+/./9*'95.J/-5<_3QC:K$OWTTU!X3BH6!.G(>>V%I*@7MG3W/N
MH<MIX-_3?"3D=J-;6P]BDLCW+EDY)#!W& ]$C(B_1/Y]?SS V45L16Z&=W'3
MVT,I<)?E286SIL;V=941'^M?=CM\[Q5;5/KSA_<H4<N3ZQ\<&FV[QLKYN]SH
M39M\@*%7I3X"3R4Y*:TX@I4A/>#I@-WW8JT5I=[6]P7N>R_R-;T0$3*.-Z_<
M-XSG/?V86Q6U]-\0L)N?IQ G%*8CG/;/,!L;=D*\*3H=FD\NP9MWH ^%JZX
MY>^[ODHL--%?AZC%K6Q9'?E8Q;>>7P%>Y4=W=TKK<0M+GZB&[_80&7U%3\TK
MP?#'K+7"_BL2#&CX/MO'PA+56TQ2P,_6^,09EH,6"]SBUA%ZOHMV"-YM(Y?S
MXP;R44(PJ[8R90&]"7J\_.5Z)F);XEW;D_JY6 NSDE<>Z^G-\GYZL0EX1"^"
MP._3!6-PT#??^E/FZZZF$&,2^%N:6#WRYU$=,.HMO?;4FK=EA5HPA+LX,&<;
M:X*BDEYFG.K,4_2/F-(@:=,7FA#9D<IO0*_CIE:!HNGB"2<DP9GLB)*IC!]=
M>F(+O3;Q*S*CCO#=,FS8^/#43=>NZ[>QD6J?='^32D<A=U:VRFUUGJWZ"('[
M@R[WO(",K40)$9U"1H.':8_%?8")N)_PN$:[8O'>;FP]HX<>0<UJK28%7R+!
MO<0](;5*YB:$7J8QWW<56V@6%L0:\F!X1(=&77;^9N+$0LG+B7+QZ+DYG%&O
ML-42Q5S%B VZ($0R?3641:B":X]5T?^3-B6G&N\E+>YH13H>K]^ENXT67IDW
MZ>MAL0)W8DOD3PQ9M^;NJBK?)"5CZ3F5BTTY8GO" ES!(Y+Q$?YGX:)2POQ=
M1@]>D 5B)<__^;)GS]$GO8?$<WP;R8O=%I3_;FG/S->^_A;LWNP)>EG*2R"^
MX.(E]Y+1X[ ZT 9R+^&RL  VM>&C[>^)2(1]Y Z!RN,V>M5/!(=DWHT>![S[
MQ-SN&*7IU3S/+O#$\ :4H]3S-V:2XT9G_&SXBA[)C,BVY5]_&M%V!*J3!LW6
M.\]OG!.01',?VQCGE9;AMUYFQ*[N!<51$M,'\LQTS4_^/=;#-HP/9_N/N&:?
M>QG6GB5M,H3\_VH:N5BUK$RFX(['LZ\B"OXD#0N)7[]YLTT-]$3QNK_1$*BV
M?1>.'8G,8MT_@7--*YEJM40Q?&;OPTH[1)2\*8MI89I;%%$;#$@RM7P ^KAX
MEQ"]9!DL*<CYJC?0M'-E2;M:@5<\<D[=NXY^[N&3/E;6K=\Y?2(C=F-7 #O8
M+4+(;W1J1%DM!AS+KVZ.<M_UM N\IGKM$!G*<AY_0VH(PGM91?H'G]1+G;VU
M4VJ\.%@^2MUWCPGKD/(^W[SI"?\Z\@:N7'_9=O<OVFZ/=+@P^/J\F\IU4NNQ
MT$D7SDD)F_S=LX)I> K[GCB+24"R_&DFRD.[#6$4BN;<$5*TYK6QKQ9D-*WC
MZ!\+NF_KIA_<7RWFR;C6@/-]."HE3DEB\.G:6*$\A9U*H4Z9LU:O  [I0<W.
M;NM^"A[UBI=[&+]>J GF\A?,:4]F*3X6TW5Z(82>.BGA,<^JN4R3I7[RZ8VW
M]#I:61$@+L?_\".LJZ$%"'WX4XUHLT.D'CEJKVH;.7+:63O''-4K!LYC?(>A
M#GM 46AOYEW"T,JYU- ++0ODFY\&MN"G8X:!)8R:E*JK3V[$N(+8E$8G-]J>
M0#&G4$:"PO+B/7OYMZG,;4\>7*90%V X*T/KU,T0PF$/ 6(-'@GC[6Q7@*4:
M6#U_Q!4 #(MO8\5!?]6ER.M\WNVN0J-3[ND$>H3;1R7JW/6CRHYV&OQR;_TN
MR%W1DBCHJ])K25/33C4$=@,7;K;CUZ1:@IP?\J[UV=SDW."KNLV[P0J([W#Y
MSUQHN[TZGL20U6T"$?7U_.GS>J+67%HSAR:QY]2ZWN,KP&71M%\<@-2>!57X
M_A/>-;G"+]#.\'0(23**FAA)[CL1_UX8<=8,2U@'T>\:/F%F^8-\=6RNY*UR
M;++40J<<&G!<?H$A*YE>HLG%\,83-=#*O/YN927M7Y"'M6//:\YG5;*^GY"]
M%@CG[9Z!R#6+?[ R('OG0(='G_>.N6/T6)^9"3S=!&R@XLFM3B-<T=@YC2+[
MZ>I!["WS?%Z>^6\A%ISY9N): QRV:2>BX6<_[L5EF0@HF^I]8N2S?[08VVZ;
M[J2B8QI/CTAR8QDP;<DKRYW]GB$SN40T^K9C(KP>Y#YJ@1X!/R.SOBF'9K:'
M!K[,EEZ=WS-QNC["A3+P&G;MDNK2IV55@-.QG7L^/N $\:PJ*2BWX"G079_
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M5$_ ZHI48SLH:B]'7,N86B/?D[);>PD:O&5JUZR</3Y#JX,^O>!0"4GYI]Q
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M[<%IIN+H6?//.86TQK\J:?CA8(4XAYC]QIUW;2*$4)?<IP8);(;$XDP=QRL
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M0#M<;"7EO]A_/WF<J9KQFO*^S%!MXW8#)JZSI+"Z(#%S5W<]I1+H3"@9>)*
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M=A],Z.=5VI1,3A9EKSQ-^]WQS+B MZ#T&-:#*MZC,7^($&K0UP7MW$C\5E$
M>W\@\@A^<:ZD!SHW*1Q-'T3B9=JX@)PF.5,O_(1.^U@A(4">UJ>P.']S][J
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M[4^/\FYMTB"B7-83MFP37-I5;M3%,PWD/TVT5YMSVT3;GX+^^':":]3B_K&
M+_38YZ_7*>5N"'Y:MX7#&SY%?=%6$/.PXWL;?E,LCJS8^;C%-B^FH^<.QVQC
MQK_RG<# "*4$P=2BB>0X^WKG5,2#?0>RT2FHL-&@-4,CIZO*B&Q#;4-=/PFG
MN'^;!!(L170-QY\OC?[3X*3J=+;2W6]Y(W-E6=_F/O^+;.]!A(%%YSRI6)IP
M'=C2]#;3O]9JJ5)!K3N0D>\<;A^)1VJFYLIE:F@]]HS<W+7Q6[S]6&V_=(1L
M85(M A6DR5J!C<+1Z]V>#<YOS9?_+GWS?_Y:N#C#1V)HKJ1$Z(D32WJICWE
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MQ&4Y3W-B\/G04U"%)>(A,-IEX9D(7WR?'<RV;IN],4(5YTA_9\2L^>!]NI+
MI/:%=T;JE"BB;LA?W.10.TX0(DIY#921P/BK7PCQ=AOZ)<4-*B>YCHNQKLK1
MO$]8PS_$<C))A_8+%WEVY5&" "B>1N] %Y5I%6]IF<B!B&Q3*!E\(2HU&I]'
MGAXH^//@TL^WD6?HCFP#C6-^RG[E/'-L3E:BSN,83D$O/2R-1ZE"P%17>V9$
M(OB3GXM<J9P\IV:X$N-JO, B:Z_:=VF6,Q^3;,3^8S#:,JRB* -JQ'H"7SA%
MB&2@4PW4?UU/4<VZT%C6J"?_:Z'=T25[8D#(C/]3#5V+U3N9;HHK?KH M[
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MW>Z6_R&L+J5_KEY2]Y%_@O^2_Y5:EOFIU4Y1;MI@WR+4#"8@UQ%.7<UR"V!
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M);TB!OJ("D(()B>96(?F;8]D%[!2.M_HU=:FC_CYTHUS+SV-/>5J5+]UO[,
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M^K!X)" Q#QNI:43CDA!:1GNY$.<\Z5&;^Z$L!:=E=W[84.CLNPXN^[=3V">
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M3_;FW/A(_D94]_Z^ \$8?V=P+J4TR]; ,13CT5J]FOXXB@U]>7)F( W 3\3
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M&!+N-?0.SZP?F>NFQ+3>$Y E.D^;T)6KMKT2/GK>P^C%:0-:F*S[!!SP0=V
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M,I$$QE7Q0ZGY<BG5KNK81+"!14KWV^#U(,NKX %DY408<HJ#Z.<JW+M:/Y"
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M+1H3M*'JMS/W&*R0&$Y:!^@BV&=,]O@4)FA&9U(!/07 M,^GN/[!M9KR\IK
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MZ[D2C*1UC XMYT;0<H;L:#+=('J6BT9@MG JH"U/MS=A'XX#42[M1J(G4JG
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M?M4C=ROT _36)UQO2WT\0*(@YVV>;#!]L^?ZW!;>'#2 'ON.^E8;KDLS\WR
MVZ_=I>,S'AUXJ$WL0O=)VNN]L$Z7V19X5?,5/%&J^^;18=MA0DL"AY(.?2EW
MN2,=:FPHF;&MYF0D3;J0UB$WG6K6EAY;*E_ZUGMQBLC5B:L97?$*.UFS,LM[
M]^O7IQ69#1P;L[CUQ\CU S$MF6T8K:'PT,*CQ46W0@?2ZN:=XP[[+L]7L8##
MD=H>?Z7%^8U-1 EGM^I<%,UZB/ B'R@*+SMVT/>$!7NHS(X<VS1C?QAG5V=0
MQD:_QC-"G&53@^EE=>L?3A*D^%[K.)Q '>J99.(]'^6%TQ]O73UPD&T<LOH6
M0E)T&;G,Y4AZ1+A E>W:TK^<T"^,^VE9EJF;^*CQ6,G*R+;!=[3%_PL\X__7
MBW?!I_+R_/08GO>?Y(>:N;JR9!9;5461HAX"FK.B&'_9PA+%\]4A\@.N])*J
M(V&2NWO>>4TZUC>^<?3<KMI7H>+B49S4]%9<$\@R0'NC/6]F)246/+(L';,M
MDAE!#M""RM()+(!]?2U<<([XB#!;**\SI7MK:0A*[@Z5BS"ZV>.":6G_"P<^
M^349^72365FJ8VFY7[4WQ4'!H#]UGFSJ3QVW(/5W6!(@;+\^WK9*-?=%:T,V
M!C'N(.C$H<\RBA!SSJ4APN=][[2,,)U7GDBR **QT]1?\F3H?\<B*T6>01 $
MR.-1=&_^M4YMB&N3?[?+-W]JX07HB6W)#?2D5Y<OYN!,K_GIAE.]V*M3T+2L
M]69(V&3FTX>6#6<?)8@?49PIO,;P8+_SEPW%LG<R]1&?SU%OL !G8Q906%$V
MI?3W57_YZ.5_E\+^E05XH'?D=[?'<"S@@GQE&@%-3T/S_-GT .Q"DXH 1*T-
M/87X:,6/!10+@OD]SK08CT:LBH!X4G S4N?"7X="PM0M%G"$EV##B.9G)M>C
M[Z'_KN8OGZ_X[U+XM1D%V 6D-\X!P3B6_-$Z!KMQJ5D)S/,R&$.H[BMS$+9A
M7K=>@66^,'=4[(#M*#J)@+U] \V,LP>6_BJ)I6<]/TY_H1H-HQR$[NI,ME0W
M_\N*OWQF\K]+T<-1XEE JCXZPN?/JP%UE@PD_ZP((Z$9416(S0OCVC13Q&?9
M<<R?W;FNR#Q$[4<LY(38,-MN8G>/>+ 7_4>0ZG_'?!$9BH1M7,:((+Y?!H%I
MQ8O2^_<U?[G8_.]2?B,FE9CG*2U;#7\V>5@IHGK_65K6CJ7P@!YS4.D6C@AB
MAL(CI]TI%K!D$C@4KO7GS=<$&(T3M)N_TO,.I/Y#E?S_H_Q/53+Y#U7RC_(/
M5?*/\@]5\@]5\@]5\@]5\@]5\O^8*HFB[.*L:K+6UD(J?)R-%6J^$(2TV(^\
M0@)LT^.+-D1+%L 915KL8%QP9,<S46[S$9=$E0R:2D.?7#QW1DDHWP:%FN,K
M&_8,)['MGC6%(Q!M>BP GS^KPRC'G/3&["?'QC;KEO2X%UB6M87F]^@I'M<3
M%)]PR[BXV/_-2'QJX"?6\)_R 7.5\1Z+S\=P,%X$%)Q4GL/)?'H\;E3S\O#4
M'G5T@ I_!K=<-%#%(0T$V_P<3X;BT9!:_GC5HVEF(P^MN1PT("HR&A>2'R2D
M)-;U9Z<]CKK/]KE5^C;[]H5XNB2IGRZ224$.^':.SQX?UC.7#:!$6)O6F>S>
MG3GL-X:A,I (_#M9$4:>5I\J%Q5G%=LFJ]X4&--K^U.U9%GH-9ND1OC@^2_W
M2Z<>X[D4'AM"@O[V?A$G?9HE?-2)G9'>+/L1EXC^/G-KS1%J7L.VKIKCGR*9
M"EQ):?P>+2&]$(DXR3R&:',S.!52>/5EB+;E %VX>&'GQ&U:Q)@&_8'%!J1=
M;382ZNV!;OVJRN1Y2[-<VH[39.HWC!0ZU6_;BT05!DSW[-%NX&J)<*2!L-3F
M5C"N5:;,.W_TL7N1Z?VY0W..?&>BA"ZQY<XDG(+9F)UA_M0!X 6#-VIG+HS;
M#A/]5GWO-%=]C'./^LG%+UWUGJ^R_,P)(P[!$<D:0TZ1G0[:/42;#91PF=IQ
MA2367J'383]>.V&/NS8>>/*SMX\ZB=0A^?ZWS"5C#8%WO69C"\B7*EA?])1W
MQ^Y%N.K(L..3]G*.ON!'^-([PZ_XC1<9K^ P?\5Y0TA#K4TK[CV:?G!CG/*,
M+(..Q,AYCL%ER77MJ%7:E%"?^UOUMT?URRWB;^TQG+[QWG#R?LGZ'Q)MYJ6,
M,-[6XB;,\2W;SZ:[ N8<B&/VHCF*!A&#M]:=Q_L2PU<CHA9$#[*MU]K,E]"%
MTSJQM1"B&LU$-4X+%F]P,K,- TGWJZO[,%+LK91Q;R<HP=?ZA=X7Z>C+(C>>
M=?CTKSK^V_L@V?SL_[.%+J<)N61UG8R[3@W&H_@\Q%S,8J9Q,._!?K4,NWR+
MUJ0[&?KOA*Y+*"PL%H=L1X(17X\2(-)-[X5[XOWXEB6%=>+&C1P2'(HNTK_$
MV!7?E'MP\/%KE_O?#+E6]442\&AQ3YA ,Z2 BCK7*)9UNLI=9*L([Q)^5<Y-
M(>B,WI-/9T7J_H_!?I'8>92D)^1 N%0%M03VD2:;4#AI&1%J,-1U.,GR-+#P
M^@!8>.B)9"1=M&_.I^>9"JX=PTW*1>6O'9Z5N:-;5I;3>$:%W"^TD'A?#'G-
M$%*U:;/( NC"BTR>LW/8R9*YNV@\4C(DP'1XW66X:*1\O?9@UC%*-[FPY["E
MPM.TGZZGG(?%UV%Y__R5,38H;U@MM!V]WWO8(PO;V<_E:3^B'JKNV?"14:2]
M[ZA_5:$G^]Y^<7FM7UKT+_!!C@8B&UDS+37<^BW(K;=JV1CJ/8>M)#]+*14"
MO;T/N/6Y-9?Q"'<6L"/' O:S@%7[8<1FALYZZ?\2K<MQ@B&9YTDQR("RE<F*
MC+AB!V 8YZ6]SX_#\/6>;PLG-@P7MBM.4)N8/+\ZX=UAF ,:9=_960!B/Q !
MQ:,260 _YHC35W<"OTR(=Y?-?<5L94Q<V=2LA:3K_B]530+JYHIC32?H*BP@
MR@@4E/-VB.]"-!":+S &_QT85II#4(^AB#_FH!,'5MK#M)\V0XN7)[_5'1Q_
MX.A]SJ8A1L'M<L&9&8E7<7KK@,^O@%:NJ8,V<PUT _0\@L&#XV<!),<(\'0O
M?H%Q58>2XGCF2BJ)M-=+ZJT7>W=^C8WFW$;?#\"'!V'ID -8?$-JW:9 R#JA
M0#E;VC*"L/(;H[8L]\(9N_X+/0B-@M1R/89ZH/?Q"X;P.\7:5=_<YW^ +UBT
M6IJ>9O+=54_:]?;CY^=_1NH+_:NW<J+R[3L[CZR(+F9A,&=T4K6$^\>/Z2[Q
M"B!!O(S,"\L"ZDS]9?=3?Y#FYTZ73OH]9<J%.'3NQN<_G_@U.5HWW69^<T(J
M#1ENX_=?F^L2H0YKTT7[YVJ\NVV;^?$C@^%?$K0MZS]LL("FQ7U1:RS NZ^G
M#M[M:8.;#'/,^=FO2A0H:M+(:7HA[8ZU!R_N/[A56?:_YR!__B_4 /#PQ7]@
M<[5_10=Z_YVG^,_/!"J25Y@7Q-K1-!X(0\;':<+I7U;\GX>'KO>L)V4IKJZ3
MD)VR4#)'P"W/R8L>\*\^R--S=@JV\TD!,SDCPM]=-T5^W5B$U&JW?A6F/*=:
M5H1#R?M'?R1GOWWI6%G.$S?G\<;B>N4/M^5(Z2=M4'N ;LK(P]Y#)R(:Q!+D
M2'5)%3\P":%G+/DY0T+T"NYRG7 [H7UI7J(/*)3@J<LD_Z8<)#>L#I.N=<R>
M)8^.YL245'AY.HO%$OMSE*O%79_7#CVIA:ZU?F^*U7LO+T(+H!DP>['[$7<=
MN6C0UEE(_-"R"6]@N>,=;UHSHM_BV3>-;UT\D8L\2@M(JC**GLT"'F-7W6$,
MA=Q( T\P:T\@/@^'E# [^] ,E2KT9!;]YK]2"2A]8@%>ZTA1;(U?J]]!ZK*S
M=$/]_5 =G]H<Q>;GJ]'<:]HR7Y&$F_IEXTH;BTS>"/(>#TUHC %WC)F XRW'
M%6V+UWL&WYGNVV8!#M!A)-@DB]1'>*P$?!0EH\DX(-48B! +*;OBJ1+(6S\3
M-1%:J0"=,3FP<* O4H>'T4>58 $<V]3C)&A'?88_5?LB^6YUJ<%P94C\-]W/
M/]/$[YH^5V_7%P'FWRHJT,^"QYI3 _W>AFS/09-5#N\_G>;L4SQ9$Z1]8/T0
M^PCO0XG-@&7OK<E(@PAJ&VTO78#:1Z"U0"^31)'YN LO$VQ)C-=!VO=/B=_<
M+QE)9:[$P+SH"HQ\#+<WML:FVRJX=;(3XS:;J=Y203]QQ3?OMJS$\/ ),T-%
M[[T29]!+05A%*+X!Q^_<,&X@$3+'?= ZD',6&7SJEI"\:P9@C=BJ8<*><WT'
M\>L2"YC46:2D,K(?)EVS_:CM=&+0S0=BF\[<'.I^=]5EV36I\$Z8'VX)9K8R
M^0,9\U#?W'9D3:C?:IA8U/3QPW/"G7@ME37KO,O6!%@:C&2B*FWA/;\>!^?W
MM.V*>./@-=AIS7/[1>?JWD>,8K9YJGD>^CT(E:4X@:,D_E7W>9&Z]/RF<86&
M09= YFHU^[%=\:LWZ![L9!3E-74+S1S!26NA1&<C"ER;/]!4D&\B;:?L]Q[F
M%C2#WSG@  F=0(8QG/\HPI<0?@,1JOS%4<R1D*">[ER]YNB[34]N)OF>+.<%
MPI\^_:FM--"T]S.7+UL7W!?1IL64GJ)?8%3KL?L\$OKJ4FRE4G>B8;MBWO/P
MF74:001A])!M 7.*D0KGI:Y;I%T:,Q +N>DA86>2L7O]]&_SE,\6+C<>ZI^]
MJL-#=P"#- K>[4XQI[ZZJ^E9J=J\?XXS->+H(V269= YO3Y/*?$[32]BULIU
MH[RW=S&GP,/KZ=#8;EC5;%69.$=FKL3(O:WS=N9?V,\K+TAL3MVW348=TX\&
M0KGH@FA*:A,9%KVU_E2'N')K^I?:?DL3]:J[-"F#B?S/3/$%CUZDQ7G\,?0'
MJ&=_G##],".7>2BD?; S>/=2DK]682K@$!7M#$K\8;,+=%/PQ![421@[<Q+"
M[^BV0=RR>#/D*W;F0,VYY?A0%I";:[=;BAY'4X\5ES<@JF!=)M':'X8+GR,I
M-^>.NE !:X(A) U' BW&4PI4 NO]5:;NE\VUJ@$?%3UC/3'Y+W8+22F'57,_
M9'G@<HOOAXVOWQ@MUQZK<;C5(=/5_&FPC^^=A,SYMIM<4=QGY,9! A6\.W<&
MZH46+*P?RV[;]A1G_HZH_ERU<QP:#1^_S/4[GW8E1-UZ(I;220YZ10AF?C.0
M&3\\LHE493JF= 8'+4.G[000K=Z[$B34LT-D]^B'/@^F[^"N5<=0U%[3J\TJ
MS^YJP4%UTG85+=?,:#0XS"VDME"9<S#5;.*WM"=E1W$@D=A#TZ+%DD[W1FCC
M2SIHEB^_V)QFR@[/96B,VOD4<L Y)($E/:LY1]4VC,Q('=%W5T;#?-AGH:FI
M^<,]!;7#&7<5!P!ODB(EBMHX#Z4><R=:N+L35HX7QV\LTA0[["V%1">G_ WN
MO?QTU5#]TS217>(09X0:*%;]&=50@MPH"A_[%!WP9FFC''/D8_2'7,)YUUH.
M!)\['PL@$J7OG=V&48_ 5KT,]E.YPZW)CG'(;LR1>LB=A@\7#7)*ZB7,^"V.
M$+(_7$YHF^7F&H766*\R\IA?<-P/_=A_7:AFI(=/K1"SG2A+D;_O^KT%V.@G
MWK64C?SZMRTN%$#@2UG 1@1*&+$&HMR;I@L;J#@HYR+)KPWQ%"9PVP)B14Y/
MSCOZ/.J<X^2RF$#U+N L(+@<O&M3AFB[ M(ES> H"YC68 %60>E;04](FN&^
M8,AIAC@K5]") 1TNU\8WY\HRE0\4AR[*]2@^5#[&WG1O\R#;$HQDSI^,(F73
M^4>9,K!I"2UKKIG0C'>K%MY2,>Z7-<9="ZZL2G#"G]C\'@8!]3?U%WP/<V3V
MX*B*+[P_WUL(X;Q<G'S02/>8C9_K"Y.%W4/H7_;@';UI*O?XMBIRW;5&&M#W
M8/]=P^15!ME6$/+T(Z1CO\Z\;_'<VZZ?>>\NW>S>RWF=!6!/?WET;KX%[N(!
MY7CSD?&2?H-\ARSAXQ-(4^5?FGXN:Y-LX2LE0RE]>@"[(C5@8TSSI/NB*"\9
M)<U7YF3TBS##^X>6=*2OI-(J[MQ).0C9'$RP0-I918S3[M.%8RE@?D7=H8JU
M_GI+F9*YVVUUSF3!(O1DL-"EB37M&C9F;RG14'8?>'?>+""M <,"JN[\9@'F
M#N-$(OP0HDT2;%WB.G;5MID%#(YMT1Z!&L&F U)70A>YU@8%MLI8P#XJU%I6
MEQR=+5[YZNC&)NVX49OY<]=/RV$%?.S/;05,@8A^4[@ M8;),T$SI<8O6SQ<
M%_"4%8O+5MJ;66ATN'1S+\$-^HIH08!1E=R)$H2IH@P6T"D)C1MT."IC8_98
ML 4Y\509F;]N"&G:M&E'54/I(@YM.-FM/GYNZK 5;$](.[GS=&HH\RXJXM"O
MA$- YVH(]PY7I'05+RQP@ WVI8<(2F5%-K(&LSO"&I1F/]!+N=A7R$D(\Q+[
MG#LC<1?%3.\SA Q:K[( %J  (6 9"?9^S-0>QZW[T!K0!3U'Q+  BK(G=M=2
M)G@$-/3L-!OX9"[ 2*T5_T$^N/Z.FKJFOHN(/2D>\0;O&KEF+6CZW"AH4]=8
M,)Z.I::#B?>,2ICKF\ 2Q!*,25HQUJD9]9:/[G/Y;%R2L$5>D4S6N<Q%W!*A
M*A%8 /4$F(1'"F;WH?6<G='FS^']I1X9'J_=$]ND??K'ZR*F:*#W:;-IUB(W
MW7I/BNVT.CW59J#4'!@SM#M[[N'4Q*4]W;RI TW"T3=/'E##*O  -,K?%#H)
M-5E&Z2:)K6827OJ%6_L?83:&%2W-0JKD9AQOXQO[!;OY;7S/R/GJV?P8[T13
M3]ITXT1A_2R NPX3B_?16S"6:2F8G3XF'[5QB4=-MD!+^F$>_]1')9)[!Y1T
MTWK2V*A%&!>"MB)+&RZN3N;&>:6@[DT56;$ Y)\W?U3UTT6@':A:Q;A:,-*H
M_68PKI!O.T]/:SB<=WN/39/X7HSQ>,T">.KQ8;Z?@<@(G*G(CC/-!M%F8Z 8
M+DIE ?/\["$N[4RA3(N!RN@"ZS*'&6N]HL,9=UP^)!E^/B,5%JS)MHLR#>U?
M72)?6)F'M>(X0W[N=LN<WKXU7-B4-3:38"[U.H;'^LRG3_T7M_2]!T''^ &6
MC!-TIYJ2W+MGM>IJD)<;!S03<LR4[%X77"!WV]UXML#W^+7-S^W5";#_O*GY
M9)?Y_B=Z$G,0GA!331_$M81+H9J?5/(_Q'[QR>_0VS@^]3JE 77%$%(62/:C
MBXPS+_:#&O)]5RPS48N2'@Y2-6<@F&$:H]A5-><_>]L#X6Q@6SP!Z[JKP0./
M;#.CTFF%L&@<Z3QT1\];E;8'AOAU'/91$XRW0[3+3- ,@&'LBCM@CZ.V+\_-
M7\/R,W(*E@;C5"I[Y_TE#EUA<\ZXP_7&6F2GD*S+Y#4E6W;::'3AT7R_# 3>
MWWNV\-%F1*4G?[;+A:Y78PBIJ;7!GP,#Z3K4,[WE=W_G,7OE'Y@O#Y5U^WJV
M'\C-(*FB$2NS!MR(-H]FY^)E2CWB(%VC9.6C1OU$H/(!#9]0;N9.8E6R];;9
M-SHECW]\5PE%XD=J0N)E]P_IV1"2S)0=C$8KQGX.;4@3!BAR&^7<)WH-3QAQ
M[.&NC(KD4?J]S>21 EOD 'E\-9OL8D3R>T+7)\R<T_TJI._TZ.N#LS_/ABX^
M,TLX6$5D__3-XNS,@$ON=BN6=/FK:#_EU"#F=+A9;=VPEN6.[[V\P8<9=_S6
M"C),KD??2LU[.FTI)."N0.+F^EYK0X!U0JE*F3TL0#0DRJ&?WVO7+TJS9?'S
M\#W-OD?EBK<W;IG+:[B\=<RCL!='#(*]T<.H#7]$NZZ85(N2/9KM'TR@KOYL
M&#GI0X]]><&-K_J8KH6L/;[4J>3L7*3!ZI]Q!?0G*%5YF_X"%P.C<'T$(;(/
MAD[?X0)O#432U&Q2'[-U&[9[UF-/+%TH@.).=2/3.A""E7"YD$OCG35+F4%7
M)O4[AQ5?5*:)L;M4/K@1MFLS:X,B62$FJG=G"&F$P-1"EZ,RYRA'\8LQ=H\A
MC]$@-.)C$1O'Z/8L $W490&F_;"26K8=?9H[HNW(0Q075?$:N:&M*<F(!=0<
M?E2&X\594J)(I4>R)B_Z3N>Y]T5TQ=R?8',@P";\*$@R_RJ6''"!#(_SU[ [
MF7"@[$WA'5W:N8XO<;'G_%.+&&/ ^.:+7HGS\G(D(_1/U?F;"9X$;&*NWM"]
MPP*VMM[;E'KR@3C)6^??82/W1$+?1' Y5)-58DN\=A^N!)0LBY)GIB[%*BE<
M/>;JO&K$12X;)2#>MZSNQJXB2*D.,<J'J?!).>OM*T$@HF&NVYREV3-Q$'ZH
M*UKIXNC82J?!J<;(6PY4A%6KOX3"R;0+N)/G+Z30+X9%RV<!NT[Q="MJ--C.
MZ=3^.<NW8AV2L-AP&;?7W4(3:%^@WRSUVGNF8/SO%BB3IY!VT6[F9$VX80Q3
M;8PWB=>:&^?X7 EN%@F-*$7WPB9P3%[]4/^*24^(.%W7[4".!G?_LUKNA6M[
MSTL5-QQI4+UZT54P6;!LR_CB"%&KXO3PE>&U?,S[IF@5Y;6*:;T LV4)1]O[
MO48<@FU[(Y6OF,*]F=,XTC7K9Z!+["%:MAH(D7#1:[4,@Z%)FX]C^8VY=DZV
M&<9(%8_V2'&^V[D:N?<!Z(5CZ.=Z+G\2@K3= 9F MD$.-E]QY@U!=V4]Z"\)
M<>IVR8[K.6!\ZLBA:U&VBU*14B\3F7XA94R>09JI]ZS<(X9V9Y9?3+GVFM6)
M#O/Z#(%&6O&BA8+>_4L$8CS P*.SH?A"[(8K"SC( E:Z^1DG8IJM*8X,3',
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M$/G=0;>:<#47$HN1'0H_5+3'Q$;R*<*WQ3]7/-7$.X6N*P69U62CJ9G".9=
MHWX#.GGG&]D]NV=LF\R>YN.?[SEWFG)$[B8]"U/.R$+@JS^7>Y_.@G3['!BV
MC"%T>L_Y[)<VWJ?X1+])]#:F\ND\[>4" "^Z<N/AUTO#]L,^6C(&RU(KO!^N
MSLTNSW3T:/KFIX_&\A4)&$D+>(T"!VU^K!,CP&:]0DTG02C/R-:1S1H$!,^T
MIZ3T\X[%Y8'IK_YJ'BXIV6K]DJ4[I+W#B8%:FV(]JM1CF;%P+N8WYAYR97Z)
M><0\4M)#- R30PA1U'7YC;>0^)$F87L%Y>N?*0]$S.5!;E^!/=%9I(L@*<C1
MP$5L+=DII]"NQNUAF;[H*'$DS#=#._,W?'0W"62&=<:;9BO:C7"N9K)Y@L\]
MY:T*;?ML\U0KG=/)9T?EHFX\SW>I0Z*>/$%FRO&!Y)!7@+G,J,'B\YWV,U+C
M/:Y,-"3HA?ISY^J+[@LO)1;>(Z;.W9*)Q#^/%)5S_\&A!?>@=C!Y9FBF(:GD
MG\-:#/GVYQF]4TOV>D*ETN3L]!>YA5@O@#%3@.4W &FSS=E )^32+OO<W4&]
M@-M2VX.SWX^\7L7$'?E@>FWM2FP=O)K9!ZUMB$5X]4>?"IGJJ!_7":OH^P[S
MW Y1MW<\7*CW*/; Z4^)XH%\ZFR? -F6_SFZN8&&C91$(Q9L02I<^09A #8;
MX_^BYO+>8A&;&QCFEZ%UU=.A*/?H'Q.O?2>+YO4_VOR @"E+55H$$SX.)D,7
M(>C;M,L*Q1J219L\B][7Q"^IY%G&#<G-F;U*CU_G8*[N[3:X!<9$S168.'P"
M1KH&V<O\\O$I4X3$*(*?)J^Z;%/\K:N'+QED"O'E,.C%$O,_CZ>@OL&$$&VV
M4$_E@,O>":IB2TS9Z+C#PU:#RK)'*'M#?B"^EK)OOXFGAU+_4' 6N3*A<LHN
MW';P7KAY7B_!;50SA+-NZX,^K*\_\YAT>-ZAE=^RZ;L3^'X)#YQ LV(1-;/C
MXU/[-W'OIH[,Y"PH_D@]+<&5:[1JU,8A8"@WL'?TX$WS!#V'PA#^#GOD,SWC
MMPZ_=E5R>&\YXAP_G)\S&DG;91M)!3YKLJ%-X=;P 1C)7OG\<J8]K&U]O[UY
M2?</L4[90^:ABD *1BGPA( LM[JH@NP5J_ );;J(->5EVF7:.>KN[+%@=HK)
M "B3E=CK+W*2$+/]8!8NF<+/T0^ 1FXHI.SBJ/(]S FJ4X_]D%W4YW<>W#YK
M<TYK=^ZJ]6WNU6'84Q'S1-XY9-0F0H1ZEZ%EQ76SP2';LK2-;6#W2>][N:B2
MYT9<*88R?S= [/?O//KBG?WO/%95RS;T']DYX.\GK=$2U'2#DOQPIT&M%7VA
M;9NH<>OO?3Y2 G:)?4EME[AG]SNR@.C1"E!404>Q9) #M QE:TQ#M>DJ%7[,
M.";X 9(%D-]!"8'>B$WK+;\_&\@G7>8J'W0";0=O&:BX"Q!EB'G0OWDAJ8[V
M.(8P ZR#@&;B.MN*IDT:HGUYC 7\0BWCJ']\GV0A4^QF PLP80&@< <U(W44
M"/LJLH C?:S#[BKN-C"A+*"[]!_7]%^\)@F4+'8A/QRTM^_S_XPEC!+3?T.1
MX3X1\_S/8 <,)@BT%M[5W8)5VLWUV;4LOOD3+:>13@68E_]\I@FK"\77(S;\
MF'M!5YF#V$P-8PBCO_7_WQG4)ULS>2W*]=>)IH0^OI3]R&B?R*M<N$=E;^[P
M.V5S06?0D[UTT"I%]2(^3WUG =^KW$'[5GF,?1E*/6R5I=B*@SCR[52'))I,
MDZ/KGB$9?.._1N%!B#9AZ *.'L "7'012PHBNXJ&G/ P$+SO:?Y:8&2'2\$1
M8VUSWV\[<9G7?'3I9]2([(K  $2;%PM8&/NSR[A+#IKY''>9JP=!,M>W*$=X
M?W;F;&TF_5CE\FR5L^!XO8N<0?:(@-TI.GS3 [Z'*GR1L_X6-9.H^#BQQUL]
M&3Q5G\LNS>832-[F5-=,2F>]Z[D^V>CP;X:TPFT71;(<7&L+2A==9UJH=B!H
M^T&K7P!Z4B+(=8XUR2N4<C('LBD0^U3EQT79GVM?S]*EQXG1<"5$FPAT8:GY
M&BA3W,:9F;;C1"M A(!H.)TC^Y8&H=^*@7W$R#:^=F7_;8:YPWRG-*/4A?6Q
MWM%$)N H)\'$_Y61QP_RQ(3?]0@QRDNJ57AT3\K<U^/?S:8L52?GIANW)2!)
M"#.$</,^=[(QH2=>#U*JEMSG-*RB.>%ZI?=D5;6O['R0^0?T(A?%/\82.2E%
M"+\B;W$R]_C0J*"9I7"P &"S^=D0\@W7SB\9DDW9QZBH0.L9%UM16 #?;)]S
MV5)5_7# O>4K7USQIUS=4C4&GL<6P\O!1B?=[)^8[6E77QZ#RXUJ*=^XHRK[
M1#;%7Z;/0%W@TZ=#TB3KE^9C+67SVZM(4@WE9?W3D/4.09C7Z:4?4UYCU5HM
MJTJ,P1,"=F86/+070I<T8&=L$6T2< Z[Y:AE1YONA@$_98I4TJ7I<V;PM:L3
M,!D,)>(7^V\4?K&#!0B#46$$O6=91IM2%+7'O M,@GO$J=G:<G'T8).#.*-U
M4XU^[8.40TB7K2=_CE.N4,^X#/Y(#%ET,J\9J'C!YQ )I/[(?/.]@^_ ZO6'
M,TC+83U54@E%F7JV'+=D;X5\ JH[A^R^">61VG%.&Z"I2E6SHKURSD*!#18'
MWBO]C] ZS*@H< B956KQPCM,MD^D[A>S2DS+Z#:P':E1FW]4U:/""83!Z,)0
MBC&*DD%%0Y'-+AP-L_M(Q.\?&A\5P&@VES^E.-^![R;&*7Q[P/.6MD5#PK2I
M\]TP?@3^-:)Z--[8H[_X%[DB)MM9ZL2T5^8WB;B[2XW?]9*_X_?*27.BOU@B
M)MTI&$:#GLO;2;K!2&"?[>TI><]9P0^2CG7QHKKLTYG&:4^8U;?J#YP1!R"-
M#VT(!G5D&J6;$4^_48).UL(*=:M(A0=A3C9*=B4MO^T[_,6QK=LL_*U(C+G\
M8:P=P@4W66;,J, (=\WEZ$Q[AK4485U&-Y\<_>UY'Y#W;%66BI)PD"U\EP5L
MZ_S'1ZD95T%8<.I.@[>Q@/TN*3<&8TK+R]6Y=7)FC41V_HSXF(.4MTH%@>E^
M/T-KTF:YY(\MNFC]3[9H*=@0DL@"ZA7;)*#NV$F-;OC^\_;ZZKP=@<555]GM
MK&B?#/4I9?<4:9]&:7$TGO"'+" FBO&2#IFSC&LF>HWQKU;8IF70;@'R&H\^
MKF8R)WEV>)F\5TA:@:J\5..Y;I1/=LYIV*K^51.GBT*BCX)=?E6')FR]\NYE
M ?A$E P7F,XAL83DPH#JCDXP/WR'4T X:BWZB&[J^(#:Q=>RT2"PDX@V"XP^
MY#&T&O<LMQ??-L<OQ+\J<Z;0>>1+Q>)YW:3W<=S.@_$V(UO4X#_S"]3?(*68
M4Y)E^8?73"8A47*GH?)N]KM6Z >X&YW^$&/AL &N/W.3M50PZ'G3*$5#@98K
M?KJ&I#"$SXSHK<)+):)5C/ AA1Y_7AL<F)2V+&!'T\&/)G$/NWE]"^03CKP_
MW^3)I#C7D$5699T:YCW-JE3PVLJEG#[7]-LN]D)7&LM1U),(>I9R R.Q'K9[
M(@R@EC&Y0?NJZ >&^IVN169R WIJ\F^8#GJWSU,XQ/>JT#_/1JY0*)%_O%%4
M$7PD$UN#:Z5J0@\XM2 3PV]OV-E/MW>YUM::0CQ?B4>,=Q0<QS\Y=/M!^LXU
MVD'FYTD4,9@<&FZ@\F983[NDAS(3<#UQ#ZFCB2=E0?#GIVF5$$#C-K&-XD<]
M"4M2)/,3G0_$?VL?-QRH\$F%$G#'0R<P1>>?, &E52A5'A))?,@_47:+K-*E
M$_M,:\FXE\O 1+# +/87$6RZQP-<PUA>%N *?8+EV@S1!",O7'\@7^U--Z:Y
MQK*LL<6R_YC[O=>OW=GU@#/E+" 14@5K0R=]E!F-:<'KRXZMN4YF8=(\97(V
ME2<R/$:$D6OU/_3;T/?! ,^&3:(H 2#7NR$2LU!1@:',*6FOAK"@HF=7_)1O
MH50N0Y_^L+-UCS$#4J(0;E#\*UQMQ3I1A*;;FK4U^&>R\*?DI7R]I%<J+MQ\
MP@T/[-2+4,V#C>LP\*K;_)H%_51C,.(A;8>G@CEG9M-.%E*'3.Q<KC&7XB\B
M,*,_<203A(B5.[EFCC]FI"&E-"142TQ\/K#EBW]E!#D(5P' N\9_J]&,P0YK
M#;\(DC\*Y*"A1N]==_1/%THLF&B1U%<@:QJ4L(#B!P-<F]=HH [YS$7U _M\
M#$S!HJJQS"YDG"0,3-88S%%R9<V'I8\B3QN&"J0ULP^F)R$F[[8C@T2R_^YK
MX[U_ A$M^96 FCBJ?W0?#T30FY(A+ <-4[!3L29@N%F #D!/&ZWSDV%.0&I/
M6/H?&@UWF]]O)1>][_ Q8YG2)Y6?[ABQ +;K"MM:M%B:)K,-Q<,"[H(]-V'J
M3:"I"H84F>U??+;UZ&'NG(7:[U"'QP)OPDZX1&J+GE7<$&;N&R8'$UA *W92
M754RW!2;9C6LR3BZ=*\D?L@AAG8]6QXXZ76>,?RUW_J+S;([7?\1Q8<%Y'?_
MT6H<F2BZ;Z0^;4ZQE3^&!8AJ6FRB14,43<8JCEB]ROW,4;7U\ZPAOQ3?:_7G
M9E9P8?@LI+J,^1DE53RPN7.WD53YEI^2'!>@X9OB?/)&?E!K7W>'Q%HQ_[7X
M/P(Q%@W_BMT\ V8I/A7,^J3Q#@CINM\DFJ!-U,^G0]-:)4<F*\L*;LTJMW\M
ML;YW4R)#Q?C\._ZO O-I_6.1!CM@FGG!!\:QM9#5_C?6%3-:BW'-NKH>64\W
M(+D(Y1OYZ2V6)K]X9<N3O9>@DB$UETC\3[:P0BO"$:@+@ZMOL$V9M"J3Z&GF
M!>^-;2:W?]ET1-,<,\,A,!]IV<B#B&YKO&H^(HC:-HVX N*2)=FM)QIQ!RM9
M4:87X)4ZL82Y XH(8SF#+\_Z6,">//XN& C$HGHW:)?#O4;H5][M\PNL"-NZ
M73T\?Z>=N\\G:NP08Y3S>EBJQ8\X:!6L&J1"10*Z#;77<SM7E[26/8^2F3:K
M<?I:=J[A9D:RX5'Q0_?R>4)^<Y_L%'Y^BNNG#<B<;0+4%<H0-73_B)+6FVS-
MW9JR/?<'C!12M$<N'-;;#</;; H:RNK.H[[_QJ,Z'8\Z0NVI,$),W$!>;I]5
M\C<"&W-A(#J0+HF1S63N4ZL(5V:4,J5#.@AC5:(E>'W=SIOV%<1Z]!F'KP9G
M%"U>&?%P])[SN0K</O])7AE6^O R&^Q;/_T@+]-:8P[+B.%G)EQ@QI7M3(!]
M\!CQ^6>X#2C*P;08]#2$U$'?6]-?];?[T?:8@F&D]8@8(K8*0N[1 %(VLS4%
M\<O*B68HJTSS0GPN"G?Z,UWX)]!,ZN"B\$[L1C",&[OJ5@W^5 $6I*M_KOS0
M[?W?,YF75@AB?P-FS<M<FZ$P41 <'!$+7[;\:'RVB%\=,$^;+BS)!K:CH>_
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M7D61[/0,-(U(A6W8B::@'463!D4&<4K;EP5XG]U&WTC6C-%*UKINRG;C^FU
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MT><<KSTWN(/V"IEBW$5^LC+KE,)S?ICE\@U!A^29%V=)6HR(HZ!=9GZB8O7
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M1YK)] FW*:T(]9! 2$SHL]*08!_71Y/&&4]4.<Y^#L]*\VN>=6\7JHE#=NT
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MW%?+;Y/>/M1L66%5@- H&!^0+%Q$#DJ).LGV5KV8W,9>,]D![G%!224-\CN
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M[V*F.UQ#+R?*& '&5545.7EJ=B':J];EVY<O6,[*;]>W]SPO/CZMJ/K K3K
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M">?&0)W(=2X&VPIMF(>OC;>&AS<RBA.ST09 59!A1U[0"FQS74D'2 /';V1
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MVTXUQMW8\>KB=C0IX78A>[HJZN;6KH;UWB; OK\"W)@3.JP)-P%.^U7BIIC
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M^*J4JZQDC>X6;L"$[S,.2:@JO ?2&C@+,<PR'F&?9FF::N7Q'AU];DRVE<_
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MP'W5$Y!22%,1JVP&#K,XC&"*,.9(\#B.#&]'#99I;G1U]?BXS*DJ;[FI[\7
M4ZVE? >?U=N7;W0ZESLYF2%U2<ZI>2;FPM\Z(P@.'EIMI '4R9FJ$*EJZ.;J
MU./ /&"MM *55 O<M7J-R9FC@3PYM0Z7U#$#CP;M(5&/-[1-AEJ;GGM-Z=-C
MSMEU40_?S*1ZR;Y]^;"J\OH :OG$U.7:XUGM6&1!'!($4Y9RB'P_@YF71% Z
MFU$88!S1--'/3QM)JKEQNE*"JW3W5C^P;A54#0L;<FB9HN[03%XD5TCZKU4U
M26P:RZ@:YQ^7,-7$_-ZI!#J=5-N^6BO0R J47N#M"V@T YUJJE*!4@[4VJFM
M?*5?^Z5+V,\D+>T"=G25E.;6GH8Y:2/CWI^1-M9D#O/11L9G/QMM[,%M<M'J
MC<KZ%;BZ*WA=H^+O>77_[8^\+#]R.0I>-LWKY(Q/1,8$?^5X6=UWF[VQ3Z(
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M,>5&/]8O,0Y1AC(<PE3U^D1,LFZJZO?SB(?"BR*/Q(:I ]:RS(UQ-?HW=VU
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M;(6L\T2TF52>\]-6D!VFK>V&L8B?ORQ8^5HR^20U5<4<(BP26 #,H@1 AF.
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MC& W_8#(KS6<ATL;==0&$&\4"IYKC6J.N>?^,F=7.\01D?80;XT@K/=H;#R
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M'C- !0X!S @#I"@PJ%O>D 0G6.CW[#TRP=2V"+6(YCW"3N*GD=4<B(IC1]<
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M(.GG+>P?PB-'H98N^WR$>E]Q10E0\Q<H%W[F&CG*(YJ&"0>\D#LM&&48H+S
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M2TS*>;E^,^XA8&\8W;C,#]RNTY1;)=KJ?MRIH4A45ITBJJJ_TR18;E49M>_
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M9JS';7>?FTH?;FJM/+RVD<IG_8-K?I6;F P4OD_P/>O^GO0V:M\$[0]POQ3
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M/+_-1@@XO,8GO'I_??<[!GYM3U@]?5U//^(\%O-U+,-X(#V119FA+ $9BQ,
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M4!/(;*)3:R)L!P^SL7N$.^,F0N/HZ)MJ3==@[ZZMZ$$D>1'+.$LX3D&2LA)
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MW53.<CNBG<KQ>L'ZJ9QEX["AROD/N(\.^*_GNK7HWJ\WS5M.2:V]FF:N5[V
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MN[!]8 MO&(13 ^_*YUWLNX/+U[?=P,(/^WF%]WI<X6MW]*MNO[ 0C+*"IC%
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M8$5PF?G3MW_@LYYN,'8-2.]7_/>*:=/FO1!=]+5DB4RPGN<C=$U"G'% H,Q
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MS7F0W0R'^K>7CV2K?OUU_?6'J#;OGU=-C>5A:URE:TB2)0Q(PE( )2L E;$
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MB\85&H@Z\TJ7]$,Q0LZDHV#1$R?]@#N4/>DYTD@U2V>RR"613(&29::9)8>
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M54F>%=;D%T3$J=%GIX'QL3L5FF*^3;;6JWZ VB&CYA2'#SM?L:QMP=9O;L/
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M_OSQ:SK#\P#CZ6(9IJDNL!C_;='\XL=9"LM&YB_2]<.3?Z+^#*[_&-1? BY
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M#@(,U]'7=/E+.$?RKB7'H!*87).EF$&(/)&S770(5J%VHHV'_KNK;@4*_\I
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M)4@^*$5B8NG ;A#/++X=3%[/#6M;<AX&7'Z_3<)>576,)(;DM,?:/R6!BEE
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M&(NAN&!B)A>GSJ84M;>0MQJ,=5B2R ;S[@F@.Y'PNBZ-=L#'WO/Z]M?0()R
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MTH("^SZ\/\^6M30L3-Y?+DF:/X^)@>5LBI_#U7H ?12UE7 !)YQ;#: /ND1
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M.>D[607[OM(:'CWH<#&$0"=QYWQ:8B*'(&9BA.[C+1\B6EM,Y!!+G?CGE8#
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MXNKK8EZ#)N=E([":Z,92"O?6 1<QUD8H 20PL@)9$4;9G',:[\CMIK$UO(9
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M*P-CW3$;-!D,'@D*44F.&,F*'=.X>Q7)\X,TWRUY?H@:6J=-'F4&G; ^:67
M%46DV_6X<_)\=&*1Z9B)PM#I$3PBFSIV\OP@->W)IAXBL];J/M7'X5J7PBNK
MM=(D1 E!60O!Q,"#ECFR;AOK_Q6S9,<\6F,K;2)OVU-?.&-@(ED%PF<27J1#
MYC$RR,%H1.=D+KZE]_+:[*@CX=$I;G&(KII?B ?& EG=9ELW"EDO25HVU98(
M7CLPI,B.,^M2ZG8##A"FG="5=QJ^!E?-Z^M1>3C1;C,)$6OC[WSSFQ%G_QWX
M^1%'_9TBF%&"<"YG;7S10/9B <5XAB!]A**LQ"220MLT_-XZ"">+]\5: ]'K
M2/)Q$9R/!HQ2W@BZ*[(<T,"<?!#N$/CT%80[1"43,1^?./G>6R;K9A?N9-U+
M7U=H)'H:F!)6$Q6)IS%KK'Z.(-Q!P.@2A#M$2Q-$VB8<P)TKB4B%9%&!\D*!
M(UL';$B<H51:VO_M8#E%\]V"<(>HH;43\J@;(_$@;!"D3LW)D"U2D\5<B[ZT
M(ZZ8*^%QIN[U=K <I*8]'2R'R*RUNA_%#WTHD0EC(3$6ZIH2"XYG#3+FZ**7
M2;ANB<=7T,%RM+I/D%EK=;_<9\$52TP'0XR@J"T<MLX3E9#(48Z<9<VR[(2
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M(;T2>;1+\BYEQWLS[@&+![?BWCJ:!<)>?/IT=I5^7WRAGW!9KK<.I1(P"G)
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M2M6FY:M6!(V*Q4'1@U#%9Z^EE?[9:.S)7Y]\P,7 *-A'B+-"@;MB0*&JI%(
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M:6]N+FAT;5!+ 0(4 Q0    ( "N :58L$JGPV <  .\@   ?
M  "  :!W  !A,3(R<V5C=&EO;C,P,F-E<G1I9FEC871I;VXN:'1M4$L! A0#
M%     @ *X!I5I_,0L.'+   U1\" !X              ( !M7\  &$Q,F]R
M9V%N:7IA=&EO;F%L<G5L97-O9G1H+FAT;5!+ 0(4 Q0    ( "N :5:G7'$S
M(@8  "$=   ?              "  7BL  !A,3,Q<V5C=&EO;CDP-F-E<G1I
M9FEC871I;VXN:'1M4$L! A0#%     @ *X!I5H_Q?K*) @  T08  !8
M         ( !U[(  &$Q-3%A=61I=&]R8V]N<V5N="YH=&U02P$"% ,4
M"  K@&E6VC0:F))& @!OTQ$ &0              @ &4M0  83(Q+61E<&]S
M:71A9W)E96UE;G0Q+FAT;5!+ 0(4 Q0    ( "N :5;IT,$SP*,  ):,!  >
M              "  5W\ @!A,C,M9&5S8W)I<'1I;VYO9G-E8W5R:71I92YH
M=&U02P$"% ,4    "  K@&E6Y^Q.D2LP   R]@$ '@              @ %9
MH , 830Q,'!S=7!L86XR,#(Q9F]R;6%N86=E;64N:'1M4$L! A0#%     @
M*X!I5JQ27!L5,   'O4! !X              ( !P- # &$T,3%P<W5P;&%N
M,C R,F9O<F5M<&QO>65E+FAT;5!+ 0(4 Q0    ( "N :5:$<?BL^B\  %GU
M 0 >              "  1$!! !A-#$R<'-U<&QA;C(P,C)?9F]R;6%N86=E
M;2YH=&U02P$"% ,4    "  K@&E6\U%B\48P  !. P( '@
M@ %',00 830Q,W!S=7!L86XR,#(S7V9O<F5M<&QO>64N:'1M4$L! A0#%
M  @ *X!I5M1N>U@D,    PD" !X              ( !R6$$ &$T,31P<W5P
M;&%N,C R,U]F;W)M86YA9V5M+FAT;5!+ 0(4 Q0    ( "N :5;"\),$NRD
M ,G" 0 ?              "  2F2! !A-#$Y<F5S=')I8W1E9'-H87)E<&QA
M;C(P,C(N:'1M4$L! A0#%     @ *X!I5AW"XYI(*@  7],! !\
M     ( !(;P$ &$T,C!R97-T<FEC=&5D<VAA<F5P;&%N,C R,RYH=&U02P$"
M% ,4    "  K@&E63]H ZL'K   5EP@ '@              @ &FY@0 830T
M;&EC96YS96%G<F5E;65N=&1A=&5D87,N:'1M4$L! A0#%     @ *X!I5GDS
M?U 9%0$ &D$) !X              ( !H](% &$T-6UO;&5C=6QA<G!A<G1N
M97)S+6YO=F%R+FAT;5!+ 0(4 Q0    ( "N :5;I3"I8(=0% %&U-@ 1
M          "  ?CG!@!M;VQN+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( "N
M:58$.3T[=R,  /Z_ 0 1              "  4B\# !M;VQN+3(P,C(Q,C,Q
M+GAS9%!+ 0(4 Q0    ( "N :58>6<17;R0  .)X 0 5              "
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M &UO;&XM,C R,C$R,S%?9S,N:G!G4$L! A0#%     @ *X!I5NF-LJ%JS08
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M,C R,C$R,S%?9S<N:G!G4$L! A0#%     @ *X!I5BQS[Q8G$P$ (2@! !0
M             ( !96DI &UO;&XM,C R,C$R,S%?9S@N:G!G4$L! A0#%
M  @ *X!I5J'_GN#)K   S4(! !0              ( !OGPJ &UO;&XM,C R
M,C$R,S%?9SDN:G!G4$L! A0#%     @ +(!I5H#/&3@P3@$ "FT. !4
M         ( !N2DK &UO;&XM,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M "R :58!P?F-6](  !C*"0 5              "  1QX+ !M;VQN+3(P,C(Q
A,C,Q7W!R92YX;6Q02P4&     "  ( #@"   JDHM

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
